
DCTN4	B-CHEM
as	O	O
a	O	O
modifier	O	O
of	O	O
chronic	B-DISO
Pseudomonas	I-DISO
aeruginosa	I-DISO
infection	I-DISO
in	O	O
cystic	B-DISO
fibrosis	I-DISO
Pseudomonas	B-DISO
aeruginosa	I-DISO
(	I-DISO
Pa	I-DISO
)	I-DISO
infection	I-DISO
in	O	O
cystic	B-DISO
fibrosis	I-DISO
(	O	O
CF	B-DISO
)	O	O
patients	B-LIVB
is	O	O
associated	O	O
with	O	O
worse	O	O
long	O
-	O
term	O
pulmonary	B-DISO
disease	I-DISO
and	O	O
shorter	O
survival	O
,	O	O
and	O	O
chronic	B-DISO
Pa	I-DISO
infection	I-DISO
(	O	O
CPA	B-DISO
)	O	O
is	O	O
associated	O	O
with	O	O
reduced	B-DISO
lung	I-DISO
function	I-DISO
,	O	O
faster	B-DISO
rate	I-DISO
of	I-DISO
lung	I-DISO
decline	I-DISO
,	O	O
increased	O	O
rates	O
of	O	O
exacerbations	B-DISO
and	O	O
shorter	O
survival	O
.	O	O

By	O	O
using	O	O
exome	B-PROC
sequencing	I-PROC
and	O	O
extreme	O
phenotype	O
design	O
,	O	O
it	O	O
was	O	O
recently	O	O
shown	O	O
that	O	O
isoforms	B-CHEM
of	O	O
dynactin	B-CHEM
4	I-CHEM
(	O	O
DCTN4	B-CHEM
)	O	O
may	O	O
influence	O	O
Pa	B-DISO
infection	I-DISO
in	O	O
CF	B-DISO
,	O	O
leading	O	O
to	O	O
worse	O	O
respiratory	B-DISO
disease	I-DISO
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O
the	O	O
role	O	O
of	O	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
on	O	O
Pa	B-DISO
infection	I-DISO
incidence	O
,	O	O
age	B-PHYS
at	O	O
first	O	O
Pa	B-DISO
infection	I-DISO
and	O	O
chronic	B-DISO
Pa	I-DISO
infection	I-DISO
incidence	O
in	O	O
a	O	O
cohort	B-LIVB
of	O	O
adult	B-LIVB
CF	B-DISO
patients	B-LIVB
from	O	O
a	O	O
single	O	O
centre	B-OBJC
.	O	O

Polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
and	O	O
direct	B-PROC
sequencing	I-PROC
were	O	O
used	O	O
to	O	O
screen	O	O
DNA	B-ANAT
samples	I-ANAT
for	O	O
DCTN4	B-CHEM
variants	B-CHEM
.	O	O

A	O	O
total	O	O
of	O	O
121	O	O
adult	B-LIVB
CF	B-DISO
patients	B-LIVB
from	O	O
the	O	O
Cochin	B-OBJC
Hospital	I-OBJC
CF	I-OBJC
centre	I-OBJC
have	O	O
been	O	O
included	O	O
,	O	O
all	O	O
of	O	O
them	O	O
carrying	O	O
two	O	O
CFTR	O
defects	O
:	O	O
103	O	O
developed	O	O
at	O	O
least	O	O
1	O	O
pulmonary	B-DISO
infection	I-DISO
with	O	O
Pa	B-LIVB
,	O	O
and	O	O
68	O	O
patients	B-LIVB
of	O	O
them	O	O
had	O	O
CPA	B-DISO
.	O	O

DCTN4	B-CHEM
variants	B-CHEM
were	O	O
identified	O	O
in	O	O
24	O	O
%	O	O
(	O	O
29	O	O
/	O	O
121	O	O
)	O	O
CF	B-DISO
patients	B-LIVB
with	O	O
Pa	B-DISO
infection	I-DISO
and	O	O
in	O	O
only	O	O
17	O	O
%	O	O
(	O	O
3	O	O
/	O	O
18	O	O
)	O	O
CF	B-DISO
patients	B-LIVB
with	O	O
no	O	O
Pa	B-DISO
infection	I-DISO
.	O	O

Of	O	O
the	O	O
patients	B-LIVB
with	O	O
CPA	B-DISO
,	O	O
29	O	O
%	O	O
(	O	O
20	O	O
/	O	O
68	O	O
)	O	O
had	O	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
vs	O	O
23	O	O
%	O	O
(	O	O
8	O	O
/	O	O
35	O	O
)	O	O
in	O	O
patients	B-LIVB
without	O	O
CPA	B-DISO
.	O	O

Interestingly	O	O
,	O	O
p	B-CHEM
.	I-CHEM
Tyr263Cys	I-CHEM
tend	O	O
to	O	O
be	O	O
more	O	O
frequently	O	O
observed	O	O
in	O	O
CF	B-DISO
patients	B-LIVB
with	O	O
CPA	B-DISO
than	O	O
in	O	O
patients	B-LIVB
without	O	O
CPA	B-DISO
(	O	O
4	O	O
/	O	O
68	O	O
vs	O	O
0	O	O
/	O	O
35	O	O
)	O	O
,	O	O
and	O	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
tend	O	O
to	O	O
be	O	O
more	O	O
frequent	O	O
in	O	O
male	B-PHYS
CF	B-DISO
patients	B-LIVB
with	O	O
CPA	B-DISO
bearing	O	O
two	O	O
class	B-PHYS
II	I-PHYS
mutations	I-PHYS
than	O	O
in	O	O
male	B-PHYS
CF	B-DISO
patients	B-LIVB
without	O	O
CPA	B-DISO
bearing	O	O
two	O	O
class	B-PHYS
II	I-PHYS
mutations	I-PHYS
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
06	O	O
)	O	O
.	O	O

Our	O	O
observations	O	O
reinforce	O	O
that	O	O
DCTN4	B-CHEM
missense	B-DISO
variants	B-CHEM
,	O	O
especially	O	O
p	B-CHEM
.	I-CHEM

Tyr263Cys	I-CHEM
,	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
CPA	B-DISO
in	O	O
male	B-PHYS
CF	B-DISO
.	O	O

Nonylphenol	B-CHEM
diethoxylate	I-CHEM
inhibits	O
apoptosis	B-PHYS
induced	O
in	O	O
PC12	B-ANAT
cells	I-ANAT
Nonylphenol	B-CHEM
and	O	O
short	B-CHEM
-	I-CHEM
chain	I-CHEM
nonylphenol	I-CHEM
ethoxylates	I-CHEM
such	O	O
as	O	O
NP2	B-CHEM
EO	I-CHEM
are	O	O
present	B-DISO
in	O	O
aquatic	B-PHEN
environment	I-PHEN
as	O	O
wastewater	B-PHEN
contaminants	B-OBJC
,	O	O
and	O	O
their	O	O
toxic	B-DISO
effects	I-DISO
on	O	O
aquatic	B-LIVB
species	I-LIVB
have	O	O
been	O	O
reported	O	O
.	O	O

Apoptosis	B-PHYS
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
induced	O
by	O	O
serum	B-ANAT
deprivation	O
or	O	O
copper	B-CHEM
treatment	O
.	O	O

To	O	O
understand	O	O
the	O	O
toxicity	O
of	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O
of	O
NP2	B-CHEM
EO	I-CHEM
on	O	O
apoptosis	B-PHYS
induced	O
by	O	O
serum	B-ANAT
deprivation	O
and	O	O
copper	B-CHEM
by	O	O
using	O	O
PC12	B-ANAT
cell	I-ANAT
system	I-ANAT
.	O	O

Nonylphenol	B-CHEM
diethoxylate	I-CHEM
itself	O	O
showed	O	O
no	O	O
toxicity	O	O
and	O	O
recovered	O	O
cell	B-PHYS
viability	I-PHYS
from	O	O
apoptosis	B-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
decreased	O
DNA	B-PHYS
fragmentation	I-PHYS
caused	O	O
by	O	O
apoptosis	B-PHYS
in	O	O
PC12	B-ANAT
cells	I-ANAT
.	O	O

This	O	O
phenomenon	B-PHEN
was	O	O
confirmed	O	O
after	O	O
treating	O
apoptotic	O
PC12	B-ANAT
cells	I-ANAT
with	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
,	O	O
whereas	O	O
the	O	O
cytochrome	B-CHEM
c	I-CHEM
release	O	O
into	O	O
the	O	O
cytosol	B-ANAT
decreased	O
as	O	O
compared	O	O
to	O	O
that	O	O
in	O	O
apoptotic	B-ANAT
cells	I-ANAT
not	O	O
treated	O
with	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
s	O	O
.	O	O

Furthermore	O	O
,	O	O
Bax	B-CHEM
contents	O
in	O	O
apoptotic	B-ANAT
cells	I-ANAT
were	O	O
reduced	O
after	O	O
exposure	O
to	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
.	O	O

Thus	O	O
,	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
has	O	O
the	O	O
opposite	O
effect	O
on	O	O
apoptosis	B-PHYS
in	O	O
PC12	B-ANAT
cells	I-ANAT
compared	O	O
to	O	O
nonylphenol	B-CHEM
,	O	O
which	O	O
enhances	O
apoptosis	B-PHYS
induced	O
by	O	O
serum	B-ANAT
deprivation	O
.	O	O

The	O	O
difference	O
in	O	O
structure	O
of	O	O
the	O	O
two	O	O
compounds	B-CHEM
is	O	O
hypothesized	O
to	O	O
be	O	O
responsible	O	O
for	O	O
this	O	O
phenomenon	B-PHEN
.	O	O

These	O	O
results	B-DISO
indicated	O	O
that	O	O
nonylphenol	B-CHEM
diethoxylate	I-CHEM
has	O	O
capability	O
to	O	O
affect	O	O
cell	B-PHYS
differentiation	I-PHYS
and	O	O
development	B-PHYS
and	O	O
has	O	O
potentially	O
harmful	B-DISO
effect	I-DISO
on	O	O
organisms	B-LIVB
because	O	O
of	O	O
its	O	O
unexpected	O	O
impact	O
on	O	O
apoptosis	B-PHYS
.	O	O

©	O	O
2015	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O
Environ	O	O
Toxicol	O	O
31	O	O
:	O	O
1389	O	O
-	O	O
1398	O	O
,	O	O
2016	O	O
.	O	O

Prevascularized	O
silicon	B-CHEM
membranes	B-OBJC
for	O	O
the	O	O
enhancement	O
of	O	O
transport	O
to	O	O
implanted	B-DISO
medical	I-DISO
devices	I-DISO
Recent	O	O
advances	O	O
in	O	O
drug	B-DEVI
delivery	I-DEVI
and	O	O
sensing	B-OBJC
devices	I-OBJC
for	O	O
in	O
situ	O
applications	B-PROC
are	O	O
limited	O
by	O	O
the	O	O
diffusion	B-PHEN
-limiting	O	O
foreign	B-DISO
body	I-DISO
response	I-DISO
of	O	O
fibrous	O
encapsulation	B-PHEN
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
fabricated	O	O
prevascularized	O
synthetic	B-OBJC
device	I-OBJC
ports	I-OBJC
to	O	O
help	O	O
mitigate	B-PHEN
this	O	O
limitation	O
.	O	O

Membranes	B-OBJC
with	O	O
rectilinear	O
arrays	O
of	O	O
square	O
pores	O
with	O	O
widths	O
ranging	O	O
from	O	O
40	O	O
to	O	O
200	O	O
μm	O	O
were	O	O
created	O	O
using	O	O
materials	B-OBJC
(	O	O
50	O	O
μm	O	O
thick	O
double	O
-	O
sided	O
polished	B-CHEM
silicon	I-CHEM
)	O	O
and	O	O
processes	B-PHEN
(	O	O
photolithography	O
and	O	O
directed	B-PHEN
reactive	I-PHEN
ion	I-PHEN
etching	I-PHEN
)	O	O
common	O	O
in	O	O
the	O	O
manufacturing	O
of	O	O
microfabricated	B-OBJC
sensors	I-OBJC
.	O	O

Vascular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
responded	O	O
to	O	O
membrane	B-OBJC
geometry	I-OBJC
by	O	O
either	O	O
forming	O	O
vascular	B-ANAT
tubes	I-ANAT
that	O	O
extended	O
through	O	O
the	O	O
pore	O
or	O	O
completely	O
filling	O
membrane	B-OBJC
pores	O
after	O	O
4	O	O
days	O	O
in	O	O
culture	B-PROC
.	O	O

Although	O	O
tube	O
formation	O
began	O	O
to	O	O
predominate	O
overgrowth	B-DISO
around	O	O
75	O	O
μm	O	O
and	O	O
continued	O	O
to	O	O
increase	O
at	O	O
even	O	O
larger	O
pore	O
sizes	O
,	O	O
tubes	O
formed	O
at	O	O
these	O	O
large	O
pore	O
sizes	O
were	O	O
not	O	O
completely	O
round	O
and	O	O
had	O	O
relatively	O	O
thin	O
walls	O
.	O	O

Thus	O	O
,	O	O
the	O	O
optimum	O
range	O
of	O	O
pore	O
size	O
for	O	O
prevascularization	O
of	O	O
these	O	O
membranes	B-OBJC
was	O	O
estimated	O
to	O	O
be	O	O
75	O	O
-	O	O
100	O	O
μm	O	O
.	O	O

This	O	O
study	B-PROC
lays	O	O
the	O	O
foundation	O	O
for	O	O
creating	O	O
a	O	O
prevascularized	O
port	B-OBJC
that	O	O
can	O	O
be	O	O
used	O	O
to	O	O
reduce	O	O
fibrous	O
encapsulation	B-PHEN
and	O	O
thus	O	O
enhance	O
diffusion	B-PHEN
to	O	O
implanted	B-DISO
medical	I-DISO
devices	I-DISO
and	O	O
sensors	B-OBJC
.	O	O

©	O	O
2015	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

J	O	O
Biomed	O	O
Mater	O	O
Res	O	O
Part	O	O
B	O	O
:	O	O
Appl	O	O
Biomater	O	O
,	O	O
104B	O	O
:	O	O
1602	O	O
-	O	O
1609	O	O
,	O	O
2016	O	O
.	O	O

Seated	B-DISO
maximum	O
flexion	B-PHYS
:	O	O
An	O	O
alternative	O
to	O	O
standing	O
maximum	O
flexion	B-PHYS
for	O	O
determining	O	O
presence	O	O
of	O	O
flexion	B-PHYS
-	O	O
relaxation	O
?	O	O

The	O	O
flexion	B-PHYS
-	O	O
relaxation	O
phenomenon	B-PHEN
(	O	O
FRP	B-PHEN
)	O	O
in	O	O
standing	O
is	O	O
a	O	O
specific	O
and	O	O
sensitive	O
diagnostic	B-PROC
tool	I-PROC
for	O	O
low	B-DISO
back	I-DISO
pain	I-DISO
.	O	O

Seated	B-PHYS
flexion	I-PHYS
as	O	O
an	O	O
alternative	O
could	O	O
be	O	O
beneficial	O	O
for	O	O
certain	O	O
populations	B-LIVB
,	O	O
yet	O	O
the	O	O
behavior	O	O
of	O	O
the	O	O
trunk	O
extensors	O
during	O	O
seated	B-DISO
maximum	O
flexion	B-PHYS
compared	O	O
to	O	O
standing	O
flexion	B-PHYS
remains	O	O
unclear	O	O
.	O	O

Compare	O	O
FRP	B-PHEN
occurrences	O	O
and	O	O
spine	B-ANAT
angles	O
between	O	O
seated	B-DISO
and	O	O
standing	O
flexion	B-PHYS
postures	B-PHYS
in	O	O
three	O	O
levels	O
of	O	O
the	O	O
erector	B-ANAT
spinae	I-ANAT
muscles	I-ANAT
.	O	O

Thirty	O	O
-	O	O
one	O	O
participants	B-LIVB
free	O	O
of	O	O
back	B-DISO
pain	I-DISO
performed	O	O
seated	B-DISO
and	O	O
standing	O
maximum	O
trunk	B-ANAT
flexion	B-PHYS
.	O	O

Electromyographical	B-PHEN
signals	I-PHEN
were	O	O
recorded	O	O
from	O	O
the	O	O
bilateral	B-ANAT
lumbar	I-ANAT
(	I-ANAT
L3	I-ANAT
)	I-ANAT
,	O	O
lower	B-ANAT
-	I-ANAT
thoracic	I-ANAT
(	I-ANAT
T9	I-ANAT
)	I-ANAT
,	O	O
and	O	O
upper	B-ANAT
-	I-ANAT
thoracic	I-ANAT
(	I-ANAT
T4	I-ANAT
)	I-ANAT
erector	B-ANAT
spinae	I-ANAT
and	O	O
assessed	O
for	O	O
the	O	O
occurrence	O	O
of	O	O
FRP	B-PHEN
.	O	O

Spine	O
angles	O
corresponding	O	O
to	O	O
FRP	B-PHEN
onset	O	O
and	O	O
cessation	O
were	O	O
determined	O	O
,	O	O
and	O	O
FRP	B-PHEN
occurrences	O	O
and	O	O
angles	O
were	O	O
compared	O
between	O	O
posture	B-PHYS
and	O	O
muscle	O
.	O	O

FRP	B-PHEN
occurrence	O	O
was	O	O
similar	O	O
in	O	O
standing	O
and	O	O
seated	B-DISO
maximum	O
flexion	B-PHYS
across	O	O
all	O	O
muscles	O
,	O	O
with	O	O
the	O	O
lumbar	O
muscles	O
showing	O	O
the	O	O
greatest	O	O
consistency	O
.	O	O

Standing	O
FRP	B-PHEN
onset	O	O
and	O	O
cessation	O
angles	O	O
were	O	O
consistently	O	O
greater	O	O
than	O	O
the	O	O
corresponding	O	O
seated	B-DISO
FRP	B-PHEN
angles	O	O
.	O	O

Considering	O	O
the	O	O
similar	O	O
number	O	O
of	O	O
FRP	B-PHEN
occurrences	O	O
,	O	O
seated	B-DISO
maximum	O
flexion	B-PHYS
may	O	O
constitute	O	O
an	O	O
objective	O	O
criterion	O
for	O	O
low	B-DISO
back	I-DISO
pain	I-DISO
diagnosis	B-DISO
.	O	O

Future	O	O
work	O	O
should	O	O
seek	O	O
to	O	O
confirm	O	O
the	O	O
utility	O	O
of	O	O
this	O	O
test	O
in	O	O
individuals	B-LIVB
with	O	O
low	B-DISO
back	I-DISO
pain	I-DISO
.	O	O

The	O	O
Relationship	O
Between	O	O
Distance	O
and	O	O
Post	B-DISO
-	I-DISO
operative	I-DISO
Visit	O
Attendance	O
Following	O	O
Medical	O
Male	B-PROC
Circumcision	I-PROC
in	O	O
Nyanza	B-GEOG
Province	I-GEOG
,	O	O
Kenya	B-GEOG
To	O	O
date	O	O
,	O	O
there	O	O
is	O	O
no	O	O
research	B-PROC
on	O	O
voluntary	O
medical	O
male	B-PROC
circumcision	I-PROC
(	O	O
VMMC	B-PROC
)	O	O
catchment	B-GEOG
areas	I-GEOG
or	O	O
the	O	O
relationship	O
between	O	O
distance	O
to	O	O
a	O	O
VMMC	B-PROC
facility	B-OBJC
and	O	O
attendance	O
at	O	O
a	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
follow	B-PROC
-	I-PROC
up	I-PROC
visit	I-PROC
.	O	O

We	O	O
analyzed	B-PROC
data	O
from	O	O
a	O	O
randomly	O
selected	O
subset	O
of	O	O
males	B-LIVB
self	B-PROC
-	I-PROC
seeking	I-PROC
circumcision	I-PROC
at	O	O
one	O	O
of	O	O
16	O	O
participating	O
facilities	B-OBJC
in	O	O
Nyanza	B-GEOG
Province	I-GEOG
,	O	O
Kenya	B-GEOG
between	O	O
2008	O	O
and	O	O
2010	O	O
.	O	O

Among	O	O
1437	O	O
participants	B-LIVB
,	O	O
46	O	O
.	O	O
7	O	O
%	O	O
attended	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

The	O	O
median	O
distance	O
from	O	O
residence	O
to	O	O
utilized	O	O
facility	B-OBJC
was	O	O
2	O	O
.	O	O
98	O	O
km	O	O
(	O	O
IQR	O
1	O	O
.	O	O
31	O	O
-	O	O
5	O	O
.	O	O
38	O	O
)	O	O
.	O	O

Nearly	O	O
all	O	O
participants	B-LIVB
(	O	O
98	O	O
.	O	O
8	O	O
%	O	O
)	O	O
lived	O
within	O	O
5	O	O
km	O	O
from	O	O
a	O	O
facility	B-OBJC
,	O	O
however	O	O
,	O	O
26	O	O
.	O	O

3	O	O
%	O	O
visited	O
a	O	O
facility	B-OBJC
more	O	O
than	O	O
5	O	O
km	O	O
away	O	O
.	O	O

Stratified	O
results	O
demonstrated	O	O
that	O	O
among	O	O
those	O	O
utilizing	O	O
fixed	O
facilities	B-OBJC
,	O	O
greater	O
distance	O
was	O	O
associated	O
with	O
higher	O
odds	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
non	O
-	O
attendance	O
(	O	O
OR	O
5	O	O
.	O	O
01	O	O
-	O	O
10	O	O
km	O	O
vs	O	O
.	O	O

0	O	O
-	O	O
1	O	O
km	O	O
=	O	O
1	O	O
.	O	O
71	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
08	O	O
,	O	O
2	O	O
.	O	O
70	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
;	O	O
OR	O
>	O	O
10	O	O
km	O	O
vs	O	O
.	O	O

0	O	O
-	O	O
1	O	O
km	O	O
=	O	O
2	O	O
.	O	O
80	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
26	O	O
,	O	O
6	O	O
.	O	O
21	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
adjusting	O	O
for	O	O
age	B-PHYS
and	O	O
district	O
of	O	O
residence	O
.	O	O

We	O	O
found	O	O
5	O	O
km	O	O
marked	O	O
the	O	O
threshold	O
distance	O
beyond	O	O
which	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
attendance	O
significantly	O
dropped	O
.	O	O

These	O	O
results	O
demonstrate	O	O
distance	O
is	O	O
an	O	O
important	O	O
predictor	O
of	O	O
attending	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
and	O	O
this	O	O
relationship	O
appears	O	O
to	O	O
be	O	O
modified	O
by	O
facility	B-OBJC
type	O
.	O	O

Promoting	O
lifestyle	O
behaviour	O
change	O
and	O	O
well	B-DISO
-	I-DISO
being	I-DISO
in	O	O
hospital	B-LIVB
patients	I-LIVB
:	O	O
a	O	O
pilot	B-PROC
study	I-PROC
of	O	O
an	O	O
evidence	O	O
-	O	O
based	O	O
psychological	O
intervention	B-PROC
Lifestyle	O	O
risk	O
behaviours	O
show	O	O
an	O	O
inverse	O
social	O
gradient	O
,	O	O
clustering	O
in	O	O
vulnerable	B-LIVB
groups	I-LIVB
.	O	O

We	O	O
designed	O	O
and	O	O
piloted	O	O
an	O	O
intervention	B-PROC
to	O	O
address	O	O
barriers	O	O
to	O	O
lifestyle	O
behaviour	O
change	O
among	O	O
hospital	B-LIVB
patients	I-LIVB
.	O	O

We	O	O
designed	O	O
our	O	O
intervention	B-PROC
using	O	O
effective	O	O
components	O	O
of	O	O
behaviour	O
change	O
interventions	B-PROC
informed	O	O
by	O	O
psychological	O
theory	O
.	O	O

Delivered	O	O
by	O	O
a	O	O
health	B-LIVB
psychologist	I-LIVB
based	O	O
at	O	O
the	O	O
Royal	O
Free	O
London	O
NHS	O
Foundation	O
Trust	O
,	O	O
the	O	O
4	O	O
-	O	O
week	O	O
intervention	B-PROC
included	O	O
detailed	O	O
baseline	B-PROC
assessment	I-PROC
,	O	O
personalized	O
goal	B-PROC
setting	I-PROC
,	O	O
psychological	B-PHYS
skills	I-PHYS
development	I-PHYS
,	O	O
motivation	B-PROC
support	I-PROC
and	O	O
referral	B-PROC
to	I-PROC
community	O
services	O
.	O	O

Primary	O
outcomes	O
were	O	O
feasibility	O	O
and	O	O
patient	B-LIVB
acceptability	O
.	O	O

We	O	O
also	O	O
evaluated	O	O
changes	O
to	O	O
health	O
and	O	O
well	B-DISO
-	I-DISO
being	I-DISO
.	O	O

From	O	O
1	O	O
July	O
2013	O	O
to	O	O
31	O	O
September	O
2014	O	O
,	O	O
686	O	O
patients	B-LIVB
were	O	O
referred	O
,	O	O
338	O	O
(	O	O
49	O	O
.	O	O

3	O	O
%	O	O
)	O	O
attended	O	O
a	O	O
first	O	O
appointment	O
and	O	O
172	O	O
(	O	O
25	O	O
.	O	O

1	O	O
%	O	O
)	O	O
completed	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Furthermore	O	O
,	O	O
72	O	O
.	O	O
1	O	O
%	O	O
of	O	O
attenders	B-LIVB
were	O	O
female	B-PHYS
with	O	O
the	O	O
median	O	O
age	B-PHYS
55	O	O
years	O
and	O	O
poor	O
self	O
-	O
reported	O
baseline	O
health	O
.	O	O

After	O	O
4	O	O
weeks	O
,	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
health	O
and	O	O
well	O
-	O
being	O
scores	O
significantly	B-DISO
improved	I-DISO
:	O	O
63	O	O
%	O	O
of	O	O
lifestyle	B-DISO
goals	I-DISO
and	O	O
89	O	O
%	O	O
of	O	O
health	B-PROC
management	I-PROC
goals	O
were	O	O
fully	O	O
achieved	B-DISO
;	O	O
58	O	O
%	O	O
of	O	O
referrals	B-PROC
to	I-PROC
community	O
lifestyle	O
behaviour	O
change	O
services	O	O
and	O	O
79	O	O
%	O	O
of	O	O
referrals	O	O
to	O	O
other	O	O
services	B-PROC
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

Citizen	B-LIVB
's	I-LIVB
Advice	I-LIVB
Bureau	I-LIVB
)	O	O
were	O	O
accepted	O	O
;	O	O
99	O	O
%	O	O
were	O	O
satisfied	O
/	O	O
very	B-DISO
satisfied	I-DISO
with	O	O
the	O	O
service	B-PROC
.	O	O

Our	O	O
hospital	B-PROC
-	I-PROC
based	I-PROC
intervention	I-PROC
was	O	O
feasible	O	O
,	O	O
acceptable	O
and	O	O
showed	O	O
preliminary	B-DISO
health	I-DISO
and	I-DISO
well	I-DISO
-	I-DISO
being	I-DISO
gains	I-DISO
.	O	O

The	O	O
Impact	O	O
of	O	O
Deployment	O
on	O	O
Parental	B-LIVB
,	O	O
Family	B-LIVB
and	O	O
Child	B-LIVB
Adjustment	O
in	O	O
Military	B-LIVB
Families	I-LIVB
Since	O	O
9	O	O
/	O	O
11	O	O
,	O	O
military	B-LIVB
service	I-LIVB
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
has	O	O
been	O	O
characterized	O	O
by	O	O
wartime	O
deployments	O
and	O	O
reintegration	O	O
challenges	O	O
that	O	O
contribute	O	O
to	O	O
a	O	O
context	O	O
of	O	O
stress	B-DISO
for	O	O
military	B-LIVB
families	I-LIVB
.	O	O

Research	B-PROC
indicates	O	O
the	O	O
negative	B-DISO
impact	I-DISO
of	O	O
wartime	O	O
deployment	O
on	O	O
the	O	O
well	O
being	O
of	O	O
service	B-LIVB
members	B-LIVB
,	O	O
military	B-LIVB
spouses	B-LIVB
,	O	O
and	O	O
children	B-LIVB
.	O	O

Yet	O	O
,	O	O
few	O	O
studies	O	O
have	O	O
considered	O	O
how	O	O
parental	B-LIVB
deployments	O
may	O	O
affect	O	O
adjustment	O
in	O	O
young	B-LIVB
children	I-LIVB
and	O	O
their	O	O
families	B-LIVB
.	O	O

Using	O	O
deployment	O
records	O
and	O	O
parent	B-LIVB
-	O	O
reported	O
measures	O	O
from	O	O
primary	O	O
caregiving	O
(	O	O
N	O	O
=	O	O
680	O	O
)	O	O
and	O	O
military	B-LIVB
(	O	O
n	O	O
=	O	O
310	O	O
)	O	O
parents	B-LIVB
,	O	O
we	O	O
examined	O	O
the	O	O
influence	O	O
of	O	O
deployment	O
on	O	O
adjustment	O
in	O	O
military	B-LIVB
families	I-LIVB
with	O	O
children	B-LIVB
ages	O	O
0	O	O
-	O	O
10	O	O
years	O	O
.	O	O

Greater	O	O
deployment	O
exposure	O	O
was	O	O
related	O	O
to	O	O
impaired	O
family	O
functioning	O
and	O	O
marital	B-DISO
instability	B-DISO
.	O	O

Parental	B-LIVB
depressive	B-DISO
and	O	O
posttraumatic	B-DISO
stress	I-DISO
symptoms	I-DISO
were	O	O
associated	O
with	O
impairments	O
in	O	O
social	O
emotional	B-DISO
adjustment	O
in	O	O
young	B-LIVB
children	I-LIVB
,	O	O
increased	O	O
anxiety	B-DISO
in	O	O
early	O	O
childhood	O
,	O	O
and	O	O
adjustment	O
problems	O	O
in	O	O
school	B-LIVB
-	I-LIVB
age	I-LIVB
children	I-LIVB
.	O	O

Conversely	O	O
,	O	O
parental	B-LIVB
sensitivity	B-PHYS
was	O	O
associated	O
with	O
improved	O	O
social	O
and	O	O
emotional	B-DISO
outcomes	I-DISO
across	O	O
childhood	O
.	O	O

These	O	O
findings	B-DISO
provide	O	O
guidance	O	O
to	O	O
developing	O	O
preventive	O
approaches	O	O
for	O	O
military	B-LIVB
families	I-LIVB
with	O	O
young	O	O
children	B-LIVB
.	O	O

Combining	O	O
electrostatic	B-OBJC
powder	I-OBJC
with	O	O
an	O	O
insecticide	B-CHEM
:	O	O
effect	O	O
on	O	O
stored	O
-	O	O
product	B-OBJC
beetles	O
and	O	O
on	O	O
the	O	O
commodity	B-OBJC
The	O	O
opportunity	O	O
to	O	O
reduce	O	O
the	O	O
amount	O	O
of	O	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
applied	O	O
to	O	O
grain	B-OBJC
by	O	O
formulating	O	O
it	O	O
in	O	O
an	O	O
electrostatic	B-OBJC
powder	I-OBJC
was	O	O
investigated	O	O
.	O	O

The	O	O
insecticidal	B-CHEM
efficacy	O
of	O	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
in	O	O
EC	B-CHEM
formulation	I-CHEM
or	O	O
formulated	O	O
using	O	O
electrostatic	B-OBJC
powder	I-OBJC
(	O	O
EP	B-OBJC
)	O	O
as	O	O
an	O	O
inert	B-OBJC
carrier	I-OBJC
was	O	O
investigated	O	O
against	O	O
Sitophilus	O
oryzae	O
(	O	O
L	O	O
.	O	O
)	O	O
,	O	O
Oryzaephilus	O
surinamensis	O
(	O	O
L	O	O
.	O	O
)	O	O
,	O	O
Rhyzopertha	O
dominica	O
(	O	O
F	O	O
.	O	O
)	O	O
and	O	O
Tribolium	O
confusum	O
Jacquelin	O
du	O
Val	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
adhesive	B-PHEN
properties	O	O
of	O	O
EP	B-OBJC
to	O	O
rice	B-OBJC
,	O	O
corn	B-OBJC
and	O	O
wheat	B-OBJC
,	O	O
together	O	O
with	O	O
the	O	O
effect	O	O
on	O	O
bulk	O	O
density	O
and	O	O
bread	B-OBJC
-	O	O
and	O	O
pasta	B-OBJC
-	O	O
making	O
properties	O
,	O	O
were	O	O
investigated	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
formulated	O	O
with	O	O
EP	B-OBJC
provided	O	O
better	O	O
efficacy	O
against	O	O
adults	O
when	O	O
compared	O	O
with	O	O
EC	B-CHEM
formulation	I-CHEM
for	O	O
O	O
.	O

surinamensis	O
and	O	O
T	O
.	O

confusum	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
difference	O	O
for	O	O
R	O
.	O

dominica	O
.	O	O

Progeny	B-LIVB
production	O	O
was	O	O
consistently	O	O
lower	O	O
in	O	O
grain	B-OBJC
treated	B-PROC
with	I-PROC
the	O	O
EP	B-OBJC
formulation	O	O
than	O	O
in	O	O
grain	B-OBJC
treated	B-PROC
with	I-PROC
the	O	O
EC	B-CHEM
.	O	O

Tests	O	O
showed	O	O
that	O	O
EP	B-OBJC
adhered	B-PHEN
to	O	O
the	O	O
kernels	B-OBJC
for	O	O
longer	O	O
on	O	O
hard	O	O
wheat	B-OBJC
than	O	O
on	O	O
maize	B-OBJC
or	O	O
rice	B-OBJC
.	O	O

In	O	O
most	O	O
commodities	B-OBJC
,	O	O
EP	B-OBJC
did	O	O
not	O	O
alter	O	O
the	O	O
bulk	O	O
density	O
.	O	O

Finally	O	O
,	O	O
the	O	O
addition	O	O
of	O	O
EP	B-OBJC
did	O	O
not	O	O
affect	O	O
flour	B-OBJC
-	O	O
and	O	O
bread	B-OBJC
-	O	O
making	O
properties	O
,	O	O
nor	O	O
the	O	O
pasta	B-OBJC
-making	O	O
properties	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
an	O	O
EP	B-OBJC
could	O	O
be	O	O
used	O	O
to	O	O
reduce	O	O
the	O	O
amount	O	O
of	O	O
pirimiphos	B-CHEM
-	I-CHEM
methyl	I-CHEM
applied	O	O
to	O	O
grain	B-OBJC
for	O	O
effective	O	O
pest	O
control	O
,	O	O
with	O	O
no	O
detrimental	O
effects	O
on	O	O
grain	B-OBJC
quality	O
.	O	O

©	O	O
2016	O	O
Society	O	O
of	O	O
Chemical	O	O
Industry	O	O
.	O	O

Radiofrequency	B-PROC
ablation	I-PROC
of	O	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
associated	O
with	O
coronary	B-DISO
sinus	I-DISO
diverticula	I-DISO
Posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
may	O	O
be	O	O
associated	O
with	O
a	O	O
coronary	B-DISO
sinus	I-DISO
(	I-DISO
CS	I-DISO
)	I-DISO
diverticulum	I-DISO
.	O	O

Our	O	O
purpose	O	O
was	O	O
to	O	O
describe	O	O
the	O	O
clinical	B-PHYS
characteristics	I-PHYS
,	O	O
mapping	O
and	O	O
ablation	B-PROC
of	I-PROC
these	I-PROC
pathways	I-PROC
.	O	O

This	O	O
was	O	O
a	O	O
retrospective	B-PROC
study	I-PROC
of	O	O
all	O	O
patients	B-LIVB
who	O	O
underwent	O	O
ablation	B-PROC
of	O	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
in	O	O
a	O	O
single	O
centre	O
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
diverticulum	B-DISO
of	I-DISO
the	I-DISO
CS	I-DISO
or	O	O
one	O	O
of	O	O
its	O	O
tributaries	B-ANAT
were	O	O
included	O	O
in	O	O
group	O
I	O
,	O	O
while	O	O
the	O	O
other	O	O
patients	B-LIVB
formed	O	O
group	O
II	O
.	O	O

Clinical	O
presentation	O
,	O	O
ablation	B-PROC
procedure	I-PROC
and	O	O
outcome	O	O
were	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O
.	O	O

A	O	O
total	O	O
of	O	O
51	O	O
patients	B-LIVB
were	O	O
included	O	O
,	O	O
16	O	O
in	O	O
group	O
I	O
and	O	O
35	O	O
in	O	O
group	O
II	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
age	O
or	O	O
sex	O
distribution	O
.	O	O

Atrial	B-DISO
fibrillation	I-DISO
(	O	O
AF	B-DISO
)	O	O
and	O	O
previous	O	O
unsuccessful	O	O
ablation	B-PROC
were	O	O
more	O	O
common	O	O
in	O	O
group	O
I	O
.	O	O

A	O	O
negative	B-DISO
delta	B-DISO
wave	I-DISO
in	O	O
lead	O
II	O
was	O	O
the	O	O
ECG	B-PROC
finding	B-DISO
with	O	O
best	O	O
sensitivity	O
and	O	O
specificity	O
for	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
diverticulum	B-DISO
.	O	O

A	O	O
pathway	B-ANAT
potential	O
was	O	O
common	O	O
at	O	O
the	O	O
successful	O	O
site	O
in	O	O
group	O
I	O
,	O	O
and	O	O
the	O	O
interval	O	O
between	O	O
local	B-PROC
ventricular	I-PROC
electrogram	I-PROC
and	O	O
delta	B-DISO
wave	I-DISO
onset	O	O
was	O	O
shorter	O
(	O	O
19	O	O
.	O	O
5	O	O
±	O	O
8	O	O
vs	O	O
33	O	O
.	O	O
1	O	O
±	O	O
7	O	O
.	O	O

6	O	O
ms	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
trend	O	O
toward	O	O
lower	O
procedural	O	O
success	O	O
rate	O
and	O	O
higher	O
recurrence	B-PHEN
rate	O
in	O	O
group	O
I	O
,	O	O
although	O	O
this	O	O
was	O	O
not	O	O
significant	O
.	O	O

CS	B-DISO
diverticula	I-DISO
should	O	O
be	O	O
suspected	O	O
in	O	O
patients	B-LIVB
with	O	O
manifest	O	O
posteroseptal	B-ANAT
accessory	I-ANAT
pathways	I-ANAT
who	O	O
have	O	O
a	O	O
previous	O	O
failed	O	O
ablation	B-PROC
,	O	O
documented	O	O
AF	B-DISO
or	O	O
typical	O	O
electrocardiographic	B-DISO
signs	I-DISO
.	O	O

A	O	O
discrete	O	O
potential	O
is	O	O
frequently	O	O
seen	O	O
at	O	O
the	O	O
successful	O	O
site	O	O
,	O	O
but	O	O
the	O	O
local	B-PROC
ventricular	I-PROC
electrogram	I-PROC
is	O	O
not	O	O
as	O	O
early	O	O
as	O	O
in	O	O
other	O	O
accessory	B-ANAT
pathways	I-ANAT
.	O	O

Association	O	O
of	O	O
RBP4	B-CHEM
levels	O	O
with	O	O
increased	O	O
arterial	B-PHYS
stiffness	I-PHYS
in	O	O
adolescents	B-LIVB
with	O	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
explore	O	O
the	O	O
impact	O	O
of	O	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
(	O	O
FH2D	B-DISO
)	O	O
on	O	O
arterial	B-PHYS
stiffness	I-PHYS
in	O	O
young	O
people	B-LIVB
and	O	O
its	O	O
relationship	O	O
to	O	O
adipocytokines	B-CHEM
.	O	O

This	O	O
case	B-PROC
-	I-PROC
control	I-PROC
study	I-PROC
included	O	O
52	O	O
adolescents	B-LIVB
(	O	O
male	B-PHYS
/	O	O
female	B-PHYS
28	O	O
/	O	O
24	O	O
)	O	O
with	O	O
FH2D	B-DISO
(	O	O
FH2D	B-DISO
+	I-DISO
)	O	O
and	O	O
40	O	O
adolescents	B-LIVB
(	O	O
male	B-PHYS
/	O	O
female	B-PHYS
21	O	O
/	O	O
19	O	O
)	O	O
without	O	O
FH2D	B-DISO
(	O	O
FH2D	B-DISO
-	I-DISO
)	O	O
.	O	O

Anthropometric	O
measurements	O
,	O	O
including	O	O
height	B-PHYS
,	O	O
weight	B-PHYS
,	O	O
waist	B-PHYS
circumference	I-PHYS
(	O	O
WC	B-PHYS
)	O	O
,	O	O
and	O	O
blood	B-PHYS
pressure	I-PHYS
,	O	O
were	O	O
obtained	O	O
.	O	O

Blood	B-ANAT
samples	I-ANAT
were	O	O
collected	O	O
,	O	O
fasting	B-PROC
plasma	I-PROC
glucose	I-PROC
(	O	O
FPG	B-PROC
)	O	O
,	O	O
serum	B-PROC
lipids	I-PROC
,	O	O
Retinol	B-CHEM
Binding	I-CHEM
Protein	I-CHEM
4	I-CHEM
(	O	O
RBP4	B-CHEM
)	O	O
,	O	O
C	B-PROC
reactive	I-PROC
protein	I-PROC
(	O	O
CRP	B-PROC
)	O	O
,	O	O
adiponectin	B-PROC
and	O	O
visfatin	B-CHEM
were	O	O
examined	O	O
.	O	O

Brachial	O
-	O
ankle	O
pulse	O
wave	O
velocity	O
(	O	O
baPWV	O
)	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
arterial	B-PHYS
stiffness	I-PHYS
.	O	O

Visceral	B-PHYS
fat	I-PHYS
area	I-PHYS
(	O	O
VFA	B-PHYS
)	O	O
was	O	O
measured	O	O
by	O	O
computerized	B-PROC
tomography	I-PROC
.	O	O

Compared	O	O
with	O	O
FH2D	B-DISO
-	I-DISO
group	B-LIVB
,	O	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
had	O	O
a	O	O
significantly	O	O
higher	O	O
oral	B-PROC
glucose	I-PROC
tolerance	I-PROC
test	I-PROC
(	I-PROC
OGTT	I-PROC
)	I-PROC
2	I-PROC
-	I-PROC
hour	I-PROC
insulin	I-PROC
,	O	O
RBP4	B-CHEM
and	O	O
baPWV	O
levels	O	O
,	O	O
a	O	O
lower	O	O
adiponectin	B-PROC
and	O	O
glucose	O
infusing	O
rate	O
(	O	O
GIR	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

BaPWV	O
was	O	O
positively	O	O
correlated	O	O
with	O	O
age	B-PHYS
,	O	O
systolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
(	O	O
SBP	B-PHYS
)	O	O
,	O	O
diastolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
(	O	O
DBP	B-PHYS
)	O	O
,	O	O
2	B-PROC
-	I-PROC
hour	I-PROC
(	I-PROC
OGTT	I-PROC
)	I-PROC
insulin	I-PROC
,	O	O
RBP4	B-CHEM
,	O	O
and	O	O
VFA	B-PHYS
,	O	O
and	O	O
negatively	O	O
correlated	O	O
with	O	O
GIR	O	O
in	O	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
.	O	O

After	O	O
multivariate	O
analysis	O
,	O	O
age	B-PHYS
,	O	O
SBP	B-PHYS
,	O	O
RBP4	B-CHEM
and	O	O
VFA	B-PHYS
maintained	O	O
an	O	O
independent	O	O
association	O	O
with	O	O
baPWV	O
in	O	O
FH2D	B-DISO
+	I-DISO
group	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
while	O	O
only	O	O
age	B-PHYS
,	O	O
SBP	B-PHYS
,	O	O
and	O	O
VFA	B-PHYS
were	O	O
independent	O	O
predictors	O
of	O	O
baPWV	O
in	O	O
FH2D	B-DISO
-	I-DISO
group	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

These	O	O
findings	B-DISO
led	O	O
to	O	O
the	O	O
conclusion	O	O
that	O	O
RBP4	B-CHEM
level	O	O
was	O	O
associated	O	O
with	O	O
increased	O	O
arterial	B-PHYS
stiffness	I-PHYS
in	O	O
young	O
subjects	B-LIVB
with	O	O
family	B-DISO
history	I-DISO
of	I-DISO
type	I-DISO
2	I-DISO
diabetes	I-DISO
.	O	O

EZH2	O
and	O	O
ZFX	O
oncogenes	O
in	O	O
malignant	O
behaviour	O
of	O	O
parathyroid	B-DISO
neoplasms	I-DISO
Several	O	O
studies	B-PROC
reported	O	O
somatic	B-DISO
mutations	I-DISO
of	O	O
many	O	O
genes	O
(	O	O
MEN1	O
,	O	O
CTNNB1	O
,	O	O
CDKIs	O
and	O	O
others	O	O
)	O	O
in	O	O
parathyroid	B-DISO
adenoma	I-DISO
,	O	O
although	O	O
with	O	O
different	O
prevalence	O
.	O	O

Recently	O	O
,	O	O
activating	O
mutations	B-PHYS
of	O	O
the	O	O
EZH2	O
and	O	O
ZFX	O
oncogenes	O
were	O	O
identified	O	O
in	O	O
benign	O
parathyroid	B-DISO
adenoma	I-DISO
by	O	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
.	O	O

The	O	O
same	O	O
mutations	B-PHYS
had	O	O
been	O	O
found	O	O
in	O	O
blood	B-ANAT
and	O	O
ovary	B-ANAT
malignant	B-DISO
tumours	I-DISO
.	O	O

On	O	O
one	O	O
hand	O	O
,	O	O
this	O	O
result	O	O
raised	O	O
the	O	O
hypothesis	O
that	O	O
these	O	O
oncogenes	O
may	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
onset	O
of	O	O
parathyroid	B-DISO
tumour	I-DISO
,	O	O
but	O	O
it	O	O
would	O	O
also	O	O
suggest	O	O
they	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
malignant	O
,	O	O
rather	O	O
benign	O
,	O	O
parathyroid	B-DISO
neoplasm	I-DISO
.	O	O

Our	O	O
aim	O
was	O	O
to	O	O
verify	O	O
the	O	O
occurrence	O
of	O	O
selected	O	O
mutations	B-PHYS
of	O	O
the	O	O
EZH2	O
and	O	O
ZFX	O
genes	O
in	O	O
an	O	O
Italian	B-LIVB
cohort	B-LIVB
of	O	O
23	O	O
sporadic	O
parathyroid	B-DISO
carcinomas	I-DISO
,	O	O
12	O	O
atypical	O
and	O	O
45	O	O
typical	O
adenomas	B-DISO
.	O	O

DNA	B-CHEM
was	O	O
extracted	B-PROC
from	O	O
paraffin	O
-	O
embedded	O
tissues	O
,	O	O
PCR	B-PROC
amplified	B-PHEN
and	O	O
directly	O	O
sequenced	O
.	O	O

No	B-DISO
mutations	B-PHYS
were	O	O
detected	B-DISO
in	O	O
the	O	O
coding	B-CHEM
sequence	I-CHEM
and	O	O
boundaries	B-CHEM
of	O	O
both	O	O
genes	O
in	O	O
any	O	O
of	O	O
the	O	O
samples	B-OBJC
.	O	O

Two	O	O
polymorphisms	B-PHYS
of	O	O
the	O	O
EZH2	O
gene	O
were	O	O
identified	O
with	O	O
different	O
prevalence	O
:	O	O
the	O	O
rs2072407	O
variant	O
was	O	O
present	B-DISO
in	O	O
the	O	O
30	O	O
%	O	O
of	O	O
the	O	O
samples	B-OBJC
,	O	O
in	O	O
keeping	O	O
with	O	O
the	O	O
overall	O
frequency	O
in	O	O
larger	O
populations	O
,	O	O
while	O	O
the	O	O
rs78589034	O
variant	O
,	O	O
located	O	O
close	O	O
to	O	O
the	O	O
5	B-CHEM
'	I-CHEM
end	I-CHEM
of	O	O
the	O	O
exon	B-CHEM
16	I-CHEM
,	O	O
was	O	O
detected	B-DISO
in	O	O
only	O	O
one	O	O
proband	B-LIVB
with	O	O
familial	O
isolated	O
hyperparathyroidism	B-DISO
;	O	O
we	O	O
investigated	O
the	O	O
possible	O	O
outcome	O
on	O	O
the	O	O
splicing	B-PHYS
process	I-PHYS
.	O	O

EZH2	O
and	O	O
ZFX	O
genes	O
do	O	O
not	O	O
seem	O	O
to	O	O
have	O	O
an	O	O
impact	O
on	O	O
the	O	O
onset	O
of	O	O
most	O	O
parathyroid	B-DISO
tumours	I-DISO
,	O	O
both	O	O
benign	O
and	O	O
malignant	O
,	O	O
though	O	O
further	O	O
studies	O	O
on	O	O
larger	O
cohorts	B-LIVB
of	O	O
different	O
ethnicity	O
are	O	O
needed	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
on	O	O
sagittal	B-ANAT
spinal	O
-	O	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
and	O	O
low	B-DISO
back	I-DISO
pain	I-DISO
in	O	O
patients	B-LIVB
with	O	O
severe	O
hip	B-DISO
osteoarthritis	I-DISO
Sagittal	B-ANAT
spinopelvic	B-ANAT
malalignment	B-DISO
has	O	O
been	O	O
reported	O	O
in	O	O
spinal	B-DISO
disorders	I-DISO
such	O	O
as	O	O
low	B-DISO
back	I-DISO
pain	I-DISO
(	O	O
LBP	B-DISO
)	O	O
,	O	O
and	O	O
restoration	O	O
of	O	O
normal	O	O
alignment	B-DISO
is	O	O
targeted	O	O
when	O	O
treating	B-PROC
these	O	O
disorders	B-DISO
.	O	O

Abnormal	B-DISO
sagittal	B-ANAT
spinal	O
-	O	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
has	O	O
been	O	O
reported	O	O
in	O	O
patients	B-LIVB
with	O	O
severe	O
hip	B-DISO
osteoarthritis	I-DISO
(	O	O
OA	B-DISO
)	O	O
,	O	O
who	O	O
have	O	O
a	O	O
high	O	O
prevalence	O
of	O	O
associated	O	O
LBP	B-DISO
.	O	O

This	O	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
aimed	O	O
to	O	O
investigate	O	O
changes	O	O
in	O	O
sagittal	B-ANAT
spinal	O
-	O	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
after	O	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
(	O	O
THA	B-PROC
)	O	O
in	O	O
patients	B-LIVB
with	O	O
severe	O
hip	B-DISO
OA	I-DISO
,	O	O
and	O	O
whether	O	O
these	O	O
changes	O	O
contribute	O	O
to	O	O
LBP	B-DISO
relief	B-DISO
.	O	O

Patients	B-LIVB
undergoing	O	O
primary	O	O
THA	B-PROC
due	O	O
to	O	O
severe	O
unilateral	O	O
hip	B-DISO
OA	I-DISO
were	O	O
recruited	O	O
.	O	O

Physical	B-PROC
examination	I-PROC
and	O	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
films	I-DEVI
were	O	O
taken	O	O
to	O	O
rule	O	O
out	O	O
any	O	O
spinal	B-DISO
disorder	I-DISO
.	O	O

Sagittal	B-ANAT
alignment	B-DISO
of	O	O
pelvis	B-ANAT
,	O	O
hip	B-ANAT
,	O	O
and	O	O
spine	B-ANAT
was	O	O
analyzed	O	O
on	O	O
lateral	B-PROC
radiographs	I-PROC
taken	O	O
before	O	O
(	O	O
baseline	O
)	O	O
and	O	O
1	O	O
year	O
after	O	O
(	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
)	O	O
THA	B-PROC
.	O	O

Functional	B-DEVI
instruments	I-DEVI
were	O	O
completed	O	O
by	O	O
patients	B-LIVB
including	O	O
:	O	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
(	O	O
VAS	B-PROC
)	O	O
for	O	O
LBP	B-DISO
,	O	O
Roland	O
-	O
Morris	O
Disability	O
Questionnaire	O
(	O	O
RMDQ	O
)	O	O
,	O	O
and	O	O
Harris	B-DISO
Hip	I-DISO
Score	I-DISO
(	O	O
HHS	B-DISO
)	O	O
.	O	O

Comparisons	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
baseline	O
and	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
and	O	O
between	O	O
patients	B-LIVB
with	O	O
and	O	O
without	O	O
LBP	B-DISO
.	O	O

The	O	O
recruited	O	O
69	O	O
patients	B-LIVB
showed	O	O
significantly	O
reduced	O
hip	B-DISO
flexion	I-DISO
and	O	O
improved	O	O
global	B-DISO
spinal	I-DISO
balance	I-DISO
at	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
compared	O	O
with	O	O
baseline	O
.	O	O

LBP	B-DISO
was	O	O
reported	O	O
by	O	O
39	O	O
patients	B-LIVB
(	O	O
56	O	O
.	O	O
5	O	O
%	O	O
)	O	O
before	O	O
surgery	O
;	O	O
at	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
17	O	O
reported	O	O
complete	O	O
resolution	O
,	O	O
while	O	O
22	O	O
reported	O	O
significant	O	O
relief	B-DISO
.	O	O

Significant	O	O
decreases	O
in	O	O
VAS	B-PHYS
and	O	O
RMDQ	O
scores	O
in	O	O
lumbar	B-ANAT
spine	I-ANAT
and	O	O
increase	O	O
in	O	O
hip	B-ANAT
HHS	B-DISO
were	O	O
observed	O	O
.	O	O

THA	B-PROC
in	O	O
patients	B-LIVB
with	O	O
severe	O
hip	B-DISO
OA	I-DISO
could	O	O
help	O	O
correct	O	O
abnormal	O	O
sagittal	B-ANAT
spinal	O
-	O	O
pelvic	B-ANAT
-	I-ANAT
leg	I-ANAT
alignment	B-DISO
and	O	O
relieve	O	O
comorbid	B-DISO
LBP	B-DISO
.	O	O

Improvements	O	O
in	O	O
hip	B-DISO
flexion	I-DISO
and	O	O
global	O
spinal	O
balance	B-PHYS
might	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
mechanism	O	O
of	O	O
LBP	B-DISO
relief	B-DISO
.	O	O

Beyond	O	O
neutral	O
and	O	O
forbidden	O
links	O
:	O	O
morphological	O
matches	O
and	O	O
the	O	O
assembly	O
of	O	O
mutualistic	B-PHEN
hawkmoth	O
-	O	O
plant	B-LIVB
networks	O
A	O	O
major	O	O
challenge	O	O
in	O	O
evolutionary	O
ecology	O
is	O	O
to	O	O
understand	O	O
how	O	O
co	B-PHEN
-	I-PHEN
evolutionary	I-PHEN
processes	I-PHEN
shape	O	O
patterns	O
of	O	O
interactions	O
between	O	O
species	O
at	O	O
community	B-LIVB
level	O
.	O	O

Pollination	B-PHYS
of	O	O
flowers	B-LIVB
with	O	O
long	B-LIVB
corolla	I-LIVB
tubes	I-LIVB
by	O	O
long	O
-	O
tongued	O
hawkmoths	O
has	O	O
been	O	O
invoked	O	O
as	O	O
a	O	O
showcase	O	O
model	B-DEVI
of	O	O
co	B-PHYS
-	I-PHYS
evolution	I-PHYS
.	O	O

Recently	O	O
,	O	O
optimal	O	O
foraging	O	O
models	B-DEVI
have	O	O
predicted	O	O
that	O	O
there	O	O
might	O	O
be	O	O
a	O	O
close	O	O
association	O
between	O	O
mouthparts	O
'	O
length	O
and	O	O
the	O	O
corolla	B-LIVB
depth	O
of	O	O
the	O	O
visited	O	O
flowers	B-LIVB
,	O	O
thus	O	O
favouring	O	O
trait	B-PHYS
convergence	O
and	O	O
specialization	O
at	O	O
community	B-LIVB
level	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
assessed	O
whether	O	O
hawkmoths	O
more	O	O
frequently	O	O
pollinate	B-LIVB
plants	I-LIVB
with	O	O
floral	O
tube	O
lengths	O
similar	O	O
to	O	O
their	O	O
proboscis	O
lengths	O
(	O	O
morphological	O
match	O
hypothesis	O
)	O	O
against	O	O
abundance	O
-based	O	O
processes	B-PHEN
(	O	O
neutral	O
hypothesis	O
)	O	O
and	O	O
ecological	B-PHYS
trait	I-PHYS
mismatches	O
constraints	O
(	O	O
forbidden	O
links	O
hypothesis	O
)	O	O
,	O	O
and	O	O
how	O	O
these	O	O
processes	B-PHEN
structure	O
hawkmoth	O
-	O	O
plant	B-LIVB
mutualistic	O
networks	O
from	O	O
five	O	O
communities	B-LIVB
in	O	O
four	O	O
biogeographical	B-GEOG
regions	I-GEOG
of	O	O
South	B-GEOG
America	I-GEOG
.	O	O

We	O	O
found	O	O
convergence	O
in	O	O
morphological	O
traits	B-PHYS
across	O	O
the	O	O
five	O	O
communities	B-LIVB
and	O	O
that	O	O
the	O	O
distribution	O
of	O	O
morphological	O
differences	O	O
between	O	O
hawkmoths	O
and	O	O
plants	B-LIVB
is	O	O
consistent	O	O
with	O	O
expectations	O	O
under	O	O
the	O	O
morphological	O
match	O
hypothesis	O
in	O	O
three	O	O
of	O	O
the	O	O
five	O	O
communities	B-LIVB
.	O	O

In	O	O
the	O	O
two	O	O
remaining	O	O
communities	B-LIVB
,	O	O
which	O	O
are	O	O
ecotones	O	O
between	O	O
two	O	O
distinct	O	O
biogeographical	B-GEOG
areas	I-GEOG
,	O	O
interactions	O
are	O	O
better	O	O
predicted	O	O
by	O	O
the	O	O
neutral	O
hypothesis	O
.	O	O

Our	O	O
findings	O
are	O	O
consistent	O	O
with	O	O
the	O	O
idea	O	O
that	O	O
diffuse	O	O
co	B-PHYS
-	I-PHYS
evolution	I-PHYS
drives	O	O
the	O	O
evolution	B-PHYS
of	O	O
extremely	O	O
long	O
proboscises	O
and	O	O
flower	B-LIVB
tubes	I-LIVB
,	O	O
and	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
morphological	O
traits	B-PHYS
,	O	O
beyond	O	O
the	O	O
forbidden	O
links	O
hypothesis	O
,	O	O
in	O	O
structuring	O	O
interactions	O
between	O	O
mutualistic	O
partners	O
,	O	O
revealing	O	O
that	O	O
the	O	O
role	O
of	O	O
niche	B-PHEN
-	I-PHEN
based	I-PHEN
processes	I-PHEN
can	O	O
be	O	O
much	O	O
more	O	O
complex	O	O
than	O	O
previously	O	O
known	O	O
.	O	O

Impact	O	O
of	O	O
totally	O	O
laparoscopic	B-PROC
combined	O	O
management	O	O
of	O	O
colorectal	B-DISO
cancer	I-DISO
with	O	O
synchronous	O
hepatic	B-DISO
metastases	I-DISO
on	O	O
severity	O	O
of	O	O
complications	O	O
:	O	O
a	O	O
propensity	O
-	O
score	O
-based	O	O
analysis	B-PROC
Thanks	O	O
to	O	O
widespread	O	O
diffusion	O	O
of	O	O
minimally	B-PROC
invasive	I-PROC
approach	I-PROC
in	O	O
the	O	O
setting	O	O
of	O	O
both	O	O
colorectal	B-PROC
and	O	O
hepatic	B-PROC
surgeries	I-PROC
,	O	O
the	O	O
interest	O	O
in	O	O
combined	O	O
resections	O	O
for	O	O
colorectal	B-DISO
cancer	I-DISO
and	O	O
synchronous	O
liver	B-DISO
metastases	I-DISO
(	O	O
SCLM	B-DISO
)	O	O
by	O	O
totally	B-PROC
laparoscopic	I-PROC
approach	I-PROC
(	O	O
TLA	B-PROC
)	O	O
has	O	O
increased	O	O
.	O	O

Aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
outcome	O	O
of	O	O
combined	O	O
resections	O	O
for	O	O
SCLM	B-DISO
performed	O	O
by	O	O
TLA	B-PROC
or	O	O
by	O	O
open	O	O
approach	O	O
,	O	O
in	O	O
a	O	O
propensity	B-PROC
-	I-PROC
score	I-PROC
-	I-PROC
based	I-PROC
study	I-PROC
.	O	O

All	O	O
25	O	O
patients	B-LIVB
undergoing	O	O
combined	O	O
TLA	B-PROC
for	O	O
SCLM	B-DISO
at	O	O
San	B-OBJC
Raffaele	I-OBJC
Hospital	I-OBJC
in	O	O
Milano	O	O
were	O	O
compared	O	O
in	O	O
a	O	O
case	B-PROC
-	I-PROC
matched	I-PROC
analysis	I-PROC
with	O	O
25	O	O
out	O	O
of	O	O
91	O	O
patients	B-LIVB
undergoing	O	O
totally	B-PROC
open	I-PROC
approach	I-PROC
(	O	O
TOA	B-LIVB
group	I-LIVB
)	O	O
.	O	O

Groups	B-LIVB
were	O	O
matched	O	O
with	O	O
1	O	O
:	O	O
2	O	O
ratio	O	O
using	O	O
propensity	O	O
scores	O	O
based	O	O
on	O	O
covariates	O	O
representing	O	O
disease	O	O
severity	O	O
.	O	O

Main	O	O
endpoints	O	O
were	O	O
postoperative	O
morbidity	O
and	O	O
long	O
-	O
term	O
outcome	O
.	O	O

The	O	O
Modified	B-PROC
Accordion	I-PROC
Severity	I-PROC
Grading	I-PROC
System	I-PROC
was	O	O
used	O	O
to	O	O
quantify	O	O
complications	O	O
.	O	O

The	O	O
groups	O	O
resulted	O	O
comparable	O	O
in	O	O
terms	O	O
of	O	O
patients	B-LIVB
and	O	O
disease	B-DISO
characteristics	I-DISO
.	O	O

The	O	O
TLA	B-LIVB
group	I-LIVB
,	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
TOA	B-LIVB
group	I-LIVB
,	O	O
had	O	O
lower	O	O
blood	B-DISO
loss	I-DISO
(	O	O
350	O	O
vs	O	O
600	O	O
mL	O	O
)	O	O
,	O	O
shorter	O	O
postoperative	O
stay	O	O
(	O	O
9	O	O
vs	O	O
12	O	O
days	O	O
)	O	O
,	O	O
lower	O	O
postoperative	O
morbidity	O
index	O
(	O	O
0	O	O
.	O	O
14	O	O
vs	O	O
0	O	O
.	O	O

20	O	O
)	O	O
and	O	O
severity	O
score	O
for	O	O
complicated	O	O
patients	B-LIVB
(	O	O
0	O	O
.	O	O
60	O	O
vs	O	O
0	O	O
.	O	O
85	O	O
)	O	O
.	O	O

Colonic	B-PROC
anastomosis	I-PROC
leakage	B-DISO
had	O	O
the	O	O
highest	O	O
fractional	O	O
complication	O	O
burden	O	O
in	O	O
both	O	O
groups	B-LIVB
.	O	O

In	O	O
spite	O	O
of	O	O
comparable	O	O
long	O	O
-	O	O
term	O	O
overall	O	O
survival	O	O
,	O	O
the	O	O
TLA	B-LIVB
group	I-LIVB
had	O	O
better	O	O
recurrence	B-DISO
-	I-DISO
free	I-DISO
survival	I-DISO
.	O	O

TLA	B-PROC
for	O	O
combined	O	O
resections	O	O
is	O	O
feasible	O	O
,	O	O
and	O	O
its	O	O
indications	O	O
can	O	O
be	O	O
widened	O	O
to	O	O
encompass	O	O
a	O	O
larger	O	O
population	O	O
of	O	O
patients	B-LIVB
,	O	O
provided	O	O
its	O	O
benefits	O	O
in	O	O
terms	O	O
of	O	O
reduced	O	O
overall	O	O
risk	O
and	O	O
severity	O
of	O	O
complications	O	O
,	O	O
rapid	O	O
functional	B-DISO
recovery	I-DISO
and	O	O
favorable	O	O
long	O
-	O
term	O
outcomes	O
.	O	O

Application	O
of	O	O
an	O	O
Analytical	O
Solution	O
as	O	O
a	O	O
Screening	B-PROC
Tool	O
for	O	O
Sea	B-OBJC
Water	I-OBJC
Intrusion	B-PHEN
Sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
into	O	O
aquifers	B-PHEN
is	O	O
problematic	B-DISO
in	O	O
many	O	O
coastal	O
areas	O
.	O	O

The	O	O
physics	O
and	O	O
chemistry	O
of	O	O
this	O	O
issue	O	O
are	O	O
complex	O
,	O	O
and	O	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
remains	O	O
challenging	O	O
to	O	O
quantify	O
.	O	O

Simple	O	O
assessment	O
tools	O
like	O	O
analytical	O
models	O
offer	O	O
advantages	O	O
of	O	O
rapid	O	O
application	O
,	O	O
but	O	O
their	O	O
applicability	O	O
to	O	O
field	O	O
situations	O	O
is	O	O
unclear	O	O
.	O	O

This	O	O
study	B-PROC
examines	O	O
the	O	O
reliability	O	O
of	O	O
a	O	O
popular	O	O
sharp	O
-	O
interface	O
analytical	O
approach	O
for	O	O
estimating	O
the	O	O
extent	O	O
of	O	O
sea	B-OBJC
water	I-OBJC
in	O	O
a	O	O
homogeneous	O
coastal	O
aquifer	B-PHEN
subjected	O	O
to	O	O
pumping	O
and	O	O
regional	B-PHEN
flow	I-PHEN
effects	O
and	O	O
under	O	O
steady	B-PHEN
-	I-PHEN
state	I-PHEN
conditions	I-PHEN
.	O	O

The	O	O
analytical	O
model	O
is	O	O
tested	O
against	O	O
observations	O
from	O	O
Canada	B-GEOG
,	O	O
the	O	O
United	B-GEOG
States	I-GEOG
,	O	O
and	O	O
Australia	B-GEOG
to	O	O
assess	B-PROC
its	O	O
utility	O	O
as	O	O
an	O	O
initial	O
approximation	B-PROC
of	O	O
sea	B-OBJC
water	I-OBJC
extent	O	O
for	O	O
the	O	O
purposes	O	O
of	O	O
rapid	O	O
groundwater	O
management	O
decision	B-PHYS
making	I-PHYS
.	O	O

The	O	O
occurrence	O
of	O	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
resulting	O	O
in	O	O
increased	O
salinity	B-PHEN
at	O	O
pumping	B-OBJC
wells	I-OBJC
was	O	O
correctly	O	O
predicted	O	O
in	O	O
approximately	O
60	O	O
%	O	O
of	O	O
cases	O
.	O	O

Application	O
of	O	O
a	O	O
correction	O
to	O	O
account	O	O
for	O	O
dispersion	O
did	O	O
not	O	O
markedly	O	O
improve	B-DISO
the	O	O
results	O
.	O	O

Failure	O
of	O	O
the	O	O
analytical	O
model	O
to	O	O
provide	O	O
correct	O
predictions	O
can	O	O
be	O	O
attributed	O	O
to	O	O
mismatches	O
between	O	O
its	O	O
simplifying	O	O
assumptions	O	O
and	O	O
more	O	O
complex	O	O
field	O	O
settings	O	O
.	O	O

The	O	O
best	O	O
results	O
occurred	O	O
where	O	O
the	O	O
toe	O	O
of	O	O
the	O	O
salt	B-CHEM
water	I-CHEM
wedge	O
is	O	O
expected	O	O
to	O	O
be	O	O
the	O	O
closest	O	O
to	O	O
the	O	O
coast	B-GEOG
under	O	O
predevelopment	O
conditions	O
.	O	O

Predictions	O
were	O	O
the	O	O
poorest	O	O
for	O	O
aquifers	B-PHEN
where	O	O
the	O	O
salt	B-CHEM
water	I-CHEM
wedge	O
was	O	O
expected	O	O
to	O	O
extend	O	O
further	O	O
inland	B-GEOG
under	O	O
predevelopment	O
conditions	O
and	O	O
was	O	O
therefore	O	O
more	O	O
dispersive	O	O
prior	O	O
to	O	O
pumping	O
.	O	O

Sharp	O
-	O
interface	O
solutions	O
remain	O	O
useful	O	O
tools	O
to	O	O
screen	B-PROC
for	O	O
the	O	O
vulnerability	B-DISO
of	O	O
coastal	O
aquifers	B-PHEN
to	O	O
sea	B-OBJC
water	I-OBJC
intrusion	B-PHEN
,	O	O
although	O	O
the	O	O
significant	O	O
sources	O	O
of	O	O
uncertainty	O	O
identified	O	O
in	O	O
this	O	O
study	B-PROC
require	O	O
careful	O	O
consideration	O	O
to	O	O
avoid	O	O
misinterpreting	O	O
sharp	O
-	O
interface	O
results	O
.	O	O

Patient	B-LIVB
-	O	O
Physician	B-LIVB
Discordance	O
in	O	O
Global	B-PROC
Assessment	I-PROC
in	O	O
Rheumatoid	B-DISO
Arthritis	I-DISO
:	O	O
A	O	O
Systematic	O
Literature	O
Review	O
With	O	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
The	O	O
integration	O	O
of	O	O
the	O	O
patient	B-LIVB
in	O	O
therapeutic	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
is	O	O
important	O	O
in	O	O
the	O	O
management	B-PROC
of	O	O
rheumatoid	B-DISO
arthritis	I-DISO
(	O	O
RA	B-DISO
)	O	O
,	O	O
but	O	O
the	O	O
patient	B-LIVB
opinion	B-PHYS
regarding	O	O
disease	B-DISO
status	O
may	O	O
differ	O	O
from	O	O
the	O	O
physician	B-LIVB
's	I-LIVB
opinion	B-PHYS
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
assess	O
in	O	O
the	O	O
published	O
literature	O
the	O	O
frequency	O
and	O	O
drivers	O	O
of	O	O
patient	B-LIVB
-	O	O
physician	B-LIVB
discordance	O
in	O	O
global	B-PROC
assessment	I-PROC
in	O	O
RA	B-DISO
.	O	O

A	O	O
systematic	O
literature	O
review	O
of	O	O
all	O	O
articles	O
published	O
up	O	O
to	O	O
January	O	O
2015	O	O
in	O	O
Medline	O
or	O	O
Embase	O
,	O	O
reporting	O	O
discordance	O
in	O	O
RA	B-DISO
,	O	O
was	O	O
conducted	O	O
by	O	O
2	O	O
investigators	B-LIVB
.	O	O

Discordance	O
was	O	O
defined	O	O
based	O	O
on	O	O
the	O	O
absolute	O
difference	O
of	O	O
patient	O
global	O
(	O	O
PGA	O
)	O	O
and	O	O
physician	B-PROC
global	I-PROC
assessments	I-PROC
(	O	O
PhGA	B-PROC
)	O	O
on	O	O
0	O	O
-	O	O
10	O	O
-	O	O
cm	O	O
scales	O	O
.	O	O

The	O	O
frequency	O
of	O	O
discordance	O
and	O	O
its	O	O
predictors	B-DISO
were	O	O
collected	O	O
in	O	O
each	O	O
study	B-PROC
.	O	O

Frequencies	O
of	O	O
discordance	O
were	O	O
pooled	O
by	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
using	O	O
random	O
effect	O
.	O	O

In	O	O
all	O	O
,	O	O
12	O	O
studies	B-PROC
were	O	O
selected	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
11	O	O
,	O	O
879	O	O
patients	B-LIVB
)	O	O
:	O	O
weighted	O
mean	O
±	O	O
SD	O	O
age	B-PHYS
was	O	O
55	O	O
.	O	O
1	O	O
±	O	O
13	O	O
.	O	O
9	O	O
years	O
,	O	O
weighted	O
mean	O
±	O	O
SD	O	O
disease	O
duration	O
was	O	O
10	O	O
.	O	O
4	O	O
±	O	O
9	O	O
.	O	O

3	O	O
years	O
,	O	O
and	O	O
80	O	O
.	O	O

7	O	O
%	O	O
were	O	O
women	B-LIVB
.	O	O

The	O	O
value	O
of	O	O
the	O	O
difference	O
|	O	O
PGA	O
-	O	O
PhGA	B-PROC
|	O	O
defining	O	O
discordance	O
varied	O	O
between	O	O
≥0	O	O
.	O	O

5	O	O
cm	O	O
(	O	O
n	O	O
=	O	O
2	O	O
studies	O	O
)	O	O
to	O	O
≥3	O	O
cm	O	O
(	O	O
n	O	O
=	O	O
5	O	O
studies	O	O
)	O	O
;	O	O
the	O	O
weighted	O
mean	O
value	O
was	O	O
2	O	O
.	O	O
7	O	O
cm	O	O
.	O	O

The	O	O
pooled	O
percentage	O
of	O	O
patients	B-LIVB
with	O	O
discordance	O
was	O	O
43	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
36	O	O
%	O	O
-	O	O
51	O	O
%	O	O
;	O	O
range	O
25	O	O
%	O	O
-	O	O
76	O	O
%	O	O
)	O	O
.	O	O

PGA	O
was	O	O
usually	O	O
higher	O
than	O	O
PhGA	B-PROC
.	O	O

The	O	O
drivers	O	O
of	O	O
PGA	O
were	O	O
pain	B-DISO
and	O	O
functional	O
incapacity	B-PHYS
,	O	O
whereas	O	O
drivers	O	O
of	O	O
PhGA	B-PROC
were	O	O
joint	O
counts	O
and	O	O
acute	B-CHEM
-	I-CHEM
phase	I-CHEM
reactants	I-CHEM
.	O	O

Discordance	O
in	O	O
global	B-PROC
assessment	I-PROC
was	O	O
most	O	O
frequently	O
defined	O	O
as	O	O
a	O	O
difference	O
of	O	O
3	O	O
points	O	O
or	O	O
more	O	O
;	O	O
even	O	O
with	O	O
such	O	O
a	O	O
stringent	O	O
definition	O	O
,	O	O
up	O	O
to	O	O
half	O
the	O	O
patients	B-LIVB
were	O	O
found	O	O
to	O	O
be	O	O
discordant	O
.	O	O

The	O	O
long	O
-	O
term	O
consequences	O
of	O	O
this	O	O
discordance	O
remain	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

Nosocomial	B-DISO
pneumonia	I-DISO
caused	O	O
by	O	O
methicillin	B-LIVB
-	I-LIVB
resistant	I-LIVB
Staphylococcus	I-LIVB
aureus	I-LIVB
treated	B-PROC
with	I-PROC
linezolid	B-CHEM
or	O	O
vancomycin	B-CHEM
:	O	O
A	O	O
secondary	O	O
economic	O
analysis	O
of	O	O
resource	O
use	O
from	O	O
a	O	O
Spanish	B-GEOG
perspective	O
Adopting	O	O
a	O	O
unique	O	O
Spanish	B-GEOG
perspective	O
,	O	O
this	O	O
study	B-PROC
aims	O	O
to	O	O
assess	O	O
healthcare	O
resource	O
utilization	O
(	O	O
HCRU	O
)	O	O
and	O	O
the	O	O
costs	O
of	O	O
treating	O
nosocomial	B-DISO
pneumonia	I-DISO
(	O	O
NP	B-DISO
)	O	O
produced	O	O
by	O	O
methicillin	B-LIVB
-	I-LIVB
resistant	I-LIVB
Staphylococcus	I-LIVB
aureus	I-LIVB
(	O	O
MRSA	B-LIVB
)	O	O
in	O	O
hospitalized	B-DISO
adults	I-DISO
using	O	O
linezolid	B-CHEM
or	O	O
vancomycin	B-CHEM
.	O	O

An	O	O
evaluation	O	O
is	O	O
also	O	O
made	O	O
of	O	O
the	O	O
renal	B-DISO
failure	I-DISO
rate	O
and	O	O
related	O	O
economic	O
outcomes	O
between	O	O
study	O
groups	O
.	O	O

An	O	O
economic	O	O
post	B-PROC
hoc	I-PROC
evaluation	I-PROC
of	O	O
a	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
multicenter	B-PROC
phase	I-PROC
4	I-PROC
study	I-PROC
was	O	O
carried	O	O
out	O	O
.	O	O

Nosocomial	B-DISO
pneumonia	I-DISO
due	O	O
to	O	O
MRSA	B-LIVB
in	O	O
hospitalized	B-DISO
adults	I-DISO
.	O	O

The	O	O
modified	O
intent	O
to	O
treat	O
(	O	O
mITT	O
)	O	O
population	B-LIVB
comprised	O	O
224	O	O
linezolid	B-CHEM
-	O	O
and	O	O
224	O	O
vancomycin	B-CHEM
-	O	O
treated	B-PROC
patients	B-LIVB
.	O	O

Costs	O
and	O	O
HCRU	O
were	O	O
evaluated	O	O
between	O	O
patients	B-LIVB
administered	O
either	O	O
linezolid	B-CHEM
or	O	O
vancomycin	B-CHEM
,	O	O
and	O	O
between	O	O
patients	B-LIVB
who	O	O
developed	O	O
renal	B-DISO
failure	I-DISO
and	O	O
those	O	O
who	O	O
did	O	O
not	O	O
.	O	O

Analysis	O	O
of	O	O
HCRU	O
outcomes	O
and	O	O
costs	O
.	O	O

Total	O	O
costs	O
were	O	O
similar	O	O
between	O	O
the	O	O
linezolid	B-CHEM
-	O	O
(	O	O
€	O	O
17	O	O
,	O	O
782±€9	O	O
,	O	O
615	O	O
)	O	O
and	O	O
vancomycin	B-CHEM
-	O	O
treated	B-PROC
patients	B-LIVB
(	O	O
€	O	O
17	O	O
,	O	O
423±€9	O	O
,	O	O
460	O	O
)	O	O
(	O	O
P	O	O
=	O	O
.	O	O

69	O	O
)	O	O
.	O	O

The	O	O
renal	B-DISO
failure	I-DISO
rate	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
linezolid	B-CHEM
-	O	O
treated	B-PROC
patients	B-LIVB
(	O	O
4	O	O
%	O	O
vs	O	O
.	O	O

15	O	O
%	O	O
;	O	O
P	O	O
<	O	O
.	O	O
001	O	O
)	O	O
.	O	O

The	O	O
total	O	O
costs	O
tended	O	O
to	O	O
be	O	O
higher	O	O
in	O	O
patients	B-LIVB
who	O	O
developed	O	O
renal	B-DISO
failure	I-DISO
(	O	O
€	O	O
19	O	O
,	O	O
626±€10	O	O
,	O	O
840	O	O
vs	O	O
.	O	O

€	O	O
17	O	O
,	O	O
388±€9	O	O
,	O	O
369	O	O
;	O	O
P	O	O
=	O	O
.	O	O

14	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
patients	B-LIVB
who	O	O
developed	O	O
renal	B-DISO
failure	I-DISO
,	O	O
HCRU	O
(	O	O
days	O
on	O	O
mechanical	B-PROC
ventilation	I-PROC
:	O	O
13	O	O
.	O	O

2±10	O	O
.	O	O

7	O	O
vs	O	O
.	O	O

7	O	O
.	O	O

6±3	O	O
.	O	O

6	O	O
days	O
;	O	O
P	O	O
=	O	O
.	O	O

21	O	O
;	O	O
ICU	O
stay	O
:	O	O
14	O	O
.	O	O

4±10	O	O
.	O	O

5	O	O
vs	O	O
.	O	O
9	O	O
.	O	O

9±6	O	O
.	O	O

6	O	O
days	O
;	O	O
P	O	O
=	O	O
.	O	O

30	O	O
;	O	O
hospital	O
stay	O
:	O	O
19	O	O
.	O	O

5±9	O	O
.	O	O

5	O	O
vs	O	O
.	O	O
16	O	O
.	O	O

1±11	O	O
.	O	O
0	O	O
days	O
;	O	O
P	O	O
=	O	O
.	O	O

26	O	O
)	O	O
and	O	O
cost	O
(	O	O
€	O	O
17	O	O
,	O	O
219±€8	O	O
,	O	O
792	O	O
vs	O	O
.	O	O

€	O	O
20	O	O
,	O	O
263±€11	O	O
,	O	O
350	O	O
;	O	O
P	O	O
=	O	O
.	O	O

51	O	O
)	O	O
tended	O	O
to	O	O
be	O	O
lower	O	O
in	O	O
the	O	O
linezolid	B-CHEM
-	O	O
vs	O	O
.	O	O

vancomycin	B-CHEM
-	O	O
treated	B-PROC
patients	B-LIVB
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
costs	O
per	O	O
patient	B-LIVB
-	O	O
day	O
between	O	O
cohorts	B-LIVB
after	O	O
correcting	O	O
for	O	O
mortality	O
(	O	O
€	O	O
1000	O	O
vs	O	O
.	O	O

€	O	O
1	O	O
,	O	O
010	O	O
;	O	O
P	O	O
=	O	O
.	O	O

98	O	O
)	O	O
.	O	O

From	O	O
a	O	O
Spanish	B-GEOG
perspective	O
,	O	O
there	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
total	O	O
costs	O
between	O	O
the	O	O
linezolid	B-CHEM
and	O	O
vancomycin	B-CHEM
pneumonia	B-DISO
cohorts	B-LIVB
.	O	O

The	O	O
drug	O
cost	O
corresponding	O	O
to	O	O
linezolid	B-CHEM
was	O	O
partially	O	O
offset	O
by	O	O
fewer	O	O
renal	B-DISO
failure	I-DISO
adverse	B-DISO
events	I-DISO
.	O	O

The	O	O
Role	O	O
of	O	O
TRAF4	O
and	O	O
B3GAT1	O
Gene	B-PHYS
Expression	I-PHYS
in	O	O
the	O	O
Food	B-DISO
Hypersensitivity	I-DISO
and	O	O
Insect	B-DISO
Venom	I-DISO
Allergy	I-DISO
in	O	O
Mastocytosis	B-DISO
Mastocytosis	B-DISO
is	O	O
an	O	O
uncommon	O	O
disease	B-DISO
classified	O	O
as	O	O
a	O	O
myeloproliferative	B-DISO
neoplasm	I-DISO
,	O	O
however	O	O
,	O	O
its	O	O
symptoms	B-DISO
are	O	O
broad	O	O
and	O	O
place	O	O
patients	B-LIVB
at	O	O
crossroads	O	O
between	O	O
dermatology	O
,	O	O
hematology	O
and	O	O
allergology	O	O
.	O	O

Patients	B-LIVB
with	O	O
mastocytosis	B-DISO
often	O	O
suffer	O	O
from	O	O
symptoms	B-DISO
resulting	O	O
from	O	O
the	O	O
activation	O
and	O	O
release	O	O
of	O	O
mediators	O	O
from	O	O
the	O	O
mast	B-ANAT
cells	I-ANAT
,	O	O
such	O	O
as	O	O
generalized	O	O
itching	B-DISO
,	O	O
redness	B-DISO
,	O	O
headache	B-DISO
,	O	O
abdominal	B-DISO
cramps	I-DISO
,	O	O
diarrhea	B-DISO
,	O	O
bone	B-DISO
pain	I-DISO
or	O	O
arthritis	B-DISO
,	O	O
hypotension	B-DISO
and	O	O
shock	B-DISO
.	O	O

The	O	O
possible	O	O
severe	O	O
,	O	O
fatal	O
or	O	O
near	O	O
fatal	O
reactions	O	O
caused	O	O
by	O	O
food	B-DISO
hypersensitivity	I-DISO
are	O	O
reasons	O	O
for	O	O
the	O	O
research	O	O
focused	O	O
on	O	O
marker	B-PHYS
identification	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	B-PROC
was	O	O
to	O	O
analyse	O	O
the	O	O
gene	B-PHYS
expression	I-PHYS
differences	O	O
in	O	O
mastocytosis	B-DISO
patients	B-LIVB
with	O	O
and	O	O
without	O	O
food	B-DISO
and	O	O
drug	B-DISO
hypersensitivity	I-DISO
and	O	O
insect	B-DISO
venom	I-DISO
allergy	I-DISO
(	O	O
IVA	B-DISO
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
57	O	O
Caucasian	B-LIVB
patients	B-LIVB
with	O	O
mastocytosis	B-DISO
were	O	O
studied	O	O
[	O	O
median	O	O
age	B-PHYS
41	O	O
.	O	O
8	O	O
;	O	O
range	O	O
18	O	O
-	O	O
77	O	O
years	O
;	O	O
15	O	O
(	O	O
26	O	O
.	O	O
3	O	O
%	O	O
)	O	O
males	B-PHYS
and	O	O
42	O	O
(	O	O
73	O	O
.	O	O
7	O	O
%	O	O
)	O	O
females	B-PHYS
]	O	O
.	O	O

Quantitative	B-PROC
RT	I-PROC
-	I-PROC
PCRs	I-PROC
of	O	O
11	O	O
genes	O
plus	O	O
ribosomal	B-CHEM
18S	I-CHEM
RNA	I-CHEM
were	O	O
run	O	O
.	O	O

Symptoms	B-DISO
of	O	O
food	B-DISO
hypersensitivity	I-DISO
were	O	O
found	O	O
in	O	O
12	O	O
patients	B-LIVB
(	O	O
21	O	O
%	O	O
)	O	O
,	O	O
including	O	O
3	O	O
patients	B-LIVB
(	O	O
13	O	O
%	O	O
)	O	O
with	O	O
cutaneous	B-DISO
mastocytosis	I-DISO
(	O	O
CM	B-DISO
)	O	O
,	O	O
and	O	O
9	O	O
(	O	O
28	O	O
%	O	O
)	O	O
with	O	O
indolent	B-DISO
systemic	I-DISO
mastocytosis	I-DISO
(	O	O
ISM	B-DISO
)	O	O
.	O	O

IVA	B-DISO
was	O	O
confirmed	O	O
in	O	O
13	O	O
patients	B-LIVB
(	O	O
22	O	O
.	O	O
8	O	O
%	O	O
)	O	O
including	O	O
6	O	O
patients	B-LIVB
(	O	O
10	O	O
.	O	O
5	O	O
%	O	O
)	O	O
with	O	O
CM	B-DISO
,	O	O
and	O	O
7	O	O
patients	B-LIVB
(	O	O
12	O	O
.	O	O

3	O	O
%	O	O
)	O	O
with	O	O
ISM	B-DISO
.	O	O

Drug	B-DISO
hypersensitivity	I-DISO
was	O	O
diagnosed	B-DISO
in	O	O
10	O	O
patients	B-LIVB
(	O	O
17	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Significant	O	O
differences	O	O
in	O	O
the	O	O
gene	B-PHYS
expression	I-PHYS
were	O	O
found	O	O
for	O	O
TRAF4	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
008	O	O
)	O	O
in	O	O
the	O	O
comparison	O	O
of	O	O
the	O	O
mastocytosis	B-DISO
patients	B-LIVB
with	O	O
and	O	O
without	O	O
concomitant	O	O
food	B-DISO
hypersensitivity	I-DISO
.	O	O

Furthermore	O	O
significant	O	O
differences	O	O
were	O	O
found	O	O
in	O	O
gene	B-PHYS
expression	I-PHYS
for	O	O
B3GAT1	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
)	O	O
in	O	O
patients	B-LIVB
with	O	O
IVA	B-DISO
compared	O	O
to	O	O
patients	B-LIVB
without	O	O
insect	B-DISO
sting	I-DISO
anaphylaxis	B-DISO
in	O	O
the	O	O
medical	O	O
history	O	O
.	O	O

The	O	O
expression	B-PHYS
of	O	O
studied	O	O
genes	O
did	O	O
not	O	O
differ	O	O
according	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
drug	B-DISO
hypersensitivity	I-DISO
.	O	O

The	O	O
TRAF4	O
expression	B-PHYS
was	O	O
higher	O	O
in	O	O
mastocytosis	B-DISO
patients	B-LIVB
with	O	O
food	B-DISO
hypersensitivity	I-DISO
in	O	O
their	O	O
medical	B-DISO
history	I-DISO
,	O	O
the	O	O
B3GAT1	O
expression	B-PHYS
was	O	O
lower	O	O
in	O	O
mastocytosis	B-DISO
patients	B-LIVB
with	O	O
IVA	B-DISO
in	O	O
history	O	O
.	O	O

Generalized	B-DISO
Weakness	I-DISO
in	O	O
a	O	O
Transplant	B-DISO
Patient	B-LIVB
:	O	O
A	O	O
Case	O
Presentation	O
Generalized	B-DISO
weakness	I-DISO
in	O	O
transplant	B-DISO
patients	B-LIVB
is	O	O
a	O	O
major	O	O
complaint	O	O
in	O	O
tertiary	O	O
rehabilitation	B-OBJC
hospitals	I-OBJC
.	O	O

The	O	O
diagnosis	B-DISO
and	O	O
management	B-PROC
of	O	O
generalized	B-DISO
weakness	I-DISO
in	O	O
this	O	O
population	B-LIVB
pose	O	O
challenges	O	O
for	O	O
physicians	B-LIVB
.	O	O

We	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
transplant	B-DISO
patient	B-LIVB
with	O	O
generalized	B-DISO
weakness	I-DISO
who	O	O
was	O	O
eventually	O	O
diagnosed	B-DISO
with	O	O
calciphylaxis	B-DISO
using	O	O
a	O	O
multidisciplinary	B-PROC
diagnostic	I-PROC
approach	I-PROC
of	O	O
electrodiagnostics	B-PROC
,	O	O
vascular	B-ANAT
study	B-PROC
,	O	O
and	O	O
skin	B-PROC
biopsy	I-PROC
.	O	O

Calciphylaxis	B-DISO
is	O	O
a	O	O
rare	O	O
cutaneous	B-DISO
disorder	I-DISO
that	O	O
mimics	O	O
other	O	O
collagen	B-DISO
vascular	I-DISO
diseases	I-DISO
in	O	O
its	O	O
presentation	O	O
and	O	O
fulminant	O	O
course	O	O
.	O	O

Physiatrists	B-LIVB
should	O	O
be	O	O
cognizant	O	O
of	O	O
calciphylaxis	B-DISO
,	O	O
as	O	O
it	O	O
signals	O	O
a	O	O
poor	B-DISO
prognosis	I-DISO
if	O	O
not	O	O
correctly	O
diagnosed	O
and	O	O
treated	O
in	O	O
a	O	O
timely	O
manner	O
,	O	O
with	O	O
high	O	O
incidence	O
of	O	O
sepsis	B-DISO
,	O	O
wound	B-DISO
pain	I-DISO
,	O	O
and	O	O
disability	B-DISO
.	O	O

V	O	O
.	O	O

Use	O	O
of	O	O
ecoacoustics	O
to	O	O
determine	O	O
biodiversity	O
patterns	O
across	O	O
ecological	O
gradients	O
The	O	O
variety	O	O
of	O	O
local	O
animal	B-LIVB
sounds	B-PHEN
characterizes	O
a	O	O
landscape	O
.	O	O

We	O	O
used	O	O
ecoacoustics	O
to	O	O
noninvasively	O	O
assess	O
the	O	O
species	O
richness	O	O
of	O	O
various	O
biotopes	B-GEOG
typical	O	O
of	O	O
an	O	O
ecofriendly	B-PHEN
forest	I-PHEN
plantation	I-PHEN
with	O	O
diverse	O
ecological	O
gradients	O
and	O	O
both	O	O
nonnative	B-DISO
and	O	O
indigenous	O
vegetation	B-LIVB
.	O	O

The	O	O
reference	O
area	B-GEOG
was	O	O
an	O	O
adjacent	O
large	O	O
World	B-GEOG
Heritage	I-GEOG
Site	I-GEOG
protected	I-GEOG
area	I-GEOG
(	O	O
PA	B-GEOG
)	O	O
.	O	O

All	O	O
sites	O
were	O	O
in	O	O
a	O	O
global	B-GEOG
biodiversity	I-GEOG
hotspot	I-GEOG
.	O	O

Our	O	O
results	O
showed	O	O
how	O	O
taxa	O
segregated	O
into	O	O
various	O
biotopes	B-GEOG
.	O	O

We	O	O
identified	O
65	O	O
singing	O
species	O
,	O	O
including	O	O
birds	B-LIVB
,	O	O
frogs	B-LIVB
,	O	O
crickets	O
,	O	O
and	O	O
katydids	O
.	O	O

Large	O
,	O	O
natural	O
,	O	O
protected	O	O
grassland	O
sites	O
in	O	O
the	O	O
PA	B-GEOG
had	O	O
the	O	O
highest	O
mean	O
acoustic	O
diversity	O
(	O	O
14	O	O
.	O	O
1	O	O
species	O
/	O	O
site	O
)	O	O
.	O	O

Areas	O
covered	O	O
in	O	O
nonnative	B-LIVB
timber	I-LIVB
or	O	O
grass	B-LIVB
species	O
were	O	O
devoid	O	O
of	O	O
acoustic	O
species	O
.	O	O

Sites	O
grazed	O	O
by	O	O
native	O
and	O	O
domestic	O
megaherbivores	B-LIVB
were	O	O
fairly	O	O
rich	O	O
(	O	O
5	O	O
.	O	O
1	O	O
)	O	O
in	O	O
acoustic	O
species	O
but	O	O
none	O	O
were	O	O
unique	O
to	O	O
this	O	O
habitat	O
type	O
,	O	O
where	O	O
acoustic	O
diversity	O
was	O	O
greater	O	O
than	O	O
in	O	O
intensively	O	O
managed	O	O
grassland	O
sites	O
(	O	O
0	O	O
.	O	O
04	O	O
)	O	O
.	O	O

Natural	B-PHEN
vegetation	I-PHEN
patches	O	O
inside	O	O
the	O	O
plantation	O
mosaic	O
supported	O	O
high	O	O
mean	O
acoustic	O
diversity	O
(	O	O
indigenous	O
forests	B-PHEN
7	O	O
.	O	O
6	O	O
,	O	O
grasslands	O
8	O	O
.	O	O
0	O	O
,	O	O
wetlands	B-PHEN
9	O	O
.	O	O
1	O	O
)	O	O
,	O	O
which	O	O
increased	O	O
as	O	O
plant	B-LIVB
heterogeneity	O
and	O	O
patch	O
size	O
increased	O
.	O	O

Indigenous	O
forest	B-PHEN
patches	I-PHEN
within	O	O
the	O	O
plantation	O
mosaic	O
contained	O	O
a	O	O
highly	O	O
characteristic	O
acoustic	O
species	O
assemblage	O
,	O	O
emphasizing	O	O
their	O	O
complementary	O	O
contribution	O
to	O	O
local	O
biodiversity	O
.	O	O

Overall	O	O
,	O	O
acoustic	B-PHEN
signals	I-PHEN
determined	O	O
spatial	O	O
biodiversity	O
patterns	O
and	O	O
can	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
for	O	O
guiding	O	O
conservation	O
.	O	O

A	O	O
Randomized	B-PROC
Controlled	I-PROC
Noninferiority	I-PROC
Trial	I-PROC
of	O	O
Single	O
Dose	O
of	O	O
Oral	B-CHEM
Dexamethasone	I-CHEM
Versus	O	O
5	O	O
Days	O
of	O	O
Oral	B-CHEM
Prednisone	I-CHEM
in	O	O
Acute	O	O
Adult	B-LIVB
Asthma	B-DISO
Oral	B-CHEM
dexamethasone	I-CHEM
demonstrates	O
bioavailability	O
similar	O
to	O	O
that	O	O
of	O	O
oral	B-CHEM
prednisone	I-CHEM
but	O	O
has	O	O
a	O	O
longer	O	O
half	O
-	O
life	O
.	O	O

We	O	O
evaluate	O	O
whether	O	O
a	O	O
single	O
dose	O
of	O	O
oral	B-CHEM
dexamethasone	I-CHEM
plus	O
4	O	O
days	O
of	O	O
placebo	B-CHEM
is	O	O
not	O	O
inferior	O
to	O	O
5	O	O
days	O
of	O	O
oral	B-CHEM
prednisone	I-CHEM
in	O	O
treatment	O
of	O	O
adults	B-LIVB
with	O	O
mild	B-DISO
to	O	O
moderate	B-DISO
asthma	B-DISO
exacerbations	I-DISO
to	O	O
prevent	O
relapse	B-PHEN
defined	O	O
as	O	O
an	O	O
unscheduled	O
return	O	O
visit	O	O
for	O	O
additional	B-DISO
treatment	I-DISO
for	O	O
persistent	B-DISO
or	O	O
worsening	O
asthma	B-DISO
within	O	O
14	O	O
days	O
.	O	O

Adult	B-LIVB
emergency	B-OBJC
department	I-OBJC
patients	B-LIVB
(	O	O
aged	B-PHYS
18	O	O
to	O	O
55	O	O
years	O
)	O	O
were	O	O
randomized	B-PROC
to	O	O
receive	O
either	O	O
a	O	O
single	O
dose	O
of	O	O
12	O	O
mg	O	O
of	O	O
oral	B-CHEM
dexamethasone	I-CHEM
with	O	O
4	O	O
days	O
of	O	O
placebo	B-CHEM
or	O	O
a	O	O
5	O	O
-	O	O
day	O
course	O
of	O	O
oral	B-CHEM
prednisone	I-CHEM
60	O	O
mg	O	O
a	O	O
day	O
.	O	O

Outcomes	O
including	O
relapse	B-PHEN
were	O	O
assessed	O
by	O	O
a	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
telephone	I-PROC
interview	I-PROC
at	O	O
2	O	O
weeks	O
.	O	O

One	O	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	B-CHEM
and	O	O
203	O	O
prednisone	B-CHEM
subjects	B-LIVB
completed	O
the	O	O
study	O	O
regimen	O	O
and	O	O
telephone	B-PROC
follow	I-PROC
-	I-PROC
up	I-PROC
.	O	O

The	O	O
dexamethasone	B-CHEM
group	O
by	O	O
a	O	O
small	O	O
margin	O	O
surpassed	O	O
the	O	O
preset	O	O
8	O	O
%	O	O
difference	O
between	O	O
groups	O
for	O	O
noninferiority	O
in	O	O
relapse	B-PHEN
rates	O
within	O	O
14	O	O
days	O
(	O	O
12	O	O
.	O	O

1	O	O
%	O	O
versus	O	O
9	O	O
.	O	O

8	O	O
%	O	O
;	O	O
difference	O
2	O	O
.	O	O

3	O	O
%	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
-4	O	O
.	O	O
1	O	O
%	O	O
to	O	O
8	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

Subjects	B-LIVB
in	O	O
the	O	O
2	O	O
groups	O
had	O	O
similar	O	O
rates	O
of	O	O
hospitalization	B-PROC
for	O	O
their	O	O
relapse	B-PHEN
visit	B-PROC
(	O	O
dexamethasone	B-CHEM
3	O	O
.	O	O
4	O	O
%	O	O
versus	O	O
prednisone	B-CHEM
2	O	O
.	O	O
9	O	O
%	O	O
;	O	O
difference	O
0	O	O
.	O	O
5	O	O
%	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
-4	O	O
.	O	O

1	O	O
%	O	O
to	O	O
3	O	O
.	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Adverse	O
effect	O
rates	O
were	O	O
generally	O	O
the	O	O
same	O	O
in	O	O
the	O	O
2	O	O
groups	O
.	O	O

A	O	O
single	O
dose	O
of	O	O
oral	B-CHEM
dexamethasone	I-CHEM
did	O	O
not	O	O
demonstrate	O
noninferiority	O
to	O	O
prednisone	B-CHEM
for	O	O
5	O	O
days	O
by	O	O
a	O	O
very	O	O
small	O	O
margin	O	O
for	O	O
treatment	O
of	O	O
adults	B-LIVB
with	O	O
mild	B-DISO
to	O	O
moderate	B-DISO
asthma	B-DISO
exacerbations	I-DISO
.	O	O

Enhanced	O
compliance	B-DISO
and	O	O
convenience	O
may	O	O
support	O	O
the	O	O
use	O
of	O	O
dexamethasone	B-CHEM
regardless	O	O
.	O	O

Relationship	O
between	O	O
XspI	B-CHEM
Site	B-DISO
Polymorphisms	I-DISO
of	O	O
LDL	O
-	O
R	O
Gene	O
and	O	O
Serum	B-CHEM
IL	I-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O	O
Patients	B-LIVB
with	O	O
Hypercholesterolemia	B-DISO
Relationship	O
has	O	O
been	O	O
identified	O
in	O	O
sporadic	B-DISO
reports	I-DISO
between	O	O
polymorphisms	B-PHYS
and	O	O
hypercholesterolemia	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
relationship	O
between	O	O
inflammatory	O
cytokines	B-CHEM
and	O	O
polymorphism	B-PHYS
of	O	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDL	O
-	O
R	O
)	O
gene	O
in	O	O
hypercholesterolemia	B-DISO
is	O	O
unclear	B-DISO
.	O	O

This	O	O
study	B-PROC
aimed	O
to	O	O
explore	O	O
the	O	O
relationship	O
and	O	O
significance	O
between	O	O
polymorphisms	B-PHYS
of	O	O
LDL	O
-	O
R	O
gene	O
and	O	O
serum	B-CHEM
Interleukin	I-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
)	O	O
,	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O	O
patients	B-LIVB
with	O	O
hypercholesterolemia	B-DISO
.	O	O

PCR	B-PROC
-	I-PROC
RFLP	I-PROC
and	O	O
direct	B-PROC
DNA	I-PROC
sequencing	I-PROC
assay	I-PROC
were	O	O
employed	B-DISO
to	O	O
determine	O	O
polymorphism	B-PHYS
of	O	O
LDL	O
-	O
R	O
gene	O
in	O	O
900	O	O
patients	B-LIVB
with	O	O
hypercholesterolemia	B-DISO
and	O	O
400	O	O
healthy	O
cases	O
.	O	O

ELISA	B-PROC
was	O	O
applied	O
to	O	O
assay	O
serum	O
concentration	O
of	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
.	O	O

Blood	B-CHEM
lipid	I-CHEM
indexes	O
were	O	O
tested	O
in	O	O
all	O	O
cases	O
.	O	O

Compared	O
with	O	O
the	O	O
healthy	O
controls	O
,	O	O
level	O
of	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
increased	O
significantly	O
,	O	O
while	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
decreased	O
significantly	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Correlation	B-PROC
analysis	I-PROC
showed	O	O
that	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
was	O	O
positively	B-DISO
correlated	O
with	O	O
total	B-CHEM
cholesterol	I-CHEM
(	O	O
TC	B-CHEM
)	O	O
,	O	O
LDL	B-CHEM
-	I-CHEM
c	I-CHEM
,	O	O
and	O	O
genotype	B-PHYS
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

542	O	O
,	O	O
0	O	O
.	O	O
410	O	O
,	O	O
0	O	O
.	O	O
598	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
negatively	B-DISO
correlated	O
with	O	O
HDL	B-CHEM
-	I-CHEM
c	I-CHEM
(	O	O
r	O	O
=	O	O
-0	O	O
.	O	O

352	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Negative	B-DISO
relationship	O
also	O	O
was	O	O
found	O	O
between	O	O
TC	B-CHEM
,	O	O
LDL	B-CHEM
-	I-CHEM
c	I-CHEM
,	O	O
genotype	B-PHYS
,	O	O
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O	O
r	O	O
=	O	O
-0	O	O
.	O	O

452	O	O
,	O	O
-0	O	O
.	O	O
390	O	O
,	O	O
-0	O	O
.	O	O

613	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
positive	B-DISO
correlation	O
between	O	O
HDL	B-CHEM
-	I-CHEM
c	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

398	O	O

,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Multiple	O
linear	O
regression	O
showed	O	O
that	O	O
genotypes	B-PHYS
and	O	O
TC	B-CHEM
were	O	O
independent	O
factors	O
affecting	O
the	O	O
levels	B-PROC
of	I-PROC
IL	I-PROC
-	I-PROC
2	I-PROC
and	O	O
IL	B-PROC
-	I-PROC
10	I-PROC
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

IL	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
were	O	O
related	O
to	O	O
gene	B-PHYS
polymorphisms	I-PHYS
of	O	O
LDL	O
-	O
R	O
,	O	O
which	O	O
might	O	O
be	O	O
involved	O
in	O	O
the	O	O
development	O
and	O	O
progress	O
of	O	O
hypercholesterolemia	B-DISO
.	O	O

HERG1	B-CHEM
potassium	B-CHEM
channel	I-CHEM
expression	B-PHYS
in	O	O
potentially	O
malignant	B-DISO
disorders	I-DISO
of	O	O
the	O	O
oral	B-ANAT
mucosa	I-ANAT
and	O	O
prognostic	O
relevance	O
in	O	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
HERG1	B-CHEM
potassium	B-CHEM
channel	I-CHEM
plays	O	O
a	O	O
critical	O
role	O
in	O	O
the	O	O
cell	B-PHYS
proliferation	I-PHYS
.	O	O

HERG1	B-CHEM
protein	I-CHEM
expression	B-PHYS
was	O	O
analyzed	B-PROC
by	O	O
immunohistochemistry	B-PROC
(	O	O
IHC	B-PROC
)	O	O
in	O	O
62	O	O
patients	B-LIVB
with	O	O
oral	B-DISO
leukoplakias	I-DISO
and	O	O
100	O	O
patients	B-LIVB
with	O	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinomas	I-DISO
(	O	O
OSCC	B-DISO
)	O	O
.	O	O

HERG1	O
mRNA	B-CHEM
levels	O
were	O	O
assessed	O
by	O	O
real	B-PROC
-	I-PROC
time	I-PROC
reverse	I-PROC
transcriptase	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
(	O	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
)	O	O
in	O	O
22	O	O
patients	B-LIVB
with	O	O
primary	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
HNSCC	B-DISO
)	O	O
.	O	O

Statistically	O
significant	O
associations	O
were	O	O
found	O	O
between	O	O
HERG1	B-CHEM
expression	B-PHYS
and	O	O
tobacco	O
consumption	O
,	O	O
disease	B-PROC
stage	I-PROC
,	O	O
tumor	B-DISO
differentiation	B-PHYS
,	O	O
tumor	B-DISO
recurrence	I-DISO
,	O	O
and	O	O
reduced	O
survival	O
.	O	O

There	O	O
was	O	O
no	O
association	O
between	O	O
HERG1	B-CHEM
expression	B-PHYS
and	O	O
the	O	O
risk	O
of	O	O
progression	B-DISO
from	O	O
oral	B-DISO
leukoplakia	I-DISO
to	O	O
OSCC	B-DISO
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
high	O
proportion	O
of	O	O
tumors	B-DISO
(	O	O
80	O	O
%	O	O
)	O	O
showed	O	O
increased	O
HERG1	O
mRNA	B-CHEM
levels	O
compared	O
to	O	O
normal	O
mucosa	O
from	O	O
nononcologic	B-LIVB
patients	I-LIVB
.	O	O

Aberrant	O
HERG1	B-CHEM
expression	B-PHYS
increases	O
as	O	O
oral	O	O
tumorigenesis	B-DISO
progresses	I-DISO
from	O	O
oral	B-DISO
hyperplasia	I-DISO
to	O	O
OSCC	B-DISO
.	O	O

Increased	O
HERG1	O
mRNA	B-CHEM
levels	O
were	O	O
also	O	O
frequently	O	O
detected	B-DISO
in	O	O
OSCC	B-DISO
and	O	O
other	O	O
HNSCC	B-DISO
subsites	O
.	O	O

HERG1	B-CHEM
expression	B-PHYS
emerges	O	O
as	O	O
a	O	O
clinically	O
relevant	O
feature	O
during	O	O
tumor	B-DISO
progression	I-DISO
and	O	O
a	O	O
potential	O
poor	O
prognostic	O
biomarker	B-PHYS
for	O	O
OSCC	B-DISO
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

Head	O	O
Neck	O	O
38	O	O
:	O	O
1708	O	O
-	O	O
1716	O	O
,	O	O
2016	O	O
.	O	O

Malignancy	B-DISO
is	O	O
associated	O
with	O
microcalcification	B-DISO
and	O	O
higher	O
AP	O
/	O
T	O
ratio	O
in	O	O
ultrasonography	B-PROC
,	O	O
but	O	O
not	O	O
with	O	O
Hashimoto	B-DISO
's	I-DISO
thyroiditis	I-DISO
in	O	O
histopathology	B-PROC
in	O	O
patients	B-LIVB
with	O	O
thyroid	B-DISO
nodules	I-DISO
evaluated	O	O
as	O	O
Bethesda	B-DISO
Category	I-DISO
III	I-DISO
(	O	O
AUS	B-DISO
/	O	O
FLUS	B-DISO
)	O	O
in	O	O
cytology	B-PROC
The	O	O
predictors	O
of	O	O
malignancy	B-DISO
are	O	O
important	O	O
for	O	O
the	O	O
decision	O	O
of	O	O
appropriate	O	O
management	B-PROC
in	O	O
nodules	B-DISO
with	O	O
atypia	B-DISO
of	I-DISO
undetermined	I-DISO
significance	I-DISO
/	O	O
follicular	B-DISO
lesion	I-DISO
of	I-DISO
undetermined	I-DISO
significance	I-DISO
(	O	O
AUS	B-DISO
/	O	O
FLUS	B-DISO
)	O	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
ultrasonographical	O
,	O	O
clinical	O
,	O	O
and	O	O
biochemical	O
predictors	O
of	O	O
malignancy	B-DISO
in	O	O
these	O	O
patients	B-LIVB
.	O	O

A	O	O
total	O	O
of	O	O
427	O	O
patients	B-LIVB
with	O	O
cytologically	B-DISO
Bethesda	I-DISO
Category	I-DISO
III	I-DISO
(	O	O
AUS	B-DISO
/	O	O
FLUS	B-DISO
)	O	O
thyroid	B-DISO
nodules	I-DISO
were	O	O
included	O	O
in	O	O
this	O	O
retrospective	B-PROC
study	I-PROC
.	O	O

We	O	O
divided	O	O
the	O	O
nodules	B-DISO
into	O	O
two	O	O
subgroups	B-LIVB
according	O	O
to	O	O
the	O	O
histopathology	B-PROC
as	O	O
benign	O
and	O	O
malignant	O
,	O	O
and	O	O
compared	O	O
the	O	O
preoperative	O
ultrasonographical	B-PHYS
,	O	O
clinical	B-PHYS
,	O	O
and	O	O
biochemical	B-DISO
findings	I-DISO
.	O	O

In	O	O
overall	O	O
,	O	O
427	O	O
patients	B-LIVB
with	O	O
449	O	O
AUS	B-DISO
/	O	O
FLUS	B-DISO
nodules	B-DISO
who	O	O
had	O	O
undergone	O	O
surgery	B-PROC
,	O	O
the	O	O
rate	O	O
of	O	O
malignancy	B-DISO
was	O	O
23	O	O
.	O	O

4	O	O
%	O	O
(	O	O
105	O	O
/	O	O
449	O	O
)	O	O
.	O	O

When	O	O
evaluated	O	O
separately	O	O
,	O	O
the	O	O
rate	O	O
of	O	O
malignancy	B-DISO
was	O	O
25	O	O
.	O	O

8	O	O
%	O	O
in	O	O
nodules	B-DISO
with	O	O
AUS	B-DISO
(	O	O
82	O	O
/	O	O
318	O	O
)	O	O
and	O	O
17	O	O
.	O	O

6	O	O
%	O	O
in	O	O
nodules	B-DISO
with	O	O
FLUS	B-DISO
(	O	O
23	O	O
/	O	O
131	O	O
)	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
061	O	O
)	O	O
.	O	O

The	O	O
vast	O	O
majority	O	O
of	O	O
malignant	O
specimens	O
in	O	O
histopathology	B-PROC
consisted	O	O
of	O	O
papillary	B-DISO
thyroid	I-DISO
carcinoma	I-DISO
(	O	O
PTC	B-DISO
)	O	O
(	O	O
n	O	O
=	O	O
91	O	O
,	O	O
86	O	O
.	O	O
7	O	O
%	O	O
)	O	O
.	O	O

Preoperative	O
ultrasonographic	B-PHYS
features	I-PHYS
of	O	O
105	O	O
malignant	B-DISO
nodules	I-DISO
in	O	O
histopathology	B-PROC
were	O	O
compared	O	O
with	O	O
the	O	O
344	O	O
benign	B-DISO
nodules	I-DISO
in	O	O
histopathology	B-PROC
.	O	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP	O
/	O
T	O
)	O
ratio	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
malignant	B-LIVB
group	I-LIVB
compared	O	O
to	O	O
benign	B-LIVB
group	I-LIVB
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
013	O	O
)	O	O
.	O	O

In	O	O
multiple	B-PROC
logistic	I-PROC
analysis	I-PROC
,	O	O
we	O	O
found	O	O
that	O	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O	O
microcalcification	B-DISO
were	O	O
independently	O	O
associated	O
with	O
malignancy	B-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
malignancy	B-DISO
-associated	O	O
cut	O	O
-	O	O
off	O	O
value	O	O
of	O	O
AP	O
/	O
T	O
ratio	O
at	O	O
maximum	O	O
sensitivity	O
and	O
specificity	O
was	O	O
≥0	O	O
.	O	O
81	O	O
.	O	O

We	O	O
did	O	O
not	O	O
find	O	O
any	O	O
correlation	O
between	O	O
malignancy	B-DISO
and	O	O
Hashimoto	B-DISO
's	I-DISO
thyroiditis	I-DISO
in	O	O
histopathology	B-PROC
in	O	O
multivariate	O
analysis	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
Bethesda	B-DISO
Category	I-DISO
III	I-DISO
nodules	I-DISO
with	O	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O	O
microcalcification	B-DISO
,	O	O
surgery	B-PROC
might	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
first	O	O
therapeutic	O	O
option	O	O
instead	O	O
of	O	O
repeat	O	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
biopsy	I-PROC
or	O	O
observation	B-PROC
.	O	O

Low	O
serum	B-ANAT
vitamin	B-CHEM
D	I-CHEM
is	O	O
associated	O
with	O
higher	O	O
cortical	B-ANAT
porosity	O
in	O	O
elderly	B-LIVB
men	B-LIVB
Bone	B-DISO
loss	I-DISO
at	O	O
peripheral	O
sites	B-ANAT
in	O	O
the	O	O
elderly	B-LIVB
is	O	O
mainly	O	O
cortical	B-ANAT
and	O	O
involves	O	O
increased	O
cortical	B-ANAT
porosity	O
.	O	O

However	O	O
,	O	O
an	O	O
association	O
between	O	O
bone	B-DISO
loss	I-DISO
at	O	O
these	O	O
sites	B-ANAT
and	O	O
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D	I-CHEM
has	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

To	O	O
investigate	O
the	O	O
association	O
between	O	O
serum	B-ANAT
levels	B-PROC
of	I-PROC
25	I-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D	I-PROC
,	O	O
bone	B-ANAT
microstructure	I-ANAT
and	O	O
areal	B-PHYS
bone	I-PHYS
mineral	I-PHYS
density	I-PHYS
(	O	O
BMD	B-PHYS
)	O	O
in	O	O
elderly	B-LIVB
men	B-LIVB
.	O	O

A	O	O
population	B-LIVB
-based	O	O
cohort	B-LIVB
of	O	O
444	O	O
elderly	B-LIVB
men	B-LIVB
(	O	O
mean	O	O
±	O	O
SD	O	O
age	B-PHYS
80	O	O
.	O	O

2	O	O
±	O	O
3	O	O
.	O	O

5	O	O
years	O
)	O	O
was	O	O
investigated	O
.	O	O

Bone	B-ANAT
microstructure	I-ANAT
was	O	O
measured	O	O
by	O	O
high	B-PROC
-	I-PROC
resolution	I-PROC
peripheral	I-PROC
quantitative	I-PROC
computed	I-PROC
tomography	I-PROC
,	O	O
areal	B-PHYS
BMD	I-PHYS
by	O	O
dual	B-PROC
-	I-PROC
energy	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
absorptiometry	I-PROC
and	O	O
serum	B-ANAT
25	B-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D	I-PROC
and	O	O
parathyroid	B-PROC
hormone	I-PROC
levels	I-PROC
by	O	O
immunoassay	B-PROC
.	O	O

Mean	O
cortical	B-ANAT
porosity	O
at	O	O
the	O	O
distal	B-ANAT
tibia	I-ANAT
was	O	O
14	O	O
.	O	O

7	O	O
%	O	O
higher	O	O
(	O	O
12	O	O
.	O	O
5	O	O
±	O	O
4	O	O
.	O	O

3	O	O
%	O	O
vs	O	O
.	O	O

10	O	O
.	O	O
9	O	O
±	O	O
4	O	O
.	O	O
1	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
whilst	O	O
cortical	B-ANAT
volumetric	B-PHYS
BMD	I-PHYS
,	O	O
area	O
,	O	O
trabecular	O
bone	O
volume	O
fraction	O
and	O	O
femoral	B-ANAT
neck	I-ANAT
areal	B-PHYS
BMD	I-PHYS
were	O	O
lower	O	O
in	O	O
men	B-LIVB
in	O	O
the	O	O
lowest	O	O
quartile	O
of	O	O
vitamin	B-PROC
D	I-PROC
levels	I-PROC
compared	O	O
to	O	O
the	O	O
highest	O	O
.	O	O

In	O	O
men	B-LIVB
with	O	O
vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
(	O	O
<	O	O
25	O	O
nmol	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
or	O	O
insufficiency	O
[	O	O
25	O	O
-	O	O
49	O	O
nmol	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
in	O	O
combination	O	O
with	O	O
an	O	O
elevated	O
serum	B-ANAT
level	B-PROC
of	I-PROC
parathyroid	I-PROC
hormone	I-PROC
(	O	O
>	O	O
6	O	O
.	O	O
8	O	O
pmol	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
]	O	O
,	O	O
cortical	B-ANAT
porosity	O
was	O	O
17	O	O
.	O	O

2	O	O
%	O	O
higher	O	O
than	O	O
in	O	O
vitamin	B-CHEM
D	I-CHEM
-	O	O
sufficient	O
men	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

A	O	O
linear	O
regression	O
model	O
including	O	O
age	B-PHYS
,	O	O
weight	B-PHYS
,	O	O
height	B-PHYS
,	O	O
daily	B-PROC
calcium	I-PROC
intake	I-PROC
,	O	O
physical	O
activity	O
,	O	O
smoking	O
vitamin	B-CHEM
D	I-CHEM
supplementation	B-CHEM
and	O	O
parathyroid	B-CHEM
hormone	I-CHEM
showed	O	O
that	O	O
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D	I-CHEM
independently	O	O
predicted	O	O
cortical	B-ANAT
porosity	O
(	O	O
standardized	O	O
β	O	O
=	O	O
-0	O	O
.	O	O
110	O	O
,	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
1	O	O
.	O	O
1	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
024	O	O
)	O	O
,	O	O
area	O
(	O	O
β	O	O
=	O	O
0	O	O
.	O	O
123	O	O
,	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
1	O	O
.	O	O
4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
007	O	O
)	O	O
and	O	O
cortical	B-ANAT
volumetric	B-PHYS
BMD	I-PHYS
(	O	O
β	O	O
=	O	O
0	O	O
.	O	O
125	O	O
,	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
1	O	O
.	O	O
4	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
007	O	O
)	O	O
of	O	O
the	O	O
tibia	B-ANAT
as	O	O
well	O	O
as	O	O
areal	B-PHYS
BMD	I-PHYS
of	O	O
the	O	O
femoral	B-ANAT
neck	I-ANAT
(	O	O
β	O	O
=	O	O
0	O	O
.	O	O
102	O	O
,	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
9	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
04	O	O
)	O	O
.	O	O

Serum	B-ANAT
vitamin	B-CHEM
D	I-CHEM
is	O	O
associated	O
with	O
cortical	B-ANAT
porosity	O
,	O	O
area	O
and	O	O
density	B-PHYS
,	O	O
indicating	O	O
that	O	O
bone	B-ANAT
fragility	B-DISO
as	O	O
a	O	O
result	O	O
of	O	O
low	O
vitamin	B-CHEM
D	I-CHEM
could	O	O
be	O	O
due	O	O
to	O	O
changes	O
in	O	O
cortical	B-ANAT
bone	B-ANAT
microstructure	I-ANAT
and	O	O
geometry	O
.	O	O

Nationwide	O
reduction	O
in	O	O
the	O	O
number	O	O
of	O	O
corneal	B-PROC
transplantations	I-PROC
for	O	O
keratoconus	B-DISO
following	O	O
the	O	O
implementation	O
of	O	O
cross	B-PROC
-	I-PROC
linking	I-PROC
Keratoconus	B-DISO
is	O	O
characterized	O	O
by	O	O
corneal	B-DISO
ectasia	I-DISO
and	O	O
irregular	B-DISO
astigmatism	I-DISO
,	O	O
which	O	O
can	O	O
lead	O	O
to	O	O
diminished	B-DISO
vision	I-DISO
and	O	O
corneal	B-DISO
scarring	I-DISO
.	O	O

Approximately	O	O
10	O	O
-	O	O
20	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
keratoconus	B-DISO
eventually	O	O
require	O	O
a	O	O
corneal	B-PROC
transplant	I-PROC
.	O	O

Corneal	B-PROC
cross	I-PROC
-	I-PROC
linking	I-PROC
(	O	O
CXL	B-PROC
)	O	O
is	O	O
a	O	O
relatively	O	O
new	O	O
treatment	B-PROC
that	O	O
may	O	O
help	O	O
prevent	O	O
the	O	O
need	O	O
for	O	O
corneal	B-PROC
transplantation	I-PROC
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O
whether	O	O
the	O	O
introduction	O
of	O	O
CXL	B-PROC
has	O	O
reduced	O	O
the	O	O
number	O	O
of	O	O
corneal	B-PROC
transplants	I-PROC
performed	O
annually	O
.	O	O

Data	O
regarding	O	O
the	O	O
transplantation	B-PROC
procedures	I-PROC
performed	O
in	O	O
patients	B-LIVB
under	O	O
the	O	O
age	B-PHYS
of	O	O
50	O	O
years	O
were	O	O
extracted	O	O
from	O	O
the	O	O
Dutch	O
National	O
Organ	O
Transplant	O
Registry	O
.	O	O

The	O	O
number	O	O
of	O	O
corneal	B-PROC
transplants	I-PROC
performed	O
prior	O	O
to	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

in	O	O
2005	O	O
through	O	O
2007	O	O
)	O	O
and	O	O
following	O	O
the	O	O
introduction	O
of	O	O
CXL	B-PROC
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

in	O	O
2012	O	O
through	O	O
2014	O	O
)	O	O
were	O	O
compared	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
trend	O
analysis	O
on	O	O
annual	O
keratoplasties	B-PROC
over	O	O
time	O	O
was	O	O
performed	O
.	O	O

Approximately	O	O
25	O	O
%	O	O
fewer	O	O
corneal	B-PROC
transplants	I-PROC
were	O	O
performed	O
in	O	O
the	O	O
3	O	O
-	O	O
year	O
period	O	O
following	O	O
the	O	O
introduction	O
of	O	O
CXL	B-PROC
compared	O
to	O	O
the	O	O
3	O	O
-	O	O
year	O
period	O	O
prior	O	O
to	O	O
the	O	O
introduction	O
of	O	O
CXL	B-PROC
(	O	O
201	O	O
versus	O	O
269	O	O
transplants	B-PROC
,	O	O
respectively	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

005	O	O
)	O	O
.	O	O

Age	B-PHYS
,	O	O
gender	B-PHYS
and	O	O
visual	B-PHYS
acuity	I-PHYS
were	O	O
similar	O	O
between	O	O
the	O	O
patient	B-LIVB
groups	O	O
in	O	O
the	O	O
two	O	O
time	O
periods	O
.	O	O

Trend	O
analysis	O
also	O	O
demonstrated	O	O
a	O	O
significant	O	O
decrease	O
in	O	O
the	O	O
amount	O	O
of	O	O
corneal	B-PROC
transplants	I-PROC
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Significantly	O	O
fewer	O	O
corneal	B-PROC
transplants	I-PROC
were	O	O
performed	O	O
for	O	O
treating	O	O
keratoconus	B-DISO
following	O	O
the	O	O
nationwide	O
introduction	O
of	O	O
CXL	B-PROC
.	O	O

This	O	O
reduction	O
suggests	O	O
that	O	O
corneal	B-PROC
cross	I-PROC
-	I-PROC
linking	I-PROC
can	O	O
significantly	O	O
reduce	O
the	O	O
need	O	O
for	O	O
corneal	B-PROC
transplantation	I-PROC
.	O	O

Rapid	O	O
Fabrication	O
of	O	O
a	O	O
Cell	B-ANAT
-	O	O
Seeded	B-PROC
Collagen	B-CHEM
Gel	B-CHEM
-Based	O	O
Tubular	B-DEVI
Construct	I-DEVI
that	O	O
Withstands	O	O
Arterial	B-PHYS
Pressure	I-PHYS
:	O	O
Rapid	O	O
Fabrication	O
of	O	O
a	O	O
Gel	B-CHEM
-Based	O	O
Media	B-OBJC
Equivalent	O	O
Based	O	O
on	O	O
plastically	B-PHEN
compressed	I-PHEN
cell	B-ANAT
-	O	O
seeded	B-PROC
collagen	B-CHEM
gels	B-CHEM
,	O	O
we	O	O
fabricated	O
a	O	O
small	O	O
-	O	O
diameter	O	O
tubular	B-DEVI
construct	I-DEVI
that	O	O
withstands	O	O
arterial	B-PHYS
pressure	I-PHYS
without	O	O
prolonged	O	O
culture	B-PROC
in	O
vitro	O
.	O	O

Specifically	O	O
,	O	O
to	O	O
mimic	O	O
the	O	O
microstructure	O
of	O	O
vascular	O
media	O
,	O	O
the	O	O
cell	B-ANAT
-	O	O
seeded	B-PROC
collagen	B-CHEM
gel	B-CHEM
was	O	O
uniaxially	O	O
stretched	O	O
prior	O	O
to	O	O
plastic	B-OBJC
compression	B-PHEN
to	O	O
align	O	O
collagen	O
fibers	O
and	O	O
hence	O	O
cells	B-ANAT
in	O	O
the	O	O
gel	B-CHEM
.	O	O

The	O	O
resulting	O	O
gel	B-CHEM
sheet	B-CHEM
was	O	O
then	O	O
wrapped	O	O
around	O	O
a	O	O
custom	O	O
-	O	O
made	O	O
multi	B-DEVI
-	I-DEVI
layered	I-DEVI
braided	I-DEVI
tube	I-DEVI
to	O	O
form	O	O
aligned	O	O
tubular	B-DEVI
constructs	I-DEVI
whereas	O	O
the	O	O
gel	B-CHEM
sheet	B-CHEM
prepared	O	O
similarly	O	O
but	O	O
without	O	O
uniaxial	O	O
stretching	O	O
formed	O	O
control	O	O
constructs	B-DEVI
.	O	O

With	O	O
the	O	O
braided	B-DEVI
tube	I-DEVI
,	O	O
fluid	B-OBJC
in	O	O
the	O	O
gel	B-CHEM
construct	B-DEVI
was	O	O
further	O	O
removed	O	O
by	O	O
vacuum	B-DEVI
suction	I-DEVI
aiming	O	O
to	O	O
consolidate	O	O
the	O	O
concentric	O	O
layers	O	O
of	O	O
the	O	O
construct	B-DEVI
.	O	O

The	O	O
construct	B-DEVI
was	O	O
finally	O	O
treated	O	O
with	O	O
transglutaminase	B-CHEM
.	O	O

Both	O	O
SEM	B-PROC
and	O	O
histology	B-PROC
confirmed	O	O
the	O	O
absence	O	O
of	O	O
gaps	O	O
in	O	O
the	O	O
wall	O	O
of	O	O
the	O	O
construct	B-DEVI
.	O	O

Particularly	O	O
,	O	O
cells	B-ANAT
in	O	O
the	O	O
wall	O	O
of	O	O
the	O	O
aligned	O	O
tubular	B-DEVI
construct	I-DEVI
were	O	O
circumferentially	O	O
aligned	O	O
.	O	O

The	O	O
enzyme	B-CHEM
-mediated	O	O
crosslinking	B-PHEN
increased	O	O
burst	B-PHEN
pressure	I-PHEN
of	O	O
both	O	O
the	O	O
constructs	B-DEVI
significantly	O	O
;	O	O
the	O	O
extent	O	O
of	O	O
the	O	O
increase	O	O
of	O	O
burst	B-PHEN
pressure	I-PHEN
for	O	O
the	O	O
aligned	O	O
tubular	B-DEVI
construct	I-DEVI
was	O	O
greater	O	O
than	O	O
that	O	O
for	O	O
the	O	O
control	O	O
counterpart	O	O
.	O	O

Increasing	O	O
crosslinking	B-PHEN
left	O	O
the	O	O
compliance	O	O
of	O	O
the	O	O
aligned	O	O
tubular	B-DEVI
construct	I-DEVI
unchanged	O	O
but	O	O
reduced	O	O
that	O	O
of	O	O
the	O	O
control	O	O
construct	B-DEVI
.	O	O

Cells	B-ANAT
remained	O	O
viable	O	O
in	O	O
transglutaminase	B-CHEM
-treated	O	O
plastically	B-PHEN
compressed	I-PHEN
gels	B-CHEM
after	O	O
6	O	O
days	O
in	O	O
culture	O	O
.	O	O

This	O	O
study	B-PROC
demonstrated	O	O
that	O	O
by	O	O
combining	O	O
stretch	O	O
-	O	O
induced	O	O
fiber	O
alignment	O
,	O	O
plastic	B-OBJC
compression	B-PHEN
,	O	O
and	O	O
enzyme	B-CHEM
-mediated	O	O
crosslinking	B-PHEN
,	O	O
a	O	O
cell	B-ANAT
-	O	O
seeded	B-PROC
collagen	B-CHEM
gel	B-CHEM
-based	O	O
tubular	B-DEVI
construct	I-DEVI
with	O	O
potential	O	O
to	O	O
be	O	O
used	O	O
as	O	O
vascular	O
media	O
can	O	O
be	O	O
made	O	O
within	O	O
3	O	O
days	O
.	O	O

Impact	O
of	O	O
cofactor	B-CHEM
-	O	O
binding	O
loop	O
mutations	B-PHYS
on	O	O
thermotolerance	B-PHYS
and	O	O
activity	B-PHYS
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
transketolase	B-CHEM
Improvement	O
of	O	O
thermostability	B-PHEN
in	O	O
engineered	B-CHEM
enzymes	I-CHEM
can	O	O
allow	O	O
biocatalysis	B-PHEN
on	O	O
substrates	B-OBJC
with	O	O
poor	O	O
aqueous	O
solubility	O
.	O	O

Denaturation	B-PHYS
of	O	O
the	O	O
cofactor	B-CHEM
-	O	O
binding	O
loops	O
of	O	O
Escherichia	B-LIVB
coli	I-LIVB
transketolase	B-CHEM
(	O	O
TK	B-CHEM
)	O	O
was	O	O
previously	O	O
linked	O	O
to	O	O
the	O	O
loss	O
of	O	O
enzyme	B-PHYS
activity	I-PHYS
under	O	O
conditions	O
of	O	O
high	O
pH	O
or	O	O
urea	B-CHEM
.	O	O

Incubation	B-PROC
at	O	O
temperatures	O
just	O	O
below	O	O
the	O	O
thermal	B-PHEN
melting	I-PHEN
transition	I-PHEN
,	O	O
above	O	O
which	O	O
the	O	O
protein	B-CHEM
aggregates	O
,	O	O
was	O	O
also	O	O
found	O	O
to	O	O
anneal	O
the	O	O
enzyme	B-CHEM
to	O	O
give	O	O
an	O	O
increased	O
specific	O	O
activity	B-PHYS
.	O	O

The	O	O
potential	O	O
role	O
of	O	O
cofactor	B-CHEM
-	O	O
binding	O
loop	O
instability	B-DISO
in	O	O
this	O	O
process	O	O
remained	O	O
unclear	O	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
the	O	O
two	O	O
cofactor	B-CHEM
-	O	O
binding	O
loops	O
(	O	O
residues	O
185	O
-	O
192	O
and	O	O
382	O
-	O
392	O
)	O	O
were	O	O
progressively	O	O
mutated	O	O
towards	O	O
the	O	O
equivalent	O	O
sequence	O
from	O	O
the	O	O
thermostable	O
Thermus	B-LIVB
thermophilus	I-LIVB
TK	B-CHEM
and	O	O
variants	O
assessed	O
for	O	O
their	O	O
impact	O
on	O	O
both	O	O
thermostability	B-PHEN
and	O	O
activity	O
.	O	O

Cofactor	O
-	O
binding	O
loop	O
2	O
variants	O
had	O	O
detrimental	O
effects	O
on	O	O
specific	O	O
activity	O
at	O	O
elevated	O
temperatures	O
,	O	O
whereas	O	O
the	O	O
H192P	B-PHYS
mutation	I-PHYS
in	O	O
cofactor	O
-	O
binding	O
loop	O
1	O
resulted	O	O
in	O	O
a	O	O
two	O	O
-	O	O
fold	O	O
improved	O	O
stability	B-PHEN
to	O	O
inactivation	O
at	O	O
elevated	O
temperatures	O
,	O	O
and	O	O
increased	O
the	O	O
critical	O
onset	O
temperature	O
for	O	O
aggregation	O
.	O	O

The	O	O
specific	O	O
activity	O
of	O	O
H192P	B-PHYS
was	O	O
3	O	O
-	O	O
fold	O	O
and	O	O
19	O	O
-	O	O
fold	O	O
higher	O
than	O	O
that	O	O
for	O	O
wild	O
-	O
type	O
at	O	O
60°C	O	O
and	O	O
65°C	O	O
respectively	O	O
,	O	O
and	O	O
also	O	O
remained	O	O
2	O	O
.	O	O
7	O	O
-	O	O
4	O	O
fold	O	O
higher	O
after	O	O
re	B-PHEN
-	I-PHEN
cooling	I-PHEN
from	O	O
pre	B-PROC
-	I-PROC
incubations	I-PROC
at	O	O
either	O	O
55°C	O	O
or	O	O
60°C	O	O
for	O	O
1h	O	O
.	O	O

Interestingly	O	O
,	O	O
H192P	B-PHYS
was	O	O
also	O	O
2	O	O
-	O	O
times	O	O
more	O	O
active	O
than	O	O
wild	O
-	O
type	O
TK	B-CHEM
at	O	O
25°C	O	O
.	O	O

Optimal	O
activity	O
was	O	O
achieved	O	O
at	O	O
60°C	O	O
for	O	O
H192P	B-PHYS
compared	O	O
to	O	O
55°C	O	O
for	O	O
wild	O
type	O
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
cofactor	O
-	O
binding	O
loop	O
1	O
,	O	O
plays	O	O
a	O	O
pivotal	O	O
role	O
in	O	O
partial	O
denaturation	B-PHYS
and	O	O
aggregation	O
at	O	O
elevated	O
temperatures	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
single	B-PHYS
rigidifying	I-PHYS
mutation	I-PHYS
within	O	O
this	O	O
loop	O
can	O	O
significantly	O	O
improve	O	O
the	O	O
enzyme	B-PHYS
specific	I-PHYS
activity	I-PHYS
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
stability	B-PHEN
to	O	O
thermal	B-PHEN
denaturation	B-PHYS
and	O	O
aggregation	O
,	O	O
to	O	O
give	O	O
an	O	O
increased	O
temperature	O
optimum	O
for	O	O
activity	B-PHYS
.	O	O

Expression	B-PHYS
and	O	O
Purification	B-PROC
of	O	O
E2	B-CHEM
Glycoprotein	I-CHEM
from	O	O
Insect	O
Cells	B-ANAT
(	O	O
Sf9	B-ANAT
)	O	O
for	O	O
Use	O	O
in	O	O
Serology	B-PROC
Chikungunya	B-LIVB
virus	I-LIVB
(	O	O
CHIKV	B-LIVB
)	O	O
is	O	O
a	O	O
mosquito	O
-	O	O
borne	B-DISO
arbovirus	B-LIVB
which	O	O
poses	O	O
a	O	O
major	O	O
threat	O
to	O	O
global	O
public	B-PROC
health	I-PROC
.	O	O

Definitive	O
CHIKV	B-LIVB
diagnosis	B-DISO
is	O	O
crucial	O	O
,	O	O
especially	O	O
in	O	O
distinguishing	O	O
the	O	O
disease	B-DISO
from	O	O
dengue	B-LIVB
virus	I-LIVB
,	O	O
which	O	O
co	O
-	O
circulates	O
in	O	O
endemic	O
areas	O
and	O	O
shares	O	O
the	O	O
same	O	O
mosquito	O
vectors	O
.	O	O

Laboratory	B-PROC
diagnosis	I-PROC
is	O	O
mainly	O	O
based	O
on	O	O
serological	O
or	O	O
molecular	O
approaches	O	O
.	O	O

The	O	O
E2	B-CHEM
glycoprotein	I-CHEM
is	O	O
a	O	O
good	O	O
candidate	O	O
for	O	O
serological	B-PROC
diagnosis	I-PROC
since	O	O
it	O	O
is	O	O
the	O	O
immunodominant	B-CHEM
antigen	I-CHEM
during	O
the	O	O
course	O
of	O	O
infection	B-DISO
,	O	O
and	O	O
reacts	O
with	O	O
seropositive	O
CHIKV	B-LIVB
sera	B-ANAT
.	O	O

In	O	O
this	O	O
chapter	O
,	O	O
we	O	O
describe	O
the	O	O
generation	O
of	O	O
stable	O
clone	B-ANAT
Sf9	B-ANAT
(	O	O
Spodoptera	O
frugiperda	O
)	O	O
cells	B-ANAT
expressing	B-PHYS
secreted	B-PHYS
,	O	O
soluble	B-ANAT
,	O	O
and	O	O
native	O
recombinant	B-LIVB
CHIKV	B-LIVB
E2	B-CHEM
glycoprotein	I-CHEM
.	O	O

We	O	O
use	O	O
direct	O	O
plasmid	B-CHEM
expression	B-PROC
in	O	O
insect	O
cells	B-ANAT
,	O	O
rather	O	O
than	O	O
the	O	O
traditional	O
technique	O
of	O	O
generating	O
recombinant	B-LIVB
baculovirus	I-LIVB
.	O	O

This	O	O
recombinant	B-CHEM
protein	I-CHEM
is	O	O
useful	O	O
for	O	O
serological	B-PROC
diagnosis	I-PROC
of	O	O
CHIKV	B-LIVB
infection	B-DISO
.	O	O

Acute	O
risk	B-DISO
factors	I-DISO
for	O	O
suicide	B-DISO
attempts	I-DISO
and	O	O
death	B-DISO
:	O	O
prospective	B-PROC
findings	I-PROC
from	O	O
the	O	O
STEP	B-PROC
-	O	O
BD	B-DISO
study	B-PROC
Suicide	B-DISO
is	O	O
unfortunately	O	O
common	O	O
in	O	O
psychiatric	O
practice	B-PHYS
,	O	O
but	O	O
difficult	O	O
to	O	O
predict	O
.	O	O

The	O	O
present	O	O
study	B-PROC
sought	O	O
to	O	O
assess	B-PROC
which	O	O
clinical	O
symptoms	B-DISO
increase	O
in	O	O
the	O	O
months	O
before	O	O
suicidal	B-DISO
behavior	I-DISO
in	O	O
a	O	O
sample	B-OBJC
of	O	O
psychiatric	O
outpatients	B-LIVB
with	O	O
bipolar	B-DISO
disorder	I-DISO
.	O	O

Data	O
from	O	O
the	O	O
Systematic	B-PROC
Treatment	I-PROC
Enhancement	I-PROC
Program	I-PROC
for	O	O
Bipolar	B-DISO
Disorder	I-DISO
(	O	O
STEP	B-PROC
-	O	O
BD	B-DISO
)	O	O
trial	B-PROC
were	O	O
used	O	O
.	O	O

A	O	O
total	O	O
of	O	O
103	O	O
participants	B-LIVB
who	O	O
attempted	B-DISO
suicide	I-DISO
or	O	O
died	B-DISO
by	O	O
suicide	B-DISO
during	O	O
the	O	O
trial	B-PROC
were	O	O
included	O	O
;	O	O
a	O	O
15	O	O
%	O	O
random	O
sample	B-OBJC
of	O	O
the	O	O
remaining	O	O
participants	B-LIVB
(	O	O
n	O	O
=	O	O
427	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
comparison	O
sample	B-OBJC
.	O	O

Linear	O
mixed	O
models	O
in	O	O
the	O	O
six	O	O
months	O
before	O	O
suicidal	B-DISO
behavior	I-DISO
were	O	O
conducted	O	O
for	O	O
each	O	O
of	O	O
five	O	O
proposed	O	O
acute	O
risk	B-DISO
factors	I-DISO
for	O	O
suicidal	B-DISO
behavior	I-DISO
.	O	O

Participants	B-LIVB
were	O	O
assessed	O
using	O	O
the	O	O
Clinical	B-PROC
Monitoring	I-PROC
Form	I-PROC
(	O	O
CMF	B-PROC
)	O	O
at	O	O
each	O	O
visit	B-PROC
for	O	O
the	O	O
following	O	O
potential	O	O
acute	O
risk	B-DISO
factors	I-DISO
for	O	O
suicidal	B-DISO
behavior	I-DISO
:	O	O
suicidal	B-DISO
ideation	I-DISO
,	O	O
loss	B-DISO
of	I-DISO
interest	I-DISO
,	O	O
anxiety	B-DISO
,	O	O
psychomotor	B-DISO
agitation	I-DISO
,	O	O
and	O	O
high	O
-	O
risk	O
behavior	O
.	O	O

Each	O	O
of	O	O
the	O	O
five	O	O
symptoms	B-DISO
was	O	O
elevated	O
overall	O	O
in	O	O
individuals	B-LIVB
who	O	O
engaged	O	O
in	O	O
suicidal	B-DISO
behavior	I-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
severity	O
of	O	O
both	O	O
suicidal	B-DISO
ideation	I-DISO
and	O	O
loss	B-DISO
of	I-DISO
interest	I-DISO
significantly	O	O
increased	O
in	O	O
the	O	O
months	O
before	O	O
suicidal	B-DISO
behavior	I-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Anxiety	B-DISO
demonstrated	O	O
comparable	O	O
effect	O
sizes	O
across	O	O
multiple	O
models	O
.	O	O

Psychomotor	B-DISO
agitation	I-DISO
and	O	O
high	O
-	O
risk	O
behavior	O
were	O	O
not	O	O
significantly	O	O
elevated	O
before	O	O
suicidal	B-DISO
behavior	I-DISO
.	O	O

Suicidal	B-DISO
ideation	I-DISO
,	O	O
loss	B-DISO
of	I-DISO
interest	I-DISO
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O
extent	O
,	O	O
anxiety	B-DISO
may	O	O
represent	O	O
acute	O
suicide	B-DISO
risk	B-DISO
factors	I-DISO
up	O	O
to	O	O
four	O	O
months	O
before	O	O
suicidal	B-DISO
behavior	I-DISO
in	O	O
outpatients	B-LIVB
with	O	O
bipolar	B-DISO
disorder	I-DISO
.	O	O

Further	O	O
investigation	B-PROC
of	O	O
these	O	O
potential	O	O
acute	O
risk	B-DISO
factors	I-DISO
in	O	O
prospective	B-PROC
analyses	I-PROC
is	O	O
warranted	O	O
.	O	O

Measurement	O
of	O	O
Outcomes	O
of	O	O
Upper	B-DISO
Limb	I-DISO
Reconstructive	I-DISO
Surgery	I-DISO
for	O	O
Tetraplegia	B-DISO
Reconstructive	B-DISO
arm	I-DISO
/	I-DISO
hand	I-DISO
surgery	I-DISO
for	O	O
tetraplegia	B-DISO
is	O	O
performed	O
to	O	O
improve	B-DISO
arm	B-PHYS
/	I-PHYS
hand	I-PHYS
function	I-PHYS
and	O	O
therefore	O	O
personal	B-DISO
well	I-DISO
-	I-DISO
being	I-DISO
for	O	O
individuals	B-LIVB
who	O	O
accept	O
such	O	O
elective	B-PROC
surgeries	I-PROC
.	O	O

However	O	O
,	O	O
changes	O
at	O	O
an	O	O
impairment	O
level	O	O
do	O	O
not	O	O
always	O	O
translate	O	O
into	O	O
functional	O
or	O	O
quality	O
of	O
life	O
changes	O
.	O	O

Therefore	O	O
,	O	O
multiple	B-OBJC
outcome	I-OBJC
tools	I-OBJC
should	O	O
be	O	O
used	O	O
that	O	O
incorporate	O
sufficient	B-DISO
responsiveness	I-DISO
to	O	O
detect	B-DISO
changes	O
in	O	O
arm	B-PHYS
/	I-PHYS
hand	I-PHYS
function	I-PHYS
,	O	O
activity	O
and	O	O
participation	O
,	O	O
and	O	O
quality	O
of	O
life	O
of	O	O
the	O	O
individuals	B-LIVB
involved	O	O
.	O	O

This	O	O
narrative	O
review	O
aims	O
to	O	O
assist	B-PROC
clinicians	B-LIVB
to	O	O
choose	O	O
the	O	O
most	O	O
appropriate	O
tools	B-OBJC
to	O	O
assess	O
the	O	O
need	O	O
for	O	O
reconstructive	B-DISO
surgery	I-DISO
and	O	O
to	O	O
evaluate	B-PROC
its	O	O
outcomes	O
.	O	O

Our	O	O
specific	O	O
objectives	O
are	O	O
(	O	O
1	O	O
)	O	O
to	O	O
describe	O
aspects	O
to	O	O
consider	O	O
when	O	O
choosing	O	O
a	O	O
measure	O
and	O	O
(	O	O
2	O	O
)	O	O
to	O	O
describe	O
the	O	O
measures	O
advised	O	O
by	O	O
an	O	O
international	O
therapist	B-LIVB
consensus	O	O
group	O
established	O
in	O	O
2007	O	O
.	O	O

All	O	O
advised	O	O
measures	O
are	O	O
appraised	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
underlying	O	O
construct	O
,	O	O
administration	B-PROC
,	O	O
and	O	O
clinical	O
relevance	O
to	O	O
arm	B-PROC
/	I-PROC
hand	I-PROC
reconstructions	I-PROC
.	O	O

Essentially	O
there	O	O
are	O	O
currently	O	O
no	O	O
criterion	O
standard	O
measures	O
to	O	O
evaluate	B-PROC
the	O	O
consequences	O
of	O
reconstructive	B-DISO
arm	I-DISO
/	I-DISO
hand	I-DISO
surgery	I-DISO
.	O	O

However	O	O
,	O	O
with	O	O
judicious	O	O
use	O
of	O	O
available	O	O
measures	O
it	O	O
is	O	O
possible	O	O
to	O	O
ensure	O	O
the	O	O
questions	B-DISO
asked	I-DISO
or	O	O
tasks	O
completed	O
are	O	O
relevant	O
to	O	O
the	O	O
surgical	B-PROC
reconstruction	I-PROC
(	O	O
s	O	O
)	O	O
undertaken	O	O
.	O	O

Further	O	O
work	O
in	O	O
this	O	O
field	O
is	O	O
required	O
.	O	O

This	O	O
would	O	O
be	O	O
best	O	O
met	O	O
by	O	O
immediate	O
collaboration	O
between	O	O
2	O	O
outcome	O
's	O
tool	O
developers	O
and	O	O
by	O	O
analysis	O
of	O	O
pre	O
-	O	O
and	O	O
postoperative	O
data	O
already	O	O
held	O	O
in	O	O
various	O	O
international	O
sites	O	O
,	O	O
which	O	O
would	O	O
allow	O	O
further	O	O
evaluation	B-PROC
of	O	O
the	O	O
measures	O
already	O	O
in	O	O
use	O
,	O	O
or	O	O
components	B-OBJC
thereof	O	O
.	O	O

Basal	B-PHYS
and	O	O
maximal	O
metabolic	B-PHYS
rates	I-PHYS
differ	O	O
in	O	O
their	O	O
response	B-PHYS
to	O	O
rapid	O	O
temperature	O
change	O
among	O	O
avian	B-LIVB
species	O
In	O	O
birds	B-LIVB
,	O	O
acclimation	B-PHYS
and	O	O
acclimatization	B-PHYS
to	O	O
temperature	O
are	O	O
associated	O	O
with	O	O
changes	O	O
in	O	O
basal	B-PHYS
(	O	O
BMR	B-PHYS
)	O	O
,	O	O
summit	B-PHYS
(	O	O
Msum	B-PHYS
)	O	O
and	O	O
maximal	O
(	O	O
MMR	B-PHYS
)	O	O
metabolic	B-PHYS
rates	I-PHYS
but	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
rate	B-PHYS
at	O	O
which	O	O
species	O
adjust	O	O
their	O	O
phenotype	B-PHYS
to	O	O
short	O
-	O
term	O
temperature	O
variations	O
.	O	O

Our	O	O
aims	O
were	O	O
(	O	O
1	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
pattern	O
of	O	O
metabolic	O
adjustments	O	O
following	O	O
a	O	O
rapid	O	O
temperature	O
change	O
,	O	O
(	O	O
2	O	O
)	O	O
to	O	O
determine	O	O
whether	O	O
performance	O	O
varies	O	O
at	O	O
similar	O	O
rates	B-PHYS
during	O	O
exposure	O
to	O
warm	B-PHEN
or	O	O
cold	B-PHEN
environments	I-PHEN
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
to	O	O
determine	O	O
if	O	O
BMR	B-PHYS
,	O	O
Msum	B-PHYS
and	O	O
MMR	B-PHYS
change	O	O
at	O	O
comparable	O	O
rates	B-PHYS
during	O	O
thermal	B-PHEN
acclimation	B-PHYS
.	O	O

We	O	O
measured	O	O
these	O	O
parameters	O	O
in	O	O
white	B-LIVB
-	I-LIVB
throated	I-LIVB
sparrows	I-LIVB
(	O	O
Zonotrichia	B-LIVB
albicollis	I-LIVB
)	O	O
,	O	O
black	B-LIVB
-	I-LIVB
capped	I-LIVB
chickadees	I-LIVB
(	O	O
Poecile	B-LIVB
atricapillus	I-LIVB
)	O	O
,	O	O
and	O	O
snow	B-LIVB
buntings	I-LIVB
(	O	O
Plectrophenax	B-LIVB
nivalis	I-LIVB
)	O	O
after	O	O
acclimation	B-PHYS
to	O	O
10	O	O
°	O	O
C	O	O
(	O	O
day	O
0	O	O
)	O	O
and	O	O
on	O	O
the	O	O
4th	O	O
and	O	O
8th	O	O
days	O
of	O	O
acclimation	B-PHYS
to	O	O
either	O	O
-5	O	O
or	O	O
28	O	O
°	O	O
C	O	O
.	O	O

Birds	B-LIVB
changed	O	O
their	O	O
metabolic	O
phenotype	B-PHYS
within	O	O
8	O	O
days	O
with	O	O
patterns	O
differing	O	O
among	O	O
species	O
.	O	O

Sparrows	B-LIVB
expressed	O	O
the	O	O
expected	O	O
metabolic	O
increases	O
in	O	O
the	O	O
cold	B-PHEN
and	O	O
decreases	O	O
at	O	O
thermoneutrality	O
while	O	O
performance	O	O
in	O	O
chickadees	B-LIVB
and	O	O
buntings	B-LIVB
was	O	O
not	O	O
influenced	O
by	O	O
temperature	O
but	O	O
changed	O	O
over	O	O
time	O	O
with	O	O
inverse	O	O
patterns	O
.	O	O

Our	O	O
results	B-DISO
suggest	O	O
that	O	O
BMR	B-PHYS
varies	O	O
at	O	O
comparable	O	O
rates	B-PHYS
in	O	O
warm	B-PHEN
and	O	O
cold	B-PHEN
environments	I-PHEN
but	O	O
changes	O	O
faster	O	O
than	O	O
Msum	B-PHYS
and	O	O
MMR	B-PHYS
,	O	O
likely	O	O
due	O	O
to	O	O
limitations	O
in	O	O
the	O	O
rate	B-PHYS
of	O	O
change	O	O
in	O	O
organ	B-PHYS
size	I-PHYS
and	O	O
function	O
.	O	O

They	O	O
also	O	O
suggest	O	O
that	O	O
maximal	O
metabolic	O
capacity	O
is	O	O
lost	O
faster	O	O
in	O	O
a	O	O
warm	B-PHEN
environment	I-PHEN
than	O	O
it	O	O
is	O	O
gained	O
in	O	O
a	O	O
cold	B-PHEN
environment	I-PHEN
.	O	O

With	O	O
the	O	O
expected	O	O
increase	O	O
in	O	O
temperature	O
stochasticity	O
at	O	O
northern	B-GEOG
latitudes	I-GEOG
,	O	O
a	O	O
loss	O
of	O	O
thermogenic	B-PHEN
capacity	O
during	O	O
warm	B-PHEN
winter	O
days	O
could	O	O
,	O	O
therefore	O	O
,	O	O
be	O	O
detrimental	O	O
if	O	O
birds	B-LIVB
are	O	O
slow	O	O
to	O	O
readjust	O	O
their	O	O
phenotype	B-PHYS
with	O	O
the	O	O
return	O	O
of	O	O
cold	B-PHEN
days	O
.	O	O

Factors	O
preventing	O
kneeling	B-PHYS
in	O	O
a	O	O
group	O
of	O	O
pre	B-PROC
-	I-PROC
educated	I-PROC
patients	B-LIVB
post	O
total	B-PROC
knee	I-PROC
arthroplasty	I-PROC
Difficulties	B-DISO
in	I-DISO
kneeling	I-DISO
,	O	O
one	O	O
of	O	O
the	O	O
poorest	B-DISO
scoring	I-DISO
functional	I-DISO
outcomes	I-DISO
post	O
total	B-PROC
knee	I-PROC
arthroplasty	I-PROC
(	O	O
TKA	B-PROC
)	O	O
,	O	O
have	O	O
been	O	O
attributed	O
to	O	O
a	O	O
lack	O
of	O	O
patient	B-LIVB
education	B-PROC
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
investigate	O
specific	O
factors	O
affecting	O
a	O	O
patient	B-LIVB
's	I-LIVB
perceived	B-PHYS
ability	B-PHYS
to	I-PHYS
kneel	I-PHYS
post	O
TKA	B-PROC
,	O	O
following	O	O
exposure	O
to	O
a	O	O
preoperative	O
kneeling	B-PHYS
education	B-PROC
session	I-PROC
.	O	O

A	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O	O
conducted	O	O
following	O	O
TKA	B-PROC
with	O	O
patients	B-LIVB
who	O	O
had	O	O
been	O	O
educated	B-PROC
about	O	O
kneeling	B-PHYS
prior	O
to	O	O
the	O	O
operation	B-PROC
.	O	O

Patients	B-LIVB
completed	O	O
kneeling	B-PHYS
questionnaires	O
at	O	O
6	O	O
(	O	O
n	O	O
=	O	O
115	O	O
)	O	O
and	O	O
12	O	O
(	O	O
n	O	O
=	O	O
82	O	O
)	O	O
months	O
post	O
TKA	B-PROC
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
12	O
-	O
month	O
kneeling	B-PHYS
questionnaire	O
,	O	O
patients	B-LIVB
also	O	O
completed	O	O
the	O	O
Oxford	B-PHYS
knee	I-PHYS
score	I-PHYS
(	O	O
OKS	B-PHYS
)	O	O
survey	O	O
.	O	O

Seventy	O	O
-	O	O
two	O	O
percent	O
of	O	O
patients	B-LIVB
perceived	B-PHYS
they	O	O
could	O	O
kneel	B-PHYS
at	O	O
12	O	O
months	O
post	O
TKA	B-PROC
.	O	O

Overall	O	O
,	O	O
pain	B-DISO
and	O	O
discomfort	B-DISO
were	O	O
the	O	O
most	O	O
common	O	O
factors	O
deterring	O	O
patients	B-LIVB
from	O	O
kneeling	B-PHYS
.	O	O

Perceived	B-PHYS
kneeling	B-PHYS
ability	B-PHYS
was	O	O
the	O	O
poorest	O	O
scored	O	O
outcome	O
on	O	O
the	O	O
OKS	B-PHYS
with	O	O
patients	B-LIVB
reporting	O	O
mild	O
to	O
moderate	O
difficulty	B-DISO
with	O	O
this	O	O
task	O	O
.	O	O

Kneeling	B-PHYS
scores	O	O
were	O	O
strongly	O	O
correlated	O
with	O	O
overall	O	O
knee	B-DISO
function	I-DISO
scores	I-DISO
(	O	O
R	O	O
=	O	O
0	O	O
.	O	O
70	O	O
)	O	O
,	O	O
strongly	O	O
correlated	O
with	O	O
pain	B-DISO
scores	I-DISO
(	O	O
R	O	O
=	O	O
0	O	O
.	O	O
45	O	O
)	O	O
and	O	O
weakly	O	O
correlated	O
with	O	O
knee	B-DISO
stability	I-DISO
scores	I-DISO
(	O	O
R	O	O
=	O	O
0	O	O
.	O	O
29	O	O
)	O	O
.	O	O

When	O	O
asked	O	O
about	O	O
other	O	O
factors	O
preventing	O
kneeling	B-PHYS
other	O	O
than	O	O
pain	B-DISO
or	O	O
discomfor	B-DISO
t	O	O
,	O	O
75	O	O
%	O	O
had	O	O
reasons	O	O
unrelated	B-DISO
to	O	O
the	O	O
knee	B-ANAT
or	O	O
TKA	B-PROC
.	O	O

The	O	O
most	O	O
common	O	O
reason	O	O
was	O	O
'	O	O
problems	O	O
with	O	O
the	O	O
other	O	O
knee	B-ANAT
'	O	O
(	O	O
n	O	O
=	O	O
19	O	O
)	O	O
.	O	O

Patients	B-LIVB
in	O	O
this	O	O
study	O	O
were	O	O
provided	O	O
with	O	O
education	B-PROC
regarding	O	O
their	O	O
kneeling	B-PHYS
ability	B-PHYS
post	O
TKA	B-PROC
,	O	O
yet	O	O
still	O	O
experienced	O	O
limitations	O	O
in	O	O
perceived	B-PHYS
kneeling	B-PHYS
ability	O	O
post	O
operatively	O	O
.	O	O

Contrary	O	O
to	O	O
previous	O	O
research	O	O
,	O	O
our	O	O
study	O	O
suggests	O	O
that	O	O
factors	O
other	O	O
than	O	O
patient	B-LIVB
education	B-PROC
affect	B-PROC
a	O	O
patient	B-LIVB
's	I-LIVB
perceived	B-PHYS
kneeling	B-PHYS
ability	B-PHYS
post	O
TKA	B-PROC
.	O	O

Improved	B-DISO
diagnostic	O
yield	O
of	O	O
neuromuscular	B-DISO
disorders	I-DISO
applying	O	O
clinical	O
exome	B-PROC
sequencing	I-PROC
in	O	O
patients	B-LIVB
arising	O	O
from	O	O
a	O	O
consanguineous	O
population	B-LIVB
Neuromuscular	B-DISO
diseases	I-DISO
(	O	O
NMDs	B-DISO
)	O	O
include	O	O
a	O	O
broad	O	O
range	O	O
of	O	O
disorders	B-DISO
affecting	O	O
muscles	O
,	O	O
nerves	O
and	O	O
neuromuscular	B-ANAT
junctions	I-ANAT
.	O	O

Their	O	O
overlapping	O	O
phenotypes	B-PHYS
and	O	O
heterogeneous	B-PHYS
genetic	I-PHYS
nature	I-PHYS
have	O	O
created	O	O
challenges	O	O
in	O	O
diagnosis	B-DISO
which	O	O
calls	O	O
for	O	O
the	O	O
implementation	O
of	O	O
massive	B-PROC
parallel	I-PROC
sequencing	I-PROC
as	O	O
a	O	O
candidate	O	O
strategy	O	O
to	O	O
increase	O	O
the	O	O
diagnostic	O
yield	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
total	O	O
of	O	O
45	O	O
patients	B-LIVB
,	O	O
mostly	O	O
offspring	B-LIVB
of	O	O
consanguineous	O
marriages	O
were	O	O
examined	O	O
using	O	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
.	O	O

Data	O
analysis	O
was	O	O
performed	O	O
to	O	O
identify	O	O
the	O	O
most	O	O
probable	O	O
pathogenic	B-DISO
rare	O
variants	O
in	O	O
known	O	O
NMD	B-DISO
genes	O
which	O	O
led	O	O
to	O	O
identification	O	O
of	O	O
causal	O
variants	O
for	O	O
33	O	O
out	O	O
of	O	O
45	O	O
patients	B-LIVB
(	O	O
73	O	O
.	O	O

3	O	O
%	O	O
)	O	O
in	O	O
the	O	O
following	O	O
known	O	O
genes	O
:	O	O
CAPN3	O
,	O	O
Col6A1	O
,	O	O
Col6A3	O
,	O	O
DMD	O
,	O	O
DYSF	O
,	O	O
FHL1	O
,	O	O
GJB1	O
,	O	O
ISPD	O
,	O	O
LAMA2	O
,	O	O
LMNA	O
,	O	O
PLEC1	O
,	O	O
RYR1	O
,	O	O
SGCA	O
,	O	O
SGCB	O
,	O	O
SYNE1	O
,	O	O
TNNT1	O
and	O	O
22	O	O
novel	O	O
pathogenic	B-DISO
variants	O
were	O	O
detected	B-DISO
.	O	O

Today	O	O
,	O	O
the	O	O
advantage	O	O
of	O	O
whole	B-PROC
exome	I-PROC
sequencing	I-PROC
in	O	O
clinical	B-PROC
diagnostic	I-PROC
strategies	O	O
of	O	O
heterogeneous	B-DISO
disorders	I-DISO
is	O	O
clear	O	O
.	O	O

In	O	O
this	O	O
cohort	B-LIVB
,	O	O
a	O	O
diagnostic	O
yield	O
of	O	O
73	O	O
.	O	O

3	O	O
%	O	O
was	O	O
achieved	O	O
which	O	O
is	O	O
quite	O	O
high	O	O
compared	O
to	O	O
the	O	O
overall	O
reported	O	O
diagnostic	O
yield	O
of	O	O
25	O	O
%	O	O
to	O	O
50	O	O
%	O	O
.	O	O

This	O	O
could	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
consanguineous	O
background	O	O
of	O	O
these	O	O
patients	B-LIVB
and	O	O
is	O	O
another	O	O
strong	O	O
advantage	O	O
of	O	O
offering	O	O
clinical	O
exome	B-PROC
sequencing	I-PROC
in	O	O
diagnostic	O
laboratories	B-OBJC
,	O	O
especially	O	O
in	O	O
populations	B-LIVB
with	O	O
high	O	O
rate	O	O
of	O	O
consanguinity	B-DISO
.	O	O

Safety	B-PROC
of	O	O
transradial	B-PROC
diagnostic	I-PROC
cardiac	I-PROC
catheterization	I-PROC
in	O	O
patients	B-LIVB
under	O	O
oral	O
anticoagulant	B-PROC
therapy	I-PROC
Cardiac	B-PROC
catheterization	I-PROC
in	O	O
anticoagulated	O
patients	B-LIVB
is	O	O
usually	O	O
performed	O
after	O	O
the	O	O
anticoagulation	B-PROC
has	O	O
been	O	O
withdrawn	B-PROC
,	O	O
at	O	O
least	O	O
in	O	O
the	O	O
previous	O	O
48h	O	O
,	O	O
and	O	O
sometimes	O	O
bridging	B-PROC
therapy	I-PROC
with	I-PROC
heparin	I-PROC
is	O	O
used	O	O
.	O	O

A	O	O
prospective	O	O
observational	B-PROC
study	I-PROC
including	O	O
489	O	O
patients	B-LIVB
undergoing	O	O
transradial	B-PROC
catheterization	I-PROC
was	O	O
conducted	O	O
.	O	O

A	O	O
total	O	O
of	O	O
140	O	O
patients	B-LIVB
were	O	O
under	O	O
acenocoumarol	B-CHEM
(	O	O
group	O
A	O
)	O	O
and	O	O
they	O	O
were	O	O
compared	O
with	O	O
the	O	O
remainder	O
(	O	O
group	O
B	O
)	O	O
for	O	O
complications	B-DISO
after	O	O
the	O	O
procedure	B-PROC
(	O	O
bleeding	B-DISO
and	O	O
vascular	B-DISO
access	I-DISO
complications	I-DISO
)	O	O
.	O	O

Patients	B-LIVB
in	O	O
group	O
A	O
were	O	O
older	B-LIVB
(	O	O
74±12	O	O
years	O	O
vs	O	O
.	O	O

68±17	O	O
years	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
the	O	O
main	O	O
indication	O
for	O	O
anticoagulation	B-PROC
was	O	O
atrial	B-DISO
fibrillation	I-DISO
(	O	O
58	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

No	B-DISO
complications	B-DISO
occurred	O	O
during	O	O
the	O	O
procedures	B-PROC
.	O	O

There	O	O
were	O	O
no	B-DISO
acute	B-DISO
bleedings	I-DISO
just	O	O
after	O
the	O	O
bandage	B-DEVI
removal	O
.	O	O

During	O	O
the	O	O
first	O	O
24h	O	O
,	O	O
only	O	O
3	O	O
(	O	O
2	O	O
.	O	O
1	O	O
%	O	O
)	O	O
radial	B-DISO
occlusions	I-DISO
in	O	O
group	O
A	O
and	O	O
2	O	O
(	O	O
0	O	O
.	O	O
6	O	O
%	O	O
)	O	O
in	O	O
group	O
B	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

14	O	O
)	O	O
were	O	O
recorded	O
.	O	O

Hematomas	B-DISO
between	O	O
5	O	O
and	O	O
10	O	O
cm	O	O
appeared	O	O
in	O	O
5	O	O
%	O	O
of	O	O
the	O	O
group	O
A	O
vs	O	O
.	O	O

4	O	O
.	O	O
6	O	O
%	O	O
in	O	O
group	O
B	O
.	O	O

During	O	O
the	O	O
1	O
-	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
,	O	O
one	O	O
more	O	O
radial	B-DISO
occlusion	I-DISO
in	O	O
each	O	O
group	O
was	O	O
recorded	O
and	O	O
there	O	O
were	O	O
4	O	O
(	O	O
1	O	O
.	O	O
1	O	O
%	O	O
)	O	O
additional	O	O
mild	O
hematomas	B-DISO
in	O	O
group	O
B	O
and	O	O
none	O	O
in	O	O
group	O
A	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
48	O	O
)	O	O
.	O	O

Performing	O
a	O	O
transradial	B-PROC
diagnostic	I-PROC
cardiac	I-PROC
catheterization	I-PROC
without	O
removal	O
of	O	O
the	O	O
oral	O
chronic	O
anticoagulation	O
appears	O	O
safe	B-DISO
in	O	O
patients	B-LIVB
under	O	O
acenocumarol	B-CHEM
therapy	B-PROC
.	O	O

Does	O	O
infrared	B-DEVI
visualization	O
improve	O	O
selection	O
of	O	O
venipuncture	B-PROC
sites	O
for	O	O
indwelling	O
needle	B-DEVI
at	O	O
the	O	O
forearm	B-ANAT
in	O	O
second	O	O
-	O	O
year	O	O
nursing	B-LIVB
students	I-LIVB
?	O	O
To	O	O
evaluate	O	O
the	O	O
effectiveness	O
of	O	O
a	O	O
vein	B-DEVI
visualization	I-DEVI
display	I-DEVI
system	I-DEVI
using	O	O
near	B-PHEN
-	I-PHEN
infrared	I-PHEN
light	I-PHEN
(	O	O
""""	O	O
Vein	B-DEVI
Display	I-DEVI
""""	O	O
)	O	O
for	O	O
the	O	O
safe	O	O
and	O	O
proper	O	O
selection	O
of	O	O
venipuncture	B-PROC
sites	O
for	O	O
indwelling	O
needle	B-DEVI
placement	O	O
in	O	O
the	O	O
forearm	B-ANAT
.	O	O

Ten	O	O
second	O	O
year	O	O
nursing	B-LIVB
students	I-LIVB
were	O	O
recruited	O	O
to	O	O
apply	O	O
an	O	O
indwelling	O
needle	B-DEVI
line	O	O
with	O	O
and	O	O
without	O	O
Vein	B-ANAT
Display	O
.	O	O

Another	O	O
ten	O	O
participants	B-LIVB
were	O	O
recruited	O	O
from	O	O
various	O	O
faculty	B-LIVB
to	O	O
serve	O	O
as	O	O
patients	B-LIVB
.	O	O

The	O	O
quality	O	O
of	O	O
the	O	O
venipuncture	B-PROC
procedure	I-PROC
at	O	O
various	O	O
selected	O	O
sites	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
scale	O
developed	O	O
by	O	O
the	O	O
authors	B-LIVB
.	O	O

Time	O
,	O	O
scores	O
and	O	O
patterns	O
of	O	O
puncture	B-PROC
-	O	O
site	O
selection	O
were	O	O
compared	O	O
with	O	O
respect	O	O
to	O	O
three	O	O
different	O	O
methods	O	O
:	O	O
[	O	O
1	O	O
]	O	O
attempt	O	O
1	O	O
(	O	O
tourniquet	B-DEVI
only	O	O
)	O	O
,	O	O
[	O	O
2	O	O
]	O	O
attempt	O	O
2	O	O
(	O	O
Vein	B-DEVI
Display	I-DEVI
only	O	O
)	O	O
and	O	O
[	O	O
3	O	O
]	O	O
attempt	O	O
3	O	O
(	O	O
both	O	O
)	O	O
.	O	O

To	O	O
validate	O	O
the	O	O
effectiveness	O
of	O	O
Vein	B-ANAT
Display	O
,	O	O
52	O	O
trials	O	O
were	O	O
conducted	O	O
in	O	O
total	O	O
.	O	O

We	O	O
found	O	O
that	O	O
venipuncture	B-PROC
site	O
selection	O
time	O	O
was	O	O
significantly	O	O
improved	O	O
with	O	O
the	O	O
Vein	B-DEVI
Display	I-DEVI
,	O	O
particularly	O	O
in	O	O
the	O	O
case	O	O
of	O	O
difficult	O	O
to	O	O
administer	O
venipuncture	B-PROC
sites	O
.	O	O

Overall	O	O
,	O	O
we	O	O
found	O	O
no	O	O
significant	O	O
difference	O	O
with	O	O
respect	O	O
to	O	O
venipuncture	B-PROC
quality	O
,	O	O
as	O	O
determined	O	O
by	O	O
our	O	O
scale	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
equipment	O	O
such	O	O
as	O	O
the	O	O
Vein	B-DEVI
Display	I-DEVI
can	O	O
contribute	O	O
immensely	O	O
to	O	O
the	O	O
improvement	O	O
of	O	O
practical	O
skills	O
,	O	O
such	O	O
as	O	O
venipuncture	B-PROC
,	O	O
especially	O	O
in	O	O
the	O	O
context	O	O
of	O	O
elderly	B-LIVB
patients	B-LIVB
.	O	O

Elective	B-PROC
Nephron	B-PROC
Sparing	I-PROC
Surgery	I-PROC
Decreases	O
Other	B-DISO
Cause	I-DISO
Mortality	I-DISO
Relative	O
to	O	O
Radical	B-PROC
Nephrectomy	I-PROC
Only	O	O
in	O	O
Specific	O
Subgroups	O
of	O	O
Patients	B-LIVB
with	O	O
Renal	B-DISO
Cell	I-DISO
Carcinoma	I-DISO
There	O	O
is	O	O
no	O	O
consensus	O
regarding	O	O
a	O	O
protective	B-DISO
effect	I-DISO
on	O	O
mortality	O
due	O	O
to	O	O
a	O	O
cause	O	O
other	O	O
than	O	O
cancer	B-DISO
in	O	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
elective	B-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
relative	O
to	O	O
their	O	O
radical	B-PROC
nephrectomy	I-PROC
counterparts	O	O
.	O	O

We	O	O
test	O
whether	O	O
the	O	O
protective	B-DISO
effect	I-DISO
of	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
relative	O
to	O	O
radical	B-PROC
nephrectomy	I-PROC
is	O	O
universal	O
or	O	O
present	O	O
in	O	O
specific	O
subgroups	O
of	O	O
patients	B-LIVB
.	O	O

A	O	O
collaborative	O
database	O
of	O	O
5	O	O
institutions	O
was	O	O
queried	O
to	O	O
evaluate	B-PROC
1	O	O
,	O	O
783	O	O
patients	B-LIVB
without	O	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
diagnosed	B-DISO
with	O	O
a	O	O
clinical	O
T1	B-DISO
renal	I-DISO
mass	I-DISO
that	O	O
was	O	O
treated	B-PROC
with	I-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
or	O	O
radical	B-PROC
nephrectomy	I-PROC
.	O	O

Multivariable	O
Cox	O
regression	O
analysis	O
was	O	O
done	O	O
to	O	O
assess	B-PROC
the	O	O
impact	O
of	O	O
surgery	B-PROC
type	O	O
(	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
vs	O	O
radical	B-PROC
nephrectomy	I-PROC
)	O	O
on	O	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
after	O	O
adjustment	O	O
for	O	O
patient	B-LIVB
and	O	O
cancer	B-DISO
characteristics	O
.	O	O

Interaction	O
terms	O	O
were	O	O
used	O	O
to	O	O
test	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
impact	O
of	O	O
surgery	B-PROC
type	O	O
varies	O	O
according	O	O
to	O	O
specific	O
subcohorts	B-LIVB
of	O	O
patients	B-LIVB
.	O	O

Ten	O
-	O
year	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
-free	O	O
survival	O
rates	O
were	O	O
90	O	O
%	O	O
and	O	O
88	O	O
%	O	O
after	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
and	O	O
radical	B-PROC
nephrectomy	I-PROC
,	O	O
respectively	O	O
.	O	O

In	O	O
the	O	O
overall	O
population	B-LIVB
radical	B-PROC
nephrectomy	I-PROC
was	O	O
not	O	O
associated	O
with	O
an	O	O
increased	O
risk	O
of	O	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
on	O	O
multivariable	O
analysis	O
compared	O	O
to	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
(	O	O
HR	O
0	O	O
.	O	O
91	O	O
,	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
6	O	O
-	O	O
1	O	O
.	O	O
38	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
6	O	O
)	O	O
.	O	O

However	O	O
,	O	O
radical	B-PROC
nephrectomy	I-PROC
increased	O
the	O	O
risk	O
of	O	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
according	O	O
to	O	O
the	O	O
increasing	O
baseline	O
Charlson	O
comorbidity	O
index	O
(	O	O
interaction	O
test	O
p	O	O
=	O	O
0	O	O
.	O	O
0008	O	O
)	O	O
.	O	O

For	O	O
example	O	O
,	O	O
in	O	O
a	O	O
patient	B-LIVB
with	O	O
a	O	O
Charlson	O
comorbidity	O
index	O
of	O	O
4	O	O
the	O	O
probability	O
of	O	O
10	O
-	O
year	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
-free	O	O
survival	O
was	O	O
86	O	O
%	O	O
after	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
and	O	O
60	O	O
%	O	O
after	O	O
radical	B-PROC
nephrectomy	I-PROC
.	O	O

Elective	B-PROC
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
does	O	O
not	O	O
improve	B-DISO
other	O	O
cause	O	O
survival	O
relative	O
to	O	O
radical	B-PROC
nephrectomy	I-PROC
consistently	O	O
in	O	O
all	O	O
patients	B-LIVB
with	O	O
kidney	B-DISO
cancer	I-DISO
.	O	O

Patients	B-LIVB
who	O	O
are	O	O
more	O	O
ill	B-DISO
with	O	O
relevant	O
comorbidities	O
are	O	O
those	O	O
who	O	O
benefit	O
the	O	O
most	O	O
from	O	O
nephron	B-PROC
sparing	I-PROC
surgery	I-PROC
in	O	O
terms	O	O
of	O	O
other	B-DISO
cause	I-DISO
mortality	I-DISO
.	O	O

A	O	O
prime	B-PHYS
a	O	O
day	O	O
keeps	O	O
calories	O
away	O	O
:	O	O
The	O	O
effects	O
of	O
supraliminal	B-PHYS
priming	I-PHYS
on	O	O
food	O
consumption	O
and	O	O
the	O	O
moderating	O
role	O
of	O	O
gender	B-PHYS
and	O	O
eating	O
restraint	O
The	O	O
link	O	O
between	O	O
intentions	B-PHYS
and	O	O
action	O
in	O	O
weight	B-PROC
control	I-PROC
is	O	O
weaker	O	O
than	O	O
previously	O	O
thought	O	O
,	O	O
so	O	O
recent	O	O
research	B-PROC
has	O	O
called	O	O
for	O	O
further	O	O
investigation	O	O
of	O	O
ways	O	O
to	O	O
improve	O	O
weight	B-PROC
control	I-PROC
that	O	O
bypass	O	O
conscious	B-PHYS
intentions	B-PHYS
.	O	O

Priming	B-PHYS
has	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
effects	O	O
on	O	O
individual	O	O
behavior	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
contexts	O	O
by	O	O
influencing	O	O
subconscious	B-PHYS
cognition	B-PHYS
.	O	O

This	O	O
paper	O	O
investigates	O	O
the	O	O
effects	O
of	O
semantic	O
priming	O
using	O	O
healthy	O
body	B-PHYS
image	I-PHYS
,	O	O
goal	O
-	O
oriented	O
words	O
on	O	O
food	O
consumption	O
.	O	O

The	O	O
moderating	O
role	O
of	O	O
both	O	O
restrained	O
eating	O
and	O	O
gender	B-PHYS
is	O	O
investigated	O	O
.	O	O

161	O	O
participants	B-LIVB
were	O	O
involved	O	O
in	O	O
an	O	O
experiment	B-PROC
using	O	O
a	O	O
novel	O	O
version	O	O
of	O	O
a	O	O
scrambled	O	O
sentence	O
priming	B-PHYS
game	O
.	O	O

The	O	O
outcome	O	O
measure	O	O
was	O	O
the	O	O
number	O	O
of	O	O
kilocalories	O
consumed	B-PROC
,	O	O
examined	O	O
using	O	O
a	O	O
between	O	O
subjects	O	O
ANCOVA	O
with	O	O
priming	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
restrained	O
eating	O
index	O
,	O	O
self	B-PROC
-	I-PROC
reported	I-PROC
BMI	B-PHYS
,	O	O
and	O	O
two	O	O
interaction	O
terms	O	O
(	O	O
priming	B-PHYS
x	O	O
gender	B-PHYS
,	O	O
and	O	O
priming	B-PHYS
x	O	O
restrained	O
eating	O
index	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
main	O	O
effect	O
of	O
priming	B-PHYS
but	O	O
there	O	O
was	O	O
an	O	O
interaction	O
of	O	O
priming	B-PHYS
with	O	O
gender	B-PHYS
.	O	O

Females	B-PHYS
consumed	O	O
significantly	O	O
fewer	O	O
kilocalories	O
after	O	O
being	O	O
exposed	O	O
to	O	O
priming	B-PHYS
words	O
related	O	O
to	O	O
a	O	O
healthy	O
body	B-PHYS
image	I-PHYS
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
""""	O	O
slim	O	O
""""	O	O
,	O	O
""""	O	O
fit	O	O
,	O	O
""""	O	O
)	O	O
compared	O	O
to	O	O
females	B-PHYS
receiving	O	O
the	O	O
neutral	O	O
prime	B-PHYS
,	O	O
with	O	O
a	O	O
medium	O	O
effect	O	O
size	O	O
(	O	O
d	O	O
=	O	O
0	O	O
.	O	O
58	O	O
)	O	O
.	O	O

The	O	O
body	B-PHYS
image	I-PHYS
prime	B-PHYS
did	O	O
not	O	O
significantly	O	O
affect	O	O
food	B-PHYS
intake	I-PHYS
for	O	O
males	B-PHYS
,	O	O
nor	O	O
did	O	O
it	O	O
have	O	O
a	O	O
differential	O	O
effect	O	O
on	O	O
restrained	B-LIVB
eaters	I-LIVB
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
priming	B-PHYS
can	O	O
be	O	O
an	O	O
effective	O	O
method	O	O
for	O	O
influencing	O	O
females	B-PHYS
to	O	O
reduce	O	O
food	B-PHYS
intake	I-PHYS
,	O	O
regardless	O	O
of	O	O
whether	O	O
they	O	O
are	O	O
restrained	B-LIVB
or	O	O
unrestrained	B-LIVB
eaters	I-LIVB
.	O	O

Future	O	O
studies	O	O
could	O	O
investigate	O	O
whether	O	O
different	O	O
priming	B-PHYS
words	O
related	O	O
to	O	O
a	O	O
male	B-PHYS
's	I-PHYS
healthy	O
body	B-PHYS
image	I-PHYS
goal	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
""""	O	O
buff	O	O
,	O	O
""""	O	O
""""	O	O
muscles	O
,	O	O
""""	O	O
etc	O	O
.	O	O
)	O	O
would	O	O
similarly	O	O
reduce	O	O
food	B-PHYS
intake	I-PHYS
for	O	O
males	B-PHYS
.	O	O

Neurotrophins	B-CHEM
and	O	O
specific	B-CHEM
receptors	I-CHEM
in	O	O
the	O	O
oviduct	B-ANAT
tracts	I-ANAT
of	O	O
Japanese	B-LIVB
quail	I-LIVB
(	O	O
Coturnix	B-LIVB
coturnix	I-LIVB
japonica	I-LIVB
)	O	O
Neurotrophins	B-CHEM
(	O	O
NGF	B-CHEM
,	O	O
BDNF	B-CHEM
and	O	O
NT	B-CHEM
-	I-CHEM
3	I-CHEM
)	O	O
and	O	O
their	O	O
specific	B-CHEM
receptors	I-CHEM
(	O	O
TrkA	B-CHEM
,	O	O
TrkB	B-CHEM
and	O	O
TrkC	B-CHEM
)	O	O
were	O	O
studied	B-PROC
in	O	O
the	O	O
oviduct	B-ANAT
of	O	O
egg	B-PHYS
laying	I-PHYS
quails	B-LIVB
.	O	O

Neurotrophins	B-CHEM
(	O	O
NTs	B-CHEM
)	O	O
are	O	O
mainly	O	O
involved	O	O
in	O	O
the	O	O
development	O
and	O	O
maintenance	O
of	O	O
neuronal	B-ANAT
populations	I-ANAT
in	O	O
the	O	O
central	B-ANAT
and	O	O
peripheral	B-ANAT
nervous	I-ANAT
system	I-ANAT
,	O	O
but	O	O
also	O	O
in	O	O
reproductive	B-ANAT
system	I-ANAT
.	O	O

In	O	O
this	O	O
survey	O	O
,	O	O
we	O	O
first	O	O
studied	B-PROC
the	O	O
morphological	O
organization	B-PHYS
of	O	O
the	O	O
quail	B-LIVB
oviduct	B-ANAT
,	O	O
distinguished	O	O
in	O	O
infundibulum	B-ANAT
,	O	O
magnum	B-ANAT
,	O	O
isthmus	B-ANAT
,	O	O
uterus	B-ANAT
and	O	O
vagina	B-ANAT
,	O	O
and	O	O
then	O	O
we	O	O
analyzed	B-PROC
the	O	O
expression	B-PHYS
and	O	O
localization	B-PHYS
of	O	O
NTs	B-CHEM
and	O	O
Trks	B-CHEM
receptors	I-CHEM
in	O	O
the	O	O
whole	O	O
tracts	B-ANAT
.	O	O

By	O	O
western	B-PROC
blotting	I-PROC
we	O	O
detected	O	O
that	O	O
the	O	O
investigated	O
NTs	B-CHEM
and	O	O
Trks	B-CHEM
receptors	I-CHEM
are	O	O
expressed	B-PHYS
in	O	O
all	O	O
oviductal	B-ANAT
tracts	I-ANAT
.	O	O

By	O	O
immunohistochemistry	B-PROC
we	O	O
were	O	O
able	O	O
to	O	O
define	O	O
the	O	O
distribution	B-PHYS
of	O	O
NTs	B-CHEM
and	O	O
Trks	B-CHEM
.	O	O

Specifically	O	O
,	O	O
NGF	B-CHEM
,	O	O
BDNF	B-CHEM
and	O	O
NT3	B-CHEM
were	O	O
localized	O	O
in	O	O
lining	O
and	O	O
ductal	B-ANAT
epithelial	I-ANAT
cells	I-ANAT
,	O	O
and	O	O
NGF	B-CHEM
was	O	O
also	O	O
detected	O	O
in	O	O
secretory	B-ANAT
cells	I-ANAT
of	O	O
tubular	B-ANAT
glands	I-ANAT
and	O	O
in	O	O
nervous	B-ANAT
fibers	I-ANAT
of	O	O
vessel	B-ANAT
wall	I-ANAT
.	O	O

TrkA	B-CHEM
and	O	O
TrkB	B-CHEM
were	O	O
present	O	O
in	O	O
the	O	O
lining	O
and	O	O
ductal	O
epithelium	O
;	O	O
TrkA	B-CHEM
and	O	O
TrkC	B-CHEM
were	O	O
present	O	O
in	O	O
nervous	B-ANAT
fibers	I-ANAT
of	O	O
vessel	B-ANAT
wall	I-ANAT
in	O	O
all	O	O
oviductal	B-ANAT
tracts	I-ANAT
.	O	O

Furthermore	O	O
,	O	O
we	O	O
also	O	O
observed	O	O
NGF	B-CHEM
and	O	O
BDNF	B-CHEM
co	O	O
-	O	O
localized	O	O
with	O	O
TrkA	B-CHEM
and	O	O
TrkB	B-CHEM
in	O	O
cells	B-ANAT
of	O	O
the	O	O
lining	O
and	O	O
ductal	O
epithelium	O
,	O	O
suggesting	O	O
an	O	O
autocrine	B-PHYS
mechanism	I-PHYS
of	O	O
action	O
.	O	O

Laser	B-OBJC
-facilitated	O	O
epicutaneous	B-PROC
immunotherapy	B-PROC
to	O	O
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergy	I-DISO
Allergen	B-PROC
specific	I-PROC
immunotherapy	I-PROC
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
the	O	O
only	O	O
effective	O
treatment	B-PROC
for	O	O
long	O
-	O
lasting	O
clinical	O
benefit	O
to	O	O
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergic	I-DISO
diseases	I-DISO
,	O	O
but	O	O
a	O	O
fewer	O	O
than	O	O
5	O	O
%	O	O
of	O	O
patients	B-LIVB
choose	O	O
the	O	O
treatment	B-PROC
because	O	O
of	O	O
inconvenience	O	O
and	O	O
a	O	O
high	B-DISO
risk	I-DISO
of	I-DISO
anaphylaxis	B-DISO
.	O	O

Recently	O	O
,	O	O
epicutaneous	B-PROC
allergen	I-PROC
-	I-PROC
specific	I-PROC
immunotherapy	I-PROC
(	O	O
EPIT	B-PROC
)	O	O
has	O	O
proven	O	O
effective	O
,	O	O
yet	O	O
with	O	O
limitations	O
owing	O	O
to	O	O
strong	B-PHYS
skin	I-PHYS
reactions	I-PHYS
.	O	O

We	O	O
demonstrate	O	O
here	O	O
safer	O	O
and	O	O
faster	O	O
EPIT	B-PROC
,	O	O
named	O	O
μEPIT	B-PROC
,	O	O
by	O	O
delivering	O
powdered	B-CHEM
allergen	I-CHEM
and	O	O
adjuvants	B-CHEM
into	O	O
many	O	O
micropores	B-ANAT
in	O	O
the	O	O
epidermis	O
.	O	O

We	O	O
fabricated	O	O
a	O	O
microarray	B-OBJC
patch	B-DEVI
fractionally	O	O
coated	O
with	O	O
a	O	O
powder	B-CHEM
mixture	I-CHEM
of	I-CHEM
ovalbumin	I-CHEM
(	O	O
OVA	B-CHEM
)	O	O
model	O	O
allergen	B-CHEM
,	O	O
CpG	B-CHEM
,	O	O
and	O	O
1	B-CHEM
,	I-CHEM
25	I-CHEM
-	I-CHEM
dihydroxyvitamin	I-CHEM
D3	I-CHEM
(	O	O
VD3	B-CHEM
)	O	O
.	O	O

Topical	B-PROC
application	I-PROC
of	O	O
the	O	O
patch	B-DEVI
onto	O	O
laser	B-DISO
-	I-DISO
microperforated	I-DISO
skin	B-ANAT
resulted	O
in	O
a	O	O
high	O	O
level	O
of	O	O
epidermal	O
delivery	O
while	O	O
greatly	O	O
minimizing	O	O
allergen	B-CHEM
leakage	B-DISO
into	O	O
circulation	B-ANAT
system	I-ANAT
as	O	O
compared	O
to	O	O
current	O	O
subcutaneous	B-PROC
immunotherapy	I-PROC
(	O	O
SCIT	B-PROC
)	O	O
.	O	O

Moreover	O	O
,	O	O
only	O	O
three	O	O
times	O	O
of	O	O
μEPIT	B-PROC
over	O	O
two	O	O
weeks	O	O
could	O	O
sufficiently	O	O
inhibit	O
allergen	B-CHEM
-	I-CHEM
specific	I-CHEM
IgE	I-CHEM
responses	B-PHYS
in	O	O
mice	B-LIVB
suffering	O	O
OVA	B-CHEM
-induced	O	O
airway	B-DISO
hyperresponsivness	I-DISO
(	O	O
AHR	B-DISO
)	O	O
,	O	O
which	O	O
was	O	O
unattainable	O	O
by	O	O
eight	O	O
times	O	O
of	O	O
SCIT	B-PROC
over	O	O
three	O	O
weeks	O	O
.	O	O

Mechanistically	O	O
,	O	O
μEPIT	B-PROC
preferably	O	O
enhanced	O
IgG2a	B-CHEM
production	B-PHEN
suggesting	O	O
TH1	B-ANAT
-	I-ANAT
biased	I-ANAT
immune	B-PHYS
responses	I-PHYS
and	O	O
induced	O
a	O	O
high	O	O
level	O
of	O	O
T	B-ANAT
-	I-ANAT
regulatory	I-ANAT
(	O	O
Treg	B-ANAT
)	O	O
cells	B-ANAT
against	O	O
repeated	O	O
allergen	B-DISO
sensitization	I-DISO
.	O	O

The	O	O
immune	B-DISO
tolerance	I-DISO
was	O	O
confirmed	O
by	O
marked	O	O
reduction	B-PROC
in	O	O
airway	B-ANAT
wall	I-ANAT
thickness	B-DISO
as	O	O
well	O	O
as	O	O
eosinophil	B-ANAT
and	O	O
neutrophil	B-PHYS
infiltration	I-PHYS
into	O	O
the	O	O
respiratory	B-ANAT
airway	I-ANAT
.	O	O

The	O	O
μEPIT	B-PROC
represents	O
a	O	O
novel	O
and	O	O
painless	O
technology	O
to	O	O
treat	B-PROC
IgE	B-DISO
-	I-DISO
mediated	I-DISO
allergic	I-DISO
diseases	I-DISO
with	O	O
little	O	O
local	B-PHYS
skin	I-PHYS
reaction	I-PHYS
and	O	O
a	O	O
minimal	O	O
risk	O	O
of	O	O
anaphylaxis	B-DISO
.	O	O

Predicting	O
real	O
-	O	O
world	B-LIVB
functional	O
milestones	O
in	O	O
schizophrenia	B-DISO
Schizophrenia	B-DISO
is	O	O
a	O	O
severe	B-DISO
disorder	I-DISO
that	O	O
often	O	O
causes	O	O
impairments	O
in	O	O
major	O	O
areas	O	O
of	O	O
functioning	O
,	O	O
and	O	O
most	O	O
patients	B-LIVB
do	O	O
not	O	O
achieve	O	O
expected	O	O
real	O
-	O	O
world	B-LIVB
functional	O
milestones	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
identify	O	O
which	O	O
variables	O
of	O	O
demography	O
,	O	O
illness	B-DISO
activity	O
,	O	O
and	O	O
functional	B-DISO
capacity	I-DISO
predict	O	O
patients	B-LIVB
'	O	O
ability	O	O
to	O	O
attain	O	O
real	O
-	O	O
world	B-LIVB
functional	O
milestones	O
.	O	O

Participants	B-LIVB
were	O	O
235	O	O
outpatients	B-LIVB
,	O	O
149	O	O
men	B-LIVB
and	O	O
86	O	O
women	B-LIVB
,	O	O
diagnosed	B-DISO
with	O	O
schizophrenia	B-DISO
spectrum	B-DISO
disorder	I-DISO
.	O	O

Our	O	O
results	O	O
showed	O	O
that	O	O
younger	O
patients	B-LIVB
managed	O	O
to	O	O
achieve	O	O
a	O	O
higher	O
level	O
of	O	O
functioning	O
in	O	O
educational	B-DISO
level	I-DISO
,	O	O
marital	O
status	O
,	O	O
and	O	O
social	B-DISO
contacts	I-DISO
.	O	O

Patients	B-LIVB
'	O	O
functional	B-DISO
capacity	I-DISO
was	O	O
primarily	O	O
associated	O	O
with	O	O
educational	B-DISO
level	I-DISO
and	O	O
housing	B-OBJC
situation	O	O
.	O	O

We	O	O
also	O	O
found	O	O
that	O	O
women	B-LIVB
needed	O	O
less	O	O
support	O	O
regarding	O	O
housing	B-OBJC
and	O	O
obtained	O	O
a	O	O
higher	O
level	O
of	O	O
marital	O
status	O
as	O	O
compared	O	O
with	O	O
men	B-LIVB
.	O	O

Our	O	O
findings	B-DISO
demonstrate	O	O
the	O	O
importance	O	O
of	O	O
considering	O	O
current	O
symptoms	B-DISO
,	O	O
especially	O	O
negative	B-DISO
symptoms	B-DISO
,	O	O
and	O	O
remission	B-DISO
stability	O
over	O	O
time	O
,	O	O
together	O	O
with	O	O
age	B-PHYS
,	O	O
duration	O
of	O
illness	O
,	O	O
gender	B-PHYS
,	O	O
educational	B-DISO
level	I-DISO
,	O	O
and	O	O
current	O
functional	B-DISO
capacity	I-DISO
,	O	O
when	O	O
predicting	O	O
patients	B-LIVB
'	O	O
future	O	O
real	O
-	O	O
world	B-LIVB
functioning	O
.	O	O

We	O	O
also	O	O
conclude	O	O
that	O	O
there	O	O
is	O	O
an	O	O
advantage	O	O
in	O	O
exploring	O	O
symptoms	B-DISO
divided	O	O
into	O	O
positive	B-DISO
,	O	O
negative	B-DISO
,	O	O
and	O	O
general	O	O
domains	O	O
considering	O	O
their	O	O
probable	O	O
impact	O
on	O	O
functional	O
achievements	O
.	O	O

LDLR	O
,	O	O
ApoB	O
and	O	O
ApoE	O
genes	O
polymorphisms	B-PHYS
and	O	O
classical	O	O
risk	B-DISO
factors	I-DISO
in	O	O
premature	B-DISO
coronary	I-DISO
artery	I-DISO
disease	I-DISO
Lipoproteins	B-CHEM
play	O	O
a	O	O
central	O	O
role	O	O
in	O	O
the	O	O
development	O
of	O	O
atherosclerotic	B-DISO
disease	I-DISO
.	O	O

So	O	O
,	O	O
with	O	O
their	O	O
ability	O	O
to	O	O
affect	O	O
lipid	B-PHEN
levels	I-PHEN
,	O	O
the	O	O
LDLR	O
,	O	O
ApoB	O
and	O	O
ApoE	O
polymorphisms	B-PHYS
could	O	O
be	O	O
one	O	O
of	O	O
the	O	O
factors	O	O
influencing	O	O
development	O
of	O	O
atherosclerosis	B-DISO
.	O	O

This	O	O
hypothesis	O
has	O	O
been	O	O
tested	O
in	O	O
different	O	O
populations	O
with	O	O
conflicting	O	O
results	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O
the	O	O
association	O	O
between	O	O
the	O	O
LDLR	O
,	O	O
ApoB	O
and	O	O
ApoE	O
genes	O
polymorphisms	B-PHYS
with	O	O
premature	B-DISO
CAD	I-DISO
(	O	O
PCAD	B-DISO
)	O	O
in	O	O
Egyptians	B-LIVB
.	O	O

One	O	O
hundred	O	O
thirty	O	O
-	O	O
five	O	O
patients	B-LIVB
of	O	O
PCAD	B-DISO
and	O	O
one	O	O
hundred	O	O
thirty	O	O
-	O	O
two	O	O
ages	B-PHYS
and	O	O
sex	B-PHYS
matched	O	O
control	O	O
subjects	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

LDLR	O
and	O	O
ApoB	O
genes	O
polymorphisms	B-PHYS
were	O	O
analyzed	B-PROC
by	O	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
(	O	O
PCR	B-PROC
)	O	O
.	O	O

The	O	O
ApoE	O
genotypes	B-PHYS
were	O	O
identified	O	O
by	O	O
multiplex	B-PROC
amplification	I-PROC
refractory	I-PROC
mutation	I-PROC
system	I-PROC
(	O	O
multi	B-PROC
-	I-PROC
AMRS	I-PROC
)	O	O
.	O	O

We	O	O
found	O	O
that	O	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O	O
ApoE	O
E4	O
allele	O
increased	O	O
the	O	O
risk	O	O
of	O	O
PCAD	B-DISO
by	O	O
1	O	O
.	O	O

8	O	O
,	O	O
2	O	O
.	O	O
1	O	O
and	O	O
12	O	O
.	O	O
1	O	O
respectively	O	O
.	O	O

The	O	O
present	O	O
study	O	O
proved	O	O
that	O	O
smoking	O
,	O	O
metabolic	B-DISO
syndrome	I-DISO
,	O	O
ApoB	O
X	O
(	O
+	O
)	O
X	O
(	O
+	O
)	O
genotype	B-PHYS
and	O	O
ApoE	O
E4	O
allele	O
were	O	O
independent	O	O
risk	B-DISO
factors	I-DISO
for	O	O
the	O	O
development	O
of	O	O
PCAD	B-DISO
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
investigate	O
the	O	O
association	O	O
between	O	O
low	O
density	O
lipoprotein	O
receptor	O
,	O	O
apolipoprotein	O
B	O
and	O	O
apolipoprotein	O
E	O
genes	O
polymorphisms	B-PHYS
with	O	O
PCAD	B-DISO
and	O	O
lipid	B-PHEN
levels	I-PHEN
in	O	O
Egyptians	B-LIVB
and	O	O
we	O	O
concluded	O	O
that	O	O
the	O	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O	O
ApoE	O
E4	O
allele	O
may	O	O
be	O	O
associated	O
with	O
an	O	O
increased	O	O
risk	O	O
for	O	O
development	O
of	O	O
PCAD	B-DISO
by	O	O
elevated	O	O
levels	B-PROC
of	I-PROC
total	I-PROC
cholesterol	I-PROC
(	I-PROC
TC	I-PROC
)	I-PROC
and	O	O
low	B-PROC
density	I-PROC
lipoprotein	I-PROC
(	O	O
LDLc	B-PROC
)	O	O
.	O	O

The	O	O
coexistence	O	O
of	O	O
CAD	B-DISO
risk	B-DISO
factors	I-DISO
with	O	O
LDLR	O
A	O
(	O
+	O
)	O
A	O
(	O
+	O
)	O
genotype	B-PHYS
,	O	O
ApoB	O
X	O
(	O
+	O
)	O
allele	O
and	O	O
ApoE	O
E4	O
allele	O
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
development	O
of	O	O
PCAD	B-DISO
in	O	O
Egyptian	B-LIVB
patients	B-LIVB
.	O	O

The	O	O
influence	O	O
of	O	O
liposomal	B-CHEM
formulation	O
on	O	O
the	O	O
incorporation	O
and	O	O
retention	O
of	O	O
PNA	B-CHEM
oligomers	I-CHEM
Liposomal	B-CHEM
formulations	O
composed	O	O
of	O	O
phospholipids	B-CHEM
with	O	O
different	O	O
unsaturation	O
degrees	O
,	O	O
head	O
groups	O
and	O	O
at	O	O
different	O	O
cholesterol	B-PROC
content	I-PROC
have	I-PROC
been	I-PROC
tested	I-PROC
for	O	O
the	O	O
encapsulation	B-PHEN
of	O	O
Peptide	B-CHEM
Nucleic	I-CHEM
Acid	I-CHEM
(	I-CHEM
PNA	I-CHEM
)	I-CHEM
oligomers	I-CHEM
.	O	O

The	O	O
best	O
loading	O
capability	O
(	O	O
177μg	O	O
,	O	O
ER	O
%	O	O
=	O	O
87	O	O
.	O	O

2	O	O
)	O	O
was	O	O
obtained	O	O
for	O	O
pure	O	O
liposomes	B-CHEM
of	O	O
phosphatidylglycerol	B-CHEM
(	O	O
DOPG	B-CHEM
)	O	O
with	O	O
negatively	B-CHEM
charged	I-CHEM
head	O
group	O
.	O	O

The	O	O
insertion	B-PROC
of	O	O
a	O	O
10	O	O
-	O	O
20	O	O
%	O	O
of	O	O
cholesterol	B-CHEM
in	O	O
DOPG	B-CHEM
based	O	O
liposomes	B-CHEM
provides	O	O
a	O	O
slight	O	O
decrease	O
(	O	O
∼160μg	O	O
)	O	O
of	O	O
the	O	O
PNA	B-CHEM
loading	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
cholesterol	B-CHEM
addition	O
(	O	O
20	O	O
-	O	O
30	O	O
%	O	O
)	O	O
slows	O	O
down	O	O
the	O	O
PNA	B-CHEM
's	I-CHEM
release	B-PHEN
(	O	O
∼27	O	O
%	O	O
)	O	O
in	O	O
fetal	B-CHEM
bovine	I-CHEM
serum	I-CHEM
from	O	O
the	O	O
liposomal	B-CHEM
formulation	O
.	O	O

Based	O	O
on	O	O
the	O	O
encapsulation	B-PHEN
and	O	O
the	O	O
release	B-PHEN
properties	I-PHEN
,	O	O
PEGylated	B-CHEM
DOPG	B-CHEM
liposomes	B-CHEM
with	O	O
a	O	O
percentage	O	O
of	O	O
cholesterol	B-CHEM
of	O	O
10	O	O
-	O	O
20	O	O
%	O	O
are	O	O
the	O	O
optimal	B-PROC
formulation	I-PROC
for	O	O
the	O	O
loading	O
of	O	O
PNA	B-CHEM
-	I-CHEM
a210	I-CHEM
.	O	O

Mandibular	B-ANAT
kinesiographic	O
pattern	O
of	O	O
women	B-LIVB
with	O	O
chronic	O
TMD	B-DISO
after	O	O
management	B-PROC
with	O	O
educational	O
and	O	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
:	O	O
A	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
Limited	B-DISO
mandibular	I-DISO
movements	I-DISO
are	O	O
one	O	O
of	O	O
the	O	O
most	O	O
important	O
signs	B-DISO
of	O	O
temporomandibular	B-DISO
disorders	I-DISO
(	O	O
TMDs	B-DISO
)	O	O
and	O	O
may	O	O
cause	O
functional	O
difficulties	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
effect	O
of	O	O
treatment	B-PROC
with	O	O
only	O	O
educational	O
or	O	O
education	O
associated	O
with	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
on	O	O
the	O	O
pattern	O
of	O	O
mandibular	B-ANAT
movements	B-PHYS
of	O	O
women	B-LIVB
with	O	O
chronic	B-DISO
painful	I-DISO
TMDs	B-DISO
.	O	O

Forty	O
-	O
two	O
women	B-LIVB
were	O	O
selected	O
and	O	O
randomly	O
divided	O
into	O	O
3	O	O
groups	O
,	O	O
control	B-LIVB
group	I-LIVB
(	O	O
CG	B-LIVB
,	O	O
n	O	O
=	O	O
13	O	O
)	O	O
,	O	O
education	O
group	O
(	O	O
EG	O
,	O	O
n	O	O
=	O	O
16	O	O
)	O	O
,	O	O
and	O	O
education	O
and	O
self	O
-	O
care	O
group	O
(	O	O
ESG	O
,	O	O
n	O	O
=	O	O
13	O	O
)	O	O
,	O	O
according	O	O
to	O	O
the	O	O
sequence	O
of	O	O
treatment	B-PROC
they	O	O
received	O
.	O	O

A	O	O
kinesiograph	B-DEVI
device	I-DEVI
recorded	O
mandibular	B-ANAT
movements	B-PHYS
during	O
maximum	O
mouth	B-ANAT
opening	B-PHYS
and	O	O
mastication	B-PHYS
at	O	O
baseline	O
(	O	O
T0	O
)	O	O
and	O	O
at	O	O
30	O
-	O
day	O
(	O	O
T1	O
)	O	O
and	O	O
60	O
-	O
day	O
(	O	O
T2	O
)	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Kinesiographic	O
data	O
were	O	O
statistically	B-PROC
analyzed	I-PROC
using	O
1	O
-	O
way	O
ANOVA	O
,	O	O
followed	O
by	O
the	O	O
Bonferroni	O
test	O
for	O	O
multiple	O
comparisons	O
of	O	O
means	O
(	O	O
α	O	O
=	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
ESG	O
group	O
demonstrated	O	O
an	O	O
improvement	O
in	O	O
the	O	O
maximum	B-PHYS
vertical	I-PHYS
opening	I-PHYS
(	O	O
MVO	B-PHYS
=	O	O
5	O	O
.	O	O
1	O	O
±3	O	O
.	O	O
4	O	O
mm	O	O
;	O	O
P	O	O
=	O	O
.	O	O

012	O	O
)	O	O
and	O	O
anteroposterior	B-PHYS
mandibular	I-PHYS
movement	I-PHYS
(	O	O
MAM	B-PHYS
)	O	O
during	O
maximum	O
opening	B-PHYS
(	O	O
7	O	O
.	O	O
4	O	O
±9	O	O
.	O	O
5	O	O
;	O	O
P	O	O
=	O	O
.	O	O

019	O	O
)	O	O
,	O	O
significantly	O
higher	O
than	O	O
that	O	O
of	O	O
the	O	O
EG	O
(	O	O
MVO	B-PHYS
=	O	O
1	O	O
.	O	O
8	O	O
±3	O	O
.	O	O
5	O	O
mm	O	O
;	O	O
MAM	B-PHYS
=	O	O
0	O	O
.	O	O
8	O	O
±5	O	O
.	O	O
0	O	O
mm	O	O
)	O	O
and	O	O
the	O	O
CG	B-LIVB
(	O	O
MVO	B-PHYS
=	O	O
0	O	O
.	O	O
9	O	O
±3	O	O
.	O	O
8	O	O
mm	O	O
;	O	O
MAM	B-PHYS
=	O	O
0	O	O
.	O	O
8	O	O
±4	O	O
.	O	O
4	O	O
mm	O	O
)	O	O
after	O	O
30	O
days	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Moreover	O	O
,	O	O
at	O	O
T1	O
,	O	O
vertical	O
mandibular	B-ANAT
movement	B-PHYS
during	O
mastication	B-PHYS
was	O	O
significantly	O
higher	O
in	O	O
the	O	O
ESG	O
group	O
(	O	O
17	O	O
.	O	O
4	O	O
±1	O	O
.	O	O
7	O	O
mm	O	O
)	O	O
than	O	O
in	O	O
the	O	O
EG	O
group	O
(	O	O
15	O	O
.	O	O
0	O	O
±2	O	O
.	O	O
8	O	O
,	O	O
P	O	O
=	O	O
.	O	O

027	O	O
)	O	O
.	O	O

No	B-DISO
significant	I-DISO
differences	O
were	O	O
found	B-DISO
between	O	O
the	O	O
women	B-LIVB
who	O	O
received	O
treatment	B-PROC
with	O	O
educational	O
and	O	O
self	B-PROC
-	I-PROC
care	I-PROC
therapies	I-PROC
for	O	O
60	O
days	O
and	O	O
the	O	O
women	B-LIVB
who	O	O
received	O
this	O	O
treatment	B-PROC
for	O	O
30	O
days	O
.	O	O

In	O	O
the	O	O
short	O
-	O
term	O
,	O	O
education	O
and	O	O
self	B-PROC
-	I-PROC
care	I-PROC
treatment	I-PROC
positively	B-DISO
influenced	O
the	O	O
mandibular	B-ANAT
movement	B-PHYS
pattern	O
of	O	O
women	B-LIVB
with	O	O
chronic	B-DISO
painful	I-DISO
TMDs	B-DISO
.	O	O

Histopathology	O
of	O	O
the	O	O
filum	B-ANAT
terminale	I-ANAT
in	O	O
children	B-LIVB
with	O	O
and	O	O
without	O
tethered	B-DISO
cord	I-DISO
syndrome	I-DISO
with	O	O
attention	O	O
to	O	O
the	O	O
elastic	O
tissue	O
within	O	O
the	O	O
filum	B-ANAT
To	O	O
compare	O
histologically	O
transected	O
fila	B-ANAT
from	O	O
pediatric	O
patients	B-LIVB
with	O	O
tethered	B-DISO
cord	I-DISO
syndrome	I-DISO
(	O	O
TCS	B-DISO
)	O	O
,	O	O
with	O	O
and	O	O
without	O
a	O	O
low	B-ANAT
conus	B-ANAT
,	O	O
with	O	O
controls	O	O
,	O	O
focusing	O	O
on	O	O
collagenous	O
and	O	O
elastic	O
tissue	O
.	O	O

Thirty	O	O
fila	B-ANAT
from	O	O
patients	B-LIVB
with	O	O
TCS	B-DISO
,	O	O
including	O	O
5	O	O
where	O	O
minimal	O
cautery	B-PROC
was	O	O
used	O	O
prior	O	O
to	O	O
filum	B-ANAT
section	B-PROC
,	O	O
were	O	O
compared	O
with	O	O
fila	B-ANAT
from	O	O
27	O	O
pediatric	O
cadavers	B-ANAT
without	O
TCS	B-DISO
(	O	O
controls	B-LIVB
)	O	O
.	O	O

Sections	B-OBJC
of	O	O
fila	B-ANAT
were	O	O
stained	B-PROC
with	O	O
H	B-PROC
&	I-PROC
E	I-PROC
,	O	O
Masson	B-PROC
trichrome	I-PROC
and	O	O
Verhoeff	B-PROC
von	I-PROC
Gieson	I-PROC
elastic	I-PROC
stains	I-PROC
,	O	O
and	O	O
7	O	O
with	O	O
Gordon	B-PROC
and	I-PROC
Sweet	I-PROC
's	I-PROC
reticulin	I-PROC
stain	I-PROC
.	O	O

Fila	B-ANAT
from	O	O
controls	B-LIVB
showed	O	O
loose	O
fibrous	O
connective	O
tissue	O
(	O	O
FCT	O
)	O	O
with	O	O
thin	O
and	O	O
evenly	O
dispersed	O
elastic	O
fibers	O
(	O	O
EFs	O
)	O	O
.	O	O

Reticulin	B-CHEM
fibers	I-CHEM
(	O	O
RFs	B-CHEM
)	O	O
were	O	O
seen	O	O
in	O	O
blood	B-ANAT
vessel	I-ANAT
walls	I-ANAT
and	O	O
nerve	O
twigs	O	O
.	O	O

Fat	B-CHEM
was	O	O
identified	O
microscopically	O
in	O	O
2	O	O
fila	B-ANAT
.	O	O

All	O	O
fila	B-ANAT
from	O	O
patients	B-LIVB
with	O	O
TCS	B-DISO
had	O	O
dense	O
FCT	O
.	O	O

The	O	O
EFs	O
were	O	O
in	O	O
normal	O
numbers	O	O
in	O	O
17	O	O
,	O	O
and	O	O
focally	O
or	O	O
diffusely	O
decreased	O
in	O	O
13	O	O
.	O	O

All	O	O
25	O	O
patients	B-LIVB
where	O	O
the	O	O
fila	B-ANAT
were	O	O
cauterized	B-PROC
during	O	O
resection	B-PROC
had	O	O
thick	O
and	O	O
coiled	O
EFs	O
.	O	O

Coiling	O
was	O	O
not	O	O
seen	O	O
when	O	O
minimal	O
cautery	B-PROC
was	O	O
applied	O	O
.	O	O

RFs	B-CHEM
were	O	O
seen	O	O
in	O	O
blood	B-ANAT
vessel	I-ANAT
walls	I-ANAT
and	O	O
nerve	O	O
twigs	O	O
.	O	O

Fat	B-CHEM
was	O	O
identified	O
in	O	O
19	O	O
patients	B-LIVB
.	O	O

Findings	B-DISO
were	O	O
similar	O
,	O	O
whether	O	O
the	O	O
conus	B-ANAT
termination	O	O
was	O	O
normal	O
or	O	O
low	O
.	O	O

The	O	O
fila	B-ANAT
of	O	O
all	O	O
patients	B-LIVB
with	O	O
TCS	B-DISO
,	O	O
whether	O	O
or	O	O
not	O	O
the	O	O
conus	B-ANAT
was	O	O
low	O
,	O	O
showed	O	O
abnormal	B-DISO
FCT	O
.	O	O

EFs	O
were	O	O
decreased	O
in	O	O
48	O	O
%	O	O
of	O	O
patients	B-LIVB
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
thick	O
and	O	O
coiled	O
EFs	O
in	O	O
all	O	O
patients	B-LIVB
.	O	O

Coiling	O
of	O	O
EFs	O
,	O	O
initially	O	O
thought	O	O
to	O	O
be	O	O
an	O	O
abnormality	B-DISO
in	O	O
patients	B-LIVB
,	O	O
is	O	O
considered	O	O
most	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
result	B-DISO
of	O	O
cautery	B-PROC
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
artifactual	B-PHEN
/	O	O
iatrogenic	O
coiling	O
)	O	O
.	O	O

Clinical	B-DISO
value	I-DISO
of	O	O
pathologic	B-PROC
examination	I-PROC
of	O	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
in	O	O
patients	B-LIVB
with	O	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
While	O	O
surgical	B-PROC
resection	I-PROC
remains	O	O
the	O	O
standard	O	O
of	O	O
care	O
in	O	O
the	O	O
treatment	B-PROC
of	O	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
,	O	O
nephrectomy	B-PROC
is	O	O
a	O	O
risk	B-DISO
factor	I-DISO
for	O	O
the	O	O
development	O
of	O	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
(	O	O
CKD	B-DISO
)	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
whether	O	O
histologic	O
evaluation	B-PROC
of	O	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
could	O	O
enable	O	O
early	B-PROC
identification	I-PROC
of	O	O
unrecognized	O	O
kidney	B-DISO
disease	I-DISO
and	O	O
could	O	O
be	O	O
of	O	O
prognostic	O
value	O	O
in	O	O
predicting	O	O
postoperative	O
renal	B-ANAT
outcomes	O
.	O	O

We	O	O
retrospectively	B-PROC
analyzed	I-PROC
51	O	O
patients	B-LIVB
with	O	O
upper	B-ANAT
urinary	I-ANAT
tract	I-ANAT
malignancies	B-DISO
who	O	O
received	O	O
uninephrectomy	B-PROC
or	O	O
uninephroureterectomy	B-PROC
.	O	O

A	O	O
thorough	O	O
pathologic	O
evaluation	B-PROC
of	O	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
including	O	O
special	B-PROC
stains	I-PROC
,	O	O
immunofluorescence	B-PROC
,	O	O
and	O	O
electron	B-PROC
microscopic	I-PROC
studies	I-PROC
was	O	O
performed	O	O
.	O	O

The	O	O
degree	O
of	O	O
parenchymal	B-ANAT
changes	O
was	O	O
graded	O	O
from	O	O
0	O	O
to	O	O
15	O	O
.	O	O

Of	O	O
51	O	O
patients	B-LIVB
,	O	O
only	O	O
13	O	O
showed	O	O
normal	O	O
kidney	B-ANAT
pathology	O
.	O	O

Fifteen	O	O
patients	B-LIVB
showed	O	O
glomerular	B-DISO
abnormalities	I-DISO
,	O	O
14	O	O
showed	O	O
diabetic	B-DISO
nephropathy	I-DISO
,	O	O
and	O	O
11	O	O
showed	O	O
vascular	B-ANAT
nephropathy	B-PROC
.	O	O

There	O	O
was	O	O
one	O	O
case	O	O
each	O	O
of	O	O
reflux	B-DISO
nephropathy	I-DISO
and	O	O
chronic	B-DISO
pyelonephritis	I-DISO
.	O	O

The	O	O
median	O	O
histologic	O
score	O
was	O	O
5	O	O
points	O	O
.	O	O

Only	O	O
25	O	O
.	O	O
4	O	O
%	O	O
of	O	O
patients	B-LIVB
had	O	O
≤	O	O
3	O	O
points	O	O
.	O	O

Score	O
more	O	O
than	O	O
5	O	O
was	O	O
observed	O	O
in	O	O
47	O	O
.	O	O

1	O	O
%	O	O
of	O	O
patients	B-LIVB
.	O	O

Postoperative	O
estimated	B-PROC
glomerular	I-PROC
filtration	I-PROC
rate	I-PROC
(	O	O
eGFR	B-PROC
)	O	O
at	O	O
3	O	O
to	O	O
36	O	O
months	O
were	O	O
obtained	O	O
from	O	O
90	O	O
.	O	O

2	O	O
%	O	O
of	O	O
patients	B-LIVB
,	O	O
and	O	O
of	O	O
those	O	O
,	O	O
34	O	O
.	O	O

8	O	O
%	O	O
had	O	O
de	O	O
novo	O	O
CKD	B-DISO
.	O	O

Since	O	O
no	O	O
one	O	O
had	O	O
CKD	B-DISO
in	O	O
partial	O	O
nephrectomized	B-LIVB
patients	I-LIVB
,	O	O
we	O	O
determined	O	O
risk	B-DISO
factors	I-DISO
for	O	O
CKD	B-DISO
in	O	O
radical	O	O
nephrectomized	B-LIVB
patients	I-LIVB
.	O	O

Cox	O
regression	O
analysis	O
revealed	O	O
that	O	O
postoperative	O
AKI	B-DISO
,	O	O
preoperative	O
eGFR	B-PROC
,	O	O
and	O	O
histologic	O
score	O	O
of	O	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
were	O	O
the	O	O
independent	O	O
predictors	O
for	O	O
CKD	B-DISO
.	O	O

We	O	O
conclude	O	O
that	O	O
routine	O	O
pathologic	O
evaluation	B-PROC
of	O	O
non	B-ANAT
-	I-ANAT
neoplastic	I-ANAT
kidney	I-ANAT
provides	O	O
valuable	O	O
diagnostic	O
and	O	O
prognostic	O
information	O	O
.	O	O

Prospective	O	O
study	O	O
of	O	O
dietary	B-OBJC
Non	B-PROC
Enzymatic	I-PROC
Antioxidant	I-PROC
Capacity	I-PROC
on	O	O
the	O	O
risk	O
of	O	O
hip	B-DISO
fracture	I-DISO
in	O	O
the	O	O
elderly	B-LIVB
Dietary	B-OBJC
antioxidants	I-OBJC
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
bone	B-DISO
loss	I-DISO
and	O	O
associated	O	O
fractures	B-DISO
by	O	O
reducing	O	O
levels	O	O
of	O	O
oxidative	B-DISO
stress	I-DISO
.	O	O

We	O	O
prospectively	O	O
investigated	O	O
the	O	O
association	O	O
between	O	O
dietary	B-OBJC
Non	B-PROC
Enzymatic	I-PROC
Antioxidant	I-PROC
Capacity	I-PROC
(	O	O
NEAC	B-PROC
)	O	O
and	O	O
the	O	O
risk	O
of	O	O
hip	B-DISO
fracture	I-DISO
and	O	O
whether	O	O
this	O	O
effect	O	O
was	O	O
modified	O	O
by	O	O
smoking	O
.	O	O

In	O	O
the	O	O
Swedish	B-LIVB
National	I-LIVB
March	I-LIVB
Cohort	I-LIVB
13	O	O
,	O	O
409	O	O
men	B-LIVB
and	O	O
women	B-LIVB
over	O	O
the	O	O
age	O	O
of	O	O
55	O	O
who	O	O
had	O	O
not	O	O
experienced	O	O
cancer	B-DISO
,	O	O
cardiovascular	B-DISO
disease	I-DISO
or	O	O
hip	B-DISO
fracture	I-DISO
,	O	O
were	O	O
followed	O	O
through	O	O
record	B-PROC
-	I-PROC
linkages	I-PROC
from	O	O
1997	O	O
through	O	O
2010	O	O
.	O	O

NEAC	B-PROC
was	O	O
assessed	O	O
by	O	O
a	O	O
validated	O	O
food	O
frequency	O
questionnaire	O
collected	O	O
at	O	O
baseline	O
.	O	O

We	O	O
categorized	O	O
the	O	O
distribution	O	O
of	O	O
NEAC	B-PROC
into	O	O
sex	B-PHYS
-	O	O
specific	O
quartiles	O
and	O	O
used	O	O
multivariable	O
adjusted	O
Cox	O
proportional	O
hazards	O
regression	O
models	O
to	O	O
estimate	O	O
hazard	O
ratios	O
(	O	O
HRs	O
)	O	O
with	O	O
95	O	O
%	O	O
confidence	O
intervals	O
(	O	O
95	O	O
%	O	O
CI	O
)	O	O
.	O	O

During	O	O
a	O	O
mean	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
time	O
of	O	O
12	O	O
.	O	O

4years	O	O
,	O	O
we	O	O
identified	O	O
491	O	O
incident	O	O
cases	O	O
of	O	O
first	O	O
hip	B-DISO
fracture	I-DISO
.	O	O

Subjects	O	O
in	O	O
the	O	O
highest	O	O
quartile	O
of	O	O
dietary	B-OBJC
NEAC	B-PROC
had	O	O
a	O	O
39	O	O
%	O	O
lower	B-DISO
risk	I-DISO
of	O	O
incident	O	O
hip	B-DISO
fracture	I-DISO
compared	O	O
to	O	O
those	O	O
in	O	O
the	O	O
lowest	O	O
quartile	O
(	O	O
HR	O
:	O	O
0	O	O
.	O	O
61	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
44	O	O
-	O	O
0	O	O
.	O	O
85	O	O
)	O	O
.	O	O

The	O	O
association	O	O
was	O	O
non	O	O
-	O	O
linear	O	O
(	O	O
p	O	O
for	O	O
non	O	O
-	O	O
linearity	O	O
:	O	O
0	O	O
.	O	O
004	O	O
)	O	O
with	O	O
a	O	O
potential	O	O
threshold	O	O
between	O	O
the	O	O
first	O	O
and	O	O
the	O	O
second	O	O
quartile	O
and	O	O
no	O	O
further	O	O
risk	O
reduction	O
at	O	O
higher	O	O
levels	O	O
of	O	O
dietary	B-OBJC
NEAC	B-PROC
.	O	O

Due	O	O
to	O	O
a	O	O
low	O	O
smoking	O	O
prevalence	O	O
in	O	O
our	O	O
study	O	O
population	O	O
,	O	O
we	O	O
had	O	O
limited	O	O
power	O	O
to	O	O
detect	O	O
effect	O	O
modification	O	O
between	O	O
dietary	B-OBJC
NEAC	B-PROC
and	O	O
smoking	O
on	O	O
a	O	O
multiplicative	O
or	O	O
additive	O
scale	O
.	O	O

Higher	O	O
dietary	O	O
NEAC	B-PROC
intake	O	O
is	O	O
associated	O	O
with	O	O
lower	O	O
risk	O
of	O	O
hip	B-DISO
fracture	I-DISO
in	O	O
the	O	O
elderly	O	O
.	O	O

MiR	O
-	O
211	O
is	O	O
epigenetically	B-PHYS
regulated	I-PHYS
by	O	O
DNMT1	O
mediated	O	O
methylation	B-PHYS
and	O	O
inhibits	O
EMT	B-PHYS
of	O	O
melanoma	B-ANAT
cells	I-ANAT
by	O	O
targeting	B-PROC
RAB22A	O
MiR	O
-	O
211	O
has	O	O
strong	O	O
inhibitive	O
effects	O	O
on	O	O
melanoma	B-DISO
cell	B-PHYS
growth	I-PHYS
,	O	O
invasion	B-DISO
and	O	O
metastasis	B-DISO
.	O	O

However	O	O
,	O	O
how	O	O
it	O	O
is	O	O
downregulated	B-PHYS
and	O	O
whether	O	O
other	O	O
genes	O
are	O	O
involved	O	O
its	O	O
downstream	O
regulation	B-PHYS
in	O	O
melanoma	B-DISO
are	O	O
not	O	O
clear	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
firstly	O	O
verified	O	O
the	O	O
expression	B-PHYS
of	O	O
miR	O
-	O
211	O
in	O	O
melanoma	B-ANAT
cell	I-ANAT
lines	I-ANAT
and	O	O
observed	O	O
that	O	O
its	O	O
downregulation	B-PHYS
is	O	O
associated	O
with	O
increased	O	O
DNMT1	O
expression	B-PHYS
.	O	O

By	O	O
performing	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
and	O	O
MSP	B-PROC
analysis	I-PROC
,	O	O
we	O	O
confirmed	O	O
that	O	O
DNMT1	O
is	O	O
negatively	B-DISO
correlated	O
with	O	O
miR	O
-	O
211	O
expression	B-PHYS
and	O	O
can	O	O
modulate	O
DNA	B-PHYS
methylation	I-PHYS
in	O	O
the	O	O
promoter	B-CHEM
region	I-CHEM
of	O	O
miR	O
-	O
211	O
.	O	O

By	O	O
performing	O	O
bioinformatics	O
analysis	O
,	O	O
we	O	O
found	O	O
that	O	O
RAB22A	O
is	O	O
a	O	O
possible	O	O
target	O
of	O	O
miR	O
-	O
211	O
,	O	O
which	O	O
has	O	O
two	O	O
broadly	O	O
conversed	O
binding	B-CHEM
sites	I-CHEM
with	O	O
miR	O
-	O
211	O
in	O	O
the	O	O
3	O
'	O
UTR	O
.	O	O

Following	O	O
dual	O	O
luciferase	B-CHEM
assay	B-PROC
,	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
and	O	O
western	B-PROC
blot	I-PROC
analysis	I-PROC
confirmed	O	O
the	O	O
direct	O	O
binding	B-PHYS
between	O	O
miR	O
-	O
211	O
and	O	O
RAB22A	O
and	O	O
the	O	O
suppressive	B-PHYS
effect	I-PHYS
of	O	O
miR	O
-	O
211	O
on	O	O
RAB22A	O
expression	B-PHYS
.	O	O

Knockdown	B-PROC
of	O	O
RAB22A	O
increased	O	O
epithelial	O
properties	O	O
and	O	O
impaired	O
mesenchymal	O
properties	O	O
of	O	O
the	O	O
melanoma	B-ANAT
cells	I-ANAT
,	O	O
suggesting	O	O
that	O	O
miR	O
-	O
211	O
modulates	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O	O
EMT	B-PHYS
)	O	O
of	O	O
melanoma	B-ANAT
cells	I-ANAT
via	O	O
downregulating	B-PHYS
RAB22A	O
.	O	O

In	O	O
summary	O	O
,	O	O
the	O	O
present	O	O
study	O	O
firstly	O	O
demonstrated	O	O
that	O	O
DNMT1	O
mediated	O	O
promoter	B-CHEM
methylation	B-PHYS
is	O	O
a	O	O
mechanism	O
of	O	O
miRNA	B-CHEM
suppression	B-PHYS
in	O	O
melanoma	B-DISO
and	O	O
revealed	O	O
a	O	O
new	O	O
tumor	O
suppressor	O
role	O	O
of	O	O
the	O	O
miR	O
-	O
211	O
by	O	O
targeting	B-PROC
RAB22A	O
in	O	O
melanoma	B-DISO
.	O	O

The	O	O
DNMT1	O
/	O	O
miR	O
-	O
211	O
/	O	O
RAB22A	O
axis	O	O
provides	O	O
a	O	O
novel	O	O
insight	O	O
into	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
melanoma	B-DISO
,	O	O
particularly	O	O
in	O	O
the	O	O
EMT	B-PHYS
process	I-PHYS
.	O	O

Concordant	O	O
but	O	O
Varied	O	O
Phenotypes	B-PHYS
among	O	O
Duchenne	B-DISO
Muscular	I-DISO
Dystrophy	I-DISO
Patient	B-LIVB
-Specific	O	O
Myoblasts	B-ANAT
Derived	O	O
using	O	O
a	O	O
Human	B-LIVB
iPSC	B-ANAT
-Based	O	O
Model	B-DISO
Duchenne	B-DISO
muscular	I-DISO
dystrophy	I-DISO
(	O	O
DMD	B-DISO
)	O	O
remains	O	O
an	O	O
intractable	O	O
genetic	B-DISO
disease	I-DISO
.	O	O

Althogh	O	O
there	O	O
are	O	O
several	O	O
animal	B-DISO
models	I-DISO
of	O	O
DMD	B-DISO
,	O	O
there	O	O
is	O	O
no	O	O
human	B-ANAT
cell	I-ANAT
model	O	O
that	O	O
carries	O	O
patient	B-LIVB
-specific	O	O
DYSTROPHIN	O
mutations	B-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
present	O	O
a	O	O
human	B-LIVB
DMD	B-DISO
model	B-DISO
using	O	O
human	B-ANAT
induced	I-ANAT
pluripotent	I-ANAT
stem	I-ANAT
cells	I-ANAT
(	O	O
hiPSCs	B-ANAT
)	O	O
.	O	O

Our	O	O
model	O	O
reveals	O	O
concordant	O	O
disease	B-DISO
-	O	O
related	O
phenotypes	B-PHYS
with	O	O
patient	B-LIVB
-	O	O
dependent	O
variation	O
,	O	O
which	O	O
are	O	O
partially	O	O
reversed	O	O
by	O	O
genetic	O
and	O	O
pharmacological	O
approaches	O	O
.	O	O

Our	O	O
""""	O	O
chemical	B-CHEM
-	I-CHEM
compound	I-CHEM
-based	O	O
""""	O	O
strategy	B-PROC
successfully	O	O
directs	O	O
hiPSCs	B-ANAT
into	O	O
expandable	O	O
myoblasts	B-ANAT
,	O	O
which	O	O
exhibit	O	O
a	O	O
myogenic	B-PHYS
transcriptional	I-PHYS
program	O
,	O	O
forming	O	O
striated	O
contractile	B-ANAT
myofibers	B-ANAT
and	O	O
participating	O	O
in	O	O
muscle	B-DISO
regeneration	I-DISO
in	O
vivo	O
.	O	O

DMD	B-DISO
-	O	O
hiPSC	B-ANAT
-derived	O	O
myoblasts	B-ANAT
show	O	O
disease	B-DISO
-	O	O
related	O
phenotypes	B-PHYS
with	O	O
patient	B-LIVB
-to	O	O
-	O	O
patient	B-LIVB
variability	O
,	O	O
including	O	O
aberrant	O
expression	O	O
of	O	O
inflammation	B-DISO
or	O	O
immune	O
-	O
response	O
genes	O
and	O	O
collagens	B-CHEM
,	O	O
increased	O	O
BMP	B-PHYS
/	O	O
TGFβ	B-PHYS
signaling	I-PHYS
,	O	O
and	O	O
reduced	O	O
fusion	O	O
competence	O	O
.	O	O

Furthermore	O	O
,	O	O
by	O	O
genetic	O
correction	O
and	O	O
pharmacological	O
""""	O	O
dual	O	O
-	O	O
SMAD	B-CHEM
""""	O	O
inhibition	B-PHYS
,	O	O
the	O	O
DMD	B-DISO
-	O	O
hiPSC	B-ANAT
-derived	O	O
myoblasts	B-ANAT
and	O	O
genetically	O
corrected	O	O
isogenic	O
myoblasts	B-ANAT
form	O	O
""""	O	O
rescued	O	O
""""	O	O
multi	O
-	O	O
nucleated	O
myotubes	B-ANAT
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
findings	O	O
demonstrate	O	O
the	O	O
feasibility	O	O
of	O	O
establishing	O	O
a	O	O
human	B-LIVB
""""	O	O
DMD	B-DISO
-in	O	O
-	O	O
a	O	O
-	O	O
dish	O	O
""""	O	O
model	B-DISO
using	O	O
hiPSC	B-ANAT
-based	O	O
disease	B-DISO
modeling	I-DISO
.	O	O

SNAI1	B-CHEM
promotes	O
the	O	O
development	O
of	O	O
HCC	B-DISO
through	O	O
the	O	O
enhancement	O
of	O	O
proliferation	O
and	O	O
inhibition	B-PHYS
of	I-PHYS
apoptosis	I-PHYS
SNAI1	B-CHEM
,	O	O
a	O	O
zinc	B-CHEM
-	I-CHEM
finger	I-CHEM
transcription	I-CHEM
factor	I-CHEM
,	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
induction	O
of	O	O
epithelial	B-PHYS
-	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O	O
EMT	B-PHYS
)	O	O
in	O	O
various	O	O
cancers	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
possible	O	O
functions	O	O
of	O	O
SNAI1	B-CHEM
in	O	O
the	O	O
proliferation	O
and	O	O
apoptosis	B-PHYS
of	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
have	O	O
not	O	O
been	O	O
clearly	O	O
identified	O	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O
and	O	O
mechanisms	O
of	O	O
SNAI1	B-CHEM
in	O	O
the	O	O
proliferation	O
and	O	O
apoptosis	B-PHYS
of	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
using	O	O
clinical	O
samples	B-OBJC
and	O	O
cell	B-ANAT
lines	I-ANAT
.	O	O

We	O	O
found	O	O
that	O	O
SNAI1	B-CHEM
is	O	O
highly	O	O
expressed	B-PHYS
in	O	O
the	O	O
tissues	O
of	O	O
liver	B-DISO
cancer	I-DISO
compared	O	O
with	O	O
adjacent	O	O
nontumor	O
tissues	O
.	O	O

SNAI1	B-CHEM
is	O	O
also	O	O
highly	O	O
expressed	B-PHYS
in	O	O
the	O	O
hepatoma	B-ANAT
cell	I-ANAT
lines	I-ANAT
HepG2	I-ANAT
,	O	O
SMMC	B-ANAT
-	I-ANAT
7721	I-ANAT
,	O	O
and	O	O
BEL	B-ANAT
-	I-ANAT
7402	I-ANAT
compared	O	O
with	O	O
the	O	O
human	B-ANAT
normal	I-ANAT
liver	I-ANAT
cell	I-ANAT
line	I-ANAT
L02	I-ANAT
.	O	O

We	O	O
also	O	O
observed	O	O
that	O	O
SNAI1	B-CHEM
expression	B-PHYS
was	O	O
correlated	O	O
with	O	O
distal	B-DISO
metastasis	I-DISO
,	O	O
incomplete	O	O
tumor	B-DISO
capsule	I-DISO
formation	I-DISO
,	O	O
and	O	O
histological	B-PHYS
differentiation	I-PHYS
in	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O	O
HCC	B-DISO
)	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
demonstrated	O	O
that	O	O
knockdown	B-PROC
of	O	O
SNAI1	O
via	O	O
lentiviral	B-LIVB
vectors	B-CHEM
of	O	O
RNAi	B-PHYS
against	O	O
SNAI	B-CHEM
inhibited	O	O
cell	O
proliferation	O
by	O	O
inducing	O	O
G1	B-PHYS
arrest	I-PHYS
,	O	O
which	O	O
was	O	O
accompanied	O	O
by	O	O
the	O	O
downregulation	B-PHYS
of	O	O
cyclin	B-CHEM
D1	I-CHEM
but	O	O
not	O	O
that	O	O
of	O	O
cyclin	B-CHEM
A	I-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
knockdown	B-PROC
of	O	O
SNAI1	O
promoted	O
apoptosis	B-PHYS
by	O	O
decreasing	O	O
the	O	O
expression	B-PHYS
of	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
findings	O	O
revealed	O	O
that	O	O
SNAI1	B-CHEM
is	O	O
involved	O	O
in	O	O
the	O	O
development	O
of	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
via	O	O
regulating	B-PHYS
the	I-PHYS
growth	I-PHYS
and	O	O
apoptosis	B-PHYS
of	O	O
tumor	B-ANAT
cells	I-ANAT
.	O	O

Function	B-PHYS
and	O	O
clinical	O
meaningfulness	O
of	O	O
treatments	B-PROC
for	O	O
mild	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
Effectiveness	O
of	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
AD	B-DISO
)	O	O
treatments	B-PROC
is	O	O
commonly	O	O
evaluated	O	O
with	O	O
coprimary	O
outcomes	O
;	O	O
cognition	B-PHYS
with	O	O
function	B-PHYS
to	O	O
ensure	O	O
clinical	O
meaningfulness	O
of	O	O
a	O	O
cognitive	B-PHYS
effect	O
.	O	O

We	O	O
reviewed	O
the	O	O
literature	O
for	O	O
functional	B-PHYS
outcomes	O
in	O	O
mild	O
AD	B-DISO
or	O	O
mild	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O	O
MCI	B-DISO
)	O	O
patients	B-LIVB
(	O	O
distinct	O	O
from	O	O
combined	O	O
mild	O
-	O
moderate	O
/	O	O
severe	O
AD	B-DISO
)	O	O
treated	B-PROC
with	I-PROC
approved	O	O
AD	B-DISO
drugs	B-CHEM
.	O	O

Cognitive	B-PROC
and	O	O
functional	B-PHYS
treatment	B-PROC
differences	O	O
in	O	O
mild	O
AD	B-DISO
patients	B-LIVB
in	O	O
solanezumab	B-CHEM
EXPEDITION	O
/	O	O
EXPEDITION2	O
studies	B-PROC
were	O	O
compared	O
across	O	O
time	O
.	O	O

Seven	O	O
publications	B-OBJC
provided	O	O
MCI	B-DISO
/	O	O
mild	O
AD	B-DISO
functional	B-PHYS
outcomes	O
,	O	O
one	O	O
of	O	O
which	O	O
reported	O	O
a	O	O
significant	O	O
functional	B-PHYS
treatment	B-DISO
effect	I-DISO
.	O	O

Secondary	O
analyses	O
of	O	O
EXPEDITION	O
studies	B-PROC
suggested	O	O
a	O	O
smaller	O	O
functional	B-PHYS
effect	O
of	O	O
solanezumab	B-CHEM
relative	O	O
to	O	O
cognition	B-PHYS
.	O	O

An	O	O
increasing	O
effect	O
of	O	O
solanezumab	B-CHEM
over	O	O
18	O	O
months	O
was	O	O
shown	O	O
for	O	O
cognition	B-PHYS
and	O	O
function	B-PHYS
.	O	O

Function	B-PHYS
as	O	O
the	O	O
sole	O	O
measure	O
to	O	O
demonstrate	O	O
clinical	O
meaningfulness	O
of	O	O
cognitive	B-PHYS
effects	O
in	O	O
mild	O
AD	B-DISO
may	O	O
have	O	O
limitations	O
.	O	O

For	O	O
disease	B-DISO
-	O	O
modifying	O
treatments	B-PROC
,	O	O
point	O	O
differences	O	O
on	O	O
cognitive	B-PHYS
and	O	O
functional	B-PHYS
scales	O
should	O	O
be	O	O
qualified	O	O
with	O	O
duration	O
of	O
treatment	O
.	O	O

Body	B-PHYS
mass	I-PHYS
index	I-PHYS
and	O	O
suicide	B-DISO
methods	O
Overweight	B-DISO
and	O	O
obesity	B-DISO
is	O	O
associated	O
with	O
lower	O
rates	O
of	O	O
suicide	B-DISO
.	O	O

However	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
association	O
with	O	O
different	O	O
suicide	B-DISO
methods	O
.	O	O

We	O	O
studied	O	O
the	O	O
association	O
between	O	O
groups	O	O
of	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
and	O	O
suicide	B-DISO
methods	O
.	O	O

We	O	O
identified	O	O
all	O	O
medicolegal	O
autopsy	B-PROC
cases	O
with	O	O
a	O	O
cause	B-DISO
of	I-DISO
death	I-DISO
due	O	O
to	O	O
external	B-DISO
causes	I-DISO
in	O	O
Sweden	B-GEOG
during	O	O
1999	O	O
-	O	O
2013	O	O
(	O	O
N	O	O
=	O	O
39	O	O
,	O	O
368	O	O
)	O	O
and	O	O
included	O
11	O	O
,	O	O
715	O	O
suicides	B-DISO
and	O	O
13	O	O
,	O	O
316	O	O
accidents	B-PHEN
or	O	O
homicides	O
as	O	O
controls	B-LIVB
.	O	O

We	O	O
applied	O	O
multinomial	O
regression	O
models	O
adjusted	O	O
for	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
year	O
and	O	O
season	O
of	O	O
death	B-DISO
.	O	O

Obesity	B-DISO
was	O	O
associated	O
with	O
suicidal	B-DISO
intoxication	B-DISO
,	O	O
OR	O
1	O	O
.	O	O

15	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
(	O	O
CI	O
)	O	O
1	O	O
.	O	O
02	O	O
,	O	O
1	O	O
.	O	O
30	O	O
]	O	O
and	O	O
negatively	B-DISO
associated	O
with	O
all	O	O
other	O	O
suicide	B-DISO
methods	O
studied	O	O
.	O	O

Underweight	B-DISO
showed	O	O
a	O	O
negative	B-DISO
association	O
with	O	O
suicidal	B-DISO
drowning	B-DISO
and	O	O
there	O	O
was	O	O
an	O	O
indication	O
towards	O	O
a	O	O
negative	B-DISO
association	O
with	O	O
hanging	B-DISO
in	O	O
men	B-LIVB
OR	O
0	O	O
.	O	O
81	O	O
(	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
65	O	O
,	O	O
1	O	O
.	O	O
01	O	O
)	O	O
.	O	O

We	O	O
conclude	O
that	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
is	O	O
associated	O
with	O
the	O	O
choice	O	O
of	O	O
suicide	B-DISO
method	O
.	O	O

This	O	O
may	O	O
be	O	O
of	O	O
importance	O	O
in	O	O
a	O	O
public	B-PROC
health	I-PROC
perspective	I-PROC
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

potential	O
for	O	O
prevention	B-PROC
of	O	O
intoxications	B-DISO
.	O	O

In	O	O
the	O	O
practice	O	O
of	O	O
forensic	O
medicine	O
,	O	O
the	O	O
physician	B-LIVB
's	I-LIVB
level	O	O
of	O	O
suspicion	B-PHYS
may	O	O
rise	O	O
if	O	O
the	O	O
apparent	O
suicidal	B-DISO
method	O	O
is	O	O
less	O
common	O
for	O	O
the	O	O
individual	O
characteristics	O
of	O	O
the	O	O
deceased	B-PHYS
,	O	O
such	O	O
as	O	O
BMI	B-PHYS
.	O	O

Quantitative	O
assessment	O
of	O	O
fluorescent	B-CHEM
proteins	I-CHEM
The	O	O
advent	O	O
of	O	O
fluorescent	B-CHEM
proteins	I-CHEM
(	O	O
FPs	B-CHEM
)	O	O
for	O	O
genetic	B-PROC
labeling	I-PROC
of	O	O
molecules	B-OBJC
and	O	O
cells	B-ANAT
has	O	O
revolutionized	O	O
fluorescence	B-PROC
microscopy	I-PROC
.	O	O

Genetic	B-PROC
manipulations	I-PROC
have	O	O
created	O	O
a	O	O
vast	O	O
array	O	O
of	O	O
bright	O	O
and	O	O
stable	O	O
FPs	B-CHEM
spanning	O	O
blue	O
to	O
red	O
spectral	O
regions	O
.	O	O

Common	O	O
to	O	O
autofluorescent	B-PROC
FPs	B-CHEM
is	O	O
their	O	O
tight	O	O
β	O
-	O
barrel	O
structure	O
,	O	O
which	O	O
provides	O	O
the	O	O
rigidity	O
and	O	O
chemical	B-CHEM
environment	O
needed	O	O
for	O	O
effectual	O	O
fluorescence	B-PHEN
.	O	O

Despite	O	O
the	O	O
common	O	O
structure	O
,	O	O
each	O	O
FP	B-CHEM
has	O	O
unique	O	O
properties	O
.	O	O

Thus	O	O
,	O	O
there	O	O
is	O	O
no	O	O
single	O	O
'	O	O
best	O	O
'	O	O
FP	B-CHEM
for	O	O
every	O	O
circumstance	O	O
,	O	O
and	O	O
each	O	O
FP	B-CHEM
has	O	O
advantages	O	O
and	O	O
disadvantages	O	O
.	O	O

To	O	O
guide	O	O
decisions	O	O
about	O	O
which	O	O
FP	B-CHEM
is	O	O
right	O	O
for	O	O
a	O	O
given	O	O
application	O	O
,	O	O
we	O	O
have	O	O
quantitatively	O
characterized	O	O
the	O	O
brightness	B-PHEN
,	O	O
photostability	B-DISO
,	O	O
pH	O
stability	O
and	O	O
monomeric	B-CHEM
properties	O
of	O	O
more	O	O
than	O	O
40	O	O
FPs	B-CHEM
to	O	O
enable	O	O
straightforward	O
and	O	O
direct	O	O
comparison	O
between	O	O
them	O	O
.	O	O

We	O	O
focus	O	O
on	O	O
popular	O	O
and	O	O
/	O	O
or	O	O
top	O	O
-	O	O
performing	O	O
FPs	B-CHEM
in	O	O
each	O	O
spectral	O
region	O
.	O	O

Cognitive	B-DISO
impairment	I-DISO
in	O	O
HIV	B-LIVB
and	O	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
:	O	O
a	O	O
systematic	O	O
review	O
and	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
Cognitive	B-DISO
impairment	I-DISO
has	O	O
been	O	O
well	O	O
documented	O	O
in	O	O
human	B-LIVB
immunodeficiency	I-LIVB
virus	I-LIVB
(	O	O
HIV	B-LIVB
)	O	O
and	O	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
(	O	O
HCV	B-LIVB
)	O	O
mono	B-DISO
-	I-DISO
infections	I-DISO
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
HIV	B-LIVB
/	O	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infection	I-DISO
the	O	O
research	O	O
is	O	O
more	O	O
limited	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
systematic	O	O
review	O
was	O	O
to	O	O
describe	O	O
the	O	O
characteristics	O	O
of	O	O
cognitive	B-DISO
impairment	I-DISO
in	O	O
HIV	B-LIVB
/	O	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infection	I-DISO
and	O	O
to	O	O
examine	B-DISO
the	O	O
differences	O	O
in	O	O
cognitive	B-PHYS
performance	I-PHYS
between	O	O
HIV	B-LIVB
/	O	O
HCV	B-LIVB
and	O	O
HIV	B-LIVB
and	O	O
HCV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O	O

Of	O	O
the	O	O
437	O	O
records	O	O
initially	O	O
screened	B-PROC
,	O	O
24	O	O
papers	O	O
met	O	O
the	O	O
inclusion	O	O
criteria	O	O
and	O	O
were	O	O
included	O	O
in	O	O
the	O	O
systematic	O	O
review	O
.	O	O

Four	O	O
studies	B-PROC
were	O	O
included	O	O
in	O	O
the	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O	O

Most	O	O
studies	B-PROC
indicated	O	O
that	O	O
HIV	B-LIVB
/	O	O
HCV	B-LIVB
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
had	O	O
a	O	O
higher	O	O
level	O	O
of	O	O
cognitive	B-DISO
impairment	I-DISO
than	O	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O	O

Meta	B-PROC
-	I-PROC
analysis	I-PROC
also	O	O
indicated	O	O
that	O	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
had	O	O
a	O	O
significantly	O	O
lower	O	O
global	O
deficit	O
score	O
than	O	O
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O	O

The	O	O
results	O	O
also	O	O
indicated	O	O
that	O	O
co	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
impaired	B-DISO
in	O	O
information	B-PHYS
processing	I-PHYS
speed	I-PHYS
than	O	O
HIV	B-LIVB
mono	B-DISO
-	I-DISO
infected	I-DISO
patients	B-LIVB
.	O	O

These	O	O
findings	B-DISO
can	O	O
be	O	O
challenged	O	O
by	O	O
biasing	O	O
factors	O	O
such	O	O
as	O	O
the	O	O
small	O	O
number	O	O
of	O	O
included	O	O
studies	B-PROC
,	O	O
heterogeneity	O
of	O	O
the	O	O
samples	O
and	O	O
a	O	O
large	O	O
diversity	O
of	O	O
methodological	O	O
procedures	O	O
.	O	O

Future	O	O
research	O	O
with	O	O
consistent	O	O
and	O	O
comprehensive	O	O
neuropsychological	O
batteries	O
and	O	O
covering	O	O
a	O	O
greater	O	O
diversity	O
of	O	O
risk	B-DISO
factors	I-DISO
is	O	O
needed	O	O
,	O	O
in	O	O
order	O	O
to	O	O
clarify	O	O
the	O	O
effects	O	O
of	O	O
both	O	O
viruses	B-LIVB
on	O	O
cognitive	B-PHYS
function	I-PHYS
and	O	O
the	O	O
mechanisms	O	O
that	O	O
underlie	O	O
these	O	O
effects	O	O
.	O	O

Because	O	O
cognitive	B-DISO
impairments	I-DISO
may	O	O
pose	O	O
significant	O	O
challenges	B-PROC
to	O	O
medication	B-DISO
adherence	I-DISO
,	O	O
quality	O
of	O
life	O
and	O	O
overall	O
functioning	O
,	O	O
such	O	O
knowledge	O	O
may	O	O
have	O	O
important	O	O
implications	O	O
to	O	O
the	O	O
planning	B-PROC
and	O	O
implementation	B-PROC
of	O	O
effective	O	O
interventions	O	O
aimed	O	O
at	O	O
optimising	O	O
the	O	O
clinical	B-PROC
management	I-PROC
of	O	O
these	O	O
infections	B-DISO
.	O	O

Consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
associated	O
with	O
other	O	O
risk	O
behaviors	O
among	O	O
adolescents	B-LIVB
in	O	O
Northeast	B-GEOG
Brazil	I-GEOG
To	O	O
determine	O	O
the	O	O
prevalence	O
of	O	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
and	O	O
identify	O	O
the	O	O
association	O
with	O
low	O
level	O
of	O	O
physical	O
activity	O
,	O	O
exposure	O
to	O
sedentary	B-DISO
behavior	I-DISO
,	O	O
consumption	O
of	O	O
soft	B-OBJC
drinks	I-OBJC
and	O	O
overweight	B-DISO
/	O	O
obesity	B-DISO
in	O	O
adolescents	B-LIVB
.	O	O

This	O	O
is	O	O
a	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
school	I-PROC
-	I-PROC
based	I-PROC
study	I-PROC
with	O	O
a	O	O
representative	O	O
sample	B-OBJC
of	O	O
3992	O	O
students	B-LIVB
aged	O	O
14	O	O
-	O	O
19	O	O
years	O
from	O	O
the	O	O
state	B-GEOG
of	I-GEOG
Sergipe	I-GEOG
,	O	O
Brazil	B-GEOG
.	O	O

The	O	O
outcome	O
was	O	O
low	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
(	O	O
<	O	O
5	O	O
servings	O
/	O
day	O
)	O	O
.	O	O

Independent	O
variables	O
were	O	O
:	O	O
level	O
of	O	O
physical	O
activity	O
,	O	O
sedentary	B-DISO
behavior	I-DISO
,	O	O
consumption	O
of	O	O
soft	B-OBJC
drinks	I-OBJC
,	O	O
and	O	O
overweight	B-DISO
/	O	O
obesity	B-DISO
.	O	O

Global	O
Student	O
Health	O
Survey	O
questionnaire	O
and	O	O
body	B-PROC
mass	I-PROC
and	O	O
height	B-PHYS
measurements	B-PROC
were	O	O
used	O	O
,	O	O
as	O	O
well	O	O
as	O	O
chi	O
-	O
square	O
test	O
and	O	O
crude	B-PROC
and	I-PROC
adjusted	I-PROC
binary	I-PROC
logistic	I-PROC
regression	I-PROC
.	O	O

The	O	O
significance	B-PROC
level	I-PROC
adopted	O	O
was	O	O
5	O	O
%	O	O
.	O	O

The	O	O
prevalence	O
of	O	O
inadequate	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
was	O	O
high	O
-	O	O
88	O	O
.	O	O

6	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
=	O	O
87	O	O
.	O	O
6	O	O
-	O	O
89	O	O
.	O	O
5	O	O
)	O	O
.	O	O

Higher	O
likelihood	O	O
of	O	O
low	O
consumption	B-PHYS
of	I-PHYS
fruits	I-PHYS
and	I-PHYS
vegetables	I-PHYS
was	O	O
verified	O	O
among	O	O
boys	B-LIVB
who	O	O
were	O	O
exposed	O
to	O
sedentary	B-DISO
behavior	I-DISO
(	O	O
OR	O
=	O	O
1	O	O
.	O	O
63	O	O
;	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
18	O	O
-	O	O
2	O	O
.	O	O
24	O	O
)	O	O
,	O	O
who	O	O
consumed	O
soft	B-OBJC
drinks	I-OBJC
(	O	O
OR	O
=	O	O
3	O	O
.	O	O
04	O	O
;	O	O
95	O	O
%	O	O
CI	O
=	O	O
2	O	O
.	O	O
10	O	O
-	O	O
4	O	O
.	O	O
40	O	O
)	O	O
,	O	O
with	O	O
insufficiently	O
physical	O
activity	O
(	O	O
OR	O
=	O	O
1	O	O
.	O	O
98	O	O
;	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
43	O	O
-	O	O
2	O	O
.	O	O
73	O	O
)	O	O
and	O	O
girls	B-LIVB
who	O	O
consumed	O
soft	B-OBJC
drinks	I-OBJC
(	O	O
OR	O
=	O	O
1	O	O
.	O	O
88	O	O
;	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
43	O	O
-	O	O
2	O	O
.	O	O
47	O	O
)	O	O
and	O	O
those	O	O
with	O	O
overweight	B-DISO
/	O	O
obesity	B-DISO
(	O	O
OR	O
=	O	O
1	O	O
.	O	O
63	O	O
;	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
19	O	O
-	O	O
2	O	O
.	O	O
23	O	O
)	O	O
.	O	O

There	O	O
is	O	O
a	O	O
need	O	O
of	O	O
public	O
policies	O
aimed	O	O
at	O	O
encouraging	O	O
the	O	O
consumption	O
of	O
healthy	O
foods	O
among	O	O
adolescents	B-LIVB
.	O	O

Usefulness	O
of	O	O
Embolization	B-PROC
for	O	O
Iatrogenic	B-DISO
Dural	B-DISO
Arteriovenous	I-DISO
Fistula	I-DISO
Associated	O
with	O
Recurrent	O
Chronic	B-DISO
Subdural	I-DISO
Hematoma	I-DISO
:	O	O
A	O	O
Case	O
Report	O
and	O	O
Literature	O
Review	O
Refractory	O
chronic	B-DISO
subdural	I-DISO
hematomas	I-DISO
due	O	O
to	O	O
iatrogenic	B-DISO
dural	B-DISO
arteriovenous	I-DISO
fistulas	I-DISO
(	O	O
dAVFs	B-DISO
)	O	O
are	O	O
difficult	O
to	O	O
treat	O
.	O	O

We	O	O
report	O	O
our	O	O
experience	O	O
and	O	O
propose	O	O
a	O	O
guideline	B-PROC
on	O	O
basis	O	O
of	O	O
a	O	O
literature	O
review	O
for	O	O
the	O	O
usefulness	O
of	O	O
embolization	B-PROC
of	O	O
middle	B-ANAT
meningeal	I-ANAT
artery	I-ANAT
(	O	O
MMA	B-ANAT
)	O	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
the	O	O
same	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O
with	O	O
right	B-DISO
hemiparesis	I-DISO
and	O	O
aphasia	B-DISO
1	O	O
month	O
after	O	O
a	O	O
fall	B-DISO
from	O	O
a	O	O
bicycle	B-OBJC
.	O	O

Computed	B-PROC
tomography	I-PROC
scan	I-PROC
of	O	O
the	O	O
head	B-ANAT
showed	O	O
left	O
chronic	B-DISO
subdural	I-DISO
hematoma	I-DISO
,	O	O
which	O	O
was	O	O
evacuated	B-PROC
by	I-PROC
burr	I-PROC
-	I-PROC
hole	I-PROC
drainage	I-PROC
.	O	O

The	O	O
postoperative	O
course	O
was	O	O
complicated	O
by	O	O
reaccumulation	B-DISO
within	O	O
short	O	O
period	O
of	O	O
time	O
.	O	O

On	O	O
superselective	B-PROC
digital	I-PROC
subtraction	I-PROC
angiography	I-PROC
of	O	O
MMA	B-ANAT
,	O	O
iatrogenic	B-DISO
dAVF	B-DISO
was	O	O
found	O	O
on	O	O
left	O
side	O
.	O	O

We	O	O
embolized	B-PROC
successfully	O
it	O	O
using	O	O
n	B-CHEM
-	I-CHEM
butyl	I-CHEM
cyanoacrylate	I-CHEM
after	O	O
a	O	O
third	O	O
irrigation	B-PROC
.	O	O

No	O	O
reaccumulation	B-DISO
found	O	O
in	O	O
the	O	O
postoperative	O
period	O
or	O	O
at	O	O
last	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

We	O	O
propose	O	O
treatment	B-PROC
protocol	I-PROC
based	O	O
on	O	O
our	O	O
experience	O
and	O	O
literature	O
review	O
.	O	O

Refractory	O
chronic	B-DISO
subdural	I-DISO
hematoma	I-DISO
with	O	O
reaccumulation	B-DISO
within	O	O
a	O	O
short	O
interval	O
should	O	O
be	O	O
subjected	O	O
to	O	O
digital	B-PROC
subtraction	I-PROC
angiography	I-PROC
of	O	O
the	O	O
MMA	B-ANAT
.	O	O

Embolization	B-PROC
of	O	O
ipsilateral	O
MMA	B-ANAT
is	O	O
safe	O	O
,	O	O
effective	O
,	O	O
and	O	O
a	O	O
useful	O	O
option	O	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
iatrogenic	B-DISO
dAVF	B-DISO
and	O	O
resolution	O
of	O	O
hematoma	B-DISO
.	O	O

In	O	O
Search	O	O
of	O	O
the	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
Compounds	B-CHEM
that	O	O
Change	O	O
the	O	O
Antibiotic	B-CHEM
Production	O
Pattern	O	O
of	O	O
Streptomyces	B-LIVB
coelicolor	I-LIVB
During	O	O
Inter	O
-	O
species	O
Interaction	O
The	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
investigate	O
the	O	O
interaction	O
between	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
and	O	O
Streptomyces	B-LIVB
coelicolor	I-LIVB
A3	I-LIVB
(	I-LIVB
2	I-LIVB
)	I-LIVB
for	O	O
the	O	O
increased	O
production	O
of	O	O
undecylprodigiosin	B-CHEM
and	O	O
identify	O	O
the	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
actives	O
mediating	O
this	O	O
inter	O
-	O
species	O
interaction	O
.	O	O

The	O	O
antibiotics	B-CHEM
of	O	O
interest	O	O
were	O	O
the	O	O
red	B-CHEM
-	I-CHEM
pigmented	I-CHEM
undecylprodigiosin	I-CHEM
and	O	O
blue	O
-	O
pigmented	O
actinorhodin	B-CHEM
.	O	O

Pure	O	O
cultures	B-PROC
of	O	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
in	O	O
a	O	O
defined	O	O
medium	B-CHEM
produced	O	O
higher	O	O
concentrations	O
of	O	O
actinorhodin	B-CHEM
compared	O
to	O	O
those	O	O
of	O	O
undecylprodigiosin	B-CHEM
.	O	O

The	O	O
latter	O	O
however	O	O
,	O	O
is	O	O
more	O	O
important	O	O
due	O	O
to	O	O
its	O	O
immunosuppressive	B-PHYS
and	O	O
antitumor	B-PHYS
properties	I-PHYS
.	O	O

As	O	O
a	O	O
strategy	O	O
to	O	O
increase	O
undecylprodigiosin	B-CHEM
production	O
,	O	O
we	O	O
added	O	O
separately	O	O
,	O	O
live	B-ANAT
cells	I-ANAT
and	O	O
heat	B-PHEN
-	I-PHEN
killed	I-PHEN
cells	B-ANAT
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
C600	I-LIVB
,	O	O
and	O	O
the	O	O
cell	B-ANAT
-	I-ANAT
free	I-ANAT
supernatant	I-ANAT
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
culture	B-PROC
to	O	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
cultures	B-PROC
in	I-PROC
shake	I-PROC
flasks	I-PROC
.	O	O

The	O	O
interaction	O
with	O	O
live	B-ANAT
cells	I-ANAT
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
altered	O	O
the	O	O
antibiotic	B-CHEM
production	O
pattern	O	O
and	O	O
undecylprodigiosin	B-CHEM
production	O
was	O	O
enhanced	O
by	O	O
3	O	O
.	O	O
5	O	O
-	O	O
fold	O	O
compared	O	O
to	O	O
the	O	O
pure	B-PROC
cultures	I-PROC
of	O	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
and	O	O
actinorhodin	B-CHEM
decreased	O
by	O	O
15	O	O
-	O	O
fold	O	O
.	O	O

The	O	O
heat	B-PHEN
-	I-PHEN
killed	I-PHEN
cells	B-ANAT
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
however	O	O
,	O	O
had	O	O
no	O
effect	O
on	O	O
antibiotic	B-CHEM
production	O
.	O	O

In	O	O
all	O	O
cases	O	O
,	O	O
growth	B-PHYS
and	O	O
glucose	B-DISO
consumption	I-DISO
of	O	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
remained	O	O
almost	O	O
the	O	O
same	O
as	O	O
those	O	O
observed	O
in	O	O
the	O	O
pure	B-PROC
culture	I-PROC
indicating	O	O
that	O	O
the	O	O
changes	O
in	O	O
antibiotic	B-CHEM
production	O
were	O	O
not	O	O
due	O	O
to	O	O
nutritional	B-PHYS
stress	B-DISO
.	O	O

Results	O
with	O	O
cell	B-ANAT
-	I-ANAT
free	I-ANAT
supernatant	I-ANAT
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
culture	B-PROC
indicated	O	O
that	O	O
the	O	O
interaction	O
between	O	O
S	B-LIVB
.	I-LIVB
coelicolor	I-LIVB
and	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
was	O	O
mediated	O
via	O	O
diffusible	B-CHEM
molecule	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
.	O	O

Using	O	O
a	O	O
set	O	O
of	O	O
extraction	B-PROC
procedures	I-PROC
and	O	O
agar	B-PROC
-	I-PROC
well	I-PROC
diffusion	I-PROC
bioassays	I-PROC
,	O	O
we	O	O
isolated	O
and	O	O
preliminarily	O	O
identified	O
a	O	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
.	O	O

For	O	O
the	O	O
preliminary	O	O
verification	O
,	O	O
we	O	O
added	O	O
the	O	O
compound	B-CHEM
which	O	O
was	O	O
the	O	O
common	O	O
chemical	B-CHEM
structural	I-CHEM
moiety	I-CHEM
in	O	O
this	O	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
to	O	O
the	O	O
pure	O	O
S	B-LIVB
.	I-LIVB

coelicolor	I-LIVB
cultures	B-PROC
.	O	O

We	O	O
observed	O	O
similar	O	O
effects	O
on	O	O
antibiotic	B-CHEM
production	O
as	O	O
with	O	O
the	O	O
live	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
cells	B-ANAT
and	O	O
their	O	O
supernatant	B-ANAT
indicating	O	O
that	O	O
this	O	O
class	B-CHEM
of	I-CHEM
compounds	I-CHEM
secreted	B-PHYS
by	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
indeed	O	O
could	O	O
act	O	O
as	O	O
actives	O
during	O	O
interspecies	O
interaction	O
and	O	O
increase	O
the	O	O
production	O
of	O	O
undecylprodigiosin	B-CHEM
.	O	O

Group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
limit	O
the	O	O
intramuscular	O
metabolic	O
perturbation	O
during	O	O
whole	B-ANAT
body	I-ANAT
exercise	O
in	O	O
humans	B-LIVB
The	O	O
purpose	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	B-PROC
the	O	O
role	O
of	O	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
in	O	O
limiting	O
the	O	O
endurance	B-DISO
exercise	O
-	O	O
induced	O
metabolic	O
perturbation	O
assayed	B-PROC
in	O	O
muscle	O
biopsy	O
samples	O
taken	O	O
from	O	O
locomotor	B-PHYS
muscle	O
.	O	O

Lumbar	B-ANAT
intrathecal	B-ANAT
fentanyl	B-CHEM
was	O	O
used	O	O
to	O	O
attenuate	O
the	O	O
central	O
projection	O
of	O	O
μ	B-CHEM
-	I-CHEM
opioid	I-CHEM
receptor	I-CHEM
-	O	O
sensitive	O
locomotor	B-PHYS
muscle	O
afferents	B-ANAT
during	O	O
a	O	O
5	O	O
km	O	O
cycling	O
time	O
trial	B-PROC
.	O	O

The	O	O
findings	B-DISO
suggest	O	O
that	O	O
the	O	O
central	O
projection	O
of	O	O
group	O
III	O
/	O
IV	O
muscle	O
afferent	B-ANAT
feedback	B-PHYS
constrains	O
voluntary	O
neural	O
'	O	O
drive	B-PHYS
'	O	O
to	O	O
working	O
locomotor	B-PHYS
muscle	O
and	O	O
limits	O
the	O	O
exercise	O
-	O	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
CNS	B-ANAT
might	O	O
regulate	B-PHEN
the	O	O
degree	O
of	O	O
metabolic	O
perturbation	O
within	O	O
locomotor	B-PHYS
muscle	O
and	O	O
thereby	O	O
limit	O
peripheral	O
fatigue	B-DISO
.	O	O

It	O	O
appears	O
that	O	O
the	O	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
are	O	O
an	O	O
important	O
neural	O
link	B-ANAT
in	O	O
this	O	O
regulatory	B-PHEN
mechanism	O
,	O	O
which	O	O
probably	O
serves	O	O
to	O	O
protect	B-DISO
locomotor	B-PHYS
muscle	O
from	O	O
the	O	O
potentially	O
severe	O
functional	B-DISO
impairment	I-DISO
as	O	O
a	O	O
consequence	O
of	O	O
severe	O
intramuscular	O
metabolic	O
disturbance	O
.	O	O

To	O	O
investigate	O
the	O	O
role	O
of	O	O
metabo	B-PHYS
-	O	O
and	O	O
mechanosensitive	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
in	O	O
limiting	O
the	O	O
intramuscular	O
metabolic	O
perturbation	O
during	O	O
whole	B-ANAT
body	I-ANAT
endurance	B-DISO
exercise	O
,	O	O
eight	O	O
subjects	B-LIVB
performed	O
5	O	O
km	O	O
cycling	O
time	O
trials	B-PROC
under	B-DISO
control	I-DISO
conditions	I-DISO
(	O	O
CTRL	B-DISO
)	O	O
and	O	O
with	O	O
lumbar	B-ANAT
intrathecal	B-ANAT
fentanyl	B-CHEM
impairing	O
lower	B-ANAT
limb	I-ANAT
muscle	O
afferent	B-ANAT
feedback	B-PHYS
(	O	O
FENT	B-PHYS
)	O	O
.	O	O

Vastus	B-ANAT
lateralis	I-ANAT
muscle	O
biopsies	O
were	O	O
obtained	O
before	O
and	O	O
immediately	O
after	O
exercise	O
.	O	O

Motoneuronal	B-ANAT
output	B-PROC
was	I-PROC
estimated	I-PROC
through	O	O
vastus	B-ANAT
lateralis	I-ANAT
surface	I-ANAT
electromyography	B-PROC
(	O	O
EMG	B-PROC
)	O	O
.	O	O

Exercise	O
-	O	O
induced	O
changes	O
in	O	O
intramuscular	O
metabolites	B-CHEM
were	O	O
determine	B-PROC
d	O	O
using	O	O
liquid	B-OBJC
and	O	O
gas	B-PROC
chromatography	I-PROC
-	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O	O

Quadriceps	B-ANAT
fatigue	B-DISO
was	O	O
quantified	O
by	O	O
pre	O
-	O	O
to	O	O
post	O
-	O	O
exercise	O
changes	O
in	O	O
potentiated	B-PHEN
quadriceps	I-PHEN
twitch	I-PHEN
torque	I-PHEN
(	O	O
ΔQTsingle	B-PHEN
)	O	O
evoked	O
by	O	O
electrical	O
femoral	B-ANAT
nerve	I-ANAT
stimulation	B-PROC
.	O	O

Although	O	O
motoneuronal	B-ANAT
output	O
was	O	O
21	O	O
±	O	O
12	O	O
%	O	O
higher	O
during	O	O
FENT	B-PHYS
compared	O
to	O	O
CTRL	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
time	O
to	O	O
complete	O
the	O	O
time	O
trial	B-PROC
was	O	O
similar	O
(	O	O
∼8	O	O
.	O	O
8	O	O
min	O	O
)	O	O
.	O	O

Compared	O
to	O	O
CTRL	B-DISO
,	O	O
power	B-PHEN
output	I-PHEN
during	O	O
FENT	B-PHYS
was	O	O
10	O	O
±	O	O
4	O	O
%	O	O
higher	O
in	O	O
the	O	O
first	B-DISO
half	I-DISO
of	O	O
the	O	O
time	O
trial	B-PROC
,	O	O
but	O	O
11	O	O
±	O	O
5	O	O
%	O	O
lower	O
in	O	O
the	O	O
second	B-DISO
half	I-DISO
(	O	O
both	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

The	O	O
exercise	O
-	O	O
induced	O
increase	O
in	O	O
intramuscular	O
inorganic	B-CHEM
phosphate	I-CHEM
,	O	O
H	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
adenosine	B-CHEM
diphosphate	I-CHEM
,	O	O
lactate	B-CHEM
and	O	O
phosphocreatine	B-CHEM
depletion	O
was	O	O
55	O	O
±	O	O
30	O	O
,	O	O
62	O	O
±	O	O
18	O	O
,	O	O
129	O	O
±	O	O
63	O	O
,	O	O
47	O	O
±	O	O
14	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
27	O	O
±	O	O
14	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
greater	O
in	O	O
FENT	B-PHYS
than	O	O
CTRL	B-DISO
.	O	O

ΔQTsingle	B-PHEN
was	O	O
greater	O
following	O	O
FENT	B-PHYS
than	O	O
CTRL	B-DISO
(	O	O
-52	O	O
±	O	O
2	O	O
vs	O	O
-31	O	O
±	O	O
1	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
this	O	O
difference	O
was	O	O
positively	B-DISO
correlated	O
with	O	O
the	O	O
difference	O
in	O	O
inorganic	B-CHEM
phosphate	I-CHEM
(	O	O
r	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
79	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
H	O	O
(	O	O
+	O	O
)	O	O
(	O	O
r	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
92	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

In	O	O
conclusion	O
,	O	O
during	O	O
whole	B-ANAT
body	I-ANAT
exercise	O
,	O	O
group	O
III	O
/	O
IV	O
muscle	O
afferents	B-ANAT
provide	O
feedback	B-PHYS
to	O	O
the	O	O
CNS	B-ANAT
which	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
constrains	O
motoneuronal	B-ANAT
output	O
to	O	O
the	O	O
active	O
skeletal	O
muscle	O
.	O	O

This	O	O
regulatory	B-PHEN
mechanism	O
limits	O
the	O	O
exercise	O
-	O	O
induced	O
intramuscular	O
metabolic	O
perturbation	O
,	O	O
preventing	O	O
an	O	O
abnormal	B-DISO
homeostatic	I-DISO
challenge	B-PROC
and	O	O
excessive	O
peripheral	O
fatigue	B-DISO
.	O	O

Incidence	O
of	O	O
crown	B-DISO
fracture	I-DISO
and	O	O
risk	B-DISO
factors	I-DISO
in	O	O
the	O	O
primary	B-ANAT
dentition	I-ANAT
:	O	O
a	O	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
Few	O	O
studies	O	O
have	O	O
assessed	O	O
the	O	O
incidence	O
and	O	O
risk	B-DISO
factors	I-DISO
to	O	O
crown	B-DISO
fractures	I-DISO
in	O	O
preschool	B-LIVB
children	I-LIVB
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
estimate	O	O
the	O	O
incidence	O
of	O	O
crown	B-DISO
fracture	I-DISO
in	O	O
the	O	O
primary	B-ANAT
dentition	I-ANAT
over	O	O
a	O	O
1	O	O
-	O	O
year	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
,	O	O
identify	O	O
risk	B-DISO
factors	I-DISO
,	O	O
and	O	O
test	O	O
the	O	O
hypothesis	O
that	O	O
children	B-LIVB
with	O	O
previous	O
crown	B-DISO
fracture	I-DISO
are	O	O
more	O	O
prone	O	O
to	O	O
experience	O	O
further	O	O
cases	O	O
of	O	O
crown	B-DISO
fracture	I-DISO
independently	O	O
of	O	O
other	O	O
risk	B-DISO
factors	I-DISO
.	O	O

This	O	O
study	O	O
was	O	O
developed	O	O
in	O	O
two	O	O
phases	O	O
:	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
and	O	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
.	O	O

The	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O	O
carried	O	O
out	O	O
261	O	O
preschool	B-LIVB
children	I-LIVB
.	O	O

The	O	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
was	O	O
carried	O	O
out	O	O
194	O	O
children	B-LIVB
allocated	O	O
to	O	O
two	O	O
groups	O	O
:	O	O
exposed	B-LIVB
group	I-LIVB
(	O	O
children	B-LIVB
with	O	O
prior	O	O
exposure	O
to	O
crown	B-DISO
fracture	I-DISO
)	O	O
and	O	O
non	B-DISO
-	O	O
exposed	B-LIVB
group	I-LIVB
(	O	O
children	B-LIVB
without	O	O
prior	O	O
exposure	O
)	O	O
.	O	O

On	O	O
both	O	O
occasions	O	O
,	O	O
children	B-LIVB
were	O	O
examined	O	O
for	O	O
the	O	O
diagnosis	B-DISO
of	O	O
crown	B-DISO
fracture	I-DISO
and	O	O
evaluation	O	O
of	O	O
lip	B-ANAT
coverage	O	O
and	O	O
overjet	B-DISO
.	O	O

The	O	O
parents	O	O
were	O	O
interviewed	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
socioeconomic	O
indicators	O
.	O	O

New	O	O
cases	O	O
of	O	O
crown	B-DISO
fracture	I-DISO
were	O	O
identified	O	O
based	O	O
on	O	O
the	O	O
comparison	O	O
of	O	O
the	O	O
two	O	O
examinations	O	O
.	O	O

Data	O
analysis	O
involved	O	O
Pearson	O
's	O
chi	O
-	O
square	O
test	O
,	O	O
McNemar	O
's	O
test	O
,	O	O
and	O	O
Poisson	O
regression	O
with	O	O
robust	O
variance	O
.	O	O

Among	O	O
the	O	O
261	O	O
children	B-LIVB
who	O	O
participated	O	O
in	O	O
the	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
,	O	O
194	O	O
were	O	O
re	O	O
-	O	O
examined	O	O
(	O	O
65	O	O
in	O	O
the	O	O
exposed	B-LIVB
group	I-LIVB
and	O	O
129	O	O
in	O	O
the	O	O
non	B-DISO
-	O	O
exposed	B-LIVB
group	I-LIVB
)	O	O
.	O	O

The	O	O
overall	O	O
incidence	O
of	O	O
crown	B-DISO
fracture	I-DISO
was	O	O
55	O	O
.	O	O

7	O	O
%	O	O
(	O	O
n	O	O
=	O	O
108	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
percentage	O	O
of	O	O
increased	B-DISO
risk	I-DISO
of	I-DISO
crown	B-DISO
fracture	I-DISO
in	O	O
exposed	O	O
and	O	O
non	B-DISO
-	O	O
exposed	B-LIVB
groups	I-LIVB
was	O	O
13	O	O
.	O	O

4	O	O
%	O	O
.	O	O

A	O	O
greater	O	O
incidence	O
of	O	O
crown	B-DISO
fracture	I-DISO
was	O	O
found	O	O
in	O	O
the	O	O
exposed	O	O
group	O	O
(	O	O
64	O	O
.	O	O
6	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0	O	O
,	O	O
001	O	O
)	O	O
.	O	O

The	O	O
children	B-LIVB
exposed	O	O
(	O	O
RR	O	O
:	O	O
1	O	O
.	O	O
30	O	O
;	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
1	O	O
.	O	O
01	O	O
-	O	O
1	O	O
.	O	O
67	O	O
)	O	O
had	O	O
a	O	O
greater	B-DISO
risk	I-DISO
of	I-DISO
developing	O	O
new	O	O
cases	O	O
of	O	O
crown	B-DISO
fracture	I-DISO
in	O	O
comparison	O	O
with	O	O
the	O	O
non	B-DISO
-	O	O
exposed	B-LIVB
group	I-LIVB
.	O	O

The	O	O
incidence	O
of	O	O
crown	B-DISO
fracture	I-DISO
was	O	O
high	O	O
and	O	O
children	B-LIVB
with	O	O
previous	O
crown	B-DISO
fracture	I-DISO
had	O	O
a	O	O
greater	B-DISO
risk	I-DISO
of	I-DISO
suffering	O	O
new	O	O
cases	O	O
of	O	O
crown	B-DISO
fracture	I-DISO
during	O	O
the	O	O
1	O	O
-	O	O
year	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
.	O	O

An	O	O
Efficient	O
and	O	O
Reliable	O
Statistical	B-PROC
Method	I-PROC
for	O	O
Estimating	O
Functional	O
Connectivity	O
in	O	O
Large	O	O
Scale	O	O
Brain	B-ANAT
Networks	B-PHYS
Using	O	O
Partial	O
Correlation	O
Currently	O	O
,	O	O
network	B-PHYS
-	I-PHYS
oriented	I-PHYS
analysis	B-PROC
of	O	O
fMRI	B-PROC
data	O
has	O	O
become	O	O
an	O	O
important	B-OBJC
tool	I-OBJC
for	O	O
understanding	O	O
brain	B-ANAT
organization	B-PHYS
and	O	O
brain	B-ANAT
networks	B-PHYS
.	O	O

Among	O	O
the	O	O
range	O	O
of	O	O
network	B-PHYS
modeling	O
methods	O
,	O	O
partial	O
correlation	O
has	O	O
shown	O	O
great	O	O
promises	O	O
in	O	O
accurately	O	O
detecting	B-DISO
true	O	O
brain	B-ANAT
network	B-PHYS
connections	O
.	O	O

However	O	O
,	O	O
the	O	O
application	O	O
of	O	O
partial	O
correlation	O
in	O	O
investigating	O
brain	B-ANAT
connectivity	O
,	O	O
especially	O	O
in	O	O
large	O	O
-	O	O
scale	O	O
brain	B-ANAT
networks	B-PHYS
,	O	O
has	O	O
been	O	O
limited	O	O
so	O	O
far	O	O
due	O	O
to	O	O
the	O	O
technical	B-PHEN
challenges	I-PHEN
in	O	O
its	O	O
estimation	O
.	O	O

In	O	O
this	O	O
paper	O	O
,	O	O
we	O	O
propose	O	O
an	O	O
efficient	O
and	O	O
reliable	O
statistical	B-PROC
method	I-PROC
for	O	O
estimating	O
partial	O
correlation	O
in	O	O
large	O	O
-	O	O
scale	O	O
brain	B-ANAT
network	B-PHYS
modeling	B-PROC
.	O	O

Our	O	O
method	O
derives	O	O
partial	O
correlation	O
based	O	O
on	O	O
the	O	O
precision	O
matrix	O
estimated	O
via	O	O
Constrained	B-PROC
L1	I-PROC
-	I-PROC
minimization	I-PROC
Approach	I-PROC
(	O	O
CLIME	B-PROC
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
recently	O	O
developed	O	O
statistical	B-PROC
method	I-PROC
that	O	O
is	O	O
more	O	O
efficient	O
and	O	O
demonstrates	O	O
better	O	O
performance	O
than	O	O
the	O	O
existing	O	O
methods	O
.	O	O

To	O	O
help	O	O
select	O	O
an	O	O
appropriate	O	O
tuning	O
parameter	O
for	O	O
sparsity	O	O
control	O
in	O	O
the	O	O
network	B-PHYS
estimation	O
,	O	O
we	O	O
propose	O	O
a	O	O
new	O	O
Dens	B-PROC
-	I-PROC
based	I-PROC
selection	I-PROC
method	I-PROC
that	O	O
provides	O	O
a	O	O
more	O	O
informative	O
and	O	O
flexible	O
tool	O
to	O	O
allow	O	O
the	O	O
users	O	O
to	O	O
select	O	O
the	O	O
tuning	O
parameter	O
based	O	O
on	O	O
the	O	O
desired	O	O
sparsity	O
level	O
.	O	O

Another	O	O
appealing	O	O
feature	O	O
of	O	O
the	O	O
Dens	B-PROC
-	I-PROC
based	I-PROC
method	I-PROC
is	O	O
that	O	O
it	O	O
is	O	O
much	O	O
faster	O	O
than	O	O
the	O	O
existing	O	O
methods	O
,	O	O
which	O	O
provides	O	O
an	O	O
important	O	O
advantage	O	O
in	O	O
neuroimaging	B-PROC
applications	I-PROC
.	O	O

Simulation	B-PROC
studies	I-PROC
show	O	O
that	O	O
the	O	O
Dens	B-PROC
-	I-PROC
based	I-PROC
method	I-PROC
demonstrates	O	O
comparable	O	O
or	O	O
better	O	O
performance	O
with	O	O
respect	O	O
to	O	O
the	O	O
existing	O	O
methods	O
in	O	O
network	B-PHYS
estimation	O
.	O	O

We	O	O
applied	O	O
the	O	O
proposed	O	O
partial	O
correlation	O
method	O
to	O	O
investigate	O
resting	B-PROC
state	I-PROC
functional	I-PROC
connectivity	I-PROC
using	I-PROC
rs	I-PROC
-	I-PROC
fMRI	I-PROC
data	I-PROC
from	O	O
the	O	O
Philadelphia	O
Neurodevelopmental	O
Cohort	O
(	O
PNC	O
)	O
study	O
.	O	O

Our	O	O
results	O
show	O	O
that	O	O
partial	O
correlation	O
analysis	B-PROC
removed	O	O
considerable	O	O
between	O	O
-	O	O
module	O	O
marginal	O
connections	O
identified	O	O
by	O	O
full	O	O
correlation	B-PROC
analysis	I-PROC
,	O	O
suggesting	O	O
these	O	O
connections	O
were	O	O
likely	O	O
caused	O	O
by	O	O
global	O	O
effects	O	O
or	O	O
common	O	O
connection	O
to	O	O
other	O	O
nodes	B-ANAT
.	O	O

Based	O	O
on	O	O
partial	O
correlation	O
,	O	O
we	O	O
find	O	O
that	O	O
the	O	O
most	O	O
significant	O	O
direct	O	O
connections	O
are	O	O
between	O	O
homologous	O	O
brain	B-ANAT
locations	B-ANAT
in	O	O
the	O	O
left	B-ANAT
and	O	O
right	B-ANAT
hemisphere	I-ANAT
.	O	O

When	O	O
comparing	O	O
partial	O
correlation	O
derived	O	O
under	O	O
different	O	O
sparse	O
tuning	O
parameters	O
,	O	O
an	O	O
important	O	O
finding	O	O
is	O	O
that	O	O
the	O	O
sparse	O	O
regularization	O	O
has	O	O
more	O	O
shrinkage	O
effects	O
on	O	O
negative	B-DISO
functional	O
connections	O
than	O	O
on	O	O
positive	B-DISO
connections	O
,	O	O
which	O	O
supports	O	O
previous	O	O
findings	O	O
that	O	O
many	O	O
of	O	O
the	O	O
negative	B-DISO
brain	B-ANAT
connections	O
are	O	O
due	O	O
to	O	O
non	B-PHYS
-	I-PHYS
neurophysiological	I-PHYS
effects	I-PHYS
.	O	O

An	O	O
R	O
package	O
""""	O
DensParcorr	O
""""	O
can	O	O
be	O	O
downloaded	O	O
from	O	O
CRAN	O
for	O	O
implementing	O	O
the	O	O
proposed	O	O
statistical	B-PROC
methods	I-PROC
.	O	O

Mitochondrial	B-ANAT
Ultrastructure	B-ANAT
and	O	O
Glucose	B-PHYS
Signaling	I-PHYS
Pathways	I-PHYS
Attributed	O	O
to	O	O
the	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
Ion	I-CHEM
Channel	I-CHEM
Gene	B-PROC
-	I-PROC
targeted	I-PROC
deletion	B-PHYS
of	O	O
the	O	O
potassium	B-CHEM
channel	I-CHEM
Kv1	I-CHEM
.	I-CHEM

3	I-CHEM
(	O	O
Kv1	B-PHEN
.	I-PHEN

3	I-PHEN
(	I-PHEN
-	I-PHEN
∕	I-PHEN
-	I-PHEN
)	I-PHEN
)	I-PHEN
results	I-PHEN
i	I-PHEN
n	O	O
""""	O	O
S	O	O
uper	B-LIVB
-	I-LIVB
smeller	I-LIVB
""""	I-LIVB
mice	I-LIVB
with	O	O
a	O	O
se	O	O
nsory	O
p	O
h	O	O
enotype	B-PHYS
t	I-PHYS
hat	O	O
includes	O	O
an	O	O
increased	O
olfactory	B-PHYS
ability	B-PHYS
linked	O	O
to	O	O
changes	O	O
in	O	O
olfactory	B-PHYS
circuitry	O
,	O	O
increased	O
abundance	O
of	O	O
olfactory	B-ANAT
cilia	I-ANAT
,	O	O
and	O	O
increased	O
expression	B-PHYS
of	O	O
odorant	B-CHEM
receptors	I-CHEM
and	O	O
the	O	O
G	B-CHEM
-	I-CHEM
protein	I-CHEM
,	I-CHEM
Golf	I-CHEM
.	O	O

Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
a	I-LIVB
lso	O	O
have	O	O
a	O	O
metabolic	O
p	O
h	O	O
enotype	B-PHYS
i	I-PHYS
ncluding	O	O
lo	O	O
wer	O
b	O
o	O	O
dy	B-PHYS
weight	I-PHYS
a	I-PHYS
nd	O	O
de	O	O
creased	O
a	O
d	O	O
iposity	B-PHYS
,	I-PHYS
in	O	O
creased	B-DISO
total	I-DISO
energy	I-DISO
expenditure	I-DISO
(	O	O
TEE	B-DISO
)	O	O
,	O	O
increased	O
locomotor	B-PHYS
activity	I-PHYS
,	O	O
and	O	O
resistance	B-PHYS
to	O	O
both	O	O
diet	B-OBJC
-	O	O
and	O	O
genetic	B-PHYS
-	I-PHYS
induced	I-PHYS
obesity	B-DISO
.	O	O

We	O	O
explored	O	O
two	O	O
cellular	O
aspects	O
to	O	O
elucidate	O	O
the	O	O
mechanism	O
by	O	O
which	O	O
loss	O
of	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
channel	I-CHEM
in	O	O
the	O	O
olfactory	B-ANAT
bulb	I-ANAT
(	O	O
OB	B-ANAT
)	O	O
may	O	O
enhance	O	O
glucose	B-PHYS
utilization	I-PHYS
and	O	O
metabolic	B-PHYS
rate	I-PHYS
.	O	O

First	O	O
,	O	O
using	O	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
we	O	O
find	O	O
that	O	O
Kv1	B-CHEM
.	I-CHEM
3	I-CHEM
and	O	O
the	O	O
insulin	B-CHEM
-	O	O
dependent	O
glucose	B-CHEM
transporter	I-CHEM
type	I-CHEM
4	I-CHEM
(	O	O
GLUT4	B-CHEM
)	O	O
are	O	O
co	O	O
-	O	O
localized	O	O
to	O	O
the	O	O
mitral	B-ANAT
cell	B-ANAT
layer	I-ANAT
of	O	O
the	O	O
OB	B-ANAT
.	O	O

Disruption	O
of	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
conduction	B-PHEN
via	O	O
construction	O	O
of	O	O
a	O	O
pore	B-PHYS
mutation	I-PHYS
(	O	O
W386F	B-PHYS
Kv1	I-PHYS
.	I-PHYS

3	I-PHYS
)	O	O
was	O	O
sufficient	O	O
to	O	O
independently	O	O
translocate	B-PHYS
GLUT4	B-CHEM
to	O	O
the	O	O
plasma	B-ANAT
membrane	I-ANAT
in	O	O
HEK	B-ANAT
293	I-ANAT
cells	I-ANAT
.	O	O

Because	O	O
olfactory	B-PHYS
sensory	I-PHYS
perception	I-PHYS
and	O	O
the	O	O
maintenance	O
of	O	O
action	B-PHYS
potential	I-PHYS
(	I-PHYS
AP	I-PHYS
)	I-PHYS
firing	O	O
frequency	O	O
by	O	O
mitral	B-ANAT
cells	B-ANAT
of	O	O
the	O	O
OB	B-ANAT
is	O	O
highly	O	O
energy	O	O
demanding	O	O
and	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
is	O	O
also	O	O
expressed	O	O
in	O	O
mitochondria	B-ANAT
,	O	O
we	O	O
next	O	O
explored	O	O
the	O	O
structure	O	O
of	O	O
this	O	O
organelle	B-ANAT
in	O	O
mitral	B-ANAT
cells	B-ANAT
.	O	O

We	O	O
challenged	O	O
wildtype	B-LIVB
(	O	O
WT	B-LIVB
)	O	O
and	O	O
Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
male	I-LIVB
mice	I-LIVB
with	O	O
a	O	O
m	O	O
oderately	B-PROC
high	I-PROC
-	I-PROC
fat	I-PROC
diet	I-PROC
(	I-PROC
M	O	O
HF	B-PROC
,	I-PROC
31	O	O
.	O	O
8	O	O
%	O	O
kcal	O	O
fat	O	O
)	O	O
for	O	O
4	O	O
months	O
and	O	O
then	O	O
examined	O	O
OB	B-ANAT
ultrastructure	B-ANAT
using	O	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O	O

In	O	O
WT	B-LIVB
mice	I-LIVB
,	O	O
mitochondria	B-ANAT
were	O	O
significantly	O	O
enlarged	O
following	O	O
diet	B-DISO
-	I-DISO
induced	I-DISO
obesity	I-DISO
(	O	O
DIO	B-DISO
)	O	O
and	O	O
there	O	O
were	O	O
fewer	O	O
mitochondria	B-ANAT
,	O	O
likely	O	O
due	O	O
to	O	O
mitophagy	B-PHYS
.	O	O

Interestingly	O	O
,	O	O
mitochondria	B-ANAT
were	O	O
significantly	O	O
smaller	O
in	O	O
Kv1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
c	I-LIVB
ompared	O	O
with	O	O
that	O	O
of	O	O
W	O	O
T	B-LIVB
mice	I-LIVB
.	I-LIVB

Similar	O	O
to	O	O
their	O	O
m	O	O
etabolic	O
r	O
esistance	O	O
to	O	O
D	O	O
IO	B-DISO
,	I-DISO
the	O	O
K	O	O
v1	B-LIVB
.	I-LIVB

3	I-LIVB
(	I-LIVB
-	I-LIVB
∕	I-LIVB
-	I-LIVB
)	I-LIVB
mice	I-LIVB
ha	I-LIVB
d	O	O
unchanged	O	O
mit	O	O
ochondria	B-ANAT
in	I-ANAT
terms	O	O
of	O	O
cros	O	O
s	O
sectional	O
area	O
and	O	O
abundance	O
following	O	O
a	O	O
challenge	O	O
with	O	O
modified	B-PROC
diet	I-PROC
.	O	O

We	O	O
are	O	O
very	O	O
interested	O	O
to	O	O
understand	O	O
how	O	O
targeted	O	O
disruption	O
of	O	O
the	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
channel	I-CHEM
in	O	O
the	O	O
OB	B-ANAT
can	O	O
modify	O	O
TEE	B-DISO
.	O	O

Our	O	O
study	O	O
demonstrates	O	O
that	O	O
Kv1	B-CHEM
.	I-CHEM

3	I-CHEM
regulates	O	O
mitochondrial	B-ANAT
structure	I-ANAT
and	O	O
alters	O	O
glucose	B-PHYS
utilization	I-PHYS
;	O	O
two	O	O
important	O	O
metabolic	O
changes	O	O
that	O	O
could	O	O
drive	O	O
whole	O	O
system	O	O
changes	O	O
in	O	O
metabolism	B-PHYS
initiated	O	O
at	O	O
the	O	O
OB	B-ANAT
.	O	O

Cobalamin	B-CHEM
Protection	B-DISO
against	O	O
Oxidative	B-DISO
Stress	I-DISO
in	O	O
the	O	O
Acidophilic	O
Iron	B-LIVB
-	I-LIVB
oxidizing	I-LIVB
Bacterium	I-LIVB
Leptospirillum	B-LIVB
Group	I-LIVB
II	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
Members	O	O
of	O	O
the	O	O
genus	O	O
Leptospirillum	B-LIVB
are	O	O
aerobic	O
iron	B-LIVB
-	I-LIVB
oxidizing	I-LIVB
bacteria	I-LIVB
belonging	O	O
to	O	O
the	O	O
phylum	B-LIVB
Nitrospira	I-LIVB
.	O	O

They	O	O
are	O	O
important	O	O
members	O	O
of	O	O
microbial	B-LIVB
communities	B-PHEN
that	O	O
catalyze	B-PHEN
the	O	O
biomining	O
of	O	O
sulfidic	B-CHEM
ores	I-CHEM
,	O	O
thereby	O	O
solubilizing	O	O
metal	B-CHEM
ions	I-CHEM
.	O	O

These	O	O
microorganisms	B-LIVB
live	O	O
under	O	O
extremely	O	O
acidic	O	O
and	O	O
metal	B-CHEM
-loaded	O	O
environments	O
and	O	O
thus	O	O
must	O	O
tolerate	O	O
high	O	O
concentrations	O
of	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
.	O	O

Cobalamin	B-CHEM
(	O	O
vitamin	B-CHEM
B12	I-CHEM
)	O	O
is	O	O
a	O	O
cobalt	B-CHEM
-containing	O	O
tetrapyrrole	B-CHEM
cofactor	B-CHEM
involved	O	O
in	O	O
intramolecular	B-PHEN
rearrangement	I-PHEN
reactions	I-PHEN
and	O	O
has	O	O
recently	O	O
been	O	O
suggested	O	O
to	O	O
be	O	O
an	O	O
intracellular	O
antioxidant	B-CHEM
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
we	O	O
investigated	O
the	O	O
effect	O
of	O	O
the	O	O
exogenous	O
addition	O	O
of	O	O
cobalamin	B-CHEM
on	O	O
oxidative	B-DISO
stress	I-DISO
parameters	O
in	O	O
Leptospirillum	B-LIVB
group	I-LIVB
II	I-LIVB
strain	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
.	O	O

Our	O	O
results	O	O
revealed	O
that	O	O
the	O	O
external	B-OBJC
supplementation	I-OBJC
of	O	O
cobalamin	B-CHEM
reduces	O	O
the	O	O
levels	O	O
of	O	O
intracellular	O
ROSs	B-CHEM
and	O	O
the	O	O
damage	O
to	O	O
biomolecules	B-CHEM
,	O	O
and	O	O
also	O	O
stimulates	B-PHEN
the	O	O
growth	B-PHYS
and	O	O
survival	B-PHYS
of	I-PHYS
cells	I-PHYS
exposed	O	O
to	O	O
oxidative	B-DISO
stress	I-DISO
exerted	O	O
by	O	O
ferric	B-CHEM
ion	I-CHEM
,	O	O
hydrogen	B-CHEM
peroxide	I-CHEM
,	O	O
chromate	B-CHEM
and	O	O
diamide	B-CHEM
.	O	O

Furthermore	O	O
,	O	O
exposure	O	O
of	O	O
strain	B-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
to	O	O
oxidative	B-DISO
stress	I-DISO
elicitors	O	O
resulted	O	O
in	O	O
the	O	O
transcriptional	B-PHYS
activation	I-PHYS
of	O	O
the	O	O
cbiA	O
gene	O
encoding	O	O
CbiA	B-CHEM
of	O	O
the	O	O
cobalamin	B-CHEM
biosynthetic	B-PHYS
pathway	I-PHYS
.	O	O

Altogether	O	O
,	O	O
these	O	O
data	O
suggest	O	O
that	O	O
cobalamin	B-CHEM
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
redox	B-PHYS
protection	B-DISO
of	O	O
Leptospirillum	B-LIVB
strain	I-LIVB
CF	I-LIVB
-	I-LIVB
1	I-LIVB
,	O	O
supporting	O	O
survival	O	O
of	O	O
this	O	O
microorganism	B-LIVB
under	O	O
extremely	O	O
oxidative	O
environmental	O
conditions	O
.	O	O

Understanding	O	O
the	O	O
mechanisms	O
underlying	O	O
the	O	O
protective	B-DISO
effect	O
of	O	O
cobalamin	B-CHEM
against	O	O
oxidative	B-DISO
stress	I-DISO
may	O	O
help	O	O
to	O	O
develop	O	O
strategies	O	O
to	O	O
make	O	O
biomining	O
processes	B-PHEN
more	O	O
effective	O
.	O	O

Metabolite	B-CHEM
Profiling	O
of	O	O
Italian	B-GEOG
Tomato	B-OBJC
Landraces	O
with	O	O
Different	O	O
Fruit	B-OBJC
Types	O
Increased	O	O
interest	O	O
toward	O	O
traditional	O
tomato	B-OBJC
varieties	O
is	O	O
fueled	O	O
by	O	O
the	O	O
need	O	O
to	O	O
rescue	O	O
desirable	O	O
organoleptic	O
traits	O
and	O	O
to	O	O
improve	B-DISO
the	O	O
quality	O
of	O	O
fresh	O
and	O	O
processed	O	O
tomatoes	B-OBJC
in	O	O
the	O	O
market	B-GEOG
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
phenotypic	B-PHYS
and	O	O
genetic	B-PHEN
variation	I-PHEN
preserved	O	O
in	O	O
tomato	B-OBJC
landraces	O
represents	O	O
a	O	O
means	O	O
to	O	O
understand	O	O
the	O	O
genetic	O
basis	O
of	O	O
traits	B-PHYS
related	O	O
to	O	O
health	O
and	O	O
organoleptic	O
aspects	O
and	O	O
improve	O	O
them	O	O
in	O	O
modern	O
varieties	O
.	O	O

To	O	O
establish	O	O
a	O	O
framework	O	O
for	O	O
this	O	O
approach	O	O
,	O	O
we	O	O
studied	B-PROC
the	O	O
content	O	O
of	O	O
several	O	O
metabolites	B-CHEM
in	O	O
a	O	O
panel	O	O
of	O	O
Italian	B-GEOG
tomato	B-OBJC
landraces	O
categorized	O	O
into	O	O
three	O	O
broad	O	O
fruit	B-OBJC
type	O	O
classes	O	O
(	O	O
flattened	O
/	O	O
ribbed	O
,	O	O
pear	B-OBJC
/	O	O
oxheart	B-OBJC
,	O	O
round	O
/	O	O
elongate	O
)	O	O
.	O	O

Three	O	O
modern	B-LIVB
hybrids	I-LIVB
,	O	O
corresponding	O	O
to	O	O
the	O	O
three	O	O
fruit	B-OBJC
shape	O
typologies	O
,	O	O
were	O	O
included	O	O
as	O	O
reference	O
.	O	O

Red	B-OBJC
ripe	I-OBJC
fruits	I-OBJC
were	O	O
morphologically	O
characterized	O
and	O	O
biochemically	B-PROC
analyzed	I-PROC
for	O	O
their	O	O
content	O	O
in	O	O
glycoalkaloids	B-CHEM
,	O	O
phenols	B-CHEM
,	O	O
amino	B-CHEM
acids	I-CHEM
,	O	O
and	O	O
Amadori	B-CHEM
products	I-CHEM
.	O	O

The	O	O
round	O
/	O	O
elongate	O
types	O	O
showed	O	O
a	O	O
higher	O	O
content	O	O
in	O	O
glycoalkaloids	B-CHEM
,	O	O
whereas	O	O
flattened	O
types	O	O
had	O	O
higher	O	O
levels	O	O
of	O	O
phenolic	B-CHEM
compounds	I-CHEM
.	O	O

Flattened	O
tomatoes	B-OBJC
were	O	O
also	O	O
rich	O
in	O	O
total	O	O
amino	B-CHEM
acids	I-CHEM
and	O	O
in	O	O
particular	O	O
in	O	O
glutamic	B-CHEM
acid	I-CHEM
.	O	O

Multivariate	O
analysis	O
of	O	O
amino	B-PROC
acid	I-PROC
content	I-PROC
clearly	O	O
separated	O	O
the	O	O
three	O	O
classes	O	O
of	O	O
fruit	B-OBJC
types	O	O
.	O	O

Making	O	O
allowance	O	O
of	O	O
the	O	O
very	O	O
low	O	O
number	O	O
of	O	O
genotypes	B-PHYS
,	O	O
phenotype	B-PHYS
-	I-PHYS
marker	I-PHYS
relationships	O
were	O	O
analyzed	B-PROC
after	O	O
retrieving	O	O
single	O
nucleotide	O
polymorphisms	O
(	O	O
SNPs	O
)	O	O
among	O	O
the	O	O
landraces	O
available	O	O
in	O	O
the	O	O
literature	O
.	O	O

Sixty	O	O
-	O	O
six	O	O
markers	O
were	O	O
significantly	O
associated	O
with	O
the	O	O
studied	B-PROC
traits	B-PHYS
.	O	O

The	O	O
positions	O	O
of	O	O
several	O	O
of	O	O
these	O	O
SNPs	O
showed	O	O
correspondence	O	O
with	O	O
already	O	O
described	O	O
genomic	O
regions	O
and	O	O
QTLs	O
supporting	O	O
the	O	O
reliability	O	O
of	O	O
the	O	O
association	O	O
.	O	O

Overall	O	O
the	O	O
data	O
indicated	O	O
that	O	O
significant	O	O
changes	O	O
in	O	O
quality	O
-related	O	O
metabolites	B-CHEM
occur	O	O
depending	O	O
on	O	O
the	O	O
genetic	B-PHYS
background	I-PHYS
in	O	O
traditional	O
tomato	B-OBJC
germplasm	B-ANAT
,	O	O
frequently	O	O
according	O	O
to	O	O
specific	O	O
fruit	B-OBJC
shape	O
categories	O	O
.	O	O

Such	O	O
a	O	O
variability	O	O
is	O	O
suitable	O	O
to	O	O
harness	O	O
association	O
mapping	O
for	O	O
metabolic	O
quality	O
traits	B-PHYS
using	O	O
this	O	O
germplasm	B-ANAT
as	O	O
an	O	O
experimental	O
population	O
,	O	O
paving	O	O
the	O	O
way	O	O
for	O	O
investigating	O
their	O	O
genetic	O
/	O	O
molecular	O
basis	O
,	O	O
and	O	O
facilitating	O	O
breeding	B-PHYS
for	O	O
quality	O
-	O
related	O
compounds	B-CHEM
in	O	O
tomato	B-OBJC
fruits	B-OBJC
.	O	O

Cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
features	O	O
of	O	O
deoxynivalenol	B-CHEM
(	O	O
DON	B-CHEM
)	O	O
-	O	O
targeted	O	O
immunoaffinity	B-PROC
columns	B-DEVI
aiming	O	O
to	O	O
achieve	O	O
simultaneous	O
analysis	B-PROC
of	O	O
DON	B-CHEM
and	O	O
major	O	O
conjugates	B-CHEM
in	O	O
cereal	B-OBJC
samples	B-OBJC
Immunoafﬁnity	B-PROC
columns	B-DEVI
(	O	O
IACs	B-DEVI
)	O	O
are	O	O
a	O	O
well	O	O
-	O	O
established	O	O
tool	O	O
in	O	O
the	O	O
determination	O	O
of	O	O
regulated	O	O
mycotoxins	B-CHEM
in	O	O
food	B-OBJC
and	O	O
feed	B-OBJC
commodities	I-OBJC
.	O	O

However	O	O
,	O	O
they	O	O
also	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
become	O	O
attractive	O	O
pre	O
-	O
concentration	O
and	O	O
clean	B-OBJC
-	I-OBJC
up	I-OBJC
materials	I-OBJC
for	O	O
the	O	O
determination	O	O
of	O	O
masked	O	O
(	O	O
also	O	O
called	O	O
modified	O	O
)	O	O
mycotoxins	B-CHEM
,	O	O
which	O	O
have	O	O
been	O	O
recognised	O	O
as	O	O
important	O	O
contributors	O	O
to	O	O
the	O	O
toxicological	B-PHEN
hazard	O
deriving	O	O
from	O	O
fungal	O
spoilage	B-PHEN
of	O	O
goods	B-OBJC
.	O	O

However	O	O
,	O	O
the	O	O
information	O	O
available	O	O
in	O	O
the	O	O
literature	O	O
concerning	O	O
the	O	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O	O
DON	B-CHEM
-	O	O
IACs	B-DEVI
against	O	O
the	O	O
major	O	O
conjugates	B-CHEM
(	O	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
,	O	O
15	B-CHEM
-	I-CHEM
AcDON	I-CHEM
and	O	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
)	O	O
is	O	O
incomplete	O	O
and	O	O
often	O	O
contradictory	O	O
.	O	O

We	O	O
have	O	O
carried	O	O
out	O	O
a	O	O
detailed	O	O
characterisation	O	O
of	O	O
the	O	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O	O
the	O	O
four	O	O
main	O	O
IACs	B-DEVI
brands	O	O
against	O	O
DON	B-CHEM
and	O	O
its	O	O
conjugates	B-CHEM
as	O	O
well	O	O
as	O	O
an	O	O
assessment	O	O
of	O	O
the	O	O
competition	O	O
among	O	O
the	O	O
analytes	B-CHEM
.	O	O

Only	O	O
one	O	O
IAC	B-DEVI
enabled	O	O
the	O	O
simultaneous	O
analysis	B-PROC
of	O	O
all	O	O
relevant	O	O
DON	B-CHEM
forms	O	O
while	O	O
two	O	O
missed	O	O
15	B-CHEM
-	I-CHEM
AcDON	I-CHEM
and	O	O
the	O	O
fourth	O	O
one	O	O
missed	O	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
and	O	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
.	O	O

In	O	O
the	O	O
case	O	O
of	O	O
the	O	O
multivalent	O	O
IAC	B-DEVI
,	O	O
the	O	O
analytes	B-CHEM
modified	O	O
at	O	O
the	O	O
C	O	O
-	O	O
3	O	O
position	O	O
compete	O	O
for	O	O
the	O	O
antibody	B-CHEM
binding	I-CHEM
with	O	O
preference	O	O
for	O	O
3	B-CHEM
-	I-CHEM
AcDON	I-CHEM
(	O	O
less	O	O
spatially	O	O
hindered	O	O
)	O	O
while	O	O
DON	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
G	I-CHEM
has	O	O
the	O	O
more	O	O
-	O	O
hindered	O	O
access	O	O
to	O	O
the	O	O
active	B-CHEM
sites	I-CHEM
.	O	O

Taking	O	O
into	O	O
consideration	O	O
the	O	O
levels	O	O
of	O	O
DON	B-CHEM
conjugates	B-CHEM
existing	O	O
in	O	O
real	B-OBJC
samples	I-OBJC
,	O	O
the	O	O
cross	B-PHYS
-	I-PHYS
reactivity	I-PHYS
of	O	O
one	O	O
DON	B-CHEM
-	O	O
IAC	B-DEVI
allows	O	O
a	O	O
quantitative	O
analysis	O
of	O	O
all	O	O
of	O	O
these	O	O
analytes	B-CHEM
.	O	O

Important	O	O
but	O	O
rather	O	O
neglected	O	O
aspects	O	O
such	O	O
as	O	O
the	O	O
continuous	O	O
supply	O	O
of	O	O
IACs	B-DEVI
with	O	O
identical	O	O
characteristics	O	O
,	O	O
and	O	O
of	O	O
columns	B-DEVI
which	O	O
are	O	O
strictly	O	O
blank	O	O
,	O	O
are	O	O
also	O	O
addressed	O	O
in	O	O
this	O	O
paper	O	O
.	O	O

A	O	O
longitudinal	B-PROC
study	I-PROC
assessing	O	O
childcare	O
services	O
'	O
adoption	O	O
of	O	O
obesity	B-DISO
prevention	B-PROC
policies	I-PROC
and	I-PROC
practices	I-PROC
Despite	O	O
ongoing	O	O
investments	O	O
to	O	O
improve	O	O
the	O	O
obesogenic	B-DISO
environments	O
of	O	O
childcare	O
settings	O	O
,	O	O
little	O	O
is	O	O
known	O	O
regarding	O	O
how	O	O
these	O	O
services	O
have	O	O
changed	O	O
their	O	O
physical	O
activity	O
and	O	O
nutrition	B-PROC
-	I-PROC
promoting	I-PROC
practices	I-PROC
.	O	O

This	O	O
study	O	O
aims	O	O
to	O	O
describe	O	O
changes	O	O
in	O	O
the	O	O
proportion	O	O
of	O	O
Australian	B-LIVB
childcare	O
services	O
that	O	O
have	O	O
adopted	O	O
best	B-PROC
-	I-PROC
practice	I-PROC
healthy	B-PROC
eating	I-PROC
and	O	O
physical	O
activity	O
practices	B-PROC
between	O	O
2006	O	O
and	O	O
2013	O	O
and	O	O
to	O	O
assess	O	O
whether	O	O
adoption	O	O
varied	O	O
by	O	O
socio	O
-	O
economic	O
status	O
and	O	O
locality	O
.	O	O

A	O	O
randomly	B-PROC
selected	I-PROC
sample	I-PROC
of	O	O
nominated	O	O
supervisors	B-LIVB
(	O	O
n	O	O
=	O	O
358	O	O
)	O	O
from	O	O
childcare	O
services	O
located	O	O
in	O	O
New	B-GEOG
South	I-GEOG
Wales	I-GEOG
,	O	O
Australia	B-GEOG
,	O	O
participated	O	O
in	O	O
a	O	O
telephone	B-PROC
survey	I-PROC
in	O	O
2006	O	O
,	O	O
2009	O	O
,	O	O
2010	O	O
and	O	O
2013	O	O
.	O	O

Supervisors	B-LIVB
reported	O	O
on	O	O
their	O	O
service	O
's	O
adoption	O	O
of	O	O
six	O	O
practices	B-PROC
:	O	O
(	O	O
i	O	O
)	O	O
having	O	O
written	O	O
nutrition	B-PROC
and	O	O
physical	O
activity	O
policies	O
;	O	O
(	O	O
ii	O	O
)	O	O
staff	B-LIVB
trained	O	O
in	O	O
physical	O
activity	O
and	O	O
nutrition	B-PROC
in	O	O
the	O	O
past	O	O
year	O	O
;	O	O
(	O	O
iii	O	O
)	O	O
scheduled	O	O
time	O
for	O	O
fundamental	O	O
movement	B-PHYS
skills	O
and	O	O
(	O	O
iv	O	O
)	O	O
outdoor	O
play	O
;	O	O
(	O	O
v	O	O
)	O	O
weekly	O
or	O	O
less	O	O
screen	B-DISO
time	I-DISO
opportunitie	I-DISO
s	O	O
;	O	O
and	O	O
(	O	O
vi	O	O
)	O	O
serving	O	O
only	O	O
non	B-OBJC
-	I-OBJC
sweetened	I-OBJC
beverages	I-OBJC
.	O	O

A	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
prevalence	O
of	O	O
services	O
adopting	O	O
all	O	O
but	O	O
one	O	O
practice	B-PROC
,	O	O
between	O	O
2006	O	O
and	O	O
2013	O	O
was	O	O
identified	O	O
.	O	O

Ninety	O	O
one	O	O
percent	O	O
of	O	O
services	O
adopted	O	O
four	O	O
or	O	O
more	O	O
practices	B-PROC
,	O	O
a	O	O
significant	O	O
increase	O	O
from	O	O
38	O	O
%	O	O
in	O	O
2006	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
proportion	O	O
of	O	O
services	O
adopting	O	O
each	O	O
practice	B-PROC
by	O	O
locality	O
and	O	O
socio	O
-	O
economic	O
status	O
.	O	O

Government	O
investment	O
in	O	O
obesity	B-DISO
prevention	B-PROC
programmes	I-PROC
can	O	O
equitably	O	O
improve	O	O
childcare	O
service	O	O
's	O	O
adoption	O	O
of	O	O
healthy	B-PROC
eating	I-PROC
and	O	O
physical	O
activity	O
promoting	O	O
practices	B-PROC
on	O	O
a	O	O
jurisdiction	O
-wide	O	O
basis	O	O
.	O	O

The	O	O
establishment	O	O
of	O	O
a	O	O
routine	O	O
system	O	O
to	O	O
monitor	O	O
adoption	O	O
of	O	O
a	O	O
broader	O	O
range	O	O
of	O	O
practices	B-PROC
by	O	O
childcare	O
services	O
is	O	O
warranted	O	O
.	O	O

Improving	O
Early	B-PROC
Identification	I-PROC
and	O	O
Ongoing	O	O
Care	O
of	O	O
Children	B-LIVB
With	O	O
Autism	B-DISO
Spectrum	I-DISO
Disorder	I-DISO
Poor	O	O
adherence	O	O
to	O	O
recommended	O	O
screening	B-PROC
for	O	O
autism	B-DISO
spectrum	I-DISO
disorder	I-DISO
(	O	O
ASD	B-DISO
)	O	O
and	O	O
pediatricians	B-LIVB
'	O	O
lack	B-DISO
of	I-DISO
confidence	I-DISO
in	O	O
providing	O	O
care	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
reflect	O	O
quality	O	O
gaps	O	O
in	O	O
primary	B-PROC
care	I-PROC
.	O	O

This	O	O
study	B-PROC
aimed	O	O
to	O	O
increase	O	O
the	O	O
proportion	O	O
of	O	O
toddlers	B-LIVB
screened	O	O
for	O	O
ASD	B-DISO
and	O	O
improve	B-DISO
physicians	B-LIVB
'	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O	O
providing	O	O
care	O
to	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

Twenty	O	O
-	O	O
six	O	O
Utah	O	O
primary	B-PROC
care	I-PROC
practices	I-PROC
participated	O	O
in	O	O
a	O	O
3	O	O
to	O	O
6	O	O
month	O
learning	O
collaborative	O
(	O	O
LC	O
)	O	O
to	O	O
improve	B-DISO
identification	B-PHYS
and	O	O
ongoing	O	O
care	O
of	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

Monthly	O
chart	O
audits	O
assessed	O	O
whether	O	O
an	O	O
ASD	B-DISO
screening	B-PROC
tool	I-PROC
was	O	O
administered	O	O
at	O	O
18	O	O
-	O	O
and	O	O
24	O	O
-	O	O
month	O
visits	B-PROC
.	O	O

Physicians	B-LIVB
completed	O	O
pre	O
-	O
LC	O
and	O	O
post	O
-	O
LC	O
surveys	O
to	O	O
assess	O	O
changes	O
in	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O	O
providing	O	O
care	O
and	O	O
changes	O	O
in	O	O
perceived	B-PHYS
barriers	O
to	O	O
implementation	O
of	O	O
screening	B-PROC
and	O	O
caring	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

Before	O	O
the	O	O
LC	O
,	O	O
15	O	O
%	O	O
of	O	O
18	O	O
-	O	O
and	O	O
24	O	O
-	O	O
month	O
visits	B-PROC
had	O	O
documented	B-PROC
ASD	B-DISO
screening	B-PROC
,	O	O
compared	O	O
with	O	O
91	O	O
%	O	O
during	O	O
the	O	O
last	O	O
month	O
of	O	O
the	O	O
LC	O
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

This	O	O
rate	O	O
of	O	O
ASD	B-DISO
screening	B-PROC
was	O	O
sustained	O	O
4	O	O
years	O
after	O	O
the	O	O
LC	O
by	O	O
most	O	O
practices	O	O
.	O	O

Compared	O	O
with	O	O
survey	B-PROC
responses	O	O
before	O	O
the	O	O
LC	O
,	O	O
physicians	B-LIVB
reported	O	O
significant	O	O
improvement	O
in	O	O
their	O	O
ability	O	O
to	O	O
care	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
and	O	O
decreases	O	O
in	O	O
their	O	O
perceived	B-PHYS
barriers	O
to	O	O
screening	B-PROC
and	O	O
caring	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

The	O	O
LC	O
was	O	O
effective	O	O
in	O	O
increasing	O	O
and	O	O
sustaining	O	O
recommended	O	O
ASD	B-DISO
screening	B-PROC
of	O	O
toddlers	B-LIVB
and	O	O
improving	O	O
physicians	B-LIVB
'	O	O
perceived	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
in	O	O
caring	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

Improving	O	O
primary	B-PROC
care	I-PROC
screening	B-PROC
,	O	O
skills	O
,	O	O
and	O	O
knowledge	B-DISO
may	O	O
improve	B-DISO
the	O	O
timing	O
of	O	O
diagnosis	B-PROC
,	O	O
initiation	O
of	O	O
treatment	B-PROC
,	O	O
quality	B-PROC
of	I-PROC
care	I-PROC
,	O	O
and	O	O
outcomes	O
for	O	O
children	B-LIVB
with	O	O
ASD	B-DISO
.	O	O

Describing	O	O
Self	O
-	O
Care	O
Self	B-PHYS
-	I-PHYS
Efficacy	I-PHYS
:	O	O
Definition	O
,	O	O
Measurement	O
,	O	O
Outcomes	O
,	O	O
and	O	O
Implications	O
The	O	O
pragmatic	B-PROC
utility	I-PROC
method	I-PROC
of	O	O
concept	O
analysis	B-PROC
was	O	O
used	O	O
to	O	O
explore	O	O
the	O	O
usefulness	O
of	O	O
the	O	O
concept	O
self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
.	O	O

Empirical	B-PROC
studies	I-PROC
across	O	O
disciplines	O
published	O	O
between	O	O
1996	O	O
and	O	O
2015	O	O
were	O	O
used	O	O
as	O	O
data	O
.	O	O

A	O	O
data	O
matrix	O
was	O	O
developed	O	O
.	O	O

Analytical	O	O
questions	O
and	O	O
responses	O
were	O	O
derived	O	O
from	O	O
the	O	O
data	O
to	O	O
understand	O	O
patterns	O	O
,	O	O
develop	O	O
new	O	O
knowledge	O
and	O	O
achieve	O	O
synthesis	O	O
.	O	O

Usefulness	O
of	O	O
the	O	O
concept	O
is	O	O
contingent	O	O
on	O	O
how	O	O
it	O	O
is	O	O
defined	O	O
and	O	O
measured	O	O
.	O	O

Self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
is	O	O
associated	O
with	O
performance	O
of	O	O
self	O
-	O
care	O
activities	O
and	O	O
positive	B-DISO
health	O
outcomes	O
in	O	O
diverse	O
populations	B-LIVB
.	O	O

Research	B-PROC
can	O	O
guide	O	O
development	O
of	O	O
targeted	O	O
interventions	B-PROC
to	O	O
increase	O	O
patients	B-LIVB
'	O	O
self	O
-	O
care	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
thus	O	O
reducing	O
costs	O
,	O	O
and	O	O
assisting	B-PROC
people	B-LIVB
to	O	O
achieve	O	O
optimal	O
health	O
.	O	O

Dynamics	B-PHEN
of	O	O
intestinal	B-ANAT
metabolites	B-CHEM
and	O	O
morphology	O
in	O	O
response	B-PHYS
to	O	O
necrotic	B-DISO
enteritis	I-DISO
challenge	B-PROC
in	O	O
broiler	B-LIVB
chickens	I-LIVB
Despite	O	O
the	O	O
relatively	O
small	O
contribution	O
to	O	O
metabolizable	O
energy	O
that	O	O
volatile	B-CHEM
fatty	I-CHEM
acids	I-CHEM
(	O	O
VFAs	B-CHEM
)	O	O
provide	O
in	O	O
chickens	B-LIVB
,	O	O
these	O	O
organic	B-CHEM
acids	I-CHEM
have	O	O
been	O	O
reported	B-PROC
to	O	O
play	O	O
beneficial	O
roles	O
in	O	O
the	O	O
gastrointestinal	B-ANAT
tract	I-ANAT
(	O	O
GIT	B-ANAT
)	O	O
of	O	O
birds	B-LIVB
,	O	O
for	O	O
example	O	O
,	O	O
inhibition	B-PHYS
of	I-PHYS
the	I-PHYS
growth	I-PHYS
of	O	O
some	O	O
pathogenic	B-LIVB
bacteria	B-LIVB
.	O	O

However	O	O
,	O	O
information	O
regarding	O	O
the	O	O
dynamics	B-PHEN
of	O	O
these	O	O
metabolites	B-CHEM
in	O	O
the	O	O
GIT	B-ANAT
of	O	O
chickens	B-LIVB
is	O	O
still	O	O
scarce	O
,	O	O
especially	O
under	O	O
disease	B-DISO
conditions	I-DISO
such	O	O
as	O	O
necrotic	B-DISO
enteritis	I-DISO
(	O	O
NE	B-DISO
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O
the	O	O
dynamics	B-PHEN
of	O	O
VFAs	B-CHEM
and	O	O
lactic	B-CHEM
acid	I-CHEM
,	O	O
and	O	O
intestinal	B-ANAT
morphology	O
in	O	O
response	B-PHYS
to	O	O
NE	B-DISO
predisposing	O
factors	O
,	O	O
that	O	O
is	O	O
,	O	O
excessive	O
dietary	B-OBJC
fishmeal	B-OBJC
and	O	O
Eimeria	O
inoculation	B-PROC
,	O	O
and	O	O
causative	B-DISO
agent	I-DISO
Clostridium	B-LIVB
perfringens	I-LIVB
producing	O	O
NetB	B-CHEM
toxin	I-CHEM
.	O	O

The	O	O
experiment	B-PROC
was	O	O
designed	B-PROC
in	O	O
a	O	O
2	O	O
×	O	O
2	O	O
×	O	O
2	O	O
factorial	O
arrangement	B-PROC
of	O	O
treatments	B-PROC
with	O	O
or	O	O
without	O	O
:	O	O
fishmeal	B-OBJC
feeding	O
,	O	O
Eimeria	O
inoculation	B-PROC
and	O	O
C	B-LIVB
.	I-LIVB

perfringens	I-LIVB
challenge	B-PROC
.	O	O

The	O	O
results	B-DISO
showed	O	O
that	O	O
these	O	O
factors	O
significantly	O
influenced	O
composition	B-PHYS
and	O	O
concentration	O
of	O	O
VFAs	B-CHEM
and	O	O
lactic	B-CHEM
acids	I-CHEM
,	O	O
pH	O
and	O	O
histomorphometry	O
in	O	O
one	O	O
way	O	O
or	O	O
another	O	O
.	O	O

These	O	O
changes	O
may	O	O
be	O	O
important	O
for	O	O
the	O	O
onset	O
of	O
NE	B-DISO
or	O	O
only	O	O
the	O	O
synergetic	B-PHYS
responses	I-PHYS
to	O	O
micro	O
environmental	O
stress	B-DISO
.	O	O

Eimeria	O
appeared	O	O
to	O	O
be	O	O
more	O
important	O
than	O	O
fishmeal	B-OBJC
in	O	O
predisposing	O
birds	B-LIVB
to	O	O
NE	B-DISO
,	O	O
thus	O	O
the	O	O
application	O
of	O	O
Eimeria	O
in	O	O
NE	B-DISO
challenge	B-PROC
provides	O
more	O	O
consistent	O
success	O
in	O	O
inducing	O
the	O	O
disease	B-DISO
.	O	O

The	O	O
metabolic	O
responses	B-PHYS
to	O	O
various	O	O
adverse	B-DISO
factors	O
such	O	O
as	O	O
excessive	O
dietary	B-OBJC
fishmeal	B-OBJC
and	O	O
Eimeria	O
infection	B-DISO
are	O	O
complex	O
.	O	O

Thus	O	O
,	O	O
intensive	O
efforts	B-PHYS
are	O	O
required	O
to	O	O
better	O
understand	B-PHYS
NE	B-DISO
so	O	O
as	O	O
to	O	O
achieve	O	O
the	O	O
control	B-PROC
of	I-PROC
the	I-PROC
disease	I-PROC
in	O	O
the	O	O
absence	O
of	O	O
antibiotics	B-CHEM
.	O	O

The	O	O
effects	O
of	O
paternal	O
high	B-OBJC
-	I-OBJC
fat	I-OBJC
diet	I-OBJC
exposure	O
on	O	O
offspring	B-LIVB
metabolism	B-PHYS
with	O	O
epigenetic	B-PHYS
changes	I-PHYS
in	O	O
the	O	O
mouse	O	O
adiponectin	O
and	O	O
leptin	O
gene	O
promoters	O
Recent	O	O
studies	B-PROC
have	O	O
demonstrated	O	O
that	O	O
epigenetic	B-PHYS
changes	I-PHYS
resulting	O	O
from	O	O
malnutrition	B-DISO
might	O	O
play	O	O
important	O	O
roles	O
in	O	O
transgenerational	O
links	O
with	O	O
metabolic	B-DISO
diseases	I-DISO
.	O	O

Previously	O	O
,	O	O
we	O	O
observed	O
that	O	O
exposure	O
to	O	O
a	O	O
high	B-OBJC
-	I-OBJC
fat	I-OBJC
diet	I-OBJC
(	O	O
HFD	B-OBJC
)	O	O
in	B-LIVB
utero	I-LIVB
caused	O
a	O	O
metabolic	O
syndrome	B-DISO
-like	O	O
phenomenon	B-PHEN
through	O
epigenetic	B-PHYS
modifications	I-PHYS
of	O	O
the	O	O
adiponectin	O
and	O	O
leptin	O
genes	O
that	O	O
persisted	O	O
for	O	O
multiple	O
generations	O
.	O	O

Recent	O	O
etiological	O
studies	B-PROC
indicated	B-DISO
that	O	O
paternal	O
BMI	B-PHYS
had	O	O
effects	O
on	O	O
offspring	B-LIVB
BMI	B-PHYS
that	O	O
were	O	O
independent	O
of	O
but	O	O
additive	O
to	O	O
maternal	B-DISO
BMI	B-PHYS
effects	O
.	O	O

Thus	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
paternal	O
HFD	B-OBJC
-	O	O
induced	O
obesity	B-DISO
affected	O
the	O	O
metabolic	O
status	O
of	O	O
offspring	B-LIVB
through	O
epigenetic	B-PHYS
changes	I-PHYS
in	O	O
the	O	O
adiponectin	O
and	O	O
leptin	O
genes	O
.	O	O

Additionally	O	O
,	O	O
we	O	O
investigated	O
whether	O	O
a	O	O
normal	O
diet	O
during	O
subsequent	O
generations	O
abolished	O
the	O	O
epigenetic	B-PHYS
changes	I-PHYS
associated	O
with	O
paternal	O
HFD	B-OBJC
exposure	O
before	O
conception	B-PHYS
.	O	O

We	O	O
observed	O
the	O	O
effects	O
of	O
paternal	O
HFD	B-OBJC
exposure	O
before	O
conception	B-PHYS
over	O	O
multiple	O
generations	O
on	O	O
offspring	B-LIVB
metabolic	O
traits	B-PHYS
,	O	O
including	O
weight	B-DISO
and	O	O
fat	B-CHEM
gain	O
,	O	O
glucose	B-DISO
intolerance	I-DISO
,	O	O
hypertriglyceridemia	B-DISO
,	O	O
abnormal	B-CHEM
adipocytokine	I-CHEM
levels	O
,	O	O
hypertension	B-DISO
,	O	O
and	O	O
adiponectin	O
and	O	O
leptin	O
gene	O
expression	B-PHYS
and	O	O
epigenetic	B-PHYS
changes	I-PHYS
.	O	O

Normal	O
diet	O
consumption	O	O
by	O	O
male	O	O
offspring	B-LIVB
during	O	O
the	O	O
subsequent	O	O
generation	O	O
following	O	O
paternal	O
HFD	B-OBJC
exposure	O
diminished	O
whereas	O	O
consumption	O
for	O	O
two	O	O
generations	O
completely	O	O
abolished	O
the	O	O
effect	O
of	O	O
paternal	O
HFD	B-OBJC
exposure	O
on	O	O
metabolic	O
traits	B-PHYS
and	O	O
adipocytokine	B-CHEM
promoter	O	O
epigenetic	B-PHYS
changes	I-PHYS
in	O	O
the	O	O
offspring	B-LIVB
.	O	O

The	O	O
effects	O
of	O
paternal	O
HFD	B-OBJC
exposure	O
on	O	O
offspring	B-LIVB
were	O	O
relatively	O	O
weaker	O
than	O	O
those	O	O
following	O
HFD	B-OBJC
exposure	O
in	B-LIVB
utero	I-LIVB
.	O	O

However	O	O
,	O	O
paternal	O
HFD	B-OBJC
exposure	O
had	O	O
an	O	O
additive	O
metabolic	O
effect	O
for	O	O
two	O	O
generations	O
,	O	O
suggesting	O	O
that	O	O
both	O	O
paternal	O
and	O	O
maternal	B-DISO
nutrition	B-PHYS
might	O	O
affect	O
offspring	B-LIVB
metabolism	B-PHYS
through	O
epigenetic	B-PHYS
modifications	I-PHYS
of	O	O
adipocytokine	O
genes	O
for	O	O
multiple	O
generations	O
.	O	O

Ehlers	B-DISO
-	I-DISO
Danlos	I-DISO
syndrome	I-DISO
The	O	O
Ehlers	B-DISO
-	I-DISO
Danlos	I-DISO
syndromes	I-DISO
(	O	O
EDSs	B-DISO
)	O	O
were	O	O
originally	O	O
described	O
by	O	O
Ehlers	B-LIVB
in	O	O
Denmark	B-GEOG
and	O	O
Danlos	B-LIVB
in	O	O
Paris	B-GEOG
in	O	O
1898	O	O
and	O	O
1908	O	O
,	O	O
respectively	O	O
.	O	O

They	O	O
had	O	O
both	O	O
published	O
individual	O	O
case	O
studies	O
in	O	O
which	O	O
the	O	O
common	O	O
factor	O	O
was	O	O
laxity	B-DISO
of	I-DISO
ligaments	I-DISO
leading	O	O
to	O	O
joint	B-DISO
hypermobility	I-DISO
and	O	O
hyperextensibility	B-DISO
of	I-DISO
the	I-DISO
skin	I-DISO
.	O	O

The	O	O
choice	O	O
of	O	O
the	O	O
name	O
of	O	O
this	O	O
eponymous	O
disease	O
had	O	O
been	O	O
made	O	O
by	O	O
Dr	B-LIVB
Parkes	I-LIVB
Weber	I-LIVB
,	O	O
an	O	O
eminent	O	O
London	B-GEOG
physician	B-LIVB
in	O	O
the	O	O
1930s	O	O
,	O	O
who	O	O
had	O	O
a	O	O
penchant	O
for	O	O
eponymous	O
diseases	O
,	O	O
having	O	O
had	O	O
no	O	O
less	O	O
than	O	O
seven	O	O
attributed	O	O
to	O	O
himself	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
.	O	O

Unfortunately	O	O
,	O	O
this	O	O
was	O	O
before	O	O
the	O	O
age	O	O
of	O	O
a	O	O
computerised	O
literature	O
search	O
,	O	O
and	O	O
Parkes	B-LIVB
Weber	I-LIVB
had	O	O
inadvertently	O	O
overlooked	O	O
the	O	O
very	O	O
first	O	O
description	O
of	O	O
EDS	B-DISO
which	O	O
had	O	O
been	O	O
made	O	O
by	O	O
Tchernabogov	B-LIVB
,	O	O
a	O	O
Russian	B-LIVB
dermatologist	B-LIVB
,	O	O
whose	O	O
description	O
was	O	O
published	O
in	O	O
1891	O	O
and	O	O
remains	O	O
one	O	O
of	O	O
the	O	O
best	O	O
descriptions	O
of	O	O
EDS	B-DISO
in	O	O
the	O	O
literature	O
.	O	O

Assessment	B-PROC
of	O	O
laparoscopic	B-PROC
stomach	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O	O
sentinel	B-PROC
basin	I-PROC
dissection	I-PROC
versus	O	O
standard	O	O
gastrectomy	B-PROC
with	O	O
lymphadenectomy	B-PROC
in	O	O
early	B-DISO
gastric	I-DISO
cancer	I-DISO
-A	O	O
multicenter	B-PROC
randomized	I-PROC
phase	I-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
(	I-PROC
SENORITA	I-PROC
trial	I-PROC
)	I-PROC
protocol	I-PROC
Along	O	O
with	O	O
the	O	O
marked	O	O
increase	O	O
in	O	O
early	B-DISO
gastric	I-DISO
cancer	I-DISO
(	O	O
EGC	B-DISO
)	O	O
in	O	O
the	O	O
Eastern	B-GEOG
countries	I-GEOG
,	O	O
there	O	O
has	O	O
been	O	O
an	O	O
effort	O	O
to	O	O
adopt	O	O
the	O	O
sentinel	B-ANAT
node	I-ANAT
concept	O	O
in	O	O
EGC	B-DISO
to	O	O
preserve	O	O
gastric	B-PHYS
function	I-PHYS
and	O	O
reduce	O	O
the	O	O
occurrence	O	O
of	O	O
postoperative	B-DISO
complications	I-DISO
.	O	O

Based	O	O
on	O	O
promising	O	O
results	O	O
from	O	O
a	O	O
previous	B-PROC
quality	I-PROC
control	I-PROC
study	I-PROC
,	O	O
this	O	O
prospective	B-PROC
multicenter	I-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
aims	O	O
to	O	O
elucidate	O	O
the	O	O
oncologic	O
safety	B-PROC
of	O	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O	O
sentinel	B-PROC
basin	I-PROC
dissection	I-PROC
(	O	O
SBD	B-PROC
)	O	O
compared	O	O
to	O	O
a	O	O
standard	O	O
laparoscopic	O
gastrectomy	B-PROC
.	O	O

This	O	O
trial	O	O
is	O	O
an	O	O
investigator	O	O
-	O	O
initiated	O	O
,	O	O
open	O	O
-	O	O
label	O	O
,	O	O
multicenter	B-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
III	I-PROC
trial	I-PROC
with	O	O
a	O	O
non	B-PROC
-	I-PROC
inferiority	I-PROC
design	I-PROC
.	O	O

Patients	O
diagnosed	O
with	O	O
a	O	O
single	B-DISO
lesion	I-DISO
of	O	O
clinical	O
stage	O
T1N0M0	O
gastric	B-DISO
adenocarcinoma	I-DISO
,	O	O
with	O	O
a	O	O
diameter	O	O
of	O	O
3	O	O
cm	O	O
or	O	O
less	O	O
are	O	O
eligible	O	O
for	O	O
the	O	O
present	O	O
study	O	O
.	O	O

A	O	O
total	O	O
of	O	O
580	O	O
patients	B-LIVB
(	O	O
290	O	O
per	O	O
group	O	O
)	O	O
will	O	O
be	O	O
randomized	B-DISO
to	O	O
either	O	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O	O
SBD	B-PROC
or	O	O
standard	B-PROC
surgery	I-PROC
.	O	O

The	O	O
primary	O	O
end	O	O
-	O	O
point	O	O
is	O	O
3	O	O
-	O	O
year	O	O
disease	O
-	O
free	O
survival	O
(	O	O
DFS	O
)	O	O
and	O	O
the	O	O
secondary	O	O
endpoints	O	O
include	O	O
postoperative	B-DISO
morbidity	I-DISO
and	O	O
mortality	O
,	O	O
quality	O
of	O
life	O
,	O	O
5	O	O
-	O	O
year	O	O
DFS	O
,	O	O
and	O	O
overall	O
survival	O
.	O	O

Qualified	B-LIVB
investigators	I-LIVB
who	O	O
completed	O	O
the	O	O
prior	O	O
quality	O
control	O
study	O
are	O	O
exclusively	O	O
allowed	O	O
to	O	O
participate	O	O
in	O	O
this	O	O
phase	B-PROC
III	I-PROC
clinical	I-PROC
trial	I-PROC
.	O	O

The	O	O
proposed	O	O
trial	O	O
is	O	O
expected	O	O
to	O	O
verify	O	O
whether	O	O
laparoscopic	B-PROC
stomach	I-PROC
-	I-PROC
preserving	I-PROC
surgery	I-PROC
with	O	O
SBD	B-PROC
achieves	O	O
similar	O	O
oncologic	B-DISO
outcomes	I-DISO
and	O	O
improved	O	O
quality	O
of	O
life	O
compared	O	O
to	O	O
a	O	O
standard	B-PROC
gastrectomy	I-PROC
in	O	O
EGC	B-DISO
patients	B-LIVB
.	O	O

This	O	O
study	O	O
was	O	O
registered	O	O
at	O	O
the	O	O
NIH	O	O
ClinicalTrial	O	O
.	O	O

gov	O	O
database	O	O
(	O	O
NCT01804998	O	O
)	O	O
on	O	O
March	O	O
4th	O	O
,	O	O
2013	O	O
.	O	O

Isolation	O
and	O	O
characterization	O
of	O	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

strain	I-LIVB
CCA53	I-LIVB
exhibiting	O	O
ligninolytic	B-PHYS
potential	O
Microbial	B-LIVB
degradation	B-PHYS
of	O	O
lignin	B-CHEM
releases	O	O
fermentable	B-CHEM
sugars	I-CHEM
,	O	O
effective	O
utilization	O
of	O	O
which	O	O
could	O	O
support	O	O
biofuel	B-CHEM
production	O
from	O	O
lignocellulosic	B-CHEM
biomass	O
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
a	O	O
lignin	B-PHYS
-	I-PHYS
degrading	I-PHYS
bacterium	B-LIVB
was	O	O
isolated	O
from	O	O
leaf	B-LIVB
soil	B-OBJC
and	O	O
identified	O	O
as	O	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

based	O	O
on	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	B-PROC
sequencing	I-PROC
.	O	O

This	O	O
strain	O
was	O	O
named	O	O
CCA53	B-LIVB
,	O	O
and	O	O
its	O	O
lignin	B-PHYS
-	I-PHYS
degrading	I-PHYS
capability	O
was	O	O
assessed	O
by	O	O
observing	O	O
its	O	O
growth	B-PHYS
on	O	O
medium	B-CHEM
containing	O	O
alkali	B-CHEM
lignin	I-CHEM
or	O	O
lignin	B-CHEM
-associated	O	O
aromatic	B-CHEM
monomers	I-CHEM
as	O	O
the	O	O
sole	O	O
carbon	B-CHEM
source	B-DISO
.	O	O

Alkali	B-CHEM
lignin	I-CHEM
and	O	O
at	O	O
least	O	O
eight	O	O
lignin	B-CHEM
-associated	O	O
aromatic	B-CHEM
monomers	I-CHEM
supported	O	O
growth	B-PHYS
of	O	O
this	O	O
strain	O
,	O	O
and	O	O
the	O	O
most	O	O
effective	O
utilization	O
was	O	O
observed	O	O
for	O	O
p	B-CHEM
-	I-CHEM
hydroxybenzene	I-CHEM
monomers	I-CHEM
.	O	O

These	O	O
findings	B-DISO
indicate	O	O
that	O	O
Burkholderia	B-LIVB
sp	I-LIVB
.	I-LIVB

strain	I-LIVB
CCA53	I-LIVB
has	O	O
fragmentary	O
activity	O
for	O	O
lignin	B-PHYS
degradation	I-PHYS
.	O	O

Association	O	O
of	O	O
Metabolites	B-CHEM
with	O	O
Obesity	B-DISO
and	O	O
Type	B-DISO
2	I-DISO
Diabetes	I-DISO
Based	O	O
on	O	O
FTO	O
Genotype	B-PHYS
The	O	O
single	O
nucleotide	O
polymorphism	O
rs9939609	O
of	O
the	O
gene	O
FTO	O
,	O	O
which	O	O
encodes	O	O
fat	B-PHYS
mass	I-PHYS
and	O	O
obesity	B-DISO
-associated	O	O
protein	B-CHEM
,	O	O
is	O	O
strongly	O	O
associated	O	O
with	O	O
obesity	B-DISO
and	O	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
(	O	O
T2D	B-DISO
)	O	O
in	O	O
multiple	O	O
populations	B-LIVB
;	O	O
however	O	O
,	O	O
the	O	O
underlying	O	O
mechanism	O	O
of	O	O
this	O	O
association	O	O
is	O	O
unclear	O	O
.	O	O

The	O	O
present	O	O
study	B-PROC
aimed	O	O
to	O	O
investigate	O	O
FTO	O
genotype	B-PHYS
-dependent	O	O
metabolic	B-PHYS
changes	O
in	O	O
obesity	B-DISO
and	O	O
T2D	B-DISO
.	O	O

To	O	O
elucidate	O	O
metabolic	B-DISO
dysregulation	I-DISO
associated	O	O
with	O	O
disease	B-PHYS
risk	I-PHYS
genotype	B-PHYS
,	O	O
genomic	O
and	O	O
metabolomic	O
datasets	O
were	O	O
recruited	O	O
from	O	O
2	O	O
,	O	O
577	O	O
participants	B-LIVB
of	O	O
the	O	O
Korean	B-LIVB
Association	I-LIVB
REsource	I-LIVB
(	I-LIVB
KARE	I-LIVB
)	I-LIVB
cohort	I-LIVB
,	O	O
including	O	O
40	O	O
homozygous	B-PHYS
carriers	B-DISO
of	O	O
the	O	O
FTO	O
risk	O	O
allele	O
(	O
AA	O
)	O
,	O	O
570	O	O
heterozygous	B-PHYS
carriers	B-DISO
(	O	O
AT	O	O
)	O	O
,	O	O
and	O	O
1	O	O
,	O	O
967	O	O
participants	B-LIVB
carrying	O	O
no	O	O
risk	O	O
allele	O
(	O
TT	O
)	O
.	O	O

A	O	O
total	O	O
of	O	O
134	O	O
serum	B-ANAT
metabolites	B-CHEM
were	O	O
quantified	O	O
using	O	O
a	O	O
targeted	O	O
metabolomics	O
approach	O	O
.	O	O

Through	O	O
comparison	O	O
of	O	O
various	O	O
statistical	B-PROC
methods	I-PROC
,	O	O
seven	O	O
metabolites	B-CHEM
were	O	O
identified	O	O
that	O	O
are	O	O
significantly	O	O
altered	O	O
in	O	O
obesity	B-DISO
and	O	O
T2D	B-DISO
based	O	O
on	O	O
the	O	O
FTO	O
risk	O	O
allele	O
(	O	O
adjusted	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

These	O	O
identified	O	O
metabolites	B-CHEM
are	O	O
relevant	O	O
to	O	O
phosphatidylcholine	B-CHEM
metabolic	O
pathway	O
,	O	O
and	O	O
previously	O	O
reported	O	O
to	O	O
be	O	O
metabolic	B-CHEM
markers	I-CHEM
of	O	O
obesity	B-DISO
and	O	O
T2D	B-DISO
.	O	O

In	O	O
conclusion	O	O
,	O	O
using	O	O
metabolomics	O
with	O	O
the	O	O
information	O	O
from	O	O
genome	B-PROC
-	I-PROC
wide	I-PROC
association	I-PROC
studies	I-PROC
revealed	O	O
significantly	O	O
altered	O	O
metabolites	B-CHEM
depending	O	O
on	O	O
the	O	O
FTO	O
genotype	B-PHYS
in	O	O
complex	O	O
disorders	O	O
.	O	O

This	O	O
study	B-PROC
may	O	O
contribute	O	O
to	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
the	O	O
biological	O	O
mechanisms	O	O
linking	O	O
obesity	B-DISO
and	O	O
T2D	B-DISO
.	O	O

Anthology	O
of	O	O
Venezuelan	B-LIVB
psychiatry	O
Reception	O
of	O	O
Psychiatry	O
in	O	O
Venezuela	B-GEOG
since	O	O
the	O	O
19th	O	O
Century	O	O
to	O	O
the	O	O
late	O	O
20th	O	O
Century	O	O
merits	O	O
a	O	O
historical	O	O
approach	O	O
.	O	O

The	O	O
following	O	O
work	O	O
proposes	O	O
to	O	O
research	B-PROC
some	O	O
of	O	O
the	O	O
very	O	O
origins	O	O
of	O	O
Venezuelan	B-LIVB
psychiatry	O
and	O	O
its	O	O
possible	O	O
influence	O
on	O	O
contemporary	O	O
mental	B-PROC
health	I-PROC
practice	I-PROC
.	O	O

Through	O	O
documental	O	O
research	O	O
,	O	O
the	O	O
early	O
works	O
of	O	O
local	B-LIVB
authors	I-LIVB
from	O	O
the	O	O
19th	O	O
Century	O	O
through	O	O
20th	O	O
Century	O	O
finals	O	O
:	O	O
Carlos	B-LIVB
Arvelo	I-LIVB
,	O	O
Lisandro	B-LIVB
Alvarado	I-LIVB
,	O	O
Francisco	B-LIVB
Herrera	I-LIVB
Luque	I-LIVB
,	O	O
Jose	B-LIVB
Luis	I-LIVB
Vethencourt	I-LIVB
and	O	O
Jose	B-LIVB
Solanes	I-LIVB
,	O	O
are	O	O
subjected	O	O
to	O	O
study	O	O
.	O	O

This	O	O
journey	O	O
illustrates	O	O
a	O	O
descriptive	O	O
panoramic	O	O
view	O	O
which	O	O
allows	O	O
to	O	O
better	O	O
comprenhend	O	O
the	O	O
current	O	O
state	O	O
of	O	O
our	O	O
psychiatry	O
.	O	O

In	O	O
a	O	O
brief	O
introduction	O
the	O	O
most	O	O
important	O	O
events	O
are	O	O
described	O	O
,	O	O
since	O	O
the	O	O
arrival	O
of	O	O
Pinel	B-LIVB
's	I-LIVB
ideas	O
,	O	O
followed	O	O
by	O	O
the	O	O
early	O	O
research	O	O
paperworks	O	O
published	O
and	O	O
the	O	O
beginnings	O	O
of	O	O
the	O	O
academic	O
teachings	O
of	O	O
this	O	O
specialty	O	O
in	O	O
Venezuela	B-GEOG
and	O	O
displaying	O
the	O	O
main	O	O
contemporary	O
research	O
groups	O
thorough	B-GEOG
the	I-GEOG
country	I-GEOG
.	O	O

Study	B-PROC
of	O	O
the	O	O
Microfocus	O
X	B-DEVI
-	I-DEVI
Ray	I-DEVI
Tube	I-DEVI
Based	O	O
on	O	O
a	O	O
Point	O
-	O
Like	O
Target	O
Used	O	O
for	O	O
Micro	B-PROC
-	I-PROC
Computed	I-PROC
Tomography	I-PROC
For	O	O
a	O	O
micro	B-PROC
-	I-PROC
Computed	I-PROC
Tomography	I-PROC
(	I-PROC
Micro	I-PROC
-	I-PROC
CT	I-PROC
)	I-PROC
system	I-PROC
,	O	O
the	O	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
is	O	O
an	O	O
essential	O
component	O	O
because	O	O
the	O	O
spatial	O
resolution	O
of	O	O
CT	B-PROC
images	O
,	O	O
in	O	O
theory	O
,	O	O
is	O	O
mainly	O	O
determined	O	O
by	O	O
the	O	O
size	O
and	O	O
stability	O
of	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
of	O	O
the	O	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
.	O	O

However	O	O
,	O	O
many	O	O
factors	O
,	O	O
including	O	O
voltage	O
fluctuations	O
,	O	O
mechanical	B-PHEN
vibrations	B-PHEN
,	O	O
and	O	O
temperature	O
changes	O
,	O	O
can	O	O
cause	O
the	O	O
size	O
and	O	O
the	O	O
stability	O
of	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
to	O	O
degrade	B-PHEN
.	O	O

A	O	O
new	O	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
based	O	O
on	O	O
a	O	O
point	O
-	O
like	O
micro	O
-	O
target	O
in	O	O
which	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
target	O
is	O	O
irradiated	B-PHEN
with	O	O
an	O	O
unfocused	O	O
electron	B-OBJC
beam	I-OBJC
was	O	O
investigated	O
.	O	O

EGS4	O
Monte	O
Carlo	O
simulation	O
code	O
was	O	O
employed	O	O
for	O	O
the	O	O
calculation	O
of	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
intensity	B-PHEN
produced	O	O
from	O	O
the	O	O
point	O
-	O
like	O
micro	O
-	O
target	O
and	O	O
the	O	O
substrate	B-OBJC
.	O	O

The	O	O
effects	O
of	O
several	O	O
arrangements	O	O
of	O	O
the	O	O
target	O
material	B-OBJC
,	O	O
target	O
and	O	O
beam	B-OBJC
size	O
were	O	O
studied	B-PROC
.	O	O

The	O	O
simulation	B-PROC
results	O
demonstrated	O	O
that	O	O
if	O	O
the	O	O
intensity	B-PHEN
of	O	O
X	B-PROC
-	I-PROC
rays	I-PROC
generated	O
at	O	O
the	O	O
point	O
-	O
like	O
target	O
is	O	O
greater	O
than	O
half	O	O
of	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
intensity	B-PHEN
produced	O	O
on	O	O
the	O	O
substrate	B-OBJC
,	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
is	O	O
determined	O	O
in	O	O
part	O	O
by	O	O
the	O	O
point	O
-	O
like	O
target	O
rather	O	O
than	O	O
by	O	O
the	O	O
electron	B-OBJC
beam	I-OBJC
in	O	O
the	O	O
conventional	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
.	O	O

In	O	O
theory	O
,	O	O
since	O	O
it	O	O
is	O	O
able	O	O
to	O	O
reduce	O
those	O	O
unfavorable	O	O
effects	O
such	O	O
as	O	O
the	O	O
electron	B-DISO
beam	I-DISO
trajectory	I-DISO
swinging	I-DISO
and	O	O
the	O	O
beam	B-OBJC
size	O
changing	O
for	O	O
the	O	O
microfocus	O
X	B-DEVI
-	I-DEVI
ray	I-DEVI
tube	I-DEVI
,	O	O
it	O	O
could	O	O
alleviate	O
CT	B-PROC
image	O
artifacts	B-PHEN
caused	O
by	O	O
the	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
focal	O
spot	O
shift	B-DISO
and	O	O
size	O
change	O
.	O	O

How	O	O
variation	O
between	O
individuals	B-LIVB
affects	O
species	O
coexistence	O
Although	O	O
the	O	O
effects	O
of	O	O
variation	O
between	O
individuals	B-LIVB
within	O	O
species	O
are	O	O
traditionally	O
ignored	O
in	O	O
studies	B-PROC
of	O	O
species	O
coexistence	O
,	O	O
the	O	O
magnitude	O
of	O	O
intraspecific	O
variation	O
in	O	O
nature	O
is	O	O
forcing	O
ecologists	B-LIVB
to	O	O
reconsider	O
.	O	O

Compelling	O	O
intuitive	O
arguments	O
suggest	O
that	O	O
individual	B-LIVB
variation	O
may	O	O
provide	O
a	O	O
previously	O	O
unrecognised	O	O
route	O
to	O	O
diversity	O
maintenance	O
by	O	O
blurring	O
species	O
-	O	O
level	O
competitive	O
differences	O
or	O	O
substituting	O
for	O	O
species	O
-	O	O
level	O
niche	O
differences	O
.	O	O

These	O	O
arguments	O
,	O	O
which	O	O
are	O	O
motivating	B-PHYS
a	O	O
large	O
body	O
of	O	O
empirical	O
work	O
,	O	O
have	O	O
rarely	O
been	O	O
evaluated	O
with	O	O
quantitative	O
theory	O
.	O	O

Here	O	O
we	O	O
incorporate	O	O
intraspecific	O
variation	O
into	O	O
a	O	O
common	O
model	O
of	O	O
competition	O
and	O	O
identify	O
three	O	O
pathways	O
by	O	O
which	O	O
this	O	O
variation	O
affects	O
coexistence	O
:	O	O
(	O	O
1	O	O
)	O	O
changes	O
in	O	O
competitive	O
dynamics	O
because	O	O
of	O	O
nonlinear	O	O
averaging	O
,	O	O
(	O	O
2	O	O
)	O	O
changes	O
in	O	O
species	O
'	O	O
mean	O
interaction	O
strengths	O
because	O	O
of	O	O
variation	O
in	O	O
underlying	O	O
traits	B-PHYS
(	O	O
also	O	O
via	O	O
nonlinear	O	O
averaging	O
)	O	O
and	O	O
(	O	O
3	O	O
)	O	O
effects	O
on	O	O
stochastic	B-PROC
demography	I-PROC
.	O	O

As	O	O
a	O	O
consequence	O
of	O
the	O	O
first	O	O
two	O	O
mechanisms	O
,	O	O
we	O	O
find	B-DISO
that	O	O
intraspecific	O
variation	O
in	O	O
competitive	O
ability	B-PHYS
increases	O
the	O	O
dominance	O
of	O	O
superior	O
competitors	B-LIVB
,	O	O
and	O	O
intraspecific	O
niche	O
variation	O
reduces	O
species	O
-	O	O
level	O
niche	O
differentiation	O
,	O	O
both	O
of	O	O
which	O	O
make	O	O
coexistence	O
more	O
difficult	O
.	O	O

In	O	O
addition	O	O
,	O	O
individual	B-LIVB
variation	O
can	O	O
exacerbate	O
the	O	O
effects	O
of	O	O
demographic	B-PROC
stochasticity	I-PROC
,	O	O
and	O	O
this	O	O
further	O	O
destabilises	O
coexistence	O
.	O	O

Our	O	O
work	O
provides	O
a	O	O
theoretical	B-PROC
foundation	I-PROC
for	O	O
emerging	O	O
empirical	O
interests	B-PHYS
in	O	O
the	O	O
effects	O
of	O	O
intraspecific	O
variation	O
on	O	O
species	O
diversity	O
.	O	O

Intracellular	B-PHYS
Metabolism	I-PHYS
of	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
Unsaturated	I-CHEM
Carbonyl	I-CHEM
Compounds	I-CHEM
,	O	O
Acrolein	B-CHEM
,	O	O
Crotonaldehyde	B-CHEM
and	O	O
Methyl	B-CHEM
Vinyl	I-CHEM
Ketone	I-CHEM
,	O	O
Active	O
Toxicants	B-CHEM
in	O	O
Cigarette	B-CHEM
Smoke	I-CHEM
:	O	O
Participation	O	O
of	O	O
Glutathione	B-CHEM
Conjugation	B-PHYS
Ability	O	O
and	O	O
Aldehyde	B-PHYS
-	I-PHYS
Ketone	I-PHYS
Sensitive	I-PHYS
Reductase	I-PHYS
Activity	I-PHYS
The	O	O
major	O	O
toxicants	B-CHEM
in	O	O
cigarette	B-CHEM
smoke	I-CHEM
,	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
,	O	O
such	O	O
as	O	O
acrolein	B-CHEM
(	O	O
ACR	B-CHEM
)	O	O
and	O	O
crotonaldehyde	B-CHEM
(	O	O
CA	B-CHEM
)	O	O
,	O	O
and	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
ketone	I-CHEM
,	O	O
methyl	B-CHEM
vinyl	I-CHEM
ketone	I-CHEM
(	O	O
MVK	B-CHEM
)	O	O
,	O	O
are	O	O
known	O	O
to	O	O
form	O	O
Michael	B-CHEM
-	I-CHEM
type	I-CHEM
adducts	I-CHEM
with	O	O
glutathione	B-CHEM
(	O	O
GSH	B-CHEM
)	O	O
and	O	O
consequently	O	O
cause	O	O
intracellular	O
GSH	B-CHEM
depletion	O
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
cigarette	B-CHEM
smoke	I-CHEM
-	O	O
induced	O
cytotoxicity	B-DISO
.	O	O

We	O	O
have	O	O
previously	O	O
clarified	O	O
that	O	O
exposure	O
to	O
cigarette	B-CHEM
smoke	I-CHEM
extract	I-CHEM
(	O	O
CSE	B-CHEM
)	O	O
of	O	O
a	O	O
mouse	B-LIVB
melanoma	B-ANAT
cell	I-ANAT
culture	B-CHEM
medium	I-CHEM
causes	O	O
rapid	O	O
reduction	O
of	O	O
intracellular	O
GSH	B-CHEM
levels	O
,	O	O
and	O	O
that	O	O
the	O	O
GSH	B-CHEM
-	O	O
MVK	B-CHEM
adduct	B-CHEM
can	O	O
be	O	O
detected	B-DISO
by	O	O
LC	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
while	O	O
the	O	O
GSH	B-CHEM
-	O	O
CA	B-CHEM
adduct	B-CHEM
is	O	O
hardly	O	O
detected	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
to	O	O
clarify	O	O
why	O	O
the	O	O
GSH	B-CHEM
-	O	O
CA	B-CHEM
adduct	B-CHEM
is	O	O
difficult	O	O
to	O	O
detect	B-DISO
in	O	O
the	O	O
cell	B-ANAT
medium	B-CHEM
,	O	O
we	O	O
conducted	O	O
detailed	O	O
investigation	O
of	O	O
the	O	O
structures	O
of	O	O
the	O	O
reaction	B-CHEM
products	I-CHEM
of	O	O
ACR	B-CHEM
,	O	O
CA	B-CHEM
,	O	O
MVK	B-CHEM
and	O	O
CSE	B-CHEM
in	O	O
the	O	O
GSH	B-CHEM
solution	B-OBJC
or	O	O
the	O	O
cell	B-ANAT
culture	B-CHEM
medium	I-CHEM
.	O	O

The	O	O
mass	B-PROC
spectra	I-PROC
indicated	O	O
that	O	O
in	O	O
the	O	O
presence	O
of	O	O
the	O	O
cells	B-ANAT
,	O	O
the	O	O
GSH	B-CHEM
-	O	O
CA	B-CHEM
and	O	O
GSH	B-CHEM
-	O	O
ACR	B-CHEM
adducts	B-CHEM
were	O	O
almost	O	O
not	O	O
detected	B-DISO
while	O	O
their	O	O
corresponding	B-CHEM
alcohols	I-CHEM
were	O	O
detected	B-DISO
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
both	O	O
the	O	O
GSH	B-CHEM
-	O	O
MVK	B-CHEM
adducts	B-CHEM
and	O	O
their	O	O
reduced	B-OBJC
products	I-OBJC
were	O	O
detected	B-DISO
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
cells	B-ANAT
,	O	O
the	O	O
reaction	O
of	O	O
GSH	B-CHEM
with	O	O
all	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
carbonyls	I-CHEM
produced	O	O
only	O	O
their	O	O
corresponding	O	O
adducts	B-CHEM
.	O	O

These	O	O
results	O
show	O	O
that	O	O
the	O	O
GSH	B-CHEM
adducts	B-CHEM
of	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
,	O	O
CA	B-CHEM
and	O	O
ACR	B-CHEM
,	O	O
are	O	O
quickly	O	O
reduced	B-PHEN
by	O	O
certain	O	O
intracellular	O
carbonyl	B-CHEM
reductase	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
and	O	O
excreted	O	O
from	O	O
the	O	O
cells	B-ANAT
,	O	O
unlike	O	O
the	O	O
GSH	B-CHEM
adduct	B-CHEM
of	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
ketone	I-CHEM
,	O	O
MVK	B-CHEM
.	O	O

Such	O	O
a	O	O
difference	O	O
in	O	O
reactivity	O
to	O	O
the	O	O
carbonyl	B-PHYS
reductase	I-PHYS
might	O	O
be	O	O
related	O	O
to	O	O
differences	O	O
in	O	O
the	O	O
cytotoxicity	B-DISO
of	O	O
α	B-CHEM
,	I-CHEM
β	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
aldehydes	I-CHEM
and	O	O
ketones	B-CHEM
.	O	O

Diagnostic	O
utility	O
of	O	O
additional	O	O
conventional	O
techniques	B-PROC
after	O	O
endobronchial	B-PROC
ultrasonography	I-PROC
guidance	B-PROC
during	O	O
transbronchial	B-PROC
biopsy	I-PROC
Endobronchial	B-PROC
ultrasonography	I-PROC
with	O	O
a	O	O
guide	B-DEVI
sheath	I-DEVI
transbronchial	B-PROC
biopsy	I-PROC
(	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
)	O	O
has	O	O
been	O	O
used	O	O
to	O	O
diagnose	B-DISO
peripheral	B-DISO
pulmonary	I-DISO
lesions	I-DISO
(	O	O
PPLs	B-DISO
)	O	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
evaluated	O	O
the	O	O
diagnostic	O
utility	O
of	O	O
conventional	O
TBB	B-PROC
after	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
.	O	O

A	O	O
retrospective	B-PROC
analysis	I-PROC
of	O	O
patients	B-LIVB
who	O	O
underwent	O	O
conventional	O
TBB	B-PROC
after	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
for	O	O
PPL	B-DISO
between	O	O
August	O	O
1	O	O
,	O	O
2012	O	O
and	O	O
December	O	O
31	O	O
,	O	O
2014	O	O
.	O	O

We	O	O
performed	O	O
multivariate	O
analysis	O
to	O	O
examine	O	O
the	O	O
association	O
of	O	O
various	O	O
clinical	O
factors	O
,	O	O
including	O	O
EBUS	B-PROC
probe	B-DEVI
distance	O
and	O	O
sample	O
size	O
area	O
,	O	O
with	O	O
diagnostic	O
yield	O
.	O	O

Of	O	O
88	O	O
eligible	O	O
patients	B-LIVB
,	O	O
57	O	O
(	O	O
65	O	O
%	O	O
)	O	O
were	O	O
successfully	O	O
diagnosed	B-DISO
by	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
.	O	O

In	O	O
31	O	O
patients	B-LIVB
not	O	O
diagnosed	B-DISO
by	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
,	O	O
15	O	O
(	O	O
48	O	O
%	O	O
)	O	O
were	O	O
successfully	O	O
diagnosed	B-DISO
by	O	O
additional	O	O
conventional	O
TBB	B-PROC
.	O	O

Ground	B-DISO
glass	I-DISO
opacity	I-DISO
(	O	O
GGO	B-DISO
)	O	O
was	O	O
a	O	O
significant	O
factor	O
associated	O	O
with	O	O
the	O	O
diagnostic	O
yield	O
of	O	O
additional	O	O
conventional	O
TBB	B-PROC
following	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
.	O	O

Multivariate	O
analysis	O
and	O	O
receiver	O
operator	O
curves	O
revealed	O	O
that	O	O
distance	O
between	O	O
the	O	O
PPL	B-DISO
and	O	O
the	O	O
EBUS	B-PROC
probe	B-DEVI
of	O	O
less	O	O
than	O	O
2	O	O
.	O	O
55	O	O
mm	O	O
favored	O	O
the	O	O
utility	O
of	O	O
conventional	O
TBB	B-PROC
.	O	O

Additional	O	O
conventional	O
TBB	B-PROC
after	O	O
EBUS	B-PROC
-	O	O
GS	B-DEVI
TBB	B-PROC
could	O	O
be	O	O
a	O	O
useful	O	O
procedure	B-PROC
for	O	O
the	O	O
diagnosis	B-DISO
of	O	O
ground	B-DISO
glass	I-DISO
opacity	I-DISO
PPLs	B-DISO
and	O	O
in	O	O
cases	O
of	O	O
a	O	O
distance	O
of	O	O
less	O	O
than	O	O
2	O	O
.	O	O

55	O	O
mm	O	O
between	O	O
the	O	O
EBUS	B-PROC
probe	B-DEVI
and	O	O
the	O	O
lesion	B-DISO
.	O	O

Strategies	B-PROC
for	O	O
Assaying	B-PROC
Lysosomal	B-ANAT
Membrane	I-ANAT
Permeabilization	B-PHYS
Late	B-ANAT
endosomal	I-ANAT
organelles	B-ANAT
have	O	O
an	O	O
acidic	O
pH	O
and	O	O
contain	O	O
hydrolytic	B-CHEM
enzymes	I-CHEM
to	O	O
degrade	O
cargo	O	O
delivered	O	O
either	O	O
from	O	O
the	O	O
extracellular	B-ANAT
environment	O
by	O	O
endocytosis	B-PHYS
or	O	O
from	O	O
within	O	O
the	O	O
cell	B-ANAT
itself	O	O
by	O	O
autophagy	B-PHYS
.	O	O

In	O	O
the	O	O
event	O	O
of	O	O
lysosomal	B-ANAT
membrane	I-ANAT
permeabilization	B-PHYS
(	O	O
LMP	B-PHYS
)	O	O
,	O	O
the	O	O
contents	O	O
of	O	O
late	B-ANAT
endosomes	I-ANAT
and	O	O
lysosomes	B-ANAT
can	O	O
be	O	O
released	O	O
into	O	O
the	O	O
cytosol	B-ANAT
and	O	O
then	O	O
initiate	O	O
apoptosis	B-PHYS
.	O	O

Compounds	O
that	O	O
can	O	O
trigger	O	O
LMP	B-PHYS
are	O	O
therefore	O	O
candidates	O	O
for	O	O
the	O	O
induction	O
of	O	O
apoptosis	B-PHYS
,	O	O
in	O	O
particular	O	O
in	O	O
anticancer	B-PROC
therapy	I-PROC
.	O	O

Alternatively	O	O
,	O	O
drug	B-DEVI
-	I-DEVI
delivery	I-DEVI
systems	I-DEVI
,	O	O
such	O	O
as	O	O
nanoparticles	B-OBJC
,	O	O
can	O	O
have	O	O
side	O	O
effects	O	O
that	O	O
can	O	O
include	O	O
LMP	B-PHYS
,	O	O
which	O	O
has	O	O
toxic	B-DISO
consequences	I-DISO
for	O	O
the	O	O
cells	B-ANAT
.	O	O

To	O	O
determine	O	O
when	O	O
,	O	O
to	O	O
what	O	O
extent	O	O
,	O	O
and	O	O
with	O	O
what	O	O
consequences	O
LMP	B-PHYS
occurs	O	O
is	O	O
therefore	O	O
of	O	O
paramount	O
importance	O
for	O	O
the	O	O
evaluation	B-PROC
of	O	O
new	O
potentially	O
LMP	B-PHYS
-	O	O
inducing	O
compounds	O
.	O	O

In	O	O
this	O	O
introduction	O	O
,	O	O
we	O	O
provide	O	O
an	O	O
overview	O	O
of	O	O
some	O	O
basic	B-PROC
assays	I-PROC
for	O	O
assessing	B-PROC
LMP	B-PHYS
,	O	O
such	O	O
as	O	O
staining	O	O
with	O	O
lysosomotropic	B-CHEM
dyes	I-CHEM
and	O	O
measurement	O	O
of	O	O
cysteine	B-CHEM
cathepsin	B-CHEM
activity	B-PHYS
,	O	O
and	O	O
discuss	O	O
additional	O	O
strategies	B-PROC
for	O	O
the	O	O
detection	B-PROC
of	O	O
the	O	O
release	O
of	O	O
endogenous	O
lysosomal	B-ANAT
molecules	B-OBJC
or	O	O
preloaded	O	O
exogenous	O
tracers	B-CHEM
into	O	O
the	O	O
cytosol	B-ANAT
.	O	O

Active	O
diffusion	B-PHEN
and	O	O
microtubule	B-PHYS
-	I-PHYS
based	I-PHYS
transport	I-PHYS
oppose	O	O
myosin	B-CHEM
forces	B-PHEN
to	O	O
position	O
organelles	B-ANAT
in	O	O
cells	B-ANAT
Even	O	O
distribution	O
of	O	O
peroxisomes	B-ANAT
(	O	O
POs	B-ANAT
)	O	O
and	O	O
lipid	B-ANAT
droplets	I-ANAT
(	O	O
LDs	B-ANAT
)	O	O
is	O	O
critical	O	O
to	O	O
their	O	O
role	O
in	O	O
lipid	B-CHEM
and	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
homeostasis	B-PHEN
.	O	O

How	O	O
even	O	O
distribution	O
is	O	O
achieved	O	O
remains	O	O
elusive	O	O
,	O	O
but	O	O
diffusive	B-PHEN
motion	I-PHEN
and	O	O
directed	O	O
motility	B-PHYS
may	O	O
play	O	O
a	O	O
role	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
in	O	O
the	O	O
fungus	B-LIVB
Ustilago	B-LIVB
maydis	I-LIVB
~95	O	O
%	O	O
of	O	O
POs	B-ANAT
and	O	O
LDs	B-ANAT
undergo	O	O
diffusive	B-PHEN
motions	I-PHEN
.	O	O

These	O	O
movements	B-PHYS
require	O	O
ATP	B-CHEM
and	O	O
involve	O	O
bidirectional	O
early	O	O
endosome	B-ANAT
motility	B-PHYS
,	O	O
indicating	O	O
that	O	O
microtubule	B-ANAT
-	O	O
associated	O
membrane	B-ANAT
trafficking	B-PHYS
enhances	O
diffusion	B-PHEN
of	O	O
organelles	B-ANAT
.	O	O

When	O	O
early	O	O
endosome	B-PHYS
transport	I-PHYS
is	O	O
abolished	O	O
,	O	O
POs	B-ANAT
and	O	O
LDs	B-ANAT
drift	O	O
slowly	O	O
towards	O	O
the	O	O
growing	B-ANAT
cell	I-ANAT
end	I-ANAT
.	O	O

This	O	O
pole	B-PHYS
-	I-PHYS
ward	I-PHYS
drift	I-PHYS
is	O	O
facilitated	O	O
by	O	O
anterograde	B-PHYS
delivery	I-PHYS
of	O	O
secretory	B-CHEM
cargo	I-CHEM
to	O	O
the	O	O
cell	B-ANAT
tip	I-ANAT
by	O	O
myosin	B-CHEM
-	I-CHEM
5	I-CHEM
.	O	O

Modelling	B-PROC
reveals	O	O
that	O	O
microtubule	B-PHYS
-	I-PHYS
based	I-PHYS
directed	I-PHYS
transport	I-PHYS
and	O	O
active	O
diffusion	B-PHEN
support	O	O
distribution	O
,	O	O
mobility	B-PHYS
and	O	O
mixing	O	O
of	O	O
POs	B-ANAT
.	O	O

In	O	O
mammalian	B-LIVB
COS	B-ANAT
-	I-ANAT
7	I-ANAT
cells	I-ANAT
,	O	O
microtubules	B-ANAT
and	O	O
F	B-CHEM
-	I-CHEM
actin	I-CHEM
also	O	O
counteract	O	O
each	O	O
other	O	O
to	O	O
distribute	O
POs	B-ANAT
.	O	O

This	O	O
highlights	O	O
the	O	O
importance	O	O
of	O	O
opposing	O	O
cytoskeletal	B-ANAT
forces	B-PHEN
in	O	O
organelle	B-ANAT
positioning	O
in	O	O
eukaryotes	O
.	O	O

Stimulation	O
of	O	O
cell	B-PHYS
proliferation	I-PHYS
by	O	O
glutathione	B-CHEM
monoethyl	I-CHEM
ester	I-CHEM
in	O	O
aged	B-ANAT
bone	I-ANAT
marrow	I-ANAT
stromal	I-ANAT
cells	I-ANAT
is	O	O
associated	O
with	O
the	O	O
assistance	O	O
of	O	O
TERT	O
gene	B-PHYS
expression	I-PHYS
and	O	O
telomerase	B-PHYS
activity	I-PHYS
The	O	O
proliferation	B-PHYS
and	O	O
differentiation	B-PHYS
potential	O
of	O	O
aged	B-ANAT
bone	I-ANAT
marrow	I-ANAT
stromal	I-ANAT
cells	I-ANAT
(	O	O
BMSCs	B-ANAT
)	O	O
are	O	O
significantly	O	O
reduced	O
.	O	O

In	O	O
order	O	O
to	O	O
improve	B-DISO
the	O	O
performance	O	O
of	O	O
the	O	O
aged	B-PHYS
BMSCs	B-ANAT
,	O	O
these	O	O
cells	B-ANAT
were	O	O
treated	O
with	O	O
2	O	O
mM	O	O
glutathione	B-CHEM
monoethyl	I-CHEM
ester	I-CHEM
(	O	O
GSH	B-CHEM
-	I-CHEM
MEE	I-CHEM
)	O	O
for	O	O
24	O	O
h	O	O
.	O	O

Proliferation	B-PHYS
rate	O
,	O	O
telomerase	B-PHYS
activity	I-PHYS
,	O	O
telomere	B-ANAT
length	O
,	O	O
and	O	O
differentiation	B-PHYS
to	O	O
cholinergic	B-ANAT
neuron	I-ANAT
-	I-ANAT
like	I-ANAT
cells	I-ANAT
(	O	O
CNLCs	B-ANAT
)	O	O
were	O	O
observed	O	O
to	O	O
increase	O
.	O	O

Though	O	O
,	O	O
the	O	O
expression	O
level	O
of	O	O
telomerase	O
reverse	O
transcriptase	O
gene	O
increased	O
,	O	O
but	O	O
CTC1	O
and	O	O
TEN1	O
genes	O
from	O	O
Ctc1	B-ANAT
-	I-ANAT
Stn1	I-ANAT
-	I-ANAT
Ten1	I-ANAT
complex	I-ANAT
encoding	O
proteins	B-CHEM
with	O	O
regulatory	B-PHYS
function	I-PHYS
significantly	O	O
decreased	O
.	O	O

Trypan	B-PROC
blue	I-PROC
exclusion	I-PROC
assay	I-PROC
was	O	O
used	O	O
to	O	O
analyze	O	O
the	O	O
proliferation	B-PHYS
and	O	O
,	O	O
while	O	O
telomere	B-ANAT
length	O
,	O	O
its	O	O
several	O	O
related	O	O
gene	B-PHYS
expressions	I-PHYS
,	O	O
and	O	O
telomerase	B-PHYS
activity	I-PHYS
were	O	O
measured	O	O
using	O	O
the	O	O
real	B-PROC
time	I-PROC
reverse	I-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
and	O	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
enzyme	B-PROC
-	I-PROC
linked	I-PROC
immunosorbent	I-PROC
assay	I-PROC
techniques	I-PROC
,	O	O
respectively	O	O
.	O	O

CNLCs	B-ANAT
differentiation	B-PHYS
potential	O
was	O	O
evaluated	O	O
by	O	O
estimating	O	O
the	O	O
percentage	O	O
of	O	O
choline	O
acetyltransferase	O
immunereactive	B-ANAT
cells	I-ANAT
.The	O	O

results	O	O
suggested	O	O
that	O	O
GSH	B-CHEM
-	I-CHEM
MEE	I-CHEM
could	O	O
improve	B-DISO
aged	O	O
rat	B-LIVB
BMSC	B-ANAT
properties	O
and	O	O
would	O	O
be	O	O
of	O	O
potential	O	O
benefit	O
for	O	O
enhancing	O
the	O	O
performance	O	O
of	O	O
aged	B-LIVB
people	I-LIVB
's	I-LIVB
BMSCs	B-ANAT
.	O	O

Wild	B-OBJC
food	I-OBJC
plants	I-OBJC
and	O	O
fungi	B-LIVB
used	O	O
in	O	O
the	O	O
mycophilous	B-OBJC
Tibetan	B-GEOG
community	B-LIVB
of	O	O
Zhagana	B-GEOG
(	O	O
Tewo	B-GEOG
County	I-GEOG
,	O	O
Gansu	B-GEOG
,	O	O
China	B-GEOG
)	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O
knowledge	O
and	O	O
use	O	O
of	O	O
wild	B-OBJC
food	I-OBJC
plants	I-OBJC
and	O	O
fungi	B-LIVB
in	O	O
a	O	O
highland	O	O
valley	O
in	O	O
the	O	O
Gannan	B-GEOG
Tibetan	I-GEOG
Autonomous	I-GEOG
Region	I-GEOG
on	O	O
the	O	O
north	O	O
-	O	O
eastern	O	O
edges	O	O
of	O	O
the	O	O
Tibetan	B-GEOG
Plateau	I-GEOG
.	O	O

Field	O
research	O
was	O	O
carried	O	O
out	O	O
in	O	O
four	O	O
neighbouring	O	O
villages	B-GEOG
in	O	O
a	O	O
mountain	B-GEOG
valley	O
of	O	O
the	O	O
Diebu	B-GEOG
(	I-GEOG
Tewo	I-GEOG
)	I-GEOG
county	I-GEOG
,	O	O
surrounded	O	O
by	O	O
spruce	B-PHEN
forests	I-PHEN
.	O	O

The	O	O
study	B-PROC
consisted	O	O
of	O	O
30	O	O
interviews	O
with	O	O
single	O	O
informants	O
,	O	O
or	O	O
group	B-PROC
interviews	I-PROC
(	O	O
altogether	O	O
63	O	O
informants	O
)	O	O
.	O	O

Apart	O	O
from	O	O
collecting	O	O
voucher	O	O
specimens	B-OBJC
,	O	O
we	O	O
also	O	O
identified	O	O
fungi	B-LIVB
using	O	O
DNA	B-PROC
barcoding	I-PROC
.	O	O

We	O	O
recorded	O	O
the	O	O
use	O	O
of	O	O
54	O	O
species	O
of	O	O
vascular	B-LIVB
plants	I-LIVB
.	O	O

We	O	O
also	O	O
recorded	O	O
the	O	O
use	O	O
of	O	O
22	O	O
mushroom	B-OBJC
taxa	I-OBJC
,	O	O
which	O	O
made	O	O
up	O	O
the	O	O
largest	O	O
category	O	O
of	O	O
wild	B-OBJC
foods	I-OBJC
.	O	O

Fruits	B-OBJC
formed	O	O
the	O	O
largest	O	O
category	O	O
of	O	O
food	B-OBJC
plants	I-OBJC
,	O	O
with	O	O
21	O	O
species	O
,	O	O
larger	O	O
than	O	O
the	O	O
wild	B-LIVB
greens	I-LIVB
category	O	O
,	O	O
which	O	O
consisted	O	O
of	O	O
20	O	O
species	O
eaten	B-PHYS
after	O	O
boiling	O
or	O	O
frying	O
and	O	O
7	O	O
as	O	O
raw	O
snacks	B-OBJC
.	O	O

We	O	O
also	O	O
recorded	O	O
the	O	O
alimentary	O	O
use	O	O
of	O	O
10	O	O
species	O
of	O	O
edible	B-LIVB
flowers	I-LIVB
and	O	O
3	O	O
species	O
with	O	O
underground	O	O
edible	B-OBJC
organs	I-OBJC
.	O	O

On	O	O
average	O	O
,	O	O
20	O	O
.	O	O
8	O	O
edible	B-OBJC
taxa	I-OBJC
were	O	O
listed	O	O
per	O	O
interview	O
(	O	O
median	O	O
-	O	O
21	O	O
)	O	O
.	O	O

The	O	O
most	O	O
listed	O	O
category	O	O
of	O	O
wild	B-OBJC
foods	I-OBJC
was	O	O
green	B-OBJC
vegetables	I-OBJC
(	O	O
mean	O	O
-	O	O
7	O	O
.	O	O
5	O	O
species	O
,	O	O
median	O	O
-	O	O
8	O	O
species	O
)	O	O
,	O	O
but	O	O
fruits	B-OBJC
and	O	O
mushrooms	B-OBJC
were	O	O
listed	O	O
nearly	O	O
as	O	O
frequently	O	O
(	O	O
mean	O	O
-	O	O
6	O	O
.	O	O
3	O	O
,	O	O
median	O	O
-	O	O
6	O	O
and	O	O
mean	O	O
-	O	O
5	O	O
.	O	O
8	O	O
,	O	O
-	O	O
median	O	O
6	O	O
respectively	O	O
)	O	O
.	O	O

Other	O	O
category	O	O
lists	O	O
were	O	O
very	O	O
short	O	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O
,	O	O
flowers	B-LIVB
(	O	O
mean	O	O
-	O	O
1	O	O
.	O	O
3	O	O
,	O	O
median	O	O
-	O	O
1	O	O
)	O	O
and	O	O
underground	O	O
edible	B-OBJC
parts	I-OBJC
(	O	O
mean	O	O
-	O	O
0	O	O
.	O	O

7	O	O
,	O	O
median	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Wild	B-OBJC
vegetables	I-OBJC
are	O	O
usually	O	O
boiled	O
and	O	O
/	O	O
or	O	O
fried	O
and	O	O
served	O
as	O	O
side	O	O
-	O	O
dishes	O	O
,	O	O
or	O	O
their	O	O
green	B-LIVB
parts	I-LIVB
are	O	O
eaten	B-PHYS
as	O	O
snacks	B-OBJC
during	O	O
mountain	B-GEOG
treks	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
,	O	O
peeled	B-LIVB
rhubarb	I-LIVB
shoots	I-LIVB
)	O	O
.	O	O

Wild	B-OBJC
fruits	I-OBJC
are	O	O
mainly	O	O
collected	O	O
by	O	O
children	B-LIVB
and	O	O
eaten	B-PHYS
raw	O
,	O	O
they	O	O
are	O	O
not	O	O
stored	O	O
for	O	O
further	O	O
use	O	O
.	O	O

The	O	O
most	O	O
widely	O	O
used	O	O
wild	B-OBJC
staple	I-OBJC
foods	I-OBJC
are	O	O
Potetilla	B-LIVB
anserina	I-LIVB
roots	B-LIVB
,	O	O
an	O	O
important	O	O
ceremonial	B-OBJC
food	I-OBJC
served	O
on	O	O
such	O	O
occasions	O
as	O	O
New	O	O
Year	O	O
or	O	O
at	O	O
funerals	O
.	O	O

They	O	O
are	O	O
boiled	O
and	O	O
served	O
with	O	O
sugar	B-CHEM
and	O	O
butter	B-OBJC
.	O	O

The	O	O
most	O	O
important	O	O
famine	B-PHEN
plants	B-LIVB
remembered	O	O
by	O	O
people	B-LIVB
are	O	O
the	O	O
aerial	B-LIVB
bulbils	I-LIVB
of	O	O
Persicaria	B-LIVB
vivipara	I-LIVB
.	O	O

Flowers	B-LIVB
are	O	O
used	O	O
as	O	O
children	B-LIVB
's	I-LIVB
snacks	B-OBJC
-	O	O
their	O	O
nectar	B-CHEM
is	O	O
sucked	O	O
.	O	O

The	O	O
number	O	O
of	O	O
wild	B-LIVB
taxa	I-LIVB
eaten	B-PHYS
in	O	O
the	O	O
studied	O	O
valley	O
is	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
other	O	O
Tibetan	B-GEOG
areas	I-GEOG
.	O	O

The	O	O
structure	O	O
of	O	O
wild	B-OBJC
food	I-OBJC
plant	I-OBJC
taxa	O	O
is	O	O
also	O	O
very	O	O
typical	O	O
for	O	O
Tibetan	O
speaking	O	O
areas	B-GEOG
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O
,	O	O
the	O	O
use	O	O
of	O	O
rhubarb	B-LIVB
shoots	I-LIVB
,	O	O
Potentilla	B-LIVB
anserina	I-LIVB
,	O	O
Persicaria	B-LIVB
vivipara	I-LIVB
)	O	O
.	O	O

The	O	O
studied	O	O
community	B-LIVB
show	O	O
a	O	O
high	O	O
level	O	O
of	O	O
mycophilia	B-OBJC
.	O	O

Early	O
assessment	B-PROC
of	O	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
:	O	O
A	O	O
comparison	O
between	O	O
the	O	O
laparoscopic	B-PROC
total	I-PROC
extraperitoneal	I-PROC
and	O	O
Stoppa	B-PROC
approaches	I-PROC
The	O	O
present	O
clinical	B-PROC
trial	I-PROC
was	O	O
designed	O	O
to	O	O
compare	O
the	O	O
results	O
of	O	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
between	O	O
patients	B-LIVB
who	O	O
underwent	O	O
the	O	O
conventional	O
Stoppa	B-PROC
technique	I-PROC
and	O	O
laparoscopic	B-PROC
total	I-PROC
extraperitoneal	I-PROC
repair	I-PROC
(	O	O
LTE	B-PROC
)	O	O
with	O	O
a	O	O
single	O	O
mesh	B-DEVI
and	O	O
without	O	O
staple	B-PROC
fixation	I-PROC
.	O	O

This	O	O
controlled	O	O
,	O	O
randomised	B-PROC
clinical	B-PROC
trial	I-PROC
was	O	O
conducted	O	O
at	O	O
General	O
Surgery	O
and	O
Trauma	O
of	O
the	O
Clinics	O
Hospital	O
,	O	O
Medical	O
School	O
,	O	O
the	O	O
University	O
of	O
Sγo	O
Paulo	O
between	O	O
September	O	O
2010	O	O
and	O	O
February	O	O
2011	O	O
.	O	O

Totally	O	O
,	O	O
50	O	O
male	B-PHYS
patients	B-LIVB
,	O	O
with	O	O
a	O	O
bilateral	B-DISO
inguinal	I-DISO
hernia	I-DISO
,	O	O
older	O	O
than	O	O
25	O	O
years	O
were	O	O
considered	O	O
eligible	O
for	O	O
the	O	O
study	B-PROC
.	O	O

The	O	O
following	O	O
parameters	O
were	O	O
analysed	B-PROC
during	O	O
the	O	O
early	O
post	O
-	O
operative	O
period	O
:	O	O
(	O	O
1	O	O
)	O	O
The	O	O
intensity	O
of	O	O
surgical	B-DISO
trauma	I-DISO
,	O	O
operation	O
time	O
,	O	O
C	B-CHEM
-	I-CHEM
reactive	I-CHEM
protein	I-CHEM
(	O	O
CRP	B-CHEM
)	O	O
levels	O
,	O	O
white	B-PROC
blood	I-PROC
cell	I-PROC
count	I-PROC
,	O	O
bleeding	B-DISO
and	O	O
pain	B-PHYS
intensity	I-PHYS
;	O	O
(	O	O
2	O	O
)	O	O
quality	O
of	O
life	O
assessment	B-PROC
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
.	O	O

LTE	B-PROC
procedure	I-PROC
was	O	O
longer	O
than	O	O
the	O	O
Stoppa	B-PROC
procedure	I-PROC
(	O	O
134	O	O
.	O	O

6	O	O
min	O	O
΁	O	O
38	O	O
.	O	O

3	O	O
vs	O	O
.	O	O

90	O	O
.	O	O
6	O	O
min	O	O
΁	O	O
41	O	O
.	O	O

3	O	O

;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
levels	O
of	O	O
CRP	B-CHEM
were	O	O
higher	O
in	O	O
the	O	O
Stoppa	B-PROC
group	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
but	O	O
the	O	O
number	O	O
of	O	O
leucocytes	B-ANAT
,	O	O
haematocrit	B-DISO
,	O	O
and	O	O
haemoglobin	B-CHEM
were	O	O
similar	O
between	O	O
the	O	O
groups	O
(	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	B-DISO
difference	I-DISO
in	O	O
pain	B-DISO
during	O	O
the	O	O
1	O	O
st	O	O
and	O	O
7	O	O
th	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
,	O	O
physical	B-DISO
functioning	I-DISO
,	O	O
physical	O
limitation	O
,	O	O
the	O	O
impact	O
of	O	O
pain	B-DISO
on	O	O
daily	O
activities	O
,	O	O
and	O	O
the	O	O
Carolinas	O
Comfort	O
Scale	O
during	O	O
the	O	O
7	O	O
th	O	O
and	O	O
15	O	O
th	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
(	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Complications	B-DISO
occurred	O	O
in	O	O
88	O	O
%	O	O
of	O	O
Stoppa	B-PROC
group	O
(	O	O
22	O	O
patients	B-LIVB
)	O	O
and	O	O
64	O	O
%	O	O
in	O	O
LTE	B-PROC
group	O
(	O	O
16	O	O
patients	B-LIVB
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
comparative	B-PROC
study	I-PROC
between	O	O
the	O	O
Stoppa	B-PROC
and	O	O
LTE	B-PROC
approaches	O	O
for	O	O
the	O	O
bilateral	B-PROC
inguinal	I-PROC
hernia	I-PROC
repair	I-PROC
demonstrated	O	O
that	O	O
:	O	O
(	O	O
1	O	O
)	O	O
The	O	O
LTE	B-PROC
approach	O	O
showed	O	O
less	O	O
surgical	B-DISO
trauma	I-DISO
despite	O	O
the	O	O
longer	O
operation	O
time	O
;	O	O
(	O	O
2	O	O
)	O	O
Quality	O
of	O
life	O
during	O	O
the	O	O
early	O
post	O
-	O
operative	O
period	O
were	O	O
similar	O
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
Complication	B-DISO
rates	O
were	O	O
higher	O
in	O	O
the	O	O
Stoppa	B-PROC
group	O
.	O	O

The	O	O
role	O	O
of	O	O
catheter	B-PROC
ablation	I-PROC
in	O	O
the	O	O
management	B-PROC
of	O	O
atrial	B-DISO
fibrillation	I-DISO
Atrial	B-DISO
fibrillation	I-DISO
is	O	O
driven	O	O
by	O	O
spontaneous	O	O
electrical	B-PHYS
activation	I-PHYS
emerging	O	O
from	O	O
the	O	O
pulmonary	B-ANAT
veins	I-ANAT
.	O	O

Catheter	B-PROC
ablation	I-PROC
using	O	O
either	O	O
radiofrequency	B-PROC
or	O	O
cryothermal	B-PROC
energy	I-PROC
electrically	O
isolates	O
these	O	O
veins	B-ANAT
from	O	O
the	O	O
left	B-ANAT
atrium	I-ANAT
,	O	O
both	O	O
reducing	O
the	O	O
burden	O
of	O	O
atrial	B-DISO
fibrillation	I-DISO
episodes	O
and	O	O
improving	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
symptoms	B-DISO
.	O	O

Catheter	B-PROC
ablation	I-PROC
is	O	O
superior	O	O
to	O	O
antiarryhthmic	B-CHEM
drugs	I-CHEM
when	O	O
patients	B-LIVB
are	O	O
carefully	O	O
selected	O	O
.	O	O

Underlying	O	O
medical	B-PHYS
problems	I-PHYS
-	O	O
including	O	O
obesity	B-DISO
,	O	O
hypertension	B-DISO
and	O	O
obstructive	B-DISO
sleep	I-DISO
apnoea	I-DISO
-	O	O
should	O	O
be	O	O
optimally	O	O
treated	O
before	O	O
considering	O	O
ablation	B-PROC
.	O	O

Although	O	O
this	O	O
treatment	B-PROC
has	O	O
the	O	O
potential	O
to	O	O
cure	O
patients	B-LIVB
of	O	O
their	O	O
symptoms	B-DISO
,	O	O
they	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
important	O	O
associated	O	O
procedural	B-DISO
complications	I-DISO
.	O	O

The	O	O
Chinese	O
Herbal	O
Mixture	B-OBJC
Tien	B-CHEM
-	I-CHEM
Hsien	I-CHEM
Liquid	I-CHEM
Augments	O
the	O	O
Anticancer	O
Immunity	B-PHYS
in	O	O
Tumor	B-ANAT
Cell	I-ANAT
-	O	O
Vaccinated	B-DISO
Mice	B-LIVB
Background	O	O
The	O	O
Chinese	O
herbal	O
mixture	B-OBJC
,	O	O
Tien	B-CHEM
-	I-CHEM
Hsien	I-CHEM
liquid	I-CHEM
(	O	O
THL	B-CHEM
)	O	O
,	O	O
has	O	O
been	O	O
used	O	O
as	O	O
an	O	O
anticancer	O
dietary	B-OBJC
supplement	I-OBJC
for	O	O
more	O	O
than	O	O
20	O	O
years	O
.	O	O

Our	O	O
previous	O
studies	B-PROC
have	O	O
shown	O	O
that	O	O
THL	B-CHEM
can	O	O
modulate	O
immune	B-PHYS
response	I-PHYS
and	O	O
inhibit	O
tumor	B-DISO
growth	I-DISO
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
further	O	O
evaluated	B-PROC
the	O	O
effect	O
of	O	O
THL	B-CHEM
on	O	O
anticancer	O
immune	B-PHYS
response	I-PHYS
in	O	O
mice	B-LIVB
vaccinated	B-DISO
with	O	O
γ	B-PHEN
-	I-PHEN
ray	I-PHEN
-	O	O
irradiated	B-PHEN
tumor	B-ANAT
cells	I-ANAT
.	O	O

Methods	O	O
The	O	O
antitumor	O
effect	O
of	O	O
THL	B-CHEM
was	O	O
determined	O
in	O	O
mice	B-LIVB
vaccinated	B-DISO
with	O	O
low	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
low	I-ANAT
colon	I-ANAT
cancer	I-ANAT
cells	I-ANAT
or	O	O
γ	B-PROC
-	I-PROC
ray	I-PROC
-	I-PROC
irradiated	I-PROC
high	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
colon	I-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O	O

The	O	O
number	O
of	O	O
natural	B-ANAT
killer	I-ANAT
(	I-ANAT
NK	I-ANAT
)	I-ANAT
cells	I-ANAT
and	O	O
T	B-ANAT
lymphocytes	I-ANAT
in	O	O
the	O	O
spleen	B-ANAT
was	O	O
analyzed	B-PROC
by	O	O
flow	B-PROC
cytometry	I-PROC
.	O	O

The	O	O
tumor	B-DISO
-	O	O
killing	B-PHYS
activities	O
of	O	O
NK	B-ANAT
cells	I-ANAT
and	O	O
cytotoxic	B-ANAT
T	I-ANAT
lymphocytes	I-ANAT
(	O	O
CTLs	B-ANAT
)	O	O
were	O	O
analyzed	B-PROC
by	O	O
flow	B-PROC
cytometry	I-PROC
using	O	O
YAC	B-ANAT
-	I-ANAT
1	I-ANAT
and	O	O
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
,	O	O
respectively	O	O
,	O	O
as	O	O
target	O
cells	B-ANAT
.	O	O

The	O	O
levels	O
of	O	O
IFN	B-CHEM
-	I-CHEM
γ	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
and	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
were	O	O
determined	O
by	O
ELISA	B-PROC
.	O	O

Results	O	O
THL	B-CHEM
suppressed	O
the	O	O
growth	B-PHYS
of	O	O
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
tumor	I-ANAT
in	O	O
mice	B-LIVB
previously	O	O
vaccinated	B-DISO
with	O	O
low	B-ANAT
-	I-ANAT
tumorigenic	I-ANAT
CT	I-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
low	I-ANAT
cells	I-ANAT
or	O	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O	O

THL	B-CHEM
increased	O
the	O	O
populations	O	O
of	O	O
NK	B-ANAT
cells	I-ANAT
and	O	O
CD4	B-ANAT
+	I-ANAT
T	I-ANAT
lymphocytes	I-ANAT
in	O	O
the	O	O
spleen	B-ANAT
and	O	O
enhanced	O
the	O	O
tumor	B-DISO
-	O	O
killing	B-PHYS
activities	O
of	O	O
NK	B-ANAT
cells	I-ANAT
and	O	O
CTL	B-ANAT
in	O	O
mice	B-LIVB
vaccinated	B-DISO
with	O	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O	O

THL	B-CHEM
increased	O
the	O	O
production	O
of	O	O
IFN	B-CHEM
-	I-CHEM
γ	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
and	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
in	O	O
mice	B-LIVB
vaccinated	B-DISO
with	O	O
γ	B-PROC
-	I-PROC
irradiated	I-PROC
CT	B-ANAT
-	I-ANAT
26	I-ANAT
-	I-ANAT
high	I-ANAT
cells	I-ANAT
.	O	O

Conclusion	O	O
THL	B-CHEM
can	O	O
enhance	O
the	O	O
antitumor	O
immune	B-PHYS
responses	I-PHYS
in	O	O
mice	B-LIVB
vaccinated	B-DISO
with	O	O
killed	O
tumor	B-ANAT
cells	I-ANAT
.	O	O

These	O	O
results	O
suggest	O	O
that	O	O
THL	B-CHEM
may	O	O
be	O	O
used	O	O
as	O	O
a	O	O
complementary	O
medicine	O
for	O	O
cancer	B-DISO
patients	B-LIVB
previously	O
treated	O
with	O	O
killed	B-CHEM
tumor	I-CHEM
cell	I-CHEM
vaccines	I-CHEM
,	O	O
radiotherapy	B-PROC
,	O	O
or	O	O
chemotherapy	B-PROC
.	O	O

Comparison	O
of	O	O
Head	B-ANAT
Elevation	B-PROC
Protocols	I-PROC
Following	O	O
Femoral	B-ANAT
Artery	I-ANAT
Sheath	I-ANAT
Removal	B-PROC
After	O	O
Coronary	B-PROC
Angiography	I-PROC
To	O	O
compare	O
2	O	O
standard	O	O
protocols	B-PROC
for	O	O
head	B-ANAT
elevation	B-PROC
following	O	O
removal	O	O
of	O	O
a	O	O
femoral	B-ANAT
artery	I-ANAT
sheath	I-ANAT
after	O	O
coronary	B-PROC
angiography	I-PROC
and	O	O
their	O	O
effects	O
on	O	O
bleeding	B-DISO
complications	B-DISO
and	O	O
reported	O	O
levels	O	O
of	O	O
back	B-DISO
pain	I-DISO
.	O	O

One	O	O
protocol	B-PROC
involved	O	O
flat	O	O
supine	O
bed	B-PROC
rest	I-PROC
;	O	O
the	O	O
other	O	O
allowed	O	O
progressive	O	O
head	B-ANAT
elevation	B-PROC
.	O	O

A	O	O
prospective	O	O
comparative	B-PROC
study	I-PROC
of	O	O
80	O	O
adult	B-LIVB
patients	B-LIVB
undergoing	O	O
coronary	B-PROC
angiography	I-PROC
via	O	O
the	O	O
femoral	B-ANAT
approach	O
.	O	O

The	O	O
Numeric	O
Rating	O
Scale	O
was	O	O
used	O	O
as	O	O
the	O	O
measure	O
of	O	O
reported	O	O
pain	B-DISO
.	O	O

No	O	O
bleeding	B-DISO
complications	B-DISO
occurred	O	O
in	O	O
either	O	O
group	O
.	O	O

Both	O	O
groups	O
had	O	O
very	O	O
low	O
mean	O
pain	B-DISO
scores	I-DISO
.	O	O

Repeated	O	O
-	O	O
measures	O
analysis	B-PROC
demonstrated	O	O
that	O	O
the	O	O
experience	O	O
of	O	O
pain	B-DISO
differed	O	O
significantly	O	O
over	O	O
time	O
by	O	O
location	B-ANAT
(	O	O
F5	O	O
,	O	O
70	O	O
=	O	O
3	O	O
.	O	O
864	O	O
,	O	O
P	O	O
=	O	O
.004	O	O
)	O	O
,	O	O
with	O	O
a	O	O
notable	O	O
decrease	O
in	O	O
pain	B-DISO
scores	I-DISO
more	O	O
than	O	O
1	O	O
hour	O
after	O	O
sheath	B-ANAT
removal	B-PROC
at	O	O
the	O	O
location	B-ANAT
that	O	O
used	O	O
the	O	O
progressive	O	O
head	B-ANAT
elevation	B-PROC
protocol	I-PROC
.	O	O

Patients	B-LIVB
'	O	O
satisfaction	O	O
scores	O
after	O	O
discharge	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
2	O	O
groups	O
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	O	O
chronic	O
back	B-DISO
pain	I-DISO
had	O	O
consistently	O	O
higher	O	O
pain	B-DISO
scores	I-DISO
,	O	O
but	O	O
those	O	O
pain	B-DISO
scores	I-DISO
did	O	O
not	O	O
differ	O	O
significantly	O	O
by	O	O
location	B-ANAT
(	O	O
or	O	O
protocol	B-PROC
)	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
using	O	O
a	O	O
progressive	O	O
head	B-ANAT
-	O	O
elevation	B-PROC
protocol	I-PROC
within	O	O
the	O	O
first	O	O
3	O	O
hours	O
after	O	O
diagnostic	O
angiography	B-PROC
is	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O
of	O	O
bleeding	B-DISO
complications	B-DISO
at	O	O
the	O	O
access	O
site	O
and	O	O
warrants	O	O
further	O	O
exploration	O	O
in	O	O
the	O	O
mitigation	O
of	O	O
back	B-DISO
pain	I-DISO
associated	O	O
with	O	O
prolonged	O
supine	O
bed	B-PROC
rest	I-PROC
.	O	O

Morphological	O
characteristics	O
regulating	O	O
phallic	B-ANAT
glans	I-ANAT
engorgement	B-DISO
in	O	O
the	O	O
American	B-LIVB
alligator	I-LIVB
The	O	O
distal	O
part	O
of	O	O
the	O	O
crocodilian	B-LIVB
phallus	B-ANAT
consists	O	O
of	O	O
a	O	O
bulbous	B-ANAT
glans	I-ANAT
containing	O	O
well	O	O
-	O	O
developed	O	O
vascular	O
tissues	O
that	O	O
can	O	O
inflate	O	O
before	O	O
or	O	O
during	O	O
sexual	O
activity	O
,	O	O
enlarging	O
and	O	O
elaborating	O	O
the	O	O
glans	B-ANAT
into	O	O
a	O	O
complex	O
,	O	O
though	O	O
still	O	O
functionally	O
undefined	O
,	O	O
copulatory	O
structure	O	O
.	O	O

An	O	O
enlarged	O
glans	B-ANAT
putatively	O	O
interacts	O
with	O	O
the	O	O
female	B-PHYS
cloaca	B-ANAT
and	O	O
may	O	O
change	O
the	O	O
shape	O
of	O	O
her	B-ANAT
reproductive	I-ANAT
tract	I-ANAT
to	O	O
facilitate	O	O
insemination	B-PHYS
and	O	O
increase	O
the	O	O
probability	O
of	O	O
fertilization	B-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
cellular	B-PHYS
-	I-PHYS
level	I-PHYS
properties	I-PHYS
of	O	O
the	O	O
glans	B-ANAT
and	O	O
other	O	O
inflatable	O
phallic	O
tissues	O
associated	O	O
with	O	O
the	O	O
sperm	B-ANAT
-conducting	O	O
sulcus	B-ANAT
spermaticus	B-ANAT
in	O	O
the	O	O
American	B-LIVB
alligator	I-LIVB
(	O	O
Alligator	B-LIVB
mississippiensis	I-LIVB
)	O	O
.	O	O

Using	O	O
histochemical	B-PROC
staining	I-PROC
,	O	O
we	O	O
visualized	O	O
and	O	O
defined	O	O
collagen	B-CHEM
and	O	O
elastin	O
fiber	O
densities	O
and	O	O
orientations	O
in	O	O
these	O	O
tissues	O
.	O	O

Extracellular	O
matrix	O
architectures	O	O
provided	O	O
insights	O	O
about	O	O
phallic	B-ANAT
glans	I-ANAT
material	O	O
properties	O	O
and	O	O
how	O	O
they	O	O
may	O	O
affect	O
tissue	O
strength	O
and	O	O
flexibility	O
during	O	O
inflation	O	O
and	O	O
in	O	O
response	O	O
to	O	O
copulatory	O
forces	B-PHEN
.	O	O

We	O	O
also	O	O
investigated	O	O
the	O	O
potential	O
sources	O	O
of	O	O
fluids	B-OBJC
that	O	O
induce	O
inflation	O	O
in	O	O
alligator	B-LIVB
phalli	B-ANAT
.	O	O

Combining	O	O
serial	B-PROC
sectioning	I-PROC
and	O	O
three	B-PROC
-	I-PROC
dimensional	I-PROC
reconstruction	I-PROC
,	O	O
we	O	O
identified	O	O
a	O	O
pair	O	O
of	O	O
supracrucal	B-ANAT
plexus	I-ANAT
vascular	I-ANAT
bodies	B-ANAT
at	O	O
the	O	O
proximal	O	O
end	O	O
of	O	O
the	O	O
alligator	B-LIVB
phallus	B-ANAT
that	O	O
extend	O	O
distally	O
adjacent	O
to	O	O
ventro	O
-	O
medial	O
sulcus	O
tissues	O
.	O	O

Together	O	O
,	O	O
our	O	O
gross	O
and	O	O
histological	B-DISO
examination	I-DISO
of	O	O
the	O	O
American	B-LIVB
alligator	I-LIVB
phallic	B-ANAT
glans	I-ANAT
suggests	O	O
that	O	O
its	O	O
tissues	O
are	O	O
arranged	O	O
in	O	O
a	O	O
manner	O	O
that	O	O
would	O	O
allow	O	O
vascular	B-ANAT
inflation	O	O
to	O	O
expand	O	O
the	O	O
glans	B-ANAT
to	O	O
a	O	O
specific	O	O
and	O	O
repeatable	O	O
shape	O
,	O	O
and	O	O
potentially	O
release	O	O
secretory	B-ANAT
products	I-ANAT
into	O	O
the	O	O
female	B-ANAT
reproductive	I-ANAT
tract	I-ANAT
.	O	O

Both	O	O
elements	O	O
could	O	O
play	O	O
roles	O	O
in	O	O
postcopulatory	O
sexual	O
selection	O
,	O	O
by	O	O
mechanically	O
and	O	O
/	O	O
or	O	O
chemically	O	O
affecting	B-PHYS
female	I-PHYS
reproductive	I-PHYS
physiology	I-PHYS
.	O	O

Heterogeneous	O
Mechanisms	O
of	O	O
Primary	B-PHEN
and	I-PHEN
Acquired	I-PHEN
Resistance	I-PHEN
to	O	O
Third	B-CHEM
-	I-CHEM
Generation	I-CHEM
EGFR	I-CHEM
Inhibitors	I-CHEM
To	O	O
identify	O	O
novel	O	O
mechanisms	O
of	O
resistance	O
to	O	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
in	O	O
patients	B-LIVB
with	O	O
lung	B-DISO
adenocarcinoma	I-DISO
that	O	O
progressed	O	O
under	O	O
therapy	B-PROC
with	O	O
either	O	O
AZD9291	B-CHEM
or	O	O
rociletinib	B-CHEM
(	O	O
CO	B-CHEM
-	I-CHEM
1686	I-CHEM
)	O	O
.	O	O

We	O	O
analyzed	B-PROC
tumor	B-PROC
biopsies	I-PROC
from	O	O
seven	O
patients	B-LIVB
obtained	O	O
before	O	O
,	O	O
during	O	O
,	O	O
and	O	O
/	O	O
or	O	O
after	O	O
treatment	B-PROC
with	O	O
AZD9291	B-CHEM
or	O	O
rociletinib	B-CHEM
(	O	O
CO	B-CHEM
-	I-CHEM
1686	I-CHEM
)	O	O
.	O	O

Targeted	B-PROC
sequencing	I-PROC
and	O	O
FISH	B-PROC
analyses	I-PROC
were	O	O
performed	O	O
,	O	O
and	O	O
the	O	O
relevance	O
of	O	O
candidate	O
genes	O
was	O	O
functionally	O
assessed	O
in	O	O
in	B-PROC
vitro	I-PROC
models	I-PROC
.	O	O

We	O	O
found	O	O
recurrent	B-PHYS
amplification	I-PHYS
of	O	O
either	O	O
MET	O
or	O	O
ERBB2	O
in	O	O
tumors	B-DISO
that	O	O
were	O	O
resistant	B-PHEN
or	O	O
developed	B-PHEN
resistance	I-PHEN
to	O	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
and	O	O
show	O	O
that	O	O
ERBB2	B-PHYS
and	O	O
MET	B-PHYS
activation	I-PHYS
can	O	O
confer	O	O
resistance	B-PHEN
to	O	O
these	B-CHEM
compounds	I-CHEM
.	O	O

Furthermore	O	O
,	O	O
we	O	O
identified	O	O
a	O	O
KRAS	B-DISO
(	I-DISO
G12S	I-DISO
)	I-DISO
mutation	I-DISO
in	O	O
a	O	O
patient	B-LIVB
with	O	O
acquired	B-PHEN
resistance	I-PHEN
to	O	O
AZD9291	B-CHEM
as	O	O
a	O	O
potential	O	O
driver	O	O
of	O	O
acquired	B-PHEN
resistance	I-PHEN
.	O	O

Finally	O	O
,	O	O
we	O	O
show	O	O
that	O	O
dual	O
inhibition	O
of	O	O
EGFR	B-CHEM
/MEK	I-CHEM
might	O	O
be	O	O
a	O	O
viable	B-PHYS
strategy	I-PHYS
to	O	O
overcome	O	O
resistance	B-PHEN
in	O	O
EGFR	B-ANAT
-	I-ANAT
mutant	I-ANAT
cells	I-ANAT
expressing	O	O
mutant	B-DISO
KRAS	I-DISO
CONCLUSIONS	O	O
:	O	O
Our	O	O
data	O
suggest	O	O
that	O	O
heterogeneous	O
mechanisms	O
of	O
resistance	O
can	O	O
drive	O	O
primary	B-PHEN
and	I-PHEN
acquired	I-PHEN
resistance	I-PHEN
to	O	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
EGFR	I-CHEM
inhibitors	I-CHEM
and	O	O
provide	O	O
a	O	O
rationale	O
for	O	O
potential	O
combination	B-PROC
strategies	I-PROC
.	O	O

Clin	O	O
Cancer	O	O
Res	O	O
;	O	O
1	O	O
-	O	O
11	O	O
.	O	O

©	O	O
2016	O	O
AACR	O	O
.	O	O

Nax	B-CHEM
signaling	B-PHYS
evoked	O
by	O
an	O	O
increase	O
in	O	O
[	O	O
Na	B-CHEM
+	I-CHEM
]	O	O
in	O	O
CSF	B-ANAT
induces	O
water	B-PHYS
intake	I-PHYS
via	O	O
EET	B-CHEM
-mediated	O	O
TRPV4	B-CHEM
activation	B-PHYS
Water	B-PHYS
-	I-PHYS
intake	I-PHYS
behavior	O	O
is	O	O
under	O	O
the	O	O
control	O
of	O	O
brain	B-ANAT
systems	I-ANAT
that	O	O
sense	O	O
body	B-ANAT
-	I-ANAT
fluid	I-ANAT
conditions	O	O
at	O	O
sensory	B-ANAT
circumventricular	I-ANAT
organs	I-ANAT
(	O	O
sCVOs	B-ANAT
)	O	O
;	O	O
however	O	O
,	O	O
the	O	O
underlying	O	O
mechanisms	O
have	O	O
not	O	O
yet	O	O
been	O	O
elucidated	O	O
in	O	O
detail	O	O
.	O	O

Nax	B-CHEM
is	O	O
a	O	O
sodium	B-CHEM
(	O	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
)	O	O
level	O
sensor	B-PHYS
in	O	O
the	O	O
brain	B-ANAT
,	O	O
and	O	O
the	O	O
transient	B-CHEM
receptor	I-CHEM
potential	I-CHEM
vanilloid	I-CHEM
(	I-CHEM
TRPV	I-CHEM
)	I-CHEM
channels	I-CHEM
,	O	O
TRPV1	B-CHEM
and	O	O
TRPV4	B-CHEM
,	O	O
have	O	O
been	O	O
proposed	O
to	O	O
function	O
as	O	O
osmosensors	B-PHYS
.	O	O

We	O	O
herein	O	O
investigated	O
voluntary	O
water	B-PHYS
intake	I-PHYS
immediately	O	O
induced	O
after	O	O
an	O	O
intracerebroventricular	O
(	O	O
icv	O
)	O	O
administration	B-PROC
of	O	O
a	O	O
hypertonic	B-CHEM
NaCl	I-CHEM
solution	I-CHEM
in	O	O
TRPV1	O
-	O
,	O	O
TRPV4	O
-	O
,	O	O
Nax	O
-	O
,	O	O
and	O	O
their	O	O
double	B-LIVB
-	I-LIVB
gene	I-LIVB
knockout	I-LIVB
(	I-LIVB
KO	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O	O

The	O	O
induction	O
of	O	O
water	B-PHYS
intake	I-PHYS
by	O	O
TRPV1	O
-	O	O
KO	B-LIVB
mice	I-LIVB
was	O	O
normal	O	O
,	O	O
whereas	O	O
that	O	O
by	O	O
TRPV4	O
-	O	O
KO	B-LIVB
and	O	O
Nax	O
-	O	O
KO	B-LIVB
mice	I-LIVB
was	O	O
significantly	O
less	O	O
than	O	O
that	O	O
by	O	O
WT	B-LIVB
mice	I-LIVB
.	O	O

Water	B-PHYS
intake	I-PHYS
by	O	O
Nax	O
/	O	O
TRPV4	O
-	O	O
double	B-LIVB
KO	I-LIVB
mice	I-LIVB
was	O	O
similar	O
to	O	O
that	O	O
by	O	O
the	O	O
respective	O	O
single	O
KO	B-LIVB
mice	I-LIVB
.	O	O

When	O	O
TRPV4	B-CHEM
activity	B-PHYS
was	O	O
blocked	O
with	O	O
a	O	O
specific	B-CHEM
antagonist	I-CHEM
HC	B-CHEM
-	I-CHEM
067047	I-CHEM
,	O	O
water	B-PHYS
intake	I-PHYS
by	O	O
WT	B-LIVB
mice	I-LIVB
was	O	O
significantly	O
reduced	O
,	O	O
whereas	O	O
that	O	O
by	O	O
TRPV4	O
-	O	O
KO	B-LIVB
and	O	O
Nax	O
-	O	O
KO	B-LIVB
mice	I-LIVB
was	O	O
not	O	O
.	O	O

Similar	O
results	B-DISO
were	O	O
obtained	O	O
with	O	O
the	O	O
administration	B-PROC
of	O	O
miconazole	B-CHEM
,	O	O
which	O	O
inhibits	O
the	O	O
biosynthesis	O
of	O	O
epoxyeicosatrienoic	B-CHEM
acids	I-CHEM
(	O	O
EETs	B-CHEM
)	O	O
,	O	O
endogenous	O
agonists	B-CHEM
for	O	O
TRPV4	B-CHEM
,	O	O
from	O	O
arachidonic	B-CHEM
acid	I-CHEM
(	O	O
AA	B-CHEM
)	O	O
.	O	O

Icv	O
injection	B-PROC
of	O	O
hypertonic	B-CHEM
NaCl	I-CHEM
with	O	O
AA	B-CHEM
or	O	O
5	B-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
EET	I-CHEM
restored	O	O
water	B-PHYS
intake	I-PHYS
by	O	O
Nax	O
-	O	O
KO	B-LIVB
mice	I-LIVB
to	O	O
the	O	O
WT	O
level	O
,	O	O
but	O	O
not	O	O
that	O	O
by	O	O
TRPV4	O
-	O	O
KO	B-LIVB
mice	I-LIVB
.	O	O

These	O	O
results	B-DISO
suggest	O	O
that	O	O
the	O	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
signal	B-PHEN
generated	O	O
in	O	O
Nax	B-CHEM
-	O	O
positive	B-DISO
glial	B-ANAT
cells	I-ANAT
leads	O	O
to	O	O
the	O	O
activation	B-PHYS
of	O	O
TRPV4	B-CHEM
-	O	O
positive	B-DISO
neurons	B-ANAT
in	O	O
sCVOs	B-ANAT
in	O	O
order	O	O
to	O	O
stimulate	B-PROC
water	B-PHYS
intake	I-PHYS
by	O	O
using	O	O
EETs	B-CHEM
as	O	O
gliotransmitters	B-CHEM
.	O	O

Timing	O
of	O	O
False	O	O
Ring	B-PHYS
Formation	I-PHYS
in	O	O
Pinus	B-LIVB
halepensis	I-LIVB
and	O	O
Arbutus	B-LIVB
unedo	I-LIVB
in	O	O
Southern	O
Italy	B-GEOG
:	O	O
Outlook	B-PHYS
from	O	O
an	O	O
Analysis	B-PROC
of	O	O
Xylogenesis	B-PHYS
and	O	O
Tree	B-LIVB
-	I-LIVB
Ring	I-LIVB
Chronologies	O
Mediterranean	B-GEOG
tree	B-LIVB
rings	I-LIVB
are	O	O
characterized	O
by	O	O
intra	O
-	O
annual	O
density	O
fluctuations	O
(	O	O
IADFs	O
)	O	O
due	O	O
to	O	O
partly	O	O
climate	B-PHEN
-	I-PHEN
driven	I-PHEN
cambial	B-PHYS
activity	I-PHYS
.	O	O

IADFs	O
are	O	O
used	O	O
as	O	O
structural	O
signals	O
to	O	O
gain	O	O
information	O
on	O	O
relations	O
between	O
environmental	O
conditions	O
and	O	O
eco	B-PHYS
-	I-PHYS
physiological	I-PHYS
processes	B-PHEN
during	O
xylogenesis	B-PHYS
,	O	O
with	O	O
intra	O
-	O
annual	O
resolution	O
.	O	O

To	O	O
reach	O	O
an	O	O
unbiased	B-PROC
synchronization	O
of	O	O
the	O	O
IADF	O
position	O
within	O	O
tree	B-LIVB
rings	O
and	O	O
seasonal	O
fluctuations	B-DISO
in	O	O
environmental	O
conditions	O
,	O	O
it	O	O
is	O	O
necessary	O	O
to	O	O
know	O	O
the	O	O
timing	O
of	O	O
cambial	B-PHYS
activity	I-PHYS
and	O	O
wood	B-OBJC
formation	O
,	O	O
which	O	O
are	O	O
species	O
-	O
and	O	O
site	O
-	O
specific	O
processes	B-PHEN
.	O	O

We	O	O
applied	O
the	O	O
microcoring	O
technique	O
to	O	O
analyze	B-PROC
xylogenesis	B-PHYS
in	O	O
Pinus	B-LIVB
halepensis	I-LIVB
and	O	O
Arbutus	B-LIVB
unedo	I-LIVB
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
attempt	O
to	O	O
study	B-PROC
xylogenesis	B-PHYS
in	O	O
a	O	O
hardwood	B-OBJC
species	O
forming	O	O
frequent	O
IADFs	O
.	O	O

Both	O	O
species	O
co	O
-	O
occur	O
at	O	O
a	O	O
site	O
in	O	O
southern	O
Italy	B-GEOG
characterized	O
by	O	O
a	O	O
Mediterranean	B-GEOG
climate	B-PHEN
.	O	O

To	O	O
facilitate	O	O
tree	B-PROC
-	I-PROC
ring	I-PROC
dating	I-PROC
and	O	O
identification	O
of	O	O
IADFs	O
,	O	O
we	O	O
performed	O
traditional	O
dendroecological	O
analysis	B-PROC
.	O	O

We	O	O
analyzed	B-PROC
xylogenesis	B-PHYS
during	O
summer	O
,	O	O
which	O	O
is	O	O
considered	O
a	O	O
constraint	O
for	O	O
xylogenesis	B-PHYS
and	O	O
a	O	O
trigger	O	O
for	O	O
IADF	O
formation	O
.	O	O

We	O	O
followed	O	O
the	O	O
different	O
phases	O
of	O	O
cell	B-PHYS
development	I-PHYS
in	O	O
the	O	O
current	O
wood	B-OBJC
increment	O
with	O	O
the	O	O
aim	O	O
of	O	O
evaluating	O	O
whether	O	O
and	O	O
which	O	O
type	O	O
of	O	O
IADFs	O
were	O	O
formed	O
.	O	O

We	O	O
additionally	O	O
analyzed	B-PROC
the	O	O
same	O	O
phases	O
again	O	O
in	O	O
September	O
and	O	O
in	O	O
winter	O
to	O	O
verify	O
the	O	O
possible	B-DISO
formation	O
of	O	O
IADFs	O
in	O	O
fall	O
and	O	O
whether	O	O
cell	B-ANAT
production	B-PHYS
and	O	O
differentiation	B-PHYS
was	O	O
completed	O
by	O	O
the	O	O
end	O	O
of	O	O
the	O	O
calendar	O
year	O
.	O	O

Both	O	O
species	O
formed	O
the	O	O
same	O	O
type	O	O
of	O	O
IADFs	O
(	O	O
earlywood	B-OBJC
-like	O	O
cells	B-ANAT
within	O	O
latewood	B-OBJC
)	O	O
,	O	O
due	O	O
to	O	O
temporary	O
growth	B-PHEN
restoration	B-DISO
triggered	O
by	O
rain	B-PHEN
events	O
during	O
the	O	O
period	O
of	O	O
summer	O
drought	B-PHEN
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
calendar	O
year	O
,	O	O
no	O	O
cells	B-ANAT
in	O	O
the	O	O
phases	O
of	O	O
enlargement	O
and	O	O
secondary	B-ANAT
cell	I-ANAT
wall	I-ANAT
deposition	O
occurred	O
.	O	O

A	B-LIVB
.	I-LIVB

unedo	I-LIVB
was	O	O
more	O	O
sensitive	O
than	O	O
P	B-LIVB
.	I-LIVB

halepensis	I-LIVB
because	O	O
IADF	O
s	O	O
were	O	O
formed	O
earlier	O
in	O	O
the	O	O
season	O
and	O	O
were	O	O
more	O	O
frequent	O
in	O	O
the	O	O
tree	B-LIVB
-	I-LIVB
ring	I-LIVB
series	O	O
.	O	O

The	O	O
dendro	O
-	O
anatomical	O
approach	O	O
,	O	O
combining	O	O
analysis	B-PROC
of	O	O
tree	B-LIVB
-	I-LIVB
ring	I-LIVB
series	O	O
and	O	O
of	O	O
xylogenesis	B-PHYS
,	O	O
helped	O	O
to	O	O
detect	B-DISO
the	O	O
period	O
of	O	O
IADF	O
formation	O
in	O	O
the	O	O
two	O	O
species	O
.	O	O

Results	O
are	O	O
discussed	O	O
in	O	O
functional	O
terms	O
,	O	O
highlighting	O	O
the	O	O
environmental	O
conditions	O
triggering	O
IADFs	O
,	O	O
and	O	O
also	O	O
in	O	O
methodological	O
terms	O
,	O	O
evaluating	O	O
the	O	O
applicability	O
of	O	O
xylogenesis	B-PHYS
analysis	B-PROC
in	O	O
Mediterranean	B-GEOG
woods	B-OBJC
,	O	O
especially	O	O
when	O	O
the	O	O
formation	O
of	O	O
IADFs	O
is	O	O
not	O	O
uniform	O
around	O	O
the	O	O
stem	B-LIVB
.	O	O

An	O	O
Accessible	O	O
and	O	O
Pragmatic	B-LIVB
Experimental	I-LIVB
Model	I-LIVB
of	O	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
BACKGROUND	O	O
There	O	O
is	O	O
no	O	O
convenient	O	O
cheap	O	O
pragmatic	B-LIVB
experimental	I-LIVB
model	I-LIVB
for	O	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
(	O	O
NAFLD	B-DISO
)	O	O
/	O	O
Nonalcoholic	B-DISO
Steatohepatitis	I-DISO
(	O	O
NASH	B-DISO
)	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
create	O	O
a	O	O
pragmatic	B-LIVB
model	I-LIVB
of	O	O
NAFLD	B-DISO
/	O	O
NASH	B-DISO
.	O	O

METHODS	O	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O	O
fed	O	O
a	O	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O	O
high	B-PROC
sugar	I-PROC
homemade	I-PROC
diet	I-PROC
ad	O	O
libitum	O	O
for	O	O
seven	O	O
weeks	O
.	O	O

The	O	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O	O
high	B-PROC
sugar	I-PROC
diet	I-PROC
included	O	O
59	O	O
%	O	O
of	O	O
energy	O
derived	O	O
from	O	O
fat	B-CHEM
,	O	O
30	O	O
%	O	O
from	O	O
carbohydrates	B-OBJC
,	O	O
and	O	O
11	O	O
%	O	O
from	O	O
protein	B-OBJC
.	O	O

Serum	B-PROC
levels	I-PROC
of	I-PROC
fasting	I-PROC
glucose	I-PROC
,	O	O
triglyceride	B-PROC
,	O	O
cholesterol	B-PROC
,	O	O
liver	B-PROC
enzymes	I-PROC
,	O	O
insulin	B-PROC
,	O	O
and	O	O
hepatic	B-ANAT
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
alpha	I-CHEM
(	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
)	O	O
gene	B-PHYS
expression	I-PHYS
were	O	O
determined	O	O
.	O	O

Hepatic	B-ANAT
histology	B-PROC
was	O	O
examined	O	O
by	O	O
H	B-PROC
&	I-PROC
E	I-PROC
stain	I-PROC
.	O	O

RESULTS	O	O
Rats	B-LIVB
fed	O	O
the	O	O
high	B-PROC
-	I-PROC
fat	I-PROC
,	O	O
high	B-PROC
sugar	I-PROC
diet	I-PROC
developed	O	O
hepatic	B-DISO
steatosis	I-DISO
,	O	O
and	O	O
a	O	O
moderate	B-DISO
inflammation	I-DISO
,	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
increased	B-DISO
serum	I-DISO
levels	I-DISO
of	I-DISO
liver	I-DISO
enzymes	I-DISO
,	O	O
glucose	B-PHEN
,	O	O
insulin	B-PHEN
,	O	O
triglyceride	B-PHEN
,	O	O
cholesterol	B-PHEN
,	O	O
and	O	O
hepatic	B-ANAT
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
gene	B-PHYS
expression	I-PHYS
.	O	O

CONCLUSION	O	O
This	O	O
rat	B-LIVB
model	B-LIVB
resembles	O	O
the	O	O
key	O	O
features	O	O
of	O	O
human	B-LIVB
NAFLD	B-DISO
/	O	O
NASH	B-DISO
and	O	O
provides	O	O
a	O	O
simple	O	O
pragmatic	B-LIVB
experimental	I-LIVB
model	I-LIVB
for	O	O
elucidating	O	O
the	O	O
disease	B-PROC
prevention	I-PROC
and	O	O
treatment	B-PROC
.	O	O

Comparison	O
of	O	O
the	O	O
Effects	O
of	O
Subcutaneous	B-PROC
Versus	O	O
Continuous	B-PROC
Infusion	I-PROC
of	O	O
Heparin	B-CHEM
on	O	O
Key	O
Inflammatory	O
Parameters	O
Following	O
Sepsis	B-DISO
Sepsis	B-DISO
is	O	O
the	O	O
result	O
of	O	O
the	O	O
interaction	O
between	O	O
inflammatory	B-CHEM
mediators	I-CHEM
and	O	O
coagulation	B-PHYS
pathway	I-PHYS
.	O	O

Unfractionated	B-CHEM
heparin	I-CHEM
may	O	O
play	O	O
a	O	O
role	O
as	O	O
an	O	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
agent	I-CHEM
beyond	O	O
its	O	O
anticoagulatory	O
effect	O
in	O	O
sepsis	B-DISO
.	O	O

As	O	O
a	O	O
result	O
,	O	O
it	O	O
may	O	O
cause	O	O
reduction	O
in	O	O
organ	B-DISO
failure	I-DISO
rate	O
in	O	O
patients	B-LIVB
with	O	O
sepsis	B-DISO
due	O	O
to	O	O
its	O	O
impact	O
on	O	O
both	O	O
inflammatory	O
and	O	O
coagulation	B-PHYS
process	I-PHYS
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
anti	O
-	O
inflammatory	O
effects	O
of	O	O
heparin	B-CHEM
in	O	O
sepsis	B-DISO
.	O	O

Plasma	B-ANAT
plasminogen	B-CHEM
activator	I-CHEM
inhibitor	I-CHEM
-	I-CHEM
1	I-CHEM
(	O	O
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
as	O	O
an	O	O
inflammatory	B-CHEM
mediator	I-CHEM
and	O	O
urinary	O
necoutrophil	B-CHEM
gelatinase	I-CHEM
-	I-CHEM
associated	I-CHEM
lipocalin	I-CHEM
(	O	O
NGAL	B-CHEM
)	O	O
as	O	O
a	O	O
marker	B-PHYS
of	O	O
kidney	B-DISO
injury	I-DISO
were	O	O
investigated	O
.	O	O

This	O	O
prospective	B-PROC
,	O	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
was	O	O
conducted	O	O
in	O	O
a	O	O
32	O	O
-	O	O
bed	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
.	O	O

Thirty	O	O
patients	B-LIVB
with	O	O
sepsis	B-DISO
were	O	O
randomized	B-PROC
to	O	O
receive	O
heparin	B-CHEM
infusion	O
of	O	O
500	O	O
units	O
/	O
hour	O
or	O	O
5000	O	O
units	O
of	O	O
heparin	B-CHEM
three	O
times	O
a	O
day	O
,	O	O
subcutaneously	B-DISO
.	O	O

The	O	O
plasma	B-ANAT
level	O
of	O	O
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
urinary	O
level	O
of	O	O
NGAL	B-CHEM
were	O	O
determined	O	O
at	O	O
day	B-DISO
0	I-DISO
,	O	O
2	B-DISO
and	O	O
7	B-DISO
.	O	O

The	O	O
infusion	O
group	O
had	O	O
a	O	O
lower	O
plasma	B-ANAT
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
level	O
compared	O
to	O	O
the	O	O
subcutaneous	O
group	O
at	O	O
day	B-DISO
7	I-DISO
(	O	O
11	O	O
.	O	O

3	O	O
±	O	O
1	O	O
.	O	O
6	O	O
vs	O	O
.	O	O

16	O	O
.	O	O
5	O	O
±	O	O
4	O	O
.	O	O
2	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

003	O	O
)	O	O
.	O	O

The	O	O
urinary	O
NGAL	B-CHEM
level	O
was	O	O
lower	O
in	O	O
the	O	O
infusion	O
group	O
at	O	O
day	B-DISO
2	I-DISO
(	O	O
131	O	O
.	O	O

3	O	O
±	O	O
11	O	O
.	O	O
9	O	O
vs	O	O
.	O	O

151	O	O
.	O	O
2	O	O
±	O	O
20	O	O
.	O	O
6	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
014	O	O
)	O	O
;	O	O
however	O	O
,	O	O
at	O	O
day	B-DISO
7	I-DISO
the	O	O
NGAL	B-CHEM
level	O
was	O	O
decreased	O
in	O	O
the	O	O
subcutaneous	O
group	O
as	O	O
much	O	O
as	O	O
the	O	O
infusion	O
group	O
and	O	O
there	O	O
was	O	O
no	O
significant	O
difference	O
between	O	O
the	O	O
two	O	O
groups	O
.	O	O

There	O	O
was	O	O
no	O
significant	O
difference	O
in	O	O
the	O	O
acute	B-PROC
physiology	I-PROC
and	I-PROC
chronic	I-PROC
health	I-PROC
evaluation	I-PROC
(	I-PROC
APACHE	I-PROC
)	I-PROC
II	I-PROC
and	O	O
sequential	B-DISO
organ	I-DISO
failure	I-DISO
assessment	I-DISO
(	I-DISO
SOFA	I-DISO
)	I-DISO
scores	I-DISO
between	O	O
the	O	O
two	O	O
groups	O
at	O	O
day	B-DISO
0	I-DISO
,	O	O
2	B-DISO
and	O	O
7	B-DISO
.	O	O

Low	O
-	O
dose	O
heparin	B-CHEM
infusion	O
compared	O
to	O	O
subcutaneous	O
heparin	B-CHEM
can	O	O
decrease	O
the	O	O
plasma	B-ANAT
PAI	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
urinary	O
NGAL	B-CHEM
levels	O
more	O	O
rapidly	O
.	O	O

It	O	O
can	O	O
be	O	O
related	O
to	O	O
anti	O
-	O
inflammatory	O
effects	O
of	O	O
heparin	B-CHEM
,	O	O
which	O	O
may	O	O
be	O	O
more	O	O
prominent	O
in	O	O
infusion	O
route	O
.	O	O

The	O	O
Spreading	O
of	O	O
Social	O
Energy	O
:	O	O
How	O	O
Exposure	O
to	O
Positive	B-DISO
and	O	O
Negative	B-DISO
Social	O
News	O
Affects	O	O
Behavior	O
Social	O
news	O
,	O	O
unlike	O	O
video	B-OBJC
games	I-OBJC
or	O	O
TV	O
programs	O
,	O	O
conveys	O	O
real	O
-	O
life	O
interactions	B-DISO
.	O	O

Theoretically	O	O
,	O	O
social	O
news	O
in	O	O
which	O	O
people	B-LIVB
help	O
or	O	O
harm	O
each	O
other	O
and	O	O
violate	O
rules	O
should	O	O
influence	O	O
both	O	O
prosocial	O
and	O	O
violation	O
behaviors	O
.	O	O

In	O	O
two	O	O
experiments	O	O
,	O	O
we	O	O
demonstrated	O	O
the	O	O
spreading	O
effects	O
of	O	O
social	O
news	O
in	O	O
a	O	O
social	B-DISO
interaction	I-DISO
context	O	O
emphasizing	O	O
social	O
conventions	B-PHEN
and	O	O
a	O	O
nonsocial	B-DISO
interaction	I-DISO
context	O	O
emphasizing	O	O
moral	O
norms	O
.	O	O

Across	O	O
the	O	O
two	O	O
studies	B-PROC
,	O	O
the	O	O
results	O	O
showed	O	O
that	O	O
positive	B-DISO
social	O
news	O
increased	O	O
cooperation	O
(	O	O
decreased	O	O
defection	O
)	O	O
but	O	O
had	O	O
no	B-DISO
effect	O
on	O	O
cheating	O
,	O	O
whereas	O	O
negative	B-DISO
social	O
news	O
increased	O	O
cheating	O
but	O	O
with	O	O
no	B-DISO
change	O
in	O	O
cooperation	O
(	O	O
or	O	O
defection	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
there	O	O
is	O	O
a	O	O
spreading	O
impact	O
of	O	O
positive	B-DISO
social	O
news	O
in	O	O
the	O	O
conventional	O
norm	O
domain	O
and	O	O
of	O	O
negative	B-DISO
social	O
news	O
in	O	O
the	O	O
moral	O
norm	O
domain	O
.	O	O

Using	O	O
Evolutionary	O
Theory	O
to	O	O
Guide	O	O
Mental	B-PHYS
Health	I-PHYS
Research	B-PROC
Evolutionary	O
approaches	O
to	O	O
medicine	O
can	O	O
shed	O
light	O
on	O	O
the	O	O
origins	O
and	O	O
etiology	O
of	O
disease	O
.	O	O

Such	O	O
an	O	O
approach	O
may	O	O
be	O	O
especially	O	O
useful	O	O
in	O	O
psychiatry	B-PROC
,	O	O
which	O	O
frequently	O	O
addresses	O	O
conditions	O
with	O	O
heterogeneous	O
presentation	O	O
and	O	O
unknown	B-DISO
causes	I-DISO
.	O	O

We	O	O
review	O
several	O	O
previous	O	O
applications	O
of	O	O
evolutionary	O
theory	O
that	O	O
highlight	O	O
the	O	O
ways	O	O
in	O	O
which	O	O
psychiatric	B-DISO
conditions	I-DISO
may	O	O
persist	O	O
despite	O	O
and	O	O
because	O	O
of	O	O
natural	B-PHEN
selection	I-PHEN
.	O	O

One	O	O
lesson	O	O
from	O	O
the	O	O
evolutionary	O
approach	O
is	O	O
that	O	O
some	O	O
conditions	O
currently	O	O
classified	O
as	O	O
disorders	B-DISO
(	O	O
because	O	O
they	O	O
cause	O	O
distress	B-DISO
and	O	O
impairment	B-DISO
)	O	O
may	O	O
actually	O	O
be	O	O
caused	O	O
by	O	O
functioning	O
adaptations	B-PHEN
operating	O	O
""""	O	O
normally	O
""""	O	O
(	O	O
as	O	O
designed	O	O
by	O	O
natural	B-PHEN
selection	I-PHEN
)	O	O
.	O	O

Such	O	O
conditions	O
suggest	O	O
an	O	O
alternative	O	O
illness	B-DISO
model	I-DISO
that	O	O
may	O	O
generate	O	O
alternative	O	O
intervention	B-PROC
strategies	I-PROC
.	O	O

Thus	O	O
,	O	O
the	O	O
evolutionary	O
approach	O
suggests	O	O
that	O	O
psychiatry	B-PROC
should	O	O
sometimes	O	O
think	O	O
differently	O
about	O	O
distress	B-DISO
and	O	O
impairment	B-DISO
.	O	O

The	O	O
complexity	O
of	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
,	O	O
including	O	O
normal	O
functioning	B-PHYS
and	O	O
potential	O
for	O	O
dysfunctions	B-DISO
,	O	O
has	O	O
developed	O	O
over	O	O
evolutionary	O
time	O
and	O	O
has	O	O
been	O	O
shaped	O	O
by	O	O
natural	B-PHEN
selection	I-PHEN
.	O	O

Understanding	O	O
the	O	O
evolutionary	O
origins	O
of	O	O
psychiatric	B-DISO
conditions	I-DISO
is	O	O
therefore	O	O
a	O	O
crucial	O
component	O
to	O	O
a	O	O
complete	O	O
understanding	O	O
of	O	O
etiology	O
.	O	O

Transcriptomic	B-PHYS
and	O	O
Physiological	B-PHYS
Responses	I-PHYS
of	O	O
the	O	O
Green	O
Microalga	O
Chlamydomonas	O
reinhardtii	O
during	O	O
Short	O	O
-	O	O
Term	O	O
Exposure	O
to	O
Subnanomolar	O
Methylmercury	B-CHEM
Concentrations	O
The	O	O
effects	O	O
of	O	O
short	O
-	O
term	O
exposure	O
to	O
subnanomolar	O
methyl	B-CHEM
-	I-CHEM
mercury	I-CHEM
(	O	O
MeHg	B-CHEM
)	O	O
concentrations	O
,	O	O
representative	O	O
of	O	O
contaminated	O
environments	O
,	O	O
on	O	O
the	O	O
microalga	O
Chlamydomonas	O
reinhardtii	O
were	O	O
assessed	O
using	O	O
both	O	O
physiological	B-PHYS
end	I-PHYS
points	I-PHYS
and	O	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
.	O	O

MeHg	B-CHEM
bioaccumulated	B-PHYS
and	O	O
induced	O	O
significant	O
increase	O
of	O	O
the	O	O
photosynthesis	B-PHEN
efficiency	O
,	O	O
while	O	O
the	O	O
algal	B-PHEN
growth	I-PHEN
,	O	O
oxidative	B-DISO
stress	I-DISO
,	O	O
and	O	O
chlorophyll	B-PHYS
fluorescence	I-PHYS
were	O	O
unaffected	O
.	O	O

At	O	O
the	O	O
molecular	O	O
level	O	O
,	O	O
MeHg	B-CHEM
significantly	O	O
dysregulated	B-PHYS
the	O	O
expression	B-PHYS
of	I-PHYS
genes	I-PHYS
involved	O	O
in	O	O
motility	B-PHYS
,	O	O
energy	B-PHYS
metabolism	I-PHYS
,	O	O
lipid	B-PHYS
metabolism	I-PHYS
,	O	O
metal	B-PHYS
transport	I-PHYS
,	O	O
and	O	O
antioxidant	B-CHEM
enzymes	B-CHEM
.	O	O

Data	O
suggest	O	O
that	O	O
the	O	O
cells	B-ANAT
were	O	O
able	B-DISO
to	I-DISO
cope	I-DISO
with	O	O
subnanomolar	O
MeHg	B-CHEM
exposure	O
,	O	O
but	O	O
this	O	O
tolerance	O	O
resulted	O	O
in	O	O
a	O	O
significant	O	O
cost	O	O
to	O	O
the	O	O
cell	B-PHYS
energy	I-PHYS
and	I-PHYS
reserve	I-PHYS
metabolism	I-PHYS
as	O	O
well	O	O
as	O	O
ample	O	O
changes	O	O
in	O	O
the	O	O
nutrition	B-PHYS
and	O	O
motility	B-PHYS
of	O	O
C	O
.	O

reinhardtii	O
.	O	O

The	O	O
present	O	O
results	O
allowed	O	O
gaining	O	O
new	O	O
insights	O	O
on	O	O
the	O	O
effects	O	O
and	O	O
uptake	B-PHYS
mechanisms	I-PHYS
of	O	O
MeHg	B-CHEM
at	O	O
subnanomolar	O
concentrations	O
in	O	O
aquatic	O
primary	O
producers	O
.	O	O

Emergence	O
of	O	O
family	O
medicine	O
in	O	O
Ethiopia	B-GEOG
[	O	O
corrected	O	O
]	O	O
:	O	O
an	O	O
international	O
collaborative	O
education	O
model	O
Family	O
Medicine	O
(	O	O
FM	O
)	O	O
is	O	O
a	O	O
new	O	O
specialty	O
in	O	O
Ethiopia	B-GEOG
.	O	O

The	O	O
first	B-LIVB
seven	I-LIVB
family	I-LIVB
physicians	I-LIVB
graduated	B-LIVB
in	O	O
February	O
2016	O	O
from	O	O
the	O	O
inaugural	O	O
residency	B-PROC
programme	O
at	O	O
Addis	B-OBJC
Ababa	I-OBJC
University	I-OBJC
.	O	O

Cooperation	O
amongst	O	O
Ethiopian	B-LIVB
and	O	O
expatriate	B-DISO
decision	B-LIVB
-	I-LIVB
makers	I-LIVB
and	O	O
physicians	B-LIVB
was	O	O
needed	O	O
to	O	O
begin	O
the	O	O
programme	O
.	O	O

Intentional	O
replacement	O
of	O	O
expatriates	B-DISO
with	O	O
Ethiopian	B-LIVB
family	B-LIVB
physicians	I-LIVB
has	O	O
begun	O
.	O	O

Barriers	O
include	O	O
lack	O
of	O
understanding	B-PHYS
of	O	O
FM	O
and	O	O
the	O	O
human	O
and	O	O
financial	B-DISO
resources	I-DISO
needed	O	O
for	O	O
scaling	O
up	O
the	O	O
programme	O
.	O	O

Regular	O
programme	O
review	O
with	O	O
resident	B-LIVB
physician	I-LIVB
involvement	O
has	O	O
allowed	O	O
the	O	O
FM	O
training	B-PROC
programme	I-PROC
to	O	O
adapt	O
and	O	O
fit	O
the	O	O
Ethiopian	B-LIVB
context	O
.	O	O

Further	O	O
successes	O
will	O	O
result	O
from	O	O
ongoing	O	O
support	O
and	O	O
advocacy	O
from	O	O
the	O	O
Federal	O
Ministry	O
of	O
Health	O
and	O	O
other	O	O
Ethiopian	B-LIVB
,	O	O
African	B-LIVB
,	O	O
and	O	O
international	O
primary	O
care	O
organisations	O
.	O	O

Hierarchical	O
Targeting	O
Strategy	B-PROC
for	O	O
Enhanced	O
Tumor	O
Tissue	O
Accumulation	O
/	O	O
Retention	B-PHYS
and	O	O
Cellular	B-PHYS
Internalization	I-PHYS
Targeted	O
delivery	B-PHEN
of	O	O
therapeutic	B-CHEM
agents	I-CHEM
is	O	O
an	O	O
important	O
way	B-PHEN
to	O	O
improve	O
the	O	O
therapeutic	O
index	O
and	O	O
reduce	O
side	B-DISO
effects	I-DISO
.	O	O

To	O	O
design	O
nanoparticles	B-OBJC
for	O	O
targeted	O
delivery	B-PHEN
,	O	O
both	O	O
enhanced	O
tumor	O
tissue	O
accumulation	O
/	O	O
retention	B-PHYS
and	O	O
enhanced	O
cellular	B-PHYS
internalization	I-PHYS
should	O	O
be	O	O
considered	O
simultaneously	O
.	O	O

So	O	O
far	O	O
,	O	O
there	O	O
have	O	O
been	O	O
very	O	O
few	O	O
nanoparticles	B-OBJC
with	O	O
immutable	O	O
structures	O
that	O	O
can	O	O
achieve	O	O
this	O	O
goal	O
efficiently	O
.	O	O

Hierarchical	O
targeting	O
,	O	O
a	O	O
novel	O
targeting	O
strategy	B-PROC
based	O	O
on	O	O
stimuli	B-PHEN
responsiveness	B-PHYS
,	O	O
shows	O	O
good	O	O
potential	O
to	O	O
enhance	O
both	O	O
tumor	O
tissue	O
accumulation	O
/	O	O
retention	B-PHYS
and	O	O
cellular	B-PHYS
internalization	I-PHYS
.	O	O

Here	O	O
,	O	O
the	O	O
recent	O	O
design	O
and	O	O
development	O
of	O	O
hierarchical	O
targeting	O
nanoplatforms	O	O
,	O	O
based	O	O
on	O	O
changeable	O
particle	O
sizes	O
,	O	O
switchable	O
surface	O
charges	O
and	O	O
activatable	O
surface	O
ligands	B-CHEM
,	O	O
will	O	O
be	O	O
introduced	O
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
targeting	O
moieties	O
in	O	O
these	O	O
nanoplatforms	O	O
are	O	O
not	O	O
activated	O	O
during	O
blood	B-PHYS
circulation	I-PHYS
for	O	O
efficient	O
tumor	O
tissue	O
accumulation	O
,	O	O
but	O	O
re	O
-	O
activated	O
by	O	O
certain	O	O
internal	O
or	O	O
external	O
stimuli	B-PHEN
in	O	O
the	O	O
tumor	B-PHEN
microenvironment	I-PHEN
for	O	O
enhanced	O
cellular	B-PHYS
internalization	I-PHYS
.	O	O

Subsolid	B-DISO
pulmonary	I-DISO
nodule	I-DISO
morphology	O
and	O	O
associated	O	O
patient	B-PHYS
characteristics	I-PHYS
in	O	O
a	O	O
routine	O
clinical	O
population	B-LIVB
To	O	O
determine	O	O
the	O	O
presence	O
and	O	O
morphology	O
of	O	O
subsolid	B-DISO
pulmonary	I-DISO
nodules	I-DISO
(	O	O
SSNs	B-DISO
)	O	O
in	O	O
a	O	O
non	O
-	O
screening	O
setting	O
and	O	O
relate	O	O
them	O	O
to	O	O
clinical	B-PHYS
and	O	O
patient	B-PHYS
characteristics	I-PHYS
.	O	O

A	O	O
total	O	O
of	O	O
16	O	O
,	O	O
890	O	O
reports	O
of	O	O
clinically	O
obtained	O	O
chest	B-PROC
CT	I-PROC
(	O	O
06	O	O
/	O	O
2011	O	O
to	O	O
11	O	O
/	O	O
2014	O	O
,	O	O
single	O	O
-	O	O
centre	O	O
)	O	O
were	O	O
searched	O	O
describing	O	O
an	O	O
SSN	B-DISO
.	O	O

Subjects	B-LIVB
with	O	O
a	O	O
visually	O
confirmed	O	O
SSN	B-DISO
and	O	O
at	O	O
least	O	O
two	O	O
thin	B-PROC
-	I-PROC
slice	I-PROC
CTs	I-PROC
were	O	O
included	O	O
.	O	O

Nodule	B-DISO
volumes	O
were	O	O
measured	O
.	O	O

Progression	O
was	O	O
defined	O	O
as	O	O
volume	O
increase	O	O
exceeding	O	O
the	O	O
software	B-PROC
interscan	I-PROC
variation	O
.	O	O

Nodule	B-DISO
morphology	O
,	O	O
location	B-ANAT
,	O	O
and	O	O
patient	B-PHYS
characteristics	I-PHYS
were	O	O
evaluated	B-PROC
.	O	O

Fifteen	O	O
transient	O
and	O	O
74	O	O
persistent	O
SSNs	B-DISO
were	O	O
included	O	O
(	O	O
median	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
19	O	O
.	O	O

6	O	O
[	O	O
8	O	O
.	O	O
3	O	O
-	O	O
36	O	O
.	O	O
8	O	O
]	O	O
months	O
)	O	O
.	O	O

Subjects	B-LIVB
with	O	O
an	O	O
SSN	B-DISO
were	O	O
slightly	O	O
older	O	O
than	O	O
those	O	O
without	O	O
(	O	O
62	O	O
vs	O	O
.	O	O

58	O	O
years	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
but	O	O
no	O	O
gender	B-PHYS
predilection	O
was	O	O
found	O	O
.	O	O

SSNs	B-DISO
were	O	O
mostly	O	O
located	O
in	O	O
the	O	O
upper	B-ANAT
lobes	I-ANAT
.	O	O

Women	B-LIVB
showed	O	O
significantly	O
more	O	O
often	O	O
persistent	O
lesions	B-DISO
than	O	O
men	B-LIVB
(	O	O
94	O	O
%	O	O
vs	O	O
.	O	O

69	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
002	O	O
)	O	O
.	O	O

Part	B-DISO
-	I-DISO
solid	I-DISO
lesions	I-DISO
were	O	O
larger	O	O
(	O	O
1638	O	O
vs	O	O
.	O	O

383	O	O
mm	O	O
(	O	O
3	O	O
)	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
more	O	O
often	O	O
progressive	O
(	O	O
68	O	O
%	O	O
vs	O	O
.	O	O

38	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
pure	O	O
ground	B-DISO
-	I-DISO
glass	I-DISO
nodules	I-DISO
.	O	O

Progressive	O
SSNs	B-DISO
were	O	O
rare	O	O
under	O	O
the	O	O
age	B-PHYS
of	O	O
50	O	O
years	O
.	O	O

Logistic	O
regression	O
analysis	O
did	O	O
not	O	O
identify	O	O
additional	O	O
nodule	B-DISO
parameters	B-DISO
of	O	O
future	O	O
progression	O
,	O	O
apart	O	O
from	O	O
part	O
-	O
solid	O
nature	O
.	O	O

This	O	O
study	B-PROC
confirms	O	O
previously	O	O
reported	O	O
characteristics	O
of	O	O
SSNs	B-DISO
and	O	O
associated	O	O
factors	O
in	O	O
a	O	O
European	B-LIVB
,	O	O
routine	O
clinical	O
population	B-LIVB
.	O	O

•	O	O
SSNs	B-DISO
in	O	O
women	B-LIVB
are	O	O
significantly	O
more	O	O
often	O	O
persistent	O
compared	O	O
to	O	O
men	B-LIVB
.	O	O

•	O	O
SSN	B-DISO
persistence	O
is	O	O
not	O	O
associated	O	O
with	O	O
age	B-PHYS
or	O	O
prior	O
malignancy	B-DISO
.	O	O

•	O	O
The	O	O
majority	O	O
of	O	O
(	O	O
persistent	O
)	O	O
SSNs	B-DISO
are	O	O
located	O	O
in	O	O
the	O	O
upper	B-ANAT
lung	I-ANAT
lobes	I-ANAT
.	O	O

•	O	O
A	O	O
part	O
-	O
solid	O
nature	O
is	O	O
associated	O
with	O
future	O	O
nodule	B-DISO
growth	B-PHYS
.	O	O

•	O	O
Progressive	O
solitary	B-DISO
SSNs	I-DISO
are	O	O
rare	O
under	O	O
the	O	O
age	B-PHYS
of	O	O
50	O	O
years	O
.	O	O

Dynamic	B-PROC
CT	I-PROC
myocardial	I-PROC
perfusion	I-PROC
imaging	I-PROC
identifies	O	O
early	O
perfusion	B-PHYS
abnormalities	B-DISO
in	O	O
diabetes	B-DISO
and	O	O
hypertension	B-DISO
:	O	O
Insights	O	O
from	O	O
a	O	O
multicenter	B-PROC
registry	O
To	O	O
identify	O	O
patients	B-LIVB
with	O	O
early	B-DISO
signs	I-DISO
of	O	O
myocardial	B-PHYS
perfusion	I-PHYS
reduction	O
,	O	O
a	O	O
reference	O	O
base	O	O
for	O	O
perfusion	B-PHYS
measures	O
is	O	O
needed	O	O
.	O	O

To	O	O
analyze	O	O
perfusion	B-PHYS
parameters	B-DISO
derived	O	O
from	O	O
dynamic	B-PROC
computed	I-PROC
tomography	I-PROC
perfusion	I-PROC
imaging	I-PROC
(	O	O
CTPI	B-PROC
)	O	O
in	O	O
patients	B-LIVB
with	O	O
suspected	O	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O	O
CAD	B-DISO
)	O	O
,	O	O
and	O	O
relationship	O
with	O	O
risk	B-DISO
factors	I-DISO
.	O	O

In	O	O
this	O	O
multicenter	B-PROC
study	I-PROC
,	O	O
coronary	B-PROC
CT	I-PROC
angiography	I-PROC
(	O	O
cCTA	B-PROC
)	O	O
and	O	O
dynamic	B-PROC
CTPI	I-PROC
were	O	O
performed	O	O
by	O	O
second	B-PROC
-	I-PROC
generation	I-PROC
dual	I-PROC
-	I-PROC
source	I-PROC
CT	I-PROC
in	O	O
patients	B-LIVB
suspected	O	O
of	O	O
CAD	B-DISO
.	O	O

Risk	B-DISO
factors	I-DISO
were	O	O
collected	O	O
from	O	O
hospital	B-OBJC
records	I-OBJC
.	O	O

Patients	B-LIVB
with	O	O
visual	O
perfusion	B-PHYS
defects	O
on	O	O
CTPI	B-PROC
,	O	O
previous	O	O
coronary	B-PROC
intervention	I-PROC
,	O	O
or	O	O
missing	O	O
risk	B-DISO
factor	I-DISO
details	O	O
were	O	O
excluded	O	O
.	O	O

This	O	O
analysis	B-PROC
included	O	O
98	O	O
patients	B-LIVB
(	O	O
mean	O	O
age	O	O
±	O	O
standard	O	O
deviation	O	O
[	O	O
SD	O	O
]	O	O
,	O	O
59	O	O
.	O	O
0	O	O
±	O	O
8	O	O
.	O	O

6yrs	O	O
;	O	O
73	O	O
male	B-LIVB
)	O	O
.	O	O

Global	O	O
measures	O
of	O	O
left	B-ANAT
ventricular	I-ANAT
myocardial	B-PHYS
blood	I-PHYS
flow	I-PHYS
(	O	O
MBF	B-PHYS
)	O	O
,	O	O
myocardial	B-PHYS
blood	I-PHYS
volume	I-PHYS
(	O	O
MBV	B-PHYS
)	O	O
and	O	O
volume	O
transfer	O
constant	O
(	O	O
K	O
(	O
trans	O
)	O
)	O	O
were	O	O
calculated	O	O
.	O	O

Mean	O	O
MBF	B-PHYS
was	O	O
139	O	O
.	O	O

3	O	O
±	O	O
31	O	O
.	O	O

4	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
/	O	O
min	O	O
,	O	O
MBV	B-PHYS
19	O	O
.	O	O
1	O	O
±	O	O
2	O	O
.	O	O

7	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
,	O	O
and	O	O
Ktrans	O	O
85	O	O
.	O	O
0	O	O
±	O	O
17	O	O
.	O	O

5	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
/	O	O
min	O	O
.	O	O

No	O	O
significant	O	O
differences	O	O
in	O	O
perfusion	B-PHYS
parameters	B-DISO
were	O	O
found	O	O
by	O	O
gender	B-PHYS
or	O	O
age	B-PHYS
category	O	O
.	O	O

Hypertension	B-DISO
and	O	O
diabetes	B-DISO
mellitus	I-DISO
resulted	O	O
in	O	O
lower	O	O
perfusion	B-PHYS
parameters	B-DISO
(	O	O
hypertension	B-DISO
vs	O	O
normotension	B-DISO
:	O	O
MBV	B-PHYS
18	O	O
.	O	O

5	O	O
±	O	O
3	O	O
.	O	O
0	O	O
vs	O	O
19	O	O
.	O	O

7	O	O
±	O	O
2	O	O
.	O	O

3	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
and	O	O
K	O
(	O
trans	O
)	O
82	O	O
.	O	O
0	O	O
±	O	O
18	O	O
.	O	O
0	O	O
vs	O	O
89	O	O
.	O	O

0	O	O
±	O	O
16	O	O
.	O	O
0	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
;	O	O
diabetes	B-DISO
vs	O	O
no	B-DISO
diabetes	I-DISO
:	O	O
MBF	B-PHYS
128	O	O
.	O	O

5	O	O
±	O	O
31	O	O
.	O	O
5	O	O
vs	O	O
144	O	O
.	O	O

0	O	O
±	O	O
30	O	O
.	O	O

5	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
/	O	O
min	O	O
and	O	O
MBV	B-PHYS
17	O	O
.	O	O
9	O	O
±	O	O
2	O	O
.	O	O
4	O	O
vs	O	O
19	O	O
.	O	O
4	O	O
±	O	O
2	O	O
.	O	O
8	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
patients	B-LIVB
with	O	O
hyperlipidemia	B-DISO
,	O	O
MBF	B-PHYS
was	O	O
higher	O	O
(	O	O
146	O	O
.	O	O
8	O	O
±	O	O
34	O	O
.	O	O

4	O	O
vs	O	O
130	O	O
.	O	O

7	O	O
±	O	O
24	O	O
.	O	O

3	O	O
mL	O	O
/	O	O
100	O	O
mL	O	O
/	O	O
min	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Smoking	O
and	O	O
family	B-DISO
history	I-DISO
did	O	O
not	O	O
show	O	O
perfusion	B-PHYS
parameter	B-DISO
differences	O	O
.	O	O

Dynamic	B-PROC
CTPI	I-PROC
identifies	O	O
early	O	O
perfusion	B-PHYS
disturbances	O
in	O	O
conditions	O	O
like	O	O
diabetes	B-DISO
and	O	O
hypertension	B-DISO
.	O	O

With	O	O
further	O	O
standardization	B-PROC
,	O	O
absolute	O	O
perfusion	B-PHYS
measures	O
may	O	O
improve	O	O
CAD	B-DISO
risk	O
stratification	B-PROC
in	O	O
patients	B-LIVB
without	O	O
visual	O
perfusion	B-PHYS
defects	O
.	O	O

Cognition	B-PHYS
Enhancing	O
Activity	O
of	O	O
Sulforaphane	B-CHEM
Against	O
Scopolamine	B-CHEM
Induced	O
Cognitive	B-DISO
Impairment	I-DISO
in	O	O
Zebra	B-LIVB
Fish	I-LIVB
(	O	O
Danio	B-LIVB
rerio	I-LIVB
)	O	O
Several	O
epidemiological	B-PROC
studies	I-PROC
have	O	O
shown	O	O
that	O	O
consumption	O
of	O	O
large	O
quantities	O
of	O	O
vegetables	B-OBJC
especially	O	O
cruciferous	B-OBJC
vegetables	I-OBJC
(	O	O
Broccoli	B-OBJC
and	O	O
Brussels	B-OBJC
sprouts	I-OBJC
)	O	O
can	O	O
protect	O	O
against	O
chronic	B-DISO
diseases	I-DISO
.	O	O

Sulforaphane	B-CHEM
,	O	O
an	O	O
isothiocynate	B-CHEM
found	B-DISO
in	O	O
cruciferous	B-OBJC
vegetables	I-OBJC
has	O	O
been	O	O
demonstrated	O	O
to	O	O
have	O	O
neuroprotective	O
effects	O
in	O	O
several	O
experimental	B-PROC
paradigms	I-PROC
.	O	O

This	O	O
study	B-PROC
was	O	O
undertaken	O	O
to	O	O
examine	O	O
the	O	O
effect	O
of	O	O
sulforaphane	B-CHEM
on	O	O
cognitive	B-DISO
impairment	I-DISO
in	O	O
zebra	B-LIVB
fish	I-LIVB
model	B-DISO
using	O	O
a	O	O
novel	O
method	O
of	O	O
fear	B-PHYS
conditioning	I-PHYS
.	O	O

Initially	O	O
,	O	O
the	O	O
normal	O
behaviour	O
of	O	O
zebra	B-LIVB
fishes	I-LIVB
was	O	O
studied	B-PROC
in	O	O
light	B-OBJC
-	I-OBJC
dark	I-OBJC
tank	I-OBJC
for	O	O
10	O	O
min	O	O
daily	O
for	O	O
10	O	O
days	O
.	O	O

Fishes	B-LIVB
were	O	O
then	O	O
divided	O
into	O	O
seven	O
groups	O
of	O	O
twelve	O
in	O	O
each	O
.	O	O

Group	O
I	O
served	O	O
as	O	O
normal	O
,	O	O
group	O
II	O
served	O	O
as	O	O
fear	B-PHYS
conditioned	I-PHYS
control	I-PHYS
,	O	O
group	O
III	O
and	O	O
group	O
IV	O
were	O	O
sulforaphane	B-CHEM
(	O	O
25	O	O
µM	O	O
/	O	O
L	O	O
)	O	O
and	O	O
piracetam	B-CHEM
(	O	O
200	O	O
mg	O	O
/	O	O
L	O	O
)	O	O
treated	O
respectively	O	O
.	O	O

Group	O
V	O
served	O	O
as	O	O
scopolamine	B-CHEM
(	O	O
400	O	O
µM	O	O
/	O	O
L	O	O
)	O	O
induced	O
memory	B-DISO
impairment	I-DISO
fishes	B-LIVB
.	O	O

Group	O
VI	O
and	O	O
VII	O
were	O	O
sulforaphane	B-CHEM
(	O	O
25	O	O
µM	O	O
/	O	O
L	O	O
)	O	O
and	O	O
piracetam	B-CHEM
(	O	O
200	O	O
mg	O	O
/	O	O
L	O	O
)	O	O
treated	O
scopolamine	B-CHEM
induced	O
memory	B-DISO
impairment	I-DISO
groups	O
respectively	O	O
.	O	O

In	O	O
normal	O
behavioural	B-PROC
analysis	I-PROC
,	O	O
fishes	B-LIVB
preferred	O	O
to	O	O
stay	O	O
in	O	O
dark	O
compartment	O
.	O	O

The	O	O
average	O
number	O
of	O	O
entries	B-OBJC
into	O	O
the	O	O
dark	O
and	O	O
time	O
spent	O	O
in	O	O
dark	O
were	O	O
significantly	O
more	O
.	O	O

Fishes	B-LIVB
in	O	O
group	O
II	O
to	O	O
VII	O
were	O	O
individually	O	O
subjected	O	O
to	O	O
fear	B-PHYS
conditioning	I-PHYS
passive	B-PROC
avoidance	I-PROC
task	I-PROC
and	O	O
evaluated	B-PROC
for	O	O
learned	B-PHYS
task	I-PHYS
memory	I-PHYS
.	O	O

It	O	O
was	O	O
observed	O
that	O	O
the	O	O
average	O
number	O
of	O	O
entries	B-OBJC
into	O	O
dark	O
and	O	O
time	O
spent	O	O
in	O	O
dark	O
were	O	O
significantly	O
decreased	O
.	O	O

After	O	O
exposure	O
to	O
respective	O	O
treatment	O
fishes	B-LIVB
in	O	O
group	O
III	O
to	O	O
VII	O
were	O	O
subjected	O	O
to	O	O
cognitive	B-PHYS
evaluation	B-PROC
.	O	O

There	O	O
was	O	O
no	B-DISO
significant	I-DISO
difference	O
in	O	O
cognition	B-PHYS
of	O	O
group	O
III	O
and	O	O
IV	O
fishes	B-LIVB
exposed	O
to	O
sulforaphane	B-CHEM
and	O	O
piracetam	B-CHEM
alone	O	O
respectively	O	O
.	O	O

Fishes	B-LIVB
exposed	O
to	O
scopolamine	B-CHEM
showed	O	O
a	O	O
significant	O
cognitive	B-DISO
impairment	I-DISO
.	O	O

Sulforaphane	B-CHEM
exposure	O	O
prior	O	O
to	O	O
scopolamine	B-CHEM
significantly	O
retained	O	O
the	O	O
memory	B-PHYS
of	O	O
learned	B-PHYS
task	O
.	O	O

These	O	O
findings	B-DISO
suggest	O
that	O	O
sulforaphane	B-CHEM
might	O	O
be	O	O
a	O	O
promising	O	O
therapeutic	B-CHEM
agent	I-CHEM
for	O	O
cognitive	B-PHYS
enhancement	O
in	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O	O

Value	O	O
of	O	O
MDM2	B-CHEM
,	O	O
CDK4	B-CHEM
and	O	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O	O
histologic	B-PHYS
diagnosis	B-DISO
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
To	O	O
investigate	O	O
the	O	O
value	O	O
of	O	O
combined	O	O
application	O	O
of	O	O
MDM2	B-CHEM
,	O	O
CDK4	B-CHEM
and	O	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O	O
pathological	O
diagnosis	B-DISO
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
.	O	O

Forty	O	O
-	O	O
seven	O	O
cases	O	O
of	O	O
low	B-DISO
grade	I-DISO
osteosarcoma	B-DISO
,	O	O
including	O	O
low	B-DISO
grade	I-DISO
central	I-DISO
osteosarcoma	I-DISO
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
and	O	O
parosteal	B-DISO
osteosarcoma	I-DISO
(	O	O
n	O	O
=	O	O
27	O	O
)	O	O
,	O	O
were	O	O
selected	O	O
from	O	O
Shanghai	B-OBJC
Jiaotong	I-OBJC
University	I-OBJC
Affiliated	O	O
the	O	O
Sixth	B-OBJC
People	I-OBJC
's	I-OBJC
Hospital	I-OBJC
.	O	O

The	O	O
clinical	O
,	O	O
radiography	B-PROC
and	O	O
histopathology	B-PHEN
were	O	O
reviewed	O
.	O	O

The	O	O
sensitivity	O
and	O
specificity	O
of	O	O
MDM2	B-CHEM
,	O	O
CDK4	B-CHEM
and	O	O
SATB2	B-CHEM
immunohistochemistry	B-PROC
in	O	O
the	O	O
diagnosis	B-DISO
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
were	O	O
assessed	B-PROC
along	O	O
with	O	O
an	O	O
evaluation	B-PROC
of	O	O
their	O	O
expressions	B-PHYS
in	O	O
fibrous	B-DISO
dysplasia	I-DISO
,	O	O
desmoplastic	B-DISO
fibroma	I-DISO
,	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
fibrosarcoma	B-DISO
and	O	O
other	O	O
fibrous	B-DISO
tumors	I-DISO
.	O	O

Low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
had	O	O
protracted	B-DISO
clinical	I-DISO
course	I-DISO
,	O	O
occurring	O	O
mostly	O	O
in	O	O
elder	B-LIVB
adults	I-LIVB
and	O	O
mainly	O	O
involving	O	O
long	O
bones	B-ANAT
.	O	O

Radiographic	O	O
studies	O	O
showed	O	O
that	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
central	I-DISO
osteosarcoma	I-DISO
had	O	O
a	O	O
mainly	O	O
malignant	O
lytic	O
presentation	O
,	O	O
however	O	O
about	O	O
5	O	O
/	O	O
18	O	O
of	O	O
t	O	O
umors	O
overlapping	O
with	O	O
intermediate	O	O
and	O	O
benign	O
bone	B-DISO
diseases	I-DISO
,	O	O
while	O	O
parosteal	B-DISO
osteosarcoma	I-DISO
was	O	O
characterized	O	O
by	O	O
a	O	O
densely	O	O
sclerotic	O
malignant	O
appearance	O
.	O	O

Histologically	B-PHYS
,	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
s	O	O
were	O	O
characterized	O	O
by	O	O
well	O	O
-	O	O
differentiated	O	O
spindle	B-ANAT
tumor	B-ANAT
cells	I-ANAT
,	O	O
various	O	O
mature	O
tumor	B-DISO
bones	I-DISO
and	O	O
an	O	O
aggressive	O
growth	B-DISO
pattern	I-DISO
.	O	O

The	O	O
positive	B-PHYS
expression	I-PHYS
rates	O	O
of	O	O
MDM2	B-CHEM
and	O	O
CDK4	B-CHEM
in	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
were	O	O
74	O	O
.	O	O

5	O	O
%	O	O
and	O	O
55	O	O
.	O	O

3	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Eighty	O	O
-	O	O
three	O	O
percent	O	O
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
expressed	O	O
one	O	O
or	O	O
both	O	O
markers	O	O
.	O	O

Low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
and	O	O
fibrous	B-DISO
dysplasia	I-DISO
were	O	O
both	O	O
positive	B-DISO
for	O	O
SATB2	B-CHEM
,	O	O
while	O	O
desmoplastic	B-DISO
fibroma	I-DISO
,	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
fibrosacoma	B-DISO
and	O	O
other	O	O
fibrous	B-DISO
tumors	I-DISO
were	O	O
negative	B-DISO
for	O	O
SATB2	B-CHEM
.	O	O

Accurate	O	O
diagnosis	B-DISO
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
should	O	O
be	O	O
based	O	O
on	O	O
combination	O
of	O	O
clinical	O
presentation	O
,	O	O
imaging	B-PROC
and	O	O
histopathology	B-PHEN
,	O	O
with	O	O
immunohistochemistry	B-PROC
as	O	O
a	O	O
diagnostic	O
adjunct	O
.	O	O

Positive	B-PROC
immunostaining	I-PROC
for	O	O
CDK4	B-CHEM
and	O	O
/	O	O
or	O	O
MDM2	B-CHEM
supports	O	O
the	O	O
diagnosis	B-DISO
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
osteosarcoma	B-DISO
,	O	O
but	O	O
the	O	O
negative	O	O
one	O	O
does	O	O
not	O	O
rule	O	O
out	O	O
such	O	O
lesion	B-DISO
.	O	O

The	O	O
negative	O	O
expression	B-PHYS
of	O	O
SATB2	B-CHEM
is	O	O
helpful	O	O
to	O	O
exclude	O	O
fibrous	B-DISO
tumors	I-DISO
originating	O	O
from	O	O
bone	B-ANAT
with	O	O
the	O	O
exception	O	O
of	O	O
fibrous	B-DISO
dysplasia	I-DISO
.	O	O

Biobank	B-OBJC
and	O	O
Genomic	O
Research	B-PROC
in	O	O
Uganda	B-GEOG
:	O	O
Are	O	O
Extant	O
Privacy	O
and	O	O
Confidentiality	O
Regimes	O
Adequate	O
?	O	O
Not	O	O
many	O	O
African	B-GEOG
countries	I-GEOG
have	O	O
been	O	O
able	O	O
to	O	O
develop	O	O
a	O	O
robust	O	O
system	O	O
for	O	O
regulating	O
health	B-PROC
research	I-PROC
within	O	O
their	O	O
respective	O	O
jurisdictions	O
,	O	O
particularly	O	O
in	O	O
the	O	O
realm	O
of	O	O
biobanking	B-OBJC
and	O	O
genomics	O
.	O	O

This	O	O
is	O	O
not	O	O
without	O	O
reason	O	O
.	O	O

Aside	O	O
from	O	O
underdevelopment	O
and	O	O
all	O	O
that	O	O
it	O	O
entails	O	O
or	O	O
perhaps	O	O
in	O	O
consequence	O
thereof	O
,	O	O
countries	B-GEOG
in	O	O
the	O	O
region	B-GEOG
have	O	O
been	O	O
unable	O	O
to	O	O
make	O	O
significant	O	O
strides	O	O
in	O	O
medical	B-PROC
research	I-PROC
.	O	O

But	O	O
there	O	O
are	O	O
exceptions	O	O
.	O	O

Amongst	O	O
the	O	O
few	O	O
seeming	O	O
success	O
stories	O	O
is	O	O
Uganda	B-GEOG
.	O	O

Nonetheless	O	O
,	O	O
although	O	O
the	O	O
country	O
has	O
developed	O
what	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
functional	O
framework	O
to	O	O
govern	O	O
genomic	O
research	B-PROC
and	O	O
biobanking	B-OBJC
,	O	O
the	O	O
consistency	O
of	O	O
key	O	O
provisions	O	O
with	O	O
international	O
standards	O
,	O	O
especially	O	O
those	O	O
pertaining	O	O
to	O	O
privacy	O
of	O	O
research	B-PROC
participants	B-LIVB
and	O	O
confidentiality	O
of	O	O
their	O	O
health	B-PROC
information	I-PROC
,	O	O
is	O	O
not	O	O
at	O	O
all	O	O
clear	O	O
.	O	O

Yet	O	O
,	O	O
making	O	O
this	O	O
determination	O	O
-	O	O
the	O	O
main	O	O
objective	O
of	O	O
this	O	O
article	O
-	O	O
is	O	O
critical	O
in	O	O
determining	O	O
the	O	O
adequacy	O
of	O	O
protection	B-DISO
available	O	O
to	O	O
human	B-LIVB
research	B-LIVB
subjects	I-LIVB
in	O	O
the	O	O
country	B-GEOG
.	O	O

Impact	O
of	O	O
a	O	O
Casino	B-OBJC
Opening	O
on	O	O
Gambling	O
Behaviors	O
of	O	O
People	B-LIVB
Engaged	O	O
in	O	O
Methadone	B-CHEM
Maintenance	O
This	O	O
study	O	O
examined	O	O
gambling	O
behavior	O
in	O	O
the	O	O
context	O	O
of	O	O
a	O	O
newly	O	O
opening	O
casino	B-OBJC
,	O	O
comparing	O
disordered	O
gamblers	O
to	O	O
non	O
-	O
disordered	O
gamblers	O
,	O	O
in	O	O
a	O	O
population	B-LIVB
of	O	O
individuals	B-LIVB
involved	O	O
in	O	O
methadone	B-PROC
maintenance	I-PROC
treatment	I-PROC
.	O	O

Disordered	O
gamblers	O
(	O	O
N	O	O
=	O	O
50	O	O
)	O	O
and	O	O
non	O
-	O
disordered	O
gamblers	O
(	O	O
N	O	O
=	O	O
50	O	O
)	O	O
were	O	O
surveyed	B-PROC
before	O	O
and	O	O
after	O	O
the	O	O
opening	O
of	O	O
a	O	O
new	O	O
casino	B-OBJC
on	O	O
gambling	O
behaviors	O
,	O	O
substance	B-DISO
use	I-DISO
,	O	O
and	O	O
psychological	B-DISO
symptoms	I-DISO
.	O	O

No	B-DISO
statistically	I-DISO
significant	I-DISO
changes	I-DISO
in	O	O
gambling	O
behaviors	O
were	O	O
observed	O	O
for	O	O
disordered	O
gamblers	O
or	O	O
non	O
-	O
disordered	O
gamblers	O
across	O	O
time	O	O
points	O	O
;	O	O
however	O	O
,	O	O
non	O
-	O
disordered	O
gamblers	O
demonstrated	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
increases	I-DISO
in	O	O
horse	O
and	O
dog	O
race	O
betting	O
,	O	O
electronic	B-OBJC
games	I-OBJC
,	O	O
and	O	O
casino	B-OBJC
table	O
games	O
.	O	O

As	O	O
expected	O	O
,	O	O
disordered	O
gamblers	O
were	O	O
found	O	O
to	O	O
spend	B-DISO
significantly	I-DISO
more	I-DISO
money	I-DISO
on	O	O
electronic	B-OBJC
games	I-OBJC
and	O	O
casino	B-OBJC
table	O
games	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
demonstrated	O	O
higher	O	O
rates	O	O
of	O	O
drug	B-DISO
use	I-DISO
and	O	O
impulsivity	O
than	O	O
non	O
-	O
disordered	O
gamblers	O
.	O	O

The	O	O
introduction	O	O
of	O	O
a	O	O
new	O	O
casino	B-OBJC
did	O	O
not	O	O
appear	O	O
to	O	O
have	O	O
a	O	O
major	O	O
impact	O
on	O	O
gambling	O
behaviors	O
of	O	O
individuals	B-LIVB
attending	O	O
methadone	B-PROC
maintenance	I-PROC
treatment	I-PROC
,	O	O
though	O	O
the	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
increases	I-DISO
in	O	O
gambling	O
among	O	O
non	O
-	O
disordered	O
gamblers	O
may	O	O
indicate	O	O
that	O	O
this	O	O
population	B-LIVB
is	O	O
preferentially	O	O
impacted	O
by	O	O
the	O	O
opening	O
of	O	O
a	O	O
new	O	O
casino	B-OBJC
.	O	O

Future	O
investigation	O
into	O	O
the	O	O
longer	B-PHEN
term	I-PHEN
effects	I-PHEN
of	O	O
opening	O
a	O	O
new	O	O
casino	B-OBJC
on	O	O
this	O	O
population	B-LIVB
may	O	O
be	O	O
warranted	O	O
.	O	O

Association	O
between	O	O
Leukoaraiosis	B-DISO
and	O	O
Poor	B-DISO
Outcome	I-DISO
is	O	O
not	O	O
due	O	O
to	O	O
Reperfusion	B-PHEN
Inefficiency	B-DISO
after	O	O
Intravenous	B-PROC
Thrombolysis	I-PROC
Leukoaraiosis	B-DISO
(	O	O
LA	B-DISO
)	O	O
is	O	O
associated	O
with	O
structural	B-DISO
and	O	O
functional	B-DISO
cerebrovascular	I-DISO
impairment	I-DISO
,	O	O
which	O	O
may	O	O
compromise	O	O
the	O	O
capacity	O
of	O	O
ischemic	O
tissue	O
to	O	O
maximize	O	O
reperfusion	B-PHEN
after	O	O
intravenous	B-PROC
thrombolysis	I-PROC
(	O	O
IVT	B-PROC
)	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
severe	O
LA	B-DISO
is	O	O
correlated	O	O
with	O	O
reperfusion	B-PHEN
inefficiency	B-DISO
,	O	O
which	O	O
contributes	O	O
to	O	O
infarct	B-PHEN
growth	I-PHEN
and	O	O
poor	B-DISO
functional	I-DISO
outcome	I-DISO
.	O	O

We	O	O
analyzed	O	O
data	O	O
from	O	O
our	O	O
consecutive	O	O
acute	B-DISO
ischemic	I-DISO
stroke	I-DISO
(	O	O
AIS	B-DISO
)	O	O
patients	B-LIVB
who	O	O
had	O	O
acquired	O	O
baseline	O
and	O	O
24	O	O
-	O	O
h	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
diffusion	B-PROC
-	I-PROC
and	O	O
perfusion	B-PROC
-	I-PROC
weighted	I-PROC
imaging	I-PROC
.	O	O

Reperfusion	B-PHEN
was	O	O
defined	O	O
as	O	O
reduction	B-PROC
of	O	O
≥70	O	O
%	O	O
of	O	O
hypoperfusion	B-DISO
lesion	B-DISO
at	O	O
24	O	O
h	O	O
from	O	O
baseline	O
.	O	O

Severe	O
LA	B-DISO
was	O	O
defined	O	O
as	O	O
Fazekas	O
score	O
2	O	O
or	O	O
3	O	O
on	O	O
FLAIR	B-PROC
images	I-PROC
.	O	O

We	O	O
investigated	O	O
the	O	O
relationship	O
between	O	O
severity	O
of	O	O
LA	B-DISO
and	O	O
reperfusion	B-PHEN
status	O	O
.	O	O

Multivariate	O
statistical	B-PROC
analysis	I-PROC
was	O	O
carried	O	O
out	O	O
for	O	O
modeling	B-PROC
the	O	O
independent	O	O
predictors	O
of	O	O
reperfusion	B-PHEN
,	O	O
infarct	B-PHEN
growth	I-PHEN
,	O	O
and	O	O
functional	O
outcome	O
.	O	O

Finally	O	O
,	O	O
79	O	O
patients	B-LIVB
were	O	O
included	O	O
,	O	O
among	O	O
them	O	O
30	O	O
(	O	O
37	O	O
.	O	O
97	O	O
%	O	O
)	O	O
had	O	O
severe	O
LA	B-DISO
.	O	O

Reperfusion	B-PHEN
was	O	O
observed	O
in	O	O
41	O	O
(	O	O
51	O	O
.	O	O
89	O	O
%	O	O
)	O	O
patients	B-LIVB
,	O	O
the	O	O
proportion	O	O
of	O	O
reperfusion	B-PHEN
was	O	O
very	O	O
similar	O	O
in	O	O
patients	B-LIVB
with	O	O
and	O	O
without	O	O
severe	O
LA	B-DISO
(	O	O
53	O	O
.	O	O
33	O	O
vs	O	O
51	O	O
.	O	O

02	O	O
%	O	O
,	O	O
p	O	O
=	O	O
1	O	O
.	O	O
000	O	O
)	O	O
.	O	O

Large	O	O
artery	B-DISO
occlusion	I-DISO
was	O	O
the	O	O
only	O	O
independent	O	O
unfavorable	O	O
predictor	O
for	O	O
reperfusion	B-PHEN
(	O	O
OR	O	O
=	O	O
0	O	O
.	O	O
202	O	O
,	O	O
95	O	O
%	O	O
confidence	O
interval	O
,	O	O
0	O	O
.	O	O
060	O	O
-	O	O
0	O	O
.	O	O
673	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

014	O	O
)	O	O
.	O	O

Multiple	O
linear	O
regression	O
analysis	O
revealed	O	O
that	O	O
severe	O
LA	B-DISO
was	O	O
independently	O	O
associated	O
with	O
infarct	B-PHEN
growth	I-PHEN
(	O	O
standardized	O	O
coefficients	O
=	O	O
0	O	O
.	O	O
191	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
040	O	O
)	O	O
.	O	O

Severe	O
LA	B-DISO
was	O	O
also	O	O
an	O	O
independent	O	O
predictor	O
of	O	O
poor	B-DISO
outcome	I-DISO
(	O	O
mRS	O	O
≥	O	O
3	O	O
)	O	O
(	O	O
OR	O	O
=	O	O
4	O	O
.	O	O

004	O	O
,	O	O
95	O	O
%	O	O
confidence	O
interval	O
,	O	O
1	O	O
.	O	O
267	O	O
-	O	O
12	O	O
.	O	O

656	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

018	O	O
)	O	O
after	O	O
adjusting	O	O
for	O	O
reperfusion	B-PHEN
and	O	O
baseline	O
severity	O
of	O	O
stroke	B-DISO
.	O	O

Severe	O
LA	B-DISO
was	O	O
associated	O
with	O
infarct	B-PHEN
growth	I-PHEN
and	O	O
poor	B-DISO
outcome	I-DISO
independent	O	O
of	O	O
reperfusion	B-PHEN
status	O	O
,	O	O
which	O	O
may	O	O
expand	O	O
the	O	O
notion	O	O
that	O	O
LA	B-DISO
contributes	O	O
the	O	O
intrinsic	B-DISO
vulnerability	I-DISO
of	O	O
brain	B-ANAT
tissue	I-ANAT
to	O	O
acute	B-DISO
ischemic	I-DISO
insults	I-DISO
.	O	O

The	O	O
burden	O	O
of	O	O
LA	B-DISO
may	O	O
not	O	O
serve	O	O
as	O	O
an	O	O
imaging	O
indicator	O
of	O	O
reperfusion	B-PHEN
inefficiency	B-DISO
after	O	O
IVT	B-PROC
for	O	O
AIS	B-DISO
patients	B-LIVB
.	O	O

The	O	O
Experience	B-PHYS
of	O	O
Women	B-LIVB
Veterans	B-LIVB
Coming	O	O
Back	O	O
from	O	O
War	O
Issues	B-DISO
surrounding	I-DISO
mental	I-DISO
health	I-DISO
are	O	O
common	O	O
for	O	O
women	B-LIVB
veterans	B-LIVB
who	O	O
have	O	O
served	O	O
in	O	O
Iraq	B-GEOG
and	O	O
Afghanistan	B-GEOG
wars	O
.	O	O

The	O	O
goal	O	O
of	O	O
this	O	O
phenomenological	O
study	B-PROC
was	O	O
to	O	O
document	O
themes	O
in	O	O
the	O	O
stories	O
gathered	O	O
from	O	O
eight	O	O
women	B-LIVB
veterans	B-LIVB
who	O	O
had	O	O
come	O	O
back	O	O
from	O	O
war	O
.	O	O

Themes	O
in	O	O
the	O	O
stories	O
were	O	O
:	O	O
arriving	O	O
with	O	O
mixed	O	O
sentiments	O
;	O	O
evolving	O	O
to	O	O
a	O	O
changed	O
view	B-PHYS
of	I-PHYS
self	I-PHYS
;	O	O
permeating	B-DISO
aggravation	I-DISO
;	O	O
confounding	O
broken	O
relationships	O
,	O	O
frequent	B-DISO
deployments	I-DISO
,	O	O
and	O	O
change	B-DISO
in	I-DISO
military	I-DISO
status	I-DISO
;	O	O
remembering	B-PHYS
war	O
experiences	B-PHYS
;	O	O
and	O	O
seeking	B-DISO
opportunity	I-DISO
for	I-DISO
what	I-DISO
is	I-DISO
possible	I-DISO
.	O	O

Mental	B-DISO
health	I-DISO
issues	I-DISO
can	O	O
be	O	O
observed	O	O
in	O	O
the	O	O
themes	O
.	O	O

Including	O	O
story	O
as	O	O
part	O	O
of	O	O
the	O	O
mental	B-PHYS
health	I-PHYS
visit	O	O
with	O	O
veterans	B-LIVB
may	O	O
be	O	O
beneficial	O	O
to	O	O
veterans	B-LIVB
as	O	O
they	O	O
deal	O	O
with	O	O
the	O	O
transition	O
of	O
coming	O
back	O
.	O	O

A	O	O
novel	O	O
role	O
for	O	O
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
proteins	I-CHEM
in	O	O
programmed	B-PHYS
ribosomal	I-PHYS
frameshifting	I-PHYS
Translational	B-PHYS
control	O
through	O	O
programmed	B-PHYS
ribosomal	I-PHYS
frameshifting	I-PHYS
(	O	O
PRF	B-PHYS
)	O	O
is	O	O
exploited	O	O
widely	O	O
by	O	O
viruses	B-LIVB
and	O	O
increasingly	O	O
documented	O	O
in	O	O
cellular	B-ANAT
genes	O
.	O	O

Frameshifting	B-PHYS
is	O	O
induced	O
by	O	O
mRNA	B-CHEM
secondary	I-CHEM
structures	I-CHEM
that	O	O
compromise	O	O
ribosome	B-ANAT
fidelity	B-PHYS
during	O	O
decoding	O
of	O	O
a	O	O
heptanucleotide	O
'	O
slippery	O
'	O
sequence	O
.	O	O

The	O	O
nsp2	B-CHEM
PRF	B-PHYS
signal	B-PHYS
of	O	O
porcine	B-LIVB
reproductive	I-LIVB
and	I-LIVB
respiratory	I-LIVB
syndrome	I-LIVB
virus	I-LIVB
is	O	O
distinctive	O	O
in	O	O
directing	O	O
both	O	O
-2	B-PHYS
and	O	O
-1	B-PHYS
PRF	I-PHYS
and	O	O
in	O	O
its	O	O
requirement	O
for	O	O
a	O	O
trans	B-CHEM
-	I-CHEM
acting	I-CHEM
protein	I-CHEM
factor	I-CHEM
,	O	O
the	O	O
viral	B-LIVB
replicase	B-CHEM
subunit	I-CHEM
nsp1β	I-CHEM
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
the	O	O
trans	B-PHYS
-	I-PHYS
activation	I-PHYS
of	O	O
frameshifting	B-PHYS
is	O	O
carried	O	O
out	O	O
by	O	O
a	O	O
protein	B-CHEM
complex	I-CHEM
composed	O	O
of	O	O
nsp1β	B-CHEM
and	O	O
a	O	O
cellular	B-ANAT
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O	O
PCBP	B-CHEM
)	O	O
.	O	O

From	O	O
the	O	O
results	O	O
of	O	O
in	O
vitro	O
translation	B-PHYS
and	O	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
,	O	O
we	O	O
demonstrate	O	O
that	O	O
a	O	O
PCBP	B-CHEM
/	O	O
nsp1β	B-CHEM
complex	B-CHEM
binds	O	O
to	O	O
a	O	O
C	O
-	O
rich	O
sequence	O
downstream	O
of	O	O
the	O	O
slippery	O
sequence	O
and	O	O
here	O	O
mimics	O	O
the	O	O
activity	O
of	O	O
a	O	O
structured	O	O
mRNA	B-CHEM
stimulator	B-CHEM
of	O	O
PRF	B-PHYS
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
description	O	O
of	O	O
a	O	O
role	O
for	O	O
a	O	O
trans	B-CHEM
-	I-CHEM
acting	I-CHEM
cellular	I-CHEM
protein	I-CHEM
in	O	O
PRF	B-PHYS
.	O	O

The	O	O
discovery	O	O
broadens	O	O
the	O	O
repertoire	O	O
of	O	O
activities	O
associated	O
with	O
poly	B-CHEM
(	I-CHEM
C	I-CHEM
)	I-CHEM
binding	I-CHEM
proteins	I-CHEM
and	O	O
prototypes	O
a	O	O
new	O	O
class	O	O
of	O	O
virus	B-LIVB
-	O	O
host	B-LIVB
interactions	O
.	O	O

RNA	B-CHEM
topoisomerase	I-CHEM
is	O	O
prevalent	O	O
in	O	O
all	O	O
domains	O	O
of	O	O
life	O	O
and	O	O
associates	O	O
with	O	O
polyribosomes	B-ANAT
in	O	O
animals	B-LIVB
DNA	B-CHEM
Topoisomerases	I-CHEM
are	O	O
essential	O	O
to	O	O
resolve	O	O
topological	O	O
problems	O	O
during	O	O
DNA	B-PHYS
metabolism	I-PHYS
in	O	O
all	O	O
species	O
.	O	O

However	O	O
,	O	O
the	O	O
prevalence	O
and	O	O
function	O
of	O	O
RNA	B-CHEM
topoisomerases	I-CHEM
remain	O	O
uncertain	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
RNA	B-PHYS
topoisomerase	I-PHYS
activity	I-PHYS
is	O	O
prevalent	O	O
in	O	O
Type	B-CHEM
IA	I-CHEM
topoisomerases	I-CHEM
from	O	O
bacteria	B-LIVB
,	O	O
archaea	B-LIVB
,	O	O
and	O	O
eukarya	O
.	O	O

Moreover	O	O
,	O	O
this	O	O
activity	B-PHYS
always	O	O
requires	O	O
the	O	O
conserved	O
Type	O
IA	O
core	O
domains	O
and	O	O
the	O	O
same	O	O
catalytic	O
residue	O
used	O	O
in	O	O
DNA	B-PHYS
topoisomerase	I-PHYS
reaction	I-PHYS
;	O	O
however	O	O
,	O	O
it	O	O
does	O	O
not	O	O
absolutely	O	O
require	O	O
the	O	O
non	O
-	O
conserved	O
carboxyl	O
-	O
terminal	O
domain	O
(	O	O
CTD	O
)	O	O
,	O	O
which	O	O
is	O	O
necessary	O	O
for	O	O
relaxation	B-PHYS
reactions	I-PHYS
of	O	O
supercoiled	B-CHEM
DNA	I-CHEM
.	O	O

The	O	O
RNA	B-PHYS
topoisomerase	I-PHYS
activity	I-PHYS
of	O	O
human	B-CHEM
Top3β	I-CHEM
differs	O	O
from	O	O
that	O	O
of	O	O
Escherichia	B-LIVB
coli	I-LIVB
topoisomerase	B-CHEM
I	I-CHEM
in	O	O
that	O	O
the	O	O
former	O	O
but	O	O
not	O	O
the	O	O
latter	O	O
requires	O	O
the	O	O
CTD	O
,	O	O
indicating	O	O
that	O	O
topoisomerases	B-CHEM
have	O	O
developed	O	O
distinct	O	O
mechanisms	O
during	O	O
evolution	O	O
to	O	O
catalyze	B-PHEN
RNA	B-CHEM
topoisomerase	I-CHEM
reactions	B-PHEN
.	O	O

Notably	O	O
,	O	O
Top3β	B-CHEM
proteins	I-CHEM
from	O	O
several	O	O
animals	B-LIVB
associate	O	O
with	O	O
polyribosomes	B-ANAT
,	O	O
which	O	O
are	O	O
units	O	O
of	O	O
mRNA	B-CHEM
translation	B-PHYS
,	O	O
whereas	O	O
the	O	O
Top3	O	O
homologs	O	O
from	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
and	O	O
yeast	B-LIVB
lack	O	O
the	O	O
association	O	O
.	O	O

The	O	O
Top3β	B-CHEM
-	O	O
polyribosome	B-ANAT
association	B-PHEN
requires	O	O
TDRD3	B-CHEM
,	O	O
which	O	O
directly	O	O
interacts	O	O
with	O	O
Top3β	B-CHEM
and	O	O
is	O	O
present	O	O
in	O	O
animals	B-LIVB
but	O	O
not	O	O
bacteria	B-LIVB
or	O	O
yeast	B-LIVB
.	O	O

We	O	O
propose	O	O
that	O	O
RNA	B-CHEM
topoisomerases	I-CHEM
arose	O	O
in	O	O
the	O	O
early	O	O
RNA	B-CHEM
world	O	O
,	O	O
and	O	O
that	O	O
they	O	O
are	O	O
retained	O
through	O	O
all	O	O
domains	O	O
of	O	O
DNA	B-CHEM
-based	O	O
life	O
,	O	O
where	O	O
they	O	O
mediate	O	O
mRNA	B-CHEM
translation	B-PHYS
as	O	O
part	O	O
of	O	O
polyribosomes	B-ANAT
in	O	O
animals	B-LIVB
.	O	O

First	O
Draft	O
Genome	O
Sequence	O
of	O	O
Staphylococcus	B-LIVB
condimenti	I-LIVB
F	I-LIVB
-	I-LIVB
2	I-LIVB
T	I-LIVB
This	O	O
report	O
describes	O	O
the	O	O
draft	O
genome	O
sequence	O
of	O	O
S	B-LIVB
.	I-LIVB

condimenti	I-LIVB
strain	I-LIVB
F	I-LIVB
-	I-LIVB
2	I-LIVB
(	I-LIVB
T	I-LIVB
)	I-LIVB
(	I-LIVB
DSM	I-LIVB
11674	I-LIVB
)	I-LIVB
,	O	O
a	O	O
potential	O
starter	B-PROC
culture	I-PROC
.	O	O

The	O	O
genome	O
assembly	O
comprised	O
2	O	O
,	O	O
616	O	O
,	O	O
174	O	O
bp	B-PHYS
with	O	O
34	O	O
.	O	O

6	O	O
%	O	O
GC	O
content	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
documentation	O
that	O	O
reports	O
the	O	O
whole	O
-	O
genome	O
sequence	O
of	O	O
S	B-LIVB
.	I-LIVB

condimenti	I-LIVB
.	O	O

Trajectories	O
of	O	O
Health	O
and	O	O
Behavioral	B-PROC
Health	I-PROC
Services	I-PROC
Use	O
among	O	O
Community	B-LIVB
Corrections	O
-Involved	O	O
Rural	B-DISO
Adults	B-LIVB
This	O	O
article	O	O
seeks	O	O
to	O	O
establish	O	O
time	O	O
-	O	O
based	O	O
trajectories	O
of	O	O
health	O
and	O	O
behavioral	B-PROC
health	I-PROC
services	I-PROC
utilization	O
for	O	O
community	O
corrections	O
-	O
involved	O
(	O	O
CCI	O
)	O	O
adults	B-LIVB
and	O	O
to	O	O
examine	O	O
demographic	O
and	O	O
clinical	O
correlates	O	O
associated	O	O
with	O	O
these	O	O
trajectories	O
.	O	O

To	O	O
accomplish	O	O
this	O	O
aim	O	O
,	O	O
the	O	O
authors	O	O
applied	O	O
a	O	O
latent	B-PROC
class	I-PROC
growth	I-PROC
analysis	I-PROC
(	O	O
LCGA	B-PROC
)	O	O
to	O	O
services	B-PROC
use	O	O
data	O	O
from	O	O
a	O	O
sample	O	O
of	O	O
rural	B-DISO
CCI	O
adults	B-LIVB
who	O	O
reported	O	O
their	O	O
medical	O
,	O	O
mental	B-PHYS
health	I-PHYS
,	O	O
and	O	O
substance	O
use	O
treatment	O
utilization	O
behavior	O
every	O	O
60	O	O
days	O
for	O	O
1	O	O
.	O	O

5	O	O
years	O
.	O	O

LCGA	B-PROC
established	O	O
1	O
.	O
5	O
-	O
year	O
trajectories	O
and	O	O
demographic	O
correlates	O	O
of	O	O
health	B-PROC
services	I-PROC
among	O	O
rural	B-DISO
CCI	O
adults	B-LIVB
.	O	O

For	O	O
medical	B-PROC
services	I-PROC
,	O	O
three	O	O
classes	O	O
emerged	O	O
(	O	O
stable	O	O
-	O	O
low	O	O
users	B-LIVB
,	O	O
13	O	O
%	O	O
;	O	O
stable	O	O
-	O	O
intermediate	O	O
users	B-LIVB
,	O	O
40	O	O
%	O	O
;	O	O
and	O	O
stable	O	O
-	O	O
high	O	O
users	B-LIVB
,	O	O
47	O	O
%	O	O
)	O	O
.	O	O

For	O	O
mental	B-PHYS
health	I-PHYS
and	O	O
substance	O
use	O
services	B-PROC
,	O	O
three	O	O
classes	O	O
emerged	O	O
(	O	O
stable	O	O
-	O	O
low	O	O
,	O	O
69	O	O
%	O	O
and	O	O
61	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
low	O	O
-	O	O
baseline	O	O
-	O	O
increase	O	O
,	O	O
10	O	O
%	O	O
and	O	O
12	O	O
%	O	O
,	O	O
respectively	O	O
;	O	O
high	O	O
-	O	O
baseline	O	O
decline	O	O
,	O	O
21	O	O
%	O	O
and	O	O
28	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Employment	O
,	O	O
gender	B-PHYS
,	O	O
medication	B-DISO
usage	I-DISO
,	O	O
and	O	O
depression	B-DISO
severity	O
predicted	O	O
membership	O
across	O	O
all	O	O
services	B-PROC
.	O	O

Results	O	O
underscore	O	O
the	O	O
importance	O	O
of	O	O
social	B-LIVB
workers	I-LIVB
and	O	O
other	O	O
community	B-PROC
services	I-PROC
providers	B-LIVB
aligning	O	O
health	B-PROC
services	I-PROC
access	O	O
with	O	O
the	O	O
needs	O	O
of	O	O
the	O	O
CCI	O
population	O	O
,	O	O
and	O	O
highlight	O	O
CCI	O
adults	B-LIVB
as	O	O
being	O	O
at	O	O
risk	O
of	O	O
underservice	O	O
in	O	O
critical	O	O
prevention	B-PROC
and	O	O
intervention	B-PROC
domains	I-PROC
.	O	O

Data	O
set	O
of	O	O
interactomes	B-PHYS
and	O	O
metabolic	O
pathways	O
of	O	O
proteins	B-CHEM
differentially	O	O
expressed	B-PHYS
in	O	O
brains	B-ANAT
with	O	O
Alzheimer׳s	B-DISO
disease	I-DISO
Alzheimer׳s	B-DISO
disease	I-DISO
is	O	O
one	O	O
of	O	O
the	O	O
main	O	O
causes	O	O
of	O	O
dementia	B-DISO
in	O	O
the	O	O
elderly	B-LIVB
and	O	O
its	O	O
frequency	O
is	O	O
on	O	O
the	O	O
rise	O	O
worldwide	B-LIVB
.	O	O

It	O	O
is	O	O
considered	O	O
the	O	O
result	O	O
of	O	O
complex	O
interactions	O
between	O	O
genetic	O
and	O	O
environmental	O
factors	O
,	O	O
being	O	O
many	O	O
of	O	O
them	O	O
unknown	O	O
.	O	O

Therefore	O	O
,	O	O
there	O	O
is	O	O
a	O	O
dire	O	O
necessity	O	O
for	O	O
the	O	O
identification	O	O
of	O	O
novel	O	O
molecular	B-CHEM
players	I-CHEM
for	O	O
the	O	O
understanding	O	O
of	O	O
this	O	O
disease	B-DISO
.	O	O

In	O	O
this	O	O
data	O
article	O
we	O	O
determined	O	O
the	O	O
protein	B-PHYS
expression	I-PHYS
profiles	O	O
of	O	O
whole	O	O
protein	B-CHEM
extracts	B-OBJC
from	O	O
cortex	B-ANAT
regions	I-ANAT
of	I-ANAT
brains	I-ANAT
from	O	O
patients	B-LIVB
with	O	O
Alzheimer׳s	B-DISO
disease	I-DISO
in	O	O
comparison	O	O
to	O	O
a	O	O
normal	B-ANAT
brain	I-ANAT
.	O	O

We	O	O
identified	O
721	O	O
iTRAQ	B-CHEM
-	I-CHEM
labeled	I-CHEM
polypeptides	B-CHEM
with	O	O
more	O	O
than	O	O
95	O	O
%	O	O
in	O	O
confidence	O	O
.	O	O

We	O	O
analyzed	B-PROC
all	O	O
proteins	B-CHEM
that	O	O
changed	O	O
in	O	O
their	O	O
expression	O
level	O
and	O	O
located	O	O
them	O	O
in	O	O
the	O	O
KEGG	O
metabolic	O
pathways	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
the	O	O
mitochondrial	B-ANAT
complexes	I-ANAT
of	I-ANAT
the	I-ANAT
electron	I-ANAT
transport	I-ANAT
chain	I-ANAT
and	O	O
ATP	B-CHEM
synthase	I-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
analyzed	B-PROC
the	O	O
over	B-CHEM
-	I-CHEM
and	I-CHEM
sub	I-CHEM
-	I-CHEM
expressed	I-CHEM
polypeptides	I-CHEM
through	O	O
IPA	B-OBJC
software	I-OBJC
,	O	O
specifically	O	O
Core	O
I	O
and	O
Biomarkers	O
I	O
modules	O
.	O	O

Data	O
in	O	O
this	O	O
article	O
is	O	O
related	O	O
to	O	O
the	O	O
research	B-PROC
article	O
""""	O	O
Identification	O	O
of	O	O
proteins	B-CHEM
that	O	O
are	O	O
differentially	O	O
expressed	B-PHYS
in	O	O
brains	B-ANAT
with	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
using	O	O
iTRAQ	B-PROC
labeling	I-PROC
and	O	O
tandem	B-PROC
mass	I-PROC
spectrometry	I-PROC
""""	O	O
(	O	O
Minjarez	O	O
et	O	O
al	O	O
.	O	O
,	O	O
2016	O	O
)	O	O
[	O	O
1	O	O
]	O	O
.	O	O

Emergency	B-PROC
general	I-PROC
surgery	I-PROC
specific	O
frailty	O
index	O
:	O	O
A	O	O
validation	B-PROC
study	I-PROC
Assessment	B-PROC
of	O	O
operative	O
risk	O
in	O	O
geriatric	B-LIVB
patients	I-LIVB
undergoing	O	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
(	O	O
EGS	B-PROC
)	O	O
is	O	O
challenging	O	O
.	O	O

Frailty	B-DISO
is	O	O
an	O	O
established	O	O
measure	O
for	O	O
risk	B-PROC
assessment	I-PROC
in	O	O
surgical	O
cases	O
.	O	O

The	O	O
aim	O	O
of	O	O
our	O	O
study	B-PROC
was	O	O
to	O	O
validate	B-PROC
a	O	O
modified	O	O
15	O	O
variable	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
specific	I-PROC
frailty	I-PROC
index	I-PROC
(	O	O
EGSFI	B-PROC
)	O	O
.	O	O

We	O	O
prospectively	O	O
collected	O
geriatric	O
(	O	O
age	B-LIVB
>	I-LIVB
65	I-LIVB
)	O	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
patients	B-LIVB
for	O	O
1	O	O
-	O	O
year	O
.	O	O

Post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
were	O	O
collected	O
.	O	O

Frailty	O
Index	O
was	O	O
calculated	B-PROC
for	O	O
200	O	O
patients	B-LIVB
based	O	O
on	O	O
their	O	O
pre	O
-	O
admission	O
condition	O
using	O	O
50	O	O
-	O	O
variable	O
modified	O	O
Rockwood	O
Frailty	O
Index	O
(	O	O
FI	O
)	O	O
.	O	O

EGSFI	B-PROC
was	O	O
developed	O	O
based	O	O
on	O	O
the	O	O
regression	O
model	O
for	O	O
complications	B-DISO
and	O	O
the	O	O
most	O	O
significant	O	O
factors	O	O
in	O	O
the	O	O
FI	O
.	O	O

ROC	O
curve	O
analysis	O
was	O	O
performed	O	O
to	O	O
determine	O	O
cutoff	O
for	O	O
frail	B-DISO
status	O
.	O	O

We	O	O
validated	B-PROC
our	O	O
results	O
using	O	O
60	O	O
patients	B-LIVB
for	O	O
predicting	O
complications	B-DISO
.	O	O

A	O	O
total	O	O
of	O	O
260	O	O
patients	B-LIVB
(	O	O
200	O	O
developing	O	O
,	O	O
60	O	O
Validation	B-PROC
)	O	O
were	O	O
enrolled	B-PROC
in	O	O
this	O	O
study	B-PROC
.	O	O

Mean	B-PHYS
age	I-PHYS
was	O	O
71	O	O
±	O	O
11	O	O
years	O
,	O	O
and	O	O
33	O	O
%	O	O
developed	O	O
complications	B-DISO
.	O	O

Most	O	O
common	O
complications	B-DISO
were	O	O
pneumonia	B-DISO
(	O	O
12	O	O
%	O	O
)	O	O
,	O	O
UTI	B-DISO
(	O	O
9	O	O
%	O	O
)	O	O
,	O	O
and	O	O
wound	B-DISO
infection	I-DISO
(	O	O
7	O	O
%	O	O
)	O	O
.	O	O

Univariate	B-PROC
analysis	I-PROC
identified	O	O
15	O	O
variables	O
significantly	O	O
associated	O
with	O
complications	B-DISO
that	O	O
were	O	O
used	O	O
to	O	O
develop	O	O
the	O	O
EGSFI	B-PROC
.	O	O

A	O	O
cutoff	O
frailty	B-DISO
score	I-DISO
of	O	O
0	O	O
.	O	O

325	O	O
was	O	O
identified	O	O
using	O	O
ROC	O
curve	O
analysis	O
for	O	O
frail	B-DISO
status	O
.Sixty	O	O
-	O	O
patients	B-LIVB
(	O	O
frail	B-DISO
:	O	O
18	O	O
,	O	O
non	B-DISO
-	I-DISO
frail	I-DISO
:	O	O
42	O	O
)	O	O
were	O	O
enrolled	B-PROC
in	O	O
the	O	O
validation	B-PROC
cohort	B-LIVB
.	O	O

Frail	B-DISO
patients	B-LIVB
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
(	O	O
47	O	O
%	O	O
vs	O	O
.	O	O

20	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
compared	O	O
to	O	O
nonfrail	B-LIVB
patients	I-LIVB
.	O	O

Frail	B-DISO
status	O
based	O	O
on	O	O
EGSFI	B-PROC
was	O	O
a	O	O
significant	O
predictor	O
of	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
(	O	O
OR	O
=	O	O
7	O	O
.	O	O

3	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
7	O	O
-	O	O
19	O	O
.	O	O
8	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

006	O	O
)	O	O
.	O	O

Age	B-PHYS
was	O	O
not	O	O
associated	O
with	O
postoperative	B-DISO
complications	I-DISO
(	O	O
OR	O
=	O	O
0	O	O
.	O	O

99	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
0	O	O
.	O	O
92	O	O
-1	O	O
.	O	O
06	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
86	O	O
)	O	O
.	O	O

The	O	O
15	O	O
-	O	O
variable	O
validated	B-PROC
EGSFI	B-PROC
is	O	O
a	O	O
simple	O	O
and	O	O
reliable	O	O
bedside	B-OBJC
tool	I-OBJC
to	O	O
determine	O	O
the	O	O
frailty	B-DISO
status	I-DISO
of	O	O
patients	B-LIVB
undergoing	O	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
.	O	O

Frail	B-DISO
status	O
as	O	O
determined	O	O
by	O	O
Abstract	O	O
the	O	O
EGSFI	B-PROC
is	O	O
an	O	O
independent	O
predictor	O
of	O	O
post	B-DISO
-	I-DISO
operative	I-DISO
complications	I-DISO
and	O	O
mortality	O
in	O	O
geriatric	O
emergency	B-PROC
general	I-PROC
surgery	I-PROC
patients	B-LIVB
.	O	O

Level	O	O
II	O	O
,	O	O
Prognostic	B-PROC
Studies	I-PROC
-	O	O
Investigating	O
the	O	O
Effect	O
of	O	O
a	O	O
Patient	B-PHYS
Characteristic	I-PHYS
on	O	O
the	O	O
Outcome	B-DISO
of	I-DISO
Disease	I-DISO
.	O	O

Comparative	O	O
Epidemiologic	O
Characteristics	O
of	O	O
Pertussis	B-DISO
in	O	O
10	O	O
Central	B-GEOG
and	O	O
Eastern	B-GEOG
European	I-GEOG
Countries	I-GEOG
,	O	O
2000	O	O
-	O	O
2013	O	O
We	O	O
undertook	O	O
an	O	O
epidemiological	B-PROC
survey	I-PROC
of	O	O
the	O	O
annual	O
incidence	O
of	O	O
pertussis	B-DISO
reported	B-PROC
from	O	O
2000	O	O
to	O	O
2013	O	O
in	O	O
ten	O	O
Central	B-GEOG
and	O	O
Eastern	B-GEOG
European	I-GEOG
countries	I-GEOG
to	O	O
ascertain	O	O
whether	O	O
increased	O	O
pertussis	B-DISO
reports	O
in	O	O
some	O	O
countries	B-GEOG
share	O	O
common	O	O
underlying	O	O
drivers	O	O
or	O	O
whether	O	O
there	O	O
are	O	O
specific	O	O
features	O
in	O	O
each	O	O
country	B-GEOG
.	O	O

The	O	O
annual	O
incidence	O
of	O	O
pertussis	B-DISO
in	O	O
the	O	O
participating	O	O
countries	B-GEOG
was	O	O
obtained	O	O
from	O	O
relevant	O	O
government	O
institutions	O
and	O	O
/	O	O
or	O	O
national	O
surveillance	O
systems	O
.	O	O

We	O	O
reviewed	O
the	O	O
changes	O
in	O	O
the	O	O
pertussis	B-DISO
incidence	O
rates	O
in	O	O
each	O	O
country	B-GEOG
to	O	O
explore	O	O
differences	O
and	O	O
/	O	O
or	O	O
similarities	O
between	O	O
countries	B-GEOG
in	O	O
relation	O	O
to	O	O
pertussis	B-DISO
surveillance	O
;	O	O
case	O
definitions	O
for	O	O
detection	B-DISO
and	O	O
confirmation	O
of	O	O
pertussis	B-DISO
;	O	O
incidence	O
and	O	O
number	O
of	O
cases	O
of	O	O
pertussis	B-DISO
by	O	O
year	O
,	O	O
overall	O	O
and	O	O
by	O	O
age	B-LIVB
group	I-LIVB
;	O	O
population	B-LIVB
by	O	O
year	O
,	O	O
overall	O	O
and	O	O
by	O	O
age	B-LIVB
group	I-LIVB
;	O	O
pertussis	B-DISO
immunization	B-PROC
schedule	I-PROC
and	O	O
coverage	O
,	O	O
and	O	O
switch	O	O
from	O	O
whole	B-CHEM
-	I-CHEM
cell	I-CHEM
pertussis	I-CHEM
vaccines	I-CHEM
(	O	O
wP	B-CHEM
)	O	O
to	O	O
acellular	B-CHEM
pertussis	I-CHEM
vaccines	I-CHEM
(	O	O
aP	B-CHEM
)	O	O
.	O	O

There	O	O
was	O	O
heterogeneity	O
in	O	O
the	O	O
reported	B-PROC
annual	O
incidence	O
rates	O
and	O	O
trends	O	O
observed	O	O
across	O	O
countries	B-GEOG
.	O	O

Reported	B-PROC
pertussis	B-DISO
incidence	O
rates	O
varied	O	O
considerably	O	O
,	O	O
ranging	O	O
from	O	O
0	O	O
.	O	O

01	O	O
to	O	O
96	O	O
per	O	O
100	O	O
,	O	O
000	O	O
population	B-LIVB
,	O	O
with	O	O
the	O	O
highest	O
rates	O
generally	O	O
reported	B-PROC
in	O	O
Estonia	B-GEOG
and	O	O
the	O	O
lowest	O
in	O	O
Hungary	B-GEOG
and	O	O
Serbia	B-GEOG
.	O	O

The	O	O
greatest	O	O
burden	O
appears	O	O
for	O	O
the	O	O
most	O	O
part	O	O
in	O	O
infants	B-LIVB
(	O	O
<	O	O
1	O	O
year	O
)	O	O
in	O	O
Bulgaria	B-GEOG
,	O	O
Hungary	B-GEOG
,	O	O
Latvia	B-GEOG
,	O	O
Romania	B-GEOG
,	O	O
and	O	O
Serbia	B-GEOG
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
other	O	O
participating	O	O
countries	B-GEOG
where	O	O
the	O	O
burden	O
may	O	O
have	O	O
shifted	O	O
to	O	O
older	B-LIVB
children	I-LIVB
,	O	O
though	O	O
surveillance	O
of	O	O
adults	B-LIVB
may	O	O
be	O	O
inappropriate	O	O
.	O	O

There	O	O
was	O	O
no	O	O
consistent	O	O
pattern	O	O
associated	O
with	O
the	O	O
switch	O	O
from	O	O
wP	B-CHEM
to	O	O
aP	B-CHEM
vaccines	I-CHEM
on	O	O
reported	B-PROC
pertussis	B-DISO
incidence	O
rates	O
.	O	O

The	O	O
heterogeneity	O
in	O	O
reported	B-PROC
data	O
may	O	O
be	O	O
related	O	O
to	O	O
a	O	O
number	O	O
of	O	O
factors	O
including	O	O
surveillance	O
system	O
characteristics	O
or	O	O
capabilities	O
,	O	O
different	O	O
case	O
definitions	O
,	O	O
type	O
of	O	O
pertussis	B-DISO
confirmation	B-PROC
tests	I-PROC
used	O	O
,	O	O
public	O
awareness	B-DISO
of	O	O
the	O	O
disease	B-DISO
,	O	O
as	O	O
well	O	O
as	O	O
real	O	O
differences	O
in	O	O
the	O	O
magnitude	O
of	O	O
the	O	O
disease	B-DISO
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
these	O	O
factors	O
.	O	O

Our	O	O
study	O	O
highlights	O	O
the	O	O
need	O	O
to	O	O
standardize	O	O
pertussis	B-DISO
detection	B-DISO
and	O	O
confirmation	O
in	O	O
surveillance	B-PROC
programs	I-PROC
across	O	O
Europe	B-GEOG
,	O	O
complemented	O	O
with	O	O
carefully	O	O
-	O	O
designed	O	O
seroprevalence	B-PROC
studies	I-PROC
using	O	O
the	O	O
same	O	O
protocols	O
and	O	O
methodologies	B-PROC
.	O	O

Efficacy	O
of	O	O
a	O	O
coaxial	O	O
system	O	O
with	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
for	O	O
navigation	O
of	O	O
the	O	O
Penumbra	B-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
in	O	O
tortuous	B-DISO
arteries	I-DISO
:	O	O
technique	O
and	O	O
case	O
experience	B-PHYS
OBJECTIVE	O
The	O	O
authors	B-LIVB
describe	O	O
a	O	O
method	O
by	O	O
which	O	O
they	O	O
easily	B-DISO
and	O	O
atraumatically	O	O
navigate	O
a	O	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O	O
the	O	O
Penumbra	B-DEVI
system	I-DEVI
to	O	O
an	O	O
embolus	B-DISO
by	O	O
using	O	O
a	O	O
coaxial	O	O
system	O	O
with	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
in	O	O
patients	B-LIVB
with	O	O
tortuous	B-DISO
arteries	I-DISO
.	O	O

METHODS	O
A	O	O
retrospective	B-PROC
review	I-PROC
of	O	O
the	O	O
prospective	O	O
endovascular	B-ANAT
database	O
was	O	O
performed	O	O
to	O	O
identify	O
cases	O
in	O	O
which	O	O
a	O	O
coaxial	O	O
system	O	O
with	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
(	O	O
Scepter	B-DEVI
C	I-DEVI
,	O	O
MicroVention	B-DEVI
/	O	O
Terumo	B-DEVI
;	O	O
or	O	O
TransForm	B-DEVI
C	I-DEVI
,	O	O
Stryker	B-DEVI
Neurovascular	B-ANAT
)	O	O
and	O	O
a	O	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O	O
the	O	O
Penumbra	B-DEVI
system	I-DEVI
(	O	O
Penumbra	O
,	O
Inc	O
.	O
)	O	O
was	O	O
used	O	O
.	O	O

The	O	O
authors	B-LIVB
achieved	O	O
a	O	O
stable	O
guiding	B-DEVI
sheath	O
position	O
and	O	O
delivered	O
the	O	O
coaxial	O	O
system	O	O
with	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
and	O	O
a	O	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
.	O	O

Then	O	O
,	O	O
the	O	O
balloon	B-DEVI
was	O	O
inflated	O	O
somewhat	O	O
when	O	O
the	O	O
distal	O
tip	O
of	O	O
the	O	O
balloon	B-DEVI
was	O	O
slightly	O	O
advanced	O
from	O	O
the	O	O
tip	O
of	O	O
the	O	O
reperfusion	B-PHEN
catheter	B-DEVI
,	O	O
and	O	O
together	O
the	O	O
coaxial	O	O
system	O	O
was	O	O
advanced	O
to	O	O
an	O	O
embolus	B-DISO
over	O	O
a	O	O
0	O	O
.	O	O
014	O	O
-	O	O
in	O	O
guidewire	B-OBJC
,	O	O
even	O	O
around	O	O
the	O	O
corner	O
.	O	O

When	O	O
the	O	O
distal	O
tip	O
of	O	O
the	O	O
balloon	B-DEVI
catheter	I-DEVI
reached	O	O
the	O	O
embolus	B-DISO
,	O	O
the	O	O
authors	B-LIVB
deflated	O	O
the	O	O
balloon	B-DEVI
and	O	O
navigated	O
the	O	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
to	O	O
the	O	O
embolus	B-DISO
.	O	O

Finally	O	O
,	O	O
the	O	O
aspiration	B-PROC
of	O	O
the	O	O
embolus	B-DISO
with	O	O
the	O	O
Penumbra	B-DEVI
MAX	B-DEVI
pump	I-DEVI
was	O	O
begun	O	O
.	O	O

RESULTS	O
Between	O	O
May	O	O
2014	O	O
and	O	O
September	O	O
2015	O	O
,	O	O
the	O	O
authors	B-LIVB
used	O	O
this	O	O
technique	O
in	O	O
17	O	O
cases	O
:	O	O
16	O	O
cases	O
of	O	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
(	O	O
including	O	O
5	O	O
cases	O
of	O	O
internal	B-DISO
carotid	I-DISO
artery	I-DISO
occlusion	I-DISO
)	O	O
and	O	O
1	O	O
case	O
of	O	O
basilar	B-DISO
artery	I-DISO
occlusion	I-DISO
(	O	O
age	B-PHYS
range	O
36	O	O
-	O	O
88	O	O
years	O	O
,	O	O
mean	O
age	B-PHYS
74	O	O
.	O	O

7	O	O
years	O	O
,	O	O
13	O	O
men	B-LIVB
)	O	O
.	O	O

For	O	O
the	O	O
reperfusion	B-PHEN
catheter	B-DEVI
of	O	O
the	O	O
Penumbra	B-DEVI
system	I-DEVI
,	O	O
the	O	O
5MAX	B-DEVI
ACE	I-DEVI
was	O	O
used	O	O
in	O	O
15	O	O
cases	O
,	O	O
and	O	O
the	O	O
5MAX	B-DEVI
was	O	O
used	O	O
in	O	O
2	O	O
cases	O
.	O	O

As	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
,	O	O
the	O	O
Scepter	B-DEVI
C	I-DEVI
was	O	O
used	O	O
in	O	O
16	O	O
cases	O
,	O	O
and	O	O
the	O	O
TransForm	B-DEVI
C	I-DEVI
was	O	O
used	O	O
in	O	O
1	O	O
case	O
.	O	O

The	O	O
technique	O
was	O	O
successful	O
in	O	O
16	O	O
cases	O
(	O	O
94	O	O
.	O	O
1	O	O
%	O	O
)	O	O
.	O	O

No	O
parent	B-LIVB
artery	B-DISO
dissections	I-DISO
were	O	O
noted	O
in	O	O
any	O	O
cases	O
.	O	O

Catheter	B-DEVI
-induced	O	O
vasospasm	B-DISO
was	O	O
noted	O
in	O	O
1	O	O
case	O
,	O	O
but	O	O
the	O	O
vasospasm	B-DISO
was	O	O
transient	O
.	O	O

CONCLUSIONS	O
A	O	O
coaxial	O	O
system	O	O
with	O	O
a	O	O
compliant	O
balloon	B-DEVI
catheter	I-DEVI
can	O	O
help	O	O
safely	O	O
and	O	O
easily	B-DISO
to	O	O
navigate	O
the	O	O
large	B-DEVI
-	I-DEVI
bore	I-DEVI
reperfusion	B-PHEN
catheter	B-DEVI
of	O	O
the	O	O
Penumbra	B-DEVI
system	I-DEVI
to	O	O
an	O	O
embolus	B-DISO
in	O	O
patients	B-LIVB
with	O	O
tortuous	B-DISO
arteries	I-DISO
.	O	O

Hepatic	B-ANAT
and	O	O
renal	B-ANAT
toxicological	O
evaluations	B-PROC
of	O	O
an	O	O
industrial	O
ovotoxic	B-CHEM
chemical	I-CHEM
,	O	O
4	B-CHEM
-	I-CHEM
vinylcyclohexene	I-CHEM
diepoxide	I-CHEM
,	O	O
in	O	O
both	O	O
sexes	B-PHYS
of	O	O
Wistar	B-LIVB
rats	I-LIVB
4	B-CHEM
-	I-CHEM
Vinylcyclohexene	I-CHEM
diepoxide	I-CHEM
(	O	O
VCD	B-CHEM
)	O	O
is	O	O
an	O	O
industrial	O
occupational	O
health	B-CHEM
hazard	I-CHEM
chemical	I-CHEM
because	O	O
it	O	O
induces	O
ovotoxicity	B-DISO
in	O	O
rodents	B-LIVB
.	O	O

The	O	O
current	O	O
study	B-PROC
investigated	O
the	O	O
impacts	O	O
of	O	O
VCD	B-CHEM
on	O	O
selected	O	O
hepatic	B-ANAT
and	O	O
renal	B-ANAT
markers	B-PHYS
of	O	O
oxidative	B-DISO
stress	I-DISO
and	O	O
inflammation	B-DISO
in	O	O
both	O	O
sexes	B-PHYS
of	O	O
Wistar	B-LIVB
rats	I-LIVB
.	O	O

Thus	O	O
,	O	O
male	B-PHYS
and	O	O
female	B-PHYS
rats	B-LIVB
were	O	O
randomly	O
distributed	O
into	O	O
four	O	O
groups	O
of	O	O
ten	O	O
rats	B-LIVB
per	O	O
group	O
,	O	O
and	O	O
dosed	O
orally	O
with	O	O
VCD	B-CHEM
for	O	O
28	O	O
days	O
.	O	O

The	O	O
control	B-LIVB
male	B-PHYS
and	O	O
female	B-PHYS
groups	O
of	O	O
rats	B-LIVB
received	O
corn	B-CHEM
oil	I-CHEM
only	O	O
,	O	O
while	O	O
each	O	O
of	O	O
the	O	O
three	O	O
remaining	O
groups	O
of	O	O
both	O	O
sexes	B-PHYS
of	O	O
rats	B-LIVB
received	O
VCD	B-CHEM
(	O	O
100	O	O
,	O	O
250	O	O
and	O	O
500	O	O
mg	O
/	O
kg	O
BW	O
)	O	O
respectively	O	O
.	O	O

Thereafter	O	O
,	O	O
biomarkers	B-PHYS
of	O	O
hepatic	B-DISO
and	O	O
renal	B-DISO
oxidative	I-DISO
damage	I-DISO
,	O	O
inflammation	B-DISO
and	O	O
immunohistochemical	B-PROC
expressions	I-PROC
of	O	O
iNOS	B-CHEM
,	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
caspase	B-CHEM
-	I-CHEM
9	I-CHEM
and	O	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
were	O	O
evaluated	B-PROC
.	O	O

The	O	O
results	O	O
revealed	O
that	O	O
VCD	B-CHEM
increased	O
markers	B-PHYS
of	O	O
liver	B-PHYS
and	O	O
kidney	B-PHYS
functions	I-PHYS
,	O	O
oxidative	B-DISO
damage	I-DISO
and	O	O
inflammation	B-DISO
,	O	O
and	O	O
disrupted	O
the	O	O
antioxidant	B-PHEN
homeostasis	I-PHEN
of	O	O
the	O	O
rats	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Lastly	O	O
,	O	O
VCD	B-CHEM
enhanced	O	O
the	O	O
immunohistochemical	B-PROC
expressions	I-PROC
of	O	O
iNOS	B-CHEM
,	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
caspase	B-CHEM
-	I-CHEM
9	I-CHEM
and	O	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
in	O	O
the	O	O
liver	B-ANAT
of	O	O
the	O	O
rats	B-LIVB
.	O	O

Thus	O	O
,	O	O
our	O	O
data	O
imply	O	O
that	O	O
VCD	B-CHEM
induced	O
toxicity	B-DISO
in	O	O
the	O	O
liver	B-ANAT
and	O	O
kidney	B-ANAT
of	O	O
rats	B-LIVB
via	O	O
the	O	O
combined	O
impacts	O
of	O	O
oxidative	B-DISO
damage	I-DISO
and	O	O
inflammation	B-DISO
.	O	O

Combinatorial	B-CHEM
Library	I-CHEM
Screening	O
Coupled	O	O
to	O	O
Mass	B-PROC
Spectrometry	I-PROC
to	O	O
Identify	O	O
Valuable	O	O
Cyclic	B-CHEM
Peptides	I-CHEM
Combinatorial	B-CHEM
library	I-CHEM
screening	O
coupled	O	O
to	O	O
mass	B-PROC
spectrometry	I-PROC
(	I-PROC
MS	I-PROC
)	I-PROC
analysis	I-PROC
is	O	O
a	O	O
practical	O	O
approach	O
to	O	O
identify	O	O
useful	O	O
peptides	B-CHEM
.	O	O

Cyclic	B-CHEM
peptides	I-CHEM
can	O	O
have	O	O
high	O	O
biological	B-PHEN
activity	I-PHEN
,	O	O
selectivity	O
,	O	O
and	O	O
affinity	B-PHEN
for	O	O
target	O	O
proteins	B-CHEM
,	O	O
and	O	O
high	O	O
stability	O
against	O	O
proteolytic	B-PHYS
degradation	I-PHYS
.	O	O

Here	O	O
we	O	O
describe	O	O
two	O	O
strategies	O	O
to	O	O
prepare	O	O
combinatorial	B-CHEM
libraries	I-CHEM
suitable	O	O
for	O	O
MS	B-PROC
analysis	I-PROC
to	O	O
accelerate	O	O
the	O	O
discovery	B-PROC
of	O	O
cyclic	B-CHEM
peptide	I-CHEM
structures	O
.	O	O

Both	O	O
approaches	O
use	O	O
ChemMatrix	B-CHEM
resin	I-CHEM
and	O	O
the	O	O
linker	O	O
4	B-CHEM
-	I-CHEM
hydroxymethylbenzoic	I-CHEM
acid	I-CHEM
.	O	O

One	O	O
strategy	O	O
involves	O	O
the	O	O
synthesis	O
of	O	O
a	O	O
one	B-CHEM
-	I-CHEM
bead	I-CHEM
-	I-CHEM
two	I-CHEM
-	I-CHEM
peptides	I-CHEM
library	I-CHEM
in	O	O
which	O	O
each	O	O
bead	O	O
contains	O	O
both	O	O
the	O	O
cyclic	B-CHEM
peptide	I-CHEM
and	O	O
its	O	O
linear	O	O
counterpart	O	O
to	O	O
facilitate	O	O
MS	B-PROC
analysis	I-PROC
.	O	O

The	O	O
other	O	O
protocol	O	O
is	O	O
based	O	O
on	O	O
the	O	O
synthesis	O
of	O	O
a	O	O
cyclic	B-CHEM
depsipeptide	I-CHEM
library	I-CHEM
in	O	O
which	O	O
a	O	O
glycolamidic	B-CHEM
ester	I-CHEM
group	I-CHEM
is	O	O
incorporated	O	O
by	O	O
adding	O	O
glycolic	B-CHEM
acid	I-CHEM
.	O	O

After	O	O
library	B-CHEM
screening	O
,	O	O
the	O	O
ring	O	O
is	O	O
opened	O	O
and	O	O
the	O	O
peptide	B-CHEM
is	O	O
released	O	O
simultaneously	O	O
for	O	O
subsequent	O	O
MS	B-PROC
analysis	I-PROC
.	O	O

©	O	O
2016	O	O
by	O	O
John	O	O
Wiley	O	O
&	O	O
Sons	O	O
,	O	O
Inc	O	O
.	O	O

Women	B-LIVB
's	I-LIVB
Sexual	O
Issues	O
After	O	O
Myocardial	B-DISO
Infarction	I-DISO
:	O	O
A	O	O
Literature	O
Review	O
Sexual	O
activity	O
after	O	O
myocardial	B-DISO
infarction	I-DISO
(	O	O
MI	B-DISO
)	O	O
is	O	O
a	O	O
concern	O
for	O	O
patients	B-LIVB
and	O	O
often	O	O
a	O	O
challenge	O	O
for	O	O
health	B-LIVB
care	I-LIVB
professionals	I-LIVB
to	O	O
address	O	O
.	O	O

It	O	O
is	O	O
widely	O	O
recognized	O	O
that	O	O
most	O	O
patients	B-LIVB
,	O	O
of	O	O
both	O	O
sexes	B-PHYS
,	O	O
report	O	O
sexual	B-DISO
problems	I-DISO
or	O	O
concerns	O
after	O	O
MI	B-DISO
.	O	O

However	O	O
,	O	O
there	O	O
are	O	O
reported	O	O
differences	O	O
between	O	O
men	B-LIVB
and	O	O
women	B-LIVB
.	O	O

Women	B-LIVB
with	O	O
sexual	O
concerns	O
may	O	O
seek	O	O
less	O	O
help	O	O
from	O	O
health	B-LIVB
care	I-LIVB
providers	I-LIVB
and	O	O
are	O	O
more	O	O
inclined	O	O
to	O	O
conceal	O
them	O	O
because	O	O
of	O	O
cultural	B-DISO
barriers	I-DISO
.	O	O

The	O	O
aim	O
of	O	O
the	O	O
current	B-PROC
study	I-PROC
is	O	O
to	O	O
present	O	O
a	O	O
comprehensive	O	O
review	O
of	O
the	O
literature	O
describing	O	O
women	B-LIVB
's	I-LIVB
sexual	O
issues	O
after	O	O
MI	B-DISO
.	O	O

A	O	O
systematic	O	O
search	O	O
of	O	O
the	O	O
relevant	O	O
literature	O
was	O	O
performed	O	O
within	O	O
international	O
databases	O
,	O	O
including	O	O
PubMed	O
/	O	O
Medline	O
,	O	O
Scopus	O
,	O	O
ScienceDirect	O
,	O	O
and	O	O
ProQuest	O
,	O	O
as	O	O
well	O	O
as	O	O
Google	O
Scholar	O
using	O	O
relevant	O	O
keywords	O
.	O	O

Also	O	O
,	O	O
Persian	O
electronic	O
databases	O
such	O	O
as	O	O
Magiran	O
,	O	O
Scientific	O
Information	O
Databases	O
,	O	O
and	O	O
Iran	O
Medex	O
were	O	O
searched	O	O
from	O	O
the	O	O
inception	O	O
to	O	O
October	O	O
2014	O	O
.	O	O

Articles	O
focusing	O	O
on	O	O
the	O	O
sexual	O
issues	O
after	O	O
MI	B-DISO
only	O	O
in	O	O
women	B-LIVB
,	O	O
as	O	O
well	O	O
as	O	O
articles	O
on	O	O
both	O	O
sexes	B-PHYS
where	O	O
women	B-LIVB
's	I-LIVB
results	O	O
could	O	O
be	O	O
separated	O	O
,	O	O
were	O	O
included	O	O
in	O	O
this	O	O
review	B-PROC
.	O	O

A	O	O
total	O	O
of	O	O
8	O	O
articles	O
were	O	O
included	O	O
in	O	O
the	O	O
final	O	O
dataset	O
.	O	O

The	O	O
main	O	O
themes	O	O
of	O	O
women	B-LIVB
's	I-LIVB
sexual	O
concerns	O
after	O	O
MI	B-DISO
were	O	O
""""	O	O
loss	O
or	O	O
decrease	O
of	O	O
sexual	O
activity	O
,	O	O
""""	O	O
""""	O	O
dissatisfaction	B-DISO
of	I-DISO
sexual	I-DISO
relationship	I-DISO
,	O	O
""""	O	O
""""	O	O
doubt	B-PHYS
about	O	O
resumption	B-DISO
time	I-DISO
of	O	O
sexual	O
activity	O
,	O	O
""""	O	O
""""	O	O
fear	B-PHYS
of	O	O
reinfarction	B-DISO
or	O	O
sudden	B-DISO
death	I-DISO
during	O	O
sexual	O
activity	O
after	O	O
MI	B-DISO
,	O	O
""""	O	O
""""	O	O
knowledge	B-DISO
deficit	I-DISO
regarding	O	O
sexual	O
activity	O
after	O	O
MI	B-DISO
,	O	O
""""	O	O
and	O	O
""""	O	O
poor	O
performance	O
of	O	O
health	B-LIVB
care	I-LIVB
providers	I-LIVB
in	O	O
sexual	B-PROC
counseling	I-PROC
.	O	O
""""	O	O
The	O	O
results	O	O
of	O	O
this	O	O
review	B-PROC
demonstrate	O	O
that	O	O
women	B-LIVB
's	I-LIVB
post	O	O
-	O	O
MI	B-DISO
sexual	O
activity	O
is	O	O
affected	O	O
by	O	O
many	O	O
concerns	O
.	O	O

The	O	O
concerns	O
may	O	O
be	O	O
a	O	O
knowledge	B-DISO
deficit	I-DISO
related	O	O
to	O	O
not	O	O
receiving	O	O
necessary	O	O
consultation	B-PROC
on	O	O
this	O	O
topic	O	O
.	O	O

Nurses	B-LIVB
,	O	O
as	O	O
first	B-LIVB
-	I-LIVB
line	I-LIVB
care	I-LIVB
givers	I-LIVB
,	O	O
can	O	O
provide	O	O
appropriate	O	O
consultation	B-PROC
and	O	O
education	O	O
for	O	O
patients	B-LIVB
post	O	O
-	O	O
MI	B-DISO
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
breaking	O	O
taboo	O
imposed	O	O
by	O	O
cultural	B-DISO
barriers	I-DISO
,	O	O
personal	O	O
assumptions	O	O
,	O	O
or	O	O
lack	B-DISO
of	I-DISO
confidence	I-DISO
on	O	O
giving	O	O
sexual	B-PROC
consultation	I-PROC
may	O	O
ultimately	O	O
help	O	O
patients	B-LIVB
to	O	O
improve	O	O
their	O	O
quality	O
of	O
life	O
.	O	O

Effect	O	O
of	O	O
autohydrolysis	B-PHEN
on	O	O
the	O	O
wettability	O
,	O	O
absorbility	B-PHEN
and	O	O
further	O	O
alkali	B-CHEM
impregnation	B-PHEN
of	O	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
Autohydrolysis	B-PHEN
with	O	O
different	O	O
severity	O
factors	O
was	O	O
performed	O	O
on	O	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
prior	O	O
to	O	O
pulping	B-PHEN
,	O	O
and	O	O
the	O	O
wettability	O
,	O	O
absorbility	B-PHEN
and	O	O
the	O	O
following	O	O
impregnation	B-PHEN
of	O	O
NaOH	B-CHEM
solution	B-OBJC
for	O	O
the	O	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
were	O	O
then	O	O
investigated	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
after	O	O
autohydrolysis	B-PHEN
pretreatment	O
the	O	O
porosity	O
,	O	O
shrinkage	O
and	O	O
fiber	B-DISO
saturation	I-DISO
point	I-DISO
(	O	O
FSP	B-DISO
)	O	O
of	O	O
the	O	O
poplar	B-LIVB
wood	B-OBJC
chips	I-OBJC
were	O	O
increased	O
,	O	O
while	O	O
the	O	O
surface	O
contact	O
angle	O
decreased	O	O
as	O	O
the	O	O
severity	O
factor	O
was	O	O
increased	O
.	O	O

The	O	O
autohydrolyzed	B-PHEN
chips	B-OBJC
absorbed	B-PHEN
more	O	O
NaOH	B-CHEM
in	O	O
impregnation	B-PHEN
that	O	O
resulted	O	O
in	O	O
a	O	O
low	O	O
NaOH	B-CHEM
concentration	O
in	O	O
the	O	O
bulk	O	O
impregnation	B-PHEN
liquor	B-OBJC
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O
,	O	O
the	O	O
impregnation	B-PHEN
liquor	B-OBJC
outside	O	O
wood	B-OBJC
chips	I-OBJC
)	O	O
,	O	O
while	O	O
the	O	O
concentration	O
in	O	O
the	O	O
entrapped	B-DISO
liquor	B-OBJC
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O
,	O	O
the	O	O
impregnation	B-PHEN
liquor	B-OBJC
inside	O	O
wood	B-OBJC
chips	I-OBJC
)	O	O
was	O	O
increased	O
.	O	O

Autohydrolysis	B-PHEN
substantially	O	O
improved	B-DISO
the	O	O
effectiveness	O
of	O	O
alkali	B-CHEM
impregnation	B-PHEN
.	O	O

Effect	O
of	O	O
Transcatheter	B-PROC
Arterial	I-PROC
Chemoembolization	I-PROC
Combined	O	O
with	O	O
Argon	B-PROC
-	I-PROC
Helium	I-PROC
Cryosurgery	I-PROC
System	I-PROC
on	O	O
the	O	O
Changes	O
of	O	O
NK	B-ANAT
Cells	I-ANAT
and	O	O
T	B-ANAT
Cell	I-ANAT
Subsets	I-ANAT
in	O	O
Peripheral	B-ANAT
Blood	I-ANAT
of	O	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
Patients	B-LIVB
Hepatocellular	B-DISO
carcinoma	I-DISO
(	O	O
HCC	B-DISO
)	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
aggressive	O
tumors	B-DISO
in	O	O
humans	B-LIVB
.	O	O

T	B-ANAT
lymphocytes	I-ANAT
and	O	O
natural	B-ANAT
killer	I-ANAT
(	O	O
NK	B-ANAT
)	O	O
cells	B-ANAT
are	O	O
the	O	O
body	B-LIVB
's	I-LIVB
first	O	O
line	O	O
of	O	O
defense	B-PHYS
to	O	O
prevent	O
tumor	B-ANAT
cell	I-ANAT
growth	B-PHYS
.	O	O

Previous	B-PROC
studies	I-PROC
have	O	O
demonstrated	O	O
that	O	O
transcatheter	B-PROC
arterial	I-PROC
chemoembolization	I-PROC
(	O	O
TACE	B-PROC
)	O	O
combined	O	O
with	O	O
argon	B-PROC
-	I-PROC
helium	I-PROC
cryosurgery	I-PROC
system	I-PROC
(	O	O
AHCS	B-PROC
)	O	O
can	O	O
effectively	O
treat	B-PROC
liver	B-DISO
cancer	I-DISO
.	O	O

However	O	O
,	O	O
the	O	O
mechanism	O
of	O	O
the	O	O
treatment	B-PROC
is	O	O
unclear	B-DISO
yet	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O
the	O	O
effects	O
of	O
TACE	B-PROC
combined	O	O
with	O	O
AHCS	B-PROC
on	O	O
the	O	O
changes	O
of	O	O
T	B-ANAT
cell	I-ANAT
subsets	I-ANAT
and	O	O
NK	B-ANAT
cells	I-ANAT
in	O	O
peripheral	B-ANAT
blood	I-ANAT
of	O	O
HCC	B-DISO
.	O	O

Our	O	O
data	O
show	O	O
that	O	O
alpha	B-CHEM
-	I-CHEM
fetoprotein	I-CHEM
(	O	O
AFP	B-CHEM
)	O	O
levels	O
in	O	O
peripheral	B-ANAT
blood	I-ANAT
were	O	O
significantly	O	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
in	O	O
HCC	B-DISO
patients	B-LIVB
before	O	O
treatment	B-PROC
when	O	O
compared	O
with	O	O
healthy	O
people	B-LIVB
and	O	O
reduced	O
after	O	O
TACE	B-PROC
combined	O	O
with	O	O
AHCS	B-PROC
treatment	B-PROC
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
found	O	O
that	O	O
CD4	B-ANAT
+	I-ANAT
cells	I-ANAT
and	O	O
NK	B-ANAT
cells	I-ANAT
decreased	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
CD8	B-ANAT
+	I-ANAT
cells	I-ANAT
increased	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
in	O	O
HCC	B-DISO
patients	B-LIVB
when	O	O
compared	O
with	O	O
healthy	O
people	B-LIVB
.	O	O

After	O	O
treatment	B-PROC
,	O	O
the	O	O
CD4	B-ANAT
+	I-ANAT
cells	I-ANAT
,	O	O
CD4	B-ANAT
+	I-ANAT
/	O	O
CD8	B-ANAT
+	I-ANAT
ratio	O
,	O	O
and	O	O
NK	B-ANAT
cells	I-ANAT
were	O	O
dramatically	O	O
increased	O
in	O	O
HCC	B-DISO
patients	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
CD8	B-ANAT
+	I-ANAT
cells	I-ANAT
were	O	O
significantly	O	O
decreased	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

TACE	B-PROC
combined	O	O
with	O	O
AHCS	B-PROC
treatment	B-PROC
significantly	O	O
prolonged	O	O
1	O	O
-	O	O
year	O
survival	O
rate	O
of	O	O
HCC	B-DISO
patients	B-LIVB
and	O	O
did	O	O
not	O	O
show	O	O
significant	O	O
side	B-DISO
effects	I-DISO
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
data	O
indicate	O	O
that	O	O
TACE	B-PROC
combined	O	O
with	O	O
AHCS	B-PROC
treatment	B-PROC
improves	B-DISO
patients	B-LIVB
'	O	O
immune	B-ANAT
system	I-ANAT
.	O	O

It	O	O
is	O	O
a	O	O
feasible	O	O
and	O	O
effective	O
therapeutic	B-PROC
method	I-PROC
for	O	O
HCC	B-DISO
patients	B-LIVB
.	O	O

Identification	O
and	O	O
characterization	O
of	O	O
Dichelobacter	B-LIVB
nodosus	I-LIVB
serogroup	O
H	O
from	O	O
ovine	B-LIVB
footrot	B-DISO
in	O	O
India	B-GEOG
A	O	O
total	O	O
of	O	O
56	O	O
foot	B-OBJC
swabs	I-OBJC
were	O	O
collected	O	O
from	O	O
inter	B-ANAT
digital	I-ANAT
spaces	I-ANAT
of	O	O
sheep	B-LIVB
with	O	O
footrot	B-DISO
lesions	B-DISO
were	O	O
screened	B-PROC
for	O	O
16	O	O
rRNA	B-CHEM
of	O	O
Dichelobacter	B-LIVB
nodosus	I-LIVB
by	O	O
PCR	B-PROC
.	O	O

Out	O	O
of	O	O
the	O	O
56	O	O
samples	O
,	O	O
38	O	O
(	O	O
67	O	O
.	O	O

85	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
be	O	O
positive	B-DISO
.	O	O

All	O	O
the	O	O
positive	B-DISO
samples	O
were	O	O
subjected	O	O
to	O	O
multiplex	B-PROC
PCR	I-PROC
targeting	B-PROC
fimA	I-PROC
gene	I-PROC
for	O	O
identification	O
of	O	O
serogroups	O
of	O	O
D	B-LIVB
.	I-LIVB

nodosus	I-LIVB
.	O	O

Serogroup	O
H	O
was	O	O
found	O	O
along	O	O
with	O	O
serogroup	O
B	O
in	O	O
12	O	O
(	O	O
55	O	O
.	O	O
26	O	O
%	O	O
)	O	O
samples	O
and	O	O
with	O	O
serogroup	O
I	O
in	O	O
8	O	O
(	O	O
22	O	O
.	O	O

2	O	O
%	O	O
)	O	O
samples	O
.	O	O

The	O	O
serogroup	O
H	O
was	O	O
identified	O
for	O	O
the	O	O
first	O	O
time	O	O
from	O	O
the	O	O
Indian	B-GEOG
subcontinent	I-GEOG
.	O	O

The	O	O
phylogenetic	B-PROC
analysis	I-PROC
of	O	O
the	O	O
present	O	O
sequence	O
with	O	O
the	O	O
available	O	O
serogroup	O
H	O
sequences	O
of	O	O
GenBank	O
revealed	O	O
to	O	O
be	O	O
in	O	O
close	O	O
association	O	O
with	O	O
the	O	O
serotype	O
H1	O
.	O	O

Production	O	O
of	O	O
bioactive	B-OBJC
conjugated	B-CHEM
linoleic	I-CHEM
acid	I-CHEM
by	O	O
the	O	O
multifunctional	B-CHEM
enolase	B-CHEM
from	O	O
Lactobacillus	B-LIVB
plantarum	I-LIVB
Lactobacillus	B-LIVB
plantarum	I-LIVB
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
,	O	O
a	O	O
multifunctional	B-CHEM
-anchorless	O	O
-	O	O
surface	B-CHEM
protein	I-CHEM
belonging	O	O
to	O	O
the	O	O
conserved	O	O
family	O	O
of	O	O
enolases	B-CHEM
with	O	O
a	O	O
central	O	O
role	O	O
in	O	O
glycolytic	B-PHYS
metabolism	B-PHYS
,	O	O
was	O	O
characterized	O
to	O	O
have	O	O
a	O	O
side	O	O
role	O	O
in	O	O
the	O	O
intricate	B-PHYS
metabolism	I-PHYS
of	O	O
biohydrogenation	B-PHEN
of	O	O
linoleic	B-CHEM
acid	I-CHEM
,	O	O
catalyzing	B-PHEN
the	O	O
formation	O
of	O	O
bioactive	B-OBJC
9	B-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
11	I-CHEM
-	I-CHEM
trans	I-CHEM
-	I-CHEM
CLA	I-CHEM
through	O	O
dehydration	B-PHEN
and	O	O
isomerization	B-PHYS
of	O	O
10	B-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
12	I-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
octadecenoic	I-CHEM
acid	I-CHEM
.	O	O

The	O	O
identity	O	O
of	O	O
the	O	O
enolase	B-CHEM
was	O	O
confirmed	O	O
through	O	O
mass	B-PROC
spectrometric	I-PROC
analysis	I-PROC
that	O	O
showed	O	O
the	O	O
characteristic	O	O
442	O	O
amino	O
acid	O
sequence	O
with	O	O
a	O	O
molecular	O
mass	O
of	O	O
48	O	O
.	O	O

03	O	O
kDa	O
.	O	O

The	O	O
enolase	B-CHEM
was	O	O
not	O	O
capable	O	O
of	O	O
using	O	O
linoleic	B-CHEM
acid	I-CHEM
directly	O	O
as	O	O
a	O	O
substrate	B-OBJC
but	O	O
instead	O	O
uses	O	O
its	O	O
hydroxyl	B-CHEM
derivative	O
10	B-CHEM
-	I-CHEM
hydroxi	I-CHEM
-	I-CHEM
12	I-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
octadecenoic	I-CHEM
acid	I-CHEM
to	O	O
finally	O	O
form	O	O
bioactive	B-OBJC
conjugated	B-CHEM
linoleic	I-CHEM
acid	I-CHEM
.	O	O

Biochemical	O
optimization	O
studies	B-PROC
were	O	O
carried	O	O
out	O	O
to	O	O
elucidate	O	O
the	O	O
conditions	O	O
for	O	O
maximum	O	O
production	O	O
of	O	O
9	B-CHEM
-	I-CHEM
cis	I-CHEM
-	I-CHEM
11	I-CHEM
-	I-CHEM
trans	I-CHEM
-	I-CHEM
CLA	I-CHEM
and	O	O
maximum	O	O
stability	B-PHYS
of	O	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
when	O	O
catalyzing	B-PHEN
this	O	O
reaction	B-PHEN
.	O	O

Furthermore	O	O
,	O	O
through	O	O
structural	B-PROC
analysis	I-PROC
of	O	O
the	O	O
protein	B-CHEM
,	O	O
we	O	O
propose	O	O
the	O	O
binding	B-CHEM
sites	I-CHEM
of	O	O
substrate	B-OBJC
and	O	O
product	B-OBJC
molecules	B-OBJC
that	O	O
were	O	O
characterized	O
as	O	O
two	O	O
hydrophobic	O
superficial	O	O
pockets	O	O
located	O	O
at	O	O
opposite	O	O
ends	O	O
of	O	O
the	O	O
enolase	B-CHEM
connected	O	O
through	O	O
a	O	O
channel	B-CHEM
where	O	O
the	O	O
catalysis	B-PHEN
of	O	O
dehydration	B-PHEN
and	O	O
isomerization	B-PHYS
might	O	O
occur	O	O
.	O	O

These	O	O
results	O	O
prove	O	O
that	O	O
multifunctional	B-CHEM
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
also	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
cell	B-PHYS
detoxification	I-PHYS
from	O	O
polyunsaturated	B-CHEM
fatty	I-CHEM
acids	I-CHEM
such	O	O
as	O	O
linoleic	B-CHEM
acid	I-CHEM
,	O	O
along	O	O
with	O	O
the	O	O
linoleate	B-CHEM
isomerase	I-CHEM
complex	B-CHEM
.	O	O

The	O	O
""""	O	O
tight	O	O
orbit	O	O
""""	O	O
:	O	O
Incidence	O
and	O	O
management	B-PROC
of	O	O
the	O	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
The	O	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
(	O	O
OCS	B-DISO
)	O	O
constitutes	O	O
a	O	O
severe	O	O
emergency	B-PHEN
,	O	O
requiring	O	O
immediate	O
clinical	B-PROC
diagnosis	I-PROC
and	O	O
surgical	B-PROC
decompression	I-PROC
.	O	O

The	O	O
key	O	O
symptom	B-DISO
is	O	O
progressive	B-DISO
visual	I-DISO
impairment	I-DISO
caused	O	O
by	O	O
an	O	O
increase	O
in	O	O
intraorbital	B-PHYS
pressure	I-PHYS
,	O	O
impairing	O
the	O	O
perfusion	B-PROC
of	O	O
relevant	O
neurovascular	B-ANAT
and	O	O
neurosensory	B-ANAT
structures	I-ANAT
.	O	O

Intraorbital	B-DISO
bleeding	I-DISO
due	O	O
to	O	O
trauma	B-DISO
and	O	O
surgical	B-DISO
intervention	I-DISO
is	O	O
known	O	O
to	O	O
be	O	O
the	O	O
main	O	O
etiological	O	O
factor	O	O
.	O	O

A	O	O
retrospective	O
analysis	B-PROC
of	O	O
all	O	O
patients	B-LIVB
affected	O
by	O	O
an	O	O
OCS	B-DISO
between	O	O
January	O	O
1	O	O
,	O	O
2012	O	O
,	O	O
and	O	O
May	O	O
31	O	O
,	O	O
2015	O	O
,	O	O
was	O	O
performed	O
.	O	O

Patients	B-LIVB
'	I-LIVB
records	O
were	O	O
reviewed	O
with	O	O
regard	O	O
to	O	O
etiology	O
,	O	O
initial	O
ophthalmologic	O
status	O
,	O	O
fracture	B-DISO
pattern	I-DISO
,	O	O
concomitant	O
medication	O
,	O	O
surgical	B-PROC
management	I-PROC
,	O	O
and	O	O
postoperative	O
outcome	O
.	O	O

The	O	O
incidence	O
of	O	O
OCS	B-DISO
was	O	O
calculated	O
based	O	O
on	O	O
the	O	O
total	O
number	O
of	O	O
craniomaxillofacial	B-ANAT
(	O	O
CMF	B-ANAT
)	O	O
emergencies	B-DISO
.	O	O

Within	O	O
3	O	O
.	O	O
5	O	O
years	O
,	O	O
a	O	O
total	O	O
of	O	O
18	O	O
,	O	O
093	O	O
CMF	B-ANAT
emergencies	B-DISO
were	O	O
registered	B-PROC
.	O	O

In	O	O
16	O	O
patients	B-LIVB
,	O	O
an	O	O
OCS	B-DISO
was	O	O
documented	B-PROC
,	O	O
corresponding	O	O
to	O	O
an	O	O
incidence	O
of	O	O
0	O	O
.	O	O

088	O	O
%	O	O
.	O	O

The	O	O
mean	O
patient	B-LIVB
age	B-PHYS
was	O	O
67	O	O
.	O	O

31	O	O
±	O	O
23	O	O
.	O	O

86	O	O
years	O
,	O	O
ranging	O
from	O	O
22	O	O
to	O	O
102	O	O
years	O
.	O	O

The	O	O
etiology	O
varied	O	O
,	O	O
but	O	O
trauma	B-DISO
with	O	O
subsequent	O	O
intraorbital	B-DISO
bleeding	I-DISO
was	O	O
the	O	O
main	O	O
cause	B-DISO
.	O	O

The	O	O
use	O	O
of	O	O
anticoagulative	B-PROC
medication	I-PROC
was	O	O
documented	B-PROC
in	O	O
50	O	O
%	O	O
of	O	O
the	O	O
cases	O
.	O	O

In	O	O
14	O	O
patients	B-LIVB
,	O	O
immediate	O
surgical	B-PROC
orbital	I-PROC
decompression	I-PROC
was	O	O
performed	O
:	O	O
in	O	O
10	O	O
patients	B-LIVB
,	O	O
vision	B-PHYS
could	O	O
be	O	O
preserved	B-PROC
;	O	O
in	O	O
three	O	O
patients	B-LIVB
,	O	O
blindness	B-DISO
resulted	O
;	O	O
and	O	O
one	O	O
patient	B-LIVB
was	O	O
lost	O
to	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Two	O	O
patients	B-LIVB
were	O	O
managed	O	O
without	O	O
surgery	B-PROC
.	O	O

With	O	O
regard	O	O
to	O	O
the	O	O
total	O
number	O
of	O	O
CMF	B-ANAT
emergencies	B-DISO
,	O	O
OCS	B-DISO
is	O	O
a	O	O
rare	O
condition	O
.	O	O

Early	O
clinical	B-PROC
diagnosis	I-PROC
and	O	O
surgical	B-PROC
decompression	I-PROC
are	O	O
required	O
to	O	O
prevent	O
permanent	O
vision	B-DISO
impairment	I-DISO
.	O	O

Anticoagulative	B-PROC
medication	I-PROC
must	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
predisposing	O
factor	O
for	O	O
an	O	O
orbital	B-DISO
compartment	I-DISO
syndrome	I-DISO
in	O	O
patients	B-LIVB
affected	O
by	O	O
periorbital	O
trauma	O
.	O	O

Ammonia	B-CHEM
as	O	O
an	O	O
In	O
Situ	O
Sanitizer	B-DEVI
:	O	O
Influence	O
of	O	O
Virus	B-LIVB
Genome	O
Type	O
on	O	O
Inactivation	O
Treatment	O
of	O	O
human	B-LIVB
excreta	B-ANAT
and	O	O
animal	B-LIVB
manure	B-OBJC
(	O	O
HEAM	B-ANAT
)	O	O
is	O	O
key	O	O
in	O	O
controlling	B-PHEN
the	O	O
spread	O	O
of	O	O
persistent	O
enteric	O
pathogens	B-LIVB
,	O	O
such	O	O
as	O	O
viruses	B-LIVB
.	O	O

The	O	O
extent	O
of	O	O
virus	B-PROC
inactivation	I-PROC
during	O	O
HEAM	B-ANAT
storage	O
and	O	O
treatment	O
appears	O	O
to	O	O
vary	O	O
with	O	O
virus	B-LIVB
genome	O
type	O
,	O	O
although	O	O
the	O	O
reasons	O	O
for	O	O
this	O	O
variability	O
are	O	O
not	O	O
clear	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O
the	O	O
inactivation	O
of	O	O
viruses	B-LIVB
of	O	O
different	O
genome	O
types	O
under	O	O
conditions	O
representative	O	O
of	O	O
HEAM	B-ANAT
storage	O
or	O	O
mesophilic	O	O
digestion	B-PHYS
.	O	O

The	O	O
goals	O	O
were	O	O
to	O	O
characterize	O	O
the	O	O
influence	O
of	O	O
HEAM	B-ANAT
solution	O	O
conditions	O
on	O	O
inactivation	O
and	O	O
to	O	O
determine	O	O
the	O	O
potential	O
mechanisms	O
involved	O	O
.	O	O

Specifically	O	O
,	O	O
eight	O	O
viruses	B-LIVB
representing	O	O
the	O	O
four	O	O
viral	O
genome	O
types	O
(	O	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
[	O	O
ssRNA	B-CHEM
]	O	O
,	O	O
double	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
[	O	O
dsRNA	B-CHEM
]	O	O
,	O	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
[	O	O
ssDNA	B-CHEM
]	O	O
,	O	O
and	O	O
double	B-CHEM
-	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
[	O	O
dsDNA	B-CHEM
]	O	O
)	O	O
were	O	O
exposed	O
to	O
synthetic	B-OBJC
solutions	I-OBJC
with	O	O
well	O
-	O
controlled	O
temperature	O
(	O	O
20	O	O
to	O	O
35°C	O	O
)	O	O
,	O	O
pH	O
(	O	O
8	O	O
to	O	O
9	O	O
)	O	O
,	O	O
and	O	O
ammonia	B-CHEM
(	O	O
NH3	B-CHEM
)	O	O
concentrations	O
(	O	O
0	O	O
to	O	O
40	O	O
mmol	O	O
liter	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
.	O	O

DNA	B-CHEM
and	O	O
dsRNA	B-CHEM
viruses	B-LIVB
were	O	O
considerably	O	O
more	O	O
resistant	O
than	O	O
ssRNA	B-LIVB
viruses	I-LIVB
,	O	O
resulting	O
in	O
up	O	O
to	O	O
1	O	O
,	O	O
000	O	O
-	O	O
fold	O	O
-	O	O
longer	O	O
treatment	O
times	O	O
to	O	O
reach	O	O
a	O	O
4	O	O
-	O	O
log	O	O
inactivation	O
.	O	O

The	O	O
apparently	O	O
slower	O	O
inactivation	O
of	O	O
DNA	B-LIVB
viruses	I-LIVB
was	O	O
rationalized	O	O
by	O	O
the	O	O
higher	O	O
stability	B-PROC
of	O	O
DNA	B-CHEM
than	O	O
that	O	O
of	O	O
ssRNA	B-CHEM
in	O	O
HEAM	B-ANAT
.	O	O

Pushing	O	O
the	O	O
system	O	O
toward	O	O
harsher	B-DISO
pH	O
(	O	O
>	O	O
9	O	O
)	O	O
and	O	O
temperature	O
(	O	O
>	O	O
35°C	O	O
)	O	O
conditions	O
,	O	O
such	O	O
as	O	O
those	O	O
encountered	O	O
in	O	O
thermophilic	B-PHEN
digestion	B-PHYS
and	O	O
alkaline	O
treatments	O
,	O	O
led	O	O
to	O	O
more	O	O
consistent	O	O
inactivation	O
kinetics	B-PHEN
among	O	O
ssRNA	B-CHEM
and	O	O
other	O	O
viruses	B-LIVB
.	O	O

This	O	O
suggests	O
that	O	O
the	O	O
dependence	O	O
of	O	O
inactivation	O
on	O	O
genome	O
type	O
disappeared	O	O
in	O	O
favor	O	O
of	O	O
protein	B-CHEM
-mediated	O	O
inactivation	O
mechanisms	O
common	O	O
to	O	O
all	O	O
viruses	B-LIVB
.	O	O

Finally	O	O
,	O	O
we	O	O
recommend	O	O
the	O	O
use	O	O
of	O	O
MS2	B-LIVB
as	O	O
a	O	O
conservative	O	O
indicator	O
to	O	O
assess	O	O
the	O	O
inactivation	O
of	O	O
ssRNA	B-LIVB
viruses	I-LIVB
and	O	O
the	O	O
stable	O	O
ΦX174	B-LIVB
or	O	O
dsDNA	B-CHEM
phages	B-LIVB
as	O	O
indicators	O
for	O	O
persistent	O
viruses	B-LIVB
.	O	O

Viruses	B-LIVB
are	O	O
among	O	O
the	O	O
most	O	O
environmentally	O
persistent	O
pathogens	B-LIVB
.	O	O

They	O	O
can	O	O
be	O	O
present	B-DISO
in	O	O
high	O	O
concentrations	O
in	O	O
human	B-LIVB
excreta	B-ANAT
and	O	O
animal	B-LIVB
manure	B-OBJC
(	O	O
HEAM	B-ANAT
)	O	O
.	O	O

Therefore	O	O
,	O	O
appropriate	O
treatment	O
of	O	O
HEAM	B-ANAT
is	O	O
important	O	O
prior	O	O
to	O	O
its	O	O
reuse	O	O
or	O	O
discharge	B-ANAT
into	O	O
the	O	O
environment	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O
the	O	O
factors	O
that	O	O
determine	O	O
the	O	O
persistence	O	O
of	O	O
viruses	B-LIVB
in	O	O
HEAM	B-ANAT
,	O	O
and	O	O
we	O	O
determined	O	O
the	O	O
main	O	O
mechanisms	O
that	O	O
lead	O	O
to	O	O
their	O	O
inactivation	O
.	O	O

Unlike	O	O
other	O	O
organisms	B-LIVB
,	O	O
viruses	B-LIVB
can	O	O
have	O	O
four	O	O
different	O
genome	O
types	O
(	O	O
double	O	O
-	O	O
or	O	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
or	O	O
DNA	B-CHEM
)	O	O
,	O	O
and	O	O
the	O	O
viruses	B-LIVB
studied	O	O
herein	O	O
represent	O	O
all	O	O
four	O	O
types	O	O
.	O	O

Genome	O
type	O
appeared	O	O
to	O	O
be	O	O
the	O	O
major	O	O
determinant	O	O
for	O	O
persistence	O	O
.	O	O

Single	B-LIVB
-	I-LIVB
stranded	I-LIVB
RNA	I-LIVB
viruses	I-LIVB
are	O	O
the	O	O
most	O	O
labile	O	O
,	O	O
because	O	O
this	O	O
genome	O
type	O
is	O	O
susceptible	O	O
to	O	O
degradation	O
in	O	O
HEAM	B-ANAT
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
other	O	O
genome	O
types	O
are	O	O
more	O	O
stable	O	O
;	O	O
therefore	O	O
,	O	O
inactivation	O
is	O	O
slower	O	O
and	O	O
mainly	O	O
driven	O	O
by	O	O
the	O	O
degradation	O
of	O	O
viral	B-CHEM
proteins	I-CHEM
.	O	O

Overall	O	O
,	O	O
this	O	O
study	O	O
allows	O	O
us	O	O
to	O	O
better	O	O
understand	O	O
the	O	O
behavior	O
of	O	O
viruses	B-LIVB
in	O	O
HEAM	B-ANAT
.	O	O

An	O	O
electrochemical	B-PROC
genosensor	B-DEVI
for	O	O
Leishmania	O
major	O
detection	B-PROC
based	O	O
on	O	O
dual	O	O
effect	O
of	O	O
immobilization	B-PROC
and	O	O
electrocatalysis	B-PHEN
of	O	O
cobalt	B-CHEM
-	I-CHEM
zinc	I-CHEM
ferrite	I-CHEM
quantum	B-OBJC
dots	I-OBJC
Identification	O
of	O	O
Leishmania	O
parasites	O
is	O	O
important	O	O
in	O	O
diagnosis	B-DISO
and	O	O
clinical	B-PROC
studies	I-PROC
of	O	O
leishmaniasis	B-DISO
.	O	O

Although	O	O
epidemiological	B-PROC
and	O	O
clinical	O
methods	O
are	O	O
available	O	O
,	O	O
they	O	O
are	O	O
not	O	O
sufficient	O
for	O	O
identification	O
of	O	O
causative	B-DISO
agents	I-DISO
of	O	O
leishmaniasis	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
quantum	B-OBJC
dots	I-OBJC
of	O	O
magnetic	B-PHEN
cobalt	B-CHEM
-	I-CHEM
zinc	I-CHEM
ferrite	I-CHEM
(	O	O
Co0	B-CHEM
.	I-CHEM

5Zn0	I-CHEM
.	I-CHEM

5Fe2O4	I-CHEM
)	O	O
were	O	O
synthesized	O
and	O	O
characterized	O
by	O	O
physicochemical	B-PHEN
methods	I-PHEN
.	O	O

The	O	O
quantum	B-OBJC
dots	I-OBJC
were	O	O
then	O	O
employed	O	O
as	O	O
an	O	O
electrode	B-DEVI
modifier	B-DEVI
to	O	O
immobilize	O
a	O	O
24	O	O
-	O	O
mer	O	O
specific	O	O
single	B-CHEM
stranded	I-CHEM
DNA	B-CHEM
probe	I-CHEM
,	O	O
and	O	O
fabrication	O	O
of	O	O
a	O	O
label	O	O
-	O	O
free	O	O
,	O	O
PCR	O	O
-	O	O
free	O	O
and	O	O
signal	O	O
-	O	O
on	O	O
electrochemical	B-PROC
genosensor	B-DEVI
for	O	O
the	O	O
detection	B-PROC
of	O	O
Leishmania	O
major	O
.	O	O

Hybridization	B-PROC
of	O	O
the	O	O
complementary	B-CHEM
single	B-CHEM
stranded	I-CHEM
DNA	O
sequence	O
with	O	O
the	O	O
probe	B-CHEM
under	O	O
the	O	O
selected	O
conditions	O
was	O	O
explored	O	O
using	O	O
methylene	B-CHEM
blue	I-CHEM
as	O	O
a	O	O
redox	B-PHYS
marker	I-PHYS
,	O	O
utilizing	O	O
the	O	O
electrocatalytic	B-PHEN
effect	O
of	O	O
the	O	O
quantum	B-OBJC
dots	I-OBJC
on	O	O
the	O	O
methylene	B-CHEM
blue	I-CHEM
electroreduction	B-PHEN
process	B-PHEN
.	O	O

The	O	O
genosensor	B-DEVI
could	O	O
detect	B-PROC
a	O	O
synthetic	B-CHEM
single	I-CHEM
stranded	I-CHEM
DNA	I-CHEM
target	I-CHEM
in	O	O
a	O	O
range	O
of	O	O
1	O	O
.	O	O

0×10	O	O
(	O	O
-	O	O
11	O	O
)	O	O
to	O	O
1	O	O
.	O	O

0×10	O	O
(	O	O
-	O	O
18	O	O
)	O	O
molL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
with	O	O
a	O	O
limit	O
of	O
detection	O
of	O	O
2	O	O
.	O	O

0×10	O	O
(	O	O
-	O	O
19	O	O
)	O	O
molL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
and	O	O
genomic	B-CHEM
DNA	I-CHEM
in	O	O
a	O	O
range	O
of	O	O
7	O	O
.	O	O

31×10	O	O
(	O	O
-	O	O
14	O	O
)	O	O
to	O	O
7	O	O
.	O	O

31×10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
ngμL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
with	O	O
a	O	O
limit	O
of	O
detection	O
of	O	O
1	O	O
.	O	O

80×10	O	O
(	O	O
-	O	O
14	O	O
)	O	O
ngμL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
with	O	O
a	O	O
high	O
selectivity	O
and	O	O
sensitivity	O
.	O	O

Associations	O
of	O	O
Body	B-PHYS
Mass	I-PHYS
Index	I-PHYS
and	O	O
Physical	O
Activity	O
With	O	O
Sexual	B-DISO
Dysfunction	I-DISO
in	O	O
Breast	B-DISO
Cancer	I-DISO
Survivors	B-LIVB
Sexual	B-DISO
dysfunction	I-DISO
is	O	O
a	O	O
common	O	O
and	O	O
distressing	B-DISO
consequence	O
of	O
breast	B-DISO
cancer	I-DISO
(	O	O
BC	B-DISO
)	O	O
treatment	B-PROC
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O	O
the	O	O
sexual	B-PHYS
functioning	I-PHYS
of	O	O
BC	B-DISO
patients	B-LIVB
and	O	O
its	O	O
association	B-PHYS
with	O	O
women	B-LIVB
's	I-LIVB
personal	B-PHYS
characteristics	O
and	O	O
cancer	B-PROC
treatments	I-PROC
.	O	O

In	O	O
this	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
,	O	O
sexual	B-PHYS
function	I-PHYS
was	O	O
assessed	O	O
using	O	O
the	O	O
Female	O
Sexual	O
Function	O
Index	O
(	O	O
FSFI	O
)	O	O
.	O	O

The	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O	O
HRQOL	O
)	O	O
was	O	O
measured	O	O
using	O	O
the	O	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O	O
EORTC	O
)	O	O
QLQ	O
-	O
C30	O
and	O	O
its	O	O
breast	O
module	O
BR	O
-	O
23	O
.	O	O

Of	O	O
the	O	O
235	O	O
participants	B-LIVB
approached	O	O
,	O	O
216	O	O
participants	B-LIVB
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
63	O	O
patients	B-LIVB
reported	O	O
no	B-DISO
sexual	I-DISO
activity	I-DISO
in	O	O
the	O	O
last	O	O
month	O
and	O	O
thus	O	O
were	O	O
analyzed	O	O
only	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
sexual	B-PHYS
desire	I-PHYS
domain	O
of	O	O
FSFI	O
.	O	O

A	O	O
total	O	O
of	O	O
154	O	O
(	O	O
71	O	O
.	O	O
3	O	O
%	O	O
)	O	O
patients	B-LIVB
were	O	O
classified	O	O
with	O	O
hypoactive	B-DISO
sexual	I-DISO
desire	I-DISO
disorder	I-DISO
(	O	O
HSDD	B-DISO
)	O	O
.	O	O

From	O	O
those	O	O
patients	B-LIVB
reporting	O	O
sexual	O
activity	O
in	O	O
the	O	O
last	O	O
month	O
,	O	O
63	O	O
.	O	O
3	O	O
%	O	O
(	O	O
97	O	O
out	O	O
of	O	O
153	O	O
)	O	O
were	O	O
classified	O	O
with	O	O
sexual	B-DISO
dysfunction	I-DISO
.	O	O

Using	O	O
hierarchical	B-PROC
logistic	I-PROC
regression	I-PROC
,	O	O
the	O	O
variance	O	O
explained	O	O
(	O	O
change	O	O
in	O	O
R	O	O
(	O	O
2	O	O
)	O	O
)	O	O
by	O	O
the	O	O
addition	O	O
of	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
and	O	O
mild	O	O
to	O	O
moderate	O	O
physical	O
activity	O
in	O	O
the	O	O
prediction	O
models	O
of	O	O
sexual	B-DISO
dysfunction	I-DISO
and	O	O
HSDD	B-DISO
were	O	O
6	O	O
.	O	O
8	O	O
and	O	O
7	O	O
.	O	O
2	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Age	B-PHYS
,	O	O
BMI	B-PHYS
,	O	O
and	O	O
physical	O
activity	O
were	O	O
independently	O	O
associated	O	O
with	O	O
sexual	B-DISO
dysfunction	I-DISO
and	O	O
HSDD	B-DISO
.	O	O

Additionally	O	O
,	O	O
BC	B-DISO
patients	B-LIVB
with	O	O
sexual	B-DISO
dysfunction	I-DISO
reported	O	O
lower	O
scores	O
on	O	O
global	O	O
HRQOL	O
,	O	O
role	O	O
functioning	O
,	O	O
and	O	O
fatigue	B-DISO
.	O	O

Based	O	O
on	O	O
our	O	O
findings	B-DISO
,	O	O
BC	B-DISO
survivors	B-LIVB
should	O	O
be	O	O
encouraged	O	O
to	O	O
practice	B-PHYS
regular	O	O
physical	O
activity	O
and	O	O
to	O	O
lose	O
weight	O
in	O	O
order	O	O
to	O	O
avoid	O	O
sexual	B-DISO
dysfunction	I-DISO
.	O	O

However	O	O
,	O	O
future	O	O
clinical	B-PROC
trials	I-PROC
are	O	O
needed	O	O
to	O	O
confirm	O	O
these	O	O
findings	B-DISO
.	O	O

The	O	O
N	B-CHEM
-	I-CHEM
Methyl	I-CHEM
d	I-CHEM
-	I-CHEM
Aspartate	I-CHEM
Glutamate	I-CHEM
Receptor	I-CHEM
Antagonist	I-CHEM
Ketamine	B-CHEM
Disrupts	O
the	O	O
Functional	O
State	O
of	O	O
the	O	O
Corticothalamic	B-ANAT
Pathway	O
The	O	O
non	O
-	O
competitive	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
d	I-CHEM
-	I-CHEM
aspartate	I-CHEM
glutamate	I-CHEM
receptor	I-CHEM
(	I-CHEM
NMDAR	I-CHEM
)	I-CHEM
antagonist	I-CHEM
ketamine	B-CHEM
elicits	O	O
a	O	O
brain	B-ANAT
state	O
resembling	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
states	O
for	O	O
developing	O	O
psychosis	B-DISO
and	O	O
early	O
stages	O
of	O	O
schizophrenia	B-DISO
characterized	O
by	O	O
sensory	B-DISO
and	O	O
cognitive	B-DISO
deficits	I-DISO
and	O	O
aberrant	O	O
ongoing	O
gamma	B-PHYS
oscillations	I-PHYS
(	O	O
30	O	O
-	O	O
80	O	O
Hz	O	O
)	O	O
in	O	O
cortical	B-ANAT
and	O	O
subcortical	B-ANAT
structures	O
,	O	O
including	O	O
the	O	O
thalamus	B-ANAT
.	O	O

The	O	O
underlying	O	O
mechanisms	O
are	O	O
unknown	O
.	O	O

The	O	O
goal	O
of	O	O
the	O	O
present	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
whether	O	O
a	O	O
ketamine	B-CHEM
-	O	O
induced	O
psychotic	B-DISO
-	O	O
relevant	O
state	O
disturbs	O
the	O	O
functional	O
state	O
of	O	O
the	O	O
corticothalamic	B-ANAT
(	O	O
CT	B-ANAT
)	O	O
pathway	O
.	O	O

Multisite	B-PROC
field	I-PROC
recordings	I-PROC
were	O	O
performed	O
in	O	O
the	O	O
somatosensory	B-ANAT
CT	I-ANAT
system	I-ANAT
of	O	O
the	O	O
sedated	B-DISO
rat	B-LIVB
.	O	O

Baseline	O
activity	O
was	O	O
challenged	O	O
by	O	O
activation	O
of	O	O
vibrissa	B-ANAT
-	O	O
related	O
prethalamic	B-ANAT
inputs	O
.	O	O

The	O	O
sensory	O
-	O	O
evoked	B-PHYS
thalamic	I-PHYS
response	I-PHYS
was	O	O
characterized	O
by	O	O
a	O	O
short	O
-	O	O
latency	O
(	O	O
∼4	O	O
ms	O	O
)	O	O
prethalamic	B-ANAT
-mediated	O	O
negative	O
sharp	O	O
potential	B-PHYS
and	O	O
a	O	O
longer	O
latency	O
(	O	O
∼10	O	O
ms	O	O
)	O	O
CT	B-ANAT
-mediated	O	O
negative	O
potential	B-PHYS
.	O	O

Following	O	O
a	O	O
single	O
subcutaneous	O
injection	O
of	O	O
ketamine	B-CHEM
(	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
spontaneously	O
occurring	O	O
and	O	O
sensory	O
-	O	O
evoked	B-PHYS
thalamic	I-PHYS
gamma	I-PHYS
oscillations	I-PHYS
increased	O
and	O	O
decreased	O
in	O	O
power	O
,	O	O
respectively	O	O
.	O	O

The	O	O
power	O
of	O	O
the	O	O
sensory	O
-related	O	O
gamma	B-PHYS
oscillations	I-PHYS
was	O	O
positively	B-DISO
correlated	O
with	O	O
both	O	O
the	O	O
amplitude	O
and	O	O
the	O	O
area	O
under	O
the	O
curve	O
of	O	O
the	O	O
corresponding	O	O
CT	B-ANAT
potential	B-PHYS
but	O	O
not	O	O
with	O	O
the	O	O
prethalamic	B-ANAT
potential	B-PHYS
.	O	O

The	O	O
present	O
results	O
show	O	O
that	O	O
the	O	O
layer	B-ANAT
VI	I-ANAT
CT	B-ANAT
pathway	O
significantly	O	O
contributes	O
in	O	O
thalamic	B-ANAT
gamma	B-PHYS
oscillations	I-PHYS
,	O	O
and	O	O
they	O	O
support	O	O
the	O	O
hypothesis	O
that	O	O
reduced	O
NMDAR	B-CHEM
activation	B-PHYS
disturbs	O
the	O	O
functional	O
state	O
of	O	O
CT	B-ANAT
and	O	O
corticocortical	B-ANAT
networks	B-PHYS
.	O	O

Combination	B-CHEM
of	O	O
telmisartan	B-CHEM
with	O	O
sildenafil	B-CHEM
ameliorate	O
progression	B-DISO
of	O	O
diabetic	B-DISO
nephropathy	I-DISO
in	O	O
streptozotocin	B-CHEM
-	O	O
induced	O
diabetic	B-DISO
model	O	O
Diabetic	B-DISO
nephropathy	I-DISO
(	O	O
DN	B-DISO
)	O	O
is	O	O
a	O	O
leading	O	O
cause	O	O
of	O	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
in	O	O
the	O	O
world	O	O
.	O	O

Several	O	O
signaling	B-PHYS
pathways	I-PHYS
are	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
DN	B-DISO
including	O	O
elevation	O
in	O	O
level	O	O
of	O	O
angiotensin	B-CHEM
II	I-CHEM
,	O	O
formation	O
of	O	O
advanced	B-CHEM
glycation	I-CHEM
end	I-CHEM
products	I-CHEM
(	O	O
AGE	B-CHEM
)	O	O
,	O	O
activation	B-PHYS
of	O	O
protein	B-CHEM
kinase	I-CHEM
c	I-CHEM
(	O	O
PKC	B-CHEM
)	O	O
,	O	O
and	O	O
lipid	B-DISO
accumulation	I-DISO
.	O	O

These	O	O
pathways	B-PHYS
activate	O
one	O	O
another	O	O
mutually	O	O
leading	O	O
to	O	O
oxidative	B-DISO
stress	I-DISO
,	O	O
increasing	O	O
expression	B-PHYS
of	O	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
-	I-CHEM
1	I-CHEM
(	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
1	I-CHEM
)	O	O
and	O	O
release	O
of	O	O
interleukins	B-CHEM
and	O	O
adhesion	B-CHEM
molecules	I-CHEM
,	O	O
so	O	O
the	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
interrupt	O	O
more	O	O
than	O	O
pathogenic	B-DISO
pathway	O
to	O	O
ameliorate	O
the	O	O
progression	B-DISO
of	O	O
DN	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
white	B-LIVB
male	I-LIVB
rats	I-LIVB
(	O	O
N	O	O
=	O	O
48	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
six	O	O
groups	O	O
(	O	O
8	O	O
rats	B-LIVB
each	O	O
)	O	O
,	O	O
the	O	O
first	O	O
two	O	O
groups	O	O
served	O	O
as	O	O
normal	B-LIVB
control	I-LIVB
and	O	O
a	O	O
control	B-LIVB
vehicle	I-LIVB
group	I-LIVB
while	O	O
the	O	O
remaining	O	O
four	O	O
groups	O	O
were	O	O
rendered	O	O
diabetic	B-DISO
by	O	O
a	O	O
single	O	O
intraperitoneal	B-PROC
injection	I-PROC
of	O	O
Streptozotocin	B-CHEM
(	O	O
STZ	B-CHEM
)	O	O
and	O	O
being	O	O
left	O	O
for	O	O
4	O	O
weeks	O	O
to	O	O
develop	O	O
DN	B-DISO
.	O	O

Thereafter	O	O
,	O	O
the	O	O
rats	B-LIVB
were	O	O
divided	O	O
into	O	O
DN	B-DISO
group	O	O
,	O	O
DN	B-DISO
group	O	O
receiving	O	O
Telmisartan	B-CHEM
or	O	O
Sildenafil	B-CHEM
or	O	O
Telmisartan	B-CHEM
Sildenafil	B-CHEM
combination	B-CHEM
.	O	O

After	O	O
the	O	O
specified	O
treatment	O
period	O
,	O	O
urine	B-ANAT
samples	I-ANAT
were	O	O
collected	O
(	O	O
using	O	O
metabolic	B-OBJC
cages	I-OBJC
)	O	O
to	O	O
measure	O	O
proteinuria	B-DISO
,	O	O
animals	B-LIVB
were	O	O
then	O	O
euthanized	O
,	O	O
blood	B-ANAT
and	O	O
tissue	O
samples	O
were	O	O
collected	O
for	O	O
measurement	B-PROC
of	I-PROC
Blood	I-PROC
glucose	I-PROC
,	O	O
BUN	B-PROC
,	O	O
S	B-PROC
.	I-PROC

Cr	I-PROC
,	O	O
LDL	B-PROC
,	O	O
NO	B-PROC
,	O	O
TGF	B-PROC
-	I-PROC
β1	I-PROC
,	O	O
IL	B-PROC
-	I-PROC
1β	I-PROC
,	O	O
AGEPs	B-PROC
,	O	O
and	O	O
SOD	B-PROC
.	O	O

The	O	O
combination	B-PROC
therapy	I-PROC
showed	O	O
significant	O	O
decrease	O	O
in	O	O
BUN	B-CHEM
,	O	O
S	B-CHEM
.	I-CHEM

Cr	I-CHEM
,	O	O
LDL	B-CHEM
,	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O	O
Proteinuria	B-DISO
and	O	O
AGEPs	B-CHEM
and	O	O
significant	O	O
increase	O	O
in	O	O
SOD	B-CHEM
and	O	O
NO	B-CHEM
.	O	O

The	O	O
findings	O	O
showed	O	O
that	O	O
combination	B-PROC
therapy	I-PROC
was	O	O
able	O	O
to	O	O
ameliorate	O
DN	B-DISO
and	O	O
that	O	O
the	O	O
effects	O	O
were	O	O
superior	O
to	O	O
the	O	O
single	O	O
drugs	B-CHEM
alone	O	O
.	O	O

Analysis	B-PROC
of	O	O
Low	O
-	O
Biomass	O
Microbial	B-LIVB
Communities	I-LIVB
in	O	O
the	O	O
Deep	O
Biosphere	O
Over	O	O
the	O	O
past	O	O
few	O
decades	O
,	O	O
the	O	O
subseafloor	O
biosphere	O
has	O	O
been	O	O
explored	O	O
by	O	O
scientific	O
ocean	O
drilling	O
to	O	O
depths	O
of	O	O
about	O	O
2	O	O
.	O	O
5	O	O
km	O	O
below	O	O
the	O	O
seafloor	O
.	O	O

Although	O	O
organic	O
-	O
rich	O
anaerobic	O
sedimentary	O
habitats	O
in	O	O
the	O	O
ocean	O
margins	O
harbor	O
large	O	O
numbers	O	O
of	O	O
microbial	B-LIVB
cells	I-LIVB
,	O	O
microbial	B-LIVB
populations	I-LIVB
in	O	O
ultraoligotrophic	O
aerobic	O
sedimentary	O
habitats	O
in	O	O
the	O	O
open	O	O
ocean	O
gyres	O
are	O	O
several	O	O
orders	O	O
of	O	O
magnitude	O
less	O	O
abundant	O
.	O	O

Despite	O	O
advances	O	O
in	O	O
cultivation	O
-	O
independent	O
molecular	O
ecological	O
techniques	O
,	O	O
exploring	O	O
the	O	O
low	O
-	O
biomass	O
environment	O
remains	O	O
technologically	O
challenging	O
,	O	O
especially	O	O
in	O	O
the	O	O
deep	O
subseafloor	O
biosphere	O
.	O	O

Reviewing	O
the	O	O
historical	O
background	O
of	O	O
deep	O
-	O
biosphere	O
analytical	O
methods	O
,	O	O
the	O	O
importance	O
of	O	O
obtaining	O	O
clean	B-OBJC
samples	I-OBJC
and	O	O
tracing	B-DISO
contamination	O
,	O	O
as	O	O
well	O	O
as	O	O
methods	O
for	O	O
detecting	B-DISO
microbial	B-LIVB
life	O
,	O	O
technological	O
aspects	O
of	O	O
molecular	O
microbiology	O
,	O	O
and	O	O
detecting	B-DISO
subseafloor	O
metabolic	B-PHYS
activity	I-PHYS
will	O	O
be	O	O
discussed	O	O
.	O	O

Novel	O
immunotherapeutic	B-PROC
strategies	I-PROC
to	O	O
target	O
alloantibody	B-CHEM
-producing	O	O
B	B-ANAT
and	O	O
plasma	B-ANAT
cells	I-ANAT
in	O	O
transplantation	B-PROC
There	O	O
is	O	O
an	O	O
unmet	O	O
need	O	O
for	O	O
immunotherapeutic	B-CHEM
agents	I-CHEM
that	O	O
target	O
humoral	B-PHYS
alloimmunity	I-PHYS
in	O	O
solid	B-PROC
organ	I-PROC
transplantation	I-PROC
.	O	O

This	O	O
includes	O	O
sensitized	B-LIVB
patients	I-LIVB
with	O	O
preformed	O	O
donor	B-LIVB
-specific	O	O
human	B-CHEM
leucocyte	I-CHEM
antigen	I-CHEM
antibodies	B-CHEM
and	O	O
patients	B-LIVB
who	O	O
develop	O	O
de	O
-	O
novo	O
donor	B-LIVB
-specific	O	O
antibodies	B-CHEM
,	O	O
both	O	O
of	O	O
which	O	O
are	O	O
associated	O
with	O
acute	O
and	O	O
chronic	O
antibody	B-DISO
-	I-DISO
mediated	I-DISO
rejection	I-DISO
and	O	O
allograft	B-PROC
loss	O
.	O	O

In	O	O
this	O	O
review	O
,	O	O
we	O	O
discuss	O	O
recent	O	O
progress	O
in	O	O
the	O	O
generation	O
of	O	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
and	O	O
plasma	B-ANAT
cell	I-ANAT
-targeted	O	O
therapeutics	B-PROC
,	O	O
with	O	O
an	O	O
emphasis	O	O
on	O	O
novel	O
agents	B-CHEM
.	O	O

To	O	O
deplete	O
or	O	O
inhibit	O
B	B-ANAT
cells	I-ANAT
,	O	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
-specific	O	O
mAbs	B-CHEM
have	O	O
been	O	O
developed	O	O
,	O	O
including	O	O
CD20	B-CHEM
,	O	O
CD22	B-CHEM
,	O	O
CD19	B-CHEM
and	O	O
bi	O	O
-	O	O
specific	O	O
antibodies	B-CHEM
that	O	O
target	O
two	O	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
antigens	B-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
inhibition	O
of	O	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
-	O	O
activating	B-PHYS
cytokines	B-CHEM
,	O	O
such	O	O
as	O	O
B	B-CHEM
cell	I-CHEM
-	I-CHEM
activating	I-CHEM
factor	I-CHEM
,	O	O
may	O	O
also	O	O
reduce	O	O
allo	B-PHYS
-	I-PHYS
B	I-PHYS
-	I-PHYS
cell	I-PHYS
activation	I-PHYS
.	O	O

Plasma	B-ANAT
cells	I-ANAT
remain	O	O
a	O	O
difficult	O	O
therapeutic	B-PROC
target	O
,	O	O
but	O	O
inhibition	O
of	O	O
germinal	O
centre	O
responses	B-PHYS
via	O	O
costimulatory	O	O
blockade	O
or	O	O
IL21	B-CHEM
neutralization	O
,	O	O
induction	O
of	O	O
plasma	B-ANAT
cell	I-ANAT
apoptosis	B-PHYS
using	O	O
proteasome	B-CHEM
inhibitors	I-CHEM
or	O	O
disruption	O
of	O	O
the	O	O
plasma	B-ANAT
cell	I-ANAT
niche	O	O
are	O	O
potential	O	O
avenues	O	O
being	O	O
explored	O	O
.	O	O

The	O	O
ultimate	O	O
aim	O
of	O	O
these	O	O
animal	B-LIVB
and	O	O
human	B-PROC
studies	I-PROC
is	O	O
to	O	O
develop	O	O
agents	O	O
that	O	O
efficiently	O	O
target	O
humoral	B-ANAT
effectors	I-ANAT
,	O	O
whilst	O	O
sparing	O	O
B	B-ANAT
and	O	O
plasma	B-ANAT
cells	I-ANAT
with	O	O
a	O	O
regulatory	O
capacity	B-DISO
to	O	O
promote	O	O
long	O	O
-	O	O
term	O	O
allograft	B-PROC
survival	B-PHYS
,	O	O
but	O	O
we	O	O
remain	O	O
some	O	O
distance	O	O
away	O	O
from	O	O
this	O	O
goal	O
.	O	O

Survival	B-DISO
status	I-DISO
and	O	O
functional	O
outcome	O
of	O	O
children	B-LIVB
who	O	O
required	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O	O
cardiac	B-PROC
surgery	I-PROC
Children	B-LIVB
who	O	O
require	O	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O	O
cardiac	B-PROC
surgery	I-PROC
are	O	O
at	O
risk	O
of	O	O
high	O
mortality	O
.	O	O

The	O	O
long	O
-	O
term	O
survival	B-DISO
and	O	O
functional	O
outcome	O
of	O	O
these	O	O
children	B-LIVB
have	O	O
not	O	O
been	O	O
studied	O	O
in	O	O
detail	O
.	O	O

Children	B-LIVB
who	O	O
stayed	B-DISO
in	O	O
intensive	B-PROC
care	I-PROC
for	O	O
>	O	O
28	O	O
days	O
after	O	O
cardiac	B-PROC
surgery	I-PROC
from	O	O
1997	O	O
to	O	O
2012	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
single	O	O
institution	O
.	O	O

A	O	O
total	O	O
of	O	O
116	O	O
patients	B-LIVB
were	O	O
identified	O
;	O	O
107	O	O
(	O	O
92	O	O
%	O	O
)	O	O
were	O	O
<	O	O
1	O	O
year	O
of	O
age	O
and	O	O
63	O	O
(	O	O
54	O	O
%	O	O
)	O	O
had	O	O
univentricular	B-DISO
physiology	I-DISO
.	O	O

The	O	O
incidence	O
of	O	O
children	B-LIVB
requiring	O	O
prolonged	O
intensive	B-PROC
care	I-PROC
increased	O
from	O	O
1	O	O
.	O	O
01	O	O
/	O	O
100	O	O
undergoing	O	O
cardiac	B-PROC
surgery	I-PROC
in	O	O
1997	O	O
to	O	O
2000	O	O
to	O	O
2	O	O
.	O	O
66	O	O
/	O	O
100	O	O
in	O	O
2009	O	O
to	O	O
2012	O	O
(	O	O
P	O	O
trend	O	O
=	O	O
.002	O	O
)	O	O
.	O	O

This	O	O
increase	O
coincided	O	O
with	O	O
an	O	O
increase	O
in	O	O
the	O	O
number	O
of	O	O
children	B-LIVB
with	O	O
hypoplastic	B-DISO
left	I-DISO
heart	I-DISO
syndrome	I-DISO
having	O	O
prolonged	O
intensive	B-PROC
care	I-PROC
during	O	O
the	O	O
same	O	O
period	O
(	O	O
0	O	O
.	O	O
13	O	O
/	O	O
100	O	O
in	O	O
1997	O	O
-	O	O
2000	O	O
to	O	O
1	O	O
.	O	O
0	O	O
/	O	O
100	O	O
in	O	O
2009	O	O
-	O	O
2012	O	O
;	O	O
P	O	O
trend	O	O
=	O	O
.001	O	O
)	O	O
.	O	O

Survival	B-DISO
to	O	O
pediatric	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
(	O	O
PICU	B-OBJC
)	O	O
discharge	B-PROC
was	O	O
74	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
,	O	O
65	O	O
-	O	O
82	O	O
)	O	O
and	O	O
51	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
41	O	O
-	O	O
59	O	O
)	O	O
at	O	O
3	O	O
years	O
.	O	O

Factors	O
associated	O
with	O
mortality	O
were	O	O
univentricular	B-PROC
repair	I-PROC
(	O	O
hazard	O
ratio	O
[	O	O
HR	O
]	O	O
,	O	O
2	O	O
.	O	O
12	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
21	O	O
-	O	O
3	O	O
.	O	O
70	O	O
;	O	O
P	O	O
=	O	O
.008	O	O
)	O	O
and	O	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
(	O	O
HR	O
,	O	O
3	O	O
.	O	O
01	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
77	O	O
-	O	O
5	O	O
.	O	O
12	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
but	O	O
era	O	O
did	O	O
not	O	O
influence	O
mortality	O
(	O	O
1997	O	O
-	O	O
2005	O	O
vs	O	O
2006	O	O
-	O	O
2012	O	O
;	O	O
log	O	O
-	O	O
rank	O	O
P	O	O
=	O	O
.66	O	O
)	O	O
.	O	O

Among	O	O
PICU	B-OBJC
survivors	B-LIVB
,	O	O
3	O	O
-	O	O
year	O
survival	B-DISO
in	O	O
those	O	O
who	O	O
did	O	O
not	O	O
need	O	O
early	O
reoperation	B-PROC
was	O	O
81	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
66	O	O
-	O	O
90	O	O
)	O	O
,	O	O
compared	O
with	O	O
58	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
42	O	O
-	O	O
71	O	O
)	O	O
in	O	O
those	O	O
who	O	O
required	O
early	O
reoperation	B-PROC
(	O	O
log	O	O
-	O	O
rank	O	O
P	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

Among	O	O
survivors	B-LIVB
,	O	O
36	O	O
%	O	O
had	O	O
either	O	O
moderate	B-DISO
or	O	O
severe	B-DISO
disability	I-DISO
and	O	O
13	O	O
%	O	O
had	O	O
poor	B-DISO
quality	I-DISO
of	I-DISO
life	I-DISO
.	O	O

The	O	O
incidence	O
of	O	O
children	B-LIVB
requiring	O	O
prolonged	O
intensive	B-PROC
care	I-PROC
after	O	O
cardiac	B-PROC
surgery	I-PROC
has	O	O
increase	O
d	O	O
in	O	O
our	O	O
institution	O
.	O	O

Our	O	O
data	O
suggest	O
that	O	O
the	O	O
long	O
-	O
term	O
outcome	O
for	O	O
most	O	O
of	O	O
these	O	O
children	B-LIVB
is	O	O
poor	O
,	O	O
especially	O	O
after	O	O
univentricular	B-PROC
repair	I-PROC
.	O	O

Haptic	B-PHYS
feedback	B-PHYS
helps	O	O
bipedal	B-ANAT
coordination	B-PHYS
The	O	O
present	O	O
study	B-PROC
investigated	O
whether	O	O
special	O
haptic	B-PHYS
or	O	O
visual	B-PHYS
feedback	I-PHYS
would	O	O
facilitate	O	O
the	O	O
coordination	B-PHYS
of	O	O
in	O
-	O
phase	O
,	O	O
cyclical	O
feet	B-ANAT
movements	B-PHYS
of	O	O
different	O
amplitudes	O
.	O	O

Seventeen	O	O
healthy	B-LIVB
participants	I-LIVB
sat	O	O
with	O	O
their	O	O
feet	B-ANAT
on	O	O
sliding	O
panels	B-OBJC
that	O	O
were	O	O
moved	O
externally	O
over	O	O
the	O	O
same	O	O
or	O	O
different	O
amplitudes	O
.	O	O

The	O	O
participants	B-LIVB
were	O	O
asked	O	O
to	O	O
generate	O
simultaneous	O
knee	B-ANAT
flexion	O
-	O
extension	O
movements	B-PHYS
,	O	O
or	O	O
to	O	O
let	O	O
their	O	O
feet	B-ANAT
be	O	O
dragged	B-DISO
,	O	O
resulting	O
in	O
reference	O
foot	B-ANAT
displacements	B-PROC
of	O	O
150	O	O
mm	O	O
and	O	O
experimental	O
foot	B-ANAT
displacements	B-PROC
of	O	O
150	O	O
,	O	O
120	O	O
,	O	O
or	O	O
90	O	O
mm	O	O
.	O	O

Four	O	O
types	O	O
of	O	O
feedback	B-PHYS
were	O	O
given	O	O
:	O	O
(	O	O
1	O	O
)	O	O
special	O
haptic	B-PHYS
feedback	B-PHYS
,	O	O
involving	O
actively	O	O
following	O
the	O	O
motions	O
of	O	O
the	O	O
sliders	B-DEVI
manipulated	B-PROC
by	O	O
two	O	O
confederates	B-LIVB
,	O	O
(	O	O
2	O	O
)	O	O
haptic	B-PHYS
feedback	B-PHYS
resulting	O	O
from	O	O
passive	B-PHYS
motion	I-PHYS
,	O	O
(	O	O
3	O	O
)	O	O
veridical	O
visual	B-PHYS
feedback	I-PHYS
,	O	O
and	O	O
(	O	O
4	O	O
)	O	O
enhanced	O
visual	B-PHYS
feedback	I-PHYS
.	O	O

Both	O	O
with	O	O
respect	O	O
to	O	O
amplitude	O
assimilation	B-PHYS
effects	O
,	O	O
correlations	O
and	O	O
standard	O
deviation	O
of	O	O
relative	O
phase	O
,	O	O
the	O	O
results	B-PHEN
showed	O	O
that	O	O
enhanced	O
visual	B-PHYS
feedback	I-PHYS
did	O	O
not	O	O
facilitate	O	O
bipedal	B-ANAT
independence	O
,	O	O
but	O	O
haptic	B-PHYS
feedback	B-PHYS
with	O	O
active	B-PHYS
movement	I-PHYS
did	O	O
.	O	O

Implications	O	O
of	O	O
the	O	O
findings	B-DISO
for	O	O
movement	B-PHYS
rehabilitation	B-DISO
contexts	O
are	O	O
discussed	O	O
.	O	O

Synthesis	O
and	O	O
in	O
vitro	O
bone	B-ANAT
cell	I-ANAT
activity	O
of	O	O
analogues	B-CHEM
of	O	O
the	O	O
cyclohexapeptide	B-CHEM
dianthin	I-CHEM
G	I-CHEM
The	O	O
cyclohexapeptide	B-CHEM
natural	I-CHEM
product	I-CHEM
dianthin	I-CHEM
G	I-CHEM
promotes	O
osteoblast	B-PHYS
(	I-PHYS
bone	I-PHYS
-	I-PHYS
forming	I-PHYS
cell	I-PHYS
)	I-PHYS
proliferation	I-PHYS
in	O
vitro	O
at	O	O
nanomolar	O
concentrations	O
,	O	O
and	O	O
is	O	O
therefore	O	O
considered	O	O
a	O	O
promising	O	O
candidate	O	O
for	O	O
the	O	O
treatment	O
of	O	O
osteoporosis	B-DISO
.	O	O

An	O	O
N	B-CHEM
(	I-CHEM
α	I-CHEM
)	I-CHEM
-	I-CHEM
methyl	I-CHEM
amide	I-CHEM
bond	I-CHEM
scan	O	O
of	O	O
dianthin	B-CHEM
G	I-CHEM
was	O	O
performed	O
to	O	O
probe	O
the	O	O
effect	O
of	O	O
modifying	O	O
amide	B-CHEM
bonds	I-CHEM
on	O	O
osteoblast	B-PHYS
proliferation	I-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
to	O	O
provide	O	O
greater	O	O
structural	O
diversity	O
,	O	O
a	O	O
series	O	O
of	O	O
dicarba	B-CHEM
dianthin	I-CHEM
G	I-CHEM
analogues	I-CHEM
was	O	O
synthesised	O
using	O	O
ring	B-PHEN
closing	I-PHEN
metathesis	I-PHEN
.	O	O

Dianthin	B-CHEM
G	I-CHEM
and	O	O
one	O	O
novel	O
dicarba	B-CHEM
analogue	I-CHEM
increased	O
the	O	O
number	O	O
of	O	O
human	B-LIVB
osteoblasts	B-ANAT
and	O	O
importantly	O	O
they	O	O
did	O	O
not	O	O
increase	O
osteoclast	B-PHYS
(	I-PHYS
bone	I-PHYS
-	I-PHYS
resorbing	I-PHYS
cell	I-PHYS
)	I-PHYS
differentiation	I-PHYS
in	O	O
bone	B-ANAT
marrow	I-ANAT
cells	I-ANAT
.	O	O

Effects	O
of	O	O
grazing	B-PHYS
cow	I-PHYS
diet	B-OBJC
on	O	O
volatile	B-CHEM
compounds	I-CHEM
as	O	O
well	O	O
as	O	O
physicochemical	B-PHEN
and	O	O
sensory	O
characteristics	O
of	O	O
12	O	O
-	O	O
month	O
-	O	O
ripened	B-OBJC
Montasio	I-OBJC
cheese	I-OBJC
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
effects	O
of	O	O
pasture	O
type	O	O
and	O	O
cow	B-LIVB
feeding	O
supplementation	B-OBJC
level	O	O
on	O	O
a	O	O
12	O	O
-	O	O
mo	O
-	O	O
ripened	B-OBJC
Montasio	I-OBJC
protected	O
designation	O
of	O
origin	O
(	O	O
PDO	O
)	O	O
cheese	B-OBJC
,	O	O
which	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
important	O	O
PDO	O
cheeses	B-OBJC
produced	O	O
in	O	O
northeast	B-GEOG
Italy	I-GEOG
.	O	O

Cheeses	B-OBJC
were	O	O
characterized	O
for	O	O
volatile	B-CHEM
compounds	I-CHEM
,	O	O
color	O
,	O	O
mechanical	O
variables	O
,	O	O
and	O	O
sensory	O
descriptors	O
.	O	O

Pasture	O
type	O	O
significantly	O
affected	O
most	O	O
of	O	O
the	O	O
instrumental	O
variables	O
considered	O	O
and	O	O
,	O	O
as	O	O
a	O	O
consequence	O	O
,	O	O
sensory	O
properties	O	O
were	O	O
affected	O
as	O	O
well	O	O
.	O	O

Cheeses	B-OBJC
from	O	O
the	O	O
pasture	O
characterized	O
by	O	O
a	O	O
nutrient	B-OBJC
-	I-OBJC
rich	I-OBJC
vegetation	B-OBJC
type	O	O
were	O	O
higher	O	O
in	O	O
protein	B-CHEM
and	O	O
lower	O	O
in	O	O
fat	B-CHEM
content	O	O
.	O	O

Furthermore	O	O
,	O	O
such	O	O
cheeses	B-OBJC
,	O	O
evaluated	B-PROC
by	O	O
a	O	O
sensory	B-LIVB
panel	I-LIVB
,	O	O
were	O	O
more	O	O
intense	O
in	O	O
color	O
with	O	O
a	O	O
more	O	O
pungent	B-PHEN
and	O	O
less	O	O
cow	B-PHEN
-	I-PHEN
like	I-PHEN
odor	I-PHEN
,	O	O
in	O	O
agreement	O	O
with	O	O
what	O	O
found	O	O
through	O	O
instrumental	O
analyses	B-PROC
.	O	O

Supplementation	B-OBJC
level	O	O
resulted	O	O
in	O	O
less	O	O
pronounced	O	O
effects	O
,	O	O
limited	O	O
to	O	O
volatile	B-CHEM
compounds	I-CHEM
and	O	O
texture	O
properties	O	O
,	O	O
which	O	O
were	O	O
not	O	O
detected	O	O
by	O	O
sensory	O
analysis	B-PROC
.	O	O

The	O	O
characterization	O
of	O	O
the	O	O
12	O	O
-	O	O
mo	O
ripened	B-OBJC
Montasio	I-OBJC
cheese	I-OBJC
reported	O	O
here	O	O
is	O	O
an	O	O
important	O	O
step	O	O
for	O	O
the	O	O
valorization	O
of	O	O
this	O	O
PDO	O
product	B-OBJC
.	O	O

Conservation	B-PROC
education	I-PROC
and	O	O
habitat	O
restoration	O
for	O	O
the	O	O
endangered	B-LIVB
Sagalla	B-LIVB
caecilian	I-LIVB
(	O	O
Boulengerula	B-LIVB
niedeni	I-LIVB
)	O	O
in	O	O
Sagalla	B-GEOG
Hill	I-GEOG
,	O	O
Kenya	B-GEOG
The	O	O
Sagalla	B-LIVB
caecilian	I-LIVB
(	O	O
Boulengerula	B-LIVB
niedeni	I-LIVB
)	O	O
is	O	O
an	O	O
endangered	B-LIVB
amphibian	B-LIVB
endemic	O
to	O	O
Sagalla	B-GEOG
Hill	I-GEOG
in	O	O
the	O	O
Taita	B-GEOG
Hills	I-GEOG
.	O	O

This	O	O
burrowing	O
worm	O
-like	O	O
species	O
prefers	O	O
soft	O
soil	B-OBJC
with	O	O
high	O
moisture	B-OBJC
and	O	O
organic	B-OBJC
matter	I-OBJC
.	O	O

The	O	O
major	O
threats	O
to	O	O
the	O	O
Sagalla	B-LIVB
caecilian	I-LIVB
are	O	O
soil	B-PHEN
erosion	I-PHEN
caused	O
by	O	O
steep	O
slopes	O
,	O	O
bare	O	O
ground	B-GEOG
and	O	O
water	B-PHEN
siphoning	I-PHEN
/	O	O
soil	B-PHEN
hardening	I-PHEN
from	O	O
exotic	B-LIVB
eucalyptus	I-LIVB
trees	I-LIVB
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
get	O	O
a	O	O
better	O
understanding	B-PHYS
of	O	O
the	O	O
local	O
people	B-LIVB
's	I-LIVB
attitude	B-PHYS
towards	O	O
this	O	O
species	O
and	O	O
how	O	O
they	O	O
can	O	O
contribute	O
to	O	O
its	O	O
continued	O
conservation	O
through	O	O
restoration	O
of	O	O
its	O	O
remaining	O
habitat	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
it	O	O
was	O	O
found	B-DISO
that	O	O
96	O	O
%	O	O
of	O	O
Sagalla	B-GEOG
people	B-LIVB
are	O	O
aware	B-PHYS
of	O	O
the	O	O
species	O
,	O	O
its	O	O
habits	O
and	O	O
its	O	O
association	O	O
with	O	O
soils	B-OBJC
high	O
in	O	O
organic	B-OBJC
matter	I-OBJC
.	O	O

It	O	O
was	O	O
also	O	O
found	B-DISO
that	O	O
96	O	O
%	O	O
of	O	O
Sagalla	B-GEOG
people	B-LIVB
use	O	O
organic	O
manure	B-OBJC
from	O	O
cow	B-LIVB
dung	B-ANAT
in	O	O
their	O	O
farms	O
.	O	O

Habitat	O
restoration	O
through	O	O
planting	O
of	O	O
indigenous	O
plants	B-LIVB
was	O	O
found	B-DISO
to	O	O
be	O	O
ongoing	O
,	O	O
especially	O
on	O	O
compounds	B-CHEM
of	O	O
public	O
institutions	O
as	O	O
well	O	O
as	O	O
on	O	O
private	O
lands	O
.	O	O

Although	O	O
drought	B-PHEN
was	O	O
found	B-DISO
to	O	O
be	O	O
a	O	O
challenge	O	O
for	O	O
seedlings	B-LIVB
development	O
especially	O	O
on	O	O
the	O	O
low	O
elevation	O
sites	O
,	O	O
destruction	O
by	O	O
livestock	B-LIVB
especially	O	O
during	O
the	O	O
dry	O
season	O
is	O	O
also	O	O
a	O	O
major	O
threat	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
it	O	O
was	O	O
recommended	O
that	O	O
any	O	O
future	O
habitat	O
restoration	O
initiative	B-PHYS
should	O	O
include	O
strong	O
chain	B-OBJC
-	I-OBJC
link	I-OBJC
fencing	O
to	O	O
protect	O	O
the	O	O
seedlings	B-LIVB
from	O	O
livestock	B-LIVB
activity	O
.	O	O

Recognizing	O	O
that	O	O
the	O	O
preferred	O
habitats	O
for	O	O
the	O	O
species	O
are	O	O
in	O	O
the	O	O
valleys	O
,	O	O
systematic	O
planting	O
of	O	O
keystone	B-LIVB
plant	I-LIVB
species	O
such	O	O
as	O	O
fig	B-LIVB
trees	I-LIVB
(	O	O
Ficus	B-LIVB
)	O	O
creates	O
the	O	O
best	O	O
microhabitats	O
.	O	O

These	O	O
are	O	O
better	O
than	O	O
general	O
woodlots	O
of	O	O
indigenous	O
trees	B-LIVB
.	O	O

The	O	O
sensitivity	O
and	O
specifity	O
of	O	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
immunoassay	B-PROC
as	O	O
a	O	O
tumor	B-CHEM
marker	I-CHEM
for	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
Lung	B-DISO
cancer	I-DISO
is	O	O
the	O	O
most	O	O
important	O	O
causes	O	O
of	O	O
the	O	O
cancer	O
related	O
mortality	O
.	O	O

Patients	B-LIVB
with	O	O
lung	B-DISO
cancer	I-DISO
are	O	O
usually	O	O
diagnosed	B-PROC
at	O	O
advanced	B-ANAT
or	O	O
locally	B-ANAT
advanced	I-ANAT
stage	I-ANAT
,	O	O
for	O	O
this	O	O
reason	O	O
early	B-PROC
diagnosis	I-PROC
of	O	O
lung	B-DISO
cancer	I-DISO
is	O	O
very	O	O
important	O	O
.	O	O

For	O	O
early	B-PROC
detection	I-PROC
of	O	O
lung	B-DISO
cancer	I-DISO
some	O	O
methods	O	O
are	O	O
emphasized	O	O
such	O	O
as	O	O
low	B-PROC
-	I-PROC
dose	I-PROC
computed	I-PROC
tomography	I-PROC
or	O	O
tumor	B-CHEM
biomarkers	I-CHEM
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
evaluate	B-PROC
DR	B-CHEM
-	I-CHEM
70	I-CHEM
sensitivity	O
and	O
specificity	O
as	O	O
a	O	O
tumor	B-CHEM
marker	I-CHEM
in	O	O
detection	B-PROC
of	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancers	I-DISO
.	O	O

Between	O	O
May	O
2013	O	O
and	O	O
April	O
2014	O	O
,	O	O
the	O	O
serum	B-ANAT
samples	I-ANAT
from	O	O
88	O	O
non	B-DISO
lung	I-DISO
cancer	I-DISO
patients	B-LIVB
,	O	O
86	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disesase	I-DISO
were	O	O
obtained	O	O
.	O	O

Blood	B-ANAT
samples	I-ANAT
from	O	O
each	O	O
participant	B-LIVB
were	O	O
analyzed	B-PROC
for	O	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
level	O
.	O	O

Totally	O	O
174	O	O
patients	B-LIVB
were	O	O
enrolled	O	O
to	O	O
the	O	O
study	B-PROC
(	O	O
152	O	O
male	B-LIVB
,	O	O
22	O	O
female	B-LIVB
)	O	O
.	O	O

Histopathologically	O
47	O	O
(	O	O
53	O	O
.	O	O

4	O	O
%	O	O
)	O	O
patients	B-LIVB
were	O	O
diagnosed	B-PROC
with	O	O
squamous	B-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
,	O	O
34	O	O
(	O	O
38	O	O
.	O	O
6	O	O
%	O	O
)	O	O
with	O	O
adenocarcinoma	B-DISO
,	O	O
and	O	O
7	O	O
(	O	O
8	O	O
%	O	O
)	O	O
with	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
.	O	O

The	O	O
mean	B-CHEM
serum	I-CHEM
DR	I-CHEM
-	I-CHEM
70	I-CHEM
levels	O
in	O	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
(	O	O
2	O	O
.	O	O
43	O	O
±	O	O
1	O	O
.	O	O
82	O	O
µg	O	O
/	O	O
mL	O	O
)	O	O
was	O	O
significantly	B-DISO
higher	I-DISO
compared	O
to	O	O
the	O	O
86	O	O
non	B-DISO
-	I-DISO
cancerous	I-DISO
subjects	B-LIVB
(	O	O
1	O	O
.	O	O
15	O	O
±	O	O
0	O	O
.	O	O

70	O	O
µg	O	O
/	O	O
mL	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

DR	B-CHEM
-	I-CHEM
70	I-CHEM
exhibited	O	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O	O
54	O	O
.	O	O

5	O	O
and	O	O
83	O	O
.	O	O

7	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
at	O	O
an	O	O
optimal	O
cut	O
off	O
at	O	O
1	O	O
.	O	O
98	O	O
µg	O	O
/	O	O
mL	O	O
.	O	O

It	O	O
could	O	O
be	O	O
said	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
disease	B-DISO
is	O	O
6	O	O
.	O	O
171	O	O
times	O	O
higher	O	O
in	O	O
the	O	O
cases	O	O
where	O	O
DR	B-CHEM
-	I-CHEM
70	I-CHEM
level	O
is	O	O
1	O	O
.	O	O
98	O	O
µg	O	O
/	O	O
mL	O	O
and	O	O
higher	O	O
.	O	O

DR	B-CHEM
-	I-CHEM
70	I-CHEM
,	O	O
a	O	O
marker	B-CHEM
used	O	O
to	O	O
measure	O
fibrin	B-CHEM
degradation	I-CHEM
products	I-CHEM
,	O	O
generated	O	O
by	O	O
all	O	O
major	O	O
cancers	B-DISO
,	O	O
may	O	O
helps	O	O
to	O	O
find	O	O
high	B-DISO
risk	I-DISO
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O	O

The	O	O
biological	O
effect	O
of	O	O
metal	B-CHEM
ions	B-CHEM
on	O	O
the	O	O
granulation	B-PROC
of	O	O
aerobic	O
granular	O
activated	O
sludge	B-PHEN
As	O	O
a	O	O
special	O	O
biofilm	B-LIVB
structure	O	O
,	O	O
microbial	B-LIVB
attachment	O
is	O	O
believed	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
granulation	B-PROC
of	O	O
aerobic	O	O
granular	O
activated	O
sludge	B-PHEN
(	O	O
AGAS	B-PHEN
)	O	O
.	O	O

This	O	O
experiment	O	O
was	O	O
to	O	O
investigate	O
the	O	O
biological	O
effect	O
of	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	I-CHEM
Mg	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
and	O	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
which	O	O
are	O	O
the	O	O
most	O	O
common	O	O
ions	B-CHEM
present	O	O
in	O	O
biological	O
wastewater	B-PHEN
treatment	O
systems	O	O
,	O	O
on	O	O
the	O	O
microbial	B-LIVB
attachment	O
of	O	O
AGAS	B-PHEN
and	O	O
flocculent	B-PHYS
activated	O
sludge	B-PHEN
(	O	O
FAS	B-PHEN
)	O	O
,	O	O
from	O	O
which	O	O
AGAS	B-PHEN
is	O	O
always	O	O
derived	O	O
,	O	O
in	O	O
order	O	O
to	O	O
provide	O	O
a	O	O
new	O	O
strategy	O	O
for	O	O
the	O	O
rapid	O
cultivation	O
and	O	O
stability	O
control	O
of	O	O
AGAS	B-PHEN
.	O	O

The	O	O
result	O	O
showed	O	O
that	O	O
attachment	O
biomass	O
of	O	O
AGAS	B-PHEN
was	O	O
about	O	O
300	O	O
%	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
FAS	B-PHEN
without	O	O
the	O	O
addition	O	O
of	O	O
metal	B-CHEM
ions	B-CHEM
.	O	O

Different	O	O
metal	B-CHEM
ions	B-CHEM
had	O	O
different	O	O
effects	O
on	O	O
the	O	O
process	B-PHEN
of	O	O
microbial	B-LIVB
attachment	O
.	O	O

FAS	B-PHEN
and	O	O
AGAS	B-PHEN
reacted	O	O
differently	O	O
to	O	O
the	O	O
metal	B-CHEM
ions	B-CHEM
as	O	O
well	O	O
,	O	O
and	O	O
in	O	O
fact	O	O
,	O	O
AGAS	B-PHEN
was	O	O
more	O	O
sensitive	O
to	O	O
the	O	O
metal	B-CHEM
ions	B-CHEM
.	O	O

Specifically	O	O
,	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Mg	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
and	O	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
could	O	O
increase	O	O
the	O	O
microbial	B-LIVB
attachment	O
ability	O	O
of	O	O
both	O	O
AGAS	B-PHEN
and	O	O
FAS	B-PHEN
under	O	O
appropriate	O
concentrations	O
,	O	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
and	O	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
were	O	O
also	O	O
beneficial	O	O
to	O	O
the	O	O
microbial	B-LIVB
attachment	O
of	O	O
FAS	B-PHEN
at	O	O
low	O
concentrations	O
,	O	O
but	O	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
Fe	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
and	O	O
Zn	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
greatly	O	O
inhibited	O	O
the	O	O
attachment	O
process	O
of	O	O
AGAS	B-PHEN
even	O	O
at	O	O
extremely	O
low	O
concentrations	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
acylated	B-CHEM
homoserine	I-CHEM
lactone	I-CHEM
(	O	O
AHL	B-CHEM
)	O	O
-	O	O
based	O	O
quorum	B-PHYS
sensing	I-PHYS
system	I-PHYS
,	O	O
the	O	O
content	O	O
of	O	O
extracellular	B-ANAT
polymeric	B-CHEM
substances	I-CHEM
and	O	O
the	O	O
relative	O	O
hydrophobicity	O
of	O	O
the	O	O
sludges	B-PHEN
were	O	O
greatly	O	O
influenced	O	O
by	O	O
metal	B-CHEM
ions	B-CHEM
.	O	O

As	O	O
all	O	O
these	O	O
parameters	O
had	O	O
close	O	O
relationships	O	O
with	O	O
the	O	O
microbial	B-LIVB
attachment	O
process	O
,	O	O
the	O	O
microbial	B-LIVB
attachment	O
may	O	O
be	O	O
affected	O	O
by	O	O
changes	O
of	O	O
these	O	O
parameters	O
.	O	O

The	O	O
clinical	O
and	O	O
economic	O
burden	O
of	O	O
significant	O
bleeding	B-DISO
during	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
:	O	O
A	O	O
retrospective	B-PROC
matched	I-PROC
cohort	I-PROC
analysis	I-PROC
of	O	O
real	O
-	O	O
world	B-LIVB
data	O
The	O	O
objective	O
of	O	O
this	O	O
retrospective	B-PROC
study	I-PROC
was	O	O
to	O	O
quantify	O
the	O	O
clinical	O
and	O	O
economic	O
burden	O
of	O	O
significant	O
bleeding	B-DISO
in	O	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
in	O	O
the	O	O
US	B-GEOG
.	O	O

This	O	O
study	B-PROC
utilized	O
2009	O	O
-	O	O
2012	O	O
data	O
from	O	O
the	O	O
Premier	O
Perspective	O
Database	O
(	O
TM	O
)	O
.	O	O

Adult	B-LIVB
patients	B-LIVB
with	O	O
primary	B-PROC
pulmonary	I-PROC
lobectomy	I-PROC
or	O	O
segmentectomy	B-PROC
procedures	I-PROC
were	O	O
categorized	O
by	O	O
the	O	O
surgical	O
approach	O
(	O	O
VATS	B-PROC
vs	O	O
open	B-PROC
)	O	O
and	O	O
primary	O
diagnosis	O
(	O	O
primary	B-PROC
or	O	O
metastatic	B-PROC
lung	I-PROC
cancer	I-PROC
vs	O	O
non	B-PROC
-	I-PROC
lung	I-PROC
cancer	I-PROC
)	O	O
.	O	O

Patients	B-LIVB
requiring	O	O
≥3	O	O
units	O
of	O	O
blood	B-CHEM
products	I-CHEM
with	O	O
at	O
least	O
1	O	O
unit	O
of	O	O
PRBCs	B-CHEM
:	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
;	O	O
those	O	O
requiring	O	O
<	O	O
3	O	O
units	O
:	O	O
""""	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
;	O	O
and	O	O
those	O	O
not	O	O
requiring	O	O
blood	B-CHEM
products	I-CHEM
:	O	O
""""	O	O
no	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
.	O	O

A	O	O
matched	O	O
cohort	B-PROC
analysis	I-PROC
was	O	O
performed	O
between	O	O
the	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
and	O	O
the	O	O
""""	O	O
no	O
bleeding	B-DISO
cohort	B-LIVB
""""	O	O
using	O	O
matching	O
variables	O
:	O	O
hospital	B-OBJC
,	O	O
lung	B-PROC
cancer	I-PROC
diagnosis	I-PROC
,	O	O
year	O
of	O
surgery	O
,	O	O
APR	O
-	O
DRG	O
severity	O
score	O
,	O	O
procedure	B-PHYS
type	I-PHYS
and	O	O
approach	O
,	O	O
age	B-PHYS
,	O	O
and	O	O
gender	B-PHYS
.	O	O

The	O	O
""""	O	O
All	O
-	O	O
patient	B-LIVB
""""	O	O
cohort	B-LIVB
comprised	O	O
21	O	O
,	O	O
429	O	O
patients	B-LIVB
:	O	O
213	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
;	O	O
2	O	O
,	O	O
780	O	O
""""	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O	O
;	O	O
and	O	O
18	O	O
,	O	O
436	O	O
""""	O	O
no	O
bleeding	B-DISO
""""	O	O
.	O	O

Overall	O
incidence	O
of	O	O
significant	O
chest	B-ANAT
bleeding	B-DISO
was	O	O
0	O	O
.	O	O

99	O	O
%	O	O
.	O	O

Patients	B-LIVB
from	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
and	O	O
""""	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
had	O	O
2	O	O
.	O	O

5	O	O
days	O
and	O	O
2	O	O
days	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
longer	O
length	O
of	O
stay	O
in	O	O
the	O	O
hospital	B-OBJC
compared	O
to	O	O
those	O	O
in	O	O
the	O	O
""""	O	O
no	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
,	O	O
respectively	O	O
.	O	O

Overall	O
,	O	O
hospital	O
costs	O
for	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
were	O	O
higher	O
than	O	O
""""	O	O
no	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
for	O	O
those	O	O
who	O	O
were	O	O
covered	O
under	O	O
Medicare	O
(	O	O
$	O	O
59	O	O
,	O	O
871	O	O
vs	O	O
$	O	O
23	O	O
,	O	O
641	O	O
)	O	O
,	O	O
were	O	O
≥76	O	O
years	O
of	O
age	O
(	O	O
$	O	O
64	O	O
,	O	O
010	O	O
vs	O	O
$	O	O
24	O	O
,	O	O
243	O	O
)	O	O
,	O	O
had	O	O
greater	O
severity	O
of	O
illness	O
(	O	O
$	O	O
97	O	O
,	O	O
813	O	O
vs	O	O
$	O	O
51	O	O
,	O	O
871	O	O
)	O	O
and	O	O
underwent	O	O
open	O	O
segmentectomy	B-PROC
(	O	O
$	O	O
74	O	O
,	O	O
220	O	O
vs	O	O
$	O	O
21	O	O
,	O	O
903	O	O
)	O	O
.	O	O

Hospital	O
costs	O
for	O	O
""""	O	O
significant	O
bleeding	B-DISO
""""	O	O
cohort	B-LIVB
and	O	O
""""	O	O
non	B-DISO
-	I-DISO
significant	I-DISO
bleeding	B-DISO
""""	O	O
were	O	O
significantly	O
higher	O
(	O	O
$	O	O
11	O	O
,	O	O
589	O	O
and	O	O
$	O	O
5	O	O
,	O	O
280	O	O
,	O	O
respectively	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
than	O	O
no	O
bleeding	B-DISO
cohort	B-LIVB
.	O	O

Although	O	O
significant	O
bleeding	B-DISO
during	O
lung	B-PROC
resection	I-PROC
surgery	I-PROC
is	O	O
rare	O
,	O	O
patients	B-LIVB
with	O	O
such	O	O
complication	B-DISO
could	O	O
stay	O
longer	O
at	O	O
the	O	O
hospital	B-OBJC
and	O	O
cost	O
an	O	O
average	O	O
of	O	O
$	O	O
13	O	O
,	O	O
103	O	O
more	O	O
than	O	O
those	O	O
without	O	O
.	O	O

Laceration	B-DISO
of	O	O
a	O	O
branch	O
of	O
the	O	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
caused	O
by	O	O
a	O	O
spike	B-DISO
of	O	O
the	O	O
displaced	O
lesser	B-ANAT
trochanter	I-ANAT
in	O	O
an	O	O
inter	B-ANAT
-	I-ANAT
trochanteric	I-ANAT
femoral	B-DISO
fracture	I-DISO
.	O	O

A	O	O
case	O
report	O
Injury	B-DISO
of	O	O
femoral	B-ANAT
vessels	I-ANAT
is	O	O
an	O	O
extremely	O
rare	O
complication	B-DISO
in	O	O
intertrochanteric	B-ANAT
femoral	B-DISO
fractures	I-DISO
.	O	O

In	O	O
most	O	O
cases	O
reported	B-PROC
,	O	O
the	O	O
vascular	B-DISO
lesion	I-DISO
involves	O
the	O	O
superficial	B-ANAT
femoral	I-ANAT
artery	I-ANAT
,	O	O
whereas	O	O
in	O	O
very	O	O
few	O	O
cases	O
does	O	O
it	O	O
involve	O
the	O	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
.	O	O

We	O	O
report	O
a	O	O
case	O
of	O	O
acute	B-DISO
bleeding	I-DISO
due	O	O
to	O	O
laceration	B-DISO
of	O	O
a	O	O
perforating	B-DISO
branch	O
of	O
the	O	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
caused	O
by	O	O
a	O	O
sharp	B-DISO
fragment	O
of	O
the	O	O
displaced	O
lesser	B-ANAT
trochanter	I-ANAT
in	O	O
an	O	O
intertrochanteric	B-ANAT
femoral	B-DISO
fracture	I-DISO
;	O	O
the	O	O
lesion	B-DISO
was	O	O
treated	O
by	O	O
transcatheter	B-PROC
embolization	I-PROC
.	O	O

The	O	O
arterial	B-DISO
injury	I-DISO
may	O	O
be	O	O
iatrogenic	O
,	O	O
occurring	O
during	O	O
intramedullary	O
internal	B-PROC
fixation	I-PROC
,	O	O
or	O	O
less	O	O
frequently	O
,	O	O
the	O	O
injury	B-DISO
may	O	O
be	O	O
due	O	O
to	O	O
the	O	O
fracture	B-DISO
itself	O	O
,	O	O
caused	O
by	O	O
a	O	O
sharp	B-DISO
bone	B-DISO
fragment	I-DISO
that	O	O
damages	O
the	O	O
profunda	B-ANAT
femoris	I-ANAT
artery	I-ANAT
or	O	O
one	O	O
of	O	O
its	O	O
perforating	B-DISO
branches	O
.	O	O

We	O	O
believe	O	O
that	O	O
intertrochanteric	B-ANAT
femoral	B-DISO
fractures	I-DISO
with	O	O
avulsed	B-DISO
lesser	B-ANAT
trochanter	I-ANAT
are	O	O
at	O
risk	O
for	O	O
femoral	B-ANAT
vessel	I-ANAT
injuries	B-DISO
caused	O
by	O	O
the	O	O
displaced	O
bone	B-ANAT
spike	B-DISO
,	O	O
and	O	O
we	O	O
advise	O	O
meticulous	O
clinical	O
and	O	O
laboratory	B-PROC
monitoring	I-PROC
pre	O
-	O
and	O	O
post	O
-	O
operatively	O
to	O	O
prevent	B-PROC
serious	I-PROC
complications	I-PROC
.	O	O

Catastrophic	O
expenditure	O
and	O	O
impoverishment	O
of	O	O
patients	B-LIVB
affected	O	O
by	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
in	O	O
China	B-GEOG
China	B-GEOG
is	O	O
actively	O	O
promoting	O
regulation	O	O
of	O	O
rare	B-DISO
diseases	I-DISO
,	O	O
rare	B-DISO
disease	I-DISO
and	O	O
orphan	B-CHEM
drugs	I-CHEM
have	O	O
been	O	O
formally	O	O
incorporated	O	O
into	O	O
the	O	O
national	O
planning	O
.	O	O

However	O	O
,	O	O
few	O	O
studies	B-PROC
have	O	O
been	O	O
done	O	O
to	O	O
evaluate	O	O
the	O	O
affordability	O
of	O	O
rare	B-DISO
disease	I-DISO
patients	B-LIVB
in	O	O
China	B-GEOG
.	O	O

This	O	O
study	O	O
aims	O	O
to	O	O
provide	O	O
policy	O
recommendations	O
for	O	O
the	O	O
establishment	O
of	O	O
social	O
security	O
mechanism	O
for	O	O
rare	B-DISO
diseases	I-DISO
in	O	O
China	B-GEOG
,	O	O
so	O	O
as	O	O
to	O	O
address	O	O
the	O	O
problem	O	O
of	O	O
poverty	O
caused	O	O
by	O	O
these	O	O
diseases	B-DISO
.	O	O

A	O	O
total	O	O
of	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
were	O	O
selected	O	O
by	O	O
Delphi	B-PROC
method	I-PROC
.	O	O

Affordability	O
of	O	O
treatment	B-PROC
for	O	O
the	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
was	O	O
assessed	O
through	O	O
annual	O
per	O
capital	O
income	O
,	O	O
catastrophic	O
expenditure	O
and	O	O
impoverishment	O
expenditure	O
among	O	O
urban	B-LIVB
and	O	O
rural	B-LIVB
residents	I-LIVB
in	O	O
China	B-GEOG
.	O	O

Assessed	O
through	O	O
annual	O
per	O
capital	O
income	O
,	O	O
health	O
expenditure	O
for	O	O
the	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
are	O	O
all	O	O
rather	O	O
high	O	O
.	O	O

The	O	O
highest	O	O
health	O
expenditure	O
is	O	O
equivalent	O	O
to	O	O
income	O
of	O	O
69	O	O
.	O	O

34	O	O
years	O
of	O	O
one	O	O
urban	B-LIVB
resident	I-LIVB
,	O	O
and	O	O
the	O	O
burden	O	O
is	O	O
heavier	O	O
for	O	O
rural	B-LIVB
residents	I-LIVB
.	O	O

Through	O	O
catastrophic	O
expenditure	O
assessment	O
,	O	O
proportions	O
of	O	O
the	O	O
population	B-LIVB
experiencing	O	O
catastrophic	O
expenditure	O
caused	O	O
by	O	O
the	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
are	O	O
all	O	O
under	O	O
0	O	O
.	O	O

167	O	O
‰	O	O
.	O	O

However	O	O
,	O	O
once	O	O
one	O	O
is	O	O
ill	B-DISO
and	O	O
taking	O	O
medications	O
,	O	O
he	O	O
will	O	O
suffer	O	O
from	O	O
catastrophic	O
health	O
expenditure	O
.	O	O

Through	O	O
impoverishment	O
expenditure	O
assessment	O
,	O	O
the	O	O
proportions	O
of	O	O
impoverishment	O
payment	O
are	O	O
low	O	O
among	O	O
both	O	O
urban	B-LIVB
and	O	O
rural	B-LIVB
residents	I-LIVB
,	O	O
but	O	O
the	O	O
7	O	O
rare	B-DISO
diseases	I-DISO
could	O	O
lead	O	O
nearly	O	O
4	O	O
.	O	O
6	O	O
million	O	O
people	B-LIVB
into	O	O
poverty	O
on	O	O
a	O	O
national	O	O
scale	O	O
.	O	O

The	O	O
affordability	O
of	O	O
treatment	B-PROC
for	O	O
rare	B-DISO
disease	I-DISO
as	O	O
well	O	O
as	O	O
orphan	B-CHEM
drugs	I-CHEM
is	O	O
rather	O	O
poor	O
.	O	O

Residents	B-LIVB
of	O	O
different	O	O
income	O
levels	O
all	O	O
have	O	O
difficulties	O	O
to	O	O
afford	O	O
the	O	O
treatment	B-PROC
for	O	O
rare	B-DISO
diseases	I-DISO
,	O	O
so	O	O
poverty	O
caused	O	O
by	O	O
rare	B-DISO
diseases	I-DISO
is	O	O
quite	O	O
widespread	O
.	O	O

Therefore	O	O
,	O	O
social	O
security	O
mechanism	O
for	O	O
rare	B-DISO
disease	I-DISO
patients	B-LIVB
should	O	O
be	O	O
established	O	O
and	O	O
specific	O	O
payment	O
pattern	O	O
for	O	O
orphan	B-CHEM
drugs	I-CHEM
should	O	O
be	O	O
set	O	O
up	O	O
.	O	O

Rh	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
-	O	O
Catalyzed	B-PHEN
Oxidative	B-PHEN
Annulation	I-PHEN
Leading	O	O
to	O	O
Substituted	B-CHEM
Indolizines	I-CHEM
by	O	O
Cleavage	B-PHEN
of	O	O
C	B-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
2	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
/	I-PHEN
C	I-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
3	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
Bonds	I-PHEN
Rhodium	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
-	O	O
catalyzed	B-PHEN
oxidative	B-PHEN
annulation	I-PHEN
reactions	I-PHEN
of	O	O
pyridinium	B-CHEM
trifluoromethanesulfonate	I-CHEM
salts	I-CHEM
with	O	O
alkynes	B-CHEM
leading	O	O
to	O	O
substituted	B-CHEM
indolizines	I-CHEM
by	O	O
cleavage	B-PHEN
of	O	O
C	B-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
2	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
/	I-PHEN
C	I-PHEN
(	I-PHEN
sp	I-PHEN
(	I-PHEN
3	I-PHEN
)	I-PHEN
)	I-PHEN
-	I-PHEN
H	I-PHEN
bonds	I-PHEN
are	O	O
developed	O	O
.	O	O

The	O	O
starting	B-OBJC
materials	I-OBJC
are	O	O
readily	O	O
available	O
,	O	O
and	O	O
the	O	O
reactions	B-PHEN
have	O	O
a	O	O
broad	O
substrate	B-OBJC
scope	O
.	O	O

This	O	O
reaction	B-PHEN
overcomes	O
some	O	O
drawbacks	O
of	O	O
the	O	O
previous	O	O
indolizine	B-CHEM
synthetic	B-PHEN
methods	I-PHEN
and	O	O
provides	O	O
a	O	O
new	O	O
efficient	O
route	O
to	O	O
indolizine	B-CHEM
derivatives	I-CHEM
.	O	O

Pyomyositis	B-DISO
in	O	O
childhood	O
-	O	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
Pyomyositis	B-DISO
is	O	O
a	O	O
pyogenic	B-DISO
infection	I-DISO
of	O	O
skeletal	O
muscle	O
that	O	O
arises	O	O
from	O	O
hematogenous	B-DISO
spread	I-DISO
and	O	O
usually	O	O
presents	O	O
with	O	O
localized	O
abscess	B-DISO
.	O	O

This	O	O
muscle	B-DISO
infection	I-DISO
has	O	O
been	O	O
rarely	O	O
reported	O	O
in	O	O
adult	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
and	O	O
,	O	O
to	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
has	B-DISO
not	I-DISO
been	I-DISO
diagnosed	I-DISO
in	O	O
pediatric	O
lupus	B-LIVB
population	I-LIVB
.	O	O

Among	O	O
our	O	O
childhood	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
population	B-LIVB
,	O	O
including	O	O
289	O	O
patients	B-LIVB
,	O	O
one	O	O
presented	O	O
pyomyositis	B-DISO
.	O	O

This	O	O
patient	B-LIVB
was	O	O
diagnosed	B-DISO
with	O	O
childhood	B-DISO
-	I-DISO
onset	I-DISO
systemic	B-DISO
lupus	I-DISO
erythematous	I-DISO
at	O	O
the	O	O
age	B-PHYS
of	O	O
10	O	O
years	O	O
-	O	O
old	O	O
.	O	O

After	O	O
six	O	O
years	O	O
,	O	O
while	O	O
being	O	O
treated	O	O
with	O	O
prednisone	B-CHEM
,	O	O
azathioprine	B-CHEM
and	O	O
hydroxychloroquine	B-CHEM
,	O	O
she	O	O
was	O	O
hospitalized	B-DISO
due	O	O
to	O	O
a	O	O
30	O	O
-	O	O
day	O	O
history	O	O
of	O	O
insidious	O
pain	O
in	O	O
the	O	O
left	B-ANAT
thigh	I-ANAT
and	O	O
no	O	O
apparent	O	O
trauma	B-DISO
or	O	O
fever	B-DISO
were	O	O
reported	O	O
.	O	O

Her	O	O
physical	B-PROC
examination	I-PROC
showed	O	O
muscle	B-DISO
tenderness	I-DISO
and	O	O
woody	B-DISO
induration	I-DISO
.	O	O

Laboratory	B-PROC
tests	I-PROC
revealed	O	O
anemia	B-DISO
,	O	O
increased	O	O
acute	B-CHEM
phase	I-CHEM
reactants	I-CHEM
and	O	O
normal	B-DISO
muscle	I-DISO
enzymes	I-DISO
.	O	O

Computer	B-ANAT
tomography	I-ANAT
of	I-ANAT
the	I-ANAT
left	I-ANAT
thigh	I-ANAT
showed	O	O
collection	O	O
on	O	O
the	O	O
middle	O
third	O
of	O	O
the	O	O
vastus	B-ANAT
intermedius	I-ANAT
,	O	O
suggesting	O	O
purulent	O
stage	O
of	O	O
pyomyositis	B-DISO
.	O	O

Treatment	B-PROC
with	O	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotic	I-CHEM
was	O	O
initiated	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
complete	O	O
clinical	O
resolution	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
we	O	O
described	O	O
the	O	O
first	O	O
case	O	O
of	O	O
pyomyositis	B-DISO
during	O	O
childhood	O
in	O	O
pediatric	O
lupus	B-LIVB
population	I-LIVB
.	O	O

This	O	O
report	O
reinforces	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
localized	B-DISO
muscle	I-DISO
pain	I-DISO
in	O	O
immunocompromised	B-DISO
patients	I-DISO
,	O	O
even	O	O
without	O
elevation	O
of	O	O
muscle	B-PROC
enzymes	I-PROC
,	O	O
should	O	O
raise	O	O
the	O	O
suspicion	B-PHYS
of	O	O
pyomyositis	B-DISO
.	O	O

A	O	O
prompt	O	O
antibiotic	B-PROC
therapy	I-PROC
is	O	O
strongly	O	O
recommended	O	O
.	O	O

Quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
and	O	O
cervical	B-PROC
length	I-PROC
to	O	O
predict	O
preterm	B-DISO
birth	I-DISO
in	O	O
asymptomatic	B-DISO
women	B-LIVB
with	O	O
previous	O	O
cervical	B-PROC
surgery	I-PROC
Quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
testing	I-PROC
has	O	O
demonstrated	B-PROC
accuracy	O
for	O	O
prediction	O
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
in	O	O
asymptomatic	B-DISO
women	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	O	O
preterm	B-DISO
birth	I-DISO
.	O	O

Predictive	O
accuracy	O
in	O	O
women	B-LIVB
with	O	O
previous	O	O
cervical	B-PROC
surgery	I-PROC
(	O	O
a	O	O
potentially	O	O
different	O	O
risk	O	O
mechanism	O	O
)	O	O
is	O	O
not	O	O
known	O	O
.	O	O

We	O	O
sought	O	O
to	O	O
compare	O	O
the	O	O
predictive	O
accuracy	O
of	O	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
and	O	O
cervical	B-PROC
length	I-PROC
testing	I-PROC
in	O	O
asymptomatic	B-DISO
women	B-LIVB
with	O	O
previous	O	O
cervical	B-PROC
surgery	I-PROC
to	O	O
that	O	O
in	O	O
women	B-LIVB
with	O	O
1	O	O
previous	O	O
preterm	B-DISO
birth	I-DISO
.	O	O

We	O	O
conducted	O	O
a	O	O
prospective	B-PROC
blinded	B-PROC
secondary	O	O
analysis	B-PROC
of	O	O
a	O	O
larger	O	O
observational	B-PROC
study	I-PROC
of	O	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
concentration	O
in	O	O
asymptomatic	B-DISO
women	B-LIVB
measured	O	O
with	O	O
a	O	O
Hologic	O
10Q	O
system	O
(	O	O
Hologic	O
,	O	O
Marlborough	B-GEOG
,	O	O
MA	B-GEOG
)	O	O
.	O	O

Prediction	O
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
(	O	O
<	O	O
30	O	O
,	O	O
<	O	O
34	O	O
,	O	O
and	O	O
<	O	O
37	O	O
weeks	O
)	O	O
with	O	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
concentration	O
in	O	O
primiparous	B-DISO
women	B-LIVB
who	O	O
had	O	O
undergone	O	O
at	O	O
least	O	O
1	O	O
invasive	O
cervical	B-PROC
procedure	I-PROC
(	O	O
n	O	O
=	O	O
473	O	O
)	O	O
was	O	O
compared	O	O
with	O	O
prediction	O
in	O	O
women	B-LIVB
who	O	O
had	O	O
previous	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
,	O	O
preterm	B-DISO
prelabor	I-DISO
rupture	I-DISO
of	I-DISO
membranes	I-DISO
,	O	O
or	O	O
late	B-DISO
miscarriage	I-DISO
(	O	O
n	O	O
=	O	O
821	O	O
)	O	O
.	O	O

Relationship	O	O
with	O	O
cervical	O
length	O
was	O	O
explored	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
<	O	O
34	O	O
weeks	O
in	O	O
the	O	O
cervical	B-PROC
surgery	I-PROC
group	O
was	O	O
3	O	O
%	O	O
compared	O	O
with	O	O
9	O	O
%	O	O
in	O	O
previous	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
group	O
.	O	O

Receiver	O
operating	O
characteristic	O
curves	O
comparing	O	O
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
for	O	O
prediction	O
at	O	O
all	O	O
3	O	O
gestational	O
end	O
points	O
were	O	O
comparable	O	O
between	O	O
the	O	O
cervical	B-PROC
surgery	I-PROC
and	O	O
previous	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
groups	O
(	O	O
34	O	O
weeks	O
:	O	O
area	O
under	O
the	O
curve	O
,	O	O
0	O	O
.	O	O
78	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
64	O	O
-	O	O
0	O	O
.	O	O
93	O	O
]	O	O
vs	O	O
0	O	O
.	O	O
71	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
64	O	O
-	O	O
0	O	O
.	O	O
78	O	O
]	O	O
;	O	O
P	O	O
=	O	O
.39	O	O
)	O	O
.	O	O

Prediction	O
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
using	O	O
cervical	B-PROC
length	I-PROC
compared	O	O
with	O	O
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
for	O	O
prediction	O
of	O	O
preterm	B-DISO
birth	I-DISO
<	O	O
34	O	O
weeks	O
of	O	O
gestation	B-PHYS
offered	O	O
similar	O	O
prediction	O
(	O	O
area	O
under	O
the	O
curve	O
,	O	O
0	O	O
.	O	O
88	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
79	O	O
-	O	O
0	O	O
.	O	O
96	O	O
]	O	O
vs	O	O
0	O	O
.	O	O

77	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
62	O	O
-	O	O
0	O	O
.	O	O
92	O	O
]	O	O
,	O	O
P	O	O
=	O	O
.12	O	O
in	O	O
the	O	O
cervical	B-PROC
surgery	I-PROC
group	O
;	O	O
and	O	O
0	O	O
.	O	O
77	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
70	O	O
-	O	O
0	O	O
.	O	O
84	O	O
]	O	O
vs	O	O
0	O	O
.	O	O
74	O	O
[	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
67	O	O
-	O	O
0	O	O
.	O	O
81	O	O
]	O	O
,	O	O
P	O	O
=	O	O
.32	O	O
in	O	O
the	O	O
previous	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
group	O
)	O	O
.	O	O

Prediction	O
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
using	O	O
cervicovaginal	B-ANAT
fluid	I-ANAT
quantitative	B-PROC
fetal	I-PROC
fibronectin	I-PROC
in	O	O
asymptomatic	B-DISO
women	B-LIVB
with	O	O
cervical	B-PROC
surgery	I-PROC
is	O	O
valid	O	O
,	O	O
and	O	O
has	O	O
comparative	O	O
accuracy	O
to	O	O
that	O	O
in	O	O
women	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	O	O
spontaneous	B-DISO
preterm	I-DISO
birth	I-DISO
.	O	O

Proteome	B-CHEM
changes	O
in	O	O
rat	B-LIVB
serum	B-ANAT
after	O	O
a	O	O
chronic	B-PHEN
ingestion	I-PHEN
of	O	O
enriched	O	O
uranium	B-CHEM
:	O	O
Toward	O	O
a	O	O
biological	B-PHYS
signature	I-PHYS
of	O	O
internal	O
contamination	O
and	O	O
radiological	O
effect	O
The	O	O
civilian	B-LIVB
and	O	O
military	B-LIVB
use	O
of	O
uranium	B-CHEM
results	O	O
in	O	O
an	O	O
increased	O
risk	O
of	O	O
human	B-LIVB
exposure	O
.	O	O

The	O	O
toxicity	B-DISO
of	O	O
uranium	B-CHEM
results	O	O
from	O	O
both	O	O
its	O	O
chemical	B-PHEN
and	O	O
radiological	O
properties	O
that	O	O
vary	O	O
with	O	O
isotopic	O
composition	B-PHYS
.	O	O

Validated	O	O
biomarkers	B-PHYS
of	O	O
health	O
effects	O
associated	O
with	O
exposure	O
to	O
uranium	B-CHEM
are	O	O
neither	O	O
sensitive	O
nor	O	O
specific	O	O
to	O	O
uranium	B-CHEM
radiotoxicity	B-DISO
and	O	O
/	O	O
or	O	O
radiological	O
effect	O
.	O	O

This	O	O
study	O	O
aimed	O	O
at	O	O
investigating	O	O
if	O	O
serum	B-CHEM
proteins	I-CHEM
could	O	O
be	O	O
useful	O	O
as	O	O
biomarkers	B-PHYS
of	O	O
both	O	O
uranium	O
exposure	O
and	O	O
radiological	O
effect	O
.	O	O

Male	O	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O	O
chronically	O
exposed	O
through	O	O
drinking	B-OBJC
water	I-OBJC
to	O	O
low	O
levels	O
(	O	O
40mg	O	O
/	O	O
L	O	O
,	O	O
corresponding	O	O
to	O	O
1	O	O
mg	O	O
of	O	O
uranium	B-CHEM
per	O	O
animal	B-LIVB
per	O	O
day	O
)	O	O
of	O	O
either	O	O
4	O	O
%	O	O
(	O	O
235	O	O
)	O	O
U	B-CHEM
-	I-CHEM
enriched	I-CHEM
uranium	I-CHEM
(	O	O
EU	B-CHEM
)	O	O
or	O	O
12	O	O
%	O	O
EU	B-CHEM
during	O	O
6	O	O
weeks	O
.	O	O

A	O	O
proteomics	O
approach	O
based	O	O
on	O	O
two	O
-	O
dimensional	O
electrophoresis	O
(	O	O
2D	B-PROC
-	I-PROC
DIGE	I-PROC
)	O	O
and	O	O
mass	B-PROC
spectrometry	I-PROC
(	O	O
MS	B-PROC
)	O	O
was	O	O
used	O	O
to	O	O
establish	O	O
protein	B-PHYS
expression	I-PHYS
profiles	B-PROC
that	O	O
could	O	O
be	O	O
relevant	O	O
for	O	O
discriminating	O	O
between	O	O
groups	O
,	O	O
and	O	O
to	O	O
identify	O	O
some	O	O
differentially	O	O
expressed	B-PHYS
proteins	I-PHYS
following	O	O
uranium	B-CHEM
ingestion	B-PHEN
.	O	O

It	O	O
demonstrated	O	O
that	O	O
the	O	O
expressions	B-PHYS
of	O	O
174	O	O
protein	B-CHEM
spots	I-CHEM
over	O	O
1045	O	O
quantified	O
spots	B-CHEM
were	O	O
altered	O	O
after	O	O
uranium	O
exposure	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Using	O	O
both	O	O
inferential	O
and	O	O
non	B-PROC
-	I-PROC
supervised	I-PROC
multivariate	I-PROC
statistics	I-PROC
,	O	O
we	O	O
show	O	O
sets	O	O
of	O	O
spots	B-CHEM
features	O
that	O	O
lead	O	O
to	O	O
a	O	O
clear	O	O
discrimination	O	O
between	O	O
controls	B-LIVB
and	O	O
EU	O
exposed	O
groups	O
on	O	O
the	O	O
one	O	O
hand	O	O
(	O	O
21	O	O
spots	B-CHEM
)	O	O
,	O	O
and	O	O
between	O	O
4	O	O
%	O	O
EU	B-CHEM
and	O	O
12	O	O
%	O	O
EU	B-CHEM
on	O	O
the	O	O
other	O	O
hand	O	O
(	O	O
7	O	O
spots	B-CHEM
)	O	O
,	O	O
showing	O	O
that	O	O
investigation	O
of	O	O
the	O	O
serum	B-ANAT
proteome	B-CHEM
may	O	O
possibly	O	O
be	O	O
of	O	O
relevance	O
to	O	O
address	O	O
both	O	O
uranium	B-CHEM
contamination	O
and	O	O
radiological	O
effect	O
.	O	O

Finally	O	O
,	O	O
using	O	O
bioinformatics	O	O
tools	O	O
,	O	O
pathway	O
analyses	O
of	O	O
differentially	O	O
expressed	B-PHYS
MS	B-PROC
-	O	O
identified	O
proteins	B-CHEM
find	O	O
that	O	O
acute	O
phase	O
,	O	O
inflammatory	O
and	O	O
immune	B-PHYS
responses	I-PHYS
as	O	O
well	O	O
as	O	O
oxidative	B-DISO
stress	I-DISO
are	O	O
likely	O	O
involved	O	O
in	O	O
the	O	O
response	O	O
to	O	O
contamination	O
,	O	O
suggesting	O	O
a	O	O
physiological	O
perturbation	O
,	O	O
but	O	O
that	O	O
does	O	O
not	O	O
necessarily	O	O
lead	O	O
to	O	O
a	O	O
toxic	B-DISO
effect	I-DISO
.	O	O

Prediction	O
of	O	O
extravasation	B-DISO
in	O	O
pelvic	B-DISO
fracture	I-DISO
using	O	O
coagulation	B-PHYS
biomarkers	B-PHYS
To	O	O
evaluate	O	O
the	O	O
usefulness	O
of	O	O
coagulation	B-PHYS
biomarkers	B-PHYS
,	O	O
which	O	O
are	O	O
easy	O	O
and	O	O
quick	O	O
to	O	O
analyze	O	O
in	O	O
emergency	B-PHEN
settings	I-PHEN
,	O	O
for	O	O
prediction	O
of	O	O
arterial	B-ANAT
extravasation	B-DISO
due	O	O
to	O	O
pelvic	B-DISO
fracture	I-DISO
.	O	O

The	O	O
medical	O
records	O
of	O	O
pelvic	B-DISO
fracture	I-DISO
patients	B-LIVB
transferred	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
of	O	O
Gunma	O	O
University	O	O
Hospital	O	O
between	O	O
December	O	O
2009	O	O
and	O	O
May	O	O
2015	O	O
were	O	O
reviewed	O	O
.	O	O

Patients	B-LIVB
were	O	O
divided	O	O
into	O	O
two	O
groups	O
,	O	O
those	O	O
with	O	O
(	O	O
Extra	B-DISO
(	I-DISO
+	I-DISO
)	I-DISO
)	O	O
and	O	O
without	O	O
(	O	O
Extra	B-DISO
(	I-DISO
-	I-DISO
)	I-DISO
)	O	O
arterial	B-ANAT
extravasation	B-DISO
on	O	O
enhanced	O	O
CT	B-PROC
or	O	O
angiography	B-PROC
.	O	O

Levels	O
of	O	O
fibrin	B-PROC
degradation	I-PROC
products	I-PROC
(	O	O
FDP	B-PROC
)	O	O
,	O	O
D	B-PROC
-	I-PROC
dimer	I-PROC
,	O	O
fibrinogen	B-PROC
,	O	O
the	O	O
ratio	B-PROC
of	I-PROC
FDP	I-PROC
to	I-PROC
fibrinogen	I-PROC
,	O	O
the	O	O
ratio	B-PROC
of	I-PROC
D	I-PROC
-	I-PROC
dimer	I-PROC
to	I-PROC
fibrinogen	I-PROC
,	O	O
systolic	B-PHYS
blood	I-PHYS
pressure	I-PHYS
,	O	O
heart	B-PHYS
rate	I-PHYS
,	O	O
the	O	O
Glasgow	O
Coma	O
Scale	O
,	O	O
pH	O
,	O	O
base	B-PROC
excess	I-PROC
,	O	O
hemoglobin	B-PROC
and	O	O
lactate	B-PROC
levels	O
,	O	O
the	O	O
pattern	O	O
of	O	O
pelvic	B-DISO
injury	I-DISO
,	O	O
and	O	O
injury	O
severity	O
score	O
were	O	O
measured	O	O
at	O	O
hospital	B-PROC
admission	I-PROC
,	O	O
and	O	O
compared	O	O
between	O	O
the	O	O
two	O
groups	O
.	O	O

Parameters	O	O
with	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
the	O	O
two	O
groups	O
were	O	O
used	O	O
to	O	O
construct	O	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
.	O	O

The	O	O
study	O	O
included	O	O
29	O	O
patients	B-LIVB
with	O	O
pelvic	B-DISO
fracture	I-DISO
.	O	O

FDP	B-CHEM
,	O	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O	O
the	O	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O	O
the	O	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
were	O	O
the	O	O
most	O	O
useful	O	O
parameters	O	O
for	O	O
predicting	O
arterial	B-ANAT
extravasation	B-DISO
due	O	O
to	O	O
pelvic	B-DISO
fracture	I-DISO
.	O	O

FDP	B-CHEM
,	O	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O	O
the	O	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O	O
the	O	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O	O
and	O	O
hemoglobin	B-PHEN
and	O	O
lactate	B-PHEN
levels	I-PHEN
were	O	O
significantly	O
higher	O
in	O	O
the	O	O
Extra	B-DISO
(	I-DISO
+	I-DISO
)	I-DISO
group	O	O
than	O	O
in	O	O
the	O	O
Extra	B-DISO
(	I-DISO
-	I-DISO
)	I-DISO
group	O	O
(	O	O
FDP	B-CHEM
,	O	O
354	O	O
.	O	O

8μg	O	O
/	O	O
mL	O	O
[	O	O
median	O	O
]	O	O
versus	O	O
96	O	O
.	O	O

6μg	O	O
/	O	O
mL	O	O
;	O	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O	O
122	O	O
.	O	O

3μg	O	O
/	O	O
mL	O	O
versus	O	O
42	O	O
.	O	O

1μg	O	O
/	O	O
mL	O	O
;	O	O
the	O	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O	O
3	O	O
.	O	O
39	O	O
versus	O	O
0	O	O
.	O	O
42	O	O
;	O	O
the	O	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O	O
1	O	O
.	O	O
14	O	O
versus	O	O
0	O	O
.	O	O
18	O	O
;	O	O
hemoglobin	B-PHEN
,	O	O
10	O	O
.	O	O

5g	O	O
/	O	O
dL	O	O
versus	O	O
13	O	O
.	O	O

5g	O	O
/	O	O
dL	O	O
;	O	O
lactate	B-PHEN
,	O	O
3	O	O
.	O	O

5mmol	O	O
/	O	O
L	O	O
versus	O	O
1	O	O
.	O	O

7mmol	O	O
/	O	O
L	O	O
)	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
ROC	O
curves	O
for	O	O
FDP	B-CHEM
,	O	O
D	B-CHEM
-	I-CHEM
dimer	I-CHEM
,	O	O
the	O	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
,	O	O
the	O	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
,	O	O
hemoglobin	B-PHEN
and	O	O
lactate	B-PHEN
levels	I-PHEN
were	O	O
0	O	O
.	O	O
900	O	O
,	O	O
0	O	O
.	O	O
882	O	O
,	O	O
0	O	O
.	O	O
918	O	O
,	O	O
0	O	O
.	O	O
900	O	O
,	O	O
0	O	O
.	O	O
815	O	O
and	O	O
0	O	O
.	O	O
765	O	O
,	O	O
respectively	O	O
.	O	O

Coagulation	B-PHYS
biomarkers	B-PHYS
,	O	O
and	O	O
hemoglobin	B-PHEN
and	O	O
lactate	B-PHEN
levels	I-PHEN
could	O	O
be	O	O
useful	O
to	O	O
predict	O
the	O	O
existence	B-DISO
of	O	O
arterial	B-ANAT
extravasation	B-DISO
due	O	O
to	O	O
pelvic	B-DISO
fracture	I-DISO
.	O	O

The	O	O
ratio	O
of	O
FDP	O
to	O
fibrinogen	O
and	O	O
the	O	O
ratio	O
of	O
D	O
-	O
dimer	O
to	O
fibrinogen	O
were	O	O
the	O	O
most	O	O
accurate	B-DEVI
markers	I-DEVI
.	O	O

Coagulation	B-PHYS
biomarkers	B-PHYS
may	O	O
enable	O	O
more	O	O
rapid	O	O
and	O	O
specific	O	O
treatment	O
for	O	O
pelvic	B-DISO
fracture	I-DISO
.	O	O

Social	O
security	O
status	O
and	O	O
mortality	B-DISO
in	O	O
Belgian	B-LIVB
and	O	O
Spanish	B-LIVB
male	B-LIVB
workers	B-LIVB
To	O	O
assess	B-PROC
differences	O
in	O	O
mortality	O
rates	O
between	O	O
social	O
security	O
statuses	O
in	O	O
two	O	O
independent	O	O
samples	B-LIVB
of	O	O
Belgian	B-LIVB
and	O	O
Spanish	B-LIVB
male	B-LIVB
workers	B-LIVB
.	O	O

Study	B-PROC
of	I-PROC
two	I-PROC
retrospective	I-PROC
cohorts	I-PROC
(	O	O
Belgium	B-GEOG
,	O	O
n	O	O
=	O	O
23	O	O
,	O	O
607	O	O
;	O	O
Spain	B-GEOG
,	O	O
n	O	O
=	O	O
44	O	O
,	O	O
385	O	O
)	O	O
of	O	O
50	O	O
-	O	O
60	O	O
year	O	O
old	O	O
male	B-LIVB
employees	B-LIVB
with	O	O
4	O	O
years	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Mortality	O
rate	O
ratios	O
(	O	O
MRR	O
)	O	O
were	O	O
estimated	O
using	O	O
Poisson	O
regression	O
models	O
.	O	O

Mortality	B-DISO
for	O	O
subjects	B-LIVB
with	O	O
permanent	O
disability	B-DISO
was	O	O
higher	O
than	O	O
for	O	O
the	O	O
employed	B-DISO
,	O	O
for	O	O
both	O	O
Belgium	B-GEOG
[	O	O
MRR	O
=	O	O
4	O	O
.	O	O
56	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
2	O	O
.	O	O
88	O	O
-	O	O
7	O	O
.	O	O
21	O	O
)	O	O
]	O	O
and	O	O
Spain	B-GEOG
[	O	O
MRR	O
=	O	O
7	O	O
.	O	O
15	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
5	O	O
.	O	O
37	O	O
-	O	O
9	O	O
.	O	O
51	O	O
)	O	O
]	O	O
.	O	O

For	O	O
the	O	O
unemployed	B-DISO
/	O	O
early	O
retirees	B-LIVB
,	O	O
mortality	B-DISO
was	O	O
higher	O
in	O	O
Spain	B-GEOG
[	O	O
MRR	O
=	O	O
1	O	O
.	O	O

64	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
24	O	O
-	O	O
2	O	O
.	O	O
17	O	O
)	O	O
]	O	O
than	O	O
in	O	O
Belgium	B-GEOG
[	O	O
MRR	O
=	O	O
0	O	O
.	O	O
88	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
46	O	O
-	O	O
1	O	O
.	O	O
71	O	O
)	O	O
]	O	O
.	O	O

MRR	O
differences	O
between	O	O
Belgium	B-GEOG
and	O	O
Spain	B-GEOG
for	O	O
unemployed	B-DISO
workers	B-LIVB
could	O	O
be	O	O
partly	O	O
explained	O	O
because	O	O
of	O	O
differences	O
between	O	O
the	O	O
two	O	O
social	O
security	O
systems	O
.	O	O

Future	O
studies	B-PROC
should	O	O
further	O	O
explore	O	O
mortality	B-DISO
differences	O
between	O	O
countries	B-GEOG
with	O	O
different	O
social	O
security	O
systems	O
.	O	O

Direct	O	O
contact	O	O
with	O	O
perivascular	B-ANAT
tumor	B-ANAT
cells	I-ANAT
enhances	O	O
integrin	B-CHEM
αvβ3	I-CHEM
signaling	B-PHYS
and	O	O
migration	B-PHYS
of	O	O
endothelial	B-ANAT
cells	I-ANAT
The	O	O
secretion	B-PHYS
of	O	O
soluble	O	O
pro	B-CHEM
-	I-CHEM
angiogenic	I-CHEM
factors	I-CHEM
by	O	O
tumor	B-ANAT
cells	I-ANAT
and	O	O
stromal	B-ANAT
cells	I-ANAT
in	O	O
the	O	O
perivascular	B-ANAT
niche	O	O
promotes	O	O
the	O	O
aggressive	B-DISO
angiogenesis	I-DISO
that	O	O
is	O	O
typical	O	O
of	O	O
glioblastoma	B-DISO
(	O	O
GBM	B-DISO
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
angiogenesis	B-DISO
also	O	O
can	O	O
be	O	O
promoted	O	O
by	O	O
a	O	O
direct	O	O
interaction	O	O
between	O	O
brain	B-ANAT
tumor	B-ANAT
cells	I-ANAT
,	O	O
including	O	O
tumor	B-ANAT
cells	I-ANAT
with	O	O
cancer	B-ANAT
stem	I-ANAT
-like	O	O
properties	O	O
(	O	O
CSCs	B-ANAT
)	O	O
,	O	O
and	O	O
endothelial	B-ANAT
cells	I-ANAT
(	O	O
ECs	B-ANAT
)	O	O
.	O	O

As	O	O
shown	O	O
in	O
vitro	O
,	O	O
this	O	O
direct	O	O
interaction	O	O
is	O	O
mediated	O	O
by	O	O
binding	B-PHYS
of	O	O
integrin	B-CHEM
αvβ3	I-CHEM
expressed	B-PHYS
on	O	O
ECs	B-ANAT
to	O	O
the	O	O
RGD	B-CHEM
-	I-CHEM
peptide	I-CHEM
in	O	O
L1CAM	B-CHEM
expressed	B-PHYS
on	O	O
CSCs	B-ANAT
.	O	O

It	O	O
promotes	O	O
both	O	O
EC	B-ANAT
network	B-PHYS
formation	I-PHYS
and	O	O
enhances	O	O
directed	O	O
migration	B-PHYS
toward	O	O
basic	O	O
fibroblast	B-CHEM
growth	I-CHEM
factor	I-CHEM
.	O	O

Activation	O
of	O	O
αvβ3	B-CHEM
and	O	O
bone	B-CHEM
marrow	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
on	I-CHEM
chromosome	I-CHEM
X	I-CHEM
(	O	O
BMX	B-CHEM
)	O	O
is	O	O
required	O	O
for	O	O
migration	B-PHYS
stimulated	O	O
by	O	O
direct	O	O
binding	B-PHYS
but	O	O
not	O	O
for	O	O
migration	B-PHYS
stimulated	O	O
by	O	O
soluble	O	O
factors	O	O
.	O	O

RGD	B-CHEM
-	I-CHEM
peptide	I-CHEM
treatment	O
of	O	O
mice	B-LIVB
with	O	O
established	O	O
intracerebral	O
GBM	B-DISO
xenografts	B-CHEM
significantly	O	O
reduced	O	O
the	O	O
percentage	O	O
of	O	O
Sox2	B-CHEM
-positive	O	O
tumor	B-ANAT
cells	I-ANAT
and	O	O
CSCs	B-ANAT
in	O	O
close	O	O
proximity	O	O
to	O	O
ECs	B-ANAT
,	O	O
decreased	O	O
integrin	B-CHEM
αvβ3	I-CHEM
and	O	O
BMX	B-CHEM
activation	O	O
and	O	O
p130CAS	B-CHEM
phosphorylation	B-PHYS
in	O	O
the	O	O
ECs	B-ANAT
,	O	O
and	O	O
reduced	O	O
the	O	O
vessel	B-ANAT
surface	O
area	O
.	O	O

These	O	O
results	O	O
reveal	O	O
a	O	O
previously	O	O
unrecognized	O	O
aspect	O	O
of	O	O
the	O	O
regulation	B-PHEN
of	O	O
angiogenesis	B-DISO
in	O	O
GBM	B-DISO
that	O	O
can	O	O
impact	O	O
therapeutic	O
anti	B-CHEM
-	I-CHEM
angiogenic	I-CHEM
targeting	O	O
.	O	O

Evaluation	O	O
of	O	O
the	O	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
for	O	O
Magnetic	B-PROC
Resonance	I-PROC
Imaging	I-PROC
Diagnosis	B-PROC
of	O	O
Prostate	B-DISO
Cancer	I-DISO
in	O	O
Patients	B-LIVB
with	O	O
Prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
Antigen	I-CHEM
<	O	O
20	O	O
ng	O	O
/	O	O
ml	O	O
The	O	O
European	O
Society	O
of	O
Urogenital	O
Radiology	O
has	O	O
built	O	O
the	O	O
Prostate	O
Imaging	O
Reporting	O
and	O
Data	O
System	O
(	O	O
PI	O
-	O
RADS	O
)	O	O
for	O	O
standardizing	O	O
the	O	O
diagnosis	B-PROC
of	O	O
prostate	B-DISO
cancer	I-DISO
(	O	O
PCa	B-DISO
)	O	O
.	O	O

This	O	O
study	B-PROC
evaluated	O	O
the	O	O
PI	O
-	O
RADS	O
diagnosis	B-PROC
method	I-PROC
in	O	O
patients	B-LIVB
with	O	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
(	O	O
PSA	B-CHEM
)	O	O
<	O	O
20	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

A	O	O
total	O	O
of	O	O
133	O	O
patients	B-LIVB
with	O	O
PSA	B-CHEM
<	O	O
20	O	O
ng	O	O
/	O	O
ml	O	O
were	O	O
prospectively	O	O
recruited	O	O
.	O	O

T2	B-PROC
-	I-PROC
weighted	I-PROC
(	O	O
T2WI	B-PROC
)	O	O
and	O	O
diffusion	B-PROC
-	I-PROC
weighted	I-PROC
(	I-PROC
DWI	I-PROC
)	I-PROC
magnetic	I-PROC
resonance	I-PROC
images	I-PROC
of	O	O
the	O	O
prostate	B-ANAT
were	O	O
acquired	O	O
before	O	O
a	O	O
12	B-PROC
-	I-PROC
core	I-PROC
transrectal	I-PROC
prostate	I-PROC
biopsy	I-PROC
.	O	O

Each	O	O
patient	B-LIVB
's	I-LIVB
peripheral	B-ANAT
zone	I-ANAT
was	O	O
divided	O	O
into	O	O
six	O	O
regions	O	O
on	O	O
the	O	O
images	O
;	O	O
each	O	O
region	O	O
corresponded	O	O
to	O	O
two	O	O
of	O	O
the	O	O
12	O	O
biopsy	B-PROC
cores	I-PROC
.	O	O

T2WI	B-PROC
,	O	O
DWI	B-PROC
,	O	O
and	O	O
T2WI	B-PROC
+	O	O
DWI	B-PROC
scores	O
were	O	O
computed	O	O
according	O	O
to	O	O
PI	O
-	O
RADS	O
.	O	O

The	O	O
diagnostic	O
accuracy	O
of	O	O
the	O	O
PI	O
-	O
RADS	O
score	O
was	O	O
evaluated	O	O
using	O	O
histopathology	O
of	O	O
prostate	B-PROC
biopsies	I-PROC
as	O	O
the	O	O
reference	O	O
standard	O	O
.	O	O

PCa	B-DISO
was	O	O
histologically	O
diagnosed	O
in	O	O
169	O	O
(	O	O
21	O	O
.	O	O
2	O	O
%	O	O
)	O	O
regions	O	O
.	O	O

Increased	O	O
PI	O
-	O
RADS	O
score	O
correlated	O	O
positively	O	O
with	O	O
increased	O	O
cancer	B-PROC
detection	I-PROC
rate	O
.	O	O

The	O	O
cancer	B-PROC
detection	I-PROC
rate	O
for	O	O
scores	O
1	O	O
to	O	O
5	O	O
was	O	O
2	O	O
.	O	O

8	O	O
%	O	O
,	O	O
15	O	O
.	O	O
0	O	O
%	O	O
,	O	O
34	O	O
.	O	O

6	O	O
%	O	O
,	O	O
52	O	O
.	O	O

6	O	O
%	O	O
,	O	O
and	O	O
88	O	O
.	O	O

9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
using	O	O
T2WI	B-PROC
and	O	O
12	O	O
.	O	O
0	O	O
%	O	O
,	O	O
20	O	O
.	O	O
2	O	O
%	O	O
,	O	O
48	O	O
.	O	O
0	O	O
%	O	O
,	O	O
85	O	O
.	O	O
7	O	O
%	O	O
,	O	O
and	O	O
93	O	O
.	O	O
3	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
using	O	O
DWI	B-PROC
.	O	O

For	O	O
T2WI	B-PROC
+	O	O
DWI	B-PROC
,	O	O
the	O	O
cancer	B-PROC
detection	I-PROC
rate	O
was	O	O
1	O	O
.	O	O

5	O	O
%	O	O
(	O	O
score	O
2	O	O
)	O	O
,	O	O
13	O	O
.	O	O
5	O	O
%	O	O
(	O	O
scores	O
3	O	O
-	O	O
4	O	O
)	O	O
,	O	O
41	O	O
.	O	O
3	O	O
%	O	O
(	O	O
scores	O
5	O	O
-	O	O
6	O	O
)	O	O
,	O	O
75	O	O
.	O	O
9	O	O
%	O	O
(	O	O
scores	O
7	O	O
-	O	O
8	O	O
)	O	O
,	O	O
and	O	O
92	O	O
.	O	O
3	O	O
%	O	O
(	O	O
scores	O
9	O	O
-	O	O
10	O	O
)	O	O
.	O	O

The	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
for	O	O
cancer	B-PROC
detection	I-PROC
was	O	O
0	O	O
.	O	O
700	O	O
(	O	O
T2WI	B-PROC
)	O	O
,	O	O
0	O	O
.	O	O
735	O	O
(	O	O
DWI	B-PROC
)	O	O
and	O	O
0	O	O
.	O	O
749	O	O
(	O	O
T2WI	B-PROC
+	O	O
DWI	B-PROC
)	O	O
.	O	O

The	O	O
sensitivity	O	O
and	O	O
specificity	O	O
were	O	O
53	O	O
.	O	O

8	O	O
%	O	O
and	O	O
89	O	O
.	O	O

2	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
when	O	O
using	O	O
scores	O
5	O	O
-	O	O
6	O	O
as	O	O
the	O	O
cutoff	O	O
value	O	O
for	O	O
T2WI	B-PROC
+	O	O
DWI	B-PROC
.	O	O

The	O	O
PI	O
-	O
RADS	O
score	O
correlates	O	O
with	O	O
the	O	O
PCa	B-PROC
detection	I-PROC
rate	O
in	O	O
patients	B-LIVB
with	O	O
PSA	B-CHEM
<	O	O
20	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

The	O	O
summed	O	O
score	O
of	O	O
T2WI	B-PROC
+	O	O
DWI	B-PROC
has	O	O
the	O	O
highest	O	O
accuracy	O	O
in	O	O
detection	O	O
of	O	O
PCa	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
sensitivity	O	O
should	O	O
be	O	O
further	O	O
improved	O	O
.	O	O

The	O	O
use	O	O
of	O	O
Ocimum	B-LIVB
americanum	I-LIVB
essential	B-CHEM
oil	I-CHEM
against	O	O
the	O	O
pathogens	B-LIVB
Aeromonas	B-LIVB
hydrophila	I-LIVB
and	O	O
Gyrodactylus	O
sp	O
.	O

in	O	O
silver	B-LIVB
catfish	I-LIVB
(	O	O
Rhamdia	B-LIVB
quelen	I-LIVB
)	O	O
The	O	O
bactericidal	B-PHEN
activity	I-PHEN
(	O	O
MIC	B-PROC
-	I-PROC
test	I-PROC
)	O	O
of	O	O
Ocimum	B-LIVB
americanum	I-LIVB
(	O	O
inflorescences	B-LIVB
)	O	O
essential	B-CHEM
oil	I-CHEM
(	O	O
OAEO	B-CHEM
)	O	O
against	O	O
Aeromonas	B-LIVB
hydrophila	I-LIVB
was	O	O
determined	O	O
in	O	O
this	O	O
study	O	O
.	O	O

It	O	O
was	O	O
also	O	O
investigated	O	O
the	O	O
potential	O	O
of	O	O
OAEO	B-CHEM
and	O	O
the	O	O
main	O	O
compound	O
found	O	O
in	O	O
the	O	O
oil	B-CHEM
(	O	O
linalool	B-CHEM
)	O	O
at	O	O
subinhibitory	O	O
concentrations	O	O
to	O	O
be	O	O
inhibitors	B-CHEM
of	O	O
hemolysis	B-DISO
caused	O	O
by	O	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
in	O	O
fish	B-LIVB
erythrocytes	B-ANAT
.	O	O

An	O	O
in	B-PROC
vivo	I-PROC
experiment	I-PROC
was	O	O
conducted	O	O
to	O	O
evaluate	O	O
survival	O
of	O	O
fish	B-LIVB
(	O	O
Rhamdia	B-LIVB
quelen	I-LIVB
)	O	O
experimentally	B-PROC
infected	B-DISO
with	O	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
and	O	O
exposed	O
to	O	O
OAEO	B-CHEM
.	O	O

A	O	O
second	O	O
experiment	B-PROC
was	O	O
conducted	O	O
to	O	O
evaluate	O	O
the	O	O
in	B-PROC
vitro	I-PROC
and	O	O
in	B-PROC
vivo	I-PROC
activity	O	O
of	O	O
OAEO	B-CHEM
(	O	O
mix	O	O
from	O	O
inflorescences	B-LIVB
and	O	O
leaves	B-LIVB
)	O	O
against	O	O
the	O	O
parasite	O
Gyrodactylus	O
sp	O
.	O

The	O	O
OAEO	B-CHEM
showed	O	O
weak	O
in	B-PROC
vitro	I-PROC
activity	O	O
against	O	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
(	O	O
6400	O	O
μg	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
.	O	O

At	O	O
subinhibitory	O	O
concentrations	O	O
OAEO	B-CHEM
(	O	O
100	O	O
μg	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
inhibited	O
hemolysis	B-DISO
(	O	O
90	O	O
%	O	O
)	O	O
caused	O	O
by	O	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
in	O	O
fish	B-LIVB
erythrocytes	B-ANAT
,	O	O
however	O	O
,	O	O
linalool	B-CHEM
did	O	O
not	O
present	O
hemolysis	B-DISO
inhibition	O
activity	O
.	O	O

At	O	O
low	O	O
concentrations	O	O
(	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
added	O	O
to	O	O
the	O	O
water	B-CHEM
OAEO	B-CHEM
promoted	O
survival	O
of	O	O
experimentally	O	O
infected	B-DISO
fish	B-LIVB
with	O	O
Aer	B-LIVB
.	I-LIVB

hydrophila	I-LIVB
.	O	O

Lastly	O	O
,	O	O
OAEO	B-CHEM
-mix	O	O
(	O	O
50	O	O
mg	O	O
l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
was	O	O
effective	O
against	O	O
Gyrodactylus	O
sp	O
.	O

significantly	O
reducing	O
(	O	O
60	O	O
%	O	O
)	O	O
the	O	O
number	O	O
of	O	O
parasites	O
in	O	O
the	O	O
fish	B-LIVB
.	O	O

This	O	O
article	O	O
is	O	O
protected	O	O
by	O	O
copyright	O	O
.	O	O

All	O	O
rights	O	O
reserved	O	O
.	O	O

Efficacy	O
and	O	O
safety	O
of	O	O
asenapine	B-CHEM
in	O	O
Asian	B-LIVB
patients	B-LIVB
with	O	O
an	O	O
acute	B-DISO
exacerbation	I-DISO
of	O	O
schizophrenia	B-DISO
:	O	O
a	O	O
multicentre	B-PROC
,	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
6	O	O
-	O	O
week	O
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
study	I-PROC
Asenapine	B-CHEM
is	O	O
a	O	O
second	O	O
generation	O	O
anti	B-CHEM
-	I-CHEM
psychotic	I-CHEM
approved	O	O
in	O	O
the	O	O
USA	B-GEOG
in	O	O
2009	O	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
schizophrenia	B-DISO
,	O	O
but	O	O
its	O	O
efficacy	O
has	O	O
not	O	O
been	O	O
proven	O	O
in	O	O
Asian	B-LIVB
patients	B-LIVB
.	O	O

The	O	O
objectives	O
of	O	O
this	O	O
study	B-PROC
are	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O
and	O	O
tolerability	O
of	O	O
asenapine	B-CHEM
in	O	O
Asian	B-LIVB
patients	B-LIVB
experiencing	O	O
an	O	O
acute	B-DISO
exacerbation	I-DISO
of	O	O
schizophrenia	B-DISO
.	O	O

In	O	O
this	O	O
prospective	O	O
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
,	O	O
patients	B-LIVB
in	O	O
Japan	B-GEOG
,	O	O
Korea	B-GEOG
,	O	O
and	O	O
Taiwan	B-GEOG
were	O	O
randomized	B-PROC
(	O	O
1	O	O
:	O	O
1	O	O
:	O	O
1	O	O
)	O	O
to	O	O
asenapine	B-CHEM
5	O	O
mg	O	O
twice	O
daily	O
(	O	O
bid	O
)	O	O
,	O	O
10	O	O
mg	O	O
bid	O
or	O	O
placebo	B-PROC
for	O	O
6	O	O
weeks	O
after	O	O
a	O	O
3	O	O
-	O	O
to	O	O
7	O	O
-	O	O
day	O
washout	O
/	O	O
screening	O
period	O
.	O	O

The	O	O
primary	B-CHEM
endpoint	I-CHEM
was	O	O
the	O	O
mean	O	O
change	O	O
in	O	O
the	O	O
positive	O
and	O
negative	O
syndrome	O
scale	O
(	O	O
PANSS	O
)	O	O
total	O	O
score	O
from	O	O
baseline	O
to	O	O
day	O
42	O	O
/	O	O
treatment	B-PROC
end	O	O
.	O	O

Of	O	O
the	O	O
532	O	O
participants	B-LIVB
randomized	B-PROC
,	O	O
530	O	O
received	O	O
treatment	B-PROC
.	O	O

The	O	O
primary	B-CHEM
endpoint	I-CHEM
was	O	O
significantly	O	O
greater	O	O
with	O	O
asenapine	B-CHEM
5	O	O
and	O	O
10	O	O
mg	O	O
bid	O
than	O	O
with	O	O
placebo	B-PROC
(	O	O
-12	O	O
.	O	O
24	O	O
and	O	O
-14	O	O
.	O	O
17	O	O
vs	O	O
.	O	O

-0	O	O
.	O	O
95	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

The	O	O
results	O
of	O	O
secondary	O
endpoints	O
including	O	O
PANSS	O
negative	O
subscale	O
scores	O
and	O	O
PANSS	O
responders	O	O
at	O	O
the	O	O
end	O	O
of	O	O
treatment	B-PROC
supported	O	O
the	O	O
results	O
of	O	O
the	O	O
primary	B-CHEM
endpoint	I-CHEM
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
incidence	O
of	O	O
treatment	O
-emergent	O
adverse	B-DISO
events	I-DISO
reported	O	O
with	O	O
asenapine	B-CHEM
5	O	O
and	O	O
10	O	O
mg	O	O
bid	O
and	O	O
placebo	B-PROC
(	O	O
84	O	O
.	O	O
6	O	O
,	O	O
80	O	O
.	O	O
7	O	O
,	O	O
and	O	O
81	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
mean	O	O
(	O	O
±	O	O
standard	O
deviation	O
)	O	O
change	O	O
in	O	O
weight	O	O
of	O	O
-1	O	O
.	O	O

76	O	O
±	O	O
2	O	O
.	O	O

45	O	O
kg	O	O
for	O	O
placebo	B-PROC
,	O	O
+0	O	O
.	O	O

42	O	O
±	O	O
2	O	O
.	O	O
65	O	O
kg	O	O
for	O	O
asenapine	B-CHEM
5	O	O
mg	O	O
bid	O
,	O	O
and	O	O
+0	O	O
.	O	O

81	O	O
±	O	O
2	O	O
.	O	O
89	O	O
kg	O	O
for	O	O
asenapine	B-CHEM
10	O	O
mg	O	O
bid	O
group	O	O
.	O	O

Asenapine	B-CHEM
was	O	O
effective	O
and	O	O
generally	O	O
well	O	O
tolerated	O
when	O	O
used	O	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
acute	B-DISO
exacerbations	I-DISO
of	O	O
schizophrenia	B-DISO
in	O	O
Asian	B-LIVB
patients	B-LIVB
.	O	O

Interleukin	B-CHEM
-	I-CHEM
1β	I-CHEM
induced	O	O
Stress	B-ANAT
Granules	I-ANAT
Sequester	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
mRNA	B-CHEM
and	O	O
Regulates	B-PHEN
its	O	O
Stability	O
and	O	O
Translation	O
in	O	O
Human	B-LIVB
OA	B-DISO
Chondrocytes	B-ANAT
Enhanced	O
and	O	O
immediate	O	O
expression	B-PHYS
of	O	O
cyclooxygenase	O
-	O
2	O
(	O	O
COX	O
-	O
2	O
)	O	O
mRNA	B-CHEM
is	O	O
observed	O	O
in	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
but	O	O
the	O	O
synthesis	B-PHYS
of	I-PHYS
protein	I-PHYS
found	O	O
significantly	O	O
delayed	O
.	O	O

Here	O	O
we	O	O
investigated	O	O
the	O	O
role	O	O
of	O	O
stress	B-ANAT
granules	I-ANAT
(	O	O
SGs	B-ANAT
)	O	O
,	O	O
ribonucleoprotein	B-ANAT
complexes	I-ANAT
that	O	O
regulate	B-PHEN
mRNA	O
translation	O
,	O	O
in	O	O
the	O	O
delayed	O
translation	O
of	O	O
COX	O
-	O
2	O
mRNAs	B-CHEM
in	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
.	O	O

Stimulation	B-PROC
of	O	O
human	B-LIVB
chondrocytes	B-ANAT
with	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
activated	O	O
the	O	O
stress	B-PHYS
response	I-PHYS
genes	O
and	O	O
the	O	O
phosphorylation	B-PHYS
of	O	O
eIF2α	B-CHEM
that	O	O
triggered	O
the	O	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
.	O	O

Using	O	O
combined	O	O
immunofluorescence	B-PROC
staining	I-PROC
of	O	O
SGs	B-ANAT
markers	B-PHYS
and	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
,	O	O
RNA	B-CHEM
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
and	O	O
RNA	B-CHEM
immunoprecipitation	B-PROC
,	O	O
the	O	O
COX	O
-	O
2	O
mRNAs	B-CHEM
were	O	O
found	O	O
sequestered	O
in	O	O
SGs	B-ANAT
in	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-	O	O
stimulated	B-PROC
OA	B-DISO
chondrocytes	B-ANAT
.	O	O

No	B-DISO
increase	O
in	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	B-PHYS
expression	I-PHYS
was	O	O
observed	O	O
during	O	O
the	O	O
persistence	O
of	O	O
SGs	B-ANAT
but	O	O
enhanced	O
expression	B-PHYS
of	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
was	O	O
noted	O	O
upon	O	O
clearance	O
of	O	O
the	O	O
SGs	B-ANAT
.	O	O

Inhibition	O
of	O	O
SGs	B-ANAT
clearance	O
blocked	O
COX	O
-	O
2	O
mRNA	B-CHEM
translation	O
whereas	O	O
blocking	O
the	O	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
by	O	O
TIA	B-CHEM
-	I-CHEM
1	I-CHEM
depletion	O
resulted	O	O
in	O	O
rapid	O	O
and	O	O
increased	O
production	O
of	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
PGE2	B-CHEM
.	O	O

Our	O	O
findings	O	O
show	O	O
for	O	O
the	O	O
first	O	O
time	O	O
assembly	B-PHYS
of	I-PHYS
SGs	I-PHYS
and	O	O
sequestration	O
of	O	O
COX	O
-	O
2	O
mRNAs	B-CHEM
in	O	O
human	B-LIVB
OA	B-DISO
chondrocytes	B-ANAT
under	O	O
pathological	B-DISO
conditions	I-DISO
.	O	O

Post	B-PHYS
-	I-PHYS
transcriptional	I-PHYS
regulation	I-PHYS
of	O	O
COX	O
-	O
2	O
mRNAs	O
translation	O
by	O	O
SGs	B-ANAT
indicates	O	O
a	O	O
role	O	O
in	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
-mediated	O	O
catabolic	O
response	B-PHYS
that	O	O
could	O	O
be	O	O
therapeutically	B-PROC
targeted	O	O
in	O	O
OA	B-DISO
.	O	O

Effect	O
of	O	O
target	O
animacy	O	O
on	O	O
hand	B-DISO
preference	I-DISO
in	O	O
Sichuan	B-LIVB
snub	I-LIVB
-	I-LIVB
nosed	I-LIVB
monkeys	I-LIVB
(	O	O
Rhinopithecus	B-LIVB
roxellana	I-LIVB
)	O	O
Twenty	O
-	O
eight	O
captive	O	O
Sichuan	B-LIVB
snub	I-LIVB
-	I-LIVB
nosed	I-LIVB
monkeys	I-LIVB
(	O	O
Rhinopithecus	B-LIVB
roxellana	I-LIVB
)	O	O
were	O	O
involved	O
in	O	O
the	O	O
current	O	O
study	B-PROC
.	O	O

Many	O	O
individuals	O	O
showed	O	O
handedness	B-PHYS
,	O	O
with	O	O
a	O	O
modest	O	O
tendency	O	O
toward	O	O
left	B-DISO
-	I-DISO
hand	I-DISO
use	I-DISO
especially	O	O
for	O	O
animate	O
targets	O
,	O	O
although	O	O
no	O	O
group	O	O
-	O	O
level	O	O
handedness	B-PHYS
was	O	O
found	B-DISO
.	O	O

There	O	O
was	O	O
no	B-DISO
significant	I-DISO
gender	B-PHYS
difference	I-PHYS
in	O	O
the	O	O
direction	O
and	O	O
strength	O
of	O	O
hand	B-DISO
preference	I-DISO
for	O	O
both	O
targets	O
.	O	O

Females	B-PHYS
showed	O	O
a	O	O
significantly	O
higher	O
overall	O
rate	O
of	O	O
actions	O
toward	O
animate	O
targets	O
than	O	O
inanimate	O
targets	O
for	O	O
both	O
hands	B-ANAT
,	O	O
whereas	O	O
males	B-PHYS
displayed	O
almost	O
the	O	O
reversed	O
pattern	O	O
.	O	O

There	O	O
were	O	O
no	B-DISO
significant	I-DISO
interactions	O
between	O	O
lateral	O
hand	B-PHYS
use	I-PHYS
and	O	O
target	O
animacy	O	O
for	O	O
either	B-DISO
males	B-PHYS
or	O	O
females	B-PHYS
.	O	O

Most	O	O
individuals	O	O
showed	O	O
rightward	O	O
or	O	O
leftward	O	O
laterality	O	O
shift	O
trends	O
between	O	O
inanimate	O	O
and	O	O
animate	O
targets	O
.	O	O

These	O	O
findings	B-DISO
to	O
some	O
extent	O
support	O
the	O	O
existence	O
of	O	O
a	O	O
potential	O
trend	O
concerning	O	O
a	O	O
categorical	O	O
neural	O
distinction	O
between	O	O
targets	O
demanding	O	O
functional	O
manipulation	B-DISO
(	O	O
inanimate	B-OBJC
objects	I-OBJC
)	O	O
and	O	O
those	O	O
demanding	O	O
social	O
manipulation	B-DISO
(	O	O
animate	B-OBJC
objects	I-OBJC
)	O	O
,	O	O
even	O	O
though	O	O
specialized	O
hand	B-DISO
preference	I-DISO
based	O	O
on	O	O
target	O
animacy	O
has	O	O
not	O	O
been	O	O
fully	O	O
established	O
in	O	O
this	O	O
arboreal	B-LIVB
Old	I-LIVB
World	I-LIVB
monkey	I-LIVB
species	I-LIVB
.	O	O

Association	O
of	O	O
Autoimmune	B-DISO
Encephalitis	I-DISO
With	O	O
Combined	O	O
Immune	B-CHEM
Checkpoint	I-CHEM
Inhibitor	I-CHEM
Treatment	O
for	O	O
Metastatic	B-DISO
Cancer	I-DISO
Paraneoplastic	B-DISO
encephalitides	I-DISO
usually	O	O
precede	O	O
a	O	O
diagnosis	B-PROC
of	I-PROC
cancer	I-PROC
and	O	O
are	O	O
often	O	O
refractory	O
to	O	O
immunosuppressive	B-PROC
therapy	I-PROC
.	O	O

Conversely	O	O
,	O	O
autoimmune	B-DISO
encephalitides	I-DISO
are	O	O
reversible	O
conditions	O
that	O	O
can	O	O
occur	O
in	O	O
the	O	O
presence	B-DISO
or	O	O
absence	O
of	O	O
cancer	B-DISO
.	O	O

To	O	O
report	O	O
the	O	O
induction	O
of	O	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O	O
2	O	O
patients	B-LIVB
after	O	O
treatment	O
of	O	O
metastatic	B-DISO
cancer	I-DISO
with	O	O
a	O	O
combination	O
of	O	O
the	O	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
nivolumab	B-CHEM
and	O	O
ipilimumab	B-CHEM
.	O	O

A	O	O
retrospective	B-PROC
case	I-PROC
study	I-PROC
was	O	O
conducted	O	O
of	O	O
the	O	O
clinical	B-PROC
and	I-PROC
management	I-PROC
course	O
of	O	O
2	O	O
patients	B-LIVB
with	O	O
progressive	O
,	O	O
treatment	O
-	O	O
refractory	B-DISO
metastatic	I-DISO
cancer	I-DISO
who	O	O
were	O	O
treated	B-PROC
with	I-PROC
a	O	O
single	O
dose	O
each	O	O
(	O	O
concomitantly	O
)	O	O
of	O	O
the	O	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
nivolumab	B-CHEM
,	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
and	O	O
ipilimumab	B-CHEM
,	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Nivolumab	B-CHEM
and	O	O
ipilimumab	B-CHEM
.	O	O

The	O	O
clinical	B-DISO
response	I-DISO
to	O	O
immunosuppressive	B-PROC
therapy	I-PROC
in	O	O
suspected	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O	O
the	O	O
setting	O	O
of	O	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitor	I-CHEM
use	O	O
.	O	O

Autoantibody	B-PROC
testing	I-PROC
confirmed	B-DISO
identification	O
of	O	O
anti	B-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
antibodies	I-CHEM
in	O	O
the	O	O
cerebrospinal	B-ANAT
fluid	I-ANAT
of	O	O
1	O	O
patient	B-LIVB
.	O	O

Withdrawal	O
of	O	O
immune	B-CHEM
checkpoint	I-CHEM
inhibitors	I-CHEM
and	O	O
initiation	O
of	O	O
immunosuppressive	B-PROC
therapy	I-PROC
,	O	O
consisting	O	O
of	O	O
intravenous	O
methylprednisolone	B-CHEM
sodium	I-CHEM
succinate	I-CHEM
equivalent	I-CHEM
to	I-CHEM
1000	I-CHEM
mg	I-CHEM
of	I-CHEM
methylprednisolone	I-CHEM
for	O	O
5	O	O
days	O
,	O	O
0	O	O
.	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
d	O	O
of	O	O
intravenous	B-CHEM
immunoglobulin	I-CHEM
for	O	O
5	O	O
days	O
,	O	O
and	O	O
2	O	O
doses	O
of	O	O
rituximab	B-CHEM
,	O	O
1000	O	O
mg	O	O
,	O	O
in	O	O
1	O	O
patient	B-LIVB
and	O	O
oral	B-CHEM
prednisone	I-CHEM
,	O	O
60	O	O
mg	O	O
/	O	O
d	O	O
,	O	O
in	O	O
the	O	O
other	O	O
patient	B-LIVB
,	O	O
resulted	O	O
in	O	O
improved	B-DISO
neurologic	B-DISO
symptoms	I-DISO
.	O	O

Immune	B-PHYS
checkpoint	I-PHYS
inhibition	I-PHYS
may	O	O
favor	O	O
the	O	O
development	O
of	O	O
immune	B-PHYS
responses	I-PHYS
against	O	O
neuronal	B-CHEM
antigens	I-CHEM
,	O	O
leading	O	O
to	O	O
autoimmune	B-DISO
encephalitis	I-DISO
.	O	O

Early	B-PROC
recognition	I-PROC
and	O	O
treatment	O
of	O	O
autoimmune	B-DISO
encephalitis	I-DISO
in	O	O
patients	B-LIVB
receiving	O	O
immune	B-PROC
checkpoint	I-PROC
blockade	I-PROC
therapy	I-PROC
will	O	O
likely	O	O
be	O	O
essential	O
for	O	O
maximizing	O	O
clinical	O
recovery	O
and	O	O
minimizing	O	O
the	O	O
effect	O	O
of	O	O
drug	B-DISO
-	I-DISO
related	I-DISO
toxic	I-DISO
effects	I-DISO
.	O	O

The	O	O
mechanisms	O	O
by	O	O
which	O	O
immune	B-PHYS
checkpoint	I-PHYS
inhibition	I-PHYS
may	O	O
contribute	O	O
to	O	O
autoimmune	B-DISO
encephalitis	I-DISO
require	O	O
further	O	O
study	O	O
.	O	O

Spatio	O
-	O
Temporal	O
Distribution	O
of	O	O
Bark	B-LIVB
and	O	O
Ambrosia	B-LIVB
Beetles	O
in	O	O
a	O	O
Brazilian	B-GEOG
Tropical	B-PHEN
Dry	I-PHEN
Forest	I-PHEN
Bark	B-LIVB
and	O	O
the	O	O
ambrosia	B-LIVB
beetles	O
dig	O	O
into	O	O
host	O
plants	O
and	O	O
live	O	O
most	O	O
of	O	O
their	O	O
lives	O	O
in	O	O
concealed	O	O
tunnels	O
.	O	O

We	O	O
assessed	O
beetle	O
community	B-LIVB
dynamics	O
in	O	O
tropical	B-PHEN
dry	I-PHEN
forest	I-PHEN
sites	O
in	O	O
early	O
,	O	O
intermediate	O
,	O	O
and	O	O
late	O
successional	O
stages	O
,	O	O
evaluating	O	O
the	O	O
influence	O	O
of	O	O
resource	O
availability	O
and	O	O
seasonal	O
variations	O
in	O	O
guild	O
structure	O
.	O	O

We	O	O
collected	O
a	O	O
total	O	O
of	O	O
763	O	O
beetles	O
from	O	O
23	O	O
species	O
,	O	O
including	O	O
14	O	O
bark	B-LIVB
beetle	O
species	O
,	O	O
and	O	O
9	O	O
ambrosia	B-LIVB
beetle	O
species	O
.	O	O

Local	O
richness	O
of	O	O
bark	B-LIVB
and	O	O
ambrosia	B-LIVB
beetles	O
was	O	O
estimated	O	O
at	O	O
31	O	O
species	O
.	O	O

Bark	B-LIVB
and	O	O
ambrosia	B-LIVB
composition	O
was	O	O
similar	O	O
over	O	O
the	O	O
successional	O
stages	O
gradient	O
,	O	O
and	O	O
beta	O
diversity	O
among	O	O
sites	O
was	O	O
primarily	O	O
determined	O	O
by	O	O
species	O
turnover	O	O
,	O	O
mainly	O	O
in	O	O
the	O	O
bark	B-LIVB
beetle	O
community	B-LIVB
.	O	O

Bark	B-LIVB
beetle	O
richness	O
and	O	O
abundance	O
were	O	O
higher	O	O
at	O	O
intermediate	O
stages	O
;	O	O
availability	O
of	O
wood	B-OBJC
was	O	O
the	O	O
main	O	O
spatial	O
mechanism	O
.	O	O

Climate	B-PHEN
factors	O
were	O	O
effectively	O	O
non	O
-	O
seasonal	O
.	O	O

Ambrosia	B-LIVB
beetles	O
were	O	O
not	O	O
influenced	O	O
by	O	O
successional	O
stages	O
,	O	O
however	O	O
the	O	O
increase	O
in	O	O
wood	B-OBJC
resulted	O	O
in	O	O
increased	O
abundance	O
.	O	O

We	O	O
found	O	O
higher	O	O
richness	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
dry	O
and	O	O
wet	O
seasons	O
,	O	O
and	O	O
abundance	O
increased	O
with	O	O
air	B-OBJC
moisture	B-OBJC
and	O	O
decreased	O	O
with	O	O
higher	O	O
temperatures	O
and	O	O
greater	O	O
rainfall	B-PHEN
.	O	O

In	O	O
summary	O	O
,	O	O
bark	B-LIVB
beetle	O
species	O
accumulation	O
was	O	O
higher	O	O
at	O	O
sites	O
with	O	O
better	O	O
wood	B-OBJC
production	O
,	O	O
while	O	O
the	O	O
needs	O	O
of	O	O
fungi	B-LIVB
(	O	O
host	O
and	O	O
air	B-OBJC
moisture	B-OBJC
)	O	O
,	O	O
resulted	O	O
in	O	O
a	O	O
favorable	O	O
conditions	O
for	O	O
species	O
accumulation	O
of	O	O
ambrosia	B-LIVB
.	O	O

The	O	O
overall	O	O
biological	O
pattern	O
among	O	O
guilds	O	O
differed	O	O
from	O	O
tropical	B-PHEN
rain	I-PHEN
forests	I-PHEN
,	O	O
showing	O	O
patterns	O	O
similar	O	O
to	O	O
dry	B-PHEN
forest	I-PHEN
areas	I-PHEN
.	O	O

Intron	B-CHEM
Derived	O
Size	O
Polymorphism	B-PHYS
in	O	O
the	O	O
Mitochondrial	O
Genomes	O
of	O	O
Closely	O
Related	O
Chrysoporthe	B-LIVB
Species	I-LIVB
In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
complete	O
mitochondrial	O
(	O
mt	O
)	O
genomes	O
of	O	O
Chrysoporthe	B-LIVB
austroafricana	I-LIVB
(	O	O
190	O	O
,	O	O
834	O	O
bp	O	O
)	O	O
,	O	O
C	B-LIVB
.	I-LIVB

cubensis	I-LIVB
(	O	O
89	O	O
,	O	O
084	O	O
bp	O	O
)	O	O
and	O	O
C	B-LIVB
.	I-LIVB

deuterocubensis	I-LIVB
(	O	O
124	O	O
,	O	O
412	O	O
bp	O	O
)	O	O
were	O	O
determined	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
mitochondrial	O
genome	O
of	O	O
another	O	O
member	O	O
of	O	O
the	O	O
Cryphonectriaceae	B-LIVB
,	O	O
namely	O	O
Cryphonectria	B-LIVB
parasitica	I-LIVB
(	O	O
158	O	O
,	O	O
902	O	O
bp	O	O
)	O	O
,	O	O
was	O	O
retrieved	O
and	O	O
annotated	O
for	O	O
comparative	B-PROC
purposes	I-PROC
.	O	O

These	O	O
genomes	O
showed	O	O
high	O	O
levels	O	O
of	O	O
synteny	B-PHYS
,	O	O
especially	O	O
in	O	O
regions	O
including	O
genes	O
involved	O
in	O
oxidative	B-PHYS
phosphorylation	I-PHYS
and	O	O
electron	B-PHYS
transfer	I-PHYS
,	O	O
unique	O
open	O
reading	O
frames	O
(	O
uORFs	O
)	O
,	O	O
ribosomal	B-CHEM
RNAs	I-CHEM
(	B-CHEM
rRNAs	I-CHEM
)	I-CHEM
and	O	O
transfer	B-CHEM
RNAs	I-CHEM
(	B-CHEM
tRNAs	I-CHEM
)	I-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
intron	B-CHEM
positions	O
.	O	O

Comparative	B-PROC
analyses	I-PROC
revealed	O
signatures	O
of	O	O
duplication	B-PHYS
events	O
,	O	O
intron	B-CHEM
number	B-PHEN
and	I-PHEN
length	I-PHEN
variation	I-PHEN
,	O	O
and	O	O
varying	B-PHEN
intronic	B-CHEM
ORFs	O
which	O	O
highlighted	O	O
the	O	O
genetic	B-PHEN
diversity	I-PHEN
of	O	O
mt	O
genomes	O
among	O	O
the	O	O
Cryphonectriaceae	B-LIVB
.	O	O

These	O	O
mt	O
genomes	O
showed	O	O
remarkable	O	O
size	O
polymorphism	B-PHYS
.	O	O

The	O	O
size	O
polymorphism	B-PHYS
in	O	O
the	O	O
mt	O
genomes	O
of	O	O
these	O	O
closely	O
related	O
Chrysoporthe	B-LIVB
species	I-LIVB
was	O	O
attributed	O	O
to	O	O
the	O	O
varying	B-PHEN
number	I-PHEN
and	I-PHEN
length	I-PHEN
of	O	O
introns	B-CHEM
,	O	O
coding	O
sequences	O
and	O	O
to	O	O
a	O	O
lesser	O
extent	O
,	O	O
intergenic	B-CHEM
sequences	I-CHEM
.	O	O

Compared	O
to	O	O
publicly	O	O
available	O	O
fungal	O
mt	O
genomes	O
,	O	O
the	O	O
C	B-LIVB
.	I-LIVB

austroafricana	I-LIVB
mt	O
genome	O
is	O	O
the	O	O
second	O	O
largest	O
in	O	O
the	O	O
Ascomycetes	B-LIVB
thus	O	O
far	O	O
.	O	O

Detection	B-PROC
and	O	O
Characterization	O	O
of	O	O
Flat	B-DISO
Aberrant	I-DISO
Crypt	I-DISO
Foci	I-DISO
(	I-DISO
Flat	I-DISO
ACF	I-DISO
)	I-DISO
in	O	O
the	O	O
Novel	O	O
A	B-DISO
/	I-DISO
J	I-DISO
Min	I-DISO
/	I-DISO
+	I-DISO
Mouse	I-DISO
Flat	B-DISO
aberrant	I-DISO
crypt	I-DISO
foci	I-DISO
(	O	O
flat	B-DISO
ACF	I-DISO
)	O	O
and	O	O
mucin	B-DISO
-	I-DISO
depleted	I-DISO
foci	I-DISO
(	O	O
MDF	B-DISO
)	O	O
have	O	O
previously	O	O
been	O	O
described	O	O
as	O	O
preneoplastic	B-DISO
colonic	I-DISO
lesions	I-DISO
.	O	O

We	O	O
used	O	O
the	O	O
novel	O	O
A	B-DISO
/	I-DISO
J	I-DISO
Min	I-DISO
/	I-DISO
+	I-DISO
mouse	I-DISO
model	I-DISO
,	O	O
that	O	O
demonstrates	O	O
extensive	O	O
spontaneous	O	O
colon	B-DISO
carcinogenesis	I-DISO
to	O	O
refine	O	O
the	O	O
method	O	O
of	O	O
detection	B-PROC
of	O	O
flat	B-DISO
ACF	I-DISO
and	O	O
further	O	O
characterize	O	O
and	O	O
define	O	O
them	O	O
as	O	O
early	O	O
lesions	B-DISO
by	O	O
histological	B-PROC
examination	I-PROC
and	O	O
comparison	O	O
with	O	O
MDF	B-DISO
.	O	O

Colons	B-ANAT
were	O	O
stained	B-PROC
with	I-PROC
methylene	I-PROC
blue	I-PROC
(	O	O
MB	B-CHEM
)	O	O
for	O	O
flat	B-DISO
ACF	I-DISO
detection	B-PROC
and	O	O
restained	B-PROC
with	O	O
high	B-CHEM
-	I-CHEM
iron	I-CHEM
diamine	I-CHEM
-	I-CHEM
alcian	I-CHEM
blue	I-CHEM
(	O	O
HID	B-CHEM
-	I-CHEM
AB	I-CHEM
)	O	O
for	O	O
MDF	B-DISO
detection	B-PROC
.	O	O

Optimal	O	O
flat	B-DISO
ACF	I-DISO
recognition	O	O
required	O	O
at	O	O
least	O	O
24	O	O
h	O	O
of	O	O
storage	O	O
post	O	O
-	O	O
MB	B-PROC
staining	I-PROC
and	O	O
adherence	O	O
to	O	O
a	O	O
set	O	O
of	O	O
characteristics	O	O
.	O	O

The	O	O
fraction	O
of	O
flat	B-DISO
ACF	I-DISO
corresponding	O	O
with	O	O
MDF	B-DISO
was	O	O
93	O	O
%	O	O
.	O	O

Flat	B-DISO
ACF	I-DISO
/	O	O
MDF	B-DISO
displayed	O	O
the	O	O
same	O	O
picture	O	O
of	O	O
severe	B-DISO
dysplasia	I-DISO
,	O	O
lack	O
of	O
mucus	B-ANAT
and	O	O
goblet	B-ANAT
cells	I-ANAT
and	O	O
accumulation	B-DISO
of	O	O
cytoplasmic	B-ANAT
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
.	O	O

The	O	O
easily	O	O
detectable	O	O
flat	B-DISO
ACF	I-DISO
are	O	O
reliable	O	O
surface	B-ANAT
biomarkers	B-PHYS
of	O	O
Apc	O
-driven	O	O
colon	B-DISO
carcinogenesis	I-DISO
.	O	O

The	O	O
flavivirus	B-LIVB
dengue	B-LIVB
induces	O	O
hypertrophy	B-DISO
of	O	O
white	O
matter	O
astrocytes	B-ANAT
Flaviviruses	B-LIVB
,	O	O
including	O	O
Zika	B-LIVB
and	O	O
dengue	B-LIVB
(	O	O
DENV	B-LIVB
)	O	O
,	O	O
pose	O	O
a	O	O
serious	O
global	O
threat	O
to	O	O
human	B-LIVB
health	O
.	O	O

Of	O	O
the	O	O
50	O	O
+	O	O
million	O	O
humans	B-LIVB
infected	B-DISO
with	O	O
DENV	B-LIVB
annually	O	O
,	O	O
approximately	O	O
1	O	O
-	O	O
3	O	O
%	O	O
progress	O	O
to	O	O
severe	B-PHEN
disease	I-PHEN
manifestations	I-PHEN
,	O	O
dengue	B-DISO
hemorrhagic	I-DISO
fever	I-DISO
(	O	O
DHF	B-DISO
)	O	O
or	O	O
dengue	B-DISO
shock	I-DISO
syndrome	I-DISO
(	O	O
DSS	B-DISO
)	O	O
.	O	O

Several	O	O
factors	O	O
are	O	O
suspected	O	O
to	O	O
mediate	O	O
the	O	O
course	O	O
of	O	O
infection	B-DISO
and	O	O
pathogenesis	B-DISO
of	O	O
DENV	B-LIVB
infection	B-DISO
.	O	O

DHF	B-DISO
and	O	O
DSS	B-DISO
are	O	O
associated	O
with	O
vascular	B-DISO
leakage	I-DISO
and	O	O
neurological	B-DISO
sequelae	I-DISO
.	O	O

Our	O	O
hypothesis	O
was	O	O
that	O	O
altered	O
astrocyte	B-PHYS
activation	I-PHYS
and	O	O
morphology	O
would	O	O
alter	O
the	O	O
dynamics	B-PHEN
of	O	O
the	O	O
extracellular	B-ANAT
space	I-ANAT
and	O	O
hence	O	O
,	O	O
neuronal	B-PHYS
and	O	O
vascular	B-PHYS
function	I-PHYS
.	O	O

We	O	O
investigated	O	O
the	O	O
mechanisms	O	O
of	O	O
neuropathogenesis	B-DISO
DENV	B-LIVB
infection	B-DISO
in	O	O
rhesus	B-LIVB
macaques	I-LIVB
.	O	O

There	O	O
were	O	O
decreased	B-DISO
numbers	I-DISO
of	O	O
GFAP	B-CHEM
immunopositive	B-ANAT
astrocytes	I-ANAT
per	O	O
unit	O	O
area	O	O
,	O	O
although	O	O
those	O	O
that	O	O
remained	O	O
had	O	O
increased	O
arbor	O
length	O
and	O	O
complexity	B-DISO
.	O	O

This	O	O
was	O	O
combined	O
with	O	O
structural	O
hypertrophy	B-DISO
of	O	O
white	O
matter	O
astrocytes	B-ANAT
in	O	O
the	O	O
absence	O
of	O	O
increased	O
vascular	B-DISO
leakage	I-DISO
.	O	O

Combined	O
,	O	O
these	O	O
studies	O	O
show	O	O
how	O	O
even	O	O
low	O
-	O
grade	O
infection	B-DISO
with	O	O
DENV	B-LIVB
induces	O	O
measurable	O
changes	O
within	O	O
the	O	O
parenchyma	B-ANAT
of	O	O
infected	B-DISO
individuals	B-LIVB
.	O	O

Transcriptional	B-PHYS
enhancement	I-PHYS
of	O	O
Smn	O
levels	B-PHEN
in	O	O
motoneurons	B-ANAT
is	O	O
crucial	O	O
for	O	O
proper	O	O
axon	B-ANAT
morphology	O
in	O	O
zebrafish	B-LIVB
An	O	O
unresolved	O	O
mystery	O	O
in	O	O
the	O	O
field	O	O
of	O	O
spinal	B-DISO
muscular	I-DISO
atrophy	I-DISO
(	O	O
SMA	B-DISO
)	O	O
is	O	O
why	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
ubiquitously	O	O
expressed	O	O
Smn	B-CHEM
protein	I-CHEM
causes	O	O
defects	B-DISO
mostly	O	O
in	O	O
motoneurons	B-ANAT
.	O	O

We	O	O
addressed	O	O
the	O	O
possibility	O	O
that	O	O
this	O	O
restricted	O	O
vulnerability	O	O
stems	O	O
from	O	O
elevated	O	O
Smn	B-PHYS
expression	I-PHYS
in	O	O
motoneurons	B-ANAT
.	O	O

To	O	O
explore	O	O
this	O	O
,	O	O
we	O	O
established	O	O
an	O	O
ex	B-DEVI
vivo	I-DEVI
zebrafish	I-DEVI
culture	I-DEVI
system	I-DEVI
of	O	O
GFP	B-CHEM
-	O	O
marked	O
motoneurons	B-ANAT
to	O	O
quantitatively	O	O
measure	O	O
Smn	B-PHEN
protein	I-PHEN
and	O	O
smn	B-CHEM
mRNA	I-CHEM
levels	O
as	O	O
well	O	O
as	O	O
promoter	O	O
activity	O	O
in	O	O
motoneurons	B-ANAT
versus	O	O
other	O	O
cell	B-ANAT
types	O	O
.	O	O

Importantly	O	O
,	O	O
we	O	O
uncovered	O	O
that	O	O
Smn	B-PHEN
levels	I-PHEN
are	O	O
elevated	O	O
in	O	O
motoneurons	B-ANAT
by	O	O
means	O	O
of	O	O
transcriptional	B-PHYS
activation	I-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
identified	O	O
the	O	O
ETS	B-CHEM
family	I-CHEM
transcription	I-CHEM
factor	I-CHEM
Etv5b	I-CHEM
to	O	O
be	O	O
responsible	O	O
for	O	O
increased	O	O
smn	B-PHYS
transcription	I-PHYS
in	O	O
motoneurons	B-ANAT
.	O	O

Moreover	O	O
,	O	O
we	O	O
established	O	O
that	O	O
the	O	O
additional	O	O
supply	O	O
of	O	O
Smn	B-CHEM
protein	I-CHEM
in	O	O
motoneurons	B-ANAT
is	O	O
necessary	O	O
for	O	O
proper	O	O
axonogenesis	B-PHYS
in	O	O
a	O	O
cell	B-PHYS
-	I-PHYS
autonomous	I-PHYS
manner	I-PHYS
.	O	O

These	O	O
findings	B-PHEN
demonstrate	O	O
the	O	O
reliance	O	O
of	O	O
motoneurons	B-ANAT
on	O	O
more	O	O
Smn	B-CHEM
,	O	O
thereby	O	O
adding	O	O
a	O	O
novel	O	O
piece	O	O
of	O	O
evidence	O
for	O	O
their	O	O
increased	O
vulnerability	B-PHYS
under	O	O
SMA	B-DISO
conditions	I-DISO
.	O	O

Experimental	B-PROC
study	I-PROC
in	O	O
pulmonary	B-ANAT
artery	I-ANAT
sealing	B-PROC
with	O	O
a	O	O
vessel	B-DEVI
-	I-DEVI
sealing	I-DEVI
device	I-DEVI
The	O	O
development	O	O
of	O	O
vessel	B-DEVI
-	I-DEVI
sealing	I-DEVI
devices	I-DEVI
will	O	O
facilitate	O	O
safety	B-PHEN
in	O	O
video	B-PROC
-	I-PROC
assisted	I-PROC
thoracoscopic	I-PROC
surgery	I-PROC
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
feasibility	O
and	O	O
safety	B-PHEN
of	O	O
sealing	B-PROC
pulmonary	B-ANAT
arteries	I-ANAT
with	O	O
the	O	O
Enseal	B-DEVI
tissue	I-DEVI
-	I-DEVI
sealing	I-DEVI
device	I-DEVI
.	O	O

Pulmonary	B-ANAT
arteries	I-ANAT
from	O	O
beagle	B-LIVB
dogs	I-LIVB
(	O	O
mean	O	O
body	O	O
weight	O	O
13	O	O
.	O	O
1	O	O
kg	O	O
,	O	O
range	O	O
10	O	O
.	O	O
5	O	O
-	O	O
15	O	O
.	O	O
4	O	O
kg	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
3	O	O
groups	B-LIVB
according	O	O
to	O	O
the	O	O
in	O
-	O
vivo	O
sealing	O
method	O
used	O	O
(	O	O
Enseal	B-DEVI
,	O	O
ligation	B-PROC
,	O	O
and	O	O
proximal	O
ligation	B-PROC
plus	O	O
distal	O
Enseal	B-DEVI
)	O	O
and	O	O
extracted	O	O
to	O	O
evaluate	O	O
the	O	O
pressure	B-PHEN
tolerance	O
up	O	O
to	O	O
75	O	O
mm	O	O
Hg	O	O
at	O	O
the	O	O
sealed	O
end	O
.	O	O

A	O	O
left	O	O
lower	O	O
lobectomy	B-PROC
was	O	O
performed	O	O
to	O	O
evaluate	O	O
chronic	O
-	O
phase	O
durability	O	O
of	O	O
the	O	O
sealed	B-DEVI
stumps	I-DEVI
in	O	O
a	O	O
survival	B-LIVB
model	I-LIVB
.	O	O

Two	O	O
or	O	O
three	O	O
branches	O	O
of	O	O
the	O	O
pulmonary	B-ANAT
arteries	I-ANAT
in	O	O
each	O	O
dog	B-LIVB
were	O	O
allocated	O	O
to	O	O
each	O	O
of	O	O
the	O	O
3	O	O
groups	B-LIVB
.	O	O

After	O	O
the	O	O
scheduled	O	O
survival	O
period	O
,	O	O
the	O	O
pulmonary	B-ANAT
arteries	I-ANAT
were	O	O
sampled	O	O
.	O	O

Pressure	B-PHEN
tolerance	O
at	O	O
the	O	O
sealed	O
end	O
was	O	O
evaluated	O	O
in	O	O
91	O	O
pulmonary	B-ANAT
artery	I-ANAT
sections	O	O
.	O	O

All	O	O
sealed	O
ends	O
showed	O	O
pressure	B-PHEN
tolerance	O
>	O	O
75	O	O
mm	O	O
Hg	O	O
.	O	O

A	O	O
left	O	O
lower	O	O
lobectomy	B-PROC
was	O	O
performed	O	O
in	O	O
13	O	O
dogs	B-LIVB
in	O	O
which	O	O
35	O	O
pulmonary	B-ANAT
artery	I-ANAT
sections	O	O
had	O	O
been	O	O
allocated	O	O
into	O	O
the	O	O
3	O	O
groups	B-LIVB
.	O	O

No	B-DISO
sealing	B-PROC
failure	O
was	O	O
found	O	O
,	O	O
and	O	O
pathological	O
findings	B-DISO
showed	O	O
healing	B-PHYS
and	O	O
persistent	O
hemostasis	B-PHYS
at	O	O
all	O	O
sealed	O
ends	O
of	O	O
the	O	O
pulmonary	B-ANAT
arteries	I-ANAT
after	O	O
2	O	O
and	O	O
4	O	O
weeks	O
of	O	O
the	O	O
survival	O
period	O
.	O	O

Pulmonary	B-ANAT
arteries	I-ANAT
sealed	O
in	O
vivo	O
with	O	O
the	O	O
Enseal	B-DEVI
device	I-DEVI
showed	O	O
pressure	B-PHEN
tolerance	O
>	O	O
75	O	O
mm	O	O
Hg	O	O
in	O	O
the	O	O
acute	O
phase	O
,	O	O
and	O	O
persistent	O
hemostasis	B-PHYS
after	O	O
2	O	O
or	O	O
4	O	O
weeks	O
.	O	O

Pulmonary	B-ANAT
artery	I-ANAT
sealing	B-PROC
with	O	O
the	O	O
Enseal	B-DEVI
device	I-DEVI
is	O	O
feasible	O
and	O	O
safe	B-PHEN
in	O	O
thoracic	B-PROC
surgery	I-PROC
settings	O	O
.	O	O

Pathophysiology	O
,	O	O
treatment	B-PROC
and	O	O
prevention	B-PROC
of	O	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
Severe	O
ovarian	B-DISO
hyperstimulation	I-DISO
syndrome	I-DISO
(	O	O
OHSS	B-DISO
)	O	O
is	O	O
an	O	O
iatrogenic	O
condition	O
that	O	O
affects	O
1	O	O
%	O	O
of	O	O
women	B-LIVB
that	O	O
undergo	O	O
treatment	B-PROC
with	O	O
assisted	B-PROC
reproductive	I-PROC
technology	I-PROC
.	O	O

The	O	O
review	O
aims	O
to	O	O
summarize	O
recent	O
evidence	O
on	O	O
pathophysiology	O
,	O	O
treatment	B-PROC
,	O	O
and	O	O
prevention	B-PROC
of	O	O
OHSS	B-DISO
.	O	O

The	O	O
pathophysiology	O
is	O	O
still	O	O
not	O	O
completely	O
understood	B-PHYS
;	O	O
however	O	O
,	O	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
is	O	O
likely	O	O
to	O	O
be	O	O
an	O	O
important	O
mediator	O	O
.	O	O

Human	B-CHEM
chorionic	I-CHEM
gonadotropin	I-CHEM
was	O	O
previously	O	O
thought	B-PHYS
to	O	O
be	O	O
necessary	O	O
for	O	O
OHSS	B-DISO
to	O	O
occur	O
;	O	O
however	O	O
,	O	O
recent	O
case	O
reports	O
have	O	O
proven	O
otherwise	O	O
.	O	O

The	O	O
contribution	O
of	O	O
an	O	O
attenuated	O
anti	B-CHEM
-	I-CHEM
Mullerian	I-CHEM
hormone	I-CHEM
signalling	B-PHYS
pathway	I-PHYS
and	O	O
CD11c	B-CHEM
+	O	O
HLA	B-CHEM
-	I-CHEM
DR	I-CHEM
+	O	O
dendritic	B-ANAT
cells	I-ANAT
and	O	O
associated	O
interleukins	B-CHEM
has	O	O
been	O	O
explored	O	O
recently	O
as	O	O
contributors	O
to	O	O
pathogenesis	B-DISO
.	O	O

Treatment	B-PROC
is	O	O
largely	O	O
supportive	B-PROC
and	O	O
is	O	O
based	O
mainly	O	O
on	O	O
consensus	O
statements	O
rather	O	O
than	O	O
evidence	O
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
important	O
to	O	O
prevent	O
this	O	O
condition	O
by	O	O
identifying	B-PROC
women	B-LIVB
at	O
risk	O
,	O	O
allowing	O
the	O	O
clinician	B-LIVB
to	O	O
implement	O
preventive	O
strategies	O
,	O	O
including	O
the	O	O
use	O	O
of	O	O
GnRH	B-CHEM
antagonist	I-CHEM
cycles	O
with	O	O
agonist	B-CHEM
triggers	O	O
.	O	O

More	O	O
research	B-PROC
is	O	O
required	O
to	O	O
elucidate	O	O
the	O	O
pathophysiology	O
behind	O	O
the	O	O
condition	O
.	O	O

Clinicians	B-LIVB
should	O	O
employ	O
strategies	B-PHYS
to	O	O
prevent	B-PROC
OHSS	B-DISO
.	O	O

A	O	O
DANGEROUS	O	O
MUDDYING	O	O
OF	O	O
THE	O	O
WATERS	O	O
?	O	O
THE	O	O
'	O	O
SIGNIFICANT	O
HARM	O
'	O	O
OF	O	O
RE	B-LIVB
B	I-LIVB
AND	I-LIVB
G	I-LIVB
(	I-LIVB
CHILDREN	I-LIVB
)	O	O
(	O	O
CARE	O
PROCEEDINGS	O
)	O	O
[	O	O
2015	O	O
]	O	O
EWFC	O	O
3	O	O
The	O	O
academic	O
debate	O
rages	B-PHYS
on	O	O
as	O	O
to	O	O
whether	O	O
male	B-PROC
circumcision	I-PROC
really	O	O
is	O	O
in	O	O
the	O	O
best	O
interests	B-PHYS
of	O	O
the	O	O
child	B-LIVB
or	O	O
if	O	O
it	O	O
constitutes	O	O
an	O	O
abusive	O
practice	O
.	O	O

This	O	O
commentary	O
discusses	O
the	O	O
recent	O
case	O
of	O	O
Re	B-LIVB
B	I-LIVB
and	I-LIVB
G	I-LIVB
(	I-LIVB
children	I-LIVB
)	I-LIVB
(	O	O
care	O
proceedings	O
)	O	O
[	O	O
2015	O	O
]	O	O
EWFC	O	O
3	O	O
,	O	O
delivered	O	O
by	O	O
the	O	O
current	O
President	B-LIVB
of	O	O
the	O	O
Family	O
Division	O
of	O
the	O
High	O
court	O
,	O	O
Sir	O	O
James	O	O
Munby	O	O
.	O	O

Two	O	O
key	O	O
issues	B-DISO
are	O	O
raised	O
by	O	O
this	O	O
judgment	B-DISO
.	O	O

First	O	O
,	O	O
that	O	O
President	B-LIVB
Munby	O	O
's	O	O
obiter	O	O
comments	O
constitute	O	O
an	O	O
attack	O
on	O	O
the	O	O
legally	O
accepted	O
act	O
of	O	O
male	B-PROC
circumcision	I-PROC
by	O	O
suggesting	O	O
a	O	O
similar	O
nature	O
between	O	O
the	O	O
illegal	O
act	O
of	O	O
female	O
genital	O
mutilation	O
(	O	O
FGM	O
)	O	O
and	O	O
that	O	O
of	O	O
male	B-PROC
circumcision	I-PROC
as	O	O
well	O	O
as	O	O
the	O	O
suggestion	O
that	O	O
male	B-PROC
circumcision	I-PROC
can	O	O
be	O	O
classed	O	O
as	O	O
a	O	O
significant	O
harm	O
.	O	O

Second	O	O
,	O	O
that	O	O
this	O	O
case	O
reflects	B-PHYS
the	O	O
woefully	O	O
unprepared	O
condition	O
of	O	O
the	O	O
UK	B-GEOG
medical	O
profession	O
in	O	O
dealing	O	O
with	O	O
FGM	O
.	O	O

Zinc	B-CHEM
transporter	I-CHEM
ZIP10	B-CHEM
forms	O	O
a	O	O
heteromer	O	O
with	O	O
ZIP6	B-CHEM
which	O	O
regulates	B-PHEN
embryonic	B-PHYS
development	I-PHYS
and	O	O
cell	B-PHYS
migration	I-PHYS
There	O	O
is	O	O
growing	O	O
evidence	O
that	O	O
zinc	B-CHEM
and	O	O
its	O	O
transporters	B-CHEM
are	O	O
involved	O
in	O	O
cell	B-PHYS
migration	I-PHYS
during	O
development	B-PHYS
and	O	O
in	O	O
cancer	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
show	O	O
that	O	O
zinc	B-CHEM
transporter	I-CHEM
ZIP10	B-CHEM
(	O	O
SLC39A10	B-CHEM
)	O	O
stimulates	B-PHEN
cell	B-PHYS
motility	I-PHYS
and	O	O
proliferation	B-PHYS
,	O	O
both	O	O
in	O	O
mammalian	B-ANAT
cells	I-ANAT
and	O	O
in	O	O
the	O	O
zebrafish	B-LIVB
embryo	B-ANAT
.	O	O

This	O	O
is	O	O
associated	O
with	O
inactivation	B-PHYS
of	O	O
GSK	B-CHEM
-	I-CHEM
3α	I-CHEM
and	O	O
-3ß	B-CHEM
and	O	O
downregulation	B-PHYS
of	O	O
E	B-CHEM
-	I-CHEM
cadherin	I-CHEM
(	O	O
CDH1	B-CHEM
)	O	O
.	O	O

Morpholino	B-CHEM
-mediated	O	O
knock	B-PROC
-	I-PROC
down	I-PROC
of	O	O
zip10	O
causes	O	O
delayed	O
epiboly	B-PHYS
and	O	O
deformities	O
of	O	O
the	O	O
head	B-ANAT
,	O	O
eye	B-ANAT
,	O	O
heart	B-ANAT
and	O	O
tail	B-ANAT
.	O	O

Furthermore	O	O
,	O	O
zip10	B-CHEM
deficiency	O
results	O	O
in	O	O
overexpression	B-PHYS
of	O	O
cdh1	B-CHEM
,	O	O
zip6	B-CHEM
and	O	O
stat3	B-CHEM
,	O	O
the	O	O
latter	O	O
gene	B-CHEM
product	I-CHEM
driving	O	O
transcription	B-PHYS
of	O	O
both	O	O
zip6	B-CHEM
and	O	O
zip10	B-CHEM
The	O	O
non	O	O
-	O	O
reduntant	O	O
requirement	O
of	O	O
Zip6	B-CHEM
and	O	O
Zip10	B-CHEM
for	O	O
epithelial	B-PHYS
to	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O	O
EMT	B-PHYS
)	O	O
is	O	O
consistent	O
with	O
our	O	O
finding	B-DISO
that	O	O
they	O	O
exist	O
as	O	O
a	O	O
heteromer	O	O
.	O	O

We	O	O
postulate	O	O
that	O	O
a	O	O
subset	O
of	O	O
ZIPs	B-CHEM
carrying	O	O
PrP	O
-	O
like	O
ectodomains	O
,	O	O
including	O
ZIP6	B-CHEM
and	O	O
ZIP10	B-CHEM
,	O	O
are	O	O
integral	O
to	O	O
cellular	B-PROC
pathways	B-PHYS
and	O	O
plasticity	B-PHYS
programs	O
,	O	O
such	O	O
as	O	O
EMT	B-PHYS
.	O	O

Evaluation	B-PROC
of	O	O
response	O	O
from	O	O
axitinib	B-CHEM
per	O	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
versus	O	O
Choi	O
criteria	O
in	O	O
previously	O	O
treated	B-DISO
patients	B-LIVB
with	O	O
metastatic	B-DISO
renal	I-DISO
cell	I-DISO
carcinoma	I-DISO
Axitinib	B-CHEM
,	O	O
a	O	O
selective	O	O
and	O	O
potent	O	O
tyrosine	B-CHEM
kinase	I-CHEM
inhibitor	I-CHEM
of	O	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
receptors	I-CHEM
,	O	O
was	O	O
available	O	O
to	O	O
patients	B-LIVB
from	O	O
Canada	B-GEOG
and	O	O
Australia	B-GEOG
,	O	O
prior	O	O
to	O	O
regulatory	O	O
approval	O
of	O	O
axitinib	B-CHEM
in	O	O
these	O	O
countries	B-GEOG
,	O	O
for	O	O
treatment	B-PROC
of	O	O
clear	B-DISO
-	I-DISO
cell	I-DISO
metastatic	I-DISO
renal	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
mRCC	B-DISO
)	O	O
after	O	O
failure	O	O
of	O	O
one	O	O
prior	O	O
systemic	O	O
regimen	B-PROC
.	O	O

This	O	O
single	B-PROC
-	I-PROC
arm	I-PROC
,	O	O
open	B-PROC
-	I-PROC
label	I-PROC
study	I-PROC
of	O	O
axitinib	B-CHEM
evaluated	O	O
the	O	O
efficacy	B-PROC
,	O	O
safety	B-PROC
,	O	O
and	O	O
quality	O
of	O
life	O
(	O	O
QoL	O
)	O	O
in	O	O
patients	B-LIVB
with	O	O
mRCC	B-DISO
whose	O	O
disease	B-DISO
progressed	B-DISO
after	O	O
one	O	O
prior	O	O
systemic	O	O
first	B-PROC
-	I-PROC
line	I-PROC
regimen	I-PROC
.	O	O

Primary	O	O
objective	O	O
was	O	O
objective	O	O
response	O
rate	O
evaluated	B-PROC
per	O	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O	O
RECIST	O
)	O	O
and	O	O
Choi	O
criteria	O
.	O	O

Progression	O
-	O
free	O
survival	O
,	O	O
overall	O
survival	O
,	O	O
safety	B-PROC
,	O	O
and	O	O
QoL	O
were	O	O
secondary	O	O
end	O	O
points	O	O
.	O	O

Due	O	O
to	O	O
the	O	O
small	O	O
study	B-PROC
size	O	O
,	O	O
analyses	O	O
comprised	O	O
of	O	O
descriptive	O	O
statistics	B-PROC
.	O	O

Fifteen	O	O
patients	B-LIVB
were	O	O
recruited	O	O
,	O	O
five	O	O
from	O	O
Canada	B-GEOG
and	O	O
ten	O	O
from	O	O
Australia	B-GEOG
,	O	O
over	O	O
a	O	O
limited	O	O
recruitment	O	O
period	O	O
.	O	O

Thirteen	O	O
patients	B-LIVB
received	O	O
sunitinib	B-CHEM
as	O	O
prior	O	O
therapy	B-PROC
.	O	O

All	O	O
patients	B-LIVB
had	O	O
clear	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
,	O	O
eleven	O	O
had	O	O
prior	O	O
nephrectomy	B-PROC
.	O	O

Liver	B-ANAT
,	O	O
lung	B-ANAT
,	O	O
and	O	O
lymph	B-ANAT
nodes	I-ANAT
were	O	O
the	O	O
most	O	O
frequent	O	O
sites	O	O
of	O	O
metastases	B-DISO
;	O	O
one	O	O
patient	B-LIVB
had	O	O
brain	B-DISO
metastasis	I-DISO
.	O	O

Median	O
time	O	O
on	O	O
axitinib	B-CHEM
was	O	O
118	O	O
.	O	O

0	O	O
days	O
(	O	O
range	O
:	O	O
3	O	O
.	O	O
5	O	O
-	O	O
645	O	O
.	O	O
0	O	O
days	O
)	O	O
;	O	O
estimated	O	O
survival	O
probability	O	O
at	O	O
12	O	O
months	O
was	O	O
57	O	O
.	O	O
8	O	O
%	O	O
.	O	O

Two	O	O
(	O	O
13	O	O
.	O	O
3	O	O
%	O	O
)	O	O
patients	B-LIVB
had	O	O
objective	O	O
responses	B-PHYS
per	O	O
RECIST	O
versus	O	O
nine	O	O
(	O	O
60	O	O
.	O	O
0	O	O
%	O	O
)	O	O
per	O	O
Choi	O
criteria	O
.	O	O

Six	O	O
patients	B-LIVB
had	O	O
progressive	B-DISO
disease	B-DISO
based	O	O
on	O	O
RECIST	O
versus	O	O
three	O	O
per	O	O
Choi	O
criteria	O
.	O	O

Nine	O	O
(	O	O
60	O	O
.	O	O

0	O	O
%	O	O
)	O	O
events	O	O
of	O	O
progression	B-DISO
or	O	O
death	B-PHYS
occurred	O	O
by	O	O
the	O	O
end	O	O
of	O	O
study	B-PROC
,	O	O
and	O	O
three	O	O
patients	B-LIVB
continued	O	O
to	O	O
receive	O	O
the	O	O
study	B-PROC
drug	B-CHEM
.	O	O

Fatigue	B-DISO
(	O	O
33	O	O
%	O	O
)	O	O
and	O	O
diarrhea	B-DISO
(	O	O
20	O	O
%	O	O
)	O	O
were	O	O
the	O	O
most	O	O
common	O	O
grade	O	O
≥3	O	O
all	O	O
-	O	O
causality	O	O
,	O	O
treatment	B-PROC
-emergent	O	O
adverse	B-DISO
events	I-DISO
.	O	O

The	O	O
mean	O
change	O	O
in	O	O
European	B-GEOG
Quality	O
of	O
Life	O
-	O	O
5	O	O
Dimensions	O	O
score	O
from	O	O
baseline	O
to	O	O
end	O	O
of	O	O
treatment	B-PROC
was	O	O
-0	O	O
.	O	O
0837	O	O
.	O	O

The	O	O
small	O	O
number	O	O
of	O	O
patients	B-LIVB
and	O	O
lack	O	O
of	O	O
a	O	O
comparator	O	O
arm	O	O
limit	O	O
the	O	O
ability	O	O
to	O	O
draw	O	O
definitive	O
conclusions	O
;	O	O
however	O	O
,	O	O
safety	B-PROC
and	O	O
efficacy	B-PROC
profiles	O	O
of	O	O
axitinib	B-CHEM
were	O	O
consistent	O	O
with	O	O
reports	O	O
from	O	O
previous	O	O
studies	B-PROC
in	O	O
patients	B-LIVB
with	O	O
mRCC	B-DISO
,	O	O
and	O	O
patients	B-LIVB
generally	O	O
maintained	O	O
QoL	O
.	O	O

The	O	O
sizeable	O	O
difference	O	O
observed	O	O
in	O	O
objective	O	O
response	O
rate	O
by	O	O
RECIST	O
versus	O	O
Choi	O
criteria	O
merits	O	O
further	O	O
research	B-PROC
.	O	O

Demographics	O
,	O	O
Health	O
,	O	O
and	O	O
Risk	O
Behaviors	O
of	O	O
Young	B-LIVB
Adults	I-LIVB
Who	O	O
Drink	B-OBJC
Energy	B-OBJC
Drinks	I-OBJC
and	O	O
Coffee	B-OBJC
Beverages	B-OBJC
Objective	O
:	O	O
The	O	O
present	B-DISO
study	B-PROC
investigates	O
risk	O
behaviors	O
,	O	O
sleep	B-DISO
habits	I-DISO
,	O	O
and	O	O
mental	B-DISO
health	I-DISO
factors	I-DISO
associated	O
with	O
caffeinated	B-OBJC
beverage	I-OBJC
use	O	O
in	O	O
young	B-LIVB
adults	I-LIVB
.	O	O

Materials	B-OBJC
and	O	O
Methods	O
:	O	O
Students	B-LIVB
from	O	O
a	O	O
midsize	B-OBJC
private	I-OBJC
university	I-OBJC
(	O	O
n	O	O
=	O	O
159	O	O
)	O	O
completed	O	O
a	O	O
15	O	O
-	O	O
minute	O
anonymous	O
questionnaire	O
,	O	O
including	O	O
questions	O
on	O	O
risk	O
behaviors	O
,	O	O
sleep	B-DISO
habits	I-DISO
,	O	O
alcohol	O
,	O	O
and	O	O
caffeine	O
consumption	O
.	O	O

We	O	O
compared	O
behaviors	O
between	O	O
the	O	O
top	O	O
∼15	O	O
%	O	O
(	O	O
""""	O	O
high	O	O
end	O	O
""""	O	O
)	O	O
of	O	O
energy	B-OBJC
drink	I-OBJC
users	B-LIVB
(	O	O
≥3	O	O
/	O	O
month	O
)	O	O
and	O	O
coffee	B-OBJC
users	B-LIVB
(	O	O
≥16	O	O
/	O	O
month	O
)	O	O
to	O	O
those	O	O
with	O	O
less	O
frequent	O
or	O	O
no	O	O
caffeine	O
consumption	O
.	O	O

Results	B-DISO
:	O	O
Caffeine	O
consumption	O
was	O	O
frequent	O
among	O	O
young	B-LIVB
adults	I-LIVB
.	O	O

In	O	O
the	O	O
last	O	O
month	O
,	O	O
36	O	O
%	O	O
of	O	O
students	B-LIVB
had	O	O
an	O	O
energy	B-OBJC
drink	I-OBJC
,	O	O
69	O	O
%	O	O
had	O	O
coffee	B-OBJC
or	O	O
espresso	B-OBJC
,	O	O
and	O	O
86	O	O
%	O	O
reported	O	O
having	O	O
any	O	O
caffeine	B-CHEM
;	O	O
however	O	O
,	O	O
the	O	O
majority	O
of	O	O
students	B-LIVB
were	O	O
unaware	B-PROC
of	O	O
the	O	O
caffeine	B-CHEM
content	O
in	O	O
these	O	O
beverages	B-OBJC
.	O	O

High	O	O
-	O	O
end	O	O
energy	B-OBJC
drink	I-OBJC
consumers	B-LIVB
reported	O	O
more	O	O
risk	O
-	O
taking	O
behaviors	O
(	O	O
increased	B-DISO
drug	I-DISO
and	O	O
alcohol	O
use	O
and	O	O
less	O
frequent	O
seat	B-DISO
belt	I-DISO
use	I-DISO
)	O	O
,	O	O
sleep	B-DISO
disturbances	I-DISO
(	O	O
later	O
bedtimes	O
,	O	O
harder	B-DISO
time	I-DISO
falling	I-DISO
asleep	I-DISO
,	O	O
and	O	O
more	O	O
all	O
-	O
nighters	O
)	O	O
,	O	O
and	O	O
higher	O	O
frequency	O
of	O	O
mental	B-DISO
illness	I-DISO
diagnoses	B-DISO
than	O	O
those	O	O
who	O	O
consumed	B-DISO
fewer	O	O
energy	B-OBJC
drinks	I-OBJC
.	O	O

In	O	O
contrast	O
,	O	O
the	O	O
frequency	O
of	O	O
most	O	O
risk	O
behaviors	O
,	O	O
sleep	B-DISO
disturbances	I-DISO
,	O	O
and	O	O
mental	B-DISO
illness	I-DISO
diagnoses	B-DISO
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
high	B-LIVB
-	I-LIVB
end	I-LIVB
and	I-LIVB
general	I-LIVB
population	I-LIVB
of	O	O
coffee	B-OBJC
drinkers	B-DISO
.	O	O

Conclusion	O
:	O	O
Students	B-LIVB
with	O	O
delayed	O
sleep	B-DISO
patterns	I-DISO
,	O	O
mental	B-DISO
illness	I-DISO
,	O	O
and	O	O
higher	O	O
frequency	O
of	O	O
substance	B-DISO
use	I-DISO
and	O	O
risk	O
behaviors	O
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
regular	O	O
energy	B-OBJC
drink	I-OBJC
users	B-LIVB
but	O	O
not	O	O
regular	B-DISO
coffee	I-DISO
drinkers	I-DISO
.	O	O

It	O	O
is	O	O
unclear	B-DISO
whether	O	O
the	O	O
psychoactive	B-CHEM
content	O
in	O	O
energy	B-OBJC
drinks	I-OBJC
results	O
in	O	O
different	O	O
behavioral	O
effects	O
than	O	O
just	O	O
caffeine	B-CHEM
in	O	O
coffee	B-OBJC
,	O	O
and	O	O
/	O	O
or	O	O
different	O	O
personality	B-PHYS
/	O	O
health	B-LIVB
populations	I-LIVB
are	O	O
drawn	O	O
to	O	O
the	O	O
two	O	O
types	O	O
of	O	O
beverages	B-OBJC
.	O	O

Eosinophilic	B-DISO
Gastroenteritis	I-DISO
as	O	O
a	O	O
Rare	O
Cause	O
of	O	O
Recurrent	O
Epigastric	O
Pain	O
Eosinophilic	B-DISO
gastroenteritis	I-DISO
(	O	O
EGE	B-DISO
)	O	O
is	O	O
a	O	O
rare	O	O
inflammatory	B-DISO
disorder	I-DISO
of	O	O
gastrointestinal	B-ANAT
tract	I-ANAT
characterized	O
by	O	O
eosinophilic	B-DISO
infiltration	I-DISO
of	O	O
the	O	O
bowel	B-ANAT
wall	I-ANAT
.	O	O

It	O	O
can	O	O
mimic	O	O
many	O	O
gastrointestinal	B-DISO
disorders	I-DISO
due	O	O
to	O	O
its	O	O
wide	B-DISO
spectrum	I-DISO
of	I-DISO
presentations	I-DISO
.	O	O

Diagnose	B-DISO
is	O	O
mostly	O	O
based	O	O
on	O	O
excluding	O
other	O
disorders	B-DISO
and	O	O
a	O	O
high	O
suspicion	B-PHYS
.	O	O

Here	O	O
we	O	O
report	O
a	O
case	O
of	O	O
26	O	O
year	O
old	O
man	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	O	O
sever	B-DISO
epigastric	I-DISO
pain	I-DISO
followed	O	O
by	O	O
nausea	B-DISO
,	O	O
vomiting	B-DISO
since	O	O
a	O	O
few	O
days	O
before	O
admission	B-PROC
with	O	O
final	O	O
diagnosis	B-DISO
of	O	O
EGE	B-DISO
.	O	O

Biochemical	O
characteristics	O
of	O	O
AtFAR2	B-CHEM
,	O	O
a	O	O
fatty	B-CHEM
acid	I-CHEM
reductase	I-CHEM
from	O	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
that	O	O
reduces	O	O
fatty	B-CHEM
acyl	I-CHEM
-	I-CHEM
CoA	I-CHEM
and	O	O
-	O	O
ACP	B-CHEM
substrates	I-CHEM
into	O	O
fatty	B-CHEM
alcohols	I-CHEM
Fatty	B-CHEM
alcohols	I-CHEM
and	O	O
derivatives	B-CHEM
are	O	O
important	O
for	O	O
proper	O	O
deposition	O
of	O	O
a	O	O
functional	O
pollen	B-ANAT
wall	I-ANAT
.	O	O

Mutations	B-PHYS
in	O	O
specific	O	O
genes	O
encoding	O	O
fatty	B-CHEM
acid	I-CHEM
reductases	I-CHEM
(	O	O
FAR	B-CHEM
)	O	O
responsible	O	O
for	O	O
fatty	B-CHEM
alcohol	I-CHEM
production	O
cause	O	O
abnormal	B-DISO
development	O
of	O	O
pollen	B-LIVB
.	O	O

A	O	O
disrupted	O
AtFAR2	O
(	O
MS2	O
)	O
gene	O
in	O	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
results	O
in	O	O
pollen	B-LIVB
developing	O
an	O	O
abnormal	B-DISO
exine	B-ANAT
layer	I-ANAT
and	O	O
a	O	O
reduced	B-DISO
fertility	I-DISO
phenotype	B-PHYS
.	O	O

AtFAR2	B-CHEM
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
targeted	O
to	O	O
chloroplasts	B-ANAT
and	O	O
in	O	O
a	O	O
purified	O
form	O
to	O	O
be	O	O
specific	O
for	O	O
acyl	B-CHEM
-	I-CHEM
ACP	I-CHEM
substrates	I-CHEM
.	O	O

Here	O	O
,	O	O
we	O	O
present	O	O
data	O
on	O	O
the	O	O
in	O
vitro	O
and	O	O
in	O	O
planta	B-LIVB
characterizations	O
of	O	O
AtFAR2	B-CHEM
from	O	O
A	B-LIVB
.	I-LIVB

thaliana	I-LIVB
and	O	O
show	O	O
that	O	O
this	O	O
enzyme	B-CHEM
has	O	O
the	O	O
ability	O	O
to	O	O
use	O	O
both	O	O
,	O	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
ACP	I-CHEM
and	O	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
CoA	I-CHEM
,	O	O
as	O	O
substrates	B-CHEM
to	O	O
produce	O	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
-	I-CHEM
alcohol	I-CHEM
.	O	O

Our	O	O
results	O	O
further	O	O
show	O	O
that	O	O
AtFAR2	B-CHEM
is	O	O
highly	O	O
similar	O	O
in	O	O
properties	O
and	O	O
substrate	B-CHEM
specificity	O
to	O	O
AtFAR6	B-CHEM
for	O	O
which	O	O
in	O
vitro	O
data	O
has	O	O
been	O	O
published	O	O
,	O	O
and	O	O
which	O	O
is	O	O
also	O	O
a	O	O
chloroplast	B-ANAT
localized	O
enzyme	B-CHEM
.	O	O

This	O	O
suggests	O	O
that	O	O
although	O	O
AtFAR2	B-CHEM
is	O	O
the	O	O
major	O	O
enzyme	B-CHEM
responsible	O	O
for	O	O
exine	B-ANAT
layer	I-ANAT
functionality	O
,	O	O
AtFAR6	B-CHEM
might	O	O
provide	O	O
functional	O
redundancy	O
to	O	O
AtFAR2	B-CHEM
.	O	O

Comparing	O
Time	B-PHYS
Perception	I-PHYS
among	O	O
Morphine	B-CHEM
-	O	O
Derived	O
Drugs	B-CHEM
Addicts	B-LIVB
and	O	O
Controls	B-LIVB
The	O	O
aim	O
of	O	O
the	O	O
present	O	O
study	B-PROC
is	O	O
to	O	O
compare	O
time	B-PHYS
perception	I-PHYS
among	O	O
drug	B-DISO
addicts	I-DISO
and	O	O
controls	B-LIVB
.	O	O

30	O	O
drug	B-DISO
addicts	I-DISO
were	O	O
selected	O
,	O	O
and	O	O
30	O	O
non	B-LIVB
-	I-LIVB
addict	I-LIVB
individuals	I-LIVB
were	O	O
selected	O
as	O	O
the	O	O
control	B-LIVB
group	I-LIVB
.	O	O

The	O	O
two	O	O
groups	O
performed	O	O
three	O	O
tests	O
of	O	O
time	O
reproduction	B-PHYS
,	O	O
time	O
estimation	O
,	O	O
and	O	O
time	O
discrimination	B-PHYS
.	O	O

There	O	O
was	O	O
a	O	O
significant	O
difference	O
between	O	O
the	O	O
addicts	B-LIVB
group	O
and	O	O
the	O	O
control	B-LIVB
group	I-LIVB
regarding	O	O
the	O	O
error	O
of	O	O
time	O
reproduction	B-PHYS
and	O	O
time	O
estimation	O
.	O	O

The	O	O
addict	B-LIVB
group	O
in	O	O
comparison	O
to	O	O
the	O	O
control	B-LIVB
group	I-LIVB
had	O	O
a	O	O
lower	O
under	O	O
-	O	O
reproduction	B-PHYS
and	O	O
a	O	O
higher	O
over	O	O
-	O	O
reproduction	B-PHYS
error	O
,	O	O
and	O	O
also	O	O
a	O	O
lower	O
under	O	O
-	O	O
estimation	B-PHYS
and	O	O
higher	O
over	O	O
-	O	O
estimation	B-PHYS
error	O
.	O	O

However	O	O
,	O	O
regarding	O	O
time	O
discrimination	B-PHYS
,	O	O
no	O	O
significant	O
difference	O
was	O	O
observed	O	O
between	O	O
the	O	O
errors	O
committed	O	O
by	O	O
both	O	O
groups	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
when	O	O
showing	O	O
images	O
of	O	O
drug	O
consumption	O
tools	B-OBJC
and	O	O
normal	O
images	O
with	O	O
same	O	O
durations	O
,	O	O
the	O	O
normal	O
group	O
believed	O	O
that	O	O
the	O	O
images	O
related	O	O
to	O	O
drug	O
consumption	O
tools	B-OBJC
were	O	O
shown	O	O
for	O	O
a	O	O
shorter	O
period	O
of	O	O
time	O
.	O	O

Time	B-PHYS
perception	I-PHYS
is	O	O
different	O
between	O	O
morphine	B-CHEM
-	O	O
derived	O
drugs	B-CHEM
addicts	B-LIVB
and	O	O
controls	B-LIVB
.	O	O

Comparison	O	O
of	O	O
sonoelastography	B-PROC
with	O	O
sonourethrography	B-PROC
and	O	O
retrograde	B-PROC
urethrography	I-PROC
in	O	O
the	O	O
evaluation	B-PROC
of	O	O
male	B-PHYS
anterior	B-DISO
urethral	I-DISO
strictures	I-DISO
Retrograde	B-PROC
urethrography	I-PROC
(	O	O
RUG	B-PROC
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
and	O	O
preferred	O	O
imaging	O
modality	O
for	O	O
imaging	B-PROC
of	O	O
the	O	O
anterior	B-DISO
urethral	I-DISO
strictures	I-DISO
despite	O	O
its	O	O
well	O	O
-	O	O
known	O	O
limitations	O
and	O	O
disadvantages	O	O
.	O	O

Sonourethrography	B-PROC
(	O	O
SUG	B-PROC
)	O	O
was	O	O
introduced	O	O
in	O	O
1988	O	O
to	O	O
overcome	O
the	O	O
limitations	O
of	O	O
RUG	B-PROC
and	O	O
to	O	O
provide	O	O
more	O	O
accurate	O
results	O
.	O	O

As	O	O
proper	O	O
selection	O	O
of	O	O
imaging	O
modality	O
is	O	O
very	O	O
important	O	O
for	O	O
planning	O
the	O
treatment	O
,	O	O
various	O	O
advances	O	O
in	O	O
this	O	O
area	O	O
are	O	O
required	O	O
.	O	O

One	O	O
of	O	O
the	O	O
major	O	O
factors	O	O
for	O	O
recurrence	B-PHEN
of	O	O
stricture	B-DISO
disease	I-DISO
is	O	O
spongiofibrosis	B-DISO
.	O	O

Sonoelastography	B-PROC
(	O	O
SE	B-PROC
)	O	O
is	O	O
a	O	O
newer	B-PROC
technique	I-PROC
,	O	O
tried	O	O
in	O	O
various	O	O
other	O	O
pathologies	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
used	O	O
this	O	O
technique	O	O
for	O	O
the	O	O
first	O	O
time	O	O
to	O	O
assess	O	O
its	O	O
efficacy	O
in	O	O
the	O	O
evaluation	O	O
of	O	O
anterior	B-DISO
urethral	I-DISO
stricture	I-DISO
disease	I-DISO
by	O	O
comparison	O	O
with	O	O
RUG	B-PROC
and	O	O
SUG	B-PROC
.	O	O

Between	O	O
August	O	O
2014	O	O
and	O	O
May	O	O
2015	O	O
,	O	O
77	O	O
patients	B-LIVB
with	O	O
clinical	O	O
features	O	O
of	O	O
anterior	B-DISO
urethral	I-DISO
stricture	I-DISO
disease	I-DISO
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
and	O	O
evaluated	O	O
by	O	O
RUG	B-PROC
followed	O	O
by	O	O
SUG	B-PROC
and	O	O
SE	B-PROC
for	O	O
stricture	B-DISO
location	O
,	O	O
length	O
,	O	O
depth	B-PHYS
of	O	O
spongiofibrosis	B-DISO
and	O	O
periurethral	B-ANAT
pathologies	O
.	O	O

The	O	O
results	O	O
were	O	O
then	O	O
correlated	O	O
with	O	O
operative	O	O
and	O	O
histopathological	O
findings	O
.	O	O

Overall	O	O
diagnostic	O
accuracy	O
of	O	O
SE	B-PROC
,	O	O
SUG	B-PROC
,	O	O
and	O	O
RGU	B-PROC
for	O	O
the	O	O
estimation	O	O
of	O	O
stricture	B-DISO
location	O
,	O	O
and	O	O
length	O
were	O	O
estimated	O	O
92	O	O
.	O	O

68	O	O
%	O	O
vs	O	O
.	O	O

91	O	O
.	O	O
54	O	O
%	O	O
,	O	O
79	O	O
%	O	O
vs	O	O
.	O	O

78	O	O
.	O	O
87	O	O
%	O	O
and	O	O
80	O	O
.	O	O
48	O	O
%	O	O
vs	O	O
.	O	O

43	O	O
.	O	O
66	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
while	O	O
for	O	O
depth	B-PHYS
of	O	O
spongiofibrosis	B-DISO
SE	B-PROC
,	O	O
and	O	O
SUG	B-PROC
had	O	O
accuracy	O
rates	O
of	O	O
87	O	O
.	O	O
3	O	O
%	O	O
,	O	O
48	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
mean	O	O
length	O	O
measured	O	O
on	O	O
SE	B-PROC
was	O	O
nearest	O	O
to	O	O
the	O	O
mean	O	O
intra	O
-	O
operative	O
stricture	B-DISO
length	O
(	O	O
21	O	O
.	O	O
34	O	O
+	O	O
11	O	O
.	O	O

8	O	O
mm	O	O
)	O	O
.	O	O

SE	B-PROC
findings	O	O
significantly	O	O
correlated	O	O
with	O	O
the	O	O
colour	B-DISO
of	I-DISO
bladder	I-DISO
mucosa	I-DISO
on	O	O
cystoscopic	B-PROC
examination	I-PROC
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
)	O	O
whereas	O	O
the	O	O
association	O	O
was	O	O
non	O	O
-	O	O
significant	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

127	O	O
)	O	O
for	O	O
difficulty	O	O
in	O	O
incision	B-PROC
.	O	O

While	O	O
a	O	O
nonsignificant	O	O
correlation	O	O
existed	O	O
between	O	O
SUG	B-PROC
findings	O	O
related	O	O
both	O	O
to	O	O
the	O	O
colour	B-DISO
of	I-DISO
the	I-DISO
bladder	I-DISO
mucosa	I-DISO
and	O	O
difficulty	O	O
in	O	O
incision	B-PROC
on	O	O
cystoscopy	B-PROC
,	O	O
SE	B-PROC
findings	O	O
had	O	O
a	O	O
significant	O	O
association	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
with	O	O
histopathology	O
findings	O
for	O	O
severe	O	O
degree	B-PROC
of	I-PROC
fibrosis	I-PROC
.	O	O

Sonoelastography	B-PROC
estimates	O	O
stricture	O
site	O
and	O
length	O
better	O	O
in	O	O
comparison	O	O
with	O	O
RUG	B-PROC
and	O	O
SUG	B-PROC
.	O	O

It	O	O
estimates	O	O
degree	O	O
of	O	O
spongiofibrosis	B-DISO
which	O	O
serves	O	O
as	O	O
an	O	O
important	O	O
prognostic	B-PHYS
factor	I-PHYS
for	O	O
stricture	B-PHEN
recurrence	I-PHEN
more	O	O
accurately	O
than	O	O
SUG	B-PROC
.	O	O

Phytoplankton	B-LIVB
production	O
and	O	O
taxon	O
-	O	O
specific	O
growth	O
rates	O
in	O	O
the	O	O
Costa	B-GEOG
Rica	I-GEOG
Dome	I-GEOG
During	O	O
summer	O
2010	O	O
,	O	O
we	O	O
investigated	O
phytoplankton	B-LIVB
production	O
and	O	O
growth	O
rates	O
at	O	O
19	O	O
stations	O
in	O
the	O
eastern	O
tropical	O
Pacific	O
,	O	O
where	O	O
winds	B-PHEN
and	O	O
strong	O
opposing	B-PHEN
currents	I-PHEN
generate	O
the	O	O
Costa	B-GEOG
Rica	I-GEOG
Dome	I-GEOG
(	O	O
CRD	B-GEOG
)	O	O
,	O	O
an	O	O
open	O
-	O	O
ocean	B-GEOG
upwelling	B-PHEN
feature	I-PHEN
.	O	O

Primary	O
production	O
(	O	O
(	B-CHEM
14	I-CHEM
)	I-CHEM
C	I-CHEM
-	O	O
incorporation	O
)	O	O
and	O	O
group	O
-	O
specific	O
growth	B-PHYS
and	O	O
net	O
growth	O
rates	O
(	O	O
two	O
-	O
treatment	O
seawater	B-OBJC
dilution	B-PROC
method	I-PROC
)	O	O
were	O	O
estimated	O
from	O	O
samples	B-LIVB
incubated	B-PROC
in	O
situ	O
at	O	O
eight	O	O
depths	O
.	O	O

Our	O	O
cruise	O	O
coincided	O	O
with	O	O
a	O	O
mild	O
El	B-PHEN
Niño	I-PHEN
event	O
,	O	O
and	O	O
only	O
weak	O
upwelling	B-PHEN
was	O	O
observed	O
in	O	O
the	O	O
CRD	B-GEOG
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
highest	O
phytoplankton	B-LIVB
abundances	O
were	O	O
found	O	O
near	O	O
the	O	O
dome	O
center	O
.	O	O

However	O	O
,	O	O
mixed	O
-	O
layer	O
growth	O
rates	O
were	O	O
lowest	O
in	O	O
the	O	O
dome	O
center	O
(	O	O
∼0	O	O
.	O	O
5	O	O
-	O	O
0	O	O
.	O	O
9	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
but	O	O
higher	O
on	O	O
the	O	O
edge	O
of	O	O
the	O	O
dome	O
(	O	O
∼0	O	O
.	O	O
9	O	O
-	O	O
1	O	O
.	O	O
0	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
and	O	O
in	O	O
adjacent	O
coastal	B-GEOG
waters	I-GEOG
(	O	O
0	O	O
.	O	O
9	O	O
-	O	O
1	O	O
.	O	O
3	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
.	O	O

We	O	O
found	O	O
good	O
agreement	O
between	O	O
independent	O
methods	O
to	O
estimate	O
growth	O
rates	O
.	O	O

Mixed	O
-	O
layer	O
growth	O
rates	O
of	O	O
Prochlorococcus	B-LIVB
and	O	O
Synechococcus	B-LIVB
were	O	O
largely	O	O
balanced	O	O
by	O	O
mortality	O
,	O	O
whereas	O	O
eukaryotic	B-LIVB
phytoplankton	I-LIVB
showed	O	O
positive	B-DISO
net	B-PHYS
growth	I-PHYS
(	O	O
∼0	O	O
.	O	O
5	O	O
-	O	O
0	O	O
.	O	O
6	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
that	O	O
is	O	O
,	O	O
growth	B-PHYS
available	O
to	O	O
support	O	O
larger	O
(	O	O
mesozooplankton	O
)	O	O
consumer	O
biomass	O
.	O	O

These	O	O
are	O	O
the	O	O
first	O
group	O
-	O
specific	O
phytoplankton	B-LIVB
rate	O
estimates	O
in	O	O
this	O	O
region	B-GEOG
,	O	O
and	O	O
they	O	O
demonstrate	O	O
that	O	O
integrated	O	O
primary	O
production	O
is	O	O
high	O
,	O	O
exceeding	O	O
1	O	O
g	O	O
C	O	O
m	O	O
(	O	O
-	O	O
2	O	O
)	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
on	O	O
average	O
,	O	O
even	O	O
during	O	O
a	O	O
period	O
of	O	O
reduced	O
upwelling	B-PHEN
.	O	O

Incidence	O
and	O	O
Impact	O
of	O	O
Patient	B-LIVB
-	O	O
Prosthesis	B-DEVI
Mismatch	O
in	O	O
Isolated	B-PROC
Aortic	I-PROC
Valve	I-PROC
Surgery	I-PROC
The	O	O
mains	O	O
topics	O	O
of	O	O
this	O	O
work	O	O
are	O	O
the	O	O
incidence	O
of	O	O
patient	B-LIVB
-	O	O
prosthesis	B-DEVI
mismatch	O
and	O	O
the	O	O
influence	O
in	O	O
the	O	O
early	O
results	O
of	O	O
isolated	B-PROC
aortic	I-PROC
valve	I-PROC
surgery	I-PROC
.	O	O

In	O	O
193	O	O
patients	B-LIVB
isolated	B-PROC
aortic	I-PROC
valve	I-PROC
surgery	I-PROC
was	O	O
performed	O
.	O	O

The	O	O
study	B-LIVB
population	I-LIVB
was	O	O
divided	O
in	O	O
three	O	O
subgroups	O
:	O	O
20	O	O
patients	B-LIVB
with	O	O
severe	O
,	O	O
131	O	O
patients	B-LIVB
with	O	O
moderate	O
and	O	O
42	O	O
patients	B-LIVB
without	O
patient	B-LIVB
-	O	O
prosthesis	B-DEVI
mismatch	O
.	O	O

The	O	O
indexed	O
effective	B-PHYS
orifice	I-PHYS
area	I-PHYS
was	O	O
used	O
to	O	O
define	O	O
the	O	O
subgroups	O
.	O	O

Operative	O
mortality	O
and	O	O
perioperative	B-DISO
complications	I-DISO
were	O	O
considered	O
the	O	O
indicators	O
of	O
the	O	O
early	O
results	O
of	O	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O	O

The	O	O
incidence	O
of	O	O
severe	O
and	O	O
moderate	O
patient	B-LIVB
-	O	O
prosthesis	B-DEVI
mismatch	O
was	O	O
respectively	O	O
10	O	O
.	O	O

3	O	O
%	O	O
and	O	O
67	O	O
.	O	O

8	O	O
%	O	O
.	O	O

Hospital	O
mortality	O
and	O	O
perioperative	B-DISO
complications	I-DISO
were	O	O
:	O	O
mortality	O
5	O	O
%	O	O
vs	O	O
.	O	O

3	O	O
.	O	O
1	O	O
%	O	O
vs	O	O
.	O	O

2	O	O
.	O	O
4	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
855	O	O
)	O	O
,	O	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
5	O	O
%	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
9	O	O
%	O	O
vs	O	O
.	O	O

4	O	O
.	O	O
8	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
861	O	O
)	O	O
;	O	O
pulmonary	B-DISO
complications	I-DISO
5	O	O
%	O	O
vs	O	O
.	O	O

3	O	O
.	O	O
1	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
0	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
430	O	O
)	O	O
;	O	O
exploration	B-PROC
for	O	O
bleeding	B-DISO
5	O	O
%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
8	O	O
%	O	O
vs	O	O
.	O	O

2	O	O
.	O	O
4	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
319	O	O
)	O	O
;	O	O
atrial	B-DISO
fibrillation	I-DISO
30	O	O
%	O	O
vs	O	O
.	O	O

19	O	O
.	O	O
8	O	O
%	O	O
vs	O	O
.	O	O

11	O	O
.	O	O

9	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
225	O	O
)	O	O
;	O	O
wound	B-DISO
infection	I-DISO
5	O	O
%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
8	O	O
%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
00	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
165	O	O
)	O	O
,	O	O
respectively	O	O
for	O	O
the	O	O
group	O
with	O	O
severe	O
,	O	O
moderate	O
and	O	O
without	O
patient	B-LIVB
-	O	O
prosthesis	B-DEVI
mismatch	O
.	O	O

Patient	B-LIVB
-	O	O
prosthesis	B-DEVI
mismatch	O
is	O	O
a	O	O
common	O
occurrence	O
in	O	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O	O

This	O	O
phenomenon	B-PHEN
does	O
not	O
affect	O
the	O	O
early	O
results	O
of	O	O
aortic	B-PROC
valve	I-PROC
surgery	I-PROC
.	O	O

Nutrient	O
Intakes	O
in	O	O
Early	O
Life	O
and	O	O
Risk	O
of	O
Obesity	B-DISO
There	O	O
is	O	O
increasing	O
evidence	O
that	O	O
environmental	O
factors	O
in	O	O
early	O
life	O
predict	O	O
later	O
health	O
.	O	O

The	O	O
early	O
adiposity	O
rebound	O
recorded	O	O
in	O	O
most	O	O
obese	B-DISO
subjects	B-LIVB
suggests	O	O
that	O	O
factors	O
promoting	O
body	B-PHYS
fat	I-PHYS
development	B-PHYS
have	O	O
operated	O	O
in	O	O
the	O	O
first	O	O
years	O
of	O	O
life	O
.	O	O

Birth	B-PHYS
weight	I-PHYS
,	O	O
growth	B-DISO
velocity	I-DISO
and	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
trajectories	O	O
seem	O	O
to	O	O
be	O	O
highly	O
sensitive	O
to	O	O
the	O	O
environmental	O
conditions	O
present	B-DISO
during	O
pregnancy	B-PHYS
and	O	O
in	O	O
early	O
life	O
(	O	O
""""	O	O
The	O	O
first	O	O
1000	O	O
days	O
""""	O	O
)	O	O
.	O	O

Particularly	O	O
,	O	O
nutritional	O
exposure	O
can	O	O
have	O	O
a	O	O
long	B-PHEN
-	I-PHEN
term	I-PHEN
effect	I-PHEN
on	O	O
health	O
in	O	O
adulthood	O
.	O	O

The	O	O
high	B-OBJC
protein	I-OBJC
-	I-OBJC
low	I-OBJC
fat	I-OBJC
diet	I-OBJC
often	O	O
recorded	O	O
in	O	O
young	O
children	B-LIVB
may	O	O
have	O	O
contributed	O	O
to	O	O
the	O	O
rapid	O
rise	O	O
of	O	O
childhood	O
obesity	B-DISO
prevalence	O
during	O
the	O	O
last	O	O
decades	O
.	O	O

Metabolic	O
programming	O
by	O	O
early	O
nutrition	B-PHYS
could	O	O
explain	O	O
the	O	O
development	B-PHYS
of	O	O
later	O
obesity	B-DISO
and	O	O
adult	B-DISO
diseases	I-DISO
.	O	O

Characteristics	O
of	O	O
the	O	O
fibroplasia	B-PHEN
and	O	O
collagen	B-CHEM
expression	B-PHYS
in	O	O
the	O	O
abdominal	B-ANAT
wall	I-ANAT
after	O	O
implant	B-PROC
of	O	O
the	O	O
polypropylene	B-CHEM
mesh	I-CHEM
and	O	O
polypropylene	B-CHEM
/	O	O
polyglecaprone	B-CHEM
mesh	I-CHEM
in	O	O
rats	B-LIVB
To	O	O
compare	O	O
fibroplasia	B-PHEN
and	O	O
the	O	O
resistance	B-PHYS
of	O	O
the	O	O
abdominal	B-ANAT
wall	I-ANAT
when	O	O
polypropylene	B-CHEM
meshes	I-CHEM
and	O	O
polypropylene	B-CHEM
/	O	O
poliglecaprone	B-CHEM
are	O	O
used	O	O
.	O	O

Seventy	O	O
-	O	O
seven	O	O
male	B-PHYS
Wistar	B-LIVB
rats	I-LIVB
were	O	O
divided	O	O
into	O	O
three	O	O
groups	B-LIVB
:	O	O
Control	B-LIVB
Group	I-LIVB
(	O	O
for	O	O
resistance	B-PHYS
)	O	O
;	O	O
Group	B-LIVB
E	I-LIVB
(	O	O
polypropylene	B-CHEM
mesh	I-CHEM
)	O	O
;	O	O
and	O	O
Group	B-LIVB
U	I-LIVB
(	O	O
polypropylene	B-CHEM
/	O	O
poliglecaprone	B-CHEM
mesh	I-CHEM
)	O	O
.	O	O

The	O	O
animals	B-LIVB
in	O	O
Groups	B-LIVB
E	I-LIVB
and	O	O
U	B-LIVB
had	O	O
a	O	O
standard	O	O
muscular	O
and	O	O
aponeurotic	B-ANAT
defect	O
,	O	O
with	O	O
integral	O
peritoneum	O
,	O	O
and	O	O
correction	O
with	O	O
the	O	O
mesh	B-DEVI
.	O	O

Measurements	O	O
were	O	O
taken	O	O
4	O	O
,	O	O
7	O	O
,	O	O
14	O	O
,	O	O
28	O	O
and	O	O
56	O	O
days	O
after	O	O
surgery	B-PROC
.	O	O

The	O	O
resistance	B-PHYS
,	O	O
and	O	O
collagen	B-CHEM
density	O
were	O	O
studied	B-PROC
.	O	O

Resistance	B-PHYS
on	O	O
the	O	O
56th	O	O
day	O
was	O	O
similar	O	O
in	O	O
both	O	O
meshes	B-DEVI
.	O	O

The	O	O
gain	O
in	O	O
resistance	B-PHYS
described	O	O
an	O	O
ascending	O
curve	O
for	O	O
the	O	O
polypropylene	B-CHEM
mesh	I-CHEM
and	O	O
was	O	O
irregular	O
in	O	O
the	O	O
case	O	O
of	O	O
the	O	O
polypropylene	B-CHEM
/	O	O
poliglecaprone	B-CHEM
.	O	O

Fibroplasia	B-PHEN
showed	O	O
a	O	O
gain	O
in	O	O
type	B-CHEM
I	I-CHEM
and	O	O
type	B-CHEM
III	I-CHEM
collagen	I-CHEM
in	O	O
both	O	O
groups	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Collagen	B-CHEM
III	I-CHEM
stabilized	B-DISO
in	O	O
the	O	O
14th	O	O
day	O
and	O	O
collagen	B-CHEM
I	I-CHEM
continued	O	O
to	O	O
ascend	O
.	O	O

The	O	O
gain	O
in	O	O
resistance	B-PHYS
of	O	O
the	O	O
polypropylene	B-CHEM
mesh	I-CHEM
is	O	O
regular	O	O
and	O	O
ascending	O
,	O	O
whereas	O	O
the	O	O
polypropylene	B-CHEM
/	O	O
poliglecaprone	B-CHEM
is	O	O
not	O	O
regular	O	O
.	O	O

The	O	O
final	O	O
resistance	B-PHYS
of	O	O
both	O	O
meshes	B-DEVI
is	O	O
similar	O	O
;	O	O
the	O	O
collagen	B-CHEM
density	O
increases	O	O
over	O	O
time	O	O
,	O	O
and	O	O
show	O	O
the	O	O
same	O	O
inflammatory	O
potential	O
.	O	O

Co	O
-	O
delivery	O
of	O	O
pemetrexed	B-CHEM
and	O	O
miR	B-CHEM
-	I-CHEM
21	I-CHEM
antisense	I-CHEM
oligonucleotide	I-CHEM
by	O	O
lipid	B-CHEM
-	O	O
polymer	B-CHEM
hybrid	B-OBJC
nanoparticles	I-OBJC
and	O	O
effects	O
on	O	O
glioblastoma	B-DISO
cells	B-ANAT
Combination	B-PROC
therapy	I-PROC
using	O	O
anticancer	B-CHEM
drugs	I-CHEM
and	O	O
nucleic	B-CHEM
acid	I-CHEM
is	O	O
a	O	O
more	O	O
promising	O	O
strategy	O	O
to	O	O
overcome	O	O
multidrug	B-PHYS
resistance	I-PHYS
in	O	O
cancer	B-DISO
and	O	O
to	O	O
enhance	O	O
apoptosis	B-PHYS
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
lipid	B-CHEM
-	O	O
polymer	B-CHEM
hybrid	B-OBJC
nanoparticles	I-OBJC
(	O	O
LPNs	B-CHEM
)	O	O
,	O	O
which	O	O
contain	O	O
both	O	O
pemetrexed	B-CHEM
and	O	O
miR	B-CHEM
-	I-CHEM
21	I-CHEM
antisense	I-CHEM
oligonucleotide	I-CHEM
(	O	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
)	O	O
,	O	O
have	O	O
been	O	O
developed	O	O
for	O	O
treatment	O
of	O	O
glioblastoma	B-DISO
,	O	O
the	O	O
most	O	O
aggressive	B-DISO
type	O	O
of	O	O
brain	B-DISO
tumor	I-DISO
.	O	O

Prepared	O	O
LPNs	B-CHEM
have	O	O
been	O	O
well	O	O
characterized	O	O
by	O	O
particle	O
size	O
distribution	O
and	O	O
zeta	B-PHEN
potential	I-PHEN
measurements	O
,	O	O
determination	O	O
of	O	O
encapsulation	B-PHEN
efficiency	O
,	O	O
and	O	O
in	O
vitro	O
release	B-PROC
experiments	I-PROC
.	O	O

Morphology	O
of	O	O
LPNs	B-CHEM
was	O	O
determined	O	O
by	O	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O	O

LPNs	B-CHEM
had	O	O
a	O	O
hydrodynamic	B-PHEN
size	O
below	O	O
100	O	O
nm	O	O
and	O	O
exhibited	O	O
sustained	O
release	O
of	O	O
pemetrexed	B-CHEM
up	O	O
to	O	O
10	O	O
h	O	O
.	O	O

Encapsulation	B-PHEN
of	O	O
pemetrexed	B-CHEM
in	O	O
LPNs	B-CHEM
increased	O	O
cellular	B-PHYS
uptake	I-PHYS
from	O	O
6	O	O
%	O	O
to	O	O
78	O	O
%	O	O
.	O	O

Results	O	O
of	O	O
confocal	B-PROC
microscopy	I-PROC
analysis	I-PROC
have	O	O
shown	O	O
that	O	O
co	O
-	O
delivery	O
of	O	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
significantly	O	O
improved	O	O
accumulation	B-DISO
of	O	O
LPNs	B-CHEM
in	O	O
the	O	O
nucleus	B-ANAT
of	O	O
U87MG	B-ANAT
cells	I-ANAT
.	O	O

Nevertheless	O	O
,	O	O
more	O	O
effective	O	O
cytotoxicity	B-DISO
results	O
could	O	O
not	O	O
be	O	O
obtained	O	O
due	O	O
to	O	O
low	O	O
concentration	O
of	O	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
,	O	O
loaded	O	O
in	O	O
LPNs	B-CHEM
.	O	O

We	O	O
expect	O	O
that	O	O
the	O	O
effective	O	O
drug	B-DEVI
delivery	I-DEVI
systems	I-DEVI
can	O	O
be	O	O
obtained	O	O
with	O	O
higher	O	O
concentration	O
of	O	O
anti	B-CHEM
-	I-CHEM
miR	I-CHEM
-	I-CHEM
21	I-CHEM
for	O	O
the	O	O
treatment	B-PROC
of	O	O
glioblastoma	B-DISO
.	O	O

Expert	B-LIVB
position	O
paper	O
on	O	O
prolonged	O
dual	B-PROC
antiplatelet	I-PROC
therapy	I-PROC
in	O	O
secondary	B-PROC
prevention	I-PROC
following	O	O
myocardial	B-DISO
infarction	I-DISO
The	O	O
protective	O
effect	O
of	O	O
dual	B-PROC
antiplatelet	I-PROC
therapy	I-PROC
(	O	O
DAPT	B-PROC
)	O	O
following	O	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
is	O	O
undisputed	O	O
,	O	O
but	O	O
its	O	O
duration	O
is	O	O
subject	O	O
of	O	O
debate	O
.	O	O

Several	O	O
studies	B-PROC
show	O	O
that	O	O
prolonged	O
therapy	B-PROC
provides	O	O
a	O	O
clinical	O
benefit	O
in	O	O
patients	B-LIVB
following	O	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
position	O
paper	O
authored	O	O
by	O	O
Austrian	B-LIVB
experts	B-LIVB
is	O	O
to	O	O
outline	O	O
the	O	O
current	O
evidence	O
and	O	O
provide	O	O
an	O	O
overview	O	O
of	O	O
recent	O	O
studies	B-PROC
.	O	O

It	O	O
is	O	O
also	O	O
intended	O	O
to	O	O
serve	O	O
as	O	O
a	O	O
practical	O
guide	O
to	O	O
identify	O	O
those	O	O
patients	B-LIVB
who	O	O
may	O	O
benefit	O
from	O	O
prolonged	O
DAPT	B-PROC
.	O	O

Clinical	B-PROC
evaluation	I-PROC
of	O	O
the	O	O
AutoPulse	B-DEVI
automated	B-DEVI
chest	I-DEVI
compression	I-DEVI
device	I-DEVI
for	O	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
in	O	O
the	O	O
northern	O
district	O	O
of	O	O
Shanghai	B-GEOG
,	O	O
China	B-GEOG
Whether	O	O
the	O	O
AutoPulse	B-DEVI
automated	B-DEVI
chest	I-DEVI
compression	I-DEVI
device	I-DEVI
is	O	O
worthy	O	O
of	O	O
clinical	O
use	O
for	O	O
out	B-DISO
-	I-DISO
of	I-DISO
-	I-DISO
hospital	I-DISO
cardiac	I-DISO
arrest	I-DISO
(	O	O
OHCA	B-DISO
)	O	O
remains	O	O
controversial	O	O
.	O	O

A	O	O
prospective	B-PROC
controlled	I-PROC
study	I-PROC
was	O	O
conducted	O	O
to	O	O
evaluate	B-PROC
the	O	O
effect	O
of	O
AutoPulse	B-DEVI
versus	O	O
manual	O
chest	B-ANAT
compression	B-PROC
for	O	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
(	O	O
CPR	B-PROC
)	O	O
of	O	O
OHCA	B-DISO
patients	B-LIVB
in	O	O
the	O	O
northern	O
district	O	O
of	O	O
Shanghai	B-GEOG
,	O	O
China	B-GEOG
.	O	O

A	O	O
total	O	O
of	O	O
133	O	O
patients	B-LIVB
with	O	O
OHCA	B-DISO
who	O	O
were	O	O
treated	O
at	O	O
the	O	O
Emergency	B-OBJC
Medical	I-OBJC
Center	I-OBJC
of	I-OBJC
the	I-OBJC
Tenth	I-OBJC
People	I-OBJC
's	I-OBJC
Hospital	I-OBJC
Affiliated	O
with	O	O
Tongji	B-OBJC
University	I-OBJC
between	O	O
March	O	O
2011	O	O
and	O	O
March	O	O
2012	O	O
were	O	O
included	O	O
.	O	O

The	O	O
patients	B-LIVB
were	O	O
randomly	O
assigned	O
to	O	O
the	O	O
Manual	O
CPR	B-PROC
(	O	O
n	O	O
=	O	O
64	O	O
)	O	O
and	O	O
AutoPulse	B-DEVI
CPR	B-PROC
groups	O
(	O	O
n	O	O
=	O	O
69	O	O
)	O	O
in	O
accordance	O
with	O
the	O	O
approach	O	O
of	O	O
chest	B-ANAT
compression	B-PROC
received	O
.	O	O

The	O	O
primary	O
outcome	O
measure	O
was	O	O
return	B-DISO
of	I-DISO
spontaneous	I-DISO
circulation	I-DISO
(	O	O
ROSC	B-DISO
)	O	O
,	O	O
and	O	O
the	O	O
secondary	O
outcome	O
measures	O
included	O	O
24	O	O
-	O	O
h	O	O
survival	O
rate	O
,	O	O
hospital	O
discharge	O
rate	O
,	O	O
and	O	O
neurological	O
prognosis	B-PROC
at	O	O
hospital	B-PROC
discharge	I-PROC
.	O	O

The	O	O
ROSC	B-DISO
rate	O
of	O	O
patients	B-LIVB
with	O	O
OHCA	B-DISO
was	O	O
significantly	O
higher	O
in	O	O
the	O	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O	O
in	O	O
the	O	O
Manual	O
CPR	B-PROC
group	O
(	O	O
44	O	O
.	O	O
9	O	O
%	O	O
vs	O	O
.	O	O

23	O	O
.	O	O
4	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

009	O	O
)	O	O
.	O	O

The	O	O
24	O	O
-	O	O
h	O	O
survival	O
rate	O
of	O	O
OHCA	B-DISO
patients	B-LIVB
was	O	O
significantly	O
higher	O
in	O	O
the	O	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O	O
in	O	O
the	O	O
Manual	O
CPR	B-PROC
group	O
(	O	O
39	O	O
.	O	O

1	O	O
%	O	O
vs	O	O
.	O	O

21	O	O
.	O	O
9	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
.	O	O

The	O	O
hospital	O
discharge	O
rate	O
of	O	O
the	O	O
patients	B-LIVB
with	O	O
OHCA	B-DISO
was	O	O
significantly	O
higher	O
in	O	O
the	O	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O	O
in	O	O
the	O	O
Manual	O
CPR	B-PROC
group	O
(	O	O
18	O	O
.	O	O

8	O	O
%	O	O
vs	O	O
.	O	O

6	O	O
.	O	O

3	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
.	O	O

The	O	O
proportion	O
of	O	O
patients	B-LIVB
with	O	O
OHCA	B-DISO
and	O	O
a	O	O
cerebral	O
performance	O
category	O
score	O
of	O	O
1	O	O
or	O	O
2	O	O
points	O	O
at	O	O
hospital	B-PROC
discharge	I-PROC
was	O	O
higher	O
in	O	O
the	O	O
AutoPulse	B-DEVI
CPR	B-PROC
group	O
than	O	O
in	O	O
the	O	O
Manual	O
CPR	B-PROC
group	O
,	O	O
but	O	O
the	O	O
difference	O
was	O	O
not	O
statistically	O
significant	O
(	O	O
16	O	O
.	O	O
2	O	O
%	O	O
vs	O	O
.	O	O

13	O	O
.	O	O
4	O	O
%	O	O
,	O	O
p	O	O
=	O	O
1	O	O
.	O	O
00	O	O
)	O	O
.	O	O

Use	O
of	O	O
the	O	O
AutoPulse	B-DEVI
increases	O
CPR	B-PROC
success	O
and	O	O
survival	O
rates	O
in	O	O
patients	B-LIVB
with	O	O
OHCA	B-DISO
,	O	O
but	O	O
its	O	O
ability	O	O
to	O	O
improve	B-DISO
cerebral	B-ANAT
performance	O
requires	O	O
further	O	O
evaluation	B-PROC
.	O	O

Medulloblastoma	B-DISO
:	O	O
molecular	B-PHYS
pathways	I-PHYS
and	O	O
histopathological	O
classification	O
Malignant	B-DISO
brain	I-DISO
tumors	I-DISO
are	O	O
the	O	O
leading	O
cause	O
of	O	O
cancer	B-DISO
death	B-DISO
among	O	O
pediatric	O
patients	B-LIVB
,	O	O
and	O	O
medulloblastoma	B-DISO
constitutes	O	O
20	O	O
%	O	O
of	O	O
them	O	O
.	O	O

Currently	O	O
,	O	O
the	O	O
treatment	B-PROC
is	O	O
risk	O	O
-	O	O
adapted	O	O
.	O	O

Maximum	O	O
surgical	B-PROC
resection	I-PROC
is	O	O
recommended	O
,	O	O
always	O	O
followed	O	O
by	O	O
chemotherapy	B-PROC
and	O	O
neuroaxis	B-ANAT
radiotherapy	B-PROC
.	O	O

In	O	O
spite	O	O
of	O	O
the	O	O
improving	O
survival	O
rate	O
,	O	O
survivors	B-LIVB
succumb	O	O
to	O	O
treatment	B-PROC
-	O	O
induced	O
side	B-DISO
effects	I-DISO
.	O	O

To	O	O
reduce	O
toxic	B-DISO
effects	I-DISO
,	O	O
molecular	B-PROC
-	I-PROC
targeted	I-PROC
treatment	I-PROC
is	O	O
proposed	O	O
.	O	O

Medulloblastoma	B-DISO
research	B-PROC
is	O	O
very	O	O
robust	O
,	O	O
and	O	O
new	O	O
articles	O
on	O	O
the	O	O
subject	O	O
are	O	O
published	O
daily	O	O
.	O	O

In	O	O
the	O	O
current	O	O
review	O
we	O	O
have	O	O
tried	O	O
to	O	O
bring	O	O
together	O	O
molecular	O
pathophysiology	O
of	O	O
the	O	O
neoplasm	B-DISO
and	O	O
current	O	O
pathological	O
classification	O
,	O	O
thus	O	O
making	O	O
an	O	O
effort	O	O
to	O	O
relate	O	O
tumor	B-PROC
biology	I-PROC
and	O	O
the	O	O
histological	B-PHYS
picture	I-PHYS
.	O	O

Expression	B-PHYS
of	O	O
the	O	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
and	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
could	O	O
be	O	O
affected	O	O
by	O	O
swimming	O
training	B-PROC
in	O	O
the	O	O
heart	B-ANAT
of	O	O
ovariectomized	B-LIVB
rats	I-LIVB
The	O	O
beneficial	O	O
and	O	O
more	O	O
potent	O	O
role	O
of	O	O
exercise	O
to	O	O
prevent	O
heart	B-ANAT
apoptosis	B-PHYS
in	O	O
ovariectomized	B-LIVB
rats	I-LIVB
has	O	O
been	O	O
known	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
the	O	O
effects	O
of	O
swimming	O
training	B-PROC
on	O	O
cardiac	B-ANAT
expression	B-PHYS
of	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
and	O	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
levels	O
and	O	O
glycogen	B-CHEM
changes	O
in	O	O
the	O	O
myocyte	B-ANAT
.	O	O

Forty	O	O
animals	B-LIVB
were	O	O
separated	O	O
into	O	O
four	O	O
groups	O
as	O	O
control	B-LIVB
,	O	O
sham	O
,	O	O
ovariectomy	O
(	O	O
OVX	O
)	O	O
and	O	O
ovariectomized	O
group	O
with	O	O
8	O	O
weeks	O
swimming	O
training	B-PROC
(	O	O
OVX	O	O
.	O	O

E	O	O
)	O	O
.	O	O

Training	B-PROC
effects	O
were	O	O
evaluated	O	O
by	O	O
measuring	O	O
lipid	B-PROC
profiles	I-PROC
,	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
expression	O
levels	O
in	O	O
the	O	O
cardiac	O
tissue	O
.	O	O

Grafts	O
were	O	O
analyzed	O	O
by	O	O
reverse	B-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
for	O	O
Bcl	O
-	O
2	O
mRNA	O
and	O	O
Mir	O
-	O
133	O
and	O	O
by	O	O
Western	B-PROC
blot	I-PROC
for	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
protein	I-CHEM
.	O	O

Ovariectomy	B-PROC
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
Mir	B-CHEM
-	I-CHEM
133	I-CHEM
expression	O
levels	O
in	O	O
the	O	O
cardiac	O
tissue	O
,	O	O
and	O	O
swimming	O
training	B-PROC
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
their	O	O
expression	B-PHYS
significantly	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
showed	O	O
that	O	O
regular	O	O
exercise	O
as	O	O
a	O	O
physical	B-PROC
replacement	I-PROC
therapy	I-PROC
could	O	O
prevent	O
and	O	O
improve	O	O
the	O	O
effects	O
of	O
estrogen	B-DISO
deficiency	I-DISO
in	O	O
the	O	O
cardia	B-ANAT
.	O	O

Changes	O
in	O	O
risk	B-DISO
factors	I-DISO
for	O	O
young	O
male	B-PHYS
suicide	B-DISO
in	O	O
Newcastle	B-GEOG
upon	I-GEOG
Tyne	I-GEOG
,	O	O
1961	O	O
-	O	O
2009	O	O
Aims	O
and	O	O
method	O
To	O	O
ascertain	O	O
differences	O
in	O	O
patterns	B-DISO
of	I-DISO
suicide	I-DISO
in	O	O
young	O
men	B-LIVB
over	O	O
three	O	O
decades	O
(	O	O
1960s	O	O
,	O	O
1990s	O	O
and	O	O
2000s	O	O
)	O	O
and	O	O
discuss	O	O
implications	O
for	O	O
suicide	B-DISO
prevention	O
.	O	O

Data	O
on	O	O
suicides	B-DISO
and	O	O
open	O
verdicts	O
in	O	O
men	B-LIVB
aged	O	O
15	O	O
-	O	O
34	O	O
were	O	O
obtained	O	O
from	O	O
coroner	O
's	O
records	O
in	O	O
Newcastle	B-GEOG
upon	I-GEOG
Tyne	I-GEOG
and	O	O
analysed	B-PROC
using	O	O
SPSS	B-OBJC
software	I-OBJC
.	O	O

Results	O
An	O	O
increase	O
in	O	O
suicide	B-DISO
rates	I-DISO
from	O	O
the	O	O
first	O	O
to	O	O
the	O	O
second	O	O
decade	O
was	O	O
followed	O	O
by	O	O
a	O	O
fall	O	O
in	O	O
the	O	O
third	O	O
decade	O
.	O	O

This	O	O
was	O	O
associated	O
with	O
an	O	O
increasing	O
proportion	O
of	O	O
single	O
men	B-LIVB
,	O	O
those	O	O
living	B-DISO
alone	I-DISO
,	O	O
unemployment	B-DISO
,	O	O
consumption	O
of	O
alcohol	O
,	O	O
use	O	O
of	O	O
hanging	B-DISO
,	O	O
previous	O
suicide	B-DISO
attempt	I-DISO
and	O	O
history	O
of	O
treatment	O
for	O	O
mental	B-DISO
illness	I-DISO
.	O	O

Clinical	O
implications	O
This	O	O
study	B-PROC
highlights	O	O
the	O	O
need	O	O
for	O	O
more	O	O
interventions	B-PROC
and	O	O
focus	B-PHYS
to	O	O
be	O	O
given	O	O
to	O	O
young	O
males	B-PHYS
in	O	O
the	O	O
suicide	B-DISO
prevention	O
area	O
and	O	O
is	O	O
of	O	O
high	O	O
importance	O	O
in	O	O
the	O	O
field	O
of	O
public	O
health	O
.	O	O

Areas	O	O
that	O	O
could	O	O
be	O	O
tackled	O	O
include	O	O
reducing	O
access	O
to	O	O
means	O
of	O	O
suicide	B-DISO
,	O	O
reducing	O
alcohol	O
use	O
,	O	O
support	O
for	O	O
relationship	O
difficulties	O
,	O	O
engagement	B-PROC
with	O	O
mental	B-PROC
health	I-PROC
services	I-PROC
and	O	O
management	B-PROC
of	O	O
chronic	B-DISO
illness	I-DISO
.	O	O

Spatio	B-PROC
-	I-PROC
Temporal	I-PROC
History	I-PROC
of	O	O
HIV	B-PHEN
-	I-PHEN
1	I-PHEN
CRF35	I-PHEN
_	I-PHEN
AD	I-PHEN
in	O	O
Afghanistan	B-GEOG
and	O	O
Iran	B-GEOG
HIV	B-LIVB
-	I-LIVB
1	I-LIVB
Circulating	I-LIVB
Recombinant	I-LIVB
Form	I-LIVB
35	I-LIVB
_	I-LIVB
AD	I-LIVB
(	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
)	O	O
has	O	O
an	O	O
important	O	O
position	O	O
in	O	O
the	O	O
epidemiological	O
profile	O
of	O	O
Afghanistan	B-GEOG
and	O	O
Iran	B-GEOG
.	O	O

Despite	O	O
the	O	O
presence	O	O
of	O	O
this	O	O
clade	B-LIVB
in	O	O
Afghanistan	B-GEOG
and	O	O
Iran	B-GEOG
for	O	O
over	O	O
a	O	O
decade	O	O
,	O	O
our	O	O
understanding	O	O
of	O	O
its	O	O
origin	O	O
and	O	O
dissemination	O
patterns	O	O
is	O	O
limited	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
Bayesian	O
phylogeographic	O
analysis	O
to	O	O
reconstruct	O	O
the	O	O
spatio	O
-	O
temporal	O
dispersion	O
pattern	O
of	O	O
this	O	O
clade	B-LIVB
using	O	O
eligible	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
gag	O
and	O
pol	O
sequences	O
available	O	O
in	O	O
the	O	O
Los	B-GEOG
Alamos	I-GEOG
HIV	O
database	O
(	O	O
432	O	O
sequences	O
available	O	O
from	O	O
Iran	B-GEOG
,	O	O
16	O	O
sequences	O
available	O	O
from	O	O
Afghanistan	B-GEOG
,	O	O
and	O	O
a	O	O
single	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
-like	O	O
pol	O
sequence	O
available	O	O
from	O	O
USA	B-GEOG
)	O	O
.	O	O

Bayesian	O
Markov	O
Chain	O
Monte	O
Carlo	O
algorithm	O
was	O	O
implemented	O	O
in	O	O
BEAST	B-OBJC
v1	I-OBJC
.	I-OBJC

8	I-OBJC
.	I-OBJC

1	I-OBJC
.	O	O
Between	O	O
-	O	O
country	O	O
dispersion	O	O
rates	O	O
were	O	O
tested	O	O
with	O	O
Bayesian	O
stochastic	O
search	O
variable	O
selection	O
method	O
and	O	O
were	O	O
considered	O	O
significant	O	O
where	O	O
Bayes	O
factor	O
values	O
were	O	O
greater	O	O
than	O	O
three	O	O
.	O	O

The	O	O
findings	O	O
suggested	O	O
that	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
were	O	O
genetically	O	O
similar	O	O
to	O	O
parental	O
sequences	O
from	O	O
Kenya	B-GEOG
and	O	O
Uganda	B-GEOG
,	O	O
and	O	O
to	O	O
a	O	O
set	O	O
of	O	O
subtype	B-PHEN
A1	I-PHEN
sequences	O
available	O	O
from	O	O
Afghan	B-GEOG
refugees	B-LIVB
living	O	O
in	O	O
Pakistan	B-GEOG
.	O	O

Our	O	O
results	O	O
also	O	O
showed	O	O
that	O	O
across	O	O
all	O	O
phylogenies	O
,	O	O
Afghan	B-GEOG
and	O	O
Iranian	B-GEOG
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
formed	O	O
a	O	O
monophyletic	O
cluster	O
(	O	O
posterior	O	O
clade	O	O
credibility	O	O
>	O	O
0	O	O
.	O	O
7	O	O
)	O	O
.	O	O

The	O	O
divergence	O	O
date	O	O
of	O	O
this	O	O
cluster	O
was	O	O
estimated	O	O
to	O	O
be	O	O
between	O	O
1990	O	O
and	O	O
1992	O	O
.	O	O

Within	O	O
this	O	O
cluster	O
,	O	O
a	O	O
bidirectional	O
dispersion	O
of	O	O
the	O	O
virus	B-LIVB
was	O	O
observed	O	O
across	O	O
Afghanistan	B-GEOG
and	O	O
Iran	B-GEOG
.	O	O

We	O	O
could	O	O
not	O	O
clearly	O	O
identify	O	O
if	O	O
Afghanistan	B-GEOG
or	O	O
Iran	B-GEOG
first	O	O
established	O	O
or	O	O
received	O	O
this	O	O
epidemic	B-DISO
,	O	O
as	O	O
the	O	O
root	O	O
location	O	O
of	O	O
this	O	O
cluster	O
could	O	O
not	O	O
be	O	O
robustly	O	O
estimated	O	O
.	O	O

Three	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
sequences	O
from	O	O
Afghan	B-GEOG
refugees	B-LIVB
living	O
in	O
Pakistan	B-GEOG
nested	O	O
among	O	O
Afghan	B-GEOG
and	O	O
Iranian	B-GEOG
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
branches	O	O
.	O	O

However	O	O
,	O	O
the	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
-like	O	O
sequence	O
available	O	O
from	O	O
USA	B-GEOG
diverged	O	O
independently	O	O
from	O	O
Kenyan	B-GEOG
subtype	B-PHEN
A1	I-PHEN
sequences	O
,	O	O
suggesting	O	O
it	O	O
not	O	O
to	O	O
be	O	O
a	O	O
true	O	O
CRF35	B-PHEN
_	I-PHEN
AD	I-PHEN
lineage	O	O
.	O	O

Potential	O
factors	O
contributing	O	O
to	O	O
viral	B-LIVB
exchange	O	O
between	O	O
Afghanistan	B-GEOG
and	O	O
Iran	B-GEOG
could	O	O
be	O	O
injection	O	O
drug	O	O
networks	O	O
and	O	O
mass	O
migration	O
of	O	O
Afghan	B-GEOG
refugees	B-LIVB
and	O	O
labours	O
to	O	O
Iran	B-GEOG
,	O	O
which	O	O
calls	O	O
for	O	O
extensive	O
preventive	O
efforts	O	O
.	O	O

Hepatitis	B-LIVB
E	I-LIVB
virus	I-LIVB
in	O	O
donor	B-LIVB
plasma	B-ANAT
collected	O	O
in	O	O
Japan	B-GEOG
Human	B-LIVB
hepatitis	B-LIVB
E	I-LIVB
virus	I-LIVB
(	O	O
HEV	B-LIVB
)	O	O
is	O	O
prevalent	B-DISO
worldwide	I-DISO
.	O	O

Iatrogenic	O
HEV	B-LIVB
has	O	O
recently	O	O
been	O	O
identified	O
based	O	O
on	O	O
the	O	O
reports	O
of	O	O
transfusion	O
-	O
transmitted	O
cases	O
.	O	O

The	O	O
detection	O
rate	O
of	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
and	O	O
seroprevalence	B-PROC
of	O	O
HEV	B-CHEM
-	I-CHEM
IgG	I-CHEM
/	O	O
IgM	B-CHEM
have	O	O
been	O	O
regionally	B-PROC
evaluated	I-PROC
in	O	O
Japan	B-GEOG
,	O	O
and	O	O
donor	B-LIVB
plasma	B-ANAT
collected	O	O
in	O	O
Hokkaido	B-GEOG
is	O	O
currently	O	O
screened	O
by	O	O
nucleic	B-PROC
acid	I-PROC
amplification	I-PROC
testing	I-PROC
.	O	O

However	O	O
,	O	O
the	O	O
detection	O
rate	O
of	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
in	O	O
blood	B-LIVB
donors	I-LIVB
in	O	O
Japan	B-GEOG
outside	O	O
of	O	O
Hokkaido	B-GEOG
has	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

A	O	O
total	O	O
of	O	O
620	O	O
140	O	O
qualified	O	O
donor	B-LIVB
plasma	B-ANAT
samples	I-ANAT
from	O	O
Japanese	B-GEOG
regions	I-GEOG
excluding	O	O
Hokkaido	B-GEOG
were	O	O
tested	O
for	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
(	O	O
pools	O	O
of	O	O
50	O	O
or	O	O
500	O	O
)	O	O
between	O	O
2004	O	O
and	O	O
2014	O	O
.	O	O

HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
-	I-CHEM
positive	I-CHEM
plasma	B-ANAT
bags	I-ANAT
were	O	O
identified	O
,	O	O
and	O	O
the	O	O
HEV	B-LIVB
viral	B-PROC
load	I-PROC
,	O	O
genotype	B-PHYS
and	O	O
anti	B-CHEM
-	I-CHEM
HEV	I-CHEM
immunoglobulin	I-CHEM
(	I-CHEM
Ig	I-CHEM
)	I-CHEM
G	I-CHEM
/	I-CHEM
IgM	I-CHEM
were	O	O
evaluated	O	O
.	O	O

The	O	O
detection	O
rate	O
of	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
(	O	O
pools	O	O
of	O	O
50	O	O
)	O	O
was	O	O
1	O	O
/	O	O
15	O	O
075	O	O
and	O	O
higher	O	O
in	O	O
eastern	B-GEOG
than	O	O
in	O	O
western	B-GEOG
Japan	I-GEOG
.	O	O

All	O	O
36	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
-	I-CHEM
positive	I-CHEM
samples	B-ANAT
were	O	O
genotype	B-PHYS
3	I-PHYS
with	O	O
viral	B-DISO
load	I-DISO
ranging	O	O
from	O	O
<	O	O
1·69	O	O
to	O	O
7·22	O	O
log10	O	O
copies	O	O
/	O	O
ml	O	O
.	O	O

Our	O	O
detection	O
rate	O
of	O	O
HEV	B-CHEM
-	I-CHEM
RNA	I-CHEM
in	O	O
donor	B-LIVB
populations	I-LIVB
in	O	O
Japan	B-GEOG
outside	O	O
Hokkaido	B-GEOG
(	O	O
1	O	O
/	O	O
15	O	O
075	O	O
donations	B-PROC
)	O	O
is	O	O
generally	O	O
lower	O	O
than	O	O
reported	O	O
in	O	O
Europe	B-GEOG
and	O	O
lower	O	O
than	O	O
previously	O	O
reported	O	O
for	O	O
Hokkaido	B-GEOG
(	O	O
1	O	O
/	O	O
8173	O	O
donations	B-PROC
)	O	O
.	O	O

As	O	O
methods	O	O
varied	O	O
,	O	O
we	O	O
cannot	O	O
exclude	O	O
that	O	O
these	O	O
differences	O	O
are	O	O
reflective	O	O
of	O	O
differing	O	O
RNA	B-CHEM
detection	O
limits	O
.	O	O

In	O	O
contrast	O	O
to	O	O
Hokkaido	B-GEOG
where	O	O
genotype	B-PHYS
4	I-PHYS
has	O	O
been	O	O
reported	O	O
among	O	O
blood	B-PROC
donations	I-PROC
,	O	O
all	O	O
our	O	O
positive	B-DISO
donations	B-PROC
were	O	O
genotype	B-PHYS
3	I-PHYS
,	O	O
which	O	O
is	O	O
less	O	O
pathogenic	B-DISO
.	O	O

Social	O
cognition	O
in	O	O
schizophrenia	B-DISO
:	O	O
Factor	O
structure	O
of	O	O
emotion	B-PHYS
processing	B-PHYS
and	O	O
theory	O
of	O
mind	O
Factor	O
analytic	O
studies	O
examining	O	O
social	O
cognition	O
in	O	O
schizophrenia	B-DISO
have	O	O
yielded	O	O
inconsistent	O	O
results	O
most	O	O
likely	O	O
due	O	O
to	O	O
the	O	O
varying	O	O
number	O	O
and	O	O
quality	O
of	O
measures	O
.	O	O

With	O	O
the	O	O
recent	O	O
conclusion	O	O
of	O	O
Phase	O
3	O
of	O	O
the	O	O
Social	O
Cognition	O
Psychometric	B-PROC
Evaluation	I-PROC
(	I-PROC
SCOPE	I-PROC
)	I-PROC
Study	I-PROC
,	O	O
the	O	O
most	O	O
psychometrically	B-PROC
sound	B-PROC
measures	I-PROC
of	O	O
social	O
cognition	O
have	O	O
been	O	O
identified	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
aims	O	O
of	O	O
the	O	O
present	O	O
study	B-PROC
were	O	O
to	O	O
:	O	O
1	O	O
)	O	O
examine	B-DISO
the	O	O
factor	O
structure	O
of	O	O
social	O
cognition	O
in	O	O
schizophrenia	B-DISO
through	O	O
the	O	O
utilization	O	O
of	O	O
psychometrically	B-PROC
sound	B-PROC
measures	I-PROC
,	O	O
2	O	O
)	O	O
examine	B-DISO
the	O	O
stability	O
of	O	O
the	O	O
factor	O
structure	O
across	O	O
two	O	O
study	B-PROC
visits	O	O
,	O	O
3	O	O
)	O	O
compare	O	O
the	O	O
factor	O
structure	O
of	O	O
social	O
cognition	O
in	O	O
schizophrenia	B-DISO
to	O	O
that	O	O
in	O	O
healthy	O
controls	O
,	O	O
and	O	O
4	O	O
)	O	O
examine	B-DISO
the	O	O
relationship	O	O
between	O	O
the	O	O
factors	O
and	O	O
relevant	O	O
outcome	O
measures	O
including	O	O
social	O
functioning	O
and	O	O
symptoms	B-DISO
.	O	O

Results	O
supported	O	O
a	O	O
one	O
-	O
factor	O
model	O
for	O	O
the	O	O
patient	B-LIVB
and	O	O
healthy	O
control	O
samples	O	O
at	O	O
both	O	O
visits	B-PROC
.	O	O

This	O	O
single	O	O
factor	O	O
was	O	O
significantly	O	O
associated	O
with	O
negative	B-DISO
symptoms	I-DISO
in	O	O
the	O	O
schizophrenia	B-DISO
sample	B-OBJC
and	O	O
with	O	O
social	O
functioning	O
in	O	O
both	O	O
groups	B-LIVB
at	O	O
both	O	O
study	B-PROC
visits	B-PROC
.	O	O

Individual	O
differences	O
in	O	O
behavioral	B-PHYS
activation	I-PHYS
and	O	O
cardiac	B-PHYS
vagal	I-PHYS
control	I-PHYS
influence	O
affective	O	O
startle	O
modification	O
The	O	O
startle	B-PHYS
response	I-PHYS
(	O	O
SR	B-PHYS
)	O	O
has	O	O
a	O	O
close	O	O
relationship	O
with	O	O
stress	B-PHYS
responses	I-PHYS
.	O	O

Startle	O
modification	O
(	O	O
SRM	O
)	O	O
has	O	O
been	O	O
widely	O	O
used	O	O
to	O	O
study	O	O
stress	B-DISO
disorders	I-DISO
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
,	O	O
posttraumatic	B-DISO
stress	I-DISO
disorder	I-DISO
)	O	O
.	O	O

The	O	O
framework	O	O
of	O	O
the	O	O
behavioral	B-PHYS
inhibition	I-PHYS
and	O	O
activation	O	O
systems	O	O
(	O	O
BIS	B-PHYS
/	O	O
BAS	O	O
)	O	O
has	O	O
been	O	O
thought	O	O
to	O	O
correspond	O	O
with	O	O
withdrawal	O	O
and	O	O
approach	O	O
motivational	B-PHYS
processes	I-PHYS
underlying	O	O
affective	O	O
SRM	O
and	O	O
can	O	O
influence	O
stress	B-PHYS
reactivity	I-PHYS
.	O	O

Vagally	B-DISO
-	I-DISO
mediated	I-DISO
cardiac	I-DISO
activity	I-DISO
as	O	O
indexed	O
by	O	O
heart	B-DISO
rate	I-DISO
variability	I-DISO
(	O	O
HRV	B-DISO
)	O	O
has	O	O
been	O	O
associated	O
with	O
SRM	O
and	O	O
regulatory	B-PHEN
processes	I-PHEN
during	O	O
stress	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
influence	O
of	O	O
individual	O
differences	O
in	O	O
the	O	O
BIS	B-PHYS
/	O	O
BAS	O	O
and	O	O
resting	O	O
HRV	B-DISO
on	O	O
affective	O	O
SRM	O
were	O	O
examined	B-DISO
.	O	O

Eighty	B-LIVB
-	I-LIVB
six	I-LIVB
subjects	I-LIVB
viewed	O	O
affective	O	O
pictures	B-OBJC
while	O	O
acoustic	B-PHEN
SR	I-PHEN
stimuli	I-PHEN
were	O	O
delivered	O	O
.	O	O

Individual	O
differences	O
in	O	O
motivation	B-PHYS
were	O	O
measured	O
by	O	O
the	O	O
BIS	O
/	O
BAS	O
scales	O
.	O	O

The	O	O
magnitude	O
of	O	O
SR	B-PHYS
was	O	O
assessed	O
as	O	O
electromyographic	B-PROC
activity	O
of	O	O
the	O	O
SR	B-PHYS
eyeblink	B-PHYS
during	O	O
pictures	B-OBJC
of	O	O
different	O	O
valences	O
.	O	O

Resting	O	O
HRV	B-DISO
was	O	O
derived	O	O
from	O	O
electrocardiography	B-PROC
.	O	O

In	O	O
contrast	O	O
to	O	O
previous	O	O
studies	O	O
,	O	O
the	O	O
present	O	O
results	O
showed	O	O
that	O	O
startle	B-PHYS
inhibition	I-PHYS
and	O	O
potentiation	B-PHYS
were	O	O
related	O	O
to	O	O
BAS	O	O
and	O	O
HRV	B-DISO
,	O	O
but	O	O
not	O	O
to	O	O
BIS	B-PHYS
.	O	O

There	O	O
was	O	O
also	O	O
an	O	O
interaction	O
of	O	O
BAS	O	O
and	O	O
HRV	B-DISO
,	O	O
indicating	O	O
that	O	O
the	O	O
relationship	O
between	O	O
HRV	B-DISO
and	O	O
SRM	O
strengthened	O	O
as	O	O
BAS	O	O
scores	O
decreased	O	O
.	O	O

The	O	O
present	O	O
findings	B-DISO
suggest	O	O
that	O	O
BAS	O	O
may	O	O
relate	O	O
to	O	O
both	O	O
withdrawal	O	O
and	O	O
approach	O	O
,	O	O
and	O	O
trait	B-PHYS
stress	B-PHYS
reactivity	I-PHYS
is	O	O
influence	O
d	O	O
by	O	O
BAS	O	O
and	O	O
cardiac	B-DISO
vagal	I-DISO
activity	I-DISO
.	O	O

In	O	O
addition	O	O
,	O	O
BAS	O	O
moderates	O	O
the	O	O
relationship	O
between	O	O
cardiac	B-DISO
vagal	I-DISO
activity	I-DISO
and	O	O
SRM	O
.	O	O

These	O	O
findings	B-DISO
have	O	O
both	O	O
theoretical	O
and	O
practical	O
implications	O
for	O	O
the	O	O
study	O	O
of	O	O
SRM	O
,	O	O
stress	B-DISO
disorders	I-DISO
,	O	O
and	O	O
health	O
.	O	O

Efficient	O	O
patient	B-LIVB
modeling	B-PROC
for	O	O
visuo	O
-	O	O
haptic	B-PHYS
VR	O
simulation	O
using	O	O
a	O	O
generic	O	O
patient	B-LIVB
atlas	B-OBJC
This	O	O
work	O	O
presents	O	O
a	O	O
new	O	O
time	O	O
-	O	O
saving	O	O
virtual	O
patient	B-LIVB
modeling	B-PROC
system	I-PROC
by	O	O
way	O	O
of	O	O
example	O	O
for	O	O
an	O	O
existing	O	O
visuo	O
-	O	O
haptic	B-PHYS
training	B-PROC
and	O	O
planning	O	O
virtual	O
reality	O
(	O
VR	O
)	O
system	O
for	O	O
percutaneous	B-PROC
transhepatic	I-PROC
cholangio	I-PROC
-	I-PROC
drainage	I-PROC
(	O	O
PTCD	B-PROC
)	O	O
.	O	O

Our	O	O
modeling	B-PROC
process	I-PROC
is	O	O
based	O	O
on	O	O
a	O	O
generic	O	O
patient	B-LIVB
atlas	B-OBJC
to	O	O
start	O	O
with	O	O
.	O	O

It	O	O
is	O	O
defined	O	O
by	O	O
organ	B-ANAT
-	O	O
specific	O
optimized	O
models	O
,	O	O
method	O
modules	O
and	O	O
parameters	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

mainly	O	O
individual	O	O
segmentation	O
masks	O
,	O	O
transfer	O
functions	O
to	O	O
fill	O	O
the	O	O
gaps	O
between	O	O
the	O	O
masks	O
and	O	O
intensity	O
image	O
data	O
.	O	O

In	O	O
this	O	O
contribution	O	O
,	O	O
we	O	O
show	O	O
how	O	O
generic	O	O
patient	B-LIVB
atlases	B-OBJC
can	O	O
be	O	O
generalized	O	O
to	O	O
new	O	O
patient	O
data	O
.	O	O

The	O	O
methodology	O	O
consists	O	O
of	O	O
patient	B-LIVB
-	O	O
specific	O
,	O	O
locally	O	O
-	O	O
adaptive	O	O
transfer	O
functions	O
and	O	O
dedicated	O	O
modeling	B-PROC
methods	I-PROC
such	O	O
as	O	O
multi	O
-	O
atlas	O
segmentation	O
,	O	O
vessel	O
filtering	O
and	O	O
spline	O
-	O
modeling	O
.	O	O

Our	O	O
full	O	O
image	O
volume	O
segmentation	O
algorithm	O
yields	O	O
median	O
DICE	O
coefficients	O
of	O	O
0	O	O
.	O	O

98	O	O
,	O	O
0	O	O
.	O	O
93	O	O
,	O	O
0	O	O
.	O	O
82	O	O
,	O	O
0	O	O
.	O	O
74	O	O
,	O	O
0	O	O
.	O	O
51	O	O
and	O	O
0	O	O
.	O	O
48	O	O
regarding	O	O
soft	O
-	O
tissue	O
,	O	O
liver	B-ANAT
,	O	O
bone	O
,	O	O
skin	B-ANAT
,	O	O
blood	B-ANAT
and	O	O
bile	B-ANAT
vessels	I-ANAT
for	O	O
ten	O	O
test	O	O
patients	B-LIVB
and	O	O
three	O	O
selected	O	O
reference	O	O
patients	B-LIVB
.	O	O

Compared	O	O
to	O	O
standard	O	O
slice	O
-	O
wise	O
manual	O
contouring	O
time	O	O
saving	O	O
is	O	O
remarkable	O	O
.	O	O

Our	O	O
segmentation	O
process	O
shows	O	O
out	O	O
efficiency	O
and	O	O
robustness	O
for	O	O
upper	O	O
abdominal	B-DISO
puncture	I-DISO
simulation	O
systems	O
.	O	O

This	O	O
marks	O	O
a	O	O
significant	O
step	O	O
toward	O	O
establishing	O	O
patient	B-LIVB
-	O	O
specific	O
training	B-PROC
and	O	O
hands	O	O
-	O	O
on	O	O
planning	O	O
systems	O	O
in	O	O
a	O	O
clinical	B-PROC
environment	I-PROC
.	O	O

The	O	O
Benefits	O
of	O	O
Combination	B-PROC
Therapy	I-PROC
with	O	O
Esomeprazole	B-CHEM
and	O	O
Rebamipide	B-CHEM
in	O	O
Symptom	B-DISO
Improvement	O
in	O	O
Reflux	B-DISO
Esophagitis	I-DISO
:	O	O
An	O	O
International	O
Multicenter	B-PROC
Study	I-PROC
To	O	O
investigate	O
the	O	O
effects	O
of	O	O
esomeprazole	B-CHEM
and	O	O
rebamipide	B-CHEM
combination	B-PROC
therapy	I-PROC
on	O	O
symptomatic	B-DISO
improvement	O
in	O	O
patients	B-LIVB
with	O	O
reflux	B-DISO
esophagitis	I-DISO
.	O	O

A	O	O
total	O	O
of	O	O
501	O	O
patients	B-LIVB
with	O	O
reflux	B-DISO
esophagitis	I-DISO
were	O	O
randomized	B-PROC
into	O	O
one	O	O
of	O	O
the	O	O
following	O	O
two	O	O
treatment	B-PROC
regimens	I-PROC
:	O	O
40	O	O
mg	O	O
esomeprazole	B-CHEM
plus	O	O
300	O	O
mg	O	O
rebamipide	B-CHEM
daily	O
(	O	O
combination	B-PROC
therapy	I-PROC
group	O
)	O	O
or	O	O
40	O	O
mg	O	O
esomeprazole	B-CHEM
daily	O
(	O	O
monotherapy	B-PROC
group	O
)	O	O
.	O	O

We	O	O
used	O	O
a	O	O
symptom	B-DISO
questionnaire	O
that	O	O
evaluated	O
heartburn	B-DISO
,	O	O
acid	B-DISO
regurgitation	I-DISO
,	O	O
and	O	O
four	O	O
upper	B-DISO
gastrointestinal	I-DISO
symptoms	I-DISO
.	O	O

The	O	O
primary	O	O
efficacy	O
end	O	O
point	O	O
was	O	O
the	O	O
mean	O	O
decrease	O
in	O	O
the	O	O
total	O	O
symptom	B-DISO
score	I-DISO
.	O	O

The	O	O
mean	O	O
decreases	O
in	O	O
the	O	O
total	O	O
symptom	B-DISO
score	I-DISO
at	O	O
4	O	O
weeks	O
were	O	O
estimated	O	O
to	O	O
be	O	O
-18	O	O
.	O	O

1±13	O	O
.	O	O

8	O	O
in	O	O
the	O	O
combination	B-PROC
therapy	I-PROC
group	O
and	O	O
-15	O	O
.	O	O

1±11	O	O
.	O	O

9	O	O
in	O	O
the	O	O
monotherapy	B-PROC
group	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
011	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
reflux	B-DISO
symptom	B-DISO
s	O	O
from	O	O
baseline	O
after	O	O
4	O	O
weeks	O
of	O	O
treatment	B-PROC
were	O	O
-8	O	O
.	O	O

4±6	O	O
.	O	O

6	O	O
in	O	O
the	O	O
combination	B-PROC
therapy	I-PROC
group	O
and	O	O
-6	O	O
.	O	O

8±5	O	O
.	O	O

9	O	O
in	O	O
the	O	O
monotherapy	B-PROC
group	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
009	O	O
)	O	O
.	O	O

Over	O	O
a	O	O
4	O	O
-	O	O
week	O
treatment	B-PROC
course	O	O
,	O	O
esomeprazole	B-CHEM
and	O	O
rebamipide	B-CHEM
combination	B-PROC
therapy	I-PROC
was	O	O
more	O	O
effective	O
in	O	O
decreasing	B-DISO
the	O	O
symptoms	B-DISO
of	O	O
reflux	B-DISO
esophagitis	I-DISO
than	O	O
esomeprazole	B-CHEM
monotherapy	B-PROC
.	O	O

Achilles	B-ANAT
tendon	I-ANAT
material	B-PHEN
properties	I-PHEN
are	O	O
greater	O
in	O	O
the	O	O
jump	B-ANAT
leg	I-ANAT
of	O	O
jumping	O
athletes	B-LIVB
The	O	O
Achilles	B-ANAT
tendon	I-ANAT
(	O	O
AT	B-ANAT
)	O	O
must	O	O
adapt	O	O
to	O	O
meet	B-PHEN
changes	O
in	O	O
demands	O
.	O	O

This	O	O
study	O	O
explored	O	O
AT	B-ANAT
adaptation	B-PHYS
by	O	O
comparing	O
properties	O
within	O	O
the	O	O
jump	O
and	O	O
non	B-DISO
-	I-DISO
jump	I-DISO
legs	B-ANAT
of	O	O
jumping	O
athletes	B-LIVB
.	O	O

Non	B-DISO
-	I-DISO
jumping	I-DISO
control	B-LIVB
athletes	I-LIVB
were	O	O
included	O
to	O	O
control	O
limb	B-ANAT
dominance	O
effects	O
.	O	O

AT	B-ANAT
properties	O
were	O	O
assessed	O
in	O	O
the	O	O
preferred	O
(	O	O
jump	O
)	O	O
and	O	O
non	B-DISO
-	I-DISO
preferred	I-DISO
(	O	O
lead	O	O
)	O	O
jumping	O
legs	B-ANAT
of	O	O
male	B-PHYS
collegiate	O
-	O
level	O
long	O
and	O	O
/	O	O
or	O	O
high	O
jump	O
(	O	O
jumpers	B-LIVB
;	O	O
n	O	O
=	O	O
10	O	O
)	O	O
and	O	O
cross	B-GEOG
-	I-GEOG
country	I-GEOG
(	O	O
controls	B-LIVB
;	O	O
n	O	O
=	O	O
10	O	O
)	O	O
athletes	B-LIVB
.	O	O

Cross	O
-	O
sectional	O
area	O
(	O	O
CSA	O
)	O	O
,	O	O
elongation	B-PHEN
,	O	O
and	O	O
force	B-PHEN
during	O	O
isometric	B-PHYS
contractions	I-PHYS
were	O	O
used	O	O
to	O	O
estimate	O
the	O	O
morphological	O
,	O	O
mechanical	B-PHEN
and	O	O
material	B-PHEN
properties	I-PHEN
of	O	O
the	O	O
ATs	B-ANAT
bilaterally	O
.	O	O

Jumpers	B-LIVB
exposed	O
their	O	O
ATs	B-ANAT
to	O	O
more	O	O
force	B-PHEN
and	O	O
stress	B-DISO
than	O	O
controls	B-LIVB
(	O	O
all	O	O
p≤0	O	O
.	O	O
03	O	O
)	O	O
.	O	O

AT	B-ANAT
force	B-PHEN
and	O	O
stress	B-DISO
were	O	O
also	O	O
greater	O
in	O	O
the	O	O
jump	O
leg	B-ANAT
of	O	O
both	O	O
jumpers	B-LIVB
and	O	O
controls	B-LIVB
than	O	O
in	O	O
the	O	O
lead	B-ANAT
leg	I-ANAT
(	O	O
all	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Jumpers	B-LIVB
had	O	O
17	O	O
.	O	O

8	O	O
%	O	O
greater	O
AT	B-ANAT
stiffness	B-DISO
and	O	O
24	O	O
.	O	O

4	O	O
%	O	O
greater	O
Young	O
's	O
modulus	O
in	O	O
their	O	O
jump	O
leg	B-ANAT
compared	O
to	O	O
lead	B-ANAT
leg	I-ANAT
(	O	O
all	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
jump	O
versus	O	O
lead	B-ANAT
leg	I-ANAT
differences	O
in	O	O
AT	B-ANAT
stiffness	B-DISO
or	O	O
Young	O
's	O
modulus	O
within	O	O
controls	B-LIVB
(	O	O
all	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

ATs	B-ANAT
chronically	O
exposed	O
to	O	O
elevated	O
mechanical	B-PHEN
loading	I-PHEN
were	O	O
found	O	O
to	O	O
exhibit	O	O
greater	O
mechanical	B-PHEN
(	O	O
stiffness	B-DISO
)	O	O
and	O	O
material	B-PHEN
(	O	O
Young	O
's	O
modulus	O
)	O	O
properties	O
.	O	O

Assessment	B-PROC
of	O	O
Residual	B-DISO
Disease	I-DISO
With	O	O
Molecular	B-PROC
Breast	I-PROC
Imaging	I-PROC
in	O	O
Patients	B-LIVB
Undergoing	O	O
Neoadjuvant	B-PROC
Therapy	I-PROC
:	O	O
Association	O	O
With	O	O
Molecular	O
Subtypes	O
Assessment	B-PROC
of	O	O
residual	B-DISO
disease	I-DISO
after	O	O
neoadjuvant	B-PROC
therapy	I-PROC
for	O	O
breast	B-DISO
cancer	I-DISO
is	O	O
an	O	O
ongoing	O	O
challenge	O	O
of	O	O
breast	B-ANAT
imaging	B-PROC
.	O	O

This	O	O
study	B-PROC
evaluates	B-PROC
the	O	O
accuracy	O
of	O	O
a	O	O
novel	O	O
dedicated	O	O
system	O	O
for	O	O
molecular	B-PROC
breast	I-PROC
imaging	I-PROC
(	O	O
MBI	B-PROC
)	O	O
composed	O	O
of	O	O
the	O	O
new	O	O
generation	O	O
of	O	O
cadmium	B-CHEM
zinc	I-CHEM
telluride	I-CHEM
detectors	B-OBJC
in	O	O
assessing	O	O
residual	B-DISO
disease	I-DISO
after	O	O
neoadjuvant	B-PROC
therapy	I-PROC
in	O	O
patients	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
.	O	O

Clinical	O
data	O
,	O	O
imaging	B-PROC
,	O	O
surgical	O
,	O	O
and	O	O
pathological	O
findings	B-DISO
of	O	O
51	O	O
women	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
undergoing	O	O
neoadjuvant	B-PROC
therapy	I-PROC
were	O	O
recorded	O	O
.	O	O

MBI	B-PROC
findings	B-DISO
were	O	O
correlated	O
with	O	O
surgical	O
pathology	O
results	O
.	O	O

Accuracy	O
of	O	O
MBI	B-PROC
in	O	O
predicting	O	O
complete	B-DISO
pathological	I-DISO
response	I-DISO
and	O	O
size	O
of	O	O
residual	B-DISO
disease	I-DISO
was	O	O
assessed	O	O
according	O	O
to	O	O
molecular	O
subtypes	O
.	O	O

The	O	O
size	O
of	O	O
the	O	O
largest	O	O
focus	O	O
of	O	O
uptake	O	O
on	O	O
MBI	B-PROC
correlated	O
with	O	O
the	O	O
largest	O	O
dimension	O	O
measured	O	O
on	O	O
pathology	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
55	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

This	O	O
correlation	O
was	O	O
stronger	O	O
for	O	O
triple	B-DISO
negative	I-DISO
and	O	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
subtypes	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
92	O	O
and	O	O
0	O	O
.	O	O
62	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Sixteen	O	O
patients	B-LIVB
(	O	O
31	O	O
%	O	O
)	O	O
had	O	O
complete	B-DISO
pathological	I-DISO
response	I-DISO
.	O	O

The	O	O
sensitivity	O
and	O	O
specificity	O
of	O	O
MBI	B-PROC
for	O	O
detecting	O	O
residual	B-DISO
disease	I-DISO
were	O	O
83	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
,	O	O
66	O	O
-	O	O
93	O	O
)	O	O
and	O	O
69	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
42	O	O
-	O	O
88	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

For	O	O
triple	B-DISO
negative	I-DISO
or	O	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
disease	O	O
the	O	O
sensitivity	O
and	O	O
specificity	O
were	O	O
88	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
62	O	O
-	O	O
98	O	O
)	O	O
and	O	O
75	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
43	O	O
-	O	O
93	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
accuracy	O
of	O	O
MBI	B-PROC
in	O	O
assessing	O	O
residual	B-DISO
disease	I-DISO
after	O	O
neoadjuvant	B-PROC
treatment	I-PROC
might	O	O
be	O	O
related	O	O
to	O	O
the	O	O
molecular	O
subtype	O
.	O	O

Accuracy	O
is	O	O
highest	O	O
in	O	O
the	O	O
triple	B-DISO
negative	I-DISO
and	O	O
HER2	B-PHYS
/	I-PHYS
neu	I-PHYS
positive	I-PHYS
subtypes	O
.	O	O

Sinus	B-PROC
augmentation	I-PROC
using	O	O
a	O	O
histone	B-CHEM
deacetylase	I-CHEM
inhibitor	I-CHEM
in	O	O
a	O	O
calcium	B-CHEM
sulfate	I-CHEM
carrier	B-CHEM
in	O	O
rabbit	B-LIVB
:	O	O
A	O	O
pilot	B-PROC
study	I-PROC
Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
such	O	O
as	O	O
sodium	B-CHEM
butyrate	I-CHEM
(	O	O
SB	B-CHEM
)	O	O
have	O	O
been	O	O
suggested	O	O
to	O	O
be	O	O
promising	O	O
candidate	B-CHEM
small	I-CHEM
molecules	I-CHEM
for	O	O
bone	B-PHYS
regeneration	I-PHYS
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
the	O	O
capacity	O
of	O	O
SB	B-CHEM
loaded	O
onto	O	O
calcium	B-CHEM
sulfate	I-CHEM
(	O	O
CaS	B-CHEM
)	O	O
to	O	O
enhance	O
bone	B-PHYS
formation	I-PHYS
was	O	O
investigated	O	O
in	O	O
a	O	O
rabbit	B-LIVB
sinus	I-LIVB
model	I-LIVB
.	O	O

Following	O	O
preparation	O	O
of	O	O
the	O	O
sinus	B-ANAT
access	O
window	O	O
on	O	O
a	O	O
randomly	O	O
selected	O	O
side	O
,	O	O
SB	B-CHEM
loaded	O
onto	O	O
CaS	B-CHEM
(	O	O
CaS	B-CHEM
/	O	O
SB	B-CHEM
)	O	O
was	O	O
grafted	B-PROC
in	O	O
five	O	O
rabbits	B-LIVB
,	O	O
and	O	O
CaS	B-CHEM
alone	O	O
(	O	O
control	B-LIVB
)	O	O
was	O	O
grafted	B-PROC
in	O	O
another	O	O
five	O	O
rabbits	B-LIVB
.	O	O

The	O	O
animals	B-LIVB
were	O	O
euthanized	B-PROC
after	O	O
4	O	O
weeks	O	O
for	O	O
radiographic	B-PROC
,	O	O
histometric	B-PROC
,	O	O
and	O	O
immunohistochemical	B-PROC
analyses	B-PROC
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O
significant	O
difference	O	O
in	O	O
the	O	O
total	O	O
augmented	O
volume	O
between	O	O
the	O	O
groups	O
in	O	O
the	O	O
radiographic	B-PROC
analysis	I-PROC
(	O	O
158	O	O
.	O	O
22	O	O
±	O	O
39	O	O
.	O	O
31	O	O
mm	O	O
(	O	O
3	O	O
)	O	O
and	O	O
107	O	O
.	O	O
09	O	O
±	O	O
39	O	O
.	O	O
69	O	O
mm	O	O
(	O	O
3	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
040	O	O
)	O	O
.	O	O

The	O	O
CaS	B-CHEM
/	O	O
SB	B-CHEM
group	O
showed	O	O
a	O	O
larger	O
portion	O
of	O	O
mature	O
lamellar	O
bone	O
and	O	O
a	O	O
higher	O	O
level	O	O
of	O	O
mineralization	B-PHYS
of	O	O
bone	O
trabeculae	O
,	O	O
characterized	O	O
by	O	O
more	O	O
intense	O	O
labeling	B-PROC
with	O	O
osteocalcin	B-CHEM
compared	O	O
with	O	O
the	O	O
control	B-LIVB
group	I-LIVB
in	O	O
the	O	O
immunohistochemical	B-PROC
analysis	B-PROC
.	O	O

The	O	O
number	O	O
of	O	O
osteocalcin	B-CHEM
-	I-CHEM
positive	I-CHEM
cells	B-ANAT
within	O	O
the	O	O
central	O
area	O
of	O	O
the	O	O
augmented	O
sinus	B-ANAT
was	O	O
significantly	O	O
higher	O
in	O	O
the	O	O
CaS	B-CHEM
/	O	O
SB	B-CHEM
group	O
than	O	O
in	O	O
the	O	O
control	B-LIVB
group	I-LIVB
(	O	O
179	O	O
±	O	O
26	O	O
.	O	O
0	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
and	O	O
123	O	O
±	O	O
33	O	O
.	O	O

2	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
027	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
CaS	B-CHEM
/	O	O
SB	B-CHEM
exhibited	O	O
superior	O
osteogenic	B-PHYS
potential	I-PHYS
,	O	O
especially	O	O
in	O	O
the	O	O
central	O
portion	O
of	O	O
the	O	O
augmented	O
sinus	B-ANAT
as	O	O
well	O	O
as	O	O
improvement	O
of	O	O
the	O	O
volume	O
maintenance	O
for	O	O
sinus	B-PROC
augmentation	I-PROC
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

J	O	O
Biomed	O	O
Mater	O	O
Res	O	O
Part	O	O
B	O	O
:	O	O
Appl	O	O
Biomater	O	O
,	O	O
2016	O	O
.	O	O

Integrating	O
Palliative	O
Care	O
in	O	O
Pediatric	O
Oncology	O
:	O	O
Evidence	O	O
for	O	O
an	O	O
Evolving	O
Paradigm	B-PROC
for	O	O
Comprehensive	B-PROC
Cancer	B-PROC
Care	I-PROC
The	O	O
demonstrated	O	O
benefit	O	O
of	O	O
integrating	O
palliative	O
care	O
(	O	O
PC	O
)	O	O
into	O	O
cancer	B-PROC
treatment	I-PROC
has	O	O
triggered	O	O
an	O	O
increased	O
need	O	O
for	O	O
PC	O
services	O	O
.	O	O

The	O	O
trajectory	O	O
of	O	O
integrating	O
PC	O
in	O	O
comprehensive	B-PROC
cancer	B-OBJC
centers	I-OBJC
,	I-OBJC
particularly	O	O
pediatric	O
centers	O
,	O	O
is	O	O
unknown	O	O
.	O	O

We	O	O
describe	O	O
our	O	O
8	O	O
-	O	O
year	O
experience	O	O
of	O	O
initiating	O	O
and	O	O
establishing	O
PC	O
with	O	O
the	O	O
Quality	B-PROC
of	I-PROC
Life	I-PROC
Service	I-PROC
(	O	O
QoLS	B-PROC
)	O	O
at	O	O
St	O
.	O

Jude	O
Children	O
's	O
Research	O
Hospital	O
.	O	O

We	O	O
retrospectively	O	O
reviewed	O	O
records	O
of	O
patients	O
seen	O	O
by	O	O
the	O	O
QoLS	B-PROC
(	O	O
n	O	O
=	O	O
615	O	O
)	O	O
from	O	O
March	O
2007	O	O
to	O	O
December	O
2014	O	O
.	O	O

Variables	O
analyzed	O	O
for	O	O
each	O	O
year	O
,	O	O
using	O	O
descriptive	O	O
statistics	O
,	O	O
included	O	O
diagnostic	O
groups	O
,	O	O
QoLS	B-PROC
encounters	B-PROC
,	O	O
goals	B-PROC
of	I-PROC
care	I-PROC
,	O	O
duration	B-PHYS
of	I-PHYS
survival	I-PHYS
,	O	O
and	O	O
location	O
of	O
death	O
.	O	O

Total	O	O
QoLS	B-PROC
patient	B-LIVB
encounters	B-PROC
increased	O
from	O	O
58	O	O
(	O	O
2007	O	O
)	O	O
to	O	O
1	O	O
,	O	O
297	O	O
(	O	O
2014	O	O
)	O	O
,	O	O
new	O	O
consults	B-PROC
increased	O
from	O	O
17	O	O
(	O	O
2007	O	O
)	O	O
to	O	O
115	O	O
(	O	O
2014	O	O
)	O	O
,	O	O
and	O	O
mean	O	O
encounters	B-PROC
per	O	O
patient	B-LIVB
increased	O
from	O	O
5	O	O
.	O	O

06	O	O
(	O	O
2007	O	O
)	O	O
to	O	O
16	O	O
.	O	O
11	O	O
(	O	O
2014	O	O
)	O	O
.	O	O

Goal	B-PROC
of	I-PROC
care	I-PROC
at	O	O
initial	B-PROC
consultation	I-PROC
shifted	O	O
from	O	O
primarily	O	O
comfort	B-PHYS
to	O	O
an	O	O
increasing	O
goal	O
of	O
cure	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
days	O	O
from	O	O
initial	B-PROC
consult	I-PROC
to	O	O
death	B-DISO
increased	O
from	O	O
52	O	O
days	O	O
(	O	O
2008	O	O
)	O	O
to	O	O
223	O	O
days	O	O
(	O	O
2014	O	O
)	O	O
.	O	O

A	O	O
trend	O	O
toward	O	O
increased	O
outpatient	B-LIVB
location	O
of	O
death	O
was	O	O
noted	O	O
with	O	O
42	O	O
%	O	O
outpatient	B-LIVB
deaths	B-DISO
in	O	O
2007	O	O
,	O	O
increasing	O
to	O	O
a	O	O
majority	O
in	O	O
each	O	O
subsequent	O	O
year	O
(	O	O
range	O	O
,	O	O
51	O	O
%	O	O
-	O	O
74	O	O
%	O	O
)	O	O
.	O	O

Hospital	O
-	O
wide	O
,	O	O
patients	B-LIVB
receiving	O	O
PC	O
services	O	O
before	O	O
death	B-DISO
increased	O
from	O	O
approximately	O
50	O	O
%	O	O
to	O	O
nearly	O	O
100	O	O
%	O	O
.	O	O

Since	O	O
its	O	O
inception	O	O
,	O	O
the	O	O
QoLS	B-PROC
experienced	O	O
a	O	O
dramatic	O	O
increase	O
in	O	O
referrals	B-PROC
and	O	O
encounters	B-PROC
per	O	O
patient	B-LIVB
,	O	O
increased	O
use	O	O
by	O	O
all	O	O
clinical	B-PROC
services	I-PROC
,	O	O
a	O	O
trend	O	O
toward	O	O
earlier	O
consultation	B-PROC
and	O	O
longer	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
increasing	O
outpatient	B-LIVB
location	O
of	O
death	O
,	O	O
and	O	O
near	O	O
-	O	O
universal	O
PC	O
involvement	O	O
at	O	O
the	O	O
end	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
life	I-PROC
.	O	O

The	O	O
successful	O	O
integration	O
of	O	O
PC	O
in	O	O
a	O	O
comprehensive	B-PROC
cancer	B-OBJC
center	I-OBJC
,	O	O
and	O	O
the	O	O
resulting	O	O
potential	O	O
for	O	O
improved	O	O
care	B-PROC
provision	I-PROC
over	O	O
time	O
,	O	O
can	O	O
serve	O	O
as	O	O
a	O	O
model	O
for	O	O
other	O	O
programs	B-PROC
on	O	O
a	O	O
broad	O	O
scale	O	O
.	O	O

Juglone	B-CHEM
ameliorates	O
skin	B-ANAT
wound	B-PHYS
healing	I-PHYS
by	O	O
promoting	O
skin	B-ANAT
cell	B-PHYS
migration	I-PHYS
through	O	O
Rac1	B-CHEM
/	O	O
Cdc42	B-CHEM
/	O	O
PAK	B-CHEM
pathway	B-PHYS
Skin	B-ANAT
cell	I-ANAT
regeneration	B-PHYS
and	O	O
wound	B-PHYS
healing	I-PHYS
are	O	O
key	O	O
processes	O	O
in	O	O
the	O	O
recovery	B-PHYS
from	O	O
skin	B-DISO
injuries	I-DISO
.	O	O

Rapid	O
cell	B-PHYS
migration	I-PHYS
and	O	O
regeneration	B-PHYS
of	O	O
skin	B-ANAT
cells	I-ANAT
lead	O	O
to	O	O
faster	O	O
and	O	O
better	O	O
healing	B-PHYS
of	O	O
wounded	B-DISO
skin	B-ANAT
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
investigate	O
the	O	O
wound	B-PHYS
healing	I-PHYS
potential	O
of	O	O
juglone	B-CHEM
,	O	O
a	O	O
naturally	O	O
occurring	O	O
Pin1	B-CHEM
inhibitor	B-CHEM
found	O	O
in	O	O
walnuts	B-OBJC
.	O	O

Cultured	B-ANAT
skin	I-ANAT
cells	I-ANAT
(	O	O
NHDF	B-ANAT
and	O	O
HaCaT	B-ANAT
)	O	O
and	O	O
hairless	B-LIVB
mice	I-LIVB
were	O	O
treated	B-PROC
with	I-PROC
juglone	B-CHEM
after	O	O
wound	O	O
creation	O	O
to	O	O
examine	O	O
its	O	O
effects	O	O
on	O	O
cell	B-PHYS
migration	I-PHYS
and	O	O
wound	O	O
healing	O	O
rate	O	O
.	O	O

The	O	O
expressions	B-PHYS
of	O	O
cell	B-PHYS
migration	I-PHYS
related	O	O
proteins	B-CHEM
(	O	O
Rac1	B-CHEM
,	O	O
Cdc42	B-CHEM
,	O	O
and	O	O
α	B-CHEM
-	I-CHEM
PAK	I-CHEM
)	O	O
,	O	O
collagen	B-CHEM
deposition	O
,	O	O
and	O	O
angiogenesis	B-PHYS
were	O	O
analyzed	B-PROC
.	O	O

Juglone	B-CHEM
treatment	B-PROC
resulted	O	O
in	O	O
faster	O	O
rate	O	O
of	O	O
growth	B-PHYS
and	O	O
migration	B-PHYS
and	O	O
recovered	O	O
cell	B-PHYS
morphology	I-PHYS
,	O	O
particularly	O	O
at	O	O
a	O	O
concentration	O
of	O	O
5	O	O
µM	O	O
,	O	O
in	O	O
skin	B-ANAT
cells	I-ANAT
compared	O	O
to	O	O
the	O	O
untreated	B-DISO
group	B-LIVB
.	O	O

In	O
vivo	O
experiments	B-PROC
showed	O	O
that	O	O
mice	B-LIVB
treated	B-PROC
with	I-PROC
juglone	B-CHEM
showed	O	O
faster	O	O
wound	B-PHYS
healing	I-PHYS
rate	O	O
with	O	O
better	O	O
skin	B-ANAT
morphology	O
and	O	O
collagen	B-CHEM
deposition	O
than	O	O
the	O	O
vehicle	B-LIVB
group	I-LIVB
.	O	O

Furthermore	O	O
,	O	O
juglone	B-CHEM
increased	O	O
the	O	O
activation	B-PHYS
and	O	O
/	O	O
or	O	O
expression	B-PHYS
of	O	O
Cdc42	B-CHEM
,	O	O
Rac1	B-CHEM
,	O	O
and	O	O
α	B-CHEM
-	I-CHEM
pak	I-CHEM
in	O	O
HaCaT	B-ANAT
cells	I-ANAT
,	O	O
and	O	O
resulted	O	O
in	O	O
enhanced	O
angiogenesis	B-PHYS
in	O	O
endothelial	B-ANAT
cells	I-ANAT
(	O	O
HUVECs	B-ANAT
)	O	O
.	O	O

Juglone	B-CHEM
also	O	O
activated	O	O
MAPKs	B-PHYS
signaling	I-PHYS
by	O	O
activation	B-PHYS
of	O	O
ERK	B-CHEM
,	O	O
JNK	B-CHEM
,	O	O
and	O	O
p38	B-CHEM
proteins	B-CHEM
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
juglone	B-CHEM
may	O	O
be	O	O
a	O	O
potential	O	O
candidate	O	O
for	O	O
wound	B-PHYS
healing	I-PHYS
and	O	O
skin	B-ANAT
regeneration	B-PHYS
which	O	O
ameliorates	O
wound	B-PHYS
healing	I-PHYS
mainly	O	O
by	O	O
promoting	O
skin	B-ANAT
cell	B-PHYS
migration	I-PHYS
through	O	O
Rac1	B-CHEM
/	O	O
Cdc42	B-CHEM
/	O	O
PAK	B-CHEM
pathway	B-PHYS
.	O	O

Tibia	B-DISO
stress	I-DISO
fracture	I-DISO
secondary	O	O
to	O	O
obsessive	B-DISO
compulsive	I-DISO
disorder	I-DISO
Obsessive	B-DISO
compulsive	I-DISO
disorder	I-DISO
(	O	O
OCD	B-DISO
)	O	O
is	O	O
a	O	O
chronic	B-DISO
psychiatric	I-DISO
disorder	I-DISO
characterized	O	O
by	O	O
obsessions	B-DISO
and	O	O
compulsions	B-DISO
.	O	O

Early	B-DISO
-	I-DISO
onset	I-DISO
OCD	B-DISO
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
common	O	O
mental	B-DISO
illnesses	I-DISO
of	O	O
children	B-LIVB
and	O	O
adolescents	B-LIVB
,	O	O
with	O	O
a	O	O
prevalence	O
of	O	O
1	O	O
%	O	O
to	O	O
3	O	O
%	O	O
.	O	O

It	O	O
is	O	O
related	O	O
to	O	O
worse	O	O
lifespan	O
symptoms	B-DISO
and	O	O
prognosis	B-PROC
.	O	O

Therefore	O	O
,	O	O
the	O	O
treatment	B-PROC
of	O	O
OCD	B-DISO
in	O	O
children	B-LIVB
and	O	O
adolescent	B-LIVB
has	O	O
gained	O	O
importance	O	O
.	O	O

If	O	O
it	O	O
is	O	O
not	O	O
treated	O
successfully	O	O
,	O	O
the	O	O
compulsive	B-DISO
behaviors	I-DISO
may	O	O
cause	O	O
extreme	O	O
stress	B-DISO
for	O	O
children	B-LIVB
and	O	O
their	O	O
parents	B-LIVB
.	O	O

Although	O	O
minor	O	O
complications	O
of	O	O
OCD	B-DISO
are	O	O
commonly	O	O
observed	O	O
,	O	O
major	O	O
complications	O
are	O	O
considerably	O	O
rare	O
due	O	O
to	O	O
the	O	O
nature	O	O
of	O	O
compulsive	B-DISO
behaviors	I-DISO
.	O	O

Apparently	O	O
,	O	O
loss	B-DISO
of	I-DISO
vision	I-DISO
,	O	O
autocastration	B-DISO
,	O	O
rectal	B-DISO
prolapse	I-DISO
are	O	O
examples	O	O
of	O	O
major	O	O
complications	O
secondary	O	O
to	O	O
OCD	B-DISO
.	O	O

As	O	O
far	O	O
as	O	O
we	O	O
know	O	O
,	O	O
it	O	O
is	O	O
the	O	O
first	O	O
case	O	O
of	O	O
tibia	B-DISO
stress	I-DISO
fracture	I-DISO
secondary	O	O
to	O	O
OCD	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
case	O
report	O
,	O	O
we	O	O
will	O	O
discuss	O	O
tibia	B-DISO
stress	I-DISO
fracture	I-DISO
developing	O	O
secondary	O	O
to	O	O
compulsive	B-DISO
behavior	I-DISO
due	O	O
to	O	O
OCD	B-DISO
.	O	O

Mutation	B-PHYS
profiles	O
of	O	O
synchronous	B-DISO
colorectal	B-DISO
cancers	I-DISO
from	O	O
a	O	O
patient	B-LIVB
with	O	O
Lynch	B-DISO
syndrome	I-DISO
suggest	O	O
distinct	O	O
oncogenic	B-DISO
pathways	O
Patients	B-LIVB
with	O	O
Lynch	B-DISO
syndrome	I-DISO
often	O	O
present	O	O
with	O	O
multiple	B-DISO
synchronous	I-DISO
or	O	O
metachronous	B-DISO
colorectal	B-DISO
cancers	I-DISO
(	O	O
CRCs	B-DISO
)	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
multiple	O
CRCs	B-DISO
with	O	O
distinct	O	O
genetic	B-PROC
profiles	I-PROC
and	O	O
driver	O	O
mutations	B-PHYS
could	O	O
complicate	O
treatment	O
as	O	O
each	O	O
cancer	B-DISO
may	O	O
respond	B-PHYS
differently	O
to	O	O
therapy	B-PROC
.	O	O

Studies	O	O
of	O	O
sporadic	B-DISO
CRCs	B-DISO
suggested	O	O
that	O	O
synchronous	B-DISO
tumors	I-DISO
have	O	O
distinct	O
etiologies	O
,	O	O
but	O	O
could	O	O
not	O	O
rule	O	O
out	O	O
differences	O	O
in	O	O
genetic	B-PHYS
background	I-PHYS
.	O	O

The	O	O
presence	O	O
of	O	O
multiple	B-DISO
cancers	I-DISO
in	O	O
a	O	O
patient	B-LIVB
with	O	O
a	O	O
predisposing	O
mutation	B-PHYS
provides	O	O
an	O	O
opportunity	B-PROC
to	O	O
profile	O
synchronous	B-DISO
cancers	I-DISO
in	O	O
the	O	O
same	O	O
genetic	B-PHYS
background	I-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
patient	B-LIVB
with	O	O
Lynch	B-DISO
syndrome	I-DISO
that	O	O
presented	O	O
with	O	O
six	O	O
synchronous	B-DISO
CRCs	B-DISO
.	O	O

Microsatellite	B-DISO
instability	I-DISO
(	O	O
MSI	B-DISO
)	O	O
and	O	O
genomic	B-PROC
profiling	I-PROC
indicated	O	O
that	O	O
each	O	O
lesion	B-DISO
had	O	O
a	O	O
unique	O
pattern	O
of	O	O
instability	B-DISO
and	O	O
a	O	O
distinct	O
profile	O
of	O	O
affected	O
genes	O
.	O	O

These	O	O
findings	O
support	O	O
the	O	O
idea	O	O
that	O	O
in	O	O
Lynch	B-DISO
syndrome	I-DISO
,	O	O
synchronous	B-DISO
CRCs	I-DISO
can	O	O
develop	O	O
in	O	O
parallel	O	O
with	O	O
distinct	O	O
mutation	B-PHYS
profiles	O
and	O	O
that	O	O
these	O	O
differences	O	O
may	O	O
inform	O	O
treatment	B-DISO
decisions	I-DISO
.	O	O

Sensitization	B-PHYS
to	O	O
the	O	O
motor	B-ANAT
stimulant	B-CHEM
effects	O
of	O	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O	O
MDPV	B-CHEM
)	O	O
and	O	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
to	O	O
methamphetamine	B-CHEM
in	O	O
rats	B-LIVB
In	O	O
recent	O	O
years	O
,	O	O
there	O	O
has	O	O
been	O	O
a	O	O
dramatic	O	O
increase	O
in	O	O
abuse	B-DISO
of	O	O
the	O	O
synthetic	B-CHEM
cathinone	I-CHEM
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O	O
MDPV	B-CHEM
)	O	O
,	O	O
often	O	O
in	O	O
combination	O
with	O	O
other	O	O
illicit	O
stimulants	B-CHEM
.	O	O

We	O	O
sought	O	O
to	O	O
determine	O	O
if	O	O
repeated	O
exposure	O
to	O
MDPV	B-CHEM
would	O	O
produce	O	O
sensitization	B-PHYS
to	O	O
the	O	O
motor	B-ANAT
stimulant	B-CHEM
effects	O
of	O	O
the	O	O
drug	B-CHEM
,	O	O
and	O	O
whether	O	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
would	O	O
develop	O
with	O	O
the	O	O
stimulant	B-CHEM
effects	O
of	O	O
methamphetamine	B-CHEM
(	O	O
METH	B-CHEM
)	O	O
.	O	O

Male	B-PHYS
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
were	O	O
administered	O
MDPV	B-CHEM
(	O	O
1	O	O
or	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
saline	B-OBJC
once	O
daily	O
for	O	O
5	O	O
days	O
at	O	O
24	O	O
hour	O
intervals	O
,	O	O
or	O	O
were	O	O
administered	O
MDPV	B-CHEM
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
saline	B-OBJC
once	O
daily	O
for	O	O
5	O	O
days	O
at	O	O
48	O	O
hour	O
intervals	O
.	O	O

For	O	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
experiments	B-PROC
,	O	O
rats	B-LIVB
were	O	O
administered	O
METH	B-CHEM
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
MDPV	B-CHEM
(	O	O
1	O	O
or	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
once	O
daily	O
for	O	O
5	O	O
days	O
at	O	O
48	O	O
hour	O
intervals	O
,	O	O
and	O	O
following	O	O
a	O	O
5	O	O
day	O
incubation	B-DISO
period	I-DISO
,	O	O
were	O	O
given	O	O
an	O	O
acute	O	O
challenge	O	O
injection	B-CHEM
of	O	O
either	O	O
MDPV	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
METH	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Rats	B-LIVB
repeatedly	O
administered	O
MDPV	B-CHEM
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
every	O	O
48	O	O
hours	O
,	O	O
but	O	O
not	O	O
every	O	O
24	O	O
hours	O
,	O	O
demonstrated	O	O
increased	O
motor	B-DISO
activity	I-DISO
when	O	O
given	O	O
either	O	O
a	O	O
subsequent	O	O
challenge	O	O
of	O	O
MDPV	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O
)	O	O
or	O	O
METH	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
indicating	O	O
the	O	O
development	B-PHYS
of	I-PHYS
behavioral	I-PHYS
sensitization	B-PHYS
and	O	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
,	O	O
respectively	O	O
.	O	O

Moreover	O	O
,	O	O
rats	B-LIVB
repeatedly	O	O
administered	O
METH	B-CHEM
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
every	O	O
48	O	O
hours	O
did	O	O
not	O	O
exhibit	O	O
cross	B-PHYS
-	I-PHYS
sensitization	I-PHYS
to	O	O
the	O	O
motor	B-ANAT
stimulating	B-PHEN
effects	O
of	O	O
a	O	O
subsequent	O	O
challenge	O	O
with	O	O
MDPV	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

These	O	O
results	O
suggest	O	O
that	O	O
specific	O	O
patterns	O
of	O	O
MDPV	B-CHEM
administration	O
may	O	O
lead	O	O
to	O	O
lasting	O	O
changes	O	O
in	O	O
behavioral	O
responses	B-PHYS
to	O	O
subsequent	O	O
METH	B-CHEM
exposure	O
.	O	O

Nonamplification	B-DISO
ERBB2	O
genomic	B-PHYS
alterations	I-PHYS
in	O	O
5605	O	O
cases	O
of	O	O
recurrent	B-DISO
and	O	O
metastatic	B-DISO
breast	I-DISO
cancer	I-DISO
:	O	O
An	O	O
emerging	O	O
opportunity	O	O
for	O	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
Activating	O	O
,	O	O
nonamplification	B-DISO
ERBB2	O
mutations	B-PHYS
(	O	O
ERBB2mut	O
)	O	O
are	O	O
not	O	O
detected	O	O
by	O	O
immunohistochemistry	B-PROC
(	O	O
IHC	B-PROC
)	O	O
or	O	O
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
(	O	O
FISH	B-PROC
)	O	O
,	O	O
but	O	O
are	O	O
detected	O	O
by	O	O
DNA	B-PROC
sequencing	I-PROC
and	O	O
may	O	O
predict	O	O
clinical	B-DISO
responses	I-DISO
to	O	O
human	B-CHEM
epidermal	I-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
(	O	O
HER2	B-CHEM
)	O	O
-	O	O
targeted	B-PROC
therapy	I-PROC
.	O	O

The	O	O
authors	O	O
queried	O	O
5605	O	O
advanced	B-DISO
/	I-DISO
metastatic	I-DISO
breast	I-DISO
cancers	I-DISO
(	O	O
mBC	B-DISO
)	O	O
to	O	O
uncover	O	O
the	O	O
frequency	O
of	O	O
ERBB2mut	O
genomic	B-PHYS
alterations	I-PHYS
.	O	O

Clinical	B-DISO
responses	I-DISO
to	O	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
therapeutics	B-PROC
were	O	O
identified	O
.	O	O

DNA	B-CHEM
was	O	O
extracted	O	O
from	O	O
40	O	O
µm	O	O
of	O	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
sections	O
.	O	O

Comprehensive	B-PROC
genomic	I-PROC
profiling	I-PROC
(	O	O
CGP	B-PROC
)	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
up	O	O
to	O	O
315	O	O
genes	O
(	O	O
592×	O	O
mean	O	O
coverage	O	O
depth	O	O
)	O	O
.	O	O

Results	O
were	O	O
analyzed	O	O
for	O	O
base	B-PHYS
substitutions	I-PHYS
,	O	O
short	B-PHYS
indels	I-PHYS
,	O	O
copy	B-PHYS
number	I-PHYS
changes	I-PHYS
,	O	O
and	O	O
selected	B-PHYS
rearrangements	I-PHYS
.	O	O

Of	O	O
5605	O	O
cases	O
,	O	O
698	O	O
(	O	O
12	O	O
.	O	O

5	O	O
%	O	O
)	O	O
featured	O	O
ERBB2	O
alterations	B-PHYS
,	O	O
including	O	O
596	O	O
(	O	O
10	O	O
.	O	O
6	O	O
%	O	O
)	O	O
ERBB2	O
amplifications	B-PHYS
(	O	O
ERBB2amp	B-PHYS
)	O	O
and	O	O
138	O	O
(	O	O
2	O	O
.	O	O
4	O	O
%	O	O
)	O	O
ERBB2mut	O
;	O	O
38	O	O
cases	O
(	O	O
0	O	O
.	O	O

7	O	O
%	O	O
)	O	O
had	O	O
co	O	O
-	O	O
occurring	O	O
ERBB2amp	B-PHYS
and	O	O
ERBB2mut	O
.	O	O

ERBB2mut	O
predominantly	O	O
affected	O	O
the	O	O
kinase	B-CHEM
(	O	O
124	O	O
cases	O
;	O	O
90	O	O
%	O	O
)	O	O
or	O	O
extracellular	B-ANAT
(	O	O
15	O	O
cases	O	O
;	O	O
11	O	O
%	O	O
)	O	O
domains	O
.	O	O

Both	O	O
primary	B-DISO
BC	I-DISO
(	O	O
52	O	O
cases	O
;	O	O
38	O	O
%	O	O
)	O	O
and	O	O
metastatic	B-DISO
site	I-DISO
biopsies	B-PROC
(	O	O
86	O	O
cases	O
;	O	O
62	O	O
%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
harbor	O	O
ERBB2mut	O
,	O	O
which	O	O
were	O	O
distributed	O	O
across	O	O
carcinoma	B-DISO
not	O	O
otherwise	O	O
specified	O	O
(	O	O
NOS	O	O
)	O	O
(	O	O
69	O	O
cases	O
;	O	O
50	O	O
%	O	O
)	O	O
,	O	O
invasive	B-DISO
ductal	I-DISO
carcinoma	I-DISO
(	O	O
IDC	B-DISO
)	O	O
(	O	O
40	O	O
cases	O
;	O	O
29	O	O
%	O	O
)	O	O
,	O	O
invasive	B-DISO
lobular	I-DISO
carcinoma	I-DISO
(	O	O
ILC	B-DISO
)	O	O
(	O	O
27	O	O
cases	O
;	O	O
20	O	O
%	O	O
)	O	O
,	O	O
and	O	O
mucinous	B-DISO
mBC	I-DISO
(	O	O
2	O	O
cases	O
;	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Genes	O
commonly	O	O
coaltered	O	O
with	O	O
ERBB2	O
were	O	O
tumor	O
protein	O
53	O
(	O	O
TP53	O
)	O	O
(	O	O
49	O	O
%	O	O
)	O	O
;	O	O
phosphatidylinositol	O
3	O
-	O
kinase	O
catalytic	O
subunit	O
alpha	O
(	O	O
PIK3CA	O
)	O	O
(	O	O
42	O	O
%	O	O
)	O	O
;	O	O
cadherin	O
1	O
,	O
type	O
1	O
(	O	O
CDH1	O
)	O	O
(	O	O
37	O	O
%	O	O
)	O	O
;	O	O
MYC	O
(	O	O
17	O	O
%	O	O
)	O	O
;	O	O
and	O	O
cyclin	O
D1	O
protein	O
(	O	O
CCND1	O
)	O	O
(	O	O
16	O	O
%	O	O
)	O	O
.	O	O

CDH1	O
mutations	B-PHYS
were	O	O
enriched	O	O
in	O	O
ERBB2mut	O
mBC	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0006	O	O
)	O	O
and	O	O
associated	O
with	O
recurrent	O
mBC	O
.	O	O

Selected	O	O
patients	B-LIVB
with	O	O
ERBB2mut	O
,	O	O
without	O	O
ERBB2amp	B-PHYS
,	O	O
who	O	O
responded	O	O
to	O	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
are	O	O
presented	O	O
herein	O	O
.	O	O

Within	O	O
this	O	O
large	O	O
series	O	O
,	O	O
1	O	O
.	O	O
8	O	O
%	O	O
of	O	O
cases	O
harbored	O	O
ERBB2mut	O
,	O	O
which	O	O
are	O	O
undetectable	O	O
by	O	O
standard	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
care	I-PROC
IHC	B-PROC
or	O	O
FISH	B-PROC
tests	I-PROC
.	O	O

Metastatic	B-DISO
BC	I-DISO
driven	O	O
by	O	O
ERBB2mut	O
respond	O	O
to	O	O
anti	B-DISO
-	I-DISO
HER2	I-DISO
targeted	B-PROC
therapies	I-PROC
,	O	O
and	O	O
expanding	O	O
clinical	B-PROC
trials	I-PROC
designed	O	O
to	O	O
detect	O	O
ERBB2mut	O
by	O	O
CGP	B-PROC
and	O	O
optimize	O	O
targeted	B-PROC
treatments	I-PROC
are	O	O
warranted	O	O
.	O	O

Cancer	O	O
2016	O	O
.	O	O

©	O	O
2016	O	O
American	O	O
Cancer	O	O
Society	O	O
.	O	O
Cancer	O	O
2016	O	O
;	O	O
122	O	O
:	O	O
2654	O	O
-	O	O
2662	O	O
.	O	O

©	O	O
2016	O	O
American	O	O
Cancer	O	O
Society	O	O
.	O	O

PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	B-CHEM
PEPTIDASE	I-CHEM
-	I-CHEM
4	I-CHEM
INHIBITORS	I-CHEM
ON	O	O
PROGRESSION	B-DISO
OF	O	O
DIABETIC	B-DISO
RETINOPATHY	I-DISO
IN	O	O
PATIENTS	B-LIVB
WITH	O	O
TYPE	B-DISO
2	I-DISO
DIABETES	I-DISO
To	O	O
investigate	O
the	O	O
effects	O
of	O
dipeptidyl	B-CHEM
peptidase	I-CHEM
-	I-CHEM
4	I-CHEM
inhibitors	I-CHEM
(	O	O
DPP4	B-CHEM
)	O	O
on	O	O
the	O	O
progression	B-DISO
of	O	O
diabetic	B-DISO
retinopathy	I-DISO
(	O	O
DR	B-DISO
)	O	O
in	O	O
patients	B-LIVB
with	O	O
Type	B-DISO
2	I-DISO
diabetes	I-DISO
based	O	O
on	O	O
the	O	O
DR	B-DISO
severity	O
scale	O
.	O	O

The	O	O
medical	O
records	O
of	O	O
82	O	O
patients	B-LIVB
with	O	O
Type	B-DISO
2	I-DISO
diabetes	I-DISO
enrolled	O	O
from	O	O
2005	O	O
to	O	O
2015	O	O
were	O	O
retrospectively	O
reviewed	O
.	O	O

Fundus	B-PROC
photographs	I-PROC
were	O	O
graded	O
using	O	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
methods	O
.	O	O

The	O	O
associations	O
between	O	O
baseline	O
risk	B-DISO
factors	I-DISO
and	O	O
progression	B-DISO
of	O	O
DR	B-DISO
were	O	O
investigated	O
.	O	O

Seven	O	O
of	O	O
28	O	O
patients	B-LIVB
treated	O
with	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
and	O	O
26	O	O
of	O	O
54	O	O
treated	O
with	O	O
other	O	O
hypoglycemic	B-CHEM
agents	I-CHEM
showed	O	O
progression	B-DISO
of	O	O
retinopathy	B-DISO
,	O	O
defined	O	O
as	O	O
one	O	O
or	O	O
more	O	O
steps	O	O
on	O	O
the	O	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
043	O	O
)	O	O
.	O	O

Only	O	O
treatment	O
with	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
significantly	O	O
reduced	O
the	O	O
progression	B-DISO
of	O	O
DR	B-DISO
in	O	O
patients	B-LIVB
after	O	O
propensity	O
score	O
matching	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
009	O	O
)	O	O
.	O	O

Treatment	O
with	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
was	O	O
associated	O
with	O
a	O	O
lower	O
risk	O
of	O	O
DR	B-DISO
progression	B-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
011	O	O
)	O	O
.	O	O

Treatment	O
with	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
was	O	O
the	O	O
independent	O
protective	O
factor	O
against	O	O
the	O	O
progression	B-DISO
of	O	O
DR	B-DISO
,	O	O
aside	O	O
from	O	O
improving	B-DISO
glycemic	I-DISO
control	I-DISO
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
show	O	O
the	O	O
benefits	O
of	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
in	O	O
reducing	O
DR	B-DISO
progression	B-DISO
,	O	O
and	O	O
provides	O	O
encouraging	O	O
preliminary	O
data	O
for	O	O
further	O	O
evaluation	B-PROC
of	O	O
DPP4	B-CHEM
inhibitors	I-CHEM
in	O	O
the	O	O
progression	B-DISO
of	O	O
DR	B-DISO
in	O	O
a	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
trial	I-PROC
.	O	O

Parasympathetic	B-ANAT
Activity	B-PHYS
and	O	O
Bronchial	B-DISO
Hyperresponsiveness	I-DISO
in	O	O
Athletes	B-LIVB
A	O	O
high	O
prevalence	O
of	O	O
asthma	B-DISO
and	O	O
bronchial	B-DISO
hyperresponsiveness	I-DISO
(	O	O
BHR	B-DISO
)	O	O
is	O	O
reported	O	O
in	O	O
swimmers	B-LIVB
and	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
increased	O
parasympathetic	B-ANAT
nervous	B-PHYS
activity	I-PHYS
is	O	O
involved	O	O
in	O	O
asthma	B-DISO
development	O	O
in	O	O
endurance	B-DISO
athletes	B-LIVB
.	O	O

We	O	O
aimed	O	O
to	O	O
assess	B-PROC
the	O	O
associations	O	O
of	O	O
BHR	B-DISO
to	O	O
parasympathetic	B-ANAT
activity	B-PHYS
in	O	O
healthy	O
and	O	O
asthmatic	B-DISO
swimmers	B-LIVB
and	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
and	O	O
healthy	O
non	O	O
athletes	B-LIVB
.	O	O

Parasympathetic	B-ANAT
activity	B-PHYS
was	O	O
measured	O
by	O	O
pupillometry	B-PROC
and	O	O
heart	B-PHYS
rate	I-PHYS
variability	O
at	O	O
the	O	O
onset	O
of	O
exercise	O
with	O	O
the	O	O
cardiac	O
vagal	O
index	O
calculated	O	O
in	O	O
28	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
(	O	O
♂	O	O
18	O	O
/	O	O
♀10	O	O
)	O	O
,	O	O
29	O	O
swimmers	O	O
(	O	O
♂	O	O
17	O	O
/	O	O
♀12	O	O
)	O	O
,	O	O
and	O	O
30	O	O
healthy	O	O
nonathlete	O	O
controls	O	O
(	O	O
♂	O	O
14	O	O
/	O	O
♀16	O	O
)	O	O
on	O	O
two	O	O
different	O	O
days	O	O
.	O	O

All	O	O
subjects	O	O
performed	O	O
a	O	O
methacholine	B-CHEM
bronchial	B-PROC
challenge	I-PROC
with	O	O
the	O	O
provocation	B-PHEN
dose	O
causing	O	O
20	O	O
%	O	O
decrease	O	O
in	O	O
the	O	O
forced	O	O
expiratory	O	O
volume	O	O
in	O	O
1	O	O
s	O	O
calculated	O
(	O	O
PD20met	B-CHEM
)	O	O
.	O	O

Data	O
were	O	O
analyzed	B-PROC
by	O	O
robust	O
regression	O
analysis	O
and	O	O
presented	O	O
as	O	O
β	O	O
coefficients	O	O
with	O	O
95	O	O
%	O	O
confidence	O
intervals	O
(	O	O
CI	O
)	O	O
.	O	O

PD20met	B-CHEM
was	O	O
negatively	O	O
associated	O
with	O
cardiac	O
vagal	O
index	O
(	O	O
-13	O	O
.	O	O
9	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
-26	O	O
.	O	O

8	O	O
to	O	O
-1	O	O
.	O	O
0	O	O
)	O	O
in	O	O
all	O	O
subjects	B-LIVB
.	O	O

When	O	O
adjusted	O	O
to	O	O
the	O	O
type	O	O
of	O	O
sport	O
,	O	O
this	O	O
association	O	O
was	O	O
stronger	O	O
in	O	O
swimmers	B-LIVB
(	O	O
-8	O	O
.	O	O
3	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
-13	O	O
.	O	O

0	O	O
to	O	O
-3	O	O
.	O	O
6	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
controls	B-LIVB
and	O	O
nonsignificant	O	O
in	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
.	O	O

Percent	O	O
pupil	B-DISO
constriction	I-DISO
was	O	O
significantly	O	O
associated	O
with	O
PD20met	B-CHEM
in	O	O
swimmers	B-LIVB
(	O	O
-9	O	O
.	O	O
4	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
-15	O	O
.	O	O

4	O	O
to	O	O
-3	O	O
.	O	O

4	O	O
)	O	O
only	O	O
after	O	O
adjusting	O	O
for	O	O
the	O	O
type	O	O
of	O	O
sport	O
.	O	O

Fourteen	O	O
swimmers	B-LIVB
(	O	O
48	O	O
%	O	O
)	O	O
and	O	O
16	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
(	O	O
57	O	O
%	O	O
)	O	O
had	O	O
doctor	B-DISO
-	I-DISO
diagnosed	I-DISO
asthma	I-DISO
in	O	O
combination	O	O
with	O	O
current	O	O
BHR	B-DISO
and	O	O
/	O	O
or	O	O
current	O	O
use	O	O
of	O	O
asthma	B-DISO
drugs	B-CHEM
.	O	O

Seventy	O	O
-	O	O
two	O	O
percent	O	O
swimmers	B-LIVB
,	O	O
44	O	O
%	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skiers	I-DISO
,	O	O
and	O	O
39	O	O
%	O	O
controls	B-LIVB
had	O	O
a	O	O
PD20met	B-CHEM
≤8	O	O
μmol	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
015	O	O
)	O	O
.	O	O

Fourteen	O	O
swimmers	B-LIVB
had	O	O
a	O	O
PD20met	B-CHEM
≤2	O	O
μmol	O	O
as	O	O
compared	O	O
with	O	O
one	O	O
cross	B-DISO
-	I-DISO
country	I-DISO
skier	I-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Parasympathetic	B-ANAT
activity	B-PHYS
measured	O
in	O	O
the	O	O
heart	B-ANAT
is	O	O
more	O	O
closely	O	O
related	O	O
to	O	O
BHR	B-DISO
as	O	O
compared	O	O
with	O	O
parasympathetic	B-ANAT
activity	B-PHYS
measured	O
in	O	O
the	O	O
pupils	B-ANAT
.	O	O

The	O	O
type	O	O
of	O	O
sport	O
influences	O	O
BHR	B-DISO
severity	O	O
and	O	O
its	O	O
relationship	O	O
to	O	O
parasympathetic	B-ANAT
activity	B-PHYS
.	O	O

The	O	O
relationship	O
between	O	O
histological	O
prostatitis	B-DISO
and	O	O
lower	B-DISO
urinary	I-DISO
tract	I-DISO
symptoms	I-DISO
and	O	O
sexual	B-PHYS
function	I-PHYS
This	O	O
prospective	B-PROC
analysis	I-PROC
assessed	O
the	O	O
effect	O
of	O	O
histological	O
prostatitis	B-DISO
on	O	O
lower	B-ANAT
urinary	I-ANAT
tract	I-ANAT
functions	O
and	O	O
sexual	B-PHYS
function	I-PHYS
.	O	O

The	O	O
patients	B-LIVB
were	O	O
separated	O
into	O	O
two	O	O
groups	O
as	O	O
histologically	O
observed	O
prostatitis	B-DISO
(	O	O
Group	O
A	O
)	O	O
and	O	O
no	B-DISO
prostatitis	I-DISO
(	O	O
Group	O
B	O
)	O	O
according	O	O
to	O	O
the	O	O
biopsy	B-PROC
outcomes	O
.	O	O

International	O
prostate	O
symptom	O
score	O
,	O	O
international	B-PHYS
index	I-PHYS
of	I-PHYS
erectile	I-PHYS
function	I-PHYS
-	I-PHYS
5	I-PHYS
scores	I-PHYS
,	O	O
maximal	B-DISO
and	O	O
average	B-DISO
flow	I-DISO
rate	I-DISO
,	O	O
and	O	O
residual	B-DISO
urine	I-DISO
volumes	I-DISO
were	O	O
compared	O
statistically	O	O
between	O	O
groups	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O
difference	O
(	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
in	O	O
baseline	O
age	B-PHYS
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
64	O	O
)	O	O
,	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
value	I-PHYS
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
51	O	O
)	O	O
,	O	O
prostate	O
volume	O
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
87	O	O
)	O	O
,	O	O
prostate	B-PROC
-	I-PROC
specific	I-PROC
antigen	I-PROC
levels	I-PROC
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
43	O	O
)	O	O
,	O	O
maximal	B-DISO
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
84	O	O
)	O	O
and	O	O
average	B-DISO
flow	I-DISO
rate	I-DISO
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
59	O	O
)	O	O
,	O	O
and	O	O
post	O
-	O
void	O
residual	B-DISO
urine	I-DISO
volume	I-DISO
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
71	O	O
)	O	O
.	O	O

Mean	O
international	O
prostate	O
symptom	O
score	O
in	O	O
patients	B-LIVB
with	O	O
prostatitis	B-DISO
was	O	O
numerically	O
but	O	O
not	O	O
significantly	O
higher	O
than	O	O
that	O	O
in	O	O
those	O	O
without	O
prostatitis	B-DISO
(	O	O
t	O	O
=	O	O
0	O	O
.	O	O
794	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
066	O	O
)	O	O
.	O	O

Mean	O
international	B-PHYS
index	I-PHYS
of	I-PHYS
erectile	I-PHYS
function	I-PHYS
-	I-PHYS
5	I-PHYS
score	I-PHYS
in	O	O
the	O	O
prostatitis	B-DISO
group	O
was	O	O
significantly	O
lower	O
than	O	O
that	O	O
in	O	O
those	O	O
without	O
prostatitis	B-DISO
(	O	O
t	O	O
=	O	O
1	O	O
.	O	O
854	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
013	O	O
)	O	O
.	O	O

Histological	O
prostatitis	B-DISO
notably	O	O
affected	O
sexual	B-PHYS
function	I-PHYS
of	O	O
patients	B-LIVB
and	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
major	O
risk	B-DISO
factor	I-DISO
for	O	O
sexual	B-DISO
dysfunction	I-DISO
while	O	O
having	O	O
little	O	O
effect	O
on	O	O
lower	B-DISO
urinary	I-DISO
tract	I-DISO
symptoms	I-DISO
.	O	O

Beyond	O	O
""""	O	O
Median	O
Waiting	O
Time	O
""""	O	O
:	O	O
Development	O
and	O	O
Validation	B-PROC
of	O	O
a	O	O
Competing	O	O
Risk	O
Model	O
to	O	O
Predict	O
Outcomes	O
on	O	O
the	O	O
Kidney	B-ANAT
Transplant	O
Waiting	O
List	O
Median	O
historical	O
time	O
to	O	O
kidney	B-PROC
transplant	I-PROC
is	O	O
misleading	O	O
because	O	O
it	O	O
does	O	O
not	O	O
convey	O	O
the	O	O
competing	O	O
risks	O
of	O	O
death	B-PHYS
or	O	O
removal	B-DISO
from	I-DISO
the	I-DISO
waiting	I-DISO
list	I-DISO
.	O	O

We	O	O
developed	O	O
and	O	O
validated	O	O
a	O	O
competing	O	O
risk	O
model	O
to	O	O
calculate	O
likelihood	O	O
of	O	O
outcomes	O
for	O	O
kidney	B-PROC
transplant	I-PROC
candidates	B-LIVB
and	O	O
demonstrate	O	O
how	O	O
this	O	O
information	O
differs	O
from	O	O
median	O
time	O
to	O	O
transplant	B-PROC
.	O	O

Data	O
were	O	O
obtained	O
from	O	O
the	O	O
US	O
Scientific	O
Registry	O
of	O	O
Transplant	B-LIVB
Recipients	I-LIVB
.	O	O

The	O	O
retrospective	B-PROC
cohort	I-PROC
included	O	O
163	O	O
636	O	O
adults	B-LIVB
listed	O	O
for	O	O
kidney	B-PROC
transplant	I-PROC
before	O	O
December	O	O
31	O	O
,	O	O
2011	O	O
.	O	O

Predictors	B-DISO
were	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
blood	B-PHYS
type	I-PHYS
,	O	O
calculated	B-PROC
panel	B-PROC
-	I-PROC
reactive	I-PROC
antibodies	I-PROC
,	O	O
donation	B-PROC
service	B-GEOG
area	I-GEOG
,	O	O
dialysis	B-PROC
duration	O
,	O	O
comorbid	B-DISO
conditions	I-DISO
,	O	O
and	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
.	O	O

Outcomes	O
were	O	O
deceased	O	O
or	O	O
living	B-LIVB
donor	I-LIVB
transplant	B-PROC
,	O	O
death	B-PHYS
or	O	O
removal	B-DISO
from	I-DISO
the	I-DISO
list	I-DISO
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O	O
or	O	O
removal	B-DISO
due	O
to	O
other	B-DISO
reasons	I-DISO
.	O	O

We	O	O
calculated	O
hazards	O
for	O	O
the	O	O
possible	B-DISO
outcomes	O
,	O	O
then	O	O
the	O	O
cumulative	O
incidence	O
function	B-PHYS
for	O	O
a	O	O
given	O	O
candidate	B-LIVB
using	O	O
competing	O	O
risk	O
methodology	O
.	O	O

Discrimination	B-PHYS
and	O	O
calibration	O
were	O	O
assessed	O
through	O
C	O
statistics	O
and	O	O
calibration	O
plots	O
for	O	O
each	O
cause	O
-	O	O
specific	O
Cox	O
proportional	O
hazard	O
model	O
.	O	O

C	O
statistics	O
ranged	O	O
from	O	O
0	O	O
.	O	O

64	O	O
to	O	O
0	O	O
.	O	O
73	O	O
.	O	O

Calibration	O
plots	O
showed	O	O
good	O
calibration	O
.	O	O

The	O	O
competing	O	O
risk	O
model	O
shows	O	O
probability	O
of	O	O
all	O	O
possible	B-DISO
outcomes	O
for	O	O
up	O	O
to	O	O
12	O
years	O
given	O	O
a	O	O
candidate	B-LIVB
's	I-LIVB
characteristics	O
,	O	O
contrasted	O	O
with	O	O
the	O	O
median	O
waiting	O
time	O
for	O	O
that	O	O
candidate	B-LIVB
's	I-LIVB
donation	B-PROC
service	B-GEOG
area	I-GEOG
.	O	O

A	O	O
competing	O	O
risk	O
model	O
conveys	O	O
more	O	O
relevant	O
information	O
than	O	O
the	O	O
median	O
waiting	O
time	O
for	O	O
a	O	O
given	O
transplant	O
center	O
.	O	O

This	O	O
model	O
will	O	O
be	O	O
updated	O
to	O	O
create	O
a	O	O
calculator	O	O
reflecting	O	O
the	O	O
most	O	O
recent	O
outcomes	O
and	O	O
changes	O
in	O	O
allocation	O
policy	O
.	O	O

It	O	O
illustrates	O	O
the	O	O
conversations	O
that	O	O
should	O	O
be	O	O
initiated	O
with	O	O
transplant	B-PROC
candidates	B-LIVB
.	O	O

Chemical	B-PHEN
Composition	I-PHEN
and	O	O
Biological	O
Activity	O
of	O	O
Essential	B-CHEM
Oils	I-CHEM
from	O	O
Different	O	O
Species	O
of	O	O
Piper	B-LIVB
from	O	O
Panama	B-GEOG
The	O	O
chemical	B-PHEN
composition	I-PHEN
of	O	O
leaf	B-LIVB
essential	B-CHEM
oils	I-CHEM
from	O	O
11	O	O
species	O
of	O	O
Piper	B-LIVB
from	O	O
Panama	B-GEOG
was	O	O
analyzed	O	O
by	O	O
a	O	O
combination	O
GC	B-PROC
-	I-PROC
FID	I-PROC
and	O	O
GC	B-PROC
-	I-PROC
MS	I-PROC
procedures	I-PROC
.	O	O

Six	O	O
of	O	O
them	O	O
had	O	O
sesquiterpene	B-CHEM
hydrocarbons	B-CHEM
as	O	O
major	B-OBJC
constituents	I-OBJC
,	O	O
three	O	O
were	O	O
characterized	O
by	O	O
monoterpene	B-CHEM
hydrocarbons	B-CHEM
,	O	O
one	O	O
by	O	O
a	O	O
diterpene	B-CHEM
,	O	O
and	O	O
one	O	O
by	O	O
a	O	O
phenylpropanoid	B-CHEM
,	O	O
dillapiole	B-CHEM
.	O	O

The	O	O
main	O	O
components	O	O
identified	O	O
in	O	O
each	O	O
species	O
were	O	O
:	O	O
cembratrienol	B-CHEM
(	O	O
25	O	O
.	O	O

4	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
augustum	I-LIVB
;	O	O
β	B-CHEM
-	I-CHEM
pinene	I-CHEM
(	O	O
26	O	O
.	O	O
6	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
corrugatum	I-LIVB
;	O	O
α	B-CHEM
-	I-CHEM
pinene	I-CHEM
(	O	O
19	O	O
.	O	O

4	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
curtispicum	I-LIVB
;	O	O
trans	B-CHEM
-	I-CHEM
β	I-CHEM
-	I-CHEM
farnesene	I-CHEM
(	O	O
63	O	O
.	O	O
7	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
darienense	I-LIVB
;	O	O
p	B-CHEM
-	I-CHEM
cymene	I-CHEM
(	O	O
43	O	O
.	O	O
9	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
grande	I-LIVB
;	O	O
dillapiole	B-CHEM
(	O	O
57	O	O
.	O	O
7	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
hispidum	I-LIVB
;	O	O
linalool	B-CHEM
(	O	O
14	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
α	B-CHEM
-	I-CHEM
phellandrene	I-CHEM
(	O	O
13	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
and	O	O
limonene	B-CHEM
(	O	O
12	O	O
.	O	O
2	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
jacquemontianum	I-LIVB
;	O	O
β	B-CHEM
-	I-CHEM
caryophyllene	I-CHEM
(	O	O
45	O	O
.	O	O
2	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
longispicum	I-LIVB
;	O	O
linalool	B-CHEM
(	O	O
16	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
α	B-CHEM
-	I-CHEM
phellandrene	I-CHEM
(	O	O
11	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
limonene	B-CHEM
(	O	O
11	O	O
.	O	O
4	O	O
%	O	O
)	O	O
,	O	O
and	O	O
p	B-CHEM
-	I-CHEM
cymene	I-CHEM
(	O	O
9	O	O
.	O	O
0	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
multiplinervium	I-LIVB
;	O	O
β	B-CHEM
-	I-CHEM
selinene	I-CHEM
(	O	O
19	O	O
.	O	O
0	O	O
%	O	O
)	O	O
,	O	O
β	B-CHEM
-	I-CHEM
elemene	I-CHEM
(	O	O
16	O	O
.	O	O
1	O	O
%	O	O
)	O	O
,	O	O
and	O	O
α	B-CHEM
-	I-CHEM
selinene	I-CHEM
(	O	O
15	O	O
.	O	O

5	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
reticulatum	I-LIVB
;	O	O
and	O	O
germacrene	B-CHEM
D	I-CHEM
(	O	O
19	O	O
.	O	O
7	O	O
%	O	O
)	O	O
in	O	O
Piper	B-LIVB
trigonum	I-LIVB
.	O	O

The	O	O
essential	B-CHEM
oils	I-CHEM
of	O	O
P	B-LIVB
.	I-LIVB

hispidum	I-LIVB
and	O	O
P	B-LIVB
.	I-LIVB

longispicum	I-LIVB
at	O	O
a	O	O
concentration	O
of	O	O
250	O	O
µg	O	O
/	O	O
mL	O	O
showed	O	O
larvicidal	B-DISO
activity	I-DISO
against	O	O
Aedes	O
aegypti	O
,	O	O
while	O	O
the	O	O
oils	B-CHEM
from	O	O
P	B-LIVB
.	I-LIVB

curtispicum	I-LIVB
,	O	O
P	B-LIVB
.	I-LIVB

multiplinervium	I-LIVB
,	O	O
P	B-LIVB
.	I-LIVB

reticulatum	I-LIVB
,	O	O
and	O	O
P	B-LIVB
.	I-LIVB

trigonum	I-LIVB
were	O	O
inactive	O
(	O	O
LC100	O	O
≥	O	O
500	O	O
µg	O	O
/	O	O
mL	O	O
)	O	O
.	O	O

The	O	O
essential	B-CHEM
oils	I-CHEM
of	O	O
P	B-LIVB
.	I-LIVB

grande	I-LIVB
,	O	O
P	B-LIVB
.	I-LIVB

jacquemontianum	I-LIVB
,	O	O
and	O	O
P	B-LIVB
.	I-LIVB

multiplinervium	I-LIVB
showed	O	O
no	O	O
significant	O	O
antifungal	B-PHYS
activity	I-PHYS
(	O	O
MIC	O	O
>	O	O
250	O	O
µg	O	O
/	O	O
mL	O	O
)	O	O
against	O	O
several	O	O
yeasts	B-LIVB
and	O	O
filamentous	B-LIVB
fungal	I-LIVB
strains	I-LIVB
.	O	O

Spatial	B-PROC
analysis	I-PROC
of	O	O
drug	B-DISO
poisoning	I-DISO
deaths	B-PHYS
in	O	O
the	O	O
American	B-GEOG
West	I-GEOG
,	O	O
particularly	O	O
Utah	B-GEOG
Most	O	O
states	B-GEOG
in	O	O
the	O	O
Western	B-GEOG
US	I-GEOG
have	O	O
high	O	O
rates	O
of	O	O
drug	B-DISO
poisoning	I-DISO
death	B-PHYS
(	O	O
DPD	B-PHYS
)	O	O
,	O	O
especially	O	O
New	B-GEOG
Mexico	I-GEOG
,	O	O
Nevada	B-GEOG
,	O	O
Arizona	B-GEOG
and	O	O
Utah	B-GEOG
(	O	O
UT	B-GEOG
)	O	O
.	O	O

This	O	O
seems	O	O
paradoxical	O
in	O	O
UT	B-GEOG
where	O	O
illicit	O
drug	O
use	O
,	O	O
smoking	O
and	O	O
drinking	O
rates	O
are	O	O
low	O
.	O	O

To	O	O
investigate	O	O
this	O	O
,	O	O
spatial	B-PROC
analysis	I-PROC
of	O	O
county	B-GEOG
level	O	O
DPD	B-PHYS
data	O
and	O	O
other	O	O
relevant	O
factors	O
in	O	O
the	O	O
Western	B-GEOG
US	I-GEOG
and	O	O
UT	B-GEOG
was	O	O
undertaken	O	O
.	O	O

Poisson	B-PROC
kriging	I-PROC
was	O	O
used	O	O
to	O	O
smooth	O	O
the	O	O
DPD	B-PHYS
data	O
,	O	O
populate	O	O
data	O
gaps	O	O
and	O	O
improve	O	O
the	O	O
reliability	O
of	O	O
rates	O
recorded	O	O
in	O	O
sparsely	B-GEOG
populated	I-GEOG
counties	I-GEOG
.	O	O

Links	O	O
between	O	O
DPD	B-PHYS
and	O	O
economic	O
,	O	O
environmental	O
,	O	O
health	O
,	O	O
lifestyle	O
,	O	O
and	O	O
demographic	O
factors	O
were	O	O
investigated	O	O
at	O	O
four	O	O
scales	O	O
using	O	O
multiple	O
linear	O
regression	O
.	O	O

LDS	O
church	O
membership	O
and	O	O
altitude	O
,	O	O
factors	O
not	O	O
previously	O	O
considered	O	O
,	O	O
were	O	O
included	O	O
.	O	O

Spatial	O
change	O
in	O	O
the	O	O
strength	O
and	O	O
sign	O	O
of	O	O
relationships	O
was	O	O
investigated	O	O
using	O	O
geographically	O
weighted	O
regression	O
and	O	O
significant	O	O
DPD	B-PHYS
clusters	O
were	O	O
identified	O	O
using	O	O
the	O	O
Local	B-PROC
Moran	I-PROC
's	I-PROC
I	I-PROC
.	O	O

Economic	O
factors	O
,	O	O
like	O	O
the	O	O
sharp	O	O
social	O
gradient	O
between	O	O
rural	O
and	O	O
urban	O
areas	O
were	O	O
important	O	O
to	O	O
DPD	B-PHYS
throughout	O	O
the	O	O
west	O	O
.	O	O

Higher	O
DPD	O
rates	O
were	O	O
also	O	O
found	O	O
in	O	O
areas	O
of	O	O
higher	O
elevation	O
and	O	O
the	O	O
desert	O
rural	O
areas	O
in	O	O
the	O	O
south	O
.	O	O

The	O	O
unique	O	O
characteristics	O
of	O	O
DPD	B-PHYS
in	O	O
UT	B-GEOG
in	O	O
terms	O	O
of	O	O
health	B-DISO
and	O	O
lifestyle	O
factors	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
demographic	O
structure	O
of	O	O
DPD	B-PHYS
in	O	O
the	O	O
most	O	O
LDS	B-GEOG
populous	I-GEOG
states	I-GEOG
(	O	O
UT	B-GEOG
,	O	O
Idaho	B-GEOG
,	O	O
Wyoming	B-GEOG
)	O	O
,	O	O
suggest	O	O
that	O	O
high	O	O
DPD	B-PHYS
in	O	O
heavily	B-GEOG
LDS	I-GEOG
areas	I-GEOG
are	O	O
predominantly	O	O
prescription	O	O
opioid	B-CHEM
related	O	O
whereas	O	O
in	O	O
other	O	O
Western	B-GEOG
states	I-GEOG
a	O	O
larger	O	O
proportion	O	O
of	O	O
DPD	B-PHYS
might	O	O
come	O	O
from	O	O
illicit	B-CHEM
drugs	I-CHEM
.	O	O

Drug	O
policies	O
need	O	O
to	O	O
be	O	O
adapted	O	O
to	O	O
the	O	O
geographical	B-DISO
differences	I-DISO
in	O	O
the	O	O
dominant	O
type	O	O
of	O	O
drug	B-CHEM
causing	O	O
death	B-PHYS
.	O	O

Educational	B-PROC
materials	I-PROC
need	O	O
to	O	O
be	O	O
marketed	O
to	O	O
the	O	O
demographic	O
groups	O
at	O	O
greatest	O
risk	O
and	O	O
take	O	O
into	O	O
account	O	O
differences	O
in	O	O
population	O
characteristics	O
between	O	O
and	O	O
within	O	O
States	B-GEOG
.	O	O

Some	O	O
suggestions	O
about	O	O
how	O	O
such	O	O
adaptations	O	O
can	O	O
be	O	O
made	O	O
are	O	O
given	O	O
and	O	O
future	O	O
research	O	O
needs	O	O
outlined	O	O
.	O	O

Electrochemically	O
assisted	O
deposition	O
of	O	O
strontium	B-CHEM
modified	O	O
magnesium	B-CHEM
phosphate	I-CHEM
on	O	O
titanium	B-CHEM
surfaces	O
Electrochemically	O
assisted	O
deposition	O
was	O	O
utilized	O	O
to	O	O
produce	O	O
ceramic	B-OBJC
coatings	O
on	O	O
the	O	O
basis	O	O
of	O	O
magnesium	B-CHEM
ammonium	I-CHEM
phosphate	I-CHEM
(	O	O
struvite	B-CHEM
)	O	O
on	O	O
corundum	B-CHEM
-	O	O
blasted	B-PHEN
titanium	B-CHEM
surfaces	O
.	O	O

By	O	O
the	O	O
addition	O	O
of	O	O
defined	O	O
concentrations	O	O
of	O	O
strontium	B-CHEM
nitrate	I-CHEM
to	O	O
the	O	O
coating	O
electrolyte	B-CHEM
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ions	I-CHEM
were	O	O
successfully	O	O
incorporated	O
into	O	O
the	O	O
struvite	B-CHEM
matrix	B-CHEM
.	O	O

By	O	O
variation	O	O
of	O	O
deposition	O
parameters	O
it	O	O
was	O	O
possible	O	O
to	O	O
fabricate	O	O
coatings	O
with	O	O
different	O	O
kinetics	B-PHEN
of	O	O
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
into	O	O
physiological	O	O
media	O	O
,	O	O
whereas	O	O
the	O	O
release	O	O
of	O	O
therapeutically	O
relevant	O
strontium	B-CHEM
doses	O
could	O	O
be	O	O
sustained	O	O
over	O	O
several	O	O
weeks	O
.	O	O

Morphological	O
and	O	O
crystallographic	B-PROC
examinations	I-PROC
of	O	O
the	O	O
immersed	O
coatings	O
revealed	O	O
that	O	O
the	O	O
degradation	O
of	O	O
struvite	B-CHEM
and	O	O
the	O	O
release	O
of	O	O
Sr	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ions	I-CHEM
were	O	O
accompanied	O	O
by	O	O
a	O	O
transformation	B-PHYS
of	O	O
the	O	O
coating	O
to	O	O
a	O	O
calcium	B-CHEM
phosphate	I-CHEM
based	O	O
phase	O	O
similar	O	O
to	O	O
low	B-CHEM
-	I-CHEM
crystalline	I-CHEM
hydroxyapatite	I-CHEM
.	O	O

These	O	O
findings	O
showed	O	O
that	O	O
strontium	B-CHEM
doped	O	O
struvite	B-CHEM
coatings	O
may	O	O
provide	O	O
a	O	O
promising	O	O
degradable	O
coating	O
system	O
for	O	O
the	O	O
local	O	O
application	O	O
of	O	O
strontium	B-CHEM
or	O	O
other	O	O
biologically	B-CHEM
active	I-CHEM
metal	B-CHEM
ions	I-CHEM
in	O	O
the	O	O
implant	B-ANAT
-	I-ANAT
bone	I-ANAT
interface	I-ANAT
.	O	O

Inflamed	O
skin	B-ANAT
predisposes	O
to	O	O
sensitization	B-PHYS
to	O	O
less	O
potent	O
allergens	B-CHEM
Irritant	B-DISO
dermatitis	I-DISO
,	O	O
caused	O	O
by	O	O
genetic	O
barrier	O
dysfunction	O
in	O	O
atopic	B-DISO
dermatitis	I-DISO
or	O	O
wet	O
work	O
in	O	O
hand	B-DISO
dermatitis	I-DISO
,	O	O
induces	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
that	O	O
might	O	O
predispose	O
to	O	O
allergic	B-DISO
contact	I-DISO
sensitization	B-PHYS
to	O	O
less	O
potent	O
sensitizers	B-CHEM
.	O	O

We	O	O
sought	O	O
to	O	O
determine	O	O
if	O	O
positive	B-PHEN
patch	I-PHEN
test	I-PHEN
results	O
to	O	O
less	O
potent	O
allergens	B-CHEM
are	O	O
more	O
prevalent	O
in	O	O
patients	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	I-DISO
childhood	I-DISO
flexural	B-DISO
dermatitis	I-DISO
or	O	O
current	O
wet	O
work	O
.	O	O

We	O	O
examined	O	O
our	O	O
database	O
of	O	O
patients	B-LIVB
presenting	O	O
to	O	O
a	O	O
contact	B-DISO
dermatitis	I-DISO
clinic	B-OBJC
tested	O
to	O	O
potential	O
contact	B-CHEM
allergens	I-CHEM
as	O	O
indicated	O	O
by	O	O
their	O	O
history	B-PROC
.	O	O

Allergens	B-CHEM
from	O	O
our	O	O
most	O	O
recent	O	O
standard	O
were	O	O
studied	B-PROC
if	O	O
they	O	O
could	O	O
be	O	O
classified	O	O
as	O	O
weak	O
,	O	O
moderate	O
,	O	O
or	O	O
strong	O
sensitizers	B-CHEM
based	O	O
on	O	O
published	O
data	O
from	O	O
the	O	O
local	O
lymph	O
node	O
assay	O
.	O	O

Patients	O
were	O	O
stratified	O
by	O	O
a	O	O
history	B-DISO
of	I-DISO
childhood	I-DISO
-	O	O
onset	B-DISO
flexural	I-DISO
dermatitis	I-DISO
as	O	O
a	O	O
proxy	O	O
for	O	O
atopic	B-DISO
dermatitis	I-DISO
and	O	O
by	O	O
occupation	B-DISO
.	O	O

History	B-DISO
of	I-DISO
childhood	I-DISO
-	O	O
onset	B-DISO
dermatitis	I-DISO
predisposed	O
to	O	O
contact	B-DISO
allergy	I-DISO
to	O	O
weak	O
sensitizers	B-CHEM
and	O	O
wet	O
work	O
to	O	O
medium	O
-	O	O
potency	O
sensitizers	B-CHEM
.	O	O

Neither	O	O
predisposed	O
to	O	O
contact	B-DISO
allergy	I-DISO
from	O	O
strong	O
sensitizers	B-CHEM
.	O	O

Association	O
cannot	O	O
prove	O	O
causation	O
.	O	O

We	O	O
conclude	O	O
that	O	O
strong	O
sensitizers	B-CHEM
do	O	O
not	O	O
require	O	O
wet	O
work	O
or	O	O
atopy	B-DISO
to	O	O
cause	O	O
sensitization	B-PHYS
.	O	O

Barrier	O
defects	O
associated	O
with	O
childhood	B-DISO
eczema	I-DISO
and	O	O
wet	O
work	O
may	O	O
promote	O
sensitization	B-PHYS
to	O	O
weak	O
antigens	B-CHEM
.	O	O

Transcription	B-PHYS
rate	O
and	O	O
transcript	B-CHEM
length	O
drive	O	O
formation	O
of	O	O
chromosomal	B-ANAT
interaction	I-ANAT
domain	I-ANAT
boundaries	I-ANAT
Chromosomes	B-ANAT
in	O	O
all	O	O
organisms	B-LIVB
are	O	O
highly	O	O
organized	O
and	O	O
divided	O
into	O	O
multiple	O
chromosomal	B-ANAT
interaction	I-ANAT
domains	I-ANAT
,	O	O
or	O	O
topological	B-ANAT
domains	I-ANAT
.	O	O

Regions	O	O
of	O	O
active	O	O
,	O	O
high	O	O
transcription	B-PHYS
help	O	O
establish	O	O
and	O	O
maintain	O	O
domain	B-ANAT
boundaries	I-ANAT
,	O	O
but	O	O
precisely	O	O
how	O	O
this	O	O
occurs	O	O
remains	O	O
unclear	B-DISO
.	O	O

Here	O	O
,	O	O
using	O	O
fluorescence	B-PROC
microscopy	I-PROC
and	O	O
chromosome	O	O
conformation	O	O
capture	O	O
in	O	O
conjunction	O	O
with	O	O
deep	B-PROC
sequencing	I-PROC
(	O	O
Hi	O	O
-	O	O
C	O	O
)	O	O
,	O	O
we	O	O
show	O	O
that	O	O
in	O	O
Caulobacter	B-LIVB
crescentus	I-LIVB
,	O	O
both	O	O
transcription	B-PHYS
rate	O
and	O	O
transcript	B-CHEM
length	O
,	O	O
independent	O
of	O
concurrent	O	O
translation	B-PHYS
,	O	O
drive	O	O
the	O	O
formation	O
of	O	O
domain	B-ANAT
boundaries	I-ANAT
.	O	O

We	O	O
find	O	O
that	O	O
long	O	O
,	O	O
highly	O	O
expressed	O	O
genes	O
do	O	O
not	O	O
form	O	O
topological	B-ANAT
boundaries	I-ANAT
simply	O	O
through	O	O
the	O	O
inhibition	O
of	O	O
supercoil	O	O
diffusion	O	O
.	O	O

Instead	O	O
,	O	O
our	O	O
results	O	O
support	O	O
a	O	O
model	O
in	O	O
which	O	O
long	O	O
,	O	O
active	O	O
regions	O	O
of	O	O
transcription	B-PHYS
drive	O	O
local	O	O
decompaction	O	O
of	O	O
the	O	O
chromosome	O	O
,	O	O
with	O	O
these	O	O
more	O	O
open	O	O
regions	B-ANAT
of	I-ANAT
the	I-ANAT
chromosome	I-ANAT
forming	O	O
spatial	O
gaps	O
in	O
vivo	O
that	O	O
diminish	O	O
contacts	O	O
between	O	O
DNA	B-CHEM
in	O	O
neighboring	O	O
domains	B-ANAT
.	O	O

These	O	O
insights	O	O
into	O	O
the	O	O
molecular	B-PHEN
forces	I-PHEN
responsible	O	O
for	O	O
domain	B-ANAT
formation	O
in	O	O
Caulobacter	B-LIVB
likely	O	O
generalize	O	O
to	O	O
other	O	O
bacteria	B-LIVB
and	O	O
possibly	O	O
eukaryotes	O
.	O	O

Tead1	O
regulates	O	O
the	O	O
expression	B-PHYS
of	O	O
Peripheral	O
Myelin	O
Protein	O
22	O
during	O	O
Schwann	B-PHYS
cell	I-PHYS
development	I-PHYS
Schwann	B-ANAT
cells	I-ANAT
are	O	O
myelinating	B-ANAT
glia	I-ANAT
in	O	O
the	O	O
peripheral	B-ANAT
nervous	I-ANAT
system	I-ANAT
that	O	O
form	O	O
the	O	O
myelin	B-ANAT
sheath	I-ANAT
.	O	O

A	O	O
major	O	O
cause	O	O
of	O	O
peripheral	B-DISO
neuropathy	I-DISO
is	O	O
a	O	O
copy	O
number	O
variant	O
involving	O	O
the	O	O
Peripheral	O
Myelin	O
Protein	O
22	O
(	O
PMP22	O
)	O
gene	O
,	O	O
which	O	O
is	O	O
located	O	O
within	O	O
a	O	O
1	O	O
.	O	O
4	O	O
-	O	O
Mb	O	O
duplication	B-PHYS
on	O	O
chromosome	B-ANAT
17	I-ANAT
associated	O	O
with	O	O
the	O	O
most	O	O
common	O	O
form	O	O
of	O	O
Charcot	B-DISO
-	I-DISO
Marie	I-DISO
-	I-DISO
Tooth	I-DISO
Disease	I-DISO
(	O	O
CMT1A	B-DISO
)	O	O
.	O	O

Rodent	B-DISO
models	I-DISO
of	O	O
CMT1A	B-DISO
have	O	O
been	O	O
used	O	O
to	O	O
show	O	O
that	O	O
reducing	O	O
Pmp22	O
overexpression	B-PHYS
mitigates	O	O
several	O	O
aspects	O	O
of	O	O
a	O	O
CMT1A	B-DISO
-related	O	O
phenotype	B-PHYS
.	O	O

Mechanistic	O
studies	B-PROC
of	O	O
Pmp22	O
regulation	B-PHYS
identified	O	O
enhancers	B-CHEM
regulated	O	O
by	O	O
the	O	O
Sox10	B-CHEM
(	O	O
SRY	B-CHEM
sex	I-CHEM
determining	I-CHEM
region	I-CHEM
Y	I-CHEM
-	I-CHEM
box	I-CHEM
10	I-CHEM
)	O	O
and	O	O
Egr2	B-CHEM
/	O	O
Krox20	B-CHEM
(	O	O
Early	B-CHEM
growth	I-CHEM
response	I-CHEM
protein	I-CHEM
2	I-CHEM
)	O	O
transcription	B-CHEM
factors	I-CHEM
in	O	O
myelinated	B-ANAT
nerves	I-ANAT
.	O	O

However	O	O
,	O	O
relatively	O	O
little	O	O
is	O	O
known	O	O
regarding	O	O
how	O	O
other	O	O
transcription	B-CHEM
factors	I-CHEM
induce	O
Pmp22	O
expression	B-PHYS
during	O	O
Schwann	B-PHYS
cell	I-PHYS
development	I-PHYS
and	O	O
myelination	B-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
examined	O	O
Pmp22	O
enhancers	B-CHEM
as	O	O
a	O	O
function	O	O
of	O	O
cell	B-PHYS
type	I-PHYS
-	I-PHYS
specificity	I-PHYS
,	O	O
nerve	B-DISO
injury	I-DISO
and	O	O
development	O
.	O	O

While	O	O
Pmp22	O
enhancers	B-CHEM
marked	O	O
by	O	O
active	O
histone	B-PHYS
modifications	I-PHYS
were	O	O
lost	O
or	O	O
remodeled	O	O
after	O	O
injury	B-DISO
,	O	O
we	O	O
found	O	O
that	O	O
these	O	O
enhancers	B-CHEM
were	O	O
permissive	O	O
in	O	O
early	O	O
development	O
prior	O	O
to	O	O
Pmp22	O
upregulation	B-PHYS
.	O	O

Pmp22	O
enhancers	B-CHEM
contain	O	O
binding	B-CHEM
motifs	I-CHEM
for	O	O
TEA	B-CHEM
domain	I-CHEM
(	O	O
Tead	B-CHEM
)	O	O
transcription	B-CHEM
factors	I-CHEM
of	O	O
the	O	O
Hippo	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O	O

We	O	O
discovered	O	O
that	O	O
Tead1	O
and	O	O
co	O	O
-	O	O
activators	O	O
Yap	O
and	O	O
Taz	O
are	O	O
required	O	O
for	O	O
Pmp22	O
expression	B-PHYS
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
the	O	O
expression	B-PHYS
of	O	O
Egr2	O
Tead1	O
directly	O	O
binds	O	O
Pmp22	O
and	O	O
Egr2	O
enhancers	B-CHEM
early	O	O
in	O	O
development	O
and	O	O
Tead1	O
binding	B-PHYS
is	O	O
induced	O
during	O	O
myelination	B-PHYS
,	O	O
correlating	O	O
with	O	O
Pmp22	O
expression	B-PHYS
.	O	O

The	O	O
data	O
identify	O	O
Tead1	O
as	O	O
a	O	O
novel	O	O
regulator	O
of	O	O
Pmp22	O
expression	B-PHYS
during	O	O
development	O
in	O	O
concert	O	O
with	O	O
Sox10	O
and	O	O
Egr2	O
.	O	O

Molecular	O
characterization	O
of	O	O
a	O	O
novel	O
putative	B-LIVB
ampelovirus	I-LIVB
tentatively	O
named	O
grapevine	B-LIVB
leafroll	I-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
13	I-LIVB
A	O	O
novel	O
putative	B-LIVB
ampelovirus	I-LIVB
was	O	O
detected	B-DISO
in	O	O
grapevines	B-LIVB
that	O	O
showed	O	O
typical	O
leafroll	B-DISO
symptoms	I-DISO
and	O	O
was	O	O
tentatively	O
named	O
grapevine	B-LIVB
leafroll	I-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
(	I-LIVB
GLRaV	I-LIVB
)	I-LIVB
-	I-LIVB
13	I-LIVB
following	O	O
the	O	O
series	O
of	O	O
numbering	O
of	O	O
other	O	O
GLRaVs	B-LIVB
.	O	O

The	O	O
complete	O
genome	O
of	O	O
GLRaV	B-LIVB
-	I-LIVB
13	I-LIVB
comprised	O	O
17	O	O
,	O	O
608	O	O
nt	O	O
and	O	O
contained	O	O
eleven	O	O
putative	O
open	O
reading	O
frames	O
,	O	O
showing	O	O
genetic	O
features	O
similar	O	O
to	O	O
those	O	O
of	O	O
viruses	B-LIVB
belonging	O	O
to	O	O
subgroup	O
I	O
of	O	O
genus	O
Ampelovirus	B-LIVB
.	O	O

Phylogenetic	O
trees	O
based	O	O
on	O	O
the	O	O
RNA	B-CHEM
-	I-CHEM
dependent	I-CHEM
RNA	I-CHEM
polymerase	I-CHEM
,	O	O
heat	B-CHEM
shock	I-CHEM
protein	I-CHEM
70	I-CHEM
homolog	O
,	O	O
and	O	O
coat	B-CHEM
protein	I-CHEM
showed	O	O
that	O	O
GLRaV	B-LIVB
-	I-LIVB
13	I-LIVB
had	O	O
the	O	O
closest	O	O
,	O	O
but	O	O
still	O	O
distant	O	O
,	O	O
relationship	O
to	O	O
GLRaV	B-LIVB
-	I-LIVB
1	I-LIVB
in	O	O
the	O	O
subgroup	O
I	O
cluster	O
.	O	O

Neutrophil	B-CHEM
gelatinase	I-CHEM
-	I-CHEM
associated	I-CHEM
lipocalin	I-CHEM
in	O	O
a	O	O
triphasic	O
rat	B-LIVB
model	I-LIVB
of	O	O
adenine	B-CHEM
-	O	O
induced	O
kidney	B-DISO
injury	I-DISO
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
whether	O	O
NGAL	B-CHEM
,	O	O
given	O	O
its	O	O
advantages	O	O
over	O	O
traditional	O	O
biomarkers	B-PHYS
,	O	O
can	O	O
be	O	O
used	O	O
to	O	O
describe	O	O
the	O	O
dynamic	O	O
characteristics	O	O
of	O	O
the	O	O
renal	B-DISO
tubulointerstitial	I-DISO
insult	I-DISO
caused	O	O
by	O	O
adenine	B-CHEM
.	O	O

Subsequently	O	O
,	O	O
it	O	O
will	O	O
be	O	O
possible	O	O
to	O	O
assess	O	O
NGAL	B-CHEM
as	O	O
a	O	O
biomarker	B-PHYS
of	O	O
any	O	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
,	O	O
on	O	O
top	O	O
of	O	O
chronic	B-DISO
interstitial	I-DISO
disease	I-DISO
,	O	O
if	O	O
NGAL	B-CHEM
levels	O
are	O	O
stable	O
through	O
the	O	O
chronic	O
phase	O
of	O	O
our	O	O
adenine	B-LIVB
model	I-LIVB
.	O	O

Study	B-LIVB
group	I-LIVB
rats	B-LIVB
were	O	O
fed	O	O
an	O	O
adenine	B-CHEM
diet	B-OBJC
,	O	O
and	O	O
control	B-LIVB
group	I-LIVB
rats	B-LIVB
were	O	O
fed	O	O
a	O	O
regular	O
diet	O
only	O	O
.	O	O

Blood	B-ANAT
and	O	O
urine	B-ANAT
samples	I-ANAT
for	O	O
urea	B-CHEM
,	O	O
creatinine	B-CHEM
and	O	O
NGAL	B-CHEM
were	O	O
drawn	O	O
from	O	O
each	O	O
rat	B-LIVB
at	O	O
the	O	O
beginning	O
of	O	O
the	O	O
study	B-PROC
and	O	O
after	O	O
1	O	O
,	O	O
3	O	O
,	O	O
4	O	O
,	O	O
5	O	O
,	O	O
6	O	O
,	O	O
7	O	O
and	O	O
8	O	O
weeks	O	O
.	O	O

Kidney	B-ANAT
slices	B-OBJC
from	O	O
these	O	O
rats	B-LIVB
were	O	O
stained	B-PROC
with	O	O
Hematoxylin	B-PROC
-	I-PROC
eosin	I-PROC
(	O	O
HE	B-PROC
)	O	O
and	O	O
β	B-CHEM
-	I-CHEM
actin	I-CHEM
stainings	B-PROC
.	O	O

Serum	B-PHEN
urea	I-PHEN
,	O	O
creatinine	B-PROC
and	O	O
NGAL	B-CHEM
levels	O
and	O	O
urinary	B-PHYS
NGAL	I-PHYS
/	I-PHYS
creatinine	I-PHYS
ratio	I-PHYS
in	O	O
the	O	O
study	O	O
group	O	O
were	O	O
higher	O	O
than	O	O
baseline	O
and	O	O
than	O	O
in	O	O
the	O	O
control	B-LIVB
group	I-LIVB
;	O	O
these	O	O
differences	O	O
were	O	O
statistically	O
significant	O
in	O	O
some	O	O
of	O	O
the	O	O
intervals	O
.	O	O

Tubulointerstitial	B-DISO
changes	O	O
and	O	O
adenine	B-CHEM
crystals	O	O
were	O	O
evident	O	O
in	O	O
the	O	O
study	O	O
group	O	O
rats	B-LIVB
.	O	O

In	O	O
the	O	O
rats	B-LIVB
fed	O	O
adenine	B-CHEM
,	O	O
serum	B-PHEN
urea	I-PHEN
,	O	O
creatinine	B-PROC
and	O	O
NGAL	B-CHEM
levels	O
and	O	O
urinary	B-PHYS
NGAL	I-PHYS
/	I-PHYS
creatinine	I-PHYS
ratio	I-PHYS
followed	O	O
a	O	O
triphasic	B-DISO
pattern	I-DISO
of	O	O
kidney	B-DISO
injury	I-DISO
:	O	O
an	O	O
acute	O
phase	O
while	O	O
on	O	O
the	O	O
adenine	B-CHEM
diet	B-OBJC
,	O	O
a	O	O
partial	O
recovery	B-PHYS
phase	O
after	O	O
switching	O	O
to	O	O
the	O	O
regular	O
diet	O
and	O	O
a	O	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
phase	O
after	O	O
stabilization	O	O
of	O	O
renal	B-PHYS
function	I-PHYS
.	O	O

NGAL	B-CHEM
can	O	O
serve	O	O
a	O	O
biomarker	B-PHYS
for	O	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
and	O	O
possibly	O	O
for	O	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
in	O	O
the	O	O
tubulointerstitial	B-DISO
rat	B-LIVB
model	I-LIVB
.	O	O

Talking	O
or	O	O
Keeping	O
Silent	O
About	O	O
Parental	B-LIVB
Mental	B-DISO
Health	I-DISO
Problems	I-DISO
-A	O	O
Grounded	O
Theory	O
of	O	O
Parents	B-LIVB
'	O	O
Decision	B-PHYS
Making	I-PHYS
and	O	O
Experiences	B-PHYS
with	O	O
Their	O	O
Children	B-LIVB
This	O	O
grounded	O
theory	O
study	B-PROC
explored	O	O
parents	B-LIVB
'	O	O
experiences	B-PHYS
of	O	O
responding	O	O
to	O	O
their	O	O
children	B-LIVB
's	I-LIVB
need	O	O
for	O	O
understanding	O	O
parental	B-LIVB
mental	B-PHYS
health	I-PHYS
concerns	O
.	O	O

Fifteen	O	O
parents	B-LIVB
with	O	O
severe	O
and	O	O
enduring	O	O
mental	B-DISO
health	I-DISO
difficulties	I-DISO
participated	O	O
in	O	O
the	O	O
study	B-PROC
.	O	O

The	O	O
findings	B-DISO
suggest	O	O
four	O	O
main	O	O
social	B-PHEN
processes	I-PHEN
that	O	O
influence	O	O
parents	B-LIVB
'	O	O
talk	O
with	O	O
their	O	O
children	B-LIVB
about	O	O
parental	B-LIVB
mental	B-DISO
health	I-DISO
issues	I-DISO
,	O	O
namely	O	O
""""	O	O
Protecting	B-PHYS
and	O	O
being	B-PHYS
protected	I-PHYS
,	O	O
""""	O	O
""""	O	O
Responding	B-PHYS
to	O	O
children	B-LIVB
's	I-LIVB
search	O
for	O	O
understanding	B-PHYS
,	O	O
""""	O	O
""""	O	O
Prioritizing	O
family	O
life	O
,	O	O
""""	O	O
and	O	O
""""	O	O
Relating	O
to	O
others	O
.	O	O
""""	O	O
Implications	O	O
of	O	O
the	O	O
findings	B-DISO
for	O	O
clinical	B-PROC
practice	I-PROC
and	O	O
future	O	O
research	B-PROC
are	O	O
considered	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
need	O	O
for	O	O
more	O	O
family	B-PROC
-	I-PROC
orientated	I-PROC
services	I-PROC
where	O	O
parents	B-LIVB
experience	B-PHYS
parental	B-LIVB
mental	B-DISO
health	I-DISO
problems	I-DISO
is	O	O
highlighted	O	O
.	O	O

Joint	B-ANAT
Development	O
Involves	O	O
a	O	O
Continuous	O
Influx	O
of	O	O
Gdf5	O
-	O	O
Positive	B-ANAT
Cells	I-ANAT
Synovial	B-ANAT
joints	I-ANAT
comprise	O
several	O	O
tissue	O
types	O
,	O	O
including	O	O
articular	O
cartilage	O
,	O	O
the	O	O
capsule	B-ANAT
,	O	O
and	O	O
ligaments	O
.	O	O

All	O	O
of	O	O
these	O	O
compartments	B-ANAT
are	O	O
commonly	O	O
assumed	O	O
to	O	O
originate	O	O
from	O	O
an	O	O
early	O	O
set	O	O
of	O	O
Gdf5	O
-	O	O
expressing	B-PHYS
progenitors	B-ANAT
populating	O	O
the	O	O
interzone	O
domain	O
.	O	O

Here	O	O
,	O	O
we	O	O
provide	O	O
evidence	O	O
that	O	O
joints	B-ANAT
develop	O	O
through	O	O
a	O	O
continuous	O
influx	O
of	O	O
cells	B-ANAT
into	O	O
the	O	O
interzone	O
,	O	O
where	O	O
they	O	O
contribute	O
differentially	O
to	O	O
forming	O
joint	O
tissues	O
.	O	O

Using	O	O
a	O	O
knockin	B-PROC
Gdf5	O
-	O	O
CreER	O
(	O
T2	O
)	O
mouse	B-LIVB
,	O	O
we	O	O
show	O	O
that	O	O
early	O	O
labeling	O	O
of	O	O
Gdf5	O
-	O	O
positive	B-DISO
interzone	O
cells	B-ANAT
failed	O	O
to	O	O
mark	O
the	O	O
entire	B-ANAT
organ	I-ANAT
.	O	O

Conversely	O	O
,	O	O
multiple	O
Cre	O
activation	B-PHYS
steps	O	O
indicated	B-DISO
a	O	O
contribution	O
of	O	O
these	O	O
cells	B-ANAT
to	O	O
various	O	O
joint	B-ANAT
compartments	I-ANAT
later	O	O
in	O	O
development	O
.	O	O

Spatiotemporal	O
differences	O
between	O	O
Gdf5	O
and	O	O
tdTomato	O
reporter	O	O
expression	B-PHYS
support	O	O
the	O	O
notion	O	O
of	O	O
a	O	O
continuous	O
recruitment	O
process	B-PHEN
.	O	O

Finally	O	O
,	O	O
differential	O
contribution	O
of	O	O
Gdf5	O
-	O	O
positive	B-DISO
cells	B-ANAT
to	O	O
various	O	O
tissues	O
suggests	O
that	O	O
the	O	O
spatiotemporal	B-PROC
dynamics	I-PROC
of	O	O
Gdf5	O
expression	B-PHYS
may	O	O
instruct	O	O
lineage	O
divergence	O
.	O	O

This	O	O
work	O	O
supports	O	O
the	O	O
influx	O
model	O	O
of	O	O
joint	B-ANAT
development	O
,	O	O
which	O	O
may	O	O
apply	O	O
to	O	O
other	O	O
organogenic	B-PHEN
processes	B-PHEN
.	O	O

Everyday	O
(	O
in	O
)	O
equality	O
at	O	O
home	O
:	O	O
complex	O	O
constructions	O	O
of	O	O
gender	B-PHYS
in	O	O
South	B-LIVB
African	I-LIVB
families	B-LIVB
High	O
rates	O
of	O	O
violence	B-DISO
and	O	O
HIV	B-DISO
have	O	O
been	O	O
documented	B-PROC
within	O	O
the	O	O
South	B-LIVB
African	I-LIVB
context	I-LIVB
.	O	O

Constructions	O	O
of	O	O
masculinity	B-PHYS
and	O	O
femininity	B-PHYS
that	O	O
position	O	O
men	B-LIVB
as	O	O
dominant	O
and	O	O
highly	O	O
sexually	B-DISO
active	I-DISO
and	O	O
women	B-LIVB
as	O	O
subordinate	O
and	O	O
acquiescent	B-DISO
have	O	O
been	O	O
found	O	O
to	O	O
contribute	O	O
towards	O	O
gender	O
inequality	O
.	O	O

This	O	O
inequality	O
is	O	O
in	O	O
turn	O	O
related	O	O
to	O	O
negative	O	O
health	O
consequences	O
,	O	O
specifically	O	O
violence	B-DISO
against	O	O
women	B-LIVB
,	O	O
children	B-LIVB
,	O	O
and	O	O
other	O	O
men	B-LIVB
,	O	O
as	O	O
well	O	O
as	O	O
sexual	B-DISO
risk	I-DISO
.	O	O

Within	O	O
this	O	O
context	O	O
it	O	O
becomes	O	O
important	O	O
to	O	O
explore	O	O
how	O	O
problematic	O	O
constructions	O	O
of	O	O
gender	B-PHYS
are	O	O
being	O	O
(	O	O
re	O	O
)	O	O
produced	O
and	O	O
how	O	O
these	O	O
constructions	O	O
are	O	O
being	O	O
challenged	O	O
.	O	O

Families	B-LIVB
have	O	O
been	O	O
identified	O	O
as	O	O
key	O	O
sites	O	O
in	O	O
which	O	O
gender	B-PHYS
is	O	O
both	O	O
constructed	O	O
and	O	O
enacted	O	O
on	O	O
a	O	O
daily	O
basis	O	O
and	O	O
it	O	O
is	O	O
within	O	O
this	O	O
space	O	O
that	O	O
children	B-LIVB
are	O	O
first	O	O
exposed	O	O
to	O	O
notions	O
of	O	O
gender	B-PHYS
.	O	O

This	O	O
article	O
draws	O	O
from	O	O
a	O	O
study	B-PROC
that	O	O
was	O	O
intended	O	O
to	O	O
expand	O	O
on	O	O
the	O	O
limited	O	O
understandings	O	O
of	O	O
the	O	O
ways	O	O
in	O	O
which	O	O
gender	O
(	O
in	O
)	O
equality	O
is	O	O
constructed	O	O
and	O	O
conveyed	O	O
within	O	O
the	O	O
context	B-LIVB
of	I-LIVB
South	I-LIVB
African	I-LIVB
families	B-LIVB
on	O	O
an	O	O
everyday	O
basis	O	O
.	O	O

Children	B-LIVB
and	O	O
parents	B-LIVB
in	O	O
18	O	O
families	B-LIVB
from	O	O
a	O	O
range	O	O
of	O	O
different	O	O
material	O	O
and	O	O
cultural	O
backgrounds	O
were	O	O
interviewed	O	O
about	O	O
the	O	O
meanings	O	O
and	O	O
practices	O	O
of	O	O
gender	B-PHYS
within	O	O
their	O	O
homes	O
.	O	O

Data	O
were	O	O
analysed	B-PROC
using	O	O
a	O	O
Foucauldian	B-PROC
discourse	I-PROC
analysis	I-PROC
.	O	O

The	O	O
data	O
reveal	O	O
how	O	O
problematic	O	O
constructions	O	O
of	O	O
masculinity	B-PHYS
and	O	O
femininity	B-PHYS
are	O	O
(	O	O
re	O	O
)	O	O
produced	O
but	O	O
also	O	O
challenged	O	O
within	O	O
a	O	O
range	O	O
of	O	O
different	O	O
families	B-LIVB
.	O	O

Gender	B-PHYS
and	O	O
gender	O
(	O
in	O
)	O
equality	O
are	O	O
therefore	O	O
routinely	O	O
accomplished	O	O
in	O	O
complex	O	O
ways	O	O
.	O	O

These	O	O
findings	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
promoting	O	O
gender	B-PHYS
equality	O
and	O	O
therefore	O	O
for	O	O
disrupting	O
violence	B-DISO
and	O	O
sexual	B-DISO
risk	I-DISO
as	O	O
gendered	O	O
health	O	O
issues	O	O
.	O	O

A	O	O
Support	O
Vector	O
Machine	O
Classification	O
of	O	O
Thyroid	B-ANAT
Bioptic	O
Specimens	O
Using	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
Data	O
Biomarkers	B-PHYS
able	O	O
to	O	O
characterise	O
and	O	O
predict	O	O
multifactorial	O
diseases	B-DISO
are	O	O
still	O	O
one	O	O
of	O	O
the	O	O
most	O	O
important	O
targets	O
for	O	O
all	O	O
the	O	O
""""	O	O
omics	O	O
""""	O	O
investigations	O
.	O	O

In	O	O
this	O	O
context	O
,	O	O
Matrix	B-PROC
-	I-PROC
Assisted	I-PROC
Laser	I-PROC
Desorption	I-PROC
/	I-PROC
Ionisation	I-PROC
-	I-PROC
Mass	I-PROC
Spectrometry	I-PROC
Imaging	I-PROC
(	O	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
)	O	O
has	O	O
gained	O
considerable	O
attention	B-PHYS
in	O	O
recent	O
years	O
,	O	O
but	O	O
it	O	O
also	O	O
led	O	O
to	O	O
a	O	O
huge	O	O
amount	O
of	O	O
complex	O
data	O
to	O	O
be	O	O
elaborated	O
and	O	O
interpreted	O
.	O	O

For	O	O
this	O	O
reason	O
,	O	O
computational	B-PROC
and	O	O
machine	O
learning	O
procedures	O
for	O	O
biomarker	B-PHYS
discovery	O
are	O	O
important	O
tools	O
to	O	O
consider	O
,	O	O
both	O
to	O	O
reduce	O
data	O
dimension	O
and	O	O
to	O	O
provide	O	O
predictive	O
markers	B-PHYS
for	O	O
specific	O
diseases	B-DISO
.	O	O

For	O	O
instance	O
,	O	O
the	O	O
availability	O
of	O
protein	B-CHEM
and	O	O
genetic	O
markers	B-PHYS
to	O	O
support	O	O
thyroid	B-ANAT
lesion	B-DISO
diagnoses	B-PROC
would	O	O
impact	O
deeply	O
on	O	O
society	B-LIVB
due	O	O
to	O	O
the	O	O
high	O	O
presence	O	O
of	O	O
undetermined	O
reports	O
(	O	O
THY3	O
)	O	O
that	O	O
are	O	O
generally	O	O
treated	O
as	O	O
malignant	O
patients	B-LIVB
.	O	O

In	O	O
this	O	O
paper	O	O
we	O	O
show	O	O
how	O	O
an	O	O
accurate	O
classification	O
of	O	O
thyroid	B-ANAT
bioptic	O
specimens	O
can	O	O
be	O	O
obtained	O
through	O
the	O	O
application	O	O
of	O	O
a	O	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
machine	O
learning	O
approach	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
Support	O
Vector	O
Machines	O
)	O	O
on	O	O
MALDI	B-PROC
-	I-PROC
MSI	I-PROC
data	O
,	O	O
together	O	O
with	O	O
a	O	O
particular	O	O
wrapper	O	O
feature	O
selection	O
algorithm	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
recursive	O
feature	O
elimination	O
)	O	O
.	O	O

The	O	O
model	B-DEVI
is	O	O
able	O	O
to	O	O
provide	O
an	O	O
accurate	O
discriminatory	O
capability	O
using	O
only	O	O
20	O	O
out	O	O
of	O	O
144	O	O
features	O
,	O	O
resulting	O
in	O	O
an	O	O
increase	O
of	O	O
the	O	O
model	B-DEVI
performances	O
,	O	O
reliability	O
,	O	O
and	O	O
computational	O
efficiency	O
.	O	O

Finally	O	O
,	O	O
tissue	O
areas	O
rather	O	O
than	O	O
average	O
proteomic	B-PHEN
profiles	I-PHEN
are	O	O
classified	O
,	O	O
highlighting	O	O
potential	O
discriminating	O
areas	O
of	O	O
clinical	O
interest	B-PHYS
.	O	O

Production	O
of	O	O
Laccase	B-CHEM
by	O	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB

Isolated	O
from	O	O
Plastic	B-OBJC
Dumped	B-OBJC
Soils	I-OBJC
and	O	O
Their	O	O
Ability	B-PHYS
to	O	O
Degrade	O
Low	B-CHEM
Molecular	I-CHEM
Weight	I-CHEM
PVC	I-CHEM
One	O	O
of	O	O
the	O	O
utmost	O	O
man	B-PHEN
-	I-PHEN
made	I-PHEN
problems	I-PHEN
faced	O	O
today	O	O
has	O	O
been	O	O
the	O	O
ever	O
-	O	O
increasing	O
plastic	B-OBJC
waste	B-OBJC
filling	O
the	O	O
world	O	O
.	O	O

It	O	O
accounts	O	O
for	O	O
an	O	O
estimated	O	O
20	O	O
-	O	O
30	O	O
%	O	O
(	O	O
by	O	O
volume	O	O
)	O	O
of	O	O
municipal	B-OBJC
solid	I-OBJC
waste	I-OBJC
in	O	O
landfill	B-OBJC
sites	I-OBJC
worldwide	O	O
.	O	O

Research	O	O
on	O	O
plastic	B-OBJC
biodegradation	B-PHEN
has	O	O
been	O	O
steadily	O	O
growing	O	O
over	O	O
the	O	O
past	O	O
four	O	O
decades	O	O
.	O	O

Several	O	O
fungi	B-LIVB
have	O	O
been	O	O
identified	O	O
that	O	O
produce	O	O
enzymes	B-CHEM
capable	O	O
of	O	O
plastic	B-OBJC
degradation	B-PHEN
in	O	O
various	O	O
laboratory	O
conditions	O
.	O	O

This	O	O
paper	O	O
presents	O	O
a	O	O
study	O	O
that	O	O
determined	O	O
the	O	O
ability	B-PHYS
of	O	O
fungi	B-LIVB
to	O	O
degrade	O
low	B-CHEM
molecular	I-CHEM
weight	I-CHEM
polyvinyl	I-CHEM
chloride	I-CHEM
(	O	O
PVC	B-CHEM
)	O	O
by	O	O
the	O	O
enzyme	B-CHEM
laccase	I-CHEM
.	O	O

We	O	O
have	O	O
isolated	O
a	O	O
fungal	B-LIVB
species	O
,	O	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB
,	O	O
from	O	O
plastic	B-OBJC
dumped	B-OBJC
soils	I-OBJC
and	O	O
they	O	O
were	O	O
cultured	B-PROC
on	O	O
Czapek	B-CHEM
Dox	I-CHEM
Agar	I-CHEM
slants	I-CHEM
at	O	O
30°C	O	O
.	O	O

The	O	O
effectiveness	O
of	O	O
this	O	O
fungal	B-LIVB
species	O
on	O	O
the	O	O
degradation	B-PHEN
of	O	O
commercial	O	O
low	B-CHEM
molecular	I-CHEM
weight	I-CHEM
polyvinyl	I-CHEM
chloride	I-CHEM
(	O	O
PVC	B-CHEM
)	O	O
was	O	O
studied	O	O
under	O	O
laboratory	O
conditions	O
.	O	O

Significant	O	O
differences	O	O
were	O	O
observed	O	O
from	O	O
the	O	O
FTIR	B-PROC
,	O	O
GC	B-PROC
-	I-PROC
MS	I-PROC
,	O	O
and	O	O
SEM	B-PROC
results	O	O
in	O	O
between	O	O
control	B-OBJC
and	O	O
Cochliobolus	B-LIVB
sp	I-LIVB
.	I-LIVB

treated	O	O
PVC	B-CHEM
.	O	O

Conformers	O
of	O	O
Gaseous	B-CHEM
Serine	B-CHEM
The	O	O
myriad	O
conformers	O
of	O	O
the	O	O
neutral	B-PHEN
form	I-PHEN
of	O	O
natural	O
amino	B-CHEM
acid	I-CHEM
serine	B-CHEM
(	O	O
Ser	B-CHEM
)	O	O
have	O	O
been	O	O
investigated	O	O
by	O	O
systematic	O	O
computations	O
with	O	O
reliable	O	O
electronic	O
wave	O
function	O
methods	O
.	O	O

A	O	O
total	O	O
of	O	O
85	O	O
unique	O	O
conformers	O
were	O	O
located	O	O
using	O	O
the	O	O
MP2	O
/	O
cc	O
-	O
pVTZ	O
level	O
of	O	O
theory	O
.	O	O

The	O	O
12	O	O
lowest	O	O
-	O	O
energy	O	O
conformers	O
of	O	O
serine	B-CHEM
fall	O	O
within	O	O
a	O	O
8	O	O
kJ	O	O
mol	O	O
(	O	O
-	O	O
1	O	O
)	O	O
window	O	O
,	O	O
and	O	O
for	O	O
these	O	O
species	B-CHEM
,	O	O
geometric	O
structures	O
,	O	O
precise	O	O
relative	O	O
energies	O
,	O	O
equilibrium	O
and	O	O
vibrationally	O
averaged	O
rotational	O
constants	O
,	O	O
anharmonic	O
vibrational	O
frequencies	O
,	O	O
infrared	B-PHEN
intensities	I-PHEN
,	O	O
quartic	O
and	O	O
sextic	O
centrifugal	O
distortion	O
constants	O
,	O	O
dipole	O
moments	O
,	O	O
and	O	O
(	O
14	O
)	O
N	O
nuclear	O
quadrupole	O
coupling	O
constants	O
were	O	O
computed	O	O
.	O	O

The	O	O
relative	O	O
energies	O
were	O	O
refined	O	O
through	O	O
composite	B-PROC
focal	I-PROC
-	I-PROC
point	I-PROC
analyses	I-PROC
employing	O	O
basis	O	O
sets	O
as	O	O
large	O	O
as	O	O
aug	O
-	O
cc	O
-	O
pV5Z	O
and	O	O
correlation	B-PROC
treatments	I-PROC
through	O	O
CCSD	O
(	O
T	O
)	O
.	O	O

The	O	O
rotational	O
constants	O
for	O	O
seven	O	O
conformers	O
measured	O	O
by	O	O
Fourier	O
-	O
transform	O
microwave	O
spectroscopy	O
are	O	O
in	O	O
good	O	O
agreement	O	O
with	O	O
the	O	O
vibrationally	O
averaged	O
rotational	O
constants	O
computed	O	O
in	O	O
this	O	O
study	O	O
.	O	O

Our	O	O
anharmonic	O
vibrational	O
frequencies	O
are	O	O
compared	O	O
to	O	O
the	O	O
large	O	O
number	O	O
of	O	O
experimental	O	O
vibrational	B-PHEN
absorptions	I-PHEN
attributable	O	O
to	O	O
at	O	O
least	O	O
six	O	O
conformers	O
.	O	O

Interpretation	O
of	O	O
verbal	O
descriptors	O
for	O	O
response	B-PHYS
options	O
commonly	O	O
used	O	O
in	O	O
verbal	O
rating	O
scales	O
in	O	O
patient	B-LIVB
-reported	O	O
outcome	O	O
instruments	O	O
To	O	O
assess	B-PROC
the	O	O
variation	O
in	O	O
the	O	O
interpretation	O
of	O	O
common	O	O
verbal	O
descriptors	O
(	O	O
VDs	O
)	O	O
used	O	O
in	O	O
response	O
scales	O
and	O	O
examine	O
factors	O
associated	O
with	O	O
those	O	O
interpretations	O
.	O	O

Subjects	B-LIVB
were	O	O
recruited	O	O
through	O	O
MediGuard	O
and	O	O
they	O	O
assigned	O	O
interpretation	O
scores	O
(	O	O
11	O	O
-	O	O
point	O	O
scale	O	O
;	O	O
0	O	O
=	O	O
lowest	O	O
possible	O	O
,	O	O
10	O	O
=	O	O
highest	O	O
possible	O	O
)	O	O
to	O	O
five	O	O
common	O	O
sets	O	O
of	O	O
VDs	O
:	O	O
set	O	O
one	O	O
(	O	O
none	O
,	O	O
mild	O
,	O	O
moderate	O
,	O	O
severe	O
,	O	O
very	O
severe	O
)	O	O
;	O	O
set	O	O
two	O	O
(	O	O
never	O
,	O	O
rarely	O
,	O	O
sometimes	O
,	O	O
often	O
,	O	O
always	O
)	O	O
;	O	O
set	O	O
three	O	O
(	O	O
poor	O
,	O	O
fair	O
,	O	O
good	O
,	O	O
very	O
good	O
,	O	O
excellent	O
)	O	O
;	O	O
set	O	O
four	O	O
(	O	O
not	B-DISO
at	I-DISO
all	I-DISO
,	O	O
a	B-DISO
little	I-DISO
bit	I-DISO
,	O	O
moderately	O
,	O	O
quite	B-DISO
a	I-DISO
bit	I-DISO
,	O	O
extremely	O
)	O	O
;	O	O
and	O	O
set	O	O
five	O	O
(	O	O
not	B-DISO
at	I-DISO
all	I-DISO
,	O	O
a	B-DISO
little	I-DISO
bit	I-DISO
,	O	O
somewhat	B-DISO
,	O	O
quite	B-DISO
a	I-DISO
bit	I-DISO
,	O	O
very	O
much	O
)	O	O
.	O	O

One	O
-	O
sample	O
test	O
for	O	O
proportions	O
and	O	O
T	O
-	O
tests	O
examined	O	O
equality	O
of	O	O
proportions	O
(	O	O
anchors	B-LIVB
)	O	O
and	O	O
means	O
scores	O
(	O	O
non	B-LIVB
-	I-LIVB
anchors	I-LIVB
)	O	O
with	O	O
the	O	O
fixed	O	O
intervals	O
(	O	O
0	O	O
.	O	O
0	O	O
,	O	O
2	O	O
.	O	O
5	O	O
,	O	O
5	O	O
.	O	O
0	O	O
,	O	O
7	O	O
.	O	O
5	O	O
,	O	O
and	O	O
10	O	O
.	O	O
0	O	O
)	O	O
.	O	O

Ordinal	O
regression	O
examined	O	O
adjusted	O	O
associations	O
between	O	O
demographic	O
/	O	O
clinical	O
factors	O
and	O	O
VD	O
scores	O
.	O	O

Of	O	O
the	O	O
350	O	O
subjects	B-LIVB
,	O	O
68	O	O
%	O	O
were	O	O
females	B-PHYS
and	O	O
mean	O	O
(	O	O
SD	O
)	O	O
age	B-PHYS
was	O	O
56	O	O
.	O	O

9	O	O
(	O	O
12	O	O
.	O	O
1	O	O
)	O	O
.	O	O

Two	O	O
sets	O	O
had	O	O
two	O	O
VDs	O
with	O	O
mean	O	O
(	O	O
95	O	O
%	O	O
CI	O
)	O	O
scores	O
not	O	O
different	O	O
than	O	O
the	O	O
fixed	O	O
intervals	O
.	O	O

Set	O	O
one	O	O
had	O	O
mild	O
=	O	O
2	O	O
.	O	O

50	O	O
(	O	O
2	O	O
.	O	O
33	O	O
;	O	O
2	O	O
.	O	O
66	O	O
)	O	O
and	O	O
moderate	O
=	O	O
5	O	O
.	O	O
01	O	O
(	O	O
4	O	O
.	O	O
89	O	O
;	O	O
5	O	O
.	O	O
13	O	O
)	O	O
with	O	O
98	O	O
.	O	O
8	O	O
%	O	O
(	O	O
97	O	O
.	O	O
3	O	O
%	O	O
;	O	O
100	O	O
%	O	O
)	O	O
assigning	O	O
none	O	O
=	O	O
0	O	O
.	O	O

Set	O	O
five	O	O
had	O	O
a	B-DISO
little	I-DISO
bit	I-DISO
=	O	O
2	O	O
.	O	O

35	O	O
(	O	O
2	O	O
.	O	O
17	O	O
;	O	O
2	O	O
.	O	O
53	O	O
)	O	O
and	O	O
quite	B-DISO
a	I-DISO
bit	I-DISO
=	O	O
7	O	O
.	O	O
65	O	O
(	O	O
7	O	O
.	O	O
43	O	O
;	O	O
7	O	O
.	O	O
87	O	O
)	O	O
with	O	O
95	O	O
.	O	O

0	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
91	O	O
.	O	O
7	O	O
;	O	O
98	O	O
.	O	O
2	O	O
)	O	O
assigning	O	O
not	B-DISO
at	I-DISO
all	I-DISO
=	O	O
0	O	O
.	O	O

Significant	O	O
associations	O	O
(	O	O
p	O	O
≤	O	O
0	O	O
.	O	O
05	O	O
)	O	O
included	O	O
age	B-PHYS
and	O	O
education	B-DISO
with	O	O
somewhat	O	O
and	O	O
income	O
and	O	O
comorbidities	O
with	O	O
very	O	O
severe	O	O
.	O	O

Age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
and	O	O
education	B-DISO
showed	O	O
associations	O	O
with	O	O
other	O	O
VDs	O
albeit	O	O
in	O	O
nonsignificant	O
models	O
.	O	O

Sets	O	O
one	O	O
and	O	O
five	O	O
yielded	O	O
data	O
closest	O	O
to	O	O
the	O	O
fixed	O	O
intervals	O
.	O	O

Demographic	O
and	O	O
clinical	O
factors	O
are	O	O
associated	O
with	O	O
the	O	O
interpretation	O
of	O	O
some	O	O
VDs	O
and	O	O
should	O	O
be	O	O
adjusted	O
for	O	O
in	O	O
analyses	B-PROC
of	O	O
non	O
-	O
randomized	O
data	O
.	O	O

Glycolysis	B-PHYS
determines	O	O
dichotomous	O
regulation	O
of	O	O
T	B-ANAT
cell	I-ANAT
subsets	I-ANAT
in	O	O
hypoxia	B-DISO
Hypoxia	B-DISO
occurs	O
in	O	O
many	O	O
pathological	B-DISO
conditions	I-DISO
,	O	O
including	O	O
chronic	B-DISO
inflammation	I-DISO
and	O	O
tumors	B-DISO
,	O	O
and	O	O
is	O	O
considered	O
to	O	O
be	O	O
an	O	O
inhibitor	O
of	O	O
T	B-ANAT
cell	I-ANAT
function	B-PHYS
.	O	O

However	O	O
,	O	O
robust	O	O
T	B-ANAT
cell	I-ANAT
responses	B-PHYS
occur	O	O
at	O	O
many	O	O
hypoxic	B-DISO
inflammatory	O
sites	O
,	O	O
suggesting	O	O
that	O	O
functions	O
of	O	O
some	O	O
subsets	B-ANAT
are	O	O
stimulated	B-PHEN
under	O	O
low	B-DISO
oxygen	I-DISO
conditions	I-DISO
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O
how	O	O
hypoxic	B-DISO
conditions	O
influence	O
human	B-LIVB
T	B-ANAT
cell	I-ANAT
functions	B-PHYS
and	O	O
found	O	O
that	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
naive	B-ANAT
and	O	O
central	B-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O	O
TN	B-ANAT
and	O	O
TCM	B-ANAT
)	O	O
,	O	O
hypoxia	B-DISO
enhances	O
the	O	O
proliferation	B-PHYS
,	O	O
viability	B-PHYS
,	O	O
and	O	O
cytotoxic	O
action	O
of	O	O
effector	B-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O	O
TEM	B-ANAT
)	O	O
.	O	O

Enhanced	O
TEM	B-ANAT
expansion	B-PHYS
in	O	O
hypoxia	B-DISO
corresponded	O	O
to	O	O
high	O	O
hypoxia	O
-	O
inducible	O
factor	O
1α	O
(	O	O
HIF1α	O
)	O	O
expression	B-PHYS
and	O	O
glycolytic	B-PHYS
activity	O
compared	O
with	O	O
that	O	O
observed	O
in	O	O
TN	B-ANAT
and	O	O
TCM	B-ANAT
.	O	O

We	O	O
determined	O
that	O	O
the	O	O
glycolytic	B-PHYS
enzyme	B-CHEM
GAPDH	I-CHEM
negatively	O	O
regulates	O
HIF1A	O
expression	B-PHYS
by	O	O
binding	B-PHYS
to	I-PHYS
adenylate	I-PHYS
-	I-PHYS
uridylate	I-PHYS
-	I-PHYS
rich	I-PHYS
elements	I-PHYS
in	O	O
the	O	O
3	O
'	O
-	O
UTR	O
region	O
of	O	O
HIF1A	O
mRNA	O
in	O	O
glycolytically	B-PHYS
inactive	O
TN	B-ANAT
and	O	O
TCM	B-ANAT
.	O	O

Conversely	O	O
,	O	O
active	O
glycolysis	B-PHYS
with	O	O
decreased	O
GAPDH	B-CHEM
availability	O
in	O	O
TEM	B-ANAT
resulted	O
in	O
elevated	O	O
HIF1α	O
expression	B-PHYS
.	O	O

Furthermore	O	O
,	O	O
GAPDH	B-CHEM
overexpression	B-PHYS
reduced	O
HIF1α	O
expression	B-PHYS
and	O	O
impaired	O
proliferation	B-PHYS
and	O	O
survival	B-PHYS
of	O	O
T	B-ANAT
cells	I-ANAT
in	O	O
hypoxia	B-DISO
,	O	O
indicating	O	O
that	O	O
high	B-PHYS
glycolytic	I-PHYS
metabolism	B-PHYS
drives	O	O
increases	O
in	O	O
HIF1α	O
to	O	O
enhance	O
TEM	B-ANAT
function	B-PHYS
during	O	O
hypoxia	B-DISO
.	O	O

This	O	O
work	O	O
demonstrates	O	O
that	O	O
glycolytic	B-PHYS
metabolism	B-PHYS
regulates	O
the	O	O
translation	B-PHYS
of	O	O
HIF1A	O
to	O	O
determine	O	O
T	B-ANAT
cell	I-ANAT
responses	B-PHYS
to	O	O
hypoxia	B-DISO
and	O	O
implicates	O	O
GAPDH	B-CHEM
as	O	O
a	O	O
potential	O
mechanism	B-PHYS
for	O	O
controlling	O	O
T	B-ANAT
cell	I-ANAT
function	B-PHYS
in	O	O
peripheral	O
tissue	O
.	O	O

Nanocatalysts	B-PHEN
promote	O	O
Streptococcus	B-LIVB
mutans	I-LIVB
biofilm	O
matrix	O
degradation	O
and	O	O
enhance	O
bacterial	B-PHEN
killing	I-PHEN
to	O	O
suppress	O
dental	B-DISO
caries	I-DISO
in	O
vivo	O
Dental	O
biofilms	B-LIVB
(	O	O
known	O	O
as	O	O
plaque	B-DISO
)	O	O
are	O	O
notoriously	O
difficult	O
to	O	O
remove	O	O
or	O	O
treat	O
because	O	O
the	O	O
bacteria	B-LIVB
can	O	O
be	O	O
enmeshed	O	O
in	O	O
a	O	O
protective	O
extracellular	O
matrix	O
.	O	O

It	O	O
can	O	O
also	O	O
create	O	O
highly	O	O
acidic	O
microenvironments	O
that	O	O
cause	O	O
acid	O	O
-	O	O
dissolution	O	O
of	O	O
enamel	B-ANAT
-	O	O
apatite	B-CHEM
on	O	O
teeth	B-ANAT
,	O	O
leading	O	O
to	O	O
the	O	O
onset	O	O
of	O	O
dental	B-DISO
caries	I-DISO
.	O	O

Current	O	O
antimicrobial	B-CHEM
agents	I-CHEM
are	O	O
incapable	B-DISO
of	O	O
disrupting	O
the	O	O
matrix	O
and	O	O
thereby	O	O
fail	O	O
to	O	O
efficiently	O	O
kill	O
the	O	O
microbes	B-LIVB
within	O	O
plaque	B-DISO
-	O	O
biofilms	B-LIVB
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
novel	O	O
strategy	O	O
to	O	O
control	O	O
plaque	B-DISO
-	O	O
biofilms	B-LIVB
using	O	O
catalytic	B-PHEN
nanoparticles	I-PHEN
(	O	O
CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
)	O	O
with	O	O
peroxidase	B-CHEM
-like	O	O
activity	O	O
that	O	O
trigger	O	O
extracellular	O
matrix	O
degradation	O
and	O	O
cause	O	O
bacterial	B-DISO
death	I-DISO
within	O	O
acidic	O	O
niches	O	O
of	O	O
caries	B-DISO
-causing	O	O
biofilm	B-LIVB
.	O	O

CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
containing	O	O
biocompatible	B-CHEM
Fe3O4	B-CHEM
were	O	O
developed	O	O
to	O	O
catalyze	B-PHEN
H2O2	B-CHEM
to	O	O
generate	O	O
free	B-CHEM
-	I-CHEM
radicals	I-CHEM
in	O
situ	O
that	O	O
simultaneously	O	O
degrade	O
the	O	O
biofilm	O
matrix	O
and	O	O
rapidly	O	O
kill	O
the	O	O
embedded	B-LIVB
bacteria	I-LIVB
with	O	O
exceptional	O
efficacy	O
(	O	O
>	O	O
5	O	O
-	O	O
log	O	O
reduction	O	O
of	O	O
cell	B-PHYS
-	I-PHYS
viability	I-PHYS
)	O	O
.	O	O

Moreover	O	O
,	O	O
it	O	O
displays	O	O
an	O	O
additional	O	O
property	O	O
of	O	O
reducing	O	O
apatite	B-CHEM
demineralization	B-DISO
in	O	O
acidic	O
conditions	O
.	O	O

Using	O	O
1	O	O
-	O	O
min	O	O
topical	O	O
daily	O
treatments	O
akin	O	O
to	O	O
a	O	O
clinical	B-PHYS
situation	I-PHYS
,	O	O
we	O	O
demonstrate	O	O
that	O	O
CAT	B-PHEN
-	I-PHEN
NP	I-PHEN
in	O	O
combination	O	O
with	O	O
H2O2	B-CHEM
effectively	O	O
suppress	O
the	O	O
onset	O	O
and	O	O
severity	O
of	O	O
dental	B-DISO
caries	I-DISO
while	O	O
sparing	O	O
normal	O	O
tissues	O
in	O
vivo	O
.	O	O

Our	O	O
results	B-PHEN
reveal	O	O
the	O	O
potential	O
to	O	O
exploit	O	O
nanocatalysts	B-PHEN
with	O	O
enzyme	B-PHYS
-	I-PHYS
like	I-PHYS
activity	I-PHYS
as	O	O
a	O	O
potent	O	O
alternative	O	O
approach	O	O
for	O	O
treatment	B-PROC
of	O	O
a	O	O
prevalent	O	O
biofilm	B-LIVB
-associated	O	O
oral	B-DISO
disease	I-DISO
.	O	O

N	B-PHYS
-	I-PHYS
linked	I-PHYS
glycosylation	I-PHYS
of	O	O
SV2	B-CHEM
is	O	O
required	O	O
for	O	O
binding	B-PHYS
and	O	O
uptake	B-PHYS
of	O	O
botulinum	B-CHEM
neurotoxin	I-CHEM
A	I-CHEM
Botulinum	B-CHEM
neurotoxin	I-CHEM
serotype	I-CHEM
A1	I-CHEM
(	O	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
)	O	O
,	O	O
a	O	O
licensed	O
drug	B-CHEM
widely	O	O
used	O	O
for	O	O
medical	B-CHEM
and	O	O
cosmetic	B-OBJC
applications	I-OBJC
,	O	O
exerts	O	O
its	O	O
action	O	O
by	O	O
invading	O	O
motoneurons	B-ANAT
.	O	O

Here	O	O
we	O	O
report	O	O
a	O	O
2	O	O
.	O	O
0	O	O
-	O	O
Å	O	O
-	O	O
resolution	O	O
crystal	B-CHEM
structure	I-CHEM
of	O	O
the	O	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
receptor	I-CHEM
-	O	O
binding	O
domain	O
in	O	O
complex	B-CHEM
with	O	O
its	O	O
neuronal	B-ANAT
receptor	I-ANAT
,	O	O
glycosylated	B-PHYS
human	B-CHEM
SV2C	I-CHEM
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
neuronal	B-CHEM
tropism	B-PHYS
of	O	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
requires	O	O
recognition	B-PHYS
of	O	O
both	O	O
the	O	O
peptide	B-CHEM
moiety	I-CHEM
and	O	O
an	O	O
N	B-CHEM
-	I-CHEM
linked	I-CHEM
glycan	I-CHEM
on	O	O
SV2	B-CHEM
.	O	O

This	O	O
N	B-CHEM
-	I-CHEM
glycan	I-CHEM
-which	O	O
is	O	O
conserved	O	O
in	O	O
all	O	O
SV2	B-CHEM
isoforms	B-CHEM
across	O	O
vertebrates	B-LIVB
-is	O	O
essential	O	O
for	O	O
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
binding	B-PHYS
to	O	O
neurons	B-ANAT
and	O	O
for	O	O
its	O	O
potent	O	O
neurotoxicity	B-DISO
.	O	O

The	O	O
glycan	B-CHEM
-	O	O
binding	B-PHYS
interface	O	O
on	O	O
SV2	B-CHEM
is	O	O
targeted	O
by	O	O
a	O	O
human	B-LIVB
BoNT	B-CHEM
/	I-CHEM
A1	I-CHEM
-	O	O
neutralizing	B-CHEM
antibody	I-CHEM
currently	O	O
licensed	O
as	O	O
an	O	O
antibotulism	B-CHEM
drug	I-CHEM
.	O	O

Our	O	O
studies	O	O
reveal	O	O
a	O	O
new	O	O
paradigm	B-PROC
of	O	O
host	B-PHYS
-	I-PHYS
pathogen	I-PHYS
interactions	I-PHYS
,	O	O
in	O	O
which	O	O
pathogens	B-LIVB
exploit	O	O
conserved	O	O
host	B-LIVB
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
,	O	O
thereby	O	O
achieving	O	O
highly	O	O
specific	O	O
receptor	B-PHYS
binding	I-PHYS
while	O	O
also	O	O
tolerating	O	O
genetic	B-DISO
changes	I-DISO
across	O	O
multiple	O	O
isoforms	B-CHEM
of	O	O
receptors	B-CHEM
.	O	O

Accuracy	O
of	O	O
Currently	O	O
Used	O	O
Paper	B-OBJC
Burn	B-DISO
Diagram	O
vs	O	O
a	O	O
Three	O
-	O
Dimensional	O
Computerized	O
Model	O
Burn	B-OBJC
units	I-OBJC
have	O	O
historically	O	O
used	O	O
paper	B-OBJC
diagrams	O
to	O	O
estimate	O
percent	O
burn	B-DISO
;	O	O
however	O	O
,	O	O
unintentional	O
errors	O
can	O	O
occur	O	O
.	O	O

The	O	O
use	O	O
of	O	O
a	O	O
computer	B-OBJC
program	I-OBJC
that	O	O
incorporates	O	O
wound	B-DISO
mapping	O
from	O	O
photographs	B-OBJC
onto	O	O
a	O	O
three	O
-	O
dimensional	O
(	O	O
3D	O
)	O	O
human	B-LIVB
diagram	O
could	O	O
decrease	O
subjectivity	O
in	O	O
preparing	O	O
burn	B-DISO
diagrams	O
and	O	O
subsequent	O	O
calculations	O
of	O	O
TBSA	B-PHYS
burned	B-DISO
.	O	O

Analyses	B-PROC
were	O	O
done	O	O
on	O	O
19	O	O
burned	B-DISO
patients	B-LIVB
who	O	O
had	O	O
an	O	O
estimated	O
TBSA	B-PHYS
burned	B-DISO
of	O	O
≥20	O	O
%	O	O
.	O	O

The	O	O
patients	B-LIVB
were	O	O
admitted	B-PROC
to	O	O
Shriners	B-OBJC
Hospitals	I-OBJC
for	O	O
Children	B-LIVB
or	O	O
the	O	O
University	O
of	O
Texas	O
Medical	O
Branch	O
in	O	O
Galveston	B-GEOG
,	I-GEOG
Texas	I-GEOG
,	O	O
from	O	O
July	O
2012	O	O
to	O	O
September	O
2013	O	O
for	O	O
treatment	B-PROC
.	O	O

Digital	O
photographs	B-OBJC
were	O	O
collected	O
before	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
first	O
surgery	B-PROC
.	O	O

Using	O	O
BurnCase	O
3D	O
(	O	O
RISC	B-OBJC
Software	I-OBJC
GmbH	I-OBJC
,	O	O
Hagenberg	O
,	O	O
Austria	B-GEOG
)	O	O
,	O	O
a	O	O
burn	B-DISO
mapping	O
software	B-OBJC
,	O	O
the	O	O
user	B-LIVB
traced	O	O
partial	O
-	O
and	O	O
full	O
-	O
thickness	O
burns	B-DISO
from	O	O
photographs	B-OBJC
.	O	O

The	O	O
program	B-OBJC
then	O	O
superimposed	O
tracings	O
onto	O	O
a	O	O
3D	O
model	O
and	O	O
calculated	O
percent	O
burned	B-DISO
.	O	O

The	O	O
results	O
were	O	O
compared	O
with	O	O
the	O	O
Lund	O
and	O
Browder	O
diagrams	O
completed	O	O
after	O	O
the	O	O
first	O
operation	B-PROC
.	O	O

A	O	O
two	O
-	O
tailed	O
t	O
-	O
test	O
was	O	O
used	O	O
to	O	O
calculate	O
statistical	O
differences	O
.	O	O

For	O	O
partial	O
-	O
thickness	O
burns	B-DISO
,	O	O
burn	B-DISO
sizes	O
calculated	O
using	O	O
Lund	O
and	O
Browder	O
diagrams	O
were	O	O
significantly	O
larger	O
than	O	O
those	O	O
calculated	O
using	O	O
BurnCase	O
3D	O
(	O	O
15	O	O
%	O	O
difference	O
,	O	O
P	O	O
<	O	O
.01	O	O
)	O	O
.	O	O

The	O	O
opposite	O
was	O	O
found	O	O
for	O	O
full	O
-	O
thickness	O
burns	B-DISO
,	O	O
with	O	O
burn	B-DISO
sizes	O
being	O	O
smaller	O	O
when	O	O
calculated	O
using	O	O
Lund	O
and	O
Browder	O
diagrams	O
(	O	O
11	O	O
%	O	O
difference	O
,	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
substantial	O
differences	O
exist	O
in	O	O
percent	O
burn	B-DISO
estimations	B-PHYS
derived	O	O
from	O	O
BurnCase	O
3D	O
and	O	O
paper	B-OBJC
diagram	O
s	O	O
.	O	O

In	O	O
our	O	O
studied	B-LIVB
cohort	I-LIVB
,	O	O
paper	B-OBJC
diagram	O
s	O	O
were	O	O
associated	O
with	O
overestimation	B-PHYS
of	O	O
partial	O
-	O
thickness	O
burn	B-DISO
size	O
and	O	O
underestimation	B-PHYS
of	O	O
full	O
-	O
thickness	O
burn	B-DISO
size	O
.	O	O

Additional	O	O
studies	B-PROC
comparing	O	O
BurnCase	O
3D	O
with	O	O
other	O	O
commonly	O	O
used	O	O
methods	O
are	O	O
warranted	O	O
.	O	O

Field	O
Measurements	O
and	O	O
Numerical	O
Simulations	O
of	O	O
Temperature	O
and	O	O
Moisture	B-OBJC
in	O	O
Highway	O
Engineering	O
Using	O	O
a	O	O
Frequency	B-OBJC
Domain	I-OBJC
Reflectometry	I-OBJC
Sensor	I-OBJC
This	O	O
paper	O	O
presents	O	O
a	O	O
systematic	O
pioneering	B-PROC
study	I-PROC
on	O	O
the	O	O
use	O
of	O
agricultural	O
-	O	O
purpose	O
frequency	B-OBJC
domain	I-OBJC
reflectometry	I-OBJC
(	I-OBJC
FDR	I-OBJC
)	I-OBJC
sensors	I-OBJC
to	O	O
monitor	O
temperature	O
and	O	O
moisture	B-OBJC
of	O	O
a	O	O
subgrade	O	O
in	O	O
highway	O
extension	O
and	O	O
reconstruction	O
engineering	O
.	O	O

The	O	O
principle	O
of	O	O
agricultural	O
-	O	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
and	O	O
the	O	O
process	B-PHEN
for	O	O
embedding	B-PROC
this	O	O
kind	O	O
of	O	O
sensors	B-OBJC
for	O	O
subgrade	O	O
engineering	O
purposes	O
are	O	O
introduced	O	O
.	O	O

Based	O	O
on	O	O
field	O
measured	O
weather	B-PHEN
data	O
,	O	O
a	O	O
numerical	O
analysis	O
model	O
for	O	O
temperature	O
and	O	O
moisture	B-OBJC
content	O	O
in	O	O
the	O	O
subgrade	O	O
's	O	O
soil	B-OBJC
is	O	O
built	O	O
.	O	O

Comparisons	O
of	O	O
the	O	O
temperature	O
and	O	O
moisture	B-OBJC
data	O
obtained	O	O
from	O	O
numerical	O
simulation	O
and	O	O
FDR	B-OBJC
-based	O	O
measurements	O
are	O	O
conducted	O	O
.	O	O

The	O	O
results	O
show	O	O
that	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
embedding	B-PROC
method	I-PROC
and	O	O
process	B-PHEN
,	O	O
data	B-PHEN
acquisition	I-PHEN
,	O	O
and	O	O
remote	B-PHEN
transmission	I-PHEN
presented	O
are	O	O
reasonable	O	O
;	O	O
(	O	O
2	O	O
)	O	O
the	O	O
temperature	O
and	O	O
moisture	B-OBJC
changes	O
are	O	O
coordinated	O
with	O	O
the	O	O
atmospheric	O
environment	O
and	O	O
they	O	O
are	O	O
also	O	O
in	O	O
close	O	O
agreement	O	O
with	O	O
numerical	O
calculations	O
;	O	O
(	O	O
3	O	O
)	O	O
the	O	O
change	O
laws	O	O
of	O	O
both	O	O
are	O	O
consistent	O
at	O	O
positions	O
where	O	O
the	O	O
subgrade	O	O
is	O	O
compacted	B-DISO
uniformly	O
.	O	O

These	O	O
results	O
suggest	O
that	O	O
the	O	O
data	O
measured	O
by	O	O
the	O	O
agricultural	O
-	O	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
are	O	O
reliable	O	O
.	O	O

The	O	O
findings	B-DISO
of	O	O
this	O	O
paper	O	O
enable	O	O
a	O	O
new	O	O
and	O	O
effective	O
real	O
-	O
time	O
monitoring	O
method	O
for	O	O
a	O	O
subgrade	O	O
's	O	O
temperature	O
and	O	O
moisture	B-OBJC
changes	O
,	O	O
and	O	O
thus	O	O
broaden	O	O
the	O	O
application	O	O
of	O	O
agricultural	O
-	O	O
purpose	O
FDR	B-OBJC
sensors	I-OBJC
.	O	O

Effects	O
of	O
Cerium	B-CHEM
and	O	O
Titanium	B-CHEM
Oxide	I-CHEM
Nanoparticles	B-OBJC
in	O	O
Soil	B-OBJC
on	O	O
the	O	O
Nutrient	B-OBJC
Composition	B-PHYS
of	O	O
Barley	B-LIVB
(	O	O
Hordeum	B-LIVB
vulgare	I-LIVB
L	I-LIVB
.	O	O
)	O	O
Kernels	B-OBJC
The	O	O
implications	O
of	O	O
metal	B-OBJC
nanoparticles	I-OBJC
(	O	O
MeNPs	B-OBJC
)	I-OBJC
are	O	O
still	O	O
unknown	O
for	O	O
many	O
food	B-LIVB
crops	I-LIVB
.	O	O

The	O	O
purpose	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O
of	O
cerium	B-CHEM
oxide	I-CHEM
(	O	O
nCeO₂	B-CHEM
)	O	O
and	O	O
titanium	B-CHEM
oxide	I-CHEM
(	O	O
nTiO₂	B-CHEM
)	O	O
nanoparticles	B-OBJC
in	O	O
soil	B-OBJC
at	O	O
0	O	O
,	O	O
500	O	O
and	O	O
1000	O	O
mg·kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
on	O	O
the	O	O
nutritional	O
parameters	O
of	O	O
barley	B-LIVB
(	O	O
Hordeum	B-LIVB
vulgare	I-LIVB
L	I-LIVB
.	I-LIVB

)	O	O
kernels	B-OBJC
.	O	O

Mineral	B-CHEM
nutrients	I-CHEM
,	O	O
amylose	B-CHEM
,	O	O
β	B-CHEM
-	I-CHEM
glucans	I-CHEM
,	O	O
amino	B-CHEM
acid	I-CHEM
and	O	O
crude	B-CHEM
protein	I-CHEM
(	O	O
CP	B-CHEM
)	O	O
concentrations	O
were	O
measured	O
in	O	O
kernels	B-OBJC
.	O	O

Whole	O
flour	B-OBJC
samples	O	O
were	O	O
analyzed	O	O
by	O	O
ICP	B-PROC
-	I-PROC
AES	I-PROC
/	I-PROC
MS	I-PROC
,	O	O
HPLC	B-PROC
and	O	O
Elemental	B-OBJC
CHNS	I-OBJC
Analyzer	I-OBJC
.	O	O

Results	O	O
showed	O	O
that	O	O
Ce	B-CHEM
and	O	O
Ti	B-CHEM
accumulation	B-DISO
under	O	O
MeNPs	B-OBJC
treatments	O
did	O	O
not	O	O
differ	O	O
from	O	O
the	O	O
control	O
treatment	O
.	O	O

However	O	O
,	O	O
nCeO₂	B-CHEM
and	O	O
nTiO₂	B-CHEM
had	O	O
an	O	O
impact	O
on	O	O
composition	B-PHYS
and	O	O
nutritional	O
quality	O
of	O	O
barley	B-LIVB
kernels	B-OBJC
in	O	O
contrasting	O
ways	O
.	O	O

Both	O	O
MeNPs	B-OBJC
left	O	O
β	B-CHEM
-	I-CHEM
glucans	I-CHEM
unaffected	O
but	O	O
reduced	O	O
amylose	B-CHEM
content	O	O
by	O	O
approximately	O	O
21	O	O
%	O	O
.	O	O

Most	O	O
amino	B-CHEM
acids	I-CHEM
and	O	O
CP	B-CHEM
increased	O
.	O	O

Among	O	O
amino	B-CHEM
acids	I-CHEM
,	O	O
lysine	B-CHEM
followed	O	O
by	O	O
proline	B-CHEM
saw	O	O
the	O	O
largest	O
increase	O
(	O	O
51	O	O
%	O	O
and	O	O
37	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Potassium	B-CHEM
and	O	O
S	B-CHEM
were	O	O
both	O	O
negatively	O
impacted	O
by	O	O
MeNPs	B-OBJC
,	O	O
while	O	O
B	O	O
was	O	O
only	O	O
affected	O
by	O	O
500	O	O
mg	O	O
nCeO₂	B-CHEM
·	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
Zn	B-PROC
and	O	O
Mn	B-PROC
concentrations	I-PROC
were	O	O
improved	O	O
by	O	O
500	O	O
mg	O	O
nTiO₂	B-CHEM
·	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
and	O	O
Ca	O	O
by	O	O
both	O	O
nTiO₂	B-CHEM
treatments	O
.	O	O

Generally	O	O
,	O	O
our	O	O
findings	O	O
demonstrated	O
that	O	O
kernels	B-OBJC
are	O	O
negatively	B-DISO
affected	I-DISO
by	O	O
nCeO₂	B-CHEM
while	O	O
nTiO₂	B-CHEM
can	O	O
potentially	O	O
have	O	O
beneficial	O
effects	O
.	O	O

However	O	O
,	O	O
both	O	O
MeNPs	B-OBJC
have	O	O
the	O	O
potential	O	O
to	O	O
negatively	O
impact	O
malt	B-OBJC
and	O	O
feed	O
production	O
.	O	O

Smart	B-CHEM
Thin	I-CHEM
Hydrogel	I-CHEM
Coatings	I-CHEM
Harnessing	O	O
Hydrophobicity	O
and	O	O
Topography	O
to	O	O
Capture	O
and	O	O
Release	O
Cancer	B-ANAT
Cells	I-ANAT
Smart	B-CHEM
thin	I-CHEM
hydrogel	I-CHEM
coatings	I-CHEM
are	O	O
fabricated	O	O
to	O	O
capture	O
and	O	O
release	O
targeted	O
cancer	B-ANAT
cells	I-ANAT
by	O	O
simultaneously	O
tuning	O	O
surface	O
hydrophobicity	O
and	O	O
topography	O
.	O	O

At	O	O
physiological	B-PHYS
temperature	I-PHYS
,	O	O
the	O	O
targeted	O
cancer	B-ANAT
cells	I-ANAT
are	O	O
capture	O
d	O	O
on	O	O
the	O	O
hydrophobic	B-PHEN
and	O	O
wrinkled	O
coating	O
surface	O
.	O	O

At	O	O
room	O
temperature	O
,	O	O
the	O	O
captured	O
cells	B-ANAT
are	O	O
released	O
from	O	O
the	O	O
hydrophilic	O
and	O	O
smooth	O
coating	O
surface	O
.	O	O

Parametric	B-PROC
Surface	I-PROC
Diffeomorphometry	I-PROC
for	O	O
Low	B-PROC
Dimensional	I-PROC
Embeddings	I-PROC
of	O	O
Dense	O
Segmentations	O
and	O	O
Imagery	B-PHYS
In	O	O
the	O	O
field	O	O
of	O	O
Computational	B-PROC
Anatomy	I-PROC
,	O	O
biological	O
form	O
(	O	O
including	O	O
our	O	O
focus	O	O
,	O	O
neuroanatomy	O
)	O	O
is	O	O
studied	B-PROC
quantitatively	O
through	O	O
the	O	O
action	O
of	O	O
the	O	O
diffeomorphism	O
group	O
on	O	O
example	O	O
anatomies	B-ANAT
-	O	O
a	O	O
technique	O
called	O	O
diffeomorphometry	B-PROC
.	O	O

Here	O	O
we	O	O
design	O
an	O	O
algorithm	O
within	O	O
this	O	O
framework	O	O
to	O	O
pass	O	O
from	O	O
dense	O
objects	O	O
common	O	O
in	O	O
neuromaging	B-PROC
studies	B-PROC
(	O	O
binary	O
segmentations	O
,	O	O
structural	O
images	O
)	O	O
to	O	O
a	O	O
sparse	O
representation	O
defined	O	O
on	O	O
the	O	O
surface	O
boundaries	O
of	O	O
anatomical	B-ANAT
structures	I-ANAT
,	O	O
and	O	O
embedded	B-PROC
into	O	O
the	O	O
low	O
dimensional	O
coordinates	O
of	O	O
a	O	O
parametric	O
model	O
.	O	O

Our	O	O
main	O	O
new	O	O
contribution	O	O
is	O	O
to	O	O
introduce	O	O
an	O	O
expanded	O
group	O
action	O
to	O	O
simultaneously	O	O
deform	O
surfaces	O
through	O	O
direct	O
mapping	O
of	O
points	O
,	O	O
as	O	O
well	O	O
as	O	O
images	O
through	O	O
functional	O
composition	B-PHYS
with	O	O
the	O	O
inverse	O
.	O	O

This	O	O
allows	O	O
us	O	O
to	O	O
index	O	O
the	O	O
diffeomorphisms	O
with	O	O
respect	O	O
to	O	O
two	O
-	O
dimensional	O
surface	O
geometries	O	O
like	O	O
subcortical	B-ANAT
gray	I-ANAT
matter	I-ANAT
structures	I-ANAT
,	O	O
but	O	O
explicitly	O	O
map	O	O
onto	O	O
cost	O	O
functions	O	O
determined	O	O
by	O	O
noisy	B-DISO
3	I-DISO
-	I-DISO
dimensional	I-DISO
measurements	I-DISO
.	O	O

We	O	O
consider	O	O
models	B-DEVI
generated	O	O
from	O	O
empirical	O
covariance	O
of	O	O
training	O
data	O
,	O	O
as	O	O
well	O	O
as	O	O
bandlimited	B-DEVI
(	I-DEVI
Laplace	I-DEVI
-	I-DEVI
Beltrami	I-DEVI
eigenfunction	I-DEVI
)	I-DEVI
models	I-DEVI
when	O	O
no	O	O
such	O	O
data	O
is	O	O
available	O	O
.	O	O

We	O	O
show	O	O
applications	O	O
to	O	O
noisy	O
or	O	O
anomalous	B-DISO
segmentations	O
,	O	O
and	O	O
other	O	O
typical	O	O
problems	O	O
in	O	O
neuroimaging	B-PROC
studies	B-PROC
.	O	O

We	O	O
reproduce	O	O
statistical	O
results	O
detecting	O	O
changes	O	O
in	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
,	O	O
despite	O	O
dimensionality	O
reduction	O
.	O	O

Lastly	O	O
we	O	O
apply	O	O
our	O	O
algorithm	O
to	O	O
the	O	O
common	O	O
problem	O	O
of	O	O
segmenting	O
subcortical	B-ANAT
structures	I-ANAT
from	O	O
T1	B-PROC
MR	I-PROC
images	I-PROC
.	O	O

Fathers	O
'	O
Roles	O
in	O	O
the	O	O
Care	O
and	O	O
Development	B-PHYS
of	O	O
Their	O	O
Children	B-LIVB
:	O	O
The	O	O
Role	O
of	O
Pediatricians	O
Fathers	B-LIVB
'	I-LIVB
involvement	O
in	O	O
and	O	O
influence	O
on	O	O
the	O	O
health	O
and	O	O
development	B-PHYS
of	O	O
their	O	O
children	B-LIVB
have	O	O
increased	O
in	O	O
a	O	O
myriad	O
of	O	O
ways	O	O
in	O	O
the	O	O
past	O	O
10	O	O
years	O
and	O	O
have	O	O
been	O	O
widely	O	O
studied	B-PROC
.	O	O

The	O	O
role	O
of	O
pediatricians	O
in	O	O
working	O	O
with	O	O
fathers	B-LIVB
has	O	O
correspondingly	O	O
increased	O
in	O	O
importance	O
.	O	O

This	O	O
report	O
reviews	O
new	O	O
studies	B-PROC
of	O	O
the	O	O
epidemiology	B-PROC
of	O	O
father	B-LIVB
involvement	O
,	O	O
including	O	O
nonresidential	B-DISO
as	O	O
well	O	O
as	O	O
residential	B-DISO
fathers	I-DISO
.	O	O

The	O	O
effects	O
of	O	O
father	B-LIVB
involvement	O
on	O	O
child	B-PHYS
outcomes	I-PHYS
are	O	O
discussed	O	O
within	O	O
each	O	O
phase	O	O
of	O	O
a	O	O
child	B-PHYS
's	I-PHYS
development	I-PHYS
.	O	O

Particular	O	O
emphasis	O	O
is	O	O
placed	O	O
on	O	O
(	O	O
1	O	O
)	O	O
fathers	B-LIVB
'	I-LIVB
involvement	O
across	O	O
childhood	O
ages	B-PHYS
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
influence	O
of	O	O
fathers	B-LIVB
'	I-LIVB
physical	B-DISO
and	O	O
mental	B-PHYS
health	I-PHYS
on	O	O
their	O	O
children	B-LIVB
.	O	O

Implications	O
and	O	O
advice	B-PROC
for	O	O
all	O	O
child	B-LIVB
health	B-LIVB
providers	I-LIVB
to	O	O
encourage	O	O
and	O	O
support	O	O
father	B-LIVB
involvement	O
are	O	O
outlined	O	O
.	O	O

Prediction	O
of	O	O
Clinically	B-DISO
Significant	I-DISO
Bleeding	I-DISO
Following	O	O
Wide	B-PROC
-	I-PROC
Field	I-PROC
Endoscopic	I-PROC
Resection	I-PROC
of	O	O
Large	O
Sessile	O
and	O	O
Laterally	O
Spreading	O
Colorectal	B-DISO
Lesions	I-DISO
:	O	O
A	O	O
Clinical	O
Risk	O
Score	O
Clinically	B-DISO
significant	I-DISO
bleeding	I-DISO
(	O	O
CSPEB	B-DISO
)	O	O
is	O	O
the	O	O
most	O	O
frequent	O
adverse	B-DISO
event	I-DISO
following	O	O
wide	B-PROC
-	I-PROC
field	I-PROC
endoscopic	I-PROC
mucosal	I-PROC
resection	I-PROC
(	O	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
)	O	O
of	O	O
large	O
sessile	O
and	O	O
laterally	O
spreading	O
colorectal	B-DISO
lesions	I-DISO
(	O	O
LSL	B-DISO
)	O	O
.	O	O

There	O	O
is	O	O
limited	O	O
knowledge	O	O
regarding	O	O
accurate	O
prediction	O
of	O	O
CSPEB	B-DISO
.	O	O

We	O	O
aimed	O	O
to	O	O
derive	O	O
a	O	O
score	O
to	O	O
predict	O	O
the	O	O
risk	O
of	O	O
CSPEB	B-DISO
.	O	O

Data	O
on	O	O
patient	B-LIVB
and	O	O
lesion	B-DISO
characteristics	O
and	O	O
outcomes	O
from	O	O
WF	B-PROC
-	I-PROC
EMRs	I-PROC
of	O	O
LSL	B-DISO
≥20	O	O
mm	O	O
at	O	O
8	O	O
referral	B-OBJC
hospitals	I-OBJC
were	O	O
analyzed	B-PROC
.	O	O

The	O	O
cohort	B-LIVB
was	O	O
divided	O	O
at	O	O
random	O
into	O	O
equal	O
sized	O
training	O
and	O
test	O
groups	O
.	O	O

Independent	O
predictors	O
of	O	O
CSPEB	B-DISO
in	O	O
the	O	O
training	B-LIVB
cohort	I-LIVB
were	O	O
identified	O
by	O	O
multiple	O
logistic	O
regression	O
analysis	O
and	O	O
used	O	O
to	O	O
develop	O	O
a	O	O
risk	O
score	O
.	O	O

The	O	O
performance	O	O
of	O	O
this	O	O
score	O
was	O	O
assessed	O
in	O	O
the	O	O
independent	O
test	B-LIVB
cohort	I-LIVB
.	O	O

Over	O	O
80	O	O
months	O
to	O	O
June	O
2015	O	O
,	O	O
2	O	O
,	O	O
128	O	O
patients	B-LIVB
with	O	O
2	O	O
,	O	O
424	O	O
LSL	B-DISO
were	O	O
referred	O	O
for	O	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
.	O	O

Two	O	O
thousand	O	O
and	O	O
twelve	O	O
patients	B-LIVB
were	O	O
eligible	O	O
for	O	O
analysis	B-PROC
.	O	O

There	O	O
were	O	O
135	O	O
cases	O
of	O	O
CSPEB	B-DISO
(	O	O
6	O	O
.	O	O
7	O	O
%	O	O
)	O	O
.	O	O

In	O	O
the	O	O
training	B-LIVB
cohort	I-LIVB
of	O	O
1	O	O
,	O	O
006	O	O
patients	B-LIVB
,	O	O
the	O	O
independent	O
predictors	O
of	O	O
CSPEB	B-DISO
were	O	O
lesion	O
size	O
>	O	O
30	O	O
mm	O	O
(	O	O
odds	O
ratio	O
(	O	O
OR	O
)	O	O
2	O	O
.	O	O
5	O	O
)	O	O
,	O	O
proximal	O
colonic	O
location	O
(	O	O
OR	O
2	O	O
.	O	O
3	O	O
)	O	O
,	O	O
presence	O
of	O	O
a	O	O
major	O
comorbidity	O
(	O	O
OR	O
1	O	O
.	O	O
5	O	O
)	O	O
,	O	O
and	O	O
epinephrine	B-CHEM
in	O	O
injection	B-CHEM
solution	I-CHEM
(	O	O
OR	O
0	O	O
.	O	O
57	O	O
)	O	O
.	O	O

The	O	O
derived	O	O
risk	O
score	O
comprised	O	O
lesion	O
size	O
>	O	O
30	O	O
mm	O	O
(	O	O
2	O	O
points	O	O
)	O	O
,	O	O
proximal	O
colon	B-ANAT
(	O	O
2	O	O
points	O	O
)	O	O
,	O	O
presence	O
of	O	O
major	O
comorbidity	O
(	O	O
1	O	O
point	O	O
)	O	O
,	O	O
and	O	O
absence	O
of	O	O
epinephrine	B-CHEM
use	O
(	O	O
1	O	O
point	O	O
)	O	O
.	O	O

The	O	O
probabilities	O
of	O	O
CSPEB	B-DISO
for	O	O
scores	O
of	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
4	O	O
,	O	O
and	O	O
≥5	O	O
in	O	O
the	O	O
training	B-LIVB
cohort	I-LIVB
were	O	O
1	O	O
.	O	O
5	O	O
,	O	O
2	O	O
.	O	O
0	O	O
,	O	O
5	O	O
.	O	O
6	O	O
,	O	O
7	O	O
.	O	O
8	O	O
,	O	O
9	O	O
.	O	O
1	O	O
,	O	O
and	O	O
17	O	O
.	O	O

5	O	O
%	O	O
and	O	O
were	O	O
0	O	O
.	O	O
9	O	O
,	O	O
6	O	O
.	O	O
7	O	O
,	O	O
4	O	O
.	O	O
9	O	O
,	O	O
6	O	O
.	O	O
2	O	O
,	O	O
9	O	O
.	O	O
0	O	O
,	O	O
and	O	O
15	O	O
.	O	O
7	O	O
%	O	O
in	O	O
the	O	O
test	B-LIVB
cohort	I-LIVB
.	O	O

The	O	O
probabilities	O
of	O	O
CSPEB	B-DISO
in	O	O
those	O	O
with	O	O
low	O
(	O	O
score	O
0	O	O
-	O	O
1	O	O
)	O	O
,	O	O
medium	O
(	O	O
score	O
2	O	O
-	O	O
4	O	O
)	O	O
,	O	O
and	O	O
elevated	O
(	O	O
score	O
5	O	O
-	O	O
6	O	O
)	O	O
risk	B-DISO
levels	I-DISO
were	O	O
1	O	O
.	O	O
7	O	O
,	O	O
7	O	O
.	O	O
1	O	O
,	O	O
and	O	O
17	O	O
.	O	O

5	O	O
%	O	O
in	O	O
the	O	O
training	B-LIVB
cohort	I-LIVB
and	O	O
3	O	O
.	O	O
4	O	O
,	O	O
6	O	O
.	O	O
2	O	O
,	O	O
and	O	O
15	O	O
.	O	O

7	O	O
%	O	O
in	O	O
the	O	O
cohort	B-LIVB
.	O	O

Patients	B-LIVB
at	O	O
elevated	O
risk	O
of	O	O
CSPEB	B-DISO
can	O	O
be	O	O
identified	O
using	O	O
four	O	O
readily	O	O
available	O	O
variables	O
.	O	O

This	O	O
knowledge	O	O
may	O	O
improve	O	O
the	O	O
management	B-PROC
of	O	O
those	O	O
undergoing	O	O
WF	B-PROC
-	I-PROC
EMR	I-PROC
and	O	O
assist	O	O
in	O	O
designing	B-PROC
studies	I-PROC
evaluating	B-PROC
CSPEB	B-DISO
.	O	O

A	O	O
case	O
of	O	O
bilateral	O
pneumothoraces	B-DISO
resulting	O	O
from	O	O
tracheostomy	B-PROC
for	O	O
advanced	O
laryngeal	B-DISO
cancer	I-DISO
Pneumothorax	B-DISO
is	O	O
a	O	O
possible	O	O
complication	B-DISO
of	O	O
tracheostomy	B-PROC
.	O	O

We	O	O
report	B-PROC
a	O	O
rare	O	O
case	O	O
of	O	O
bilateral	O
pneumothoraces	B-DISO
resulting	O	O
from	O	O
tracheostomy	B-PROC
in	O	O
an	O	O
advanced	O
laryngeal	B-DISO
cancer	I-DISO
patient	B-LIVB
.	O	O

A	O	O
59	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	B-PHYS
was	O	O
referred	O	O
to	O	O
our	O	O
clinic	B-OBJC
for	O	O
evaluation	B-PROC
and	O	O
treatment	B-PROC
of	O	O
laryngeal	B-DISO
tumor	I-DISO
.	O	O

Laryngeal	B-PROC
endoscopy	I-PROC
showed	O	O
limited	B-DISO
movement	I-DISO
of	O	O
bilateral	B-ANAT
vocal	I-ANAT
cords	I-ANAT
,	O	O
and	O	O
computed	B-PROC
tomography	I-PROC
revealed	O	O
a	O	O
tumor	B-DISO
lesion	B-DISO
extending	O	O
from	O	O
the	O	O
vocal	B-ANAT
cords	I-ANAT
to	O	O
the	O	O
subglottic	B-ANAT
area	I-ANAT
.	O	O

Three	O	O
days	O
after	O	O
the	O	O
first	B-DISO
visit	I-DISO
,	O	O
the	O	O
patient	B-LIVB
developed	O	O
respiratory	B-DISO
difficulty	I-DISO
,	O	O
and	O	O
we	O	O
elected	O	O
to	O	O
perform	O	O
emergency	B-PROC
tracheostomy	I-PROC
for	O	O
airway	B-PROC
management	I-PROC
.	O	O

Immediately	O	O
after	O	O
the	O	O
start	O	O
of	O	O
the	O	O
procedure	B-PROC
,	O	O
he	O	O
began	O	O
hyperventilating	B-DISO
,	O	O
and	O	O
complained	O	O
of	O	O
respiratory	B-DISO
discomfort	I-DISO
and	O	O
chest	B-DISO
pain	I-DISO
.	O	O

We	O	O
then	O	O
recognized	O	O
a	O	O
mediastinal	B-ANAT
air	B-DISO
leak	I-DISO
,	O	O
and	O	O
we	O	O
suspected	O
pneumothorax	B-DISO
resulting	O	O
from	O	O
the	O	O
tracheostomy	B-PROC
.	O	O

Chest	B-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
showed	O	O
bilateral	O
pneumothoraces	B-DISO
;	O	O
therefore	O	O
,	O	O
we	O	O
inserted	B-PROC
bilateral	O
chest	B-ANAT
drainage	B-DEVI
tubes	I-DEVI
,	O	O
which	O	O
stabilized	B-DISO
his	O	O
respiratory	B-DISO
condition	I-DISO
.	O	O

We	O	O
speculated	O	O
that	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
the	O	O
bilateral	O
pneumothoraces	B-DISO
was	O	O
weakened	O
alveolar	B-ANAT
walls	I-ANAT
secondary	O	O
to	O	O
long	O
-	O
term	O
smoking	O
,	O	O
and	O	O
a	O	O
significant	O	O
rise	O
in	O	O
airway	B-PHYS
pressure	I-PHYS
because	O	O
of	O	O
airway	B-DISO
constriction	I-DISO
by	O	O
the	O	O
neck	O
-	O
extended	O
position	O
and	O	O
hyperventilation	B-DISO
,	O	O
during	O	O
tracheostomy	B-PROC
.	O	O

Therapeutic	O
Review	O
of	O	O
Methylprednisolone	B-CHEM
Acetate	I-CHEM
Intra	I-CHEM
-	I-CHEM
Articular	I-CHEM
Injection	I-CHEM
in	O	O
the	O	O
Management	B-PROC
of	O	O
Osteoarthritis	B-DISO
of	I-DISO
the	I-DISO
Knee	I-DISO
-	O	O
Part	O	O
1	O	O
:	O	O
Clinical	O
Effectiveness	O
Intra	B-PROC
-	I-PROC
articular	I-PROC
(	I-PROC
IA	I-PROC
)	I-PROC
corticosteroid	I-PROC
injections	I-PROC
are	O	O
a	O	O
common	O	O
approach	O
in	O	O
the	O	O
management	B-PROC
of	O	O
osteoarthritis	B-DISO
(	I-DISO
OA	I-DISO
)	I-DISO
of	I-DISO
the	I-DISO
knee	I-DISO
.	O	O

The	O	O
effectiveness	O
of	O	O
injections	B-CHEM
and	O	O
particular	O	O
injection	B-CHEM
products	B-OBJC
is	O	O
often	O	O
discussed	O	O
and	O	O
debated	O	O
in	O	O
clinical	B-PHYS
arenas	I-PHYS
.	O	O

The	O	O
following	O	O
therapeutic	O
review	O
examines	O	O
the	O	O
evidence	O
for	O	O
intra	O
-	O
articular	O
methylprednisolone	B-CHEM
acetate	I-CHEM
(	I-CHEM
MPA	I-CHEM
)	I-CHEM
injections	I-CHEM
in	O	O
the	O	O
management	B-PROC
of	O	O
OA	B-DISO
knee	I-DISO
.	O	O

A	O	O
review	O
of	O	O
research	O	O
evidence	O
,	O	O
published	O
guidelines	O
and	O	O
clinical	O
literature	O
was	O	O
undertaken	O	O
following	O	O
an	O	O
electronic	O
database	O
and	O	O
relevant	O
literature	O
search	O
.	O	O

The	O	O
review	O
found	O	O
that	O	O
there	O	O
is	O	O
limited	O	O
evidence	O
which	O	O
indicates	O	O
that	O	O
a	O	O
single	O
dose	O
intra	O
-	O
articular	O
MPA	B-CHEM
injection	I-CHEM
can	O	O
provide	O	O
short	O	O
to	O	O
medium	O	O
term	O	O
benefits	O
for	O	O
pain	B-DISO
,	O	O
with	O	O
less	O	O
evidence	O
for	O	O
beneficial	O
effects	O
on	O	O
function	B-PHYS
or	O	O
stiffness	B-DISO
.	O	O

There	O	O
is	O	O
heterogeneity	O
across	O	O
studies	O	O
and	O	O
until	O	O
recently	O	O
,	O	O
most	O	O
studies	O	O
had	O	O
only	O	O
short	O	O
to	O	O
medium	O	O
term	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
periods	I-PROC
,	O	O
thus	O	O
limiting	O	O
the	O	O
evidence	O
available	O	O
on	O	O
longer	O	O
term	O	O
benefit	O
.	O	O

There	O	O
was	O	O
also	O	O
evidence	O
indicating	O	O
equivalent	O	O
overall	O	O
efficacy	O
of	O	O
MPA	B-CHEM
to	O	O
that	O	O
of	O	O
other	O	O
corticosteroid	B-CHEM
products	I-CHEM
.	O	O

Most	O	O
guideline	O
recommendations	O
concerning	O	O
IA	B-PROC
injections	I-PROC
for	O	O
OA	B-DISO
knee	I-DISO
have	O	O
drawn	O	O
on	O	O
evidence	O
from	O	O
pooled	O	O
data	O	O
for	O	O
several	O	O
corticosteroid	B-CHEM
products	I-CHEM
.	O	O

The	O	O
review	O
also	O	O
found	O	O
there	O	O
was	O	O
limited	O	O
reporting	O	O
of	O	O
the	O	O
incidence	O
of	O	O
adverse	B-DISO
events	I-DISO
in	O	O
most	O	O
studies	O	O
.	O	O

Overall	O	O
,	O	O
MPA	B-CHEM
shows	O	O
efficacy	O
for	O	O
symptom	B-DISO
relief	B-PROC
in	O	O
OA	B-DISO
knee	I-DISO
.	O	O

At	O	O
an	O	O
individual	B-LIVB
management	B-PROC
level	O
,	O	O
evidence	O
for	O	O
a	O	O
limited	O	O
duration	O	O
of	O	O
effect	O	O
needs	O	O
consideration	O	O
in	O	O
injections	B-CHEM
decisions	O	O
.	O	O

Furthermore	O	O
,	O	O
consensus	O	O
across	O	O
clinical	O
guidelines	O
suggests	O	O
that	O	O
the	O	O
management	B-PROC
of	O	O
OA	B-DISO
knee	I-DISO
should	O	O
be	O	O
individualized	O
to	O	O
a	O	O
person	B-LIVB
'	O	O
s	O	O
clinical	B-PHYS
history	I-PHYS
,	O	O
degree	O
of	O	O
disability	B-DISO
,	O	O
risk	B-DISO
factors	I-DISO
,	O	O
quality	O
of	O
life	O
and	O	O
personal	B-DISO
preferences	I-DISO
,	O	O
whereby	O	O
injecting	O	O
involves	O	O
a	O	O
shared	O	O
decision	O	O
and	O	O
forms	O	O
part	O	O
of	O	O
a	O	O
multimodal	B-PROC
approach	I-PROC
.	O	O

Copyright	O	O
©	O	O
2016	O	O
John	O	O
Wiley	O	O
&	O	O
Sons	O	O
Ltd	O	O
.	O	O

Arsenic	B-CHEM
Triglutathione	I-CHEM
[	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
]	O	O
Transport	B-PHYS
by	O	O
Multidrug	B-CHEM
Resistance	I-CHEM
Protein	I-CHEM
1	I-CHEM
(	O	O
MRP1	B-CHEM
/	O	O
ABCC1	B-CHEM
)	O	O
Is	O	O
Selectively	O	O
Modified	O
by	O	O
Phosphorylation	B-PHYS
of	O	O
Tyr920	O
/	O
Ser921	O
and	O	O
Glycosylation	B-PHYS
of	O	O
Asn19	O
/	O
Asn23	O
The	O	O
ATP	B-CHEM
-	I-CHEM
binding	I-CHEM
cassette	I-CHEM
(	I-CHEM
ABC	I-CHEM
)	I-CHEM
transporter	I-CHEM
multidrug	B-CHEM
resistance	I-CHEM
protein	I-CHEM
1	I-CHEM
(	O	O
MRP1	B-CHEM
/	O	O
ABCC1	B-CHEM
)	O	O
is	O	O
responsible	O	O
for	O	O
the	O	O
cellular	B-ANAT
export	B-PHEN
of	O	O
a	O	O
chemically	O	O
diverse	O
array	O
of	O	O
xenobiotics	B-CHEM
and	O	O
endogenous	O
compounds	B-OBJC
.	O	O

Arsenic	B-CHEM
,	O	O
a	O	O
human	B-LIVB
carcinogen	B-CHEM
,	O	O
is	O	O
a	O	O
high	O
-	O
affinity	O
MRP1	B-CHEM
substrate	B-OBJC
as	O	O
arsenic	B-CHEM
triglutathione	I-CHEM
[	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
]	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
marked	O	O
differences	O	O
in	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
kinetics	O
were	O	O
observed	O	O
between	O	O
MRP1	B-CHEM
-enriched	O	O
membrane	B-ANAT
vesicles	B-ANAT
prepared	O
from	O	O
human	B-LIVB
embryonic	B-ANAT
kidney	B-ANAT
293	B-ANAT
(	I-ANAT
HEK	I-ANAT
)	I-ANAT
(	O	O
Km	O
3	O	O
.	O	O
8	O	O
µM	O	O
and	O	O
Vmax	B-PHEN
307	O	O
pmol	O	O
/	O	O
mg	O	O
per	O	O
minute	O	O
)	O	O
and	O	O
HeLa	B-ANAT
(	O	O
Km	O
0	O	O
.	O	O

32	O	O
µM	O	O
and	O	O
Vmax	B-PHEN
42	O	O
pmol	O	O
/	O	O
mg	O	O
per	O	O
minute	O	O
)	O	O
cells	B-ANAT
.	O	O

Mutant	B-CHEM
MRP1	B-CHEM
lacking	O	O
N	O	O
-	O	O
linked	O	O
glycosylation	B-PHYS
[	O	O
Asn19	O
/	O
23	O
/	O
1006Gln	O
;	O	O
sugar	O	O
-	O	O
free	O	O
(	B-CHEM
SF	I-CHEM
)	I-CHEM
-	I-CHEM
MRP1	I-CHEM
]	O	O
expressed	B-PHYS
in	O	O
either	O	O
HEK293	B-ANAT
or	O	O
HeLa	B-ANAT
cells	I-ANAT
had	O	O
low	O	O
Km	O
and	O	O
Vmax	B-PHEN
values	O	O
for	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
,	O	O
similar	O
to	O	O
HeLa	B-ANAT
wild	I-ANAT
-	I-ANAT
type	I-ANAT
(	O	O
WT	O	O
)	O	O
MRP1	B-CHEM
.	O	O

When	O	O
prepared	O
in	O	O
the	O	O
presence	B-DISO
of	O	O
phosphatase	B-CHEM
inhibitors	I-CHEM
,	O	O
both	O	O
WT	B-CHEM
-	I-CHEM
and	O	O
SF	B-CHEM
-	I-CHEM
MRP1	I-CHEM
-enriched	O	O
membrane	B-ANAT
vesicles	B-ANAT
had	O	O
a	O	O
high	O	O
Km	O
value	O	O
for	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
(	O	O
3	O	O
-	O	O
6	O	O
µM	O	O
)	O	O
,	O	O
regardless	O	O
of	O	O
the	O	O
cell	B-ANAT
line	I-ANAT
.	O	O

Kinetic	B-DISO
parameters	I-DISO
of	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
for	O	O
HEK	B-ANAT
-	O	O
Asn19	B-CHEM
/	I-CHEM
23Gln	I-CHEM
-	I-CHEM
MRP1	I-CHEM
were	O	O
similar	O
to	O	O
those	O	O
of	O	O
HeLa	B-ANAT
/	O	O
HEK	B-ANAT
-	O	O
SF	B-CHEM
-	I-CHEM
MRP1	I-CHEM
and	O	O
HeLa	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O	O
MRP1	B-CHEM
,	O	O
whereas	O	O
those	O	O
of	O	O
single	O
glycosylation	B-PHYS
mutants	B-CHEM
were	O	O
like	O	O
those	O	O
of	O	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-MRP1	O	O
.	O	O

Mutation	B-PHYS
of	O	O
19	O	O
potential	O
MRP1	O	O
phosphorylation	B-PHYS
sites	O
revealed	O	O
that	O	O
HEK	B-ANAT
-	O	O
Tyr920Phe	B-CHEM
/	I-CHEM
Ser921Ala	I-CHEM
-	I-CHEM
MRP1	I-CHEM
transported	B-PHYS
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
like	O	O
HeLa	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O	O
MRP1	B-CHEM
,	O	O
whereas	O	O
individual	O	O
HEK	B-ANAT
-	O	O
Tyr920Phe	B-CHEM
-	I-CHEM
and	O	O
-	O	O
Ser921Ala	B-CHEM
-	I-CHEM
MRP1	I-CHEM
mutants	B-CHEM
were	O	O
similar	O
to	O	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O	O
MRP1	B-CHEM
.	O	O

Together	O	O
,	O	O
these	O	O
results	B-DISO
suggest	O	O
that	O	O
Asn19	O
/	O
Asn23	O
glycosylation	B-PHYS
and	O	O
Tyr920	O
/	O
Ser921	O
phosphorylation	B-PHYS
are	O	O
responsible	O	O
for	O	O
altering	O
the	O	O
kinetics	O
of	O	O
MRP1	B-CHEM
-mediated	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
.	O	O

The	O	O
kinetics	O
of	O	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transport	B-PHYS
by	O	O
HEK	B-ANAT
-	O	O
Asn19	O
/	O
23Gln	O
/	O
Tyr920Glu	O
/	O
Ser921Glu	O
were	O	O
similar	O
to	O	O
HEK	B-ANAT
-	I-ANAT
WT	I-ANAT
-	O	O
MRP1	B-CHEM
,	O	O
indicating	O	O
that	O	O
the	O	O
phosphorylation	B-PHYS
-mimicking	O	O
substitutions	O	O
abrogated	O	O
the	O	O
influence	O
of	O	O
Asn19	O
/	O
23Gln	O
glycosylation	B-PHYS
.	O	O

Overall	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
that	O	O
cross	O	O
-	O	O
talk	O	O
between	O	O
MRP1	B-CHEM
glycosylation	B-PHYS
and	O	O
phosphorylation	B-PHYS
occurs	O	O
and	O	O
that	O	O
phosphorylation	B-PHYS
of	O	O
Tyr920	O
and	O	O
Ser921	O
can	O	O
switch	O	O
MRP1	B-CHEM
to	O	O
a	O	O
lower	O
-	O
affinity	O
,	O	O
higher	O
-	O
capacity	O
As	B-CHEM
(	I-CHEM
GS	I-CHEM
)	I-CHEM
3	I-CHEM
transporter	B-CHEM
,	O	O
allowing	O	O
arsenic	B-CHEM
detoxification	B-PHYS
over	O	O
a	O	O
broad	O
concentration	O
range	O
.	O	O

Twelve	O	O
ways	O	O
to	O	O
confirm	O
targets	O
of	O	O
activity	B-CHEM
-	I-CHEM
based	I-CHEM
probes	I-CHEM
in	O	O
plants	B-LIVB
Activity	B-CHEM
-	I-CHEM
based	I-CHEM
probes	I-CHEM
are	O	O
powerful	O	O
tools	O	O
to	O	O
interrogate	O	O
the	O	O
functional	O	O
proteome	B-CHEM
.	O	O

Their	O	O
covalent	B-PHYS
and	O	O
often	O	O
irreversible	B-PROC
labeling	I-PROC
of	O	O
proteins	B-CHEM
facilitates	O	O
the	O	O
purification	B-PROC
,	O	O
identification	B-PROC
and	O	O
quantification	O
of	O	O
labeled	B-CHEM
proteins	B-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
detection	B-PROC
of	O	O
labeled	B-CHEM
proteins	B-CHEM
often	O	O
requires	O	O
a	O	O
confirmation	B-DISO
,	O	O
especially	O	O
when	O	O
unexpected	B-DISO
proteins	B-CHEM
are	O	O
identified	O
,	O	O
or	O	O
to	O	O
unravel	O	O
fluorescent	B-PHEN
activity	I-PHEN
profiles	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
review	O	O
twelve	O	O
approaches	O	O
towards	O	O
target	O
confirmation	O	O
,	O	O
grouped	O	O
in	O	O
approaches	O	O
by	O	O
direct	O	O
target	O
detection	B-DISO
,	O	O
target	O
expression	B-PHYS
or	O	O
target	O
depletion	O
.	O	O

We	O	O
discuss	O	O
their	O	O
proper	O	O
use	O
and	O	O
limitations	O
and	O	O
illustrate	O	O
these	O	O
approaches	O	O
with	O	O
examples	O	O
from	O	O
plant	O
science	O
.	O	O

Naphthohydroquinones	B-CHEM
,	O	O
naphthoquinones	B-CHEM
,	O	O
anthraquinones	B-CHEM
,	O	O
and	O	O
a	O	O
naphthohydroquinone	B-CHEM
dimer	B-CHEM
isolated	O
from	O	O
the	O	O
aerial	B-LIVB
parts	I-LIVB
of	O	O
Morinda	B-LIVB
parvifolia	I-LIVB
and	O	O
their	O	O
cytotoxic	B-DISO
effects	I-DISO
through	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
p53	O
Five	O	O
unknown	O
compounds	B-CHEM
,	O	O
morindaparvins	B-CHEM
C	I-CHEM
-	I-CHEM
G	I-CHEM
,	O	O
consisting	O	O
of	O	O
naphthohydroquinones	B-CHEM
,	O	O
a	O	O
naphthoquinone	B-CHEM
,	O	O
an	O	O
anthraquinone	B-CHEM
,	O	O
and	O	O
a	O	O
naphthohydroquinone	B-CHEM
dimer	B-CHEM
,	O	O
together	O	O
with	O	O
three	O	O
known	O	O
quinones	B-CHEM
and	O	O
seven	O	O
other	O	O
known	O	O
compounds	B-CHEM
,	O	O
were	O	O
isolated	O
from	O	O
the	O	O
aerial	B-LIVB
parts	I-LIVB
of	O	O
Morinda	B-LIVB
parvifolia	I-LIVB
.	O	O

The	O	O
structures	O	O
of	O	O
morindaparvins	B-CHEM
C	I-CHEM
,	O	O
D	B-CHEM
,	O	O
E	B-CHEM
,	O	O
F	B-CHEM
,	O	O
and	O	O
G	B-CHEM
were	O	O
elucidated	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
spectroscopic	B-PROC
or	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
diffraction	I-PROC
analysis	I-PROC
as	O	O
methyl	B-CHEM
4	I-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dimethoxy	I-CHEM
-	I-CHEM
naphthalene	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
carboxylate	I-CHEM
,	O	O
methyl	B-CHEM
4	I-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
1	I-CHEM
-	I-CHEM
methoxy	I-CHEM
-	I-CHEM
naphthalene	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
carboxylate	I-CHEM
,	O	O
3	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
6	I-CHEM
-	I-CHEM
methoxy	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
methoxycarbonyl	I-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
naphthoquinone	I-CHEM
,	O	O
1	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
7	I-CHEM
-	I-CHEM
hydroxymethyl	I-CHEM
-	I-CHEM
anthraquinone	I-CHEM
,	O	O
and	O	O
dimethyl	B-CHEM
1	I-CHEM
,	I-CHEM
1	I-CHEM
'	I-CHEM
-	I-CHEM
dihydroxy	I-CHEM
-	I-CHEM
4	I-CHEM
,	I-CHEM
4	I-CHEM
'	I-CHEM
,	I-CHEM
7	I-CHEM
,	I-CHEM
7	I-CHEM
'	I-CHEM
-	I-CHEM
tetramethoxy	I-CHEM
-	I-CHEM
2	I-CHEM
,	I-CHEM
2	I-CHEM
'	I-CHEM
-	I-CHEM
binaphthalene	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
3	I-CHEM
'	I-CHEM
-	I-CHEM
dicarboxylate	I-CHEM
,	O	O
respectively	O	O
.	O	O

Naphthoquinones	B-CHEM
and	O	O
naphthohydroquinone	B-CHEM
dimers	B-CHEM
were	O	O
previously	O	O
unknown	O
in	O	O
the	O	O
genus	O
Morinda	B-LIVB
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
compounds	B-CHEM
were	O	O
tested	O
for	O	O
cytotoxicity	B-DISO
against	O	O
four	O	O
human	B-LIVB
cancer	B-ANAT
cell	I-ANAT
lines	I-ANAT
HeLa	B-ANAT
,	O	O
A2780	B-ANAT
,	O	O
Ketr3	B-ANAT
and	O	O
MCF	B-ANAT
-	I-ANAT
7	I-ANAT
and	O	O
their	O	O
effects	O
on	O	O
p53	O
-	O	O
activated	O
transcription	B-PHYS
.	O	O

Three	O	O
naphthoquinones	B-CHEM
had	O	O
moderate	O
cytotoxic	B-DISO
effects	I-DISO
with	O	O
IC50	O
values	O	O
ranging	O
from	O	O
1	O	O
.	O	O

51	O	O
to	O	O
9	O	O
.	O	O

56	O	O
μM	O	O
,	O	O
through	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
p53	O
transcriptional	B-PHYS
activity	I-PHYS
.	O	O

Common	O	O
and	O	O
Uncommon	O	O
Anatomical	B-ANAT
Variants	I-ANAT
of	O	O
Intrahepatic	B-ANAT
Bile	I-ANAT
Ducts	I-ANAT
in	O	O
Magnetic	B-PROC
Resonance	I-PROC
Cholangiopancreatography	I-PROC
and	O	O
its	O	O
Clinical	B-DISO
Implication	I-DISO
Preoperative	O
knowledge	O	O
of	O	O
intrahepatic	B-ANAT
bile	I-ANAT
duct	I-ANAT
(	O	O
IHD	B-ANAT
)	O	O
anatomy	B-ANAT
is	O	O
critical	O	O
for	O	O
planning	O	O
liver	B-PROC
resections	I-PROC
,	O	O
liver	B-PROC
transplantations	I-PROC
and	O	O
complex	B-PROC
biliary	I-PROC
reconstructive	I-PROC
surgery	I-PROC
.	O	O

The	O	O
purpose	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
demonstrate	O	O
the	O	O
imaging	O
features	O
of	O	O
various	O	O
anatomical	B-ANAT
variants	I-ANAT
of	O	O
IHD	B-ANAT
using	O	O
magnetic	B-PROC
resonance	I-PROC
cholangio	I-PROC
-	I-PROC
pancreatography	I-PROC
(	O	O
MRCP	B-PROC
)	O	O
and	O	O
their	O	O
prevalence	O	O
in	O	O
our	O	O
population	B-LIVB
.	O	O

This	O	O
observational	O	O
clinical	B-PROC
evaluation	I-PROC
study	O	O
included	O	O
224	O	O
patients	B-LIVB
who	O	O
were	O	O
referred	O	O
for	O	O
MRCP	B-PROC
.	O	O

MRCP	B-PROC
was	O	O
performed	O	O
in	O	O
a	O	O
1	B-DEVI
.	I-DEVI
5	I-DEVI
-	I-DEVI
Tesla	I-DEVI
magnet	I-DEVI
(	O	O
Philips	O	O
)	O	O
with	O	O
SSH	B-PROC
MRCP	I-PROC
3DHR	O	O
and	O	O
SSHMRCP	B-PROC
rad	O	O
protocol	O	O
.	O	O

A	O	O
senior	O	O
radiologist	B-LIVB
assessed	O
the	O	O
biliary	B-ANAT
passage	O
for	O	O
anatomical	B-DISO
variations	I-DISO
.	O	O

The	O	O
branching	O
pattern	O
of	O	O
the	O	O
right	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O	O
RHD	B-ANAT
)	O	O
was	O	O
typical	O	O
in	O	O
55	O	O
.	O	O

3	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

The	O	O
most	O	O
common	O	O
variant	B-ANAT
was	O	O
right	B-ANAT
posterior	I-ANAT
sectoral	I-ANAT
duct	I-ANAT
(	O	O
RPSD	B-ANAT
)	O	O
draining	O	O
into	O	O
the	O	O
left	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O	O
LHD	B-ANAT
)	O	O
in	O	O
27	O	O
.	O	O

6	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

Trifurcation	O
pattern	O
was	O	O
noted	O	O
in	O	O
9	O	O
.	O	O

3	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

In	O	O
4	O	O
%	O	O
of	O	O
subjects	B-LIVB
,	O	O
RPSD	B-ANAT
was	O	O
draining	O	O
into	O	O
the	O	O
common	B-ANAT
hepatic	I-ANAT
duct	I-ANAT
(	O	O
CHD	B-ANAT
)	O	O
and	O	O
in	O	O
0	O	O
.	O	O

8	O	O
%	O	O
of	O	O
subjects	B-LIVB
into	O	O
the	O	O
cystic	B-ANAT
duct	I-ANAT
.	O	O

Other	O	O
variants	B-ANAT
were	O	O
noted	O	O
in	O	O
2	O	O
.	O	O

6	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

In	O	O
4	O	O
.	O	O
9	O	O
%	O	O
of	O	O
cases	O	O
there	O	O
was	O	O
an	O	O
accessory	B-DISO
duct	I-DISO
.	O	O

The	O	O
most	O	O
common	O	O
type	O	O
of	O	O
LHD	B-ANAT
branching	O
pattern	O
was	O	O
a	O	O
common	O
trunk	O
of	O
segment	O
2	O	O
and	O	O
3	O	O
ducts	B-ANAT
joining	O	O
the	O	O
segment	O
4	O	O
duct	B-ANAT
in	O	O
67	O	O
.	O	O

8	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

In	O	O
23	O	O
.	O	O

2	O	O
%	O	O
of	O	O
subjects	B-LIVB
,	O	O
segment	O
2	O	O
duct	B-ANAT
united	O	O
with	O	O
the	O	O
common	O
trunk	O
of	O
segment	O
3	O	O
and	O	O
4	O	O
and	O	O
in	O	O
3	O	O
.	O	O

4	O	O
%	O	O
of	O	O
subjects	B-LIVB
segment	O
2	O	O
,	O	O
3	O	O
,	O	O
and	O	O
4	O	O
ducts	B-ANAT
united	O	O
together	O	O
to	O	O
form	O	O
LHD	B-ANAT
.	O	O

Other	O	O
uncommon	O	O
branching	O
patterns	O
of	O	O
LHD	B-ANAT
were	O	O
seen	O	O
in	O	O
4	O	O
.	O	O

9	O	O
%	O	O
of	O	O
subjects	B-LIVB
.	O	O

Intrahepatic	B-ANAT
bile	I-ANAT
duct	I-ANAT
anatomy	B-ANAT
is	O	O
complex	O
with	O	O
many	O	O
common	O	O
and	O	O
uncommon	O	O
variations	O
.	O	O

MRCP	B-PROC
is	O	O
a	O	O
reliable	O	O
non	O
-	O
invasive	O
imaging	B-PROC
method	I-PROC
for	O	O
demonstration	O	O
of	O	O
bile	B-ANAT
duct	I-ANAT
morpholog	O
y	O	O
,	O	O
which	O	O
is	O	O
useful	O	O
to	O	O
plan	O	O
complex	O
surgeries	B-PROC
and	O	O
to	O	O
prevent	O	O
iatrogenic	B-DISO
injuries	I-DISO
.	O	O

Cortical	B-ANAT
Reorganization	O
following	O	O
Injury	B-DISO
Early	O
in	O	O
Life	O
The	O	O
brain	B-ANAT
has	O	O
a	O	O
remarkable	O	O
capacity	O
for	O	O
reorganization	O
following	O	O
injury	B-DISO
,	O	O
especially	O	O
during	O	O
the	O	O
first	O	O
years	O
of	O	O
life	O
.	O	O

Knowledge	O	O
of	O	O
structural	O
reorganization	O
and	O	O
its	O	O
consequences	O
following	O	O
perinatal	B-DISO
injury	I-DISO
is	O	O
sparse	O	O
.	O	O

Here	O	O
we	O	O
studied	O	O
changes	O	O
in	O	O
brain	B-ANAT
tissue	I-ANAT
volume	O
,	O	O
morphology	O
,	O	O
perfusion	B-PROC
,	O	O
and	O	O
integrity	O
in	O	O
children	B-LIVB
with	O	O
hemiplegia	B-DISO
compared	O	O
to	O	O
typically	O	O
developing	O	O
children	B-LIVB
,	O	O
using	O	O
MRI	B-PROC
.	O	O

Children	B-LIVB
with	O	O
hemiplegia	B-DISO
demonstrated	O	O
reduced	B-DISO
total	I-DISO
cerebral	I-DISO
volume	I-DISO
,	O	O
with	O	O
increased	B-DISO
cerebrospinal	I-DISO
fluid	I-DISO
(	O	O
CSF	B-ANAT
)	O	O
and	O	O
reduced	B-DISO
total	I-DISO
white	I-DISO
matter	I-DISO
volumes	I-DISO
,	O	O
with	O	O
no	B-DISO
differences	I-DISO
in	O	O
total	O
gray	O
matter	O
volume	O
,	O	O
compared	O	O
to	O	O
typically	O	O
developing	O	O
children	B-LIVB
.	O	O

An	O	O
increase	O
in	O	O
cortical	B-ANAT
thickness	O
at	O	O
the	O	O
hemisphere	B-ANAT
contralateral	O
to	O	O
the	O	O
lesion	B-DISO
(	O	O
CLH	B-ANAT
)	O	O
was	O	O
detected	B-DISO
in	O	O
motor	B-ANAT
and	O	O
language	B-ANAT
areas	I-ANAT
,	O	O
which	O	O
may	O	O
reflect	O	O
compensation	O	O
for	O	O
the	O	O
gray	O
matter	O
loss	O
in	O	O
the	O	O
lesion	B-DISO
area	O
or	O	O
retention	O	O
of	O	O
ipsilateral	O
pathways	B-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
reduced	O
cortical	B-ANAT
thickness	O
,	O	O
perfusion	B-PROC
,	O	O
and	O	O
surface	O
area	O
were	O	O
detected	B-DISO
in	O	O
limbic	B-ANAT
areas	B-ANAT
.	O	O

Increased	B-DISO
CSF	I-DISO
volume	I-DISO
and	O	O
precentral	B-ANAT
cortical	I-ANAT
thickness	O
and	O	O
reduced	B-DISO
white	I-DISO
matter	I-DISO
volume	I-DISO
were	O	O
correlated	O	O
with	O	O
worse	O	O
motor	B-PHYS
performance	I-PHYS
.	O	O

Brain	B-ANAT
reorganization	O
of	O	O
the	O	O
gray	O
matter	O
within	O	O
the	O	O
CLH	B-ANAT
,	O	O
while	O	O
not	O	O
necessarily	O	O
indicating	O	O
better	O	O
outcome	O
,	O	O
is	O	O
suggested	O	O
as	O	O
a	O	O
response	O	O
to	O	O
neuronal	B-ANAT
deficits	O
following	O	O
injury	B-DISO
early	O
in	O	O
life	O
.	O	O

Simultaneous	O
Bilateral	O
Femur	B-DISO
Neck	I-DISO
Fracture	I-DISO
in	O	O
A	O	O
Young	B-LIVB
Adult	I-LIVB
with	O	O
Chronic	B-DISO
Renal	I-DISO
Failure	I-DISO
-	O	O
A	O	O
Case	O
Report	O
and	O	O
Review	O
of	O
Literature	O
Pathological	O
bilateral	O
femoral	B-DISO
neck	I-DISO
fracture	I-DISO
due	O	O
to	O	O
renal	B-DISO
osteodystrophy	I-DISO
is	O	O
rare	O
.	O	O

This	O	O
is	O	O
a	O	O
report	O
of	O	O
a	O	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
patient	B-LIVB
who	O	O
had	O	O
sustained	O
bilateral	O
intra	O
-	O
capsular	O
displaced	O	O
fracture	B-DISO
neck	I-DISO
of	I-DISO
femur	I-DISO
following	O	O
an	O	O
episode	O
of	O
convulsion	B-DISO
and	O	O
the	O	O
difficulties	B-PROC
encountered	I-PROC
in	O	O
early	B-PROC
diagnosis	I-PROC
and	O	O
treatment	B-PROC
.	O	O

The	O	O
pathophysiology	B-DISO
of	O	O
renal	B-DISO
osteodystrophy	I-DISO
and	O	O
the	O	O
treatment	B-PROC
of	O	O
hip	B-DISO
fractures	I-DISO
in	O	O
patients	B-LIVB
with	O	O
renal	B-DISO
failure	I-DISO
are	O	O
also	O	O
discussed	O	O
.	O	O

A	O	O
23	O	O
years	O
old	O	O
male	B-PHYS
patient	B-LIVB
admitted	O	O
with	O	O
h	B-DISO
/	I-DISO
o	I-DISO
dysuria	I-DISO
,	O	O
pyuria	B-DISO
and	O	O
loss	B-DISO
of	I-DISO
appetite	I-DISO
since	O	O
3	O	O
months	O
.	O	O

He	O	O
was	O	O
a	O	O
known	O	O
case	O	O
of	O	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
and	O	O
reflux	B-DISO
nephropathy	I-DISO
.	O	O

On	O	O
investigating	O
,	O	O
patient	B-LIVB
's	I-LIVB
renal	B-ANAT
parameters	O
were	O	O
high	O
and	O	O
he	O	O
was	O	O
started	O
with	O	O
haemodialysis	B-PROC
.	O	O

The	O	O
next	O
day	O
patient	B-LIVB
had	O	O
c	O
/	O
o	O
bilateral	O
hip	B-DISO
pain	I-DISO
and	O	O
inability	B-DISO
to	I-DISO
move	I-DISO
bilateral	O
lower	B-ANAT
limbs	I-ANAT
following	O	O
an	O	O
episode	O
of	O
seizure	B-DISO
.	O	O

Radiograph	B-PROC
of	I-PROC
pelvis	I-PROC
showed	O	O
vertical	B-DISO
sub	I-DISO
capital	I-DISO
fractures	I-DISO
of	O	O
bilateral	O
neck	B-ANAT
of	I-ANAT
femur	I-ANAT
.	O	O

In	O	O
this	O	O
patient	B-LIVB
,	O	O
considering	O	O
his	O	O
age	B-PHYS
,	O	O
general	B-DISO
condition	I-DISO
&	O	O
prognosis	B-PROC
,	O	O
an	O	O
elective	B-PROC
surgery	I-PROC
in	O	O
the	O	O
form	O	O
of	O	O
bilateral	O
uncemented	O
modular	O
bipolar	O
hemiarthroplasty	B-PROC
was	O	O
done	O
.	O	O

Overall	O
risk	O
of	O	O
hip	B-DISO
fracture	I-DISO
among	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
renal	I-DISO
failure	I-DISO
is	O	O
considerably	O	O
higher	O
than	O	O
in	O	O
the	O	O
general	B-LIVB
population	I-LIVB
,	O	O
independent	O
of	O
age	B-PHYS
and	O	O
gender	B-PHYS
.	O	O

Simultaneous	O
spontaneous	O
bilateral	O
fractures	B-DISO
of	I-DISO
the	I-DISO
femoral	I-DISO
neck	I-DISO
are	O	O
rare	O
and	O	O
a	O	O
delayed	O
diagnosis	O
is	O	O
usual	O
.	O	O

The	O	O
study	B-PROC
of	O	O
etiological	O
factors	O
of	O	O
these	O	O
fractures	B-DISO
is	O	O
essential	O	O
to	O	O
guide	O	O
us	O	O
in	O	O
choosing	O
the	O	O
treatment	B-PROC
of	O	O
choice	O
.	O	O

Obviously	O	O
patient	B-LIVB
's	I-LIVB
age	B-PHYS
,	O	O
life	O
expectancy	O
as	O	O
well	O	O
as	O	O
renal	O	O
co	O
morbidity	O
has	O	O
an	O	O
influence	O
over	O	O
deciding	O	O
treatment	B-PROC
and	O	O
outcome	O
.	O	O

Anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
and	O	O
antimicrobial	B-CHEM
coumarins	B-CHEM
from	O	O
the	O	O
stems	B-LIVB
of	O	O
Eurya	B-LIVB
chinensis	I-LIVB
Two	O	O
new	O	O
coumarins	B-CHEM
,	O	O
named	O	O
(	B-CHEM
±	I-CHEM
)	I-CHEM
-	I-CHEM
euryacoumarin	I-CHEM
A	I-CHEM
(	O	O
1	O	O
)	O	O
and	O	O
6	B-CHEM
-	I-CHEM
demethylobtusinin	I-CHEM
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
one	O	O
new	O	O
natural	B-CHEM
coumarin	I-CHEM
,	O	O
named	O	O
euryacoumarin	B-CHEM
B	I-CHEM
(	O	O
3	O	O
)	O	O
,	O	O
along	O	O
with	O	O
two	O	O
known	O	O
compounds	O	O
,	O	O
scopoletin	B-CHEM
(	O	O
4	O	O
)	O	O
and	O	O
obtusinol	B-CHEM
(	O	O
5	O	O
)	O	O
,	O	O
were	O	O
isolated	O
from	O	O
the	O	O
stems	B-LIVB
of	O	O
Eurya	B-LIVB
chinensis	I-LIVB
.	O	O

Their	O	O
structures	O
were	O	O
elucidated	O	O
by	O	O
means	O	O
of	O	O
extensive	O	O
spectroscopic	B-PROC
methods	I-PROC
and	O	O
comparison	O
with	O	O
data	O
reported	O	O
in	O	O
the	O	O
literatures	O
.	O	O

Compound	B-CHEM
1	I-CHEM
exhibited	O	O
significant	O	O
inhibition	O
of	O	O
LPS	B-PHYS
-	I-PHYS
induced	I-PHYS
nitric	I-PHYS
oxide	I-PHYS
(	I-PHYS
NO	I-PHYS
)	I-PHYS
production	I-PHYS
in	O	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
with	O	O
IC50	O
value	O	O
of	O	O
35	O	O
.	O	O

64	O	O
±	O	O
1	O	O
.	O	O
73	O	O
μM	O	O
,	O	O
and	O	O
showed	O	O
marginal	O	O
antibacterial	B-CHEM
activities	O
against	O	O
Bacillus	B-LIVB
subtilis	I-LIVB
and	O	O
B	B-LIVB
.	I-LIVB

cereus	I-LIVB
with	O	O
MIC	B-PHEN
values	I-PHEN
of	O	O
50	O	O
.	O	O
59	O	O
±	O	O
2	O	O
.	O	O
12	O	O
and	O	O
35	O	O
.	O	O

42	O	O
±	O	O
0	O	O
.	O	O
96	O	O
μM	O	O
,	O	O
respectively	O	O
.	O	O

Extrapulmonary	B-DISO
Small	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
of	O	O
the	O	O
Seminal	B-ANAT
Vesicles	I-ANAT
and	O	O
Prostate	B-ANAT
Demonstrated	O	O
on	O	O
18F	B-PROC
-	I-PROC
FDG	I-PROC
Positron	I-PROC
Emission	I-PROC
Tomography	I-PROC
/	I-PROC
Computed	I-PROC
Tomography	I-PROC
Extrapulmonary	B-DISO
primary	I-DISO
small	I-DISO
cell	I-DISO
carcinomas	I-DISO
arising	O	O
from	O	O
the	O	O
urogenital	B-ANAT
tract	I-ANAT
is	O	O
infrequent	O
.	O	O

It	O	O
can	O	O
rarely	O
arise	O	O
from	O	O
the	O	O
prostate	B-ANAT
and	O	O
even	O	O
more	O	O
rarely	O
from	O	O
the	O	O
seminal	B-ANAT
vesicles	I-ANAT
.	O	O

We	O	O
present	O	O
a	O	O
79	O	O
-	O	O
year	O
-old	O	O
male	B-PHYS
who	O	O
was	O	O
admitted	B-PROC
due	O	O
to	O	O
acute	B-DISO
renal	I-DISO
failure	I-DISO
with	O	O
a	O	O
history	B-DISO
of	O	O
radical	B-PROC
radiotherapy	I-PROC
for	O	O
prostate	B-DISO
adenocarcinoma	I-DISO
13	O	O
years	O
ago	O	O
.	O	O

The	O	O
prostate	B-CHEM
specific	I-CHEM
antigen	I-CHEM
level	O
was	O	O
not	O	O
elevated	O	O
.	O	O

An	O	O
abdominopelvic	B-PROC
computed	I-PROC
tomography	I-PROC
(	I-PROC
CT	I-PROC
)	I-PROC
scan	I-PROC
showed	O	O
markedly	O	O
enlarged	O	O
seminal	B-ANAT
vesicles	I-ANAT
causing	O	O
bilateral	B-ANAT
ureteral	I-ANAT
obstruction	B-DISO
and	O	O
a	O	O
mildly	O	O
enlarged	O	O
prostate	B-ANAT
.	O	O

Further	O	O
evaluation	O	O
with	O	O
fluorine	B-PROC
-	I-PROC
18	I-PROC
-	I-PROC
fluorodeoxyglucose	I-PROC
(	I-PROC
18F	I-PROC
-	I-PROC
FDG	I-PROC
)	I-PROC
positron	I-PROC
emission	I-PROC
tomography	I-PROC
/	I-PROC
CT	I-PROC
demonstrated	O	O
extensive	O	O
18F	B-CHEM
-	I-CHEM
FDG	I-CHEM
uptake	B-PHYS
in	O	O
the	O	O
pelvis	B-ANAT
with	O	O
diffuse	B-DISO
involvement	I-DISO
of	O	O
both	O	O
seminal	B-ANAT
vesicles	I-ANAT
and	O	O
the	O	O
prostate	B-ANAT
without	O	O
pathologic	O
uptake	B-PHYS
in	O	O
the	O	O
lungs	B-ANAT
or	O	O
elsewhere	O	O
in	O	O
the	O	O
body	B-LIVB
.	O	O

Core	B-PROC
biopsies	I-PROC
of	O	O
the	O	O
prostate	B-ANAT
and	O	O
both	O	O
seminal	B-ANAT
vesicles	I-ANAT
revealed	O	O
diffuse	B-DISO
involvement	I-DISO
by	O	O
small	B-DISO
cell	I-DISO
carcinoma	I-DISO
.	O	O

Therapy	B-PROC
could	O	O
not	O	O
be	O	O
instituted	O	O
due	O	O
to	O	O
a	O	O
rapid	O	O
deterioration	B-PHEN
in	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
clinical	O
condition	O
.	O	O

Phosphodiesterase	B-CHEM
Type	I-CHEM
5	I-CHEM
Inhibitors	I-CHEM
and	O	O
Risk	O
of	O	O
Malignant	B-DISO
Melanoma	I-DISO
:	O	O
Matched	B-PROC
Cohort	O
Study	O
Using	O	O
Primary	B-PROC
Care	I-PROC
Data	O
from	O	O
the	O	O
UK	B-GEOG
Clinical	O	O
Practice	O	O
Research	O	O
Datalink	O	O
Laboratory	B-OBJC
evidence	O
suggests	O	O
that	O	O
reduced	O
phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
(	O	O
PDE5	B-CHEM
)	O	O
expression	B-PHYS
increases	O
the	O	O
invasiveness	B-DISO
of	O	O
melanoma	B-ANAT
cells	I-ANAT
;	O	O
hence	O	O
,	O	O
pharmacological	O
inhibition	B-PHYS
of	O	O
PDE5	B-CHEM
could	O	O
affect	O	O
melanoma	B-DISO
risk	O
.	O	O

Two	O	O
major	O	O
epidemiological	B-PROC
studies	I-PROC
have	O	O
investigated	O
this	O	O
and	O	O
come	O	O
to	O	O
differing	O	O
conclusions	O
.	O	O

We	O	O
therefore	O	O
aimed	O	O
to	O	O
investigate	O
whether	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O	O
is	O	O
associated	O
with	O
an	O	O
increased	O
risk	O
of	O	O
malignant	B-DISO
melanoma	I-DISO
,	O	O
and	O	O
whether	O	O
any	O	O
increase	O
in	O	O
risk	O
is	O	O
likely	O	O
to	O	O
represent	O	O
a	O	O
causal	O	O
relationship	O
.	O	O

We	O	O
conducted	O	O
a	O	O
matched	B-PROC
cohort	O
study	O
using	O	O
primary	B-PROC
care	I-PROC
data	O
from	O	O
the	O	O
UK	B-GEOG
Clinical	O	O
Practice	O	O
Research	O	O
Datalink	O	O
.	O	O

All	O	O
men	B-LIVB
initiating	O	O
a	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
and	O	O
with	O	O
no	O	O
prior	O	O
cancer	B-PROC
diagnosis	I-PROC
were	O	O
identified	O
and	O	O
matched	O
on	O	O
age	B-PHYS
,	O	O
diabetes	B-DISO
status	I-DISO
,	O	O
and	O	O
general	O
practice	O
to	O	O
up	O	O
to	O	O
four	O	O
unexposed	B-LIVB
controls	I-LIVB
.	O	O

Ever	O	O
use	O	O
of	O	O
a	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
and	O	O
time	O
-	O
updated	O
cumulative	O
number	O
of	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
prescriptions	O
were	O	O
investigated	O
as	O	O
exposures	B-DISO
,	O	O
and	O	O
the	O	O
primary	O
outcome	O
was	O	O
malignant	B-DISO
melanoma	I-DISO
.	O	O

Basal	B-DISO
cell	I-DISO
carcinoma	I-DISO
,	O	O
solar	B-DISO
keratosis	I-DISO
,	O	O
and	O	O
colorectal	B-DISO
cancer	I-DISO
were	O	O
investigated	O
as	O	O
negative	O
control	O
outcomes	B-PROC
to	O	O
exclude	O	O
bias	O
.	O	O

Hazard	O
ratios	O
(	O	O
HRs	O
)	O	O
were	O	O
estimated	O
from	O	O
Cox	O
models	O
stratified	O
by	O	O
matched	O
set	O
and	O	O
adjusted	O	O
for	O	O
potential	O	O
confounders	O
.	O	O

145	O	O
,	O	O
104	O	O
men	B-LIVB
with	O	O
≥1	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
prescription	O
,	O	O
and	O	O
560	O	O
,	O	O
933	O	O
unexposed	B-LIVB
matched	I-LIVB
controls	I-LIVB
were	O	O
included	O	O
.	O	O

In	O	O
total	O	O
,	O	O
1	O	O
,	O	O
315	O	O
incident	B-PHEN
malignant	B-DISO
melanoma	I-DISO
diagnoses	B-DISO
were	O	O
observed	O	O
during	O	O
3	O	O
.	O	O
44	O	O
million	O
person	O
-	O
years	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O	O
mean	O	O
4	O	O
.	O	O

9	O	O
y	O
per	O
person	O
)	O	O
.	O	O

After	O	O
adjusting	O	O
for	O	O
potential	O	O
confounders	O
,	O	O
there	O	O
was	O	O
weak	O	O
evidence	O
of	O	O
a	O	O
small	O	O
positive	O
association	O
between	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O	O
and	O	O
melanoma	B-DISO
risk	O
(	O	O
HR	O
=	O	O
1	O	O
.	O	O
14	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
01	O	O
-	O	O
1	O	O
.	O	O
29	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
04	O	O
)	O	O
.	O	O

A	O	O
similar	O	O
increase	O
in	O	O
risk	O
was	O	O
seen	O	O
for	O	O
the	O	O
two	O	O
negative	O
control	O
outcomes	B-PROC
related	O	O
to	O	O
sun	B-DISO
exposure	I-DISO
(	O	O
HR	O
=	O	O
1	O	O
.	O	O
15	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
11	O	O
-	O	O
1	O	O
.	O	O
19	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
for	O	O
basal	B-DISO
cell	I-DISO
carcinoma	I-DISO
;	O	O
HR	O
=	O	O
1	O	O
.	O	O
21	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
17	O	O
-	O	O
1	O	O
.	O	O
25	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
for	O	O
solar	B-DISO
keratosis	I-DISO
)	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
increased	O
risk	O
for	O	O
colorectal	B-DISO
cancer	I-DISO
(	O	O
HR	O
=	O	O
0	O	O
.	O	O
91	O	O
,	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
85	O	O
-	O	O
0	O	O
.	O	O
98	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O
evidence	O
that	O	O
risk	O
increased	O
with	O	O
number	O	O
of	O	O
prescriptions	O
received	O
(	O	O
p	O	O
-	O	O
trend	O	O
=	O	O
0	O	O
.	O	O

83	O	O
)	O	O
.	O	O

In	O	O
a	O	O
post	B-PROC
hoc	I-PROC
analysis	I-PROC
,	O	O
there	O	O
was	O	O
strong	O	O
evidence	O
that	O	O
solar	B-DISO
keratosis	I-DISO
was	O	O
associated	O
with	O
future	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
use	O	O
(	O	O
odds	O
ratio	O
=	O	O
1	O	O
.	O	O
28	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
23	O	O
-	O	O
1	O	O
.	O	O

34	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O

suggesting	O	O
that	O	O
men	B-LIVB
with	O	O
higher	O	O
sun	B-DISO
exposure	I-DISO
were	O	O
more	O	O
likely	O	O
to	O	O
become	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
users	B-LIVB
.	O	O

However	O	O
,	O	O
a	O	O
limitation	O
of	O	O
our	O	O
study	B-PROC
was	O	O
that	O	O
we	O	O
did	O	O
not	O	O
have	O	O
individual	O
-	O
level	O
data	O
on	O	O
sun	B-DISO
exposure	I-DISO
,	O	O
so	O	O
we	O	O
could	O	O
not	O	O
directly	O	O
control	O
for	O	O
this	O	O
in	O	O
the	O	O
primary	B-PROC
analysis	I-PROC
.	O	O

Our	O	O
results	O	O
were	O	O
not	O	O
consistent	O	O
with	O	O
PDE5	B-CHEM
inhibitors	I-CHEM
being	O	O
causally	O	O
associated	O
with	O
melanoma	B-DISO
risk	O
,	O	O
and	O	O
strongly	O	O
suggest	O	O
that	O	O
observed	O	O
risk	O
increases	O
are	O	O
driven	O	O
by	O	O
greater	O	O
sun	B-DISO
exposure	I-DISO
among	O	O
patients	B-LIVB
exposed	O
to	O
a	O	O
PDE5	B-CHEM
inhibitor	I-CHEM
.	O	O

Parent	B-LIVB
-	O	O
Youth	B-LIVB
Differences	O
in	O	O
Familism	O
Values	O
from	O	O
Adolescence	O
into	O	O
Young	B-LIVB
Adulthood	I-LIVB
:	O	O
Developmental	O
Course	O
and	O	O
Links	O	O
with	O	O
Parent	B-LIVB
-	O	O
Youth	B-LIVB
Conflict	O
A	O	O
critical	O	O
step	O	O
in	O	O
capturing	B-PROC
family	I-PROC
processes	I-PROC
is	O	O
to	O	O
incorporate	O
the	O	O
perspectives	O
and	O	O
experiences	B-PHYS
of	O	O
multiple	O
family	B-LIVB
members	I-LIVB
toward	O	O
characterizing	O
how	O	O
families	B-LIVB
operate	O
as	O	O
systems	B-LIVB
.	O	O

Although	O	O
some	O	O
research	B-PROC
has	O	O
examined	B-DISO
differences	O
between	O	O
parents	B-LIVB
'	I-LIVB
and	O	O
youth	B-LIVB
's	I-LIVB
family	B-LIVB
experiences	B-PHYS
,	O	O
most	O	O
studies	B-PROC
have	O	O
focused	O
on	O	O
European	B-LIVB
American	I-LIVB
families	B-LIVB
,	O	O
and	O	O
we	O	O
know	O	O
little	O	O
about	O	O
the	O	O
nature	O
and	O	O
implications	O
of	O	O
divergent	O
parent	B-LIVB
-	O	O
youth	B-LIVB
experiences	B-PHYS
in	O	O
other	O	O
ethnic	B-LIVB
groups	I-LIVB
.	O	O

Accordingly	O	O
,	O	O
we	O	O
focused	O
on	O	O
Mexican	B-LIVB
-origin	O	O
families	B-LIVB
and	O	O
assessed	O
the	O	O
links	O	O
between	O	O
mother	B-LIVB
-	O	O
youth	B-LIVB
and	O	O
father	B-LIVB
-	O	O
youth	B-LIVB
differences	O
in	O	O
familism	O
values	O
and	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
conflict	O
from	O	O
early	O
adolescence	O
into	O	O
young	B-LIVB
adulthood	I-LIVB
.	O	O

Participants	B-LIVB
were	O	O
mothers	B-LIVB
,	O	O
fathers	B-LIVB
,	O	O
and	O	O
two	O	O
siblings	B-LIVB
(	O	O
248	O	O
female	B-LIVB
and	O	O
244	O	O
male	B-LIVB
,	O	O
51	O	O
%	O	O
female	B-LIVB
;	O	O
M	O	O
age	B-PHYS
=	O	O
14	O	O
.	O	O
02	O	O
years	O
)	O	O
from	O	O
246	O	O
families	B-LIVB
who	O	O
were	O	O
interviewed	O
in	O	O
their	O	O
homes	O
on	O	O
three	O	O
occasions	O	O
over	O	O
8	O	O
years	O
.	O	O

We	O	O
operationalized	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
differences	O
in	O	O
familism	O
values	O
using	O	O
difference	O
scores	O
,	O	O
controlling	O	O
for	O	O
mean	O	O
levels	O
of	O	O
familism	O
.	O	O

Multilevel	O
models	O
revealed	O
that	O	O
mothers	B-LIVB
'	O	O
and	O	O
fathers	B-LIVB
'	O	O
familism	O
values	O
remained	O	O
relatively	O	O
stable	O
over	O	O
time	O
,	O	O
but	O	O
youth	B-LIVB
's	I-LIVB
familism	O
values	O
declined	O
until	O	O
age	B-PHYS
17	O	O
,	O	O
stabilized	B-DISO
,	O	O
and	O	O
then	O	O
increased	O
slightly	O	O
in	O	O
young	B-LIVB
adulthood	I-LIVB
.	O	O

Lagged	O
models	O
tested	O
directions	O
of	O	O
effect	O
by	O	O
examining	B-DISO
whether	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
differences	O
in	O	O
familism	O
values	O
predicted	O
parent	B-LIVB
-	O	O
youth	B-LIVB
conflict	O
or	O	O
vice	O	O
versa	O	O
.	O	O

The	O	O
findings	B-DISO
revealed	O
that	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
conflict	O
predicted	O
greater	O	O
differences	O
in	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
familism	O
values	O
,	O	O
but	O	O
differences	O
in	O	O
familism	O
values	O
did	O	O
not	O	O
predict	O
conflict	O
.	O	O

Our	O	O
findings	B-DISO
align	O	O
with	O	O
a	O	O
family	B-LIVB
systems	I-LIVB
perspective	O
in	O	O
documenting	B-PROC
the	O	O
significance	O
of	O	O
differences	O
between	O	O
family	B-LIVB
members	I-LIVB
'	O	O
perspectives	O
and	O	O
highlighting	O	O
that	O	O
such	O	O
processes	B-PHEN
are	O	O
dynamic	O
.	O	O

Further	O	O
,	O	O
by	O	O
testing	O
bi	O
-	O
directional	O
associations	O
in	O	O
longitudinal	O
models	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
disentangle	O	O
the	O	O
temporal	O
ordering	O
of	O	O
differences	O
in	O	O
familism	O
values	O
and	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
conflict	O
thereby	O	O
advancing	O
understanding	B-PHYS
of	O	O
parent	B-LIVB
-	O	O
youth	B-LIVB
discrepancies	B-DISO
in	O	O
cultural	O
values	O
.	O	O

Low	O
Soluble	O
Syndecan	B-CHEM
-	I-CHEM
1	I-CHEM
Precedes	O	O
Preeclampsia	B-DISO
Syndecan	B-CHEM
-	I-CHEM
1	I-CHEM
(	O	O
Sdc1	B-CHEM
;	O	O
CD138	B-CHEM
)	O	O
is	O	O
a	O	O
major	O	O
transmembrane	B-CHEM
heparan	I-CHEM
sulfate	I-CHEM
proteoglycan	I-CHEM
expressed	B-PHYS
on	O	O
the	O	O
extracellular	B-ANAT
,	O	O
luminal	O
surface	O
of	O	O
epithelial	B-ANAT
cells	I-ANAT
and	O	O
syncytiotrophoblast	B-ANAT
,	O	O
thus	O	O
comprising	O	O
a	O	O
major	O	O
component	O	O
of	O	O
the	O	O
glycocalyx	B-ANAT
of	O	O
these	O	O
cells	B-ANAT
.	O	O

The	O	O
""""	O	O
soluble	O
""""	O	O
(	O	O
shed	O	O
)	O	O
form	O	O
of	O	O
Sdc1	B-CHEM
has	O	O
paracrine	B-PHYS
and	O	O
autocrine	B-PHYS
functions	I-PHYS
and	O	O
is	O	O
normally	O	O
produced	O	O
in	O	O
a	O	O
regulated	O	O
fashion	O	O
.	O	O

We	O	O
compared	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
concentrations	O
,	O	O
in	O	O
relation	O	O
to	O	O
placental	B-ANAT
Sdc1	B-CHEM
expression	B-PHYS
,	O	O
in	O	O
uncomplicated	B-DISO
(	O	O
control	B-LIVB
)	O	O
and	O	O
preeclamptic	B-DISO
pregnancies	B-PHYS
.	O	O

We	O	O
evaluated	O	O
soluble	O
Sdc1	B-CHEM
across	O	O
uncomplicated	B-DISO
pregnancy	I-DISO
,	O	O
and	O	O
between	O	O
preeclamptic	B-DISO
,	O	O
gestational	B-DISO
hypertensive	I-DISO
and	O	O
control	B-LIVB
patients	B-LIVB
at	O	O
mid	O
-	O
pregnancy	O
(	O
20	O
weeks	O
)	O
and	O	O
3rd	O
trimester	O
by	O	O
ELISA	B-PROC
.	O	O

Placental	B-ANAT
expression	B-PHYS
level	O
of	O	O
Sdc1	B-CHEM
was	O	O
compared	O
between	O	O
groups	B-LIVB
in	O	O
relation	O	O
to	O	O
pre	O
-	O
delivery	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
.	O	O

Participants	B-LIVB
were	O	O
recruited	O	O
from	O	O
Magee	B-OBJC
-	I-OBJC
Womens	I-OBJC
Hospital	I-OBJC
.	O	O

In	O	O
uncomplicated	B-DISO
pregnancy	I-DISO
,	O	O
plasma	B-ANAT
soluble	O
Sdc1	B-CHEM
rose	O	O
significantly	O	O
in	O	O
the	O	O
1st	O
trimester	O
,	O	O
and	O	O
reached	O	O
an	O	O
approximate	O	O
50	O	O
-	O	O
fold	O	O
increase	O	O
at	O	O
term	O	O
compared	O
to	O	O
post	O
pregnancy	O
levels	O
.	O	O

Soluble	O
Sdc1	B-CHEM
was	O	O
lower	O
at	O	O
mid	O
-	O
pregnancy	O
in	O	O
women	B-LIVB
who	O	O
later	O	O
developed	O	O
preeclampsia	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
but	O	O
not	O	O
gestational	B-DISO
hypertension	I-DISO
,	O	O
compared	O
to	O	O
controls	B-LIVB
,	O	O
and	O	O
remained	O	O
lower	O
at	O	O
late	B-DISO
pregnancy	I-DISO
in	O	O
preeclampsia	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
compared	O
to	O	O
controls	B-LIVB
.	O	O

Sdc1	B-CHEM
was	O	O
prominently	O	O
expressed	B-PHYS
on	O	O
syncytiotrophoblast	B-ANAT
of	O	O
microvilli	B-ANAT
.	O	O

Syncytiotrophoblast	B-ANAT
Sdc1	B-CHEM
immunostaining	B-PROC
intensities	I-PROC
,	O	O
and	O	O
mRNA	B-CHEM
content	O	O
in	O	O
villous	O
homogenates	O
,	O	O
were	O	O
lower	O
in	O	O
preeclampsia	B-DISO
vs	O	O
.	O	O

controls	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Soluble	O
Sdc1	B-CHEM
and	O	O
Sdc1	B-CHEM
immunostaining	B-PROC
scores	O
were	O	O
inversely	O	O
associated	O
with	O
systolic	B-PHYS
blood	I-PHYS
pressures	I-PHYS
,	O	O
and	O	O
positively	O	O
correlated	O
with	O	O
infant	B-LIVB
birth	B-PHYS
weight	I-PHYS
percentile	O
.	O	O

Soluble	O
Sdc1	B-CHEM
is	O	O
significantly	O	O
lower	O
before	O	O
the	O	O
clinical	O
onset	O
of	O
preeclampsia	B-DISO
,	O	O
with	O	O
reduced	O
expression	B-PHYS
of	O	O
Sdc1	B-CHEM
in	O	O
the	O	O
delivered	B-DISO
placenta	B-ANAT
,	O	O
suggesting	O	O
a	O	O
role	O	O
for	O	O
glycocalyx	B-ANAT
disturbance	O	O
in	O	O
preeclampsia	B-DISO
pathophysiology	B-DISO
.	O	O

Identification	B-PHYS
and	O	O
SAR	O
Evaluation	B-PROC
of	O	O
Hemozoin	B-CHEM
-	O	O
Inhibiting	O
Benzamides	B-CHEM
Active	O
against	O	O
Plasmodium	O
falciparum	O
Quinoline	B-CHEM
antimalarials	B-CHEM
target	O
hemozoin	B-CHEM
formation	O
causing	O	O
a	O	O
cytotoxic	O
accumulation	B-DISO
of	O	O
ferriprotoporphyrin	B-CHEM
IX	I-CHEM
(	O	O
Fe	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
PPIX	I-CHEM
)	O	O
.	O	O

Well	O	O
-	O	O
developed	O	O
SAR	O
models	O
exist	O	O
for	O	O
β	B-CHEM
-	I-CHEM
hematin	I-CHEM
inhibition	O
,	O	O
parasite	O
activity	O
,	O	O
and	O	O
cellular	B-PHYS
mechanisms	I-PHYS
for	O	O
this	O	O
compound	O
class	O
,	O	O
but	O	O
no	O	O
comparably	O	O
detailed	O	O
investigations	B-DISO
exist	O	O
for	O	O
other	O	O
hemozoin	B-CHEM
inhibiting	O
chemotypes	B-CHEM
.	O	O

Here	O	O
,	O	O
benzamide	B-CHEM
analogues	B-CHEM
based	O	O
on	O	O
previous	O	O
HTS	B-PROC
hits	O	O
have	O	O
been	O	O
purchased	O
or	O	O
synthesized	O
.	O	O

Only	O	O
derivatives	B-CHEM
containing	I-CHEM
an	I-CHEM
electron	I-CHEM
deficient	I-CHEM
aromatic	I-CHEM
ring	I-CHEM
and	O	O
capable	O	O
of	O	O
adopting	O	O
flat	O
conformations	O
,	O	O
optimal	O	O
for	O	O
π	O
-	O
π	O
interactions	O
with	O	O
Fe	B-CHEM
(	I-CHEM
III	I-CHEM
)	I-CHEM
PPIX	I-CHEM
,	O	O
inhibited	O
β	B-CHEM
-	I-CHEM
hematin	I-CHEM
formation	O
.	O	O

The	O	O
two	O	O
most	O	O
potent	O	O
analogues	B-CHEM
showed	O	O
nanomolar	O
parasite	O
activity	O
,	O	O
with	O	O
little	O	O
CQ	B-CHEM
cross	B-DISO
-	I-DISO
resistance	I-DISO
,	O	O
low	O	O
cytotoxicity	B-DISO
,	O	O
and	O	O
high	O	O
in	O
vitro	O
microsomal	O
stability	O
.	O	O

Selected	O	O
analogues	B-CHEM
inhibited	O
hemozoin	B-CHEM
formation	O
in	O	O
Plasmodium	O
falciparum	O
causing	O	O
high	O	O
levels	O
of	O	O
free	O	O
heme	B-CHEM
.	O	O

In	O	O
contrast	O	O
to	O	O
quinolines	B-CHEM
,	O	O
introduction	O
of	O	O
amine	B-CHEM
side	I-CHEM
chains	I-CHEM
did	O	O
not	O	O
lead	O	O
to	O	O
benzamide	B-CHEM
accumulation	B-DISO
in	O	O
the	O	O
parasite	O
.	O	O

These	O	O
data	O
reveal	O	O
complex	O	O
relationships	O
between	O	O
heme	B-PHYS
binding	I-PHYS
,	O	O
free	O	O
heme	B-CHEM
levels	O
,	O	O
cellular	B-PHYS
accumulation	I-PHYS
,	O	O
and	O	O
in	O
vitro	O
activity	O
of	O	O
potential	O	O
novel	O
antimalarials	B-CHEM
.	O	O

Synthesis	O	O
and	O	O
Photophysical	B-PHYS
Properties	I-PHYS
of	O	O
Fluorescence	B-PHEN
Molecular	B-CHEM
Probe	I-CHEM
for	O	O
Turn	B-PROC
-	I-PROC
ON	I-PROC
-	I-PROC
Type	I-PROC
Detection	I-PROC
of	O	O
Cytosine	B-CHEM
Bulge	I-CHEM
DNA	B-CHEM
A	O	O
fluorescent	B-CHEM
molecule	I-CHEM
DANP	I-CHEM
that	O	O
binds	O	O
to	O	O
cytosine	B-CHEM
bulge	I-CHEM
DNA	B-CHEM
and	O	O
emits	O	O
characteristic	O	O
fluorescence	B-PHEN
was	O	O
conjugated	O
to	O	O
pyrene	B-CHEM
to	O	O
give	O	O
a	O	O
new	O	O
fluorescence	B-CHEM
probe	I-CHEM
PyDANP	I-CHEM
.	O	O

Temperature	O
-	O	O
and	O	O
solvent	B-CHEM
-dependent	O	O
absorption	O
changes	O
showed	O	O
that	O	O
DANP	B-CHEM
and	O	O
pyrene	B-CHEM
chromophores	I-CHEM
stacked	O
at	O	O
room	B-DISO
temperature	I-DISO
in	O	O
an	O	O
aqueous	B-CHEM
buffer	I-CHEM
solution	I-CHEM
and	O	O
quenched	B-PROC
fluorescence	I-PROC
.	O	O

Upon	O	O
binding	O
of	O	O
DANP	B-CHEM
moiety	O	O
in	O	O
PyDANP	B-CHEM
to	O	O
cytosine	B-CHEM
bulge	I-CHEM
DNA	B-CHEM
,	O	O
the	O	O
fluorescence	B-PHEN
from	O	O
DANP	B-CHEM
bound	O	O
to	O	O
C	B-CHEM
-	I-CHEM
bulge	I-CHEM
increased	O	O
by	O	O
∼12	O	O
-	O	O
fold	O	O
,	O	O
showing	O	O
that	O	O
PyDANP	B-CHEM
is	O	O
a	O	O
turn	B-PROC
-	I-PROC
ON	I-PROC
probe	I-PROC
for	I-PROC
the	I-PROC
detection	I-PROC
of	O	O
C	B-CHEM
-	I-CHEM
bulge	I-CHEM
DNA	B-CHEM
.	I-CHEM

Bispectral	B-PROC
pairwise	I-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
for	O	O
identifying	O	O
systems	O
of	O	O
cross	O
-	O
frequency	O
interacting	O
brain	B-ANAT
sources	B-DISO
from	O	O
electroencephalographic	B-PROC
or	O	O
magnetoencephalographic	B-PROC
signals	B-PHEN
Brain	B-ANAT
cognitive	B-PHYS
functions	I-PHYS
arise	O	O
through	O	O
the	O	O
coordinated	B-PHYS
activity	I-PHYS
of	O	O
several	O	O
brain	B-ANAT
regions	I-ANAT
,	O	O
which	O	O
actually	O	O
form	O	O
complex	O
dynamical	O
systems	O
operating	O	O
at	O	O
multiple	O
frequencies	O
.	O	O

These	O	O
systems	O
often	O	O
consist	O	O
of	O	O
interacting	O
subsystems	O
,	O	O
whose	O	O
characterization	O
is	O	O
of	O	O
importance	O	O
for	O	O
a	O	O
complete	O	O
understanding	O	O
of	O	O
the	O	O
brain	B-PHYS
interaction	I-PHYS
processes	I-PHYS
.	O	O

To	O	O
address	O	O
this	O	O
issue	O	O
,	O	O
we	O	O
present	O	O
a	O	O
technique	O
,	O	O
namely	O	O
the	O	O
bispectral	B-PROC
pairwise	I-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
(	O	O
biPISA	B-PROC
)	O	O
,	O	O
for	O	O
analyzing	O	O
systems	O
of	O	O
cross	O
-	O
frequency	O
interacting	O
brain	B-ANAT
sources	B-DISO
when	O	O
multichannel	B-PROC
electroencephalographic	I-PROC
(	O	O
EEG	B-PROC
)	O	O
or	O	O
magnetoencephalographic	B-PROC
(	O	O
MEG	B-PROC
)	O	O
data	O
are	O	O
available	O	O
.	O	O

Specifically	O	O
,	O	O
the	O	O
biPISA	B-PROC
makes	O	O
it	O	O
possible	O	O
to	O	O
identify	O	O
one	O	O
or	O	O
many	O	O
subsystems	O
of	O	O
cross	O
-	O
frequency	O
interacting	O
sources	B-DISO
by	O	O
decomposing	O	O
the	O	O
antisymmetric	O
components	O
of	O	O
the	O	O
cross	B-PROC
-	I-PROC
bispectra	I-PROC
between	O	O
EEG	B-PROC
or	O	O
MEG	B-PROC
signals	B-PHEN
,	O	O
based	O	O
on	O	O
the	O	O
assumption	O	O
that	O	O
interactions	O
are	O	O
pairwise	O
.	O	O

Thanks	O	O
to	O	O
the	O	O
properties	O	O
of	O	O
the	O	O
antisymmetric	O
components	O
of	O	O
the	O	O
cross	B-PROC
-	I-PROC
bispectra	I-PROC
,	O	O
biPISA	B-PROC
is	O	O
also	O	O
robust	O	O
to	O	O
spurious	O	O
interactions	O
arising	O	O
from	O	O
mixing	O	O
artifacts	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O
,	O	O
volume	O
conduction	O
or	O	O
field	O
spread	O
,	O	O
which	O	O
always	O	O
affect	O	O
EEG	B-PROC
or	O	O
MEG	B-PROC
functional	O
connectivity	O
estimates	O	O
.	O	O

This	O	O
method	O	O
is	O	O
an	O	O
extension	O	O
of	O	O
the	O	O
pairwise	B-PROC
interacting	I-PROC
source	I-PROC
analysis	I-PROC
(	I-PROC
PISA	I-PROC
)	I-PROC
,	O	O
which	O	O
was	O	O
originally	O	O
introduced	O	O
for	O	O
investigating	O
interactions	O
at	O	O
the	O	O
same	O	O
frequency	O
,	O	O
to	O	O
the	O	O
study	O	O
of	O	O
cross	O
-	O
frequency	O
interactions	O
.	O	O

The	O	O
effectiveness	O
of	O	O
this	O	O
approach	O
is	O	O
demonstrated	O	O
in	O	O
simulations	B-PROC
for	O	O
up	O	O
to	O	O
three	O	O
interacting	O
source	O	O
pairs	O
and	O	O
for	O	O
real	O	O
MEG	B-PROC
recordings	O	O
of	O	O
spontaneous	O	O
brain	B-PHYS
activity	I-PHYS
.	O	O

Simulations	B-PROC
show	O	O
that	O	O
the	O	O
performances	O	O
of	O	O
biPISA	B-PROC
in	O	O
estimating	O	O
the	O	O
phase	O
difference	O
between	O	O
the	O	O
interacting	O
sources	B-DISO
are	O	O
affected	O	O
by	O	O
the	O	O
increasing	O
level	O
of	O	O
noise	B-PHEN
rather	O	O
than	O	O
by	O	O
the	O	O
number	O	O
of	O	O
the	O	O
interacting	O
subsystems	O
.	O	O

The	O	O
analysis	B-PROC
of	O	O
real	O	O
MEG	B-PROC
data	O
reveals	O	O
an	O	O
interaction	O
between	O	O
two	O	O
pairs	O
of	O	O
sources	B-DISO
of	O	O
central	B-PHYS
mu	I-PHYS
and	O	O
beta	B-PHYS
rhythms	I-PHYS
,	O	O
localizing	O	O
in	O	O
the	O	O
proximity	O	O
of	O	O
the	O	O
left	B-ANAT
and	O	O
right	B-ANAT
central	I-ANAT
sulci	I-ANAT
.	O	O

Shear	O
modulus	O
of	O	O
structured	O
electrorheological	B-OBJC
fluid	I-OBJC
mixtures	B-OBJC
Some	O	O
immiscible	B-OBJC
blends	I-OBJC
under	O	O
a	O	O
strong	O	O
electric	B-PHEN
field	I-PHEN
often	O	O
exhibit	O	O
periodic	O
structures	O
,	O	O
bridging	O	O
the	O	O
gap	O	O
between	O	O
two	O	O
electrodes	B-DEVI
.	O	O

Upon	O	O
shear	B-PHEN
,	O	O
the	O	O
structures	O
tilt	O
,	O	O
and	O	O
exhibit	O	O
an	O	O
elastic	O
response	O	O
which	O	O
is	O	O
mostly	O	O
governed	O	O
by	O	O
the	O	O
electric	B-PHEN
energy	I-PHEN
.	O	O

Assuming	O	O
a	O	O
two	O
-	O
dimensional	O
stripe	O
structure	O
,	O	O
we	O	O
calculate	O	O
the	O	O
Maxwell	B-PHEN
stress	I-PHEN
,	O	O
and	O	O
derive	O	O
an	O	O
expression	O
for	O	O
the	O	O
shear	O
modulus	O
,	O	O
demonstrating	O	O
how	O	O
it	O	O
depends	O	O
on	O	O
the	O	O
external	O	O
electric	B-PHEN
field	I-PHEN
,	O	O
the	O	O
composition	B-PHEN
,	O	O
and	O	O
the	O	O
dielectric	O
properties	O
of	O	O
the	O	O
blend	B-OBJC
.	O	O

We	O	O
also	O	O
suggest	O	O
the	O	O
notion	O	O
of	O	O
effective	O	O
interfacial	B-PHEN
tension	I-PHEN
,	O	O
which	O	O
renormalizes	O	O
the	O	O
effect	O
of	O
the	O	O
electric	B-PHEN
field	I-PHEN
.	O	O

This	O	O
leads	O	O
to	O	O
a	O	O
simple	O	O
derivation	O
of	O	O
the	O	O
scaling	O
law	O
for	O	O
the	O	O
selection	O	O
of	O	O
the	O	O
wavelength	O
of	O	O
the	O	O
structure	O
formed	O	O
under	O	O
an	O	O
electric	B-PHEN
field	I-PHEN
.	O	O

Palmitoyl	B-CHEM
Glycol	I-CHEM
Chitosan	I-CHEM
Micelles	B-CHEM
for	O	O
Corneal	B-ANAT
Delivery	O
of	O	O
Cyclosporine	B-CHEM
Different	O	O
substitution	B-PHYS
degrees	O	O
of	O	O
palmitoyl	B-CHEM
glycol	I-CHEM
chitosan	I-CHEM
(	O	O
PGC	B-CHEM
)	O	O
,	O	O
prepared	B-DISO
according	O	O
to	O	O
the	O	O
literature	O
,	O	O
were	O	O
used	O	O
to	O	O
obtain	O
polymeric	B-CHEM
micelles	B-CHEM
that	O	O
have	O	O
been	O	O
assessed	O
in	O	O
comparison	O
with	O	O
Pluronic	B-CHEM
F127	I-CHEM
micelles	B-CHEM
as	O	O
possible	O	O
carriers	B-CHEM
for	O	O
poorly	O	O
soluble	O
drugs	B-CHEM
,	O	O
such	O	O
as	O	O
cyclosporine	B-CHEM
A	I-CHEM
.	O	O

Both	O	O
PGC	B-CHEM
and	O	O
Pluronic	B-CHEM
micelles	B-CHEM
were	O	O
studied	O	O
for	O	O
their	O	O
interactions	B-PHYS
with	O	O
cell	B-PROC
culture	I-PROC
substrates	B-OBJC
.	O	O

The	O	O
least	O	O
substituted	B-PHYS
and	O	O
most	O	O
hydrophilic	O
derivative	O
,	O	O
PGC21	B-CHEM
(	O	O
approximately	O
5	O	O
%	O	O
substitution	B-PHYS
)	O	O
,	O	O
showed	O	O
a	O	O
strong	O	O
association	O
with	O
cyclosporine	B-CHEM
,	O	O
more	O	O
than	O	O
tripling	O	O
the	O	O
colloidal	B-CHEM
concentration	O
with	O	O
respect	O	O
to	O	O
the	O	O
saturated	B-PHEN
solution	B-OBJC
.	O	O

It	O	O
showed	O	O
a	O	O
greater	O	O
ability	B-PHYS
to	O	O
open	O	O
Caco	B-ANAT
-	I-ANAT
2	I-ANAT
tight	B-ANAT
junctions	I-ANAT
and	O	O
to	O	O
enhance	O
the	O	O
permeability	B-PHEN
of	O	O
Caco	B-ANAT
-	I-ANAT
2	I-ANAT
substrates	B-OBJC
with	O	O
respect	O	O
to	O	O
micelles	B-CHEM
based	O	O
on	O	O
higher	O	O
palmitoyl	B-CHEM
substitution	B-PHYS
,	O	O
conceivably	O	O
due	O	O
to	O	O
the	O	O
lower	O	O
modification	O
of	O	O
the	O	O
chitosan	B-CHEM
chains	I-CHEM
.	O	O

Permeation	B-PHEN
and	O	O
penetration	O
experiments	B-PROC
were	O	O
performed	O
with	O	O
PGC21	B-CHEM
and	O	O
Pluronic	B-CHEM
micelles	B-CHEM
on	O	O
a	O	O
rabbit	B-LIVB
corneal	B-ANAT
epithelial	I-ANAT
cell	I-ANAT
line	I-ANAT
(	O	O
RCE	B-ANAT
)	O	O
and	O	O
on	O	O
excised	O	O
pig	B-LIVB
corneas	B-ANAT
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
both	O	O
PGC	B-CHEM
and	O	O
Pluronic	B-CHEM
micelles	B-CHEM
could	O	O
increase	O
the	O	O
permeation	B-PHEN
of	O	O
the	O	O
fluorescent	B-CHEM
probe	I-CHEM
rhodamine	B-CHEM
B	I-CHEM
through	O	O
RCE	B-ANAT
cells	I-ANAT
by	O	O
more	O	O
than	O	O
ten	O	O
-	O	O
fold	O	O
.	O	O

In	O	O
RCE	B-ANAT
and	O	O
in	O	O
pig	B-LIVB
cornea	B-ANAT
,	O	O
the	O	O
micelles	B-CHEM
improved	B-DISO
the	O	O
penetration	O
of	O	O
both	O	O
rhodamine	B-CHEM
andr	O	O
cyclosporine	B-CHEM
.	O	O

For	O	O
cyclosporine	B-CHEM
,	O	O
the	O	O
PGC21	B-CHEM
micelles	B-CHEM
allowed	O	O
penetration	O
of	O	O
approximately	O
1	O	O
μg	O	O
/	O	O
mg	O	O
cyclosporine	B-CHEM
A	I-CHEM
in	O	O
corneal	B-ANAT
tissue	O
,	O	O
demonstrating	O	O
a	O	O
potential	O
for	O	O
use	O	O
in	O	O
immunosuppression	B-PROC
therapies	I-PROC
.	O	O

Plasmodium	O
falciparum	O
parasite	O
population	O
structure	O
and	O	O
gene	B-PHYS
flow	I-PHYS
associated	O
to	O	O
anti	B-CHEM
-	I-CHEM
malarial	I-CHEM
drugs	B-PHEN
resistance	I-PHEN
in	O	O
Cambodia	B-GEOG
Western	B-GEOG
Cambodia	I-GEOG
is	O	O
recognized	O	O
as	O	O
the	O	O
epicentre	O	O
of	O	O
emergence	B-DISO
of	O	O
Plasmodium	O
falciparum	O
multi	B-PHYS
-	I-PHYS
drug	I-PHYS
resistance	I-PHYS
.	O	O

The	O	O
emergence	B-DISO
of	O	O
artemisinin	B-CHEM
resistance	B-PHEN
has	O	O
been	O	O
observed	O	O
in	O	O
this	O	O
area	B-GEOG
since	O	O
2008	O	O
-	O	O
2009	O	O
and	O	O
molecular	O
signatures	O
associated	O
to	O	O
artemisinin	B-CHEM
resistance	B-PHEN
have	O	O
been	O	O
characterized	O	O
in	O	O
k13	O
gene	O
.	O	O

At	O	O
present	O	O
,	O	O
one	O	O
of	O	O
the	O	O
major	O	O
threats	O
faced	O	O
,	O	O
is	O	O
the	O	O
possible	O	O
spread	O	O
of	O	O
Asian	B-GEOG
artemisinin	B-CHEM
resistant	B-PHEN
parasites	O
over	O	O
the	O	O
world	O	O
threatening	O	O
millions	O	O
of	O	O
people	B-LIVB
and	O	O
jeopardizing	O	O
malaria	B-DISO
elimination	B-PROC
programme	I-PROC
efforts	O	O
.	O	O

To	O	O
anticipate	O	O
the	O	O
diffusion	O	O
of	O	O
artemisinin	B-CHEM
resistance	B-PHEN
,	O	O
the	O	O
identification	O
of	O	O
the	O	O
P	O
.	O

falciparum	O
population	O
structure	O
and	O	O
the	O	O
gene	B-PHYS
flow	I-PHYS
among	O	O
the	O	O
parasite	O
population	O
in	O	O
Cambodia	B-GEOG
are	O	O
essential	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
a	O	O
mid	O	O
-	O	O
throughput	O	O
PCR	B-PROC
-	O	O
LDR	B-PROC
-	I-PROC
FMA	I-PROC
approach	O	O
based	O	O
on	O	O
LUMINEX	B-PROC
technology	I-PROC
was	O	O
developed	O	O
to	O	O
screen	O	O
for	O	O
genetic	O
barcode	O
in	O	O
533	O	O
blood	B-ANAT
samples	I-ANAT
collected	O	O
in	O	O
2010	O	O
-	O	O
2011	O	O
from	O	O
16	O	O
health	B-OBJC
centres	I-OBJC
in	O	O
malaria	B-DISO
endemics	O
areas	O	O
in	O	O
Cambodia	B-GEOG
.	O	O

Based	O	O
on	O	O
successful	O	O
typing	B-PROC
of	O	O
282	O	O
samples	B-ANAT
,	O	O
subpopulations	O
were	O	O
characterized	O	O
along	O	O
the	O	O
borders	O	O
of	O	O
the	O	O
country	B-GEOG
.	O	O

Each	O	O
11	O
-	O
loci	O
barcode	O
provides	O	O
evidence	O
supporting	O	O
allele	O
distribution	O
gradient	O
related	O	O
to	O	O
subpopulations	O
and	O	O
gene	B-PHYS
flow	I-PHYS
.	O	O

The	O	O
11	O
-	O
loci	O
barcode	O
successfully	O	O
identifies	O	O
recently	O	O
emerging	O	O
parasite	O
subpopulations	O
in	O	O
western	B-GEOG
Cambodia	I-GEOG
that	O	O
are	O	O
associated	O
with	O	O
the	O	O
C580Y	O
dominant	O
allele	O
for	O	O
artemisinin	B-CHEM
resistance	B-PHEN
in	O	O
k13	O
gene	O
.	O	O

A	O	O
subpopulation	O
was	O	O
identified	O	O
in	O	O
northern	B-GEOG
Cambodia	I-GEOG
that	O	O
was	O	O
associated	O
to	O	O
artemisinin	B-CHEM
(	O	O
R539	O
T	O
resistant	O
allele	O
of	O	O
k13	O
gene	O
)	O	O
and	O	O
mefloquine	B-CHEM
resistance	B-PHEN
.	O	O

The	O	O
gene	B-PHYS
flow	I-PHYS
between	O	O
these	O	O
subpopulations	O
might	O	O
have	O	O
driven	O	O
the	O	O
spread	O	O
of	O	O
artemisinin	B-CHEM
resistance	B-PHEN
over	O	O
Cambodia	B-GEOG
.	O	O

Sequence	B-PHYS
-	I-PHYS
specific	I-PHYS
DNA	I-PHYS
binding	I-PHYS
by	O	O
long	B-CHEM
hairpin	I-CHEM
pyrrole	B-CHEM
-	I-CHEM
imidazole	I-CHEM
polyamides	I-CHEM
containing	O	O
an	O	O
8	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dioxaoctanoic	I-CHEM
acid	I-CHEM
unit	O	O
With	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
aqueous	O
solubility	O
,	O	O
we	O	O
designed	O
and	O	O
synthesized	O
five	O	O
N	B-CHEM
-	I-CHEM
methylpyrrole	I-CHEM
(	I-CHEM
Py	I-CHEM
)	I-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
methylimidazole	I-CHEM
(	I-CHEM
Im	I-CHEM
)	I-CHEM
polyamides	I-CHEM
capable	O	O
of	O	O
recognizing	O	O
9	O
-	O
bp	O
sequences	O
.	O	O

Their	O	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
affinities	B-PHEN
and	O	O
sequence	O
specificities	O
were	O	O
evaluated	O	O
by	O	O
SPR	B-PROC
and	O	O
Bind	B-PROC
-	I-PROC
n	I-PROC
-	I-PROC
Seq	I-PROC
analyses	I-PROC
.	O	O

The	O	O
design	O
of	O	O
polyamide	B-CHEM
1	I-CHEM
was	O	O
based	O	O
on	O	O
a	O	O
conventional	O	O
model	O
,	O	O
with	O	O
three	O	O
consecutive	O	O
Py	B-CHEM
or	O	O
Im	B-CHEM
rings	O	O
separated	O	O
by	O	O
a	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
to	O	O
match	O	O
the	O	O
curvature	O	O
and	O	O
twist	O
of	O	O
long	O	O
DNA	B-CHEM
helices	O
.	O	O

Polyamides	B-CHEM
2	I-CHEM
and	I-CHEM
3	I-CHEM
contained	O	O
an	O	O
8	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
dioxaoctanoic	I-CHEM
acid	I-CHEM
(	O	O
AO	B-CHEM
)	O	O
unit	O	O
,	O	O
which	O	O
has	O	O
previously	O	O
only	O	O
been	O	O
used	O	O
as	O	O
a	O	O
linker	B-CHEM
within	O	O
linear	O	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
polyamides	I-CHEM
or	O	O
between	O	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
hairpin	I-CHEM
motifs	I-CHEM
for	O	O
tandem	B-CHEM
hairpin	I-CHEM
.	O	O

It	O	O
is	O	O
demonstrated	O	O
herein	O	O
that	O	O
AO	B-CHEM
also	O	O
functions	O	O
as	O	O
a	O	O
linker	B-CHEM
element	I-CHEM
that	O	O
can	O	O
extend	O	O
to	O	O
2	O
-	O
bp	O
in	O	O
hairpin	B-CHEM
motifs	I-CHEM
.	O	O

Notably	O	O
,	O	O
although	O	O
the	O	O
AO	B-CHEM
-containing	O	O
unit	O	O
can	O	O
fail	O
to	O	O
bind	O
the	O	O
expected	O	O
sequence	O
,	O	O
polyamide	B-CHEM
4	I-CHEM
,	O	O
which	O	O
has	O	O
two	O	O
AO	B-CHEM
units	O	O
facing	O	O
each	O	O
other	O	O
in	O	O
a	O	O
hairpin	O
form	O
,	O	O
successfully	O	O
showed	O	O
the	O	O
expected	O	O
motif	O
and	O	O
a	O	O
KD	O
value	O
of	O	O
16nM	O	O
was	O	O
recorded	O	O
.	O	O

Polyamide	B-CHEM
5	I-CHEM
,	O	O
containing	O	O
a	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
-	I-CHEM
β	I-CHEM
-	I-CHEM
alanine	I-CHEM
unit	O	O
instead	O	O
of	O	O
the	O	O
AO	B-CHEM
of	O	O
polyamide	B-CHEM
2	I-CHEM
,	O	O
was	O	O
synthesized	O
for	O	O
comparison	O
.	O	O

The	O	O
aqueous	O
solubilities	O
and	O	O
nuclear	B-PHEN
localization	I-PHEN
of	O	O
three	O	O
of	O	O
the	O	O
polyamides	B-CHEM
were	O	O
also	O	O
examined	O	O
.	O	O

The	O	O
results	O
suggest	O	O
the	O	O
possibility	O	O
of	O	O
applying	O	O
the	O	O
AO	B-CHEM
unit	O	O
in	O	O
the	O	O
core	O
of	O	O
Py	B-CHEM
-	I-CHEM
Im	I-CHEM
polyamide	I-CHEM
compounds	I-CHEM
.	O	O

Mining	O
Health	O
App	O
Data	O
to	O	O
Find	O	O
More	O	O
and	O	O
Less	O	O
Successful	O
Weight	B-DISO
Loss	I-DISO
Subgroups	O	O
More	O	O
than	O	O
half	O	O
of	O	O
all	O	O
smartphone	O
app	O
downloads	O	O
involve	O	O
weight	B-PHYS
,	O	O
diet	B-OBJC
,	I-OBJC
and	O	O
exercise	O
.	O	O

If	O	O
successful	O	O
,	O	O
these	O	O
lifestyle	O
apps	O
may	O	O
have	O	O
far	O	O
-	O	O
reaching	O	O
effects	O
for	O	O
disease	B-PROC
prevention	I-PROC
and	O	O
health	O
cost	O
-	O
savings	O
,	O	O
but	O	O
few	O	O
researchers	B-LIVB
have	O	O
analyzed	O	O
data	O
from	O	O
these	O	O
apps	O
.	O	O

The	O	O
purposes	O
of	O
this	O
study	O
were	O	O
to	O	O
analyze	O	O
data	O
from	O	O
a	O	O
commercial	O
health	O
app	O
(	O	O
Lose	O
It	O
!	O
)	O	O
in	O	O
order	O	O
to	O	O
identify	O	O
successful	B-DISO
weight	I-DISO
loss	I-DISO
subgroups	O
via	O	O
exploratory	B-PROC
analyses	I-PROC
and	O	O
to	O	O
verify	O	O
the	O	O
stability	O
of	O	O
the	O	O
results	O
.	O	O

Cross	O
-	O
sectional	O
,	O	O
de	O	O
-	O	O
identified	O	O
data	O
from	O	O
Lose	O
It	O
!	O
were	O	O
analyzed	O	O
.	O	O

This	O	O
dataset	O
(	O	O
n	O	O
=	O	O
12	O	O
,	O	O
427	O	O
,	O	O
196	O	O
)	O	O
was	O	O
randomly	O	O
split	O	O
into	O	O
24	O	O
subsamples	O
,	O	O
and	O	O
this	O	O
study	O	O
used	O	O
3	O	O
subsamples	O
(	O	O
combined	O	O
n	O	O
=	O	O
972	O	O
,	O	O
687	O	O
)	O	O
.	O	O

Classification	O
and	O	O
regression	O
tree	O
methods	O
were	O	O
used	O	O
to	O	O
explore	O	O
groupings	O
of	O	O
weight	B-DISO
loss	I-DISO
with	O	O
one	O	O
subsample	O
,	O	O
with	O	O
descriptive	B-PROC
analyses	I-PROC
to	O	O
examine	O	O
other	O	O
group	O
characteristics	O
.	O	O

Data	O
mining	O
validation	O
methods	O
were	O	O
conducted	O	O
with	O	O
2	O	O
additional	O	O
subsamples	O
.	O	O

In	O	O
subsample	O
1	O	O
,	O	O
14	O	O
.	O	O
96	O	O
%	O	O
of	O	O
users	B-LIVB
lost	B-DISO
5	O	O
%	O	O
or	O	O
more	O	O
of	O	O
their	O	O
starting	O	O
body	B-PHYS
weight	I-PHYS
.	O	O

Classification	O
and	O	O
regression	O
tree	O
analysis	O
identified	O	O
3	O	O
distinct	O	O
subgroups	O
:	O	O
""""	O	O
the	O	O
occasional	O
users	B-LIVB
""""	O	O
had	O	O
the	O	O
lowest	O
proportion	O	O
(	O	O
4	O	O
.	O	O
87	O	O
%	O	O
)	O	O
of	O	O
individuals	B-LIVB
who	O	O
successfully	O	O
lost	B-DISO
weight	I-DISO
;	O	O
""""	O	O
the	O	O
basic	O	O
users	B-LIVB
""""	O	O
had	O	O
37	O	O
.	O	O
61	O	O
%	O	O
weight	B-DISO
loss	I-DISO
success	O	O
;	O	O
and	O	O
""""	O	O
the	O	O
power	B-LIVB
users	I-LIVB
""""	O	O
achieved	O	O
the	O	O
highest	O
percentage	O	O
of	O	O
weight	B-DISO
loss	I-DISO
success	I-DISO
at	O	O
72	O	O
.	O	O

70	O	O
%	O	O
.	O	O

Behavioral	O
factors	O
delineated	O	O
the	O	O
subgroups	O
,	O	O
though	O	O
app	O
-related	O	O
behavioral	O
characteristics	O
further	O	O
distinguished	O	O
them	O	O
.	O	O

Results	O
were	O	O
replicated	O
in	O	O
further	O	O
analyses	B-PROC
with	O	O
separate	O	O
subsamples	O
.	O	O

This	O	O
study	B-PROC
demonstrates	O	O
that	O	O
distinct	O	O
subgroups	O
can	O	O
be	O	O
identified	O	O
in	O	O
""""	O	O
messy	O	O
""""	O	O
commercial	O
app	O
data	O
and	O	O
the	O	O
identified	O	O
subgroups	O
can	O	O
be	O	O
replicated	O
in	O	O
independent	O	O
samples	O	O
.	O	O

Behavioral	O
factors	O
and	O	O
use	O
of	O
custom	O	O
app	O
features	O
characterized	O	O
the	O	O
subgroups	O
.	O	O

Targeting	O	O
and	O	O
tailoring	O	O
information	O
to	O	O
particular	O	O
subgroups	O
could	O	O
enhance	O	O
weight	O
loss	O
success	O
.	O	O

Future	O	O
studies	B-PROC
should	O	O
replicate	O
data	O
mining	O
analyses	B-PROC
to	O	O
increase	O	O
methodology	O	O
rigor	O	O
.	O	O

Recognising	B-PHYS
and	O	O
responding	B-PHYS
to	O	O
'	O	O
cutting	O
corners	O
'	O	O
when	O	O
providing	O	O
nursing	B-PROC
care	I-PROC
:	O	O
a	O	O
qualitative	B-PROC
study	I-PROC
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
report	O	O
on	O	O
a	O	O
key	O	O
finding	B-DISO
of	O	O
a	O	O
larger	B-PROC
study	I-PROC
investigating	O	O
the	O	O
'	O	O
gaps	O
'	O	O
in	O	O
patient	B-PROC
care	I-PROC
that	O	O
registered	B-LIVB
nurses	I-LIVB
encounter	O	O
during	O	O
the	O	O
course	O	O
of	O	O
their	O	O
practice	O
.	O	O

A	O	O
key	O	O
finding	B-DISO
of	O	O
this	O	O
larger	B-PROC
study	I-PROC
was	O	O
that	O	O
'	O	O
cutting	O
corners	O
'	O	O
was	O	O
a	O	O
gap	O
discerned	O	O
by	O	O
nurses	B-LIVB
.	O	O
'	O	O
Cutting	O
corners	O
'	O	O
has	O	O
been	O	O
characterised	O	O
as	O	O
a	O	O
'	O	O
violation	O
'	O	O
and	O	O
threat	O
to	O	O
patient	B-PROC
safety	I-PROC
,	O	O
although	O	O
there	O	O
is	O	O
a	O	O
paucity	O	O
of	O	O
research	B-PROC
on	O	O
this	O	O
issue	O	O
.	O	O

Naturalistic	B-PROC
inquiry	I-PROC
using	O	O
a	O	O
qualitative	O
exploratory	O
descriptive	O
approach	O
.	O	O

Data	O
were	O	O
collected	O	O
from	O	O
a	O	O
purposeful	O	O
sample	O	O
of	O	O
71	O	O
registered	B-LIVB
nurses	I-LIVB
from	O	O
emergency	B-OBJC
department	I-OBJC
,	O	O
critical	B-PROC
care	I-PROC
,	O	O
perioperative	O
,	O	O
rehabilitation	O
and	O	O
transitional	B-PROC
care	I-PROC
and	O	O
neurosciences	B-PROC
settings	I-PROC
in	O	O
Australia	B-GEOG
and	O	O
analysed	O	O
using	O	O
content	B-PROC
and	O	O
thematic	B-PROC
analysis	I-PROC
strategies	O	O
.	O	O

Cutting	O
corners	O
was	O	O
a	O	O
common	O	O
practice	O
that	O	O
encompassed	O	O
(	O	O
1	O	O
)	O	O
the	O	O
partial	O	O
or	O	O
complete	O	O
omission	B-DISO
of	O	O
patient	B-PROC
care	I-PROC
,	O	O
(	O	O
2	O	O
)	O	O
delays	O
in	O	O
providing	B-PROC
care	I-PROC
and	O	O
(	O	O
3	O	O
)	O	O
the	O	O
failure	O
to	O	O
do	O	O
things	O	O
correctly	O	O
.	O	O

Corners	O
were	O	O
cut	O	O
in	O	O
patient	B-LIVB
assessment	B-PROC
,	O	O
essential	O	O
nursing	B-PROC
care	I-PROC
,	O	O
the	O	O
care	B-PROC
of	I-PROC
central	I-PROC
venous	I-PROC
catheters	I-PROC
and	O	O
medication	B-PROC
administration	I-PROC
.	O	O

The	O	O
practice	O
of	O	O
cutting	O
corners	O
was	O	O
perceived	O	O
as	O	O
contributing	O	O
to	O	O
preventable	B-DISO
adverse	B-DISO
events	I-DISO
.	O	O

The	O	O
study	B-PROC
found	O	O
that	O	O
cutting	O
corners	O
created	O	O
gaps	O
that	O	O
contributed	O	O
to	O	O
unfinished	O	O
nursing	B-PROC
care	I-PROC
and	O	O
preventable	B-DISO
adverse	B-DISO
events	I-DISO
.	O	O

The	O	O
findings	B-DISO
of	O	O
the	O	O
study	B-PROC
raise	O	O
the	O	O
possibility	O	O
that	O	O
cutting	O
corners	O
is	O	O
a	O	O
salient	O	O
but	O	O
underinvestigated	O	O
characteristic	O	O
of	O	O
nursing	B-PROC
practice	I-PROC
.	O	O

Further	O	O
research	B-PROC
and	O	O
inquiry	O
are	O	O
needed	O	O
to	O	O
deepen	O	O
understanding	O	O
of	O	O
cutting	O
corners	O
and	O	O
its	O	O
impact	O
on	O	O
patient	B-PROC
safety	I-PROC
.	O	O

Identifying	O	O
the	O	O
nature	O	O
and	O	O
implications	B-DISO
of	O	O
cutting	O
corners	O
when	O	O
providing	O	O
nursing	B-PROC
care	I-PROC
is	O	O
an	O	O
important	O	O
contributing	O	O
factor	O	O
to	O	O
improving	O	O
patient	B-PROC
safety	I-PROC
and	O	O
quality	B-PROC
care	I-PROC
.	O	O

The	O	O
PP	B-CHEM
-	O	O
motif	O
in	O	O
luminal	O
loop	O
2	O	O
of	O	O
ZnT	B-CHEM
transporters	I-CHEM
plays	O	O
a	O	O
pivotal	O	O
role	O	O
in	O	O
TNAP	B-CHEM
activation	B-PHYS
Secretory	B-CHEM
and	O	O
membrane	B-ANAT
-	O	O
bound	O
zinc	B-CHEM
-requiring	O	O
enzymes	B-CHEM
are	O	O
thought	O	O
to	O	O
be	O	O
activated	B-PHYS
by	O	O
binding	B-PHYS
zinc	B-CHEM
in	O	O
the	O	O
early	O
secretory	B-PHYS
pathway	I-PHYS
.	O	O

One	O	O
such	O	O
enzyme	B-CHEM
,	O	O
tissue	B-CHEM
-	I-CHEM
non	I-CHEM
-	I-CHEM
specific	I-CHEM
alkaline	I-CHEM
phosphatase	I-CHEM
(	O	O
TNAP	B-CHEM
)	O	O
,	O	O
is	O	O
activated	B-PHYS
through	O	O
a	O	O
two	O	O
-	O	O
step	O	O
mechanism	O
,	O	O
via	O	O
protein	B-PHYS
stabilization	I-PHYS
and	O	O
subsequent	O	O
enzyme	B-PHYS
activation	I-PHYS
through	O	O
metalation	B-PHEN
,	O	O
by	O	O
ZnT5	B-CHEM
-	O	O
ZnT6	B-CHEM
heterodimers	B-CHEM
or	O	O
ZnT7	B-CHEM
homodimers	B-CHEM
.	O	O

However	O	O
,	O	O
little	O	O
is	O	O
known	O
about	O	O
the	O	O
molecular	O
basis	O
underlying	O	O
the	O	O
activation	B-PHYS
process	B-PHEN
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
di	B-CHEM
-	I-CHEM
proline	I-CHEM
motif	O
(	O	O
PP	B-CHEM
-	O	O
motif	O
)	O	O
in	O	O
luminal	O
loop	O
2	O	O
of	O	O
ZnT5	B-CHEM
and	O	O
ZnT7	B-CHEM
is	O	O
important	O	O
for	O	O
TNAP	B-CHEM
activation	B-PHYS
.	O	O

TNAP	B-CHEM
activity	B-PHYS
was	O	O
significantly	O
reduced	O
in	O	O
cells	B-ANAT
lacking	O
ZnT5	B-CHEM
-	O	O
ZnT6	B-CHEM
heterodimers	B-CHEM
and	O	O
ZnT7	B-CHEM
homodimers	B-CHEM
[	O	O
triple	O	O
knockout	O	O
(	O	O
TKO	O	O
)	O	O
cells	B-ANAT
]	O	O
.	O	O

The	O	O
decreased	O
TNAP	B-CHEM
activity	B-PHYS
was	O	O
restored	O	O
by	O	O
expressing	B-PHYS
hZnT5	O
with	O	O
hZnT6	O
or	O	O
hZnT7	O
,	O	O
but	O	O
significantly	O
less	O
so	O	O
(	O	O
almost	O	O
90	O	O
%	O	O
less	O	O
)	O	O
by	O	O
expressing	B-PHYS
mutants	B-DISO
thereof	O	O
in	O	O
which	O	O
the	O	O
PP	B-CHEM
-	O	O
motif	O
was	O	O
mutated	B-PHYS
to	O	O
alanine	B-CHEM
(	O	O
PP	B-CHEM
-	O	O
AA	B-CHEM
)	O	O
.	O	O

In	O	O
TKO	O	O
cells	B-ANAT
,	O	O
overexpressed	B-PHYS
hTNAP	B-CHEM
was	O	O
not	O	O
completely	O	O
activated	B-PHYS
,	O	O
and	O	O
it	O	O
was	O	O
converted	O
less	O	O
efficiently	O
into	O	O
the	O	O
holo	O	O
form	O	O
by	O	O
expressing	B-PHYS
a	O	O
PP	B-CHEM
-	O	O
AA	B-CHEM
mutant	B-DISO
of	O	O
hZnT5	O
with	O	O
hZnT6	O
,	O	O
whose	O	O
defects	O
were	O	O
not	O	O
restored	B-PROC
by	O	O
zinc	B-CHEM
supplementation	B-PROC
.	O	O

The	O	O
zinc	B-PHYS
transport	I-PHYS
activity	B-PHYS
of	O	O
hZnT7	O
was	O	O
not	B-DISO
significantly	I-DISO
impaired	O
by	O	O
the	O	O
PP	B-CHEM
-	O	O
AA	B-CHEM
mutation	B-PHYS
,	O	O
indicating	O	O
that	O	O
the	O	O
PP	B-CHEM
-	O	O
motif	O
is	O	O
involved	O	O
in	O	O
the	O	O
TNAP	B-CHEM
maturation	B-PHYS
process	B-PHEN
,	O	O
although	O	O
it	O	O
does	O	O
not	O	O
control	O
zinc	B-PHYS
transport	I-PHYS
activity	B-PHYS
.	O	O

The	O	O
PP	B-CHEM
-	O	O
motif	O
is	O	O
highly	O
conserved	O
in	O	O
ZnT5	B-CHEM
and	O	O
ZnT7	B-CHEM
orthologues	O
,	O	O
and	O	O
its	O	O
importance	O	O
for	O	O
TNAP	B-CHEM
activation	B-PHYS
is	O	O
conserved	O	O
in	O	O
the	O	O
Caenorhabditis	O
elegans	O
hZnT5	B-CHEM
orthologue	O
CDF5	B-LIVB
.	O	O

These	O	O
results	O
provide	O	O
novel	O	O
molecular	O
insights	O	O
into	O	O
the	O	O
TNAP	B-CHEM
activation	B-PHYS
process	B-PHEN
in	O	O
the	O	O
early	O
secretory	B-PHYS
pathway	I-PHYS
.	O	O

Novel	O
protein	B-CHEM
-	O	O
inhibitor	B-CHEM
interactions	O
in	O	O
site	B-CHEM
3	I-CHEM
of	I-CHEM
Ca	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	I-CHEM
bound	I-CHEM
S100B	I-CHEM
as	O	O
discovered	O
by	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallography	I-PROC
Structure	B-PROC
-	I-PROC
based	I-PROC
drug	I-PROC
discovery	I-PROC
is	O	O
under	O	O
way	O	O
to	O	O
identify	O	O
and	O	O
develop	O	O
small	B-CHEM
-	I-CHEM
molecule	I-CHEM
S100B	B-CHEM
inhibitors	B-CHEM
(	O	O
SBiXs	B-CHEM
)	O	O
.	O	O

Such	O	O
inhibitors	B-CHEM
have	O	O
therapeutic	O
potential	O
for	O	O
treating	O
malignant	B-DISO
melanoma	I-DISO
,	O	O
since	O	O
high	O	O
levels	O	O
of	O	O
S100B	B-CHEM
downregulate	B-PHYS
wild	B-CHEM
-	I-CHEM
type	I-CHEM
p53	I-CHEM
tumor	B-PHYS
suppressor	I-PHYS
function	I-PHYS
in	O	O
this	O	O
cancer	B-DISO
.	O	O

Computational	B-PROC
and	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallographic	I-PROC
studies	I-PROC
of	O	O
two	O	O
S100B	B-CHEM
-	O	O
SBiX	B-CHEM
complexes	B-CHEM
are	O	O
described	O	O
,	O	O
and	O	O
both	O	O
compounds	O
(	O	O
apomorphine	B-CHEM
hydrochloride	I-CHEM
and	O	O
ethidium	B-CHEM
bromide	I-CHEM
)	O	O
occupy	O	O
an	O	O
area	O	O
of	O	O
the	O	O
S100B	B-CHEM
hydrophobic	O
cleft	O
which	O	O
is	O	O
termed	O	O
site	O
3	O
.	O	O

These	O	O
data	O
also	O	O
reveal	O	O
novel	O	O
protein	B-CHEM
-	O	O
inhibitor	B-CHEM
interactions	O
which	O	O
can	O	O
be	O	O
used	O	O
in	O	O
future	O	O
drug	O
-	O
design	O
studies	O
to	O	O
improve	B-DISO
SBiX	B-CHEM
affinity	B-PHEN
and	O	O
specificity	O
.	O	O

Of	O	O
particular	O	O
interest	O	O
,	O	O
apomorphine	B-CHEM
hydrochloride	I-CHEM
showed	O	O
S100B	B-CHEM
-dependent	O	O
killing	B-PHYS
in	O	O
melanoma	B-ANAT
cell	I-ANAT
assays	B-PROC
,	O	O
although	O	O
the	O	O
efficacy	O
exceeds	O	O
its	O	O
affinity	B-PHEN
for	O	O
S100B	B-CHEM
and	O	O
implicates	O	O
possible	O	O
off	O	O
-	O	O
target	O	O
contributions	O	O
.	O	O

Because	O	O
there	O	O
are	O	O
no	O	O
structural	O
data	O
available	O	O
for	O	O
compounds	O
occupying	O	O
site	O
3	O
alone	O	O
,	O	O
these	O	O
studies	B-PROC
contribute	O	O
towards	O	O
the	O	O
structure	O	O
-	O	O
based	O	O
approach	O	O
to	O	O
targeting	O	O
S100B	B-CHEM
by	O	O
including	O	O
interactions	O
with	O	O
residues	O
in	O	O
site	O
3	O
of	O	O
S100B	B-CHEM
.	O	O

Ownership	O
and	O	O
Agency	O
of	O	O
an	O	O
Independent	B-OBJC
Supernumerary	I-OBJC
Hand	I-OBJC
Induced	O
by	O	O
an	O	O
Imitation	B-DEVI
Brain	I-DEVI
-	I-DEVI
Computer	I-DEVI
Interface	I-DEVI
To	O	O
study	O	O
body	B-ANAT
ownership	O
and	O	O
control	O
,	O	O
illusions	B-DISO
that	O	O
elicit	O	O
these	O	O
feelings	B-PHYS
in	O	O
non	B-OBJC
-	I-OBJC
body	I-OBJC
objects	I-OBJC
are	O	O
widely	O	O
used	O	O
.	O	O

Classically	O	O
introduced	O	O
with	O	O
the	O	O
Rubber	B-DISO
Hand	I-DISO
Illusion	I-DISO
,	O	O
these	O	O
illusions	B-DISO
have	O	O
been	O	O
replicated	O
more	O	O
recently	O	O
in	O	O
virtual	O
reality	O
and	O	O
by	O	O
using	O	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interfaces	I-DEVI
.	O	O

Traditionally	O	O
these	O	O
illusions	B-DISO
investigate	O
the	O	O
replacement	O
of	O	O
a	O	O
body	B-ANAT
part	I-ANAT
by	O	O
an	O	O
artificial	B-DEVI
counterpart	I-DEVI
,	O	O
however	O	O
as	O	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interface	I-DEVI
research	B-PROC
develops	O	O
it	O	O
offers	O	O
us	O	O
the	O	O
possibility	O	O
to	O	O
explore	O	O
the	O	O
case	O	O
where	O	O
non	B-OBJC
-	I-OBJC
body	I-OBJC
objects	I-OBJC
are	O	O
controlled	O
in	O	O
addition	O	O
to	O	O
movements	B-PHYS
of	I-PHYS
our	I-PHYS
own	I-PHYS
limbs	I-PHYS
.	O	O

Therefore	O	O
we	O	O
propose	O	O
a	O	O
new	O	O
illusion	B-DISO
designed	O	O
to	O	O
test	O	O
the	O	O
feeling	B-PHYS
of	O	O
ownership	O
and	O	O
control	O
of	O	O
an	O	O
independent	B-OBJC
supernumerary	I-OBJC
hand	I-OBJC
.	O	O

Subjects	B-LIVB
are	O	O
under	O	O
the	O	O
impression	O	O
they	O	O
control	O
a	O	O
virtual	B-OBJC
reality	I-OBJC
hand	I-OBJC
via	O	O
a	O	O
brain	B-DEVI
-	I-DEVI
computer	I-DEVI
interface	I-DEVI
,	O	O
but	O	O
in	O	O
reality	O
there	O	O
is	O	O
no	O	O
causal	O
connection	O
between	O	O
brain	B-PHYS
activity	I-PHYS
and	O	O
virtual	O
hand	O
movement	O
but	O	O
correct	O	O
movements	B-PHYS
are	O	O
observed	O	O
with	O	O
80	O	O
%	O	O
probability	O
.	O	O

These	O	O
imitation	B-PROC
brain	I-PROC
-	I-PROC
computer	I-PROC
interface	I-PROC
trials	I-PROC
are	O	O
interspersed	O	O
with	O	O
movements	B-PHYS
in	O	O
both	O	O
the	O	O
subjects	B-LIVB
'	O	O
real	B-ANAT
hands	I-ANAT
,	O	O
which	O	O
are	O	O
in	O	O
view	O	O
throughout	O	O
the	O	O
experiment	B-PROC
.	O	O

We	O	O
show	O	O
that	O	O
subjects	B-LIVB
develop	O	O
strong	B-PHYS
feelings	I-PHYS
of	O	O
ownership	O
and	O	O
control	O
over	O	O
the	O	O
third	B-OBJC
hand	I-OBJC
,	O	O
despite	O	O
only	O	O
receiving	O	O
visual	B-PHYS
feedback	I-PHYS
with	O	O
no	O	O
causal	O
link	O
to	O	O
the	O	O
actual	O	O
brain	B-ANAT
signals	B-PHEN
.	O	O

Our	O	O
illusion	B-DISO
is	O	O
crucially	O	O
different	O	O
from	O	O
previously	O	O
reported	O	O
studies	O	O
as	O	O
we	O	O
demonstrate	O	O
independent	B-DISO
ownership	O
and	O	O
control	O
of	O	O
the	O	O
third	B-OBJC
hand	I-OBJC
without	O	O
loss	O	O
of	O	O
ownership	O
in	O	O
the	O	O
real	B-ANAT
hands	I-ANAT
.	O	O

Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
in	O	O
pregnancy	B-PHYS
may	O	O
affect	O	O
fetal	B-ANAT
thymus	B-ANAT
development	O	O
The	O	O
aim	O	O
of	O	O
our	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
association	O
of	O	O
vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
(	O	O
VDD	B-DISO
)	O	O
during	O
pregnancy	B-PHYS
with	O	O
thymus	B-ANAT
size	O
in	O	O
full	O	O
-	O	O
term	O	O
fetuses	O	O
.	O	O

In	O	O
this	O	O
prospective	O	O
study	O	O
,	O	O
we	O	O
evaluated	B-PROC
mid	O
-	O
pregnancy	O
serum	O	O
25	B-PROC
-	I-PROC
hydroxyvitamin	I-PROC
D3	I-PROC
(	I-PROC
25	I-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
)	I-PROC
concentrations	I-PROC
.	O	O

The	O	O
fetal	B-ANAT
thymus	B-ANAT
size	O
was	O	O
measured	O
by	O	O
ultrasound	B-PROC
in	O	O
the	O	O
third	O
trimester	O
.	O	O

Neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
levels	I-PROC
were	O	O
evaluated	B-PROC
by	O	O
umbilical	B-ANAT
cord	I-ANAT
blood	B-PROC
sampling	I-PROC
.	O	O

Correlation	O
of	O	O
maternal	B-DISO
and	O	O
neonatal	O
vitamin	B-PROC
D	I-PROC
levels	I-PROC
and	O	O
association	O
between	O	O
thymus	B-ANAT
size	O
and	O	O
both	O	O
,	O	O
maternal	B-DISO
and	O	O
neonatal	O
vitamin	B-PROC
D	I-PROC
concentrations	I-PROC
were	O	O
investigated	O
.	O	O

Serum	B-PROC
25	I-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentrations	I-PROC
were	O	O
within	O	O
the	O	O
normal	O
range	O
in	O	O
48	O	O
(	O	O
29	O	O
.	O	O

8	O	O
%	O	O
)	O	O
mothers	B-LIVB
and	O	O
10	O	O
(	O	O
13	O	O
.	O	O

1	O	O
%	O	O
)	O	O
new	B-LIVB
-	I-LIVB
borns	I-LIVB
.	O	O

A	O	O
strong	O	O
correlation	O
between	O	O
mid	O
-	O
pregnancy	O
maternal	B-DISO
and	O	O
neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentration	I-PROC
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
8	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
was	O	O
found	O	O
.	O	O

A	O	O
significant	O
linear	O
correlation	O
was	O	O
observed	O	O
between	O	O
both	O	O
,	O	O
maternal	B-DISO
and	O	O
neonatal	O
25	B-PROC
(	I-PROC
OH	I-PROC
)	I-PROC
D3	I-PROC
concentrations	I-PROC
and	O	O
thymus	B-ANAT
perimeter	O
length	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
45	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
04	O	O
and	O	O
r	O	O
=	O	O
0	O	O
.	O	O

43	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Both	O	O
,	O	O
maternal	B-DISO
and	O	O
fetal	B-ANAT
VDDs	B-DISO
were	O	O
associated	O
with	O
decreased	O
thymus	B-ANAT
perimeter	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

04	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
.	O	O

Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
during	O
pregnancy	B-PHYS
may	O	O
be	O	O
associated	O
with	O
smaller	O	O
fetal	B-ANAT
thymus	B-ANAT
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
VDD	B-DISO
in	O	O
pregnancy	B-PHYS
may	O	O
lead	O	O
to	O	O
systemic	B-DISO
inflammatory	I-DISO
response	I-DISO
in	O	O
the	O	O
fetus	B-ANAT
.	O	O

Causes	B-DISO
of	I-DISO
Death	I-DISO
among	O	O
Children	B-LIVB
Aged	B-PHYS
5	O	O
to	O	O
14	O	O
Years	O
Old	O
from	O	O
2008	O	O
to	O	O
2013	O	O
in	O	O
Kersa	O	O
Health	O	O
and	O	O
Demographic	O	O
Surveillance	O	O
System	O	O
(	O	O
Kersa	O	O
HDSS	O	O
)	O	O
,	O	O
Ethiopia	B-GEOG
The	O	O
global	O	O
burden	O	O
of	O	O
mortality	O
among	O
children	O
is	O	O
still	O	O
very	O	O
huge	O	O
though	O	O
its	O	O
trend	O
has	O	O
started	O	O
declining	O	O
following	O	O
the	O	O
improvements	O
in	O	O
the	O	O
living	O
standard	O
.	O	O

It	O	O
presents	O	O
serious	O	O
challenges	B-PROC
to	O	O
the	O	O
well	O	O
-	O	O
being	O	O
of	O	O
children	B-LIVB
in	O	O
many	O	O
African	B-GEOG
countries	I-GEOG
.	O	O

Today	O	O
,	O	O
Sub	B-GEOG
-	I-GEOG
Saharan	I-GEOG
Africa	I-GEOG
alone	O	O
accounts	O	O
for	O	O
about	O	O
50	O	O
%	O	O
of	O	O
global	O
child	O
mortality	O
.	O	O

The	O	O
overall	O	O
objective	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
magnitude	O
and	O	O
distribution	O
of	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
among	O	O
children	B-LIVB
aged	B-PHYS
5	O	O
to	O	O
14	O	O
year	O	O
olds	O	O
in	O	O
the	O	O
population	B-LIVB
of	O	O
Kersa	O	O
HDSS	O	O
using	O	O
verbal	O
autopsy	B-PROC
method	O	O
for	O	O
the	O	O
period	O
2008	O	O
to	O	O
2013	O	O
.	O	O
Kersa	O	O
Health	O	O
and	O	O
Demographic	O	O
Surveillance	O	O
System	O	O
(	O	O
Kersa	O	O
HDSS	O	O
)	O	O
was	O	O
established	O	O
in	O	O
September	O
2007	O	O
.	O	O

The	O	O
center	O	O
consists	O	O
of	O	O
10	O	O
rural	O
and	O	O
2	O	O
urban	O
kebeles	B-LIVB
which	O	O
were	O	O
selected	O	O
randomly	O	O
from	O	O
38	O	O
kebeles	B-LIVB
in	O	O
the	O	O
district	B-GEOG
.	O	O

Thus	O	O
this	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
Kersa	O	O
HDSS	O	O
and	O	O
data	O
was	O	O
taken	O	O
from	O	O
Kersa	O
HDSS	O
database	O
.	O	O

The	O	O
study	B-PROC
population	B-LIVB
included	O	O
all	O	O
children	B-LIVB
aged	B-PHYS
5	O	O
to	O	O
14	O	O
years	O	O
registered	O	O
during	O	O
the	O	O
period	O
of	O	O
2008	O	O
to	O	O
2013	O	O
in	O	O
Kersa	O	O
HDSS	O	O
using	O	O
age	B-PHYS
specific	O	O
VA	O	O
questionnaires	O
.	O	O

Data	O
were	O	O
extracted	O	O
from	O	O
SPSS	O
database	O
and	O	O
analyzed	O	O
using	O	O
STATA	O
.	O	O

A	O	O
total	O	O
of	O	O
229	O	O
deaths	B-DISO
were	O	O
recorded	O	O
over	O	O
the	O	O
period	O
of	O	O
six	O	O
years	O	O
with	O	O
a	O	O
crude	O	O
death	O
rate	O
of	O	O
219	O	O
.	O	O

6	O	O
per	O	O
100	O	O
,	O	O
000	O	O
population	B-LIVB
of	O	O
this	O	O
age	B-LIVB
group	I-LIVB
over	O	O
the	O	O
study	B-PROC
period	O
.	O	O

This	O	O
death	O
rate	O
was	O	O
217	O	O
.	O	O
5	O	O
and	O	O
221	O	O
.	O	O

5	O	O
per	O	O
100	O	O
,	O	O
000	O	O
populations	B-LIVB
for	O	O
females	B-PHYS
and	O	O
males	B-PHYS
,	O	O
respectively	O	O
.	O	O

75	O	O
%	O	O
of	O	O
deaths	B-DISO
took	O	O
place	O	O
at	O	O
home	O	O
.	O	O

The	O	O
study	B-PROC
identified	O	O
severe	O	O
malnutrition	B-DISO
(	O	O
33	O	O
.	O	O
9	O	O
%	O	O
)	O	O
,	O	O
intestinal	B-DISO
infectious	I-DISO
diseases	I-DISO
(	O	O
13	O	O
.	O	O
8	O	O
%	O	O
)	O	O
and	O	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
infections	I-DISO
(	O	O
9	O	O
.	O	O
2	O	O
%	O	O
)	O	O
to	O	O
be	O	O
the	O	O
three	O	O
most	O	O
leading	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
.	O	O

In	O	O
broad	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
classification	O
,	O	O
injuries	B-DISO
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
the	O	O
second	O	O
most	O	O
cause	B-DISO
of	I-DISO
death	I-DISO
next	O	O
to	O	O
communicable	B-DISO
diseases	I-DISO
(	O	O
56	O	O
.	O	O

3	O	O
%	O	O
)	O	O
attributing	O	O
to	O	O
13	O	O
.	O	O

1	O	O
%	O	O
of	O	O
the	O	O
total	O	O
deaths	B-DISO
.	O	O

In	O	O
specific	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
classification	O
severe	O	O
malnutrition	B-DISO
,	O	O
intestinal	B-DISO
infectious	I-DISO
diseases	I-DISO
and	O	O
acute	B-DISO
lower	I-DISO
respiratory	I-DISO
infections	I-DISO
were	O	O
the	O	O
three	O	O
leading	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
where	O	O
,	O	O
in	O	O
broad	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
communicable	B-DISO
diseases	I-DISO
and	O	O
injuries	B-DISO
were	O	O
among	O	O
the	O	O
leading	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
.	O	O

Hence	O	O
,	O	O
concerned	O	O
bodies	O	O
should	O	O
take	O	O
measures	O	O
to	O	O
avert	O	O
the	O	O
situation	O	O
of	O	O
mortality	O
from	O	O
these	O	O
causes	B-DISO
of	I-DISO
death	I-DISO
and	O	O
further	O	O
inferential	B-PROC
analysis	I-PROC
into	O	O
the	O	O
prevention	B-PROC
and	O	O
management	B-PROC
of	O	O
infectious	B-DISO
diseases	I-DISO
should	O	O
also	O	O
be	O	O
taken	O	O
.	O	O

What	O	O
will	O	O
it	O	O
take	O	O
to	O	O
improve	O	O
prevention	O
of	O
chronic	O
diseases	O
in	O	O
Australia	B-GEOG
?	O	O

A	O
case	O
study	O
of	O	O
two	O	O
national	O	O
approaches	O	O
Objective	O	O
Despite	O	O
being	O	O
a	O	O
healthy	O
country	O
by	O	O
international	O	O
standards	O	O
,	O	O
Australia	B-GEOG
has	O	O
a	O	O
growing	O	O
and	O	O
serious	O
burden	O
from	O	O
chronic	B-DISO
diseases	I-DISO
.	O	O

There	O	O
have	O	O
been	O	O
several	O	O
national	O
efforts	O
to	O	O
tackle	O	O
this	O	O
problem	O	O
,	O	O
but	O	O
despite	O	O
some	O	O
important	O	O
advances	O	O
much	O	O
more	O	O
needs	O	O
to	O	O
be	O	O
done	O	O
.	O	O

From	O	O
the	O	O
viewpoint	O	O
of	O	O
diverse	O
stakeholders	O
,	O	O
the	O	O
present	O	O
study	O	O
examined	O	O
two	O	O
approaches	O
to	O	O
controlling	B-DISO
chronic	I-DISO
disease	I-DISO
in	O	O
Australia	B-GEOG
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
2005	O	O
National	O
Chronic	O
Disease	O
Strategy	O
(	O	O
NCDS	O
)	O	O
;	O	O
and	O	O
(	O	O
2	O	O
)	O	O
the	O	O
2008	O	O
National	B-PROC
Partnership	I-PROC
Agreement	I-PROC
on	I-PROC
Preventive	I-PROC
Health	I-PROC
(	O	O
NPAPH	B-PROC
)	O	O
.	O	O

Methods	O	O
Individual	O
and	O	O
small	B-PROC
group	I-PROC
semistructured	I-PROC
interviews	I-PROC
were	O	O
undertaken	O	O
with	O	O
29	O	O
leaders	O
across	O	O
Australia	B-GEOG
,	O	O
reflecting	O	O
a	O	O
diverse	O	O
cross	O	O
-	O	O
section	O	O
of	O	O
senior	B-LIVB
public	I-LIVB
health	I-LIVB
managers	I-LIVB
and	O	O
program	O
implementation	O
staff	O
from	O	O
state	O
and	O
territory	O
health	O
departments	O
,	O	O
as	O	O
well	O	O
as	O	O
academics	O
,	O	O
thought	O	O
leaders	O
and	O	O
public	B-LIVB
health	I-LIVB
advocates	I-LIVB
.	O	O

A	O	O
grounded	O
theory	O
approach	O
was	O	O
used	O	O
to	O	O
generate	O	O
themes	O
relevant	O	O
to	O	O
the	O	O
research	O	O
.	O	O

Results	O	O
There	O	O
is	O	O
general	O	O
support	O	O
for	O	O
national	O
approaches	O
to	O
the	O
prevention	O
of	O	O
chronic	B-DISO
disease	I-DISO
.	O	O

The	O	O
NCDS	O
was	O	O
viewed	O	O
as	O	O
necessary	O	O
and	O	O
useful	O	O
for	O	O
national	O
coordination	O
,	O	O
setting	O	O
a	O	O
common	O	O
agenda	O
and	O	O
serving	O	O
as	O	O
an	O	O
anchor	O	O
to	O	O
align	O	O
jurisdictional	O
priorities	O
and	O
action	O
.	O	O

However	O	O
,	O	O
without	O	O
funding	O	O
or	O	O
other	O	O
infrastructure	O
commitments	O
or	O	O
implementation	B-PROC
plans	I-PROC
,	O	O
any	O	O
expectations	O	O
as	O	O
to	O	O
what	O	O
could	O	O
be	O	O
meaningfully	O	O
achieved	O	O
were	O	O
limited	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
although	O	O
jurisdictions	O
welcomed	O	O
the	O	O
NPAPH	B-PROC
,	O	O
its	O	O
associated	O
funding	O
and	O	O
the	O	O
opportunity	O	O
to	O	O
tailor	O
strategy	O
to	O	O
their	O	O
unique	O
needs	O
and	O	O
populations	B-LIVB
,	O	O
there	O	O
were	O	O
calls	O	O
for	O	O
greater	O	O
national	O
leadership	O
as	O	O
well	O	O
as	O	O
guidance	B-PROC
on	O	O
the	O	O
evidence	O	O
base	O	O
to	O	O
inform	O	O
decision	O
making	O
.	O	O

Key	O	O
aspects	O	O
of	O	O
successful	O	O
national	O	O
action	O	O
were	O	O
strong	O	O
Australian	O
Government	O
leadership	O
and	O
coordination	O
,	O	O
setting	O	O
a	O	O
common	O
agenda	O
,	O	O
national	O
alignment	O
on	O
priorities	O
,	O	O
evidence	O	O
-	O	O
informed	O	O
implementation	B-PROC
strategies	I-PROC
,	O	O
partnerships	O
within	O	O
and	O	O
across	O
governments	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
other	B-LIVB
sectors	I-LIVB
,	O	O
and	O	O
funding	O
and	O	O
infrastructure	O
to	O	O
support	O
implementation	O
.Conclusions	O	O
Both	O	O
the	O	O
NCDS	O
and	O	O
NPAPH	B-PROC
were	O	O
seen	O	O
to	O	O
have	O	O
overlapping	O	O
strengths	O
and	O	O
weaknesses	O
.	O	O

A	O	O
key	O	O
need	O	O
identified	O	O
was	O	O
for	O	O
future	O
approaches	O
to	O	O
focus	O	O
on	O	O
generating	O	O
more	O	O
sustainable	O	O
,	O	O
system	O	O
-	O	O
wide	O	O
change	O	O
.	O	O

What	O	O
is	O	O
known	O	O
about	O	O
the	O	O
topic	O	O
?	O	O

Despite	O	O
some	O	O
important	O	O
advances	O	O
,	O	O
chronic	B-DISO
diseases	I-DISO
remain	O	O
Australia	B-GEOG
'	O	O
s	O	O
greatest	O	O
health	B-PROC
challenge	I-PROC
.	O	O

In	O	O
efforts	O	O
to	O	O
tackle	O	O
this	O	O
increasing	O
burden	O
from	O	O
chronic	B-DISO
diseases	I-DISO
,	O	O
several	O	O
large	O	O
-	O	O
scale	O	O
,	O	O
national	B-PHYS
initiatives	I-PHYS
have	O	O
been	O	O
released	O	O
in	O	O
Australia	B-GEOG
over	O	O
recent	O	O
years	O	O
,	O	O
including	O	O
the	O	O
2005	O	O
NCDS	O
and	O	O
the	O	O
2008	O	O
NPAPH	B-PROC
.What	O	O
does	O	O
this	O	O
paper	O	O
add	O	O
?	O	O
From	O	O
the	O	O
viewpoint	O	O
of	O	O
practitioners	B-LIVB
,	O	O
policy	B-LIVB
makers	I-LIVB
,	O	O
advocates	O
,	O	O
researchers	B-LIVB
and	O	O
public	O
health	O
thought	O
leaders	O
,	O	O
this	O	O
paper	O	O
examines	O	O
the	O	O
usefulness	O	O
and	O	O
significance	O	O
of	O	O
the	O	O
NCDS	O
and	O	O
NPAPH	B-PROC
as	O	O
national	B-PHYS
initiatives	I-PHYS
for	O	O
achieving	O	O
improvements	O	O
to	O	O
the	O	O
prevention	O
of	O
chronic	O
disease	O
.What	O	O
are	O	O
the	O	O
implications	O	O
for	O	O
practitioners	B-LIVB
?	O	O

By	O	O
better	O	O
understanding	O	O
how	O	O
previous	O	O
countrywide	O	O
chronic	B-DISO
disease	I-DISO
initiatives	B-PHYS
were	O	O
viewed	O	O
and	O	O
used	O	O
at	O	O
national	O
,	O	O
state	O	O
and	O	O
local	O	O
levels	O	O
,	O	O
this	O	O
research	O	O
is	O	O
well	O	O
placed	O	O
to	O	O
inform	O	O
current	O	O
,	O	O
planned	O	O
and	O	O
future	O	O
large	O	O
-	O	O
scale	O	O
,	O	O
population	O
-	O
level	O
health	O
initiatives	O
.	O	O

Quantifying	O
Nonlinear	O	O
Contributions	O
to	O	O
Cortical	B-PROC
Responses	I-PROC
Evoked	I-PROC
by	O	O
Continuous	B-PROC
Wrist	I-PROC
Manipulation	I-PROC
Cortical	B-PROC
responses	I-PROC
to	O	O
continuous	B-PHYS
stimuli	I-PHYS
as	O	O
recorded	O	O
using	O	O
either	O	O
magneto	B-PROC
-	I-PROC
or	O	O
electroencephalography	B-PROC
(	O	O
EEG	B-PROC
)	O	O
have	O	O
shown	O	O
power	O	O
at	O	O
harmonics	O	O
of	O	O
the	O	O
stimulated	O
frequency	O
,	O	O
indicating	O	O
nonlinear	O
behavior	O
.	O	O

Even	O	O
though	O	O
the	O	O
selection	O	O
of	O	O
analysis	B-PROC
techniques	O
depends	O	O
on	O	O
the	O	O
linearity	O
of	O	O
the	O	O
system	O	O
under	O	O
study	O	O
,	O	O
the	O	O
importance	O	O
of	O	O
nonlinear	O	O
contributions	O
to	O	O
cortical	B-PROC
responses	I-PROC
has	O	O
not	O	O
been	O	O
formally	O	O
addressed	O	O
.	O	O

The	O	O
goal	O
of	O
this	O
paper	O
is	O	O
to	O	O
quantify	O
the	O	O
nonlinear	O	O
contributions	O
to	O	O
the	O	O
cortical	B-PROC
response	I-PROC
obtained	O	O
from	O	O
continuous	O
sensory	B-PROC
stimulation	I-PROC
.	O	O

EEG	B-PROC
was	O	O
used	O	O
to	O	O
record	O	O
the	O	O
cortical	B-PROC
response	I-PROC
evoked	I-PROC
by	O	O
continuous	B-DISO
movement	I-DISO
of	I-DISO
the	I-DISO
wrist	I-DISO
joint	I-DISO
of	O	O
healthy	O	O
subjects	O	O
applied	O	O
with	O	O
a	O	O
robotic	B-OBJC
manipulator	I-OBJC
.	O	O

Multisine	O	O
stimulus	B-PHEN
signals	I-PHEN
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
the	O	O
sum	O	O
of	O	O
several	O
sinusoids	B-ANAT
)	O	O
elicit	O	O
a	O	O
periodic	O
cortical	B-PROC
response	I-PROC
and	O	O
allow	O	O
to	O	O
assess	O
the	O	O
nonlinear	O	O
contributions	O
to	O	O
the	O	O
response	O	O
.	O	O

Wrist	B-PROC
dynamics	I-PROC
(	O	O
relation	O	O
between	O	O
joint	B-ANAT
angle	I-ANAT
and	O	O
torque	B-PHEN
)	O	O
were	O	O
successfully	O	O
linearized	O
,	O	O
explaining	O	O
99	O	O
%	O	O
of	O	O
the	O	O
response	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
cortical	B-PROC
response	I-PROC
revealed	O	O
a	O	O
highly	O	O
nonlinear	O	O
relation	O	O
;	O	O
where	O	O
most	O	O
power	O	O
(	O	O
∼	O	O
80	O	O
%	O	O
)	O	O
occurred	O	O
at	O	O
non	O	O
-	O	O
stimulated	O	O
frequencies	O	O
.	O	O

Moreover	O	O
,	O	O
only	O	O
10	O	O
%	O	O
of	O	O
the	O	O
response	O	O
could	O	O
be	O	O
explained	O	O
using	O	O
a	O	O
nonparametric	O
linear	O
model	O
.	O	O

These	O	O
results	B-DISO
indicate	O	O
that	O	O
the	O	O
recorded	O	O
evoked	B-PROC
cortical	I-PROC
responses	I-PROC
are	O	O
governed	O	O
by	O	O
nonlinearities	O	O
and	O	O
that	O	O
linear	O
methods	O	O
do	O	O
not	O	O
suffice	O	O
when	O	O
describing	O	O
the	O	O
relation	O	O
between	O	O
mechanical	B-PHEN
stimulus	I-PHEN
and	O	O
cortical	B-DISO
response	I-DISO
.	O	O

Directed	O
Functional	O
Networks	O
in	O	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
:	O	O
Disruption	O
of	O	O
Global	O	O
and	O	O
Local	O	O
Connectivity	O	O
Measures	O	O
Techniques	O
available	O	O
in	O	O
graph	O
theory	O
can	O	O
be	O	O
applied	O	O
to	O	O
signals	B-PHEN
recorded	I-PHEN
from	O	O
human	B-ANAT
brain	I-ANAT
.	O	O

In	O	O
network	B-PROC
analysis	I-PROC
of	O	O
EEG	B-PROC
signals	B-PHEN
,	O	O
the	O	O
individual	O
nodes	O
are	O	O
EEG	B-PROC
sensor	B-OBJC
locations	O
and	O	O
the	O	O
edges	O
correspond	O	O
to	O	O
functional	O
relations	O
between	O	O
them	O	O
that	O	O
are	O	O
extracted	O	O
from	O	O
EEG	B-PROC
time	O
series	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
we	O	O
study	O	O
EEG	B-PROC
-based	O	O
directed	O
functional	O
networks	O
in	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
AD	B-DISO
)	O	O
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
directed	O
connectivity	O
matrices	O
of	O	O
25	O	O
AD	B-DISO
patients	B-LIVB
and	O	O
26	O	O
healthy	B-LIVB
subjects	I-LIVB
are	O	O
processed	B-PHEN
and	O	O
a	O	O
number	O	O
of	O	O
neurophysiologically	B-PHYS
meaningful	O	O
graph	O
theory	O
metrics	O
are	O	O
studied	O	O
.	O	O

Our	O	O
data	O
show	O	O
that	O	O
functional	O
networks	O
of	O	O
AD	B-DISO
brains	B-ANAT
have	O	O
significantly	O
reduced	O
global	O	O
connectivity	O	O
in	O	O
alpha	O
and	O	O
beta	O
bands	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
AD	B-DISO
brains	B-ANAT
have	O	O
significantly	O
higher	O
local	O	O
connectivity	O	O
than	O	O
healthy	O
controls	O
in	O	O
alpha	O
and	O	O
beta	O
bands	O
.	O	O

This	O	O
decreased	B-DISO
profile	I-DISO
in	O	O
global	O	O
connectivity	O	O
can	O	O
be	O	O
linked	O	O
to	O	O
compensatory	O	O
increased	O	O
local	O	O
connectivity	O	O
as	O	O
a	O	O
result	O	O
of	O	O
widespread	O
decline	O
in	O	O
the	O	O
long	O	O
-	O	O
range	O	O
connections	O	O
.	O	O

We	O	O
also	O	O
study	O	O
resiliency	O
of	O	O
brain	B-ANAT
networks	I-ANAT
against	O	O
targeted	B-DISO
attack	I-DISO
to	O	O
hub	O
nodes	O
and	O	O
find	O	O
that	O	O
AD	B-DISO
networks	B-ANAT
are	O	O
less	B-DISO
resilient	I-DISO
than	O	O
healthy	O
brains	B-ANAT
in	O	O
alpha	O
and	O	O
beta	O
bands	O
.	O	O

Assessment	O
of	O	O
Interleukin	B-CHEM
-	I-CHEM
17A	I-CHEM
,	O	O
Interleukin	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
Transforming	B-CHEM
Growth	I-CHEM
Factor	I-CHEM
-	I-CHEM
Beta1	I-CHEM
Serum	B-ANAT
Titers	O
in	O	O
Relapsing	B-PHEN
Remitting	O
Multiple	B-DISO
Sclerosis	I-DISO
Patients	B-LIVB
Treated	O
with	O	O
Avonex	B-CHEM
,	O	O
Possible	B-DISO
Biomarkers	B-PHYS
for	O	O
Treatment	B-PHYS
Response	I-PHYS
Individual	B-LIVB
response	B-PHYS
to	O	O
interferon	B-CHEM
beta	I-CHEM
(	I-CHEM
IFN	I-CHEM
-	I-CHEM
β	I-CHEM
)	I-CHEM
1a	I-CHEM
treatment	O
is	O	O
heterogeneous	O
in	O	O
multiple	B-DISO
sclerosis	I-DISO
(	O	O
MS	B-DISO
)	O	O
.	O	O

Our	O	O
objective	O
was	O	O
to	O	O
find	O	O
a	O	O
connection	O
between	O	O
serum	B-ANAT
levels	O
of	O	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
10	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
(	I-CHEM
TGF	I-CHEM
-	I-CHEM
β	I-CHEM
)	I-CHEM
1	I-CHEM
in	O	O
MS	B-DISO
patients	B-LIVB
treated	O
with	O	O
IFN	B-CHEM
-	I-CHEM
β	I-CHEM
in	O	O
order	O	O
to	O	O
identify	B-DISO
the	O	O
nonresponders	B-DISO
(	O	O
NR	B-DISO
)	O	O
.	O	O

We	O	O
included	O	O
in	O	O
the	O	O
study	B-PROC
32	O	O
healthy	B-LIVB
subjects	I-LIVB
and	O	O
32	O	O
MS	B-DISO
patients	B-LIVB
:	O	O
10	O	O
naive	O
,	O	O
10	O	O
early	O
treated	O
and	O	O
12	O	O
late	O	O
treated	O
with	O	O
INF	B-CHEM
-	I-CHEM
β1a	I-CHEM
.	O	O

Serum	B-ANAT
determination	B-PROC
of	O	O
cytokines	B-CHEM
and	O	O
brain	B-PROC
MRI	I-PROC
were	O	O
performed	O
at	O	O
the	O	O
beginning	O
of	O	O
the	O	O
study	B-PROC
,	O	O
after	O	O
6	O	O
and	O	O
12	O	O
months	O
.	O	O

Rio	O
score	O
was	O	O
calculated	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	B-PROC
.	O	O

MS	B-DISO
patients	B-LIVB
had	O	O
initially	O
a	O	O
significant	O
higher	O
level	O
of	O	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O	O
a	O	O
lower	O
level	O
of	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
compared	O
to	O	O
healthy	B-LIVB
subjects	I-LIVB
.	O	O

IL	B-CHEM
-	I-CHEM
17	I-CHEM
level	O
in	O	O
early	O
treated	O
patients	B-LIVB
was	O	O
significantly	O
lower	O
compared	O
to	O	O
the	O	O
naive	O	O
and	O	O
late	O
treated	O
groups	B-LIVB
.	O	O

INF	B-CHEM
-	I-CHEM
β1a	I-CHEM
treatment	O
significantly	O
increased	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
decreased	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
levels	O
.	O	O

Initial	O
low	O
levels	O
of	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
were	O	O
associated	O
with	O
an	O	O
increase	O
in	O	O
physical	B-DISO
disability	I-DISO
.	O	O

IL	B-CHEM
-	I-CHEM
17	I-CHEM
levels	O
positively	O
correlated	O
with	O	O
the	O	O
number	O
of	O	O
relapses	B-PHEN
and	O	O
MRI	B-PROC
activity	O
.	O	O

Nine	O	O
patients	B-LIVB
were	O	O
NR	B-DISO
to	O	O
Avonex	B-CHEM
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
Rio	O
score	O
of	O	O
3	O	O
had	O	O
higher	O
initial	O
levels	O
of	O	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O	O
those	O	O
with	O	O
a	O	O
Rio	O
score	O
of	O	O
0	O	O
had	O	O
higher	O
initial	O
levels	O
of	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
.	O	O

IFN	B-CHEM
-	I-CHEM
β1a	I-CHEM
decreased	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O	O
increased	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
seric	B-ANAT
levels	O
;	O	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
significantly	O
correlated	O
with	O	O
MS	B-DISO
activity	O
;	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
activity	O
is	O	O
titer	O
-	O
dependent	O
,	O	O
increased	O
levels	O
were	O	O
associated	O
with	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
inhibition	O
;	O	O
NR	B-DISO
patients	B-LIVB
to	O	O
IFN	B-CHEM
-	I-CHEM
β1a	I-CHEM
will	O	O
have	O	O
initial	O
high	O
IL	B-CHEM
-	I-CHEM
17	I-CHEM
and	O	O
low	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
seric	B-ANAT
levels	O
.	O	O

Cardiovascular	B-PROC
magnetic	I-PROC
resonance	I-PROC
features	O	O
of	O	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O	O
patients	B-LIVB
with	O	O
left	B-DISO
bundle	I-DISO
branch	I-DISO
block	I-DISO
Patients	B-LIVB
with	O	O
left	B-DISO
bundle	I-DISO
branch	I-DISO
block	I-DISO
(	O	O
LBBB	B-DISO
)	O	O
can	O	O
exhibit	O	O
mechanical	B-ANAT
dyssynchrony	B-DISO
which	O	O
may	O	O
contribute	O	O
to	O	O
heart	B-DISO
failure	I-DISO
;	O	O
such	O	O
patients	B-LIVB
may	O	O
benefit	O	O
from	O	O
cardiac	B-PROC
resynchronization	I-PROC
treatment	I-PROC
(	O	O
CRT	B-PROC
)	O	O
.	O	O

While	O	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
CMR	B-PROC
)	O	O
has	O	O
become	O	O
a	O	O
common	O	O
part	O	O
of	O	O
heart	B-DISO
failure	I-DISO
work	B-PROC
-	I-PROC
up	I-PROC
,	O	O
CMR	B-PROC
features	O	O
of	O	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O	O
patients	B-LIVB
with	O	O
LBBB	B-DISO
have	O	O
not	O	O
been	O	O
well	O	O
characterized	O	O
.	O	O

This	O	O
study	O	O
aims	O	O
to	O	O
investigate	O	O
the	O	O
potential	O	O
of	O	O
CMR	B-PROC
to	O	O
characterize	O	O
mechanical	B-ANAT
features	O	O
of	O	O
LBBB	B-DISO
.	O	O

CMR	B-PROC
examinations	O	O
from	O	O
43	O	O
patients	B-LIVB
with	O	O
LBBB	B-DISO
on	O	O
their	O	O
electrocardiogram	B-DISO
,	O	O
but	O	O
without	O	O
significant	O	O
focal	O
structural	B-DISO
abnormalities	I-DISO
,	O	O
and	O	O
from	O	O
43	O	O
age	O	O
-	O	O
and	O	O
gender	B-PHYS
-matched	O	O
normal	O
controls	O
were	O	O
retrospectively	B-PROC
reviewed	I-PROC
.	O	O

The	O	O
following	O	O
mechanical	B-ANAT
features	O	O
of	O	O
LBBB	B-DISO
were	O	O
evaluated	O	O
:	O	O
septal	B-DISO
flash	I-DISO
(	O	O
SF	B-DISO
)	O	O
,	O	O
apical	B-DISO
rocking	I-DISO
(	O	O
AR	B-DISO
)	O	O
,	O	O
delayed	B-DISO
aortic	I-DISO
valve	I-DISO
opening	I-DISO
measured	I-DISO
relative	I-DISO
to	I-DISO
both	I-DISO
end	I-DISO
-	I-DISO
diastole	I-DISO
(	O	O
AVOED	B-DISO
)	O	O
and	O	O
pulmonic	B-DISO
valve	I-DISO
opening	I-DISO
(	O	O
AVOPVO	B-DISO
)	O	O
,	O	O
delayed	B-DISO
left	I-DISO
-	I-DISO
ventricular	I-DISO
(	I-DISO
LV	I-DISO
)	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
contraction	I-DISO
,	O	O
and	O	O
curvatures	B-DISO
of	I-DISO
the	I-DISO
septum	I-DISO
and	I-DISO
LV	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
.	O	O

Septal	B-PHYS
displacement	I-PHYS
curves	I-PHYS
were	O	O
also	O	O
generated	O	O
,	O	O
using	O	O
feature	O
-tracking	O	O
techniques	O	O
.	O	O

The	O	O
echocardiographic	B-PROC
findings	O	O
of	O	O
LBBB	B-DISO
were	O	O
also	O	O
reviewed	O	O
in	O	O
those	O	O
subjects	O	O
for	O	O
whom	O	O
they	O	O
were	O	O
available	O	O
.	O	O

LBBB	B-DISO
was	O	O
significantly	O	O
associated	O
with	O
the	O	O
presence	O	O
of	O	O
SF	B-DISO
and	O	O
AR	B-DISO
;	O	O
within	O	O
the	O	O
LBBB	B-DISO
group	O
,	O	O
79	O	O
%	O	O
had	O	O
SF	B-DISO
and	O	O
65	O	O
%	O	O
had	O	O
AR	B-DISO
.	O	O

Delayed	B-DISO
AVOED	I-DISO
,	O	O
AVOPVO	B-DISO
,	O	O
and	O	O
delayed	B-DISO
LV	I-DISO
free	I-DISO
-	I-DISO
wall	I-DISO
contraction	I-DISO
were	O	O
significantly	O	O
associated	O
with	O
LBBB	B-DISO
.	O	O

AVOED	B-DISO
and	O	O
AVOPVO	B-DISO
positively	O	O
correlated	O	O
with	O	O
QRS	B-PHYS
duration	I-PHYS
and	O	O
negatively	O	O
correlated	O	O
with	O	O
ejection	B-PROC
fraction	I-PROC
.	O	O

Hearts	B-ANAT
with	O	O
electrocardiographic	B-PROC
evidence	O	O
of	O	O
LBBB	B-DISO
showed	O	O
lower	O
septal	O
-	O
to	O
-	O
LV	O
free	O
-	O
wall	O
curvature	O
ratios	O
at	O	O
end	O
-	O
diastole	O
compared	O	O
to	O	O
normal	O
controls	O
.	O	O

CMR	B-PROC
can	O	O
be	O	O
used	O	O
to	O	O
identify	O	O
and	O	O
evaluate	O	O
mechanical	B-ANAT
dyssynchrony	B-DISO
in	O	O
patients	B-LIVB
with	O	O
LBBB	B-DISO
.	O	O

None	O	O
of	O	O
the	O	O
normal	O
controls	O
showed	O	O
the	O	O
mechanical	B-ANAT
features	O	O
associated	O
with	O
LBBB	B-DISO
.	O	O

Moreover	O	O
,	O	O
not	O	O
all	O	O
patients	B-LIVB
with	O	O
LBBB	B-DISO
showed	O	O
the	O	O
same	O	O
degree	O	O
of	O	O
mechanical	B-ANAT
dyssynchrony	B-DISO
,	O	O
which	O	O
could	O	O
have	O	O
implications	O	O
for	O	O
CRT	B-PROC
.	O	O

Delayed	O
progression	B-DISO
of	O	O
rabies	B-DISO
transmitted	B-DISO
by	O	O
a	O	O
vampire	B-LIVB
bat	I-LIVB
Here	O	O
,	O	O
we	O	O
compared	O
the	O	O
growth	B-PHYS
kinetics	B-PHEN
,	O	O
cell	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
cell	I-PHYS
spread	I-PHYS
,	O	O
and	O	O
virus	B-PHEN
internalization	I-PHEN
kinetics	B-PHEN
in	O	O
N2a	B-ANAT
cells	I-ANAT
of	O	O
RABV	B-LIVB
variants	B-DISO
isolated	O
from	O	O
vampire	B-LIVB
bats	I-LIVB
(	O	O
V	B-DISO
-	I-DISO
3	I-DISO
)	O	O
,	O	O
domestic	B-LIVB
dogs	I-LIVB
(	O	O
V	B-DISO
-	I-DISO
2	I-DISO
)	O	O
and	O	O
marmosets	B-LIVB
(	O	O
V	B-DISO
-	I-DISO
M	I-DISO
)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
clinical	O
symptoms	B-DISO
and	O	O
mortality	O
caused	O	O
by	O	O
these	O	O
variants	B-DISO
.	O	O

The	O	O
replication	B-PHYS
rate	O
of	O	O
V	B-DISO
-	I-DISO
3	I-DISO
was	O	O
significantly	O
higher	O
than	O	O
those	O	O
of	O	O
V	B-DISO
-	I-DISO
2	I-DISO
and	O	O
V	B-DISO
-	I-DISO
M	I-DISO
.	O	O

However	O	O
,	O	O
the	O	O
uptake	B-PHYS
and	O	O
spread	B-PHYS
of	O	O
these	O	O
RABV	B-LIVB
variants	B-DISO
into	O	O
N2a	B-ANAT
cells	I-ANAT
were	O	O
inversely	O
proportional	O
.	O	O

Nevertheless	O	O
,	O	O
V	B-DISO
-	I-DISO
3	I-DISO
had	O	O
longer	O
incubation	B-DISO
and	O	O
evolution	B-PHYS
periods	O
.	O	O

Our	O	O
results	O
provide	O	O
evidence	O
that	O	O
the	O	O
clinical	O
manifestations	O
of	O
infection	B-DISO
with	O	O
bat	B-LIVB
RABV	B-LIVB
variant	B-DISO
occur	O
at	O	O
a	O	O
later	O
time	O
when	O	O
compared	O
to	O	O
what	O	O
was	O	O
observed	O
with	O	O
canine	B-LIVB
and	O	O
marmoset	B-LIVB
rabies	B-LIVB
virus	I-LIVB
variants	B-DISO
.	O	O

Using	O
melanopsin	B-CHEM
to	O	O
study	B-PROC
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O	O
cortical	B-ANAT
neurons	B-ANAT
Our	O	O
understanding	B-PHYS
of	O	O
G	B-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptors	I-CHEM
(	O	O
GPCRs	B-CHEM
)	O	O
in	O	O
the	O	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O	O
CNS	B-ANAT
)	O	O
has	O	O
been	O	O
hampered	O	O
by	O	O
the	O	O
limited	O	O
availability	O	O
of	O	O
tools	B-OBJC
allowing	O	O
for	O	O
the	O	O
study	B-PROC
of	O	O
their	O	O
signaling	B-PHEN
with	O	O
precise	O
temporal	O
control	O
.	O	O

To	O	O
overcome	O
this	O	O
,	O	O
we	O	O
tested	O
the	O	O
utility	O	O
of	O	O
the	O	O
bistable	O
mammalian	B-LIVB
opsin	B-CHEM
melanopsin	B-CHEM
to	O	O
examine	O	O
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O	O
CNS	B-ANAT
neurons	B-ANAT
.	O	O

Specifically	O	O
,	O	O
we	O	O
used	O
biolistic	B-PROC
(	O	O
gene	B-DEVI
gun	I-DEVI
)	O	O
approaches	O	O
to	O	O
transfect	B-CHEM
melanopsin	I-CHEM
into	O	O
cortical	B-ANAT
pyramidal	B-ANAT
cells	I-ANAT
maintained	O
in	O	O
organotypic	B-PROC
slice	I-PROC
culture	I-PROC
.	O	O

Whole	B-PROC
cell	I-PROC
recordings	I-PROC
from	O	O
transfected	B-ANAT
neurons	I-ANAT
indicated	O	O
that	O	O
application	O	O
of	O	O
blue	B-PHEN
light	I-PHEN
effectively	O
activated	O
the	O	O
transfected	B-CHEM
melanopsin	I-CHEM
to	O	O
elicit	O
the	O	O
canonical	O	O
biphasic	O
modulation	O
of	O	O
membrane	B-ANAT
excitability	B-DISO
previously	O	O
associated	O
with	O
the	O	O
activation	O
of	O	O
GPCRs	B-CHEM
coupling	O
to	O	O
Gαq	B-CHEM
-	I-CHEM
11	I-CHEM
Remarkably	O	O
,	O	O
full	O	O
mimicry	O	O
of	O	O
exogenous	O
agonist	B-CHEM
concentration	O
could	O	O
be	O	O
obtained	O
with	O	O
pulses	B-PHEN
as	O	O
short	O	O
as	O	O
a	O	O
few	O
milliseconds	O
,	O	O
suggesting	O	O
that	O	O
their	O	O
triggering	O
required	O	O
a	O	O
single	O
melanopsin	B-CHEM
activation	O
-	O
deactivation	O
cycle	O
.	O	O

The	O	O
resulting	O
temporal	O
control	O
over	O	O
melanopsin	B-CHEM
activation	O
allowed	O	O
us	O	O
to	O	O
compare	O
the	O	O
activation	O
kinetics	B-PHEN
of	O	O
different	O	O
components	O	O
of	O	O
the	O	O
electrophysiological	B-PHYS
response	B-PHYS
.	O	O

We	O	O
also	O	O
replaced	O	O
the	O	O
intracellular	O
loops	O
of	O	O
melanopsin	B-CHEM
with	O	O
those	O	O
of	O	O
the	O	O
5	B-CHEM
-	I-CHEM
HT2A	I-CHEM
receptor	I-CHEM
to	O	O
create	O	O
a	O	O
light	B-PHEN
-	I-PHEN
activated	I-PHEN
GPCR	B-CHEM
capable	O	O
of	O	O
interacting	O
with	O	O
the	O	O
5	B-CHEM
-	I-CHEM
HT2A	I-CHEM
receptor	I-CHEM
interacting	O
proteins	B-CHEM
.	O	O

The	O	O
resulting	O
chimera	B-CHEM
expressed	O
weak	O
activity	O
but	O	O
validated	B-PROC
the	O	O
potential	O
usefulness	O
of	O	O
melanopsin	B-CHEM
as	O	O
a	O	O
tool	B-OBJC
for	O	O
the	O	O
study	B-PROC
of	O	O
G	B-PHYS
protein	I-PHYS
signaling	I-PHYS
in	O	O
CNS	B-ANAT
neurons	B-ANAT
.	O	O

Naïve	B-ANAT
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cell	I-ANAT
derived	O	O
tumor	B-DISO
-	O	O
specific	O
cytotoxic	B-ANAT
effectors	I-ANAT
as	O	O
a	O	O
potential	O	O
remedy	O
for	O	O
overcoming	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
immunosuppression	B-DISO
in	O	O
the	O	O
tumor	B-PHEN
microenvironment	I-PHEN
Despite	O	O
of	O	O
the	O	O
potential	O	O
implications	O	O
for	O	O
cancer	B-PROC
immunotherapy	I-PROC
,	O	O
conventional	O
approaches	O
using	O	O
in	O
vitro	O
expanded	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
have	O	O
suboptimal	O
outcomes	O
,	O	O
mostly	O	O
due	O	O
to	O	O
loss	O
of	O	O
functionality	O
from	O	O
cellular	B-ANAT
exhaustion	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
the	O	O
phenotypic	B-PHYS
and	O	O
functional	O
differences	O
among	O	O
in	O
vitro	O
activated	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
of	O	O
three	O	O
different	O	O
sources	B-DISO
,	O	O
namely	O	O
naïve	B-ANAT
(	O	O
NTeff	B-ANAT
)	O	O
,	O	O
memory	B-ANAT
(	O	O
MTeff	B-ANAT
)	O	O
and	O	O
tumor	B-ANAT
-	I-ANAT
infiltrating	I-ANAT
lymphocytes	I-ANAT
(	O	O
TILeff	B-ANAT
)	O	O
from	O	O
human	B-LIVB
and	O	O
mice	B-LIVB
,	O	O
to	O	O
better	O	O
understand	O	O
mechanisms	O
behind	O	O
potent	O	O
effector	B-ANAT
functions	O
and	O	O
potential	O	O
for	O	O
overcoming	O	O
current	O	O
limitations	O
.	O	O

In	O	O
line	O	O
with	O	O
the	O	O
greater	O	O
proliferation	B-PHYS
activity	O
and	O	O
longer	O	O
telomere	B-ANAT
lengths	O
of	O	O
NTeff	B-ANAT
populations	I-ANAT
,	O	O
cells	B-ANAT
of	O	O
naïve	O
origin	O
exhibited	O	O
significantly	O	O
less	O	O
amounts	O	O
of	O	O
T	B-ANAT
cell	I-ANAT
exhaustion	O
markers	B-PHYS
than	O	O
those	O	O
of	O	O
MTeff	B-ANAT
and	O	O
TILeff	B-ANAT
,	O	O
and	O	O
moreover	O	O
,	O	O
acquired	O	O
distinct	O	O
expression	B-PHYS
patterns	I-PHYS
of	O	O
memory	B-CHEM
-	I-CHEM
promoting	I-CHEM
transcription	I-CHEM
factors	I-CHEM
,	O	O
T	B-CHEM
-	I-CHEM
bet	I-CHEM
and	O	O
Eomes	B-CHEM
,	O	O
induced	O
in	O	O
a	O	O
rapid	O
and	O	O
sustainable	O
manner	O
.	O	O

NTeff	B-ANAT
cells	I-ANAT
appeared	O	O
to	O	O
have	O	O
lower	O	O
expression	B-PHYS
of	O	O
Foxp1	B-CHEM
and	O	O
were	O	O
refractory	O	O
to	O	O
apoptosis	B-PHYS
upon	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
conditioning	O
,	O	O
implying	O	O
better	O	O
survival	B-PHYS
potential	O
and	O	O
resistance	O
to	O	O
tumor	B-DISO
-	O	O
induced	O
immune	B-DISO
suppression	I-DISO
.	O	O

Of	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cell	I-ANAT
pools	O	O
activated	O
to	O	O
tumor	B-DISO
-	O	O
specific	O
CTLs	B-ANAT
,	O	O
naïve	B-ANAT
cell	I-ANAT
generated	O
effectors	B-ANAT
possessed	O	O
the	O	O
most	O	O
potent	O	O
cytotoxic	B-DISO
activity	I-DISO
,	O	O
validating	O	O
implications	O	O
for	O	O
use	O	O
in	O	O
rational	O	O
design	O
of	O	O
adoptive	B-PROC
immunotherapy	I-PROC
.	O	O

SHOT	B-CHEM
-	O	O
RNAs	B-CHEM
:	O	O
A	O	O
novel	O	O
class	O	O
of	O	O
tRNA	B-CHEM
-derived	O	O
functional	O
RNAs	B-CHEM
expressed	B-PHYS
in	O	O
hormone	B-DISO
-	I-DISO
dependent	I-DISO
cancers	I-DISO
Sex	B-CHEM
hormones	I-CHEM
and	O	O
their	O	O
receptors	B-CHEM
play	O	O
critical	O	O
roles	O	O
in	O	O
the	O	O
genesis	B-DISO
and	O	O
progression	B-DISO
of	O	O
breast	B-DISO
and	O	O
prostate	B-DISO
cancers	I-DISO
.	O	O

We	O	O
recently	O	O
discovered	O	O
that	O	O
sex	B-CHEM
hormone	I-CHEM
signaling	B-PHYS
pathways	I-PHYS
promote	O	O
the	O	O
expression	B-PHYS
of	O	O
specific	O	O
tRNA	B-CHEM
halves	O	O
termed	O	O
Sex	B-CHEM
HOrmone	I-CHEM
-dependent	O	O
TRNA	B-CHEM
-derived	O	O
RNAs	B-CHEM
(	O	O
SHOT	B-CHEM
-	O	O
RNAs	B-CHEM
)	O	O
.	O	O

Functional	O
involvement	O	O
of	O	O
SHOT	B-CHEM
-	O	O
RNAs	B-CHEM
in	O	O
cell	B-PHYS
proliferation	I-PHYS
suggests	O	O
a	O	O
novel	O	O
tRNA	B-CHEM
-engaged	O	O
pathway	B-PHYS
in	O	O
tumorigenesis	B-DISO
.	O	O

Maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
and	O	O
the	O	O
risk	O
of	O	O
perinatal	B-DISO
death	I-DISO
To	O	O
determine	O	O
the	O	O
association	O
between	O	O
maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
and	O	O
perinatal	B-DISO
death	I-DISO
.	O	O

A	O	O
retrospective	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
of	O	O
all	O	O
non	O	O
-	O	O
anomalous	O	O
,	O	O
singleton	B-LIVB
births	B-PHYS
(	O	O
≥24	O	O
weeks	O
)	O	O
with	O	O
perinatal	B-DISO
death	I-DISO
compared	O	O
to	O	O
a	O	O
matched	O	O
control	B-LIVB
group	I-LIVB
.	O	O

Only	O	O
pregnancies	B-PHYS
with	O	O
a	O	O
recorded	O	O
vitamin	B-CHEM
D	I-CHEM
level	O
at	O	O
booking	O	O
(	O	O
8	O	O
-	O	O
19	O	O
weeks	O
gestation	B-PHYS
)	O	O
were	O	O
included	O	O
for	O	O
analysis	B-PROC
.	O	O

Maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
were	O	O
categorized	O	O
into	O	O
normal	O
,	O	O
deficient	O
and	O	O
insufficient	O
cohorts	B-LIVB
and	O	O
variables	O
compared	O	O
between	O	O
the	O	O
three	O	O
groups	B-LIVB
.	O	O

There	O	O
were	O	O
31	O	O
perinatal	B-DISO
deaths	I-DISO
which	O	O
were	O	O
compared	O	O
to	O	O
111	O	O
controls	B-LIVB
.	O	O

Median	O	O
vitamin	B-CHEM
D	I-CHEM
levels	O
were	O	O
lower	O	O
in	O	O
the	O	O
perinatal	B-DISO
death	I-DISO
cohort	B-LIVB
compared	O	O
to	O	O
the	O	O
control	B-LIVB
group	I-LIVB
(	O	O
55	O	O
nmol	O	O
/	O	O
L	O	O
versus	O	O
64	O	O
nmol	O	O
/	O	O
L	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
43	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
increase	O	O
in	O	O
deaths	B-PHYS
between	O	O
the	O	O
normal	O
and	O	O
deficient	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

33	O	O
)	O	O
or	O	O
insufficient	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
09	O	O
)	O	O
groups	B-LIVB
.	O	O

Low	O	O
maternal	B-LIVB
vitamin	B-CHEM
D	I-CHEM
levels	O
at	O	O
booking	O	O
were	O	O
not	O	O
associated	O
with	O
an	O	O
increased	O	O
risk	O
of	O	O
perinatal	B-DISO
demise	I-DISO
.	O	O

Antiadipogenic	B-DISO
Activity	I-DISO
of	O	O
γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
and	O	O
Its	O	O
Stability	O
in	O	O
Pigmented	O
Rice	B-OBJC
γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
,	O	O
a	O	O
prevalent	O	O
compound	O	O
in	O	O
pigmented	O
rice	B-OBJC
varieties	O
,	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
ameliorate	O	O
obesity	B-DISO
-	I-DISO
associated	I-DISO
metabolic	I-DISO
disorders	I-DISO
.	O	O

Antiadipogenic	B-DISO
activities	I-DISO
of	O	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
were	O	O
determined	O	O
in	O	O
human	B-LIVB
adipose	O
-	O	O
derived	O
mesenchymal	B-ANAT
stem	I-ANAT
cells	I-ANAT
and	O	O
mouse	B-LIVB
-	O	O
derived	O
3T3	B-ANAT
-	I-ANAT
L1	I-ANAT
cells	I-ANAT
.	O	O

γ	B-CHEM
-	I-CHEM
Oryzanol	I-CHEM
significantly	O	O
decreased	O
lipid	B-DISO
accumulation	I-DISO
and	O	O
reduced	O
glycerol	B-PHYS
-	I-PHYS
3	I-PHYS
-	I-PHYS
phosphate	I-PHYS
dehydrogenase	I-PHYS
activities	I-PHYS
in	O	O
both	O	O
adipocytes	B-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
in	O	O
four	O	O
pigmented	O
rice	B-OBJC
varieties	O
(	O	O
black	B-OBJC
with	I-OBJC
giant	I-OBJC
embryo	I-OBJC
,	O	O
brown	B-OBJC
,	O	O
sugary	B-OBJC
brown	I-OBJC
,	O	O
and	O	O
red	B-OBJC
)	O	O
was	O	O
stable	O
when	O	O
stored	O
at	O	O
4°C	O	O
and	O	O
also	O	O
at	O	O
room	O
temperature	O
for	O	O
22	O	O
weeks	O	O
,	O	O
whereas	O	O
other	O	O
bioactives	B-OBJC
such	O	O
as	O	O
lutein	B-CHEM
and	O	O
β	B-CHEM
-	I-CHEM
carotene	I-CHEM
were	O	O
stable	O
only	O	O
at	O	O
-80°C	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
yield	O
of	O	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
from	O	O
these	O	O
rice	B-OBJC
varieties	O
was	O	O
significantly	O	O
increased	O	O
through	O	O
steaming	B-PHEN
and	O	O
roasting	B-PHEN
processes	I-PHEN
.	O	O

Therefore	O	O
,	O	O
γ	B-CHEM
-	I-CHEM
oryzanol	I-CHEM
exerts	O	O
antiadipogenic	B-DISO
activity	I-DISO
by	O	O
suppressing	O
adipocyte	B-PHYS
differentiations	I-PHYS
and	O	O
is	O	O
stable	O
in	O	O
pigmented	O
rice	B-OBJC
for	O	O
an	O	O
extended	O
period	O
of	O
time	O
during	O	O
storage	O
and	O	O
after	O
cooking	O
.	O	O

Thus	O	O
,	O	O
the	O	O
intake	O
of	O	O
pigmented	O
rice	B-OBJC
may	O	O
be	O	O
a	O	O
useful	O	O
strategy	O	O
for	O	O
preventing	O
obesity	B-DISO
.	O	O

Upstream	B-PHYS
Pathways	I-PHYS
Controlling	O	O
Mitochondrial	O
Function	O
in	O	O
Major	O	O
Psychosis	B-DISO
:	O	O
A	O	O
Focus	O	O
on	O	O
Bipolar	B-DISO
Disorder	I-DISO
Mitochondrial	B-DISO
dysfunction	I-DISO
is	O	O
commonly	O	O
observed	O	O
in	O	O
bipolar	B-DISO
disorder	I-DISO
(	O	O
BD	B-DISO
)	O	O
and	O	O
schizophrenia	B-DISO
(	O	O
SCZ	B-DISO
)	O	O
and	O	O
may	O	O
be	O	O
a	O	O
central	O
feature	O
of	O	O
psychosis	B-DISO
.	O	O

These	O	O
illnesses	B-DISO
are	O	O
complex	O
and	O	O
heterogeneous	B-DISO
,	O	O
which	O	O
is	O	O
reflected	O	O
by	O	O
the	O	O
complexity	O	O
of	O	O
the	O	O
processes	B-PHEN
regulating	O	O
mitochondrial	O
function	O
.	O	O

Mitochondria	B-ANAT
are	O	O
typically	O	O
associated	O	O
with	O	O
energy	B-PHYS
production	I-PHYS
;	O	O
however	O	O
,	O	O
dysfunction	O
of	O	O
mitochondria	B-ANAT
affects	O	O
not	O	O
only	O	O
energy	B-PHYS
production	I-PHYS
but	O	O
also	O	O
vital	O	O
cellular	B-PHYS
processes	I-PHYS
,	O	O
including	O	O
the	O	O
formation	B-PHEN
of	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
,	O	O
cell	B-PHYS
cycle	I-PHYS
and	O	O
survival	B-PHYS
,	O	O
intracellular	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
homeostasis	I-PHYS
,	O	O
and	O	O
neurotransmission	B-PHYS
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
characterize	O	O
the	O	O
upstream	B-CHEM
components	I-CHEM
controlling	O	O
mitochondrial	O
function	O
,	O	O
including	O	O
1	O	O
)	O	O
mutations	B-PHYS
in	O	O
nuclear	B-CHEM
and	O	O
mitochondrial	B-CHEM
DNA	I-CHEM
,	O	O
2	O	O
)	O	O
mitochondrial	B-PHYS
dynamics	I-PHYS
,	O	O
and	O	O
3	O	O
)	O	O
intracellular	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
homeostasis	I-PHYS
.	O	O

Characterizing	O	O
and	O	O
understanding	O	O
the	O	O
upstream	B-CHEM
factors	I-CHEM
that	O	O
regulate	O	O
mitochondrial	O
function	O
is	O	O
essential	O	O
to	O	O
understand	O	O
progression	B-DISO
of	O	O
these	O	O
illnesses	B-DISO
and	O	O
develop	O	O
biomarkers	B-PHYS
and	O	O
therapeutics	B-PROC
.	O	O

Impact	O
of	O	O
Chemotherapy	B-PROC
on	O	O
Diet	B-OBJC
and	O	O
Nutritional	B-DISO
Status	I-DISO
of	O	O
Women	B-LIVB
with	O	O
Breast	B-DISO
Cancer	I-DISO
:	O	O
A	O	O
Prospective	B-PROC
Study	I-PROC
Certain	O	O
food	B-OBJC
groups	I-OBJC
are	O	O
often	O	O
rejected	O
during	O	O
chemotherapy	B-PROC
(	O	O
CT	B-PROC
)	O	O
due	O	O
to	O	O
the	O	O
side	B-DISO
effects	I-DISO
of	I-DISO
treatment	I-DISO
,	O	O
which	O	O
may	O	O
interfere	O
with	O
adequate	O
diet	O
and	O	O
nutritional	B-DISO
status	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
treatment	O
impact	O
on	O	O
the	O	O
diet	B-OBJC
and	O	O
nutritional	B-DISO
status	I-DISO
of	O	O
women	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
(	O	O
BC	B-DISO
)	O	O
.	O	O

In	O	O
this	O	O
prospective	B-PROC
longitudinal	I-PROC
study	I-PROC
,	O	O
conducted	O	O
in	O	O
2014	O	O
-	O	O
2015	O	O
,	O	O
55	O	O
women	B-LIVB
diagnosed	O	O
with	O	O
BC	B-DISO
,	O	O
with	O	O
a	O	O
mean	O	O
age	B-PHYS
51	O	O
.	O	O

5±10	O	O
.	O	O

1	O	O
years	O
,	O	O
were	O	O
followed	O	O
and	O	O
data	O
were	O	O
collected	O	O
at	O	O
three	O	O
different	O	O
times	O	O
.	O	O

Anthropometric	O
and	O	O
dietary	B-PROC
assessments	I-PROC
were	O	O
performed	O	O
,	O	O
the	O	O
latter	O	O
by	O	O
applying	O	O
nine	O	O
24h	O	O
dietary	B-PROC
recall	I-PROC
s	O	O
,	O	O
by	O	O
using	O	O
the	O	O
Brazilian	O
Healthy	O
Eating	O
Index	O
Revised	O
(	O	O
BHEI	O
-	O
R	O
)	O	O
,	O	O
and	O	O
calculating	O
the	O	O
prevalence	O
of	O	O
inadequacy	O
by	O	O
the	O	O
EAR	O
cut	O
-	O
off	O
point	O
method	O
.	O	O

Regarding	O	O
the	O	O
BHEI	O
-	O
R	O
analysis	B-PROC
,	O	O
the	O	O
majority	O	O
of	O	O
women	B-LIVB
had	O	O
a	O	O
""""	O	O
diet	B-OBJC
requires	O	O
modification	B-DISO
'	O	O
,	O	O
both	O	O
at	O	O
the	O	O
beginning	O
(	O	O
T0	O	O
,	O	O
58	O	O
.	O	O
2	O	O
%	O	O
,	O	O
n	O	O
=	O	O
32	O	O
)	O	O
and	O	O
during	O
treatment	O
(	O	O
T1	O	O
,	O	O
54	O	O
.	O	O

5	O	O
%	O	O
,	O	O
n	O	O
=	O	O
30	O	O
)	O	O
.	O	O

However	O	O
,	O	O
after	O	O
the	O	O
end	O	O
of	O	O
the	O	O
CT	B-PROC
,	O	O
the	O	O
greater	O
percentage	O
of	O	O
patients	B-LIVB
(	O	O
T2	O	O
,	O	O
49	O	O
.	O	O
1	O	O
%	O	O
,	O	O
n	O	O
=	O	O
27	O	O
)	O	O
were	O	O
classified	O	O
as	O	O
having	O	O
an	O	O
""""	O	O
inadequate	B-DISO
diet	I-DISO
""""	O	O
,	O	O
since	O	O
the	O	O
Total	O
Fruit	B-OBJC
consumption	O
as	O	O
well	O	O
as	O	O
the	O	O
Dark	B-OBJC
Green	I-OBJC
and	O	O
Orange	B-OBJC
Vegetable	I-OBJC
and	O	O
Legume	B-LIVB
consumption	O
decreased	O
significantly	O
during	O
treatment	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

043	O	O
and	O	O
p	O	O
=	O	O
0	O	O
.	O	O

026	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O
reduction	O
in	O	O
the	O	O
intake	O
of	O	O
macro	O
and	O	O
micronutrients	B-CHEM
,	O	O
with	O	O
a	O	O
high	O	O
prevalence	O
of	O	O
inadequacy	O
,	O	O
of	O	O
up	O	O
to	O	O
100	O	O
%	O	O
,	O	O
for	O	O
calcium	B-CHEM
,	O	O
iron	B-CHEM
,	O	O
phosphorus	B-CHEM
,	O	O
magnesium	B-CHEM
,	O	O
niacin	B-CHEM
,	O	O
riboflavin	B-CHEM
,	O	O
thiamin	B-CHEM
,	O	O
vitamin	B-CHEM
B6	I-CHEM
,	O	O
vitamin	B-CHEM
C	I-CHEM
and	O	O
zinc	B-CHEM
.	O	O

Assessment	B-PROC
of	O	O
the	O	O
nutritional	B-DISO
status	I-DISO
indicated	O	O
that	O	O
56	O	O
%	O	O
(	O	O
n	O	O
=	O	O
31	O	O
)	O	O
of	O	O
patients	B-LIVB
were	O	O
overweight	B-DISO
at	O	O
these	O	O
three	O	O
different	O	O
times	O	O
.	O	O

Weight	B-PHYS
,	O	O
BMI	B-PHYS
and	O	O
Waist	B-PHYS
Circumference	I-PHYS
increased	O
significantly	O
,	O	O
indicating	O	O
a	O	O
worse	B-DISO
nutritional	B-DISO
status	I-DISO
,	O	O
and	O	O
there	O	O
was	O	O
a	O	O
correlation	O
between	O	O
poor	O
diet	O
quality	O
and	O	O
higher	O
values	O
for	O	O
BMI	B-PHYS
,	O	O
Waist	B-PHYS
-	I-PHYS
Hip	I-PHYS
Ratio	I-PHYS
and	O	O
Waist	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
Height	I-DISO
Ratio	I-DISO
.	O	O

Chemotherapy	B-PROC
interferes	O
in	O	O
the	O	O
patients	B-LIVB
'	O	O
diet	B-OBJC
generating	O	O
a	O	O
negative	O
impact	O
on	O	O
the	O	O
quality	O
and	O	O
intake	O
of	O	O
micro	B-CHEM
and	O	O
macronutrients	O
,	O	O
as	O	O
well	O	O
as	O	O
an	O	O
impact	O
on	O	O
their	O	O
nutritional	B-DISO
status	I-DISO
,	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
anthropometric	O
measurements	O
.	O	O

The	O	O
Origin	O
of	O	O
Selectivity	O
in	O	O
the	O	O
Complexation	O
of	O	O
N	B-CHEM
-	I-CHEM
Methyl	I-CHEM
Amino	I-CHEM
Acids	I-CHEM
by	O	O
Tetraphosphonate	B-CHEM
Cavitands	I-CHEM
We	O	O
report	O
on	O	O
the	O	O
eligibility	O
of	O	O
tetraphosphonate	B-CHEM
resorcinarene	I-CHEM
cavitands	I-CHEM
for	O	O
the	O	O
molecular	B-PHYS
recognition	I-PHYS
of	O	O
amino	B-CHEM
acids	I-CHEM
.	O	O

We	O	O
determined	O
the	O	O
crystal	B-CHEM
structure	I-CHEM
of	O	O
13	O	O
complexes	O
of	O	O
the	O	O
tetraphosphonate	B-CHEM
cavitand	I-CHEM
Tiiii	B-CHEM
[	I-CHEM
H	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
CH3	I-CHEM
]	I-CHEM
with	O	O
amino	B-CHEM
acids	I-CHEM
.	O	O

(	O	O
1	O	O
)	O	O
H	B-CHEM
NMR	B-PHEN
and	O	O
(	O	O
31	O	O
)	O	O
P	B-CHEM
NMR	B-PHEN
experiments	B-PROC
and	O	O
ITC	B-DEVI
analysis	B-PROC
were	O	O
performed	O
to	O	O
probe	B-PROC
the	O	O
binding	B-PHYS
between	O
cavitand	B-CHEM
Tiiii	B-CHEM
[	I-CHEM
C3H7	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
C2H5	I-CHEM
]	I-CHEM
or	O	O
the	O	O
water	B-CHEM
-	O	O
soluble	O
counterpart	O
Tiiii	B-CHEM
[	I-CHEM
C3H6Py	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
Cl	I-CHEM
(	I-CHEM
-	I-CHEM
)	I-CHEM
,	I-CHEM
CH3	I-CHEM
,	I-CHEM
C2H5	I-CHEM
]	I-CHEM
and	O	O
a	O	O
selection	O
of	O	O
representative	O
amino	B-CHEM
acids	I-CHEM
.	O	O

The	O	O
reported	O
studies	B-PROC
and	O	O
results	B-DISO
allowed	O	O
us	O	O
(	O	O
i	O	O
)	O	O
to	O	O
highlight	O	O
the	O	O
noncovalent	B-PHEN
interactions	I-PHEN
involved	O
in	O	O
the	O	O
binding	B-PHYS
event	O
in	O	O
each	O	O
case	O
;	O	O
(	O	O
ii	O	O
)	O	O
to	O	O
investigate	O
the	O	O
ability	B-PHYS
of	O	O
tetraphosphonate	B-CHEM
cavitand	I-CHEM
receptors	B-CHEM
to	O	O
discriminate	O
between	O
the	O	O
different	O
amino	B-CHEM
acids	I-CHEM
;	O	O
(	O	O
iii	O	O
)	O	O
to	O	O
calculate	O
the	O	O
Ka	O
values	O
of	O	O
the	O	O
different	O
complexes	O
formed	O
and	O	O
evaluate	B-PROC
the	O	O
thermodynamic	O
parameters	O
of	O	O
the	O	O
complexation	O
process	B-PHEN
,	O	O
dissecting	O
the	O	O
entropic	B-PHEN
and	O	O
enthalpic	O
contributions	O
;	O	O
and	O	O
(	O	O
iv	O	O
)	O	O
to	O	O
determine	B-PROC
the	O	O
solvent	B-CHEM
influence	O
on	O	O
the	O	O
complexation	O
selectivity	O
.	O	O

By	O	O
moving	B-PHYS
from	O	O
methanol	B-CHEM
to	O	O
water	B-CHEM
,	O	O
the	O	O
complexation	O
changed	O
from	O	O
entropy	B-PHEN
driven	O
to	O	O
entropy	B-PHEN
opposed	O
,	O	O
leading	O	O
to	O	O
a	O	O
drop	O
of	O	O
almost	O	O
three	O	O
orders	B-PHEN
in	O	O
the	O	O
magnitude	O
of	O	O
the	O	O
Ka	O
.	O	O

However	O	O
,	O	O
this	O	O
reduction	O
in	O	O
binding	B-PHYS
affinity	B-PHEN
is	O	O
associated	O
with	O
a	O	O
dramatic	O	O
increase	O
in	O	O
selectivity	O
,	O	O
since	O	O
in	O	O
aqueous	B-CHEM
solutions	I-CHEM
only	O	O
N	B-CHEM
-	I-CHEM
methylated	I-CHEM
amino	I-CHEM
acids	I-CHEM
are	O	O
effectively	O
recognized	B-PHYS
.	O	O

The	O	O
thermodynamic	O
profile	B-PROC
of	O	O
the	O	O
binding	B-PHYS
does	O	O
not	O	O
change	O
in	O	O
PBS	B-OBJC
solution	I-OBJC
.	O	O

The	O	O
pivotal	O	O
role	O
played	O	O
by	O	O
cation	B-PHEN
-	I-PHEN
π	I-PHEN
interactions	I-PHEN
is	O	O
demonstrated	O
by	O	O
the	O	O
linear	O
correlation	O
found	O	O
between	O
the	O	O
log	O
Ka	O
in	O	O
methanol	B-CHEM
solution	B-OBJC
and	O	O
the	O	O
depth	O
of	O	O
(	B-CHEM
+	I-CHEM
)	I-CHEM
N	I-CHEM
-	I-CHEM
CH3	I-CHEM
cavity	B-DISO
inclusion	O
in	O	O
the	O	O
molecular	O
structures	O
.	O	O

These	O	O
findings	B-DISO
are	O	O
relevant	O
for	O	O
the	O	O
potential	O
use	O
of	O	O
phosphonate	B-CHEM
cavitands	I-CHEM
as	O	O
synthetic	O
receptors	B-CHEM
for	O	O
the	O	O
detection	B-PROC
of	O	O
epigenetic	B-PHYS
modifications	B-DISO
of	O	O
histones	B-CHEM
in	O	O
physiological	O
media	B-OBJC
.	O	O

Computed	B-PROC
Tomography	I-PROC
Imaging	I-PROC
Features	O	O
and	O	O
Changes	O	O
in	O	O
Hemostatic	B-CHEM
Agents	I-CHEM
After	O	O
Laparoscopic	B-PROC
Partial	I-PROC
Nephrectomy	I-PROC
Urologists	B-LIVB
and	O	O
radiologists	B-LIVB
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
CT	B-PROC
scan	I-PROC
appearance	O	O
of	O	O
laparoscopic	B-PROC
partial	I-PROC
nephrectomy	I-PROC
(	O	O
LPN	B-PROC
)	O	O
with	O	O
the	O	O
various	O	O
hemostatic	B-CHEM
agents	I-CHEM
since	O	O
they	O	O
may	O	O
confound	O	O
the	O	O
interpretation	O	O
of	O	O
these	O	O
radiographic	B-DISO
findings	I-DISO
.	O	O

We	O	O
report	O	O
the	O	O
various	O	O
postoperative	O
CT	B-PROC
scan	I-PROC
appearance	O	O
and	O	O
changes	O	O
after	O	O
LPN	B-PROC
.	O	O

We	O	O
reviewed	O	O
CT	B-PROC
scans	I-PROC
retrospectively	O
(	O	O
within	O	O
3	O	O
months	O	O
)	O	O
of	O	O
86	O	O
patients	B-LIVB
who	O	O
underwent	O	O
LPN	B-PROC
using	O	O
various	O	O
hemostatic	B-CHEM
agents	I-CHEM
between	O	O
March	O	O
2008	O	O
and	O	O
July	O	O
2014	O	O
.	O	O

We	O	O
analyzed	O	O
the	O	O
CT	B-PROC
findings	B-DISO
after	O	O
LPN	B-PROC
,	O	O
including	O	O
postoperative	O
changes	O	O
,	O	O
tumor	B-DISO
recurrence	I-DISO
,	O	O
and	O	O
complications	B-DISO
.	O	O

We	O	O
also	O	O
discuss	O	O
changes	O	O
in	O	O
abnormal	B-DISO
features	O	O
,	O	O
such	O	O
as	O	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
and	O	O
gas	O
formation	O
,	O	O
on	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
CT	B-PROC
scans	I-PROC
.	O	O

To	O	O
categorize	O	O
the	O	O
postoperative	O
changes	O	O
,	O	O
we	O	O
classified	O	O
them	O	O
according	O	O
to	O	O
their	O	O
specific	O	O
CT	B-PROC
findings	B-DISO
:	O	O
(	O	O
1	O	O
)	O	O
a	O	O
combination	O	O
of	O	O
perinephric	B-DISO
stranding	I-DISO
and	O	O
postsurgical	B-DISO
fluid	B-ANAT
collection	O
(	O	O
n	O	O
=	O	O
46	O	O
)	O	O
,	O	O
(	O	O
2	O	O
)	O	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
(	O	O
n	O	O
=	O	O
35	O	O
)	O	O
,	O	O
(	O	O
3	O	O
)	O	O
a	O	O
parenchymal	B-ANAT
defect	O
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
(	O	O
4	O	O
)	O	O
local	B-PHEN
recurrence	I-PHEN
at	O	O
the	O	O
surgical	O
site	O
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
(	O	O
5	O	O
)	O	O
a	O	O
large	O	O
hematoma	B-DISO
as	O	O
a	O	O
complication	B-DISO
after	O	O
LPN	B-PROC
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
(	O	O
6	O	O
)	O	O
gas	O	O
pockets	O	O
,	O	O
which	O	O
may	O	O
be	O	O
a	O	O
response	B-PHYS
to	I-PHYS
postsurgical	B-DISO
fluid	B-ANAT
collection	O
around	O	O
soft	O
tissue	O
(	O	O
n	O	O
=	O	O
35	O	O
)	O	O
,	O	O
(	O	O
7	O	O
)	O	O
fat	B-PHYS
at	O	O
the	O	O
excision	B-DISO
site	I-DISO
(	O	O
n	O	O
=	O	O
2	O	O
;	O	O
Fig	O	O
.	O	O
7	O	O
)	O	O
,	O	O
and	O	O
(	O	O
8	O	O
)	O	O
contrast	B-DISO
extravasation	I-DISO
in	O	O
the	O	O
delayed	O
phase	O
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
.	O	O

Mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
were	O	O
visible	O	O
in	O	O
35	O	O
cases	O	O
.	O	O

The	O	O
average	O	O
change	O	O
in	O	O
size	O	O
of	O	O
bolster	B-DISO
masses	I-DISO
was	O	O
-1	O	O
.	O	O

19	O	O
mm	O	O
/	O	O
month	O	O
.	O	O

However	O	O
,	O	O
the	O	O
overall	O	O
change	O	O
in	O	O
enhancement	O
of	O	O
mass	B-DISO
-	I-DISO
like	I-DISO
lesions	I-DISO
was	O	O
not	B-DISO
significant	I-DISO
over	O	O
time	O	O
.	O	O

Foci	O
of	O	O
gas	O	O
were	O	O
noted	O	O
in	O	O
16	O	O
patients	B-LIVB
at	O	O
the	O	O
resection	B-PROC
site	O	O
in	O	O
the	O	O
first	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	I-PROC
(	O	O
<	O	O
3	O	O
months	O	O
)	O	O
,	O	O
as	O	O
late	O	O
as	O	O
40	O	O
days	O	O
after	O	O
the	O	O
procedure	B-PROC
.	O	O

Knowledge	O	O
of	O	O
CT	B-PROC
imaging	I-PROC
features	O	O
and	O	O
changes	O	O
in	O	O
hemostatic	B-CHEM
agents	I-CHEM
following	O	O
LPN	B-PROC
is	O	O
important	O	O
in	O	O
interpreting	O	O
postoperative	O
CT	B-PROC
scans	I-PROC
,	O	O
as	O	O
postoperative	O
changes	O	O
can	O	O
be	O	O
confused	O	O
with	O	O
tumor	B-DISO
recurrence	I-DISO
and	O	O
can	O	O
mimic	O	O
abscesses	O	O
.	O	O

Benefit	O	O
and	O	O
risk	B-PROC
in	O	O
short	O	O
term	O	O
after	O	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
by	O	O
direct	O
anterior	O
approach	O
combined	O	O
with	O	O
dual	B-DEVI
mobility	I-DEVI
cup	I-DEVI
No	O	O
previous	O	O
reports	O	O
have	O	O
described	O	O
the	O	O
benefits	O	O
and	O	O
risks	B-PROC
associated	O	O
with	O	O
the	O	O
dual	B-DEVI
mobility	I-DEVI
cup	I-DEVI
(	O	O
DMC	B-DEVI
)	O	O
in	O	O
primary	O	O
THA	B-PROC
via	O	O
direct	O
anterior	O
approach	O
(	O	O
DAA	O
)	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
compare	O	O
the	O	O
safety	B-PROC
and	O	O
rate	O	O
of	O	O
early	O	O
postoperative	B-DISO
complication	I-DISO
of	O	O
the	O	O
DAA	O
with	O	O
the	O	O
DMC	B-DEVI
for	O	O
THA	B-PROC
with	O	O
those	O	O
of	O	O
the	O	O
DAA	O
with	O	O
a	O	O
single	B-DEVI
standard	I-DEVI
cup	I-DEVI
,	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
influence	O	O
of	O	O
the	O	O
learning	O	O
curve	O	O
of	O	O
the	O	O
use	O	O
of	O	O
DMC	B-DEVI
on	O	O
intra	O
-	O	O
and	O	O
perioperative	O
outcomes	O
.	O	O

We	O	O
retrospectively	O	O
investigated	O	O
60	O	O
hips	B-ANAT
treated	B-PROC
in	O	O
the	O	O
single	O	O
-	O	O
DAA	O
group	O
and	O	O
60	O	O
hips	B-ANAT
treated	B-PROC
in	O	O
the	O	O
dual	O	O
-	O	O
DAA	O
group	O
.	O	O

A	O	O
primary	O
/	O	O
secondary	O
outcome	O
variable	O	O
was	O	O
the	O	O
presence	O	O
of	O	O
any	O	O
intra	B-DISO
-	O	O
or	O	O
perioperative	O
complication	B-DISO
within	O	O
the	O	O
first	O	O
6	O	O
months	O
/the	O	O
operative	O
time	O
and	O	O
hip	O	O
function	O	O
at	O	O
6	O	O
months	O
postoperatively	O
.	O	O

We	O	O
also	O	O
analyzed	O	O
influence	O	O
of	O	O
the	O	O
learning	O	O
curve	O	O
of	O	O
the	O	O
use	O	O
of	O	O
DMC	B-DEVI
on	O	O
intra	O
-	O	O
and	O	O
perioperative	O
outcomes	O
.	O	O

No	B-DISO
intraoperative	B-DISO
complications	I-DISO
were	O	O
observed	O	O
in	O	O
either	O	O
group	O
.	O	O

One	O	O
anterior	B-DISO
dislocation	I-DISO
and	O	O
one	O	O
periprosthetic	B-DISO
hip	I-DISO
fracture	I-DISO
were	O	O
occurred	O	O
in	O	O
the	O	O
single	O	O
-	O	O
DAA	O
group	O
.	O	O

The	O	O
surgical	O
times	O
in	O	O
the	O	O
single	O	O
-	O	O
DAA	O
and	O	O
dual	O	O
-	O	O
DAA	O
groups	O
were	O	O
112	O	O
.	O	O

0	O	O
±	O	O
20	O	O
.	O	O
9	O	O
and	O	O
121	O	O
.	O	O

0	O	O
±	O	O
26	O	O
.	O	O

9	O	O
min	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
6	O	O
-	O	O
month	O
postoperative	O
hip	O
function	O
scores	O
between	O	O
the	O	O
two	O	O
groups	O
.	O	O

There	O	O
was	O	O
no	O	O
influence	O	O
of	O	O
the	O	O
learning	O	O
curve	O	O
of	O	O
the	O	O
use	O	O
of	O	O
DMC	B-DEVI
on	O	O
intra	O
-	O	O
and	O	O
perioperative	O
outcomes	O
.	O	O

We	O	O
have	O	O
demonstrated	O	O
the	O	O
short	O	O
-	O	O
term	O	O
safety	B-PROC
and	O	O
lack	O	O
of	O	O
inferiority	O	O
of	O	O
using	O	O
the	O	O
DMC	B-DEVI
in	O	O
the	O	O
DAA	O
compared	O	O
with	O	O
the	O	O
standard	B-DEVI
single	I-DEVI
mobility	I-DEVI
cup	I-DEVI
.	O	O

Incidence	O
of	O	O
an	O	O
Anomalous	B-DISO
Course	O	O
of	O	O
the	O	O
Palmar	B-ANAT
Cutaneous	I-ANAT
Branch	I-ANAT
of	I-ANAT
the	I-ANAT
Median	I-ANAT
Nerve	I-ANAT
During	O	O
Volar	B-ANAT
Plate	B-PROC
Fixation	I-PROC
of	O	O
Distal	B-DISO
Radius	I-DISO
Fractures	I-DISO
Volar	B-PROC
plating	I-PROC
of	O	O
distal	B-DISO
radius	I-DISO
fractures	I-DISO
using	O	O
an	O	O
approach	O	O
through	O	O
the	O	O
flexor	B-ANAT
carpi	I-ANAT
radialis	I-ANAT
(	O	O
FCR	B-ANAT
)	O	O
sheath	B-ANAT
is	O	O
commonplace	O	O
.	O	O

The	O	O
palmar	B-ANAT
cutaneous	I-ANAT
branch	I-ANAT
of	I-ANAT
the	I-ANAT
median	I-ANAT
nerve	I-ANAT
(	O	O
PCB	B-ANAT
)	O	O
is	O	O
considered	O	O
to	O	O
run	O	O
in	O	O
a	O	O
position	O	O
adjacent	O	O
to	O	O
,	O	O
but	O	O
outside	O	O
,	O	O
the	O	O
ulnar	B-ANAT
FCR	B-ANAT
sheath	B-ANAT
.	O	O

Anatomic	O
studies	B-PROC
have	O	O
not	O	O
identified	O	O
anatomic	B-DISO
abnormalities	I-DISO
relevant	O	O
to	O	O
volar	B-PROC
plating	I-PROC
.	O	O

The	O	O
purpose	O
of	O
this	O
study	O
was	O	O
to	O	O
determine	O	O
the	O	O
frequency	O
of	O	O
anomalous	B-DISO
PCB	B-ANAT
branches	I-ANAT
entering	O	O
the	O	O
FCR	B-ANAT
sheath	B-ANAT
during	O	O
volar	B-PROC
plating	I-PROC
.	O	O

This	O	O
observational	B-PROC
study	I-PROC
involved	O	O
10	O	O
attending	O	O
hand	B-LIVB
surgeons	I-LIVB
during	O	O
a	O	O
7	O	O
-	O	O
month	O
period	O	O
(	O	O
July	O
2015	O	O
-	O	O
January	O
2016	O	O
)	O	O
.	O	O

Surgeons	B-LIVB
assessed	O
,	O	O
documented	B-PROC
,	O	O
and	O	O
reported	O	O
any	O	O
PCB	B-ANAT
anomalies	B-DISO
that	O	O
were	O	O
encountered	O	O
during	O	O
volar	B-PROC
plating	I-PROC
through	O	O
a	O	O
trans	O	O
-	O	O
FCR	B-ANAT
approach	O	O
.	O	O

There	O	O
were	O	O
182	O	O
volar	B-ANAT
plates	I-ANAT
applied	O	O
that	O	O
made	O	O
up	O	O
the	O	O
study	O
group	O
.	O	O

There	O	O
were	O	O
10	O	O
cases	O
(	O	O
5	O	O
.	O	O
5	O	O
%	O	O
)	O	O
of	O	O
anomalous	B-DISO
PCBs	B-ANAT
entering	O	O
the	O	O
FCR	B-ANAT
sheath	B-ANAT
.	O	O

In	O	O
4	O	O
cases	O
,	O	O
the	O	O
PCB	B-ANAT
pierced	O	O
the	O	O
radial	O	O
FCR	B-ANAT
sheath	B-ANAT
proximally	O	O
,	O	O
crossed	O	O
beneath	O	O
the	O	O
tendon	B-ANAT
,	O	O
and	O	O
traveled	O	O
distally	O
on	O	O
the	O	O
ulnar	B-ANAT
side	O	O
.	O	O

In	O	O
4	O	O
other	O	O
cases	O
,	O	O
the	O	O
PCB	B-ANAT
entered	O	O
the	O	O
FCR	B-ANAT
sheath	B-ANAT
proximally	O
on	O	O
the	O	O
ulnar	B-ANAT
or	O	O
central	O
aspect	O	O
of	O	O
the	O	O
sheath	B-ANAT
and	O	O
remained	O	O
within	O	O
the	O	O
sheath	B-ANAT
,	O	O
staying	O	O
along	O	O
the	O	O
ulnar	B-ANAT
or	O	O
dorsal	B-ANAT
side	I-ANAT
of	O	O
the	O	O
tendon	B-ANAT
.	O	O

In	O	O
1	O	O
case	O	O
,	O	O
the	O	O
PCB	B-ANAT
pierced	B-DISO
the	O	O
ulnar	B-ANAT
distal	O
aspect	O	O
of	O	O
the	O	O
sheath	B-ANAT
and	O	O
split	O	O
into	O	O
2	O	O
branches	O
.	O	O

In	O	O
1	O	O
case	O
,	O	O
the	O	O
PCB	B-ANAT
ran	O	O
within	O	O
the	O	O
sheath	B-ANAT
along	O	O
the	O	O
radial	O
aspect	O	O
of	O	O
the	O	O
FCR	B-ANAT
.	O	O

Anomalies	B-DISO
in	O	O
the	O	O
course	O	O
of	O	O
the	O	O
PCB	B-ANAT
are	O	O
more	O	O
common	O	O
than	O	O
often	O	O
considered	O	O
.	O	O

These	O	O
variants	O
are	O	O
at	O
risk	O
during	O	O
volar	B-ANAT
surgical	O
approaches	O
to	O	O
the	O	O
wrist	B-ANAT
that	O	O
proceed	O	O
through	O	O
the	O	O
FCR	B-ANAT
sheath	B-ANAT
.	O	O

Although	O	O
dissecting	O
along	O	O
the	O	O
radial	O
side	O
of	O	O
the	O	O
FCR	B-ANAT
sheath	B-ANAT
may	O	O
protect	O	O
the	O	O
PCB	B-ANAT
in	O	O
most	O	O
cases	O
,	O	O
care	O	O
must	O	O
be	O	O
taken	O	O
to	O	O
identify	O	O
anomalous	B-DISO
branches	O
(	O	O
if	O	O
present	O	O
)	O	O
and	O	O
protect	O	O
them	O	O
during	O	O
surgery	B-PROC
.	O	O

Individualizing	O
drug	O
dosage	O
with	O	O
longitudinal	O
data	O
We	O	O
propose	O	O
a	O	O
two	O
-	O
step	O
procedure	O
to	O	O
personalize	O	O
drug	O
dosage	O
over	O	O
time	O
under	O	O
the	O	O
framework	O	O
of	O	O
a	O	O
log	O
-	O
linear	O
mixed	O
-	O
effect	O
model	O
.	O	O

We	O	O
model	B-PROC
patients	B-LIVB
'	O	O
heterogeneity	O
using	O	O
subject	O
-	O	O
specific	O
random	O
effects	O
,	O	O
which	O	O
are	O	O
treated	O	O
as	O	O
the	O	O
realizations	O
of	O	O
an	O	O
unspecified	O
stochastic	O
process	O
.	O	O

We	O	O
extend	O	O
the	O	O
conditional	O
quadratic	O
inference	O
function	O
to	O	O
estimate	O	O
both	O	O
fixed	O
-	O
effect	O
coefficients	O
and	O	O
individual	O
random	O
effects	O
on	O	O
a	O	O
longitudinal	O
training	O
data	O
sample	O
in	O	O
the	O	O
first	O	O
step	O
and	O	O
propose	O	O
an	O	O
adaptive	O	O
procedure	O
to	O	O
estimate	O	O
new	O
patients	B-LIVB
'	O	O
random	O
effects	O
and	O	O
provide	O	O
dosage	O
recommendations	O
for	O	O
new	O	O
patients	B-LIVB
in	O	O
the	O	O
second	O	O
step	O
.	O	O

An	O	O
advantage	O	O
of	O	O
our	O	O
approach	O
is	O	O
that	O	O
we	O	O
do	O	O
not	O	O
impose	O	O
any	O	O
distribution	O
assumption	O
on	O	O
estimating	O	O
random	O
effects	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
new	O	O
approach	O
can	O	O
accommodate	O	O
more	O	O
general	O	O
time	O
-varying	O	O
covariates	O
corresponding	O	O
to	O	O
random	O
effects	O
.	O	O

We	O	O
show	O	O
in	O	O
theory	O
and	O	O
numerical	B-PROC
studies	I-PROC
that	O	O
the	O	O
proposed	O	O
method	O
is	O	O
more	O	O
efficient	O
compared	O	O
with	O	O
existing	O	O
approaches	O
,	O	O
especially	O	O
when	O	O
covariates	O
are	O	O
time	O
varying	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
real	O	O
data	O
example	O
of	O	O
a	O	O
clozapine	B-CHEM
study	B-PROC
confirms	O	O
that	O	O
our	O	O
two	O
-	O
step	O
procedure	O
leads	O	O
to	O	O
more	O	O
accurate	O
drug	O
dosage	O
recommendations	O
.	O	O

Copyright	O	O
©	O	O
2016	O	O
John	O	O
Wiley	O	O
&	O	O
Sons	O	O
,	O	O
Ltd	O	O
.	O	O

Association	O
of	O	O
Low	O	O
Ficolin	B-CHEM
-	O	O
Lectin	B-CHEM
Pathway	B-PHYS
Parameters	O
with	O	O
Cardiac	B-DISO
Syndrome	I-DISO
X	I-DISO
In	O	O
patients	B-LIVB
with	O	O
typical	B-DISO
angina	I-DISO
pectoris	I-DISO
,	O	O
inducible	O
myocardial	B-DISO
ischaemia	I-DISO
and	O	O
macroscopically	O
normal	O
coronaries	B-ANAT
(	O	O
cardiac	B-DISO
syndrome	I-DISO
X	I-DISO
(	O	O
CSX	B-DISO
)	O	O
)	O	O
,	O	O
a	O	O
significantly	O	O
elevated	O
plasma	B-ANAT
level	O
of	O	O
terminal	B-CHEM
complement	I-CHEM
complex	I-CHEM
(	O	O
TCC	B-CHEM
)	O	O
,	O	O
the	O	O
common	O	O
end	O	O
product	O	O
of	O	O
complement	B-PHYS
activation	I-PHYS
,	O	O
has	O	O
been	O	O
observed	O
without	O	O
accompanying	O	O
activation	O
of	O	O
the	O	O
classical	B-PHYS
or	O	O
the	O	O
alternative	B-PHYS
pathways	I-PHYS
.	O	O

Therefore	O	O
,	O	O
our	O	O
aim	O
was	O	O
to	O	O
clarify	O
the	O	O
role	O
of	O	O
the	O	O
ficolin	B-CHEM
-	O	O
lectin	B-CHEM
pathway	B-PHYS
in	O	O
CSX	B-DISO
.	O	O

Eighteen	O	O
patients	B-LIVB
with	O	O
CSX	B-DISO
,	O	O
37	O	O
stable	O
angina	B-DISO
patients	B-LIVB
with	O	O
significant	O
coronary	B-DISO
stenosis	I-DISO
(	O	O
CHD	B-DISO
)	O	O
and	O	O
54	O	O
healthy	B-LIVB
volunteers	I-LIVB
(	O	O
HC	B-LIVB
)	O	O
were	O	O
enrolled	B-PROC
.	O	O

Serum	B-ANAT
levels	O
of	O	O
ficolin	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
,	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
and	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
-mediated	O	O
TCC	B-CHEM
deposition	O
(	O	O
FCN3	B-CHEM
-	O	O
TCC	B-CHEM
)	O	O
were	O	O
determined	O	O
.	O	O

Plasma	B-ANAT
level	O
of	O	O
TCC	B-CHEM
was	O	O
significantly	O	O
higher	O
in	O	O
the	O	O
CSX	O
than	O	O
in	O	O
the	O	O
HC	B-LIVB
or	O	O
CHD	O
group	O
(	O	O
5	O	O
.	O	O
45	O	O
versus	O	O
1	O	O
.	O	O
30	O	O
versus	O	O
2	O	O
.	O	O
04	O	O
AU	O	O
/	O	O
ml	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Serum	B-ANAT
levels	O
of	O	O
ficolin	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
were	O	O
significantly	O	O
lower	O
in	O	O
the	O	O
CSX	O
compared	O	O
to	O	O
the	O	O
HC	B-LIVB
or	O	O
CHD	O
group	O
(	O	O
3	O	O
.	O	O
60	O	O
versus	O	O
5	O	O
.	O	O
80	O	O
or	O	O
5	O	O
.	O	O
20	O	O
μg	O	O
/	O	O
ml	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
;	O	O
17	O	O
.	O	O
80	O	O
versus	O	O
24	O	O
.	O	O
10	O	O
or	O	O
26	O	O
.	O	O
80	O	O
μg	O	O
/	O	O
ml	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
was	O	O
significantly	O	O
lower	O
in	O	O
the	O	O
CSX	B-DISO
group	O
compared	O	O
to	O	O
the	O	O
HC	B-LIVB
group	I-LIVB

(	O	O
92	O	O
.	O	O
90	O	O
versus	O	O
144	O	O
.	O	O

90	O	O
AU	O	O
/	O	O
ml	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
006	O	O
)	O	O
.	O	O

FCN3	B-CHEM
-	O	O
TCC	B-CHEM
deposition	O
was	O	O
significantly	O	O
lower	O
in	O	O
the	O	O
CSX	B-DISO
group	O
compared	O	O
to	O	O
the	O	O
HC	B-LIVB
and	O	O
CHD	O
groups	O
(	O	O
67	O	O
.	O	O
8	O	O
%	O	O
versus	O	O
143	O	O
.	O	O

3	O	O
%	O	O
or	O	O
159	O	O
.	O	O

7	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
the	O	O
CSX	B-DISO
group	O
,	O	O
a	O	O
significant	O	O
correlation	O
was	O	O
found	O	O
between	O	O
TCC	B-CHEM
and	O	O
FCN3	B-CHEM
-	O	O
TCC	B-CHEM
level	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
507	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
032	O	O
)	O	O
and	O	O
between	O	O
ficolin	B-CHEM
-	I-CHEM
3	I-CHEM
/	O	O
MASP	B-CHEM
-	I-CHEM
2	I-CHEM
complex	B-CHEM
level	O
and	O	O
FCN3	B-CHEM
-	O	O
TCC	B-CHEM
deposition	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
651	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
003	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
in	O	O
patients	B-LIVB
with	O	O
typical	B-DISO
angina	I-DISO
and	O	O
myocardial	B-DISO
ischaemia	I-DISO
despite	O	O
macroscopically	O
normal	B-DISO
coronary	I-DISO
arteries	I-DISO
,	O	O
low	O
levels	O
of	O	O
several	O	O
lectin	B-CHEM
pathway	B-PHYS
parameters	O
were	O	O
observed	O	O
,	O	O
indicating	O	O
complement	B-PHYS
activation	I-PHYS
and	O	O
consumption	B-PHYS
.	O	O

Complement	B-PHYS
activation	I-PHYS
through	O	O
the	O	O
ficolin	B-CHEM
-	O	O
lectin	B-CHEM
pathway	B-PHYS
might	O	O
play	O	O
a	O	O
role	O
in	O	O
the	O	O
complex	O
pathomechanism	O
of	O	O
CSX	B-DISO
.	O	O

Specialized	O
morphology	O
corresponds	O	O
to	O	O
a	O	O
generalist	O
diet	B-OBJC
:	O	O
linking	O	O
form	O	O
and	O	O
function	B-PHYS
in	O	O
smashing	O
mantis	O
shrimp	O
crustaceans	O
Many	O	O
animals	B-LIVB
are	O	O
considered	O	O
to	O	O
be	O	O
specialists	O
because	O	O
they	O	O
have	O	O
feeding	O
structures	O
that	O	O
are	O	O
fine	O	O
-	O	O
tuned	O	O
for	O	O
consuming	B-PHYS
specific	O
prey	B-LIVB
.	O	O

For	O	O
example	O	O
,	O	O
""""	O
smasher	O
""""	O
mantis	O
shrimp	O
have	O	O
highly	O
specialized	O
predatory	B-PHYS
appendages	B-ANAT
that	O	O
generate	O
forceful	O
strikes	O
to	O	O
break	O
apart	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
.	O	O

Anecdotal	O
observations	O
suggest	O	O
,	O	O
however	O	O
,	O	O
that	O	O
the	O	O
diet	B-OBJC
of	O	O
smashers	O
may	O	O
include	O	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
as	O	O
well	O	O
.	O	O

Our	O	O
goal	O
was	O	O
to	O	O
examine	O
the	O	O
diet	O
breadth	O
of	O	O
the	O	O
smasher	O
mantis	O
shrimp	O
,	O	O
Neogonodactylus	O
bredini	O
,	O	O
to	O	O
determine	O	O
whether	O	O
it	O	O
has	O	O
a	O	O
narrow	O
diet	B-OBJC
of	O	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
.	O	O

We	O	O
combined	O	O
studies	O	O
of	O	O
prey	B-LIVB
abundance	O
,	O	O
feeding	O
behavior	O
,	O	O
and	O	O
stable	B-PROC
isotope	I-PROC
analyses	I-PROC
of	O	O
diet	B-OBJC
in	O	O
both	O	O
seagrass	O
and	O	O
coral	O
rubble	O
to	O	O
determine	O	O
if	O	O
N	O
.	O
bredini	O
's	O
diet	B-OBJC
was	O	O
consistent	O
across	O	O
different	O
habitat	O
types	O
.	O	O

The	O	O
abundances	O
of	O	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
and	O	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
varied	O	O
between	O	O
habitats	O
.	O	O

In	O	O
feeding	O
experiments	B-PROC
,	O	O
N	O
.	O
bredini	O
consumed	B-PHYS
both	O	O
prey	B-LIVB
types	I-LIVB
.	O	O

N	O
.	O
bredini	O
consumed	B-PHYS
a	O	O
range	O
of	O	O
different	O
prey	B-LIVB
in	O
the	O
field	O
as	O	O
well	O	O
and	O	O
,	O	O
unexpectedly	B-DISO
,	O	O
the	O	O
stable	B-PROC
isotope	I-PROC
analysis	I-PROC
demonstrated	O	O
that	O	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
comprised	O	O
a	O	O
large	O
proportion	O
(	O	O
29	O	O
-	O	O
53	O	O
%	O	O
)	O	O
of	O	O
the	O	O
diet	B-OBJC
in	O	O
both	O	O
habitats	O
.	O	O

Using	O	O
a	O	O
Bayesian	O
mixing	O
model	O
framework	O
(	O	O
MixSIAR	O
)	O	O
,	O	O
we	O	O
found	O	O
that	O	O
this	O	O
result	O	O
held	O	O
even	O	O
when	O	O
we	O	O
used	O	O
uninformative	O
,	O	O
or	O	O
generalist	O	O
,	O	O
priors	O
and	O	O
informative	O
priors	O
reflecting	O	O
a	O	O
specialist	O
diet	B-OBJC
on	O	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
prey	I-LIVB
and	O	O
prey	B-LIVB
abundances	O
in	O
the	O
field	O
.	O	O

Thus	O	O
,	O	O
contrary	O	O
to	O	O
expectation	O
,	O	O
the	O	O
specialized	O
feeding	O
morphology	O
of	O	O
N	O
.	O

bredini	O
corresponds	O	O
to	O	O
a	O	O
broad	O
diet	B-OBJC
of	O	O
both	O	O
hard	B-LIVB
-	I-LIVB
shelled	I-LIVB
and	O	O
soft	B-LIVB
-	I-LIVB
bodied	I-LIVB
prey	I-LIVB
.	O	O

Using	O	O
multiple	O	O
lines	O	O
of	O	O
study	O	O
to	O	O
describe	O	O
the	O	O
natural	O
diets	B-OBJC
of	O	O
other	O	O
presumed	O	O
specialists	O
may	O	O
demonstrate	O	O
that	O	O
specialized	O
morphology	O
often	O	O
broadens	O	O
rather	O	O
than	O	O
narrows	O
diet	O
breadth	O
.	O	O

Toxicity	B-DISO
assessment	O
of	O	O
water	B-OBJC
-	I-OBJC
accommodated	I-OBJC
fractions	I-OBJC
from	O	O
two	O	O
different	O	O
oils	B-CHEM
using	O	O
a	O	O
zebrafish	B-LIVB
(	O	O
Danio	B-LIVB
rerio	I-LIVB
)	O	O
embryo	B-ANAT
-	O	O
larval	O
bioassay	B-PROC
with	O	O
a	O	O
multilevel	B-PROC
approach	I-PROC
Petroleum	B-CHEM
compounds	I-CHEM
from	O	O
chronic	O
discharges	O
and	O	O
oil	B-PHEN
spills	I-PHEN
represent	O	O
an	O	O
important	O	O
source	O	O
of	O	O
environmental	B-PHEN
pollution	I-PHEN
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
deleterious	O
effects	O
of	O	O
these	O	O
compounds	B-CHEM
,	O	O
the	O	O
toxicity	B-DISO
of	O	O
water	B-OBJC
-	I-OBJC
accommodated	I-OBJC
fractions	I-OBJC
(	O	O
WAF	B-OBJC
)	O	O
from	O	O
two	O	O
different	O	O
oils	B-CHEM
(	O	O
brut	B-CHEM
Arabian	I-CHEM
Light	I-CHEM
and	O	O
Erika	B-CHEM
heavy	I-CHEM
fuel	I-CHEM
oils	I-CHEM
)	O	O
were	O	O
used	O	O
in	O	O
this	O	O
study	B-PROC
.	O	O

Zebrafish	B-LIVB
embryos	B-ANAT
(	O	O
Danio	B-LIVB
rerio	I-LIVB
)	O	O
were	O	O
exposed	O	O
during	O	O
96	O	O
h	O
at	O	O
three	O	O
WAF	B-OBJC
concentrations	O
(	O	O
1	O	O
,	O	O
10	O	O
and	O	O
100	O	O
%	O	O
for	O	O
Arabian	B-CHEM
Light	I-CHEM
and	O	O
10	O	O
,	O	O
50	O	O
and	O	O
100	O	O
%	O	O
for	O	O
Erika	B-CHEM
)	O	O
in	O	O
order	O	O
to	O	O
cover	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
polycyclic	B-CHEM
aromatic	I-CHEM
hydrocarbon	I-CHEM
(	O	O
PAH	B-CHEM
)	O	O
concentrations	O
,	O	O
representative	O
of	O	O
the	O	O
levels	O
found	O	O
after	O	O
environmental	O
oil	B-PHEN
spills	I-PHEN
.	O	O

Several	O	O
endpoints	O
were	O	O
recorded	O	O
at	O	O
different	O	O
levels	O
of	O	O
biological	B-PHYS
organization	I-PHYS
,	O	O
including	O	O
lethal	B-DISO
endpoints	O
,	O	O
morphological	B-DISO
abnormalities	I-DISO
,	O	O
photomotor	O
behavioral	O
responses	O
,	O	O
cardiac	B-DISO
activity	I-DISO
,	O	O
DNA	B-DISO
damage	I-DISO
and	O	O
exposure	O
level	O
measurements	O
(	O	O
EROD	B-CHEM
activity	B-PHYS
,	O	O
cyp1a	B-CHEM
and	O	O
PAH	B-CHEM
metabolites	B-CHEM
)	O	O
.	O	O

Neither	O	O
morphological	O
nor	O	O
behavioral	O
or	O	O
physiological	O
alterations	O
were	O	O
observed	O	O
after	O	O
exposure	O
to	O	O
Arabian	B-CHEM
Light	I-CHEM
fractions	B-OBJC
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
Erika	B-CHEM
fractions	B-OBJC
led	O	O
a	O	O
high	O	O
degree	O
of	O	O
toxicity	B-DISO
in	O	O
early	O
life	O
stages	O
of	O	O
zebrafish	B-LIVB
.	O	O

Despite	O	O
of	O	O
defense	O
mechanisms	O
induced	O	O
by	O	O
oil	B-CHEM
,	O	O
acute	O
toxic	B-DISO
effects	I-DISO
have	O	O
been	O	O
recorded	O	O
including	O	O
mortality	O
,	O	O
delayed	O
hatching	B-PHYS
,	O	O
high	O	O
rates	O
of	O	O
developmental	B-DISO
abnormalities	I-DISO
,	O	O
disrupted	O
locomotor	B-PHYS
activity	I-PHYS
and	O	O
cardiac	B-DISO
failures	I-DISO
at	O	O
the	O	O
highest	O	O
PAH	B-CHEM
concentrations	O
(	O	O
∑TPAHs	O	O
=	O	O
257	O	O
,	O	O
029±47	O	O
,	O	O
231ng·L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
.	O	O

Such	O	O
differences	O	O
in	O	O
toxicity	B-DISO
are	O	O
likely	O	O
related	O	O
to	O	O
the	O	O
oil	B-CHEM
composition	B-PHEN
.	O	O

The	O	O
use	O	O
of	O	O
developing	O	O
zebrafish	B-LIVB
is	O	O
a	O	O
good	O	O
tool	O	O
to	O	O
identify	O	O
wide	O	O
range	O	O
of	O	O
detrimental	O
effects	O
and	O	O
elucidate	O	O
their	O	O
underlying	O	O
foundations	O	O
.	O	O

Our	O	O
work	O	O
highlights	O	O
once	O	O
more	O	O
,	O	O
the	O	O
cardiotoxic	B-CHEM
action	I-CHEM
(	O	O
and	O	O
potentially	O	O
neurotoxic	B-CHEM
)	O	O
of	O	O
petroleum	B-CHEM
-related	O	O
PAHs	B-CHEM
.	O	O

Effect	O
of	O	O
constitutive	B-PHYS
inactivation	I-PHYS
of	O	O
the	O	O
myostatin	O
gene	O
on	O	O
the	O	O
gain	O
in	O	O
muscle	B-PHYS
strength	I-PHYS
during	O	O
postnatal	B-PHYS
growth	I-PHYS
in	O	O
two	O	O
murine	B-LIVB
models	B-LIVB
The	O	O
effect	O
of	O	O
constitutive	B-PHYS
inactivation	I-PHYS
of	O	O
the	O	O
gene	O
encoding	O
myostatin	O
on	O	O
the	O	O
gain	O
in	O	O
muscle	B-PHYS
performance	I-PHYS
during	O	O
postnatal	B-PHYS
growth	I-PHYS
has	O	O
not	O	O
been	O	O
well	O	O
characterized	O	O
.	O	O

We	O	O
analyzed	O	O
2	O	O
murine	B-LIVB
myostatin	O
knockout	B-LIVB
(	I-LIVB
KO	I-LIVB
)	I-LIVB
models	I-LIVB
,	O	O
(	O	O
i	O	O
)	O	O
the	O	O
Lee	B-LIVB
model	I-LIVB
(	O	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	O	O
)	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
the	O	O
Grobet	B-LIVB
model	I-LIVB
(	O	O
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
)	O	O
,	O	O
and	O	O
measured	O
the	O	O
contraction	B-PHYS
of	O	O
tibialis	B-ANAT
anterior	I-ANAT
muscle	I-ANAT
in	O
situ	O
.	O	O

Absolute	B-PHYS
maximal	I-PHYS
isometric	I-PHYS
force	I-PHYS
was	O	O
increased	O
in	O	O
6	O	O
-	O	O
month	O	O
-	O	O
old	O	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
and	O	O
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O	O
as	O	O
compared	O
to	O	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
mice	I-LIVB
.	O	O

Similarly	O	O
,	O	O
absolute	B-PHYS
maximal	I-PHYS
power	I-PHYS
was	O	O
increased	O
in	O	O
6	O	O
-	O	O
month	O	O
-	O	O
old	O	O
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O	O

In	O	O
contrast	O	O
,	O	O
specific	O
maximal	B-PHYS
force	I-PHYS
(	O	O
relative	O
maximal	B-PHYS
force	I-PHYS
per	O	O
unit	O	O
of	O	O
muscle	O
mass	B-DISO
was	O	O
decreased	O
in	O	O
all	O	O
6	O	O
-	O	O
month	O	O
-	O	O
old	O	O
male	B-PHYS
and	O	O
female	B-PHYS
KO	B-LIVB
mice	I-LIVB
,	O	O
except	O
in	O	O
6	O
-	O
month	O
-old	O	O
female	B-PHYS
KO	B-LIVB
(	I-LIVB
Grobet	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O	O
whereas	O	O
specific	O
maximal	B-PHYS
power	I-PHYS
was	O	O
reduced	O
only	O	O
in	O	O
male	B-PHYS
KO	B-LIVB
(	I-LIVB
Lee	I-LIVB
)	I-LIVB
mice	I-LIVB
.	O	O

Genetic	B-PHYS
inactivation	I-PHYS
of	O	O
myostatin	O
increases	O
maximal	B-PHYS
force	I-PHYS
and	O	O
power	B-PHYS
,	O	O
but	O	O
in	O	O
return	O
it	O	O
reduces	O
muscle	O
quality	O
,	O	O
particularly	O	O
in	O	O
male	B-PHYS
mice	B-LIVB
.	O	O

Muscle	O	O
Nerve	O	O
55	O	O
:	O	O
254	O	O
-	O	O
261	O	O
,	O	O
2017	O	O
.	O	O

Evaluation	B-PROC
of	O	O
the	O	O
in	O
vitro	O
growth	B-PHYS
of	O	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
-causing	O	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
in	O	O
a	O	O
proposed	O
synthetic	O
human	B-LIVB
urine	B-ANAT
(	O	O
SHU	B-ANAT
)	O	O
medium	B-CHEM
Bacteriuria	B-DISO
is	O	O
a	O	O
hallmark	O	O
of	O	O
urinary	B-DISO
tract	I-DISO
infection	I-DISO
(	O	O
UTI	B-DISO
)	O	O
and	O	O
asymptomatic	B-DISO
bacteriuria	I-DISO
(	O	O
ABU	B-DISO
)	O	O
,	O	O
which	O	O
are	O	O
among	O	O
the	O	O
most	O	O
frequent	O
infections	B-DISO
in	O	O
humans	B-LIVB
.	O	O

A	O	O
variety	O	O
of	O	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
are	O	O
associated	O
with	O
these	O	O
infections	B-DISO
but	O	O
Escherichia	B-LIVB
coli	I-LIVB
contributes	O
up	O	O
to	O	O
80	O	O
%	O	O
of	O	O
cases	O
.	O	O

Multiple	O
bacterial	B-LIVB
species	I-LIVB
including	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
can	O	O
grow	B-PHYS
in	O	O
human	B-LIVB
urine	B-ANAT
as	O	O
a	O	O
means	O	O
to	O	O
maintain	O
colonization	B-DISO
during	O	O
infections	B-DISO
.	O	O

In	O
vitro	O
bacteriuria	B-DISO
studies	B-PROC
aimed	O
at	O	O
modeling	B-PROC
microbial	B-PHYS
growth	I-PHYS
in	O	O
urine	B-ANAT
have	O	O
utilized	O	O
various	O	O
compositions	B-PHYS
of	O	O
synthetic	O
human	B-LIVB
urine	B-ANAT
(	O	O
SHU	B-ANAT
)	O	O
and	O	O
a	O	O
Composite	O
SHU	B-ANAT
formulation	B-OBJC
was	O	O
recently	O	O
proposed	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
sought	O	O
to	O	O
validate	B-PROC
the	O	O
recently	O	O
proposed	O
Composite	O
SHU	B-ANAT
as	O	O
a	O	O
medium	B-CHEM
that	O	O
supports	O
the	O	O
growth	B-PHYS
of	O	O
several	O
bacterial	B-LIVB
species	I-LIVB
that	O	O
are	O	O
known	O	O
to	O	O
grow	B-PHYS
in	O	O
normal	O
human	B-LIVB
urine	B-ANAT
and	O	O
/	O	O
or	O	O
artificial	O
urine	B-ANAT
.	O	O

Comparative	B-PROC
growth	B-PHEN
assays	I-PHEN
of	O	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
and	O	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
,	O	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
,	O	O
Proteus	B-LIVB
mirabilis	I-LIVB
,	O	O
Streptococcus	B-LIVB
agalactiae	I-LIVB
,	O	O
Staphylococcus	B-LIVB
saprophyticus	I-LIVB
and	O	O
Enterococcus	B-LIVB
faecalis	I-LIVB
were	O	O
undertaken	O	O
using	O	O
viable	O
bacterial	B-PROC
count	I-PROC
and	O	O
optical	B-PROC
density	I-PROC
measurements	I-PROC
over	O	O
a	O	O
48h	O	O
culture	B-PROC
period	O
.	O	O

Three	O	O
different	O	O
SHU	B-ANAT
formulations	B-OBJC
were	O	O
tested	O
in	O	O
various	O
culture	B-DEVI
vessels	I-DEVI
,	O	O
shaking	O
conditions	O
and	O	O
volumes	O
and	O	O
showed	O	O
that	O	O
Composite	O
SHU	B-ANAT
can	O	O
support	O
the	O	O
robust	O
growth	B-PHYS
of	O	O
gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacteria	I-LIVB
but	O	O
requires	O
supplementation	O
with	O	O
0	O	O
.	O	O

2	O	O
%	O	O
yeast	B-LIVB
extract	I-LIVB
to	O	O
support	O
the	O	O
growth	B-PHYS
of	O	O
gram	B-LIVB
-	I-LIVB
positive	I-LIVB
bacteria	I-LIVB
.	O	O

Experiments	B-PROC
are	O	O
also	O	O
presented	O	O
that	O	O
show	O	O
an	O	O
unexpected	O
but	O	O
major	O
influence	O
of	O	O
P	B-LIVB
.	I-LIVB

mirabilis	I-LIVB
towards	O	O
the	O	O
ability	O	O
to	O	O
measure	B-PHEN
bacterial	I-PHEN
growth	I-PHEN
in	O	O
generally	O
accepted	O
multiwell	B-PROC
assays	I-PROC
using	O	O
absorbance	B-PHYS
readings	I-PHYS
,	O	O
predicted	O
to	O	O
have	O	O
a	O	O
basis	O
in	O	O
the	O	O
release	O
of	O	O
volatile	B-CHEM
organic	I-CHEM
compound	I-CHEM
(	I-CHEM
s	I-CHEM
)	I-CHEM
from	O	O
P	B-LIVB
.	I-LIVB

mirabilis	I-LIVB
during	O	O
growth	B-PHYS
in	O	O
Composite	O
SHU	B-ANAT
medium	B-CHEM
.	O	O

This	O	O
study	B-PROC
represents	O	O
an	O	O
essential	O
methodological	O
validation	B-PROC
of	O	O
a	O	O
more	O
chemically	B-CHEM
defined	O
type	O	O
of	O	O
synthetic	O
urine	B-ANAT
that	O	O
can	O	O
be	O	O
applied	O	O
to	O	O
study	B-PROC
mechanisms	O
of	O	O
bacteriuria	B-DISO
and	O	O
we	O	O
conclude	O
will	O	O
offer	O	O
a	O	O
useful	O	O
in	B-PROC
vitro	I-PROC
model	I-PROC
to	O	O
investigate	O
the	O	O
basis	O
of	O	O
some	O	O
of	O	O
the	O	O
most	O	O
common	O	O
infections	B-DISO
of	O	O
humans	B-LIVB
.	O	O

Osteopontin	B-CHEM
expression	B-PHYS
in	O	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
of	O	O
human	B-LIVB
squamous	B-DISO
cell	I-DISO
carcinoma	I-DISO
-derived	O	O
cells	B-ANAT
and	O	O
osteoblastic	B-ANAT
cells	I-ANAT
and	O	O
its	O	O
effects	O
on	O	O
the	O	O
neoplastic	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
and	O	O
osteoclastic	B-ANAT
activation	B-PHYS
This	O	O
study	B-PROC
evaluated	O
the	O	O
temporal	O
expression	B-PHYS
of	O	O
osteopontin	B-CHEM
(	O	O
OPN	B-CHEM
)	O	O
in	O	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
of	O	O
human	B-LIVB
osteoblastic	B-ANAT
cells	I-ANAT
(	O	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
)	O	O
and	O	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
OSCC	B-DISO
)	O	O
-	O	O
derived	O	O
cells	B-ANAT
(	O	O
SCC9	B-ANAT
)	O	O
and	O	O
examined	B-DISO
the	O	O
effects	O
of	O	O
osteoblast	B-ANAT
-derived	O	O
OPN	B-CHEM
on	O	O
the	O	O
neoplastic	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
.	O	O

Additionally	O	O
,	O	O
the	O	O
effects	O
of	O	O
these	O	O
co	B-ANAT
-	I-ANAT
cultures	I-ANAT
on	O	O
subsequent	O	O
osteoclastic	B-ANAT
activity	B-PHYS
were	O	O
explored	O	O
.	O	O

SCC9	B-ANAT
cells	I-ANAT
were	O	O
plated	O	O
on	O	O
Transwell	B-OBJC
®	I-OBJC
membranes	I-OBJC
that	O	O
were	O	O
either	O	O
coated	O
or	O	O
not	O	O
coated	O	O
with	O	O
Matrigel	B-CHEM
and	O	O
were	O	O
then	O	O
co	B-PROC
-	I-PROC
cultured	I-PROC
with	O	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
during	O	O
the	O	O
peak	O	O
of	O	O
OPN	B-CHEM
expression	B-PHYS
.	O	O

SCC9	B-ANAT
cells	I-ANAT
exposed	O	O
to	O	O
OPN	B-CHEM
-silenced	O	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cultures	B-ANAT
and	O	O
SCC9	B-ANAT
cells	I-ANAT
cultured	B-PROC
alone	O	O
served	O	O
as	O	O
controls	B-LIVB
.	O	O

SCC9	B-ANAT
cells	I-ANAT
were	O	O
quantitatively	O
evaluated	O
for	O	O
cell	B-PHYS
adhesion	I-PHYS
,	O	O
proliferation	B-PHYS
,	O	O
migration	B-PHYS
,	O	O
and	O	O
invasion	B-DISO
into	O	O
Matrigel	B-CHEM
.	O	O

The	O	O
impact	O	O
of	O	O
co	B-PROC
-	I-PROC
culturing	I-PROC
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
and	O	O
SCC9	B-ANAT
cells	I-ANAT
on	O	O
the	O	O
resorptive	O	O
capacity	O	O
of	O	O
U	B-ANAT
-	I-ANAT
937	I-ANAT
-derived	O	O
osteoclastic	B-ANAT
cells	I-ANAT
was	O	O
also	O	O
investigated	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
reciprocal	O
induction	O
of	O	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
and	O	O
SCC9	B-ANAT
cells	I-ANAT
in	O	O
terms	O	O
of	O	O
OPN	B-CHEM
expression	B-PHYS
over	O	O
the	O	O
co	B-ANAT
-	I-ANAT
culture	I-ANAT
interval	O	O
was	O	O
identified	O	O
.	O	O

SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
-secreted	O	O
OPN	B-CHEM
altered	O	O
the	O	O
SCC9	B-ANAT
cell	I-ANAT
phenotype	B-PHYS
,	O	O
leading	O	O
to	O	O
enhanced	O
cell	B-PHYS
adhesion	I-PHYS
and	O	O
proliferation	B-PHYS
and	O	O
higher	O	O
Matrigel	B-CHEM
invasion	B-DISO
.	O	O

This	O	O
invasion	B-DISO
was	O	O
also	O	O
enhanced	O	O
,	O	O
albeit	O	O
to	O	O
a	O	O
lesser	O	O
degree	O	O
,	O	O
by	O	O
co	B-ANAT
-	I-ANAT
culture	I-ANAT
with	O	O
OPN	O
-	O	O
silenced	B-PHYS
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
.	O	O

Cell	B-PHYS
migration	I-PHYS
was	O	O
not	O	O
affected	O	O
.	O	O

Co	B-ANAT
-	I-ANAT
culture	I-ANAT
with	O	O
SAOS	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
-mainly	O	O
during	O	O
the	O	O
period	O	O
of	O	O
peak	O	O
OPN	B-CHEM
expression	B-PHYS
-promoted	O	O
over	B-PHYS
-	I-PHYS
expression	I-PHYS
of	O	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
by	O	O
SCC9	B-ANAT
cells	I-ANAT
and	O	O
enhanced	O	O
the	O	O
resorptive	O
capacity	O	O
of	O	O
osteoclastic	B-ANAT
cells	I-ANAT
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	B-DISO
suggest	O	O
that	O	O
osteoblast	B-ANAT
-derived	O	O
OPN	B-CHEM
affects	O
the	O	O
interactions	B-PHYS
among	O	O
OSCC	B-DISO
-derived	O	O
epithelial	B-ANAT
cells	I-ANAT
,	O	O
osteoblasts	B-ANAT
,	O	O
and	O	O
osteoclasts	B-ANAT
,	O	O
which	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
process	B-PHEN
of	O	O
bone	B-DISO
destruction	I-DISO
during	O	O
bone	B-ANAT
invasion	B-DISO
by	O	O
OSCC	B-DISO
.	O	O

Traumatic	B-DISO
Brain	I-DISO
Injury	I-DISO
Induces	O
Alterations	O
in	O	O
Cortical	B-ANAT
Glutamate	B-CHEM
Uptake	B-PHYS
without	O	O
a	O	O
Reduction	O
in	O	O
Glutamate	B-CHEM
Transporter	I-CHEM
-	I-CHEM
1	I-CHEM
Protein	I-CHEM
Expression	B-PHYS
We	O	O
hypothesize	O	O
that	O	O
the	O	O
primary	O
mechanism	O
for	O	O
removal	O
of	O	O
glutamate	B-CHEM
from	O	O
the	O	O
extracellular	B-ANAT
space	I-ANAT
is	O	O
altered	O
after	O	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O	O
TBI	B-DISO
)	O	O
.	O	O

To	O	O
evaluate	B-PROC
this	O	O
hypothesis	O
,	O	O
we	O	O
initiated	O
TBI	B-DISO
in	O	O
adult	B-LIVB
male	I-LIVB
rats	I-LIVB
using	O	O
a	O	O
2	O	O
.	O	O
0	O	O
atm	O	O
lateral	O
fluid	O
percussion	O
injury	O
(	O
LFPI	O
)	O
model	O
.	O	O

In	O	O
the	O	O
ipsilateral	O
cortex	B-ANAT
and	O	O
hippocampus	B-ANAT
,	O	O
we	O	O
found	O	O
no	B-DISO
differences	I-DISO
in	O	O
expression	B-PHYS
of	O	O
the	O	O
primary	B-CHEM
glutamate	I-CHEM
transporter	I-CHEM
in	O	O
the	O	O
brain	B-ANAT
(	O	O
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
24	O	O
h	O	O
after	O	O
TBI	B-DISO
.	O	O

In	O	O
contrast	O
,	O	O
we	O	O
found	O	O
a	O	O
decrease	O
in	O	O
glutamate	B-CHEM
uptake	B-PHYS
in	O	O
the	O	O
cortex	B-ANAT
,	O	O
but	O	O
not	O	O
the	O	O
hippocampus	B-ANAT
,	O	O
24	O	O
h	O	O
after	O	O
injury	B-DISO
.	O	O

Because	O	O
glutamate	B-CHEM
uptake	B-PHYS
is	O	O
potently	O	O
regulated	O
by	O	O
protein	B-CHEM
kinases	I-CHEM
,	O	O
we	O	O
assessed	O
global	O	O
serine	B-CHEM
-	I-CHEM
threonine	I-CHEM
protein	I-CHEM
kinase	I-CHEM
activity	B-PHYS
using	O	O
a	O	O
kinome	O
array	O
platform	O
.	O	O

Twenty	O
-	O
five	O
kinome	O
array	O
peptide	B-CHEM
substrates	I-CHEM
were	O	O
differentially	O	O
phoshorylated	B-PHYS
between	O	O
LFPI	O
and	O	O
controls	B-LIVB
in	O	O
the	O	O
cortex	B-ANAT
,	O	O
whereas	O	O
19	O	O
peptide	B-CHEM
substrates	I-CHEM
were	O	O
differentially	O	O
phosphorylated	B-PHYS
in	O	O
the	O	O
hippocampus	B-ANAT
(	O	O
fold	O	O
change	O	O
≥	O	O
±	O	O
1	O	O
.	O	O
15	O	O
)	O	O
.	O	O

We	O	O
identified	O
several	B-CHEM
kinases	I-CHEM
as	O	O
likely	O	O
to	O	O
be	O	O
involved	O
in	O	O
acute	O
TBI	B-DISO
,	O	O
including	O	O
protein	B-CHEM
kinase	I-CHEM
B	I-CHEM
(	O	O
Akt	B-CHEM
)	O	O
and	O	O
protein	B-CHEM
kinase	I-CHEM
C	I-CHEM
(	O	O
PKC	B-CHEM
)	O	O
,	O	O
which	O	O
are	O	O
well	O
-	O
characterized	O
modulators	B-CHEM
of	O	O
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
.	O	O

Exploratory	B-PROC
studies	I-PROC
using	O	O
an	O	O
inhibitor	O
of	O	O
Akt	B-CHEM
suggest	O	O
selective	O
activation	O
of	O	O
kinases	B-CHEM
in	O	O
LFPI	O
versus	O	O
controls	B-LIVB
.	O	O

Ingenuity	O
pathway	O
analyses	O
of	O	O
implicated	O	O
kinases	B-CHEM
from	O	O
our	O	O
network	O
model	O
found	O	O
apoptosis	B-PHYS
and	O	O
cell	B-PHYS
death	I-PHYS
pathways	O
as	O	O
top	O	O
functions	O
in	O	O
acute	O
LFPI	O
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
data	O
suggest	O	O
diminished	O
activity	O
of	O	O
glutamate	B-CHEM
transporters	O	O
in	O	O
the	O	O
prefrontal	B-ANAT
cortex	I-ANAT
,	O	O
with	O	O
no	B-DISO
changes	I-DISO
in	O	O
protein	B-PHYS
expression	I-PHYS
of	O	O
the	O	O
primary	O	O
glutamate	B-CHEM
transporter	I-CHEM
GLT	B-CHEM
-	I-CHEM
1	I-CHEM
,	O	O
and	O	O
global	O	O
alteration	O
s	O	O
in	O	O
signaling	B-PHYS
networks	I-PHYS
that	O	O
include	O	O
serine	B-CHEM
-	I-CHEM
threonine	I-CHEM
kinases	I-CHEM
that	O	O
are	O	O
known	O	O
modulators	B-CHEM
of	O	O
glutamate	B-PHYS
transport	I-PHYS
activity	I-PHYS
.	O	O

Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	O	O
Clock	B-PHYS
-	I-PHYS
Dependent	I-PHYS
Pacemaking	B-PROC
in	O	O
the	O	O
Sinus	B-ANAT
Node	I-ANAT
Is	O	O
Impaired	O
in	O	O
Mice	B-LIVB
with	O	O
a	O	O
Cardiac	B-ANAT
Specific	O	O
Reduction	O
in	O	O
SERCA2	B-CHEM
Abundance	O
The	O	O
sarcoplasmic	B-CHEM
reticulum	I-CHEM
Ca	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	I-CHEM
ATPase	I-CHEM

Frequency	O	O
of	O	O
BCR	O
-	O
ABL	O
Transcript	B-CHEM
Types	O	O
in	O	O
Syrian	B-LIVB
CML	B-DISO
Patients	B-LIVB
Background	O	O
.	O	O

In	O	O
Syria	B-GEOG
,	O	O
CML	B-DISO
patients	B-LIVB
are	O	O
started	O	O
on	O	O
tyrosine	B-PHYS
kinase	I-PHYS
inhibitors	I-PHYS
(	O	O
TKIs	B-PHYS
)	O	O
and	O	O
monitored	O	O
until	O	O
complete	O	O
molecular	B-DISO
response	I-DISO
is	O	O
achieved	O	O
.	O	O

BCR	O
-	O
ABL	O
mRNA	B-CHEM
transcript	B-CHEM
type	O	O
is	O	O
not	O	O
routinely	O	O
identified	O	O
,	O	O
contrary	O	O
to	O	O
the	O	O
recommendations	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
frequency	O	O
of	O	O
different	O	O
BCR	O
-	O
ABL	O
transcripts	B-CHEM
in	O	O
Syrian	B-LIVB
CML	B-DISO
patients	B-LIVB
and	O	O
highlight	O	O
their	O	O
significance	O	O
on	O	O
monitoring	O	O
and	O	O
treatment	B-PROC
protocols	I-PROC
.	O	O

Methods	O	O
.	O	O

CML	B-DISO
patients	B-LIVB
positive	B-DISO
for	O	O
BCR	O
-	O
ABL	O
transcripts	B-CHEM
by	O	O
quantitative	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
were	O	O
enrolled	O	O
.	O	O

BCR	O
-	O
ABL	O
transcript	B-CHEM
types	O	O
were	O	O
investigated	O
using	O	O
a	O	O
home	O	O
-	O	O
made	O	O
PCR	B-PROC
method	O	O
that	O	O
was	O	O
adapted	O	O
from	O	O
published	O
protocols	O
and	O	O
optimized	O
.	O	O

The	O	O
transcript	B-CHEM
types	O	O
were	O	O
then	O	O
confirmed	O	O
using	O	O
a	O	O
commercially	O	O
available	O	O
research	B-DEVI
kit	I-DEVI
.	O	O

Results	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
transcripts	B-CHEM
were	O	O
found	O	O
in	O	O
21	O	O
patients	B-LIVB
.	O	O

The	O	O
most	O	O
common	O	O
was	O	O
b2a2	B-CHEM
,	O	O
followed	O	O
by	O	O
b3a2	B-CHEM
,	O	O
b3a3	B-CHEM
,	O	O
and	O	O
e1a3	B-CHEM
present	O	O
solely	O	O
in	O	O
12	O	O
(	O	O
57	O	O
.	O	O
1	O	O
%	O	O
)	O	O
,	O	O
3	O	O
(	O	O
14	O	O
.	O	O

3	O	O
%	O	O
)	O	O
,	O	O
2	O	O
(	O	O
9	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
1	O	O
(	O	O
4	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Three	O	O
samples	O	O
(	O	O
14	O	O
.	O	O
3	O	O
%	O	O
)	O	O
contained	O	O
dual	O	O
transcripts	B-CHEM
.	O	O

While	O	O
b3a2	B-CHEM
transcript	I-CHEM
was	O	O
apparently	O	O
associated	O
with	O
warning	O	O
molecular	B-DISO
response	I-DISO
to	O	O
imatinib	B-CHEM
treatment	B-PROC
,	O	O
b2a2	B-CHEM
,	O	O
b3a3	B-CHEM
,	O	O
and	O	O
e1a3	B-CHEM
transcripts	I-CHEM
collectively	O	O
proved	O	O
otherwise	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
047	O	O
)	O	O
.	O	O

Conclusion	O	O
.	O	O

It	O	O
might	O	O
be	O	O
advisable	O	O
to	O	O
identify	O	O
the	O	O
BCR	O
-	O
ABL	O
transcript	B-CHEM
type	O	O
in	O	O
CML	B-DISO
patients	B-LIVB
at	O	O
diagnosis	O	O
,	O	O
using	O	O
an	O	O
empirically	O	O
verified	O	O
method	O	O
,	O	O
in	O	O
order	O	O
to	O	O
link	O	O
the	O	O
detected	O	O
transcript	B-CHEM
with	O	O
the	O	O
clinical	O
findings	O
,	O	O
possible	O	O
resistance	O
to	O	O
treatment	B-PROC
,	O	O
and	O	O
appropriate	O	O
monitoring	B-PROC
methods	I-PROC
.	O	O

Steamed	B-PHEN
and	I-PHEN
Fermented	I-PHEN
Ethanolic	B-CHEM
Extract	I-CHEM
from	O	O
Codonopsis	B-LIVB
lanceolata	I-LIVB
Attenuates	O
Amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O	O
Induced	O
Memory	B-DISO
Impairment	I-DISO
in	O	O
Mice	B-LIVB
Codonopsis	B-LIVB
lanceolata	I-LIVB
(	O	O
C	B-LIVB
.	I-LIVB

lanceolata	I-LIVB
)	O	O
is	O	O
a	O	O
traditional	O	O
medicinal	B-LIVB
plant	I-LIVB
used	O	O
for	O	O
the	O	O
treatment	O
of	O	O
certain	O	O
inflammatory	B-DISO
diseases	I-DISO
such	O	O
as	O	O
asthma	B-DISO
,	O	O
tonsillitis	B-DISO
,	O	O
and	O	O
pharyngitis	B-DISO
.	O	O

We	O	O
evaluated	O	O
whether	O	O
steamed	B-PHEN
and	I-PHEN
fermented	I-PHEN
C	B-LIVB
.	I-LIVB

lanceolata	I-LIVB
(	O	O
SFC	B-LIVB
)	O	O
extract	B-CHEM
improves	B-DISO
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O	O
(	O	O
Aβ	B-CHEM
-	I-CHEM
)	O	O
induced	O
learning	B-PHYS
and	O	O
memory	B-DISO
impairment	I-DISO
in	O	O
mice	B-LIVB
.	O	O

The	O	O
Morris	B-PROC
water	I-PROC
maze	I-PROC
and	O	O
passive	B-PHYS
avoidance	I-PHYS
tests	B-PROC
were	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
effect	O
of	O	O
SFC	B-CHEM
extract	I-CHEM
.	O	O

Moreover	O	O
,	O	O
we	O	O
investigated	O
acetylcholinesterase	B-PHYS
(	I-PHYS
AChE	I-PHYS
)	I-PHYS
activity	I-PHYS
and	O	O
brain	B-CHEM
-	I-CHEM
derived	I-CHEM
neurotrophic	I-CHEM
factor	I-CHEM
(	O	O
BDNF	B-CHEM
)	O	O
,	O	O
cyclic	B-CHEM
AMP	I-CHEM
response	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O	O
CREB	B-CHEM
)	O	O
,	O	O
and	O	O
extracellular	B-CHEM
signal	I-CHEM
-	I-CHEM
regulated	I-CHEM
kinase	I-CHEM
(	O	O
ERK	B-CHEM
)	O	O
signaling	B-PHYS
in	O	O
the	O	O
hippocampus	B-ANAT
of	O	O
mice	B-LIVB
to	O	O
determine	O	O
a	O	O
possible	O	O
mechanism	O
for	O	O
the	O	O
cognitive	B-PHYS
-	O	O
enhancing	O
effect	O
.	O	O

Saponin	B-CHEM
compounds	B-CHEM
in	O	O
SFC	B-LIVB
were	O	O
identified	O
by	O	O
Ultra	B-PROC
Performance	I-PROC
Liquid	I-PROC
Chromatography	I-PROC
-	I-PROC
Quadrupole	I-PROC
-	I-PROC
Time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
Flight	I-PROC
Mass	I-PROC
Spectrometry	I-PROC
(	O	O
UPLC	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
)	O	O
.	O	O

SFC	B-CHEM
extract	I-CHEM
ameliorated	B-DISO
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O	O
induced	O
memory	B-DISO
impairment	I-DISO
in	O	O
the	O	O
Morris	B-PROC
water	I-PROC
maze	I-PROC
and	O	O
passive	B-PHYS
avoidance	I-PHYS
tests	B-PROC
.	O	O

SFC	B-CHEM
extract	I-CHEM
inhibited	O
AChE	B-PHYS
activity	I-PHYS
and	O	O
also	O	O
significantly	O	O
increased	O
the	O	O
level	O
of	O	O
CREB	B-CHEM
phosphorylation	B-PHYS
,	O	O
BDNF	B-CHEM
expression	B-PHYS
,	O	O
and	O	O
ERK	B-CHEM
activation	B-PHYS
in	O	O
hippocampal	B-ANAT
tissue	I-ANAT
of	O	O
amyloid	B-CHEM
-	I-CHEM
β	I-CHEM
-	O	O
treated	O
mice	B-LIVB
.	O	O

Lancemasides	B-CHEM
A	I-CHEM
,	O	O
B	B-CHEM
,	O	O
C	B-CHEM
,	O	O
D	B-CHEM
,	O	O
E	B-CHEM
,	O	O
and	O	O
G	B-CHEM
and	O	O
foetidissimoside	B-CHEM
A	I-CHEM
compounds	B-CHEM
present	O	O
in	O	O
SFC	B-LIVB
were	O	O
determined	O	O
by	O	O
UPLC	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
.	O	O

These	O	O
results	O
indicate	O	O
that	O	O
SFC	B-CHEM
extract	I-CHEM
improves	B-DISO
Aβ	B-CHEM
-	O	O
induced	O
memory	B-DISO
deficits	I-DISO
and	O	O
that	O	O
AChE	B-CHEM
inhibition	O
and	O	O
CREB	B-CHEM
/	O	O
BDNF	B-CHEM
/	O	O
ERK	B-CHEM
expression	B-PHYS
is	O	O
important	O
for	O	O
the	O	O
effect	O
of	O	O
the	O	O
SFC	B-CHEM
extract	I-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
lancemaside	B-CHEM
A	I-CHEM
specifically	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
efficacious	O
effect	O
of	O	O
SFC	B-LIVB
.	O	O

Significance	O
of	O	O
ETV6	O
rearrangement	B-PHYS
in	O	O
acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
with	O	O
t	O	O
(	O	O
15	O	O
;	O	O
17	O	O
)	O	O
/	O	O
promyelocytic	B-DISO
leukemia	I-DISO
/	O	O
retinoic	B-CHEM
acid	I-CHEM
receptor	I-CHEM
alpha	I-CHEM
Acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
(	O	O
APL	B-DISO
)	O	O
is	O	O
a	O	O
common	O	O
subtype	O
of	O	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
in	O	O
China	B-GEOG
.	O	O

Since	O	O
the	O	O
application	O	O
of	O	O
arsenic	B-CHEM
trioxide	I-CHEM
and	O	O
all	B-CHEM
-	I-CHEM
trans	I-CHEM
retinoic	I-CHEM
acid	I-CHEM
in	O	O
the	O	O
treatment	O
of	O	O
APL	B-DISO
,	O	O
the	O	O
prognosis	B-PROC
has	O	O
greatly	O	O
improved	O
.	O	O

However	O	O
,	O	O
~20	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
APL	B-DISO
relapse	B-PHEN
upon	O	O
completing	O	O
chemotherapy	B-PROC
.	O	O

Decreasing	O
the	O	O
relapse	B-PHEN
rate	O
and	O	O
incidence	O
of	O	O
early	B-DISO
mortality	I-DISO
may	O	O
pose	O	O
the	O	O
greatest	O
challenges	B-PROC
for	O	O
the	O	O
future	O	O
management	B-PROC
of	O	O
APL	B-DISO
.	O	O

Recently	O	O
,	O	O
Ets	O
variant	O
6	O
(	O	O
ETV6	O
)	O	O
was	O	O
reported	B-PROC
to	O	O
be	O	O
involved	O
in	O	O
a	O	O
variety	O	O
of	O	O
translocations	B-PHYS
associated	O	O
with	O	O
hematological	B-DISO
malignancies	I-DISO
of	O	O
myeloid	O
and	O	O
lymphoid	O
origin	O
.	O	O

To	O	O
date	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
clinical	O
implication	O
of	O	O
ETV6	O
rearrangement	B-PHYS
in	O	O
APL	B-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
ETV6	O
rearrangement	B-PHYS
was	O	O
examined	O	O
by	O	O
split	B-PROC
-	I-PROC
signal	I-PROC
fluorescence	I-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
in	O	O
258	O	O
adults	B-LIVB
with	O	O
APL	B-DISO
,	O	O
and	O	O
its	O	O
association	O
with	O	O
the	O	O
clinical	B-PHYS
features	I-PHYS
and	O	O
outcomes	O
of	O	O
the	O	O
patients	B-LIVB
was	O	O
analyzed	B-PROC
.	O	O

The	O	O
data	O
suggested	O	O
that	O	O
ETV6	O
rearrangement	B-PHYS
may	O	O
be	O	O
an	O	O
independent	O	O
unfavorable	O
prognostic	B-PHYS
factor	I-PHYS
for	O	O
overall	O
survival	O
in	O	O
APL	B-DISO
patients	B-LIVB
.	O	O

Early	O
Cognitive	B-DISO
Deficits	I-DISO
in	O	O
Type	B-DISO
2	I-DISO
Diabetes	I-DISO
:	O	O
A	O	O
Population	B-PROC
-	I-PROC
Based	I-PROC
Study	I-PROC
Evidence	O
links	O	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
to	O	O
dementia	B-DISO
risk	I-DISO
.	O	O

However	O	O
,	O	O
our	O	O
knowledge	O
on	O	O
the	O	O
initial	O
cognitive	B-DISO
deficits	I-DISO
in	O	O
diabetic	B-DISO
individuals	B-LIVB
and	O	O
the	O	O
factors	O
that	O	O
might	O	O
promote	O	O
such	O	O
deficits	B-DISO
is	O	O
still	O	O
limited	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
cognitive	B-PHYS
domains	I-PHYS
initially	O
impaired	O
by	O	O
diabetes	B-DISO
and	O	O
the	O	O
factors	O
that	O	O
play	O	O
a	O	O
role	O	O
in	O	O
this	O	O
first	O	O
stage	O	O
.	O	O

Within	O	O
the	O	O
population	B-PROC
-	I-PROC
based	I-PROC
Swedish	I-PROC
National	I-PROC
Study	I-PROC
on	I-PROC
Aging	I-PROC
and	I-PROC
Care	I-PROC
-	I-PROC
Kungsholmen	I-PROC
,	O	O
2305	O	O
cognitively	O
intact	O
participants	B-LIVB
aged	O	O
≥60	O	O
y	O	O
were	O	O
identified	O	O
.	O	O

Attention	B-PHYS
/	O	O
working	B-PHYS
memory	I-PHYS
,	O	O
perceptual	B-PHYS
speed	B-DISO
,	O	O
category	O
fluency	O
,	O	O
letter	O
fluency	O
,	O	O
semantic	B-PHYS
memory	I-PHYS
,	O	O
and	O	O
episodic	B-PHYS
memory	I-PHYS
were	O	O
assessed	O
.	O	O

Diabetes	B-DISO
(	O	O
controlled	O
and	O	O
uncontrolled	O
)	O	O
and	O	O
prediabetes	B-DISO
were	O	O
ascertained	O	O
by	O	O
clinicians	B-LIVB
,	O	O
who	O	O
also	O	O
collected	O	O
information	O
on	O	O
vascular	B-DISO
disorders	I-DISO
(	O	O
hypertension	B-DISO
,	O	O
heart	B-DISO
diseases	I-DISO
,	O	O
and	O	O
stroke	B-DISO
)	O	O
and	O	O
vascular	B-DISO
risk	I-DISO
factors	I-DISO
(	O	O
VRFs	B-DISO
,	O	O
including	O	O
smoking	O
and	O	O
overweight	B-DISO
/	O	O
obesity	B-DISO
)	O	O
.	O	O

Data	O
were	O	O
analyzed	B-PROC
with	O	O
linear	O
regression	O
models	O
.	O	O

Overall	O	O
,	O	O
196	O	O
participants	B-LIVB
(	O	O
8	O	O
.	O	O
5	O	O
%	O	O
)	O	O
had	O	O
diabetes	B-DISO
,	O	O
of	O	O
which	O	O
144	O	O
(	O	O
73	O	O
.	O	O
5	O	O
%	O	O
)	O	O
had	O	O
elevated	O
glycaemia	B-CHEM
(	O	O
uncontrolled	O
diabetes	B-DISO
)	O	O
;	O	O

571	O	O
(	O	O
24	O	O
.	O	O

8	O	O
%	O	O
)	O	O
persons	O	O
had	O	O
prediabetes	B-DISO
.	O	O

In	O	O
addition	O	O
,	O	O
diabetes	B-DISO
,	O	O
mainly	O	O
uncontrolled	O
,	O	O
was	O	O
related	O	O
to	O	O
lower	O
performance	O
in	O	O
perceptual	B-PHYS
speed	B-DISO
(	O	O
β	O	O
-	O	O
1	O	O
.	O	O
10	O	O
[	O	O
95	O	O
%	O	O
CI	O
-	O	O
1	O	O
.	O	O
98	O	O
,	O	O
-	O	O
0	O	O
.	O	O
23	O	O
]	O	O
)	O	O
,	O	O
category	O
fluency	O
(	O	O
β	O	O
-	O	O
1	O	O
.	O	O
27	O	O
[	O	O
95	O	O
%	O	O
CI	O
-	O	O
2	O	O
.	O	O
52	O	O
,	O	O
-	O	O
0	O	O
.	O	O
03	O	O
]	O	O
)	O	O
,	O	O
and	O	O
digit	B-PHYS
span	I-PHYS
forward	I-PHYS
(	O	O
β	O	O
-	O	O
0	O	O
.	O	O
35	O	O
[	O	O
95	O	O
%	O	O
CI	O
-	O	O
0	O	O
.	O	O
54	O	O
,	O	O
-	O	O
0	O	O
.	O	O
17	O	O
]	O	O
)	O	O
.	O	O

Critically	O	O
,	O	O
these	O	O
associations	O	O
were	O	O
present	O	O
only	O	O
among	O	O
APOEɛ4	B-CHEM
non	O	O
-	O	O
carriers	O	O
.	O	O

The	O	O
associations	O	O
of	O	O
diabetes	B-DISO
with	O	O
perceptual	B-PHYS
speed	B-DISO
and	O	O
category	O
fluency	O
were	O	O
present	O	O
only	O	O
among	O	O
participants	B-LIVB
with	O	O
VRFs	B-DISO
or	O	O
vascular	B-DISO
disorders	I-DISO
.	O	O

Diabetes	B-DISO
,	O	O
especially	O	O
uncontrolled	O
diabetes	B-DISO
,	O	O
is	O	O
associated	O	O
with	O	O
poorer	O
performance	O
in	O	O
perceptual	B-PHYS
speed	B-DISO
,	O	O
category	O
fluency	O
,	O	O
and	O	O
attention	B-PHYS
/	O	O
primary	B-PHYS
memory	I-PHYS
.	O	O

VRFs	B-DISO
,	O	O
vascular	B-DISO
disorders	I-DISO
,	O	O
and	O	O
APOE	B-CHEM
status	O	O
play	O	O
a	O	O
role	O	O
in	O	O
these	O	O
associations	O	O
.	O	O

Methylation	B-PHYS
status	O
of	O	O
the	O	O
promoter	B-CHEM
region	I-CHEM
of	O	O
the	O	O
human	B-LIVB
frizzled	O
9	O
gene	O
in	O	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
The	O	O
FZD9	O
gene	O
is	O	O
located	O	O
at	O	O
chromosome	O
7q11	O
.	O

23	O
,	O	O
and	O	O

has	O	O
been	O	O
indicated	O	O
to	O	O
be	O	O
a	O	O
tumor	O
suppressor	O
gene	O
.	O	O

The	O	O
present	O	O
study	B-PROC
examined	B-DISO
the	O	O
involvement	O
of	O	O
FZD9	O
promoter	B-CHEM
methylation	B-PHYS
in	O	O
the	O	O
downregulation	B-PHYS
of	O	O
FZD9	O
expression	B-PHYS
in	O	O
leukemia	B-DISO
cells	B-ANAT
.	O	O

The	O	O
expression	B-PHYS
of	O	O
the	O	O
FZD9	O
gene	O
was	O	O
absent	O
in	O	O
various	O	O
leukemic	B-DISO
cell	B-ANAT
lines	I-ANAT
,	O	O
while	O	O
it	O	O
was	O	O
restored	O	O
following	O	O
treatment	O
with	O	O
DNA	B-CHEM
demethylating	I-CHEM
agent	I-CHEM
5	B-CHEM
-	I-CHEM
aza	I-CHEM
-	I-CHEM
2	I-CHEM
'	I-CHEM
-	I-CHEM
deoxycytidine	I-CHEM
.	O	O

Bisulfite	B-PROC
sequencing	I-PROC
analysis	I-PROC
of	O	O
the	O	O
FZD9	O
promoter	B-CHEM
region	I-CHEM
showed	O	O
that	O	O
it	O	O
was	O	O
partially	O	O
methylated	B-PHYS
in	O	O
cell	B-ANAT
lines	I-ANAT
in	O	O
which	O	O
FZD9	O
gene	O
was	O	O
not	O	O
expressed	B-PHYS
.	O	O

Thus	O	O
,	O	O
DNA	B-PHYS
methylation	I-PHYS
in	O	O
the	O	O
promoter	B-CHEM
region	I-CHEM
may	O	O
lead	O	O
to	O	O
inactivation	O
of	O	O
the	O	O
FZD9	O
gene	O
,	O	O
which	O	O
may	O	O
represent	O	O
and	O	O
aberration	O	O
associated	O
with	O
leukemia	B-DISO
,	O	O
since	O	O
DNA	B-CHEM
was	O	O
not	O	O
methylated	B-PHYS
in	O	O
normal	O	O
peripheral	B-ANAT
blood	I-ANAT
mononuclear	I-ANAT
cells	I-ANAT
.	O	O

Methylation	B-PHYS
-specific	O	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
analysis	I-PROC
revealed	O	O
that	O	O
the	O	O
promoter	B-CHEM
region	I-CHEM
of	O	O
the	O	O
FZD9	O
gene	O
was	O	O
frequently	O
methylated	B-PHYS
in	O	O
primary	O
or	O	O
relapse	B-PHEN
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
(	O	O
52	O	O
.	O	O

9	O	O
%	O	O
;	O	O
excluding	O	O
acute	B-DISO
promyelocytic	I-DISO
leukemia	I-DISO
)	O	O
;	O	O
however	O	O
,	O	O
methylation	B-PHYS
was	O	O
infrequent	O	O
in	O	O
B	B-ANAT
-	I-ANAT
cell	I-ANAT
acute	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O	O
5	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
present	O	O
study	B-PROC
indicated	O	O
that	O	O
the	O	O
methylation	B-PHYS
profile	B-PROC
of	O	O
the	O	O
FZD9	O
gene	O
corresponded	O	O
to	O	O
that	O	O
of	O	O
a	O	O
candidate	O	O
tumor	O
-	O
suppressor	O
gene	O
in	O	O
acute	B-DISO
myeloid	I-DISO
leukemia	I-DISO
.	O	O

Functional	O
conservation	O
of	O	O
the	O	O
lncRNA	B-CHEM
NEAT1	O
in	O	O
the	O	O
ancestrally	O	O
diverged	O	O
marsupial	B-LIVB
lineage	O
:	O	O
Evidence	O
for	O
NEAT1	O
expression	B-PHYS
and	O	O
associated	O
paraspeckle	B-ANAT
assembly	B-PHYS
during	O	O
late	O
gestation	B-PHYS
in	O	O
the	O	O
opossum	B-LIVB
Monodelphis	B-LIVB
domestica	I-LIVB
Long	B-CHEM
non	I-CHEM
-	I-CHEM
coding	I-CHEM
RNAs	I-CHEM
(	O	O
lncRNAs	B-CHEM
)	O	O
are	O	O
widely	O	O
expressed	B-PHYS
and	O	O
play	O	O
various	O	O
roles	O	O
in	O	O
cell	B-PHYS
homeostasis	I-PHYS
.	O	O

However	O	O
,	O	O
because	O	O
of	O	O
their	O	O
low	O
conservation	O
at	O	O
the	O	O
sequence	O
level	O
,	O	O
recapitulating	O	O
lncRNA	B-CHEM
evolutionary	O	O
history	O	O
is	O	O
often	O	O
challenging	O	O
.	O	O

While	O	O
performing	O	O
an	O	O
ultrastructural	B-ANAT
analysis	B-PROC
of	O	O
viral	B-ANAT
particles	I-ANAT
present	O	O
in	O	O
uterine	B-ANAT
glands	I-ANAT
of	O	O
gestating	O
opossum	B-LIVB
females	B-PHYS
,	O	O
we	O	O
serendipitously	O	O
noticed	O	O
the	O	O
presence	B-DISO
of	O	O
numerous	O
structures	B-ANAT
similar	O	O
to	O	O
paraspeckles	B-ANAT
,	O	O
nuclear	B-ANAT
bodies	I-ANAT
which	O	O
in	O	O
human	B-PHEN
and	O	O
mouse	B-ANAT
cells	I-ANAT
are	O	O
assembled	O	O
around	O	O
an	O	O
architectural	O	O
NEAT1	O
/	O
MENϵ	O
/	O
β	O
lncRNA	B-CHEM
.	O	O

Here	O	O
,	O	O
using	O	O
an	O	O
opossum	B-LIVB
kidney	B-ANAT
(	O	O
OK	B-ANAT
)	O	O
cell	O
line	O
,	O	O
we	O	O
confirmed	O
by	O
immuno	B-PROC
-	I-PROC
electron	I-PROC
microscopy	I-PROC
the	O	O
presence	B-DISO
of	O	O
paraspeckles	B-ANAT
in	O	O
marsupials	B-LIVB
.	O	O

We	O	O
then	O	O
identified	O
the	O	O
orthologous	O
opossum	B-LIVB
NEAT1	O
gene	O
which	O	O
,	O	O
although	O	O
poorly	O	O
conserved	O
at	O	O
the	O	O
sequence	O
level	O
,	O	O
displays	O	O
NEAT1	B-CHEM
characteristic	O
features	O
such	O	O
as	O	O
short	O
and	O	O
long	O
isoforms	B-CHEM
expressed	B-PHYS
from	O	O
a	O	O
unique	O
promoter	B-CHEM
and	O	O
for	O	O
the	O	O
latter	O	O
an	O	O
RNase	B-CHEM
P	I-CHEM
cleavage	B-PHYS
site	O
at	O	O
its	O	O
3	O
'	O
-	O
end	O
.	O	O

Combining	O	O
tissue	O
-	O	O
specific	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
,	O	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
at	O	O
the	O	O
optical	B-PROC
and	O	O
electron	B-PROC
microscopic	I-PROC
levels	O	O
,	O	O
we	O	O
show	O	O
that	O	O
(	O	O
i	O	O
)	O	O
NEAT1	O
is	O	O
paraspeckle	B-ANAT
-	O	O
associated	O
in	O	O
opossum	B-LIVB
(	O	O
ii	O	O
)	O	O
NEAT1	O
expression	B-PHYS
is	O	O
strongly	O	O
induced	O
in	O	O
late	O
gestation	B-PHYS
in	O	O
uterine	B-OBJC
/	O	O
placental	B-CHEM
extracts	I-CHEM
(	O	O
iii	O	O
)	O	O
NEAT1	O
induction	B-PHYS
occurs	O	O
in	O	O
the	O	O
uterine	B-ANAT
gland	I-ANAT
nuclei	B-ANAT
in	O	O
which	O	O
paraspeckles	B-ANAT
were	O	O
detected	O	O
.	O	O

Finally	O	O
,	O	O
treatment	B-PROC
of	O	O
OK	B-ANAT
cells	O
with	O	O
proteasome	B-CHEM
inhibitors	I-CHEM
induces	O
paraspeckle	B-ANAT
assembly	B-PHYS
,	O	O
as	O	O
previously	O	O
observed	O	O
in	O	O
human	B-PHEN
cells	I-PHEN
.	O	O

Altogether	O	O
,	O	O
these	O	O
results	O	O
demonstrate	O	O
that	O	O
paraspeckles	B-ANAT
are	O	O
tissue	O
-	O	O
specific	O
,	O	O
stress	B-DISO
-responding	O	O
nuclear	B-ANAT
bodies	I-ANAT
in	O	O
marsupials	B-LIVB
,	O	O
illustrating	O	O
their	O	O
structural	O
and	O	O
functional	O
continuity	O
over	O	O
200	O	O
My	O	O
of	O	O
evolution	O	O
throughout	O	O
the	O	O
mammalian	B-LIVB
lineage	O
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
rapid	O	O
evolution	B-PHYS
of	O	O
the	O	O
NEAT1	O
transcripts	B-CHEM
highlights	O	O
the	O	O
relaxed	O	O
constraint	O	O
that	O	O
,	O	O
despite	O	O
functional	O
conservation	O
,	O	O
is	O	O
exerted	O	O
on	O	O
this	O	O
lncRNA	B-CHEM
.	O	O

Ag	B-CHEM
nanoclusters	B-OBJC
could	O	O
efficiently	O
quench	B-PHYS
the	O	O
photoresponse	B-PHEN
of	O	O
CdS	B-CHEM
quantum	B-OBJC
dots	I-OBJC
for	O	O
novel	O	O
energy	B-PHYS
transfer	I-PHYS
-based	O	O
photoelectrochemical	O
bioanalysis	O
Herein	O	O
the	O	O
influence	O	O
of	O	O
ultrasmall	O	O
Ag	B-CHEM
nanoclusters	B-OBJC
(	O	O
Ag	B-CHEM
NCs	B-OBJC
)	O	O
against	O	O
CdS	B-CHEM
quantum	B-OBJC
dots	I-OBJC
(	O	O
QDs	B-OBJC
)	O	O
in	O	O
a	O	O
photoelectrochemical	O
(	O	O
PEC	O
)	O	O
nanosystem	B-OBJC
was	O	O
exploited	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
based	O	O
on	O	O
which	O	O
a	O	O
novel	O	O
PEC	O
bioanalysis	O
was	O	O
successfully	O
developed	O
via	O	O
the	O	O
efficient	O
quenching	B-PHYS
effect	O	O
of	O	O
Ag	B-CHEM
NCs	B-OBJC
against	O	O
the	O	O
CdS	B-CHEM
QDs	B-OBJC
.	O	O

In	O	O
a	O	O
model	B-DEVI
system	I-DEVI
,	O	O
DNA	B-PROC
assay	I-PROC
was	O	O
achieved	O	O
by	O	O
using	O	O
molecular	B-CHEM
beacon	I-CHEM
(	O	O
MB	B-CHEM
)	O	O
probes	B-DEVI
anchored	B-PROC
on	O	O
a	O	O
CdS	B-CHEM
QDs	B-OBJC
modified	O	O
electrode	B-OBJC
,	O	O
and	O	O
the	O	O
MB	B-CHEM
probes	B-DEVI
contain	O	O
two	O	O
segments	O	O
that	O	O
can	O	O
hybridize	B-PHEN
with	O	O
both	O	O
target	O
DNA	O
sequence	O
and	O	O
the	O	O
label	B-OBJC
of	O	O
DNA	B-CHEM
encapsulated	O
Ag	B-CHEM
NCs	B-OBJC
.	O	O

After	O	O
the	O	O
MB	B-CHEM
probe	B-DEVI
was	O	O
unfolded	O	O
by	O	O
the	O	O
target	O
DNA	O
sequence	O
,	O	O
the	O	O
labels	B-OBJC
of	O	O
oligonucleotide	B-CHEM
encapsulated	O
Ag	B-CHEM
NCs	B-OBJC
would	O	O
be	O	O
brought	O	O
in	O	O
close	O	O
proximity	O
to	O	O
the	O	O
CdS	B-CHEM
QDs	B-OBJC
electrode	B-OBJC
surface	I-OBJC
,	O	O
and	O	O
efficient	O
photocurrent	B-PHEN
quenching	I-PHEN
of	O	O
QDs	B-OBJC
could	O	O
be	O	O
resulted	O
from	O	O
an	O	O
energy	B-PHYS
transfer	I-PHYS
process	B-PHEN
that	O	O
originated	O	O
from	O	O
NCs	B-OBJC
.	O	O

Thus	O	O
,	O	O
by	O	O
monitoring	B-PROC
the	O	O
attenuation	O
in	O	O
the	O	O
photocurrent	B-PHEN
signal	I-PHEN
,	O	O
an	O	O
elegant	O	O
and	O	O
sensitive	O
PEC	O
DNA	B-PROC
bioanalysis	I-PROC
could	O	O
be	O	O
accomplished	O	O
.	O	O

The	O	O
developed	O
biosensor	B-DEVI
displayed	O
a	O	O
linear	O
range	O
from	O	O
1	O	O
.	O	O

0pM	O	O
to	O	O
10nM	O	O
and	O	O
the	O	O
detection	B-PROC
limit	O
was	O	O
experimentally	O
found	B-DISO
to	O	O
be	O	O
of	O	O
0	O	O
.	O	O

3pM	O	O
.	O	O

This	O	O
work	O
presents	O	O
a	O	O
feasible	O	O
signaling	O	O
principle	O
that	O	O
could	O	O
act	O	O
as	O	O
a	O	O
common	O	O
basis	O	O
for	O	O
general	O	O
PEC	O
bioanalysis	O
development	O
.	O	O

Does	O	O
obtaining	O
an	O	O
initial	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
decrease	O
the	O	O
reamputation	B-PROC
rates	O
in	O	O
the	O	O
diabetic	B-DISO
foot	I-DISO
?	O	O

Diabetes	B-DISO
mellitus	I-DISO
(	O	O
DM	B-DISO
)	O	O
through	O	O
its	O	O
over	O	O
glycosylation	B-PHEN
of	O	O
neurovascular	B-ANAT
structures	I-ANAT
and	O	O
resultant	O	O
peripheral	B-DISO
neuropathy	I-DISO
continues	O	O
to	O	O
be	O	O
the	O	O
major	O
risk	B-DISO
factor	I-DISO
for	O	O
pedal	B-PROC
amputation	I-PROC
.	O	O

Repetitive	B-DISO
trauma	B-DISO
to	O	O
the	O	O
insensate	B-DISO
foot	B-ANAT
results	O
in	O
diabetic	B-DISO
foot	I-DISO
ulcers	I-DISO
,	O	O
which	O	O
are	O	O
at	O	O
high	B-DISO
risk	I-DISO
to	O	O
develop	O	O
osteomyelitis	B-DISO
.	O	O

Many	O	O
patients	B-LIVB
who	O	O
present	O	O
with	O	O
diabetic	B-DISO
foot	I-DISO
complications	B-DISO
will	O	O
undergo	O	O
one	O	O
or	O	O
more	O	O
pedal	B-PROC
amputations	I-PROC
during	O
the	O	O
course	O
of	O	O
their	O	O
disease	B-DISO
.	O	O

The	O	O
purpose	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
if	O	O
obtaining	O
an	O	O
initial	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
MRI	B-PROC
)	O	O
,	O	O
prior	O
to	O	O
the	O	O
first	O	O
amputation	B-PROC
,	O	O
is	O	O
associated	O
with	O
a	O	O
decreased	O
rate	O
of	O	O
reamputation	B-PROC
in	O	O
the	O	O
diabetic	B-DISO
foot	I-DISO
.	O	O

Our	O	O
hypothesis	O
was	O	O
that	O	O
the	O	O
rate	O
of	O	O
reamputation	B-PROC
may	O	O
be	O	O
associated	O
with	O
underutilization	O	O
of	O	O
obtaining	O
an	O	O
initial	O
MRI	B-PROC
,	O	O
useful	O	O
in	O	O
presurgical	B-PROC
planning	O
.	O	O

This	O	O
study	B-PROC
was	O	O
designed	O
to	O	O
determine	O	O
whether	O	O
there	O	O
was	O	O
an	O	O
association	O
between	O	O
the	O	O
reamputation	B-PROC
rate	O
in	O	O
diabetic	B-DISO
patients	B-LIVB
and	O	O
utilization	O
of	O	O
MRI	B-PROC
in	O	O
the	O	O
presurgical	B-PROC
planning	O
and	O	O
prior	O
to	O	O
initial	O
forefoot	B-PROC
amputations	I-PROC
.	O	O

Following	O
approval	O
by	O	O
our	O	O
institutional	B-LIVB
review	I-LIVB
board	I-LIVB
,	O	O
our	O	O
study	B-PROC
design	I-PROC
consisted	O	O
of	O	O
a	O	O
retrospective	B-PROC
cohort	I-PROC
analysis	I-PROC
of	O	O
413	O	O
patients	B-LIVB
at	O	O
Staten	B-OBJC
Island	I-OBJC
University	I-OBJC
Hospital	I-OBJC
,	O	O
a	O	O
700	B-OBJC
-	I-OBJC
bed	I-OBJC
tertiary	I-OBJC
referral	I-OBJC
center	I-OBJC
between	O	O
2008	O	O
and	O	O
2013	O	O
who	O	O
underwent	O	O
an	O	O
initial	O
great	B-PROC
toe	I-PROC
(	I-PROC
hallux	I-PROC
)	I-PROC
amputation	I-PROC
.	O	O

Of	O	O
the	O	O
413	O	O
patients	B-LIVB
with	O	O
a	O	O
hallux	B-PROC
amputation	I-PROC
,	O	O
there	O	O
were	O	O
368	O	O
eligible	O
patients	B-LIVB
who	O	O
had	O	O
a	O	O
history	B-DISO
of	O	O
DM	B-DISO
with	O	O
documented	O	O
hemoglobin	B-CHEM
A1c	I-CHEM
(	O	O
HbA1c	B-CHEM
)	O	O
within	O	O
3	O	O
months	O
of	O	O
the	O	O
initial	O
first	B-ANAT
ray	I-ANAT
(	O	O
hallux	B-ANAT
and	O	O
first	B-ANAT
metatarsal	I-ANAT
)	O	O
amputation	B-PROC
and	O	O
available	O	O
radiographic	B-PHEN
data	O
.	O	O

Statistical	B-PROC
analysis	I-PROC
compared	O
the	O	O
incidence	O
rates	O
of	O	O
reamputation	B-PROC
between	O	O
patients	B-LIVB
who	O	O
underwent	O	O
initial	O
MRI	B-PROC
and	O	O
those	O	O
who	O	O
did	O	O
not	O	O
obtain	O	O
an	O	O
initial	O
MRI	B-PROC
prior	O
to	O	O
their	O	O
first	O
amputation	B-PROC
.	O	O

The	O	O
reamputation	B-PROC
rate	O
was	O	O
compared	O
after	O	O
adjustment	O
for	O	O
age	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
ethnicity	O
,	O	O
HbA1c	B-CHEM
,	O	O
cardiovascular	B-DISO
disease	I-DISO
,	O	O
hypoalbuminemia	B-DISO
,	O	O
smoking	O
,	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O	O
and	O	O
prior	O
antibiotic	B-PROC
treatment	I-PROC
.	O	O

The	O	O
results	B-DISO
of	O	O
our	O	O
statistical	B-PROC
analysis	I-PROC
failed	O
to	O	O
reveal	O
a	O	O
significant	O
association	O
between	O	O
obtaining	O
an	O	O
initial	O
MRI	B-PROC
and	O	O
the	O	O
reamputation	B-PROC
rate	O
.	O	O

We	O	O
did	O	O
,	O	O
however	O	O
,	O	O
find	O	O
a	O	O
statistical	O
association	O
between	O	O
obtaining	O
an	O	O
early	O
MRI	B-PROC
and	O	O
decreased	O
mortality	O
rates	O
.	O	O

Obtaining	O
an	O	O
early	O
MRI	B-PROC
was	O	O
not	O
associated	O
with	O
the	O	O
reamputation	B-PROC
rate	O
incidence	O
in	O	O
the	O	O
treatment	B-PROC
of	O	O
the	O	O
diabetic	B-DISO
foot	I-DISO
.	O	O

It	O	O
did	O	O
,	O	O
however	O	O
,	O	O
have	O	O
a	O	O
statistically	O
significant	O
association	O
with	O	O
the	O	O
mortality	O
rate	O
as	O	O
demonstrated	O	O
by	O	O
the	O	O
increased	O
survival	O
rate	O
in	O	O
patients	B-LIVB
undergoing	O	O
MRI	B-PROC
prior	O
to	O	O
initial	O
amputation	B-PROC
.	O	O

Diffuse	B-DISO
traumatic	I-DISO
brain	I-DISO
injury	I-DISO
affects	O	O
chronic	O
corticosterone	B-CHEM
function	O
in	O	O
the	O	O
rat	B-LIVB
As	O	O
many	O	O
as	O	O
20	O	O
-	O	O
55	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
a	O	O
history	B-DISO
of	O	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O	O
TBI	B-DISO
)	O	O
experience	O	O
chronic	O
endocrine	B-DISO
dysfunction	I-DISO
,	O	O
leading	O	O
to	O	O
impaired	O
quality	O
of	O
life	O
,	O	O
impaired	O
rehabilitation	O
efforts	O
and	O	O
lowered	B-DISO
life	I-DISO
expectancy	I-DISO
.	O	O

Endocrine	B-DISO
dysfunction	I-DISO
after	O	O
TBI	B-DISO
is	O	O
thought	O	O
to	O	O
result	O
from	O	O
acceleration	B-PHEN
-	O	O
deceleration	B-PHEN
forces	B-PHEN
to	O	O
the	O	O
brain	B-ANAT
within	O	O
the	O	O
skull	B-ANAT
,	O	O
creating	O	O
enduring	O	O
hypothalamic	B-ANAT
and	O	O
pituitary	B-ANAT
neuropathology	B-DISO
,	O	O
and	O	O
subsequent	O	O
hypothalamic	B-ANAT
-pituitary	I-ANAT
endocrine	I-ANAT
(	O	O
HPE	B-ANAT
)	O	O
dysfunction	B-DISO
.	O	O

These	O	O
experiments	B-PROC
were	O	O
designed	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O
that	O	O
a	O	O
single	O	O
diffuse	B-DISO
TBI	I-DISO
results	O
in	O	O
chronic	O
dysfunction	B-DISO
of	O	O
corticosterone	B-CHEM
(	O	O
CORT	B-CHEM
)	O	O
,	O	O
a	O	O
glucocorticoid	B-CHEM
released	O
in	O	O
response	O	O
to	O	O
stress	B-DISO
and	O	O
testosterone	B-CHEM
.	O	O

We	O	O
used	O	O
a	O	O
rodent	B-DISO
model	I-DISO
of	O	O
diffuse	B-DISO
TBI	I-DISO
induced	O	O
by	O	O
midline	B-DISO
fluid	I-DISO
percussion	I-DISO
injury	I-DISO
(	O	O
mFPI	B-DISO
)	O	O
.	O	O

At	O	O
2	O	O
months	O
postinjury	O
compared	O
with	O	O
uninjured	B-LIVB
control	I-LIVB
animals	I-LIVB
,	O	O
circulating	O
levels	O
of	O	O
CORT	B-CHEM
were	O	O
evaluated	O	O
at	O
rest	O
,	O	O
under	O	O
restraint	B-DISO
stress	I-DISO
and	O	O
in	O	O
response	O	O
to	O	O
dexamethasone	B-CHEM
,	O	O
a	O	O
synthetic	B-CHEM
glucocorticoid	I-CHEM
commonly	O	O
used	O	O
to	O	O
test	O	O
HPE	B-ANAT
axis	O
regulation	B-PHEN
.	O	O

Testosterone	B-CHEM
was	O	O
evaluated	O
at	O
rest	O
.	O	O

Further	O	O
,	O	O
we	O	O
assessed	O	O
changes	O
in	O	O
injury	B-DISO
-	O	O
induced	O
neuron	B-ANAT
morphology	O
(	O	O
Golgi	B-PROC
stain	I-PROC
)	O	O
,	O	O
neuropathology	B-DISO
(	O	O
silver	B-PROC
stain	I-PROC
)	O	O
and	O	O
activated	B-PHYS
astrocytes	B-ANAT
(	O	O
GFAP	B-PROC
)	O	O
in	O	O
the	O	O
paraventricular	B-ANAT
nucleus	I-ANAT
(	O	O
PVN	B-ANAT
)	O	O
of	O	O
the	O	O
hypothalamus	B-ANAT
.	O	O

Resting	O	O
plasma	B-ANAT
CORT	B-CHEM
levels	O
were	O	O
decreased	O
at	O	O
2	O	O
months	O
postinjury	O
and	O	O
there	O	O
was	O	O
a	O	O
blunted	O	O
CORT	B-CHEM
increase	O
in	O	O
response	O	O
to	O	O
restraint	B-DISO
induced	I-DISO
stress	I-DISO
.	O	O

No	B-DISO
changes	I-DISO
in	O	O
testosterone	B-CHEM
were	O	O
measured	O
.	O	O

These	O	O
changes	O
in	O	O
CORT	B-CHEM
were	O	O
observed	O	O
concomitantly	O
with	O	O
altered	O
complexity	O
of	O	O
neuron	B-ANAT
processes	B-PHYS
in	O	O
the	O	O
PVN	B-ANAT
over	O	O
time	O
,	O	O
devoid	O	O
of	O	O
neuropathology	B-DISO
or	O	O
astrocytosis	B-DISO
.	O	O

Results	O
provide	O	O
evidence	O	O
that	O	O
a	O	O
single	O	O
moderate	O	O
diffuse	B-DISO
TBI	I-DISO
leads	O	O
to	O	O
changes	O
in	O	O
CORT	B-CHEM
function	O
,	O	O
which	O	O
can	O	O
contribute	O	O
to	O	O
the	O	O
persistence	B-DISO
of	I-DISO
symptoms	I-DISO
related	O	O
to	O	O
endocrine	B-DISO
dysfunction	I-DISO
.	O	O

Future	O	O
experiments	B-PROC
aim	O	O
to	O	O
evaluate	O
additional	O	O
HP	B-CHEM
-	I-CHEM
related	I-CHEM
hormones	I-CHEM
and	O	O
endocrine	B-ANAT
circuit	O
pathology	O
following	O	O
diffuse	B-DISO
TBI	I-DISO
.	O	O

Systematic	O
and	O	O
detailed	B-PROC
analysis	I-PROC
of	O	O
behavioural	B-PROC
tests	I-PROC
in	O	O
the	O	O
rat	B-LIVB
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
model	B-LIVB
of	O	O
stroke	B-DISO
:	O	O
Tests	O
for	O	O
long	O
-	O
term	O
assessment	O
In	O	O
order	O	O
to	O	O
test	O	O
therapeutics	B-PROC
,	O	O
functional	B-PROC
assessments	I-PROC
are	O	O
required	O	O
.	O	O

In	O	O
pre	O
-	O
clinical	O
stroke	B-DISO
research	B-PROC
,	O	O
there	O	O
is	O	O
little	O	O
consensus	O	O
regarding	O	O
the	O	O
most	O	O
appropriate	O	O
behavioural	B-PROC
tasks	I-PROC
to	O	O
assess	O	O
deficits	O
,	O	O
especially	O	O
when	O	O
testing	O	O
over	O	O
extended	O	O
times	O	O
in	O	O
milder	O	O
models	B-LIVB
with	O	O
short	O
occlusion	O
times	O
and	O	O
small	O
lesion	O
volumes	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
comprehensively	O	O
assessed	O
16	O	O
different	O	O
behavioural	B-PROC
tests	I-PROC
,	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
identifying	O	O
those	O	O
that	O	O
show	O	O
robust	O
,	O	O
reliable	O
and	O	O
stable	O
deficits	O
for	O	O
up	O	O
to	O	O
two	O	O
months	O
.	O	O

These	O	O
tasks	O	O
are	O	O
regularly	O	O
used	O	O
in	O	O
stroke	B-DISO
research	B-PROC
,	O	O
as	O	O
well	O	O
as	O	O
being	O	O
useful	O	O
for	O	O
examining	O	O
striatal	B-DISO
dysfunction	I-DISO
in	O	O
models	B-LIVB
of	O	O
Huntington	B-DISO
's	I-DISO
and	O	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
.	O	O

Two	O	O
cohorts	B-LIVB
of	O	O
male	B-PHYS
Wistar	B-LIVB
rats	I-LIVB
underwent	O	O
the	O	O
intraluminal	O
filament	O
model	O
of	O	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
(	O	O
30	O	O
min	O
)	O	O
and	O	O
were	O	O
imaged	B-PROC
24	O	O
h	O
later	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
primarily	O	O
subcortical	B-DISO
infarcts	I-DISO
,	O	O
with	O	O
a	O	O
small	O	O
amount	O	O
of	O	O
cortical	B-DISO
damage	I-DISO
.	O	O

Animals	B-LIVB
were	O	O
tested	O	O
,	O	O
along	O	O
with	O	O
sham	B-LIVB
and	I-LIVB
naïve	I-LIVB
groups	I-LIVB
at	O	O
24	O	O
h	O
,	O	O
seven	O	O
days	O
,	O	O
and	O	O
one	O	O
and	O	O
two	O	O
months	O
.	O	O

Following	O	O
behavioural	B-PROC
testing	I-PROC
,	O	O
brains	B-ANAT
were	O	O
processed	O	O
and	O	O
striatal	O
neuronal	O
counts	O
were	O	O
performed	O	O
alongside	O	O
measurements	O	O
of	O	O
total	O	O
brain	B-ANAT
and	O	O
white	B-DISO
matter	I-DISO
atrophy	I-DISO
.	O	O

The	O	O
staircase	B-PROC
,	O	O
adjusting	B-PROC
steps	I-PROC
,	O	O
rotarod	B-PROC
and	O	O
apomorphine	B-PROC
-induced	I-PROC
rotations	I-PROC
were	O	O
the	O	O
most	O	O
reliable	O	O
for	O	O
assessing	O	O
long	O	O
-	O	O
term	O	O
deficits	O
in	O	O
the	O	O
30	O	O
min	O
transient	O	O
middle	B-DISO
cerebral	I-DISO
artery	I-DISO
occlusion	I-DISO
model	B-LIVB
of	O	O
stroke	B-DISO
.	O	O

The	O	O
next	O	O
frontier	O	O
of	O	O
office	B-OBJC
-based	O	O
inferior	O
vena	O
cava	O
filter	O
placement	O
There	O	O
is	O	O
an	O	O
increasing	O	O
number	O	O
of	O	O
procedures	B-PROC
that	O	O
traditionally	O	O
were	O	O
performed	O	O
in	O	O
the	O	O
inpatient	B-LIVB
setting	O	O
that	O	O
are	O	O
now	O	O
becoming	O	O
office	B-OBJC
-based	O	O
procedures	B-PROC
.	O	O

These	O	O
include	O	O
peripheral	O
endovascular	B-PROC
procedures	I-PROC
such	O	O
as	O	O
angiograms	B-PROC
,	O	O
angioplasties	B-PROC
,	O	O
dialysis	O
access	O
interventions	B-PROC
,	O	O
and	O	O
treatment	B-PROC
for	O	O
venous	B-DISO
insufficiency	I-DISO
.	O	O

We	O	O
chose	O	O
to	O	O
evaluate	O	O
the	O	O
feasibility	B-PROC
,	O	O
safety	B-PHEN
of	O	O
inferior	O
vena	O
cava	O
(	O
IVC	O
)	O
filter	O
placement	O
in	O	O
the	O	O
office	B-OBJC
-	I-OBJC
based	I-OBJC
setting	I-OBJC
.	O	O

All	O	O
procedures	B-PROC
were	O	O
performed	O	O
using	O	O
local	B-PROC
anesthesia	I-PROC
,	O	O
and	O	O
ultrasound	B-PROC
guidance	I-PROC
for	O	O
puncture	B-PROC
.	O	O

All	O	O
venograms	B-PROC
were	O	O
performed	O	O
with	O	O
manual	B-PROC
injection	I-PROC
of	O	O
iodinated	B-CHEM
contrast	I-CHEM
.	O	O

An	O	O
IVC	B-DEVI
filter	I-DEVI
was	O	O
placed	O	O
in	O	O
the	O	O
cases	O
(	O	O
except	O	O
one	O	O
failure	O
of	O	O
placement	B-PROC
)	O	O
using	O	O
fluoroscopy	B-PROC
in	O	O
the	O	O
infrarenal	B-ANAT
position	I-ANAT
.	O	O

Patients	B-LIVB
were	O	O
observed	O	O
in	O	O
a	O	O
recovery	B-PHYS
area	O
and	O	O
then	O	O
discharged	B-PROC
.	O	O

Follow	O
-	O
up	O
data	O
were	O	O
obtained	O	O
through	O	O
an	O	O
interview	O
,	O	O
physical	B-PROC
examination	I-PROC
,	O	O
and	O	O
24	B-PROC
-	I-PROC
hour	I-PROC
postoperative	I-PROC
phone	I-PROC
call	I-PROC
.	O	O

Over	O	O
the	O	O
course	O	O
of	O	O
27	O	O
months	O
,	O	O
29	O	O
Greenfield	B-DEVI
filters	I-DEVI
(	O	O
Boston	O	O
Scientific	O	O
,	O	O
Marlborough	O	O
,	O	O
Mass	O	O
)	O	O
and	O	O
three	O	O
Celect	B-DEVI
temporary	I-DEVI
filters	I-DEVI
(	O	O
Cook	O	O
,	O	O
Bloomington	O	O
,	O	O
Ind	O	O
)	O	O
were	O	O
placed	O	O
in	O	O
the	O	O
infrarenal	B-ANAT
IVC	B-ANAT
for	O	O
18	O	O
women	B-LIVB
and	O	O
14	O	O
men	B-LIVB
,	O	O
with	O	O
an	O	O
average	O	O
age	B-PHYS
of	O	O
75	O	O
.	O	O

3	O	O
±	O	O
15	O	O
.	O	O
6	O	O
years	O
(	O	O
range	O	O
,	O	O
38	O	O
-	O	O
97	O	O
years	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
four	O	O
acute	O
,	O	O
6	O	O
recent	O	O
(	O	O
<	O	O
6	O	O
months	O	O
ago	O	O
)	O	O
and	O	O
three	O	O
subacute	B-ANAT
lower	I-ANAT
extremity	I-ANAT
deep	B-DISO
vein	I-DISO
thromboses	I-DISO
(	O	O
DVTs	B-DISO
)	O	O
were	O	O
identified	O	O
.	O	O

The	O	O
indications	O
for	O	O
the	O	O
procedure	B-PROC
were	O	O
patients	B-LIVB
with	O	O
:	O	O
DVT	B-DISO
who	O	O
were	O	O
to	O	O
undergo	O	O
surgery	B-PROC
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
acute	O
large	O	O
free	O	O
-	O	O
floating	O	O
iliofemoral	B-DISO
DVT	I-DISO
(	O	O
deemed	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
for	O	O
long	O
-	O
term	O
anticoagulation	B-PHYS
)	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
new	O	O
DVT	B-DISO
during	O	O
anticoagulation	B-PROC
therapy	I-PROC
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
DVT	B-DISO
with	O	O
gastrointestinal	B-DISO
bleeding	I-DISO
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
,	O	O
DVT	B-DISO
with	O	O
hematuria	B-DISO
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
recent	O	O
DVT	B-DISO
(	O	O
which	O	O
extended	O	O
during	O	O
full	O	O
dose	O	O
anticoagulation	B-PROC
treatment	I-PROC
)	O	O
while	O	O
undergoing	O	O
a	O	O
long	O	O
flight	O	O
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
(	O	O
temporary	O
filter	B-DEVI
placement	B-PROC
)	O	O
,	O	O
DVT	B-DISO
with	O	O
arm	B-ANAT
hematoma	B-DISO
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
DVT	B-DISO
with	O	O
unsteady	B-DISO
gait	I-DISO
and	O	O
history	B-DISO
of	I-DISO
falls	I-DISO
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
,	O	O
DVT	B-DISO
with	O	O
nose	B-DISO
bleeding	I-DISO
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
DVT	B-DISO
with	O	O
dementia	B-DISO
and	O	O
inability	B-DISO
to	O	O
receive	O	O
anticoagulation	B-PROC
treatment	I-PROC
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
DVT	B-DISO
and	O	O
receiving	O	O
chemotherapy	B-PROC
and	O	O
with	O	O
thrombocytopenia	B-DISO
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
,	O	O
and	O	O
DVT	B-DISO
and	O	O
refusal	O
to	O	O
take	O	O
anticoagulation	B-PROC
medication	I-PROC
(	O	O
n	O	O
=	O	O
1	O	O
)	O	O
.	O	O

One	O	O
patient	B-LIVB
had	O	O
a	O	O
failure	O
to	O	O
place	O	O
a	O	O
filter	B-DEVI
because	O	O
of	O	O
chronic	O
IVC	B-ANAT
occlusion	B-DISO
found	O	O
on	O	O
venogram	B-PROC
.	O	O

One	O	O
patient	B-LIVB
with	O	O
history	B-DISO
of	O	O
gastrointestinal	B-DISO
bleeding	I-DISO
,	O	O
acute	O	O
DVT	B-DISO
,	O	O
and	O	O
atrial	B-DISO
fibrillation	I-DISO
suffered	O	O
IVC	B-DEVI
filter	I-DEVI
thrombosis	B-DISO
1	O	O
month	O	O
after	O	O
the	O	O
procedure	B-PROC
.	O	O

We	O	O
attempted	O	O
removal	B-PROC
of	O	O
the	O	O
temporary	O
filters	B-DEVI
in	O	O
the	O	O
hospital	B-OBJC
in	O	O
two	O	O
patients	B-LIVB
but	O	O
failed	O	O
to	O	O
retrieve	O	O
the	O	O
filter	B-DEVI
in	O	O
these	O	O
two	O	O
cases	O
.	O	O

We	O	O
noted	O	O
no	O	O
insertion	O	O
site	O	O
DVT	B-DISO
,	O	O
extension	O
of	O	O
DVT	B-DISO
,	O	O
or	O	O
pulmonary	B-DISO
embolism	I-DISO
.	O	O

Our	O	O
preliminary	O
experience	B-PHYS
suggests	O	O
that	O	O
placement	B-PROC
of	O	O
IVC	B-DEVI
filters	I-DEVI
for	O	O
treatment	B-PROC
of	O	O
venous	B-DISO
thrombotic	I-DISO
events	I-DISO
in	O	O
an	O	O
office	B-OBJC
-	I-OBJC
based	I-OBJC
facility	I-OBJC
is	O	O
safe	O	O
and	O	O
efficacious	O
with	O	O
basic	O	O
endovascular	B-DEVI
equipment	I-DEVI
.	O	O

Long	O
-	O
term	O
outcome	O
cannot	O	O
be	O	O
determined	O	O
at	O	O
this	O	O
point	O	O
.	O	O

Insensitivity	B-DISO
of	O	O
astrocytes	B-ANAT
to	O	O
interleukin	B-CHEM
10	I-CHEM
signaling	B-PHEN
following	O	O
peripheral	O
immune	B-ANAT
challenge	O	O
results	O	O
in	O	O
prolonged	O
microglial	B-PHYS
activation	I-PHYS
in	O	O
the	O	O
aged	B-PHYS
brain	B-ANAT
Immune	B-PHYS
-	I-PHYS
activated	I-PHYS
microglia	B-ANAT
from	O	O
aged	B-PHYS
mice	B-LIVB
produce	O	O
exaggerated	O
levels	O
of	O	O
cytokines	B-CHEM
.	O	O

Despite	O	O
high	O
levels	O
of	O	O
microglia	B-ANAT
l	O	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
10	I-CHEM
in	O	O
the	O	O
aged	B-PHYS
brain	B-ANAT
,	O	O
neuroinflammation	B-DISO
was	O	O
prolonged	O
and	O	O
associated	O
with	O
depressive	B-DISO
-	I-DISO
like	I-DISO
deficits	I-DISO
.	O	O

Because	O	O
astrocytes	B-ANAT
respond	O	O
to	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
attenuate	O
microglial	B-PHYS
activation	I-PHYS
,	O	O
we	O	O
investigated	O	O
if	O	O
astrocyte	B-PHYS
-	I-PHYS
mediated	I-PHYS
resolution	I-PHYS
of	I-PHYS
microglial	I-PHYS
activation	I-PHYS
was	O	O
impaired	O
with	O	O
age	B-PHYS
.	O	O

Here	O	O
,	O	O
aged	B-PHYS
astrocytes	B-ANAT
had	O	O
a	O	O
dysfunctional	B-DISO
profile	I-DISO
with	O	O
higher	O
glial	B-CHEM
fibrillary	I-CHEM
acidic	I-CHEM
protein	I-CHEM
,	O	O
lower	O
glutamate	B-CHEM
transporter	I-CHEM
expression	B-PHYS
,	O	O
and	O	O
significant	O
cytoskeletal	O	O
re	O	O
-	O	O
arrangement	O	O
.	O	O

Moreover	O	O
,	O	O
aged	B-PHYS
astrocytes	B-ANAT
had	O	O
reduced	O
expression	B-PHYS
of	O	O
growth	B-CHEM
factors	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
receptor	I-CHEM
-	I-CHEM
1	I-CHEM
(	B-CHEM
IL	I-CHEM
-	I-CHEM
10R1	I-CHEM
)	O	O
.	O	O

After	O	O
in	O
vivo	O
lipopolysaccharide	B-CHEM
immune	B-ANAT
challenge	O	O
,	O	O
aged	B-PHYS
astrocytes	B-ANAT
had	O	O
a	O	O
molecular	O
signature	O
associated	O
with	O
reduced	B-DISO
responsiveness	I-DISO
to	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
.	O	O

This	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
insensitivity	B-DISO
of	O	O
aged	B-PHYS
astrocytes	B-ANAT
resulted	O	O
in	O	O
a	O	O
failure	O
to	O	O
induce	O
IL	B-CHEM
-	I-CHEM
10R1	I-CHEM
and	O	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
β	I-CHEM
and	O	O
resolve	O	O
microglial	B-PHYS
activation	I-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
adult	B-LIVB
astrocytes	B-ANAT
reduced	O	O
microglial	B-PHYS
activation	I-PHYS
when	O	O
co	B-PROC
-	I-PROC
cultured	I-PROC
ex	O
vivo	O
,	O	O
whereas	O	O
aged	B-PHYS
astrocytes	B-ANAT
did	O	O
not	O	O
.	O	O

Consistent	O	O
with	O	O
the	O	O
aging	O	O
studies	O	O
,	O	O
IL	O
-	O
10R	O
(	O
KO	O
)	O
astrocytes	B-ANAT
did	O	O
not	O	O
augment	O	O
transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
β	I-CHEM
after	O	O
immune	B-ANAT
challenge	O	O
and	O	O
failed	O	O
to	O	O
resolve	O	O
microglial	B-PHYS
activation	I-PHYS
.	O	O

Collectively	O	O
,	O	O
a	O	O
major	O	O
cytokine	B-CHEM
-	O	O
regulatory	O
loop	O
between	O	O
activated	O
microglia	B-ANAT
and	O	O
astrocytes	B-ANAT
is	O	O
impaired	O
in	O	O
the	O	O
aged	B-PHYS
brain	B-ANAT
.	O	O

Identification	O
of	O	O
a	O	O
group	O
of	O	O
XTHs	B-CHEM
genes	O
responding	O	O
to	O	O
heavy	B-CHEM
metal	I-CHEM
mercury	B-CHEM
,	O	O
salinity	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
in	O	O
Medicago	B-LIVB
truncatula	I-LIVB
Xyloglucan	B-CHEM
endotransglucosylase	I-CHEM
/	I-CHEM
hydrolases	I-CHEM
(	O	O
XTH	B-CHEM
)	O	O
are	O	O
one	O	O
of	O	O
the	O	O
key	O	O
enzymes	B-CHEM
regulating	B-PHEN
cell	B-PHYS
wall	I-PHYS
construction	I-PHYS
,	O	O
extension	O
and	O	O
metabolism	B-ANAT
.	O	O

In	O	O
the	O	O
study	B-PROC
,	O	O
44	O	O
XTH	B-CHEM
protein	I-CHEM
genes	O
from	O	O
Medicago	B-LIVB
truncatula	I-LIVB
genome	O
were	O	O
identified	O	O
using	O	O
bioinformatics	O
,	O	O
microarray	B-OBJC
and	O	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
.	O	O

Each	O	O
XTH	B-CHEM
was	O	O
showed	O	O
to	O	O
possess	O	O
a	O	O
highly	O
conserved	O
domain	O
(	O	O
(	O	O
D	O	O
/	O	O
N	O	O
)	O	O
-	O	O
E	O	O
-	O	O
(	O	O
I	O	O
/	O	O
L	O	O
/	O	O
F	O	O
/	O	O
V	O	O
)	O	O
-	O	O
D	O	O
-	O	O
(	O	O
F	O	O
/	O	O
I	O	O
/	O	O
L	O	O
)	O	O
-	O	O
E	O	O
-	O	O
(	O	O
F	O	O
/	O	O
L	O	O
)	O	O
-	O	O
L	O	O
-	O	O
G	O	O
)	O	O
,	O	O
and	O	O
most	O	O
of	O	O
XTHs	B-CHEM
possess	O	O
four	O	O
Cys	B-CHEM
in	O	O
the	O	O
C	O
terminal	O
region	O
,	O	O
which	O	O
suggests	O	O
the	O	O
potential	O
for	O	O
generating	O	O
disulfide	O
bonds	O
.	O	O

Based	O	O
on	O	O
the	O	O
XTH	B-CHEM
protein	O
sequences	O
,	O	O
these	O	O
XTHs	B-CHEM
can	O	O
be	O	O
classified	O	O
into	O	O
three	O	O
major	O	O
families	B-CHEM
and	O	O
each	O	O
family	B-CHEM
can	O	O
be	O	O
subdivided	O	O
into	O	O
more	O	O
groups	O
.	O	O

Examination	O	O
of	O	O
the	O	O
genomic	O
location	O
of	O	O
XTH	O
genes	O
on	O	O
M	B-LIVB
.	I-LIVB

truncatula	I-LIVB
chromosomes	B-ANAT
showed	O	O
that	O	O
the	O	O
evolutional	B-PHEN
expansion	I-PHEN
of	O	O
the	O	O
genes	O
was	O	O
possibly	O	O
attributed	O	O
to	O	O
localized	O
gene	B-PHYS
duplications	I-PHYS
.	O	O

To	O	O
investigate	O	O
the	O	O
possible	O	O
involvement	O
of	O	O
the	O	O
XTHs	B-CHEM
responding	O	O
to	O	O
heavy	B-CHEM
metals	I-CHEM
and	O	O
other	O	O
abiotic	B-PHEN
stresses	I-PHEN
,	O	O
the	O	O
XTH	O
genes	O
were	O	O
exposed	O	O
to	O	O
heavy	B-CHEM
metal	I-CHEM
(	O	O
Hg	B-CHEM
or	O	O
Cu	B-CHEM
)	O	O
,	O	O
salt	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
.	O	O

There	O	O
were	O	O
28	O	O
,	O	O
21	O	O
and	O	O
21	O	O
MtXTH	O
genes	O
found	O	O
to	O	O
respond	O	O
to	O	O
HgCl2	B-CHEM
,	O	O
salt	B-PHEN
and	I-PHEN
drought	I-PHEN
stresses	I-PHEN
,	O	O
respectively	O	O
,	O	O
but	O	O
their	O	O
expression	B-PHYS
were	O	O
different	O	O
under	O	O
the	O	O
stresses	B-PHEN
.	O	O

Some	O	O
of	O	O
the	O	O
XTH	O
genes	O
were	O	O
well	O	O
confirmed	O	O
by	O	O
quantitative	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
(	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
)	O	O
.	O	O

We	O	O
further	O	O
specified	O
expression	B-PHYS
of	O	O
a	O	O
XTH	O
gene	O
Medtr4g128580	O
(	O	O
MtXTH3	O
)	O	O
under	O	O
different	O	O
environmental	B-PHEN
stresses	I-PHEN
,	O	O
and	O	O
showed	O	O
that	O	O
MtXTH3	O
was	O	O
induced	O	O
by	O	O
Hg	B-CHEM
exposure	O
.	O	O

These	O	O
results	O
indicated	O	O
that	O	O
a	O	O
group	O
of	O	O
MtXTHs	O
could	O	O
be	O	O
differentially	O	O
expressed	B-PHYS
under	O	O
the	O	O
environmental	B-PHEN
stresses	I-PHEN
.	O	O

Vestibular	B-DISO
disorders	I-DISO
and	O	O
nausea	B-DISO
during	O	O
head	B-DISO
and	O	O
neck	B-DISO
intensity	B-PROC
-	I-PROC
modulated	I-PROC
radiation	I-PROC
therapy	I-PROC
We	O	O
studied	O	O
whether	O	O
there	O	O
is	O	O
a	O	O
relationship	O
between	O	O
nausea	B-DISO
and	O	O
vestibular	B-DISO
disorders	I-DISO
in	O	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
intensity	B-PROC
modulated	I-PROC
radiation	I-PROC
therapy	I-PROC
(	O	O
IMRT	B-PROC
)	O	O
for	O	O
head	B-DISO
and	O	O
neck	B-DISO
cancer	I-DISO
.	O	O

We	O	O
performed	O	O
a	O	O
prospective	B-PROC
single	I-PROC
-	I-PROC
centre	I-PROC
study	I-PROC
that	O	O
enrolled	B-PROC
31	O	O
patients	B-LIVB
.	O	O

A	O	O
videonystagmography	B-PROC
was	O	O
carried	O	O
out	O	O
before	O	O
and	O	O
within	O	O
15	O	O
days	O	O
after	O	O
radiation	B-PROC
therapy	I-PROC
for	O	O
each	O	O
patient	B-LIVB
.	O	O

Nausea	B-DISO
was	O	O
assessed	O	O
at	O	O
baseline	O
,	O	O
every	O	O
week	O	O
,	O	O
and	O	O
at	O	O
the	O	O
post	B-PROC
-	I-PROC
radiotherapy	I-PROC
videonystagmography	B-PROC
visit	O	O
.	O	O

Twenty	O	O
-	O	O
six	O	O
patients	B-LIVB
had	O	O
benefited	O	O
from	O	O
a	O	O
complete	O	O
interpretable	O	O
videonystagmography	B-PROC
.	O	O

For	O	O
14	O	O
of	O	O
these	O	O
patients	B-LIVB
vestibular	B-DISO
damage	I-DISO
was	O	O
diagnosed	B-DISO
post	B-PROC
-	I-PROC
radiotherapy	I-PROC
.	O	O

During	O	O
irradiation	B-PHEN
,	O	O
six	O	O
patients	B-LIVB
felt	O	O
nauseous	B-DISO
,	O	O
but	O	O
without	O	O
dizziness	B-DISO
.	O	O

In	O	O
univariate	B-PROC
analysis	I-PROC
,	O	O
we	O	O
found	O	O
a	O	O
relationship	O
statistically	O
significant	O
between	O	O
the	O	O
average	O	O
dose	O
received	O	O
by	O	O
the	O	O
vestibules	B-ANAT
and	O	O
vestibular	B-DISO
disorder	I-DISO
videonystagmography	B-PROC
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

001	O	O
,	O	O
odds	O
ratio	O
[	O	O
OR	O
]	O	O
:	O	O
1	O	O
.	O	O
08	O	O
[	O	O
1	O	O
.	O	O
025	O	O
-	O	O
.	O	O
138	O	O
]	O	O
)	O	O
,	O	O
but	O	O
there	O	O
was	O	O
no	B-DISO
relationship	O
between	O	O
vestibular	B-DISO
disorder	I-DISO
videonystagmography	B-PROC
and	O	O
nausea	B-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
701	O	O
)	O	O
.	O	O

Irradiation	B-PHEN
of	O	O
the	O	O
vestibular	B-ANAT
system	I-ANAT
during	O	O
IMRT	B-PROC
does	O	O
not	O	O
seem	O	O
to	O	O
explain	O	O
the	O	O
nausea	B-DISO
.	O	O

Preventing	O	O
Youth	B-LIVB
Internalizing	B-DISO
Symptoms	I-DISO
Through	O	O
the	O	O
Familias	O
Unidas	O
Intervention	O
:	O	O
Examining	O	O
Variation	O
in	O	O
Response	B-PHYS
Prevention	O
programs	O
that	O	O
strengthen	O	O
parenting	O
and	O	O
family	O
functioning	O
have	O	O
been	O	O
found	O	O
to	O	O
reduce	B-PROC
poor	B-DISO
behavioral	I-DISO
outcomes	O	O
in	O	O
adolescents	B-LIVB
,	O	O
including	O	O
substance	B-DISO
use	I-DISO
,	O	O
HIV	B-DISO
risk	I-DISO
,	O	O
externalizing	O	O
and	O	O
internalizing	B-DISO
problems	I-DISO
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
evidence	O	O
that	O	O
not	O	O
all	O	O
youth	B-LIVB
benefit	O	O
similarly	O	O
from	O	O
these	O	O
programs	O
.	O	O

Familias	O
Unidas	O
is	O	O
a	O	O
family	O
-	O
focused	O
intervention	O
designed	O	O
to	O	O
prevent	O	O
substance	B-DISO
use	I-DISO
and	O	O
sexual	B-DISO
risk	I-DISO
among	O	O
Hispanic	B-LIVB
youth	B-LIVB
and	O	O
has	O	O
recently	O	O
demonstrated	O	O
unanticipated	O	O
reductions	B-PROC
in	O	O
internalizing	B-DISO
symptoms	I-DISO
for	O	O
some	O	O
youth	B-LIVB
.	O	O

This	O	O
paper	O	O
examines	O	O
variation	O	O
in	O	O
intervention	O
response	O	O
for	O	O
internalizing	B-DISO
symptoms	I-DISO
using	O	O
individual	O
-	O
level	O
data	O
pooled	O	O
across	O	O
four	O	O
distinct	O	O
Familias	O
Unidas	O
trials	B-PROC
:	O	O
(	O	O
1	O	O
)	O	O
266	O	O
eighth	B-DISO
grade	I-DISO
students	B-LIVB
recruited	O	O
from	O	O
the	O	O
general	O	O
school	B-LIVB
population	I-LIVB
;	O	O
(	O	O
2	O	O
)	O	O
160	O	O
ninth	B-DISO
grade	I-DISO
students	B-LIVB
from	O	O
the	O	O
general	O	O
school	B-LIVB
population	I-LIVB
;	O	O
(	O	O
3	O	O
)	O	O
213	O	O
adolescents	B-LIVB
with	O	O
conduct	B-DISO
,	O	O
aggression	O
,	O	O
and	O	O
/	O	O
or	O	O
attention	B-DISO
problems	I-DISO
;	O	O
and	O	O
(	O	O
4	O	O
)	O	O
242	O	O
adolescents	B-LIVB
with	O	O
a	O	O
delinquency	B-DISO
history	O	O
.	O	O

Causal	O
inference	O
growth	O
mixture	O
modeling	O
suggests	O	O
a	O	O
three	O	O
-	O	O
class	O
model	O
.	O	O

The	O	O
two	O	O
largest	O	O
classes	O
represent	O	O
youth	B-LIVB
with	O	O
low	O
(	O	O
60	O	O
%	O	O
)	O	O
and	O	O
medium	O
(	O	O
27	O	O
%	O	O
)	O	O
internalizing	B-DISO
symptoms	I-DISO
at	O	O
baseline	O
,	O	O
and	O	O
both	O	O
intervention	O
and	O	O
control	B-LIVB
participants	B-LIVB
show	O	O
reductions	B-PROC
in	O	O
internalizing	B-DISO
symptoms	I-DISO
.	O	O

The	O	O
third	O	O
class	O
(	O	O
13	O	O
%	O	O
)	O	O
represents	O	O
youth	B-LIVB
with	O	O
high	O
levels	O
of	O	O
baseline	O
internalizing	B-DISO
symptoms	I-DISO
who	O	O
remain	O	O
at	O	O
steady	O
levels	O
of	O	O
internalizing	B-DISO
symptoms	I-DISO
when	O	O
exposed	O
to	O
the	O	O
intervention	O
,	O	O
but	O	O
who	O	O
experience	O	O
an	O	O
increase	O	O
in	O	O
symptoms	B-DISO
under	O	O
the	O	O
control	O
condition	O
.	O	O

Female	B-PHYS
gender	I-PHYS
,	O	O
low	O
baseline	O
levels	O
of	O	O
parent	B-LIVB
-	O	O
adolescent	B-LIVB
communication	O
,	O	O
and	O	O
older	B-LIVB
age	I-LIVB
were	O	O
associated	O	O
with	O	O
membership	O	O
in	O	O
the	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
class	O
.	O	O

These	O	O
synthesis	O	O
analyses	O	O
involving	O	O
a	O	O
large	O	O
sample	O	O
of	O	O
youth	B-LIVB
with	O	O
varying	O	O
initial	O
risk	O
levels	O
represent	O	O
a	O	O
further	O	O
step	O	O
toward	O	O
strengthening	O	O
our	O	O
knowledge	O	O
of	O	O
preventive	O
intervention	O
response	B-PHYS
and	O	O
improving	O	O
preventive	O
interventions	O
.	O	O

Percutaneous	B-PROC
Bullectomy	I-PROC
in	O	O
Conjunction	O
with	O	O
Endobronchial	B-DEVI
Valve	I-DEVI
Placement	B-PROC
as	O	O
an	O	O
Alternative	O
to	O	O
Surgical	B-PROC
Management	I-PROC
of	O	O
Giant	B-DISO
Bullae	I-DISO
We	O	O
present	O	O
the	O	O
first	O	O
reported	O	O
case	O
of	O	O
the	O	O
treatment	B-PROC
and	O	O
management	B-PROC
of	O	O
a	O	O
giant	B-DISO
bulla	I-DISO
using	O	O
percutaneous	B-PROC
bullectomy	I-PROC
and	O	O
endobronchial	B-DEVI
valve	I-DEVI
placement	B-PROC
.	O	O

A	O	O
74	O	O
-	O	O
year	O
-old	O	O
woman	B-LIVB
with	O	O
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
and	O	O
a	O	O
known	O	O
large	O	O
bulla	B-DISO
in	O	O
the	O	O
left	O	O
chest	B-ANAT
presented	O	O
to	O	O
the	O	O
emergency	B-OBJC
department	I-OBJC
with	O	O
acute	B-DISO
-	I-DISO
onset	I-DISO
confusion	I-DISO
after	O	O
a	O	O
traumatic	O
fall	B-DISO
.	O	O

She	O	O
was	O	O
subsequently	O	O
diagnosed	B-DISO
with	O	O
an	O	O
intracranial	B-DISO
hemorrhage	I-DISO
in	O	O
the	O	O
distribution	O	O
of	O	O
the	O	O
right	B-ANAT
basal	I-ANAT
ganglia	I-ANAT
.	O	O

Chest	B-PROC
imaging	I-PROC
revealed	O	O
a	O	O
giant	B-DISO
apical	I-DISO
bulla	I-DISO
occupying	O	O
80	O	O
%	O	O
of	O	O
the	O	O
left	B-ANAT
hemithorax	I-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
there	O	O
was	O	O
midline	B-DISO
shift	I-DISO
away	O	O
from	O	O
the	O	O
affected	B-DISO
side	I-DISO
associated	O	O
with	O	O
volume	O
loss	O
in	O	O
the	O	O
right	B-ANAT
hemithorax	I-ANAT
and	O	O
no	O	O
radiographic	O
evidence	O
of	O	O
aeration	B-PHYS
in	O	O
the	O	O
remainder	O	O
of	O	O
the	O	O
left	B-ANAT
lung	I-ANAT
.	O	O

Arterial	B-PROC
blood	I-PROC
gas	I-PROC
analysis	I-PROC
revealed	O	O
significant	O	O
hypercapnia	B-DISO
.	O	O

Surgical	B-PROC
bullectomy	B-PROC
was	O	O
not	O	O
an	O	O
option	O	O
,	O	O
and	O	O
thus	O	O
,	O	O
a	O	O
novel	O	O
approach	O
was	O	O
utilized	O	O
to	O	O
treat	O
this	O	O
patient	B-LIVB
.	O	O

Acute	B-DISO
Kidney	I-DISO
Injury	I-DISO
Severity	O
and	O	O
Long	O
-	O
Term	O
Readmission	B-PROC
and	O	O
Mortality	O
After	O	O
Cardiac	B-PROC
Surgery	I-PROC
Acute	B-DISO
kidney	I-DISO
injury	I-DISO
(	O	O
AKI	B-DISO
)	O	O
is	O	O
a	O	O
common	O	O
complication	B-DISO
after	O	O
cardiac	B-PROC
surgery	I-PROC
.	O	O

While	O	O
AKI	B-DISO
severity	O
is	O	O
known	O	O
to	O	O
be	O	O
associated	O
with	O
increased	O	O
risk	O
of	O	O
short	O
-	O
term	O
outcomes	O	O
,	O	O
its	O	O
long	O
-	O
term	O
impact	O	O
is	O	O
less	O	O
well	O	O
understood	O	O
.	O	O

Adult	O	O
patients	B-LIVB
undergoing	O	O
isolated	O	O
coronary	B-PROC
artery	I-PROC
bypass	I-PROC
graft	I-PROC
surgery	I-PROC
at	O	O
eight	O	O
centers	O	O
were	O	O
enrolled	O	O
into	O	O
the	O	O
Northern	O
New	O
England	O
biomarker	O
registry	O
(	O	O
n	O	O
=	O	O
1	O	O
,	O	O
610	O	O
)	O	O
.	O	O

Patients	B-LIVB
were	O	O
excluded	O	O
if	O	O
they	O	O
had	O	O
renal	B-DISO
failure	I-DISO
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
or	O	O
died	B-DISO
during	O	O
index	B-PROC
admission	I-PROC
(	O	O
n	O	O
=	O	O
38	O	O
)	O	O
.	O	O

Severity	O
of	O	O
AKI	B-DISO
was	O	O
defined	O	O
using	O	O
the	O	O
Acute	O
Kidney	O
Injury	O
Network	O
(	O	O
AKIN	O
)	O	O
.	O	O

We	O	O
linked	O	O
our	O	O
cohort	O
to	O	O
national	O
Medicare	O
and	O	O
state	O
all	O
-	O
payer	O
claims	O
to	O	O
ascertain	O	O
readmissions	B-PROC
and	O	O
to	O	O
the	O	O
National	O
Death	O
Index	O
to	O	O
ascertain	O	O
survival	O
.	O	O

Kaplan	O
-	O
Meier	O
and	O	O
multivariate	O
Cox	O
proportional	O
hazards	O
modeling	O
was	O	O
conducted	O	O
for	O	O
time	O	O
to	O	O
readmission	B-PROC
and	O	O
death	B-DISO
over	O	O
5	O	O
years	O	O
.	O	O

Within	O	O
5	O	O
years	O	O
,	O	O
513	O	O
patients	B-LIVB
(	O	O
33	O	O
.	O	O
8	O	O
%	O	O
)	O	O
had	O	O
AKI	B-DISO
with	O	O
AKIN	O
stage	O	O
1	O	O
(	O	O
29	O	O
.	O	O
9	O	O
%	O	O
)	O	O
and	O	O
stage	O	O
2	O	O
to	O	O
3	O	O
(	O	O
3	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

There	O	O
were	O	O
620	O	O
readmissions	B-PROC
(	O	O
39	O	O
.	O	O

9	O	O
%	O	O
)	O	O
and	O	O
370	O	O
deaths	B-DISO
(	O	O
23	O	O
.	O	O
8	O	O
%	O	O
)	O	O
.	O	O

After	O	O
adjustment	O	O
,	O	O
stage	O	O
1	O	O
AKI	B-DISO
patients	B-LIVB
had	O	O
a	O	O
31	O	O
%	O	O
increased	O	O
risk	O
of	O	O
readmission	B-PROC
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
:	O	O
1	O	O
.	O	O
10	O	O
to	O	O
1	O	O
.	O	O
57	O	O
)	O	O
,	O	O
whereas	O	O
stage	O	O
2	O	O
or	O	O
3	O	O
patients	B-LIVB
had	O	O
a	O	O
98	O	O
%	O	O
increased	O	O
risk	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
41	O	O
to	O	O
2	O	O
.	O	O
78	O	O
)	O	O
compared	O	O
with	O	O
patients	B-LIVB
having	O	O
no	B-DISO
AKI	B-DISO
.	O	O

Relative	O	O
to	O	O
patients	B-LIVB
without	O	O
AKI	B-DISO
,	O	O
stage	O	O
1	O	O
patients	B-LIVB
had	O	O
a	O	O
56	O	O
%	O	O
increased	O	O
risk	O
of	O	O
mortality	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
14	O	O
to	O	O
2	O	O
.	O	O
13	O	O
)	O	O
,	O	O
whereas	O	O
stage	O	O
2	O	O
or	O	O
3	O	O
patients	B-LIVB
had	O	O
a	O	O
3	O	O
.	O	O
5	O	O
times	O	O
higher	O	O
risk	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
2	O	O
.	O	O
16	O	O
to	O	O
5	O	O
.	O	O
60	O	O
)	O	O
.	O	O

Severity	O
of	O	O
AKI	B-DISO
using	O	O
the	O	O
AKIN	O
stage	O	O
criteria	O	O
is	O	O
associated	O
with	O
a	O	O
significantly	O	O
increased	O	O
risk	O
of	O	O
5	O	O
-	O	O
year	O	O
readmission	B-PROC
and	O	O
mortality	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
efforts	O	O
to	O	O
reduce	O	O
AKI	B-DISO
in	O	O
the	O	O
perioperative	O
period	O
may	O	O
have	O	O
a	O	O
significant	O	O
long	O
-	O
term	O
impact	O	O
on	O	O
patients	B-LIVB
and	O	O
payers	O	O
in	O	O
reducing	O	O
mortality	O
and	O	O
health	B-PROC
care	I-PROC
utilization	I-PROC
.	O	O

Methamphetamine	B-CHEM
,	O	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxymethamphetamine	I-CHEM
(	O	O
MDMA	B-CHEM
)	O	O
and	O	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O	O
MDPV	B-CHEM
)	O	O
induce	O
differential	O
cytotoxic	B-DISO
effects	I-DISO
in	O	O
bovine	B-LIVB
brain	B-ANAT
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
Designer	B-CHEM
drugs	I-CHEM
such	O	O
as	O	O
synthetic	B-CHEM
psychostimulants	I-CHEM
are	O	O
indicative	O	O
of	O	O
a	O	O
worldwide	O	O
problem	B-DISO
of	O	O
drug	B-DISO
abuse	I-DISO
and	O	O
addiction	B-DISO
.	O	O

In	O	O
addition	O	O
to	O	O
methamphetamine	B-CHEM
(	O	O
METH	B-CHEM
)	O	O
,	O	O
these	O	O
drugs	B-CHEM
include	O	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxy	I-CHEM
-	I-CHEM
methamphetamine	I-CHEM
(	O	O
MDMA	B-CHEM
)	O	O
and	O	O
commercial	O
preparations	O
of	O	O
synthetic	B-CHEM
cathinones	I-CHEM
including	O	O
3	B-CHEM
,	I-CHEM
4	I-CHEM
-	I-CHEM
methylenedioxypyrovalerone	I-CHEM
(	O	O
MDPV	B-CHEM
)	O	O
,	O	O
typically	O	O
referred	O	O
to	O	O
as	O	O
""""	O	O
bath	B-CHEM
salts	I-CHEM
.	O	O
""""	O	O
These	O	O
psychostimulants	B-CHEM
exert	O	O
neurotoxic	B-DISO
effects	I-DISO
by	O	O
altering	O
monoamine	O
systems	O
in	O	O
the	O	O
brain	B-ANAT
.	O	O

Additionally	O	O
,	O	O
METH	B-CHEM
and	O	O
MDMA	B-CHEM
adversely	B-DISO
affect	I-DISO
the	O	O
integrity	O
of	O	O
the	O	O
blood	B-ANAT
-	I-ANAT
brain	I-ANAT
barrier	I-ANAT
(	O	O
BBB	B-ANAT
)	O	O
:	O	O
there	O	O
are	O	O
no	O	O
current	O	O
reports	O
on	O	O
the	O	O
effects	O
of	O
MDPV	B-CHEM
on	O	O
the	O	O
BBB	B-ANAT
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
compare	O
the	O	O
effects	O
of	O
METH	B-CHEM
,	O	O
MDMA	B-CHEM
and	O	O
MDPV	B-CHEM
on	O	O
bovine	B-LIVB
brain	B-ANAT
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
(	O	O
bBMVECs	B-ANAT
)	O	O
,	O	O
an	O	O
accepted	O	O
in	B-PROC
vitro	I-PROC
model	I-PROC
of	O	O
the	O	O
BBB	B-ANAT
.	O	O

Confluent	O
bBMVEC	B-ANAT
monolayers	B-ANAT
were	O	O
treated	O
with	O	O
METH	B-CHEM
,	O	O
MDMA	B-CHEM
and	O	O
MDPV	B-CHEM
(	O	O
0	O	O
.	O	O
5mM	O	O
-	O	O
2	O	O
.	O	O
5mM	O	O
)	O	O
for	O	O
24h	O	O
.	O	O

METH	B-CHEM
and	O	O
MDMA	B-CHEM
increased	O
lactate	B-CHEM
dehydrogenase	I-CHEM
release	O
only	O	O
at	O	O
the	O	O
highest	O
concentration	O
(	O	O
2	O	O
.	O	O
5mM	O	O
)	O	O
,	O	O
whereas	O	O
MDPV	B-CHEM
induced	O
cytotoxicity	B-DISO
at	O	O
all	O	O
concentration	O
s	O	O
.	O	O

MDMA	B-CHEM
and	O	O
METH	B-CHEM
decreased	O
cellular	B-PHYS
proliferation	I-PHYS
only	O	O
at	O	O
2	O	O
.	O	O

5mM	O	O
,	O	O
with	O	O
similar	O	O
effects	O
observed	O	O
after	O	O
MDPV	B-CHEM
exposures	O
starting	O	O
at	O	O
1mM	O	O
.	O	O

Only	O	O
MDPV	B-CHEM
increased	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
production	O
at	O	O
all	O	O
concentrations	O
tested	O
whereas	O	O
all	O	O
3	O	O
drugs	B-CHEM
increased	O
nitric	B-CHEM
oxide	I-CHEM
production	O
.	O	O

Morphological	B-PROC
analysis	I-PROC
revealed	O	O
different	O
patterns	O	O
of	O	O
compound	B-CHEM
-	O	O
induced	O
cell	B-DISO
damage	I-DISO
.	O	O

METH	B-CHEM
induced	O
vacuole	B-ANAT
formatio	O
n	O	O
at	O	O
1mM	O	O
and	O	O
disruption	O
of	O	O
the	O	O
monolayer	B-ANAT
at	O	O
2	O	O
.	O	O

5mM	O	O
.	O	O

MDMA	B-CHEM
induced	O
disruption	O
of	O	O
the	O	O
endothelial	B-ANAT
monolayer	B-ANAT
from	O	O
1mM	O	O
without	O	O
vacuolization	B-DISO
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
MDPV	B-CHEM
induced	O
monolayer	B-ANAT
disruption	O
at	O	O
doses	O
≥0	O	O
.	O	O

5mM	O	O
without	O	O
vacuole	B-ANAT
formation	O
;	O	O
at	O	O
2	O	O
.	O	O
5mM	O	O
,	O	O
the	O	O
few	O	O
remaining	O	O
cells	B-ANAT
lacked	O	O
endothelial	O
morphology	O
.	O	O

These	O	O
data	O
suggest	O	O
that	O	O
even	O	O
though	O	O
these	O	O
synthetic	B-CHEM
psychostimulants	I-CHEM
alter	O	O
monoaminergic	O
systems	O
,	O	O
they	O	O
each	O	O
induce	O
BBB	B-ANAT
toxicity	B-DISO
by	O	O
different	O
mechanisms	O
with	O	O
MDPV	B-CHEM
being	O	O
the	O	O
most	O	O
toxic	O
.	O	O

Alleviation	O
of	O	O
hepatic	B-ANAT
fat	B-DISO
accumulation	I-DISO
by	O	O
betaine	B-CHEM
involves	O	O
reduction	O
of	O	O
homocysteine	B-CHEM
via	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
betaine	B-CHEM
-	I-CHEM
homocysteine	I-CHEM
methyltransferase	I-CHEM
(	O	O
BHMT	B-CHEM
)	O	O
We	O	O
investigated	O
the	O	O
anti	O
-	O
lipogenic	O
effect	O
of	O	O
betaine	B-CHEM
in	O	O
rats	B-LIVB
fed	O	O
methionine	B-CHEM
and	O	O
choline	B-CHEM
-	O	O
deficient	O
diet	B-OBJC
(	O	O
MCD	B-OBJC
)	O	O
.	O	O

Intake	O	O
of	O	O
MCD	B-OBJC
for	O	O
3	O	O
wk	O	O
resulted	O	O
in	O	O
a	O	O
significant	O
accumulation	B-DISO
of	O	O
hepatic	B-ANAT
lipids	B-CHEM
,	O	O
which	O	O
was	O	O
prevented	O
by	O	O
betaine	B-CHEM
supplementation	B-PROC
in	O	O
drinking	B-OBJC
water	I-OBJC
(	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Phosphorylation	B-PHYS
of	O	O
AMP	B-CHEM
-	I-CHEM
activated	I-CHEM
protein	I-CHEM
kinase	I-CHEM
(	O	O
AMPK	B-CHEM
)	O	O
,	O	O
acetyl	B-CHEM
-	I-CHEM
CoA	I-CHEM
carboxylase	I-CHEM
(	O	O
ACC	B-CHEM
)	O	O
,	O	O
sterol	B-CHEM
regulatory	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
1c	I-CHEM
(	O	O
SREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
)	O	O
,	O	O
and	O	O
liver	B-CHEM
kinase	I-CHEM
B1	I-CHEM
(	O	O
LKB1	B-CHEM
)	O	O
was	O	O
inhibited	O
by	O	O
MCD	B-OBJC
intake	O
,	O	O
and	O	O
these	O	O
changes	O	O
were	O	O
all	O	O
inhibited	O
by	O	O
betaine	B-CHEM
feeding	B-PROC
.	O	O

Meanwhile	O	O
,	O	O
betaine	B-CHEM
supplementation	B-PROC
reversed	O
the	O	O
reduction	O
of	O	O
methionine	B-PHYS
and	I-PHYS
S	I-PHYS
-	I-PHYS
adenosylmethionine	I-PHYS
(	O	O
SAM	B-PHYS
)	O	O
,	O	O
and	O	O
the	O	O
elevation	O
of	O	O
homocysteine	B-PROC
levels	I-PROC
in	O	O
the	O	O
liver	B-ANAT
,	I-ANAT
which	O	O
could	O	O
be	O	O
attributable	O	O
to	O	O
the	O	O
induction	B-PHYS
of	O	O
betaine	B-CHEM
-	I-CHEM
homocysteine	I-CHEM
methyltransfease	I-CHEM
(	O	O
BHMT	B-CHEM
)	O	O
and	O	O
methionine	B-CHEM
adenosyltransferase	I-CHEM
(	O	O
MAT	B-CHEM
)	O	O
.	O	O

Different	O
cell	B-ANAT
lines	I-ANAT
were	O	O
used	O	O
to	O	O
clarify	O	O
the	O	O
role	O	O
of	O	O
homocysteine	B-CHEM
on	O	O
activation	B-PHYS
of	O	O
the	O	O
AMPK	B-CHEM
pathway	B-PHYS
.	O	O

Homocysteine	B-CHEM
treatment	O
decreased	O
pAMPK	B-CHEM
,	O	O
pACC	B-CHEM
,	O	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
and	O	O
pLKB1	B-CHEM
in	O	O
HepG2	B-ANAT
cells	I-ANAT
.	O	O

Metformin	B-CHEM
-	O	O
induced	O
activation	B-PHYS
of	O	O
AMPK	B-CHEM
was	O	O
also	O	O
inhibited	O
by	O	O
homocysteine	B-CHEM
.	O	O

Treatment	O
with	O	O
hydroxylamine	B-CHEM
,	O	O
a	O	O
cystathionine	B-CHEM
β	I-CHEM
-	I-CHEM
synthase	I-CHEM
inhibitor	B-CHEM
,	O	O
resulted	O	O
in	O	O
a	O	O
reduction	O
of	O	O
pAMPK	B-CHEM
,	O	O
pACC	B-CHEM
and	O	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
,	O	O
accompanied	O	O
by	O	O
an	O	O
elevation	O
of	O	O
intracellular	O
homocysteine	B-CHEM
.	O	O

Betaine	B-CHEM
treatment	B-PROC
prevented	O
the	O	O
homocysteine	B-CHEM
-	O	O
induced	O
reduction	O
of	O	O
pAMPK	B-CHEM
,	O	O
pACC	B-CHEM
,	O	O
pSREBP	B-CHEM
-	I-CHEM
1c	I-CHEM
and	O	O
pLKB1	B-CHEM
in	O	O
H4IIE	B-ANAT
cells	I-ANAT
,	O	O
but	O	O
not	O	O
in	O	O
HepG2	B-ANAT
cells	I-ANAT
.	O	O

Also	O	O
the	O	O
elevation	O
of	O	O
cellular	O	O
homocysteine	B-CHEM
and	O	O
inhibition	O
of	O	O
protein	B-PHYS
expression	I-PHYS
of	O	O
BHMT	B-CHEM
were	O	O
prevented	O
by	O	O
betaine	B-CHEM
only	O	O
in	O	O
H4IIE	B-ANAT
cells	I-ANAT
which	O	O
express	B-PHYS
BHMT	B-CHEM
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
beneficial	O	O
effect	O	O
of	O	O
betaine	B-CHEM
against	O	O
hepatic	B-ANAT
lipid	B-CHEM
accumulation	B-DISO
may	O	O
be	O	O
attributed	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
to	O	O
the	O	O
depletion	O
of	O	O
homocysteine	B-CHEM
via	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
BHMT	B-CHEM
in	O	O
hepatocytes	B-ANAT
.	O	O

Constitutive	O	O
expression	B-PHYS
of	O	O
cytochrome	B-CHEM
P450	I-CHEM
in	O	O
foetal	B-ANAT
and	O	O
adult	B-LIVB
porcine	B-LIVB
livers	B-ANAT
-	O	O
Effects	O
of	O	O
body	B-PHYS
weight	I-PHYS
The	O	O
liver	B-ANAT
hosts	O	O
a	O	O
great	O	O
number	O	O
of	O	O
enzymatically	B-CHEM
driven	O	O
processes	B-PHEN
,	O	O
including	O	O
detoxification	B-PHYS
.	O	O

The	O	O
super	O	O
-	O	O
family	O	O
of	O	O
enzymes	B-CHEM
named	O	O
cytochrome	B-CHEM
P450	I-CHEM
(	O	O
CYP	B-CHEM
)	O	O
is	O	O
the	O	O
major	O	O
participant	O	O
in	O	O
that	O	O
process	B-PHYS
.	O	O

The	O	O
expression	B-PHYS
of	O	O
CYPs	B-CHEM
is	O	O
affected	O	O
by	O	O
several	O	O
factors	O	O
including	O	O
life	O
-	O
stage	O
(	O	O
foetal	B-ANAT
vs	O	O
.	O	O

adult	B-LIVB
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
we	O	O
investigated	O
the	O	O
impact	O	O
of	O	O
birth	B-PHYS
-	I-PHYS
weight	I-PHYS
(	O	O
high	O
or	O	O
low	O
birth	B-PHYS
weight	I-PHYS
)	O	O
and	O	O
life	O
-	O
stage	O
on	O	O
constitutive	O	O
expression	B-PHYS
of	O	O
porcine	B-LIVB
hepatic	B-ANAT
CYP1A1	B-CHEM
,	O	O
CYP1A2	B-CHEM
,	O	O
CYP2A19	B-CHEM
,	O	O
CYP2B22	B-CHEM
,	O	O
CYP2C33	B-CHEM
,	O	O
CYP2D25	B-CHEM
,	O	O
CYP2E1	B-CHEM
and	O	O
CYP3A29	B-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
transcription	B-CHEM
factors	I-CHEM
controlling	O	O
their	O	O
expression	B-PHYS
;	O	O
aryl	B-CHEM
hydrocarbon	I-CHEM
receptor	I-CHEM
,	O	O
constitutive	B-CHEM
androstane	I-CHEM
receptor	I-CHEM
,	O	O
pregnane	B-CHEM
X	I-CHEM
receptor	I-CHEM
,	O	O
C	B-CHEM
/	I-CHEM
EBP	I-CHEM
and	O	O
hepatocyte	B-CHEM
nuclear	I-CHEM
factors	I-CHEM
1	I-CHEM
and	O	O
4	B-CHEM
.	O	O

Both	O	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
and	O	O
western	B-PROC
blotting	I-PROC
showed	O	O
a	O	O
marked	O	O
increase	O
in	O	O
the	O	O
expression	B-PHYS
of	O	O
the	O	O
adult	B-LIVB
pigs	I-LIVB
compared	O
with	O	O
prenatal	B-LIVB
pigs	B-LIVB
.	O	O

Moreover	O	O
,	O	O
CYP2E1	B-CHEM
mRNA	B-PHYS
expression	I-PHYS
was	O	O
7	O	O
.	O	O

5	O	O
fold	O	O
higher	O	O
in	O	O
foetuses	B-ANAT
with	O	O
low	O
birth	B-PHYS
weight	I-PHYS
compared	O
with	O	O
foetuses	B-ANAT
with	O	O
high	O
birth	B-PHYS
weight	I-PHYS
.	O	O

Gender	B-PHYS
did	O	O
not	O	O
affect	O	O
the	O	O
mRNA	B-PHYS
expression	I-PHYS
within	O	O
the	O	O
different	O	O
life	O
-	O
stages	O
.	O	O

These	O	O
results	O	O
indicate	O	O
a	O	O
similarity	O	O
to	O	O
what	O	O
is	O	O
observed	O	O
in	O	O
humans	B-LIVB
and	O	O
porcine	B-LIVB
foetuses	B-ANAT
may	O	O
therefore	O	O
be	O	O
a	O	O
model	B-DEVI
for	O	O
humans	B-LIVB
when	O	O
studying	B-PROC
expression	B-PHYS
of	O	O
CYPs	B-CHEM
.	O	O

Association	O
of	O	O
abdominal	O
fat	O
with	O	O
serum	B-ANAT
amylase	B-CHEM
in	O	O
an	O	O
older	B-LIVB
cohort	B-LIVB
:	O	O
The	O	O
Baltimore	B-GEOG
Longitudinal	B-PROC
Study	I-PROC
of	O	O
Aging	B-PHYS
Abdominal	O
fat	O
is	O	O
a	O	O
major	O	O
determinant	O
of	O	O
metabolic	B-DISO
diseases	I-DISO
in	O	O
older	B-LIVB
individuals	B-LIVB
.	O	O

Obesity	B-DISO
and	O	O
diabetes	B-DISO
are	O	O
associated	O
with	O
low	O
serum	B-DISO
amylase	I-DISO
(	I-DISO
SA	I-DISO
)	I-DISO
levels	I-DISO
,	O	O
but	O	O
the	O	O
association	O
between	O	O
SA	B-DISO
and	O	O
metabolic	B-DISO
disease	I-DISO
is	O	O
poorly	O	O
understood	O	O
.	O	O

We	O	O
investigated	O
the	O	O
association	O
of	O	O
low	O
SA	B-DISO
with	O	O
diabetes	B-DISO
and	O	O
sex	B-PHYS
-	O	O
specific	O
associations	O
of	O	O
serum	B-ANAT
amylase	B-CHEM
with	O	O
abdominal	O
fat	O
in	O	O
older	B-LIVB
adults	I-LIVB
.	O	O

In	O	O
community	O
-	O
dwelling	O
volunteers	B-LIVB
from	O	O
the	O	O
Baltimore	B-GEOG
Longitudinal	B-PROC
Study	I-PROC
of	O	O
Aging	B-PHYS
(	O	O
778	O	O
participants	B-LIVB
,	O	O
age	B-PHYS
66	O	O
.	O	O

8±13	O	O
.	O	O
6	O	O
years	O
)	O	O
,	O	O
we	O	O
assessed	O
abdominal	O
fat	O
by	O	O
computed	B-PROC
tomography	I-PROC
and	O	O
diabetes	B-DISO
status	I-DISO
using	O	O
the	O	O
American	O
Diabetes	O
Association	O
criteria	O
.	O	O

Linear	O
regression	O
analyses	O
assessed	O
the	O	O
cross	O
-	O
sectional	O
associations	O
between	O	O
abdominal	O
fat	O
and	O	O
SA	B-DISO
,	O	O
and	O	O
logistic	B-PROC
regression	I-PROC
assessed	O
the	O	O
odds	O
of	O	O
diabetes	B-DISO
,	O	O
given	O	O
low	O
SA	B-DISO
.	O	O

In	O	O
unadjusted	B-PROC
analyses	I-PROC
,	O	O
individuals	B-LIVB
in	O	O
the	O	O
lowest	O
SA	B-DISO
quartile	O
(	O	O
<	O	O
48μ	O	O
/	O	O
L	O	O
)	O	O
had	O	O
1	O	O
.	O	O

97	O	O
greater	O	O
odds	O
of	O	O
diabetes	B-DISO
,	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
01	O	O
-	O	O
3	O	O
.	O	O
83	O	O
)	O	O
than	O	O
those	O	O
in	O	O
the	O	O
highest	O	O
quartile	O
(	O	O
⩾80μ	O	O
/	O	O
L	O	O
)	O	O
.	O	O

This	O	O
association	O
was	O	O
no	O	O
longer	O	O
significant	O
after	O	O
adjusting	O	O
for	O	O
visceral	O
adipose	O
tissue	O
area	O
(	O	O
VAT	O
,	O	O
dm	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
abdominal	O
subcutaneous	O
adipose	O
tissue	O
(	O	O
SAT	O
,	O	O
dm	O	O
(	O	O
2	O	O
)	O	O
)	O	O
or	O	O
BMI	B-PHYS
.	O	O

In	O	O
adjusted	B-PROC
analyses	I-PROC
,	O	O
VAT	O
and	O	O
SAT	O
were	O	O
significantly	O
associated	O
with	O
SA	B-DISO
in	O	O
both	O	O
sexes	B-PHYS
.	O	O

Among	O	O
women	B-LIVB
,	O	O
SA	B-DISO
was	O	O
more	O	O
strongly	O	O
associated	O
with	O
VAT	O
than	O	O
with	O	O
SAT	O
or	O	O
BMI	B-PHYS
;	O	O
VAT	O
(	O	O
β	O	O
=	O	O
-	O	O
0	O	O
.	O	O
117±0	O	O
.	O	O
048	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
SAT	O
(	O	O
β	O	O
=	O	O
-	O	O
0	O	O
.	O	O

023±0	O	O
.	O	O
025	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
346	O	O
)	O	O
and	O	O
BMI	B-PHYS
(	O	O
β	O	O
=	O	O
-	O	O
0	O	O
.	O	O

0052±0	O	O
.	O	O

075	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
49	O	O
)	O	O
.	O	O

The	O	O
association	O
between	O	O
SA	B-CHEM
and	O	O
diabetes	B-DISO
was	O	O
explained	O	O
mainly	O	O
by	O	O
abdominal	O
visceral	O
fat	O
.	O	O

In	O	O
women	B-LIVB
,	O	O
SA	B-CHEM
was	O	O
more	O	O
strongly	O	O
associated	O
with	O
VAT	O
than	O	O
with	O	O
BMI	B-PHYS
or	O	O
SAT	O
.	O	O

These	O	O
findings	O	O
provide	O	O
motivation	O	O
for	O	O
future	O	O
mechanistic	O
studies	O
on	O	O
SA	B-CHEM
's	I-CHEM
role	O	O
in	O	O
metabolic	B-DISO
diseases	I-DISO
.	O	O

Efficacy	O
of	O	O
Intravenous	O
Chlorothiazide	B-CHEM
for	O	O
Refractory	O
Acute	B-DISO
Decompensated	I-DISO
Heart	I-DISO
Failure	I-DISO
Unresponsive	O
to	O	O
Adjunct	O
Metolazone	B-CHEM
To	O	O
assess	O	O
the	O	O
efficacy	O
of	O	O
intravenous	O
chlorothiazide	B-CHEM
in	O	O
patients	B-LIVB
with	O	O
acute	B-DISO
decompensated	I-DISO
heart	I-DISO
failure	I-DISO
(	O	O
ADHF	B-DISO
)	O	O
who	O	O
were	O	O
determined	O	O
to	O	O
be	O	O
loop	B-CHEM
diuretic	I-CHEM
resistant	O
and	O	O
refractory	O
to	O	O
metolazone	B-CHEM
.	O	O

Retrospective	B-PROC
cohort	I-PROC
study	I-PROC
with	O	O
patients	B-LIVB
serving	O	O
as	O	O
their	O	O
own	O	O
controls	B-LIVB
.	O	O

Large	O
,	O	O
academic	O
,	O	O
tertiary	B-OBJC
care	I-OBJC
hospital	I-OBJC
.	O	O

Forty	O	O
-	O	O
five	O	O
patients	B-LIVB
with	O	O
ADHF	B-DISO
who	O	O
had	O	O
an	O	O
inadequate	O
response	B-PHYS
to	O	O
high	O
-	O
dose	O
loop	B-CHEM
diuretics	I-CHEM
and	O	O
then	O	O
received	O	O
at	O	O
least	O	O
one	O	O
dose	O
of	O	O
oral	O
metolazone	B-CHEM
5	O	O
mg	O	O
or	O	O
greater	O
(	O	O
metolazone	B-CHEM
index	O
dose	O
)	O	O
followed	O	O
by	O	O
at	O	O
least	O	O
one	O	O
dose	O
of	O	O
intravenous	O
chlorothiazide	B-CHEM
500	O	O
mg	O	O
(	O	O
chlorothiazide	B-CHEM
index	O
dose	O
)	O	O
if	O	O
the	O	O
response	O	O
to	O	O
metolazone	B-CHEM
was	O	O
considered	O	O
inadequate	O
,	O	O
according	O	O
to	O	O
the	O	O
institutional	O
protocol	O
,	O	O
between	O	O
February	O	O
4	O	O
,	O	O
2013	O	O
,	O	O
and	O	O
February	O	O
28	O	O
,	O	O
2015	O	O
,	O	O
were	O	O
included	O	O
.	O	O

If	O	O
multiple	O	O
doses	O
of	O	O
metolazone	B-CHEM
were	O	O
administered	B-PROC
,	O	O
the	O	O
last	O	O
dose	O
given	O	O
before	O	O
the	O	O
chlorothiazide	B-CHEM
index	O
dose	O
was	O	O
considered	O	O
the	O	O
index	O
dose	O
;	O	O
the	O	O
metolazone	B-CHEM
index	O
dose	O
had	O	O
to	O	O
have	O	O
been	O	O
administered	B-PROC
more	O	O
than	O	O
2	O	O
hours	O
before	O	O
the	O	O
chlorothiazide	B-CHEM
index	O
dose	O
.	O	O

Data	O
for	O	O
a	O	O
total	O	O
of	O	O
90	O	O
diuretic	B-CHEM
doses	O
(	O	O
45	O	O
metolazone	B-CHEM
,	O	O
45	O	O
chlorothiazide	B-CHEM
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	B-PROC
.	O	O

The	O	O
median	O	O
dose	O
of	O	O
loop	B-CHEM
diuretic	I-CHEM
in	O	O
intravenous	O
furosemide	B-CHEM
equivalents	O	O
given	O	O
over	O	O
the	O	O
24	O	O
-	O	O
hour	O
period	O
before	O	O
the	O	O
metolazone	B-CHEM
index	O
dose	O
was	O	O
400	O	O
mg	O	O
.	O	O

The	O	O
average	O	O
length	O	O
of	O	O
stay	O
was	O	O
34	O	O
.	O	O

7	O	O
days	O
,	O	O
and	O	O
in	O
-	O
hospital	O
mortality	O
was	O	O
35	O	O
.	O	O

6	O	O
%	O	O
(	O	O
16	O	O
/	O	O
45	O	O
patients	B-LIVB
)	O	O
.	O	O

The	O	O
primary	O	O
end	O
point	O
of	O	O
a	O	O
net	B-DISO
-	I-DISO
negative	I-DISO
urine	B-PHYS
output	I-PHYS
of	O	O
500	O	O
ml	O	O
or	O	O
greater	O	O
during	O	O
the	O	O
12	O	O
hours	O
after	O	O
the	O	O
index	O
dose	O
occurred	O	O
in	O	O
42	O	O
.	O	O

2	O	O
%	O	O
(	O	O
19	O	O
/	O	O
45	O	O
patients	B-LIVB
)	O	O
and	O	O
35	O	O
.	O	O
5	O	O
%	O	O
(	O	O
16	O	O
/	O	O
45	O	O
patients	B-LIVB
)	O	O
for	O	O
the	O	O
chlorothiazide	B-CHEM
and	O	O
metolazone	B-CHEM
doses	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
581	O	O
)	O	O
.	O	O

The	O	O
median	O	O
12	O	O
-	O	O
hour	O
urine	B-PHYS
output	I-PHYS
following	O	O
administration	O
of	O	O
metolazone	B-CHEM
was	O	O
810	O	O
ml	O	O
(	O	O
interquartile	O
range	O
[	O	O
IQR	O
]	O	O
866	O	O
ml	O	O
)	O	O
versus	O	O
1075	O	O
ml	O	O
(	O	O
IQR	O
940	O	O
ml	O	O
)	O	O
following	O	O
administration	O
of	O	O
chlorothiazide	B-CHEM
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
363	O	O
)	O	O
.	O	O

Compared	O
with	O	O
metolazone	B-CHEM
,	O	O
the	O	O
chlorothiazide	B-CHEM
doses	O
did	O	O
not	O	O
result	O	O
in	O	O
an	O	O
increase	O
in	O	O
urine	B-PHYS
output	I-PHYS
of	O	O
at	O	O
least	O	O
500	O	O
ml	O	O
during	O	O
the	O	O
12	O	O
hours	O
following	O	O
the	O	O
dose	O
relative	O	O
to	O	O
the	O	O
12	O	O
hours	O
before	O	O
the	O	O
dose	O
(	O	O
31	O	O
.	O	O
1	O	O
%	O	O
vs	O	O
22	O	O
.	O	O
2	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
754	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
in	O	O
achievement	O	O
of	O	O
net	B-DISO
-	I-DISO
negative	I-DISO
urine	B-PHYS
output	I-PHYS
of	O	O
500	O	O
ml	O	O
or	O	O
greater	O	O
during	O	O
the	O	O
12	O	O
hours	O
following	O	O
the	O	O
chlorothiazide	B-CHEM
or	O	O
metolazone	B-CHEM
dose	O
was	O	O
noted	O	O
(	O	O
42	O	O
.	O	O
2	O	O
%	O	O
for	O	O
chlorothiazide	B-CHEM
vs	O	O
35	O	O
.	O	O

5	O	O
%	O	O
for	O	O
metolazone	B-CHEM
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
581	O	O
)	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
intravenous	O
chlorothiazide	B-CHEM
did	O	O
not	O	O
result	O	O
in	O	O
improved	B-DISO
diuresis	B-PHYS
in	O	O
patients	B-LIVB
with	O	O
ADHF	B-DISO
determined	O	O
to	O	O
be	O	O
refractory	O
to	O	O
loop	B-CHEM
diuretic	I-CHEM
s	O	O
and	O	O
adjunctive	O
oral	O
metolazone	B-CHEM
.	O	O

Antipsychotic	B-CHEM
Drugs	I-CHEM
and	O	O
Risk	O
of	O
Hip	B-DISO
Fracture	I-DISO
in	O	O
People	B-LIVB
Aged	B-PHYS
60	O	O
and	O	O
Older	B-LIVB
in	O	O
Norway	B-GEOG
To	O	O
examine	O	O
associations	O
between	O	O
exposure	O
to	O	O
various	O	O
subgroups	O	O
of	O	O
antipsychotic	B-CHEM
drugs	I-CHEM
and	O	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
in	O	O
older	B-LIVB
adults	B-LIVB
.	O	O

Nationwide	O	O
cohort	O
study	O
.	O	O

Norway	B-GEOG
,	O	O
2005	O	O
-	O	O
2010	O	O
.	O	O

Everyone	O	O
living	O	O
in	O	O
Norway	B-GEOG
born	O	O
before	O	O
1945	O	O
(	O	O
N	O	O
=	O	O
906	O	O
,	O	O
422	O	O
)	O	O
.	O	O

Information	O
was	O	O
obtained	O	O
on	O	O
all	O	O
prescriptions	O
of	O	O
antipsychotic	B-CHEM
drugs	I-CHEM
dispensed	O	O
from	O	O
2004	O	O
to	O	O
2010	O	O
(	O	O
Norwegian	O
Prescription	O
Database	O
)	O	O
and	O	O
data	O
on	O	O
all	O	O
primary	O
hip	B-DISO
fractures	I-DISO
from	O	O
2005	O	O
to	O	O
2010	O	O
(	O	O
Norwegian	O
Hip	O
Fracture	O
Registry	O
)	O	O
.	O	O

Incidence	O
rates	O
of	O	O
hip	B-DISO
fracture	I-DISO
during	O
person	O	O
-	O	O
time	O	O
exposed	O
and	O	O
unexposed	O	O
to	O	O
antipsychotic	B-CHEM
drugs	I-CHEM
were	O	O
compared	O
by	O	O
calculating	O
the	O	O
standardized	O
incidence	O
ratio	O
(	O	O
SIR	O
)	O	O
.	O	O

Thirty	O	O
-	O	O
nine	O	O
thousand	O	O
nine	O	O
hundred	O	O
thirty	O	O
-	O	O
eight	O	O
(	O	O
4	O	O
.	O	O
4	O	O
%	O	O
)	O	O
participants	B-LIVB
experienced	O	O
a	O	O
primary	O
hip	B-DISO
fracture	I-DISO
.	O	O

Greater	O	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
was	O	O
associated	O
with	O
exposure	O
to	O	O
any	O	O
antipsychotic	B-CHEM
(	O	O
SIR	O
=	O	O
2	O	O
.	O	O
1	O	O
,	O	O
95	O	O
%	O	O
confidence	O
interval	O
(	O	O
CI	O
)	O	O
=	O	O
1	O	O
.	O	O
9	O	O
-	O	O
2	O	O
.	O	O
1	O	O
)	O	O
,	O	O
first	O
-	O
generation	O
antipsychotics	B-CHEM
(	O	O
SIR	O
=	O	O
2	O	O
.	O	O
0	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
8	O	O
-	O	O
2	O	O
.	O	O
2	O	O
)	O	O
,	O	O
second	O
-	O
generation	O
antipsychotics	B-CHEM
(	O	O
SIR	O
=	O	O
2	O	O
.	O	O
2	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O

9	O	O
-	O	O
2	O	O
.	O	O
4	O	O
)	O	O
,	O	O
prolactin	B-CHEM
-sparing	O	O
antipsychotics	B-CHEM
(	O	O
SIR	O
=	O	O
2	O	O
.	O	O
4	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
8	O	O
-	O	O
3	O	O
.	O	O
1	O	O
)	O	O
and	O	O
prolactin	B-CHEM
-elevating	O	O
antipsychotics	B-CHEM
(	O	O
SIR	O
=	O	O
2	O	O
.	O	O
0	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O

9	O	O
-	O	O
2	O	O
.	O	O
2	O	O
)	O	O
.	O	O

In	O	O
people	B-LIVB
aged	B-PHYS
60	O	O
and	O	O
older	B-LIVB
in	O	O
Norway	B-GEOG
,	O	O
those	O	O
who	O	O
took	O	O
an	O	O
antipsychotic	B-CHEM
drug	I-CHEM
had	O	O
twice	O	O
the	O	O
risk	O
of	O
sustaining	O	O
a	O	O
hip	B-DISO
fracture	I-DISO
during	O	O
exposure	O
than	O	O
during	O	O
nonexposure	O	O
.	O	O

Although	O	O
confounding	O
by	O	O
indication	O
,	O	O
comorbidity	O
,	O	O
or	O	O
other	O	O
drugs	B-CHEM
used	O	O
cannot	O	O
be	O	O
excluded	O	O
,	O	O
this	O	O
association	O
is	O	O
relevant	O	O
for	O	O
clinical	O
practice	O
because	O	O
hip	B-DISO
fracture	I-DISO
and	O	O
antipsychotic	B-CHEM
drug	I-CHEM
use	B-DISO
are	O	O
prevalent	O	O
in	O	O
vulnerable	O
older	B-LIVB
individuals	B-LIVB
.	O	O

Clinical	B-PROC
studies	I-PROC
examining	O	O
mechanisms	O
or	O	O
causality	O
of	O	O
the	O	O
observed	O	O
association	O
between	O	O
antipsychotic	B-CHEM
drug	I-CHEM
use	O	O
and	O	O
excess	O	O
risk	O
of	O
hip	B-DISO
fracture	I-DISO
are	O	O
needed	O	O
.	O	O

Bisphenol	B-CHEM
-	I-CHEM
A	I-CHEM
removal	B-PROC
by	O	O
the	O	O
halophyte	B-LIVB
Juncus	B-LIVB
acutus	I-LIVB
in	O	O
a	O	O
phytoremediation	B-PHEN
pilot	B-PROC
:	O	O
Characterization	O
and	O	O
potential	O
role	O
of	O	O
the	O	O
endophytic	B-LIVB
community	B-LIVB
A	O	O
phytoremediation	B-PHEN
pilot	B-PROC
emulating	O	O
a	O	O
shallow	O
aquifer	B-PHEN
planted	O	O
with	O	O
Juncus	B-LIVB
acutus	I-LIVB
showed	O	O
to	O	O
be	O	O
effective	O
for	O	O
remediating	B-PHEN
Bisphenol	B-CHEM
-	I-CHEM
A	I-CHEM
(	O	O
BPA	B-CHEM
)	O	O
contaminated	O
groundwater	B-CHEM
.	O	O

Biostimulation	O
with	O	O
root	B-LIVB
exudates	B-OBJC
,	O	O
low	O
molecular	O
weight	O
organic	B-CHEM
acids	I-CHEM
,	O	O
of	O	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
did	O	O
not	O	O
improve	B-DISO
BPA	B-CHEM
-	O	O
degradation	O
rates	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
endophytic	B-LIVB
bacterial	B-LIVB
community	B-LIVB
of	O	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
was	O	O
isolated	O
and	O	O
characterized	O
.	O	O

Many	O	O
strains	B-LIVB
were	O	O
found	O	O
to	O	O
possess	O
increased	B-DISO
tolerance	I-DISO
to	O	O
metals	B-CHEM
such	O	O
as	O	O
Zn	B-CHEM
,	O	O
Ni	B-CHEM
,	O	O
Pb	B-CHEM
and	O	O
Cd	B-CHEM
.	O	O

Moreover	O	O
,	O	O
several	O
endophytic	B-LIVB
bacterial	B-LIVB
strains	B-LIVB
tolerated	O	O
and	O	O
even	O	O
used	O	O
BPA	B-CHEM
and	O	O
/	O	O
or	O	O
two	O	O
antibiotics	B-CHEM
(	O	O
ciprofloxacin	B-CHEM
and	O	O
sulfamethoxazole	B-CHEM
)	O	O
as	O	O
a	O	O
sole	O	O
carbon	B-CHEM
source	B-DISO
.	O	O

Our	O	O
results	B-DISO
demonstrate	O	O
that	O	O
the	O	O
cultivable	O	O
bacterial	B-LIVB
endophytic	B-LIVB
community	B-LIVB
of	O	O
J	B-LIVB
.	I-LIVB

acutus	I-LIVB
is	O	O
able	O	O
to	O	O
use	O	O
organic	B-CHEM
contaminants	B-OBJC
as	O	O
carbon	B-CHEM
sources	B-DISO
,	O	O
tolerates	O	O
metals	B-CHEM
and	O	O
is	O	O
equipped	O	O
with	O	O
plant	B-PHYS
-	I-PHYS
growth	I-PHYS
promoting	O
traits	B-PHYS
.	O	O

Therefore	O	O
,	O	O
J	B-LIVB
.	I-LIVB
acutus	I-LIVB
has	O	O
potential	O
to	O	O
be	O	O
exploited	O	O
in	O	O
constructed	O	O
wetlands	B-PHEN
when	O	O
co	O
-	O
contamination	O
is	O	O
one	O	O
of	O	O
the	O	O
restricting	O
factors	O
.	O	O

Dual	B-PROC
-	I-PROC
color	I-PROC
STED	I-PROC
microscopy	I-PROC
reveals	O	O
a	O	O
sandwich	O
structure	O
of	O	O
Bassoon	B-CHEM
and	O	O
Piccolo	B-CHEM
in	O	O
active	B-ANAT
zones	I-ANAT
of	O	O
adult	B-LIVB
and	O	O
aged	B-PHYS
mice	B-LIVB
Presynaptic	B-ANAT
active	I-ANAT
zones	I-ANAT
play	O	O
a	O	O
pivotal	O	O
role	O	O
as	O	O
synaptic	B-ANAT
vesicle	I-ANAT
release	B-ANAT
sites	I-ANAT
for	O	O
synaptic	B-PHYS
transmission	I-PHYS
,	O	O
but	O	O
the	O	O
molecular	O
architecture	O
of	O	O
active	B-ANAT
zones	I-ANAT
in	O	O
mammalian	B-LIVB
neuromuscular	B-ANAT
junctions	I-ANAT
(	O	O
NMJs	B-ANAT
)	O	O
at	O	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
remains	O	O
unknown	O	O
.	O	O

Bassoon	B-CHEM
and	O	O
Piccolo	B-CHEM
are	O	O
active	B-ANAT
zone	I-ANAT
specific	O	O
cytosolic	B-ANAT
proteins	B-CHEM
essential	O	O
for	O	O
active	B-PHYS
zone	I-PHYS
assembly	I-PHYS
in	O	O
NMJs	B-ANAT
,	O	O
ribbon	B-ANAT
synapses	I-ANAT
,	O	O
and	O	O
brain	B-ANAT
synapses	B-ANAT
.	O	O

These	O	O
proteins	B-CHEM
are	O	O
thought	O	O
to	O	O
colocalize	O
and	O	O
share	O	O
some	O	O
functions	O	O
at	O	O
active	B-ANAT
zones	I-ANAT
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
an	O	O
unexpected	O	O
finding	O	O
of	O	O
non	B-PHYS
-	I-PHYS
overlapping	I-PHYS
localization	I-PHYS
of	O	O
these	O	O
two	O	O
proteins	B-CHEM
in	O	O
mouse	B-LIVB
NMJs	B-ANAT
revealed	O	O
using	O	O
dual	B-PHEN
-	I-PHEN
color	I-PHEN
stimulated	I-PHEN
emission	I-PHEN
depletion	I-PHEN
(	O	O
STED	B-PHEN
)	O	O
super	B-PROC
resolution	I-PROC
microscopy	I-PROC
.	O	O

Piccolo	B-CHEM
puncta	B-DISO
sandwiched	O	O
Bassoon	B-CHEM
puncta	B-DISO
and	O	O
aligned	O
in	O	O
a	O	O
Piccolo	B-CHEM
-	O	O
Bassoon	B-CHEM
-	O	O
Piccolo	B-CHEM
structure	O
in	O	O
adult	B-LIVB
NMJs	B-ANAT
.	O	O

P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
voltage	I-CHEM
-	I-CHEM
gated	I-CHEM
calcium	I-CHEM
channel	I-CHEM
(	O	O
VGCC	B-CHEM
)	O	O
puncta	B-DISO
colocalized	O
with	O	O
Bassoon	B-CHEM
puncta	B-DISO
.	O	O

The	O	O
P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
VGCC	I-CHEM
and	O	O
Bassoon	B-CHEM
protein	B-PHEN
levels	I-PHEN
decreased	O
significantly	O	O
in	O	O
NMJs	B-ANAT
from	O	O
aged	B-PHYS
mouse	B-LIVB
.	O	O

In	O	O
contrast	O	O
,	O	O
the	O	O
Piccolo	B-CHEM
levels	B-PHEN
in	O	O
NMJs	B-ANAT
from	O	O
aged	B-PHYS
mice	B-LIVB
were	O	O
comparable	O	O
to	O	O
levels	B-PHEN
in	O	O
adult	B-LIVB
mice	B-LIVB
.	O	O

This	O	O
study	O	O
revealed	O	O
the	O	O
molecular	O
architecture	O
of	O	O
active	B-ANAT
zones	I-ANAT
in	O	O
mouse	B-LIVB
NMJs	B-ANAT
at	O	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
,	O	O
and	O	O
described	O	O
the	O	O
selective	B-PHYS
degeneration	I-PHYS
mechanism	I-PHYS
of	O	O
active	B-ANAT
zone	I-ANAT
proteins	B-CHEM
in	O	O
NMJs	B-ANAT
from	O	O
aged	B-PHYS
mice	B-LIVB
.	O	O

Interestingly	O	O
,	O	O
the	O	O
localization	B-PHYS
pattern	I-PHYS
of	O	O
active	B-ANAT
zone	I-ANAT
proteins	B-CHEM
described	O	O
herein	O	O
is	O	O
similar	O	O
to	O	O
active	B-ANAT
zone	I-ANAT
structures	O
described	O	O
using	O	O
electron	B-PROC
microscope	I-PROC
tomography	I-PROC
.	O	O

Structure	O
of	O	O
Carbon	B-CHEM
Nanotube	I-CHEM
Porins	B-CHEM
in	O	O
Lipid	B-ANAT
Bilayers	I-ANAT
:	O	O
An	O	O
in	O
Situ	O
Small	B-PROC
-	I-PROC
Angle	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
Scattering	I-PROC
(	O	O
SAXS	B-PROC
)	O	O
Study	B-PROC
Carbon	B-CHEM
nanotube	I-CHEM
porins	B-CHEM
(	O	O
CNTPs	B-CHEM
)	I-CHEM
,	O	O
small	O	O
segments	O	O
of	O	O
carbon	B-CHEM
nanotubes	I-CHEM
capable	O	O
of	O	O
forming	O	O
defined	O	O
pores	B-ANAT
in	O	O
lipid	B-ANAT
membranes	I-ANAT
,	O	O
are	O	O
important	O	O
future	O	O
components	B-OBJC
for	O	O
bionanoelectronic	B-DEVI
devices	I-DEVI
as	O	O
they	O	O
could	O	O
provide	O	O
a	O	O
robust	O
analog	B-CHEM
of	O	O
biological	B-ANAT
membrane	I-ANAT
channels	B-CHEM
.	O	O

In	O	O
order	O	O
to	O	O
control	O
the	O	O
incorporation	O
of	O	O
these	O	O
CNT	B-CHEM
channels	B-CHEM
into	O	O
lipid	B-ANAT
bilayers	I-ANAT
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
understand	O	O
the	O	O
structure	O
of	O	O
the	O	O
CNTPs	B-CHEM
before	O	O
and	O	O
after	O	O
insertion	O
into	O	O
the	O	O
lipid	B-ANAT
bilayer	I-ANAT
as	O	O
well	O	O
as	O	O
the	O	O
impact	O
of	O	O
such	O	O
insertion	O
on	O	O
the	O	O
bilayer	B-ANAT
structure	O
.	O	O

Here	O	O
we	O	O
employed	O	O
a	O	O
noninvasive	O
in	O
situ	O
probe	B-DEVI
,	O	O
small	B-PROC
-	I-PROC
angle	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
scattering	I-PROC
,	O	O
to	O	O
study	B-PROC
the	O	O
integration	O
of	O	O
CNT	B-CHEM
porins	B-CHEM
into	O	O
dioleoylphosphatidylcholine	B-CHEM
bilayers	I-CHEM
.	O	O

Our	O	O
results	B-DISO
show	O	O
that	O	O
CNTPs	B-CHEM
in	O	O
solution	B-OBJC
are	O	O
stabilized	B-DISO
by	O	O
a	O	O
monolayer	B-ANAT
of	O	O
lipid	B-CHEM
molecules	I-CHEM
wrapped	O	O
around	O	O
their	O	O
outer	O	O
surface	O
.	O	O

We	O	O
also	O	O
demonstrate	O	O
that	O	O
insertion	O
of	O	O
CNTPs	B-CHEM
into	O	O
the	O	O
lipid	B-ANAT
bilayer	I-ANAT
results	O
in	O	O
decreased	O
bilayer	B-ANAT
thickness	O
with	O	O
the	O	O
magnitude	O
of	O	O
this	O	O
effect	O
increasing	O
with	O	O
the	O	O
concentration	O
of	O	O
CNTPs	B-CHEM
.	O	O

Comparisons	O
of	O	O
Safety	B-PHEN
and	O	O
Clinical	O
Outcomes	O
Between	O	O
Multiple	B-PROC
-	I-PROC
level	I-PROC
and	O	O
Single	B-PROC
-	I-PROC
level	I-PROC
Cervical	I-PROC
Disk	I-PROC
Replacement	I-PROC
for	O	O
Cervical	B-DISO
Spondylosis	I-DISO
:	O	O
A	O	O
Systematic	O
Review	O
and	O	O
Meta	O
-	O
analysis	O
This	O	O
is	O	O
a	O	O
systematic	O
review	O
and	O	O
meta	O
-	O
analysis	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	O
the	O	O
efficacy	O
and	O	O
safety	B-PHEN
of	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
cervical	I-PROC
disk	I-PROC
replacement	I-PROC
(	O	O
CDR	B-PROC
)	O	O
over	O	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O	O
the	O	O
treatment	B-PROC
of	O	O
cervical	B-DISO
spondylosis	I-DISO
.	O	O

Some	O	O
authors	O	O
advocate	O	O
for	O	O
the	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
instead	O	O
of	O	O
anterior	O
decompression	B-PROC
and	O	O
fusion	B-PROC
in	O	O
cervical	B-DISO
multiple	I-DISO
-	I-DISO
level	I-DISO
spondylosis	I-DISO
.	O	O

However	O	O
,	O	O
whether	O	O
the	O	O
efficacy	O
and	O	O
safety	B-PHEN
of	O	O
multi	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
are	O	O
as	O	O
favorable	O	O
as	O	O
that	O	O
of	O	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
remains	O	O
controversial	O	O
.	O	O

MEDLINE	O
,	O	O
EMBASE	O
,	O	O
and	O	O
Cochrane	O
library	O
databases	O
were	O	O
searched	O	O
up	O	O
to	O	O
November	O	O
2015	O	O
for	O	O
controlled	B-PROC
studies	I-PROC
that	O	O
compared	O
the	O	O
clinical	O
outcomes	O
of	O	O
single	B-PROC
-	I-PROC
level	I-PROC
and	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O	O
the	O	O
treatment	B-PROC
of	O	O
cervical	B-DISO
spondylosis	I-DISO
.	O	O

The	O	O
following	O	O
outcomes	O
were	O	O
extracted	O	O
and	O	O
analyzed	B-PROC
:	O	O
prevalence	O
of	O	O
heterotopic	B-DISO
ossification	I-DISO
and	O	O
reoperation	B-PROC
,	O	O
preoperative	O
and	O	O
postoperative	O
Neck	B-DISO
Disability	I-DISO
Index	I-DISO
scores	I-DISO
,	O	O
preoperative	O
and	O	O
postoperative	O
Visual	B-PHYS
Analog	I-PHYS
Scale	I-PHYS
scores	I-PHYS
,	O	O
and	O	O
success	O
rate	O
using	O	O
the	O	O
Odom	O
grading	O
system	O
.	O	O

Ten	O	O
studies	B-PROC
involving	O	O
1402	O	O
patients	B-LIVB
were	O	O
included	O	O
:	O	O
including	O	O
3	O	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
,	O	O
5	O	O
prospective	B-PROC
studies	I-PROC
,	O	O
and	O	O
3	O	O
retrospective	B-PROC
studies	I-PROC
.	O	O

No	O	O
significant	O	O
differences	O	O
between	O	O
single	B-PROC
-	I-PROC
level	I-PROC
and	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
groups	O	O
were	O	O
found	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
prevalence	O
of	O	O
heterotopic	B-DISO
ossification	I-DISO
and	O	O
reoperation	B-PROC
rate	O
,	O	O
Neck	B-DISO
Disability	I-DISO
Index	I-DISO
score	I-DISO
,	O	O
Visual	B-PHYS
Analog	I-PHYS
Scale	I-PHYS
score	I-PHYS
,	O	O
and	O	O
success	O
rate	O
using	O	O
the	O	O
Odom	O
grading	O
system	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
this	O	O
meta	O
-	O
analysis	O
,	O	O
clinical	O
outcomes	O
of	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
are	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
for	O	O
cervical	B-DISO
spondylosis	I-DISO
,	O	O
which	O	O
suggests	O	O
the	O	O
multiple	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
is	O	O
as	O	O
effective	O
and	O	O
safe	B-PHEN
as	O	O
the	O	O
single	B-PROC
-	I-PROC
level	I-PROC
CDR	I-PROC
.	O	O

Nonetheless	O	O
,	O	O
more	O	O
well	O	O
-	O	O
designed	O	O
studies	B-PROC
are	O	O
needed	O	O
for	O	O
further	O	O
evaluation	B-PROC
.	O	O

The	O	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
PON2	B-CHEM
protein	I-CHEM
is	O	O
Wnt	B-CHEM
/	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
-	O	O
regulated	B-PHEN
and	O	O
correlates	O
with	O	O
radiotherapy	B-PROC
resistance	O
in	O	O
OSCC	O
patients	B-LIVB
Aberrant	O	O
Wnt	B-PHYS
signaling	I-PHYS
and	O	O
control	O	O
of	O	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
mechanisms	O
are	O	O
pivotal	O	O
features	O	O
in	O	O
different	O	O
types	O	O
of	O	O
cancer	B-DISO
to	O	O
undergo	O	O
cell	B-PHYS
death	I-PHYS
programs	O	O
.	O	O

The	O	O
intracellular	O
human	B-LIVB
enzyme	B-CHEM
Paraoxonase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
PON2	B-CHEM
)	O	O
is	O	O
known	O	O
to	O	O
have	O	O
anti	B-PHYS
-	I-PHYS
apoptotic	I-PHYS
properties	O	O
in	O	O
leukemia	B-DISO
and	O	O
oral	O
squamous	O
cell	O
cancer	O
(	O	O
OSCC	O
)	O	O
cells	B-ANAT
.	O	O

However	O	O
,	O	O
the	O	O
distinct	O	O
regulating	B-PHEN
pathways	O
are	O	O
poorly	O	O
understood	O	O
.	O	O

First	O	O
,	O	O
we	O	O
present	O	O
a	O	O
so	O	O
far	O	O
unknown	O	O
regulation	B-PHEN
of	O	O
PON2	B-CHEM
protein	I-CHEM
expression	B-PHYS
through	O	O
the	O	O
Wnt	B-PHYS
/	O	O
GSK3β	B-CHEM
/	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
pathway	B-PHYS
in	O	O
leukemia	B-DISO
and	O	O
OSCC	O
cells	B-ANAT
.	O	O

This	O	O
was	O	O
confirmed	O	O
via	O	O
in	O	O
silico	B-PROC
analysis	I-PROC
,	O	O
promoter	B-PROC
reporter	I-PROC
studies	I-PROC
and	O	O
treatment	B-PROC
of	O	O
multiple	O	O
cell	B-ANAT
lines	I-ANAT
(	O	O
K562	B-ANAT
,	O	O
SCC	B-ANAT
-	I-ANAT
4	I-ANAT
,	O	O
PCI	B-ANAT
-	I-ANAT
13	I-ANAT
)	O	O
with	O	O
different	O	O
Wnt	B-CHEM
ligands	B-PHYS
/	O	O
inhibitors	B-CHEM
in	O
vitro	O
.	O	O

Ex	O
vivo	O
analysis	B-PROC
of	O	O
OSCC	O
patients	B-LIVB
revealed	O	O
a	O	O
correlation	O
between	O	O
PON2	B-CHEM
and	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
expression	B-PHYS
in	O	O
tumor	O
tissue	O
.	O	O

Higher	O	O
PON2	B-CHEM
expression	B-PHYS
in	O	O
OSCC	O
is	O	O
associated	O
with	O
relapse	B-PHEN
independently	O	O
of	O	O
treatment	B-PROC
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O
surgery	B-PROC
/	O	O
radio	B-PROC
-	O	O
/	O	O
chemotherapy	B-PROC
)	O	O
.	O	O

These	O	O
results	O	O
emphasize	O	O
the	O	O
clinical	O
impact	O	O
of	O	O
the	O	O
newly	O	O
described	O	O
regulation	B-PHEN
of	O	O
PON2	B-CHEM
through	O	O
Wnt	B-CHEM
/	O	O
GSK3β	B-CHEM
/	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
.	O	O

More	O	O
importantly	O	O
,	O	O
the	O	O
study	O	O
revealed	O	O
the	O	O
fundamental	B-DISO
finding	I-DISO
of	O	O
an	O	O
overall	O	O
Wnt	B-CHEM
/	O	O
GSK3β	B-CHEM
/	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
dependent	O	O
regulation	B-PHEN
of	O	O
PON2	B-CHEM
in	O	O
different	O	O
cancers	B-DISO
,	O	O
which	O	O
was	O	O
confirmed	O	O
by	O	O
systematic	O
and	O	O
multimethodological	O
approaches	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
herein	O	O
presented	O	O
mechanistic	O	O
insight	O	O
contributes	O	O
to	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
tumor	B-DISO
specific	O	O
escape	O	O
from	O	O
cell	B-PHYS
death	I-PHYS
strategies	O	O
and	O	O
suggests	O	O
PON2	B-CHEM
as	O	O
a	O	O
new	O	O
potential	O
biomarker	B-PHYS
for	O	O
therapy	B-PROC
resistance	O
or	O	O
as	O	O
a	O	O
prognostic	O
tumor	B-CHEM
marker	I-CHEM
.	O	O

Has	O	O
dementia	B-DISO
research	B-PROC
lost	O	O
its	O	O
sense	O
of	O
reality	O
?	O	O

A	O	O
descriptive	O	O
analysis	O	O
of	O	O
eligibility	O
criteria	O
of	O	O
Dutch	B-LIVB
dementia	B-DISO
research	B-PROC
protocols	I-PROC
A	O	O
substantial	O	O
proportion	O	O
of	O	O
dementia	B-DISO
patients	B-LIVB
are	O	O
excluded	O	O
from	O	O
research	B-PROC
participation	O
,	O	O
while	O	O
for	O	O
extrapolation	B-DISO
of	O	O
the	O	O
study	B-PROC
findings	O	O
,	O	O
it	O	O
is	O	O
important	O	O
that	O	O
the	O	O
research	B-PROC
population	O
represents	O	O
the	O	O
patient	O
population	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
provide	O	O
an	O	O
analysis	O	O
of	O	O
dementia	B-DISO
research	B-PROC
and	O	O
its	O	O
exclusion	O
criteria	O
in	O	O
order	O	O
to	O	O
get	O	O
a	O	O
clearer	O	O
picture	O	O
whether	O	O
the	O	O
research	B-PROC
participants	B-LIVB
represent	O	O
the	O	O
general	O	O
dementia	B-DISO
population	O
.	O	O

Dementia	B-DISO
studies	B-PROC
registered	O	O
at	O	O
ToetsingOnline	O
.	O

nl	O
between	O	O
2006	O	O
-	O	O
2015	O	O
were	O	O
analysed	B-PROC
.	O	O

Study	B-PROC
characteristics	O
,	O	O
funding	O
and	O	O
eligibility	O
criteria	O
were	O	O
described	O	O
and	O	O
analysed	O	O
using	O	O
a	O	O
standardised	O
score	O
sheet	O
.	O	O

The	O	O
search	O	O
yielded	O	O
103	O	O
usable	O	O
study	O
protocols	O
.	O	O

The	O	O
number	O	O
of	O	O
trials	B-PROC
has	O	O
increased	O	O
over	O	O
the	O	O
years	O	O
,	O	O
and	O	O
35	O	O
%	O	O
of	O	O
the	O	O
studies	B-PROC
were	O	O
industry	O
-	O	O
financed	O
.	O	O

Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
was	O	O
the	O	O
most	O	O
researched	B-PROC
type	O	O
of	O	O
dementia	B-DISO
(	O	O
84	O	O
%	O	O
)	O	O
.	O	O

In	O	O
observational	O	O
studies	O	O
the	O	O
most	O	O
frequently	O	O
observed	O	O
exclusion	O
criterion	O
is	O	O
a	O	O
neurological	B-DISO
condition	I-DISO
,	O	O
while	O	O
in	O	O
drug	B-PROC
studies	I-PROC
and	O	O
other	O	O
intervention	B-PROC
studies	I-PROC
this	O	O
is	O	O
a	O	O
somatic	O
condition	O
.	O	O

Of	O	O
all	O	O
protocols	O
,	O	O
86	O	O
%	O	O
had	O	O
at	O	O
least	O	O
one	O	O
exclusion	O
criterion	O
concerning	O	O
comorbidity	O
.	O	O

Most	O	O
studies	B-PROC
focused	O	O
on	O	O
mild	B-DISO
or	O	O
moderate	B-DISO
dementia	I-DISO
(	O	O
78	O	O
%	O	O
)	O	O
.	O	O

Our	O	O
study	B-PROC
has	O	O
shown	O	O
that	O	O
the	O	O
distribution	O
of	O	O
dementia	B-DISO
research	B-PROC
over	O	O
the	O	O
different	O	O
subtypes	O
of	O	O
dementia	B-DISO
does	O	O
not	O	O
correspond	O	O
with	O	O
the	O	O
prevalence	O
of	O	O
these	O	O
subtypes	O
in	O	O
clinical	B-PROC
practice	I-PROC
.	O	O

The	O	O
research	B-PROC
population	O
in	O	O
the	O	O
protocols	O
is	O	O
not	O	O
representative	O	O
of	O	O
the	O	O
larger	O	O
patient	O
population	O
.	O	O

A	O	O
greater	O	O
number	O	O
of	O	O
dementia	B-DISO
patients	B-LIVB
could	O	O
derive	O	O
benefit	O	O
from	O	O
the	O	O
conducted	O	O
research	B-PROC
if	O	O
the	O	O
research	B-PROC
agenda	I-PROC
were	O	O
more	O	O
closely	O	O
aligned	O	O
with	O	O
disease	O
prevalence	O
.	O	O

A	O	O
better	O	O
representation	O	O
of	O	O
all	O	O
dementia	B-DISO
patients	B-LIVB
in	O	O
research	B-PROC
will	O	O
help	O	O
to	O	O
meet	O	O
the	O	O
needs	O	O
of	O	O
these	O	O
patients	B-LIVB
.	O	O

Tissue	O
-selective	O	O
inflammation	B-DISO
in	O	O
the	O	O
oral	B-ANAT
cavity	I-ANAT
of	O	O
the	O	O
rat	B-LIVB
In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
carrageenan	B-CHEM
(	O	O
CG	B-CHEM
;	O	O
100	O	O
-	O	O
1000	O	O
μg	O	O
/	O	O
site	O	O
)	O	O
was	O	O
injected	O
intraorally	O
in	O	O
the	O	O
cheeks	B-ANAT
of	O	O
Holtzman	B-LIVB
or	O	O
Wistar	B-LIVB
rats	I-LIVB
to	O	O
evaluate	O	O
the	O	O
consequences	O	O
of	O	O
administration	B-PROC
of	O	O
a	O	O
non	B-DISO
-	I-DISO
immunogenic	I-DISO
stimulus	B-PHEN
in	O	O
the	O	O
orofacial	O
region	O
.	O	O

Subsequent	O	O
inflammation	B-DISO
was	O	O
measured	O	O
as	O	O
oedema	B-DISO
(	O	O
increased	B-DISO
thickness	I-DISO
of	O	O
the	O	O
cheek	B-ANAT
wall	I-ANAT
using	O	O
digital	B-DEVI
calipers	I-DEVI
)	O	O
,	O	O
relative	O	O
to	O	O
the	O	O
other	O	O
cheek	B-ANAT
injected	O
with	O	O
saline	B-OBJC
.	O	O

Oedema	B-DISO
formation	O
and	O	O
tissue	O
collection	O	O
for	O	O
histopathological	O
studies	O
were	O	O
assessed	O	O
at	O	O
0	O	O
.	O	O

5	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
24	O	O
,	O	O
48	O	O
,	O	O
72	O	O
,	O	O
96	O	O
,	O	O
120	O	O
and	O	O
144	O	O
h	O	O
after	O	O
injection	B-PROC
.	O	O

In	O	O
parallel	O	O
,	O	O
other	O	O
groups	O	O
of	O	O
rats	B-LIVB
were	O	O
injected	O
with	O	O
CG	B-CHEM
in	O	O
the	O	O
hind	B-ANAT
paw	I-ANAT
,	O	O
to	O	O
provide	O	O
a	O	O
reference	O	O
response	O	O
.	O	O

The	O	O
inhibitor	B-CHEM
of	O	O
prostaglandin	B-PHYS
biosynthesis	I-PHYS
,	O	O
indomethacin	B-CHEM
,	O	O
and	O	O
antagonists	B-CHEM
of	I-CHEM
histamine	I-CHEM
,	O	O
serotonin	B-CHEM
and	O	O
NK1	B-PHYS
receptors	I-PHYS
were	O	O
injected	O
s	O	O
.	O	O

c	O	O
.	O	O
,	O	O
0	O	O
.	O	O
5	O	O
h	O	O
before	O	O
CG	B-CHEM
.	O	O

CG	B-CHEM
induced	O	O
a	O	O
dose	O
-related	O	O
oedema	B-DISO
more	O	O
rapidly	O	O
from	O	O
0	O	O
to	O	O
2	O	O
h	O	O
which	O	O
lasted	O	O
for	O	O
at	O	O
least	O	O
72	O	O
h	O	O
,	O	O
showing	O	O
a	O	O
biphasic	O
profile	O
(	O	O
peak	O	O
at	O	O
2	O	O
and	O	O
24	O	O
h	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
monophasic	O
oedema	B-DISO
induced	O	O
in	O	O
rat	B-LIVB
paws	B-ANAT
(	O	O
maximal	O	O
duration	O	O
of	O	O
24	O	O
h	O	O
)	O	O
.	O	O

Histopathological	O
analysis	B-PROC
of	O	O
the	O	O
CG	B-CHEM
-	O	O
injected	O
cheek	B-ANAT
revealed	O	O
oedema	B-DISO
formation	O
with	O	O
little	O	O
leukocyte	B-ANAT
recruitment	B-PHYS
at	O	O
1	O	O
-	O	O
3	O	O
h	O	O
,	O	O
mast	B-PHYS
cell	I-PHYS
degranulation	I-PHYS
at	O	O
6	O	O
h	O	O
,	O	O
and	O	O
a	O	O
mixed	O	O
polymorphonuclear	B-DISO
and	O	O
mononuclear	B-DISO
cell	I-DISO
infiltrate	I-DISO
by	O	O
24	O	O
h	O	O
.	O	O

Histamine	B-CHEM
and	O	O
serotonin	B-CHEM
antagonists	I-CHEM
and	O	O
indomethacin	B-CHEM
,	O	O
but	O	O
not	O	O
the	O	O
NK1	B-PHYS
antagonist	I-PHYS
,	O	O
decreased	O	O
cheek	B-ANAT
oedema	B-DISO
in	O	O
the	O	O
first	O	O
4	O	O
h	O	O
following	O	O
carrageenan	B-CHEM
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
data	O	O
indicated	O	O
important	O	O
differences	O	O
in	O	O
the	O	O
pattern	O	O
of	O	O
inflammation	B-DISO
between	O	O
the	O	O
oral	B-ANAT
cavity	I-ANAT
and	O	O
the	O	O
paw	B-ANAT
which	O	O
will	O	O
determine	O	O
the	O	O
therapeutic	O
approach	O
to	O	O
the	O	O
treatment	B-PROC
of	O	O
inflammatory	O
conditions	O
in	O	O
the	O	O
oral	B-ANAT
cavity	I-ANAT
.	O	O

Mercury	B-CHEM
Mining	O
in	O	O
Mexico	B-GEOG
:	O	O
I	O	O
.	O	O

Community	O
Engagement	O
to	O	O
Improve	B-DISO
Health	B-DISO
Outcomes	I-DISO
from	O	O
Artisanal	O
Mining	O
Mercury	B-CHEM
is	O	O
an	O	O
element	B-CHEM
that	O	O
cannot	O	O
be	O	O
destroyed	O
and	O	O
is	O	O
a	O	O
global	O
threat	O	O
to	O	O
human	B-LIVB
and	O	O
environmental	O
health	O
.	O	O

In	O	O
Latin	B-GEOG
America	I-GEOG
and	O	O
the	O	O
Caribbean	B-GEOG
,	O	O
artisanal	O
and	O	O
small	O	O
-	O	O
scale	O	O
gold	B-CHEM
mining	O
represents	O	O
the	O	O
main	O
source	B-DISO
of	O	O
mercury	B-CHEM
emissions	B-CHEM
,	O	O
releases	B-PHEN
,	O	O
and	O	O
consumption	O
.	O	O

However	O	O
,	O	O
another	O	O
source	B-DISO
of	O	O
concern	O
is	O	O
the	O	O
primary	O
production	B-CHEM
of	O	O
mercury	B-CHEM
.	O	O

In	O	O
the	O	O
case	O	O
of	O	O
Mexico	B-GEOG
,	O	O
in	O	O
the	O	O
past	O	O
2	O	O
years	O	O
the	O	O
informal	O	O
production	B-CHEM
of	O	O
mercury	B-CHEM
mining	O
has	O	O
increased	O
10	O	O
-	O	O
fold	O	O
.	O	O

Considering	O	O
this	O	O
scenario	O
,	O	O
an	O	O
intervention	B-PROC
program	I-PROC
was	O	O
initiated	O	O
to	O	O
reduce	O
health	O
risks	O
in	O	O
the	O	O
mining	O
communities	B-LIVB
.	O	O

The	O	O
program	B-PROC
's	I-PROC
final	O	O
goal	O
is	O	O
to	O	O
introduce	O
different	O	O
alternatives	O
in	O	O
line	O	O
to	O	O
stop	O
the	O	O
mining	O
of	O	O
mercury	B-CHEM
,	O	O
but	O	O
introducing	O	O
at	O	O
the	O	O
same	O	O
time	O	O
,	O	O
a	O	O
community	B-LIVB
-based	O	O
development	O
program	O
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
present	O	O
results	B-DISO
from	O	O
a	O	O
preliminary	O
study	B-PROC
in	O	O
the	O	O
community	B-LIVB
of	O	O
Plazuela	B-GEOG
,	O	O
located	O
in	O	O
the	O	O
municipality	B-GEOG
of	O	O
Peñamiller	B-GEOG
in	O	O
the	O	O
State	B-GEOG
of	I-GEOG
Queretaro	I-GEOG
,	O	O
Mexico	B-GEOG
.	O	O

Total	O
mercury	B-CHEM
was	O	O
measured	O
in	O	O
urine	B-ANAT
and	O	O
environmental	O
samples	B-OBJC
using	O	O
atomic	B-PROC
absorption	I-PROC
spectrometry	I-PROC
by	I-PROC
cold	I-PROC
vapor	I-PROC
technique	I-PROC
.	O	O

Urine	B-ANAT
samples	I-ANAT
were	O	O
collected	O
from	O	O
children	B-LIVB
aged	O	O
6	O	O
-	O	O
14	O	O
years	O
and	O	O
who	O	O
had	O	O
lived	O	O
in	O	O
the	O	O
selected	O	O
area	B-GEOG
from	O	O
birth	B-PHYS
.	O	O

Urine	B-ANAT
samples	I-ANAT
were	O	O
also	O	O
collected	O
from	O	O
miners	B-LIVB
who	O	O
were	O	O
currently	O
working	O
in	O	O
the	O	O
mine	O
.	O	O

To	O	O
confirm	B-DISO
the	O	O
presence	B-DISO
of	O	O
mercury	B-CHEM
in	O	O
the	O	O
community	B-LIVB
,	O	O
mining	B-OBJC
waste	I-OBJC
,	O	O
water	B-CHEM
,	O	O
soil	B-OBJC
,	O	O
and	O	O
sediment	B-OBJC
samples	I-OBJC
were	O	O
collected	O
from	O	O
those	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
areas	I-DISO
identified	O
by	O	O
members	B-LIVB
of	O	O
the	O	O
community	B-LIVB
.	O	O

Children	B-LIVB
,	O	O
women	B-LIVB
,	O	O
and	O	O
miners	B-LIVB
were	O	O
heavily	O
exposed	O
to	O
mercury	B-CHEM
(	O	O
urine	B-ANAT
samples	I-ANAT
)	O	O
;	O	O
and	O	O
in	O	O
agreement	O
,	O	O
we	O	O
registered	B-PROC
high	O
concentrations	O
of	O	O
mercury	B-CHEM
in	O	O
soils	B-OBJC
and	O	O
sediments	B-OBJC
.	O	O

Considering	O	O
these	O	O
results	B-DISO
and	O	O
taking	O	O
into	O	O
account	O	O
that	O	O
the	O	O
risk	O
perception	O	O
toward	O	O
mercury	B-CHEM
toxicity	O
is	O	O
very	B-DISO
low	I-DISO
in	O	O
the	O	O
community	B-LIVB
(	O	O
mining	O
is	O	O
the	O	O
only	O	O
economic	O
activity	O
)	O	O
,	O	O
an	O	O
integral	B-PROC
intervention	I-PROC
program	I-PROC
has	O	O
started	O
.	O	O

Molecular	O
serum	B-ANAT
signature	B-PHYS
of	O	O
treatment	B-DISO
resistant	I-DISO
depression	I-DISO
A	O	O
substantial	O	O
number	O	O
of	O	O
patients	O	O
suffering	O	O
from	O	O
major	B-DISO
depressive	I-DISO
disorder	I-DISO
(	O	O
MDD	B-DISO
)	O	O
do	O	O
not	O	O
respond	O	O
to	O	O
multiple	O
trials	B-PROC
of	O	O
anti	B-CHEM
-	I-CHEM
depressants	I-CHEM
,	O	O
develop	O	O
a	O	O
chronic	O
course	B-DISO
of	I-DISO
disease	I-DISO
and	O	O
become	O	O
treatment	B-PROC
resistant	B-PHYS
.	O	O

Most	O	O
of	O	O
the	O	O
studies	O	O
investigating	O	O
molecular	O
changes	O
in	O	O
treatment	B-DISO
-	I-DISO
resistant	I-DISO
depression	I-DISO
(	O	O
TRD	B-DISO
)	O	O
have	O	O
only	O	O
examined	O	O
a	O	O
limited	O	O
number	O	O
of	O	O
molecules	O	O
and	O	O
genes	O
.	O	O

Consequently	O	O
,	O	O
biomarkers	B-PHYS
associated	O	O
with	O	O
TRD	B-DISO
are	O	O
still	O	O
lacking	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
use	O	O
recently	O	O
advanced	O	O
high	O
-	O
throughput	O
proteomic	O
platforms	O
to	O	O
identify	O	O
peripheral	O
biomarkers	B-PHYS
of	O	O
TRD	B-DISO
defined	O	O
by	O	O
two	O	O
staging	O
models	O
,	O	O
the	O	O
Thase	O
and	O
Rush	O
staging	O
model	O
(	O	O
TRM	O
)	O	O
and	O	O
the	O	O
Maudsley	O
Staging	O
Model	O
(	O	O
MSM	O
)	O	O
.	O	O

Serum	B-ANAT
collected	O	O
from	O	O
an	O	O
inpatient	B-LIVB
cohort	O	O
of	O	O
65	O	O
individuals	B-LIVB
suffering	O	O
from	O	O
MDD	B-DISO
was	O	O
analysed	O	O
using	O	O
two	O	O
different	O	O
mass	B-PROC
spectrometric	I-PROC
-	I-PROC
based	I-PROC
platforms	I-PROC
,	O	O
label	B-PROC
-	I-PROC
free	I-PROC
liquid	I-PROC
chromatography	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O	O
LC	B-PROC
-	I-PROC
MS	I-PROC
(	I-PROC
E	I-PROC
)	I-PROC
)	O	O
and	O	O
selective	O
reaction	O
monitoring	O
(	O	O
SRM	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
multiplex	B-PROC
bead	I-PROC
based	I-PROC
assay	I-PROC
.	O	O

In	O	O
the	O	O
LC	B-PROC
-	I-PROC
MS	I-PROC
(	I-PROC
E	I-PROC
)	I-PROC
analysis	I-PROC
,	O	O
proteins	B-CHEM
involved	O	O
in	O	O
the	O	O
acute	B-DISO
phase	I-DISO
response	I-DISO
and	O	O
complement	B-PHYS
activation	I-PHYS
and	O	O
coagulation	B-PHYS
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
staging	O
groups	O
in	O	O
both	O	O
models	O
.	O	O

In	O	O
the	O	O
multiplex	B-PROC
bead	I-PROC
-	I-PROC
based	I-PROC
assay	I-PROC
analysis	O	O
TNF	B-PROC
-	I-PROC
α	I-PROC
levels	I-PROC
(	O	O
log	O
(	O
odds	O
)	O
=	O	O
-4	O	O
.	O	O
95	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

045	O	O
)	O	O
were	O	O
significantly	O
different	O
in	O	O
the	O	O
TRM	O
comparison	O
.	O	O

Using	O	O
SRM	O
,	O	O
significant	O
changes	O
of	O	O
three	O	O
apolipoproteins	B-CHEM
A	I-CHEM
-	I-CHEM
I	I-CHEM
(	O	O
β	O	O
=	O	O
0	O	O
.	O	O

029	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
035	O	O
)	O	O
,	O	O
M	B-CHEM
(	O	O
β	O	O
=	O	O
-0	O	O
.	O	O

017	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
009	O	O
)	O	O
and	O	O
F	B-CHEM
(	O	O
β	O	O
=	O	O
-0	O	O
.	O	O
031	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
024	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
the	O	O
TRM	O
but	O	O
not	O	O
the	O	O
MSM	O
.	O	O

Overall	O	O
,	O	O
our	O	O
findings	B-DISO
suggest	O	O
that	O	O
proteins	B-CHEM
,	O	O
which	O	O
are	O	O
involved	O	O
in	O	O
immune	B-PHYS
and	O	O
complement	B-PHYS
activation	I-PHYS
,	O	O
may	O	O
represent	O	O
potential	O	O
biomarkers	B-PHYS
that	O	O
could	O	O
be	O	O
used	O	O
by	O	O
clinicians	B-LIVB
to	O	O
identify	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
.	O	O

Nevertheless	O	O
,	O	O
given	O	O
that	O	O
the	O	O
molecular	O
changes	O
between	O	O
the	O	O
staging	O
groups	O
were	O	O
subtle	O	O
,	O	O
the	O	O
results	O	O
need	O	O
to	O	O
be	O	O
interpreted	O
cautiously	O	O
.	O	O

Benchmark	O	O
study	B-PROC
on	O	O
fine	B-OBJC
-	I-OBJC
mode	I-OBJC
aerosol	I-OBJC
in	O	O
a	O	O
big	O
urban	O
area	O
and	O	O
relevant	O
doses	O
deposited	O
in	O	O
the	O	O
human	B-LIVB
respiratory	B-ANAT
tract	I-ANAT
It	O	O
is	O	O
well	O	O
-	O	O
known	O	O
that	O	O
the	O	O
health	O
effects	O
of	O	O
PM	B-CHEM
increase	O	O
as	O	O
particle	O
size	O
decreases	O	O
:	O	O
particularly	O	O
,	O	O
great	O	O
concern	O	O
has	O	O
risen	O	O
on	O	O
the	O	O
role	O	O
of	O	O
UltraFine	B-CHEM
Particles	I-CHEM
(	O	O
UFPs	B-CHEM
)	O	O
.	O	O

Starting	O	O
from	O	O
the	O	O
knowledge	O	O
that	O	O
the	O	O
main	O	O
fraction	O
of	O
atmospheric	B-PHEN
aerosol	B-OBJC
in	O	O
Rome	B-GEOG
is	O	O
characterized	O	O
by	O	O
significant	O	O
levels	O
of	O	O
PM2	B-CHEM
.	I-CHEM

5	I-CHEM
(	O	O
almost	O	O
75	O	O
%	O	O
of	O	O
PM10	B-CHEM
fraction	O	O
is	O	O
PM2	B-CHEM
.	I-CHEM

5	I-CHEM
)	O	O
,	O	O
the	O	O
paper	O	O
is	O	O
focused	O	O
on	O	O
submicron	B-CHEM
particles	I-CHEM
in	O	O
such	O	O
great	O
urban	O
area	O
.	O	O

The	O	O
daytime	O
/	O	O
nighttime	O
,	O	O
work	O
-	O
/	O	O
weekdays	O
and	O	O
cold	B-PHEN
/	O	O
hot	B-PHEN
seasonal	O
trends	O
of	O	O
submicron	B-CHEM
particles	I-CHEM
will	O	O
be	O	O
investigated	O	O
and	O	O
discussed	O	O
along	O	O
with	O	O
NOx	B-CHEM
and	O	O
total	O	O
PAH	B-CHEM
drifts	O	O
demonstrating	O	O
the	O	O
primary	O	O
origin	O	O
of	O	O
UFPs	B-CHEM
from	O	O
combustion	B-PHEN
processes	I-PHEN
.	O	O

Furthermore	O	O
,	O	O
moving	O	O
from	O	O
these	O	O
data	O	O
,	O	O
the	O	O
total	O	O
dose	O
of	O	O
submicron	B-CHEM
particles	I-CHEM
deposited	O
in	O	O
the	O	O
respiratory	B-ANAT
system	I-ANAT
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
head	B-ANAT
,	O	O
tracheobronchial	B-ANAT
and	O	O
alveolar	B-ANAT
regions	I-ANAT
in	O	O
different	O	O
lung	B-ANAT
lobes	I-ANAT
)	O	O
has	O	O
been	O	O
estimated	O	O
.	O	O

Dosimeter	B-DEVI
estimates	O
were	O	O
performed	O	O
with	O	O
the	O	O
Multiple	O
-	O
Path	O
Particle	O
Dosimetry	O
model	O
(	O	O
MPPD	O
v	O
.	O
2	O
.	O
1	O
)	O	O
.	O	O

The	O	O
paper	O	O
discusses	O	O
the	O	O
aerosol	B-OBJC
doses	O
deposited	O
in	O	O
the	O	O
respiratory	B-ANAT
system	I-ANAT
of	O	O
individuals	B-LIVB
exposed	O
in	O	O
proximity	O	O
of	O	O
traffic	B-DISO
.	O	O

During	O	O
traffic	B-DISO
peak	O	O
hours	O
,	O	O
about	O	O
6	O	O
.	O	O

6	O	O
×	O	O
10	O	O
(	O	O
10	O	O
)	O	O
particles	B-CHEM
are	O	O
deposited	O
into	O	O
the	O	O
respiratory	B-ANAT
system	I-ANAT
.	O	O

Such	O	O
dose	O
is	O	O
almost	O	O
entirely	O	O
made	O	O
of	O	O
UFPs	B-CHEM
.	O	O

According	O	O
to	O	O
the	O	O
greater	O	O
dose	O
estimated	O
,	O	O
right	B-ANAT
lung	I-ANAT
lobes	I-ANAT
are	O	O
expected	O	O
to	O	O
be	O	O
more	O	O
susceptible	O
to	O	O
respiratory	O
pathologies	B-DISO
than	O	O
left	B-ANAT
lobes	I-ANAT
.	O	O

Anomalous	B-DISO
Left	B-ANAT
Anterior	I-ANAT
Descending	I-ANAT
Coronary	I-ANAT
Artery	I-ANAT
Arising	O	O
from	O	O
Pulmonary	B-ANAT
Artery	I-ANAT
in	O	O
a	O	O
63	O	O
Year	O	O
-	O	O
old	O	O
Male	B-PHYS
Patient	I-PHYS
:	O	O
Case	O
Report	O
and	O	O
Literature	O
Review	O
To	O	O
present	O
a	O	O
case	O
of	O	O
a	O	O
rare	O
congenital	B-DISO
coronary	I-DISO
anomaly	I-DISO
in	O	O
an	O	O
adult	B-LIVB
patient	B-LIVB
,	O	O
which	O	O
was	O	O
not	O	O
reported	B-PROC
before	O	O
in	O	O
Palestine	B-GEOG
,	O	O
review	O
the	O	O
literature	O
,	O	O
and	O	O
compare	O
with	O	O
previously	O	O
reported	O
cases	O
.	O	O

International	O
Liver	O
Transplant	O
Society	O
Practice	O
Guidelines	O
:	O	O
Diagnosis	B-DISO
and	O	O
Management	B-PROC
of	O	O
Hepatopulmonary	B-DISO
Syndrome	I-DISO
and	O	O
Portopulmonary	B-DISO
Hypertension	I-DISO
Two	O	O
distinct	O	O
pulmonary	B-DISO
vascular	I-DISO
disorders	I-DISO
,	O	O
hepatopulmonary	B-DISO
syndrome	I-DISO
(	O	O
HPS	B-DISO
)	O	O
and	O	O
portopulmonary	B-DISO
hypertension	I-DISO
(	O	O
POPH	B-DISO
)	O	O
may	O	O
occur	O	O
as	O	O
a	O	O
consequence	O
of	O
hepatic	B-ANAT
parenchymal	I-ANAT
or	O	O
vascular	B-DISO
abnormalities	I-DISO
.	O	O

HPS	B-DISO
and	O	O
POPH	B-DISO
have	O	O
major	O	O
clinical	O
implications	B-DISO
for	O	O
liver	B-PROC
transplantation	I-PROC
.	O	O

A	O	O
European	O
Respiratory	O
Society	O
Task	O
Force	O
on	O	O
Pulmonary	B-DISO
-	I-DISO
Hepatic	I-DISO
Disorders	I-DISO
convened	O	O
in	O	O
2002	O	O
to	O	O
standardize	O	O
the	O	O
diagnosis	B-DISO
and	O	O
guide	O
management	O
of	O	O
these	O	O
disorders	B-DISO
.	O	O

These	O	O
International	O
Liver	O
Transplant	O
Society	O
diagnostic	O
and	O
management	O
guidelines	O
are	O	O
based	O	O
on	O	O
that	O	O
task	O
force	O
consensus	O	O
and	O	O
should	O	O
continue	O	O
to	O	O
evolve	O	O
as	O	O
clinical	O
experience	O	O
dictates	O	O
.	O	O

Based	O	O
on	O	O
a	O	O
review	O	O
of	O	O
over	O	O
1000	O	O
published	O	O
HPS	B-DISO
and	O	O
POPH	B-DISO
articles	O	O
identified	O	O
via	O	O
a	O	O
MEDLINE	O
search	O
(	O	O
1985	O	O
-	O	O
2015	O	O
)	O	O
,	O	O
clinical	O
guidelines	O
were	O	O
based	O	O
on	O	O
,	O	O
selected	B-PROC
single	I-PROC
care	I-PROC
reports	I-PROC
,	O	O
small	O
series	O
,	O	O
registries	O
,	O	O
databases	O
,	O	O
and	O	O
expert	O
opinion	O
.	O	O

The	O	O
paucity	O	O
of	O	O
randomized	B-PROC
,	I-PROC
controlled	I-PROC
trials	I-PROC
in	O	O
either	O	O
of	O	O
these	O	O
disorders	B-DISO
was	O	O
noted	O	O
.	O	O

Guidelines	O
are	O	O
presented	O	O
in	O	O
5	O	O
parts	O	O
;	O	O
I	O	O
.	O	O

Definitions	O
/	O	O
Diagnostic	O
criteria	O
;	O	O
II	O	O
.	O	O

Hepatopulmonary	B-DISO
syndrome	I-DISO
;	O	O
III	O	O
.	O	O

Portopulmonary	B-DISO
hypertension	I-DISO
;	O	O
IV	O	O
.	O	O

Implications	B-DISO
for	O	O
liver	B-PROC
transplantation	I-PROC
;	O	O
and	O	O
V	O	O
.	O	O

Suggestions	O
for	O	O
future	O	O
clinical	B-PROC
research	I-PROC
.	O	O

Prevalence	O
of	O	O
Coronary	B-DISO
Artery	I-DISO
to	O	O
Pulmonary	B-DISO
Artery	I-DISO
Collaterals	I-DISO
in	O	O
Patients	B-LIVB
with	O	O
Chronic	B-DISO
Thromboembolic	I-DISO
Pulmonary	I-DISO
Hypertension	I-DISO
:	O	O
Retrospective	B-PROC
Analysis	I-PROC
from	O	O
a	O	O
Single	O	O
Center	O	O
Background	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O
of	O	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
in	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
thromboembolic	I-DISO
pulmonary	I-DISO
hypertension	I-DISO
(	O	O
CTEPH	B-DISO
)	O	O
by	O	O
retrospectively	B-PROC
evaluating	O	O
coronary	B-PROC
angiograms	I-PROC
of	O	O
eligible	O	O
consecutive	O
patients	B-LIVB
who	O	O
had	O	O
undergone	O	O
pulmonary	B-PROC
endarterectomy	I-PROC
(	O	O
PEA	B-PROC
)	O	O
.	O	O

We	O	O
also	O	O
aimed	O	O
to	O	O
evaluate	B-PROC
predictors	O
and	O	O
potential	O	O
clinical	O
associates	O
of	O	O
these	O	O
collaterals	B-ANAT
.	O	O

Methods	O	O
Coronary	B-PROC
angiograms	I-PROC
of	O	O
83	O	O
consecutive	O
CTEPH	B-DISO
patients	B-LIVB
who	O	O
had	O	O
undergone	O	O
coronary	B-PROC
angiography	I-PROC
before	O	O
PEA	B-PROC
operation	B-PROC
between	O	O
January	O
1	O	O
,	O	O
2012	O	O
and	O	O
June	O
1	O	O
,	O	O
2015	O	O
were	O	O
retrospectively	B-PROC
evaluated	B-PROC
for	O	O
presence	O	O
of	O	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
.	O	O

Medical	O
records	O
of	O	O
all	O	O
patients	B-LIVB
were	O	O
also	O	O
retrospectively	B-PROC
reviewed	O	O
for	O	O
demographic	B-DISO
information	I-DISO
,	O	O
cardiovascular	B-DISO
risk	I-DISO
factors	I-DISO
,	O	O
preoperative	O
right	O
heart	O
catheterization	O
reports	O
,	O	O
operation	O
reports	O
,	O	O
and	O	O
follow	O
-	O
up	O
data	O
.	O	O

Data	O
of	O	O
CTEPH	B-DISO
patients	B-LIVB
with	O	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
were	O	O
compared	O	O
with	O	O
data	O	O
of	O	O
CTEPH	B-DISO
patients	B-LIVB
without	O	O
such	O	O
collaterals	B-ANAT
.	O	O

Results	O	O
There	O	O
were	O	O
15	O	O
patients	B-LIVB
(	O	O
18	O	O
.	O	O
1	O	O
%	O	O
)	O	O
with	O	O
definite	O
and	O	O
4	O	O
patients	B-LIVB
(	O	O
4	O	O
.	O	O
8	O	O
%	O	O
)	O	O
with	O	O
probable	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
among	O	O
the	O	O
study	B-LIVB
population	I-LIVB
.	O	O

CTEPH	B-DISO
patients	B-LIVB
with	O	O
collaterals	B-ANAT
had	O	O
higher	O	O
preoperative	O
pulmonary	B-PHEN
artery	I-PHEN
pressures	I-PHEN
,	O	O
higher	O
pulmonary	B-DISO
vascular	I-DISO
resistance	I-DISO
(	O	O
PVR	B-DISO
)	O	O
and	O	O
lower	O
cardiac	B-DISO
index	I-DISO
values	I-DISO
compared	O	O
with	O	O
CTEPH	B-DISO
patients	B-LIVB
without	O	O
collaterals	B-ANAT
.	O	O

However	O	O
,	O	O
CTEPH	B-DISO
patients	B-LIVB
with	O	O
collaterals	B-ANAT
displayed	O	O
higher	O	O
amount	O	O
of	O	O
reduction	B-DISO
in	I-DISO
PVR	I-DISO
after	O	O
PEA	B-PROC
compared	O	O
with	O	O
patients	B-LIVB
without	O	O
collaterals	B-ANAT
.	O	O

There	O	O
were	O	O
no	B-DISO
significant	I-DISO
differences	I-DISO
between	O	O
groups	O
regarding	O	O
incidence	O
of	O	O
reperfusion	B-DISO
injury	I-DISO
or	O	O
mortality	O
.	O	O

Conclusion	O	O
Prevalence	O
of	O	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
seems	O	O
to	O	O
be	O	O
increased	O	O
in	O	O
our	O	O
CTEPH	B-DISO
patients	B-LIVB
compared	O	O
with	O	O
the	O	O
general	B-LIVB
population	I-LIVB
.	O	O

The	O	O
presence	O	O
of	O	O
coronary	B-DISO
artery	I-DISO
-	O	O
pulmonary	B-DISO
artery	I-DISO
collaterals	I-DISO
is	O	O
often	O	O
combined	O	O
with	O	O
proximal	O
disease	B-DISO
with	O	O
the	O	O
possibility	O	O
of	O	O
increased	O	O
reduction	B-DISO
of	I-DISO
PVR	I-DISO
after	O	O
PEA	B-PROC
operation	O	O
.	O	O

Uveitis	B-DISO
in	O	O
children	B-LIVB
The	O	O
review	O	O
provides	O	O
updates	O	O
on	O	O
novel	O
risk	O
markers	O
for	O	O
the	O	O
development	O
of	O	O
pediatric	O
inflammatory	B-DISO
uveitis	I-DISO
and	O	O
a	O	O
severe	B-DISO
disease	I-DISO
course	I-DISO
,	O	O
on	O	O
treatment	B-PROC
of	O	O
refractory	B-DISO
disease	I-DISO
,	O	O
and	O	O
on	O	O
the	O	O
measurement	O
of	O	O
visual	O
outcomes	O
.	O	O

There	O	O
are	O	O
several	O	O
new	O	O
genetic	B-PHYS
markers	I-PHYS
,	O	O
biomarkers	B-PHYS
,	O	O
and	O	O
clinical	O
factors	O
that	O	O
may	O	O
influence	O	O
a	O	O
child	B-LIVB
's	I-LIVB
uveitis	B-DISO
disease	B-DISO
course	I-DISO
.	O	O

It	O	O
is	O	O
important	O	O
to	O	O
identify	O	O
children	B-LIVB
at	O	O
risk	O
for	O	O
poor	O
visual	O
outcomes	O
and	O	O
who	O	O
are	O	O
refractory	O
to	O	O
traditional	B-PROC
therapy	I-PROC
.	O	O

Racial	B-DISO
disparities	I-DISO
have	O	O
recently	O	O
been	O	O
reported	O
.	O	O

We	O	O
describe	O	O
agents	B-CHEM
of	O	O
potential	O
benefit	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
discuss	O	O
the	O	O
importance	O	O
of	O	O
patient	O
reported	O
outcomes	O
in	O	O
this	O	O
population	B-LIVB
.	O	O

Uveitis	B-DISO
can	O	O
lead	O	O
to	O	O
vision	B-DISO
-	I-DISO
threatening	I-DISO
complications	I-DISO
.	O	O

Timely	B-PROC
and	I-PROC
aggressive	I-PROC
treatment	I-PROC
of	O	O
children	B-LIVB
identified	O	O
to	O	O
be	O	O
at	O	O
risk	O
for	O	O
a	O	O
severe	B-DISO
uveitis	I-DISO
course	I-DISO
may	O	O
lead	O	O
to	O	O
improved	O
outcomes	O
.	O	O

The	O	O
integration	O
of	O	O
cyanide	B-CHEM
hydratase	I-CHEM
and	O	O
tyrosinase	B-CHEM
catalysts	B-PHEN
enables	O	O
effective	O
degradation	O
of	O	O
cyanide	B-CHEM
and	O	O
phenol	B-CHEM
in	O	O
coking	B-PHEN
wastewaters	I-PHEN
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
design	O
an	O	O
effective	O
method	O
for	O	O
the	O	O
bioremediation	B-PHEN
of	O	O
coking	B-PHEN
wastewaters	I-PHEN
,	O	O
specifically	O	O
for	O	O
the	O	O
concurrent	O
elimination	B-PHEN
of	O	O
their	O	O
highly	O	O
toxic	O
components	O
-	O	O
cyanide	B-CHEM
and	O	O
phenols	B-CHEM
.	O	O

Almost	O	O
full	O	O
degradation	O
of	O	O
free	B-CHEM
cyanide	I-CHEM
(	O	O
0	O	O
.	O	O
32	O	O
-	O	O
20	O	O
mM	O	O
;	O	O
8	O	O
.	O	O
3	O	O
-	O	O
520	O	O
mg	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
in	O	O
the	O	O
model	B-DEVI
and	O	O
the	O	O
real	O	O
coking	B-PHEN
wastewaters	I-PHEN
was	O	O
achieved	O	O
by	O	O
using	O	O
a	O	O
recombinant	B-CHEM
cyanide	B-CHEM
hydratase	I-CHEM
in	O	O
the	O	O
first	O
step	O
.	O	O

The	O	O
removal	O
of	O	O
cyanide	B-CHEM
,	O	O
a	O	O
strong	O	O
inhibitor	O
of	O	O
tyrosinase	B-CHEM
,	O	O
enabled	O	O
an	O	O
effective	O
degradation	O
of	O	O
phenols	B-CHEM
by	O	O
this	O	O
enzyme	B-CHEM
in	O	O
the	O	O
second	O	O
step	O	O
.	O	O

Phenol	B-CHEM
(	O	O
16	O	O
.	O	O
5	O	O
mM	O	O
,	O	O
1	O	O
,	O	O
552	O	O
mg	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
was	O	O
completely	O	O
removed	O
from	O	O
a	O	O
real	O	O
coking	B-PHEN
wastewater	I-PHEN
within	O	O
20	O	O
h	O
and	O	O
cresols	B-CHEM
(	O	O
5	O	O
.	O	O
0	O	O
mM	O	O
,	O	O
540	O	O
mg	O	O
L	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
were	O	O
removed	O
by	O	O
66	O	O
%	O	O
under	O	O
the	O	O
same	O	O
conditions	O
.	O	O

The	O	O
integration	O
of	O	O
cyanide	B-CHEM
hydratase	I-CHEM
and	O	O
tyrosinase	B-CHEM
open	O	O
up	O	O
new	O	O
possibilities	O	O
for	O	O
the	O	O
bioremediation	B-PHEN
of	O	O
wastewaters	B-PHEN
with	O	O
complex	O	O
pollution	B-PHEN
.	O	O

Utility	O
of	O	O
a	O	O
mHealth	O
App	O
for	O	O
Self	B-PROC
-	I-PROC
Management	I-PROC
and	O	O
Education	B-PROC
of	O	O
Cardiac	B-DISO
Diseases	I-DISO
in	O	O
Spanish	B-GEOG
Urban	B-GEOG
and	I-GEOG
Rural	I-GEOG
Areas	I-GEOG
Analyze	B-PROC
the	O	O
utility	O
of	O	O
a	O	O
mobile	O
health	O
app	O
named	O	O
HeartKeeper	O
in	O	O
several	B-LIVB
groups	I-LIVB
of	I-LIVB
population	I-LIVB
and	O	O
obtain	O
conclusions	O
to	O	O
be	O	O
applied	O
to	O	O
other	O
similar	O
apps	O
.	O	O

A	O	O
questionnaire	O
has	O	O
been	O	O
designed	O
to	O	O
evaluate	O	O
the	O	O
usage	O
and	O	O
utility	O
of	O	O
the	O	O
HeartKeeper	O
app	O
.	O	O

The	O	O
questionnaire	O
information	O
was	O	O
collected	O
by	O	O
collaborating	O	O
cardiologists	B-LIVB
from	O	O
32	O	O
patients	B-LIVB
before	O
and	O
after	O
they	O	O
used	O
the	O	O
app	O
.	O	O

Patients	B-LIVB
were	O	O
randomly	B-PROC
selected	I-PROC
with	O	O
established	O	O
quotas	B-PROC
within	O	O
interest	B-LIVB
groups	I-LIVB
,	O	O
so	O	O
that	O	O
men	B-LIVB
and	O	O
women	B-LIVB
,	O	O
patients	B-LIVB
older	B-LIVB
or	O	O
younger	O
than	O	O
60	O	O
years	O
old	O
and	O	O
patients	B-LIVB
living	O	O
in	O	O
urban	B-GEOG
or	I-GEOG
rural	I-GEOG
areas	I-GEOG
were	O	O
equally	O
represented	O
.	O	O

Using	O	O
the	O	O
appropriate	O	O
statistical	B-PROC
techniques	I-PROC
we	O	O
see	O	O
that	O	O
the	O	O
HeartKeeper	O
app	O
was	O	O
useful	O	O
for	O	O
patients	B-LIVB
as	O	O
they	O	O
qualify	O
with	O	O
70	O	O
points	O	O
(	O	O
out	O	O
of	O	O
100	O	O
)	O	O
the	O	O
overall	B-DISO
opinion	I-DISO
of	O	O
the	O	O
app	O
,	O	O
it	O	O
helps	O	O
them	O	O
remember	B-PHYS
more	O	O
easily	O	O
taking	O	O
their	O	O
pills	B-CHEM
with	O	O
a	O	O
mean	O	O
improvement	O
of	O	O
20	O	O
.	O	O

94	O	O
points	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
they	O	O
perceive	O	O
a	O	O
global	O
improvement	O
of	O	O
their	O	O
health	O	O
(	O	O
8	O	O
.	O	O
28	O	O
points	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

We	O	O
also	O	O
observe	O
that	O	O
these	O	O
improvements	O
do	O	O
not	O	O
depend	O	O
,	O	O
in	O	O
general	O	O
,	O	O
on	O	O
the	O	O
area	B-GEOG
(	I-GEOG
urban	I-GEOG
or	I-GEOG
rural	I-GEOG
)	I-GEOG
where	O	O
the	O	O
patient	B-LIVB
comes	O	O
from	O	O
or	O	O
on	O	O
their	O	O
sex	B-PHYS
.	O	O

Although	O	O
older	B-LIVB
patients	I-LIVB
needed	O
more	O	O
help	O	O
to	O	O
use	O
the	O	O
app	O
and	O	O
used	O
it	O	O
slightly	O	O
less	O
frequently	O
,	O	O
the	O	O
improvements	O
on	O	O
several	O
measures	O
considered	O	O
,	O	O
such	O	O
as	O	O
remembering	B-PHYS
taking	O	O
pills	B-CHEM
,	O	O
breathing	B-DISO
problems	I-DISO
or	O	O
trouble	B-DISO
developing	I-DISO
activities	I-DISO
,	O	O
depend	O	O
significantly	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
on	O	O
age	O	O
with	O	O
older	B-LIVB
patients	I-LIVB
reporting	O	O
higher	O
improvements	O
than	O	O
younger	B-LIVB
ones	I-LIVB
.	O	O

The	O	O
results	O
obtained	O	O
with	O	O
the	O	O
sample	O
of	O	O
patients	B-LIVB
considered	O	O
in	O	O
this	O	O
research	B-PROC
prove	O	O
the	O	O
utility	O
of	O	O
the	O	O
HeartKeeper	O
app	O
.	O	O

This	O	O
utility	O
is	O	O
similar	O	O
in	O	O
urban	B-GEOG
and	I-GEOG
rural	I-GEOG
areas	I-GEOG
and	O	O
for	O	O
patients	B-LIVB
of	O	O
both	B-PHYS
sexes	I-PHYS
and	O	O
,	O	O
to	O
some	O
extent	O
,	O	O
depends	O	O
on	O	O
the	O	O
age	B-LIVB
of	O	O
the	O	O
patient	B-LIVB
with	O	O
older	B-LIVB
patients	I-LIVB
reporting	O	O
slightly	O
lower	O
frequency	O
of	O	O
use	O
but	O	O
higher	O
health	O
improvements	O
than	O	O
younger	B-LIVB
ones	I-LIVB
.	O	O

MiR	O
-	O
4638	O
-	O
5p	O
inhibits	O	O
castration	B-DISO
resistance	I-DISO
of	I-DISO
prostate	I-DISO
cancer	I-DISO
through	O	O
repressing	O	O
Kidins220	O
expression	B-PHYS
and	O	O
PI3K	O
/	O
AKT	O
pathway	O
activity	O	O
MicroRNAs	B-CHEM
(	O	O
miRNAs	B-CHEM
)	O	O
are	O	O
short	O	O
,	O	O
conserved	O
segments	O
of	O	O
non	B-CHEM
-	I-CHEM
coding	I-CHEM
RNA	I-CHEM
which	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
prostate	B-DISO
cancer	I-DISO
development	O	O
and	O	O
progression	B-DISO
.	O	O

To	O	O
identify	O	O
miRNAs	B-CHEM
associated	O	O
with	O	O
castration	B-DISO
resistance	I-DISO
,	O	O
we	O	O
performed	O	O
miRNA	B-PROC
microarray	I-PROC
analysis	I-PROC
comparing	O	O
castration	B-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O	O
CRPC	B-DISO
)	O	O
with	O	O
androgen	B-DISO
dependent	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O	O
ADPC	B-DISO
)	O	O
.	O	O

We	O	O
identified	O	O
common	O	O
underexpression	B-PHYS
of	O	O
miR	O
-	O
4638	O
-	O
5p	O
in	O	O
CRPC	B-DISO
compared	O	O
to	O	O
ADPC	B-DISO
samples	O
,	O	O
which	O	O
were	O	O
further	O	O
confirmed	O	O
by	O	O
quantitative	B-PROC
PCR	I-PROC
analysis	I-PROC
.	O	O

The	O	O
role	O	O
of	O	O
miR	O
-	O
4638	O
-	O
5p	O
in	O	O
prostate	B-DISO
cancer	I-DISO
androgen	B-DISO
-	I-DISO
independent	I-DISO
growth	I-DISO
has	O	O
been	O	O
demonstrated	O	O
both	O	O
in	O
vitro	O
and	O	O
in	O
vivo	O
.	O	O

We	O	O
also	O	O
identified	O	O
Kidins220	O
as	O	O
a	O	O
target	O	O
gene	O
directly	O	O
regulated	O	O
by	O	O
miR	O
-	O
4638	O
-	O
5p	O
and	O	O
shRNA	B-CHEM
-mediated	O	O
knockdown	B-PROC
of	O	O
Kidins220	O
phenocopied	O	O
miR	O
-	O
4638	O
-	O
5p	O
restoration	O	O
.	O	O

Subsequently	O	O
,	O	O
we	O	O
revealed	O	O
that	O	O
Kidins220	O
activates	O	O
PI3K	O
/	O
AKT	O
pathway	O
,	O	O
which	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
CRPC	B-DISO
.	O	O

Loss	O	O
of	O	O
miR	O
-	O
4638	O
-	O
5p	O
may	O	O
lead	O	O
to	O	O
CRPC	B-DISO
through	O	O
the	O	O
activity	O	O
of	O	O
Kidins220	O
and	O	O
PI3K	O
/	O
AKT	O
pathway	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
found	O	O
that	O	O
miR	O
-	O
4638	O
-	O
5p	O
,	O	O
through	O	O
regulating	O	O
Kidins220	O
and	O	O
the	O	O
downstream	O
activity	O	O
of	O	O
VEGF	B-CHEM
and	O	O
PI3K	O
/	O
AKT	O
pathway	O
,	O	O
influences	O	O
prostate	B-DISO
cancer	I-DISO
progression	I-DISO
via	O	O
angiogenesis	B-PHYS
.	O	O

The	O	O
identification	O	O
of	O	O
miR	O
-	O
4638	O
-	O
5p	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
in	O	O
CRPC	B-DISO
and	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
functional	O	O
role	O	O
of	O	O
miR	O
-	O
4638	O
-	O
5p	O
and	O	O
its	O	O
downstream	O
genes	O
/	O	O
pathways	B-PHYS
have	O	O
the	O	O
potential	O	O
to	O	O
develop	O	O
biomarkers	B-PHYS
for	O	O
CRPC	B-DISO
onset	O	O
and	O	O
to	O	O
identify	O	O
novel	O	O
targets	O	O
for	O	O
novel	O	O
forms	O	O
of	O	O
treatments	B-PROC
of	O	O
this	O	O
lethal	O	O
form	O	O
of	O	O
PCa	B-DISO
.	O	O

Evaluation	B-PROC
of	O	O
the	O	O
Effects	O
of	O
Intravenous	O
and	O	O
Percutaneous	O
Low	B-PROC
Level	I-PROC
Laser	I-PROC
Therapy	I-PROC
in	O	O
the	O	O
Management	B-PROC
of	O	O
Shoulder	B-ANAT
Myofascial	B-DISO
Pain	I-DISO
Syndrome	I-DISO
Myofascial	B-DISO
pain	I-DISO
syndrome	I-DISO
(	O	O
MPS	B-DISO
)	O	O
treatment	B-PROC
is	O	O
challenging	O	O
with	O	O
a	O	O
high	O	O
recurrence	O	O
rate	O	O
and	O	O
still	O	O
lacks	O	O
a	O	O
clear	O	O
treatment	B-PROC
frame	I-PROC
.	O	O

Therefore	O	O
research	O	O
on	O	O
new	O	O
,	O	O
more	O	O
efficient	O
and	O	O
long	O	O
lasting	O	O
effect	O	O
treatment	B-PROC
modalities	O
is	O	O
necessary	O	O
.	O	O

This	O	O
study	O	O
looked	O	O
at	O	O
the	O	O
effects	O
of	O
intravenous	O
laser	B-PROC
therapy	I-PROC
(	O	O
IVL	B-PROC
)	O	O
and	O	O
percutaneous	O
low	B-PROC
level	I-PROC
laser	I-PROC
(	O	O
PLLL	B-PROC
)	O	O
in	O	O
the	O	O
management	B-PROC
of	O	O
shoulder	B-ANAT
MPS	B-DISO
.	O	O

In	O	O
this	O	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
,	O	O
30	O	O
patients	B-LIVB
fulfilling	O	O
inclusion	O
criteria	O
were	O	O
randomly	O	O
equally	O	O
allocated	O	O
to	O	O
3	O	O
groups	O	O
,	O	O
control	B-LIVB
,	O	O
IVL	B-LIVB
and	O	O
PLLL	B-LIVB
.	O	O

Control	B-LIVB
group	I-LIVB
received	O	O
12	O	O
sessions	O	O
of	O	O
placebo	B-PROC
low	B-PROC
level	I-PROC
laser	I-PROC
,	O	O
IVL	B-LIVB
group	I-LIVB
received	O	O
12	O	O
sessions	O	O
of	O	O
IVL	B-PROC
therapy	I-PROC
,	O	O
and	O	O
PLLL	B-LIVB
group	I-LIVB
received	O	O
12	O	O
sessions	O	O
of	O	O
PLLL	B-PROC
therapy	I-PROC
.	O	O

All	O	O
patients	B-LIVB
were	O	O
trained	O	O
for	O	O
better	O
body	B-PHYS
posture	I-PHYS
,	O	O
body	B-ANAT
mechanics	I-ANAT
,	O	O
gentle	B-PROC
massage	I-PROC
of	O	O
trigger	B-ANAT
points	I-ANAT
,	O	O
stretching	B-PROC
exercises	I-PROC
of	O	O
affected	O
muscle	O
(	O	O
trapezius	B-ANAT
)	O	O
,	O	O
and	O	O
received	O	O
10	O	O
mg	O	O
of	O	O
oral	O
nortriptyline	B-CHEM
regimen	B-PROC
every	O	O
night	O	O
for	O	O
3	O	O
months	O	O
.	O	O

Outcomes	O	O
included	O	O
pain	O
severity	O
,	O	O
functional	B-DISO
disability	I-DISO
,	O	O
and	O	O
quality	O
of	O
life	O
.	O	O

Patients	B-LIVB
were	O	O
assessed	O	O
using	O	O
Numeric	O
Rating	O
Scale	O
(	O	O
NRS	O
)	O	O
,	O	O
Pain	O
Disability	O
Index	O
(	O	O
PDI	O
)	O	O
,	O	O
and	O	O
Short	O
Form	O
Health	O
Survey	O
(	O	O
SF	O
-	O
12	O
)	O	O
.	O	O

Data	B-DISO
collected	I-DISO
were	O	O
analyzed	B-PROC
using	O	O
analysis	O
of	O
variance	O
(	O	O
ANOVA	O
)	O	O
,	O	O
Mann	O
-	O
Whitney	O
and	O	O
t	O
tests	O
.	O	O

The	O	O
mean	O	O
of	O	O
PDI	O
and	O	O
maximum	O	O
pain	B-PHYS
intensity	I-PHYS
during	O	O
day	O	O
and	O	O
night	O	O
significantly	O	O
reduced	O
in	O	O
both	O	O
PLLL	B-LIVB
and	O	O
IVL	B-LIVB
groups	I-LIVB
compared	O	O
to	O	O
control	B-LIVB
group	I-LIVB
.	O	O

Although	O	O
pain	O	O
severity	O	O
and	O	O
PDI	O
reduction	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
IVL	B-LIVB
group	I-LIVB
compared	O	O
to	O	O
PLLL	B-LIVB
group	I-LIVB
,	O	O
the	O	O
differences	O	O
were	O	O
not	O	O
statistically	O
significant	O
.	O	O

Also	O	O
,	O	O
quality	O
of	O
life	O
statistically	O
significantly	O
improved	O	O
in	O	O
both	O	O
IVL	B-LIVB
and	O	O
PLLL	B-LIVB
groups	I-LIVB
compared	O	O
to	O	O
control	B-LIVB
group	I-LIVB
was	O	O
more	O	O
,	O	O
and	O	O
although	O	O
higher	O	O
in	O	O
IVL	B-LIVB
group	I-LIVB
,	O	O
the	O	O
difference	O	O
was	O	O
not	O	O
statistically	O
significant	O
when	O	O
compared	O	O
to	O	O
PLLL	B-LIVB
group	I-LIVB
.	O	O

No	B-DISO
side	I-DISO
effects	I-DISO
were	O	O
observed	O	O
in	O	O
the	O	O
intervention	B-LIVB
groups	I-LIVB
.	O	O

Intravenous	O
laser	B-PROC
and	O	O
PLLL	B-PROC
therapy	I-PROC
had	O	O
a	O	O
positive	O	O
effect	O
on	O	O
pain	O
severity	O
and	O	O
PDI	O
reduction	O	O
,	O	O
and	O	O
quality	O
of	O
life	O
in	O	O
this	O	O
study	O	O
.	O	O

Also	O	O
no	B-DISO
adverse	I-DISO
event	I-DISO
was	O	O
recorded	O	O
.	O	O

Thus	O	O
,	O	O
intravenous	O
lasers	B-PROC
and	O	O
PLLL	B-PROC
therapy	I-PROC
seem	O	O
to	O	O
be	O	O
effective	O
complementary	O	O
modalities	O
in	O	O
managing	B-PROC
patients	B-LIVB
with	O	O
shoulder	B-ANAT
MPS	B-DISO
.	O	O

Comparison	O	O
of	O	O
the	O	O
Antibacterial	B-PHYS
Effect	I-PHYS
of	O	O
810	O	O
nm	O	O
Diode	B-DEVI
Laser	I-DEVI
and	O	O
Photodynamic	B-DEVI
Therapy	I-DEVI
in	O	O
Reducing	O	O
the	O	O
Microbial	B-LIVB
Flora	I-LIVB
of	O	O
Root	B-ANAT
Canal	I-ANAT
in	O	O
Endodontic	B-PROC
Retreatment	I-PROC
in	O	O
Patients	B-LIVB
With	O	O
Periradicular	B-DISO
Lesions	I-DISO
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
compare	O	O
the	O	O
antibacterial	B-PHYS
efficacy	I-PHYS
of	O	O
diode	B-DEVI
laser	I-DEVI
810	O	O
nm	O	O
and	O	O
photodynamic	B-DEVI
therapy	I-DEVI
(	O	O
PDT	B-DEVI
)	O	O
in	O	O
reducing	O	O
bacterial	B-LIVB
microflora	I-LIVB
in	O	O
endodontic	B-PROC
retreatment	I-PROC
of	O	O
teeth	B-ANAT
with	O	O
periradicular	B-DISO
lesion	I-DISO
.	O	O

In	O	O
this	O	O
in	O
vivo	O
clinical	B-PROC
trial	I-PROC
,	O	O
20	O	O
patients	B-LIVB
who	O	O
needed	O	O
endodontic	B-PROC
retreatment	I-PROC
were	O	O
selected	O	O
.	O	O

After	O	O
conventional	O	O
chemo	B-PROC
mechanical	I-PROC
preparation	I-PROC
of	O	O
root	B-ANAT
canals	I-ANAT
,	O	O
microbiological	O
samples	O
were	O	O
taken	O	O
with	O	O
sterile	B-CHEM
paper	I-CHEM
point	I-CHEM
(	O	O
PP	B-CHEM
)	O	O
,	O	O
held	O	O
in	O	O
thioglycollate	B-CHEM
broth	I-CHEM
,	O	O
and	O	O
then	O	O
were	O	O
transferred	O	O
to	O	O
the	O	O
microbiological	B-OBJC
lab	I-OBJC
.	O	O

In	O	O
the	O	O
first	O	O
group	O
,	O	O
PDT	B-DEVI
with	O	O
methylene	B-CHEM
blue	I-CHEM
(	O	O
MB	B-CHEM
)	O	O
and	O	O
diode	B-DEVI
laser	I-DEVI
(	O	O
810	O	O
nm	O	O
,	O	O
0	O	O
.	O	O
2	O	O
W	O	O
,	O	O
40	O	O
seconds	O	O
)	O	O
was	O	O
performed	O	O
and	O	O
in	O	O
the	O	O
second	O	O
group	O
diode	B-DEVI
laser	I-DEVI
(	O	O
810	O	O
nm	O	O
,	O	O
1	O	O
.	O	O
2	O	O
W	O	O
,	O	O
30	O	O
seconds	O	O
)	O	O
was	O	O
irradiated	B-PHEN
.	O	O

Then	O	O
second	O	O
samples	O
were	O	O
taken	O	O
from	O	O
all	O	O
canals	B-ANAT
.	O	O

CFU	O
/	O
ml	O
amounts	O	O
showed	O	O
statistically	O	O
significant	O	O
reduction	O	O
in	O	O
both	O	O
groups	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

CFU	O
/	O
ml	O
amounts	O	O
were	O	O
compared	O	O
between	O	O
the	O	O
two	O	O
groups	O
and	O	O
there	O	O
was	O	O
no	O	O
statistical	O	O
difference	O	O
.	O	O

PDT	B-DEVI
and	O	O
diode	B-DEVI
laser	I-DEVI
810	O	O
nm	O	O
irradiation	B-PHEN
are	O	O
effective	O	O
methods	O	O
for	O	O
root	B-ANAT
canal	I-ANAT
disinfection	B-PROC
.	O	O

PDT	B-DEVI
is	O	O
a	O	O
suitable	O	O
alternative	O	O
for	O	O
diode	B-DEVI
laser	I-DEVI
810	O	O
nm	O	O
irradiation	B-PHEN
,	O	O
because	O	O
of	O	O
lower	O	O
thermal	B-DISO
risk	I-DISO
on	O	O
root	B-ANAT
dentin	I-ANAT
.	O	O

A	O	O
comparative	B-PROC
analysis	I-PROC
of	O	O
lncRNAs	B-CHEM
in	O	O
prostate	B-DISO
cancer	I-DISO
exosomes	B-ANAT
and	O	O
their	O	O
parental	O
cell	B-ANAT
lines	I-ANAT
Prostate	B-DISO
cancer	I-DISO
is	O	O
the	O	O
second	O
leading	O
cancer	B-DISO
in	O	O
men	B-LIVB
world	B-LIVB
-	O	O
wide	O
.	O	O

Due	O
to	O
its	O	O
heterogeneous	O
nature	O
,	O	O
a	O	O
considerable	O	O
amount	O
of	O	O
research	B-PROC
effort	B-PHYS
has	O	O
been	O	O
dedicated	O	O
in	O	O
identifying	O
effective	O
clinical	O
biomarkers	B-PHYS
with	O	O
a	O	O
focus	O
on	O	O
proteins	B-CHEM
,	O	O
messenger	B-CHEM
RNA	I-CHEM
and	O	O
microRNAs	B-CHEM
[	O	O
1	O	O
]	O	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
limited	O
data	O
on	O	O
the	O	O
role	O
and	O	O
expression	B-PHYS
of	O	O
long	B-CHEM
noncoding	I-CHEM
RNAs	I-CHEM
(	O	O
lncRNAs	B-CHEM
)	O	O
in	O	O
prostate	B-DISO
cancer	I-DISO
exosomes	B-ANAT
[	O	O
2	O	O
]	O	O
.	O	O

This	O	O
array	O
dataset	O
which	O	O
is	O	O
linked	O	O
to	O	O
our	O	O
publication	B-OBJC
describes	O	O
the	O	O
profiling	O
of	O	O
human	B-LIVB
lncRNAs	B-CHEM
in	O	O
prostate	B-DISO
cancer	I-DISO
and	O	O
their	O	O
exosomes	B-ANAT
from	O	O
five	O	O
different	O
cell	B-ANAT
lines	I-ANAT
[	O	O
3	O	O
]	O	O
.	O	O

From	O	O
this	O	O
dataset	O
,	O	O
we	O	O
identified	O
a	O	O
list	O	O
of	O	O
statistically	O
significant	O
prostate	B-DISO
cancer	I-DISO
lncRNAs	B-CHEM
which	O	O
are	O	O
differentially	O
expressed	B-PHYS
in	O	O
the	O	O
exosomes	B-ANAT
compared	O
to	O	O
their	O	O
parent	O	O
cell	B-ANAT
lines	I-ANAT
.	O	O

This	O	O
dataset	O
has	O	O
been	O	O
deposited	O
into	O	O
Gene	O
Expression	O
Omnibus	O
(	O	O
GSE81034	O	O
)	O	O
.	O	O

Structural	O
Insights	B-PHYS
into	O	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O	O
D4	B-CHEM
Selectivity	B-PHEN
of	O	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
Analogues	B-CHEM
:	O	O
Molecular	B-PROC
Modeling	I-PROC
,	O	O
Synthesis	O
,	O	O
and	O	O
in	O
Vitro	O
Binding	B-PHYS
The	O	O
resurgence	O	O
of	O	O
interest	O	O
in	O	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
receptors	I-CHEM
as	O	O
a	O	O
therapeutic	O
target	O
requires	O	O
the	O	O
existence	O	O
of	O	O
highly	O	O
selective	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
ligands	B-CHEM
.	O	O

To	O	O
date	O	O
,	O	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
has	O	O
been	O	O
the	O	O
prototypical	B-CHEM
antagonist	I-CHEM
of	O	O
these	O	O
receptors	B-CHEM
.	O	O

However	O	O
,	O	O
this	O	O
compound	O
also	O	O
has	O	O
significant	O	O
affinity	O
for	O	O
and	O	O
activity	O	O
at	O	O
D4	B-CHEM
dopamine	I-CHEM
receptors	I-CHEM
.	O	O

In	O	O
this	O	O
context	O	O
,	O	O
this	O	O
work	O	O
was	O	O
aimed	O	O
at	O	O
better	O	O
understanding	O	O
the	O	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O	O
D4	B-CHEM
selectivity	B-PHEN
of	O	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
and	O	O
analogues	B-CHEM
from	O	O
a	O	O
structural	O
point	O	O
of	O	O
view	O	O
.	O	O

In	O
silico	O
investigations	O
revealed	O	O
two	O	O
key	O	O
interactions	O
for	O	O
the	O	O
5	B-CHEM
-	I-CHEM
HT1A	I-CHEM
/	O	O
D4	B-CHEM
selectivity	B-PHEN
of	O	O
WAY	B-CHEM
-	I-CHEM
100635	I-CHEM
and	O	O
analogues	B-CHEM
.	O	O

First	O	O
,	O	O
a	O	O
hydrogen	B-PHEN
bond	I-PHEN
only	O	O
found	O	O
with	O	O
the	O	O
Ser	B-CHEM
7	I-CHEM
.	I-CHEM

36	I-CHEM
of	O	O
D4	B-CHEM
receptor	I-CHEM
appeared	O	O
to	O	O
be	O	O
the	O	O
key	O	O
for	O	O
a	O	O
higher	O	O
D4	B-CHEM
affinity	O
for	O	O
newly	O	O
synthesized	O
aza	B-CHEM
analogues	B-CHEM
.	O	O

The	O	O
role	O	O
of	O	O
Ser	B-CHEM
7	I-CHEM
.	I-CHEM

36	I-CHEM
was	O	O
confirmed	O	O
as	O	O
the	O	O
affinity	O
of	O	O
aza	B-CHEM
analogues	B-CHEM
for	O	O
the	O	O
mutant	B-DISO
D4	B-CHEM
receptor	I-CHEM
S7	I-CHEM
.	I-CHEM

36A	I-CHEM
was	O	O
reduced	O	O
.	O	O

Then	O	O
,	O	O
the	O	O
formation	O	O
of	O	O
another	O	O
hydrogen	B-PHEN
bond	I-PHEN
with	O	O
the	O	O
conserved	O	O
Ser	B-CHEM
5	I-CHEM
.	I-CHEM

42	I-CHEM
residue	I-CHEM
appeared	O	O
to	O	O
be	O	O
also	O	O
critical	O	O
for	O	O
D4	B-CHEM
binding	B-PHYS
.	O	O

Differential	O
Apoptosis	B-PHYS
Radiosensitivity	B-PHYS
of	O	O
Neural	B-ANAT
Progenitors	I-ANAT
in	O	O
Adult	B-LIVB
Mouse	I-LIVB
Hippocampus	B-ANAT
Mammalian	B-LIVB
tissue	O
-	O
specific	O
stem	B-ANAT
cells	I-ANAT
and	O	O
progenitors	B-ANAT
demonstrate	O	O
differential	O
DNA	B-PHYS
damage	I-PHYS
response	I-PHYS
.	O	O

Neural	B-ANAT
progenitors	I-ANAT
in	O	O
dentate	B-ANAT
gyrus	I-ANAT
of	O	O
the	O	O
hippocampus	B-ANAT
are	O	O
known	O	O
to	O	O
undergo	O	O
apoptosis	B-PHYS
after	O	O
irradiation	B-PHEN
.	O	O

Using	O	O
a	O	O
mouse	B-DISO
model	I-DISO
of	O	O
hippocampal	B-ANAT
neuronal	B-PHYS
development	I-PHYS
,	O	O
we	O	O
characterized	O	O
the	O	O
apoptosis	B-PHYS
sensitivity	B-PHYS
of	O	O
the	O	O
different	O	O
neural	B-ANAT
progenitor	I-ANAT
subpopulations	B-LIVB
in	O	O
adult	B-LIVB
mouse	I-LIVB
dentate	B-ANAT
gyrus	I-ANAT
after	O	O
irradiation	B-PHEN
.	O	O

Two	O	O
different	O	O
bromodeoxyuridine	B-CHEM
incorporation	O
paradigms	B-PROC
were	O	O
used	O	O
for	O	O
cell	B-PHYS
fate	I-PHYS
mapping	I-PHYS
.	O	O

We	O	O
identified	O	O
two	O	O
apoptosis	B-PHYS
sensitive	B-PHYS
neural	B-ANAT
progenitor	I-ANAT
subpopulations	B-LIVB
after	O	O
irradiation	B-PHEN
.	O	O

The	O	O
first	O	O
represented	O	O
non	B-PHYS
-	I-PHYS
proliferative	I-PHYS
and	O	O
non	B-DISO
-	I-DISO
newborn	I-DISO
neuroblasts	B-ANAT
and	O	O
immature	B-ANAT
neurons	I-ANAT
that	O	O
expressed	O	O
doublecortin	B-CHEM
,	O	O
calretinin	B-CHEM
or	O	O
both	O	O
.	O	O

The	O	O
second	O	O
consisted	O	O
of	O	O
proliferative	O
intermediate	B-ANAT
neural	I-ANAT
progenitors	I-ANAT
.	O	O

The	O	O
putative	O	O
radial	B-ANAT
glia	I-ANAT
-	I-ANAT
like	I-ANAT
neural	I-ANAT
stem	I-ANAT
cells	I-ANAT
or	O	O
type	B-ANAT
-	I-ANAT
1	I-ANAT
cells	I-ANAT
,	O	O
regardless	O	O
of	O	O
proliferation	O
status	O
,	O	O
were	O	O
apoptosis	B-PHYS
resistant	O
after	O	O
irradiation	B-PHEN
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
radiation	B-PHEN
-	O	O
induced	O
apoptosis	B-PHYS
in	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
Trp53	O
(	O
p53	O
)	O
gene	O
but	O	O
absence	O	O
of	O	O
Cdkn1a	O
(	O
p21	O
)	O
did	O	O
not	O	O
alter	O	O
the	O	O
apoptotic	B-PHYS
response	O	O
.	O	O

Upregulation	B-PHYS
of	O	O
nuclear	B-CHEM
p53	I-CHEM
was	O	O
observed	O	O
in	O	O
neuroblasts	B-ANAT
after	O	O
irradiation	B-PHEN
.	O	O

We	O	O
conclude	O	O
that	O	O
adult	B-ANAT
hippocampal	I-ANAT
neural	B-ANAT
progenitors	I-ANAT
may	O	O
demonstrate	O	O
differential	O
p53	B-CHEM
-dependent	O	O
apoptosis	B-PHYS
sensitivity	B-PHYS
after	O	O
irradiation	B-PHEN
.	O	O

Information	B-PHYS
Literacy	I-PHYS
in	O	O
a	O	O
Digital	O
Era	O
:	O	O
Understanding	B-PHYS
the	O	O
Impact	O
of	O	O
Mobile	B-OBJC
Information	O
for	O	O
Undergraduate	B-PROC
Nursing	I-PROC
Students	I-PROC
Recent	O
entry	O
-to	O	O
-	O	O
practice	B-PHYS
nursing	O
informatics	O
competencies	O
for	O	O
Registered	B-LIVB
Nurses	I-LIVB
in	O	O
Canada	B-GEOG
mean	O
nurse	B-LIVB
educators	I-LIVB
need	O	O
educational	B-PROC
strategies	I-PROC
to	O	O
promote	O
student	B-LIVB
competency	O
within	O	O
the	O	O
rapidly	O
evolving	O
informatics	O
field	O
.	O	O

A	O	O
collaborative	B-PROC
research	I-PROC
team	B-LIVB
from	O	O
three	O	O
Canadian	B-DISO
nursing	B-PROC
programs	I-PROC
completed	O
a	O	O
mixed	O
method	O
survey	O
to	O	O
describe	O	O
how	O	O
nursing	B-LIVB
students	I-LIVB
used	O	O
mobile	B-OBJC
nursing	O
information	O
support	O
and	O	O
the	O	O
extent	O
of	O	O
this	O	O
support	O
for	O	O
learning	B-PHYS
.	O	O

The	O	O
Mobile	O
Information	O
Support	O
Evaluation	O
Tool	O
(	O
MISET	O
)	O
assessed	O
Usefulness	O
/	O	O
Helpfulness	O
,	O	O
Information	B-PHYS
Literacy	I-PHYS
Support	O
,	O	O
and	O	O
Use	O
of	O
Evidence	O
-Based	O	O
Sources	B-DISO
.	O	O

The	O	O
quantitative	O
and	O	O
qualitative	O
data	O
were	O	O
analyzed	B-PROC
to	O	O
describe	O	O
students	B-LIVB
'	I-LIVB
perspectives	O
and	O	O
the	O	O
ways	O	O
they	O	O
used	O	O
mobile	B-OBJC
resources	O
in	O	O
learning	B-PHYS
situations	O	O
.	O	O

Findings	B-DISO
suggest	O
nursing	B-LIVB
students	I-LIVB
mainly	O	O
accessed	O
mobile	B-OBJC
resources	O
to	O	O
support	O
clinical	O
learning	B-PHYS
,	O	O
and	O	O
specifically	O
for	O	O
task	O
-	O	O
oriented	B-DISO
information	O
such	O	O
as	O	O
drug	B-PROC
medication	I-PROC
or	O	O
patient	O
conditions	O
/	O
diagnoses	O
.	O	O

Researchers	B-LIVB
recommend	O
a	O	O
paradigm	B-PROC
shift	I-PROC
whereby	O	O
educators	B-LIVB
emphasize	O	O
information	B-PHYS
literacy	I-PHYS
in	O	O
a	O	O
way	O	O
that	O	O
supports	O
evidence	O
-based	O	O
quality	B-PROC
care	I-PROC
.	O	O

Improving	O
EMR	O
Usability	O	O
:	O	O
Critical	O
Elements	O
When	O	O
Designing	O
Perioperative	O
Emergencies	B-PHEN
Template	O
Perianesthesia	B-PROC
nursing	I-PROC
care	I-PROC
involves	O	O
monitoring	O
of	O
unexpected	O
outcomes	O
before	O
and	O	O
after	O
surgical	B-PROC
and	O	O
anesthetic	B-PROC
procedures	I-PROC
.	O	O

When	O	O
adverse	B-DISO
events	I-DISO
occur	O
,	O	O
reviewing	O
patient	O
data	O
is	O	O
critical	O
to	O	O
provide	O	O
appropriate	O	O
intervention	B-PROC
.	O	O

Current	O	O
EMR	O
software	B-OBJC
systems	I-OBJC
are	O	O
limited	O
in	O	O
structure	O
and	O	O
are	O	O
not	O
cohesive	O
in	O	O
recording	O
adverse	B-DISO
events	I-DISO
.	O	O

Users	B-LIVB
tend	O	O
to	O	O
develop	O	O
workarounds	O	O
when	O	O
systems	B-OBJC
fail	O
to	O	O
capture	O	O
workflow	O
.	O	O

Analysis	B-PROC
of	O	O
adverse	B-DISO
incident	I-DISO
is	O	O
incomplete	O
because	O	O
data	O
entered	O
is	O	O
not	O
retrievable	O
.	O	O

Narrative	O
data	O
,	O	O
while	O	O
sometimes	O	O
necessary	O	O
,	O	O
cannot	O	O
easily	O	O
be	O	O
analyzed	B-PROC
or	O	O
linked	O	O
to	O	O
the	O	O
structured	O
portion	O
of	O	O
the	O	O
record	O
.	O	O

Designing	O
templates	O
to	O	O
capture	O
essential	O
data	O
during	O	O
emergency	B-PHEN
situations	I-PHEN
improves	O
usability	O	O
and	O	O
compliance	B-DISO
.	O	O

The	O	O
presentation	O
of	O	O
information	O
in	O	O
terms	O	O
of	O	O
layout	O
and	O	O
structure	O
is	O	O
important	O
because	O	O
it	O	O
can	O	O
influence	O	O
data	O
retrieval	B-PROC
,	O	O
interpretation	O
and	O	O
clinical	B-PHYS
decision	I-PHYS
making	I-PHYS
in	O	O
fundamental	O	O
ways	O	O
.	O	O

Sewage	B-PHEN
sludge	B-PHEN
pretreatment	O
by	O	O
microwave	B-PHEN
irradiation	I-PHEN
combined	O	O
with	O	O
activated	B-CHEM
carbon	I-CHEM
fibre	I-CHEM
at	O	O
alkaline	O
pH	O
for	O	O
anaerobic	O
digestion	B-PHEN
This	O	O
research	B-PROC
focuses	O	O
on	O	O
the	O	O
effects	O
of	O
microwave	B-PHEN
-assisted	O	O
activated	B-CHEM
carbon	I-CHEM
fibre	I-CHEM
(	O	O
ACF	B-CHEM
)	O	O
(	O	O
MW	B-PHEN
-	O	O
ACF	B-CHEM
)	O	O
treatment	O
on	O	O
sewage	B-PHEN
sludge	B-PHEN
at	O	O
alkaline	O
pH	O
.	O	O

The	O	O
disintegration	O
and	O	O
biodegradability	B-PHEN
of	O	O
sewage	B-PHEN
sludge	B-PHEN
were	O	O
studied	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
the	O	O
MW	O	O
-	O	O
ACF	O	O
process	O	O
at	O	O
alkaline	O
pH	O
provided	O	O
a	O	O
rapid	O
and	O	O
efficient	O
process	B-PHEN
to	O	O
disrupt	O	O
the	O	O
microbial	B-LIVB
cells	B-ANAT
in	O	O
the	O	O
sludge	B-PHEN
.	O	O

The	O	O
results	O
suggested	O	O
that	O	O
when	O	O
irradiated	B-PHEN
at	O	O
800	O	O
W	O	O
MW	O	O
for	O	O
110	O	O
s	O	O
with	O	O
a	O	O
dose	O
of	O	O
1	O	O
.	O	O

0	O	O
g	O	O
ACF	B-CHEM
/g	O	O
solid	O
concentration	O
(	O	O
SS	O
)	O	O
at	O	O
pH	O
10	O	O
.	O	O

5	O	O
,	O	O
the	O	O
MW	B-PHEN
-	O	O
ACF	B-CHEM
pretreatment	O
achieved	O	O
55	O	O
%	O	O
SS	O
disintegration	O
,	O	O
23	O	O
%	O	O
greater	O	O
than	O	O
the	O	O
value	O	O
of	O	O
MW	O	O
alone	O	O
(	O	O
32	O	O
%	O	O
)	O	O
.	O	O

The	O	O
concentration	O
of	O	O
total	B-PROC
nitrogen	I-PROC
,	O	O
total	B-PROC
phosphorus	I-PROC
,	O	O
supernatant	B-PROC
soluble	I-PROC
chemical	I-PROC
oxygen	I-PROC
demand	I-PROC
,	O	O
protein	B-PROC
,	O	O
and	O	O
polysaccharide	B-CHEM
increased	O
by	O	O
60	O	O
%	O	O
,	O	O
144	O	O
%	O	O
,	O	O
145	O	O
%	O	O
,	O	O
74	O	O
%	O	O
,	O	O
and	O	O
77	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

An	O	O
increase	O
in	O	O
biogas	B-CHEM
production	O
by	O	O
63	O	O
.	O	O

7	O	O
%	O	O
was	O	O
achieved	O	O
after	O	O
20	O	O
days	O	O
of	O	O
anaerobic	O
digestion	B-PHEN
(	O	O
AD	B-PHEN
)	O	O
,	O	O
compared	O	O
to	O	O
the	O	O
control	O
.	O	O

The	O	O
results	O
indicated	O	O
that	O	O
the	O	O
MW	O
-	O
ACF	O
pretreatment	O
process	O
at	O	O
alkaline	O
pH	O
provides	O	O
novel	O	O
sludge	B-PHEN
management	O
options	O
in	O	O
disintegration	O
of	O	O
sewage	B-PHEN
sludge	B-PHEN
for	O	O
further	O	O
AD	B-PHEN
.	O	O

The	O	O
Effects	O
of	O
Sequential	O
Environmental	B-DISO
and	O	O
Harvest	O
Stressors	O
on	O	O
the	O	O
Sensory	O
Characteristics	O
of	O	O
Cultured	B-LIVB
Channel	I-LIVB
Catfish	I-LIVB
(	O	O
Ictalurus	B-LIVB
Punctatus	I-LIVB
)	O	O
Fillets	B-OBJC
Stress	B-DISO
during	O	O
fish	O
culture	O
alters	O	O
physiological	B-PHEN
homeostasis	I-PHEN
and	O	O
affects	O	O
fillet	B-OBJC
quality	O
.	O	O

Maintenance	O	O
of	O	O
high	O	O
-	O	O
quality	O
seafood	B-OBJC
is	O	O
important	O	O
to	O	O
ensure	O	O
the	O	O
production	O
of	O	O
a	O	O
marketable	B-OBJC
product	I-OBJC
.	O	O

This	O	O
study	O	O
assessed	O	O
how	O	O
sequential	O
stressors	B-DISO
affect	O	O
the	O	O
sensory	O
and	O	O
quality	O
characteristics	O
of	O	O
catfish	B-LIVB
(	O	O
Ictalurus	B-LIVB
punctatus	I-LIVB
)	O	O
fillets	B-OBJC
.	O	O

Three	O	O
stress	O	O
trials	O	O
were	O	O
conducted	O	O
where	O	O
temperature	O
(	O	O
25	O	O
or	O	O
33	O	O
°	O	O
C	O	O
)	O	O
and	O	O
dissolved	B-CHEM
oxygen	I-CHEM
(	O	O
DO	B-CHEM
,	O	O
approximately	O	O
2	O	O
.	O	O
5	O	O
or	O	O
>	O	O
5	O	O
mg	O	O
/	O	O
L	O	O
)	O	O
were	O	O
manipulated	O	O
followed	O	O
by	O	O
socking	B-PHEN
and	O	O
transport	B-DISO
stress	I-DISO
.	O	O

After	O	O
each	O	O
stage	O	O
of	O	O
harvest	B-PHEN
(	O	O
environmental	B-PHEN
stress	I-PHEN
,	O	O
socking	B-PHEN
,	O	O
and	O	O
transport	O
)	O	O
,	O	O
fillet	B-OBJC
yield	O
,	O	O
consumer	B-LIVB
acceptability	O
,	O	O
descriptive	O
evaluation	O
,	O	O
cook	O
loss	O
,	O	O
tenderness	O
,	O	O
and	O	O
pH	O
were	O	O
evaluated	O	O
.	O	O

Fillet	B-OBJC
yield	O
decreased	O	O
with	O	O
increasing	O	O
severity	O
of	O	O
environmental	B-PHEN
stress	I-PHEN
.	O	O

Fillets	B-OBJC
from	O	O
the	O	O
severe	O
stress	B-PROC
treatment	I-PROC
(	O	O
33	O	O
°	O	O
C	O	O
,	O	O
approximately	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
/	O	O
L	O	O
)	O	O
received	O	O
the	O	O
highest	O	O
acceptability	O
scores	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Control	B-LIVB
fillets	B-OBJC
(	O	O
25	O	O
°	O	O
C	O	O
,	O	O
>	O	O
5	O	O
mg	O	O
/	O	O
L	O	O
)	O	O
were	O	O
the	O	O
least	B-DISO
acceptable	I-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Increased	O
intensity	O
of	O	O
less	O
favorable	O
flavor	O
attributes	O
commonly	O	O
associated	O
with	O
catfish	B-LIVB
resulted	O	O
in	O	O
the	O	O
differences	O	O
in	O	O
acceptability	O	O
among	O	O
treatments	O
.	O	O

As	O	O
fish	O	O
progressed	O	O
through	O	O
the	O	O
harvest	B-PHEN
event	O	O
,	O	O
cook	O
loss	O
decreased	O
,	O	O
tenderness	O
increased	O
,	O	O
and	O	O
pH	O
increased	O
,	O	O
indicating	O	O
that	O	O
stress	B-PHEN
induced	O	O
textural	O
changes	O
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
although	O	O
environmental	B-PHEN
stress	I-PHEN
results	O	O
in	O	O
slight	O	O
changes	O
in	O	O
flavor	O
attributes	O
,	O	O
its	O	O
effects	O	O
on	O	O
acceptability	O	O
are	O	O
minor	O
with	O	O
fillets	B-OBJC
from	O	O
all	O	O
treatments	O
still	O	O
liked	O	O
(	O	O
>	O	O
6	O	O
on	O	O
a	O	O
9	O	O
point	O	O
scale	O	O
)	O	O
.	O	O

Socking	B-PHEN
and	O	O
transport	O
were	O	O
identified	O	O
to	O	O
positively	B-DISO
affect	O	O
textural	O
characteristics	O
of	O	O
catfish	B-LIVB
fillets	B-OBJC
.	O	O

Although	O	O
the	O	O
effects	O
observed	O	O
were	O	O
not	O	O
likely	O	O
to	O	O
negatively	B-DISO
impact	O
consumer	B-LIVB
acceptance	O
,	O	O
a	O	O
strict	O	O
management	O
plan	O
should	O	O
be	O	O
followed	O	O
to	O	O
maintain	O	O
consistency	O
in	O	O
the	O	O
product	O	O
and	O	O
avoid	O	O
changes	O
in	O	O
stressors	O
that	O	O
might	O	O
alter	O	O
quality	O
more	O	O
drastically	O	O
.	O	O

Proteomic	O
analysis	B-PROC
of	O	O
docetaxel	B-CHEM
resistance	B-PHEN
in	O	O
human	B-LIVB
nasopharyngeal	B-DISO
carcinoma	I-DISO
cells	B-ANAT
using	O	O
the	O	O
two	B-PROC
-	I-PROC
dimensional	I-PROC
gel	I-PROC
electrophoresis	I-PROC
method	I-PROC
Docetaxel	B-CHEM
-based	O	O
chemotherapy	B-PROC
has	O	O
been	O	O
recommended	O
for	O	O
advanced	O	O
nasopharyngeal	B-DISO
carcinoma	I-DISO
(	O	O
NPC	B-DISO
)	O	O
.	O	O

However	O	O
,	O	O
treatment	B-DISO
failure	I-DISO
often	O	O
occurs	O	O
because	O	O
of	O	O
acquired	O
drug	B-PHEN
resistance	I-PHEN
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
a	O	O
docetaxel	B-CHEM
-	O	O
resistant	B-PHEN
NPC	B-DISO
cell	B-ANAT
line	I-ANAT
CNE	I-ANAT
-	I-ANAT
2R	I-ANAT
was	O	O
established	O
with	O	O
increasing	O
doses	O
of	O	O
docetaxel	B-CHEM
for	O	O
more	O
than	O
6	O	O
months	O
.	O	O

Two	B-PROC
-	I-PROC
dimensional	I-PROC
gel	I-PROC
electrophoresis	I-PROC
and	O	O
ESI	B-PROC
-	I-PROC
Q	I-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
were	O	O
used	O	O
to	O	O
compare	O
the	O	O
differential	O	O
expression	B-PHYS
of	O	O
docetaxel	B-CHEM
-	O	O
resistance	B-PHEN
-	O	O
associated	B-CHEM
proteins	I-CHEM
between	O	O
human	B-LIVB
NPC	B-DISO
CNE	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
and	O	O
docetaxel	B-CHEM
-	O	O
resistant	B-PHEN
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
cells	I-ANAT
.	O	O

As	O	O
a	O	O
result	B-DISO
,	O	O
24	O	O
differentially	O
expressed	B-PHYS
proteins	I-PHYS
were	O	O
identified	O
,	O	O
including	O	O
11	O	O
proteins	B-CHEM
with	O	O
increased	O
expression	B-PHYS
and	O	O
13	O	O
proteins	B-CHEM
with	O	O
decreased	O
expression	B-PHYS
.	O	O

These	O	O
proteins	B-PHYS
function	I-PHYS
in	O	O
diverse	O
biological	B-PHEN
processes	I-PHEN
such	O	O
as	O	O
metabolism	O
,	O	O
signal	B-PHYS
transduction	I-PHYS
,	O	O
calcium	B-PHYS
ion	I-PHYS
binding	I-PHYS
,	O	O
immune	B-PHYS
response	I-PHYS
,	O	O
proteolysis	B-PHYS
,	O	O
and	O	O
so	O	O
on	O	O
.	O	O

Among	O	O
these	O	O
,	O	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
(	O	O
ENO1	B-CHEM
)	O	O
,	O	O
significantly	O	O
upregulated	O	O
in	O	O
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
,	O	O
was	O	O
selected	O
for	O	O
detailed	O	O
analysis	B-PROC
.	O	O

Inhibition	O
of	O	O
ENO1	B-CHEM
by	O	O
shRNA	B-CHEM
restored	O	O
CNE	B-ANAT
-	I-ANAT
2R	I-ANAT
cells	I-ANAT
'	O	O
sensitivity	O
to	O	O
docetaxel	B-CHEM
.	O	O

Moreover	O	O
,	O	O
overexpression	B-PHYS
of	O	O
ENO1	B-CHEM
could	O	O
facilitate	O	O
the	O	O
development	O
of	O	O
acquired	O
resistance	B-PHEN
of	O	O
docetaxel	B-CHEM
in	O	O
CNE	B-ANAT
-	I-ANAT
2	I-ANAT
cells	I-ANAT
.	O	O

Western	B-PROC
blot	I-PROC
and	O	O
reverse	B-PROC
-	I-PROC
transcription	I-PROC
PCR	I-PROC
data	O
of	O	O
clinical	O
samples	O
confirmed	O
that	O	O
α	B-CHEM
-	I-CHEM
enolase	I-CHEM
was	O	O
upregulated	O	O
in	O	O
docetaxel	B-CHEM
-	O	O
resistant	B-PHEN
human	B-LIVB
NPC	B-DISO
tissues	O
.	O	O

Finding	B-DISO
such	O	O
proteins	B-CHEM
might	O	O
improve	B-DISO
interpretation	O
of	O	O
the	O	O
molecular	B-PHYS
mechanisms	I-PHYS
leading	O
to	O	O
the	O	O
acquisition	O
of	O	O
docetaxel	B-CHEM
chemoresistance	B-PHEN
.	O	O

A	O	O
holistic	O
approach	O
to	O	O
age	B-PHYS
estimation	B-PHYS
in	O	O
refugee	B-LIVB
children	B-LIVB
Many	O	O
refugee	B-LIVB
children	B-LIVB
arriving	O	O
in	O	O
Australia	B-GEOG
have	O	O
an	O	O
inaccurately	O
documented	B-PROC
date	O
of	O
birth	O
(	O	O
DOB	O
)	O	O
.	O	O

A	O	O
medical	B-PROC
assessment	I-PROC
of	O	O
a	O	O
child	B-PHYS
's	I-PHYS
age	I-PHYS
is	O	O
often	O	O
requested	O	O
when	O	O
there	O	O
is	O	O
a	O	O
concern	O
that	O	O
their	O	O
documented	B-PROC
DOB	O
is	O	O
incorrect	O
.	O	O

This	O	O
study	O	O
's	O	O
aim	O	O
was	O	O
to	O	O
assess	B-PROC
the	O	O
accuracy	O
a	O	O
holistic	O
age	O
assessment	O
tool	O
(	O	O
AAT	O
)	O	O
in	O	O
estimating	B-PHYS
the	O	O
age	B-PHYS
of	O	O
refugee	B-LIVB
children	B-LIVB
newly	O	O
settled	O	O
in	O	O
Australia	B-GEOG
.	O	O

A	O	O
holistic	O
AAT	O
that	O	O
combines	O	O
medical	O
and	O	O
non	O
-	O
medical	O
approaches	O
was	O	O
used	O	O
to	O	O
estimate	B-PHYS
the	O	O
ages	B-PHYS
of	O	O
60	O	O
refugee	B-LIVB
children	B-LIVB
with	O	O
a	O	O
known	O	O
DOB	O
.	O	O

The	O	O
tool	O
used	O	O
four	O	O
components	O
to	O	O
assess	B-PROC
age	B-PHYS
:	O	O
an	O	O
oral	O
narrative	O
,	O	O
developmental	O
assessment	B-PROC
,	O	O
anthropometric	O
measures	O
and	O	O
pubertal	B-DISO
assessment	B-PROC
.	O	O

Assessors	B-LIVB
were	O	O
blinded	B-PROC
to	O	O
the	O	O
true	O
age	B-PHYS
of	O	O
the	O	O
child	B-LIVB
.	O	O

Correlation	O
coefficients	O
for	O	O
the	O	O
actual	O
and	O	O
estimated	B-PHYS
age	B-PHYS
were	O	O
calculated	O
for	O	O
the	O	O
tool	O
overall	O
and	O
individual	O
components	O
.	O	O

The	O	O
correlation	O
coefficient	O
between	O	O
the	O	O
actual	O
and	O	O
estimated	B-PHYS
age	B-PHYS
from	O	O
the	O	O
AAT	O
was	O	O
very	O	O
strong	O	O
at	O	O
0	O	O
.	O	O

9802	O	O
(	O	O
boys	B-LIVB
0	O	O
.	O	O
9748	O	O
,	O	O
girls	B-LIVB
0	O	O
.	O	O
9876	O	O
)	O	O
.	O	O

The	O	O
oral	O
narrative	O
component	O
of	O	O
the	O	O
tool	O
performed	O	O
best	O	O
(	O	O
R	O	O
=	O	O
0	O	O
.	O	O
9603	O	O
)	O	O
.	O	O

Overall	O	O
,	O	O
86	O	O
.	O	O
7	O	O
%	O	O
of	O	O
age	B-PHYS
estimates	B-PHYS
were	O	O
within	O	O
1	O	O
year	O
of	O	O
the	O	O
true	O
age	B-PHYS
.	O	O

The	O	O
range	O	O
of	O	O
differences	O	O
was	O	O
-1	O	O
.	O	O

43	O	O
to	O	O
3	O	O
.	O	O

92	O	O
years	O
with	O	O
a	O	O
standard	O
deviation	O
of	O	O
0	O	O
.	O	O

77	O	O
years	O
(	O	O
9	O	O
.	O	O

24	O	O
months	O
)	O	O
.	O	O

The	O	O
AAT	O
is	O	O
a	O	O
holistic	O
,	O	O
simple	O
and	O	O
safe	O
instrument	O	O
that	O	O
can	O	O
be	O	O
used	O	O
to	O	O
estimate	B-PHYS
age	B-PHYS
in	O	O
refugee	B-LIVB
children	B-LIVB
with	O	O
results	O	O
comparable	O	O
with	O	O
radiological	O
methods	O
currently	O	O
used	O	O
.	O	O

Genomic	B-PROC
analysis	I-PROC
of	O	O
nontypeable	B-LIVB
pneumococci	I-LIVB
causing	O	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O	O
South	B-GEOG
Africa	I-GEOG
,	O	O
2003	O	O
-	O	O
2013	O	O
The	O	O
capsular	B-CHEM
polysaccharide	I-CHEM
is	O	O
the	O	O
principal	O	O
virulence	B-CHEM
factor	I-CHEM
of	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
and	O	O
a	O	O
target	O
for	O	O
current	O	O
pneumococcal	B-CHEM
vaccines	I-CHEM
.	O	O

However	O	O
,	O	O
some	O	O
pathogenic	B-DISO
pneumococci	B-LIVB
are	O	O
serologically	O
nontypeable	O
[	O	O
nontypeable	B-LIVB
pneumococci	I-LIVB
(	O	O
NTPn	B-LIVB
)	O	O
]	O	O
.	O	O

Due	O	O
to	O	O
their	O	O
relative	O	O
rarity	O
,	O	O
NTPn	B-LIVB
are	O	O
poorly	O	O
characterized	O
,	O	O
and	O	O
,	O	O
as	O	O
such	O	O
,	O	O
limited	O	O
data	O
exist	O	O
which	O	O
describe	O	O
these	O	O
organisms	B-LIVB
.	O	O

We	O	O
aimed	O	O
to	O	O
describe	O	O
disease	B-DISO
and	O	O
genotypically	B-PHYS
characterize	O
NTPn	B-LIVB
causing	O	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O	O
South	B-GEOG
Africa	I-GEOG
.	O	O

Isolates	B-CHEM
were	O	O
detected	O	O
through	O	O
national	O	O
,	O	O
laboratory	B-OBJC
-	O	O
based	O
surveillance	O
for	O	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O	O
South	B-GEOG
Africa	I-GEOG
and	O	O
characterized	O
by	O	O
whole	O	O
genome	B-PROC
analysis	I-PROC
.	O	O

We	O	O
predicted	O	O
ancestral	O
serotypes	O
(	O	O
serotypes	O
from	O	O
which	O	O
NTPn	B-LIVB
may	O	O
have	O	O
originated	O	O
)	O	O
for	O	O
Group	O
I	O
NTPn	B-LIVB
using	O	O
multilocus	B-PROC
sequence	I-PROC
typing	I-PROC
and	O	O
capsular	O
region	O
sequence	B-PROC
analyses	I-PROC
.	O	O

Antimicrobial	B-PHYS
resistance	I-PHYS
patterns	O
and	O	O
mutations	B-PHYS
potentially	O
causing	O	O
nontypeability	O
were	O	O
identified	O
.	O	O

From	O	O
2003	O	O
-	O	O
2013	O	O
,	O	O
39	O	O
(	O	O
0	O	O
.	O	O
1	O	O
%	O	O
,	O	O
39	O	O
/	O	O
32	O	O
,	O	O
824	O	O
)	O	O
NTPn	B-LIVB
were	O	O
reported	O	O
.	O	O

Twenty	O
-	O
two	O
(	O	O
56	O	O
%	O	O
)	O	O
had	O	O
partial	O
capsular	O
genes	O
(	O	O
Group	O
I	O
)	O	O
and	O	O
17	O	O
(	O	O
44	O	O
%	O	O
)	O	O
had	O	O
complete	O
capsular	B-PHYS
deletion	I-PHYS
of	O	O
which	O	O
15	O	O
had	O	O
replacement	O
by	O	O
other	O	O
genes	O
(	O	O
Group	O
II	O
)	O	O
.	O	O

Seventy	O
-	O
nine	O
percent	O
(	O	O
31	O	O
/	O	O
39	O	O
)	O	O
of	O	O
our	O	O
NTPn	B-LIVB
isolates	B-CHEM
were	O	O
derived	O	O
from	O	O
encapsulated	O
S	B-LIVB
.	I-LIVB

pneumoniae	I-LIVB
.	O	O

Ancestral	O	O
serotypes	O
1	O	O
(	O	O
27	O	O
%	O	O
,	O	O
6	O	O
/	O	O
22	O	O
)	O	O
and	O	O
8	O	O
(	O	O
14	O	O
%	O	O
,	O	O
3	O	O
/	O	O
22	O	O
)	O	O
were	O	O
most	O	O
prevalent	O	O
,	O	O
and	O	O
59	O	O
%	O	O
(	O	O
13	O	O
/	O	O
22	O	O
)	O	O
of	O	O
ancestral	O
serotypes	O
were	O	O
serotypes	O
included	O	O
in	O	O
the	O	O
13	B-CHEM
-	I-CHEM
valent	I-CHEM
pneumococcal	I-CHEM
conjugate	I-CHEM
vaccine	I-CHEM
.	O	O

We	O	O
identified	O	O
a	O	O
variety	O	O
of	O	O
mutations	B-PHYS
within	O	O
the	O	O
capsular	O
region	O
of	O	O
Group	O
I	O
NTPn	B-LIVB
,	O	O
some	O	O
of	O	O
which	O	O
may	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
nontypeable	O
phenotype	B-PHYS
.	O	O

Nonsusceptibility	B-PHEN
to	O	O
tetracycline	B-CHEM
and	O	O
erythromycin	B-CHEM
was	O	O
higher	O	O
in	O	O
NTPn	B-LIVB
than	O	O
encapsulated	O
S	B-LIVB
.	I-LIVB

pneumoniae	I-LIVB
.	O	O

NTPn	B-LIVB
are	O	O
currently	O	O
a	O	O
rare	O	O
cause	O	O
of	O	O
invasive	B-DISO
pneumococcal	I-DISO
disease	I-DISO
in	O	O
South	B-GEOG
Africa	I-GEOG
and	O	O
represent	O	O
a	O	O
genetically	O	O
diverse	O	O
collection	O	O
of	O	O
isolates	O	O
.	O	O

CAGEd	O
-	O
oPOSSUM	O
:	O	O
motif	B-PROC
enrichment	I-PROC
analysis	I-PROC
from	O	O
CAGE	O
-derived	O	O
TSSs	B-CHEM
With	O	O
the	O	O
emergence	O	O
of	O	O
large	O
-	O
scale	O
Cap	O
Analysis	O
of	O
Gene	O
Expression	O
(	O
CAGE	O
)	O
datasets	O
from	O	O
individual	B-OBJC
labs	I-OBJC
and	O	O
the	O	O
FANTOM	O
consortium	O
,	O	O
one	O	O
can	O	O
now	O	O
analyze	O	O
the	O	O
cis	B-CHEM
-	I-CHEM
regulatory	I-CHEM
regions	I-CHEM
associated	O	O
with	O	O
gene	B-PHYS
transcription	I-PHYS
at	O	O
an	O	O
unprecedented	O
level	O
of	O
refinement	O
.	O	O

By	O	O
coupling	O	O
transcription	B-PHYS
factor	I-PHYS
binding	I-PHYS
site	I-PHYS
(	O	O
TFBS	B-PHYS
)	O	O
enrichment	B-PROC
analysis	I-PROC
with	O	O
CAGE	O
-derived	O	O
genomic	O
regions	O
,	O	O
CAGEd	O
-	O
oPOSSUM	O
can	O	O
identify	O
TFs	B-CHEM
that	O	O
act	O	O
as	O	O
key	O
regulators	O
of	O	O
genes	O
involved	O	O
in	O	O
specific	O
mammalian	B-ANAT
cell	I-ANAT
and	O	O
tissue	O
types	O
.	O	O

The	O	O
webtool	O
allows	O	O
for	O	O
the	O	O
analysis	B-PROC
of	O	O
CAGE	O
-derived	O	O
transcription	B-CHEM
start	I-CHEM
sites	I-CHEM
(	O	O
TSSs	B-CHEM
)	O	O
either	O	O
provided	O	O
by	O	O
the	O	O
user	B-LIVB
or	O	O
selected	O	O
from	O	O
∼1300	O	O
mammalian	B-LIVB
samples	B-OBJC
from	O	O
the	O	O
FANTOM5	O
project	O
with	O	O
pre	O
-	O
computed	O
TFBS	B-PHYS
predicted	O	O
with	O	O
JASPAR	O
TF	O
binding	O
profiles	O
.	O	O

The	O	O
tool	O
helps	O	O
power	O	O
insights	B-PHYS
into	O	O
the	O	O
regulation	B-PHYS
of	I-PHYS
genes	I-PHYS
through	O	O
the	O	O
study	B-PROC
of	O	O
the	O	O
specific	O
usage	O
of	O	O
TSSs	B-CHEM
within	O	O
specific	O
cell	O
types	O
and	O	O
/	O	O
or	O	O
under	O	O
specific	O
conditions	O
.	O	O

The	O	O
CAGEd	O
-	O
oPOSUM	O
web	O
tool	O
is	O	O
implemented	O	O
in	O	O
Perl	O
,	O	O
MySQL	O
and	O	O
Apache	O
and	O	O
is	O	O
available	O	O
at	O	O
http	O
:	O
/	O
/	O
cagedop	O
.	O

cmmt	O
.	O

ubc	O
.	O
ca	O
/	O
CAGEd	O
_	O
oPOSSUM	O
CONTACTS	O	O
:	O	O
anthony	O
.	O

mathelier	O
@	O
ncmm	O
.	O

uio	O
.	O
no	O
or	O	O
wyeth	O
@	O
cmmt	O
.	O

ubc	O
.	O
ca	O
Supplementary	O
information	O
:	O	O
Supplementary	O
data	O
are	O	O
available	O	O
at	O	O
Bioinformatics	O
online	B-OBJC
.	O	O

Pre	B-DISO
-	I-DISO
hypertension	I-DISO
,	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
or	O	O
both	O	O
:	O	O
which	O	O
is	O	O
best	O	O
at	O	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
in	O	O
the	O	O
long	O
term	O
?	O	O

The	O	O
present	O	O
study	B-PROC
aimed	O	O
to	O	O
assess	O	O
the	O	O
value	O	O
of	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
and	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
in	O	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
.	O	O

A	O	O
population	O
-based	O	O
,	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O	O
conducted	O	O
,	O	O
representing	O	O
a	O	O
large	O	O
sample	O	O
of	O	O
the	O	O
general	O	O
Iranian	B-LIVB
population	B-LIVB
aged	O	O
35	O	O
years	O
and	O	O
older	O	O
from	O	O
the	O	O
Isfahan	B-GEOG
Province	I-GEOG
and	O	O
determined	O	O
using	O	O
a	O	O
random	B-PROC
,	I-PROC
multistage	I-PROC
cluster	I-PROC
-	I-PROC
sampling	I-PROC
10	O	O
-	O	O
year	O	O
cohort	B-LIVB
.	O	O

The	O	O
five	O	O
end	O	O
points	O	O
considered	O	O
as	O	O
study	O
outcome	O
were	O	O
unstable	B-DISO
angina	I-DISO
(	O	O
UA	B-DISO
)	O	O
,	O	O
acute	O
occurrence	O
of	O	O
myocardial	B-DISO
infarction	I-DISO
(	O	O
MI	B-DISO
)	O	O
,	O	O
sudden	B-DISO
cardiac	I-DISO
death	I-DISO
(	O	O
SCD	B-DISO
)	O	O
,	O	O
brain	B-DISO
stroke	I-DISO
and	O	O
cardiovascular	B-DISO
disease	I-DISO
(	O	O
CVD	B-DISO
)	O	O
.	O	O

Of	O	O
the	O	O
6323	O	O
subjects	O	O
scheduled	O	O
for	O	O
assessment	B-PROC
of	O	O
diabetes	B-DISO
state	I-DISO
617	O	O
were	O	O
diabetics	B-DISO
and	O	O
712	O	O
were	O	O
pre	B-DISO
-	I-DISO
diabetic	I-DISO
.	O	O

In	O	O
addition	O	O
,	O	O
of	O	O
these	O	O
subjects	O	O
,	O	O
1754	O	O
had	O	O
hypertension	B-DISO
and	O	O
2500	O	O
had	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
.	O	O

Analysing	O	O
only	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
,	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
and	O	O
its	O	O
combination	O	O
and	O	O
adjusted	O	O
for	O	O
gender	B-PHYS
and	O	O
age	O	O
variables	O	O
,	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
status	O	O
together	O	O
,	O	O
could	O	O
only	O	O
effectively	O	O
predict	O	O
occurrence	O
of	O	O
MI	B-DISO
(	O	O
hazard	O
ratio	O
(	O	O
HR	O
)	O	O
=	O	O
3	O	O
.	O	O
21	O	O
,	O	O

95	O	O
%	O	O
confidence	O
interval	O
(	O	O
CI	O
)	O	O
:	O	O
1	O	O
.	O	O
06	O	O
-	O	O
9	O	O
.	O	O
76	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
04	O	O
)	O	O
.	O	O

In	O	O
the	O	O
same	O	O
COX	O
regression	O
models	O
,	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
status	O	O
could	O	O
predict	O	O
UA	B-DISO
and	O	O
CVD	B-DISO
occurrence	O
(	O	O
HR	O
=	O	O
2	O	O
.	O	O
94	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
68	O	O
-	O	O
5	O	O
.	O	O
14	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
and	O	O
HR	O
=	O	O
1	O	O
.	O	O
74	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
23	O	O
-	O	O
2	O	O
.	O	O
47	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
002	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

However	O	O
,	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
status	O	O
could	O	O
not	O	O
predict	O	O
any	O	O
of	O	O
these	O	O
events	O	O
after	O	O
adjustment	O	O
for	O	O
gender	B-PHYS
and	O	O
age	B-PHYS
.	O	O

Our	O	O
data	O
provide	O	O
valuable	O	O
evidence	O
of	O	O
the	O	O
triggering	O	O
role	O	O
of	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
together	O	O
,	O	O
on	O	O
appearance	O
and	O	O
progression	B-DISO
of	O	O
MI	B-DISO
even	O	O
in	O	O
healthy	B-LIVB
individuals	I-LIVB
and	O	O
the	O	O
significant	O	O
predicting	O
value	O	O
of	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
on	O	O
the	O	O
occurrence	O
of	O	O
UA	B-DISO
and	O	O
CVD	B-DISO
.	O	O

In	O	O
this	O	O
regard	O	O
,	O	O
the	O	O
value	O	O
of	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
and	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
together	O	O
,	O	O
and	O	O
the	O	O
pre	B-DISO
-	I-DISO
hypertension	I-DISO
state	O	O
alone	O	O
,	O	O
are	O	O
clearly	O	O
superior	O	O
to	O	O
pre	B-DISO
-	I-DISO
diabetes	I-DISO
state	O	O
alone	O	O
in	O	O
predicting	O
cardiovascular	B-DISO
events	I-DISO
.	O	O

Self	B-PHYS
-	I-PHYS
assembled	I-PHYS
polymeric	B-CHEM
vectors	B-DEVI
mixtures	B-OBJC
:	O	O
characterization	O
of	O	O
the	O	O
polymorphism	O
and	O	O
existence	O	O
of	O	O
synergistic	O
effects	O
in	O	O
photodynamic	B-PROC
therapy	I-PROC
The	O	O
objective	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
relation	O	O
between	O	O
the	O	O
purity	O
of	O	O
polymeric	B-CHEM
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
vectors	B-DEVI
solution	B-OBJC
and	O	O
their	O	O
photodynamic	B-PROC
therapeutic	I-PROC
efficiency	O
.	O	O

For	O	O
this	O	O
,	O	O
several	O	O
amphiphilic	B-CHEM
block	B-CHEM
copolymers	I-CHEM
of	O	O
poly	B-CHEM
(	I-CHEM
ethyleneoxide	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
ε	I-CHEM
-	I-CHEM
caprolactone	I-CHEM
)	I-CHEM
have	O	O
been	O	O
used	O	O
to	O	O
form	O	O
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
with	O	O
different	O	O
morphologies	O
(	O	O
micelles	B-CHEM
,	O	O
worm	B-CHEM
-	I-CHEM
like	I-CHEM
micelles	I-CHEM
or	O	O
vesicles	O
)	O	O
.	O	O

In	O	O
a	O	O
first	O	O
step	O	O
,	O	O
controlled	B-OBJC
mixtures	I-OBJC
of	O	O
preformed	O	O
micelles	B-CHEM
and	O	O
vesicles	O
have	O	O
been	O	O
characterized	O	O
both	O	O
by	O	O
dynamic	B-PROC
light	I-PROC
scattering	I-PROC
and	O	O
asymmetrical	B-PROC
flow	I-PROC
field	I-PROC
flow	I-PROC
fractionation	I-PROC
(	O	O
AsFlFFF	B-PROC
)	O	O
.	O	O

For	O	O
this	O	O
,	O	O
a	O	O
custom	O
-	O
made	O
program	B-OBJC
,	O	O
STORMS	B-OBJC
,	O	O
was	O	O
developed	O	O
to	O	O
analyze	O	O
DLS	B-PROC
data	O
in	O	O
a	O	O
thorough	O	O
manner	O	O
by	O	O
providing	O	O
a	O	O
large	O	O
set	O	O
of	O	O
fitting	O	O
parameters	O
.	O	O

This	O	O
showed	O	O
that	O	O
DLS	B-PROC
only	O	O
sensed	O	O
the	O	O
larger	O
vesicles	O
when	O	O
the	O	O
micelles	B-CHEM
/	O	O
vesicles	O
ratio	O
was	O	O
80	O	O
/	O	O
20	O	O
w	O	O
/	O	O
w	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
AsFlFFF	B-PROC
allowed	O	O
clear	O	O
detection	B-DISO
of	O	O
the	O	O
presence	O	O
of	O	O
micelles	B-CHEM
when	O	O
this	O	O
same	O	O
ratio	O
was	O	O
as	O	O
low	O	O
as	O	O
10	O	O
/	O	O
90	O	O
.	O	O

Subsequently	O	O
,	O	O
the	O	O
photodynamic	B-PROC
therapy	I-PROC
efficiency	O
of	O	O
various	O	O
controlled	B-OBJC
mixtures	I-OBJC
was	O	O
assessed	O	O
using	O	O
multicellular	O	O
spheroids	B-DISO
when	O	O
a	O	O
photosensitizer	B-CHEM
,	O	O
pheophorbide	B-CHEM
a	I-CHEM
,	O	O
was	O	O
encapsulated	O
in	O	O
the	O	O
polymer	B-CHEM
self	B-PHYS
-	I-PHYS
assemblies	I-PHYS
.	O	O

Some	O	O
mixtures	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
as	O	O
efficient	O
as	O	O
monomorphous	B-DISO
systems	I-DISO
.	O	O

In	O	O
some	O	O
cases	O	O
,	O	O
mixtures	B-OBJC
were	O	O
found	O	O
to	O	O
exhibit	O	O
a	O	O
higher	O	O
PDT	B-PROC
efficiency	O
compared	O	O
to	O	O
the	O	O
individual	O	O
nano	O
-	O	O
objects	B-OBJC
,	O	O
revealing	O	O
a	O	O
synergistic	O
effect	O
for	O	O
the	O	O
efficient	O	O
delivery	B-PHEN
of	O	O
the	O	O
photosensitizer	B-CHEM
.	O	O

Polymorphous	O
vectors	B-DEVI
can	O	O
therefore	O	O
be	O	O
superior	O	O
in	O	O
therapeutic	O
applications	O
.	O	O

Fuzheng	B-CHEM
Qingjie	I-CHEM
Granules	I-CHEM
Inhibit	O
Growth	B-PHYS
of	O	O
Hepatoma	B-ANAT
Cells	I-ANAT
via	O	O
Inducing	O
Mitochondria	B-ANAT
-Mediated	O	O
Apoptosis	B-PHYS
and	O	O
Enhancing	O
Immune	B-PHYS
Function	I-PHYS
Fuzheng	B-CHEM
Qingjie	I-CHEM
(	B-CHEM
FZQJ	I-CHEM
)	I-CHEM
granules	I-CHEM
,	O	O
a	O	O
compound	B-CHEM
Chinese	O
medicine	O
,	O	O
have	O	O
been	O	O
used	O	O
as	O	O
an	O	O
adjuvant	B-PROC
therapy	I-PROC
for	O	O
alimentary	B-ANAT
tract	I-ANAT
cancers	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
underlying	O	O
anticancer	B-DISO
mechanisms	O
are	O	O
still	O	O
not	O	O
well	O	O
understood	O	O
.	O	O

In	O	O
the	O	O
present	O
study	B-PROC
,	O	O
HepG2	B-ANAT
cells	I-ANAT
were	O	O
treated	O
with	O	O
FZQJ	B-CHEM
-	O	O
containing	O
serum	B-ANAT
.	O	O

Cell	B-PHYS
proliferation	I-PHYS
was	O	O
evaluated	B-PROC
using	O	O
MTT	B-PROC
assay	I-PROC
.	O	O

Apoptosis	B-PHYS
was	O	O
analyzed	B-PROC
using	O	O
a	O	O
flow	B-DEVI
cytometer	I-DEVI
.	O	O

Cell	B-ANAT
ultrastructure	I-ANAT
was	O	O
observed	O
under	O	O
a	O	O
transmission	B-DEVI
electron	I-DEVI
microscope	I-DEVI
.	O	O

The	O	O
mitochondrial	B-PHYS
membrane	I-PHYS
potential	I-PHYS
(	O	O
Δψ	B-PHYS
)	O	O
was	O	O
examined	B-DISO
with	O	O
JC	B-CHEM
-	I-CHEM
1	I-CHEM
dye	I-CHEM
.	O	O

In	O	O
H22	B-DISO
tumor	I-DISO
-	I-DISO
bearing	I-DISO
mice	I-DISO
,	O	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O	O
CD3	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
,	O	O
and	O	O
natural	B-ANAT
killer	I-ANAT
cells	I-ANAT
(	O	O
NK	B-ANAT
)	O	O
in	O	O
peripheral	B-ANAT
blood	I-ANAT
were	O	O
evaluated	O	O
cytometrically	B-DEVI
.	O	O

Interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	B-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
levels	O
were	O	O
measured	O
using	O	O
radioimmunoassay	B-PROC
.The	O	O

mRNA	B-CHEM
levels	O
of	O	O
Bax	O
and	O	O
Bcl	O
-	O
2	O
were	O	O
examined	B-DISO
by	O	O
reverse	B-PROC
transcription	I-PROC
-	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
.	O	O

The	O	O
protein	B-CHEM
levels	O
of	O	O
Bax	B-CHEM
,	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
cytochrome	B-CHEM
C	I-CHEM
,	O	O
caspase	B-CHEM
3	I-CHEM
and	O	O
9	B-CHEM
,	O	O
PARP	B-CHEM
,	O	O
and	O	O
CD69	B-CHEM
were	O	O
examined	B-DISO
by	O	O
Western	B-PROC
blotting	I-PROC
.	O	O

The	O	O
apoptotic	O
cells	B-ANAT
in	O	O
tissues	O
were	O	O
observed	O
using	O	O
TUNEL	B-PROC
method	I-PROC
.	O	O

Alanine	B-CHEM
transaminase	I-CHEM
(	O	O
ALT	B-CHEM
)	O	O
,	O	O
aspartate	B-CHEM
transaminase	I-CHEM
(	O	O
AST	B-CHEM
)	O	O
,	O	O
blood	B-CHEM
urea	I-CHEM
nitrogen	I-CHEM
(	O	O
BUN	B-CHEM
)	O	O
,	O	O
and	O	O
creatinine	B-CHEM
(	O	O
CRE	B-CHEM
)	O	O
were	O	O
detected	B-DISO
by	O	O
an	O	O
automatic	O
biochemical	O
analyzer	B-DEVI
.	O	O

The	O	O
results	O
showed	O	O
that	O	O
FZQJ	B-CHEM
-	O	O
containing	O
serum	B-ANAT
remarkably	O	O
inhibited	O
proliferation	B-PHYS
of	O	O
HepG2	B-ANAT
cells	I-ANAT
in	O	O
dose	O
-	O	O
and	O	O
time	O
-	O	O
dependent	O
manners	O	O
,	O	O
induced	O
HepG2	B-ANAT
cell	I-ANAT
apoptosis	B-PHYS
and	O	O
caused	O	O
a	O	O
decrease	O
of	O	O
Δψ	B-PHYS
.	O	O

Analysis	B-PROC
of	O	O
tumor	O
tissue	O
showed	O	O
that	O	O
FZQJ	B-CHEM
-	O	O
induced	O
apoptosis	B-PHYS
was	O	O
accompanied	O	O
by	O	O
downregulation	B-PHYS
of	O	O
Bcl	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
upregulation	B-PHYS
of	O	O
Bax	B-CHEM
,	O	O
release	O
of	O	O
cytochrome	B-CHEM
c	I-CHEM
,	O	O
activation	B-PHYS
of	O	O
caspase	B-CHEM
3	I-CHEM
and	O	O
9	B-CHEM
,	O	O
and	O	O
cleavage	B-PHYS
of	O	O
PARP	B-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
FZQJ	B-CHEM
increased	O
the	O	O
percentages	O
of	O	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
and	O	O
NK	B-ANAT
cells	I-ANAT
,	O	O
the	O	O
ratio	O
of	O	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
/	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
as	O	O
well	O	O
as	O	O
the	O	O
levels	O
of	O	O
serum	B-ANAT
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
.	O	O

FZQJ	B-CHEM
also	O	O
increased	O
CD69	B-CHEM
expression	B-PHYS
in	O	O
tumor	O
tissue	O
.	O	O

No	B-DISO
hepatorenal	I-DISO
toxicity	I-DISO
was	O	O
observed	O
in	O	O
H22	B-DISO
tumor	I-DISO
-	I-DISO
bearing	I-DISO
mice	I-DISO
.	O	O

These	O	O
results	O
indicated	B-DISO
that	O	O
FZQJ	B-CHEM
could	O	O
inhibit	O
the	O	O
growth	B-PHYS
of	O	O
hepatoma	B-ANAT
cells	I-ANAT
via	O	O
regulating	O	O
immune	B-PHYS
function	I-PHYS
and	O	O
inducing	O
mitochondria	B-ANAT
mediated	O	O
apoptosis	B-PHYS
.	O	O

A	O	O
simple	O
and	O	O
biosafe	O
method	O
for	O
isolation	O
of	O	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
Human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O	O
HUVECS	B-ANAT
)	O	O
are	O	O
used	O	O
as	O	O
an	O	O
irreplaceable	O	O
tool	O	O
for	O	O
the	O	O
study	B-PROC
of	O	O
vascular	B-DISO
diseases	I-DISO
.	O	O

However	O	O
,	O	O
the	O	O
technicians	O
who	O	O
isolate	B-PROC
HUVECs	B-ANAT
are	O	O
largely	O	O
exposed	O
to	O	O
potential	O
infectious	O
threats	O
.	O	O

Here	O	O
we	O	O
report	B-PROC
the	O	O
development	O
of	O
a	O
specialized	O
instrument	O
to	O	O
protect	B-PROC
researchers	B-LIVB
from	O	O
known	O
or	O	O
unknown	O
infectious	B-LIVB
agents	I-LIVB
when	O	O
they	O	O
operate	O
on	O	O
human	B-LIVB
umbilical	B-ANAT
cords	I-ANAT
.	O	O

This	O	O
instrument	B-DEVI
can	O	O
be	O	O
assembled	B-PROC
by	O	O
common	O	O
laboratory	B-DEVI
supplies	I-DEVI
and	O	O
adapted	O	O
to	O	O
accommodate	O	O
umbilical	B-ANAT
cords	I-ANAT
of	O	O
different	O	O
lengths	O
.	O	O

When	O	O
the	O	O
cord	B-ANAT
is	O	O
enclosed	O	O
within	O	O
the	O	O
instrument	B-DEVI
,	O	O
the	O	O
risk	O
of	O	O
sample	B-OBJC
contamination	O
and	O	O
operator	B-LIVB
infection	B-DISO
is	O	O
greatly	O	O
reduced	O
.	O	O

Using	O	O
our	O	O
instrument	B-DEVI
,	O	O
endothelial	B-ANAT
cells	I-ANAT
were	O	O
successfully	O	O
isolated	O	O
from	O	O
human	B-LIVB
umbilical	B-ANAT
veins	I-ANAT
without	O	O
contamination	O
.	O	O

The	O	O
cells	B-ANAT
were	O	O
verified	O	O
by	O	O
their	O	O
cobblestone	O
-	O
like	O
morphology	O
and	O	O
by	O	O
immunofluorescence	B-PROC
staining	I-PROC
(	O	O
Factor	B-PROC
VIII	I-PROC
and	O	O
CD31	B-PHEN
positivity	I-PHEN
and	O	O
α	B-PHEN
-	I-PHEN
SMA	I-PHEN
negativity	I-PHEN
)	O	O
.	O	O

Our	O	O
instrument	B-DEVI
simplifies	O	O
and	O	O
optimizes	O	O
the	O	O
cell	B-ANAT
extraction	B-PROC
process	I-PROC
,	O	O
and	O	O
most	O	O
importantly	O	O
elevates	O
the	O	O
biosafety	O
to	O	O
a	O	O
higher	O	O
level	O	O
during	O	O
the	O	O
isolation	B-PROC
of	O	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
.	O	O

Iron	B-DISO
Deficiency	I-DISO
Is	O	O
Common	O	O
During	O	O
Remission	B-DISO
in	O	O
Children	B-LIVB
With	O	O
Inflammatory	B-DISO
Bowel	I-DISO
Disease	I-DISO
The	O	O
aim	O	O
was	O	O
to	O	O
study	B-PROC
prevalence	O
of	O	O
iron	B-DISO
deficiency	I-DISO
in	O	O
children	B-LIVB
with	O	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
(	O	O
IBD	B-DISO
)	O	O
during	O	O
remission	B-DISO
.	O	O

In	O	O
addition	O	O
,	O	O
there	O	O
was	O	O
an	O	O
observational	B-PROC
evaluation	B-PROC
of	O	O
hematological	B-PROC
response	B-PHYS
to	O	O
oral	O
iron	B-CHEM
.	O	O

A	O	O
population	B-PROC
-	I-PROC
based	I-PROC
retrospective	B-PROC
study	I-PROC
including	O	O
90	O	O
Swedish	B-LIVB
children	B-LIVB
(	O	O
median	O
13	O	O
years	O
)	O	O
with	O	O
IBD	B-DISO
was	O	O
performed	O	O
.	O	O

Patient	O
records	O
covered	O	O
in	O	O
median	O
25	O	O
months	O
.	O	O

Iron	B-DISO
deficiency	I-DISO
was	O	O
present	O	O
in	O	O
70	O	O
/	O	O
77	O	O
children	B-LIVB
(	O	O
91	O	O
%	O	O
)	O	O
in	O	O
which	O	O
iron	B-PROC
status	I-PROC
could	O	O
be	O	O
assessed	O
.	O	O

In	O	O
clinical	O
and	O	O
biochemical	O
remission	B-DISO
,	O	O
iron	B-DISO
deficiency	I-DISO
was	O	O
found	O	O
in	O	O
57	O	O
/	O	O
67	O	O
(	O	O
85	O	O
%	O	O
)	O	O
of	O	O
children	B-LIVB
,	O	O
and	O	O
23	O	O
(	O	O
34	O	O
%	O	O
)	O	O
of	O	O
them	O	O
had	O	O
iron	B-DISO
deficiency	I-DISO
anemia	I-DISO
.	O	O

Thirty	O	O
-	O	O
six	O	O
iron	B-DISO
-	I-DISO
deficient	I-DISO
children	B-LIVB
were	O	O
prescribed	B-PROC
oral	B-PROC
iron	B-PROC
supplementation	I-PROC
and	O	O
32	O	O
(	O	O
89	O	O
%	O	O
)	O	O
improved	O	O
hemoglobin	B-PHEN
levels	I-PHEN
over	O	O
6	O	O
months	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
iron	B-DISO
deficiency	I-DISO
is	O	O
common	O	O
during	O	O
clinical	O
remission	B-DISO
in	O	O
children	B-LIVB
with	O	O
IBD	B-DISO
,	O	O
even	O	O
in	O	O
cohorts	B-LIVB
with	O	O
low	O
prevalence	O
of	O	O
anemia	B-DISO
.	O	O

Therefore	O	O
,	O	O
regular	O	O
biochemical	B-PROC
screening	I-PROC
for	O	O
iron	B-DISO
deficiency	I-DISO
is	O	O
warranted	O	O
during	O	O
all	O	O
stages	O
of	O	O
disease	B-DISO
,	O	O
irrespective	O	O
of	O	O
symptoms	B-DISO
and	O	O
inflammatory	O
blood	B-ANAT
markers	B-PHYS
.	O	O

Chemisorption	O
of	O	O
Perfluorooctanoic	B-CHEM
Acid	I-CHEM
on	O	O
Powdered	B-CHEM
Activated	I-CHEM
Carbon	I-CHEM
Initiated	O	O
by	O	O
Persulfate	B-CHEM
in	O	O
Aqueous	O
Solution	B-OBJC
Perfluorooctanoic	B-CHEM
acid	I-CHEM
(	O	O
PFOA	B-CHEM
)	O	O
is	O	O
a	O	O
perfluorocarboxylic	B-CHEM
acid	I-CHEM
that	O	O
is	O	O
difficult	O	O
to	O	O
treat	O	O
by	O	O
most	O	O
conventional	O
methods	O	O
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
it	O	O
is	O	O
often	O	O
removed	O	O
from	O	O
solution	B-OBJC
by	O	O
adsorption	B-PROC
on	O	O
powdered	B-CHEM
activated	I-CHEM
carbon	I-CHEM
(	O	O
PAC	B-CHEM
)	O	O
,	O	O
followed	O	O
by	O	O
incineration	B-PHEN
of	O	O
the	O	O
spent	O	O
carbon	B-CHEM
.	O	O

To	O	O
provide	O	O
a	O	O
new	O	O
approach	O	O
for	O	O
treatment	O
,	O	O
PFOA	B-CHEM
was	O	O
exposed	O	O
to	O	O
sulfate	B-CHEM
radicals	I-CHEM
(	O	O
SO4	B-CHEM
(	I-CHEM
-	I-CHEM
•	I-CHEM
)	I-CHEM
)	O	O
produced	O	O
by	O	O
thermolysis	B-PHEN
of	O	O
persulfate	B-CHEM
(	O	O
S2O8	B-CHEM
(	I-CHEM
2	I-CHEM
-	I-CHEM
)	I-CHEM
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
PAC	B-CHEM
.	O	O

Under	O	O
acidic	O	O
conditions	O	O
,	O	O
thermal	B-PHEN
activation	O
of	O	O
persulfate	B-CHEM
resulted	O	O
in	O	O
transformation	O	O
of	O	O
PFOA	B-CHEM
to	O	O
shorter	O	O
-	O	O
chain	O	O
-	O	O
length	O	O
perfluorinated	B-CHEM
compounds	I-CHEM
,	O	O
as	O	O
previously	O	O
reported	O	O
.	O	O

However	O	O
,	O	O
when	O	O
thermolysis	B-PHEN
of	O	O
persulfate	B-CHEM
occurred	O	O
under	O	O
circumneutral	O
pH	O
conditions	O
in	O	O
the	O	O
presence	O	O
of	O	O
PAC	B-CHEM
,	O	O
a	O	O
new	O	O
removal	O
pathway	O	O
for	O	O
PFOA	B-CHEM
was	O	O
observed	O	O
.	O	O

Under	O	O
these	O	O
conditions	O	O
,	O	O
the	O	O
removal	O
of	O	O
PFOA	B-CHEM
was	O	O
attributable	O	O
to	O	O
chemisorption	O
,	O	O
a	O	O
process	O	O
in	O	O
which	O	O
PAC	B-CHEM
catalyzed	B-PHEN
persulfate	B-CHEM
decomposition	O	O
and	O	O
reacted	O	O
with	O	O
the	O	O
transformation	O	O
products	O	O
to	O	O
produce	O	O
covalently	B-PHEN
bound	I-PHEN
PFOA	B-CHEM
.	O	O

At	O	O
PAC	B-CHEM
concentrations	O
between	O	O
200	O	O
and	O	O
1000	O	O
mg	O	O
/	O	O
L	O	O
and	O	O
an	O	O
initial	O	O
PFOA	B-CHEM
concentration	O
of	O	O
0	O	O
.	O	O

5	O	O
μM	O	O
,	O	O
covalent	B-PHEN
bonding	I-PHEN
resulted	O	O
in	O	O
removal	O
of	O	O
10	O	O
-	O	O
40	O	O
%	O	O
of	O	O
the	O	O
PFOA	B-CHEM
.	O	O

Under	O	O
these	O	O
conditions	O	O
,	O	O
the	O	O
process	O	O
resulted	O	O
in	O	O
removal	O
of	O	O
more	O	O
than	O	O
half	O	O
of	O	O
a	O	O
more	O	O
hydrophilic	O	O
perfluoroalkyl	B-CHEM
acid	I-CHEM
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
perfluorobutanoic	B-CHEM
acid	I-CHEM
,	O	O
PFBA	B-CHEM
)	O	O
,	O	O
which	O	O
was	O	O
greater	O	O
than	O	O
the	O	O
amount	O	O
of	O	O
PFBA	B-CHEM
removed	O	O
by	O	O
physical	O	O
adsorption	B-PROC
on	O	O
PAC	B-CHEM
.	O	O

Although	O	O
the	O	O
high	O
reaction	B-PHEN
temperatures	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
80	O	O
°	O	O
C	O	O
)	O	O
and	O	O
relatively	O	O
high	O	O
doses	O	O
of	O	O
PAC	B-CHEM
used	O	O
in	O	O
this	O	O
study	O	O
may	O	O
be	O	O
impractical	O	O
for	O	O
drinking	B-OBJC
water	I-OBJC
treatment	O
,	O	O
this	O	O
process	O	O
may	O	O
be	O	O
applied	O	O
to	O	O
the	O	O
treatment	O
of	O	O
these	O	O
recalcitrant	O	O
compounds	O	O
in	O	O
industrial	O
wastewater	B-PHEN
,	O	O
reverse	B-PHEN
osmosis	I-PHEN
concentrate	O
,	O	O
and	O	O
other	O	O
waters	B-CHEM
that	O	O
contain	O	O
high	O	O
concentrations	O
of	O	O
PFOA	B-CHEM
and	O	O
other	O	O
perfluorocarboxylic	B-CHEM
acids	I-CHEM
.	O	O

Professional	O
reinventions	O
:	O	O
Swedish	B-LIVB
psychologists	B-LIVB
,	O	O
1990	O	O
-	O	O
2010	O	O
Since	O	O
the	O	O
early	O	O
20th	O
century	O
,	O	O
the	O	O
Swedish	B-LIVB
psychology	O
profession	O
has	O	O
undergone	O	O
several	O	O
changes	O
in	O	O
its	O	O
essential	O
tasks	O
,	O	O
epistemological	O
foundations	O
,	O	O
and	O	O
social	O
roles	O
.	O	O

These	O	O
changes	O
occurred	O
through	O	O
an	O	O
ongoing	O	O
""""	O	O
tuning	O	O
""""	O	O
with	O	O
Swedish	B-LIVB
society	O
,	O	O
in	O	O
which	O	O
the	O	O
profession	O
strove	O	O
to	O	O
appear	O	O
relevant	O	O
to	O	O
society	O
's	O
concerns	O
and	O	O
problems	B-DISO
as	O	O
well	O	O
as	O	O
enroll	O	O
others	O	O
to	O	O
share	O	O
the	O	O
profession	O
's	O
goals	O
and	O	O
aims	O
.	O	O

Studying	O	O
the	O	O
history	O
of	O	O
the	O	O
profession	O
can	O	O
thus	O	O
shed	O	O
light	O	O
on	O	O
the	O	O
changing	O
definitions	O
and	O	O
contours	O
of	O	O
the	O	O
psychology	O
profession	O
itself	O	O
as	O	O
well	O	O
as	O	O
on	O	O
the	O	O
organization	O
of	O	O
the	O	O
society	O
in	O	O
which	O	O
it	O	O
acts	O	O
.	O	O

This	O	O
article	O
examines	O	O
the	O	O
history	O
of	O	O
the	O	O
Swedish	B-LIVB
psychology	O
profession	O
from	O	O
1990	O	O
to	O	O
2010	O	O
,	O	O
through	O	O
an	O	O
analysis	B-PROC
of	O	O
the	O	O
discussions	O
and	O	O
debates	O
taking	O	O
place	O	O
in	O	O
the	O	O
Swedish	B-LIVB
Psychological	B-OBJC
Association	I-OBJC
's	I-OBJC
journal	I-OBJC
.	O	O

The	O	O
analytical	O
framework	O
used	O	O
draws	O	O
on	O	O
work	O	O
done	O	O
within	O	O
actor	O
-	O
network	O
theory	O
and	O	O
science	B-PROC
studies	I-PROC
.	O	O

We	O	O
argue	O	O
that	O	O
the	O	O
profession	O
's	O
institutional	O
connections	O
,	O	O
defining	O	O
tasks	O
,	O	O
epistemological	O
underpinnings	O
,	O	O
and	O	O
social	O
position	O
have	O	O
changed	O
in	O	O
major	O	O
ways	O	O
during	O	O
these	O	O
2	O	O
decades	O
.	O	O

Overall	O	O
,	O	O
as	O	O
a	O	O
result	O	O
of	O	O
an	O	O
increasingly	O	O
felt	O	O
insecurity	B-PHYS
,	O	O
the	O	O
profession	O
has	O	O
turned	O	O
outward	O	O
and	O	O
tried	O	O
to	O	O
find	O	O
new	O	O
ways	O	O
to	O	O
legitimize	O
itself	O	O
to	O	O
politicians	B-LIVB
,	O	O
the	O	O
media	O
,	O	O
patients	B-LIVB
,	O	O
and	O	O
customers	O
through	O	O
means	O	O
such	O	O
as	O	O
a	O	O
more	O	O
economized	O
vocabulary	O
and	O	O
novel	O
forms	O	O
of	O	O
empirical	B-PROC
research	I-PROC
.	O	O

These	O	O
changes	O
have	O	O
led	O	O
to	O	O
a	O	O
more	O	O
socialized	O
profession	O
,	O	O
now	O	O
more	O	O
closely	O	O
tuned	O	O
to	O	O
other	O	O
actors	B-LIVB
in	O	O
Swedish	B-LIVB
society	O
,	O	O
leading	O	O
to	O	O
conflicts	O
within	O	O
the	O	O
profession	O
over	O	O
whether	O	O
this	O	O
is	O	O
an	O	O
opportunity	O	O
to	O	O
better	O	O
control	O
their	O	O
own	O	O
destiny	O	O
or	O	O
if	O	O
it	O	O
will	O	O
lead	O	O
to	O	O
a	O	O
loss	B-DISO
of	I-DISO
autonomy	I-DISO
.	O	O

(	O	O
PsycINFO	O
Database	O
Record	O

Clinical	O
manifestations	O
,	O	O
course	O
,	O	O
and	O	O
outcome	O
of	O
patients	O
with	O	O
neutralizing	B-CHEM
anti	I-CHEM
-	I-CHEM
interferon	I-CHEM
-	I-CHEM
γ	I-CHEM
autoantibodies	I-CHEM
and	O	O
disseminated	O
nontuberculous	B-LIVB
mycobacterial	I-LIVB
infections	B-DISO
Neutralizing	B-CHEM
anti	I-CHEM
-	I-CHEM
interferon	I-CHEM
-	I-CHEM
γ	I-CHEM
autoantibody	I-CHEM
(	O	O
nAIGA	B-CHEM
)	O	O
-	O	O
associated	O	O
immunodeficiency	B-DISO
is	O	O
an	O	O
emerging	O	O
medical	B-PROC
issue	I-PROC
worldwide	O
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
describe	O	O
and	O	O
discuss	O	O
the	O	O
clinical	B-DISO
features	I-DISO
and	O	O
outcomes	B-DISO
of	O	O
patients	B-LIVB
with	O	O
nAIGAs	B-CHEM
and	O	O
disseminated	O
infections	B-DISO
by	O	O
nontuberculous	B-LIVB
mycobacteria	I-LIVB
(	O	O
dNTM	B-LIVB
)	O	O
.	O	O

We	O	O
thoroughly	O	O
reviewed	O	O
the	O	O
medical	B-PHYS
records	I-PHYS
of	O	O
all	O	O
patients	B-LIVB
.	O	O

Microorganisms	B-LIVB
and	O	O
nAIGAs	B-CHEM
were	O	O
identified	O
using	O	O
previously	O	O
described	O
methods	O	O
with	O	O
modifications	O	O
.	O	O

All	O	O
data	O	O
were	O	O
calculated	O	O
and	O	O
analyzed	B-PROC
using	O	O
SPSS	O
software	O
.Among	O	O
46	O	O
adult	O	O
patients	B-LIVB
with	O	O
dNTM	B-LIVB
infections	B-DISO
,	O	O
we	O	O
identified	O
45	O	O
cases	O	O
(	O	O
97	O	O
.	O	O
8	O	O
%	O	O
)	O	O
with	O	O
nAIGAs	B-CHEM
.	O	O

The	O	O
average	O	O
patient	B-LIVB
age	O	O
was	O	O
58	O	O
.	O	O

6	O	O
years	O	O
,	O	O
and	O	O
there	O	O
was	O	O
no	B-DISO
sex	B-PHYS
predominance	B-DISO
.	O	O

Cervical	B-DISO
lymphadenitis	I-DISO
(	O	O
81	O	O
.	O	O

8	O	O
%	O	O
)	O	O
was	O	O
the	O	O
most	O	O
common	O	O
clinical	O
manifestation	O
.	O	O

Endocrine	B-DISO
disorder	I-DISO
was	O	O
the	O	O
leading	O	O
comorbidity	O
(	O	O
7	O	O
cases	O	O
)	O	O
.	O	O

Malignancies	B-DISO
were	O	O
found	O	O
in	O	O
4	O	O
patients	B-LIVB
,	O	O
and	O	O
all	O	O
of	O	O
the	O	O
malignancies	B-DISO
originated	O	O
from	O	O
the	O	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
/	O	O
macrophage	B-ANAT
lineage	O
.	O	O

More	O	O
than	O	O
half	O	O
of	O	O
the	O	O
identifiable	O	O
isolates	B-CHEM
were	O	O
slow	B-DISO
-	I-DISO
growing	I-DISO
NTMs	B-LIVB
.	O	O

Twenty	O	O
-	O	O
eight	O	O
(	O	O
62	O	O
.	O	O
2	O	O
%	O	O
)	O	O
and	O	O
18	O	O
(	O	O
40	O	O
.	O	O
0	O	O
%	O	O
)	O	O
patients	B-LIVB
had	O	O
a	O	O
history	O	O
of	O	O
zoster	B-DISO
and	O	O
salmonellosis	B-DISO
,	O	O
respectively	O	O
.	O	O

A	O	O
high	O	O
proportion	O
of	O	O
patients	B-LIVB
with	O	O
recurrent	O
episodes	O	O
of	O	O
NTM	B-LIVB
infection	B-DISO
or	O	O
a	O	O
history	O	O
of	O	O
zoster	B-DISO
and	O	O
dNTM	B-LIVB
infection	B-DISO
had	O	O
initial	O	O
nAIGA	B-PROC
titers	I-PROC
≥10	O	O
dilution	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
seven	O	O
patients	B-LIVB
(	O	O
60	O	O
.	O	O

0	O	O
%	O	O
)	O	O
required	O	O
long	O	O
-	O	O
term	O	O
antimycobacterial	B-CHEM
therapy	B-PROC
and	O	O
had	O	O
at	O	O
least	O	O
1	O	O
episode	O	O
of	O	O
recurrent	O
NTM	B-LIVB
disease	B-DISO
.	O	O

No	O	O
mortality	O	O
was	O	O
related	O	O
to	O	O
dNTM	B-LIVB
infection	B-DISO
.In	O	O

Taiwan	B-GEOG
,	O	O
nAIGAs	B-CHEM
are	O	O
a	O	O
recently	O	O
recognized	O	O
mechanism	O
of	O	O
dNTM	B-LIVB
infection	B-DISO
.	O	O

Long	O	O
term	O	O
of	O	O
antibiotic	B-PROC
treatment	I-PROC
and	O	O
adherence	O
to	O	O
medical	B-DISO
advice	I-DISO
are	O	O
necessary	O	O
to	O	O
improve	O	O
the	O	O
clinical	O
outcome	O
of	O
patients	O
with	O	O
nAIGAs	B-CHEM
.	O	O

Strategies	B-PROC
for	O	O
Successful	O
Clinical	O
Teaching	B-PROC
This	O	O
article	O
is	O	O
one	O	O
in	O	O
a	O	O
series	O	O
on	O	O
the	O	O
roles	O
of	O	O
adjunct	B-LIVB
clinical	I-LIVB
faculty	I-LIVB
and	O	O
preceptors	B-LIVB
,	O	O
who	O	O
teach	B-PROC
nursing	B-LIVB
students	I-LIVB
and	O	O
new	O
graduates	B-LIVB
to	O	O
apply	O
knowledge	O
in	O	O
clinical	O
settings	O
.	O	O

This	O	O
article	O
describes	O	O
teaching	B-PROC
strategies	I-PROC
as	O	O
well	O	O
as	O	O
the	O	O
importance	O	O
of	O	O
the	O	O
learning	O
environment	O
.	O	O

Personally	O
Meaningful	O
Rituals	O
:	O	O
A	O	O
Way	O	O
to	O	O
Increase	O
Compassion	O
and	O	O
Decrease	O
Burnout	B-DISO
among	O	O
Hospice	B-PROC
Staff	B-LIVB
and	O	O
Volunteers	B-LIVB
Rituals	O
can	O	O
increase	O
a	O	O
sense	O
of	O
connectedness	O
,	O	O
meaning	O
,	O	O
and	O	O
support	O
,	O	O
especially	O	O
after	O	O
the	O	O
death	B-PHYS
of	O	O
those	O	O
for	O	O
whom	O	O
we	O	O
care	O	O
.	O	O

Hospice	B-PROC
staff	B-LIVB
may	O	O
benefit	O	O
from	O	O
the	O	O
use	O	O
of	O	O
personal	O
rituals	O
as	O	O
they	O	O
cope	O
with	O
the	O	O
frequent	O
deaths	O
of	O	O
their	O	O
patients	B-LIVB
,	O	O
ultimately	O	O
aiming	O	O
to	O	O
provide	O	O
compassionate	O
care	O
while	O	O
minimizing	O	O
burnout	B-DISO
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
role	O	O
of	O	O
personally	O
meaningful	O
rituals	O
in	O	O
increasing	O
compassion	O
and	O	O
decreasing	O
burnout	B-DISO
among	O	O
hospice	B-PROC
staff	B-LIVB
and	O	O
volunteers	B-LIVB
.	O	O

An	O	O
online	O
survey	O
was	O	O
completed	O	O
by	O	O
members	O	O
of	O	O
the	O	O
National	B-OBJC
Hospice	I-OBJC
and	I-OBJC
Palliative	I-OBJC
Care	I-OBJC
Organization	I-OBJC
(	O	O
NHPCO	B-OBJC
)	O	O
which	O	O
inquired	O	O
about	O	O
personal	O
ritual	O
practices	O	O
,	O	O
and	O	O
included	O	O
the	O	O
Professional	O
Quality	O
of	O
Life	O
(	O
ProQOL	O
)	O
scale	O
to	O	O
measure	O	O
current	O	O
levels	O	O
of	O	O
Compassion	O
Satisfaction	B-PHYS
,	O	O
Burnout	B-DISO
,	O	O
and	O	O
Secondary	B-DISO
Traumatic	I-DISO
Stress	I-DISO
.	O	O

Three	O	O
hundred	O	O
ninety	O	O
hospice	B-PROC
staff	B-LIVB
and	O	O
volunteers	B-LIVB
from	O	O
across	O	O
38	O	O
states	B-GEOG
completed	O	O
the	O	O
online	O
survey	O
.	O	O

The	O	O
majority	O	O
of	O	O
participants	B-LIVB
were	O	O
Caucasian	B-LIVB
and	O	O
female	B-PHYS
,	O	O
with	O	O
an	O	O
average	O	O
of	O	O
nine	O	O
years	O	O
of	O	O
experience	O	O
in	O	O
hospice	B-OBJC
and	I-OBJC
palliative	I-OBJC
care	I-OBJC
.	O	O

The	O	O
majority	O	O
of	O	O
hospice	B-PROC
staff	B-LIVB
and	O	O
volunteers	B-LIVB
used	O	O
personally	O	O
meaningful	O	O
rituals	O
after	O	O
the	O	O
death	B-PHYS
of	O	O
their	O	O
patients	B-LIVB
to	O	O
help	O	O
them	O	O
cope	O
(	O	O
71	O	O
%	O	O
)	O	O
.	O	O

Those	O	O
who	O	O
used	O	O
rituals	O
demonstrated	O	O
significantly	O	O
higher	O	O
Compassion	O
Satisfaction	B-PHYS
and	O	O
significantly	O	O
lower	O	O
Burnout	B-DISO
as	O	O
measured	O	O
by	O	O
the	O	O
ProQOL	O
,	O	O
with	O	O
professional	B-DISO
support	I-DISO
,	O	O
social	O
support	O
,	O	O
and	O	O
age	B-PHYS
playing	O	O
significant	B-DISO
roles	I-DISO
as	O	O
well	O	O
.	O	O

Rituals	O
may	O	O
be	O	O
an	O	O
important	O	O
way	O	O
to	O	O
increase	O
compassion	O
and	O	O
decrease	O
burnout	B-DISO
among	O	O
hospice	B-PROC
staff	B-LIVB
and	O	O
volunteers	B-LIVB
.	O	O

Organizations	B-OBJC
may	O	O
benefit	O	O
from	O	O
providing	O	O
training	B-PROC
and	I-PROC
support	I-PROC
for	O	O
personalized	O
rituals	O
among	O	O
team	O	O
members	O	O
,	O	O
especially	O	O
new	B-LIVB
staff	I-LIVB
who	O	O
may	O	O
be	O	O
at	O
greater	O
risk	O
for	O	O
burnout	B-DISO
.	O	O

Learned	B-PHYS
helplessness	I-PHYS
at	O	O
fifty	O	O
:	O	O
Insights	B-PHYS
from	O	O
neuroscience	O
Learned	B-PHYS
helplessness	I-PHYS
,	O	O
the	O	O
failure	O
to	O	O
escape	B-PHYS
shock	B-DISO
induced	O
by	O	O
uncontrollable	O	O
aversive	O
events	O
,	O	O
was	O	O
discovered	O	O
half	O	O
a	O	O
century	O	O
ago	O	O
.	O	O

Seligman	B-LIVB
and	I-LIVB
Maier	I-LIVB
(	O	O
1967	O	O
)	O	O
theorized	O
that	O	O
animals	B-LIVB
learned	B-PHYS
that	O	O
outcomes	O
were	O	O
independent	O
of	O
their	O	O
responses	B-PHYS
-that	O	O
nothing	O	O
they	O	O
did	O	O
mattered	O	O
-	O	O
and	O	O
that	O	O
this	O	O
learning	B-PHYS
undermined	O	O
trying	O	O
to	O	O
escape	B-PHYS
.	O	O

The	O	O
mechanism	O	O
of	O	O
learned	B-PHYS
helplessness	I-PHYS
is	O	O
now	O	O
very	O	O
well	O
-	O
charted	O
biologically	O
,	O	O
and	O	O
the	O	O
original	O	O
theory	O
got	O	O
it	O	O
backward	O	O
.	O	O

Passivity	O
in	O	O
response	B-PHYS
to	O	O
shock	B-DISO
is	O	O
not	O	O
learned	B-PHYS
.	O	O

It	O	O
is	O	O
the	O	O
default	O	O
,	O	O
unlearned	O	O
response	B-PHYS
to	O	O
prolonged	O
aversive	O
events	O
and	O	O
it	O	O
is	O	O
mediated	O	O
by	O	O
the	O	O
serotonergic	B-PHYS
activity	I-PHYS
of	O	O
the	O	O
dorsal	B-ANAT
raphe	I-ANAT
nucleus	I-ANAT
,	O	O
which	O	O
in	O	O
turn	O	O
inhibits	O
escape	B-PHYS
.	O	O

This	O	O
passivity	O
can	O	O
be	O	O
overcome	O	O
by	O	O
learning	B-PHYS
control	O
,	O	O
with	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
medial	B-ANAT
prefrontal	I-ANAT
cortex	I-ANAT
,	O	O
which	O	O
subserves	O	O
the	O	O
detection	B-DISO
of	O	O
control	O
leading	O	O
to	O	O
the	O	O
automatic	O
inhibition	O
of	O	O
the	O	O
dorsal	B-ANAT
raphe	I-ANAT
nucleus	I-ANAT
.	O	O

So	O	O
animals	B-LIVB
learn	B-PHYS
that	O	O
they	O	O
can	O	O
control	O
aversive	O
events	O
,	O	O
but	O	O
the	O	O
passive	O
failure	O
to	O	O
learn	B-PHYS
to	O	O
escape	B-PHYS
is	O	O
an	O	O
unlearned	O	O
reaction	O
to	O	O
prolonged	O
aversive	B-PROC
stimulation	I-PROC
.	O	O

In	O	O
addition	O	O
,	O	O
alterations	O
of	O	O
the	O	O
ventromedial	B-ANAT
prefrontal	I-ANAT
cortex	I-ANAT
-	O	O
dorsal	B-ANAT
raphe	I-ANAT
pathway	O
can	O	O
come	O	O
to	O	O
subserve	O	O
the	O	O
expectation	O
of	O	O
control	O
.	O	O

We	O	O
speculate	O	O
that	O	O
default	O	O
passivity	O
and	O	O
the	O	O
compensating	O
detection	B-DISO
and	O	O
expectation	O
of	O	O
control	O
may	O	O
have	O	O
substantial	O	O
implications	O	O
for	O	O
how	O	O
to	O	O
treat	O
depression	B-DISO
.	O	O

(	O	O
PsycINFO	O	O
Database	O	O
Record	O	O

STRANGULATION	O
-INDUCED	O	O
CENTRAL	B-DISO
RETINAL	I-DISO
ARTERY	I-DISO
OCCLUSION	I-DISO
:	O	O
CASE	O
REPORT	O
AND	O	O
REVIEW	O
OF	O
THE	O
LITERATURE	O
To	O	O
describe	O	O
a	O	O
patient	B-LIVB
with	O	O
central	B-DISO
retinal	I-DISO
artery	I-DISO
occlusion	I-DISO
following	O	O
an	O	O
episode	O	O
of	O	O
mechanical	O	O
strangulation	O
.	O	O

A	O	O
retrospective	B-PROC
case	O
report	O
.	O	O

An	O	O
83	O	O
-	O	O
year	B-LIVB
-	I-LIVB
old	I-LIVB
man	B-LIVB
presented	O	O
with	O	O
acute	B-DISO
vision	I-DISO
loss	I-DISO
in	O	O
his	O	O
right	B-ANAT
eye	I-ANAT
after	O	O
a	O	O
strangling	O
episode	O	O
.	O	O

Multimodal	B-PROC
clinical	I-PROC
imaging	I-PROC
was	O	O
performed	O	O
.	O	O

Visual	B-PHYS
acuity	I-PHYS
in	O	O
the	O	O
affected	O
right	B-ANAT
eye	I-ANAT
was	O	O
no	B-PHEN
light	I-PHEN
perception	I-PHEN
.	O	O

Examination	B-PROC
revealed	O
optic	B-DISO
nerve	I-DISO
edema	I-DISO
and	O	O
optic	B-DISO
nerve	I-DISO
pallor	I-DISO
and	O	O
also	O	O
severe	O	O
vascular	B-DISO
attenuation	I-DISO
and	O	O
a	O	O
cherry	B-DISO
-	I-DISO
red	I-DISO
spot	I-DISO
in	O	O
the	O	O
macula	B-ANAT
.	O	O

Mechanical	B-PROC
disruption	I-PROC
of	O	O
carotid	B-DISO
plaque	I-DISO
can	O	O
lead	O	O
to	O	O
occlusion	B-DISO
of	I-DISO
the	I-DISO
central	I-DISO
retinal	I-DISO
artery	I-DISO
,	O	O
which	O	O
may	O	O
portend	O	O
a	O	O
dismal	B-DISO
visual	O
prognosis	B-PHYS
.	O	O

Glomerulonephritis	B-DISO
With	O	O
Masked	O	O
Monotypic	B-DISO
Immunoglobulin	I-DISO
Deposits	I-DISO
and	O	O
Concurrent	O
Lymphomatous	B-DISO
Infiltration	I-DISO
Kidney	B-DISO
injury	I-DISO
can	O	O
be	O	O
a	O	O
complication	B-DISO
of	O	O
hematopoietic	B-DISO
neoplasia	I-DISO
by	O	O
both	O	O
direct	O
and	O	O
indirect	O
mechanisms	O
.	O	O

Virtually	O	O
all	O	O
lymphomas	B-DISO
and	O	O
plasma	B-DISO
cell	I-DISO
dyscrasias	I-DISO
can	O	O
show	O	O
kidney	B-ANAT
involvement	O
,	O	O
including	O	O
parenchymal	B-DISO
infiltration	I-DISO
and	O	O
by	O	O
secondary	O	O
injury	B-DISO
.	O	O

Recently	O	O
,	O	O
a	O	O
unique	O	O
form	O	O
of	O	O
glomerulonephritis	B-DISO
with	O	O
masked	O	O
monotypic	B-DISO
immunoglobulin	I-DISO
deposits	I-DISO
has	O	O
been	O	O
reported	O	O
,	O	O
which	O	O
shows	O	O
frequent	O	O
association	O	O
with	O	O
hematopoietic	B-DISO
neoplasia	I-DISO
and	O	O
a	O	O
propensity	O	O
for	O	O
progressive	O
kidney	B-DISO
disease	I-DISO
.	O	O

In	O	O
many	O	O
instances	O	O
,	O	O
these	O	O
cases	O	O
are	O	O
likely	O	O
diagnosed	B-DISO
as	O	O
glomerulonephritis	B-DISO
with	O	O
dominant	O
C3	B-DISO
due	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
immunoglobulin	B-DISO
staining	I-DISO
by	O	O
routine	O	O
immunofluorescence	B-PROC
microscopy	I-PROC
.	O	O

The	O	O
patient	B-LIVB
reported	O	O
here	O	O
showed	O	O
lymphomatous	B-DISO
infiltration	I-DISO
on	O	O
kidney	B-PROC
biopsy	I-PROC
and	O	O
mesangial	B-DISO
proliferative	I-DISO
glomerulonephritis	I-DISO
with	O	O
dominant	O
staining	B-DISO
for	O	O
C3	B-DISO
without	O	O
immunoglobulins	B-CHEM
on	O	O
initial	O	O
immunofluorescence	B-PROC
;	O	O
however	O	O
,	O	O
monotypic	B-CHEM
immunoglobulin	I-CHEM
G	I-CHEM
κ	I-CHEM
light	B-CHEM
chain	I-CHEM
was	O	O
revealed	O	O
after	O	O
additional	O	O
immunofluorescence	B-PROC
staining	I-PROC
was	O	O
performed	O	O
on	O	O
the	O	O
paraffin	O
-	O
embedded	O
tissue	O
.	O	O

This	O	O
patient	B-LIVB
's	I-LIVB
case	O	O
highlights	O	O
the	O	O
evolving	O	O
state	O	O
of	O	O
kidney	B-PROC
biopsy	I-PROC
interpretation	O	O
and	O	O
the	O	O
expanding	O	O
spectrum	O	O
of	O	O
kidney	B-DISO
disease	I-DISO
in	O	O
the	O	O
setting	O	O
of	O	O
hematopoietic	B-DISO
neoplasia	I-DISO
.	O	O

Does	O	O
genistein	B-CHEM
lower	O	O
plasma	B-PROC
lipids	I-PROC
and	O	O
homocysteine	B-PROC
levels	I-PROC
in	O	O
postmenopausal	B-PHYS
women	B-LIVB
?	O	O

A	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
To	O	O
perform	O
a	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
examining	B-DISO
the	O	O
effects	O
of	O	O
genistein	B-CHEM
on	O	O
homocysteine	O	O
and	O	O
lipid	B-PROC
levels	I-PROC
in	O	O
postmenopausal	B-PHYS
women	B-LIVB
.	O	O

We	O	O
systematically	O
searched	O
the	O	O
PubMed	O
,	O	O
MEDLINE	O
,	O	O
and	O	O
Cochrane	O
Library	O
databases	O
and	O	O
the	O	O
ClinicalTrials	O
.	O

gov	O
website	O
for	O	O
studies	B-PROC
.	O	O

We	O	O
performed	O	O
a	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
using	O	O
weighted	O
mean	O
differences	O
(	O	O
WMD	O
)	O	O
and	O	O
95	O	O
%	O	O
confidence	O
intervals	O
in	O	O
a	O	O
random	O
-	O
effects	O
model	O
.	O	O

We	O	O
assessed	O
between	O	O
-	O	O
study	B-PROC
heterogeneity	O
using	O	O
the	O	O
Cochran	O
's	O
Q	O
and	O	O
I	O
(	O
2	O
)	O
statistics	O
.	O	O

Eight	O	O
randomized	B-PROC
,	I-PROC
controlled	I-PROC
trials	I-PROC
with	O	O
a	O	O
total	O	O
of	O	O
476	O	O
subjects	O	O
were	O	O
included	O	O
in	O	O
the	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O	O

Compared	O	O
with	O	O
placebos	B-PROC
,	O	O
genistein	B-CHEM
was	O	O
effective	O
in	O	O
reducing	O	O
plasma	B-ANAT
levels	O	O
of	O	O
homocysteine	B-CHEM
(	O	O
WMD	O
,	O	O
-0	O	O
.	O	O
58	O	O
μmol	O	O
/	O	O
l	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
increasing	O	O
high	B-CHEM
density	I-CHEM
lipoprotein	I-CHEM
(	I-CHEM
HDL	I-CHEM
)	I-CHEM
cholesterol	I-CHEM
levels	O	O
(	O	O
WMD	O
,	O	O
4	O	O
.	O	O
9	O	O
mg	O	O
/	O	O
dl	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0002	O	O
)	O	O
.	O	O

Subgroup	B-PROC
analyses	I-PROC
revealed	O	O
that	O	O
genistein	B-CHEM
significantly	O	O
decreased	O	O
the	O	O
levels	O	O
of	O	O
low	B-CHEM
density	I-CHEM
lipoprotein	I-CHEM
(	I-CHEM
LDL	I-CHEM
)	I-CHEM
cholesterol	I-CHEM
(	O	O
WMD	O
,	O	O
-16	O	O
.	O	O
90	O	O
mg	O	O
/	O	O
dl	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
total	B-CHEM
cholesterol	I-CHEM
(	O	O
WMD	O
,	O	O
-15	O	O
.	O	O
83	O	O
mg	O	O
/	O	O
dl	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

008	O	O
)	O	O
,	O	O
and	O	O
triglycerides	B-CHEM
(	O	O
WMD	O
,	O	O
-46	O	O
.	O	O
58	O	O
mg	O	O
/	O	O
dl	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
in	O	O
postmenopausal	B-PHYS
women	B-LIVB
with	O	O
metabolic	B-DISO
syndrome	I-DISO
,	O	O
but	O	O

had	O	O
no	O	O
significant	O	O
effects	O	O
in	O	O
those	O	O
with	O	O
no	B-DISO
metabolic	I-DISO
syndrome	I-DISO
.	O	O

Our	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
demonstrates	O	O
that	O	O
genistein	B-CHEM
significantly	O	O
reduces	O	O
homocysteine	B-PROC
levels	I-PROC
and	O	O
increases	O	O
HDL	B-PROC
cholesterol	I-PROC
levels	I-PROC
in	O	O
postmenopausal	B-PHYS
women	B-LIVB
.	O	O

Genistein	B-CHEM
also	O	O
significantly	O	O
decreases	O	O
LDL	B-PROC
cholesterol	I-PROC
,	O	O
total	B-PROC
cholesterol	I-PROC
and	O	O
triglyceride	B-PROC
levels	I-PROC
in	O	O
postmenopausal	B-PHYS
women	B-LIVB
with	O	O
metabolic	B-DISO
syndrome	I-DISO
.	O	O

Neonatal	B-DISO
Heart	I-DISO
-Enriched	O	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
Promotes	O	O
Differentiation	B-PHYS
of	O	O
Cardiac	B-ANAT
Progenitor	I-ANAT
Cells	I-ANAT
in	O	O
Rats	B-LIVB
Cardiovascular	B-DISO
disease	I-DISO
is	O	O
becoming	O	O
the	O	O
leading	O	O
cause	B-DISO
of	I-DISO
death	I-DISO
throughout	O	O
the	O	O
world	B-LIVB
.	O	O

However	O	O
,	O	O
adult	B-LIVB
hearts	B-ANAT
have	O	O
limited	O	O
potential	O	O
for	O	O
regeneration	B-PHYS
after	O	O
pathological	O
injury	B-DISO
,	O	O
partly	O	O
due	O	O
to	O	O
the	O	O
quiescent	O	O
status	O	O
of	O	O
stem	B-ANAT
/	O	O
progenitor	B-ANAT
cells	I-ANAT
.	O	O

Reactivation	O
of	O	O
cardiac	B-ANAT
stem	I-ANAT
/	O	O
progenitor	B-ANAT
cells	I-ANAT
to	O	O
create	O	O
more	O	O
myocyte	B-ANAT
progeny	B-ANAT
is	O	O
one	O	O
of	O	O
the	O	O
key	O	O
steps	O	O
in	O	O
the	O	O
regeneration	B-PHYS
of	O	O
a	O	O
damaged	O
heart	B-ANAT
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
was	O	O
identified	O	O
to	O	O
be	O	O
enriched	O	O
in	O	O
the	O	O
neonatal	O
cardiomyocytes	B-ANAT
of	O	O
rats	B-LIVB
,	O	O
but	O	O
this	O	O
has	O	O
not	O	O
yet	O	O
been	O	O
proven	O	O
in	O	O
adult	B-LIVB
humans	B-LIVB
.	O	O

A	O	O
lower	O	O
level	O	O
of	O	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
in	O	O
c	O
-	O
kit	O
(	O
+	O
)	O
stem	B-ANAT
/	O	O
progenitor	B-ANAT
cells	I-ANAT
was	O	O
detected	O	O
compared	O	O
to	O	O
non	B-ANAT
-	I-ANAT
progenitors	I-ANAT
.	O	O

Overexpression	B-PHYS
of	O	O
miR	O
-	O
708	O
induced	O	O
cardiomyocyte	B-ANAT
differentiation	O	O
of	O	O
cardiac	B-ANAT
stem	I-ANAT
/	O	O
progenitor	B-ANAT
cells	I-ANAT
.	O	O

This	O	O
finding	O	O
strengthened	O	O
the	O	O
potential	O	O
of	O	O
applying	O	O
miRNAs	B-CHEM
in	O	O
the	O	O
regeneration	B-PHYS
of	O	O
injured	O
hearts	B-ANAT
,	O	O
and	O	O
this	O	O
indicates	O	O
that	O	O
miR	B-CHEM
-	I-CHEM
708	I-CHEM
could	O	O
be	O	O
a	O	O
novel	O	O
candidate	O	O
for	O	O
treatment	B-PROC
of	O	O
heart	B-DISO
diseases	I-DISO
.	O	O

Coarse	O
Fraction	O
Particle	B-OBJC
Matter	I-OBJC
and	O	O
Exhaled	B-PHYS
Nitric	B-CHEM
Oxide	I-CHEM
in	O	O
Non	B-DISO
-	O	O
Asthmatic	B-DISO
Children	B-LIVB
Coarse	O
particle	B-OBJC
matter	I-OBJC
,	O	O
PMcoarse	B-OBJC
,	O	O
is	O	O
associated	O	O
with	O	O
increased	O
respiratory	B-DISO
morbidity	I-DISO
and	O	O
mortality	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O	O
the	O	O
association	O	O
between	O	O
short	O
-	O
term	O
changes	O
in	O	O
PMcoarse	B-OBJC
and	O	O
sub	O
-	O
clininal	O
airway	B-ANAT
inflammation	B-DISO
in	O	O
children	B-LIVB
.	O	O

Healthy	B-DISO
children	I-DISO
aged	B-PHYS
11	O	O
years	O
from	O	O
two	O	O
northern	B-GEOG
Swedish	I-GEOG
elementary	B-OBJC
schools	I-OBJC
underwent	O	O
fraction	O
of	O
exhaled	B-PHYS
nitrogen	B-CHEM
oxide	I-CHEM
(	O	O
FENO	O
)	O	O
measurements	O
to	O	O
determine	O	O
levels	O
of	O	O
airway	B-ANAT
inflammation	B-DISO
twice	O	O
weekly	O
during	O	O
the	O	O
study	B-PROC
period	O
from	O	O
11	O	O
April	O	O
-	O	O
6	O	O
June	O	O
2011	O	O
.	O	O

Daily	O
exposure	O
to	O
PMcoarse	B-OBJC
,	O	O
PM2	B-OBJC
.	I-OBJC

5	I-OBJC
,	O	O
NO₂	B-CHEM
,	O	O
NOx	B-CHEM
,	O	O
NO	B-CHEM
and	O	O
O₃	B-CHEM
and	O	O
birch	B-LIVB
pollen	I-LIVB
was	O	O
estimated	O	O
.	O	O

Multiple	O	O
linear	O
regression	O
was	O	O
used	O	O
.	O	O

Personal	O
covariates	O
were	O	O
included	O	O
as	O	O
fixed	O
effects	O
and	O	O
subjects	B-LIVB
were	O	O
included	O	O
as	O	O
a	O	O
random	O
effect	O
.	O	O

In	O	O
total	O	O
,	O	O
95	O	O
children	B-LIVB
participated	O	O
in	O	O
the	O	O
study	B-PROC
,	O	O
and	O	O
in	O	O
all	O	O
493	O	O
FENO	O
measurements	O
were	O	O
made	O	O
.	O	O

The	O	O
mean	O
level	O
of	O	O
PMcoarse	B-OBJC
was	O	O
16	O	O
.	O	O

1	O	O
μg	O	O
/	O	O
m³	O	O
(	O	O
range	O
4	O	O
.	O	O
1	O	O
-	O	O
42	O	O
.	O	O
3	O	O
)	O	O
,	O	O
and	O	O
that	O	O
of	O	O
O₃	B-CHEM
was	O	O
75	O	O
.	O	O
0	O	O
μg	O	O
/	O	O
m³	O	O
(	O	O
range	O
:	O	O
51	O	O
.	O	O
3	O	O
-	O	O
106	O	O
.	O	O
3	O	O
)	O	O
.	O	O

That	O	O
of	O	O
NO₂	B-CHEM
was	O	O
17	O	O
.	O	O
0	O	O
μg	O	O
/	O	O
m³	O	O
(	O	O
range	O
:	O	O
4	O	O
.	O	O
7	O	O
-	O	O
31	O	O
.	O	O

3	O	O
)	O	O
,	O	O
NOx	B-CHEM
was	O	O
82	O	O
.	O	O

1	O	O
μg	O	O
/	O	O
m³	O	O
(	O	O
range	O
:	O	O
13	O	O
.	O	O
3	O	O
-	O	O
165	O	O
.	O	O
3	O	O
)	O	O
,	O	O
and	O	O
NO	B-CHEM
was	O	O
65	O	O
μg	O	O
/	O	O
m³	O	O
(	O	O
range	O
:	O	O
8	O	O
.	O	O
7	O	O
-	O	O
138	O	O
.	O	O
4	O	O
)	O	O
during	O	O
the	O	O
study	B-PROC
period	O
.	O	O

In	O	O
multi	B-CHEM
-	I-CHEM
pollutant	I-CHEM
models	O
an	O	O
interquartile	O
range	O
increase	O
in	O	O
24	O	O
h	O	O
PMcoarse	B-OBJC
was	O	O
associated	O	O
with	O	O
increases	O
in	O	O
FENO	O
by	O	O
between	O	O
6	O	O
.	O	O

9	O	O
ppb	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
0	O	O
-	O	O
14	O	O
)	O	O
and	O	O
7	O	O
.	O	O

3	O	O
ppb	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
0	O	O
.	O	O
4	O	O
-	O	O
14	O	O
.	O	O
9	O	O
)	O	O
.	O	O

PMcoarse	B-OBJC
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O
in	O	O
FENO	O
,	O	O
indicating	O	O
sub	O
-	O
clinical	O
airway	B-ANAT
inflammation	B-DISO
in	O	O
healthy	B-DISO
children	I-DISO
.	O	O

NLRC5	B-CHEM
promotes	O
cell	B-PHYS
proliferation	I-PHYS
via	O	O
regulating	O	O
the	O	O
AKT	B-PHYS
/	O	O
VEGF	B-PHYS
-	I-PHYS
A	I-PHYS
signaling	I-PHYS
pathway	I-PHYS
in	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
NLRC5	B-CHEM
,	O	O
a	O	O
newly	O
found	O	O
member	B-LIVB
of	O	O
the	O	O
NLR	B-CHEM
family	I-CHEM
and	O	O
the	O	O
largest	O
member	B-LIVB
of	O	O
nucleotide	B-PHYS
-	I-PHYS
binding	I-PHYS
,	O	O
has	O	O
been	O	O
reported	O
to	O	O
regulate	O
immune	B-PHYS
responses	I-PHYS
and	O	O
is	O	O
associated	O
with	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O	O
HCC	B-DISO
)	O	O
.	O	O

We	O	O
investigated	O
the	O	O
mechanisms	O
and	O	O
signaling	B-PHYS
pathways	I-PHYS
of	O	O
NLRC5	B-CHEM
in	O	O
HCC	B-DISO
progression	B-DISO
.	O	O

Increased	O
expression	B-PHYS
of	O	O
NLRC5	B-CHEM
,	O	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
-	I-CHEM
A	I-CHEM
(	O	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
)	O	O
were	O	O
found	O	O
in	O	O
human	B-LIVB
HCC	B-DISO
tissue	O
.	O	O

There	O	O
was	O	O
a	O	O
positive	B-DISO
correlation	O
between	O	O
NLRC5	B-CHEM
and	O	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
expression	B-PHYS
and	O	O
cell	B-PHYS
proliferation	I-PHYS
were	O	O
enhanced	O
in	O	O
NLRC5	B-CHEM
-	O	O
overexpressing	B-PHYS
HepG2	B-ANAT
cells	I-ANAT
,	O	O
but	O	O
inhibited	O
in	O	O
cells	B-ANAT
with	O	O
NLRC5	B-CHEM
silencing	B-PHYS
treatment	O	O
.	O	O

Interestingly	O	O
,	O	O
we	O	O
found	O	O
that	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
NLRC5	B-CHEM
also	O	O
coordinated	O
the	O	O
activation	O
of	O	O
PI3K	O
/	O
AKT	O
signaling	O
pathway	O
.	O	O

An	O	O
AKT	B-CHEM
inhibitor	I-CHEM
LY294002	I-CHEM
blocked	O
VEGF	B-CHEM
-	I-CHEM
A	I-CHEM
expression	B-PHYS
and	O	O
AKT	B-CHEM
phosphorylation	B-PHYS
in	O	O
HepG2	B-ANAT
cells	I-ANAT
and	O	O
NLRC5	B-CHEM
-	O	O
overexpressing	B-PHYS
HepG2	B-ANAT
cells	I-ANAT
.	O	O

These	O	O
results	B-DISO
demonstrate	O	O
that	O	O
NLRC5	B-CHEM
promotes	O
HCC	B-DISO
progression	B-DISO
via	O	O
the	O	O
AKT	B-PHYS
/	O	O
VEGF	B-PHYS
-	I-PHYS
A	I-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O	O

Community	B-LIVB
Design	O
Impacts	O
on	O	O
Health	O
Habits	O
in	O	O
Low	B-DISO
-	I-DISO
income	I-DISO
Southern	B-LIVB
Nevadans	I-LIVB
The	O	O
purposes	O	O
of	O	O
this	O	O
exploratory	B-PROC
study	I-PROC
were	O	O
to	O	O
:	O	O
(	O	O
1	O	O
)	O	O
characterize	O	O
selected	O	O
community	B-LIVB
design	O
features	O
;	O	O
and	O	O
(	O	O
2	O	O
)	O	O
determine	O	O
the	O	O
relationship	O
between	O	O
select	O	O
features	O
and	O	O
physical	O
activity	O
(	O	O
PA	O
)	O	O
levels	O
and	O	O
nutrition	O
habits	O
for	O	O
a	O	O
small	O	O
sample	O	O
of	O	O
low	B-DISO
-	I-DISO
income	I-DISO
southern	B-LIVB
Nevadans	I-LIVB
.	O	O

Secondary	O
analysis	O
was	O	O
conducted	O	O
on	O	O
data	O
from	O	O
selected	O	O
participants	B-LIVB
of	O	O
the	O	O
Nevada	O
Healthy	O
Homes	O
Partnership	O
program	O
;	O	O
self	B-PROC
-	I-PROC
report	I-PROC
data	O
on	O	O
PA	O
and	O	O
diet	O
habits	O
were	O	O
compared	O
to	O	O
national	O
guidelines	O
.	O	O

Community	B-LIVB
design	O
features	O
were	O	O
identified	O	O
via	O	O
GIS	O
within	O	O
a	O	O
one	O	O
-	O	O
mile	O	O
radius	O
of	O	O
participants	B-LIVB
'	O	O
homes	B-OBJC
.	O	O

Descriptive	O
statistics	O
characterized	O	O
these	O	O
features	O
and	O	O
chi	O
-	O
square	O
analyses	O
were	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
relationship	O
between	O	O
select	O	O
features	O
and	O	O
habits	O
.	O	O

Data	O
from	O	O
71	O	O
participants	B-LIVB
were	O	O
analyzed	B-PROC
;	O	O
the	O	O
majority	O	O
failed	O	O
to	O	O
reach	O	O
either	O	O
PA	O
or	O	O
fruit	O
and	O
vegetable	O
guidelines	O
(	O	O
81	O	O
.	O	O

7	O	O
%	O	O
and	O	O
93	O	O
.	O	O

0	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Many	O	O
neighborhoods	B-GEOG
were	O	O
absent	O	O
of	O	O
parks	B-GEOG
(	O	O
71	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
trailheads	O
(	O	O
36	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
or	O	O
pay	B-OBJC
-	I-OBJC
for	I-OBJC
-	I-OBJC
use	I-OBJC
PA	I-OBJC
facilities	I-OBJC
(	O	O
47	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
number	O	O
of	O	O
grocery	B-OBJC
stores	I-OBJC
was	O	O
3	O	O
.	O	O
4	O	O
±	O	O
2	O	O
.	O	O
3	O	O
per	O	O
neighborhood	B-GEOG
.	O	O

Chi	O
-	O
square	O
analyses	O
were	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

Findings	B-DISO
were	O	O
insufficient	O	O
to	O	O
make	O	O
meaningful	O	O
conclusions	O	O
,	O	O
but	O	O
support	O	O
the	O	O
need	O	O
for	O	O
health	B-PROC
promotion	I-PROC
to	O	O
meet	O	O
guidelines	O
.	O	O

More	O	O
research	B-PROC
is	O	O
needed	O	O
to	O	O
assess	O	O
the	O	O
impact	O	O
of	O	O
health	B-PROC
-	I-PROC
promoting	I-PROC
community	B-LIVB
design	O
and	O	O
healthy	O
behaviors	O
,	O	O
particularly	O	O
in	O	O
vulnerable	B-LIVB
populations	I-LIVB
.	O	O

A	O	O
peptide	B-CHEM
from	O	O
human	B-CHEM
β	I-CHEM
thymosin	I-CHEM
as	O	O
a	O	O
platform	O	O
for	O	O
the	O	O
development	O	O
of	O	O
new	O	O
anti	B-CHEM
-	I-CHEM
biofilm	I-CHEM
agents	I-CHEM
for	O	O
Staphylococcus	B-LIVB
spp	I-LIVB
.	I-LIVB

and	O	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
Conventional	O	O
antibiotics	B-CHEM
might	O	O
fail	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
biofilm	B-LIVB
-associated	O	O
infections	B-DISO
causing	O	O
infection	B-DISO
recurrence	B-DISO
and	O	O
chronicity	O
.	O	O

The	O	O
search	O	O
for	O	O
antimicrobial	B-CHEM
peptides	I-CHEM
has	O	O
been	O	O
performed	O	O
with	O	O
the	O	O
aim	O	O
to	O	O
discover	O
novel	O	O
anti	B-CHEM
-	I-CHEM
infective	I-CHEM
agents	I-CHEM
active	O
on	O	O
pathogens	B-LIVB
in	O	O
both	O	O
planktonic	B-LIVB
and	O	O
biofilm	B-LIVB
associated	O	O
forms	O	O
.	O	O

The	O	O
fragment	B-CHEM
9	O	O
-	O	O
19	O	O
of	O	O
human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
was	O	O
studied	B-PROC
through	O	O
1	O	O
μs	O	O
MD	O
simulation	O
.	O	O

Two	O	O
main	O	O
conformations	O
of	O
the	O
peptide	O
were	O	O
detected	O	O
,	O	O
both	O	O
constituted	O	O
by	O	O
a	O	O
central	O
hydrophobic	O
core	O
and	O	O
by	O	O
the	O	O
presence	O	O
of	O	O
peripheral	O
charged	O	O
residues	O
suggesting	O	O
a	O	O
possible	O	O
mechanism	O	O
of	O	O
interaction	O
with	O	O
two	O	O
models	O
of	O	O
biological	B-ANAT
membranes	I-ANAT
,	O	O
related	O	O
to	O	O
eukaryotic	O
or	O	O
bacterial	B-ANAT
membrane	I-ANAT
respectively	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
peptide	B-CHEM
was	O	O
chemically	O	O
synthesized	O	O
and	O	O
its	O	O
antimicrobial	B-PHEN
activity	I-PHEN
was	O	O
tested	O	O
in	B-PROC
vitro	I-PROC
against	O	O
planktonic	B-LIVB
and	O	O
biofilm	B-LIVB
form	O	O
of	O	O
a	O	O
group	O
of	O	O
reference	O	O
strains	B-LIVB
of	O	O
Staphylococcus	B-LIVB
spp	I-LIVB
.	I-LIVB

and	O	O

one	O	O
P	B-LIVB
.	I-LIVB

aeruginosa	I-LIVB
strain	B-LIVB
.	O	O

The	O	O
human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
fragment	B-CHEM
EIEKFDKSKLK	O
showed	O	O
antibacterial	B-PHYS
activity	I-PHYS
against	O	O
staphylococcal	B-LIVB
strains	B-LIVB
and	O	O
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
ATCC	O	O
15442	O	O
at	O	O
concentrations	O
from	O	O
12	O	O
.	O	O

5	O	O
to	O	O
6	O	O
.	O	O
2	O	O
mg	O	O
/	O	O
ml	O	O
and	O	O
inhibited	O	O
biofilm	B-PHYS
formation	I-PHYS
at	O	O
sub	O
-	O
inhibitory	O
concentrations	O
(	O	O
3	O	O
.	O	O
1	O	O
-	O	O
0	O	O
.	O	O
75	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

The	O	O
activity	O
of	O	O
the	O	O
fragment	B-CHEM
in	O	O
inhibiting	O	O
biofilm	B-PHYS
formation	I-PHYS
,	O	O
could	O	O
be	O	O
due	O	O
to	O	O
the	O	O
conformations	O
highlighted	O	O
by	O	O
the	O	O
MD	O
simulations	O
,	O	O
suggesting	O	O
its	O	O
interaction	O
with	O	O
the	O	O
bacterial	B-ANAT
membrane	I-ANAT
.	O	O

Human	B-CHEM
thymosin	I-CHEM
β4	I-CHEM
fragment	B-CHEM
can	O	O
be	O	O
considered	O	O
a	O	O
promising	O	O
lead	B-CHEM
compound	I-CHEM
to	O	O
develop	O	O
novel	O	O
synthetic	O	O
or	O	O
recombinant	B-CHEM
derivatives	I-CHEM
with	O	O
improved	O	O
pharmaceutical	O
potential	O	O
.	O	O

Identification	B-PROC
of	O	O
yeasts	B-LIVB
isolated	O
from	O	O
raffia	B-OBJC
wine	I-OBJC
(	O	O
Raphia	B-LIVB
hookeri	I-LIVB
)	O	O
produced	O	O
in	O	O
Côte	B-GEOG
d	I-GEOG
'	I-GEOG
Ivoire	I-GEOG
and	O	O
genotyping	B-PROC
of	O	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
strains	B-LIVB
by	O	O
PCR	B-PROC
inter	I-PROC
-	I-PROC
delta	I-PROC
Raffia	B-OBJC
wine	I-OBJC
is	O	O
a	O	O
traditional	O
alcoholic	B-OBJC
beverage	I-OBJC
produced	O	O
in	O	O
several	O
African	B-GEOG
countries	I-GEOG
where	O	O
it	O	O
plays	O	O
a	O	O
significant	O
role	O
in	O	O
traditional	O
customs	O
and	O	O
population	O
diet	B-OBJC
.	O	O

Alcoholic	B-PHYS
fermentation	I-PHYS
of	O	O
this	O	O
beverage	B-OBJC
is	O	O
ensured	O	O
by	O	O
a	O	O
complex	O
natural	O
yeast	B-LIVB
flora	O	O
which	O	O
plays	O	O
a	O	O
decisive	O	O
role	O
in	O	O
the	O	O
quality	O
of	O	O
the	O	O
final	O
product	B-OBJC
.	O	O

This	O	O
present	O	O
study	B-PROC
aims	O	O
to	O	O
evaluate	O	O
the	O	O
distribution	O
and	O	O
the	O	O
diversity	O
of	O	O
the	O	O
yeast	B-LIVB
strains	B-LIVB
isolated	O
in	O	O
raffia	B-OBJC
wine	I-OBJC
from	O	O
four	O	O
sampling	O
areas	O
(	O	O
Abengourou	O
,	O	O
Alépé	O
,	O	O
Grand	O
-	O
Lahou	O
and	O	O
Adzopé	O
)	O	O
in	O	O
Côte	B-GEOG
d	I-GEOG
'	I-GEOG
Ivoire	I-GEOG
.	O	O

Based	O	O
on	O	O
the	O	O
D1	O
/	O
D2	O
domain	O
of	O	O
the	O	O
LSU	B-PROC
rDNA	I-PROC
sequence	I-PROC
analysis	I-PROC
,	O	O
nine	O
species	O
belonging	O	O
to	O	O
six	O
genera	O
were	O	O
distinguished	O	O
.	O	O

With	O	O
a	O	O
percentage	O
of	O	O
69	O	O
.	O	O

5	O	O
%	O	O
out	O	O
of	O	O
171	O	O
yeast	B-LIVB
isolates	B-CHEM
,	O	O
Saccharomyces	B-LIVB
cerevisiae	I-LIVB
was	O	O
the	O	O
predominant	O
species	O
in	O	O
the	O	O
raffia	B-OBJC
wine	I-OBJC
,	O	O
followed	O	O
by	O	O
Kodamaea	B-LIVB
ohmeri	I-LIVB
(	O	O
20	O	O
.	O	O
4	O	O
%	O	O
)	O	O
.	O	O

The	O	O
other	O	O
species	O
isolated	O
were	O	O
Candida	B-LIVB
haemulonii	I-LIVB
(	O	O
4	O	O
.	O	O
1	O	O
%	O	O
)	O	O
,	O	O
Candida	B-LIVB
phangngensis	I-LIVB
(	O	O
1	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
Pichia	B-LIVB
kudriavzevii	I-LIVB
(	O	O
1	O	O
.	O	O

2	O	O
%	O	O
)	O	O
,	O	O
Hanseniaspora	B-LIVB
jakobsenii	I-LIVB
(	O	O
1	O	O
.	O	O
2	O	O
%	O	O
)	O	O
,	O	O
Candida	B-LIVB
silvae	I-LIVB
(	O	O
0	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
Hanseniaspora	B-LIVB
guilliermondii	I-LIVB
(	O	O
0	O	O
.	O	O
6	O	O
%	O	O
)	O	O
and	O	O
Meyerozyma	B-LIVB
caribbica	I-LIVB
(	O	O
0	O	O
.	O	O

6	O	O
%	O	O
)	O	O
.	O	O

The	O	O
molecular	O
characterization	O
of	O	O
S	B-LIVB
.	I-LIVB

cerevisiae	I-LIVB
isolates	B-CHEM
at	O	O
the	O	O
strain	B-LIVB
level	O
using	O	O
the	O	O
PCR	B-PROC
-	I-PROC
interdelta	I-PROC
method	O
revealed	O	O
the	O	O
presence	B-DISO
of	O	O
21	O	O
profiles	B-PROC
(	O	O
named	O	O
I	O	O
to	O	O
XXI	O	O
)	O	O
within	O	O
115	O	O
isolates	B-CHEM
.	O	O

Only	O	O
four	O
profiles	B-PROC
(	O	O
I	O	O
,	O	O
III	O	O
,	O	O
V	O	O
and	O	O
XI	O	O
)	O	O
were	O	O
shared	O	O
by	O	O
the	O	O
four	O
areas	O
under	O	O
study	B-PROC
.	O	O

Phenotypic	O
characterization	O
of	O	O
K	B-LIVB
.	I-LIVB

ohmeri	I-LIVB
strains	B-LIVB
showed	O	O
two	O
subgroups	O
for	O	O
sugar	O
fermentation	O
and	O	O
no	O	O
diversity	O
for	O	O
the	O	O
nitrogen	B-CHEM
compound	I-CHEM
assimilations	O
and	O	O
the	O	O
growth	B-PHYS
at	O	O
different	O
temperatures	O
.	O	O

Structural	O
Basis	O
for	O	O
Simvastatin	B-CHEM
Competitive	B-PHYS
Antagonism	I-PHYS
of	O	O
Complement	B-CHEM
Receptor	I-CHEM
3	I-CHEM
The	O	O
complement	B-CHEM
system	I-CHEM
is	O	O
an	O	O
important	O	O
part	O	O
of	O	O
the	O	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
to	O	O
infection	B-DISO
but	O	O
may	O	O
also	O	O
cause	O	O
severe	B-DISO
complications	I-DISO
during	O	O
inflammation	B-DISO
.	O	O

Small	B-CHEM
molecule	I-CHEM
antagonists	B-CHEM
to	O	O
complement	B-CHEM
receptor	I-CHEM
3	I-CHEM
(	O	O
CR3	B-CHEM
)	O	O
have	O	O
been	O	O
widely	O	O
sought	O	O
,	O	O
but	O	O
a	O	O
structural	O
basis	O
for	O	O
their	O	O
mode	O
of	O
action	O
is	O	O
not	O	O
available	O	O
.	O	O

We	O	O
report	O
here	O	O
on	O	O
the	O	O
structure	O
of	O	O
the	O	O
human	B-LIVB
CR3	B-CHEM
ligand	O
-	O
binding	O
I	O
domain	O
in	O	O
complex	B-CHEM
with	O	O
simvastatin	B-CHEM
.	O	O

Simvastatin	B-CHEM
targets	O
the	O	O
metal	B-CHEM
ion	O
-	O
dependent	O
adhesion	O
site	O
of	O	O
the	O	O
open	O	O
,	O	O
ligand	B-PHYS
-	I-PHYS
binding	I-PHYS
conformation	O
of	O	O
the	O	O
CR3	B-CHEM
I	O
domain	O
by	O	O
direct	O	O
contact	O
with	O
the	O	O
chelated	B-CHEM
Mg	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ion	I-CHEM
.	O	O

Simvastatin	B-CHEM
antagonizes	B-DISO
I	O
domain	O
binding	O
to	O	O
the	O	O
complement	B-CHEM
fragments	I-CHEM
iC3b	B-CHEM
and	O	O
C3d	B-CHEM
but	O	O
not	O	O
to	O	O
intercellular	B-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
1	I-CHEM
.	O	O

By	O	O
virtue	O
of	O	O
the	O	O
I	O
domain	O
's	O
wide	O	O
distribution	O
in	O	O
binding	B-PHYS
kinetics	I-PHYS
to	O	O
ligands	B-CHEM
,	O	O
it	O	O
was	O	O
possible	B-DISO
to	O	O
identify	O	O
ligand	B-PHYS
binding	I-PHYS
kinetics	B-PHYS
as	O	O
discriminator	O	O
for	O	O
simvastatin	B-CHEM
antagonism	B-PHYS
.	O	O

In	O	O
static	O
cellular	B-PROC
experiments	B-PROC
,	O	O
15	O	O
-	O	O
25	O	O
μm	O	O
simvastatin	B-CHEM
reduced	O
adhesion	B-PHEN
by	O	O
K562	B-ANAT
cells	I-ANAT
expressing	B-PHYS
recombinant	B-LIVB
CR3	B-CHEM
and	O	O
by	O	O
primary	O
human	B-LIVB
monocytes	B-ANAT
,	O	O
with	O	O
an	O	O
endogenous	O
expression	B-PHYS
of	O	O
this	O	O
receptor	B-CHEM
.	O	O

Application	B-PROC
of	O	O
force	B-PHEN
to	O	O
adhering	B-PHEN
monocytes	B-ANAT
potentiated	O	O
the	O	O
effects	O
of	O
simvastatin	B-CHEM
where	O	O
only	O	O
a	O	O
50	O	O
-	O	O
100	O	O
nm	O	O
concentration	O
of	O	O
the	O	O
drug	B-CHEM
reduced	O
the	O	O
adhesion	B-PHEN
by	O	O
20	O	O
-	O	O
40	O	O
%	O	O
compared	O
with	O	O
untreated	O
cells	B-ANAT
.	O	O

The	O	O
ability	B-PHYS
of	O	O
simvastatin	B-CHEM
to	O	O
target	O
CR3	B-CHEM
in	O	O
its	O	O
ligand	B-PHYS
binding	I-PHYS
-	O	O
activated	O
conformation	O
is	O	O
a	O	O
novel	O
mechanism	B-PHYS
to	O	O
explain	O	O
the	O	O
known	O	O
anti	O
-	O
inflammatory	O
effects	O
of	O	O
this	O	O
compound	B-CHEM
,	O	O
in	O	O
particular	O	O
because	O	O
this	O	O
CR3	B-CHEM
conformation	O
is	O	O
found	O	O
in	O	O
pro	O
-	O
inflammatory	O
environments	O
.	O	O

Our	O	O
report	O
points	O	O
to	O	O
new	O	O
designs	O
of	O	O
CR3	B-CHEM
antagonists	B-CHEM
and	O	O
opens	O	O
new	O	O
perspectives	O	O
and	O	O
identifies	B-DISO
druggable	O
receptors	B-CHEM
from	O	O
characterization	O
of	O	O
the	O	O
ligand	B-PHYS
binding	I-PHYS
kinetics	B-PHYS
in	O	O
the	O	O
presence	O
of	O	O
antagonists	B-CHEM
.	O	O

Inducement	O
of	O	O
tissue	B-PHYS
regeneration	I-PHYS
of	O	O
harvested	B-PROC
hamstring	B-ANAT
tendons	I-ANAT
in	O	O
a	O	O
rabbit	B-LIVB
model	B-DEVI
The	O	O
objective	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
use	O
of	O
fascia	B-ANAT
lata	I-ANAT
as	O	O
a	O	O
tendon	B-ANAT
regeneration	B-PROC
guide	O	O
(	O	O
placed	O	O
into	O	O
the	O	O
tendon	B-ANAT
canal	I-ANAT
following	O	O
harvesting	B-PROC
the	O	O
semitendinosus	B-ANAT
tendon	I-ANAT
)	O	O
would	O	O
improve	B-DISO
the	O	O
incidence	O
of	O	O
tissue	B-PHYS
regeneration	I-PHYS
and	O	O
prevent	O
fatty	B-DISO
degeneration	I-DISO
of	O	O
the	O	O
semitendinosus	B-ANAT
muscle	I-ANAT
.	O	O

Bilateral	O
semitendinosus	B-ANAT
tendons	I-ANAT
were	O	O
harvested	B-PROC
from	O	O
rabbits	B-LIVB
using	O	O
a	O	O
tendon	B-DEVI
stripper	I-DEVI
.	O	O

On	O	O
the	O	O
inducing	O
graft	O
(	O	O
IG	O
)	O	O
side	O
,	O	O
the	O	O
tendon	B-ANAT
canal	I-ANAT
and	O	O
semitendinosus	B-ANAT
tibial	B-ANAT
attachment	O
site	O
were	O	O
connected	O	O
by	O	O
the	O	O
fascia	B-ANAT
lata	I-ANAT
,	O	O
which	O	O
was	O	O
harvested	B-PROC
at	O	O
the	O	O
same	O	O
width	O
as	O	O
the	O	O
semitendinosus	B-ANAT
tendon	I-ANAT
.	O	O

On	O	O
the	O	O
control	O
side	O
,	O	O
no	O	O
special	O	O
procedures	O
were	O	O
performed	O
.	O	O

Two	O	O
groups	O
of	O	O
six	O	O
rabbits	B-LIVB
were	O	O
killed	B-DISO
at	O	O
post	O
-	O
operative	O
weeks	O
4	O	O
and	O	O
8	O	O
,	O	O
respectively	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
three	O	O
healthy	O
rabbits	B-LIVB
were	O	O
killed	B-DISO
to	O	O
obtain	O
normal	O
tissue	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
incidence	O
of	O	O
tendon	B-ANAT
tissue	B-PHYS
regeneration	I-PHYS
,	O	O
cross	O
-	O
sectional	O
area	O
of	O	O
the	O	O
regenerated	O
tendon	B-ANAT
tissue	I-ANAT
and	O	O
proportion	O
of	O	O
fatty	O
tissue	O
in	O	O
the	O	O
semitendinosus	B-ANAT
muscle	I-ANAT
.	O	O

At	O	O
post	O
-	O
operative	O
week	O
8	O	O
,	O	O
the	O	O
distal	O
end	O
of	O	O
the	O	O
regenerated	O
tissue	O
reached	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
tibial	B-ANAT
insertion	B-PROC
on	O	O
the	O	O
control	O
side	O
in	O	O
two	O	O
of	O	O
six	O	O
specimens	B-LIVB
.	O	O

On	O	O
the	O	O
IG	O
side	O
,	O	O
the	O	O
regenerated	O
tissue	O
maintained	O	O
continuity	O
with	O	O
the	O	O
tibial	B-ANAT
insertion	B-PROC
in	O	O
all	O	O
specimens	B-LIVB
.	O	O

The	O	O
cross	O
-	O
sectional	O
area	O
of	O	O
the	O	O
IG	O
side	O
was	O	O
significantly	O	O
greater	O
than	O	O
that	O	O
of	O	O
the	O	O
control	O
side	O
.	O	O

The	O	O
proportion	O
of	O	O
fatty	O
tissue	O
in	O	O
the	O	O
semitendinosus	B-ANAT
muscle	I-ANAT
on	O	O
the	O	O
IG	O
side	O
was	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
the	O	O
control	O
side	O
,	O	O
but	O	O
was	O	O
significantly	O	O
greater	O
than	O	O
that	O	O
of	O	O
the	O	O
normal	O
muscle	O
.	O	O

Tendon	B-ANAT
tissue	I-ANAT
regenerated	O
with	O	O
the	O	O
fascia	B-ANAT
lata	I-ANAT
graft	O
was	O	O
thicker	O
than	O	O
naturally	O	O
occurring	O	O
regenerated	O
tissue	O
.	O	O

However	O	O
,	O	O
the	O	O
proportion	O
of	O	O
fatty	O
tissue	O
in	O	O
the	O	O
semitendinosus	B-ANAT
muscle	I-ANAT
was	O	O
greater	O
than	O	O
that	O	O
of	O	O
normal	O
muscle	O
.Cite	O	O
this	O	O
article	O	O
:	O	O
K	O	O
.	O	O

Tabuchi	O	O
,	O	O
T	O	O
.	O	O

Soejima	O	O
,	O	O
H	O	O
.	O	O

Murakami	O	O
,	O	O
K	O	O
.	O	O

Noguchi	O	O
,	O	O
N	O	O
.	O	O

Shiba	O	O
,	O	O
K	O	O
.	O	O

Nagata	O	O
.	O	O

Inducement	O
of	O	O
tissue	B-PHYS
regeneration	I-PHYS
of	O	O
harvested	B-PROC
hamstring	B-ANAT
tendons	I-ANAT
in	O	O
a	O	O
rabbit	B-LIVB
model	B-DEVI
.	O	O

Bone	O	O
Joint	O	O
Res	O	O
2016	O	O
;	O	O
5	O	O
:	O	O
247	O	O
-	O	O
252	O	O
.	O	O

DOI	O	O
:	O	O
10	O	O
.	O	O
1302	O	O
/	O	O
2046	O	O
-	O	O
3758	O	O
.	O	O
56	O	O
.	O	O

2000585	O	O
.	O	O

Immediate	O
and	O	O
Delayed	O
Effects	O
of	O
Diode	B-DEVI
Laser	I-DEVI
on	O	O
Debonding	B-PROC
of	O	O
Ceramic	B-DEVI
Brackets	I-DEVI
:	O	O
An	O	O
in	B-PROC
vitro	I-PROC
Study	I-PROC
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
evaluate	B-PROC
the	O	O
immediate	O
and	O	O
delayed	O
effects	O
of	O
diode	B-DEVI
laser	I-DEVI
on	O	O
debonding	B-PROC
of	O	O
ceramic	B-DEVI
brackets	I-DEVI
.	O	O

A	O	O
total	O	O
of	O	O
60	O	O
human	B-LIVB
extracted	O	O
premolar	B-ANAT
teeth	I-ANAT
were	O	O
randomly	B-PROC
assigned	I-PROC
to	O	O
three	O	O
different	O	O
treatment	O
groups	O
.	O	O

All	O	O
teeth	B-ANAT
were	O	O
bonded	B-PROC
with	I-PROC
adhesive	B-CHEM
precoated	I-CHEM
(	O	O
APC	B-CHEM
)	O	O
ceramic	B-DEVI
brackets	I-DEVI
(	O	O
3	B-CHEM
M	I-CHEM
Unitek	I-CHEM
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
20	O	O
teeth	B-ANAT
were	O	O
debonded	B-PROC
without	O	O
lasing	B-PHEN
(	O	O
group	O
1	O	O
)	O	O
,	O	O
20	O	O
immediately	O
after	O	O
lasing	B-PHEN
(	O	O
group	O
2	O	O
)	O	O
,	O	O
and	O	O
20	O	O
1	O	O
hour	O	O
after	O	O
lasing	B-PHEN
(	O	O
group	O
3	O	O
)	O	O
.	O	O

For	O	O
the	O	O
lasing	B-PHEN
groups	O
(	O	O
groups	O
2	O	O
and	O	O
3	O	O
)	O	O
,	O	O
access	B-PROC
cavity	I-PROC
was	I-PROC
prepared	I-PROC
on	O	O
the	O	O
occlusal	B-ANAT
surface	I-ANAT
to	O	O
a	O	O
2	O	O
mm	O	O
diameter	O	O
.	O	O

A	O	O
transbond	B-CHEM
plus	I-CHEM
self	I-CHEM
-	I-CHEM
etching	I-CHEM
primer	I-CHEM
(	O	O
3	B-CHEM
M	I-CHEM
Unitek	I-CHEM
,	O	O
Monrovia	B-GEOG
,	O	O
CA	B-GEOG
,	O	O
USA	B-GEOG
)	O	O
and	O	O
APC	B-CHEM
PLUS	I-CHEM
clarity	B-DEVI
advanced	I-DEVI
brackets	I-DEVI
(	O	O
3	B-CHEM
M	I-CHEM
,	I-CHEM
Unitek	I-CHEM
,	O	O
Monrovia	B-GEOG
,	O	O
CA	B-GEOG
,	O	O
USA	B-GEOG
)	O	O
were	O	O
used	O	O
.	O	O

The	O	O
shear	O
bond	O
strength	O
(	O	O
SBS	O
)	O	O
and	O	O
adhesive	B-DISO
remnant	I-DISO
index	I-DISO
(	I-DISO
ARI	I-DISO
)	I-DISO
were	O	O
measured	O	O
.	O	O

The	O	O
internal	O
pulpal	B-ANAT
wall	I-ANAT
temperature	O
was	O	O
noted	O	O
for	O	O
the	O	O
laser	O
groups	O
.	O	O

The	O	O
mean	O	O
SBS	O
was	O	O
15	O	O
.	O	O
4	O	O
,	O	O
11	O	O
.	O	O
57	O	O
,	O	O
and	O	O
11	O	O
.	O	O

79	O	O
MPa	O	O
for	O	O
groups	O
1	O	O
to	O	O
3	O	O
respectively	O	O
.	O	O

Post	O
hoc	O
test	O
showed	O	O
significant	O	O
difference	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
between	O	O
the	O	O
control	B-LIVB
group	I-LIVB
and	O	O
the	O	O
lased	O
groups	O
.	O	O

For	O	O
groups	O
2	O	O
and	O	O
3	O	O
,	O	O
the	O	O
rise	O	O
in	O	O
temperature	O
was	O	O
at	O	O
an	O	O
average	O	O
of	O	O
1	O	O
.	O	O
4	O	O
and	O	O
1	O	O
.	O	O

3°C	O	O
respectively	O	O
.	O	O

The	O	O
SBS	O
of	O	O
APC	B-CHEM
brackets	B-DEVI
decreased	O	O
by	O	O
33	O	O
.	O	O

3	O	O
%	O	O
on	O	O
application	O	O
of	O	O
diode	B-DEVI
laser	I-DEVI
without	O	O
increasing	O	O
the	O	O
internal	O
pulp	B-ANAT
chamber	I-ANAT
wall	I-ANAT
temperature	O
significantly	O	O
.	O	O

Shear	O
bond	O
strength	O
remains	O	O
more	O	O
or	O	O
less	O	O
the	O	O
same	O	O
whether	O	O
debonding	B-PROC
is	O	O
done	O	O
immediately	O
after	O	O
lasing	B-PHEN
or	O	O
1	O	O
hour	O	O
after	O	O
lasing	B-PHEN
.	O	O

Diode	B-DEVI
lasers	I-DEVI
increased	O	O
the	O	O
ARI	B-DISO
scores	I-DISO
and	O	O
thus	O	O
decreased	O	O
the	O	O
risk	O
of	O	O
enamel	B-DISO
fracture	I-DISO
.	O	O

Activation	O
of	O	O
the	O	O
orphan	B-CHEM
receptor	I-CHEM
GPR55	I-CHEM
by	O	O
lysophosphatidylinositol	B-CHEM
promotes	O
metastasis	B-DISO
in	O	O
triple	B-DISO
-	I-DISO
negative	I-DISO
breast	I-DISO
cancer	I-DISO
The	O	O
orphan	B-CHEM
G	I-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptor	I-CHEM
GPR55	B-CHEM
has	O	O
been	O	O
directly	O
or	O	O
indirectly	O
related	O
to	O	O
basic	O	O
alterations	O
that	O	O
drive	O	O
malignant	O
growth	B-PHYS
:	O	O
uncontrolled	O
cancer	O	O
cell	B-PHYS
proliferation	I-PHYS
,	O	O
sustained	B-PHYS
angiogenesis	I-PHYS
,	O	O
and	O	O
cancer	O	O
cell	B-PHYS
adhesion	I-PHYS
and	O	O
migration	B-PHEN
.	O	O

However	O	O
,	O	O
little	O
is	O	O
known	O
about	O	O
the	O	O
involvement	O
of	O	O
this	O	O
receptor	B-CHEM
in	O	O
metastasis	B-DISO
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
elevated	O
GPR55	B-PHYS
expression	I-PHYS
in	O	O
human	B-LIVB
tumors	B-DISO
is	O	O
associated	O
with	O
the	O	O
aggressive	B-DISO
basal	I-DISO
/	O	O
triple	B-DISO
-	I-DISO
negative	I-DISO
breast	I-DISO
cancer	I-DISO
population	B-LIVB
,	O	O
higher	O
probability	O
to	O	O
develop	O	O
metastases	B-DISO
,	O	O
and	O	O
therefore	O	O
poor	O
patient	B-LIVB
prognosis	B-PROC
.	O	O

Activation	O
of	O	O
GPR55	B-CHEM
by	O	O
its	O	O
proposed	O	O
endogenous	O
ligand	B-CHEM
lysophosphatidylinositol	B-CHEM
confers	O	O
pro	O
-	O
invasive	O
features	O
on	O	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
both	O	O
in	O
vitro	O
and	O	O
in	O
vivo	O
.	O	O

Specifically	O	O
,	O	O
this	O	O
effect	O
is	O	O
elicited	O
by	O
coupling	O
to	O	O
Gq	B-CHEM
/	I-CHEM
11	I-CHEM
heterotrimeric	I-CHEM
proteins	I-CHEM
and	O	O
the	O	O
subsequent	O
activation	O
,	O	O
through	O	O
ERK	B-CHEM
,	O	O
of	O	O
the	O	O
transcription	B-CHEM
factor	I-CHEM
ETV4	I-CHEM
/	O	O
PEA3	B-CHEM
.	O	O

Together	O
,	O	O
these	O	O
data	O
show	O	O
that	O	O
GPR55	B-CHEM
promotes	O
breast	B-DISO
cancer	I-DISO
metastasis	B-DISO
,	O	O
and	O	O
supports	O
the	O	O
notion	O	O
that	O	O
this	O	O
orphan	B-CHEM
receptor	I-CHEM
may	O	O
constitute	O	O
a	O	O
new	O
therapeutic	O
target	O
and	O	O
potential	O
biomarker	B-PHYS
in	O	O
the	O	O
highly	O	O
aggressive	O
triple	O
-	O
negative	O
subtype	O
.	O	O

The	O	O
number	O	O
of	O	O
tumorspheres	B-ANAT
cultured	O	O
from	O	O
peripheral	B-ANAT
blood	I-ANAT
is	O	O
a	O	O
predictor	O
for	O	O
presence	O	O
of	O	O
metastasis	B-DISO
in	O	O
patients	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
Tumor	B-DISO
metastases	I-DISO
are	O	O
the	O	O
major	O	O
cause	O	O
of	O	O
cancer	B-DISO
morbidity	I-DISO
and	O	O
mortality	O
.	O	O

A	O	O
subpopulation	B-LIVB
of	O	O
tumor	B-ANAT
cells	I-ANAT
with	I-ANAT
stem	I-ANAT
-	I-ANAT
like	I-ANAT
properties	I-ANAT
is	O	O
assumed	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
tumor	B-DISO
invasion	I-DISO
,	O	O
metastasis	B-DISO
,	O	O
heterogeneity	O
and	O	O
therapeutic	B-PROC
resistance	B-PHYS
.	O	O

This	O	O
population	O	O
is	O	O
termed	O	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	O	O
CSCs	B-ANAT
)	O	O
.	O	O

We	O	O
have	O	O
developed	O	O
a	O	O
simple	O	O
method	O	O
for	O	O
identification	O	O
and	O	O
characterization	O	O
of	O	O
circulating	O	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
among	O	O
circulating	B-ANAT
epithelial	I-ANAT
tumor	I-ANAT
cells	I-ANAT
(	O	O
CETCs	B-ANAT
)	O	O
.	O	O

CETCs	B-ANAT
were	O	O
cultured	O	O
under	O	O
conditions	O	O
favoring	O	O
growth	B-PHYS
of	O	O
tumorspheres	B-ANAT
from	O	O
72	O	O
patients	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
,	O	O
including	O	O
a	O	O
subpopulation	B-LIVB
of	O	O
23	O	O
patients	B-LIVB
with	O	O
metastatic	B-DISO
disease	I-DISO
.	O	O

CETCs	B-ANAT
were	O	O
determined	O	O
using	O	O
the	O	O
maintrac	B-PROC
®	I-PROC
method	I-PROC
.	O	O

Gene	O
expression	O
profiles	O
of	O	O
single	O	O
CETCs	B-ANAT
and	O	O
tumorspheres	B-ANAT
of	O	O
the	O	O
same	O	O
patients	B-LIVB
were	O	O
analyzed	O	O
using	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
.	O	O

Sphere	O
formation	O
was	O	O
observed	O	O
in	O	O
79	O	O
%	O	O
of	O	O
patients	B-LIVB
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
number	O	O
of	O	O
tumorspheres	B-ANAT
depended	O	O
on	O	O
stage	B-PROC
of	I-PROC
disease	I-PROC
.	O	O

Furthermore	O	O
,	O	O
the	O	O
most	O	O
important	O	O
factor	O	O
for	O	O
growing	O	O
of	O	O
tumorspheres	B-ANAT
is	O	O
obtaining	O	O
chemotherapy	B-PROC
.	O	O

Patients	B-LIVB
with	O	O
chemotherapy	B-PROC
treatment	B-PROC
had	O	O
lower	O	O
numbers	O	O
of	O	O
tumorspheres	B-ANAT
compared	O	O
to	O	O
patients	B-LIVB
without	B-DISO
chemotherapy	I-DISO
.	O	O

Patients	B-LIVB
with	O	O
HER2	B-DISO
positive	I-DISO
primary	I-DISO
tumor	I-DISO
had	O	O
higher	O	O
number	O	O
of	O	O
tumorspheres	B-ANAT
.	O	O

Analysis	O	O
of	O	O
surface	B-PHYS
marker	I-PHYS
expression	B-PHYS
profile	O	O
of	O	O
tumorspheres	B-ANAT
showed	O	O
that	O	O
cells	B-ANAT
in	O	O
the	O	O
spheres	O
had	O	O
typical	O	O
phenotype	B-PHYS
of	O	O
cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
.	O	O

There	O	O
was	O	O
no	B-DISO
sphere	I-DISO
formation	I-DISO
in	O	O
a	O	O
control	B-LIVB
group	I-LIVB
with	O	O
50	O	O
healthy	O
donors	B-LIVB
.	O	O

This	O	O
study	B-PROC
demonstrates	O	O
that	O	O
a	O	O
small	O	O
fraction	O	O
of	O	O
CETCs	B-ANAT
has	O	O
proliferative	B-PHEN
activity	I-PHEN
.	O	O

Identifying	O	O
the	O	O
CETC	B-ANAT
subset	O	O
with	O	O
cancer	B-ANAT
stem	I-ANAT
cell	I-ANAT
properties	O	O
may	O	O
provide	O	O
more	O	O
clinically	O	O
useful	O	O
prognostic	O
information	O
.	O	O

Chemotherapy	B-PROC
is	O	O
the	O	O
most	O	O
important	O	O
component	O	O
in	O	O
cancer	B-PROC
therapy	I-PROC
because	O	O
it	O	O
frequently	O	O
reduces	O	O
the	O	O
number	O	O
of	O	O
tumorspheres	B-ANAT
.	O	O

Undiagnosed	B-DISO
Primary	B-DISO
Open	I-DISO
-	I-DISO
Angle	I-DISO
Glaucoma	I-DISO
in	O	O
Korea	B-GEOG
:	O	O
The	O	O
Korean	B-PROC
National	I-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
2008	O	O
-	O	O
2009	O	O
To	O	O
evaluate	B-PROC
the	O	O
characteristics	O
of	O	O
patients	B-LIVB
with	O	O
previously	O	O
undiagnosed	B-DISO
primary	B-DISO
open	I-DISO
-	I-DISO
angle	I-DISO
glaucoma	I-DISO
(	O	O
POAG	B-DISO
)	O	O
in	O	O
Korea	B-GEOG
.	O	O

This	O	O
study	B-PROC
examined	O	O
data	O
from	O	O
391	O	O
subjects	B-LIVB
obtained	O
from	O	O
the	O	O
2008	O	O
-	O	O
2009	O	O
Korean	B-PROC
National	I-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
(	O	O
KNHANES	B-PROC
)	O	O
.	O	O

The	O	O
KNHANES	B-PROC
is	O	O
a	O	O
population	B-PROC
-	I-PROC
based	I-PROC
,	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
epidemiological	I-PROC
survey	I-PROC
.	O	O

Participants	B-LIVB
aged	B-PHYS
19	O
years	O
or	O	O
older	B-LIVB
completed	O	O
standardized	O
interviews	O
and	O	O
dilated	B-PROC
ocular	I-PROC
examinations	I-PROC
,	O	O
including	O	O
measurement	O
of	O	O
intraocular	B-PHYS
pressure	I-PHYS
,	O	O
visual	O
fields	O
with	O	O
frequency	B-PROC
doubling	I-PROC
perimetry	I-PROC
,	O	O
and	O	O
fundus	B-PROC
photography	I-PROC
.	O	O

Data	O
from	O	O
the	O	O
361	O	O
patients	B-LIVB
with	O	O
previously	O
undiagnosed	B-DISO
POAG	B-DISO
were	O	O
analyzed	B-PROC
and	O	O
compared	O
with	O	O
data	O
from	O	O
the	O	O
30	O	O
patients	B-LIVB
with	O	O
previously	O	O
diagnosed	B-DISO
glaucoma	B-DISO
.	O	O

A	O	O
total	O	O
of	O	O
92	O	O
.	O	O

3	O	O
%	O	O
of	O	O
POAG	B-DISO
cases	O	O
were	O	O
undiagnosed	B-DISO
before	O	O
this	O	O
study	B-PROC
.	O	O

Adjusted	O
for	O	O
age	B-PHYS
and	O	O
sex	B-PHYS
,	O	O
the	O	O
strongest	B-DISO
risk	I-DISO
factor	I-DISO
for	O	O
undiagnosed	B-DISO
glaucoma	B-DISO
was	O	O
longer	O	O
elapsed	O
time	O
since	O	O
last	O	O
eye	B-PROC
doctor	I-PROC
visit	I-PROC
.	O	O

Glaucoma	B-DISO
patients	B-LIVB
who	O	O
had	O	O
not	O	O
visited	B-PROC
an	I-PROC
eye	I-PROC
specialist	I-PROC
in	O	O
the	O	O
last	O	O
3	O	O
years	O
were	O	O
22	O	O
times	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
,	O	O
CI	O
,	O	O
4	O	O
.	O	O
49	O	O
-	O	O
105	O	O
.	O	O
64	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
undiagnosed	B-DISO
disease	B-DISO
compared	O
with	O	O
patients	B-LIVB
who	O	O
had	O	O
visited	B-PROC
an	I-PROC
eye	I-PROC
specialist	I-PROC
in	O	O
the	O	O
last	O	O
month	O
.	O	O

Another	O	O
significant	O
factor	O
for	O	O
previously	O	O
undiagnosed	B-DISO
glaucoma	B-DISO
was	O	O
smaller	O	O
cup	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
disc	I-DISO
ratio	I-DISO
(	O	O
odds	O
ratio	O
,	O	O
OR	O
,	O	O
0	O	O
.	O	O
60	O	O
/	O	O
0	O	O
.	O	O
1	O	O
units	O	O
,	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
43	O	O
-	O	O
0	O	O
.	O	O
85	O	O
/	O	O
0	O	O
.	O	O
1	O	O
units	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
004	O	O
)	O	O
.	O	O

The	O	O
higher	O	O
vertical	B-PHYS
cup	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
disc	I-PHYS
ratio	I-PHYS
of	O	O
a	O	O
subject	B-LIVB
's	I-LIVB
two	O	O
eyes	B-ANAT
was	O	O
significantly	O	O
different	O	O
between	O	O
those	O	O
with	O	O
previously	O
undiagnosed	B-DISO
(	O	O
0	O	O
.	O	O
69	O	O
)	O	O
and	O	O
diagnosed	B-DISO
(	O	O
0	O	O
.	O	O
78	O	O
)	O	O
POAG	B-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

The	O	O
undiagnosed	B-DISO
POAG	B-DISO
group	O	O
had	O	O
a	O	O
longer	O
interval	O
from	O	O
last	O	O
eye	B-PROC
doctor	I-PROC
visit	I-PROC
and	O	O
smaller	O	O
vertical	B-PHYS
cup	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
disc	I-PHYS
ratio	I-PHYS
compared	O	O
to	O	O
the	O	O
diagnosed	B-DISO
group	I-DISO
.	O	O

Nest	O
-	O	O
site	O
competition	O
between	O	O
invasive	O
and	O	O
native	O
cavity	O
nesting	O
birds	B-LIVB
and	O	O
its	O	O
implication	O
for	O	O
conservation	O
Nesting	O
cavities	O
are	O	O
often	O	O
a	O	O
limited	O
resource	O
that	O	O
multiple	O
species	O
use	O
.	O	O

There	O	O
is	O	O
an	O	O
ongoing	O	O
discussion	O
on	O	O
whether	O	O
invasive	O
cavity	O
nesting	O
birds	B-LIVB
restrict	O
the	O	O
availability	O	O
of	O	O
this	O	O
key	O	O
limited	O
resource	O
.	O	O

While	O	O
the	O	O
answer	O	O
to	O	O
this	O	O
question	O	O
has	O	O
important	O	O
conservation	O
implications	O	O
,	O	O
little	O	O
experimental	B-PROC
work	I-PROC
has	O	O
been	O	O
done	O	O
to	O	O
examine	B-DISO
it	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
experimentally	O	O
test	O	O
whether	O	O
alien	B-LIVB
cavity	O
nesting	O
birds	B-LIVB
affect	O	O
the	O	O
occupancy	O
of	O	O
cavities	O
and	O	O
the	O	O
resulting	O	O
breeding	B-PHYS
success	O
of	O	O
native	O
cavity	O
breeders	B-LIVB
in	O	O
a	O	O
large	O
urban	B-GEOG
park	B-OBJC
located	O	O
in	O	O
Tel	O
Aviv	O
,	O	O
Israel	B-GEOG
.	O	O

Over	O	O
three	O	O
breeding	B-PHYS
seasons	O
,	O	O
we	O	O
manipulated	O
the	O	O
entry	O
size	O
of	O	O
nest	B-OBJC
boxes	I-OBJC
and	O	O
compared	O
the	O	O
occupancy	O
and	O	O
breeding	B-PHYS
success	O
of	O	O
birds	B-LIVB
in	O	O
nest	B-OBJC
boxes	I-OBJC
of	O	O
two	O	O
treatments	O
.	O	O

These	O	O
included	O	O
nest	B-OBJC
boxes	I-OBJC
with	O	O
large	O
-	O	O
entrance	O
and	O	O
small	O
-	O	O
entrance	O
holes	O
.	O	O

The	O	O
large	O
-	O	O
entrance	O
holes	O
allowed	O	O
access	O
for	O	O
both	O	O
the	O	O
native	O
and	O	O
invasive	O
birds	B-LIVB
(	O	O
the	O	O
two	O	O
main	O	O
aliens	B-LIVB
in	O	O
the	O	O
park	B-OBJC
are	O	O
the	O	O
common	B-LIVB
mynas	I-LIVB
and	O	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeets	I-LIVB
)	O	O
.	O	O

The	O	O
smaller	O
-	O	O
entrance	O
boxes	B-OBJC
,	O	O
on	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
allowed	O	O
only	O	O
the	O	O
smaller	O
sized	O
native	O
cavity	O
breeders	B-LIVB
(	O	O
great	B-LIVB
tits	I-LIVB
and	O	O
house	B-LIVB
sparrows	I-LIVB
)	O	O
to	O	O
enter	O	O
the	O	O
boxes	B-OBJC
but	O	O
prevented	O
the	O	O
alien	O
species	O
from	O	O
entering	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
large	O
-	O	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
were	O	O
occupied	O
by	O	O
five	O	O
different	O
bird	B-LIVB
species	I-LIVB
,	O	O
comprising	O	O
three	O	O
natives	O
(	O	O
great	B-LIVB
tit	I-LIVB
,	O	O
house	B-LIVB
sparrow	I-LIVB
,	O	O
Scops	B-LIVB
owl	I-LIVB
)	O	O
and	O	O
two	O	O
invasive	O
species	O
(	O	O
common	B-LIVB
myna	I-LIVB
,	O	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeet	I-LIVB
)	O	O
while	O	O
the	O	O
small	O
-	O	O
entrance	O
boxes	B-OBJC
were	O	O
only	O	O
occupied	O
by	O	O
the	O	O
two	O	O
native	O
species	O
.	O	O

The	O	O
alien	B-LIVB
common	B-LIVB
mynas	I-LIVB
and	O	O
rose	B-LIVB
-	I-LIVB
ringed	I-LIVB
parakeets	I-LIVB
occupied	O
77	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
large	O
-	O	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
whereas	O	O
native	O
species	B-LIVB
,	O	O
mainly	O
great	B-LIVB
tits	I-LIVB
,	O	O
occupied	O
less	O
than	O
9	O	O
%	O	O
of	O	O
the	O	O
large	O
-	O	O
entrance	O
boxes	B-OBJC
and	O	O
36	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
small	O
-	O	O
entrance	O
boxes	B-OBJC
.	O	O

When	O	O
examining	B-DISO
the	O	O
occupancy	O
of	O	O
those	O	O
cavities	O
that	O	O
were	O	O
not	O	O
occupied	O
by	O	O
the	O	O
aliens	B-LIVB
,	O	O
natives	O
occupied	O
both	O	O
the	O	O
small	O
and	O	O
large	O
-	O	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
equally	O	O
.	O	O

Three	O	O
quarters	O
(	O	O
78	O	O
%	O	O
)	O	O
of	O	O
the	O	O
great	B-LIVB
tits	I-LIVB
breeding	B-PHYS
in	O	O
the	O	O
large	O
-	O	O
entrance	O
boxes	B-OBJC
were	O	O
usurped	O
by	O	O
common	B-LIVB
mynas	I-LIVB
during	O	O
the	O	O
breeding	B-PHYS
season	O
and	O	O
as	O	O
a	O	O
result	O	O
breeding	B-PHYS
success	O
was	O	O
significantly	O
lower	O
for	O	O
great	B-LIVB
tits	I-LIVB
breeding	B-PHYS
in	O	O
the	O	O
large	O
-	O	O
entrance	O
boxes	B-OBJC
compared	O
with	O	O
the	O	O
small	O
-	O	O
entrance	O
boxes	B-OBJC
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
invasive	O
alien	O
species	O
can	O	O
reduce	O
the	O	O
breeding	B-PHYS
potential	O
of	O	O
native	O
cavity	O
breeders	B-LIVB
both	O	O
by	O	O
exploiting	O
the	O	O
limited	O
breeding	B-PHYS
resource	O
(	O	O
nest	O
cavities	O
)	O	O
and	O	O
by	O	O
directly	O
usurping	O
cavities	O
already	O	O
occupied	O
by	O	O
the	O	O
native	O
species	O
.	O	O

Since	O	O
the	O	O
majority	O
of	O	O
large	O
-	O	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
were	O	O
occupied	O
by	O	O
the	O	O
large	O
r	O	O
alien	B-LIVB
birds	I-LIVB
,	O	O
less	O	O
native	O
species	B-LIVB
bred	B-PHYS
in	O	O
the	O	O
limited	O
number	O
of	O	O
unoccupied	O
large	O
-	O	O
entrance	O
nest	B-OBJC
boxes	I-OBJC
because	O	O
of	O	O
exploitation	O
competition	O
.	O	O

We	O	O
propose	O	O
that	O	O
for	O	O
management	O
purposes	O
,	O	O
nest	B-OBJC
-	I-OBJC
box	I-OBJC
programs	O
that	O	O
alter	O
the	O	O
entrance	O
size	O
of	O	O
available	O	O
natural	O
cavities	O
may	O	O
be	O	O
a	O	O
practical	O	O
approach	O	O
,	O	O
reducing	O
the	O	O
competition	O
between	O	O
native	O
cavity	O
breeders	B-LIVB
and	O	O
alien	B-LIVB
invasive	I-LIVB
birds	I-LIVB
,	O	O
and	O	O
especially	O	O
benefiting	O	O
the	O	O
smaller	O
native	O
cavity	O
breeders	B-LIVB
.	O	O

Family	B-LIVB
Psychosocial	O
Risk	B-PROC
Screening	I-PROC
in	O	O
Infants	B-LIVB
and	O	O
Older	B-LIVB
Children	I-LIVB
in	O	O
the	O	O
Acute	O
Pediatric	O
Hospital	O
Setting	O
Using	O	O
the	O	O
Psychosocial	O
Assessment	O
Tool	O
To	O	O
examine	O	O
the	O	O
validity	O
of	O	O
the	O	O
Psychosocial	O
Assessment	O
Tool	O
(	O	O
PAT	O
)	O	O
with	O	O
families	B-LIVB
of	O	O
infants	B-LIVB
(	O	O
<	B-DISO
2	I-DISO
years	I-DISO
)	O	O
and	O	O
children	B-LIVB
admitted	B-PROC
to	I-PROC
hospital	I-PROC
with	O	O
acute	O
life	B-DISO
-	I-DISO
threatening	I-DISO
illnesses	B-DISO
.	O	O

METHODS	O
:	O	O
A	O	O
total	O
of	O	O
235	O	O
parents	B-LIVB
of	O	O
177	O	O
children	B-LIVB
admitted	B-PROC
to	O	O
oncology	O
,	O	O
cardiology	O
,	O	O
or	O	O
pediatric	O
intensive	O
care	O
completed	O
the	O	O
PAT	O
and	O	O
measures	O
of	O	O
acute	B-DISO
stress	I-DISO
,	O	O
trait	B-PHYS
anxiety	B-DISO
,	O	O
family	O
functioning	O
,	O	O
and	O	O
quality	O
of	O
life	O
,	O	O
a	O	O
mean	O
3	O	O
.	O	O
7	O	O
weeks	O
following	O	O
diagnosis	B-DISO
.	O	O

A	O	O
modified	O
PAT	O
was	O	O
used	O	O
for	O	O
families	B-LIVB
of	O	O
infants	B-LIVB
,	O	O
rendering	O	O
two	O	O
forms	O
,	O	O
PAT	O
(	O	O
<	B-DISO
2	I-DISO
)	O	O
and	O	O
PAT	O
(	O	O
2	B-DISO
+	I-DISO
)	O	O
.	O	O

RESULTS	B-PHEN
:	O	O
Psychometrics	B-PROC
for	O	O
PAT	O
(	O	O
<	B-DISO
2	I-DISO
)	O	O
and	O	O
PAT	O
(	O	O
2	B-DISO
+	I-DISO
)	O	O
were	O	O
acceptable	O
.	O	O

PAT	O
Total	O
and	O	O
Subscale	O
scores	O
for	O	O
each	O
version	B-DISO
were	O	O
significantly	O
correlated	O
with	O	O
validation	B-PROC
measures	O
.	O	O

Internal	O
consistency	O
for	O	O
PAT	O
subscales	O
was	O	O
variable	O
.	O	O

Receiver	O
Operating	O
Characteristics	O
provided	O
some	O	O
support	O	O
for	O	O
PAT	O
cutoffs	O
.	O	O

PAT	O
scores	O
across	O	O
illness	B-DISO
groups	B-LIVB
were	O	O
comparable	O
.	O	O

CONCLUSIONS	O
:	O	O
This	O	O
study	B-PROC
provides	O
promising	O
support	O
for	O	O
the	O	O
PAT	O
as	O	O
a	O	O
psychosocial	O
screener	B-PROC
for	O	O
families	B-LIVB
of	O	O
infants	B-LIVB
and	O	O
older	B-LIVB
children	I-LIVB
across	O	O
illness	B-DISO
conditions	O
.	O	O

Design	O
and	O	O
synthesis	O
of	O	O
pH	O
-	O	O
sensitive	O
polymeric	B-CHEM
micelles	B-CHEM
for	O	O
oral	B-ANAT
delivery	B-DEVI
of	O	O
poorly	O
water	B-CHEM
-	O	O
soluble	O
drugs	B-CHEM
pH	O
-	O	O
sensitive	O
polymer	B-CHEM
poly	B-CHEM
(	I-CHEM
polylactide	I-CHEM
-	I-CHEM
co	I-CHEM
-	I-CHEM
methacrylic	I-CHEM
acid	I-CHEM
)	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
poly	I-CHEM
(	I-CHEM
acrylic	I-CHEM
acid	I-CHEM
)	I-CHEM
was	O	O
synthesized	O
using	O	O
atom	B-PHEN
transfer	I-PHEN
radical	I-PHEN
polymerization	I-PHEN
and	O	O
ring	B-PHEN
-	I-PHEN
opening	I-PHEN
polymerization	I-PHEN
and	O	O
characterized	O	O
by	O	O
gel	B-PROC
permeation	I-PROC
chromatography	I-PROC
and	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
.	O	O

The	O	O
polymers	B-CHEM
can	O	O
self	O
-	O
assemble	O
to	O	O
form	O	O
micelles	B-CHEM
in	O	O
aqueous	B-CHEM
medium	I-CHEM
,	O	O
which	O	O
respond	O	O
rapidly	O	O
to	O	O
pH	O
change	O
within	O	O
the	O	O
gastrointestinal	O
relevant	O
pH	O
range	O	O
.	O	O

Critical	O	O
micelle	B-CHEM
concentrations	O
and	O	O
pH	O
response	O	O
behavior	O	O
of	O	O
the	O	O
polymeri	B-CHEM
c	O	O
micelle	B-CHEM
were	O	O
investigated	O	O
.	O	O

Water	B-CHEM
-	O	O
insoluble	B-DISO
drug	B-CHEM
nifedipine	B-CHEM
was	O	O
loaded	O
and	O	O
the	O	O
drug	B-CHEM
-	O	O
loading	O
content	O	O
can	O	O
be	O	O
controlled	O	O
by	O	O
tuning	O	O
the	O	O
composition	B-PHYS
of	O	O
the	O	O
polymers	B-CHEM
.	O	O

The	O	O
in	O
vitro	O
release	B-PHEN
studies	B-PROC
indicate	O	O
pH	O
sensitivity	O
enabled	O	O
rapid	O	O
drug	B-PHEN
release	I-PHEN
at	O	O
the	O	O
environment	O
of	O	O
simulated	O	O
intestinal	B-ANAT
fluid	I-ANAT
(	O	O
pH	O
7	O	O
.	O	O
36	O	O
)	O	O
,	O	O
the	O	O
cumulative	O
released	O	O
amount	O	O
of	O	O
NFD	B-CHEM
reached	O	O
more	O	O
than	O	O
80	O	O
%	O	O
within	O	O
24	O	O
h	O	O
,	O	O
while	O	O
only	O	O
35	O	O
%	O	O
in	O	O
the	O	O
simulated	O	O
gastric	B-ANAT
fluid	I-ANAT
(	O	O
pH	O
1	O	O
.	O	O
35	O	O
)	O	O
.	O	O

All	O	O
the	O	O
results	O	O
showed	O	O
that	O	O
the	O	O
pH	O
-	O	O
sensitive	O
P	B-CHEM
(	I-CHEM
PLAMA	I-CHEM
-	I-CHEM
co	I-CHEM
-	I-CHEM
MAA	I-CHEM
)	I-CHEM
-	I-CHEM
b	I-CHEM
-	I-CHEM
PAA	I-CHEM
micelle	B-CHEM
may	O	O
be	O	O
a	O	O
prospective	O	O
candidate	O	O
as	O	O
oral	B-ANAT
drug	B-CHEM
delivery	B-CHEM
carrier	I-CHEM
for	O	O
hydrophobic	O
drugs	B-CHEM
with	O	O
controlled	O
release	O
behavior	O	O
.	O	O

Effect	O
of	O	O
ultrasonic	O
processing	O
on	O	O
the	O	O
changes	O	O
in	O	O
activity	B-PHYS
,	O	O
aggregation	O
and	O	O
the	O	O
secondary	O
and	O	O
tertiary	O
structure	O
of	O	O
polyphenol	B-CHEM
oxidase	I-CHEM
in	O	O
oriental	B-GEOG
sweet	B-OBJC
melon	I-OBJC
(	O	O
Cucumis	B-LIVB
melo	I-LIVB
var	I-LIVB
.	I-LIVB

makuwa	I-LIVB
Makino	I-LIVB
)	O	O
Polyphenol	B-CHEM
oxidase	I-CHEM
(	O	O
PPO	B-CHEM
)	O	O
mainly	O	O
contributes	O
to	O	O
the	O	O
browning	B-PHEN
reaction	I-PHEN
of	O	O
fruits	B-OBJC
and	O	O
vegetables	B-OBJC
and	O	O
causes	O	O
serious	O
damage	O
to	O	O
the	O	O
quality	O
of	O	O
sweet	B-OBJC
melon	I-OBJC
products	B-OBJC
.	O	O

However	O	O
,	O	O
traditional	O
methods	O
to	O	O
inactivate	O
browning	B-PHEN
may	O	O
induce	O
more	O	O
unexpected	O
risks	O
than	O	O
ultrasonic	O
processing	O
.	O	O

Meanwhile	O	O
,	O	O
there	O	O
are	O	O
no	O	O
reports	O
on	O	O
the	O	O
effect	O
of	O	O
ultrasound	B-PHEN
on	O	O
PPO	B-CHEM
directly	O	O
purified	O
from	O	O
sweet	B-OBJC
melon	I-OBJC
.	O	O

The	O	O
PPO	B-CHEM
in	O	O
the	O	O
original	O
juice	B-OBJC
was	O	O
less	O	O
inactivated	O
than	O	O
the	O	O
purified	O
form	O	O
when	O	O
treated	B-PROC
with	I-PROC
ultrasound	B-PHEN
.	O	O

As	O	O
for	O	O
purified	O
PPO	B-CHEM
,	O	O
superior	O	O
to	O	O
thermal	B-PROC
treatment	I-PROC
,	O	O
less	O	O
heat	B-PHEN
was	O	O
needed	O	O
to	O	O
inactivate	O
the	O	O
PPO	B-CHEM
with	O	O
ultrasonic	O
treatment	B-PROC
.	O	O

At	O	O
intensity	B-DISO
lower	I-DISO
than	O	O
200	O	O
W	O	O
,	O	O
ultrasound	B-PHEN
did	O	O
not	O	O
significantly	O
affect	O	O
the	O	O
structure	O
and	O	O
activity	O
of	O	O
PPO	B-CHEM
(	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
latent	O
PPO	B-CHEM
was	O	O
activated	O
.	O	O

At	O	O
intensity	B-DISO
higher	I-DISO
than	O	O
200	O	O
W	O	O
,	O	O
ultrasound	B-PHEN
inactivated	O
PPO	B-CHEM
,	O	O
induced	O
aggregation	O
and	O	O
dissociation	B-PHYS
of	O	O
PPO	B-CHEM
particles	B-CHEM
and	O	O
significantly	O
decreased	O
the	O	O
α	O
-	O
helix	O
structure	O
content	O	O
.	O	O

Low	O
-	O
frequency	O
high	O
-	O
intensity	O
ultrasound	B-PHEN
caused	O	O
an	O	O
inactivation	O
effect	O
and	O	O
conformational	B-PHYS
changes	I-PHYS
of	O	O
purified	O
PPO	B-CHEM
from	O	O
oriental	B-GEOG
sweet	B-OBJC
melons	I-OBJC
.	O	O

Changes	O
in	O	O
the	O	O
PPO	B-CHEM
structure	O
induced	O
by	O	O
ultrasound	B-PHEN
eventually	O	O
inactivated	O
the	O	O
enzyme	B-CHEM
.	O	O

Ultrasound	B-PHEN
may	O	O
be	O	O
a	O	O
potential	O
method	O
to	O	O
inactivate	O
PPO	B-CHEM
in	O	O
oriental	B-GEOG
sweet	B-OBJC
melons	I-OBJC
.	O	O

©	O	O
2016	O	O
Society	O	O
of	O	O
Chemical	O	O
Industry	O	O
.	O	O

Phylogeography	O
of	O	O
the	O	O
Spanish	B-LIVB
Moon	O
Moth	O
Graellsia	O
isabellae	O
(	O	O
Lepidoptera	O
,	O	O
Saturniidae	O
)	O	O
Geographic	O
and	O	O
demographic	O
factors	O
as	O	O
well	O	O
as	O	O
specialisation	O
to	O	O
a	O	O
new	O	O
host	O
-	O
plant	O
may	O	O
lead	O	O
to	O	O
host	O
-	O	O
associated	O
differentiation	O
in	O	O
plant	B-LIVB
-feeding	O	O
insects	O
.	O	O

We	O	O
explored	O	O
the	O	O
phylogeography	O
of	O	O
a	O	O
protected	O
moth	O
,	O	O
Graellsia	O
isabellae	O
,	O	O
and	O	O
its	O	O
two	O	O
recognised	O	O
host	O
-	O
plant	O
species	O
(	O	O
Pinus	B-LIVB
sylvestris	I-LIVB
and	O	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
)	O	O
in	O	O
order	O	O
to	O	O
seek	O	O
for	O	O
any	O	O
concordance	O	O
useful	O	O
to	O	O
disentangle	O	O
the	O	O
evolutionary	O
history	O
of	O	O
this	O	O
iconic	O	O
lepidopteran	O
.	O	O

DNA	B-CHEM
variation	B-PHEN
in	O	O
one	O	O
mitochondrial	B-ANAT
marker	O
and	O	O
nine	O	O
nuclear	B-ANAT
microsatellite	O
loci	O
revealed	O	O
a	O	O
strong	O	O
phylogeographic	B-DISO
pattern	I-DISO
across	O	O
28	O	O
populations	O	O
of	O	O
G	O
.	O

isabellae	O
studied	O	O
in	O	O
Spain	B-GEOG
and	O	O
France	B-GEOG
comprising	O	O
six	O	O
groups	O
mostly	O	O
distributed	O
along	O	O
different	O
mountain	B-GEOG
ranges	I-GEOG
.	O	O

Reanalysis	B-PROC
of	O	O
a	O	O
previously	O	O
published	O	O
chloroplast	B-ANAT
microsatellite	O
dataset	O
revealed	O
a	O	O
three	O	O
and	O	O
two	O	O
-	O	O
group	O
structure	O
for	O	O
Spanish	B-LIVB
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
,	O	O
respectively	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
population	O	O
groupings	O	O
of	O	O
this	O	O
protected	O
moth	O
did	O	O
not	O	O
match	O
the	O	O
ones	O	O
of	O	O
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
.	O	O

There	O	O
was	O	O
no	O
evidence	O
of	O
host	O
-	O	O
associated	O
differentiation	O
between	O	O
populations	O	O
using	O	O
P	B-LIVB
.	I-LIVB

sylvestris	I-LIVB
and	O	O
the	O	O
ones	O	O
inhabiting	O
P	B-LIVB
.	I-LIVB

nigra	I-LIVB
.	O	O

The	O	O
two	O	O
major	O
mitochondrial	B-ANAT
clades	O
of	O	O
G	O
.	O

isabellae	O
likely	O	O
diverged	O	O
before	O	O
the	O	O
Last	O
Glacial	O
Maximum	O
and	O	O
geographically	O
separated	O
the	O	O
species	O
into	O	O
a	O	O
""""	O	O
southern	O
""""	O	O
(	O	O
Central	O
and	O
Southern	O
Iberian	O
clusters	O
)	O	O
and	O	O
a	O	O
""""	O	O
northern	O
""""	O	O
lineage	O
(	O	O
Eastern	O
Iberian	O
,	O	O
Pyrenean	O
and	O	O
French	O
Alpine	O
clusters	O
)	O	O
.	O	O

The	O	O
Eastern	O
Iberian	O
System	O
,	O	O
where	O	O
this	O	O
insect	O
uses	O	O
both	O	O
host	O
-	O
plants	O
,	O	O
harboured	O	O
the	O	O
highest	O
level	O
of	O	O
genetic	O
diversity	O
.	O	O

Such	O	O
a	O	O
group	O
independently	O	O
colonised	B-DISO
the	O	O
West	O
and	O	O
East	O
parts	O
of	O	O
the	O	O
Pyrenees	O
.	O	O

Our	O	O
results	O	O
point	O	O
to	O	O
a	O	O
native	O
origin	O
for	O	O
the	O	O
French	O
populations	O
occurring	O
in	O	O
the	O	O
Alps	B-GEOG
,	O	O
genetically	O
related	O	O
to	O	O
the	O	O
Eastern	O
Iberian	O
and	O	O
Pyrenean	O
sites	O
.	O	O

The	O	O
Central	O
Iberian	O
group	O
derived	O	O
from	O	O
Southern	O
Iberian	O
ancestors	B-LIVB
.	O	O

Secondary	O
contacts	O
were	O	O
inferred	O	O
between	O	O
the	O	O
Southern	O
/	O
Central	O
Iberian	O
populations	O
and	O	O
Eastern	O
Iberian	O
cluster	O
as	O	O
well	O	O
as	O	O
between	O	O
the	O	O
two	O	O
Pyrenean	O
ones	O
.	O	O

The	O	O
mito	O
-	O
nuclear	O
discordance	O
observed	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
Eastern	O
Iberian	O
cluster	O
is	O	O
congruent	O
with	O	O
a	O	O
secondary	O
contact	O
after	O	O
the	O	O
evolution	B-PHYS
of	O	O
mito	O
-	O
nuclear	O
incompatibilities	O
in	O	O
geographically	O
isolated	O
areas	O
.	O	O

Prevalence	O
of	O	O
Physical	O
Activity	O
and	O	O
Sitting	B-PHYS
Time	O
Among	O	O
South	B-LIVB
Korean	I-LIVB
Adolescents	B-LIVB
:	O	O
Results	B-DISO
From	O	O
the	O	O
Korean	B-LIVB
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
,	O	O
2013	O	O
This	O	O
study	O	O
aimed	O	O
to	O	O
describe	O	O
physical	O
activity	O
(	O	O
PA	O
)	O	O
and	O	O
sitting	B-PHYS
time	O
,	O	O
and	O	O
to	O	O
examine	O	O
associations	O
between	O	O
sociodemographic	O
factors	O
,	O	O
weight	B-PHYS
status	O
,	O	O
PA	O
,	O	O
and	O	O
sitting	B-PHYS
time	O
among	O	O
South	B-LIVB
Korean	I-LIVB
adolescents	B-LIVB
(	O	O
12	O	O
-	O	O
18	O	O
years	O
)	O	O
.	O	O

Findings	O
are	O	O
based	O	O
on	O	O
self	B-PROC
-	I-PROC
report	I-PROC
data	I-PROC
from	O	O
638	O	O
participants	B-LIVB
in	O	O
the	O	O
2013	O	O
Korea	B-GEOG
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
.	O	O

Only	O	O
4	O	O
.	O	O
9	O	O
%	O	O
of	O	O
adolescents	B-LIVB
accumulated	O	O
60	O	O
minutes	O
of	O	O
moderate	O
-	O
to	O
-	O
vigorous	O
PA	O
daily	O
.	O	O

Adolescents	B-LIVB
spent	O	O
532	O	O
.	O	O

4	O	O
±	O	O
9	O	O
.	O	O

3	O	O
mins	O
/	O
d	O
sitting	B-PHYS
.	O	O

After	O	O
controlling	O	O
for	O	O
age	B-PHYS
and	O	O
sex	B-PHYS
,	O	O
individuals	B-LIVB
in	O	O
higher	B-LIVB
income	I-LIVB
groups	I-LIVB
compared	O
with	O	O
the	O	O
lowest	B-LIVB
income	I-LIVB
group	I-LIVB
,	O	O
living	O
in	O	O
nonmetro	O
Seoul	B-GEOG
compared	O
with	O	O
metro	O
Seoul	B-GEOG
,	O	O
and	O	O
who	O	O
were	O	O
overweight	B-DISO
compared	O
with	O	O
nonoverweight	B-PHYS
were	O	O
more	O	O
likely	O	O
to	O	O
meet	O	O
PA	O
guidelines	O
.	O	O

Participants	B-LIVB
in	O	O
the	O	O
highest	B-LIVB
income	I-LIVB
group	I-LIVB
compared	O
with	O	O
lowest	B-LIVB
income	I-LIVB
group	I-LIVB
,	O	O
and	O	O
residing	O
in	O	O
nonmetro	O
Seoul	B-GEOG
compared	O
with	O	O
metro	O
Seoul	B-GEOG
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
in	O	O
the	O	O
high	O	O
sitting	B-PHYS
time	O
group	O
(	O	O
>	O	O
720	O	O
min	O
/	O
d	O
)	O	O
(	O	O
P	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

Increasing	O
PA	O
and	O	O
reducing	O
sitting	B-PHYS
should	O	O
be	O	O
a	O	O
public	O
health	O
priority	O
in	O	O
South	B-GEOG
Korea	I-GEOG
.	O	O

Graphene	B-CHEM
/	O	O
Nafion	B-CHEM
composite	B-OBJC
film	I-OBJC
modified	O	O
glassy	O
carbon	B-DEVI
electrode	I-DEVI
for	O	O
simultaneous	O
determination	B-PROC
of	O	O
paracetamol	B-CHEM
,	O	O
aspirin	B-CHEM
and	O	O
caffeine	B-CHEM
in	O	O
pharmaceutical	O
formulations	O
A	O	O
graphene	B-CHEM
-	O	O
Nafion	B-CHEM
composite	B-OBJC
film	I-OBJC
was	O	O
fabricated	O
on	O	O
the	O	O
glassy	O
carbon	B-DEVI
electrode	I-DEVI
(	O	O
GR	B-DEVI
-	I-DEVI
NF	I-DEVI
/	I-DEVI
GCE	I-DEVI
)	O	O
,	O	O
and	O	O
used	O	O
for	O	O
simultaneous	O
determination	B-PROC
of	O	O
paracetamol	B-CHEM
(	O	O
PAR	B-CHEM
)	O	O
,	O	O
aspirin	B-CHEM
(	O	O
ASA	B-CHEM
)	O	O
and	O	O
caffeine	B-CHEM
(	O	O
CAF	B-CHEM
)	O	O
.	O	O

The	O	O
electrochemical	O
behaviors	O
of	O	O
PAR	B-CHEM
,	O	O
ASA	B-CHEM
and	O	O
CAF	B-CHEM
were	O	O
investigated	O
by	O	O
cyclic	O
voltammetry	O
and	O	O
square	B-PROC
-	I-PROC
wave	I-PROC
adsorptive	I-PROC
anodic	I-PROC
stripping	I-PROC
voltammetry	I-PROC
.	O	O

By	O	O
using	O	O
stripping	B-PROC
one	O	O
for	O	O
simultaneous	O
determination	B-PROC
of	O	O
PAR	B-CHEM
,	O	O
ASA	B-CHEM
and	O	O
CAF	B-CHEM
,	O	O
their	O	O
electrochemical	O
oxidation	O
peaks	O
appeared	O
at	O	O
+0	O	O
.	O	O

64	O	O
,	O	O
1	O	O
.	O	O
04	O	O
and	O	O
1	O	O
.	O	O
44V	O	O
,	O	O
and	O	O
good	O
linear	O
current	O
responses	O
were	O	O
obtained	O
with	O	O
the	O	O
detection	O
limits	O
of	O	O
18ngmL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
1	O	O
.	O	O
2×10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
M	O	O
)	O	O
,	O	O
11	O	O
.	O	O

7ngmL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
6	O	O
.	O	O

5×10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
)	O	O
and	O	O
7	O	O
.	O	O

3ngmL	O	O
(	O	O
-	O	O
1	O	O
)	O	O
(	O	O
3	O	O
.	O	O
8×10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
proposed	O
electrochemical	B-OBJC
sensor	I-OBJC
was	O	O
successfully	O
applied	O
for	O	O
quantifying	O
PAR	B-CHEM
,	O	O
ASA	B-CHEM
and	O	O
CAF	B-CHEM
in	O	O
commercial	O
tablet	O
formulations	O
.	O	O

Targeting	O
tumor	B-DISO
tolerance	O
:	O	O
A	O	O
new	O	O
hope	O	O
for	O	O
pancreatic	B-DISO
cancer	I-DISO
therapy	B-PROC
?	O	O
With	O	O
a	O	O
5	O	O
-	O	O
year	O	O
survival	O
rate	O
of	O	O
just	O	O
8	O	O
%	O	O
,	O	O
pancreatic	B-DISO
cancer	I-DISO
(	O	O
PC	B-DISO
)	O	O
is	O	O
projected	O	O
to	O	O
be	O	O
the	O	O
second	O
leading	O
cause	O
of	O	O
cancer	O
deaths	O
by	O	O
2030	O	O
.	O	O

Most	O	O
PC	B-DISO
patients	B-LIVB
are	O	O
not	O	O
eligible	O
for	O	O
surgery	B-PROC
with	O	O
curative	B-PROC
intent	I-PROC
upon	O	O
diagnosis	B-DISO
,	O	O
emphasizing	O	O
a	O	O
need	O	O
for	O	O
more	O	O
effective	O
therapies	B-PROC
.	O	O

However	O	O
,	O	O
PC	B-DISO
is	O	O
notoriously	O	O
resistant	B-PHYS
to	O	O
chemoradiation	B-PROC
regimens	I-PROC
.	O	O

As	O	O
an	O	O
alternative	O
,	O	O
immune	B-PHYS
modulating	I-PHYS
strategies	B-PHYS
have	O	O
recently	O	O
achieved	O	O
success	O	O
in	O	O
melanoma	B-DISO
,	O	O
prompting	O
their	O	O
application	O
to	O	O
other	O	O
solid	B-DISO
tumors	I-DISO
.	O	O

For	O	O
such	O	O
therapeutic	B-PROC
approaches	O
to	O	O
succeed	O	O
,	O	O
a	O	O
state	O	O
of	O	O
immunologic	B-DISO
tolerance	I-DISO
must	O	O
be	O	O
reversed	O	O
in	O	O
the	O	O
tumor	B-PHEN
microenvironment	I-PHEN
and	O	O
that	O	O
has	O	O
been	O	O
especially	O	O
challenging	O	O
in	O	O
PC	B-DISO
.	O	O

Nonetheless	O	O
,	O	O
knowledge	O	O
of	O	O
the	O	O
PC	B-DISO
immune	O
microenvironment	O
has	O	O
advanced	O
considerably	O	O
over	O	O
the	O	O
past	O	O
decade	O	O
,	O	O
yielding	O	O
new	O
insights	B-PHYS
and	O	O
perspectives	O	O
to	O	O
guide	O	O
multimodal	B-PROC
therapies	I-PROC
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
catalog	O
the	O	O
historical	O	O
groundwork	O	O
and	O	O
discuss	O
the	O	O
evolution	B-PROC
of	O	O
the	O	O
cancer	O
immunology	O
field	O	O
to	O	O
its	O	O
present	O	O
state	O	O
with	O	O
a	O	O
specific	O	O
focus	O
on	O	O
PC	B-DISO
.	O	O

Strategies	B-PHYS
currently	O	O
employing	O	O
immune	B-PHYS
modulation	I-PHYS
in	O	O
PC	B-DISO
are	O	O
reviewed	O
,	O	O
specifically	O	O
highlighting	O	O
66	O	O
clinical	B-PROC
trials	I-PROC
across	O	O
the	O	O
United	B-GEOG
States	I-GEOG
and	O	O
Europe	B-GEOG
.	O	O

Parent	B-LIVB
's	I-LIVB
pro	B-DISO
-	I-DISO
health	I-DISO
awareness	I-DISO
concerning	O	O
oral	B-PROC
health	I-PROC
of	O	O
their	O	O
children	B-LIVB
in	O	O
the	O	O
light	O	O
of	O	O
survey	B-PROC
research	I-PROC
Oral	O
hygiene	O
is	O	O
a	O	O
crucial	O	O
part	O	O
of	O	O
caring	O
for	O	O
young	O	O
children	B-LIVB
.	O	O

This	O	O
problem	B-DISO
is	O	O
frequently	O
marginalized	O
or	O	O
even	O	O
ignored	O
by	O	O
parents	B-LIVB
/	O	O
guardians	B-LIVB
,	O	O
what	O	O
affects	O
child	B-LIVB
's	I-LIVB
whole	O	O
further	O
life	O
.	O	O

The	O	O
assessment	O
of	O	O
parents	B-LIVB
'	I-LIVB
knowledge	B-DISO
concerning	O	O
oral	O
hygiene	O
and	O	O
prevention	O
of	O	O
dental	B-DISO
caries	I-DISO
in	O	O
infants	B-LIVB
and	O	O
young	O
children	B-LIVB
.	O	O

The	O	O
test	O
group	O
consisted	O	O
of	O	O
parents	B-LIVB
,	O	O
as	O	O
well	O	O
as	O	O
men	B-LIVB
and	O	O
women	B-LIVB
currently	O	O
expecting	O	O
a	O	O
child	B-LIVB
.	O	O

The	O	O
study	B-PROC
was	O	O
conducted	O
in	O	O
a	O	O
form	O	O
of	O	O
a	O	O
survey	O
,	O	O
using	O	O
an	O	O
original	O
questionnaire	O
,	O	O
which	O	O
was	O	O
carried	O	O
out	O	O
in	O	O
several	O
hospitals	B-OBJC
in	O	O
Lodz	O
and	O	O
online	O
,	O	O
on	O	O
a	O	O
popular	O	O
local	O	O
forum	O
for	O	O
parents	B-LIVB
.	O	O

The	O	O
data	O
obtained	O
were	O	O
analyzed	B-PROC
statistically	I-PROC
,	O	O
allowing	O	O
the	O	O
assessment	O
of	O	O
health	B-DISO
awareness	I-DISO
of	O	O
respondents	B-LIVB
and	O	O
the	O	O
creation	O
of	O	O
various	O	O
profiles	O	O
of	O	O
parental	B-DISO
knowledge	I-DISO
on	O	O
the	O	O
subject	O
investigated	O
.	O	O

Most	O	O
of	O	O
respondents	B-LIVB
knew	O	O
the	O	O
age	B-PHYS
at	O	O
which	O	O
milk	B-ANAT
and	O	O
permanent	B-ANAT
teeth	I-ANAT
erupt	O
,	O	O
gave	O	O
the	O	O
correct	O	O
frequency	O
of	O	O
brushing	B-PROC
child	B-LIVB
's	I-LIVB
teeth	B-ANAT
and	O	O
were	O	O
in	O	O
favor	O	O
of	O	O
limiting	O
sweets	B-OBJC
in	O	O
the	O	O
diet	B-OBJC
.	O	O

A	O	O
total	O
of	O	O
59	O	O
%	O	O
correctly	O	O
gave	O	O
the	O	O
number	O
of	O	O
deciduous	B-ANAT
teeth	I-ANAT
and	O	O
66	O	O
%	O	O
had	O	O
heard	O	O
of	O	O
the	O	O
""""	O	O
bottle	B-DISO
tooth	I-DISO
decay	I-DISO
""""	O	O
.	O	O

All	O	O
respondents	B-LIVB
thought	O	O
that	O	O
helping	O
and	O	O
controlling	O
a	O	O
child	B-LIVB
while	O	O
brushing	B-PROC
their	O	O
teeth	B-ANAT
is	O	O
indispensable	O	O
,	O	O
but	O	O
they	O	O
did	O	O
not	O	O
know	O	O
the	O	O
best	O
time	O
to	O	O
start	O
using	O	O
the	O	O
toothpaste	B-CHEM
with	I-CHEM
fluoride	I-CHEM
.	O	O

The	O	O
information	O
about	O	O
child	B-LIVB
's	I-LIVB
oral	O
hygiene	O
was	O	O
more	O	O
often	O	O
looked	O	O
for	O	O
by	O	O
women	B-LIVB
(	O	O
67	O	O
%	O	O
)	O	O
than	O	O
by	O	O
men	B-LIVB
(	O	O
29	O	O
%	O	O
)	O	O
.	O	O

The	O	O
study	B-PROC
also	O	O
showed	O	O
that	O	O
if	O	O
a	O	O
training	B-PROC
on	O	O
the	O	O
given	O	O
subject	O
was	O	O
organized	O
,	O	O
60	O	O
%	O	O
of	O	O
respondents	B-LIVB
would	O	O
be	O	O
willing	B-DISO
to	O	O
participate	O
in	O	O
it	O	O
.	O	O

In	O	O
the	O	O
test	O
group	O
,	O	O
pro	B-DISO
-	I-DISO
health	I-DISO
awareness	I-DISO
is	O	O
insufficient	O
to	O	O
maintain	O
the	O	O
oral	B-PROC
health	I-PROC
of	O	O
the	O	O
offspring	B-LIVB
and	O	O
requires	O
constant	O
developing	O	O
.	O	O

oral	B-PHYS
health	I-PHYS
behaviors	I-PHYS
,	O	O
oral	B-PROC
health	I-PROC
,	O	O
prophylaxis	B-PROC
of	O	O
dental	B-DISO
caries	I-DISO
,	O	O
parent	B-LIVB
questionnaire	O
survey	O
.	O	O

Depressive	B-DISO
symptoms	I-DISO
and	O	O
long	O
-	O
term	O
income	O
:	O	O
The	O	O
Young	O
Finns	O
Study	O
Higher	O
depressive	B-DISO
symptoms	I-DISO
have	O	O
been	O	O
associated	O
with	O
lower	O
future	O
income	O
.	O	O

However	O	O
,	O	O
studies	B-PROC
examining	B-DISO
this	O	O
issue	B-DISO
have	O	O
had	O	O
limited	O
follow	B-PROC
-	I-PROC
up	I-PROC
times	O
and	O	O
have	O	O
used	O	O
self	B-PROC
-	I-PROC
reported	I-PROC
measures	O
of	O	O
income	O
.	O	O

Also	O	O
,	O	O
possible	B-DISO
confounders	O
or	O	O
mediators	O
have	O	O
not	O	O
been	O	O
accounted	O
.	O	O

971	O	O
women	B-LIVB
and	O	O
738	O	O
men	B-LIVB
were	O	O
selected	O
from	O	O
the	O	O
ongoing	O
prospective	B-PROC
Young	O
Finns	O
Study	O
(	O	O
YFS	O
)	O	O
that	O	O
began	O	O
in	O	O
1980	O	O
.	O	O

Depressive	B-DISO
symptoms	I-DISO
were	O	O
measured	O
in	O	O
1992	O	O
when	O	O
participants	B-LIVB
were	O	O
from	O	O
15	O	O
to	O	O
30	O	O
years	O
old	O
.	O	O

Information	O
on	O	O
annual	O
income	O
and	O	O
earnings	O
from	O	O
1993	O	O
to	O	O
2010	O	O
were	O	O
obtained	O
from	O	O
the	O	O
Finnish	O
Longitudinal	O
Employer	O
-	O
Employee	O
Data	O
(	O
FLEED	O
)	O
of	O
Statistics	O
Finland	B-GEOG
and	O	O
linked	O
to	O	O
the	O	O
YFS	O
.	O	O

Higher	O
depressive	B-DISO
symptoms	I-DISO
were	O	O
associated	O
with	O
lower	O
future	O
income	O
and	O	O
earnings	O
.	O	O

For	O	O
men	B-LIVB
,	O	O
the	O	O
associations	B-PHYS
were	O	O
robust	O
for	O	O
controlling	B-PHEN
childhood	O
parental	B-LIVB
socioeconomic	O
status	O
,	O	O
history	O
of	O	O
unemployment	B-DISO
,	O	O
and	O	O
adulthood	O
health	O
behavior	O
,	O	O
but	O	O
attenuated	O
circa	O	O
35	O	O
%	O	O
when	O	O
three	O	O
major	O
temperament	B-PHYS
traits	B-PHYS
were	O	O
taken	O	O
into	O	O
account	O	O
.	O	O

For	O	O
women	B-LIVB
,	O	O
similar	O
pattern	O
was	O	O
found	O	O
,	O	O
however	O	O
,	O	O
in	O	O
the	O	O
models	O
adjusted	O
for	O	O
temperament	B-PHYS
traits	B-PHYS
the	O	O
associations	O
did	O	O
not	O	O
remain	O	O
statistically	O
significant	O
.	O	O

The	O	O
association	B-PHYS
between	O	O
depressive	B-DISO
symptoms	I-DISO
and	O	O
earnings	O
was	O	O
three	O	O
times	O	O
stronger	O
for	O	O
men	B-LIVB
than	O	O
women	B-LIVB
.	O	O

Previous	O
depressive	B-DISO
episodes	I-DISO
could	O	O
have	O	O
influenced	O
on	O	O
some	O	O
participants	B-LIVB
'	O	O
economic	O
and	O	O
educational	B-PROC
choices	O
.	O	O

Higher	O
depressive	B-DISO
symptoms	I-DISO
in	O	O
adolescence	O
and	O	O
early	O	O
adulthood	O
lead	O	O
to	O	O
significant	O
future	O
losses	O
of	O	O
total	O
income	O
and	O	O
earnings	O
,	O	O
and	O	O
this	O	O
association	B-PHYS
is	O	O
particularly	O	O
strong	O
for	O	O
men	B-LIVB
.	O	O

miR	B-CHEM
-	I-CHEM
376c	I-CHEM
inhibits	O	O
cervical	B-DISO
cancer	I-DISO
cell	B-PHYS
proliferation	I-PHYS
and	O	O
invasion	B-DISO
by	O	O
targeting	O	O
BMI1	O
MicroRNAs	B-CHEM
(	O	O
miRNAs	B-CHEM
)	O	O
play	O	O
crucial	O	O
roles	O	O
in	O	O
cancer	B-DISO
development	O
and	O	O
progression	B-DISO
.	O	O

The	O	O
purposes	O	O
of	O	O
this	O	O
study	B-PROC
were	O	O
to	O	O
explore	O	O
the	O	O
role	O	O
of	O	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
in	O	O
cervical	B-DISO
cancer	I-DISO
and	O	O
to	O	O
clarify	O	O
the	O	O
regulation	B-PHYS
of	O	O
BMI1	O
by	O	O
miR	O
-	O
376c	O
.	O	O

Quantitative	B-PROC
RT	I-PROC
-	I-PROC
PCR	I-PROC
was	O	O
used	O	O
to	O	O
measure	O	O
miR	O
-	O
376c	O
expression	B-PHYS
in	O	O
cervical	B-DISO
cancer	I-DISO
tissues	O
and	O	O
cell	B-ANAT
lines	I-ANAT
.	O	O

The	O	O
cell	B-PROC
proliferation	I-PROC
,	O	O
cell	B-PROC
cycle	I-PROC
and	O	O
Transwell	B-PROC
invasion	I-PROC
assays	I-PROC
were	O	O
performed	O	O
.	O	O

A	O	O
luciferase	B-PROC
reporter	I-PROC
assay	I-PROC
was	O	O
conducted	O	O
to	O	O
confirm	O	O
the	O	O
target	O
gene	O
of	O	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
,	O	O
and	O	O
the	O	O
results	O	O
were	O	O
validated	O	O
in	O	O
cervical	B-DISO
cancer	I-DISO
cell	B-ANAT
lines	I-ANAT
and	O	O
tissues	O
.	O	O

MiR	O
-	O
376c	O
was	O	O
significantly	O	O
downregulated	B-PHYS
in	O	O
cervical	B-DISO
cancer	I-DISO
cell	B-ANAT
lines	I-ANAT
and	O	O
clinical	O
tissues	O
.	O	O

Upregulation	B-PHYS
of	O	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
impaired	O	O
cell	B-PHYS
proliferation	I-PHYS
,	O	O
blocked	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
checkpoint	I-PHYS
of	O	O
cell	B-PHYS
cycle	I-PHYS
and	O	O
suppressed	O
cell	B-DISO
invasion	I-DISO
in	O
vitro	O
.	O	O

BMI1	O
was	O	O
verified	O	O
as	O	O
a	O	O
direct	O	O
target	O
of	O	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
,	O	O
which	O	O
was	O	O
further	O	O
confirmed	O	O
by	O	O
the	O	O
inverse	B-PHYS
expression	I-PHYS
of	O	O
miR	O
-	O
376c	O
and	O	O
BMI1	O
in	O	O
patient	B-LIVB
specimens	B-OBJC
.	O	O

The	O	O
newly	O	O
identified	O	O
miR	B-CHEM
-	I-CHEM
376c	I-CHEM
/	O	O
BMI1	O
pathway	B-PHYS
provides	O	O
an	O	O
insight	O	O
into	O	O
cervical	B-DISO
cancer	I-DISO
progression	B-DISO
and	O	O
may	O	O
represent	O	O
a	O	O
novel	O	O
therapeutic	O
target	O
.	O	O

Phenol	B-CHEM
red	I-CHEM
-	O	O
silk	B-CHEM
tyrosine	I-CHEM
cross	B-PHEN
-	I-PHEN
linked	I-PHEN
hydrogels	B-CHEM
Phenol	B-CHEM
red	I-CHEM
is	O	O
a	O	O
cytocompatible	O
pH	B-CHEM
sensing	I-CHEM
dye	I-CHEM
that	O	O
is	O	O
commonly	O	O
added	O	O
to	O	O
cell	B-CHEM
culture	I-CHEM
media	I-CHEM
,	O	O
but	O	O
removed	O
from	O	O
some	O	O
media	B-CHEM
formulations	O	O
due	O	O
to	O	O
its	O	O
structural	O
mimicry	B-PHYS
of	O	O
estrogen	B-CHEM
.	O	O

Phenol	B-CHEM
red	I-CHEM
free	O	O
media	B-CHEM
is	O	O
also	O	O
used	O	O
during	O	O
live	B-PROC
cell	I-PROC
imaging	I-PROC
,	O	O
to	O	O
avoid	O	O
absorbance	B-PHEN
and	O	O
fluorescence	B-PHYS
quenching	I-PHYS
of	O	O
fluorophores	B-CHEM
.	O	O

To	O	O
overcome	O
these	O	O
complications	B-DISO
,	O	O
we	O	O
developed	O	O
cytocompatible	O
and	O	O
degradable	O
phenol	B-CHEM
red	I-CHEM
-	O	O
silk	B-CHEM
tyrosine	I-CHEM
cross	B-PHEN
-	I-PHEN
linked	I-PHEN
hydrogels	B-CHEM
using	O	O
horseradish	B-CHEM
peroxidase	I-CHEM
(	I-CHEM
HRP	I-CHEM
)	I-CHEM
enzyme	I-CHEM
and	O	O
hydrogen	B-CHEM
peroxide	I-CHEM
(	O	O
H2O2	B-CHEM
)	O	O
.	O	O

Phenol	B-CHEM
red	I-CHEM
added	O	O
to	O	O
silk	B-CHEM
during	O	O
tyrosine	B-CHEM
crosslinking	B-PHEN
accelerated	O
di	B-CHEM
-	I-CHEM
tyrosine	I-CHEM
formation	O
in	O	O
a	O	O
concentration	O
-	O	O
dependent	B-PHEN
reaction	I-PHEN
.	O	O

Phenol	B-CHEM
red	I-CHEM
diffusion	B-PHEN
studies	B-PROC
and	O	O
UV	B-PROC
-	I-PROC
Vis	I-PROC
spectra	I-PROC
of	O	O
phenol	B-CHEM
red	I-CHEM
-	O	O
silk	B-CHEM
tyrosine	I-CHEM
hydrogels	B-CHEM
at	O	O
different	O	O
pHs	O
showed	O	O
altered	O
absorption	B-PHEN
bands	O	O
,	O	O
confirming	B-DISO
entrapment	B-DISO
of	O	O
dye	B-CHEM
within	O	O
the	O	O
hydrogel	B-CHEM
network	I-CHEM
.	O	O

LC	B-PROC
-	I-PROC
MS	I-PROC
of	O	O
HRP	B-CHEM
-reacted	O	O
phenol	B-CHEM
red	I-CHEM
and	O	O
N	B-CHEM
-	I-CHEM
acetyl	I-CHEM
-	I-CHEM
l	I-CHEM
-	I-CHEM
tyrosine	I-CHEM
reaction	B-OBJC
products	I-OBJC
confirmed	B-DISO
covalent	B-PHEN
bonds	I-PHEN
between	O	O
the	O	O
phenolic	B-CHEM
hydroxyl	I-CHEM
group	I-CHEM
of	O	O
phenol	B-CHEM
red	I-CHEM
and	O	O
tyrosine	B-CHEM
on	O	O
the	O	O
silk	B-CHEM
.	O	O

At	O	O
lower	O	O
phenol	B-CHEM
red	I-CHEM
concentrations	O
,	O	O
leak	O	O
-	O	O
proof	O	O
hydrogels	B-CHEM
which	O	O
did	O	O
not	O	O
release	O	O
phenol	B-CHEM
red	I-CHEM
were	O	O
fabricated	O	O
and	O	O
found	O	O
to	O	O
be	O	O
cytocompatible	O
based	O	O
on	O	O
live	B-PROC
-	I-PROC
dead	I-PROC
staining	I-PROC
and	O	O
alamar	B-CHEM
blue	I-CHEM
assessments	O
of	O	O
encapsulated	O
fibroblasts	B-ANAT
.	O	O

Due	O	O
to	O	O
the	O	O
spectral	B-DISO
overlap	I-DISO
between	O	O
phenol	B-CHEM
red	I-CHEM
absorbance	B-PHEN
at	O	O
415	O	O
nm	O
and	O	O
di	B-CHEM
-	I-CHEM
tyrosine	I-CHEM
fluorescence	B-PHEN
at	O	O
417	O	O
nm	O
,	O	O
phenol	B-CHEM
red	I-CHEM
-	O	O
silk	B-CHEM
hydrogels	B-CHEM
provide	O	O
both	O	O
absorbance	B-PHEN
and	O	O
fluorescence	B-PHEN
-based	O	O
pH	O
sensing	O
.	O	O

With	O	O
an	O	O
average	O	O
pKa	O
of	O	O
6	O	O
.	O	O

8	O	O
and	O	O
good	O
cytocompatibiltiy	O
,	O	O
phenol	B-CHEM
red	I-CHEM
-	O	O
silk	B-CHEM
hydrogels	B-CHEM
are	O	O
useful	O	O
for	O	O
pH	O
sensing	O
in	O	O
phenol	O
red	O
free	O
systems	O
,	O	O
cellular	B-PHEN
microenvironments	I-PHEN
and	O	O
bioreactors	B-DEVI
.	O	O

Phenol	B-CHEM
red	I-CHEM
entrapped	B-DISO
within	O	O
hydrogels	B-CHEM
facilitates	O	O
pH	O
sensing	O
in	O	O
phenol	B-CHEM
red	I-CHEM
free	O
environments	O
.	O	O

Leak	O	O
-	O	O
proof	O	O
phenol	B-CHEM
red	I-CHEM
based	O	O
pH	B-OBJC
sensors	I-OBJC
require	O	O
covalent	O
binding	O
techniques	O
,	O	O
but	O	O
are	O	O
complicated	O
due	O	O
to	O	O
the	O	O
lack	O
of	O	O
amino	B-CHEM
or	O	O
carboxyl	B-CHEM
groups	I-CHEM
on	O	O
phenol	B-CHEM
red	I-CHEM
.	O	O

Currently	O	O
,	O	O
there	O	O
is	O	O
no	O
simple	O
,	O	O
reliable	O
technique	O
to	O	O
covalently	B-PHEN
link	B-PHEN
phenol	B-CHEM
red	I-CHEM
to	O	O
hydrogel	B-CHEM
matrices	O	O
,	O	O
for	O	O
real	O
-	O
time	O
pH	O
sensing	O
in	O	O
cell	B-PROC
culture	I-PROC
environments	O
.	O	O

Herein	O	O
,	O	O
we	O	O
take	O	O
advantage	O	O
of	O	O
phenolic	B-CHEM
groups	I-CHEM
for	O	O
covalent	B-PHEN
linkage	O
of	O	O
phenol	B-CHEM
red	I-CHEM
to	O	O
silk	B-CHEM
tyrosine	I-CHEM
in	O	O
the	O	O
presence	O	O
of	O	O
HRP	B-CHEM
and	O	O
H2O2	B-CHEM
.	O	O

The	O	O
novelty	O
of	O	O
the	O	O
current	B-OBJC
system	I-OBJC
stems	O	O
from	O	O
its	O	O
simplicity	O	O
and	O	O
the	O	O
use	O	O
of	O	O
silk	B-CHEM
protein	I-CHEM
to	O	O
create	O	O
a	O	O
cytocompatible	O
,	O	O
degradable	O
sensor	B-OBJC
capable	O	O
of	O	O
real	O
-	O
time	O
pH	O
sensing	O
in	O	O
cell	B-PHEN
culture	I-PHEN
microenvironments	I-PHEN
.	O	O

Common	O
Laboratory	B-OBJC
Parameters	B-DISO
for	O	O
Differentiating	O
Between	O	O
Community	B-DISO
-	I-DISO
Acquired	I-DISO
and	O	O
Healthcare	B-DISO
-	I-DISO
Associated	I-DISO
Pneumonia	I-DISO
The	O	O
correct	O
diagnosis	B-DISO
of	O	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonia	I-DISO
(	O	O
HCAP	B-DISO
)	O	O
as	O	O
opposed	O	O
to	O	O
community	B-DISO
-	I-DISO
acquired	I-DISO
pneumonia	I-DISO
is	O	O
essential	O
for	O	O
the	O	O
selection	O
of	O	O
a	O	O
correct	O
empirical	O
antimicrobial	B-CHEM
approach	O	O
,	O	O
reserving	O	O
the	O	O
broad	O
-	O
spectrum	O
or	O	O
highly	O
potent	O
antimicrobial	B-PROC
therapies	I-PROC
for	O	O
resistant	O
strains	B-LIVB
most	O	O
commonly	O	O
present	O	O
in	O	O
HCAP	B-DISO
,	O	O
whereas	O	O
treating	O
the	O	O
less	O	O
resistant	O
strains	B-LIVB
,	O	O
most	O	O
commonly	O	O
associated	O
with	O
community	B-LIVB
and	O	O
long	B-OBJC
-	I-OBJC
term	I-OBJC
care	I-OBJC
facility	I-OBJC
-	O	O
acquired	B-DISO
infections	I-DISO
,	O	O
with	O	O
a	O	O
more	O	O
targeted	O
empirical	B-PROC
approach	I-PROC
.	O	O

The	O	O
standard	O
approach	O
today	O
is	O	O
to	O	O
differentiate	O
between	O	O
the	O	O
two	O	O
based	O	O
on	O	O
the	O	O
medical	B-DISO
history	I-DISO
of	O	O
the	O	O
past	O
90	O	O
days	O
prior	O	O
to	O	O
admission	B-PROC
.	O	O

Measurable	O
,	O	O
quantitative	O
assessment	B-PROC
may	O	O
be	O	O
able	O	O
to	O	O
assist	O
in	O	O
this	O	O
decision	B-PHYS
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
find	O	O
a	O	O
measurable	O
method	O
of	O	O
differentiating	O
between	O	O
community	B-DISO
-	I-DISO
acquired	I-DISO
and	O	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonias	I-DISO
.	O	O

The	O	O
records	O
of	O	O
126	O	O
patients	B-LIVB
admitted	B-PROC
with	O	O
a	O	O
diagnosis	B-DISO
of	O	O
pneumonia	B-DISO
were	O	O
divided	O	O
into	O	O
two	O	O
groups	O
based	O	O
on	O	O
the	O	O
probable	O	O
cause	O
of	O
their	O
disease	O
,	O	O
in	O	O
accordance	O	O
with	O	O
common	B-PHYS
practice	I-PHYS
.	O	O

The	O	O
routine	O
laboratory	B-PROC
work	I-PROC
taken	O	O
upon	O	O
admittance	B-PROC
was	O	O
analyzed	B-PROC
using	O	O
logistical	B-PROC
regression	I-PROC
and	O	O
Student	O
's	O
t	O
-	O
test	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
the	O	O
red	B-PROC
blood	I-PROC
cell	I-PROC
distribution	I-PROC
width	I-PROC
and	O	O
the	O	O
neutrophil	O
-to	O
-	O
lymphocyte	O
ratio	O
,	O	O
both	O	O
routine	B-DISO
parameters	I-DISO
obtained	O	O
in	O	O
a	O	O
simple	O	O
blood	B-PROC
count	I-PROC
,	O	O
can	O	O
each	O	O
assist	O
in	O	O
differentiating	O
between	O	O
community	B-DISO
-	I-DISO
acquired	I-DISO
and	O	O
healthcare	B-DISO
-	I-DISO
associated	I-DISO
pneumonias	I-DISO
.	O	O

We	O	O
have	O	O
found	O	O
two	O	O
statistically	O
significant	O
parameters	O
that	O	O
may	O	O
be	O	O
used	O	O
as	O	O
adjuncts	O	O
to	O	O
the	O	O
medical	B-DISO
history	I-DISO
,	O	O
chest	B-PROC
radiography	I-PROC
and	O	O
other	B-DISO
parameters	I-DISO
in	O	O
forming	O	O
an	O	O
immediate	O
clinical	B-DISO
impression	I-DISO
of	O	O
a	O	O
patient	B-LIVB
presenting	O	O
with	O	O
pneumonia	B-DISO
.	O	O

Long	O
-	O
term	O
antibiofilm	O
activity	O
of	O	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
on	O	O
mixed	B-LIVB
biofilm	I-LIVB
on	O	O
silicone	B-CHEM
Silicone	B-CHEM
voice	B-DEVI
prostheses	I-DEVI
are	O	O
most	O	O
frequently	O
used	O	O
in	O	O
voice	B-PROC
rehabilitation	I-PROC
of	O	O
laryngectomized	B-PROC
patients	B-LIVB
.	O	O

However	O	O
,	O	O
the	O	O
functional	B-DISO
device	I-DISO
lifetimes	O
are	O	O
limited	O
due	O
to	O
formation	O
of	O	O
mixed	B-LIVB
biofilms	I-LIVB
.	O	O

Existing	O	O
in	B-PROC
vitro	I-PROC
models	I-PROC
simulating	O	O
biofilm	B-PHYS
formation	I-PHYS
are	O	O
restricted	O
to	O	O
only	O	O
short	O
-	O
term	O
periods	O
.	O	O

The	O	O
goal	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
the	O	O
effect	O
of	O	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
on	O	O
mixed	B-PHYS
biofilm	I-PHYS
formation	I-PHYS
of	O	O
fungi	B-LIVB
and	O	O
bacteria	B-LIVB
on	O	O
silicone	B-CHEM
over	O	O
a	O	O
long	O
-	O
term	O
period	O
.	O	O

Mixed	O	O
species	O
biofilms	B-LIVB
of	O	O
Candida	B-LIVB
albicans	I-LIVB
,	O	O
Candida	B-LIVB
tropicalis	I-LIVB
,	O	O
Lactobacillus	B-LIVB
gasseri	I-LIVB
,	O	O
Streptococcus	B-LIVB
salivarius	I-LIVB
,	O	O
Rothia	B-LIVB
dentocariosa	I-LIVB
,	O	O
and	O	O
Staphylococcus	B-LIVB
epidermidis	I-LIVB
were	O	O
cultivated	B-PHEN
on	O	O
the	O	O
surfaces	O
of	O	O
medical	B-CHEM
-	I-CHEM
grade	I-CHEM
silicone	I-CHEM
with	O	O
and	O	O
without	O	O
addition	O	O
of	O	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
.	O	O

Biofilm	B-PHEN
kinetics	I-PHEN
was	O	O
monitored	O	O
using	O	O
specially	O	O
designed	O
image	O
analysis	O
software	O
to	O	O
calculate	O
the	O	O
percentual	O
surface	O
covering	O
of	O	O
each	O	O
platelet	B-ANAT
.	O	O

Biofilm	O
architecture	O
was	O	O
investigated	O
by	O	O
scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
.	O	O

A	O	O
cover	O
of	O	O
living	O
mixed	B-LIVB
biofilm	I-LIVB
could	O	O
be	O	O
generated	O	O
over	O	O
22	O	O
days	O
on	O	O
silicone	B-CHEM
and	O	O
the	O	O
maximum	O
of	O	O
22	O	O
%	O	O
biofilm	B-LIVB
surface	O
covering	O
at	O	O
day	O
22	O	O
.	O	O

However	O	O
,	O	O
less	O
than	O
4	O	O
%	O	O
surface	O
coverage	O
was	O	O
observed	O
on	O	O
the	O	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
-	O	O
treated	O
plates	O	O
in	O	O
the	O	O
testing	O
period	O
.	O	O

Scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
confirms	B-DISO
that	O	O
,	O	O
on	O	O
surfaces	O
treated	O
by	O	O
carboxymethyl	B-CHEM
chitosan	I-CHEM
,	O	O
the	O	O
biofilm	B-LIVB
was	O	O
less	O
dense	O
.	O	O

In	O	O
addition	O	O
,	O	O
there	O	O
were	O	O
fewer	O
layers	O	O
of	O	O
cells	B-ANAT
and	O	O
profuse	B-DISO
cellular	I-DISO
debris	I-DISO
,	O	O
together	O
with	O	O
degrading	O	O
and	O	O
morphologically	B-DISO
altered	I-DISO
yeast	B-ANAT
cells	I-ANAT
.	O	O

Carboxymethyl	B-CHEM
chitosan	I-CHEM
may	O	O
serve	O	O
as	O	O
a	O	O
possible	B-DISO
antibiofilm	B-OBJC
agent	I-OBJC
to	O	O
limit	O	O
biofilm	B-PHYS
formation	I-PHYS
on	O	O
voice	B-DEVI
prostheses	I-DEVI
.	O	O

NA	O	O
Laryngoscope	B-DEVI
,	O	O
126	O	O
:	O	O
E404	O	O
-	O	O
E408	O	O
,	O	O
2016	O	O
.	O	O

Online	B-DISO
public	I-DISO
reactions	I-DISO
to	O	O
frequency	O
of	O	O
diagnostic	O
errors	O
in	O	O
US	B-GEOG
outpatient	B-OBJC
care	I-OBJC
Diagnostic	O
errors	O
pose	O	O
a	O	O
significant	O	O
threat	O
to	O	O
patient	B-PROC
safety	I-PROC
but	O	O
little	O	O
is	O	O
known	O	O
about	O	O
public	O
perceptions	B-PHYS
of	O	O
diagnostic	O
errors	O
.	O	O

A	O	O
study	B-PROC
published	O
in	O	O
BMJ	O
Quality	O
&	O
Safety	O
in	O	O
2014	O	O
estimated	O	O
that	O	O
diagnostic	O
errors	O
affect	O	O
at	O	O
least	O	O
5	O	O
%	O	O
of	O	O
US	B-GEOG
adults	B-LIVB
(	O	O
or	O	O
12	O	O
million	O	O
)	O	O
per	O
year	O
.	O	O

We	O	O
sought	O	O
to	O	O
explore	O	O
online	B-DISO
public	I-DISO
reactions	I-DISO
to	O	O
media	O
reports	O
on	O	O
the	O	O
reported	O	O
frequency	O
of	O	O
diagnostic	O
errors	O
in	O	O
the	O	O
US	B-GEOG
adult	B-LIVB
population	O
.	O	O

We	O	O
searched	O	O
the	O	O
World	B-OBJC
Wide	I-OBJC
Web	I-OBJC
for	O	O
any	O	O
news	O
article	O
reporting	O	O
findings	O
from	O	O
the	O	O
study	B-PROC
.	O	O

We	O	O
then	O	O
gathered	O	O
all	O	O
the	O	O
online	B-OBJC
comments	O
made	O	O
in	O	O
response	O
to	O	O
the	O	O
news	O
articles	O
to	O	O
evaluate	B-PROC
public	B-DISO
reaction	I-DISO
to	O	O
the	O	O
newly	O	O
reported	O	O
diagnostic	O
error	O
frequency	O
(	O	O
n	O	O
=	O	O
241	O	O
)	O	O
.	O	O

Two	O	O
coders	B-LIVB
conducted	O	O
content	B-PROC
analyses	I-PROC
of	O	O
the	O	O
comments	O
and	O	O
an	O	O
experienced	B-PHYS
qualitative	O
researcher	B-LIVB
resolved	B-DISO
differences	O
.	O	O

Overall	O	O
,	O	O
there	O	O
were	O	O
few	O	O
comments	O
made	O	O
regarding	O	O
the	O	O
frequency	O
of	O	O
diagnostic	O
errors	O
.	O	O

However	O	O
,	O	O
in	O	O
response	O
to	O	O
the	O	O
media	O
coverage	O
,	O	O
44	O	O
commenters	B-LIVB
shared	O	O
personal	O
experiences	O
of	O	O
diagnostic	O
errors	O
.	O	O

Additionally	O	O
,	O	O
commentary	O
centered	O	O
on	O	O
diagnosis	O
-	O	O
related	O
quality	B-PROC
of	I-PROC
care	I-PROC
as	O	O
affected	O	O
by	O	O
two	O	O
emergent	O	O
categories	O
:	O	O
(	O	O
1	O	O
)	O	O
US	B-GEOG
health	B-LIVB
care	I-LIVB
providers	I-LIVB
(	O	O
n	O	O
=	O	O
79	O	O
;	O	O
63	O	O
commenters	B-LIVB
)	O	O
and	O	O
(	O	O
2	O	O
)	O	O
US	B-GEOG
health	O
care	O
reform	O
-	O
related	O
policies	O
,	O	O
most	O	O
commonly	O	O
the	O	O
Affordable	O
Care	O
Act	O
(	O	O
ACA	O
)	O	O
and	O	O
insurance	O
/	O
reimbursement	O
issues	O
(	O	O
n	O	O
=	O	O
62	O	O
;	O	O
47	O	O
commenters	B-LIVB
)	O	O
.	O	O

The	O	O
public	O
appears	O	O
to	O	O
have	O	O
substantial	O
concerns	O
about	O	O
the	O	O
impact	O
of	O	O
the	O	O
ACA	O
and	O	O
other	O	O
reform	B-PHYS
initiatives	I-PHYS
on	O	O
the	O	O
diagnosis	O
-	O	O
related	O
quality	B-PROC
of	I-PROC
care	I-PROC
.	O	O

However	O	O
,	O	O
policy	O
discussions	O
on	O	O
diagnostic	O
errors	O
are	O	O
largely	O	O
absent	O
from	O	O
the	O	O
current	O	O
national	O
conversation	O
on	O	O
improving	O	O
quality	O
and	O	O
safety	B-PHEN
.	O	O

Because	O	O
outpatient	B-LIVB
diagnostic	O
errors	O
have	O	O
emerged	O	O
as	O	O
a	O	O
major	O	O
safety	B-PHEN
concern	O
,	O	O
researchers	B-LIVB
and	O	O
policymakers	B-LIVB
should	O	O
consider	O	O
evaluating	B-PROC
the	O	O
effects	O
of	O
policy	O
and	O	O
practice	B-PHYS
changes	O
on	O	O
diagnostic	O
accuracy	O
.	O	O

Retroperitoneal	B-DISO
hemorrhage	I-DISO
after	O	O
ureteroscopy	B-PROC
without	O
laser	B-PROC
lithotripsy	I-PROC
:	O	O
an	O	O
extreme	O	O
example	O	O
of	O	O
an	O	O
underreported	O
event	O
?	O	O

Retroperitoneal	B-DISO
hemorrhage	I-DISO
and	O	O
an	O	O
associated	O	O
hematoma	B-DISO
are	O	O
uncommon	O
but	O	O
potentially	O	O
serious	O
complications	B-DISO
following	O
ureteroscopy	B-PROC
with	O	O
laser	B-PROC
lithotripsy	I-PROC
.	O	O

However	O	O
,	O	O
no	O
reports	O
of	O	O
serious	O
bleeding	B-DISO
complications	B-DISO
have	O	O
been	O	O
published	O	O
regarding	O	O
ureteroscopy	B-PROC
without	O
laser	B-PROC
lithotripsy	I-PROC
in	O	O
the	O	O
management	B-PROC
of	O	O
stone	B-ANAT
disease	I-ANAT
.	O	O

We	O	O
report	O	O
of	O	O
such	O	O
a	O	O
case	O	O
here	O	O
and	O	O
then	O	O
review	O
the	O	O
current	O	O
literature	O
in	O	O
order	O	O
to	O	O
discuss	O	O
the	O	O
incidence	O
,	O	O
risk	B-DISO
factors	I-DISO
,	O	O
and	O	O
management	B-PROC
of	O	O
such	O	O
events	O
.	O	O

Spectral	B-PROC
fingerprints	I-PROC
of	O	O
large	O	O
-	O	O
scale	O	O
cortical	B-ANAT
dynamics	B-PHEN
during	O
ambiguous	O
motion	B-PHYS
perception	I-PHYS
Ambiguous	O
stimuli	B-PHEN
have	O	O
been	O	O
widely	O	O
used	O	O
to	O	O
study	O	O
the	O	O
neuronal	B-ANAT
correlates	O
of	O	O
consciousness	B-PHYS
.	O	O

Recently	O	O
,	O	O
it	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
conscious	B-PHYS
perception	B-PHYS
might	O	O
arise	O	O
from	O	O
the	O	O
dynamic	O
interplay	O	O
of	O	O
functionally	O	O
specialized	O	O
but	O	O
widely	O	O
distributed	O	O
cortical	B-ANAT
areas	I-ANAT
.	O	O

While	O	O
previous	O	O
research	O	O
mainly	O	O
focused	O	O
on	O	O
phase	B-PHYS
coupling	I-PHYS
as	O	O
a	O	O
correlate	O
of	O	O
cortical	B-ANAT
communication	O	O
,	O	O
more	O	O
recent	O	O
findings	O	O
indicated	O	O
that	O	O
additional	O	O
coupling	B-PHYS
modes	I-PHYS
might	O	O
coexist	O	O
and	O	O
possibly	O	O
subserve	O	O
distinct	O	O
cortical	B-PHYS
functions	I-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
studied	O	O
two	O	O
coupling	B-PHYS
modes	I-PHYS
,	O	O
namely	O	O
phase	B-PHYS
and	I-PHYS
envelope	I-PHYS
coupling	I-PHYS
,	O	O
which	O	O
might	O	O
differ	O	O
in	O	O
their	O	O
origins	O	O
,	O	O
putative	O	O
functions	O	O
and	O	O
dynamics	B-PHEN
.	O	O

Therefore	O	O
,	O	O
we	O	O
recorded	O	O
128	O	O
-	O	O
channel	O	O
EEG	B-PROC
while	O	O
participants	B-LIVB
performed	O	O
a	O	O
bistable	B-PROC
motion	I-PROC
task	I-PROC
and	O	O
utilized	O	O
state	O	O
-	O	O
of	O	O
-	O	O
the	O	O
-	O	O
art	O	O
source	O	O
-	O	O
space	O	O
connectivity	O
analysis	B-PROC
techniques	O
to	O	O
study	O	O
the	O	O
functional	O
relevance	O
of	O	O
different	O	O
coupling	B-PHYS
modes	I-PHYS
for	O	O
cortical	B-ANAT
communication	O	O
.	O	O

Our	O	O
results	O	O
indicate	O	O
that	O	O
gamma	B-PHYS
-	I-PHYS
band	I-PHYS
phase	I-PHYS
coupling	I-PHYS
in	O	O
extrastriate	B-ANAT
visual	B-ANAT
cortex	I-ANAT
might	O	O
mediate	O	O
the	O	O
integration	O	O
of	O	O
visual	B-PROC
tokens	I-PROC
into	O	O
a	O	O
moving	B-PHYS
stimulus	B-PHEN
during	O	O
ambiguous	O
visual	B-PROC
stimulation	I-PROC
.	O	O

Furthermore	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
long	O	O
-	O	O
range	O	O
fronto	O	O
-	O	O
occipital	O	O
gamma	O	O
-	O	O
band	O	O
envelope	B-PHYS
coupling	I-PHYS
sustains	O	O
the	O	O
horizontal	O	O
percept	O	O
during	O	O
ambiguous	O
motion	B-PHYS
perception	I-PHYS
.	O	O

Additionally	O	O
,	O	O
our	O	O
results	O	O
support	O	O
the	O	O
idea	O	O
that	O	O
local	B-ANAT
parieto	I-ANAT
-	I-ANAT
occipital	I-ANAT
alpha	B-PHYS
-	I-PHYS
band	I-PHYS
phase	I-PHYS
coupling	I-PHYS
controls	O	O
the	O	O
inter	O	O
-	O	O
hemispheric	O
information	O
transfer	O
.	O	O

These	O	O
findings	O	O
provide	O	O
correlative	O
evidence	O
for	O	O
the	O	O
notion	O	O
that	O	O
synchronized	O
oscillatory	O	O
brain	B-PHYS
activity	I-PHYS
reflects	O	O
the	O	O
processing	B-PHYS
of	I-PHYS
sensory	I-PHYS
input	O	O
as	O	O
well	O	O
as	O	O
the	O	O
information	B-PHYS
integration	I-PHYS
across	O	O
several	O	O
spatiotemporal	B-PROC
scales	I-PROC
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
distinct	O
coupling	O
modes	O
are	O	O
involved	O	O
in	O	O
different	O	O
cortical	B-ANAT
computations	O
and	O	O
that	O	O
the	O	O
rich	O	O
spatiotemporal	B-PROC
correlation	I-PROC
structure	B-ANAT
of	I-ANAT
the	I-ANAT
brain	I-ANAT
might	O	O
constitute	O	O
the	O	O
functional	O
architecture	O	O
for	O	O
cortical	B-ANAT
processing	O	O
and	O	O
specific	O	O
multi	O	O
-	O	O
site	O	O
communication	O	O
.	O	O

Hum	O	O
Brain	O	O
Mapp	O	O
37	O	O
:	O	O
4099	O	O
-	O	O
4111	O	O
,	O	O
2016	O	O
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

A	O	O
quasi	B-PROC
-	I-PROC
experimental	I-PROC
study	I-PROC
of	O	O
a	O	O
reminiscence	B-PROC
program	I-PROC
focused	O	O
on	O	O
autobiographical	B-PHYS
memory	I-PHYS
in	O	O
institutionalized	O	O
older	B-LIVB
adults	I-LIVB
with	O	O
cognitive	B-DISO
impairment	I-DISO
Working	O	O
with	O	O
past	B-PHYS
memories	I-PHYS
through	O	O
reminiscence	B-PROC
interventions	I-PROC
has	O	O
been	O	O
practiced	O	O
for	O	O
several	O
decades	O
with	O	O
successful	O	O
outcomes	O
on	O	O
mental	B-PHYS
health	I-PHYS
in	O	O
older	B-LIVB
adults	I-LIVB
.	O	O

Few	O	O
studies	B-PROC
however	O	O
have	O	O
focused	O	O
on	O	O
autobiographical	B-PHYS
memory	I-PHYS
recall	B-PHYS
in	O	O
older	B-LIVB
individuals	I-LIVB
with	O	O
cognitive	B-DISO
impairment	I-DISO
.	O	O

This	O	O
study	B-PROC
aims	O	O
to	O	O
analyze	O	O
the	O	O
impact	O	O
of	O	O
an	O	O
individual	B-LIVB
reminiscence	B-PROC
program	I-PROC
in	O	O
a	O	O
group	O	O
of	O	O
older	B-LIVB
persons	I-LIVB
with	O	O
cognitive	B-DISO
decline	I-DISO
living	O	O
in	O	O
nursing	B-OBJC
homes	I-OBJC
on	O	O
the	O	O
dimensions	O	O
of	O	O
cognition	B-PHYS
,	O	O
autobiographical	B-PHYS
memory	I-PHYS
,	O	O
mood	B-PHYS
,	O	O
behavior	O
and	O	O
anxiety	B-DISO
.	O	O

A	O	O
two	O	O
-	O	O
group	O	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
design	O
with	O	O
single	B-PROC
blinded	I-PROC
assessment	I-PROC
was	O	O
conducted	O	O
.	O	O

Forty	O	O
-	O	O
one	O	O
participants	B-LIVB
were	O	O
randomized	O	O
to	O	O
an	O	O
experimental	B-LIVB
group	I-LIVB
(	O	O
n	O	O
=	O	O
20	O	O
)	O	O
and	O	O
a	O	O
control	B-LIVB
group	I-LIVB
(	O	O
n	O	O
=	O	O
21	O	O
)	O	O
.	O	O

The	O	O
first	O	O
group	O	O
attended	O	O
five	O	O
weekly	O	O
individual	B-LIVB
reminiscence	B-PHYS
sessions	O
.	O	O

Changes	O	O
in	O	O
the	O	O
outcome	O
measures	O
were	O	O
examined	B-DISO
for	O	O
cognition	B-PHYS
(	O	O
Montreal	O
Cognitive	O
Assessment	O
;	O	O
Autobiographical	O
Memory	O
Test	O
)	O	O
,	O	O
behavior	O
(	O	O
Alzheimer	O
Disease	O
Assessment	O
Subscale	O
Non	O
-	O
Cog	O
)	O	O
and	O	O
emotional	B-DISO
status	I-DISO
(	O	O
Cornell	O
Scale	O
for	O
Depression	O
in	O	O
Dementia	B-DISO
;	O	O
Geriatric	O
Depression	O
Scale	O
,	O	O
and	O	O
Geriatric	O
Anxiety	O
Inventory	O
)	O	O
.	O	O

Participants	B-LIVB
attending	O	O
reminiscence	O
sessions	O
exhibited	O	O
better	O	O
outcomes	O
compared	O	O
to	O	O
the	O	O
control	B-LIVB
group	I-LIVB
in	O	O
cognition	B-PHYS
,	O	O
anxiety	B-DISO
and	O	O
depression	B-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
presented	O	O
a	O	O
higher	O	O
number	O	O
of	O	O
retrieved	B-PHYS
autobiographical	O
events	O
,	O	O
specificity	O	O
of	O	O
evoked	O	O
memories	B-PHYS
and	O	O
positive	O	O
valence	O	O
of	O	O
events	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
also	O	O
presented	O	O
lower	O	O
latency	O	O
time	O	O
for	O	O
recalling	B-PHYS
events	O
,	O	O
and	O	O
lower	O	O
negative	O	O
recalled	B-PHYS
events	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
the	O	O
potential	O	O
value	O	O
of	O	O
reminiscence	B-PROC
therapy	I-PROC
in	O	O
improving	O	O
the	O	O
recall	B-PHYS
of	O	O
autobiographical	B-PHYS
memory	I-PHYS
.	O	O

Reminiscence	B-PROC
therapy	I-PROC
can	O	O
be	O	O
helpful	O	O
to	O	O
maintain	O	O
or	O	O
improve	O	O
cognitive	B-PHYS
function	I-PHYS
,	O	O
decrease	O	O
anxiety	B-DISO
and	O	O
manage	O	O
depressive	B-DISO
symptoms	I-DISO
and	O	O
altered	O
behavior	O
,	O	O
but	O	O
further	O	O
investigation	O	O
is	O	O
needed	O	O
to	O	O
clarify	O	O
long	O	O
-	O	O
term	O	O
effects	O	O
.	O	O

Characterization	O
and	O	O
Genomic	B-PROC
Analysis	I-PROC
of	O	O
a	O	O
Highly	O
Efficient	O
Dibutyl	B-CHEM
Phthalate	I-CHEM
-	O	O
Degrading	B-PHYS
Bacterium	B-LIVB
Gordonia	I-LIVB
sp	I-LIVB
.	I-LIVB

Strain	I-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
A	O	O
bacterial	B-LIVB
strain	I-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
isolated	O
from	O	O
activated	B-PHEN
sludge	I-PHEN
was	O	O
identified	O	O
as	O	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

based	O	O
on	O	O
analysis	B-PROC
of	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequence	O
and	O	O
was	O	O
found	O	O
to	O	O
be	O	O
capable	O	O
of	O	O
utilizing	O	O
dibutyl	B-CHEM
phthalate	I-CHEM
(	O	O
DBP	B-CHEM
)	O	O
and	O	O
other	O	O
common	O	O
phthalate	B-CHEM
esters	I-CHEM
(	O	O
PAEs	B-CHEM
)	O	O
as	O	O
the	O	O
sole	O	O
carbon	B-CHEM
and	O	O
energy	B-DISO
source	I-DISO
.	O	O

The	O	O
degradation	B-PHYS
kinetics	B-PHEN
of	O	O
DBP	B-CHEM
under	O	O
different	O
concentrations	O
by	O	O
the	O	O
strain	B-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
fit	O	O
well	O	O
with	O	O
the	O	O
modified	O
Gompertz	O
model	O
(	O	O
R²	O	O
>	O	O
0	O	O
.	O	O
98	O	O
)	O	O
.	O	O

However	O	O
,	O	O
strain	B-LIVB
QH	I-LIVB
-	I-LIVB
12	I-LIVB
could	O	O
not	O	O
utilize	O	O
the	O	O
major	B-OBJC
intermediate	I-OBJC
product	I-OBJC
phthalate	B-CHEM
(	O	O
phthalic	B-CHEM
acid	I-CHEM
;	O	O
PA	B-CHEM
)	O	O
as	O	O
the	O	O
sole	O	O
carbon	B-CHEM
and	O	O
energy	B-DISO
source	I-DISO
,	O	O
and	O	O
only	O	O
a	O	O
little	O
amount	O
of	O	O
PA	B-CHEM
was	O	O
detected	B-DISO
.	O	O

The	O	O
QH	B-LIVB
-	I-LIVB
12	I-LIVB
genome	B-PROC
analysis	I-PROC
revealed	O	O
the	O	O
presence	O	O
of	O	O
putative	O
hydrolase	O
/	O	O
esterase	O
genes	O
involved	O	O
in	O	O
PAEs	B-CHEM
-	O	O
degradation	B-PHYS
but	O	O
no	O	O
phthalic	B-CHEM
acid	I-CHEM
catabolic	O
gene	O
cluster	O
was	O	O
found	O	O
,	O	O
suggesting	O	O
that	O	O
a	O	O
novel	O
degradation	O
pathway	O
of	O	O
PAEs	B-CHEM
was	O	O
present	O	O
in	O	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

QH	I-LIVB
-	I-LIVB
12	I-LIVB
.	O	O

This	O	O
information	O	O
will	O	O
be	O	O
valuable	O	O
for	O	O
obtaining	O	O
a	O	O
more	O	O
holistic	O	O
understanding	O	O
on	O	O
diverse	O	O
genetic	O
mechanisms	O
of	O	O
PAEs	B-CHEM
-degrading	O	O
Gordonia	B-LIVB
sp	I-LIVB
.	I-LIVB

strains	I-LIVB
.	O	O

Multimorbidity	O
in	O	O
Heart	B-DISO
Failure	I-DISO
:	O	O
Effect	O	O
on	O	O
Outcomes	B-DISO
To	O	O
investigate	O
the	O	O
effect	O	O
of	O	O
the	O	O
number	O	O
and	O	O
type	O	O
of	O	O
comorbid	B-DISO
conditions	I-DISO
on	O	O
death	B-PHYS
and	O	O
hospitalizations	B-PROC
in	O	O
individuals	B-LIVB
with	O	O
incident	O	O
heart	B-DISO
failure	I-DISO
(	O	O
HF	B-DISO
)	O	O
.	O	O

Population	B-PROC
-	I-PROC
based	I-PROC
cohort	O
study	O
.	O	O

Olmsted	B-GEOG
County	I-GEOG
,	I-GEOG
Minnesota	I-GEOG
.	O	O

Olmsted	B-GEOG
County	I-GEOG
,	I-GEOG
Minnesota	I-GEOG
,	O	O
residents	O	O
with	O	O
incident	O	O
HF	B-DISO
from	O	O
2000	O	O
to	O	O
2010	O	O
(	O	O
mean	O
age	B-PHYS
76	O	O
±	O	O
14	O	O
,	O	O
56	O	O
%	O	O
female	B-PHYS
)	O	O
(	O	O
N	O	O
=	O	O
1	O	O
,	O	O
714	O	O
)	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
16	O	O
chronic	O
conditions	B-DISO
obtained	O	O
at	O	O
HF	B-DISO
diagnosis	B-PROC
classified	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
cardiovascular	B-ANAT
(	O	O
CV	B-ANAT
)	O	O
related	O	O
,	O	O
other	O	O
physical	O
,	O	O
and	O	O
mental	B-PHYS
.	O	O

The	O	O
mean	O
number	O	O
of	O	O
conditions	B-DISO
per	O	O
participant	B-LIVB
was	O	O
2	O	O
.	O	O
6	O	O
±	O	O
1	O	O
.	O	O

5	O	O
for	O	O
CV	B-ANAT
-related	O	O
conditions	B-DISO
,	O	O
1	O	O
.	O	O
3	O	O
±	O	O
1	O	O
.	O	O
1	O	O
for	O	O
other	O	O
physical	B-PHYS
conditions	I-PHYS
,	O	O
and	O	O
0	O	O
.	O	O
30	O	O
±	O	O
0	O	O
.	O	O
61	O	O
for	O	O
mental	O
conditions	O
.	O	O

After	O	O
a	O	O
mean	O
follow	O	O
-	O	O
up	O	O
of	O	O
4	O	O
.	O	O
2	O	O
years	O
,	O	O
1	O	O
,	O	O
073	O	O
death	B-PHYS
s	O	O
and	O	O
6	O	O
,	O	O
306	O	O
hospitalizations	B-PROC
had	O	O
occurred	O	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
ejection	B-PROC
fraction	I-PROC
,	O	O
in	O	O
-	O	O
or	O	O
outpatient	B-LIVB
status	O	O
,	O	O
and	O	O
number	O	O
of	O	O
other	O	O
conditions	B-DISO
,	O	O
an	O	O
increase	O	O
of	O	O
one	O	O
other	O	O
physical	B-PHYS
condition	I-PHYS
was	O	O
associated	O	O
with	O	O
a	O	O
14	O	O
%	O	O
(	O	O
HR	B-PHYS
=	O	O
1	O	O
.	O	O
14	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
08	O	O
-	O	O
1	O	O
.	O	O
20	O	O
)	O	O
greater	O	O
risk	O
of	O	O
death	B-PHYS
and	O	O
a	O	O
26	O	O
%	O	O
(	O	O
HR	B-PHYS
=	O	O
1	O	O
.	O	O
26	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
20	O	O
-	O	O
1	O	O
.	O	O
32	O	O
)	O	O
greater	O	O
risk	O
of	O	O
hospitalization	B-PROC
,	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
one	O	O
mental	O
condition	O
was	O	O
associated	O	O
with	O	O
a	O	O
31	O	O
%	O	O
(	O	O
HR	B-PHYS
=	O	O
1	O	O
.	O	O
31	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
19	O	O
-	O	O
1	O	O
.	O	O
44	O	O
)	O	O
greater	O	O
risk	O
of	O	O
death	B-PHYS
and	O	O
an	O	O
18	O	O
%	O	O
(	O	O
HR	B-PHYS
=	O	O
1	O	O
.	O	O
18	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
07	O	O
-	O	O
1	O	O
.	O	O
29	O	O
)	O	O
greater	O	O
risk	O
of	O	O
hospitalization	B-PROC
.	O	O

In	O	O
contrast	O	O
,	O	O
an	O	O
increase	O	O
of	O	O
one	O	O
CV	B-ANAT
-related	O	O
condition	B-DISO
was	O	O
not	O	O
associated	O	O
with	O	O
greater	O	O
risk	O
of	O	O
death	B-PHYS
and	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
10	O	O
%	O	O
(	O	O
HR	B-PHYS
=	O	O
1	O	O
.	O	O
10	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
06	O	O
-	O	O
1	O	O
.	O	O
15	O	O
)	O	O
greater	O	O
risk	O
of	O	O
hospitalization	B-PROC
.	O	O

CV	B-ANAT
-related	O	O
conditions	B-DISO
are	O	O
the	O	O
most	O	O
common	O	O
type	O	O
of	O	O
comorbid	B-DISO
conditions	I-DISO
in	O	O
individuals	B-LIVB
with	O	O
HF	B-DISO
,	O	O
but	O	O
other	O	O
physical	O
and	O	O
mental	O
conditions	O
are	O	O
more	O	O
strongly	O	O
associated	O	O
with	O	O
death	B-PHYS
and	O	O
hospitalizations	B-PROC
.	O	O

This	O	O
underscores	O	O
the	O	O
effect	O	O
of	O	O
non	B-DISO
-	I-DISO
CV	I-DISO
conditions	I-DISO
on	O	O
outcomes	O	O
in	O	O
HF	B-DISO
.	O	O

Economic	O
Burden	O
of	O	O
Illness	B-DISO
Among	O	O
Patients	B-LIVB
with	O	O
Severe	B-DISO
Asthma	I-DISO
in	O	O
a	O	O
Managed	O	O
Care	B-OBJC
Setting	I-OBJC
Despite	O	O
intensive	O	O
pharmacotherapy	B-PROC
,	O	O
a	O	O
considerable	O	O
number	O
of	O	O
patients	B-LIVB
with	O	O
severe	B-DISO
asthma	I-DISO
have	O	O
inadequate	O
disease	B-DISO
control	O
.	O	O

Patients	B-LIVB
with	O	O
severe	B-DISO
asthma	I-DISO
who	O	O
experience	B-PHYS
exacerbations	B-DISO
consume	O	O
significant	O	O
health	O
care	O
resources	O
.	O	O

To	O	O
assess	O
health	O
care	O
resource	O
utilization	O
and	O	O
associated	O	O
costs	O
among	O	O
patients	B-LIVB
with	O	O
persistent	O
severe	B-DISO
asthma	I-DISO
who	O	O
experienced	B-PHYS
exacerbations	B-DISO
compared	O	O
with	O	O
patients	B-LIVB
with	O	O
persistent	O
but	O	O
nonsevere	O	O
asthma	B-DISO
.	O	O

This	O	O
retrospective	O
analysis	B-PROC
of	O	O
a	O	O
national	O
administrative	O
claims	O
database	O
identified	O
patients	B-LIVB
aged	B-PHYS
≥	O	O
12	O	O
years	O
who	O	O
had	O	O
at	O	O
least	O	O
1	O	O
medical	O
claim	O
with	O	O
an	O	O
asthma	B-DISO
diagnosis	B-DISO
in	O	O
2012	O	O
and	O	O
had	O	O
continuous	O	O
medical	B-DISO
and	O	O
pharmacy	B-DISO
coverage	I-DISO
under	O	O
a	O	O
commercial	O
or	O	O
Medicare	O
Advantage	O
plan	O
from	O	O
January	O	O
1	O	O
,	O	O
2012	O	O
,	O	O
to	O	O
December	O	O
31	O	O
,	O	O
2013	O	O
.	O	O

Patients	B-LIVB
were	O	O
assigned	O
to	O	O
1	O	O
of	O	O
2	O	O
mutually	O	O
exclusive	O	O
cohorts	B-LIVB
-	O	O
persistent	B-DISO
asthma	I-DISO
(	O	O
PA	B-DISO
)	O	O
or	O	O
severe	B-DISO
asthma	I-DISO
(	O	O
SA	B-DISO
)	O	O
-	O	O
according	O	O
to	O	O
an	O	O
established	O	O
algorithm	O
based	O	O
on	O	O
asthma	B-DISO
-related	O	O
health	O
care	O
resource	O
use	O
and	O	O
pharmacy	B-DISO
claims	I-DISO
for	O	O
controller	B-CHEM
medication	I-CHEM
.	O	O

SA	B-DISO
patients	B-LIVB
were	O	O
required	O	O
to	O	O
meet	B-PHEN
PA	B-DISO
criteria	O
and	O	O
also	O	O
have	O	O
evidence	O
of	O	O
≥2	O	O
asthma	B-DISO
exacerbations	I-DISO
in	O	O
2012	O	O
.	O	O

Asthma	B-DISO
-related	O	O
health	O
care	O
resource	O
utilization	O
and	O	O
costs	O
were	O	O
computed	O
from	O	O
asthma	B-DISO
medication	B-PROC
use	O
(	O	O
rescue	O
and	O	O
controller	O
therapy	O
)	O	O
and	O	O
medical	O
claims	O
with	O	O
an	O	O
asthma	B-DISO
diagnosis	B-DISO
in	O	O
the	O	O
primary	O
position	O
in	O	O
2012	O	O
and	O	O
2013	O	O
.	O	O

Adherence	O
to	O	O
controller	O
therapy	O
was	O	O
assessed	O
over	O	O
365	O	O
days	O
by	O	O
using	O	O
the	O	O
proportion	O
of	O
days	O
covered	O
(	O	O
PDC	O
)	O	O
,	O	O
starting	O	O
with	O	O
the	O	O
first	O	O
claim	O
for	O	O
controller	O
therapy	O
in	O	O
2012	O	O
.	O	O

Differences	O
between	O	O
the	O	O
PA	B-DISO
and	O	O
SA	B-DISO
cohorts	B-LIVB
were	O	O
analyzed	B-PROC
by	O	O
t	O
-	O
test	O
for	O	O
continuous	O
variables	O
and	O	O
chi	O
-	O
square	O
test	O
for	O	O
categorical	O
variables	O
.	O	O

Asthma	B-DISO
-related	O	O
costs	O
in	O	O
2013	O	O
were	O	O
also	O	O
analyzed	B-PROC
using	O	O
a	O	O
generalized	O	O
linear	O
model	O
with	O	O
a	O	O
gamma	O
distribution	O
and	O	O
log	O
link	O
,	O	O
adjusted	O
for	O	O
patient	B-LIVB
demographics	O
(	O	O
age	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
region	B-GEOG
,	O	O
and	O	O
insurance	O
type	O
)	O	O
and	O	O
Quan	O
-	O
Charlson	O
comorbidity	O
score	O
.	O	O

A	O	O
total	O	O
of	O	O
65	O	O
,	O	O
359	O	O
patients	B-LIVB
were	O	O
included	O	O
:	O	O
63	O	O
,	O	O
597	O	O
(	O	O
97	O	O
.	O	O
3	O	O
%	O	O
)	O	O
PA	B-DISO
patients	B-LIVB
and	O	O
1	O	O
,	O	O
762	O	O
SA	B-DISO
patients	B-LIVB
(	O	O
2	O	O
.	O	O

7	O	O
%	O	O
)	O	O
.	O	O

Compared	O
with	O	O
the	O	O
PA	B-DISO
cohort	B-LIVB
,	O	O
the	O	O
SA	B-DISO
cohort	B-LIVB
was	O	O
older	B-LIVB
(	O	O
mean	B-PHYS
age	I-PHYS
=	O	O
50	O	O
.	O	O

8	O	O
years	O
vs	O	O
.	O	O

46	O	O
.	O	O
5	O	O
years	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
had	O	O
higher	O	O
mean	O	O
comorbidity	O
score	O
(	O	O
1	O	O
.	O	O
47	O	O
vs	O	O
.	O	O

1	O	O
.	O	O
31	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
count	O	O
of	O	O
all	O	O
asthma	B-DISO
medications	B-PROC
fills	O	O
was	O	O
2	O	O
.	O	O
2	O	O
-	O	O
fold	O	O
(	O	O
2012	O	O
)	O	O
and	O	O
2	O	O
.	O	O
1	O	O
-	O	O
fold	O	O
(	O	O
2013	O	O
)	O	O
higher	O	O
in	O	O
the	O	O
SA	B-DISO
cohort	B-LIVB
,	I-LIVB
compared	O
with	O	O
the	O	O
PA	B-DISO
cohort	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Mean	O	O
PDC	O
for	O	O
all	O	O
oral	B-CHEM
and	O	O
inhaled	B-PHYS
controller	B-PROC
therapy	I-PROC
was	O	O
also	O	O
higher	O	O
in	O	O
the	O	O
SA	B-DISO
cohort	B-LIVB
compared	O
with	O	O
the	O	O
PA	B-DISO
cohort	B-LIVB
(	O	O
0	O	O
.	O	O
80	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
65	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

SA	B-DISO
patients	B-LIVB
had	O	O
a	O	O
significantly	O	O
greater	O
mean	O
count	O
of	O	O
asthma	B-DISO
-related	O	O
hospitalizations	B-PROC
,	O	O
emergency	B-PROC
room	I-PROC
visits	I-PROC
,	O	O
and	O	O
ambulatory	B-DISO
visits	I-DISO
in	O	O
2012	O	O
and	O	O
2013	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Unadjusted	O	O
mean	O	O
annual	O	O
asthma	B-DISO
-related	O	O
costs	O
in	O	O
the	O	O
SA	B-DISO
versus	O	O
PA	B-DISO
cohorts	B-LIVB
were	O	O
$	O	O
6	O	O
,	O	O
496	O	O
versus	O	O
$	O	O
2	O	O
,	O	O
739	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
in	O	O
2012	O	O
and	O	O
$	O	O
5	O	O
,	O	O
174	O	O
versus	O	O
$	O	O
1	O	O
,	O	O
775	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
in	O	O
2013	O	O
.	O	O

Higher	O	O
asthma	B-DISO
-related	O	O
costs	O
were	O	O
driven	O	O
by	O	O
greater	O	O
mean	O	O
annual	O	O
asthma	B-DISO
medication	B-PROC
costs	O
in	O	O
2012	O	O
(	O	O
$	O	O
4	O	O
,	O	O
545	O	O
vs	O	O
.	O	O

$	O	O
1	O	O
,	O	O
738	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
2013	O	O
(	O	O
$	O	O
4	O	O
,	O	O
068	O	O
vs	O	O
.	O	O

$	O	O
1	O	O
,	O	O
348	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Adjusted	O
mean	O	O
annual	O	O
asthma	B-DISO
-related	O	O
costs	O
in	O	O
2013	O	O
were	O	O
$	O	O
3	O	O
,	O	O
336	O	O
greater	O	O
(	O	O
cost	O
ratio	O
=	O	O
2	O	O
.	O	O

878	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
in	O	O
the	O	O
SA	B-DISO
cohort	B-LIVB
,	O	O
and	O	O
adjusted	O
mean	O	O
annual	O	O
asthma	B-DISO
medication	B-PROC
costs	O
were	O	O
$	O	O
2	O	O
,	O	O
672	O	O
higher	O	O
(	O	O
cost	O	O
ratio	O	O
=	O	O
2	O	O
.	O	O
982	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
in	O	O
the	O	O
SA	B-DISO
cohort	B-LIVB
.	O	O

Patients	B-LIVB
with	O	O
SA	B-DISO
who	O	O
experienced	B-PHYS
2	O	O
or	O	O
more	O	O
exacerbations	B-DISO
had	O	O
2	O	O
.	O	O
1	O	O
-	O	O
fold	O	O
greater	O	O
use	O
of	O	O
controller	B-PROC
medications	I-PROC
across	O	O
both	O	O
study	O	O
years	O
and	O	O
were	O	O
more	O	O
adherent	O
to	O	O
controller	O
therapy	O
than	O	O
patients	B-LIVB
with	O	O
PA	B-DISO
.	O	O

Despite	O	O
more	O	O
intensive	O	O
pharmacotherapy	B-PROC
,	O	O
SA	B-DISO
patients	B-LIVB
incurred	O	O
2	O	O
.	O	O
9	O	O
-	O	O
fold	O	O
higher	O	O
adjusted	O
asthma	B-DISO
-related	O	O
costs	O
and	O	O
3	O	O
-	O	O
fold	O	O
higher	O	O
adjusted	O
asthma	B-DISO
medication	B-PROC
costs	O
than	O	O
PA	B-DISO
patients	B-LIVB
.	O	O

Patients	B-LIVB
with	O	O
SA	B-DISO
consistently	O
demonstrated	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
health	B-PROC
care	I-PROC
utilization	O
.	O	O

Funding	O
for	O	O
this	O	O
study	B-PROC
(	O	O
HO	O	O
-	O	O
14	O	O
-	O	O
14443	O	O
)	O	O
was	O	O
provided	O	O
by	O	O
GlaxoSmithKline	O
(	O	O
GSK	O
)	O	O
.	O	O

All	O	O
listed	O	O
authors	B-LIVB
meet	B-PHEN
the	O	O
criteria	O
for	O	O
authorship	O
set	O	O
forth	O	O
by	O	O
the	O	O
International	B-LIVB
Committee	I-LIVB
for	I-LIVB
Medical	I-LIVB
Journal	I-LIVB
Editors	I-LIVB
.	O	O

Albers	O
,	O	O
Forshag	O
,	O	O
and	O	O
Yancey	O
are	O	O
employees	B-LIVB
of	O	O
GSK	O
and	O	O
hold	O	O
stock	O	O
in	O	O
GSK	O
.	O	O

Dalal	O
,	O	O
Nagar	O
,	O	O
and	O	O
Ortega	O
were	O	O
employees	B-LIVB
of	O	O
GSK	O
at	O	O
the	O	O
time	O
this	O	O
research	B-PROC
was	O	O
conducted	O	O
.	O	O

Chastek	O
and	O	O
Korrer	O
are	O	O
employees	B-LIVB
of	O	O
Optum	O
,	O	O
which	O	O
received	O	O
consulting	O
fees	O
from	O	O
GSK	O
for	O	O
research	B-PROC
related	O	O
to	O	O
this	O	O
study	B-PROC
.	O	O

Study	O
concept	O
and	O	O
design	O
were	O	O
contributed	O
by	O	O
Chastek	O
,	O	O
Nagar	O
,	O	O
and	O	O
Dalal	O
.	O	O

Korrer	O
took	O	O
the	O	O
lead	O	O
in	O	O
data	B-PROC
collection	I-PROC
,	O	O
along	O	O
with	O	O
Chastek	O
,	O	O
and	O	O
data	O
interpretation	O
was	O	O
performed	O	O
by	O	O
Chastek	O
,	O	O
Ortega	O
,	O	O
Forshag	O
,	O	O
and	O	O
Dalal	O
.	O	O

The	O	O
manuscript	B-OBJC
was	O	O
written	O	O
by	O	O
Chastek	O
and	O	O
Dalal	O
and	O	O
revised	O
by	O	O
Albers	O
and	O	O
Yancy	O
,	O	O
assisted	O
by	O	O
the	O	O
other	O	O
authors	B-LIVB
.	O	O

Contemporary	O
mandibular	B-PROC
reconstruction	I-PROC
Multiple	O
disease	B-DISO
processes	I-DISO
,	O	O
including	O	O
neoplasia	B-DISO
,	O	O
trauma	B-DISO
,	O	O
and	O	O
medication	O
side	O
-	O
effects	O
,	O	O
necessitate	O	O
segmental	B-PROC
resection	I-PROC
and	O	O
subsequent	O
reconstruction	B-PROC
of	I-PROC
the	I-PROC
mandible	I-PROC
.	O	O

As	O	O
surgical	O
techniques	O
have	O	O
advanced	O
,	O	O
several	O	O
technologies	O
have	O	O
been	O	O
developed	O	O
with	O	O
the	O	O
potential	O
to	O	O
significantly	O	O
transform	O	O
a	O	O
surgeon	B-LIVB
's	I-LIVB
approach	O
to	O	O
the	O	O
restoration	O
of	O	O
mandibular	B-ANAT
continuity	I-ANAT
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
review	O
is	O	O
to	O	O
highlight	O	O
many	O	O
of	O	O
these	O	O
relatively	O	O
newer	O	O
tools	O
and	O	O
discuss	O	O
their	O	O
evolving	O	O
role	O	O
in	O	O
mandibular	B-PROC
reconstruction	I-PROC
.	O	O

Several	O	O
contemporary	B-PROC
studies	I-PROC
have	O	O
documented	B-PROC
the	O	O
application	O	O
of	O	O
different	O	O
approaches	O
and	O	O
modifications	O
to	O	O
mandibular	B-PROC
reconstruction	I-PROC
-	O	O
including	O	O
computer	O
-	O
aided	O
design	O
or	O	O
computer	O
-	O
aided	O
modeling	O
,	O	O
contemporary	O
plating	B-DEVI
systems	I-DEVI
,	O	O
osseointegrated	B-DEVI
implants	I-DEVI
,	O	O
and	O	O
various	O	O
modifications	O
to	O	O
existing	O	O
osseocutaneous	O
free	O
tissue	O
transfer	O
options	O
-	O	O
and	O	O
have	O	O
reported	O	O
relatively	O	O
high	O
success	O
rates	O
.	O	O

In	O	O
discussing	O	O
these	O	O
reports	O
,	O	O
we	O	O
present	O	O
a	O	O
survey	O
of	O	O
current	O	O
and	O	O
developing	O	O
technologies	O
in	O	O
the	O	O
field	O	O
of	O	O
mandibular	B-PROC
reconstruction	I-PROC
and	O	O
aim	O	O
to	O	O
provide	O	O
sufficient	O	O
context	O	O
for	O	O
the	O	O
gradual	O	O
integration	O	O
of	O	O
these	O	O
techniques	O
into	O	O
practice	O
.	O	O

Differential	B-PHYS
regulation	I-PHYS
of	O	O
spontaneous	O
and	O	O
evoked	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O	O
somatosensory	B-ANAT
cortex	I-ANAT
by	O	O
retinoic	B-CHEM
acid	I-CHEM
Retinoic	B-CHEM
acid	I-CHEM
(	O	O
RA	B-CHEM
)	O	O
,	O	O
a	O	O
developmental	O
morphogen	B-CHEM
,	O	O
has	O	O
emerged	O	O
in	O	O
recent	O	O
studies	O	O
as	O	O
a	O	O
novel	O
synaptic	B-PHYS
signaling	B-CHEM
molecule	I-CHEM
that	O	O
acts	O	O
in	O	O
mature	O
hippocampal	B-ANAT
neurons	B-ANAT
to	O	O
modulate	O
excitatory	B-PHYS
and	O	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O	O
the	O	O
context	O	O
of	O	O
homeostatic	B-PHEN
synaptic	B-PHYS
plasticity	I-PHYS
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
RA	B-CHEM
is	O	O
capable	O	O
of	O	O
modulating	O
neural	O
circuits	O
outside	O
of	O	O
the	O	O
hippocampus	B-ANAT
,	O	O
and	O	O
if	O	O
so	O	O
,	O	O
whether	O	O
the	O	O
mode	O
of	O
RA	O
's	O
action	O
at	O	O
synapses	B-ANAT
is	O	O
similar	O
to	O	O
that	O	O
within	O
the	O	O
hippocampal	B-ANAT
network	O	O
.	O	O

Here	O	O
we	O	O
explore	O	O
for	O	O
the	O	O
first	O	O
time	O	O
RA	B-CHEM
'	O	O
s	O	O
synaptic	B-PHYS
function	I-PHYS
outside	O
the	O	O
hippocampus	B-ANAT
and	O	O
uncover	O	O
a	O	O
novel	O
function	O
of	O	O
all	B-CHEM
-	I-CHEM
trans	I-CHEM
retinoic	I-CHEM
acid	I-CHEM
at	O	O
inhibitory	B-ANAT
synapses	I-ANAT
.	O	O

Acute	O
RA	B-CHEM
treatment	O
increases	O
spontaneous	O
inhibitory	B-PHYS
synaptic	I-PHYS
transmission	I-PHYS
in	O	O
L2	B-ANAT
/	I-ANAT
3	I-ANAT
pyramidal	I-ANAT
neurons	I-ANAT
of	O	O
the	O	O
somatosensory	B-ANAT
cortex	I-ANAT
,	O	O
and	O	O
this	O	O
effect	O
requires	O	O
expression	B-PHYS
of	O	O
RA	B-CHEM
's	I-CHEM
receptor	I-CHEM
RARα	B-CHEM
both	O	O
pre	B-PHYS
-	I-PHYS
and	I-PHYS
post	I-PHYS
-	I-PHYS
synaptically	I-PHYS
.	O	O

Intriguingly	O	O
,	O	O
RA	B-CHEM
does	O	O
not	O	O
seem	O	O
to	O	O
affect	O	O
evoked	O
inhibitory	B-PHYS
transmission	I-PHYS
assayed	O	O
with	O	O
either	O	O
extracellular	B-ANAT
stimulation	O	O
or	O	O
direct	O	O
activation	B-PHYS
of	I-PHYS
action	I-PHYS
potentials	I-PHYS
in	O	O
presynaptic	B-ANAT
interneurons	B-ANAT
at	O	O
connected	O	O
pairs	O	O
of	O	O
interneurons	B-ANAT
and	O	O
pyramidal	B-ANAT
neurons	I-ANAT
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	B-DISO
suggest	O	O
that	O	O
RA	B-CHEM
's	I-CHEM
action	O
at	O	O
synapses	B-ANAT
is	O	O
not	O	O
monotonous	O	O
,	O	O
but	O	O
is	O	O
diverse	O
depending	O	O
on	O	O
the	O	O
type	O	O
of	O	O
synaptic	B-PHYS
connection	I-PHYS
(	O	O
excitatory	B-PHYS
versus	O	O
inhibitory	B-PHYS
)	O	O
and	O	O
circuit	O
(	O	O
hippocampal	B-ANAT
versus	O	O
cortical	B-ANAT
)	I-ANAT
.	O	O

Thus	O	O
,	O	O
synaptic	B-PHYS
signaling	I-PHYS
of	O	O
RA	B-CHEM
may	O	O
mediate	O	O
multi	O	O
-	O	O
faceted	O	O
regulation	B-PHYS
of	I-PHYS
synaptic	I-PHYS
plasticity	I-PHYS
.	O	O

In	O	O
addition	O	O
to	O	O
its	O	O
classic	O
roles	O
in	O	O
brain	B-PHYS
development	I-PHYS
,	O	O
retinoic	B-CHEM
acid	I-CHEM
(	O	O
RA	B-CHEM
)	O	O
has	O	O
recently	O	O
been	O	O
shown	O	O
to	O	O
regulate	B-PHYS
excitatory	B-PHYS
and	O	O
inhibitory	B-PHYS
transmission	I-PHYS
in	O	O
the	O	O
adult	B-LIVB
brain	B-ANAT
.	O	O

Here	O	O
,	O	O
the	O	O
authors	B-LIVB
show	O	O
that	O	O
in	O	O
layer	B-ANAT
2	I-ANAT
/	I-ANAT
3	I-ANAT
(	O	O
L2	B-ANAT
/	I-ANAT
3	I-ANAT
)	O	O
of	O	O
the	O	O
somatosensory	B-ANAT
cortex	I-ANAT
(	O	O
S1	B-ANAT
)	O	O
,	O	O
acute	O
RA	B-CHEM
induces	O
increases	O
in	O	O
spontaneous	O
but	O	O
not	O	O
action	B-PHYS
-	I-PHYS
potential	I-PHYS
evoked	O
transmission	B-PHYS
,	O	O
and	O	O
that	O	O
this	O	O
requires	O	O
retinoic	B-CHEM
acid	I-CHEM
receptor	I-CHEM
(	O	O
RARα	B-CHEM
)	O	O
both	O	O
in	O	O
presynaptic	B-ANAT
PV	B-CHEM
-positive	O	O
interneurons	B-ANAT
and	O	O
postsynaptic	O
pyramidal	B-ANAT
(	I-ANAT
PN	I-ANAT
)	I-ANAT
neurons	I-ANAT
.	O	O

Radiolabeled	O
B9958	B-CHEM
Derivatives	I-CHEM
for	O	O
Imaging	B-PROC
Bradykinin	B-CHEM
B1	I-CHEM
Receptor	I-CHEM
Expression	B-PHYS
with	O	O
Positron	B-PROC
Emission	I-PROC
Tomography	I-PROC
:	O	O
Effect	O	O
of	O	O
the	O	O
Radiolabel	B-CHEM
-	O	O
Chelator	B-CHEM
Complex	B-CHEM
on	O	O
Biodistribution	O
and	O	O
Tumor	B-DISO
Uptake	B-PHYS
Bradykinin	B-CHEM
B1	I-CHEM
receptor	I-CHEM
(	O	O
B1R	B-CHEM
)	O	O
,	O	O
which	O	O
is	O	O
upregulated	B-PHYS
in	O	O
a	O	O
variety	O	O
of	O	O
malignancies	B-DISO
,	O	O
is	O	O
an	O	O
attractive	O	O
cancer	B-PROC
imaging	I-PROC
biomarker	B-PHYS
.	O	O

In	O	O
this	O	O
study	B-PROC
we	O	O
optimized	O	O
the	O	O
selection	O	O
of	O	O
radiolabel	B-CHEM
-	O	O
chelator	B-CHEM
complex	B-CHEM
to	O	O
improve	O	O
tumor	B-DISO
uptake	B-PHYS
and	O	O
tumor	B-DISO
-to	O	O
-	O	O
background	O	O
contrast	O	O
of	O	O
radiolabeled	O
analogues	B-CHEM
of	O	O
B9958	B-CHEM
(	O	O
Lys	O
-	O
Lys	O
-	O
Arg	O
-	O
Pro	O
-	O
Hyp	O
-	O
Gly	O
-	O
Cpg	O
-	O
Ser	O
-	O
d	O
-	O
Tic	O
-	O
Cpg	O
)	O	O
,	O	O
a	O	O
potent	O	O
B1R	B-CHEM
antagonist	I-CHEM
.	O	O

Peptide	B-CHEM
sequences	I-CHEM
were	O	O
assembled	O	O
on	O	O
solid	O
phase	O
.	O	O

Cold	O
standards	O
were	O	O
prepared	O	O
by	O	O
incubating	O	O
DOTA	B-CHEM
-	O	O
/	O	O
NODA	B-CHEM
-	O	O
conjugated	O
peptides	B-CHEM
with	O	O
GaCl3	B-CHEM
,	O	O
and	O	O
by	O	O
incubating	O	O
AlOH	B-CHEM
-	O	O
NODA	B-CHEM
-conjugated	O	O
peptide	B-CHEM
with	O	O
NaF	B-CHEM
.	O	O

Binding	B-PHYS
affinities	B-PHEN
were	O	O
measured	O	O
via	O	O
in	B-PROC
vitro	I-PROC
competition	I-PROC
binding	I-PROC
assays	I-PROC
.	O	O

(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
and	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
labeling	B-PROC
experiments	I-PROC
were	O	O
performed	O	O
in	O	O
acidic	B-CHEM
buffer	I-CHEM
and	O	O
purified	O	O
by	O	O
HPLC	B-PROC
.	O	O

Imaging	B-PROC
/	O	O
biodistribution	O
studies	B-PROC
were	O	O
performed	O	O
in	O	O
mice	B-LIVB
bearing	O	O
both	O	O
B1R	B-CHEM
-	I-CHEM
positive	I-CHEM
(	O	O
B1R	B-CHEM
+	I-CHEM
)	O	O
HEK293	B-ANAT
T	I-ANAT
:	O	O
:	O	O
hB1R	B-ANAT
and	O	O
B1R	B-DISO
-	I-DISO
negative	I-DISO
(	O	O
B1R	B-DISO
-	I-DISO
)	O	O
HEK293	B-ANAT
T	I-ANAT
tumors	B-DISO
.	O	O

Z02176	B-CHEM
(	O	O
Ga	B-CHEM
-	I-CHEM
DOTA	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
;	O	O
Pip	B-CHEM
:	O	O
4	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
(	I-CHEM
1	I-CHEM
-	I-CHEM
carboxymethyl	I-CHEM
)	I-CHEM
piperidine	I-CHEM
)	I-CHEM
,	O	O
Z02137	B-CHEM
(	O	O
Ga	B-CHEM
-	I-CHEM
NODA	I-CHEM
-	I-CHEM
Mpaa	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
;	O	O
Mpaa	B-CHEM
:	O	O
4	B-CHEM
-	I-CHEM
methylphenylacetic	I-CHEM
acid	I-CHEM
)	O	O
,	O	O
and	O	O
Z04139	B-CHEM
(	O	O
AlF	B-CHEM
-	I-CHEM
NODA	I-CHEM
-	I-CHEM
Mpaa	I-CHEM
-	I-CHEM
Pip	I-CHEM
-	I-CHEM
B9958	I-CHEM
)	O	O
bound	O	O
h	O	O
B1R	B-CHEM
with	O	O
high	O	O
affinity	B-PHEN
(	O	O
Ki	O	O
=	O	O
1	O	O
.	O	O
4	O	O
-	O	O
2	O	O
.	O	O
5	O	O
nM	O	O
)	O	O
.	O	O

(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
/	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O	O
labeled	O
peptides	B-CHEM
were	O	O
obtained	O	O
on	O	O
average	O	O
in	O	O
≥32	O	O
%	O	O
decay	O	O
-	O	O
corrected	O	O
radiochemical	B-CHEM
yield	O
with	O	O
>	O	O
99	O	O
%	O	O
radiochemical	B-CHEM
purity	O
and	O	O
100	O	O
-	O	O
261	O	O
GBq	O	O
/	O	O
μmol	O	O
specific	O
activity	O
.	O	O

Biodistribution	O
/	O	O
imaging	B-PROC
studies	B-PROC
at	O	O
1	O	O
h	O
postinjection	O	O
showed	O	O
that	O	O
all	O	O
tracers	B-CHEM
cleared	O	O
rapidly	O	O
from	O	O
background	O	O
tissues	O
(	O	O
except	O	O
kidneys	B-ANAT
)	O	O
and	O	O
were	O	O
excreted	B-PHYS
predominantly	O	O
via	O	O
the	O	O
renal	B-PHYS
pathway	I-PHYS
.	O	O

Only	O	O
kidneys	B-ANAT
,	O	O
bladders	B-ANAT
,	O	O
and	O	O
B1R	B-CHEM
+	I-CHEM
tumors	B-DISO
were	O	O
clearly	O	O
visualized	O	O
in	O	O
PET	B-PROC
images	O
.	O	O

Uptake	B-PHYS
in	O	O
B1R	B-CHEM
+	I-CHEM
tumor	B-DISO
was	O	O
higher	O	O
by	O	O
using	O	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
Z02176	B-CHEM
(	O	O
28	O	O
.	O	O
9	O	O
±	O	O
6	O	O
.	O	O

21	O	O
%	O	O
ID	O	O
/	O	O
g	O	O
)	O	O
and	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O	O
Z04139	B-CHEM
(	O	O
22	O	O
.	O	O
6	O	O
±	O	O
3	O	O
.	O	O
41	O	O
%	O	O
ID	O	O
/	O	O
g	O	O
)	O	O
than	O	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
Z02137	B-CHEM
(	O	O
14	O	O
.	O	O
0	O	O
±	O	O
4	O	O
.	O	O

86	O	O
%	O	O
ID	O	O
/	O	O
g	O	O
)	O	O
.	O	O

The	O	O
B1R	O
+	O
tumor	O
-	O
to	O
-	O
blood	O
and	O	O
B1R	O
+	O
tumor	O
-	O
to	O
-	O
muscle	O
contrast	O
ratios	O
were	O	O
also	O	O
higher	O	O
for	O	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
Z02176	B-CHEM
(	O	O
56	O	O
.	O	O
1	O	O
±	O	O
17	O	O
.	O	O

3	O	O
and	O	O
167	O	O
±	O	O
57	O	O
.	O	O
6	O	O
)	O	O
and	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O	O
Z04139	B-CHEM
(	O	O
58	O	O
.	O	O
0	O	O
±	O	O
20	O	O
.	O	O
9	O	O
and	O	O
173	O	O
±	O	O
42	O	O
.	O	O
9	O	O
)	O	O
than	O	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
Z02137	B-CHEM
(	O	O
34	O	O
.	O	O

3	O	O
±	O	O
15	O	O
.	O	O
2	O	O
and	O	O
103	O	O
±	O	O
30	O	O
.	O	O
2	O	O
)	O	O
.	O	O

With	O	O
improved	O	O
target	O
-	O
to	O
-	O
background	O
contrast	O
(	B-CHEM
68	I-CHEM
)	I-CHEM
Ga	I-CHEM
-	O	O
Z02176	B-CHEM
and	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
F	I-CHEM
-	O	O
Z04139	B-CHEM
are	O	O
promising	O	O
for	O	O
imaging	B-PROC
B1R	B-CHEM
expression	B-PHYS
in	O	O
cancers	B-DISO
with	O	O
PET	B-PROC
.	O	O

Heterogeneous	O
silicon	B-CHEM
mesostructures	B-CHEM
for	O	O
lipid	B-CHEM
-supported	O	O
bioelectric	B-DEVI
interfaces	B-PHYS
Silicon	B-CHEM
-based	O	O
materials	B-OBJC
have	O	O
widespread	O
application	O	O
as	O	O
biophysical	B-PHEN
tools	B-OBJC
and	O	O
biomedical	B-DEVI
devices	I-DEVI
.	O	O

Here	O	O
we	O	O
introduce	O	O
a	O	O
biocompatible	B-CHEM
and	O	O
degradable	B-CHEM
mesostructured	B-CHEM
form	O	O
of	O	O
silicon	B-CHEM
with	O	O
multi	O
-	O
scale	O
structural	O
and	O	O
chemical	O
heterogeneities	O
.	O	O

The	O	O
material	B-OBJC
was	O	O
synthesized	O
using	O	O
mesoporous	B-CHEM
silica	I-CHEM
as	O	O
a	O	O
template	O
through	O	O
a	O	O
chemical	B-PHEN
vapour	I-PHEN
deposition	I-PHEN
process	I-PHEN
.	O	O

It	O	O
has	O	O
an	O	O
amorphous	O
atomic	B-CHEM
structure	O
,	O	O
an	O	O
ordered	O
nanowire	B-OBJC
-based	O	O
framework	O	O
and	O	O
random	O
submicrometre	O
voids	O
,	O	O
and	O	O
shows	O	O
an	O	O
average	O
Young	O
's	O
modulus	O
that	O	O
is	O	O
2	O	O
-	O	O
3	O	O
orders	O	O
of	O	O
magnitude	O
smaller	O
than	O
that	O	O
of	O	O
single	B-CHEM
-	I-CHEM
crystalline	I-CHEM
silicon	B-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
used	O	O
the	O	O
heterogeneous	O
silicon	B-CHEM
mesostructures	B-CHEM
to	O	O
design	O	O
a	O	O
lipid	B-ANAT
-	I-ANAT
bilayer	I-ANAT
-supported	O	O
bioelectric	B-PHYS
interface	B-PHYS
that	O	O
is	O	O
remotely	O
controlled	O
and	O	O
temporally	O
transient	O
,	O	O
and	O	O
that	O	O
permits	O
non	O
-	O	O
genetic	O
and	O	O
subcellular	B-ANAT
optical	O
modulation	O
of	O	O
the	O	O
electrophysiology	O
dynamics	B-PHEN
in	O	O
single	O
dorsal	B-ANAT
root	I-ANAT
ganglia	I-ANAT
neurons	B-ANAT
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
biomimetic	O
expansion	O
of	O	O
silicon	B-CHEM
into	O	O
heterogeneous	O
and	O	O
deformable	O
forms	O
can	O	O
open	O	O
up	O	O
opportunities	O	O
in	O	O
extracellular	B-ANAT
biomaterial	B-CHEM
or	O	O
bioelectric	B-DEVI
systems	I-DEVI
.	O	O

Gender	B-PHYS
Authorship	O
Trends	O
of	O	O
Plastic	O
Surgery	O
Research	B-PROC
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
An	O	O
increasing	O
number	O	O
of	O	O
women	B-LIVB
are	O	O
entering	O	O
the	O	O
medical	O
profession	O
,	O	O
but	O	O
plastic	O
surgery	O
remains	O	O
a	O	O
male	B-PHYS
-	O	O
dominated	O
profession	O
,	O	O
especially	O	O
within	O	O
academia	O
.	O	O

As	O	O
academic	O
aspirations	B-PHYS
and	O	O
advancement	O	O
depend	O	O
largely	O	O
on	O	O
research	B-PROC
productivity	O
,	O	O
the	O	O
authors	B-LIVB
assessed	O
the	O	O
number	O	O
of	O	O
articles	O
authored	O	O
by	O	O
women	B-LIVB
published	O
in	O	O
the	O	O
journal	O
Plastic	O
and	O
Reconstructive	O
Surgery	O
.	O	O

Original	O	O
articles	O	O
in	O	O
Plastic	O	O
and	O	O
Reconstructive	O	O
Surgery	O	O
published	O
during	O	O
the	O	O
years	O	O
1970	O	O
,	O	O
1980	O	O
,	O	O
1990	O	O
,	O	O
2000	O	O
,	O	O
2004	O	O
,	O	O
and	O	O
2014	O	O
were	O	O
analyzed	O	O
.	O	O

First	O	O
and	O	O
senior	B-LIVB
authors	B-LIVB
with	O	O
an	O	O
M	O
.	O

D	O
.	O	O

degree	O
and	O	O
U	O	O
.	O	O

S	O	O
.	O	O

institutional	O	O
affiliation	O	O
were	O	O
categorized	O	O
by	O	O
gender	B-PHYS
.	O	O

Authorship	O
trends	O
were	O	O
compared	O	O
with	O	O
those	O	O
from	O	O
other	O	O
specialties	O
.	O	O

Findings	O	O
were	O	O
placed	O	O
in	O	O
the	O	O
context	O	O
of	O	O
gender	B-PHYS
trends	O
among	O	O
plastic	O
surgery	O
residents	O	O
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
.	O	O

The	O	O
percentage	O	O
of	O	O
female	B-PHYS
authors	B-LIVB
in	O	O
Plastic	O	O
and	O	O
Reconstructive	O	O
Surgery	O	O
increased	O
from	O	O
2	O	O
.	O	O
4	O	O
percent	O	O
in	O	O
1970	O	O
to	O	O
13	O	O
.	O	O

3	O	O
percent	O	O
in	O	O
2014	O	O
.	O	O

Over	O	O
the	O	O
same	O	O
time	O	O
period	O	O
,	O	O
the	O	O
percentage	O	O
of	O	O
female	B-PHYS
plastic	O
surgery	O
residents	O	O
increased	O
from	O	O
2	O	O
.	O	O

6	O	O
percent	O	O
to	O	O
32	O	O
.	O	O

5	O	O
percent	O	O
.	O	O

By	O	O
2014	O	O
,	O	O
there	O	O
were	O	O
more	O	O
female	B-PHYS
first	O	O
authors	B-LIVB
(	O	O
19	O	O
.	O	O
1	O	O
percent	O	O
)	O	O
than	O	O
senior	O	O
authors	B-LIVB
(	O	O
7	O	O
.	O	O

7	O	O
percent	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

As	O	O
a	O	O
field	O	O
,	O	O
plastic	O
surgery	O
had	O	O
fewer	O	O
female	B-PHYS
authors	B-LIVB
than	O	O
other	O	O
medical	O
specialties	O
including	O	O
pediatrics	O
,	O	O
obstetrics	O
and	O
gynecology	O
,	O	O
general	O
surgery	O
,	O	O
internal	O
medicine	O
,	O	O
and	O	O
radiation	O
oncology	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
increase	O
in	O	O
representation	O
of	O	O
female	B-PHYS
authors	B-LIVB
in	O	O
plastic	O
surgery	O
is	O	O
encouraging	O	O
but	O	O
lags	O	O
behind	O	O
advances	O	O
in	O	O
other	O	O
specialties	O
.	O	O

Understanding	O	O
reasons	O	O
for	O	O
these	O	O
trends	O
may	O	O
help	O	O
improve	O	O
gender	B-PHYS
equity	O	O
in	O	O
academic	O
plastic	O
surgery	O
.	O	O

Utilization	O
Pattern	O
and	O	O
Drug	B-PHYS
Use	I-PHYS
of	O	O
Traditional	O
Chinese	O
Medicine	O
,	O	O
Western	O
Medicine	O
,	O	O
and	O	O
Integrated	O
Chinese	O
-	O
Western	O
Medicine	O
Treatments	B-PROC
for	O	O
Allergic	B-DISO
Rhinitis	I-DISO
Under	O	O
the	O	O
National	B-PROC
Health	I-PROC
Insurance	I-PROC
Program	I-PROC
in	O	O
Taiwan	B-GEOG
Patients	B-LIVB
in	O	O
Taiwan	B-GEOG
with	O	O
allergic	B-DISO
rhinitis	I-DISO
seek	O	O
not	O	O
only	O	O
Western	O
medicine	O
treatment	B-PROC
but	O	O
also	O	O
Traditional	O
Chinese	O
Medicine	O
treatment	B-PROC
or	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
.	O	O

Various	O	O
studies	O	O
have	O	O
conducted	O	O
pairwise	O
comparison	O
on	O	O
Traditional	O
Chinese	O
Medicine	O
,	O	O
Western	O
medicine	O
,	O	O
and	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatments	B-PROC
.	O	O

However	O	O
,	O	O
none	O	O
conducted	O	O
simultaneous	O
analysis	B-PROC
of	O	O
the	O	O
three	O	O
treatments	B-PROC
.	O	O

This	O	O
study	O	O
analyzed	B-PROC
patients	B-LIVB
with	O	O
allergic	B-DISO
rhinitis	I-DISO
receiving	O	O
the	O	O
three	O	O
treatments	B-PROC
to	O	O
identify	O	O
differences	O	O
in	O	O
demographic	O
characteristic	O
and	O	O
medical	O
use	O
and	O	O
thereby	O	O
to	O	O
determine	O	O
drug	B-PHYS
use	I-PHYS
patterns	I-PHYS
of	O	O
different	O	O
treatments	B-PROC
.	O	O

The	O	O
National	O
Health	O
Insurance	O
Research	O
Database	O
was	O	O
the	O	O
data	O
source	O
,	O	O
and	O	O
included	O	O
patients	B-LIVB
were	O	O
those	O	O
diagnosed	B-DISO
with	O	O
allergic	B-DISO
rhinitis	I-DISO
(	O	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
,	O	O
Clinical	O
Modification	O
codes	O
470	O
-	O
478	O
)	O	O
.	O	O

Chi	O
-	O
square	O
test	O
and	O	O
Tukey	O
studentized	O
range	O
(	O
honest	O
significant	O
difference	O
)	O
test	O
were	O	O
conducted	O	O
to	O	O
investigate	O
the	O	O
differences	O	O
among	O	O
the	O	O
three	O	O
treatments	B-PROC
.	O	O

Visit	O
frequency	O
for	O	O
allergic	B-DISO
rhinitis	I-DISO
treatment	B-PROC
was	O	O
higher	O	O
in	O	O
female	B-LIVB
than	O	O
male	B-LIVB
patients	B-LIVB
,	O	O
regardless	O	O
of	O	O
treatment	B-PROC
with	O	O
Traditional	O
Chinese	O
Medicine	O
,	O	O
Western	O
medicine	O
,	O	O
or	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
.	O	O

Persons	B-LIVB
aged	O	O
0	O	O
-	O	O
19	O	O
years	O	O
ranked	O	O
the	O	O
highest	O
in	O	O
proportion	O
of	O	O
visits	B-PROC
for	O	O
allergic	B-DISO
rhinitis	I-DISO
.	O	O

Traditional	O
Chinese	O
Medicine	O
treatment	B-PROC
had	O	O
more	O	O
medical	O
items	O	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O	O
daily	O
drug	O
cost	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O	O
had	O	O
the	O	O
lowest	O
total	O
expenditure	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
.	O	O

In	O	O
contrast	O	O
,	O	O
Western	O
medicine	O
had	O	O
the	O	O
lowest	O
daily	O
drug	O
cost	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
and	O	O
the	O	O
highest	O
total	O
expenditure	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
.	O	O

The	O	O
total	O
expenditure	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
,	O	O
daily	O
drug	O
cost	O
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
,	O	O
and	O	O
medical	O
items	B-OBJC
per	O	O
person	B-LIVB
-	I-LIVB
time	I-LIVB
of	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
lay	O	O
between	O	O
those	O	O
seen	O	O
with	O	O
Traditional	O
Chinese	O
Medicine	O
and	O	O
Western	O
medicine	O
treatments	B-PROC
.	O	O

Although	O	O
only	O	O
6	O	O
.	O	O
82	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
allergic	B-DISO
rhinitis	I-DISO
chose	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
treatment	B-PROC
,	O	O
the	O	O
visit	O
frequency	O
per	O	O
person	O	O
-	O	O
year	O	O
of	O	O
integrated	O
Chinese	O
-	O
Western	O
medicine	O
ranked	O	O
highest	O
.	O	O

In	O	O
addition	O	O
,	O	O
multiple	O
-	O
composition	O
medicines	B-CHEM
were	O	O
used	O	O
more	O	O
frequently	O
than	O	O
single	O
-	O
composition	O
medicines	B-CHEM
,	O	O
and	O	O
mar	B-CHEM
huang	I-CHEM
(	O	O
Ephedra	B-LIVB
sinica	I-LIVB
Stapf	I-LIVB
)	O	O
was	O	O
seldom	O	O
used	O	O
to	O	O
decrease	O
the	O	O
risk	O
of	O
combining	O	O
medications	B-CHEM
.	O	O

Beneficial	O
effects	O
of	O	O
voglibose	B-CHEM
administration	B-PROC
on	O	O
body	B-PHYS
weight	I-PHYS
and	O	O
lipid	B-PHYS
metabolism	I-PHYS
via	O	O
gastrointestinal	B-ANAT
bile	B-CHEM
acid	I-CHEM
modification	O
This	O	O
study	B-PROC
was	O	O
designed	O	O
with	O	O
the	O	O
goal	O
of	O	O
examining	O	O
the	O	O
effects	O
of	O	O
voglibose	B-CHEM
administration	B-PROC
on	O	O
body	B-PHYS
weight	I-PHYS
and	O	O
lipid	B-PHYS
metabolism	I-PHYS
and	O	O
underlying	O	O
mechanism	O
high	B-PROC
fat	I-PROC
diet	I-PROC
-induced	O	O
obese	B-LIVB
mice	I-LIVB
.	O	O

Male	B-PHYS
C57BL	B-LIVB
/	I-LIVB
6	I-LIVB
mice	I-LIVB
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
four	O	O
groups	B-LIVB
:	O	O
a	O	O
control	B-LIVB
diet	I-LIVB
(	O	O
CTL	B-LIVB
)	O	O
,	O	O
high	B-LIVB
-	I-LIVB
fat	I-LIVB
diet	I-LIVB
(	O	O
HF	B-LIVB
)	O	O
,	O	O
high	B-LIVB
-	I-LIVB
fat	I-LIVB
diet	I-LIVB
supplemented	I-LIVB
with	I-LIVB
voglibose	I-LIVB
(	O	O
VO	B-LIVB
)	O	O
,	O	O
and	O	O
high	B-LIVB
fat	I-LIVB
diet	I-LIVB
pair	I-LIVB
-	I-LIVB
fed	I-LIVB
group	I-LIVB
(	O	O
PF	B-LIVB
)	O	O
.	O	O

After	O	O
12	O	O
weeks	O
,	O	O
the	O	O
following	O	O
characteristics	O
were	O	O
investigated	O	O
:	O	O
serum	B-PROC
lipid	I-PROC
and	O	O
glucose	B-PHEN
levels	I-PHEN
,	O	O
serum	O	O
polar	O	O
metabolite	O	O
profiles	O	O
,	O	O
and	O	O
expression	O
levels	O
of	O	O
genes	O
involved	O	O
in	O	O
lipid	B-PHYS
and	O	O
bile	B-PHYS
acid	I-PHYS
metabolism	I-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
pyrosequencing	B-PROC
was	O	O
used	O	O
to	O	O
analyze	O	O
the	O	O
composition	B-PHYS
of	O	O
gut	B-LIVB
microbiota	I-LIVB
found	O	O
in	O	O
feces	B-ANAT
.	O	O

Total	B-DISO
body	I-DISO
weight	I-DISO
gain	I-DISO
was	O	O
significantly	O
lower	O
in	O	O
the	O	O
VO	B-LIVB
group	I-LIVB
than	O	O
in	O	O
the	O	O
CTL	B-LIVB
,	O	O
HF	B-LIVB
,	O	O
and	O	O
PF	B-LIVB
groups	I-LIVB
.	O	O

The	O	O
VO	B-LIVB
group	I-LIVB
exhibited	O	O
improved	O	O
metabolic	B-PHYS
profiles	I-PHYS
including	O	O
those	O	O
of	O	O
blood	B-PROC
glucose	I-PROC
,	O	O
triglyceride	B-PHEN
,	O	O
and	O	O
total	B-PHEN
cholesterol	I-PHEN
levels	I-PHEN
.	O	O

The	O	O
12	O	O
-	O	O
week	O
voglibose	B-CHEM
administration	B-PROC
decreased	O	O
the	O	O
ratio	O	O
of	O	O
Firmicutes	B-LIVB
to	O	O
Bacteroidetes	B-LIVB
found	O	O
in	O	O
feces	B-ANAT
.	O	O

Circulating	O	O
levels	O
of	O	O
taurocholic	B-CHEM
and	O	O
cholic	B-CHEM
acid	I-CHEM
were	O	O
significantly	O
higher	O
in	O	O
the	O	O
VO	B-LIVB
group	I-LIVB
than	O	O
in	O	O
the	O	O
HF	B-LIVB
and	O	O
CTL	B-LIVB
groups	I-LIVB
.	O	O

Deoxycholic	B-CHEM
acid	I-CHEM
levels	O
tended	O	O
to	O	O
be	O	O
higher	O	O
in	O	O
the	O	O
VO	B-LIVB
group	I-LIVB
than	O	O
in	O	O
the	O	O
HF	B-LIVB
group	I-LIVB
.	O	O

Voglibose	B-CHEM
administration	B-PROC
downregulated	B-PHYS
expression	O
levels	O
of	O	O
CYP8B1	O
and	O	O
HNF4α	O
genes	O
and	O	O
upregulated	B-PHYS
those	O	O
of	O	O
PGC1α	O
,	O	O
whereas	O	O
FXRα	O
was	O	O
not	O	O
affected	O	O
.	O	O

Voglibose	B-CHEM
administration	B-PROC
elicits	O	O
changes	O	O
in	O	O
the	O	O
composition	B-PHYS
of	O	O
the	O	O
intestinal	B-LIVB
microbiota	I-LIVB
and	O	O
circulating	B-CHEM
metabolites	I-CHEM
,	O	O
which	O	O
ultimately	O	O
has	O	O
systemic	O
effects	O
on	O	O
body	B-PHYS
weight	I-PHYS
and	O	O
lipid	B-PHYS
metabolism	I-PHYS
in	O	O
mice	B-LIVB
.	O	O

REST	O
levels	O
affect	B-PROC
the	O	O
functional	O
expression	B-PHYS
of	O	O
voltage	B-CHEM
dependent	I-CHEM
calcium	I-CHEM
channels	I-CHEM
and	O	O
the	O	O
migratory	O
activity	O
in	O	O
immortalized	B-PROC
GnRH	B-CHEM
neurons	B-ANAT
The	O	O
repressor	O
element	O
-	O
1	O
silencing	O
transcription	O
factor	O
(	O	O
REST	O
)	O	O
has	O	O
emerged	O	O
as	O	O
a	O	O
key	O	O
controller	O	O
of	O	O
neuronal	B-CHEM
differentiation	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
expression	B-PHYS
of	O	O
the	O	O
neuronal	B-CHEM
phenotype	B-PHYS
;	O	O
however	O	O
,	O	O
much	O	O
has	O	O
still	O	O
to	O	O
be	O	O
learned	O	O
about	O	O
its	O	O
role	O	O
at	O	O
specific	O	O
developmental	O
stages	O
and	O	O
about	O	O
the	O	O
functional	O
targets	O	O
affected	O	O
.	O	O

Among	O	O
these	O	O
targets	O	O
,	O	O
calcium	B-PHYS
signaling	I-PHYS
mechanisms	O
are	O	O
critically	O
dependent	O
on	O	O
the	O	O
developmental	O
stage	O
and	O	O
their	O	O
full	O	O
expression	B-PHYS
is	O	O
a	O	O
hallmark	O	O
of	O	O
the	O	O
mature	O	O
,	O	O
functional	O
neuron	B-ANAT
.	O	O

We	O	O
have	O	O
analyzed	O	O
the	O	O
role	O	O
played	O	O
by	O	O
REST	O
in	O	O
GN11	B-ANAT
cells	I-ANAT
,	O	O
an	O	O
immortalized	B-ANAT
cell	I-ANAT
line	O	O
derived	O	O
from	O	O
gonadotropin	B-CHEM
hormone	I-CHEM
releasing	I-CHEM
hormone	I-CHEM
(	O	O
GnRH	B-CHEM
)	O	O
neurons	B-ANAT
at	O	O
an	O	O
early	O
developmental	O
stage	O
,	O	O
electrically	B-PHEN
non	B-DISO
-	I-DISO
excitable	I-DISO
and	O	O
with	O	O
a	O	O
strong	O	O
migratory	O
activity	O
.	O	O

We	O	O
show	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
functional	O
voltage	B-CHEM
-	I-CHEM
dependent	I-CHEM
calcium	I-CHEM
channels	I-CHEM
are	O	O
expressed	B-PHYS
in	O	O
wild	O
type	O
GN11	B-ANAT
cells	I-ANAT
;	O	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
REST	O
by	O	O
a	O	O
silencing	B-PHYS
approach	O	O
shifts	O	O
these	O	O
cells	B-ANAT
towards	O	O
a	O	O
more	O	O
differentiated	O	O
phenotype	B-PHYS
,	O	O
increasing	O	O
the	O	O
functional	O
expression	B-PHYS
of	O	O
P	B-CHEM
/	O	O
Q	B-CHEM
-	I-CHEM
type	I-CHEM
channels	I-CHEM
and	O	O
reducing	O	O
their	O	O
migratory	O
potential	O
.	O	O

The	O	O
knee	B-DISO
joint	I-DISO
loose	I-DISO
body	I-DISO
as	O	O
a	O	O
source	O	O
of	O	O
viable	O
autologous	O
human	B-LIVB
chondrocytes	B-ANAT
Loose	B-DISO
bodies	I-DISO
are	O	O
fragments	O	O
of	O	O
cartilage	O
or	O	O
bone	B-ANAT
present	O	O
in	O	O
the	O	O
synovial	B-ANAT
fluid	I-ANAT
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
we	O	O
assessed	O	O
if	O	O
loose	B-DISO
bodies	I-DISO
could	O	O
be	O	O
used	O	O
as	O	O
a	O	O
source	O	O
of	O	O
autologous	O
human	B-LIVB
chondrocytes	B-ANAT
for	O	O
experimental	B-PROC
purposes	I-PROC
.	O	O

Histochemical	B-PROC
examination	I-PROC
of	O	O
loose	B-DISO
bodies	I-DISO
and	O	O
differential	O	O
enzymatic	B-PROC
digestions	I-PROC
were	O	O
undertaken	O	O
,	O	O
the	O	O
isolated	O	O
cells	B-ANAT
were	O	O
cultured	B-ANAT
in	O	O
alginate	B-CHEM
bead	I-CHEM
microspheres	B-DEVI
and	O	O
immunolocalisations	B-PROC
were	O	O
undertaken	O	O
for	O	O
chondrogenic	B-PHYS
markers	B-PHYS
such	O	O
as	O	O
aggrecan	B-CHEM
,	O	O
and	O	O
type	B-CHEM
II	I-CHEM
collagen	I-CHEM
.	O	O

Isolated	O	O
loose	B-DISO
body	I-DISO
cells	B-ANAT
had	O	O
high	O	O
viability	B-PHYS
(	O	O
≥90	O	O
%	O	O
viable	O	O
)	O	O
,	O	O
expressed	O	O
chondrogenic	B-PHYS
markers	B-PHYS
(	O	O
aggrecan	B-CHEM
,	O	O
type	B-CHEM
II	I-CHEM
collagen	I-CHEM
)	O	O
but	O	O
no	B-DISO
type	B-CHEM
I	I-CHEM
collagen	I-CHEM
.	O	O

Loose	B-DISO
bodies	I-DISO
may	O	O
be	O	O
a	O	O
useful	O	O
source	O	O
of	O	O
autologous	O
chondrocytes	B-ANAT
of	O	O
high	O	O
viability	B-PHYS
.	O	O

Supramolecular	B-PHYS
Recognition	I-PHYS
of	O	O
Amino	B-CHEM
Acids	I-CHEM
by	O	O
Twisted	B-CHEM
Cucurbit	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
uril	I-CHEM
Binding	B-PHYS
interactions	O
between	O
twisted	B-CHEM
cucurbit	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
uril	I-CHEM
(	B-CHEM
tQ	I-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
)	I-CHEM
and	O	O
twenty	O	O
standard	O
amino	B-CHEM
acids	I-CHEM
(	B-CHEM
AAs	I-CHEM
)	I-CHEM
have	O	O
been	O	O
investigated	O
by	O	O
NMR	B-PROC
spectroscopy	I-PROC
and	O	O
isothermal	B-PROC
titration	I-PROC
calorimetry	I-PROC
(	B-PROC
ITC	I-PROC
)	I-PROC
in	O	O
aqueous	B-CHEM
HCl	B-CHEM
solutions	I-CHEM
and	O	O
in	O	O
DMSO	B-CHEM
.	O	O

The	O	O
results	O
showed	O	O
that	O	O
tQ	B-CHEM
[	I-CHEM
14	I-CHEM
]	I-CHEM
displays	O
clear	O	O
binding	B-PHYS
affinity	B-PHEN
for	O	O
AAs	B-CHEM
with	O	O
a	O	O
positively	B-CHEM
charged	I-CHEM
side	I-CHEM
chain	I-CHEM
or	O	O
containing	O
an	O	O
aromatic	B-CHEM
ring	I-CHEM
,	O	O
but	O	O
weaker	O
binding	B-PHYS
affinity	B-PHEN
for	O	O
AAs	B-CHEM
with	O	O
hydrophobic	B-CHEM
or	O	O
polar	B-CHEM
side	I-CHEM
chains	I-CHEM
,	O	O
with	O	O
the	O	O
binding	B-PHYS
mode	O
depending	O	O
on	O	O
the	O	O
type	O	O
of	O	O
side	B-CHEM
chain	I-CHEM
present	O	O
in	O	O
the	O	O
AAs	B-CHEM
.	O	O

Comparison	O
of	O	O
alkaline	B-PHYS
phosphatase	I-PHYS
activity	I-PHYS
of	O	O
MC3T3	B-ANAT
-	I-ANAT
E1	I-ANAT
cells	I-ANAT
cultured	O	O
on	O	O
different	O	O
Ti	B-CHEM
surfaces	O
:	O	O
modified	O	O
sandblasted	B-PHEN
with	O	O
large	O	O
grit	B-CHEM
and	O	O
acid	B-PHEN
-	I-PHEN
etched	I-PHEN
(	O	O
MSLA	B-CHEM
)	O	O
,	O	O
laser	B-PHEN
-	I-PHEN
treated	I-PHEN
,	O	O
and	O	O
laser	B-PHEN
and	I-PHEN
acid	I-PHEN
-	I-PHEN
treated	I-PHEN
Ti	B-CHEM
surfaces	O
In	O	O
this	O	O
study	B-PROC
,	O	O
the	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
effect	O	O
of	O	O
implant	O	O
surface	O
treatment	O	O
on	O	O
cell	B-PHYS
differentiation	I-PHYS
of	O	O
osteoblast	B-ANAT
cells	I-ANAT
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
three	O	O
surfaces	O
were	O	O
compared	O	O
:	O	O
(	O	O
1	O	O
)	O	O
a	O	O
modified	O	O
SLA	O	O
(	O	O
MSLA	O	O
:	O	O
sand	O	O
-	O	O
blasted	O	O
with	O	O
large	O	O
grit	B-CHEM
,	O	O
acid	O	O
-	O	O
etched	O	O
,	O	O
and	O	O
immersed	O	O
in	O	O
0	O	O
.	O	O

9	O	O
%	O	O
NaCl	B-CHEM
)	O	O
,	O	O
(	O	O
2	O	O
)	O	O
a	O	O
laser	B-PHEN
treatment	I-PHEN
(	O	O
LT	B-PHEN
:	O	O
laser	B-PHEN
treatment	I-PHEN
)	O	O
titanium	B-CHEM
surface	O
and	O	O
(	O	O
3	O	O
)	O	O
a	O	O
laser	B-PHEN
and	I-PHEN
acid	I-PHEN
-	I-PHEN
treated	I-PHEN
(	O	O
LAT	O	O
:	O	O
laser	B-PHEN
treatment	I-PHEN
,	I-PHEN
acid	I-PHEN
-	I-PHEN
etched	I-PHEN
)	O	O
titanium	B-CHEM
surface	O
.	O	O

The	O	O
MSLA	B-CHEM
surfaces	O
were	O	O
considered	O	O
as	O	O
the	O	O
control	B-LIVB
group	I-LIVB
,	O	O
and	O	O
LT	B-CHEM
and	O	O
LAT	B-CHEM
surfaces	O
as	O	O
test	O
groups	O
.	O	O

Alkaline	B-CHEM
phosphatase	I-CHEM
expression	B-PHYS
(	O	O
ALP	B-CHEM
)	O	O
was	O	O
used	O	O
to	O	O
quantify	O	O
osteoblastic	B-PHYS
differentiation	I-PHYS
of	O	O
MC3T3	B-ANAT
-	I-ANAT
E1	I-ANAT
cell	I-ANAT
.	O	O

Surface	O
roughness	O
was	O	O
evaluated	B-PROC
by	O	O
a	O	O
contact	B-DEVI
profilometer	I-DEVI
(	O	O
URFPAK	O	O
-	O	O
SV	O	O
;	O	O
Mitutoyo	O	O
,	O	O
Kawasaki	O	O
,	O	O
Japan	B-GEOG
)	O	O
and	O	O
characterized	O	O
by	O	O
two	O	O
parameters	O	O
:	O	O
mean	O
roughness	O
(	O	O
Ra	O
)	O	O
and	O	O
maximum	O
peak	O
-	O
to	O
-	O
valley	O
height	O
(	O	O
Rt	O
)	O	O
.	O	O

Scanning	B-DEVI
electron	I-DEVI
microscope	I-DEVI
revealed	O	O
that	O	O
MSLA	O	O
(	O	O
control	B-LIVB
group	I-LIVB
)	O	O
surface	O
was	O	O
not	O	O
as	O	O
rough	O
as	O	O
LT	B-CHEM
,	O	O
LAT	B-CHEM
surface	O
(	O	O
test	O
groups	O
)	O	O
.	O	O

Alkaline	B-CHEM
phosphatase	I-CHEM
expression	B-PHYS
,	O	O
the	O	O
measure	O	O
of	O	O
osteoblastic	B-PHYS
differentiation	I-PHYS
,	O	O
and	O	O
total	O	O
ALP	B-CHEM
expression	B-PHYS
by	O	O
surface	B-ANAT
-	I-ANAT
adherent	I-ANAT
cells	I-ANAT
were	O	O
found	O	O
to	O	O
be	O	O
highest	O	O
at	O	O
21	O	O
days	O
for	O	O
all	O	O
three	O	O
surfaces	O
tested	O	O
(	O	O
P	O	O
<	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
ALP	B-CHEM
expression	B-PHYS
levels	O
of	O	O
MSLA	B-CHEM
and	O	O
LAT	B-CHEM
surfaces	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
expression	B-PHYS
levels	O
of	O	O
LT	B-CHEM
surface	B-ANAT
-	I-ANAT
adherent	I-ANAT
cells	I-ANAT
at	O	O
7	O	O
,	O	O
14	O	O
,	O	O
and	O	O
21	O	O
days	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
.	O	O
05	O	O
)	O	O
.	O	O

However	O	O
,	O	O
ALP	B-CHEM
expression	B-PHYS
levels	O
between	O	O
MSLA	B-CHEM
and	O	O
LAT	B-CHEM
surface	O
were	O	O
equal	O	O
at	O	O
7	O	O
,	O	O
14	O	O
,	O	O
and	O	O
21	O	O
days	O
(	O	O
P	O	O
>	O	O
.	O	O
05	O	O
)	O	O
.	O	O

This	O	O
study	B-PROC
suggested	O	O
that	O	O
MSLA	B-CHEM
and	O	O
LAT	B-CHEM
surfaces	O
exhibited	O	O
more	O	O
favorable	O
environment	O
for	O	O
osteoblast	B-PHYS
differentiation	I-PHYS
when	O	O
compared	O	O
with	O	O
LT	B-CHEM
surface	O
,	O	O
the	O	O
results	O	O
that	O	O
are	O	O
important	O	O
for	O	O
implant	B-DEVI
surface	O
modification	O
studies	B-PROC
.	O	O

Liganded	B-ANAT
Vitamin	B-CHEM
D	I-CHEM
Receptor	I-CHEM
Through	O
Its	O	O
Interacting	O
Repressor	B-CHEM
Inhibits	O
the	O	O
Expression	B-PHYS
of	O	O
Type	B-CHEM
I	I-CHEM
Collagen	I-CHEM
α1	I-CHEM
Hepatic	B-DISO
fibrosis	I-DISO
is	O	O
a	O	O
reversible	O
process	B-PHEN
involving	O
plenty	O
of	O	O
transcription	B-CHEM
factors	I-CHEM
and	O	O
pathways	B-PHYS
.	O	O

Vitamin	B-CHEM
D	I-CHEM
receptor	I-CHEM
(	O	O
VDR	B-CHEM
)	O	O
as	O	O
a	O	O
member	O	O
of	O	O
ligand	B-CHEM
-	O	O
induced	O
transcription	B-CHEM
factors	I-CHEM
can	O	O
interact	O
with	O	O
9	B-CHEM
-	I-CHEM
cis	I-CHEM
retinoid	I-CHEM
X	I-CHEM
receptor	I-CHEM
(	O	O
RXR	B-CHEM
)	O	O
and	O	O
VDR	O
-	O
interacting	O
repressor	O
(	O	O
VDIR	O
)	O	O
to	O	O
mediate	O	O
transactivation	B-PHYS
or	O	O
transrepression	B-PHYS
in	O	O
the	O	O
absence	O
or	O	O
in	O	O
the	O	O
presence	B-DISO
of	O	O
VDR	B-CHEM
ligand	B-PHYS
to	O	O
regulate	B-PHYS
the	O	O
expression	B-PHYS
of	O	O
VDR	O
target	O
genes	O
.	O	O

The	O	O
active	O
form	O
of	O	O
vitamin	B-CHEM
D	I-CHEM
[	O	O
1α	B-CHEM
,	I-CHEM
25	I-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
2D3	I-CHEM
]	O	O
can	O	O
downregulate	B-PHYS
the	O	O
expression	B-PHYS
of	O	O
type	B-CHEM
I	I-CHEM
collagen	I-CHEM
both	I-CHEM
α1	I-CHEM
and	O	O
α2	B-CHEM
(	O	O
COLIα1	B-CHEM
and	O	O
COLIα2	B-CHEM
)	O	O
in	O	O
hepatic	B-ANAT
stellate	I-ANAT
cells	I-ANAT
(	O	O
HSC	B-ANAT
-	I-ANAT
T6	I-ANAT
)	O	O
in	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
fashion	O	O
,	O	O
which	O	O
provides	O	O
a	O	O
new	O	O
direction	O	O
for	O	O
hepatic	B-DISO
fibrosis	I-DISO
therapy	B-PROC
.	O	O

As	O	O
one	O	O
of	O	O
VDR	O
target	O
genes	O
,	O	O
rat	B-LIVB
COLIα1	O
gene	O
contains	O	O
1αnVDRE	B-CHEM
(	O	O
E	B-CHEM
-	I-CHEM
box1	I-CHEM
and	O	O
E	B-CHEM
-	I-CHEM
box2	I-CHEM
)	O	O
in	O	O
its	O	O
promoter	B-CHEM
,	O	O
and	O	O
unliganded	B-DISO
VDR	B-CHEM
/	O	O
RXR	B-CHEM
may	O	O
bind	B-PHYS
to	O	O
1αnVDRE	B-CHEM
through	O
VDIR	O
to	O	O
mediate	O	O
transactivation	B-PHYS
,	O	O
whereas	O	O
liganded	B-ANAT
VDR	B-CHEM
/	O	O
RXR	B-CHEM
may	O	O
bind	B-PHYS
to	O	O
1αnVDRE	B-CHEM
through	O
VDIR	O
for	O	O
transrepression	B-PHYS
.	O	O

The	O	O
results	O	O
suggested	O	O
a	O	O
sort	O	O
of	O	O
relying	O	O
on	O	O
each	O	O
other	O	O
relationship	O
between	O	O
VDR	B-CHEM
/	O	O
RXR	B-CHEM
and	O	O
VDIR	O
in	O	O
regulating	B-PHYS
the	O	O
expression	B-PHYS
of	O	O
COLIα1	O
gene	O
in	O	O
HSC	B-ANAT
-	I-ANAT
T6	I-ANAT
cells	I-ANAT
,	O	O
which	O	O
established	O	O
VDR	B-CHEM
as	O	O
a	O	O
potential	O
target	O
for	O	O
blocking	O
and	O	O
even	O	O
reversing	O
hepatic	B-DISO
fibrosis	I-DISO
.	O	O

Treatment	B-PROC
with	O	O
high	O
dose	O
of	O	O
atorvastatin	B-CHEM
reduces	O	O
vascular	B-DISO
injury	I-DISO
in	O	O
diabetic	B-DISO
rats	B-LIVB
Previous	O	O
reports	O	O
showed	O	O
conflicting	O	O
results	O	O
regarding	O	O
the	O	O
treatment	B-PROC
effects	O	O
of	O	O
statin	B-CHEM
on	O	O
Diabetes	B-DISO
mellitus	I-DISO
(	O	O
DM	B-DISO
)	O	O
.	O	O

We	O	O
investigated	O	O
how	O	O
treatment	B-PROC
with	O	O
high	O
dose	O
of	O	O
atorvastatin	B-CHEM
affects	O	O
the	O	O
impaired	O
vascular	B-PHYS
function	I-PHYS
in	O	O
diabetic	B-DISO
rats	B-LIVB
.	O	O

Atorvastatin	B-CHEM
(	O	O
80mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
oral	O
gavage	O
,	O	O
4	O	O
weeks	O
)	O	O
or	O	O
its	O	O
vehicle	B-CHEM
was	O	O
administered	O
to	O	O
male	B-LIVB
control	I-LIVB
or	O	O
streptozotocin	B-CHEM
(	O	O
STZ	B-CHEM
)	O	O
-	O	O
induced	O	O
diabetic	B-DISO
rats	B-LIVB
.	O	O

Aortic	B-ANAT
segments	I-ANAT
were	O	O
used	O	O
to	O	O
investigate	O	O
the	O	O
vascular	B-PHYS
reactivity	I-PHYS
,	O	O
protein	B-PHYS
expression	I-PHYS
of	O	O
cyclooxygenase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
)	O	O
and	O	O
nicotinamide	B-CHEM
adenine	I-CHEM
dinucleotide	I-CHEM
phosphate	I-CHEM
oxidase	I-CHEM
(	I-CHEM
NADPH	I-CHEM
oxidase	I-CHEM
)	I-CHEM
1	I-CHEM
(	O	O
NOX1	B-CHEM
)	O	O
and	O	O
superoxide	B-CHEM
anions	I-CHEM
levels	O
.	O	O

Atorvastatin	B-CHEM
treatment	B-PROC
did	O	O
not	O	O
affect	O	O
glycemia	B-PROC
levels	I-PROC
.	O	O

In	O	O
diabetic	B-DISO
rats	B-LIVB
,	O	O
the	O	O
vascular	B-PHYS
reactivity	I-PHYS
to	O	O
phenylephrine	B-CHEM
increased	O
compared	O	O
with	O	O
controls	B-OBJC
and	O	O
the	O	O
atorvastatin	B-CHEM
treatment	B-PROC
reduced	O
this	O	O
response	B-PHYS
.	O	O

Removal	O
of	O	O
the	O	O
endothelium	O
increased	O
the	O	O
response	B-PHYS
to	O	O
phenylephrine	B-CHEM
in	O	O
control	B-LIVB
rats	I-LIVB
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
diabetic	O
group	O
.	O	O

Atorvastatin	B-CHEM
increased	O
the	O	O
endothelial	O
modulation	O
in	O	O
diabetic	B-DISO
rats	B-LIVB
.	O	O

L	B-CHEM
-	I-CHEM
NAME	I-CHEM
(	O	O
100μM	O	O
)	O	O
increased	O
the	O	O
reactivity	O
in	O	O
all	O	O
groups	O
,	O	O
but	O	O
this	O	O
effect	O	O
was	O	O
greater	O	O
in	O	O
atorvastatin	B-CHEM
-treated	O	O
diabetic	B-DISO
rats	B-LIVB
.	O	O

Indomethacin	B-CHEM
(	O	O
10μM	O	O
)	O	O
and	O	O
NS398	B-CHEM
(	O	O
1μM	O	O
)	O	O
decreased	O
the	O	O
contractile	B-ANAT
response	B-PHYS
in	O	O
diabetic	B-DISO
rats	B-LIVB
and	O	O
atorvastatin	B-CHEM
reversed	O
these	O	O
effects	O
,	O	O
without	O	O
changing	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
expression	B-PHYS
.	O	O

Apocynin	B-CHEM
(	O	O
30μM	O	O
)	O	O
decreased	O
the	O	O
phenylephrine	B-CHEM
response	B-PHYS
in	O	O
diabetic	B-DISO
rats	B-LIVB
,	O	O
which	O	O
also	O	O
showed	O	O
increased	O
NOX1	B-CHEM
and	O	O
superoxide	B-CHEM
anions	I-CHEM
;	O	O
these	O	O
effects	O
were	O	O
prevented	O	O
by	O	O
atorvastatin	B-CHEM
treatment	B-PROC
.	O	O

The	O	O
results	O
suggest	O	O
that	O	O
treatment	B-PROC
with	O	O
high	O
dose	O
of	O	O
atorvastatin	B-CHEM
,	O	O
independent	O
of	O
glycemia	B-CHEM
,	O	O
improves	O	O
endothelial	O
function	O
in	O	O
aortas	B-ANAT
from	O	O
diabetic	B-DISO
rats	B-LIVB
by	O	O
reducing	O
the	O	O
constrictor	B-CHEM
prostanoids	I-CHEM
derived	O	O
from	O	O
COX	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
by	O	O
reducing	O
the	O	O
oxidative	B-DISO
stress	I-DISO
by	O	O
NADPH	B-CHEM
oxidase	I-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
possible	O	O
increasing	O
of	O	O
nitric	B-CHEM
oxide	I-CHEM
participation	O
.	O	O

Fracture	B-DISO
Resistance	I-DISO
of	O	O
Endodontically	B-DISO
Treated	I-DISO
Teeth	I-DISO
Restored	B-PROC
With	O	O
Bulk	B-CHEM
Fill	I-CHEM
,	O	O
Bulk	B-CHEM
Fill	I-CHEM
Flowable	I-CHEM
,	O	O
Fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
,	O	O
and	O	O
Conventional	B-CHEM
Resin	I-CHEM
Composite	I-CHEM
The	O	O
aim	O	O
of	O	O
this	O	O
in	B-PROC
vitro	I-PROC
study	I-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
fracture	B-DISO
resistance	I-DISO
of	O	O
endodontically	B-DISO
treated	I-DISO
teeth	I-DISO
restored	B-PROC
with	O	O
different	O
types	O
of	O	O
restorative	B-DEVI
resins	I-DEVI
.	O	O

Seventy	O
-	O
two	O
sound	O	O
maxillary	B-ANAT
premolar	B-ANAT
teeth	I-ANAT
were	O	O
randomly	O	O
divided	O
into	O	O
six	O
groups	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
.	O	O

The	O	O
teeth	B-ANAT
in	O	O
the	O	O
first	O
group	O
were	O	O
left	O	O
intact	O
and	O	O
tested	O
as	O	O
unprepared	O
negative	O
control	O
(	O	O
group	O
I	O
)	O	O
specimens	B-OBJC
.	O	O

The	O	O
teeth	B-ANAT
in	O	O
the	O	O
remaining	O	O
five	O
groups	O
were	O	O
prepared	O
with	O	O
MOD	B-DISO
cavities	I-DISO
and	O	O
endodontically	B-PROC
treated	I-PROC
.	O	O

The	O	O
teeth	B-ANAT
in	O	O
one	O
of	O	O
the	O	O
five	O
groups	O
(	O	O
positive	B-LIVB
control	I-LIVB
group	I-LIVB
II	I-LIVB
)	O	O
were	O	O
unrestored	B-DISO
.	O	O

The	O	O
rest	O	O
of	O	O
the	O	O
prepared	O	O
cavities	B-DISO
were	O	O
restored	B-PROC
as	O	O
follows	O	O
:	O	O
group	O
III	O
:	O	O
bulk	B-CHEM
fill	I-CHEM
resin	I-CHEM
composite	I-CHEM
/	O	O
Filtek	B-CHEM
Bulk	I-CHEM
Fill	I-CHEM
(	O	O
3	O
M	O
ESPE	O
)	O	O
;	O	O
group	O
IV	O
:	O	O
bulk	B-CHEM
fill	I-CHEM
flowable	I-CHEM
resin	I-CHEM
composite	I-CHEM
+	O	O
nanohybrid	B-CHEM
/	O	O
SureFil	B-CHEM
SDR	I-CHEM
Flow	I-CHEM
+	O	O
Ceram	B-CHEM
.	I-CHEM

X	I-CHEM
Mono	I-CHEM
(	O	O
Dentsply	O
)	O	O
;	O	O
group	O
V	O
:	O	O
fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
composite	I-CHEM
+	O	O
posterior	B-CHEM
resin	I-CHEM
composite	I-CHEM
/	O	O
GC	B-CHEM
everX	I-CHEM
posterior	I-CHEM
+	O	O
G	B-CHEM
-	I-CHEM
aenial	I-CHEM
posterior	I-CHEM
(	O	O
GC	O
Corp	O
.	O	O
)	O	O
;	O	O
and	O	O
group	O
VI	O
:	O	O
nanohybrid	B-CHEM
resin	I-CHEM
composite	I-CHEM
/	O	O
Tetric	B-CHEM
N	I-CHEM
-	I-CHEM
Ceram	I-CHEM
(	O	O
Ivoclar	O
/	O
Vivadent	O
)	O	O
.	O	O

Each	O
restorative	B-CHEM
material	I-CHEM
was	O	O
used	O
with	O	O
its	O	O
respective	O	O
adhesive	B-CHEM
system	I-CHEM
.	O	O

The	O	O
restored	B-PROC
teeth	B-ANAT
were	O	O
stored	O
in	O	O
distilled	B-CHEM
water	I-CHEM
for	O	O
24	O	O
hours	O
at	O	O
37°C	O	O
and	O	O
were	O	O
then	O	O
thermocycled	O
(	O	O
5	O	O
-	O	O
55°C	O	O
,	O	O
1000×	O	O
)	O	O
.	O	O

Specimens	B-OBJC
were	O	O
subjected	O
to	O	O
a	O	O
compressive	O
load	O
until	O	O
fracture	B-DISO
at	O	O
a	O	O
crosshead	O
speed	O
of	O	O
0	O	O
.	O	O
5	O	O
mm	O	O
/	O	O
min	O	O
.	O	O

The	O	O
data	O
were	O	O
analyzed	B-PROC
using	O	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
followed	O
by	O
the	O	O
post	B-PROC
hoc	I-PROC
Tukey	I-PROC
honestly	O	O
significantly	O	O
different	O
test	B-PROC
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Sound	B-ANAT
premolar	I-ANAT
teeth	I-ANAT
(	O	O
group	O
I	O
negative	O
control	O
)	O	O
showed	O	O
significantly	O
higher	O
fracture	B-DISO
resistance	I-DISO
than	O	O
did	O	O
the	O	O
other	O
tested	O
groups	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

No	O
statistically	O
significant	O
differences	O
were	O	O
found	B-DISO
in	O	O
the	O	O
fracture	B-DISO
resistance	I-DISO
values	O
of	O	O
the	O	O
restored	B-PROC
groups	O
(	O	O
groups	O
III	O
,	O	O
IV	O
,	O	O
V	O
,	O	O
and	O	O
VI	O
)	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
lowest	O
values	O
were	O	O
obtained	O
in	O	O
the	O	O
positive	B-LIVB
control	I-LIVB
group	I-LIVB
(	O	O
group	O
II	O
)	O	O
;	O	O
these	O	O
values	O
were	O	O
significantly	O
lower	O
than	O	O
those	O	O
of	O	O
the	O	O
other	O
groups	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
fracture	B-DISO
resistance	I-DISO
values	O
of	O	O
endodontically	B-DISO
treated	I-DISO
teeth	I-DISO
restored	B-PROC
with	O	O
either	O	O
bulk	B-CHEM
fill	I-CHEM
/	O	O
bulk	B-CHEM
fill	I-CHEM
flowable	I-CHEM
or	O	O
fiber	B-CHEM
-	I-CHEM
reinforced	I-CHEM
composite	I-CHEM
were	O	O
not	O
different	O
from	O	O
those	O	O
restored	B-PROC
with	O	O
conventional	O
nanohybrid	B-CHEM
resin	I-CHEM
composite	I-CHEM
.	O	O

The	O	O
phonetic	O
landscape	O	O
in	O	O
infant	B-LIVB
consonant	O
perception	B-PHYS
is	O	O
an	O	O
uneven	B-GEOG
terrain	I-GEOG
Previous	O	O
research	B-PROC
revealing	O	O
universal	O	O
biases	O
in	O	O
infant	B-LIVB
vowel	O
perception	B-PHYS
forms	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
Natural	O
Referent	O
Vowel	O
(	O
NRV	O
)	O
framework	O
(	O	O
Polka	O	O
&	O	O
Bohn	O	O
,	O	O
2011	O	O
)	O	O
.	O	O

To	O	O
explore	O	O
the	O	O
feasibility	B-PROC
of	O	O
extending	O	O
this	O	O
framework	O
to	O	O
consonant	O
manner	O	O
perception	B-PHYS
,	O	O
we	O	O
investigated	O	O
perception	B-PHYS
of	O	O
the	O	O
stop	O
vs	O	O
.	O	O

fricative	O
consonant	O
contrast	O	O
/b	O	O
/	O	O
-	O	O
/	O	O
v	O	O
/	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O
that	O	O
young	O
infants	B-LIVB
will	O	O
display	O	O
a	O	O
perceptual	B-PHYS
bias	O
grounded	O	O
in	O	O
the	O	O
acoustic	B-PHEN
-	O	O
phonetic	O
properties	O	O
of	O	O
these	O	O
sounds	B-PHEN
.	O	O

We	O	O
examined	O	O
perception	B-PHYS
of	O	O
stop	O	O
-	O	O
initial	O	O
/bas	O	O
/	O	O
and	O	O
fricative	O	O
-	O	O
initial	O	O
/vas	O	O
/	O	O
syllables	O
in	O	O
English	O
-	O	O
learning	B-PHYS
and	O	O
French	O
-	O	O
learning	B-PHYS
5	O	O
-	O	O
to	O	O
6	O	O
-	O	O
month	O	O
-	O	O
olds	O	O
.	O	O

The	O	O
/b	O	O
/	O	O
and	O	O
/v	O	O
/	O	O
sounds	B-PHEN
distinguish	O	O
words	O
in	O	O
English	O
and	O	O
French	O
but	O	O
have	O	O
different	O	O
distributional	O	O
patterns	O	O
;	O	O
in	O	O
spoken	O
English	O
/b	O	O
/	O	O
occurs	O	O
more	O	O
frequently	O	O
than	O	O
/v	O	O
/	O	O
whereas	O	O
in	O	O
spoken	O
French	O
/v	O	O
/	O	O
occurs	O	O
more	O	O
frequently	O	O
than	O	O
/b	O	O
/	O	O
.	O	O

A	O	O
perceptual	B-PHYS
bias	O
favoring	O	O
/b	O	O
/	O	O
over	O	O
/v	O	O
/	O	O
emerged	O	O
in	O	O
two	O	O
experiments	B-PROC
.	O	O

In	O	O
Experiment	B-PROC
1	I-PROC
,	O	O
a	O	O
directional	O
asymmetry	O
was	O	O
observed	O	O
in	O	O
discrimination	B-PHYS
;	O	O
infants	B-LIVB
noticed	O	O
when	O	O
/vas	O	O
/	O	O
changed	O	O
to	O	O
/bas	O	O
/	O	O
but	O	O
not	O	O
when	O	O
/bas	O	O
/	O	O
changed	O	O
to	O	O
/vas	O	O
/	O	O
.	O	O

In	O	O
Experiment	B-PROC
2	I-PROC
,	O	O
a	O	O
robust	O	O
listening	B-PHYS
preference	O	O
favoring	O	O
stop	O	O
-	O	O
initial	O	O
/bas	O	O
/	O	O
was	O	O
evident	O	O
in	O	O
responses	B-PHYS
from	O	O
the	O	O
same	O	O
infants	B-LIVB
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	B-PROC
to	O	O
show	O	O
a	O	O
perceptual	B-PHYS
bias	O
related	O	O
to	O	O
consonant	O
manner	O	O
and	O	O
to	O	O
directly	O	O
measure	O	O
a	O	O
consonant	O
perception	B-PHYS
bias	O
within	O	O
the	O	O
same	O	O
infants	B-LIVB
.	O	O

These	O	O
data	O
encourage	O	O
further	O	O
efforts	O	O
to	O	O
extend	O	O
the	O	O
NRV	O
principles	O	O
to	O	O
perception	B-PHYS
of	O	O
consonant	O
manner	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
we	O	O
need	O	O
to	O	O
reform	O	O
our	O	O
view	O	O
of	O	O
infant	B-LIVB
speech	B-PHYS
perception	B-PHYS
to	O	O
accommodate	O	O
the	O	O
fact	O	O
that	O	O
both	O	O
discrimination	B-PHYS
abilities	O	O
and	O	O
biases	O
shape	O	O
speech	B-PHYS
perception	B-PHYS
during	O	O
infancy	O
.	O	O

Propensity	O
-	O	O
matched	B-PROC
Analysis	B-PROC
of	O	O
Outcomes	O
and	O	O
Hospital	O
Charges	O
for	O	O
Anterior	O
Versus	O	O
Posterior	O
Cervical	O
Fusion	O
for	O	O
Cervical	B-DISO
Spondylotic	I-DISO
Myelopathy	I-DISO
Retrospective	O
analysis	B-PROC
of	O	O
data	O
from	O	O
the	O	O
Nationwide	O
Inpatient	B-LIVB
Sample	B-OBJC
,	O	O
a	O	O
nationally	O	O
representative	O	O
,	O	O
all	O
-	O
payer	O
database	O
of	O	O
inpatient	B-LIVB
diagnoses	B-PROC
and	I-PROC
procedures	I-PROC
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
compare	O
anterior	O
cervical	O
fusion	O
(	O	O
ACF	O
)	O	O
to	O	O
posterior	O
cervical	O
fusion	O
(	O	O
PCF	O
)	O	O
in	O	O
the	O	O
treatment	B-PROC
of	O	O
cervical	B-DISO
spondylotic	I-DISO
myelopathy	I-DISO
(	O	O
CSM	B-DISO
)	O	O
.	O	O

Previous	O
studies	B-PROC
used	O
retrospective	O
single	O
-	O	O
institution	O
level	O
data	O
to	O	O
quantify	O
outcomes	O
for	O	O
CSM	B-DISO
patients	B-LIVB
fusion	B-PROC
.	O	O

It	O	O
is	O	O
unclear	B-DISO
whether	O	O
ACF	O
or	O	O
PCF	O
is	O	O
superior	O
with	O	O
regards	O	O
to	O	O
charges	O
or	O	O
outcomes	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
CSM	B-DISO
.	O	O

We	O	O
used	O	O
Nationwide	O
Inpatient	B-LIVB
Sample	B-OBJC
data	O
to	O	O
compare	O
ACF	O
to	O	O
PCF	O
in	O	O
the	O	O
management	B-PROC
of	O	O
CSM	B-DISO
.	O	O

All	O	O
patients	B-LIVB
18	B-PHYS
years	I-PHYS
or	I-PHYS
older	I-PHYS
with	O	O
a	O	O
diagnosis	B-PROC
of	O	O
CSM	B-DISO
between	O	O
1998	O	O
and	O	O
2011	O	O
were	O	O
included	O	O
.	O	O

ACF	O
patients	B-LIVB
were	O	O
matched	B-PROC
to	O	O
PCF	O
patients	B-LIVB
using	O	O
propensity	O
scores	O
based	O	O
on	O	O
patient	B-PHYS
characteristics	I-PHYS
(	O	O
number	O
of	O
levels	O
fused	O
,	O	O
spine	O	O
alignment	O	O
,	O	O
comorbidities	O
)	O	O
,	O	O
hospital	B-OBJC
characteristics	O
,	O	O
and	O	O
patient	B-PHYS
demographics	I-PHYS
.	O	O

Multivariable	O
regression	O
was	O	O
used	O
to	O	O
measure	O
the	O	O
effect	O
of	O	O
treatment	B-PROC
assignment	B-PROC
on	O	O
in	O	O
-	O	O
hospital	O
charges	O
,	O	O
length	O
of	O
hospital	O
stay	O
,	O	O
in	O
-	O
hospital	O
mortality	O
,	O	O
discharge	B-PHYS
disposition	I-PHYS
,	O	O
and	O	O
dysphagia	B-DISO
diagnosis	B-PROC
.	O	O

From	O	O
1998	O	O
to	O	O
2011	O	O
,	O	O
we	O	O
identified	O
109	O	O
,	O	O
728	O	O
hospitalizations	B-PROC
with	O	O
a	O	O
CSM	B-DISO
diagnosis	B-PROC
.	O	O

Of	O	O
these	O	O
patients	B-LIVB
,	O	O
45	O	O
,	O	O
629	O	O
(	O	O
41	O	O
.	O	O

6	O	O
%	O	O
)	O	O
underwent	O	O
ACF	O
and	O	O
14	O	O
,	O	O
439	O	O
(	O	O
13	O	O
.	O	O
2	O	O
%	O	O
)	O	O
underwent	O	O
PCF	O
.	O	O

The	O	O
PCF	O
cohort	B-LIVB
incurred	O	O
an	O	O
average	O
of	O	O
$	O	O
41	O	O
,	O	O
683	O	O
more	O
in	O
-	O
hospital	O
charges	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
inflation	O
adjusted	O
to	O	O
2011	O	O
dollars	O
)	O	O
and	O	O
remained	O	O
in	O	O
hospital	B-OBJC
an	O	O
average	O
of	O	O
2	O	O
.	O	O

4	O	O
days	O
longer	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
than	O	O
the	O	O
ACF	O
cohort	B-LIVB
.	O	O

The	O	O
ACF	O
cohort	B-LIVB
was	O	O
just	O	O
as	O	O
likely	O	O
to	O	O
die	B-PHYS
in	O	O
the	O	O
hospital	B-OBJC
[	O	O
odds	O
ratio	O
0	O	O
.	O	O
91	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
(	O	O
CI	O
)	O	O
,	O	O
0	O	O
.	O	O
68	O	O
-	O	O
1	O	O
.	O	O
2	O	O
]	O	O
,	O	O
3	O	O
.	O	O
0	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
discharged	B-PROC
to	I-PROC
home	I-PROC
or	O	O
self	B-OBJC
-	I-OBJC
care	I-OBJC
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
2	O	O
.	O	O
9	O	O
-	O	O
3	O	O
.	O	O
2	O	O
)	O	O
,	O	O
and	O	O
2	O	O
.	O	O

5	O	O
times	O	O
more	O	O
likely	O	O
to	O	O
experience	B-PHYS
dysphagia	B-DISO
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
2	O	O
.	O	O
0	O	O
-	O	O
3	O	O
.	O	O

1	O	O
)	O	O
than	O	O
the	O	O
PCF	O
cohort	B-LIVB
.	O	O

In	O	O
treating	O
CSM	B-DISO
,	O	O
ACF	O
led	O	O
to	O	O
lower	O
hospital	O
charges	O
,	O	O
shorter	O
hospital	O
stays	O
,	O	O
and	O	O
an	O	O
increased	O
likelihood	O
of	O	O
being	O	O
discharged	B-PROC
to	I-PROC
home	I-PROC
relative	O
to	O	O
PCF	O
.	O	O

Overcoming	O
structural	O
inequalities	O
in	O	O
oral	B-PROC
health	I-PROC
:	O	O
the	O	O
role	O	O
of	O	O
dental	B-PROC
curricula	O
To	O	O
date	O	O
the	O	O
role	O	O
of	O	O
health	B-OBJC
professional	I-OBJC
schools	I-OBJC
in	O	O
addressing	O	O
oral	B-PROC
health	I-PROC
inequalities	O
have	O	O
been	O	O
minimal	O	O
,	O	O
as	O	O
attempts	O
have	O	O
focused	O
principally	O	O
upon	O	O
systemic	O
reform	O
and	O	O
broader	O	O
societal	O
obligations	O
.	O	O

Professionalism	O
is	O	O
a	O	O
broad	O	O
competency	O
that	O	O
is	O	O
taught	O	O
throughout	O	O
dental	B-OBJC
schools	I-OBJC
and	O	O
encompasses	O	O
a	O	O
range	O
of	O	O
attributes	O	O
.	O	O

Professionalism	O
as	O	O
a	O	O
competency	O
draws	O	O
some	O	O
debate	O
and	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
shifting	O
phenomenon	O
.	O	O

We	O	O
may	O	O
ask	O	O
if	O	O
professionalism	O
in	O	O
the	O	O
dental	B-PROC
curricula	O
may	O	O
be	O	O
better	O	O
addressed	O	O
by	O	O
social	O
accountability	O
?	O	O

Social	O
accountability	O
directs	O	O
oral	B-PROC
health	I-PROC
professional	O
curricula	O
(	O	O
education	O
,	O	O
research	B-PROC
,	O	O
and	O	O
service	B-PROC
activities	I-PROC
)	O	O
towards	O	O
addressing	O	O
the	O	O
priority	O
health	O
concerns	O
of	O	O
the	O	O
community	B-LIVB
,	O	O
in	O	O
our	O	O
case	O	O
oral	B-PROC
health	I-PROC
inequalities	O
.	O	O

Although	O	O
working	O	O
toward	O	O
dental	B-OBJC
schools	I-OBJC
becoming	O	O
more	O	O
socially	O
accountable	O
seems	O	O
like	O	O
a	O	O
sensible	O	O
way	O	O
to	O	O
address	O
oral	B-PROC
health	I-PROC
inequalities	O
,	O	O
it	O	O
might	O	O
have	O	O
limitations	O	O
.	O	O

We	O	O
will	O	O
consider	O	O
some	O	O
of	O	O
the	O	O
challenges	O	O
in	O	O
the	O	O
dental	B-PROC
curricula	O
by	O	O
considering	O	O
some	O	O
of	O	O
the	O	O
political	B-PHEN
,	O	O
structural	O
,	O	O
social	O
and	O	O
ethical	O
factors	O
that	O	O
influence	O
our	O	O
institutions	O
and	O	O
our	O	O
graduates	B-LIVB
.	O	O

Readers	O	O
'	O	O
panel	O	O
-	O	O
Should	O	O
nurses	B-LIVB
be	O	O
prosecuted	B-DISO
if	O	O
they	O	O
fail	O
to	O	O
report	O
child	O
abuse	O
?	O	O

Our	O	O
experts	B-LIVB
consider	O	O
a	O	O
hot	O	O
topic	O
of	O	O
the	O	O
day	O	O
.	O	O

Function	O
analysis	B-PROC
of	O	O
Mef2c	O
promoter	B-CHEM
in	O	O
muscle	B-PHYS
differentiation	I-PHYS
Regeneration	B-PHYS
of	I-PHYS
adult	I-PHYS
skeletal	I-PHYS
muscle	I-PHYS
following	O	O
injury	B-DISO
occurs	O	O
through	O	O
the	O	O
activation	B-PHYS
of	O	O
satellite	B-ANAT
cells	I-ANAT
,	O	O
that	O	O
proliferates	B-PHYS
,	O	O
differentiates	B-PHYS
,	O	O
and	O	O
fuses	B-PHYS
with	O	O
injured	O
myofibers	B-ANAT
.	O	O

Myocyte	B-CHEM
enhancer	I-CHEM
factor	I-CHEM
2	I-CHEM
(	I-CHEM
MEF2	I-CHEM
)	I-CHEM
proteins	I-CHEM
are	O	O
reported	O	O
that	O	O
they	O	O
have	O	O
the	O	O
potential	O	O
contributions	O	O
to	O	O
adult	B-LIVB
muscle	B-DISO
regeneration	I-DISO
.	O	O

In	O	O
order	O	O
to	O	O
further	O	O
understand	O	O
Mef2c	O
gene	O
,	O	O
the	O	O
promoter	B-CHEM
of	O	O
pig	B-LIVB
Mef2c	O
gene	O
was	O	O
analyzed	O	O
in	O	O
this	O	O
paper	O	O
.	O	O

Quantitative	B-PROC
real	I-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
(	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
)	O	O
revealed	O	O
the	O	O
expression	B-PHYS
pattern	O	O
of	O	O
Mef2c	O
gene	O
in	O	O
muscle	O
of	O	O
eight	O	O
tissues	O
.	O	O

The	O	O
Mef2c	O
promoter	B-CHEM
had	O	O
the	O	O
higher	O	O
transcriptional	B-PHYS
activity	I-PHYS
in	O	O
differentiated	B-PHYS
C2C12	B-ANAT
cells	I-ANAT
than	O	O
that	O	O
in	O	O
proliferating	B-PHYS
C2C12	B-ANAT
cells	I-ANAT
,	O	O
which	O	O
was	O	O
accompanied	O	O
by	O	O
the	O	O
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
mRNA	B-PHYS
expression	I-PHYS
of	O	O
Mef2c	O
gene	O
.	O	O

Function	O
deletion	B-PHYS
and	O	O
mutation	B-PHYS
analyses	B-PROC
showed	O	O
that	O	O
MyoD	B-CHEM
and	O	O
MEF2	B-CHEM
binding	O
sites	O
within	O	O
the	O	O
Mef2c	O
promoter	B-CHEM
were	O	O
responsible	O	O
for	O	O
the	O	O
regulation	B-PHYS
of	O	O
Mef2c	O
transcription	B-PHYS
.	O	O

MEF2C	O
could	O	O
up	B-PHYS
-	I-PHYS
regulate	I-PHYS
the	I-PHYS
transcriptional	I-PHYS
activities	I-PHYS
of	O	O
Mef2c	O
promoter	B-CHEM
constructs	I-CHEM
which	O	O
contained	O	O
a	O	O
3	O
'	O
-	O
end	O
nucleotide	O
sequence	O
with	O	O
p300	B-CHEM
binding	O
site	O
.	O	O

The	O	O
Electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
(	O	O
EMSA	B-PROC
)	O	O
and	O	O
chromatin	B-PROC
immunoprecipitation	I-PROC
(	I-PROC
ChIP	I-PROC
)	I-PROC
assays	I-PROC
determined	O	O
the	O	O
MyoD	B-CHEM
binding	O
site	O
in	O	O
Mef2c	O
promoter	B-CHEM
.	O	O

These	O	O
results	O	O
advanced	O	O
our	O	O
knowledge	O	O
of	O	O
the	O	O
promoter	B-CHEM
of	O	O
the	O	O
pig	B-LIVB
Mef2c	O
gene	O
.	O	O

And	O	O
the	O	O
study	O	O
of	O	O
Mef2c	O
promoter	B-CHEM
regulator	O	O
elements	O	O
helped	O	O
to	O	O
elucidating	O	O
the	O	O
regulation	B-PHYS
mechanisms	I-PHYS
of	O	O
Mef2c	O
in	O	O
muscle	B-PHYS
differentiation	I-PHYS
or	O	O
muscle	B-PROC
repair	I-PROC
and	O	O
regeneration	B-DISO
.	O	O

This	O	O
article	O	O
is	O	O
protected	O	O
by	O	O
copyright	O	O
.	O	O

All	O	O
rights	O	O
reserved	O	O
.	O	O

TLR9	O
Deficiency	O
Leads	O	O
to	O	O
Accelerated	O
Renal	B-DISO
Disease	I-DISO
and	O	O
Myeloid	B-ANAT
Lineage	I-ANAT
Abnormalities	B-DISO
in	O	O
Pristane	B-CHEM
-Induced	O	O
Murine	B-LIVB
Lupus	B-DISO
Systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O	O
SLE	B-DISO
)	I-DISO
is	O	O
a	O	O
chronic	O
,	O	O
life	B-DISO
-	I-DISO
threatening	I-DISO
autoimmune	B-DISO
disorder	I-DISO
,	O	O
leading	O	O
to	O	O
multiple	O	O
organ	B-ANAT
pathologies	O
and	O	O
kidney	B-ANAT
destruction	O
.	O	O

Analyses	O	O
of	O	O
numerous	O	O
murine	B-LIVB
models	B-DISO
of	O	O
spontaneous	O	O
SLE	B-DISO
have	O	O
revealed	O	O
a	O	O
critical	O	O
role	O	O
for	O	O
endosomal	B-ANAT
TLRs	B-CHEM
in	O	O
the	O	O
production	O	O
of	O	O
autoantibodies	B-CHEM
and	O	O
development	O	O
of	O	O
other	O	O
clinical	O
disease	B-DISO
manifestations	O
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
corresponding	O	O
TLR9	O
-	O	O
deficient	O
autoimmune	B-DISO
-prone	O	O
strains	B-LIVB
consistently	O	O
develop	O	O
more	O	O
severe	O	O
disease	B-DISO
pathology	O
.	O	O

Injection	B-PROC
of	O	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
with	O	O
2	B-CHEM
,	I-CHEM
6	I-CHEM
,	I-CHEM
10	I-CHEM
,	I-CHEM
14	I-CHEM
-	I-CHEM
tetramethylpentadecane	I-CHEM
(	O	O
TMPD	B-CHEM
)	O	O
,	O	O
commonly	O	O
known	O	O
as	O	O
pristane	B-CHEM
,	O	O
also	O	O
results	O	O
in	O	O
the	O	O
development	O	O
of	O	O
SLE	B-DISO
-	I-DISO
like	I-DISO
disease	I-DISO
.	O	O

We	O	O
now	O	O
show	O	O
that	O	O
Tlr9	O
(	O
-	O
/	O
-	O
)	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
injected	B-PROC
i	I-PROC
.	I-PROC

p	I-PROC
.	I-PROC

with	O	O
TMPD	B-CHEM
develop	O	O
more	O	O
severe	O	O
autoimmunity	B-DISO
than	O	O
do	O	O
their	O	O
TLR	B-CHEM
-sufficient	O	O
cohorts	O	O
.	O	O

Early	O	O
indications	O	O
include	O	O
an	O	O
increased	O	O
accumulation	B-DISO
of	O	O
TLR7	O
-	O	O
expressing	B-PHYS
Ly6C	B-CHEM
(	I-CHEM
hi	I-CHEM
)	I-CHEM
inflammatory	O
monocytes	B-ANAT
at	O	O
the	O	O
site	O
of	O
injection	O
,	O	O
upregulation	B-PHYS
of	O	O
IFN	B-CHEM
-regulated	O	O
gene	B-PHYS
expression	I-PHYS
in	O	O
the	O	O
peritoneal	B-ANAT
cavity	I-ANAT
,	O	O
and	O	O
an	O	O
increased	O	O
production	O	O
of	O	O
myeloid	B-ANAT
lineage	I-ANAT
precursors	I-ANAT
(	O	O
common	B-ANAT
myeloid	I-ANAT
progenitors	I-ANAT
and	O	O
granulocyte	B-ANAT
myeloid	B-ANAT
precursors	I-ANAT
)	O	O
in	O	O
the	O	O
bone	O
marrow	O
.	O	O

TMPD	B-CHEM
-	O	O
injected	B-PROC
Tlr9	O
(	O
-	O
/	O
-	O
)	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
develop	O	O
higher	O	O
autoantibody	B-CHEM
titers	O	O
against	O	O
RNA	B-CHEM
,	O	O
neutrophil	B-ANAT
cytoplasmic	B-ANAT
Ags	B-CHEM
,	O	O
and	O	O
myeloperoxidase	B-CHEM
than	O	O
do	O	O
TMPD	B-CHEM
-	O	O
injected	B-PROC
wild	B-LIVB
-	I-LIVB
type	I-LIVB
BALB	I-LIVB
/	I-LIVB
c	I-LIVB
mice	I-LIVB
.	O	O

The	O	O
TMP	B-CHEM
-	O	O
injected	B-PROC
Tlr9	O
(	O
-	O
/	O
-	O
)	O
mice	B-LIVB
,	O	O
and	O	O
not	O	O
the	O	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
mice	I-LIVB
,	O	O
also	O	O
develop	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
glomerular	B-CHEM
IgG	I-CHEM
deposition	O
and	O	O
infiltrating	O	O
granulocytes	B-ANAT
,	O	O
much	O	O
more	O	O
severe	O	O
glomerulonephritis	B-DISO
,	O	O
and	O	O
a	O	O
reduced	O
lifespan	O
.	O	O

Collectively	O	O
,	O	O
the	O	O
data	O	O
point	O	O
to	O	O
a	O	O
major	O	O
role	O	O
for	O	O
TLR7	O
in	O	O
the	O	O
response	B-PHYS
to	O	O
self	B-CHEM
-	I-CHEM
antigens	I-CHEM
in	O	O
this	O	O
model	B-DISO
of	O	O
experimental	O	O
autoimmunity	B-DISO
.	O	O

Therefore	O	O
,	O	O
the	O	O
BALB	B-LIVB
/	I-LIVB
c	I-LIVB
pristane	B-CHEM
model	B-DISO
recapitulates	O	O
other	O	O
TLR7	O
-driven	O	O
spontaneous	O	O
models	B-DISO
of	O	O
SLE	B-DISO
and	O	O
is	O	O
negatively	B-DISO
regulated	O	O
by	O	O
TLR9	O
.	O	O

Novel	O	O
insights	O	O
into	O	O
development	O	O
of	O	O
diabetic	B-DISO
bladder	B-DISO
disorder	I-DISO
provided	O	O
by	O	O
metabolomic	O
analysis	O
of	O	O
the	O	O
rat	B-LIVB
nondiabetic	O	O
and	O	O
diabetic	B-DISO
detrusor	B-ANAT
and	O	O
urothelial	O
layer	O
There	O	O
are	O	O
at	O	O
present	O	O
no	O	O
published	O	O
studies	O	O
providing	O	O
a	O	O
global	O	O
overview	O	O
of	O	O
changes	O
in	O	O
bladder	B-ANAT
metabolism	B-PHYS
resulting	O	O
from	O	O
diabetes	B-DISO
.	O	O

Such	O	O
studies	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
provide	O	O
mechanistic	O	O
insight	O	O
into	O	O
the	O	O
development	O	O
of	O	O
diabetic	B-DISO
bladder	B-DISO
disorder	I-DISO
(	I-DISO
DBD	I-DISO
)	I-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
compared	O	O
the	O	O
metabolome	B-PHEN
of	O	O
detrusor	B-ANAT
and	O	O
urothelial	O
layer	O
in	O	O
a	O	O
1	O	O
-	O	O
mo	O	O
streptozotocin	B-CHEM
-induced	O	O
rat	B-LIVB
model	B-DISO
of	O	O
type	B-DISO
1	I-DISO
diabetes	I-DISO
with	O	O
nondiabetic	B-LIVB
controls	I-LIVB
.	O	O

Our	O	O
studies	O	O
revealed	O	O
that	O	O
diabetes	B-DISO
caused	O	O
both	O	O
common	O	O
and	O	O
differential	O	O
changes	O
in	O	O
the	O	O
detrusor	B-ANAT
and	O	O
urothelial	O
layer	O
's	O
metabolome	B-PHEN
.	O	O

Diabetes	B-DISO
resulted	O	O
in	O	O
similar	O	O
changes	O
in	O	O
the	O	O
levels	O	O
of	O	O
previously	O	O
described	O	O
diabetic	B-DISO
markers	B-PHYS
in	O	O
both	O	O
tissues	O
,	O	O
such	O	O
as	O	O
glucose	B-CHEM
,	O	O
lactate	B-CHEM
,	O	O
2	B-CHEM
-	I-CHEM
hydroxybutyrate	I-CHEM
,	O	O
branched	B-CHEM
-	I-CHEM
chain	I-CHEM
amino	I-CHEM
acid	I-CHEM
degradation	I-CHEM
products	I-CHEM
,	O	O
bile	B-CHEM
acids	I-CHEM
,	O	O
and	O	O
1	B-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
anhydroglucitol	I-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
markers	B-PHYS
of	O	O
oxidative	B-DISO
stress	I-DISO
.	O	O

In	O	O
the	O	O
detrusor	B-ANAT
(	O	O
but	O	O
not	O	O
the	O	O
urothelial	O
layer	O
)	O	O
,	O	O
diabetes	B-DISO
caused	O	O
activation	O	O
of	O	O
the	O	O
pentose	B-CHEM
-	I-CHEM
phosphate	I-CHEM
and	O	O
polyol	B-CHEM
pathways	B-PHYS
,	O	O
concomitant	O	O
with	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
TCA	B-PHYS
cycle	I-PHYS
and	O	O
β	B-PHYS
-	I-PHYS
oxidation	I-PHYS
.	O	O

Changes	O
in	O	O
detrusor	B-ANAT
energy	B-PHYS
-	I-PHYS
generating	I-PHYS
pathways	I-PHYS
resulted	O	O
in	O	O
an	O	O
accumulation	O	O
of	O	O
sorbitol	B-CHEM
that	O	O
,	O	O
through	O	O
generation	O	O
of	O	O
advanced	B-CHEM
glycation	I-CHEM
end	I-CHEM
products	I-CHEM
,	O	O
is	O	O
likely	O	O
to	O	O
play	O	O
a	O	O
central	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
DBD	B-DISO
.	O	O

In	O	O
the	O	O
diabetic	B-DISO
urothelial	O
layer	O
there	O	O
was	O	O
decreased	O	O
flux	B-PHEN
of	O	O
glucose	B-CHEM
via	O	O
glycolysis	B-PHYS
and	O	O
changes	O
in	O	O
lipid	B-PHYS
metabolism	I-PHYS
,	O	O
particularly	O	O
prostaglandin	B-CHEM
synthesis	O
,	O	O
which	O	O
also	O	O
potentially	O	O
contributes	O	O
to	O	O
detrusor	B-ANAT
dysfunction	B-DISO
.	O	O

Development	O
of	O	O
an	O	O
Evaluation	B-PROC
Device	B-OBJC
for	O	O
Phagocytic	B-ANAT
Activity	O
of	O	O
New	O	O
Phagocytes	B-ANAT
Using	O	O
Simple	O	O
and	O	O
pH	B-CHEM
-	I-CHEM
sensitive	I-CHEM
Particles	I-CHEM
that	O	O
Do	O	O
Not	O	O
Require	O	O
Pre	O
-	O
treatment	O
Phagocytic	B-ANAT
activity	O
is	O	O
affected	O	O
by	O	O
a	O	O
number	O	O
of	O	O
different	O	O
stress	B-DISO
and	O	O
age	B-PHYS
-dependent	O	O
factors	O	O
.	O	O

An	O	O
easy	O	O
measurement	O
of	O	O
phagocytic	B-ANAT
activity	O
is	O	O
thought	O	O
to	O	O
allow	O	O
an	O	O
indicator	O	O
of	O	O
an	O	O
individual	B-LIVB
'	O	O
s	O	O
health	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O	O
conditions	O	O
of	O	O
measurement	O
to	O	O
easily	O	O
evaluate	O	O
the	O	O
activity	O
of	O	O
phagocytosis	B-PHYS
of	O	O
phagocytic	B-ANAT
cells	I-ANAT
(	O	O
macrophages	B-ANAT
and	O	O
neutrophils	B-ANAT
)	O	O
using	O	O
an	O	O
easy	O	O
-	O	O
to	O	O
-	O	O
use	O	O
prototype	O	O
,	O	O
which	O	O
was	O	O
improved	O	O
from	O	O
the	O	O
device	B-OBJC
by	O	O
Hamamatsu	O
Photonics	O
K	O
.	O

K	O
.	O
,	O	O
to	O	O
detect	O	O
neutrophil	B-ANAT
activity	O
using	O	O
subtle	O	O
fluorescence	B-PHEN
.	O	O

pH	B-CHEM
-	I-CHEM
sensitive	I-CHEM
fluorescent	I-CHEM
particles	I-CHEM
(	O	O
pHrodo	B-CHEM
-	I-CHEM
Green	I-CHEM
E	I-CHEM
.	I-CHEM

coli	I-CHEM
Bio	I-CHEM
particles	I-CHEM
,	O	O
GE	B-CHEM
particles	I-CHEM
)	O	O
were	O	O
added	O	O
to	O	O
mouse	B-LIVB
-derived	O	O
macrophage	B-ANAT
cell	I-ANAT
lines	I-ANAT
(	O	O
J774	B-ANAT
.	I-ANAT

1	I-ANAT
)	O	O
and	O	O
then	O	O
incubated	B-PROC
for	O	O
2	O	O
h	O	O
at	O	O
37°C	O	O
.	O	O

For	O	O
negative	O
control	O
,	O	O
the	O	O
phagocytosis	B-PHYS
inhibitor	O
cytochalasin	B-CHEM
D	I-CHEM
(	O	O
CyD	B-CHEM
)	O	O
,	O	O
was	O	O
added	O	O
prior	O	O
to	O	O
culture	B-PROC
.	O	O

Next	O	O
,	O	O
fluorescence	B-PHEN
intensity	O
was	O	O
measured	O	O
by	O	O
the	O	O
Prototype	O	O
to	O	O
evaluate	O	O
the	O	O
phagocytic	B-ANAT
activity	O
of	O	O
macrophages	B-ANAT
and	O	O
neutrophils	B-ANAT
.	O	O

Phagocytosis	B-PHYS
was	O	O
also	O	O
confirmed	O	O
by	O	O
flow	B-PROC
cytometry	I-PROC
.	O	O

The	O	O
Prototype	O	O
detected	O	O
a	O	O
steady	O	O
fluorescence	B-PHEN
increase	O	O
in	O	O
5	O	O
sec	O	O
in	O	O
J774	B-ANAT
.	I-ANAT

1	I-ANAT
after	O	O
phagocytosis	B-PHYS
,	O	O
using	O	O
GE	B-CHEM
particles	I-CHEM
as	O	O
a	O	O
negative	O
control	O
in	O	O
the	O	O
presence	O	O
of	O	O
CyD	B-CHEM
.	O	O

Furthermore	O	O
,	O	O
detection	B-PROC
was	O	O
possible	O	O
at	O	O
10	O	O
(	O	O
4	O	O
)	O	O
cells	O	O
/	O	O
test	O	O
,	O	O
a	O	O
concentration	O	O
where	O	O
the	O	O
flow	B-DEVI
cytometer	I-DEVI
had	O	O
difficulty	O	O
for	O	O
detection	B-PROC
.	O	O

The	O	O
Prototype	O	O
enables	O	O
measurement	O
of	O	O
the	O	O
phagocytic	B-ANAT
activity	O
within	O	O
a	O	O
short	O	O
period	O	O
of	O	O
time	O
,	O	O
even	O	O
with	O	O
a	O	O
small	O	O
sample	O
amount	O
,	O	O
thus	O	O
establishing	O	O
the	O	O
basic	O	O
conditions	O	O
of	O	O
measurements	O
of	O	O
phagocytosis	B-PHYS
.	O	O

Effect	O
of	O	O
Xenotransplantation	B-PROC
Site	O
on	O	O
MicroRNA	B-CHEM
Expression	B-PHYS
of	O	O
Human	B-LIVB
Colon	B-DISO
Cancer	I-DISO
Stem	B-ANAT
Cells	I-ANAT
Cancer	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	O	O
CSCs	B-ANAT
)	O	O
have	O	O
a	O	O
high	O
tumorigenic	B-DISO
ability	B-PHYS
to	O	O
form	O	O
patient	B-DISO
-	I-DISO
derived	I-DISO
tumor	I-DISO
xenografts	I-DISO
(	O	O
PDXs	B-DISO
)	O	O
.	O	O

PDXs	B-DISO
are	O	O
an	O	O
attractive	O
pre	O
-	O
clinical	O
model	O
,	O	O
but	O	O
gene	B-PHYS
expression	I-PHYS
and	O	O
biological	B-PHEN
behavior	I-PHEN
of	O	O
cancer	B-ANAT
cells	I-ANAT
in	O	O
the	O	O
tumor	B-DISO
will	O	O
change	O
during	O	O
establishment	O
and	O	O
passage	O	O
of	O	O
PDXs	B-DISO
.	O	O

Human	B-LIVB
colon	B-DISO
cancer	I-DISO
PDX	B-DISO
was	O	O
established	O
and	O	O
passaged	B-PROC
either	O	O
subcutaneously	O
or	O	O
orthotopically	O
into	O	O
the	O	O
murine	B-LIVB
intestine	B-ANAT
.	O	O

Histology	O
and	O	O
flow	B-PROC
cytometric	I-PROC
profile	B-PROC
of	O	O
the	O	O
surgical	B-PROC
specimen	O
and	O	O
the	O	O
PDX	B-DISO
were	O	O
analyzed	B-PROC
.	O	O

CSCs	B-ANAT
were	O	O
then	O	O
isolated	O
from	O	O
the	O	O
tumors	B-DISO
and	O	O
their	O	O
microRNA	B-CHEM
(	O	O
miRNA	B-CHEM
)	O	O
expression	B-PHYS
was	O	O
analyzed	B-PROC
by	O	O
semi	B-PROC
-	I-PROC
quantitative	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
.	O	O

The	O	O
surgical	B-PROC
specimens	O
and	O	O
PDXs	B-DISO
were	O	O
histologically	O
similar	O
.	O	O

The	O	O
size	O
of	O	O
CSC	B-ANAT
population	B-LIVB
increased	O
and	O	O
expression	B-PHYS
of	O	O
miRNA	B-CHEM
s	O	O
in	O	O
CSCs	B-ANAT
changed	O
in	O	O
the	O	O
passaged	B-PROC
PDXs	B-DISO
.	O	O

Expression	B-PHYS
of	O	O
oncogenic	B-CHEM
miRNAs	B-CHEM
was	O	O
highly	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
in	O	O
the	O	O
CSCs	B-ANAT
of	O	O
the	O	O
orthotopically	O
passaged	B-PROC
PDXs	B-DISO
.	O	O

The	O	O
xenotransplantation	B-PROC
site	O
and	O	O
the	O	O
number	O
of	O	O
tumor	B-DISO
passages	B-PROC
affect	B-PHYS
the	O	O
miRNA	B-CHEM
expression	B-PHYS
of	O	O
human	B-LIVB
colon	B-ANAT
CSCs	B-ANAT
.	O	O

Survival	B-PROC
of	O	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
in	O	O
Denmark	B-GEOG
:	O	O
Results	O	O
from	O	O
the	O	O
Danish	B-LIVB
gynaecological	I-LIVB
cancer	I-LIVB
group	I-LIVB
(	O
DGCG	O
)	O
database	O
,	O	O
1995	O	O
-	O	O
2012	O	O
Ovarian	B-DISO
cancer	I-DISO
has	O	O
a	O	O
high	O
mortality	O
rate	O
,	O	O
especially	O	O
in	O	O
Denmark	B-GEOG
where	O	O
mortality	O
rates	O
have	O	O
been	O	O
reported	O	O
higher	O	O
than	O	O
in	O	O
adjacent	B-GEOG
countries	I-GEOG
with	O	O
similar	O
demographics	O
.	O	O

This	O	O
study	O	O
therefore	O	O
examined	O	O
recent	O	O
survival	O
and	O	O
mortality	O
among	O	O
Danish	B-DISO
ovarian	I-DISO
cancer	I-DISO
patients	B-LIVB
over	O	O
an	O	O
18	O	O
-	O	O
year	O	O
study	O	O
period	O	O
.	O	O

This	O	O
nationwide	O
registry	O
-	O
based	O
observational	B-PROC
study	I-PROC
used	O	O
data	O	O
from	O	O
the	O	O
Danish	O
Gynecology	O
Cancer	O
Database	O
,	O	O
Danish	O
Pathology	O
Registry	O
,	O	O
and	O	O
Danish	B-PROC
National	I-PROC
Patient	I-PROC
Registry	I-PROC
.	O	O

All	O	O
patients	B-LIVB
with	O	O
ovarian	B-DISO
cancer	I-DISO
diagnosed	B-PROC
between	O	O
1995	O	O
and	O	O
2012	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

The	O	O
data	O
sources	O
were	O	O
linked	O	O
via	O	O
the	O	O
patients	B-LIVB
'	O	O
personal	O
identification	O
number	O
and	O	O
the	O	O
analyses	O
included	O
data	O
on	O	O
cancer	B-PROC
stage	I-PROC
,	O	O
age	B-PHYS
,	O	O
survival	B-PROC
,	O	O
surgery	B-DISO
status	I-DISO
and	O	O
comorbidity	O
.	O	O

The	O	O
computed	O	O
outcome	O
measures	O
were	O	O
age	O
-	O
adjusted	O
mortality	O
rates	O
and	O	O
age	O	O
-	O	O
adjusted	O	O
overall	O
and	O	O
relative	O
survival	O
rates	O
for	O	O
one	O
and	O
five	O
years	O
.	O	O

We	O	O
identified	O	O
9972	O	O
patients	B-LIVB
diagnosed	I-LIVB
with	O	O
ovarian	B-DISO
cancer	I-DISO
in	O	O
the	O	O
period	O	O
1995	O	O
-	O	O
2012	O	O
.	O	O

The	O	O
absolute	O	O
one	O
-	O
year	O
mortality	O
rate	O
decreased	O
from	O	O
42	O	O
.	O	O

8	O	O
(	O	O
CI	O
40	O	O
.	O	O
3	O	O
-	O	O
45	O	O
.	O	O
6	O	O
)	O	O
in	O	O
1995	O	O
-	O	O
1999	O	O
to	O	O
28	O	O
.	O	O
3	O	O
(	O	O
CI	O
25	O	O
.	O	O
9	O	O
-	O	O
30	O	O
.	O	O
9	O	O
)	O	O
in	O	O
2010	O	O
-	O	O
2012	O	O
,	O	O
and	O	O
the	O	O
five	O
-	O
year	O
mortality	O
rate	O
decreased	O
from	O	O
28	O	O
.	O	O
2	O	O
(	O	O
CI	O
27	O	O
.	O	O
0	O	O
-	O	O
29	O	O
.	O	O
5	O	O
)	O	O
in	O	O
1995	O	O
-	O	O
1999	O	O
to	O	O
23	O	O
.	O	O
9	O	O
(	O	O
CI	O
22	O	O
.	O	O
9	O	O
-	O	O
25	O	O
.	O	O
0	O	O
)	O	O
in	O	O
2005	O	O
-	O	O
2009	O	O
.	O	O

After	O	O
stratification	B-PROC
by	I-PROC
age	I-PROC
,	O	O
comorbidity	O
and	O	O
cancer	B-PROC
stage	I-PROC
,	O	O
the	O	O
decrease	O
in	O
one	O
-	O
year	O
mortality	O
was	O	O
most	O	O
substantial	O	O
in	O	O
the	O	O
65	O	O
-	O	O
74	O	O
year	O	O
old	B-LIVB
age	I-LIVB
group	I-LIVB
41	O	O
.	O	O

1	O	O
(	O	O
CI	O
38	O	O
.	O	O
8	O	O
-	O	O
43	O	O
.	O	O
5	O	O
)	O	O
to	O	O
26	O	O
.	O	O
5	O	O
(	O	O
CI	O
24	O	O
.	O	O
4	O	O
-	O	O
28	O	O
.	O	O
7	O	O
)	O	O
and	O	O
for	O	O
stage	B-DISO
III	I-DISO
39	O	O
.	O	O
1	O	O
(	O	O
CI	O
35	O	O
.	O	O
1	O	O
-	O	O
43	O	O
.	O	O
6	O	O
)	O	O
to	O	O
22	O	O
.	O	O
9	O	O
(	O	O
CI	O
19	O	O
.	O	O
9	O	O
-	O	O
26	O	O
.	O	O
5	O	O
)	O	O
and	O	O
stage	B-DISO
IV	I-DISO
91	O	O
.	O	O
3	O	O
(	O	O
CI	O
80	O	O
.	O	O
8	O	O
-	O	O
103	O	O
.	O	O
2	O	O
)	O	O
to	O	O
41	O	O
.	O	O
9	O	O
(	O	O
CI	O
35	O	O
.	O	O
5	O	O
-	O	O
49	O	O
.	O	O
5	O	O
)	O	O
.	O	O

For	O	O
overall	O
survival	O
,	O	O
we	O	O
showed	O	O
an	O	O
increase	O
in	O	O
one	O
-	O
year	O
survival	O
from	O	O
68	O	O
%	O	O
(	O	O
CI	O
66	O	O
-	O	O
69	O	O
%	O	O
)	O	O
in	O	O
1995	O	O
-	O	O
1999	O	O
to	O	O
76	O	O
%	O	O
(	O	O
CI	O
74	O	O
-	O	O
78	O	O
%	O	O
)	O	O
in	O	O
2010	O	O
-	O	O
2012	O	O
and	O	O
an	O	O
increase	O
in	O	O
five	O
-	O
year	O
survival	O
from	O	O
33	O	O
%	O	O
(	O	O
CI	O
32	O	O
-	O	O
35	O	O
%	O	O
)	O	O
in	O	O
1995	O	O
-	O	O
1999	O	O
to	O	O
36	O	O
%	O	O
(	O	O
CI	O
34	O	O
-	O	O
38	O	O
%	O	O
)	O	O
in	O	O
2005	O	O
-	O	O
2009	O	O
.	O	O

Relative	O
survival	O
showed	O	O
similar	O	O
increases	O
through	O	O
the	O	O
period	O	O
.	O	O

Ovarian	B-DISO
cancer	I-DISO
survival	O
in	O	O
Denmark	B-GEOG
has	O	O
improved	O	O
substantially	O	O
from	O	O
1995	O	O
to	O	O
2012	O	O
,	O	O
bringing	O	O
Denmark	B-GEOG
closer	O	O
to	O	O
the	O	O
standards	O	O
set	O	O
by	O	O
adjacent	B-GEOG
countries	I-GEOG
.	O	O

Proximal	B-PROC
Soil	I-PROC
Sensing	I-PROC
-	O	O
A	O	O
Contribution	O
for	O	O
Species	O
Habitat	O
Distribution	O
Modelling	B-PROC
of	O	O
Earthworms	O
in	O	O
Agricultural	O
Soils	B-OBJC
?	O	O

Earthworms	O
are	O	O
important	O	O
for	O	O
maintaining	O	O
soil	B-OBJC
ecosystem	B-PHEN
functioning	O
and	O	O
serve	O	O
as	O	O
indicators	B-CHEM
of	O	O
soil	B-OBJC
fertility	O
.	O	O

However	O	O
,	O	O
detection	O	O
of	O	O
earthworms	O
is	O	O
time	O
-	O
consuming	O
,	O	O
which	O	O
hinders	O	O
the	O	O
assessment	O
of	O	O
earthworm	O
abundances	O
with	O	O
high	O	O
sampling	O
density	O
over	O	O
entire	O	O
fields	O
.	O	O

Recent	O	O
developments	O	O
of	O	O
mobile	B-OBJC
terrestrial	I-OBJC
sensor	I-OBJC
platforms	I-OBJC
for	O	O
proximal	B-PROC
soil	I-PROC
sensing	I-PROC
(	O	O
PSS	B-PROC
)	O	O
provided	O	O
new	O	O
tools	B-OBJC
for	O	O
collecting	O	O
dense	O	O
spatial	O	O
information	O
of	O	O
soils	B-OBJC
using	O	O
various	O	O
sensing	O
principles	O
.	O	O

Yet	O	O
,	O	O
the	O	O
potential	O	O
of	O	O
PSS	B-PROC
for	O	O
assessing	O
earthworm	O
habitats	O
is	O	O
largely	O	O
unexplored	O	O
.	O	O

This	O	O
study	B-PROC
investigates	O
whether	O	O
PSS	B-PROC
data	O
contribute	O	O
to	O	O
the	O	O
spatial	O	O
prediction	O
of	O	O
earthworm	O
abundances	O
in	O	O
species	O
distribution	O
models	O
of	O	O
agricultural	O
soils	B-OBJC
.	O	O

Proximal	B-PROC
soil	I-PROC
sensing	I-PROC
data	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O
,	O	O
soil	B-OBJC
electrical	O
conductivity	O
(	O	O
EC	O
)	O	O
,	O	O
pH	O
,	O	O
and	O	O
near	B-PROC
infrared	I-PROC
absorbance	I-PROC
(	O	O
NIR	B-PROC
)	O	O
,	O	O
were	O	O
collected	O
in	O	O
real	O
-	O
time	O
in	O	O
a	O	O
field	O
with	O	O
two	O	O
management	O
strategies	O
(	O	O
reduced	O
tillage	B-PHEN
/	O	O
conventional	O	O
tillage	B-PHEN
)	O	O
and	O	O
sandy	B-OBJC
to	O	O
loam	B-OBJC
soils	I-OBJC
.	O	O

PSS	B-PROC
was	O	O
related	O	O
to	O	O
observations	B-PROC
from	O	O
a	O	O
long	O
-	O
term	O
(	O	O
11	O	O
years	O
)	O	O
earthworm	O
observation	B-DISO
study	I-DISO
conducted	O	O
at	O	O
42	O	O
plots	O
.	O	O

Earthworms	O
were	O	O
sampled	O
from	O	O
0	O	O
.	O	O

5	O	O
x	O	O
0	O	O
.	O	O
5	O	O
x	O	O
0	O	O
.	O	O

2	O	O
m³	O	O
soil	B-OBJC
blocks	O	O
and	O	O
identified	O
to	O	O
species	O
level	O
.	O	O

Sensor	B-DEVI
data	O
were	O	O
highly	O	O
correlated	O	O
with	O	O
earthworm	O
abundances	O
observed	O
in	O	O
reduced	O
tillage	B-PHEN
but	O	O
less	O	O
correlated	O
with	O	O
earthworm	O
abundances	O
observed	O
in	O	O
conventional	B-PHEN
tillage	I-PHEN
.	O	O

This	O	O
may	O	O
indicate	O	O
that	O	O
management	O
influences	O
the	O	O
sensor	B-DEVI
-	O	O
earthworm	O
relationship	O	O
.	O	O

Generalized	O	O
additive	O	O
models	O
and	O	O
state	O
-	O
space	O
models	O
showed	O	O
that	O	O
modelling	B-PROC
based	O	O
on	O	O
data	O
fusion	O	O
from	O	O
EC	O
,	O	O
pH	O
,	O	O
and	O	O
NIR	B-PROC
sensors	B-DEVI
produced	O	O
better	O	O
results	B-DISO
than	O	O
modelling	B-PROC
without	O	O
sensor	B-DEVI
data	O
or	O	O
data	O
from	O	O
just	O	O
a	O	O
single	O	O
sensor	B-DEVI
.	O	O

Regarding	O	O
the	O	O
individual	O	O
earthworm	O
species	O
,	O	O
particular	O	O
sensor	B-DEVI
combinations	O	O
were	O	O
more	O	O
appropriate	O	O
than	O	O
others	O	O
due	O	O
to	O	O
the	O	O
different	O	O
habitat	O
requirements	O
of	O	O
the	O	O
earthworms	O
.	O	O

Earthworm	O
species	O
with	O	O
soil	B-OBJC
-specific	O	O
habitat	O
preferences	O
were	O	O
spatially	O	O
predicted	O	O
with	O	O
higher	O	O
accuracy	O
by	O	O
PSS	B-PROC
than	O	O
more	O	O
ubiquitous	O
species	O
.	O	O

Our	O	O
findings	B-DISO
suggest	O	O
that	O	O
PSS	B-PROC
contributes	O	O
to	O	O
the	O	O
spatial	O	O
modelling	B-PROC
of	O	O
earthworm	O
abundances	O
at	O	O
field	O
scale	O
and	O	O
that	O	O
it	O	O
will	O	O
support	O	O
species	O
distribution	O
modelling	B-PROC
in	O	O
the	O	O
attempt	O	O
to	O	O
understand	O	O
the	O	O
soil	B-OBJC
-	O	O
earthworm	O
relationships	O	O
in	O	O
agroecosystems	B-PHEN
.	O	O

Chemosensitivity	B-DISO
,	O	O
Cardiovascular	B-DISO
Risk	I-DISO
,	O	O
and	O	O
the	O	O
Ventilatory	B-PHYS
Response	I-PHYS
to	O	O
Exercise	O
in	O	O
COPD	B-DISO
COPD	B-DISO
is	O	O
associated	O	O
with	O	O
elevated	O
cardiovascular	B-DISO
risk	I-DISO
and	O	O
a	O	O
potentiated	O
ventilatory	B-PHYS
response	I-PHYS
to	O	O
exercise	O
.	O	O

Enhanced	O	O
carotid	B-ANAT
chemoreceptor	B-ANAT
(	O	O
CC	B-ANAT
)	O	O
activity	B-PHYS
/	O	O
sensitivity	B-PHYS
is	O	O
present	O	O
in	O	O
other	O	O
clinical	B-PHYS
conditions	I-PHYS
,	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
contribute	O	O
to	O	O
sympathetic	B-ANAT
vasoconstrictor	B-DISO
outflow	I-DISO
,	O	O
and	O	O
is	O	O
predictive	O
of	O	O
mortality	B-DISO
.	O	O

CC	B-ANAT
activity	B-PHYS
/	O	O
sensitivity	B-PHYS
,	O	O
and	O	O
the	O	O
resulting	O	O
functional	O
significance	O
,	O	O
has	O	O
not	O
been	O
well	O
examined	O
in	O	O
COPD	B-DISO
.	O	O

We	O	O
hypothesized	O	O
that	O	O
CC	B-ANAT
activity	B-PHYS
/	O	O
sensitivity	B-PHYS
would	O	O
be	O	O
elevated	O
in	O	O
COPD	B-DISO
,	O	O
and	O	O
related	O	O
to	O	O
increased	O
pulse	O
wave	O
velocity	O
(	O	O
a	O	O
marker	B-PHYS
of	O	O
CV	B-DISO
risk	I-DISO
)	O	O
and	O	O
the	O	O
ventilatory	B-PHYS
response	I-PHYS
to	O	O
exercise	O
.	O	O

30	O	O
COPD	B-DISO
patients	B-LIVB
and	O	O
10	O	O
healthy	O
age	O	O
-	O	O
matched	O	O
controls	B-LIVB
were	O	O
examined	B-DISO
.	O	O

Participants	B-LIVB
performed	O	O
baseline	O
cardiopulmonary	B-PROC
exercise	I-PROC
and	O	O
pulmonary	B-PROC
function	I-PROC
testing	I-PROC
.	O	O

CC	B-ANAT
activity	B-PHYS
was	O	O
later	O	O
evaluated	B-PROC
by	O	O
the	O	O
drop	B-DISO
in	I-DISO
ventilation	B-PHYS
with	O	O
breathing	B-PHYS
100	O	O
%	O	O
O2	B-CHEM
,	O	O
and	O	O
CC	B-ANAT
sensitivity	B-PHYS
was	O	O
then	O	O
assessed	O	O
by	O	O
the	O	O
ventilatory	B-PROC
response	I-PROC
to	I-PROC
hypoxia	I-PROC
(	O	O
ΔVE	O	O
/	O	O
ΔS	O	O
pO2	B-PROC
)	O	O
.	O	O

Peripheral	O
arterial	B-PHYS
stiffness	I-PHYS
was	O	O
subsequently	O	O
evaluated	B-PROC
by	O	O
measurement	O
of	O	O
pulse	O
wave	O
velocity	O
(	O	O
PWV	O
)	O	O
using	O	O
applanation	B-PROC
tonometry	I-PROC
while	O	O
the	O	O
subjects	O	O
were	O	O
breathing	B-PHYS
room	B-DISO
air	I-DISO
,	O	O
and	O	O
then	O	O
following	O	O
chemoreceptor	B-ANAT
inhibition	O
by	O	O
breathing	B-PHYS
100	O
%	O
O2	B-CHEM
for	O	O
2	O	O
minutes	O	O
.	O	O

CC	B-ANAT
activity	B-PHYS
,	O	O
CC	B-ANAT
sensitivity	B-PHYS
,	O	O
PWV	O
and	O	O
the	O	O
ventilatory	B-PHYS
response	I-PHYS
to	O	O
exercise	O
were	O	O
all	O	O
increased	O	O
in	O	O
COPD	B-DISO
relative	O	O
to	O	O
controls	B-LIVB
.	O	O

CC	B-ANAT
sensitivity	B-PHYS
was	O	O
related	O	O
to	O	O
PWV	O
;	O	O
however	O	O
,	O	O
neither	O	O
CC	B-ANAT
activity	B-PHYS
nor	O	O
CC	B-ANAT
sensitivity	B-PHYS
was	O	O
related	O	O
to	O	O
the	O	O
ventilatory	B-PHYS
response	I-PHYS
to	O	O
exercise	O
in	O	O
COPD	B-DISO
.	O	O

CC	B-ANAT
inhibition	O	O
by	O	O
breathing	B-PHYS
100	O
%	O
O2	B-CHEM
normalized	O	O
PWV	O
in	O	O
COPD	B-DISO
,	O	O
while	O	O
no	O
effect	O
was	O	O
observed	O	O
in	O	O
controls	B-LIVB
.	O	O

CC	B-ANAT
activity	B-PHYS
and	O	O
sensitivity	B-PHYS
are	O	O
elevated	O
in	O	O
COPD	B-DISO
,	O	O
and	O	O
appear	O	O
related	O	O
to	O	O
cardiovascular	B-DISO
risk	I-DISO
;	O	O
however	O	O
,	O	O
CC	B-ANAT
activity	B-PHYS
/	O	O
sensitivity	B-PHYS
does	O	O
not	O	O
contribute	O	O
to	O	O
the	O	O
potentiated	O
ventilatory	B-PHYS
response	I-PHYS
to	O	O
exercise	O
.	O	O

Size	O
matters	O	O
to	O	O
function	O	O
:	O	O
Brain	O
volume	O
correlates	O
with	O	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
across	O	O
healthy	O
individuals	B-LIVB
A	O	O
fundamental	O	O
issue	O	O
in	O	O
neuroscience	O
is	O	O
to	O	O
understand	O	O
the	O	O
structural	O
substrates	O
of	O	O
neural	O	O
activities	O	O
.	O	O

Intrinsic	O
brain	B-PHYS
activity	I-PHYS
has	O	O
been	O	O
increasingly	O	O
recognized	O	O
as	O	O
an	O	O
important	O	O
functional	O	O
activity	O	O
mode	O	O
and	O	O
is	O	O
tightly	O	O
linked	O	O
with	O	O
various	O	O
cognitive	B-PHYS
functions	I-PHYS
.	O	O

Structurally	O	O
,	O	O
cognitive	B-PHYS
functions	I-PHYS
have	O	O
also	O	O
shown	O	O
a	O	O
relation	O	O
with	O	O
brain	O
volume	O
/	O	O
size	O
.	O	O

Therefore	O	O
,	O	O
an	O	O
association	O
between	O	O
intrinsic	O
brain	B-PHYS
activities	I-PHYS
and	O	O
brain	O
volume	O
/	O	O
size	O
can	O	O
be	O	O
hypothesized	O	O
,	O	O
and	O	O
brain	O
volume	O
/	O	O
size	O
may	O	O
impact	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
in	O	O
human	B-LIVB
brains	B-ANAT
.	O	O

The	O	O
present	O	O
study	B-PROC
aimed	O	O
to	O	O
explicitly	O	O
investigate	O
this	O	O
brain	B-ANAT
structure	I-ANAT
-	O	O
function	B-PHYS
relationship	O
using	O	O
two	O	O
large	O	O
independent	O	O
cohorts	B-LIVB
of	O	O
176	O	O
and	O	O
236	O	O
young	B-LIVB
adults	I-LIVB
.	O	O

Structural	O
-	O	O
MRI	B-PROC
was	O	O
performed	O
to	O	O
estimate	O
the	O	O
brain	O
volume	O
,	O	O
and	O	O
resting	B-PROC
-	I-PROC
state	I-PROC
functional	I-PROC
-	I-PROC
MRI	I-PROC
was	O	O
applied	O	O
to	O	O
extract	O	O
the	O	O
amplitude	O
of	O
low	O
-	O
frequency	O
fluctuations	O
(	O	O
ALFF	O
)	O	O
,	O	O
an	O	O
imaging	O	O
measure	O	O
of	O	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
.	O	O

Intriguingly	O	O
,	O	O
our	O	O
results	O	O
revealed	O	O
a	O	O
robust	O	O
linear	O
correlation	O
between	O	O
whole	O
-	O
brain	O
size	O
and	O	O
ALFF	O
.	O	O

Moreover	O	O
,	O	O
specific	O
brain	B-ANAT
lobes	I-ANAT
/	O	O
regions	B-ANAT
,	O	O
including	O	O
the	O	O
frontal	B-ANAT
lobe	I-ANAT
,	O	O
the	O	O
left	B-ANAT
middle	I-ANAT
frontal	I-ANAT
gyrus	I-ANAT
,	O	O
anterior	B-ANAT
cingulate	I-ANAT
gyrus	I-ANAT
,	O	O
Rolandic	B-ANAT
operculum	I-ANAT
,	O	O
and	O	O
insula	B-ANAT
,	O	O
also	O	O
showed	O	O
a	O	O
reliable	O
,	O	O
positive	B-DISO
volume	O
-	O	O
ALFF	O
correlation	O
in	O	O
the	O	O
two	O	O
cohorts	B-LIVB
.	O	O

These	O	O
findings	O	O
offer	O	O
direct	O
,	O	O
empirical	O
evidence	O
of	O
a	O	O
strong	O
association	O
between	O	O
brain	O
size	O
/	O	O
volume	O
and	O	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
,	O	O
as	O	O
well	O	O
as	O	O
provide	O	O
novel	O	O
insight	O	O
into	O	O
the	O	O
structural	O
substrates	O
of	O	O
the	O	O
intrinsic	O
brain	B-PHYS
activity	I-PHYS
of	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
.	O	O

Cavity	O
partition	O
and	O	O
functionalization	O
of	O	O
a	O	O
[	O	O
2	O	O
+	O	O
3	O	O
]	O	O
organic	B-CHEM
molecular	I-CHEM
cage	I-CHEM
by	O	O
inserting	O
polar	B-PHYS
P	I-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
The	O	O
cavity	O
of	O	O
a	O	O
[	O	O
2	O	O
+	O	O
3	O	O
]	O	O
organic	B-CHEM
molecular	I-CHEM
cage	I-CHEM
was	O	O
partitioned	O
and	O	O
functionalized	O
by	O	O
inserting	O
inner	O
-	O
directed	O
P	B-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
,	O	O
which	O	O
shows	O	O
CO2	B-CHEM
capture	O	O
and	O	O
CH4	B-CHEM
exclusion	O
due	O	O
to	O	O
the	O	O
size	O
-	O	O
matching	O
and	O	O
polarity	O
effects	O
.	O	O

Computational	O
results	B-DISO
demonstrate	O
that	O	O
the	O	O
successful	O
segmentation	O
via	O	O
polar	B-PHYS
P	I-PHYS
[	I-PHYS
double	I-PHYS
bond	I-PHYS
,	I-PHYS
length	I-PHYS
as	I-PHYS
m	I-PHYS
-	I-PHYS
dash	I-PHYS
]	I-PHYS
O	I-PHYS
bonds	I-PHYS
facilitates	O	O
the	O	O
CO2	B-CHEM
molecules	B-OBJC
to	O	O
reside	O
selectively	O
inside	O	O
the	O	O
cavity	O
.	O	O

Succession	O
Planning	O
and	O	O
Financial	O
Performance	O
:	O	O
Does	O	O
Competition	O
Matter	O	O
?	O	O
Succession	O
planning	O
has	O	O
been	O	O
defined	O	O
as	O	O
the	O	O
process	B-PHEN
by	O	O
which	O	O
one	O	O
or	O	O
more	O	O
successors	B-LIVB
are	O	O
identified	O
for	O	O
key	O	O
positions	O
,	O	O
development	O
activities	O
are	O	O
planned	O
for	O	O
identified	O
successors	B-LIVB
,	O	O
or	O	O
both	O	O
.	O	O

Limited	O
research	B-PROC
exists	O	O
pertaining	O	O
to	O	O
the	O	O
relationship	O
between	O	O
hospital	B-OBJC
succession	O
planning	O
and	O	O
financial	O
performance	O
,	O	O
particularly	O	O
in	O	O
the	O	O
context	O
of	O	O
market	O
competition	O
.	O	O

We	O	O
used	O	O
the	O	O
resource	O
-	O
based	O
view	O
framework	O
to	O	O
analyze	B-PROC
the	O	O
differential	O	O
effect	O
of	O
succession	O
planning	O
on	O	O
hospitals	B-OBJC
'	O	O
financial	O
performance	O
based	O	O
on	O	O
market	O
competition	O
.	O	O

According	O	O
to	O	O
RBV	O
,	O	O
organizations	O
can	O	O
achieve	O	O
higher	O
performance	O
by	O	O
using	O	O
their	O	O
superior	O
resources	O
and	O	O
capabilities	O
.	O	O

We	O	O
used	O	O
a	O	O
panel	O
design	O
consisting	O	O
of	O	O
a	O	O
national	O
sample	O
of	O	O
hospitals	B-OBJC
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
for	O	O
2006	O	O
-	O	O
2010	O	O
.	O	O

We	O	O
analyzed	B-PROC
data	O
using	O	O
multivariate	O
linear	O
regression	O
with	O	O
facility	O
random	O
effects	O
and	O	O
year	O
and	O	O
state	B-GEOG
fixed	O
effects	O
.	O	O

The	O	O
sample	O
included	O	O
22	O	O
,	O	O
717	O	O
hospital	B-OBJC
-	O	O
year	O
observations	O
;	O	O
more	O	O
than	O	O
one	O	O
half	O	O
of	O	O
the	O	O
hospitals	B-OBJC
(	O	O
55	O	O
.	O	O
4	O	O
%	O	O
)	O	O
had	O	O
a	O	O
succession	O
planning	O
program	O
.	O	O

The	O	O
study	O	O
found	O	O
a	O	O
positive	B-DISO
relationship	O
between	O	O
the	O	O
presence	B-DISO
of	O	O
succession	O
planning	O
and	O	O
financial	O
performance	O
(	O	O
β	O	O
=	O	O
1	O	O
.	O	O
41	O	O
,	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
,	O	O
which	O	O
was	O	O
stronger	O	O
in	O	O
competitive	O
market	O
s	O	O
(	O	O
β	O	O
=	O	O
2	O	O
.	O	O
31	O	O
,	O	O
p	O	O
=	O	O
.03	O	O
)	O	O
than	O	O
in	O	O
monopolistic	O
markets	O
(	O	O
β	O	O
=	O	O
1	O	O
.	O	O
06	O	O
,	O	O
p	O	O
=	O	O
.01	O	O
)	O	O
.	O	O

Hospitals	B-OBJC
can	O	O
use	O	O
these	O	O
results	O	O
to	O	O
make	O	O
informed	O	O
decisions	B-PHYS
about	O	O
investing	O	O
in	O	O
succession	O
planning	O
programs	O
on	O	O
the	O	O
basis	O	O
of	O	O
competition	O
in	O	O
their	O	O
market	O
.	O	O

On	O	O
the	O	O
Control	O
of	O	O
Social	O
Approach	B-DISO
-	I-DISO
Avoidance	I-DISO
Behavior	I-DISO
:	O	O
Neural	O
and	O	O
Endocrine	O
Mechanisms	O
The	O	O
ability	B-PHYS
to	O	O
control	O
our	O	O
automatic	O
action	O
tendencies	O
is	O	O
crucial	O
for	O	O
adequate	O
social	B-DISO
interactions	I-DISO
.	O	O

Emotional	B-DISO
events	O
trigger	O
automatic	O
approach	B-DISO
and	I-DISO
avoidance	I-DISO
tendencies	O
.	O	O

Although	O	O
these	O	O
actions	O
may	O	O
be	O	O
generally	O	O
adaptive	O
,	O	O
the	O	O
capacity	O
to	O	O
override	O
these	O	O
emotional	B-DISO
reactions	I-DISO
may	O	O
be	O	O
key	O
to	O	O
flexible	O
behavior	O
during	O	O
social	B-DISO
interaction	I-DISO
.	O	O

The	O	O
present	O
chapter	O
provides	O
a	O	O
review	O
of	O	O
the	O	O
neuroendocrine	B-ANAT
mechanisms	O
underlying	O	O
this	O	O
ability	B-PHYS
and	O	O
their	O	O
relation	O
to	O	O
social	O
psychopathologies	O
.	O	O

Aberrant	O
social	O
behavior	O
,	O	O
such	O	O
as	O	O
observed	O
in	O	O
social	B-DISO
anxiety	I-DISO
or	O	O
psychopathy	B-DISO
,	O	O
is	O	O
marked	O
by	O	O
abnormalities	B-DISO
in	O	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
tendencies	O
and	O	O
the	O	O
ability	B-PHYS
to	O	O
control	O
them	O	O
.	O	O

Key	O
neural	O
regions	O
involved	O
in	O	O
the	O	O
regulation	B-PHEN
of	O	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
behavior	I-DISO
are	O	O
the	O	O
amygdala	B-ANAT
,	O	O
widely	O	O
implicated	O
in	O	O
automatic	O
emotional	B-DISO
processing	B-PHYS
,	O	O
and	O	O
the	O	O
anterior	O
prefrontal	B-ANAT
cortex	I-ANAT
,	O	O
which	O	O
exerts	B-PHYS
control	O
over	O	O
the	O	O
amygdala	B-ANAT
.	O	O

Hormones	B-CHEM
,	O	O
especially	O	O
testosterone	B-CHEM
and	O	O
cortisol	B-CHEM
,	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
affect	B-PHYS
approach	B-DISO
-	I-DISO
avoidance	I-DISO
behavior	I-DISO
and	O	O
the	O	O
associated	O
neural	O
mechanisms	O
.	O	O

The	O	O
present	O
chapter	O
also	O	O
discusses	O	O
ways	O	O
to	O	O
directly	O
influence	O
social	O
approach	B-DISO
and	I-DISO
avoidance	I-DISO
behavior	I-DISO
and	O	O
will	O	O
end	O	O
with	O	O
a	O	O
research	B-PROC
agenda	O
to	O	O
further	O	O
advance	O
this	O	O
important	O
research	B-PROC
field	I-PROC
.	O	O

Control	O
over	O	O
approach	B-DISO
-	I-DISO
avoidance	I-DISO
tendencies	O
may	O	O
serve	O	O
as	O	O
an	O	O
exemplar	O
of	O	O
emotional	B-DISO
action	O
regulation	B-PHEN
and	O	O
might	O	O
have	O	O
a	O	O
great	O
value	O
in	O	O
understanding	B-PHYS
the	O	O
underlying	O	O
mechanisms	O
of	O	O
the	O	O
development	O
of	O	O
affective	B-DISO
disorders	I-DISO
.	O	O

High	O	O
Occurrence	O	O
of	O	O
Non	B-DISO
-	I-DISO
Clear	I-DISO
Cell	I-DISO
Renal	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
in	O	O
Oman	B-GEOG
It	O	O
is	O	O
conventionally	O	O
accepted	O	O
that	O	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
RCC	B-DISO
)	O	O
occurs	O	O
in	O	O
older	B-LIVB
patients	I-LIVB
and	O	O
the	O	O
clear	B-DISO
cell	I-DISO
type	I-DISO
is	O	O
the	O	O
most	O	O
common	O	O
histology	O
.	O	O

However	O	O
,	O	O
ethnic	O
variations	O
exist	O	O
and	O	O
this	O	O
study	B-PROC
was	O	O
carried	O	O
out	O	O
to	O	O
determine	O	O
the	O	O
epidemiological	O
pattern	O
of	O	O
RCC	B-DISO
in	O	O
Oman	B-GEOG
.	O	O

Ninety	O	O
RCC	B-DISO
patients	B-LIVB
who	O	O
presented	O
to	O	O
a	O	O
tertiary	B-OBJC
care	I-OBJC
center	I-OBJC
in	O	O
the	O	O
Sultanate	B-GEOG
of	I-GEOG
Oman	I-GEOG
from	O	O
2010	O	O
to	O	O
2014	O	O
were	O	O
studied	B-PROC
.	O	O

The	O	O
main	B-DISO
findings	I-DISO
were	O	O
that	O	O
the	O	O
median	B-PHYS
age	I-PHYS
of	O	O
presentation	O
was	O	O
low	O
,	O	O
more	O	O
patients	B-LIVB
presented	O
with	O	O
localized	O
stage	O
,	O	O
and	O	O
there	O	O
was	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
non	B-DISO
-	I-DISO
clear	I-DISO
(	O	O
especially	O	O
papillary	B-DISO
)	O	O
histology	O
.	O	O

Data	O
from	O	O
other	O	O
Gulf	B-GEOG
countries	I-GEOG
and	O	O
possible	O	O
reasons	O	O
for	O	O
the	O	O
different	O	O
profile	O	O
are	O	O
discussed	O	O
.	O	O

""""	O	O
Bridge	B-CHEM
Proteins	I-CHEM
""""	O	O
Link	O	O
Inflammation	B-DISO
and	O	O
Metabolic	B-DISO
Diseases	I-DISO
:	O	O
Potential	O	O
Targets	O
for	O	O
Therapeutics	O
Clinical	B-PROC
observations	I-PROC
support	O	O
the	O	O
postulate	O	O
that	O	O
chronic	O
low	O
-	O	O
grade	O
inflammation	B-DISO
underlies	O	O
metabolic	B-DISO
diseases	I-DISO
and	O	O
inflammatory	B-CHEM
mediators	I-CHEM
can	O	O
trigger	O
some	O	O
metabolic	B-DISO
diseases	I-DISO
.	O	O

In	O	O
disorder	B-DISO
condition	O
,	O	O
what	O	O
is	O	O
the	O	O
first	O	O
one	O	O
:	O	O
metabolic	B-DISO
diseases	I-DISO
cause	O	O
inflammation	B-DISO
or	O	O
conversely	O	O
?	O	O

This	O	O
""""	O	O
chicken	O	O
or	O	O
egg	O	O
""""	O	O
type	O	O
question	O
was	O	O
hard	O	O
to	O	O
answer	O	O
.	O	O

However	O	O
,	O	O
instead	O	O
of	O	O
focusing	O	O
on	O	O
this	O	O
difficult	O
issue	B-DISO
,	O	O
we	O	O
should	O	O
ask	O	O
another	O	O
challenging	O	O
question	O
:	O	O
what	O	O
are	O	O
the	O	O
links	O
between	O	O
inflammation	B-DISO
and	O	O
metabolic	B-DISO
diseases	I-DISO
?	O	O
Seizing	O	O
the	O	O
key	O	O
from	O	O
this	O	O
chaos	B-DISO
may	O	O
be	O	O
the	O	O
best	O	O
way	O	O
to	O	O
solve	O	O
the	O	O
problem	B-DISO
and	O	O
break	O	O
the	O	O
cycle	O	O
.	O	O

To	O	O
answer	O	O
this	O	O
question	O
,	O	O
we	O	O
review	O	O
the	O	O
regulators	B-CHEM
(	O	O
such	O	O
as	O	O
NF	B-CHEM
-	I-CHEM
κB	I-CHEM
,	O	O
PPARs	B-CHEM
,	O	O
mTOR	B-CHEM
,	O	O
and	O	O
STAT3	B-CHEM
)	O	O
that	O	O
have	O	O
important	O	O
roles	O	O
in	O	O
both	O	O
metabolism	B-PHYS
and	O	O
inflammation	B-DISO
.	O	O

These	O	O
""""	O	O
bridge	B-CHEM
proteins	I-CHEM
""""	O	O
that	O	O
link	O	O
metabolic	B-DISO
diseases	I-DISO
and	O	O
inflammation	B-DISO
not	O	O
only	O	O
increase	O
our	O	O
understanding	O	O
of	O	O
these	O	O
two	O	O
diseases	B-DISO
,	O	O
but	O	O
also	O	O
provide	O	O
potential	O	O
targets	O
for	O	O
therapeutics	O
and	O	O
practical	O	O
clinical	O
applications	O
.	O	O

Isolation	B-PROC
of	I-PROC
Cells	I-PROC
Specialized	O
in	O	O
Anticancer	B-CHEM
Alkaloid	B-PHYS
Metabolism	I-PHYS
by	O	O
Fluorescence	B-PROC
-	I-PROC
Activated	I-PROC
Cell	I-PROC
Sorting	I-PROC
Plant	B-LIVB
specialized	O
metabolism	B-PHYS
often	O	O
presents	O	O
a	O	O
complex	O
cell	B-ANAT
-	O	O
specific	O
compartmentation	B-PHYS
essential	O	O
to	O	O
accomplish	O	O
the	O	O
biosynthesis	O
of	O	O
valuable	O	O
plant	B-LIVB
natural	B-CHEM
products	I-CHEM
.	O	O

Hence	O	O
,	O	O
the	O	O
disclosure	O	O
and	O	O
potential	O	O
manipulation	O
of	O	O
such	O	O
pathways	O
may	O	O
depend	O	O
on	O	O
the	O	O
capacity	O	O
to	O	O
isolate	B-PROC
and	O	O
characterize	O
specific	O
cell	O
types	O
.	O	O

Catharanthus	B-LIVB
roseus	I-LIVB
is	O	O
the	O	O
source	O	O
of	O	O
several	O	O
medicinal	B-CHEM
terpenoid	B-CHEM
indole	I-CHEM
alkaloids	I-CHEM
,	O	O
including	O	O
the	O	O
low	O	O
-	O	O
level	O	O
anticancer	B-CHEM
vinblastine	B-CHEM
and	O	O
vincristine	B-CHEM
,	O	O
for	O	O
which	O	O
the	O	O
late	O	O
biosynthetic	O
steps	O
occur	O	O
in	O	O
specialized	O
mesophyll	B-ANAT
cells	I-ANAT
called	O	O
idioblasts	B-ANAT
.	O	O

Here	O	O
,	O	O
the	O	O
optical	O
,	O	O
fluorescence	B-PHEN
,	O	O
and	O	O
alkaloid	B-CHEM
-	O	O
accumulating	B-DISO
properties	O	O
of	O	O
C	B-LIVB
.	I-LIVB

roseus	I-LIVB
leaf	B-LIVB
idioblasts	B-ANAT
are	O	O
characterized	O
,	O	O
and	O	O
a	O	O
methodology	O
for	O	O
the	O	O
isolation	B-PROC
of	O	O
idioblast	B-ANAT
protoplasts	B-ANAT
by	O	O
fluorescence	B-PROC
-	I-PROC
activated	I-PROC
cell	I-PROC
sorting	I-PROC
is	O	O
established	O	O
,	O	O
taking	O	O
advantage	O	O
of	O	O
the	O	O
distinctive	O	O
autofluorescence	B-PROC
of	O	O
these	O	O
cells	B-ANAT
.	O	O

This	O	O
achievement	O	O
represents	O	O
a	O	O
crucial	O	O
step	O	O
for	O	O
the	O	O
development	O	O
of	O	O
differential	O	O
omic	B-PROC
strategies	I-PROC
leading	O	O
to	O	O
the	O	O
identification	O
of	O	O
candidate	O
genes	O
putatively	O	O
involved	O	O
in	O	O
the	O	O
biosynthesis	O
,	O	O
pathway	O
regulation	B-PHEN
,	O	O
and	O	O
transmembrane	B-PHYS
transport	I-PHYS
leading	O	O
to	O	O
the	O	O
anticancer	B-DISO
alkaloids	B-CHEM
from	O	O
C	B-LIVB
.	I-LIVB

roseus	I-LIVB
.	O	O

Interaction	O
of	O	O
the	O	O
Antimicrobial	B-CHEM
Peptides	I-CHEM
Rhesus	B-CHEM
θ	I-CHEM
-	I-CHEM
Defensin	I-CHEM
and	O	O
Porcine	B-LIVB
Protegrin	B-CHEM
-	I-CHEM
1	I-CHEM
with	O	O
Anionic	B-CHEM
Phospholipid	I-CHEM
Monolayers	I-CHEM
A	O	O
combination	O	O
of	O	O
Langmuir	O
isotherm	O
,	O	O
Brewster	B-PROC
angle	I-PROC
microscopy	I-PROC
(	O	O
BAM	B-PROC
)	O	O
,	O	O
and	O	O
neutron	B-PROC
reflectivity	I-PROC
studies	I-PROC
have	O	O
been	O	O
performed	O	O
to	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
effects	O	O
on	O	O
model	O
bacterial	B-ANAT
cell	I-ANAT
membranes	I-ANAT
of	O	O
the	O	O
antimicrobial	B-CHEM
peptides	I-CHEM
,	O	O
Rhesus	B-CHEM
θ	I-CHEM
-	I-CHEM
defensin	I-CHEM
1	I-CHEM
(	O	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
,	O	O
and	O	O
porcine	B-LIVB
protegrin	B-CHEM
1	I-CHEM
(	O	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
.	O	O

The	O	O
peptides	B-CHEM
were	O	O
interacted	O
with	O	O
monolayers	B-CHEM
spread	O	O
at	O	O
the	O	O
air	B-OBJC
-	O	O
water	B-CHEM
interface	O	O
and	O	O
prepared	O	O
from	O	O
a	O	O
3	O	O
:	O	O
1	O	O
molar	O	O
mixture	O	O
of	O	O
phosphatidylethanolamine	B-CHEM
and	O	O
phosphatidylglycerol	B-CHEM
used	O	O
to	O	O
approximate	O
the	O	O
cell	B-ANAT
membranes	I-ANAT
of	O	O
Gram	B-LIVB
positive	I-LIVB
bacteria	I-LIVB
.	O	O

The	O	O
Langmuir	B-OBJC
film	I-OBJC
balance	O	O
measurements	O
show	O	O
that	O	O
both	O	O
peptides	B-CHEM
perturb	O
the	O	O
lipid	B-CHEM
monolayers	I-CHEM
causing	O	O
an	O	O
increase	O	O
in	O	O
surface	B-PHEN
pressure	I-PHEN
,	O	O
and	O	O
the	O	O
BAM	B-PROC
studies	O	O
show	O	O
that	O	O
each	O	O
results	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
small	O
domains	O
within	O	O
the	O	O
lipid	O
films	O
,	O	O
around	O	O
5	O	O
μm	O	O
diameter	O	O
.	O	O

The	O	O
overall	O	O
change	O	O
in	O	O
monolayer	B-CHEM
surface	B-PHEN
pressure	I-PHEN
caused	O	O
by	O	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
,	O	O
however	O	O
,	O	O
is	O	O
a	O	O
little	O	O
more	O	O
pronounced	O	O
than	O	O
that	O	O
due	O	O
to	O	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
(	O	O
+8	O	O
.	O	O

5	O	O
mN·m	O	O
(	O	O
-	O	O
1	O	O
)	O	O
vs	O	O
+5	O	O
.	O	O

5	O	O
mN·m	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
,	O	O
and	O	O
the	O	O
rate	O	O
of	O	O
its	O	O
initial	O	O
interaction	O
with	O	O
the	O	O
monolayer	B-CHEM
is	O	O
a	O	O
little	O	O
more	O	O
rapid	O	O
than	O	O
that	O	O
for	O	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
.	O	O

The	O	O
neutron	B-DEVI
reflectivity	I-DEVI
studies	I-DEVI
also	O	O
show	O	O
differences	O	O
for	O	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
,	O	O
with	O	O
the	O	O
model	O
fits	O	O
to	O	O
these	O	O
data	O	O
showing	O	O
that	O	O
the	O	O
more	O	O
amphiphilic	B-CHEM
PG	B-CHEM
-	I-CHEM
1	I-CHEM
becomes	O	O
fully	O	O
embedded	B-PROC
within	O	O
the	O	O
lipid	O
film	O
-causing	O	O
an	O	O
extension	O	O
of	O	O
the	O	O
lipid	B-CHEM
acyl	I-CHEM
chains	I-CHEM
but	O	O
leaving	O	O
the	O	O
thickness	O
of	O	O
the	O	O
lipid	B-CHEM
headgroup	I-CHEM
layer	I-CHEM
unaffected	O	O
-	O	O
while	O	O
RTD	B-CHEM
-	I-CHEM
1	I-CHEM
is	O	O
seen	O	O
to	O	O
insert	O	O
less	O	O
deeply	O	O
-	O	O
causing	O	O
the	O	O
same	O	O
extension	O	O
of	O	O
the	O	O
lipid	B-CHEM
acyl	I-CHEM
chains	I-CHEM
as	O	O
PG	B-CHEM
-	I-CHEM
1	I-CHEM
but	O	O
also	O	O
causing	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
thickness	O
of	O	O
the	O	O
lipid	B-CHEM
headgroup	I-CHEM
layer	I-CHEM
.	O	O

The	O	O
various	O	O
differing	O	O
effects	O	O
of	O	O
the	O	O
two	O	O
peptides	B-CHEM
on	O	O
anionic	B-CHEM
lipid	I-CHEM
monolayers	I-CHEM
are	O	O
discussed	O	O
in	O	O
the	O	O
context	O	O
of	O	O
their	O	O
differing	O	O
hemolytic	B-PROC
activities	I-PROC
,	O	O
and	O	O
their	O	O
proposed	O	O
differing	O
propensities	O
to	O	O
form	O	O
transmembrane	B-ANAT
pores	B-ANAT
.	O	O

Lipidomic	B-PROC
Signatures	I-PROC
and	O	O
Associated	O	O
Transcriptomic	O
Profiles	O
of	O	O
Clear	B-DISO
Cell	I-DISO
Renal	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
Renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
RCC	B-DISO
)	I-DISO
is	O	O
the	O	O
most	O	O
common	O	O
histological	B-PHYS
type	I-PHYS
of	O	O
adult	B-LIVB
kidney	B-DISO
cancer	I-DISO
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
obtained	O	O
lipidomic	B-PROC
profiles	I-PROC
of	O	O
clear	B-DISO
cell	I-DISO
RCC	I-DISO
(	O	O
ccRCC	B-DISO
)	O	O
,	O	O
a	O	O
major	O	O
RCC	B-DISO
subtype	O
,	O	O
by	O	O
performing	O	O
a	O	O
lipidomic	B-PROC
analysis	I-PROC
of	O	O
specimens	B-OBJC
of	O	O
cancerous	B-DISO
tissue	I-DISO
and	O	O
the	O	O
surrounding	O	O
normal	O	O
renal	B-ANAT
cortex	I-ANAT
obtained	O	O
from	O	O
the	O	O
same	O	O
patients	B-LIVB
(	O	O
N	O	O
=	O	O
49	O	O
)	O	O
.	O	O

We	O	O
also	O	O
compared	O	O
the	O	O
lipidomic	B-PROC
profiles	I-PROC
with	O	O
the	O	O
lipogenic	O
transcriptome	O
of	O	O
specimens	B-OBJC
of	O	O
cancerous	B-DISO
tissue	I-DISO
and	O	O
the	O	O
surrounding	O	O
normal	O	O
renal	B-ANAT
cortex	I-ANAT
for	O	O
an	O	O
additional	O	O
set	O	O
of	O	O
patient	B-LIVB
samples	O	O
(	O	O
N	O	O
=	O	O
95	O	O
)	O	O
.	O	O

Overall	O	O
,	O	O
we	O	O
detected	O	O
326	O	O
lipids	B-CHEM
,	O	O
including	O	O
phospholipids	B-CHEM
,	O	O
sphingolipids	B-CHEM
,	O	O
neutral	B-CHEM
lipids	I-CHEM
,	O	O
and	O	O
eicosanoids	B-CHEM
.	O	O

The	O	O
levels	O	O
of	O	O
more	O	O
than	O	O
70	O	O
%	O	O
of	O	O
the	O	O
detected	O	O
lipids	B-CHEM
were	O	O
significantly	O	O
different	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
,	O	O
corrected	O	O
by	O	O
the	O	O
false	O	O
discovery	O	O
rate	O	O
)	O	O
.	O	O

The	O	O
cancerous	B-DISO
tissue	I-DISO
was	O	O
distinguished	O	O
by	O	O
higher	O	O
levels	O	O
of	O	O
ether	B-CHEM
-	I-CHEM
type	I-CHEM
phospholipids	I-CHEM
,	O	O
cholesterol	B-CHEM
esters	I-CHEM
,	O	O
and	O	O
triacylglycerols	B-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
by	O	O
lower	O	O
levels	O	O
of	O	O
phospholipids	B-CHEM
(	O	O
except	O	O
for	O	O
phosphatidylcholines	B-CHEM
)	O	O
and	O	O
polyunsaturated	B-CHEM
fatty	I-CHEM
acids	I-CHEM
.	O	O

Characteristic	O	O
changes	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
mRNAs	B-CHEM
and	O	O
metabolites	B-CHEM
suggested	O	O
that	O	O
the	O	O
phosphatidylethanolamine	B-PHYS
(	I-PHYS
PE	I-PHYS
)	I-PHYS
synthesis	I-PHYS
pathway	I-PHYS
is	O	O
suppressed	O
in	O	O
ccRCC	B-DISO
and	O	O
associated	O	O
with	O	O
cell	B-PHYS
proliferation	I-PHYS
.	O	O

The	O	O
present	O	O
study	B-PROC
represents	O	O
the	O	O
lipidomic	B-PROC
profiles	I-PROC
of	O	O
ccRCC	B-DISO
,	O	O
which	O	O
provides	O	O
novel	O	O
information	O	O
about	O	O
the	O	O
metabolic	B-PHYS
changes	O
in	O	O
renal	B-ANAT
cancerous	B-DISO
tissue	I-DISO
and	O	O
RCC	B-DISO
pathophysiology	B-DISO
.	O	O

Patient	B-PROC
Mobility	I-PROC
for	O	O
Elective	O
Secondary	B-PROC
Health	I-PROC
Care	I-PROC
Services	I-PROC
in	O	O
Response	B-PHYS
to	O	O
Patient	O
Choice	O
Policies	O
:	O	O
A	O	O
Systematic	O
Review	O
Our	O	O
review	O	O
establishes	O	O
the	O	O
empirical	O
evidence	O
for	O	O
patient	B-PROC
mobility	I-PROC
for	O	O
elective	B-PROC
secondary	I-PROC
care	I-PROC
services	I-PROC
in	O	O
countries	B-GEOG
that	O	O
allow	O	O
patients	B-LIVB
to	O	O
choose	O	O
their	O	O
health	B-LIVB
care	I-LIVB
provider	I-LIVB
.	O	O

PubMed	O
and	O	O
Embase	O
were	O	O
searched	O	O
for	O	O
relevant	O	O
articles	O
between	O	O
1990	O	O
and	O	O
2015	O	O
.	O	O

Of	O	O
5	O	O
,	O	O
994	O	O
titles	O
/	O	O
abstracts	O
reviewed	O
,	O	O
26	O	O
studies	B-PROC
were	O	O
included	O	O
.	O	O

The	O	O
studies	B-PROC
used	O	O
three	O	O
main	O	O
methodological	O
models	O
to	O	O
establish	O	O
mobility	B-DISO
.	O	O

Variation	O
in	O	O
the	O	O
extent	O	O
of	O	O
patient	B-PROC
mobility	I-PROC
was	O	O
observed	O	O
across	O	O
the	O	O
studies	O	O
.	O	O

Mobility	B-DISO
was	O	O
positively	O	O
associated	O
with	O
lower	O
waiting	O
times	O
,	O	O
indicators	O
of	O	O
better	B-PROC
service	I-PROC
quality	I-PROC
,	O	O
and	O	O
access	O	O
to	O	O
advanced	O
technology	O
.	O	O

It	O	O
was	O	O
negatively	O	O
associated	O	O
with	O	O
advanced	B-LIVB
age	I-LIVB
or	O	O
lower	O	O
socioeconomic	O
backgrounds	O	O
.	O	O

From	O	O
a	O	O
policy	O
perspective	O
we	O	O
demonstrate	O	O
that	O	O
a	O	O
significant	O	O
proportion	O
of	O	O
patients	B-LIVB
are	O	O
prepared	O	O
to	O	O
travel	O
beyond	O	O
their	O	O
nearest	O	O
provider	B-LIVB
for	O	O
elective	O
services	O
.	O	O

As	O	O
a	O	O
consequence	O	O
,	O	O
some	O	O
providers	B-LIVB
are	O	O
likely	O	O
to	O	O
be	O	O
""""	O	O
winners	B-PROC
""""	O	O
and	O	O
others	O	O
""""	O	O
losers	B-DISO
,	O	O
""""	O	O
which	O	O
could	O	O
result	O	O
in	O	O
overall	O	O
decreased	O
provider	B-LIVB
capacity	O
or	O	O
inefficient	O
utilization	O	O
of	O	O
existing	O	O
services	B-PROC
.	O	O

Equity	O
also	O	O
remains	O	O
a	O	O
key	O	O
concern	O	O
.	O	O

Bone	B-ANAT
-	O	O
Albumin	B-CHEM
filling	B-PROC
decreases	O
donor	B-ANAT
site	I-ANAT
morbidity	O
and	O	O
enhances	O
bone	B-PHYS
formation	I-PHYS
after	O	O
anterior	B-ANAT
cruciate	I-ANAT
ligament	I-ANAT
reconstruction	B-PROC
with	O	O
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
autografts	B-CHEM
Donor	B-ANAT
site	I-ANAT
pain	B-DISO
affects	O	O
32	O	O
-	O	O
43	O	O
%	O	O
of	O	O
patients	B-LIVB
after	O	O
anterior	B-ANAT
cruciate	I-ANAT
ligament	I-ANAT
surgery	O
when	O	O
the	O	O
autograft	B-CHEM
is	O	O
freshly	O
harvested	B-PROC
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
tissue	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
compare	O
functional	O
and	O	O
morphological	O
differences	O
between	O	O
donor	B-ANAT
sites	I-ANAT
with	O	O
and	O	O
without	O	O
serum	B-CHEM
albumin	I-CHEM
-	O	O
coated	O
bone	B-ANAT
allograft	B-CHEM
filling	B-PROC
.	O	O
After	O	O
harvesting	B-PROC
and	O	O
implanting	B-PROC
the	O	O
graft	B-CHEM
,	O	O
the	O	O
tibia	B-ANAT
site	B-ANAT
was	O	O
filled	O	O
with	O	O
either	O	O
fresh	O
autologous	O
cancellous	O
bone	O
enhanced	O
with	O	O
albumin	B-CHEM
-	O	O
coated	O
allograft	B-CHEM
or	O	O
autologous	O
bone	B-ANAT
alone	O	O
.	O	O

The	O	O
patella	B-ANAT
site	B-ANAT
was	O	O
filled	O	O
either	O	O
with	O	O
albumin	B-CHEM
-	O	O
coated	O
allograft	B-CHEM
or	O	O
with	O	O
blood	B-DISO
clot	I-DISO
.	O	O

Knee	B-ANAT
function	B-PHYS
was	O	O
evaluated	B-PROC
by	O	O
the	O	O
VISA	B-PHYS
,	O	O
Lysholm	O
and	O	O
IKDC	O
scores	O
and	O	O
a	O	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
of	I-PROC
pain	I-PROC
during	O	O
standing	O
,	O	O
kneeling	B-DISO
and	O	O
crouching	B-DISO
after	O	O
six	O	O
weeks	O
and	O	O
six	O	O
months	O
.	O	O

Computed	B-PROC
tomography	I-PROC
was	O	O
performed	O	O
at	O	O
six	O	O
months	O
for	O	O
morphological	O
evaluation	B-PROC
.	O	O

At	O	O
six	O	O
weeks	O
,	O	O
both	O	O
groups	O
were	O	O
still	O	O
recovering	O
from	O
surgery	O
and	O	O
the	O	O
overall	O
knee	B-ANAT
function	B-PHYS
was	O	O
still	O	O
impaired	O
but	O	O
the	O	O
functional	O
scores	O
were	O	O
significantly	O
higher	O
in	O	O
the	O	O
Bone	B-ANAT
-	O	O
Albumin	B-CHEM
group	O
.	O	O

The	O	O
pain	B-DISO
with	O	O
crouching	B-DISO
and	O	O
kneeling	B-DISO
was	O	O
also	O	O
lower	O
as	O	O
compared	O
to	O	O
controls	B-LIVB
.	O	O

At	O	O
six	O	O
months	O
,	O	O
the	O	O
knee	B-ANAT
function	B-PHYS
scores	O
were	O	O
close	O	O
to	O	O
normal	O
,	O	O
with	O	O
a	O	O
slight	O	O
decrease	O
in	O	O
the	O	O
controls	B-LIVB
.	O	O

Pain	B-DISO
at	O	O
kneeling	B-DISO
was	O	O
still	O	O
prominent	O
in	O	O
the	O	O
controls	B-LIVB
,	O	O
but	O	O
significantly	O
lower	O
in	O	O
the	O	O
Bone	B-ANAT
-	O	O
Albumin	B-CHEM
group	O
.	O	O

Computed	B-PROC
tomography	I-PROC
showed	O	O
significantly	O
smaller	O
bone	B-ANAT
defects	O
and	O	O
higher	O
bone	B-PHYS
density	I-PHYS
in	O	O
the	O	O
Bone	B-ANAT
-	O	O
Albumin	B-CHEM
group	O
.	O	O

Results	B-PHEN
from	O	O
the	O	O
present	O	O
study	B-PROC
indicate	O
that	O	O
donor	B-ANAT
site	I-ANAT
pain	B-DISO
,	O	O
a	O	O
disturbing	O	O
long	O
-	O
term	O
side	B-DISO
effect	I-DISO
of	O	O
bone	O
-	O
patellar	O
tendon	O
-	O
bone	O
surgery	O
,	O	O
is	O	O
significantly	O
reduced	O
if	O	O
bone	B-ANAT
buildup	O	O
in	O	O
the	O	O
patella	B-ANAT
and	O	O
the	O	O
tibia	B-ANAT
is	O	O
augmented	O	O
by	O	O
serum	B-CHEM
albumin	I-CHEM
-	O	O
coated	O
bone	B-ANAT
allografts	B-CHEM
.	O	O

Development	B-PHYS
of	O	O
chrysin	B-CHEM
loaded	O	O
poloxamer	B-CHEM
micelles	O	O
and	O	O
toxicity	O
evaluation	B-PROC
in	O	O
fish	B-LIVB
embryos	B-ANAT
Poloxamer	B-CHEM
micelles	B-CHEM
promise	O	O
safety	B-PHEN
and	O	O
efficacy	O
for	O	O
many	O	O
water	B-CHEM
insoluble	O
drugs	B-CHEM
.	O	O

Chrysin	B-CHEM
has	O	O
been	O	O
reported	O	O
to	O	O
have	O	O
anticancer	O
,	O	O
anti	O
-	O
inflammatory	O
,	O	O
antioxidant	B-PHYS
,	O	O
and	O	O
anti	B-PHYS
-	I-PHYS
aromatase	I-PHYS
activities	I-PHYS
but	O	O
its	O	O
water	B-CHEM
insoluble	O
properties	O
limit	O	O
its	O	O
pharmaceutical	O
application	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
chrysin	B-CHEM
loaded	O	O
poloxamer	B-CHEM
micelles	B-CHEM
were	O	O
developed	O	O
.	O	O

Two	O	O
types	O	O
of	O	O
poloxamers	B-CHEM
,	O	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
68	I-CHEM
and	O	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
127	I-CHEM
were	O	O
compared	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
chrysin	B-CHEM
loaded	O	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
68	I-CHEM
micelles	B-CHEM
(	O	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
)	O	O
and	O	O
chrysin	B-CHEM
loaded	O	O
Pluronic	B-CHEM
F	I-CHEM
-	I-CHEM
127	I-CHEM
micelles	B-CHEM
(	O	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
)	O	O
obviously	O	O
increase	O
the	O	O
aqueous	O
solubility	O
of	O	O
chrysin	B-CHEM
.	O	O

The	O	O
results	O
also	O	O
indicated	O	O
that	O	O
the	O	O
type	O	O
of	O	O
polymer	B-CHEM
and	O	O
ratio	O	O
of	O	O
drug	B-CHEM
to	O	O
polymer	B-CHEM
affected	O	O
size	O
and	O	O
desirable	O	O
characteristics	O
of	O	O
the	O	O
micelles	B-CHEM
.	O	O

The	O	O
micelle	B-CHEM
system	I-CHEM
of	O	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
formed	O	O
at	O	O
drug	B-CHEM
to	O	O
polymer	B-CHEM
ratios	O
of	O	O
1	O	O
:	O	O
4	O	O
and	O	O
1	O	O
:	O	O
2	O	O
,	O	O
respectively	O	O
,	O	O
was	O	O
found	O	O
to	O	O
be	O	O
the	O	O
most	O	O
suitable	O	O
monodispersed	O	O
system	O	O
with	O	O
a	O	O
nanosize	O
-	O
range	O
diameter	O
.	O	O

The	O	O
in	B-PROC
vivo	I-PROC
study	I-PROC
in	O	O
zebrafish	B-LIVB
eggs	B-ANAT
indicates	O	O
that	O	O
the	O	O
toxicity	O
of	O	O
CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
is	O	O
a	O	O
dose	O
response	O
.	O	O

CS	B-CHEM
-	I-CHEM
P68	I-CHEM
and	O	O
CS	B-CHEM
-	I-CHEM
P127	I-CHEM
at	O	O
a	O	O
drug	O
dose	O
of	O	O
10	O	O
ng	O	O
/	O	O
mL	O	O
or	O	O
less	O
is	O	O
safe	O	O
for	O	O
zebrafish	B-LIVB
embryo	B-ANAT
growth	B-PHYS
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	B-PROC
indicate	O	O
enhanced	O
water	O
solubility	O
of	O	O
chrysin	B-CHEM
.	O	O

Chrysin	B-CHEM
loaded	O	O
poloxamer	B-CHEM
micelles	B-CHEM
are	O	O
promising	O	O
for	O	O
further	O	O
use	O	O
in	O	O
in	B-PROC
vivo	I-PROC
studies	I-PROC
in	O	O
mammalian	B-LIVB
animals	B-LIVB
and	O	O
humans	B-LIVB
.	O	O

Adenoviral	B-LIVB
Delivery	B-PROC
of	O	O
Tumor	B-CHEM
Necrosis	I-CHEM
Factor	I-CHEM
-	I-CHEM
α	I-CHEM
and	O	O
Interleukin	B-CHEM
-	I-CHEM
2	I-CHEM
Enables	O	O
Successful	O	O
Adoptive	B-PROC
Cell	I-PROC
Therapy	I-PROC
of	O	O
Immunosuppressive	B-CHEM
Melanoma	B-DISO
Adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
is	O	O
a	O	O
promising	O	O
treatment	O
approach	O
for	O	O
metastatic	B-DISO
cancer	I-DISO
,	O	O
but	O	O
efficacy	O
in	O	O
solid	B-DISO
tumors	I-DISO
has	O	O
only	O	O
been	O	O
achieved	O	O
with	O	O
toxic	O
pre	O	O
-	O	O
and	O	O
postconditioning	O	O
regimens	O	O
.	O	O

Thus	O	O
,	O	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
therapies	I-PROC
would	O	O
benefit	O
from	O	O
complementary	O	O
modalities	O
that	O	O
enable	O	O
their	O	O
full	O
potential	O
without	O	O
excessive	O
toxicity	O
.	O	O

We	O	O
aimed	O
to	O	O
improve	O
the	O	O
efficacy	O
and	O	O
safety	O
of	O	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
by	O	O
using	O	O
adenoviral	B-CHEM
vectors	I-CHEM
for	O	O
direct	O	O
delivery	O
of	O	O
immunomodulatory	B-PROC
murine	B-LIVB
cytokines	B-CHEM
into	O	O
B16	B-ANAT
.	I-ANAT

OVA	I-ANAT
melanoma	B-DISO
tumors	I-DISO
with	O	O
concomitant	O
T	B-CHEM
-	I-CHEM
cell	I-CHEM
receptor	I-CHEM
transgenic	B-PROC
OT	I-PROC
-	I-PROC
I	I-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
.	O	O

Armed	O	O
adenoviruses	B-LIVB
expressed	O	O
high	O	O
local	O	O
and	O	O
low	O	O
systemic	O	O
levels	O	O
of	O	O
cytokine	B-CHEM
when	O	O
injected	O
into	O	O
B16	B-ANAT
.	I-ANAT

OVA	I-ANAT
tumors	B-DISO
,	O	O
suggesting	O	O
safety	O
of	O	O
virus	B-PROC
-	I-PROC
mediated	I-PROC
cytokine	I-PROC
delivery	I-PROC
.	O	O

Antitumor	O
efficacy	O
was	O	O
significantly	O	O
enhanced	O
with	O	O
adenoviruses	B-LIVB
coding	O	O
for	O	O
murine	B-LIVB
interleukin	B-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
)	O	O
and	O	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
α	I-CHEM
(	O	O
mTNFα	B-CHEM
)	O	O
when	O	O
compared	O	O
with	O	O
T	B-PROC
-	I-PROC
cell	I-PROC
transfer	I-PROC
alone	O	O
or	O	O
viruses	B-LIVB
alone	O	O
.	O	O

Further	O	O
improvement	O
in	O	O
efficacy	O
was	O	O
achieved	O	O
with	O	O
a	O	O
triple	O
combination	O
of	O	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
mTNFα	B-CHEM
,	O	O
and	O	O
OT	B-ANAT
-	I-ANAT
I	I-ANAT
T	I-ANAT
-	I-ANAT
cells	I-ANAT
.	O	O

Mechanistic	O
studies	O
suggest	O	O
that	O	O
mIL	B-CHEM
-	I-CHEM
2	I-CHEM
has	O	O
an	O	O
important	O
role	O
in	O	O
activating	O
T	B-ANAT
-	I-ANAT
cells	I-ANAT
at	O	O
the	O	O
tumor	B-DISO
,	O	O
while	O	O
mTNFα	B-CHEM
induces	O	O
chemokine	B-CHEM
expression	B-PHYS
.	O	O

Furthermore	O	O
,	O	O
adenovirus	B-LIVB
treatments	B-PROC
enhanced	O
tumor	B-DISO
-	O	O
infiltration	O	O
of	O	O
OT	B-ANAT
-	I-ANAT
I	I-ANAT
T	I-ANAT
-	I-ANAT
cells	I-ANAT
as	O	O
demonstrated	O
by	O	O
SPECT	B-PROC
/	I-PROC
CT	I-PROC
imaging	I-PROC
of	O	O
(	B-ANAT
111	I-ANAT
)	I-ANAT
In	I-ANAT
-	I-ANAT
labeled	I-ANAT
cells	I-ANAT
.	O	O

Our	O	O
results	O
suggest	O
the	O	O
utility	O	O
of	O	O
cytokine	B-CHEM
-	I-CHEM
coding	I-CHEM
adenoviruses	B-LIVB
for	O	O
improving	O
the	O	O
efficacy	O
of	O	O
adoptive	B-PROC
T	I-PROC
-	I-PROC
cell	I-PROC
therapies	I-PROC
.	O	O

New	O
Breast	B-DISO
Pain	I-DISO
Chart	B-DEVI
for	O	O
Objective	O
Record	O
of	O	O
Mastalgia	B-DISO
Mastalgia	B-DISO
is	O	O
the	O	O
commonest	O
affliction	B-PHYS
of	O	O
mammary	B-ANAT
gland	I-ANAT
among	O	O
ladies	B-LIVB
of	O	O
the	O	O
reproductive	O
age	B-LIVB
group	I-LIVB
.	O	O

Since	O	O
etiopathogenesis	O
and	O	O
therapy	B-PROC
are	O	O
different	O
for	O	O
cyclical	B-DISO
and	O	O
noncyclical	B-DISO
pain	I-DISO
,	O	O
it	O	O
is	O	O
imperative	O	O
to	O	O
ascertain	O	O
the	O	O
exact	O	O
type	O	O
correctly	O	O
.	O	O

This	O	O
is	O	O
usually	O	O
done	O	O
in	O	O
the	O	O
breast	B-OBJC
clinics	I-OBJC
by	O	O
advising	O	O
the	O	O
patient	B-LIVB
to	O	O
fill	O	O
a	O	O
pain	O
diary	O
over	O	O
a	O	O
period	O
of	O	O
2	O	O
months	O
over	O	O
two	O	O
menstrual	B-PHYS
cycles	I-PHYS
.	O	O

The	O	O
Cardiff	B-DEVI
pain	I-DEVI
chart	I-DEVI
records	I-DEVI
the	O	O
severity	O
of	O	O
pain	B-DISO
in	O	O
the	O	O
form	O	O
of	O	O
a	O	O
triangle	O
for	O	O
mild	O
to	O	O
moderate	B-DISO
pain	I-DISO
and	O	O
a	O	O
square	O
for	O	O
severe	B-DISO
pain	I-DISO
.	O	O

Moreover	O	O
,	O	O
Cardiff	B-DEVI
pain	I-DEVI
chart	I-DEVI
does	O	O
not	O	O
allow	O	O
a	O	O
patient	B-LIVB
to	O	O
record	O
the	O	O
severity	O
of	O	O
pain	B-DISO
on	O	O
days	O
of	O	O
menses	B-PHYS
,	O	O
as	O	O
she	O	O
has	O	O
to	O	O
put	O	O
the	O	O
letter	O	O
""""	O	O
P	O	O
""""	O	O
in	O	O
the	O	O
box	O	O
.	O	O

These	O	O
problems	B-DISO
have	O	O
been	O	O
resolved	O
in	O	O
the	O	O
new	O
breast	B-DISO
pain	I-DISO
chart	B-DEVI
.	O	O

In	O	O
the	O	O
new	O
pain	B-DEVI
chart	I-DEVI
,	O	O
the	O	O
lady	B-LIVB
records	O
pain	B-DISO
severity	O
in	O	O
the	O	O
form	O	O
of	O	O
visual	B-PHYS
linear	I-PHYS
analogue	I-PHYS
scale	I-PHYS
score	I-PHYS
on	O	O
every	O
day	O
of	O	O
menstrual	B-PHYS
cycle	I-PHYS
.	O	O

She	O	O
enters	O	O
her	O	O
menstrual	B-PHYS
experience	B-PHYS
on	O	O
a	O	O
separate	O	O
part	O	O
of	O	O
chart	B-DEVI
,	O	O
which	O	O
allows	O	O
us	O	O
to	O	O
visualize	O
the	O	O
full	O	O
month	O
's	O
pain	B-DISO
severity	O
in	O	O
an	O	O
uncluttered	O	O
way	O	O
.	O	O

Graphene	B-CHEM
oxide	I-CHEM
/	O	O
multi	B-CHEM
-	I-CHEM
walled	I-CHEM
carbon	I-CHEM
nanotubes	I-CHEM
as	O	O
nanofeatured	B-OBJC
scaffolds	I-OBJC
for	O	O
the	O	O
assisted	O
deposition	O
of	O	O
nanohydroxyapatite	B-CHEM
:	O	O
characterization	O
and	O	O
biological	O
evaluation	O
Nanohydroxyapatite	B-CHEM
(	O	O
nHAp	B-CHEM
)	O	O
is	O	O
an	O	O
emergent	O
bioceramic	B-CHEM
that	O	O
shows	O	O
similar	O	O
chemical	B-PHEN
and	O	O
crystallographic	O
properties	O
as	O	O
the	O	O
mineral	B-CHEM
phase	O
present	B-DISO
in	O	O
bone	B-ANAT
.	O	O

However	O	O
,	O	O
nHAp	B-CHEM
presents	B-DISO
low	O	O
fracture	B-DISO
toughness	O
and	O	O
tensile	O
strength	O
,	O	O
limiting	O
its	O	O
application	O
in	O	O
bone	O
tissue	O
engineering	B-PROC
.	O	O

Conversely	O	O
,	O	O
multi	B-CHEM
-	I-CHEM
walled	I-CHEM
carbon	I-CHEM
nanotubes	I-CHEM
(	O	O
MWCNTs	B-CHEM
)	O	O
have	O	O
been	O	O
widely	O	O
used	B-DISO
for	O	O
composite	O
applications	O
due	O	O
to	O	O
their	O	O
excellent	O
mechanical	B-PHEN
and	O	O
physicochemical	B-PHEN
properties	O
,	O	O
although	O	O
their	O	O
hydrophobicity	O
usually	O	O
impairs	O
some	O	O
applications	O
.	O	O

To	O	O
improve	O	O
MWCNT	B-CHEM
wettability	O
,	O	O
oxygen	B-PHEN
plasma	I-PHEN
etching	I-PHEN
has	O	O
been	O	O
applied	O
to	O	O
promote	O
MWCNT	B-CHEM
exfoliation	B-PHEN
and	O	O
oxidation	B-PHYS
and	O	O
to	O	O
produce	O	O
graphene	B-CHEM
oxide	I-CHEM
(	O	O
GO	B-CHEM
)	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
tips	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
prepared	B-DISO
a	O	O
series	O	O
of	O	O
nHAp	B-CHEM
/	O	O
MWCNT	B-CHEM
-	O	O
GO	B-CHEM
nanocomposites	B-OBJC
aimed	O
at	O	O
producing	O	O
materials	B-OBJC
that	O	O
combine	O	O
similar	O	O
bone	B-ANAT
characteristics	O
(	O	O
nHAp	B-CHEM
)	O	O
with	O	O
high	O	O
mechanical	O
strength	O
(	O	O
MWCNT	B-CHEM
-	O	O
GO	B-CHEM
)	O	O
.	O	O

After	O	O
MWCNT	B-CHEM
production	O
and	O	O
functionalization	O
to	O	O
produce	O	O
MWCNT	B-CHEM
-	O	O
GO	B-CHEM
,	O	O
ultrasonic	O
irradiation	B-PHEN
was	O	O
employed	B-DISO
to	O	O
precipitate	O
nHAp	B-CHEM
onto	O	O
the	O	O
MWCNT	B-CHEM
-	O	O
GO	B-CHEM
scaffolds	B-OBJC
(	O	O
at	O	O
1	O	O
-	O	O
3	O	O
wt	O	O
%	O	O
)	O	O
.	O	O

We	O	O
employed	B-DISO
various	O	O
techniques	O
to	O	O
characterize	O
the	O	O
nanocomposites	B-OBJC
,	O	O
including	O	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
(	O	O
TEM	B-PROC
)	O	O
,	O	O
Raman	B-PROC
spectroscopy	I-PROC
,	O	O
thermogravimetry	B-PROC
,	O	O
and	O	O
gas	B-PROC
adsorption	I-PROC
(	O	O
the	O	O
Brunauer	B-PROC
-	I-PROC
Emmett	I-PROC
-	I-PROC
Teller	I-PROC
method	I-PROC
)	O	O
.	O	O

We	O	O
used	O	O
simulated	B-PROC
body	B-ANAT
fluid	I-ANAT
to	O	O
evaluate	B-PROC
their	O	O
bioactivity	O
and	O	O
human	B-LIVB
osteoblasts	B-ANAT
(	O	O
bone	B-ANAT
-	I-ANAT
forming	I-ANAT
cells	I-ANAT
)	O	O
to	O	O
evaluate	B-PROC
cytocompatibility	B-DISO
.	O	O

We	O	O
also	O	O
investigated	O
their	O	O
bactericidal	B-CHEM
effect	O
against	O	O
Staphylococcus	B-LIVB
aureus	I-LIVB
and	O	O
Escherichia	B-LIVB
coli	I-LIVB
.	O	O

TEM	B-PROC
analysis	B-PROC
revealed	O	O
homogeneous	O
distributions	O
of	O	O
nHAp	B-CHEM
crystal	I-CHEM
grains	I-CHEM
along	O	O
the	O	O
MWCNT	B-CHEM
-	O	O
GO	B-CHEM
surfaces	O
.	O	O

All	O	O
nanocomposites	B-OBJC
were	O	O
proved	O	O
to	O	O
be	O	O
bioactive	B-OBJC
,	O	O
since	O	O
carbonated	B-CHEM
nHAp	I-CHEM
was	O	O
found	B-DISO
after	O	O
21	O	O
days	O
in	O	O
simulated	B-PROC
body	B-ANAT
fluid	I-ANAT
.	O	O

All	O	O
nanocomposites	B-OBJC
showed	O	O
potential	O
for	O	O
biomedical	B-CHEM
applications	O
with	O	O
no	O	O
cytotoxicity	B-DISO
toward	O	O
osteoblasts	B-ANAT
and	O	O
impressively	O	O
demonstrated	O	O
a	O	O
bactericidal	B-CHEM
effect	O
without	O	O
the	O	O
use	O	O
of	O	O
antibiotics	B-CHEM
.	O	O

All	O	O
of	O	O
the	O	O
aforementioned	O	O
properties	O
make	O	O
these	O	O
materials	B-OBJC
very	O	O
attractive	O
for	O	O
bone	B-PROC
tissue	I-PROC
engineering	I-PROC
applications	I-PROC
,	O	O
either	O	O
as	O	O
a	O	O
matrix	O
or	O	O
as	O	O
a	O	O
reinforcement	B-CHEM
material	I-CHEM
for	O	O
numerous	O
polymeric	B-CHEM
nanocomposites	B-OBJC
.	O	O

Diagnostic	O
value	O
of	O	O
diffusion	B-PROC
weighted	I-PROC
MRI	I-PROC
and	O	O
ADC	O
in	O	O
differential	B-PROC
diagnosis	I-PROC
of	O	O
cavernous	B-DISO
hemangioma	I-DISO
of	O	O
the	O	O
liver	B-ANAT
To	O	O
investigate	O
the	O	O
use	O
of	O
diffusion	B-PROC
weighted	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
DWI	B-PROC
)	O	O
and	O	O
the	O	O
apparent	O
diffusion	O
coefficient	O
(	O	O
ADC	O
)	O	O
values	O
in	O	O
the	O	O
diagnosis	B-PROC
of	O	O
hemangioma	B-DISO
.	O	O

The	O	O
study	B-LIVB
population	I-LIVB
consisted	O	O
of	O	O
72	O	O
patients	B-LIVB
with	O	O
liver	B-DISO
masses	I-DISO
larger	O	O
than	O	O
1	O	O
cm	O	O
(	O	O
72	O	O
focal	B-DISO
lesions	I-DISO
)	O	O
.	O	O

DWI	B-PROC
examination	B-PROC
with	O	O
a	O	O
b	O	O
value	O	O
of	O	O
600	O	O
s	O	O
/	O	O
mm2	O	O
was	O	O
carried	O	O
out	O	O
for	O	O
all	O	O
patients	B-LIVB
.	O	O

After	O	O
DWI	B-PROC
examination	B-PROC
,	O	O
an	O	O
ADC	O
map	O	O
was	O	O
created	O	O
and	O	O
ADC	O
values	O
were	O	O
measured	O	O
for	O	O
72	O	O
liver	B-DISO
masses	I-DISO
and	O	O
normal	O
liver	B-ANAT
tissue	I-ANAT
(	O	O
control	B-LIVB
group	I-LIVB
)	O	O
.	O	O

The	O	O
average	O
ADC	O
values	O
of	O	O
normal	O
liver	B-ANAT
tissue	I-ANAT
and	O	O
focal	B-DISO
liver	I-DISO
lesions	I-DISO
,	O	O
the	O	O
""""	O	O
cut	O
-	O
off	O
""""	O	O
ADC	O
values	O
,	O	O
and	O	O
the	O	O
diagnostic	O
sensitivity	O
and	O	O
specificity	O
of	O	O
the	O	O
ADC	O
map	O	O
in	O	O
diagnosing	B-PROC
hemangioma	B-DISO
,	O	O
benign	O
and	O	O
malignant	O
lesions	B-DISO
were	O	O
researched	O	O
.	O	O

Of	O	O
the	O	O
72	O	O
liver	B-DISO
masses	I-DISO
,	O	O
51	O	O
were	O	O
benign	O
and	O	O
21	O	O
were	O	O
malignant	O
.	O	O

Benign	O
lesions	B-DISO
comprised	O	O
38	O	O
hemangiomas	B-DISO
and	O	O
13	O	O
simple	B-DISO
cysts	I-DISO
.	O	O

Malignant	O
lesions	B-DISO
comprised	O	O
9	O	O
hepatocellular	B-DISO
carcinomas	I-DISO
,	O	O
and	O	O
12	O	O
metastases	B-DISO
.	O	O

The	O	O
highest	O	O
ADC	O
values	O
were	O	O
measured	O	O
for	O	O
cysts	B-DISO
(	O	O
3	O	O
.	O	O
782±0	O	O
.	O	O

53×10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/	O	O
s	O	O
)	O	O
and	O	O
hemangiomas	B-DISO
(	O	O
2	O	O
.	O	O
705±0	O	O
.	O	O

63×10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/	O	O
s	O	O
)	O	O
.	O	O

The	O	O
average	O
ADC	O
value	O
of	O	O
hemangiomas	B-DISO
was	O	O
significantly	O
higher	O
than	O	O
malignant	O
lesions	B-DISO
and	O	O
the	O	O
normal	B-LIVB
control	I-LIVB
group	I-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

The	O	O
average	O
ADC	O
value	O
of	O	O
cysts	B-DISO
were	O	O
significantly	O
higher	O
when	O	O
compared	O	O
to	O	O
hemangiomas	B-DISO
and	O	O
normal	B-LIVB
control	I-LIVB
group	I-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

To	O	O
distinguish	O	O
hemangiomas	B-DISO
from	O	O
malignant	O
liver	B-DISO
lesions	I-DISO
,	O	O
the	O	O
""""	O	O
cut	O
-	O
off	O
""""	O	O
ADC	O
value	O
of	O	O
1	O	O
.	O	O

800×10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/	O	O
s	O	O
had	O	O
a	O	O
sensitivity	O
of	O	O
97	O	O
.	O	O

4	O	O
%	O	O
and	O	O
a	O	O
specificity	O
of	O	O
90	O	O
.	O	O
9	O	O
%	O	O
.	O	O

To	O	O
distinguish	O	O
hemangioma	B-DISO
from	O	O
normal	O
liver	B-ANAT
parenchyma	I-ANAT
the	O	O
""""	O	O
cut	O
-	O
off	O
""""	O
value	O
of	O	O
1	O	O
.	O	O

858×10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/	O	O
s	O	O
had	O	O
a	O	O
sensitivity	O
of	O	O
97	O	O
.	O	O

4	O	O
%	O	O
and	O	O
a	O	O
specificity	O
of	O	O
95	O	O
.	O	O

7	O	O
%	O	O
.	O	O

To	O	O
distinguish	O	O
benign	O
liver	B-DISO
lesions	I-DISO
from	O	O
malignant	O
liver	B-DISO
lesions	I-DISO
the	O	O
""""	O	O
cut	O
-	O
off	O
""""	O
value	O
of	O	O
1	O	O
.	O	O

800×10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/	O	O
s	O	O
had	O	O
a	O	O
sensitivity	O
of	O	O
96	O	O
.	O	O

1	O	O
%	O	O
and	O	O
a	O	O
specificity	O
of	O	O
90	O	O
.	O	O
0	O	O
%	O	O
.	O	O

DWI	B-PROC
and	O	O
quantitative	O
measurement	O
of	O	O
ADC	O
values	O
can	O	O
be	O	O
used	O	O
in	O	O
differential	B-PROC
diagnosis	I-PROC
of	O	O
benign	O
and	O	O
malignant	O
liver	B-DISO
lesions	I-DISO
and	O	O
also	O	O
in	O	O
the	O	O
diagnosis	B-PROC
and	O	O
differentiation	O
of	O	O
hemangiomas	B-DISO
.	O	O

When	O	O
dynamic	B-PROC
examination	I-PROC
cannot	O	O
distinguish	O	O
cases	O
with	O	O
vascular	B-DISO
metastasis	I-DISO
and	O	O
lesions	B-DISO
from	O	O
hemangioma	B-DISO
,	O	O
DWI	B-PROC
and	O	O
ADC	O
values	O
can	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
primary	O
diagnosis	O
and	O	O
differential	B-PROC
diagnosis	I-PROC
.	O	O

The	O	O
technique	O
does	O	O
not	O	O
require	O	O
contrast	B-CHEM
material	I-CHEM
,	O	O
so	O	O
it	O	O
can	O	O
safely	O	O
be	O	O
used	O	O
in	O	O
patients	B-LIVB
with	O	O
renal	B-DISO
failure	I-DISO
.	O	O

The	O	O
Demand	O	O
for	O	O
Cigarettes	B-OBJC
in	O	O
Tanzania	B-GEOG
and	O	O
Implications	O
for	O	O
Tobacco	B-CHEM
Taxation	O
Policy	O
The	O	O
study	B-PROC
attempts	O	O
to	O	O
estimate	O	O
the	O	O
demand	O	O
for	O	O
cigarettes	B-OBJC
in	O	O
Tanzania	B-GEOG
and	O	O
presents	O	O
simulation	B-PROC
results	O
on	O	O
the	O	O
effect	O
of	O	O
the	O	O
cigarette	B-OBJC
excise	O
tax	O
on	O	O
smoking	O
participation	O
,	O	O
government	O
revenue	O
,	O	O
and	O	O
related	O	O
topics	O	O
.	O	O

After	O	O
briefly	O	O
summarizing	O	O
the	O	O
magnitude	O
and	O	O
spread	O	O
of	O	O
cigarette	B-DISO
consumption	I-DISO
in	O	O
the	O	O
country	B-GEOG
,	O	O
the	O	O
paper	O	O
reviews	O	O
some	O	O
empirical	O	O
estimates	O	O
from	O	O
African	B-GEOG
and	O	O
other	O	O
countries	B-GEOG
.	O	O

The	O	O
2008	O	O
Tanzanian	B-GEOG
household	O
budget	O
survey	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
demand	O	O
for	O	O
cigarettes	B-OBJC
in	O	O
Tanzania	B-GEOG
.	O	O

The	O	O
descriptive	O	O
statistics	O	O
suggest	O	O
that	O	O
the	O	O
smoking	O
prevalence	O	O
for	O	O
Tanzania	B-GEOG
is	O	O
15	O	O
.	O	O
35	O	O
percent	O	O
with	O	O
low	O	O
variability	O	O
across	O	O
expenditure	O
(	O
income	O
)	O
groups	O
.	O	O

Smoking	O
intensity	O	O
and	O	O
per	O
capita	O
consumption	O
were	O	O
estimated	O	O
at	O	O
7	O	O
.	O	O

08	O	O
cigarettes	B-OBJC
and	O	O
1	O	O
.	O	O
33	O	O
cigarettes	B-OBJC
,	O	O
respectively	O	O
,	O	O
a	O	O
relatively	O	O
low	O	O
value	O	O
.	O	O

A	O	O
two	O
-	O
part	O
demand	O
equation	O
model	O
was	O	O
used	O	O
to	O	O
estimate	O	O
various	O	O
elasticities	O
.	O	O

For	O	O
the	O	O
overall	O	O
equation	O
,	O	O
the	O	O
price	O
elasticities	O
of	O	O
smoking	O
participation	O
,	O	O
smoking	O
intensity	O	O
,	O	O
and	O	O
total	O	O
elasticity	O
were	O	O
estimated	O	O
at	O	O
-0	O	O
.	O	O

879	O	O
,	O	O
-0	O	O
.	O	O
853	O	O
,	O	O
and	O	O
-1	O	O
.	O	O

732	O	O
,	O	O
respectively	O	O
.	O	O

Compared	O	O
to	O	O
similar	O	O
results	O	O
in	O	O
other	O	O
developing	O
countries	O
,	O	O
the	O	O
estimates	O	O
appear	O	O
quite	O	O
high	O	O
.	O	O

When	O	O
estimated	O	O
by	O	O
expenditure	O
(	O
income	O
)	O
groups	O
,	O	O
the	O	O
magnitude	O
of	O	O
the	O	O
elasticity	O
appears	O	O
higher	O	O
among	O	O
high	O
expenditure	O
groups	O
than	O	O
among	O	O
low	O
expenditure	O
groups	O
.	O	O

Two	O	O
simulation	B-PROC
exercises	O	O
were	O	O
undertaken	O	O
.	O	O

First	O	O
,	O	O
the	O	O
effect	O
of	O	O
different	O	O
excise	O
rates	O
on	O	O
smoking	O
participation	O
rate	O
,	O	O
cigarette	B-DISO
consumption	I-DISO
,	O	O
tax	O
revenue	O
,	O	O
and	O	O
related	O	O
responses	O	O
was	O	O
estimated	O	O
and	O	O
highlighted	O	O
.	O	O

Second	O	O
,	O	O
the	O	O
same	O	O
exercise	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
effect	O
of	O	O
a	O	O
given	O	O
increase	O
in	O	O
the	O	O
cigarette	B-OBJC
excise	O
tax	O
on	O	O
various	O	O
expenditure	O
groups	O
.	O	O

The	O	O
overall	O	O
results	O
suggest	O	O
that	O	O
an	O	O
increase	O
in	O	O
the	O	O
excise	O
tax	O
on	O	O
cigarettes	B-OBJC
in	O	O
Tanzania	B-GEOG
would	O	O
reduce	O	O
cigarette	B-DISO
consumption	I-DISO
and	O	O
increase	O
government	O
tax	O
revenue	O
.	O	O

Functional	O
Analysis	B-PROC
of	O	O
a	O	O
Bacterial	B-LIVB
Antifreeze	B-CHEM
Protein	I-CHEM
Indicates	O	O
a	O	O
Cooperative	B-DISO
Effect	O
between	O	O
Its	O	O
Two	O	O
Ice	B-PHYS
-	I-PHYS
Binding	I-PHYS
Domains	O
Antifreeze	B-CHEM
proteins	I-CHEM
make	O	O
up	O	O
a	O	O
class	O	O
of	O	O
ice	B-CHEM
-	I-CHEM
binding	I-CHEM
proteins	I-CHEM
(	O	O
IBPs	B-CHEM
)	O	O
that	O	O
are	O	O
possessed	O	O
and	O	O
expressed	B-PHYS
by	O	O
certain	O	O
cold	B-PHEN
-	O	O
adapted	B-PHYS
organisms	B-LIVB
to	O	O
enhance	O
their	O	O
freezing	B-PHEN
tolerance	I-PHEN
.	O	O

Here	O	O
we	O	O
report	O	O
the	O	O
biophysical	B-PHEN
and	O	O
functional	O
characterization	O
of	O	O
an	O	O
IBP	B-CHEM
discovered	O	O
in	O	O
a	O	O
bacterium	B-LIVB
recovered	O	O
from	O	O
a	O	O
deep	O
glacial	B-PHEN
ice	B-CHEM
core	I-CHEM
drilled	O	O
at	O	O
Vostok	B-GEOG
Station	I-GEOG
,	I-GEOG
Antarctica	I-GEOG
(	O	O
IBPv	B-CHEM
)	O	O
.	O	O

Our	O	O
study	B-PROC
showed	O	O
that	O	O
the	O	O
recombinant	B-CHEM
protein	I-CHEM
rIBPv	B-CHEM
exhibited	O	O
a	O	O
thermal	B-PHEN
hysteresis	B-DISO
of	O	O
2	O	O
°	O	O
C	O	O
at	O	O
concentrations	O
of	O	O
>	O	O
50	O	O
μM	O	O
,	O	O
effectively	O	O
inhibited	O
ice	B-CHEM
recrystallization	B-PHEN
,	O	O
and	O	O
enhanced	O
bacterial	B-PHEN
viability	I-PHEN
during	O	O
freeze	B-PHEN
-	I-PHEN
thaw	I-PHEN
cycling	I-PHEN
.	O	O

Circular	B-PROC
dichroism	I-PROC
scans	I-PROC
indicated	O	O
that	O	O
rIBPv	B-CHEM
mainly	O	O
consists	O	O
of	O	O
β	O
strands	O
,	O	O
and	O	O
its	O	O
denaturing	B-PHYS
temperature	O
was	O	O
53	O	O
.	O	O
5	O	O
°	O	O
C	O	O
.	O	O

Multiple	B-PROC
-	I-PROC
sequence	I-PROC
alignment	I-PROC
of	O	O
homologous	B-CHEM
IBPs	I-CHEM
predicted	O	O
that	O	O
IBPv	B-CHEM
contains	O	O
two	O	O
ice	O
-	O
binding	O
domains	O
,	O	O
a	O	O
feature	O	O
unique	O
among	O	O
known	O	O
IBPs	B-CHEM
.	O	O

To	O	O
examine	O	O
functional	O
differences	O	O
between	O	O
the	O	O
IBPv	O
domains	O
,	O	O
each	O	O
domain	O
was	O	O
cloned	B-PROC
,	O	O
expressed	B-PHYS
,	O	O
and	O	O
purified	O
.	O	O

The	O	O
second	O
domain	O
(	O	O
domain	O
B	O
)	O	O
expressed	B-PHYS
greater	O	O
ice	B-PHYS
binding	I-PHYS
activity	I-PHYS
.	O	O

Data	O	O
from	O	O
thermal	B-PHEN
hysteresis	B-DISO
and	O	O
gel	B-PROC
filtration	I-PROC
assays	I-PROC
supported	O	O
the	O	O
idea	O	O
that	O	O
the	O	O
two	O	O
domains	O
cooperate	O	O
to	O	O
achieve	O	O
a	O	O
higher	O	O
ice	B-PHYS
binding	I-PHYS
effect	I-PHYS
by	O	O
forming	O	O
heterodimers	B-CHEM
.	O	O

However	O	O
,	O	O
physical	O	O
linkage	O	O
of	O	O
the	O	O
domains	O
was	O	O
not	O	O
required	O	O
for	O	O
this	O	O
effect	O	O
.	O	O

Structural	B-PHYS
Remodeling	I-PHYS
of	O	O
Sympathetic	B-PHYS
Innervation	I-PHYS
in	O	O
Atherosclerotic	B-DISO
Blood	B-ANAT
Vessels	I-ANAT
:	O	O
Role	O	O
of	O	O
Atherosclerotic	B-DISO
Disease	B-DISO
Progression	I-DISO
and	O	O
Chronic	O
Social	B-DISO
Stress	I-DISO
The	O	O
sympathetic	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O	O
SNS	B-ANAT
)	O	O
can	O	O
undergo	O	O
dramatic	B-PHYS
structural	I-PHYS
plasticity	I-PHYS
in	O	O
response	O	O
to	O	O
behavioral	O
factors	O
and	O	O
/	O	O
or	O	O
the	O	O
presence	O
of	O	O
disease	B-DISO
,	O	O
leading	O	O
to	O	O
SNS	B-ANAT
hyperinnervation	B-PHYS
of	O	O
peripheral	O
tissues	O
.	O	O

The	O	O
SNS	B-ANAT
has	O	O
been	O	O
proposed	O	O
as	O	O
an	O	O
important	O	O
mediator	O	O
between	O	O
stressful	O
behavior	O
and	O	O
the	O	O
progression	B-DISO
of	O	O
atherosclerosis	B-DISO
in	O	O
the	O	O
vasculature	B-ANAT
.	O	O

The	O	O
present	O	O
study	B-PROC
examined	O	O
whether	O	O
structural	B-PHYS
remodeling	I-PHYS
of	O	O
the	O	O
SNS	B-ANAT
occurs	O	O
in	O	O
the	O	O
vasculature	B-ANAT
in	O	O
a	O	O
genetically	O
hyperlipidemic	B-DISO
animal	B-LIVB
model	I-LIVB
of	O	O
atherosclerosis	B-DISO
,	O	O
the	O	O
Watanabe	B-LIVB
heritable	I-LIVB
hyperlipidemic	I-LIVB
rabbit	I-LIVB
(	O	O
WHHL	B-LIVB
;	O	O
relative	O	O
to	O	O
normolipidemic	B-DISO
New	B-LIVB
Zealand	I-LIVB
white	I-LIVB
rabbits	I-LIVB
[	O	O
NZW	B-LIVB
]	O	O
)	O	O
,	O	O
and	O	O
whether	O	O
SNS	B-ANAT
plasticity	B-PHYS
is	O	O
driven	O	O
by	O	O
the	O	O
progression	B-DISO
of	I-DISO
disease	I-DISO
and	O	O
/	O	O
or	O	O
by	O	O
stressful	O
social	O
behavior	O
.	O	O

WHHL	B-LIVB
and	O	O
NZW	B-LIVB
rabbits	B-LIVB
were	O	O
assigned	O	O
to	O	O
an	O	O
unstable	B-DISO
or	O	O
stable	O
social	O
environment	O
for	O	O
4	O	O
months	O
.	O	O

Aortic	B-DISO
atherosclerosis	I-DISO
was	O	O
assessed	O	O
and	O	O
SNS	B-ANAT
aortic	B-ANAT
innervation	B-PHYS
quantified	O	O
using	O	O
immunofluorescent	B-PROC
microscopy	I-PROC
.	O	O

Numerous	O	O
SNS	B-ANAT
varicosities	B-DISO
were	O	O
observed	O	O
throughout	O	O
the	O	O
aorta	B-ANAT
in	O	O
WHHLs	B-LIVB
and	O	O
NZWs	B-LIVB
,	O	O
extending	O	O
into	O	O
the	O	O
vascular	O
media	O
and	O	O
intima	O
,	O	O
an	O	O
innervation	B-PHYS
pattern	O	O
not	O	O
previously	O	O
reported	O	O
.	O	O

WHHLs	B-LIVB
exhibited	O	O
significantly	O
greater	O
innervation	B-PHYS
than	O	O
NZWs	B-LIVB
(	O	O
F	O	O
(	O	O
1	O	O
,	O	O
41	O	O
)	O	O
=	O	O
55	O	O
.	O	O

3	O	O
,	O	O
p	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
with	O	O
extensive	O	O
innervation	B-PHYS
of	O	O
the	O	O
atherosclerotic	B-DISO
neointima	B-DISO
.	O	O

The	O	O
innervation	B-PHYS
density	O
was	O	O
highly	O	O
correlated	O
with	O	O
the	O	O
extent	O	O
of	O	O
disease	B-DISO
in	O	O
the	O	O
WHHLs	B-LIVB
(	O	O
r	O	O
(	O	O
21	O	O
)	O	O
=	O	O
0	O	O
.	O	O
855	O	O
,	O	O
p	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Social	O
environment	O
did	O	O
not	O	O
influence	O	O
innervation	B-PHYS
in	O	O
NZWs	B-LIVB
(	O	O
aortic	B-ANAT
arch	I-ANAT
:	O	O
p	O	O
=	O	O
.078	O	O
,	O	O
thoracic	B-ANAT
aorta	I-ANAT
:	O	O
p	O	O
=	O	O
.34	O	O
)	O	O
or	O	O
WHHLs	B-LIVB
(	O	O
arch	B-ANAT
:	O	O
p	O	O
=	O	O
.97	O	O
,	O	O
thoracic	B-ANAT
:	O	O
p	O	O
=	O	O
.61	O	O
)	O	O
.	O	O

The	O	O
findings	B-DISO
suggest	O	O
that	O	O
hyperinnervation	B-PHYS
is	O	O
driven	O	O
largely	O	O
by	O	O
the	O	O
progression	B-DISO
of	I-DISO
disease	I-DISO
rather	O	O
than	O	O
social	O
environment	O
.	O	O

SNS	B-ANAT
innervation	B-PHYS
patterns	O
observed	O	O
in	O	O
atherosclerotic	B-DISO
human	B-LIVB
and	O	O
mouse	B-LIVB
aortas	B-ANAT
were	O	O
consistent	O	O
with	O	O
the	O	O
rabbit	B-LIVB
,	O	O
suggesting	O	O
that	O	O
SNS	B-ANAT
hyperinnervation	B-PHYS
of	O	O
the	O	O
diseased	B-DISO
vessel	B-ANAT
wall	I-ANAT
is	O	O
a	O	O
general	O	O
feature	O	O
across	O	O
mammalian	B-LIVB
species	I-LIVB
.	O	O

""""	O	O
You	O	O
get	O	O
to	O	O
know	O	O
the	O	O
people	B-LIVB
and	O	O
whether	O	O
they	O	O
'	O	O
re	O	O
talking	O
sense	O	O
or	O	O
not	O	O
""""	O	O
:	O	O
Negotiating	O
trust	O
on	O	O
health	O
-related	O	O
forums	O
The	O	O
internet	B-OBJC
is	O	O
increasingly	O
being	O	O
used	O	O
as	O	O
a	O	O
source	B-DISO
of	O	O
health	B-DISO
advice	I-DISO
and	O	O
information	B-PROC
by	O	O
individuals	B-LIVB
with	O	O
long	O
term	O
conditions	O
(	O	O
LTCs	O
)	O	O
.	O	O

Specifically	O	O
,	O	O
online	O
forums	O
allow	O	O
people	B-LIVB
to	O	O
interact	O	O
with	O	O
others	O	O
with	O	O
similar	O
conditions	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
how	O	O
online	O
health	B-PROC
information	I-PROC
is	O	O
assessed	O
by	O	O
those	O	O
with	O	O
LTCs	O
.	O	O

This	O	O
study	B-PROC
aims	O	O
to	O	O
address	O	O
this	O	O
gap	O	O
by	O	O
exploring	O	O
how	O	O
individuals	B-LIVB
with	O	O
contested	O	O
and	O	O
uncontested	O	O
LTCs	O
utilise	O	O
internet	O
forums	O
.	O	O

Semi	B-PROC
-	I-PROC
structured	I-PROC
interviews	I-PROC
were	O	O
conducted	O	O
with	O	O
20	O	O
participants	B-LIVB
with	O	O
ME	B-DISO
/	O	O
CFS	B-DISO
and	O	O
21	O	O
participants	B-LIVB
with	O	O
type	B-DISO
1	I-DISO
and	O	O
2	B-DISO
diabetes	I-DISO
and	O	O
analysed	B-PROC
using	O	O
thematic	B-PROC
analysis	I-PROC
.	O	O

Participants	B-LIVB
were	O	O
recruited	O	O
via	O	O
online	O
and	O	O
offline	B-DISO
routes	I-DISO
,	O	O
namely	O	O
forums	O
,	O	O
email	O
lists	O
,	O	O
newsletters	B-OBJC
,	O	O
and	O	O
face	O
-	O
to	O
-	O
face	O
support	O
groups	O
.	O	O

The	O	O
findings	B-DISO
indicate	O	O
that	O	O
the	O	O
use	O	O
of	O	O
online	O
forums	O
was	O	O
a	O	O
complex	O
and	O	O
nuanced	O	O
process	B-PHEN
and	O	O
was	O	O
influenced	O
by	O	O
a	O	O
number	O	O
of	O	O
individual	B-LIVB
and	O	O
illness	B-DISO
-	O	O
specific	O
factors	O
.	O	O

Participants	B-LIVB
trusted	O
those	O	O
with	O	O
similar	O
experiences	B-PHYS
and	O	O
perspectives	O
as	O	O
themselves	O	O
,	O	O
while	O	O
also	O	O
valuing	O	O
conventional	O
biomedical	O
information	O
and	O	O
advice	B-PROC
.	O	O

By	O	O
accessing	O
support	O	O
online	O
forum	O
users	B-LIVB
were	O	O
able	O	O
to	O	O
draw	O	O
on	O	O
a	O	O
personalised	B-OBJC
form	I-OBJC
of	O	O
support	O	O
based	O	O
on	O	O
the	O	O
lived	O	O
experiences	B-PHYS
of	O	O
their	O	O
peers	B-LIVB
.	O	O

However	O	O
,	O	O
the	O	O
role	O	O
of	O	O
digital	O
literacy	O
in	O	O
developing	O	O
and	O	O
maintaining	O	O
online	O
relationships	O
must	O	O
be	O	O
acknowledged	O
.	O	O

Colony	B-ANAT
Expansion	B-PHYS
of	O	O
Socially	B-PHYS
Motile	I-PHYS
Myxococcus	B-LIVB
xanthus	I-LIVB
Cells	B-ANAT
Is	O	O
Driven	O	O
by	O	O
Growth	B-PHYS
,	O	O
Motility	B-PHYS
,	O	O
and	O	O
Exopolysaccharide	B-CHEM
Production	O
Myxococcus	B-LIVB
xanthus	I-LIVB
,	O	O
a	O	O
model	O
organism	B-LIVB
for	O	O
studies	B-PROC
of	O	O
multicellular	B-PHEN
behavior	I-PHEN
in	O	O
bacteria	B-LIVB
,	O	O
moves	O	O
exclusively	O	O
on	O	O
solid	O
surfaces	O
using	O	O
two	O	O
distinct	O	O
but	O	O
coordinated	O
motility	B-PHYS
mechanisms	O
.	O	O

One	O	O
of	O	O
these	O	O
,	O	O
social	B-PHYS
(	I-PHYS
S	I-PHYS
)	I-PHYS
motility	I-PHYS
is	O	O
powered	O	O
by	O	O
the	O	O
extension	O
and	O	O
retraction	B-DISO
of	O	O
type	B-ANAT
IV	I-ANAT
pili	I-ANAT
and	O	O
requires	O	O
the	O	O
presence	O	O
of	O	O
exopolysaccharides	B-CHEM
(	O	O
EPS	B-CHEM
)	O	O
produced	O	O
by	O	O
neighboring	O
cells	B-ANAT
.	O	O

As	O	O
a	O	O
result	O	O
,	O	O
S	B-PHYS
motility	I-PHYS
requires	O	O
close	O	O
cell	B-ANAT
-	I-ANAT
to	I-ANAT
-	I-ANAT
cell	I-ANAT
proximity	O
and	O	O
isolated	O
cells	B-ANAT
do	O	O
not	O	O
translocate	B-PHYS
.	O	O

Previous	O
studies	O
measuring	O
S	B-PHYS
motility	I-PHYS
by	O	O
observing	O
the	O	O
colony	B-ANAT
expansion	B-PHYS
of	O	O
cells	B-ANAT
deposited	O
on	O	O
agar	B-CHEM
have	O	O
shown	O	O
that	O	O
the	O	O
expansion	B-PHYS
rate	O
increases	O
with	O	O
initial	O
cell	O
density	O
,	O	O
but	O	O
the	O	O
biophysical	O
mechanisms	O
involved	O
remain	O	O
largely	O	O
unknown	O
.	O	O

To	B-PHYS
understand	I-PHYS
the	O	O
dynamics	B-PHEN
of	O	O
S	B-PHYS
motility	I-PHYS
-driven	O	O
colony	B-ANAT
expansion	B-PHYS
,	O	O
we	O	O
developed	O	O
a	O	O
reaction	O
-	O	O
diffusion	B-PHEN
model	O
describing	O
the	O	O
effects	O
of	O
cell	O
density	O
,	O	O
EPS	B-CHEM
deposition	O
and	O	O
nutrient	O
exposure	O
on	O	O
the	O	O
expansion	B-PHYS
rate	O
.	O	O

Our	O	O
results	O	O
show	O	O
that	O	O
at	O	O
steady	B-PHEN
state	I-PHEN
the	O	O
population	B-LIVB
expands	O
as	O	O
a	O	O
traveling	O	O
wave	O	O
with	O	O
a	O	O
speed	O
determined	O
by	O
the	O	O
interplay	O	O
of	O	O
cell	B-PHYS
motility	I-PHYS
and	O	O
growth	B-PHYS
,	O	O
a	O	O
well	O	O
-	O	O
known	O	O
characteristic	O
of	O	O
Fisher	O
's	O
equation	O
.	O	O

The	O	O
model	O
explains	O	O
the	O	O
density	O
-	O	O
dependence	O
of	O	O
the	O	O
colony	B-ANAT
expansion	B-PHYS
by	O	O
demonstrating	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
lag	O	O
phase	O
-a	O	O
transient	O
period	O
of	O	O
very	B-DISO
slow	I-DISO
expansion	B-PHYS
with	O	O
a	O	O
duration	B-CHEM
dependent	O
on	O	O
the	O	O
initial	O
cell	O
density	O
.	O	O

We	O	O
propose	O	O
that	O	O
at	O	O
a	O	O
low	O
initial	O
density	O
,	O	O
more	O	O
time	O	O
is	O	O
required	O	O
for	O	O
the	O	O
cells	B-ANAT
to	O	O
accumulate	B-DISO
enough	O	O
EPS	B-CHEM
to	O	O
activate	O
S	B-PHYS
-	I-PHYS
motility	I-PHYS
resulting	O
in	O
a	O	O
longer	O	O
lag	O	O
period	O
.	O	O

Furthermore	O	O
,	O	O
our	O	O
model	O
makes	O	O
the	O	O
novel	O
prediction	O
that	O	O
following	O
the	O	O
lag	O	O
phase	O
the	O	O
population	B-LIVB
expands	O
at	O	O
a	O	O
constant	O
rate	O
independent	O
of	O
the	O	O
cell	O
density	O
.	O	O

These	O	O
predictions	O
were	O	O
confirmed	O
by	O
S	B-PHYS
motility	I-PHYS
experiments	B-PROC
capturing	O	O
long	O
-	O
term	O
expansion	B-PHYS
dynamics	B-PHEN
.	O	O

Ultrasound	B-PROC
assessment	B-PROC
of	O	O
lung	B-DISO
consolidation	I-DISO
and	O	O
reaeration	B-PROC
after	O	O
pleural	B-DISO
effusion	I-DISO
drainage	B-PROC
in	O	O
patients	B-LIVB
with	O	O
Acute	B-DISO
Respiratory	I-DISO
Distress	I-DISO
Syndrome	I-DISO
:	O	O
a	O	O
pilot	B-PROC
study	I-PROC
The	O	O
aim	O
of	O	O
the	O	O
pilot	B-PROC
study	I-PROC
was	O	O
to	O	O
assess	B-PROC
by	O	O
ultrasound	B-PROC
changes	O	O
in	O	O
dimensions	O
of	O	O
lung	B-DISO
consolidation	I-DISO
and	O	O
reaeration	B-PROC
after	O	O
drainage	B-PROC
of	O	O
large	O	O
pleural	B-DISO
effusion	I-DISO
in	O	O
patients	B-LIVB
with	O	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O	O
ARDS	B-DISO
)	O	O
.	O	O

Lung	B-PROC
ultrasound	I-PROC
and	O	O
blood	B-PROC
gas	I-PROC
were	O	O
performed	O
before	O	O
,	O	O
2	O
hours	O
(	O	O
H2	O
)	O	O
and	O	O
24	O
hours	O
(	O	O
H24	O
)	O	O
after	O	O
drainage	B-PROC
of	O	O
pleural	B-DISO
effusion	I-DISO
.	O	O

Lung	O
ultrasound	O
aeration	O
score	O
was	O	O
calculated	O	O
.	O	O

Cephalocaudal	B-ANAT
dimension	I-ANAT
and	O	O
diaphragmatic	B-ANAT
transversal	I-ANAT
area	I-ANAT
of	O	O
lung	B-DISO
consolidation	I-DISO
were	O	O
measured	O	O
.	O	O

Ten	O	O
patients	B-LIVB
were	O	O
studied	O	O
.	O	O

Median	O
volume	O
of	O	O
drained	B-PROC
effusion	B-DISO
was	O	O
675	O	O
ml	O	O
at	O	O
H2	O
and	O	O
895	O	O
at	O	O
H24	O
.	O	O

Two	O
hours	O
after	O	O
drainage	B-PROC
,	O	O
dimension	B-ANAT
of	I-ANAT
cephalocaudal	I-ANAT
consolidation	I-ANAT
and	O	O
diaphragmatic	B-ANAT
transversal	I-ANAT
area	I-ANAT
decreased	O	O
significantly	O	O
.	O	O

Lung	B-PROC
reaeration	I-PROC
after	O	O
drainage	B-PROC
occurred	O	O
mainly	O	O
in	O	O
latero	B-ANAT
-	I-ANAT
inferior	I-ANAT
and	O	O
postero	B-ANAT
-	I-ANAT
superior	I-ANAT
regions	I-ANAT
.	O	O

PaO2	B-PROC
/	I-PROC
FiO2	I-PROC
increased	O	O
significantly	O	O
at	O	O
H24	O
.	O	O

Ultrasound	B-PROC
is	O	O
a	O	O
useful	O	O
method	O	O
to	O	O
assess	B-PROC
lung	B-DISO
consolidation	I-DISO
after	O	O
pleural	B-DISO
effusion	I-DISO
drainage	B-PROC
.	O	O

Drainage	B-PROC
of	O	O
pleural	B-DISO
effusion	I-DISO
may	O	O
lead	O	O
to	O	O
a	O	O
decrease	O
of	O	O
lung	B-DISO
consolidation	I-DISO
and	O	O
improvement	O
of	O	O
lung	B-PROC
reaeration	I-PROC
.	O	O

The	O	O
Maternal	B-DISO
Legacy	O
:	O	O
Female	B-PHYS
Identity	O
Predicts	O	O
Offspring	B-LIVB
Sex	O
Ratio	O
in	O	O
the	O	O
Loggerhead	B-LIVB
Sea	I-LIVB
Turtle	I-LIVB
In	O	O
organisms	B-LIVB
with	O	O
temperature	O
-	O
dependent	O
sex	B-PHEN
determination	I-PHEN
,	O	O
the	O	O
incubation	O
environment	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
determining	O	O
offspring	B-LIVB
sex	O
ratios	O
.	O	O

Given	O	O
that	O	O
global	O
temperatures	O
have	O	O
warmed	B-PHEN
approximately	O	O
0	O	O
.	O	O

6	O	O
°	O	O
C	O	O
in	O	O
the	O	O
last	O	O
century	O	O
,	O	O
it	O	O
is	O	O
necessary	O	O
to	O	O
consider	O	O
how	O	O
organisms	B-LIVB
will	O	O
adjust	B-DISO
to	O	O
climate	B-PHEN
change	I-PHEN
.	O	O

To	O	O
better	O	O
understand	O	O
the	O	O
degree	O
to	O	O
which	O	O
mothers	B-LIVB
influence	O
the	O	O
sex	O
ratios	O
of	O	O
their	O	O
offspring	B-LIVB
,	O	O
we	O	O
use	O	O
24	O	O
years	O
of	O	O
nesting	O
data	O
for	O	O
individual	B-LIVB
female	B-PHYS
loggerhead	B-LIVB
sea	I-LIVB
turtles	I-LIVB
(	O	O
Caretta	B-LIVB
caretta	I-LIVB
)	O	O
observed	O	O
on	O	O
Bald	B-GEOG
Head	I-GEOG
Island	I-GEOG
,	O	O
North	B-GEOG
Carolina	I-GEOG
.	O	O

We	O	O
find	O	O
that	O	O
maternal	B-DISO
identity	O
is	O	O
the	O	O
best	O	O
predictor	O	O
of	O	O
nest	O
sex	O
ratio	O
in	O	O
univariate	B-PROC
and	O	O
multivariate	B-PROC
predictive	I-PROC
models	I-PROC
.	O	O

We	O	O
find	O	O
significant	O	O
variability	O
in	O	O
estimated	O	O
nest	O
sex	O
ratios	O
among	O	O
mothers	B-LIVB
,	O	O
but	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
consistency	O
within	O	O
mothers	B-LIVB
,	O	O
despite	O	O
substantial	O	O
spatial	O
and	O	O
temporal	O
thermal	B-PHEN
variation	I-PHEN
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
individual	B-LIVB
differences	O	O
in	O	O
nesting	O
preferences	O
are	O	O
the	O	O
main	O	O
driver	O	O
behind	O	O
divergences	O
in	O	O
nest	O
sex	O
ratios	O
.	O	O

As	O	O
such	O	O
,	O	O
a	O	O
female	B-PHYS
's	I-PHYS
ability	O	O
to	O	O
plastically	O	O
adjust	O	O
her	O	O
nest	O
sex	O
ratios	O
in	O	O
response	O	O
to	O	O
environmental	O
conditions	O
is	O	O
constrained	O
,	O	O
potentially	O	O
limiting	O	O
how	O	O
individuals	B-LIVB
behaviorally	O	O
mitigate	B-PHEN
the	O	O
effects	O	O
of	O	O
environmental	B-DISO
change	I-DISO
.	O	O

Given	O	O
that	O	O
many	O	O
loggerhead	B-LIVB
populations	B-LIVB
already	O	O
show	O	O
female	O
-	O
biased	O
offspring	B-LIVB
sex	O
ratios	O
,	O	O
understanding	O	O
maternal	O
behavioral	O
responses	O	O
is	O	O
critical	O
for	O	O
predicting	O	O
the	O	O
future	O	O
of	O	O
long	O	O
-	O	O
lived	O	O
species	O
vulnerable	O
to	O	O
extinction	B-PHEN
.	O	O

Physicians	B-LIVB
'	I-LIVB
knowledge	O	O
on	O	O
the	O	O
work	B-DISO
-	I-DISO
related	I-DISO
chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
Chronic	B-DISO
obstructive	I-DISO
pulmonary	I-DISO
disease	I-DISO
(	O	O
COPD	B-DISO
)	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
work	O
environment	O
conditions	O
.	O	O

According	O	O
to	O	O
the	O	O
estimates	O
,	O	O
10	O	O
-	O	O
20	O	O
%	O	O
of	O	O
all	O	O
COPD	B-DISO
cases	O
are	O	O
associated	O
with	O
occupational	B-DISO
exposure	I-DISO
to	O	O
dusts	B-OBJC
and	O	O
irritant	B-CHEM
gases	B-CHEM
.	O	O

However	O	O
,	O	O
in	O	O
2014	O	O
,	O	O
only	O	O
11	O	O
cases	O
of	O	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
were	O	O
recognized	O	O
in	O	O
Poland	B-GEOG
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	B-PROC
was	O	O
to	O	O
analyze	B-PROC
the	O	O
reasons	O	O
for	O	O
the	O	O
low	O
incidence	O
of	O	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
in	O	O
the	O	O
context	O
of	O	O
pulmonologists	B-LIVB
'	O	O
knowledge	O	O
about	O	O
occupational	O
risk	B-DISO
factors	I-DISO
and	O	O
procedures	O
on	O	O
reporting	B-PROC
suspected	B-DISO
occupational	B-DISO
diseases	I-DISO
.	O	O

A	O	O
survey	O
included	O	O
94	O	O
pulmonologists	B-LIVB
randomly	O
selected	O	O
out	O	O
of	O	O
225	O	O
specialists	B-LIVB
registered	O	O
at	O	O
the	O	O
Local	O
Physicians	O
Chamber	O
in	O	O
Łódź	O
.	O	O

The	O	O
study	B-PROC
was	O	O
performed	O
anonymously	O
with	O	O
the	O	O
use	O	O
of	O	O
original	O	O
questionnaire	O
.	O	O

More	O	O
than	O	O
a	O	O
half	O	O
of	O	O
the	O	O
surveyed	O
pulmonologists	B-LIVB
identified	O
environmental	O
risk	B-DISO
factors	I-DISO
for	O	O
COPD	B-DISO
correctly	O	O
,	O	O
while	O	O
only	O	O
23	O	O
.	O	O

4	O	O
%	O	O
properly	O	O
identified	O
the	O	O
main	O	O
occupational	O
risk	B-DISO
factors	I-DISO
as	O	O
the	O	O
cause	O
of	O	O
COPD	B-DISO
.	O	O

Only	O	O
58	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
pulmonologists	B-LIVB
always	O	O
asked	O	O
their	O	O
patients	B-LIVB
suffering	B-DISO
from	O	O
COPD	B-DISO
about	O	O
their	O	O
job	O
/	O	O
profession	O
and	O	O
60	O	O
.	O	O

6	O	O
%	O	O
of	O	O
them	O	O
did	O	O
not	O	O
have	O	O
any	O	O
knowledge	O	O
about	O	O
procedures	O
on	O	O
reporting	B-PROC
suspected	B-DISO
occupational	B-DISO
diseases	I-DISO
.	O	O

The	O	O
physicians	B-LIVB
rarely	O
ask	O	O
patients	B-LIVB
suffering	B-DISO
from	O	O
COPD	B-DISO
about	O	O
their	O	O
job	O
/	O	O
profession	O
and	O	O
the	O	O
relationship	O
between	O	O
their	O	O
ailments	B-DISO
and	O	O
occupational	B-DISO
exposure	I-DISO
.	O	O

What	O	O
is	O	O
more	O	O
,	O	O
they	O	O
do	O	O
not	O	O
know	O	O
legal	O
regulations	O
on	O	O
proper	O	O
referral	B-PROC
of	I-PROC
a	I-PROC
patient	I-PROC
with	O	O
a	O	O
suspected	B-DISO
case	O
of	O	O
occupational	B-DISO
disease	I-DISO
.	O	O

The	O	O
results	O
of	O	O
the	O	O
study	B-PROC
clearly	O	O
indicate	O
that	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
for	O	O
increasing	O
pulmonologists	B-LIVB
'	O	O
knowledge	O	O
on	O	O
work	B-DISO
-	I-DISO
related	I-DISO
COPD	B-DISO
.	O	O

Med	O	O
Pr	O	O
2016	O	O
;	O	O
67	O	O
(	O	O
3	O	O
)	O	O
:	O	O
375	O	O
-	O	O
384	O	O
.	O	O

Increased	O	O
RhoA	B-CHEM
Activity	B-PHYS
Predicts	O	O
Worse	B-DISO
Overall	O
Survival	O
in	O	O
Patients	B-LIVB
Undergoing	O	O
Surgical	B-PROC
Resection	I-PROC
for	O	O
Lauren	O
Diffuse	B-DISO
-	I-DISO
Type	I-DISO
Gastric	I-DISO
Adenocarcinoma	I-DISO
Several	O	O
studies	O	O
have	O	O
reported	O	O
a	O	O
high	O	O
rate	O	O
of	O	O
RHOA	O
mutations	B-PHYS
in	O	O
the	O	O
Lauren	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
gastric	I-DISO
adenocarcinoma	I-DISO
(	O	O
GA	B-DISO
)	O	O
but	O	O
not	O	O
in	O	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
RhoA	B-CHEM
activity	B-PHYS
is	O	O
prognostic	B-PHYS
for	O	O
overall	O
survival	O
(	O	O
OS	O
)	O	O
in	O	O
patients	B-LIVB
with	O	O
resectable	O	O
GA	B-DISO
.	O	O

Retrospective	B-PROC
review	I-PROC
was	O	O
performed	O	O
on	O	O
a	O	O
prospective	O	O
database	O	O
of	O	O
GA	B-DISO
patients	B-LIVB
who	O	O
underwent	O	O
potentially	O	O
curative	B-PROC
resection	I-PROC
between	O	O
2003	O	O
and	O	O
2012	O	O
at	O	O
a	O	O
single	O
institution	O
.	O	O

Tissue	O
microarrays	B-OBJC
were	O	O
constructed	O	O
from	O	O
surgical	B-PROC
specimens	I-PROC
and	O	O
analyzed	O	O
for	O	O
phosphorylated	B-CHEM
RhoA	B-CHEM
,	O	O
a	O	O
marker	B-PHYS
of	O	O
inactive	O	O
RhoA	B-CHEM
signaling	B-PHYS
.	O	O

OS	O
was	O	O
estimated	O	O
by	O	O
the	O	O
Kaplan	B-PROC
-	I-PROC
Meier	I-PROC
method	I-PROC
,	O	O
and	O	O
multivariate	O
analysis	O
was	O	O
performed	O	O
by	O	O
Cox	O
proportional	O
hazards	O
regression	O
modeling	O
.	O	O

One	O	O
hundred	O	O
thirty	O	O
-	O	O
six	O	O
patients	B-LIVB
with	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
and	O	O
129	O	O
patients	B-LIVB
with	O	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
were	O	O
examined	O	O
.	O	O

Compared	O	O
to	O	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
,	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
tumors	B-DISO
were	O	O
significantly	O	O
associated	O
with	O
increased	O	O
tumor	O
size	O
and	O	O
advanced	O
tumor	O
,	O
node	O
,	O
metastasis	O
(	O
TNM	O
)	O
classification	O
system	O
stage	O
.	O	O

In	O	O
patients	B-LIVB
with	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
,	O	O
high	O	O
RhoA	B-CHEM
activity	B-PHYS
was	O	O
associated	O
with	O
significantly	O	O
worse	B-DISO
OS	O
when	O	O
compared	O	O
to	O	O
low	O	O
RhoA	B-CHEM
activity	B-PHYS
(	O	O
5	O	O
-	O	O
year	O	O
OS	O
52	O	O
.	O	O

5	O	O
vs	O	O
.	O	O
81	O	O
.	O	O
0	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
017	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
in	O	O
OS	O
was	O	O
not	O	O
observed	O	O
in	O	O
patients	B-LIVB
with	O	O
intestinal	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
(	O	O
5	O	O
-	O	O
year	O	O
OS	O
83	O	O
.	O	O

9	O	O
vs	O	O
.	O	O

81	O	O
.	O	O
6	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
766	O	O
)	O	O
.	O	O

On	O	O
multivariate	O
analysis	O
of	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
patients	B-LIVB
,	O	O
high	O	O
RhoA	B-CHEM
activity	B-PHYS
was	O	O
an	O	O
independent	O	O
negative	O	O
prognostic	B-PHYS
factor	I-PHYS
for	O	O
OS	O
(	O	O
hazard	O
ratio	O
2	O	O
.	O	O
38	O	O
,	O	O
95	O	O
%	O	O
confidence	O
interval	O
1	O	O
.	O	O
07	O	O
-	O	O
5	O	O
.	O	O
28	O	O
)	O	O
.	O	O

Increased	O	O
RhoA	B-CHEM
activity	B-PHYS
is	O	O
predictive	O	O
of	O	O
worse	B-DISO
OS	O
in	O	O
patients	B-LIVB
with	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
who	O	O
undergo	O	O
potentially	O	O
curative	B-PROC
surgical	I-PROC
resection	I-PROC
.	O	O

Along	O	O
with	O	O
findings	O	O
from	O	O
genomic	O
studies	O
,	O	O
these	O	O
results	O	O
suggest	O	O
RhoA	B-CHEM
may	O	O
be	O	O
a	O	O
novel	O	O
therapeutic	B-PROC
target	O
in	O	O
diffuse	B-DISO
-	I-DISO
type	I-DISO
GA	I-DISO
.	O	O

Doxifluridine	B-CHEM
-	O	O
conjugated	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
shows	O	O
strong	O
RNase	B-CHEM
L	I-CHEM
activation	B-PHYS
ability	O
and	O	O
tumor	B-PHYS
suppressive	I-PHYS
effect	O
RNase	B-CHEM
L	I-CHEM
is	O	O
activated	B-PHYS
by	O	O
2	B-CHEM
'	I-CHEM
,	I-CHEM
5	I-CHEM
'	I-CHEM
-	I-CHEM
oligoadenylates	I-CHEM
(	O	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
)	O	O
at	O	O
subnanomolar	O
levels	O
to	O	O
cleave	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
.	O	O

We	O	O
previously	O	O
reported	O
the	O	O
hypothesis	O
that	O	O
the	O	O
introduction	O
of	O	O
an	O	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
residue	O	O
at	O	O
the	O	O
2	O	O
'	O	O
-	O	O
terminus	O
of	O	O
the	O	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
tetramer	I-CHEM
shifts	O
the	O	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
binding	B-CHEM
site	I-CHEM
of	O	O
RNase	B-CHEM
L	I-CHEM
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
synthesized	O
various	O	O
5	O	O
'	O	O
-	O	O
modified	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
s	O	O
with	O	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
at	O	O
the	O	O
2	O	O
'	O	O
-	O	O
terminus	O
.	O	O

The	O	O
doxifluridine	B-CHEM
-	O	O
conjugated	O
8	B-CHEM
-	I-CHEM
methyladenosine	I-CHEM
-	O	O
substituted	O
2	B-CHEM
-	I-CHEM
5A	I-CHEM
analog	B-CHEM
was	O	O
significantly	O
more	O
effective	O
as	O	O
an	O	O
activator	O
of	O	O
RNase	B-CHEM
L	I-CHEM
than	O	O
the	O	O
parent	O
5	O	O
'	O	O
-	O	O
monophophorylated	B-PHYS
2	B-CHEM
-	I-CHEM
5A	I-CHEM
tetramer	I-CHEM
and	O	O
showed	O	O
a	O	O
tumor	B-PHYS
suppressive	I-PHYS
effect	O
against	O
human	B-LIVB
cervical	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O	O

Naphthoquinone	B-CHEM
glycosides	B-CHEM
for	O	O
bioelectroanalytical	O
enumeration	O
of	O	O
the	O	O
faecal	B-ANAT
indicator	B-CHEM
Escherichia	B-LIVB
coli	I-LIVB
Microbial	B-LIVB
water	O
quality	O
monitoring	B-PROC
for	O	O
the	O	O
presence	O	O
of	O	O
faecal	B-LIVB
indicator	I-LIVB
bacteria	I-LIVB
(	O	O
FIB	B-LIVB
)	O	O
is	O	O
a	O	O
mandatory	O
activity	O
in	O	O
many	O	O
countries	B-GEOG
and	O	O
is	O	O
key	O	O
in	O	O
public	B-PROC
health	I-PROC
protection	I-PROC
.	O	O

Despite	O	O
technological	O
advances	O
and	O	O
a	O	O
need	O	O
for	O	O
methodological	O
improvements	O
,	O	O
chromogenic	B-PROC
and	O	O
fluorogenic	O
enzymatic	O
techniques	O
remain	O	O
the	O	O
mainstays	O	O
of	O	O
water	O
quality	O
monitoring	B-PROC
for	O	O
both	O	O
public	O
health	O
agencies	O
and	O
regulated	O
utilities	O
.	O	O

We	O	O
demonstrated	O	O
that	O	O
bioelectroanalytical	B-PROC
approaches	I-PROC
to	O	O
FIB	B-LIVB
enumeration	O
are	O	O
possible	O	O
and	O	O
can	O	O
be	O	O
achieved	O	O
using	O	O
commercially	O	O
available	O	O
enzyme	B-CHEM
-	O	O
specific	O
resorufin	B-CHEM
glycosides	B-CHEM
,	O	O
although	O	O
these	O	O
are	O	O
expensive	O	O
,	O	O
not	O	O
widely	O	O
available	O	O
or	O	O
designed	O	O
for	O	O
purpose	O	O
.	O	O

Following	O	O
this	O	O
,	O	O
we	O	O
designed	O	O
two	O	O
naphthoquinone	B-CHEM
glycosides	B-CHEM
which	O	O
performed	O
better	O
,	O	O
achieving	O	O
Escherichia	B-PROC
coli	I-PROC
detection	I-PROC
in	O	O
the	O	O
range	O	O
5	O	O
.	O	O

0	O	O
×	O	O
10	O	O
(	O	O
2	O	O
)	O	O
to	O	O
5	O	O
.	O	O
0	O	O
×	O	O
10	O	O
(	O	O
5	O	O
)	O	O
CFU	O	O
ml	O	O
(	O	O
-	O	O
1	O	O
)	O	O
22	O	O
-	O	O
54	O	O
%	O	O
quicker	O
than	O	O
commercially	O	O
available	O	O
resorufin	B-CHEM
glycosides	B-CHEM
.	O	O

The	O	O
molecular	O
design	O
of	O	O
the	O	O
naphthoquinone	B-CHEM
glycosides	B-CHEM
requires	O	O
fewer	O	O
synthetic	O
steps	O
allowing	O	O
them	O	O
to	O	O
be	O	O
produced	O	O
for	O	O
as	O	O
little	O	O
as	O	O
US$	O	O
50	O	O
per	O	O
kg	O	O
.	O	O

Tests	O
with	O	O
environmental	O
samples	B-OBJC
demonstrated	O	O
the	O	O
low	O	O
tendency	O	O
for	O	O
abiotic	O
interference	O
and	O	O
that	O	O
,	O	O
despite	O	O
specificity	O
being	O	O
maintained	O	O
between	O	O
β	B-CHEM
-	I-CHEM
glucuronidase	I-CHEM
and	O	O
β	B-CHEM
-	I-CHEM
galactosidase	I-CHEM
,	O	O
accurate	O	O
enumeration	O
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
in	O	O
environmental	O
samples	B-OBJC
necessitates	O	O
development	O	O
of	O	O
a	O	O
selective	O
medium	O
.	O	O

In	O	O
comparison	O
to	O	O
a	O	O
commercially	O	O
available	O	O
detection	B-DISO
method	O
,	O	O
which	O	O
has	O	O
U	O
.	O

S	O
.	O

Environmental	O
Protection	O
Agency	O
(	O	O
EPA	O
)	O	O
approval	O
,	O	O
our	O	O
approach	O	O
performed	O
better	O
at	O	O
high	O	O
organism	B-LIVB
concentrations	O
,	O	O
detecting	O	O
500	O	O
organisms	B-LIVB
in	O	O
9	O	O
h	O	O
compared	O
with	O	O
13	O	O
.	O	O

5	O	O
h	O	O
for	O	O
the	O	O
commercial	B-PROC
method	I-PROC
.	O	O

Bioelectroanalytical	B-PROC
detection	I-PROC
is	O	O
comparable	O
to	O	O
current	B-PROC
approved	I-PROC
methods	I-PROC
and	O	O
with	O	O
further	B-PHYS
development	I-PHYS
could	O	O
result	O
in	O	O
improved	O	O
detection	B-DISO
times	O
.	O	O

A	O	O
recent	O	O
trend	O	O
for	O	O
low	O	O
-	O	O
cost	O	O
open	B-OBJC
-	I-OBJC
source	I-OBJC
hardware	I-OBJC
means	O	O
that	O	O
automated	O
,	O	O
potentiostatically	O	O
controlled	O
E	B-PROC
.	I-PROC

coli	I-PROC
detection	I-PROC
systems	O	O
could	O	O
be	O	O
constructed	O	O
for	O	O
less	O	O
than	O	O
US$	O	O
100	O	O
per	O	O
channel	O	O
.	O	O

Evaluation	B-PROC
of	O	O
Local	O
CYP17A1	O
and	O	O
CYP19A1	O
Expression	O
Levels	O
as	O	O
Prognostic	B-PHYS
Factors	I-PHYS
in	O	O
Postmenopausal	B-DISO
Invasive	B-DISO
Ductal	I-DISO
Breast	I-DISO
Cancer	I-DISO
Cases	O
There	O	O
is	O	O
growing	O	O
attention	O	O
focused	O	O
on	O	O
local	O
estrogen	B-PHYS
production	I-PHYS
in	O	O
the	O	O
breast	O
tissue	O
and	O	O
its	O	O
possible	O	O
role	O
in	O	O
breast	B-DISO
cancer	I-DISO
initiation	O
and	O	O
progression	B-DISO
.	O	O

Understanding	O	O
the	O	O
underlying	O	O
mechanisms	O
for	O	O
estrogen	B-PHYS
synthesis	I-PHYS
and	O	O
the	O	O
microenvironment	B-PHEN
consisting	O	O
of	O	O
tumor	B-DISO
and	O	O
its	O	O
surrounding	O	O
adipose	O
tissue	O
might	O	O
open	O	O
new	O	O
avenues	O	O
in	O	O
breast	B-PROC
cancer	I-PROC
prevention	I-PROC
,	O	O
prognosis	B-PHYS
and	O	O
treatment	B-PROC
.	O	O

In	O	O
order	O	O
to	O	O
obtain	O	O
insight	O	O
,	O	O
we	O	O
compared	O	O
peritumoral	O
and	O	O
tumor	O
tissue	O
expressions	B-PHYS
of	O	O
CYP17A1	O
and	O	O
CYP19A1	O
genes	O	O
,	O	O
which	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
estrogen	B-PHYS
biosynthesis	I-PHYS
.	O	O

The	O	O
paired	O	O
tissue	O
samples	O
of	O	O
20	O	O
postmenopausal	B-DISO
ER	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	O	O
PR	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	B-LIVB
diagnosed	B-DISO
with	O	O
invasive	B-DISO
ductal	I-DISO
breast	I-DISO
cancer	I-DISO
were	O	O
studied	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
12	O	O
breast	B-ANAT
tissue	I-ANAT
samples	I-ANAT
obtained	O	O
from	O	O
premenopausal	B-DISO
women	B-LIVB
without	O	O
a	O	O
history	O	O
of	O	O
breast	B-DISO
cancer	I-DISO
were	O	O
also	O	O
investigated	O	O
as	O	O
representative	O	O
of	O	O
normal	B-DISO
conditions	I-DISO
.	O	O

Peritumoral	O
adipose	O
tissues	O
expressed	O	O
CYP19A1	O
approximately	O	O
threefold	O	O
higher	O	O
than	O	O
tumor	B-DISO
itself	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

A	O	O
nonsignificant	O	O
trend	O	O
toward	O	O
low	O
expression	B-PHYS
of	O	O
CYP17A1	O
was	O	O
observed	O	O
in	O	O
peritumoral	O
compared	O	O
to	O	O
tumor	O
tissue	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
687	O	O
)	O	O
.	O	O

Clinicopathological	O
parameters	O
and	O	O
patient	B-PHYS
characteristics	I-PHYS
which	O	O
are	O	O
accepted	O	O
as	O	O
risk	B-DISO
factors	I-DISO
for	O	O
breast	B-DISO
cancer	I-DISO
were	O	O
also	O	O
associated	O	O
with	O	O
individual	O	O
and	O	O
combined	O	O
expressions	B-PHYS
of	O	O
CYP17A1	O
and	O	O
CYP19A1	O
.	O	O

This	O	O
study	O	O
offers	O	O
that	O	O
evaluation	B-PROC
of	O	O
CYP17A1	O
and	O	O
CYP19A1	O
local	O
expression	O
levels	O
might	O	O
be	O	O
useful	O	O
for	O	O
deciding	O	O
on	O	O
personalized	O
treatment	O
approaches	O
and	O	O
more	O
accurate	O
diagnosis	B-DISO
,	O	O
when	O	O
evaluated	B-PROC
together	O	O
with	O	O
several	O	O
clinicopathological	O
and	O	O
disease	B-DISO
risk	I-DISO
factors	I-DISO
.	O	O

Considering	O	O
the	O	O
key	O
role	O
of	O	O
these	O	O
CYPs	O
in	O	O
estrogen	B-PHYS
synthesis	I-PHYS
,	O	O
determining	O	O
their	O	O
expression	O
levels	O
may	O	O
be	O	O
useful	O	O
as	O	O
a	O	O
postdiagnostic	B-PHYS
marker	I-PHYS
and	O	O
for	O	O
choosing	O	O
the	O	O
right	O
treatment	B-PROC
method	I-PROC
in	O	O
addition	O	O
to	O	O
the	O	O
conventional	O	O
approach	O	O
.	O	O

Case	O
Report	O
of	O	O
Necrotizing	B-DISO
Fasciitis	I-DISO
Associated	O
with	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
Necrotizing	B-DISO
fasciitis	I-DISO
,	O	O
caused	O	O
by	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
,	O	O
is	O	O
an	O	O
extremely	O
rare	O
and	O	O
life	B-DISO
-	I-DISO
threatening	I-DISO
bacterial	B-LIVB
soft	B-DISO
tissue	I-DISO
infection	I-DISO
.	O	O

We	O	O
report	B-PROC
a	O	O
case	O
of	O	O
early	O	O
necrotizing	B-DISO
fasciitis	I-DISO
associated	O
with	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
infection	B-DISO
in	O	O
a	O	O
26	O	O
-	O	O
year	O
-old	O	O
man	B-LIVB
who	O	O
was	O	O
immunocompromised	B-DISO
with	O	O
mixed	B-DISO
connective	I-DISO
tissue	I-DISO
disease	I-DISO
.	O	O

The	O	O
patient	B-LIVB
presented	O	O
with	O	O
acute	O
,	O	O
painful	B-DISO
,	O	O
erythematous	O
,	O	O
and	O	O
edematous	B-DISO
skin	I-DISO
lesions	B-DISO
of	O	O
his	O	O
right	B-ANAT
lower	I-ANAT
back	I-ANAT
,	O	O
which	O	O
rapidly	O	O
progressed	O
to	O	O
the	O	O
right	B-ANAT
knee	I-ANAT
.	O	O

The	O	O
patient	B-LIVB
underwent	O	O
surgical	B-PROC
exploration	I-PROC
,	O	O
and	O	O
a	O	O
diagnosis	B-DISO
of	O	O
necrotizing	B-DISO
fasciitis	I-DISO
was	O	O
confirmed	O	O
by	O	O
pathological	O
evidence	O
of	O	O
necrosis	B-PHYS
of	O	O
the	O	O
fascia	O
and	O	O
neutrophil	B-PHYS
infiltration	I-PHYS
in	O	O
tissue	B-PROC
biopsies	I-PROC
.	O	O

Cultures	B-PROC
of	O	O
fascial	B-ANAT
tissue	B-PROC
biopsies	I-PROC
and	O	O
blood	B-ANAT
samples	I-ANAT
were	O	O
positive	B-DISO
for	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	B-PROC
of	O	O
necrotizing	B-DISO
fasciitis	I-DISO
resulting	O	O
from	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
diagnosed	B-DISO
at	O	O
early	O	O
phase	O
;	O	O
the	O	O
patient	B-PHYS
recovered	I-PHYS
well	O	O
without	O	O
surgical	B-PROC
debridement	I-PROC
.	O	O

A	O	O
Comparative	B-PROC
Study	I-PROC
of	O	O
the	O	O
Efficacy	O
of	O	O
IV	O
Dexketoprofen	B-CHEM
,	O	O
Lornoxicam	B-CHEM
,	O	O
and	O	O
Diclophenac	B-CHEM
Sodium	I-CHEM
on	O	O
Postoperative	B-PROC
Analgesia	I-PROC
and	O	O
Tramadol	B-CHEM
Consumption	O
in	O	O
Patients	B-LIVB
Receiving	O	O
Patient	B-PROC
-	I-PROC
Controlled	I-PROC
Tramadol	B-CHEM
This	O	O
study	B-PROC
was	O	O
designed	O
to	O	O
compare	O
the	O	O
effects	O
of	O
dexketoprofen	B-CHEM
,	O	O
lornoxicam	B-CHEM
,	O	O
and	O	O
diclophenac	B-CHEM
sodium	I-CHEM
on	O	O
postoperative	B-PROC
analgesia	I-PROC
and	O	O
tramadol	B-CHEM
consumption	O
in	O	O
patients	B-LIVB
receiving	O	O
postoperative	O
patient	B-PROC
-	I-PROC
controlled	I-PROC
tramadol	B-CHEM
after	O	O
a	O	O
major	O
abdominal	B-PROC
surgery	I-PROC
.	O	O

Eighty	O	O
patients	B-LIVB
were	O	O
randomized	B-DISO
to	O	O
receive	O	O
one	O	O
of	O	O
the	O	O
four	O	O
study	B-PROC
drugs	B-CHEM
.	O	O

Patients	B-LIVB
in	O	O
group	O
dexketoprofen	B-CHEM
(	O	O
DT	B-CHEM
)	O	O
received	O	O
IV	O
50	O	O
mg	O	O
dexketoprofen	B-CHEM
,	O	O
group	O
lornoxicam	B-CHEM
(	O	O
LR	B-CHEM
)	O	O
received	O	O
IV	O
8	O	O
mg	O	O
lornoxicam	B-CHEM
,	O	O
group	O
diclophenac	B-CHEM
sodium	I-CHEM
(	O	O
DS	B-CHEM
)	O	O
received	O	O
75	O	O
mg	O	O
IV	O
diclophenac	B-CHEM
sodium	I-CHEM
and	O	O
group	O
saline	B-OBJC
(	O	O
S	B-OBJC
)	O	O
received	O	O
0	O	O
.	O	O

9	O	O
%	O	O
saline	B-OBJC
in	O	O
2	O	O
mL	O	O
syringes	B-DEVI
,	O	O
20	O	O
min	O
before	O	O
the	O	O
end	O	O
of	O	O
anaesthesia	B-PROC
.	O	O

A	O	O
standardized	O
(	O	O
1	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
dose	O
of	O	O
tramadol	B-CHEM
was	O	O
routinely	O
administered	O
to	O	O
all	O	O
patients	B-LIVB
as	O	O
the	O	O
loading	O
dose	O
at	O	O
the	O	O
end	O	O
of	O	O
surgery	B-PROC
.	O	O

Postoperatively	O
,	O	O
whenever	O	O
patients	B-LIVB
requested	O	O
,	O	O
they	O	O
were	O	O
allowed	O	O
to	O	O
use	O	O
a	O	O
tramadol	B-CHEM
patient	B-DISO
-	I-DISO
controlled	I-DISO
analgesia	I-DISO
device	I-DISO
giving	O	O
a	O	O
bolus	B-PROC
dose	I-PROC
(	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
of	O	O
tramadol	B-CHEM
.	O	O

Pain	B-DISO
,	O	O
discomfort	B-DISO
,	O	O
and	O	O
sedation	B-DISO
scores	O
,	O	O
cumulative	O
tramadol	B-CHEM
consumption	O
,	O	O
supplemental	O
meperidine	B-CHEM
requirement	O
,	O	O
and	O	O
side	B-DISO
effects	I-DISO
were	O	O
recorded	O	O
.	O	O

Visual	O
rating	O
scale	O
and	O	O
patient	B-LIVB
discomfort	B-DISO
scores	O
were	O	O
significantly	O
lower	O
in	O	O
DT	B-CHEM
,	O	O
LR	B-CHEM
and	O	O
DS	B-CHEM
groups	O
compared	O	O
to	O	O
those	O	O
in	O	O
in	O	O
group	O
S	B-OBJC
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Cumulative	O
tramadol	B-CHEM
consumption	O
was	O	O
significantly	O
lower	O
in	O	O
non	B-CHEM
-	I-CHEM
steroidal	I-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drug	I-CHEM
(	O	O
NSAID	B-CHEM
)	O	O
-	O	O
treated	O
groups	O
at	O	O
each	O	O
study	B-PROC
period	I-PROC
after	O	O
the	O	O
second	O	O
postoperative	O
hour	O
than	O	O
in	O	O
group	O
S	B-OBJC
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Supplemental	O
meperidine	B-CHEM
requirement	O
was	O	O
significantly	O
higher	O	O
in	O	O
group	O
S	B-OBJC
at	O	O
each	O	O
study	B-PROC
period	I-PROC
after	O	O
postoperative	O
30	O	O
min	O
than	O	O
in	O	O
NSAID	B-CHEM
-	O	O
treated	O
groups	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

After	O	O
major	O
abdominal	B-PROC
surgery	I-PROC
,	O	O
adding	O	O
IV	O
diclophenac	B-CHEM
,	O	O
lornoxicam	B-CHEM
or	O	O
dexketoprofen	B-CHEM
to	O	O
patient	B-PROC
-	I-PROC
controlled	I-PROC
tramadol	B-CHEM
resulted	O	O
in	O	O
lower	O
pain	B-DISO
scores	O
,	O	O
smaller	O
tramadol	B-CHEM
consumption	O
,	O	O
less	O	O
rescue	O	O
supplemental	O
analgesic	B-CHEM
requirement	O
,	O	O
and	O	O
fewer	O	O
side	B-DISO
effects	I-DISO
compared	O	O
with	O	O
the	O	O
tramadol	B-CHEM
alone	O	O
group	O
.	O	O

Does	O	O
Video	B-DEVI
Laryngoscopy	I-DEVI
Offer	O	O
Advantages	O
over	O	O
Direct	B-PROC
Laryngoscopy	I-PROC
during	O
Cardiopulmonary	B-PROC
Resuscitation	I-PROC
?	O	O
Interruption	O
of	O	O
chest	B-PROC
compressions	I-PROC
should	O	O
be	O	O
minimized	O
because	O	O
of	O	O
its	O	O
negative	B-DISO
effects	O
on	O	O
survival	O
.	O	O

This	O	O
randomized	B-PROC
,	O	O
controlled	O
,	O	O
cross	B-PROC
-	I-PROC
over	I-PROC
study	I-PROC
aimed	O
to	O	O
analyze	B-PROC
the	O	O
effectiveness	O
of	O	O
Macintosh	B-DEVI
,	O	O
Miller	B-DEVI
,	O	O
McCoy	B-DEVI
and	O	O
McGrath	B-DEVI
laryngoscopes	I-DEVI
during	O
with	O	O
or	O	O
without	O	O
chest	B-PROC
compressions	I-PROC
in	O	O
the	O	O
scope	O
of	O	O
a	O	O
simulated	O	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
scenario	O
.	O	O

The	O	O
time	O
required	O
for	O	O
successful	O
tracheal	B-PROC
intubation	I-PROC
,	O	O
number	B-PHYS
of	I-PHYS
attempts	I-PHYS
,	O	O
dental	B-DISO
trauma	I-DISO
severity	O
and	O	O
the	O	O
need	O
for	O	O
optimization	O
manoeuvres	O
were	O	O
recorded	B-DISO
during	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
with	O	O
and	O	O
without	O	O
chest	B-PROC
compressions	I-PROC
.	O	O

The	O	O
experience	B-PHYS
with	O	O
computer	B-OBJC
games	I-OBJC
during	O
the	O	O
last	O	O
10	O	O
years	O
were	O	O
asked	O	O
to	O	O
the	O	O
participants	B-LIVB
and	O	O
recorded	B-DISO
.	O	O

McCoy	B-DEVI
laryngoscope	I-DEVI
yielded	O	O
the	O	O
shortest	O
time	O
for	O	O
successful	O
tracheal	B-PROC
intubation	I-PROC
both	O	O
in	O	O
the	O	O
presence	B-DISO
of	O	O
and	O	O
without	O	O
chest	B-PROC
compressions	I-PROC
.	O	O

During	O
the	O	O
use	O
of	O	O
McCoy	B-DEVI
laryngoscopes	I-DEVI
,	O	O
fewer	O
tracheal	B-PROC
intubation	I-PROC
attempts	O
,	O	O
lower	O
incidence	O
of	O	O
dental	B-DISO
trauma	I-DISO
and	O	O
lower	O
visual	B-PHYS
analogue	I-PHYS
scale	I-PHYS
scores	I-PHYS
on	O	O
the	O	O
ease	O	O
of	O	O
intubation	B-PROC
were	O	O
recorded	B-DISO
.	O	O

Participants	B-LIVB
who	O	O
are	O	O
experienced	B-PHYS
computer	B-OBJC
game	I-OBJC
players	B-LIVB
using	O	O
Macintosh	B-DEVI
,	O	O
McCoy	B-DEVI
and	O	O
McGrath	B-DEVI
achieved	B-DISO
successful	O
tracheal	B-PROC
intubation	I-PROC
in	O	O
a	O	O
significantly	O
shorter	O
time	O
during	O
resuscitation	B-PROC
without	O	O
chest	B-PROC
compressions	I-PROC
.	O	O

Dental	B-DISO
trauma	I-DISO
incidence	O
and	O	O
number	O
of	O	O
tracheal	B-PROC
intubation	I-PROC
attempts	O
did	O	O
not	O	O
show	O	O
any	O	O
significant	O
difference	O
between	O	O
the	O	O
four	O
laryngoscopes	B-DEVI
being	O	O
related	O	O
to	O	O
the	O	O
rate	O
of	O	O
playing	O
computer	B-OBJC
games	I-OBJC
.	O	O

McGrath	B-DEVI
video	I-DEVI
laryngoscopes	I-DEVI
do	O	O
not	O	O
appear	O	O
to	O	O
have	O	O
advantages	O
over	O	O
direct	B-PROC
laryngoscopes	I-PROC
for	O	O
securing	O	O
a	O	O
smooth	O
and	O	O
successful	O
tracheal	B-PROC
intubation	I-PROC
during	O
rhythmic	B-PROC
chest	I-PROC
compressions	I-PROC
.	O	O

We	O	O
believe	O	O
that	O	O
as	O	O
McCoy	B-DEVI
laryngoscope	I-DEVI
provided	O
tracheal	B-PROC
intubation	I-PROC
in	O	O
a	O	O
shorter	O
time	O
and	O	O
with	O	O
fewer	O
attempts	O
,	O	O
this	O	O
laryngoscope	B-DEVI
may	O	O
increase	O
the	O	O
success	O
rate	O
of	O	O
resuscitation	B-PROC
.	O	O

Perioperative	B-PROC
Management	I-PROC
of	O	O
Severe	B-DISO
Hypertension	I-DISO
during	O	O
Laparoscopic	B-PROC
Surgery	I-PROC
for	O	O
Pheochromocytoma	B-DISO
Phaeochromocytoma	B-DISO
is	O	O
a	O	O
catecholamine	B-PHYS
-	I-PHYS
secreting	I-PHYS
vascular	B-DISO
tumour	I-DISO
that	O	O
is	O	O
derived	O	O
from	O	O
chromaffin	B-ANAT
cell	I-ANAT
.	O	O

Lethal	B-DISO
cardiovascular	B-DISO
complications	I-DISO
,	O	O
such	O	O
as	O	O
serious	O	O
hypertension	B-DISO
,	O	O
myocardial	B-DISO
infarction	I-DISO
and	O	O
aortic	B-DISO
dissection	I-DISO
,	O	O
may	O	O
occur	O	O
because	O	O
of	O	O
uncontrolled	B-DISO
catecholamine	I-DISO
release	I-DISO
.	O	O

Each	O	O
stage	O
of	O	O
anaesthesia	B-PROC
management	I-PROC
has	O	O
vital	O	O
importance	O	O
because	O	O
of	O	O
this	O	O
destructive	B-DISO
catecholamine	I-DISO
secretion	I-DISO
that	O	O
may	O	O
occur	O	O
during	O	O
induction	B-PROC
,	O	O
perioperative	O
stage	O
and	O	O
surgical	B-PROC
manipulation	I-PROC
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
report	O	O
regarding	O	O
the	O	O
preoperative	B-PROC
preparation	I-PROC
and	O	O
severe	B-PROC
,	I-PROC
persistent	I-PROC
hypertension	I-PROC
attack	I-PROC
management	I-PROC
with	O	O
a	O	O
combination	O	O
of	O	O
α	B-CHEM
-	I-CHEM
adrenergic	I-CHEM
blockade	I-CHEM
,	O	O
β	B-CHEM
-	I-CHEM
adrenergic	I-CHEM
blockade	I-CHEM
,	O	O
sodium	B-CHEM
nitroprusside	I-CHEM
and	O	O
remifentanil	B-CHEM
in	O	O
a	O	O
patient	B-LIVB
who	O	O
underwent	O	O
laparoscopic	B-PROC
surgery	I-PROC
for	O	O
phaeochromocytoma	B-DISO
.	O	O

A	O	O
case	O
study	O
of	O	O
the	O	O
introduction	O
of	O	O
the	O	O
International	O
Classification	O
for	O
Nursing	O
Practice	O
(	O	O
®	O	O
)	O	O
in	O	O
Poland	B-GEOG
The	O	O
development	O
of	O	O
a	O	O
nursing	B-PROC
practice	I-PROC
,	O	O
improvements	O	O
in	O	O
nurses	O
'	O
autonomy	O
,	O	O
and	O	O
increased	O	O
professional	O
and	O	O
personal	O
responsibility	O
for	O	O
the	O	O
medical	B-PROC
services	I-PROC
provided	O	O
all	O	O
require	O	O
professional	O
documentation	O
with	O	O
records	O
of	O
health	O
status	O
assessments	B-PROC
,	O	O
decisions	B-DISO
undertaken	I-DISO
,	O	O
actions	O
and	O	O
their	O	O
outcomes	O
for	O	O
each	O	O
patient	B-LIVB
.	O	O

The	O	O
International	O
Classification	O
for	O
Nursing	O
Practice	O
is	O	O
a	O	O
tool	O	O
that	O	O
meets	O	O
all	O	O
of	O	O
these	O	O
needs	O	O
,	O	O
and	O	O
although	O	O
it	O	O
requires	O	O
continuous	O	O
evaluation	B-PROC
,	O	O
it	O	O
offers	O	O
professional	O
documentation	O
and	O	O
communication	O
in	O	O
the	O	O
practitioner	B-LIVB
and	O	O
researcher	B-PROC
community	I-PROC
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
paper	O	O
is	O	O
to	O	O
present	O	O
a	O	O
theoretical	B-PROC
critique	I-PROC
of	O	O
an	O	O
issue	B-DISO
related	O	O
to	O	O
policy	O
and	O	O
experience	O	O
of	O	O
the	O	O
current	O	O
situation	O	O
in	O	O
Polish	B-GEOG
nursing	O
-	O	O
especially	O	O
of	O	O
the	O	O
efforts	O	O
to	O	O
standardize	O	O
nursing	B-PROC
practices	I-PROC
through	O	O
the	O	O
introduction	O
and	O	O
development	O
of	O	O
the	O	O
Classification	O
in	O	O
Poland	B-GEOG
.	O	O

Despite	O	O
extensive	O
promotion	O
and	O	O
training	B-PROC
by	O	O
International	O
Council	O
of	O
Nurses	O
members	B-LIVB
worldwide	O	O
,	O	O
there	O	O
are	O	O
still	O	O
many	O	O
countries	B-GEOG
where	O	O
the	O	O
Classification	O
has	O	O
not	O	O
been	O	O
implemented	O
as	O	O
a	O	O
standard	O	O
tool	O	O
in	O	O
healthcare	B-OBJC
facilities	I-OBJC
.	O	O

Recently	O	O
,	O	O
a	O	O
number	O	O
of	O	O
initiatives	O	O
were	O	O
undertaken	O	O
in	O	O
cooperation	O
with	O	O
the	O	O
local	B-LIVB
and	O	O
state	O
authorities	O
to	O	O
disseminate	O
the	O	O
Classification	O
in	O	O
healthcare	B-OBJC
facilities	I-OBJC
.	O	O

Thanks	O	O
to	O	O
intense	O	O
efforts	O
by	O	O
the	O	O
Polish	O
Nurses	O
Association	O
and	O	O
the	O	O
International	O
Council	O
of	O
Nurses	O
Accredited	O	O
Center	O	O
for	O	O
ICNP	O
(	O	O
®	O	O
)	O	O
Research	B-PROC
&	I-PROC
Development	I-PROC
at	O	O
the	O	O
Medical	O
University	O
of	O
Łódź	O
,	O	O
the	O	O
Classification	O
is	O	O
known	O	O
in	O	O
Poland	B-GEOG
and	O	O
has	O	O
been	O	O
tested	O	O
at	O	O
several	O	O
centres	O	O
.	O	O

Nevertheless	O	O
,	O	O
an	O	O
actual	O	O
implementation	O
that	O	O
would	O	O
allow	O	O
for	O	O
national	O	O
and	O	O
international	O
interoperability	B-DISO
requires	O	O
strategic	O
governmental	O
decisions	O
and	O	O
close	O	O
cooperation	O
with	O	O
information	O
technology	O
companies	B-OBJC
operating	O	O
in	O	O
the	O	O
country	B-GEOG
.	O	O

Discussing	O	O
the	O	O
barriers	B-DISO
to	O	O
the	O	O
implementation	O
of	O	O
the	O	O
Classification	O
can	O	O
improve	B-DISO
understanding	O	O
of	O	O
it	O	O
and	O	O
its	O	O
use	O	O
.	O	O

At	O	O
a	O	O
policy	O
level	O	O
,	O	O
decision	O	O
makers	O	O
need	O	O
to	O	O
understand	O	O
that	O	O
use	O	O
Classification	O
in	O	O
eHealth	B-PROC
services	I-PROC
and	O	O
tools	O	O
it	O	O
is	O	O
necessary	O	O
to	O	O
achieve	O	O
interoperability	B-DISO
.	O	O

A	O	O
case	O
based	O	O
reflection	B-DISO
on	O	O
communicating	O
end	O
of	O	O
life	O
information	O
in	O	O
non	B-DISO
-	I-DISO
English	I-DISO
speaking	I-DISO
patients	B-LIVB
Mr	O	O
X	O	O
was	O	O
a	O	O
56	O	O
year	O
old	O
Chinese	B-LIVB
man	B-LIVB
(	O	O
non	B-DISO
-	I-DISO
English	I-DISO
speaking	I-DISO
)	O	O
,	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
emergency	B-OBJC
department	I-OBJC
with	O	O
a	O	O
range	O	O
of	O	O
non	O
-	O
specific	O
symptoms	B-DISO
.	O	O

On	O	O
full	O	O
workup	O	O
,	O	O
he	O	O
was	O	O
diagnosed	B-DISO
with	O	O
an	O	O
advanced	B-DISO
cancer	I-DISO
of	I-DISO
the	I-DISO
pancreas	I-DISO
.	O	O

It	O	O
was	O	O
an	O	O
aggressive	B-DISO
,	O	O
highly	O	O
treatment	B-DISO
resistant	I-DISO
cancer	I-DISO
,	O	O
with	O	O
an	O	O
alarmingly	O	O
poor	B-DISO
prognosis	I-DISO
.	O	O

Before	O	O
the	O	O
diagnosis	B-DISO
had	O	O
been	O	O
made	O	O
,	O	O
the	O	O
family	B-LIVB
had	O	O
informed	O	O
our	O	O
team	B-PROC
that	O	O
we	O	O
were	O	O
not	O	O
to	O	O
discuss	O	O
medical	O
issues	B-DISO
with	O	O
Mr	O	O
X	O	O
directly	O	O
,	O	O
and	O	O
that	O	O
upon	O	O
arriving	O	O
on	O	O
a	O	O
diagnosis	B-DISO
we	O	O
were	O	O
to	O	O
come	O	O
to	O	O
them	O	O
first	O	O
and	O	O
they	O	O
would	O	O
subsequently	O	O
inform	O	O
him	O	O
.	O	O

They	O	O
reported	O	O
that	O	O
Mr	O	O
X	O	O
was	O	O
in	O	O
support	O
of	O	O
this	O	O
arrangement	O	O
.	O	O

Eventually	O	O
we	O	O
told	O	O
the	O	O
family	B-LIVB
about	O	O
Mr	O	O
X	O	O
's	O	O
diagnosis	B-DISO
,	O	O
and	O	O
they	O	O
asserted	O	O
their	O	O
collective	O
will	O
to	O	O
keep	O	O
this	O	O
information	O
from	O	O
him	O	O
,	O	O
reaffirming	O	O
that	O	O
all	O	O
medical	O
discussion	B-PROC
go	O	O
through	O	O
them	O	O
.	O	O

However	O	O
,	O	O
the	O	O
doctor	B-LIVB
in	I-LIVB
charge	I-LIVB
explained	O	O
the	O	O
diagnosis	B-DISO
to	O	O
Mr	O	O
X	O	O
using	O	O
an	O	O
interpreter	B-LIVB
while	O	O
his	O	O
family	B-LIVB
were	O	O
away	O	O
from	O	O
his	O	O
bed	B-OBJC
.	O	O

In	O	O
this	O	O
discussion	O	O
,	O	O
I	O	O
consider	O	O
this	O	O
case	O
from	O	O
the	O	O
perspective	O	O
of	O	O
respecting	B-PROC
patients	I-PROC
'	I-PROC
and	I-PROC
families	I-PROC
'	I-PROC
preferences	I-PROC
around	O	O
medical	B-PROC
treatment	I-PROC
and	I-PROC
care	I-PROC
.	O	O

A	O	O
Cyclin	B-CHEM
D2	I-CHEM
-derived	O	O
peptide	B-CHEM
acts	O	O
on	O	O
specific	O
cell	B-PHYS
cycle	I-PHYS
phases	I-PHYS
by	O	O
activating	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
to	O	O
cause	B-DISO
the	I-DISO
death	I-DISO
of	O	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
Protein	B-PHYS
degradation	I-PHYS
by	O	O
the	O	O
proteasome	B-PHYS
generates	O	O
functional	O
intracellular	O
peptides	B-CHEM
.	O	O

Pep5	B-CHEM
,	O	O
a	O	O
peptide	B-CHEM
derived	O	O
from	O	O
Cyclin	B-CHEM
D2	I-CHEM
,	O	O
induces	O
cell	B-PHYS
death	I-PHYS
in	O	O
tumor	B-ANAT
cell	I-ANAT
lines	I-ANAT
and	O	O
reduces	O
the	O	O
volume	O
of	O	O
rat	B-LIVB
C6	B-DISO
glioblastoma	I-DISO
tumors	I-DISO
in	O
vivo	O
.	O	O

Here	O	O
,	O	O
we	O	O
chose	O	O
the	O	O
human	B-DISO
MDA	I-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O	O
evaluate	B-PROC
the	O	O
mechanism	B-PHYS
of	I-PHYS
cell	I-PHYS
death	I-PHYS
induced	O
by	O	O
pep5	B-CHEM
in	O	O
different	O
phases	B-PHYS
of	I-PHYS
the	I-PHYS
cell	I-PHYS
cycle	I-PHYS
.	O	O

Fluorescently	B-PROC
labeled	I-PROC
pep5	B-CHEM
,	O	O
monitored	O	O
by	O	O
real	B-PROC
time	I-PROC
confocal	I-PROC
microscopy	I-PROC
,	O	O
entered	O	O
the	O	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
3min	O	O
after	O	O
application	O	O
and	O	O
localized	O
to	O	O
the	O	O
nucleus	B-ANAT
and	O	O
cytoplasm	B-ANAT
.	O	O

Pep5	B-CHEM
-	O	O
induced	O
cell	B-PHYS
death	I-PHYS
was	O	O
increased	O
when	O	O
the	O	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cell	B-ANAT
population	I-ANAT
was	O	O
arrested	O
at	O	O
the	O	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
transition	I-PHYS
or	O	O
in	O	O
S	O
phase	O
compared	O
to	O	O
asynchronous	O
cells	B-ANAT
.	O	O

Pep5	B-CHEM
induced	O
permanent	O
extracellular	B-CHEM
signal	I-CHEM
-	I-CHEM
regulated	I-CHEM
kinase	I-CHEM
(	O	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
)	O	O
phosphorylation	B-PHYS
in	O	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
synchronized	O
in	O	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
or	O	O
S	O
phase	O
.	O	O

Affinity	B-PROC
chromatography	I-PROC
followed	O	O
by	O	O
mass	B-PROC
spectrometry	I-PROC
identified	O
CLIC1	B-CHEM
and	O	O
Plectin	B-CHEM
as	O	O
the	O	O
only	O	O
two	O	O
proteins	B-CHEM
that	O	O
interacted	O
with	O	O
pep5	B-CHEM
in	O	O
both	O	O
asynchronous	O
and	O	O
synchronized	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
.	O	O

These	O	O
interactions	O
could	O	O
explain	O	O
the	O	O
long	O	O
-	O	O
lasting	O	O
ERK1	B-CHEM
/	I-CHEM
2	I-CHEM
phosphorylation	B-PHYS
and	O	O
the	O	O
cytoskeleton	B-ANAT
perturbations	O
in	O	O
the	O	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
cells	B-ANAT
,	O	O
in	O	O
which	O	O
the	O	O
stress	B-ANAT
fibers	I-ANAT
'	O	O
integrity	O
is	O	O
affected	O	O
by	O	O
pep5	B-CHEM
treatments	B-PROC
.	O	O

These	O	O
data	O
suggest	O	O
that	O	O
pep5	B-CHEM
has	O	O
potential	O
therapeutic	O
properties	O
for	O	O
treating	B-PROC
specific	O
types	O
of	O	O
cancers	B-DISO
,	O	O
such	O	O
as	O	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O	O

Pep5	B-CHEM
,	O	O
a	O	O
natural	O	O
intracellular	O
peptide	B-CHEM
formed	O	O
by	O	O
the	O	O
degradation	B-PHYS
of	I-PHYS
Cyclin	I-PHYS
D2	I-PHYS
through	O	O
the	O	O
ubiquitin	B-PHYS
-	I-PHYS
proteasome	I-PHYS
system	I-PHYS
,	O	O
induces	O
cell	B-PHYS
death	I-PHYS
when	O	O
reintroduced	O	O
into	O	O
MDA	B-DISO
-	I-DISO
MB	I-DISO
-	I-DISO
231	I-DISO
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
,	O	O
which	O	O
express	O	O
low	O
levels	O
of	O	O
Cyclin	B-CHEM
D2	I-CHEM
,	O	O
specifically	O	O
in	O	O
G1	B-PHYS
/	I-PHYS
S	I-PHYS
arrested	B-ANAT
cells	I-ANAT
or	O	O
in	O	O
cells	B-ANAT
that	O	O
are	O	O
passing	O	O
through	O	O
S	O
phase	O
.	O	O

Under	O	O
these	O	O
conditions	O	O
,	O	O
pep5	B-CHEM
is	O	O
able	O	O
to	O	O
interact	O
with	O	O
different	O	O
intracellular	O
proteins	B-CHEM
,	O	O
primarily	O	O
cytoskeleton	B-ANAT
and	O	O
proteasome	B-CHEM
components	I-CHEM
,	O	O
which	O	O
can	O	O
lead	O
to	O	O
cellular	B-PHYS
apoptosis	I-PHYS
.	O	O

Together	O	O
,	O	O
our	O	O
data	O
suggest	O	O
that	O	O
pep5	B-CHEM
is	O	O
an	O	O
intracellular	O
peptide	B-CHEM
with	O	O
therapeutic	O
potential	O
for	O	O
treating	B-PROC
specific	O
types	O
of	O	O
tumors	B-DISO
with	O	O
low	O
expression	B-PHYS
of	O	O
Cyclin	B-CHEM
D2	I-CHEM
by	O	O
inhibiting	O
cell	B-PHYS
proliferation	I-PHYS
.	O	O

Maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
during	O	O
pregnancy	B-PHYS
and	O	O
offspring	B-LIVB
body	B-PHYS
composition	I-PHYS
:	O	O
The	O	O
Healthy	B-PROC
Start	I-PROC
Study	I-PROC
Consistent	O	O
evidence	O
of	O	O
an	O	O
influence	O
of	O	O
maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
during	O	O
pregnancy	B-PHYS
on	O	O
infant	B-LIVB
body	B-PHYS
size	I-PHYS
and	O	O
composition	B-PHYS
in	O	O
human	B-LIVB
populations	B-LIVB
is	O	O
lacking	O	O
,	O	O
despite	O	O
robust	O	O
evidence	O
in	O	O
animal	B-LIVB
models	I-LIVB
.	O	O

We	O	O
sought	O	O
to	O	O
evaluate	O
the	O	O
influence	O
of	O	O
maternal	B-LIVB
macronutrient	O
intake	B-PHYS
and	O	O
balance	O	O
during	O	O
pregnancy	B-PHYS
on	O	O
neonatal	B-LIVB
body	B-PHYS
size	I-PHYS
and	O	O
composition	B-PHYS
,	O	O
including	O	O
fat	B-PHYS
mass	I-PHYS
and	O	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
.	O	O

The	O	O
analysis	B-PROC
was	O	O
conducted	O	O
among	O	O
1040	O	O
mother	B-LIVB
-	O	O
offspring	B-LIVB
pairs	O
enrolled	O	O
in	O	O
the	O	O
prospective	O
prebirth	O
observational	O
cohort	O
:	O	O
the	O	O
Healthy	B-PROC
Start	I-PROC
Study	I-PROC
.	O	O

Diet	B-OBJC
during	O	O
pregnancy	B-PHYS
was	O	O
collected	O
using	O	O
repeated	O	O
24	O	O
-	O	O
hour	O
dietary	B-OBJC
recalls	O	O
(	O	O
up	O	O
to	O	O
8	O	O
)	O	O
.	O	O

Direct	O
measures	O
of	O	O
body	B-PHYS
composition	I-PHYS
were	O	O
obtained	O	O
using	O	O
air	B-PROC
displacement	I-PROC
plethysmography	I-PROC
.	O	O

The	O	O
National	O
Cancer	O
Institute	O
measurement	O
error	O
model	O
was	O	O
used	O	O
to	O	O
estimate	O	O
usual	O	O
dietary	B-PHYS
intake	I-PHYS
during	O	O
pregnancy	B-PHYS
.	O	O

Multivariable	O
partition	O
(	O
nonisocaloric	O
)	O
and	O	O
nutrient	O
density	O
(	O
isocaloric	O
)	O
linear	O
regression	O
models	O
were	O	O
used	O	O
to	O	O
test	O	O
the	O	O
associations	O	O
between	O	O
maternal	B-LIVB
dietary	B-PHYS
intake	I-PHYS
and	O	O
neonatal	B-LIVB
body	B-PHYS
composition	I-PHYS
.	O	O

The	O	O
median	O	O
macronutrient	O
composition	O
during	O	O
pregnancy	B-PHYS
was	O	O
32	O	O
.	O	O

2	O	O
%	O	O
from	O	O
fat	B-CHEM
,	O	O
15	O	O
.	O	O
0	O	O
%	O	O
from	O	O
protein	B-OBJC
,	O	O
and	O	O
47	O	O
.	O	O

8	O	O
%	O	O
from	O	O
carbohydrates	B-OBJC
.	O	O

In	O	O
the	O	O
partition	O
multivariate	O
regression	O
model	O
,	O	O
individual	B-LIVB
macronutrient	O
intake	B-PHYS
values	O
were	O	O
not	O	O
associated	O	O
with	O	O
birthweight	B-PHYS
or	O	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
,	O	O
but	O	O
were	O	O
associated	O	O
with	O	O
fat	B-PHYS
mass	I-PHYS
.	O	O

Respectively	O	O
,	O	O
418	O	O
kJ	O	O
increases	O	O
in	O	O
total	B-CHEM
fat	I-CHEM
,	O	O
saturated	O
fat	O
,	O	O
unsaturated	B-CHEM
fat	I-CHEM
,	O	O
and	O	O
total	B-OBJC
carbohydrates	I-OBJC
were	O	O
associated	O	O
with	O	O
4	O	O
.	O	O
2	O	O
-	O	O
g	O	O
(	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
,	O	O
11	O	O
.	O	O
1	O	O
-	O	O
g	O	O
(	O	O
P	O	O
=	O	O
.003	O	O
)	O	O
,	O	O
5	O	O
.	O	O
9	O	O
-	O	O
g	O	O
(	O	O
P	O	O
=	O	O
.04	O	O
)	O	O
,	O	O
and	O	O
2	O	O
.	O	O
9	O	O
-	O	O
g	O	O
(	O	O
P	O	O
=	O	O
.02	O	O
)	O	O
increases	O	O
in	O	O
neonatal	B-LIVB
fat	B-PHYS
mass	I-PHYS
,	O	O
independent	O	O
of	O	O
prepregnancy	B-PHYS
body	I-PHYS
mass	I-PHYS
index	I-PHYS
.	O	O

In	O	O
the	O	O
nutrient	O
density	O
multivariate	O
regression	O
model	O
,	O	O
macronutrient	O
balance	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
fat	B-PHYS
mass	I-PHYS
,	O	O
fat	B-DISO
-	I-DISO
free	I-DISO
mass	I-DISO
,	O	O
or	O	O
birthweight	B-PHYS
after	O	O
adjustment	O	O
for	O	O
prepregnancy	B-PHYS
body	I-PHYS
mass	I-PHYS
index	I-PHYS
.	O	O

Neonatal	B-LIVB
adiposity	B-PHYS
,	O	O
but	O	O
not	O	O
birthweight	B-PHYS
,	O	O
is	O	O
independently	O	O
associated	O	O
with	O	O
increased	O	O
maternal	B-LIVB
intake	B-PHYS
of	O	O
total	B-CHEM
fat	I-CHEM
,	O	O
saturated	O
fat	O
,	O	O
unsaturated	B-CHEM
fat	I-CHEM
,	O	O
and	O	O
total	B-OBJC
carbohydrates	I-OBJC
,	O	O
but	O	O
not	O	O
protein	B-OBJC
,	O	O
suggesting	O	O
that	O	O
most	O	O
forms	O	O
of	O	O
increased	O
caloric	O
intake	O
contribute	O	O
to	O	O
fetal	B-ANAT
fat	B-DISO
accretion	I-DISO
.	O	O

Difference	B-PROC
-	I-PROC
in	I-PROC
-	I-PROC
Differences	I-PROC
Method	I-PROC
in	O	O
Comparative	B-PROC
Effectiveness	I-PROC
Research	I-PROC
:	O	O
Utility	O	O
with	O	O
Unbalanced	O
Groups	O
Comparative	B-PROC
effectiveness	I-PROC
research	I-PROC
(	O	O
CER	B-PROC
)	O	O
often	O	O
includes	O	O
observational	O
studies	O
utilizing	O	O
administrative	B-DISO
data	I-DISO
.	O	O

Multiple	O	O
conditioning	O	O
methods	O	O
can	O	O
be	O	O
used	O	O
for	O	O
CER	B-PROC
to	O	O
adjust	O	O
for	O	O
group	O
differences	O
,	O	O
including	O	O
difference	B-PROC
-	I-PROC
in	I-PROC
-	I-PROC
differences	I-PROC
(	I-PROC
DiD	I-PROC
)	I-PROC
estimation	I-PROC
.	O	O

This	O	O
study	O	O
presents	O	O
DiD	B-PROC
and	O	O
demonstrates	O	O
how	O	O
to	O	O
apply	O	O
this	O	O
conditioning	O	O
method	O
to	O	O
estimate	O	O
treatment	O
outcomes	O
in	O	O
the	O	O
CER	B-PROC
setting	O	O
by	O	O
utilizing	O	O
the	O	O
MarketScan	O
®	O
Databases	O
for	O	O
multiple	B-DISO
sclerosis	I-DISO
(	O	O
MS	B-DISO
)	O	O
patients	B-LIVB
receiving	O	O
different	O	O
therapies	B-PROC
.	O	O

The	O	O
sample	O	O
included	O	O
6762	O	O
patients	B-LIVB
,	O	O
with	O	O
363	O	O
in	O	O
the	O	O
Test	B-LIVB
Cohort	I-LIVB
[	O	O
glatiramer	B-CHEM
acetate	I-CHEM
(	O	O
GA	B-CHEM
)	O	O
switched	B-PROC
to	O	O
fingolimod	B-CHEM
(	O	O
FTY	B-CHEM
)	O	O
]	O	O
and	O	O
6399	O	O
in	O	O
the	O	O
Control	B-LIVB
Cohort	I-LIVB
(	O	O
GA	B-CHEM
only	O	O
,	O	O
no	B-DISO
switch	I-DISO
)	O	O
from	O	O
a	O	O
US	O
administrative	O
claims	O
database	O
.	O	O

A	O	O
trend	O
analysis	O
was	O	O
conducted	O	O
to	O	O
rule	O	O
out	O	O
concerns	O	O
regarding	O	O
regression	O
to	O	O
the	O	O
mean	O
and	O	O
to	O	O
compare	O	O
relapse	B-PHEN
rates	O	O
among	O	O
treatment	B-LIVB
cohorts	I-LIVB
.	O	O

DiD	B-PROC
analysis	I-PROC
was	O	O
used	O	O
to	O	O
enable	O	O
comparisons	O
among	O	O
the	O	O
Test	B-LIVB
and	O	O
Control	B-LIVB
Cohorts	I-LIVB
.	O	O

Logistic	B-PROC
regression	I-PROC
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
probability	O
of	O	O
relapse	B-PHEN
after	O	O
switching	B-PROC
from	O	O
GA	B-CHEM
to	O	O
FTY	B-CHEM
,	O	O
and	O	O
to	O	O
compare	O
group	O
differences	O
in	O	O
the	O	O
pre	O
-	O	O
and	O	O
post	O
-	O	O
index	O
periods	O
.	O	O

Crude	O	O
DiD	B-PROC
analysis	I-PROC
showed	O	O
that	O	O
in	O	O
the	O	O
pre	O
-	O	O
index	O
period	O
more	O	O
patients	B-LIVB
in	O	O
the	O	O
Test	B-LIVB
Cohort	I-LIVB
experienced	O	O
an	O	O
MS	B-DISO
relapse	B-PHEN
and	O	O
had	O	O
a	O	O
higher	O	O
mean	O
number	O
of	O	O
relapses	B-PHEN
than	O	O
in	O	O
the	O	O
Control	B-LIVB
Cohort	I-LIVB
.	O	O

During	O	O
the	O	O
pre	O
-	O	O
index	O
period	O
,	O	O
numeric	O
and	O	O
relative	O	O
data	O	O
for	O	O
MS	B-DISO
relapses	B-PHEN
in	O	O
patients	B-LIVB
in	O	O
the	O	O
Test	B-LIVB
Cohort	I-LIVB
were	O	O
significantly	O	O
higher	O	O
than	O	O
in	O	O
the	O	O
Control	B-LIVB
Cohort	I-LIVB
,	O	O
while	O	O
no	B-DISO
significant	I-DISO
between	O	O
-	O	O
group	O
differences	O
emerged	O	O
during	O	O
the	O	O
post	O
-	O	O
index	O
period	O
.	O	O

Generalized	O	O
linear	O
modeling	O
with	O	O
DiD	B-PROC
regression	O
estimation	O
showed	O	O
that	O	O
the	O	O
mean	O	O
number	O	O
of	O	O
MS	B-DISO
relapses	B-PHEN
decreased	O	O
significantly	O	O
in	O	O
the	O	O
post	O
-	O	O
index	O
period	O
among	O	O
patients	B-LIVB
in	O	O
the	O	O
Test	B-LIVB
Cohort	I-LIVB
compared	O	O
with	O	O
patients	B-LIVB
in	O	O
the	O	O
Control	B-LIVB
Cohort	I-LIVB
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
an	O	O
MS	B-DISO
population	B-LIVB
was	O	O
utilized	O	O
to	O	O
demonstrate	O	O
how	O	O
DiD	B-PROC
can	O	O
be	O	O
applied	O	O
to	O	O
estimate	O	O
treatment	B-DISO
effects	I-DISO
in	O	O
a	O	O
heterogeneous	O
population	B-LIVB
,	O	O
where	O	O
the	O	O
Test	B-LIVB
and	O	O
Control	B-LIVB
Cohorts	I-LIVB
varied	O	O
greatly	O	O
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
DiD	B-PROC
offers	O	O
a	O	O
robust	O	O
method	O	O
for	O	O
comparing	O
diverse	O
cohorts	B-LIVB
when	O	O
other	O	O
risk	O
-	O
adjustment	O
methods	O
may	O	O
not	O	O
be	O	O
adequate	O	O
.	O	O

Variation	O	O
in	O	O
the	O	O
Use	O	O
of	O	O
Vestibular	B-PROC
Diagnostic	I-PROC
Testing	I-PROC
for	O	O
Patients	B-LIVB
Presenting	O	O
to	O	O
Otolaryngology	O
Clinics	O
with	O	O
Dizziness	B-DISO
We	O	O
used	O	O
a	O	O
national	O
otolaryngology	O
practice	O
-	O
based	O
research	O
network	O
database	O
to	O	O
characterize	O	O
the	O	O
utilization	O	O
of	O	O
vestibular	B-PROC
function	I-PROC
testing	I-PROC
in	O	O
patients	B-LIVB
diagnosed	B-DISO
with	O	O
dizziness	B-DISO
and	O	O
/	O	O
or	O	O
a	O	O
vestibular	B-DISO
disorder	I-DISO
.	O	O

Database	O	O
review	O	O
.	O	O

The	O	O
Creating	B-PROC
Healthcare	I-PROC
Excellence	I-PROC
through	O	O
Education	B-PROC
and	O	O
Research	B-PROC
(	O	O
CHEER	B-PROC
)	O	O
practice	O
-	O
based	O
research	O
network	O
of	O	O
academic	O
and	O	O
community	B-LIVB
providers	I-LIVB
Dizzy	B-LIVB
patients	I-LIVB
in	O	O
the	O	O
CHEER	B-PROC
retrospective	B-PROC
database	I-PROC
were	O	O
identified	O	O
through	O	O
ICD	O
-	O
9	O
codes	O
;	O	O
vestibular	B-PROC
testing	I-PROC
procedures	I-PROC
were	O	O
identified	O	O
with	O	O
CPT	O
codes	O
.	O	O

Demographics	O
and	O	O
procedures	B-PROC
per	I-PROC
patient	I-PROC
were	O	O
tabulated	O
.	O	O

Analysis	B-PROC
included	O	O
number	O	O
and	O	O
type	O	O
of	O	O
vestibular	B-PROC
tests	I-PROC
ordered	O	O
,	O	O
stratified	B-PROC
by	I-PROC
individual	I-PROC
clinic	I-PROC
and	O	O
by	O	O
practice	O
type	O
(	O	O
community	B-LIVB
vs	O	O
academic	O
)	O	O
.	O	O

Chi	O
-	O
square	O
tests	O
were	O	O
performed	O	O
to	O	O
assess	O	O
if	O	O
the	O	O
percentage	O	O
of	O	O
patients	B-LIVB
receiving	I-LIVB
testing	I-LIVB
was	O	O
statistically	O
significant	O
across	O
clinics	O
.	O	O

A	O	O
logistic	B-PROC
regression	I-PROC
model	O
was	O	O
used	O	O
to	O	O
examine	O	O
the	O	O
association	O	O
between	O	O
receipt	O
of	O
testing	O
and	O	O
being	O	O
tested	O	O
on	O	O
initial	O	O
visit	O	O
.	O	O

A	O	O
total	O	O
of	O	O
12	O	O
,	O	O
468	O	O
patients	B-LIVB
diagnosed	B-DISO
with	O	O
dizziness	B-DISO
and	O	O
/	O	O
or	O	O
a	O	O
vestibular	B-DISO
disorder	I-DISO
were	O	O
identified	O	O
from	O	O
7	O	O
community	B-LIVB
and	O	O
5	O	O
academic	O
CHEER	B-PROC
network	O	O
clinics	B-OBJC
across	O	O
the	O	O
country	O	O
.	O	O

One	O	O
-	O	O
fifth	O	O
of	O	O
these	O	O
patients	B-LIVB
had	O	O
at	O	O
least	O	O
1	O	O
vestibular	B-PROC
function	I-PROC
test	I-PROC
.	O	O

The	O	O
percentage	O	O
of	O	O
patients	B-LIVB
tested	O	O
varied	O	O
widely	O	O
by	O	O
site	O	O
,	O	O
from	O	O
3	O	O
%	O	O
to	O	O
72	O	O
%	O	O
;	O	O
academic	B-OBJC
clinics	I-OBJC
were	O	O
twice	O	O
as	O	O
likely	O	O
to	O	O
test	O	O
.	O	O

Initial	O	O
visit	O	O
vestibular	B-PROC
testing	I-PROC
also	O	O
varied	O	O
,	O	O
from	O	O
0	O	O
%	O	O
to	O	O
96	O	O
%	O	O
of	O	O
dizzy	B-LIVB
patients	I-LIVB
,	O	O
and	O	O
was	O	O
15	O	O
times	O	O
more	O	O
likely	O	O
in	O	O
academic	B-OBJC
clinics	I-OBJC
.	O	O

There	O	O
is	O	O
significant	O	O
variation	O	O
in	O	O
use	O	O
and	O	O
timing	O	O
of	O	O
vestibular	B-PROC
diagnostic	I-PROC
testing	I-PROC
across	O	O
otolaryngology	O
clinics	O
.	O	O

The	O	O
CHEER	B-PROC
network	O
research	O
database	O
does	O	O
not	O	O
contain	O	O
outcome	O	O
data	O	O
.	O	O

These	O	O
results	O	O
illustrate	O	O
the	O	O
critical	O	O
need	O	O
for	O	O
research	B-PROC
that	I-PROC
examines	I-PROC
outcomes	I-PROC
as	O	O
related	O	O
to	O	O
vestibular	B-PROC
testing	I-PROC
.	O	O

Metabolomic	O
analysis	O
of	O	O
glycerophospholipid	B-CHEM
signatures	O	O
of	O	O
inflammation	B-DISO
treated	B-PROC
with	I-PROC
non	B-CHEM
-	I-CHEM
steroidal	I-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
-induced	O	O
-	O	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
using	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
and	O	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
Non	B-PROC
-	I-PROC
destructive	I-PROC
proton	I-PROC
nuclear	I-PROC
magnetic	I-PROC
resonance	I-PROC
(	I-PROC
(	I-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
)	I-PROC
spectroscopy	I-PROC
and	O	O
highly	O
sensitive	O
ultra	B-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	B-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
)	O	O
coupled	O	O
to	O	O
data	O
processing	O
methods	O
were	O	O
applied	O	O
to	O	O
analyze	O	O
the	O	O
metabolic	O
profiling	O
changes	O	O
of	O	O
glycerophospholipids	B-CHEM
(	O	O
GPLs	B-CHEM
)	O	O
in	O	O
RAW264	B-ANAT
.	I-ANAT

7	I-ANAT
cells	I-ANAT
from	O	O
inflammation	B-DISO
to	O	O
prognosis	B-PROC
.	O	O

Analysis	B-PROC
of	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
was	O	O
shown	O	O
that	O	O
the	O	O
models	O
were	O	O
grouped	O
successfully	O	O
,	O	O
illustrating	O	O
that	O	O
all	O	O
of	O	O
them	O	O
had	O	O
significant	O	O
differences	O
.	O	O

Based	O	O
on	O	O
the	O	O
highly	O
simple	O
,	O	O
accurate	O
,	O	O
non	O	O
-	O	O
targeted	O	O
and	O	O
non	O	O
-	O	O
destructively	O	O
advantages	O	O
of	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
,	O	O
it	O	O
could	O	O
be	O	O
used	O	O
as	O	O
a	O	O
new	O	O
screening	O	O
tool	O	O
of	O	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
in	O	O
the	O	O
metabolic	O
profiling	O
of	O	O
GPLs	B-CHEM
.	O	O

58	O	O
GPLs	B-CHEM
were	O	O
identified	O
by	O	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
,	O	O
and	O	O
19	O	O
components	O	O
were	O	O
firstly	O	O
identified	O
in	O	O
this	O	O
study	B-PROC
compared	O	O
with	O	O
our	O	O
previous	O	O
results	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
ten	O	O
potential	O
biomarkers	B-PHYS
were	O	O
proved	O	O
,	O	O
of	O	O
which	O	O
phosphatidylcholine	B-CHEM
(	O	O
PC	B-CHEM
)	O	O
(	O	O
16	O	O
:	O	O
0	O	O
/	O	O
18	O	O
:	O	O
1	O	O
)	O	O
and	O	O
(	O	O
18	O	O
:	O	O
0	O	O
/	O	O
18	O	O
:	O	O
1	O	O
)	O	O
changed	O
consistently	O	O
in	O	O
three	O	O
drug	O
-	O
induced	O
groups	O
and	O	O
might	O	O
be	O	O
the	O	O
important	O	O
biomarkers	B-PHYS
.	O	O

Compared	O	O
with	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
,	O	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
showed	O	O
higher	O
sensitivity	O
and	O
specificity	O
and	O	O
was	O	O
more	O	O
suitable	O	O
for	O	O
the	O	O
determination	B-PROC
of	O	O
biomarkers	B-PHYS
apart	O	O
from	O	O
the	O	O
deficiency	O
of	O	O
time	O
-	O
consuming	O
sample	B-PROC
preparation	I-PROC
steps	I-PROC
and	O	O
unambiguous	O	O
metabolite	B-CHEM
identification	O
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
feasible	O	O
to	O	O
analyze	O	O
the	O	O
changes	O
of	O	O
GPLs	B-CHEM
during	O	O
inflammation	B-DISO
by	O	O
combining	O	O
(	B-PROC
1	I-PROC
)	I-PROC
H	I-PROC
NMR	I-PROC
spectroscopy	I-PROC
with	O	O
U	B-PROC
-	I-PROC
HPLC	I-PROC
/	O	O
Q	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
.	O	O

The	O	O
metabolic	O
profiling	O
of	O	O
GPLs	B-CHEM
provides	O	O
valuable	O	O
evidence	O
for	O	O
inflammation	B-DISO
diagnosis	B-DISO
and	O	O
prognosis	B-PROC
,	O	O
and	O	O
might	O	O
unravel	O	O
the	O	O
mechanisms	O
involved	O	O
in	O	O
inflammation	B-DISO
progression	B-DISO
.	O	O

Design	O
considerations	B-DISO
for	O	O
patient	O
-	O
specific	O
surgical	B-DEVI
templates	I-DEVI
for	O	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
with	O	O
respect	O	O
to	O	O
acetabular	B-ANAT
cartilage	O
Patient	B-DEVI
-	I-DEVI
specific	I-DEVI
instruments	I-DEVI
(	O	O
PSIs	B-DEVI
)	O	O
are	O	O
clinically	O
used	O	O
to	O	O
support	O	O
the	O	O
surgeon	B-LIVB
during	O	O
a	O	O
planned	O
intervention	O
.	O	O

The	O	O
planning	B-PHYS
is	O	O
typically	O	O
done	O	O
based	O	O
on	O	O
volumetric	O
image	O
data	O
from	O	O
medical	B-PROC
imaging	I-PROC
systems	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

computed	B-PROC
tomography	I-PROC
(	O	O
CT	B-PROC
)	O	O
.	O	O

The	O	O
PSI	B-DEVI
uses	O	O
the	O	O
known	O	O
surface	B-ANAT
structure	I-ANAT
of	I-ANAT
a	I-ANAT
bone	I-ANAT
for	O	O
orientation	O
during	O	O
the	O	O
intervention	B-PROC
.	O	O

Some	O	O
surfaces	B-ANAT
of	I-ANAT
human	I-ANAT
bone	I-ANAT
are	O	O
covered	O
with	O	O
a	O	O
layer	B-ANAT
of	O	O
cartilage	O
which	O	O
is	O	O
hardly	B-DISO
visible	O
in	O	O
clinically	O
applied	O
CT	B-PROC
-	I-PROC
imaging	I-PROC
.	O	O

This	O	O
experimental	B-PROC
study	I-PROC
investigates	O
ten	O	O
different	O
PSI	B-DEVI
designs	O
and	O	O
their	O	O
effect	O
to	O	O
the	O	O
overall	O
accuracy	O
when	O	O
neglecting	O	O
the	O	O
cartilage	O
in	O	O
the	O	O
design	O
process	B-PHEN
.	O	O

Therefore	O	O
,	O	O
a	O	O
model	B-DEVI
of	O	O
an	O	O
acetabulum	B-ANAT
is	O	O
used	O	O
to	O	O
simulate	B-PROC
the	O	O
use	O	O
case	O
of	O	O
PSI	B-DEVI
in	O	O
total	B-PROC
hip	I-PROC
arthroplasty	I-PROC
.	O	O

The	O	O
concept	O
of	O	O
the	O	O
different	O
designs	O
is	O	O
to	O	O
create	O
structural	O
elasticities	O
in	O	O
the	O	O
PSI	B-DEVI
to	O	O
avoid	O	O
shifting	O
of	O	O
the	O	O
whole	O	O
instrument	B-DEVI
and	O	O
rather	O	O
have	O	O
a	O	O
small	O	O
part	O	O
of	O	O
it	O	O
deformed	O
by	O	O
cartilage	O
.	O	O

A	O	O
needle	B-DEVI
array	I-DEVI
structure	I-DEVI
,	O	O
for	O	O
instance	O	O
,	O	O
should	O	O
also	O	O
be	O	O
able	O	O
to	O	O
oust	O	O
or	O	O
penetrate	O
remaining	O	O
soft	O
tissue	O
in	O	O
the	O	O
acetabulum	B-ANAT
.	O	O

The	O	O
nurse	O
-	O
patient	O
communication	O
:	O	O
voices	O	O
from	O	O
nursing	B-LIVB
students	I-LIVB
Effective	B-PHYS
communication	I-PHYS
skills	I-PHYS
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
one	O	O
of	O	O
the	O	O
pivotal	O
factors	O
in	O	O
building	O	O
positive	O
interpersonal	O
relationships	O
.	O	O

Little	O	O
is	O	O
known	O	O
about	O	O
nursing	B-LIVB
undergraduates	I-LIVB
'	O	O
perspectives	O
on	O	O
communicating	O
with	O	O
patients	B-LIVB
.	O	O

This	O	O
study	B-PROC
aimed	O	O
to	O	O
explore	O	O
nursing	B-LIVB
students	I-LIVB
'	I-LIVB
perspectives	O
and	O	O
experiences	B-PHYS
of	O	O
nurse	O
-	O
patient	O
communication	O
in	O	O
their	O	O
clinical	O
placement	O
.	O	O

The	O	O
participants	B-LIVB
included	O	O
21	O	O
second	B-LIVB
-	I-LIVB
year	I-LIVB
undergraduates	I-LIVB
and	O	O
21	O	O
first	B-LIVB
-	I-LIVB
year	I-LIVB
master	I-LIVB
's	I-LIVB
students	I-LIVB
.	O	O

Interviews	O
were	O	O
conducted	O	O
in	O	O
Cantonese	O
and	O	O
then	O	O
transcribed	O	O
in	O	O
Chinese	O
and	O	O
translated	O	O
into	O	O
English	O
.	O	O

A	O	O
content	B-PROC
analysis	I-PROC
approach	O
was	O	O
adopted	O	O
to	O	O
analyze	O	O
the	O	O
data	O
.	O	O

Five	O	O
themes	O
emerged	O	O
from	O	O
the	O	O
interview	O
data	O
.	O	O
'	O	O
The	O	O
necessity	O	O
of	O	O
nurse	O
-	O
patient	O
communication	O
'	O	O
reveals	O
why	O	O
the	O	O
students	B-LIVB
valued	O	O
nurse	O
-	O
patient	O
communication	O
.	O	O
'	O	O
The	O	O
conversation	B-DISO
contents	I-DISO
'	O	O
describes	O	O
the	O	O
content	B-DISO
of	I-DISO
the	I-DISO
conversations	I-DISO
that	O	O
students	B-LIVB
typically	O	O
had	O	O
with	O	O
patients	B-LIVB
.	O	O

The	O	O
third	O	O
theme	O
is	O	O
'	O	O
self	B-DISO
-	I-DISO
reflection	I-DISO
on	O	O
the	O	O
nurse	O
-	O
patient	O
communication	O
'	O	O
.	O	O

The	O	O
last	O	O
two	O	O
themes	O
,	O	O
'	O	O
the	O	O
communication	B-DISO
pattern	I-DISO
in	I-DISO
different	I-DISO
hospital	B-OBJC
settings	I-OBJC
'	O	O
and	O	O
'	O	O
the	O	O
obstacles	O	O
impeding	O	O
nurse	O
-	O
patient	O
communication	O
'	O	O
,	O	O
are	O	O
about	O	O
the	O	O
students	B-LIVB
'	I-LIVB
communication	O
styles	O
in	O	O
different	O	O
hospitals	B-OBJC
and	O	O
the	O	O
barriers	O	O
they	O	O
encounter	O
.	O	O

To	O	O
improve	B-DISO
students	B-LIVB
'	I-LIVB
communication	B-PHYS
skills	I-PHYS
,	O	O
educators	B-LIVB
and	O	O
clinical	B-LIVB
staff	I-LIVB
should	O	O
listen	O	O
to	O	O
students	B-LIVB
,	O	O
enhance	O
students	B-LIVB
'	I-LIVB
reflective	O
skills	O
and	O	O
strengthen	O	O
their	O	O
confidence	B-PHYS
.	O	O

Through	O	O
understanding	B-PHYS
students	B-LIVB
'	I-LIVB
difficulties	O
in	O	O
the	O	O
nurse	O
-	O
patient	O
communication	O
experience	B-PHYS
and	O	O
the	O	O
skills	O
that	O	O
they	O	O
lack	O	O
,	O	O
educators	B-LIVB
can	O	O
provide	O	O
them	O	O
with	O	O
helpful	O	O
recommendations	O
to	O	O
improve	B-DISO
their	O	O
communication	B-PHYS
skills	I-PHYS
in	O	O
clinical	O
practice	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	B-PROC
reveal	O
that	O	O
students	B-LIVB
'	I-LIVB
nurse	O
-	O
patient	O
communication	O
skills	B-PHYS
need	O	O
to	O	O
be	O	O
improved	B-DISO
.	O	O

Fabrication	B-PHEN
and	O	O
characterization	O
of	O	O
poly	B-CHEM
(	I-CHEM
vinyl	I-CHEM
alcohol	I-CHEM
)	I-CHEM
-	O	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
for	O	O
orthopedic	B-PROC
applications	I-PROC
Poly	B-CHEM
(	I-CHEM
vinyl	I-CHEM
alcohol	I-CHEM
)	I-CHEM
(	O	O
PVA	B-CHEM
)	O	O
is	O	O
reinforced	O	O
with	O	O
TiO2	B-CHEM
nanoparticles	B-OBJC
in	O	O
order	O	O
to	O	O
enhance	O	O
thermo	O
-	O
mechanical	O
stabilities	O
,	O	O
surface	O
characteristics	O
and	O	O
osteoblastic	B-ANAT
cell	B-PHYS
adhesion	I-PHYS
.	O	O

PVA	B-CHEM
-	O	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
with	O	O
desirable	O	O
mechanical	O
,	O	O
thermal	O
and	O	O
biocompatible	O
properties	O
are	O	O
fabricated	O	O
through	O	O
solution	B-PHEN
casting	I-PHEN
method	I-PHEN
followed	O	O
by	O	O
de	B-PHEN
-	I-PHEN
hydrothermal	I-PHEN
cross	I-PHEN
-	I-PHEN
linking	I-PHEN
treatment	I-PHEN
.	O	O

The	O	O
composition	B-PHEN
of	O	O
TiO2	B-CHEM
nanoparticles	B-OBJC
was	O	O
standardized	O	O
to	O	O
achieve	O	O
mechanically	O
stable	O
nanocomposite	B-OBJC
films	B-OBJC
,	O	O
based	O	O
on	O	O
tensile	O
strength	O
measurements	O
composition	B-PHEN
of	O	O
TiO2	B-CHEM
is	O	O
determined	O	O
as	O	O
optimal	O
at	O	O
3wt	O	O
%	O	O
.	O	O

PVA	B-CHEM
-	O	O
TiO2	B-CHEM
nanocomposite	B-OBJC
films	B-OBJC
were	O	O
characterized	O
by	O	O
Scanning	B-PROC
electron	I-PROC
microscopy	I-PROC
,	O	O
Energy	B-PROC
dispersive	I-PROC
spectroscopy	I-PROC
,	O	O
Atomic	B-PROC
force	I-PROC
microscopy	I-PROC
,	O	O
Ultra	B-PROC
violet	I-PROC
and	O	O
Fourier	B-PROC
transform	I-PROC
infrared	I-PROC
spectroscopic	I-PROC
techniques	I-PROC
.	O	O

Elemental	B-PROC
mapping	I-PROC
studies	I-PROC
substantiate	O	O
incorporation	O	O
of	O	O
TiO2	B-CHEM
nanoparticles	B-OBJC
within	O	O
the	O	O
PVA	B-CHEM
matrix	B-CHEM
.	O	O

Dimensional	O
stability	O
evaluated	O	O
by	O	O
soaking	O
films	B-OBJC
in	O	O
SBF	B-OBJC
for	O	O
24h	O	O
insinuates	O	O
the	O	O
role	O
of	O	O
TiO2	B-CHEM
in	O	O
the	O	O
direction	O
of	O	O
controlling	O	O
degree	O
of	O
swelling	O
.	O	O

In	B-PROC
-	I-PROC
vitro	I-PROC
bioactivity	I-PROC
test	I-PROC
and	O	O
cell	B-PHYS
adhesion	I-PHYS
results	O	O
also	O	O
predict	O	O
that	O	O
presence	O
of	O	O
TiO2	B-CHEM
is	O	O
advantageous	O	O
to	O	O
enhance	O	O
apatite	B-PHEN
growth	I-PHEN
and	O	O
promote	O	O
cell	B-ANAT
-	O	O
substrate	B-OBJC
interaction	O
.	O	O

SEM	B-PROC
studies	I-PROC
illustrate	O	O
improved	O	O
surface	O
morphology	O
of	O	O
PVA	B-CHEM
-	O	O
TiO2	B-CHEM
nanocomposite	B-OBJC
film	B-OBJC
with	O	O
homogenously	O
distributed	O
TiO2	B-CHEM
nanoparticles	B-OBJC
,	O	O
which	O	O
help	O	O
to	O	O
enhance	O	O
thermo	O
-	O
mechanical	O
behavior	O
.	O	O

TiO2	B-CHEM
nanoparticles	B-OBJC
construct	O	O
cell	O
-	O
adhesive	O
hydrophilic	O
nano	O
-	O
domains	O
that	O	O
act	O	O
as	O	O
potential	O	O
cell	B-PHYS
adhesion	I-PHYS
sites	O
and	O	O
promotes	O	O
osteointegration	O
.	O	O

Bio	B-PROC
compatibility	I-PROC
studies	I-PROC
proved	O	O
that	O	O
thermally	O
cross	O
-	O
linked	O
PVA	B-CHEM
is	O	O
non	B-DISO
-	I-DISO
toxic	I-DISO
in	O	O
relation	O	O
to	O	O
PVA	B-CHEM
cross	O
-	O
linked	O
with	O	O
glutaraldehyde	B-CHEM
.	O	O

Cytotoxicity	B-DISO
and	O	O
cell	B-PHYS
adhesion	I-PHYS
of	O	O
nanocomposite	B-OBJC
films	B-OBJC
evaluated	O	O
through	O	O
cell	B-PROC
viability	I-PROC
(	I-PROC
MMT	I-PROC
)	I-PROC
assay	I-PROC
and	O	O
crystal	B-PROC
violet	I-PROC
staining	I-PROC
revealed	O	O
that	O	O
PVA	B-CHEM
-3wt	O	O
%	O	O
TiO2	B-CHEM
nanocomposite	B-OBJC
could	O	O
act	O	O
as	O	O
an	O	O
excellent	O	O
composite	O
and	O	O
hence	O	O
suitable	O	O
to	O	O
be	O	O
used	O	O
in	O	O
bone	B-DEVI
implant	I-DEVI
applications	I-DEVI
.	O	O

Characterization	O
of	O	O
novel	O
DeoR	B-CHEM
-	I-CHEM
family	I-CHEM
member	B-LIVB
from	O	O
the	O	O
Streptomyces	B-LIVB
ahygroscopicus	I-LIVB
strain	B-LIVB
CK	I-LIVB
-	I-LIVB
15	I-LIVB
that	O	O
acts	O	O
as	O	O
a	O	O
repressor	B-CHEM
of	O	O
morphological	O
development	O
Wuyiencin	B-CHEM
is	O	O
produced	O
by	O	O
Streptomyces	B-LIVB
ahygroscopicus	I-LIVB
var	I-LIVB
.	I-LIVB

wuyiensis	I-LIVB
,	O	O
which	O	O
has	O	O
been	O	O
widely	O	O
used	O	O
in	O	O
China	B-GEOG
as	O	O
an	O	O
industrially	O
produced	O
biopesticide	B-CHEM
to	O	O
control	O
various	O	O
fungal	B-DISO
diseases	I-DISO
.	O	O

Although	O	O
its	O	O
mechanism	O
of	O	O
action	O
,	O	O
breeding	B-PHYS
,	O	O
and	O	O
fermentation	B-PHYS
had	O	O
been	O	O
extensively	O	O
characterized	O
,	O	O
less	O	O
is	O	O
known	O	O
about	O	O
the	O	O
regulatory	B-PHYS
functions	I-PHYS
that	O	O
affect	O	O
its	O	O
biosynthesis	O
or	O	O
morphological	O
development	O
.	O	O

The	O	O
wysR3	O
gene	O
of	O	O
S	B-LIVB
.	I-LIVB

ahygroscopicus	I-LIVB
strain	B-LIVB
CK	I-LIVB
-	I-LIVB
15	I-LIVB
,	O	O
a	O	O
novel	O
member	B-LIVB
of	O	O
the	O	O
DeoR	B-CHEM
family	I-CHEM
of	O	O
regulatory	O
genes	O
,	O	O
was	O	O
assessed	O
to	O	O
determine	O	O
its	O	O
function	O
by	O	O
gene	B-PROC
knockdown	I-PROC
.	O	O

Herein	O	O
,	O	O
we	O	O
demonstrate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
DeoR	B-CHEM
family	I-CHEM
proteins	I-CHEM
derived	O	O
from	O	O
the	O	O
same	O	O
source	B-DISO
are	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
single	O
branch	O
in	O	O
a	O	O
phylogenetic	O
tree	O
and	O	O
show	O	O
that	O	O
wysR3	O
acts	O	O
as	O	O
a	O	O
repressor	B-CHEM
for	O	O
its	O	O
morphological	O
development	O
without	O	O
effecting	O	O
wuyiencin	B-CHEM
production	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
ΔwysR3	O
strain	B-LIVB
can	O	O
grow	O	O
quickly	O	O
to	O	O
reach	O	O
a	O	O
plateau	O
stage	O
of	O	O
maximum	O	O
biomass	O
at	O	O
60	O	O
h	O	O
,	O	O
which	O	O
is	O	O
~12	O	O
h	O	O
faster	O
than	O	O
the	O	O
wild	O
-	O
type	O
strain	B-LIVB
.	O	O

In	O	O
the	O	O
industrial	O
fermentation	B-PHYS
production	O
process	B-PHEN
,	O	O
the	O	O
ΔwysR3	O
strain	B-LIVB
can	O	O
reduce	O
consumption	O
and	O	O
save	O	O
both	O	O
time	O
and	O	O
money	B-OBJC
.	O	O

Targeting	O
the	O	O
ecology	O
within	O	O
:	O	O
The	O	O
role	O
of	O	O
the	O	O
gut	O
-	O
brain	O
axis	O
and	O	O
human	B-LIVB
microbiota	B-LIVB
in	O	O
drug	B-DISO
addiction	I-DISO
Despite	O	O
major	O
advances	O
in	O	O
our	O	O
understanding	B-PHYS
of	O	O
the	O	O
brain	B-ANAT
using	O
traditional	O
neuroscience	O
,	O	O
reliable	O
and	O	O
efficacious	O
treatments	B-PROC
for	O	O
drug	B-DISO
addiction	I-DISO
have	O	O
remained	B-DISO
elusive	I-DISO
.	O	O

Hence	O	O
,	O	O
the	O	O
time	O
has	O	O
come	O	O
to	O	O
utilize	O
novel	O
approaches	O
,	O	O
particularly	O	O
those	O	O
drawing	O
upon	O	O
contemporary	O
advances	O
in	O	O
fields	O
outside	O	O
of	O	O
established	O
neuroscienc	O
e	O	O
and	O	O
psychiatry	O
.	O	O

Put	O	O
another	O	O
way	O	O
,	O	O
the	O	O
time	O
has	O	O
come	O	O
for	O	O
a	O	O
paradigm	B-PROC
shift	I-PROC
in	O	O
the	O	O
addiction	B-DISO
sciences	O
.	O	O

Apropos	O
,	O	O
a	O	O
revolution	O
in	O	O
the	O	O
area	O
of	O	O
human	B-LIVB
health	O
is	O	O
underway	O
,	O	O
which	O	O
is	O	O
occurring	O
at	O	O
the	O	O
nexus	O
between	O	O
enteric	O
microbiology	O
and	O	O
neuroscience	O
.	O	O

It	O	O
has	O	O
become	O	O
increasingly	O
clear	O
that	O	O
the	O	O
human	B-LIVB
microbiota	B-LIVB
(	O	O
the	O	O
vast	O	O
ecology	O
of	O	O
bacteria	B-LIVB
residing	O
within	O	O
the	O	O
human	B-LIVB
organism	B-LIVB
)	O	O
,	O	O
plays	O	O
an	O	O
important	O
role	O
in	O	O
health	O
and	O	O
disease	B-DISO
.	O	O

This	O	O
is	O	O
not	O	O
surprising	O	O
,	O	O
as	O	O
it	O	O
has	O	O
been	O	O
estimated	O
that	O	O
bacteria	B-LIVB
living	O
in	O	O
the	O	O
human	B-LIVB
body	I-LIVB
(	O	O
approximately	O
1	O	O
kg	O	O
of	O	O
mass	O
,	O	O
roughly	O	O
equivalent	O
to	O	O
that	O	O
of	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
)	O	O
outnumber	O	O
human	B-PHEN
cells	I-PHEN
10	O	O
to	O	O
1	O	O
.	O	O

While	O	O
advances	O	O
in	O	O
the	O	O
understanding	B-PHYS
of	O	O
the	O	O
role	O
of	O	O
microbiota	B-LIVB
in	O	O
other	O	O
areas	O
of	O	O
human	B-LIVB
health	O
have	O	O
yielded	O
intriguing	O
results	O
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O
,	O	O
Clostridium	B-DISO
difficile	I-DISO
,	O	O
irritable	B-DISO
bowel	I-DISO
syndrome	I-DISO
,	O	O
autism	B-DISO
,	O	O
etc	O	O
.	O	O
)	O	O
,	O	O
to	O	O
date	O
,	O	O
no	O	O
systematic	O
programs	O
of	O	O
research	B-PROC
have	O	O
examined	B-DISO
the	O	O
role	O
of	O	O
microbiota	B-LIVB
in	O	O
drug	B-DISO
addiction	I-DISO
.	O	O

The	O	O
current	O
hypothesis	O
,	O	O
therefore	O	O
,	O	O
is	O	O
that	O	O
gut	B-DISO
dysbiosis	I-DISO
plays	O	O
a	O	O
key	O	O
role	O
in	O	O
addictive	B-DISO
disorders	B-DISO
.	O	O

In	O	O
the	O	O
context	O
of	O	O
this	O	O
hypothesis	O
,	O	O
this	O	O
paper	O
provides	O
a	O	O
rationale	O
for	O	O
future	O
research	B-PROC
to	O	O
target	O
the	O	O
""""	O	O
gut	B-ANAT
-	O	O
brain	B-ANAT
axis	O
""""	O	O
in	O	O
addiction	B-DISO
.	O	O

A	O	O
brief	O	O
background	O
of	O	O
the	O	O
gut	B-ANAT
-	O	O
brain	B-ANAT
axis	O
is	O	O
provided	O
,	O	O
along	O	O
with	O	O
a	O	O
series	O
of	O	O
hypothesis	O
-	O
driven	O
ideas	O
outlining	O	O
potential	O
treatments	B-PROC
for	O	O
addiction	B-DISO
via	O	O
manipulations	B-DISO
of	O	O
the	O	O
""""	O	O
ecology	O
within	O	O
.	O	O
""""	O	O

Homogeneous	O
synthesis	O
of	O	O
Ag	B-OBJC
nanoparticles	I-OBJC
-doped	O	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
cellulose	I-CHEM
acetate	I-CHEM
for	O	O
versatile	O
applications	O
We	O	O
report	O
a	O	O
facile	O
and	O	O
efficient	O
approach	O
for	O	O
synthesis	O
of	O	O
well	O
-	O
dispersed	O
and	O	O
stable	O
silver	B-OBJC
nanoparticles	I-OBJC
(	O	O
Ag	B-OBJC
NPs	I-OBJC
)	O	O
using	O	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
cellulose	I-CHEM
acetate	I-CHEM
(	O	O
CA	B-CHEM
)	O	O
as	O	O
both	O	O
reductant	B-CHEM
and	O	O
stabilizer	B-OBJC
.	O	O

Partially	O
substituted	O	O
CA	B-CHEM
with	O	O
highly	O
active	O
hydroxyl	B-CHEM
groups	I-CHEM
and	O	O
excellent	O
water	O
-	O
solubility	O
is	O	O
able	B-DISO
to	O	O
reduce	B-PHEN
silver	B-CHEM
ions	I-CHEM
in	O	O
homogeneous	O
aqueous	O
medium	B-OBJC
effectively	O
.	O	O

The	O	O
synthesized	O
Ag	B-OBJC
NPs	I-OBJC
were	O	O
characterized	O
by	O	O
UV	B-PROC
-	I-PROC
vis	I-PROC
spectroscopy	I-PROC
,	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
diffraction	I-PROC
,	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
photoelectron	I-PROC
spectroscopy	I-PROC
,	O	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
and	O	O
energy	B-PROC
dispersive	I-PROC
X	I-PROC
-	I-PROC
ray	I-PROC
spectroscope	I-PROC
analysis	B-PROC
.	O	O

The	O	O
as	O	O
-	O	O
prepared	B-DISO
Ag	B-OBJC
NPs	I-OBJC
were	O	O
well	O
-	O
dispersed	O
,	O	O
showing	O	O
a	O	O
surface	B-PROC
plasmon	I-PROC
resonance	I-PROC
peak	O
at	O	O
426	O	O
nm	O
.	O	O

The	O	O
resulted	O	O
Ag	B-OBJC
NPs	I-OBJC
@	O	O
CA	B-CHEM
nanohybrids	B-OBJC
exhibit	O	O
high	O
catalytic	O
activity	O
for	O	O
the	O	O
reduction	B-PHEN
of	O	O
4	B-CHEM
-	I-CHEM
nitrophenol	I-CHEM
to	O	O
4	B-CHEM
-	I-CHEM
aminophenol	I-CHEM
in	O	O
the	O	O
presence	O	O
of	O	O
NaBH4	B-CHEM
.	O	O

Meanwhile	O	O
,	O	O
the	O	O
nanohybrids	B-OBJC
are	O	O
also	O	O
effective	O
in	O	O
inhibiting	O
the	O	O
growth	B-PHYS
of	O	O
bacterial	B-LIVB
.	O	O

This	O	O
environmentally	O
friendly	O
method	O
promotes	O
the	O	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O	O
prepare	O
a	O	O
variety	O
of	O	O
inorganic	B-OBJC
-	I-OBJC
organic	I-OBJC
materials	I-OBJC
for	O	O
catalysis	B-PHEN
,	O	O
antibacterial	B-CHEM
,	O	O
sensors	B-OBJC
and	O	O
other	O	O
applications	O
.	O	O

Acceleration	B-PHEN
of	O	O
Acid	B-PHEN
-	I-PHEN
Catalyzed	I-PHEN
Hydrolysis	B-PHEN
in	O	O
a	O	O
Biphasic	O
System	O
by	O	O
Sodium	B-CHEM
Tetracyanocyclopentadienides	I-CHEM
The	O	O
hydrolysis	B-PHEN
of	O	O
tert	B-CHEM
-	I-CHEM
butyldimethylsilyl	I-CHEM
L	I-CHEM
-	I-CHEM
menthyl	I-CHEM
ether	I-CHEM
(	O	O
3	O	O
)	O	O
in	O	O
a	O	O
CH2Cl2	B-CHEM
-1	O	O
M	O	O
HCl	B-CHEM
biphasic	O
solvent	B-CHEM
system	I-CHEM
was	O	O
accelerated	B-PHEN
by	O	O
the	O	O
addition	O	O
of	O	O
sodium	B-CHEM
tetracyanocyclopentadienides	I-CHEM
1	I-CHEM
.	O	O

Particularly	O	O
,	O	O
the	O	O
reaction	O
rate	O
was	O	O
enhanced	O
using	O	O
sodium	B-CHEM
salt	I-CHEM
1a	I-CHEM
-	I-CHEM
c	I-CHEM
with	O	O
a	O	O
lipophilic	B-OBJC
substituent	I-OBJC
on	O	O
the	O	O
cyclopentadienide	B-CHEM
ring	I-CHEM
.	O	O

From	O	O
the	O	O
results	O	O
obtained	O	O
by	O	O
a	O	O
triphasic	O
experiment	B-PROC
,	O	O
hydrolysis	B-PHEN
proceeds	O	O
via	O	O
the	O	O
formation	O
of	O	O
hydronium	B-CHEM
ion	I-CHEM
2	I-CHEM
in	O	O
the	O	O
aqueous	O
phase	O
by	O	O
ion	B-PHYS
exchange	I-PHYS
,	O	O
followed	O	O
by	O	O
the	O	O
transfer	O	O
of	O	O
2	O	O
to	O	O
the	O	O
CH2Cl2	B-CHEM
phase	I-CHEM
.	O	O

A	O	O
novel	O	O
,	O	O
lineage	O
-	O	O
primed	O
prestalk	B-ANAT
cell	I-ANAT
subtype	O
involved	O	O
in	O	O
the	O	O
morphogenesis	B-PHYS
of	O	O
D	O
.	O

discoideum	O
Dictyostelium	O
morphogenesis	B-PHYS
requires	O	O
the	O	O
tip	O
,	O	O
which	O	O
acts	O	O
as	O	O
an	O	O
organizer	B-DEVI
and	O	O
conducts	O	O
orchestrated	B-PHYS
cell	I-PHYS
movement	I-PHYS
and	O	O
cell	B-PHYS
differentiation	I-PHYS
.	O	O

At	O	O
the	O	O
slug	O
stage	O	O
the	O	O
tip	O
region	O
contains	O	O
prestalk	B-ANAT
A	I-ANAT
(	I-ANAT
pstA	I-ANAT
)	I-ANAT
cells	I-ANAT
,	O	O
which	O	O
are	O	O
usually	O	O
recognized	O	O
by	O	O
their	O	O
expression	B-PHYS
of	O	O
reporter	O
constructs	O
that	O	O
utilize	O	O
a	O	O
fragment	O
of	O
the	O	O
promoter	B-CHEM
of	O	O
the	O	O
ecmA	O
gene	O
.	O	O

Here	O	O
,	O	O
using	O	O
the	O	O
promoter	B-CHEM
region	I-CHEM
of	O	O
the	O	O
o	O
-	O
methyl	O
transferase	O
12	O
gene	O
(	O	O
omt12	O
)	O	O
to	O	O
drive	O	O
reporter	B-PHYS
expression	I-PHYS
,	I-PHYS
we	O	O
demonstrate	O	O
the	O	O
presence	O	O
,	O	O
also	O	O
within	O	O
the	O	O
pstA	O
region	O
,	O	O
of	O	O
a	O	O
novel	O	O
prestalk	B-ANAT
cell	I-ANAT
subtype	O
:	O	O
the	O	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
.	O	O

Surprisingly	O	O
,	O	O
a	O	O
sub	O	O
-	O	O
population	O	O
of	O	O
the	O	O
vegetative	B-PHYS
cells	I-PHYS
express	O	O
a	O	O
pstV	B-PHYS
(	I-PHYS
A	I-PHYS
)	I-PHYS
:	I-PHYS
GFP	I-PHYS
marker	I-PHYS
and	O	O
,	O	O
sort	O	O
out	O	O
to	O	O
the	O	O
tip	O
,	O	O
both	O	O
when	O	O
developing	O	O
alone	O	O
and	O	O
when	O	O
co	O	O
-	O	O
developed	O	O
with	O	O
an	O	O
excess	O	O
of	O	O
unmarked	B-ANAT
cells	I-ANAT
.	O	O

The	O	O
development	O
of	O	O
such	O	O
a	O	O
purified	O	O
GFP	B-ANAT
-	I-ANAT
marked	I-ANAT
population	I-ANAT
is	O	O
greatly	O	O
accelerated	O
:	O	O
by	O	O
precocious	O	O
cell	B-PHYS
aggregation	I-PHYS
and	O	O
tip	O
formation	O
with	O	O
accompanying	O	O
precocious	O
elevation	O
of	O	O
developmental	O
gene	B-PHYS
transcription	I-PHYS
.	O	O

We	O	O
therefore	O	O
suggest	O	O
that	O	O
the	O	O
tip	O
contains	O	O
at	O	O
least	O	O
two	O	O
prestalk	B-ANAT
cell	I-ANAT
subtypes	O
:	O	O
the	O	O
developmentally	O
-	O	O
specified	B-ANAT
pstA	I-ANAT
cells	I-ANAT
and	O	O
the	O	O
lineage	O
-	O	O
primed	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
.	O	O

It	O	O
is	O	O
presumably	O	O
the	O	O
pstV	B-ANAT
(	I-ANAT
A	I-ANAT
)	I-ANAT
cells	I-ANAT
that	O	O
play	O	O
the	O	O
dominant	O	O
role	O	O
in	O	O
morphogenesis	B-PHYS
during	O	O
the	O	O
earlier	O	O
stages	O
of	O	O
development	B-PHYS
.	O	O

The	O	O
basis	O	O
for	O	O
the	O	O
lineage	O
priming	O
is	O	O
,	O	O
however	O	O
,	O	O
unclear	O	O
because	O	O
we	O	O
can	O	O
find	O	O
no	O	O
correlation	O
between	O	O
pstV	B-PHYS
(	I-PHYS
A	I-PHYS
)	I-PHYS
differentiation	I-PHYS
and	O	O
nutrient	B-OBJC
status	O
during	O	O
growth	B-PHYS
or	O	O
cell	B-PHYS
cycle	I-PHYS
position	I-PHYS
at	O	O
the	O	O
time	O	O
of	O	O
starvation	B-DISO
,	O	O
the	O	O
two	O	O
known	O	O
determinants	O
of	O	O
probable	O	O
cell	B-PHYS
fate	I-PHYS
.	O	O

ISX	B-CHEM
-	I-CHEM
9	I-CHEM
can	O	O
potentiate	O	O
cell	B-PHYS
proliferation	I-PHYS
and	O	O
neuronal	B-ANAT
commitment	B-PHYS
in	O	O
the	O	O
rat	B-LIVB
dentate	B-ANAT
gyrus	I-ANAT
Adult	B-LIVB
hippocampal	B-ANAT
neurogenesis	B-PHYS
can	O	O
be	O	O
modulated	O
by	O	O
various	O	O
physiological	B-PHYS
and	O	O
pathological	B-DISO
conditions	I-DISO
,	O	O
including	O	O
stress	B-DISO
,	O	O
affective	B-DISO
disorders	I-DISO
,	O	O
and	O	O
several	O	O
neurological	O
conditions	O
.	O	O

Given	O	O
the	O	O
proposed	O	O
role	O	O
of	O	O
this	O	O
form	O	O
of	O	O
structural	B-PHYS
plasticity	I-PHYS
in	O	O
the	O	O
functioning	B-PHYS
of	O	O
the	O	O
hippocampus	B-ANAT
(	O	O
namely	O	O
learning	B-PHYS
and	O	O
memory	B-PHYS
and	O	O
affective	O
behaviors	O
)	O	O
,	O	O
it	O	O
is	O	O
believed	O	O
that	O	O
alterations	O
in	O	O
hippocampal	B-ANAT
neurogenesis	B-PHYS
might	O	O
underlie	O	O
some	O	O
of	O	O
the	O	O
behavioral	O
deficits	O
associated	O
with	O
these	O	O
psychiatric	O
and	O	O
neurological	O
conditions	O
.	O	O

Thus	O	O
,	O	O
the	O	O
search	O
for	O	O
compounds	B-CHEM
that	O	O
can	O	O
reverse	O
these	O	O
deficits	O
with	O	O
minimal	O
side	B-DISO
effects	I-DISO
has	O	O
become	O	O
a	O	O
recognized	O	O
priority	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
we	O	O
tested	O
the	O	O
pro	O
-	O
neurogenic	O
effects	O
of	O	O
isoxazole	B-CHEM
9	I-CHEM
(	O	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
)	O	O
,	O	O
a	O	O
small	O	O
synthetic	O
molecule	B-OBJC
that	O	O
has	O	O
been	O	O
recently	O	O
identified	O
through	O	O
the	O	O
screening	B-PROC
of	I-PROC
chemical	I-PROC
libraries	I-PROC
in	O	O
stem	B-PROC
cell	I-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
.	O	O

We	O	O
found	O	O
that	O	O
administration	B-PROC
of	O	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
for	O	O
14days	O	O
was	O	O
able	O	O
to	O	O
potentiate	O	O
cell	B-PHYS
proliferation	I-PHYS
and	O	O
increase	O
the	O	O
number	O
of	O	O
immature	O
neurons	B-ANAT
in	O	O
the	O	O
hippocampal	B-ANAT
DG	B-ANAT
of	O	O
adult	B-LIVB
rats	B-LIVB
.	O	O

In	O
addition	O
,	O	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
treatment	B-PROC
was	O	O
able	O	O
to	O	O
completely	O
reverse	O
the	O	O
marked	O
reduction	O
in	O	O
these	O	O
initial	O
stages	O
of	O	O
the	O	O
neurogenic	B-PHYS
process	I-PHYS
observed	O
in	O	O
vehicle	B-CHEM
-	O	O
treated	O
animals	B-LIVB
(	O	O
which	O	O
were	O	O
submitted	O	O
to	O	O
repeated	O
handling	B-PROC
and	O	O
exposure	O
to	O
daily	O
intraperitoneal	B-PROC
injections	I-PROC
)	O	O
.	O	O

Based	O	O
on	O	O
these	O	O
results	B-PHEN
,	O	O
we	O	O
recommend	O	O
that	O	O
future	O	O
neurogenesis	B-PHYS
studies	B-PROC
that	O	O
require	O	O
repeated	O
handling	B-PROC
and	O	O
manipulation	B-PROC
of	O	O
animals	B-LIVB
should	O	O
include	O	O
a	O	O
naïve	O	O
(	O	O
non	O	O
-	O	O
manipulated	O	O
)	O	O
control	O
to	O	O
determine	O	O
the	O	O
baseline	O
levels	O
of	O	O
hippocampal	B-ANAT
cell	B-PHYS
proliferation	I-PHYS
and	O	O
neuronal	B-ANAT
differentiation	B-PHYS
.	O	O

Overall	O	O
,	O	O
these	O	O
findings	B-DISO
demonstrate	O	O
that	O	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
is	O	O
a	O	O
promising	O	O
synthetic	O
compound	B-CHEM
for	O	O
the	O	O
mitigation	B-PHEN
of	O	O
stress	B-DISO
-	O	O
induced	O
deficits	O
in	O	O
adult	B-LIVB
hippocampal	B-ANAT
neurogenesis	B-PHYS
.	O	O

Future	O	O
studies	B-PROC
are	O	O
thus	O	O
warranted	O	O
to	O	O
evaluate	B-PROC
the	O	O
pro	O
-	O
neurogenic	O
properties	O
of	O	O
Isx	B-CHEM
-	I-CHEM
9	I-CHEM
in	O	O
animal	B-LIVB
models	I-LIVB
of	O	O
affective	B-DISO
and	O	O
neurological	B-DISO
disorders	I-DISO
associated	O
with	O
impaired	O
hippocampal	B-ANAT
structural	B-PHYS
plasticity	I-PHYS
.	O	O

NBLAST	O
:	O	O
Rapid	O
,	O	O
Sensitive	O
Comparison	O
of	O	O
Neuronal	B-ANAT
Structure	O
and	O	O
Construction	O
of	O	O
Neuron	B-ANAT
Family	O
Databases	O
Neural	O
circuit	O
mapping	O
is	O	O
generating	O	O
datasets	O
of	O	O
tens	O	O
of	O	O
thousands	O	O
of	O	O
labeled	O
neurons	B-ANAT
.	O	O

New	O	O
computational	O
tools	O
are	O	O
needed	O	O
to	O	O
search	O
and	O	O
organize	O
these	O	O
data	O
.	O	O

We	O	O
present	O	O
NBLAST	O
,	O	O
a	O	O
sensitive	O
and	O	O
rapid	O
algorithm	O
,	O	O
for	O	O
measuring	O
pairwise	O
neuronal	O
similarity	O
.	O	O

NBLAST	O
considers	O	O
both	O	O
position	O
and	O	O
local	O
geometry	O
,	O	O
decomposing	O
neurons	B-ANAT
into	O	O
short	O
segments	O
;	O	O
matched	O
segments	O
are	O	O
scored	O
using	O	O
a	O	O
probabilistic	O
scoring	O
matrix	O
defined	O	O
by	O	O
statistics	O
of	O	O
matches	O
and	O	O
non	O
-	O
matches	O
.	O	O

We	O	O
validated	O	O
NBLAST	O
on	O	O
a	O	O
published	O
dataset	O
of	O	O
16	O	O
,	O	O
129	O	O
single	O
Drosophila	O
neurons	B-ANAT
.	O	O

NBLAST	O
can	O	O
distinguish	O	O
neuronal	B-ANAT
types	O
down	O
to	O	O
the	O	O
finest	O
level	O
(	O	O
single	O
identified	O
neurons	B-ANAT
)	O	O
without	O	O
a	O	O
priori	O
information	O
.	O	O

Cluster	B-PROC
analysis	I-PROC
of	O	O
extensively	O	O
studied	O	O
neuronal	B-ANAT
classes	O
identified	O
new	O	O
types	O
and	O	O
unreported	B-DISO
topographical	O
features	O
.	O	O

Fully	B-PROC
automated	I-PROC
clustering	I-PROC
organized	O
the	O	O
validation	B-PROC
dataset	O
into	O	O
1	O	O
,	O	O
052	O	O
clusters	O
,	O	O
many	O	O
of	O	O
which	O	O
map	O
onto	O	O
previously	O	O
described	O	O
neuronal	B-ANAT
types	O
.	O	O

NBLAST	O
supports	O	O
additional	O	O
query	O
types	O
,	O	O
including	O	O
searching	O
neurons	B-ANAT
against	O	O
transgene	O
expression	O
patterns	O
.	O	O

Finally	O	O
,	O	O
we	O	O
show	O	O
that	O	O
NBLAST	O
is	O	O
effective	O	O
with	O	O
data	O
from	O	O
other	O	O
invertebrates	O
and	O	O
zebrafish	B-LIVB
.	O	O

Components	O	O
of	O	O
treatment	B-PROC
delay	O
in	O	O
rheumatoid	B-DISO
arthritis	I-DISO
differ	O
according	O	O
to	O	O
autoantibody	B-CHEM
status	O
:	O	O
validation	B-PROC
of	O	O
a	O	O
single	O	O
-	O	O
centre	O	O
observation	O
using	O
national	O
audit	O
data	O
To	O	O
determine	O	O
whether	O	O
time	O
to	O
treatment	O
following	O
symptom	O
onset	O
differs	O
between	O	O
RA	B-DISO
patients	B-LIVB
according	O	O
to	O	O
autoantibody	B-CHEM
status	O
.	O	O

A	O	O
single	O	O
-	O	O
centre	O	O
retrospective	O
analysis	B-PROC
of	O	O
a	O	O
UK	B-GEOG
early	O	O
RA	B-DISO
inception	O
cohort	O
was	O	O
first	O	O
undertaken	O	O
to	O	O
identify	O
those	O	O
components	O	O
of	O	O
the	O	O
patient	B-LIVB
journey	O
that	O	O
differed	O
by	O	O
serological	O
subtype	O
.	O	O

Data	O
from	O	O
a	O	O
UK	B-GEOG
national	O
audit	O
of	O	O
early	O	O
inflammatory	B-DISO
arthritis	I-DISO
patients	B-LIVB
was	O	O
accessed	O
to	O	O
replicate	O
the	O	O
key	O	O
finding	B-DISO
.	O	O

A	O	O
total	O	O
of	O	O
173	O	O
RA	B-DISO
patients	B-LIVB
were	O	O
diagnosed	B-PROC
over	O
a	O	O
31	O	O
-	O	O
month	O
period	O
,	O	O
of	O	O
whom	O	O
80	O	O
(	O	O
46	O	O
%	O	O
)	O	O
were	O	O
ACPA	B-PHEN
/	I-PHEN
RF	I-PHEN
double	I-PHEN
-	I-PHEN
seropositive	I-PHEN
(	O	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
)	O	O
,	O	O
53	O	O
(	O	O
31	O	O
%	O	O
)	O	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
,	O	O
17	O	O
(	O	O
10	O	O
%	O	O
)	O	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
and	O	O
23	O	O
(	O	O
13	O	O
%	O	O
)	O	O
RF	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
ACPA	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
Overall	O	O
,	O	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	B-LIVB
experienced	O	O
significantly	O	O
longer	O
symptom	O
duration	O
before	O	O
DMARD	B-CHEM
initiation	O
.	O	O

This	O	O
was	O	O
accounted	O	O
for	O	O
by	O	O
delays	O
in	O	O
their	O	O
presentation	O	O
to	O	O
primary	B-PROC
care	I-PROC
following	O
symptom	O
onset	O
-a	O	O
finding	B-DISO
that	O	O
was	O	O
robustly	O	O
confirmed	O
in	O	O
an	O	O
independent	O
dataset	O
of	O	O
2192	O	O
UK	B-GEOG
early	O	O
RA	B-DISO
patients	B-LIVB
.	O	O

In	O	O
contrast	O	O
,	O	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
patients	I-PHEN
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
delays	O
in	O	O
DMARD	B-CHEM
initiation	O
after	O	O
presenting	O	O
to	O	O
secondary	B-PROC
care	I-PROC
.	O	O

Causes	O
of	O	O
treatment	B-PROC
delays	O
in	O	O
early	O	O
RA	B-DISO
differ	O
according	O	O
to	O	O
patients	B-LIVB
'	O	O
autoantibody	B-CHEM
status	O
.	O	O

More	O	O
insidious	O
symptom	O
onset	O
and	O	O
/	O	O
or	O	O
distinct	O	O
health	O
-	O
seeking	O
behaviours	O
among	O	O
ACPA	B-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
+	I-PHEN
)	I-PHEN
patients	I-PHEN
may	O	O
contribute	O
to	O	O
late	O	O
presentations	O	O
in	O	O
primary	B-PROC
care	I-PROC
,	O	O
whereas	O	O
ACPA	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
/	I-PHEN
RF	I-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
patients	I-PHEN
experience	O	O
delayed	O
diagnosis	O
and	O	O
treatment	B-PROC
in	O	O
secondary	B-PROC
care	I-PROC
.	O	O

These	O	O
observations	O
inform	B-PROC
the	O	O
research	B-PROC
agenda	I-PROC
,	O	O
potentially	O	O
influencing	O
the	O	O
design	O
of	O	O
service	B-PROC
delivery	I-PROC
for	O	O
early	B-DISO
arthritis	I-DISO
patients	B-LIVB
.	O	O

Indications	O
for	O	O
embolization	B-PROC
in	O	O
a	O	O
French	B-OBJC
level	I-OBJC
1	I-OBJC
trauma	I-OBJC
center	I-OBJC
Abdominal	B-DISO
trauma	I-DISO
accounts	O	O
for	O	O
nearly	O	O
20	O	O
%	O	O
of	O	O
all	O	O
traumatic	B-DISO
injuries	I-DISO
.	O	O

It	O	O
often	O	O
involves	O	O
young	O
patients	B-LIVB
sustaining	O
multiple	B-DISO
injuries	I-DISO
,	O	O
with	O	O
a	O	O
high	O	O
associated	O	O
mortality	O
rate	O
.	O	O

Management	O
should	O	O
begin	O	O
at	O	O
the	O	O
scene	O
of	O	O
injury	B-DISO
and	O	O
relies	O	O
on	O	O
a	O	O
structured	O	O
chain	O
of	O
care	O
in	O	O
order	O	O
to	O	O
transport	O	O
the	O	O
trauma	B-DISO
patient	B-LIVB
to	O	O
the	O	O
appropriate	O	O
hospital	B-OBJC
center	I-OBJC
.	O	O

Management	O
is	O	O
multi	B-PROC
-	I-PROC
disciplinary	I-PROC
,	O	O
involving	O	O
intensive	B-LIVB
care	I-LIVB
specialists	I-LIVB
,	O	O
surgeons	B-LIVB
and	O	O
radiologists	B-LIVB
.	O	O

Imaging	O	O
to	O	O
precisely	O	O
define	O	O
injury	B-DISO
is	O	O
best	O	O
performed	O	O
with	O	O
whole	B-PROC
body	I-PROC
dual	I-PROC
phase	I-PROC
computed	I-PROC
tomography	I-PROC
,	O	O
which	O	O
can	O	O
also	O	O
identify	O	O
the	O	O
source	O	O
of	O	O
bleeding	B-DISO
.	O	O

Non	O
-	O
operative	O
management	O
has	O	O
developed	O	O
considerably	O	O
over	O	O
the	O	O
years	O
:	O	O
this	O	O
includes	O	O
selective	B-PROC
embolization	I-PROC
in	O	O
case	O	O
of	O	O
active	B-DISO
bleeding	I-DISO
or	O	O
vascular	B-DISO
anomalies	I-DISO
in	O	O
stable	O	O
or	O	O
stabilized	O	O
patients	B-LIVB
after	O	O
resuscitation	B-PROC
.	O	O

Embolization	B-PROC
has	O	O
become	O	O
one	O	O
of	O	O
the	O	O
corner	O	O
stones	O	O
of	O	O
abdominal	B-DISO
trauma	I-DISO
management	O
and	O	O
interventional	B-LIVB
radiologists	I-LIVB
must	O	O
play	O	O
an	O	O
active	O	O
role	O	O
on	O	O
the	O	O
trauma	B-LIVB
team	I-LIVB
.	O	O

This	O	O
overview	O	O
details	O	O
the	O	O
different	O	O
embolization	B-PROC
procedures	I-PROC
according	O	O
to	O	O
the	O	O
involved	O	O
organ	B-ANAT
and	O	O
embolic	B-CHEM
agent	I-CHEM
used	O	O
.	O	O

Early	O	O
hippocampal	B-ANAT
volume	B-DISO
loss	I-DISO
as	O	O
a	O	O
marker	B-PHYS
of	O	O
eventual	O	O
memory	B-DISO
deficits	I-DISO
caused	O	O
by	O	O
repeated	B-DISO
stress	I-DISO
Exposure	O
to	O
severe	O
and	O	O
prolonged	O
stress	B-DISO
has	O	O
detrimental	B-DISO
effects	I-DISO
on	O	O
the	O	O
hippocampus	B-ANAT
.	O	O

However	O	O
,	O	O
relatively	O
little	O
is	O	O
known	O
about	O	O
the	O	O
gradual	O
changes	O
in	O	O
hippocampal	B-ANAT
structure	I-ANAT
,	O	O
and	O	O
its	O	O
behavioral	O
consequences	O
,	O	O
over	O	O
the	O	O
course	O	O
of	O	O
repeated	B-DISO
stress	I-DISO
.	O	O

Behavioral	B-PROC
analyses	I-PROC
during	O	O
10	O	O
days	O	O
of	O	O
chronic	O
stress	O
pointed	O	O
to	O	O
a	O	O
delayed	O	O
decline	O
in	O	O
spatial	B-PHYS
memory	I-PHYS
,	O	O
the	O	O
full	O	O
impact	O
of	O	O
which	O	O
is	O	O
evident	O	O
only	O	O
after	O	O
the	O	O
end	O	O
of	O	O
stress	B-DISO
.	O	O

In	O	O
contrast	O	O
,	O	O
concurrent	O
volumetric	O
measurements	O
in	O	O
the	O	O
same	O	O
animals	B-LIVB
revealed	O	O
significant	O	O
reduction	O
in	O	O
hippocampal	B-ANAT
volumes	O
in	O	O
stressed	B-DISO
animals	B-LIVB
relative	O	O
to	O	O
their	O	O
unstressed	B-DISO
counterparts	I-DISO
,	O	O
as	O	O
early	O	O
as	O	O
the	O	O
third	O	O
day	O	O
of	O	O
stress	B-DISO
.	O	O

Notably	O	O
,	O	O
animals	B-LIVB
that	O	O
were	O	O
behaviorally	O
the	O	O
worst	O
affected	O
at	O	O
the	O	O
end	O	O
of	O	O
chronic	O
stress	O
suffered	B-DISO
the	O	O
most	O	O
pronounced	O	O
early	B-DISO
loss	I-DISO
in	I-DISO
hippocampal	I-DISO
volume	I-DISO
.	O	O

Together	O	O
,	O	O
these	O	O
findings	O	O
support	O	O
the	O	O
view	O	O
that	O	O
not	O	O
only	O	O
is	O	O
smaller	O	O
hippocampal	B-ANAT
volume	O
linked	O	O
to	O	O
stress	B-DISO
-	O	O
induced	O
memory	B-DISO
deficits	I-DISO
,	O	O
but	O	O
it	O	O
may	O	O
also	O	O
act	O	O
as	O	O
an	O	O
early	O	O
risk	B-DISO
factor	I-DISO
for	O	O
the	O	O
eventual	O	O
development	O	O
of	O	O
cognitive	B-DISO
impairments	I-DISO
seen	O	O
in	O	O
stress	B-DISO
-	I-DISO
related	I-DISO
psychiatric	I-DISO
disorders	I-DISO
.	O	O

A	O	O
novel	O	O
functional	O	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
hard	I-OBJC
cheese	I-OBJC
containing	O	O
liposomal	B-CHEM
nanoencapsulated	O
green	B-CHEM
tea	I-CHEM
catechins	I-CHEM
:	O	O
manufacture	O
and	O	O
recovery	O
following	O	O
simulated	B-PROC
digestion	O
(	B-CHEM
+	I-CHEM
)	I-CHEM
-Catechin	I-CHEM
or	O	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
were	O	O
encapsulated	O
in	O	O
soy	B-CHEM
lecithin	I-CHEM
nanoliposomes	B-CHEM
and	O	O
incorporated	O	O
into	O	O
a	O	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
cheese	I-OBJC
,	O	O
then	O	O
ripened	B-PHEN
at	O	O
8	O	O
°	O	O
C	O	O
for	O	O
90	O	O
days	O	O
.	O	O

Cheese	B-OBJC
samples	I-OBJC
were	O	O
subjected	O	O
to	O	O
simulated	B-PROC
gastrointestinal	O
digestion	O
to	O	O
measure	O	O
total	B-PHEN
phenolic	I-PHEN
conten	I-PHEN
t	O	O
(	O	O
TPC	B-PHEN
)	O	O
and	O	O
antioxidant	B-PHYS
activity	I-PHYS
of	O	O
the	O	O
cheese	B-OBJC
digesta	B-OBJC
,	O	O
and	O	O
to	O	O
determine	O	O
the	O	O
catechin	B-CHEM
recovery	O
after	O	O
digestion	O
by	O	O
high	B-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
(	O	O
HPLC	B-PROC
)	O	O
.	O	O

Addition	B-PHEN
of	O	O
catechin	B-CHEM
or	O	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
significantly	O	O
(	O	O
P	O	O
≤	O	O
0	O	O
.	O	O
05	O	O
)	O	O
increased	O	O
TPC	B-PHEN
and	O	O
antioxidant	B-PHYS
activity	I-PHYS
(	O	O
measured	O	O
by	O	O
ferric	B-PROC
reducing	I-PROC
antioxidant	I-PROC
power	I-PROC
and	O	O
oxygen	B-PROC
radical	I-PROC
absorbance	I-PROC
capacity	I-PROC
)	O	O
of	O	O
the	O	O
full	B-OBJC
-	I-OBJC
fat	I-OBJC
cheese	I-OBJC
without	O	O
affecting	O
pH	O
or	O	O
proximate	B-PHEN
composition	I-PHEN
.	O	O

HPLC	B-PROC
analysis	I-PROC
confirmed	O	O
retention	O
of	O	O
encapsulated	O
catechins	B-CHEM
in	O	O
the	O	O
cheese	B-OBJC
curd	I-OBJC
;	O	O
however	O	O
,	O	O
individual	O	O
catechins	B-CHEM
were	O	O
recovered	O	O
in	O	O
differing	O	O
amounts	O	O
(	O	O
15	O	O
-	O	O
52	O	O
%	O	O
)	O	O
from	O	O
cheese	B-OBJC
digesta	B-OBJC
after	O	O
6	O	O
h	O	O
of	O	O
digestion	O
.	O	O

Transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
and	O	O
Fourier	B-PROC
transform	I-PROC
infrared	I-PROC
spectroscopy	I-PROC
provided	O	O
evidence	O
for	O	O
association	B-PHEN
of	O	O
nanoliposomes	B-CHEM
with	O	O
the	O	O
surface	O
of	O	O
milk	B-CHEM
fat	I-CHEM
globules	I-CHEM
inside	O	O
the	O	O
cheese	B-OBJC
matrix	O
.	O	O

The	O	O
study	O	O
shows	O	O
the	O	O
potential	O	O
for	O	O
using	O	O
cheese	B-OBJC
as	O	O
a	O	O
delivery	B-CHEM
vehicle	I-CHEM
for	O	O
green	B-CHEM
tea	I-CHEM
antioxidants	I-CHEM
.	O	O

Plasmablastic	B-PHYS
transformation	I-PHYS
of	O	O
plasma	B-DISO
cell	I-DISO
myeloma	I-DISO
with	O	O
heterotropic	B-PHYS
expression	I-PHYS
of	O	O
CD3	B-CHEM
and	O	O
CD4	B-CHEM
:	O	O
a	O	O
case	O
report	O
Plasmablastic	B-DISO
lymphoma	I-DISO
(	O	O
PBL	B-DISO
)	O	O
can	O	O
rarely	O	O
be	O	O
seen	O	O
as	O	O
a	O	O
transformation	B-PHYS
from	O	O
plasma	B-DISO
cell	I-DISO
myeloma	I-DISO
(	O	O
PCM	B-DISO
)	O	O
,	O	O
especially	O	O
in	O	O
late	O
stages	O
of	O	O
the	O	O
disease	B-DISO
where	O	O
it	O	O
portends	O	O
a	O	O
poorer	B-DISO
prognosis	I-DISO
and	O	O
a	O	O
different	O	O
line	O	O
of	O	O
management	B-PROC
for	O	O
the	O	O
patient	B-LIVB
.	O	O

When	O	O
unrelated	O	O
to	O	O
PCM	B-DISO
,	O	O
PBL	B-DISO
is	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
separate	O	O
aggressive	O
variant	O
of	O	O
B	B-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
typically	O	O
seen	O	O
in	O	O
the	O	O
oral	B-ANAT
cavity	I-ANAT
of	O	O
immunocompromised	B-DISO
adults	B-LIVB
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
plasmablastic	B-PHYS
transformation	I-PHYS
having	O	O
a	O	O
pan	B-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
phenotype	I-CHEM
with	O	O
CD3	B-CHEM
and	O	O
CD4	B-CHEM
positivity	O	O
,	O	O
in	O	O
an	O	O
immunocompetent	B-PHYS
elderly	B-LIVB
lady	I-LIVB
diagnosed	B-DISO
with	O	O
PCM	B-DISO
.	O	O

This	O	O
60	O	O
-	O	O
year	O
-	O	O
old	B-LIVB
lady	I-LIVB
presented	O	O
with	O	O
worsening	B-DISO
backache	B-DISO
and	O	O
a	O	O
2	O	O
-	O	O
cm	O	O
skin	B-DISO
nodule	I-DISO
in	O	O
the	O	O
left	B-ANAT
cervical	I-ANAT
region	I-ANAT
,	O	O
while	O	O
she	O	O
was	O	O
on	O	O
treatment	B-PROC
with	O	O
vincristine	B-CHEM
,	O	O
cyclophosphamide	B-CHEM
,	O	O
dexamethasone	B-CHEM
(	O	O
VCD	B-CHEM
)	O	O
,	O	O
and	O	O
bortezomib	B-CHEM
.	O	O

On	O	O
biopsy	B-PROC
,	O	O
the	O	O
skin	B-DISO
nodule	I-DISO
showed	O	O
an	O	O
infiltrating	B-DISO
lymphoid	B-DISO
tumor	I-DISO
composed	O	O
of	O	O
immunoblastic	B-ANAT
cells	I-ANAT
with	O	O
brisk	O	O
mitosis	B-PHYS
and	O	O
apoptosis	B-PHYS
.	O	O

On	O	O
Immunohistochemistry	B-PROC
(	O	O
IHC	B-PROC
)	O	O
,	O	O
lymphoid	B-ANAT
cells	I-ANAT
revealed	O	O
plasma	B-ANAT
cell	I-ANAT
markers	B-PHYS
CD38	B-CHEM
,	O	O
CD138	B-CHEM
,	O	O
CD56	B-CHEM
,	O	O
and	O	O
MUM1	B-CHEM
.	O	O

Pan	B-CHEM
-	I-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
markers	I-CHEM
CD3	B-CHEM
and	O	O
CD4	B-CHEM
were	O	O
also	O	O
diffusely	B-PHYS
expressed	I-PHYS
in	O	O
tumor	B-ANAT
cells	I-ANAT
.	O	O

B	B-CHEM
-	I-CHEM
cell	I-CHEM
markers	I-CHEM
CD20	B-CHEM
and	O	O
PAX5	B-CHEM
were	O	O
not	O	O
expressed	O	O
;	O	O
c	O
-	O
Myc	O
IHC	B-PROC
and	O	O
EBER	B-CHEM
by	O	O
in	B-PROC
situ	I-PROC
hybridization	I-PROC
(	O	O
ISH	B-PROC
)	O	O
were	O	O
negative	B-DISO
in	O	O
the	O	O
tumor	B-DISO
.	O	O

Mitotic	B-PHEN
index	I-PHEN
by	O	O
Ki67	B-PROC
was	O	O
>	O	O
95	O	O
%	O	O
.	O	O

Thus	O	O
,	O	O
a	O	O
diagnosis	B-DISO
of	O	O
plasmablastic	B-PHYS
transformation	I-PHYS
in	O	O
a	O	O
known	O	O
PCM	B-DISO
case	O	O
was	O	O
made	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
case	O	O
,	O	O
to	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
with	O	O
a	O	O
heterotropic	B-CHEM
T	I-CHEM
-	I-CHEM
cell	I-CHEM
phenotype	I-CHEM
in	O	O
a	O	O
plasmablastic	B-PHYS
transformation	I-PHYS
from	O	O
PCM	B-DISO
.	O	O

It	O	O
is	O	O
critical	O	O
to	O	O
correctly	O	O
diagnose	B-DISO
such	O	O
cases	O	O
as	O	O
they	O	O
may	O	O
occasionally	O	O
be	O	O
misinterpreted	O	O
as	O	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
neoplasms	B-DISO
.	O	O

Clinically	O
,	O	O
a	O	O
more	O	O
aggressive	B-PROC
treatment	I-PROC
is	O	O
indicated	O	O
for	O	O
such	O	O
patients	B-LIVB
.	O	O

Further	O	O
studies	B-PROC
in	O	O
these	O	O
cases	O
may	O	O
enhance	O
our	O	O
understanding	O	O
of	O	O
complex	O
underpinnings	O
of	O	O
lymphoma	B-DISO
biology	O
.	O	O

pH	O
affects	O	O
bacterial	B-LIVB
community	B-LIVB
composition	B-PHYS
in	O	O
soils	B-OBJC
across	O	O
the	O	O
Huashan	B-GEOG
Watershed	I-GEOG
,	O	O
China	B-GEOG
To	O	O
investigate	O	O
soil	B-OBJC
bacterial	B-LIVB
richness	O
and	O	O
diversity	O
and	O	O
to	O	O
determine	O	O
the	O	O
correlations	O
between	O	O
bacterial	B-LIVB
communities	B-LIVB
and	O	O
soil	B-OBJC
properties	O
,	O	O
8	O	O
soil	B-OBJC
samples	I-OBJC
were	O	O
collected	O	O
from	O	O
the	O	O
Huashan	B-GEOG
watershed	I-GEOG
in	O	O
Anhui	B-GEOG
,	O	O
China	B-GEOG
.	O	O

Subsequently	O	O
,	O	O
454	O	O
high	B-PROC
-	I-PROC
throughput	I-PROC
pyrosequencing	I-PROC
and	O	O
bioinformatics	B-PROC
analyses	I-PROC
were	O	O
performed	O	O
to	O	O
examine	O	O
the	O	O
soil	B-OBJC
bacterial	B-LIVB
community	B-LIVB
compositions	B-PHYS
.	O	O

The	O	O
operational	B-PROC
taxonomic	I-PROC
unit	I-PROC
richness	O
of	O	O
the	O	O
bacterial	B-LIVB
community	B-LIVB
ranged	O	O
from	O	O
3664	O	O
to	O	O
5899	O	O
,	O	O
and	O	O
the	O	O
diversity	O
indices	O
,	O	O
including	O	O
Chao1	O
,	O	O
Shannon	O	O
-	O	O
Wiener	O	O
,	O	O
and	O	O
Faith	O	O
's	O	O
phylogenetic	O
diversity	O
ranged	O	O
from	O	O
7751	O	O
to	O	O
15	O	O
204	O	O
,	O	O
7	O	O
.	O	O

386	O	O
to	O	O
8	O	O
.	O	O
327	O	O
,	O	O
and	O	O
415	O	O
.	O	O
77	O	O
to	O	O
679	O	O
.	O	O
11	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
2	O	O
most	O	O
dominant	O	O
phyla	O
in	O	O
the	O	O
soil	B-OBJC
samples	I-OBJC
were	O	O
Actinobacteria	B-LIVB
and	O	O
Proteobacteria	B-LIVB
.	O	O

The	O	O
richness	O
and	O	O
diversity	O
of	O	O
the	O	O
bacterial	B-LIVB
community	B-LIVB
were	O	O
positively	O	O
correlated	O	O
with	O	O
soil	B-OBJC
pH	O
.	O	O

The	O	O
Mantel	O
test	O
revealed	O	O
that	O	O
the	O	O
soil	B-OBJC
pH	O
was	O	O
the	O	O
dominant	O	O
factor	O	O
influencing	O	O
the	O	O
bacterial	B-LIVB
community	B-LIVB
.	O	O

The	O	O
positive	O	O
modular	O
structure	O
of	O	O
co	O
-	O
occurrence	O
patterns	O
at	O	O
the	O	O
genus	O
level	O
was	O	O
discovered	O	O
by	O	O
network	O
analysis	O
.	O	O

The	O	O
results	O	O
obtained	O	O
in	O	O
this	O	O
study	B-PROC
provide	O	O
useful	O	O
information	O	O
that	O	O
enhances	O	O
our	O	O
understanding	O	O
of	O	O
the	O	O
effects	O
of	O	O
soil	B-OBJC
properties	O
on	O	O
the	O	O
bacterial	B-LIVB
communities	B-LIVB
.	O	O

Long	B-PROC
-	I-PROC
term	I-PROC
lamivudine	I-PROC
therapy	I-PROC
in	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
One	O	O
to	O	O
5	O	O
years	O	O
of	O	O
therapy	B-PROC
of	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
with	O	O
oral	O
nucleoside	B-CHEM
analogues	I-CHEM
result	O	O
in	O	O
significant	O	O
clinical	O
improvements	O
,	O	O
but	O	O
effects	O
of	O
more	O	O
prolonged	B-PROC
therapy	I-PROC
are	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

To	O	O
describe	O	O
outcomes	B-PROC
of	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
with	O	O
long	B-PROC
-	I-PROC
term	I-PROC
lamivudine	I-PROC
therapy	I-PROC
.	O	O

Forty	O	O
-	O	O
two	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
treated	B-PROC
with	I-PROC
lamivudine	B-CHEM
were	O	O
followed	O	O
for	O	O
3	O	O
.	O	O
2	O	O
-	O	O
19	O	O
.	O	O

5	O	O
(	O	O
median	O	O
=	O	O
16	O	O
.	O	O
1	O	O
)	O	O
years	O	O
.	O	O

Therapy	B-PROC
was	O	O
switched	O	O
to	O	O
other	O	O
agents	B-CHEM
(	O	O
n	O	O
=	O	O
16	O	O
)	O	O
if	O	O
patients	B-LIVB
developed	O	O
lamivudine	B-CHEM
resistance	B-PHEN
and	O	O
relapse	B-DISO
of	I-DISO
disease	I-DISO
.	O	O

Among	O	O
22	O	O
HBeAg	B-PHEN
-	I-PHEN
positive	I-PHEN
patients	B-LIVB
,	O	O
17	O	O
(	O	O
77	O	O
%	O	O
)	O	O
became	O	O
HBeAg	B-PHEN
negative	I-PHEN
,	O	O
of	O	O
whom	O	O
5	O	O
(	O	O
23	O	O
%	O	O
)	O	O
subsequently	O	O
cleared	B-PHYS
HBsAg	B-CHEM
.	O	O

Among	O	O
20	O	O
HBeAg	B-PHEN
-	I-PHEN
negative	I-PHEN
patients	B-LIVB
,	O	O
10	O	O
(	O	O
50	O	O
%	O	O
)	O	O
cleared	B-PHYS
HBsAg	B-CHEM
.	O	O

The	O	O
time	O	O
to	O	O
HBsAg	B-CHEM
clearance	B-PHYS
ranged	O	O
from	O	O
0	O	O
.	O	O

9	O	O
to	O	O
16	O	O
.	O	O

8	O	O
(	O	O
median	O	O
=	O	O
9	O	O
.	O	O

3	O	O
)	O	O
years	O	O
.	O	O

Lamivudine	B-CHEM
resistance	B-PHEN
arose	O	O
in	O	O
24	O	O
patients	B-LIVB
(	O	O
57	O	O
%	O	O
)	O	O
of	O	O
whom	O	O
6	O	O
(	O	O
25	O	O
%	O	O
)	O	O
lost	O	O
HBsAg	B-CHEM
.	O	O

HBsAg	B-CHEM
clearance	B-PHYS
was	O	O
not	O	O
always	O	O
accompanied	O	O
by	O	O
seroconversion	B-PHEN
;	O	O
anti	B-PROC
-	I-PROC
HBs	I-PROC
appearing	O	O
concurrently	O	O
in	O	O
only	O	O
five	O	O
patients	B-LIVB
(	O	O
33	O	O
%	O	O
)	O	O
.	O	O

Nevertheless	O	O
,	O	O
HBsAg	B-CHEM
loss	O	O
allowed	O	O
for	O	O
stopping	O	O
therapy	B-PROC
in	O	O
all	O	O
patients	B-LIVB
,	O	O
none	O	O
re	O	O
-	O	O
developing	O	O
HBsAg	B-CHEM
or	O	O
suffering	O	O
relapse	B-DISO
;	O	O
all	O	O
having	O	O
normal	O	O
alanine	B-PROC
aminotransferase	I-PROC
levels	I-PROC
and	O	O
no	O	O
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
or	O	O
unquantifiable	O	O
HBV	B-PROC
DNA	I-PROC
levels	I-PROC
(	O	O
n	O	O
=	O	O
2	O	O
)	O	O
when	O	O
last	O	O
seen	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
seven	O	O
of	O	O
27	O	O
patients	B-LIVB
(	O	O
26	O	O
%	O	O
)	O	O
who	O	O
remained	O	O
HBsAg	B-PHEN
-	I-PHEN
positive	I-PHEN
died	B-DISO
of	O	O
liver	B-DISO
disease	I-DISO
or	O	O
liver	B-DISO
cancer	I-DISO
or	O	O
underwent	O	O
liver	B-PROC
transplantation	I-PROC
,	O	O
all	O	O
of	O	O
whom	O	O
had	O	O
cirrhosis	B-DISO
.	O	O

Long	O
-	O
term	O
viral	B-LIVB
suppression	B-PROC
with	O	O
nucleoside	B-CHEM
analogues	I-CHEM
leads	O	O
to	O	O
HBsAg	B-CHEM
loss	O	O
in	O	O
a	O	O
substantial	O	O
proportion	O
of	O	O
patients	B-LIVB
,	O	O
particularly	O	O
if	O	O
HBeAg	B-PHEN
-	I-PHEN
negative	I-PHEN
.	O	O

Serious	O	O
outcomes	B-PROC
during	O	O
the	O	O
first	O	O
10	O	O
-	O	O
20	O	O
years	O	O
of	O	O
treatment	B-PROC
occur	O	O
largely	O	O
among	O	O
patients	B-LIVB
with	O	O
pre	O
-	O
existing	O
cirrhosis	B-DISO
who	O	O
do	O	O
not	O	O
clear	B-PHYS
HBsAg	B-CHEM
with	O	O
therapy	B-PROC
.	O	O

The	O	O
Enigma	O	O
of	O	O
the	O	O
Dichotomic	B-PHEN
Pressure	I-PHEN
Response	B-PHYS
of	O	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	O	O
b	B-CHEM
Splice	B-CHEM
Variants	I-CHEM
of	O	O
NMDA	B-CHEM
Receptor	I-CHEM
:	O	O
Experimental	B-PROC
and	O	O
Statistical	B-PROC
Analyses	I-PROC
Professional	B-LIVB
deep	I-LIVB
-	I-LIVB
water	I-LIVB
divers	I-LIVB
,	O	O
exposed	O	O
to	O	O
hyperbaric	B-PHEN
pressure	I-PHEN
(	O	O
HP	B-PHEN
)	O	O
above	O	O
1	O	O
.	O	O
1	O	O
MPa	O	O
,	O	O
develop	O	O
High	B-DISO
Pressure	I-DISO
Neurological	I-DISO
Syndrome	I-DISO
(	O	O
HPNS	B-DISO
)	O	O
,	O	O
which	O	O
is	O	O
associated	O
with	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
(	O	O
CNS	B-ANAT
)	O	O
hyperexcitability	B-PHYS
.	O	O

It	O	O
was	O	O
previously	O	O
reported	O	O
that	O	O
HP	B-PHEN
augments	O	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
(	O	O
NMDAR	B-CHEM
)	O	O
synaptic	B-PHYS
response	I-PHYS
,	O	O
increases	O
neuronal	O
excitability	B-DISO
and	O	O
potentially	O	O
causes	O	O
irreversible	O
neuronal	B-DISO
damage	I-DISO
.	O	O

Our	O	O
laboratory	B-OBJC
has	O	O
reported	O	O
differential	B-PHEN
current	I-PHEN
responses	B-PHYS
under	O	O
HP	B-PHEN
conditions	O
in	O	O
NMDAR	B-CHEM
subtypes	O
that	O	O
contain	O	O
either	O	O
GluN1	B-CHEM
-	I-CHEM
1a	I-CHEM
or	O	O
GluN1	B-CHEM
-	I-CHEM
1b	I-CHEM
splice	B-CHEM
variants	I-CHEM
co	B-PHYS
-	I-PHYS
expressed	I-PHYS
in	O	O
Xenopus	B-LIVB
laevis	I-LIVB
oocytes	B-ANAT
with	O	O
all	O	O
four	O	O
GluN2	B-CHEM
subunits	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
reported	O	O
that	O	O
the	O	O
increase	O
in	O	O
ionic	B-PHEN
currents	I-PHEN
measured	O
under	O	O
HP	B-PHEN
conditions	O
is	O	O
also	O	O
dependent	O	O
on	O	O
which	O	O
of	O	O
the	O	O
eight	O	O
splice	B-CHEM
variants	I-CHEM
of	O	O
GluN1	B-CHEM
is	O	O
co	B-PHYS
-	I-PHYS
expressed	I-PHYS
with	O	O
the	O	O
GluN2	B-CHEM
subunit	O	O
.	O	O

We	O	O
now	O	O
report	O	O
that	O	O
the	O	O
NMDAR	B-CHEM
subtype	O
that	O	O
contains	O	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	I-CHEM
b	I-CHEM
splice	B-CHEM
variants	I-CHEM
exhibited	O	O
""""	O	O
dichotomic	O	O
""""	O	O
(	O	O
either	O	O
increased	O
or	O	O
decreased	O
)	O	O
response	B-PHYS
s	O	O
at	O	O
HP	B-PHEN
.	O	O

The	O	O
distribution	O	O
of	O	O
the	O	O
results	O
is	O	O
not	O	O
normal	O	O
thus	O	O
analysis	O
of	O
variance	O
(	O	O
ANOVA	O
)	O	O
test	O	O
and	O	O
clustering	B-PROC
analysis	I-PROC
were	O	O
employed	O	O
for	O	O
statistical	O
verification	O
of	O	O
the	O	O
grouping	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
calculated	O
constants	O
of	O	O
alpha	O
function	O
distribution	B-PROC
analysis	I-PROC
for	O	O
the	O	O
two	O	O
groups	O
were	O	O
similar	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
mechanism	O
underlying	O	O
the	O	O
switch	O	O
between	O	O
an	O	O
increase	O
or	O	O
a	O	O
decrease	O
of	O	O
the	O	O
current	B-PHEN
at	O	O
HP	B-PHEN
is	O	O
a	O	O
single	O
process	B-PHEN
,	O	O
the	O	O
nature	O	O
of	O	O
which	O	O
is	O	O
still	O	O
unknown	O	O
.	O	O

This	O	O
dichotomic	B-PHYS
response	I-PHYS
of	O	O
the	O	O
GluN1	B-CHEM
-	I-CHEM
4a	I-CHEM
/	O	O
b	B-CHEM
splice	B-CHEM
variant	I-CHEM
may	O	O
be	O	O
used	O	O
as	O	O
a	O	O
model	B-DEVI
for	O	O
studying	O	O
reduced	O
response	B-PHYS
in	O	O
NMDAR	B-CHEM
at	O	O
HP	B-PHEN
.	O	O

Successful	O	O
reversal	O
of	O	O
other	O	O
NMDAR	B-CHEM
subtypes	O
response	B-PHYS
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O

,	O	O
current	B-PHEN
reduction	O
)	O	O
may	O	O
allow	O	O
the	O	O
elimination	O	O
of	O	O
the	O	O
reversible	O
malfunctioning	O
short	O
term	O
effects	O
(	O	O
HPNS	B-DISO
)	O	O
,	O	O
or	O	O
even	O	O
deleterious	O	O
long	O
term	O
effects	O
induced	O	O
by	O	O
increased	O
NMDAR	B-CHEM
function	O	O
during	O	O
HP	B-PHEN
exposure	O
.	O	O

Matrix	O
metalloproteinase	O
-	O
9	O
Gene	O
-	O
1562C	O
>	O
T	O
Gene	O
Polymorphism	B-PHYS
and	O	O
Coronary	B-DISO
Artery	I-DISO
Disease	I-DISO
in	O	O
the	O	O
Chinese	O
Han	O
Population	O
:	O	O
A	O	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
of	O	O
5468	O	O
Subjects	B-LIVB
Multiple	O	O
studies	B-PROC
indicate	O	O
that	O	O
the	O	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
may	O	O
be	O	O
associated	O
with	O
an	O	O
increased	B-DISO
risk	I-DISO
of	O	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O	O
CAD	B-DISO
)	O	O
in	O	O
the	O	O
Chinese	O
Han	O
population	O
.	O	O

However	O	O
,	O	O
a	O	O
clear	O	O
consensus	O
has	O	O
yet	O	O
to	O	O
be	O	O
established	O	O
.	O	O

A	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O	O
5468	O	O
subjects	B-LIVB
from	O	O
10	O	O
separate	O	O
studies	B-PROC
was	O	O
performed	O	O
to	O	O
explore	O	O
the	O	O
possible	O	O
relationship	O
between	O	O
the	O	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
and	O	O
CAD	B-DISO
within	O	O
the	O	O
Chinese	O
Han	O
population	O
.	O	O

Pooled	O
odds	O
ratio	O
(	O	O
ORs	O
)	O	O
for	O	O
the	O	O
association	O	O
and	O	O
the	O	O
corresponding	O	O
95	O	O
%	O	O
confidence	O
intervals	O
(	O	O
CIs	O
)	O	O
were	O	O
evaluated	O	O
by	O	O
a	O	O
random	B-DEVI
or	O	O
fixed	B-DEVI
-	I-DEVI
effect	I-DEVI
model	I-DEVI
.	O	O

Our	O	O
analysis	B-PROC
confirms	O	O
the	O	O
association	O	O
between	O	O
the	O	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
and	O	O
an	O	O
increased	B-DISO
risk	I-DISO
of	O	O
CAD	B-DISO
within	O	O
the	O	O
Chinese	O
Han	O
population	O
under	O	O
allelic	O
(	O	O
OR	O
:	O	O
1	O	O
.	O	O
60	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
25	O	O
-	O	O
2	O	O
.	O	O
04	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0002	O	O
)	O	O
,	O	O
recessive	O
(	O	O
OR	O
:	O	O
3	O	O
.	O	O
05	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
67	O	O
-	O	O
5	O	O
.	O	O
56	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0003	O	O
)	O	O
,	O	O
dominant	O
(	O	O
OR	O
:	O	O
2	O	O
.	O	O
23	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
49	O	O
-	O	O
3	O	O
.	O	O
35	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
homozygous	B-PHYS
(	O	O
OR	O
:	O	O
3	O	O
.	O	O
41	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
87	O	O
-	O	O
6	O	O
.	O	O

23	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
heterozygous	B-PHYS
(	O	O
OR	O
:	O	O
2	O	O
.	O	O
03	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
40	O	O
-	O	O
2	O	O
.	O	O
93	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0002	O	O
)	O	O
,	O	O
and	O	O
additive	O	O
genetic	O
models	O
(	O	O
OR	O
:	O	O
1	O	O
.	O	O
78	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
33	O	O
-	O	O
2	O	O
.	O	O
39	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Chinese	O
Han	O
population	O
,	O	O
the	O	O
MMP	O
-	O
9	O
-	O
1562C	O
>	O
T	O
gene	O
polymorphism	B-PHYS
is	O	O
correlated	O
with	O	O
an	O	O
increased	B-DISO
risk	I-DISO
of	O	O
CAD	B-DISO
.	O	O

Therefore	O	O
,	O	O
Han	O
Chinese	O
carriers	B-DISO
of	O	O
the	O	O
-	O	O
1562	O
T	O
allele	O
may	O	O
be	O	O
at	O	O
an	O	O
increased	B-DISO
risk	I-DISO
of	O	O
CAD	B-DISO
.	O	O

Changes	O
in	O	O
parenting	O
strategies	B-PHYS
after	O	O
a	O	O
young	O
person	B-LIVB
's	I-LIVB
self	B-DISO
-	I-DISO
harm	I-DISO
:	O	O
a	O	O
qualitative	B-PROC
study	I-PROC
When	O	O
faced	O	O
with	O	O
the	O	O
discovery	O
of	O	O
their	O	O
child	B-LIVB
's	I-LIVB
self	B-DISO
-	I-DISO
harm	I-DISO
,	O	O
mothers	B-LIVB
and	O	O
fathers	B-LIVB
may	O	O
re	B-PROC
-	I-PROC
evaluate	I-PROC
their	O	O
parenting	O
strategies	B-PHYS
.	O	O

This	O	O
can	O	O
include	O	O
changes	O
to	O	O
the	O	O
amount	O	O
of	O	O
support	O
they	O	O
provide	O	O
their	O	O
child	B-LIVB
and	O	O
changes	O
to	O	O
the	O	O
degree	O
to	O	O
which	O	O
they	O	O
control	O
and	O	O
monitor	O
their	O	O
child	B-LIVB
.	O	O

We	O	O
conducted	O	O
an	O	O
in	B-PROC
-	I-PROC
depth	I-PROC
qualitative	I-PROC
study	I-PROC
with	O	O
37	O	O
parents	B-LIVB
of	O	O
young	O
people	B-LIVB
who	O	O
had	O	O
self	B-DISO
-	I-DISO
harmed	I-DISO
in	O	O
which	O	O
we	O	O
explored	O	O
how	O	O
and	O	O
why	O	O
their	O	O
parenting	O
changed	O
after	O	O
the	O	O
discovery	O
of	O	O
self	B-DISO
-	I-DISO
harm	I-DISO
.	O	O

Early	O
on	O	O
,	O	O
parents	B-LIVB
often	O	O
found	O	O
themselves	O	O
""""	O	O
walking	O	O
on	O	O
eggshells	O	O
""""	O	O
so	O	O
as	O	O
not	O	O
to	O	O
upset	B-PHYS
their	O	O
child	B-LIVB
,	O	O
but	O	O
later	O	O
they	O	O
felt	O	O
more	O	O
able	O	O
to	O	O
take	O	O
some	O	O
control	O
.	O	O

Parents	B-LIVB
'	O	O
reactions	O
to	O	O
the	O	O
self	B-DISO
-	I-DISO
harm	I-DISO
often	O	O
depended	O	O
on	O	O
how	O	O
they	O	O
conceptualised	O	O
it	O	O
:	O	O
as	O	O
part	O	O
of	O	O
adolescence	O
,	O	O
as	O	O
a	O	O
mental	B-DISO
health	I-DISO
issue	I-DISO
or	O	O
as	O	O
""""	O	O
naughty	O
behaviour	O
""""	O	O
.	O	O

Parenting	O
of	O	O
other	O	O
children	B-LIVB
in	O	O
the	O	O
family	B-LIVB
could	O	O
also	O	O
be	O	O
affected	O	O
,	O	O
with	O	O
parents	B-LIVB
worrying	O	O
about	O	O
less	O	O
of	O	O
their	O	O
time	O
being	O	O
available	O	O
for	O	O
siblings	B-LIVB
.	O	O

Many	O	O
parents	B-LIVB
developed	O	O
specific	O	O
strategies	B-PHYS
they	O	O
felt	O	O
helped	O	O
them	O	O
to	O	O
be	O	O
more	O	O
effective	O	O
parents	B-LIVB
,	O	O
such	O	O
as	O	O
learning	B-PHYS
to	O	O
avoid	O	O
blaming	B-PHYS
themselves	O	O
or	O	O
their	O	O
child	B-LIVB
for	O	O
the	O	O
self	B-DISO
-	I-DISO
harm	I-DISO
and	O	O
developing	O	O
new	O	O
ways	O	O
to	O	O
communicate	B-DISO
with	O	O
their	O	O
child	B-LIVB
.	O	O

Parents	B-LIVB
were	O	O
generally	O	O
eager	O	O
to	O	O
pass	O	O
their	O	O
knowledge	O
on	O	O
to	O	O
other	O	O
people	B-LIVB
in	O	O
the	O	O
same	O	O
situation	O
.	O	O

Parents	B-LIVB
reported	O	O
changes	O
in	O	O
their	O	O
parenting	O
behaviours	O
after	O	O
the	O	O
discovery	O
of	O	O
a	O	O
child	B-LIVB
'	O	O
s	O	O
self	B-DISO
-	I-DISO
harm	I-DISO
.	O	O

Professionals	B-LIVB
involved	O	O
in	O	O
the	O	O
care	O
of	O	O
young	O
people	B-LIVB
who	O	O
self	B-DISO
-	I-DISO
harm	I-DISO
might	O	O
use	O	O
this	O	O
information	O
in	O	O
supporting	O
and	O	O
advising	O
parents	B-LIVB
.	O	O

The	O	O
Association	O
between	O	O
C9orf72	O
Repeats	O
and	O	O
Risk	O
of	O	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
and	O	O
Amyotrophic	B-DISO
Lateral	I-DISO
Sclerosis	I-DISO
:	O	O
A	O	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
C9orf72	O
is	O	O
the	O	O
most	O	O
common	O	O
genetic	O
cause	O
of	O	O
amyotrophic	B-DISO
lateral	I-DISO
sclerosis	I-DISO
(	O	O
ALS	B-DISO
)	O	O
and	O	O
frontotemporal	B-DISO
dementia	I-DISO
(	O	O
FTD	B-DISO
)	O	O
in	O	O
Caucasian	B-LIVB
populations	I-LIVB
.	O	O

However	O	O
,	O	O
the	O	O
relationship	O
between	O	O
C9orf72	O
repeats	O
and	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
AD	B-DISO
)	O	O
was	O	O
not	B-DISO
clear	I-DISO
.	O	O

Additionally	O	O
,	O	O
there	O	O
were	O	O
few	O	O
articles	O
assessing	O
C9orf72	O
in	O	O
other	O	O
ethnicities	O
with	O	O
ALS	B-DISO
.	O	O

In	O	O
this	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
,	O	O
we	O	O
aimed	O	O
to	O	O
investigate	O
the	O	O
relationship	O
between	O	O
C9orf72	O
repeat	B-DISO
expansions	I-DISO
(	O	O
≥30	O	O
repeats	O
)	O	O
and	O	O
intermediate	O
repeat	O
copies	O
(	O	O
20	O	O
-	O	O
29	O	O
repeats	O
)	O	O
and	O	O
AD	B-DISO
or	O	O
ALS	B-DISO
.	O	O

The	O	O
results	O
suggested	O	O
positive	B-DISO
correlations	O
between	O	O
C9orf72	O
repeat	B-DISO
expansions	I-DISO
and	O	O
the	O	O
risk	O
of	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
OR	O
=	O	O
6	O	O
.	O	O
36	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
3	O	O
.	O	O
13	O	O
-	O	O
12	O	O
.	O	O
92	O	O
,	O	O
and	O	O
p	O
<	O	O
0	O	O
.	O	O
00001	O	O
)	O	O
,	O	O
while	O	O
intermediate	O
repeat	O
copies	O
of	O	O
C9orf72	O
gene	O
were	O	O
not	O	O
associated	O
with	O
the	O	O
risk	O
of	O	O
the	O	O
disease	B-DISO
.	O	O

C9orf72	O
repeat	B-DISO
expansions	I-DISO
were	O	O
positively	B-DISO
correlated	O
with	O	O
the	O	O
risk	O
of	O	O
familial	B-DISO
and	O	O
sporadic	B-DISO
ALS	I-DISO
(	O	O
OR	O
=	O	O
293	O	O
.	O	O

25	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
148	O	O
.	O	O
17	O	O
-	O	O
580	O	O
.	O	O
38	O	O
,	O	O
and	O	O
p	O
<	O	O
0	O	O
.	O	O
00001	O	O
;	O	O
OR	O
=	O	O
35	O	O
.	O	O
57	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
19	O	O
.	O	O
61	O	O
-	O	O
64	O	O
.	O	O
51	O	O
,	O	O
and	O	O
p	O
<	O	O
0	O	O
.	O	O
00001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
positive	B-DISO
correlation	O
between	O	O
the	O	O
gene	B-PHEN
variations	I-PHEN
and	O	O
ALS	B-DISO
risk	O
among	O	O
Caucasians	B-LIVB
and	O	O
Asians	B-LIVB
(	O	O
OR	O
=	O	O
57	O	O
.	O	O
56	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
36	O	O
.	O	O
73	O	O
-	O	O
90	O	O
.	O	O
22	O	O
,	O	O
and	O	O
p	O
<	O	O
0	O	O
.	O	O
00001	O	O
;	O	O
OR	O
=	O	O
6	O	O
.	O	O

35	O	O
,	O	O
95	O	O
%	O	O
CI	O
=	O	O
1	O	O
.	O	O
39	O	O
-	O	O
29	O	O
.	O	O
02	O	O
,	O	O
and	O	O
p	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

Variability	O
in	O	O
Saponin	B-CHEM
Content	O
,	O	O
Cancer	B-DISO
Antiproliferative	B-DISO
Activity	I-DISO
and	O	O
Physicochemical	O
Properties	O
of	O	O
Concentrated	B-OBJC
Agave	I-OBJC
Sap	I-OBJC
Concentrated	B-OBJC
agave	I-OBJC
sap	I-OBJC
(	O	O
CAS	B-OBJC
)	O	O
has	O	O
gained	O	O
popularity	O	O
as	O	O
an	O	O
unrefined	B-CHEM
sweetener	I-CHEM
.	O	O

It	O	O
is	O	O
obtained	O	O
by	O	O
boiling	B-PHEN
""""	O	O
aguamiel	B-LIVB
""""	O	O
that	O	O
contains	O	O
phytochemicals	B-CHEM
with	O	O
diverse	O	O
bioactivities	O
.	O	O

Saponins	B-CHEM
have	O	O
been	O	O
the	O	O
most	O	O
widely	O	O
studied	O	O
agave	B-LIVB
phytochemicals	B-CHEM
due	O	O
to	O	O
their	O	O
cancer	B-DISO
antiproliferative	B-DISO
effect	I-DISO
but	O	O
their	O	O
concentration	O
may	O	O
vary	O	O
due	O	O
to	O	O
maturity	O
of	O	O
the	O	O
agave	B-LIVB
plant	I-LIVB
and	O	O
collection	O
site	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
18	O	O
CAS	B-OBJC
samples	B-OBJC
produced	O	O
in	O	O
different	O
states	B-GEOG
of	O	O
Mexico	B-GEOG
were	O	O
analyzed	B-PROC
using	O	O
multivariate	O
methods	O
to	O	O
determine	O	O
which	O	O
physicochemical	B-DISO
or	O	O
phytochemical	B-DISO
parameters	I-DISO
were	O	O
responsible	B-DISO
for	O	O
variation	O
.	O	O

Additionally	O	O
,	O	O
extracts	B-CHEM
with	O	O
different	O
saponin	B-CHEM
profiles	B-PROC
were	O	O
tested	O
to	O	O
determine	O	O
possible	O	O
correlations	O
with	O	O
antiproliferative	B-DISO
activity	I-DISO
.	O	O

Total	O
soluble	O
solids	O
,	O	O
pH	O
,	O	O
and	O	O
water	O
activity	O
were	O	O
similar	O	O
to	O	O
those	O	O
reported	O	O
for	O	O
other	O	O
agave	B-LIVB
sweeteners	B-CHEM
.	O	O

Antioxidant	O
capacity	O
of	O	O
samples	B-OBJC
was	O	O
correlated	O
to	O	O
browning	O
index	O
.	O	O

Eleven	O	O
steroidal	B-CHEM
saponins	I-CHEM
were	O	O
found	O	O
in	O	O
CAS	B-OBJC
samples	B-OBJC
and	O	O
they	O	O
were	O	O
the	O	O
main	O	O
source	B-DISO
of	O	O
variability	O
.	O	O

Magueyoside	B-CHEM
B	I-CHEM
,	O	O
a	O	O
kammogenin	B-CHEM
tetraglycoside	I-CHEM
,	O	O
was	O	O
the	O	O
most	O	O
abundant	O
saponin	B-CHEM
in	O	O
all	O	O
samples	B-OBJC
.	O	O

With	O	O
respect	O	O
to	O	O
bioactivity	O
,	O	O
multivariate	O
analysis	O
indicated	O	O
that	O	O
magueyoside	B-CHEM
B	I-CHEM
and	O	O
a	O	O
gentrogenin	B-CHEM
tetraglycoside	I-CHEM
were	O	O
compounds	B-CHEM
strongly	O	O
related	O	O
with	O	O
bioactivity	O
.	O	O

CAS	B-OBJC
from	O	O
Hidalgo	B-GEOG
,	O	O
Puebla	B-GEOG
,	O	O
and	O	O
Veracruz	B-GEOG
had	O	O
higher	O
concentration	O
of	O	O
magueyoside	B-CHEM
B	I-CHEM
than	O	O
from	O	O
the	O	O
other	O	O
kamogenin	B-CHEM
tetraglycoside	I-CHEM
found	O	O
in	O	O
the	O	O
samples	B-OBJC
from	O	O
other	O	O
Mexican	B-GEOG
states	I-GEOG
.	O	O

These	O	O
results	O	O
could	O	O
be	O	O
used	O	O
as	O	O
a	O	O
first	O	O
approach	O	O
to	O	O
characterize	O
and	O	O
standardize	O
CAS	B-OBJC
to	O	O
validate	O	O
the	O	O
potential	O	O
health	O
benefits	O
derived	O	O
from	O	O
its	O	O
consumption	O
.	O	O

Association	O
of	O	O
CDKAL1	O
,	O	O
CDKN2A	O
/	O	O
B	O
&	O	O
HHEX	O
gene	B-PHYS
polymorphisms	I-PHYS
with	O	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
in	O	O
the	O	O
population	B-LIVB
of	O	O
Hyderabad	O
,	O	O
India	B-GEOG
The	O	O
genome	B-PROC
-	I-PROC
wide	I-PROC
association	I-PROC
studies	I-PROC
(	O	O
GWAS	B-PROC
)	O	O
have	O	O
shown	O	O
an	O	O
association	O
of	O	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
(	O	O
T2DM	B-DISO
)	O	O
with	O	O
several	O	O
novel	O
genes	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
findings	B-DISO
on	O	O
the	O	O
pattern	O	O
of	O	O
genetic	O
association	O
of	O	O
three	O	O
genes	O
(	O	O
CDKAL1	O
,	O	O
CDKN2A	O
/	O	O
B	O
and	O	O
HHEX	O
)	O	O
with	O	O
T2DM	B-DISO
in	O	O
the	O	O
population	B-LIVB
of	O	O
Hyderabad	O
,	O	O
south	O	O
India	B-GEOG
.	O	O

A	O	O
sample	B-OBJC
of	O	O
1379	O	O
individuals	B-LIVB
(	O	O
758	O	O
T2DM	B-DISO
cases	O	O
and	O	O
621	O	O
controls	B-LIVB
)	O	O
from	O	O
Hyderabad	O
,	O	O
India	B-GEOG
,	O	O
were	O	O
genotyped	B-PHYS
for	O	O
five	O	O
single	O
nucleotide	O
polymorphisms	O
(	O	O
SNPs	O
)	O	O
of	O	O
CDKAL1	O
(	O
rs7754840	O
,	O
rs7756992	O
)	O
CDKN2A	O
/	O	O
B	O
(	O
rs10811661	O
)	O
and	O	O
HHEX	O
(	O
rs1111875	O
,	O
rs7923837	O
)	O
genes	O
on	O	O
Sequenom	O
Mass	O
Array	O
platform	O
.	O	O

The	O	O
risk	O
allele	O
frequencies	O
of	O	O
the	O	O
CDKAL1	O
and	O	O
CDKN2A	O
/	O	O
B	O
SNPs	O
were	O	O
relatively	O	O
higher	O
in	O	O
cases	O	O
than	O	O
in	O	O
the	O	O
controls	B-LIVB
and	O	O
the	O	O
logistic	O
regression	O
analysis	O
yielded	O	O
significant	O	O
odds	O
ratios	O
suggesting	O	O
that	O	O
the	O	O
variant	O
alleles	O
conferred	O	O
risk	O
for	O	O
developing	O	O
T2DM	B-DISO
in	O	O
this	O	O
population	B-LIVB
.	O	O

The	O	O
HHEX	O
gene	O
did	O	O
not	O	O
show	O	O
either	O	O
allelic	O
or	O	O
genotypic	B-PHYS
association	O
with	O	O
T2DM	B-DISO
.	O	O

The	O	O
multivariate	O
logistic	O
regression	O
analysis	O
with	O	O
reference	O	O
to	O	O
both	O	O
alleles	O
and	O	O
genotypes	B-PHYS
of	O	O
CDKAL1	O
SNPs	O
showed	O	O
significant	O	O
association	O
,	O	O
suggesting	O	O
an	O	O
important	O	O
role	O	O
for	O	O
this	O	O
gene	O
in	O	O
the	O	O
T2DM	B-DISO
pathophysiology	O
.	O	O

A	O	O
significant	O	O
association	O
was	O	O
seen	O	O
of	O	O
all	O	O
the	O	O
three	O	O
SNPs	O
of	O	O
CDKAL1	O
and	O	O
CDKN2A	O
/	O	O
B	O
genes	O
with	O	O
T2DM	B-DISO
but	O	O
none	O	O
of	O	O
the	O	O
two	O	O
SNPs	O
of	O	O
HHEX	O
.	O	O

Further	O	O
studies	O	O
are	O	O
required	O	O
to	O	O
cross	B-PROC
-	I-PROC
validate	I-PROC
our	O	O
findings	B-DISO
in	O	O
a	O	O
relatively	O	O
larger	O
sample	B-OBJC
.	O	O

It	O	O
is	O	O
also	O	O
necessary	O	O
to	O	O
explore	O	O
other	O	O
SNPs	O
of	O	O
HHEX	O
gene	O
to	O	O
unequivocally	O	O
establish	O	O
the	O	O
pattern	O	O
of	O	O
association	O
of	O	O
this	O	O
gene	O
with	O	O
T2DM	B-DISO
in	O	O
this	O	O
population	B-LIVB
.	O	O

Demonstration	O	O
and	O	O
validation	B-PROC
of	O	O
a	O	O
new	O	O
pressure	B-PHEN
-based	O	O
MRI	B-DEVI
-safe	O	O
pain	B-DISO
tolerance	I-DISO
device	B-DEVI
One	O	O
of	O	O
the	O	O
barriers	O	O
to	O	O
studying	O	O
the	O	O
behavioral	O
and	O	O
emotional	B-PHYS
effects	O
of	O	O
pain	B-DISO
using	O	O
functional	B-PROC
Magnetic	I-PROC
Resonance	I-PROC
Imaging	I-PROC
(	O	O
fMRI	B-PROC
)	O	O
is	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
commercially	O	O
available	O	O
,	O	O
MRI	B-DEVI
-	O	O
compatible	O
,	O	O
pressure	B-PHEN
-based	O	O
algometer	B-DEVI
to	O	O
elicit	O
pain	B-DISO
.	O	O

The	O	O
present	O	O
study	O	O
sought	O	O
to	O	O
address	O	O
this	O	O
barrier	O	O
through	O	O
creation	O	O
and	O	O
validation	O	O
of	O	O
a	O	O
novel	O	O
MRI	B-DEVI
-safe	O	O
apparatus	B-DEVI
capable	O	O
of	O	O
delivering	O	O
incremental	O
,	O	O
measurable	O
amounts	O	O
of	O	O
pressure	B-PHEN
inside	O	O
a	O	O
scanning	B-DEVI
bore	I-DEVI
.	O	O

We	O	O
introduced	O	O
an	O	O
MR	O	O
-	O	O
safe	O	O
device	B-DEVI
used	O	O
to	O	O
administer	O	O
pressure	B-PHEN
-based	O	O
pain	B-DISO
.	O	O

To	O	O
test	B-PROC
against	O	O
a	O	O
commercially	O	O
available	O	O
,	O	O
MRI	B-DEVI
-	O	O
incompatible	O
algometer	B-DEVI
(	O	O
AlgoMed	B-DEVI
)	O	O
,	O	O
199	O	O
participants	O	O
reported	O	O
their	O	O
pain	B-DISO
tolerance	I-DISO
for	O	O
both	O	O
devices	O	O
.	O	O

A	O	O
second	O	O
experiment	O	O
tested	B-PROC
the	O	O
validity	O	O
of	O	O
pressure	B-PHEN
-based	O	O
pain	B-DISO
in	O	O
an	O	O
MRI	B-DEVI
environment	O
by	O	O
comparing	O	O
brain	B-ANAT
activation	O
with	O	O
established	O	O
neural	B-ANAT
networks	I-ANAT
for	O	O
pain	B-DISO
.	O	O

10	O	O
participants	O	O
performed	O	O
an	O	O
identical	O	O
procedure	O	O
to	O	O
test	B-PROC
for	O	O
pain	B-DISO
tolerance	O	O
while	O	O
being	O	O
scanned	B-PROC
in	O	O
a	O	O
7	O	O
T	O	O
MRI	B-DEVI
scanner	I-DEVI
.	O	O

Results	O	O
support	O	O
the	O	O
validity	O
and	O
reliability	O
of	O	O
our	O	O
novel	O	O
device	B-DEVI
.	O	O

In	O	O
Study	O	O
1	O	O
,	O	O
pain	B-DISO
tolerance	I-DISO
with	O	O
this	O	O
device	B-DEVI
was	O	O
strongly	O	O
correlated	O	O
with	O	O
pain	B-DISO
tolerance	I-DISO
as	O	O
measured	O	O
by	O	O
a	O	O
commercially	O	O
available	O	O
algometer	B-DEVI
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
78	O	O
)	O	O
.	O	O

In	O	O
Study	O	O
2	O	O
,	O	O
this	O	O
device	B-DEVI
yielded	O	O
BOLD	B-PHYS
activation	O	O
within	O	O
the	O	O
insula	B-ANAT
(	O	O
BA	B-ANAT
13	I-ANAT
)	O	O
and	O	O
anterior	B-ANAT
cingulate	I-ANAT
gyrus	I-ANAT
(	O	O
BA	B-ANAT
24	I-ANAT
)	O	O
;	O	O
as	O	O
pressure	B-PHEN
increased	O
,	O	O
activation	O	O
in	O	O
these	O	O
areas	O	O
parametrically	O
increased	O
.	O	O

These	O	O
findings	O	O
correspond	O	O
to	O	O
other	O	O
studies	O	O
using	O	O
thermal	B-PROC
,	O	O
electrical	B-PROC
,	O	O
or	O	O
mechanical	B-PROC
pain	B-DISO
applications	I-DISO
.	O	O

Behavioral	O
and	O	O
functional	O
data	O
demonstrate	O	O
that	O	O
this	O	O
new	O	O
device	B-DEVI
is	O	O
a	O	O
valid	O	O
method	O	O
of	O	O
administering	B-PROC
pressure	B-PHEN
-related	O	O
pain	B-DISO
in	O	O
MRI	B-DEVI
environments	O
.	O	O

Our	O	O
novel	O	O
MRI	B-DEVI
-safe	O	O
device	B-DEVI
is	O	O
a	O	O
valid	O	O
instrument	B-DEVI
to	O	O
measure	O
and	O	O
administer	O
pressure	B-PHEN
-based	O	O
pain	B-DISO
.	O	O

Mandibular	B-DISO
dysostosis	I-DISO
without	O	O
microphthalmia	B-DISO
caused	O
by	O
OTX2	B-PHYS
deletion	I-PHYS
Mutations	B-PHYS
in	O	O
OTX2	O
are	O	O
mostly	O	O
identified	O
in	O	O
patients	B-LIVB
with	O	O
anophthalmia	B-DISO
/	O	O
microphthalmia	B-DISO
with	O	O
variable	O
severity	O
.	O	O

The	O	O
OTX2	O
homeobox	O
gene	O
plays	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
craniofacial	B-ANAT
morphogenesis	B-PHYS
during	O	O
early	O	O
embryo	B-PHYS
development	I-PHYS
.	O	O

We	O	O
report	O	O
for	O	O
the	O	O
first	O	O
time	O	O
a	O	O
patient	B-LIVB
with	O	O
a	O	O
mandibular	B-DISO
dysostosis	I-DISO
caused	O
by	O
a	O	O
120	B-PHYS
kb	I-PHYS
deletion	I-PHYS
including	O	O
the	O	O
entire	O
coding	O
sequence	O
of	O
OTX2	O
,	O	O
identified	O
by	O	O
array	B-PROC
CGH	I-PROC
.	O	O

No	O	O
ocular	B-DISO
malformations	I-DISO
were	O	O
identified	O
after	O	O
extended	O	O
ophthalmologic	B-PROC
examination	I-PROC
.	O	O

Our	O	O
data	O
refine	O	O
the	O	O
clinical	B-PROC
spectrum	I-PROC
associated	O	O
with	O	O
OTX2	B-PHYS
mutations	I-PHYS
and	O	O
suggests	O	O
that	O	O
OTX2	O
haploinsufficiency	B-DISO
should	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
possible	O	O
cause	O
for	O	O
isolated	O	O
mandibular	B-DISO
dysostosis	I-DISO
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

Optimizing	O
Survival	O
of	O	O
Patients	B-LIVB
With	O	O
Marginally	O
Operable	O
Stage	B-DISO
IIIA	I-DISO
Non	I-DISO
-	I-DISO
Small	I-DISO
-	I-DISO
Cell	I-DISO
Lung	I-DISO
Cancer	I-DISO
Receiving	O	O
Chemoradiotherapy	B-PROC
With	O
or	O	O
Without	O
Surgery	O
For	O	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
non	I-DISO
-	I-DISO
small	I-DISO
-	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
(	O	O
NSCLC	B-DISO
)	O	O
,	O	O
surgery	O
might	O	O
not	O	O
be	O	O
done	O	O
as	O	O
planned	O	O
after	O	O
neoadjuvant	B-PROC
concurrent	B-PROC
chemoradiotherapy	I-PROC
(	O	O
CCRT	B-PROC
)	O	O
for	O	O
reasons	O	O
(	O	O
unresectable	B-PHYS
or	O	O
medically	O
inoperable	O
conditions	O
,	O	O
or	O	O
patient	O
refusal	O
)	O	O
.	O	O

This	O	O
study	B-PROC
aims	O	O
to	O	O
investigate	O
the	O	O
outcomes	O
of	O	O
a	O	O
phased	B-PROC
CCRT	I-PROC
protocol	I-PROC
established	O	O
to	O	O
maximize	O	O
the	O	O
operability	O
of	O	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
and	O	O
to	O	O
care	O	O
for	O	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
,	O	O
in	O	O
comparison	O	O
with	O	O
continuous	B-PROC
-	I-PROC
course	I-PROC
definitive	I-PROC
CCRT	I-PROC
.	O	O

Forty	O	O
-	O	O
seven	O	O
patients	B-LIVB
with	O	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
receiving	O	O
CCRT	B-PROC
were	O	O
included	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
patients	B-LIVB
were	O	O
treated	O
with	O	O
our	O	O
phased	B-PROC
CCRT	I-PROC
protocol	I-PROC
,	O	O
including	O	O
neoadjuvant	B-PROC
CCRT	B-PROC
followed	O	O
by	O	O
surgery	O
(	O	O
group	O
A	O
,	O	O
n	O	O
=	O	O
16	O	O
)	O	O
or	O	O
,	O	O
for	O	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
,	O	O
maintenance	B-DISO
chemotherapy	I-DISO
and	O	O
split	B-PROC
-	I-PROC
course	I-PROC
CCRT	I-PROC
boost	O
(	O	O
group	O
B	O
,	O	O
n	O	O
=	O	O
12	O	O
)	O	O
.	O	O

The	O	O
other	O	O
19	O	O
were	O	O
treated	O
with	O	O
continuous	B-PROC
-	I-PROC
course	I-PROC
definitive	I-PROC
CCRT	I-PROC
(	O	O
group	O
C	O
)	O	O
.	O	O

Overall	O
survival	O
(	O	O
OS	O
)	O	O
and	O	O
progression	O
-	O
free	O
survival	O
(	O	O
PFS	O
)	O	O
were	O	O
analyzed	B-PROC
.	O	O

Among	O	O
all	O	O
,	O	O
median	O
OS	O
and	O	O
PFS	O
were	O	O
35	O	O
.	O	O
6	O	O
and	O	O
12	O	O
.	O	O

8	O	O
months	O
,	O	O
respectively	O	O
(	O	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
22	O	O
.	O	O
3	O	O
months	O
)	O	O
.	O	O

The	O	O
median	O
OS	O
of	O	O
group	O
A	O
(	O	O
not	O	O
reached	O	O
)	O	O
was	O	O
better	O	O
than	O	O
that	O	O
of	O	O
group	O
B	O
(	O	O
34	O	O
.	O	O
4	O	O
months	O
)	O	O
and	O	O
group	O
C	O
(	O	O
15	O	O
.	O	O

2	O	O
months	O
)	O	O
(	O	O
P	O	O
=	O	O
.009	O	O
)	O	O
.	O	O

On	O	O
multivariate	O
analysis	O
,	O	O
performance	B-PHYS
status	I-PHYS
0	O	O
to	O	O
1	O	O
(	O	O
hazard	O
ratio	O
[	O	O
HR	O
]	O	O
,	O	O
0	O	O
.	O	O
026	O	O
;	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
,	O	O
adenocarcinoma	B-DISO
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
156	O	O
;	O	O
P	O	O
=	O	O
.003	O	O
)	O	O
,	O	O
and	O	O
group	O
A	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
199	O	O
;	O	O
P	O	O
=	O	O
.033	O	O
)	O	O
were	O	O
independent	B-PHYS
prognostic	I-PHYS
factors	I-PHYS
.	O	O

The	O	O
OS	O
of	O	O
group	O
B	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
450	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
,	O	O
0	O	O
.	O	O
118	O	O
-	O	O
1	O	O
.	O	O
717	O	O
;	O	O
P	O	O
=	O	O
.243	O	O
)	O	O
was	O	O
not	O	O
statistically	O
different	O
from	O	O
that	O	O
of	O	O
group	O
C	O
.	O	O

For	O	O
marginally	O
operable	O
stage	B-DISO
IIIA	I-DISO
NSCLC	I-DISO
,	O	O
our	O	O
phased	B-PROC
CCRT	I-PROC
strategy	I-PROC
may	O	O
optimize	O
survival	O
by	O	O
maximizing	O	O
operability	O
and	O	O
maintain	O	O
an	O	O
acceptable	O	O
survival	O
for	O	O
reassessed	O
inoperable	B-LIVB
patients	I-LIVB
by	O	O
split	B-PROC
-	I-PROC
course	I-PROC
CCRT	I-PROC
boost	O
following	O	O
maintenance	B-DISO
chemotherapy	I-DISO
.	O	O

Anti	O
-	O
Inflammatory	O
Properties	O
of	O	O
Menthol	B-CHEM
and	O	O
Menthone	B-CHEM
in	O	O
Schistosoma	B-DISO
mansoni	I-DISO
Infection	I-DISO
Schistosomiasis	B-DISO
is	O	O
a	O	O
parasitic	B-DISO
disease	I-DISO
caused	O	O
by	O	O
several	O	O
species	O
of	O	O
trematode	O
worms	O
and	O	O
it	O	O
is	O	O
believed	O	O
that	O	O
more	O	O
than	O	O
261	O	O
million	O	O
people	B-LIVB
are	O	O
affected	O
worldwide	O	O
.	O	O

New	O	O
drug	O
development	O
has	O	O
become	O	O
essential	O
because	O	O
there	O	O
is	O	O
a	O	O
risk	O	O
of	O	O
the	O	O
parasite	O
becoming	O	O
resistant	B-PHYS
to	O	O
Praziquantel	B-CHEM
,	O	O
the	O	O
only	O	O
drug	B-CHEM
available	O	O
for	O	O
this	O	O
infection	B-DISO
.	O	O

This	O	O
study	B-PROC
evaluated	B-PROC
parasitological	O
,	O	O
immunological	O
and	O	O
histological	O
parameters	B-DISO
in	O	O
mice	B-LIVB
infected	B-DISO
with	O	O
Schistosoma	O
mansoni	O
and	O	O
treated	B-PROC
with	I-PROC
an	O	O
herbal	B-CHEM
commercial	I-CHEM
medicine	I-CHEM
.	O	O

This	O	O
drug	B-CHEM
consists	O	O
of	O	O
menthol	B-CHEM
(	O	O
30	O	O
-	O	O
55	O	O
%	O	O
)	O	O
and	O	O
menthone	B-CHEM
(	O	O
14	O	O
-	O	O
32	O	O
%	O	O
)	O	O
.	O	O

A	O	O
60	O	O
day	O	O
treatment	B-PROC
regimen	I-PROC
with	O	O
the	O	O
herbal	B-CHEM
medicine	I-CHEM
decreased	O
the	O	O
number	O	O
of	O	O
S	O
.	O

mansoni	O
eggs	O
in	O	O
the	O	O
feces	B-ANAT
,	O	O
liver	B-ANAT
,	O	O
and	O	O
intestine	B-ANAT
and	O	O
reduced	O
the	O	O
number	O	O
of	O	O
hepatic	B-DISO
granulomas	I-DISO
.	O	O

We	O	O
observed	O
a	O	O
reduction	B-PROC
of	O	O
84	O	O
%	O	O
in	O	O
blood	B-DISO
eosinophilia	I-DISO
and	O	O
a	O	O
decrease	O
in	O	O
the	O	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
blood	B-ANAT
levels	I-ANAT
after	O	O
treatment	B-PROC
.	O	O

Therefore	O	O
,	O	O
we	O	O
propose	O	O
that	O	O
schistosomiasis	B-DISO
treatment	B-PROC
with	O	O
this	O	O
herbal	B-CHEM
medicine	I-CHEM
for	O	O
60	O	O
days	O	O
has	O	O
an	O	O
immunomodulatory	O
and	O	O
anti	O
-	O
inflammatory	O
action	O
in	O	O
this	O	O
animal	B-LIVB
model	I-LIVB
for	O	O
schistosomiasis	B-DISO
thus	O	O
contributing	O
to	O	O
the	O	O
decrease	O
in	O	O
physio	O	O
pathological	O
effects	O
caused	O	O
by	O	O
S	B-DISO
.	I-DISO

mansoni	I-DISO
infection	I-DISO
.	O	O

Evaluation	O	O
of	O	O
Three	O
Protein	B-PROC
-	I-PROC
Extraction	I-PROC
Methods	I-PROC
for	O	O
Proteome	B-CHEM
Analysis	B-PROC
of	O	O
Maize	B-LIVB
Leaf	B-LIVB
Midrib	O
,	O	O
a	O	O
Compound	B-ANAT
Tissue	I-ANAT
Rich	O	O
in	O	O
Sclerenchyma	B-ANAT
Cells	I-ANAT
Leaf	B-LIVB
morphology	O
is	O	O
closely	O	O
related	O	O
to	O	O
the	O	O
growth	B-PHYS
and	I-PHYS
development	I-PHYS
of	O	O
maize	B-LIVB
(	I-LIVB
Zea	I-LIVB
mays	I-LIVB
L	I-LIVB
.	I-LIVB

)	I-LIVB
plants	I-LIVB
and	O	O
final	O	O
kernel	B-OBJC
production	O	O
.	O	O

As	O	O
an	O	O
important	O	O
part	O	O
of	O	O
the	O	O
maize	B-LIVB
leaf	B-LIVB
,	O	O
the	O	O
midrib	O
holds	O	O
leaf	B-LIVB
blades	O	O
in	O	O
the	O	O
aerial	B-LIVB
position	I-LIVB
for	O	O
maximum	O	O
sunlight	B-PHEN
capture	O	O
.	O	O

Leaf	B-LIVB
midrib	O
s	O	O
of	O	O
adult	O
plants	B-LIVB
contain	O	O
substantial	O	O
sclerenchyma	B-ANAT
cells	I-ANAT
with	O	O
heavily	O
thickened	O
and	O	O
lignified	B-CHEM
secondary	B-ANAT
walls	I-ANAT
and	O	O
have	O	O
a	O	O
high	O	O
amount	O	O
of	O	O
phenolics	B-CHEM
,	O	O
making	O	O
protein	B-PROC
extraction	I-PROC
and	O	O
proteome	B-CHEM
analysis	B-PROC
difficult	O	O
in	O	O
leaf	B-LIVB
midrib	O
tissue	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
three	O	O
protein	B-PROC
-	I-PROC
extraction	I-PROC
methods	I-PROC
that	O	O
are	O	O
commonly	O	O
used	O	O
in	O	O
plant	B-LIVB
proteomics	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O
,	O	O
phenol	B-CHEM
extraction	B-PROC
,	O	O
TCA	B-CHEM
/	O	O
acetone	B-CHEM
extraction	B-PROC
,	O	O
and	O	O
TCA	B-CHEM
/	O	O
acetone	B-CHEM
/	O	O
phenol	B-CHEM
extraction	B-PROC
,	O	O
were	O	O
qualitatively	O
and	O	O
quantitatively	O
evaluated	O
based	O	O
on	O	O
2DE	O	O
maps	O	O
and	O	O
MS	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
using	O	O
the	O	O
midribs	O
of	O	O
the	O	O
10th	O	O
newly	O	O
expanded	O	O
leaves	B-LIVB
of	O	O
maize	B-LIVB
plants	I-LIVB
.	O	O

Microscopy	B-PROC
revealed	O	O
the	O	O
existence	O	O
of	O	O
substantial	O	O
amounts	O	O
of	O	O
sclerenchyma	B-ANAT
underneath	O	O
maize	B-LIVB
midrib	O
epidermises	B-LIVB
(	O	O
particularly	O	O
abaxial	O
epidermises	B-LIVB
)	O	O
.	O	O

The	O	O
spot	O	O
-	O	O
number	O	O
order	O	O
obtained	O	O
via	O	O
2DE	B-PROC
mapping	I-PROC
was	O	O
as	O	O
follows	O	O
:	O	O
phenol	B-CHEM
extraction	B-PROC
(	O	O
655	O	O
)	O	O
>	O	O
TCA	B-CHEM
/	O	O
acetone	B-CHEM
extraction	B-PROC
(	O	O
589	O	O
)	O	O
>	O	O
TCA	B-CHEM
/	O	O
acetone	B-CHEM
/	O	O
phenol	B-CHEM
extraction	B-PROC
(	O	O
545	O	O
)	O	O
.	O	O

MS	B-PROC
/	I-PROC
MS	I-PROC
analysis	I-PROC
identified	O	O
a	O	O
total	O	O
of	O	O
17	O	O
spots	O
that	O	O
exhibited	O	O
2	O	O
-	O	O
fold	O	O
changes	O	O
in	O	O
abundance	O	O
among	O	O
the	O	O
three	O
methods	O	O
(	O	O
using	O	O
phenol	B-CHEM
extraction	B-PROC
as	O	O
a	O	O
control	B-LIVB
)	O	O
.	O	O

Sixteen	O	O
of	O	O
the	O	O
proteins	B-CHEM
identified	O	O
were	O	O
hydrophilic	O
,	O	O
with	O	O
GRAVY	O
values	O
ranging	O	O
from	O	O
-0	O	O
.	O	O

026	O	O
to	O	O
-0	O	O
.	O	O
487	O	O
.	O	O

For	O	O
all	O	O
three	O
methods	O	O
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
obtain	O	O
high	O	O
-	O	O
quality	O	O
protein	B-CHEM
samples	O	O
and	O	O
good	O	O
2DE	B-PROC
maps	I-PROC
for	O	O
the	O	O
maize	B-LIVB
leaf	B-LIVB
midrib	O
.	O	O

However	O	O
,	O	O
phenol	B-CHEM
extraction	B-PROC
produced	O	O
a	O	O
better	O	O
2DE	B-PROC
map	I-PROC
with	O	O
greater	O	O
resolution	O
between	O	O
spots	O
,	O	O
and	O	O
TCA	B-CHEM
/	O	O
acetone	B-CHEM
extraction	B-PROC
produced	O	O
higher	O	O
protein	B-CHEM
yields	O
.	O	O

Thus	O	O
,	O	O
this	O	O
paper	O	O
includes	O	O
a	O	O
discussion	O	O
regarding	O	O
the	O	O
possible	O	O
reasons	O	O
for	O	O
differential	O
protein	B-PROC
extraction	I-PROC
among	O	O
the	O	O
three	O
methods	O	O
.	O	O

This	O	O
study	O	O
provides	O	O
useful	O	O
information	O	O
that	O	O
can	O	O
be	O	O
used	O	O
to	O	O
select	O	O
suitable	O	O
protein	B-PROC
extraction	I-PROC
methods	O	O
for	O	O
the	O	O
proteome	B-CHEM
analysis	B-PROC
of	O	O
recalcitrant	O	O
plant	B-ANAT
tissues	I-ANAT
that	O	O
are	O	O
rich	O	O
in	O	O
sclerenchyma	B-ANAT
cells	I-ANAT
.	O	O

Comparison	O
of	O	O
Individual	B-LIVB
Radiosensitivity	B-PHYS
to	O	O
γ	B-PHEN
-	I-PHEN
Rays	I-PHEN
and	O	O
Carbon	B-CHEM
Ions	I-CHEM
Carbon	B-CHEM
ions	I-CHEM
are	O	O
an	O	O
up	O	O
-	O	O
and	O	O
-	O	O
coming	O	O
ion	B-CHEM
species	I-CHEM
,	O	O
currently	O	O
being	O	O
used	O	O
in	O	O
charged	B-PROC
particle	I-PROC
radiotherapy	I-PROC
.	O	O

As	O	O
it	O	O
is	O	O
well	O	O
established	O	O
that	O	O
there	O	O
are	O	O
considerable	O	O
interindividual	B-LIVB
differences	O
in	O	O
radiosensitivity	B-PHYS
in	O	O
the	O	O
general	B-LIVB
population	I-LIVB
that	O	O
can	O	O
significantly	O	O
influence	O	O
clinical	B-PHEN
outcomes	I-PHEN
of	O	O
radiotherapy	B-PROC
,	O	O
we	O	O
evaluate	O	O
the	O	O
degree	O
of	O	O
these	O	O
differences	O
in	O	O
the	O	O
context	O	O
of	O	O
carbon	B-PROC
ion	I-PROC
therapy	I-PROC
compared	O	O
with	O	O
conventional	O
radiotherapy	B-PROC
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluate	O	O
individual	B-LIVB
radiosensitivity	B-PHYS
following	O	O
exposure	O
to	O
carbon	B-CHEM
-	I-CHEM
13	I-CHEM
ions	B-CHEM
or	O	O
γ	B-PHEN
-	I-PHEN
rays	I-PHEN
in	O	O
peripheral	B-ANAT
blood	I-ANAT
lymphocytes	I-ANAT
of	O	O
healthy	O
individuals	B-LIVB
based	O	O
on	O	O
the	O	O
frequency	O
of	O	O
ionizing	B-PHEN
radiation	I-PHEN
(	O	O
IR	B-PHEN
)	O	O
-	O	O
induced	O
DNA	B-DISO
double	I-DISO
strand	I-DISO
breaks	I-DISO
(	O	O
DSBs	B-DISO
)	O	O
that	O	O
was	O	O
either	O	O
misrepaired	O	O
or	O	O
left	O	O
unrepaired	O	O
to	O	O
form	O	O
chromosomal	B-DISO
aberrations	I-DISO
(	O	O
CAs	B-DISO
)	O	O
(	O	O
simply	O	O
referred	O	O
to	O	O
here	O	O
as	O	O
DSBs	B-DISO
for	O	O
brevity	O	O
)	O	O
.	O	O

Levels	O
of	O	O
DSBs	B-DISO
were	O	O
estimated	O	O
from	O	O
the	O	O
scoring	O
of	O	O
CAs	B-DISO
visualized	O	O
with	O	O
telomere	B-ANAT
/	O	O
centromere	B-ANAT
-	O	O
fluorescence	B-PROC
in	I-PROC
situ	I-PROC
hybridization	I-PROC
(	O	O
TC	B-PROC
-	I-PROC
FISH	I-PROC
)	O	O
.	O	O

We	O	O
examine	O	O
radiosensitivity	B-PHYS
at	O	O
the	O	O
dose	O
of	O	O
2	O	O
Gy	O	O
,	O	O
a	O	O
routinely	O	O
administered	O
dose	O
during	O	O
fractionated	B-PROC
radiotherapy	I-PROC
,	O	O
and	O	O
we	O	O
determined	O	O
that	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
DSBs	B-DISO
were	O	O
induced	O
by	O	O
the	O	O
given	O
dose	O
among	O	O
healthy	O
individuals	B-LIVB
,	O	O
with	O	O
highly	O	O
radiosensitive	O
individuals	B-LIVB
harboring	O	O
more	O	O
IR	B-PHEN
-	O	O
induced	O
breaks	O
in	O	O
the	O	O
genome	O
than	O	O
radioresistant	O
individuals	B-LIVB
following	O	O
exposure	B-DISO
to	I-DISO
the	O	O
same	O	O
dose	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
relative	O
effectiveness	O
of	O	O
carbon	B-CHEM
irradiation	B-PROC
in	O	O
comparison	O	O
to	O	O
γ	B-PROC
-	I-PROC
irradiation	I-PROC
in	O	O
the	O	O
induction	O
of	O	O
DSBs	B-DISO
at	O	O
each	O	O
studied	O	O
dose	O
(	O	O
isodose	O
effect	O
)	O	O
,	O	O
a	O	O
quality	O	O
we	O	O
term	O	O
""""	O	O
relative	O
dose	O
effect	O
""""	O	O
(	O	O
RDE	O
)	O	O
.	O	O

This	O	O
ratio	O
is	O	O
advantageous	O	O
,	O	O
as	O	O
it	O	O
allows	O	O
for	O	O
simple	O	O
comparison	O	O
of	O	O
dose	O
-	O
response	O
curves	O
.	O	O

At	O	O
2	O	O
Gy	O	O
,	O	O
carbon	B-PROC
irradiation	I-PROC
was	O	O
three	O	O
times	O	O
more	O	O
effective	O
in	O	O
inducing	O
DSBs	B-DISO
compared	O	O
with	O	O
γ	B-PROC
-	I-PROC
irradiation	I-PROC
(	O	O
RDE	O
of	O	O
3	O	O
)	O	O
;	O	O
these	O	O
results	O	O
were	O	O
confirmed	O	O
using	O	O
a	O	O
second	O	O
cytogenetic	B-PROC
technique	I-PROC
,	O	O
multicolor	B-PROC
-	I-PROC
FISH	I-PROC
.	O	O

We	O	O
also	O	O
analyze	O	O
radiosensitivity	B-PHYS
at	O	O
other	O	O
doses	O
(	O	O
0	O	O
.	O	O
2	O	O
-	O	O
15	O	O
Gy	O	O
)	O	O
,	O	O
to	O	O
represent	O	O
hypo	B-PROC
-	O	O
and	O	O
hyperfractionation	O
doses	O
and	O	O
determined	O	O
that	O	O
RDE	O
is	O	O
dose	O
dependent	O
:	O	O
high	O	O
ratios	O	O
at	O	O
low	B-PROC
doses	I-PROC
,	O	O
and	O	O
approaching	O	O
1	O	O
at	O	O
high	O	O
doses	O
.	O	O

These	O	O
results	O	O
could	O	O
have	O	O
clinical	O
implications	O
as	O	O
IR	B-DISO
-	I-DISO
induced	I-DISO
DNA	I-DISO
damage	I-DISO
and	O	O
the	O	O
ensuing	O	O
CAs	B-DISO
and	O	O
genomic	B-DISO
instability	I-DISO
can	O	O
have	O	O
significant	O
cellular	B-ANAT
consequences	O
that	O	O
could	O	O
potentially	O	O
have	O	O
profound	O
implications	O
for	O	O
long	O
-	O
term	O
human	B-DISO
health	I-DISO
after	O	O
IR	B-DISO
exposure	I-DISO
,	O	O
such	O	O
as	O	O
the	O	O
emergence	O	O
of	O	O
secondary	B-DISO
cancers	I-DISO
and	O	O
other	O	O
pathobiological	O
conditions	O
after	O	O
radiotherapy	B-PROC
.	O	O

Dynamic	B-PROC
Contrast	I-PROC
-	I-PROC
enhanced	I-PROC
MR	I-PROC
Imaging	I-PROC
in	O	O
Renal	B-DISO
Cell	I-DISO
Carcinoma	I-DISO
:	O	O
Reproducibility	O
of	O	O
Histogram	B-OBJC
Analysis	O	O
on	O	O
Pharmacokinetic	O
Parameters	O
Pharmacokinetic	O
parameters	O
derived	O	O
from	O	O
dynamic	B-PROC
contrast	I-PROC
-	I-PROC
enhanced	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
)	O	O
have	O	O
been	O	O
increasingly	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
permeability	B-PHEN
of	O	O
tumor	B-DISO
vessel	I-DISO
.	O	O

Histogram	B-OBJC
metrics	O	O
are	O	O
a	O	O
recognized	O	O
promising	O	O
method	O	O
of	O	O
quantitative	O	O
MR	B-PROC
imaging	I-PROC
that	O	O
has	O	O
been	O	O
recently	O	O
introduced	O	O
in	O	O
analysis	O	O
of	O	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
in	O	O
oncology	O
due	O	O
to	O	O
tumor	O
heterogeneity	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
21	O	O
patients	B-LIVB
with	O	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
RCC	B-DISO
)	O	O
underwent	O	O
paired	O	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
studies	O	O
on	O	O
a	O	O
3	O	O
.	O	O
0	O	O
T	O	O
MR	B-DEVI
system	I-DEVI
.	O	O

Extended	O	O
Tofts	O
model	O
and	O	O
population	B-PROC
-	I-PROC
based	I-PROC
arterial	O
input	O
function	O
were	O	O
used	O	O
to	O	O
calculate	O	O
kinetic	O
parameters	O
of	O	O
RCC	B-DISO
tumors	B-DISO
.	O	O

Mean	O
value	O
and	O	O
histogram	B-OBJC
metrics	O	O
(	O	O
Mode	O
,	O	O
Skewness	O
and	O	O
Kurtosis	O
)	O	O
of	O	O
each	O	O
pharmacokinetic	O
parameter	O	O
were	O	O
generated	O	O
automatically	O	O
using	O	O
ImageJ	O
software	O
.	O	O

Intra	O
-	O
and	O	O
inter	O
-	O
observer	O
reproducibility	O
and	O	O
scan	O	O
-	O	O
rescan	O	O
reproducibility	O
were	O	O
evaluated	O	O
using	O	O
intra	O
-	O
class	O
correlation	O
coefficients	O
(	O	O
ICCs	O
)	O	O
and	O	O
coefficient	O
of	O
variation	O
(	O	O
CoV	O
)	O	O
.	O	O

Our	O	O
results	O	O
demonstrated	O	O
that	O	O
the	O	O
histogram	B-OBJC
method	O	O
(	O	O
Mode	O
,	O	O
Skewness	O
and	O	O
Kurtosis	O
)	O	O
was	O	O
not	O	O
superior	O	O
to	O	O
the	O	O
conventional	O	O
Mean	O
value	O
method	O	O
in	O	O
reproducibility	O
evaluation	O	O
on	O	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
(	O	O
K	O	O
(	O	O
trans	O	O
)	O	O
&	O	O
Ve	O	O
)	O	O
in	O	O
renal	B-DISO
cell	I-DISO
carcinoma	I-DISO
,	O	O
especially	O	O
for	O	O
Skewness	O
and	O
Kurtosis	O
which	O	O
showed	O	O
lower	O	O
intra	O
-	O
,	O	O
inter	O
-	O
observer	O
and	O	O
scan	O	O
-	O	O
rescan	O	O
reproducibility	O
than	O	O
Mean	O
value	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
additional	O	O
studies	O	O
are	O	O
necessary	O	O
before	O	O
wide	O	O
incorporation	O	O
of	O	O
histogram	B-OBJC
metrics	O	O
in	O	O
quantitative	O
analysis	O	O
of	O	O
DCE	B-PROC
-	I-PROC
MRI	I-PROC
pharmacokinetic	O
parameters	O
.	O	O

Catastrophic	B-DISO
health	O
expenditure	O
:	O	O
a	O	O
comparative	B-PROC
analysis	I-PROC
of	O	O
empty	O
-	O
nest	O
and	O	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
with	O	O
seniors	B-LIVB
in	O	O
Shandong	B-GEOG
,	I-GEOG
China	I-GEOG
The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
compare	O
the	O	O
catastrophic	B-DISO
health	O
expenditure	O
(	O	O
CHE	O
)	O	O
prevalence	O
and	O	O
its	O	O
determinants	O
between	O	O
empty	O
-	O
nest	O
and	O	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-LIVB
households	B-LIVB
.	O	O

Shandong	B-GEOG
province	I-GEOG
of	I-GEOG
China	I-GEOG
.	O	O

A	O	O
total	O
of	O	O
2761	O	O
elderly	B-LIVB
households	B-LIVB
are	O	O
included	O
in	O	O
the	O	O
analysis	B-PROC
.	O	O

CHE	O
incidence	O
among	O	O
elderly	B-LIVB
households	B-LIVB
was	O	O
44	O	O
.	O	O

9	O	O
%	O	O
.	O	O

The	O	O
CHE	O
incidence	O
of	O	O
empty	O
-	O
nest	O
singles	B-DISO
(	O	O
59	O	O
.	O	O
3	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

000	O	O
,	O	O
OR	O	O
=	O	O
3	O	O
.	O	O

19	O	O
)	O	O
and	O	O
empty	O
-	O
nest	O
couples	B-LIVB
(	O	O
52	O	O
.	O	O
9	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

000	O	O
,	O	O
OR	O	O
=	O	O
2	O	O
.	O	O

45	O	O
)	O	O
are	O	O
both	O	O
statistically	O
higher	O
than	O	O
that	O	O
of	O	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-LIVB
households	B-LIVB
(	O	O
31	O	O
.	O	O

4	O	O
%	O	O
)	O	O
.	O	O

An	O	O
inverse	O
association	O
was	O	O
observed	O
between	O	O
CHE	O
incidence	O
and	O	O
income	O
level	O
in	O	O
all	O	O
elderly	B-LIVB
household	B-LIVB
types	O
.	O	O

Factors	O
including	O
1	O	O
or	O	O
more	O	O
household	B-LIVB
elderly	B-LIVB
members	I-LIVB
with	O	O
non	B-DISO
-	I-DISO
communicable	I-DISO
chronic	I-DISO
diseases	I-DISO
in	O	O
the	O	O
past	O	O
6	O	O
months	O	O
,	O	O
1	O	O
or	O	O
more	O	O
elderly	B-LIVB
household	B-LIVB
members	I-LIVB
being	O	O
hospitalised	B-DISO
in	O	O
the	O	O
past	O
year	O
and	O	O
lower	O
household	B-LIVB
income	O
,	O	O
are	O	O
significant	O
risk	B-DISO
factors	I-DISO
for	O	O
CHE	O
in	O	O
all	O	O
3	O	O
household	B-LIVB
types	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Health	B-PROC
insurance	I-PROC
status	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
significant	O
determinant	O
of	O	O
CHE	O
among	O	O
empty	O
-	O
nest	O
singles	B-DISO
and	O	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

CHE	O
incidence	O
among	O	O
elderly	B-LIVB
households	B-LIVB
is	O	O
high	O
in	O	O
China	B-GEOG
.	O	O

Empty	O
-	O
nest	O
households	B-LIVB
are	O	O
at	O	O
higher	O
risk	O
for	O	O
CHE	O
than	O	O
non	O
-	O
empty	O
-	O
nest	O
households	B-LIVB
.	O	O

Based	O	O
on	O	O
these	O	O
findings	B-DISO
,	O	O
we	O	O
suggest	O
that	O	O
special	O
insurance	B-PROC
be	O	O
developed	O	O
to	O	O
broaden	O
the	O	O
coverage	O
of	O	O
health	B-PROC
services	I-PROC
and	O	O
heighten	O
the	O	O
reimbursement	B-PROC
rate	I-PROC
for	O	O
empty	O
-	O
nest	O
elderly	B-LIVB
in	O	O
the	O	O
existing	O	O
health	B-PROC
insurance	I-PROC
schemes	O
.	O	O

Financial	O
and	O	O
social	O
protection	O
interventions	B-PROC
are	O	O
also	O	O
essential	O
for	O	O
identifie	O
d	O	O
at	O
-	O
risk	O
subgroups	O
among	O	O
different	O	O
types	O	O
of	O	O
elderly	B-LIVB
households	B-LIVB
.	O	O

Antidiabetic	B-CHEM
potential	O
of	O	O
bioactive	B-OBJC
molecules	I-OBJC
coated	O	O
chitosan	B-CHEM
nanoparticles	I-CHEM
in	O	O
experimental	O
rats	B-LIVB
The	O	O
present	O	O
study	B-PROC
was	O	O
carried	O	O
out	O	O
to	O	O
examine	O	O
the	O	O
antidiabetic	B-CHEM
effects	O
of	O
chitosan	B-CHEM
nanoparticles	I-CHEM
(	O	O
CNPs	B-CHEM
)	O	O
loaded	O	O
with	O	O
(	O	O
Stevia	B-CHEM
rebaudiana	I-CHEM
leaf	I-CHEM
extract	I-CHEM
-	O	O
SRLE	B-CHEM
)	O	O
bioactive	B-OBJC
molecules	I-OBJC
in	O	O
a	O	O
rat	B-LIVB
model	B-DISO
of	O	O
streptozotocin	B-CHEM
(	O	O
STZ	B-CHEM
)	O	O
induced	O
diabetes	B-DISO
mellitus	I-DISO
.	O	O

Successful	O	O
crosslinking	B-PHEN
of	O	O
the	O	O
bioactive	B-OBJC
molecules	I-OBJC
to	O	O
the	O	O
chitosan	B-CHEM
nanoparticles	I-CHEM
was	O	O
confirmed	O	O
by	O	O
Fourier	B-PROC
Transform	I-PROC
Infrared	I-PROC
Spectroscopy	I-PROC
(	O	O
FTIR	B-PROC
)	O	O
.	O	O

The	O	O
colloidal	O
characteristics	O
of	O	O
the	O	O
synthesized	O
nanoparticles	B-CHEM
were	O	O
revealed	O	O
by	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
Diffraction	I-PROC
(	I-PROC
XRD	I-PROC
)	I-PROC
analysis	I-PROC
.	O	O

Morphological	O
analysis	B-PROC
by	O	O
Transmission	B-PROC
Electron	I-PROC
Microscopy	I-PROC
(	O	O
TEM	B-PROC
)	O	O
revealed	O	O
that	O	O
the	O	O
bioactive	B-OBJC
molecule	I-OBJC
-loaded	O	O
CNPs	B-CHEM
were	O	O
well	O
-	O
dispersed	O
and	O	O
spherical	O
or	O	O
polygonal	O
in	O	O
shape	O
with	O	O
an	O	O
average	O
size	O
of	O	O
<	O	O
73	O	O
.	O	O
27	O	O
nm	O	O
than	O	O
the	O	O
z	O
-	O
average	O
value	O
(	O	O
327	O	O
nm	O	O
)	O	O
as	O	O
measured	O	O
by	O	O
Dynamic	B-PROC
Light	I-PROC
Scattering	I-PROC
(	O	O
DLS	B-PROC
)	O	O
.	O	O

SRLE	B-CHEM
CNP	B-CHEM
-	O	O
treated	O
diabetic	B-DISO
rats	B-LIVB
showed	O	O
a	O	O
significant	O
reduction	O
in	O	O
their	O	O
mean	O	O
fasting	B-PHEN
blood	I-PHEN
glucose	I-PHEN
level	I-PHEN
compared	O	O
with	O	O
the	O	O
diabetic	B-DISO
control	B-LIVB
group	I-LIVB
.	O	O

The	O	O
serum	B-ANAT
levels	O
of	O	O
various	O	O
enzymes	B-CHEM
viz	O	O
.	O	O
,	O	O
serum	B-CHEM
glutamic	I-CHEM
oxaloacetic	I-CHEM
transaminase	I-CHEM
(	O	O
SGOT	B-CHEM
)	O	O
,	O	O
serum	B-CHEM
glutamic	I-CHEM
pyruvic	I-CHEM
transaminase	I-CHEM
(	O	O
SGPT	B-CHEM
)	O	O
,	O	O
alkaline	B-CHEM
phosphatases	I-CHEM
(	O	O
ALP	B-CHEM
)	O	O
,	O	O
lipid	B-PHYS
peroxidation	I-PHYS
,	O	O
and	O	O
antioxidant	B-CHEM
such	O	O
as	O	O
catalase	B-CHEM
(	O	O
CAT	B-CHEM
)	O	O
,	O	O
reduced	B-PHEN
glutathione	I-PHEN
(	O	O
GSH	B-PHEN
)	O	O
,	O	O
and	O	O
superoxide	B-CHEM
dismutase	I-CHEM
(	O	O
SOD	B-CHEM
)	O	O
in	O	O
the	O	O
SRLE	B-CHEM
CNP	B-CHEM
-	O	O
treated	O
group	O
were	O	O
closer	O	O
to	O	O
normal	O
levels	O
than	O	O
those	O	O
in	O	O
the	O	O
diabetic	B-DISO
control	B-LIVB
group	I-LIVB
.	O	O

Role	O	O
of	O	O
agonistic	B-CHEM
autoantibodies	I-CHEM
against	O	O
type	B-CHEM
-	I-CHEM
1	I-CHEM
angiotensin	I-CHEM
II	I-CHEM
receptor	I-CHEM
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
retinopathy	B-DISO
in	O	O
preeclampsia	B-DISO
To	O	O
investigate	O
the	O	O
mechanism	O
underlying	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
-induced	O	O
retinopathy	B-DISO
in	O	O
severe	O	O
preeclampsia	B-DISO
by	O	O
measuring	O	O
the	O	O
positive	O
rate	O
and	O	O
titer	O
of	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
in	O	O
plasma	B-ANAT
from	O	O
women	B-LIVB
with	O	O
severe	B-DISO
preeclampsia	I-DISO
and	O	O
normal	O	O
pregnant	B-LIVB
women	I-LIVB
to	O	O
see	O	O
whether	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
titer	O
was	O	O
correlated	O
with	O	O
the	O	O
grade	O	O
of	O	O
retinopathy	B-DISO
.	O	O

A	O	O
preeclampsia	B-DISO
rat	B-LIVB
model	B-LIVB
was	O	O
also	O	O
established	O	O
by	O	O
intravenous	O
injection	O
of	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
extracted	O	O
from	O	O
the	O	O
plasma	B-ANAT
of	O	O
patient	B-LIVB
suffering	O	O
from	O	O
severe	B-DISO
preeclampsia	I-DISO
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
the	O	O
plasma	B-ANAT
titer	O
and	O	O
positive	O
rate	O
of	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
were	O	O
significantly	O	O
higher	O	O
in	O	O
women	B-LIVB
with	O	O
severe	B-DISO
preeclampsia	I-DISO
than	O	O
normal	O	O
pregnant	B-LIVB
women	I-LIVB
.	O	O

The	O	O
antibody	B-CHEM
titer	O
in	O	O
cases	O	O
of	O	O
severe	O	O
preeclampsia	B-DISO
was	O	O
associated	O	O
with	O	O
the	O	O
grade	O	O
of	O	O
retinopathy	B-DISO
,	O	O
and	O	O
positively	O	O
correlated	O
with	O	O
the	O	O
level	O	O
of	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O	O
VEGF	B-CHEM
.	O	O

The	O	O
animal	B-PROC
experiment	I-PROC
results	O
showed	O	O
that	O	O
the	O	O
modeled	B-LIVB
rats	I-LIVB
presented	O	O
symptoms	B-DISO
very	O	O
similar	O	O
to	O	O
symptoms	B-DISO
of	O	O
human	B-LIVB
preeclampsia	B-DISO
,	O	O
including	O	O
retinopathy	B-DISO
.	O	O

Ocular	B-ANAT
fundus	I-ANAT
examination	B-PROC
showed	O	O
retinal	B-DISO
microvascular	I-DISO
abnormalities	I-DISO
,	O	O
hemorrhaging	B-DISO
and	O	O
leakage	B-DISO
in	O	O
the	O	O
severe	B-DISO
preeclampsia	I-DISO
.	O	O

Morphological	O
changes	O
included	O	O
edema	B-DISO
,	O	O
thickening	B-DISO
of	O	O
the	O	O
INL	B-ANAT
and	O	O
ONL	B-ANAT
,	O	O
and	O	O
pigment	B-DISO
atrophy	I-DISO
.	O	O

TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O	O
VEGF	B-CHEM
levels	O	O
were	O	O
increased	O	O
in	O	O
the	O	O
vitreous	B-ANAT
humor	I-ANAT
and	O	O
retina	B-ANAT
of	O	O
the	O	O
model	B-LIVB
rats	I-LIVB
.	O	O

Our	O	O
studies	B-PROC
results	O
suggest	O	O
that	O	O
abnormal	B-PHYS
expression	I-PHYS
of	O	O
AT1	B-CHEM
-	I-CHEM
AA	I-CHEM
could	O	O
induce	O	O
damage	O
to	O	O
retinal	B-ANAT
capillary	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
and	O	O
increase	O	O
vascular	B-PHYS
permeability	I-PHYS
,	O	O
resulting	O
in	O
retinopathy	B-DISO
.	O	O

Monosubstituted	B-CHEM
Benzene	I-CHEM
Derivatives	I-CHEM
from	O	O
Fruits	B-OBJC
of	O	O
Ficus	B-LIVB
hirta	I-LIVB
and	O	O
Their	O	O
Antifungal	B-DISO
Activity	I-DISO
against	O
Phytopathogen	B-LIVB
Penicillium	B-LIVB
italicum	I-LIVB
Ficus	B-LIVB
hirta	I-LIVB
,	O	O
a	O	O
widely	O	O
consumed	O	O
food	B-OBJC
by	O	O
Hakka	O
people	B-LIVB
,	O	O
has	O	O
been	O	O
reported	B-PROC
to	O	O
show	O	O
potent	O	O
antifungal	B-DISO
activity	I-DISO
against	O
phytopathogen	B-LIVB
Penicillium	B-LIVB
italicum	I-LIVB
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
report	B-PROC
of	O	O
chemical	B-OBJC
constituents	I-OBJC
responsible	O	O
for	O	O
the	O	O
antifungal	B-DISO
activity	I-DISO
.	O	O

In	O	O
the	O	O
current	O	O
study	B-PROC
,	O	O
nine	O	O
monosubstituted	B-CHEM
benzene	I-CHEM
derivatives	I-CHEM
,	O	O
including	O	O
three	O	O
new	O	O
derivatives	B-CHEM
(	O	O
1	O	O
-	O	O
3	O	O
)	O	O
,	O	O
were	O	O
isolated	O
from	O	O
the	O	O
fruits	B-OBJC
of	O	O
F	B-LIVB
.	I-LIVB

hirta	I-LIVB
.	O	O

The	O	O
structures	O
of	O	O
these	O	O
isolates	B-CHEM
were	O	O
elucidated	O	O
on	O	O
the	O	O
basis	O
of	O	O
the	O	O
analysis	B-PROC
of	O	O
spectroscopic	O
data	O
(	O	O
mass	B-PROC
spectrometry	I-PROC
and	O	O
nuclear	B-PHEN
magnetic	I-PHEN
resonance	I-PHEN
)	O	O
.	O	O

All	O	O
of	O	O
the	O	O
isolates	B-CHEM
were	O	O
evaluated	B-PROC
for	O	O
antifungal	B-DISO
activities	I-DISO
against	O
P	B-LIVB
.	I-LIVB

italicum	I-LIVB
.	O	O

At	O	O
an	O	O
equivalent	O
concentration	O
,	O	O
compound	O
1	O	O
exhibited	O	O
stronger	O
antifungal	B-DISO
activity	I-DISO
than	O	O
that	O	O
of	O	O
the	O	O
ethanol	B-CHEM
extract	B-OBJC
of	O	O
F	B-LIVB
.	I-LIVB

hirta	I-LIVB
fruits	B-OBJC
.	O	O

Characterizing	O
sexual	B-PHYS
function	I-PHYS
in	O	O
patients	B-LIVB
with	O	O
generalized	B-DISO
anxiety	I-DISO
disorder	I-DISO
:	O	O
a	O	O
pooled	B-PROC
analysis	I-PROC
of	O	O
three	O	O
vilazodone	B-CHEM
studies	B-PROC
Vilazodone	B-CHEM
has	O	O
been	O	O
shown	O	O
to	O	O
reduce	O
core	B-DISO
symptoms	I-DISO
of	O	O
generalized	B-DISO
anxiety	I-DISO
disorder	I-DISO
(	O	O
GAD	B-DISO
)	O	O
in	O	O
three	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
trials	I-PROC
.	O	O

Since	O	O
sexual	B-DISO
dysfunction	I-DISO
(	O	O
SD	B-DISO
)	O	O
is	O	O
not	O	O
well	O	O
characterized	O	O
in	O	O
GAD	B-DISO
,	O	O
a	O	O
post	B-PROC
hoc	I-PROC
analysis	I-PROC
of	O	O
these	O	O
trials	B-PROC
was	O	O
conducted	O	O
to	O	O
evaluate	B-PROC
the	O	O
effects	O
of	O
vilazodone	B-CHEM
on	O	O
sexual	B-PHYS
functioning	I-PHYS
in	O	O
GAD	B-DISO
patients	B-LIVB
.	O	O

Data	O
were	O	O
pooled	O
from	O	O
one	O	O
fixed	B-PROC
-	I-PROC
dose	I-PROC
trial	I-PROC
of	O	O
vilazodone	B-CHEM
20	O	O
and	O	O
40	O	O
mg	O
/	O
day	O
(	O	O
NCT01629966	O
)	O	O
and	O	O
two	O	O
flexible	B-PROC
-	I-PROC
dose	I-PROC
studies	I-PROC
of	O	O
vilazodone	B-CHEM
20	O	O
-	O	O
40	O	O
mg	O
/	O
day	O
(	O	O
NCT01766401	O
,	O	O
NCT01844115	O
)	O	O
in	O	O
adults	B-LIVB
with	O	O
GAD	B-DISO
.	O	O

Sexual	B-PHYS
functioning	I-PHYS
was	O	O
assessed	O
using	O	O
the	O	O
Changes	O
in	O
Sexual	O
Functioning	O
Questionnaire	O
(	O	O
CSFQ	O
)	O	O
.	O	O

Outcomes	B-PROC
included	O	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
(	O	O
EOT	O
)	O	O
in	O	O
CSFQ	B-DISO
total	I-DISO
score	I-DISO
and	O	O
percentage	O
of	O	O
patients	B-LIVB
shifting	O
from	O	O
SD	B-DISO
at	O	O
baseline	O
(	O	O
CSFQ	B-DISO
total	I-DISO
score	I-DISO
≤47	O	O
for	O	O
males	B-LIVB
,	O	O
≤41	O	O
for	O	O
females	B-LIVB
)	O	O
to	O	O
normal	B-DISO
functioning	I-DISO
at	O	O
EOT	O
.	O	O

Treatment	B-DISO
-	I-DISO
emergent	I-DISO
adverse	I-DISO
events	I-DISO
related	O	O
to	O	O
sexual	B-PHYS
functioning	I-PHYS
were	O	O
also	O	O
analyzed	B-PROC
.	O	O

A	O	O
total	O
of	O	O
1	O	O
,	O	O
373	O	O
patients	B-LIVB
were	O	O
included	O	O
in	O	O
the	O	O
analyses	B-PROC
.	O	O

SD	B-DISO
at	O	O
baseline	O
was	O	O
more	O	O
common	O	O
in	O	O
females	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
46	O	O
.	O	O
4	O	O
%	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
49	O	O
%	O	O
)	O	O
than	O	O
in	O	O
males	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
35	O	O
.	O	O
1	O	O
%	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
40	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

CSFQ	B-DISO
total	I-DISO
score	I-DISO
improvement	O
was	O	O
found	O	O
in	O	O
both	O	O
females	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
+1	O	O
.	O	O

2	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
+1	O	O
.	O	O

6	O	O
)	O	O
and	O	O
males	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
+2	O	O
.	O	O
1	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
+1	O	O
.	O	O

0	O	O
)	O	O
,	O	O
with	O	O
no	B-DISO
statistically	I-DISO
significant	I-DISO
differences	I-DISO
between	O	O
treatment	O
groups	O
.	O	O

The	O	O
percentage	O
of	O	O
patients	B-LIVB
who	O	O
shifted	O
from	O	O
SD	B-DISO
at	O	O
baseline	O
to	O	O
normal	O
sexual	B-PHYS
functioning	I-PHYS
at	O	O
EOT	O
was	O	O
higher	O	O
in	O	O
males	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
40	O	O
.	O	O

6	O	O
%	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
35	O	O
.	O	O
7	O	O
%	O	O
)	O	O
than	O	O
in	O	O
females	B-LIVB
(	O	O
placebo	B-CHEM
,	O	O
24	O	O
.	O	O
9	O	O
%	O	O
;	O	O
vilazodone	B-CHEM
,	O	O
34	O	O
.	O	O
9	O	O
%	O	O
)	O	O
;	O	O
no	B-DISO
statistical	I-DISO
testing	I-DISO
was	O	O
performed	O	O
.	O	O

Except	O	O
for	O	O
erectile	B-DISO
dysfunction	I-DISO
and	O	O
delayed	B-DISO
ejaculation	I-DISO
in	O	O
vilazodone	B-CHEM
-	O	O
treated	O
males	B-LIVB
(	O	O
2	O	O
.	O	O
4	O	O
%	O	O
and	O	O
2	O	O
.	O	O
1	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
no	B-DISO
treatment	I-DISO
-	I-DISO
emergent	I-DISO
adverse	I-DISO
events	I-DISO
related	O	O
to	O	O
sexual	B-PHYS
functioning	I-PHYS
occurred	O
in	O	O
≥2	O	O
%	O	O
of	O	O
patients	B-LIVB
in	O	O
either	O	O
treatment	O
group	O
.	O	O

Approximately	O
35	O	O
%	O	O
-	O	O
50	O	O
%	O	O
of	O	O
patients	B-LIVB
in	O	O
the	O	O
vilazodone	B-CHEM
GAD	B-DISO
studies	B-PROC
had	O	O
SD	B-DISO
at	O	O
baseline	O
.	O	O

Vilazodone	B-CHEM
and	O	O
placebo	B-CHEM
had	O	O
similar	O	O
effects	O
on	O	O
CSFQ	O
outcomes	B-PROC
in	O	O
both	O	O
females	B-LIVB
and	O	O
males	B-LIVB
,	O	O
indicating	O	O
a	O	O
limited	O
adverse	B-DISO
impact	I-DISO
on	O	O
sexual	B-PHYS
functioning	I-PHYS
with	O	O
vilazodone	B-CHEM
.	O	O

Effects	O
of	O
analgesics	B-CHEM
and	O	O
antidepressants	B-CHEM
on	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
currents	B-PHYS
TWIK	B-CHEM
-	I-CHEM
related	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
channel	I-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
)	O	O
and	O	O
TWIK	B-CHEM
-	I-CHEM
related	I-CHEM
spinal	I-CHEM
cord	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
(	I-CHEM
TRESK	I-CHEM
)	I-CHEM
channel	I-CHEM
are	O	O
members	O	O
of	O	O
two	B-CHEM
-	I-CHEM
pore	I-CHEM
domain	I-CHEM
K	I-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
channel	I-CHEM
family	I-CHEM
.	O	O

They	O	O
are	O	O
well	O	O
expressed	B-PHYS
and	O	O
help	O	O
to	O	O
set	O	O
the	O	O
resting	B-PHYS
membrane	I-PHYS
potential	I-PHYS
in	O	O
sensory	B-ANAT
neurons	I-ANAT
.	O	O

Modulation	B-PHEN
of	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
channels	I-CHEM
are	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
pain	B-DISO
,	O	O
and	O	O
specifi	O
c	O
activators	B-CHEM
of	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
may	O	O
be	O	O
benefi	O
cial	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
pain	B-DISO
symptoms	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
effect	O
of	O
commonly	O	O
used	O	O
analgesics	B-CHEM
on	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
channels	I-CHEM
are	O	O
not	O	O
known	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O
of	O
analgesics	B-CHEM
on	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
channels	B-CHEM
.	O	O

The	O	O
effects	O
of	O
analgesics	B-CHEM
were	O	O
examined	O	O
in	O	O
HEK	B-ANAT
cells	I-ANAT
transfected	B-PROC
with	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
or	O	O
TRESK	B-CHEM
.	O	O

Amitriptyline	B-CHEM
,	O	O
citalopram	B-CHEM
,	O	O
escitalopram	B-CHEM
,	O	O
and	O	O
fluoxetine	B-CHEM
significantly	O
inhibited	B-PHYS
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
currents	B-PHYS
in	O	O
HEK	B-ANAT
cells	I-ANAT
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
,	O	O
n	O	O
=	O	O
10	O	O
)	O	O
.	O	O

Acetaminophen	B-CHEM
,	O	O
ibuprofen	B-CHEM
,	O	O
nabumetone	B-CHEM
,	O	O
and	O	O
bupropion	B-CHEM
inhibited	O	O
TRESK	B-CHEM
,	O	O
but	O	O
had	O	O
no	O
effect	O
on	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
.	O	O

These	O	O
results	O	O
show	O	O
that	O	O
all	O	O
analgesics	B-CHEM
tested	O
in	O	O
this	O	O
study	O	O
inhibit	B-PHYS
TRESK	B-CHEM
activity	B-PHYS
.	O	O

Further	O	O
study	O	O
is	O	O
needed	O	O
to	O	O
identify	O	O
the	O	O
mechanisms	B-PHYS
by	O	O
which	O	O
the	O	O
analgesics	B-CHEM
modulate	O	O
TREK	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
TRESK	B-CHEM
differently	O	O
.	O	O

Establishment	O	O
of	O	O
a	O	O
mouse	B-DISO
model	I-DISO
of	O	O
70	O	O
%	O	O
lethal	O
dose	O
by	O	O
total	B-PROC
-	I-PROC
body	I-PROC
irradiation	I-PROC
Whereas	O	O
increasing	O	O
concerns	O	O
about	O	O
radiation	B-DISO
exposure	I-DISO
to	O	O
nuclear	B-PHEN
disasters	I-PHEN
or	O	O
side	B-DISO
effects	I-DISO
of	O	O
anticancer	B-PROC
radiotherapy	B-PROC
,	O	O
relatively	O	O
little	O	O
research	B-PROC
for	O	O
radiation	B-DISO
damages	I-DISO
or	O	O
remedy	O
has	O	O
been	O	O
done	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
establish	O	O
level	O
of	O	O
LD	O
70	O	O
/	O	O
30	O	O
(	O	O
a	O	O
lethal	O
dose	O
for	O	O
70	O	O
%	O	O
of	O	O
mice	B-LIVB
within	O	O
30	O	O
days	O
)	O	O
by	O	O
total	B-PROC
-	I-PROC
body	I-PROC
γ	I-PROC
irradiation	I-PROC
(	O	O
TBI	B-PROC
)	O	O
in	O	O
a	O	O
mouse	B-DISO
model	I-DISO
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
at	O	O
first	O	O
,	O	O
8	O	O
-	O	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
and	O	O
C57BL	B-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
from	O	O
A	B-OBJC
and	O	O
B	B-OBJC
companies	I-OBJC
were	O	O
received	O	O
high	O
dose	O
(	O	O
10	O	O
,	O	O
11	O	O
,	O	O
12	O	O
Gy	O
)	O	O
TBI	B-PROC
.	O	O

After	O	O
irradiation	B-PHEN
,	O	O
the	O	O
body	B-PHYS
weight	I-PHYS
and	O	O
survival	O
rate	O
were	O	O
monitored	B-PROC
for	O	O
30	O	O
days	O
consecutively	O
.	O	O

In	O	O
next	O	O
experiment	B-PROC
,	O	O
5	O	O
-	O	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
and	O	O
C57BL	B-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
from	O	O
B	B-OBJC
company	I-OBJC
were	O	O
received	O	O
same	O
dose	O
irradiation	B-PHEN
.	O	O

Results	O
showed	O	O
that	O	O
survival	O
rate	O
and	O	O
body	B-DISO
weight	I-DISO
change	I-DISO
rate	O
in	O	O
inbred	B-LIVB
C57BL	I-LIVB
/	I-LIVB
6N	I-LIVB
mice	I-LIVB
were	O	O
similar	O
between	O	O
A	B-OBJC
and	O	O
B	B-OBJC
company	I-OBJC
.	O	O

In	O	O
ICR	B-LIVB
mice	I-LIVB
,	O	O
however	O	O
,	O	O
survival	O
rate	O
and	O	O
body	B-DISO
weight	I-DISO
change	I-DISO
rate	O
were	O	O
completely	O
different	O
among	O	O
the	O	O
companies	B-OBJC
.	O	O

Significant	O
difference	O
of	O	O
survival	O
rate	O
both	O	O
ICR	B-LIVB
and	O	O
C57BL6N	B-LIVB
mice	I-LIVB
was	O	O
not	O
observed	O
in	O	O
between	O	O
5	O	O
-	O	O
week	O
-	O
old	O
and	O	O
8	O	O
-	O	O
week	O
-	O
old	O
groups	O
receiving	O	O
10	O	O
or	O	O
12	O	O
Gy	O
TBI	B-PROC
.	O	O

Our	O	O
results	O
indicate	O	O
that	O	O
the	O	O
strain	B-LIVB
and	O	O
age	B-PHYS
of	O	O
mice	B-LIVB
,	O	O
and	O	O
even	O	O
purchasing	O	O
company	B-OBJC
(	O	O
especially	O	O
outbred	B-LIVB
)	O	O
,	O	O
should	O	O
be	O	O
matched	O	O
over	O	O
experimental	O
groups	O
in	O	O
TBI	B-PROC
experiment	B-PROC
.	O	O

Based	O	O
on	O	O
our	O	O
results	O
,	O	O
8	O	O
-	O	O
week	O
-	O
old	O
male	B-PHYS
ICR	B-LIVB
mice	O	O
from	O	O
B	B-OBJC
company	I-OBJC
subjected	O	O
to	O	O
12	O	O
Gy	O
of	O	O
TBI	B-PROC
showed	O	O
LD	O
70	O	O
/	O	O
30	O	O
and	O	O
suitable	O	O
as	O	O
a	O	O
mouse	B-DISO
model	I-DISO
for	O	O
further	O	O
development	O	O
of	O	O
new	O
drug	B-CHEM
using	O	O
the	O	O
ideal	O
total	B-PROC
-	I-PROC
body	I-PROC
irradiation	I-PROC
model	O
.	O	O

Dominant	B-DISO
and	O	O
Non	O	O
-	O	O
Dominant	B-DISO
Frequency	O
Structure	O	O
of	O	O
Evoked	O
Ventricular	B-DISO
Fibrillation	I-DISO
in	O	O
Dogs	B-LIVB
with	O	O
Myocardial	B-DISO
Ischemia	I-DISO
The	O	O
first	O	O
10	O	O
min	O	O
of	O	O
electrically	B-PROC
provoked	I-PROC
ventricular	B-DISO
fibrillation	I-DISO
in	O	O
dogs	B-LIVB
with	O	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
were	O	O
characterized	O
by	O	O
organized	O
myocardial	B-PHYS
activity	I-PHYS
evidenced	O	O
by	O	O
the	O	O
dominant	B-DISO
ECG	I-DISO
frequency	I-DISO
structure	O	O
.	O	O

During	O	O
the	O	O
first	O	O
2	O	O
min	O	O
of	O	O
ventricular	B-DISO
fibrillation	I-DISO
,	O	O
low	O
-	O
frequency	O
oscillations	O
(	O	O
4	O	O
-	O	O
7	O	O
Hz	O	O
)	O	O
dominated	O	O
,	O	O
while	O	O
on	O	O
min	O	O
3	O	O
to	O	O
10	O	O
after	O	O
the	O	O
onset	O	O
of	O	O
fibrillation	B-DISO
,	O	O
the	O	O
dominant	B-DISO
frequencies	I-DISO
were	O	O
low	O
and	O	O
medium	O
(	O	O
4	O	O
-	O	O
12	O	O
Hz	O	O
)	O	O
.	O	O

After	O	O
10	O	O
-	O	O
min	O	O
fibrillation	B-DISO
,	O	O
the	O	O
oscillations	B-PROC
became	O	O
non	O	O
-	O	O
dominant	B-DISO
.	O	O

Thus	O	O
,	O	O
ischemic	B-DISO
myocardium	I-DISO
maintains	O
the	O	O
organized	O
structure	O
of	O	O
ventricular	B-DISO
fibrillation	I-DISO
for	O	O
the	O	O
first	O	O
10	O	O
min	O	O
,	O	O
which	O	O
is	O	O
important	O	O
for	O	O
the	O	O
development	O
of	O	O
automatic	B-PROC
diagnostics	I-PROC
of	O	O
abnormal	B-DISO
cardiac	I-DISO
activity	I-DISO
in	O	O
humans	B-LIVB
.	O	O

Adverse	B-DISO
events	I-DISO
risk	O
associated	O
with	O
angiogenesis	B-CHEM
inhibitors	I-CHEM
addition	O	O
to	O	O
therapy	B-PROC
in	O	O
ovarian	B-DISO
cancer	I-DISO
:	O	O
a	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
Inhibition	B-PHYS
of	I-PHYS
angiogenesis	I-PHYS
has	O	O
been	O	O
regarded	O	O
as	O	O
an	O	O
attractive	O	O
treatment	B-PROC
strategy	I-PROC
for	O	O
advanced	B-DISO
or	O	O
recurrent	B-DISO
ovarian	I-DISO
cancer	I-DISO
.	O	O

We	O	O
conduct	O	O
this	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
to	O	O
investigate	O
the	O	O
risk	O
of	O	O
adverse	B-DISO
events	I-DISO
of	O	O
special	O	O
interest	O	O
related	O	O
to	O	O
angiogenesis	B-CHEM
inhibitors	I-CHEM
(	O	O
AIs	B-CHEM
)	O	O
in	O	O
ovarian	B-DISO
cancer	I-DISO
.	O	O

Databases	O
from	O	O
PubMed	O
,	O	O
Web	O
of	O
Science	O
and	O	O
Cochrane	B-OBJC
library	I-OBJC
up	O	O
to	O	O
December	O	O
2015	O	O
were	O	O
searched	O	O
to	O	O
identify	O	O
relevant	O
studies	B-PROC
.	O	O

Eligible	O	O
studies	B-PROC
included	O	O
prospective	B-PROC
randomized	I-PROC
controlled	I-PROC
phase	I-PROC
II	I-PROC
/	I-PROC
III	I-PROC
clinical	I-PROC
trials	I-PROC
evaluating	B-PROC
therapy	B-PROC
with	O	O
or	O	O
without	O	O
AIs	B-CHEM
for	O	O
ovarian	B-DISO
cancer	I-DISO
.	O	O

Summary	O	O
relative	O
risk	O
(	O	O
RR	O
)	O	O
and	O	O
95	O	O
%	O	O
confidence	O
intervals	O
(	O	O
CIs	O
)	O	O
were	O	O
calculated	O
using	O	O
random	O
-	O
effects	O
or	O	O
fixed	O
-	O
effects	O
according	O	O
to	O	O
the	O	O
heterogeneity	O
among	O	O
included	O	O
trials	B-PROC
.	O	O

A	O	O
total	O	O
of	O	O
7	O	O
,	O	O
761	O	O
patients	B-LIVB
from	O	O
ten	O	O
clinical	B-PROC
trials	I-PROC
were	O	O
included	O	O
in	O	O
the	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O	O

Pooled	O
RR	O
showed	O	O
that	O	O
the	O	O
use	O
of	O
AIs	B-CHEM
was	O	O
associated	O
with	O
a	O	O
statistically	O	O
increased	O
risk	O
in	O	O
four	O	O
of	O	O
the	O	O
adverse	O
outcomes	O
studied	O	O
:	O	O
arterial	B-DISO
thromboembolic	I-DISO
events	O
(	O	O
RR	O
=	O	O
2	O	O
.	O	O
0	O	O
)	O	O
,	O	O
gastrointestinal	B-DISO
(	I-DISO
GI	I-DISO
)	I-DISO
perforation	I-DISO
(	O	O
RR	O
=	O	O
3	O	O
.	O	O
86	O	O
)	O	O
,	O	O
proteinuria	B-DISO
(	O	O
RR	O
=	O	O
2	O	O
.	O	O
44	O	O
)	O	O
,	O	O
and	O	O
hypertension	B-DISO
(	O	O
RR	O
=	O	O
5	O	O
.	O	O
39	O	O
)	O	O
.	O	O

No	B-DISO
statistically	I-DISO
significant	I-DISO
differences	O
were	O	O
found	O	O
for	O	O
hemorrhagic	B-DISO
events	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

07	O	O
)	O	O
,	O	O
venous	B-DISO
thromboembolic	I-DISO
events	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
13	O	O
)	O	O
,	O	O
or	O	O
fatal	O
adverse	B-DISO
events	I-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
26	O	O
)	O	O
.	O	O

The	O	O
addition	O	O
of	O	O
AIs	B-CHEM
to	O	O
therapy	B-PROC
in	O	O
ovarian	B-DISO
cancer	I-DISO
did	O	O
significantly	O	O
increase	O
the	O	O
risk	O
of	O	O
arterial	B-DISO
thromboembolic	I-DISO
events	O
,	O	O
GI	B-DISO
perforation	I-DISO
,	O	O
proteinuria	B-DISO
and	O	O
hypertension	B-DISO
,	O	O
but	O	O
not	O	O
for	O	O
venous	B-DISO
thromboembolic	I-DISO
events	O
,	O	O
hemorrhagic	B-DISO
events	O
,	O	O
or	O	O
fatal	O
adverse	B-DISO
events	I-DISO
.	O	O

Phytochemical	B-CHEM
screening	B-PROC
,	O	O
antiglycation	B-PHEN
and	O	O
antioxidant	B-PHEN
activities	I-PHEN
of	O	O
whole	B-LIVB
plant	I-LIVB
of	O	O
Boerhavia	B-LIVB
repens	I-LIVB
L	I-LIVB
.	I-LIVB
from	O	O
Cholistan	B-GEOG
,	O	O
Pakistan	B-GEOG
Present	O	O
study	B-PROC
was	O	O
aimed	O	O
to	O	O
explore	O	O
a	O	O
traditionally	O	O
used	O	O
indigenous	O
medicinal	B-LIVB
plant	I-LIVB
Boerhavia	B-LIVB
repens	I-LIVB
(	O	O
Nyctaginaceae	B-LIVB
family	B-LIVB
)	O	O
of	O	O
the	O	O
Cholistan	B-GEOG
desert	I-GEOG
,	O	O
Pakistan	B-GEOG
.	O	O

Crude	B-OBJC
aqueous	I-OBJC
and	O	O
methanolic	B-OBJC
extracts	I-OBJC
of	O	O
the	O	O
whole	B-LIVB
plant	I-LIVB
were	O	O
investigated	O
in	O
vitro	O
for	O	O
preliminary	O	O
phytochemical	B-CHEM
screening	B-PROC
,	O	O
antioxidant	B-PHYS
and	O	O
antiglycation	B-PHEN
activities	I-PHEN
.	O	O

Antioxidant	B-PHYS
activities	I-PHYS
were	O	O
determined	O	O
by	O	O
total	O	O
phenolic	B-CHEM
contents	O	O
,	O	O
1	B-CHEM
,	I-CHEM
1	I-CHEM
-	I-CHEM
diphenyl	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
picrylhydrazyl	I-CHEM
(	I-CHEM
DPPH	I-CHEM
)	I-CHEM
free	I-CHEM
radical	I-CHEM
scavenging	B-PHEN
and	O	O
inhibition	O
of	O	O
lipid	B-CHEM
peroxidation	B-PHEN
.	O	O

For	O	O
antiglycation	B-PHEN
activities	I-PHEN
browning	B-PHEN
production	O	O
was	O	O
noted	O	O
and	O	O
thiobarbituric	B-CHEM
acid	I-CHEM
(	O	O
TBA	B-CHEM
)	O	O
technique	B-PROC
was	O	O
used	O	O
to	O	O
determine	O	O
glycation	O
level	O
.	O	O

Boerhavia	B-LIVB
repens	I-LIVB
expressed	O	O
considerable	O	O
amounts	O	O
of	O	O
phytochemicals	B-CHEM
.	O	O

Extract	B-OBJC
yield	O	O
was	O	O
found	O	O
to	O	O
be	O	O
4	O	O
.	O	O

59	O	O
%	O	O
-	O	O
7	O	O
.	O	O

85	O	O
%	O	O
g	O	O
/	O	O
100	O	O
g	O	O
of	O	O
dry	B-OBJC
matter	I-OBJC
with	O	O
total	O	O
phenolics	B-CHEM
ranging	O	O
from	O	O
47	O	O
.	O	O

9	O	O
-	O	O
190	O	O
.	O	O

77mg	O	O
/	O	O
GAE	O	O
per	O	O
g	O	O
for	O	O
aqueous	B-OBJC
and	O	O
methanol	B-OBJC
extract	I-OBJC
respectively	O	O
.	O	O

Strong	O	O
inhibitory	O
effect	O
was	O	O
exhibited	O	O
by	O	O
methanolic	B-OBJC
extract	I-OBJC
in	O	O
linoleic	B-CHEM
acid	I-CHEM
per	B-PHEN
oxidation	I-PHEN
system	O	O
(	O	O
86	O	O
.	O	O
11	O	O
%	O	O
,	O	O
EC50	O	O
=	O	O
0	O	O
.	O	O
99mg	O	O
/	O	O
mL	O	O
)	O	O
and	O	O
DPPH	B-CHEM
assay	B-PROC
(	O	O
88	O	O
.	O	O
65	O	O
%	O	O
,	O	O
EC50	O	O
=	O	O
212	O	O
.	O	O

33μg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

In	O	O
term	O	O
of	O	O
browning	B-PHEN
maximum	O	O
inhibition	O
(	O	O
81	O	O
.	O	O

50	O	O
%	O	O
)	O	O
was	O	O
exhibited	O	O
by	O	O
methanolic	B-OBJC
extract	I-OBJC
at	O	O
37°C	O	O
at	O	O
third	O	O
week	O
of	O	O
incubation	B-PROC
.	O	O

Both	O	O
extracts	B-OBJC
expressed	O	O
significant	O	O
(	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
comparable	O	O
inhibition	O
of	O	O
glycation	O
level	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
Boerhavia	B-LIVB
repens	I-LIVB
showed	O	O
promising	O	O
antioxidant	B-PHYS
and	O	O
antiglycation	B-PHEN
activities	I-PHEN
validating	O	O
its	O	O
therapeutic	O
potential	O
.	O	O

In	O
vitro	O
genotoxicity	B-DISO
of	O	O
pyridine	B-CHEM
in	O	O
human	B-LIVB
lymphocytes	B-ANAT
This	O	O
work	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
study	O	O
the	O	O
genotoxicity	B-DISO
of	O	O
pyridine	B-CHEM
in	O
vitro	O
on	O	O
human	B-LIVB
leucocyte	B-ANAT
culture	O
.	O	O

Cyclophosphamide	B-CHEM
,	O	O
a	O	O
well	O	O
-	O	O
known	O	O
carcinogen	B-CHEM
was	O	O
used	O	O
as	O	O
positive	O
control	O
.	O	O

The	O	O
four	O	O
different	O	O
concentrations	O
of	O	O
pyridine	B-CHEM
and	O	O
cyclophosphamide	B-CHEM
showed	O	O
breaks	B-DISO
and	O	O
pulverization	B-DISO
of	I-DISO
chromosomes	I-DISO
in	O	O
dose	O
dependent	O
manner	O	O
.	O	O

Higher	O
number	O
of	O	O
pulverization	B-DISO
was	O	O
observed	O	O
with	O	O
higher	O
concentration	O
of	O	O
pyridine	B-CHEM

(	O	O
3	O	O
.	O	O
25μg	O	O
/	O	O
mL	O	O
)	O	O
.	O	O

Based	O	O
on	O	O
this	O	O
data	O	O
,	O	O
our	O	O
results	O
confirm	O
that	O	O
both	O	O
pyridine	B-CHEM
and	O	O
its	O	O
precursor	O
showed	O	O
genotoxicity	B-DISO
against	O	O
human	B-LIVB
lymphocytes	B-ANAT
.	O	O

Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
against	O	O
peptides	B-CHEM
products	I-CHEM
of	O	O
enzymatic	B-CHEM
cleavage	B-PHYS
of	O	O
APP	B-CHEM
protein	I-CHEM
.	O	O

Forming	O
and	O	O
variety	O	O
of	O	O
fibrillating	B-CHEM
peptides	I-CHEM
-	O	O
some	O	O
aspects	O	O
Various	O	O
and	O	O
different	O	O
peptides	B-CHEM
products	I-CHEM
resulting	O	O
from	O	O
enzymatic	B-CHEM
protein	B-PHYS
cleavage	I-PHYS
of	O	O
Amyloid	B-CHEM
Precursor	I-CHEM
Proteins	I-CHEM
(	O	O
APP	B-CHEM
)	O	O
are	O	O
the	O	O
main	O	O
agents	B-CHEM
in	O	O
the	O	O
pathophysiology	O
of	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
AD	B-DISO
)	O	O
.	O	O

Although	O	O
relatively	O	O
well	O	O
-	O	O
known	O	O
,	O	O
they	O	O
still	O	O
arouse	O	O
interest	O	O
leading	O	O
to	O	O
further	O	O
intense	O	O
and	O	O
wide	O	O
-	O	O
ranging	O	O
research	B-PROC
.	O	O

Their	O	O
biology	B-PHYS
and	O	O
physico	O
-	O
chemical	O
properties	O
still	O	O
are	O	O
challenging	O	O
for	O	O
basic	O	O
,	O	O
experimental	B-PROC
research	I-PROC
and	O	O
are	O	O
matter	O	O
of	O	O
scientific	O
debate	O
.	O	O

The	O	O
APP	B-CHEM
itself	O	O
and	O	O
its	O	O
functions	B-PHYS
are	O	O
still	O	O
somewhat	O	O
enigmatic	O	O
and	O	O
therefore	O	O
it	O	O
is	O	O
also	O	O
called	O	O
the	O	O
All	O	O
Purpose	O	O
Protein	B-CHEM
.	O	O

Apart	O	O
from	O	O
well	O	O
known	O	O
amyloidogenic	B-PHYS
and	O	O
antiamyloidogenic	B-PHYS
(	I-PHYS
non	I-PHYS
-	I-PHYS
amyloidogenic	I-PHYS
)	I-PHYS
enzymatic	I-PHYS
cleavage	I-PHYS
pathways	I-PHYS
of	O	O
APP	B-CHEM
protein	I-CHEM
this	O	O
paper	O
deals	O	O
with	O	O
issues	B-DISO
connected	O	O
with	O	O
other	O	O
,	O	O
alternative	O
pathways	B-PHYS
that	O	O
seem	O	O
to	O	O
be	O	O
interesting	O	O
and	O	O
important	O	O
as	O	O
well	O	O
.	O	O

They	O	O
lead	O	O
to	O	O
other	O	O
than	O	O
Aβ	B-CHEM
forms	I-CHEM
of	I-CHEM
peptide	I-CHEM
products	I-CHEM
such	O	O
as	O	O
:	O	O
N	B-CHEM
-	I-CHEM
APP	I-CHEM
,	O	O
N	O	O
-	O	O
terminally	O	O
cleavage	O	O
products	O	O
of	O	O
APP	B-CHEM
(	O	O
N	B-CHEM
-	I-CHEM
terminally	I-CHEM
truncated	I-CHEM
)	O	O
Aβ	B-CHEM
'	I-CHEM
,	O	O
γ	B-CHEM
-	I-CHEM
secretase	I-CHEM
-independent	I-CHEM
pathway	I-CHEM
products	I-CHEM
that	O	O
involve	O	O
concerted	O	O
cleavages	B-PHYS
of	O	O
APP	B-CHEM
by	O	O
α	B-CHEM
-	I-CHEM
and	O	O
β	B-CHEM
-	I-CHEM
secretase	I-CHEM
or	O	O
products	B-CHEM
that	O	O
emerge	O	O
after	O	O
caspase	B-PHYS
activity	I-PHYS
.	O	O

Presence	O	O
of	O	O
all	O	O
these	O	O
peptides	B-CHEM
in	O	O
CSF	B-ANAT
,	O	O
ISF	B-ANAT
,	O	O
blood	B-ANAT
serum	I-ANAT
and	O	O
urine	B-ANAT
of	O	O
the	O	O
AD	B-DISO
patients	B-LIVB
is	O	O
crucial	O	O
for	O	O
successful	O	O
diagnosis	B-PROC
,	O	O
giving	O	O
rise	O	O
to	O	O
hope	O	O
of	O	O
their	O	O
better	O	O
detection	B-DISO
and	O	O
potentially	O	O
better	O	O
treatment	B-PROC
of	O	O
AD	B-DISO
.	O	O

Therefore	O	O
,	O	O
newly	O	O
discovered	O	O
products	B-CHEM
of	O	O
the	O	O
AβT	B-PHYS
domain	I-PHYS
cleavage	I-PHYS
(	O	O
Aβ	B-CHEM
total	I-CHEM
i	O	O
.	O	O

e	O	O
.	O	O

full	O	O
fibrillating	B-CHEM
domain	I-CHEM
of	I-CHEM
APP	I-CHEM
)	O	O
,	O	O
Aβ	B-CHEM
type	I-CHEM
products	I-CHEM
and	O	O
other	O	O
peptides	B-CHEM
because	O	O
of	O	O
their	O	O
biology	B-PHYS
and	O	O
physico	O
-	O
chemical	O
properties	O
are	O	O
very	O	O
intriguing	O	O
and	O	O
deserve	O	O
further	O	O
experimental	B-PROC
research	I-PROC
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
after	O	O
better	O	O
recognition	O	O
and	O	O
better	O	O
understanding	O	O
their	O	O
biology	B-PHYS
they	O	O
might	O	O
be	O	O
enormously	O	O
useful	O	O
in	O	O
the	O	O
future	O	O
for	O	O
diagnosis	B-PROC
and	O	O
therapy	B-PROC
for	O	O
example	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O	O

Clinical	B-DISO
Significance	I-DISO
of	O	O
2	O	O
Deep	B-ANAT
Posterior	I-ANAT
Perianal	I-ANAT
Spaces	I-ANAT
to	O	O
Complex	O
Cryptoglandular	B-ANAT
Fistulas	B-DISO
Confusion	O	O
exists	O	O
regarding	O	O
the	O	O
clinical	B-DISO
significance	I-DISO
of	O	O
the	O	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
and	O	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
to	O	O
complex	O
perianal	B-DISO
fistulas	I-DISO
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
assess	O	O
the	O	O
clinical	B-DISO
significance	I-DISO
of	O	O
the	O	O
2	O	O
deep	B-ANAT
posterior	I-ANAT
perianal	I-ANAT
spaces	I-ANAT
and	O	O
to	O	O
describe	O	O
in	O	O
detail	O	O
the	O	O
courses	O	O
of	O	O
posterior	O
complex	O
cryptoglandular	B-ANAT
fistula	B-DISO
extensions	O
.	O	O

This	O	O
was	O	O
a	O	O
retrospective	B-PROC
study	I-PROC
.	O	O

MRI	B-PROC
-	O	O
based	O
characteristics	O
of	O	O
selected	O
perianal	B-DISO
fistulas	I-DISO
were	O	O
independently	O	O
evaluated	B-PROC
by	O	O
examiners	B-LIVB
who	O	O
focused	O
on	O	O
lesions	B-DISO
in	O	O
these	O	O
2	O	O
spaces	B-ANAT
and	O	O
were	O	O
blinded	O	O
to	O	O
each	O	O
other	O	O
's	O	O
findings	O	O
.	O	O

This	O	O
study	B-PROC
was	O	O
conducted	O	O
in	O	O
the	O	O
colorectal	O
surgery	O
and	O	O
radiology	O
departments	O
of	O	O
a	O	O
large	O	O
university	B-OBJC
teaching	I-OBJC
hospital	I-OBJC
in	O	O
China	B-GEOG
.	O	O

Included	O	O
in	O	O
the	O	O
study	O	O
were	O	O
patients	B-LIVB
who	O	O
underwent	O	O
pelvic	B-PROC
MRI	I-PROC
for	O	O
posterior	O
perianal	B-DISO
fistula	I-DISO
between	O	O
October	O
2012	O	O
and	O	O
December	O
2014	O	O
.	O	O

The	O	O
occurrence	O
rates	O
of	O	O
these	O	O
2	O	O
deep	B-ANAT
perianal	I-ANAT
space	I-ANAT
lesions	B-DISO
in	O	O
posterior	O
cryptoglandular	B-ANAT
fistulas	B-DISO
were	O	O
determined	O
.	O	O

A	O	O
total	O	O
of	O	O
513	O	O
primary	O
posterior	O
cryptoglandular	B-ANAT
fistulas	B-DISO
were	O	O
identified	O
in	O	O
508	O	O
patients	B-LIVB
,	O	O
including	O	O
167	O	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
lesions	B-DISO
(	O	O
32	O	O
.	O	O

6	O	O
%	O	O
)	O	O
and	O	O
23	O	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
lesions	B-DISO
(	O	O
4	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Of	O	O
those	O	O
,	O	O
173	O	O
fistulas	B-DISO
(	O	O
33	O	O
.	O	O
7	O	O
%	O	O
)	O	O
were	O	O
evaluated	B-PROC
as	O	O
complex	O
.	O	O

The	O	O
former	O
and	O	O
latter	O
spaces	B-ANAT
were	O	O
involved	O
in	O	O
79	O	O
.	O	O

2	O	O
%	O	O
(	O	O
137	O	O
/	O	O
173	O	O
)	O	O
and	O	O
13	O	O
.	O	O

3	O	O
%	O	O
(	O	O
23	O	O
/	O	O
173	O	O
)	O	O
of	O	O
posterior	O
complex	O
fistulas	B-DISO
.	O	O

Compared	O
with	O	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
lesions	B-DISO
,	O	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
lesions	B-DISO
were	O	O
more	O	O
common	O
in	O	O
cases	O
with	O	O
high	O
transsphincteric	B-DISO
or	O	O
suprasphincteric	B-DISO
fistulas	I-DISO
(	O	O
80	O	O
.	O	O
1	O	O
%	O	O
vs	O	O
15	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
synchronous	O
multiple	O
transsphincteric	B-DISO
fistulas	I-DISO
(	O	O
82	O	O
.	O	O
4	O	O
%	O	O
vs	O	O
20	O	O
.	O	O

6	O	O
%	O	O
)	O	O
,	O	O
horseshoe	B-DISO
-	I-DISO
like	I-DISO
fistulas	I-DISO
(	O	O
85	O	O
.	O	O
5	O	O
%	O	O
vs	O	O
14	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
supralevator	B-ANAT
fistulas	B-DISO
(	O	O
93	O	O
.	O	O
5	O	O
%	O	O
vs	O	O
16	O	O
.	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Similar	O	O
incidences	O
were	O	O
also	O	O
seen	O	O
in	O	O
cases	O
with	O	O
ischioanal	B-ANAT
-	O	O
involved	O
horseshoe	B-DISO
-	I-DISO
like	I-DISO
fistulas	I-DISO
(	O	O
75	O	O
.	O	O
0	O	O
%	O	O
vs	O	O
25	O	O
.	O	O
0	O	O
%	O	O
)	O	O
.	O	O

This	O	O
study	B-PROC
was	O	O
limited	O	O
by	O	O
its	O	O
retrospective	O
nature	O	O
.	O	O

The	O	O
deep	O
posterior	O
intersphincteric	B-ANAT
space	I-ANAT
is	O	O
more	O	O
likely	O	O
than	O	O
the	O	O
deep	B-ANAT
postanal	I-ANAT
space	I-ANAT
to	O	O
be	O	O
involved	O
in	O	O
complex	O
cryptoglandular	B-ANAT
fistulas	B-DISO
and	O	O
is	O	O
likely	O	O
to	O	O
play	O	O
a	O	O
more	O	O
important	O
role	O	O
in	O	O
the	O	O
management	B-PROC
of	O	O
complex	O
cryptoglandular	B-ANAT
fistulas	B-DISO
.	O	O

Conditional	O	O
ablation	B-PROC
of	O	O
myeloid	O
TNF	B-CHEM
increases	O	O
lesion	B-DISO
volume	O
after	O	O
experimental	B-DISO
stroke	I-DISO
in	I-DISO
mice	I-DISO
,	O	O
possibly	O	O
via	O	O
altered	O	O
ERK1	B-PHYS
/	I-PHYS
2	I-PHYS
signaling	I-PHYS
Microglia	B-ANAT
are	O	O
activated	O	O
following	O	O
cerebral	B-DISO
ischemia	I-DISO
and	O	O
increase	O	O
their	O	O
production	O	O
of	O	O
the	O	O
neuro	B-CHEM
-	O	O
and	O	O
immunomodulatory	B-CHEM
cytokine	B-CHEM
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	O	O
TNF	B-CHEM
)	O	O
.	O	O

To	O	O
address	O	O
the	O	O
function	O
of	O	O
TNF	B-CHEM
from	O	O
this	O	O
cellular	B-DISO
source	I-DISO
in	O	O
focal	B-DISO
cerebral	I-DISO
ischemia	I-DISO
we	O	O
used	O	O
TNF	B-CHEM
conditional	O	O
knock	B-LIVB
out	I-LIVB
mice	I-LIVB
(	I-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
)	I-LIVB
in	O	O
which	O	O
the	O	O
TNF	O
gene	O
was	O	O
deleted	O
in	O	O
cells	B-ANAT
of	O	O
the	O	O
myeloid	O
lineage	O
,	O	O
including	O	O
microglia	B-ANAT
.	O	O

The	O	O
deletion	B-PHYS
reduced	O	O
secreted	O	O
TNF	B-CHEM
levels	O
in	O	O
lipopolysaccharide	B-CHEM
-stimulated	O	O
cultured	B-ANAT
primary	I-ANAT
microglia	I-ANAT
by	O	O
~93	O	O
%	O	O
.	O	O

Furthermore	O	O
,	O	O
phosphorylated	B-CHEM
-	I-CHEM
ERK	I-CHEM
/	O	O
ERK	B-CHEM
ratios	O
were	O	O
significantly	O	O
decreased	O	O
in	O	O
naïve	B-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
demonstrating	O	O
altered	O	O
ERK	B-CHEM
signal	B-PHYS
transduction	I-PHYS
.	O	O

Micro	B-PROC
-	I-PROC
PET	I-PROC
using	O	O
(	B-CHEM
18	I-CHEM
)	I-CHEM
[	I-CHEM
F	I-CHEM
]	I-CHEM
-	I-CHEM
fluorodeoxyglucose	I-CHEM
immediately	O	O
after	O	O
focal	B-DISO
cerebral	I-DISO
ischemia	I-DISO
showed	O	O
increased	O	O
glucose	B-PHYS
uptake	I-PHYS
in	O	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O	O
representing	O	O
significant	O	O
metabolic	B-PHYS
changes	O
,	O	O
that	O	O
translated	O	O
into	O	O
increased	O	O
infarct	B-DISO
volumes	O
at	O	O
24	O	O
hours	O	O
and	O	O
5	O	O
days	O
compared	O	O
to	O	O
littermates	B-LIVB
(	I-LIVB
TNFfl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
.	O	O

In	O	O
naïve	B-LIVB
LysMcreTNF	I-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
cytokine	B-CHEM
levels	O
were	O	O
low	O	O
and	O	O
comparable	O	O
to	O	O
littermates	B-LIVB
.	O	O

At	O	O
6	O	O
hours	O	O
,	O	O
TNF	B-CHEM
producing	O	O
microglia	B-ANAT
were	O	O
reduced	O	O
by	O	O
56	O	O
%	O	O
in	O	O
the	O	O
ischemic	B-DISO
cortex	I-DISO
in	O	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
compared	O	O
to	O	O
littermate	B-LIVB
mice	I-LIVB
,	O	O
whereas	O	O
no	O	O
TNF	O
(	O
+	O
)	O
leukocytes	B-ANAT
were	O	O
detected	O	O
.	O	O

At	O	O
24	O	O
hours	O	O
,	O	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokine	I-CHEM
(	O	O
TNF	B-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
5	I-CHEM
and	O	O
CXCL1	B-CHEM
)	O	O
levels	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
LysMcreTNF	B-LIVB
(	I-LIVB
fl	I-LIVB
/	I-LIVB
fl	I-LIVB
)	I-LIVB
mice	I-LIVB
,	O	O
despite	O	O
comparable	O	O
infiltrating	O	O
leukocyte	B-ANAT
populations	I-ANAT
.	O	O

Our	O	O
results	O	O
identify	O	O
microglia	B-ANAT
l	O	O
TNF	B-CHEM
as	O	O
beneficial	O	O
and	O	O
neuroprotective	O
in	O	O
the	O	O
acute	O
phase	O
and	O	O
as	O	O
a	O	O
modulator	O	O
of	O	O
neuroinflammation	B-DISO
at	O	O
later	O	O
time	O	O
points	O	O
after	O	O
experimental	O	O
ischemia	B-DISO
,	O	O
which	O	O
may	O	O
contribute	O	O
to	O	O
regenerative	B-PHYS
recovery	I-PHYS
.	O	O

Screening	B-PROC
of	O	O
Conditionally	O
Reprogrammed	O
Patient	B-LIVB
-Derived	O	O
Carcinoma	B-ANAT
Cells	I-ANAT
Identifies	O	O
ERCC3	B-CHEM
-	O	O
MYC	B-CHEM
Interactions	O
as	O	O
a	O	O
Target	O
in	O	O
Pancreatic	B-DISO
Cancer	I-DISO
Even	O	O
when	O	O
diagnosed	B-PROC
prior	O	O
to	O	O
metastasis	B-DISO
,	O	O
pancreatic	B-DISO
ductal	I-DISO
adenocarcinoma	I-DISO
(	O	O
PDAC	B-DISO
)	O	O
is	O	O
a	O	O
devastating	B-DISO
malignancy	I-DISO
with	O	O
almost	O	O
90	O	O
%	O	O
lethality	B-DISO
,	O	O
emphasizing	O	O
the	O	O
need	O	O
for	O	O
new	O	O
therapies	B-PROC
optimally	O
targeting	O
the	O	O
tumors	B-DISO
of	O	O
individual	O	O
patients	B-LIVB
.	O	O

We	O	O
first	O	O
developed	O	O
a	O	O
panel	O
of	O	O
new	O	O
physiologic	O
models	O
for	O	O
study	B-PROC
of	O	O
PDAC	B-DISO
,	O	O
expanding	O	O
surgical	O
PDAC	B-DISO
tumor	O
samples	O
in	O	O
culture	B-PROC
using	O	O
short	O
-	O
term	O
culture	B-PROC
and	O	O
conditional	O
reprogramming	O
with	O	O
the	O	O
Rho	B-CHEM
kinase	I-CHEM
inhibitor	B-CHEM
Y	B-CHEM
-	I-CHEM
27632	I-CHEM
,	O	O
and	O	O
creating	O	O
matched	O	O
patient	B-CHEM
-	I-CHEM
derived	I-CHEM
xenografts	I-CHEM
(	O	O
PDX	B-CHEM
)	O	O
.	O	O

These	O	O
were	O	O
evaluated	B-PROC
for	O	O
sensitivity	O
to	O	O
a	O	O
large	O	O
panel	O
of	O	O
clinical	B-CHEM
agents	I-CHEM
,	O	O
and	O	O
promising	O	O
leads	O	O
further	O	O
evaluated	B-PROC
mechanistically	O
.	O	O

Only	O	O
a	O	O
small	O	O
minority	O	O
of	O	O
tested	B-CHEM
agents	I-CHEM
was	O	O
cytotoxic	O
in	O	O
minimally	O	O
passaged	O	O
PDAC	B-DISO
cultures	B-PROC
in	O
vitro	O
Drugs	B-CHEM
interfering	O	O
with	O	O
protein	B-PHYS
turnover	I-PHYS
and	O	O
transcription	B-PHYS
were	O	O
among	O	O
most	O	O
cytotoxic	O
.	O	O

Among	O	O
transcriptional	B-CHEM
repressors	I-CHEM
,	O	O
triptolide	B-CHEM
,	O	O
a	O	O
covalent	B-CHEM
inhibitor	I-CHEM
of	O	O
ERCC3	B-CHEM
,	O	O
was	O	O
most	O	O
consistently	O
effective	O
in	O
vitro	O
and	O	O
in	O
vivo	O
causing	O	O
prolonged	B-DISO
complete	I-DISO
regression	I-DISO
in	O	O
multiple	O
PDX	B-PROC
models	O
resistant	O
to	O	O
standard	O
PDAC	B-DISO
therapies	B-PROC
.	O	O

Importantly	O	O
,	O	O
triptolide	B-CHEM
showed	O	O
superior	O
activity	O
in	O	O
MYC	B-CHEM
-	I-CHEM
amplified	I-CHEM
PDX	B-CHEM
models	O
and	O	O
elicited	O	O
rapid	O
and	O	O
profound	O	O
depletion	O
of	O	O
the	O	O
oncoprotein	B-CHEM
MYC	I-CHEM
,	O	O
a	O	O
transcriptional	B-PHYS
regulator	I-PHYS
.	O	O

Expression	B-PHYS
of	O	O
ERCC3	B-CHEM
and	O	O
MYC	B-CHEM
was	O	O
interdependent	O	O
in	O	O
PDACs	B-DISO
,	O	O
and	O	O
acquired	B-PHEN
resistance	I-PHEN
to	O	O
triptolide	B-CHEM
depended	O	O
on	O	O
elevated	O	O
ERCC3	B-CHEM
and	O	O
MYC	B-CHEM
expression	B-PHYS
.	O	O

The	B-PROC
Cancer	I-PROC
Genome	I-PROC
Atlas	I-PROC
analysis	I-PROC
indicates	O	O
ERCC3	B-CHEM
expression	B-PHYS
predicts	O	O
poor	B-DISO
prognosis	I-DISO
,	O	O
particularly	O	O
in	O	O
CDKN2A	B-DISO
-	I-DISO
null	I-DISO
,	O	O
highly	B-DISO
proliferative	I-DISO
tumors	I-DISO
.	O	O

This	O	O
provides	O	O
initial	O	O
preclinical	O
evidence	O
for	O	O
an	O	O
essential	O	O
role	O	O
of	O	O
MYC	B-CHEM
-	O	O
ERCC3	B-CHEM
interactions	O
in	O	O
PDAC	B-DISO
,	O	O
and	O	O
suggests	O	O
a	O	O
new	O	O
mechanistic	O	O
approach	O	O
for	O	O
disruption	O
of	O	O
critical	O
survival	O
signaling	B-PHEN
in	O	O
MYC	B-CHEM
-dependent	O	O
cancers	B-DISO
.	O	O

Clin	O	O
Cancer	O	O
Res	O	O
;	O	O
22	O	O
(	O	O
24	O	O
)	O	O
;	O	O
6153	O	O
-	O	O
63	O	O
.	O	O

©	O	O
2016	O	O
AACR	O	O
.	O	O

Relationship	O
between	O	O
LRRK2	O
R1628P	O
polymorphism	O
and	O	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
in	O	O
Asian	B-LIVB
populations	I-LIVB
Although	O	O
the	O	O
leucine	O
-	O
rich	O
repeat	O
kinase	O
2	O
(	O	O
LRRK2	O
)	O	O
R1628P	O
polymorphism	O
has	O	O
been	O	O
associated	O
with	O
the	O	O
risk	O
of	O	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
PD	B-DISO
)	O	O
in	O	O
Taiwan	B-GEOG
,	O	O
China	B-GEOG
,	O	O
and	O	O
Singapore	B-GEOG
,	O	O
there	O	O
are	O	O
conflicting	O	O
findings	O	O
regarding	O	O
this	O	O
relationship	O
.	O	O

Thus	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
was	O	O
to	O	O
evaluate	O	O
the	O	O
associations	O
between	O	O
the	O	O
LRRK2	O
R1628P	O
polymorphism	O
(	O	O
rs33949390	O
)	O	O
and	O	O
PD	B-DISO
in	O	O
Asian	B-LIVB
populations	I-LIVB
.	O	O

A	O	O
search	O	O
for	O	O
eligible	O	O
studies	B-PROC
was	O	O
performed	O	O
in	O	O
PubMed	O
,	O	O
Embase	O
,	O	O
SinoMed	O
,	O	O
and	O	O
the	O	O
China	O
Knowledge	O
Resource	O
Integrated	O
Database	O
,	O	O
and	O	O
pooled	O	O
odds	O	O
ratios	O	O
and	O	O
95	O	O
%	O	O
confidence	O
intervals	O
were	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
strength	O	O
of	O	O
the	O	O
association	O
between	O	O
the	O	O
R1628P	O
polymorphism	O
and	O	O
PD	B-DISO
.	O	O

This	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
assessed	O	O
19	O	O
studies	B-PROC
from	O	O
14	O	O
papers	O	O
that	O	O
involved	O	O
a	O	O
total	O	O
of	O	O
9	O	O
,	O	O
927	O	O
PD	B-DISO
patients	B-LIVB
and	O	O
8	O	O
,	O	O
602	O	O
controls	B-LIVB
and	O	O
found	O	O
that	O	O
the	O	O
R1628P	O
polymorphism	O
was	O	O
significantly	O	O
associated	O
with	O
the	O	O
risk	O
of	O	O
PD	B-DISO
in	O	O
Asian	B-LIVB
populations	I-LIVB
.	O	O

Moreover	O	O
,	O	O
stratification	B-PROC
analyses	I-PROC
indicated	O	O
that	O	O
the	O	O
R1628P	O
polymorphism	O
was	O	O
significantly	O	O
associated	O
with	O
an	O	O
increased	O	O
risk	O
of	O	O
PD	B-DISO
among	O	O
Chinese	B-LIVB
as	O	O
well	O	O
as	O	O
non	B-LIVB
-	I-LIVB
Chinese	I-LIVB
Asian	I-LIVB
populations	I-LIVB
and	O	O
an	O	O
increased	O	O
risk	O
of	O	O
PD	B-DISO
in	O	O
Chinese	B-LIVB
patients	I-LIVB
from	O	O
China	B-GEOG
,	O	O
Taiwan	B-GEOG
,	O	O
and	O	O
Singapore	B-GEOG
.	O	O

In	O	O
a	O	O
stratified	B-PROC
analysis	I-PROC
conducted	O	O
according	O	O
to	O	O
age	B-PHYS
,	O	O
significant	O	O
associations	O
were	O	O
found	O	O
for	O	O
both	O	O
late	O	O
-	O	O
onset	O	O
PD	B-DISO
and	O	O
early	O	O
-	O	O
onset	O	O
PD	B-DISO
.	O	O

The	O	O
present	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
R1628P	O
polymorphism	O
of	O	O
the	O	O
LRRK2	O
gene	O
contributes	O	O
to	O	O
PD	B-DISO
susceptibility	B-PHYS
in	O	O
Asian	B-LIVB
,	O	O
especially	O	O
Chinese	B-LIVB
,	O	O
populations	B-LIVB
.	O	O

Efficacy	O
and	O	O
safety	O
of	O	O
cisplatin	B-CHEM
,	O	O
dexamethasone	B-CHEM
,	O	O
gemcitabine	B-CHEM
and	O	O
pegaspargase	B-CHEM
(	O	O
DDGP	B-CHEM
)	O	O
regimen	B-PROC
in	O	O
newly	O
diagnosed	O
,	O	O
advanced	O
-	O
stage	O
extranodal	B-DISO
natural	I-DISO
killer	I-DISO
/	I-DISO
T	I-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
:	O	O
interim	O
analysis	B-PROC
of	O	O
a	O	O
phase	O
4	O
study	B-PROC
NCT01501149	O	O
To	O	O
explore	O	O
a	O	O
more	O	O
effective	O
treatment	O
for	O	O
newly	O
diagnosed	O
,	O	O
advanced	O
-	O
stage	O
extranodal	B-DISO
natural	I-DISO
killer	I-DISO
/	I-DISO
T	I-DISO
-	I-DISO
cell	I-DISO
lymphoma	I-DISO
,	I-DISO
nasal	I-DISO
type	I-DISO
(	O	O
ENKTL	B-DISO
)	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
phase	O
4	O
study	B-PROC
of	O	O
the	O	O
cisplatin	B-CHEM
,	O	O
dexamethasone	B-CHEM
,	O	O
gemcitabine	B-CHEM
,	O	O
pegaspargase	B-CHEM
(	O	O
DDGP	B-CHEM
)	O	O
regimen	B-PROC
.	O	O

The	O	O
primary	O	O
end	O
point	O
was	O	O
the	O	O
2	O	O
-	O	O
year	O	O
progression	O
-	O
free	O
survival	O
(	O	O
PFS	O
)	O	O
after	O	O
the	O	O
protocol	B-PROC
treatment	I-PROC
.	O	O

Secondary	O	O
endpoints	O
included	O	O
response	O
rate	O
(	O	O
RR	O
)	O	O
,	O	O
overall	O
survival	O
(	O	O
OS	O
)	O	O
and	O	O
median	O
survival	O
time	O
(	O	O
MST	O
)	O	O
.	O	O

The	O	O
interim	O
analysis	B-PROC
included	O	O
data	O
only	O	O
from	O	O
March	O	O
2011	O	O
to	O	O
September	O	O
2013	O	O
,	O	O
who	O	O
received	O
six	O	O
cycles	O	O
of	O	O
DDGP	B-CHEM
chemotherapy	B-PROC
.	O	O

A	O	O
total	O	O
of	O	O
25	O	O
eligible	O
patients	B-LIVB
were	O	O
enrolled	O	O
.	O	O

Seventeen	O	O
patients	B-LIVB
(	O	O
17	O	O
/	O	O
24	O	O
,	O	O
70	O	O
.	O	O

83	O	O
%	O	O
)	O	O
achieved	O	O
complete	B-DISO
response	I-DISO
(	O	O
CR	B-DISO
)	O	O
and	O	O
four	O	O
(	O	O
4	O	O
/	O	O
24	O	O
,	O	O
16	O	O
.	O	O
67	O	O
%	O	O
)	O	O
achieved	O	O
partial	B-DISO
response	I-DISO
(	O	O
PR	B-DISO
)	O	O
,	O	O
three	O	O
(	O	O
3	O	O
/	O	O
24	O	O
,	O	O
12	O	O
.	O	O

50	O	O
%	O	O
)	O	O
had	O	O
progressive	B-DISO
disease	I-DISO
(	O	O
PD	B-DISO
)	O	O
.	O	O

The	O	O
RR	O
after	O	O
treatment	O
was	O	O
87	O	O
.	O	O

50	O	O
%	O	O
.	O	O

After	O	O
a	O	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
of	O	O
24	O	O
.	O	O
67	O	O
months	O
(	O	O
range	O	O
4	O	O
-	O	O
48	O	O
months	O
)	O	O
.	O	O

The	O	O
2	O	O
-	O	O
year	O	O
PFS	O
and	O	O
OS	O
rate	O
were	O	O
61	O	O
.	O	O
80	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
42	O	O
.	O	O
00	O	O
%	O	O
to	O	O
81	O	O
.	O	O
60	O	O
%	O	O
)	O	O
and	O	O
68	O	O
.	O	O

50	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
48	O	O
.	O	O
70	O	O
%	O	O
to	O	O
88	O	O
.	O	O
30	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
MST	O
was	O	O
36	O	O
.	O	O
55	O	O
months	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
29	O	O
.	O	O
41	O	O
months	O
to	O	O
43	O	O
.	O	O
70	O	O
months	O
)	O	O
.	O	O

Grade	O
3	O	O
/	O	O
4	O	O
leukopenia	B-DISO
occurred	O
in	O	O
fourteen	O	O
patients	B-LIVB
(	O	O
58	O	O
.	O	O
33	O	O
%	O	O
)	O	O
and	O	O
grade	O
3	O	O
/	O	O
4	O	O
thrombocytopenia	B-DISO
occurred	O
in	O	O
eleven	O	O
patients	B-LIVB
(	O	O
45	O	O
.	O	O
83	O	O
%	O	O
)	O	O
.	O	O

Twelve	O	O
patients	B-LIVB
(	O	O
50	O	O
.	O	O
00	O	O
%	O	O
)	O	O
experienced	O	O
Activated	B-PROC
Partial	I-PROC
Phromboplastin	I-PROC
Ptime	I-PROC
(	O	O
APTT	B-PROC
)	O	O
elongation	B-DISO
and	O	O
fourteen	O	O
patients	B-LIVB
(	O	O
58	O	O
.	O	O
33	O	O
%	O	O
)	O	O
experienced	O	O
hypofibrinogenemia	B-DISO
.	O	O

In	O	O
conclusion	O	O
,	O	O
DDGP	B-CHEM
regimen	B-PROC
is	O	O
an	O	O
effective	O
and	O	O
tolerated	B-DISO
treatment	O
for	O	O
newly	O
diagnosed	O
,	O	O
advanced	O
-	O
stage	O
ENKTL	B-DISO
.	O	O

This	O	O
trial	B-PROC
was	O	O
registered	B-PROC
at	O	O
www	O
.	O

ClinicalTrials	O
.	O

gov	O
as	O	O
#	O	O
NCT01501149	O	O
.	O	O

Biogeochemical	O
Controls	O
of	O	O
Uranium	B-CHEM
Bioavailability	O
from	O	O
the	O	O
Dissolved	O
Phase	O
in	O	O
Natural	O
Freshwaters	B-OBJC
To	O	O
gain	O	O
insights	O	O
into	O	O
the	O	O
risks	O
associated	O
with	O
uranium	B-CHEM
(	O	O
U	B-CHEM
)	O	O
mining	O
and	O	O
processing	O
,	O	O
we	O	O
investigated	O
the	O	O
biogeochemical	O
controls	O
of	O	O
U	B-CHEM
bioavailability	O
in	O	O
the	O	O
model	O	O
freshwater	B-OBJC
species	O
Lymnaea	O
stagnalis	O
(	O	O
Gastropoda	O
)	O	O
.	O	O

Bioavailability	O
of	O	O
dissolved	B-CHEM
U	I-CHEM
(	I-CHEM
VI	I-CHEM
)	I-CHEM
was	O	O
characterized	O
in	O	O
controlled	O
laboratory	B-OBJC
experiments	B-PROC
over	O	O
a	O	O
range	O	O
of	O	O
water	B-CHEM
hardness	O
,	O	O
pH	O
,	O	O
and	O	O
in	O	O
the	O	O
presence	B-DISO
of	O	O
complexing	B-CHEM
ligands	I-CHEM
in	O	O
the	O	O
form	O	O
of	O	O
dissolved	B-OBJC
natural	I-OBJC
organic	I-OBJC
matter	I-OBJC
(	O	O
DOM	B-OBJC
)	O	O
.	O	O

Results	B-PHEN
show	O	O
that	O	O
dissolved	B-CHEM
U	I-CHEM
is	O	O
bioavailable	O
under	O	O
all	O	O
the	O	O
geochemical	O
conditions	O
tested	O
.	O	O

Uranium	B-CHEM
uptake	B-PHYS
rates	O
follow	O	O
first	O
order	O
kinetics	O
over	O	O
a	O	O
range	O	O
encompassing	O	O
most	O	O
environmental	O
concentrations	O
.	O	O

Uranium	B-CHEM
uptake	B-PHYS
rates	O
in	O	O
L	O
.	O

stagnalis	O
ultimately	O	O
demonstrate	O	O
saturation	B-PHEN
uptake	B-PHYS
kinetics	B-PHEN
when	O	O
exposure	O
concentrations	O
exceed	O	O
100	O	O
nM	O	O
,	O	O
suggesting	O
uptake	B-PHYS
via	O	O
a	O	O
finite	O	O
number	O	O
of	O	O
carriers	O	O
or	O	O
ion	B-CHEM
channels	I-CHEM
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
relationship	O	O
between	O	O
U	B-CHEM
uptake	B-PHYS
rate	O	O
constants	O
and	O	O
Ca	B-CHEM
uptake	B-PHYS
rates	O
suggest	O
that	O	O
U	B-CHEM
does	O	O
not	O	O
exclusively	O	O
use	O	O
Ca	B-CHEM
membrane	B-CHEM
transporters	I-CHEM
.	O	O

In	O	O
general	O	O
,	O	O
U	B-CHEM
bioavailability	O
decreases	B-DISO
with	O	O
increasing	O
pH	O
,	O	O
increasing	O
Ca	B-CHEM
and	O	O
Mg	B-CHEM
concentrations	O
,	O	O
and	O	O
when	O	O
DOM	B-OBJC
is	O	O
present	B-DISO
.	O	O

Competing	O	O
ions	B-CHEM
did	O	O
not	O	O
affect	O	O
U	B-CHEM
uptake	B-PHYS
rates	O
.	O	O

Speciation	B-PROC
modeling	I-PROC
that	O	O
includes	O	O
formation	O
constants	O
for	O	O
U	B-CHEM
ternary	B-CHEM
complexes	I-CHEM
reveals	O
that	O	O
the	O	O
aqueous	O
concentration	O
of	O	O
dicarbonato	B-CHEM
U	I-CHEM
species	O
(	O	O
UO2	O	O
(	O	O
CO3	O	O
)	O	O
2	O	O
(	O	O
-	O	O
2	O	O
)	O	O
)	O	O
best	O	O
predicts	O	O
U	B-CHEM
bioavailability	O
to	O	O
L	O
.	O

stagnalis	O
,	O	O
challenging	O	O
the	O	O
free	O
-	O
ion	O
activity	O
model	O	O
postulate	O	O
.	O	O

Subluxation	B-DISO
and	O	O
semantics	O
:	O	O
a	O	O
corpus	B-PROC
linguistics	O
study	B-PROC
The	O	O
purpose	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
analyze	B-PROC
the	O	O
curriculum	B-PROC
of	O	O
one	O	O
chiropractic	O
college	B-OBJC
in	O	O
order	O	O
to	O	O
discover	O
if	O	O
there	O	O
were	O	O
any	O	O
implicit	B-PHYS
consensus	O
definitions	O
of	O	O
the	O	O
term	O
subluxation	B-DISO
.	O	O

Using	O	O
the	O	O
software	O
WordSmith	O
Tools	O
,	O	O
the	O	O
corpus	B-PROC
of	O	O
an	O	O
undergraduate	O
chiropractic	O
curriculum	B-PROC
was	O	O
analyzed	B-PROC
by	O	O
reviewing	O
collocated	O
terms	O
and	O	O
through	O	O
discourse	B-PROC
analysis	I-PROC
of	O	O
text	O
blocks	O
containing	O	O
words	O
based	O
on	O	O
the	O	O
root	O	O
'	O	O
sublux	O
.	O	O
'	O	O
It	O	O
was	O	O
possible	B-DISO
to	O	O
identify	B-PHYS
3	O	O
distinct	O	O
concepts	O
which	O	O
were	O	O
each	O	O
referred	O
to	O	O
as	O	O
'	O	O
subluxation	B-DISO
:	O	O
'	O	O
i	O	O
)	O	O
an	O	O
acute	O
or	O	O
instantaneous	O
injurious	B-DISO
event	O
;	O	O
ii	O	O
)	O	O
a	O	O
clinical	O
syndrome	O
which	O	O
manifested	O
post	O
-	O	O
injury	B-DISO
;	O	O
iii	O	O
)	O	O
a	O	O
physical	O
lesion	B-DISO
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

an	O	O
anatomical	O
or	O	O
physiological	O
derangement	B-DISO
which	O	O
in	O	O
most	O	O
instances	O
acted	O
as	O	O
a	O	O
pain	B-DISO
generator	O
.	O	O

In	O	O
fact	O	O
,	O	O
coherent	B-DISO
implicit	B-PHYS
definitions	O
of	O	O
subluxation	B-DISO
exist	O	O
and	O	O
may	O	O
enjoy	O	O
broad	O
but	O	O
subconscious	B-PHYS
acceptance	B-DISO
.	O	O

However	O	O
,	O	O
confusion	B-DISO
likely	O	O
arises	O	O
from	O	O
failure	O
to	O	O
distinguish	B-PHYS
which	O	O
concept	O
an	O	O
author	B-LIVB
or	O	O
speaker	B-LIVB
is	O	O
referring	O
to	O	O
when	O	O
they	O	O
employ	O
the	O	O
term	O
subluxation	B-DISO
.	O	O

Espindolol	B-CHEM
for	O	O
the	O	O
treatment	B-PROC
and	O	O
prevention	B-PROC
of	O	O
cachexia	B-DISO
in	O	O
patients	B-LIVB
with	O	O
stage	B-DISO
III	I-DISO
/	I-DISO
IV	I-DISO
non	I-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
or	O	O
colorectal	B-DISO
cancer	I-DISO
:	O	O
a	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
,	O	O
international	B-PROC
multicentre	I-PROC
phase	I-PROC
II	I-PROC
study	I-PROC
(	I-PROC
the	I-PROC
ACT	I-PROC
-	I-PROC
ONE	I-PROC
trial	I-PROC
)	I-PROC
Cancer	B-DISO
cachexia	I-DISO
is	O	O
a	O	O
major	O	O
cause	O
of	O	O
morbidity	O
and	O	O
mortality	O
with	O	O
no	O	O
widely	O	O
approved	O	O
treatment	B-PROC
.	O	O

The	O	O
ACT	B-PROC
-	I-PROC
ONE	I-PROC
trial	I-PROC
is	O	O
a	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
parallel	B-PROC
group	I-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
,	O	O
phase	B-PROC
II	I-PROC
multicentre	I-PROC
trial	I-PROC
in	O	O
patients	B-LIVB
(	O	O
25	O	O
-	O	O
80	O	O
years	O	O
)	O	O
with	O	O
stages	B-DISO
III	I-DISO
or	I-DISO
IV	I-DISO
colorectal	I-DISO
cancer	I-DISO
or	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
-related	O	O
cachexia	B-DISO
that	O	O
tested	O	O
two	O	O
doses	O
of	O	O
espindolol	B-CHEM
(	O	O
a	O	O
novel	O	O
non	B-CHEM
-	I-CHEM
selective	I-CHEM
β	I-CHEM
blocker	I-CHEM
with	O	O
central	B-CHEM
5	I-CHEM
-	I-CHEM
HT1a	I-CHEM
and	O	O
partial	O	O
β2	B-CHEM
receptor	I-CHEM
agonist	I-CHEM
effects	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
endpoint	O
was	O	O
the	O	O
difference	O	O
in	O	O
the	O	O
rate	O	O
of	O	O
weight	B-DISO
change	I-DISO
over	O	O
16	O	O
weeks	O
(	O	O
linear	B-DEVI
mixed	I-DEVI
-	I-DEVI
effect	I-DEVI
model	I-DEVI
for	O	O
repeated	O	O
measures	O	O
)	O	O
between	O	O
high	O
-	O
dose	O
espindolol	B-CHEM
and	O	O
placebo	B-CHEM
.	O	O

Eighty	O	O
-	O	O
seven	O	O
patients	B-LIVB
were	O	O
randomized	B-PROC
centrally	O	O
in	O	O
blocks	O	O
in	O	O
a	O	O
ratio	O	O
3	O	O
:	O	O
2	O	O
:	O	O
1	O	O
[	O	O
42	O	O
high	O
dose	O
,	O	O
10	O	O
mg	O	O
twice	O	O
daily	O
(	O	O
bd	O	O
)	O	O
:	O	O
31	O	O
placebo	B-CHEM
:	O	O
14	O	O
low	O
dose	O
,	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
bd	O	O
]	O	O
.	O	O

High	O
-	O
dose	O
espindolol	B-CHEM
produced	O	O
a	O	O
statistically	O
and	O	O
clinically	O
significant	O
weight	B-DISO
gain	I-DISO
(	O	O
+0	O	O
.	O	O
54	O	O
kg	O	O
/	O	O
4	O	O
weeks	O
,	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
.	O	O
38	O	O
-	O	O
0	O	O
.	O	O
70	O	O
)	O	O
compared	O	O
with	O	O
a	O	O
weight	B-DISO
loss	I-DISO
on	O	O
placebo	B-CHEM
(	O	O
-0	O	O
.	O	O
21	O	O
kg	O	O
/	O	O
4	O	O
weeks	O
,	O	O
95	O	O
%	O	O
CI	O	O
-0	O	O
.	O	O
37	O	O
-	O	O
0	O	O
.	O	O
05	O	O
)	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
.	O	O

High	O
-	O
dose	O
espindolol	B-CHEM
produced	O	O
a	O	O
statistically	O
significant	O
increase	O	O
in	O	O
lean	B-PHYS
body	I-PHYS
mass	I-PHYS
,	O	O
whilst	O	O
changes	O	O
in	O	O
fat	B-PHYS
mass	I-PHYS
were	O	O
neutral	O	O
.	O	O

Hand	B-DISO
grip	I-DISO
strength	I-DISO
significantly	O	O
(	O	O
high	O
dose	O
-1	O	O
.	O	O

15	O	O
±	O	O
0	O	O
.	O	O

7	O	O
kg	O	O
,	O	O
placebo	B-CHEM
-3	O	O
.	O	O

51	O	O
±	O	O
0	O	O
.	O	O

8	O	O
kg	O	O
change	O	O
per	O	O
4	O	O
weeks	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

0134	O	O
)	O	O
,	O	O
stair	B-DISO
climbing	I-DISO
power	O	O
,	O	O
and	O	O
6	B-PROC
-	I-PROC
min	I-PROC
walk	I-PROC
test	I-PROC
non	O	O
-	O	O
significantly	O	O
were	O	O
all	O	O
directionally	O	O
in	O	O
favour	O	O
of	O	O
high	O
-	O
dose	O
espindolol	B-CHEM
.	O	O

There	O	O
were	O	O
no	O
clinically	O
significant	O
differences	O	O
in	O	O
safety	O	O
signals	O	O
or	O	O
survival	O
between	O	O
treatment	B-PROC
groups	O	O
,	O	O
although	O	O
a	O	O
numerical	O	O
excess	O	O
of	O	O
dyspnoea	B-DISO
was	O	O
seen	O	O
with	O	O
high	O
-	O
dose	O
espindolol	B-CHEM
(	O	O
19	O	O
.	O	O
1	O	O
%	O	O
)	O	O
compared	O	O
with	O	O
placebo	B-CHEM
(	O	O
3	O	O
.	O	O
2	O	O
%	O	O
)	O	O
.	O	O

This	O	O
positive	B-PROC
trial	I-PROC
showed	O	O
that	O	O
espindolol	B-CHEM
10	O	O
mg	O	O
bd	O	O
significantly	O	O
reversed	O	O
weight	B-DISO
loss	I-DISO
,	O	O
improved	O	O
fat	B-DISO
free	I-DISO
mass	I-DISO
,	O	O
and	O	O
maintained	O	O
fat	B-PHYS
mass	I-PHYS
in	O	O
advanced	O	O
colorectal	B-DISO
cancer	I-DISO
and	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
-related	O	O
cachexia	B-DISO
.	O	O

This	O	O
was	O	O
associated	O
with	O
a	O	O
significant	O	O
improvement	O
in	O	O
handgrip	B-DISO
strength	I-DISO
,	O	O
supporting	O	O
the	O	O
further	O	O
investigation	O	O
of	O	O
10	O	O
mg	O	O
bd	O	O
espindolol	B-CHEM
for	O	O
the	O	O
treatment	B-PROC
of	O	O
cancer	B-DISO
cachexia	I-DISO
.	O	O

Although	O	O
not	O	O
powered	O	O
to	O	O
look	O	O
at	O	O
dose	B-PROC
response	I-PROC
,	O	O
most	O	O
treatment	B-PROC
effects	O	O
for	O	O
low	O
dose	O
lay	O	O
between	O	O
high	O
dose	O
and	O	O
placebo	B-CHEM
,	O	O
suggesting	O	O
that	O	O
there	O	O
may	O	O
be	O	O
a	O	O
dose	B-PROC
response	I-PROC
in	O	O
the	O	O
effects	O
of	O
espindolol	B-CHEM
.	O	O

Interleukin	B-CHEM
-	I-CHEM
21	I-CHEM
plays	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
and	O	O
severity	O	O
of	O	O
type	B-DISO
I	I-DISO
autoimmune	I-DISO
hepatitis	I-DISO
Recently	O	O
,	O	O
the	O	O
number	O	O
of	O	O
follicular	B-ANAT
helper	B-ANAT
T	I-ANAT
(	I-ANAT
Tfh	I-ANAT
)	I-ANAT
cells	I-ANAT
expressing	O	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
21	I-CHEM
was	O	O
found	O	O
to	O	O
increase	O	O
in	O	O
peripheral	B-ANAT
blood	I-ANAT
of	O	O
human	B-LIVB
and	O	O
murine	B-LIVB
models	B-DISO
of	O	O
autoimmune	B-DISO
hepatitis	I-DISO
(	O	O
AIH	B-DISO
)	O	O
.	O	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
,	O	O
the	O	O
most	O	O
recently	O	O
discovered	O	O
member	O	O
of	O	O
the	O	O
type	B-CHEM
-	I-CHEM
I	I-CHEM
cytokine	I-CHEM
family	I-CHEM
,	O	O
exerts	O	O
various	O	O
effects	O	O
on	O	O
the	O	O
immune	B-ANAT
system	I-ANAT
,	O	O
including	O	O
B	B-PHYS
cell	I-PHYS
activation	I-PHYS
,	O	O
plasma	B-PHYS
cell	I-PHYS
differentiation	I-PHYS
,	O	O
and	O	O
immunoglobulin	B-PHEN
production	I-PHEN
.	O	O

We	O	O
aimed	O	O
to	O	O
assess	O	O
the	O	O
relationship	O	O
of	O	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
in	O	O
patients	B-LIVB
with	O	O
type	B-DISO
I	I-DISO
AIH	I-DISO
with	O	O
clinical	O
and	O	O
laboratory	B-OBJC
parameters	O
and	O	O
histology	O
.	O	O

Ninety	O	O
-	O	O
two	O	O
Japanese	B-LIVB
patients	B-LIVB
with	O	O
liver	B-DISO
disease	I-DISO
(	O	O
22	O	O
AIH	B-DISO
,	O	O
20	O	O
primary	B-DISO
biliary	I-DISO
cholangitis	I-DISO
,	O	O
19	O	O
drug	B-DISO
-	I-DISO
induced	I-DISO
liver	I-DISO
injury	I-DISO
,	O	O
8	O	O
acute	B-DISO
hepatitis	I-DISO
B	I-DISO
,	O	O
8	O	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
,	O	O
10	O	O
non	B-DISO
-	I-DISO
alcoholic	I-DISO
steatohepatitis	I-DISO
,	O	O
5	O	O
viral	B-DISO
hepatitis	I-DISO
)	O	O
and	O	O
10	O	O
healthy	B-LIVB
volunteers	I-LIVB
were	O	O
recruited	O	O
.	O	O

Serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O	O
detected	O	O
by	O	O
enzyme	B-PROC
-	I-PROC
linked	I-PROC
immunosorbent	I-PROC
assay	I-PROC
.	O	O

Real	B-PROC
-	I-PROC
time	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
measured	O	O
mRNA	B-CHEM
levels	O
of	O	O
Bcl	O
-	O
6	O
,	O	O
IL	O
-	O
21	O
,	O	O
and	O	O
CXCR5	O
(	O	O
Tfh	B-CHEM
-	I-CHEM
related	I-CHEM
factors	I-CHEM
)	O	O
in	O	O
peripheral	O
mononuclear	B-ANAT
cells	I-ANAT
.	O	O

Mean	O	O
age	O	O
at	O	O
diagnosis	B-DISO
of	O	O
AIH	B-DISO
was	O	O
58	O	O
.	O	O

6	O	O
years	O	O
,	O	O
male	B-DISO
-	I-DISO
to	I-DISO
-	I-DISO
female	I-DISO
ratio	I-DISO
was	O	O
4	O	O
:	O	O
18	O	O
,	O	O
18	O	O
.	O	O
2	O	O
%	O	O
of	O	O
participants	O	O
had	O	O
cirrhosis	B-DISO
,	O	O
and	O	O
22	O	O
.	O	O

7	O	O
%	O	O
had	O	O
severe	O
disease	B-DISO
.	O	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O	O
significantly	O	O
increased	O
in	O	O
the	O	O
serum	B-ANAT
of	O	O
patients	B-LIVB
with	O	O
AIH	B-DISO
compared	O	O
to	O	O
those	O	O
with	O	O
other	O
liver	O
diseases	O
and	O	O
controls	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

Particularly	O	O
,	O	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
were	O	O
significantly	O	O
increased	O
in	O	O
severe	O
AIH	B-DISO
cases	O	O
compared	O	O
to	O	O
non	O	O
-	O	O
severe	O	O
cases	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
correlated	O	O
positively	O	O
with	O	O
total	O	O
serum	B-ANAT
bilirubin	B-PROC
levels	I-PROC
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
46	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
grading	B-DISO
of	I-DISO
necroinflammatory	I-DISO
activity	I-DISO
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
68	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
005	O	O
)	O	O
and	O	O
negatively	O	O
with	O	O
serum	B-PHEN
albumin	I-PHEN
levels	I-PHEN
in	O	O
patients	B-LIVB
with	O	O
AIH	B-DISO
(	O	O
r	O	O
=	O	O
-0	O	O
.	O	O

49	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
patients	B-LIVB
with	O	O
biochemical	O
remission	B-DISO
of	O	O
AIH	B-DISO
,	O	O
serum	B-ANAT
IL	B-CHEM
-	I-CHEM
21	I-CHEM
levels	O
remained	O	O
elevated	O
and	O	O
correlated	O
positively	B-DISO
with	O	O
serum	B-PROC
IgG	I-PROC
levels	I-PROC
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
84	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Expression	B-PHYS
of	O	O
Tfh	B-CHEM
-	I-CHEM
related	I-CHEM
factors	I-CHEM
,	O	O
such	O	O
as	O	O
Bcl	B-CHEM
-	I-CHEM
6	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
21	I-CHEM
,	O	O
in	O	O
peripheral	B-ANAT
blood	I-ANAT
mononuclear	I-ANAT
cells	I-ANAT
of	O	O
patients	B-LIVB
with	O	O
AIH	B-DISO
was	O	O
significantly	O	O
higher	O
than	O	O
that	O	O
in	O	O
healthy	B-LIVB
volunteers	I-LIVB
.	O	O

IL	B-CHEM
-	I-CHEM
21	I-CHEM
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
and	O	O
severity	O	O
of	O	O
AIH	B-DISO
,	O	O
and	O	O
may	O	O
present	O	O
a	O	O
promising	O	O
target	O	O
for	O	O
AIH	B-DISO
therapy	O
.	O	O

Mono	B-CHEM
-	I-CHEM
sulfonated	I-CHEM
tetrazolium	I-CHEM
salt	I-CHEM
based	O	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
detection	B-PROC
reagents	B-CHEM
suitable	O	O
for	O	O
dehydrogenase	B-CHEM
and	O	O
real	O
-	O
time	O
cell	B-PROC
viability	I-PROC
assays	I-PROC
Glutamate	B-CHEM
dehydrogenase	I-CHEM
(	O	O
GDH	B-CHEM
)	O	O
catalyzes	O	O
the	O	O
oxidative	O
deamination	B-PHEN
of	O	O
L	B-CHEM
-	I-CHEM
glutamate	I-CHEM
and	O	O
is	O	O
important	O	O
for	O	O
several	O	O
biological	B-PHEN
processes	I-PHEN
.	O	O

For	O	O
GDH	B-CHEM
inhibitor	B-CHEM
screening	B-PROC
,	O	O
we	O	O
developed	O	O
a	O	O
novel	O	O
mono	B-CHEM
-	I-CHEM
sulfonated	I-CHEM
tetrazolium	I-CHEM
salt	I-CHEM
(	O	O
EZMTT	B-CHEM
)	O	O
,	O	O
which	O	O
can	O	O
be	O	O
synthesized	O
using	O	O
H2O2	B-CHEM
oxidation	B-PHYS
and	O	O
purified	O
easily	O	O
on	O	O
silica	B-CHEM
gel	I-CHEM
in	O	O
large	O	O
quantities	O	O
.	O	O

The	O	O
EZMTT	B-CHEM
detection	O
method	O
showed	O	O
linear	B-PHEN
dose	I-PHEN
responses	I-PHEN
to	O	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
,	O	O
dehydrogenase	B-CHEM
concentration	O	O
and	O	O
cell	B-PROC
numbers	I-PROC
.	O	O

In	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-PROC
assay	I-PROC
,	O	O
the	O	O
EZMTT	B-CHEM
method	O	O
showed	O	O
excellent	O	O
assay	O
reproducibility	O
with	O	O
a	O	O
Z	O
factor	O
of	O	O
0	O	O
.	O	O
9	O	O
and	O	O
caused	O	O
no	B-PHEN
false	I-PHEN
positives	I-PHEN
in	O	O
the	O	O
presence	O	O
of	O	O
antioxidants	B-CHEM
(	O	O
such	O	O
as	O	O
BME	B-CHEM
)	O	O
.	O	O

Using	O	O
the	O	O
EZMTT	B-CHEM
-	O	O
formazan	B-CHEM
-	O	O
NAD	B-CHEM
(	I-CHEM
P	I-CHEM
)	I-CHEM
H	I-CHEM
system	O	O
,	O	O
we	O	O
showed	O	O
that	O	O
EGCG	B-CHEM
is	O	O
a	O	O
potent	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-CHEM
inhibitor	B-CHEM
(	O	O
IC50	O
45	O	O
nM	O	O
)	O	O
and	O	O
identified	O	O
that	O	O
Ebselen	B-CHEM
,	O	O
a	O	O
multifunctional	O	O
thioredoxin	B-CHEM
reductase	I-CHEM
inhibitor	B-CHEM
,	O	O
inactivated	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
GDH	B-CHEM
(	O	O
IC50	O
213	O	O
nM	O	O
)	O	O
.	O	O

In	O	O
cell	B-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
at	O	O
0	O	O
.	O	O

5	O	O
mM	O	O
tetrazolium	B-CHEM
concentration	O	O
,	O	O
EZMTT	B-CHEM
showed	O	O
essentially	O	O
no	O
toxicity	O
after	O	O
a	O	O
3	O	O
-	O	O
day	O	O
incubation	B-DISO
,	O	O
whereas	O	O
40	O	O
%	O	O
of	O	O
inhibition	B-PHYS
was	O	O
observed	O	O
for	O	O
WST	B-CHEM
-	I-CHEM
8	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
EZMTT	B-CHEM
is	O	O
a	O	O
novel	O	O
tetrazolium	B-CHEM
salt	I-CHEM
which	O	O
provides	O	O
improved	O	O
features	O	O
that	O	O
are	O	O
suitable	O	O
for	O	O
dehydrogenases	B-CHEM
and	O	O
real	O
-	O
time	O
cell	B-PROC
-	I-PROC
based	I-PROC
high	B-PROC
-	I-PROC
throughput	I-PROC
screening	I-PROC
(	O	O
HTS	O	O
)	O	O
.	O	O

Is	O	O
Localized	B-DISO
Scleroderma	I-DISO
Caused	O
by	O
Borrelia	B-LIVB
burgdorferi	I-LIVB
?	O	O
Despite	O	O
considerable	O	O
achievements	O	O
in	O	O
the	O	O
study	B-PROC
of	O	O
localized	B-DISO
scleroderma	I-DISO
,	O	O
the	O	O
etiology	O
of	O	O
the	O	O
disease	B-DISO
has	O	O
not	O	O
been	O	O
investigated	O
completely	O	O
.	O	O

Borrelia	B-LIVB
burgdorferi	I-LIVB
-the	O	O
agent	O	O
of	O	O
Lyme	B-DISO
disease	I-DISO
-is	O	O
suggested	O	O
to	O	O
be	O	O
one	O	O
of	O	O
the	O	O
possible	O	O
etiological	O
factors	O
of	O	O
localized	B-DISO
scleroderma	I-DISO
.	O	O

However	O	O
,	O	O
among	O	O
scientists	B-LIVB
,	O	O
this	O	O
hypothesis	O
is	O	O
quite	O	O
controversial	O
.	O	O

We	O	O
have	O	O
conducted	O	O
investigations	B-PROC
of	O	O
the	O	O
level	O
of	O	O
IgM	B-CHEM
and	O	O
IgG	B-CHEM
class	O	O
antibodies	B-CHEM
to	O	O
B	B-LIVB
.	I-LIVB

burgdorferi	I-LIVB
in	O	O
the	O	O
serum	B-ANAT
of	O	O
patients	B-LIVB
with	O	O
localized	B-DISO
scleroderma	I-DISO
.	O	O

To	O	O
rationally	O	O
substantiate	O	O
the	O	O
role	O	O
of	O	O
B	B-LIVB
.	I-LIVB

burgdorferi	I-LIVB
in	O	O
the	O	O
occurrence	O	O
of	O	O
localized	B-DISO
scleroderma	I-DISO
,	O	O
thirty	O	O
-	O	O
two	O	O
patients	B-LIVB
with	O	O
localized	B-DISO
scleroderma	I-DISO
treated	O
at	O	O
an	O	O
in	B-LIVB
-	I-LIVB
patient	I-LIVB
department	O
were	O	O
examined	O	O
.	O	O

The	O	O
level	O
of	O	O
anti	B-CHEM
-	I-CHEM
Borrelia	I-CHEM
antibodies	I-CHEM
was	O	O
determined	O	O
in	O	O
ELISA	B-PROC
.	O	O

Diagnostic	O
levels	O
of	O	O
IgM	B-CHEM
and	O	O
/	O	O
or	O	O
IgG	B-CHEM
were	O	O
detected	O	O
in	O	O
18	O	O
.	O	O

8	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
localized	B-DISO
scleroderma	I-DISO
,	O	O
which	O	O
is	O	O
more	O	O
than	O	O
in	O	O
the	O	O
population	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Positive	B-DISO
levels	I-DISO
of	O	O
anti	B-CHEM
-	I-CHEM
Borrelia	I-CHEM
antibodies	I-CHEM
in	O	O
patients	B-LIVB
with	O	O
localized	B-DISO
scleroderma	I-DISO
confirm	O	O
the	O	O
borreliosis	B-DISO
nature	O
of	O
the	O
disease	O
,	O	O
requiring	O	O
conduction	O	O
of	O	O
complex	O	O
antimicrobial	B-CHEM
treatment	B-PROC
.	O	O

RF	B-PROC
Ablation	I-PROC
of	O	O
Giant	B-DISO
Hemangiomas	I-DISO
Inducing	O
Acute	B-DISO
Renal	I-DISO
Failure	I-DISO
:	O	O
A	O	O
Report	O
of	O	O
Two	O	O
Cases	O
In	O	O
patients	B-LIVB
that	O	O
require	O
treatment	O
for	O	O
hepatic	B-ANAT
giant	B-DISO
cavernous	I-DISO
hemangiomas	I-DISO
(	O	O
GCH	B-DISO
)	O	O
,	O	O
radiofrequency	B-PROC
ablation	I-PROC
(	O	O
RFA	B-PROC
)	O	O
has	O	O
been	O	O
suggested	O
to	O	O
represent	O	O
a	O	O
safe	O	O
and	O	O
effective	O
alternative	O
to	O	O
invasive	O
surgery	B-PROC
.	O	O

In	O	O
a	O	O
recent	O	O
report	O
of	O	O
bipolar	B-PROC
RFA	I-PROC
,	O	O
using	O	O
two	O	O
expandable	B-DEVI
needle	I-DEVI
electrodes	I-DEVI
,	O	O
was	O	O
uneventfully	O	O
performed	O
in	O	O
patients	B-LIVB
with	O	O
large	O
GCH	B-DISO
(	O	O
>	O	O
10	O	O
cm	O	O
)	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
report	O
is	O	O
to	O	O
present	O	O
two	O	O
cases	O
in	O	O
which	O	O
bipolar	B-PROC
RFA	I-PROC
of	O	O
symptomatic	O
GCH	B-DISO
was	O	O
complicated	O
by	O	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
.	O	O

In	O	O
2015	O	O
we	O	O
treated	O
two	O	O
patients	B-LIVB
for	O	O
very	O	O
large	O
symptomatic	O
GCH	B-DISO
(	O	O
15	O	O
.	O	O
7	O	O
and	O	O
25	O	O
.	O	O
0	O	O
cm	O	O
)	O	O
with	O	O
bipolar	B-PROC
RFA	I-PROC
during	O	O
open	B-PROC
laparotomy	I-PROC
.	O	O

In	O	O
both	O	O
patients	B-LIVB
the	O	O
urine	B-ANAT
showed	O	O
a	O	O
red	B-DISO
-	I-DISO
brown	I-DISO
discoloration	I-DISO
directly	O	O
after	O	O
the	O	O
ablation	B-PROC
.	O	O

They	O	O
became	O	O
anuric	B-DISO
and	O	O
presented	O
with	O	O
progressive	B-DISO
dyspnea	I-DISO
,	O	O
tachypnea	B-DISO
,	O	O
and	O	O
tachycardia	B-DISO
,	O	O
requiring	O	O
hemodialysis	B-PROC
for	O	O
a	O	O
period	O
of	O	O
1	O	O
month	O
in	O	O
one	O	O
case	O
.	O	O

Lab	O
results	O
revealed	O	O
hemepigment	B-CHEM
-	O	O
induced	O
acute	B-DISO
kidney	I-DISO
.	O	O

Both	O	O
patients	B-LIVB
fully	O	O
recovered	O
and	O	O
both	O	O
showed	O	O
a	O	O
complete	O
relief	B-DISO
of	O	O
symptoms	B-DISO
at	O	O
3	O	O
months	O
following	O	O
the	O	O
procedure	O
.	O	O

RFA	B-PROC
for	O	O
large	O
GCHs	B-DISO
can	O	O
cause	O	O
hemepigment	B-CHEM
-	O	O
induced	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
due	O	O
to	O	O
massive	O
intravascular	B-DISO
hemolysis	I-DISO
.	O	O

The	O	O
presented	O	O
cases	O
suggest	O	O
that	O	O
caution	O	O
is	O	O
warranted	O	O
and	O	O
advocate	O	O
an	O	O
upper	O	O
limit	O	O
regarding	O	O
the	O	O
volume	O
of	O	O
GCHs	B-DISO
that	O	O
can	O	O
be	O	O
safely	O	O
ablated	B-PROC
.	O	O

Effect	O
of	O	O
Hepatitis	B-DISO
C	I-DISO
Virus	I-DISO
Coinfection	I-DISO
on	O	O
the	O	O
Content	O	O
of	O	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
and	I-ANAT
CD8	I-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	B-ANAT
Cell	I-ANAT
Subpopulations	O
in	O	O
HIV	B-LIVB
-	O	O
Infected	B-DISO
Patients	B-LIVB
Receiving	O
Antiretroviral	B-PROC
Therapy	I-PROC
We	O	O
studied	O	O
the	O	O
effect	O
of	O	O
hepatitis	B-DISO
C	I-DISO
virus	I-DISO
coinfection	I-DISO
on	O	O
T	B-ANAT
cell	I-ANAT
subpopulations	O
in	O	O
HIV	B-LIVB
-	O	O
infected	B-DISO
patients	B-LIVB
receiving	O	O
antiretroviral	B-PROC
therapy	I-PROC
.	O	O

Coinfection	B-DISO
with	O	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
was	O	O
followed	O	O
by	O	O
a	O	O
decrease	O
in	O	O
the	O	O
number	O	O
of	O	O
naive	B-ANAT
CD4	I-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
and	O	O
an	O	O
increase	O
in	O	O
the	O	O
count	O
of	O	O
central	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
in	O	O
these	O	O
patients	B-LIVB
.	O	O

Hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
had	O	O
no	O
effect	O
on	O	O
the	O	O
number	O	O
of	O	O
CD4	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
memory	I-ANAT
T	I-ANAT
cells	I-ANAT
(	O	O
main	O	O
target	O	O
for	O	O
HIV	B-LIVB
)	O	O
.	O	O

This	O	O
can	O	O
explain	O	O
the	O	O
absence	O	O
of	O	O
strong	O	O
negative	B-DISO
effect	O
of	O	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
on	O	O
the	O	O
course	O
of	O	O
HIV	B-LIVB
infection	B-DISO
.	O	O

Examining	O
the	O	O
contribution	O
of	O	O
motor	O
movement	O
and	O	O
language	O
dominance	O
to	O	O
increased	O
left	O
lateralization	B-PHYS
during	O	O
sign	O
generation	O
in	O	O
native	O
signers	B-LIVB
The	O	O
neural	B-ANAT
systems	I-ANAT
supporting	O	O
speech	B-PHYS
and	O	O
sign	O
processing	B-PHYS
are	O	O
very	O	O
similar	O
,	O	O
although	O	O
not	O	O
identical	O	O
.	O	O

In	O	O
a	O	O
previous	O	O
fTCD	B-PROC
study	I-PROC
of	O	O
hearing	B-PHYS
native	O
signers	B-LIVB
(	O	O
Gutierrez	O	O
-	O	O
Sigut	O	O
,	O	O
Daws	O	O
,	O	O
et	O	O
al	O	O
.	O	O
,	O	O
2015	O	O
)	O	O
we	O	O
found	O	O
stronger	O	O
left	O
lateralization	B-PHYS
for	O	O
sign	O
than	O	O
speech	B-PHYS
.	O	O

Given	O	O
that	O	O
this	O	O
increased	O
lateralization	B-PHYS
could	O	O
not	O	O
be	O	O
explained	O	O
by	O	O
hand	B-ANAT
movement	B-PHYS
alone	O	O
,	O	O
the	O	O
contribution	O	O
of	O	O
motor	O
movement	O
versus	O	O
'	O	O
linguistic	O
'	O	O
processes	B-PHYS
to	O	O
the	O	O
strength	O
of	O	O
hemispheric	O
lateralization	B-PHYS
during	O	O
sign	O
production	B-PHYS
remains	O	O
unclear	O	O
.	O	O

Here	O	O
we	O	O
directly	O	O
contrast	O
lateralization	B-PHYS
strength	O
of	O	O
covert	O
versus	O	O
overt	O
signing	O
during	O	O
phonological	O
and	O	O
semantic	O
fluency	O
tasks	O
.	O	O

To	O	O
address	O	O
the	O	O
possibility	O	O
that	O	O
hearing	B-PHYS
native	O
signers	B-LIVB
'	O	O
elevated	O
lateralization	O
indices	O
(	O	O
LIs	O
)	O	O
were	O	O
due	O	O
to	O	O
performing	O	O
a	O	O
task	O
in	O	O
their	O	O
less	O	O
dominant	O
language	O
,	O	O
here	O	O
we	O	O
test	O	O
deaf	B-LIVB
native	O
signers	B-LIVB
,	O	O
whose	O	O
dominant	O
language	O
is	O	O
British	O
Sign	O
Language	O
(	O	O
BSL	O
)	O	O
.	O	O

Signers	B-LIVB
were	O	O
more	O	O
strongly	O	O
left	O
lateralized	B-PHYS
for	O	O
overt	O
than	O	O
covert	O
sign	O
generation	O	O
.	O	O

However	O	O
,	O	O
the	O	O
strength	O
of	O	O
lateralization	B-PHYS
was	O	O
not	O	O
correlated	O
with	O	O
the	O	O
amount	O	O
of	O	O
time	O	O
producing	O	O
movements	B-PHYS
of	O	O
the	O	O
right	B-ANAT
hand	I-ANAT
.	O	O

Comparisons	O
with	O	O
previous	O	O
data	O
from	O	O
hearing	B-PHYS
native	O
English	O
speakers	B-LIVB
suggest	O	O
stronger	O	O
laterality	O
indices	O
for	O	O
sign	O
than	O	O
speech	B-PHYS
in	O	O
both	O	O
covert	O
and	O	O
overt	O
tasks	O
.	O	O

This	O	O
increased	O
left	O
lateralization	B-PHYS
may	O	O
be	O	O
driven	O	O
by	O	O
specific	O	O
properties	O
of	O	O
sign	O
production	B-PHYS
such	O	O
as	O	O
the	O	O
increased	O
use	O
of	O	O
self	O
-	O
monitoring	O
mechanisms	O
or	O	O
the	O	O
nature	O
of	O	O
phonological	B-PHYS
encoding	I-PHYS
of	O	O
signs	O
.	O	O

Resistance	O
Exercise	O
in	O	O
Pregnancy	B-PHYS
and	O	O
Outcome	B-DISO
As	O	O
the	O	O
health	O
benefits	O
of	O	O
exercise	O
are	O	O
increasingly	O	O
recognized	O	O
,	O	O
the	O	O
traditional	B-PROC
advice	I-PROC
to	O	O
rest	O
during	O	O
pregnancy	B-PHYS
has	O	O
changed	O
toward	O	O
a	O	O
more	O	O
healthy	O
and	O	O
active	O
pregnancy	B-PHYS
,	O	O
therefore	O	O
different	O	O
forms	O	O
of	O	O
exercise	O
have	O	O
been	O	O
integrated	O	O
into	O	O
the	O	O
life	O
of	O	O
the	O	O
pregnant	B-LIVB
woman	I-LIVB
.	O	O

Although	O	O
the	O	O
benefits	O
of	O	O
using	O	O
a	O	O
combination	O
of	O	O
resistance	O
and	O	O
aerobic	B-PROC
exercises	I-PROC
are	O	O
not	O	O
yet	O	O
determined	O	O
,	O	O
studies	B-PROC
about	O	O
resistance	O
and	O	O
strengthen	O	O
training	B-PROC
programs	I-PROC
are	O	O
few	O	O
although	O	O
no	B-DISO
adverse	I-DISO
outcomes	B-DISO
were	O	O
reported	O	O
.	O	O

Identifying	O	O
and	O	O
integrating	O	O
patient	B-LIVB
and	O	O
caregiver	B-LIVB
perspectives	O
for	O	O
clinical	O
practice	O
guidelines	O
on	O	O
the	O	O
screening	B-PROC
and	O	O
management	O	O
of	O	O
infectious	O
microorganisms	B-LIVB
in	O	O
hemodialysis	B-OBJC
units	I-OBJC
The	O	O
integration	O	O
of	O	O
patient	B-LIVB
and	O	O
caregiver	B-LIVB
input	O	O
into	O	O
guideline	O
development	O	O
can	O	O
help	O	O
to	O	O
ensure	O	O
that	O	O
clinical	O
care	O
addresses	O	O
patient	B-LIVB
expectations	O
,	O	O
priorities	O
,	O	O
and	O	O
needs	O
.	O	O

We	O	O
aimed	O	O
to	O	O
identify	O	O
topics	O	O
and	O	O
outcomes	O
salient	O	O
to	O	O
patients	B-LIVB
and	O	O
caregivers	B-LIVB
for	O	O
inclusion	O	O
in	O	O
the	O	O
Kidney	O
Health	O
Australia	O
Caring	B-PROC
for	I-PROC
Australasians	I-PROC
with	I-PROC
Renal	I-PROC
Impairment	I-PROC
(	O	O
KHA	O
-	O	O
CARI	B-PROC
)	O	O
clinical	O
practice	O
guideline	O
on	O	O
the	O	O
screening	B-PROC
and	O	O
management	O	O
of	O	O
infectious	O
microorganisms	B-LIVB
in	O	O
hemodialysis	B-OBJC
units	I-OBJC
.	O	O

A	O	O
facilitated	O	O
workshop	O
was	O	O
conducted	O	O
with	O	O
11	O	O
participants	B-LIVB
(	O	O
patients	B-LIVB
[	O	O
n	O	O
=	O	O
8	O	O
]	O	O
,	O	O
caregivers	B-LIVB
[	O	O
n	O	O
=	O	O
3	O	O
]	O	O
)	O	O
.	O	O

Participants	B-LIVB
identified	O	O
and	O	O
discussed	O	O
potential	O	O
topics	O	O
for	O	O
inclusion	O	O
in	O	O
the	O	O
guidelines	O
,	O	O
which	O	O
were	O	O
compared	O	O
to	O	O
those	O	O
developed	O	O
by	O	O
the	O	O
guideline	O
working	B-LIVB
group	I-LIVB
.	O	O

The	O	O
workshop	O
transcript	O	O
was	O	O
thematically	O	O
analyzed	O	O
to	O	O
identify	O	O
and	O	O
describe	O	O
the	O	O
reasons	O	O
underpinning	O	O
their	O	O
priorities	O	O
.	O	O

Patients	B-LIVB
and	O	O
caregivers	B-LIVB
identified	O	O
a	O	O
range	O	O
of	O	O
topics	O	O
already	O	O
covered	O	O
by	O	O
the	O	O
scope	O	O
of	O	O
the	O	O
proposed	O	O
guidelines	O
and	O	O
also	O	O
suggested	O	O
additional	O	O
topics	O	O
:	O	O
privacy	O
and	O	O
confidentiality	O
,	O	O
psychosocial	B-PROC
care	I-PROC
during	O	O
/	O	O
after	O	O
disease	B-PROC
notification	I-PROC
,	O	O
quality	O
of	O	O
transportation	B-PROC
,	O	O
psychosocial	O
treatment	O
of	O	O
patients	B-LIVB
in	O	O
isolation	B-PROC
,	O	O
patient	B-LIVB
/	O	O
caregiver	B-PROC
education	I-PROC
and	O	O
engagement	B-PROC
,	O	O
and	O	O
patient	B-PROC
advocacy	I-PROC
.	O	O

Five	O	O
themes	O	O
characterized	O	O
discussion	O	O
and	O	O
underpinned	O	O
their	O	O
choices	O	O
:	O	O
shock	B-DISO
and	O	O
vulnerability	B-DISO
,	O	O
burden	B-DISO
of	I-DISO
isolation	I-DISO
,	O	O
fear	B-PHYS
of	I-PHYS
infection	I-PHYS
,	O	O
respect	B-PROC
for	I-PROC
privacy	I-PROC
and	O	O
confidentiality	O
,	O	O
and	O	O
confusion	B-DISO
over	I-DISO
procedural	I-DISO
inconsistencies	I-DISO
.	O	O

Patients	B-LIVB
and	O	O
caregivers	B-LIVB
emphasized	O	O
the	O	O
need	O	O
for	O	O
guidelines	O
to	O	O
address	O	O
patient	B-PROC
education	I-PROC
and	O	O
engagement	B-PROC
,	O	O
and	O	O
the	O	O
psychosocial	O
implications	O
of	O	O
communication	O	O
and	O	O
provision	B-PROC
of	I-PROC
care	I-PROC
in	O	O
the	O	O
context	O	O
of	O	O
infectious	O
microorganisms	B-LIVB
in	O	O
hemodialysis	B-OBJC
units	I-OBJC
.	O	O

Integrating	O	O
patient	B-LIVB
and	O	O
caregiver	B-LIVB
perspectives	O
can	O	O
help	O	O
to	O	O
improve	O	O
the	O	O
relevance	O	O
of	O	O
guidelines	O
to	O	O
enhance	O	O
quality	B-PROC
of	I-PROC
care	I-PROC
,	O	O
patient	B-LIVB
experiences	O	O
,	O	O
and	O	O
health	O
and	O	O
psychosocial	O
outcomes	O
.	O	O

Longitudinal	B-PROC
live	I-PROC
imaging	I-PROC
of	O	O
retinal	B-ANAT
α	B-CHEM
-	I-CHEM
synuclein	I-CHEM
:	O	O
:	O	O
GFP	B-CHEM
deposits	B-DISO
in	O	O
a	O	O
transgenic	B-LIVB
mouse	I-LIVB
model	I-LIVB
of	O	O
Parkinson	B-DISO
's	I-DISO
Disease	I-DISO
/	O	O
Dementia	B-DISO
with	I-DISO
Lewy	I-DISO
Bodies	I-DISO
Abnormal	B-CHEM
α	B-CHEM
-	I-CHEM
synuclein	I-CHEM
(	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
)	O	O
accumulation	B-DISO
in	O	O
the	O	O
CNS	B-ANAT
may	O	O
underlie	O	O
neuronal	B-ANAT
cell	I-ANAT
and	O	O
synaptic	B-ANAT
dysfunction	B-DISO
leading	O	O
to	O	O
motor	B-DISO
and	O	O
cognitive	B-DISO
deficits	I-DISO
in	O	O
synucleinopathies	B-DISO
including	O	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
PD	B-DISO
)	O	O
and	O	O
Dementia	B-DISO
with	I-DISO
Lewy	I-DISO
Bodies	I-DISO
(	O	O
DLB	B-DISO
)	O	O
.	O	O

Multiple	O	O
groups	O	O
demonstrated	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
accumulation	B-DISO
in	O	O
CNS	B-ANAT
accessory	B-ANAT
structures	I-ANAT
,	O	O
including	O	O
the	O	O
eyes	B-ANAT
and	O	O
olfactory	B-ANAT
terminals	I-ANAT
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
peripheral	O
organs	B-ANAT
of	O	O
Parkinsonian	B-DISO
patients	B-LIVB
.	O	O

Retinal	B-ANAT
imaging	B-PROC
studies	I-PROC
of	O	O
mice	B-LIVB
overexpressing	B-PHYS
fused	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O	O
:	O	O
GFP	B-CHEM
were	O	O
conducted	O	O
to	O	O
evaluate	B-PROC
the	O	O
presence	O	O
and	O	O
progression	O
of	O	O
retinal	B-ANAT
pathology	O
in	O	O
a	O	O
PD	B-DISO
/	O	O
DLB	B-DISO
transgenic	B-LIVB
mouse	I-LIVB
model	I-LIVB
.	O	O

Bright	B-PROC
-	I-PROC
field	I-PROC
image	I-PROC
retinal	B-PHEN
maps	I-PHEN
and	O	O
fluorescent	B-PROC
images	I-PROC
were	O	O
acquired	O	O
at	O	O
1	O	O
-	O	O
month	O	O
intervals	O	O
for	O	O
3	O	O
months	O	O
.	O	O

Retinal	B-ANAT
imaging	B-PROC
revealed	O	O
the	O	O
accumulation	B-DISO
of	O	O
GFP	B-CHEM
-tagged	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
in	O	O
retinal	B-ANAT
ganglion	I-ANAT
cell	I-ANAT
layer	I-ANAT
and	O	O
in	O	O
the	O	O
edges	O	O
of	O	O
arterial	O
blood	B-ANAT
vessels	I-ANAT
in	O	O
the	O	O
transgenic	B-LIVB
mice	I-LIVB
.	O	O

Double	B-PROC
labeling	I-PROC
studies	I-PROC
confirmed	O	O
that	O	O
the	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O	O
:	O	O
GFP	B-CHEM
-positive	O	O
cells	B-ANAT
were	O	O
retinal	B-ANAT
ganglion	I-ANAT
cells	I-ANAT
containing	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O	O

Accumulation	B-DISO
of	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
persisted	O	O
in	O	O
the	O	O
same	O	O
cells	B-ANAT
and	O	O
increased	O	O
with	O	O
age	B-PHYS
.	O	O

Accumulation	B-DISO
of	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O	O
:	O	O
GFP	B-CHEM
was	O	O
reduced	O	O
by	O	O
immunization	B-PROC
with	O	O
single	B-CHEM
chain	I-CHEM
antibodies	I-CHEM
against	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
longitudinal	B-PROC
live	I-PROC
imaging	I-PROC
of	O	O
the	O	O
retina	B-ANAT
in	O	O
the	O	O
PDGF	B-CHEM
-	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
:	O	O
:	O	O
GFP	B-CHEM
mice	B-LIVB
might	O	O
represent	O	O
a	O	O
useful	O	O
,	O	O
non	O
-	O
invasive	O
tool	O	O
to	O	O
monitor	O	O
the	O	O
fate	O	O
of	O	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
accumulation	B-DISO
in	O	O
the	O	O
CNS	B-ANAT
and	O	O
to	O	O
evaluate	B-PROC
the	O	O
therapeutic	B-PHYS
effects	I-PHYS
of	O	O
compounds	B-CHEM
targeting	O
α	B-CHEM
-	I-CHEM
syn	I-CHEM
.	O	O

Custom	O	O
ocular	B-DEVI
prosthesis	I-DEVI
in	O	O
rehabilitation	B-PROC
of	O	O
a	O	O
child	B-LIVB
operated	O	O
for	O	O
retinoblastoma	B-DISO
A	O	O
maxillofacial	B-PROC
prosthodontist	I-PROC
forms	O	O
an	O	O
important	O
link	O	O
in	O	O
the	O	O
interdisciplinary	O	O
management	B-PROC
of	I-PROC
a	I-PROC
patient	I-PROC
with	O	O
anopthalmosis	B-DISO
.	O	O

Prosthetic	B-PROC
management	I-PROC
of	O	O
an	O	O
anopthalmic	B-DISO
defect	I-DISO
aims	O	O
to	O	O
deliver	O	O
a	O	O
well	O	O
-	O	O
fitting	O	O
ocular	B-DEVI
prosthesis	I-DEVI
that	O	O
can	O	O
mimic	O	O
the	O	O
original	O	O
eye	B-ANAT
as	O	O
closely	O	O
as	O	O
possible	O	O
,	O	O
and	O	O
thus	O	O
restoring	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
self	B-PHYS
-	I-PHYS
confidence	I-PHYS
and	O	O
thereby	O	O
rehabilitating	O
them	O	O
in	O	O
the	O	O
society	O
.	O	O

The	O	O
fabrication	B-PROC
of	O	O
a	O	O
custom	O	O
ocular	B-DEVI
prosthesis	I-DEVI
is	O	O
a	O	O
demanding	O	O
art	O	O
.	O	O

This	O	O
case	O
report	O
presents	O	O
a	O	O
simplified	O	O
technique	O
for	O	O
the	O	O
fabrication	B-PROC
of	O	O
a	O	O
custom	O	O
ocular	B-DEVI
prosthesis	I-DEVI
for	O	O
a	O	O
child	B-LIVB
who	O	O
had	O	O
lost	O
his	O	O
eye	B-ANAT
to	O	O
enucleation	B-PROC
following	O	O
retinoblastoma	B-DISO
.	O	O

Early	O	O
and	O	O
effective	O	O
rehabilitation	B-PROC
of	O	O
the	O	O
defect	O	O
goes	O	O
a	O	O
long	O	O
way	O	O
in	O	O
restoring	O	O
the	O	O
self	B-PROC
-	I-PROC
image	I-PROC
of	O	O
a	O	O
child	B-LIVB
in	O	O
its	O	O
early	O	O
character	O	O
building	O	O
age	O	O
.	O	O

Health	B-PROC
technology	I-PROC
assessment	I-PROC
:	O	O
Off	O
-	O
site	O
sterilization	B-PROC
Every	O	O
year	O
millions	O
of	O
dollars	O
are	O	O
expended	O
to	O	O
equip	O	O
and	O	O
maintain	O
the	O	O
hospital	B-OBJC
sterilization	B-PROC
centers	B-OBJC
,	O	O
and	O	O
our	O	O
country	B-GEOG
is	O	O
not	O	O
an	O	O
exception	O
of	O	O
this	O	O
matter	O	O
.	O	O

According	O	O
to	O	O
this	O	O
,	O	O
it	O	O
is	O	O
important	O
to	O	O
use	O	O
more	O	O
effective	O
technologies	O
and	O	O
methods	O
in	O	O
health	O
system	O
in	O	O
order	O	O
to	O	O
reach	O	O
more	O	O
effectiveness	O
and	O	O
saving	O
in	O
costs	O
.	O	O

This	O	O
study	B-PROC
was	O	O
conducted	O	O
with	O	O
the	O	O
aim	O
of	O	O
evaluating	B-PROC
the	O	O
technology	O
of	O	O
regional	O
sterilization	B-PROC
centers	B-OBJC
.	O	O

This	O	O
study	B-PROC
was	O	O
done	O	O
in	O	O
four	O	O
steps	O	O
.	O	O

At	O	O
the	O	O
first	O	O
step	O	O
,	O	O
safety	B-PHEN
and	O	O
effectiveness	O
of	O	O
technology	O
was	O	O
studied	B-PROC
via	O	O
systematic	O
study	B-PROC
of	O	O
evidence	O
.	O	O

The	O	O
next	O	O
step	O	O
was	O	O
done	O	O
to	O	O
evaluate	B-PROC
the	O	O
economical	O
aspect	O
of	O	O
off	O
-	O
site	O
sterilization	B-PROC
technology	O
using	O	O
gathered	O	O
data	O
from	O	O
systematic	O
review	O
of	O	O
the	O	O
texts	O
which	O	O
were	O	O
related	O
to	O	O
the	O	O
technology	O
and	O	O
costs	O
of	O	O
off	O
-	O
site	O
and	O	O
in	O
-	O
site	O
hospital	B-OBJC
sterilization	B-PROC
.	O	O

Third	O	O
step	O	O
was	O	O
conducted	O	O
to	O	O
collect	O	O
experiences	B-PHYS
of	O	O
using	O	O
technology	O
in	O	O
some	O	O
selected	O
hospitals	B-OBJC
around	O	O
the	O	O
world	B-LIVB
.	O	O

And	O	O
in	O	O
the	O	O
last	O	O
step	O	O
different	O
aspects	O
of	O	O
acceptance	B-DISO
and	O	O
use	O	O
of	O	O
this	O	O
technology	O
in	O	O
Iran	B-GEOG
were	O	O
evaluated	B-PROC
.	O	O

Review	O
of	O	O
the	O	O
selected	O
articles	O
indicated	B-DISO
that	O	O
efficacy	B-PROC
and	O	O
effectiveness	O
of	O	O
this	O	O
technology	O
is	O	O
Confirmed	B-DISO
.	O	O

The	O	O
results	B-DISO
also	O	O
showed	O	O
that	O	O
using	O	O
this	O	O
method	O
is	O	O
not	O	O
economical	O
in	O	O
Iran	B-GEOG
.	O	O

According	O	O
to	O	O
the	O	O
revealed	O
evidences	O
and	O	O
also	O	O
cost	O
analysis	O
,	O	O
due	O	O
to	O	O
shortage	B-DISO
of	O	O
necessary	O	O
substructures	O	O
and	O	O
economical	O
aspect	O
,	O	O
installing	O	O
the	O	O
off	O
-	O
site	O
sterilization	B-PROC
health	B-PROC
technology	I-PROC
in	O	O
hospitals	B-OBJC
is	O	O
not	B-DISO
possible	B-DISO
currently	O
.	O	O

But	O	O
this	O	O
method	O
can	O	O
be	O	O
used	O	O
to	O	O
provide	O
sterilization	B-PROC
services	B-PROC
for	O	O
clinics	B-OBJC
and	O	O
outpatients	B-LIVB
centers	B-OBJC
.	O	O

Pulmonary	B-PHYS
function	I-PHYS
and	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
1	O	O
-	O	O
year	O
follow	B-PROC
up	I-PROC
after	O	O
cardiac	B-PROC
surgery	I-PROC
Pulmonary	B-PHYS
function	I-PHYS
is	O	O
severely	O
reduced	O
in	O	O
the	O	O
early	O
period	O
after	O	O
cardiac	B-PROC
surgery	I-PROC
,	O	O
and	O	O
impairments	B-DISO
have	O	O
been	O	O
described	O	O
up	O	O
to	O	O
4	O	O
-	O	O
6	O	O
months	O
after	O
surgery	O
.	O	O

Evaluation	B-PROC
of	O	O
pulmonary	B-PHYS
function	I-PHYS
in	O	O
a	O	O
longer	O	O
perspective	O	O
is	O	O
lacking	O
.	O	O

In	O	O
this	O	O
prospective	B-PROC
study	I-PROC
pulmonary	B-PHYS
function	I-PHYS
and	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
were	O	O
investigated	O
1	O	O
year	O
after	O	O
cardiac	B-PROC
surgery	I-PROC
.	O	O

Pulmonary	B-PHYS
function	I-PHYS
measurements	O
,	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O	O
SF	O
-	O
36	O
)	O	O
,	O	O
dyspnoea	B-DISO
,	O	O
subjective	O
breathing	B-PHYS
and	O	O
coughing	B-DISO
ability	B-PHYS
and	O	O
pain	B-DISO
were	O	O
evaluated	B-PROC
before	O
and	O	O
1	O	O
year	O
after	O
surgery	O
in	O	O
150	O	O
patients	B-LIVB
undergoing	O	O
coronary	B-PROC
artery	I-PROC
bypass	I-PROC
grafting	I-PROC
,	O	O
valve	B-PROC
surgery	I-PROC
or	O	O
combined	O	O
surgery	B-PROC
.	O	O

One	O	O
year	O
after	O
surgery	O
the	O	O
forced	B-PHYS
vital	I-PHYS
capacity	I-PHYS
and	O	O
forced	B-PHYS
expiratory	I-PHYS
volume	I-PHYS
in	O	O
1	O	O
s	O	O
were	O	O
significantly	O	O
decreased	O
(	O	O
by	O	O
4	O	O
-	O	O
5	O	O
%	O	O
)	O	O
compared	O
to	O	O
preoperative	O
values	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Saturation	B-PHYS
of	I-PHYS
peripheral	I-PHYS
oxygen	I-PHYS
was	O	O
unchanged	B-DISO
1	O	O
year	O
postoperatively	O
compared	O
to	O	O
baseline	O
.	O	O

A	O	O
significantly	O	O
improved	B-DISO
health	O
-	O
related	O
quality	O
of	O
life	O
was	O	O
found	O	O
1	O	O
year	O
after	O
surgery	O
,	O	O
with	O	O
improvements	O
in	O	O
all	O	O
eight	O	O
aspects	O
of	O	O
SF	O
-	O
36	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Sternotomy	B-PROC
-related	O	O
pain	B-DISO
was	O	O
low	O
1	O	O
year	O
postoperatively	O
at	O
rest	O
(	O	O
median	O	O
0	O	O
[	O	O
min	O	O
-	O	O
max	O	O
;	O	O
0	O	O
-	O	O
7	O	O
]	O	O
)	O	O
,	O	O
while	O	O
taking	O	O
a	O	O
deep	B-DISO
breath	I-DISO
(	O	O
0	O	O
[	O	O
0	O	O
-	O	O
4	O	O
]	O	O
)	O	O
and	O	O
while	O	O
coughing	B-DISO
(	O	O
0	O	O
[	O	O
0	O	O
-	O	O
8	O	O
]	O	O
)	O	O
.	O	O

A	O	O
more	O	O
pronounced	O	O
decrease	O	O
in	O	O
pulmonary	B-PHYS
function	I-PHYS
was	O	O
associated	O
with	O
dyspnoea	B-DISO
limitations	O
and	O	O
impaired	B-DISO
subjective	O
breathing	B-PHYS
and	O	O
coughing	B-DISO
ability	B-PHYS
.	O	O

One	O	O
year	O
after	O	O
cardiac	B-PROC
surgery	I-PROC
static	O
and	O	O
dynamic	O
lung	B-PROC
function	I-PROC
measurements	I-PROC
were	O	O
slightly	O	O
decreased	O
,	O	O
while	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O	O
improved	B-DISO
in	O	O
comparison	O
to	O	O
preoperative	O
values	O
.	O	O

Measured	O
levels	O
of	O	O
pain	B-DISO
were	O	O
low	O
and	O	O
saturation	B-PHYS
of	I-PHYS
peripheral	I-PHYS
oxygen	I-PHYS
was	O	O
same	O
as	O	O
preoperatively	O
.	O	O

Weed	B-LIVB
seed	B-LIVB
inactivation	O
in	O	O
soil	B-OBJC
mesocosms	O
via	O	O
biosolarization	O	O
with	O	O
mature	B-OBJC
compost	I-OBJC
and	O	O
tomato	B-OBJC
processing	I-OBJC
waste	I-OBJC
amendments	I-OBJC
Biosolarization	O	O
is	O	O
a	O	O
fumigation	B-PHEN
alternative	O	O
that	O	O
combines	O	O
passive	O	O
solar	B-PHEN
heating	B-PHEN
with	O	O
amendment	O	O
-	O	O
driven	O	O
soil	B-OBJC
microbial	B-PHEN
activity	I-PHEN
to	O	O
temporarily	O	O
create	O	O
antagonistic	O
soil	O
conditions	O
,	O	O
such	O	O
as	O	O
elevated	B-DISO
temperature	I-DISO
and	O	O
acidity	O
,	O	O
that	O	O
can	O	O
inactivate	O	O
weed	B-LIVB
seeds	B-LIVB
and	O	O
other	O	O
pest	B-LIVB
propagules	I-LIVB
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
use	O	O
a	O	O
mesocosm	O
-based	O	O
field	O	O
trial	O	O
to	O	O
assess	O	O
soil	B-OBJC
heating	B-PHEN
,	O	O
pH	O	O
,	O	O
volatile	B-CHEM
fatty	I-CHEM
acid	I-CHEM
accumulation	B-DISO
and	O	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
during	O	O
biosolarization	O	O
.	O	O

Biosolarization	O	O
for	O	O
8	O	O
days	O
using	O	O
2	O	O
%	O	O
mature	B-OBJC
green	I-OBJC
waste	I-OBJC
compost	I-OBJC
and	O	O
2	O	O
or	O	O
5	O	O
%	O	O
tomato	B-OBJC
processing	I-OBJC
residues	I-OBJC
in	O	O
the	O	O
soil	B-OBJC
resulted	O	O
in	O	O
accumulation	B-DISO
of	O	O
volatile	B-CHEM
fatty	I-CHEM
acids	I-CHEM
in	O	O
the	O	O
soil	B-OBJC
,	O	O
particularly	O	O
acetic	B-CHEM
acid	I-CHEM
,	O	O
and	O	O
>	O	O
95	O	O
%	O	O
inactivation	O
of	O	O
Brassica	B-LIVB
nigra	I-LIVB
and	O	O
Solanum	B-LIVB
nigrum	I-LIVB
seeds	B-LIVB
.	O	O

Inactivation	O
kinetics	B-PHEN
data	O
showed	O	O
that	O	O
near	O	O
complete	O	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
in	O	O
soil	B-OBJC
was	O	O
achieved	O	O
within	O	O
the	O	O
first	O	O
5	O	O
days	O
of	O	O
biosolarization	O	O
.	O	O

This	O	O
was	O	O
significantly	O	O
greater	O	O
than	O	O
the	O	O
inactivation	O
achieved	O	O
in	O	O
control	B-OBJC
soils	I-OBJC
that	O	O
were	O	O
solar	B-PHEN
heated	O	O
without	O	O
amendment	O	O
or	O	O
were	O	O
amended	O	O
but	O	O
not	O	O
solar	B-PHEN
heated	O	O
.	O	O

The	O	O
composition	B-PHEN
and	O	O
concentration	O
of	O	O
organic	B-LIVB
matter	I-LIVB
amendments	I-LIVB
in	O	O
soil	B-OBJC
significantly	O	O
affected	O	O
volatile	B-CHEM
fatty	I-CHEM
acid	I-CHEM
accumulation	B-DISO
at	O	O
various	O	O
soil	B-OBJC
depths	O
during	O	O
biosolarization	O	O
.	O	O

Combining	O	O
solar	B-PHEN
heating	B-PHEN
with	O	O
organic	B-LIVB
matter	I-LIVB
amendment	I-LIVB
resulted	O	O
in	O	O
accelerated	O	O
weed	B-LIVB
seed	B-LIVB
inactivation	O
compared	O	O
with	O	O
either	O	O
approach	O	O
alone	O	O
.	O	O

©	O	O
2016	O	O
Society	O	O
of	O	O
Chemical	O	O
Industry	O	O
.	O	O

Phenotypic	B-DISO
and	O	O
genetic	B-PHYS
heterogeneity	I-PHYS
of	O	O
tumor	O
tissue	O
and	O	O
circulating	B-ANAT
tumor	I-ANAT
cells	I-ANAT
in	O	O
patients	B-LIVB
with	O	O
metastatic	B-DISO
castration	I-DISO
-	I-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
:	O	O
A	O	O
report	O
from	O	O
the	O	O
PETRUS	B-PROC
prospective	I-PROC
study	I-PROC
Molecular	O
characterization	O
of	O
cancer	O
samples	O
is	O	O
hampered	O
by	O	O
tumor	O
tissue	O
availability	O	O
in	O	O
metastatic	B-DISO
castration	I-DISO
-	I-DISO
resistant	I-DISO
prostate	I-DISO
cancer	I-DISO
(	O	O
mCRPC	B-DISO
)	O	O
patients	B-LIVB
.	O	O

We	O	O
reported	B-PROC
the	O	O
results	O
of	O	O
prospective	B-PROC
PETRUS	I-PROC
study	I-PROC
of	O	O
biomarker	B-PROC
assessment	I-PROC
in	O	O
paired	O	O
primary	O	O
prostatic	B-DISO
tumors	I-DISO
,	O	O
metastatic	B-DISO
biopsies	B-PROC
and	O	O
circulating	B-ANAT
tumor	I-ANAT
cells	I-ANAT
(	O	O
CTCs	B-ANAT
)	O	O
.	O	O

Among	O	O
54	O	O
mCRPC	B-DISO
patients	B-LIVB
enrolled	O	O
,	O	O
38	O	O
(	O	O
70	O	O
%	O	O
)	O	O
had	O	O
biopsies	B-PROC
containing	O	O
more	O	O
than	O	O
50	O	O
%	O	O
tumour	B-ANAT
cells	I-ANAT
.	O	O

28	O	O
(	O	O
52	O	O
%	O	O
)	O	O
patients	B-LIVB
were	O	O
analyzed	B-PROC
for	O	O
both	O	O
tissue	O
samples	O
and	O	O
CTCs	B-ANAT
.	O	O

FISH	B-PROC
for	O	O
AR	O
-	O	O
amplification	B-PROC
and	O	O
TMPRSS2	O
-	O	O
ERG	O
translocation	B-PHYS
were	O	O
successful	O	O
in	O	O
54	O	O
%	O	O
and	O	O
32	O	O
%	O	O
in	O	O
metastatic	B-DISO
biopsies	B-PROC
and	O	O
primary	B-DISO
tumors	I-DISO
,	O	O
respectively	O	O
.	O	O

By	O	O
comparing	O	O
CellSearch	B-PROC
and	O	O
filtration	B-PROC
(	I-PROC
ISET	I-PROC
)	O	O
-	O	O
enrichment	O	O
combined	O	O
to	O	O
four	O	O
color	O	O
immunofluorescent	B-PROC
staining	I-PROC
,	O	O
we	O	O
showed	O	O
that	O	O
CellSearch	B-PROC
and	O	O
ISET	B-PROC
isolated	O
distinct	O	O
subpopulations	B-PROC
of	O	O
CTCs	B-ANAT
:	O	O
CTCs	B-ANAT
undergoing	O	O
epithelial	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
,	O	O
CTC	B-ANAT
clusters	I-ANAT
and	O	O
large	O
CTCs	B-ANAT
with	O	O
cytomorphological	O
characteristics	O
but	O	O
no	O	O
detectable	B-PHYS
markers	B-PHYS
were	O	O
isolated	O
using	O	O
ISET	B-PROC
.	O	O

Epithelial	O
CTCs	B-ANAT
detected	B-DISO
by	O	O
the	O	O
CellSearch	B-PROC
were	O	O
mostly	O	O
lost	O	O
during	O	O
the	O	O
ISET	B-PROC
-	I-PROC
filtration	I-PROC
.	O	O

AR	O
-	O	O
amplification	B-PROC
was	O	O
detected	B-DISO
in	O	O
CellSearch	B-PROC
-captured	O	O
CTCs	B-ANAT
,	O	O
but	O	O
not	O	O
in	O	O
ISET	B-PROC
-enriched	O	O
CTCs	B-ANAT
which	O	O
harbor	O	O
exclusively	O	O
AR	O
gain	O	O
of	O	O
copies	O
.	O	O

Eighty	O	O
-	O	O
eight	O	O
percent	O	O
concordance	O	O
for	O	O
ERG	B-DISO
-	I-DISO
rearrangement	I-DISO
was	O	O
observed	O	O
between	O	O
metastatic	B-DISO
biopsies	B-PROC
and	O	O
CTCs	B-ANAT
even	O	O
if	O	O
additional	O	O
ERG	B-DISO
-	I-DISO
alteration	I-DISO
patterns	O	O
were	O	O
detected	B-DISO
in	O	O
ISET	B-PROC
-enriched	O	O
CTCs	B-ANAT
indicating	O	O
a	O	O
higher	O
heterogeneity	O
in	O	O
CTCs	B-ANAT
.	O	O

Molecular	O
screening	B-PROC
of	O	O
metastatic	B-DISO
biopsies	B-PROC
is	O	O
achievable	O	O
in	O	O
a	O	O
multicenter	B-PROC
context	I-PROC
.	O	O

Our	O	O
data	O
indicate	O	O
that	O	O
CTCs	B-ANAT
detected	B-DISO
by	O	O
the	O	O
CellSearch	B-PROC
and	O	O
the	O	O
ISET	B-PROC
-	I-PROC
filtration	I-PROC
systems	I-PROC
are	O	O
not	O	O
only	O	O
phenotypically	B-PHYS
but	O	O
also	O	O
genetically	O
different	O
.	O	O

Close	O	O
attention	O	O
must	O	O
be	O	O
paid	O	O
to	O	O
CTC	B-ANAT
characterization	O
since	O	O
neither	O	O
approach	O	O
tested	O
here	O	O
fully	O	O
reflects	O	O
the	O	O
tremendous	O	O
phenotypic	B-DISO
and	O	O
genetic	B-PHYS
heterogeneity	I-PHYS
present	O	O
in	O	O
CTCs	B-ANAT
from	O	O
mCRPC	B-DISO
patients	B-LIVB
.	O	O

Impact	O
of	O	O
Soil	B-OBJC
Salinity	O
on	O	O
the	O	O
Structure	O
of	O	O
the	O	O
Bacterial	B-LIVB
Endophytic	B-LIVB
Community	B-LIVB
Identified	O
from	O	O
the	O	O
Roots	B-LIVB
of	O	O
Caliph	B-LIVB
Medic	I-LIVB
(	O	O
Medicago	B-LIVB
truncatula	I-LIVB
)	O	O
In	O	O
addition	O	O
to	O	O
being	O	O
a	O	O
forage	B-LIVB
crop	I-LIVB
,	O	O
Caliph	B-LIVB
medic	I-LIVB
(	O	O
Medicago	B-LIVB
truncatula	I-LIVB
)	O	O
is	O	O
also	O	O
a	O	O
model	B-PROC
legume	I-PROC
plant	I-PROC
and	O	O
is	O	O
used	O	O
for	O	O
research	O	O
focusing	O	O
on	O	O
the	O	O
molecular	O
characterization	O
of	O	O
the	O	O
interaction	O
between	O	O
rhizobia	B-LIVB
and	O	O
plants	B-LIVB
.	O	O

However	O	O
,	O	O
the	O	O
endophytic	B-LIVB
microbiome	I-LIVB
in	O	O
this	O	O
plant	B-LIVB
is	O	O
poorly	O	O
defined	O	O
.	O	O

Endophytic	B-LIVB
bacteria	B-LIVB
play	O	O
a	O	O
role	O	O
in	O	O
supplying	O	O
plants	B-LIVB
with	O	O
the	O	O
basic	O	O
requirements	O
necessary	O	O
for	O	O
growth	B-PHYS
and	O	O
development	B-PHYS
.	O	O

Moreover	O	O
,	O	O
these	O	O
bacteria	B-LIVB
also	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
mechanism	O
of	O	O
salinity	B-PHEN
stress	I-PHEN
adaptation	B-PHEN
in	O	O
plants	B-LIVB
.	O	O

As	O	O
a	O	O
prelude	O	O
to	O	O
the	O	O
isolation	B-PROC
and	O	O
utilization	O
of	O	O
these	O	O
bacteria	B-LIVB
in	O	O
Caliph	B-LIVB
medic	I-LIVB
farming	O
,	O	O
41	O	O
bacterial	B-LIVB
OTUs	O
were	O	O
identified	O
in	O	O
this	O	O
project	O	O
from	O	O
within	O	O
the	O	O
interior	O
of	O	O
the	O	O
roots	B-LIVB
of	O	O
this	O	O
plant	B-LIVB
by	O	O
pyrosequencing	B-PROC
of	O	O
the	O	O
small	O
ribosomal	O
subunit	O
gene	O
(	O	O
16S	O
rDNA	O
)	O	O
using	O	O
a	O	O
cultivation	B-PROC
-	I-PROC
independent	I-PROC
approach	I-PROC
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
differential	O
abundance	O
of	O	O
these	O	O
bacteria	B-LIVB
was	O	O
studied	O	O
following	O	O
exposure	O	O
of	O	O
the	O	O
plants	B-LIVB
to	O	O
salinity	B-PHEN
stress	I-PHEN
.	O	O

About	O	O
29	O	O
,	O	O
064	O	O
high	O
-	O
quality	O
reads	O
were	O	O
obtained	O	O
from	O	O
the	O	O
sequencing	B-PROC
of	O	O
six	O	O
libraries	O
prepared	O	O
from	O	O
control	O
and	O	O
salinity	O
-	O
treated	O
tissues	O
.	O	O

Statistical	B-PROC
analysis	I-PROC
revealed	O	O
that	O	O
the	O	O
abundance	O
of	O	O
~70	O	O
%	O	O
of	O	O
the	O	O
OTUs	O
was	O	O
significantly	O	O
(	O	O
p	O	O
≤	O	O
0	O	O
.	O	O

05	O	O
)	O	O
altered	O	O
in	O	O
roots	B-LIVB
that	O	O
were	O	O
exposed	O
to	O
salinity	B-PHEN
stress	I-PHEN
.	O	O

Sequence	B-PROC
analysis	I-PROC
showed	O	O
a	O	O
similarity	O	O
between	O	O
some	O	O
of	O	O
the	O	O
identified	O
species	O
and	O	O
other	O	O
,	O	O
known	O	O
,	O	O
growth	B-LIVB
-	I-LIVB
promoting	I-LIVB
bacteria	I-LIVB
,	O	O
marine	B-LIVB
and	O	O
salt	B-LIVB
-	I-LIVB
stressed	I-LIVB
soil	I-LIVB
-	I-LIVB
borne	I-LIVB
bacteria	I-LIVB
,	O	O
and	O	O
nitrogen	B-LIVB
-	I-LIVB
fixing	I-LIVB
bacterial	I-LIVB
isolates	B-CHEM
.	O	O

Determination	O	O
of	O	O
the	O	O
amendments	O	O
to	O	O
the	O	O
bacteria	B-LIVB
l	O	O
community	B-LIVB
due	O	O
to	O	O
salinity	B-PHEN
stress	I-PHEN
in	O	O
Caliph	B-LIVB
medic	I-LIVB
provides	O	O
a	O	O
crucial	O	O
step	O	O
toward	O	O
developing	O	O
an	O	O
understanding	O	O
of	O	O
the	O	O
association	O
of	O	O
these	O	O
endophytes	B-LIVB
,	O	O
under	O	O
salt	B-PHEN
stress	I-PHEN
conditions	I-PHEN
,	O	O
in	O	O
this	O	O
model	B-PROC
plant	I-PROC
.	O	O

To	O	O
provide	O	O
direct	O	O
evidence	O
regarding	O	O
their	O	O
growth	O
promoting	O
activity	O
,	O	O
a	O	O
group	O
of	O	O
endophytic	B-LIVB
bacteria	B-LIVB
were	O	O
isolated	O
from	O	O
inside	O	O
of	O	O
plant	B-LIVB
roots	I-LIVB
using	O	O
a	O	O
cultivation	B-PROC
-	I-PROC
dependent	I-PROC
approach	I-PROC
.	O	O

Several	O	O
of	O	O
these	O	O
isolates	B-CHEM
were	O	O
able	O	O
to	O	O
produce	O	O
ACC	B-CHEM
-	I-CHEM
deaminase	I-CHEM
,	O	O
ammonia	B-CHEM
and	O	O
IAA	B-CHEM
;	O	O
and	O	O
to	O	O
solubilize	O
Zn	B-CHEM
+	I-CHEM
2	I-CHEM
and	O	O
PO4	B-CHEM
-	I-CHEM
3	I-CHEM
.	O	O

This	O	O
data	O
is	O	O
consistent	O	O
with	O	O
the	O	O
predicted	O	O
occurrence	O
(	O	O
based	O	O
on	O	O
cultivation	B-PROC
-	I-PROC
independent	I-PROC
techniques	I-PROC
)	O	O
of	O	O
these	O	O
bacteria	B-LIVB
and	O	O
provides	O	O
some	O	O
insight	O	O
into	O	O
the	O	O
importance	O	O
of	O	O
the	O	O
endophytic	B-LIVB
bacteria	B-LIVB
in	O	O
Caliph	B-LIVB
medic	I-LIVB
when	O	O
grown	O	O
under	O	O
normal	O
and	O	O
saline	B-OBJC
conditions	O
.	O	O

Role	O	O
of	O	O
the	O	O
Membrane	B-ANAT
for	O	O
Mechanosensing	B-PHYS
by	O	O
Tethered	O
Channels	B-CHEM
Biologically	O
important	O	O
membrane	B-CHEM
channels	I-CHEM
are	O	O
gated	B-PHYS
by	O	O
force	B-PHEN
at	O	O
attached	B-PHEN
tethers	O
.	O	O

Here	O	O
,	O	O
we	O	O
generically	O	O
characterize	O	O
the	O	O
nontrivial	O	O
interplay	O	O
of	O	O
force	B-PHEN
,	O	O
membrane	B-PHYS
tension	I-PHYS
,	O	O
and	O	O
channel	B-CHEM
deformations	B-DISO
that	O	O
can	O	O
affect	O	O
gating	B-PHYS
.	O	O

A	O	O
central	O	O
finding	O	O
is	O	O
that	O	O
minute	O	O
conical	B-CHEM
channel	I-CHEM
deformation	B-DISO
under	O	O
force	B-PHEN
leads	O	O
to	O	O
significant	O	O
energy	B-PHYS
release	I-PHYS
during	O	O
opening	B-PHYS
.	O	O

We	O	O
also	O	O
calculate	O	O
channel	B-PHYS
-	I-PHYS
channel	I-PHYS
interactions	I-PHYS
and	O	O
show	O	O
that	O	O
they	O	O
can	O	O
amplify	O	O
the	O	O
force	B-PHEN
sensitivity	B-PHYS
of	O	O
tethered	O
channels	B-CHEM
.	O	O

Caregiver	B-DISO
satisfaction	I-DISO
with	O	O
paediatric	B-DISO
HIV	I-DISO
treatment	B-PROC
and	O	O
care	O
in	O	O
Nigeria	B-GEOG
and	O	O
equity	O
implications	O	O
for	O	O
children	B-LIVB
living	O
with	O	O
HIV	B-DISO
Caregiver	B-DISO
satisfaction	I-DISO
has	O	O
the	O	O
potential	O
to	O	O
promote	O
equity	O
for	O	O
children	B-LIVB
living	O
with	O	O
HIV	B-DISO
,	O	O
by	O	O
influencing	O
health	O
-	O
seeking	O
behaviour	O
.	O	O

We	O	O
measured	O
dimensions	O	O
of	O	O
caregiver	B-DISO
satisfaction	I-DISO
with	O	O
paediatric	B-DISO
HIV	I-DISO
treatment	B-PROC
in	O	O
Nigeria	B-GEOG
,	O	O
and	O	O
discuss	O	O
its	O	O
implications	O	O
for	O	O
equity	O
by	O	O
conducting	O	O
facility	O	O
-	O	O
based	O	O
exit	O
interviews	O
for	O	O
caregivers	B-LIVB
of	O	O
children	B-LIVB
receiving	O
antiretroviral	B-PROC
therapy	I-PROC
in	O	O
20	O	O
purposively	O	O
selected	O	O
facilities	B-OBJC
within	O	O
5	O	O
geopolitical	B-GEOG
zones	I-GEOG
.	O	O

Descriptive	O	O
analysis	B-PROC
and	O	O
factor	O
analysis	O
were	O	O
performed	O
.	O	O

Due	O	O
to	O	O
the	O	O
hierarchical	O	O
nature	O	O
of	O	O
the	O	O
data	O
,	O	O
multilevel	B-PROC
regression	I-PROC
modelling	I-PROC
was	O	O
performed	O
to	O	O
investigate	O
relationships	O
between	O	O
satisfaction	B-PHYS
factors	I-PHYS
and	O	O
socio	O
-	O
demographic	O
variables	O
.	O	O

Of	O	O
1550	O	O
caregivers	B-LIVB
interviewed	O
,	O	O
63	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
60	O	O
.	O	O
6	O	O
-	O	O
65	O	O
.	O	O

4	O	O
)	O	O
reported	O	O
being	O	O
very	O	O
satisfied	O
overall	O
;	O	O
however	O	O
,	O	O
satisfaction	B-PHYS
varied	O	O
in	O	O
some	O	O
dimensions	O	O
:	O	O
only	O	O
55	O	O
.	O	O

6	O	O
%	O	O
(	O	O
53	O	O
.	O	O
1	O	O
-	O	O
58	O	O
.	O	O
1	O	O
)	O	O
of	O	O
caregivers	B-LIVB
could	O	O
talk	O	O
privately	O	O
with	O	O
health	B-LIVB
workers	I-LIVB
,	O	O
56	O	O
.	O	O

9	O	O
%	O	O
(	O	O
54	O	O
.	O	O
4	O	O
-	O	O
59	O	O
.	O	O
3	O	O
)	O	O
reported	O	O
that	O	O
queues	O
to	O	O
see	O	O
health	B-LIVB
workers	I-LIVB
were	O	O
too	O	O
long	O
,	O	O
and	O	O
89	O	O
.	O	O

9	O	O
%	O	O
(	O	O
88	O	O
.	O	O
4	O	O
-	O	O
91	O	O
.	O	O
4	O	O
)	O	O
said	O	O
that	O	O
some	O	O
health	B-LIVB
workers	I-LIVB
did	O	O
not	O	O
treat	O
patients	B-LIVB
living	O
with	O	O
HIV	B-DISO
with	O	O
sufficient	O	O
respect	O
.	O	O

Based	O	O
on	O	O
factor	O
analysis	O
,	O	O
two	O	O
underlying	O	O
factors	O
,	O	O
labelled	O	O
Availability	O
and	O	O
Attitude	B-PHYS
,	O	O
were	O	O
identified	O
.	O	O

In	O	O
multilevel	B-PROC
regression	I-PROC
,	O	O
the	O	O
satisfaction	B-PHYS
with	O	O
availability	O
of	O
services	O
correlated	O
with	O	O
formal	O	O
employment	B-DISO
status	I-DISO
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
,	O	O
whereas	O	O
caregivers	B-LIVB
receiving	O
care	O
in	O	O
private	B-OBJC
facilities	I-OBJC
were	O	O
less	O	O
likely	O	O
satisfied	O
with	O	O
both	O	O
availability	O
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
and	O	O
attitude	B-PHYS
of	O	O
health	B-LIVB
workers	I-LIVB
(	O	O
p	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

State	B-GEOG
and	O	O
facility	B-OBJC
levels	O
influenced	O
attitudes	B-PHYS
of	O	O
the	O	O
health	B-LIVB
workers	I-LIVB
(	O	O
p	O	O
<	O	O
.01	O	O
)	O	O
,	O	O
but	O	O
not	O	O
availability	O
of	O
services	O
.	O	O

We	O	O
conclude	O	O
that	O	O
high	O	O
levels	O
of	O	O
overall	O
satisfaction	B-PHYS
among	O	O
caregivers	B-LIVB
masked	O	O
dissatisfaction	B-PHYS
with	O	O
some	O	O
aspects	O	O
of	O	O
services	O
.	O	O

The	O	O
two	O	O
underlying	O	O
satisfaction	B-PHYS
factors	O	O
are	O	O
part	O	O
of	O	O
access	O	O
typology	B-PROC
critical	O
for	O	O
closing	O	O
equity	O
gaps	O	O
in	O	O
access	O
to	O	O
HIV	B-DISO
treatment	B-PROC
between	O	O
adults	B-LIVB
and	O	O
children	B-LIVB
,	O	O
and	O	O
across	O	O
socio	B-LIVB
-	I-LIVB
economic	I-LIVB
groups	I-LIVB
.	O	O

Eliminating	O	O
Cancer	B-ANAT
Stem	I-ANAT
Cells	I-ANAT
in	O	O
CML	B-DISO
with	O	O
Combination	O	O
Transcriptional	B-PHYS
Therapy	B-PROC
Leukemia	B-DISO
stem	B-ANAT
cells	I-ANAT
(	O	O
LSCs	B-ANAT
)	O	O
are	O	O
resistant	O	O
to	O	O
current	O	O
therapies	B-PROC
used	O	O
to	O	O
treat	O	O
chronic	B-DISO
myeloid	I-DISO
leukemia	I-DISO
(	O	O
CML	B-DISO
)	O	O
.	O	O

Abraham	O	O
et	O	O
al	O	O
.	O	O
(	O	O
2016	O	O
)	O	O
have	O	O
identified	O	O
a	O	O
molecular	B-PHYS
network	I-PHYS
critical	O
for	O	O
CML	B-DISO
LSC	B-ANAT
survival	B-PHYS
and	O	O
propose	O	O
that	O	O
simultaneously	O	O
targeting	O	O
two	O	O
of	O	O
their	O	O
major	O	O
transcriptional	B-CHEM
regulators	I-CHEM
,	O	O
p53	O
and	O	O
c	B-CHEM
-	I-CHEM
Myc	I-CHEM
,	O	O
may	O	O
facilitate	O	O
their	O	O
eradication	B-PHYS
.	O	O

Energy	B-PHYS
Expenditure	I-PHYS
and	O	O
Intensity	O
of	O	O
Classroom	B-OBJC
Physical	O
Activity	O
in	O	O
Elementary	O
School	O
Children	B-LIVB
There	O	O
is	O	O
limited	O
data	O
regarding	O	O
objectively	O	O
measured	O
energy	O
cost	O
and	O	O
intensity	O
of	O	O
classroom	B-PROC
instruction	I-PROC
.	O	O

Therefore	O	O
,	O	O
the	O	O
purpose	O	O
of	O	O
current	O	O
study	B-PROC
was	O	O
to	O	O
objectively	O	O
measure	O
energy	O
cost	O
and	O	O
subsequently	O	O
calculate	O
MET	B-PROC
values	I-PROC
using	O	O
a	O	O
portable	O
indirect	B-DEVI
calorimeter	I-DEVI
(	O	O
IC	B-DEVI
)	O	O
for	O	O
both	O	O
normal	O
classroom	B-PROC
instruction	I-PROC
(	O	O
NCI	B-PROC
)	O	O
and	O	O
active	O
classroom	B-PROC
instruction	I-PROC
(	O	O
ACI	B-PROC
)	O	O
.	O	O

We	O	O
assessed	O
energy	B-PHYS
expenditure	I-PHYS
(	O	O
EE	B-PHYS
)	O	O
and	O	O
intensity	O
levels	O
(	O	O
METs	B-PROC
)	O	O
in	O	O
elementary	O
school	O
children	B-LIVB
(	O	O
17	O	O
boys	B-LIVB
and	O	O
15	O	O
girls	B-LIVB
)	O	O
using	O	O
an	O	O
IC	B-DEVI
(	O	O
COSMED	B-DEVI
K4b2	I-DEVI
)	O	O
.	O	O

Independent	O
t	O
-	O
tests	O
were	O	O
used	O	O
to	O	O
evaluate	B-PROC
potential	O	O
sex	B-PHYS
and	O	O
grade	O
level	O
differences	O	O
for	O	O
age	B-PHYS
,	O	O
BMI	B-PHYS
,	O	O
VO2	B-PROC
,	O	O
EE	B-PHYS
,	O	O
and	O	O
METs	B-PROC
.	O	O

The	O	O
average	O
EE	B-PHYS
for	O	O
NCI	B-PROC
and	O	O
ACI	B-PROC
were	O	O
1	O	O
.	O	O
8	O	O
±	O	O
0	O	O
.	O	O
4	O	O
and	O	O
3	O	O
.	O	O

9	O	O
±	O	O
1	O	O
.	O	O
0	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
average	O
intensity	O
level	O
for	O	O
NCI	B-PROC
and	O	O
ACI	B-PROC
were	O	O
1	O	O
.	O	O
9	O	O
±	O	O
0	O	O
.	O	O
4	O	O
and	O	O
4	O	O
.	O	O
2	O	O
±	O	O
0	O	O
.	O	O

9	O	O
METs	B-PROC
,	O	O
respectively	O	O
.	O	O

PA	O
delivered	O	O
through	O	O
ACI	B-PROC
can	O	O
elicit	O	O
EE	B-PHYS
at	O	O
a	O	O
moderate	O	O
intensity	O
level	O
.	O	O

These	O	O
results	O	O
provide	O	O
evidence	O
for	O	O
ACI	B-PROC
as	O	O
a	O	O
convenient	O	O
/	O	O
feasible	O	O
avenue	O	O
for	O	O
increasing	O
PA	O
in	O	O
youth	B-LIVB
without	O	O
decreasing	B-DISO
instruction	O
time	O
.	O	O

Liver	B-ANAT
-	O	O
specific	O
mono	B-CHEM
-	I-CHEM
unsaturated	I-CHEM
fatty	I-CHEM
acid	I-CHEM
synthase	I-CHEM
-	I-CHEM
1	I-CHEM
inhibitor	B-CHEM
for	O	O
anti	B-DISO
-	I-DISO
hepatitis	I-DISO
C	I-DISO
treatment	B-PROC
Recently	O	O
,	O	O
direct	O	O
antiviral	B-CHEM
agents	I-CHEM
against	O
hepatitis	B-DISO
C	I-DISO
virus	I-DISO
(	I-DISO
HCV	I-DISO
)	I-DISO
infection	I-DISO
have	O	O
been	O	O
developed	O	O
as	O	O
highly	O
effective	O
anti	B-CHEM
-	I-CHEM
HCV	I-CHEM
drugs	I-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
appearance	O
of	O	O
resistant	O
viruses	B-LIVB
against	O
direct	O	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
is	O	O
an	O	O
unsolved	O
problem	B-DISO
.	O	O

One	O	O
of	O	O
the	O	O
strategies	O	O
considered	O
to	O	O
suppress	O
the	O	O
emergence	O
of	O	O
the	O	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
viruses	B-LIVB
is	O	O
to	O	O
use	O	O
drugs	B-CHEM
inhibiting	O
the	O	O
host	B-LIVB
factor	O
,	O	O
which	O	O
contributes	O	O
to	O	O
HCV	B-LIVB
proliferation	O
,	O	O
in	O	O
combination	O	O
with	O	O
direct	O	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
.	O	O

The	O	O
replication	B-ANAT
complex	I-ANAT
was	O	O
reported	O	O
to	O	O
be	O	O
present	B-DISO
in	O	O
the	O	O
membranous	O
compartment	O
in	O	O
the	O	O
cells	B-ANAT
.	O	O

Thus	O	O
,	O	O
lipid	B-PHYS
metabolism	I-PHYS
modulators	B-CHEM
are	O	O
good	O	O
candidates	O	O
to	O	O
regulate	O
virus	B-PHEN
assembly	I-PHEN
and	O	O
HCV	B-LIVB
replication	B-PHYS
.	O	O

Recent	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
stearoyl	B-CHEM
-	I-CHEM
CoA	I-CHEM
desaturase	I-CHEM
(	O	O
SCD	B-CHEM
)	O	O
,	O	O
an	O	O
enzyme	B-CHEM
for	O	O
long	B-CHEM
-	I-CHEM
chain	I-CHEM
mono	I-CHEM
-	I-CHEM
unsaturated	I-CHEM
fatty	I-CHEM
acid	I-CHEM
(	O	O
LCMUFA	B-CHEM
)	O	O
synthesis	B-PHEN
,	O	O
is	O	O
a	O	O
key	O	O
factor	O
that	O	O
defines	O	O
HCV	B-LIVB
replication	B-PHYS
efficiency	O
.	O	O

Systemic	O
exposure	O
to	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibor	B-CHEM
induces	O
some	O	O
side	B-DISO
effects	I-DISO
in	O	O
the	O	O
eyes	B-ANAT
and	O	O
skin	B-ANAT
.	O	O

Thus	O	O
,	O	O
systemic	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
are	O	O
considered	O
inappropriate	O
for	O	O
HCV	B-DISO
therapy	O
.	O	O

To	O	O
avoid	O	O
the	O	O
side	B-DISO
effects	I-DISO
of	O	O
systemic	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
,	O	O
the	O	O
liver	B-ANAT
-	O	O
specific	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitor	B-CHEM
,	O	O
MK8245	B-CHEM
,	O	O
was	O	O
synthesized	O
;	O	O
it	O	O
showed	O	O
antidiabetic	B-DISO
effects	I-DISO
in	O	O
diabetic	B-DISO
model	B-LIVB
mice	I-LIVB
with	O	O
no	B-DISO
side	B-DISO
effects	I-DISO
.	O	O

In	O	O
the	O	O
phase	O
1	O
clinical	B-PROC
study	I-PROC
on	O	O
measurement	O
of	O	O
MK8245	B-CHEM
tolerability	B-PROC
,	O	O
no	B-DISO
significant	I-DISO
side	B-DISO
effects	I-DISO
were	O	O
reported	O	O
(	O	O
ClinicalTrials	O
.	O
gov	O
Identifier	O	O
:	O	O
NCT00790556	O	O
)	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
thought	O	O
liver	B-ANAT
-	O	O
specific	O
SCD	B-CHEM
-	I-CHEM
1	I-CHEM
inhibitors	B-CHEM
would	O	O
be	O	O
suitable	O
agents	B-CHEM
for	O	O
HCV	B-LIVB
-	O	O
infected	B-DISO
patients	B-LIVB
.	O	O

MK8245	B-CHEM
was	O	O
evaluated	O	O
using	O	O
recombinant	B-LIVB
HCV	I-LIVB
culture	B-PROC
systems	I-PROC
.	O	O

Considering	O	O
current	O
HCV	B-LIVB
treatments	B-PROC
,	O	O
to	O	O
avoid	O	O
the	O	O
emergence	O
of	O	O
direct	O	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
-	O	O
resistant	O
viruses	B-LIVB
,	O	O
combination	B-PROC
therapy	I-PROC
with	O	O
direct	O	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
and	O	O
host	B-LIVB
-	O	O
targeted	O
agents	B-CHEM
would	O	O
be	O	O
optimal	O
.	O	O

With	O	O
this	O	O
viewpoint	O	O
,	O	O
we	O	O
confirmed	O
MK8245	B-CHEM
'	O	O
s	O	O
additive	O
or	O	O
synergistic	O
anti	B-DISO
-	I-DISO
HCV	I-DISO
effects	I-DISO
on	O	O
current	O	O
direct	O	O
anti	B-CHEM
-	I-CHEM
viral	I-CHEM
agents	I-CHEM
and	O	O
interferon	B-PROC
-	I-PROC
alpha	I-PROC
therapy	I-PROC
.	O	O

The	O	O
results	O
suggest	O	O
that	O	O
MK8245	B-CHEM
is	O	O
an	O	O
option	O
for	O	O
anti	B-DISO
-	I-DISO
HCV	I-DISO
multi	B-PROC
-	I-PROC
drug	I-PROC
therapy	I-PROC
with	O	O
a	O	O
low	O	O
risk	O
of	O	O
emergence	O
of	O	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
HCV	B-LIVB
without	O	O
significant	O
side	B-DISO
effects	I-DISO
.	O	O

Relation	O	O
of	O	O
Left	B-DISO
Ventricular	I-DISO
Mass	I-DISO
and	O	O
Infarct	B-DISO
Size	I-DISO
in	O	O
Anterior	B-DISO
Wall	I-DISO
ST	I-DISO
-	I-DISO
Segment	I-DISO
Elevation	I-DISO
Acute	I-DISO
Myocardial	I-DISO
Infarction	I-DISO
(	O	O
from	O	O
the	O	O
EMBRACE	O	O
STEMI	B-DISO
Clinical	B-PROC
Trial	I-PROC
)	O	O
Biomarker	B-PHYS
measures	O
of	O	O
infarct	B-DISO
size	I-DISO
and	O	O
myocardial	O
salvage	O
index	O
(	O	O
MSI	O
)	O	O
are	O	O
important	O	O
surrogate	O	O
measures	O
of	O	O
clinical	O
outcomes	O
after	O	O
a	O	O
myocardial	B-DISO
infarction	I-DISO
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
variability	O	O
in	O	O
infarct	B-DISO
size	I-DISO
unaccounted	O	O
for	O	O
by	O	O
conventional	O	O
adjustment	O
factors	O
.	O	O

This	O	O
post	O
hoc	O
analysis	O
of	O	O
Evaluation	O	O
of	O	O
Myocardial	O
Effects	O
of	O	O
Bendavia	B-CHEM
for	O	O
Reducing	O	O
Reperfusion	B-DISO
Injury	I-DISO
in	O	O
Patients	B-LIVB
With	O	O
Acute	B-DISO
Coronary	I-DISO
Events	I-DISO
(	O	O
EMBRACE	O	O
)	O	O
ST	B-DISO
-	I-DISO
Segment	I-DISO
Elevation	I-DISO
Myocardial	I-DISO
Infarction	I-DISO
(	O	O
STEMI	B-DISO
)	O	O
trial	B-PROC
evaluates	O	O
the	O	O
association	O	O
between	O	O
left	B-DISO
ventricular	I-DISO
(	I-DISO
LV	I-DISO
)	I-DISO
mass	I-DISO
and	O	O
infarct	B-DISO
size	I-DISO
as	O	O
assessed	O	O
by	O	O
areas	O
under	O
the	O
curve	O
for	O	O
creatine	B-PROC
kinase	I-PROC
-	I-PROC
MB	I-PROC
(	O	O
CK	B-PROC
-	I-PROC
MB	I-PROC
)	O	O
and	O	O
troponin	B-PROC
I	I-PROC
release	I-PROC
over	O	O
the	O	O
first	O	O
72	O	O
hours	O
(	O	O
CK	B-PROC
-	I-PROC
MB	I-PROC
area	O
under	O
the	O
curve	O
[	O	O
AUC	O
]	O	O
and	O	O
troponin	B-CHEM
I	I-CHEM
[	O	O
TnI	B-CHEM
]	O	O
AUC	O
)	O	O
and	O	O
the	O	O
MSI	O
.	O	O

Patients	B-LIVB
with	O	O
first	O	O
anterior	B-DISO
STEMI	I-DISO
,	O	O
occluded	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
artery	I-ANAT
,	O	O
and	O	O
available	O	O
LV	B-DISO
mass	I-DISO
measurement	O
in	O	O
EMBRACE	O	O
STEMI	B-DISO
trial	B-PROC
were	O	O
included	O	O
(	O	O
n	O	O
=	O	O
100	O	O
)	O	O
(	O	O
ClinicalTrials	O	O
.	O	O
govNCT01572909	O	O
)	O	O
.	O	O

MSI	O
,	O	O
end	B-PHYS
-	I-PHYS
diastolic	I-PHYS
LV	B-DISO
mass	I-DISO
on	O	O
day	O	O
4	O	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
,	O	O
and	O	O
CK	B-PROC
-	I-PROC
MB	I-PROC
and	O	O
troponin	B-CHEM
I	I-CHEM
concentrations	O
were	O	O
evaluated	O	O
by	O	O
a	O	O
core	B-OBJC
laboratory	I-OBJC
.	O	O

After	O	O
saturated	O	O
multivariate	O
analysis	O
,	O	O
dominance	B-PROC
analysis	I-PROC
was	O	O
performed	O	O
to	O	O
estimate	O	O
the	O	O
contribution	O	O
of	O	O
each	O	O
independent	O	O
variable	O	O
to	O	O
the	O	O
predicted	O	O
variance	O
of	O	O
each	O	O
outcome	O	O
.	O	O

In	O	O
multivariate	O
models	O
that	O	O
included	O	O
age	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
body	B-PHYS
surface	I-PHYS
area	I-PHYS
,	O	O
lesion	B-DISO
location	I-DISO
,	O	O
smoking	O
,	O	O
and	O	O
ischemia	B-DISO
time	O
,	O	O
LV	B-DISO
mass	I-DISO
remained	O	O
independently	O	O
associated	O	O
with	O	O
biomarker	B-PHYS
measures	O
of	O	O
infarct	B-DISO
size	I-DISO
(	O	O
CK	B-PROC
-	I-PROC
MB	I-PROC
AUC	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
,	O	O
TnI	B-CHEM
AUC	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
and	O	O
MSI	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
003	O	O
)	O	O
.	O	O

Dominance	B-PROC
analysis	I-PROC
demonstrated	O	O
that	O	O
LV	B-DISO
mass	I-DISO
accounted	O	O
for	O	O
58	O	O
%	O	O
,	O	O
47	O	O
%	O	O
,	O	O
and	O	O
60	O	O
%	O	O
of	O	O
the	O	O
predicted	O	O
variances	O
for	O	O
CK	B-PROC
-	I-PROC
MB	I-PROC
AUC	O
,	O	O
TnI	B-CHEM
AUC	O
,	O	O
and	O	O
MSI	O
,	O	O
respectively	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
LV	B-DISO
mass	I-DISO
accounts	O	O
for	O	O
approximately	O	O
half	O	O
of	O	O
the	O	O
predicted	O	O
variance	O
in	O	O
biomarker	B-PHYS
measures	O
of	O	O
infarct	B-DISO
size	I-DISO
.	O	O

It	O	O
should	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
adjustment	O
variable	O
in	O	O
studies	B-PROC
evaluating	O	O
infarct	B-DISO
size	I-DISO
.	O	O

Hard	O
ticks	O
(	O	O
Acari	O
:	O
Ixodidae	O
)	O	O
of	O	O
livestock	B-LIVB
in	O	O
Nicaragua	B-GEOG
,	O	O
with	O	O
notes	O
about	O	O
distribution	O
We	O	O
document	O
the	O	O
species	O
of	O	O
ticks	O
that	O	O
parasitize	B-DISO
livestock	B-LIVB
in	O	O
Nicaragua	B-GEOG
.	O	O

The	O	O
study	B-PROC
was	O	O
based	O	O
on	O	O
tick	O
collection	O
on	O	O
cattle	B-LIVB
and	O	O
horses	B-LIVB
from	O	O
437	O	O
farms	O
in	O	O
nine	O	O
departments	O
.	O	O

Of	O	O
4841	O	O
animals	B-LIVB
examined	O	O
(	O	O
4481	O	O
cows	B-LIVB
and	O	O
360	O	O
horses	B-LIVB
)	O	O
,	O	O
3299	O	O
were	O	O
parasitized	B-DISO
,	O	O
which	O	O
represent	O	O
68	O	O
%	O	O
of	O	O
the	O	O
bovines	B-LIVB
and	O	O
67	O	O
%	O	O
of	O	O
the	O	O
equines	B-LIVB
in	O	O
study	B-PROC
:	O	O
59	O	O
cows	B-LIVB
and	O	O
25	O	O
horses	B-LIVB
were	O	O
parasitized	B-DISO
by	O	O
more	O	O
than	O	O
one	O	O
species	O
.	O	O

In	O	O
addition	O	O
,	O	O
280	O	O
specimens	B-OBJC
of	O	O
the	O	O
entomological	O
museum	B-OBJC
in	O	O
León	B-GEOG
were	O	O
examined	O	O
.	O	O

The	O	O
ticks	O
found	O	O
on	O	O
cattle	B-LIVB
were	O	O
Rhipicephalus	O
microplus	O
(	O	O
75	O	O
.	O	O
2	O	O
%	O	O
of	O	O
the	O	O
ticks	O
collected	O
)	O	O
,	O	O
Amblyomma	O
mixtum	O
(	O	O
20	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

parvum	O
(	O	O
2	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

tenellum	O
(	O	O
0	O	O
.	O	O
7	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

maculatum	O
(	O	O
0	O	O
.	O	O

7	O	O
%	O	O
)	O	O
.	O	O

While	O	O
the	O	O
ticks	O
collected	O
from	O	O
the	O	O
horses	B-LIVB
were	O	O
:	O	O
Dermacentor	O
nitens	O
(	O	O
41	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

mixtum	O
(	O	O
31	O	O
.	O	O
7	O	O
%	O	O
)	O	O
,	O	O
R	O
.	O

microplus	O
(	O	O
13	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

parvum	O
(	O	O
6	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
A	O
.	O

tenellum	O
(	O	O
3	O	O
.	O	O
3	O	O
%	O	O
)	O	O
,	O	O
D	O
.	O

dissimilis	O
(	O	O
2	O	O
.	O	O
4	O	O
%	O	O
)	O	O
and	O	O
A	O
.	O

maculatum	O
(	O	O
0	O	O
.	O	O

8	O	O
%	O	O
)	O	O
.	O	O

Crocetin	B-CHEM
improves	B-DISO
the	O	O
quality	O
of	O	O
in	O
vitro	O
-	O	O
produced	O
bovine	B-LIVB
embryos	B-ANAT
:	O	O
Implications	O	O
for	O	O
blastocyst	B-PHYS
development	I-PHYS
,	O	O
cryotolerance	O
,	O	O
and	O	O
apoptosis	B-PHYS
The	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
assess	B-PROC
the	O	O
effect	O
of	O	O
supplementation	B-PROC
of	O	O
bovine	B-LIVB
culture	B-CHEM
medium	I-CHEM
with	O	O
the	O	O
natural	B-CHEM
antioxidant	I-CHEM
crocetin	B-CHEM
on	O	O
in	O
vitro	O
blastocyst	B-PHYS
development	I-PHYS
and	O	O
quality	O
.	O	O

This	O	O
was	O	O
evaluated	B-PROC
as	O	O
cryotolerance	O
,	O	O
apoptosis	O
index	O
,	O	O
and	O	O
total	B-PROC
cells	I-PROC
number	I-PROC
and	O	O
allocation	O
.	O	O

Abattoir	B-OBJC
-derived	O	O
oocytes	B-ANAT
were	O	O
matured	O
and	O	O
fertilized	O
in	O
vitro	O
according	O	O
to	O	O
standard	O
procedure	O
.	O	O

Twenty	O	O
hours	O
after	O	O
IVF	B-PROC
,	O	O
presumptive	O
zygotes	B-ANAT
were	O	O
cultured	B-PROC
in	O	O
synthetic	B-ANAT
oviduct	I-ANAT
fluid	B-OBJC
medium	I-OBJC
,	O	O
supplemented	O	O
with	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
.	O	O
5	O	O
,	O	O
and	O	O
5	O	O
μM	O	O
crocetin	B-CHEM
(	O	O
experiment	O	O
1	O	O
)	O	O
at	O	O
39	O	O
°	O	O
C	O	O
under	O	O
humidified	B-PROC
air	I-PROC
with	O	O
5	O	O
%	O	O
CO2	B-CHEM
,	O	O
7	O	O
%	O	O
O2	B-CHEM
,	O	O
and	O	O
88	O	O
%	O	O
N2	B-CHEM
.	O	O

On	O	O
Day	O
7	O	O
,	O	O
embryo	O
yields	O
were	O	O
assessed	O
and	O	O
the	O	O
blastocysts	B-ANAT
were	O	O
vitrified	O	O
by	O	O
Cryotop	O
method	O
in	O	O
16	O	O
.	O	O

5	O	O
%	O	O
ethylene	B-CHEM
glycol	I-CHEM
,	O	O
16	O	O
.	O	O

5	O	O
%	O	O
DMSO	B-CHEM
,	O	O
and	O	O
0	O	O
.	O	O

5	O	O
M	O	O
sucrose	B-CHEM
.	O	O

Finally	O	O
,	O	O
blastocysts	B-ANAT
produced	O	O
on	O	O
Day	O
8	O	O
in	O	O
the	O	O
absence	O
(	O	O
control	B-LIVB
)	O	O
and	O	O
presence	B-DISO
of	O	O
1	O	O
μM	O	O
crocetin	B-CHEM
were	O	O
used	O	O
for	O	O
terminal	B-PROC
deoxynucleotidyl	I-PROC
transferase	I-PROC
-	I-PROC
mediated	I-PROC
dUTP	I-PROC
nick	I-PROC
end	I-PROC
labelling	I-PROC
and	O	O
differential	B-PROC
staining	I-PROC
to	O	O
evaluate	B-PROC
,	O	O
respectively	O	O
,	O	O
the	O	O
apoptotic	O
rate	O
and	O	O
the	O	O
allocation	O
of	O	O
cells	B-ANAT
into	O	O
inner	B-ANAT
cell	I-ANAT
mass	I-ANAT
(	O	O
ICM	B-ANAT
)	O	O
and	O	O
trophectoderm	B-ANAT
(	O	O
TE	B-ANAT
)	O	O
lineages	O
(	O	O
experiment	O	O
2	O	O
)	O	O
.	O	O

Embryo	B-PHYS
development	I-PHYS
was	O	O
higher	O	O
in	O	O
the	O	O
1	O	O
μM	O	O
crocetin	O
group	O
compared	O	O
to	O	O
the	O	O
control	B-LIVB
,	O	O
both	O	O
in	O	O
terms	O	O
of	O	O
total	O
embryo	B-ANAT
output	B-DISO
(	O	O
37	O	O
.	O	O
7	O	O
±	O	O
4	O	O
.	O	O
2	O	O
%	O	O
,	O	O
52	O	O
.	O	O
9	O	O
±	O	O
6	O	O
.	O	O

3	O	O
%	O	O
,	O	O
40	O	O
.	O	O
9	O	O
±	O	O
7	O	O
.	O	O
6	O	O
%	O	O
,	O	O
and	O	O
42	O	O
.	O	O
4	O	O
±	O	O
8	O	O
.	O	O

7	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
.	O	O
5	O	O
,	O	O
and	O	O
5	O	O
μM	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
grade	O
1	O
and	O	O
2	O
blastocysts	B-ANAT
(	O	O
33	O	O
.	O	O
6	O	O
±	O	O
4	O	O
.	O	O
9	O	O
%	O	O
,	O	O
46	O	O
.	O	O
1	O	O
±	O	O
7	O	O
.	O	O

3	O	O
%	O	O
,	O	O
37	O	O
.	O	O
8	O	O
±	O	O
7	O	O
.	O	O
9	O	O
%	O	O
,	O	O
and	O	O
39	O	O
.	O	O
4	O	O
±	O	O
7	O	O
.	O	O
9	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
.	O	O
5	O	O
,	O	O
and	O	O
5	O	O
μM	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
percentage	O
of	O	O
fast	B-PHYS
-	I-PHYS
developing	I-PHYS
embryos	I-PHYS
increased	O
in	O	O
1	O	O
μM	O	O
crocetin	O
group	O
compared	O	O
to	O	O
the	O	O
control	B-LIVB
(	O	O
23	O	O
.	O	O
4	O	O
±	O	O
4	O	O
.	O	O

7	O	O
%	O	O
,	O	O
32	O	O
.	O	O

7	O	O
±	O	O
6	O	O
.	O	O

6	O	O
%	O	O
,	O	O
27	O	O
.	O	O
2	O	O
±	O	O
6	O	O
.	O	O

6	O	O
%	O	O
,	O	O
and	O	O
30	O	O
.	O	O
1	O	O
±	O	O
7	O	O
.	O	O
2	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
.	O	O
5	O	O
,	O	O
and	O	O
5	O	O
μM	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
enrichment	B-CHEM
of	I-CHEM
culture	I-CHEM
medium	I-CHEM
with	O	O
1	O	O
μM	O	O
crocetin	B-CHEM
improved	B-DISO
embryo	B-ANAT
cryotolerance	O
compared	O	O
to	O	O
the	O	O
control	B-LIVB
,	O	O
as	O	O
indicated	O	O
by	O	O
higher	O	O
hatching	B-PHYS
rates	O
recorded	O	O
after	O	O
48	O	O
hours	O
postwarming	B-CHEM
culture	I-CHEM
(	O	O
46	O	O
.	O	O
5	O	O
%	O	O
vs	O	O
.	O	O

60	O	O
.	O	O
4	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
1	O	O
μM	O	O
crocetin	B-CHEM
decreased	O
both	O	O
the	O	O
average	O	O
number	O	O
(	O	O
9	O	O
.	O	O
9	O	O
±	O	O
0	O	O
.	O	O

4	O	O
vs	O	O
.	O	O

7	O	O
.	O	O
1	O	O
±	O	O
0	O	O
.	O	O
3	O	O
)	O	O
and	O	O
the	O	O
percentage	O
of	O	O
apoptotic	O
cells	B-ANAT
(	O	O
7	O	O
.	O	O
1	O	O
±	O	O
0	O	O
.	O	O
4	O	O
vs	O	O
.	O	O

4	O	O
.	O	O
2	O	O
±	O	O
0	O	O
.	O	O
2	O	O
)	O	O
in	O	O
blastocysts	B-ANAT
compared	O	O
to	O	O
the	O	O
control	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

However	O	O
,	O	O
no	O	O
differences	O	O
were	O	O
recorded	O	O
in	O	O
the	O	O
average	O	O
number	O	O
of	O	O
ICM	B-ANAT
,	O	O
TE	B-ANAT
,	O	O
and	O	O
total	O
cells	B-ANAT
between	O	O
1	O	O
μM	O	O
crocetin	B-CHEM
and	O	O
control	B-LIVB
groups	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
the	O	O
enrichment	B-CHEM
of	I-CHEM
bovine	I-CHEM
culture	I-CHEM
medium	I-CHEM
with	O	O
1	O	O
μM	O	O
crocetin	B-CHEM
increased	O
both	O	O
blastocyst	O
yield	O
and	O	O
quality	O
,	O	O
as	O	O
indicated	O	O
by	O	O
the	O	O
improved	B-DISO
chronology	O
of	O	O
embryo	B-PHYS
development	I-PHYS
,	O	O
increased	O
resistance	O
to	O	O
cryopreservation	B-PROC
,	O	O
and	O	O
reduced	O
incidence	O
of	O	O
apoptosis	B-PHYS
.	O	O

Parkinson	B-DISO
subtype	O
-specific	O	O
Granger	B-PROC
-	I-PROC
causal	I-PROC
coupling	I-PROC
and	O	O
coherence	B-PHYS
frequency	O	O
in	O	O
the	O	O
subthalamic	B-ANAT
area	O	O
Previous	O	O
work	O	O
on	O	O
Parkinson	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
PD	B-DISO
)	O	O
has	O	O
indicated	O	O
a	O	O
predominantly	O	O
afferent	O
coupling	O
between	O	O
affected	O	O
arm	B-ANAT
muscle	B-PHYS
activity	I-PHYS
and	O	O
electrophysiological	B-PHYS
activity	I-PHYS
within	O	O
the	O	O
subthalamic	B-ANAT
nucleus	I-ANAT
(	O	O
STN	B-ANAT
)	O	O
.	O	O

So	O	O
far	O	O
,	O	O
no	O	O
information	O	O
is	O	O
available	O	O
indicating	O	O
which	O	O
frequency	O	O
components	O	O
drive	O	O
the	O	O
afferent	O
information	O
flow	O
in	O	O
PD	B-DISO
patients	B-LIVB
.	O	O

Non	O	O
-	O	O
directional	O	O
coupling	O	O
e	O	O
.	O	O

g	O	O
.	O	O

by	O	O
measuring	O	O
coherence	B-PHYS
is	O	O
primarily	O	O
established	O	O
in	O	O
the	O	O
beta	B-ANAT
band	I-ANAT
as	O	O
well	O	O
as	O	O
at	O	O
tremor	B-DISO
frequency	O
.	O	O

Based	O	O
on	O	O
previous	O	O
evidence	O	O
it	O	O
is	O	O
likely	O	O
that	O	O
different	O	O
subtypes	O
of	O	O
the	O	O
disease	B-DISO
are	O	O
associated	O
with	O
different	O	O
connectivity	O
patterns	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
determined	O	O
coherence	B-PHYS
and	O	O
causality	O	O
between	O	O
local	B-PHYS
field	I-PHYS
potentials	I-PHYS
(	O	O
LFPs	B-PHYS
)	O	O
in	O	O
the	O	O
STN	B-ANAT
and	O	O
surface	O	O
electromyograms	B-DISO
(	O	O
EMGs	B-DISO
)	O	O
from	O	O
the	O	O
contralateral	O
arm	O
in	O	O
18	O	O
akinetic	B-DISO
-	I-DISO
rigid	I-DISO
(	O	O
AR	B-DISO
)	O	O
PD	B-DISO
patients	B-LIVB
and	O	O
8	O	O
tremor	B-DISO
-	I-DISO
dominant	I-DISO
(	O	O
TD	B-DISO
)	O	O
PD	B-DISO
patients	B-LIVB
.	O	O

During	O	O
the	O	O
intraoperative	O
recording	O	O
,	O	O
patients	B-LIVB
were	O	O
asked	O	O
to	O	O
lift	O	O
their	O	O
forearm	B-ANAT
contralateral	O
to	O	O
the	O	O
recording	O	O
side	O	O
.	O	O

Significantly	O	O
more	O	O
afferent	O
connections	O
were	O	O
detected	O	O
for	O	O
the	O	O
TD	B-DISO
patients	B-LIVB
for	O	O
tremor	B-DISO
-periods	O	O
and	O	O
non	O	O
-	O	O
tremor	B-DISO
-periods	O	O
combined	O	O
as	O	O
well	O	O
as	O	O
for	O	O
only	O	O
tremor	B-DISO
periods	O	O
.	O	O

Within	O	O
the	O	O
STN	B-ANAT
74	O	O
%	O	O
and	O	O
63	O	O
%	O	O
of	O	O
the	O	O
afferent	O
connections	O
are	O	O
associated	O
with	O
coherence	B-PHYS
from	O	O
4	O	O
-	O	O
8Hz	O	O
and	O	O
8	O	O
-	O	O
12Hz	O	O
,	O	O
respectively	O	O
.	O	O

However	O	O
,	O	O
when	O	O
considering	O	O
only	O	O
tremor	B-DISO
-periods	O	O
significantly	O	O
more	O	O
afferent	O
than	O	O
efferent	O
connections	O
were	O	O
associated	O
with	O
coherence	B-PHYS
from	O	O
12	O	O
to	O	O
20Hz	O	O
across	O	O
all	O	O
recording	O	O
heights	O	O
.	O	O

No	O	O
difference	O	O
between	O	O
efferent	O
and	O	O
afferent	O
connections	O
is	O	O
seen	O	O
in	O	O
the	O	O
frequency	O
range	O
from	O	O
4	O	O
to	O	O
12Hz	O	O
for	O	O
all	O	O
recording	O	O
heights	O	O
.	O	O

For	O	O
the	O	O
AR	B-DISO
patients	B-LIVB
,	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
afferent	O
and	O	O
efferent	O
connections	O
within	O	O
the	O	O
STN	B-ANAT
was	O	O
found	O	O
for	O	O
the	O	O
different	O	O
frequency	O
bands	O
.	O	O

Still	O	O
,	O	O
for	O	O
the	O	O
AR	B-DISO
patients	B-LIVB
dorsal	O
of	O	O
the	O	O
STN	B-ANAT
significantly	O	O
more	O	O
afferent	O
than	O	O
efferent	O
connections	O
were	O	O
associated	O
with	O
coherence	B-PHYS
in	O	O
the	O	O
frequency	O	O
range	O	O
from	O	O
12	O	O
to	O	O
16Hz	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
further	O	O
evidence	O	O
for	O	O
the	O	O
differential	O	O
pathological	O
oscillations	O
and	O	O
pathways	O
present	O	O
in	O	O
AR	B-DISO
and	O	O
TD	B-DISO
Parkinson	B-DISO
patients	B-LIVB
.	O	O

Incidence	O
and	O	O
growth	B-PHYS
of	O	O
Salmonella	B-LIVB
enterica	I-LIVB
on	O	O
the	O	O
peel	B-OBJC
and	O	O
pulp	B-OBJC
of	O	O
avocado	B-OBJC
(	O	O
Persea	B-LIVB
americana	I-LIVB
)	O	O
and	O	O
custard	B-OBJC
apple	I-OBJC
(	O	O
Annona	B-LIVB
squamosa	I-LIVB
)	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
assess	O
the	O	O
incidence	O
and	O	O
to	O	O
estimate	O
the	O	O
growth	O
kinetic	O
parameters	O
(	O	O
maximum	O
growth	O
rate	O
,	O	O
μ	O
;	O	O
lag	O
time	O
,	O	O
λ	O
;	O	O
and	O	O
maximum	O
population	O
,	O	O
κ	O
)	O	O
of	O	O
Salmonella	B-LIVB
on	O	O
the	O	O
peel	B-OBJC
and	O	O
pulp	B-OBJC
of	O	O
avocado	B-OBJC
(	O	O
Perseaamericana	B-LIVB
var	I-LIVB
.	I-LIVB

americana	I-LIVB
)	O	O
and	O	O
custard	B-OBJC
apple	I-OBJC
(	O	O
Annona	B-LIVB
squamosa	I-LIVB
L	I-LIVB
.	I-LIVB
)	O	O
as	O	O
affected	O	O
by	O	O
temperature	O
(	O	O
10	O	O
-	O	O
30°C	O	O
)	O	O
.	O	O

The	O	O
incidence	O
of	O	O
Salmonella	B-LIVB
was	O	O
assessed	O
on	O	O
the	O	O
peel	B-OBJC
and	O	O
pulp	B-OBJC
of	O	O
the	O	O
fruits	B-OBJC
(	O	O
n	O	O
=	O	O
200	O	O
of	O	O
each	O	O
fruit	B-OBJC
)	O	O
,	O	O
separately	O	O
,	O	O
totalizing	O	O
800	O	O
analyses	O	O
.	O	O

Only	O	O
three	O	O
samples	O	O
of	O	O
custard	B-OBJC
apple	I-OBJC
pulp	B-OBJC
were	O	O
positive	O	O
for	O	O
Salmonella	B-LIVB
enterica	I-LIVB
and	O	O
the	O	O
three	O	O
isolates	B-CHEM
recovered	O	O
belonged	O	O
to	O	O
serotype	O
S	B-LIVB
.	I-LIVB

Typhimurium	I-LIVB
.	O	O

Salmonella	B-LIVB
was	O	O
not	O	O
recovered	O
from	O	O
avocado	B-OBJC
and	O	O
custard	B-OBJC
apple	I-OBJC
peel	B-OBJC
s	O	O
and	O	O
from	O	O
avocado	B-OBJC
pulp	B-OBJC
.	O	O

Generally	O	O
,	O	O
the	O	O
substrate	B-OBJC
(	O	O
pulp	B-OBJC
or	O	O
peel	B-OBJC
)	O	O
of	O	O
growth	O	O
did	O	O
not	O	O
affect	O	O
μ	O
values	O	O
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Very	O	O
similar	O	O
μ	O
values	O	O
were	O	O
found	O	O
for	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
inoculated	O
in	O	O
custard	B-OBJC
apple	I-OBJC
and	O	O
avocado	B-OBJC
.	O	O

S	B-LIVB
.	I-LIVB

enterica	I-LIVB
presented	O	O
the	O	O
highest	O	O
λ	O
in	O	O
the	O	O
peel	B-OBJC
of	O	O
the	O	O
fruits	O	O
.	O	O

The	O	O
growth	B-PHYS
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
resulted	O	O
in	O	O
larger	O	O
λ	O
in	O	O
custard	B-OBJC
apple	I-OBJC
in	O	O
comparison	O	O
to	O	O
avocado	B-OBJC
.	O	O

For	O	O
example	O	O
,	O	O
the	O	O
λ	O
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O	O
the	O	O
pulp	B-OBJC
of	O	O
custard	B-OBJC
apple	I-OBJC
and	O	O
avocado	B-OBJC
were	O	O
47	O	O
.	O	O

0±0	O	O
.	O	O

78h	O	O
and	O	O
10	O	O
.	O	O

0±3	O	O
.	O	O

78h	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
lowest	O	O
values	O	O
of	O	O
κ	O
were	O	O
obtained	O	O
at	O	O
the	O	O
lower	O
storage	O
temperature	O
conditions	O	O
(	O	O
10°C	O	O
)	O	O
.	O	O

For	O	O
instance	O	O
,	O	O
κ	O
values	O	O
of	O	O
3	O	O
.	O	O

7±0	O	O
.	O	O

06log	O	O
CFU	O
/	O
g	O
and	O	O
2	O	O
.	O	O

9±0	O	O
.	O	O

03log	O	O
CFU	O
/	O
g	O
were	O	O
obtained	O	O
from	O	O
the	O	O
growth	B-PHYS
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O	O
avocado	B-OBJC
and	O	O
custard	B-OBJC
apple	I-OBJC
pulps	B-OBJC
at	O	O
10°C	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
at	O	O
30°C	O	O
,	O	O
κ	O
values	O	O
were	O	O
6	O	O
.	O	O

5±0	O	O
.	O	O

25log	O	O
CFU	O
/	O
g	O
and	O	O
6	O	O
.	O	O

5±0	O	O
.	O	O

05log	O	O
CFU	O
/	O
g	O
,	O	O
respectively	O	O
.	O	O

Significantly	O	O
higher	O	O
κ	O
were	O	O
obtained	O	O
from	O	O
the	O	O
growth	B-PHYS
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O	O
the	O	O
pulp	B-OBJC
than	O	O
in	O	O
the	O	O
peel	B-OBJC
of	O	O
the	O	O
fruits	B-OBJC
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

For	O	O
instance	O	O
,	O	O
the	O	O
growth	B-PHYS
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
in	O	O
the	O	O
pulp	B-OBJC
of	O	O
avocado	B-OBJC
led	O	O
to	O	O
a	O	O
κ	O
value	O	O
of	O	O
6	O	O
.	O	O

5±0	O	O
.	O	O

25log	O	O
CFU	O
/	O
g	O
,	O	O
while	O	O
in	O	O
the	O	O
peel	B-OBJC
led	O	O
to	O	O
a	O	O
κ	O
value	O	O
of	O	O
4	O	O
.	O	O

6±0	O	O
.	O	O

23log	O	O
CFU	O
/	O
g	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
general	O	O
,	O	O
growth	O
kinetic	O
parameters	O
indicated	O	O
that	O	O
avocado	B-OBJC
comprises	O	O
a	O	O
better	O	O
substrate	B-OBJC
than	O	O
custard	B-OBJC
apple	I-OBJC
for	O	O
the	O	O
growth	B-PHYS
of	O	O
S	B-LIVB
.	I-LIVB

enterica	I-LIVB
.	O	O

The	O	O
square	O
root	O
model	O
fitted	O	O
to	O	O
the	O	O
data	O
obtained	O	O
in	O	O
this	O	O
study	B-PROC
and	O	O
to	O	O
the	O	O
growth	O
data	O
available	O	O
in	O	O
the	O	O
literature	O	O
for	O	O
other	O	O
tropical	B-OBJC
low	I-OBJC
acid	I-OBJC
fruits	I-OBJC
indicated	O	O
high	O	O
variability	O
in	O	O
μ	O
and	O	O
λ	O
of	O	O
Salmonella	B-LIVB
.	O	O

The	O	O
results	O	O
obtained	O	O
in	O	O
this	O	O
study	B-PROC
show	O	O
that	O	O
whole	O	O
low	B-OBJC
acid	I-OBJC
tropical	I-OBJC
fruits	I-OBJC
can	O	O
harbor	O	O
Salmonella	B-LIVB
,	O	O
and	O	O
that	O	O
this	O	O
foodborne	O
pathogen	B-LIVB
can	O	O
not	O	O
only	O	O
survive	O	O
but	O	O
also	O	O
grow	O	O
both	O	O
on	O	O
the	O	O
peel	B-OBJC
and	O	O
pulp	B-OBJC
of	O	O
low	B-OBJC
acid	I-OBJC
tropical	I-OBJC
fruits	I-OBJC
,	O	O
such	O	O
as	O	O
avocado	B-OBJC
and	O	O
custard	B-OBJC
apple	I-OBJC
.	O	O

Photocatalytic	O
and	O	O
antibacterial	B-DISO
response	I-DISO
of	O	O
biosynthesized	O
gold	B-CHEM
nanoparticles	B-OBJC
Increase	O
in	O	O
the	O	O
bacterial	B-DISO
resistance	I-DISO
to	O	O
available	O	O
antibiotics	B-CHEM
and	O	O
water	B-PHEN
contamination	I-PHEN
by	O	O
different	O
toxic	O
organic	B-CHEM
dyes	I-CHEM
are	O	O
both	O	O
severe	O
problems	B-DISO
throughout	O	O
the	O	O
world	O
.	O	O

To	O	O
overcome	O
these	O	O
concerns	O
,	O	O
new	O	O
methodologies	B-PROC
including	O	O
synthesis	O
of	O	O
nontoxic	O
,	O	O
human	B-LIVB
friendly	O
and	O	O
efficient	O
nanoparticles	B-OBJC
is	O	O
required	O
.	O	O

These	O	O
nanoparticles	B-OBJC
not	O	O
even	O	O
inhibit	O
the	O	O
growth	B-PHYS
of	I-PHYS
microorganisms	I-PHYS
but	O	O
are	O	O
also	O	O
effective	O
in	O	O
the	O	O
degradation	O
of	O	O
toxic	O
organics	B-CHEM
in	O	O
waste	B-GEOG
water	I-GEOG
thus	O	O
providing	O	O
a	O	O
clean	O
and	O	O
human	B-LIVB
friendly	O
environment	O
.	O	O

The	O	O
use	O	O
of	O	O
plants	B-CHEM
extracts	I-CHEM
to	O	O
synthesize	O
and	O	O
stabilize	B-DISO
noble	O	O
metal	B-OBJC
nanoparticles	I-OBJC
have	O	O
been	O	O
considered	O
as	O	O
safe	O	O
,	O	O
cost	O
-	O
effective	O
,	O	O
eco	O
-	O
benign	O
and	O	O
green	O
approach	O
nowadays	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
Longan	B-LIVB
fruit	B-CHEM
juice	I-CHEM
proficiently	O	O
reduced	O
ionic	B-CHEM
gold	I-CHEM
(	B-CHEM
Au	I-CHEM
(	I-CHEM
+	I-CHEM
3	I-CHEM
)	I-CHEM
)	I-CHEM
to	O	O
gold	B-CHEM
nanoparticles	B-OBJC
(	O	O
AuNPs	B-OBJC
)	O	O
as	O	O
well	O	O
as	O	O
mediated	O	O
the	O	O
stabilization	O
of	O	O
AuNPs	B-OBJC
.	O	O

The	O	O
antibacterial	B-DISO
activity	I-DISO
of	O	O
AuNPs	B-OBJC
was	O	O
carried	O	O
out	O	O
against	O
both	O	O
gram	B-LIVB
positive	I-LIVB
and	O	O
gram	B-LIVB
negative	I-LIVB
bacteria	I-LIVB
using	O	O
agar	B-PROC
well	I-PROC
diffusion	I-PROC
method	I-PROC
,	O	O
followed	O	O
by	O	O
the	O	O
determination	O	O
of	O	O
Minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
(	O	O
MIC	B-PROC
)	O	O
values	O
.	O	O

AuNPs	B-OBJC
were	O	O
found	B-DISO
to	O	O
have	O	O
significant	O
antibacterial	B-DISO
activity	I-DISO
against	O
Escherichia	B-LIVB
coli	I-LIVB
with	O	O
MIC	B-PROC
values	O
of	O	O
75μg	O	O
/	O	O
ml	O	O
while	O	O
outstanding	O	O
MIC	B-PROC
values	O
of	O	O
50μg	O	O
/	O	O
ml	O	O
against	O
Staphylococcus	B-LIVB
areous	I-LIVB
and	O	O
Basilus	B-LIVB
subtilus	I-LIVB
.	O	O

AuNPs	B-OBJC
revealed	O
significant	O
photocatalytic	O
degradation	O
(	O	O
76	O	O
%	O	O
)	O	O
of	O	O
methylene	B-CHEM
blue	I-CHEM
in	O	O
time	O
period	O
of	O	O
55	O	O
min	O
,	O	O
indicating	O	O
the	O	O
effective	O
photocatalytic	O
property	O
of	O	O
biosynthesized	O
AuNPs	B-OBJC
(	O	O
K	O	O
=	O	O
0	O	O
.	O	O
29	O	O
/	O	O
min	O	O
,	O	O
r	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
95	O	O
)	O	O
.	O	O

The	O	O
considerable	O	O
antibacterial	B-DISO
and	O	O
photocatalytic	O
activities	O
of	O	O
the	O	O
photosynthesized	O
AuNPs	B-OBJC
can	O	O
be	O	O
attributed	O	O
towards	O	O
their	O	O
small	B-DISO
size	I-DISO
,	O	O
spherical	O
morphology	O
and	O	O
uniform	O
dispersion	O
.	O	O

Our	O	O
finding	O	O
suggests	O	O
the	O	O
possible	O	O
therapeutic	O
potential	O
of	O	O
biogenic	B-OBJC
AuNPs	I-OBJC
in	O	O
the	O	O
development	O
of	O	O
new	O	O
antibacterial	B-CHEM
agents	I-CHEM
as	O	O
well	O	O
as	O	O
in	O	O
the	O	O
development	O
of	O	O
effective	O
photocatalysts	B-PHEN
.	O	O

Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O	O
an	O	O
unreliable	O
lateralizing	B-DISO
sign	I-DISO
in	O	O
tuberous	B-DISO
sclerosis	I-DISO
complex	I-DISO
Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O	O
an	O	O
uncommon	O
but	O	O
reportedly	O	O
reliable	O	O
lateralizing	B-DISO
sign	I-DISO
,	O	O
indicating	O	O
an	O	O
ipsilateral	O
seizure	B-DISO
focus	I-DISO
.	O	O

We	O	O
aimed	O	O
to	O	O
determine	O	O
its	O	O
lateralizing	B-DISO
utility	I-DISO
in	O	O
patients	B-LIVB
with	O	O
tuberous	B-DISO
sclerosis	I-DISO
complex	I-DISO
(	O	O
TSC	B-DISO
)	O	O
.	O	O

We	O	O
reviewed	O	O
the	O	O
video	B-PROC
-	I-PROC
EEGs	I-PROC
of	O	O
92	O	O
children	B-LIVB
with	O	O
TSC	B-DISO
and	O	O
drug	B-DISO
-	I-DISO
resistant	I-DISO
epilepsy	I-DISO
.	O	O

Eleven	O	O
(	O	O
12	O	O
%	O	O
)	O	O
had	O	O
seizures	B-DISO
with	O	O
unilateral	O
blinking	B-PHYS
,	O	O
of	O	O
which	O	O
10	O	O
underwent	O	O
epilepsy	B-DISO
surgery	B-PROC
.	O	O

Lateralization	B-DISO
of	O	O
seizures	B-DISO
was	O	O
inferred	O	O
from	O	O
other	O	O
semiology	B-DISO
,	O	O
ictal	B-DISO
scalp	B-PROC
EEG	I-PROC
and	O	O
outcome	O
following	O	O
tuberectomy	B-PROC
.	O	O

Seizures	B-DISO
manifesting	O	O
with	O	O
unilateral	O
blinking	B-PHYS
were	O	O
focal	B-DISO
motor	I-DISO
in	O	O
four	O	O
patients	B-LIVB
,	O	O
focal	B-DISO
motor	I-DISO
evolving	O	O
into	O	O
epileptic	B-DISO
spasms	I-DISO
in	O	O
six	O	O
,	O	O
and	O	O
epileptic	B-DISO
spasms	I-DISO
with	O	O
focal	B-DISO
features	I-DISO
in	O	O
one	O	O
.	O	O

Associated	O	O
unilateral	O
facial	B-DISO
contraction	I-DISO
was	O	O
seen	O	O
in	O	O
five	O	O
patients	B-LIVB
and	O	O
arm	B-DISO
jerking	I-DISO
in	O	O
four	O	O
.	O	O

Lateralized	B-DISO
scalp	B-ANAT
ictal	B-DISO
rhythms	B-DISO
were	O	O
seen	O	O
in	O	O
seven	O	O
patients	B-LIVB
.	O	O

Following	O	O
tuberectomies	B-PROC
,	O	O
seven	O	O
patients	B-LIVB
are	O	O
seizure	B-DISO
free	I-DISO
and	O	O
two	O	O
had	O	O
>	O	O
90	O	O
%	O	O
reduction	O
.	O	O

Overall	B-DISO
lateralization	I-DISO
of	O	O
seizures	B-DISO
with	O	O
unilateral	O
blinking	B-PHYS
was	O	O
contralateral	O
in	O	O
six	O	O
patients	B-LIVB
and	O	O
ipsilateral	O	O
in	O	O
four	O	O
.	O	O

When	O	O
unilateral	O
blinking	B-PHYS
was	O	O
early	O	O
in	O	O
seizures	B-DISO
,	O	O
overall	B-DISO
lateralization	I-DISO
was	O	O
more	O	O
often	O	O
contralateral	O
(	O	O
6	O	O
/	O	O
7	O	O
patients	B-LIVB
,	O	O
PPV	O	O
85	O	O
%	O	O
)	O	O
.	O	O

Ictal	B-DISO
unilateral	O
blinking	B-PHYS
is	O	O
not	O
infrequent	O
but	O	O
unreliable	O
in	O	O
lateralizing	B-DISO
seizures	B-DISO
in	O	O
TSC	B-DISO
.	O	O

Unrecognized	O
seizure	B-DISO
propagation	O
to	O	O
contralateral	O
symptomatogenic	O
regions	O
and	O	O
potentially	O	O
different	O	O
mechanisms	O
may	O	O
account	O	O
for	O	O
the	O	O
variable	O
lateralization	B-DISO
.	O	O

Assessment	B-PROC
the	O	O
Exposure	O
Level	O
of	O	O
Rare	B-CHEM
Earth	I-CHEM
Elements	I-CHEM
in	O	O
Workers	B-LIVB
Producing	O
Cerium	B-CHEM
,	O	O
Lanthanum	B-CHEM
Oxide	I-CHEM
Ultrafine	B-CHEM
and	O	O
Nanoparticles	B-OBJC
In	O	O
order	O	O
to	O	O
assess	B-PROC
occupational	O
exposure	O
level	O
of	O	O
15	O	O
rare	B-CHEM
earth	I-CHEM
elements	I-CHEM
(	O	O
REEs	B-CHEM
)	O	O
and	O	O
identify	O
the	O	O
associated	O
influence	O
,	O	O
we	O	O
used	O	O
inductively	B-PROC
coupled	I-PROC
plasma	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O	O
ICP	B-PROC
-	I-PROC
MS	I-PROC
)	O	O
based	O
on	O	O
closed	O
-	O	O
vessel	B-OBJC
microwave	B-PHEN
-	O	O
assisted	O
wet	O
digestion	O
procedure	O
to	O	O
determinate	B-PROC
the	O	O
concentration	O
of	O	O
Y	B-CHEM
,	O	O
La	B-CHEM
,	O	O
Ce	B-CHEM
,	O	O
Pr	B-CHEM
,	O	O
Nd	B-CHEM
,	O	O
Sm	B-CHEM
,	O	O
Eu	B-CHEM
,	O	O
Gd	B-CHEM
,	O	O
Tb	B-CHEM
,	O	O
Dy	B-CHEM
,	O	O
Ho	B-CHEM
,	O	O
Er	B-CHEM
,	O	O
Tm	B-CHEM
,	O	O
Yb	B-CHEM
and	O	O
Lu	B-CHEM
in	O	O
urinary	B-ANAT
samples	I-ANAT
obtained	O
from	O	O
workers	B-LIVB
producing	O
ultrafine	B-CHEM
and	O	O
nanoparticles	B-OBJC
containing	O	O
cerium	B-CHEM
and	O	O
lanthanum	B-CHEM
oxide	I-CHEM
.	O	O

The	O	O
results	B-PHEN
suggest	O
that	O	O
La	B-CHEM
and	O	O
Ce	B-CHEM
were	O	O
the	O	O
primary	O
component	O
,	O	O
together	O	O
accounting	O
for	O	O
97	O	O
%	O	O
of	O	O
total	O	O
REEs	B-CHEM
in	O	O
workers	B-LIVB
.	O	O

The	O	O
urinary	B-ANAT
levels	O
of	O	O
La	B-CHEM
,	O	O
and	O	O
Ce	B-CHEM
among	O	O
the	O	O
workers	B-LIVB
(	O	O
6	O	O
.	O	O
36	O	O
,	O	O
15	O	O
.	O	O

32	O	O
μg	O	O
.	O	O

g	O	O
(	O	O
-	O	O
1	O	O
)	O	O
creatinine	B-CHEM
,	O	O
respectively	O	O
)	O	O
were	O	O
significantly	O
enriched	O
compared	O
to	O	O
those	O	O
levels	O
measured	O
in	O	O
the	O	O
control	B-LIVB
subjects	B-LIVB
(	O	O
1	O	O
.	O	O
52	O	O
,	O	O
4	O	O
.	O	O
04	O	O
μg	O	O
.	O	O

g	O	O
(	O	O
-	O	O
1	O	O
)	O	O
creatinine	B-CHEM
,	O	O
respectively	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

This	O	O
study	B-PROC
simultaneously	O
identified	O
the	O	O
associated	O
individual	B-LIVB
factors	O
,	O	O
the	O	O
results	B-PHEN
indicate	O
that	O	O
the	O	O
concentrations	O
in	O	O
over	O	O
5	O	O
years	O	O
group	O
(	O	O
11	O	O
.	O	O
64	O	O
±	O	O
10	O	O
.	O	O
93	O	O
for	O	O
La	B-CHEM
,	O	O
27	O	O
.	O	O
83	O	O
±	O	O
24	O	O
.	O	O
38	O	O
for	O	O
Ce	B-CHEM
)	O	O
were	O	O
significantly	O
elevated	O
compared	O
to	O	O
1	O	O
-	O	O
5	O	O
years	O	O
group	O
(	O	O
2	O	O
.	O	O
58	O	O
±	O	O
1	O	O
.	O	O

51	O	O
for	O	O
La	B-CHEM
,	O	O
6	O	O
.	O	O
87	O	O
±	O	O
3	O	O
.	O	O
90	O	O
for	O	O
Ce	B-CHEM
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Compared	O
the	O	O
urinary	B-ANAT
levels	O
of	O	O
La	B-CHEM
and	O	O
Ce	B-CHEM
at	O	O
the	O	O
separation	O
and	O	O
packaging	B-PHEN
locations	O
(	O	O
9	O	O
.	O	O
10	O	O
±	O	O
9	O	O
.	O	O
51	O	O
for	O	O
La	B-CHEM
,	O	O
22	O	O
.	O	O
29	O	O
±	O	O
21	O	O
.	O	O

01	O	O
for	O	O
Ce	B-CHEM
)	O	O
with	O	O
the	O	O
other	O	O
locations	O
(	O	O
2	O	O
.	O	O
85	O	O
±	O	O
0	O	O
.	O	O

98	O	O
for	O	O
La	B-CHEM
,	O	O
6	O	O
.	O	O

37	O	O
±	O	O
2	O	O
.	O	O
12	O	O
for	O	O
Ce	B-CHEM
)	O	O
,	O	O
the	O	O
results	B-PHEN
show	O	O
urinary	B-ANAT
concentrations	O
were	O	O
significantly	O
higher	O
in	O	O
workers	B-LIVB
at	O	O
separation	O
and	O	O
packaging	B-PHEN
locations	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Inter	O
-	O	O
individual	B-LIVB
variation	O
in	O	O
levels	O
of	O	O
La	B-CHEM
and	O	O
Ce	B-CHEM
in	O	O
urine	B-ANAT
is	O	O
the	O	O
result	O
of	O	O
multi	O
-	O
factorial	O
comprehensive	O
action	O
.	O	O

Further	O	O
researches	B-LIVB
should	O	O
focus	O
on	O	O
the	O	O
multiple	O
factors	O
contributing	O
to	O	O
the	O	O
REEs	B-CHEM
levels	O
of	O	O
the	O	O
occupationally	O
exposed	O
workers	B-LIVB
.	O	O

A	O	O
remarkable	O	O
new	O
species	O
of	O	O
Eutrichopoda	O
Townsend	O
,	O	O
1908	O	O
(	O	O
Diptera	O
:	O	O
Tachinidae	O
:	O	O
Phasiinae	O
)	O	O
A	O	O
new	O
Tachinidae	O
species	O
,	O	O
Eutrichopoda	O
flavipenna	O
sp	O
.	O

nov	O
.	O
(	O	O
Diptera	O
:	O	O
Tachinidae	O
:	O	O
Phasiinae	O
)	O	O
,	O	O
from	O	O
Brazil	B-GEOG
and	O	O
Paraguay	B-GEOG
is	O	O
described	O	O
and	O	O
illustrated	O	O
by	O	O
photographs	B-OBJC
and	O	O
line	O
drawings	O
.	O	O

The	O	O
remarkable	O	O
yellow	O
,	O	O
feather	O
-	O
like	O
setae	B-ANAT
on	O	O
the	O	O
hind	B-ANAT
tibia	I-ANAT
distinguishes	O	O
the	O	O
new	O
species	O
from	O	O
all	O	O
other	O	O
species	O
in	O	O
the	O	O
tribe	O
Trichopodini	O
.	O	O

Two	O	O
known	O
and	O	O
one	O	O
new	O
species	O
of	O	O
Draconematidae	O
and	O	O
Epsilonematida	O
(	O	O
Nematoda	O
,	O	O
Desmodorida	O
)	O	O
from	O	O
the	O	O
White	B-GEOG
Sea	I-GEOG
,	O	O
North	B-GEOG
Russia	I-GEOG
Morphological	O
descriptions	O
of	O	O
three	O	O
""""	O	O
walking	O
nematode	O
""""	O	O
species	O
found	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
the	O	O
White	B-GEOG
Sea	I-GEOG
are	O	O
presented	O	O
.	O	O

Draconema	O
ophicephalum	O
(	O	O
Claparède	O
,	O	O
1863	O	O
)	O	O
(	O	O
Draconematidae	O
)	O	O
and	O	O
Epsilonema	O
steineri	O
Chitwood	O
,	O	O
1935	O	O
(	O	O
Epsilonematidae	O
)	O	O
,	O	O
both	O	O
known	O	O
from	O	O
insufficient	O
material	O	O
and	O	O
females	B-PHYS
only	O	O
,	O	O
are	O	O
re	O	O
-	O	O
described	O	O
and	O	O
problems	B-DISO
of	O	O
their	O	O
taxonomic	O
identification	O
as	O	O
well	O	O
as	O	O
species	O
compositions	B-PHYS
of	O	O
respective	O	O
genera	O
are	O	O
discussed	O	O
.	O	O

The	O	O
new	O
species	O
Prochaetosoma	O
marisalbi	O
sp	O
.	O	O

n	O	O
.	O	O
(	O	O
Draconematidae	O
)	O	O
differs	O	O
from	O	O
other	O	O
Prochaetosoma	O
species	O
except	O	O
P	O
.	O

longicapitatum	O
(	O	O
Allgén	O
,	O	O
1935	O	O
)	O	O
in	O	O
that	O	O
the	O	O
pharyngeal	B-ANAT
bulb	B-ANAT
lumen	B-ANAT
is	O	O
not	B-DISO
cuticularised	I-DISO
,	O	O
from	O	O
P	O
.	O

longicapitatum	O
by	O	O
shape	B-ANAT
of	I-ANAT
body	I-ANAT
and	O	O
rostrum	B-ANAT
,	O	O
greater	O
number	O	O
of	O	O
cephalic	O
adhesive	B-ANAT
tubes	I-ANAT
,	O	O
and	O	O
from	O	O
P	O
.	O

maertensi	O
Decraemer	O
,	O	O
1989	O	O
by	O	O
having	O	O
a	O	O
relatively	O	O
longer	O
tail	B-ANAT
,	O	O
fewer	O	O
anterior	O
adhesive	B-ANAT
tubes	I-ANAT
and	O	O
longer	O
spicules	O
,	O	O
besides	O	O
lacking	O	O
cuticular	B-PHYS
thickening	I-PHYS
in	O	O
the	O	O
pharyngeal	B-ANAT
bulb	B-ANAT
.	O	O

Draconema	O
hoonsooi	O
,	O	O
D	O
.	O

youngeouni	O
,	O	O
P	O
.	O

rochaetosoma	O
beomseomense	O
,	O	O
P	O
.	O

brevicaudatum	O
,	O	O
P	O
.	O

byungilli	O
,	O	O
P	O
.	O

cracense	O
,	O	O
P	O
.	O

saheungi	O
,	O	O
P	O
.	O

sujungi	O
,	O	O
P	O
.	O

supseomense	O
erected	O
by	O	O
Rho	O
&	O	O
Min	O
(	O	O
2011	O	O
)	O	O
are	O	O
considered	O	O
as	O	O
invalid	O
species	O
while	O	O
Prochaetosoma	O
arcticum	O
,	O	O
P	O
.	O

lugubre	O
and	O	O
Epsilonema	O
cygnoides	O
are	O	O
assumed	O	O
as	O	O
species	O
inquirenda	O
.	O	O

From	O	O
a	O	O
phylogenetic	B-PROC
tree	I-PROC
based	O	O
on	O	O
the	O	O
18S	O
rRNA	O
gene	O
,	O	O
all	O	O
three	O	O
White	B-GEOG
Sea	I-GEOG
species	O
adjoin	O
to	O	O
unidentified	O
species	O
of	O	O
their	O	O
respective	O	O
genera	O
.	O	O

Differential	O
effects	O
of	O
crude	B-CHEM
oil	I-CHEM
on	O	O
denitrification	B-PHEN
and	O	O
anammox	B-PHYS
,	O	O
and	O	O
the	O	O
impact	O
on	O	O
N2O	B-CHEM
production	B-PHEN
Denitrification	B-PHEN
and	O	O
anammox	B-PHYS
are	O	O
key	O	O
processes	B-PHEN
for	O	O
reducing	O
the	O	O
external	O
nitrogen	B-CHEM
loads	O	O
delivered	O
to	O	O
coastal	O
ecosystems	B-PHEN
,	O	O
and	O	O
these	O	O
processes	B-PHEN
can	O	O
be	O	O
affected	O
by	O	O
pollutants	B-CHEM
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O
the	O	O
effect	O
of	O
crude	B-CHEM
oil	I-CHEM
on	O	O
denitrification	B-PHEN
and	O	O
anammox	B-PHYS
.	O	O

Controlled	B-PROC
laboratory	I-PROC
experiments	I-PROC
were	O	O
performed	O	O
using	O	O
sediment	B-OBJC
slurries	B-OBJC
from	O	O
the	O	O
Lima	B-GEOG
Estuary	B-PHEN
(	O	O
NW	O
Portugal	B-GEOG
)	O	O
.	O	O

Anammox	B-PHYS
and	O	O
denitrification	B-PHEN
rates	O
were	O	O
measured	O	O
using	O	O
(	B-CHEM
15	I-CHEM
)	I-CHEM
N	I-CHEM
-	I-CHEM
labeled	I-CHEM
NO3	B-CHEM
(	I-CHEM
-	I-CHEM
)	I-CHEM
,	O	O
and	O	O
the	O	O
production	B-PHEN
of	O	O
(	B-CHEM
29	I-CHEM
)	I-CHEM
N2	I-CHEM
and	O	O
(	B-CHEM
30	I-CHEM
)	I-CHEM
N2	I-CHEM
quantified	O	O
by	O	O
membrane	B-PROC
inlet	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O	O

Results	O	O
revealed	O	O
that	O	O
while	O	O
denitrification	B-PHEN
rates	O
were	O	O
stimulated	O	O
between	O	O
10	O	O
and	O	O
25	O	O
000	O	O
times	O	O
after	O	O
crude	B-CHEM
oil	I-CHEM
amendment	O
,	O	O
anammox	B-PHYS
activity	O
was	O	O
partially	O	O
(	O	O
between	O	O
2	O	O
and	O	O
5	O	O
times	O	O
)	O	O
or	O	O
completely	O
inhibited	O
by	O	O
the	O	O
addition	O
of	O	O
crude	B-CHEM
oil	I-CHEM
when	O	O
comparing	O	O
to	O	O
rates	O
in	O	O
unamended	O
controls	O
.	O	O

Similar	O	O
results	O	O
were	O	O
observed	O	O
across	O	O
four	O	O
estuarine	O
sediment	B-OBJC
types	O
,	O	O
despite	O	O
their	O	O
different	O	O
physical	O
-	O
chemical	O
characteristics	O
.	O	O

Moreover	O	O
,	O	O
N2O	B-CHEM
production	B-PHEN
was	O	O
reduced	O
by	O	O
2	O	O
-	O	O
36	O	O
times	O	O
following	O	O
crude	B-CHEM
oil	I-CHEM
addition	O
.	O	O

Further	O	O
work	O	O
is	O	O
required	O	O
to	O	O
fully	O	O
understand	O	O
the	O	O
mechanism	O
(	O
s	O
)	O
of	O	O
the	O	O
observed	O
reduction	O
in	O	O
N2O	B-CHEM
production	B-PHEN
.	O	O

This	O	O
study	B-PROC
represents	O	O
one	O	O
of	O	O
the	O	O
first	O	O
contributions	O
to	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
impact	O
of	O	O
crude	B-CHEM
oil	I-CHEM
pollution	B-PHEN
on	O	O
denitrification	B-PHEN
and	O	O
anammox	B-PHYS
,	O	O
with	O	O
profound	O	O
implications	O	O
for	O	O
the	O	O
management	O
of	O	O
aquatic	B-PHEN
ecosystems	B-PHEN
regarding	O	O
eutrophication	B-PHEN
(	O	O
N	O
-	O
removal	O
)	O	O
.	O	O

Lateral	B-ANAT
hypothalamus	I-ANAT
orexinergic	I-ANAT
system	I-ANAT
modulates	O
the	O	O
stress	B-DISO
effect	O
on	O	O
pentylenetetrazol	B-CHEM
induced	O
seizures	B-DISO
through	O	O
corticotropin	B-CHEM
releasing	I-CHEM
hormone	I-CHEM
receptor	I-CHEM
type	I-CHEM
1	I-CHEM
Stress	B-DISO
is	O	O
a	O	O
trigger	B-PHYS
factor	I-PHYS
for	I-PHYS
seizure	I-PHYS
initiation	O
which	O	O
activates	O
hypothalamic	B-ANAT
pituitary	I-ANAT
adrenal	I-ANAT
(	I-ANAT
HPA	I-ANAT
)	I-ANAT
axis	I-ANAT
as	O	O
well	O	O
other	O	O
brain	B-ANAT
areas	O
.	O	O

In	O	O
this	O	O
respect	O	O
,	O	O
corticotropin	B-CHEM
releasing	I-CHEM
hormone	I-CHEM
(	B-CHEM
CRH	I-CHEM
)	I-CHEM
and	O	O
lateral	B-ANAT
hypothalamus	I-ANAT
(	I-ANAT
LH	I-ANAT
)	I-ANAT
orexinergic	I-ANAT
system	I-ANAT
are	O	O
involved	O
in	O	O
seizure	B-DISO
occurrence	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O
the	O	O
role	O
of	O	O
LH	B-ANAT
area	I-ANAT
and	O	O
orexin	B-CHEM
expression	B-PHYS
in	O	O
(	O	O
mediation	O
of	O	O
)	O	O
stress	B-DISO
effect	O
on	O	O
pentylenetetrazol	B-CHEM
(	B-CHEM
PTZ	I-CHEM
)	I-CHEM
-	O	O
induced	O
seizures	B-DISO
with	O	O
hippocampal	B-ANAT
involvement	O
.	O	O

Two	O	O
mild	O
foot	B-DISO
shock	I-DISO
stresses	I-DISO
were	O	O
applied	O
to	O	O
intact	O
and	O	O
adrenalectomized	B-PROC
animals	B-LIVB
;	O	O
with	O	O
or	O	O
without	O	O
CRHr1	B-CHEM
blocking	O
(	O	O
NBI	B-CHEM
27914	I-CHEM
)	O	O
in	O	O
the	O	O
LH	B-ANAT
area	I-ANAT
.	O	O

Then	O	O
,	O	O
changes	O
in	O	O
orexin	B-CHEM
production	O	O
were	O	O
evaluated	B-PROC
by	O	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
.	O	O

Intravenous	O
PTZ	B-CHEM
infusion	B-PROC
(	O	O
25	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
-	O	O
induced	O
convulsions	B-DISO
were	O	O
scored	O
upon	O	O
modified	O
Racine	O
scale	O
.	O	O

Finally	O	O
,	O	O
hippocampal	B-ANAT
glutamate	B-CHEM
and	O	O
GABA	B-CHEM
were	O	O
evaluated	B-PROC
to	O	O
study	B-PROC
excitability	B-DISO
changes	O
.	O	O

We	O	O
demonstrated	O	O
that	O	O
the	O	O
duration	O
and	O	O
severity	O
of	O	O
convulsions	B-DISO
in	O	O
stress	B-DISO
-	O	O
induced	O
as	O	O
well	O	O
as	O	O
adrenalectomized	B-PROC
group	O	O
were	O	O
increased	O
.	O	O

Plasma	B-ANAT
corticosterone	B-CHEM
(	B-CHEM
CRT	I-CHEM
)	I-CHEM
level	O	O
and	O	O
orexin	O
mRNA	B-PHYS
expression	I-PHYS
were	O	O
built	O	O
up	O	O
in	O	O
the	O	O
stress	B-DISO
and	O	O
/	O	O
or	O	O
seizure	B-DISO
groups	O
.	O	O

Furthermore	O	O
,	O	O
glutamate	B-CHEM
and	O	O
GABA	B-CHEM
content	O	O
was	O	O
increased	O
and	O	O
decreased	O
respectively	O	O
due	O	O
to	O	O
stress	B-DISO
and	O	O
seizures	B-DISO
.	O	O

In	O	O
contrast	O	O
,	O	O
rats	B-LIVB
receiving	O	O
CRHr1	B-CHEM
inhibitor	O
showed	O	O
reduced	O
severity	O
and	O	O
duration	O
of	O	O
seizures	B-DISO
,	O	O
increased	O
GABA	B-CHEM
,	O	O
decreased	O
glutamate	B-CHEM
and	O	O
corticosterone	B-CHEM
and	O	O
also	O	O
orexin	B-CHEM
mRNA	B-CHEM
compared	O
to	O	O
the	O	O
inhibitor	O
free	O	O
rats	B-LIVB
.	O	O

Stress	B-DISO
and	O	O
adrenalectomy	B-PROC
induced	O
augmenting	O
effect	O
on	O	O
seizure	B-DISO
severity	O
and	O	O
duration	O
and	O	O
the	O	O
subsequent	O	O
reduction	O
due	O	O
to	O	O
CRHr1	B-CHEM
blocking	O
with	O	O
parallel	O	O
orexin	O
mRNA	B-CHEM
changes	O
,	O	O
indicated	B-DISO
the	O	O
likely	O	O
involvement	O
of	O	O
CRH1r	B-CHEM
induced	O
orexin	B-CHEM
expression	B-PROC
of	O	O
the	O	O
LH	B-ANAT
in	O	O
gating	O	O
stress	B-DISO
effect	O
on	O	O
convulsions	B-DISO
.	O	O

Shining	O	O
the	O	O
light	O	O
on	O	O
the	O	O
dark	O	O
side	O	O
of	O	O
medical	O
leadership	O
-	O	O
a	O	O
qualitative	B-PROC
study	I-PROC
in	O	O
Australia	B-GEOG
Purpose	O	O
The	O	O
paper	O	O
aims	O
to	O	O
explore	O	O
the	O	O
beliefs	O
of	O	O
doctors	B-LIVB
in	O	O
leadership	O
roles	O	O
of	O	O
the	O	O
concept	O
of	O	O
""""	O	O
the	O	O
dark	O	O
side	O	O
""""	O	O
,	O	O
using	O	O
data	O
collected	O	O
from	O	O
interviews	O
carried	O	O
out	O	O
with	O	O
45	O	O
doctors	B-LIVB
in	O	O
medical	O
leadership	O
roles	O	O
across	O	O
Australia	B-GEOG
.	O	O

The	O	O
paper	O	O
looks	O	O
at	O	O
the	O	O
beliefs	O
from	O	O
the	O	O
perspectives	O
of	O	O
doctors	B-LIVB
who	O	O
are	O	O
already	O	O
in	O	O
leadership	O
roles	O	O
themselves	O	O
;	O	O
to	O	O
identify	O	O
potential	O	O
barriers	B-DISO
they	O	O
might	O	O
have	O	O
encountered	O	O
and	O	O
to	O	O
arrive	O	O
at	O	O
better	O	O
-	O	O
informed	O	O
strategies	O	O
to	O	O
engage	O	O
more	O	O
doctors	B-LIVB
in	O	O
the	O	O
leadership	O
of	O	O
the	O	O
Australian	B-LIVB
health	O
system	O
.	O	O

The	O	O
research	B-PROC
question	O	O
is	O	O
:	O	O
""""	O	O
What	O	O
are	O	O
the	O	O
beliefs	O
of	O	O
medical	O
leaders	B-LIVB
that	O	O
form	O	O
the	O	O
key	O	O
themes	O
or	O	O
dimensions	O
of	O	O
the	O	O
negative	O	O
perception	O	O
of	O	O
the	O	O
'	O	O
dark	O	O
side	O	O
'	O	O
?	O	O
""""	O	O
.	O	O

Design	O	O
/	O	O
methodology	O	O
/	O	O
approach	O	O
The	O	O
paper	O	O
analysed	O	O
data	O
from	O	O
two	O	O
similar	O	O
qualitative	B-PROC
studies	I-PROC
examining	O	O
medical	O
leadership	O
and	O	O
engagement	O	O
in	O	O
Australia	B-GEOG
by	O	O
the	O	O
same	O	O
author	O	O
,	O	O
in	O	O
collaboration	O
with	O	O
other	O	O
researchers	B-LIVB
,	O	O
which	O	O
used	O	O
in	O	O
-	O	O
depth	O	O
semi	O
-	O
structured	O
interviews	O
with	O	O
45	O	O
purposively	O	O
sampled	O	O
senior	O	O
medical	O
leaders	B-LIVB
in	O	O
leadership	O
roles	O	O
across	O	O
Australia	B-GEOG
in	O	O
health	B-PROC
services	I-PROC
,	O	O
private	B-OBJC
and	O	O
public	B-OBJC
hospitals	I-OBJC
,	O	O
professional	O
associations	O
and	O	O
health	O
departments	O
.	O	O

The	O	O
data	O
were	O	O
analysed	O	O
using	O	O
deductive	O	O
and	O	O
inductive	O	O
approaches	O
through	O	O
a	O	O
coding	O
framework	O	O
based	O	O
on	O	O
the	O	O
interview	O
data	O
and	O	O
literature	O
review	O
,	O	O
with	O	O
all	O	O
sections	O	O
of	O	O
coded	O
data	O
grouped	O
into	O	O
themes	O
.	O	O

Findings	O	O
Medical	O
leaders	B-LIVB
had	O	O
four	O	O
key	O	O
beliefs	O
about	O	O
the	O	O
""""	O	O
dark	O	O
side	O	O
""""	O	O
as	O	O
perceived	O	O
through	O	O
the	O	O
eyes	B-ANAT
of	O	O
their	O	O
own	O	O
past	O	O
clinical	O
experience	O
and	O	O
/	O	O
or	O	O
their	O	O
clinical	O
colleagues	B-LIVB
.	O	O

These	O	O
four	O	O
beliefs	O
or	O	O
dimensions	O
of	O	O
the	O	O
negative	O	O
perception	O	O
colloquially	O	O
known	O	O
as	O	O
""""	O	O
the	O	O
dark	O	O
side	O	O
""""	O	O
are	O	O
the	O	O
belief	O
that	O	O
they	O	O
lack	O	O
both	O	O
managerial	O
and	O	O
clinical	O
credibility	O
,	O	O
they	O	O
have	O	O
confused	O	O
identities	O	O
,	O	O
they	O	O
may	O	O
be	O	O
in	O	O
conflict	O
with	O	O
clinicians	B-LIVB
,	O	O
their	O	O
clinical	O
colleagues	B-LIVB
lack	O	O
insight	O	O
into	O	O
the	O	O
complexities	O	O
of	O	O
medical	O
leadership	O
and	O	O
,	O	O
as	O	O
a	O	O
result	O	O
,	O	O
doctors	B-LIVB
are	O	O
actively	O	O
discouraged	O	O
from	O	O
making	O	O
the	O	O
transition	O	O
from	O	O
clinical	O
practice	O
to	O	O
medical	O
leadership	O
roles	O	O
in	O	O
the	O	O
first	O	O
place	O	O
.	O	O

Research	O	O
limitations	O	O
/	O	O
implications	O	O
This	O	O
research	B-PROC
was	O	O
conducted	O	O
within	O	O
the	O	O
Western	O
developed	O
-	O
nation	O
setting	O	O
of	O	O
Australia	B-GEOG
and	O	O
only	O	O
involved	O	O
interviews	O
with	O	O
doctors	B-LIVB
in	O	O
medical	O
leadership	O
roles	O	O
.	O	O

The	O	O
findings	O	O
are	O	O
therefore	O	O
limited	O	O
to	O	O
the	O	O
doctors	B-LIVB
'	O	O
own	O	O
perceptions	O	O
of	O	O
themselves	O	O
based	O	O
on	O	O
their	O	O
past	O	O
experiences	O	O
and	O	O
beliefs	O
.	O	O

Future	O	O
research	B-PROC
involving	O	O
doctors	B-LIVB
who	O	O
have	O	O
not	O	O
chosen	O	O
to	O	O
transition	O
to	O	O
leadership	O
roles	O	O
,	O	O
or	O	O
other	O	O
health	B-LIVB
practitioners	I-LIVB
in	O	O
other	O	O
settings	O	O
,	O	O
may	O	O
provide	O	O
a	O	O
broader	O	O
perspective	O
.	O	O

Also	O	O
,	O	O
this	O	O
research	B-PROC
was	O	O
exploratory	O	O
and	O	O
descriptive	B-DISO
in	O	O
nature	O	O
using	O	O
qualitative	B-PROC
methods	I-PROC
,	O	O
and	O	O
quantitative	B-PROC
research	I-PROC
can	O	O
be	O	O
carried	O	O
out	O	O
in	O	O
the	O	O
future	O	O
to	O	O
extend	O	O
this	O	O
research	B-PROC
for	O	O
statistical	B-PROC
generalisation	I-PROC
.	O	O

Practical	O	O
implications	O	O
The	O	O
paper	O	O
includes	O	O
implications	O	O
for	O	O
health	B-OBJC
organisations	I-OBJC
,	O	O
training	O	O
providers	O	O
,	O	O
medical	O
employers	B-LIVB
and	O	O
health	O
departments	O
and	O	O
describes	O	O
a	O	O
multi	O	O
-	O	O
prong	O	O
strategy	O	O
to	O	O
address	O	O
this	O	O
important	O	O
issue	O	O
.	O	O

Originality	O	O
/	O	O
value	O	O
This	O	O
paper	O	O
fulfils	O	O
an	O	O
identified	O	O
need	O	O
to	O	O
study	B-PROC
the	O	O
concept	O
of	O	O
""""	O	O
moving	O	O
to	O	O
the	O	O
dark	O	O
side	O	O
""""	O	O
as	O	O
a	O	O
negative	O	O
perception	O	O
of	O	O
medical	O
leadership	O
and	O	O
contributes	O	O
to	O	O
the	O	O
evidence	O
in	O	O
this	O	O
under	O	O
-	O	O
researched	B-PROC
area	O	O
.	O	O

This	O	O
paper	O	O
has	O	O
used	O	O
data	O
from	O	O
two	O	O
similar	O	O
studies	B-PROC
,	O	O
combined	O	O
together	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
with	O	O
new	O	O
analysis	B-PROC
and	O	O
coding	O
,	O	O
looking	O	O
at	O	O
the	O	O
concept	O
of	O	O
the	O	O
""""	O	O
dark	O	O
side	O	O
""""	O	O
to	O	O
discover	O	O
new	O	O
emergent	O	O
findings	O	O
.	O	O

A	O	O
parametric	O	O
ribcage	B-ANAT
geometry	O	O
model	O
accounting	O
for	O	O
variations	O
among	O	O
the	O	O
adult	B-LIVB
population	B-LIVB
The	O	O
objective	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
develop	O	O
a	O	O
parametric	O	O
ribcage	B-ANAT
model	O
that	O	O
can	O	O
account	O	O
for	O	O
morphological	O
variations	O
among	O	O
the	O	O
adult	B-LIVB
population	B-LIVB
.	O	O

Ribcage	B-ANAT
geometries	O
,	O	O
including	O	O
12	O	O
pair	B-ANAT
of	I-ANAT
ribs	I-ANAT
,	O	O
sternum	B-ANAT
,	O	O
and	O	O
thoracic	B-ANAT
spine	I-ANAT
,	O	O
were	O	O
collected	O	O
from	O	O
CT	B-PROC
scans	I-PROC
of	O	O
101	O	O
adult	B-LIVB
subjects	B-LIVB
through	O	O
image	O
segmentation	O
,	O	O
landmark	B-ANAT
identification	O
(	O	O
1016	O	O
for	O	O
each	O	O
subject	B-LIVB
)	O	O
,	O	O
symmetry	B-DISO
adjustment	O
,	O	O
and	O	O
template	O
mesh	O
mapping	O
(	O	O
26	O	O
,	O	O
180	O	O
elements	O
for	O	O
each	O	O
subject	B-LIVB
)	O	O
.	O	O

Generalized	O
procrustes	O
analysis	O
(	O	O
GPA	O
)	O	O
,	O	O
principal	O
component	O
analysis	O
(	O	O
PCA	O
)	O	O
,	O	O
and	O	O
regression	O
analysis	O
were	O	O
used	O	O
to	O	O
develop	O	O
a	O	O
parametric	O	O
ribcage	B-ANAT
model	O
,	O	O
which	O	O
can	O	O
predict	O	O
nodal	O
locations	O
of	O	O
the	O	O
template	O
mesh	O
according	O	O
to	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
height	B-PHYS
,	O	O
and	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
.	O	O

Two	O	O
regression	O
models	O
,	O	O
a	O	O
quadratic	O
model	O
for	O	O
estimating	O
the	O	O
ribcage	B-ANAT
size	O
and	O	O
a	O	O
linear	O
model	O
for	O	O
estimating	O	O
the	O	O
ribcage	B-ANAT
shape	O
,	O	O
were	O	O
developed	O	O
.	O	O

The	O	O
results	O
showed	O	O
that	O	O
the	O	O
ribcage	B-ANAT
size	O
was	O	O
dominated	O	O
by	O	O
the	O	O
height	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
000	O	O
)	O	O
and	O	O
age	B-PHYS
-	O	O
sex	B-PHYS
-	O	O
interaction	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
007	O	O
)	O	O
and	O	O
the	O	O
ribcage	B-ANAT
shape	O
was	O	O
significantly	O	O
affected	O	O
by	O	O
the	O	O
age	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0005	O	O
)	O	O
,	O	O
sex	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0002	O	O
)	O	O
,	O	O
height	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0064	O	O
)	O	O
and	O	O
BMI	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0000	O	O
)	O	O
.	O	O

Along	O	O
with	O	O
proper	O	O
assignment	O
of	O	O
cortical	B-ANAT
bone	I-ANAT
thickness	O
,	O	O
material	B-OBJC
properties	O
and	O	O
failure	O
properties	O
,	O	O
this	O	O
parametric	O	O
ribcage	B-ANAT
model	O
can	O	O
directly	O	O
serve	O	O
as	O	O
the	O	O
mesh	O
of	O	O
finite	O
element	O
ribcage	B-ANAT
models	O
for	O	O
quantifying	O
effects	O
of	O	O
human	B-LIVB
characteristics	O
on	O	O
thoracic	B-DISO
injury	I-DISO
risks	O	O
.	O	O

Hyaluronan	B-CHEM
Depolymerization	B-PHYS
by	O	O
Megakaryocyte	B-ANAT
Hyaluronidase	B-CHEM
-	I-CHEM
2	I-CHEM
Is	O	O
Required	O	O
for	O	O
Thrombopoiesis	B-PHYS
Hyaluronan	B-CHEM
is	O	O
the	O	O
predominant	O	O
glycosaminoglycan	B-CHEM
component	I-CHEM
of	O	O
the	O	O
extracellular	O
matrix	O
with	O	O
an	O	O
emerging	O	O
role	O	O
in	O	O
hematopoiesis	B-PHYS
.	O	O

Modulation	O
of	O	O
hyaluronan	B-CHEM
polymer	O
size	O
is	O	O
responsible	O	O
for	O	O
its	O	O
control	O	O
over	O	O
cellular	B-PHYS
functions	I-PHYS
,	O	O
and	O	O
the	O	O
balance	O	O
of	O	O
hyaluronan	B-CHEM
synthesis	B-PHEN
and	O	O
degradation	B-PHYS
determines	O	O
its	O	O
molecular	O
size	O
.	O	O

Although	O	O
two	O	O
active	O	O
somatic	O
hyaluronidases	B-CHEM
are	O	O
expressed	B-PHYS
in	O	O
mammals	B-LIVB
,	O	O
only	O	O
deficiency	O	O
in	O	O
hyaluronidase	B-CHEM
-	I-CHEM
2	I-CHEM
(	O	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
)	O	O
results	O	O
in	O	O
thrombocytopenia	B-DISO
of	O	O
unknown	O	O
mechanism	O	O
.	O	O

Our	O	O
results	O	O
reveal	O	O
that	O	O
Hyal	O
-	O
2	O
knockout	B-LIVB
mice	I-LIVB
accumulate	O	O
hyaluronan	B-CHEM
within	O	O
their	O	O
bone	O
marrow	O
and	O	O
within	O	O
megakaryocytes	B-ANAT
,	O	O
the	O	O
cells	B-ANAT
responsible	O	O
for	O	O
platelet	B-PHYS
generation	I-PHYS
.	O	O

Proplatelet	B-PHYS
formation	I-PHYS
by	O	O
Hyal	O
-	O
2	O
knockout	B-DISO
megakaryocytes	B-ANAT
was	O	O
disrupted	O
because	O	O
of	O	O
abnormal	B-DISO
formation	O
of	O	O
the	O	O
demarcation	B-ANAT
membrane	I-ANAT
system	I-ANAT
,	O	O
which	O	O
was	O	O
dilated	O	O
and	O	O
poorly	O	O
developed	O	O
.	O	O

Importantly	O	O
,	O	O
peptide	B-PROC
-	I-PROC
mediated	I-PROC
delivery	I-PROC
of	O	O
exogenous	O
hyaluronidase	B-CHEM
rescued	O	O
deficient	O	O
proplatelet	B-PHYS
formation	I-PHYS
in	O	O
murine	B-LIVB
and	O	O
human	B-LIVB
megakaryocytes	B-ANAT
lacking	O	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
.	O	O

Together	O	O
,	O	O
our	O	O
data	O
uncover	O	O
a	O	O
previously	O	O
unsuspected	O	O
mechanism	O	O
of	O	O
how	O	O
hyaluronan	B-CHEM
and	O	O
Hyal	B-CHEM
-	I-CHEM
2	I-CHEM
control	O	O
platelet	B-PHYS
generation	I-PHYS
.	O	O

Vitamin	B-CHEM
D	I-CHEM
serum	B-ANAT
level	O
is	O	O
associated	O
with	O
Child	O
-	O
Pugh	O
score	O
and	O	O
metabolic	O
enzyme	B-CHEM
imbalances	B-DISO
,	O	O
but	O	O
not	O	O
viral	B-DISO
load	I-DISO
in	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
patients	B-LIVB
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
is	O	O
common	O	O
in	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
liver	I-DISO
diseases	I-DISO
.	O	O

However	O	O
,	O	O
vitamin	B-CHEM
D	I-CHEM
status	O
in	O	O
persons	B-LIVB
with	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
virus	I-DISO
(	I-DISO
HBV	I-DISO
)	I-DISO
infection	I-DISO
is	O	O
not	O	O
consistently	O	O
reported	O	O
.	O	O

Specifically	O	O
,	O	O
the	O	O
impact	O	O
of	O	O
liver	B-DISO
dysfunction	I-DISO
on	O	O
vitamin	B-CHEM
D	I-CHEM
status	O
has	O	O
not	O	O
been	O	O
well	O	O
addressed	O	O
.	O	O

We	O	O
recruited	O	O
a	O	O
group	B-LIVB
of	O	O
patients	B-LIVB
(	O	O
n	O	O
=	O	O
345	O	O
)	O	O
with	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
(	O	O
n	O	O
=	O	O
115	O	O
)	O	O
,	O	O
hepatitis	B-DISO
B	I-DISO
related	I-DISO
cirrhosis	I-DISO
(	O	O
n	O	O
=	O	O
115	O	O
)	O	O
,	O	O
and	O	O
age	B-PHYS
-	O	O
and	O	O
gender	B-PHYS
-matched	O	O
healthy	O
controls	O
(	O	O
n	O	O
=	O	O
115	O	O
)	O	O
.	O	O

Serum	B-ANAT
25	B-CHEM
-	I-CHEM
hydroxyvitamin	I-CHEM
D3	I-CHEM
[	O	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
]	O	O
,	O	O
its	O	O
related	O	O
metabolic	O
enzymes	B-CHEM
,	O	O
intact	O	O
parathyroid	B-CHEM
hormone	I-CHEM
were	O	O
measured	O
.	O	O

Calcium	B-PHEN
,	O	O
magnesium	B-PHEN
,	O	O
and	O	O
phosphorus	B-PHEN
were	O	O
obtained	O	O
from	O	O
medical	O
record	O
.	O	O

Serum	B-ANAT
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
in	O	O
chronic	B-DISO
hepatitis	I-DISO
B	I-DISO
patients	B-LIVB
(	O	O
7	O	O
.	O	O
83	O	O
±	O	O
3	O	O
.	O	O
47	O	O
ng	O	O
/	O	O
mL	O	O
)	O	O
were	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
in	O	O
healthy	O
controls	O
(	O	O
9	O	O
.	O	O
76	O	O
±	O	O
4	O	O
.	O	O

36	O	O
ng	O	O
/	O	O
mL	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
but	O	O
significantly	O	O
higher	O
than	O	O
that	O	O
in	O	O
hepatitis	B-DISO
B	I-DISO
-	I-DISO
related	I-DISO
cirrhotic	I-DISO
patients	B-LIVB
(	O	O
5	O	O
.	O	O
21	O	O
±	O	O
3	O	O
.	O	O
67	O	O
ng	O	O
/	O	O
mL	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
decreased	O
stepwise	O	O
with	O	O
higher	O
Child	O
-	O
Pugh	O
classification	O
.	O	O

However	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
between	O	O
(	O	O
1	O	O
)	O	O
hepatitis	B-PHEN
B	I-PHEN
e	I-PHEN
antigen	I-PHEN
(	I-PHEN
HBeAg	I-PHEN
+	I-PHEN
)	I-PHEN
and	O	O
HBeAg	B-PHEN
(	I-PHEN
-	I-PHEN
)	I-PHEN
persons	B-LIVB
,	O	O
or	O	O
(	O	O
2	O	O
)	O	O
among	O	O
persons	B-LIVB
with	O	O
different	O	O
HBV	B-LIVB
viral	B-DISO
load	I-DISO
,	O	O
or	O	O
(	O	O
3	O	O
)	O	O
between	O	O
treatment	B-PHYS
naïve	I-PHYS
and	O	O
patients	B-LIVB
on	O	O
antiviral	B-PROC
therapy	I-PROC
.	O	O

Multiple	O
logistic	O
regression	O
analyses	O
confirmed	O	O
that	O	O
higher	O
Child	O
-	O
Pugh	O
score	O
was	O	O
independently	O	O
associated	O
with	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
deficiency	O
(	O	O
<	O	O
10	O	O
ng	O	O
/	O	O
mL	O	O
)	O	O
with	O	O
an	O	O
odds	O
ratio	O
of	O	O
1	O	O
.	O	O

20	O	O
(	O	O
confidence	O
interval	O
1	O	O
.	O	O
03	O	O
-	O	O
1	O	O
.	O	O
39	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
016	O	O
)	O	O
.	O	O

Levels	O
of	O	O
cytochrome	B-CHEM
P450	I-CHEM
(	I-CHEM
CYP	I-CHEM
)	I-CHEM
27A1	I-CHEM
were	O	O
significantly	O	O
decreased	O
,	O	O
whereas	O	O
levels	O
of	O	O
CYP24A1	B-CHEM
were	O	O
significantly	O	O
elevated	O	O
in	O	O
cirrhotic	B-DISO
patients	B-LIVB
.These	O	O

results	O
suggest	O	O
that	O	O
decreasing	B-DISO
vitamin	B-CHEM
D	I-CHEM
levels	O
are	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
result	O
,	O	O
rather	O	O
than	O	O
a	O	O
cause	O	O
,	O	O
of	O	O
liver	B-DISO
dysfunction	I-DISO
and	O	O
irrespective	O	O
of	O	O
HBV	B-LIVB
viral	B-DISO
load	I-DISO
.	O	O

Reduction	O
in	O	O
25	B-CHEM
(	I-CHEM
OH	I-CHEM
)	I-CHEM
D3	I-CHEM
levels	O
is	O	O
possibly	O	O
due	O	O
to	O	O
downregulation	B-PHYS
of	O	O
the	O	O
synthetic	B-CHEM
hydroxylase	I-CHEM
CYP27A1	B-CHEM
and	O	O
concurrent	O	O
upregulation	B-PHYS
of	O	O
degrading	B-PHYS
CYP24A1	B-CHEM
in	O	O
patients	B-LIVB
with	O	O
liver	B-DISO
cirrhosis	I-DISO
.	O	O

359	O	O
Delayed	B-DISO
Treatment	I-DISO
of	O	O
Ruptured	B-DISO
Arteriovenous	B-DISO
Malformations	I-DISO
:	O	O
Is	O	O
It	O	O
Ok	O	O
to	O	O
Wait	O	O
?	O	O
Emergent	O
surgery	B-PROC
on	O	O
a	O	O
ruptured	B-DISO
brain	B-ANAT
arteriovenous	B-DISO
malformation	I-DISO
(	O	O
AVM	B-DISO
)	O	O
is	O	O
indicated	O	O
for	O	O
a	O	O
large	O	O
hematoma	B-DISO
in	O	O
an	O	O
acutely	O	O
deteriorating	B-DISO
patient	B-LIVB
.	O	O

The	O	O
majority	O	O
of	O	O
ruptured	B-DISO
AVMs	B-DISO
,	O	O
however	O	O
,	O	O
present	O	O
in	O	O
clinically	O
stable	O
patients	B-LIVB
with	O	O
neurological	B-DISO
deficits	I-DISO
.	O	O

Controversy	O	O
exists	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
timing	O	O
of	O	O
treatment	O
for	O	O
ruptured	B-DISO
AVMs	B-DISO
in	O	O
these	O	O
stable	O
patients	B-LIVB
.	O	O

This	O	O
study	B-PROC
aims	O	O
to	O	O
determine	O	O
the	O	O
safety	B-PHEN
of	O	O
delaying	O
AVM	B-DISO
treatment	O
in	O	O
clinically	O
stable	O
patients	B-LIVB
by	O	O
investigating	O
the	O	O
rate	O	O
of	O	O
rehemorrhage	B-DISO
in	O	O
a	O	O
cohort	B-LIVB
of	O	O
patients	B-LIVB
with	O	O
ruptured	B-DISO
brain	B-ANAT
AVMs	B-DISO
.	O	O

Patients	B-LIVB
presenting	O	O
to	O	O
our	O	O
institution	O
from	O	O
January	O
2000	O	O
to	O	O
December	O
2015	O	O
with	O	O
ruptured	B-DISO
brain	B-ANAT
AVMs	B-DISO
treated	O	O
at	O	O
least	O	O
4	O	O
weeks	O
posthemorrhage	B-DISO
were	O	O
included	O	O
in	O	O
the	O	O
analysis	B-PROC
.	O	O

Exclusion	O
criteria	O
were	O	O
ruptured	B-DISO
AVMs	B-DISO
that	O	O
required	O	O
emergent	O
surgery	B-PROC
involving	O	O
AVM	B-DISO
resection	B-PROC
,	O	O
previous	O	O
treatment	O
at	O	O
another	O	O
institution	O
,	O	O
or	O	O
subacute	O
AVM	B-DISO
treatment	O
.	O	O

The	O	O
primary	O
outcome	O
measure	O
was	O	O
time	O
from	O	O
initial	O
hemorrhage	B-DISO
to	O	O
rehemorrhage	B-DISO
.	O	O

Patient	B-LIVB
follow	B-PROC
-	I-PROC
up	I-PROC
data	O	O
were	O	O
included	O	O
up	O	O
until	O	O
the	O	O
point	O	O
of	O	O
AVM	B-DISO
treatment	O
.	O	O

Of	O	O
the	O	O
103	O	O
ruptured	B-DISO
AVMs	B-DISO
(	O	O
49	O	O
M	O	O
:	O	O
54	O	O
F	O	O
)	O	O
meeting	O	O
inclusion	O
criteria	O
,	O	O
the	O	O
median	O
time	O
from	O	O
rupture	B-DISO
to	O	O
treatment	O
or	O	O
rehemorrhage	B-DISO
was	O	O
112	O	O
days	O
(	O	O
interquartile	O
range	O
[	O	O
IQR	O
]	O	O
:	O	O
110	O	O
)	O	O
.	O	O

Six	O	O
(	O	O
5	O	O
.	O	O
8	O	O
%	O	O
)	O	O
patients	B-LIVB
rehemorrhaged	B-DISO
in	O	O
a	O	O
median	O
of	O	O
248	O	O
days	O
(	O	O
IQR	O
:	O	O
1331	O	O
)	O	O
.	O	O

Two	O	O
of	O	O
these	O	O
patients	B-LIVB
rehemorrhaged	B-DISO
on	O	O
the	O	O
same	O	O
day	O
of	O	O
their	O	O
index	O	O
hemorrhage	B-DISO
.	O	O

The	O	O
total	O	O
at	O
-	O
risk	O
period	O
was	O	O
19	O	O
445	O	O
patient	B-LIVB
-	O	O
days	O
,	O	O
yielding	O	O
a	O	O
rehemorrhage	B-DISO
risk	O	O
of	O	O
11	O	O
.	O	O

3	O	O
%	O	O
per	O	O
patient	B-LIVB
-	O	O
year	O
,	O	O
or	O	O
0	O	O
.	O	O

93	O	O
%	O	O
per	O	O
patient	B-LIVB
-	O	O
month	O
.	O	O

Our	O	O
data	O
support	O	O
stabilizing	O	O
a	O	O
patient	B-LIVB
after	O	O
the	O	O
initial	O	O
AVM	B-DISO
rupture	B-DISO
.	O	O

It	O	O
is	O	O
safe	O	O
to	O	O
closely	B-PROC
monitor	I-PROC
the	I-PROC
patient	I-PROC
,	O	O
initiate	O	O
the	O	O
rehabilitation	O
process	O	O
,	O	O
and	O	O
then	O	O
,	O	O
in	O	O
a	O	O
semielective	O	O
manner	O	O
,	O	O
bring	O	O
the	O	O
patient	B-LIVB
back	O	O
for	O	O
treatment	O
.	O	O

Delaying	O
intervention	O	O
for	O	O
4	O	O
weeks	O
after	O	O
initial	O	O
hemorrhage	B-DISO
subjects	O	O
the	O	O
patient	B-LIVB
to	O	O
a	O	O
low	O
(	O
<	O
1	O
%	O
)	O
risk	O
of	O	O
rehemorrhage	B-DISO
.	O	O

Prescribing	O
Patterns	O
in	O	O
Outpatient	B-OBJC
Clinics	I-OBJC
of	O	O
Township	O
Hospitals	B-OBJC
in	O	O
China	B-GEOG
:	O	O
A	O	O
Comparative	B-PROC
Study	I-PROC
before	O	O
and	O	O
after	O	O
the	O	O
2009	O	O
Health	O
System	O
Reform	O
Objective	O	O
:	O	O
China	B-GEOG
introduced	O	O
a	O	O
series	O	O
of	O	O
health	O
reforms	O
in	O	O
2009	O	O
,	O	O
including	O	O
a	O	O
national	O
essential	O
medicines	O
policy	O
and	O	O
a	O	O
medical	B-DISO
insurance	I-DISO
system	O
for	O	O
primary	B-OBJC
care	I-OBJC
institutions	I-OBJC
.	O	O

This	O	O
study	B-PROC
aimed	O	O
to	O	O
determine	O	O
the	O	O
changing	O	O
prescribing	O
patterns	O
associated	O
with	O
those	O	O
reforms	O
in	O	O
township	O
hospitals	B-OBJC
.	O	O

Methods	O	O
:	O	O
A	O	O
multi	O
-	O
stage	O
stratified	B-PROC
random	I-PROC
cluster	I-PROC
sampling	I-PROC
method	I-PROC
was	O	O
adopted	O	O
to	O	O
identify	O	O
29	O	O
township	O
hospitals	B-OBJC
from	O	O
six	O	O
counties	B-GEOG
in	O	O
three	O	O
provinces	B-GEOG
.	O	O

A	O	O
total	O	O
of	O	O
2899	O	O
prescriptions	O
were	O	O
collected	O	O
from	O	O
the	O	O
participating	O	O
township	O
hospitals	B-OBJC
using	O	O
a	O	O
systematic	B-PROC
random	I-PROC
sampling	I-PROC
strategy	I-PROC
.	O	O

Seven	O	O
prescribing	B-DISO
indicators	I-DISO
were	O	O
calculated	O
and	O	O
compared	O	O
between	O	O
2008	O	O
and	O	O
2013	O	O
,	O	O
assessing	O	O
use	O	O
of	O	O
medicines	B-CHEM
(	O	O
antibiotics	B-CHEM
and	O	O
adrenal	B-CHEM
corticosteroids	I-CHEM
)	O	O
and	O	O
polypharmacy	B-DISO
,	O	O
administration	O
route	O
of	O
medicines	O
(	O	O
injections	O
)	O	O
,	O	O
and	O	O
affordability	O
of	O	O
medicines	B-CHEM
.	O	O

Results	O	O
:	O	O
Significant	O	O
changes	O	O
in	O	O
prescribing	O
patterns	O
were	O	O
found	O	O
.	O	O

The	O	O
average	O
number	O
of	O	O
medicines	B-CHEM
and	O	O
costs	O
per	O	O
-	O	O
prescription	O
dropped	O	O
by	O	O
about	O	O
50	O	O
%	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
prescriptions	O
requiring	O	O
antibiotics	B-CHEM
declined	O
from	O	O
54	O	O
%	O	O
to	O	O
38	O	O
%	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
prescriptions	O
requiring	O	O
adrenal	B-CHEM
corticosteroid	I-CHEM
declined	O	O
from	O	O
14	O	O
%	O	O
to	O	O
4	O	O
%	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
prescriptions	O
requiring	O	O
injections	O
declined	O
from	O	O
54	O	O
%	O	O
to	O	O
25	O	O
%	O	O
.	O	O

Despite	O	O
similar	O	O
changing	O	O
patterns	O	O
,	O	O
significant	B-DISO
regional	I-DISO
differences	I-DISO
were	O	O
observed	O	O
.	O	O

Conclusions	O	O
:	O	O
Significant	O	O
changes	O	O
in	O	O
prescribing	O
patterns	O
are	O	O
evident	O
in	O	O
township	O
hospitals	B-OBJC
in	O	O
China	B-GEOG
.	O	O

Overprescription	B-PROC
of	O	O
antibiotics	B-CHEM
,	O	O
injections	O
and	O	O
adrenal	B-CHEM
corticosteroids	I-CHEM
has	O	O
been	O	O
reduced	O
.	O	O

However	O	O
,	O	O
salient	O	O
regional	O
disparities	O
still	O	O
exist	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
determine	O	O
potential	O	O
shifts	O	O
in	O	O
the	O	O
risk	O
of	O	O
the	O	O
inappropriate	O	O
use	O	O
of	O	O
medicines	B-CHEM
from	O	O
primary	B-OBJC
care	I-OBJC
settings	I-OBJC
to	O	O
metropolitan	O
hospitals	O
.	O	O

Neural	O
activity	O
promotes	O	O
long	O	O
-	O	O
distance	O	O
,	O	O
target	O
-	O	O
specific	O
regeneration	B-PHYS
of	O	O
adult	O	O
retinal	B-ANAT
axons	B-ANAT
Axons	B-ANAT
in	O	O
the	O	O
mammalian	B-LIVB
CNS	B-ANAT
fail	O
to	O	O
regenerate	B-PHYS
after	O	O
injury	B-DISO
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
if	O	O
the	O	O
activity	O
of	O	O
mouse	B-LIVB
retinal	B-ANAT
ganglion	I-ANAT
cells	I-ANAT
(	O	O
RGCs	B-ANAT
)	O	O
is	O	O
increased	O
by	O	O
visual	B-PROC
stimulation	I-PROC
or	O	O
using	O	O
chemogenetics	O	O
,	O	O
their	O	O
axons	B-ANAT
regenerate	B-PHYS
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
if	O	O
enhancement	O
of	O	O
neural	O
activity	O
is	O	O
combined	O	O
with	O	O
elevation	O
of	O	O
the	O	O
cell	B-PHYS
-	I-PHYS
growth	I-PHYS
-promoting	O	O
pathway	B-PHYS
involving	O	O
mammalian	B-CHEM
target	I-CHEM
of	I-CHEM
rapamycin	I-CHEM
(	O	O
mTOR	B-CHEM
)	O	O
,	O	O
RGC	B-ANAT
axons	B-ANAT
regenerate	B-PHYS
long	O	O
distances	O	O
and	O	O
re	O
-	O
innervate	O
the	O	O
brain	B-ANAT
.	O	O

Analysis	B-PROC
of	O	O
genetically	O
labeled	O
RGCs	B-ANAT
revealed	O	O
that	O	O
this	O	O
regrowth	B-PHYS
can	O	O
be	O	O
target	O
specific	O
:	O	O
RGC	B-ANAT
axons	B-ANAT
navigated	O	O
back	O	O
to	O	O
their	O	O
correct	O	O
visual	O
targets	O
and	O	O
avoided	O	O
targets	O
incorrect	O
for	O	O
their	O	O
function	O
.	O	O

Moreover	O	O
,	O	O
these	O	O
regenerated	O
connections	B-ANAT
were	O	O
successful	O	O
in	O	O
partially	O	O
rescuing	O	O
a	O	O
subset	O	O
of	O	O
visual	O
behaviors	O
.	O	O

Our	O	O
findings	B-DISO
indicate	O	O
that	O	O
combining	O	O
neural	O
activity	O
with	O	O
activation	O
of	O	O
mTOR	B-CHEM
can	O	O
serve	O	O
as	O	O
powerful	O	O
tool	O	O
for	O	O
enhancing	O
axon	B-PHYS
regeneration	I-PHYS
,	O	O
and	O	O
they	O	O
highlight	O	O
the	O	O
remarkable	O
capacity	O
of	O	O
CNS	B-ANAT
neurons	B-ANAT
to	O	O
re	O	O
-	O	O
establish	O	O
accurate	O	O
circuit	O
connections	B-ANAT
in	O	O
adulthood	O
.	O	O

Expression	B-PHYS
of	O	O
WNT10A	O
Gene	O
in	O	O
Oral	B-DISO
Squamous	I-DISO
Cell	I-DISO
Carcinoma	I-DISO
Oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
OSCC	B-DISO
)	O	O
constitutes	O	O
the	O	O
most	O
frequent	O
malignant	B-DISO
tumour	I-DISO
of	O	O
the	O	O
oral	B-ANAT
cavity	I-ANAT
.	O	O

Considering	O	O
the	O	O
significant	O
roles	O
the	O	O
Wnt	O
family	O
plays	O	O
in	O	O
physiological	B-PHYS
and	O	O
pathological	O
events	O
,	O	O
this	O	O
study	B-PROC
aims	O	O
to	O	O
investigate	O
WNT10A	O
gene	O
expression	B-PHYS
in	O	O
OSCC	B-DISO
.	O	O

The	O	O
cohort	O
was	O	O
composed	O	O
of	O	O
59	O	O
specimens	B-OBJC
:	O	O
49	O	O
with	O	O
OSCC	B-DISO
and	O	O
10	O	O
controls	O
.	O	O

Total	O
RNA	B-CHEM
from	O	O
the	O	O
samples	B-OBJC
was	O	O
extracted	B-PROC
,	O	O
cDNA	B-CHEM
was	O	O
synthesized	O
and	O	O
Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
analyses	I-PROC
were	O	O
performed	O
,	O	O
with	O	O
β	O
-	O
ACTIN	O
as	O	O
internal	O
control	O
.	O	O

The	O	O
number	O
of	O	O
OSCC	B-DISO
samples	B-OBJC
for	O	O
the	O	O
4	O	O
TNM	O
stages	O
was	O	O
:	O	O
5	O	O
(	O	O
10	O	O
.	O	O
2	O	O
%	O	O
)	O	O
stage	B-DISO
I	I-DISO
,	O	O
10	O	O
(	O	O
20	O	O
.	O	O
4	O	O
%	O	O
)	O	O
stage	B-DISO
II	I-DISO
,	O	O
9	O	O
(	O	O
18	O	O
.	O	O
3	O	O
%	O	O
)	O	O
stage	B-DISO
III	I-DISO
,	O	O
and	O	O
25	O	O
(	O	O
51	O	O
.	O	O
1	O	O
%	O	O
)	O	O
stage	B-DISO
IV	I-DISO
.	O	O

For	O	O
Real	B-PROC
-	I-PROC
Time	I-PROC
PCR	I-PROC
analysis	I-PROC
,	O	O
significant	O
difference	O
was	O	O
found	B-DISO
between	O	O
control	O
samples	O
and	O	O
OSCC	B-DISO
stage	I-DISO
IV	I-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Higher	O
levels	O
of	O	O
WNT10A	O
expression	B-PHYS
was	O	O
observed	O
in	O	O
OSCC	B-DISO
stage	I-DISO
IV	I-DISO
suggesting	O
a	O	O
potential	O
role	O
in	O	O
tumour	B-DISO
progression	I-DISO
.	O	O

Erlotinib	B-CHEM
plus	O	O
gemcitabine	B-CHEM
versus	O	O
gemcitabine	B-CHEM
for	O	O
pancreatic	B-DISO
cancer	I-DISO
:	O	O
real	O
-	O	O
world	B-LIVB
analysis	B-PROC
of	O	O
Korean	B-GEOG
national	O
database	O
A	O	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
has	O	O
found	O	O
that	O	O
the	O	O
addition	B-PHEN
of	O	O
erlotinib	B-CHEM
to	O	O
gemcitabine	B-CHEM
(	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
)	O	O
for	O	O
pancreatic	B-DISO
cancer	I-DISO
led	O	O
to	O	O
a	O	O
modest	O
increase	O
in	O	O
survival	O
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
national	O
population	B-LIVB
-	O	O
based	O
retrospective	B-PROC
study	I-PROC
was	O	O
to	O	O
compare	O
the	O	O
effectiveness	O
of	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
to	O	O
GEM	B-CHEM
alone	O	O
for	O	O
pancreatic	B-DISO
cancer	I-DISO
patients	B-LIVB
in	O	O
real	O
clinical	O
practice	O
.	O	O

Patients	B-LIVB
with	O	O
pancreatic	B-DISO
cancer	I-DISO
(	O
ICD	O
-	O
10	O
:	O	O
C25	O	O
)	O	O
with	O	O
prescription	O
claims	O	O
of	O	O
gemcitabine	B-CHEM
or	O	O
erlotinib	B-CHEM
between	O	O
Jan	O	O
1	O	O
,	O	O
2007	O	O
and	O	O
Dec	O	O
31	O	O
,	O	O
2012	O	O
were	O	O
retrospectively	O
identified	O
from	O	O
the	O	O
Korean	B-GEOG
Health	B-PROC
Insurance	I-PROC
claims	O	O
database	O
.	O	O

To	O	O
be	O	O
included	O	O
in	O	O
the	O	O
study	B-PROC
population	B-LIVB
,	O	O
patients	B-LIVB
were	O	O
required	O
to	O	O
have	O	O
had	O	O
a	O	O
histological	O
or	O	O
cytological	B-DISO
diagnosis	I-DISO
within	O	O
one	O	O
year	O	O
before	O	O
chemotherapy	B-PROC
.	O	O

Patients	B-LIVB
treated	B-DISO
with	I-DISO
prior	O	O
radiotherapy	B-PROC
,	O	O
surgery	B-PROC
,	O	O
or	O	O
chemotherapy	B-PROC
were	O	O
excluded	O
to	O	O
reduce	B-PROC
heterogeneity	O
.	O	O

Overall	O	O
survival	O
from	O	O
the	O	O
initiation	O
of	O	O
therapy	B-PROC
and	O	O
the	O	O
medical	O
costs	O
of	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
and	O	O
GEM	B-CHEM
were	O	O
compared	O
.	O	O

A	O	O
total	O	O
of	O	O
4	O	O
,	O	O
267	O	O
patients	B-LIVB
were	O	O
included	O	O
in	O	O
the	O	O
analysis	B-PROC
.	O	O

Overall	O	O
survival	O
was	O	O
not	O	O
significantly	O
longer	O
in	O	O
patients	B-LIVB
treated	B-DISO
with	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
(	O	O
median	O
6	O	O
.	O	O

77	O	O
months	O	O
for	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
vs	O	O
.	O	O

6	O	O
.	O	O
68	O	O
months	O	O
for	O	O
GEM	B-CHEM
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0977	O	O
)	O	O
.	O	O

There	O	O
was	O	O
also	O	O
no	B-DISO
significant	I-DISO
difference	O
in	O	O
the	O	O
respective	O	O
one	O	O
-	O	O
year	O	O
survival	O
rates	O
(	O	O
27	O	O
.	O	O
0	O	O
%	O	O
vs	O	O
.	O	O

27	O	O
.	O	O
3	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
5988	O	O
)	O	O
.	O	O

Multivariate	O
analysis	O
using	O	O
age	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
and	O	O
comorbidities	O
as	O	O
covariates	O
did	O	O
not	O	O
reveal	O
any	O	O
significant	O
differences	O
in	O	O
survival	O
.	O	O

Based	O
on	O	O
this	O	O
relative	O
effectiveness	O
,	O	O
the	O	O
incremental	O
cost	O
per	O	O
life	O
year	O
gained	O
over	O	O
GEM	B-CHEM
was	O	O
estimated	O
at	O	O
USD	O
70	O	O
,	O	O
843	O	O
.	O	O

64	O	O
for	O	O
GEM	B-CHEM
-	O	O
E	B-CHEM
.	O	O

GEM	B-CHEM
-	O	O
E	B-CHEM
for	O	O
pancreatic	B-DISO
cancer	I-DISO
is	O	O
not	O	O
more	O	O
effective	O
than	O	O
GEM	B-CHEM
in	O	O
a	O	O
real	O
-	O	O
world	B-LIVB
setting	O
,	O	O
and	O	O
it	O	O
does	O	O
not	O	O
provide	O
reasonable	B-DISO
cost	O
-	O
effectiveness	O
over	O	O
GEM	B-CHEM
.	O	O

Predicting	O
Risk	O
of	O	O
Suicide	B-DISO
Attempt	I-DISO
Using	O	O
History	B-DISO
of	O	O
Physical	B-DISO
Illnesses	I-DISO
From	O	O
Electronic	O
Medical	O
Records	O
Although	O	O
physical	B-DISO
illnesses	I-DISO
,	O	O
routinely	O	O
documented	B-PROC
in	O	O
electronic	O
medical	O
records	O
(	O	O
EMR	O
)	O	O
,	O	O
have	O	O
been	O	O
found	O	O
to	O	O
be	O	O
a	O	O
contributing	O
factor	O
to	O	O
suicides	B-DISO
,	O	O
no	O	O
automated	O
systems	O
use	O	O
this	O	O
information	O
to	O	O
predict	O
suicide	B-DISO
risk	I-DISO
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
quantify	O
the	O	O
impact	O
of	O	O
physical	B-DISO
illnesses	I-DISO
on	O	O
suicide	B-DISO
risk	I-DISO
,	O	O
and	O	O
develop	O	O
a	O	O
predictive	B-DEVI
model	I-DEVI
that	O	O
captures	O	O
this	O	O
relationship	O
using	O	O
EMR	O
data	O
.	O	O

We	O	O
used	O	O
history	B-DISO
of	O	O
physical	B-DISO
illnesses	I-DISO
(	O	O
except	B-DISO
chapter	I-DISO
V	I-DISO
:	I-DISO
Mental	I-DISO
and	I-DISO
behavioral	I-DISO
disorders	I-DISO
)	O	O
from	O	O
EMR	O
data	O
over	O	O
different	O
time	O
-	O
periods	O
to	O	O
build	O	O
a	O	O
lookup	O
table	O
that	O	O
contains	O	O
the	O	O
probability	O
of	O	O
suicide	B-DISO
risk	I-DISO
for	O	O
each	O	O
chapter	O	O
of	O	O
the	O	O
International	O
Statistical	O
Classification	O
of	O
Diseases	O
and	O
Related	O
Health	O
Problems	O
,	O
10th	O
Revision	O
(	O
ICD	O
-	O
10	O
)	O
codes	O
.	O	O

The	O	O
lookup	O
table	O
was	O	O
then	O	O
used	O	O
to	O	O
predict	O
the	O	O
probability	O
of	O	O
suicide	B-DISO
risk	I-DISO
for	O	O
any	O	O
new	O
assessment	B-PROC
.	O	O

Based	O	O
on	O	O
the	O	O
different	O
lengths	O
of	O	O
history	B-DISO
of	O	O
physical	B-DISO
illnesses	I-DISO
,	O	O
we	O	O
developed	O	O
six	O	O
different	O
models	B-DEVI
to	O	O
predict	O
suicide	B-DISO
risk	I-DISO
.	O	O

We	O	O
tested	O
the	O	O
performance	O
of	O	O
developed	O	O
models	B-DEVI
to	O	O
predict	O
90	O	O
-	O	O
day	O	O
risk	B-DISO
using	O	O
historical	B-DISO
data	O
over	O	O
differing	O	O
time	O
-	O
periods	O
ranging	O	O
from	O	O
3	O	O
to	O	O
48	O	O
months	O	O
.	O	O

A	O	O
total	O	O
of	O	O
16	O	O
,	O	O
858	O	O
assessments	B-PROC
from	O	O
7399	O	O
mental	B-PHYS
health	I-PHYS
patients	B-LIVB
with	O	O
at	O	O
least	O	O
one	O	O
risk	B-DISO
assessment	B-PROC
was	O	O
used	O	O
for	O	O
the	O	O
validation	B-PROC
of	O	O
the	O	O
developed	O	O
model	B-DEVI
.	O	O

The	O	O
performance	O
was	O	O
measured	O	O
using	O	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O	O
AUC	O
)	O	O
.	O	O

The	O	O
best	O	O
predictive	O
results	O
were	O	O
derived	O	O
(	O	O
AUC	O
=	O	O
0	O	O
.	O	O
71	O	O
)	O	O
using	O	O
combined	O
data	O
across	O	O
all	O	O
time	O
-	O
periods	O
,	O	O
which	O	O
significantly	O
outperformed	O	O
the	O	O
clinical	O
baseline	O
derived	O	O
from	O	O
routine	O
risk	B-PROC
assessment	I-PROC
(	O	O
AUC	O
=	O	O
0	O	O
.	O	O
56	O	O
)	O	O
.	O	O

The	O	O
proposed	O
approach	O	O
thus	O	O
shows	O	O
potential	O
to	O	O
be	O	O
incorporated	O	O
in	O	O
the	O	O
broader	O	O
risk	B-PROC
assessment	I-PROC
processes	B-PHEN
used	O	O
by	O	O
clinicians	B-LIVB
.	O	O

This	O	O
study	B-PROC
provides	O	O
a	O	O
novel	O
approach	O	O
to	O	O
exploit	O	O
the	O	O
history	B-DISO
of	O	O
physical	B-DISO
illnesses	I-DISO
extracted	O	O
from	O	O
EMR	O
(	O	O
ICD	O
-	O
10	O
codes	O
without	B-DISO
chapter	I-DISO
V	I-DISO
-	I-DISO
mental	I-DISO
and	I-DISO
behavioral	I-DISO
disorders	I-DISO
)	O	O
to	O	O
predict	O
suicide	B-DISO
risk	I-DISO
,	O	O
and	O	O
this	O	O
model	B-DEVI
outperforms	O	O
existing	O	O
clinical	O
assessments	B-PROC
of	O	O
suicide	B-DISO
risk	I-DISO
.	O	O

Development	O	O
of	O	O
a	O	O
Novel	O	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
Model	O
to	O	O
Accurately	O	O
Predict	O	O
Pulmonary	B-PHYS
Absorption	I-PHYS
and	O	O
Replace	O	O
Routine	O	O
Use	O	O
of	O	O
the	O	O
Isolated	O
Perfused	O
Respiring	B-PHYS
Rat	B-ANAT
Lung	I-ANAT
Model	O
We	O	O
developed	O	O
and	O	O
tested	O	O
a	O	O
novel	O	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
(	O	O
QSAR	O
)	O	O
model	O
to	O	O
better	O	O
understand	O	O
the	O	O
physicochemical	B-PHEN
drivers	O	O
of	O	O
pulmonary	B-PHYS
absorption	I-PHYS
,	O	O
and	O	O
to	O	O
facilitate	O	O
compound	O
design	O
through	O	O
improved	O	O
prediction	O
of	O	O
absorption	B-PHEN
.	O	O

The	O	O
model	O
was	O	O
tested	O	O
using	O	O
a	O	O
large	O	O
array	O	O
of	O	O
both	O	O
existing	O	O
and	O	O
newly	O	O
designed	O	O
compounds	B-CHEM
.	O	O

Pulmonary	B-PHYS
absorption	I-PHYS
data	O	O
was	O	O
generated	O	O
using	O	O
the	O	O
isolated	O
perfused	O
respiring	B-PHYS
rat	B-ANAT
lung	I-ANAT
(	O	O
IPRLu	B-ANAT
)	O	O
model	O
for	O	O
82	O	O
drug	B-PROC
discovery	I-PROC
compounds	B-CHEM
and	O	O
17	O	O
marketed	B-CHEM
drugs	I-CHEM
.	O	O

This	O	O
dataset	O	O
was	O	O
used	O	O
to	O	O
build	O	O
a	O	O
novel	O	O
QSAR	O
model	O
based	O	O
on	O	O
calculated	O	O
physicochemical	B-PHEN
properties	I-PHEN
.	O	O

A	O	O
further	O	O
9	O	O
compounds	B-CHEM
were	O	O
used	O	O
to	O	O
test	O	O
the	O	O
model	O
's	O
predictive	O	O
capability	O
.	O	O

The	O	O
QSAR	O
model	O
performed	O	O
well	O	O
on	O	O
the	O	O
9	O	O
compounds	B-CHEM
in	O	O
the	O	O
""""	O	O
Test	O
set	O
""""	O	O
with	O	O
a	O	O
predicted	O	O
versus	O	O
observed	O	O
correlation	O
of	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
85	O	O
,	O	O
and	O	O
>	O	O
65	O	O
%	O	O
of	O	O
compounds	B-CHEM
correctly	O	O
categorised	O	O
.	O	O

Calculated	O	O
descriptors	O	O
associated	O	O
with	O	O
permeability	B-PHEN
and	O	O
hydrophobicity	O
positively	O	O
correlated	O	O
with	O	O
pulmonary	B-PHYS
absorption	I-PHYS
,	O	O
whereas	O	O
those	O	O
associated	O	O
with	O	O
charge	O
,	O	O
ionisation	B-PHEN
and	O	O
size	O
negatively	O	O
correlated	O	O
.	O	O

The	O	O
novel	O	O
QSAR	O
model	O
described	O	O
here	O	O
can	O	O
replace	O	O
routine	O	O
generation	O	O
of	O	O
IPRLu	B-ANAT
model	O
data	O	O
for	O	O
ranking	O
and	O	O
classifying	O
compounds	B-CHEM
prior	O	O
to	O	O
synthesis	O
.	O	O

It	O	O
will	O	O
also	O	O
provide	O	O
scientists	O	O
working	O	O
in	O	O
the	O	O
field	O	O
of	O	O
inhaled	B-PROC
drug	I-PROC
discovery	I-PROC
with	O	O
a	O	O
deeper	O	O
understanding	O	O
of	O	O
the	O	O
physicochemical	B-PHEN
drivers	O	O
of	O	O
pulmonary	B-PHYS
absorption	I-PHYS
based	O	O
on	O	O
a	O	O
relevant	O	O
respiratory	O	O
compound	B-CHEM
dataset	O
.	O	O

Matrix	B-PROC
solid	I-PROC
-	I-PROC
phase	I-PROC
dispersion	I-PROC
combined	O	O
to	O	O
liquid	B-PROC
chromatography	I-PROC
-	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
for	O	O
the	O	O
determination	B-PROC
of	O	O
paraben	B-CHEM
preservatives	B-CHEM
in	O	O
mollusks	O
A	O	O
method	O
for	O
the	O
extraction	O
and	O	O
determination	B-PROC
of	O	O
seven	O	O
parabens	B-CHEM
,	O	O
esters	B-CHEM
of	O	O
4	B-CHEM
-	I-CHEM
hydroxybenzoic	I-CHEM
acid	I-CHEM
,	O	O
widely	O	O
used	O	O
as	O	O
preservatives	B-CHEM
in	O	O
personal	B-OBJC
care	I-OBJC
products	I-OBJC
,	O	O
pharmaceuticals	B-CHEM
,	O	O
etc	O	O
.	O	O
,	O	O
and	O	O
two	O	O
chlorinated	B-CHEM
derivatives	I-CHEM
(	O	O
mono	B-CHEM
-	I-CHEM
and	O	O
di	B-CHEM
-	I-CHEM
chloro	I-CHEM
methyl	I-CHEM
paraben	I-CHEM
)	O	O
from	O	O
mollusk	O
samples	O
was	O	O
developed	O	O
by	O	O
combining	O	O
matrix	B-PROC
solid	I-PROC
-	I-PROC
phase	I-PROC
dispersion	I-PROC
(	O	O
MSPD	B-PROC
)	O	O
and	O	O
liquid	B-PROC
chromatography	I-PROC
-	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
.	O	O

MSPD	O
parameters	O
,	O	O
such	O	O
as	O	O
solvent	B-CHEM
,	O	O
solid	B-CHEM
support	I-CHEM
and	O	O
clean	B-CHEM
-	I-CHEM
up	I-CHEM
sorbent	I-CHEM
,	O	O
were	O	O
optimized	O
.	O	O

Besides	O	O
,	O	O
since	O	O
blank	O	O
problems	O	O
were	O	O
observed	O	O
for	O	O
some	O	O
parabens	B-CHEM
,	O	O
these	O	O
were	O	O
investigated	O
and	O	O
blanks	O	O
were	O	O
tackled	O	O
by	O	O
precleaning	O
all	O	O
sorbents	B-CHEM
prior	O	O
to	O	O
use	O	O
.	O	O

Under	O	O
final	O	O
conditions	O	O
,	O	O
0	O	O
.	O	O
5	O	O
g	O	O
of	O	O
freeze	B-PROC
-	I-PROC
dried	I-PROC
mollusk	O
were	O	O
dispersed	O
with	O	O
1	O	O
.	O	O

2	O	O
g	O	O
of	O	O
silica	B-CHEM
and	O	O
packed	O
into	O	O
a	O	O
cartridge	O
containing	O	O
3	O	O
g	O	O
of	O	O
C18	B-CHEM
,	O	O
as	O	O
on	O	O
-	O	O
line	O	O
clean	B-CHEM
-	I-CHEM
up	I-CHEM
sorbent	I-CHEM
.	O	O

This	O	O
cartridge	O
was	O	O
eluted	O	O
with	O	O
10mL	O	O
of	O	O
acetonitrile	B-CHEM
,	O	O
evaporated	B-PHEN
and	O	O
reconstituted	O
in	O	O
methanol	B-CHEM
for	O	O
analysis	B-PROC
.	O	O

In	O	O
the	O	O
validation	B-PROC
stage	O	O
,	O	O
successful	O	O
linearity	O	O
(	O	O
R	O	O
(	O	O
2	O	O
)	O	O
>	O	O
0	O	O
.	O	O
999	O	O
)	O	O
,	O	O
recoveries	O
(	O	O
between	O	O
71	O	O
and	O	O
117	O	O
%	O	O
for	O	O
most	O	O
analytes	B-OBJC
)	O	O
,	O	O
precision	O
(	O	O
RSD	O	O
lower	O	O
than	O	O
21	O	O
%	O	O
)	O	O
and	O	O
limits	O
of	O
detection	O
and	O	O
quantification	O
(	O	O
LOD	O
and	O	O
LOQ	B-PROC
,	O	O
lower	O	O
than	O	O
0	O	O
.	O	O
4	O	O
and	O	O
1	O	O
.	O	O

4ngg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
dry	O
weight	O
respectively	O	O
)	O	O
levels	O
were	O	O
achieved	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
new	O	O
methodology	O
was	O	O
applied	O	O
to	O	O
mussel	O
,	O	O
clam	O
and	O	O
cockle	O
samples	O
.	O	O

Methyl	B-CHEM
paraben	I-CHEM
was	O	O
above	O	O
the	O	O
LOQ	O
in	O	O
five	O	O
of	O	O
the	O	O
six	O	O
samples	O
(	O	O
not	O	O
found	O	O
in	O	O
one	O	O
clam	O
sample	O
)	O	O
at	O	O
concentrations	O
up	O	O
to	O	O
7ngg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
dry	O
weight	O
.	O	O

Ethyl	B-CHEM
paraben	I-CHEM
was	O	O
found	O	O
above	O	O
the	O	O
LOQ	O
in	O	O
mussel	O
and	O	O
cockle	O
samples	O
at	O	O
a	O	O
concentration	O
level	O
around	O	O
0	O	O
.	O	O

3ngg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

n	B-CHEM
-	I-CHEM
Propyl	I-CHEM
paraben	I-CHEM
was	O	O
only	O	O
above	O	O
the	O	O
LOQ	O
in	O	O
one	O	O
mussel	O
sample	O
.	O	O

The	O	O
EpiDerm	O
™	O
3D	B-PROC
human	I-PROC
reconstructed	I-PROC
skin	I-PROC
micronucleus	I-PROC
(	I-PROC
RSMN	I-PROC
)	I-PROC
assay	I-PROC
:	O	O
Historical	B-PROC
control	I-PROC
data	O
and	O	O
proof	B-DISO
of	O	O
principle	B-PROC
studies	I-PROC
for	O	O
mechanistic	B-PROC
assay	I-PROC
adaptations	O	O
The	O	O
in	B-PROC
vitro	I-PROC
human	I-PROC
reconstructed	I-PROC
skin	I-PROC
micronucleus	I-PROC
(	I-PROC
RSMN	I-PROC
)	I-PROC
assay	I-PROC
in	O	O
EpiDerm	O
™	O
is	O	O
a	O	O
promising	O	O
novel	O	O
animal	B-PROC
alternative	I-PROC
for	O	O
evaluating	O	O
genotoxicity	B-DISO
of	O	O
topically	B-PROC
applied	I-PROC
chemicals	B-CHEM
.	O	O

It	O	O
is	O	O
particularly	O	O
useful	O	O
for	O	O
assessing	B-PROC
cosmetic	B-CHEM
ingredients	I-CHEM
that	O	O
can	O	O
no	O	O
longer	O	O
be	O	O
tested	O
using	O	O
in	O
vivo	O
assays	B-PROC
.	O	O

To	O	O
advance	O	O
the	O	O
use	O	O
of	O	O
this	O	O
test	O
especially	O	O
for	O	O
regulatory	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
,	O	O
we	O	O
have	O	O
established	O	O
the	O	O
RSMN	B-PROC
assay	I-PROC
in	O	O
our	O	O
laboratory	B-OBJC
according	O	O
to	O	O
Good	O
Laboratory	O
Practice	O
and	O	O
following	O	O
the	O	O
principles	O	O
of	O	O
the	O	O
OECD	O
test	O
guideline	O
487	O
in	O
vitro	O
mammalian	B-ANAT
cell	I-ANAT
micronucleus	B-PROC
test	I-PROC
.	O	O

Proficiency	O	O
with	O	O
the	O	O
assay	B-PROC
was	O	O
established	O	O
by	O	O
correctly	O	O
identifying	O	O
direct	B-CHEM
-	I-CHEM
acting	I-CHEM
genotoxins	I-CHEM
and	O	O
genotoxins	B-CHEM
requiring	O	O
metabolism	B-PHYS
,	O	O
as	O	O
well	O	O
as	O	O
non	B-DISO
-	I-DISO
genotoxic	I-DISO
/	O	O
non	B-DISO
-	I-DISO
carcinogenic	I-DISO
chemicals	B-CHEM
.	O	O

We	O	O
also	O	O
report	O
the	O	O
analysis	B-PROC
of	O	O
our	O	O
historical	B-PROC
control	I-PROC
data	O
that	O	O
demonstrate	O	O
vehicle	O	O
control	O	O
and	O	O
positive	O
control	O
values	O
for	O	O
%	O	O
micronuclei	B-ANAT
in	O	O
binucleated	B-DISO
cells	I-DISO
are	O	O
in	O	O
the	O	O
ranges	O	O
reported	O	O
previously	O	O
.	O	O

Technical	B-PHEN
issues	I-PHEN
including	O	O
evaluating	O	O
various	O	O
solvents	B-CHEM
with	O	O
both	O	O
48h	O	O
and	O	O
72h	O	O
treatment	B-PROC
regimens	I-PROC
were	O	O
investigated	O
.	O	O

For	O	O
the	O	O
first	O	O
time	O	O
,	O	O
mechanistic	O
studies	O
using	O	O
CREST	B-PROC
analysis	I-PROC
revealed	O	O
that	O	O
the	O	O
RSMN	B-PROC
assay	I-PROC
is	O	O
suitable	O	O
for	O	O
distinguishing	O	O
aneugens	B-CHEM
and	O	O
clastogens	B-CHEM
.	O	O

Moreover	O	O
,	O	O
the	O	O
assay	B-PROC
is	O	O
also	O	O
suitable	O	O
for	O	O
measuring	O	O
cytokines	B-CHEM
as	O	O
markers	O
for	O	O
proliferative	B-DISO
and	O	O
toxic	B-DISO
effects	I-DISO
of	O	O
chemicals	B-CHEM
.	O	O

Two	O	O
-	O	O
stage	O	O
reconstructive	B-PROC
overlapping	B-DEVI
stent	I-DEVI
LEO	B-DEVI
+	I-DEVI
and	O	O
SILK	B-DEVI
for	O	O
treatment	B-PROC
of	O	O
intracranial	B-ANAT
circumferential	O
fusiform	B-DISO
aneurysms	I-DISO
in	O	O
the	O	O
posterior	O
circulation	B-PHYS
Intracranial	B-ANAT
circumferential	O
fusiform	B-DISO
aneurysms	I-DISO
of	O	O
the	O	O
posterior	O
circulation	B-PHYS
involving	O	O
arterial	B-ANAT
branches	I-ANAT
or	O	O
perforating	B-DISO
vessels	B-ANAT
are	O	O
difficult	O
to	O	O
treat	O
.	O	O

This	O	O
article	O	O
shows	O	O
an	O	O
endovascular	B-ANAT
reconstruction	B-PROC
technique	I-PROC
not	O	O
yet	O	O
described	O	O
,	O	O
using	O	O
a	O	O
telescoping	B-DEVI
self	I-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
(	O	O
LEO	B-DEVI
+	I-DEVI
)	O	O
and	O	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
(	O	O
SILK	B-DEVI
)	O	O
at	O	O
different	O
surgical	O
times	O
.	O	O

Two	O	O
patients	B-LIVB
with	O	O
circumferential	O
fusiform	B-DISO
aneurysm	I-DISO
,	O	O
one	O	O
being	O	O
an	O	O
aneurysm	B-DISO
of	O	O
the	O	O
segments	O	O
P2	O	O
and	O	O
P3	O	O
of	O	O
the	O	O
posterior	B-ANAT
cerebral	I-ANAT
artery	I-ANAT
,	O	O
diagnosed	B-DISO
after	O	O
a	O	O
headache	B-DISO
,	O	O
and	O	O
the	O	O
other	O	O
a	O	O
partially	O
thrombosed	B-DISO
aneurysm	I-DISO
of	O	O
the	O	O
lower	B-ANAT
basilar	B-ANAT
artery	I-ANAT
,	O	O
diagnosed	B-DISO
following	O	O
ischemia	B-DISO
of	O	O
the	O	O
brain	B-ANAT
stem	I-ANAT
.	O	O

Endovascular	B-ANAT
treatment	B-PROC
was	O	O
performed	O	O
by	O	O
means	O	O
of	O	O
a	O	O
vascular	B-ANAT
reconstruction	B-PROC
technique	I-PROC
that	O	O
used	O	O
at	O	O
different	O
surgical	O
times	O
:	O	O
overlapping	B-PROC
;	I-PROC
a	I-PROC
telescoped	I-PROC
self	I-PROC
-	I-PROC
expandable	I-PROC
stent	I-PROC
,	O	O
LEO	B-DEVI
+	I-DEVI
;	O	O
and	O	O
a	O	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
,	O	O
SILK	B-DEVI
.	O	O

Angiographic	B-PROC
control	O
was	O	O
carried	O	O
out	O	O
at	O	O
6	O	O
and	O	O
12	O	O
months	O
,	O	O
to	O	O
evaluate	O	O
arterial	B-PHYS
patency	I-PHYS
,	O	O
flow	B-PHEN
maintenance	O
in	O	O
the	O	O
arterial	B-ANAT
branches	I-ANAT
and	O	O
perforating	B-DISO
vessels	B-ANAT
,	O	O
and	O	O
thrombosis	B-DISO
of	O	O
the	O	O
aneurysm	B-DISO
.	O	O

The	O	O
combined	O
use	O	O
at	O	O
different	O
surgical	O
times	O
of	O	O
the	O	O
self	B-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
and	O	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
was	O	O
technically	O	O
successful	O
in	O	O
both	O	O
patients	B-LIVB
.	O	O

There	O	O
were	O	O
no	O	O
complications	B-DISO
during	O	O
the	O	O
procedure	O
,	O	O
nor	O	O
in	O	O
the	O	O
long	O
-	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
with	O	O
full	O	O
arterial	B-ANAT
vascular	B-ANAT
reconstruction	B-PROC
,	O	O
maintenance	O
of	O	O
cerebral	B-PROC
perfusion	I-PROC
and	O	O
complete	O
aneurysm	B-DISO
occlusion	O
at	O	O
the	O	O
6	O	O
-	O	O
and	O	O
12	O	O
-	O	O
month	O
angiographic	B-PROC
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

There	O	O
was	O	O
no	O	O
aneurysm	B-DISO
recanalization	I-DISO
nor	O	O
intra	B-DISO
-	I-DISO
stent	I-DISO
stenosis	I-DISO
.	O	O

Circumferential	O
fusiform	B-DISO
aneurysm	I-DISO
of	O	O
the	O	O
posterior	O
circulation	B-PHYS
involving	O	O
arterial	B-ANAT
branches	I-ANAT
or	O	O
perforating	B-DISO
vessels	B-ANAT
to	O	O
the	O	O
brain	B-ANAT
stem	I-ANAT
may	O	O
be	O	O
treated	O
with	O	O
this	O	O
arterial	B-ANAT
reconstruction	B-PROC
technique	I-PROC
at	O	O
different	O
surgical	O
times	O
,	O	O
using	O	O
the	O	O
self	B-DEVI
-	I-DEVI
expandable	I-DEVI
stent	I-DEVI
called	O	O
LEO	B-DEVI
+	I-DEVI
and	O	O
the	O	O
flow	B-DEVI
-	I-DEVI
diverter	I-DEVI
device	I-DEVI
SILK	B-DEVI
,	O	O
minimizing	O
the	O	O
risk	O
of	O	O
complications	B-DISO
and	O	O
failure	O
of	O	O
the	O	O
endovascular	B-ANAT
technique	B-PROC
,	O	O
with	O	O
the	O	O
potential	O
for	O	O
arterial	B-PROC
reconstruction	I-PROC
with	O	O
thrombosis	B-DISO
of	O	O
the	O	O
aneurysmatic	B-DISO
sac	I-DISO
,	O	O
as	O	O
well	O	O
as	O	O
flow	B-PHEN
maintenance	O
in	O	O
the	O	O
eloquent	B-ANAT
arteries	I-ANAT
,	O	O
in	O	O
this	O	O
type	O	O
of	O	O
cerebral	B-DISO
aneurysm	I-DISO
.	O	O

Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
/	O	O
Frizzled9	B-CHEM
receptor	B-PHYS
signaling	I-PHYS
through	O	O
the	O	O
Gαo	B-CHEM
/	O	O
Gβγ	B-CHEM
complex	I-CHEM
regulates	B-PHEN
dendritic	B-ANAT
spine	I-ANAT
formation	B-PHYS
Wnt	B-CHEM
ligands	I-CHEM
play	O	O
crucial	O	O
roles	O	O
in	O	O
the	O	O
development	B-PHYS
and	O	O
regulation	B-PHYS
of	I-PHYS
synapse	I-PHYS
structure	I-PHYS
and	I-PHYS
function	I-PHYS
.	O	O

Specifically	O	O
,	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
acts	O	O
as	O	O
a	O	O
secreted	B-CHEM
growth	I-CHEM
factor	I-CHEM
that	O	O
regulates	B-PHEN
dendritic	B-ANAT
spine	I-ANAT
formation	B-PHYS
in	O	O
rodent	B-LIVB
hippocampal	B-ANAT
neurons	B-ANAT
,	O	O
resulting	O	O
in	O	O
postsynaptic	B-ANAT
development	B-PHYS
that	O	O
promotes	O	O
the	O	O
clustering	B-PHYS
of	I-PHYS
the	I-PHYS
postsynaptic	I-PHYS
density	I-PHYS
protein	I-PHYS
-	I-PHYS
95	I-PHYS
(	I-PHYS
PSD	I-PHYS
-	I-PHYS
95	I-PHYS
)	I-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
focused	O	O
on	O	O
the	O	O
early	O
events	O
occurring	O	O
after	O	O
the	O	O
interaction	B-PHYS
between	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
and	O	O
its	O	O
Frizzled	B-CHEM
receptor	I-CHEM
at	O	O
the	O	O
neuronal	B-ANAT
cell	B-ANAT
surface	I-ANAT
.	O	O

Additionally	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
role	O
of	O	O
heterotrimeric	B-CHEM
G	I-CHEM
proteins	I-CHEM
in	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-dependent	O	O
synaptic	B-ANAT
development	B-PHYS
.	O	O

We	O	O
report	O	O
that	O	O
Frizzled9	B-CHEM
(	O	O
FZD9	B-CHEM
)	O	O
,	O	O
a	O	O
Wnt	B-CHEM
receptor	B-CHEM
related	O	O
to	O	O
Williams	B-DISO
'	I-DISO
syndrome	I-DISO
,	O	O
is	O	O
localized	O	O
in	O	O
the	O	O
postsynaptic	O
region	O
,	O	O
where	O	O
it	O	O
interacts	B-PHYS
with	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
.	O	O

Functionally	O	O
,	O	O
FZD9	B-CHEM
is	O	O
required	O	O
for	O	O
the	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-mediated	O	O
increase	O
in	O	O
dendritic	B-ANAT
spine	I-ANAT
density	I-ANAT
.	O	O

FZD9	B-CHEM
forms	O	O
a	O	O
pre	B-ANAT
-	I-ANAT
coupled	I-ANAT
complex	I-ANAT
with	O	O
Gαo	B-CHEM
under	O	O
basal	B-PHEN
conditions	I-PHEN
that	O	O
dissociates	B-PHYS
after	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
stimulation	B-PHYS
.	O	O

Accordingly	O	O
,	O	O
we	O	O
found	O	O
that	O	O
G	B-PHYS
-	I-PHYS
protein	I-PHYS
inhibition	I-PHYS
abrogates	I-PHYS
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-dependent	O	O
pathway	B-PHYS
in	O	O
hippocampal	B-ANAT
neurons	B-ANAT
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
activation	O
of	O	O
Gαo	B-CHEM
appears	O	O
to	O	O
be	O	O
a	O	O
key	O	O
factor	O	O
controlling	B-PHEN
the	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-	O	O
induced	O
dendritic	B-ANAT
spine	I-ANAT
density	I-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
found	O	O
that	O	O
Gβγ	B-CHEM
is	O	O
required	O	O
for	O	O
the	O	O
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
-mediated	O	O
increase	O
in	O	O
cytosolic	B-ANAT
calcium	B-CHEM
levels	O
and	O	O
spinogenesis	B-PHYS
.	O	O

Our	O	O
findings	O
reveal	O	O
that	O	O
FZD9	B-CHEM
and	O	O
heterotrimeric	B-CHEM
G	I-CHEM
proteins	I-CHEM
regulate	B-PHEN
Wnt	B-CHEM
-	I-CHEM
5a	I-CHEM
signaling	B-PHYS
and	O	O
dendritic	B-ANAT
spines	I-ANAT
in	O	O
cultured	B-ANAT
hippocampal	B-ANAT
neurons	B-ANAT
.	O	O

A	O	O
Delayed	O
Diagnosis	B-DISO
of	O	O
Chronic	B-DISO
Mesenteric	I-DISO
Ischaemia	I-DISO
:	O	O
The	O	O
Role	O	O
of	O	O
Clinicians	B-LIVB
'	O	O
Cognitive	O
Errors	O
Chronic	O
diarrhoeal	B-DISO
illnesses	I-DISO
with	O	O
nausea	B-DISO
and	O	O
weight	B-DISO
loss	I-DISO
are	O	O
a	O	O
common	O
indication	O
for	O	O
gastroenterology	O
review	O
.	O	O

While	O	O
many	O	O
such	O	O
cases	O	O
have	O	O
intra	O
-	O
luminal	O
aetiologies	O
,	O	O
such	O	O
as	O	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
,	O	O
coeliac	B-DISO
disease	I-DISO
or	O	O
other	O	O
malabsorptive	B-DISO
conditions	I-DISO
,	O	O
with	O	O
many	O	O
other	O	O
cases	O	O
due	O	O
to	O	O
functional	O
gut	B-ANAT
disorders	B-DISO
or	O	O
systemic	O
malignancy	B-DISO
,	O	O
clinicians	B-LIVB
must	O	O
also	O	O
keep	O	O
vascular	B-DISO
disorders	I-DISO
in	O	O
mind	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
a	O	O
patient	B-LIVB
with	O	O
a	O	O
delayed	O
diagnosis	B-DISO
of	O	O
chronic	B-DISO
mesenteric	I-DISO
ischaemia	I-DISO
after	O	O
6	O	O
months	O
of	O	O
gastrointestinal	B-DISO
symptoms	I-DISO
strongly	O	O
mimicking	O	O
an	O	O
alternative	O
diagnosis	B-DISO
such	O	O
as	O	O
inflammatory	B-DISO
bowel	I-DISO
disease	I-DISO
due	O	O
an	O	O
atypical	O
predominance	O
of	O	O
nausea	B-DISO
and	O	O
diarrhoea	B-DISO
rather	O	O
than	O	O
pain	B-DISO
.	O	O

We	O	O
briefly	O	O
review	O
the	O	O
literature	O
on	O	O
treatment	O
of	O	O
this	O	O
condition	B-DISO
but	O	O
also	O	O
discuss	O	O
with	O	O
particular	O	O
attention	O	O
the	O	O
sequence	O
of	O	O
cognitive	O
errors	O
made	O	O
by	O	O
clinicians	B-LIVB
that	O	O
led	O	O
to	O	O
a	O	O
diagnostic	B-DISO
delay	O
,	O	O
inviting	O	O
readers	O	O
to	O	O
thus	O	O
reflect	O	O
on	O	O
how	O	O
such	O	O
errors	O
can	O	O
be	O	O
minimised	O
in	O	O
their	O	O
practice	O
.	O	O

Evaluation	B-PROC
of	O	O
Choroidal	B-ANAT
Thickness	O
in	O	O
Patients	B-LIVB
with	O	O
Pseudoexfoliation	B-DISO
Syndrome	I-DISO
and	O	O
Pseudoexfoliation	B-DISO
Glaucoma	I-DISO
Purpose	O
.	O	O

To	O	O
compare	O
the	O	O
macular	O
and	O	O
peripapillary	O
choroidal	B-ANAT
thickness	O
in	O	O
eyes	B-ANAT
with	O	O
pseudoexfoliation	B-DISO
(	I-DISO
PEX	I-DISO
)	I-DISO
syndrome	I-DISO
and	O	O
PEX	B-DISO
glaucoma	I-DISO
with	O	O
the	O	O
normal	O
eyes	B-ANAT
of	O	O
healthy	O
controls	B-LIVB
.	O	O

Materials	O	O
and	O	O
Methods	O	O
.	O	O

In	O	O
this	O	O
prospective	B-PROC
study	I-PROC
,	O	O
30	O	O
eyes	B-ANAT
of	O	O
30	O	O
patients	B-LIVB
with	O	O
PEX	B-DISO
syndrome	I-DISO
,	O	O
28	O	O
eyes	B-ANAT
of	O	O
28	O	O
patients	B-LIVB
with	O	O
PEX	B-DISO
glaucoma	I-DISO
,	O	O
and	O	O
30	O	O
eyes	B-ANAT
of	O	O
30	O	O
age	B-PHYS
-matched	O	O
healthy	O
subjects	B-LIVB
were	O	O
enrolled	O	O
.	O	O

Choroidal	B-ANAT
thicknesses	O
in	O	O
the	O	O
macular	O
and	O	O
peripapillary	O
areas	O
were	O	O
measured	O
by	O	O
using	O	O
spectral	B-DEVI
domain	I-DEVI
optical	I-DEVI
coherence	I-DEVI
tomography	I-DEVI
.	O	O

Results	O	O
.	O	O

Gender	B-PHYS
,	O	O
age	B-PHYS
,	O	O
and	O	O
axial	O
length	O
did	O	O
not	B-DISO
significantly	I-DISO
differ	O	O
between	O	O
the	O	O
groups	O
(	O	O
all	O	O
,	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
mean	O
values	O
of	O	O
choroidal	B-ANAT
thickness	O
in	O	O
the	O	O
macular	O
and	O	O
peripapillary	O
areas	O
(	O	O
except	O
the	O	O
superior	O
quadrant	O
)	O	O
in	O	O
the	O	O
patients	B-LIVB
with	O	O
PEX	B-DISO
syndrome	I-DISO
and	O	O
PEX	B-DISO
glaucoma	I-DISO
were	O	O
lower	O
compared	O
with	O	O
controls	B-LIVB
(	O	O
all	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
mean	O
values	O
of	O	O
the	O	O
macular	O
and	O	O
peripapillary	O
choroidal	B-ANAT
thickness	O
in	O	O
the	O	O
PEX	B-DISO
glaucoma	I-DISO
group	O
were	O	O
lower	O
compared	O
with	O	O
PEX	B-DISO
syndrome	I-DISO
group	O
;	O	O
however	O	O
this	O	O
difference	O
was	O	O
not	B-DISO
significant	I-DISO
.	O	O

Conclusions	O	O
.	O	O

The	O	O
findings	B-DISO
of	O	O
this	O	O
study	B-PROC
revealed	O
that	O	O
macular	O
and	O	O
peripapillary	O
choroidal	B-ANAT
thicknesses	O
were	O	O
decreased	O
in	O	O
PEX	B-DISO
syndrome	I-DISO
and	O	O
PEX	B-DISO
glaucoma	I-DISO
cases	O
.	O	O

The	O	O
role	O	O
of	O	O
choroid	B-ANAT
in	O	O
the	O	O
development	O
of	O	O
glaucomatous	B-DISO
damage	O
in	O	O
patients	B-LIVB
with	O	O
PEX	B-DISO
syndrome	I-DISO
remains	O	O
unclear	B-DISO
.	O	O

Polysaccharide	B-CHEM
-	O	O
Specific	O
Memory	B-ANAT
B	I-ANAT
Cells	I-ANAT
Predict	O	O
Protection	B-DISO
against	O	O
Experimental	O
Human	B-LIVB
Pneumococcal	B-LIVB
Carriage	B-DISO
We	O	O
have	O	O
previously	O
demonstrated	O	O
that	O	O
experimental	O
pneumococcal	B-LIVB
carriage	B-DISO
enhances	O
immunity	B-PHYS
and	O	O
protects	B-DISO
healthy	O
adults	B-LIVB
against	O
carriage	B-DISO
reacquisition	O
after	O	O
rechallenge	B-PROC
with	O	O
a	O	O
homologous	B-PHYS
strain	B-LIVB
.	O	O

To	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
naturally	O
acquired	O
pneumococcal	B-CHEM
protein	I-CHEM
and	O	O
polysaccharide	B-CHEM
(	O	O
PS	B-CHEM
)	O	O
-	O	O
specific	O
immunity	B-PHYS
in	O	O
protection	B-DISO
against	O
carriage	B-DISO
acquisition	O
using	O	O
a	O	O
heterologous	B-PHYS
challenge	I-PHYS
model	O	O
.	O	O

We	O	O
identified	O	O
healthy	B-LIVB
volunteers	I-LIVB
that	O	O
were	O	O
naturally	O
colonized	B-ANAT
with	O	O
pneumococcus	B-LIVB
and	O	O
,	O	O
after	O	O
clearance	O
of	O	O
their	O	O
natural	O
carriage	B-DISO
episode	O
,	O	O
challenged	O	O
them	O	O
with	O	O
a	O	O
heterologous	B-PHYS
6B	B-LIVB
strain	I-LIVB
.	O	O

In	O	O
another	O	O
cohort	B-LIVB
of	O	O
volunteers	B-LIVB
we	O	O
assessed	O	O
6BPS	B-CHEM
-	O	O
specific	O
,	O	O
PspA	B-CHEM
-	O	O
specific	O
,	O	O
and	O	O
PspC	B-CHEM
-	O	O
specific	O
IgG	B-CHEM
and	O	O
IgA	B-CHEM
plasma	B-ANAT
and	O	O
memory	B-ANAT
B	I-ANAT
-	I-ANAT
cell	I-ANAT
populations	I-ANAT
before	O
and	O	O
7	O	O
,	O	O
14	O	O
,	O	O
and	O	O
35	O	O
days	O	O
after	O
experimental	O
pneumococcal	B-LIVB
inoculation	B-PROC
.	O	O

Heterologous	B-PHYS
challenge	I-PHYS
with	O	O
6B	B-LIVB
resulted	O	O
in	O	O
50	O	O
%	O	O
carriage	B-DISO
among	O	O
volunteers	B-LIVB
with	O	O
previous	O
natural	O
pneumococcal	B-LIVB
carriage	B-DISO
.	O	O

Protection	B-DISO
from	O	O
carriage	B-DISO
was	O	O
associated	O
with	O
a	O	O
high	O
number	O	O
of	O	O
circulating	O
6BPS	B-CHEM
IgG	B-CHEM
-	O	O
secreting	B-PHYS
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
at	O	O
baseline	O
.	O	O

There	O	O
were	O	O
no	O	O
associations	O
between	O	O
protection	B-DISO
from	O	O
carriage	B-DISO
and	O	O
baseline	O
levels	O
of	O	O
6BPS	B-CHEM
IgG	B-CHEM
in	O	O
serum	B-ANAT
or	O	O
nasal	B-ANAT
wash	I-ANAT
,	O	O
PspA	B-CHEM
-	O	O
specific	O
,	O	O
or	O	O
PspC	B-CHEM
-	O	O
specific	O
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
or	O	O
plasma	B-ANAT
cells	I-ANAT
.	O	O

In	O	O
volunteers	B-LIVB
who	O	O
did	O	O
not	B-DISO
develop	I-DISO
carriage	B-DISO
,	O	O
the	O	O
number	O	O
of	O	O
circulating	O
6BPS	B-CHEM
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
decreased	O
and	O	O
the	O	O
number	O	O
of	O	O
6BPS	B-CHEM
plasma	B-ANAT
cells	I-ANAT
increased	O
postinoculation	B-DISO
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
naturally	O
acquired	O
PS	B-CHEM
-	O	O
specific	O
memory	B-ANAT
B	I-ANAT
cells	I-ANAT
,	O	O
but	O	O
not	B-DISO
levels	I-DISO
of	O	O
circulating	O
IgG	B-CHEM
at	O	O
time	O	O
of	O	O
pneumococcal	B-LIVB
exposure	O
,	O	O
are	O	O
associated	O
with	O
protection	B-DISO
against	O
carriage	B-DISO
acquisition	O
.	O	O

A	O	O
Retrospective	O
Review	O
of	O	O
Forensic	O
Odontology	O
Reports	O
Written	O	O
by	O	O
the	O	O
Joint	O
POW	O
/	O
MIA	O
Accounting	O
Command	O
Central	B-OBJC
Identification	I-OBJC
Laboratory	I-OBJC
for	O	O
Remains	B-ANAT
Identified	O
from	O	O
the	O	O
Korean	O
War	O
As	O	O
of	O	O
August	O	O
2014	O	O
,	O	O
the	O	O
Joint	O
POW	O
/	O
MIA	O
Accounting	O
Command	O
has	O	O
identified	O
the	O	O
remains	B-ANAT
of	O	O
1980	O	O
previously	O	O
unknown	O	O
U	B-GEOG
.	I-GEOG

S	I-GEOG
.	I-GEOG

service	B-LIVB
members	I-LIVB
;	O	O
280	O	O
were	O	O
from	O	O
the	O	O
Korean	O
War	O
.	O	O

To	O	O
determine	O	O
the	O	O
accuracy	O
and	O	O
completeness	O
of	O	O
the	O	O
available	O	O
antemortem	O
(	O	O
AM	O
)	O	O
dental	O
records	O
,	O	O
a	O	O
review	O
of	O	O
the	O	O
AM	O
/	O	O
postmortem	O
(	O	O
AM	O
/	O	O
PM	O
)	O	O
dental	O
record	O
comparisons	O
from	O	O
233	O	O
Forensic	O
Odontology	O
Reports	O
written	O	O
in	O	O
support	O	O
of	O	O
remains	B-ANAT
identified	O
from	O	O
the	O	O
Korean	O
War	O
was	O	O
performed	O	O
.	O	O

Seventy	O	O
-	O	O
two	O	O
AM	O
/	O	O
PM	O
comparisons	O
resulted	O	O
in	O	O
exact	O	O
dental	O
chartings	O
while	O	O
161	O	O
contained	O	O
discrepancies	B-DISO
which	O	O
were	O	O
explainable	O	O
.	O	O

Explainable	O	O
discrepancies	B-DISO
include	O	O
undocumented	B-DISO
treatment	B-PROC
(	O	O
103	O	O
)	O	O
,	O	O
incorrectly	O	O
charted	O
third	O
molars	B-ANAT
as	O	O
missing	O
(	O	O
82	O	O
)	O	O
,	O	O
differing	O	O
opinions	O	O
of	O	O
specific	O	O
molars	B-ANAT
present	B-DISO
/	O	O
missing	O
(	O	O
20	O	O
)	O	O
,	O	O
and	O	O
erroneous	O
treatment	B-PROC
documentation	O
and	O	O
/	O	O
or	O	O
misidentification	B-DISO
of	O	O
teeth	B-ANAT
present	B-DISO
/	O	O
missing	O
(	O	O
22	O	O
,	O	O
other	O	O
than	O	O
molars	B-ANAT
)	O	O
.	O	O

Reassessment	O	O
has	O	O
revealed	O	O
varying	O	O
levels	O
of	O	O
completeness	O
for	O	O
our	O	O
available	O	O
AM	O
dental	O
records	O
,	O	O
the	O	O
need	O	O
to	O	O
thoroughly	O	O
review	O
our	O	O
computerized	O
comparisons	O
,	O	O
adjust	O	O
our	O	O
comparisons	O
to	O	O
include	O	O
molar	B-ANAT
pattern	O
variations	O
/	O	O
third	O
molars	B-ANAT
,	O	O
and	O	O
updating	O	O
our	O	O
database	O
comparison	O
program	O
.	O	O

Predicting	O	O
Sources	B-DISO
of	O	O
Dissolved	O	O
Organic	B-CHEM
Nitrogen	I-CHEM
to	O	O
an	O	O
Estuary	O	O
from	O	O
an	O	O
Agro	O
-	O	O
Urban	B-GEOG
Coastal	B-GEOG
Watershed	I-GEOG
Dissolved	O	O
organic	B-CHEM
nitrogen	I-CHEM
(	O	O
DON	B-CHEM
)	O	O
is	O	O
the	O	O
nitrogen	B-CHEM
(	I-CHEM
N	I-CHEM
)	I-CHEM
-containing	O	O
component	O
of	O	O
dissolved	O	O
organic	B-CHEM
matter	I-CHEM
(	O	O
DOM	B-CHEM
)	O	O
and	O	O
in	O	O
aquatic	B-PHEN
ecosystems	I-PHEN
is	O	O
part	O	O
of	O	O
the	O	O
biologically	B-CHEM
-	I-CHEM
reactive	I-CHEM
nitrogen	B-CHEM
pool	O	O
that	O	O
can	O	O
degrade	O	O
water	O	O
quality	O	O
in	O	O
N	B-CHEM
-	O	O
sensitive	O
waters	B-CHEM
.	O	O

Unlike	O	O
inorganic	B-CHEM
N	I-CHEM
(	O	O
nitrate	B-CHEM
and	O	O
ammonium	B-CHEM
)	O	O
DON	B-CHEM
is	O	O
comprised	O	O
of	O	O
many	O	O
different	O	O
molecules	O	O
of	O	O
variable	O	O
reactivity	O
.	O	O

Few	O	O
methods	O	O
exist	O	O
to	O	O
track	O	O
the	O	O
sources	B-DISO
of	O	O
DON	B-CHEM
in	O	O
watersheds	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
DOM	B-CHEM
excitation	B-PROC
-	I-PROC
emission	I-PROC
matrix	I-PROC
(	I-PROC
EEM	I-PROC
)	I-PROC
fluorescence	I-PROC
of	O	O
eight	O	O
discrete	O	O
DON	B-CHEM
sources	B-DISO
was	O	O
measured	O	O
and	O	O
modeled	O	O
with	O	O
parallel	O
factor	O
analysis	O
(	O	O
PARAFAC	O
)	O	O
and	O	O
the	O	O
resulting	O	O
model	O
(	O	O
""""	O	O
FluorMod	O
""""	O	O
)	O	O
was	O	O
fit	O	O
to	O	O
516	O	O
EEMs	B-PROC
measured	O	O
in	O	O
surface	O
waters	B-CHEM
from	O	O
the	O	O
main	O	O
stem	O	O
of	O	O
the	O	O
Neuse	B-PHEN
River	I-PHEN
and	O	O
its	O	O
tributaries	B-PHEN
,	O	O
located	O	O
in	O	O
eastern	O
North	B-GEOG
Carolina	I-GEOG
.	O	O

PARAFAC	O
components	O	O
were	O	O
positively	O	O
correlated	O
to	O	O
DON	B-CHEM
concentration	O
and	O	O
principle	O
components	O
analysis	O
(	O	O
PCA	O
)	O	O
was	O	O
used	O	O
to	O	O
confirm	O	O
separation	O	O
of	O	O
the	O	O
eight	O	O
sources	B-DISO
.	O	O

Model	O
validation	B-PROC
was	O	O
achieved	O	O
by	O	O
measurement	O	O
of	O	O
source	B-DISO
samples	B-OBJC
not	O	O
included	O	O
in	O	O
the	O	O
model	O
development	O
with	O	O
an	O	O
error	O	O
of	O	O
<	O	O
10	O	O
%	O	O
.	O	O

Application	O	O
of	O	O
FluorMod	O
to	O	O
surface	O	O
waters	B-CHEM
of	O	O
streams	B-PHEN
within	O	O
the	O	O
Neuse	B-PHEN
River	I-PHEN
Basin	O	O
showed	O	O
while	O	O
>	O	O
70	O	O
%	O	O
of	O	O
DON	B-CHEM
was	O	O
attributed	O	O
to	O	O
natural	O
sources	B-DISO
,	O	O
non	O	O
-	O	O
point	O	O
sources	B-DISO
,	O	O
such	O	O
as	O	O
soil	B-OBJC
and	O	O
poultry	B-LIVB
litter	B-OBJC
leachates	B-CHEM
and	O	O
street	B-OBJC
runoff	I-OBJC
,	O	O
accounted	O	O
for	O	O
the	O	O
remaining	O	O
30	O	O
%	O	O
.	O	O

This	O	O
result	O	O
was	O	O
consistent	O	O
with	O	O
changes	O	O
in	O	O
land	O	O
use	O	O
from	O	O
urbanized	B-PHEN
Raleigh	B-GEOG
metropolitan	I-GEOG
area	I-GEOG
to	O	O
the	O	O
largely	O	O
agricultural	O
Southeastern	O
coastal	O
plain	O
.	O	O

Overall	O	O
,	O	O
the	O	O
predicted	O	O
fraction	O	O
of	O	O
non	O	O
-	O	O
point	O	O
DON	B-CHEM
sources	B-DISO
was	O	O
consistent	O	O
with	O	O
previous	O	O
reports	O	O
of	O	O
increased	O	O
organic	B-CHEM
N	I-CHEM
inputs	O	O
in	O	O
this	O	O
river	B-PHEN
basin	I-PHEN
,	O	O
which	O	O
are	O	O
suspected	O	O
of	O	O
impacting	O	O
the	O	O
water	O
quality	O
of	O	O
its	O	O
estuary	B-PHEN
.	O	O

Clinical	B-DISO
Features	I-DISO
and	O	O
Complications	B-DISO
of	O	O
the	O	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
-associated	O	O
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
:	O	O
A	O	O
Metanalysis	B-PROC
In	O	O
this	O	O
article	O
,	O	O
we	O	O
report	O	O
a	O	O
literature	O
-	O
based	O
metanalysis	B-PROC
we	O	O
have	O	O
conducted	O	O
to	O	O
outline	O	O
the	O	O
clinical	B-DISO
features	I-DISO
of	O	O
the	O	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
(	O	O
AAU	B-DISO
)	O	O
.	O	O

The	O	O
examined	B-DISO
material	O	O
was	O	O
based	O	O
on	O	O
observational	B-PROC
studies	I-PROC
in	O	O
which	O	O
participants	B-LIVB
were	O	O
affected	O	O
by	O	O
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
and	O	O
divided	O	O
into	O	O
HLA	B-PHEN
B27	I-PHEN
+	I-PHEN
and	O	O
HLA	B-PHEN
B27	I-PHEN
-	I-PHEN
.	O	O

We	O	O
performed	O	O
a	O	O
search	O	O
on	O	O
articles	O
with	O	O
the	O	O
words	O	O
""""	O	O
HLA	B-DISO
B27	I-DISO
uveitis	I-DISO
""""	O	O
dated	O	O
before	O	O
May	O	O
2014	O	O
.	O	O

Among	O	O
these	O	O
,	O	O
29	O	O
articles	O
were	O	O
selected	O	O
for	O	O
a	O	O
second	O	O
review	O
.	O	O

After	O	O
a	O	O
further	O	O
evaluation	O	O
,	O	O
22	O	O
articles	O
were	O	O
analyzed	B-PROC
.	O	O

The	O	O
clinical	B-PHYS
characteristics	I-PHYS
studied	O	O
in	O	O
the	O	O
metanalysis	B-PROC
were	O	O
:	O	O
(	O	O
1	O	O
)	O	O
systemic	B-DISO
disease	I-DISO
;	O	O
(	O	O
2	O	O
)	O	O
sex	O
distribution	O
;	O	O
(	O	O
3	O	O
)	O	O
laterality	B-PHYS
;	O	O
(	O	O
4	O	O
)	O	O
visual	B-PHYS
acuity	I-PHYS
;	O	O
(	O	O
5	O	O
)	O	O
hypopion	B-DISO
;	O	O
(	O	O
6	O	O
)	O	O
anterior	B-CHEM
chamber	I-CHEM
's	I-CHEM
fibrin	I-CHEM
;	O	O
(	O	O
7	O	O
)	O	O
elevated	B-DISO
intraocular	I-DISO
pressure	I-DISO
(	O	O
IOP	B-PHYS
)	O	O
during	O	O
inflammation	B-DISO
;	O	O
(	O	O
8	O	O
)	O	O
glaucoma	B-DISO
;	O	O
(	O	O
9	O	O
)	O	O
posterior	B-DISO
synechiae	I-DISO
;	O	O
(	O	O
10	O	O
)	O	O
cataract	B-DISO
;	O	O
(	O	O
11	O	O
)	O	O
cystoid	B-DISO
macular	I-DISO
edema	I-DISO
;	O	O
(	O	O
12	O	O
)	O	O
papillitis	B-DISO
.	O	O

We	O	O
have	O	O
calculated	O	O
a	O	O
relative	O
risk	O
(	O	O
RR	O
)	O	O
for	O	O
each	O	O
outcome	O
measured	O
.	O	O

The	O	O
results	O
obtained	O	O
remark	O	O
some	O	O
of	O	O
the	O	O
peculiar	O	O
features	O	O
linked	O	O
to	O	O
the	O	O
HLA	B-CHEM
B27	I-CHEM
Acute	B-DISO
Anterior	I-DISO
Uveitis	I-DISO
,	O	O
such	O	O
as	O	O
strong	O	O
association	O
with	O
ankylosing	B-DISO
spondylitis	I-DISO

(	O	O
RR	O
=	O	O
6	O	O
.	O	O
80	O	O
)	O	O
and	O	O
systemic	B-DISO
diseases	I-DISO
(	O	O
RR	O
=	O	O
9	O	O
.	O	O
9	O	O
)	O	O
,	O	O
male	B-PHYS
prevalence	O
(	O	O
RR	O
=	O	O
1	O	O
.	O	O
2	O	O
)	O	O
,	O	O
unilateral	O
(	O	O
RR	O
=	O	O
1	O	O
.	O	O
1	O	O
)	O	O
or	O	O
alternating	O	O
bilateral	O
(	O	O
RR	O
=	O	O
2	O	O
.	O	O
2	O	O
)	O	O
involvement	O
,	O	O
hypopion	B-DISO
(	O	O
RR	O
=	O	O
5	O	O
.	O	O
5	O	O
)	O	O
,	O	O
fibrinous	B-CHEM
reaction	O
and	O	O
even	O	O
papillitis	B-DISO
(	O	O
R	O	O
=	O	O
7	O	O
.	O	O
7	O	O
)	O	O
.	O	O

Simultaneous	O	O
bilateral	O
(	O	O
RR	O
=	O	O
0	O	O
.	O	O
3	O	O
)	O	O
AAU	B-DISO
is	O	O
more	O	O
frequent	O
in	O	O
HLA	B-CHEM
-	I-CHEM
B27	I-CHEM
negative	B-DISO
form	O	O
.	O	O

We	O	O
report	O	O
higher	O	O
risk	O
of	O	O
elevated	B-DISO
IOP	I-DISO
and	O	O
glaucoma	B-DISO
(	O	O
RR	O
=	O	O
0	O	O
.	O	O
6	O	O
)	O	O
in	O	O
B27	B-DISO
-	I-DISO
Acute	I-DISO
Anterior	I-DISO
Uveitis	I-DISO
.	O	O

No	O	O
significant	O	O
difference	O	O
between	O	O
HLA	B-DISO
B	I-DISO
27	I-DISO
positive	I-DISO
and	O	O
negative	B-DISO
AAU	B-DISO
was	O	O
observed	O
according	O	O
to	O	O
final	O	O
visual	B-PHYS
acuity	I-PHYS
and	O	O
complications	B-DISO
such	O	O
as	O	O
posterior	B-DISO
synechiae	I-DISO
,	O	O
cataract	B-DISO
,	O	O
and	O	O
maculare	B-DISO
edema	I-DISO
.	O	O

We	O	O
trust	O	O
that	O	O
this	O	O
will	O	O
inform	O	O
on	O	O
the	O	O
clinical	B-PROC
evaluation	I-PROC
and	O	O
therapeutic	O
decision	B-PHYS
in	O	O
addressing	O	O
a	O	O
still	O	O
ill	O	O
-	O	O
defined	O	O
ophthalmologic	O
condition	O
.	O	O

Effect	O
of	O	O
nivolumab	B-CHEM
on	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
in	O	O
patients	B-LIVB
with	O	O
treatment	B-PHYS
-	I-PHYS
naïve	I-PHYS
advanced	O
melanoma	B-DISO
:	O	O
results	O
from	O	O
the	O	O
phase	B-PROC
III	I-PROC
CheckMate	I-PROC
066	I-PROC
study	I-PROC
Nivolumab	B-CHEM
has	O	O
shown	O	O
significant	O	O
survival	O
benefit	O
and	O	O
a	O	O
favorable	O	O
safety	B-PROC
profile	I-PROC
compared	O
with	O	O
dacarbazine	B-CHEM
chemotherapy	B-PROC
among	O	O
treatment	B-PHYS
-	I-PHYS
naïve	I-PHYS
patients	B-LIVB
with	O	O
metastatic	B-DISO
melanoma	I-DISO
in	O	O
the	O	O
CheckMate	B-PROC
066	I-PROC
phase	I-PROC
III	I-PROC
study	I-PROC
.	O	O

Results	O
from	O	O
the	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O	O
HRQoL	O
)	O	O
analyses	B-PROC
from	O	O
CheckMate	B-PROC
066	I-PROC
are	O	O
presented	O	O
.	O	O

HRQoL	O
was	O	O
evaluated	B-PROC
at	O	O
baseline	O
and	O	O
every	O	O
6	O	O
weeks	O
while	O	O
on	O	O
treatment	B-PROC
using	O	O
the	O	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Care	O
(	O
EORTC	O
)	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
(	O
QLQ	O
-	O
C30	O
)	O
and	O	O
the	O	O
EuroQoL	O
Five	O
Dimensions	O
Questionnaire	O
(	O	O
EQ	O
-	O
5D	O
)	O	O
.	O	O

Via	O	O
a	O	O
multi	O
-	O
step	O
statistical	O
plan	O
,	O	O
data	O
were	O	O
analyzed	B-PROC
descriptively	O
,	O	O
cross	B-PROC
-	I-PROC
sectionally	I-PROC
,	O	O
and	O	O
longitudinally	B-PROC
,	O	O
adjusting	O	O
for	O	O
baseline	O
covariates	O
,	O	O
in	O	O
patients	B-LIVB
having	O	O
baseline	O
plus	O	O
≥1	O	O
post	O
-	O
baseline	O
assessment	B-PROC
.	O	O

Baseline	O
-	O
adjusted	O
completion	O
rates	O
for	O	O
all	O	O
HRQoL	O
questionnaires	O
across	O	O
treatment	B-PROC
arms	I-PROC
were	O	O
65	O	O
%	O	O
and	O	O
70	O	O
%	O	O
for	O	O
dacarbazine	B-CHEM
and	O	O
nivolumab	B-CHEM
,	O	O
respectively	O	O
,	O	O
and	O	O
remained	O	O
similar	O	O
throughout	O	O
treatment	B-PROC
.	O	O

The	O	O
mean	O
baseline	O
HRQoL	O
scores	O
were	O	O
similar	O	O
for	O	O
patients	B-LIVB
treated	B-PROC
with	O	O
nivolumab	B-CHEM
and	O	O
dacarbazine	B-CHEM
.	O	O

Baseline	O
HRQoL	O
levels	O
with	O	O
nivolumab	B-CHEM
were	O	O
maintained	O	O
over	O
time	O
.	O	O

This	O	O
exploratory	B-PROC
analysis	I-PROC
showed	O	O
a	O	O
between	O	O
-	O	O
arm	O	O
difference	O
in	O	O
favor	O	O
of	O	O
nivolumab	B-CHEM
on	O	O
the	O	O
EQ	O
-	O
5D	O
utility	O
index	O
and	O	O
clinically	O
meaningful	O	O
EQ	O
-	O
5D	O
improvements	O
from	O	O
baseline	O
at	O	O
several	O	O
time	O
points	O
for	O	O
patients	B-LIVB
receiving	O	O
nivolumab	B-CHEM
.	O	O

Patients	B-LIVB
treated	B-PROC
with	O	O
nivolumab	B-CHEM
did	O	O
not	O	O
show	O	O
increased	O
symptom	B-DISO
burden	O
as	O	O
assessed	O
by	O	O
the	O	O
EORTC	O
QLQ	O
-	O
C30	O
.	O	O

No	O	O
HRQoL	O
change	O
was	O	O
noted	O	O
with	O	O
dacarbazine	B-CHEM
patients	B-LIVB
up	O	O
to	O	O
week	O
43	O	O
,	O	O
although	O	O
the	O	O
high	O	O
attrition	O
rate	O
after	O	O
week	O
13	O	O
did	O	O
not	O	O
allow	O	O
any	O	O
meaningful	O	O
analyses	B-PROC
.	O	O

Patients	B-LIVB
receiving	O	O
nivolumab	B-CHEM
deteriorated	O	O
significantly	O	O
later	O	O
than	O	O
those	O	O
receiving	O	O
dacarbazine	B-CHEM
on	O	O
several	O	O
EORTC	O
QLQ	O
-	O
C30	O
scales	O
and	O	O
the	O	O
EQ	O
-	O
5D	O
utility	O
index	O
.	O	O

In	O	O
addition	O	O
to	O	O
prolonged	O
survival	O
,	O	O
these	O	O
exploratory	O	O
HRQoL	O
results	O
show	O	O
that	O	O
nivolumab	B-CHEM
maintains	O	O
baseline	O
HRQoL	O
levels	O
to	O	O
provide	O	O
long	O
-	O
term	O
quality	B-DISO
of	I-DISO
survival	I-DISO
benefit	I-DISO
,	O	O
compared	O
with	O	O
dacarbazine	B-CHEM
in	O	O
patients	B-LIVB
with	O	O
advanced	O
melanoma	B-DISO
.	O	O

Risk	O
stratification	B-PROC
of	O	O
prostate	B-DISO
cancer	I-DISO
utilizing	O	O
apparent	O
diffusion	O
coefficient	O
value	O
and	O	O
lesion	B-DISO
volume	I-DISO
on	O	O
multiparametric	B-PROC
MRI	I-PROC
To	O	O
evaluate	B-PROC
the	O	O
performance	O	O
of	O	O
apparent	O
diffusion	O
coefficient	O
(	O	O
ADC	O
)	O	O
and	O	O
lesion	B-DISO
volume	I-DISO
in	O	O
potentially	O	O
risk	O
-	O	O
stratifying	B-PROC
patients	B-LIVB
with	O	O
prostate	B-DISO
cancer	I-DISO
(	O	O
PCa	B-DISO
)	O	O
.	O	O

Men	B-LIVB
with	O	O
elevated	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
or	O	O
abnormal	B-PROC
digital	I-PROC
rectal	I-PROC
exam	I-PROC
underwent	O	O
a	O	O
3	B-PROC
T	I-PROC
multiparametric	I-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
mpMRI	B-PROC
)	O	O
with	O	O
endorectal	B-DEVI
coil	I-DEVI
.	O	O

ADC	O
maps	O
were	O	O
calculated	O	O
using	O	O
b	O	O
values	O	O
of	O	O
0	O	O
,	O	O
500	O	O
,	O	O
1000	O	O
,	O	O
and	O	O
1500	O	O
;	O	O
additional	O	O
images	O
were	O	O
obtained	O	O
with	O	O
b	O	O
value	O	O
of	O	O
2000	O	O
.	O	O

We	O	O
prospectively	O	O
enrolled	O	O
312	O	O
men	B-LIVB
with	O	O
lesions	B-DISO
suspicious	O
for	O	O
cancer	B-DISO
(	O	O
suspicion	O
score	O
2	O	O
-	O	O
5	O	O
)	O	O
on	O	O
mpMRI	B-PROC
.	O	O

MRI	B-PROC
/	I-PROC
ultrasound	I-PROC
fusion	I-PROC
-	I-PROC
guided	I-PROC
prostate	I-PROC
biopsies	I-PROC
were	O	O
performed	O	O
.	O	O

Mean	O	O
ADC	O
of	O	O
suspicious	O
lesions	B-DISO
were	O	O
correlated	O	O
against	O	O
lesion	B-DISO
volume	I-DISO
,	O	O
Gleason	O
and	O
D	O
'	O
Amico	O
risk	O
.	O	O

The	O	O
cancer	B-DISO
detection	O
rate	O
of	O	O
fusion	B-PROC
biopsy	I-PROC
per	O	O
lesion	B-DISO
was	O	O
45	O	O
.	O	O

6	O	O
%	O	O
(	O	O
206	O	O
/	O	O
452	O	O
)	O	O
.	O	O

Cancerous	B-DISO
lesions	B-DISO
were	O	O
larger	O	O
(	O	O
median	O	O
volume	O	O
:	O	O
0	O	O
.	O	O
40	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
30	O	O
cm	O	O
(	O	O
3	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
016	O	O
)	O	O
.	O	O

The	O	O
median	O	O
ADC	O
(	O	O
×10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
/sec	O	O
)	O	O
for	O	O
lesions	B-DISO
negative	B-DISO
and	I-DISO
positive	I-DISO
for	O	O
PCa	B-DISO
were	O	O
984	O	O
.	O	O
5	O	O
and	O	O
666	O	O
.	O	O
5	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

The	O	O
AUC	O
of	O	O
ADC	O
in	O	O
predicting	O	O
PCa	B-DISO
was	O	O
0	O	O
.	O	O
79	O	O
.	O	O

Larger	O	O
lesions	B-DISO
were	O	O
associated	O
with	O
higher	B-DISO
risk	I-DISO
PCa	B-DISO
(	O	O
Gleason	O
and	O
D	O
'	O
Amico	O
)	O	O
and	O	O
lower	B-DISO
ADC	I-DISO
(	O	O
all	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
ADC	O
of	O	O
suspicious	O
lesions	B-DISO
on	O	O
mpMRI	B-PROC
was	O	O
inversely	O	O
correlated	O	O
,	O	O
while	O	O
lesion	B-DISO
volume	I-DISO
had	O	O
a	O	O
direct	O	O
correlation	O
with	O	O
PCa	B-DISO
detection	B-DISO
.	O	O

Future	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
studies	I-PROC
are	O	O
needed	O	O
to	O	O
assess	O	O
longitudinal	B-DISO
cancer	I-DISO
risks	O
of	O	O
suspicious	O
mpMRI	B-PROC
lesions	B-DISO
.	O	O

2	O	O
J	O	O
.	O	O
Magn	O	O
.	O	O

Reson	O	O
.	O	O

Imaging	O	O
2017	O	O
;	O	O
45	O	O
:	O	O
610	O	O
-	O	O
616	O	O
.	O	O

Hounsfield	O
unit	O
recovery	O
in	O	O
clinical	O
cone	B-PROC
beam	I-PROC
CT	I-PROC
images	O
of	O	O
the	O	O
thorax	B-ANAT
acquired	O	O
for	O	O
image	B-PROC
guided	I-PROC
radiation	I-PROC
therapy	I-PROC
A	O	O
comprehensive	O
artefact	B-PHEN
correction	O
method	O
for	O	O
clinical	O
cone	B-PROC
beam	I-PROC
CT	I-PROC
(	O	O
CBCT	B-PROC
)	O	O
images	O
acquired	O	O
for	O	O
image	B-PROC
guided	I-PROC
radiation	I-PROC
therapy	I-PROC
(	O	O
IGRT	B-PROC
)	O	O
on	O	O
a	O	O
commercial	O	O
system	O	O
is	O	O
presented	O	O
.	O	O

The	O	O
method	O
is	O	O
demonstrated	O	O
to	O	O
reduce	O
artefacts	B-PHEN
and	O	O
recover	O
CT	B-PROC
-like	O	O
Hounsfield	O
units	O
(	O	O
HU	O
)	O	O
in	O	O
reconstructed	O
CBCT	B-PROC
images	O
of	O	O
five	O	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O	O

Projection	O
image	O
based	O	O
artefact	B-PHEN
corrections	O
of	O	O
image	B-PHEN
lag	I-PHEN
,	O	O
detector	B-PHEN
scatter	I-PHEN
,	O	O
body	B-PHEN
scatter	I-PHEN
and	O	O
beam	B-DISO
hardening	I-DISO
are	O	O
described	O	O
and	O	O
applied	O	O
to	O	O
CBCT	B-PROC
images	O
of	O	O
five	O	O
lung	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O	O

Image	O
quality	O
is	O	O
evaluated	B-PROC
through	O	O
visual	O
appearance	O
of	O	O
the	O	O
reconstructed	O
images	O
,	O	O
HU	O
-correspondence	O	O
with	O	O
the	O	O
planning	O	O
CT	B-PROC
images	O
,	O	O
and	O	O
total	O
volume	O
HU	O
error	O
.	O	O

Artefacts	B-PHEN
are	O	O
reduced	O
and	O	O
CT	B-PROC
-like	O	O
HUs	O
are	O	O
recovered	O
in	O	O
the	O	O
artefact	B-PHEN
corrected	O
CBCT	B-PROC
images	O
.	O	O

Visual	B-PROC
inspection	I-PROC
confirms	B-DISO
that	O	O
artefacts	B-PHEN
are	O	O
indeed	O	O
suppressed	O
by	O	O
the	O	O
proposed	O	O
method	O
,	O	O
and	O	O
the	O	O
HU	O
root	O
mean	O
square	O
difference	O
between	O	O
reconstructed	O
CBCTs	B-PROC
and	O	O
the	O	O
reference	O
CT	B-PROC
images	O
are	O	O
reduced	O
by	O	O
31	O	O
%	O	O
when	O	O
using	O	O
the	O	O
artefact	B-PHEN
corrections	O
compared	O
to	O	O
the	O	O
standard	O
clinical	O
CBCT	B-PROC
reconstruction	O
.	O	O

A	O	O
versatile	O	O
artefact	B-PHEN
correction	O
method	O
for	O	O
clinical	O
CBCT	B-PROC
images	O
acquired	O	O
for	O	O
IGRT	B-PROC
has	O	O
been	O	O
developed	O	O
.	O	O

HU	O
values	O
are	O	O
recovered	O
in	O	O
the	O	O
corrected	O
CBCT	B-PROC
images	O
.	O	O

The	O	O
proposed	O	O
method	O
relies	O	O
on	O	O
post	O
processing	O
of	O	O
clinical	O
projection	O
images	O
,	O	O
and	O	O
does	O	O
not	O	O
require	O	O
patient	B-LIVB
specific	O
optimisation	O
.	O	O

It	O	O
is	O	O
thus	O	O
a	O	O
powerful	O	O
tool	O
for	O	O
image	O
quality	O
improvement	O
of	O	O
large	O
numbers	O
of	O	O
CBCT	B-PROC
images	O
.	O	O

Vestibular	B-ANAT
ablation	B-PROC
and	O	O
a	O	O
semicircular	B-ANAT
canal	I-ANAT
prosthesis	B-DEVI
affect	O
postural	B-PHYS
stability	I-PHYS
during	O
head	B-PHYS
turns	I-PHYS
In	O	O
our	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
postural	B-PHYS
stability	I-PHYS
during	O
head	B-PHYS
turns	I-PHYS
for	O	O
two	O
rhesus	B-LIVB
monkeys	I-LIVB
:	O	O
one	O
animal	B-LIVB
study	I-LIVB
contrasted	O	O
normal	O
and	O	O
mild	O
bilateral	O
vestibular	B-ANAT
ablation	B-PROC
and	O	O
a	O	O
second	O
animal	B-LIVB
study	I-LIVB
contrasted	O	O
severe	O
bilateral	O
vestibular	B-ANAT
ablation	B-PROC
with	O	O
and	O	O
without	O	O
prosthetic	B-DEVI
stimulation	B-PROC
.	O	O

The	O	O
monkeys	B-LIVB
freely	O
stood	O
,	O	O
unrestrained	O
on	O	O
a	O	O
balance	B-DEVI
platform	O	O
and	O	O
made	O	O
voluntary	O
head	B-PHYS
turns	I-PHYS
between	O	O
visual	O
targets	O
.	O	O

To	O	O
quantify	O
each	O	O
animals	B-LIVB
'	O	O
posture	B-PHYS
,	O	O
motions	B-PHEN
of	O	O
the	O	O
head	B-ANAT
and	O	O
trunk	B-ANAT
,	O	O
as	O	O
well	O	O
as	O	O
torque	B-PHEN
about	O	O
the	O	O
body	B-PHYS
's	I-PHYS
center	I-PHYS
of	I-PHYS
mass	I-PHYS
,	O	O
were	O	O
measured	O
.	O	O

In	O	O
the	O	O
mildly	O
ablated	B-PROC
animal	B-LIVB
,	O	O
we	O	O
observed	O
less	O
foretrunk	B-ANAT
sway	B-DISO
in	O	O
comparison	O
with	O	O
the	O	O
normal	O
state	O
.	O	O

When	O	O
the	O	O
canal	B-DEVI
prosthesis	I-DEVI
provided	O	O
electric	B-PROC
stimulation	I-PROC
to	O	O
the	O	O
severely	O
ablated	B-LIVB
animal	I-LIVB
,	O	O
it	O	O
showed	O	O
a	O	O
decrease	O
in	O	O
trunk	B-ANAT
sway	B-DISO
during	O
head	B-PHYS
turns	I-PHYS
.	O	O

Because	O	O
the	O	O
rhesus	B-LIVB
monkey	I-LIVB
with	O	O
severe	O
bilateral	B-DISO
vestibular	I-DISO
loss	I-DISO
exhibited	O	O
a	O	O
decrease	O
in	O	O
trunk	B-ANAT
sway	B-DISO
when	O	O
receiving	O
vestibular	B-ANAT
prosthetic	B-DEVI
stimulation	B-PROC
,	O	O
we	O	O
propose	O	O
that	O	O
the	O	O
prosthetic	B-DEVI
electrical	B-PROC
stimulation	I-PROC
partially	O
restored	B-PROC
head	B-PHYS
velocity	I-PHYS
information	O
.	O	O

Our	O	O
results	O
provide	O	O
an	O	O
indication	B-DISO
that	O	O
a	O	O
semicircular	B-ANAT
canal	I-ANAT
prosthesis	B-DEVI
may	O	O
be	O	O
an	O	O
effective	O
way	O
to	O	O
improve	O
postural	B-PHYS
stability	I-PHYS
in	O	O
patients	B-LIVB
with	O	O
severe	O
peripheral	B-DISO
vestibular	I-DISO
dysfunction	I-DISO
.	O	O

Expression	B-PHYS
of	O	O
metalloproteinases	B-CHEM
(	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
)	O	O
in	O	O
basal	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
compare	O
the	O	O
expressions	B-PHYS
of	O	O
mRNA	O
for	O	O
metalloproteinases	B-CHEM
(	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
)	O	O
and	O	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
in	O	O
two	O	O
different	O	O
histological	B-PHYS
types	I-PHYS
of	O	O
basal	B-DISO
-	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
BCCs	B-DISO
;	O	O
nodular	B-DISO
and	O	O
infiltrative	B-DISO
)	O	O
and	O	O
in	O	O
normal	B-DISO
tissues	I-DISO
from	O	O
the	O	O
tumor	B-DISO
interface	O
.	O	O

The	O	O
study	B-PROC
included	O	O
biopsy	O
specimens	O
of	O	O
the	O	O
skin	B-ANAT
involved	O
with	O	O
BCC	B-DISO
and	O	O
normal	B-ANAT
skin	I-ANAT
adjacent	O
the	O	O
lesion	B-DISO
.	O	O

The	O	O
expressions	B-PHYS
of	O	O
mRNA	O
for	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
and	O	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
were	O	O
determined	O
by	O
means	O	O
of	O	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
(	O	O
Reverse	B-PROC
transcription	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
)	O	O
.	O	O

The	O	O
level	O
of	O	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
mRNA	O
in	O	O
nodular	B-DISO
and	O	O
infiltrative	B-DISO
BCCs	I-DISO
turned	O	O
out	O	O
to	O	O
be	O	O
significantly	O
lower	O
,	O	O
and	O	O
the	O	O
expressions	B-PHYS
of	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
mRNA	O
significantly	O
higher	O
than	O	O
in	O	O
normal	B-DISO
tissues	I-DISO
adjacent	O
to	O	O
these	O	O
tumors	B-DISO
.	O	O

The	O	O
expression	B-PHYS
of	O	O
mRNA	O
for	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
but	O	O
not	O	O
for	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
was	O	O
significantly	O
higher	O
in	O	O
infiltrative	B-DISO
BCCs	I-DISO
than	O	O
in	O	O
the	O	O
nodular	B-DISO
BCCs	I-DISO
.	O	O

In	O	O
turn	O	O
,	O	O
normal	B-DISO
tissues	I-DISO
adjacent	O
to	O	O
nodular	B-DISO
BCCs	I-DISO
showed	O	O
significantly	O
higher	O
levels	O
of	O	O
mRNA	O
for	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
significantly	O
lower	O
levels	O
of	O	O
type	B-CHEM
IV	I-CHEM
collagen	I-CHEM
mRNA	O
than	O	O
the	O	O
normal	B-DISO
tissues	I-DISO
from	O	O
the	O	O
interface	O
of	O	O
infiltrative	B-DISO
BCCs	I-DISO
.	O	O

The	O	O
findings	B-DISO
suggest	O
that	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
could	O	O
be	O	O
used	O	O
as	O	O
prognostic	B-PHYS
factors	I-PHYS
of	O	O
BCCs	B-DISO
.	O	O

Effects	O
of	O
Covering	O
Surgical	B-DISO
Wounds	I-DISO
with	O	O
Polyglycolic	B-CHEM
Acid	I-CHEM
Sheets	B-DEVI
for	O	O
Posttonsillectomy	B-DISO
Pain	I-DISO
Postoperative	B-DISO
pain	I-DISO
is	O	O
a	O	O
remaining	O	O
issue	O	O
in	O	O
tonsillectomy	B-PROC
.	O	O

Polyglycolic	B-CHEM
acid	I-CHEM
(	O	O
PGA	B-CHEM
)	O	O
is	O	O
a	O	O
biocompatible	B-CHEM
material	I-CHEM
used	O	O
for	O	O
absorbent	B-DEVI
suture	I-DEVI
reinforcement	B-PROC
,	O	O
and	O	O
its	O	O
sheet	B-DEVI
has	O	O
been	O	O
applied	O	O
for	O	O
covering	O
defects	O
after	O	O
resection	B-PROC
of	O	O
oral	B-DISO
carcinoma	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
examine	O	O
whether	O	O
the	O	O
attachment	O	O
of	O	O
a	O	O
PGA	B-CHEM
sheet	B-DEVI
to	O	O
surgical	B-DISO
wounds	I-DISO
would	O	O
reduce	O	O
posttonsillectomy	B-DISO
pain	I-DISO
.	O	O

In	O	O
this	O	O
prospective	B-PROC
single	I-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
,	O	O
17	O	O
consecutive	O	O
adult	O	O
patients	B-LIVB
were	O	O
recruited	O	O
who	O	O
needed	O	O
to	O	O
undergo	O	O
tonsillectomy	B-PROC
,	O	O
mainly	O	O
due	O	O
to	O	O
habitual	O
tonsillitis	B-DISO
.	O	O

Following	O	O
bilateral	B-PROC
tonsillectomies	I-PROC
,	O	O
a	O	O
PGA	B-CHEM
sheet	B-DEVI
was	O	O
attached	O	O
with	O	O
fibrin	B-CHEM
glue	I-CHEM
to	O	O
only	O	O
1	O	O
side	O	O
,	O	O
without	O	O
notification	O	O
to	O	O
patients	B-LIVB
of	O	O
which	O	O
side	O	O
.	O	O

Postoperative	B-DISO
pain	I-DISO
of	O	O
each	O	O
side	O	O
was	O	O
separately	O	O
evaluated	B-PROC
with	O	O
a	O	O
visual	B-PROC
analog	I-PROC
scale	I-PROC
at	O	O
4	O	O
time	O	O
points	O	O
:	O	O
before	O
each	O
meal	O
and	O	O
before	O
sleep	O
.	O	O

Postoperative	B-DISO
pain	I-DISO
of	O	O
both	O	O
the	O	O
PGA	B-CHEM
sheet	B-DEVI
-attached	O	O
and	O	O
nonattached	O	O
sides	O	O
was	O	O
most	O	O
severe	O	O
before	O
breakfast	O
among	O	O
4	O	O
time	O	O
points	O	O
.	O	O

Postoperative	B-DISO
pain	I-DISO
measured	O	O
before	O
breakfast	O
was	O	O
significantly	O	O
more	O	O
severe	O
in	O	O
the	O	O
PGA	B-CHEM
sheet	B-DEVI
-attached	O	O
side	O	O
than	O	O
the	O	O
nonattached	O	O
side	O	O
.	O	O

As	O	O
such	O	O
,	O	O
this	O	O
study	O	O
provided	O	O
solid	O	O
data	O	O
on	O	O
the	O	O
negative	O	O
effects	O
of	O
PGA	B-CHEM
sheeting	B-DEVI
on	O	O
posttonsillectomy	B-DISO
pain	I-DISO
.	O	O

Risk	B-DISO
Factors	I-DISO
for	O	O
Infection	B-DISO
After	O	O
Knee	B-PROC
Arthroscopy	I-PROC
:	O	O
Analysis	B-PROC
of	O	O
595	O	O
,	O	O
083	O	O
Cases	O
From	O	O
3	O	O
United	B-GEOG
States	I-GEOG
Databases	O
To	O	O
identify	O
and	O	O
quantify	O
patient	B-DISO
-	I-DISO
and	O	O
procedure	B-DISO
-	I-DISO
related	I-DISO
risk	I-DISO
factors	I-DISO
for	O	O
post	O
-	O
arthroscopic	O
knee	B-DISO
infections	I-DISO
using	O	O
a	O	O
large	O	O
dataset	O
.	O	O

An	O	O
administrative	O
health	O
care	O
database	O
including	O	O
8	O	O
years	O
of	O	O
records	O	O
from	O	O
2	O	O
large	O	O
commercial	O	O
insurers	O
and	O	O
Medicare	O
(	O	O
a	O	O
5	O	O
%	O	O
random	B-PROC
sample	I-PROC
)	O	O
was	O	O
queried	O	O
to	O	O
identify	O	O
all	O	O
knee	B-PROC
arthroscopies	I-PROC
performed	O
on	O	O
patients	B-LIVB
aged	B-PHYS
at	O	O
least	O	O
15	O	O
years	O
using	O	O
Current	O
Procedural	O
Terminology	O
(	O
CPT	O
)	O
codes	O
.	O	O

Each	O	O
CPT	O
code	O
was	O	O
designated	O	O
as	O	O
a	O	O
high	B-PROC
-	I-PROC
or	O	O
low	B-PROC
-	I-PROC
complexity	I-PROC
procedure	I-PROC
,	O	O
with	O	O
the	O	O
former	O	O
typically	O	O
requiring	O	O
accessory	O	O
incisions	B-PROC
or	O	O
increased	O	O
operative	O
time	O
.	O	O

Deep	O	O
infections	B-DISO
were	O	O
identified	O	O
by	O	O
a	O	O
CPT	O
code	O
for	O	O
incision	B-PROC
and	O	O
drainage	B-PROC
within	O	O
90	O	O
days	O
of	O	O
surgery	O
.	O	O

Superficial	B-DISO
infections	I-DISO
were	O	O
identified	O	O
by	O	O
International	O
Classification	O
of	O
Diseases	O
,	O
Ninth	O
Revision	O
infection	O
codes	O
without	O	O
any	O	O
record	O
of	O	O
incision	B-PROC
and	O	O
drainage	B-PROC
.	O	O

Patients	B-LIVB
were	O	O
compared	O	O
based	O	O
on	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O	O
tobacco	O
use	O
,	O	O
presence	O
of	O	O
diabetes	B-DISO
,	O	O
and	O	O
Charlson	O
Comorbidity	O
Index	O
.	O	O

A	O	O
total	O	O
of	O	O
526	O	O
,	O	O
537	O	O
patients	B-LIVB
underwent	O	O
595	O	O
,	O	O
083	O	O
arthroscopic	B-PROC
knee	I-PROC
procedures	I-PROC
.	O	O

Deep	O	O
postoperative	B-DISO
infections	I-DISO
occurred	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
0	O	O
.	O	O

22	O	O
%	O	O
.	O	O

Superficial	B-DISO
infections	I-DISO
occurred	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
0	O	O
.	O	O

29	O	O
%	O	O
.	O	O

Tobacco	O
use	O
and	O	O
morbid	B-DISO
obesity	I-DISO
were	O	O
the	O	O
largest	O	O
risk	B-DISO
factors	I-DISO
for	O	O
deep	B-DISO
and	O	O
superficial	B-DISO
infections	I-DISO
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
.001	O	O
;	O	O
relative	O
risk	O
of	O	O
1	O	O
.	O	O
90	O	O
and	O	O
2	O	O
.	O	O
19	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

There	O	O
were	O	O
also	O	O
higher	O	O
infection	B-DISO
rates	I-DISO
among	O	O
patients	B-LIVB
undergoing	O	O
relatively	O	O
high	B-PROC
-	I-PROC
complexity	I-PROC
arthroscopies	I-PROC
,	O	O
men	B-LIVB
,	O	O
obese	B-DISO
patients	B-LIVB
,	O	O
diabetic	B-DISO
patients	B-LIVB
,	O	O
and	O	O
younger	O
patients	B-LIVB
(	O	O
in	O	O
order	O	O
of	O	O
decreasing	O	O
relative	O
risk	O
)	O	O
.	O	O

Increased	O	O
Charlson	O
Comorbidity	O
Index	O
was	O	O
associated	O
with	O
superficial	B-DISO
and	O	O
total	B-DISO
infections	I-DISO
(	O	O
P	O	O
<	O	O
.001	O	O
)	O	O
.	O	O

Post	O
-	O
arthroscopic	O
knee	B-DISO
infections	I-DISO
were	O	O
more	O	O
frequent	O	O
among	O	O
morbidly	B-DISO
obese	I-DISO
patients	B-LIVB
,	O	O
tobacco	B-DISO
users	I-DISO
,	O	O
patients	B-LIVB
undergoing	O	O
relatively	O	O
complex	B-PROC
procedures	I-PROC
,	O	O
men	B-LIVB
,	O	O
obese	B-LIVB
patients	I-LIVB
,	O	O
diabetic	B-LIVB
patients	I-LIVB
,	O	O
relatively	O	O
young	B-LIVB
patients	I-LIVB
,	O	O
and	O	O
patients	B-LIVB
with	O	O
increased	O	O
comorbidity	O
burdens	O	O
in	O	O
this	O	O
study	O	O
population	O
.	O	O

This	O	O
knowledge	O	O
may	O	O
allow	O	O
more	O	O
informed	O	O
preoperative	B-PROC
counseling	I-PROC
,	O	O
aid	B-LIVB
surgeons	I-LIVB
in	O	O
patient	B-PROC
selection	I-PROC
,	O	O
and	O	O
facilitate	O	O
infection	B-PROC
prevention	I-PROC
by	O	O
targeting	O	O
individuals	B-LIVB
with	O	O
higher	O	O
inherent	O
risk	O
.	O	O

Level	O	O
IV	O	O
,	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
.	O	O

A	O	O
Case	O	O
Presenting	O	O
with	O	O
Splenic	B-DISO
Infarct	I-DISO
Diagnosed	B-DISO
as	O	O
Primary	O
Bone	O
Marrow	O
CD5	B-ANAT
Positive	I-ANAT
DLBCL	B-DISO
:	O	O
A	O	O
Clinicopathological	O
Correlation	O
De	O
novo	O
CD5	B-ANAT
+	I-ANAT
Diffuse	B-DISO
large	I-DISO
B	I-DISO
cell	I-DISO
lymphoma	I-DISO
(	O	O
DLBCL	B-DISO
)	O	O
is	O	O
a	O	O
rare	O
and	O	O
aggressive	B-DISO
subtype	I-DISO
of	O	O
DLBCL	B-DISO
.	O	O

It	O	O
is	O	O
a	O	O
distinct	O	O
clinicopathologic	B-DISO
entity	B-OBJC
with	O	O
complex	O
molecular	O
profile	O
and	O	O
poor	B-DISO
prognosis	I-DISO
.	O	O

A	O	O
59	O	O
year	O
old	O	O
female	B-PHYS
presented	B-DISO
with	I-DISO
pyrexia	B-DISO
of	I-DISO
unknown	I-DISO
origin	I-DISO
since	O	O
1	O	O
month	O
.	O	O

On	O	O
examination	B-PROC
,	O	O
there	O	O
was	O	O
severe	B-DISO
pallor	I-DISO
,	O	O
hepatosplenomegaly	B-DISO
and	O	O
no	O
palpable	O
lymphadenopathy	B-DISO
.	O	O

Complete	B-PROC
blood	I-PROC
count	I-PROC
revealed	O
bicytopenia	B-PHEN
with	O	O
normal	B-DISO
total	I-DISO
leucocyte	I-DISO
count	I-DISO
.	O	O

Liver	B-PROC
and	O	O
renal	B-PROC
function	I-PROC
tests	I-PROC
were	O	O
normal	O
.	O	O

Ultrasonography	B-PROC
abdomen	I-PROC
revealed	O
splenic	B-DISO
enlargement	I-DISO
with	O	O
two	B-DISO
focal	I-DISO
lesions	I-DISO
attributed	O	O
to	O	O
either	O	O
splenic	B-DISO
abscess	I-DISO
or	O	O
infarcts	B-DISO
.	O	O

Patient	B-LIVB
was	O	O
being	O	O
managed	O	O
as	O	O
splenic	B-DISO
infarct	I-DISO
but	O	O
continued	O	O
to	O	O
have	O	O
bicytopenia	B-PHEN
.	O	O

Further	O	O
investigation	B-PROC
showed	O	O
elevated	B-DISO
serum	I-DISO
ferritin	I-DISO
,	O	O
triglycerides	B-DISO
and	O	O
LDH	B-PHEN
.	O	O

With	O	O
a	O	O
clinical	O
suspicion	B-PHYS
of	O	O
infection	B-DISO
and	O	O
haemophagocytic	B-DISO
lymphohistiocytosis	I-DISO
bone	B-PROC
marrow	I-PROC
aspiration	I-PROC
(	I-PROC
BMA	I-PROC
)	I-PROC
and	I-PROC
biopsy	I-PROC
(	I-PROC
BMBx	I-PROC
)	I-PROC
was	O	O
done	O	O
.	O	O

BMA	O	O
showed	O	O
extensive	O
haemophagocytosis	B-DISO
and	O	O
~7	O	O
.	O	O

4	O	O
%	O	O
large	B-DISO
lymphoma	I-DISO
-	I-DISO
like	I-DISO
cells	I-DISO
.	O	O

On	O	O
this	O	O
basis	O	O
PET	B-PROC
-	I-PROC
CT	I-PROC
was	O	O
suggested	O	O
which	O	O
showed	O	O
enlarged	B-DISO
spleen	I-DISO
with	O	O
diffuse	B-DISO
uptake	I-DISO
.	O	O

BMBx	B-PROC
showed	O	O
nodular	B-DISO
and	O	O
intrasinusoidal	O
collection	O	O
of	O	O
abnormal	B-ANAT
lymphoid	I-ANAT
cells	I-ANAT
.	O	O

On	O	O
immunohistochemistry	B-PROC
,	O	O
these	O	O
cells	B-ANAT
were	O	O
positive	B-PHEN
for	I-PHEN
CD20	I-PHEN
,	O	O
CD5	B-CHEM
,	O	O
MUM1	B-CHEM
,	O	O
BCL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
BCL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O	O
negative	B-DISO
for	O	O
CD3	B-CHEM
,	O	O
CD10	B-CHEM
and	O	O
CD23	B-CHEM
.	O	O

CD34	B-CHEM
highlighted	O	O
focal	O
intrasinusoidal	O
pattern	O
.	O	O

The	O	O
complete	O	O
clinicopathological	B-PROC
profile	I-PROC
suggested	O	O
the	O	O
diagnosis	B-DISO
of	O	O
de	O
novo	O
CD5	B-ANAT
+	I-ANAT
DLBCL	B-DISO
,	O	O
with	O	O
primary	B-DISO
hepatosplenic	I-DISO
pattern	O
of	O	O
involvement	O	O
.	O	O

CD5	B-ANAT
+	I-ANAT
DLBCL	B-DISO
presenting	O	O
as	O	O
splenic	B-DISO
infarct	I-DISO
is	O	O
very	B-DISO
rare	I-DISO
.	O	O

This	O	O
case	O	O
was	O	O
unusual	O
as	O	O
the	O	O
diagnosis	B-DISO
of	O	O
a	O	O
primary	B-DISO
aggressive	I-DISO
lymphoma	I-DISO
with	O	O
haemophagocytosis	B-DISO
was	O	O
established	O
in	O	O
a	O	O
patient	B-LIVB
who	O	O
presented	O	O
with	O	O
fever	B-DISO
and	O	O
splenic	B-DISO
infarct	I-DISO
without	O	O
lymphadenopathy	B-DISO
.	O	O

This	O	O
indicates	O	O
the	O	O
importance	O	O
of	O	O
good	O	O
morphological	O
assessment	O
of	O	O
a	O	O
bone	B-ANAT
marrow	I-ANAT
aspirate	I-ANAT
and	O	O
biopsy	B-PROC
to	O	O
make	O	O
a	O	O
correct	B-DISO
diagnosis	I-DISO
.	O	O

Slow	B-DISO
-	I-DISO
Growing	I-DISO
Large	O
Irritation	B-DISO
Fibroma	I-DISO
of	O	O
the	O	O
Anterior	B-ANAT
Hard	I-ANAT
Palate	I-ANAT
:	O	O
A	O	O
Case	O
Report	O
Using	O	O
Immunohistochemical	B-PROC
Analysis	I-PROC
Irritation	B-DISO
fibromas	I-DISO
are	O	O
recognized	O	O
as	O	O
fibrous	O
lesions	B-DISO
,	O	O
usually	O	O
reactive	B-DISO
hyperplasias	I-DISO
;	O	O
however	O	O
,	O	O
the	O	O
mechanism	B-PROC
of	I-PROC
enlargement	I-PROC
is	O	O
unclear	O	O
.	O	O

This	O	O
paper	O	O
reports	O	O
on	O	O
an	O	O
abnormally	B-DISO
large	O	O
irritation	B-DISO
fibroma	I-DISO
of	O	O
extremely	O	O
gradual	B-DISO
growth	I-DISO
.	O	O

The	O	O
immunohistochemical	B-PROC
features	O
(	O	O
CD34	B-CHEM
,	O	O
α	B-CHEM
-	I-CHEM
SMA	I-CHEM
,	O	O
vimentin	B-CHEM
,	O	O
Ki	B-CHEM
-	I-CHEM
67	I-CHEM
,	O	O
and	O	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
)	O	O
of	O	O
this	O	O
irritation	B-DISO
fibroma	I-DISO
are	O	O
presented	O	O
to	O	O
distinguish	O	O
reactive	O	O
hyperplasia	B-DISO
from	O	O
other	O	O
true	B-DISO
fibrous	I-DISO
neoplasm	I-DISO
diseases	I-DISO
.	O	O

In	O	O
the	O	O
only	O	O
previous	O	O
study	O	O
,	O	O
it	O	O
was	O	O
reported	B-PROC
that	O	O
the	O	O
expression	B-PHYS
of	O	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
might	O	O
be	O	O
associated	O
with	O
the	O	O
development	O	O
of	O	O
oral	B-DISO
fibromas	I-DISO
.	O	O

Therefore	O	O
,	O	O
we	O	O
investigated	O
the	O	O
relationship	O
between	O	O
this	O	O
exceptionally	O	O
-	O	O
large	O	O
fibrous	O
lesion	B-DISO
of	O	O
extremely	O	O
slow	B-DISO
growth	I-DISO
and	O	O
the	O	O
immunohistochemical	O
reactivity	O
of	O	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
,	O	O
finding	O	O
that	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
previous	O	O
study	O	O
,	O	O
TGF	B-CHEM
-	I-CHEM
α	I-CHEM
was	O	O
not	O	O
expressed	B-PHYS
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
study	O	O
to	O	O
evaluate	B-PROC
the	O	O
enlargement	B-PROC
mechanism	I-PROC
of	O	O
such	O	O
a	O	O
large	O	O
irritation	B-DISO
fibroma	I-DISO
using	O	O
the	O	O
approach	O	O
of	O	O
immunohistochemical	B-PROC
analysis	I-PROC
,	O	O
and	O	O
it	O	O
indicates	O	O
that	O	O
such	O	O
analysis	B-PROC
can	O	O
help	O	O
elucidate	O	O
the	O	O
diverse	O	O
causes	O
and	O	O
enlargement	B-PROC
mechanisms	I-PROC
of	O	O
irritation	B-DISO
fibromas	I-DISO
.	O	O

Mass	B-PROC
-	I-PROC
spectrometry	I-PROC
analysis	B-PROC
of	O	O
histone	B-PHYS
post	I-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
in	O	O
pathology	O
tissue	O
using	O	O
the	O	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
approach	O	O
Aberrant	O
histone	B-PHYS
post	I-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
(	O	O
hPTMs	B-PHYS
)	O	O
have	O	O
been	O	O
implicated	O	O
with	O	O
various	O	O
pathologies	O
,	O	O
including	O	O
cancer	B-DISO
,	O	O
and	O	O
may	O	O
represent	O	O
useful	O	O
epigenetic	B-PHYS
biomarkers	I-PHYS
.	O	O

The	O	O
data	O
described	O	O
here	O	O
provide	O	O
a	O	O
mass	B-PROC
spectrometry	I-PROC
-based	O	O
quantitative	O
analysis	B-PROC
of	O	O
hPTMs	B-PHYS
from	O	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
tissues	O
,	O	O
from	O	O
which	O	O
histones	B-CHEM
were	O	O
extracted	B-PROC
through	O	O
the	O	O
recently	O	O
developed	O	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
method	I-PROC
.	O	O

First	O	O
,	O	O
we	O	O
analyzed	B-PROC
FFPE	O
samples	O
from	O	O
mouse	O
spleen	O
and	O	O
liver	B-ANAT
or	O	O
human	B-LIVB
breast	B-DISO
cancer	I-DISO
up	O	O
to	O	O
six	O	O
years	O
old	O	O
,	O	O
together	O	O
with	O	O
their	O	O
corresponding	O	O
fresh	B-ANAT
frozen	O
tissue	O
.	O	O

We	O	O
then	O	O
combined	O	O
the	O	O
PAT	B-PROC
-	I-PROC
H	I-PROC
-	I-PROC
MS	I-PROC
approach	O	O
with	O	O
a	O	O
histone	B-CHEM
-focused	O	O
version	O	O
of	O	O
the	O	O
super	B-PROC
-	I-PROC
SILAC	I-PROC
strategy	I-PROC
-using	O	O
a	O	O
mix	O	O
of	O	O
histones	B-CHEM
from	O	O
four	O	O
breast	B-ANAT
cancer	I-ANAT
cell	I-ANAT
lines	I-ANAT
as	O	O
a	O	O
spike	O
-	O
in	O
standard	O
-	O	O
to	O	O
accurately	O	O
quantify	O
hPTMs	B-PHYS
from	O	O
breast	B-DISO
cancer	I-DISO
specimens	B-OBJC
belonging	O	O
to	O	O
different	O	O
subtypes	O
.	O	O

The	O	O
data	O
,	O	O
which	O	O
are	O	O
associated	O
with	O
a	O	O
recent	O	O
publication	B-OBJC
(	O	O
Pathology	O
tissue	O
-	O	O
quantitative	B-PROC
mass	I-PROC
spectrometry	I-PROC
analysis	B-PROC
to	O	O
profile	B-PROC
histone	B-CHEM
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modification	I-PHYS
patterns	I-PHYS
in	O	O
patient	B-LIVB
samples	B-OBJC
(	O	O
Noberini	O	O
,	O	O
2015	O	O
)	O	O
[	O	O
1	O	O
]	O	O
)	O	O
,	O	O
are	O	O
deposited	O
at	O	O
the	O	O
ProteomeXchange	B-LIVB
Consortium	I-LIVB
via	O	O
the	O	O
PRIDE	O	O
partner	O	O
repository	B-OBJC
with	O	O
the	O	O
dataset	O
identifier	O
PXD002669	O
.	O	O

Pregnancy	B-PHYS
suppresses	O
the	O	O
daily	B-PHYS
rhythmicity	I-PHYS
of	O	O
core	B-DISO
body	I-DISO
temperature	I-DISO
and	O	O
adipose	O
metabolic	B-PHYS
gene	I-PHYS
expression	I-PHYS
in	O	O
the	O	O
mouse	B-LIVB
Maternal	B-DISO
adaptations	B-PHEN
in	O	O
lipid	B-PHYS
metabolism	I-PHYS
are	O	O
crucial	O	O
for	O	O
pregnancy	B-PHYS
success	O	O
due	O	O
to	O	O
the	O	O
role	O	O
of	O	O
white	O
adipose	O
tissue	O
as	O	O
an	O	O
energy	O
store	O	O
and	O	O
the	O	O
dynamic	O	O
nature	O	O
of	O	O
energy	O
needs	O	O
across	O	O
gestation	B-PHYS
.	O	O

Because	O	O
lipid	B-PHYS
metabolism	I-PHYS
is	O	O
regulated	O	O
by	O	O
the	O	O
rhythmic	B-PHYS
expression	B-PHYS
of	O	O
clock	O
genes	O
,	O	O
it	O	O
was	O	O
hypothesised	O	O
that	O	O
maternal	B-DISO
metabolic	B-PHEN
adaptations	I-PHEN
involve	O	O
changes	O	O
in	O	O
both	O	O
adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
and	O	O
the	O	O
rhythmic	B-PHYS
expression	B-PHYS
of	O	O
downstream	O	O
metabolic	O
genes	O
.	O	O

Maternal	B-DISO
core	B-DISO
body	I-DISO
temperature	I-DISO
(	O	O
Tc	B-DISO
)	O	O
was	O	O
investigated	O	O
as	O	O
a	O	O
possible	O	O
mechanism	O	O
driving	O	O
pregnancy	B-PHYS
-induced	O	O
changes	O	O
in	O	O
clock	O
gene	B-PHYS
expression	I-PHYS
.	O	O

Gonadal	B-ANAT
adipose	O
tissue	O
and	O	O
plasma	B-ANAT
were	O	O
collected	O	O
from	O	O
C57Bl	B-LIVB
/	I-LIVB
6J	I-LIVB
mice	I-LIVB
before	O	O
and	O	O
on	O	O
days	O
6	O	O
,	O	O
10	O	O
,	O	O
14	O	O
and	O	O
18	O	O
of	O	O
pregnancy	B-PHYS
(	O	O
term	O	O
=	O	O
d19	O	O
)	O	O
at	O	O
4	O	O
hourly	O
intervals	O	O
across	O	O
a	O	O
24	O	O
-	O	O
h	O	O
period	O	O
.	O	O

Adipose	O
expression	B-PHYS
of	O	O
clock	O
genes	O
and	O	O
downstream	O	O
metabolic	O
genes	O
were	O	O
determined	O	O
by	O	O
RT	B-PROC
-	I-PROC
qPCR	I-PROC
and	O	O
Tc	B-DISO
was	O	O
measured	O	O
by	O	O
intraperitoneal	O
temperature	B-PHYS
loggers	O	O
.	O	O

Adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
showed	O	O
robust	O	O
rhythmicity	O
throughout	O	O
pregnancy	B-PHYS
,	O	O
but	O	O
absolute	O	O
levels	O	O
varied	O	O
substantially	O	O
across	O	O
gestation	B-PHYS
.	O	O

Rhythmic	B-PHYS
expression	B-PHYS
of	O	O
the	O	O
metabolic	O
genes	O
Lipe	O
,	O	O
Pnpla2	O
and	O	O
Lpl	O
was	O	O
clearly	O	O
evident	O	O
before	O	O
pregnancy	B-PHYS
;	O	O
however	O	O
,	O	O
this	O	O
rhythmicity	O
was	O	O
lost	O	O
with	O	O
the	O	O
onset	O	O
of	O	O
pregnancy	B-PHYS
.	O	O

Tc	B-DISO
rhythm	B-PHYS
was	O	O
significantly	O	O
altered	O	O
by	O	O
pregnancy	B-PHYS
with	O	O
a	O	O
65	O	O
%	O	O
decrease	O	O
in	O	O
amplitude	O	O
by	O	O
term	O	O
and	O	O
a	O	O
0	O	O
.	O	O

61°C	O	O
decrease	O	O
in	O	O
mesor	O	O
between	O	O
days	O
6	O	O
and	O	O
18	O	O
.	O	O

These	O	O
changes	O	O
in	O	O
Tc	B-DISO
,	O	O
however	O	O
,	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
linked	O	O
to	O	O
adipose	O
clock	O
gene	B-PHYS
expression	I-PHYS
across	O	O
pregnancy	B-PHYS
.	O	O

Overall	O	O
,	O	O
our	O	O
data	O
show	O	O
marked	O	O
adaptations	B-PHEN
in	O	O
the	O	O
adipose	O
clock	O
in	O	O
pregnancy	B-PHYS
,	O	O
with	O	O
an	O	O
apparent	O	O
decoupling	O	O
of	O	O
adipose	O
clock	O
and	O	O
lipolytic	O
/	O	O
lipogenic	O
gene	O
rhythms	B-PHYS
from	O	O
early	O
in	O	O
gestation	B-PHYS
.	O	O

Bilateral	O
en	B-PROC
-	I-PROC
masse	I-PROC
distalization	I-PROC
of	O	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
with	O	O
skeletal	O
anchorage	O
:	O	O
a	O	O
case	O
report	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
introduce	O	O
a	O	O
new	O	O
method	O	O
for	O	O
bilateral	O
distal	O
movement	B-PROC
of	O	O
the	O	O
entire	B-ANAT
maxillary	I-ANAT
posterior	I-ANAT
segment	I-ANAT
.	O	O

A	O	O
17	O	O
-	O	O
year	O
-	O	O
old	B-LIVB
girl	I-LIVB
with	O	O
Class	O	O
I	O	O
skeletal	B-DISO
malocclusion	I-DISO
(	O	O
end	O
-	O
to	O
-	O
end	O
molar	O
relationships	O
,	O	O
deviated	O	O
midline	O
and	O	O
space	B-ANAT
deficiency	O
for	O	O
left	B-ANAT
maxillary	I-ANAT
canine	I-ANAT
)	O	O
was	O	O
referred	O	O
for	O	O
orthodontic	B-PROC
treatment	I-PROC
.	O	O

She	O	O
did	O	O
not	O	O
accept	O	O
maxillary	B-ANAT
first	O	O
premolars	B-PROC
extraction	I-PROC
.	O	O

A	O	O
modified	O	O
Hyrax	B-DEVI
appliance	I-DEVI
(	O	O
Dentaurum	O
Ispringen	O
,	O	O
Germany	B-GEOG
)	O	O
was	O	O
used	O	O
for	O	O
bilateral	O
distalization	B-PROC
of	O	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
simultaneously	O
.	O	O

Expansion	O	O
vector	O	O
was	O	O
set	O	O
anteroposteriorly	O
.	O	O

Posterior	B-DEVI
legs	I-DEVI
of	I-DEVI
Hyrax	I-DEVI
were	O	O
welded	O	O
to	O	O
first	O	O
maxillary	B-ANAT
molar	I-ANAT
bands	I-ANAT
.	O	O

All	O	O
posterior	O
teeth	B-ANAT
on	O	O
each	O	O
side	O	O
consolidated	O
with	O	O
a	O	O
segment	O
of	O	O
0	O	O
.	O	O

017	O	O
×	O	O
0	O	O
.	O	O
025	O	O
-	O	O
in	O	O
stainless	B-DEVI
steel	I-DEVI
wire	I-DEVI
from	O	O
the	O	O
buccal	O
side	O	O
.	O	O

Anterior	B-DEVI
legs	I-DEVI
of	I-DEVI
Hyrax	I-DEVI
were	O	O
bent	O	O
into	O	O
eyelet	O
form	O	O
and	O	O
attached	O	O
to	O	O
the	O	O
anterior	O
palate	B-ANAT
with	O	O
two	O	O
mini	O
-	O
screws	O
(	O	O
2	O	O
×	O	O
10	O	O
mm	O	O
)	O	O
(	O	O
Jeil	O
Medical	O
Corporation	O
Seoul	B-GEOG
,	O	O
South	B-GEOG
Korea	I-GEOG
)	O	O
.	O	O

Hyrax	O
opening	O
rate	O
was	O	O
0	O	O
.	O	O

8	O	O
mm	O	O
per	O	O
month	O
.	O	O

Lateral	B-DEVI
cephalometric	I-DEVI
radiographs	I-DEVI
were	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
extent	O
of	O	O
distal	O
movement	B-PROC
.	O	O

3	O	O
.	O	O
5	O	O
-	O	O
mm	O	O
distalization	B-PROC
of	O	O
posterior	B-ANAT
maxillary	I-ANAT
teeth	I-ANAT
was	O	O
achieved	O	O
in	O	O
five	O	O
months	O
.	O	O

A	O	O
nearly	O	O
bodily	O	O
distal	O
movement	B-PROC
without	O	O
anchorage	O
loss	O	O
was	O	O
obtained	O
.	O	O

The	O	O
mini	O
-	O
screw	O
-supported	O	O
modified	O
Hyrax	B-DEVI
appliance	I-DEVI
was	O	O
found	O	O
to	O	O
be	O	O
helpful	O	O
for	O	O
achieving	O	O
en	O	O
-	O	O
masse	O	O
distal	O
movement	B-PROC
of	O	O
maxillary	B-ANAT
posterior	I-ANAT
teeth	I-ANAT
.	O	O

Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
regulate	O	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
in	O	O
colorectal	B-DISO
cancer	I-DISO
via	O	O
transcriptional	B-PHYS
activation	I-PHYS
and	O	O
mRNA	B-PHYS
stabilization	I-PHYS
Histone	B-CHEM
deacetylase	I-CHEM
inhibitors	I-CHEM
(	O	O
HDACIs	B-CHEM
)	O	O
are	O	O
emerging	O	O
as	O	O
a	O	O
novel	O
class	O
of	O	O
anti	B-CHEM
-	I-CHEM
tumor	I-CHEM
drugs	I-CHEM
.	O	O

But	O	O
the	O	O
effect	O
of	O	O
HDACIs	B-CHEM
in	O	O
tumors	B-DISO
treatment	B-PROC
has	O	O
been	O	O
disappointing	O	O
,	O	O
which	O	O
mainly	O	O
due	O	O
to	O	O
the	O	O
acquisition	O
of	O	O
resistance	B-PHEN
to	O	O
HDACIs	B-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
underlying	O	O
mechanisms	B-DISO
have	O	O
not	O	O
been	O	O
clearly	O	O
understood	O	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
it	O	O
was	O	O
found	O	O
that	O	O
HDACIs	B-CHEM
SAHA	B-CHEM
and	O	O
TSA	B-CHEM
increased	O	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
in	O	O
CRC	B-ANAT
cells	I-ANAT
,	O	O
which	O	O
has	O	O
been	O	O
well	O	O
known	O	O
to	O	O
contribute	O
to	O	O
drug	B-PHEN
resistant	I-PHEN
.	O	O

The	O	O
mechanisms	B-DISO
underlying	O	O
these	O	O
effects	O
were	O	O
investigated	O
.	O	O

We	O	O
showed	O	O
that	O	O
HDACIs	B-CHEM
enhanced	O
transcriptional	B-PHYS
activity	I-PHYS
of	O	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
protein	O
encoding	O
gene	O
ABCB1	O
.	O	O

HDACIs	B-CHEM
treatment	B-PROC
also	O	O
increased	O	O
the	O	O
protein	B-CHEM
and	O	O
mRNA	B-PHYS
expression	I-PHYS
of	O	O
STAT3	B-CHEM
,	O	O
but	O	O
not	O	O
PXR	B-CHEM
,	O	O
CAR	B-CHEM
,	O	O
Foxo3a	B-CHEM
or	O	O
β	B-CHEM
-	I-CHEM
catenin	I-CHEM
,	O	O
which	O	O
are	O	O
known	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
ABCB	B-PHYS
transcription	I-PHYS
regulation	I-PHYS
.	O	O

Interestingly	O	O
,	O	O
knockdown	B-PROC
of	O	O
STAT3	B-CHEM
significantly	O	O
attenuated	O
HDACIs	B-CHEM
-	O	O
induced	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
up	B-PHYS
-	I-PHYS
regulation	I-PHYS
in	O	O
colorectal	B-ANAT
cancer	I-ANAT
cells	I-ANAT
,	O	O
suggesting	O	O
that	O	O
STAT3	B-CHEM
plays	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
HDACIs	B-CHEM
-	O	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
P	B-CHEM
-	I-CHEM
gp	I-CHEM
.	O	O

Furthermore	O	O
,	O	O
this	O	O
study	B-PROC
revealed	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
HDACIs	B-CHEM
enhanced	O
the	O	O
stability	B-PHYS
of	I-PHYS
ABCB1	I-PHYS
at	O	O
post	B-PHYS
-	I-PHYS
transcriptional	I-PHYS
level	I-PHYS
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	B-DISO
proved	O	O
that	O	O
HDACIs	B-CHEM
induced	O
P	B-CHEM
-	I-CHEM
gp	I-CHEM
expression	B-PHYS
by	O	O
two	O	O
distinct	O	O
ways	O	O
,	O	O
transcriptional	B-PHYS
activation	I-PHYS
and	O	O
mRNA	B-PHYS
stabilization	I-PHYS
.	O	O

Our	O	O
results	B-DISO
suggested	O
that	O	O
more	O	O
attention	O	O
should	O	O
be	O	O
paid	O	O
to	O	O
the	O	O
cancer	B-PROC
treatment	I-PROC
using	O	O
HDACIs	B-CHEM
since	O	O
they	O	O
will	O	O
induce	O
multidrug	B-PHYS
resistance	I-PHYS
in	O	O
cancer	B-ANAT
cells	I-ANAT
.	O	O

Mother	B-LIVB
-	O	O
Infant	B-LIVB
Emotion	B-PHYS
Regulation	I-PHYS
at	O	O
Three	O
Months	O
:	O	O
The	O	O
Role	O
of	O	O
Maternal	B-PHYS
Anxiety	I-PHYS
,	O	O
Depression	B-DISO
and	O	O
Parenting	B-DISO
Stress	I-DISO
While	O	O
the	O	O
association	O
between	O	O
anxiety	B-PHYS
and	O	O
postpartum	B-DISO
depression	I-DISO
is	O	O
well	O	O
known	O	O
,	O	O
few	O	O
studies	B-PROC
have	O	O
investigated	O
the	O	O
relationship	O
between	O	O
these	O	O
two	O	O
states	O
and	O	O
parenting	B-DISO
stress	I-DISO
.	O	O

Furthermore	O	O
,	O	O
a	O	O
number	O	O
of	O	O
studies	B-PROC
have	O	O
found	O	O
that	O	O
postpartum	B-DISO
depression	I-DISO
affects	O	O
mother	B-LIVB
-	O	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
,	O	O
but	O	O
there	O	O
has	O	O
been	O	O
only	O	O
one	O	O
study	B-PROC
on	O	O
anxiety	B-PHYS
and	O	O
emotion	B-PHYS
regulation	I-PHYS
and	O	O
no	O	O
studies	B-PROC
at	O	O
all	O	O
on	O	O
parenting	B-DISO
stress	I-DISO
and	O	O
emotion	B-PHYS
regulation	I-PHYS
.	O	O

Therefore	O	O
,	O	O
the	O	O
primary	O	O
aim	O	O
of	O	O
our	O	O
study	B-PROC
is	O	O
to	O	O
identify	O	O
,	O	O
in	O	O
a	O	O
community	B-LIVB
sample	B-OBJC
of	O	O
71	O	O
mothers	B-LIVB
,	O	O
the	O	O
relationship	O
between	O	O
maternal	B-DISO
depression	I-DISO
,	O	O
anxiety	B-PHYS
,	O	O
and	O	O
parenting	B-DISO
stress	I-DISO
.	O	O

The	O	O
second	O	O
aim	O	O
is	O	O
to	O	O
examine	O	O
the	O	O
relationship	O
between	O	O
anxiety	B-PHYS
,	O	O
postpartum	B-DISO
depression	I-DISO
,	O	O
and	O	O
parenting	B-DISO
stress	I-DISO
and	O	O
mother	B-LIVB
-	O	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
assessed	O
at	O	O
3	O
months	O
.	O	O

Mother	B-LIVB
-	O	O
infant	B-LIVB
interaction	O
was	O	O
coded	O
with	O	O
a	O	O
modified	O
version	O
of	O	O
the	O	O
Infant	O
Caregiver	O
and	O
Engagement	O
Phases	O
(	O	O
ICEP	O
)	O	O
using	O	O
a	O	O
microanalytic	B-PROC
approach	I-PROC
.	O	O

The	O	O
Edinburgh	O
Postnatal	O
Depression	O
Scale	O
(	O	O
EPDS	O
)	O	O
,	O	O
State	B-PROC
-	I-PROC
Trait	I-PROC
Anxiety	I-PROC
Inventory	I-PROC
(	O	O
STAI	B-PROC
)	O	O
,	O	O
and	O	O
Parenting	O
Stress	O
Index	O
-	O
Short	O
Form	O
(	O	O
PSI	O
-	O
SF	O
)	O	O
were	O	O
administered	O	O
to	O	O
the	O	O
mothers	B-LIVB
to	O	O
assess	B-PROC
depression	B-DISO
,	O	O
anxiety	B-PHYS
,	O	O
and	O	O
parenting	B-DISO
stress	I-DISO
,	O	O
respectively	O	O
.	O	O

Analysis	B-PROC
revealed	O	O
correlations	O
between	O	O
anxiety	B-PHYS
and	O	O
depression	B-DISO
,	O	O
showing	O	O
that	O	O
parenting	B-DISO
stress	I-DISO
is	O	O
associated	O
with	O
both	O	O
states	O
.	O	O

In	O	O
a	O	O
laboratory	B-PHEN
observation	I-PHEN
,	O	O
depression	B-DISO
was	O	O
correlated	O
with	O	O
both	O	O
negative	B-DISO
maternal	B-DISO
states	O
and	O	O
negative	B-DISO
dyadic	O
matches	O
as	O	O
well	O	O
as	O	O
infant	B-LIVB
positive	B-DISO
/	O	O
mother	B-LIVB
negative	B-DISO
mismatches	O
;	O	O
anxiety	B-PHYS
was	O	O
correlated	O
with	O	O
both	O	O
negative	B-DISO
maternal	B-DISO
states	O
and	O	O
infant	B-LIVB
negative	B-DISO
states	O
as	O	O
well	O	O
as	O	O
mismatches	O
involving	O	O
one	O	O
of	O	O
the	O	O
partners	B-LIVB
having	O	O
a	O	O
negative	B-DISO
state	O
.	O	O

Multiple	O
regression	O
analysis	O
showed	O	O
that	O	O
anxiety	B-PHYS
is	O	O
a	O	O
greater	O	O
predictor	O
than	O	O
depression	B-DISO
of	O	O
less	O	O
adequate	O
styles	O
of	O	O
mother	B-LIVB
-	O	O
infant	B-LIVB
emotion	B-PHYS
regulation	I-PHYS
.	O	O

Parenting	B-DISO
stress	I-DISO
was	O	O
not	O	O
shown	O	O
to	O	O
predict	O
such	O	O
regulation	B-PHYS
.	O	O

Medical	B-DEVI
Devices	I-DEVI
;	O	O
Gastroenterology	B-DEVI
-	I-DEVI
Urology	I-DEVI
Devices	I-DEVI
;	O	O
Classification	O
of	O	O
the	O	O
Metallic	B-CHEM
Biliary	B-DEVI
Stent	I-DEVI
System	O
for	O	O
Benign	B-DISO
Strictures	I-DISO
.	O	O

Final	O	O
order	O	O
The	O	O
Food	O
and	O
Drug	O
Administration	O
(	O	O
FDA	O
)	O	O
is	O	O
classifying	O
the	O	O
metallic	B-CHEM
biliary	B-DEVI
stent	I-DEVI
system	O
for	O	O
benign	B-DISO
strictures	I-DISO
into	O	O
class	O
II	O
(	O	O
special	O
controls	O
)	O	O
.	O	O

The	O	O
special	O
controls	O
that	O	O
will	O	O
apply	O	O
to	O	O
the	O	O
device	B-DEVI
are	O	O
identified	O
in	O	O
this	O	O
order	O	O
and	O	O
will	O	O
be	O	O
part	O	O
of	O	O
the	O	O
codified	O
language	O
for	O	O
the	O	O
metallic	B-CHEM
biliary	B-DEVI
stent	I-DEVI
system	O
for	O	O
benign	B-DISO
strictures	I-DISO
'	O	O
classification	O
.	O	O

The	O	O
Agency	O
is	O	O
classifying	O
the	O	O
device	B-DEVI
into	O	O
class	O
II	O
(	O	O
special	O
controls	O
)	O	O
in	O	O
order	O	O
to	O	O
provide	O	O
a	O	O
reasonable	O	O
assurance	O	O
of	O	O
safety	B-PROC
and	O	O
effectiveness	O
of	O	O
the	O	O
device	B-DEVI
.	O	O

Environmental	B-DISO
Exposure	I-DISO
to	O	O
Cadmium	B-CHEM
:	O	O
Health	B-PROC
Risk	I-PROC
Assessment	I-PROC
and	O	O
its	O	O
Associations	O
with	O	O
Hypertension	B-DISO
and	O	O
Impaired	B-DISO
Kidney	I-DISO
Function	I-DISO
Cadmium	B-CHEM
(	O	O
Cd	B-CHEM
)	O	O
is	O	O
a	O	O
toxic	O
metal	B-CHEM
.	O	O

This	O	O
study	B-PROC
was	O	O
aimed	O	O
to	O	O
estimate	O	O
the	O	O
potential	O
health	O
risks	O
in	O	O
a	O	O
Cd	B-CHEM
-	O	O
polluted	B-PHEN
district	O	O
in	O	O
China	B-GEOG
,	O	O
and	O	O
examine	O	O
the	O	O
relationship	O
between	O	O
urinary	B-CHEM
cadmium	I-CHEM
(	O	O
UCd	B-CHEM
)	O	O
and	O	O
hypertension	B-DISO
and	O	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
at	O	O
low	O
exposure	O
levels	O
(	O	O
UCd	B-CHEM
:	O	O
GM	O	O
1	O	O
.	O	O
3	O	O
μg	O	O
/	O	O
g	O	O
creatinine	B-CHEM
)	O	O
.	O	O

Blood	B-PROC
pressure	I-PROC
measurement	I-PROC
,	O	O
questionnaires	O
,	O	O
and	O	O
collection	O	O
of	O	O
urinary	B-ANAT
samples	I-ANAT
were	O	O
conducted	O	O
from	O	O
217	O	O
residents	B-LIVB
.	O	O

Environmental	O
samples	B-OBJC
,	O	O
food	B-OBJC
,	O	O
and	O	O
cigarette	B-OBJC
samples	B-OBJC
were	O	O
collected	O
and	O	O
detected	B-DISO
to	O	O
estimate	O	O
the	O	O
risks	O
posed	O	O
by	O	O
Cd	B-CHEM
and	O	O
the	O	O
contribution	O	O
of	O	O
inhalation	B-DISO
,	O	O
ingestion	B-DISO
,	O	O
and	O	O
dermal	B-DISO
contact	I-DISO
pathways	I-DISO
to	O	O
these	O	O
risks	O
.	O	O

A	O	O
logistic	O
regression	O
model	O
was	O	O
used	O	O
in	O	O
examining	O	O
associations	O
between	O	O
exposure	O
and	O	O
hypertension	B-DISO
and	O	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
.	O	O

Results	O
show	O	O
that	O	O
this	O	O
population	B-LIVB
is	O	O
at	O	O
high	O	O
risk	O	O
.	O	O

For	O	O
non	B-DISO
-	I-DISO
smokers	I-DISO
,	O	O
incremental	O
lifetime	O
cancer	O
risk	O
(	O	O
ILCR	O
)	O	O
and	O	O
hazard	O
quotient	O
(	O	O
HQ	O
)	O	O
are	O	O
1	O	O
.	O	O

74E	O	O
-	O	O
04	O	O
and	O	O
2	O	O
.	O	O
96	O	O
,	O	O
and	O	O
for	O	O
smokers	B-DISO
,	O	O
they	O	O
are	O	O
1	O	O
.	O	O

07E	O	O
-	O	O
03	O	O
and	O	O
52	O	O
.	O	O
5	O	O
,	O	O
respectively	O	O
.	O	O

Among	O	O
all	O	O
exposure	O
pathways	O
,	O	O
smoking	O
and	O	O
foods	B-OBJC
cause	O	O
the	O	O
major	O	O
increases	O	O
in	O	O
ILCR	O
and	O	O
HQ	O
.	O	O

UCd	B-CHEM
is	O	O
significantly	O	O
associated	O	O
with	O	O
hypertension	B-DISO
(	O	O
odds	O
ratio	O
(	O	O
OR	O
)	O	O
=	O	O
1	O	O
.	O	O
468	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
(	O	O
CI	O
)	O	O
:	O	O
1	O	O
.	O	O
104	O	O
,	O	O
1	O	O
.	O	O
953	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
008	O	O
)	O	O
and	O	O
impaired	B-DISO
kidney	I-DISO
function	I-DISO
(	O	O
OR	O
=	O	O
1	O	O
.	O	O
902	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
054	O	O
,	O	O
3	O	O
.	O	O
432	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
033	O	O
)	O	O
.	O	O

The	O	O
results	O
demonstrate	O	O
that	O	O
Cd	B-CHEM
can	O	O
potentially	O	O
lead	O	O
to	O	O
adverse	O	O
health	O
effects	O
.	O	O

Altererythrobacter	B-LIVB
confluentis	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O	O
isolated	O	O
from	O	O
water	O	O
of	O	O
an	O	O
estuary	B-PHEN
environment	O	O
A	O	O
Gram	B-DISO
-	I-DISO
stain	I-DISO
-	I-DISO
negative	I-DISO
,	O	O
aerobic	O
,	O	O
non	B-LIVB
-	I-LIVB
motile	I-LIVB
and	O	O
ovoid	O
or	O	O
rod	O
-	O
shaped	O
bacterial	O
strain	O
,	O	O
designated	O	O
KEM	B-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
,	O	O
was	O	O
isolated	O	O
from	O	O
water	O	O
of	O	O
an	O	O
estuary	B-PHEN
environment	O	O
on	O	O
the	O	O
Yellow	B-GEOG
Sea	I-GEOG
,	O	O
South	B-GEOG
Korea	I-GEOG
,	O	O
and	O	O
subjected	O	O
to	O	O
a	O	O
polyphasic	B-PROC
taxonomic	I-PROC
study	I-PROC
.	O	O

Strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
grew	O	O
optimally	O	O
at	O	O
pH	O	O
7	O	O
.	O	O

0	O	O
-	O	O
8	O	O
.	O	O
0	O	O
,	O	O
at	O	O
30	O	O
°	O	O
C	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
1	O	O
.	O	O
0	O	O
-	O	O
2	O	O
.	O	O
0	O	O
%	O	O
(	O	O
w	O	O
/	O	O
v	O	O
)	O	O
NaCl	O	O
.	O	O

The	O	O
phylogenetic	O
trees	O	O
based	O	O
on	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	I-CHEM
sequences	I-CHEM
showed	O	O
that	O	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
fell	O	O
within	O	O
the	O	O
clade	O
comprising	O	O
the	O	O
type	O	O
strains	O	O
of	O	O
Altererythrobacter	B-LIVB
species	I-LIVB
,	O	O
clustering	O	O
with	O	O
the	O	O
type	O	O
strains	O	O
of	O	O
Altererythrobacter	B-LIVB
aestiaquae	I-LIVB
,	O	O
Altererythrobacter	B-LIVB
gangjinensis	I-LIVB
and	O	O
Altererythrobacter	B-LIVB
luteolus	I-LIVB
showing	O	O
95	O	O
.	O	O
0	O	O
-	O	O
96	O	O
.	O	O

5	O	O
%	O	O
sequence	O
similarity	O
.	O	O

Sequences	O
similarities	O
to	O	O
the	O	O
type	O	O
strains	O	O
of	O	O
the	O	O
other	O	O
Altererythrobacter	B-LIVB
species	I-LIVB
were	O	O
93	O	O
.	O	O
1	O	O
-	O	O
95	O	O
.	O	O
1	O	O
%	O	O
.	O	O

Strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
contained	O	O
Q	B-CHEM
-	I-CHEM
10	I-CHEM
as	O	O
the	O	O
predominant	O	O
ubiquinone	B-CHEM
and	O	O
C18	B-CHEM
:	I-CHEM
1	I-CHEM
ω7c	I-CHEM
,	O	O
summed	O	O
feature	O	O
3	O	O
(	O	O
C16	B-CHEM
:	I-CHEM
1	I-CHEM
ω6c	I-CHEM
and	O	O
/	O	O
or	O	O
C16	B-CHEM
:	I-CHEM
1	I-CHEM
ω7c	I-CHEM
)	O	O
and	O	O
C17	B-CHEM
:	I-CHEM
1	I-CHEM
ω6c	I-CHEM
as	O	O
the	O	O
major	O	O
fatty	B-CHEM
acids	I-CHEM
.	O	O

The	O	O
major	O	O
polar	O	O
lipids	B-CHEM
were	O	O
phosphatidylcholine	B-CHEM
,	O	O
phosphatidylethanolamine	B-CHEM
,	O	O
phosphatidylglycerol	B-CHEM
and	O	O
sphingoglycolipid	B-CHEM
.	O	O

The	O	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
was	O	O
59	O	O
.	O	O

5	O	O
mol	O	O
%	O	O
.	O	O

Differential	O	O
phenotypic	B-DISO
properties	I-DISO
,	O	O
together	O	O
with	O	O
the	O	O
phylogenetic	O
distinctiveness	O
,	O	O
revealed	O	O
that	O	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
is	O	O
separated	O	O
from	O	O
recognized	O	O
Altererythrobacter	B-LIVB
species	I-LIVB
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
data	O	O
presented	O	O
,	O	O
strain	B-LIVB
KEM	I-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
is	O	O
considered	O	O
to	O	O
represent	O	O
a	O	O
novel	O	O
species	O
of	O	O
the	O	O
genus	O
Altererythrobacter	B-LIVB
,	O	O
for	O	O
which	O	O
the	O	O
name	O	O
Altererythrobacter	B-LIVB
confluentis	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O	O
proposed	O	O
.	O	O

The	O	O
type	O	O
strain	O	O
of	O	O
is	O	O
KEM	B-LIVB
-	I-LIVB
4	I-LIVB
T	I-LIVB
(	O	O
=	O	O
KCTC	O	O
52259	O	O
T	O	O
=	O	O
NBRC	O	O
112305	O	O
T	O	O
)	O	O
.	O	O

Nonstenotic	B-DISO
carotid	B-DISO
plaque	I-DISO
on	O	O
CT	B-PROC
angiography	I-PROC
in	O	O
patients	B-LIVB
with	O	O
cryptogenic	O
stroke	B-DISO
To	O	O
determine	O	O
whether	O	O
large	O	O
(	O	O
≥3	O	O
mm	O	O
thick	O	O
)	O	O
but	O	O
nonstenotic	B-DISO
(	O	O
<	O	O
50	O	O
%	O	O
)	O	O
carotid	B-DISO
artery	I-DISO
atherosclerotic	I-DISO
plaque	I-DISO
predominantly	O	O
occurs	O	O
ipsilateral	O
rather	O	O
than	O	O
contralateral	O
to	O	O
cryptogenic	O
stroke	B-DISO
.	O	O

This	O	O
was	O	O
a	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
observational	I-PROC
study	I-PROC
.	O	O

Using	O	O
a	O	O
stroke	B-DISO
registry	O
,	O	O
we	O	O
identified	O	O
consecutive	O
patients	B-LIVB
with	O	O
anterior	B-DISO
circulation	I-DISO
embolic	I-DISO
stroke	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
(	O	O
ESUS	B-DISO
)	O	O
.	O	O

Using	O	O
CT	B-PROC
angiography	I-PROC
,	O	O
we	O	O
measured	O	O
carotid	B-DISO
plaque	I-DISO
size	O
(	O	O
thickness	O
,	O	O
mm	O	O
)	O	O
and	O	O
carotid	B-DISO
artery	I-DISO
stenosis	I-DISO
(	O	O
North	O
American	O
Symptomatic	O
Carotid	O
Endarterectomy	O
Trial	O
method	O
)	O	O
for	O	O
each	O	O
patient	B-LIVB
.	O	O

We	O	O
dichotomized	O
plaque	B-DISO
size	O
at	O	O
several	O	O
predefined	O	O
thresholds	O
and	O	O
calculated	O	O
the	O	O
frequency	O
of	O	O
plaque	B-DISO
size	O
above	O	O
each	O	O
threshold	O
ipsilateral	O
vs	O	O
contralateral	O
to	O	O
stroke	B-DISO
.	O	O

We	O	O
included	O	O
85	O	O
patients	B-LIVB
with	O	O
ESUS	B-DISO
.	O	O

Plaque	B-DISO
with	O	O
thickness	O
≥5	O	O
mm	O	O
was	O	O
present	O	O
ipsilateral	O
to	O	O
stroke	B-DISO
in	O	O
11	O	O
%	O	O
of	O	O
patients	B-LIVB
,	O	O
and	O	O
contralateral	O
in	O	O
1	O	O
%	O	O
(	O	O
9	O	O
/	O	O
85	O	O
vs	O	O
1	O	O
/	O	O
85	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
008	O	O
)	O	O
.	O	O

Plaque	B-DISO
with	O	O
thickness	O
≥4	O	O
mm	O	O
was	O	O
present	O	O
ipsilateral	O
to	O	O
stroke	B-DISO
in	O	O
19	O	O
%	O	O
of	O	O
patients	B-LIVB
,	O	O
and	O	O
contralateral	O
in	O	O
5	O	O
%	O	O
(	O	O
16	O	O
/	O	O
85	O	O
vs	O	O
4	O	O
/	O	O
85	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
002	O	O
)	O	O
.	O	O

Plaque	B-DISO
with	O	O
thickness	O
≥3	O	O
mm	O	O
was	O	O
present	O	O
ipsilateral	O
to	O	O
stroke	B-DISO
in	O	O
35	O	O
%	O	O
of	O	O
patients	B-LIVB
,	O	O
and	O	O
contralateral	O
in	O	O
15	O	O
%	O	O
(	O	O
30	O	O
/	O	O
85	O	O
vs	O	O
13	O	O
/	O	O
85	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
percentage	O	O
stenosis	B-DISO
ipsilateral	O
vs	O	O
contralateral	O
to	O	O
stroke	B-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
98	O	O
)	O	O
,	O	O
and	O	O
weak	O	O
correlation	O	O
between	O	O
plaque	B-DISO
size	O
and	O	O
stenosis	B-DISO
(	O	O
R	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
26	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Large	O	O
but	O	O
nonstenotic	B-DISO
carotid	B-DISO
artery	I-DISO
plaque	I-DISO
is	O	O
considerably	O	O
more	O	O
common	O	O
ipsilateral	O
than	O	O
contralateral	O
to	O	O
cryptogenic	O
stroke	B-DISO
,	O	O
suggesting	O	O
that	O	O
nonstenotic	B-DISO
plaque	B-DISO
is	O	O
an	O	O
underrecognized	O	O
cause	O	O
of	O	O
stroke	B-DISO
.	O	O

We	O	O
measured	O	O
plaque	B-DISO
size	O
using	O	O
CT	B-PROC
angiography	I-PROC
,	O	O
a	O	O
method	O	O
that	O	O
could	O	O
be	O	O
easily	O	O
implemented	O	O
in	O	O
clinical	B-PHYS
practice	I-PHYS
.	O	O

Association	O
of	O	O
prenatal	B-LIVB
and	O	O
early	O	O
life	O	O
exposure	O
to	O
tetrachloroethylene	B-CHEM
(	O	O
PCE	B-CHEM
)	O	O
with	O	O
polycystic	B-DISO
ovary	I-DISO
syndrome	I-DISO
and	O	O
other	O	O
reproductive	B-DISO
disorders	I-DISO
in	O	O
the	O	O
cape	B-GEOG
cod	I-GEOG
health	B-PROC
study	I-PROC
:	O	O
A	O	O
retrospective	B-PROC
cohort	I-PROC
study	I-PROC
Tetrachloroethylene	B-CHEM
(	O	O
PCE	B-CHEM
)	O	O
is	O	O
an	O	O
organic	O
lipophilic	O
solvent	B-CHEM
with	O	O
possible	O	O
neuroendocrine	B-ANAT
toxicity	O
.	O	O

The	O	O
objective	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
the	O	O
association	O
of	O	O
prenatal	B-LIVB
and	O	O
early	O
childhood	O
exposure	O
to	O
PCE	B-CHEM
-	O	O
contaminated	O
drinking	B-OBJC
water	I-OBJC
and	O	O
development	B-PHYS
of	O	O
adult	B-DISO
-	I-DISO
onset	I-DISO
Polycystic	B-DISO
Ovary	I-DISO
Syndrome	I-DISO
(	O	O
PCOS	B-DISO
)	O	O
,	O	O
endometriosis	B-DISO
,	O	O
difficulty	B-DISO
conceiving	I-DISO
and	O	O
miscarriage	B-DISO
.	O	O

Five	O	O
-	O	O
hundred	O	O
exposed	O
and	O	O
331	O	O
unexposed	B-LIVB
female	B-PHYS
participants	B-LIVB
born	O	O
between	O	O
1969	O	O
and	O	O
1983	O	O
completed	O
questionnaires	O
on	O	O
demographic	O
and	O	O
lifestyle	O
characteristics	O
,	O	O
and	O	O
reproductive	B-DISO
disorders	I-DISO
.	O	O

Residential	O
locations	O
from	O	O
the	O	O
prenatal	B-LIVB
period	O
through	O	O
five	O	O
years	O	O
of	O	O
age	B-PHYS
were	O	O
used	O	O
to	O	O
estimate	O
early	O	O
life	O	O
PCE	B-CHEM
exposure	O
with	O	O
water	B-OBJC
modeling	I-OBJC
software	I-OBJC
.	O	O

For	O	O
any	O	O
early	O	O
life	O	O
exposure	O
to	O
PCE	B-CHEM
,	O	O
the	O	O
adjusted	O
risk	O
ratio	O
for	O	O
PCOS	B-DISO
was	O	O
0	O	O
.	O	O

9	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
5	O	O
-	O	O
1	O	O
.	O	O
6	O	O
)	O	O
.	O	O

No	O	O
statistically	O
significan	O
t	O	O
associations	O
were	O	O
observed	O
for	O	O
increasing	O
levels	O
of	O	O
exposure	O
with	O	O
PCOS	B-DISO
or	O	O
the	O	O
other	O	O
reproductive	B-DISO
disorders	I-DISO
.	O	O

No	O	O
meaningful	O	O
associations	O
were	O	O
found	B-DISO
among	O	O
adult	B-LIVB
women	B-LIVB
with	O	O
early	O	O
life	O	O
exposure	O
to	O
PCE	B-CHEM
-	O	O
contaminated	O
drinking	B-OBJC
water	I-OBJC
and	O	O
adult	B-DISO
-	I-DISO
onset	I-DISO
reproductive	B-DISO
disorders	I-DISO
.	O	O

Host	B-LIVB
plant	I-LIVB
affects	O	O
the	O	O
sexual	B-LIVB
attractiveness	I-LIVB
of	O	O
the	O	O
female	B-PHYS
white	O
-	O
spotted	O
longicorn	O
beetle	O
,	O	O
Anoplophora	O
malasiaca	O
Anoplophora	O
malasiaca	O
(	O	O
Coleoptera	O
:	O	O
Cerambycidae	O
)	O	O
is	O	O
a	O	O
serious	O	O
pest	O	O
that	O	O
destroys	O	O
various	O	O
landscape	O
and	O	O
crop	B-LIVB
trees	B-LIVB
in	O	O
Japan	B-GEOG
.	O	O

We	O	O
evaluated	O	O
the	O	O
precopulatory	O
responses	B-PHYS
of	O	O
three	O	O
different	O	O
A	O
.	O

malasiaca	O
populations	B-LIVB
collected	O	O
from	O	O
mandarin	B-LIVB
orange	I-LIVB
,	O	O
willow	B-LIVB
and	O	O
blueberry	B-LIVB
trees	I-LIVB
.	O	O

Most	O	O
of	O	O
the	O	O
males	B-PHYS
accepted	O	O
mates	O	O
from	O	O
within	O	O
the	O	O
same	O	O
host	B-LIVB
plant	I-LIVB
population	B-LIVB
as	O	O
well	O	O
as	O	O
females	B-PHYS
from	O	O
the	O	O
willow	B-LIVB
and	O	O
blueberry	B-LIVB
populations	O
.	O	O

However	O	O
,	O	O
significant	O	O
number	O	O
of	O	O
males	B-PHYS
from	O	O
the	O	O
blueberry	B-LIVB
and	O	O
willow	B-LIVB
populations	B-LIVB
rejected	O	O
females	B-PHYS
from	O	O
the	O	O
mandarin	B-LIVB
orange	I-LIVB
population	O
immediately	O	O
after	O	O
touching	O	O
them	O	O
with	O	O
their	O	O
antennae	B-ANAT
.	O	O

Because	O	O
all	O	O
three	O	O
of	O	O
the	O	O
female	B-PHYS
populations	B-LIVB
produced	O	O
contact	O	O
sex	B-CHEM
pheromones	I-CHEM
on	O	O
their	O	O
elytra	B-ANAT
,	O	O
the	O	O
females	B-PHYS
of	O	O
the	O	O
mandarin	B-LIVB
orange	I-LIVB
population	O
were	O	O
predicted	O	O
to	O	O
possess	O	O
extra	O	O
chemicals	B-CHEM
that	O	O
repelled	O	O
the	O	O
males	B-PHYS
of	O	O
the	O	O
other	O	O
two	O	O
populations	O
.	O	O

β	B-CHEM
-	I-CHEM
Elemene	I-CHEM
was	O	O
identified	O	O
as	O	O
a	O	O
key	O	O
component	O	O
that	O	O
was	O	O
only	O	O
found	O	O
in	O	O
mandarin	B-LIVB
orange	I-LIVB
-fed	O	O
females	B-PHYS
and	O	O
induced	O	O
a	O	O
rejection	O
response	B-PHYS
in	O	O
willow	B-LIVB
-fed	O	O
males	B-PHYS
.	O	O

Our	O	O
results	O	O
represent	O	O
the	O	O
first	O	O
example	O	O
of	O	O
a	O	O
female	B-PHYS
-acquired	O	O
repellent	B-CHEM
against	O	O
conspecific	O	O
males	B-PHYS
of	O	O
different	O	O
host	B-LIVB
plant	I-LIVB
populations	O
,	O	O
indicating	O	O
that	O	O
the	O	O
host	B-LIVB
plant	I-LIVB
greatly	O	O
affects	O	O
the	O	O
female	B-PHYS
's	I-PHYS
sexual	B-LIVB
attractiveness	I-LIVB
.	O	O

Variability	O
in	O	O
conditioned	B-PROC
pain	I-PROC
modulation	I-PROC
predicts	O	O
response	B-PHYS
to	O	O
NSAID	B-CHEM
treatment	B-PROC
in	O	O
patients	B-LIVB
with	O	O
knee	B-DISO
osteoarthritis	I-DISO
Patients	B-LIVB
with	O	O
painful	B-DISO
knee	B-DISO
osteoarthritis	I-DISO
(	O	O
OA	B-DISO
)	O	O
demonstrate	O	O
hyperalgesia	B-DISO
and	O	O
altered	O
pain	B-PROC
-	I-PROC
modulatory	I-PROC
responses	B-PHYS
.	O	O

While	O	O
some	O	O
prior	O	O
work	O	O
has	O	O
demonstrated	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
associations	I-PROC
between	O	O
laboratory	B-OBJC
and	O	O
clinical	O
pain	O	O
measures	O
,	O	O
it	O	O
is	O	O
unknown	O	O
whether	O	O
individual	O	O
variability	O
in	O	O
quantitative	B-PROC
sensory	I-PROC
testing	I-PROC
(	O	O
QST	B-PROC
)	O	O
responses	B-PHYS
at	O	O
baseline	O
can	O	O
prospectively	O	O
predict	O	O
analgesic	B-CHEM
treatment	B-PHYS
responses	I-PHYS
.	O	O

Patients	B-LIVB
with	O	O
knee	B-DISO
OA	I-DISO
(	O	O
n	O	O
=	O	O
35	O	O
)	O	O
were	O	O
compared	O	O
on	O	O
QST	B-PROC
responses	B-PHYS
to	O	O
a	O	O
demographically	O
-matched	O	O
pain	O
-	O
free	O
control	B-LIVB
group	I-LIVB
(	O	O
n	O	O
=	O	O
39	O	O
)	O	O
,	O	O
after	O	O
which	O	O
patients	B-LIVB
completed	O	O
a	O	O
month	O	O
-	O	O
long	O	O
treatment	B-PROC
study	I-PROC
of	O	O
diclofenac	B-CHEM
sodium	I-CHEM
topical	I-CHEM
gel	I-CHEM
(	O	O
1	O	O
%	O	O
)	O	O
,	O	O
applied	O
up	O	O
to	O	O
4	O	O
times	O	O
daily	O	O
.	O	O

OA	B-DISO
patients	B-LIVB
demonstrated	O	O
reduced	O
pain	B-DISO
thresholds	I-DISO
at	O	O
multiple	O	O
anatomic	B-ANAT
sites	I-ANAT
,	O	O
as	O	O
well	O	O
as	O	O
reduced	O
conditioned	B-PROC
pain	I-PROC
modulation	I-PROC
(	O	O
CPM	B-PROC
)	O	O
and	O	O
enhanced	O
temporal	B-PHYS
summation	I-PHYS
of	O	O
pain	B-DISO
.	O	O

The	O	O
most	O	O
pain	B-DISO
-	I-DISO
sensitive	I-DISO
patients	B-LIVB
tended	O	O
to	O	O
report	O	O
the	O	O
most	O	O
intense	O
and	O	O
neuropathic	B-DISO
OA	B-DISO
pain	B-DISO
.	O	O

Following	O	O
diclofenac	B-CHEM
treatment	B-PROC
,	O	O
the	O	O
knee	B-DISO
OA	I-DISO
cohort	B-LIVB
showed	O	O
a	O	O
roughly	O	O
30	O	O
%	O	O
improvement	O	O
in	O	O
pain	B-DISO
,	O	O
regardless	O
of	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
neuropathic	B-DISO
symptoms	I-DISO
.	O	O

Baseline	O
CPM	B-PROC
scores	O	O
,	O	O
an	O	O
index	O	O
of	O	O
endogenous	O
pain	B-PHYS
-	I-PHYS
inhibitory	I-PHYS
capacity	I-PHYS
,	O	O
were	O	O
prospectively	O	O
associated	O
with	O
treatment	B-PROC
-related	O	O
changes	O	O
in	O	O
clinical	O
pain	B-DISO
.	O	O

Specifically	O	O
,	O	O
participants	B-LIVB
with	O	O
higher	O	O
CPM	B-PROC
at	O	O
baseline	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O

,	O	O
better	O	O
functioning	O	O
endogenous	O
pain	B-DISO
-	O	O
inhibitory	B-CHEM
systems	I-CHEM
)	O	O
showed	O	O
more	O	O
reduction	B-PROC
in	O	O
pain	B-DISO
at	O	O
the	O	O
end	O	O
of	O	O
treatment	B-PROC
(	O	O
p	O	O
<	O	O
.05	O	O
)	O	O
.	O	O

These	O	O
results	B-PHEN
support	O	O
prior	O	O
findings	B-DISO
of	O	O
amplified	B-DISO
pain	I-DISO
sensitivity	I-DISO
and	O	O
reduced	O
pain	B-PHYS
-	I-PHYS
inhibition	I-PHYS
in	O	O
OA	B-DISO
patients	B-LIVB
.	O	O

Moreover	O	O
,	O	O
the	O	O
moderate	O	O
to	O	O
strong	O	O
associations	O	O
between	O	O
laboratory	B-OBJC
-	I-OBJC
based	I-OBJC
measures	O
of	O	O
pain	B-DISO
sensitivity	I-DISO
and	O	O
indices	O
of	O	O
clinical	O
pain	B-DISO
highlight	O	O
the	O	O
clinical	O
relevance	O
of	O	O
QST	B-PROC
in	O	O
this	O	O
sample	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
prospective	O	O
association	O	O
between	O	O
CPM	B-PROC
and	O	O
diclofenac	B-CHEM
response	B-PHYS
suggests	O
that	O	O
QST	B-PROC
-	I-PROC
based	I-PROC
phenotyping	O
may	O	O
have	O	O
utility	O	O
in	O	O
explaining	O	O
inter	B-LIVB
-	I-LIVB
patient	I-LIVB
variability	O
in	O	O
long	O
-	O
term	O
analgesic	B-CHEM
treatment	O
outcomes	O
.	O	O

ClinicalTrials	B-PROC
.Gov	O	O
Identifier	O	O
:	O	O
NCT01383954	O	O
.	O	O

Registered	O	O
June	O	O
22	O	O
,	O	O
2011	O	O
.	O	O

In	B-PROC
Vitro	I-PROC
Assays	I-PROC
for	O	O
the	O	O
Discovery	O
of	O	O
PCSK9	B-CHEM
Autoprocessing	I-CHEM
Inhibitors	I-CHEM
PCSK9	B-CHEM
plays	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
regulating	B-PHEN
low	B-PROC
-	I-PROC
density	I-PROC
lipoprotein	I-PROC
(	I-PROC
LDL	I-PROC
)	I-PROC
cholesterol	I-PROC
levels	I-PROC
and	O	O
has	O	O
become	O	O
an	O	O
important	O	O
drug	O
target	O
for	O	O
treating	O
hypercholesterolemia	B-DISO
.	O	O

Although	O	O
a	O	O
member	O	O
of	O	O
the	O	O
serine	B-CHEM
protease	I-CHEM
family	I-CHEM
,	O	O
PCSK9	B-CHEM
only	O	O
catalyzes	B-PHEN
a	O	O
single	O
reaction	O
,	O	O
the	O	O
autocleavage	B-PHEN
of	O	O
its	O	O
prodomain	O
.	O	O

The	O	O
maturation	B-PHYS
of	O	O
the	O	O
proprotein	B-CHEM
is	O	O
an	O	O
essential	O	O
prerequisite	O
for	O	O
the	O	O
secretion	B-PHEN
of	O	O
PCSK9	B-CHEM
to	O	O
the	O	O
extracellular	B-ANAT
space	I-ANAT
where	O	O
it	O	O
binds	O
the	O	O
LDL	B-CHEM
receptor	I-CHEM
and	O	O
targets	O
it	O	O
for	O	O
degradation	O
.	O	O

We	O	O
have	O	O
found	O	O
that	O	O
a	O	O
construct	B-CHEM
of	I-CHEM
proPCSK9	I-CHEM
where	O	O
the	O	O
C	O
-	O
terminal	O
domain	O
has	O	O
been	O	O
truncated	O
has	O	O
sufficient	O	O
stability	O
to	O	O
be	O	O
expressed	B-PHYS
and	O	O
purified	O
from	O	O
Escherichia	B-LIVB
coli	I-LIVB
for	O	O
the	O	O
in	B-PROC
vitro	I-PROC
study	I-PROC
of	O	O
autoprocessing	B-PHEN
.	O	O

Using	O	O
automated	B-PROC
Western	I-PROC
analysis	I-PROC
,	O	O
we	O	O
demonstrate	O	O
that	O	O
autoprocessing	B-PHEN
exhibits	O	O
the	O	O
anticipated	B-DISO
first	O
-	O
order	O
kinetics	O
.	O	O

A	O	O
high	B-PROC
-	I-PROC
throughput	I-PROC
time	B-PROC
-	I-PROC
resolved	I-PROC
fluorescence	I-PROC
resonance	I-PROC
energy	I-PROC
transfer	I-PROC
assay	I-PROC
for	O	O
autocleavage	B-PHEN
has	O	O
been	O	O
developed	O	O
using	O	O
a	O	O
PCSK9	B-CHEM
monoclonal	I-CHEM
antibody	I-CHEM
that	O	O
is	O	O
sensitive	O
to	O	O
the	O	O
conformational	B-PHYS
changes	I-PHYS
that	O	O
occur	O	O
upon	O	O
maturation	B-PHYS
of	O	O
the	O	O
proprotein	B-CHEM
.	O	O

Kinetic	B-PHEN
theory	I-PHEN
has	O	O
been	O	O
developed	O	O
that	O	O
describes	O	O
the	O	O
behavior	O
of	O	O
both	O	O
reversible	B-CHEM
and	O	O
irreversible	B-CHEM
inhibitors	I-CHEM
of	O	O
autocleavage	B-PHEN
.	O	O

The	O	O
analysis	B-PROC
of	O	O
an	O	O
irreversible	B-CHEM
lactone	I-CHEM
inhibitor	I-CHEM
validates	O	O
the	O	O
expected	O	O
relationship	O
between	O	O
potency	O
and	O	O
the	O	O
reaction	O
end	O
point	O
.	O	O

An	O	O
orthogonal	B-PROC
liquid	I-PROC
chromatography	I-PROC
-	I-PROC
mass	I-PROC
spectrometry	I-PROC
assay	I-PROC
has	O	O
also	O	O
been	O	O
implemented	B-DISO
for	O	O
the	O	O
confirmation	O	O
of	O	O
hits	O	O
from	O	O
the	O	O
antibody	B-PROC
-	I-PROC
based	I-PROC
assays	I-PROC
.	O	O

The	O	O
cost	O
-	O
effectiveness	O
of	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O	O
treatment	O
of	O	O
externalizing	B-DISO
disorders	I-DISO
,	O	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O	O
delinquency	B-DISO
:	O	O
a	O	O
systematic	O	O
review	O
Family	B-PROC
therapy	I-PROC
and	O	O
family	O
-	O
based	O
treatment	O
has	O	O
been	O	O
commonly	O	O
applied	O	O
in	O	O
children	B-LIVB
and	O	O
adolescents	B-LIVB
in	O	O
mental	B-PROC
health	I-PROC
care	I-PROC
and	O	O
has	O	O
been	O	O
proven	O	O
to	O	O
be	O	O
effective	O	O
.	O	O

There	O	O
is	O	O
an	O	O
increased	O	O
interest	O	O
in	O	O
economic	O
evaluations	O
of	O	O
these	O	O
,	O	O
often	O	O
expensive	O	O
,	O	O
interventions	B-PROC
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
systematic	O	O
review	O
is	O	O
to	O	O
summarize	O	O
and	O	O
evaluate	B-PROC
the	O	O
evidence	O	O
on	O	O
cost	O
-	O
effectiveness	O
of	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O	O
externalizing	B-DISO
disorders	I-DISO
,	O	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O	O
delinquency	B-DISO
.	O	O

A	O	O
systematic	O	O
literature	O	O
search	O	O
was	O	O
performed	O	O
in	O	O
PubMed	O
,	O	O
Education	B-OBJC
Resource	I-OBJC
information	I-OBJC
Centre	I-OBJC
(	O	O
ERIC	B-OBJC
)	O	O
,	O	O
Psycinfo	O
and	O	O
Cochrane	O
reviews	O
including	O	O
studies	B-PROC
conducted	O	O
after	O	O
1990	O	O
and	O	O
before	O	O
the	O	O
first	O	O
of	O	O
August	O	O
of	O	O
2013	O	O
.	O	O

Full	O	O
economic	O
evaluations	O
investigating	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
interventions	I-PROC
for	O	O
adolescents	B-LIVB
between	O	O
10	O	O
and	O	O
20	O	O
years	O
treated	O
for	O	O
substance	B-DISO
use	I-DISO
disorders	I-DISO
,	O	O
delinquency	B-DISO
or	O	O
externalizing	B-DISO
disorders	I-DISO
were	O	O
included	O	O
.	O	O

Seven	O	O
hundred	O	O
thirty	O	O
-	O	O
one	O	O
articles	O
met	O	O
the	O	O
search	O	O
criteria	O	O
and	O	O
51	O	O
studies	B-PROC
were	O	O
initially	O	O
selected	O	O
.	O	O

The	O	O
final	O	O
selection	O	O
resulted	O	O
in	O	O
the	O	O
inclusion	O	O
of	O	O
11	O	O
studies	B-PROC
.	O	O

The	O	O
quality	O
of	O	O
these	O	O
studies	B-PROC
was	O	O
assessed	O
.	O	O

Within	O	O
the	O	O
identified	O	O
studies	B-PROC
,	O	O
there	O	O
was	O	O
great	O	O
variation	O	O
in	O	O
the	O	O
specific	O	O
type	O	O
of	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
interventions	I-PROC
and	O	O
disorders	B-DISO
.	O	O

According	O	O
to	O	O
the	O	O
outcomes	O
of	O	O
the	O	O
checklists	O	O
,	O	O
the	O	O
overall	O	O
quality	O
of	O	O
the	O	O
economic	O
evaluations	O
was	O	O
low	O	O
.	O	O

Results	O	O
varied	O	O
by	O	O
study	B-PROC
.	O	O

Due	O	O
to	O	O
the	O	O
variations	O	O
in	O	O
setting	O	O
,	O	O
design	O	O
and	O	O
outcome	O	O
it	O	O
was	O	O
not	O	O
feasible	O	O
to	O	O
pool	O	O
results	O	O
using	O	O
a	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O	O

The	O	O
quality	O
of	O	O
the	O	O
identified	O	O
economic	O
evaluations	O
of	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
for	O	O
treatment	O
of	O	O
externalizing	B-DISO
disorders	I-DISO
,	O	O
adolescent	B-LIVB
substance	B-DISO
use	I-DISO
disorders	I-DISO
and	O	O
delinquency	B-DISO
was	O	O
insufficient	O	O
to	O	O
determine	O	O
the	O	O
cost	O
-	O
effectiveness	O
.	O	O

Although	O	O
commonly	O	O
applied	O	O
,	O	O
family	B-LIVB
/	O	O
family	B-PROC
-	I-PROC
based	I-PROC
therapy	I-PROC
is	O	O
costly	O	O
and	O	O
more	O	O
research	O	O
of	O	O
higher	O	O
quality	O
is	O	O
needed	O	O
.	O	O

Molecular	O
detection	B-PROC
of	O	O
infection	B-DISO
homogeneity	O
and	O	O
impact	O
of	O	O
miltefosine	B-CHEM
treatment	O
in	O	O
a	O	O
Syrian	B-LIVB
golden	I-LIVB
hamster	I-LIVB
model	O	O
of	O	O
Leishmania	O
donovani	O
and	O	O
L	O
.	O

infantum	O
visceral	B-DISO
leishmaniasis	I-DISO
Control	O
of	O	O
visceral	B-DISO
leishmaniasis	I-DISO
caused	O	O
by	O	O
Leishmania	O
infantum	O
and	O	O
Leishmania	O
donovani	O
primarily	O	O
relies	O	O
on	O	O
chemotherapy	B-PROC
using	O	O
an	O	O
increasingly	O	O
compromised	B-DISO
repertoire	O	O
of	O	O
antileishmanial	B-CHEM
compounds	I-CHEM
.	O	O

For	O	O
evaluation	B-PROC
of	O	O
novel	O
drugs	B-CHEM
,	O	O
the	O	O
Syrian	B-LIVB
golden	I-LIVB
hamster	I-LIVB
is	O	O
considered	O	O
as	O	O
a	O	O
clinically	O
relevant	O
laboratory	O
model	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
two	O	O
molecular	B-PROC
parasite	I-PROC
detection	I-PROC
assays	I-PROC
were	O	O
developed	O	O
targeting	O
cathepsin	B-CHEM
-	I-CHEM
like	I-CHEM
cysteine	I-CHEM
protease	I-CHEM
B	I-CHEM
(	O	O
CPB	B-CHEM
)	O	O
DNA	B-CHEM
and	O	O
18S	O	O
rRNA	B-CHEM
to	O	O
achieve	O	O
absolute	O
amastigote	O
quantification	O
in	O	O
the	O	O
major	O	O
target	O
organs	B-ANAT
liver	B-ANAT
and	O	O
spleen	B-ANAT
.	O	O

Both	O	O
quantitative	B-PROC
PCR	I-PROC
(	B-PROC
qPCR	I-PROC
)	I-PROC
techniques	I-PROC
showed	O	O
excellent	O	O
agreement	O	O
with	O	O
a	O	O
strong	O	O
correlation	O
with	O	O
the	O	O
conventional	O	O
microscopic	B-PROC
reading	I-PROC
of	O	O
Giemsa	B-PROC
-	I-PROC
stained	I-PROC
tissue	O
smears	B-PROC
.	O	O

Using	O	O
multiple	O
single	O
tissue	O
pieces	O
and	O	O
all	O	O
three	O	O
detection	B-DISO
methods	O
,	O	O
we	O	O
confirmed	O	O
homogeneity	O
of	O	O
infection	B-DISO
in	O	O
liver	B-ANAT
and	O	O
spleen	B-ANAT
and	O	O
the	O	O
robustness	O
of	O	O
extrapolating	O	O
whole	O
organ	O
burdens	O
from	O	O
a	O	O
small	O
single	O
tissue	O
piece	O
.	O	O

Comparison	O
of	O	O
pre	O
-	O	O
and	O	O
post	O
-	O
treatment	O
burdens	O
in	O	O
infected	B-DISO
hamsters	B-LIVB
using	O	O
the	O	O
three	O	O
detection	B-DISO
methods	O
consistently	O	O
revealed	O
a	O	O
stronger	O	O
parasite	O
reduction	O
in	O	O
the	O	O
spleen	B-ANAT
compared	O
to	O	O
the	O	O
liver	B-ANAT
,	O	O
indicating	O	O
an	O	O
organ	B-ANAT
-	O	O
dependent	O
clearance	O
efficacy	O
for	O	O
miltefosine	B-CHEM
.	O	O

In	O	O
conclusion	O
,	O	O
this	O	O
study	B-PROC
in	O	O
the	O	O
hamster	B-LIVB
demonstrated	O	O
high	O
homogeneity	O
of	O	O
infection	B-DISO
in	O	O
liver	B-ANAT
and	O	O
spleen	B-ANAT
and	O	O
advocates	O	O
the	O	O
use	O	O
of	O	O
molecular	O
detection	B-PROC
methods	O
for	O	O
assessment	B-PROC
of	O	O
low	O
(	O	O
post	O
-	O
treatment	O
)	O	O
tissue	O
burdens	O
.	O	O

Abstract	B-PHYS
and	O	O
Effector	B-PHYS
-	I-PHYS
Selective	I-PHYS
Decision	I-PHYS
Signals	I-PHYS
Exhibit	O	O
Qualitatively	O
Distinct	O
Dynamics	B-PHEN
before	O	O
Delayed	O
Perceptual	B-PHYS
Reports	O
Electrophysiological	B-PROC
research	I-PROC
has	O	O
isolated	O
neural	O
signatures	B-PHYS
of	O	O
decision	B-PHYS
formation	I-PHYS
in	O	O
a	O	O
variety	O	O
of	O	O
brain	B-ANAT
regions	I-ANAT
.	O	O

Studies	B-PROC
in	O	O
rodents	B-LIVB
and	O	O
monkeys	B-LIVB
have	O	O
focused	O
primarily	O
on	O	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
signals	I-PHYS
that	O	O
translate	O
the	O	O
emerging	O	O
decision	B-PHYS
into	O	O
a	O	O
specific	O	O
motor	O
plan	O
,	O	O
but	O	O
,	O	O
more	O	O
recently	O	O
,	O	O
research	B-PROC
on	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
has	O	O
identified	O
an	O	O
abstract	B-PHYS
signature	B-PHYS
of	O	O
evidence	O
accumulation	B-DISO
that	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
play	O	O
any	O	O
direct	O	O
role	O
in	O	O
action	O
preparation	O
.	O	O

The	O	O
functional	O
dissociations	B-PHYS
between	O	O
these	O	O
distinct	O
signal	B-PHEN
types	O	O
have	O	O
only	O	O
begun	O	O
to	O	O
be	O	O
characterized	O
,	O	O
and	O	O
their	O	O
dynamics	B-PHEN
during	O	O
decisions	B-PHYS
with	O	O
deferred	O
actions	O
with	O	O
or	O	O
without	O	O
foreknowledge	B-PHYS
of	O	O
stimulus	B-PHYS
-	I-PHYS
effector	I-PHYS
mapping	I-PHYS
,	O	O
a	O	O
commonly	O	O
studied	B-PROC
task	O
scenario	O
in	O	O
single	B-PROC
-	I-PROC
unit	I-PROC
and	O	O
functional	B-PROC
imaging	I-PROC
investigations	B-PROC
,	O	O
have	O	O
not	O	O
been	O	O
established	O
.	O	O

Here	O	O
we	O	O
traced	B-DISO
the	O	O
dynamics	B-PHEN
of	O	O
distinct	O
abstract	B-PHYS
and	O	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
in	O	O
the	O	O
form	O	O
of	O	O
the	O	O
broad	O	O
-	O	O
band	O	O
centro	B-DISO
-	I-DISO
parietal	I-DISO
positivity	I-DISO
(	O	O
CPP	B-DISO
)	O	O
and	O	O
limb	B-DISO
-	I-DISO
selective	I-DISO
β	I-DISO
-	I-DISO
band	I-DISO
(	O	O
8	O	O
-	O	O
16	O	O
and	O	O
18	O	O
-	O	O
30	O	O
Hz	O	O
)	O	O
EEG	B-PROC
activity	O
,	O	O
respectively	O	O
,	O	O
during	O	O
delayed	O
-	O	O
reported	B-PROC
motion	O
direction	O
decisions	B-PHYS
with	O	O
and	O	O
without	O	O
foreknowledge	B-PHYS
of	O	O
direction	O
-	O	O
response	B-PHYS
mapping	O
.	O	O

With	O	O
foreknowledge	B-PHYS
,	O	O
the	O	O
CPP	B-DISO
and	O	O
β	B-PHEN
-	I-PHEN
band	I-PHEN
signals	I-PHEN
exhibited	O	O
a	O	O
similar	O	O
gradual	O
build	O	O
-	O	O
up	O	O
following	O	O
evidence	O
onset	O
,	O	O
but	O	O
whereas	O	O
choice	O
-	O	O
predictive	O
β	O
-	O
band	O
activity	O
persisted	O
up	O	O
until	O	O
the	O	O
delayed	O
response	B-PHYS
,	O	O
the	O	O
CPP	B-DISO
dropped	O
toward	O	O
baseline	O
after	O	O
peaking	O
.	O	O

Without	O	O
foreknowledge	B-PHYS
,	O	O
the	O	O
CPP	B-DISO
exhibited	O
identical	O
dynamics	B-PHEN
,	O	O
whereas	O	O
choice	O
-	O	O
selective	O
β	O
-	O
band	O
activity	O
was	O	O
eliminated	O
.	O	O

These	O	O
findings	B-DISO
highlight	O	O
qualitative	O
functional	O
distinctions	O
between	O	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
and	O	O
abstract	B-PHYS
decision	B-PHYS
signals	B-PHEN
and	O	O
are	O	O
of	O	O
relevance	O
to	O	O
the	O	O
assumptions	O
founding	B-DISO
functional	B-PROC
neuroimaging	I-PROC
investigations	B-PROC
of	O	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
.	O	O

Neural	O
signatures	B-PHYS
of	O	O
evidence	O
accumulation	B-DISO
have	O	O
been	O	O
isolated	O
in	O	O
numerous	O	O
brain	B-ANAT
regions	I-ANAT
.	O	O

Although	O	O
animal	B-LIVB
neurophysiology	B-PHYS
has	O	O
largely	O	O
concentrated	O
on	O	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
that	O	O
translate	O
the	O	O
emerging	O	O
decision	B-PHYS
into	O	O
a	O	O
specific	O	O
motor	O
plan	O
,	O	O
recent	O	O
research	B-PROC
on	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
has	O	O
isolated	O
abstract	B-PHYS
neural	O
signatures	B-PHYS
of	O	O
decision	B-PHYS
formation	I-PHYS
that	O	O
are	O	O
independent	O
of	O
specific	O
sensory	O
and	O	O
motor	O
requirements	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
examine	B-PROC
the	O	O
functional	O
distinctions	O
between	O	O
the	O	O
two	O	O
distinct	O
classes	O
of	O	O
decision	B-PHYS
variable	O
signal	B-PHEN
during	O	O
decisions	B-PHYS
with	O	O
deferred	O
actions	O
with	O	O
and	O	O
without	O	O
foreknowledge	B-PHYS
of	O	O
stimulus	B-PHYS
-	I-PHYS
effector	I-PHYS
mapping	I-PHYS
.	O	O

We	O	O
find	O	O
salient	O
distinctions	O
in	O	O
the	O	O
dynamics	B-PHEN
of	O	O
abstract	B-PHYS
versus	O	O
effector	B-PHYS
-	I-PHYS
selective	I-PHYS
decision	I-PHYS
signals	I-PHYS
in	O	O
the	O	O
human	B-LIVB
brain	B-ANAT
,	O	O
in	O	O
terms	O	O
of	O	O
sustainment	O
through	O	O
response	B-PHYS
delays	O
and	O	O
contingency	O
on	O	O
foreknowledge	B-PHYS
of	O	O
stimulus	B-PHYS
-	I-PHYS
response	I-PHYS
mapping	I-PHYS
.	O	O

Prevalence	O
of	O	O
gastrointestinal	B-ANAT
parasites	O
in	O	O
dogs	B-LIVB
of	O	O
Palampur	B-GEOG
,	O	O
Himachal	B-GEOG
Pradesh	I-GEOG
A	O	O
total	O	O
of	O	O
246	O	O
faecal	B-ANAT
/	O	O
scat	B-ANAT
samples	I-ANAT
of	O	O
the	O	O
dogs	B-LIVB
were	O	O
screened	B-PROC
by	O	O
direct	O
and	O	O
floatation	B-PROC
concentration	I-PROC
technique	I-PROC
to	O	O
study	O	O
the	O	O
gastrointestinal	B-ANAT
(	I-ANAT
GI	I-ANAT
)	I-ANAT
tract	I-ANAT
parasitism	B-PHEN
in	O	O
dogs	B-LIVB
of	O	O
Palampur	B-GEOG
,	O	O
Himachal	B-GEOG
Pradesh	I-GEOG
,	O	O
India	B-GEOG
.	O	O

Detailed	O	O
coprological	B-PROC
examination	I-PROC
targeting	O	O
different	O	O
seasons	O
,	O	O
age	B-LIVB
groups	I-LIVB
and	O	O
living	O
styles	O
of	O	O
the	O	O
dogs	B-LIVB
revealed	O	O
an	O	O
overall	O	O
28	O	O
.	O	O
04	O	O
%	O	O
of	O	O
GI	B-ANAT
parasitism	B-PHEN
with	O	O
highest	O	O
prevalence	O
in	O	O
summer	O
season	O
(	O	O
37	O	O
.	O	O
87	O	O
%	O	O
)	O	O
.	O	O

Stray	B-LIVB
dogs	I-LIVB
harbored	O	O
47	O	O
.	O	O

29	O	O
%	O	O
GI	B-ANAT
parasites	O
in	O	O
comparison	O
to	O	O
19	O	O
.	O	O

19	O	O
%	O	O
of	O	O
pet	B-LIVB
dogs	I-LIVB
.	O	O

Highest	O	O
prevalence	O
of	O	O
GI	B-ANAT
parasitism	B-PHEN
was	O	O
observed	O	O
in	O	O
the	O	O
pups	B-LIVB
,	O	O
below	O	O
3	O	O
months	O
of	O	O
age	B-PHYS
(	O	O
39	O	O
.	O	O
13	O	O
%	O	O
)	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
dogs	B-LIVB
with	O	O
the	O	O
age	B-PHYS
ranging	O	O
from	O	O
3	O	O
months	O
to	O	O
1	O	O
year	O
(	O	O
26	O	O
.	O	O
38	O	O
%	O	O
)	O	O
and	O	O
lowest	O	O
in	O	O
dogs	B-LIVB
of	O	O
the	O	O
age	B-PHYS
ranging	O	O
from	O	O
1	O	O
to	O	O
3	O	O
years	O
(	O	O
6	O	O
.	O	O
77	O	O
%	O	O
)	O	O
.	O	O

Amongst	O	O
all	O	O
the	O	O
parasites	O
,	O	O
Toxocara	B-DISO
canis	I-DISO
(	I-DISO
44	I-DISO
.	I-DISO
93	I-DISO
%	I-DISO
)	I-DISO
infection	I-DISO
was	O	O
highest	O	O
,	O	O
followed	O	O
by	O	O
Dipylidium	O
caninum	O
(	O	O
17	O	O
.	O	O
39	O	O
%	O	O
)	O	O
and	O	O
hookworms	O
(	O	O
15	O	O
.	O	O
94	O	O
%	O	O
)	O	O
.	O	O

Developing	O
Community	O
-	O	O
Level	O
Policy	O
and	O	O
Practice	B-PHYS
to	O	O
Reduce	O
Traffic	B-DISO
-	O	O
Related	O
Air	B-DISO
Pollution	I-DISO
Exposure	I-DISO
The	O	O
literature	O
consistently	O
shows	O	O
associations	O
of	O	O
adverse	B-DISO
cardiovascular	B-ANAT
and	O	O
pulmonary	B-ANAT
outcomes	O
with	O	O
residential	O
proximity	O
to	O	O
highways	O
and	O	O
major	O
roadways	B-OBJC
.	O	O

Air	O
monitoring	O
shows	O	O
that	O	O
traffic	B-DISO
-	O	O
related	O
pollutants	B-CHEM
(	O	O
TRAP	B-CHEM
)	O	O
are	O	O
elevated	O
within	O	O
200	O	O
-	O	O
400	O	O
m	O	O
of	O	O
these	O	O
roads	B-OBJC
.	O	O

Community	B-LIVB
-	O	O
level	O
tactics	B-PHYS
for	O	O
reducing	O
exposure	B-DISO
include	O
the	O	O
following	O	O
:	O	O
1	O	O
)	O	O
HEPA	B-OBJC
filtration	I-OBJC
;	O	O
2	O	O
)	O	O
Appropriate	O
air	B-PHEN
-	I-PHEN
intake	I-PHEN
locations	O
;	O	O
3	O	O
)	O	O
Sound	B-PHEN
proofing	B-OBJC
,	O	O
insulation	B-OBJC
and	O	O
other	O	O
features	O
;	O	O
4	O	O
)	O	O
Land	O
-	O
use	O
buffers	B-OBJC
;	O	O
5	O	O
)	O	O
Vegetation	B-LIVB
or	O	O
wall	B-OBJC
barriers	B-OBJC
;	O	O
6	O	O
)	O	O
Street	O
-	O
side	O
trees	B-LIVB
,	O	O
hedges	B-OBJC
and	O	O
vegetation	B-LIVB
;	O	O
7	O	O
)	O	O
Decking	B-OBJC
over	O
highways	B-DISO
;	O	O
8	O	O
)	O	O
Urban	O
design	O
including	O	O
placement	O
of	O	O
buildings	B-OBJC
;	O	O
9	O	O
)	O	O
Garden	O
and	O	O
park	B-OBJC
locations	O
;	O	O
and	O	O
10	O	O
)	O	O
Active	O
travel	O
locations	O
,	O	O
including	O	O
bicycling	O
and	O	O
walking	O
paths	O
.	O	O

A	O	O
multidisciplinary	O
design	O
charrette	O
was	O	O
held	O	O
to	O	O
test	O
the	O	O
feasibility	O
of	O	O
incorporating	O
these	O	O
tactics	B-PHYS
into	O	O
near	O
-	O	O
highway	O
housing	B-OBJC
and	O	O
school	B-OBJC
developments	O
that	O	O
were	O	O
in	O	O
the	O	O
planning	B-PHYS
stages	O
.	O	O

The	O	O
resulting	O	O
designs	O
successfully	O
utilized	O
many	O	O
of	O	O
the	O	O
protective	O
tactics	B-PHYS
and	O	O
also	O	O
led	O	O
to	O	O
engagement	B-DISO
with	O	O
the	O	O
designers	B-LIVB
and	I-LIVB
developers	I-LIVB
of	O	O
the	O	O
sites	O
.	O	O

There	O	O
is	O	O
a	O	O
need	O	O
to	O	O
increase	O
awareness	B-PHYS
of	O	O
TRAP	B-CHEM
in	O	O
terms	O	O
of	O	O
building	O
design	O
and	O	O
urban	O
planning	O
.	O	O

Learning	B-PHYS
Is	O	O
Better	O
with	O	O
the	O	O
Hands	O
Free	O
:	O	O
The	O	O
Role	O
of	O	O
Posture	B-PHYS
in	O	O
the	O	O
Memory	B-PHYS
of	O	O
Manipulable	B-OBJC
Objects	I-OBJC
Grounded	O
cognition	B-PHYS
proposes	O
that	O	O
memory	B-PHYS
shares	O	O
processing	O
resources	O
with	O	O
sensorimotor	B-ANAT
systems	I-ANAT
.	O	O

The	O	O
aim	O
of	O	O
the	O	O
present	O	O
study	B-PROC
was	O	O
to	O	O
show	O	O
that	O	O
motor	B-ANAT
simulation	B-PROC
participates	O
in	O	O
the	O	O
conceptual	B-PHYS
representation	I-PHYS
of	O	O
manipulable	B-OBJC
objects	I-OBJC
in	O	O
long	B-PHYS
-	I-PHYS
term	I-PHYS
memory	I-PHYS
.	O	O

In	O	O
two	O	O
experiments	B-PROC
,	O	O
lists	O
of	O	O
manipulable	B-OBJC
and	O	O
nonmanipulable	B-OBJC
objects	I-OBJC
were	O	O
presented	O
.	O	O

Participants	B-LIVB
were	O	O
instructed	O
to	O	O
memorize	O	O
the	O	O
items	B-OBJC
while	O	O
adopting	O	O
different	O
postures	B-PHYS
.	O	O

In	O	O
the	O	O
control	O
condition	O
,	O	O
they	O	O
had	O	O
to	O	O
keep	O	O
their	O	O
hands	B-ANAT
at	O	O
rest	O
in	O	O
front	O	O
of	O	O
them	O	O
.	O	O

In	O	O
the	O	O
interference	B-PHYS
condition	I-PHYS
,	O	O
participants	B-LIVB
had	O	O
to	O	O
keep	O	O
their	O	O
hands	B-ANAT
crossed	O
behind	O	O
their	O	O
back	B-ANAT
to	O	O
make	O	O
their	O	O
hands	B-ANAT
less	O	O
free	O
for	O	O
action	O
.	O	O

After	O	O
each	O	O
list	O
,	O	O
participants	B-LIVB
had	O	O
to	O	O
perform	O
first	O	O
a	O	O
distractive	O
task	O
,	O	O
and	O	O
then	O	O
an	O	O
oral	O
free	O
recall	B-PHYS
.	O	O

The	O	O
results	O
showed	O	O
that	O	O
the	O	O
interfering	O
posture	B-PHYS
produced	O	O
a	O	O
specific	O
decrease	O
in	O	O
the	O	O
recall	B-PHYS
of	O	O
manipulable	B-OBJC
objects	I-OBJC
,	O	O
but	O	O
not	O	O
of	O	O
nonmanipulable	B-OBJC
ones	I-OBJC
.	O	O

This	O	O
decrease	O
was	O	O
similar	O
when	O	O
the	O	O
items	B-OBJC
were	O	O
presented	O
as	O	O
pictures	B-OBJC
(	O	O
Experiment	B-PROC
1	O	O
)	O	O
or	O	O
as	O	O
words	O
(	O	O
Experiment	B-PROC
2	O	O
)	O	O
,	O	O
thus	O	O
excluding	O
a	O	O
purely	O	O
visual	O
effect	O
.	O	O

These	O	O
results	O
provide	O	O
strong	O	O
evidence	O
that	O	O
the	O	O
motor	B-ANAT
simulation	B-PROC
plays	O	O
a	O	O
role	O
in	O	O
the	O	O
memory	B-PHYS
trace	I-PHYS
of	O	O
the	O	O
object	B-OBJC
.	O	O

Approximate	O
Bayesian	O
computation	O
for	O	O
estimating	O
number	O
concentrations	O
of	O	O
monodisperse	O
nanoparticles	B-OBJC
in	O	O
suspension	B-OBJC
by	O	O
optical	B-PROC
microscopy	I-PROC
We	O	O
present	O
an	O	O
approximate	O
Bayesian	O
computation	O
scheme	O
for	O	O
estimating	O
number	O
concentrations	O
of	O	O
monodisperse	O
diffusing	B-PHEN
nanoparticles	B-OBJC
in	O	O
suspension	B-OBJC
by	O	O
optical	B-PROC
particle	I-PROC
tracking	I-PROC
microscopy	I-PROC
.	O	O

The	O	O
method	O
is	O	O
based	O
on	O	O
the	O	O
probability	O
distribution	O
of	O	O
the	O	O
time	O
spent	O
by	O	O
a	O	O
particle	B-CHEM
inside	O
a	O	O
detection	B-PROC
region	O
.	O	O

We	O	O
validate	O	O
the	O	O
method	O
on	O	O
suspensions	B-OBJC
of	O	O
well	O
-	O
controlled	O
reference	O
particles	B-CHEM
.	O	O

We	O	O
illustrate	O	O
its	O	O
usefulness	O
with	O	O
an	O	O
application	O
in	O	O
gene	B-PROC
therapy	I-PROC
,	O	O
applying	O
the	O	O
method	O
to	O	O
estimate	O
number	O
concentrations	O
of	O	O
plasmid	B-CHEM
DNA	B-CHEM
molecules	I-CHEM
and	O	O
the	O	O
average	O
number	O
of	O	O
DNA	B-CHEM
molecules	I-CHEM
complexed	B-CHEM
with	O	O
liposomal	B-CHEM
drug	B-DEVI
delivery	I-DEVI
particles	B-CHEM
.	O	O

Developing	O	O
and	O	O
Field	O
Testing	O
a	O	O
Community	B-PROC
Based	I-PROC
Youth	B-PROC
Initiative	I-PROC
to	O	O
Increase	O
Tuberculosis	B-DISO
Awareness	B-PHYS
in	O	O
Remote	O
Arctic	B-GEOG
Inuit	B-LIVB
Communities	I-LIVB
Inuit	B-LIVB
in	O	O
Canada	B-GEOG
have	O	O
the	O	O
highest	O	O
reported	B-PROC
tuberculosis	B-DISO
(	O	O
TB	B-DISO
)	O	O
incidence	O
rate	O
in	O	O
Canada	B-GEOG
,	O	O
even	O	O
higher	O	O
than	O	O
other	O	O
Canadian	B-LIVB
Indigenous	I-LIVB
groups	I-LIVB
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
increase	O
TB	B-DISO
awareness	B-PHYS
among	O	O
Inuit	B-LIVB
youth	I-LIVB
and	O	O
their	O	O
communities	B-LIVB
by	O	O
equipping	O	O
those	O	O
who	O	O
can	O	O
best	O	O
reach	O	O
this	O	O
population	O
with	O	O
a	O	O
community	B-LIVB
based	O	O
,	O	O
youth	B-LIVB
focused	O
,	O	O
education	B-PROC
initiative	I-PROC
built	O	O
on	O	O
interventions	B-PROC
adapted	O	O
from	O	O
a	O	O
previous	O	O
TB	B-DISO
awareness	B-PHYS
study	B-PROC
.	O	O

The	O	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
was	O	O
a	O	O
field	O
test	O
case	O
study	O
of	O	O
a	O	O
knowledge	B-PROC
translation	I-PROC
(	O	O
KT	B-PROC
)	O	O
strategy	O	O
aimed	O	O
at	O	O
community	B-LIVB
members	I-LIVB
who	O	O
provide	O	O
health	B-PROC
education	I-PROC
in	O	O
these	O	O
communities	B-LIVB
.	O	O

In	O	O
the	O	O
first	O	O
stage	O	O
of	O	O
this	O	O
study	B-PROC
,	O	O
interventions	B-PROC
from	O	O
a	O	O
larger	O	O
TB	B-DISO
awareness	B-PROC
campaign	I-PROC
were	O	O
adapted	O	O
to	O	O
focus	O	O
on	O	O
youth	B-LIVB
living	O	O
in	O	O
remote	O
Inuit	B-LIVB
communities	I-LIVB
.	O	O

During	O	O
the	O	O
second	O	O
stage	O	O
of	O	O
the	O	O
study	B-PROC
,	O	O
investigators	B-LIVB
field	O
tested	O
the	O	O
initiative	B-DISO
in	O	O
two	O	O
isolated	O
Inuit	B-LIVB
communities	I-LIVB
.	O	O

It	O	O
was	O	O
then	O	O
applied	O	O
by	O	O
local	O
implementation	O
teams	O
in	O	O
two	O	O
other	O	O
communities	B-LIVB
.	O	O

Evaluation	O
criteria	O
included	O	O
feasibility	B-PROC
,	O	O
acceptability	O
,	O	O
knowledge	B-DISO
uptake	I-DISO
and	O	O
health	O
behavior	O
change	O	O
.	O	O

Implementation	O
of	O	O
the	O	O
adapted	O	O
KT	B-PROC
interventions	B-PROC
resulted	O	O
in	O	O
participation	O
of	O	O
a	O	O
total	O	O
of	O	O
41	O	O
youth	B-LIVB
(	O	O
19	O	O
females	O	O
,	O	O
22	O	O
males	O	O
)	O	O
with	O	O
an	O	O
average	O
age	B-PHYS
of	O	O
16	O	O
years	O	O
(	O	O
range	O	O
12	O	O
-	O	O
21	O	O
years	O	O
)	O	O
in	O	O
four	O	O
different	O	O
communities	B-LIVB
in	O	O
Nunavut	B-GEOG
.	O	O

Community	B-LIVB
celebration	O
events	O
were	O	O
attended	O
by	O	O
271	O	O
community	B-LIVB
members	I-LIVB
where	O	O
TB	B-DISO
messaging	O	O
were	O	O
presented	O
and	O	O
discussed	O	O
.	O	O

All	O	O
of	O	O
the	O	O
health	O
care	O
workers	O
and	O	O
community	B-PROC
members	I-PROC
surveyed	I-PROC
reported	B-PROC
that	O	O
the	O	O
adapted	O	O
interventions	B-PROC
were	O	O
acceptable	O
and	O	O
a	O	O
useful	O	O
way	B-PHYS
of	I-PHYS
learning	I-PHYS
to	O	O
some	O	O
extent	O	O
.	O	O

Knowledge	B-DISO
uptake	I-DISO
measures	O	O
indicated	B-DISO
an	O	O
average	O
TB	B-DISO
knowledge	B-DISO
score	I-DISO
of	O	O
64	O	O
out	O	O
of	O	O
100	O	O
.	O	O

Local	B-LIVB
partners	I-LIVB
in	O	O
all	O	O
four	O	O
communities	B-LIVB
indicated	B-DISO
that	O	O
they	O	O
would	O	O
use	O	O
the	O	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
again	O	O
to	O	O
raise	O	O
awareness	B-PHYS
about	O	O
TB	B-DISO
among	O	O
youth	B-LIVB
in	O	O
their	O	O
communities	B-LIVB
.	O	O

The	O	O
TB	B-DISO
awareness	B-PHYS
interventions	B-PROC
adapted	O	O
for	O	O
the	O	O
Taima	B-PROC
TB	I-PROC
Youth	I-PROC
Education	I-PROC
Initiative	I-PROC
were	O	O
acceptable	O
to	O	O
the	O	O
Inuit	B-LIVB
communities	I-LIVB
involved	O	O
in	O	O
the	O	O
study	B-PROC
.	O	O

They	O	O
resulted	O	O
in	O	O
uptake	B-DISO
of	I-DISO
knowledge	I-DISO
among	O	O
participants	B-LIVB
.	O	O

Implementation	O
by	O	O
local	O
implementation	O
teams	O
was	O	O
feasible	O	O
as	O	O
evidenced	O	O
by	O	O
the	O	O
participation	O
and	O	O
attendance	O
of	O	O
youth	B-LIVB
and	O	O
community	B-LIVB
members	I-LIVB
in	O	O
all	O	O
communities	B-LIVB
.	O	O

The	O	O
ability	O	O
to	O	O
implement	O
the	O	O
interventions	B-PROC
by	O	O
local	O
implementation	O
teams	O
indicates	B-DISO
there	O	O
is	O	O
potential	O
to	O	O
scale	O	O
up	O	O
in	O	O
other	O	O
remote	O
communities	B-LIVB
in	O	O
the	O	O
arctic	B-GEOG
setting	I-GEOG
.	I-GEOG

An	O	O
efficient	O
approach	O	O
to	O	O
identify	O
different	O	O
chemical	B-CHEM
markers	I-CHEM
between	O	O
fibrous	B-LIVB
root	I-LIVB
and	O	O
rhizome	B-LIVB
of	O	O
Anemarrhena	B-LIVB
asphodeloides	I-LIVB
by	O	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
with	O	O
multivariate	O
statistical	O
analysis	O
An	O	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
approach	O	O
coupled	O	O
with	O	O
multivariate	O
statistical	O
analysis	O
was	O	O
established	O	O
and	O	O
applied	O	O
to	O	O
rapidly	O	O
distinguish	O	O
the	O	O
chemical	O
differences	O
between	O	O
fibrous	B-LIVB
root	I-LIVB
and	O	O
rhizome	B-LIVB
of	O	O
Anemarrhena	B-LIVB
asphodeloides	I-LIVB
.	O	O

The	O	O
datasets	O
of	O	O
tR	O	O
-	O	O
m	O	O
/	O	O
z	O	O
pairs	O	O
,	O	O
ion	B-CHEM
intensity	O	O
and	O	O
sample	O	O
code	O	O
were	O	O
processed	B-PHEN
by	O	O
principal	O
component	O
analysis	O
and	O	O
orthogonal	B-PROC
partial	I-PROC
least	I-PROC
squares	I-PROC
discriminant	I-PROC
analysis	I-PROC
.	O	O

Chemical	B-CHEM
markers	I-CHEM
could	O	O
be	O	O
identified	O
based	O	O
on	O	O
their	O	O
exact	O	O
mass	O
data	O
,	O	O
fragmentation	O
characteristics	O
,	O	O
and	O	O
retention	O
times	O
.	O	O

And	O	O
the	O	O
new	O	O
compounds	O	O
among	O	O
chemical	B-CHEM
markers	I-CHEM
could	O	O
be	O	O
isolated	O
rapidly	O	O
guided	O	O
by	O	O
the	O	O
ultra	B-PROC
high	I-PROC
-	I-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
quadrupole	I-PROC
time	I-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
tandem	I-PROC
mass	I-PROC
spectrometry	I-PROC
and	O	O
their	O	O
definitive	O	O
structures	O
would	O	O
be	O	O
further	O	O
elucidated	O	O
by	O	O
NMR	B-PROC
spectra	I-PROC
.	O	O

Using	O	O
this	O	O
approach	O	O
,	O	O
twenty	O	O
-	O	O
four	O	O
markers	B-CHEM
were	O	O
identified	O
on	O	O
line	O	O
including	O	O
nine	O	O
new	O	O
saponins	B-CHEM
and	O	O
five	O	O
new	O	O
steroidal	B-CHEM
saponins	I-CHEM
of	O	O
them	O	O
were	O	O
obtained	O	O
in	O	O
pure	O	O
form	O	O
.	O	O

The	O	O
study	B-PROC
validated	O	O
this	O	O
proposed	O
approach	O	O
as	O	O
a	O	O
suitable	O	O
method	B-PROC
for	O	O
identification	O
of	O	O
the	O	O
chemical	O
differences	O
between	O	O
various	O	O
medicinal	B-LIVB
parts	I-LIVB
in	O	O
order	O	O
to	O	O
expand	O	O
medicinal	B-LIVB
parts	I-LIVB
and	O	O
increase	O	O
the	O	O
utilization	O	O
rate	O	O
of	O	O
resources	O
.	O	O

Gestational	B-PHYS
age	I-PHYS
specific	O	O
stillbirth	B-DISO
risk	O
among	O	O
Indigenous	O
and	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
in	O	O
Queensland	B-GEOG
,	O	O
Australia	B-GEOG
:	O	O
a	O	O
population	B-PROC
based	I-PROC
study	I-PROC
In	O	O
Australia	B-GEOG
,	O	O
significant	O	O
disparity	O	O
persists	O	O
in	O	O
stillbirth	B-DISO
rates	O
between	O	O
Aboriginal	B-LIVB
and	O	O
Torres	B-LIVB
Strait	I-LIVB
Islander	I-LIVB
(	O	O
Indigenous	B-LIVB
Australian	I-LIVB
)	O	O
and	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
.	O	O

Diabetes	B-DISO
,	O	O
hypertension	B-DISO
,	O	O
antepartum	B-DISO
haemorrhage	I-DISO
and	O	O
small	B-DISO
-	I-DISO
for	I-DISO
-	I-DISO
gestational	I-DISO
age	I-DISO
(	O	O
SGA	B-DISO
)	O	O
have	O	O
been	O	O
identified	O
as	O	O
important	O
contributors	O	O
to	O	O
higher	O	O
rates	O
among	O	O
Indigenous	O
women	B-LIVB
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
examine	O	O
gestational	B-PHYS
age	I-PHYS
specific	O	O
risk	O
of	O	O
stillbirth	B-DISO
associated	O
with	O
these	O	O
conditions	O
among	O	O
Indigenous	O
and	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
.	O	O

Retrospective	O
population	B-PROC
-	I-PROC
based	I-PROC
study	I-PROC
of	O	O
all	O	O
singleton	B-LIVB
births	O
of	O	O
at	O	O
least	O	O
20	O	O
weeks	O
gestation	B-PHYS
or	O	O
at	O	O
least	O	O
400	O	O
grams	O
birthweight	B-PHYS
in	O	O
Queensland	B-GEOG
between	O	O
July	O
2005	O	O
and	O	O
December	O
2011	O	O
using	O	O
data	O
from	O	O
the	O	O
Queensland	B-GEOG
Perinatal	O
Data	B-PROC
Collection	I-PROC
,	O	O
which	O	O
is	O	O
a	O	O
routinely	O
-	O
maintained	O
database	O
that	O	O
collects	O	O
data	O
on	O	O
all	O	O
births	O
in	O	O
Queensland	B-GEOG
.	O	O

Multivariate	B-PROC
logistic	I-PROC
regression	I-PROC
was	O	O
used	O	O
to	O	O
calculate	O	O
adjusted	O
odds	O
ratios	O
(	O	O
aOR	O
)	O	O
and	O	O
95	O	O
%	O	O
confidence	O
intervals	O
,	O	O
adjusting	O	O
for	O	O
maternal	B-DISO
demographic	O
and	O	O
pregnancy	B-DISO
factors	I-DISO
.	O	O

Of	O	O
360987	O	O
births	O
analysed	B-PROC
,	O	O
20273	O	O
(	O	O
5	O	O
.	O	O
6	O	O
%	O	O
)	O	O
were	O	O
to	O	O
Indigenous	O
women	B-LIVB
and	O	O
340714	O	O
(	O	O
94	O	O
.	O	O
4	O	O
%	O	O
)	O	O
were	O	O
to	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
.	O	O

Stillbirth	B-DISO
rates	O
were	O	O
7	O	O
.	O	O
9	O	O
(	O	O
95	O	O
%	O	O
CI	O
6	O	O
.	O	O
8	O	O
-	O	O
9	O	O
.	O	O
2	O	O
)	O	O
and	O	O
4	O	O
.	O	O
1	O	O
(	O	O
95	O	O
%	O	O
CI	O
3	O	O
.	O	O
9	O	O
-	O	O
4	O	O
.	O	O
3	O	O
)	O	O
per	O	O
1000	O	O
births	O
,	O	O
respectively	O	O
.	O	O

For	O	O
both	O	O
Indigenous	O
and	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
across	O	O
most	O	O
gestational	O
age	B-LIVB
groups	I-LIVB
,	O	O
antepartum	B-DISO
haemorrhage	I-DISO
,	O	O
SGA	B-DISO
,	O	O
pre	B-DISO
-	I-DISO
existing	I-DISO
diabetes	I-DISO
and	O	O
pre	B-DISO
-	I-DISO
existing	I-DISO
hypertension	I-DISO
were	O	O
associated	O
with	O
increased	O
risk	O
of	O	O
stillbirth	B-DISO
.	O	O

There	O	O
were	O	O
mixed	O	O
results	O	O
for	O	O
pre	B-DISO
-	I-DISO
eclampsia	I-DISO
and	O	O
eclampsia	B-DISO
and	O	O
a	O	O
consistently	O	O
raised	O	O
risk	O
of	O	O
stillbirth	B-DISO
was	O	O
not	O	O
seen	O	O
for	O	O
gestational	B-DISO
diabetes	I-DISO
.	O	O

This	O	O
study	B-PROC
highlights	O	O
gestational	B-PHYS
age	I-PHYS
specific	O	O
stillbirth	B-DISO
risk	O
for	O	O
Indigenous	O
and	O	O
non	O
-	O	O
Indigenous	O
women	B-LIVB
;	O	O
and	O	O
disparity	O	O
in	O	O
risk	O
at	O	O
term	B-PHYS
gestations	I-PHYS
.	O	O

Improving	O	O
access	O	O
to	O	O
and	O	O
utilisation	O	O
of	O	O
appropriate	O
and	O	O
responsive	O
healthcare	B-PROC
may	O	O
help	O	O
to	O	O
address	O	O
disparities	O	O
in	O	O
stillbirth	B-DISO
risk	O
for	O	O
Indigenous	O
women	B-LIVB
.	O	O

Defining	B-PROC
,	O	O
Describing	O
,	O	O
and	O	O
Categorizing	O
Public	B-PROC
Health	I-PROC
Infrastructure	I-PROC
Priorities	O
for	O	O
Tropical	B-PHEN
Cyclone	I-PHEN
,	O	O
Flood	B-PHEN
,	O	O
Storm	B-PHEN
,	O	O
Tornado	B-PHEN
,	O	O
and	O	O
Tsunami	B-PHEN
-	I-PHEN
Related	I-PHEN
Disasters	I-PHEN
The	O	O
study	B-PROC
aim	O	O
was	O	O
to	O	O
undertake	O	O
a	O	O
qualitative	O	O
research	O	O
literature	O
review	O
to	O	O
analyze	O	O
available	O	O
databases	O
to	O	O
define	B-PROC
,	O	O
describe	O
,	O	O
and	O	O
categorize	O
public	B-PROC
health	I-PROC
infrastructure	I-PROC
(	O	O
PHI	B-PROC
)	O	O
priorities	O
for	O	O
tropical	B-PHEN
cyclone	I-PHEN
,	O	O
flood	B-PHEN
,	O	O
storm	B-PHEN
,	O	O
tornado	B-PHEN
,	O	O
and	O	O
tsunami	B-PHEN
-	I-PHEN
related	I-PHEN
disasters	I-PHEN
.	O	O

Five	O	O
electronic	O	O
publication	O
databases	O
were	O	O
searched	O	O
to	O	O
define	B-PROC
,	O	O
describe	O
,	O	O
or	O	O
categorize	O
PHI	B-PROC
and	O	O
discuss	O
tropical	B-PHEN
cyclone	I-PHEN
,	O	O
flood	B-PHEN
,	O	O
storm	B-PHEN
,	O	O
tornado	B-PHEN
,	O	O
and	O	O
tsunami	B-PHEN
-	I-PHEN
related	I-PHEN
disasters	I-PHEN
and	O	O
their	O	O
impact	O
on	O	O
PHI	B-PROC
.	O	O

The	O	O
data	O
were	O	O
analyzed	O	O
through	O	O
aggregation	O
of	O	O
individual	O	O
articles	O
to	O	O
create	O	O
an	O	O
overall	O	O
data	O	O
description	O	O
.	O	O

The	O	O
data	O
were	O	O
grouped	O
into	O	O
PHI	B-PROC
themes	O
,	O	O
which	O	O
were	O	O
then	O	O
prioritized	O
on	O	O
the	O	O
basis	O	O
of	O	O
degree	O	O
of	O	O
interdependency	O	O
.	O	O

Sixty	O	O
-	O	O
seven	O	O
relevant	O	O
articles	O
were	O	O
identified	O	O
.	O	O

PHI	B-PROC
was	O	O
categorized	O
into	O	O
13	O	O
themes	O
with	O	O
a	O	O
total	O	O
of	O	O
158	O	O
descriptors	O
.	O	O

The	O	O
highest	O	O
priority	O
PHI	B-PROC
identified	O	O
was	O	O
workforce	O
.	O	O

This	O	O
was	O	O
followed	O	O
by	O	O
water	B-OBJC
,	O	O
sanitation	O
,	O	O
equipment	B-OBJC
,	O	O
communication	O
,	O	O
physical	B-OBJC
structure	I-OBJC
,	O	O
power	B-OBJC
,	O	O
governance	O
,	O	O
prevention	O
,	O	O
supplies	O
,	O	O
service	O
,	O	O
transport	B-OBJC
,	O	O
and	O	O
surveillance	O
.	O	O

This	O	O
review	O
identified	O	O
workforce	O
as	O	O
the	O	O
most	O	O
important	O	O
of	O	O
the	O	O
13	O	O
thematic	O
areas	O
related	O	O
to	O	O
PHI	B-PROC
and	O	O
disasters	B-PHEN
.	O	O

If	O	O
its	O	O
functionality	O	O
fails	O	O
,	O	O
workforce	O
has	O	O
the	O	O
greatest	O	O
impact	O	O
on	O	O
the	O	O
performance	O	O
of	O	O
health	B-PROC
services	I-PROC
.	O	O

If	O	O
addressed	O	O
post	O
-	O
disaster	O
,	O	O
the	O	O
remaining	O	O
forms	O	O
of	O	O
PHI	B-PROC
will	O	O
then	O	O
be	O	O
progressively	O	O
addressed	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
a	O	O
step	O	O
toward	O	O
providing	O	O
an	O	O
evidence	O	O
base	O	O
to	O	O
inform	O	O
PHI	B-PROC
priorities	O
in	O	O
the	O	O
disaster	B-PHEN
setting	O	O
.	O	O

(	O	O
Disaster	O	O
Med	O	O
Public	O	O
Health	O	O
Preparedness	O	O
.	O	O
2016	O	O
;	O	O
10	O	O
:	O	O
598	O	O
-	O	O
610	O	O
)	O	O
.	O	O

Baby	O
FaceTime	O
:	O	O
can	O	O
toddlers	B-LIVB
learn	B-PHYS
from	O	O
online	O
video	O
chat	O
?	O	O
There	O	O
is	O	O
abundant	O	O
evidence	O
for	O	O
the	O	O
'	O	O
video	O
deficit	O
'	O	O
:	O	O
children	B-LIVB
under	B-DISO
2	I-DISO
years	I-DISO
old	O	O
learn	B-PHYS
better	I-PHYS
in	O	O
person	O	O
than	O	O
from	O	O
video	O
.	O	O

We	O	O
evaluated	O	O
whether	O	O
these	O	O
findings	B-DISO
applied	O	O
to	O	O
video	O
chat	O
by	O	O
testing	O	O
whether	O	O
children	B-LIVB
aged	O	O
12	O	O
-	O	O
25	O	O
months	O
could	O	O
form	O	O
relationships	O
with	O	O
and	O	O
learn	B-PHYS
from	O	O
on	O	O
-	O	O
screen	O	O
partners	O	O
.	O	O

We	O	O
manipulated	O	O
social	O
contingency	O
:	O	O
children	B-LIVB
experienced	O	O
either	O	O
real	O
-	O
time	O
FaceTime	O
conversations	O
or	O	O
pre	B-OBJC
-	I-OBJC
recorded	I-OBJC
Videos	I-OBJC
as	O	O
the	O	O
partner	O	O
taught	O	O
novel	O
words	O
,	O	O
actions	O
and	O	O
patterns	O
.	O	O

Children	B-LIVB
were	O	O
attentive	B-PHYS
and	O	O
responsive	O
in	O	O
both	O	O
conditions	O	O
,	O	O
but	O	O
only	O	O
children	B-LIVB
in	O	O
the	O	O
FaceTime	O
group	O
responded	O	O
to	O	O
the	O	O
partner	O	O
in	O	O
a	O	O
temporally	O
synced	O
manner	O
.	O	O

After	O	O
one	O
week	O
,	O	O
children	B-LIVB
in	O	O
the	O	O
FaceTime	O
condition	O	O
(	O	O
but	O	O
not	O	O
the	O	O
Video	O	O
condition	O	O
)	O	O
preferred	O
and	O	O
recognized	B-PHYS
their	O	O
Partner	O	O
,	O	O
learned	B-DISO
more	O	O
novel	O
patterns	O
,	O	O
and	O	O
the	O	O
oldest	O	O
children	B-LIVB
learned	B-DISO
more	O	O
novel	O
words	O
.	O	O

Results	O
extend	O	O
previous	O	O
studies	B-PROC
to	O	O
demonstrate	O	O
that	O	O
children	B-LIVB
under	O	O
2	O	O
years	O
show	O	O
social	B-PHYS
and	O	O
cognitive	B-PHYS
learning	I-PHYS
from	O	O
video	O
chat	O
because	O	O
it	O	O
retains	O	O
social	O
contingency	O
.	O	O

A	O	O
video	O	O
abstract	O	O
of	O	O
this	O	O
article	O	O
can	O	O
be	O	O
viewed	O	O
at	O	O
:	O	O
https	O	O
:	O	O
/	O	O
/	O	O
youtu	O	O
.	O	O

be	O	O
/	O	O
rTXaAYd5adA	O	O
.	O	O

Fragment	B-CHEM
-Based	O	O
Discovery	O
of	O	O
5	B-CHEM
-	I-CHEM
Arylisatin	I-CHEM
-Based	O	O
Inhibitors	B-CHEM
of	O	O
Matrix	B-CHEM
Metalloproteinases	I-CHEM
2	I-CHEM
and	O	O
13	B-CHEM
Matrix	B-CHEM
metalloproteinases	I-CHEM
(	O	O
MMPs	B-CHEM
)	O	O
are	O	O
well	O	O
-	O	O
established	O	O
targets	O	O
for	O	O
several	O	O
pathologies	B-DISO
.	O	O

In	O	O
particular	O	O
,	O	O
MMP	B-CHEM
-	I-CHEM
2	I-CHEM
and	O	O
MMP	B-CHEM
-	I-CHEM
13	I-CHEM
play	O	O
a	O	O
prominent	O	O
role	O	O
in	O	O
cancer	B-DISO
progression	I-DISO
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
a	O	O
structure	B-PROC
-	I-PROC
based	I-PROC
screening	I-PROC
campaign	O	O
was	O	O
applied	O	O
to	O	O
prioritize	O	O
metalloproteinase	B-CHEM
-oriented	O	O
fragments	B-CHEM
.	O	O

This	O	O
computational	O
model	O
was	O	O
applied	O	O
to	O	O
a	O	O
representative	O	O
fragment	B-CHEM
set	O
from	O	O
the	O	O
publically	O	O
available	O	O
EDASA	O
Scientific	O
compound	O
library	O
.	O	O

These	O	O
fragments	B-CHEM
were	O	O
prioritized	O	O
,	O	O
and	O	O
the	O	O
top	O	O
-	O	O
ranking	O	O
hits	O	O
were	O	O
tested	O	O
in	O	O
a	O	O
biological	B-PROC
assay	I-PROC
to	O	O
validate	B-PROC
the	O	O
model	O
.	O	O

Two	O	O
scaffolds	B-CHEM
showed	O	O
consistent	O	O
activity	O
in	O	O
the	O	O
assay	B-PROC
,	O	O
and	O	O
the	O	O
isatin	B-CHEM
-	I-CHEM
based	I-CHEM
compounds	I-CHEM
were	O	O
the	O	O
most	O	O
interesting	O	O
.	O	O

These	O	O
latter	O	O
fragments	B-CHEM
have	O	O
significant	O	O
potential	O	O
as	O	O
tools	O	O
for	O	O
the	O	O
design	O
and	O	O
realization	O	O
of	O	O
novel	O	O
MMP	B-CHEM
inhibitors	I-CHEM
.	O	O

In	O	O
addition	O	O
to	O	O
their	O	O
micromolar	O
activity	O
,	O	O
the	O	O
chemical	B-PHEN
synthesis	I-PHEN
affords	O	O
flexible	O
and	O	O
creative	O
access	O
to	O	O
their	O	O
analogues	B-CHEM
.	O	O

Dental	B-LIVB
Students	I-LIVB
'	O	O
Educational	B-PHEN
Environment	I-PHEN
and	O	O
Perceived	B-PHYS
Stress	B-DISO
:	O	O
The	O	O
University	B-OBJC
of	I-OBJC
Malaya	I-OBJC
Experience	B-PHYS
An	O	O
equitable	O	O
and	O	O
positive	O	O
learning	O
environment	O
fosters	O	O
deep	O	O
self	B-PROC
-	I-PROC
directed	I-PROC
learning	I-PROC
in	O	O
students	B-LIVB
and	O	O
,	O	O
consequently	O	O
,	O	O
good	O	O
practice	B-PHYS
in	O	O
their	O	O
profession	O
.	O	O

Although	O	O
demotivating	O
weaknesses	O
may	O	O
lead	O	O
to	O	O
repeated	O	O
day	O
-	O
to	O
-	O
day	O
stress	B-DISO
with	O	O
a	O	O
cascade	O	O
of	O	O
deleterious	O	O
consequences	O
at	O	O
both	O	O
personal	B-PHYS
and	O	O
professional	O
levels	O	O
,	O	O
a	O	O
possible	O	O
relationship	O
between	O	O
these	O	O
parameters	B-DISO
has	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
relationship	O
between	O	O
students	B-LIVB
'	O	O
perceptions	B-PHYS
of	O	O
their	O	O
educational	B-PHEN
environment	I-PHEN
and	O	O
their	O	O
stress	B-DISO
levels	O	O
.	O	O

Sixty	O	O
-	O	O
one	O	O
first	O	O
year	O	O
students	B-LIVB
at	O	O
the	O	O
Dental	B-LIVB
Faculty	I-LIVB
,	O	O
University	B-OBJC
of	I-OBJC
Malaya	I-OBJC
,	O	O
Malaysia	B-GEOG
participated	O
.	O	O

The	O	O
Dundee	O
Ready	O
Education	O
Environment	O
Measure	O
(	O	O
DREEM	O
)	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
educational	B-PHEN
environment	I-PHEN
while	O	O
self	O
-	O
rated	O
perceived	B-PHYS
stress	B-DISO
level	O	O
was	O	O
measured	O
by	O	O
the	O	O
Depression	O
Anxiety	O
Stress	O
Scale	O
(	O	O
DASS	O
)	O	O
.	O	O

Most	O	O
students	B-LIVB
(	O	O
62	O	O
.	O	O
39	O	O
%	O	O
)	O	O
showed	O	O
positive	O	O
perceptions	B-PHYS
for	O	O
the	O	O
total	O	O
and	O	O
five	O	O
domains	O	O
of	O	O
DREEM	O
.	O	O

The	O	O
highest	O	O
percentage	O	O
was	O	O
observed	O	O
for	O	O
""""	O	O
Students	B-LIVB
perception	B-PHYS
of	O	O
learning	B-PHYS
""""	O	O
(	O	O
64	O	O
.	O	O
04	O	O
%	O	O
)	O	O
while	O	O
the	O	O
lowest	O	O
was	O	O
for	O	O
""""	O	O
Students	B-LIVB
'	O	O
social	O	O
self	O	O
-	O	O
perception	B-PHYS
""""	O	O
(	O	O
60	O	O
.	O	O
32	O	O
%	O	O
)	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
61	O	O
%	O	O
of	O	O
students	B-LIVB
showed	O	O
high	O	O
perceived	B-PHYS
stress	B-DISO
levels	I-DISO
.	O	O

However	O	O
,	O	O
this	O	O
was	O	O
not	O	O
associated	O
with	O
their	O	O
DREEM	O
scores	O	O
.	O	O

Although	O	O
a	O	O
positive	O	O
perception	B-PHYS
of	O	O
their	O	O
educational	B-PHEN
environment	I-PHEN
was	O	O
found	O	O
,	O	O
minor	O	O
corrective	O
measures	O
need	O	O
to	O	O
be	O	O
implemented	O
.	O	O

Furthermore	O	O
,	O	O
longitudinal	B-PROC
studies	I-PROC
on	O	O
an	O	O
annual	O
basis	O
would	O	O
provide	O	O
useful	O	O
input	O	O
for	O	O
strategic	O
planning	O
purposes	O
.	O	O

Bacterial	O
Suppression	O
of	O	O
RNA	B-CHEM
Polymerase	I-CHEM
II	I-CHEM
-	O	O
Dependent	O
Host	B-LIVB
Gene	B-PHYS
Expression	I-PHYS
Asymptomatic	B-DISO
bacteriuria	I-DISO
(	O	O
ABU	B-DISO
)	O	O
is	O	O
a	O	O
bacterial	O	O
carrier	O	O
state	O	O
in	O	O
the	O	O
urinary	B-ANAT
tract	I-ANAT
that	O	O
resembles	O	O
commensalism	B-PHEN
at	O	O
other	O	O
mucosal	O
sites	O
.	O	O

ABU	B-DISO
strains	B-LIVB
often	O	O
lack	O	O
the	O	O
virulence	B-CHEM
factors	I-CHEM
that	O	O
characterize	O	O
uropathogenic	B-LIVB
Escherichia	I-LIVB
coli	I-LIVB
(	I-LIVB
E	I-LIVB
.	I-LIVB
coli	I-LIVB
)	I-LIVB
strains	I-LIVB
and	O	O
therefore	O	O
elicit	O	O
weak	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
in	O	O
the	O	O
urinary	B-ANAT
tract	I-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
ABU	B-DISO
strains	B-LIVB
are	O	O
active	O	O
modifiers	O	O
of	O	O
the	O	O
host	B-LIVB
environment	O
,	O	O
which	O	O
they	O	O
influence	O
by	O	O
suppressing	O
RNA	B-CHEM
polymerase	I-CHEM
II	I-CHEM
(	O	O
Pol	B-CHEM
II	I-CHEM
)	O	O
-	O	O
dependent	O
host	B-LIVB
gene	B-PHYS
expression	I-PHYS
.	O	O

In	O	O
patients	B-LIVB
inoculated	O	O
with	O	O
the	O	O
ABU	B-DISO
strain	B-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB

,	O	O
gene	B-PHYS
expression	I-PHYS
was	O	O
markedly	O	O
reduced	O
after	O	O
24	O	O
h	O
(	O	O
>	O	O
60	O	O
%	O	O
of	O	O
all	O	O
regulated	O	O
genes	O
)	O	O
.	O	O

Specific	O	O
repressors	B-CHEM
and	O	O
activators	B-CHEM
of	O	O
Pol	B-CHEM
II	I-CHEM
-	O	O
dependent	O
transcription	B-PHYS
were	O	O
modified	O
,	O	O
and	O	O
Pol	B-PHYS
II	I-PHYS
Serine	I-PHYS
2	I-PHYS
phosphorylation	I-PHYS
was	O	O
significantly	O	O
inhibited	O
,	O	O
indicating	O	O
reduced	O
activity	B-PHYS
of	O	O
the	O	O
polymerase	B-CHEM
.	O	O

This	O	O
active	O	O
inhibition	O
included	O	O
disease	B-DISO
-associated	O	O
innate	B-PHYS
immune	I-PHYS
response	I-PHYS
pathways	B-PHYS
,	O	O
defined	O	O
by	O	O
TLR4	B-CHEM
,	O	O
IRF	B-CHEM
-	I-CHEM
3	I-CHEM
and	O	O
IRF	B-CHEM
-	I-CHEM
7	I-CHEM
,	O	O
suggesting	O	O
that	O	O
ABU	B-DISO
strains	B-LIVB
persist	O	O
in	O	O
human	B-LIVB
hosts	B-LIVB
by	O	O
active	O	O
suppression	O
of	O	O
the	O	O
antibacterial	B-PHYS
defense	I-PHYS
.	O	O

In	O	O
a	O	O
search	O	O
for	O	O
the	O	O
mechanism	O
of	O	O
inhibition	O
,	O	O
we	O	O
compared	O
the	O	O
whole	O
genome	O
sequences	O
of	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
and	O	O
the	O	O
uropathogenic	B-LIVB
strain	I-LIVB
E	I-LIVB
.	I-LIVB

coli	I-LIVB
CFT073	I-LIVB
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
known	O	O
loss	O	O
of	O	O
virulence	B-PHEN
genes	O
,	O	O
we	O	O
observed	O	O
that	O	O
the	O	O
ABU	B-DISO
strain	B-LIVB
has	O	O
acquired	O	O
several	O	O
phages	B-LIVB
and	O	O
identified	O	O
the	O	O
lytic	B-LIVB
Prophage	I-LIVB
3	I-LIVB
as	O	O
a	O	O
candidate	O	O
Pol	B-CHEM
II	I-CHEM
inhibitor	O
.	O	O

Intact	O	O
phage	B-LIVB
particles	O	O
were	O	O
released	O	O
by	O	O
ABU	B-DISO
during	O	O
in	O
vitro	O
growth	B-PHYS
in	O	O
human	B-LIVB
urine	B-ANAT
.	O	O

To	O	O
address	O	O
if	O	O
Prophage	B-LIVB
3	I-LIVB
affects	O	O
Pol	B-CHEM
II	I-CHEM
activity	B-PHYS
,	O	O
we	O	O
constructed	O	O
a	O	O
Prophage	B-LIVB
3	I-LIVB
negative	O	O
deletion	B-PHYS
mutant	I-PHYS
in	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
and	O	O
compared	O
the	O	O
effect	O
on	O	O
Pol	B-PHYS
II	I-PHYS
phosphorylation	I-PHYS
between	O	O
the	O	O
mutant	O
and	O	O
the	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
83972	I-LIVB
wild	O
type	O
(	O	O
WT	O
)	O	O
strains	B-LIVB
.	O	O

No	O	O
difference	O	O
was	O	O
detected	O	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
Pol	B-CHEM
II	I-CHEM
inhibitor	O
is	O	O
not	O	O
encoded	O	O
by	O	O
the	O	O
phage	B-LIVB
.	O	O

The	O	O
review	O	O
summarizes	O	O
the	O	O
evidence	O
that	O	O
the	O	O
ABU	B-DISO
strain	B-LIVB
E	B-LIVB
.	I-LIVB
coli	I-LIVB
83972	I-LIVB
modifies	O	O
host	B-LIVB
gene	B-PHYS
expression	I-PHYS
by	O	O
inhibition	O
of	O	O
Pol	B-PHYS
II	I-PHYS
phosphorylation	I-PHYS
,	O	O
and	O	O
discusses	O	O
the	O	O
ability	O	O
of	O	O
ABU	B-DISO
strains	B-LIVB
to	O	O
actively	O	O
create	O	O
an	O	O
environment	O
that	O	O
enhances	O
their	O	O
persistence	B-PHYS
.	O	O

Regulation	B-PHYS
of	O	O
ABCA1	O
and	O	O
ABCG1	O
gene	B-PHYS
expression	I-PHYS
in	O	O
the	O	O
intraabdominal	O
adipose	O
tissue	O
Tissue	B-PHYS
specific	I-PHYS
expression	I-PHYS
of	I-PHYS
genes	I-PHYS
encoding	O
cholesterol	B-CHEM
transporters	B-CHEM
ABCA1	B-CHEM
and	O	O
ABCG1	B-CHEM
as	O	O
well	O	O
as	O	O
genes	O
encoding	O
the	O	O
most	O	O
important	O	O
transcriptional	B-PHYS
regulators	B-CHEM
of	O	O
adipogenesis	B-PHYS
-	O	O
LXRa	B-CHEM
,	O	O
LXRb	B-CHEM
,	O	O
PPARg	B-CHEM
and	O	O
RORa	B-CHEM
has	O	O
been	O	O
investigated	O
in	O	O
intraabdominal	O
adipose	O
tissue	O
(	O	O
IAT	O
)	O	O
samples	B-OBJC
.A	O	O

direct	O	O
correlation	O
between	O	O
the	O	O
content	O	O
of	O	O
ABCA1	B-CHEM
and	O	O
ABCG1	B-CHEM
proteins	I-CHEM
with	O	O
RORa	B-CHEM
protein	I-CHEM
level	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
480	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
;	O	O
r	O	O
=	O	O
0	O	O
.	O	O
435	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
,	O	O
respectively	O	O
)	O	O
suggests	O
the	O	O
role	O	O
of	O	O
the	O	O
transcription	B-CHEM
factor	I-CHEM
RORa	B-CHEM
in	O	O
the	O	O
regulation	B-PHEN
of	O	O
IAT	O
ABCA1	B-CHEM
and	O	O
ABCG1	B-CHEM
protein	I-CHEM
levels	O
.	O	O

ABCA1	O
and	O	O
ABCG1	O
gene	B-PHYS
expression	I-PHYS
positively	O	O
correlated	O
with	O	O
obesity	B-DISO
indicators	B-CHEM
such	O	O
as	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

522	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
004	O	O
;	O	O
r	O	O
=	O	O
0	O	O
.	O	O

594	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
waist	B-PHYS
circumference	I-PHYS
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
403	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
033	O	O
;	O	O
r	O	O
=	O	O
0	O	O
.	O	O

474	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
013	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
development	O
of	O	O
obesity	B-DISO
is	O	O
associated	O
with	O
decreased	O
IAT	O
levels	O
of	O	O
RORa	O
and	O	O
LXRb	O
mRNA	B-CHEM
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
016	O	O
and	O	O
p	O	O
=	O	O
0	O	O
.	O	O

002	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

These	O	O
data	O
suggest	O
that	O	O
the	O	O
nuclear	B-CHEM
factor	I-CHEM
RORa	I-CHEM
can	O	O
play	O	O
a	O	O
significant	O
role	O	O
in	O	O
the	O	O
regulation	B-PHEN
of	O	O
cholesterol	B-PHYS
metabolism	I-PHYS
and	O	O
control	O
IAT	O
expression	B-PHYS
of	O	O
ABCA1	B-CHEM
and	O	O
ABCG1	B-CHEM
,	O	O
while	O	O
the	O	O
level	O
of	O	O
IAT	O
LXRb	O
gene	B-PHYS
expression	I-PHYS
may	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
associated	O
with	O
the	O	O
development	O
of	O	O
obesity	B-DISO
.	O	O

Evaluation	O
of	O	O
the	O	O
effects	O
of	O
an	O	O
offer	O	O
of	O	O
a	O	O
monetary	B-OBJC
incentive	O
on	O	O
the	O	O
rate	O
of	O
questionnaire	O
return	O
during	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O	O
a	O	O
clinical	B-PROC
trial	I-PROC
:	O	O
a	O	O
randomised	B-PROC
study	I-PROC
within	I-PROC
a	I-PROC
trial	I-PROC
A	O	O
systematic	O
review	O
on	O	O
the	O	O
use	O	O
of	O	O
incentives	O
to	O	O
promote	O
questionnaire	O
return	O
in	O	O
clinical	B-PROC
trials	I-PROC
suggest	O	O
they	O	O
are	O	O
effective	O
,	O	O
but	O	O
not	O	O
all	O	O
studies	B-PROC
have	O	O
sufficient	O	O
funds	O
to	O	O
use	O	O
them	O	O
.	O	O

Promising	O
an	O	O
incentive	O
once	O	O
data	O
are	O	O
returned	O
can	O	O
reduce	O
the	O	O
cost	O
-	O
burden	O
of	O	O
this	O	O
approach	O	O
,	O	O
with	O	O
possible	O	O
further	O	O
cost	O
-	O
savings	O
if	O	O
the	O	O
offer	O	O
were	O	O
restricted	O
to	O	O
reminder	O
letters	O
only	O	O
.	O	O

This	O	O
study	B-PROC
aimed	O	O
to	O	O
evaluate	B-PROC
the	O	O
effect	O
of	O	O
promising	O
a	O	O
monetary	B-OBJC
incentive	O
at	O	O
first	O	O
mailout	B-OBJC
versus	O	O
a	O	O
promise	O
on	O	O
reminder	O
letters	O
only	O	O
.	O	O

This	O	O
was	O	O
a	O	O
randomised	B-PROC
Study	I-PROC
Within	I-PROC
A	I-PROC
Trial	I-PROC
(	O	O
SWAT	B-PROC
)	O	O
nested	O	O
within	O	O
BUMPES	B-PROC
,	O	O
a	O	O
multicentre	B-PROC
randomised	I-PROC
controlled	I-PROC
trial	I-PROC
of	O	O
maternal	B-DISO
position	O
in	O	O
the	O	O
late	O
stage	O
of	O	O
labour	B-PHYS
in	O	O
women	B-LIVB
with	O	O
an	O	O
epidural	B-ANAT
.	O	O

The	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
questionnaire	O
asked	O	O
for	O	O
information	O
on	O	O
the	O	O
women	O
's	O
health	O
,	O	O
wellbeing	O
and	O	O
health	B-PROC
service	I-PROC
use	O	O
one	O
year	O
following	O	O
the	O	O
birth	B-PHYS
of	O	O
their	O	O
baby	B-LIVB
.	O	O

Women	B-LIVB
who	O	O
consented	O
to	O	O
be	O	O
contacted	O	O
were	O	O
randomised	B-PROC
to	O	O
a	O	O
promise	O
of	O	O
a	O	O
monetary	B-OBJC
incentive	O
at	O	O
first	O	O
mailout	B-OBJC
or	O	O
a	O	O
promise	O	O
on	O	O
reminder	O
letters	O
only	O	O
.	O	O

Women	B-LIVB
were	O	O
given	O	O
an	O	O
option	O
of	O	O
completing	O	O
the	O	O
questionnaire	O
on	O	O
paper	B-OBJC
or	O	O
on	O	O
online	B-OBJC
.	O	O

The	O	O
incentive	O
was	O	O
posted	B-OBJC
out	I-OBJC
on	O	O
receipt	O	O
of	O	O
a	O	O
completed	O	O
questionnaire	O
.	O	O

The	O	O
primary	O
outcome	O
was	O	O
the	O	O
overall	O
return	O
rate	O
,	O	O
and	O	O
secondary	O
outcomes	O
were	O	O
the	O	O
return	O
rate	O
without	O	O
any	O	O
chasing	O	O
from	O	O
the	O	O
study	B-OBJC
office	I-OBJC
,	O	O
and	O	O
the	O	O
total	O
cost	O
of	O	O
the	O	O
vouchers	O
.	O	O

A	O	O
total	O	O
of	O	O
1	O	O
,	O	O
029	O	O
women	B-LIVB
were	O	O
randomised	B-PROC
,	O	O
508	O	O
to	O	O
the	O	O
first	O	O
mailout	B-OBJC
group	O
and	O	O
518	O	O
to	O	O
the	O	O
reminder	O
group	O
.	O	O

There	O	O
was	O	O
no	O
evidence	O
to	O	O
suggest	O	O
a	O	O
difference	O
between	O	O
groups	O
in	O	O
the	O	O
overall	O
return	O
rate	O
(	O	O
adjusted	O
RR	O
1	O	O
.	O	O
03	O	O
(	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
96	O	O
to	O	O
1	O	O
.	O	O
11	O	O
)	O	O
,	O	O
however	O	O
the	O	O
proportion	O
returned	O
without	O	O
chasing	O	O
was	O	O
higher	O	O
in	O	O
the	O	O
first	O	O
mailout	B-OBJC
group	O
(	O	O
adjusted	O
RR	O
1	O	O
.	O	O
22	O	O
,	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O

07	O	O
to	O	O
1	O	O
.	O	O
39	O	O
)	O	O
.	O	O

The	O	O
total	O
cost	O
of	O	O
the	O	O
vouchers	O
per	O	O
participant	B-LIVB
was	O	O
higher	O	O
in	O	O
the	O	O
first	O	O
mailout	B-OBJC
group	O
(	O	O
mean	O
difference	O
£	O	O
4	O	O
.	O	O
56	O	O
,	O	O
95	O	O
%	O	O
CI	O
£	O	O
4	O	O
.	O	O

02	O	O
to	O	O
£	O	O
5	O	O
.	O	O
11	O	O
)	O	O
.	O	O

Offering	O	O
a	O	O
monetary	B-OBJC
incentive	O
when	O	O
a	O	O
reminder	O
is	O	O
required	O
could	O	O
be	O	O
cost	O
-	O
effective	O
depending	O	O
on	O	O
the	O	O
sample	O
size	O
of	O	O
the	O	O
study	B-PROC
and	O	O
the	O	O
resources	O
available	O	O
to	O	O
administer	O
the	O	O
reminder	O
letters	O
.	O	O

The	O	O
BUMPES	B-PROC
Trial	I-PROC
is	O	O
registered	B-PROC
with	O	O
Current	B-PROC
Controlled	I-PROC
Trials	I-PROC
:	O	O
ISRCTN35706297	O	O
,	O	O
26	O	O
(	O	O
th	O	O
)	O	O
August	O	O
2009	O	O
.	O	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
expression	B-PHYS
and	O	O
high	O	O
microvessel	O
density	O
are	O	O
characteristic	O	O
features	O	O
in	O	O
serrated	B-DISO
colorectal	I-DISO
cancer	I-DISO
Serrated	B-DISO
colorectal	I-DISO
adenocarcinoma	I-DISO
(	O	O
SAC	B-DISO
)	O	O
is	O	O
a	O	O
morphologically	O
distinct	O	O
subtype	O
of	O	O
colorectal	B-DISO
cancer	I-DISO
(	O	O
CRC	B-DISO
)	O	O
,	O	O
in	O	O
which	O	O
increased	O	O
HIF	O
-	O
1α	O
mRNA	B-PHYS
expression	I-PHYS
and	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
stabilization	B-PHYS
are	O	O
typical	O	O
features	O	O
.	O	O

Here	O	O
we	O	O
aimed	O	O
to	O	O
further	O	O
elucidate	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	B-PHYS
expression	I-PHYS
in	O	O
serrated	B-DISO
and	O	O
non	B-DISO
-	I-DISO
serrated	I-DISO
colorectal	I-DISO
carcinomas	I-DISO
(	O	O
CRCs	B-DISO
)	O	O
and	O	O
their	O	O
precursor	B-DISO
lesions	I-DISO
and	O	O
its	O	O
association	O
with	O
vascular	B-CHEM
endothelial	I-CHEM
growth	I-CHEM
factor	I-CHEM
(	O	O
VEGF	B-CHEM
)	O	O
and	O	O
microvascular	O
density	O
(	O	O
MVD	O
)	O	O
.	O	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
and	O	O
VEGF	B-CHEM
expressions	B-PHYS
were	O	O
determined	O	O
immunohistochemically	B-PROC
in	O	O
134	O	O
serrated	B-DISO
polyps	I-DISO
(	O	O
SPs	B-DISO
)	O	O
,	O	O
104	O	O
non	B-DISO
-	I-DISO
serrated	I-DISO
adenomas	I-DISO
(	O	O
NSAs	B-DISO
)	O	O
,	O	O
81	O	O
SACs	B-DISO
,	O	O
and	O	O
74	O	O
matched	O	O
conventional	B-DISO
adenocarcinomas	I-DISO
(	O	O
CCs	B-DISO
)	O	O
and	O	O
were	O	O
correlated	O
with	O	O
morphology	O
,	O	O
clinicopathological	O
features	O
,	O	O
and	O	O
MVD	O
.	O	O

In	O	O
premalignant	B-DISO
lesions	I-DISO
,	O	O
both	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
and	O	O
VEGF	B-CHEM
were	O	O
expressed	B-PHYS
in	O	O
the	O	O
vast	O	O
majority	O	O
of	O	O
SPs	B-DISO
and	O	O
NSAs	B-DISO
.	O	O

In	O	O
CRCs	B-DISO
,	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
was	O	O
also	O	O
present	O	O
in	O	O
77	O	O
.	O	O

8	O	O
%	O	O
of	O	O
SACs	B-DISO
,	O	O
while	O	O
only	O	O
20	O	O
.	O	O
3	O	O
%	O	O
of	O	O
CCs	B-DISO
were	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
proficient	O	O
.	O	O

MVD	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
SACs	B-DISO
,	O	O
but	O	O
the	O	O
serrated	B-DISO
morphology	O
was	O	O
the	O	O
only	O	O
significant	O	O
predictor	O	O
of	O	O
MVD	O
in	O	O
CRC	B-DISO
in	O	O
multivariate	O
analyses	O
.	O	O

HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
protein	I-CHEM
is	O	O
often	O	O
stabilized	B-PROC
in	O	O
well	O
-	O
vascularized	O
SACs	B-DISO
,	O	O
suggesting	O	O
hypoxia	B-DISO
-	O	O
independent	B-PROC
stabilization	I-PROC
of	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
.	O	O

Moreover	O	O
,	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
stabilization	B-PHYS
did	O	O
not	O	O
associate	O
with	O
oncogenic	B-CHEM
activation	B-PHYS
of	O	O
BRAF	O
or	O	O
KRAS	O
or	O	O
Von	O
Hippel	O
-	O
Lindau	O
(	O	O
VHL	O
)	O	O
mutation	B-PHYS
.	O	O

Prevalent	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
expression	B-PHYS
in	O	O
SAC	B-DISO
and	O	O
its	O	O
precursors	O	O
support	O	O
the	O	O
importance	O	O
of	O	O
HIF	B-CHEM
-	I-CHEM
1α	I-CHEM
-mediated	O	O
pathways	B-PHYS
for	O	O
the	O	O
serrated	B-DISO
route	I-DISO
of	I-DISO
colorectal	I-DISO
carcinogenesis	I-DISO
.	O	O

Structure	O
-	O
Activity	O
Studies	O
of	O	O
β	B-CHEM
-	I-CHEM
Hairpin	I-CHEM
Peptide	B-CHEM
Inhibitors	B-CHEM
of	O	O
the	O	O
Plasmodium	O
falciparum	O
AMA1	B-CHEM
-	O	O
RON2	B-CHEM
Interaction	B-PHYS
The	O	O
interaction	B-PHYS
between	O	O
apical	B-CHEM
membrane	I-CHEM
antigen	I-CHEM
1	I-CHEM
(	O	O
AMA1	B-CHEM
)	O	O
and	O	O
rhoptry	B-CHEM
neck	I-CHEM
protein	I-CHEM
2	I-CHEM
(	O	O
RON2	B-CHEM
)	O	O
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
the	O	O
invasion	B-DISO
of	O	O
red	B-ANAT
blood	I-ANAT
cells	I-ANAT
by	O	O
Plasmodium	O
parasites	O
.	O	O

Disruption	O
of	O	O
this	O	O
critical	O	O
protein	B-PHYS
-	I-PHYS
protein	I-PHYS
interaction	I-PHYS
represents	O	O
a	O	O
promising	O	O
avenue	O	O
for	O	O
antimalarial	B-CHEM
drug	B-PROC
discovery	I-PROC
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
we	O	O
exploited	O	O
a	O	O
13	B-CHEM
-	I-CHEM
residue	I-CHEM
β	I-CHEM
-	I-CHEM
hairpin	I-CHEM
based	O	O
on	O	O
the	O	O
C	O
-	O
terminal	O
loop	O
of	O	O
RON2	B-CHEM
to	O	O
probe	B-DEVI
a	O	O
conserved	O	O
binding	B-CHEM
site	I-CHEM
on	O	O
Plasmodium	O
falciparum	O
AMA1	B-CHEM
.	O	O

A	O	O
series	O	O
of	O	O
mutations	B-PHYS
was	O	O
synthetically	O	O
engineered	B-PROC
into	O	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptides	B-CHEM
to	O	O
establish	O	O
structure	O
-	O
activity	O
relationships	O
.	O	O

The	O	O
best	O	O
mutations	B-PHYS
improved	O	O
the	O	O
binding	O
affinity	B-PHEN
of	O	O
the	O	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptide	B-CHEM
by	O	O
~7	O	O
-	O	O
fold	O	O
for	O	O
3D7	O	O
AMA1	B-CHEM
and	O	O
~14	O	O
-	O	O
fold	O	O
for	O	O
FVO	O
AMA1	B-CHEM
.	O	O

We	O	O
determined	O	O
the	O	O
crystal	B-CHEM
structures	I-CHEM
of	O	O
several	O	O
β	B-CHEM
-	I-CHEM
hairpin	I-CHEM
peptides	B-CHEM
in	O	O
complex	O	O
with	O	O
AMA1	B-CHEM
in	O	O
order	O	O
to	O	O
define	O	O
the	O	O
structural	B-CHEM
features	I-CHEM
and	O	O
specific	O	O
interactions	B-PHYS
that	O	O
contribute	O	O
to	O	O
improved	B-DISO
binding	O
affinity	B-PHEN
.	O	O

The	O	O
same	O	O
mutations	B-PHYS
in	O	O
the	O	O
longer	O	O
RON2sp2	B-CHEM
peptide	I-CHEM
(	O	O
residues	O
2027	O
-	O
2055	O
of	O	O
RON2	B-CHEM
)	O	O
increased	O	O
the	O	O
binding	O
affinity	B-PHEN
by	O	O
>	O	O
30	O	O
-	O	O
fold	O	O
for	O	O
3D7	O	O
and	O	O
FVO	O
AMA1	B-CHEM
,	O	O
producing	O	O
KD	O
values	O
of	O	O
2	O	O
.	O	O

1nM	O	O
and	O	O
0	O	O
.	O	O
4nM	O	O
,	O	O
respectively	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
most	O	O
potent	O
strain	O
-transcending	O	O
peptide	B-CHEM
reported	O	O
to	O	O
date	O	O
and	O	O
represents	O	O
a	O	O
valuable	O	O
tool	O	O
to	O	O
characterize	O	O
the	O	O
AMA1	B-CHEM
-	O	O
RON2	B-CHEM
interaction	B-PHYS
.	O	O

Haemophilus	B-DISO
influenzae	I-DISO
type	I-DISO
b	I-DISO
meningitis	I-DISO
in	O	O
a	O	O
vaccinated	B-PROC
and	O	O
immunocompetent	B-PHYS
child	B-LIVB
Invasive	B-DISO
Haemophilus	I-DISO
influenzae	I-DISO
type	I-DISO
b	I-DISO
(	I-DISO
Hib	I-DISO
)	I-DISO
disease	I-DISO
decreased	O	O
dramatically	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
conjugate	B-CHEM
vaccine	I-CHEM
in	O	O
routine	O
immunization	B-PROC
schedules	I-PROC
.	O	O

We	O	O
report	O
a	O	O
case	O	O
of	O	O
a	O	O
fifteen	O	O
-	O	O
months	O	O
-	O	O
old	O	O
girl	B-LIVB
,	O	O
previously	O	O
healthy	O
and	O	O
vaccinated	B-PROC
,	O	O
admitted	B-PROC
in	O	O
the	O	O
emergency	B-OBJC
room	I-OBJC
with	O	O
fever	B-DISO
and	O	O
vomiting	B-DISO
.	O	O

She	O	O
was	O	O
irritable	B-DISO
and	O	O
the	O	O
Brudzinski	B-DISO
's	I-DISO
sign	I-DISO
was	O	O
positive	B-DISO
.	O	O

The	O	O
cerebrospinal	B-ANAT
fluid	I-ANAT
(	O	O
CSF	B-ANAT
)	O	O
analysis	O	O
showed	O	O
pleocytosis	B-DISO
and	O	O
high	B-PHEN
protein	I-PHEN
level	I-PHEN
.	O	O

Empiric	O
intravenous	O
antibiotics	B-CHEM
(	O	O
ceftriaxone	B-CHEM
and	O	O
vancomycin	B-CHEM
)	O	O
were	O	O
administered	B-PROC
for	O	O
suspected	O	O
bacterial	B-DISO
meningitis	I-DISO
during	O	O
10	O	O
days	O
.	O	O

Serotyping	B-PROC
of	O	O
the	O	O
Haemophilus	B-LIVB
influenzae	I-LIVB
strain	I-LIVB
found	O	O
in	O	O
CSF	B-ANAT
revealed	O	O
a	O	O
serotype	O
b	O
.	O	O

After	O	O
one	O
year	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
no	B-DISO
Hib	I-DISO
meningitis	I-DISO
sequelae	O	O
were	O	O
noted	O	O
.	O	O

Despite	O	O
vaccination	B-PROC
compliance	B-DISO
and	O	O
absence	O	O
of	O	O
risk	B-DISO
factors	I-DISO
,	O	O
invasive	B-DISO
Hib	I-DISO
disease	I-DISO
can	O	O
occur	O	O
due	O	O
to	O	O
vaccine	B-CHEM
failure	O
.	O	O

Efforts	O	O
to	O	O
keep	O	O
the	O	O
low	O	O
incidence	O
of	O	O
invasive	B-DISO
Hib	I-DISO
disease	I-DISO
should	O	O
be	O	O
directed	O	O
to	O	O
the	O	O
maintenance	O	O
of	O	O
high	O	O
vaccination	B-PROC
coverage	O	O
rates	O	O
,	O	O
combined	O	O
with	O	O
the	O	O
notification	B-PROC
and	O	O
surveillance	B-PROC
strategies	I-PROC
already	O	O
implemented	O
in	O	O
each	O	O
country	B-GEOG
.	O	O

BRG1	B-CHEM
in	O	O
the	O	O
Nucleus	B-ANAT
Accumbens	I-ANAT
Regulates	O	O
Cocaine	B-DISO
-	I-DISO
Seeking	I-DISO
Behavior	I-DISO
Drug	B-DISO
addiction	I-DISO
is	O	O
defined	O	O
as	O	O
a	O	O
chronic	B-DISO
disease	I-DISO
characterized	O	O
by	O	O
compulsive	O	O
drug	B-DISO
seeking	I-DISO
and	O	O
episodes	O
of	O
relapse	O
despite	O	O
prolonged	O
periods	O
of	O	O
drug	O
abstinence	O
.	O	O

Neurobiological	B-PHEN
adaptations	I-PHEN
,	O	O
including	O	O
transcriptional	B-PHYS
and	O	O
epigenetic	B-PHYS
alterations	I-PHYS
in	O	O
the	O	O
nucleus	B-ANAT
accumbens	I-ANAT
,	O	O
are	O	O
thought	O	O
to	O	O
contribute	O	O
to	O	O
this	O	O
life	B-DISO
-	I-DISO
long	I-DISO
disease	I-DISO
state	I-DISO
.	O	O

We	O	O
previously	O	O
demonstrated	O	O
that	O	O
the	O	O
transcription	B-CHEM
factor	I-CHEM
SMAD3	B-CHEM
is	O	O
increased	O	O
after	O	O
7	O	O
days	O	O
of	O	O
withdrawal	B-DISO
from	I-DISO
cocaine	I-DISO
self	B-PROC
-	I-PROC
administration	I-PROC
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
still	O	O
unknown	O	O
which	O	O
additional	O	O
factors	O
participate	O	O
in	O	O
the	O	O
process	O	O
of	O	O
chromatin	B-PHYS
remodeling	I-PHYS
and	O	O
facilitate	O	O
the	O	O
binding	O	O
of	O	O
SMAD3	B-CHEM
to	O	O
promoter	B-CHEM
regions	I-CHEM
of	O	O
target	O
genes	O
.	O	O

Here	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
possible	O	O
interaction	B-PHYS
of	O	O
BRG1	B-CHEM
-also	O	O
known	O	O
as	O	O
SMARCA4	B-CHEM
,	O	O
an	O	O
adenosine	B-CHEM
triphosphatase	I-CHEM
-containing	O	O
chromatin	B-CHEM
remodeler	I-CHEM
-and	O	O
SMAD3	B-CHEM
in	O	O
response	O	O
to	O	O
cocaine	B-DISO
exposure	I-DISO
.	O	O

The	O	O
expression	B-PHYS
of	O	O
BRG1	B-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
its	O	O
binding	O	O
to	O	O
SMAD3	B-CHEM
and	O	O
target	B-CHEM
gene	I-CHEM
promoter	I-CHEM
regions	I-CHEM
,	I-CHEM
was	O	O
evaluated	O	O
in	O	O
the	O	O
nucleus	B-ANAT
accumbens	I-ANAT
and	O	O
dorsal	B-ANAT
striatum	I-ANAT
of	O	O
rats	B-LIVB
using	O	O
western	B-PROC
blotting	I-PROC
,	O	O
co	B-PROC
-	I-PROC
immunoprecipitation	I-PROC
,	O	O
and	O	O
chromatin	B-PROC
immunoprecipitation	I-PROC
following	O	O
abstinence	B-PROC
from	O	O
cocaine	B-PROC
self	I-PROC
-	I-PROC
administration	I-PROC
.	O	O

Rats	B-LIVB
were	O	O
assessed	O	O
for	O	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviors	I-DISO
after	O	O
either	O	O
intra	B-PROC
-	I-PROC
accumbal	I-PROC
injections	I-PROC
of	O	O
the	O	O
BRG1	B-CHEM
inhibitor	B-CHEM
PFI3	I-CHEM
or	O	O
viral	B-PHYS
-	I-PHYS
mediated	I-PHYS
overexpression	I-PHYS
of	O	O
BRG1	B-CHEM
.	O	O

After	O	O
withdrawal	B-DISO
from	I-DISO
cocaine	I-DISO
self	B-PROC
-	I-PROC
administration	I-PROC
,	O	O
BRG1	B-CHEM
expression	B-PHYS
and	O	O
complex	B-PHYS
formation	I-PHYS
with	I-PHYS
SMAD3	B-CHEM
are	O	O
increased	O	O
in	O	O
the	O	O
nucleus	B-ANAT
accumbens	I-ANAT
,	O	O
resulting	O	O
in	O	O
increased	O	O
binding	O	O
of	O	O
BRG1	B-CHEM
to	O	O
the	O	O
promoter	B-CHEM
regions	I-CHEM
of	O	O
Ctnnb1	O
,	O	O
Mef2d	O
,	O	O
and	O	O
Dbn1	O
.	O	O

Intra	B-PROC
-	I-PROC
accumbal	I-PROC
infusion	I-PROC
of	O	O
PFI3	B-CHEM
attenuated	O
,	O	O
whereas	O	O
viral	B-PHYS
overexpression	I-PHYS
of	O	O
Brg1	O
enhanced	O	O
,	O	O
cocaine	O
-	O
reinstatement	O
behavior	O
.	O	O

BRG1	B-CHEM
is	O	O
a	O	O
key	O	O
mediator	O	O
of	O	O
the	O	O
SMAD3	B-CHEM
-dependent	O	O
regulation	B-PHYS
of	I-PHYS
cellular	I-PHYS
and	I-PHYS
behavioral	I-PHYS
plasticity	I-PHYS
that	O	O
mediates	O	O
cocaine	B-DISO
seeking	I-DISO
after	O	O
a	O	O
period	O
of	O	O
withdrawal	B-DISO
.	O	O

The	O	O
blood	B-PHYS
lipid	I-PHYS
regulation	I-PHYS
of	O	O
Monascus	B-LIVB
-produced	O	O
monascin	B-CHEM
and	O	O
ankaflavin	B-CHEM
via	O	O
the	O	O
suppression	B-PHYS
of	O	O
low	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
assembly	O	O
and	O	O
stimulation	B-PROC
of	O	O
apolipoprotein	B-CHEM
A1	I-CHEM
expression	B-PHYS
in	O	O
the	O	O
liver	B-ANAT
Monascin	B-CHEM
(	O	O
MS	B-CHEM
)	O	O
and	O	O
ankaflavin	B-CHEM
(	O	O
AK	B-CHEM
)	O	O
produced	O	O
by	O	O
Monascus	B-LIVB
purpureus	I-LIVB
NTU	I-LIVB
568	I-LIVB
were	O	O
proven	O	O
to	O	O
show	O	O
excellent	O	O
hypolipidemic	B-DISO
effects	I-DISO
in	O	O
our	O	O
previous	O	O
studies	B-PROC
;	O	O
however	O	O
,	O	O
the	O	O
mechanism	B-PHYS
is	O	O
still	O	O
unclear	O	O
.	O	O

This	O	O
study	B-PROC
used	O	O
MS	B-CHEM
,	O	O
AK	B-CHEM
,	O	O
and	O	O
monacolin	B-CHEM
K	I-CHEM
as	O	O
test	B-OBJC
substances	I-OBJC
and	O	O
performed	O
tests	O
on	O	O
rats	B-LIVB
fed	O	O
high	B-PROC
-	I-PROC
fat	I-PROC
and	O	O
high	B-PROC
-	I-PROC
cholesterol	I-PROC
diet	I-PROC
for	O	O
8	O	O
weeks	O	O
.	O	O

The	O	O
lipid	O	O
levels	O	O
and	O	O
the	O	O
related	O	O
protein	O	O
levels	O	O
of	O	O
the	O	O
rats	B-LIVB
were	O	O
assessed	O
to	O	O
understand	O	O
the	O	O
effects	O
of	O
MS	B-CHEM
,	O	O
AK	B-CHEM
,	O	O
and	O	O
monacolin	B-CHEM
K	I-CHEM
on	O	O
lipid	O	O
metabolism	O	O
.	O	O

MS	B-CHEM
and	O	O
AK	B-CHEM
lowered	O	O
low	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
(	O	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
)	O	O
and	O	O
preserved	O	O
high	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
contents	O	O
.	O	O

MS	B-CHEM
and	O	O
AK	B-CHEM
inhibited	O
acetyl	B-CHEM
-	I-CHEM
coenzyme	I-CHEM
A	I-CHEM
acetyltransferase	I-CHEM
,	O	O
microsomal	B-CHEM
triglyceride	I-CHEM
transfer	I-CHEM
protein	I-CHEM
,	O	O
and	O	O
apolipoprotein	B-CHEM
(	I-CHEM
apo	I-CHEM
)	I-CHEM
B	I-CHEM
-	I-CHEM
100	I-CHEM
expression	B-PHYS
,	O	O
thereby	O	O
preventing	O	O
LDL	B-CHEM
assembly	B-PHYS
.	O	O

In	O	O
addition	O	O
,	O	O
enhanced	O	O
LDL	B-CHEM
-	O	O
receptor	B-PHYS
expression	I-PHYS
increased	O	O
the	O	O
transport	B-PHYS
of	O	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
to	O	O
the	O	O
liver	B-ANAT
for	O	O
metabolism	B-PHYS
.	O	O

MS	B-CHEM
and	O	O
AK	B-CHEM
also	O	O
significantly	O
increase	O
apo	B-CHEM
A1	I-CHEM
expression	B-PHYS
,	O	O
which	O	O
facilitates	O	O
high	B-CHEM
-	I-CHEM
density	I-CHEM
lipoprotein	I-CHEM
cholesterol	I-CHEM
formation	O	O
.	O	O

Monascus	B-LIVB
-	O	O
fermented	B-PHYS
MS	B-CHEM
and	O	O
AK	B-CHEM
can	O	O
perform	O
blood	B-PHYS
lipid	I-PHYS
regulation	I-PHYS
via	O	O
the	O	O
suppression	B-PHYS
of	O	O
LDL	B-CHEM
-	I-CHEM
C	I-CHEM
assembly	B-PHYS
and	O	O
stimulation	B-PROC
of	O	O
apo	B-CHEM
A1	I-CHEM
expression	B-PHYS
in	O	O
liver	B-ANAT
.	O	O

Acoustic	B-PHEN
Analysis	B-PROC
Before	O	O
and	O	O
After	O	O
Voice	B-PROC
Therapy	I-PROC
for	O	O
Laryngeal	B-DISO
Pathology	I-DISO
Background	O	O
Voice	B-DISO
problems	I-DISO
caused	O	O
by	O	O
pathologies	O
in	O	O
vocal	B-DISO
folds	I-DISO
are	O	O
well	O
known	O
.	O	O

Some	O	O
types	O	O
of	O	O
laryngeal	B-DISO
pathologies	I-DISO
have	O	O
certain	O	O
acoustic	B-PHEN
characteristics	O
.	O	O

Objective	B-PROC
evaluation	I-PROC
helps	O	O
characterize	O	O
the	O	O
voice	B-PHYS
and	O	O
voice	B-DISO
problems	I-DISO
providing	O	O
supporting	O	O
evidences	O
,	O	O
severity	O
of	O
disorders	O
.	O	O

It	O	O
helps	O	O
assess	B-PROC
the	O	O
response	B-PHYS
to	I-PHYS
the	I-PHYS
treatment	I-PHYS
and	O	O
measures	O
the	O
outcomes	O
.	O	O

Objective	O	O
The	O	O
objective	O
of	O
the	O
study	O
is	O	O
to	O	O
determine	O	O
the	O	O
effectiveness	O
of	O	O
the	O	O
voice	B-PROC
therapy	I-PROC
and	O	O
quantify	O
the	O	O
results	O
objectively	O	O
by	O	O
voice	B-DISO
parameters	I-DISO
.	O	O

Method	O	O
Study	B-PROC
includes	O	O
61	O	O
patients	B-LIVB
who	O	O
presented	O	O
with	O	O
different	O
types	O
of	O	O
laryngeal	B-DISO
pathologies	I-DISO
.	O	O

Acoustic	B-PHEN
analyses	B-PROC
and	O	O
voice	B-PROC
assessment	I-PROC
was	O	O
done	O	O
with	O	O
Dr	O
.	O

Speech	O
ver	O
4	O
(	O	O
Tiger	O
DRS	O
Inc	O
.	O
)	O	O
.	O	O

Acoustic	B-PHEN
parameters	O
including	O	O
fundamental	O
frequency	O
,	O	O
jitters	B-DISO
,	O	O
shimmers	O
,	O	O
Harmonic	O
to	O
noise	O
ratio	O
(	O	O
HNR	O
)	O	O
,	O	O
Normalized	O
noise	O
energy	O
(	O	O
NNE	O
)	O	O
were	O	O
analyzed	O	O
before	O	O
and	O	O
after	O	O
voice	B-PROC
therapy	I-PROC
.	O	O

Result	O
Bilateral	O
vocal	B-DISO
nodules	I-DISO
were	O	O
the	O	O
most	O	O
common	O	O
pathologies	O
comprising	O	O
44	O	O
.	O	O
26	O	O
%	O	O
.	O	O

All	O	O
acoustic	B-PHEN
parameters	O
showed	O	O
a	O	O
significant	O	O
difference	O
after	O	O
the	O	O
therapy	B-PROC
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
except	O	O
for	O	O
NNE	O
.	O	O

Dysphonia	B-DISO
due	O	O
to	O	O
vocal	B-DISO
fold	I-DISO
polyp	I-DISO
showed	O	O
no	B-DISO
improvement	I-DISO
even	O	O
after	O	O
voice	B-PROC
therapy	I-PROC
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Conclusion	O	O
Acoustic	B-PHEN
analysis	B-PROC
provides	O	O
an	O	O
objective	O
,	O	O
recordable	O
data	O
regarding	O	O
the	O	O
voice	B-DISO
parameters	I-DISO
and	O	O
its	O	O
pathologies	O
.	O	O

Though	O	O
,	O	O
few	O	O
pathology	O
require	O	O
alternative	B-PROC
therapy	I-PROC
rather	O	O
than	O	O
voice	B-PROC
therapy	I-PROC
,	O	O
overall	O	O
it	O	O
has	O	O
a	O	O
good	B-DISO
effect	I-DISO
on	O	O
glottic	B-PHYS
closure	I-PHYS
.	O	O

As	O	O
the	O	O
voice	B-PROC
therapy	I-PROC
can	O	O
improve	O	O
the	O	O
different	O
indices	O
of	O	O
voice	B-PHYS
,	O	O
it	O	O
can	O	O
be	O	O
viewed	O	O
as	O	O
imperative	O
part	O
of	O	O
treatment	B-PROC
and	O	O
to	O	O
monitor	B-PROC
progression	O
.	O	O

MALDI	B-PROC
-	I-PROC
TOF	I-PROC
mass	I-PROC
spectrometry	I-PROC
for	O	O
the	O	O
identification	O
of	O	O
lactic	B-LIVB
acid	I-LIVB
bacteria	I-LIVB
isolated	O
from	O	O
a	O	O
French	B-OBJC
cheese	I-OBJC
:	O	O
The	O	O
Maroilles	B-OBJC
In	O	O
this	O	O
study	B-PROC
we	O	O
identified	O
the	O	O
culturable	B-PROC
population	B-LIVB
of	O	O
mesophilic	O
lactic	B-LIVB
acid	I-LIVB
bacteria	I-LIVB
(	O	O
LAB	B-LIVB
)	O	O
from	O	O
a	O	O
French	B-OBJC
cheese	I-OBJC
Maroilles	I-OBJC
made	O	O
either	O	O
with	O	O
raw	B-OBJC
or	O	O
pasteurized	B-OBJC
milk	I-OBJC
using	O	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
mass	I-PROC
spectrometry	I-PROC
(	O	O
MS	B-PROC
)	O	O
.	O	O

Samples	B-OBJC
from	O	O
rind	O
and	O	O
heart	O
of	O	O
Maroilles	B-OBJC
cheese	I-OBJC
were	O	O
used	O	O
,	O	O
the	O	O
LAB	B-LIVB
were	O	O
selected	O	O
on	O	O
MRS	B-CHEM
agar	I-CHEM
at	O	O
30°C	O	O
and	O	O
197	O	O
Gram	B-PHEN
-	I-PHEN
positive	I-PHEN
and	O	O
catalase	B-PHYS
-	I-PHYS
negative	I-PHYS
strains	O
were	O	O
subjected	O	O
to	O	O
identification	O
by	O	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
MS	I-PROC
profiling	O
.	O	O

All	O	O
strains	O
were	O	O
unambiguously	O	O
identified	O
:	O	O
105	O	O
strains	O
from	O	O
Maroilles	B-OBJC
made	O	O
with	O	O
raw	B-OBJC
milk	I-OBJC
(	O	O
38	O	O
on	O	O
the	O	O
rind	O
and	O	O
67	O	O
in	O	O
the	O	O
heart	O
)	O	O
and	O	O
92	O	O
strains	O
from	O	O
Maroilles	B-OBJC
made	O	O
with	O	O
pasteurized	B-OBJC
milk	I-OBJC
(	O	O
39	O	O
on	O	O
the	O	O
rind	O
and	O	O
53	O	O
in	O	O
the	O	O
heart	O
)	O	O
.	O	O

MALDI	B-PROC
-	I-PROC
TOF	I-PROC
MS	I-PROC
identification	O
allowed	O	O
identification	O
of	O	O
three	O
genera	O
belonging	O	O
to	O	O
LAB	B-LIVB
including	O	O
Lactobacillus	B-LIVB
,	O	O
Enterococcus	B-LIVB
and	O	O
Leuconostoc	B-LIVB
.	O	O

Lactobacillus	B-LIVB
was	O	O
the	O	O
most	O	O
represented	O	O
genus	O
with	O	O
seven	O
species	O
:	O	O
Lactobacillus	B-LIVB
plantarum	I-LIVB
(	O	O
L	B-LIVB
.	I-LIVB
plantarum	I-LIVB
)	O	O
,	O	O
L	B-LIVB
.	I-LIVB

paracasei	I-LIVB
,	O	O
L	B-LIVB
.	I-LIVB

curvatus	I-LIVB
,	O	O
L	B-LIVB
.	I-LIVB

rhamnosus	I-LIVB
,	O	O
L	B-LIVB
.	I-LIVB

fructivorans	I-LIVB
,	O	O
L	B-LIVB
.	I-LIVB

parabuchneri	I-LIVB
,	O	O
L	B-LIVB
.	I-LIVB

brevis	I-LIVB
found	O	O
in	O	O
Maroilles	B-OBJC
made	O	O
with	O	O
both	O	O
kind	O	O
of	O	O
milk	B-OBJC
.	O	O

The	O	O
correlation	O
between	O	O
the	O	O
16S	B-CHEM
rDNA	I-CHEM
-based	O	O
identification	O
performed	O	O
on	O	O
selected	O	O
strains	O
and	O	O
those	O	O
obtained	O	O
by	O	O
MALDI	B-PROC
-	I-PROC
TOF	I-PROC
-	I-PROC
MS	I-PROC
demonstrates	O	O
that	O	O
this	O	O
fast	O	O
,	O	O
economically	O	O
affordable	O	O
,	O	O
robust	O
and	O	O
reliable	O
method	O
for	O	O
bacteria	B-LIVB
characterisation	O
stands	O	O
as	O	O
an	O	O
attractive	O	O
alternative	O	O
to	O	O
the	O	O
commonly	O	O
-	O	O
used	O	O
methods	O
and	O	O
its	O	O
application	O	O
in	O	O
food	O
industry	O
is	O	O
discussed	O	O
.	O	O

Is	O	O
there	O	O
a	O	O
role	O
for	O	O
surgical	B-PROC
resection	I-PROC
in	O	O
patients	B-LIVB
with	O	O
pancreatic	B-DISO
cancer	I-DISO
with	O	O
liver	B-DISO
metastases	I-DISO
responding	O	O
to	O	O
chemotherapy	B-PROC
?	O	O

New	O
chemotherapeutic	B-PROC
regimens	I-PROC
have	O	O
improved	O	O
survival	O
for	O	O
stage	O
IV	O
pancreatic	B-DISO
ductal	I-DISO
adenocarcinoma	I-DISO
and	O	O
occasionally	O	O
major	O	O
response	B-DISO
of	O	O
liver	B-DISO
metastases	I-DISO
can	O	O
be	O	O
observed	O	O
.	O	O

Aim	O	O
of	O	O
this	O	O
work	O	O
is	O	O
to	O	O
analyze	O	O
the	O	O
outcomes	O
of	O	O
patients	B-LIVB
undergoing	O	O
primary	O
chemotherapy	B-PROC
for	O	O
liver	B-DISO
metastases	I-DISO
from	O	O
pancreatic	B-DISO
cancer	I-DISO
and	O	O
to	O	O
evaluate	B-PROC
the	O	O
results	B-PHEN
of	O	O
surgical	B-PROC
resection	I-PROC
.	O	O

Retrospective	B-PROC
analysis	I-PROC
.	O	O

patients	B-LIVB
with	O	O
extra	B-ANAT
-	I-ANAT
hepatic	I-ANAT
metastases	B-DISO
,	O	O
patients	B-LIVB
with	O	O
Eastern	B-PHYS
Cooperative	I-PHYS
Oncology	I-PHYS
Group	I-PHYS
performance	I-PHYS
status	I-PHYS
≥3	O	O
,	O	O
patients	B-LIVB
undergoing	O	O
supportive	B-PROC
care	I-PROC
alone	O	O
.	O	O

127	O	O
patients	B-LIVB
were	O	O
identified	O	O
.	O	O

Liver	B-DISO
metastases	I-DISO
were	O	O
unilobar	O	O
in	O	O
28	O	O
.	O	O

5	O	O
%	O	O
of	O	O
patients	B-LIVB
.	O	O

Chemotherapy	B-PROC
regimens	I-PROC
included	O	O
gemcitabine	B-CHEM
alone	O	O
or	O	O
in	O	O
association	O
with	O
other	O	O
agents	B-CHEM
(	O	O
44	O	O
%	O	O
)	O	O
,	O	O
oxaliplatin	B-CHEM
,	O	O
irinotecan	B-CHEM
,	O	O
fluorouracil	B-CHEM
and	O	O
leucovorin	B-CHEM
(	O	O
FOLFIRINOX	B-PROC
8	O	O
%	O	O
)	O	O
,	O	O
and	O	O
cisplatin	B-CHEM
,	O	O
gemcitabine	B-CHEM
plus	O	O
capecitabine	B-CHEM
and	O	O
epirubicin	B-CHEM
(	O	O
PEXG	B-PROC
)	O	O
or	O	O
capecitabine	B-CHEM
and	O	O
docetaxel	B-CHEM
(	O	O
PDXG	B-PROC
)	O	O
or	O	O
epirubicin	B-CHEM
and	O	O
fluorouracil	B-CHEM
(	O	O
PEFG	B-PROC
)	O	O
(	O	O
48	O	O
%	O	O
)	O	O
.	O	O

56	O	O
patients	B-LIVB
(	O	O
44	O	O
%	O	O
)	O	O
had	O	O
a	O	O
complete	O
(	O	O
7	O	O
%	O	O
)	O	O
or	O	O
partial	O
response	B-DISO
(	O	O
37	O	O
%	O	O
)	O	O
.	O	O

surgical	B-PROC
resection	I-PROC
was	O	O
carried	O	O
out	O	O
in	O	O
11	O	O
patients	B-LIVB
(	O	O
8	O	O
.	O	O
5	O	O
%	O	O
)	O	O
.	O	O

Median	O
overall	O
survival	O
was	O	O
11	O	O
months	O
for	O	O
the	O	O
entire	O	O
cohort	B-LIVB
and	O	O
15	O	O
months	O
for	O	O
those	O	O
with	O	O
partial	O
/	O	O
complete	O
response	B-DISO
.	O	O

In	O	O
this	O	O
sub	O
-	O
group	O
median	O
survival	O
was	O	O
significantly	O
longer	O	O
(	O	O
46	O	O
versus	O	O
11	O	O
months	O
)	O	O
for	O	O
patients	B-LIVB
undergoing	O	O
resection	B-PROC
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

Independent	O
predictors	O
of	O	O
overall	O
survival	O
were	O	O
chemotherapy	B-PROC
with	O	O
multiple	O
agents	B-CHEM
(	O	O
HR	O
:	O	O
0	O	O
.	O	O
512	O	O
)	O	O
,	O	O
surgical	B-PROC
resection	I-PROC
(	O	O
HR	O
:	O	O
0	O	O
.	O	O
360	O	O
)	O	O
,	O	O
>	O	O
5	O	O
liver	B-DISO
metastases	I-DISO
at	O	O
diagnosis	B-DISO
(	O	O
HR	O
:	O	O
3	O	O
.	O	O
515	O	O
)	O	O
,	O	O
and	O	O
CA	B-PROC
19	I-PROC
.	I-PROC

9	I-PROC
reduction	O
<	O	O
50	O	O
%	O	O
of	O	O
baseline	O
value	O
(	O	O
HR	O
:	O	O
2	O	O
.	O	O
708	O	O
)	O	O
.	O	O

Surgical	B-PROC
resection	I-PROC
of	O	O
primary	O
pancreatic	B-DISO
tumor	I-DISO
with	O	O
or	O	O
without	O	O
residual	O
liver	B-DISO
disease	I-DISO
can	O	O
be	O	O
considered	O	O
in	O	O
selected	O	O
cases	O	O
after	O	O
primary	O
chemotherapy	B-PROC
and	O	O
it	O	O
is	O	O
associated	O
with	O
improved	B-DISO
survival	O
.	O	O

Applying	O	O
a	O	O
participatory	O
approach	O
to	O	O
the	O	O
promotion	O	O
of	O	O
a	O	O
culture	O
of	O
respect	O
during	O	O
childbirth	B-PHYS
Disrespect	O
and	O	O
abuse	O
(	O	O
D	O
&	O
A	O
)	O	O
during	O	O
facility	B-OBJC
-	I-OBJC
based	I-OBJC
childbirth	B-PHYS
is	O	O
a	O	O
topic	O	O
of	O	O
growing	O	O
concern	O	O
and	O	O
attention	O	O
globally	O	O
.	O	O

Several	O	O
recent	O	O
studies	B-PROC
have	O	O
sought	O	O
to	O	O
quantify	O	O
the	O	O
prevalence	O
of	O	O
D	O
&	O
A	O
,	O	O
however	O	O
little	O	O
evidence	O
exists	O	O
about	O	O
effective	O
interventions	B-PROC
to	O	O
mitigate	O	O
disrespect	O
and	O	O
abuse	O
,	O	O
and	O	O
promote	O	O
respectful	O	O
maternity	B-PROC
care	I-PROC
.	O	O

In	O	O
an	O	O
accompanying	O	O
article	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
process	O	O
of	O	O
selecting	O
,	O	O
implementing	O
,	O	O
and	O	O
evaluating	B-PROC
a	O	O
package	O	O
of	O	O
interventions	B-PROC
designed	O	O
to	O	O
prevent	O	O
and	O	O
reduce	O	O
disrespect	O
and	O	O
abuse	O
in	O	O
a	O	O
large	O	O
urban	O
hospital	O
in	O	O
Tanzania	B-GEOG
.	O	O

Though	O	O
that	O	O
study	B-PROC
was	O	O
not	O	O
powered	O	O
to	O	O
detect	B-DISO
a	O	O
definitive	O
impact	O
on	O	O
reducing	O	O
D	O
&	O
A	O
,	O	O
the	O	O
results	O
showed	O	O
important	O
changes	O	O
in	O	O
intermediate	O	O
outcomes	O
associated	O
with	O
this	O	O
goal	O
.	O	O

In	O	O
this	O	O
commentary	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
factors	O
that	O	O
enabled	O	O
this	O	O
effect	O
,	O	O
especially	O	O
the	O	O
participatory	O
approach	O
we	O	O
adopted	O	O
to	O	O
engage	O	O
key	O	O
stakeholders	O	O
throughout	O	O
the	O	O
planning	B-PHYS
and	O	O
implementation	O
of	O	O
the	O	O
program	O
.	O	O

Based	O	O
on	O	O
our	O	O
experience	O	O
and	O	O
findings	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
a	O	O
visible	O	O
,	O	O
sustained	O
,	O	O
and	O	O
participatory	B-PROC
intervention	I-PROC
process	I-PROC
;	O	O
committed	O	O
facility	B-OBJC
leadership	O
;	O	O
management	O
support	O
;	O	O
and	O	O
staff	O
engagement	O
throughout	O	O
the	O	O
project	O
contributed	O
to	O	O
a	O	O
marked	O	O
change	O	O
in	O	O
the	O	O
culture	O
of	O	O
the	O	O
hospital	B-OBJC
to	O	O
one	O	O
that	O	O
values	O	O
and	O	O
promotes	O
respectful	O	O
maternity	B-PROC
care	I-PROC
.	O	O

For	O	O
these	O	O
changes	O	O
to	O	O
translate	O	O
into	O	O
dignified	O
care	O
during	O	O
childbirth	B-PHYS
for	O	O
all	O	O
women	B-LIVB
in	O	O
a	O	O
sustainable	O	O
fashion	O	O
,	O	O
institutional	O
commitment	O
to	O	O
providing	O	O
the	O	O
necessary	O	O
resources	O
and	O	O
staff	B-LIVB
will	O	O
be	O	O
needed	O	O
.	O	O

Triterpenoids	B-CHEM
from	O	O
the	O	O
stems	B-LIVB
of	O	O
Tripterygium	B-LIVB
regelii	I-LIVB
Three	O	O
new	O	O
triterpenoids	B-CHEM
,	O	O
triregelolides	B-CHEM
A	O	O
,	O	O
B	O	O
(	O	O
1	O	O
,	O	O
2	O	O
)	O	O
,	O	O
and	O	O
triregeloic	B-CHEM
acid	I-CHEM
(	O	O
3	O	O
)	O	O
,	O	O
were	O	O
isolated	O
from	O	O
the	O	O
stems	B-LIVB
of	O	O
Tripterygium	B-LIVB
regelii	I-LIVB
along	O	O
with	O	O
twenty	O	O
known	O	O
triterpene	B-CHEM
analogues	B-CHEM
(	O	O
4	O	O
-	O	O
23	O	O
)	O	O
.	O	O

The	O	O
structures	O	O
of	O	O
three	O	O
new	O	O
compounds	B-CHEM
were	O	O
identified	O	O
by	O	O
analyzing	O	O
their	O	O
NMR	B-PROC
spectroscopic	I-PROC
and	O	O
HRESIMS	B-PROC
data	O	O
.	O	O

Compounds	B-CHEM
4	B-CHEM
,	O	O
7	B-CHEM
,	O	O
8	B-CHEM
,	O	O
10	B-CHEM
,	O	O
13	B-CHEM
,	O	O
14	B-CHEM
,	O	O
17	B-CHEM
,	O	O
21	B-CHEM
-	I-CHEM
23	I-CHEM
were	O	O
isolated	O
from	O	O
T	B-LIVB
.	I-LIVB

regelii	I-LIVB
for	O	O
the	O	O
first	O	O
time	O	O
.	O	O

Compounds	B-CHEM
3	B-CHEM
,	O	O
5	B-CHEM
,	O	O
6	B-CHEM
,	O	O
8	B-CHEM
,	O	O
9	B-CHEM
,	O	O
10	B-CHEM
,	O	O
14	B-CHEM
and	O	O
16	B-CHEM
showed	O	O
inhibitory	B-PHYS
effects	I-PHYS
on	I-PHYS
the	I-PHYS
proliferation	I-PHYS
of	O	O
human	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
MCF	B-ANAT
-	I-ANAT
7	I-ANAT
by	O	O
24	O	O
.	O	O

1	O	O
%	O	O
,	O	O
69	O	O
.	O	O
6	O	O
%	O	O
,	O	O
72	O	O
.	O	O
8	O	O
%	O	O
,	O	O
21	O	O
.	O	O
6	O	O
%	O	O
,	O	O
23	O	O
.	O	O
1	O	O
%	O	O
,	O	O
43	O	O
.	O	O
3	O	O
%	O	O
,	O	O
25	O	O
.	O	O
5	O	O
%	O	O
and	O	O
23	O	O
.	O	O

5	O	O
%	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
at	O	O
a	O	O
concentration	O
of	O	O
10μM	O	O
,	O	O
respectively	O	O
.	O	O

Prevalence	O
and	O	O
Self	B-PHYS
-	I-PHYS
recognition	I-PHYS
of	O	O
Chronic	B-DISO
Constipation	I-DISO
:	O	O
Results	O	O
of	O	O
an	O	O
Internet	O
Survey	O
Although	O	O
chronic	B-DISO
constipation	I-DISO
is	O	O
a	O	O
common	O	O
symptom	B-DISO
,	O	O
to	O	O
date	O	O
no	O	O
international	O
consensus	O
has	O	O
been	O	O
reached	O	O
regarding	O	O
its	O	O
definition	O	O
.	O	O

The	O	O
aims	O	O
of	O	O
this	O	O
study	B-PROC
were	O	O
(	O	O
1	O	O
)	O	O
to	O	O
investigate	O
defecation	B-PHYS
habits	O
and	O	O
(	O	O
2	O	O
)	O	O
to	O	O
examine	O	O
the	O	O
prevalence	O
of	O	O
constipation	B-DISO
using	O	O
the	O	O
Japanese	O
Society	O
of	O
Internal	O
Medicine	O
(	O	O
JSIM	O
)	O	O
and	O	O
the	O	O
Rome	O
III	O
criteria	O
using	O	O
an	O	O
online	O
survey	O
.	O	O

An	O	O
online	O	O
questionnaire	O
composed	O	O
of	O	O
items	O	O
on	O	O
the	O	O
frequency	O
,	O	O
interval	O
,	O	O
form	O	O
of	O	O
defecation	B-PHYS
,	O	O
the	O	O
management	O
,	O	O
and	O	O
self	B-PHYS
-	I-PHYS
recognition	I-PHYS
of	O	O
constipation	B-DISO
(	O	O
reference	O
standard	O
of	O	O
constipation	B-DISO
)	O	O
was	O	O
created	O	O
.	O	O

A	O	O
total	O	O
of	O	O
5155	O	O
valid	O	O
responses	O
were	O	O
received	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
constipation	B-DISO
symptoms	B-DISO
were	O	O
evaluated	B-PROC
through	O	O
a	O	O
survey	O
using	O	O
the	O	O
JSIM	O
and	O	O
the	O	O
Rome	O
III	O
criteria	O
.	O	O

In	O	O
the	O	O
internet	O
survey	O
,	O	O
28	O	O
.	O	O

4	O	O
%	O	O
of	O	O
the	O	O
respondents	B-LIVB
considered	O	O
themselves	O	O
to	O	O
be	O	O
constipated	B-DISO
.	O	O

Stratified	O
by	O	O
sex	B-PHYS
,	O	O
significantly	O	O
more	O	O
females	B-PHYS
(	O	O
37	O	O
.	O	O
5	O	O
%	O	O
)	O	O
than	O	O
males	B-PHYS
(	O	O
19	O	O
.	O	O
1	O	O
%	O	O
)	O	O
considered	O	O
themselves	O	O
to	O	O
be	O	O
constipated	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

The	O	O
prevalence	O
of	O	O
constipation	B-DISO
among	O	O
the	O	O
respondents	B-LIVB
was	O	O
28	O	O
.	O	O

0	O	O
%	O	O
using	O	O
the	O	O
Rome	O
III	O
,	O	O
but	O	O
only	O	O
10	O	O
.	O	O
1	O	O
%	O	O
using	O	O
the	O	O
JSIM	O
.	O	O

The	O	O
diagnostic	O
accuracy	O
was	O	O
73	O	O
.	O	O

2	O	O
%	O	O
for	O	O
the	O	O
Rome	O
III	O
and	O	O
78	O	O
.	O	O

1	O	O
%	O	O
for	O	O
the	O	O
JSIM	O
,	O	O
while	O	O
the	O	O
diagnostic	O
specificity	O
was	O	O
81	O	O
.	O	O
1	O	O
%	O	O
for	O	O
the	O	O
Rome	O
III	O
and	O	O
97	O	O
.	O	O

5	O	O
%	O	O
for	O	O
the	O	O
JSIM	O
.	O	O

However	O	O
,	O	O
the	O	O
diagnostic	O
sensitivities	O
for	O	O
both	O	O
measures	O
were	O	O
low	O	O
,	O	O
at	O	O
52	O	O
.	O	O

2	O	O
%	O	O
and	O	O
29	O	O
.	O	O
2	O	O
%	O	O
for	O	O
the	O	O
Rome	O
III	O
and	O	O
the	O	O
JSIM	O
,	O	O
respectively	O	O
.	O	O

The	O	O
online	O
survey	O
developed	O	O
for	O	O
this	O	O
study	B-PROC
was	O	O
able	O	O
to	O	O
provide	O	O
clarification	O
regarding	O	O
defecation	B-PHYS
patterns	O
.	O	O

The	O	O
results	O	O
also	O	O
suggest	O	O
a	O	O
discrepancy	B-DISO
between	O	O
the	O	O
self	B-PHYS
-	I-PHYS
recognized	I-PHYS
prevalence	O
of	O	O
constipation	B-DISO
in	O	O
Japan	B-GEOG
and	O	O
prevalence	O
of	O	O
constipation	B-DISO
based	O	O
on	O	O
the	O	O
JSIM	O
criteria	O	O
.	O	O

Development	O	O
of	O	O
Community	B-LIVB
Based	O	O
Learning	B-PHYS
and	O	O
Education	B-PROC
system	O
within	O	O
Undergraduate	B-PROC
Medical	I-PROC
Curriculum	O
of	O	O
Patan	O
Academy	O
of	O
Health	O
Sciences	O
In	O	O
response	O	O
to	O	O
continuing	O	O
health	B-DISO
disparities	I-DISO
between	O	O
rural	B-LIVB
and	O	O
urban	B-LIVB
population	I-LIVB
,	O	O
Patan	O
Academy	O
of	O
Health	O
Sciences	O
(	O	O
PAHS	O
)	O	O
was	O	O
established	O	O
in	O	O
2008	O	O
.	O	O

It	O	O
aimed	O	O
to	O	O
produce	O	O
physicians	B-LIVB
who	O	O
would	O	O
be	O	O
able	O	O
and	O	O
willing	O	O
to	O	O
serve	O	O
in	O	O
the	O	O
rural	O
areas	O
.	O	O

In	O	O
order	O	O
to	O	O
empower	B-PHYS
them	O	O
with	O	O
understanding	O	O
and	O	O
tools	O	O
to	O	O
address	O	O
health	B-DISO
issues	I-DISO
of	O	O
rural	B-LIVB
population	I-LIVB
,	O	O
an	O	O
innovative	O
curriculum	O
was	O	O
developed	O	O
.	O	O

This	O	O
paper	O	O
aims	O	O
to	O	O
describe	O	O
the	O	O
community	O
based	O
learning	O
and	O
education	O
(	O
CBLE	O
)	O
system	O
within	O	O
the	O	O
overall	O	O
framework	O	O
of	O	O
PAHS	O
undergraduate	B-PROC
medical	I-PROC
curriculum	O
.	O	O

A	O	O
Medical	B-LIVB
School	I-LIVB
Steering	I-LIVB
Committee	I-LIVB
(	O	O
MSSC	B-LIVB
)	O	O
comprising	O	O
of	O	O
a	O	O
group	O
of	O	O
committed	O	O
medical	O
educators	B-LIVB
led	O	O
the	O	O
curriculum	O
development	B-PHEN
process	I-PHEN
.	O	O

The	O	O
committee	B-LIVB
reviewed	O	O
different	O	O
medical	O
curricula	O
,	O	O
relevant	O
literatures	O
,	O	O
and	O	O
held	O	O
a	O	O
series	O	O
of	O	O
consultative	O
meetings	O
with	O	O
the	O	O
stakeholders	O	O
and	O	O
experts	O	O
within	O	O
and	O	O
outside	O	O
Nepal	B-GEOG
.	O	O

This	O	O
process	O	O
resulted	O	O
in	O	O
defining	O	O
the	O	O
desirable	O	O
attributes	O	O
,	O	O
terminal	O
competencies	O
of	O	O
the	O	O
graduates	B-LIVB
,	O	O
and	O	O
then	O	O
the	O	O
actual	O	O
development	O	O
of	O	O
the	O	O
entire	O	O
curriculum	O
including	O	O
CBLE	O
.	O	O

Given	O	O
the	O	O
critical	O
importance	O
of	O	O
population	B-PROC
health	I-PROC
,	O	O
25	O	O
%	O	O
of	O	O
the	O	O
curricular	O
weightage	O	O
was	O	O
allocated	O	O
to	O	O
the	O	O
Community	B-PROC
Health	I-PROC
Sciences	I-PROC
(	O	O
CHS	B-PROC
)	O	O
.	O	O

CBLE	O
system	O	O
was	O	O
developed	O	O
as	O	O
the	O	O
primary	O	O
means	O	O
of	O	O
delivering	O	O
CHS	B-PROC
curriculum	O
.	O	O

The	O	O
details	O	O
of	O	O
CBLE	O
system	O
was	O	O
finalized	O	O
for	O	O
implementation	O
with	O	O
the	O	O
first	O	O
cohort	B-LIVB
of	O	O
medical	B-LIVB
students	I-LIVB
commencing	O	O
their	O	O
studies	B-PROC
from	O	O
June	O
2010	O	O
.	O	O

The	O	O
CBLE	O
,	O	O
a	O	O
key	B-PHYS
educational	I-PHYS
strategy	I-PHYS
of	O	O
PAHS	O
curriculum	O
,	O	O
is	O	O
envisaged	O	O
to	O	O
improve	B-DISO
retention	O	O
and	O	O
performance	O
of	O	O
PAHS	O
graduates	B-LIVB
and	O	O
,	O	O
thereby	O	O
,	O	O
health	O
status	O
of	O	O
rural	B-LIVB
population	I-LIVB
.	O	O

However	O	O
,	O	O
whether	O	O
or	O	O
not	O	O
that	O	O
goal	O
will	O	O
be	O	O
achieved	O	O
needs	O	O
to	O	O
be	O	O
verified	O	O
after	O	O
the	O	O
graduates	B-LIVB
join	O	O
the	O	O
health	O
system	O
.	O	O

Antihypertensive	B-CHEM
medicines	I-CHEM
utilization	O
:	O	O
A	O	O
decade	O	O
-	O	O
long	O	O
nationwide	O	O
study	O	O
of	O	O
octogenarians	B-LIVB
,	O	O
nonagenarians	B-LIVB
and	O	O
centenarians	B-LIVB
Gaining	O	O
an	O	O
insight	O	O
into	O	O
the	O	O
utilization	O
of	O	O
antihypertensive	B-CHEM
medicines	I-CHEM
against	O	O
a	O	O
background	O	O
of	O	O
evolving	O	O
hypertension	B-PROC
treatment	I-PROC
guidelines	O
that	O	O
might	O	O
not	O	O
be	O	O
relevant	O	O
to	O	O
the	O	O
oldest	B-LIVB
old	I-LIVB
is	O	O
important	O	O
.	O	O

The	O	O
aim	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
characterize	O	O
the	O	O
overall	O
trends	O
in	O	O
the	O	O
utilization	O
of	O	O
antihypertensive	B-CHEM
medicines	I-CHEM
in	O	O
the	O	O
oldest	B-LIVB
old	I-LIVB
by	O	O
therapeutic	O
class	O
and	O	O
chemical	O
type	O
,	O	O
stratified	O	O
by	O	O
age	B-PHYS
and	O	O
sex	B-PHYS
over	O	O
a	O	O
decade	O	O
.	O	O

Antihypertensive	B-CHEM
medicines	I-CHEM
utilization	O
was	O	O
examined	O	O
using	O	O
the	O	O
therapeutic	B-PROC
and	O	O
chemical	B-CHEM
groups	I-CHEM
based	O	O
on	O	O
the	O	O
World	O
Health	O
Organization	O
Collaborating	O
Center	O
for	O
Drug	O
Statistics	O
Mythology	O
's	O
Anatomical	O
Therapeutic	O
Chemical	O
classification	O
system	O
for	O	O
all	O	O
individuals	B-LIVB
aged	O	O
≥80	B-LIVB
years	I-LIVB
.	O	O

Regression	O
and	O	O
repeated	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
analyses	I-PROC
was	O	O
carried	O	O
out	O	O
,	O	O
and	O	O
defined	O	O
daily	O
dose	O
was	O	O
used	O	O
to	O	O
describe	O	O
the	O	O
utilization	O
per	O	O
thousand	O	O
older	B-LIVB
people	I-LIVB
per	O	O
day	O	O
.	O	O

Utilization	O
of	O	O
antihypertensive	B-CHEM
medicines	I-CHEM
increased	O
over	O	O
the	O	O
decade	O	O
from	O	O
187	O	O
.	O	O

28	O	O
in	O	O
2005	O	O
to	O	O
205	O	O
.	O	O

01	O	O
defined	O	O
daily	O
dose	O
per	O	O
thousand	O	O
older	B-LIVB
people	I-LIVB
per	O	O
day	O	O
in	O	O
2014	O	O
,	O	O
and	O	O
shifted	O	O
from	O	O
mainly	O	O
diuretics	B-CHEM
to	O	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
.	O	O

Interestingly	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
diuretics	B-CHEM
,	O	O
utilization	O
of	O	O
all	O	O
medicines	B-CHEM
decreased	O
gradually	O	O
with	O	O
increasing	O	O
age	B-PHYS
.	O	O

Single	O	O
products	O	O
use	O	O
increased	O
by	O	O
1	O	O
.	O	O
48	O	O
-	O	O
fold	O	O
in	O	O
2014	O	O
compared	O	O
with	O	O
2005	O	O
,	O	O
and	O	O
for	O	O
fixed	O	O
-	O	O
dose	O	O
combinations	O	O
the	O	O
increase	O
was	O	O
1	O	O
.	O	O
41	O	O
-	O	O
fold	O	O
for	O	O
the	O	O
same	O	O
period	O	O
.	O	O

The	O	O
increased	O
utilization	O
of	O	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
is	O	O
consistent	O	O
with	O	O
recommendations	O
from	O	O
cardiovascular	B-ANAT
guidelines	O
formulated	O	O
from	O	O
large	O	O
randomized	B-PROC
control	I-PROC
trials	I-PROC
that	O	O
often	O	O
exclude	O	O
the	O	O
oldest	B-LIVB
old	I-LIVB
.	O	O

Interestingly	O	O
,	O	O
the	O	O
utilization	O
of	O	O
beta	B-CHEM
-	I-CHEM
blockers	I-CHEM
decreased	O
and	O	O
diuretics	B-CHEM
increased	O
in	O	O
centenarians	B-LIVB
.	O	O

The	O	O
utilization	O
of	O	O
calcium	B-CHEM
channel	I-CHEM
blockers	I-CHEM
and	O	O
angiotensin	B-CHEM
-	I-CHEM
converting	I-CHEM
enzyme	I-CHEM
inhibitors	I-CHEM
across	O	O
the	O	O
study	O	O
period	O	O
increased	O
in	O	O
all	O	O
age	B-PHYS
categories	O	O
.	O	O

Geriatr	O	O
Gerontol	O	O
Int	O	O
2016	O	O
;	O	O
••	O	O
:	O	O
••	O	O
-	O	O
••	O	O
.	O	O

Incidence	O
of	O	O
environmental	O
and	O	O
genetic	O
factors	O
causing	O	O
congenital	B-DISO
cataract	I-DISO
in	O	O
Children	B-LIVB
of	O	O
Lahore	O
To	O	O
check	O	O
the	O	O
incidence	O
of	O	O
environmental	O
and	O	O
genetic	O
factors	O
causing	O	O
congenital	B-DISO
cataract	I-DISO
in	O	O
infants	B-LIVB
.	O	O

The	O	O
descriptive	B-PROC
study	I-PROC
was	O	O
conducted	O	O
at	O	O
Layton	O
Rahmatullah	O
Benevolent	O
Trust	O
,	O	O
Lahore	O
,	O	O
Pakistan	B-GEOG
,	O	O
from	O	O
October	O	O
2013	O	O
to	O	O
April	O	O
2014	O	O
,	O	O
and	O	O
comprised	O	O
children	B-LIVB
under	O	O
15	O	O
years	O
of	O	O
age	B-PHYS
who	O	O
had	O	O
rubella	B-DISO
syndrome	I-DISO
,	O	O
herpes	B-DISO
simplex	I-DISO
,	O	O
birth	B-DISO
trauma	I-DISO
,	O	O
trisomy	B-DISO
21	I-DISO
,	O	O
Nance	B-DISO
-	I-DISO
Horan	I-DISO
syndrome	I-DISO
or	O	O
Lowe	B-DISO
's	I-DISO
syndrome	I-DISO
.	O	O

Of	O	O
the	O	O
38	O	O
,	O	O
000	O	O
cases	O
examined	O	O
,	O	O
120	O	O
(	O	O
0	O	O
.	O	O
3	O	O
%	O	O
)	O	O
patients	B-LIVB
were	O	O
diagnosed	B-DISO
with	O	O
congenital	B-DISO
cataract	I-DISO
.	O	O

Of	O	O
them	O	O
,	O	O
52	O	O
(	O	O
43	O	O
.	O	O
33	O	O
%	O	O
)	O	O
were	O	O
aged	B-PHYS
between	O	O
2	O	O
and	O	O
5	O	O
years	O
,	O	O
22	O	O
(	O	O
18	O	O
.	O	O

33	O	O
%	O	O
)	O	O
<	O	O
11	O	O
years	O
and	O	O
10	O	O
(	O	O
8	O	O
.	O	O
33	O	O
%	O	O
)	O	O
?	O	O
15	O	O
years	O
.	O	O

Bilateral	B-DISO
congenital	I-DISO
cataract	I-DISO
was	O	O
observed	O	O
in	O	O
91	O	O
(	O	O
75	O	O
.	O	O
83	O	O
%	O	O
)	O	O
patients	B-LIVB
and	O	O
unilateral	B-DISO
congenital	I-DISO
cataract	I-DISO
in	O	O
29	O	O
(	O	O
24	O	O
.	O	O
17	O	O
%	O	O
)	O	O
.	O	O

Environmental	O
factors	O
caused	O	O
72	O	O
(	O	O
62	O	O
.	O	O

07	O	O
%	O	O
)	O	O
cases	O
and	O	O
genetic	O
factors	O
caused	O	O
44	O	O
(	O	O
37	O	O
.	O	O
93	O	O
%	O	O
)	O	O
..	O	O
Congenital	B-DISO
cataract	I-DISO
predominated	O
in	O	O
boys	B-LIVB
compared	O	O
to	O	O
girls	B-LIVB
.	O	O

Early	O	O
diagnosis	B-DISO
and	O	O
adequate	O	O
therapy	B-PROC
requires	O	O
specific	O	O
technology	O
,	O	O
as	O	O
well	O	O
as	O	O
long	O
-	O
term	O
and	O	O
permanent	O
care	O
..	O	O

Biochemical	O
evidence	O	O
for	O	O
a	O	O
mitochondrial	B-ANAT
genetic	O
modifier	O
in	O	O
the	O	O
phenotypic	B-PHYS
manifestation	O
of	O	O
Leber	B-DISO
's	I-DISO
hereditary	I-DISO
optic	I-DISO
neuropathy	I-DISO
-associated	O	O
mitochondrial	B-DISO
DNA	I-DISO
mutation	I-DISO
Leber	B-DISO
's	I-DISO
hereditary	I-DISO
optic	I-DISO
neuropathy	I-DISO
(	O	O
LHON	B-DISO
)	O	O
is	O	O
the	O	O
most	O	O
common	O	O
mitochondrial	B-DISO
disease	I-DISO
.	O	O

Mitochondrial	B-ANAT
modifiers	O
are	O	O
proposed	O	O
to	O	O
modify	O	O
the	O	O
phenotypic	B-PHYS
expression	I-PHYS
of	O	O
primary	O	O
LHON	B-DISO
-associated	O	O
mitochondrial	B-CHEM
DNA	I-CHEM
(	O	O
mtDNA	B-CHEM
)	O	O
mutations	B-DISO
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
demonstrated	O	O
that	O	O
the	O	O
LHON	B-DISO
susceptibility	B-PHYS
allele	O
(	O	O
m	O
.	O
14502	O
T	O
>	O
C	O
,	O	O
p	O
.	O

58I	O
>	O
V	O
)	O	O
in	O	O
the	O	O
ND6	O
gene	O
modulated	O
the	O	O
phenotypic	B-PHYS
expression	I-PHYS
of	O	O
primary	O	O
LHON	B-DISO
-associated	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O	O

Twenty	O	O
-	O	O
two	O	O
Han	O
Chinese	O
pedigrees	O
carrying	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutations	I-PHYS
exhibited	O	O
significantly	O	O
higher	O	O
penetrance	O
of	O	O
optic	B-DISO
neuropathy	I-DISO
than	O	O
those	O	O
carrying	O	O
only	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O	O

We	O	O
performed	O	O
functional	O
assays	B-PROC
using	O	O
the	O	O
cybrid	B-ANAT
cell	I-ANAT
models	I-ANAT
,	O	O
generated	O	O
by	O	O
fusing	O	O
mtDNA	B-ANAT
-	I-ANAT
less	I-ANAT
ρ	I-ANAT
(	I-ANAT
o	I-ANAT
)	I-ANAT
cells	I-ANAT
with	O	O
enucleated	B-ANAT
cells	I-ANAT
from	O	O
LHON	B-DISO
patients	B-LIVB
carrying	O	O
both	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
and	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutations	I-PHYS
,	O	O
only	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
or	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
and	O	O
a	O	O
control	O	O
belonging	O	O
to	O	O
the	O	O
same	O	O
mtDNA	B-CHEM
haplogroup	B-PHYS
.	O	O

These	O	O
cybrids	B-ANAT
cell	I-ANAT
lines	I-ANAT
bearing	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
exhibited	O	O
mild	O	O
effects	O
on	O	O
mitochondrial	B-ANAT
functions	O
compared	O	O
with	O	O
those	O	O
carrying	O	O
only	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O	O

However	O	O
,	O	O
more	O	O
severe	O	O
mitochondrial	B-ANAT
dysfunctions	O
were	O	O
observed	O	O
in	O	O
cell	B-ANAT
lines	I-ANAT
bearing	O	O
both	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutations	I-PHYS
than	O	O
those	O	O
carrying	O	O
only	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
or	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
mutation	I-PHYS
altered	O	O
assemble	O	O
of	O	O
complex	B-CHEM
I	I-CHEM
,	O	O
thereby	O	O
aggravating	O	O
the	O	O
respiratory	O
phenotypes	B-PHYS
associated	O	O
with	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
,	O	O
resulted	O	O
in	O	O
a	O	O
more	O	O
defective	O
complex	B-CHEM
I	I-CHEM
.	O	O

Furthermore	O	O
,	O	O
more	O	O
reductions	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
mitochondrial	B-ANAT
ATP	B-CHEM
and	O	O
increasing	O	O
production	O	O
of	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
were	O	O
also	O	O
observed	O	O
in	O	O
mutant	B-DISO
cells	B-ANAT
bearing	O	O
both	O	O
m	B-PHYS
.	I-PHYS

14502	I-PHYS
T	I-PHYS
>	I-PHYS
C	I-PHYS
and	O	O
m	B-PHYS
.	I-PHYS

11778	I-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
than	O	O
those	O	O
carrying	O	O
only	O	O
11778	B-PHYS
G	I-PHYS
>	I-PHYS
A	I-PHYS
mutation	I-PHYS
.	O	O

Our	O	O
findings	O	O
provided	O	O
new	O	O
insights	O	O
into	O	O
the	O	O
pathophysiology	O
of	O	O
LHON	B-DISO
that	O	O
were	O	O
manifested	O
by	O
interaction	O	O
between	O	O
primary	O	O
and	O	O
secondary	O	O
mtDNA	B-CHEM
mutations	B-DISO
.	O	O

Improving	O
Care	B-PROC
Transitions	I-PROC
Across	O	O
Healthcare	B-PROC
Settings	O
Through	O	O
a	O	O
Human	B-DISO
Factors	I-DISO
Approach	O	O
After	O	O
more	O	O
than	O	O
two	O	O
decades	O
of	O	O
research	B-PROC
focused	O	O
on	O	O
care	B-PROC
transition	I-PROC
improvement	O
and	O	O
intervention	B-PROC
development	O
,	O	O
unfavorable	B-DISO
outcome	I-DISO
measures	O
associated	O
with	O
care	B-PROC
transitions	I-PROC
across	O	O
healthcare	B-PROC
settings	O
persist	O	O
.	O	O

Readmissions	O
rates	O
remain	O	O
an	O	O
important	O	O
outcome	O
to	O	O
target	O
for	O	O
intervention	B-PROC
,	O	O
adverse	B-DISO
events	I-DISO
associated	O
with	O
care	B-PROC
transitions	I-PROC
continue	O	O
to	O	O
be	O	O
an	O	O
issue	B-DISO
,	O	O
and	O	O
patients	B-LIVB
are	O	O
often	O	O
dissatisfied	B-PHYS
with	O	O
the	O	O
quality	O
of	O	O
their	O	O
care	O
.	O	O

Currently	O	O
,	O	O
interventions	B-PROC
to	O	O
improve	O	O
care	B-PROC
transitions	I-PROC
are	O	O
disease	B-DISO
specific	O
,	O	O
require	O	O
substantial	O
financial	B-PROC
investments	I-PROC
in	O	O
training	B-PROC
allied	B-LIVB
healthcare	I-LIVB
professionals	I-LIVB
,	O	O
or	O	O
focus	O	O
primarily	O	O
on	O	O
hospital	B-PROC
-	I-PROC
based	I-PROC
discharge	I-PROC
planning	I-PROC
with	O	O
mixed	O	O
results	O	O
.	O	O

This	O	O
complex	O
situation	O
requires	O	O
a	O	O
method	B-PROC
of	I-PROC
evaluation	I-PROC
that	O	O
can	O	O
provide	O	O
a	O	O
comprehensive	O
,	O	O
in	O
-	O
depth	O
,	O	O
and	O	O
context	O
-	O
driven	O
investigation	B-PROC
of	O	O
potential	B-DISO
risks	I-DISO
to	O	O
safe	O	O
care	B-PROC
transitions	I-PROC
across	O	O
healthcare	B-PROC
settings	O
,	O	O
which	O	O
can	O	O
lead	O	O
to	O	O
the	O	O
creation	O
of	O	O
effective	O
,	O	O
usable	O
,	O	O
and	O	O
sustainable	O
interventions	B-PROC
.	O	O

A	O	O
systems	O	O
'	O	O
approach	O	O
known	O	O
as	O	O
Human	O
Factors	O
and	O
Ergonomics	O
(	O	O
HFE	O
)	O	O
evaluates	O
the	O	O
factors	O
in	O	O
a	O	O
system	O	O
that	O	O
affect	O	O
human	O
performance	O
.	O	O

This	O	O
article	O
describes	O	O
how	O	O
HFE	O
can	O	O
complement	O	O
and	O	O
further	O	O
strengthen	O	O
efforts	O	O
to	O	O
improve	O
care	B-PROC
transitions	I-PROC
.	O	O

Transcriptome	O
and	O	O
Metabolome	B-PHEN
Analyses	B-PROC
of	O	O
Glucosinolates	B-CHEM
in	O	O
Two	O	O
Broccoli	B-LIVB
Cultivars	I-LIVB
Following	O	O
Jasmonate	B-CHEM
Treatment	O
for	O	O
the	O	O
Induction	O
of	O	O
Glucosinolate	B-CHEM
Defense	O
to	O	O
Trichoplusia	O
ni	O
(	O	O
Hübner	O
)	O	O
Lepidopteran	O
larvae	O
growth	B-PHYS
is	O	O
influenced	O
by	O	O
host	B-LIVB
plant	B-LIVB
glucosinolate	B-CHEM
(	O	O
GS	B-CHEM
)	O	O
concentrations	O
,	O	O
which	O	O
are	O	O
,	O	O
in	O	O
turn	O	O
,	O	O
influenced	O
by	O	O
the	O	O
phytohormone	B-CHEM
jasmonate	B-CHEM
(	O	O
JA	B-CHEM
)	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
insect	O
resistance	O
biomarkers	B-PHYS
to	O	O
lepidopteran	O
pests	B-LIVB
,	O	O
transcriptome	O
and	O	O
metabolome	B-PHEN
analyses	B-PROC
following	O	O
JA	B-CHEM
treatments	O
were	O	O
conducted	O	O
with	O	O
two	O	O
broccoli	B-LIVB
cultivars	I-LIVB
,	O	O
Green	B-LIVB
Magic	I-LIVB
and	O	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
,	O	O
which	O	O
have	O	O
differentially	O	O
induced	O
indole	B-CHEM
GSs	I-CHEM
,	O	O
neoglucobrassicin	B-CHEM
and	O	O
glucobrassicin	B-CHEM
,	O	O
respectively	O	O
.	O	O

To	O	O
test	O
these	O	O
two	O	O
inducible	O
GSs	B-CHEM
on	O	O
growth	B-PHYS
of	O	O
cabbage	O
looper	O
(	O	O
Trichoplusia	O
ni	O
)	O	O
,	O	O
eight	O	O
neonate	O	O
cabbage	O
looper	O
larvae	O
were	O	O
placed	O	O
onto	O	O
each	O	O
of	O	O
three	O	O
plants	B-LIVB
per	O	O
JA	B-CHEM
treatments	O
(	O	O
0	O	O
,	O	O
100	O	O
,	O	O
200	O	O
,	O	O
400	O	O
µM	O	O
)	O	O
three	O	O
days	O
after	O	O
treatment	O
.	O	O

After	O	O
five	O	O
days	O
of	O	O
feeding	O
,	O	O
weight	O
of	O	O
larvae	O
and	O	O
their	O	O
survival	O
rate	O
was	O	O
found	O	O
to	O	O
decrease	O
with	O	O
increasing	O
JA	B-CHEM
concentrations	O
in	O	O
both	O	O
broccoli	B-LIVB
cultivars	I-LIVB
.	O	O

JA	B-CHEM
-	O	O
inducible	O
GSs	B-CHEM
were	O	O
measured	O
by	O	O
high	B-PROC
performance	I-PROC
liquid	I-PROC
chromatography	I-PROC
.	O	O

Neoglucobrassicin	B-CHEM
in	O	O
Green	B-LIVB
Magic	I-LIVB
and	O	O
glucobrassicin	B-CHEM
in	O	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
leaves	B-LIVB
were	O	O
increased	O
in	O	O
a	O	O
dose	O
-	O
dependent	O
manner	O	O
.	O	O

One	O	O
or	O	O
both	O	O
of	O	O
these	O	O
glucosinolates	B-CHEM
and	O	O
/	O	O
or	O	O
their	O	O
hydrolysis	B-PHEN
products	B-OBJC
showed	O	O
significant	O	O
inverse	O
correlations	O
with	O	O
larval	O
weight	O
and	O	O
survival	O
(	O	O
five	O	O
days	O
after	O	O
treatment	O
)	O	O
while	O	O
being	O	O
positively	B-DISO
correlated	O
with	O	O
the	O	O
number	O	O
of	O	O
days	O
to	O	O
pupation	B-PHYS
.	O	O

This	O	O
implies	O	O
that	O	O
these	O	O
two	O	O
JA	B-CHEM
-	O	O
inducible	O
glucosinolates	B-CHEM
can	O	O
influence	O
the	O	O
growth	B-PHYS
and	O	O
survival	O
of	O	O
cabbage	O
looper	O
larvae	O
.	O	O

Transcriptome	B-PROC
profiling	I-PROC
supported	O	O
the	O	O
observed	O	O
changes	O
in	O	O
glucosinolate	B-CHEM
and	O	O
their	O	O
hydrolysis	B-PHEN
product	B-OBJC
concentrations	O
following	O	O
JA	B-CHEM
treatments	O
.	O	O

Several	O	O
genes	O
related	O	O
to	O	O
GS	B-CHEM
metabolism	B-PHYS
differentiate	O
the	O	O
two	O	O
broccoli	B-LIVB
cultivars	I-LIVB
in	O	O
their	O	O
pattern	O
of	O	O
transcriptional	B-PHYS
response	B-PHYS
to	O	O
JA	B-CHEM
treatments	O
.	O	O

Indicative	O	O
of	O	O
the	O	O
corresponding	O	O
change	O
in	O	O
indole	B-CHEM
GS	I-CHEM
concentrations	O
,	O	O
transcripts	B-CHEM
of	O	O
the	O	O
transcription	B-CHEM
factor	I-CHEM
MYB122	B-CHEM
,	O	O
core	O	O
structure	O	O
biosynthesis	O
genes	O
(	O	O
CYP79B2	O
,	O	O
UGT74B1	O
,	O	O
SUR1	O
,	O	O
SOT16	O
,	O	O
SOT17	O
,	O	O
and	O	O
SOT18	O
)	O	O
,	O	O
an	O	O
indole	B-CHEM
glucosinolate	I-CHEM
side	O	O
chain	O	O
modification	B-DISO
gene	O
(	O	O
IGMT1	O
)	O	O
,	O	O
and	O	O
several	O	O
glucosinolate	B-CHEM
hydrolysis	B-PHEN
genes	O	O
(	O	O
TGG1	O
,	O	O
TGG2	O
,	O	O
and	O	O
ESM1	O
)	O	O
were	O	O
significantly	O	O
increased	O
in	O	O
Green	B-LIVB
Magic	I-LIVB
(	O	O
statistically	O	O
significant	O	O
in	O	O
most	O	O
cases	O	O
at	O	O
400	O	O
µM	O	O
)	O	O
while	O	O
UGT74B1	O
and	O	O
MYB122	O
were	O	O
significantly	O	O
increased	O
in	O	O
VI	B-LIVB
-	I-LIVB
158	I-LIVB
.	O	O

Therefore	O	O
,	O	O
these	O	O
metabolite	B-CHEM
and	O	O
transcript	B-CHEM
biomarker	B-PHYS
results	O	O
indicate	O	O
that	O	O
transcriptome	B-PROC
profiling	I-PROC
can	O	O
identify	O
genes	O
associated	O	O
with	O	O
the	O	O
formation	O
of	O	O
two	O	O
different	O	O
indole	B-CHEM
GS	I-CHEM
and	O	O
their	O	O
hydrolysis	B-PHEN
products	B-OBJC
.	O	O

Therefore	O	O
,	O	O
these	O	O
metabolite	B-CHEM
and	O	O
transcript	B-CHEM
biomarkers	B-PHYS
could	O	O
be	O	O
useful	O	O
in	O	O
an	O	O
effective	O
marker	B-PHYS
-	O	O
assisted	O
breeding	B-PHYS
strategy	O	O
for	O	O
resistance	O
to	O	O
generalist	O	O
lepidopteran	O
pests	B-LIVB
in	O	O
broccoli	B-LIVB
and	O	O
potentially	O	O
other	O	O
Brassica	B-OBJC
vegetables	I-OBJC
.	O	O

Autoimmune	B-DISO
Myelofibrosis	I-DISO
in	O	O
Systemic	B-DISO
Lupus	I-DISO
Erythematosus	I-DISO
Report	O	O
of	O	O
Two	O	O
Cases	O
and	O	O
Review	O
of	O
the	O	O
Literature	O
Autoimmune	B-DISO
myelofibrosis	I-DISO
(	O	O
AIMF	B-DISO
)	O	O
is	O	O
a	O	O
rare	B-OBJC
entity	I-OBJC
of	O	O
steroid	B-CHEM
-	O	O
responsive	O
bone	B-DISO
marrow	I-DISO
fibrosis	I-DISO
that	O	O
accompanies	O	O
a	O	O
variety	O	O
of	O	O
autoimmune	B-DISO
diseases	I-DISO
,	O	O
particularly	O	O
systemic	B-DISO
lupus	I-DISO
erythematosus	I-DISO
(	O	O
SLE	B-DISO
)	O	O
.	O	O

Rarely	O
it	O	O
may	O	O
occur	O
in	O	O
patients	B-LIVB
with	O	O
autoimmune	B-PHYS
markers	I-PHYS
but	O	O
no	O	O
definable	O	O
autoimmune	B-DISO
disease	I-DISO
(	O	O
Primary	B-DISO
-	I-DISO
AIMF	I-DISO
)	O	O
.	O	O

We	O	O
report	O	O
the	O	O
cases	O
of	O	O
two	O	O
young	O
women	B-LIVB
with	O	O
SLE	B-DISO
-	O	O
associated	O
AIMF	B-DISO
(	O	O
SLE	B-DISO
-	O	O
AIMF	B-DISO
)	O	O
.	O	O

The	O	O
first	O	O
patient	B-LIVB
was	O	O
a	O	O
young	O
woman	B-LIVB
who	O	O
had	O	O
pancytopenia	B-DISO
,	O	O
massive	B-DISO
splenomegaly	I-DISO
and	O	O
reticulin	B-DISO
fibrosis	I-DISO
in	O	O
the	O	O
marrow	B-PROC
biopsy	I-PROC
.	O	O

The	O	O
pancytopenia	B-DISO
and	O	O
splenomegaly	B-DISO
resolved	B-DISO
completely	O	O
within	O	O
weeks	O
of	O	O
treatment	O
with	O	O
corticosteroids	B-CHEM
.	O	O

Repeat	O	O
marrow	B-PROC
biopsy	I-PROC
showed	O	O
marked	B-DISO
regression	I-DISO
of	O	O
marrow	B-DISO
fibrosis	I-DISO
.	O	O

The	O	O
second	O	O
patient	B-LIVB
was	O	O
a	O	O
young	O
woman	B-LIVB
with	O	O
fever	B-DISO
,	O	O
anasarca	B-DISO
,	O	O
bicytopenia	B-PHEN
and	O	O
reticulin	B-DISO
fibrosis	I-DISO
in	O	O
the	O	O
marrow	B-PROC
biopsy	I-PROC
.	O	O

Steroid	B-PROC
therapy	I-PROC
resulted	O
in	O	O
rapid	O	O
clinical	O
improvement	O
and	O	O
resolution	O
of	O	O
pancytopenia	B-DISO
.	O	O

A	O	O
review	O
of	O
the	O	O
literature	O
revealed	O
a	O	O
total	O	O
of	O	O
30	O	O
patients	B-LIVB
with	O	O
SLE	B-DISO
-	O	O
AIMF	B-DISO
reported	O	O
to	O	O
-	O	O
date	O
.	O	O

Patients	B-LIVB
with	O	O
SLE	B-DISO
-	O	O
AIMF	B-DISO
are	O	O
young	O
women	B-LIVB
with	O	O
SLE	B-DISO
and	O	O
blood	B-DISO
cytopenia	I-DISO
who	O	O
are	O	O
found	O	O
to	O	O
have	O	O
increased	O
bone	B-DISO
marrow	I-DISO
reticulin	I-DISO
on	O	O
marrow	B-PROC
biopsy	I-PROC
.	O	O

Steroid	B-PROC
therapy	I-PROC
results	O
in	O	O
rapid	O	O
hematological	O
recovery	O
and	O	O
regression	B-DISO
of	O	O
marrow	B-DISO
fibrosis	I-DISO
.	O	O

Whether	O	O
AIMF	B-DISO
is	O	O
one	O	O
of	O	O
several	O	O
hematological	O
complications	B-DISO
of	O	O
SLE	B-DISO
,	O	O
or	O	O
represents	O	O
a	O	O
unique	O
and	O	O
distinct	O
subset	O	O
of	O	O
patients	B-LIVB
with	O	O
SLE	B-DISO
in	O	O
not	O	O
clear	O	O
.	O	O

Prospective	B-PROC
studies	I-PROC
with	O	O
longer	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
are	O	O
needed	O	O
to	O	O
better	O
define	O	O
the	O	O
prevalence	O
and	O	O
clinical	B-PHYS
spectrum	I-PHYS
of	O	O
SLE	B-DISO
-	O	O
AIMF	B-DISO
.	O	O

The	O	O
clinical	B-DISO
prognosis	I-DISO
of	O	O
implants	B-DEVI
that	O	O
are	O	O
placed	O	O
against	O	O
super	B-DISO
-	I-DISO
erupted	I-DISO
opposing	O	O
dentition	B-ANAT
If	O	O
teeth	B-ANAT
are	O	O
missing	B-DISO
,	O	O
super	B-DISO
-	I-DISO
eruption	I-DISO
of	I-DISO
teeth	I-DISO
in	O	O
the	O	O
opposing	O
arch	O
can	O	O
occur	O	O
in	O	O
the	O	O
area	O
and	O	O
can	O	O
change	O	O
the	O	O
occlusal	B-PHYS
plane	I-PHYS
.	O	O

When	O	O
missing	B-DISO
teeth	I-DISO
are	O	O
replaced	O	O
with	O	O
implants	B-DEVI
,	O	O
the	O	O
oral	B-LIVB
surgeon	I-LIVB
must	O	O
determine	O	O
whether	O	O
or	O	O
not	O	O
the	O	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
need	O	O
to	O	O
be	O	O
treated	O
in	O	O
order	O	O
to	O	O
normalize	B-PROC
the	O	O
occlusal	B-PHYS
plane	I-PHYS
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
evaluated	B-PROC
the	O	O
clinical	B-DISO
prognosis	I-DISO
of	O	O
dentition	B-ANAT
after	O	O
implant	B-PROC
placement	I-PROC
and	O	O
prosthetic	B-PROC
treatment	I-PROC
were	O	O
completed	O
in	O	O
an	O	O
occlusal	B-PHYS
plane	I-PHYS
altered	O	O
by	O	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
in	O	O
the	O	O
opposing	O
arch	O
without	O	O
additional	O	O
treatment	O
of	O	O
the	O	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
teeth	I-ANAT
.	O	O

Twenty	O	O
-	O	O
two	O	O
patients	B-LIVB
(	O	O
9	O	O
males	B-PHYS
,	O	O
13	O	O
females	B-PHYS
)	O	O
were	O	O
treated	O
with	O	O
implants	B-DEVI
and	O	O
prosthetics	B-DEVI
without	O	O
addressing	O	O
the	O	O
super	B-DISO
-	I-DISO
erupted	I-DISO
opposing	O	O
dentition	B-ANAT
from	O	O
April	O	O
2004	O	O
to	O	O
August	O	O
2012	O	O
at	O	O
Seoul	B-GEOG
National	B-OBJC
University	I-OBJC
Bundang	I-OBJC
Hospital	I-OBJC
.	O	O

A	O	O
total	O	O
of	O	O
33	O	O
implants	B-DEVI
were	O	O
placed	O	O
.	O	O

Values	O	O
of	O	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
,	O	O
survival	O
rates	O
,	O	O
and	O	O
surgical	B-DISO
and	O	O
prosthetic	B-DISO
complications	I-DISO
for	O	O
an	O	O
average	O	O
of	O	O
29	O	O
.	O	O
6	O	O
months	O
after	O	O
prosthetic	B-PROC
loading	I-PROC
were	O	O
recorded	O	O
.	O	O

In	O	O
one	O	O
case	O
,	O	O
the	O	O
cover	B-DEVI
screw	I-DEVI
was	O	O
exposed	O	O
after	O	O
implant	B-PROC
surgery	I-PROC
.	O	O

The	O	O
mean	O	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
was	O	O
0	O	O
.	O	O

09±0	O	O
.	O	O
30	O	O
mm	O	O
.	O	O

Of	O	O
the	O	O
33	O	O
implants	B-DEVI
,	O	O
31	O	O
survived	B-PHEN
,	O	O
a	O	O
survival	O
rate	O
of	O	O
93	O	O
.	O	O

94	O	O
%	O	O
.	O	O

A	O	O
prosthetic	B-DISO
complication	I-DISO
occurred	O	O
in	O	O
one	O	O
case	O
but	O	O
functioned	O	O
well	O	O
after	O	O
correction	O	O
.	O	O

Favorable	O	O
clinical	B-PHEN
results	I-PHEN
from	O	O
prosthetic	B-DISO
complications	I-DISO
,	O	O
crestal	B-DISO
bone	I-DISO
loss	I-DISO
,	O	O
and	O	O
implant	B-DEVI
survival	O
rates	O
were	O	O
exhibited	O	O
in	O	O
implants	B-DEVI
next	O	O
to	O	O
a	O	O
super	B-ANAT
-	I-ANAT
erupted	I-ANAT
opposing	I-ANAT
tooth	I-ANAT
.	O	O

Adenosine	B-CHEM
and	O	O
the	O	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O	O
CGS21680	B-CHEM
,	O	O
upregulate	B-PHYS
CD39	B-CHEM
and	O	O
CD73	B-CHEM
expression	B-PHYS
through	O	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
CREB	B-CHEM
in	O	O
regulatory	B-ANAT
T	I-ANAT
cells	I-ANAT
isolated	O
from	O	O
septic	O
mice	B-LIVB
The	O	O
number	O	O
of	O	O
regulatory	B-ANAT
T	I-ANAT
cells	I-ANAT
(	O	O
Treg	B-ANAT
cells	I-ANAT
)	O	O
and	O	O
the	O	O
expression	B-PHYS
of	O	O
ectonucleoside	B-CHEM
triphosphate	I-CHEM
diphosphohydrolase	I-CHEM
1	I-CHEM
(	O	O
ENTPD1	B-CHEM
;	O	O
also	O	O
known	O	O
as	O	O
CD39	B-CHEM
)	O	O
and	O	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
ectonucleotidase	I-CHEM
(	O	O
NT5E	B-CHEM
;	O	O
also	O	O
known	O	O
as	O	O
CD73	B-CHEM
)	O	O
on	O	O
the	O	O
Treg	B-ANAT
cell	I-ANAT
surface	O
are	O	O
increased	O
during	O	O
sepsis	B-DISO
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
to	O	O
determine	O	O
the	O	O
factors	B-CHEM
leading	O	O
to	O	O
the	O	O
high	O
expression	B-PHYS
of	O	O
CD39	B-CHEM
and	O	O
CD73	B-CHEM
,	O	O
and	O	O
the	O	O
regulation	B-PHEN
of	I-PHEN
the	O	O
CD39	B-CHEM
/	O	O
CD73	B-CHEM
/	O	O
adenosine	B-CHEM
pathway	O
in	O	O
Treg	B-ANAT
cells	I-ANAT
under	O	O
septic	O
conditions	O	O
,	O	O
we	O	O
constructed	O	O
a	O	O
mouse	B-DISO
model	I-DISO
of	O	O
sepsis	B-DISO
and	O	O
separated	O	O
the	O	O
Treg	B-ANAT
cells	I-ANAT
using	O	O
a	O	O
flow	B-DEVI
cytometer	I-DEVI
.	O	O

The	O	O
Treg	B-ANAT
cells	I-ANAT
isolated	O
from	O	O
the	O	O
peritoneal	B-PROC
lavage	I-PROC
and	O	O
splenocytes	B-ANAT
of	O	O
the	O	O
mice	B-LIVB
were	O	O
treated	B-PROC
with	I-PROC
adenosine	B-CHEM
or	O	O
the	O	O
specific	O	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O	O
CGS21680	B-CHEM
,	O	O
and	O	O
were	O	O
transfected	B-PROC
with	O	O
specific	O	O
siRNA	B-CHEM
targeting	O
E2F	B-CHEM
transcription	I-CHEM
factor	I-CHEM
1	I-CHEM
(	O	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
or	O	O
cyclic	B-CHEM
adenosine	I-CHEM
monophosphate	I-CHEM
(	I-CHEM
cAMP	I-CHEM
)	I-CHEM
response	I-CHEM
element	I-CHEM
-	I-CHEM
binding	I-CHEM
protein	I-CHEM
(	O	O
CREB	B-CHEM
)	O	O
,	O	O
which	O	O
are	O	O
predicted	O	O
transcription	B-CHEM
regulatory	I-CHEM
factors	I-CHEM
of	O	O
CD39	B-CHEM
or	O	O
CD73	B-CHEM
.	O	O

The	O	O
regulatory	B-PHEN
relationships	O	O
among	O	O
these	O	O
factors	B-CHEM
were	O	O
then	O	O
determined	O	O
by	O	O
western	B-PROC
blot	I-PROC
analysis	I-PROC
and	O	O
dual	B-PROC
-	I-PROC
luciferase	I-PROC
reporter	I-PROC
assay	I-PROC
.	O	O

In	O	O
addition	O	O
,	O	O
changes	O
in	O	O
adenosine	B-PHYS
metabolism	I-PHYS
were	O	O
measured	O	O
in	O	O
the	O	O
treated	O
cells	B-ANAT
.	O	O

The	O	O
results	O	O
revealed	O	O
that	O	O
adenosine	B-CHEM
and	O	O
CGS21680	B-CHEM
significantly	O	O
upregulated	B-PHYS
CD39	B-CHEM
and	O	O
CD73	B-CHEM
expression	B-PHYS
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
CREB	B-CHEM
induced	O	O
CD39	B-CHEM
and	O	O
CD73	B-CHEM
expression	B-PHYS
,	O	O
and	O	O
were	O	O
upregulated	B-PHYS
by	O	O
adenosine	B-CHEM
and	O	O
CGS21680	B-CHEM
.	O	O

Adenosine	B-PHYS
triphosphate	I-PHYS
(	I-PHYS
ATP	I-PHYS
)	I-PHYS
hydrolysis	I-PHYS
and	O	O
adenosine	B-CHEM
generation	O
were	O	O
inhibited	O
by	O	O
the	O	O
knockdown	O
of	O	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
or	O	O
CREB	B-CHEM
,	O	O
and	O	O
were	O	O
accelerated	O
in	O	O
the	O	O
presence	O	O
of	O	O
CGS21680	B-CHEM
.	O	O

Based	O	O
on	O	O
these	O	O
results	O	O
,	O	O
it	O	O
can	O	O
be	O	O
inferred	O	O
that	O	O
adenosine	B-CHEM
,	O	O
the	O	O
adenosine	B-CHEM
A2A	I-CHEM
receptor	I-CHEM
agonist	I-CHEM
,	O	O
E2F	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
CREB	B-CHEM
are	O	O
the	O	O
possible	O	O
factors	B-CHEM
contributing	O	O
to	O	O
the	O	O
high	O
expression	B-PHYS
of	O	O
CD39	B-CHEM
and	O	O
CD73	B-CHEM
on	O	O
the	O	O
Treg	B-ANAT
cell	I-ANAT
surface	O
during	O	O
sepsis	B-DISO
.	O	O

Adenosine	B-CHEM
and	O	O
its	O	O
A2A	B-CHEM
receptor	I-CHEM
agonist	I-CHEM
served	O	O
as	O	O
the	O	O
signal	B-PHYS
transducer	I-PHYS
factors	B-CHEM
of	O	O
the	O	O
CD39	B-CHEM
/	O	O
CD73	B-CHEM
/	O	O
adenosine	B-CHEM
pathway	O
,	O	O
accelerating	O
adenosine	B-CHEM
generation	O
.	O	O

Our	O	O
study	O	O
may	O	O
benefit	O	O
further	O	O
research	B-PROC
on	O	O
adenosine	B-PHYS
metabolism	I-PHYS
for	O	O
the	O	O
treatment	B-PROC
of	O	O
sepsis	B-DISO
.	O	O

Exploring	O	O
Consumer	B-LIVB
and	O	O
Patient	B-LIVB
Knowledge	O
,	O	O
Behavior	O
,	O	O
and	O	O
Attitude	B-PHYS
Toward	O
Medicinal	B-CHEM
and	O	O
Lifestyle	B-OBJC
Products	I-OBJC
Purchased	O
From	O	O
the	O	O
Internet	B-OBJC
:	O	O
A	O	O
Web	B-OBJC
-	O	O
Based	O
Survey	O
In	O	O
recent	O	O
years	O	O
,	O	O
lifestyle	B-OBJC
products	I-OBJC
have	O	O
emerged	O	O
to	O	O
help	O	O
improve	B-DISO
people	B-LIVB
's	I-LIVB
physical	B-PHYS
and	O	O
mental	B-PHYS
performance	O
.	O	O

The	O	O
Internet	B-OBJC
plays	O	O
a	O	O
major	O
role	O
in	O	O
the	O	O
spread	O
of	O	O
these	O	O
products	B-OBJC
.	O	O

However	O	O
,	O	O
the	O	O
literature	O
has	O	O
reported	O	O
issues	O	O
regarding	O	O
the	O	O
authenticity	O
of	O	O
medicines	B-CHEM
purchased	O
from	O	O
the	O	O
Internet	B-OBJC
and	O	O
the	O	O
impact	O
of	O	O
counterfeit	B-CHEM
medicines	I-CHEM
on	O	O
public	O
health	O
.	O	O

Little	O	O
or	O	O
no	O
data	O
are	O
available	O
on	O	O
the	O	O
authenticity	O
of	O	O
lifestyle	B-OBJC
products	I-OBJC
and	O	O
actual	O	O
toxicity	O
associated	O
with	O
their	O	O
use	O
and	O	O
misuse	B-DISO
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
investigate	O
consumer	O
and	O	O
patient	B-PHYS
attitudes	I-PHYS
toward	O
the	O	O
purchase	O
of	O	O
lifestyle	B-OBJC
products	I-OBJC
from	O	O
the	O	O
Internet	B-OBJC
,	O	O
their	O	O
knowledge	O
of	O	O
product	B-OBJC
authenticity	O
and	O	O
toxicity	O
,	O	O
and	O	O
their	O	O
experiences	B-PHYS
with	O	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
.	O	O

A	O	O
Web	B-OBJC
-	O	O
based	O
study	B-PROC
was	O	O
performed	O
between	O	O
May	O	O
2014	O	O
and	O	O
May	O	O
2015	O	O
.	O	O

Uniform	O
collection	B-PROC
of	I-PROC
data	I-PROC
was	O	O
performed	O
through	O
an	O	O
anonymous	O
online	B-OBJC
questionnaire	O
.	O	O

Participants	B-LIVB
were	O	O
invited	O	O
worldwide	O
via	O	O
email	O
,	O	O
social	O
media	O
,	O	O
or	O	O
personal	O
communication	O
to	O	O
complete	O
the	O	O
online	B-OBJC
questionnaire	O
.	O	O

A	O	O
total	O
of	O	O
320	O	O
participants	B-LIVB
completed	O
the	O	O
questionnaire	O
.	O	O

The	O	O
results	O
of	O	O
the	O	O
questionnaire	O
showed	O	O
that	O	O
208	O	O
(	O	O
65	O	O
.	O	O
0	O	O
%	O	O
)	O	O
participants	B-LIVB
purchased	O
lifestyle	B-OBJC
products	I-OBJC
from	O	O
the	O	O
Internet	B-OBJC
mainly	O
due	O
to	O
convenience	O
and	O	O
reduced	O
cost	O
.	O	O

More	O
than	O
half	O
(	O	O
55	O	O
.	O	O
6	O	O
%	O	O
,	O	O
178	O	O
/	O	O
320	O	O
)	O	O
of	O	O
participants	B-LIVB
purchased	O
cosmetic	B-OBJC
products	I-OBJC
,	O	O
whereas	O	O
only	O	O
a	O	O
minority	O
purchased	O
medicinal	B-CHEM
products	I-CHEM
.	O	O

Yet	O	O
,	O	O
62	O	O
.	O	O
8	O	O
%	O	O
(	O	O
201	O	O
/	O	O
320	O	O
)	O	O
of	O	O
participants	B-LIVB
were	O	O
aware	B-PHYS
of	O	O
the	O	O
presence	B-DISO
of	O	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
from	O	O
the	O	O
Internet	B-OBJC
,	O	O
and	O	O
11	O	O
.	O	O

9	O	O
%	O	O
(	O	O
38	O	O
/	O	O
320	O	O
)	O	O
experienced	B-PHYS
counterfeit	O
products	B-OBJC
.	O	O

In	O	O
only	O	O
0	O	O
.	O	O
9	O	O
%	O	O
(	O	O
3	O	O
/	O	O
320	O	O
)	O	O
of	O	O
those	O	O
cases	O
were	O	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
reported	B-PROC
to	O	O
authorities	O
.	O	O

Moreover	O	O
,	O	O
7	O	O
.	O	O
2	O	O
%	O	O
(	O	O
23	O	O
/	O	O
320	O	O
)	O	O
of	O	O
the	O	O
participants	B-LIVB
experienced	B-PHYS
adverse	B-DISO
effects	I-DISO
due	O	O
to	O	O
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
.	O	O

In	O	O
summary	O	O
,	O	O
patients	B-LIVB
experienced	B-PHYS
counterfeit	O
lifestyle	B-OBJC
products	I-OBJC
that	O	O
resulted	O
in	O
adverse	B-DISO
effects	I-DISO
on	O	O
their	O	O
health	O
.	O	O

Although	O	O
certain	O	O
adverse	B-DISO
effects	I-DISO
were	O	O
reported	B-PROC
in	O	O
this	O	O
study	B-PROC
,	O	O
counterfeit	O
products	B-OBJC
were	O	O
underreported	B-PROC
to	O	O
authorities	O
.	O	O

Further	O	O
public	O
awareness	O
campaigns	O
and	O	O
patient	B-PROC
education	I-PROC
are	O	O
needed	O
.	O	O

Evaluation	O
of	O	O
Mathisen	O
's	O
technique	O
for	O	O
ureteral	B-PROC
reimplantation	I-PROC
in	O	O
children	B-LIVB
with	O	O
primary	O
vesicoureteral	B-DISO
reflux	I-DISO
Although	O	O
cross	B-PROC
-	I-PROC
trigonal	I-PROC
ureteral	I-PROC
reimplantation	I-PROC
(	I-PROC
Cohen	I-PROC
)	I-PROC
is	O	O
a	O	O
commonly	O	O
used	O	O
technique	O
in	O	O
children	B-LIVB
,	O	O
it	O	O
represents	O	O
a	O	O
non	B-PHYS
-	I-PHYS
physiological	I-PHYS
transfer	I-PHYS
of	O	O
the	O	O
ureteral	B-ANAT
orifices	I-ANAT
and	O	O
may	O	O
prove	O	O
challenging	O	O
with	O	O
regard	O	O
to	O	O
endoscopic	B-PROC
ureteral	I-PROC
operations	I-PROC
in	O	O
later	O
life	O
.	O	O

In	O	O
1964	O	O
,	O	O
Mathisen	O	O
described	O
an	O	O
alternative	O
method	O
of	O	O
ureteral	B-PROC
reimplantation	I-PROC
with	O	O
lateralization	O
of	O	O
the	O	O
neohiatus	O
,	O	O
creating	O	O
an	O	O
orthotopic	O
course	O
of	O	O
the	O	O
submucosal	B-ANAT
ureter	I-ANAT
.	O	O

We	O	O
have	O	O
evaluated	O
success	O
and	O	O
complication	O
rates	O
of	O	O
both	O	O
techniques	O
that	O	O
were	O	O
applied	O
sequentially	O
at	O	O
our	O	O
departments	O
.	O	O

Forty	O	O
-	O	O
eight	O	O
consecutive	O
patients	B-LIVB
(	O	O
83	O	O
ureters	B-LIVB
,	O	O
24	O	O
males	B-LIVB
/24	O	O
females	B-LIVB
)	O	O
following	O	O
Mathisen	B-PROC
reimplantation	I-PROC
were	O	O
compared	O
with	O	O
53	O	O
consecutive	O
patients	B-LIVB
(	O	O
98	O	O
ureters	B-LIVB
,	O	O
30	O	O
males	B-LIVB
/23	O	O
females	B-LIVB
)	O	O
following	O	O
Cohen	B-PROC
reimplantation	I-PROC
.	O	O

Inclusion	O
criteria	O
were	O	O
primary	O
vesicoureteral	B-DISO
reflux	I-DISO
(	O	O
VUR	B-DISO
)	O	O
and	O	O
no	O	O
previous	O
intervention	B-PROC
.	O	O

Reflux	B-DISO
grades	O
(	O	O
Mathisen	O	O
58	O	O
ureters	B-LIVB
/69	O	O
.	O	O

9	O	O
%	O	O
VUR	B-DISO
≥	I-DISO
III	I-DISO
;	O	O
Cohen	O	O
66	O	O
ureters	B-LIVB
/66	O	O
.	O	O

7	O	O
%	O	O
VUR	B-DISO
≥	I-DISO
III	I-DISO
)	O	O
and	O	O
the	O	O
occurence	O	O
of	O	O
other	O	O
complicating	O
factors	O
(	O	O
ureteroceles	B-DISO
,	O	O
megaureters	B-DISO
,	O	O
posterior	B-DISO
urethral	I-DISO
valves	I-DISO
)	O	O
in	O	O
both	O	O
groups	O
were	O	O
comparable	O
.	O	O

After	O	O
Cohen	B-PROC
's	I-PROC
reimplantation	I-PROC
there	O	O
were	O	O
no	O	O
immediate	O
complications	B-DISO
requiring	O	O
intervention	B-PROC
;	O	O
during	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O	O
mean	O
28	O	O
.	O	O
2	O	O
months	O
)	O	O
three	O	O
patients	B-LIVB
(	O	O
5	O	O
.	O	O
6	O	O
%	O	O
)	O	O
suffered	B-DISO
febrile	B-DISO
urinary	I-DISO
tract	I-DISO
infections	I-DISO
(	O	O
UTIs	B-DISO
)	O	O
,	O	O
of	O	O
which	O	O
one	O	O
(	O	O
1	O	O
.	O	O
8	O	O
%	O	O
)	O	O
was	O	O
diagnosed	B-DISO
with	O	O
a	O	O
persisting	O
VUR	B-DISO
.	O	O

Persistent	O
hydronephroses	B-DISO
(	O	O
≥II	O	O
SFU	B-DISO
)	O	O
were	O	O
recorded	O	O
in	O	O
six	O	O
patients	B-LIVB
(	O	O
13	O	O
.	O	O
2	O	O
%	O	O
)	O	O
.	O	O

After	O	O
reimplantation	B-PROC
using	O	O
Mathisen	O
's	O
technique	O
,	O	O
two	O	O
patients	B-LIVB
(	O	O
4	O	O
.	O	O
1	O	O
%	O	O
)	O	O
suffered	B-DISO
significant	O
intravesical	B-DISO
bleeding	I-DISO
;	O	O
during	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
(	O	O
mean	O
23	O	O
.	O	O
06	O	O
months	O
)	O	O
four	O	O
patients	B-LIVB
(	O	O
8	O	O
.	O	O
3	O	O
%	O	O
)	O	O
suffered	B-DISO
febrile	B-DISO
UTIs	I-DISO
,	O	O
and	O	O
seven	O	O
patients	B-LIVB
(	O	O
14	O	O
.	O	O
5	O	O
%	O	O
)	O	O
were	O	O
diagnosed	B-DISO
with	O	O
persisting	O
VUR	B-DISO
after	O	O
a	O	O
mean	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O	O
10	O	O
.	O	O

8	O	O
months	O
.	O	O

The	O	O
patients	B-LIVB
with	O	O
persistent	O
VUR	B-DISO
had	O	O
more	O	O
commonly	O	O
high	O
-	O
grade	O
(	O	O
IV	O	O
and	O	O
V	O	O
)	O	O
VUR	B-DISO
initially	O	O
,	O	O
compared	O
to	O	O
the	O	O
whole	O
group	O
.	O	O

Two	O	O
patients	B-LIVB
(	O	O
4	O	O
.	O	O
1	O	O
%	O	O
)	O	O
had	O	O
persistent	O
hydronephroses	B-DISO
(	O	O
≥II	O	O
SFU	B-DISO
)	O	O
.	O	O

Mathisen	O
's	O
technique	O
for	O	O
ureteral	B-PROC
reimplantation	I-PROC
yielded	O	O
a	O	O
significantly	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0256	O	O
patients	B-LIVB
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

006	O	O
ureterorenal	O
units	O
)	O	O
lower	O
success	O
rate	O
(	O	O
85	O	O
.	O	O
5	O	O
%	O	O
patients	B-LIVB
,	O	O
89	O	O
.	O	O

2	O	O
%	O	O
ureterorenal	O
units	O
)	O	O
in	O	O
comparison	O
with	O	O
Cohen	O
's	O
technique	O
(	O	O
98	O	O
.	O	O

2	O	O
%	O	O
patients	B-LIVB
,	O	O
99	O	O
%	O	O
ureterorenal	O
units	O
)	O	O
.	O	O

Although	O	O
there	O	O
was	O	O
no	O	O
intervention	B-PROC
for	O	O
obstruction	B-DISO
,	O	O
persistent	O
hydronephrosis	B-DISO
was	O	O
more	O	O
common	O	O
in	O	O
the	O	O
Cohen	O
group	O
(	O	O
13	O	O
.	O	O
2	O	O
%	O	O
vs	O	O
.	O	O

4	O	O
.	O	O
1	O	O
%	O	O
,	O	O
n	O	O
.	O	O

s	O	O
.	O	O
)	O	O
.	O	O

Despite	O	O
the	O	O
advantages	O	O
of	O	O
an	O	O
orthotopic	O
ureteral	B-ANAT
orifice	I-ANAT
close	O	O
to	O	O
the	O	O
bladder	B-ANAT
neck	I-ANAT
,	O	O
as	O	O
achieved	O	O
by	O	O
Mathisen	B-PROC
's	I-PROC
reimplantation	I-PROC
,	O	O
cross	B-PROC
-	I-PROC
trigonal	I-PROC
ureteral	I-PROC
reimplantation	I-PROC
proved	O	O
more	O	O
reliable	O
for	O	O
VUR	B-DISO
correction	O
.	O	O

As	O	O
regards	O	O
optimizing	O	O
the	O	O
results	O	O
,	O	O
patient	B-PROC
selection	I-PROC
for	O	O
either	O	O
technique	O
could	O	O
prove	O
essential	O
.	O	O

Nevertheless	O	O
,	O	O
as	O	O
regards	O	O
the	O	O
difficulties	O
with	O	O
ectopic	O
ureteral	B-ANAT
orifices	I-ANAT
in	O	O
the	O	O
Cohen	O
technique	O
in	O	O
the	O	O
long	O
-	O
term	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
the	O	O
concept	O
of	O	O
anatomic	O
,	O	O
orthotopic	O
ureteral	B-PROC
reimplantation	I-PROC
should	O	O
be	O	O
pursued	O	O
and	O	O
the	O	O
technique	O
should	O	O
be	O	O
further	O	O
refined	O	O
.	O	O

Experimental	B-PROC
study	I-PROC
of	O	O
GeneXpert	B-DEVI
(	I-DEVI
®	I-DEVI
)	I-DEVI
system	I-DEVI
in	O	O
the	O	O
diagnosis	B-PROC
of	O	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
To	O	O
explore	O	O
the	O	O
application	O	O
value	O	O
of	O	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
for	O	O
detection	B-PROC
of	O	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
and	O	O
resistance	B-PHEN
to	O	O
rifampin	B-CHEM
.	O	O

A	O	O
total	O	O
of	O	O
150	O	O
samples	B-ANAT
were	O	O
collected	O	O
,	O	O
including	O	O
33	O	O
needle	B-DEVI
aspirates	B-ANAT
from	O	O
lymphoid	B-DISO
tuberculosis	I-DISO
,	O	O
23	O	O
needle	B-DEVI
aspirates	B-ANAT
from	O	O
spinal	B-DISO
tuberculosis	I-DISO
,	O	O
49	O	O
from	O	O
tuberculous	B-DISO
pleural	I-DISO
effusions	I-DISO
,	O	O
24	O	O
from	O	O
cerebrospinal	B-ANAT
fluid	I-ANAT
of	O	O
tuberculous	B-DISO
cephalomeningitis	I-DISO
,	O	O
and	O	O
21	O	O
urinary	B-ANAT
sediment	I-ANAT
samples	I-ANAT
from	O	O
renal	B-DISO
tuberculosis	I-DISO
.	O	O

Smear	B-PROC
microscopy	I-PROC
,	O	O
mycobacterium	B-PROC
tuberculosis	I-PROC
culture	I-PROC
and	O	O
the	O	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
were	O	O
used	O	O
to	O	O
examine	O	O
these	O	O
samples	O	O
and	O	O
their	O	O
positive	O	O
rates	O	O
were	O	O
compared	O	O
.	O	O

Rifampin	B-PROC
susceptibility	I-PROC
tests	I-PROC
was	O	O
performed	O	O
for	O	O
culture	B-LIVB
-	I-LIVB
positive	I-LIVB
strains	I-LIVB
using	O	O
proportion	O	O
method	O	O
,	O	O
which	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
result	O	O
from	O	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
.	O	O

Of	O	O
the	O	O
150	O	O
cases	O	O
of	O	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
,	O	O
17	O	O
samples	O	O
were	O	O
smear	B-DISO
-	I-DISO
positive	I-DISO
,	O	O
with	O	O
a	O	O
sensitivity	O
of	O	O
11	O	O
.	O	O

3	O	O
%	O	O
(	O	O
17	O	O
/	O	O
150	O	O
)	O	O
;	O	O
30	O	O
were	O	O
culture	B-DISO
-	I-DISO
positive	I-DISO
with	O	O
a	O	O
sensitivity	O
of	O	O
20	O	O
.	O	O

0	O	O
%	O	O
(	O	O
30	O	O
/	O	O
150	O	O
)	O	O
;	O	O
and	O	O
96	O	O
were	O	O
positive	B-DISO
by	O	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
with	O	O
a	O	O
sensitivity	O
of	O	O
64	O	O
.	O	O

0	O	O
%	O	O
(	O	O
96	O	O
/	O	O
150	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
and	O	O
the	O	O
culture	B-PROC
method	I-PROC
(	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
59	O	O
.	O	O
61	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

The	O	O
differences	O	O
were	O	O
also	O	O
significant	O	O
when	O	O
the	O	O
MTB	B-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
was	O	O
compared	O	O
with	O	O
the	O	O
smear	B-PROC
method	I-PROC
(	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
88	O	O
.	O	O
60	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
or	O	O
compared	O	O
with	O	O
culture	B-PROC
plus	I-PROC
smear	I-PROC
methods	I-PROC
(	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
4	O	O
.	O	O
26	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Separately	O	O
,	O	O
the	O	O
differences	O	O
were	O	O
statistically	O	O
significant	O	O
between	O	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
method	I-PROC
and	O	O
other	O	O
2	O	O
methods	B-PROC
for	O	O
diagnosis	B-PROC
of	O	O
lymphoid	B-DISO
tuberculosis	I-DISO
(	O	O
n	O	O
=	O	O
33	O	O
,	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
20	O	O
.	O	O
56	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
vs	O	O
.	O	O

culture	B-PROC
method	I-PROC
;	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
27	O	O
.	O	O
13	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
vs	O	O
.	O	O

smear	B-PHEN
results	I-PHEN
)	O	O
while	O	O
no	O	O
difference	O	O
was	O	O
found	O	O
between	O	O
culture	B-PROC
and	O	O
smear	B-PROC
method	I-PROC
(	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
0	O	O
.	O	O
67	O	O
,	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
spinal	B-DISO
tuberculosis	I-DISO
(	O	O
n	O	O
=	O	O
23	O	O
,	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
12	O	O
.	O	O
74	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
vs	O	O
.	O	O

culture	B-PROC
method	I-PROC
;	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
14	O	O
.	O	O
81	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
vs	O	O
.	O	O

smear	B-PROC
method	I-PROC
)	O	O
,	O	O
tuberculous	B-DISO
pleurisy	I-DISO
(	O	O
n	O	O
=	O	O
49	O	O
,	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
32	O	O
.	O	O
34	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
vs	O	O
.	O	O

culture	B-PROC
method	I-PROC
;	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
49	O	O
.	O	O
69	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
vs	O	O
.	O	O

smear	B-PROC
method	I-PROC
)	O	O
and	O	O
renal	B-DISO
tuberculosis	I-DISO
(	O	O
n	O	O
=	O	O
21	O	O
,	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
4	O	O
.	O	O
20	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
vs	O	O
.	O	O

culture	B-PROC
method	I-PROC
;	O	O
χ	O	O
(	O	O
2	O	O
)	O	O
=	O	O
8	O	O
.	O	O
40	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
vs	O	O
.	O	O

smear	B-PHEN
results	I-PHEN
)	O	O
.	O	O

The	O	O
sensitivity	O
for	O	O
tuberculous	B-DISO
meningitis	I-DISO
had	O	O
no	O	O
difference	O	O
among	O	O
these	O	O
3	O	O
methods	B-PROC
(	O	O
n	O	O
=	O	O
24	O	O
,	O	O
P	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Rifampicin	B-PHEN
-	I-PHEN
resistance	I-PHEN
of	O	O
the	O	O
strains	B-LIVB
from	O	O
the	O	O
30	O	O
culture	B-DISO
-	I-DISO
positive	I-DISO
cases	I-DISO
of	O	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
(	O	O
20	O	O
.	O	O
0	O	O
%	O	O
,	O	O
6	O	O
/	O	O
30	O	O
)	O	O
exhibited	O	O
agreement	O	O
with	O	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
test	I-PROC
.	O	O

The	O	O
simplicity	O	O
and	O	O
high	O	O
sensitivity	O
of	O	O
GeneXpert	B-PROC
MTB	I-PROC
/	I-PROC
RIF	I-PROC
technology	I-PROC
make	O	O
it	O	O
a	O	O
good	O	O
diagnostic	B-PROC
test	I-PROC
for	O	O
rapid	O	O
detection	B-PROC
of	O	O
extra	B-DISO
-	I-DISO
pulmonary	I-DISO
tuberculosis	I-DISO
and	O	O
resistance	B-PHEN
to	O	O
rifampin	B-CHEM
.	O	O

Influence	O
of	O	O
climatic	O
factors	O
on	O	O
the	O	O
flight	B-PHEN
activity	I-PHEN
of	O	O
the	O	O
stingless	O
bee	O
Partamona	O
orizabaensis	O
and	O	O
its	O	O
competition	O
behavior	O
at	O	O
food	B-OBJC
sources	B-DISO
Stingless	O
bee	O
s	O	O
have	O	O
evolved	O	O
several	O	O
ways	O	O
to	O	O
share	O
contested	O	O
resources	O
to	O	O
ensure	O	O
the	O	O
coexistence	O
between	O	O
different	O
species	O
.	O	O

Partamona	O
orizabaensis	O
quickly	O	O
exploits	O	O
food	B-OBJC
sources	B-DISO
by	O	O
fast	O
and	O
direct	O
recruitment	O
that	O	O
does	O	O
not	O	O
rely	O	O
on	O	O
scent	B-DISO
marks	I-DISO
deposited	O
on	O	O
substrates	B-OBJC
.	O	O

In	O	O
this	O	O
study	B-PROC
we	O	O
show	O	O
that	O	O
the	O	O
flight	B-PHEN
activity	I-PHEN
of	O	O
P	O
.	O

orizabaensis	O
is	O	O
influenced	O
by	O	O
weather	B-PHEN
conditions	O
,	O	O
with	O	O
higher	O	O
activity	O
during	O	O
periods	O
of	O	O
colder	O
temperatures	O
,	O	O
higher	O	O
relative	O
humidity	O
and	O	O
even	O	O
during	O	O
rainfall	B-PHEN
.	O	O

We	O	O
showed	O	O
that	O	O
the	O	O
outcome	O
of	O	O
aggression	O
experiments	B-PROC
between	O	O
the	O	O
non	B-DISO
-	I-DISO
aggressive	I-DISO
species	O
P	O
.	O

orizabaensis	O
and	O	O
its	O	O
aggressive	O
competitor	B-LIVB
Trigona	O
fuscipennis	O
is	O	O
influenced	O
by	O	O
the	O	O
number	O	O
of	O	O
bees	O
that	O	O
arrive	O	O
early	O	O
after	O	O
food	B-OBJC
source	B-DISO
discovery	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
increased	O
activity	O
during	O	O
less	O	O
favorable	O	O
weather	B-PHEN
conditions	O
and	O	O
the	O	O
fast	O
recruitment	O
of	O	O
nestmates	B-LIVB
following	O	O
the	O	O
discovery	O
of	O	O
a	O	O
food	B-OBJC
source	B-DISO
,	O	O
as	O	O
observed	O	O
for	O	O
P	O
.	O

orizabaensis	O
,	O	O
may	O	O
be	O	O
adaptations	B-PHEN
that	O	O
evolved	O	O
to	O	O
coexist	O
even	O	O
with	O	O
more	O	O
aggressive	O
and	O	O
dominant	O
species	O
of	O	O
stingless	O
bees	O
,	O	O
with	O	O
which	O	O
P	O
.	O

orizabaensis	O
has	O	O
to	O	O
compete	O	O
for	O	O
resources	O
.	O	O

Withdrawal	O
of	O	O
Anticancer	B-PROC
Therapy	I-PROC
in	O	O
Advanced	O
Disease	O
Because	O	O
of	O	O
Side	B-DISO
Effects	I-DISO
Withdrawal	O
of	O	O
chemotherapy	B-PROC
because	O	O
of	O	O
side	B-DISO
effects	I-DISO
may	O	O
be	O	O
due	O	O
to	O	O
""""	O	O
problems	O
with	O	O
toxicity	O
""""	O	O
or	O	O
""""	O	O
patient	B-LIVB
refusal	O
""""	O	O
.	O	O
""""	O	O
Problems	O
with	O	O
toxicity	O
""""	O	O
is	O	O
intended	O	O
to	O	O
secure	B-PHYS
patient	B-PROC
safety	I-PROC
and	O	O
decisions	B-PHYS
about	O	O
it	O	O
are	O	O
primarily	O	O
made	O	O
by	O	O
the	O	O
oncologist	B-LIVB
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
""""	O	O
patient	B-LIVB
refusal	O
""""	O	O
is	O	O
influenced	O
by	O	O
the	O	O
degree	B-DISO
of	I-DISO
distress	I-DISO
the	O	O
patient	B-LIVB
is	O	O
experiencing	B-PHYS
and	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
preference	O
.	O	O

Providing	O
sufficient	O	O
medical	O
information	O
is	O	O
essential	O
in	O	O
decision	B-PHYS
making	I-PHYS
,	O	O
because	O	O
it	O	O
is	O	O
a	O	O
decision	B-PHYS
made	O	O
by	O	O
the	O	O
patient	B-LIVB
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
perception	O	O
of	O	O
side	B-DISO
effects	I-DISO
has	O	O
changed	O
owing	O	O
to	O	O
progress	O
in	O	O
supportive	B-PROC
therapy	I-PROC
in	O	O
recent	O	O
years	O
.	O	O

In	O	O
particular	O	O
,	O	O
cancer	B-DISO
patients	B-LIVB
are	O	O
concerned	O	O
about	O	O
changes	O
in	O	O
appearance	B-PHYS
.	O	O

In	O	O
our	O	O
study	O	O
(	O	O
4	O	O
/	O	O
2015	O	O
to	O	O
3	O	O
/	O	O
2016	O	O
)	O	O
,	O	O
chemotherapy	B-PROC
was	O	O
withdrawn	B-DISO
because	O	O
of	O	O
side	B-DISO
effects	I-DISO
during	O	O
treatment	B-PROC
for	O	O
solid	B-DISO
carcinomas	I-DISO
in	O	O
8	O	O
%	O	O
(	O	O
4	O	O
/	O	O
51	O	O
)	O	O
of	O	O
the	O	O
patients	B-LIVB
.	O	O

Two	O	O
of	O	O
these	O	O
patients	B-LIVB
experienced	B-PHYS
liver	B-PHYS
function	I-PHYS
disorders	B-DISO
,	O	O
and	O	O
2	O	O
developed	O	O
interstitial	B-DISO
pneumonitis	I-DISO
.	O	O

Patient	B-LIVB
refusal	O
was	O	O
observed	O	O
in	O	O
2	O	O
%	O	O
(	O	O
1	O	O
/	O	O
51	O	O
)	O	O
of	O	O
the	O	O
patients	B-LIVB
.	O	O

Molecular	B-PHYS
Mechanisms	I-PHYS
of	O	O
Resistance	B-PHYS
to	O	O
First	B-CHEM
-	I-CHEM
and	O	O
Second	B-CHEM
-	I-CHEM
Generation	I-CHEM
ALK	I-CHEM
Inhibitors	I-CHEM
in	O	O
ALK	B-CHEM
-Rearranged	O	O
Lung	B-DISO
Cancer	I-DISO
Advanced	O	O
,	O	O
anaplastic	B-CHEM
lymphoma	I-CHEM
kinase	I-CHEM
(	O	O
ALK	B-CHEM
)	O	O
-	O	O
positive	O	O
lung	B-DISO
cancer	I-DISO
is	O	O
currently	O	O
treated	B-PROC
with	I-PROC
the	O	O
first	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
crizotinib	B-CHEM
followed	O	O
by	O	O
more	O	O
potent	O	O
,	O	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O
,	O	O
ceritinib	B-CHEM
and	O	O
alectinib	B-CHEM
)	O	O
upon	O	O
progression	B-DISO
.	O	O

Second	B-CHEM
-	I-CHEM
generation	I-CHEM
inhibitors	I-CHEM
are	O	O
generally	O	O
effective	O	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
crizotinib	B-CHEM
-	O	O
resistant	B-PHYS
ALK	O
mutations	B-PHYS
,	O	O
likely	O	O
reflecting	O	O
incomplete	O	O
inhibition	B-PHYS
of	O	O
ALK	B-CHEM
by	O	O
crizotinib	B-CHEM
in	O	O
many	O	O
cases	O	O
.	O	O

Herein	O	O
,	O	O
we	O	O
analyzed	O	O
103	O	O
repeat	O	O
biopsies	B-PROC
from	O	O
ALK	B-CHEM
-positive	O	O
patients	B-LIVB
progressing	O	O
on	O	O
various	O	O
ALK	B-CHEM
inhibitors	I-CHEM
.	O	O

We	O	O
find	O	O
that	O	O
each	O	O
ALK	B-CHEM
inhibitor	I-CHEM
is	O	O
associated	O	O
with	O	O
a	O	O
distinct	O	O
spectrum	O
of	O	O
ALK	O
resistance	B-PHYS
mutations	I-PHYS
and	O	O
that	O	O
the	O	O
frequency	O
of	O	O
one	O	O
mutation	B-PHYS
,	O	O
ALK	O
(	O
G1202R	O
)	O
,	O	O
increases	O	O
significantly	O	O
after	O	O
treatment	B-PROC
with	I-PROC
second	B-CHEM
-	I-CHEM
generation	I-CHEM
agents	I-CHEM
.	O	O

To	O	O
investigate	O	O
strategies	O	O
to	O	O
overcome	O	O
resistance	B-PHYS
to	O	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
,	O	O
we	O	O
examine	O	O
the	O	O
activity	B-PHYS
of	O	O
the	O	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
lorlatinib	B-CHEM
in	O	O
a	O	O
series	O	O
of	O	O
ceritinib	B-CHEM
-	O	O
resistant	B-PHYS
,	O	O
patient	B-LIVB
-derived	O	O
cell	B-ANAT
lines	I-ANAT
,	O	O
and	O	O
observe	O	O
that	O	O
the	O	O
presence	O	O
of	O	O
ALK	O
resistance	B-PHYS
mutations	I-PHYS
is	O	O
highly	O	O
predictive	O	O
for	O	O
sensitivity	O	O
to	O	O
lorlatinib	B-CHEM
,	O	O
whereas	O	O
those	O	O
cell	B-ANAT
lines	I-ANAT
without	O	O
ALK	O
mutations	B-PHYS
are	O	O
resistant	B-PHYS
.	O	O

Secondary	O	O
ALK	O
mutations	B-PHYS
are	O	O
a	O	O
common	O	O
resistance	B-PHYS
mechanism	B-PHYS
to	O	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
and	O	O
predict	O	O
for	O	O
sensitivity	O	O
to	O	O
the	O	O
third	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitor	I-CHEM
lorlatinib	B-CHEM
.	O	O

These	O	O
findings	O	O
highlight	O	O
the	O	O
importance	O	O
of	O	O
repeat	O	O
biopsies	B-PROC
and	O	O
genotyping	B-PROC
following	O	O
disease	B-DISO
progression	I-DISO
on	O	O
targeted	O	O
therapies	B-PROC
,	O	O
particularly	O	O
second	B-CHEM
-	I-CHEM
generation	I-CHEM
ALK	I-CHEM
inhibitors	I-CHEM
.	I-CHEM

Cancer	O	O
Discov	O	O
;	O	O
6	O	O
(	O	O
10	O	O
)	O	O
;	O	O
1118	O	O
-	O	O
33	O	O
.	O	O

©	O	O
2016	O	O
AACRSee	O	O
related	O	O
commentary	O	O
by	O	O
Qiao	O	O
and	O	O
Lovly	O	O
,	O	O
p	O	O
.	O	O

1084This	O	O
article	O	O
is	O	O
highlighted	O	O
in	O	O
the	O	O
In	O	O
This	O	O
Issue	O	O
feature	O	O
,	O	O
p	O	O
.	O	O

1069	O	O
.	O	O

The	O	O
use	O
of	O
neonatal	O
extracorporeal	B-PROC
life	I-PROC
support	I-PROC
in	O	O
pediatric	O
cardiac	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
evaluate	B-PROC
extracorporeal	B-PROC
life	I-PROC
support	I-PROC
system	I-PROC
(	O	O
ECLS	B-PROC
)	O	O
employed	O	O
in	O	O
neonates	B-LIVB
in	O	O
pediatric	O
cardiac	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
.	O	O

Twenty	O	O
-	O	O
five	O	O
neonates	B-LIVB
that	O	O
required	O	O
ECLS	B-PROC
in	O	O
between	O	O
November	O	O
2010	O	O
and	O	O
November	O	O
2015	O	O
were	O	O
evaluated	B-PROC
.	O	O

The	O	O
median	O
age	B-PHYS
was	O	O
12	O	O
days	O
(	O	O
range	O
3	O	O
-	O	O
28	O	O
days	O
)	O	O
and	O	O
the	O	O
median	O
body	B-PHYS
weight	I-PHYS
was	O	O
3	O	O
kg	O	O
(	O	O
range	O
2	O	O
.	O	O
5	O	O
-	O	O
5	O	O
kg	O	O
)	O	O
.	O	O

Venoarterial	O
ECLS	B-PROC
was	O	O
performed	O
in	O	O
all	O	O
of	O	O
the	O	O
cases	O	O
.	O	O

Ascendan	B-ANAT
aorta	I-ANAT
-	O	O
right	B-ANAT
atrial	I-ANAT
cannulation	B-PROC
in	O	O
22	O	O
patients	B-LIVB
and	O	O
neck	B-ANAT
cannulation	B-PROC
in	O	O
three	O	O
patients	B-LIVB
were	O	O
performed	O
.	O	O

The	O	O
reason	O	O
for	O	O
ECLS	B-PROC
was	O	O
E	B-PROC
-	I-PROC
CPR	I-PROC
in	O	O
two	O	O
patients	B-LIVB
,	O	O
inability	B-DISO
to	I-DISO
wean	I-DISO
from	O	O
cardiopulmonary	B-PROC
bypass	I-PROC
(	O	O
CPB	B-PROC
)	O	O
in	O	O
seven	O	O
patients	B-LIVB
,	O	O
respiratory	B-DISO
insufficiency	I-DISO
and	O	O
hypoxia	B-DISO
in	O	O
nine	O	O
patients	B-LIVB
,	O	O
low	B-DISO
cardiac	I-DISO
output	I-DISO
(	O	O
LCOS	B-DISO
)	O	O
in	O	O
seven	O	O
patients	B-LIVB
.	O	O

Median	O
duration	O
of	O	O
ECLS	B-PROC
was	O	O
four	O	O
days	O
(	O	O
range	O
1	O	O
-	O	O
15	O	O
)	O	O
.	O	O

Hemorrhagic	O
complications	B-DISO
developed	O	O
in	O	O
15	O	O
,	O	O
renal	B-DISO
complications	I-DISO
in	O	O
13	O	O
,	O	O
pulmonary	B-DISO
complications	I-DISO
in	O	O
12	O	O
,	O	O
infectious	B-DISO
complications	B-DISO
in	O	O
11	O	O
,	O	O
neurologic	B-DISO
complications	I-DISO
in	O	O
three	O	O
and	O	O
mechanical	B-DISO
complications	I-DISO
in	O	O
two	O	O
of	O	O
the	O	O
patients	B-LIVB
.	O	O

Weaning	B-DISO
was	O	O
successful	O
in	O	O
15	O	O
of	O	O
the	O	O
patients	B-LIVB
.	O	O

Eleven	O	O
patients	B-LIVB
were	O	O
successfully	O
discharged	B-PROC
.	O	O

ECLS	B-PROC
is	O	O
an	O	O
important	O
treatment	B-PROC
option	I-PROC
that	O	O
is	O	O
performed	O
successfully	O
in	O	O
many	O	O
centers	B-OBJC
around	O	O
the	O	O
world	B-LIVB
to	O	O
maintain	O
life	B-PROC
support	I-PROC
in	O	O
patients	B-LIVB
unresponsive	O
to	O
medical	O
treatment	O
.	O	O

The	O	O
utilization	O
of	O	O
this	O	O
modality	O
especially	O	O
in	O	O
newborns	B-LIVB
with	O	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
should	O	O
be	O	O
taken	O	O
into	O	O
consideration	O	O
.	O	O

It	O	O
's	O	O
not	O	O
All	O	O
Doom	O	O
and	O	O
Gloom	O	O
:	O	O
Prune	B-DISO
Belly	I-DISO
Syndrome	I-DISO
Associated	B-DISO
with	I-DISO
VACTERL	I-DISO
Prune	B-DISO
belly	I-DISO
syndrome	I-DISO
is	O	O
a	O	O
rare	O
abnormality	B-DISO
;	O	O
its	O	O
association	B-DISO
with	I-DISO
VACTERL	I-DISO
is	O	O
even	O	O
rarer	O
.	O	O

This	O	O
association	B-DISO
has	O	O
been	O	O
reported	B-PROC
in	O	O
literature	O
a	O	O
few	O	O
times	O	O
since	O	O
first	O	O
reported	B-PROC
in	O	O
1993	O	O
and	O	O
so	O	O
far	O	O
the	O	O
majority	O
have	O	O
either	O	O
been	O	O
stillbirths	B-DISO
or	I-DISO
died	I-DISO
shortly	I-DISO
after	I-DISO
birth	I-DISO
.	O	O

We	O	O
present	O	O
a	O	O
case	O
of	O	O
Prune	B-DISO
belly	I-DISO
syndrome	I-DISO
associated	B-DISO
with	I-DISO
VACTERL	I-DISO
who	O	O
is	O	O
now	O	O
one	O	O
year	O	O
old	O	O
.	O	O

Targeted	O
DNA	O
Sequencing	O
Reveals	O
Patterns	O
of	O	O
Local	O
Progression	B-DISO
in	O	O
the	O	O
Pancreatic	B-ANAT
Remnant	B-ANAT
Following	O	O
Resection	B-PROC
of	O	O
Intraductal	B-DISO
Papillary	I-DISO
Mucinous	I-DISO
Neoplasm	I-DISO
(	O	O
IPMN	B-DISO
)	O	O
of	O	O
the	O	O
Pancreas	B-ANAT
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
characterize	O
patterns	O
of	O	O
local	O
progression	B-DISO
following	O	O
resection	B-PROC
for	O	O
pancreatic	B-DISO
intraductal	I-DISO
papillary	I-DISO
mucinous	I-DISO
neoplasms	I-DISO
(	O	O
IPMN	B-DISO
)	O	O
using	O	O
targeted	O
next	O
-	O
generation	O
sequencing	O
(	O	O
NGS	O
)	O	O
.	O	O

Progression	B-DISO
of	O	O
neoplastic	B-DISO
disease	I-DISO
in	O	O
the	O	O
remnant	B-ANAT
pancreas	B-ANAT
following	O	O
resection	B-PROC
of	O	O
IPMN	B-DISO
may	O	O
include	O	O
development	O
of	O	O
a	O	O
new	O	O
IPMN	B-DISO
or	O	O
ductal	B-DISO
adenocarcinoma	I-DISO
(	O	O
PDAC	B-DISO
)	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
this	O	O
progression	B-DISO
represents	O	O
recurrence	B-DISO
of	O	O
the	O	O
same	O	O
neoplasm	B-DISO
or	O	O
an	O	O
independent	O
second	B-DISO
neoplasm	I-DISO
.	O	O

Targeted	B-PROC
-	I-PROC
NGS	I-PROC
on	O	O
genes	O
commonly	O	O
mutated	B-PHYS
in	O	O
IPMN	B-DISO
and	O	O
PDAC	B-DISO
was	O	O
performed	O	O
on	O	O
tumors	B-DISO
from	O	O
(	O	O
1	O	O
)	O	O
13	O	O
patients	B-LIVB
who	O	O
developed	O	O
disease	B-DISO
progression	I-DISO
in	O	O
the	O	O
remnant	B-ANAT
pancreas	B-ANAT
following	O	O
resection	B-PROC
of	O	O
IPMN	B-DISO
;	O	O
and	O	O
(	O	O
2	O	O
)	O	O
10	O	O
patients	B-LIVB
who	O	O
underwent	O	O
a	O	O
resection	B-PROC
for	O	O
PDAC	B-DISO
and	O	O
had	O	O
a	O	O
concomitant	O
IPMN	B-DISO
.	O	O

Mutations	B-PHYS
in	O	O
the	O	O
tumors	B-DISO
were	O	O
compared	O	O
in	O	O
order	O	O
to	O	O
determine	O	O
the	O	O
relationship	O
between	O	O
neoplasms	B-DISO
.	O	O

In	O	O
parallel	O	O
,	O	O
clinical	B-PHYS
and	O	O
pathological	O
characteristics	O
of	O	O
260	O	O
patients	B-LIVB
who	O	O
underwent	O	O
resection	B-PROC
of	O	O
noninvasive	B-DISO
IPMN	I-DISO
were	O	O
reviewed	O
to	O	O
identify	O	O
risk	B-DISO
factors	I-DISO
associated	O
with	O
local	O
progression	B-DISO
.	O	O

We	O	O
identified	O
3	O	O
mechanisms	O
underlying	O	O
local	O
progression	B-DISO
in	O	O
the	O	O
remnant	B-ANAT
pancreas	B-ANAT
:	O	O
(	O	O
1	O	O
)	O	O
residual	B-DISO
microscopic	I-DISO
disease	I-DISO
at	O	O
the	O	O
resection	B-ANAT
margin	I-ANAT
,	O	O
(	O	O
2	O	O
)	O	O
intraparenchymal	B-ANAT
spread	B-DISO
of	O	O
neoplastic	B-ANAT
cells	I-ANAT
,	O	O
leading	O	O
to	O	O
an	O	O
anatomically	O
separate	O
but	O	O
genetically	O
related	O
recurrence	B-DISO
,	O	O
and	O	O
(	O	O
3	O	O
)	O	O
multifocal	B-DISO
disease	I-DISO
with	O	O
genetically	O
distinct	O
lesions	B-DISO
.	O	O

Analysis	B-PROC
of	O	O
the	O	O
260	O	O
patients	B-LIVB
with	O	O
noninvasive	B-DISO
IPMNs	I-DISO
showed	O	O
that	O	O
family	B-DISO
history	I-DISO
of	O	O
pancreatic	B-DISO
cancer	I-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
027	O	O
)	O	O
and	O	O
high	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O	O
HGD	B-DISO
)	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
003	O	O
)	O	O
were	O	O
independent	O
risk	B-DISO
factors	I-DISO
for	O	O
the	O	O
development	O
of	O	O
an	O	O
IPMN	B-DISO
with	O	O
HGD	B-DISO
or	O	O
an	O	O
invasive	B-DISO
carcinoma	I-DISO
in	O	O
the	O	O
remnant	B-ANAT
pancreas	B-ANAT
.	O	O

Using	O	O
NGS	O
,	O	O
we	O	O
identify	O	O
distinct	O	O
mechanisms	O
for	O	O
development	O
of	O	O
metachronous	B-DISO
or	O	O
synchronous	B-DISO
neoplasms	I-DISO
in	O	O
patients	B-LIVB
with	O	O
IPMN	B-DISO
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
primary	O
IPMN	B-DISO
with	O	O
HGD	B-DISO
or	O	O
with	O	O
positive	B-DISO
family	B-DISO
history	I-DISO
are	O	O
at	O	O
an	O	O
increased	O
risk	O
to	O	O
develop	O	O
subsequent	O
high	B-DISO
-	I-DISO
risk	I-DISO
neoplasms	B-DISO
in	O	O
the	O	O
remnant	B-ANAT
pancreas	B-ANAT
.	O	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
as	O	O
a	O	O
useful	O	O
diagnostic	B-PHYS
marker	I-PHYS
for	O	O
the	O	O
distinction	O	O
of	O	O
systemic	B-DISO
juvenile	I-DISO
idiopathic	I-DISO
arthritis	I-DISO
and	O	O
Kawasaki	B-DISO
disease	I-DISO
The	O	O
clinical	O
features	O
and	O	O
laboratory	B-PROC
parameters	I-PROC
of	O	O
patients	B-LIVB
with	O	O
Kawasaki	B-DISO
disease	I-DISO
(	O	O
KD	B-DISO
)	O	O
and	O	O
systemic	B-DISO
juvenile	I-DISO
idiopathic	I-DISO
arthritis	I-DISO
(	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
)	O	O
tend	O	O
to	O	O
overlap	O
.	O	O

Furthermore	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
definitive	O
biomarkers	B-PHYS
for	O	O
these	O	O
disease	B-DISO
s	I-DISO
,	O	O
making	O	O
clinical	B-PROC
diagnosis	I-PROC
difficult	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	B-PROC
the	O	O
diagnostic	B-DISO
value	I-DISO
of	O	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
for	O	O
differentiating	O
KD	B-DISO
from	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
and	O	O
predicting	O	O
the	O	O
disease	O
severity	O
of	O	O
KD	B-DISO
.	O	O

We	O	O
analyzed	O	O
228	O	O
patients	B-LIVB
with	O	O
KD	B-DISO
and	O	O
81	O	O
patients	B-LIVB
with	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
.	O	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
were	O	O
compared	O	O
between	O	O
patients	B-LIVB
with	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
and	O	O
KD	B-DISO
.	O	O

Furthermore	O	O
,	O	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O	O
patients	B-LIVB
with	O	O
KD	B-DISO
were	O	O
compared	O	O
with	O	O
respect	O	O
to	O	O
clinical	O
features	O
such	O	O
as	O	O
responsiveness	B-PHYS
to	O	O
intravenous	O	O
immunoglobulin	B-PROC
(	I-PROC
IVIG	I-PROC
)	I-PROC
therapy	I-PROC
.	O	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O	O
KD	B-DISO
patients	B-LIVB
with	O	O
no	B-DISO
response	I-DISO
to	O	O
IVIG	B-PROC
therapy	I-PROC
were	O	O
significantly	O
higher	O
than	O	O
those	O	O
in	O	O
KD	B-DISO
patients	B-LIVB
with	O	O
a	O	O
good	O	O
response	B-PHYS
to	O	O
IVIG	B-PROC
therapy	I-PROC
.	O	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
in	O	O
patients	B-LIVB
with	O	O
KD	B-DISO
needing	O	O
plasma	B-PROC
exchange	I-PROC
(	O	O
PE	B-PROC
)	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
patients	B-LIVB
not	O	O
needing	O	O
PE	B-PROC
.	O	O

However	O	O
,	O	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
overlapped	O	O
between	O	O
severe	O	O
KD	B-DISO
patients	B-LIVB
with	O	O
nonresponsiveness	B-DISO
to	O	O
IVIG	B-PROC
therapy	I-PROC
or	O	O
needing	O	O
PE	B-PROC
and	O	O
other	O	O
patients	B-LIVB
with	O	O
mild	O	O
KD	B-DISO
.	O	O

Furthermore	O	O
,	O	O
patients	B-LIVB
with	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
showed	O	O
a	O	O
distinct	O	O
elevation	O	O
of	O	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
compared	O	O
with	O	O
KD	B-DISO
patients	B-LIVB
.	O	O

The	O	O
cutoff	O
value	O
of	O	O
serum	B-PROC
ferritin	I-PROC
levels	I-PROC
for	O	O
differentiating	O
KD	B-DISO
from	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
was	O	O
369	O	O
.	O	O

6	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

Serum	B-PROC
ferritin	I-PROC
levels	I-PROC
were	O	O
significantly	O	O
elevated	O	O
in	O	O
s	B-DISO
-	I-DISO
JIA	I-DISO
patients	B-LIVB
compared	O	O
with	O	O
KD	B-DISO
patients	B-LIVB
.	O	O

Measurement	B-PROC
of	I-PROC
serum	I-PROC
ferritin	I-PROC
levels	I-PROC
can	O	O
be	O	O
useful	O	O
for	O	O
differentiating	O
s	B-DISO
-	I-DISO
JIA	I-DISO
from	O	O
KD	B-DISO
.	O	O

Changes	O
in	O	O
Cardiovascular	B-ANAT
Health	O
Status	O
and	O	O
the	O	O
Risk	O
of	O
New	O
-	O
Onset	O
Hypertension	O
in	O	O
Kailuan	B-LIVB
Cohort	O
Study	O
American	O
Heart	O
Association	O
cardiovascular	B-ANAT
health	O
metrics	O
are	O	O
intimately	O	O
related	O	O
to	O	O
cardiovascular	B-DISO
diseases	I-DISO
.	O	O

Acting	O	O
as	O	O
a	O	O
key	O
independent	O	O
risk	B-DISO
factor	I-DISO
for	O	O
high	O
morbidity	O
and	O	O
mortality	O
of	O	O
cardiovascular	B-DISO
diseases	I-DISO
,	O	O
hypertension	B-DISO
and	O	O
its	O	O
relationship	O
between	O	O
health	O
status	O
get	O	O
urgent	O	O
attention	B-PHYS
.	O	O

While	O	O
the	O	O
influence	O
of	O	O
individual	B-LIVB
health	O
status	O
changes	O
and	O	O
the	O	O
future	O	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
is	O	O
rarely	O	O
understood	O	O
,	O	O
the	O	O
present	O	O
study	O	O
applied	O	O
this	O	O
construct	O	O
to	O	O
assess	B-PROC
the	O	O
changes	O
of	O	O
cardiovascular	B-ANAT
health	O
status	O
and	O	O
the	O	O
morbidity	O
of	O	O
hypertension	B-DISO
in	O	O
Kailuan	B-LIVB
cohort	O
study	O
in	O	O
north	O
China	B-GEOG
.	O	O

The	O	O
Cardiovascular	B-ANAT
Health	O
Score	O
(	O	O
CHS	O
)	O	O
was	O	O
evaluated	B-PROC
by	O	O
the	O	O
follow	B-PROC
-	I-PROC
ups	I-PROC
of	O	O
2006	O	O
-	O	O
2007	O	O
,	O	O
2008	O	O
-	O	O
2009	O	O
,	O	O
2010	O	O
-	O	O
2011	O	O
and	O	O
2012	O	O
-	O	O
2013	O	O
.	O	O

The	O	O
study	B-LIVB
population	I-LIVB
(	O	O
n	O	O
=	O	O
19381	O	O
)	O	O
was	O	O
divided	O
into	O	O
5	O	O
groups	O
based	O	O
on	O	O
the	O	O
changes	O
in	O	O
their	O	O
CHS	O
score	O
between	O	O
the	O	O
first	O	O
two	O	O
follow	B-PROC
-	I-PROC
ups	I-PROC
(	O	O
△	O	O
CHS	O	O
)	O	O
of	O	O
2006	O	O
-	O	O
2007	O	O
and	O	O
2008	O	O
-	O	O
2009	O	O
(	O	O
≤	O	O
-	O	O
2	O	O
,	O	O
-1	O	O
,	O	O
0	O	O
,	O	O
1	O	O
,	O	O
≥2	O	O
)	O	O
.	O	O

The	O	O
morbidity	O
of	O	O
hypertension	B-DISO
was	O	O
collected	O
during	O
2010	O	O
-	O	O
2011	O	O
and	O	O
2012	O	O
-	O	O
2013	O	O
follow	B-PROC
-	I-PROC
ups	I-PROC
.	O	O

Data	O
analysis	O
showed	O	O
that	O	O
during	O
a	O	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
of	O	O
3	O	O
.	O	O

79±0	O	O
.	O	O

96	O	O
years	O	O
,	O	O
morbidity	O
of	O	O
hypertension	B-DISO
had	O	O
a	O	O
graded	O	O
relationship	O
with	O	O
△	O	O
CHS	O	O
.	O	O

As	O	O
△	O	O
CHS	O	O
scored	O	O
from	O	O
low	O	O
to	O	O
high	O	O
,	O	O
the	O	O
standardized	B-PROC
morbidity	O
of	O	O
hypertension	B-DISO
for	O	O
all	O	O
participants	B-LIVB
were	O	O
81	O	O
.	O	O
40	O	O
,	O	O
75	O	O
.	O	O
47	O	O
,	O	O
68	O	O
.	O	O
37	O	O
,	O	O
71	O	O
.	O	O
43	O	O
and	O	O
83	O	O
.	O	O
13	O	O
per	O	O
1000	O	O
person	O	O
-	O	O
year	O	O
,	O	O
respectively	O	O
.	O	O

An	O	O
increased	O
△	O	O
CHS	O	O
score	O	O
of	O	O
1	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
10	O	O
%	O	O
decrease	O
in	O	O
the	O	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
(	O	O
HR	O	O
:	O	O
0	O	O
.	O	O
90	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
88	O	O
-	O	O
0	O	O
.	O	O
92	O	O
)	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
there	O	O
was	O	O
a	O	O
strong	O	O
inverse	O	O
relationship	O
between	O	O
the	O	O
incidence	O	O
of	O	O
new	O
-	O
onset	O
hypertension	O
and	O	O
elevation	O
of	O	O
cardiovascular	B-ANAT
health	O
metrics	O
.	O	O

Population	B-LIVB
-wide	O	O
prevention	O
,	O	O
especially	O	O
the	O	O
promotion	B-PROC
of	O	O
lifestyle	O
improvements	O
,	O	O
is	O	O
critical	O
to	O	O
reducing	O
the	O	O
morbidity	O
of	O	O
new	O
-	O
onset	O
hypertension	O
.	O	O

Phenozan	B-CHEM
,	O	O
a	O	O
Synthetic	B-CHEM
Phenolic	I-CHEM
Antioxidant	B-CHEM
,	O	O
Inhibits	O
the	O	O
Development	O
of	O	O
Spontaneous	O
Tumors	B-DISO
in	O	O
Rats	B-LIVB
and	O	O
Mice	B-LIVB
Synthetic	B-CHEM
phenolic	I-CHEM
antioxidant	B-CHEM
β	B-CHEM
-	I-CHEM
(	I-CHEM
4	I-CHEM
-	I-CHEM
hydroxy	I-CHEM
-	I-CHEM
3	I-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
di	I-CHEM
-	I-CHEM
tert	I-CHEM
-	I-CHEM
butylphenyl	I-CHEM
)	I-CHEM
propionic	I-CHEM
acid	I-CHEM
,	O	O
named	O	O
phenozan	B-CHEM
,	O	O
is	O	O
a	O	O
potential	O
antiepileptic	B-CHEM
drug	I-CHEM
.	O	O

In	O	O
pre	O
-	O
clinical	O
trials	B-PROC
this	O	O
substance	B-OBJC
did	O	O
not	O	O
manifest	O
any	O	O
toxicity	B-DISO
,	O	O
and	O	O
also	O	O
inhibited	O
the	O	O
development	O
of	O	O
some	O	O
spontaneous	O
tumors	B-DISO
in	O	O
animals	B-LIVB
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
inhibiting	O
effect	O
of	O
phenozan	B-CHEM
on	O	O
spontaneous	O
carcinogenesis	B-DISO
in	O	O
rats	B-LIVB
and	O	O
mice	B-LIVB
.	O	O

In	O	O
experiments	B-PROC
with	O	O
rats	B-LIVB
LIO	I-LIVB
and	O	O
mice	B-LIVB
SHR	I-LIVB
of	O	O
local	O
breeding	B-PHYS
,	O	O
with	O	O
high	O
spontaneous	O
tumor	B-DISO
incidence	O
,	O	O
phenozan	B-CHEM
was	O	O
dissolved	O	O
in	O	O
sunflower	B-CHEM
oil	I-CHEM
and	O	O
administered	O
by	O	O
gavage	O
in	O	O
therapeutic	O
dose	O
5	O	O
mg	O	O
/	O	O
kg	O	O
3	O	O
times	O
per	O	O
week	O
for	O	O
18	O	O
months	O
.	O	O

There	O	O
were	O	O
no	O	O
any	O	O
signs	O	O
of	O	O
toxicity	B-DISO
and	O	O
differences	O
in	O	O
weight	B-PHYS
of	O	O
animals	B-LIVB
during	O	O
the	O	O
phenozan	B-CHEM
treatment	O	O
compared	O
with	O	O
the	O	O
control	B-LIVB
(	O	O
sunflower	B-CHEM
oil	I-CHEM
)	O	O
.	O	O

Phenozan	B-CHEM
significantly	O
reduced	O
the	O	O
overall	O
incidence	O
and	O	O
multiplicity	O
of	O	O
all	O	O
tumors	B-DISO
but	O	O
only	O	O
multiplicity	O
of	O	O
malignant	B-DISO
tumors	I-DISO
,	O	O
compared	O
with	O	O
the	O	O
control	B-LIVB
.	O	O

Moreover	O	O
a	O	O
significant	O
decrease	O
of	O	O
overall	O
incidence	O
and	O	O
multiplicity	O
was	O	O
observed	O	O
in	O	O
pituitary	B-DISO
and	O	O
breast	B-DISO
tumors	I-DISO
in	O	O
females	B-PHYS
and	O	O
only	O	O
overall	O
multiplicity	O
of	O	O
tumors	B-DISO
of	O	O
pituitary	B-ANAT
and	O	O
lymphoid	O
tissue	O
in	O	O
males	B-PHYS
.	O	O

In	O	O
mice	B-LIVB
phenozan	B-CHEM
reduced	O	O
overall	O
incidence	O
and	O	O
multiplicity	O
of	O	O
lung	B-DISO
tumors	I-DISO
(	O	O
in	O	O
females	B-PHYS
)	O	O
and	O	O
also	O	O
overall	O
multiplicity	O
of	O	O
all	O	O
tumors	B-DISO
(	O	O
in	O	O
females	B-PHYS
)	O	O
and	O	O
only	O	O
malignant	B-DISO
tumors	I-DISO
(	O	O
in	O	O
males	B-PHYS
)	O	O
.	O	O

These	O	O
findings	O	O
allow	O	O
us	O	O
to	O	O
classify	O	O
phenozan	B-CHEM
as	O	O
anticarcinogenic	B-CHEM
agent	I-CHEM
.	O	O

Anticarcinogenic	B-CHEM
activity	O
of	O	O
phenozan	B-CHEM
is	O	O
important	O
because	O	O
clinical	B-PROC
study	I-PROC
of	O	O
this	O	O
drug	B-CHEM
as	O	O
the	O	O
possible	O	O
antiepileptic	B-CHEM
drug	I-CHEM
goes	O	O
along	O	O
and	O	O
it	O	O
is	O	O
known	O	O
that	O	O
such	O	O
drugs	B-CHEM
are	O	O
designed	O	O
for	O	O
long	O
-	O
term	O
use	O
.	O	O

Medicare	O
claims	O
indicators	O
of	O	O
healthcare	B-PROC
utilization	O
differences	O
after	O	O
hospitalization	B-PROC
for	O	O
ischemic	B-DISO
stroke	I-DISO
:	O	O
Race	B-LIVB
,	O	O
gender	B-PHYS
,	O	O
and	O	O
caregiving	O
effects	O
Background	O
Differences	O
in	O	O
healthcare	B-PROC
utilization	O
after	O	O
stroke	B-DISO
may	O	O
partly	O	O
explain	O	O
race	B-LIVB
or	O	O
gender	B-PHYS
differences	O
in	O	O
stroke	B-DISO
outcomes	O	O
and	O	O
identify	O	O
factors	O
that	O	O
might	O	O
reduce	O
post	O
-	O	O
acute	B-DISO
stroke	I-DISO
care	O
costs	O
.	O	O

Aim	O	O
To	O	O
examine	O	O
systematic	O
differences	O
in	O	O
Medicare	O
claims	O
for	O	O
healthcare	B-PROC
utilization	O
after	O	O
hospitalization	B-PROC
for	O	O
ischemic	B-DISO
stroke	I-DISO
in	O	O
a	O	O
US	B-GEOG
population	B-LIVB
-based	O	O
sample	B-LIVB
.	O	O

Methods	O	O
Claims	O
were	O	O
examined	B-DISO
over	O	O
a	O	O
six	O
-	O
month	O
period	O
after	O	O
hospitalization	B-PROC
for	O	O
279	O	O
ischemic	B-DISO
stroke	I-DISO
survivors	B-LIVB
65	O	O
years	O
or	O	O
older	B-LIVB
from	O	O
the	O	O
REasons	O
for	O	O
Geographic	O
And	O	O
Racial	B-DISO
Differences	I-DISO
in	O	O
Stroke	B-DISO
(	O	O
REGARDS	B-DISO
)	O	O
study	O	O
.	O	O

Statistical	B-PROC
analyses	I-PROC
examined	B-DISO
differences	O
in	O	O
post	O
-	O	O
acute	B-PROC
healthcare	I-PROC
utilization	O
,	O	O
adjusted	O	O
for	O	O
pre	O
-	O	O
stroke	B-DISO
utilization	O
,	O	O
as	O	O
a	O	O
function	O
of	O	O
race	B-LIVB
(	O	O
African	B-LIVB
-	I-LIVB
American	I-LIVB
vs	O	O
.	O	O

White	B-LIVB
)	O	O
,	O	O
gender	B-PHYS
,	O	O
age	B-PHYS
,	O	O
stroke	O
belt	O
residence	O
,	O	O
income	O
,	O	O
Medicaid	O
dual	O
-	O
eligibility	O
,	O	O
Charlson	O
comorbidity	O
index	O
,	O	O
and	O	O
whether	O	O
the	O	O
person	B-LIVB
lived	O
with	O	O
an	O	O
available	O
caregiver	B-LIVB
.	O	O

Results	O	O
After	O	O
adjusting	O	O
for	O	O
covariates	O	O
,	O	O
women	B-LIVB
were	O	O
more	O	O
likely	O	O
than	O	O
men	B-LIVB
to	O	O
receive	O
home	B-PROC
health	I-PROC
care	I-PROC
and	O	O
to	O	O
use	O	O
emergency	B-PROC
department	I-PROC
services	I-PROC
during	O	O
the	O	O
post	O
-	O	O
acute	B-PROC
care	I-PROC
period	O
.	O	O

These	O	O
effects	O
were	O	O
maintained	O
even	O	O
after	O	O
further	O
adjustment	O
for	O	O
acute	B-DISO
stroke	I-DISO
severity	O
.	O	O

African	B-LIVB
-	I-LIVB
Americans	I-LIVB
had	O	O
more	O	O
home	B-PROC
health	I-PROC
care	I-PROC
visits	B-PROC
than	O	O
Whites	B-LIVB
among	O	O
patients	B-LIVB
who	O	O
received	O
some	O	O
home	B-PROC
health	I-PROC
care	I-PROC
.	O	O

Having	O	O
a	O	O
co	O
-	O
residing	O
caregiver	B-LIVB
was	O	O
associated	O
with	O
reduced	O
acute	B-PROC
hospitalization	I-PROC
length	O
of	O
stay	O
and	O	O
fewer	O	O
post	O
-	O	O
acute	B-PROC
emergency	I-PROC
department	I-PROC
and	O	O
primary	B-PROC
care	I-PROC
physician	I-PROC
visits	I-PROC
.	O	O

Conclusions	O	O
Underutilization	O
of	O
healthcare	O
after	O	O
stroke	B-DISO
does	O	O
not	O	O
appear	O	O
to	O	O
explain	O	O
poorer	O	O
long	O
-	O
term	O
stroke	B-DISO
outcomes	O	O
for	O	O
women	B-LIVB
and	O	O
African	B-LIVB
-	I-LIVB
Americans	I-LIVB
in	O	O
this	O	O
epidemiologically	O
-derived	O	O
sample	B-LIVB
.	O	O

Caregiver	B-LIVB
availability	O
may	O	O
contribute	O
to	O	O
reduced	O
formal	O
care	O
and	O	O
cost	O
during	O	O
the	O	O
post	O
-	O	O
acute	B-PROC
period	O
.	O	O

Towards	O	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
analytics	I-PROC
for	O	O
foodborne	O
RNA	B-LIVB
viruses	I-LIVB
:	O	O
Examining	O	O
the	O	O
effect	O
of	O	O
RNA	B-CHEM
input	O	O
quantity	O
and	O	O
viral	B-CHEM
RNA	I-CHEM
purity	O
Detection	B-PROC
and	O	O
identification	B-PROC
of	O	O
viruses	B-LIVB
in	O	O
food	B-OBJC
samples	I-OBJC
are	O	O
technically	O	O
challenging	O	O
due	O	O
largely	O	O
to	O	O
the	O	O
low	O	O
viral	B-LIVB
copy	O
number	O
in	O	O
contaminated	B-OBJC
food	I-OBJC
items	I-OBJC
,	O	O
and	O	O
the	O	O
lack	O	O
of	O	O
effective	O	O
culture	B-PROC
enrichment	I-PROC
methods	I-PROC
that	O	O
are	O	O
amenable	O	O
to	O	O
regulatory	O
applications	O
for	O	O
many	O	O
of	O	O
the	O	O
common	O	O
foodborne	O
viruses	B-LIVB
.	O	O

Using	O	O
an	O	O
Illumina	O
MiSeq	O
platform	O
and	O	O
two	O	O
hepatitis	B-LIVB
A	I-LIVB
virus	I-LIVB
(	O	O
HAV	B-LIVB
)	O	O
cell	B-PROC
-	I-PROC
culture	I-PROC
adapted	O	O
strains	O
as	O	O
a	O	O
representative	O	O
enteric	O	O
virus	B-LIVB
species	O	O
,	O	O
this	O	O
study	B-PROC
examined	O	O
the	O	O
limits	O	O
of	O	O
single	B-CHEM
-	I-CHEM
stranded	I-CHEM
RNA	I-CHEM
(	O	O
ssRNA	B-CHEM
)	O	O
viral	B-PROC
detection	I-PROC
following	O	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
without	O	O
pre	B-PHYS
-	I-PHYS
amplification	I-PHYS
of	O	O
the	O	O
viral	O
genome	O
.	O	O

Complete	O	O
viral	O
genome	O
sequences	O
were	O	O
obtained	O	O
from	O	O
HAV	B-LIVB
samples	O	O
of	O	O
varying	O	O
purities	O
and	O	O
with	O	O
an	O	O
input	O	O
as	O	O
low	O	O
as	O	O
2ng	O	O
total	O	O
RNA	B-CHEM
containing	O	O
1	O	O
.	O	O

4×10	O	O
(	O	O
5	O	O
)	O	O
copies	O	O
of	O	O
viral	B-CHEM
RNA	I-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
single	O
nucleotide	O
variations	O
were	O	O
reproducibly	O	O
detected	O	O
over	O	O
the	O	O
range	O	O
of	O	O
concentrations	O	O
examined	O	O
,	O	O
and	O	O
their	O	O
identity	O	O
confirmed	O	O
by	O	O
alternate	B-PROC
sequencing	I-PROC
technology	I-PROC
.	O	O

In	O	O
summary	O	O
,	O	O
next	B-PROC
-	I-PROC
generation	I-PROC
sequencing	I-PROC
technology	I-PROC
has	O	O
the	O	O
potential	O	O
for	O	O
sensitive	O	O
detection	B-PROC
/	O	O
identification	B-PROC
of	O	O
a	O	O
viral	O
genome	O
at	O	O
a	O	O
low	O	O
copy	O
number	O
.	O	O

This	O	O
study	B-PROC
provides	O	O
a	O	O
benchmark	O	O
for	O	O
metagenomic	B-PROC
sequencing	I-PROC
application	I-PROC
as	O	O
is	O	O
required	O	O
for	O	O
virus	B-PROC
detection	I-PROC
in	O	O
complex	O	O
food	B-OBJC
matrices	O	O
using	O	O
a	O	O
culture	B-PROC
-independent	O	O
diagnostic	B-PROC
approach	I-PROC
.	O	O

Long	B-PROC
-	I-PROC
Term	I-PROC
Safety	I-PROC
Follow	I-PROC
-	I-PROC
Up	I-PROC
of	O	O
Subjects	B-LIVB
Previously	O
Treated	B-PROC
with	I-PROC
Non	O
-	O
Replicating	O
Retroviral	B-CHEM
Vector	I-CHEM
-Based	O	O
Gene	B-PROC
Therapies	I-PROC
Our	O	O
objective	O
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
life	B-PROC
-	I-PROC
long	I-PROC
safety	I-PROC
profile	I-PROC
of	O	O
gene	B-PROC
therapy	I-PROC
using	O	O
retroviral	B-CHEM
(	I-CHEM
non	I-CHEM
-	I-CHEM
replicating	I-CHEM
)	I-CHEM
vectors	I-CHEM
(	O	O
nRCR	B-CHEM
)	O	O
,	O	O
or	O	O
cell	B-ANAT
products	B-OBJC
in	O	O
127	O	O
subjects	B-LIVB
with	O	O
hemophilia	B-DISO
,	O	O
human	B-LIVB
immunodeficiency	I-LIVB
virus	I-LIVB
(	O	O
HIV	B-LIVB
)	O	O
,	O	O
or	O	O
cancer	B-DISO
,	O	O
previously	O
treated	B-PROC
with	I-PROC
such	O	O
gene	B-PROC
therapy	I-PROC
.	O	O

We	O	O
assessed	O
the	O	O
occurrence	O
of	O	O
serious	B-DISO
adverse	I-DISO
events	I-DISO
(	O	O
SAEs	B-DISO
)	O	O
,	O	O
deaths	B-PHYS
and	O	O
presence	O
of	O	O
replication	B-CHEM
competent	I-CHEM
retrovirus	I-CHEM
(	O	O
RCR	B-CHEM
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
23	O	O
subjects	B-LIVB
remained	O	O
until	O	O
the	O	O
data	O	O
cut	O	O
-	O	O
off	O	O
date	O	O
of	O	O
31	O	O
July	O	O
2013	O	O
and	O	O
provided	O
safety	O
information	O
of	O	O
up	O	O
to	O	O
18	O	O
years	O	O
.	O	O

Of	O	O
the	O	O
104	O	O
subjects	B-LIVB
who	O	O
discontinued	B-DISO
,	O	O
the	O	O
primary	O
reason	O
was	O	O
loss	B-DISO
to	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
(	O	O
47	O	O
.	O	O
2	O	O
%	O	O
;	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

The	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
for	O	O
the	O	O
60	O	O
subjects	B-LIVB
lost	B-DISO
to	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
was	O	O
7	O	O
-	O	O
10	O	O
years	O	O
.	O	O

A	O	O
total	O	O
of	O	O
41	O	O
subjects	B-LIVB
experienced	B-PHYS
at	O	O
least	O	O
one	O	O
SAE	B-DISO
,	O	O
and	O	O
15	O	O
subjects	B-LIVB
died	B-PHYS
.	O	O

We	O	O
reviewed	O
SAEs	B-DISO
and	O	O
cause	B-DISO
of	I-DISO
death	I-DISO
(	O	O
none	O	O
related	O	O
to	O	O
the	O	O
active	O
therapy	B-PROC
)	O	O
,	O	O
but	O	O
no	O	O
evidence	O
was	O	O
found	O	O
for	O	O
safety	B-PHEN
signals	B-PHEN
related	O	O
to	O	O
new	O	O
malignancy	B-DISO
or	O	O
neurologic	O
,	O	O
rheumatological	B-DISO
,	O	O
autoimmune	B-DISO
,	O	O
or	O	O
hematologic	B-DISO
disorder	I-DISO
.	O	O

RCR	B-CHEM
results	B-PHEN
were	O	O
negative	B-DISO
,	O	O
indicating	O
no	O
evidence	O
for	O	O
in	O
vivo	O
vector	B-LIVB
persistence	O
.	O	O

Despite	O	O
the	O	O
loss	B-DISO
of	I-DISO
follow	I-DISO
-	I-DISO
up	I-DISO
,	O	O
which	O	O
is	O	O
the	O	O
limiting	O
factor	O
in	O	O
this	O	O
long	O
-	O
term	O
safety	B-PROC
trial	I-PROC
,	O	O
the	O	O
findings	B-DISO
from	O	O
this	O	O
long	B-PROC
-	I-PROC
term	I-PROC
follow	I-PROC
-	I-PROC
up	I-PROC
study	B-PROC
are	O	O
encouraging	O	O
.	O	O

An	O	O
HIV	B-LIVB
-	O	O
tailored	B-PROC
quit	O
-	O	O
smoking	O
counselling	B-PROC
pilot	B-PROC
intervention	B-PROC
targeting	O
depressive	B-DISO
symptoms	I-DISO
plus	O	O
Nicotine	B-PROC
Replacement	I-PROC
Therapy	I-PROC
Cardiovascular	B-DISO
disease	I-DISO
(	O	O
CVD	B-DISO
)	O	O
rates	O
among	O	O
people	B-LIVB
living	B-LIVB
with	I-LIVB
HIV	I-LIVB
/	I-LIVB
AIDS	I-LIVB
(	O	O
PHAs	B-LIVB
)	O	O
are	O	O
high	O
.	O	O

Rates	O
of	O	O
cigarette	O
smoking	O
,	O	O
a	O	O
leading	O
contributor	O
to	O	O
CVD	B-DISO
among	O	O
PHAs	B-LIVB
,	O	O
are	O	O
40	O	O
-	O	O
70	O	O
%	O	O
(	O	O
2	O	O
-	O	O
3	O	O
times	O	O
higher	O
than	O	O
the	O	O
general	B-LIVB
population	I-LIVB
)	O	O
.	O	O

Furthermore	O	O
,	O	O
PHAs	B-LIVB
have	O	O
high	O
rates	O
of	O	O
depression	B-DISO
(	O	O
40	O	O
-	O	O
60	O	O
%	O	O
)	O	O
,	O	O
a	O	O
risk	B-DISO
factor	I-DISO
for	O	O
smoking	O
cessation	O
relapse	B-PHEN
.	O	O

The	O	O
current	O	O
pilot	B-PROC
study	I-PROC
examined	B-DISO
the	O	O
effectiveness	O
of	O	O
a	O	O
specifically	O	O
tailored	B-PROC
5	O	O
-	O	O
session	O
smoking	O
cessation	O
counselling	B-PROC
programme	I-PROC
for	O	O
PHAs	B-LIVB
,	O	O
which	O	O
addressed	O	O
depression	B-DISO
,	O	O
in	O	O
combination	O	O
with	O	O
Nicotine	B-PROC
Replacement	I-PROC
Therapy	I-PROC
(	O	O
NRT	B-PROC
)	O	O
in	O	O
a	O	O
cohort	B-LIVB
of	O	O
PHA	B-LIVB
smokers	B-DISO
(	O	O
n	O	O
=	O	O
50	O	O
)	O	O
.	O	O

At	O	O
6	O	O
-	O	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
,	O	O
28	O	O
%	O	O
of	O	O
participants	B-LIVB
demonstrated	O	O
biochemically	O
verified	O
abstinence	B-PROC
from	O	O
smoking	O
.	O	O

This	O	O
result	B-DISO
compares	O
favourably	O	O
to	O	O
other	O	O
quit	O
-	O	O
smoking	O
intervention	B-PROC
studies	B-PROC
,	O	O
particularly	O	O
given	O	O
the	O	O
high	O
percentage	O
of	O	O
HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
with	O	O
depression	B-DISO
.	O	O

At	O	O
study	B-PROC
baseline	O
,	O	O
52	O	O
%	O	O
of	O	O
HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
scored	O	O
above	O	O
the	O	O
clinical	O
cut	O
-	O
off	O
for	O	O
depression	B-DISO
on	O	O
the	O	O
Centre	O
for	O
Epidemiological	O
Studies	O
-	O
Depression	O
(	O
CES	O
-	O
D	O
)	O
scale	O
.	O	O

HIV	B-PHEN
+	I-PHEN
smokers	B-DISO
with	O	O
depression	B-DISO
at	O	O
study	B-PROC
baseline	O
demonstrated	O	O
quantitatively	O
lower	O
depression	B-DISO
at	O	O
6	O	O
-	O	O
month	O
follow	B-PROC
-	I-PROC
up	I-PROC
with	O	O
a	O	O
large	O
effect	O
size	O
(	O	O
d	O	O
=	O	O
1	O	O
)	O	O
,	O	O
though	O	O
it	O	O
did	O	O
not	O	O
reach	O	O
statistical	O
significance	O
(	O	O
p	O	O
=	O	O
.058	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
those	O	O
with	O	O
depression	B-DISO
were	O	O
no	O	O
more	O	O
likely	O	O
to	O	O
relapse	B-PHEN
than	O	O
those	O	O
without	O	O
depression	B-DISO
(	O	O
p	O	O
=	O	O
.33	O	O
)	O	O
,	O	O
suggesting	O	O
that	O	O
our	O	O
counselling	B-PROC
programme	I-PROC
adequately	O
addressed	O	O
this	O	O
significant	O
barrier	O
to	O	O
smoking	O
cessation	O
among	O	O
PHAs	B-LIVB
.	O	O

Our	O	O
pilot	B-PROC
study	I-PROC
indicates	O	O
the	O	O
importance	O
of	O	O
tailored	B-PROC
programmes	I-PROC
to	O	O
help	O	O
PHAs	B-LIVB
quit	O
smoking	O
,	O	O
the	O	O
significance	O
of	O	O
addressing	O	O
depressive	B-DISO
symptoms	I-DISO
,	O	O
and	O	O
the	O	O
need	O	O
for	O	O
tailored	B-PROC
counselling	I-PROC
programmes	I-PROC
to	O	O
enhance	O
quit	O
rates	O
among	O	O
PHAs	B-LIVB
.	O	O

Growth	B-DISO
arrest	I-DISO
of	O	O
lung	B-DISO
carcinoma	I-DISO
cells	B-ANAT
(	B-ANAT
A549	I-ANAT
)	I-ANAT
by	O	O
polyacrylate	B-CHEM
-	O	O
anchored	B-PROC
peroxovanadate	B-CHEM
by	O	O
activating	O
Rac1	B-CHEM
-	O	O
NADPH	B-CHEM
oxidase	I-CHEM
signalling	B-PHYS
axis	O
Hydrogen	B-CHEM
peroxide	I-CHEM
is	O	O
often	O	O
required	O
in	O	O
sublethal	B-DISO
,	O	O
millimolar	O
concentrations	O
to	O	O
show	O	O
its	O	O
oxidant	B-CHEM
effects	I-CHEM
on	O	O
cells	B-PROC
in	I-PROC
culture	I-PROC
as	O	O
it	O	O
is	O	O
easily	O	O
destroyed	O
by	O	O
cellular	B-ANAT
catalase	B-CHEM
.	O	O

Previously	O	O
,	O	O
we	O	O
had	O	O
shown	O	O
that	O	O
diperoxovanadate	B-CHEM
,	O	O
a	O	O
physiologically	O
stable	O
peroxovanadium	B-CHEM
compound	I-CHEM
,	O	O
can	O	O
substitute	O
H2O2	B-CHEM
effectively	O
in	O	O
peroxidation	B-PHEN
reactions	I-PHEN
.	O	O

We	O	O
report	O
here	O	O
that	O	O
peroxovanadate	B-CHEM
when	O	O
anchored	B-PROC
to	O	O
polyacrylic	B-CHEM
acid	I-CHEM
(	B-CHEM
PAPV	I-CHEM
)	I-CHEM
becomes	O	O
a	O	O
highly	O
potent	O
inhibitor	O
of	O	O
growth	B-PHYS
of	O	O
lung	B-DISO
carcinoma	I-DISO
cells	B-ANAT
(	O	O
A549	B-ANAT
)	O	O
.	O	O

The	O	O
early	O
events	O
associated	O
with	O
PAPV	B-CHEM
treatment	O
included	O
cytoskeletal	B-ANAT
modifications	B-DISO
,	O	O
increase	O
in	O	O
GTPase	B-PHYS
activity	I-PHYS
of	O	O
Rac1	B-CHEM
,	O	O
accumulation	B-DISO
of	O	O
the	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
,	O	O
and	O	O
also	O	O
increase	O
in	O	O
phosphorylation	B-PHYS
of	O	O
H2AX	B-CHEM
(	B-CHEM
γH2AX	I-CHEM
)	I-CHEM
,	O	O
a	O	O
marker	O
of	O	O
DNA	B-DISO
damage	I-DISO
.	O	O

These	O	O
effects	O
persisted	O
even	O	O
at	O	O
24	O	O
h	O	O
after	O	O
removal	O
of	O	O
the	O	O
compound	O
and	O	O
culminated	O	O
in	O	O
increased	O
levels	O
of	O	O
p53	B-CHEM
and	O	O
p21	B-CHEM
together	O	O
with	O	O
growth	B-DISO
arrest	I-DISO
.	O	O

The	O	O
PAPV	B-CHEM
-mediated	O	O
growth	B-DISO
arrest	I-DISO
was	O	O
significantly	O
abrogated	O
in	O	O
cells	B-ANAT
pre	O
-	O
treated	O
with	O	O
the	O	O
N	B-CHEM
-	I-CHEM
acetylcysteine	I-CHEM
,	O	O
Rac1	B-CHEM
knocked	B-PROC
down	I-PROC
by	O	O
siRNA	B-CHEM
and	O	O
DPI	B-CHEM
an	O	O
inhibitor	O
of	O	O
NADPH	B-CHEM
oxidase	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
results	O
show	O	O
that	O	O
polyacrylate	B-CHEM
derivative	O	O
of	O	O
peroxovanadate	B-CHEM
efficiently	O
arrests	B-DISO
growth	I-DISO
of	O	O
A549	B-ANAT
cancerous	B-ANAT
cells	I-ANAT
by	O	O
activating	O
the	O	O
axis	O
of	O	O
Rac1	B-CHEM
-	O	O
NADPH	B-CHEM
oxidase	I-CHEM
leading	O	O
to	O	O
oxidative	B-DISO
stress	I-DISO
and	O	O
DNA	B-DISO
damage	I-DISO
.	O	O

Fractal	O
analysis	B-PROC
of	O	O
the	O	O
ischemic	O
transition	O
region	O
in	O	O
chronic	B-DISO
ischemic	I-DISO
heart	I-DISO
disease	I-DISO
using	O	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
To	O	O
introduce	O	O
a	O	O
novel	O
hypothesis	O
and	O	O
method	O
to	O	O
characterise	O	O
pathomechanisms	B-DISO
underlying	O	O
myocardial	B-DISO
ischemia	I-DISO
in	O	O
chronic	B-DISO
ischemic	I-DISO
heart	I-DISO
disease	I-DISO
by	O	O
local	O	O
fractal	O
analysis	B-PROC
(	O	O
FA	B-PROC
)	O	O
of	O	O
the	O	O
ischemic	O
myocardial	O
transition	O
region	O
in	O	O
perfusion	B-PROC
imaging	I-PROC
.	O	O

Vascular	B-ANAT
mechanisms	O
to	O	O
compensate	O
ischemia	B-DISO
are	O	O
regulated	B-PHEN
at	O	O
various	O	O
vascular	B-ANAT
scales	O
with	O	O
their	O	O
superimposed	B-PROC
perfusion	I-PROC
pattern	O
being	O	O
hypothetically	O
self	O
-	O
similar	O
.	O	O

Dedicated	O	O
FA	B-PROC
software	B-OBJC
(	O	O
""""	O	O
FraktalWandler	O
""""	O	O
)	O	O
has	O	O
been	O	O
developed	O	O
.	O	O

Fractal	O
dimensions	O
during	O	O
first	O
-	O
pass	O
(	O	O
FDfirst	O
-	O
pass	O
)	O	O
and	O	O
recirculation	B-PHYS
(	O	O
FDrecirculation	B-PHYS
)	O	O
are	O	O
hypothesised	O
to	O	O
indicate	O	O
the	O	O
predominating	O	O
pathomechanism	B-DISO
and	O	O
ischemic	O
severity	O
,	O	O
respectively	O	O
.	O	O
Twenty	O	O
-	O	O
six	O	O
patients	B-LIVB
with	O	O
evidence	O	O
of	O	O
myocardial	B-DISO
ischemia	I-DISO
in	O	O
108	O	O
ischemic	O
myocardial	O
segments	O
on	O	O
magnetic	B-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
MRI	B-PROC
)	O	O
were	O	O
analysed	O	O
.	O	O

The	O	O
40th	O	O
and	O	O
60th	O	O
percentiles	O
of	O	O
FDfirst	O
-	O
pass	O
were	O	O
used	O	O
for	O	O
pathomechanical	O
classification	O
,	O	O
assigning	O	O
lesions	B-DISO
with	O	O
FDfirst	O
-	O
pass	O
≤	O	O
2	O	O
.	O	O

335	O	O
to	O	O
predominating	O	O
coronary	B-DISO
microvascular	I-DISO
dysfunction	I-DISO
(	O	O
CMD	B-DISO
)	O	O
and	O	O
≥2	O	O
.	O	O
387	O	O
to	O	O
predominating	O	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O	O
CAD	B-DISO
)	O	O
.	O	O

Optimal	O
classification	O
point	O	O
in	O	O
ROC	O
analysis	B-PROC
was	O	O
FDfirst	O
-	O
pass	O
=	O	O
2	O	O
.	O	O
358	O	O
.	O	O

FDrecirculation	B-PHYS
correlated	O
moderately	O	O
with	O	O
per	O
cent	O
diameter	O
stenosis	O
in	O	O
invasive	O
coronary	B-PROC
angiography	I-PROC
in	O	O
lesions	B-DISO
classified	O	O
CAD	B-DISO
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
472	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

001	O	O

)	O	O

but	O	O
not	O	O
CMD	B-DISO
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
082	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
600	O	O
)	O	O
.	O	O

The	O	O
ischemic	B-DISO
transition	O
region	B-ANAT
may	O	O
provide	O	O
information	O
on	O	O
pathomechanical	O
composition	O
and	O	O
severity	O
of	O	O
myocardial	B-DISO
ischemia	I-DISO
.	O	O

FA	B-PROC
of	O	O
this	O	O
region	B-ANAT
is	O	O
feasible	O	O
and	O	O
may	O	O
improve	B-DISO
diagnosis	B-DISO
compared	O	O
to	O	O
traditional	O
noninvasive	O
myocardial	B-PHYS
perfusion	I-PHYS
analysis	B-PROC
.	O	O

•	O	O
A	O	O
novel	O
hypothesis	O
and	O	O
method	O
is	O	O
introduced	O	O
to	O	O
pathophysiologically	O
characterise	O	O
myocardial	B-DISO
ischemia	I-DISO
.	O	O

•	O	O
The	O	O
ischemic	B-DISO
transition	O
region	B-ANAT
appears	O	O
a	O	O
meaningful	O	O
diagnostic	O	O
target	O	O
in	O	O
perfusion	B-PROC
imaging	I-PROC
.	O	O

•	O	O
Fractal	O
analysis	B-PROC
may	O	O
characterise	O	O
pathomechanical	O	O
composition	O	O
and	O	O
severity	O
of	O	O
myocardial	B-DISO
ischemia	I-DISO
.	O	O

Do	O	O
dynamic	O
global	O
vegetation	O
models	O
capture	O	O
the	O	O
seasonality	O
of	O	O
carbon	B-PHEN
fluxes	I-PHEN
in	O	O
the	O	O
Amazon	B-GEOG
basin	I-GEOG
?	O	O

A	O	O
data	O
-	O	O
model	O
intercomparison	O
To	O	O
predict	O	O
forest	B-PHEN
response	B-PHYS
to	O	O
long	O
-	O
term	O
climate	B-PHEN
change	I-PHEN
with	O	O
high	O	O
confidence	O	O
requires	O	O
that	O	O
dynamic	O
global	O
vegetation	O
models	O
(	O	O
DGVMs	O
)	O	O
be	O	O
successfully	O	O
tested	O	O
against	O	O
ecosystem	B-PHEN
response	B-PHYS
to	O	O
short	O
-	O
term	O
variations	O
in	O	O
environmental	O
drivers	O
,	O	O
including	O	O
regular	O	O
seasonal	O
patterns	O
.	O	O

Here	O	O
,	O	O
we	O	O
used	O	O
an	O	O
integrated	O	O
dataset	O
from	O	O
four	O	O
forests	B-PHEN
in	O	O
the	O	O
Brasil	O
flux	O
network	O
,	O	O
spanning	O	O
a	O	O
range	O	O
of	O	O
dry	O
-	O
season	O
intensities	O
and	O	O
lengths	O
,	O	O
to	O	O
determine	O	O
how	O	O
well	O	O
four	O	O
state	O	O
-	O	O
of	O	O
-	O	O
the	O	O
-	O	O
art	O	O
models	O
(	O	O
IBIS	O
,	O	O
ED2	O
,	O	O
JULES	O
,	O	O
and	O	O
CLM3	O
.	O

5	O
)	O	O
simulated	O	O
the	O	O
seasonality	O
of	O	O
carbon	B-PHEN
exchanges	I-PHEN
in	O	O
Amazonian	B-GEOG
tropical	B-PHEN
forests	I-PHEN
.	O	O

We	O	O
found	O	O
that	O	O
most	O	O
DGVMs	O
poorly	O	O
represented	O	O
the	O	O
annual	O	O
cycle	O	O
of	O	O
gross	O
primary	O
productivity	O
(	O	O
GPP	O
)	O	O
,	O	O
of	O	O
photosynthetic	O
capacity	O
(	O	O
Pc	O
)	O	O
,	O	O
and	O	O
of	O	O
other	O	O
fluxes	B-PHEN
and	O	O
pools	O	O
.	O	O

Models	O
simulated	O	O
consistent	O	O
dry	O
-	O
season	O
declines	O
in	O	O
GPP	O
in	O	O
the	O	O
equatorial	B-GEOG
Amazon	I-GEOG
(	O	O
Manaus	B-GEOG
K34	I-GEOG
,	O	O
Santarem	B-GEOG
K67	I-GEOG
,	O	O
and	O	O
Caxiuanã	B-GEOG
CAX	I-GEOG
)	O	O
;	O	O
a	O	O
contrast	O	O
to	O	O
observed	O	O
GPP	O
increases	O	O
.	O	O

Model	O
simulated	O	O
dry	O
-	O
season	O
GPP	O
reductions	O
were	O	O
driven	O	O
by	O	O
an	O	O
external	O	O
environmental	O
factor	O
,	O	O
'	O	O
soil	B-DISO
water	I-DISO
stress	I-DISO
'	O	O
and	O	O
consequently	O	O
by	O	O
a	O	O
constant	O	O
or	O	O
decreasing	O	O
photosynthetic	B-PHEN
infrastructure	I-PHEN
(	O	O
Pc	O
)	O	O
,	O	O
while	O	O
observed	O	O
dry	O
-	O
season	O
GPP	O
resulted	O	O
from	O	O
a	O	O
combination	O	O
of	O	O
internal	O	O
biological	O
(	O	O
leaf	B-LIVB
-flush	O	O
and	O	O
abscission	B-PHYS
and	O	O
increased	O	O
Pc	O
)	O	O
and	O	O
environmental	O
(	O	O
incoming	O	O
radiation	B-PHEN
)	O	O
causes	O	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
found	O	O
models	O
generally	O	O
overestimated	O	O
observed	O	O
seasonal	O	O
net	O
ecosystem	O
exchange	O
(	O	O
NEE	O
)	O	O
and	O	O
respiration	B-PHYS
(	O	O
Re	B-PHYS
)	O	O
at	O	O
equatorial	O	O
locations	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
a	O	O
southern	B-GEOG
Amazon	I-GEOG
forest	B-PHEN
(	O	O
Jarú	O	O
RJA	O	O
)	O	O
exhibited	O	O
dry	O
-	O
season	O
declines	O
in	O	O
GPP	O
and	O	O
Re	B-PHYS
consistent	O	O
with	O	O
most	O	O
DGVMs	O
simulations	B-PROC
.	O	O

While	O	O
water	O	O
limitation	O	O
was	O	O
represented	O	O
in	O	O
models	O
and	O	O
the	O	O
primary	O	O
driver	O	O
of	O	O
seasonal	O	O
photosynthesis	B-PHEN
in	O	O
southern	B-GEOG
Amazonia	I-GEOG
,	O	O
changes	O	O
in	O	O
internal	O	O
biophysical	B-PHEN
processes	I-PHEN
,	O	O
light	B-PHYS
-	I-PHYS
harvesting	I-PHYS
adaptations	B-PHEN
(	O	O
e	O	O
.	O	O
g	O	O
.	O	O

,	O	O
variations	O	O
in	O	O
leaf	O
area	O
index	O
(	O	O
LAI	O
)	O	O
and	O	O
increasing	O	O
leaf	B-LIVB
-level	O	O
assimilation	B-PHEN
rate	O
related	O	O
to	O	O
leaf	O
demography	O
)	O	O
,	O	O
and	O	O
allocation	O	O
lags	O	O
between	O	O
leaf	B-LIVB
and	O	O
wood	B-LIVB
,	O	O
dominated	O	O
equatorial	B-GEOG
Amazon	I-GEOG
carbon	B-PHEN
flux	I-PHEN
dynamics	O	O
and	O	O
were	O	O
deficient	O	O
or	O	O
absent	O	O
from	O	O
current	O	O
model	O
formulations	O	O
.	O	O

Correctly	O	O
simulating	O	O
flux	B-PHEN
seasonality	O
at	O	O
tropical	B-PHEN
forests	I-PHEN
requires	O	O
a	O	O
greater	O	O
understanding	O	O
and	O	O
the	O	O
incorporation	O	O
of	O	O
internal	O	O
biophysical	B-PHYS
mechanisms	I-PHYS
in	O	O
future	O	O
model	O
developments	O
.	O	O

Detailed	O	O
Morphology	O
of	O	O
All	O	O
Life	O
Stages	O
of	O	O
the	O	O
Agave	O
Red	O
Worm	O
,	O	O
Comadia	O
redtenbacheri	O
(	O	O
Hammerschmidt	O	O
)	O	O
(	O	O
Lepidoptera	O
:	O	O
Cossidae	O
)	O	O
The	O	O
agave	O
red	O
worm	O
,	O	O
Comadia	O
redtenbacheri	O
(	O	O
Hammerschmidt	O	O
)	O	O
,	O	O
is	O	O
an	O	O
important	O	O
source	O	O
of	O	O
food	B-OBJC
and	O	O
income	O
in	O	O
Mexico	B-GEOG
.	O	O

Despite	O	O
its	O	O
importance	O	O
,	O	O
several	O	O
aspects	O	O
of	O	O
its	O	O
biology	O
,	O	O
morphology	O
,	O	O
and	O	O
behavior	O
remain	O	O
poorly	O	O
studied	O	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
we	O	O
describe	O	O
and	O	O
illustrate	O	O
the	O	O
morphology	O
of	O	O
all	O	O
the	O	O
life	O
stages	O
that	O	O
may	O	O
aid	O	O
in	O	O
understanding	O	O
certain	O	O
aspects	O
of	O	O
its	O	O
biology	O
.	O	O

To	O	O
obtain	O	O
all	O	O
life	O
stages	O
,	O	O
last	O
instar	O
larvae	O
were	O	O
collected	O	O
from	O	O
agave	B-LIVB
plants	I-LIVB
and	O	O
allowed	O	O
to	O	O
pupate	O
;	O	O
after	O	O
the	O	O
adults	O
emerged	O	O
,	O	O
they	O	O
were	O	O
allowed	O	O
to	O	O
mate	B-PHYS
and	O	O
oviposit	B-PHYS
.	O	O

The	O	O
frenulum	O
is	O	O
longer	O	O
in	O	O
males	B-PHYS
;	O	O
epiphysis	B-ANAT
I	I-ANAT
is	O	O
longer	O	O
in	O	O
females	B-PHYS
than	O	O
in	O	O
males	B-PHYS
;	O	O
the	O	O
abdomen	B-ANAT
bears	O	O
two	O	O
types	O	O
of	O	O
tubercles	B-ANAT
of	O	O
unknown	O	O
function	O	O
.	O	O

Eggs	B-ANAT
present	O	O
a	O	O
reticulate	B-ANAT
chorion	I-ANAT
;	O	O
primary	O	O
rosette	B-ANAT
cells	I-ANAT
are	O	O
highly	O	O
variable	O	O
in	O	O
shape	O	O
;	O	O
the	O	O
micropylar	O
formula	O
is	O	O
(	O	O
10	O	O
-	O	O
14	O	O
)	O	O
:	O	O
(	O	O
12	O	O
-	O	O
13	O	O
)	O	O
.	O	O

First	O
instar	O
larvae	O
are	O	O
white	O
,	O	O
becoming	O	O
red	O
as	O	O
they	O	O
develop	B-PHYS
;	O	O
L3	B-ANAT
in	O	O
the	O	O
prothorax	B-ANAT
is	O	O
subprimary	B-DISO
;	O	O
the	O	O
SV	B-ANAT
setal	I-ANAT
group	O
in	O	O
A1	O
is	O	O
comprised	O	O
of	O	O
only	O	O
SV1	O
on	O	O
first	O
instar	O
larvae	O
;	O	O
last	O
instars	O
have	O	O
several	O	O
secondary	O	O
setae	B-ANAT
.	O	O

Pupae	O
are	O	O
adecticous	B-DISO
and	O	O
obtect	B-DISO
;	O	O
there	O	O
are	O	O
rows	O	O
of	O	O
spines	B-ANAT
on	O	O
the	O	O
dorsum	B-ANAT
of	I-ANAT
the	I-ANAT
abdomen	I-ANAT
.	O	O

The	O	O
biological	O
significance	O
of	O	O
some	O	O
of	O	O
the	O	O
findings	B-DISO
is	O	O
discussed	O	O
.	O	O

Scald	B-DISO
burn	I-DISO
,	O	O
a	O	O
preventable	B-PROC
injury	I-PROC
:	O	O
Analysis	B-PROC
of	O	O
4306	O	O
patients	B-LIVB
from	O	O
a	O	O
major	O	O
tertiary	B-OBJC
care	I-OBJC
center	I-OBJC
Scalds	B-DISO
have	O	O
distinct	O	O
epidemiological	O
and	O	O
predisposing	O
risk	B-DISO
factors	I-DISO
amongst	O	O
all	O	O
types	O
of	O	O
burns	B-DISO
.	O	O

Though	O	O
scald	B-DISO
affects	O
all	O	O
age	B-LIVB
groups	I-LIVB
,	O	O
the	O	O
brunt	O	O
falls	O	O
on	O	O
the	O	O
minor	B-LIVB
age	B-LIVB
groups	I-LIVB
.	O	O

It	O	O
may	O	O
result	O
in	O	O
major	O	O
physical	B-DISO
disabilities	I-DISO
and	O	O
significant	O
loss	O
of	O	O
school	B-OBJC
years	O
.	O	O

Apart	O	O
from	O	O
the	O	O
economic	O
burden	O
on	O	O
family	B-LIVB
,	O	O
major	O	O
scald	B-DISO
burn	I-DISO
may	O	O
compromise	B-DISO
overall	O	O
development	B-PHYS
of	O	O
the	O	O
affected	O
children	B-LIVB
.	O	O

Most	O	O
of	O	O
the	O	O
scald	B-DISO
injuries	I-DISO
occur	O
in	O	O
domestic	O
settings	O
and	O	O
are	O	O
preventable	O
.	O	O

Despite	O	O
improvement	O
in	O	O
living	O
conditions	O
,	O	O
the	O	O
incidence	O
of	O	O
scald	B-DISO
burn	I-DISO
has	O	O
failed	O
to	O	O
decline	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
study	B-PROC
the	O	O
detailed	O
epidemiology	O
and	O	O
severity	O
of	O	O
scald	B-DISO
burn	I-DISO
amongst	O	O
all	O	O
age	B-LIVB
groups	I-LIVB
.	O	O

A	O	O
retrospective	B-PROC
study	I-PROC
was	O	O
carried	O	O
out	O	O
from	O	O
the	O	O
records	O
of	O	O
all	O	O
burn	B-DISO
patients	B-LIVB
who	O	O
attended	O
a	O	O
tertiary	O
burn	O
care	O
center	O
from	O	O
January	O
2013	O	O
and	O	O
December	O
2014	O	O
.	O	O

Data	O
of	O	O
the	O	O
patients	B-LIVB
with	O	O
scald	B-DISO
injury	I-DISO
was	O	O
segregated	O
and	O	O
analyzed	B-PROC
using	O	O
Microsoft	B-OBJC
excel	I-OBJC
spreadsheet	I-OBJC
.	O	O

10	O	O
,	O	O
175	O	O
burn	B-DISO
patients	B-LIVB
attended	O
the	O	O
burn	O
casualty	O
during	O	O
the	O	O
study	B-PROC
period	O
,	O	O
of	O	O
which	O	O
42	O	O
.	O	O

3	O	O
%	O	O
had	O	O
sustained	O
scald	B-DISO
.	O	O

56	O	O
.	O	O

85	O	O
%	O	O
of	O	O
patients	B-LIVB
were	O	O
under	O	O
15	O	O
years	O
of	O	O
age	B-PHYS
with	O	O
preschool	B-LIVB
children	I-LIVB
(	O	O
36	O	O
.	O	O

4	O	O
%	O	O
)	O	O
being	O	O
the	O	O
prime	B-LIVB
victims	I-LIVB
of	O	O
scald	B-DISO
.	O	O

The	O	O
%	O	O
TBSA	B-PHYS
involved	O
is	O	O
also	O	O
relatively	O	O
larger	O
in	O	O
children	B-LIVB
.	O	O

Scald	B-DISO
follows	O	O
definite	O	O
seasonal	O
variation	O
peaking	O
in	O	O
winters	O
.	O	O

36	O	O
.	O	O

8	O	O
%	O	O
patients	B-DISO
arrived	I-DISO
to	O	O
the	O	O
hospital	B-OBJC
without	O	O
any	O	O
first	B-PROC
aid	I-PROC
.	O	O

74	O	O
.	O	O
2	O	O
%	O	O
of	O	O
patients	B-LIVB
reported	O
to	O	O
casualty	O
with	O	O
in	O	O
24hours	O	O
after	O	O
sustaining	O
scald	B-DISO
injury	I-DISO
.	O	O

The	O	O
median	O	O
time	O
interval	O
between	O	O
injury	B-DISO
and	O	O
reporting	O
to	O	O
casualty	O
was	O	O
3hours	O	O
30	O	O
minutes	O
.	O	O

This	O	O
study	B-PROC
concludes	O	O
that	O	O
the	O	O
scald	B-DISO
is	O	O
injury	B-DISO
of	O	O
all	O	O
age	B-LIVB
groups	I-LIVB
,	O	O
though	O	O
majority	O
of	O	O
them	O	O
are	O	O
children	B-LIVB
.	O	O

The	O	O
first	B-PROC
aid	I-PROC
is	O	O
not	O	O
given	O	O
to	O	O
large	O
number	O
of	O	O
patients	B-LIVB
and	O	O
late	O	O
reporting	O
is	O	O
quite	O
common	O
.	O	O

These	O	O
are	O	O
the	O	O
factors	O
which	O	O
may	O	O
affect	O
the	O	O
course	O	O
of	O	O
scald	B-DISO
burn	I-DISO
.	O	O

Spreading	O
public	O
awareness	B-PHYS
regarding	O	O
safe	B-PHEN
household	B-LIVB
practises	O	O
and	O	O
educating	O
them	O	O
for	O	O
proper	O	O
first	B-PROC
aid	I-PROC
management	O
after	O	O
scald	B-DISO
may	O	O
have	O	O
significant	O
impact	O
on	O	O
the	O	O
burden	O
of	O	O
care	O
and	O	O
outcome	O
.	O	O

Effects	O
of	O
complex	O
life	O
cycles	O
on	O	O
genetic	B-PHEN
diversity	I-PHEN
:	O	O
cyclical	B-PHYS
parthenogenesis	I-PHYS
Neutral	O	O
patterns	O	O
of	O	O
population	B-LIVB
genetic	B-PHEN
diversity	I-PHEN
in	O	O
species	O
with	O	O
complex	O
life	O
cycles	O
are	O	O
difficult	O	O
to	O	O
anticipate	O
.	O	O

Cyclical	B-PHYS
parthenogenesis	I-PHYS
(	O	O
CP	B-PHYS
)	O	O
,	O	O
in	O	O
which	O	O
organisms	B-LIVB
undergo	O	O
several	O	O
rounds	O	O
of	O	O
clonal	O
reproduction	B-PHYS
followed	O	O
by	O	O
a	O	O
sexual	O
event	O
,	O	O
is	O	O
one	O	O
such	O	O
life	O
cycle	O
.	O	O

Many	O	O
species	O
,	O	O
including	O	O
crop	B-LIVB
pests	B-LIVB
(	O	O
aphids	O
)	O	O
,	O	O
human	O
parasites	O
(	O	O
trematodes	O
)	O	O
or	O	O
models	O
used	O	O
in	O	O
evolutionary	O
science	O
(	O	O
Daphnia	O
)	O	O
,	O	O
are	O	O
cyclical	B-LIVB
parthenogens	I-LIVB
.	O	O

It	O	O
is	O	O
therefore	O	O
crucial	O	O
to	O	O
understand	O	O
the	O	O
impact	O	O
of	O	O
such	O	O
a	O	O
life	O
cycle	O
on	O	O
neutral	O	O
genetic	B-PHEN
diversity	I-PHEN
.	O	O

In	O	O
this	O	O
paper	O	O
,	O	O
we	O	O
describe	O	O
distributions	O
of	O	O
genetic	B-PHEN
diversity	I-PHEN
under	O	O
conditions	O
of	O	O
CP	B-PHYS
with	O	O
various	O	O
clonal	O
phase	O
lengths	O
.	O	O

Using	O	O
a	O	O
Markov	O
chain	O
model	O
of	O	O
CP	B-PHYS
for	O	O
a	O	O
single	O
locus	O
and	O	O
individual	O	O
-	O	O
based	O	O
simulations	B-PROC
for	O	O
two	O
loci	O
,	O	O
our	O	O
analysis	O	O
first	O	O
demonstrates	O	O
that	O	O
strong	O	O
departures	O
from	O	O
full	O	O
sexuality	O
are	O	O
observed	O	O
after	O	O
only	O	O
a	O	O
few	O	O
generations	O
of	O	O
clonality	O
.	O	O

The	O	O
convergence	O
towards	O	O
predictions	O
made	O	O
under	O	O
conditions	O	O
of	O	O
full	O	O
clonality	O
during	O	O
the	O	O
clonal	O
phase	O
depends	O	O
on	O	O
the	O	O
balance	O	O
between	O	O
mutations	B-PHYS
and	O	O
genetic	B-PHYS
drift	I-PHYS
.	O	O

Second	O	O
,	O	O
the	O	O
sexual	O
event	O
of	O	O
CP	B-PHYS
usually	O	O
resets	O	O
the	O	O
genetic	B-PHEN
diversity	I-PHEN
at	O	O
a	O	O
single	O
locus	O
towards	O	O
predictions	O
made	O	O
under	O	O
full	O	O
sexuality	O
.	O	O

However	O	O
,	O	O
this	O	O
single	O	O
recombination	B-PHYS
event	O	O
is	O	O
insufficient	O	O
to	O	O
reshuffle	O	O
gametic	B-PHYS
phases	I-PHYS
towards	O	O
full	O
-	O
sexuality	O
predictions	O
.	O	O

Finally	O	O
,	O	O
for	O	O
similar	O	O
levels	O	O
of	O	O
clonality	O
,	O	O
CP	B-PHYS
and	O	O
acyclic	O	O
partial	O
clonality	O
(	O	O
wherein	O	O
a	O	O
fixed	O	O
proportion	O	O
of	O	O
individuals	B-LIVB
are	O	O
clonally	O
produced	O	O
within	O	O
each	O	O
generation	O
)	O	O
differentially	O	O
affect	O	O
the	O	O
distribution	O
of	O	O
genetic	B-PHEN
diversity	I-PHEN
.	O	O

Overall	O	O
,	O	O
this	O	O
work	O	O
provides	O	O
solid	O	O
predictions	O
of	O	O
neutral	O	O
genetic	B-PHEN
diversity	I-PHEN
that	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
null	O
model	O
in	O	O
detecting	O	O
the	O	O
action	O	O
of	O	O
common	O	O
evolutionary	B-PHYS
or	O	O
demographic	O
processes	B-PHEN
in	O	O
cyclical	B-LIVB
parthenogens	I-LIVB
(	O	O
for	O	O
example	O	O
,	O	O
selection	O	O
or	O	O
bottlenecks	O	O
)	O	O
.	O	O

Blood	B-PHYS
Pressure	I-PHYS
and	O	O
All	B-DISO
-	I-DISO
Cause	I-DISO
Mortality	I-DISO
by	O	O
Level	O
of	O	O
Cognitive	B-PHYS
Function	I-PHYS
in	O	O
the	O	O
Elderly	B-LIVB
:	O	O
Results	B-DISO
From	O	O
a	O	O
Population	B-PROC
-	I-PROC
Based	I-PROC
Study	I-PROC
in	O	O
Rural	B-GEOG
Greece	I-GEOG
This	O	O
study	B-PROC
aimed	O
to	O	O
investigate	O
whether	O	O
the	O	O
effect	O
of	O	O
blood	B-PHYS
pressure	I-PHYS
(	O	O
BP	B-PHYS
)	O	O
on	O	O
mortality	B-DISO
differs	O	O
by	O	O
levels	O
of	O	O
cognitive	B-PHYS
function	I-PHYS
.	O	O

The	O	O
associations	O
of	O	O
brachial	O
systolic	B-PHYS
BP	I-PHYS
,	O	O
diastolic	B-PHYS
BP	I-PHYS
,	O	O
mean	B-DISO
arterial	I-DISO
pressure	I-DISO
(	O	O
MAP	B-DISO
)	O	O
,	O	O
and	O	O
pulse	B-PHYS
pressure	I-PHYS
with	O	O
all	B-DISO
-	I-DISO
cause	I-DISO
mortality	I-DISO
were	O	O
prospectively	B-DISO
explored	I-DISO
(	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
7	O	O
.	O	O

0±2	O	O
.	O	O

2	O	O
years	O
)	O	O
in	O	O
660	O	O
community	O
-	O
dwelling	O
individuals	B-LIVB
(	O	O
≥60	B-DISO
years	I-DISO
)	O	O
using	O	O
adjusted	O
Cox	O
models	O
,	O	O
stratified	O
by	O	O
cognitive	B-DISO
impairment	I-DISO
(	O	O
Mini	B-PROC
-	I-PROC
Mental	I-PROC
State	I-PROC
Examination	I-PROC
[	O	O
MMSE	B-PROC
]	O	O
<	O	O
24	O	O
)	O	O
.	O	O

No	O
association	O
between	O	O
brachial	O
BP	B-PHYS
variables	O
and	O	O
mortality	B-DISO
was	O	O
shown	O	O
for	O	O
the	O	O
total	O
sample	B-OBJC
in	O	O
quartiles	B-PROC
analysis	I-PROC
;	O	O
however	O	O
,	O	O
MAP	B-DISO
in	O	O
the	O	O
highest	O
quartile	O
,	O	O
compared	O
with	O	O
the	O	O
second	O
,	O	O
was	O	O
associated	O
with	O
mortality	B-DISO
(	O	O
hazard	O
ratio	O
,	O	O
1	O	O
.	O	O
85	O	O
;	O	O
95	O	O
%	O	O
confidence	O
intervals	O
,	O	O
1	O	O
.	O	O
09	O	O
-	O	O
3	O	O
.	O	O
12	O	O
)	O	O
among	O	O
cognitively	B-DISO
impaired	I-DISO
individuals	B-LIVB
.	O	O

The	O	O
fractional	B-PROC
-	I-PROC
polynomials	I-PROC
approach	I-PROC
for	O	O
BP	B-PHYS
confirmed	B-DISO
this	O	O
finding	B-DISO
and	O	O
further	O
showed	O	O
,	O	O
solely	O
in	O	O
the	O	O
MMSE	B-PROC
<	O	O
24	O	O
subcohort	O
,	O	O
U	O
-	O
shaped	O
trends	O
of	O	O
MAP	B-DISO
and	O	O
systolic	B-PHYS
BP	I-PHYS
,	O	O
with	O	O
increased	O
mortality	O
risk	O
in	O	O
extremely	O
low	O
or	O
high	O
values	O
;	O	O
no	O	O
such	O	O
pattern	O
was	O	O
evident	O
for	O	O
patients	B-LIVB
with	O	O
MMSE	B-PROC
≥24	O	O
.	O	O

Elderly	B-LIVB
individuals	B-LIVB
with	O	O
cognitive	B-DISO
impairment	I-DISO
might	O	O
be	O	O
more	O
susceptible	O
to	O	O
the	O	O
detrimental	B-DISO
effects	I-DISO
of	O	O
low	O
and	O	O
elevated	O
MAP	B-DISO
and	O	O
systolic	B-PHYS
BP	I-PHYS
.	O	O

Epigenotype	B-PHYS
,	O	O
genotype	B-PHYS
,	O	O
and	O	O
phenotype	B-PHYS
analysis	B-PROC
of	O	O
patients	B-LIVB
in	O	O
Taiwan	B-GEOG
with	O	O
Beckwith	B-DISO
-	I-DISO
Wiedemann	I-DISO
syndrome	I-DISO
Beckwith	B-DISO
-	I-DISO
Wiedemann	I-DISO
syndrome	I-DISO
(	O	O
BWS	B-DISO
)	O	O
is	O	O
a	O	O
congenital	B-DISO
overgrowth	I-DISO
disorder	I-DISO
predisposing	O
to	O	O
tumorigenesis	B-DISO
that	O	O
results	O	O
from	O	O
abnormal	B-DISO
expression	B-PHYS
or	O	O
function	O	O
of	O	O
imprinted	O
genes	O
of	O	O
chromosome	O
11p15	O
.	O

5	O
.	O	O
Forty	O	O
-	O	O
seven	O	O
patients	B-LIVB
in	O	O
Taiwan	B-GEOG
with	O	O
clinical	O
suspicion	B-PHYS
of	O	O
BWS	B-DISO
were	O	O
referred	O	O
for	O	O
diagnostic	O
testing	O
based	O	O
on	O	O
methylation	B-PROC
profiling	I-PROC
of	O	O
H19	O
-associated	O	O
imprinting	O	O
center	O	O
(	O	O
IC	O	O
)	O	O
1	O	O
and	O	O
KCNQ1OT1	O
-associated	O	O
IC2	O	O
using	O	O
high	B-PROC
-	I-PROC
resolution	I-PROC
melting	I-PROC
analysis	I-PROC
,	O	O
multiplex	B-PROC
ligation	I-PROC
-	I-PROC
dependent	I-PROC
probe	I-PROC
amplification	I-PROC
,	O	O
or	O	O
high	B-PROC
-	I-PROC
resolution	I-PROC
quantitative	I-PROC
methylation	I-PROC
profiling	I-PROC
.	O	O

Twenty	O	O
-	O	O
eight	O	O
patients	B-LIVB
received	O	O
a	O	O
clinical	B-PROC
diagnosis	I-PROC
of	O	O
BWS	B-DISO
(	O	O
the	O	O
presence	O	O
of	O	O
3	O	O
major	O	O
features	O
or	O	O
2	O	O
major	O	O
features	O
and	O	O
at	O	O
least	O	O
1	O	O
minor	O	O
feature	O
)	O	O
,	O	O
18	O	O
had	O	O
suspected	O	O
BWS	B-DISO
(	O	O
the	O	O
presence	O	O
of	O	O
at	O	O
least	O	O
1	O	O
major	O	O
feature	O
)	O	O
,	O	O
and	O	O
1	O	O
had	O	O
isolated	O
Wilms	B-DISO
'	I-DISO
tumor	I-DISO
.	O	O

Nineteen	O	O
patients	B-LIVB
were	O	O
identified	O	O
with	O	O
IC2	O	O
hypomethylation	B-PHYS
(	O	O
including	O	O
1	O	O
with	O	O
isolated	O
Wilms	B-DISO
'	I-DISO
tumor	I-DISO
)	O	O
,	O	O
1	O	O
with	O	O
IC1	O	O
hypermethylation	B-PHYS
,	O	O
2	O	O
with	O	O
paternal	B-DISO
uniparental	I-DISO
disomy	I-DISO
,	O	O
and	O	O
1	O	O
with	O	O
CDKN1C	O
mutation	B-PHYS
.	O	O

Several	O	O
clinical	B-DISO
features	I-DISO
were	O	O
found	O	O
to	O	O
be	O	O
statistically	O	O
different	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
between	O	O
the	O	O
2	O	O
groups	O	O
-	O	O
clinical	B-PROC
diagnosis	I-PROC
of	O	O
BWS	B-DISO
(	O	O
n	O	O
=	O	O
28	O	O
)	O	O
or	O	O
suspected	O	O
BWS	B-DISO
(	O	O
n	O	O
=	O	O
18	O	O
)	O	O
-	O	O
including	O	O
macroglossia	B-DISO
,	O	O
pre	B-PHYS
-	I-PHYS
or	O	O
postnatal	B-PHYS
gigantism	B-DISO
,	O	O
abdominal	B-DISO
wall	I-DISO
defect	I-DISO
,	O	O
ear	B-DISO
creases	I-DISO
,	O	O
facial	B-ANAT
nevus	B-DISO
flammeus	I-DISO
,	O	O
BWS	B-DISO
score	O	O
,	O	O
and	O	O
the	O	O
molecular	B-PROC
diagnosis	I-PROC
rate	O
.	O	O

Molecular	B-DISO
lesion	I-DISO
was	O	O
detected	O	O
in	O	O
81	O	O
%	O	O
of	O	O
patients	B-LIVB
with	O	O
the	O	O
presence	O	O
of	O	O
three	O	O
major	O	O
features	O
,	O	O
compared	O	O
with	O	O
33	O	O
%	O	O
and	O	O
28	O	O
%	O	O
of	O	O
those	O	O
with	O	O
two	O	O
or	O	O
one	O	O
major	O	O
feature	O
,	O	O
respectively	O	O
.	O	O

The	O	O
mean	O	O
BWS	B-DISO
score	O	O
was	O	O
5	O	O
.	O	O
6	O	O
for	O	O
19	O	O
subjects	B-LIVB
with	O	O
""""	O	O
IC2	O	O
hypomethylation	B-PHYS
""""	O	O
,	O	O
compared	O	O
with	O	O
3	O	O
.	O	O
8	O	O
for	O	O
2	O	O
subjects	B-LIVB
with	O	O
pUPD	B-DISO
.	O	O

The	O	O
BWS	B-DISO
score	O	O
of	O	O
one	O	O
subject	B-LIVB
with	O	O
CDKN1C	O
mutation	B-PHYS
and	O	O
one	O	O
with	O	O
IC1	O	O
hypermethylation	B-PHYS
was	O	O
6	O	O
and	O	O
7	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
BWS	B-DISO
score	O	O
was	O	O
positively	O	O
correlated	O
with	O	O
the	O	O
molecular	B-PROC
diagnosis	I-PROC
rate	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

The	O	O
BWS	B-DISO
database	O
of	O	O
epigenotype	B-PHYS
,	O	O
genotype	B-PHYS
,	O	O
and	O	O
phenotype	B-PHYS
is	O	O
expected	O	O
to	O	O
promote	O
better	O	O
genetic	B-PROC
counseling	I-PROC
and	O	O
medical	B-DISO
care	I-DISO
of	O	O
these	O	O
patients	B-LIVB
.	O	O

Assessing	B-PROC
Commercially	O
Available	O	O
Personal	O
Health	O
Records	O
for	O	O
Home	B-PROC
Health	I-PROC
:	O	O
Recommendations	O
for	O	O
Design	O
Home	B-LIVB
health	I-LIVB
nurses	I-LIVB
and	O	O
clients	B-LIVB
experience	B-PHYS
unmet	O	O
information	O
needs	O	O
when	O	O
transitioning	B-PHEN
from	O	O
hospital	B-OBJC
to	O	O
home	B-PROC
health	I-PROC
.	O	O

Personal	O
health	O
records	O
(	O	O
PHRs	O
)	O	O
support	O
consumer	B-LIVB
-centered	O	O
information	O
management	O
activities	O
.	O	O

Previous	O	O
work	O
has	O	O
assessed	O
PHRs	O
associated	O
with	O
healthcare	B-LIVB
providers	I-LIVB
,	O	O
but	O	O
these	O	O
systems	O
leave	O	O
home	B-LIVB
health	I-LIVB
nurses	I-LIVB
unable	O	O
to	O	O
access	O
necessary	O	O
information	O
.	O	O

To	O	O
evaluate	B-PROC
the	O	O
ability	O	O
of	O	O
publically	O	O
available	O	O
PHRs	O
to	O	O
accept	O
,	O	O
manage	B-PROC
,	O	O
and	O	O
share	O
information	O
from	O	O
a	O	O
home	B-PROC
health	I-PROC
case	O
study	O
.	O	O

Two	O	O
researchers	B-LIVB
accessed	O
the	O	O
publically	O	O
available	O	O
PHRs	O
on	O	O
myPHR	O
.	O

com	O
,	O	O
and	O	O
attempted	O	O
to	O	O
enter	O
,	O	O
manage	B-PROC
,	O	O
and	O	O
share	O
the	O	O
case	O
study	O
data	O
.	O	O

We	O	O
qualitatively	O
described	O	O
the	O	O
PHR	O
features	O
,	O	O
and	O	O
identified	O
gaps	O
between	O	O
the	O	O
case	O
study	O
information	O
and	O	O
PHR	O
functionality	O
.	O	O

Eighteen	O	O
PHRs	O
were	O	O
identified	O
in	O	O
our	O	O
initial	O
search	O
.	O	O

Seven	O	O
systems	O
met	O	O
our	O	O
inclusion	O	O
criteria	O
,	O	O
and	O	O
are	O	O
included	O	O
in	O	O
this	O	O
review	O
.	O	O

The	O	O
PHRs	O
were	O	O
able	O	O
to	O	O
accept	O	O
basic	O	O
medical	O
information	O
.	O	O

Gaps	O
occurred	O
when	O	O
entering	O
,	O	O
managing	B-PROC
,	O	O
and	O	O
/	O	O
or	O	O
sharing	O
data	O
from	O	O
the	O	O
acute	O
care	O
and	O	O
home	B-PROC
health	I-PROC
episodes	B-PROC
.	O	O

The	O	O
PHRs	O
that	O	O
were	O	O
reviewed	O
were	O	O
unable	O	O
to	O	O
effectively	O	O
manage	B-PROC
the	O	O
case	O
study	O
information	O
.	O	O

Therefore	O	O
,	O	O
increasing	O
consumer	B-LIVB
health	B-PROC
literacy	I-PROC
through	O	O
these	O	O
systems	O
may	O	O
be	O	O
difficult	O	O
.	O	O

The	O	O
PHRs	O
that	O	O
we	O	O
reviewed	O
were	O	O
also	O	O
unable	O	O
to	O	O
electronically	O
share	O
their	O	O
data	O
.	O	O

The	O	O
gap	O
between	O	O
the	O	O
existing	O	O
functionality	O
and	O	O
the	O	O
information	O
needs	O	O
from	O	O
the	O	O
case	O
study	O
may	O	O
make	O	O
these	O	O
PHRs	O
difficult	O	O
to	O	O
use	O	O
for	O	O
home	O
health	B-PHEN
environments	I-PHEN
.	O	O

Additional	O	O
work	O
is	O	O
needed	O	O
to	O	O
increase	O
the	O	O
functionality	O
of	O	O
the	O	O
PHR	O
systems	O
to	O	O
better	O	O
fit	O	O
the	O	O
data	O
needs	O	O
of	O	O
home	B-PROC
health	I-PROC
clients	B-LIVB
.	O	O

A	O	O
Web	O
-	O
based	O
Alternative	O
Non	O
-	O
animal	O
Method	O
Database	O
for	O	O
Safety	B-PHEN
Cosmetic	B-OBJC
Evaluations	B-PROC
Animal	B-PROC
testing	I-PROC
was	O	O
used	O	O
traditionally	O	O
in	O	O
the	O	O
cosmetics	B-OBJC
industry	O
to	O	O
confirm	O	O
product	O
safety	O
,	O	O
but	O	O
has	O	O
begun	O	O
to	O	O
be	O	O
banned	O
;	O	O
alternative	B-PROC
methods	I-PROC
to	O	O
replace	O	O
animal	B-PROC
experiments	I-PROC
are	O	O
either	O	O
in	O	O
development	O
,	O	O
or	O	O
are	O	O
being	O	O
validated	O	O
,	O	O
worldwide	O	O
.	O	O

Research	B-PROC
data	I-PROC
related	O	O
to	O	O
test	O
substances	B-OBJC
are	O	O
critical	O	O
for	O	O
developing	O	O
novel	O
alternative	O
tests	O
.	O	O

Moreover	O	O
,	O	O
safety	O
information	O
on	O	O
cosmetic	B-OBJC
materials	I-OBJC
has	O	O
neither	O	O
been	O	O
collected	O
in	O	O
a	O	O
database	O
nor	O	O
shared	O	O
among	O	O
researchers	B-LIVB
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
imperative	O	O
to	O	O
build	O	O
and	O	O
share	O	O
a	O	O
database	O
of	O	O
safety	O
information	O
on	O	O
toxicological	O
mechanisms	O
and	O	O
pathways	O
collected	O
through	O	O
in	O
vivo	O
,	O	O
in	O
vitro	O
,	O	O
and	O	O
in	O
silico	O
methods	B-PROC
.	O	O

We	O	O
developed	O	O
the	O	O
CAMSEC	O
database	O
(	O	O
named	O	O
after	O	O
the	O	O
research	B-LIVB
team	I-LIVB
;	O	O
the	O	O
Consortium	O
of	O
Alternative	O
Methods	O
for	O
Safety	O
Evaluation	O
of	O
Cosmetics	O
)	O	O
to	O	O
fulfill	O	O
this	O	O
purpose	O	O
.	O	O

On	O	O
the	O	O
same	O	O
website	O
,	O	O
our	O	O
aim	O	O
is	O	O
to	O	O
provide	O	O
updates	O	O
on	O	O
current	O	O
alternative	B-PROC
research	I-PROC
methods	I-PROC
in	O	O
Korea	B-GEOG
.	O	O

The	O	O
database	O
will	O	O
not	O	O
be	O	O
used	O	O
directly	O	O
to	O	O
conduct	O	O
safety	B-PHEN
evaluations	B-PROC
,	O	O
but	O	O
researchers	B-LIVB
or	O	O
regulatory	O
individuals	B-LIVB
can	O	O
use	O	O
it	O	O
to	O	O
facilitate	O	O
their	O	O
work	O	O
in	O	O
formulating	O	O
safety	B-PHEN
evaluations	B-PROC
for	O	O
cosmetic	B-OBJC
materials	I-OBJC
.	O	O

We	O	O
hope	O	O
this	O	O
database	O
will	O	O
help	O	O
establish	O
new	O	O
alternative	B-PROC
research	I-PROC
methods	I-PROC
to	O	O
conduct	O	O
efficient	O	O
safety	B-PHEN
evaluations	B-PROC
of	O	O
cosmetic	B-OBJC
materials	I-OBJC
.	O	O

Hypovitaminosis	B-DISO
D	I-DISO
and	O	O
Associated	O	O
Cardiometabolic	O
Risk	O
in	O	O
Women	B-LIVB
with	O	O
PCOS	B-DISO
Women	B-LIVB
with	O	O
Polycystic	B-DISO
Ovary	I-DISO
Syndrome	I-DISO
(	O	O
PCOS	B-DISO
)	O	O
frequently	O	O
suffer	O	O
from	O	O
metabolic	B-DISO
disturbances	I-DISO
like	O	O
insulin	B-DISO
resistance	I-DISO
,	O	O
hypertension	B-DISO
and	O	O
atherogenic	B-DISO
dyslipidemia	I-DISO
.	O	O

Accumulating	B-DISO
evidences	O	O
suggest	O	O
that	O	O
Vitamin	B-DISO
D	I-DISO
deficiency	I-DISO
is	O	O
common	O	O
in	O	O
PCOS	B-DISO
and	O	O
may	O	O
be	O	O
associated	O
with	O
metabolic	B-DISO
and	O	O
endocrinal	B-DISO
dysfunctions	I-DISO
in	O	O
PCOS	B-DISO
.	O	O

Thus	O	O
women	B-LIVB
with	O	O
PCOS	B-DISO
may	O	O
be	O	O
at	O	O
elevated	O	O
risk	O
of	O	O
cardiovascular	B-DISO
disease	I-DISO
.	O	O

Present	O	O
study	B-PROC
aims	O	O
to	O	O
evaluate	O	O
Vitamin	B-CHEM
D	I-CHEM
status	O	O
and	O	O
to	O	O
assess	O	O
its	O	O
association	O	O
with	O	O
metabolic	B-DISO
and	O	O
endocrinal	B-DISO
dysregulations	I-DISO
in	O	O
women	B-LIVB
with	O	O
PCOS	B-DISO
,	O	O
which	O	O
might	O	O
help	O	O
in	O	O
early	B-PROC
identification	I-PROC
and	O	O
prevention	B-PROC
of	O	O
future	O	O
symptomatic	O
cardiac	B-DISO
disease	I-DISO
.	O	O

A	O	O
total	O	O
of	O	O
44	O	O
women	B-LIVB
with	O	O
PCOS	B-DISO
,	O	O
diagnosed	O	O
by	O	O
Rotterdam	O
criteria	O
and	O	O
45	O	O
healthy	O
control	O
without	O	O
PCOS	B-DISO
,	O	O
were	O	O
evaluated	O	O
for	O	O
Vitamin	B-CHEM
D	I-CHEM
and	O	O
cardiometabolic	B-DISO
risk	I-DISO
factors	I-DISO
,	O	O
including	O	O
fasting	B-PHEN
plasma	I-PHEN
glucose	I-PHEN
,	O	O
insulin	B-DISO
resistance	I-DISO
,	O	O
dyslipidemia	B-DISO
,	O	O
hs	B-DISO
-	I-DISO
CRP	I-DISO
.	O	O

That	O	O
apart	O	O
,	O	O
several	O	O
endocrinal	O
parameters	O
of	O	O
hyperandrogenism	B-DISO
were	O	O
also	O	O
examined	O	O
.	O	O

Several	O	O
correlation	B-PROC
studies	I-PROC
were	O	O
determined	O	O
to	O	O
establish	O	O
the	O	O
role	O	O
of	O	O
Vitamin	B-CHEM
D	I-CHEM
as	O	O
a	O	O
cardiometabolic	B-DISO
risk	I-DISO
factor	I-DISO
in	O	O
PCOS	B-DISO
.	O	O

Results	O	O
were	O	O
expressed	O	O
as	O	O
mean±SD	O	O
and	O	O
were	O	O
statistically	B-PROC
analysed	I-PROC
using	O	O
SPSS	B-OBJC
software	I-OBJC
version	I-OBJC
16	I-OBJC
,	O	O
unpaired	O
student	O
's	O
t	O
-	O
test	O
and	O	O
Pearson	O
's	O
correlation	O
coefficient	O
.	O	O

We	O	O
found	O	O
lower	O	O
levels	O	O
of	O	O
Vitamin	B-CHEM
D	I-CHEM
,	O	O
which	O	O
was	O	O
statistically	O	O
significant	O	O
as	O	O
compared	O	O
to	O	O
healthy	O
controls	O
.	O	O

Hyperinsulinemia	B-DISO
,	O	O
rise	O	O
in	O	O
insulin	B-DISO
resistance	I-DISO
and	O	O
marked	O	O
dyslipidemia	B-DISO
was	O	O
observed	O	O
in	O	O
the	O	O
present	O	O
study	B-PROC
.	O	O

Another	O	O
relevant	O	O
finding	O	O
was	O	O
significant	O	O
correlation	O	O
of	O	O
Vitamin	B-CHEM
D	I-CHEM
with	O	O
insulin	B-CHEM
and	O	O
Homeostatic	B-PROC
Model	I-PROC
of	I-PROC
Assessment	I-PROC
-	I-PROC
Insulin	I-PROC
Resistance	I-PROC
Index	I-PROC
(	O	O
HOMA	B-PROC
-	I-PROC
IR	I-PROC
)	O	O
.	O	O

Hypovitaminosis	B-DISO
D	I-DISO
was	O	O
prevalent	O	O
in	O	O
PCOS	B-DISO
.	O	O

This	O	O
was	O	O
related	O	O
to	O	O
metabolic	B-DISO
and	O	O
hormonal	B-DISO
disorders	I-DISO
in	O	O
PCOS	B-DISO
.	O	O

Possibly	O	O
this	O	O
combined	O	O
with	O	O
impaired	B-DISO
fasting	I-DISO
glucose	I-DISO
,	O	O
IR	B-DISO
and	O	O
dyslipidemia	B-DISO
,	O	O
could	O	O
account	O	O
for	O	O
Cardio	O
vascular	O
risks	O
in	O	O
PCOS	B-DISO
.	O	O

Further	O	O
prospective	O	O
observational	O
studies	O
and	O	O
randomized	B-PROC
control	I-PROC
trials	I-PROC
are	O	O
required	O	O
to	O	O
explore	O	O
the	O	O
above	O	O
hypothesis	O
.	O	O

Update	O
on	O	O
the	O	O
Role	O	O
of	O	O
Cardiac	B-PROC
Magnetic	I-PROC
Resonance	I-PROC
in	O	O
Acquired	O
Nonischemic	B-DISO
Cardiomyopathies	I-DISO
Cardiomyopathies	B-DISO
refer	O	O
to	O	O
a	O	O
variety	O	O
of	O	O
myocardial	B-DISO
disorders	I-DISO
without	O	O
underlying	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O	O
valvular	B-DISO
heart	I-DISO
disease	I-DISO
,	O	O
hypertension	B-DISO
,	O	O
or	O	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
.	O	O

Several	O	O
imaging	O
modalities	O
are	O	O
available	O	O
,	O	O
but	O	O
cardiac	B-PROC
magnetic	I-PROC
resonance	I-PROC
(	O	O
CMR	B-PROC
)	O	O
has	O	O
now	O	O
established	O	O
itself	O	O
as	O	O
a	O	O
crucial	O	O
imaging	B-PROC
technique	I-PROC
in	O	O
the	O	O
evaluation	B-PROC
of	O	O
several	O	O
cardiomyopathies	B-DISO
.	O	O

It	O	O
not	O	O
only	O	O
provides	O	O
comprehensive	O
information	O
on	O	O
structure	O
and	O	O
function	O
,	O	O
but	O	O
also	O	O
can	O	O
perform	O
tissue	O
characterization	O
,	O	O
which	O	O
helps	O	O
in	O	O
establishing	O
the	O	O
etiology	O
of	O	O
cardiomyopathy	B-DISO
.	O	O

CMR	B-PROC
is	O	O
also	O	O
useful	O	O
in	O	O
establishing	O
the	O	O
diagnosis	B-DISO
,	O	O
providing	O
guidance	B-PROC
for	O	O
endomyocardial	B-PROC
biopsy	I-PROC
,	O	O
accurate	O
quantification	O
of	O	O
function	O
,	O	O
volumes	O
,	O	O
and	O	O
fibrosis	B-DISO
,	O	O
prognostic	O
determination	O
,	O	O
risk	O
stratification	B-PROC
,	O	O
and	O	O
monitoring	B-PROC
response	I-PROC
to	I-PROC
therapy	I-PROC
.	O	O

In	O	O
this	O	O
article	O
,	O	O
we	O	O
review	O
the	O	O
current	O
role	O	O
of	O	O
CMR	B-PROC
in	O	O
the	O	O
evaluation	B-PROC
of	O	O
several	O	O
acquired	O
nonischemic	B-DISO
cardiomyopathies	I-DISO
,	O	O
particularly	O	O
focusing	O	O
on	O	O
recent	O
advances	O	O
in	O	O
knowledge	O
.	O	O

We	O	O
also	O	O
discuss	O	O
in	O	O
detail	O	O
a	O	O
select	B-LIVB
group	I-LIVB
of	O	O
common	O	O
acquired	O
nonischemic	B-DISO
cardiomyopathies	I-DISO
.	O	O

Modern	O	O
Image	B-PROC
-	I-PROC
Guided	I-PROC
Intensity	I-PROC
-	I-PROC
Modulated	I-PROC
Radiotherapy	I-PROC
for	O	O
Oropharynx	B-DISO
Cancer	I-DISO
and	O	O
Severe	O	O
Late	B-DISO
Toxic	I-DISO
Effects	I-DISO
:	O	O
Implications	O	O
for	O	O
Clinical	B-PHYS
Trial	I-PHYS
Design	I-PHYS
Late	B-DISO
toxic	I-DISO
effects	I-DISO
are	O	O
common	O	O
after	O	O
definitive	O	O
radiotherapy	B-PROC
and	O	O
chemoradiotherapy	B-PROC
for	O	O
oropharynx	B-DISO
cancer	I-DISO
and	O	O
are	O	O
considered	O	O
a	O	O
significant	O	O
contributor	O	O
to	O	O
decreased	O	O
quality	O
of	O
life	O
for	O	O
survivors	B-LIVB
.	O	O

The	O	O
incidence	O	O
of	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
may	O	O
be	O	O
reduced	O	O
by	O	O
modern	O	O
narrow	B-PHYS
-	I-PHYS
margin	I-PHYS
image	B-PROC
-	I-PROC
guided	I-PROC
intensity	I-PROC
-	I-PROC
modulated	I-PROC
radiotherapy	I-PROC
(	O	O
IG	B-PROC
-	I-PROC
IMRT	I-PROC
)	O	O
,	O	O
current	O	O
supportive	O	O
care	O	O
improvements	O	O
,	O	O
and	O	O
the	O	O
changing	O	O
epidemiology	O
of	O	O
oropharynx	B-DISO
cancer	I-DISO
.	O	O

Assess	O	O
the	O	O
incidence	O	O
of	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
after	O	O
modern	O	O
definitive	O	O
non	B-PROC
-	I-PROC
operative	I-PROC
treatment	I-PROC
for	O	O
oropharynx	B-DISO
cancer	I-DISO
.	O	O

For	O	O
this	O	O
single	O	O
-	O	O
institution	O	O
retrospective	O	O
review	O	O
,	O	O
156	O	O
patients	B-LIVB
with	O	O
stage	O	O
I	O	O
-	O	O
IVB	O	O
squamous	B-DISO
cell	I-DISO
carcinoma	I-DISO
of	I-DISO
the	I-DISO
oropharynx	I-DISO
treated	B-PROC
between	O	O
April	O	O
2009	O	O
and	O	O
February	O	O
2015	O	O
at	O	O
a	O	O
tertiary	B-OBJC
-	I-OBJC
referral	I-OBJC
academic	I-OBJC
multidisciplinary	I-OBJC
head	I-OBJC
and	I-OBJC
neck	I-OBJC
practice	I-OBJC
were	O	O
recruited	O	O
.	O	O

Definitive	O	O
narrow	B-PHYS
-	I-PHYS
margin	I-PHYS
IG	B-PROC
-	I-PROC
IMRT	I-PROC
to	O	O
a	O	O
dose	O
of	O	O
66	O	O
Gy	O	O
(	O	O
to	O	O
convert	O	O
milligray	O	O
to	O	O
rad	O	O
,	O	O
multiply	O	O
by	O	O
0	O	O
.	O	O

1	O	O
)	O	O
or	O	O
higher	O	O
with	O	O
or	O	O
without	O	O
concurrent	O	O
cisplatin	B-CHEM
.	O	O

The	O	O
primary	O	O
outcome	O
was	O	O
the	O	O
prospectively	O	O
collected	O	O
2	O	O
-	O	O
year	O
cumulative	O
incidence	O
of	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
(	O	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
grade	B-DISO
3	I-DISO
or	O	O
higher	O	O
)	O	O
occurring	O	O
3	O	O
months	O
or	O	O
more	O	O
after	O	O
radiotherapy	B-PROC
.	O	O

Toxic	B-DISO
effect	I-DISO
end	O	O
points	O	O
investigated	O	O
included	O	O
esophageal	B-DISO
stricture	I-DISO
requiring	O	O
dilation	B-PROC
,	O	O
aspiration	B-DISO
pneumonia	I-DISO
hospitalization	B-PROC
,	O	O
vocal	B-DISO
dysfunction	I-DISO
,	O	O
delayed	O	O
feeding	B-PROC
tube	I-PROC
insertions	I-PROC
,	O	O
and	O	O
osteoradionecrosis	B-DISO
.	O	O

Feeding	B-DEVI
tube	I-DEVI
dependence	O	O
at	O	O
1	O	O
year	O
was	O	O
also	O	O
considered	O	O
a	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effect	I-DISO
.	O	O

Secondary	O
outcomes	O
collected	O	O
include	O	O
physician	B-LIVB
-reported	O	O
grade	O
2	O
or	O	O
higher	O	O
neck	B-ANAT
fibrosis	B-DISO
and	O	O
xerostomia	B-DISO
.	O	O

The	O	O
competing	O	O
risks	B-PROC
of	O	O
recurrence	O	O
and	O	O
death	B-PHYS
were	O	O
accounted	O	O
for	O	O
using	O	O
the	O	O
Gray	O
method	O
.	O	O

One	O	O
-	O	O
hundred	O	O
fifty	O	O
-	O	O
six	O	O
patients	B-LIVB
(	O	O
median	O	O
[	O	O
range	O	O
]	O	O
age	B-PHYS
,	O	O
58	O	O
[	O	O
37	O	O
-	O	O
96	O	O
]	O	O
years	O
)	O	O
were	O	O
identified	O	O
;	O	O
130	O	O
patients	B-LIVB
(	O	O
83	O	O
%	O	O
)	O	O
were	O	O
HPV	B-PHEN
positive	I-PHEN
.	O	O

Concurrent	O	O
cisplatin	B-CHEM
was	O	O
delivered	O	O
in	O	O
131	O	O
patients	B-LIVB
(	O	O
84	O	O
%	O	O
)	O	O
and	O	O
5	O	O
patients	B-LIVB
(	O	O
3	O	O
%	O	O
)	O	O
underwent	O	O
an	O	O
adjuvant	O	O
neck	B-PROC
dissection	I-PROC
.	O	O

The	O	O
median	O	O
(	O	O
range	O	O
)	O	O
follow	O	O
-	O	O
up	O	O
for	O	O
survivors	B-LIVB
was	O	O
22	O	O
(	O	O
4	O	O
-	O	O
73	O	O
)	O	O
months	O
from	O	O
diagnosis	B-DISO
.	O	O

The	O	O
projected	O	O
2	O	O
-	O	O
year	O
locoregional	O
control	O
was	O	O
93	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
88	O	O
.	O	O
4	O	O
%	O	O
-	O	O
97	O	O
.	O	O
6	O	O
%	O	O
)	O	O
and	O	O
overall	O
survival	O
was	O	O
88	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
82	O	O
.	O	O
2	O	O
%	O	O
-	O	O
94	O	O
.	O	O
0	O	O
%	O	O
)	O	O
.	O	O

Thirty	O	O
-	O	O
eight	O	O
patients	B-LIVB
(	O	O
23	O	O
%	O	O
)	O	O
required	O	O
a	O	O
feeding	B-DEVI
tube	I-DEVI
during	O	O
treatment	B-PROC
.	O	O

The	O	O
cumulative	O
incidence	O
of	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
adjusted	O	O
for	O	O
competing	O	O
risks	B-PROC
at	O	O
2	O	O
-	O	O
year	O
posttreatment	O
was	O	O
2	O	O
.	O	O

3	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
,	O	O
0	O	O
%	O	O
-	O	O
5	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

One	O	O
patient	B-LIVB
required	O	O
free	B-PROC
-	I-PROC
flap	I-PROC
reconstruction	I-PROC
for	O	O
grade	O	O
3	O	O
osteoradionecrosis	B-DISO
at	O	O
47	O	O
months	O
.	O	O

At	O	O
1	O	O
year	O
,	O	O
2	O	O
patients	B-LIVB
(	O	O
1	O	O
%	O	O
)	O	O
experienced	O	O
grade	O
2	O
neck	B-ANAT
fibrosis	B-DISO
and	O	O
38	O	O
patients	B-LIVB
(	O	O
23	O	O
%	O	O
)	O	O
experienced	O	O
grade	B-DISO
2	I-DISO
xerostomia	I-DISO
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
severe	O	O
late	B-DISO
toxic	I-DISO
effects	I-DISO
after	O	O
modern	O	O
definitive	O	O
IG	B-PROC
-	I-PROC
IMRT	I-PROC
,	O	O
with	O	O
or	O	O
without	O	O
cisplatin	B-CHEM
,	O	O
for	O	O
oropharynx	B-DISO
cancer	I-DISO
is	O	O
likely	O	O
uncommon	O	O
.	O	O

The	O	O
importance	O	O
of	O	O
late	B-DISO
toxic	I-DISO
effect	I-DISO
reduction	O	O
in	O	O
current	O	O
and	O	O
future	O	O
investigational	O	O
strategies	O	O
,	O	O
including	O	O
clinical	B-PROC
trials	I-PROC
,	O	O
should	O	O
be	O	O
considered	O	O
.	O	O

Family	B-LIVB
close	B-DISO
but	O	O
friends	B-LIVB
closer	B-DISO
:	O	O
exploring	O	O
social	O
support	O
and	O	O
resilience	O
in	O	O
older	B-LIVB
spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
Spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
have	O	O
unique	O	O
support	O
needs	O
;	O	O
they	O	O
are	O	O
likely	O	O
to	O	O
disengage	O
from	O	O
their	O	O
existing	O
social	B-LIVB
networks	I-LIVB
as	O	O
they	O	O
need	O	O
to	O	O
devote	O	O
more	O	O
time	O
to	O	O
caring	O
as	O	O
the	O	O
disease	B-DISO
progresses	I-DISO
.	O	O

Previously	O	O
we	O	O
showed	O	O
that	O	O
support	O
resources	O
can	O	O
facilitate	O	O
resilience	O
in	O	O
carers	B-LIVB
,	O	O
but	O	O
the	O	O
relationship	O
is	O	O
complex	O
and	O	O
varies	O	O
by	O	O
relationship	O
type	O
.	O	O

The	O	O
current	O	O
paper	O	O
aims	O	O
to	O	O
explore	O	O
social	O
support	O
as	O	O
a	O	O
key	O	O
component	O	O
of	O	O
resilience	O
to	O	O
identify	O	O
the	O	O
availability	O
,	O	O
function	O
and	O	O
perceived	O
functional	O
aspects	O
of	O	O
support	O
provided	O	O
to	O	O
older	B-LIVB
spousal	B-LIVB
dementia	B-DISO
carers	B-LIVB
.	O	O

We	O	O
conducted	O	O
23	O	O
in	O
-	O
depth	O
qualitative	O
interviews	O
with	O	O
spousal	B-LIVB
carers	B-LIVB
from	O	O
two	O	O
carer	B-LIVB
support	O
groups	O
and	O	O
a	O	O
care	O	O
home	O	O
in	O	O
North	B-GEOG
West	I-GEOG
England	I-GEOG
.	O	O

Family	B-LIVB
and	O	O
friends	B-LIVB
served	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
functions	O
but	O	O
were	O	O
equally	O	O
available	O	O
to	O	O
resilient	B-LIVB
and	O	O
non	B-LIVB
-	I-LIVB
resilient	I-LIVB
participants	I-LIVB
.	O	O

Family	B-PROC
support	I-PROC
was	O	O
perceived	B-PHYS
as	O	O
unhelpful	O	O
if	O	O
it	O	O
created	O
feelings	B-PHYS
of	O	O
over	O
-	O
dependence	O
.	O	O

Participants	B-LIVB
were	O	O
less	O	O
likely	O	O
to	O	O
resist	O
involvement	O
of	O	O
grandchildren	B-LIVB
due	O	O
to	O	O
their	O	O
relatively	O	O
narrow	O
and	O
low	O
-	O
level	O
support	O
functions	O
.	O	O

Friend	B-LIVB
support	O
was	O	O
perceived	B-PHYS
as	O	O
most	O	O
helpful	O
when	O	O
it	O	O
derived	O	O
from	O	O
those	O	O
in	O	O
similar	O	O
circumstances	O
.	O	O

Neighbours	B-LIVB
played	O	O
a	O	O
functionally	O	O
unique	O	O
role	O	O
of	O	O
crisis	B-PROC
management	I-PROC
.	O	O

These	O	O
perceptions	B-PHYS
may	O	O
moderate	O
the	O	O
effect	O
of	O	O
support	O
on	O	O
resilience	O
.	O	O

Family	B-PROC
and	O	O
friend	B-LIVB
support	O
is	O	O
not	O	O
always	O	O
sufficient	O
to	O	O
facilitate	O	O
resilience	O
.	O	O

Support	O
functions	O
facilitate	O	O
resilience	O
only	O	O
if	O	O
they	O	O
are	O	O
perceived	B-PHYS
to	O	O
match	O	O
need	O
.	O	O

Implications	B-DISO
of	O	O
these	O	O
findings	O
are	O	O
discussed	O	O
.	O	O

Axially	O
Chiral	B-PHEN
Dimeric	B-CHEM
Naphthalene	B-CHEM
and	O	O
Naphthoquinone	B-CHEM
Metabolites	B-CHEM
,	O	O
from	O	O
Root	B-LIVB
Cultures	B-PROC
of	O	O
the	O	O
West	B-GEOG
African	I-GEOG
Liana	B-LIVB
Triphyophyllum	B-LIVB
peltatum	I-LIVB
Root	B-LIVB
cultures	B-PROC
of	O	O
the	O	O
West	B-GEOG
African	I-GEOG
liana	B-LIVB
Triphyophyllum	B-LIVB
peltatum	I-LIVB
were	O	O
initiated	O	O
from	O	O
stem	B-LIVB
explants	B-PROC
of	O	O
in	O
vitro	O
cultivated	O
shoots	O
.	O	O

From	O	O
these	O	O
organ	B-PROC
cultures	I-PROC
,	O	O
three	O	O
new	O	O
binaphthalenes	B-CHEM
,	O	O
one	O	O
binaphthoquinone	B-CHEM
,	O	O
and	O	O
two	O	O
(	B-CHEM
bi	I-CHEM
)	I-CHEM
naphthalene	I-CHEM
glucosides	I-CHEM
were	O	O
isolated	O
,	O	O
with	O	O
substitution	O	O
patterns	O	O
related	O	O
to	O	O
those	O	O
of	O	O
the	O	O
naphthylisoquinoline	B-CHEM
alkaloids	I-CHEM
,	O	O
which	O	O
are	O	O
the	O	O
""""	O	O
normal	O	O
""""	O	O
main	O	O
metabolites	B-CHEM
of	O	O
T	B-LIVB
.	I-LIVB

peltatum	I-LIVB
.	O	O

The	O	O
structures	O
of	O	O
the	O	O
diglucoside	B-CHEM
dioncoquinoside	I-CHEM
A	I-CHEM
(	O	O
1	O	O
)	O	O
and	O	O
of	O	O
the	O	O
axially	O
chiral	B-PHEN
biaryls	B-CHEM
triphyoquinols	I-CHEM
A1	I-CHEM
(	O	O
3	O	O
)	O	O
,	O	O
A2	B-CHEM
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
B	B-CHEM
(	O	O
5	O	O
)	O	O
,	O	O
triphyoquinoside	B-CHEM
A	I-CHEM
(	O	O
6	O	O
)	O	O
,	O	O
and	O	O
triphyoquinone	B-CHEM
A	I-CHEM
(	O	O
7	O	O
)	O	O
were	O	O
elucidated	O	O
by	O	O
spectroscopic	B-PROC
analysis	I-PROC
(	O	O
HRESIMS	B-PROC
,	O	O
1D	B-PROC
and	O	O
2D	B-PROC
NMR	I-PROC
)	O	O
and	O	O
by	O	O
application	O	O
of	O	O
electronic	B-PHEN
circular	I-PHEN
dichroism	I-PHEN
(	I-PHEN
ECD	I-PHEN
)	I-PHEN
spectroscopy	I-PHEN
in	O	O
combination	O
with	O	O
the	O	O
exciton	O
chirality	O
method	O
and	O	O
quantum	B-PROC
-	I-PROC
chemical	I-PROC
ECD	I-PROC
calculations	I-PROC
.	O	O

The	O	O
root	B-LIVB
cultures	B-PROC
likewise	O	O
produced	O	O
the	O	O
known	O	O
alkaloids	B-CHEM
dioncophylline	B-CHEM
A	I-CHEM
(	O	O
8	O	O
)	O	O
,	O	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
O	I-CHEM
-	I-CHEM
demethyldioncophylline	I-CHEM
A	I-CHEM
(	O	O
9	O	O
)	O	O
,	O	O
dioncopeltine	B-CHEM
A	I-CHEM
(	O	O
10	O	O
)	O	O
,	O	O
habropetaline	B-CHEM
A	I-CHEM
(	O	O
11	O	O
)	O	O
,	O	O
and	O	O
5	B-CHEM
'	I-CHEM
-	I-CHEM
O	I-CHEM
-	I-CHEM
methyldioncophylline	I-CHEM
D	I-CHEM
(	O	O
12a	O	O
/	O	O
b	O	O
)	O	O
,	O	O
the	O	O
naphthalene	B-CHEM
glucoside	I-CHEM
plumbaside	I-CHEM
A	I-CHEM
(	O	O
2	O	O
)	O	O
,	O	O
and	O	O
the	O	O
naphthoquinones	B-CHEM
plumbagin	I-CHEM
(	O	O
13	O	O
)	O	O
,	O	O
droserone	B-CHEM
(	O	O
14	O	O
)	O	O
,	O	O
and	O	O
8	B-CHEM
-	I-CHEM
hydroxydroserone	I-CHEM
(	O	O
15	O	O
)	O	O
.	O	O

Tubular	B-DISO
,	O	O
lactating	B-DISO
,	O	O
and	O	O
ductal	B-DISO
adenomas	I-DISO
are	O	O
devoid	O
of	O	O
MED12	O
Exon2	B-CHEM
mutations	B-PHYS
,	O	O
and	O	O
ductal	B-DISO
adenomas	I-DISO
show	O	O
recurrent	O	O
mutations	B-PHYS
in	O	O
GNAS	O
and	O	O
the	O	O
PI3K	O
-	O
AKT	O
pathway	O
Adenomas	B-DISO
of	O	O
the	O	O
breast	B-ANAT
are	O	O
rare	O	O
benign	B-DISO
tumors	I-DISO
although	O	O
single	O	O
cases	O
with	O	O
malignant	O
behavior	O
have	O	O
been	O	O
reported	O	O
.	O	O

However	O	O
,	O	O
the	O	O
genetic	O
basis	O	O
of	O	O
these	O	O
tumors	B-DISO
is	O	O
unknown	O	O
.	O	O

Employing	O	O
targeted	O	O
next	B-PROC
generation	I-PROC
sequencing	I-PROC
of	O	O
50	O	O
cancer	O
-	O
related	O
genes	O
as	O	O
well	O	O
as	O	O
Sanger	B-PROC
sequencing	I-PROC
,	O	O
we	O	O
profiled	O	O
a	O	O
cohort	O
of	O	O
18	O	O
mammary	B-DISO
adenomas	I-DISO
comprising	O	O
9	O	O
ductal	B-DISO
,	O	O
6	O	O
tubular	B-DISO
,	O	O
and	O	O
3	O	O
lactating	B-DISO
adenoma	I-DISO
.	O	O

Missense	B-PHYS
mutations	I-PHYS
were	O	O
detected	O	O
in	O	O
8	O	O
of	O	O
the	O	O
18	O	O
cases	O
(	O	O
44	O	O
%	O	O
)	O	O
.	O	O

Specifically	O	O
,	O	O
five	O	O
(	O	O
56	O	O
%	O	O
)	O	O
ductal	B-DISO
adenomas	I-DISO
and	O	O
three	O	O
(	O	O
50	O	O
%	O	O
)	O	O
tubular	B-DISO
adenomas	I-DISO
harbored	O	O
mutated	O
genes	O
.	O	O

No	B-DISO
mutations	B-PHYS
were	O	O
detected	O	O
in	O	O
lactating	B-DISO
adenomas	I-DISO
.	O	O

Three	O	O
of	O	O
the	O	O
nine	O	O
ductal	B-DISO
adenomas	I-DISO
showed	O	O
mutant	B-DISO
AKT1	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

E17	I-DISO
K	I-DISO
)	I-DISO
with	O	O
two	O	O
of	O	O
them	O	O
harboring	O	O
an	O	O
additional	O	O
GNAS	B-DISO
mutation	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO
R201C	I-DISO
)	I-DISO
.	O	O

One	O	O
case	O
had	O	O
mutant	B-DISO
PIK3CA	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

H1047R	I-DISO
)	I-DISO
and	O	O
another	O	O
case	O
a	O	O
mutation	B-DISO
in	I-DISO
GNAS	I-DISO
(	I-DISO
p	I-DISO
.	I-DISO

R201C	I-DISO
)	I-DISO
.	O	O

The	O	O
three	O	O
cases	O
of	O	O
mutated	B-DISO
tubular	I-DISO
adenomas	I-DISO
showed	O	O
mutations	B-PHYS
in	O	O
either	O	O
MET	O
or	O	O
FGFR3	O
.	O	O

Of	O	O
note	O	O
,	O	O
we	O	O
did	O	O
not	O	O
detect	O	O
copy	O	O
number	O	O
changes	O	O
and	O	O
none	O	O
of	O	O
the	O	O
cases	O
including	O	O
tubular	B-DISO
adenomas	I-DISO
had	O	O
mutations	B-PHYS
in	O	O
exon	B-CHEM
2	I-CHEM
of	O	O
MED12	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
ductal	B-DISO
adenomas	I-DISO
are	O	O
related	O	O
to	O	O
papillomas	B-DISO
of	O	O
the	O	O
breast	B-ANAT
and	O	O
screening	B-PROC
for	O	O
mutations	B-PHYS
in	O	O
exon	B-CHEM
2	I-CHEM
of	O	O
MED12	O
might	O	O
help	O	O
to	O	O
facilitate	O	O
differential	O	O
diagnosis	B-PROC
between	O	O
tubular	B-DISO
adenoma	I-DISO
and	O	O
fibroadenoma	B-DISO
in	O	O
difficult	O	O
cases	O
.	O	O

Lastly	O	O
,	O	O
our	O	O
data	O	O
exemplarily	O	O
demonstrate	O	O
that	O	O
mutations	B-PHYS
in	O	O
cancer	O
-	O
related	O
genes	O
per	O	O
se	O	O
do	O	O
not	O	O
indicate	O	O
malignancy	B-DISO
but	O	O
occur	O	O
in	O	O
benign	B-DISO
tumors	I-DISO
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

Recent	O
advances	O
in	O	O
chitosan	B-CHEM
-based	O	O
nanoparticulate	B-OBJC
pulmonary	B-ANAT
drug	B-DEVI
delivery	I-DEVI
The	O	O
advent	O	O
of	O	O
biodegradable	B-CHEM
polymer	I-CHEM
-	O	O
encapsulated	O
drug	B-CHEM
nanoparticles	B-OBJC
has	O	O
made	O	O
the	O	O
pulmonary	B-ANAT
route	O
of	O
administration	O
an	O	O
exciting	O	O
area	O	O
of	O	O
drug	B-DEVI
delivery	I-DEVI
research	B-PROC
.	O	O

Chitosan	B-CHEM
,	O	O
a	O	O
natural	O
biodegradable	B-CHEM
and	O	O
biocompatible	B-CHEM
polysaccharide	B-CHEM
has	O	O
received	O
enormous	O	O
attention	O	O
as	O	O
a	O	O
carrier	B-CHEM
for	O	O
drug	B-DEVI
delivery	I-DEVI
.	O	O

Recently	O	O
,	O	O
nanoparticles	B-OBJC
of	O	O
chitosan	B-CHEM
(	O	O
CS	B-CHEM
)	O	O
and	O	O
its	O	O
synthetic	B-CHEM
derivatives	I-CHEM
have	O	O
been	O	O
investigated	O
for	O	O
the	O	O
encapsulation	B-PHEN
and	O	O
delivery	O
of	O	O
many	O	O
drugs	B-CHEM
with	O	O
improved	B-DISO
targeting	O
and	O	O
controlled	O
release	O
.	O	O

Herein	O	O
,	O	O
recent	O
advances	O
in	O	O
the	O	O
preparation	O
and	O	O
use	O
of	O
micro	B-ANAT
-	I-ANAT
/	O	O
nanoparticles	B-OBJC
of	O	O
chitosan	B-CHEM
and	O	O
its	O	O
derivatives	B-CHEM
for	O	O
pulmonary	B-ANAT
delivery	O
of	O	O
various	O	O
therapeutic	B-OBJC
agents	I-OBJC
(	O	O
drugs	B-CHEM
,	O	O
genes	O
,	O	O
vaccines	B-CHEM
)	O	O
are	O	O
reviewed	O
.	O	O

Although	O	O
chitosan	B-CHEM
has	O	O
wide	O	O
applications	O
in	O	O
terms	O	O
of	O	O
formulations	B-PROC
and	O	O
routes	O
of	O
drug	O
delivery	O
,	O	O
this	O	O
review	O
is	O	O
focused	O	O
on	O	O
pulmonary	B-ANAT
delivery	B-PROC
of	I-PROC
drug	I-PROC
-	I-PROC
encapsulated	I-PROC
nanoparticles	I-PROC
of	O	O
chitosan	B-CHEM
and	O	O
its	O	O
derivatives	B-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
controversial	O
toxicological	B-DISO
effects	I-DISO
of	O	O
chitosan	B-CHEM
nanoparticles	B-OBJC
for	O	O
lung	B-ANAT
delivery	O
will	O	O
also	O	O
be	O	O
discussed	O	O
.	O	O

EctD	B-CHEM
-mediated	O	O
biotransformation	O
of	O	O
the	O	O
chemical	B-CHEM
chaperone	B-CHEM
ectoine	B-CHEM
into	O	O
hydroxyectoine	B-CHEM
and	O	O
its	O	O
mechanosensitive	O
channel	O
-independent	O	O
excretion	B-PHYS
Ectoine	B-CHEM
and	O	O
its	O	O
derivative	B-CHEM
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
are	O	O
cytoprotectants	B-CHEM
widely	O	O
synthesized	O
by	O	O
microorganisms	B-LIVB
as	O	O
a	O	O
defense	O
against	O	O
the	O	O
detrimental	O	O
effects	O	O
of	O	O
high	O	O
osmolarity	B-PHYS
on	O	O
cellular	B-PHYS
physiology	I-PHYS
and	O	O
growth	B-PHYS
.	O	O

Both	O	O
ectoines	B-CHEM
possess	O	O
the	O	O
ability	O	O
to	O	O
preserve	O	O
the	O	O
functionality	B-PHYS
of	O	O
proteins	B-CHEM
,	O	O
macromolecular	B-CHEM
complexes	I-CHEM
,	O	O
and	O	O
even	O	O
entire	O	O
cells	B-ANAT
,	O	O
attributes	O	O
that	O	O
led	O	O
to	O	O
their	O	O
description	O	O
as	O	O
chemical	B-CHEM
chaperones	B-CHEM
.	O	O

As	O	O
a	O	O
consequence	O	O
,	O	O
there	O	O
is	O	O
growing	O	O
interest	O	O
in	O	O
using	O	O
ectoines	B-CHEM
for	O	O
biotechnological	O
purposes	O	O
,	O	O
in	O	O
skin	B-PROC
care	I-PROC
,	O	O
and	O	O
in	O	O
medical	O
applications	O	O
.	O	O

5	B-CHEM
-	I-CHEM
Hydroxyectoine	I-CHEM
is	O	O
synthesized	O
from	O	O
ectoine	B-CHEM
through	O	O
a	O	O
region	O	O
-	O	O
and	O	O
stereo	O	O
-	O	O
specific	O	O
hydroxylation	B-PHEN
reaction	O
mediated	O	O
by	O	O
the	O	O
EctD	B-CHEM
enzyme	I-CHEM
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
non	B-CHEM
-	I-CHEM
heme	I-CHEM
-	I-CHEM
containing	I-CHEM
iron	I-CHEM
(	I-CHEM
II	I-CHEM
)	I-CHEM
and	O	O
2	B-CHEM
-	I-CHEM
oxoglutarate	I-CHEM
-dependent	O	O
dioxygenases	B-CHEM
.	O	O

This	O	O
chemical	B-CHEM
modification	B-DISO
endows	O	O
the	O	O
newly	O	O
formed	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
with	O	O
either	O	O
superior	O	O
or	O	O
different	O	O
stress	O	O
-	O	O
protecting	O	O
and	O	O
stabilizing	O	O
properties	O	O
.	O	O

Microorganisms	B-LIVB
producing	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
typically	O	O
contain	O	O
a	O	O
mixture	O	O
of	O	O
both	O	O
ectoines	B-CHEM
.	O	O

We	O	O
aimed	O
to	O	O
establish	O	O
a	O	O
recombinant	B-LIVB
microbial	B-LIVB
cell	B-ANAT
factory	I-ANAT
where	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
is	O	O
(	O	O
i	O	O
)	O	O
produced	O	O
in	O	O
highly	O	O
purified	O	O
form	O	O
,	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
secreted	B-PHYS
into	O	O
the	O	O
growth	B-CHEM
medium	I-CHEM
.	O	O

We	O	O
used	O	O
an	O	O
Escherichia	B-LIVB
coli	I-LIVB
strain	B-LIVB
(	O	O
FF4169	B-LIVB
)	O	O
defective	O	O
in	O	O
the	O	O
synthesis	O
of	O	O
the	O	O
osmostress	B-DISO
protectant	O	O
trehalose	B-CHEM
as	O	O
the	O	O
chassis	O	O
for	O	O
our	O	O
recombinant	B-LIVB
cell	B-ANAT
factory	I-ANAT
.	O	O

We	O	O
expressed	B-PHYS
in	O	O
this	O	O
strain	B-LIVB
a	O	O
plasmid	B-CHEM
-encoded	O	O
ectD	O
gene	O
from	O	O
Pseudomonas	B-LIVB
stutzeri	I-LIVB
A1501	I-LIVB
under	O	O
the	O	O
control	O	O
of	O	O
the	O	O
anhydrotetracycline	B-CHEM
-inducible	O	O
tet	B-CHEM
promoter	I-CHEM
.	O	O

We	O	O
chose	O	O
the	O	O
ectoine	B-CHEM
hydroxylase	I-CHEM
from	O	O
P	B-LIVB
.	I-LIVB

stutzeri	I-LIVB
A1501	I-LIVB
for	O	O
our	O	O
cell	B-ANAT
factory	I-ANAT
after	O	O
a	O	O
careful	O	O
comparison	O
of	O	O
the	O	O
in	O
vivo	O
performance	O	O
of	O	O
seven	O	O
different	O	O
EctD	B-CHEM
proteins	I-CHEM
.	O	O

In	O	O
the	O	O
final	O	O
set	O	O
-	O	O
up	O	O
of	O	O
the	O	O
cell	B-ANAT
factory	I-ANAT
,	O	O
ectoine	B-CHEM
was	O	O
provided	O	O
to	O	O
salt	B-PROC
-	I-PROC
stressed	I-PROC
cultures	I-PROC
of	O	O
strain	B-LIVB
FF4169	B-LIVB
(	O	O
pMP41	O
;	O	O
ectD	O
(	O
+	O
)	O
)	O	O
.	O	O

Ectoine	B-CHEM
was	O	O
imported	O	O
into	O	O
the	O	O
cells	B-ANAT
via	O	O
the	O	O
osmotically	B-PHEN
inducible	O	O
ProP	B-CHEM
and	O	O
ProU	B-CHEM
transport	B-PHYS
systems	I-PHYS
,	O	O
intracellularly	O
converted	O	O
to	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
,	O	O
which	O	O
was	O	O
then	O	O
almost	O	O
quantitatively	O
secreted	B-PHYS
into	O	O
the	O	O
growth	B-CHEM
medium	I-CHEM
.	O	O

Experiments	O	O
with	O	O
an	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
mutant	B-DISO
lacking	O	O
all	O	O
currently	O	O
known	O	O
mechanosensitive	O
channels	O
(	O	O
MscL	B-CHEM
,	O	O
MscS	B-CHEM
,	O	O
MscK	B-CHEM
,	O	O
MscM	B-CHEM
)	O	O
revealed	O	O
that	O	O
the	O	O
release	O	O
of	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
under	O	O
osmotic	B-PHEN
steady	B-PHEN
-	I-PHEN
state	I-PHEN
conditions	O	O
occurred	O	O
independently	O	O
of	O	O
these	O	O
microbial	B-LIVB
safety	O	O
valves	O	O
.	O	O

In	O	O
shake	B-PROC
-	I-PROC
flask	I-PROC
experiments	I-PROC
,	O	O
2	O	O
.	O	O
13	O	O
g	O	O
l	O	O
(	O	O
-	O	O
1	O	O
)	O	O
ectoine	B-CHEM
(	O	O
15	O	O
mM	O	O
)	O	O
was	O	O
completely	O	O
converted	O	O
into	O	O
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
within	O	O
24	O	O
h	O	O
.	O	O

We	O	O
describe	O	O
here	O	O
a	O	O
recombinant	B-LIVB
E	B-LIVB
.	I-LIVB

coli	I-LIVB
cell	B-ANAT
factory	I-ANAT
for	O	O
the	O	O
production	O	O
and	O	O
secretion	B-PHYS
of	O	O
the	O	O
chemical	B-CHEM
chaperone	B-CHEM
5	B-CHEM
-	I-CHEM
hydroxyectoine	I-CHEM
free	O	O
from	O	O
contaminating	O
ectoine	B-CHEM
.	O	O

Remote	O
monitoring	B-PROC
of	O	O
patients	B-LIVB
with	O	O
cardiac	B-DEVI
implantable	I-DEVI
electronic	I-DEVI
devices	I-DEVI
:	O	O
a	O	O
Southeast	B-LIVB
Asian	I-LIVB
,	O	O
single	O
-	O
centre	O
pilot	B-PROC
study	I-PROC
Remote	O
monitoring	B-PROC
of	O	O
cardiac	B-DEVI
implantable	I-DEVI
electronic	I-DEVI
devices	I-DEVI
(	O	O
CIED	B-DEVI
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
improve	B-DISO
patient	B-PROC
safety	I-PROC
and	O	O
reduce	O
in	B-PROC
-	I-PROC
office	I-PROC
visits	I-PROC
.	O	O

We	O	O
report	O
our	O	O
experience	B-PHYS
with	O	O
remote	O
monitoring	B-PROC
via	O	O
the	O	O
Medtronic	O
CareLink	O
(	O
®	O
)	O
network	O
.	O	O

Patients	B-LIVB
were	O	O
followed	B-PROC
up	I-PROC
for	O	O
six	O	O
months	O	O
with	O	O
scheduled	O
monthly	O
remote	O
monitoring	B-PROC
transmissions	O
in	O	O
addition	O	O
to	O	O
routine	O
in	B-PROC
-	I-PROC
office	I-PROC
checks	I-PROC
.	O	O

The	O	O
efficacy	O
of	O	O
remote	O
monitoring	B-PROC
was	O	O
evaluated	B-PROC
by	O	O
recording	O	O
compliance	B-DISO
to	O	O
transmissions	O
,	O	O
number	O	O
of	O	O
device	B-DEVI
alerts	O
requiring	O	O
intervention	B-PROC
and	O	O
time	O	O
from	O	O
transmission	O
to	O	O
review	O
.	O	O

Questionnaires	O
were	O	O
administered	O
to	O	O
evaluate	B-PROC
the	O	O
experiences	B-PHYS
of	O	O
patients	B-LIVB
,	O	O
physicians	B-LIVB
and	O	O
medical	B-LIVB
technicians	I-LIVB
.	O	O

A	O	O
total	O	O
of	O	O
57	O	O
patients	B-LIVB
were	O	O
enrolled	O	O
;	O	O
16	O	O
(	O	O
28	O	O
.	O	O

1	O	O
%	O	O
)	O	O
had	O	O
permanent	B-DEVI
pacemakers	I-DEVI
,	O	O
34	O	O
(	O	O
59	O	O
.	O	O
6	O	O
%	O	O
)	O	O
had	O	O
implantable	B-DEVI
cardioverter	I-DEVI
defibrillators	I-DEVI
and	O	O
7	O	O
(	O	O
12	O	O
.	O	O

3	O	O
%	O	O
)	O	O
had	O	O
cardiac	B-DEVI
resynchronisation	I-DEVI
therapy	I-DEVI
defibrillators	I-DEVI
.	O	O

Overall	O
,	O	O
of	O	O
334	O	O
remote	O
transmissions	O
scheduled	O
,	O	O
73	O	O
.	O	O

7	O	O
%	O	O
were	O	O
on	O
time	O
,	O	O
14	O	O
.	O	O
5	O	O
%	O	O
were	O	O
overdue	O
and	O	O
11	O	O
.	O	O

8	O	O
%	O	O
were	O	O
missed	O	O
.	O	O

84	O	O
.	O	O

6	O	O
%	O	O
of	O	O
wireless	O
transmissions	O
were	O	O
on	O
time	O
,	O	O
compared	O	O
to	O	O
53	O	O
.	O	O

8	O	O
%	O	O
of	O	O
non	O
-	O
wireless	O
transmissions	O
.	O	O

Among	O	O
all	O	O
transmissions	O
,	O	O
4	O	O
.	O	O
4	O	O
%	O	O
contained	O	O
alerts	O
for	O	O
which	O	O
physicians	B-LIVB
were	O	O
informed	O
and	O	O
only	O	O
1	O	O
.	O	O
8	O	O
%	O	O
required	O
intervention	B-PROC
.	O	O

98	O	O
.	O	O

6	O	O
%	O	O
of	O	O
remote	O
transmissions	O
were	O	O
reviewed	O
by	O	O
the	O	O
second	O	O
working	O	O
day	O	O
.	O	O

73	O	O
.	O	O
2	O	O
%	O	O
of	O	O
patients	B-LIVB
preferred	O
remote	O
monitoring	B-PROC
.	O	O

Physicians	B-LIVB
agreed	O	O
that	O	O
remote	O
transmissions	O
provided	O
information	O
equivalent	O
to	O	O
in	B-PROC
-	I-PROC
office	I-PROC
checks	I-PROC
97	O	O
.	O	O

1	O	O
%	O	O
of	O	O
the	O	O
time	O	O
.	O	O

77	O	O
.	O	O
8	O	O
%	O	O
of	O	O
medical	B-LIVB
technicians	I-LIVB
felt	O	O
that	O	O
remote	O
monitoring	B-PROC
would	O	O
help	O	O
the	O	O
hospital	B-OBJC
improve	B-DISO
patient	B-PROC
management	I-PROC
.	O	O

No	B-DISO
adverse	B-DISO
events	I-DISO
were	O	O
reported	B-PROC
.	O	O

Remote	O
monitoring	B-PROC
of	O	O
CIED	B-DEVI
is	O	O
safe	O	O
and	O	O
feasible	O	O
.	O	O

It	O	O
has	O	O
possible	B-DISO
benefits	O
to	O	O
patient	B-PROC
safety	I-PROC
through	O	O
earlier	O
detection	B-PROC
of	O	O
arrhythmias	B-DISO
or	O	O
device	B-DISO
malfunction	I-DISO
,	O	O
permitting	O	O
earlier	O	O
intervention	B-PROC
.	O	O

Wireless	O
remote	O
monitoring	B-PROC
,	O	O
in	O	O
particular	O	O
,	O	O
may	O	O
improve	B-DISO
compliance	B-DISO
to	O	O
device	B-DEVI
monitoring	I-DEVI
.	O	O

Patients	B-LIVB
may	O	O
prefer	O	O
remote	O
monitoring	B-PROC
due	O	O
to	O	O
possible	B-DISO
improvements	O
in	O	O
quality	O
of	O
life	O
.	O	O

c	O
-	O
Src	O
Suppresses	O
Dendritic	B-ANAT
Cell	I-ANAT
Antitumor	O
Activity	O
via	O	O
T	B-CHEM
Cell	I-CHEM
Ig	I-CHEM
and	I-CHEM
Mucin	I-CHEM
Protein	I-CHEM
-	I-CHEM
3	I-CHEM
Receptor	B-CHEM
The	O	O
enhanced	O	O
expression	B-PHYS
of	O	O
T	B-CHEM
cell	I-CHEM
Ig	I-CHEM
and	I-CHEM
mucin	I-CHEM
protein	I-CHEM
-	I-CHEM
3	I-CHEM
(	O	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
)	O	O
on	O	O
tumor	B-DISO
-	O	O
associated	O
dendritic	B-ANAT
cells	I-ANAT
(	O	O
DCs	B-ANAT
)	O	O
attenuates	O
antitumor	O
effects	O
of	O	O
DNA	B-CHEM
vaccines	I-CHEM
.	O	O

To	O	O
identify	O	O
a	O	O
potential	O	O
target	O
(	O	O
or	O	O
targets	O
)	O	O
for	O	O
reducing	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O	O
tumor	B-DISO
-	O	O
associated	O
DCs	B-ANAT
,	O	O
we	O	O
explored	O	O
the	O	O
molecular	O	O
mechanisms	O	O
regulating	O	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
identified	O
a	O	O
novel	O
signaling	B-PHYS
pathway	I-PHYS
(	O	O
c	O
-	O
Src	O
→	O	O
Bruton	B-CHEM
's	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
→	O	O
transcription	B-CHEM
factors	I-CHEM
Ets1	B-CHEM
,	O	O
Ets2	B-CHEM
,	O	O
USF1	B-CHEM
,	O	O
and	O	O
USF2	B-CHEM
)	O	O
necessary	O	O
for	O	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
upregulation	B-PHYS
on	O	O
DCs	B-ANAT
.	O	O

Both	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
and	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
,	O	O
which	O	O
are	O	O
produced	O	O
in	O	O
the	O	O
tumor	B-PHEN
microenvironment	I-PHEN
,	O	O
upregulated	B-PHYS
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O	O
DCs	B-ANAT
via	O	O
this	O	O
pathway	B-PHYS
.	O	O

Suppressed	O
expression	B-PHYS
of	O	O
c	O
-	O
Src	O
or	O	O
downstream	O	O
Bruton	B-CHEM
's	I-CHEM
tyrosine	I-CHEM
kinase	I-CHEM
,	O	O
Ets1	B-CHEM
,	O	O
Ets2	B-CHEM
,	O	O
USF1	B-CHEM
,	O	O
or	O	O
USF2	B-CHEM
blocked	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
-	I-CHEM
and	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
-	O	O
induced	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
upregulation	B-PHYS
on	O	O
DCs	B-ANAT
.	O	O

Notably	O	O
,	O	O
in	O
vivo	O
knockdown	B-PROC
of	O	O
c	O
-	O
Src	O
in	O	O
mice	B-LIVB
reduced	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
on	O	O
tumor	B-DISO
-	O	O
associated	O
DCs	B-ANAT
.	O	O

Furthermore	O	O
,	O	O
adoptive	B-PROC
transfer	I-PROC
of	O	O
c	O
-	O
Src	O
-	O	O
silenced	B-PROC
DCs	B-ANAT
in	O	O
mouse	B-LIVB
tumors	B-DISO
enhanced	O
the	O	O
in	O
vivo	O
antitumor	O
effects	O
of	O	O
immunostimulatory	B-CHEM
CpG	I-CHEM
DNA	I-CHEM
;	O	O
however	O	O
,	O	O
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
overexpression	B-PHYS
in	O	O
c	O
-	O
Src	O
-	O	O
silenced	B-PROC
DCs	B-ANAT
blocked	O
this	O	O
effect	O
.	O	O

Collectively	O	O
,	O	O
our	O	O
data	O	O
reveal	O	O
the	O	O
molecular	O
mechanism	O
regulating	B-PHEN
TIM	B-CHEM
-	I-CHEM
3	I-CHEM
expression	B-PHYS
in	O	O
DCs	B-ANAT
and	O	O
identify	O	O
c	O
-	O
Src	O
as	O	O
a	O	O
target	O
for	O	O
improving	O
the	O	O
efficacy	O
of	O	O
nucleic	B-CHEM
acid	I-CHEM
-mediated	O	O
anticancer	B-PROC
therapy	I-PROC
.	O	O

Distal	O
,	O	O
not	O	O
proximal	O
,	O	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
promote	O
fat	B-PHEN
oxidation	I-PHEN
and	O	O
improve	B-DISO
metabolic	B-CHEM
markers	I-CHEM
in	O	O
overweight	B-DISO
/	O	O
obese	B-DISO
men	B-LIVB
Gut	B-LIVB
microbial	I-LIVB
-derived	O	O
short	B-CHEM
-	I-CHEM
chain	I-CHEM
fatty	I-CHEM
acids	I-CHEM
(	O	O
SCFA	B-CHEM
)	O	O
are	O	O
believed	O	O
to	O	O
affect	O	O
host	B-LIVB
metabolism	B-PHYS
and	O	O
cardiometabolic	B-DISO
risk	I-DISO
factors	I-DISO
.	O	O

The	O	O
present	O	O
study	O	O
aim	O	O
was	O	O
to	O	O
investigate	O
the	O	O
effects	O
of	O	O
proximal	O
and	O	O
distal	O
colonic	B-ANAT
infusions	B-PROC
with	O	O
the	O	O
SCFA	B-CHEM
acetate	I-CHEM
on	O	O
fat	B-PHEN
oxidation	I-PHEN
and	O	O
other	O	O
metabolic	O
parameters	O
in	O	O
men	B-LIVB
.	O	O

In	O	O
this	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
crossover	B-PROC
trial	I-PROC
,	O	O
six	O	O
overweight	B-DISO
/	O	O
obese	B-DISO
men	B-LIVB
[	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
(	O	O
BMI	B-PHYS
)	O	O
25	O	O
-	O	O
35	O	O
kg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
]	O	O
underwent	O	O
two	O	O
experimental	O
periods	O
:	O	O
one	O	O
with	O	O
distal	O
and	O	O
one	O	O
with	O	O
proximal	O
colonic	B-ANAT
sodium	B-PROC
acetate	I-PROC
infusions	I-PROC
.	O	O

A	O	O
feeding	B-DEVI
catheter	I-DEVI
was	O	O
endoscopically	O
positioned	O
at	O	O
the	O	O
beginning	O
of	O	O
each	O	O
period	O
and	O	O
remained	O	O
in	O	O
the	O	O
colon	B-ANAT
for	O	O
three	O	O
consecutive	O	O
test	O	O
days	O
,	O	O
enabling	O	O
colonic	B-ANAT
acetate	B-PROC
(	O	O
100	O	O
or	O	O
180	O	O
mmol	O	O
/	O	O
l	O	O
)	O	O
or	O	O
placebo	B-CHEM
infusion	B-PROC
during	O	O
fasting	B-DISO
conditions	O
and	O	O
after	O	O
an	O	O
oral	B-CHEM
glucose	I-CHEM
load	I-CHEM
(	O	O
postprandial	O
)	O	O
.	O	O

Fat	O	O
oxidation	O	O
and	O	O
energy	B-PHYS
expenditure	I-PHYS
were	O	O
measured	O
using	O	O
an	O	O
open	B-DEVI
-	I-DEVI
circuit	I-DEVI
ventilated	I-DEVI
hood	I-DEVI
system	I-DEVI
and	O	O
blood	B-ANAT
samples	I-ANAT
were	O	O
repeatedly	O	O
collected	O
for	O	O
2	O	O
h	O	O
during	O	O
fasting	B-DISO
and	O	O
postprandial	O
conditions	O
.	O	O

Distal	O
colonic	B-ANAT
180	O	O
mmol	O	O
/	O	O
l	O	O
acetate	B-PROC
infusions	I-PROC
increased	O	O
fasting	B-DISO
fat	B-PHEN
oxidation	I-PHEN
(	O	O
1	O	O
.	O	O
78±0	O	O
.	O	O

28	O	O
compared	O	O
with	O	O
-0	O	O
.	O	O

78±0	O	O
.	O	O

89	O	O
g	O	O
fat	O	O
2	O	O
h	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
015	O	O
)	O	O
,	O	O
fasting	B-DISO
peptide	B-CHEM
YY	I-CHEM
(	O	O
PYY	B-CHEM
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
and	O	O
postprandial	O
glucose	B-CHEM
and	O	O
insulin	B-CHEM
concentrations	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
and	O	O
tended	O	O
to	O	O
increase	O
fasting	B-DISO
plasma	B-ANAT
acetate	B-CHEM
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
069	O	O
)	O	O
compared	O
with	O	O
placebo	B-CHEM
.	O	O

Distal	O
100	O	O
mmol	O	O
/	O	O
l	O	O
acetate	B-PROC
administration	I-PROC
tended	O	O
to	O	O
decrease	O
fasting	B-DISO
tumour	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
-	I-CHEM
α	I-CHEM
(	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
067	O	O
)	O	O
compared	O	O
with	O	O
placebo	B-CHEM
.	O	O

In	O	O
contrast	O	O
,	O	O
proximal	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
showed	O	O
no	O	O
effects	O
on	O	O
substrate	B-OBJC
metabolism	B-PHYS
,	O	O
circulating	O
hormones	B-CHEM
or	O	O
inflammatory	O
markers	B-PHYS
.	O	O

In	O	O
conclusion	O	O
distal	O
colonic	B-ANAT
acetate	B-PROC
infusions	I-PROC
affected	O	O
whole	B-ANAT
-	I-ANAT
body	I-ANAT
substrate	B-OBJC
metabolism	B-PHYS
,	O	O
with	O	O
a	O	O
pronounced	O	O
increase	O
in	O	O
fasting	B-DISO
fat	B-PHEN
oxidation	I-PHEN
and	O	O
plasma	B-ANAT
PYY	B-CHEM
.	O	O

Modulating	O
colonic	B-ANAT
acetate	B-CHEM
may	O	O
be	O	O
a	O	O
nutritional	O
target	O
to	O	O
treat	B-PROC
or	O	O
prevent	O	O
metabolic	B-DISO
disorders	I-DISO
.	O	O

Form	O
and	O	O
function	O
in	O	O
gene	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
:	O	O
the	O	O
structure	O
of	O	O
network	O
motifs	O
determines	O	O
fundamental	O
properties	O
of	O	O
their	O	O
dynamical	O
state	O
space	O
Network	O
motifs	O
have	O	O
been	O	O
studied	O	O
extensively	O	O
over	O	O
the	O	O
past	O	O
decade	O	O
,	O	O
and	O	O
certain	O	O
motifs	O
,	O	O
such	O	O
as	O	O
the	O	O
feed	O
-	O
forward	O
loop	O
,	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
regulatory	B-PHYS
networks	I-PHYS
.	O	O

Recent	O
studies	B-PROC
have	O	O
used	O	O
Boolean	O
network	O
motifs	O
to	O	O
explore	O	O
the	O	O
link	O	O
between	O	O
form	O
and	O	O
function	O
in	O	O
gene	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
and	O	O
have	O	O
found	O	O
that	O	O
the	O	O
structure	O
of	O	O
a	O	O
motif	O
does	O	O
not	O	O
strongly	O	O
determine	O	O
its	O	O
function	O
,	O	O
if	O	O
this	O	O
is	O	O
defined	O	O
in	O	O
terms	O	O
of	O	O
the	O	O
gene	B-PHYS
expression	I-PHYS
patterns	O
the	O	O
motif	O
can	O	O
produce	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
offer	O	O
a	O	O
different	O	O
,	O	O
higher	O
-	O	O
level	O
definition	O
of	O	O
the	O	O
'	O	O
function	O
'	O	O
of	O	O
a	O	O
motif	O
,	O	O
in	O	O
terms	O	O
of	O	O
two	O	O
fundamental	O
properties	O
of	O	O
its	O	O
dynamical	O
state	O
space	O
as	O	O
a	O	O
Boolean	O
network	O
.	O	O

One	O	O
is	O	O
the	O	O
basin	O
entropy	O
,	O	O
which	O	O
is	O	O
a	O	O
complexity	O
measure	O
of	O	O
the	O	O
dynamics	B-PHEN
of	O	O
Boolean	O
networks	O
.	O	O

The	O	O
other	O	O
is	O	O
the	O	O
diversity	O
of	O	O
cyclic	O
attractor	O
lengths	O
that	O	O
a	O	O
given	O	O
motif	O
can	O	O
produce	O	O
.	O	O

Using	O	O
these	O	O
two	O	O
measures	O
,	O	O
we	O	O
examine	O	O
all	O	O
104	O	O
topologically	O	O
distinct	O	O
three	O
-	O
node	O
motifs	O
and	O	O
show	O	O
that	O	O
the	O	O
structural	O
properties	O
of	O	O
a	O	O
motif	O
,	O	O
such	O	O
as	O	O
the	O	O
presence	O	O
of	O	O
feedback	O
loops	O
and	O	O
feed	O
-	O
forward	O
loops	O
,	O	O
predict	O	O
fundamental	O
characteristics	O
of	O	O
its	O	O
dynamical	O
state	O
space	O
,	O	O
which	O	O
in	O	O
turn	O	O
determine	O	O
aspects	O	O
of	O	O
its	O	O
functional	O
versatility	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
these	O	O
higher	O
-	O	O
level	O
properties	O
have	O	O
a	O	O
direct	O	O
bearing	O	O
on	O	O
real	O	O
regulatory	B-PHYS
networks	I-PHYS
,	O	O
as	O	O
both	O	O
basin	O
entropy	O
and	O	O
cycle	O
length	O
diversity	O
show	O	O
a	O	O
close	O	O
correspondence	O	O
with	O	O
the	O	O
prevalence	O
,	O	O
in	O	O
neural	B-PHYS
and	O	O
genetic	B-PHYS
regulatory	I-PHYS
networks	I-PHYS
,	O	O
of	O	O
the	O	O
13	O	O
connected	O	O
motifs	O
without	O	O
self	O
-	O
interactions	O
that	O	O
have	O	O
been	O	O
studied	O	O
extensively	O	O
in	O	O
the	O	O
literature	O
.	O	O

Multiplexing	B-PHEN
Fluorescence	I-PHEN
Anisotropy	I-PHEN
Using	O
Frequency	B-PROC
Encoding	I-PROC
In	O	O
this	O	O
report	O	O
,	O	O
a	O	O
method	O	O
to	O	O
multiplex	B-PHEN
fluorescence	I-PHEN
anisotropy	I-PHEN
measurements	O
is	O	O
described	O
using	O	O
frequency	B-PROC
encoding	I-PROC
.	O	O

As	O	O
a	O	O
demonstration	O	O
of	O	O
the	O	O
method	O	O
,	O	O
simultaneous	O
competitive	O	O
immunoassays	B-PROC
for	O	O
insulin	B-CHEM
and	O	O
glucagon	B-CHEM
were	O	O
performed	O
by	O	O
measuring	O
the	O	O
ratio	O
of	O	O
bound	B-CHEM
and	O	O
free	B-CHEM
Cy5	I-CHEM
-	I-CHEM
insulin	I-CHEM
and	O	O
FITC	B-CHEM
-	I-CHEM
glucagon	I-CHEM
in	O	O
the	O	O
presence	O	O
of	O	O
their	O	O
respective	O	O
antibodies	B-CHEM
.	O	O

A	O	O
vertically	B-PHEN
polarized	I-PHEN
635	I-PHEN
nm	I-PHEN
laser	I-PHEN
was	O	O
pulsed	B-PHEN
at	O	O
73	O	O
Hz	O	O
and	O	O
used	O
to	O	O
excite	O	O
Cy5	B-CHEM
-	I-CHEM
insulin	I-CHEM
,	O	O
while	O	O
a	O	O
vertically	B-PHEN
polarized	I-PHEN
488	I-PHEN
nm	I-PHEN
laser	I-PHEN
pulsed	B-PHEN
at	O	O
137	O	O
Hz	O	O
excited	O	O
FITC	B-CHEM
-	I-CHEM
glucagon	I-CHEM
.	O	O

The	O	O
total	O
emission	B-PHEN
was	O	O
split	O
into	O	O
parallel	O
and	O	O
perpendicular	O
polarizations	B-PROC
and	O	O
collected	O
onto	O	O
separate	O
photomultiplier	B-OBJC
tubes	I-OBJC
.	O	O

The	O	O
signals	B-PHEN
from	O	O
each	O	O
channel	O
were	O	O
demodulated	O	O
using	O
a	O	O
fast	O
Fourier	O
transform	O
,	O	O
resolving	O	O
the	O	O
contributions	O
from	O	O
each	O
fluorophore	B-CHEM
.	O	O

Anisotropy	B-PHEN
calculations	B-PROC
were	O	O
carried	O
out	O	O
using	O
the	O	O
magnitude	O
of	O	O
the	O	O
peaks	O	O
in	O	O
the	O	O
frequency	O
domain	O
.	O	O

The	O	O
method	O	O
produced	O	O
the	O	O
expected	O
shape	O
of	O	O
the	O	O
calibration	O
curves	O
with	O	O
limits	O	O
of	O	O
detection	B-DISO
of	O	O
0	O	O
.	O	O

6	O	O
and	O	O
5	O	O
nM	O	O
for	O	O
insulin	B-CHEM
and	O	O
glucagon	B-CHEM
,	O	O
respectively	O	O
.	O	O

This	O	O
methodology	O
could	O	O
readily	O	O
be	O	O
expanded	O
to	O	O
other	O
biological	B-ANAT
systems	I-ANAT
and	O	O
further	O
multiplexed	O
to	O	O
monitor	O	O
increased	O
numbers	O
of	O	O
analytes	B-OBJC
.	O	O

Jak1	B-CHEM
-	O	O
STAT3	B-CHEM
Signals	B-PHYS
Are	O	O
Essential	O
Effectors	B-CHEM
of	O	O
the	O	O
USP6	B-CHEM
/	O	O
TRE17	B-CHEM
Oncogene	I-CHEM
in	O	O
Tumorigenesis	B-DISO
Bone	B-DISO
and	O	O
soft	B-DISO
tissue	I-DISO
tumors	I-DISO
(	O	O
BSTT	B-DISO
)	O	O
are	O	O
relatively	O	O
poorly	O	O
understood	O	O
,	O	O
hampering	O	O
the	O	O
development	O
of	O	O
effective	O
therapies	B-PROC
.	O	O

Here	O	O
we	O	O
report	O
a	O	O
role	O	O
for	O	O
the	O	O
ubiquitin	B-CHEM
-	I-CHEM
specific	I-CHEM
protease	I-CHEM
6	I-CHEM
(	O	O
USP6	B-CHEM
)	O	O
/	O	O
TRE17	B-CHEM
oncogene	I-CHEM
,	O	O
which	O	O
is	O	O
overexpressed	B-PHYS
upon	O	O
chromosome	B-DISO
translocation	I-DISO
in	O	O
various	O	O
human	B-LIVB
tumors	B-DISO
,	O	O
including	O	O
aneurysmal	B-DISO
bone	I-DISO
cyst	I-DISO
(	O	O
ABC	B-DISO
)	O	O
,	O	O
and	O	O
the	O	O
related	O	O
benign	O
lesion	B-DISO
nodular	B-DISO
fasciitis	I-DISO
.	O	O

Ectopic	B-PHYS
expression	I-PHYS
of	O	O
USP6	B-CHEM
is	O	O
known	O	O
to	O	O
drive	O	O
formation	O
of	O	O
tumors	B-DISO
,	O	O
which	O	O
recapitulate	O	O
key	O
features	O
of	O	O
ABC	B-DISO
and	O	O
nodular	B-DISO
fasciitis	I-DISO
;	O	O
however	O	O
,	O	O
the	O	O
identity	O
of	O	O
USP6	B-CHEM
's	I-CHEM
relevant	O	O
substrates	B-CHEM
has	O	O
been	O	O
obscure	O	O
.	O	O

Here	O	O
we	O	O
report	O
that	O	O
the	O	O
Jak1	B-CHEM
-	O	O
STAT3	B-CHEM
signaling	B-PHYS
pathway	I-PHYS
serves	O	O
as	O	O
an	O	O
essential	O
effector	B-CHEM
of	O	O
USP6	B-CHEM
in	O	O
BSTT	B-DISO
formation	O
.	O	O

We	O	O
found	O	O
that	O	O
USP6	B-CHEM
directly	O	O
deubiquitinated	B-PHYS
Jak1	B-CHEM
,	O	O
leading	O
to	O	O
its	O	O
stabilization	B-DISO
and	O	O
activation	B-PHYS
of	O	O
STAT3	B-CHEM
.	O	O

The	O	O
tumorigenic	B-DISO
potential	O
of	O	O
USP6	B-CHEM
was	O	O
attenuated	O
significantly	O
by	O
CRISPR	B-CHEM
-mediated	O	O
deletion	B-PHYS
of	O	O
Jak1	O
or	O	O
STAT3	O
,	O	O
or	O	O
by	O	O
administration	O
of	O	O
a	O	O
Jak	B-CHEM
family	I-CHEM
inhibitor	O
.	O	O

Analysis	B-PROC
of	O	O
primary	O
clinical	O
samples	O
of	O	O
nodular	B-DISO
fasciitis	I-DISO
confirmed	B-DISO
the	O	O
activation	B-PHYS
of	O	O
a	O	O
Jak1	B-CHEM
-	O	O
STAT3	B-CHEM
gene	O
signature	O
in	B-PROC
vivo	I-PROC
Together	O	O
,	O	O
our	O	O
studies	B-PROC
highlight	O	O
Jak1	B-CHEM
as	O	O
the	O	O
first	O	O
identified	O	O
substrate	B-CHEM
for	O	O
USP6	B-CHEM
,	O	O
and	O	O
they	O	O
offer	O	O
a	O	O
mechanistic	O
rationale	O
for	O	O
the	O	O
clinical	B-PROC
investigation	I-PROC
of	O	O
Jak	B-CHEM
and	O	O
STAT3	B-CHEM
inhibitors	O
as	O	O
therapeutics	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
bone	B-DISO
and	O	O
soft	B-DISO
tissue	I-DISO
tumors	I-DISO
along	O	O
with	O	O
other	O	O
neoplasms	B-DISO
driven	O	O
by	O	O
USP6	B-CHEM
overexpression	B-PHYS
.	O	O

Cancer	O	O
Res	O	O
;	O	O
76	O	O
(	O	O
18	O	O
)	O	O
;	O	O
5337	O	O
-	O	O
47	O	O
.	O	O

©	O	O
2016	O	O
AACR	O	O
.	O	O

Measure	B-PROC
Up	I-PROC
Pressure	I-PROC
Down	I-PROC
:	I-PROC
Provider	I-PROC
Toolkit	I-PROC
to	O	O
Improve	O
Hypertension	B-DISO
Control	B-PHYS
Hypertension	B-DISO
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
important	O	O
risk	B-DISO
factors	I-DISO
for	O	O
heart	B-DISO
disease	I-DISO
,	O	O
stroke	B-DISO
,	O	O
kidney	B-DISO
failure	I-DISO
,	O	O
and	O	O
diabetes	B-DISO
complications	I-DISO
.	O	O

Nearly	O	O
one	O	O
in	O	O
three	O	O
Americans	B-LIVB
adults	B-LIVB
has	O	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
,	O	O
and	O	O
the	O	O
cost	O
associated	O
with	O
treating	B-PROC
this	O	O
condition	B-DISO
is	O	O
staggering	O	O
.	O	O

The	O	O
Measure	B-PROC
Up	I-PROC
Pressure	I-PROC
Down	I-PROC
:	I-PROC
Provider	I-PROC
Toolkit	I-PROC
to	O	O
Improve	O
Hypertension	B-DISO
Control	B-PHYS
is	O	O
a	O	O
resource	O
developed	O
by	O	O
the	O	O
American	O
Medical	O
Group	O
Foundation	O
in	O	O
partnership	O
with	O	O
the	O	O
American	O
Medical	O
Group	O
Association	O
.	O	O

The	O	O
goal	O
of	O	O
this	O	O
toolkit	O
is	O	O
to	O	O
mobilize	O	O
health	B-LIVB
care	I-LIVB
practitioners	I-LIVB
to	O	O
work	O
together	O
through	O	O
team	B-LIVB
-based	O	O
approaches	O	O
to	O	O
achieve	O	O
an	O	O
80	O	O
%	O	O
control	B-PHYS
rate	O
of	O	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
among	O	O
their	O	O
patient	B-LIVB
population	I-LIVB
.	O	O

The	O	O
toolkit	O
can	O	O
be	O	O
used	O	O
by	O	O
health	B-LIVB
educators	I-LIVB
,	O	O
clinic	B-LIVB
administrators	I-LIVB
,	O	O
physicians	B-LIVB
,	O	O
students	B-LIVB
,	O	O
and	O	O
other	O	O
clinic	B-LIVB
staff	I-LIVB
as	O	O
a	O	O
step	O	O
-	O	O
by	O	O
-	O	O
step	O	O
resource	O
for	O	O
developing	O
the	O	O
infrastructure	B-PROC
needed	O	O
to	O	O
better	O	O
identify	O	O
and	O	O
treat	B-PROC
individuals	B-LIVB
with	O	O
high	B-DISO
blood	I-DISO
pressure	I-DISO
or	O	O
other	O	O
chronic	B-DISO
conditions	I-DISO
.	I-DISO

Foreign	B-DISO
-	I-DISO
body	I-DISO
ingestion	B-PHEN
in	O	O
Egyptian	B-LIVB
children	B-LIVB
:	O	O
a	O	O
10	O	O
-	O	O
year	O
experience	B-PHYS
of	O	O
endoscopic	B-PROC
intervention	B-PROC
in	O	O
a	O	O
tertiary	B-OBJC
hospital	I-OBJC
There	O	O
was	O	O
a	O	O
lack	O
of	O	O
data	O
about	O	O
foreign	B-DISO
body	I-DISO
(	O	O
FB	B-DISO
)	O	O
ingestion	B-PHEN
among	O	O
Middle	B-GEOG
-	I-GEOG
East	I-GEOG
children	B-LIVB
.	O	O

We	O	O
conducted	O	O
a	O	O
retrospective	O
analysis	B-PROC
of	O	O
FB	B-DISO
ingestion	B-PHEN
among	O	O
Egyptian	B-LIVB
children	B-LIVB
and	O	O
determined	O	O
the	O	O
predictors	O
that	O	O
affect	O	O
the	O	O
occurrence	O	O
of	O	O
complications	B-DISO
.	O	O

This	O	O
retrospective	O
study	B-PROC
was	O	O
carried	O	O
out	O	O
on	O	O
1546	O	O
patients	B-LIVB
'	O	O
≤	O	O
13	O	O
years	O
old	O	O
,	O	O
presented	O	O
with	O	O
FB	B-DISO
ingestion	B-PHEN
and	O	O
were	O	O
in	O	O
need	O	O
of	O	O
endoscopic	B-PROC
removal	B-PROC
of	O	O
FB	B-DISO
.	O	O

There	O	O
were	O	O
711	O	O
males	B-PHYS
(	O	O
46	O	O
%	O	O
)	O	O
and	O	O
835	O	O
females	B-PHYS
(	O	O
54	O	O
%	O	O
)	O	O
(	O	O
mean	O	O
age	B-PHYS
4	O	O
.	O	O
56	O	O
±2	O	O
.	O	O
26	O	O
years	O
)	O	O
.	O	O

Symptoms	B-DISO
were	O	O
present	B-DISO
in	O	O
1414	O	O
patients	B-LIVB
(	O	O
91	O	O
.	O	O
5	O	O
%	O	O
)	O	O
while	O	O
complications	B-DISO
were	O	O
present	B-DISO
in	O	O
137	O	O
patients	B-LIVB
(	O	O
8	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
complicated	O
and	O	O
non	O
-	O
complicated	O
cases	O
as	O	O
regard	O	O
higher	O	O
age	B-LIVB
group	I-LIVB
,	O	O
duration	O
of	O	O
impaction	B-DISO
,	O	O
site	O
of	O	O
impaction	B-DISO
and	O	O
type	O
of	O	O
FB	B-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

001	O	O
,	O	O
0	O	O
.	O	O
001	O	O
,	O	O
0	O	O
.	O	O
001	O	O
and	O	O
<	O	O
0	O	O
.	O	O
001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
highest	O	O
rate	O
of	O	O
complications	B-DISO
was	O	O
observed	O	O
in	O	O
FB	B-DISO
impacted	O
in	O	O
duodenum	B-ANAT
and	O	O
those	O	O
without	O	O
symptoms	B-DISO
while	O	O
symptomatic	O
cases	O
and	O	O
impaction	B-DISO
in	O	O
upper	B-ANAT
esophagus	I-ANAT
were	O	O
associated	O	O
with	O	O
higher	O	O
success	O	O
rate	O
of	O	O
removal	O
.	O	O

The	O	O
Evidence	O
Behind	O	O
Integrating	O
Palliative	O
Care	O
Into	O	O
Oncology	B-DISO
Practice	O
Palliative	O
care	O
services	O
provided	O
alongside	O	O
traditional	O
oncology	B-PROC
care	I-PROC
have	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
beneficial	O
to	O	O
patients	B-LIVB
and	O	O
families	B-LIVB
.	O	O

This	O	O
article	O
provides	O	O
a	O	O
brief	O
history	O
of	O	O
palliative	O
care	O
,	O	O
a	O	O
pathway	O	O
to	O	O
implementing	O
these	O	O
services	O
into	O	O
currently	O
established	O
oncology	B-PROC
programs	I-PROC
,	O	O
and	O	O
a	O	O
brief	O	O
discussion	O
of	O	O
common	O
barriers	O
.	O	O

Potentiation	B-PROC
of	O	O
LPS	B-CHEM
-	O	O
Induced	B-DISO
Apoptotic	B-PHYS
Cell	I-PHYS
Death	I-PHYS
in	O	O
Human	B-ANAT
Hepatoma	I-ANAT
HepG2	I-ANAT
Cells	I-ANAT
by	O	O
Aspirin	B-CHEM
via	O	O
ROS	B-CHEM
and	O	O
Mitochondrial	B-DISO
Dysfunction	I-DISO
:	O	O
Protection	B-DISO
by	O	O
N	B-CHEM
-	I-CHEM
Acetyl	I-CHEM
Cysteine	I-CHEM
Cytotoxicity	B-DISO
and	O	O
inflammation	B-DISO
-	O	O
associated	B-DISO
toxic	O
responses	B-PHYS
have	O	O
been	O	O
observed	O
to	O	O
be	O	O
induced	O
by	O	O
bacterial	O
lipopolysaccharides	B-CHEM
(	O	O
LPS	B-CHEM
)	O	O
in	O
vitro	O
and	O	O
in	O
vivo	O
respectively	O	O
.	O	O

Use	O	O
of	O	O
nonsteroidal	B-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
(	O	O
NSAIDs	B-CHEM
)	O	O
,	O	O
such	O	O
as	O	O
aspirin	B-CHEM
,	O	O
has	O	O
been	O	O
reported	B-PROC
to	O	O
be	O	O
beneficial	O	O
in	O	O
inflammation	B-DISO
-	O	O
associated	B-DISO
diseases	I-DISO
like	O	O
cancer	B-DISO
,	O	O
diabetes	B-DISO
and	O	O
cardiovascular	B-DISO
disorders	I-DISO
.	O	O

Their	O	O
precise	O	O
molecular	O
mechanisms	O
,	O	O
however	O	O
,	O	O
are	O	O
not	O	O
clearly	O	O
understood	O	O
.	O	O

Our	O	O
previous	O	O
studies	B-PROC
on	O	O
aspirin	B-CHEM
treated	B-PROC
HepG2	B-ANAT
cells	I-ANAT
strongly	O	O
suggest	O	O
cell	B-PHYS
cycle	I-PHYS
arrest	I-PHYS
and	O	O
induction	O
of	O	O
apoptosis	B-PHYS
associated	O
with	O
mitochondrial	B-DISO
dysfunction	I-DISO
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
have	O	O
further	O	O
demonstrated	O	O
that	O	O
HepG2	B-ANAT
cells	I-ANAT
treated	B-PROC
with	I-PROC
LPS	B-CHEM
alone	O	O
or	O	O
in	O	O
combination	O
with	O	O
aspirin	B-CHEM
induces	O
subcellular	B-ANAT
toxic	B-PHYS
responses	I-PHYS
which	O	O
are	O	O
accompanied	O	O
by	O	O
increase	O
in	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
production	O	O
,	O	O
oxidative	B-DISO
stress	I-DISO
,	O	O
mitochondrial	B-DISO
respiratory	I-DISO
dysfunction	I-DISO
and	O	O
apoptosis	B-PHYS
.	O	O

The	O	O
LPS	B-CHEM
/	O	O
Aspirin	B-CHEM
induced	O
toxicity	B-DISO
was	O	O
attenuated	O
by	O	O
pre	O
-	O
treatment	O
of	O	O
cells	B-ANAT
with	O	O
N	B-CHEM
-	I-CHEM
acetyl	I-CHEM
cysteine	I-CHEM
(	O	O
NAC	B-CHEM
)	O	O
.	O	O

Alterations	O	O
in	O	O
oxidative	B-DISO
stress	I-DISO
and	O	O
glutathione	B-CHEM
-	O	O
dependent	O
redox	B-PHYS
-	I-PHYS
homeostasis	I-PHYS
were	O	O
more	O	O
pronounced	O	O
in	O	O
mitochondria	B-ANAT
compared	O
to	O	O
extra	O
-	O	O
mitochondrial	B-ANAT
cellular	B-ANAT
compartments	I-ANAT
.	O	O

Pre	O
-	O
treatment	O
of	O	O
HepG2	B-ANAT
cells	I-ANAT
with	O	O
NAC	B-CHEM
exhibited	O	O
a	O	O
selective	O	O
protection	B-DISO
in	O	O
redox	B-PHYS
homeostasis	I-PHYS
and	O	O
mitochondrial	B-DISO
dysfunction	I-DISO
.	O	O

Our	O	O
results	B-DISO
suggest	O	O
that	O	O
the	O	O
altered	O
redox	B-PHYS
metabolism	I-PHYS
,	O	O
oxidative	B-DISO
stress	I-DISO
and	O	O
mitochondrial	B-ANAT
function	O
in	O	O
HepG2	B-ANAT
cells	I-ANAT
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
LPS	B-CHEM
/	O	O
aspirin	B-CHEM
-	O	O
induced	O
cytotoxicity	B-DISO
.	O	O

These	O	O
results	B-DISO
may	O	O
help	O	O
in	O	O
better	O	O
understanding	O	O
the	O	O
pharmacological	O
,	O	O
toxicological	O
and	O	O
therapeutic	O
properties	O
of	O	O
NSAIDs	B-CHEM
in	O	O
cancer	B-ANAT
cells	I-ANAT
exposed	O
to	O	O
bacterial	B-CHEM
endotoxins	I-CHEM
.	O	O

Learning	B-PHYS
in	O	O
Complex	O
Environments	O
:	O	O
The	O	O
Effects	O
of	O	O
Background	O
Speech	B-PHYS
on	O	O
Early	O
Word	B-PHYS
Learning	I-PHYS
Although	O	O
most	O	O
studies	B-PROC
of	O	O
language	O
learning	B-PHYS
take	O	O
place	O	O
in	O	O
quiet	O
laboratory	B-OBJC
settings	O	O
,	O	O
everyday	O
language	O
learning	B-PHYS
occurs	O
under	O	O
noisy	B-PHEN
conditions	O
.	O	O

The	O	O
current	O
research	B-PROC
investigated	O
the	O	O
effects	O
of	O	O
background	O
speech	B-PHYS
on	O	O
word	B-PHYS
learning	I-PHYS
.	O	O

Both	O	O
younger	O
(	O	O
22	O	O
-	O	O
to	O	O
24	O	O
-	O	O
month	O	O
-	O	O
olds	O	O
;	O	O
n	O	O
=	O	O
40	O	O
)	O	O
and	O	O
older	O	O
(	O	O
28	O	O
-	O	O
to	O	O
30	O	O
-	O	O
month	O	O
-	O	O
olds	O	O
;	O	O
n	O	O
=	O	O
40	O	O
)	O	O
toddlers	B-LIVB
successfully	O
learned	B-PHYS
novel	O
label	O
-	O	O
object	B-OBJC
pairings	O
when	O	O
target	O
speech	B-PHYS
was	O	O
10	O	O
dB	O	O
louder	O
than	O	O
background	O
speech	B-PHYS
but	O	O
not	O	O
when	O	O
the	O	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O	O
SNR	O
)	O	O
was	O	O
5	O	O
dB	O	O
.	O	O

Toddlers	B-LIVB
(	O	O
28	O	O
-	O	O
to	O	O
30	O	O
-	O	O
month	O	O
-	O	O
olds	O	O
;	O	O
n	O	O
=	O	O
26	O	O
)	O	O
successfully	O
learned	B-PHYS
novel	O
words	O
with	O	O
a	O	O
5	O	O
-	O	O
dB	O	O
SNR	O
when	O	O
they	O	O
initially	O
heard	B-PHYS
the	O	O
labels	O
embedded	B-PROC
in	O	O
fluent	B-PHYS
speech	I-PHYS
without	O	O
background	O
noise	B-PHEN
,	O	O
before	O	O
they	O	O
were	O	O
mapped	O
to	O	O
objects	B-OBJC
.	O	O

The	O	O
results	O
point	O	O
to	O	O
both	O	O
challenges	O	O
and	O	O
protective	O
factors	O
that	O	O
may	O	O
impact	O
language	O
learning	B-PHYS
in	O	O
complex	O
auditory	O
environments	O
.	O	O

Secondary	B-ANAT
Ossification	I-ANAT
Center	I-ANAT
Appearance	O
and	O	O
Closure	B-PROC
in	I-PROC
the	I-PROC
Pelvis	I-PROC
and	O	O
Proximal	B-ANAT
Femur	I-ANAT
Variable	O	O
ossification	B-PHYS
patterns	O
of	O	O
the	O	O
pelvis	B-ANAT
in	O	O
skeletally	B-ANAT
immature	O
patients	B-LIVB
can	O	O
make	O	O
the	O	O
interpretation	O	O
of	O	O
pelvic	B-ANAT
radiographs	B-PROC
challenging	O	O
.	O	O

Inconsistencies	O	O
among	O	O
prior	O	O
studies	O	O
and	O	O
lack	O	O
of	O	O
sex	B-PHYS
comparisons	O
underscore	O	O
the	O	O
need	O	O
for	O	O
a	O	O
more	O	O
comprehensive	O	O
characterization	O	O
of	O	O
the	O	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
.	O	O

This	O	O
study	O	O
evaluates	B-PROC
the	O	O
chronology	O
and	O	O
sex	B-PHYS
differences	I-PHYS
for	O	O
appearance	O
and	O	O
closure	B-PROC
of	I-PROC
pelvic	I-PROC
and	O	O
proximal	B-ANAT
femoral	I-ANAT
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
using	O	O
computed	B-PROC
tomography	I-PROC
(	O	O
CT	B-PROC
)	O	O
.	O	O

Patients	B-LIVB
who	O	O
underwent	O	O
abdominal	B-PROC
and	O	O
pelvic	B-PROC
CT	I-PROC
scans	I-PROC
between	O	O
January	O	O
2009	O	O
and	O	O
December	O	O
2014	O	O
at	O	O
2	O	O
tertiary	O	O
level	O	O
1	O	O
trauma	B-OBJC
centers	I-OBJC
were	O	O
retrospectively	O
reviewed	O
.	O	O

Patients	B-LIVB
between	O	O
the	O	O
ages	B-PHYS
of	O	O
2	O	O
and	O	O
32	O	O
years	O	O
with	O	O
adequate	O	O
imaging	B-PROC
of	O	O
the	O	O
pelvis	B-ANAT
and	O	O
proximal	B-ANAT
femurs	I-ANAT
were	O	O
included	O	O
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
history	O	O
of	O	O
orthopaedic	O
trauma	O
or	O	O
pathology	O
affecting	O
ossification	B-PHYS
were	O	O
excluded	O	O
.	O	O

CT	B-PROC
scans	I-PROC
were	O	O
assessed	O
for	O	O
the	O	O
appearance	O
and	O	O
closure	B-PROC
of	O	O
the	O	O
following	O	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
:	O	O
anterior	B-ANAT
inferior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O	O
AIIS	B-ANAT
)	O	O
,	O	O
anterior	B-ANAT
superior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O	O
ASIS	B-ANAT
)	O	O
,	O	O
femoral	B-ANAT
head	I-ANAT
(	O	O
FH	B-ANAT
)	O	O
,	O	O
greater	B-ANAT
trochanter	I-ANAT
(	O	O
GT	B-ANAT
)	O	O
,	O	O
iliac	B-ANAT
crest	I-ANAT
(	O	O
IC	B-ANAT
)	O	O
,	O	O
ischial	B-ANAT
tuberosity	I-ANAT
(	O	O
IT	B-ANAT
)	O	O
,	O	O
lesser	B-ANAT
trochanter	I-ANAT
(	O	O
LT	B-ANAT
)	O	O
,	O	O
posterior	B-ANAT
superior	I-ANAT
iliac	I-ANAT
spine	I-ANAT
(	O	O
PSIS	B-ANAT
)	O	O
,	O	O
symphysis	B-ANAT
pubis	I-ANAT
(	O	O
SP	B-ANAT
)	O	O
,	O	O
and	O	O
triradiate	O
cartilage	O
(	O	O
TRC	O
)	O	O
.	O	O

Basic	O	O
descriptive	O	O
statistics	O	O
are	O	O
reported	O	O
.	O	O

A	O	O
total	O	O
of	O	O
496	O	O
CT	B-PROC
scans	I-PROC
met	O	O
inclusion	O
criteria	O
(	O	O
240	O	O
males	B-PHYS
and	O	O
256	O	O
females	B-PHYS
)	O	O
.	O	O

The	O	O
order	O	O
of	O	O
appearance	O
of	O	O
the	O	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
was	O	O
:	O	O
(	O	O
male	B-PHYS
)	O	O
GT	B-ANAT
,	O	O
LT	B-ANAT
,	O	O
AIIS	B-ANAT
,	O	O
IT	B-ANAT
,	O	O
ASIS	B-ANAT
,	O	O
PSIS	B-ANAT
,	O	O
IC	B-ANAT
,	O	O
and	O	O
SP	B-ANAT
;	O	O
(	O	O
female	B-PHYS
)	O	O
GT	B-ANAT
,	O	O
LT	B-ANAT
,	O	O
IT	B-ANAT
,	O	O
AIIS	B-ANAT
,	O	O
PSIS	B-ANAT
,	O	O
IC	B-ANAT
,	O	O
ASIS	B-ANAT
,	O	O
and	O	O
SP	B-ANAT
.	O	O

The	O	O
order	O	O
of	O	O
closure	B-PROC
was	O	O
similar	O	O
:	O	O
(	O	O
male	B-PHYS
)	O	O
TRC	O
,	O	O
LT	B-ANAT
,	O	O
FH	B-ANAT
,	O	O
AIIS	B-ANAT
,	O	O
GT	B-ANAT
,	O	O
ASIS	B-ANAT
,	O	O
PSIS	B-ANAT
,	O	O
IT	B-ANAT
,	O	O
IC	B-ANAT
,	O	O
and	O	O
SP	B-ANAT
;	O	O
(	O	O
female	B-PHYS
)	O	O
LT	B-ANAT
,	O	O
TRC	O
,	O	O
AIIS	B-ANAT
,	O	O
FH	B-ANAT
,	O	O
GT	B-ANAT
,	O	O
ASIS	B-ANAT
,	O	O
PSIS	B-ANAT
,	O	O
IT	B-ANAT
,	O	O
IC	B-ANAT
,	O	O
and	O	O
SP	B-ANAT
.	O	O

Female	B-PHYS
ossification	B-ANAT
centers	I-ANAT
appeared	O	O
~1	O	O
to	O	O
2	O	O
years	O	O
before	O	O
males	B-PHYS
in	O	O
all	O	O
locations	B-ANAT
.	O	O

Female	B-PHYS
ossification	B-ANAT
centers	I-ANAT
closed	O	O
~1	O	O
to	O	O
2	O	O
years	O	O
before	O	O
males	B-PHYS
in	O	O
all	O	O
locations	B-ANAT
except	O	O
TRC	O
,	O	O
IC	B-ANAT
,	O	O
and	O	O
SP	B-ANAT
.	O	O

The	O	O
appearance	O
and	O	O
closure	B-PROC
of	I-PROC
the	I-PROC
pelvis	I-PROC
and	O	O
proximal	B-ANAT
femur	I-ANAT
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
follow	O	O
a	O	O
predictable	O	O
pattern	O	O
of	O	O
development	O	O
,	O	O
occurring	O	O
slightly	O	O
earlier	O	O
in	O	O
females	B-PHYS
than	O	O
males	B-PHYS
.	O	O

Knowledge	O	O
of	O	O
more	O	O
precise	O	O
ages	B-DISO
of	I-DISO
developmen	I-DISO
t	O	O
and	O	O
sex	B-PHYS
differences	I-PHYS
better	O	O
characterize	O	O
this	O	O
complex	O	O
skeletal	B-PHYS
development	I-PHYS
.	O	O

Future	O	O
studies	O	O
may	O	O
use	O	O
secondary	B-ANAT
ossification	I-ANAT
centers	I-ANAT
to	O	O
further	O	O
evaluate	B-PROC
skeletal	B-PROC
maturity	I-PROC
,	O	O
assess	O	O
pediatric	O
pathology	O
,	O	O
and	O	O
aid	O	O
surgical	B-PROC
management	I-PROC
.	O	O

Level	O	O
III	O	O
.	O	O

Pediatric	B-LIVB
Orthopaedic	B-ANAT
Trauma	B-DISO
and	O	O
Associated	B-DISO
Injuries	I-DISO
of	O	O
Snowmobile	B-DISO
,	O	O
ATV	B-PHEN
,	O	O
and	O	O
Dirtbike	B-PHEN
Accidents	I-PHEN
:	O	O
A	O	O
19	O
-	O
Year	O
Experience	O	O
at	O	O
a	O	O
Level	O	O
1	O	O
Pediatric	B-LIVB
Trauma	B-OBJC
Center	I-OBJC
The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	O	O
the	O	O
type	O
and	O	O
severity	O
of	O	O
orthopaedic	B-DISO
and	O	O
associated	O
injuries	O
for	O	O
snowmobile	B-DISO
,	O	O
All	B-PHEN
-	I-PHEN
terrain	I-PHEN
vehicles	I-PHEN
(	O	O
ATV	B-PHEN
)	O	O
and	O	O
motorized	B-PHEN
dirtbike	I-PHEN
accidents	I-PHEN
in	O	O
a	O	O
pediatric	B-LIVB
patient	B-LIVB
population	I-LIVB
.	O	O

A	O	O
total	O	O
of	O	O
758	O	O
patients	B-LIVB
who	O	O
presented	O	O
following	O	O
either	O	O
snowmobile	B-DISO
(	O	O
n	O	O
=	O	O
87	O	O
)	O	O
,	O	O
ATV	B-DISO
-	I-DISO
related	I-DISO
(	O	O
n	O	O
=	O	O
308	O	O
)	O	O
or	O	O
dirtbike	B-DISO
(	I-DISO
n	I-DISO
=	I-DISO
363	I-DISO
)	I-DISO
-	I-DISO
related	I-DISO
trauma	I-DISO
at	O	O
our	O	O
institution	O
between	O	O
1996	O	O
and	O	O
2015	O	O
were	O	O
retrospectively	O	O
reviewed	O
.	O	O

A	O	O
total	O	O
of	O	O
441	O	O
axial	B-DISO
and	O	O
appendicular	B-DISO
fractures	I-DISO
occurred	O	O
requiring	O	O
533	O	O
procedures	O
.	O	O

Snowmobile	B-DISO
and	O	O
dirtbike	B-PHEN
accidents	I-PHEN
were	O	O
associated	O
with	O
a	O	O
higher	O	O
rate	O	O
of	O	O
fractures	B-DISO
(	O	O
63	O	O
%	O	O
,	O	O
64	O	O
%	O	O
)	O	O
than	O	O
the	O	O
ATV	B-LIVB
group	I-LIVB
(	O	O
50	O	O
%	O	O
)	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0008	O	O
)	O	O
.	O	O

Snowmobile	O
injuries	O
had	O	O
the	O	O
highest	O	O
rate	O	O
of	O	O
spinal	B-DISO
(	O	O
23	O	O
%	O	O
)	O	O
and	O	O
lower	B-DISO
extremity	I-DISO
fractures	I-DISO
(	O	O
53	O	O
%	O	O
)	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
0004	O	O
)	O	O
.	O	O

Snowmobile	B-LIVB
and	O	O
dirtbike	B-LIVB
cohorts	I-LIVB
had	O	O
higher	O	O
rate	O	O
of	O	O
femur	B-DISO
fractures	I-DISO
(	O	O
22	O	O
%	O	O
,	O	O
17	O	O
%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
whereas	O	O
the	O	O
ATV	B-LIVB
cohort	I-LIVB
had	O	O
higher	O	O
rates	O	O
of	O	O
upper	B-ANAT
extremity	I-ANAT
(	O	O
18	O	O
%	O	O
)	O	O
,	O	O
hand	B-ANAT
(	O	O
11	O	O
%	O	O
)	O	O
,	O	O
scapula	B-ANAT
(	O	O
4	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
and	O	O
open	B-DISO
fractures	I-DISO
(	O	O
28	O	O
.	O	O
6	O	O
%	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Head	B-DISO
trauma	I-DISO
was	O	O
the	O	O
most	O	O
commonly	O	O
associated	O
injury	O
in	O	O
275	O	O
patients	B-LIVB
with	O	O
the	O	O
highest	O	O
rate	O	O
in	O	O
the	O	O
ATV	B-LIVB
group	I-LIVB
(	O	O
44	O	O
%	O	O
)	O	O
who	O	O
also	O	O
had	O	O
the	O	O
highest	O	O
rate	O	O
of	O	O
no	O	O
helmet	O	O
use	O	O
(	O	O
76	O	O
%	O	O
)	O	O
.	O	O

Snowmobile	B-LIVB
and	O	O
ATV	B-LIVB
patients	I-LIVB
had	O	O
higher	O	O
Injury	O
Severity	O
Score	O
(	O	O
11	O	O
.	O	O
3	O	O
,	O	O
9	O	O
.	O	O
6	O	O
)	O	O
than	O	O
dirtbike	B-LIVB
patients	I-LIVB
(	O	O
7	O	O
.	O	O
8	O	O
)	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

ATV	B-LIVB
patients	I-LIVB
were	O	O
found	O	O
to	O	O
be	O	O
younger	O
(	O	O
11	O	O
.	O	O

8	O	O
y	O	O
)	O	O
compared	O	O
with	O	O
snowmobile	B-LIVB
(	O	O
13	O	O
.	O	O
2	O	O
y	O	O
)	O	O
and	O	O
dirtbike	B-LIVB
(	O	O
13	O	O
.	O	O
5	O	O
y	O	O
)	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Pediatric	B-LIVB
snowmobile	B-DISO
,	O	O
ATV	B-PHEN
and	O	O
dirtbike	B-PHEN
accidents	I-PHEN
result	O	O
in	O	O
severe	O
orthopaedic	B-DISO
and	O	O
associated	O
injuries	O
with	O	O
each	O	O
vehicle	B-OBJC
demonstrating	O	O
significantly	O	O
different	O	O
injury	B-DISO
patterns	O
.	O	O

Injury	B-PROC
prevention	I-PROC
should	O	O
focus	O	O
on	O	O
improved	O	O
safety	B-PROC
mechanisms	I-PROC
,	O	O
protective	B-OBJC
gear	I-OBJC
,	O	O
safe	O	O
areas	O	O
for	O	O
off	B-OBJC
-	I-OBJC
road	I-OBJC
vehicle	I-OBJC
use	O	O
and	O	O
strict	O
laws	O
with	O	O
minimum	O	O
age	B-PHYS
requirements	O	O
LEVEL	O	O
OF	O	O
EVIDENCE	O	O
:	O	O
:	O	O
Level	O	O
IV	O	O
.	O	O

Content	O
of	O	O
cardiolipin	B-CHEM
of	O	O
the	O	O
membrane	O
and	O	O
sensitivity	B-DISO
to	O	O
cationic	B-CHEM
surfactants	I-CHEM
in	O	O
Pseudomonas	B-LIVB
putida	I-LIVB
To	O	O
establish	O	O
the	O	O
role	O
of	O	O
cardiolipin	B-CHEM
(	O	O
CL	B-CHEM
)	O	O
of	O	O
the	O	O
membrane	O
in	O	O
response	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
tetradecyltrimethylammonium	B-CHEM
in	O	O
Pseudomonas	B-LIVB
putida	I-LIVB
A	I-LIVB
(	I-LIVB
ATCC	I-LIVB
12633	I-LIVB
)	I-LIVB
.	O	O

Two	O	O
ORFs	O
of	O	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
A	I-LIVB
(	I-LIVB
ATCC	I-LIVB
12633	I-LIVB
)	I-LIVB
,	O	O
which	O	O
in	O	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
KT2440	I-LIVB
encode	O
the	O	O
putative	O	O
CL	B-CHEM
synthase	I-CHEM
genes	O	O
cls	O
and	O	O
cls2	O
,	O	O
were	O	O
cloned	B-PROC
,	O	O
sequenced	B-PROC
and	O	O
mutated	O	O
.	O	O

Only	O	O
the	O	O
double	O
mutant	O
lacking	O
cls	O
and	O	O
cls2	O
showed	O	O
a	O	O
reduction	O
of	O	O
the	O	O
CL	B-CHEM
content	O
,	O	O
83	O	O
%	O	O
lower	O	O
than	O	O
the	O	O
amount	O
produced	O	O
by	O	O
the	O	O
wild	O
-	O
type	O
.	O	O

Accompanying	O	O
this	O	O
change	O	O
was	O	O
a	O	O
40	O	O
%	O	O
decrease	O
in	O	O
the	O	O
content	O
of	O	O
unsaturated	B-CHEM
fatty	I-CHEM
acid	I-CHEM
.	O	O

Consequently	O	O
,	O	O
the	O	O
membrane	O
of	O	O
the	O	O
mutant	O
was	O	O
more	O	O
rigid	O	O
than	O	O
the	O	O
one	O	O
of	O	O
the	O	O
parental	B-LIVB
strain	I-LIVB
,	O	O
as	O	O
observed	O	O
using	O	O
fluorescence	B-PROC
polarization	I-PROC
techniques	I-PROC
.	O	O

The	O	O
mutant	B-LIVB
strain	I-LIVB
showed	O	O
reduced	O
viability	O
in	O	O
the	O	O
presence	O	O
of	O	O
tetradecyltrimethylammonium	B-CHEM
.	O	O

The	O	O
incorporation	O
of	O	O
exogenous	O
CL	B-CHEM
into	O	O
its	O	O
membrane	O
relieved	O	O
sensitivity	B-DISO
to	O	O
the	O	O
cationic	B-CHEM
detergent	I-CHEM
.	O	O

Pseudomonas	B-ANAT
Putida	I-ANAT
cells	I-ANAT
with	O	O
low	O	O
levels	O	O
of	O	O
CL	B-CHEM
die	B-PHYS
in	O	O
the	O	O
presence	O
of	O	O
tetradecyltrimethylammonium	B-CHEM
,	O	O
because	O	O
they	O	O
cannot	O	O
counter	O	O
the	O	O
fluidizing	O	O
effect	O	O
of	O	O
the	O	O
cationic	B-CHEM
surfactant	I-CHEM
.	O	O

The	O	O
modification	O	O
in	O	O
the	O	O
membrane	B-CHEM
phospholipids	I-CHEM
composition	O	O
allows	O	O
knowing	O	O
the	O	O
adaptation	B-PHEN
strategy	O	O
of	O	O
Ps	B-LIVB
.	I-LIVB

putida	I-LIVB
when	O	O
these	O	O
bacteria	B-LIVB
are	O	O
exposed	O
to	O
cationic	B-CHEM
surfactant	I-CHEM
.	O	O

NADPH	B-CHEM
oxidase	I-CHEM
-	I-CHEM
produced	I-CHEM
superoxide	I-CHEM
mediated	O	O
a	O	O
50	O	O
-	O	O
Hz	O	O
magnetic	B-PHEN
field	I-PHEN
-induced	O	O
epidermal	B-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
clustering	B-PHYS
A	O	O
50	O	O
-	O	O
Hz	O	O
magnetic	B-PHEN
field	I-PHEN
(	O	O
MF	B-PHEN
)	O	O
was	O	O
found	O	O
to	O	O
induce	O	O
epidermal	B-CHEM
growth	I-CHEM
factor	I-CHEM
receptor	I-CHEM
(	O	O
EGFR	B-CHEM
)	O	O
clustering	B-PHYS
in	O	O
our	O	O
previous	O	O
study	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
molecular	B-PHYS
mechanisms	I-PHYS
that	O	O
mediated	O	O
MF	B-PHEN
-induced	O	O
EGFR	B-CHEM
clustering	B-PHYS
.	O	O

Human	B-ANAT
amniotic	I-ANAT
epithelial	I-ANAT
(	I-ANAT
FL	I-ANAT
)	I-ANAT
cells	I-ANAT
were	O	O
exposed	O	O
to	O	O
a	O	O
50	O	O
-	O	O
Hz	O	O
MF	B-PHEN
.	O	O

Total	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
,	O	O
cytoplasmic	B-ANAT
and	O	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
were	O	O
detected	O	O
by	O	O
DCFH	B-CHEM
-	I-CHEM
DA	I-CHEM
,	O	O
DHE	B-CHEM
and	O	O
MitoSOX	B-CHEM
,	O	O
respectively	O	O
.	O	O

EGFR	B-CHEM
clustering	B-PHYS
was	O	O
analyzed	O	O
using	O	O
confocal	B-PROC
microscopy	I-PROC
after	O	O
indirect	B-PROC
immunofluorescence	I-PROC
staining	B-PROC
.	O	O

Results	O	O
showed	O	O
that	O	O
exposing	O	O
FL	B-ANAT
cells	I-ANAT
to	O	O
MF	B-PHEN
at	O	O
intensity	O
higher	O
than	O	O
0	O	O
.	O	O

2	O	O
mT	O	O
for	O	O
15	O	O
min	O	O
enhanced	O	O
total	O	O
ROS	B-CHEM
production	O	O
.	O	O

Additionally	O	O
,	O	O
enhanced	O	O
total	O	O
ROS	B-CHEM
and	O	O
cytoplasmic	B-ANAT
superoxide	B-CHEM
production	O
were	O	O
observed	O	O
after	O	O
exposing	O	O
cells	B-ANAT
to	O	O
MF	B-PHEN
at	O	O
0	O	O
.	O	O

4	O	O
mT	O	O
for	O	O
5	O	O
,	O	O
15	O	O
,	O	O
or	O	O
30	O	O
min	O	O
,	O	O
while	O	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
for	O	O
15	O	O
or	O	O
30	O	O
min	O	O
.	O	O

Pretreatment	O
with	O	O
Nox	B-CHEM
inhibitor	B-CHEM
,	O	O
DPI	B-CHEM
,	O	O
effectively	O	O
inhibited	O
MF	B-PHEN
-induced	O	O
cytoplasmic	B-ANAT
superoxide	B-CHEM
production	O
and	O	O
subsequent	O	O
EGFR	B-CHEM
clustering	B-PHYS
while	O	O
mitochondrial	B-ANAT
superoxide	B-CHEM
production	O
was	O	O
not	O
affected	O
.	O	O

Nox	B-CHEM
-	I-CHEM
produced	I-CHEM
superoxide	I-CHEM
mediated	O	O
a	O	O
50	O	O
-	O	O
Hz	O
magnetic	B-PHEN
field	I-PHEN
-induced	O	O
EGFR	B-CHEM
clustering	B-PHYS
.	O	O

Placental	B-ANAT
Pathologic	O
Associations	O
with	O	O
Morbidly	B-DISO
Adherent	I-DISO
Placenta	I-DISO
:	O	O
Potential	O	O
insights	O	O
into	O	O
Pathogenesis	B-DISO
The	O	O
pathology	O
that	O	O
underlies	O	O
morbidly	B-DISO
adherent	I-DISO
placenta	I-DISO
(	O	O
MAP	B-DISO
)	O	O
is	O	O
poorly	O	O
understood	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
describe	O	O
the	O	O
placental	B-ANAT
pathology	O
,	O	O
especially	O	O
implantation	O
site	O
pathology	O
,	O	O
associated	O
with	O
MAP	B-DISO
.	O	O

This	O	O
was	O	O
a	O	O
single	O
institution	O
,	O	O
retrospective	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
design	O	O
examining	O	O
placentas	B-ANAT
of	O	O
patients	B-LIVB
who	O	O
delivered	B-DISO
between	O	O
January	O	O
2008	O	O
and	O	O
September	O	O
2013	O	O
.	O	O

MAP	B-DISO
cases	O
were	O	O
defined	O	O
by	O	O
the	O	O
need	O	O
for	O	O
clinical	O
intervention	B-PROC
at	O	O
delivery	B-PROC
beyond	O	O
spontaneous	O
placental	B-PROC
delivery	I-PROC
or	O	O
simple	O	O
manual	B-PROC
extraction	I-PROC
of	O	O
the	O	O
placenta	B-ANAT
.	O	O

Controls	B-LIVB
consisted	O	O
of	O	O
patients	B-LIVB
with	O	O
placentas	B-ANAT
sent	O	O
for	O	O
examination	B-PROC
due	O	O
to	O	O
a	O	O
history	B-DISO
of	O	O
maternal	B-LIVB
malignancy	B-DISO
with	O	O
no	B-DISO
clinical	O
suspicion	O
of	O	O
accreta	B-DISO
.	O	O

Placental	B-ANAT
pathologic	B-DISO
findings	I-DISO
of	O	O
maternal	B-DISO
vascular	I-DISO
underperfusion	I-DISO
(	O	O
MVU	B-DISO
)	O	O
,	O	O
acute	B-DISO
inflammation	I-DISO
,	O	O
chronic	B-DISO
inflammation	I-DISO
,	O	O
fetal	B-ANAT
vascular	B-DISO
obstruction	I-DISO
and	O	O
hemorrhage	B-DISO
were	O	O
recorded	O	O
and	O	O
compared	O	O
using	O	O
bivariable	O
and	O
multivariable	O
analyses	O
.	O	O

Three	O	O
categories	O
of	O	O
pathologic	O
changes	O
were	O	O
seen	O	O
more	O	O
commonly	O	O
in	O	O
MAP	B-DISO
placentas	B-ANAT
(	O	O
N	O	O
=	O	O
101	O	O
)	O	O
than	O	O
control	B-LIVB
placentas	B-ANAT
(	O	O
N	O	O
=	O	O
110	O	O
)	O	O
:	O	O
chronic	B-DISO
basal	I-DISO
inflammation	I-DISO
,	O	O
villous	O	O
changes	O
of	O	O
MVU	B-DISO
and	O	O
retromembranous	O	O
and	O	O
retromembranous	B-DISO
/	O	O
intervillous	B-DISO
hemorrhage	I-DISO
.	O	O

In	O	O
multivariable	O
analyses	O
adjusted	O	O
for	O	O
confounders	O
,	O	O
chronic	B-DISO
basal	I-DISO
villitis	I-DISO
(	O	O
aOR	O
5	O	O
.	O	O
6	O	O
,	O	O
1	O	O
.	O	O
73	O	O
-	O	O
18	O	O
.	O	O
18	O	O
)	O	O
,	O	O
plasma	B-DISO
cell	I-DISO
deciduitis	I-DISO
(	O	O
aOR	O
2	O	O
.	O	O
63	O	O
,	O	O
1	O	O
.	O	O
08	O	O
-	O	O
6	O	O
.	O	O
39	O	O
)	O	O
,	O	O
increased	B-DISO
syncytial	I-DISO
knots	I-DISO
(	O	O
aOR	O
3	O	O
.	O	O
92	O	O
,	O	O
1	O	O
.	O	O
57	O	O
-	O	O
9	O	O
.	O	O
75	O	O
)	O	O
,	O	O
villous	O	O
agglutination	O	O
(	O	O
aOR	O
24	O	O
.	O	O
85	O	O
,	O	O
2	O	O
.	O	O
78	O	O
-	O	O
221	O	O
.	O	O
75	O	O
)	O	O
,	O	O
increased	B-DISO
perivillous	I-DISO
fibrin	I-DISO
(	O	O
aOR	O
5	O	O
.	O	O
08	O	O
,	O	O
1	O	O
.	O	O
49	O	O
-	O	O
17	O	O
.	O	O
34	O	O
)	O	O
,	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
subchorionic	B-DISO
/	O	O
intervillous	B-DISO
thrombi	I-DISO
(	O	O
aOR	O
4	O	O
.	O	O
01	O	O
,	O	O
1	O	O
.	O	O
63	O	O
-	O	O
9	O	O
.	O	O
86	O	O
)	O	O
remained	O	O
associated	O
with	O
MAP	B-DISO
.	O	O

MAP	B-DISO
is	O	O
highly	O	O
associated	O
with	O
evidence	O	O
of	O	O
intraparenchymal	B-DISO
placental	I-DISO
hemorrhage	I-DISO
villous	O
changes	O
of	O	O
MVU	B-DISO
,	O	O
and	O	O
a	O	O
lymphoplasmacytic	B-DISO
infiltrate	I-DISO
at	O	O
the	O	O
implantation	O
site	O
.	O	O

The	O	O
contribution	O	O
of	O	O
this	O	O
basal	B-DISO
chronic	I-DISO
inflammatory	I-DISO
infiltrate	I-DISO
to	O	O
MAP	B-DISO
requires	O	O
further	O	O
investigation	O	O
.	O	O

Hospitalist	B-LIVB
Co	O
-	O
management	O
of	O	O
Pediatric	O
Orthopaedic	B-PROC
Surgical	B-LIVB
Patients	I-LIVB
at	O	O
a	O	O
Community	B-OBJC
Hospital	I-OBJC
The	O	O
benefits	O	O
of	O	O
hospitalist	B-LIVB
co	O
-	O
management	O
of	O	O
pediatric	O
surgical	B-LIVB
patients	I-LIVB
include	O	O
bettering	O
patient	B-PROC
safety	I-PROC
,	O	O
decreasing	B-DISO
negative	O
patient	O
outcomes	O
,	O	O
providing	O	O
comprehensive	B-PROC
medical	I-PROC
care	I-PROC
,	O	O
and	O	O
establishing	O	O
a	O	O
dedicated	O
resource	O
to	O	O
patients	B-LIVB
for	O	O
postoperative	B-PROC
care	I-PROC
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
characterize	O
the	O	O
nature	O
of	O	O
patients	B-LIVB
co	O	O
-	O	O
managed	O	O
by	O	O
a	O	O
pediatric	O
hospitalist	B-LIVB
.	O	O

The	O	O
authors	B-LIVB
hypothesize	O
that	O	O
hospitalist	B-LIVB
co	O
-	O
management	O
is	O	O
safe	B-DISO
and	O	O
efficacious	O
in	O	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
who	O	O
are	O	O
admitted	B-PROC
to	O	O
a	O	O
community	B-OBJC
hospital	I-OBJC
.	O	O

A	O	O
retrospective	B-PROC
review	I-PROC
was	O	O
performed	O	O
of	O	O
all	O	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
admitted	B-PROC
to	O	O
a	O	O
community	B-OBJC
hospital	I-OBJC
who	O	O
were	O	O
co	O	O
-	O	O
managed	O	O
by	O	O
a	O	O
pediatric	O
hospitalist	B-LIVB
.	O	O

Indications	O	O
for	O	O
hospitalization	B-PROC
included	O	O
pain	B-PROC
control	I-PROC
,	O	O
antibiotic	B-PROC
infusion	I-PROC
,	O	O
and	O	O
need	O	O
for	O	O
neurovascular	B-PROC
monitoring	I-PROC
.	O	O

Parameters	O
of	O	O
postoperative	B-PROC
care	I-PROC
and	O	O
co	O
-	O
management	O
were	O	O
assessed	O
,	O	O
including	O	O
presence	B-DISO
of	O	O
complications	O
,	O	O
medication	B-PROC
introduction	I-PROC
or	O	O
adjustment	O	O
by	O	O
the	O	O
hospitalist	B-LIVB
,	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
adherence	O
,	O	O
and	O	O
readmission	B-PROC
/	O	O
complication	O
rates	O
after	O	O
discharge	B-PROC
.	O	O

Thirty	O	O
-	O	O
two	O	O
patients	B-LIVB
were	O	O
assessed	O
with	O	O
an	O	O
average	B-PHYS
age	I-PHYS
of	O	O
8	O	O
.	O	O

8	O	O
years	O
.	O	O

Twenty	O	O
-	O	O
five	O	O
percent	O
of	O	O
patients	B-LIVB
had	O	O
an	O	O
associated	O
comorbidity	O
,	O	O
including	O	O
asthma	B-DISO
,	O	O
attention	B-DISO
deficit	I-DISO
disorder	I-DISO
,	O	O
and	O	O
/	O	O
or	O	O
autism	B-DISO
.	O	O

The	O	O
pediatric	O
hospitalist	B-LIVB
added	O	O
pain	B-PROC
medication	I-PROC
to	O	O
the	O	O
original	O	O
postoperative	B-PROC
orders	I-PROC
placed	O	O
by	O	O
the	O	O
orthopaedics	B-LIVB
team	I-LIVB
in	O	O
44	O	O
percent	O
of	O	O
patients	B-LIVB
(	O	O
14	O	O
of	O	O
the	O	O
32	O	O
)	O	O
either	O	O
for	O	O
breakthrough	B-DISO
pain	I-DISO
or	O	O
better	O	O
long	O	O
-	O	O
term	O	O
coverage	O	O
.	O	O

Additionally	O	O
,	O	O
25	O	O
percent	O
of	O	O
patients	B-LIVB
had	O	O
pain	B-PROC
medication	I-PROC
adjusted	O	O
from	O	O
the	O	O
original	O	O
dosing	O
and	O	O
schedule	B-PROC
.	O	O

The	O	O
hospitalist	B-LIVB
team	B-LIVB
contacted	O	O
the	O	O
surgeon	B-LIVB
about	O	O
the	O	O
four	O	O
patients	B-LIVB
(	O	O
12	O	O
.	O	O
5	O	O
percent	O
)	O	O
.	O	O

In	O	O
three	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
the	O	O
surgeon	B-LIVB
was	O	O
contacted	O	O
to	O	O
discuss	O	O
pain	B-PROC
medication	I-PROC
,	O	O
and	O	O
one	O	O
patient	B-LIVB
woke	O	O
up	O	O
agitated	O	O
from	O	O
anesthesia	B-PROC
,	O	O
necessitating	O	O
a	O	O
visit	O	O
from	O	O
the	O	O
surgeon	B-LIVB
on	O	O
the	O	O
pediatrics	O	O
floor	O	O
.	O	O

The	O	O
length	O	O
of	O	O
stay	O	O
was	O	O
one	O	O
day	O	O
for	O	O
all	O	O
patients	B-LIVB
.	O	O

The	O	O
hospitalists	B-LIVB
rounded	O	O
on	O	O
and	O	O
discharged	B-PROC
patients	I-PROC
the	O	O
subsequent	O	O
morning	O	O
.	O	O

All	O	O
patients	B-LIVB
were	O	O
given	O	O
a	O	O
follow	O
-	O
up	O
appointment	O
and	O
schedule	O
by	O	O
the	O	O
hospitalist	B-LIVB
team	O	O
,	O	O
and	O	O
every	B-LIVB
patient	I-LIVB
followed	B-PROC
up	I-PROC
accordingly	O	O
within	O	O
ten	O	O
days	O
of	O	O
discharge	B-PROC
.	O	O

No	O	O
complications	O
or	O	O
hospital	B-PROC
readmissions	I-PROC
occurred	O	O
within	O	O
thirty	O	O
days	O
of	O	O
discharge	B-PROC
.	O	O

Hospitalist	B-LIVB
co	O
-	O
management	O
of	O	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
in	O	O
a	O	O
community	B-OBJC
hospital	I-OBJC
allows	O	O
for	O	O
better	O	O
medical	O
comorbidity	O
and	O	O
medication	B-PROC
management	I-PROC
.	O	O

Hospitalist	B-LIVB
s	O	O
can	O	O
provide	O	O
closer	O	O
observation	O	O
during	O	O
the	O	O
inpatient	O
stay	O
and	O	O
help	O
streamline	O
communication	O
between	O	O
providers	B-LIVB
and	O	O
patients	B-LIVB
while	O	O
allowing	O	O
the	O	O
surgeon	B-LIVB
the	O	O
ability	O	O
to	O	O
be	O	O
more	O	O
mobile	O	O
.	O	O

Co	O
-	O
management	O
is	O	O
safe	B-DISO
and	O	O
efficacious	O
in	O	O
pediatric	O
orthopaedic	B-PROC
surgical	B-LIVB
patients	I-LIVB
who	O	O
are	O	O
admitted	B-PROC
to	O	O
a	O	O
community	B-OBJC
hospital	I-OBJC
.	O	O

Biosynthetic	B-DISO
Gene	O
Cluster	O
for	O	O
Surugamide	B-CHEM
A	I-CHEM
Encompasses	O	O
an	O	O
Unrelated	O	O
Decapeptide	B-CHEM
,	O	O
Surugamide	B-CHEM
F	I-CHEM
Genome	O
mining	B-PROC
is	O	O
a	O	O
powerful	O	O
method	O	O
for	O	O
finding	O	O
novel	O	O
secondary	B-CHEM
metabolites	I-CHEM
.	O	O

In	O	O
our	O	O
study	B-PROC
on	O	O
the	O	O
biosynthetic	B-DISO
gene	O
cluster	O
for	O	O
the	O	O
cyclic	B-CHEM
octapeptides	I-CHEM
surugamides	B-CHEM
A	I-CHEM
-	I-CHEM
E	I-CHEM
(	O	O
inhibitors	B-CHEM
of	O	O
cathepsin	B-CHEM
B	I-CHEM
)	O	O
,	O	O
we	O	O
found	O	O
a	O	O
putative	O	O
gene	O
cluster	O
consisting	O	O
of	O	O
four	O	O
successive	O	O
non	O
-	O
ribosomal	O
peptide	O
synthetase	O
(	O
NRPS	O
)	O
genes	O
,	O	O
surA	O
,	O	O
surB	O
,	O	O
surC	O
,	O	O
and	O	O
surD	O
.	O	O

Prediction	O
of	O	O
amino	O
acid	O
sequence	O
based	O	O
on	O	O
the	O	O
NRPSs	O
and	O	O
gene	B-PHYS
inactivation	I-PHYS
revealed	O	O
that	O	O
surugamides	B-CHEM
A	I-CHEM
-	I-CHEM
E	I-CHEM
are	O	O
produced	O	O
by	O	O
two	O	O
NRPS	O
genes	O
,	O	O
surA	O
and	O	O
surD	O
,	O	O
which	O	O
were	O	O
separated	O	O
by	O	O
two	O	O
NRPS	O
genes	O
,	O	O
surB	O
and	O	O
surC	O
.	O	O

The	O	O
latter	O	O
genes	O
are	O	O
responsible	O	O
for	O	O
the	O	O
biosynthesis	B-PHEN
of	O	O
an	O	O
unrelated	O	O
peptide	B-CHEM
,	O	O
surugamide	B-CHEM
F	I-CHEM
.	O	O

The	O	O
pattern	O	O
of	O	O
intercalation	B-PHYS
observed	O	O
in	O	O
the	O	O
sur	O
genes	O
is	O	O
unprecedented	O	O
.	O	O

The	O	O
structure	O
of	O	O
surugamide	B-CHEM
F	I-CHEM
,	O	O
a	O	O
linear	O	O
decapeptide	B-CHEM
containing	O	O
one	O	O
3	B-CHEM
-	I-CHEM
amino	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
methylpropionic	I-CHEM
acid	I-CHEM
(	O	O
AMPA	B-CHEM
)	O	O
residue	O
,	O	O
was	O	O
determined	O	O
by	O	O
spectroscopic	B-PROC
methods	I-PROC
and	O	O
was	O	O
confirmed	O	O
by	O	O
solid	O
-	O
phase	O
peptide	O
synthesis	O
.	O	O

An	O	O
ion	O	O
-	O	O
gating	O	O
multinanochannel	O	O
system	O	O
based	O	O
on	O	O
a	O	O
copper	B-CHEM
-	O	O
responsive	O
self	O
-	O	O
cleaving	O
DNAzyme	B-CHEM
We	O	O
developed	O	O
an	O	O
ion	O	O
-	O	O
gating	O	O
nanochannel	O	O
composite	O	O
system	O	O
by	O	O
immobilizing	O
a	O	O
Cu	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-	O	O
responsive	O
self	O
-	O	O
cleaving	O
DNAzyme	B-CHEM
into	O	O
PET	B-CHEM
conical	B-CHEM
multinanochannels	I-CHEM
,	O	O
which	O	O
could	O	O
control	O
the	O	O
ion	B-PHYS
transport	I-PHYS
by	O	O
regulating	B-PHEN
the	O	O
surface	O
charge	B-PHYS
density	O
of	O	O
the	O	O
channels	B-CHEM
.	O	O

Pain	B-DISO
and	O	O
alcohol	O
consumption	O
among	O	O
older	B-LIVB
adults	I-LIVB
:	O	O
findings	B-DISO
from	O	O
the	O	O
World	O
Health	O
Organization	O
Study	B-PROC
on	O	O
global	O
AGEing	B-PHYS
and	O	O
adult	B-LIVB
health	O
,	O	O
Wave	O	O
1	O	O
To	O	O
investigate	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
associations	O
between	O	O
self	B-PROC
-	I-PROC
reported	I-PROC
recent	O	O
pain	B-DISO
and	O	O
alcohol	O
use	O
/	O	O
abstinence	O
,	O	O
and	O	O
previous	O
-	O	O
day	O
pain	B-DISO
and	O	O
previous	O
-	O	O
week	O
alcohol	O
consumption	O
in	O	O
adults	B-LIVB
aged	O	O
50	O	O
+	O	O
in	O	O
six	O	O
low	B-DISO
-	O	O
and	O	O
middle	O
-	O
income	O
countries	B-GEOG
(	O	O
LMICs	B-GEOG
)	O	O
.	O	O

The	O	O
WHO	O
Study	B-PROC
on	O	O
global	O
AGEing	B-PHYS
and	O	O
adult	B-LIVB
health	O
(	O	O
SAGE	B-PROC
)	O	O
Wave	O	O
1	O	O
(	O	O
2007	O	O
-	O	O
2010	O	O
)	O	O
in	O	O
China	B-GEOG
,	O	O
Ghana	B-GEOG
,	O	O
India	B-GEOG
,	O	O
Mexico	B-GEOG
,	O	O
Russia	B-GEOG
and	O	O
South	B-GEOG
Africa	I-GEOG
is	O	O
the	O	O
data	O
source	O
.	O	O

Prevalence	O
of	O	O
alcohol	O
use	O
/	O	O
abstinence	O
is	O	O
reported	O	O
by	O	O
previous	O
-	O	O
day	O
and	O	O
previous	O
-	O	O
month	O
pain	B-DISO
.	O	O

Multinomial	O
logistic	B-PROC
regressions	I-PROC
(	O	O
crude	B-CHEM
and	O	O
adjusted	O	O
for	O	O
sex	B-PHYS
and	O	O
country	B-GEOG
)	O	O
tested	O
associations	O
between	O	O
recent	O	O
pain	B-DISO
and	O	O
alcohol	O
use	O
in	O	O
the	O	O
pooled	B-OBJC
multicountry	B-GEOG
sample	B-OBJC
.	O	O

Across	O	O
the	O	O
six	O	O
SAGE	B-PROC
countries	B-GEOG
,	O	O
about	O	O
one	O	O
-	O	O
third	O	O
of	O	O
respondents	B-LIVB
reported	O	O
alcohol	O
use	O
,	O	O
being	O	O
highest	O
in	O	O
Russia	B-GEOG
(	O	O
74	O	O
%	O	O
)	O	O
and	O	O
lowest	O
in	O	O
India	B-GEOG
(	O	O
16	O	O
%	O	O
)	O	O
.	O	O

Holding	O	O
the	O	O
effects	O
of	O	O
sex	B-PHYS
and	O	O
country	B-GEOG
constant	O
,	O	O
compared	O
with	O	O
abstainers	B-DISO
,	O	O
people	B-LIVB
with	O	O
previous	O
-	O	O
day	O
pain	B-DISO
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
previous	O
-	O	O
day	O
or	O	O
other	B-LIVB
users	I-LIVB
.	O	O

With	O	O
regard	O	O
to	O	O
the	O	O
quantity	O
and	O	O
frequency	O
of	O	O
alcohol	O
use	O
,	O	O
people	B-LIVB
with	O	O
previous	O
-	O	O
day	O
pain	B-DISO
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
non	B-DISO
-	I-DISO
heavy	I-DISO
drinkers	I-DISO
.	O	O

Overall	O	O
,	O	O
we	O	O
found	O	O
that	O	O
,	O	O
in	O	O
this	O	O
population	B-LIVB
of	O	O
older	B-LIVB
adults	I-LIVB
in	O	O
six	O	O
LMICs	B-GEOG
,	O	O
recent	O	O
pain	B-DISO
was	O	O
associated	O
with	O
moderate	O
use	O
of	O
alcohol	O
,	O	O
although	O	O
there	O	O
were	O	O
differences	O
between	O	O
countries	B-GEOG
.	O	O

The	O	O
findings	B-DISO
provide	O	O
a	O	O
platform	B-DEVI
for	O	O
country	B-GEOG
-	O	O
specific	O
research	B-PROC
to	O	O
better	O	O
understand	B-PHYS
bi	O
-	O
directional	O
associations	O
between	O	O
pain	B-DISO
and	O	O
alcohol	B-CHEM
in	O	O
older	B-LIVB
adults	I-LIVB
.	O	O

Extra	O	O
carbohydrate	B-CHEM
binding	I-CHEM
module	I-CHEM
contributes	O
to	O	O
the	O	O
processivity	O
and	O	O
catalytic	B-PHYS
activity	I-PHYS
of	O	O
a	O	O
non	B-CHEM
-	I-CHEM
modular	I-CHEM
hydrolase	I-CHEM
family	O	O
5	B-CHEM
endoglucanase	I-CHEM
from	O	O
Fomitiporia	B-LIVB
mediterranea	I-LIVB
MF3	I-LIVB
/	I-LIVB
22	I-LIVB
FmEG	B-CHEM
from	O	O
Fomitiporia	B-LIVB
mediterranea	I-LIVB
is	O	O
a	O	O
non	B-CHEM
-	I-CHEM
modular	I-CHEM
endoglucanase	I-CHEM
composed	O	O
of	O	O
a	O	O
24	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
extension	O
and	O	O
13	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
linker	B-CHEM
-	I-CHEM
like	I-CHEM
peptide	I-CHEM
at	O	O
the	O	O
N	O
-	O
terminus	O
and	O	O
a	O	O
312	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
GH5	O
catalytic	O
domain	O
(	O	O
CD	O
)	O	O
at	O	O
the	O	O
C	O
-	O
terminus	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
six	O	O
FmEG	B-CHEM
derivatives	O	O
with	O	O
deletion	O
of	O	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
fragments	I-CHEM
or	O	O
fusion	B-CHEM
with	O	O
an	O	O
extra	O	O
family	B-CHEM
1	I-CHEM
carbohydrate	I-CHEM
-	I-CHEM
binding	I-CHEM
module	I-CHEM
(	O	O
CBM1	B-CHEM
)	O	O
was	O	O
constructed	O	O
in	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
contribution	O
of	O	O
CBM1	B-CHEM
to	O	O
FmEG	B-CHEM
processivity	O
and	O	O
catalytic	B-PHYS
activity	I-PHYS
.	O	O

FmEG	B-CHEM
showed	O	O
a	O	O
weak	O	O
processivity	O
and	O	O
released	O	O
cellobiose	B-CHEM
(	O	O
G2	B-CHEM
)	O	O
and	O	O
cellotriose	B-CHEM
(	O	O
G3	B-CHEM
)	O	O
as	O	O
main	B-OBJC
end	I-OBJC
products	I-OBJC
,	O	O
and	O	O
cellotriose	B-CHEM
(	O	O
G4	B-CHEM
)	O	O
as	O	O
minor	B-OBJC
end	I-OBJC
product	I-OBJC
from	O	O
filter	B-DEVI
paper	I-DEVI
(	O	O
FP	B-DEVI
)	O	O
,	O	O
but	O	O
more	O	O
amount	O	O
of	O	O
G4	B-CHEM
was	O	O
released	O	O
from	O	O
regenerated	B-CHEM
amorphous	I-CHEM
cellulose	I-CHEM
(	O	O
RAC	B-CHEM
)	O	O
.	O	O

All	O	O
derivatives	B-CHEM
had	O	O
similar	O	O
activity	O	O
on	O	O
carboxymethylcellulose	B-CHEM
(	O	O
CMC	B-CHEM
)	O	O
with	O	O
the	O	O
same	O
optimal	O
pH	O
(	O	O
7	O	O
.	O	O
0	O	O
)	O	O
and	O	O
temperature	O
(	O	O
50°C	O	O
)	O	O
.	O	O

However	O	O
,	O	O
fusing	O	O
an	O	O
extra	O	O
CBM1	B-CHEM
to	O	O
FmEG△24	B-CHEM
or	O	O
FmEG△37	B-CHEM
with	O	O
flexible	B-CHEM
peptide	I-CHEM
significantly	O	O
improved	O	O
its	O	O
processivity	O
and	O	O
catalytic	O
activity	O
to	O	O
FP	B-DEVI
and	O	O
RAC	B-CHEM
.	O	O

Overall	O	O
,	O	O
1	O	O
.	O	O
79	O	O
-	O	O
and	O	O
1	O	O
.	O	O
84	O	O
-	O	O
fold	O	O
increases	O	O
in	O	O
the	O	O
soluble	O
/insoluble	O	O
product	O	O
ratio	O
on	O	O
FP	B-DEVI
,	O	O
and	O	O
1	O	O
.	O	O
38	O	O
-	O	O
and	O	O
1	O	O
.	O	O
39	O	O
-	O	O
fold	O	O
increases	O	O
on	O	O
RAC	B-CHEM
,	O	O
compared	O	O
to	O	O
FmEG△24	B-CHEM
,	O	O
were	O	O
recorded	O	O
for	O	O
CBM1	B-CHEM
-	O	O
FmEG△24	B-CHEM
and	O	O
CBM1	B-CHEM
-linker	O	O
-	O	O
FmEG△24	B-CHEM
,	O	O
respectively	O	O
.	O	O

Meanwhile	O	O
,	O	O
they	O	O
displayed	O	O
2	O	O
.	O	O
64	O	O
-	O	O
and	O	O
2	B-DISO
.	I-DISO
67	I-DISO
-	I-DISO
fold	I-DISO
more	I-DISO
activity	I-DISO
on	O	O
RAC	B-CHEM
,	O	O
and	O	O
1	O	O
.	O	O
68	O	O
-	O	O
and	O	O
1	O	O
.	O	O
77	O	O
-	O	O
fold	O	O
on	O	O
FP	B-DEVI
,	O	O
respectively	O	O
.	O	O

Similar	O	O
improvement	O	O
was	O	O
also	O	O
obtained	O	O
for	O	O
CBM1	B-CHEM
-linker	O	O
-	O	O
FmEG△37	B-CHEM
as	O	O
compared	O	O
with	O	O
FmEG△37	B-CHEM
.	O	O

Interestingly	O	O
,	O	O
fusion	O	O
of	O	O
an	O	O
extra	O	O
CBM1	B-CHEM
with	O	O
FmEG	B-CHEM
also	O	O
caused	O	O
an	O	O
alteration	O
of	O	O
cleavage	B-PHEN
pattern	I-PHEN
on	O	O
insoluble	B-CHEM
celluloses	I-CHEM
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
such	O	O
improvements	O	O
in	O	O
processivity	O
and	O	O
catalytic	O
activity	O
may	O	O
arise	O	O
from	O	O
CBM1	B-CHEM
binding	B-PHYS
affinity	I-PHYS
.	O	O

The	O	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
24	I-CHEM
-	I-CHEM
or	I-CHEM
37	I-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
may	O	O
serve	O	O
as	O	O
linker	O	O
for	O	O
sufficient	O	O
spatial	O
separation	O
of	O	O
the	O	O
two	O
domains	O
required	O	O
for	O	O
processivity	O
and	O	O
catalytic	O
activity	O
.	O	O

In	O	O
addition	O	O
,	O	O
deletion	O
of	O	O
the	O	O
N	B-CHEM
-	I-CHEM
terminal	I-CHEM
24	I-CHEM
-	I-CHEM
or	I-CHEM
37	I-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
led	O	O
to	O	O
significant	O
reduction	O
in	O	O
thermostability	B-PHEN
but	O	O
not	O	O
the	O	O
enzymatic	B-PHYS
activity	I-PHYS
.	O	O

Overnight	O
switching	B-PROC
from	O	O
oxcarbazepine	B-CHEM
to	O	O
eslicarbazepine	B-CHEM
acetate	I-CHEM
:	O	O
an	O	O
observational	B-PROC
study	I-PROC
There	O	O
are	O	O
clinical	B-PHEN
situations	I-PHEN
where	O	O
it	O	O
might	O	O
be	O	O
appropriate	O
to	O	O
switch	B-PROC
patients	B-LIVB
from	O	O
immediate	B-CHEM
-	I-CHEM
release	I-CHEM
oxcarbazepine	B-CHEM
(	O	O
OXC	B-CHEM
)	O	O
to	O	O
eslicarbazepine	B-CHEM
acetate	I-CHEM
(	O	O
ESL	B-CHEM
)	O	O
.	O	O

We	O	O
investigated	O
the	O	O
effects	O
of	O
transitioning	O	O
patients	B-LIVB
overnight	O
from	O	O
OXC	B-CHEM
to	O	O
ESL	B-CHEM
.	O	O

A	O	O
retrospective	B-PROC
,	O	O
single	B-PROC
-	I-PROC
center	I-PROC
study	I-PROC
was	O	O
conducted	O	O
in	O	O
which	O	O
patients	B-LIVB
with	O	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
focal	B-DISO
epilepsy	I-DISO
on	O	O
a	O	O
stable	O	O
dose	O
of	O	O
immediate	B-CHEM
-	I-CHEM
release	I-CHEM
OXC	B-CHEM
for	O	O
at	O	O
least	O	O
4	O
weeks	O
were	O	O
switched	B-PROC
overnight	O
to	O	O
ESL	B-CHEM
.	O	O

Patients	B-LIVB
were	O	O
switched	B-PROC
because	O	O
they	O	O
experienced	O	O
persistent	O
seizures	B-DISO
with	O	O
OXC	B-CHEM
but	O	O
were	O	O
unable	B-DISO
to	O	O
tolerate	O
increased	O	O
OXC	B-CHEM
dosing	O
due	O	O
to	O	O
adverse	B-DISO
events	I-DISO
.	O	O

Tolerability	O
was	O	O
assessed	O
using	O	O
the	O	O
Adverse	O
Events	O
Profile	O
(	O	O
AEP	O
)	O	O
,	O	O
quality	O
of	O
life	O
was	O	O
assessed	O
using	O	O
the	O	O
Quality	O
of	O
Life	O
in	O
Epilepsy	O
Inventory	O
10	O
(	O	O
QOLIE	O
-	O
10	O
)	O	O
,	O	O
and	O	O
alertness	B-PHYS
was	O	O
assessed	O
as	O	O
reaction	O
time	O
using	O	O
a	O	O
subtest	O	O
of	O	O
the	O	O
Test	B-OBJC
Battery	I-OBJC
for	I-OBJC
Attention	I-OBJC
Performance	I-OBJC
version	I-OBJC
2	I-OBJC
.	I-OBJC

3	I-OBJC
.	O	O

Assessments	B-PROC
were	O	O
performed	O
immediately	O
prior	O
to	O
and	O	O
5	O
days	O
after	O	O
switching	B-PROC
from	O	O
OXC	B-CHEM
to	O	O
ESL	B-CHEM
(	O	O
days	O
0	O	O
and	O	O
5	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
analysis	B-PROC
included	O	O
21	O	O
patients	B-LIVB
(	O	O
12	O	O
women	B-LIVB
,	O	O
9	O	O
men	B-LIVB
;	O	O
mean	B-DISO
age	I-DISO
36	I-DISO
years	I-DISO
)	O	O
.	O	O

After	O	O
switching	B-PROC
from	O	O
OXC	B-CHEM
to	O	O
ESL	B-CHEM
,	O	O
there	O	O
were	O	O
significant	O	O
improvements	O
in	O	O
mean	O
scores	O
for	O	O
AEP	O
(	O	O
P	O	O
<	O	O
.	O	O
001	O	O
)	O	O
,	O	O
QOLIE	O
-	O
10	O
(	O	O
P	O	O
=	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
alertness	B-PHYS
(	O	O
P	O	O
<	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Adverse	O
Events	O
Profile	O
total	O
scores	O
improved	B-DISO
for	O	O
21	O	O
/	O	O
21	O	O
(	O	O
100	O	O
.	O	O
0	O	O
%	O	O
)	O	O
patients	B-LIVB
,	O	O
QOLIE	O
-	O
10	O
total	O
scores	O
improved	B-DISO
for	O	O
17	O	O
/	O	O
21	O	O
(	O	O
81	O	O
.	O	O
0	O	O
%	O	O
)	O	O
patients	B-LIVB
,	O	O
and	O	O
alertness	B-PHYS
scores	O
improved	B-DISO
for	O	O
16	O	O
/	O	O
21	O	O
(	O	O
76	O	O
.	O	O
2	O	O
%	O	O
)	O	O
patients	B-LIVB
.	O	O

In	O	O
this	O	O
short	O
-	O
term	O
,	O	O
single	B-PROC
-	I-PROC
center	I-PROC
study	I-PROC
,	O	O
an	O	O
overnight	O
switch	B-PROC
from	O	O
twice	O
-	O
daily	O
OXC	B-CHEM
to	O	O
once	O
-	O
daily	O
ESL	B-CHEM
in	O	O
patients	B-LIVB
with	O	O
drug	B-PHEN
-	I-PHEN
resistant	I-PHEN
focal	B-DISO
epilepsies	I-DISO
resulted	B-DISO
in	O	O
improvements	O
in	O	O
side	B-DISO
effects	I-DISO
,	O	O
quality	O
of	O
life	O
,	O	O
and	O	O
alertness	B-PHYS
.	O	O

Pregnancy	B-PHYS
at	O	O
high	B-PHEN
altitude	I-PHEN
in	O	O
the	O	O
Andes	B-GEOG
leads	O	O
to	O	O
increased	O
total	O
vessel	O
density	O
in	O	O
healthy	O
newborns	B-LIVB
The	O	O
developing	O	O
human	B-LIVB
fetus	B-ANAT
is	O	O
able	O	O
to	O	O
cope	O	O
with	O	O
the	O	O
physiological	O
reduction	O
in	O	O
oxygen	B-PHEN
supply	I-PHEN
occurring	O
in	B-LIVB
utero	I-LIVB
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
not	O	O
known	O	O
if	O	O
microvascularization	O
of	O	O
the	O	O
fetus	B-ANAT
is	O	O
augmented	O	O
when	O	O
pregnancy	B-PHYS
occurs	O
at	O	O
high	B-PHEN
altitude	I-PHEN
.	O	O

Fifty	O	O
-	O	O
three	O	O
healthy	B-LIVB
term	I-LIVB
newborns	I-LIVB
in	O	O
Puno	O
,	O	O
Peru	B-GEOG
(	O	O
3	O	O
,	O	O
840	O	O
m	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
sea	B-GEOG
-	O	O
level	O
controls	B-LIVB
.	O	O

Pre	B-PHEN
-	I-PHEN
and	I-PHEN
postductal	I-PHEN
arterial	I-PHEN
oxygen	I-PHEN
saturation	I-PHEN
(	O	O
SpO2	B-PHEN
)	O	O
was	O	O
determined	O	O
.	O	O

Cerebral	B-ANAT
and	O	O
calf	B-ANAT
muscle	I-ANAT
regional	O
tissue	B-PHYS
oxygenation	I-PHYS
was	O	O
measured	O
using	O	O
near	B-PROC
infrared	I-PROC
spectroscopy	I-PROC
(	O	O
NIRS	B-PROC
)	O	O
.	O	O

Skin	B-ANAT
microcirculation	B-PHYS
was	O	O
noninvasively	B-PROC
measured	O
using	O	O
incident	B-PROC
dark	I-PROC
field	I-PROC
imaging	I-PROC
.	O	O

Pre	B-PHEN
-	I-PHEN
and	I-PHEN
postductal	I-PHEN
SpO2	I-PHEN
in	O	O
Peruvian	B-LIVB
babies	B-LIVB
was	O	O
88	O	O
.	O	O
1	O	O
and	O	O
88	O	O
.	O	O

4	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
which	O	O
was	O	O
10	O	O
.	O	O
4	O	O
and	O	O
9	O	O
.	O	O

7	O	O
%	O	O
lower	O
than	O	O
in	O	O
newborns	B-LIVB
at	O	O
sea	B-GEOG
level	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Cerebral	B-ANAT
and	O	O
regional	O
oxygen	B-PHYS
saturation	I-PHYS
was	O	O
significantly	O	O
lower	O
in	O	O
the	O	O
Peruvian	B-LIVB
newborns	B-LIVB
(	O	O
cerebral	B-ANAT
:	O	O
71	O	O
.	O	O
0	O	O
vs	O	O
.	O	O

74	O	O
.	O	O
9	O	O
%	O	O
;	O	O
regional	O
:	O	O
68	O	O
.	O	O
5	O	O
vs	O	O
.	O	O

76	O	O
.	O	O
0	O	O
%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Transcutaneously	O
measured	O
total	O
vessel	O
density	O
in	O	O
the	O	O
Peruvian	B-LIVB
newborns	B-LIVB
was	O	O
14	O	O
%	O	O
higher	O
than	O	O
that	O	O
in	O	O
the	O	O
newborns	B-LIVB
born	B-PHYS
at	O	O
sea	B-GEOG
level	O
(	O	O
29	O	O
.	O	O
7	O	O
vs	O	O
.	O	O

26	O	O
.	O	O
0	O	O
mm	O	O
/	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
;	O	O
P	O	O
≤	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

This	O	O
study	B-PROC
demonstrates	O	O
that	O	O
microvascular	O
vessel	O
density	O
in	O	O
neonates	B-LIVB
born	B-PHYS
to	O	O
mothers	B-LIVB
living	O
at	O	O
high	B-PHEN
altitude	I-PHEN
is	O	O
higher	O
than	O	O
that	O	O
in	O	O
neonates	B-LIVB
born	B-PHYS
at	O	O
sea	B-GEOG
level	O
.	O	O

Morphological	O
and	O	O
enzymatic	B-PHYS
response	I-PHYS
of	O	O
the	O	O
thermotolerant	B-PHYS
fungus	B-LIVB
Fomes	B-LIVB
sp	I-LIVB
.	I-LIVB

EUM1	I-LIVB
in	O	O
solid	B-PHYS
state	I-PHYS
fermentation	I-PHYS
under	O	O
thermal	O
stress	B-DISO
Thermotolerance	B-PHYS
of	O	O
the	O	O
fungus	B-LIVB
Fomes	B-LIVB
sp	I-LIVB
.	I-LIVB

EUM1	I-LIVB
was	O	O
evaluated	O	O
in	O	O
solid	B-PHYS
state	I-PHYS
fermentation	I-PHYS
(	O	O
SSF	B-PHYS
)	O	O
.	O	O

This	O	O
thermotolerant	B-PHYS
strain	B-LIVB
improved	O	O
both	O	O
hyphal	B-LIVB
invasiveness	O
(	O	O
38	O	O
%	O	O
)	O	O
and	O	O
length	O
(	O	O
17	O	O
%	O	O
)	O	O
in	O	O
adverse	O
thermal	O
conditions	O
exceeding	O	O
30°C	O	O
and	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
40°C	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
hyphal	B-PHYS
branching	I-PHYS
decreased	O
by	O	O
46	O	O
%	O	O
at	O	O
45°C	O	O
.	O	O

The	O	O
production	O
of	O	O
cellulases	B-CHEM
over	O	O
corn	B-LIVB
stover	I-LIVB
increased	O
1	O	O
.	O	O

6	O	O
-	O	O
fold	O	O
in	O	O
30°C	O	O
culture	B-CHEM
conditions	O
,	O	O
xylanases	B-CHEM
increased	O
2	O	O
.	O	O
8	O	O
-	O	O
fold	O	O
at	O	O
40°C	O	O
,	O	O
while	O	O
laccase	B-CHEM
production	O
improved	O	O
2	O	O
.	O	O

7	O	O
-	O	O
fold	O	O
at	O	O
35°C	O	O
.	O	O

Maximum	O	O
production	O
of	O	O
lignocellulolytic	B-CHEM
enzymes	I-CHEM
was	O	O
obtained	O	O
at	O	O
elevated	O
temperatures	O
in	O	O
shorter	O	O
fermentation	B-PHYS
times	O
(	O	O
8	O	O
to	O	O
6	O	O
days	O
)	O	O
,	O	O
although	O	O
the	O	O
proteases	B-CHEM
appeared	O	O
as	O	O
a	O	O
thermal	O
stress	B-DISO
response	B-PHYS
associated	O
with	O
a	O	O
drop	O	O
in	O	O
lignocellulolytic	B-PHYS
activities	I-PHYS
.	O	O

Novel	O	O
and	O	O
multiple	O	O
isoenzymes	B-CHEM
of	O	O
xylanase	B-CHEM
(	O	O
four	O	O
bands	O	O
)	O	O
and	O	O
cellulase	B-CHEM
(	O	O
six	O	O
bands	O	O
)	O	O
were	O	O
secreted	O	O
in	O	O
the	O	O
range	O	O
of	O	O
20	O	O
-	O	O
150	O	O
kDa	O	O
during	O	O
growth	B-PHYS
in	O	O
adverse	O
temperature	O
conditions	O
.	O	O

However	O	O
,	O	O
only	O	O
a	O	O
single	O	O
laccase	B-CHEM
isoenzyme	B-CHEM
(	O	O
46	O	O
kDa	O	O
)	O	O
was	O	O
detected	B-DISO
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O
describing	O	O
the	O	O
advantages	O	O
of	O	O
a	O	O
thermotolerant	B-PHYS
white	B-LIVB
-	I-LIVB
rot	I-LIVB
fungus	I-LIVB
in	O	O
SSF	B-PHYS
.	O	O

These	O	O
results	O
have	O	O
important	O	O
implications	O	O
for	O	O
large	B-PHYS
-	I-PHYS
scale	I-PHYS
SSF	I-PHYS
,	O	O
where	O	O
effects	O
of	O	O
metabolic	B-PHYS
heat	B-PHEN
are	O	O
detrimental	O
to	O	O
growth	B-PHYS
and	O	O
enzyme	B-CHEM
production	O
,	O	O
which	O	O
are	O	O
severely	O	O
affected	O
by	O	O
the	O	O
formation	O
of	O	O
high	O	O
temperature	O
gradients	O
.	O	O

Complete	O
Genome	O
Sequences	O
of	O	O
Three	O	O
Outbreak	B-PHEN
-Associated	O	O
Legionella	B-LIVB
pneumophila	I-LIVB
Isolates	B-CHEM
We	O	O
report	O	O
here	O	O
the	O	O
complete	O
genome	O
sequences	O
of	O	O
three	O	O
Legionella	B-LIVB
pneumophila	I-LIVB
isolates	B-CHEM
that	O	O
are	O	O
associated	O
with	O
a	O	O
Legionnaires	B-DISO
'	I-DISO
disease	I-DISO
outbreak	B-PHEN
in	O	O
New	B-GEOG
York	I-GEOG
in	O	O
2012	O	O
.	O	O

Two	O	O
clinical	O
isolates	B-CHEM
(	O	O
D7630	B-LIVB
and	O	O
D7632	B-LIVB
)	O	O
and	O	O
one	O	O
environmental	O
isolate	B-CHEM
(	O	O
D7631	B-LIVB
)	O	O
were	O	O
recovered	O
from	O	O
this	O	O
outbreak	B-PHEN
.	O	O

A	O	O
single	O	O
isolate	B-CHEM
-	I-CHEM
specific	I-CHEM
virulence	B-PHEN
gene	O
was	O	O
found	O	O
in	O	O
D7632	B-LIVB
.	O	O

These	O	O
isolates	B-CHEM
were	O	O
included	O	O
in	O	O
a	O	O
large	O	O
study	O	O
evaluating	B-PROC
the	O	O
genomic	O
resolution	O
of	O	O
various	O	O
bioinformatics	O
approaches	O
for	O	O
L	B-LIVB
.	I-LIVB

pneumophila	I-LIVB
serogroup	O
1	O
isolates	B-CHEM
.	O	O

Complete	O	O
Genome	B-PROC
Sequence	I-PROC
Analysis	I-PROC
of	O	O
a	O	O
Naturally	O	O
Reassorted	O	O
Infectious	B-LIVB
Bursal	I-LIVB
Disease	I-LIVB
Virus	I-LIVB
from	O	O
India	B-GEOG
The	O	O
novel	O	O
infectious	B-LIVB
bursal	I-LIVB
disease	I-LIVB
virus	I-LIVB
(	O	O
IBDV	B-LIVB
)	O	O
isolate	B-CHEM
BGE14	B-LIVB
/	I-LIVB
ABT1	I-LIVB
/	I-LIVB
MVC	I-LIVB
/	I-LIVB
India	I-LIVB
is	O	O
a	O	O
very	O	O
virulent	O
IBDV	B-LIVB
that	O	O
was	O	O
isolated	B-CHEM
from	O	O
broiler	B-LIVB
flocks	I-LIVB
in	O	O
southern	O	O
parts	O	O
of	O	O
India	B-GEOG
during	O	O
2014	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
India	B-GEOG
,	O	O
the	O	O
complete	O	O
genome	O
sequence	O
of	O	O
BGE14	B-LIVB
/	I-LIVB
ABT1	I-LIVB
/	I-LIVB
MVC	I-LIVB
/	I-LIVB
India	I-LIVB
,	O	O
a	O	O
reassortment	O	O
strain	B-LIVB
with	O	O
segments	O
A	O
and	O
B	O
derived	O	O
from	O	O
a	O	O
very	O	O
virulent	O
IBDV	B-LIVB
strain	B-LIVB
and	O	O
an	O	O
attenuated	O
IBDV	B-LIVB
,	O	O
respectively	O	O
.	O	O

The	O	O
findings	O	O
from	O	O
this	O	O
study	O	O
provide	O	O
additional	O	O
insight	O	O
into	O	O
the	O	O
genetic	B-PHYS
exchange	I-PHYS
between	O	O
attenuated	O
and	O	O
very	O	O
virulent	O
strains	B-LIVB
of	O	O
IBDV	B-LIVB
circulating	O
in	O
the	O
field	O
.	O	O

Brood	O
size	O
constrains	O
the	O	O
development	O
of	O	O
endothermy	B-PHYS
in	O	O
blue	B-LIVB
tits	I-LIVB
Altricial	B-LIVB
birds	I-LIVB
are	O	O
unable	B-DISO
to	O	O
maintain	O
body	B-PHYS
temperature	I-PHYS
when	O	O
exposed	O
to	O	O
low	O
ambient	B-PHEN
temperatures	I-PHEN
during	O	O
the	O	O
first	O	O
days	O
after	O	O
hatching	B-PHYS
.	O	O

Thermoregulatory	B-PHYS
capacity	O	O
begins	O	O
to	O	O
form	O	O
as	O	O
postnatal	O
development	O
progresses	O
,	O	O
and	O	O
eventually	O	O
nestlings	B-LIVB
become	O	O
homeothermic	B-PHYS
.	O	O

Several	O	O
factors	O
may	O	O
influence	O
this	O	O
development	O
at	O	O
both	O	O
the	O	O
level	O
of	O	O
the	O	O
individual	O
and	O	O
the	O	O
level	O
of	O	O
the	O	O
whole	O
brood	B-LIVB
,	O	O
but	O	O
to	O	O
our	O	O
knowledge	O	O
no	O	O
studies	O	O
have	O	O
focused	O	O
on	O	O
the	O	O
effect	O
of	O	O
brood	O
size	O
per	O	O
se	O	O
on	O	O
the	O	O
development	O
of	O	O
endothermy	B-PHYS
in	O	O
individual	O
nestlings	B-LIVB
.	O	O

We	O	O
performed	O
cooling	B-PHEN
experiments	B-PROC
on	O	O
blue	B-LIVB
tit	I-LIVB
(	O	O
Cyanistes	B-LIVB
caeruleus	I-LIVB
)	O	O
nestlings	B-LIVB
in	O	O
the	O	O
field	O	O
,	O	O
to	O	O
study	O	O
how	O	O
different	O
experimental	O
brood	O
sizes	O
affected	O
the	O	O
development	O
of	O	O
endothermy	B-PHYS
in	O	O
individual	O
nestlings	B-LIVB
and	O	O
the	O	O
thermal	B-PHEN
environment	I-PHEN
experienced	O	O
by	O	O
the	O	O
whole	O
brood	B-LIVB
in	O	O
the	O	O
nest	O
.	O	O

Nestlings	B-LIVB
from	O	O
all	O	O
experimental	O
brood	O
sizes	O
showed	O	O
a	O	O
decrease	O
in	O	O
cooling	B-PHEN
rate	O
as	O	O
they	O	O
grew	O
older	O
,	O	O
but	O	O
birds	B-LIVB
from	O	O
reduced	O
broods	B-LIVB
showed	O	O
an	O	O
earlier	O
onset	O	O
of	O	O
endothermy	B-PHYS
compared	O
with	O	O
nestlings	B-LIVB
from	O	O
enlarged	O
and	O	O
control	B-LIVB
broods	B-LIVB
.	O	O

This	O	O
difference	O
manifested	O
during	O	O
early	O
development	O
and	O	O
gradually	O	O
disappeared	O
as	O	O
nestlings	B-LIVB
grew	O
older	O
.	O	O

The	O	O
thermal	B-PHEN
environment	I-PHEN
in	O	O
the	O	O
nests	O
differed	O	O
between	O	O
treatments	O	O
during	O	O
nestling	B-LIVB
development	O
,	O	O
such	O	O
that	O	O
nest	O
temperature	O
in	O	O
reduced	O
broods	B-LIVB
was	O	O
lower	O
than	O	O
that	O	O
in	O	O
enlarged	O
broods	B-LIVB
during	O	O
all	O	O
days	O
and	O	O
during	O	O
nights	O
at	O	O
the	O	O
end	O
of	O	O
the	O	O
experimental	O
period	O
.	O	O

We	O	O
suggest	O	O
that	O	O
the	O	O
development	O
of	O	O
endothermy	B-PHYS
in	O	O
blue	B-LIVB
tit	I-LIVB
nestlings	B-LIVB
is	O	O
not	O	O
ontogenetically	O	O
fixed	O	O
,	O	O
but	O	O
instead	O	O
may	O	O
vary	O	O
according	O	O
to	O	O
differences	O
in	O	O
developmental	B-PHYS
,	O	O
nutritional	B-DISO
and	O	O
thermal	B-PHEN
conditions	I-PHEN
as	O	O
determined	O
by	O
brood	O
size	O
.	O	O

Elevated	O
Plasma	B-ANAT
Level	O
of	O	O
Interferon	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O	O
Chronic	B-DISO
Spontaneous	I-DISO
Urticaria	I-DISO
:	O	O
Upregulated	B-PHYS
Expression	B-PHYS
in	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
and	O	O
Epithelial	B-ANAT
Cells	I-ANAT
and	O	O
Induction	O
of	O	O
Inflammatory	B-ANAT
Cell	I-ANAT
Accumulation	B-DISO
Interferon	B-CHEM
-	I-CHEM
(	I-CHEM
IFN	I-CHEM
-	I-CHEM
)	I-CHEM
λ1	I-CHEM
is	O	O
regarded	O	O
as	O	O
a	O	O
potent	O	O
bio	B-OBJC
-	I-OBJC
active	I-OBJC
molecule	I-OBJC
in	O	O
innate	B-PHYS
immunity	I-PHYS
.	O	O

However	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
its	O	O
role	O	O
in	O	O
chronic	B-DISO
spontaneous	I-DISO
urticaria	I-DISO
(	O	O
CSU	B-DISO
)	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O
expression	B-PHYS
of	O	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O	O
CSU	B-DISO
,	O	O
its	O	O
cellular	B-ANAT
location	I-ANAT
,	O	O
and	O	O
its	O	O
influence	O	O
on	O	O
inflammatory	B-ANAT
cell	I-ANAT
accumulation	B-DISO
by	O	O
using	O	O
flow	B-PROC
cytometry	I-PROC
analysis	I-PROC
,	O	O
skin	O
tissue	O
dispersion	O
,	O	O
immunohistochemical	B-PROC
stain	I-PROC
,	O	O
and	O	O
a	O	O
mouse	B-LIVB
peritoneal	B-DISO
inflammation	I-DISO
model	B-DISO
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
level	O	O
of	O	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
was	O	O
2	O	O
.	O	O
0	O	O
-	O	O
fold	O	O
higher	O
in	O	O
plasma	B-ANAT
of	O	O
the	O	O
patients	B-LIVB
with	O	O
CSU	B-DISO
than	O	O
the	O	O
level	O
in	O	O
healthy	O
control	O
(	O	O
HC	O
)	O	O
subjects	B-LIVB
.	O	O

Among	O	O
leukocytes	B-ANAT
examined	O	O
,	O	O
only	O	O
CD8	B-ANAT
(	I-ANAT
+	I-ANAT
)	I-ANAT
T	I-ANAT
cells	I-ANAT
expressed	B-PHYS
more	O	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
in	O	O
CSU	B-DISO
blood	B-ANAT
.	O	O

Double	B-PROC
labeling	I-PROC
immunohistochemical	I-PROC
staining	I-PROC
revealed	O	O
that	O	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
(	O	O
+	O	O
)	O	O
inflammatory	B-ANAT
cells	I-ANAT
such	O	O
as	O	O
mast	B-ANAT
cells	I-ANAT
,	O	O
eosinophils	B-ANAT
,	O	O
B	B-ANAT
cells	I-ANAT
,	O	O
neutrophils	B-ANAT
,	O	O
and	O	O
macrophages	B-ANAT
were	O	O
mainly	O	O
located	B-ANAT
in	O	O
dermis	O
,	O	O
whereas	O	O
epidermis	O
tissue	O
highly	O	O
expressed	B-PHYS
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
.	O	O

IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
induced	O
a	O	O
dose	O
-	O
dependent	O
increase	O
in	O	O
number	O	O
of	O	O
eosinophils	B-ANAT
,	O	O
lymphocytes	B-ANAT
,	O	O
mast	B-ANAT
cells	I-ANAT
,	O	O
macrophages	B-ANAT
,	O	O
and	O	O
neutrophils	B-ANAT
in	O	O
the	O	O
peritoneum	O
of	O	O
mice	B-LIVB
at	O	O
6	O	O
h	O	O
following	O	O
injection	B-CHEM
,	O	O
which	O	O
was	O	O
inhibited	O
by	O	O
pretreatment	O
of	O	O
the	O	O
animals	B-LIVB
with	O	O
anti	B-CHEM
-	I-CHEM
intercellular	I-CHEM
adhesion	I-CHEM
molecule	I-CHEM
-	I-CHEM
(	I-CHEM
ICAM	I-CHEM
-	I-CHEM
)	I-CHEM
1	I-CHEM
and	O	O
/	O	O
or	O	O
anti	B-CHEM
-	I-CHEM
L	I-CHEM
-	I-CHEM
selectin	I-CHEM
antibodies	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
is	O	O
likely	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
CSU	B-DISO
.	O	O

Blocking	O
IFN	B-CHEM
-	I-CHEM
λ1	I-CHEM
production	O
may	O	O
help	O	O
to	O	O
reduce	O
the	O	O
accumulation	B-DISO
of	O	O
inflammatory	B-ANAT
cells	I-ANAT
in	O	O
the	O	O
involved	O	O
CSU	B-DISO
skin	B-ANAT
.	O	O

Patient	O
Satisfaction	O
With	O	O
Postpartum	O
Teaching	B-PROC
Methods	O
Postpartum	O
discharge	O
instructions	O
are	O	O
a	O	O
crucial	O	O
part	O	O
of	O	O
a	O	O
mother	B-LIVB
's	I-LIVB
birth	B-PHYS
experience	B-PHYS
.	O	O

Finding	B-DISO
the	O	O
method	O
to	O	O
provide	O	O
those	O	O
discharge	O
instructions	O
in	O	O
a	O	O
manner	O	O
that	O	O
increases	O
the	O	O
mother	B-LIVB
's	I-LIVB
satisfaction	B-PHYS
with	O	O
her	O	O
hospital	B-OBJC
experience	B-PHYS
is	O	O
important	O	O
.	O	O

This	O	O
quasi	B-PROC
-	I-PROC
experimental	I-PROC
study	I-PROC
examined	B-DISO
the	O	O
relationship	O
between	O	O
new	O
mothers	B-LIVB
'	I-LIVB
interaction	B-DISO
with	O	O
nurses	B-LIVB
providing	O	O
postpartum	O
instructions	O
by	O	O
the	O	O
traditional	O
and	O	O
class	O	O
methods	O
and	O	O
their	O	O
satisfaction	B-PHYS
with	O	O
discharge	B-PROC
teaching	I-PROC
.	O	O

The	O	O
results	O	O
indicated	O	O
new	O
mothers	B-LIVB
were	O	O
satisfied	B-PHYS
with	O	O
both	O	O
methods	O
of	O	O
discharge	B-PROC
teaching	I-PROC
;	O	O
however	O	O
,	O	O
they	O	O
were	O	O
more	O	O
likely	O	O
to	O	O
report	O	O
stronger	O	O
agreement	O
with	O	O
overall	O	O
satisfaction	B-PHYS
with	O	O
the	O	O
traditional	O
method	O
of	O	O
discharge	B-PROC
teaching	I-PROC
than	O	O
with	O	O
attending	O
the	O	O
discharge	B-PROC
class	I-PROC
.	O	O

High	O
-	O
Intensity	O
Intermittent	O
Training	O
Positively	B-DISO
Affects	O
Aerobic	B-PROC
and	O	O
Anaerobic	O
Performance	O
in	O	O
Judo	O
Athletes	B-LIVB
Independently	O	O
of	O	O
Exercise	O
Mode	O
The	O	O
present	O	O
study	O	O
investigated	O	O
the	O	O
effects	O
of	O	O
high	O
-	O
intensity	O
intermittent	O
training	O
(	O	O
HIIT	O
)	O	O
on	O	O
lower	B-ANAT
-	O	O
and	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
graded	O
exercise	O
and	O	O
high	O
-	O
intensity	O
intermittent	O
exercise	O
(	O	O
HIIE	O
,	O	O
four	O	O
Wingate	O	O
bouts	O	O
)	O	O
performance	O
,	O	O
and	O	O
on	O	O
physiological	O
and	O	O
muscle	B-DISO
damage	I-DISO
markers	B-DISO
responses	I-DISO
in	O	O
judo	O
athletes	B-LIVB
.	O	O

Thirty	O	O
-	O	O
five	O	O
subjects	B-LIVB
were	O	O
randomly	B-PROC
allocated	I-PROC
to	O	O
a	O	O
control	B-LIVB
group	I-LIVB
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
or	O	O
to	O	O
one	O	O
of	O	O
the	O	O
following	O	O
HIIT	O
groups	O
(	O	O
n	O	O
=	O	O
9	O	O
for	O	O
each	O	O
)	O	O
and	O	O
tested	O
pre	O
-	O
and	O
post	O
-four	O	O
weeks	O	O
(	O	O
2	O	O
training	O	O
d·wk	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
:	O	O
(	O	O
1	O	O
)	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
cycle	B-PROC
-	I-PROC
ergometer	I-PROC
;	O	O
(	O	O
2	O	O
)	O	O
upper	O	O
-	O	O
body	O	O
cycle	B-PROC
-	I-PROC
ergometer	I-PROC
;	O	O
(	O	O
3	O	O
)	O	O
uchi	O
-	O
komi	O
(	O	O
judo	O
technique	O
entrance	O
)	O	O
.	O	O

All	O	O
HIIT	O
were	O	O
constituted	O	O
by	O	O
two	O	O
blocks	O	O
of	O	O
10	O	O
sets	O	O
of	O	O
20	O	O
s	O	O
of	O	O
all	O	O
out	O	O
effort	O	O
interspersed	O	O
by	O	O
10	O	O
s	O	O
set	O	O
intervals	O	O
and	O	O
5	O	O
-	O	O
min	O	O
between	O	O
blocks	O	O
.	O	O

For	O	O
the	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
group	O
there	O	O
was	O	O
an	O	O
increase	O
in	O	O
maximal	B-PHYS
aerobic	I-PHYS
power	I-PHYS
in	O	O
graded	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
exercise	B-DISO
test	I-DISO
(	O	O
12	O	O
.	O	O

3	O	O
%	O	O
)	O	O
.	O	O

The	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
group	O
increased	O
power	B-PHYS
at	O	O
onset	B-CHEM
blood	I-CHEM
lactate	I-CHEM
in	O	O
graded	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
exercise	B-DISO
test	I-DISO
(	O	O
22	O	O
.	O	O
1	O	O
%	O	O
)	O	O
.	O	O

The	O	O
uchi	O
-	O
komi	O
group	O
increased	O
peak	O	O
power	O	O
in	O	O
upper	B-ANAT
-	O	O
(	O	O
16	O	O
.	O	O
7	O	O
%	O	O
)	O	O
and	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
(	O	O
8	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
while	O	O
the	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
group	O	O
increased	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
mean	O	O
power	O	O
(	O	O
14	O	O
.	O	O
2	O	O
%	O	O
)	O	O
during	O	O
the	O	O
HIIE	O
.	O	O

There	O	O
was	O	O
a	O	O
decrease	O
in	O	O
the	O	O
delta	B-CHEM
blood	I-CHEM
lactate	I-CHEM
for	O	O
the	O	O
uchi	B-PROC
-	I-PROC
komi	I-PROC
training	I-PROC
group	O
and	O	O
in	O	O
the	O	O
third	O	O
and	O	O
fourth	O	O
bouts	O	O
for	O	O
the	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
training	B-PROC
group	O
.	O	O

Training	B-PROC
induced	O	O
testosterone	O
-	O
cortisol	O
ratio	O
increased	O
in	O	O
the	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
HIIE	O
for	O	O
the	O	O
lower	B-ANAT
-	I-ANAT
body	I-ANAT
(	O	O
14	O	O
.	O	O
9	O	O
%	O	O
)	O	O
and	O	O
uchi	B-PROC
-	I-PROC
komi	I-PROC
(	I-PROC
61	I-PROC
.	I-PROC

4	I-PROC
%	I-PROC
)	I-PROC
training	I-PROC
groups	O
.	O	O

Thus	O	O
,	O	O
short	O
-	O
duration	O
low	O	O
-	O	O
volume	O	O
HIIT	O
added	O	O
to	O	O
regular	B-PROC
judo	I-PROC
training	I-PROC
was	O	O
able	O	O
to	O	O
increase	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
aerobic	B-PHYS
power	I-PHYS
,	O	O
lower	B-ANAT
-	O	O
and	O	O
upper	B-ANAT
-	I-ANAT
body	I-ANAT
HIIE	O
performance	O
.	O	O

Translating	O
Neurocognitive	O
Models	O
of	O	O
Auditory	B-DISO
-	I-DISO
Verbal	I-DISO
Hallucinations	I-DISO
into	O	O
Therapy	O
:	O	O
Using	O	O
Real	O
-	O
time	O
fMRI	B-PROC
-	O	O
Neurofeedback	B-PROC
to	O	O
Treat	O	O
Voices	B-PHYS
Auditory	B-DISO
-	I-DISO
verbal	I-DISO
hallucinations	I-DISO
(	O	O
AVHs	B-DISO
)	O	O
are	O	O
frequent	O	O
and	O	O
disabling	O	O
symptoms	B-DISO
,	O	O
which	O	O
can	O	O
be	O	O
refractory	O	O
to	O	O
conventional	O	O
psychopharmacological	O
treatment	O
in	O	O
more	O	O
than	O	O
25	O	O
%	O	O
of	O	O
the	O	O
cases	O	O
.	O	O

Recent	O	O
advances	O	O
in	O	O
brain	B-PROC
imaging	I-PROC
allow	O	O
for	O	O
a	O	O
better	O	O
understanding	O	O
of	O	O
the	O	O
neural	O
underpinnings	O	O
of	O	O
AVHs	B-DISO
.	O	O

These	O	O
findings	O	O
strengthened	O	O
transdiagnostic	O
neurocognitive	O
models	O
that	O	O
characterize	O	O
these	O	O
frequent	O	O
and	O	O
disabling	O	O
experiences	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O
,	O	O
technical	O	O
improvements	O	O
in	O	O
real	O
-	O
time	O
functional	B-PROC
magnetic	I-PROC
resonance	I-PROC
imaging	I-PROC
(	O	O
fMRI	B-PROC
)	O	O
enabled	O	O
the	O	O
development	O
of	O	O
innovative	O	O
and	O	O
non	O
-	O
invasive	O
methods	O	O
with	O	O
the	O	O
potential	O	O
to	O	O
relieve	O
psychiatric	B-DISO
symptoms	I-DISO
,	O	O
such	O	O
as	O	O
fMRI	B-PROC
-based	O	O
neurofeedback	B-PROC
(	O	O
fMRI	B-PROC
-	O	O
NF	B-PROC
)	O	O
.	O	O

During	O	O
fMRI	B-PROC
-	O	O
NF	B-PROC
,	O	O
brain	B-PHYS
activity	I-PHYS
is	O	O
measured	O	O
and	O	O
fed	O	O
back	O	O
in	O	O
real	O
time	O
to	O	O
the	O	O
participant	B-LIVB
in	O	O
order	O	O
to	O	O
help	O	O
subjects	B-LIVB
to	O	O
progressively	O	O
achieve	O	O
voluntary	B-PHYS
control	I-PHYS
over	O	O
their	O	O
own	O	O
neural	B-PHYS
activity	I-PHYS
.	O	O

Precisely	O	O
defining	O	O
the	O	O
target	O
brain	B-ANAT
area	I-ANAT
/	O	O
network	O
(	O
s	O
)	O
appears	O	O
critical	O	O
in	O	O
fMRI	B-PROC
-	O	O
NF	B-PROC
protocols	O
.	O	O

After	O	O
reviewing	O	O
the	O	O
available	O	O
neurocognitive	O
models	O
for	O	O
AVHs	B-DISO
,	O	O
we	O	O
elaborate	O	O
on	O	O
how	O	O
recent	O	O
findings	B-DISO
in	O	O
the	O	O
field	O	O
may	O	O
help	O	O
to	O	O
develop	O	O
strong	O	O
a	O	O
priori	O	O
strategies	B-PHYS
for	O	O
fMRI	B-PROC
-	O	O
NF	B-PROC
target	O
localization	O
.	O	O

The	O	O
first	O	O
approach	O	O
relies	O	O
on	O	O
imaging	B-PROC
-based	O	O
""""	O	O
trait	B-PHYS
markers	B-PHYS
""""	O	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
persistent	O	O
traits	B-PHYS
or	O	O
vulnerability	O	O
markers	B-PHYS
that	O	O
can	O	O
also	O	O
be	O	O
detected	O	O
in	O	O
the	O	O
presymptomatic	B-DISO
and	O	O
remitted	O
phases	O
of	O	O
AVHs	B-DISO
)	O	O
.	O	O

The	O	O
goal	O
of	O	O
such	O	O
strategies	O	O
is	O	O
to	O	O
target	O
areas	O
that	O	O
show	O	O
aberrant	O
activations	O
during	O	O
AVHs	B-DISO
or	O	O
are	O	O
known	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
compensatory	O
activation	O
(	O	O
or	O	O
resilience	B-PHEN
processes	I-PHEN
)	O	O
.	O	O

Brain	B-ANAT
regions	I-ANAT
,	O	O
from	O	O
which	O	O
the	O	O
NF	B-PROC
signal	B-PHEN
is	O	O
derived	O	O
,	O	O
can	O	O
be	O	O
based	O	O
on	O	O
structural	B-PROC
MRI	I-PROC
and	O	O
neurocognitive	O
knowledge	O
,	O	O
or	O	O
functional	B-PROC
MRI	I-PROC
information	O
collected	O	O
during	O	O
specific	O	O
cognitive	O
tasks	O
.	O	O

Because	O	O
hallucinations	B-DISO
are	O	O
acute	O	O
and	O	O
intrusive	O	O
symptoms	B-DISO
,	O	O
a	O	O
second	O	O
strategy	O	O
focuses	O	O
more	O	O
on	O	O
""""	O	O
state	B-PHYS
markers	I-PHYS
.	O	O
""""	O	O
In	O	O
this	O	O
case	O	O
,	O	O
the	O	O
signal	B-PHEN
of	O	O
interest	O	O
relies	O	O
on	O	O
fMRI	B-PROC
capture	O	O
of	O	O
the	O	O
neural	B-ANAT
networks	I-ANAT
exhibiting	O	O
increased	O	O
activity	O	O
during	O	O
AVHs	B-DISO
occurrences	O	O
,	O	O
by	O	O
means	O	O
of	O	O
multivariate	O
pattern	O
recognition	O
methods	O
.	O	O

The	O	O
fine	O	O
-	O	O
grained	O	O
activity	O
patterns	O
concomitant	O
to	O	O
hallucinations	B-DISO
can	O	O
then	O	O
be	O	O
fed	O	O
back	O	O
to	O	O
the	O	O
patients	B-LIVB
for	O	O
therapeutic	O
purpose	O	O
.	O	O

Considering	O	O
the	O	O
potential	O	O
cost	O	O
necessary	O	O
to	O	O
implement	O	O
fMRI	B-PROC
-	O	O
NF	B-PROC
,	O	O
proof	O	O
-	O	O
of	O	O
-	O	O
concept	O	O
studies	B-PROC
are	O	O
urgently	O	O
required	O	O
to	O	O
define	O	O
the	O	O
optimal	O	O
strategy	O	O
for	O	O
application	O
in	O	O
patients	B-LIVB
with	O	O
AVHs	B-DISO
.	O	O

This	O	O
technique	O
has	O	O
the	O	O
potential	O	O
to	O	O
establish	O	O
a	O	O
new	O	O
brain	B-PROC
imaging	I-PROC
-guided	O	O
psychotherapy	B-PROC
for	O	O
patients	B-LIVB
that	O	O
do	O	O
not	O	O
respond	O	O
to	O	O
conventional	O	O
treatments	O
and	O	O
take	O	O
functional	B-PROC
neuroimaging	I-PROC
to	O	O
therapeutic	O
applications	B-PROC
.	O	O

Microbiomes	B-LIVB
of	O	O
Muricea	O
californica	O
and	O	O
M	O
.	O
fruticosa	O
:	O	O
Comparative	B-PROC
Analyses	I-PROC
of	O	O
Two	O	O
Co	O	O
-	O	O
occurring	O	O
Eastern	B-GEOG
Pacific	I-GEOG
Octocorals	O
Octocorals	O
are	O	O
sources	O	O
of	O	O
novel	O	O
but	O	O
understudied	B-PROC
microbial	B-LIVB
diversity	O
.	O	O

Conversely	O	O
,	O	O
scleractinian	O
or	O	O
reef	B-LIVB
-	I-LIVB
building	I-LIVB
coral	I-LIVB
microbiomes	I-LIVB
have	O	O
been	O	O
heavily	O	O
examined	B-DISO
in	O	O
light	O	O
of	O	O
the	O	O
threats	O
of	O	O
climate	B-PHEN
change	I-PHEN
.	O	O

Muricea	O
californica	O
and	O	O
Muricea	O
fruticosa	O
are	O	O
two	O	O
co	O
-	O
occurring	O
species	O
of	O	O
gorgonian	O
octocoral	O
abundantly	B-DISO
found	I-DISO
in	O	O
the	O	O
kelp	O
forests	B-PHEN
of	O	O
southern	B-GEOG
California	I-GEOG
,	O	O
and	O	O
thus	O	O
provide	O	O
an	O	O
excellent	O
basis	O
to	O	O
determine	O	O
if	O	O
octocoral	O
microbiomes	B-LIVB
are	O	O
host	B-LIVB
specific	O
.	O	O

Using	O	O
Illumina	O
MiSeq	O
amplicon	O
sequencing	O
and	O	O
replicate	O
samples	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
microbiomes	B-LIVB
collected	O	O
from	O	O
multiple	O
colonies	O
of	O	O
both	O	O
species	O
of	O	O
Muricea	O
to	O	O
measure	O
both	O	O
inter	B-ANAT
-	I-ANAT
and	O	O
intra	B-ANAT
-	I-ANAT
colony	I-ANAT
microbiome	B-LIVB
variabilities	O
.	O	O

In	O	O
addition	O	O
,	O	O
microbiomes	B-LIVB
from	O	O
overlying	O	O
sea	B-OBJC
water	I-OBJC
and	O	O
nearby	O	O
zoanthids	O
(	O	O
another	O	O
benthic	O
invertebrate	O
)	O	O
were	O	O
also	O	O
included	O	O
in	O	O
the	O	O
analysis	B-PROC
to	O	O
evaluate	O	O
whether	O	O
bacterial	O
taxa	O
specifically	O	O
associate	O
with	O
octocorals	O
.	O	O

This	O	O
is	O	O
also	O	O
the	O	O
first	O
report	O
of	O	O
microbiomes	B-LIVB
from	O	O
these	O	O
species	O
of	O	O
Muricea	O
.	O	O

We	O	O
show	O	O
that	O	O
microbiomes	B-LIVB
isolated	O
from	O	O
each	O	O
sample	O
type	O
are	O	O
distinct	O
,	O	O
and	O	O
specifically	O	O
,	O	O
that	O	O
octocoral	O
species	O
type	O
had	O	O
the	O	O
greatest	O	O
effect	O	O
on	O	O
predicting	O
the	O	O
composition	B-PHYS
of	O	O
the	O	O
Muricea	O
microbiome	B-LIVB
.	O	O

Bacterial	O
taxa	O
contributing	O	O
to	O	O
compositional	O
differences	O
include	O	O
distinct	O
strains	B-LIVB
of	O	O
Mycoplasma	B-LIVB
associated	O
with	O
either	O	O
M	O
.	O

californica	O
or	O	O
M	O
.	O

fruticosa	O
,	O	O
an	O	O
abundance	O
of	O	O
Spirochaetes	B-LIVB
observed	O
on	O	O
M	O
.	O

californica	O
,	O	O
and	O	O
a	O	O
greater	O
diversity	O
of	O	O
γ	B-LIVB
-	I-LIVB
Proteobacteria	I-LIVB
associated	O
with	O
M	O
.	O

fruticosa	O
.	O	O

Many	O	O
of	O	O
the	O	O
bacterial	O
taxa	O
contributing	O	O
to	O	O
these	O	O
differences	O
are	O	O
known	O	O
for	O	O
their	O	O
presence	B-DISO
in	O	O
photosymbiont	O
-	O
containing	O
invertebrate	O
microbiomes	B-LIVB
.	O	O

The	O	O
Crystal	B-CHEM
Structure	I-CHEM
of	O	O
the	O	O
C	O
-	O
Terminal	O
Domain	O
of	O	O
the	O	O
Salmonella	B-LIVB
enterica	I-LIVB
PduO	B-CHEM
Protein	I-CHEM
:	O	O
An	O	O
Old	O	O
Fold	O	O
with	O	O
a	O	O
New	O	O
Heme	B-PHYS
-	I-PHYS
Binding	I-PHYS
Mode	O	O
The	O	O
two	B-CHEM
-	I-CHEM
domain	I-CHEM
protein	I-CHEM
PduO	I-CHEM
,	O	O
involved	O	O
in	O	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
utilization	O	O
in	O	O
the	O	O
pathogenic	B-LIVB
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacterium	I-LIVB
Salmonella	B-LIVB
enterica	I-LIVB
is	O	O
an	O	O
ATP	B-CHEM
:	O	O
Cob	B-CHEM
(	I-CHEM
I	I-CHEM
)	I-CHEM
alamin	I-CHEM
adenosyltransferase	I-CHEM
,	O	O
but	O	O
this	O	O
is	O	O
a	O	O
function	B-PHYS
of	O	O
the	O	O
N	O
-	O
terminal	O
domain	O
alone	O	O
.	O	O

The	O	O
role	O	O
of	O	O
its	O	O
C	O
-	O
terminal	O
domain	O
(	O	O
PduOC	B-CHEM
)	O	O
is	O	O
,	O	O
however	O	O
,	O	O
unknown	O	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
comparative	O	O
growth	B-PROC
assays	I-PROC
with	O	O
a	O	O
set	O	O
of	O	O
Salmonella	B-LIVB
mutant	I-LIVB
strains	I-LIVB
showed	O	O
that	O	O
this	O	O
domain	O
is	O	O
necessary	O	O
for	O	O
effective	O	O
in	O
vivo	O
catabolism	B-PHYS
of	O	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
.	O	O

It	O	O
was	O	O
also	O	O
shown	O	O
that	O	O
isolated	O
,	O	O
recombinantly	B-CHEM
-	I-CHEM
expressed	I-CHEM
PduOC	I-CHEM
binds	B-PHYS
heme	B-CHEM
in	O
vivo	O
.	O	O

The	O	O
structure	O
of	O	O
PduOC	B-CHEM
co	B-CHEM
-	I-CHEM
crystallized	I-CHEM
with	O	O
heme	B-CHEM
was	O	O
solved	O	O
(	O	O
1	O	O
.	O	O
9	O	O
Å	O	O
resolution	O	O
)	O	O
showing	O	O
an	O	O
octameric	B-PHYS
assembly	I-PHYS
with	O	O
four	O	O
heme	B-CHEM
moieities	O	O
.	O	O

The	O	O
four	O	O
heme	B-CHEM
groups	O	O
are	O	O
highly	O	O
solvent	O	O
-	O	O
exposed	O	O
and	O	O
the	O	O
heme	B-CHEM
iron	I-CHEM
is	O	O
hexa	O
-	O
coordinated	O
with	O	O
bis	B-PHYS
-	I-PHYS
His	I-PHYS
ligation	I-PHYS
by	O	O
histidines	B-CHEM
from	O	O
different	O	O
monomers	B-CHEM
.	O	O

Static	B-PROC
light	I-PROC
scattering	I-PROC
confirmed	O	O
the	O	O
octameric	B-PHYS
assembly	I-PHYS
in	O	O
solution	B-OBJC
,	O	O
but	O	O
a	O	O
mutation	B-PHYS
of	O	O
the	O	O
heme	B-CHEM
-	O	O
coordinating	O
histidine	B-CHEM
caused	O	O
dissociation	B-PHYS
into	O	O
dimers	B-CHEM
.	O	O

Isothermal	B-PROC
titration	I-PROC
calorimetry	I-PROC
using	O	O
the	O	O
PduOC	B-CHEM
apoprotein	I-CHEM
showed	O	O
strong	O	O
heme	B-PHYS
binding	I-PHYS
(	O	O
K	O	O
d	O	O
=	O	O
1	O	O
.	O	O
6	O	O
×	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
M	O	O
)	O	O
.	O	O

Biochemical	O
experiments	B-PROC
showed	O	O
that	O	O
the	O	O
absence	O
of	O	O
the	O	O
C	O
-	O
terminal	O
domain	O
in	O	O
PduO	B-CHEM
did	O	O
not	O	O
affect	O	O
adenosyltransferase	B-CHEM
activity	B-PHYS
in	O
vitro	O
.	O	O

The	O	O
evidence	O
suggests	O	O
that	O	O
PduOC	B-CHEM
:	O	O
heme	B-CHEM
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
set	O	O
of	O	O
cobalamin	B-CHEM
transformations	B-PHYS
required	O	O
for	O	O
effective	O	O
catabolism	B-PHYS
of	O	O
1	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
propanediol	I-CHEM
.	O	O

Salmonella	B-LIVB
PduO	B-CHEM
is	O	O
one	O	O
of	O	O
the	O	O
rare	O	O
proteins	B-CHEM
which	O	O
binds	O	O
the	O	O
redox	B-PHYS
-	I-PHYS
active	I-PHYS
metabolites	B-CHEM
heme	B-CHEM
and	O	O
cobalamin	B-CHEM
,	O	O
and	O	O
the	O	O
heme	B-PHYS
-	I-PHYS
binding	I-PHYS
mode	O	O
of	O	O
the	O	O
C	O
-	O
terminal	O
domain	O
differs	O	O
from	O	O
that	O	O
in	O	O
other	O	O
members	O	O
of	O	O
this	O	O
protein	B-CHEM
family	I-CHEM
.	O	O

The	O	O
Therapeutic	B-PHYS
Effect	I-PHYS
of	O	O
Berberine	B-CHEM
in	O	O
the	O	O
Treatment	B-PROC
of	O	O
Nonalcoholic	B-DISO
Fatty	I-DISO
Liver	I-DISO
Disease	I-DISO
:	O	O
A	O	O
Meta	B-PROC
-	I-PROC
Analysis	I-PROC
Aim	O	O
.	O	O

To	O	O
assess	B-PROC
the	O	O
efficacy	O
of	O	O
berberine	B-CHEM
in	O	O
the	O	O
treatment	B-PROC
of	O	O
nonalcoholic	B-DISO
fatty	I-DISO
liver	I-DISO
disease	I-DISO
through	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
.	O	O

Method	O	O
.	O	O

We	O	O
searched	O	O
Embase	O
,	O	O
Pubmed	O
,	O	O
Cochrane	O
Library	O
,	O	O
and	O	O
so	O	O
forth	O	O
,	O	O
until	O	O
March	O	O
2016	O	O
for	O	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
using	O	O
berberine	B-CHEM
to	O	O
treat	O	O
NAFLD	B-DISO
.	O	O

Result	O	O
.	O	O

Six	O	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
involving	O	O
501	O	O
patients	B-LIVB
were	O	O
included	O	O
in	O	O
this	O	O
study	B-PROC
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
the	O	O
efficacy	O
of	O	O
reducing	O
TC	B-CHEM
,	O	O
LDL	B-CHEM
,	O	O
ALT	B-CHEM
,	O	O
2hPG	B-PHYS
,	O	O
and	O	O
HbA1c	B-CHEM
in	O	O
NAFLD	B-DISO
patients	B-LIVB
of	O	O
the	O	O
berberine	B-CHEM
group	B-LIVB
were	O	O
significantly	O
higher	O
than	O	O
that	O	O
of	O	O
control	B-LIVB
group	I-LIVB
.	O	O

The	O	O
subgroup	B-LIVB
analyses	O	O
on	O	O
TG	B-CHEM
,	O	O
AST	B-CHEM
,	O	O
and	O	O
FBG	B-PROC
indicated	O	O
that	O	O
treatment	B-PROC
combined	O	O
with	O	O
berberine	B-CHEM
decreased	O	O
TG	B-PHEN
level	I-PHEN
in	O	O
NAFLD	B-DISO
patients	B-LIVB
significantly	O	O
.	O	O

Compared	O	O
with	O	O
other	O	O
drugs	B-CHEM
,	O	O
berberine	B-CHEM
alone	O	O
decreased	B-PHEN
TG	I-PHEN
level	I-PHEN
in	O	O
NAFLD	B-DISO
patients	B-LIVB
significantly	O	O
.	O	O

We	O	O
also	O	O
conducted	O	O
a	O	O
descriptive	B-PROC
analysis	I-PROC
on	O	O
insulin	B-DISO
resistance	I-DISO
and	O	O
radiography	B-PROC
results	O	O
that	O	O
berberine	B-CHEM
can	O	O
improve	O	O
NAFLD	B-DISO
patients	B-LIVB
'	O	O
insulin	B-DISO
resistance	I-DISO
and	O	O
fatty	B-DISO
liver	I-DISO
.	O	O

Conclusion	O	O
.	O	O

According	O	O
to	O	O
analysis	O
result	O
,	O	O
berberine	B-CHEM
has	O	O
positive	O	O
efficacy	O
on	O	O
blood	B-CHEM
lipids	I-CHEM
,	O	O
blood	B-CHEM
glucose	I-CHEM
,	O	O
liver	B-PHYS
function	I-PHYS
,	O	O
insulin	B-DISO
resistance	I-DISO
,	O	O
and	O	O
fatty	B-DISO
liver	I-DISO
condition	I-DISO
of	O	O
NAFLD	B-DISO
patients	B-LIVB
.	O	O

However	O	O
,	O	O
due	O	O
to	O	O
the	O	O
limitation	O	O
of	O	O
number	O	O
and	O	O
quality	O	O
of	O	O
trials	O	O
included	O	O
,	O	O
more	O	O
clinical	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
with	O	O
high	O	O
quality	O	O
are	O	O
needed	O	O
for	O	O
further	O	O
verification	O
of	O	O
the	O	O
efficacy	O
of	O	O
berberine	B-CHEM
on	O	O
NAFLD	B-DISO
patients	B-LIVB
.	O	O

Perfusion	B-PROC
Angiography	B-PROC
in	O	O
Acute	O
Ischemic	B-DISO
Stroke	I-DISO
Visualization	O	O
and	O	O
quantification	O
of	O	O
blood	B-PHYS
flow	I-PHYS
are	O	O
essential	O
for	O	O
the	O	O
diagnosis	B-DISO
and	O	O
treatment	B-PROC
evaluation	I-PROC
of	O	O
cerebrovascular	B-DISO
diseases	I-DISO
.	O	O

For	O	O
rapid	O
imaging	B-PROC
of	O	O
the	O	O
cerebrovasculature	B-ANAT
,	O	O
digital	B-PROC
subtraction	I-PROC
angiography	I-PROC
(	O	O
DSA	B-PROC
)	O	O
remains	O	O
the	O	O
gold	O
standard	O
as	O	O
it	O	O
offers	O	O
high	B-PROC
spatial	I-PROC
resolution	I-PROC
.	O	O

This	O	O
paper	O	O
lays	O	O
out	O	O
a	O	O
methodological	O
framework	O
,	O	O
named	O	O
perfusion	B-PROC
angiography	B-PROC
,	O	O
for	O	O
the	O	O
quantitative	B-PROC
analysis	I-PROC
and	O	O
visualization	O	O
of	O	O
blood	B-PHYS
flow	I-PHYS
parameters	B-DISO
from	O	O
DSA	B-PROC
images	O
.	O	O

The	O	O
parameters	B-DISO
,	O	O
including	O	O
cerebral	B-DISO
blood	I-DISO
flow	I-DISO
(	O	O
CBF	B-DISO
)	O	O
and	O	O
cerebral	B-PHYS
blood	I-PHYS
volume	I-PHYS
(	O	O
CBV	B-PHYS
)	O	O
,	O	O
mean	O
transit	O
time	O
(	O	O
MTT	O
)	O	O
,	O	O
time	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
peak	I-PHYS
(	O	O
TTP	B-PHYS
)	O	O
,	O	O
and	O	O
T	O
max	O
,	O	O
are	O	O
computed	O
using	O	O
a	O	O
bolus	B-PROC
tracking	I-PROC
method	I-PROC
based	O	O
on	O	O
the	O	O
deconvolution	O
of	O	O
the	O	O
time	O	O
-	O	O
density	O	O
curve	O	O
on	O	O
a	O	O
pixel	O	O
-	O	O
by	O	O
-	O	O
pixel	O	O
basis	O	O
.	O	O

The	O	O
method	O
is	O	O
tested	O	O
on	O	O
66	O	O
acute	O
ischemic	B-DISO
stroke	I-DISO
patients	B-LIVB
treated	B-PROC
with	I-PROC
thrombectomy	B-PROC
and	O	O
/	O	O
or	O	O
tissue	B-CHEM
plasminogen	I-CHEM
activator	I-CHEM
(	O	O
tPA	B-CHEM
)	O	O
and	O	O
also	O	O
evaluated	B-PROC
on	O	O
an	O	O
estimation	B-PHYS
task	O
with	O	O
known	O	O
ground	O	O
truth	O	O
.	O	O

This	O	O
novel	O
imaging	B-DEVI
tool	I-DEVI
provides	O	O
unique	O	O
insights	B-PHYS
into	O	O
flow	O	O
mechanisms	O
that	O	O
cannot	O	O
be	O	O
observed	O
directly	O	O
in	O	O
DSA	B-PROC
sequences	O	O
and	O	O
might	O	O
be	O	O
used	O	O
to	O	O
evaluate	B-PROC
the	O	O
impact	O
of	O	O
endovascular	B-PROC
interventions	I-PROC
more	O	O
precisely	O	O
.	O	O

Splicing	B-PHYS
variants	O	O
of	O	O
ADAR2	B-CHEM
and	O	O
ADAR2	B-CHEM
-mediated	O	O
RNA	B-PHYS
editing	I-PHYS
in	O	O
glioma	B-DISO
The	O	O
roles	O	O
of	O	O
alternative	B-PHYS
splicing	I-PHYS
and	O	O
RNA	B-PHYS
editing	I-PHYS
in	O	O
gene	B-PHYS
regulation	I-PHYS
and	O	O
transcriptome	O
diversity	O	O
are	O	O
well	O	O
documented	O	O
.	O	O

Adenosine	B-CHEM
deaminases	I-CHEM
acting	O	O
on	O	O
RNA	B-CHEM
(	O	O
ADARs	B-CHEM
)	O	O
are	O	O
responsible	O	O
for	O	O
adenosine	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
inosine	I-PHYS
(	I-PHYS
A	I-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
I	I-PHYS
)	I-PHYS
editing	I-PHYS
and	O	O
exemplify	O	O
the	O	O
complex	O	O
association	O	O
between	O	O
RNA	B-PHYS
editing	I-PHYS
and	O	O
alternative	B-PHYS
splicing	I-PHYS
.	O	O

The	O	O
self	B-PHYS
-	I-PHYS
editing	I-PHYS
activity	O	O
of	O	O
ADAR2	B-CHEM
,	O	O
which	O	O
acts	O	O
on	O	O
its	O	O
own	O	O
pre	B-CHEM
-	I-CHEM
mRNA	I-CHEM
,	O	O
leads	O	O
to	O	O
its	O	O
alternative	B-PHYS
splicing	I-PHYS
.	O	O

Alternative	B-PHYS
splicing	I-PHYS
occurs	O	O
independently	O	O
at	O	O
nine	O	O
splicing	B-PHYS
sites	O	O
on	O	O
ADAR2	B-CHEM
pre	B-CHEM
-	I-CHEM
mRNA	I-CHEM
,	O	O
generating	O	O
numerous	O	O
alternative	B-PHYS
splicing	I-PHYS
variants	O	O
with	O	O
various	O	O
catalytic	B-PHYS
activities	I-PHYS
.	O	O

A	B-PHYS
-	I-PHYS
to	I-PHYS
-	I-PHYS
I	I-PHYS
RNA	I-PHYS
editing	I-PHYS
is	O	O
important	O	O
in	O	O
a	O	O
range	O	O
of	O	O
physiological	B-PHYS
processes	I-PHYS
in	O	O
humans	B-LIVB
and	O	O
is	O	O
associated	O	O
with	O	O
several	O	O
diseases	B-DISO
,	O	O
including	O	O
amyotrophic	B-DISO
lateral	I-DISO
sclerosis	I-DISO
,	O	O
mood	B-DISO
disorders	I-DISO
,	O	O
epilepsy	B-DISO
and	O	O
glioma	B-DISO
.	O	O

Reduced	O	O
editing	B-PHYS
at	O	O
the	O	O
glutamine	B-CHEM
/	O	O
arginine	B-CHEM
site	O	O
of	O	O
the	O	O
AMPA	B-CHEM
receptor	I-CHEM
subunit	I-CHEM
GluA2	I-CHEM
in	O	O
glioma	B-DISO
,	O	O
without	O	O
any	O	O
alteration	O	O
in	O	O
ADAR2	B-CHEM
expression	B-PHYS
,	O	O
is	O	O
a	O	O
notable	O	O
phenomenon	O	O
.	O	O

Several	O	O
studies	O	O
have	O	O
tried	O	O
to	O	O
explain	O	O
this	O	O
alteration	O
in	O	O
the	O	O
catalytic	B-PHYS
activity	I-PHYS
of	O	O
ADAR2	B-CHEM
;	O	O
however	O	O
,	O	O
the	O	O
underlying	O	O
mechanism	O	O
remains	O	O
unclear	O	O
.	O	O

The	O	O
present	O	O
review	O
summarizes	O	O
the	O	O
relevant	O	O
literature	O
and	O	O
shares	O	O
experimental	B-DISO
results	I-DISO
concerning	O	O
ADAR2	B-CHEM
alternative	B-PHYS
splicing	I-PHYS
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
present	O	O
review	O
demonstrates	O	O
that	O	O
shifts	O	O
in	O	O
the	O	O
relative	O	O
abundance	O	O
of	O	O
the	O	O
active	O	O
and	O	O
inactive	O	O
splicing	B-PHYS
variants	O	O
of	O	O
ADAR2	B-CHEM
may	O	O
reduce	O	O
the	O	O
ADAR2	B-CHEM
editing	B-PHYS
activity	O	O
in	O	O
glioma	B-DISO
.	O	O

Dominant	O	O
expression	B-PHYS
of	O	O
ADAR2	B-CHEM
splicing	B-PHYS
variant	O	O
with	O	O
low	O	O
enzyme	B-PHYS
activity	I-PHYS
causes	O	O
reduced	O	O
RNA	B-PHYS
editing	I-PHYS
of	O	O
GluA2	B-CHEM
subunit	I-CHEM
at	O	O
the	O	O
glutamine	B-CHEM
/	O	O
arginine	B-CHEM
site	O	O
in	O	O
glioma	B-DISO
.	O	O

Heat	B-CHEM
-	I-CHEM
shock	I-CHEM
protein	I-CHEM
60	I-CHEM
of	O	O
Porphyromonas	B-LIVB
gingivalis	I-LIVB
may	O	O
induce	O	O
dysfunction	O
of	O	O
human	B-ANAT
umbilical	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
via	O	O
regulation	B-PHEN
of	O	O
endothelial	B-CHEM
-	I-CHEM
nitric	I-CHEM
oxide	I-CHEM
synthase	I-CHEM
and	O	O
vascular	B-CHEM
endothelial	I-CHEM
-	I-CHEM
cadherin	I-CHEM
Accumulating	O	O
evidence	O	O
has	O	O
established	O	O
that	O	O
periodontitis	B-DISO
was	O	O
an	O	O
independent	O	O
risk	B-DISO
factor	I-DISO
for	O	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
(	O	O
CAD	B-DISO
)	O	O
.	O	O

Porphyromonus	B-LIVB
gingivalis	I-LIVB
(	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
)	O	O
,	O	O
a	O	O
major	O	O
periodontal	O
pathogen	B-LIVB
,	O	O
has	O	O
already	O	O
been	O	O
shown	O	O
to	O	O
have	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
the	O	O
inflammatory	B-DISO
response	I-DISO
of	O	O
CAD	B-DISO
in	O
vivo	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	B-PROC
was	O	O
to	O	O
identify	O	O
whether	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
heat	B-CHEM
-	I-CHEM
shock	I-CHEM
protein	I-CHEM
60	I-CHEM
(	O	O
HSP60	B-CHEM
)	O	O
induced	O	O
the	O	O
dysfunction	O
of	O	O
human	B-ANAT
umbilical	I-ANAT
vein	I-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O	O
HUVECs	B-ANAT
)	O	O
in	O
vitro	O
.	O	O

HUVECs	B-ANAT
were	O	O
stimulated	B-PHEN
with	O	O
a	O	O
range	O	O
of	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
concentrations	O
(	O	O
1	O	O
,	O	O
10	O	O
and	O	O
100	O	O
ng	O	O
/	O	O
l	O	O
)	O	O
at	O	O
different	O	O
time	O
-	O
points	O
.	O	O

The	O	O
levels	O
of	O	O
vascular	B-CHEM
endothelial	I-CHEM
(	I-CHEM
VE	I-CHEM
)	I-CHEM
-	I-CHEM
cadherin	I-CHEM
,	O	O
endothelial	B-CHEM
nitric	I-CHEM
oxide	I-CHEM
synthase	I-CHEM
(	O	O
eNOS	B-CHEM
)	O	O
and	O	O
cysteinyl	B-CHEM
aspartate	I-CHEM
-	I-CHEM
specific	I-CHEM
protease	I-CHEM
-	I-CHEM
3	I-CHEM
(	O	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
)	O	O
were	O	O
measured	O	O
using	O	O
western	B-PROC
blot	I-PROC
analysis	B-PROC
.	O	O

The	O	O
apoptotic	B-PHYS
rate	O
of	O	O
HUVECs	B-ANAT
was	O	O
detected	O	O
using	O	O
flow	B-PROC
cytometry	I-PROC
.	O	O

P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
at	O	O
a	O	O
concentration	O
of	O	O
10	O	O
ng	O	O
/	O	O
l	O	O
significantly	O	O
decreased	O	O
the	O	O
expression	B-PHYS
levels	O
of	O	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O	O
eNOS	B-CHEM
protein	I-CHEM
at	O	O
24	O	O
h	O
stimulation	B-PHEN
,	O	O
whereas	O	O
no	O	O
difference	O	O
in	O	O
these	O	O
proteins	B-CHEM
was	O	O
identified	O	O
following	O	O
a	O	O
low	O
dose	O
of	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
(	O	O
1	O	O
ng	O	O
/	O	O
l	O	O
)	O	O
.	O	O

P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
at	O	O
100	O	O
ng	O	O
/	O	O
l	O	O
significantly	O	O
downregulated	B-PHYS
the	O	O
expression	B-PHYS
levels	O
of	O	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O	O
eNOS	B-CHEM
protein	I-CHEM
at	O	O
12	O	O
h	O	O
in	O	O
HUVECs	B-ANAT
.	O	O

However	O	O
,	O	O
the	O	O
cleavage	B-PHEN
of	O	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
showed	O	O
an	O	O
opposing	O	O
change	O	O
at	O	O
different	O	O
concentrations	O
.	O	O

Consistently	O	O
,	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
induced	O	O
apoptosis	B-PHYS
of	O	O
HUVECs	B-ANAT
in	O	O
a	O	O
concentration	O
-	O	O
dependent	O
manner	O	O
.	O	O

These	O	O
results	O
indicated	O	O
that	O	O
P	B-LIVB
.	I-LIVB

gingivalis	I-LIVB
HSP60	B-CHEM
may	O	O
induce	O	O
dysfunction	O
and	O	O
apoptosis	B-PHYS
in	O	O
HUVECs	B-ANAT
via	O	O
downregulating	B-PHYS
the	O	O
expression	B-PHYS
levels	O
of	O	O
VE	B-CHEM
-	I-CHEM
cadherin	I-CHEM
and	O	O
eNOS	B-CHEM
,	O	O
and	O	O
promoting	O	O
the	O	O
cleavage	B-PHEN
of	O	O
caspase	B-CHEM
-	I-CHEM
3	I-CHEM
.	O	O

A	O	O
new	O	O
marker	B-PHYS
for	O	O
breast	B-PROC
cancer	I-PROC
diagnosis	I-PROC
,	O	O
human	B-CHEM
epididymis	I-CHEM
protein	I-CHEM
4	I-CHEM
:	O	O
A	O	O
preliminary	O
study	B-PROC
Breast	B-DISO
cancer	I-DISO
is	O	O
the	O	O
most	O	O
frequently	O	O
diagnosed	B-DISO
cancer	B-DISO
type	O
in	O	O
women	B-LIVB
.	O	O

Tumor	B-CHEM
markers	I-CHEM
have	O	O
been	O	O
widely	O	O
used	O	O
for	O	O
assessing	B-PROC
the	O	O
treatment	B-PHYS
response	I-PHYS
and	O	O
early	B-PROC
diagnosis	I-PROC
of	O	O
recurrence	B-DISO
.	O	O

Human	B-CHEM
epididymis	I-CHEM
protein	I-CHEM
4	I-CHEM
(	O	O
HE4	B-CHEM
)	O	O
is	O	O
expressed	B-PHYS
in	O	O
ductal	B-DISO
carcinoma	I-DISO
of	I-DISO
the	I-DISO
breast	I-DISO
tissue	I-DISO
;	O	O
however	O	O
,	O	O
its	O	O
serum	B-ANAT
levels	O
and	O	O
their	O	O
diagnostic	B-DISO
and	O	O
prognostic	B-PHYS
potential	O
in	O	O
breast	B-DISO
cancer	I-DISO
have	O	O
not	O	O
been	O	O
investigated	O
,	O	O
which	O	O
was	O	O
therefore	O	O
the	O	O
aim	O
of	O	O
the	O	O
present	O
study	B-PROC
.	O	O

The	O	O
serum	B-ANAT
levels	O
of	O	O
HE4	B-CHEM
were	O	O
determined	B-PROC
in	O	O
36	O	O
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
,	O	O
11	O	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
and	O	O
16	O	O
healthy	B-LIVB
volunteers	I-LIVB
.	O	O

The	O	O
association	O
between	O	O
clinicopathological	O
characteristics	O
of	O	O
breast	B-DISO
cancer	I-DISO
and	O	O
serum	B-ANAT
HE4	B-CHEM
levels	O
was	O	O
investigated	O
.	O	O

A	O	O
significant	O
difference	O
in	O	O
the	O	O
median	O
serum	B-ANAT
levels	O
of	O	O
HE4	B-CHEM
was	O	O
identified	O
between	O	O
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
,	O	O
ovarian	B-DISO
cancer	I-DISO
patients	B-LIVB
and	O	O
healthy	B-LIVB
volunteers	I-LIVB
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
013	O	O
)	O	O
.	O	O

The	O	O
cutoff	O
value	O
for	O	O
the	O	O
prediction	O
of	O	O
breast	B-DISO
cancer	I-DISO
was	O	O
determined	B-PROC
at	O	O
>	O	O
13	O	O
.	O	O

24	O	O
pmol	O	O
/	O	O
l	O	O
for	O	O
HE4	B-CHEM
,	O	O
with	O	O
a	O	O
sensitivity	O
of	O	O
61	O	O
.	O	O

11	O	O
%	O	O
,	O	O
specificity	O
of	O	O
68	O	O
.	O	O
75	O	O
%	O	O
,	O	O
positive	O
predictive	O
value	O
of	O	O
81	O	O
.	O	O
48	O	O
%	O	O
,	O	O
negative	O
predictive	O
value	O
of	O	O
44	O	O
.	O	O
0	O	O
%	O	O
and	O	O
accuracy	O
of	O	O
63	O	O
.	O	O

46	O	O
%	O	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
positive	B-DISO
correlation	O
between	O	O
the	O	O
serum	B-ANAT
levels	O
of	O	O
HE4	B-CHEM
and	O	O
cancer	B-CHEM
antigen	I-CHEM
15	O	O
-	O	O
3	O	O
was	O	O
determined	B-PROC
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
399	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
026	O	O
)	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O
,	O	O
the	O	O
present	O
study	B-PROC
was	O	O
the	O	O
first	O	O
to	O	O
determine	B-PROC
the	O	O
diagnostic	O
value	O
of	O	O
serum	B-ANAT
HE4	B-CHEM
for	O	O
breast	B-DISO
cancer	I-DISO
.	O	O

A	O	O
significant	O
elevation	O
of	O	O
serum	B-ANAT
HE4	B-CHEM
levels	O
in	O	O
patients	B-LIVB
with	O	O
breast	B-DISO
cancer	I-DISO
compared	O
with	O	O
that	O	O
in	O	O
healthy	O
controls	B-LIVB
was	O	O
identified	O
.	O	O

HE4	B-CHEM
may	O	O
serve	O	O
as	O	O
a	O	O
novel	O	O
biomarker	B-PHYS
for	O	O
the	O	O
diagnosis	B-DISO
of	O	O
breast	B-DISO
cancer	I-DISO
.	O	O

Duodenal	B-DISO
Villous	I-DISO
Atrophy	I-DISO
in	O	O
a	O	O
TTG	B-PROC
-	O	O
Negative	B-DISO
Patient	B-LIVB
Taking	O	O
Olmesartan	B-CHEM
:	O	O
A	O	O
Case	O
Report	O
and	O	O
Review	O
of	O
the	O
Literature	O
Olmesartan	B-CHEM
,	O	O
an	O	O
angiotensin	B-CHEM
II	I-CHEM
receptor	I-CHEM
antagonist	I-CHEM
used	O	O
to	O	O
treat	B-PROC
hypertension	B-DISO
,	O	O
is	O	O
associated	O
with	O
few	O	O
adverse	B-DISO
effects	I-DISO
.	O	O

Here	O	O
,	O	O
a	O	O
case	O	O
of	O	O
severe	O
sprue	B-DISO
-	I-DISO
like	I-DISO
enteropathy	I-DISO
and	O	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
is	O	O
described	O	O
in	O	O
a	O	O
68	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	B-PHYS
taking	O	O
olmesartan	B-CHEM
for	O	O
3	O	O
-	O	O
4	O	O
years	O
.	O	O

He	O	O
presented	O	O
to	O	O
hospital	B-OBJC
with	O	O
a	O	O
five	O	O
-	O	O
week	O	O
history	B-DISO
of	O	O
diarrhea	B-DISO
,	O	O
vomiting	B-DISO
,	O	O
and	O	O
a	O	O
20	O	O
lb	O	O
weight	B-DISO
loss	I-DISO
.	O	O

Anti	B-DISO
-	I-DISO
TTG	I-DISO
was	O	O
negative	B-DISO
with	O	O
a	O	O
normal	O
IgA	B-CHEM
.	O	O

Biopsies	B-PROC
of	O	O
the	O	O
distal	B-ANAT
duodenum	I-ANAT
and	O	O
duodenal	B-ANAT
cap	I-ANAT
revealed	O	O
marked	O	O
blunting	O
of	O	O
the	O	O
villi	B-ANAT
with	O	O
near	O	O
complete	O	O
villous	B-DISO
atrophy	I-DISO
of	O	O
the	O	O
biopsies	B-PROC
from	O	O
the	O	O
bulb	B-ANAT
.	O	O

There	O	O
was	O	O
an	O	O
increase	O
in	O	O
intraepithelial	O
lymphocytes	B-ANAT
as	O	O
well	O	O
as	O	O
neutrophils	B-ANAT
in	O	O
the	O	O
surface	B-ANAT
epithelium	I-ANAT
.	O	O

The	O	O
patient	B-LIVB
's	I-LIVB
diarrhea	B-DISO
improved	B-DISO
upon	O	O
discontinuation	B-PROC
of	O	O
olmesartan	B-CHEM
and	O	O
he	O	O
returned	O	O
to	O	O
his	O	O
previous	O	O
weight	B-PHYS
.	O	O

Repeat	O	O
endoscopy	B-PROC
four	O	O
months	O
later	O	O
demonstrated	O	O
complete	O	O
resolution	B-DISO
of	O	O
inflammatory	O
change	O
with	O	O
normal	O
villous	B-ANAT
architecture	O	O
.	O	O

Long	O
-	O
term	O
olmesartan	B-CHEM
use	O	O
is	O	O
associated	O
with	O
severe	O
sprue	B-DISO
-	I-DISO
like	I-DISO
enteropathy	I-DISO
.	O	O

The	O	O
mechanism	O
of	O	O
intestinal	B-DISO
injury	I-DISO
is	O	O
unknown	O	O
.	O	O

Duodenal	B-PROC
biopsy	I-PROC
results	O	O
may	O	O
mimic	O	O
other	O	O
enteropathies	B-DISO
such	O	O
as	O	O
celiac	B-DISO
disease	I-DISO
.	O	O

Physicians	B-LIVB
should	O	O
consider	O	O
medications	B-PROC
as	O	O
potential	O
etiologies	O
of	O	O
enteropathy	B-DISO
.	O	O

Personalized	B-PROC
Medicine	I-PROC
Approaches	I-PROC
in	O	O
Prostate	B-DISO
Cancer	I-DISO
Employing	O
Patient	B-LIVB
Derived	O
3D	O
Organoids	O
and	O	O
Humanized	B-LIVB
Mice	I-LIVB
Prostate	B-DISO
cancer	I-DISO
(	O	O
PCa	B-DISO
)	O	O
is	O	O
the	O	O
most	O	O
common	O
malignancy	B-DISO
and	O	O
the	O	O
second	O	O
most	O	O
common	O
cause	O
of	O	O
cancer	O
death	O
in	O	O
Western	O
men	B-LIVB
.	O	O

Despite	O	O
its	O	O
prevalence	O	O
,	O	O
PCa	B-DISO
has	O	O
proven	O	O
very	O	O
difficult	O
to	O	O
propagate	O	O
in	O
vitro	O
.	O	O

PCa	B-DISO
represents	O	O
a	O	O
complex	O
organ	B-ANAT
-	I-ANAT
like	I-ANAT
multicellular	O
structure	O
maintained	O
by	O	O
the	O	O
dynamic	O
interaction	O
of	O	O
tumoral	B-ANAT
cells	I-ANAT
with	O	O
parenchymal	B-ANAT
stroma	I-ANAT
,	O	O
endothelial	B-ANAT
and	O	O
immune	B-ANAT
cells	I-ANAT
,	O	O
and	O	O
components	B-ANAT
of	O	O
the	O	O
extracellular	O
matrix	O
(	O	O
ECM	O
)	O	O
.	O	O

The	O	O
lack	O
of	O	O
PCa	B-DISO
models	B-DISO
that	O	O
recapitulate	O	O
this	O	O
intricate	O	O
system	O	O
has	O	O
hampered	O
progress	O
toward	O	O
understanding	B-PHYS
disease	B-DISO
progression	I-DISO
and	O	O
lackluster	O
therapeutic	B-PHYS
responses	I-PHYS
.	O	O

Tissue	B-PROC
slices	I-PROC
,	O	O
monolayer	B-PROC
cultures	I-PROC
and	O	O
genetically	B-DISO
engineered	I-DISO
mouse	I-DISO
models	I-DISO
(	O	O
GEMM	B-DISO
)	O	O
fail	O
to	O	O
mimic	O	O
the	O	O
complexities	O
of	O	O
the	O	O
PCa	B-DISO
microenvironment	O	O
or	O	O
reproduce	O	O
the	O	O
diverse	O
mechanisms	O
of	O	O
therapy	B-PROC
resistance	O
.	O	O

Moreover	O	O
,	O	O
patient	B-DISO
derived	I-DISO
xenografts	I-DISO
(	O	O
PDXs	B-DISO
)	O	O
are	O	O
expensive	O	O
,	O	O
time	O
consuming	O
,	O	O
difficult	O
to	O	O
establish	O
for	O	O
prostate	B-DISO
cancer	I-DISO
,	O	O
lack	O
immune	B-PHYS
cell	I-PHYS
-	I-PHYS
tumor	I-PHYS
regulation	I-PHYS
,	O	O
and	O	O
often	O	O
tumors	B-DISO
undergo	O	O
selective	O	O
engraftments	B-PHYS
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
an	O	O
interdisciplinary	B-PROC
approach	I-PROC
using	O	O
primary	O
PCa	B-DISO
and	O	O
tumor	B-ANAT
initiating	I-ANAT
cells	I-ANAT
(	O	O
TICs	B-ANAT
)	O	O
,	O	O
three	O
-	O
dimensional	O
(	O	O
3D	O
)	O	O
tissue	B-PROC
engineering	I-PROC
,	O	O
genetic	B-PROC
and	O	O
morphometric	B-PROC
profiling	I-PROC
,	O	O
and	O	O
humanized	B-LIVB
mice	I-LIVB
to	O	O
generate	O	O
patient	B-LIVB
-	O	O
derived	O
organoids	O
for	O	O
examining	O	O
personalized	O
therapeutic	B-PHYS
responses	I-PHYS
in	O
vitro	O
and	O	O
in	O	O
mice	B-LIVB
co	O
-	O
engrafted	O
with	O	O
a	O	O
human	B-ANAT
immune	I-ANAT
system	I-ANAT
(	O	O
HIS	B-ANAT
)	O	O
,	O	O
employing	O	O
adaptive	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
-	I-ANAT
and	O	O
chimeric	B-CHEM
antigen	I-CHEM
receptor	I-CHEM
-	I-CHEM
(	O	O
CAR	B-CHEM
)	O	O
immunotherapy	B-PROC
.	O	O

The	O	O
development	O	O
of	O	O
patient	B-LIVB
specific	O
therapies	B-PROC
targeting	O
the	O	O
vulnerabilities	B-DISO
of	O	O
cancer	B-DISO
,	O	O
when	O	O
combined	O
with	O	O
antiproliferative	B-PROC
and	O	O
immunotherapy	B-PROC
approaches	B-PROC
could	O	O
help	O	O
to	O	O
achieve	O	O
the	O	O
full	O	O
transformative	O
power	O
of	O	O
cancer	B-DISO
precision	B-PROC
medicine	I-PROC
.	O	O

Effect	O
of	O	O
endodontic	B-PROC
access	I-PROC
cavity	I-PROC
preparation	I-PROC
on	O	O
monolithic	O
and	O	O
ceramic	B-CHEM
veneered	B-CHEM
zirconia	B-CHEM
restorations	B-PROC
Due	O	O
to	O	O
the	O	O
high	O	O
chipping	B-DISO
rates	O	O
observed	O	O
in	O	O
veneered	B-CHEM
zirconia	B-CHEM
ceramic	B-CHEM
restorations	B-PROC
,	O	O
the	O	O
use	O	O
of	O	O
monolithic	O
zirconia	B-CHEM
restorations	B-PROC
has	O	O
been	O	O
recommended	O	O
.	O	O

This	O	O
study	O	O
tried	O	O
to	O	O
compare	O	O
veneered	B-CHEM
and	O	O
monolithic	O
zirconia	B-CHEM
fixed	B-DEVI
dental	I-DEVI
prostheses	I-DEVI
(	O	O
FDPs	B-DEVI
)	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
amount	O	O
of	O	O
damage	O
induced	O	O
by	O	O
endodontic	B-PROC
access	I-PROC
preparation	I-PROC
.	O	O

Monolithic	O
and	O	O
ceramic	B-CHEM
veneered	B-CHEM
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
three	O	O
-	O	O
unit	O	O
restorations	B-PROC
(	O	O
retainers	B-DEVI
:	O	O
first	B-ANAT
premolar	I-ANAT
and	O	O
first	B-ANAT
molar	I-ANAT
;	O	O
pontic	B-DEVI
:	O	O
second	B-ANAT
premolar	I-ANAT
)	O	O
were	O	O
subject	O	O
to	O	O
endodontic	B-PROC
access	I-PROC
cavity	I-PROC
preparation	I-PROC
in	O	O
both	O	O
retainers	B-DEVI
using	O	O
a	O	O
diamond	B-DEVI
rotary	I-DEVI
instrument	I-DEVI
under	O	O
continuous	O
water	B-CHEM
cooling	B-PHEN
.	O	O

The	O	O
number	O	O
of	O	O
chipping	B-DISO
fractures	I-DISO
and	O	O
microfractures	B-DISO
detected	O	O
using	O	O
the	O	O
fluorescent	B-PROC
penetrant	I-PROC
method	I-PROC
were	O	O
recorded	O	O
.	O	O

Statistical	B-PROC
analysis	I-PROC
was	O	O
based	O	O
on	O	O
Wilcoxon	O
rank	O
sum	O
tests	O
with	O	O
Bonferroni	O
correction	O
(	O	O
level	B-PROC
of	I-PROC
significance	I-PROC
α	O	O
=	O	O
.05	O	O
)	O	O
.	O	O

Only	O	O
one	O	O
microfracture	B-DISO
could	O	O
be	O	O
identified	O	O
in	O	O
the	O	O
group	O	O
of	O	O
monolithic	O
FDPs	B-DEVI
while	O	O
a	O	O
maximum	O	O
of	O	O
seven	O	O
microfractures	B-DISO
and	O	O
three	O	O
chipping	B-DISO
fractures	I-DISO
per	O	O
retainer	B-DEVI
crown	I-DEVI
were	O	O
recorded	O	O
in	O	O
the	O	O
group	O	O
of	O	O
veneered	B-CHEM
restorations	B-PROC
.	O	O

At	O	O
the	O	O
premolar	O	O
site	O	O
,	O	O
the	O	O
veneered	B-CHEM
restorations	B-PROC
showed	O	O
significantly	O	O
more	O	O
microfractures	B-DISO
(	O	O
P	O	O
=	O	O
.0055	O	O
)	O	O
and	O	O
chipping	B-DISO
fractures	I-DISO
(	O	O
P	O	O
=	O	O
.0008	O	O
)	O	O
.	O	O

At	O	O
the	O	O
molar	B-ANAT
site	I-ANAT
,	O	O
no	B-DISO
significant	I-DISO
difference	I-DISO
with	O	O
respect	O	O
to	O	O
microfractures	B-DISO
could	O	O
be	O	O
detected	O	O
(	O	O
P	O	O
=	O	O
.0767	O	O
)	O	O
,	O	O
while	O	O
significantly	O	O
more	O	O
chipping	B-DISO
fractures	I-DISO
occurred	O	O
in	O	O
the	O	O
veneered	B-CHEM
samples	O	O
(	O	O
P	O	O
=	O	O
.0293	O	O
)	O	O
.	O	O

Monolithic	O
zirconia	B-CHEM
restorations	B-PROC
seem	O	O
to	O	O
be	O	O
less	O	O
susceptible	O
to	O	O
damage	O
when	O	O
endodontic	B-PROC
access	I-PROC
cavities	I-PROC
have	O	O
to	O	O
be	O	O
prepared	O	O
as	O	O
compared	O	O
to	O	O
veneered	B-CHEM
zirconia	B-CHEM
reconstructions	B-PROC
.	O	O

However	O	O
,	O	O
no	O	O
conclusions	O	O
can	O	O
be	O	O
drawn	O	O
on	O	O
the	O	O
longterm	B-PHEN
performance	I-PHEN
of	O	O
a	O	O
specific	O	O
restoration	B-PROC
based	O	O
on	O	O
this	O	O
study	O	O
.	O	O

The	O	O
relationship	O
between	O	O
hemorheological	B-PHYS
parameters	B-DISO
and	O	O
mortality	O
in	O	O
critically	B-DISO
ill	I-DISO
patients	B-LIVB
with	O	O
and	O	O
without	O	O
sepsis	B-DISO
The	O	O
prognostic	B-PROC
scoring	O
systems	O
for	O	O
mortality	O
of	O	O
intensive	B-PROC
care	I-PROC
patients	B-LIVB
estimate	O
clinical	B-DISO
outcome	I-DISO
using	O	O
several	O	O
physiological	O
and	O	O
biochemical	O
parameters	B-DISO
.	O	O

In	O	O
altered	O	O
hemodynamic	B-PHYS
conditions	O
of	O	O
critically	B-DISO
ill	I-DISO
patients	B-LIVB
,	O	O
hemorheological	B-PHYS
variables	B-PROC
may	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
appropriate	O	O
tissue	O
perfusion	B-PROC
.	O	O

We	O	O
investigated	O
if	O	O
hemorheological	B-PHYS
parameters	B-DISO
are	O	O
altered	O	O
in	O	O
critical	B-DISO
status	I-DISO
and	O	O
if	O	O
they	O	O
could	O	O
be	O	O
markers	B-PHYS
of	O	O
mortality	O
.	O	O

112	O	O
patients	B-LIVB
(	O	O
67	O	O
.	O	O
8	O	O
±	O	O
12	O	O
years	O
,	O	O
58	O	O
males	B-PHYS
,	O	O
54	O	O
females	B-PHYS
)	O	O
treated	O
in	O	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
with	O	O
different	O	O
non	O
-	O
surgical	O
diseases	B-DISO
were	O	O
investigated	O
.	O	O

Routine	O	O
laboratory	B-PROC
parameters	I-PROC
and	O	O
prognostic	O
scores	O
were	O	O
determined	O	O
and	O	O
hemorheological	B-PHYS
variables	B-PROC
(	O	O
hematocrit	B-DISO
,	O	O
plasma	B-ANAT
and	O	O
whole	B-ANAT
blood	I-ANAT
viscosity	B-PHEN
,	O	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
and	O	O
deformability	B-PHYS
)	O	O
were	O	O
measured	O
on	O	O
the	O	O
1st	O	O
and	O	O
the	O	O
2nd	O	O
day	O	O
after	O	O
admission	B-PROC
.	O	O

ICU	O
scores	O
predicted	O	O
35	O	O
.	O	O

2	O	O
-	O	O
41	O	O
.	O	O
3	O	O
%	O	O
mortality	O
rate	O
,	O	O
real	O	O
mortality	O
in	O	O
intensive	B-OBJC
care	I-OBJC
unit	I-OBJC
was	O	O
37	O	O
.	O	O
5	O	O
%	O	O
,	O	O
while	O	O
30	O	O
-	O	O
day	O	O
mortality	O
was	O	O
46	O	O
.	O	O

6	O	O
%	O	O
.	O	O

Whole	B-PHEN
blood	I-PHEN
viscosity	I-PHEN
(	O	O
WBV	B-PHEN
)	O	O
and	O	O
red	B-PHYS
blood	I-PHYS
cell	I-PHYS
(	I-PHYS
RBC	I-PHYS
)	I-PHYS
deformability	I-PHYS
were	O	O
lower	O	O
,	O	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
was	O	O
higher	O
in	O	O
septic	O
than	O	O
in	O	O
nonseptic	O
patients	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
septic	B-DISO
patients	B-LIVB
calcium	B-CHEM
was	O	O
increased	O
,	O	O
osmolality	B-PHYS
was	O	O
decreased	O
,	O	O
while	O	O
in	O	O
nonseptic	O	O
patients	B-LIVB
WBV	B-PHEN
and	O	O
RBC	B-ANAT
aggregation	B-PHYS
were	O	O
higher	O
in	O	O
nonsurvivors	B-LIVB
compared	O	O
to	O	O
survivors	B-LIVB
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Worsening	O
of	O	O
RBC	B-ANAT
deformability	B-PHYS
from	O	O
day	O	O
1	O	O
to	O	O
day	O	O
2	O	O
predicted	O	O
higher	O
mortality	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Calcium	B-PROC
and	O	O
osmolality	B-PHEN
level	I-PHEN
were	O	O
associated	O
with	O
outcome	O	O
in	O	O
sepsis	B-DISO
.	O	O

Whole	B-ANAT
blood	I-ANAT
viscosity	B-PHEN
,	O	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
aggregation	B-PHYS
and	O	O
change	O	O
in	O	O
red	B-ANAT
blood	I-ANAT
cell	I-ANAT
deformability	B-PHYS
could	O	O
predict	O	O
mortality	O
in	O	O
nonseptic	O
patients	B-LIVB
and	O	O
they	O	O
may	O	O
add	O	O
prognostic	B-PROC
information	O
over	O	O
the	O	O
ICU	O
scores	O
.	O	O

Further	O	O
investigations	B-PROC
are	O	O
needed	O	O
to	O	O
evaluate	B-PROC
the	O	O
benefit	O	O
of	O	O
our	O	O
findings	B-DISO
in	O	O
clinical	O
practice	O
.	O	O

2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
Dihydroxyadenine	I-CHEM
Nephropathy	B-DISO
Identified	O	O
as	O	O
Cause	O
of	O	O
End	B-DISO
-	I-DISO
Stage	I-DISO
Renal	I-DISO
Disease	I-DISO
After	O	O
Renal	B-PROC
Transplant	I-PROC
Adenine	B-DISO
phosphoribosyltransferase	I-DISO
deficiency	I-DISO
is	O	O
a	O	O
rare	O	O
autosomal	B-DISO
recessive	I-DISO
disorder	I-DISO
of	O	O
uric	B-CHEM
acid	I-CHEM
metabolism	B-PHYS
that	O	O
leads	O	O
to	O	O
formation	O
and	O	O
excretion	B-PHYS
of	O	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
into	O	O
urine	B-ANAT
.	O	O

The	O	O
low	O	O
solubility	O
of	O	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
results	O	O
in	O	O
precipitation	B-PHEN
and	O	O
formation	O
of	O	O
urinary	B-PHEN
crystals	I-PHEN
and	O	O
renal	B-DISO
stones	I-DISO
.	O	O

Patients	B-LIVB
with	O	O
this	O	O
disorder	B-DISO
usually	O	O
have	O	O
recurrent	B-DISO
nephrolithiasis	I-DISO
and	O	O
can	O	O
develop	O	O
nephropathy	B-DISO
secondary	I-DISO
to	O	O
crystal	B-ANAT
precipitation	B-PHEN
in	O	O
the	O	O
renal	B-ANAT
parenchyma	I-ANAT
.	O	O

The	O	O
disease	B-DISO
is	O	O
most	O	O
often	O	O
underdiagnosed	B-DISO
and	O	O
can	O	O
recur	B-PHEN
in	O	O
renal	B-PROC
transplant	I-PROC
,	O	O
causing	O
graft	B-DISO
failure	I-DISO
.	O	O

Lack	O	O
of	O	O
specific	O	O
clinical	O
manifestations	O
,	O	O
chemical	B-PHEN
and	O	O
radiologic	B-DISO
features	I-DISO
identical	O	O
to	O	O
those	O	O
shown	O	O
with	O	O
uric	B-ANAT
acid	I-ANAT
stones	I-ANAT
,	O	O
and	O	O
lack	B-DISO
of	I-DISO
awareness	I-DISO
among	O	O
clinicians	B-LIVB
are	O	O
among	O	O
the	O	O
causes	O
for	O	O
the	O	O
underdiagnoses	B-DISO
of	O	O
this	O	O
treatable	O
disease	B-DISO
.	O	O

Allopurinol	B-CHEM
,	O	O
a	O	O
xanthine	B-CHEM
dehydrogenase	I-CHEM
inhibitor	B-CHEM
,	O	O
is	O	O
the	O	O
mainstay	O	O
of	O	O
treatment	O
,	O	O
supported	O	O
by	O	O
high	O	O
fluid	B-PHYS
intake	I-PHYS
and	O	O
dietary	B-PROC
modifications	I-PROC
.	O	O

The	O	O
possibility	O	O
of	O	O
adenine	B-DISO
phosphoribosyl	I-DISO
transferase	I-DISO
deficiency	I-DISO
should	O	O
be	O	O
considered	O	O
in	O	O
all	O	O
cases	O	O
of	O	O
urolithiasis	B-DISO
in	O	O
children	B-LIVB
,	O	O
patients	B-LIVB
with	O	O
recurrent	O
urolithiasis	O
,	O	O
and	O	O
patients	B-LIVB
with	O	O
urolithiasis	B-DISO
associated	O
with	O
renal	B-DISO
failure	I-DISO
of	O	O
unknown	O	O
cause	O
,	O	O
including	O	O
patients	B-LIVB
with	O	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
and	O	O
renal	B-LIVB
transplant	I-LIVB
recipients	I-LIVB
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
41	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	B-PHYS
patient	I-PHYS
who	O	O
had	O	O
a	O	O
late	O
diagnosis	O
of	O	O
2	B-CHEM
,	I-CHEM
8	I-CHEM
-	I-CHEM
dihydroxyadenine	I-CHEM
nephropathy	B-DISO
-induced	O	O
end	B-DISO
-	I-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
,	O	O
made	O	O
on	O	O
the	O	O
native	O
nephrectomy	B-PROC
that	O	O
accompanied	O	O
the	O	O
renal	B-PROC
transplant	I-PROC
,	O	O
and	O	O
who	O	O
had	O	O
a	O	O
timely	O	O
intervention	O	O
that	O	O
prevented	O
recurrence	B-DISO
in	O	O
the	O	O
graft	B-PROC
.	O	O

Effect	O
of	O	O
Low	O
-	O	O
Dose	O
MDCT	B-PROC
and	O	O
Iterative	B-PROC
Reconstruction	I-PROC
on	O	O
Trabecular	O
Bone	O
Microstructure	O
Assessment	O
We	O	O
investigated	O
the	O	O
effects	O
of	O
low	O
-	O	O
dose	O
multi	B-PROC
detector	I-PROC
computed	I-PROC
tomography	I-PROC
(	O	O
MDCT	B-PROC
)	O	O
in	O	O
combination	O
with	O	O
statistical	B-PROC
iterative	I-PROC
reconstruction	I-PROC
algorithms	O
on	O	O
trabecular	O
bone	O
microstructure	O
parameters	O
.	O	O

Twelve	O
donated	B-PROC
vertebrae	B-ANAT
were	O	O
scanned	B-PROC
with	O	O
the	O	O
routine	O
radiation	B-PROC
exposure	I-PROC
used	O	O
in	O	O
our	O	O
department	O
(	O	O
standard	O
-	O
dose	O
)	O	O
and	O	O
a	O	O
low	O
-	O	O
dose	O
protocol	B-PROC
.	O	O

Reconstructions	B-PROC
were	O	O
performed	O
with	O	O
filtered	B-PROC
backprojection	I-PROC
(	O	O
FBP	B-PROC
)	O	O
and	O	O
maximum	B-PROC
-	I-PROC
likelihood	I-PROC
based	O	O
statistical	B-PROC
iterative	I-PROC
reconstruction	I-PROC
(	O	O
SIR	B-PROC
)	O	O
.	O	O

Trabecular	O
bone	O
microstructure	O
parameters	O
were	O	O
assessed	O
and	O	O
statistically	O
compared	O
for	O	O
each	O	O
reconstruction	B-PROC
.	O	O

Moreover	O	O
,	O	O
fracture	B-DISO
loads	I-DISO
of	O	O
the	O	O
vertebrae	B-ANAT
were	O	O
biomechanically	B-PROC
determined	O	O
and	O	O
correlated	O
to	O	O
the	O	O
assessed	O
microstructure	O
parameters	O
.	O	O

Trabecular	O
bone	O
microstructure	O
parameters	O
based	O	O
on	O	O
low	O
-	O	O
dose	O
MDCT	B-PROC
and	O	O
SIR	B-PROC
significantly	O	O
correlated	O
with	O	O
vertebral	B-ANAT
bone	I-ANAT
strength	O
.	O	O

There	O	O
was	O	O
no	B-DISO
significant	I-DISO
difference	O	O
between	O	O
microstructure	O
parameters	O
calculated	O	O
on	O	O
low	O
-	O	O
dose	O
SIR	B-PROC
and	O	O
standard	O
-	O	O
dose	O
FBP	B-PROC
images	O
.	O	O

However	O	O
,	O	O
the	O	O
results	O	O
revealed	O
a	O	O
strong	O
dependency	O
on	O	O
the	O	O
regularization	B-PHEN
strength	O
applied	O	O
during	O	O
SIR	B-PROC
.	O	O

It	O	O
was	O	O
observed	O	O
that	O	O
stronger	O
regularization	B-PHEN
might	O	O
corrupt	O
the	O	O
microstructure	O
analysis	O
,	O	O
because	O	O
the	O	O
trabecular	O
structure	O
is	O	O
a	O	O
very	O
small	O
detail	O	O
that	O	O
might	O	O
get	O	O
lost	O
during	O	O
the	O	O
regularization	B-PHEN
process	I-PHEN
.	O	O

As	O	O
a	O	O
consequence	O
,	O	O
the	O	O
introduction	O
of	O	O
SIR	B-PROC
for	O	O
trabecular	O
bone	O
microstructure	O
analysis	O
requires	O	O
a	O	O
specific	O
optimization	O
of	O	O
the	O	O
regularization	B-PHEN
parameters	O
.	O	O

Moreover	O	O
,	O	O
in	O	O
comparison	O
to	O	O
other	O	O
approaches	O
,	O	O
superior	O
noise	B-PHEN
-	O	O
resolution	O
trade	O
-	O
offs	O
can	O	O
be	O	O
found	O	O
with	O	O
the	O	O
proposed	O
methods	O
.	O	O

Social	O
capital	O
and	O	O
healthy	O
ageing	B-PHYS
in	O	O
Indonesia	B-GEOG
A	O	O
large	O
international	O
literature	O
has	O	O
found	O	O
a	O	O
positive	B-DISO
association	O
between	O	O
social	O
capital	O
and	O	O
measures	O
of	O	O
physical	B-DISO
and	O	O
mental	B-PHYS
health	I-PHYS
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
a	O	O
paucity	O	O
of	O	O
research	B-PROC
on	O	O
the	O	O
links	O
between	O	O
social	O
capital	O
and	O	O
healthy	O
ageing	B-PHYS
in	O	O
a	O	O
developing	O
country	O
environment	O
,	O	O
where	O	O
universal	O
social	O
security	O
coverage	O
is	O	O
absent	O
and	O	O
health	O
infrastructure	O
is	O	O
poor	O
.	O	O

In	O	O
this	O	O
paper	O	O
,	O	O
we	O	O
develop	O	O
and	O	O
empirically	O	O
test	O
a	O	O
model	O
of	O	O
the	O	O
linkages	O
between	O	O
social	O
capital	O
and	O	O
the	O	O
health	O
outcomes	O
for	O	O
older	B-LIVB
adults	I-LIVB
in	O	O
Indonesia	B-GEOG
,	O	O
using	O	O
data	O
from	O	O
the	O	O
Indonesian	O
Family	O
Life	O
Survey	O
-	O
East	O
(	O	O
IFLS	O
-	O
East	O
)	O	O
,	O	O
conducted	O	O
in	O	O
2012	O	O
.	O	O

Using	O	O
multivariate	O
regression	O
analysis	O
,	O	O
we	O	O
examine	O	O
whether	O	O
social	O
capital	O
plays	O	O
a	O	O
role	O
in	O	O
mitigating	O
poor	B-DISO
health	I-DISO
among	O	O
older	B-LIVB
individuals	B-LIVB
aged	B-PHYS
50	O	O
years	O
and	O	O
above	O	O
in	O	O
Indonesia	B-GEOG
'	O	O
s	O	O
most	O	O
vulnerable	B-GEOG
provinces	I-GEOG
.	O	O

We	O	O
test	O
the	O	O
robustness	O
of	O	O
these	O	O
social	O
capital	O
variables	O
across	O	O
different	O	O
health	O
measures	O
(	O	O
self	O
-	O
assessed	O
health	O
,	O	O
Activities	O
of	O
Daily	O
Living	O
(	O	O
ADL	O
)	O	O
,	O	O
measures	O
of	O	O
chronic	B-DISO
illness	I-DISO
and	O	O
mental	B-PHYS
health	I-PHYS
measures	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
across	O	O
different	O	O
demographic	O
groups	O
,	O	O
after	O	O
controlling	O
for	O	O
an	O	O
array	O
of	O	O
socio	O
-	O
economic	O
,	O	O
demographic	O
and	O	O
geographic	O
characteristics	O
.	O	O

Our	O	O
findings	B-DISO
show	O	O
that	O	O
access	O
to	O	O
better	O	O
social	O
capital	O
(	O	O
using	O	O
measures	O
of	O	O
neighbourhood	B-LIVB
trust	O
and	O	O
community	O
participation	O
)	O	O
is	O	O
associated	O
with	O
a	O	O
higher	O
degree	O
of	O	O
physical	B-PHYS
mobility	I-PHYS
,	O	O
independence	O
,	O	O
and	O	O
mental	B-PHYS
well	I-PHYS
-	I-PHYS
being	I-PHYS
among	O	O
older	B-LIVB
individuals	B-LIVB
but	O	O
has	O	O
no	O	O
influence	O
on	O	O
chronic	B-DISO
illnesses	I-DISO
.	O	O

These	O	O
results	O
are	O	O
consistent	O
when	O	O
we	O	O
estimate	O
samples	B-LIVB
disaggregated	O	O
by	O	O
gender	B-PHYS
,	O	O
rural	B-DISO
/	O	O
urban	O
residence	O
,	O	O
and	O	O
by	O	O
age	B-PHYS
categories	O
.	O	O

From	O	O
a	O	O
policy	O
perspective	O	O
these	O	O
results	O
point	O	O
to	O	O
the	O	O
importance	O	O
of	O	O
social	O
capital	O
measures	O
in	O	O
moderating	O
the	O	O
influence	O
of	O	O
poor	B-DISO
health	I-DISO
,	O	O
particularly	O	O
in	O	O
the	O	O
Activities	O
of	O
Daily	O
Living	O
.	O	O

Modulation	O
of	O	O
Interleukins	B-CHEM
in	O	O
Sepsis	B-DISO
-	O	O
Associated	O
Clotting	B-DISO
Disorders	I-DISO
:	O	O
Interplay	O	O
With	O	O
Hemostatic	B-DISO
Derangement	I-DISO
Interleukins	B-CHEM
play	O	O
a	O	O
central	O
role	O
in	O	O
the	O	O
immune	B-ANAT
system	I-ANAT
and	O	O
are	O	O
involved	O
in	O	O
a	O	O
variety	O	O
of	O	O
immunological	B-DISO
,	O	O
inflammatory	B-DISO
,	O	O
and	O	O
infectious	B-DISO
disease	I-DISO
states	O
including	O	O
sepsis	B-DISO
syndrome	I-DISO
.	O	O

Levels	O
of	O	O
interleukins	B-CHEM
may	O	O
correlate	O
with	O	O
overall	O
survival	O
and	O	O
may	O	O
directly	O
or	O	O
indirectly	O
affect	B-PHYS
some	O	O
of	O	O
the	O	O
regulators	B-CHEM
of	O	O
coagulation	B-PHYS
and	O	O
fibrinolysis	B-PHYS
,	O	O
thereby	O	O
disrupting	O	O
hemostasis	B-PHYS
and	O	O
thrombosis	B-DISO
.	O	O

Our	O	O
hypothesis	O
is	O	O
that	O	O
in	O	O
sepsis	B-DISO
-	I-DISO
associated	I-DISO
coagulopathies	I-DISO
(	O	O
SACs	B-DISO
)	O	O
,	O	O
interleukins	B-CHEM
may	O	O
be	O	O
upregulated	B-PHYS
,	O	O
leading	O	O
to	O	O
hemostatic	B-DISO
imbalance	I-DISO
by	O	O
generating	O	O
thrombogenic	B-CHEM
mediators	I-CHEM
.	O	O

We	O	O
profiled	O
the	O	O
levels	O
of	O	O
interleukins	B-CHEM
IL	B-CHEM
-	I-CHEM
1α	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
,	O	O
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
in	O
addition	O
to	O
d	B-CHEM
-	I-CHEM
dimer	I-CHEM
(	O	O
DD	B-CHEM
)	O	O
in	O	O
patients	B-LIVB
with	O	O
SAC	B-DISO
and	O	O
in	O	O
normal	O
donors	B-LIVB
.	O	O

We	O	O
observed	O
the	O	O
highest	O
increase	O
in	O	O
interleukins	B-CHEM
IL	B-CHEM
-	I-CHEM
6	I-CHEM
(	O	O
322	O
-	O
fold	O
)	O	O
,	O	O
IL	B-CHEM
-	I-CHEM
8	I-CHEM
(	O	O
48	O
-	O
fold	O
)	O	O
,	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
(	O	O
72	O
-	O
fold	O
)	O	O
,	O	O
and	O	O
DD	B-CHEM
(	O	O
18	O
-	O
fold	O
)	O	O
.	O	O

This	O	O
suggests	O
that	O	O
interleukins	B-CHEM
such	O	O
as	O	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
have	O	O
a	O	O
close	O	O
association	O
with	O
coagulopathy	B-DISO
and	O	O
fibrinolytic	O
dysregulation	O
in	O	O
sepsis	B-DISO
and	O	O
can	O	O
be	O	O
considered	O
as	O	O
candidates	B-CHEM
for	O	O
potential	O
therapeutic	O
targets	O
in	O	O
SAC	B-DISO
.	O	O

Fine	O
-	O	O
scale	O
spatial	O
genetic	O
structure	O
of	O	O
a	O	O
fungal	B-LIVB
parasite	O
of	O	O
coffee	O
scale	O
insects	O
The	O	O
entomopathogenic	B-LIVB
fungus	I-LIVB
Lecanicillium	B-LIVB
lecanii	I-LIVB
persists	O	O
in	O	O
a	O	O
highly	O
dynamic	O
network	O
of	O	O
habitat	O
patches	O
(	O	O
i	O	O
.	O	O
e	O	O
.	O	O
,	O	O
a	O	O
metapopulation	B-LIVB
)	O	O
formed	O
by	O	O
its	O	O
primary	O
host	B-LIVB
,	O	O
the	O	O
green	O
coffee	O
scale	O
Coccus	O
viridis	O
.	O	O

Lecanicillium	B-LIVB
lecanii	I-LIVB
is	O	O
an	O	O
important	O
biological	B-PHEN
control	I-PHEN
of	O	O
both	O
C	O
.	O

viridis	O
and	O	O
the	O	O
coffee	B-LIVB
rust	I-LIVB
,	O	O
Hemileia	B-LIVB
vastatrix	I-LIVB
.	O	O

Successfully	O	O
managing	O	O
this	O	O
biocontrol	B-PHEN
agent	B-CHEM
will	O	O
depend	O	O
on	O	O
an	O	O
increased	O
understanding	B-PHYS
of	O	O
the	O	O
characteristics	O
of	O	O
its	O	O
dispersal	O
,	O	O
as	O	O
migration	O	O
between	O	O
occupied	O
and	O	O
unoccupied	O
patches	O
is	O	O
essential	O
for	O	O
the	O	O
persistence	B-PHYS
of	O	O
this	O	O
metapopulation	B-LIVB
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
employ	O
a	O	O
population	O
genetics	O
approach	O
,	O	O
and	O	O
show	O	O
that	O	O
in	O	O
our	O	O
study	B-PROC
system	O
,	O	O
a	O	O
coffee	B-OBJC
farm	O
in	O	O
the	O	O
Soconusco	B-GEOG
region	B-GEOG
of	O	O
southern	O
Mexico	B-GEOG
,	O	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
is	O	O
characterized	O
by	O	O
clear	O
spatial	O
genetic	O
structure	O
among	O	O
plots	O	O
within	O	O
the	O	O
farm	O
but	O	O
a	O	O
lack	O
of	O	O
apparent	O
structure	O
at	O	O
smaller	O	O
scales	O	O
.	O	O

This	O	O
is	O	O
consistent	O
with	O
dispersal	O
dominated	O
by	O	O
highly	O
localized	O
transport	O
,	O	O
such	O	O
as	O	O
by	O	O
insects	O
or	O	O
rain	B-PHEN
splash	O	O
,	O	O
and	O	O
less	O
dependence	B-DISO
on	O	O
longer	O
distance	O
dispersal	O
such	O	O
as	O	O
wind	B-PHEN
transport	O
.	O	O

The	O	O
study	O
site	O
was	O	O
dominated	O
by	O	O
a	O	O
few	O
multi	B-PHYS
-	I-PHYS
locus	I-PHYS
microsatellite	I-PHYS
genotypes	I-PHYS
,	O	O
and	O	O
their	O	O
identities	O
and	O	O
large	O
-	O	O
scale	O
locations	O
persist	O	O
across	O	O
both	O
study	B-PROC
years	O
,	O	O
suggesting	O
that	O	O
local	O
epizootics	B-PHEN
(	O	O
outbreaks	B-PHEN
)	O	O
are	O	O
initiated	O
each	O	O
wet	O
season	O
by	O	O
residual	O
propagules	O	O
from	O	O
the	O	O
previous	O
wet	O
season	O
,	O	O
and	O	O
not	O	O
by	O	O
long	O
-	O	O
distance	O
transport	O
of	O	O
propagules	O	O
from	O	O
other	O
sites	O
.	O	O

The	O	O
index	O
of	O
association	O
,	O	O
a	O	O
measure	O
of	O	O
linkage	O
disequilibrium	O
,	O	O
indicates	O
that	O	O
epizootics	B-PHEN
are	O	O
primarily	O	O
driven	O	O
by	O	O
asexual	B-PHYS
,	O	O
clonal	B-PHYS
reproduction	I-PHYS
,	O	O
which	O	O
is	O	O
consistent	O
with	O
the	O	O
apparent	O
lack	O
of	O	O
a	O	O
teleomorph	B-LIVB
in	O	O
the	O	O
study	O
site	O
and	O	O
the	O	O
presence	B-DISO
of	O	O
only	O	O
a	O	O
single	O
mating	B-PHYS
type	I-PHYS
across	O	O
the	O	O
site	O
(	O	O
MAT	B-PHYS
-	I-PHYS
1	I-PHYS
-	I-PHYS
2	I-PHYS
-	I-PHYS
1	I-PHYS
)	O	O
.	O	O

Although	O	O
the	O	O
same	O
predominant	O
clonal	O
genotypes	B-PHYS
were	O	O
found	B-DISO
across	O	O
years	O
,	O	O
a	O	O
drastic	O
difference	O
in	O	O
genotypic	B-PHYS
diversity	O
was	O	O
witnessed	O	O
across	O	O
two	O
sites	O
between	O	O
the	O	O
two	O
years	O
,	O	O
suggesting	O
that	O	O
interclonal	O	O
selection	O	O
was	O	O
occurring	O
.	O	O

In	O	O
light	O	O
of	O	O
the	O	O
dispersal	O
limitation	O	O
of	O	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
,	O	O
spatial	O
structure	O
may	O	O
be	O	O
an	O	O
essential	O
axis	O	O
of	O	O
management	O	O
to	O	O
ensure	O	O
the	O	O
persistence	O	O
of	O	O
L	B-LIVB
.	I-LIVB

lecanii	I-LIVB
and	O	O
preserve	O	O
the	O	O
ecosystem	B-PHEN
services	O
provided	O	O
by	O	O
this	O	O
versatile	O	O
biocontrol	B-PHEN
agent	B-CHEM
in	O	O
this	O	O
and	O	O
similar	O
coffee	O
farms	O
.	O	O

Estradiol	B-CHEM
prodrugs	B-CHEM
(	O	O
EP	B-CHEM
)	O	O
for	O	O
efficient	O	O
oral	B-PROC
estrogen	O
treatment	O
and	O	O
abolished	O	O
effects	O	O
on	O	O
estrogen	B-CHEM
modulated	O	O
liver	B-PHYS
functions	I-PHYS
Oral	B-PROC
compared	O	O
to	O	O
parenteral	B-PROC
estrogen	O
administration	O
is	O	O
characterized	O	O
by	O	O
reduced	O	O
systemic	O
but	O	O
prominent	O	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
on	O	O
lipids	B-CHEM
,	O	O
hemostatic	B-PHYS
factors	I-PHYS
,	O	O
GH	B-CHEM
-	O	O
/	O	O
IGF	B-CHEM
I	I-CHEM
axis	O	O
,	O	O
angiotensinogen	B-CHEM
.	O	O

In	O	O
order	O	O
to	O	O
avoid	O	O
such	O	O
adverse	O	O
metabolic	B-PHYS
effects	I-PHYS
of	O	O
oral	B-PROC
treatment	I-PROC
,	O	O
estradiol	B-CHEM
(	O	O
E2	B-CHEM
)	O	O
prodrugs	B-CHEM
(	O	O
EP	B-CHEM
)	O	O
were	O	O
designed	O	O
which	O	O
bypass	O	O
the	O	O
liver	B-ANAT
tissue	I-ANAT
as	O	O
inactive	O	O
molecules	O	O
.	O	O

Carbone17	B-CHEM
-	I-CHEM
OH	I-CHEM
sulfonamide	I-CHEM
[	I-CHEM
-O2	I-CHEM
-	I-CHEM
NH2	I-CHEM
]	I-CHEM
substituted	I-CHEM
esters	I-CHEM
of	O	O
E2	B-CHEM
(	O	O
EC508	B-CHEM
,	O	O
others	O	O
)	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
carbonic	B-CHEM
anhydrase	I-CHEM
II	I-CHEM
(	O	O
CA	B-CHEM
-	I-CHEM
II	I-CHEM
)	O	O
binding	B-PHYS
.	O	O

CA	B-CHEM
II	I-CHEM
in	O	O
erythrocytes	B-ANAT
is	O	O
thought	O	O
to	O	O
oppose	O	O
extraction	O	O
of	O	O
EP	B-CHEM
from	O	O
portal	O
vein	O
blood	O
during	O	O
liver	B-ANAT
passage	O
.	O	O

Ovariectomized	B-DISO
(	O	O
OVX	B-DISO
,	O	O
day	O	O
minus	O	O
14	O	O
)	O	O
rats	B-LIVB
were	O	O
orally	B-PROC
treated	I-PROC
once	O	O
daily	O	O
from	O	O
day	O	O
1	O	O
-	O	O
3	O	O
.	O	O

Sacrifice	O	O
day	O	O
4	O	O
.	O	O

Uteri	B-ANAT
were	O	O
dissected	O
and	O	O
weighed	B-PROC
.	O	O

Cholesterol	B-PROC
fractions	I-PROC
and	O	O
angiotensinogen	B-PROC
were	O	O
determined	O	O
in	O	O
plasma	B-ANAT
.	O	O

Oral	B-CHEM
E2	I-CHEM
and	O	O
ethinyl	B-CHEM
estradiol	I-CHEM
(	O	O
EE	B-CHEM
)	O	O
generated	O	O
dose	O	O
related	O	O
uterine	B-ANAT
growth	B-PHYS
and	O	O
important	O	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
.	O	O

EP	B-CHEM
induced	O	O
uterine	B-PHYS
growth	I-PHYS
at	O	O
about	O	O
hundred	O	O
-	O	O
fold	O	O
lower	O	O
doses	O	O
.	O	O

This	O	O
was	O	O
possible	O	O
with	O	O
almost	O	O
absent	O	O
effects	O	O
on	O	O
plasma	B-ANAT
cholesterol	B-CHEM
or	O	O
angiotensinogen	B-CHEM
.	O	O

Preliminary	O	O
pharmacokinetic	B-PROC
studies	I-PROC
with	O	O
EC508	B-CHEM
used	O	O
intravenous	O
and	O	O
oral	B-PROC
administration	I-PROC
in	O	O
male	B-PHYS
rats	B-LIVB
.	O	O

Resulting	O	O
blood	O	O
levels	O	O
revealed	O	O
complete	O	O
oral	B-PROC
bioavailability	O
.	O	O

Further	O	O
high	O	O
blood	B-ANAT
-	O	O
but	O	O
low	O	O
plasma	B-ANAT
concentrations	O	O
indicated	O	O
erythrocyte	B-ANAT
binding	O
of	O	O
EC508	B-CHEM
in	O
vivo	O
as	O	O
potential	O	O
mechanism	O	O
of	O	O
low	O	O
extraction	O	O
at	O	O
liver	B-ANAT
passage	O
.	O	O

Very	O	O
high	O	O
systemic	O
estrogenicity	B-CHEM
combined	O	O
with	O	O
markedly	O	O
lower	O	O
or	O	O
absent	O	O
adverse	O	O
hepatic	B-ANAT
estrogenic	B-DISO
effects	I-DISO
is	O	O
evidence	O	O
for	O	O
a	O	O
systemic	O
release	O	O
of	O	O
E2	B-CHEM
from	O	O
sulfonamide	B-CHEM
EP	I-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
tested	O	O
oral	B-PROC
EP	B-CHEM
bypass	O	O
the	O	O
liver	B-ANAT
in	O	O
erythrocytes	B-ANAT
furnishing	O	O
systemic	O
estradiol	B-CHEM
at	O	O
hydrolysis	B-PHEN
.	O	O

This	O	O
mechanism	O	O
avoids	O	O
the	O	O
hepatic	B-ANAT
estrogenic	O
impact	O	O
of	O	O
conventional	O	O
oral	B-PROC
estrogen	B-PROC
therapy	I-PROC
.	O	O

Externally	O
Connected	O
Zirconia	B-CHEM
Abutments	B-DEVI
with	O	O
Standard	O	O
Platform	O	O
are	O	O
Successful	O	O
Long	O
Term	O
in	O	O
Anterior	B-ANAT
Regions	I-ANAT
Performance	O
of	O	O
zirconia	B-CHEM
abutments	B-DEVI
for	O	O
implant	B-PROC
-	I-PROC
supported	I-PROC
single	I-PROC
-	I-PROC
tooth	I-PROC
crowns	I-PROC
in	O	O
esthetic	B-ANAT
areas	I-ANAT
:	O	O
a	O	O
retrospective	B-PROC
study	I-PROC
up	O	O
to	O	O
12	O
-	O
year	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Passos	O	O
SP	O	O
,	O	O
Linke	O	O
B	O	O
,	O	O
Larjava	O	O
H	O	O
,	O	O
French	O	O
D	O	O
.	O	O

Clin	O	O
Oral	O	O
Implants	O	O
Res	O	O
2016	O	O
;	O	O
27	O	O
(	O	O
1	O	O
)	O	O
:	O	O
47	O	O
-	O	O
54	O	O
.	O	O

Information	O	O
not	O	O
available	O	O
Retrospective	B-PROC
cohort	I-PROC
study	I-PROC
.	O	O

Peripheral	O
interactions	O
between	O	O
cannabinoid	B-CHEM
and	O	O
opioid	B-CHEM
receptor	I-CHEM
agonists	B-CHEM
in	O	O
a	O	O
model	B-DISO
of	O	O
inflammatory	B-DISO
mechanical	B-DISO
hyperalgesia	I-DISO
Activation	B-PHYS
of	O	O
opioid	B-CHEM
and	O	O
cannabinoid	B-CHEM
receptors	I-CHEM
expressed	B-PHYS
in	O	O
nociceptors	B-ANAT
induces	O	O
effective	O	O
antihyperalgesia	B-DISO
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
combinations	O
of	O	O
opioid	B-CHEM
and	O	O
cannabinoid	B-CHEM
receptor	I-CHEM
agonists	B-CHEM
directed	O	O
at	O	O
the	O	O
injured	O
site	O
would	O	O
enhance	O	O
therapeutic	O
effectiveness	O
.	O	O

Behavioral	O
pharmacology	O
experiments	B-PROC
were	O	O
performed	O	O
to	O	O
compare	O
the	O	O
effects	O
of	O
DAMGO	B-CHEM
,	O	O
a	O	O
selective	O	O
agonist	B-CHEM
for	O	O
μ	B-CHEM
-	I-CHEM
opioid	I-CHEM
receptor	I-CHEM
(	O	O
MOR	B-CHEM
)	O	O
,	O	O
ACPA	B-CHEM
,	O	O
a	O	O
specific	O	O
agonist	B-CHEM
for	O	O
CB1	B-CHEM
,	O	O
and	O	O
combinations	O
of	O	O
DAMGO	B-CHEM
and	O	O
ACPA	B-CHEM
in	O	O
attenuating	O
complete	B-CHEM
Freund	I-CHEM
's	I-CHEM
adjuvant	I-CHEM
(	O	O
CFA	B-CHEM
)	O	O
-	O	O
induced	O	O
mechanical	B-DISO
hyperalgesia	I-DISO
in	O	O
the	O	O
rat	B-LIVB
hindpaw	B-ANAT
.	O	O

DAMGO	B-CHEM
(	O	O
1μg	O	O
-	O	O
1	O	O
mg	O	O
)	O	O
or	O	O
ACPA	B-CHEM
(	O	O
1μg	O	O
-	O	O
2	O	O
mg	O	O
)	O	O
was	O	O
administered	O
into	O	O
the	O	O
inflamed	B-DISO
paw	B-ANAT
when	O	O
mechanical	B-DISO
hyperalgesia	I-DISO
was	O	O
fully	O	O
developed	O	O
.	O	O

When	O	O
administered	O
individually	O	O
,	O	O
DAMGO	B-CHEM
and	O	O
ACPA	B-CHEM
dose	O
-dependently	O	O
reversed	O	O
the	O	O
mechanical	B-DISO
hyperalgesia	I-DISO
.	O	O

DAMGO	B-CHEM
displayed	O	O
a	O	O
lower	O	O
ED50	O
value	O
(	O	O
57	O	O
.	O	O

4±2	O	O
.	O	O

49μg	O	O
)	O	O
than	O	O
ACPA	B-CHEM
(	O	O
111	O	O
.	O	O

6±2	O	O
.	O	O

18μg	O	O
)	O	O
,	O	O
but	O	O
ACPA	B-CHEM
produced	O	O
longer	O	O
lasting	O	O
antihyperalgesic	B-DISO
effects	I-DISO
.	O	O

Combinations	O
of	O	O
DAMGO	B-CHEM
and	O	O
ACPA	B-CHEM
also	O	O
dose	O
-dependently	O	O
attenuated	O
mechanical	B-DISO
hyperalgesia	I-DISO
,	O	O
but	O	O
the	O	O
antihyperalgesic	B-DISO
effects	I-DISO
were	O	O
partial	O
and	O	O
transient	O
even	O	O
at	O	O
high	O
doses	O
.	O	O

Using	O	O
isobolographic	B-PROC
analysis	I-PROC
,	O	O
we	O	O
determined	O	O
that	O	O
combined	O	O
treatment	B-PROC
with	O	O
DAMGO	B-CHEM
and	O	O
ACPA	B-CHEM
produced	O	O
antagonistic	O
effects	O
with	O	O
the	O	O
observed	O	O
ED50	O
of	O	O
128	O	O
.	O	O

4±2	O	O
.	O	O

28μg	O	O
.	O	O

Our	O	O
findings	O
showed	O	O
that	O	O
MOR	B-CHEM
and	O	O
CB1	B-CHEM
agonists	B-CHEM
directed	O	O
at	O	O
the	O	O
inflamed	B-DISO
site	O
effectively	O	O
attenuate	O
mechanical	B-DISO
hyperalgesia	I-DISO
when	O	O
administered	O
individually	O	O
,	O	O
but	O	O
exert	B-PHYS
opposing	O	O
effects	O	O
when	O	O
administered	O
together	O	O
.	O	O

The	O	O
antagonistic	O
interactions	O
between	O	O
the	O	O
two	O	O
classes	O	O
of	O	O
drugs	B-CHEM
at	O	O
the	O	O
inflamed	B-DISO
site	O
suggest	O	O
distinct	O	O
mechanisms	O	O
unique	O
to	O	O
peripheral	O
nociceptors	B-ANAT
or	O	O
inflamed	B-DISO
tissue	O
,	O	O
and	O	O
therefore	O	O
require	O	O
further	O	O
studies	O	O
to	O	O
investigate	O
whether	O	O
the	O	O
therapeutic	O
utility	O
of	O	O
the	O	O
combined	O
drug	B-PROC
treatments	I-PROC
in	O	O
chronic	B-DISO
pain	I-DISO
conditions	O	O
can	O	O
be	O	O
optimized	O
.	O	O

Thymosin	B-CHEM
β4	I-CHEM
:	O	O
Roles	O	O
in	O	O
Development	O
,	O	O
Repair	B-PHYS
,	O	O
and	O	O
Engineering	O
of	O	O
the	O	O
Cardiovascular	B-ANAT
System	I-ANAT
The	O	O
burden	O	O
of	O	O
cardiovascular	B-DISO
disease	I-DISO
is	O	O
a	O	O
growing	O	O
worldwide	O	O
issue	O	O
that	O	O
demands	O	O
attention	O	O
.	O	O

While	O	O
many	O	O
clinical	B-PROC
trials	I-PROC
are	O	O
ongoing	O	O
to	O	O
test	O
therapies	B-PROC
for	O	O
treating	O
the	O	O
heart	B-ANAT
after	O	O
myocardial	B-DISO
infarction	I-DISO
(	O	O
MI	B-DISO
)	O	O
and	O	O
heart	B-DISO
failure	I-DISO
,	O	O
there	O	O
are	O	O
few	O	O
options	O	O
doctors	B-LIVB
able	O	O
to	O	O
currently	O	O
give	O	O
patients	B-LIVB
to	O	O
repair	B-PROC
the	I-PROC
heart	I-PROC
.	O	O

This	O	O
eventually	O	O
leads	O	O
to	O	O
decreased	O	O
ventricular	B-PHYS
contractility	I-PHYS
and	O	O
increased	O	O
systemic	B-DISO
disease	I-DISO
,	O	O
including	O	O
vascular	B-DISO
disorders	I-DISO
that	O	O
could	O	O
result	O	O
in	O	O
stroke	B-DISO
.	O	O

Small	O	O
peptides	B-CHEM
such	O	O
as	O	O
thymosin	B-CHEM
β4	I-CHEM
(	O	O
Tβ4	B-CHEM
)	O	O
are	O	O
upregulated	O	O
in	O	O
the	O	O
cardiovascular	B-ANAT
niche	B-ANAT
during	O	O
fetal	B-PHYS
development	I-PHYS
and	O	O
after	O	O
injuries	B-DISO
such	O	O
as	O	O
MI	B-DISO
,	O	O
providing	O	O
increased	O	O
neovasculogenesis	B-DISO
and	O	O
paracrine	B-PHYS
signals	I-PHYS
for	O	O
endogenous	B-ANAT
stem	I-ANAT
cell	I-ANAT
recruitment	O	O
to	O	O
aid	O	O
in	O	O
wound	B-PHYS
repair	I-PHYS
.	O	O

New	O	O
research	B-PROC
is	O	O
looking	O	O
into	O	O
the	O	O
effects	O	O
of	O	O
in	O
vivo	O
administration	B-PROC
of	O	O
Tβ4	B-CHEM
through	O	O
injections	B-PROC
and	O	O
coatings	B-CHEM
on	O	O
implants	B-DEVI
,	O	O
as	O	O
well	O	O
as	O	O
its	O	O
effect	O	O
on	O	O
cell	B-PHYS
differentiation	I-PHYS
.	O	O

Results	O	O
so	O	O
far	O	O
demonstrate	O	O
Tβ4	B-CHEM
administration	B-PROC
leads	O	O
to	O	O
robust	O	O
increases	O	O
in	O	O
angiogenesis	B-PHYS
and	O	O
wound	B-PHYS
healing	I-PHYS
in	O	O
the	O	O
heart	B-ANAT
after	O	O
MI	B-DISO
and	O	O
the	O	O
brain	B-ANAT
after	O	O
stroke	B-DISO
,	O	O
and	O	O
can	O	O
differentiate	O	O
adult	B-ANAT
stem	I-ANAT
cells	I-ANAT
toward	O	O
the	O	O
cardiac	B-ANAT
lineage	O
for	O	O
implantation	B-PROC
to	O	O
the	O	O
heart	B-ANAT
to	O	O
increase	O	O
contractility	B-PHYS
and	O	O
survival	O
.	O	O

Future	O	O
work	O	O
,	O	O
some	O	O
of	O	O
which	O	O
is	O	O
currently	O	O
in	O	O
clinical	B-PROC
trials	I-PROC
,	O	O
will	O	O
demonstrate	O	O
the	O	O
in	O
vivo	O
effect	O
of	O	O
these	O	O
therapies	B-PROC
on	O	O
human	B-LIVB
patients	B-LIVB
,	O	O
with	O	O
the	O	O
goal	O
of	O	O
helping	O	O
the	O	O
millions	O	O
of	O	O
people	B-LIVB
worldwide	O	O
affected	O	O
by	O	O
cardiovascular	B-DISO
disease	I-DISO
.	O	O

Differences	O
in	O	O
pain	B-DISO
experience	B-PHYS
and	O	O
cooperation	O
between	O	O
consecutive	B-PROC
surgeries	I-PROC
in	O	O
patients	B-LIVB
undergoing	O	O
phacoemulsification	B-PROC
The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
compare	O	O
pain	B-DISO
experience	B-PHYS
and	O	O
cooperation	O
between	O	O
consecutive	B-PROC
surgeries	I-PROC
in	O	O
patients	B-LIVB
undergoing	O	O
phacoemulsification	B-PROC
in	O	O
both	O	O
eyes	B-ANAT
,	O	O
using	O	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
local	I-PROC
anesthesia	I-PROC
without	O	O
sedation	B-PROC
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
268	O	O
patients	B-LIVB
with	O	O
bilateral	B-DISO
senile	I-DISO
cataracts	I-DISO
were	O	O
recruited	O	O
.	O	O

All	O	O
operations	B-PROC
were	O	O
performed	O	O
without	O	O
sedation	B-PROC
,	O	O
using	O	O
a	O	O
clear	O	O
corneal	B-ANAT
phacoemulsification	B-PROC
technique	I-PROC
and	O	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
local	I-PROC
anesthesia	I-PROC
,	O	O
by	O	O
one	O	O
of	O	O
four	O	O
surgeons	B-LIVB
.	O	O

The	O	O
first	O	O
surgery	B-PROC
was	O	O
performed	O	O
on	O	O
the	O	O
eye	B-ANAT
with	O	O
the	O	O
higher	O	O
grade	O	O
cataract	B-DISO
.	O	O

The	O	O
other	O	O
eye	B-ANAT
was	O	O
operated	O
on	O	O
within	O	O
3	O
months	O
by	O	O
the	O	O
same	O	O
surgeon	B-LIVB
(	O	O
mean	O	O
interval	O	O
1	O	O
.	O	O
9	O	O
±	O	O
1	O	O
.	O	O
1	O	O
months	O
)	O	O
.	O	O

All	O	O
patients	B-LIVB
were	O	O
asked	O	O
to	O	O
grade	O	O
their	O	O
pain	B-DISO
experience	B-PHYS
during	O	O
induction	B-PROC
and	O	O
maintenance	O
of	O	O
anesthesia	B-PROC
and	O	O
also	O	O
during	O	O
the	O	O
phacoemulsification	B-PROC
surgery	I-PROC
,	O	O
using	O	O
a	O	O
visual	B-PROC
analogue	I-PROC
scale	I-PROC
(	O	O
VAS	B-PROC
)	O	O
from	O	O
0	O	O
(	O	O
no	B-DISO
pain	I-DISO
)	O	O
to	O	O
10	O	O
(	O	O
unbearable	B-DISO
pain	I-DISO
)	O	O
administered	O	O
after	O	O
the	O	O
surgery	B-PROC
.	O	O

The	O	O
cooperation	O
of	O	O
the	O	O
patient	B-LIVB
was	O	O
graded	O	O
from	O	O
0	O	O
(	O	O
no	O	O
event	O	O
)	O	O
to	O	O
3	O	O
(	O	O
markedeye	B-PHYS
and	O	O
head	B-PHYS
movement	I-PHYS
and	O	O
lid	B-DISO
squeezing	I-DISO
)	O	O
by	O	O
the	O	O
attending	O	O
surgeon	B-LIVB
.	O	O

The	O	O
VAS	O
scores	O
and	O	O
cooperation	O
scores	O
of	O	O
the	O	O
patients	B-LIVB
were	O	O
the	O	O
outcome	O
measurements	O
.	O	O

The	O	O
mean	B-DISO
pain	I-DISO
score	I-DISO
was	O	O
2	O	O
.	O	O
11	O	O
±	O	O
0	O	O
.	O	O
79	O	O
in	O	O
the	O	O
first	O	O
eye	B-ANAT
and	O	O
3	O	O
.	O	O

33	O	O
±	O	O
0	O	O
.	O	O
80	O	O
in	O	O
the	O	O
second	O	O
eye	B-ANAT
during	O	O
the	O	O
administration	B-PROC
of	O	O
sub	B-PROC
-	I-PROC
Tenon	I-PROC
's	I-PROC
anesthesia	I-PROC
,	O	O
and	O	O
1	O	O
.	O	O
50	O	O
±	O	O
0	O	O
.	O	O
60	O	O
in	O	O
the	O	O
first	O	O
eye	B-ANAT
and	O	O
2	O	O
.	O	O
10	O	O
±	O	O
0	O	O
.	O	O
57	O	O
in	O	O
the	O	O
second	O	O
eye	B-ANAT
during	O	O
the	O	O
phacoemulsification	B-PROC
surgery	I-PROC
.	O	O

The	O	O
patient	O
cooperation	O
score	O
was	O	O
1	O	O
.	O	O
60	O	O
±	O	O
0	O	O
.	O	O
75	O	O
in	O	O
the	O	O
first	O	O
surgery	B-PROC
and	O	O
2	O	O
.	O	O
08	O	O
±	O	O
0	O	O
.	O	O
72	O	O
in	O	O
the	O	O
second	O	O
surgery	B-PROC
.	O	O

The	O	O
differences	O
between	O	O
the	O	O
first	O	O
and	O	O
second	O	O
surgeries	B-PROC
were	O	O
statistically	O	O
significant	O	O
for	O	O
all	O	O
outcome	O
measures	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Patients	B-LIVB
who	O	O
previously	O	O
underwent	O	O
phaco	B-PROC
surgery	I-PROC
in	O	O
one	O	O
eye	B-ANAT
experienced	O	O
more	O	O
pain	B-DISO
and	O	O
showed	O	O
worse	B-DISO
cooperation	O
during	O	O
the	O	O
phaco	B-PROC
surgery	I-PROC
in	O	O
the	O	O
second	O	O
eye	B-ANAT
,	O	O
especially	O	O
if	O	O
there	O	O
was	O	O
a	O	O
short	O	O
time	O	O
between	O	O
the	O	O
surgeries	B-PROC
,	O	O
viz	O	O
.	O	O
,	O	O
less	O	O
than	O	O
3	O	O
months	O
.	O	O

Therefore	O	O
,	O	O
if	O	O
the	O	O
surgeon	B-LIVB
has	O	O
difficulty	O
in	O	O
the	O	O
first	O	O
operation	B-PROC
gaining	O	O
the	O	O
patient	O
's	O
cooperation	O
,	O	O
the	O	O
surgeon	B-LIVB
must	O	O
be	O	O
careful	O	O
:	O	O
if	O	O
contralateral	B-PROC
eye	I-PROC
surgery	I-PROC
is	O	O
required	O	O
,	O	O
the	O	O
addition	O	O
of	O	O
sedation	B-PROC
/	O	O
analgesia	B-PROC
should	O	O
be	O	O
considered	O	O
or	O	O
the	O	O
surgery	B-PROC
postponed	O	O
for	O	O
a	O	O
while	O	O
to	O	O
abolish	O	O
the	O	O
influence	O
of	O	O
recent	B-PHYS
memory	I-PHYS
on	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
subsequent	O	O
pain	B-DISO
experience	B-PHYS
.	O	O

Yersinia	B-LIVB
ruckeri	I-LIVB
Isolates	B-CHEM
Recovered	O
from	O
Diseased	B-DISO
Atlantic	B-LIVB
Salmon	I-LIVB
(	O	O
Salmo	B-LIVB
salar	I-LIVB
)	O	O
in	O	O
Scotland	B-GEOG
Are	O	O
More	O	O
Diverse	O	O
than	O	O
Those	O	O
from	O	O
Rainbow	B-LIVB
Trout	I-LIVB
(	O	O
Oncorhynchus	B-LIVB
mykiss	I-LIVB
)	O	O
and	O	O
Represent	O
Distinct	O	O
Subpopulations	B-LIVB
Yersinia	B-LIVB
ruckeri	I-LIVB
is	O	O
the	O	O
etiological	O
agent	O
of	O	O
enteric	B-DISO
redmouth	I-DISO
(	O	O
ERM	B-DISO
)	O	O
disease	B-DISO
of	O	O
farmed	O	O
salmonids	B-LIVB
.	O	O

Enteric	B-DISO
redmouth	I-DISO
disease	I-DISO
is	O	O
traditionally	O	O
associated	O
with	O
rainbow	B-LIVB
trout	I-LIVB
(	O	O
Oncorhynchus	B-LIVB
mykiss	I-LIVB
,	O	O
Walbaum	B-LIVB
)	O	O
,	O	O
but	O	O
its	O	O
incidence	O
in	O	O
Atlantic	B-LIVB
salmon	I-LIVB
(	O	O
Salmo	B-LIVB
salar	I-LIVB
)	O	O
is	O	O
increasing	O
.	O	O

Yersinia	B-LIVB
ruckeri	I-LIVB
isolates	B-CHEM
recovered	O
from	O
diseased	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
have	O	O
been	O	O
poorly	O
characterized	O
,	O	O
and	O	O
very	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
relationship	O
of	O	O
the	O	O
isolates	B-CHEM
associated	O
with	O
these	O	O
two	O	O
species	O
.	O	O

Phenotypic	B-PHYS
approaches	O	O
were	O	O
used	O	O
to	O	O
characterize	O	O
109	O	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
isolates	B-CHEM
recovered	O	O
over	O	O
a	O	O
14	O	O
-	O	O
year	O	O
period	O	O
from	O	O
infected	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
in	O	O
Scotland	B-GEOG
;	O	O
26	O	O
isolates	B-CHEM
from	O	O
infected	B-DISO
rainbow	B-LIVB
trout	I-LIVB
were	O	O
also	O	O
characterized	O
.	O	O

Biotyping	B-PROC
,	O	O
serotyping	B-PROC
,	O	O
and	O	O
comparison	O
of	O	O
outer	B-ANAT
membrane	I-ANAT
protein	B-PHEN
profiles	I-PHEN
identified	O	O
19	O	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
clones	O
associated	O
with	O
Atlantic	B-LIVB
salmon	I-LIVB
but	O	O
only	O	O
five	O	O
associated	O
with	O
rainbow	B-LIVB
trout	I-LIVB
;	O	O
none	O	O
of	O	O
the	O	O
Atlantic	B-LIVB
salmon	I-LIVB
clones	O
occurred	O	O
in	O	O
rainbow	B-LIVB
trout	I-LIVB
and	O	O
vice	O	O
versa	O	O
These	O	O
findings	B-DISO
suggest	O	O
that	O	O
distinct	O	O
subpopulations	B-LIVB
of	O	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
are	O	O
associated	O
with	O
each	O	O
species	O
.	O	O

A	O	O
new	O	O
O	O
serotype	O
(	O	O
designated	O	O
O8	O	O
)	O	O
was	O	O
identified	O	O
in	O	O
56	O
biotype	O
1	O
Atlantic	B-LIVB
salmon	I-LIVB
isolates	B-CHEM
and	O	O
was	O	O
the	O	O
most	O	O
common	O	O
serotype	O
identified	O	O
from	O	O
2006	O	O
to	O	O
2011	O	O
and	O	O
in	O	O
2014	O	O
,	O	O
suggesting	O	O
an	O	O
increased	O
prevalence	O
during	O	O
the	O	O
time	O	O
period	O	O
sampled	O	O
.	O	O

Rainbow	B-LIVB
trout	I-LIVB
isolates	B-CHEM
were	O	O
represented	O
almost	O	O
exclusively	O	O
by	O	O
the	O	O
same	O	O
biotype	O
2	O
,	O	O
serotype	O
O1	O
clone	O	O
that	O	O
has	O	O
been	O	O
responsible	O	O
for	O	O
the	O	O
majority	O	O
of	O	O
ERM	B-DISO
outbreaks	O	O
in	O	O
this	O	O
species	O
within	O	O
the	O	O
United	B-GEOG
Kingdom	I-GEOG
since	O	O
the	O	O
1980s	O	O
.	O	O

However	O	O
,	O	O
the	O	O
identification	O	O
of	O	O
two	O	O
biotype	O
2	O
,	O	O
serotype	O
O8	O
isolates	B-CHEM
in	O	O
rainbow	B-LIVB
trout	I-LIVB
suggests	O	O
that	O	O
vaccines	B-CHEM
containing	O	O
serotypes	O
O1	O
and	O
O8	O
should	O	O
be	O	O
evaluated	O	O
in	O	O
both	O	O
rainbow	B-LIVB
trout	I-LIVB
and	O	O
Atlantic	B-LIVB
salmon	I-LIVB
for	O	O
application	O	O
in	O	O
Scotland	B-GEOG
.	O	O

Vaccination	B-PROC
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
protecting	O	O
Atlantic	B-LIVB
salmon	I-LIVB
against	O	O
the	O	O
bacterial	B-LIVB
pathogen	O	O
Yersinia	B-LIVB
ruckeri	I-LIVB
,	O	O
but	O	O
,	O	O
in	O	O
recent	O	O
years	O	O
,	O	O
there	O	O
has	O	O
been	O	O
an	O	O
increasing	O
incidence	O
of	O	O
vaccine	B-CHEM
breakdown	O	O
in	O	O
salmon	B-LIVB
.	O	O

This	O	O
is	O	O
largely	O	O
because	O	O
current	O	O
vaccines	B-CHEM
are	O	O
aimed	O	O
at	O	O
rainbow	B-LIVB
trout	I-LIVB
and	O	O
are	O	O
based	O	O
on	O	O
serotypes	O
specific	O	O
for	O	O
this	O	O
species	O
.	O	O

A	O	O
wider	O	O
range	O	O
of	O	O
serotypes	O
is	O	O
responsible	O	O
for	O	O
infection	B-DISO
in	O	O
Atlantic	B-LIVB
salmon	I-LIVB
,	O	O
but	O	O
very	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
diversity	O	O
of	O	O
these	O	O
strains	B-LIVB
and	O	O
their	O	O
relationships	O
to	O	O
those	O	O
recovered	O
from	O
rainbow	B-LIVB
trout	I-LIVB
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
isolates	B-CHEM
recovered	O
from	O
diseased	B-DISO
Atlantic	B-LIVB
salmon	I-LIVB
in	O	O
Scotland	B-GEOG
are	O	O
more	O	O
diverse	O	O
than	O	O
those	O	O
from	O	O
rainbow	B-LIVB
trout	I-LIVB
;	O	O
furthermore	O	O
,	O	O
isolates	B-CHEM
from	O	O
the	O	O
two	O	O
species	O
represent	O
distinct	O	O
subpopulations	B-LIVB
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
new	O	O
O	O
serotype	O
was	O	O
identified	O	O
that	O	O
is	O	O
responsible	O	O
for	O	O
a	O	O
significant	O
proportion	O
of	O	O
the	O	O
disease	B-DISO
in	O	O
Atlantic	B-LIVB
salmon	I-LIVB
.	O	O

Our	O	O
findings	B-DISO
are	O	O
likely	O	O
to	O	O
have	O	O
important	O	O
implications	O	O
for	O	O
the	O	O
development	B-PROC
of	I-PROC
improved	I-PROC
vaccines	I-PROC
against	O	O
Y	B-LIVB
.	I-LIVB

ruckeri	I-LIVB
.	O	O

Making	O	O
use	O	O
of	O	O
longitudinal	O
information	O
in	O	O
pattern	B-PHYS
recognition	I-PHYS
Longitudinal	O
designs	O	O
are	O	O
widely	O	O
used	O	O
in	O	O
medical	B-PROC
studies	I-PROC
as	O	O
a	O	O
means	O	O
of	O	O
observing	O	O
within	O	O
-	O	O
subject	B-LIVB
changes	O	O
over	O	O
time	O	O
in	O	O
groups	O	O
of	O	O
subjects	B-LIVB
,	O	O
thereby	O	O
aiming	O	O
to	O	O
improve	O	O
sensitivity	O	O
for	O	O
detecting	O	O
disease	B-DISO
effects	O	O
.	O	O

Paralleling	B-PROC
an	O	O
increased	O	O
use	O	O
of	O	O
such	O	O
studies	O	O
in	O	O
neuroimaging	B-PROC
has	O	O
been	O	O
the	O	O
adoption	O	O
of	O	O
pattern	O
recognition	O
algorithms	O
for	O	O
making	O	O
individualized	O
predictions	O
of	O	O
disease	B-DISO
.	O	O

However	O	O
,	O	O
at	O	O
present	O	O
few	O	O
pattern	O
recognition	O
methods	O
exist	O	O
to	O	O
make	O	O
full	O	O
use	O	O
of	O	O
neuroimaging	B-PROC
data	O	O
that	O	O
have	O	O
been	O	O
collected	O	O
longitudinally	O
,	O	O
with	O	O
most	O	O
methods	O	O
relying	O	O
instead	O	O
on	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
style	I-PROC
analysis	I-PROC
.	O	O

This	O	O
article	O	O
presents	O	O
a	O	O
principal	O
component	O
analysis	O
-based	O	O
feature	O	O
construction	O
method	O
that	O	O
uses	O	O
longitudinal	O
high	O
-	O
dimensional	O
data	O
to	O	O
improve	O	O
predictive	O
performance	O
of	O	O
pattern	O
recognition	O
algorithms	O
.	O	O

The	O	O
method	O	O
can	O	O
be	O	O
applied	O	O
to	O	O
data	O	O
from	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
longitudinal	O
study	O	O
designs	O	O
and	O	O
permits	O	O
an	O	O
arbitrary	O
number	O	O
of	O	O
time	O
-	O
points	O
per	O	O
subject	B-LIVB
.	O	O

We	O	O
apply	O	O
the	O	O
method	O	O
to	O	O
two	O	O
longitudinal	O
datasets	O	O
,	O	O
one	O	O
containing	O	O
subjects	B-LIVB
with	O	O
mild	B-DISO
cognitive	I-DISO
impairment	I-DISO
along	O	O
with	O	O
healthy	O
controls	O
,	O	O
the	O	O
other	O	O
with	O	O
early	O	O
dementia	B-DISO
subjects	B-LIVB
and	O	O
healthy	O
controls	O
.	O	O

Across	O	O
both	O	O
datasets	O	O
,	O	O
we	O	O
show	O	O
improvements	O	O
in	O	O
predictive	O
accuracy	O
relative	O	O
to	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
classifiers	O	O
for	O	O
discriminating	O	O
disease	B-LIVB
subjects	I-LIVB
from	O	O
healthy	O
controls	O
on	O	O
the	O	O
basis	O	O
of	O	O
whole	O	O
-	O	O
brain	B-ANAT
structural	O	O
magnetic	B-PROC
resonance	I-PROC
image	I-PROC
-based	O	O
voxels	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
can	O	O
transfer	O	O
longitudinal	O
information	O
from	O	O
one	O	O
set	O	O
of	O	O
subjects	B-LIVB
to	O	O
make	O	O
disease	B-DISO
predictions	O
in	O	O
another	O	O
set	O	O
of	O	O
subjects	B-LIVB
.	O	O

The	O	O
proposed	O	O
method	O	O
is	O	O
simple	O	O
and	O	O
,	O	O
as	O	O
a	O	O
feature	O	O
construction	O
method	O
,	O	O
flexible	O
with	O	O
respect	O	O
to	O	O
the	O	O
choice	O	O
of	O	O
classifier	O	O
and	O	O
image	O
registration	O
algorithm	O
.	O	O

Hum	O	O
Brain	O	O
Mapp	O	O
,	O	O
2016	O	O
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

Protective	O
effect	O
of	O	O
epigallocatechin	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
gallate	I-CHEM
(	O	O
EGCG	B-CHEM
)	O	O
via	O	O
Nrf2	B-CHEM
pathway	B-PHYS
against	O	O
oxalate	B-CHEM
-induced	O	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O	O
EMT	B-PHYS
)	O	O
of	O	O
renal	B-ANAT
tubular	B-ANAT
cells	I-ANAT
This	O	O
study	B-PROC
evaluated	O	O
effect	O	O
of	O	O
oxalate	B-CHEM
on	O	O
epithelial	B-PHYS
mesenchymal	I-PHYS
transition	I-PHYS
(	O	O
EMT	B-PHYS
)	O	O
and	O	O
potential	O	O
anti	B-DISO
-	I-DISO
fibrotic	I-DISO
property	I-DISO
of	O	O
epigallocatechin	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
gallate	I-CHEM
(	O	O
EGCG	B-CHEM
)	O	O
.	O	O

MDCK	B-ANAT
renal	I-ANAT
tubular	I-ANAT
cells	I-ANAT
were	O	O
incubated	B-PROC
with	O	O
0	O	O
.	O	O

5	O	O
mM	O	O
sodium	B-CHEM
oxalate	I-CHEM
for	O	O
24	O	O
-	O	O
h	O	O
with	O	O
/	O	O
without	O	O
1	O	O
-	O	O
h	O	O
pretreatment	O
with	O	O
25	O	O
μM	O	O
EGCG	B-CHEM
.	O	O

Microscopic	B-PROC
examination	I-PROC
,	O	O
immunoblotting	B-PROC
and	O	O
immunofluorescence	B-PROC
staining	I-PROC
revealed	O	O
that	O	O
oxalate	B-CHEM
-treated	O	O
cells	B-ANAT
gained	O	O
mesenchymal	B-ANAT
phenotypes	B-PHYS
by	O	O
fibroblast	B-ANAT
-like	O	O
morphological	B-DISO
change	I-DISO
and	O	O
increasing	O	O
expression	B-PHYS
of	O	O
vimentin	B-CHEM
and	O	O
fibronectin	B-CHEM
,	O	O
while	O	O
levels	O	O
of	O	O
epithelial	B-CHEM
markers	I-CHEM
(	O	O
E	B-CHEM
-	I-CHEM
cadherin	I-CHEM
,	O	O
occludin	B-CHEM
,	O	O
cytokeratin	B-CHEM
and	O	O
ZO	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
were	O	O
decreased	O	O
.	O	O

EGCG	B-CHEM
pretreatment	O
could	O	O
prevent	O	O
all	O	O
these	O	O
changes	O	O
and	O	O
molecular	B-PHYS
mechanisms	I-PHYS
underlying	O	O
the	O	O
prevention	O	O
by	O	O
EGCG	B-CHEM
were	O	O
most	O	O
likely	O	O
due	O	O
to	O	O
reduced	O	O
production	B-PHEN
of	O	O
intracellular	B-CHEM
ROS	I-CHEM
through	O	O
activation	O
of	O	O
Nrf2	B-CHEM
signaling	B-PHEN
and	O	O
increased	O	O
catalase	B-CHEM
anti	I-CHEM
-	I-CHEM
oxidant	I-CHEM
enzyme	I-CHEM
.	O	O

Knockdown	B-PROC
of	O	O
Nrf2	O
by	O	O
small	B-CHEM
interfering	I-CHEM
RNA	I-CHEM
(	O	O
siRNA	B-CHEM
)	O	O
abrogated	O	O
all	O	O
the	O	O
effects	O	O
of	O	O
EGCG	B-CHEM
,	O	O
confirming	O	O
that	O	O
the	O	O
EGCG	B-CHEM
protection	B-DISO
against	O	O
oxalate	B-CHEM
-induced	O	O
EMT	B-PHYS
was	O	O
mediated	O	O
via	O	O
Nrf2	B-CHEM
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
data	O	O
indicate	O	O
that	O	O
oxalate	B-CHEM
turned	O	O
on	O	O
EMT	B-PHYS
of	O	O
renal	B-ANAT
tubular	B-ANAT
cells	I-ANAT
that	O	O
could	O	O
be	O	O
prevented	O	O
by	O	O
EGCG	B-CHEM
via	O	O
Nrf2	B-CHEM
pathway	B-PHYS
.	O	O

These	O	O
findings	O	O
also	O	O
shed	O	O
light	O	O
onto	O	O
development	O	O
of	O	O
novel	O	O
therapeutics	O
or	O	O
preventive	O
strategies	O
of	O	O
renal	B-DISO
fibrosis	I-DISO
in	O	O
the	O	O
future	O	O
.	O	O

CD84	B-CHEM
mediates	O	O
CLL	B-DISO
-	O	O
microenvironment	B-PHEN
interactions	B-PHYS
Chronic	B-DISO
lymphocytic	I-DISO
leukemia	I-DISO
(	O	O
CLL	B-DISO
)	O	O
is	O	O
a	O	O
malignant	B-DISO
disease	I-DISO
of	O	O
small	O	O
mature	B-ANAT
lymphocytes	I-ANAT
.	O	O

Signals	B-PHEN
from	O	O
the	O	O
CLL	B-DISO
microenvironment	B-PHEN
promote	O
progression	B-DISO
of	I-DISO
the	I-DISO
disease	I-DISO
and	O	O
induce	O
drug	B-PHEN
resistance	I-PHEN
.	O	O

This	O	O
phenomenon	B-PHEN
is	O	O
largely	O	O
dependent	O
on	O	O
direct	O	O
contact	O	O
between	O	O
the	O	O
malignant	B-DISO
B	I-DISO
cells	I-DISO
and	O	O
stromal	B-ANAT
cells	I-ANAT
.	O	O

CD84	B-CHEM
belongs	O	O
to	O	O
the	O	O
signaling	B-CHEM
lymphocyte	I-CHEM
activation	I-CHEM
molecule	I-CHEM
family	I-CHEM
of	O	O
immunoreceptors	B-CHEM
,	O	O
which	O	O
self	B-PHYS
-	I-PHYS
associates	I-PHYS
,	O	O
forming	O	O
an	O	O
orthogonal	B-CHEM
homophilic	I-CHEM
dimer	I-CHEM
.	O	O

We	O	O
therefore	O	O
hypothesized	O	O
that	O	O
CD84	B-CHEM
may	O	O
bridge	O	O
between	O	O
CLL	B-DISO
cells	B-ANAT
and	O	O
their	O	O
microenvironment	B-PHEN
,	O	O
promoting	O
cell	B-PHYS
survival	I-PHYS
.	O	O

Our	O	O
in	O
vitro	O
results	O
show	O	O
that	O	O
CD84	B-PHYS
expressed	I-PHYS
on	O	O
CLL	B-DISO
cells	B-ANAT
interact	O
with	O	O
CD84	B-PHYS
expressed	I-PHYS
on	O	O
cells	B-ANAT
in	O	O
their	O	O
microenvironment	B-PHEN
,	O	O
inducing	O
cell	B-PHYS
survival	I-PHYS
in	O	O
both	O	O
sides	O	O
.	O	O

Blocking	O
CD84	B-CHEM
in	O
vitro	O
and	O	O
in	O
vivo	O
disrupt	O
the	O	O
interaction	O
of	O	O
CLL	B-DISO
cells	B-ANAT
with	O	O
their	O	O
microenvironment	B-PHEN
,	O	O
resulting	O
in	O
induced	O
cell	B-PHYS
death	I-PHYS
.	O	O

Thus	O	O
,	O	O
our	O	O
findings	B-DISO
suggest	O	O
novel	O
therapeutic	O
strategies	O	O
based	O	O
on	O	O
the	O	O
blockade	B-CHEM
of	O	O
this	O	O
CD84	B-CHEM
-	O	O
dependent	O
survival	B-PHYS
pathway	B-PHYS
.	O	O

A	O	O
review	O
of	O
risk	B-DISO
factors	I-DISO
for	O	O
bovine	B-DISO
tuberculosis	I-DISO
infection	B-DISO
in	O	O
cattle	B-LIVB
in	O	O
the	O	O
UK	B-GEOG
and	O	O
Ireland	B-GEOG
Bovine	B-DISO
tuberculosis	I-DISO
(	O	O
bTB	B-DISO
)	O	O
is	O	O
an	O	O
important	O	O
disease	B-DISO
of	O	O
cattle	B-LIVB
caused	O	O
by	O	O
infection	B-DISO
with	O	O
Mycobacterium	B-LIVB
bovis	I-LIVB
,	O	O
a	O	O
pathogen	B-LIVB
that	O	O
may	O	O
be	O	O
extremely	O	O
difficult	O	O
to	O	O
eradicate	O	O
in	O	O
the	O	O
presence	B-DISO
of	O	O
a	O	O
true	O	O
wildlife	B-LIVB
reservoir	B-GEOG
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
identify	B-DISO
and	O	O
review	O
relevant	O
literature	O
and	O	O
provide	O	O
a	O	O
succinct	O	O
summary	O
of	O	O
current	O	O
knowledge	O	O
of	O	O
risk	B-DISO
factors	I-DISO
for	O	O
transmission	B-DISO
of	O	O
infection	B-DISO
of	O	O
cattle	B-LIVB
.	O	O

Search	O
strings	O
were	O	O
developed	O	O
to	O	O
identify	B-DISO
publications	B-OBJC
from	O	O
electronic	O
databases	O
to	O	O
February	O	O
2015	O	O
.	O	O

Abstracts	O
of	O	O
4255	O	O
papers	O
identified	O
were	O	O
reviewed	O
by	O
three	O	O
reviewers	B-LIVB
to	O	O
determine	O	O
whether	O	O
the	O	O
entire	O	O
article	O
was	O	O
likely	O	O
to	O	O
contain	O	O
relevant	O
information	O
.	O	O

Risk	B-DISO
factors	I-DISO
could	O	O
be	O	O
broadly	O	O
grouped	O
as	O	O
follows	O	O
:	O	O
animal	B-LIVB
(	O	O
including	O	O
nutrition	B-DISO
and	O	O
genetics	O
)	O	O
,	O	O
herd	O
(	O	O
including	O	O
bTB	B-DISO
and	O	O
testing	O
history	O
)	O	O
,	O	O
environment	O
,	O	O
wildlife	B-LIVB
and	O	O
social	O
factors	O
.	O	O

Many	O	O
risk	B-DISO
factors	I-DISO
are	O	O
inter	O	O
-	O	O
related	O	O
and	O	O
study	B-PROC
designs	I-PROC
often	O	O
do	O	O
not	O	O
enable	O	O
differentiation	O
between	O	O
cause	O
and	O	O
consequence	O
of	O
infection	B-DISO
.	O	O

Despite	O	O
differences	O
in	O	O
study	B-PROC
design	I-PROC
and	O	O
location	O
,	O	O
some	O	O
risk	B-DISO
factors	I-DISO
are	O	O
consistently	O	O
identified	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

herd	O
size	O
,	O	O
bTB	B-DISO
history	O
,	O	O
presence	O	O
of	O	O
infected	B-DISO
wildlife	B-LIVB
,	O	O
whereas	O	O
the	O	O
evidence	O
for	O	O
others	O	O
is	O	O
less	O	O
consistent	O
and	O	O
coherent	B-DISO
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

nutrition	B-DISO
,	O	O
local	O
cattle	B-LIVB
movements	B-PHYS
.	O	O

We	O	O
have	O	O
identified	O
knowledge	O	O
gaps	O	O
where	O	O
further	O	O
research	B-PROC
may	O	O
result	O	O
in	O	O
an	O	O
improved	O	O
understanding	O	O
of	O	O
bTB	B-DISO
transmission	B-DISO
dynamics	B-PHEN
.	O	O

The	O	O
application	O
of	O	O
targeted	O
,	O	O
multifactorial	B-DISO
disease	B-DISO
control	O
regimens	O
that	O	O
address	O	O
a	O	O
range	O	O
of	O	O
risk	B-DISO
factors	I-DISO
simultaneously	O
is	O	O
likely	O	O
to	O	O
be	O	O
a	O	O
key	O	O
to	O	O
effective	O
,	O	O
evidence	O
-informed	O	O
control	O
strategies	O
.	O	O

Aurantimonas	B-LIVB
endophytica	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O	O
a	O	O
novel	O	O
endophytic	B-LIVB
bacterium	I-LIVB
isolated	O	O
from	O	O
roots	B-LIVB
of	O	O
Anabasis	B-LIVB
elatior	I-LIVB
(	I-LIVB
C	I-LIVB
.	I-LIVB

A	I-LIVB
.	I-LIVB

Mey	I-LIVB
.	I-LIVB
)	I-LIVB
Schischk	I-LIVB
An	O	O
orange	O
-	O
coloured	O
,	O	O
aerobic	O
,	O	O
motile	B-DISO
and	O	O
short	B-LIVB
-	I-LIVB
rods	I-LIVB
bacterial	I-LIVB
strain	I-LIVB
,	O	O
designated	O	O
EGI	B-LIVB
6500337	I-LIVB
T	I-LIVB
,	O	O
was	O	O
isolated	O	O
from	O	O
the	O	O
surface	O	O
-	O	O
sterilized	O	O
root	B-LIVB
of	O	O
a	O	O
halophyte	B-LIVB
Anabasis	B-LIVB
elatior	I-LIVB
(	I-LIVB
C	I-LIVB
.	I-LIVB

A	I-LIVB
.	I-LIVB

Mey	I-LIVB
.	I-LIVB
)	I-LIVB
Schischk	I-LIVB
collected	O	O
from	O	O
Urumqi	B-GEOG
,	O	O
Xinjiang	B-GEOG
province	I-GEOG
,	O	O
north	B-GEOG
-	I-GEOG
west	I-GEOG
China	I-GEOG
.	O	O

Growth	B-PHYS
occurred	O	O
at	O	O
5	O	O
-	O	O
35	O	O
°	O	O
C	O	O
(	O	O
optimum	O	O
30	O	O
°	O	O
C	O	O
)	O	O
,	O	O
at	O	O
pH	O
6	O	O
.	O	O
0	O	O
-	O	O
9	O	O
.	O	O
0	O	O
(	O	O
optimum	O	O
pH	O
7	O	O
.	O	O
0	O	O
)	O	O
,	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
0	O	O
-	O	O
6	O	O
%	O	O
NaCl	B-CHEM
(	O	O
w	O	O
/	O	O
v	O	O
)	O	O
(	O	O
optimum	O	O
0	O	O
-	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Phylogenetic	O
tree	O
based	O	O
on	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
indicated	O	O
that	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
formed	O	O
a	O	O
distinct	O	O
lineage	O	O
in	O	O
the	O	O
cluster	O	O
that	O	O
comprised	O	O
the	O	O
genera	B-LIVB
Aurantimonas	I-LIVB
and	O	O
Aureimonas	B-LIVB
in	O	O
the	O	O
family	B-LIVB
Aurantimonadaceae	I-LIVB
.	O	O

The	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequence	O
of	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
shared	O	O
the	O	O
highest	O	O
similarities	O	O
to	O	O
those	O	O
of	O	O
Aurantimonas	B-LIVB
coralicida	I-LIVB
DSM	I-LIVB
14790	I-LIVB
T	I-LIVB
(	O	O
97	O	O
.	O	O
15	O	O
%	O	O
)	O	O
and	O	O
Aurantimonas	B-LIVB
manganoxydans	I-LIVB
DSM	I-LIVB
21871	I-LIVB
T	I-LIVB
(	O	O
97	O	O
.	O	O
15	O	O
%	O	O
)	O	O
.	O	O

Strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
contained	O	O
Q	B-CHEM
-	I-CHEM
10	I-CHEM
as	O	O
the	O	O
dominant	O	O
isoprenoid	B-CHEM
quinone	I-CHEM
.	O	O

The	O	O
major	O	O
cellular	O	O
fatty	B-CHEM
acids	I-CHEM
were	O	O
C18	B-CHEM
:	I-CHEM
1	I-CHEM
7c	I-CHEM
(	O	O
66	O	O
.	O	O

4	O	O
%	O	O
)	O	O
and	O	O
C19	B-CHEM
:	I-CHEM
0	I-CHEM
8c	I-CHEM
cyclo	I-CHEM
(	O	O
23	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

The	O	O
polar	O	O
lipid	B-CHEM
profile	I-CHEM
of	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
contained	O	O
diphosphatidylglycerol	B-CHEM
,	O	O
phosphatidylglycerol	B-CHEM
,	O	O
phosphatidylcholine	B-CHEM
,	O	O
phosphatidylethanolamine	B-CHEM
as	O	O
major	O	O
components	O	O
,	O	O
similarly	O	O
to	O	O
the	O	O
members	O	O
of	O	O
the	O	O
genus	B-LIVB
Aurantimonas	I-LIVB
.	O	O

The	O	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
was	O	O
66	O	O
.	O	O

8	O	O
mol	O	O
%	O	O
.	O	O

The	O	O
DNA	B-CHEM
-	O	O
DNA	B-CHEM
relatedness	O	O
between	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
and	O	O
Aurantimonas	B-LIVB
coralicida	I-LIVB
DSM	I-LIVB
14790	I-LIVB
T	I-LIVB
was	O	O
24	O	O
.	O	O

7	O	O
±	O	O
2	O	O
.	O	O
9	O	O
%	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
phylogenetic	B-PROC
analysis	I-PROC
,	O	O
chemotaxonomic	O
data	O
and	O	O
phenotypic	B-PHYS
characteristics	I-PHYS
,	O	O
strain	B-LIVB
EGI	I-LIVB
6500337	I-LIVB
T	I-LIVB
represents	O	O
a	O	O
novel	O	O
species	O	O
of	O	O
the	O	O
genus	B-LIVB
Aurantimonas	I-LIVB
,	O	O
for	O	O
which	O	O
the	O	O
name	O	O
Aurantimonas	B-LIVB
endophytica	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O	O
proposed	O	O
.	O	O

The	O	O
type	O	O
strain	B-LIVB
is	O	O
EGI	B-LIVB
6500337	I-LIVB
T	I-LIVB
(	O	O
=	O	O
KCTC	B-LIVB
52296	I-LIVB
T	I-LIVB
=	O	O
CPCC	B-LIVB
100904	I-LIVB
T	I-LIVB
)	O	O
.	O	O

Infectivity	O
,	O	O
effects	O	O
on	O	O
helper	B-LIVB
viruses	I-LIVB
and	O	O
whitefly	O
transmission	B-PHYS
of	O	O
the	O	O
deltasatellites	B-LIVB
associated	O
with	O
sweepoviruses	B-LIVB
(	O	O
genus	O
Begomovirus	B-LIVB
,	O	O
family	B-LIVB
Geminiviridae	I-LIVB
)	O	O
Begomoviruses	B-LIVB
(	O	O
family	O
Geminiviridae	B-LIVB
)	O	O
are	O	O
whitefly	O
-	O	O
transmitted	B-PHYS
viruses	B-LIVB
with	O	O
single	B-ANAT
-	I-ANAT
stranded	I-ANAT
DNA	I-ANAT
genomes	I-ANAT
that	O	O
are	O	O
frequently	O	O
associated	O
with	O
DNA	B-CHEM
satellites	I-CHEM
.	O	O

These	O	O
satellites	B-LIVB
include	O	O
non	O	O
-	O	O
coding	O	O
satellites	O	O
,	O	O
for	O	O
which	O	O
the	O	O
name	O	O
deltasatellites	B-LIVB
has	O	O
been	O	O
proposed	O	O
.	O	O

Although	O	O
the	O	O
first	O	O
deltasatellite	B-LIVB
was	O	O
identified	O	O
in	O	O
the	O	O
late	O	O
1990s	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
effects	O	O
they	O	O
have	O	O
on	O	O
infections	B-DISO
of	O	O
their	O	O
helper	B-LIVB
begomoviruses	B-LIVB
.	O	O

Recently	O	O
a	O	O
group	O	O
of	O	O
deltasatellites	B-LIVB
were	O	O
identified	O	O
associated	O
with	O
sweepoviruses	B-LIVB
,	O	O
a	O	O
group	O	O
of	O	O
phylogenetically	O	O
distinct	O	O
begomoviruses	B-LIVB
that	O	O
infect	B-DISO
plants	B-LIVB
of	O	O
the	O	O
family	B-LIVB
Convolvulaceae	I-LIVB
including	O	O
sweet	B-LIVB
potato	I-LIVB
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
the	O	O
deltasatellites	B-LIVB
associated	O
with	O
sweepoviruses	B-LIVB
are	O	O
shown	O	O
to	O	O
be	O	O
transreplicated	B-PHYS
and	O	O
maintained	O	O
in	O	O
plants	B-LIVB
by	O	O
the	O	O
virus	B-LIVB
with	O	O
which	O	O
they	O	O
were	O	O
identified	O	O
,	O	O
sweet	B-LIVB
potato	I-LIVB
leaf	I-LIVB
curl	I-LIVB
virus	I-LIVB
(	O	O
SPLCV	B-LIVB
)	O	O
.	O	O

These	O	O
deltasatellites	B-LIVB
were	O	O
shown	O	O
generally	O	O
to	O	O
reduce	O
symptom	B-DISO
severity	I-DISO
of	O	O
the	O	O
virus	B-DISO
infection	I-DISO
by	O	O
reducing	O
virus	B-CHEM
DNA	I-CHEM
levels	O
.	O	O

Additionally	O	O
they	O	O
were	O	O
shown	O	O
to	O	O
be	O	O
maintained	O	O
in	O	O
plants	B-LIVB
,	O	O
and	O	O
reduce	O
the	O	O
symptoms	B-DISO
induced	O
by	O	O
two	O	O
Old	B-LIVB
World	I-LIVB
monopartite	I-LIVB
begomoviruses	I-LIVB
,	O	O
tomato	B-LIVB
yellow	I-LIVB
leaf	I-LIVB
curl	I-LIVB
virus	I-LIVB
and	O	O
tomato	B-LIVB
yellow	I-LIVB
leaf	I-LIVB
curl	I-LIVB
Sardinia	I-LIVB
virus	I-LIVB
.	O	O

Finally	O	O
one	O	O
of	O	O
the	O	O
satellites	B-LIVB
was	O	O
shown	O	O
to	O	O
be	O	O
transmitted	B-PHYS
plant	B-LIVB
-to	O	O
-	O	O
plant	B-LIVB
in	O	O
the	O	O
presence	O	O
of	O	O
SPLCV	B-LIVB
by	O	O
the	O	O
whitefly	O
vector	B-CHEM
of	I-CHEM
the	I-CHEM
virus	I-CHEM
,	O	O
Bemisia	O
tabaci	O
,	O	O
being	O	O
the	O	O
first	O	O
time	O	O
a	O	O
deltasatellite	B-LIVB
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
insect	O
transmitted	B-PHYS
.	O	O

Reintervention	B-PROC
after	O	O
endovascular	B-PROC
repair	I-PROC
for	O	O
aortic	B-DISO
dissection	I-DISO
:	O	O
A	O	O
systematic	O
review	O
and	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
Thoracic	B-PROC
endovascular	I-PROC
aortic	I-PROC
repair	I-PROC
has	O	O
been	O	O
chosen	O	O
as	O	O
a	O	O
less	O
-	O
invasive	O
alternative	O
to	O	O
open	B-PROC
surgery	I-PROC
for	O	O
the	O	O
treatment	O
of	O	O
aortic	B-DISO
dissections	I-DISO
;	O	O
however	O	O
,	O	O
the	O	O
advantages	O	O
have	O	O
been	O	O
challenged	O	O
by	O	O
the	O	O
postoperative	O
reintervention	B-PROC
during	O	O
the	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
period	O
.	O	O

This	O	O
study	O	O
aimed	O	O
at	O	O
evaluating	O	O
the	O	O
incidence	O
,	O	O
reasons	O
,	O	O
and	O	O
potential	O
risk	B-DISO
factors	I-DISO
for	O	O
reintervention	B-PROC
.	O	O

Studies	O	O
reporting	O	O
reintervention	B-PROC
after	O	O
endovascular	B-PROC
repair	I-PROC
were	O	O
identified	O
by	O	O
searching	O
PubMed	O
and	O	O
Embase	O
in	O	O
accordance	O	O
with	O	O
preferred	O	O
reporting	O	O
items	O	O
for	O	O
systematic	O
reviews	O
and	O	O
meta	B-PROC
-	I-PROC
analyses	I-PROC
guidelines	O
,	O	O
and	O	O
by	O	O
reviewing	O
the	O	O
reference	O
lists	O
of	O	O
retrieved	O
articles	O
.	O	O

Sensitivity	O
analysis	B-PROC
and	O	O
subgroup	O
analyses	B-PROC
were	O	O
performed	O
to	O	O
determine	O	O
the	O	O
sources	B-DISO
of	O	O
heterogeneity	O
.	O	O

Funnel	O
plot	O
and	O	O
Egger	O
's	O
test	O
were	O	O
used	O	O
to	O	O
determine	O	O
the	O	O
publication	O
bias	O
.	O	O

A	O	O
total	O	O
of	O	O
27	O	O
studies	O	O
encompassing	O	O
2403	O	O
patients	B-LIVB
with	O	O
aortic	B-DISO
dissection	I-DISO
were	O	O
identified	O
.	O	O

The	O	O
pooled	O
incidence	O
of	O	O
reintervention	B-PROC
after	O	O
endovascular	B-PROC
repair	I-PROC
was	O	O
15	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
,	O	O
12	O	O
-	O	O
19	O	O
)	O	O
during	O	O
33	O	O
.	O	O

7	O	O
months	O
of	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

The	O	O
3	O	O
most	O	O
common	O	O
reasons	O
for	O	O
reintervention	B-PROC
were	O	O
endoleak	B-DISO
(	O	O
33	O	O
.	O	O
2	O	O
%	O	O
)	O	O
,	O	O
false	B-DISO
lumen	I-DISO
perfusion	I-DISO
and	O	O
aortic	B-DISO
dilation	I-DISO
(	O	O
19	O	O
.	O	O
8	O	O
%	O	O
)	O	O
,	O	O
and	O	O
new	O
dissection	B-DISO
(	O	O
6	O	O
.	O	O
9	O	O
%	O	O
)	O	O
.	O	O

The	O	O
potential	O
factors	O
for	O	O
reintervention	B-PROC
were	O	O
the	O	O
mean	O	O
age	O
of	O
onset	O
and	O	O
diabetes	B-DISO
mellitus	I-DISO
determined	O	O
by	O	O
performing	O	O
a	O	O
single	O
meta	O
-	O
regression	O
analysis	O
(	O	O
P	O	O
<	O	O
.001	O	O
and	O	O
.044	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Current	O	O
data	O
suggest	O	O
that	O	O
the	O	O
incidence	O
of	O	O
reintervention	B-PROC
after	O	O
endovascular	B-PROC
therapy	I-PROC
is	O	O
relatively	O	O
high	O	O
during	O	O
midterm	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Advanced	O	O
age	O
of	O
onset	O
is	O	O
a	O	O
risk	B-DISO
factor	I-DISO
and	O	O
diabetes	B-DISO
mellitus	I-DISO
is	O	O
a	O	O
protective	O
factor	O
of	O	O
reintervention	B-PROC
after	O	O
endovascular	B-PROC
therapy	I-PROC
.	O	O

The	O	O
possible	O	O
mechanism	O
that	O	O
diabetes	B-DISO
mellitus	I-DISO
protects	O	O
patients	B-LIVB
from	O	O
reintervention	B-PROC
should	O	O
be	O	O
explored	O	O
further	O
.	O	O

Assessment	B-PROC
and	O	O
classification	O
of	O	O
protocol	B-DISO
deviations	I-DISO
Deviations	B-DISO
from	O	O
the	O	O
approved	O	O
trial	O
protocol	O
are	O	O
common	O	O
during	O	O
clinical	B-PROC
trials	I-PROC
.	O	O

They	O	O
have	O	O
been	O	O
conventionally	O	O
classified	O
as	O	O
deviations	B-DISO
or	O	O
violations	B-PROC
,	O	O
depending	O	O
on	O	O
their	O	O
impact	O
on	O	O
the	O	O
trial	B-PROC
.	O	O

A	O	O
new	O	O
method	O	O
has	O	O
been	O	O
proposed	O	O
by	O	O
which	O	O
deviations	B-DISO
are	O	O
classified	O
in	O	O
five	O	O
grades	O
from	O
1	O
to	O
5	O
.	O	O

A	O	O
deviation	B-DISO
of	O	O
Grade	B-DISO
1	I-DISO
has	O	O
no	B-DISO
impact	O
on	O	O
the	O	O
subjects	B-LIVB
'	I-LIVB
well	B-DISO
-	I-DISO
being	I-DISO
or	O	O
on	O	O
the	O	O
quality	O
of	O
data	O
.	O	O

At	O	O
the	O	O
maximum	O	O
,	O	O
a	O	O
deviation	B-DISO
Grade	O
5	O
leads	O	O
to	O	O
the	O	O
death	B-DISO
of	O	O
the	O	O
subject	B-LIVB
.	O	O

This	O	O
method	O	O
of	O	O
classification	O
was	O	O
applied	O	O
to	O	O
deviations	B-DISO
noted	O	O
in	O	O
the	O	O
center	O	O
over	O	O
the	O	O
last	O	O
3	O	O
years	O	O
.	O	O

It	O	O
was	O	O
observed	O	O
that	O	O
most	O	O
deviations	B-DISO
were	O	O
of	O	O
Grades	O
1	O
and	O
2	O
,	O	O
with	O	O
fewer	O	O
falling	O	O
in	O	O
Grades	O
3	O
and	O
4	O
.	O	O

There	O	O
were	O	O
no	O	O
deviations	B-DISO
that	O	O
led	O	O
to	O	O
the	O	O
death	B-DISO
of	I-DISO
the	I-DISO
subject	I-DISO
(	O	O
Grade	O	O
5	O	O
)	O	O
.	O	O

This	O	O
method	O	O
of	O	O
classification	O
would	O	O
help	O	O
trial	B-PROC
managers	B-LIVB
decide	O	O
on	O	O
the	O	O
action	O	O
to	O	O
be	O	O
taken	O	O
on	O	O
the	O	O
occurrence	O
of	O	O
deviations	B-DISO
,	O	O
which	O	O
would	O	O
be	O	O
based	O	O
on	O	O
their	O	O
impact	O
.	O	O

Optimizing	O
Prone	O
Cardiopulmonary	B-PROC
Resuscitation	I-PROC
:	O	O
Identifying	O	O
the	O	O
Vertebral	B-ANAT
Level	I-ANAT
Correlating	O
With	O	O
the	O	O
Largest	O
Left	B-ANAT
Ventricle	I-ANAT
Cross	O
-	O
Sectional	O
Area	O
via	O	O
Computed	B-PROC
Tomography	I-PROC
Scan	I-PROC
Placing	O	O
the	O	O
patient	B-LIVB
in	O	O
the	O	O
prone	O
position	O
frequently	O
is	O	O
required	O
for	O	O
some	O	O
surgical	B-PROC
procedures	I-PROC
.	O	O

If	O	O
cardiac	B-DISO
arrest	I-DISO
occurs	O
and	O	O
the	O	O
patient	B-LIVB
cannot	O	O
be	O	O
safely	O	O
turned	O	O
supine	O
,	O	O
cardiopulmonary	B-PROC
resuscitation	I-PROC
(	O	O
CPR	B-PROC
)	O	O
may	O	O
need	O	O
to	O	O
be	O	O
performed	O
with	O	O
the	O	O
patient	B-LIVB
in	O	O
the	O	O
prone	O
position	O
.	O	O

Although	O	O
clear	O	O
landmarks	O	O
have	O	O
been	O	O
defined	O
for	O	O
supine	O
CPR	B-PROC
,	O	O
the	O	O
optimal	O
hand	O
position	O
for	O	O
CPR	B-PROC
in	O	O
the	O	O
prone	O
position	O
has	O	O
not	O
been	O
clearly	O
determined	O
.	O	O

The	O	O
purpose	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
determine	O	O
anatomically	O
the	O	O
optimal	O
hand	O
position	O
for	O	O
CPR	B-PROC
in	O	O
the	O	O
prone	O
position	O
.	O	O

We	O	O
reviewed	O
retrospectively	O
the	O	O
chest	B-PROC
computed	I-PROC
tomography	I-PROC
images	B-OBJC
of	O	O
100	O	O
patients	B-LIVB
taken	O	O
in	O	O
the	O	O
prone	O
position	O
.	O	O

The	O	O
vertebral	B-ANAT
body	I-ANAT
levels	I-ANAT
crossing	O	O
the	O	O
medial	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
,	O	O
the	O	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
,	O	O
and	O	O
the	O	O
spinous	B-ANAT
process	I-ANAT
of	O	O
the	O	O
vertebral	B-ANAT
body	I-ANAT
connected	O
to	O	O
the	O	O
most	B-ANAT
inferior	I-ANAT
rib	I-ANAT
were	O	O
identified	O	O
,	O	O
and	O	O
we	O	O
selected	O	O
the	O	O
image	O
level	O
at	O	O
which	O	O
the	O	O
left	B-ANAT
ventricular	I-ANAT
(	O	O
LV	B-ANAT
)	O	O
cross	O
-	O
sectional	O
area	O
was	O	O
the	O	O
largest	O
.	O	O

This	O	O
level	O
was	O	O
defined	O	O
as	O	O
the	O	O
optimal	O
compression	B-PHEN
level	O
and	O	O
correlated	O
to	O	O
surface	O	O
anatomical	B-ANAT
landmarks	I-ANAT
.	O	O

We	O	O
calculated	B-PROC
the	O	O
ratio	O	O
of	O	O
the	O	O
distance	O
from	O	O
the	O	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O	O
the	O	O
level	O
of	O	O
the	O	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
divided	O
by	O	O
the	O	O
distance	O
from	O	O
the	O	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O	O
the	O	O
spinous	B-ANAT
process	I-ANAT
of	O	O
the	O	O
vertebral	B-ANAT
body	I-ANAT
connected	O
with	O	O
the	O	O
most	B-ANAT
inferior	I-ANAT
rib	I-ANAT
.	O	O

The	O	O
level	O
of	O	O
the	O	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
in	O	O
the	O	O
prone	O
position	O
was	O	O
1	B-ANAT
vertebral	I-ANAT
segment	I-ANAT
below	O	O
the	O	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
in	O	O
45	O	O
%	O	O
(	O	O
99	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
,	O	O
33	O	O
-	O	O
58	O	O
)	O	O
of	O	O
patients	B-LIVB
and	O	O
0	B-ANAT
to	I-ANAT
2	I-ANAT
vertebral	I-ANAT
segments	I-ANAT
below	O	O
that	O	O
in	O	O
95	O	O
%	O	O
(	O	O
99	O	O
%	O	O
CI	O
,	O	O
86	O	O
-	O	O
98	O	O
)	O	O
of	O	O
patients	B-LIVB
.	O	O

The	O	O
mean	O	O
(	O	O
SD	O
)	O	O
ratio	O	O
of	O	O
the	O	O
distance	O
from	O	O
the	O	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O	O
the	O	O
level	O
of	O	O
the	O	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
divided	O
by	O	O
the	O	O
distance	O
from	O	O
the	O	O
C7	B-ANAT
spinous	I-ANAT
process	I-ANAT
to	O	O
T12	B-ANAT
spinous	I-ANAT
process	I-ANAT
was	O	O
67	O	O
%	O	O
±	O	O
7	O	O
%	O	O
(	O	O
99	O	O
%	O	O
CI	O
,	O	O
65	O	O
-	O	O
69	O	O
)	O	O
.	O	O

When	O	O
the	O	O
patient	B-LIVB
is	O	O
positioned	O
prone	O
,	O	O
the	O	O
largest	O
LV	B-ANAT
cross	O
-	O
sectional	O
area	O
is	O	O
0	B-ANAT
to	I-ANAT
2	I-ANAT
vertebral	I-ANAT
segments	I-ANAT
below	O	O
the	O	O
inferior	B-ANAT
angle	I-ANAT
of	I-ANAT
the	I-ANAT
scapula	I-ANAT
in	O	O
at	O	O
least	O	O
86	O	O
%	O	O
of	O	O
patients	B-LIVB
.	O	O

Further	O	O
studies	B-PROC
are	O	O
needed	O	O
to	O	O
determine	O	O
whether	O	O
this	O	O
position	O
is	O	O
optimal	O
for	O	O
chest	B-PROC
compressions	I-PROC
in	O	O
the	O	O
prone	O
position	O
.	O	O

12	B-PROC
-	I-PROC
Lead	I-PROC
electrocardiogram	I-PROC
as	O	O
a	O	O
predictor	O
of	O	O
sudden	B-DISO
cardiac	I-DISO
death	I-DISO
:	O	O
from	O	O
epidemiology	O
to	O	O
clinical	B-PROC
practice	I-PROC
Sudden	B-DISO
cardiac	I-DISO
death	I-DISO
(	O	O
SCD	B-DISO
)	O	O
causes	O	O
a	O	O
high	O	O
burden	O	O
of	O	O
premature	B-DISO
deaths	I-DISO
in	O	O
the	O	O
population	B-LIVB
affecting	O	O
subjects	O	O
of	O	O
all	O	O
ages	B-LIVB
.	O	O

The	O	O
identification	O	O
of	O	O
subjects	O	O
at	O	O
high	O	O
risk	B-PROC
for	O	O
SCD	B-DISO
is	O	O
of	O	O
great	O	O
importance	O	O
as	O	O
the	O	O
prevention	O	O
of	O	O
many	O	O
of	O	O
these	O	O
events	O	O
would	O	O
be	O	O
possible	O	O
with	O	O
the	O	O
treatment	B-PROC
of	O	O
underlying	O	O
cardiac	B-DISO
diseases	I-DISO
and	O	O
the	O	O
use	O	O
of	O	O
implantable	B-DEVI
cardioverter	I-DEVI
-	I-DEVI
defibrillators	I-DEVI
(	O	O
ICD	B-DEVI
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
current	O	O
selection	O	O
of	O	O
patients	B-LIVB
for	O	O
ICD	B-DEVI
therapy	B-PROC
is	O	O
based	O	O
solely	O	O
on	O	O
left	B-PHYS
ventricular	I-PHYS
ejection	I-PHYS
fraction	I-PHYS
,	O	O
and	O	O
thus	O	O
a	O	O
substantial	O	O
portion	O	O
of	O	O
patients	B-LIVB
at	O	O
high	O	O
risk	B-PROC
does	O	O
not	O	O
qualify	O	O
for	O	O
the	O	O
therapy	B-PROC
.	O	O

Role	O	O
of	O	O
the	O	O
standard	B-PROC
electrocardiogram	I-PROC
(	O	O
ECG	B-PROC
)	O	O
in	O	O
SCD	B-DISO
risk	B-PROC
stratification	B-PROC
has	O	O
been	O	O
under	O	O
active	O	O
research	B-PROC
during	O	O
the	O	O
last	O	O
decade	O
and	O	O
multiple	O	O
abnormalities	B-DISO
of	O	O
depolarization	B-DISO
and	O	O
repolarization	B-DISO
on	O	O
the	O	O
ECG	B-PROC
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	B-PROC
of	O	O
SCD	B-DISO
have	O	O
been	O	O
identified	O	O
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
basic	O	O
pathophysiological	B-DISO
principles	O	O
behind	O	O
these	O	O
changes	O	O
.	O	O

We	O	O
also	O	O
review	O	O
the	O	O
current	O	O
knowledge	B-DISO
of	O	O
the	O	O
prognostic	O
significance	O	O
of	O	O
ECG	B-PROC
predictors	O
of	O	O
SCD	B-DISO
in	O	O
the	O	O
general	B-LIVB
population	I-LIVB
,	O	O
and	O	O
in	O	O
patients	B-LIVB
with	O	O
coronary	B-DISO
heart	I-DISO
disease	I-DISO
(	O	O
CHD	B-DISO
)	O	O
,	O	O
heart	B-DISO
failure	I-DISO
,	O	O
cardiomyopathies	B-DISO
,	O	O
and	O	O
in	O	O
inheritable	O
arrhythmia	B-DISO
syndromes	I-DISO
.	O	O

Also	O	O
,	O	O
insights	O	O
into	O	O
the	O	O
novel	O	O
digital	O	O
ECG	B-PROC
signal	B-PHEN
processing	O	O
techniques	O
are	O	O
provided	O	O
.	O	O

How	O	O
Can	O	O
We	O	O
Estimate	O
Sepsis	B-DISO
Incidence	O
and	O	O
Mortality	O
?	O	O
Sepsis	B-DISO
is	O	O
one	O	O
of	O	O
the	O	O
oldest	B-DISO
and	I-DISO
complex	I-DISO
syndromes	I-DISO
in	O	O
medicine	O
that	O	O
has	O	O
been	O	O
in	O	O
debate	O
for	O	O
over	O	O
two	O
millennia	O
.	O	O

Valid	O
and	O	O
comparable	O
data	O
on	O	O
the	O	O
population	B-LIVB
burden	O
of	O	O
sepsis	B-DISO
constitute	O	O
an	O	O
essential	O	O
resource	O
for	O	O
guiding	O	O
health	O
policy	O
and	O	O
resource	O
allocation	O
.	O	O

Despite	O	O
current	O	O
epidemiological	O
data	O
suggesting	O	O
that	O	O
the	O	O
global	O
burden	O
of	O
sepsis	O
is	O	O
huge	O	O
,	O	O
the	O	O
knowledge	O	O
of	O	O
its	O	O
incidence	O
,	O
prevalence	O
,	O	O
mortality	O
,	O	O
and	O	O
case	O
-	O
fatality	O
rates	O
is	O	O
subject	O	O
to	O	O
several	O	O
flaws	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
narrative	O
review	O
is	O	O
to	O	O
assess	O	O
how	O	O
sepsis	B-DISO
incidence	O
and	O	O
mortality	O
can	O	O
be	O	O
estimated	O
,	O	O
providing	O	O
examples	O
on	O	O
how	O	O
it	O	O
has	O	O
been	O	O
done	O	O
so	O	O
far	O	O
in	O	O
medical	O
literature	O
and	O	O
discussing	O	O
its	O	O
possible	O	O
biases	O
.	O	O

Results	O	O
of	O	O
recent	O	O
studies	O	O
suggest	O	O
that	O	O
sepsis	B-DISO
incidence	O
rates	O
are	O	O
increasing	O
consistently	O	O
during	O	O
the	O	O
last	O	O
decades	O
.	O	O

Although	O	O
estimates	O
might	O	O
be	O	O
biased	O
,	O	O
this	O	O
probably	O	O
reflects	O	O
a	O	O
real	O	O
increase	O
in	O	O
incidence	O
over	O	O
time	O
.	O	O

Nevertheless	O	O
,	O	O
case	O
fatality	O
rates	O
have	O	O
decreased	O
,	O	O
which	O	O
is	O	O
a	O	O
probable	O	O
reflex	O	O
of	O	O
advances	O	O
in	O	O
critical	O
care	O
provision	O
to	O	O
this	O	O
very	O	O
sick	B-DISO
population	B-LIVB
at	O	O
high	B-DISO
risk	I-DISO
of	I-DISO
death	I-DISO
.	O	O

This	O	O
conclusion	O
can	O	O
only	O	O
be	O	O
drawn	O	O
with	O	O
a	O	O
reasonable	O	O
degree	O
of	O
certainty	O
for	O	O
high	B-DISO
-	I-DISO
income	I-DISO
countries	B-GEOG
.	O	O

Conversely	O	O
,	O	O
adequately	O	O
designed	O	O
studies	O	O
from	O	O
middle	B-DISO
-	O	O
and	O	O
low	B-DISO
-	I-DISO
income	I-DISO
countries	B-GEOG
are	O	O
urgently	O	O
needed	O	O
.	O	O

In	O	O
these	O	O
countries	B-GEOG
,	O	O
sepsis	B-DISO
incidence	O
and	O	O
case	O
-	O
fatality	O
rates	O
could	O	O
be	O	O
disproportionally	O	O
higher	O	O
due	O	O
to	O	O
health	B-DISO
care	I-DISO
provision	I-DISO
constraints	O
and	O	O
ineffective	O
preventive	O
measures	O
.	O	O

Fabrication	B-PHEN
and	O	O
modelling	B-PROC
of	O	O
fractal	O
,	O	O
biomimetic	O
,	O	O
micro	O
and	O	O
nano	O
-	O
topographical	O
surfaces	O
Natural	O
surface	O
topographies	O
are	O	O
often	O	O
self	O	O
-	O	O
similar	O	O
with	O	O
hierarchical	O
features	O
at	O	O
the	O	O
micro	O
and	O	O
nanoscale	O
,	O	O
which	O	O
may	O	O
be	O	O
mimicked	O	O
to	O	O
overcome	O	O
modern	O
tissue	B-PROC
engineering	I-PROC
and	O	O
biomaterial	B-CHEM
design	O
limitations	O
.	O	O

Specifically	O	O
,	O	O
a	O	O
cell	B-PHEN
's	I-PHEN
microenvironment	I-PHEN
within	O	O
the	O	O
human	B-LIVB
body	I-LIVB
contains	O	O
highly	O	O
optimised	O	O
,	O	O
fractal	B-ANAT
topographical	I-ANAT
cues	I-ANAT
,	O	O
which	O	O
directs	O	O
precise	O	O
cell	B-ANAT
behaviour	O
.	O	O

However	O	O
,	O	O
recreating	O
biomimetic	O
,	O	O
fractal	O
topographies	O
in	O
vitro	O
is	O	O
not	O	O
a	O	O
trivial	B-PHEN
process	I-PHEN
and	O	O
a	O	O
number	O	O
of	O	O
fabrication	B-PHEN
methods	I-PHEN
have	O	O
been	O	O
proposed	O	O
but	O	O
often	O	O
fail	O
to	O	O
precisely	O	O
control	O
the	O	O
spatial	O
resolution	O
of	O	O
features	O
at	O	O
different	O
lengths	O
scales	B-DEVI
and	O	O
hence	O	O
,	O	O
to	O	O
provide	O	O
true	O	O
biomimetic	O
properties	O
.	O	O

Here	O	O
,	O	O
we	O	O
propose	O	O
a	O	O
method	O
of	O	O
accurately	O
reproducing	O
the	O	O
self	O	O
-	O	O
similar	O	O
,	O	O
micro	O
and	O	O
nanoscale	O
topography	O
of	O	O
a	O	O
human	B-LIVB
biological	O
tissue	O
into	O	O
a	O	O
synthetic	B-CHEM
polymer	I-CHEM
through	O	O
an	O	O
innovative	O	O
fabrication	B-PHEN
process	I-PHEN
.	O	O

The	O	O
biological	O
tissue	O
surface	O
was	O	O
characterised	O
using	O	O
atomic	B-PROC
force	I-PROC
microscopy	I-PROC
(	O	O
AFM	B-PROC
)	O	O
to	O	O
obtain	O	O
spatial	O
data	O
in	O	O
X	O	O
,	O	O
Y	O	O
and	O	O
Z	O	O
,	O	O
which	O	O
was	O	O
converted	O	O
into	O	O
a	O	O
grayscale	B-OBJC
'	I-OBJC
digital	I-OBJC
photomask	I-OBJC
'	I-OBJC
.	O	O

As	O	O
a	O	O
result	O	O
of	O	O
maskless	O
grayscale	O
optical	O
lithography	O
followed	O	O
by	O	O
modified	B-PHEN
deep	I-PHEN
reactive	I-PHEN
ion	I-PHEN
etching	I-PHEN
and	O	O
replica	B-PHEN
molding	I-PHEN
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
accurately	O
reproduce	O	O
the	O	O
fractal	O
topography	O
of	O	O
acellular	O
dermal	O
matrix	O
(	O	O
ADM	O
)	O	O
into	O	O
polydimethylsiloxane	B-CHEM
(	O	O
PDMS	B-CHEM
)	O	O
.	O	O

Characterisation	O
using	O	O
AFM	B-PROC
at	O	O
three	O	O
different	O
length	O
scales	B-DEVI
revealed	O	O
that	O	O
the	O	O
nano	O
and	O	O
micro	O
-	O
topographical	O
features	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
fractal	O
dimension	O
,	O	O
of	O	O
native	O
ADM	O
were	O	O
reproduced	O
in	O	O
PDMS	B-CHEM
.	O	O

In	O	O
conclusion	O	O
,	O	O
it	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
the	O	O
fractal	O
topography	O
of	O	O
biological	O
surfaces	O
can	O	O
be	O	O
mimicked	O	O
in	O	O
synthetic	B-OBJC
materials	I-OBJC
using	O	O
the	O	O
novel	O
fabrication	B-PHEN
process	I-PHEN
outlined	O	O
,	O	O
which	O	O
may	O	O
be	O	O
applied	O	O
to	O	O
significantly	O	O
enhance	O	O
medical	B-DEVI
device	I-DEVI
biocompatibility	B-PHYS
and	O	O
performance	O
.	O	O

An	O	O
Anechoic	B-ANAT
Space	I-ANAT
at	O	O
the	O	O
Carpal	B-ANAT
Tunnel	I-ANAT
Inlet	O
is	O	O
a	O	O
Consistent	O	O
Ultrasonographic	B-PROC
Entity	B-OBJC
which	O	O
Accommodates	O	O
Tendon	B-DISO
Displacement	I-DISO
during	O	O
Finger	B-ANAT
Flexion	B-PHYS
We	O	O
consistently	O	O
observed	O
the	O	O
presence	O	O
of	O	O
anechoic	B-ANAT
spaces	I-ANAT
on	O	O
standard	O	O
ultrasonographic	B-PROC
imaging	I-PROC
of	O	O
the	O	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
in	O	O
normal	O
subjects	B-LIVB
.	O	O

These	O	O
spaces	B-ANAT
change	O
in	O
size	O
during	O	O
finger	B-ANAT
flexion	B-PHYS
and	O	O
have	O	O
not	O	O
been	O	O
characterized	O
in	O	O
a	O	O
large	O	O
sample	O	O
of	O	O
normal	O
individuals	B-LIVB
.	O	O

Ultrasonographic	B-PROC
quantification	O
of	O	O
these	O	O
spaces	B-ANAT
may	O	O
indicate	O	O
the	O	O
available	O	O
space	O
in	O	O
the	O	O
region	O
of	O	O
the	O	O
carpal	B-ANAT
tunnel	I-ANAT
,	O	O
which	O	O
allows	O	O
the	O	O
normal	O
motion	B-PHYS
of	O	O
tendons	B-ANAT
and	O	O
the	O	O
median	B-ANAT
nerve	I-ANAT
.	O	O

Transverse	O	O
ultrasonographic	B-PROC
images	O
of	O	O
the	O	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
from	O	O
33	O	O
asymptomatic	B-DISO
volunteers	B-LIVB
were	O	O
obtained	O	O
at	O	O
Position	O
A	O
(	O	O
fingers	B-ANAT
in	O	O
extension	B-PHYS
)	O	O
and	O	O
B	O
(	O	O
fingers	B-ANAT
in	O	O
flexion	B-PHYS
)	O	O
.	O	O

Cross	O
-	O
sectional	O
area	O
(	O	O
CSA	O
)	O	O
,	O	O
perimeter	O
and	O	O
position	O
of	O	O
anechoic	B-ANAT
space	I-ANAT
relative	O	O
to	O	O
median	B-ANAT
nerve	I-ANAT
were	O	O
recorded	O	O
.	O	O

Analysis	B-PROC
showed	O	O
a	O	O
75	O	O
.	O	O
4	O	O
%	O	O
prevalence	O
rate	O
of	O	O
a	O	O
single	O	O
anechoic	B-ANAT
space	I-ANAT
.	O	O

Two	O	O
discrete	O
patterns	O
were	O	O
observed	O	O
.	O	O

89	O	O
.	O	O

1	O	O
%	O	O
had	O	O
a	O	O
decrease	O
in	O	O
CSA	O
and	O	O
perimeter	O
of	O	O
anechoic	B-ANAT
space	I-ANAT
from	O	O
Position	O
A	O
to	O	O
B	O
while	O	O
10	O	O
.	O	O

9	O	O
%	O	O
exhibited	O	O
an	O	O
increase	O
.	O	O

Mean	O	O
position	O
of	O	O
the	O	O
anechoic	B-ANAT
space	I-ANAT
is	O	O
ulnar	B-ANAT
(	O	O
7	O	O
.	O	O
49	O	O
±	O	O
3	O	O
.	O	O
57	O	O
mm	O	O
)	O	O
and	O	O
dorsal	O
(	O	O
2	O	O
.	O	O
18	O	O
±	O	O
1	O	O
.	O	O
28	O	O
mm	O	O
)	O	O
to	O	O
the	O	O
median	B-ANAT
nerve	I-ANAT
.	O	O

A	O	O
consistent	O	O
anechoic	B-ANAT
space	I-ANAT
at	O	O
the	O	O
carpal	B-ANAT
tunnel	I-ANAT
inlet	O
is	O	O
seen	O	O
in	O	O
75	O	O
.	O	O

4	O	O
%	O	O
of	O	O
normal	O
hands	B-ANAT
and	O	O
can	O	O
be	O	O
quantified	O
(	O	O
cross	O
sectional	O
area	O
11	O	O
.	O	O

75	O	O
±	O	O
7	O	O
.	O	O
36	O	O
mm	O	O
(	O	O
2	O	O
)	O	O
)	O	O
.	O	O

It	O	O
allows	O	O
for	O	O
the	O	O
accommodation	O	O
of	O	O
flexor	B-ANAT
tendons	I-ANAT
during	O	O
finger	B-ANAT
flexion	B-PHYS
.	O	O

Co	B-PROC
-	I-PROC
ChIP	I-PROC
enables	O	O
genome	B-PROC
-	I-PROC
wide	I-PROC
mapping	I-PROC
of	O	O
histone	O
mark	O
co	O
-	O
occurrence	O
at	O	O
single	O
-	O
molecule	O
resolution	O
Histone	B-PHYS
modifications	I-PHYS
play	O	O
an	O	O
important	O
role	O
in	O	O
chromatin	B-PHYS
organization	I-PHYS
and	O	O
transcriptional	B-PHYS
regulation	I-PHYS
,	O	O
but	O	O
despite	O	O
the	O	O
large	O
amount	O
of	O	O
genome	O
-	O
wide	O
histone	B-PHYS
modification	I-PHYS
data	O
collected	O
in	O	O
different	O
cells	B-ANAT
and	O	O
tissues	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
co	O
-	O
occurrence	O
of	O	O
modifications	B-PHYS
on	O	O
the	O	O
same	O	O
nucleosome	B-CHEM
.	O	O

Here	O	O
we	O	O
present	O
a	O	O
genome	B-PROC
-	I-PROC
wide	I-PROC
quantitative	I-PROC
method	I-PROC
for	O	O
combinatorial	O
indexed	O
chromatin	B-PROC
immunoprecipitation	I-PROC
(	O	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
)	O	O
to	O	O
characterize	O	O
co	O
-	O
occurrence	O
of	O	O
histone	B-PHYS
modifications	I-PHYS
on	O	O
nucleosomes	B-CHEM
.	O	O

Using	O	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
,	O	O
we	O	O
study	B-PROC
the	O	O
genome	O
-	O
wide	O
co	O
-	O
occurrence	O
of	O	O
14	O	O
chromatin	O
marks	O
(	O	O
70	O	O
pairwise	O
combinations	O
)	O	O
,	O	O
and	O	O
find	O	O
previously	O	O
undescribed	O	O
co	O
-	O
occurrence	O
patterns	O
,	O	O
including	O	O
the	O	O
co	O
-	O
occurrence	O
of	O	O
H3K9me1	O
and	O	O
H3K27ac	O
in	O	O
super	O
-	O
enhancers	O
.	O	O

Finally	O	O
,	O	O
we	O	O
apply	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
to	O	O
measure	O
the	O	O
distribution	O
of	O	O
the	O	O
bivalent	O
H3K4me3	O
-	O	O
H3K27me3	O
domains	O
in	O	O
two	O	O
distinct	O	O
mouse	B-ANAT
embryonic	I-ANAT
stem	I-ANAT
cell	I-ANAT
(	O	O
mESC	B-ANAT
)	O	O
states	O	O
and	O	O
in	O	O
four	O	O
adult	O
tissues	O
.	O	O

We	O	O
observe	O
dynamic	O
changes	O
in	O	O
5	O	O
,	O	O
786	O	O
regions	O	O
and	O	O
discover	O
both	O	O
loss	O
and	O	O
de	O
novo	O
gain	O
of	O	O
bivalency	O
in	O	O
key	O	O
tissue	O
-	O
specific	O
regulatory	O
genes	O
,	O	O
suggesting	O
a	O	O
functional	O
role	O
for	O	O
bivalent	O
domains	O
during	O	O
different	O	O
stages	O
of	O	O
development	O
.	O	O

These	O	O
results	B-DISO
show	O	O
that	O	O
co	B-PROC
-	I-PROC
ChIP	I-PROC
can	O	O
reveal	O
the	O	O
complex	O
interactions	O
between	O	O
histone	B-PHYS
modifications	I-PHYS
.	O	O

Prognosis	B-PROC
of	O	O
Fibrolamellar	B-DISO
Carcinoma	I-DISO
Compared	O
to	O	O
Non	O
-	O
cirrhotic	O
Conventional	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
Fibrolamellar	B-DISO
carcinoma	I-DISO
(	O	O
FLC	B-DISO
)	O	O
and	O	O
conventional	O
hepatocellular	B-DISO
carcinoma	I-DISO
(	O	O
HCC	B-DISO
)	O	O
share	O	O
the	O	O
same	O	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O	O
AJCC	O
)	O	O
staging	O
.	O	O

The	O	O
worse	O	O
survival	O
with	O	O
HCC	B-DISO
is	O	O
attributed	O	O
to	O	O
the	O	O
underlying	O	O
cirrhosis	B-DISO
.The	O	O

aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O
stage	B-PHYS
-	I-PHYS
matched	I-PHYS
prognosis	B-PROC
after	O	O
resection	B-PROC
of	O	O
FLC	B-DISO
and	O	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
.	O	O

Outcomes	O
after	O	O
resection	B-PROC
of	O	O
65	O	O
consecutive	O
patients	B-LIVB
with	O	O
FLC	B-DISO
and	O	O
158	O	O
non	O
-	O
cirrhotic	O
patients	B-LIVB
with	O	O
HCC	B-DISO
were	O	O
compared	O
.	O	O

Patients	B-LIVB
were	O	O
staged	B-PHYS
according	O	O
to	O	O
the	O	O
7th	O	O
edition	O	O
AJCC	O
staging	O
.	O	O

The	O	O
AJCC	O
stage	O
distributions	O
for	O	O
FLC	B-DISO
and	O	O
HCC	B-DISO
demonstrated	O	O
a	O	O
predominance	O	O
of	O	O
stage	B-PHYS
IV	I-PHYS
disease	I-PHYS
in	O	O
FLC	B-DISO
and	O	O
stage	B-PHYS
I	I-PHYS
in	O	O
HCC	B-DISO
(	O	O
FLC	B-DISO
stage	B-PHYS
I	O	O
-	O	O
23	O	O
%	O	O
,	O	O
II	O	O
-	O	O
15	O	O
%	O	O
,	O	O
III	O	O
-	O	O
15	O	O
%	O	O
,	O	O
IV	O	O
-	O	O
46	O	O
%	O	O
vs	O	O
.	O	O

HCC	B-DISO
stage	B-PHYS
I	O	O
-	O	O
42	O	O
%	O	O
,	O	O
II	O	O
-	O	O
32	O	O
%	O	O
,	O	O
III	O	O
-	O	O
20	O	O
%	O	O
,	O	O
IV	O	O
-	O	O
6	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Among	O	O
stage	B-PHYS
IV	I-PHYS
FLC	B-DISO
patients	B-LIVB
,	O	O
81	O	O
%	O	O
had	O	O
isolated	O	O
nodal	O
metastases	B-DISO
,	O	O
which	O	O
did	O	O
not	O	O
affect	O	O
overall	O
survival	O
(	O	O
OS	O
)	O	O
or	O	O
recurrence	B-DISO
-	I-DISO
free	I-DISO
survival	I-DISO
(	O	O
RFS	B-DISO
)	O	O
.	O	O

In	O	O
FLC	B-DISO
,	O	O
OS	O
was	O	O
significantly	O	O
affected	O
by	O	O
the	O	O
number	O
of	O
tumors	O
and	O	O
vascular	B-DISO
invasion	I-DISO
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Recurrent	B-DISO
disease	I-DISO
developed	O	O
in	O	O
56	O	O
(	O	O
86	O	O
%	O	O
)	O	O
FLC	O	O
patients	B-LIVB
and	O	O
was	O	O
treated	B-PROC
with	I-PROC
repeat	O	O
surgical	B-PROC
resection	I-PROC
in	O	O
25	O	O
(	O	O
45	O	O
%	O	O
)	O	O
patients	B-LIVB
.	O	O

Vascular	B-DISO
invasion	I-DISO
was	O	O
associated	O	O
with	O	O
recurrent	O
FLC	B-DISO
,	O	O
with	O	O
3	O	O
-	O	O
year	O	O
RFS	B-DISO
rates	O
of	O	O
9	O	O
%	O	O
and	O	O
35	O	O
%	O	O
,	O	O
with	O	O
and	O	O
without	O	O
vascular	B-DISO
invasion	I-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
034	O	O
)	O	O
.	O	O

With	O	O
respect	O	O
to	O	O
RFS	B-DISO
,	O	O
the	O	O
AJCC	O
staging	O
did	O	O
not	O	O
stratify	O	O
FLC	B-DISO
patients	O	O
,	O	O
compared	O
to	O	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
.	O	O

When	O	O
compared	O
to	O	O
non	O
-	O
cirrhotic	O
HCC	B-DISO
,	O	O
patients	B-LIVB
with	O	O
FLC	B-DISO
are	O	O
not	O	O
adequately	O	O
stratified	O
by	O	O
AJCC	O
staging	O
with	O	O
respect	O	O
to	O	O
RFS	B-DISO
.	O	O

Our	O	O
results	B-DISO
support	O	O
classifying	O	O
lymph	B-ANAT
node	I-ANAT
metastases	B-DISO
in	O	O
FLC	B-DISO
as	O	O
regional	B-DISO
disease	I-DISO
,	O	O
rather	O	O
than	O	O
systemic	B-DISO
disease	I-DISO
.	O	O

Important	O	O
prognostic	B-PHYS
factors	I-PHYS
in	O	O
FLC	B-DISO
are	O	O
the	O	O
number	O
of	O
tumors	O
and	O	O
vascular	B-DISO
invasion	I-DISO
.	O	O

Hand	B-PROC
-	I-PROC
Assisted	I-PROC
Laparoscopic	I-PROC
Versus	O	O
Standard	B-PROC
Laparoscopic	I-PROC
Colectomy	I-PROC
:	O	O
Are	O	O
Outcomes	O
and	O	O
Operative	O
Time	O
Different	O	O
?	O	O
HAL	B-PROC
colectomy	B-PROC
is	O	O
a	O	O
technique	O
perceived	O	O
to	O	O
provide	O	O
the	O	O
benefits	O	O
of	O	O
laparoscopic	B-PROC
surgery	I-PROC
while	O	O
improving	O	O
tactile	O	O
feedback	O	O
and	O	O
operative	O
time	O
.	O	O

Published	O	O
data	O
are	O	O
largely	O	O
limited	O	O
to	O	O
small	O	O
,	O	O
single	B-PROC
-	I-PROC
institution	I-PROC
studies	I-PROC
.	O	O

The	O	O
2012	O	O
-	O	O
2013	O	O
National	O
Surgical	O
Quality	O
Improvement	O
Program	O
Participant	O
Data	O
Use	O
File	O
was	O	O
queried	O	O
for	O	O
patients	B-LIVB
undergoing	O	O
elective	O	O
SL	B-PROC
or	O	O
HAL	B-PROC
colectomy	B-PROC
.	O	O

Patients	B-LIVB
underwent	O	O
1	O	O
:	O	O
1	O	O
propensity	O	O
matching	O	O
and	O	O
had	O	O
outcomes	O
compared	O	O
.	O	O

An	O	O
additional	O	O
subgroup	B-PROC
analysis	I-PROC
was	O	O
performed	O	O
for	O	O
patients	B-LIVB
undergoing	O	O
segmental	O
resections	B-PROC
only	O	O
.	O	O

13	O	O
,	O	O
949	O	O
patients	B-LIVB
were	O	O
identified	O	O
,	O	O
of	O	O
whom	O	O
6084	O	O
(	O	O
43	O	O
.	O	O
6	O	O
%	O	O
)	O	O
underwent	O	O
HAL	B-PROC
colectomy	B-PROC
.	O	O

Patients	B-LIVB
undergoing	O	O
HAL	B-PROC
versus	O	O
SL	B-PROC
colectomy	I-PROC
had	O	O
higher	O	O
rates	O
of	O	O
postoperative	B-DISO
ileus	I-DISO
(	O	O
8	O	O
.	O	O
7	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
3	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
wound	B-DISO
complication	I-DISO
(	O	O
8	O	O
.	O	O
8	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
8	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

006	O	O
)	O	O
,	O	O
and	O	O
30	O	O
-	O	O
day	O
readmission	B-PROC
(	O	O
7	O	O
.	O	O
5	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
0	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
002	O	O
)	O	O
,	O	O
without	O	O
any	O	O
differences	O	O
in	O	O
operative	O
time	O
(	O	O
156	O	O
vs	O	O
.	O	O

157	O	O
min	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

713	O	O
)	O	O
.	O	O

Amongst	O	O
segmental	O
colectomies	B-PROC
,	O	O
HAL	B-PROC
remained	O	O
associated	O	O
with	O	O
higher	O	O
rates	O
of	O	O
wound	B-DISO
complications	I-DISO
(	O	O
8	O	O
.	O	O
6	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
5	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
016	O	O
)	O	O
,	O	O
postoperative	B-DISO
ileus	I-DISO
(	O	O
8	O	O
.	O	O
9	O	O
vs	O	O
.	O	O

6	O	O
.	O	O
3	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
and	O	O
30	O	O
-	O	O
day	O
readmission	B-PROC
(	O	O
7	O	O
.	O	O
1	O	O
vs	O	O
.	O	O

5	O	O
.	O	O
9	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
041	O	O
)	O	O
with	O	O
no	O	O
difference	O	O
in	O	O
operative	O
time	O
between	O	O
HAL	B-PROC
and	O	O
SL	O	O
(	O	O
145	O	O
vs	O	O
.	O	O

145	O	O
min	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
334	O	O
)	O	O
.	O	O

Use	O	O
of	O	O
HAL	B-PROC
colectomy	B-PROC
is	O	O
associated	O	O
with	O	O
increased	O	O
risk	B-PROC
of	O	O
wound	B-DISO
complications	I-DISO
,	O	O
postoperative	B-DISO
ileus	I-DISO
,	O	O
and	O	O
readmissions	B-PROC
.	O	O

Importantly	O	O
,	O	O
this	O	O
technique	O
is	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
decrease	O	O
in	O	O
operative	O
time	O
.	O	O

Somatic	B-PROC
Therapy	I-PROC
of	O	O
a	O	O
Mouse	B-LIVB
SMA	B-DISO
Model	B-DISO
with	O	O
a	O	O
U7	O
snRNA	O
Gene	O
Correcting	O	O
SMN2	O
Splicing	B-PHYS
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
is	O	O
due	O
to	O
the	O	O
loss	O
of	O	O
SMN1	O
gene	B-PHYS
function	I-PHYS
.	O	O

The	O	O
duplicate	O
gene	O
SMN2	O
produces	O	O
some	O	O
,	O	O
but	O	O
not	O	O
enough	O	O
,	O	O
SMN	B-CHEM
protein	I-CHEM
because	O	O
most	O	O
transcripts	B-CHEM
lack	O	O
exon	B-CHEM
7	I-CHEM
.	O	O

Thus	O	O
,	O	O
promoting	O	O
the	O	O
inclusion	O
of	O	O
this	O	O
exon	B-CHEM
is	O	O
a	O	O
therapeutic	O
option	O
.	O	O

We	O	O
show	O	O
that	O	O
a	O	O
somatic	B-PROC
gene	I-PROC
therapy	I-PROC
using	O
the	O	O
gene	O
for	O	O
a	O	O
modified	O
U7	O
RNA	O
which	O	O
stimulates	O	O
this	O	O
splicing	B-PHYS
has	O	O
a	O	O
profound	O
and	O	O
persistent	O
therapeutic	B-PHYS
effect	I-PHYS
on	O	O
the	O	O
phenotype	B-PHYS
of	O	O
a	O	O
severe	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
mouse	B-DISO
model	I-DISO
.	O	O

To	O	O
this	O	O
end	O	O
,	O	O
the	O	O
U7	O
gene	O
and	O	O
vector	B-CHEM
and	O	O
the	O	O
production	O	O
of	O	O
pure	O
,	O	O
highly	O
concentrated	O	O
self	B-LIVB
-	I-LIVB
complementary	I-LIVB
(	I-LIVB
sc	I-LIVB
)	I-LIVB
adenovirus	I-LIVB
-	O	O
associated	O
virus	B-LIVB
9	I-LIVB
vector	B-CHEM
particles	I-CHEM
were	O	O
optimized	O
.	O	O

Introduction	O	O
of	O	O
the	O	O
functional	O
vector	B-CHEM
into	O	O
motoneurons	B-ANAT
of	O	O
newborn	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
mice	B-LIVB
by	O	O
intracerebroventricular	O
injection	B-PROC
led	O	O
to	O	O
a	O	O
highly	O
significant	O
,	O	O
dose	O
-	O
dependent	O
increase	O
in	O	O
life	O
span	O
and	O	O
improvement	O
of	O	O
muscle	B-PHYS
functions	I-PHYS
.	O	O

Besides	O	O
the	O	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
,	O	O
the	O	O
therapeutic	O
U7	O
RNA	O
was	O	O
expressed	B-PHYS
in	O	O
the	O	O
heart	B-ANAT
and	O	O
liver	B-ANAT
which	O	O
may	O	O
additionally	O	O
have	O	O
contributed	O
to	O	O
the	O	O
observed	O
therapeutic	O
efficacy	O
.	O	O

This	O	O
approach	O
provides	O
an	O	O
additional	O
therapeutic	O
option	O
for	O	O
Spinal	B-DISO
Muscular	I-DISO
Atrophy	I-DISO
and	O	O
could	O	O
also	O	O
be	O	O
adapted	O	O
to	O	O
treat	B-PROC
other	O
diseases	B-DISO
of	O	O
the	O	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
with	O	O
regulatory	O
small	O
RNA	O
genes	O
.	O	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O	O
Proliferation	B-PHYS
,	O	O
Invasion	B-DISO
and	O	O
Drug	B-CHEM
-	O	O
Induced	O
Apoptosis	B-PHYS
in	O	O
Lymphoblastic	B-DISO
Leukemia	I-DISO
Some	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
extracellular	B-ANAT
pH	O
in	O	O
tumors	B-DISO
,	O	O
which	O	O
results	O	O
in	O	O
tumor	B-DISO
progression	I-DISO
,	O	O
is	O	O
less	O	O
than	O	O
that	O	O
in	O	O
normal	O
tissues	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O
the	O	O
effects	O
of	O
extracellular	B-ANAT
acidic	O
pH	O
on	O	O
proliferation	B-PHYS
,	O	O
invasion	B-DISO
,	O	O
and	O	O
drug	B-CHEM
-	O	O
induced	O
apoptosis	B-PHYS
in	O	O
acute	B-ANAT
lymphoblastic	I-ANAT
cells	I-ANAT
.	O	O

The	O	O
cells	B-ANAT
were	O	O
cultured	O	O
in	O	O
different	O
pH	O
(	O	O
pH	O
6	O	O
.	O	O
6	O	O
and	O	O
pH	O
7	O	O
.	O	O
4	O	O
)	O	O
for	O	O
12	O	O
days	O
.	O	O

Cell	B-PHYS
proliferation	I-PHYS
was	O	O
assessed	O
by	O	O
MTT	B-PROC
assay	I-PROC
and	O	O
cell	B-DISO
invasion	I-DISO
was	O	O
assayed	O	O
by	O	O
invasion	B-PROC
assay	I-PROC
and	O	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
of	O	O
MMP	B-CHEM
-	I-CHEM
9	I-CHEM
.	O	O

Drug	B-CHEM
-	O	O
induced	O
apoptosis	B-PHYS
was	O	O
evaluated	O	O
after	O	O
exposure	O
to	O
doxorubicin	B-CHEM
for	O	O
24	O	O
hours	O	O
by	O	O
annexin	B-CHEM
V	I-CHEM
/	O	O
PI	B-CHEM
staining	B-PROC
and	O	O
gene	B-PROC
expression	I-PROC
analysis	I-PROC
of	O	O
BAX	B-CHEM
pro	I-CHEM
-	I-CHEM
apoptotic	I-CHEM
protein	I-CHEM
.	O	O

The	O	O
results	O	O
indicated	O	O
the	O	O
enhanced	O	O
growth	B-PHYS
and	O	O
invasion	B-DISO
of	O	O
leukemic	B-DISO
cells	B-ANAT
at	O	O
pH	O
6	O	O
.	O	O

6	O	O
(	O	O
P	O	O
≤	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
cells	B-ANAT
at	O	O
pH	O
6	O	O
.	O	O

6	O	O
were	O	O
resistant	O
to	O	O
apoptosis	B-PHYS
by	O	O
doxorubicin	B-CHEM
(	O	O
P	O	O
≤	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

It	O	O
can	O	O
be	O	O
concluded	O	O
that	O	O
acidic	O
pH	O
increases	O
the	O	O
proliferation	B-PHYS
,	O	O
invasion	B-DISO
and	O	O
reduces	O
the	O	O
drug	B-CHEM
-	O	O
induced	O
apoptosis	B-PHYS
in	O	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
.	O	O

Extracellular	B-ANAT
acidity	O
can	O	O
influence	O	O
the	O	O
behavior	O	O
of	O	O
leukemic	B-DISO
cells	B-ANAT
and	O	O
therefore	O	O
,	O	O
the	O	O
manipulation	O
of	O	O
extracellular	B-ANAT
liquid	I-ANAT
can	O	O
be	O	O
selected	O	O
as	O	O
a	O	O
therapeutic	B-PROC
strategy	I-PROC
for	O	O
leukemia	B-DISO
,	O	O
especially	O	O
for	O	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
.	O	O

Safety	B-PHEN
and	O	O
immunogenecity	B-PROC
of	O	O
a	O	O
live	O	O
attenuated	B-CHEM
Rift	B-CHEM
Valley	I-CHEM
fever	I-CHEM
vaccine	I-CHEM
(	O	O
CL13	B-CHEM
T	I-CHEM
)	O	O
in	O	O
camels	B-LIVB
Rift	B-DISO
Valley	I-DISO
fever	I-DISO
is	O	O
an	O	O
emerging	O	O
zoonotic	B-LIVB
viral	B-DISO
disease	I-DISO
,	O	O
enzootic	B-DISO
and	O	O
endemic	B-DISO
in	O	O
Africa	B-GEOG
and	O	O
the	O	O
Arabian	B-GEOG
Peninsula	I-GEOG
,	O	O
which	O	O
poses	O	O
a	O	O
significant	O
threat	O
to	O	O
both	O	O
human	B-LIVB
and	O	O
animal	B-LIVB
health	B-DISO
.	O	O

The	O	O
disease	B-DISO
is	O	O
most	O	O
severe	O
in	O	O
ruminants	B-LIVB
causing	O
abortions	B-DISO
in	O	O
pregnant	B-PHYS
animals	B-LIVB
,	O	O
especially	O	O
sheep	B-LIVB
animals	I-LIVB
and	O	O
high	O	O
mortality	O
in	O	O
young	O
populations	B-LIVB
.	O	O

High	O	O
mortality	O
rates	O
and	O	O
severe	O
clinical	O
manifestation	O
have	O	O
also	O	O
been	O	O
reported	O
among	O	O
camel	B-LIVB
populations	B-LIVB
in	O	O
Africa	B-GEOG
,	O	O
to	O	O
attend	O	O
however	O	O
none	O	O
of	O	O
the	O	O
currently	O
available	O
live	B-CHEM
vaccines	I-CHEM
against	O	O
RVF	B-DISO
have	O	O
been	O	O
tested	O
for	O	O
safety	B-PHEN
and	O	O
efficacy	O
in	O	O
this	O	O
species	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
the	O	O
safety	B-PHEN
and	O	O
efficacy	O
(	O	O
through	O	O
a	O	O
neutralizing	B-CHEM
antibody	I-CHEM
response	B-PHYS
)	O	O
of	O	O
the	O	O
thermostable	B-CHEM
live	I-CHEM
attenuated	I-CHEM
RVF	B-CHEM
CL13	I-CHEM
T	I-CHEM
vaccine	I-CHEM
were	O	O
evaluated	B-PROC
in	O	O
camels	B-LIVB
in	O	O
two	O	O
different	O
preliminary	O
experiments	B-PROC
involving	O	O
16	O	O
camels	B-LIVB
,	O	O
(	O	O
that	O	O
12	O	O
camels	B-LIVB
and	O	O
4	O	O
pregnant	B-PHYS
camels	B-LIVB
)	O	O
.	O	O

The	O	O
study	B-PROC
revealed	O
that	O	O
the	O	O
CL13	B-CHEM
T	I-CHEM
vaccine	I-CHEM
was	O	O
safe	B-PHEN
to	O	O
use	O
in	O	O
camels	B-LIVB
and	O	O
no	O	O
abortions	B-DISO
or	O	O
teratogenic	B-DISO
effects	I-DISO
were	O	O
observed	O
.	O	O

The	O	O
single	O	O
dose	O
of	O	O
the	O	O
vaccine	B-CHEM
stimulated	O	O
a	O	O
strong	O
and	O	O
long	O	O
-	O	O
lasting	O	O
neutralizing	B-CHEM
antibody	I-CHEM
response	B-PHYS
for	O	O
up	O	O
to	O	O
12	O	O
months	O
.	O	O

The	O	O
presence	B-DISO
of	O	O
neutralization	B-CHEM
antibodies	I-CHEM
is	O	O
likely	O	O
to	O	O
correlate	O
with	O
protection	B-DISO
;	O	O
however	O	O
protection	B-DISO
would	O	O
need	O	O
to	O	O
be	O	O
confirmed	O
by	O
challenge	O	O
experiments	B-PROC
using	O	O
the	O	O
virulent	O
RVF	B-LIVB
virus	I-LIVB
.	O	O

Highly	B-PROC
sensitive	I-PROC
detection	I-PROC
of	I-PROC
influenza	I-PROC
virus	I-PROC
by	O	O
boron	B-DEVI
-	I-DEVI
doped	I-DEVI
diamond	I-DEVI
electrode	I-DEVI
terminated	O	O
with	O	O
sialic	B-CHEM
acid	I-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
The	O	O
progression	B-DISO
of	I-DISO
influenza	I-DISO
varies	O	O
according	O	O
to	O	O
age	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
underlying	B-DISO
disease	I-DISO
;	O	O
appropriate	B-PHYS
treatment	I-PHYS
is	O	O
therefore	O	O
required	O	O
to	O	O
prevent	B-PROC
severe	I-PROC
disease	I-PROC
.	O	O

Anti	B-PROC
-	I-PROC
influenza	I-PROC
therapy	I-PROC
,	O	O
such	O	O
as	O	O
with	O	O
neuraminidase	B-CHEM
inhibitors	I-CHEM
,	O	O
is	O	O
effective	O
,	O	O
but	O	O
diagnosis	B-DISO
at	O	O
an	O	O
early	O
phase	O
of	O
infection	O
before	O	O
viral	B-DISO
propagation	I-DISO
is	O	O
critical	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
several	O	O
dozen	O	O
plaque	O
-	O
forming	O
units	O
(	O	O
pfu	O
)	O	O
of	O	O
influenza	B-LIVB
virus	I-LIVB
(	O	O
IFV	B-LIVB
)	O	O
can	O	O
be	O	O
detected	O	O
using	O	O
a	O	O
boron	B-DEVI
-	I-DEVI
doped	I-DEVI
diamond	I-DEVI
(	I-DEVI
BDD	I-DEVI
)	I-DEVI
electrode	I-DEVI
terminated	O	O
with	O	O
a	O	O
sialic	B-CHEM
acid	I-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
.	O	O

The	O	O
peptide	B-CHEM
was	O	O
used	O	O
instead	O	O
of	O	O
the	O	O
sialyloligosaccharide	B-CHEM
receptor	I-CHEM
,	O	O
which	O	O
is	O	O
the	O	O
common	O	O
receptor	B-CHEM
of	O	O
influenza	B-LIVB
A	I-LIVB
and	O	O
B	B-LIVB
viruses	I-LIVB
required	O	O
during	O	O
the	O	O
early	O
phase	O
of	O
infection	O
,	O	O
to	O	O
capture	O	O
IFV	B-ANAT
particles	I-ANAT
.	O	O

The	O	O
peptide	B-CHEM
,	O	O
which	O	O
was	O	O
previously	O	O
identified	O	O
by	O	O
phage	B-PROC
-	I-PROC
display	I-PROC
technology	I-PROC
,	O	O
was	O	O
immobilized	B-CHEM
by	O	O
click	B-PROC
chemistry	I-PROC
on	O	O
the	O	O
BDD	B-DEVI
electrode	I-DEVI
,	O	O
which	O	O
has	O	O
excellent	O
electrochemical	O
characteristics	O
such	O	O
as	O	O
low	O
background	O
current	O
and	O	O
weak	O	O
adsorption	B-PROC
of	I-PROC
biomolecules	I-PROC
.	O	O

Electrochemical	B-PROC
impedance	I-PROC
spectroscopy	I-PROC
revealed	O	O
that	O	O
H1N1	B-LIVB
and	O	O
H3N2	B-LIVB
IFVs	I-LIVB
were	O	O
detectable	B-PHYS
in	O	O
the	O	O
range	O	O
of	O	O
20	O	O
-	O	O
500	O	O
pfu	O
by	O	O
using	O	O
the	O	O
peptide	B-DEVI
-	I-DEVI
terminated	I-DEVI
BDD	I-DEVI
electrode	I-DEVI
.	O	O

Our	O	O
results	O	O
demonstrate	O	O
that	O	O
the	O	O
BDD	B-DEVI
device	I-DEVI
integrated	O	O
with	O	O
the	O	O
receptor	B-CHEM
-	I-CHEM
mimic	I-CHEM
peptide	I-CHEM
has	O	O
high	O
sensitivity	O
for	O	O
detection	B-PROC
of	O	O
a	O	O
low	O	O
number	O	O
of	O	O
virus	B-ANAT
particles	I-ANAT
in	O	O
the	O	O
early	O
phase	O
of	O
infection	O
.	O	O

Identification	O	O
of	O	O
a	O	O
peroxisomal	B-ANAT
-targeted	O	O
aldolase	B-CHEM
involved	O	O
in	O	O
chlorophyll	B-CHEM
biosynthesis	O
and	O	O
sugar	B-CHEM
metabolism	B-PHYS
in	O	O
rice	B-OBJC
Chlorophyll	B-CHEM
plays	O	O
remarkable	O	O
and	O	O
critical	O	O
roles	O	O
in	O	O
photosynthetic	B-PHYS
light	I-PHYS
-	I-PHYS
harvesting	I-PHYS
,	I-PHYS
energy	B-PHYS
transduction	I-PHYS
and	O	O
plant	B-PHYS
development	I-PHYS
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
identified	O	O
a	O	O
rice	B-OBJC
Chl	B-CHEM
-deficient	O	O
mutant	B-DISO
,	O	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
(	O	O
yellow	B-DISO
green	I-DISO
and	I-DISO
droopy	I-DISO
leaf	I-DISO
-	I-DISO
1	I-DISO
)	O	O
,	O	O
which	O	O
showed	O	O
yellow	B-LIVB
-	I-LIVB
green	I-LIVB
leaves	I-LIVB
throughout	O	O
plant	B-PHYS
development	I-PHYS
with	O	O
decreased	O	O
content	O	O
of	O	O
Chls	B-CHEM
and	O	O
carotene	B-CHEM
and	O	O
an	O	O
increased	O	O
Chl	B-CHEM
a	O	O
/	O	O
b	O	O
ratio	O	O
.	O	O

The	O	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
mutant	I-DISO
also	O	O
exhibited	O	O
severe	O
defects	O
in	O	O
chloroplast	B-ANAT
development	B-PHYS
,	O	O
including	O	O
disorganized	O	O
grana	B-ANAT
stacks	I-ANAT
.	O	O

Sequence	B-PROC
analysis	I-PROC
revealed	O	O
that	O	O
the	O	O
mutant	B-DISO
contained	O	O
a	O	O
T	B-CHEM
-	I-CHEM
DNA	I-CHEM
insertion	O	O
within	O	O
the	O	O
promoter	B-CHEM
of	O	O
a	O	O
fructose	B-CHEM
-	I-CHEM
1	I-CHEM
,	I-CHEM
6	I-CHEM
-	I-CHEM
bisphosphate	I-CHEM
aldolase	I-CHEM
(	O	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
)	O	O
,	O	O
which	O	O
dramatically	O	O
reduced	O	O
the	O	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
mRNA	B-CHEM
level	O
,	O	O
and	O	O
its	O	O
identity	O	O
was	O	O
verified	O	O
by	O	O
transgenic	B-PHYS
complementation	I-PHYS
.	O	O

Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
analysis	I-PROC
showed	O	O
that	O	O
the	O	O
expression	O
levels	O
of	O	O
genes	O
associated	O	O
with	O	O
chlorophyll	B-CHEM
biosynthesis	O
and	O	O
chloroplast	B-ANAT
development	B-PHYS
were	O	O
concurrently	O	O
altered	O	O
in	O	O
the	O	O
ygdl	B-DISO
-	I-DISO
1	I-DISO
mutant	I-DISO
.	O	O

The	O	O
expression	B-PHYS
of	O	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
-	O	O
GFP	B-CHEM
fusion	B-CHEM
protein	I-CHEM
in	O	O
tobacco	B-LIVB
epidermal	B-ANAT
cells	I-ANAT
showed	O	O
that	O	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
was	O	O
localized	O	O
to	O	O
the	O	O
peroxisome	B-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
analysis	B-PROC
of	O	O
primary	B-CHEM
carbon	I-CHEM
metabolites	I-CHEM
revealed	O	O
the	O	O
significantly	O	O
reduced	O	O
levels	O	O
of	O	O
sucrose	B-CHEM
and	O	O
fructose	B-CHEM
in	O	O
the	O	O
mutant	B-DISO
leaves	B-LIVB
,	O	O
while	O	O
the	O	O
glucose	B-CHEM
content	O	O
was	O	O
similar	O	O
to	O	O
wild	B-LIVB
-	I-LIVB
type	I-LIVB
plants	I-LIVB
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
OsAld	B-CHEM
-	I-CHEM
Y	I-CHEM
participates	O	O
in	O	O
Chl	B-CHEM
accumulation	B-DISO
,	O	O
chloroplast	B-ANAT
development	B-PHYS
and	O	O
plant	B-PHYS
growth	I-PHYS
by	O	O
influencing	O	O
the	O	O
photosynthetic	B-PHEN
rate	O
of	O	O
leaves	B-LIVB
and	O	O
the	O	O
sugar	B-CHEM
metabolism	B-PHYS
of	O	O
rice	B-OBJC
.	O	O

Autoantibodies	B-CHEM
to	O	O
MOG	B-CHEM
in	O	O
a	O	O
distinct	O	O
subgroup	O
of	O	O
adult	B-LIVB
multiple	B-DISO
sclerosis	I-DISO
To	O	O
evaluate	B-PROC
the	O	O
presence	O	O
of	O	O
antibodies	B-CHEM
to	O	O
conformation	O
-intact	O	O
myelin	B-CHEM
oligodendrocyte	I-CHEM
glycoprotein	I-CHEM
(	O	O
MOG	B-CHEM
)	O	O
in	O	O
a	O	O
subgroup	O
of	O	O
adult	B-LIVB
patients	B-LIVB
with	O	O
clinically	O
definite	O	O
multiple	B-DISO
sclerosis	I-DISO
(	O	O
MS	B-DISO
)	O	O
preselected	O	O
for	O	O
a	O	O
specific	O	O
clinical	O
phenotype	B-PHYS
including	O	O
severe	O
spinal	B-ANAT
cord	I-ANAT
,	O	O
optic	B-ANAT
nerve	I-ANAT
,	O	O
and	O	O
brainstem	B-ANAT
involvement	O	O
.	O	O

Antibodies	B-CHEM
to	O	O
MOG	B-CHEM
were	O	O
investigated	O
using	O	O
a	O	O
cell	B-PROC
-	I-PROC
based	I-PROC
assay	I-PROC
in	O	O
3	O	O
groups	B-LIVB
of	O	O
patients	B-LIVB
:	O	O
104	O	O
preselected	O	O
patients	B-LIVB
with	O	O
MS	B-DISO
(	O	O
group	B-LIVB
1	I-LIVB
)	O	O
,	O	O
55	O	O
age	B-PHYS
-	O	O
and	O	O
sex	B-PHYS
-matched	O	O
,	O	O
otherwise	O	O
unselected	O	O
patients	B-LIVB
with	O	O
MS	B-DISO
(	O	O
group	B-LIVB
2	I-LIVB
)	O	O
,	O	O
and	O	O
in	O	O
22	O	O
brain	B-PROC
-	I-PROC
biopsied	I-PROC
patients	B-LIVB
with	O	O
demyelinating	B-DISO
diseases	I-DISO
of	O	O
the	O	O
CNS	B-ANAT
(	O	O
n	O	O
=	O	O
19	O	O
with	O	O
MS	B-DISO
)	O	O
,	O	O
4	O	O
of	O	O
whom	O	O
classified	O
as	O	O
MS	B-DISO
type	I-DISO
II	I-DISO
(	O	O
group	B-LIVB
3	I-LIVB
)	O	O
.	O	O

Recognized	O	O
epitopes	B-CHEM
were	O	O
identified	O	O
with	O	O
mutated	B-PHYS
variants	O
of	O	O
MOG	O
.	O	O

Antibodies	B-CHEM
to	O	O
MOG	B-CHEM
were	O	O
found	O	O
in	O	O
about	O	O
5	O	O
%	O	O
(	O	O
5	O	O
/	O	O
104	O	O
)	O	O
of	O	O
preselected	O	O
adult	B-LIVB
patients	B-LIVB
with	O	O
MS	B-DISO
.	O	O

In	O	O
contrast	O	O
,	O	O
in	O	O
groups	B-LIVB
2	I-LIVB
and	O	O
3	B-LIVB
,	O	O
none	O	O
of	O	O
the	O	O
patients	B-LIVB
tested	O
positive	O	O
for	O	O
MOG	B-CHEM
antibodies	B-CHEM
.	O	O

Patients	B-LIVB
with	O	O
MS	B-DISO
with	O	O
antibodies	B-CHEM
to	O	O
MOG	B-CHEM
predominantly	O	O
manifested	O
with	O	O
concomitant	O
severe	O
brainstem	B-ANAT
and	O	O
spinal	B-ANAT
cord	I-ANAT
involvement	O	O
and	O	O
had	O	O
a	O	O
severe	O
disease	B-DISO
course	I-DISO
with	O	O
high	O	O
relapse	B-PHEN
rates	O
and	O	O
failure	B-DISO
to	O	O
several	O	O
disease	B-PROC
-	I-PROC
modifying	I-PROC
therapies	I-PROC
.	O	O

Three	O	O
of	O	O
them	O	O
had	O	O
been	O	O
treated	B-PROC
with	I-PROC
plasma	B-PROC
exchange	I-PROC
with	O	O
a	O	O
favorable	O
response	O
.	O	O

All	O	O
anti	B-CHEM
-	I-CHEM
MOG	I-CHEM
-positive	O	O
patients	B-LIVB
with	O	O
MS	B-DISO
showed	O	O
typical	O	O
MS	B-DISO
lesions	B-DISO
on	O	O
brain	B-PROC
MRI	I-PROC
.	O	O

Longitudinal	O
analysis	O
up	O	O
to	O	O
9	O	O
years	O
revealed	O	O
fluctuations	B-DISO
and	O	O
reappearance	O	O
of	O	O
anti	B-PHYS
-	I-PHYS
MOG	I-PHYS
reactivity	I-PHYS
.	O	O

Epitope	B-PROC
mapping	I-PROC
indicated	O	O
interindividual	O
heterogeneity	O
,	O	O
yet	O	O
intraindividual	O
stability	O
of	O	O
the	O	O
antibody	B-PHEN
response	I-PHEN
.	O	O

Antibodies	B-CHEM
to	O	O
MOG	B-CHEM
can	O	O
be	O	O
found	O	O
in	O	O
a	O	O
distinct	O	O
subgroup	O
of	O	O
adult	B-LIVB
MS	B-DISO
with	O	O
a	O	O
specific	O	O
clinical	O
phenotype	B-PHYS
and	O	O
may	O	O
indicate	O	O
disease	B-DISO
heterogeneity	O
.	O	O

Brassinosteroid	B-CHEM
/	O	O
Abscisic	B-CHEM
Acid	I-CHEM
Antagonism	O
in	O	O
Balancing	O	O
Growth	B-PHYS
and	O	O
Stress	B-DISO
In	O	O
this	O	O
issue	O
of	O	O
Developmental	B-PHYS
Cell	I-PHYS
,	O	O
Gui	O	O
et	O	O
al	O	O
.	O	O
(	O	O
2016	O	O
)	O	O
show	O	O
that	O	O
an	O	O
abscisic	B-CHEM
acid	I-CHEM
-	O	O
inducible	O
remorin	B-CHEM
protein	I-CHEM
in	O	O
rice	B-LIVB
directly	O	O
interacts	O	O
with	O	O
critical	O
brassinosteroid	B-CHEM
signaling	B-CHEM
components	I-CHEM
to	O	O
attenuate	O
the	O	O
brassinosteroid	B-CHEM
response	B-PHYS
,	O	O
thus	O	O
illuminating	O	O
one	O	O
aspect	O
of	O	O
the	O	O
brassinosteroid	B-CHEM
/	O	O
abscisic	B-CHEM
acid	I-CHEM
antagonism	O
.	O	O

Salvage	B-PROC
surgery	B-PROC
after	O	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
The	O	O
purpose	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
describe	O	O
the	O	O
results	B-DISO
and	O	O
complications	B-DISO
of	O	O
primary	B-PHYS
site	I-PHYS
salvage	B-PROC
surgery	B-PROC
after	O	O
head	B-DISO
and	I-DISO
neck	I-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
HNSCC	B-DISO
)	O	O
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
.	O	O

We	O	O
conducted	O	O
a	O	O
retrospective	B-PROC
chart	O
review	O
of	O	O
268	O	O
patients	B-LIVB
treated	B-PROC
with	I-PROC
bioradiotherapy	B-PROC
between	O	O
March	O	O
2006	O	O
and	O	O
December	O	O
2013	O	O
at	O	O
the	O	O
Hospital	B-OBJC
Universitari	I-OBJC
de	I-OBJC
Bellvitge	I-OBJC
-	I-OBJC
ICO	I-OBJC
.	O	O
Fifty	O	O
-	O	O
nine	O	O
patients	B-LIVB
developed	O	O
local	B-DISO
recurrence	I-DISO
or	O	O
had	O	O
residual	B-DISO
disease	I-DISO
with	O	O
a	O	O
1	O	O
-	O	O
year	O
and	O	O
3	O	O
-	O	O
year	O
overall	O
survival	O
of	O	O
47	O	O
%	O	O
and	O	O
15	O	O
.	O	O
4	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Salvage	B-PROC
surgery	B-PROC
was	O	O
feasible	O	O
in	O	O
22	O	O
patients	B-LIVB
(	O	O
37	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

There	O	O
were	O	O
16	O	O
complications	B-DISO
in	O	O
these	O	O
22	O	O
patients	B-LIVB
(	O	O
72	O	O
.	O	O
7	O	O
%	O	O
)	O	O
,	O	O
11	O	O
(	O	O
50	O	O
%	O	O
)	O	O
of	O	O
which	O	O
were	O	O
major	O	O
.	O	O

Bilateral	O
neck	B-PROC
dissection	I-PROC
was	O	O
identified	O	O
as	O	O
a	O	O
risk	B-DISO
factor	I-DISO
for	O	O
complications	B-DISO
.	O	O

Salvage	B-PROC
surgery	B-PROC
after	O	O
bioradiotherapy	B-PROC
is	O	O
associated	O	O
with	O	O
a	O	O
high	O	O
rate	O
of	O	O
complications	B-DISO
.	O	O

Neck	B-PROC
dissection	I-PROC
seems	O	O
to	O	O
be	O	O
related	O	O
to	O	O
an	O	O
increased	O	O
rate	O
of	O	O
complications	B-DISO
with	O	O
no	B-DISO
survival	O
improvement	O
.	O	O

©	O	O
2016	O	O
Wiley	O	O
Periodicals	O	O
,	O	O
Inc	O	O
.	O	O

Head	O	O
Neck	O	O
39	O	O
:	O	O
116	O	O
-	O	O
121	O	O
,	O	O
2017	O	O
.	O	O

Acute	B-DISO
Ph	I-DISO
-	I-DISO
negative	I-DISO
lymphoblastic	I-DISO
leukemias	I-DISO
in	O	O
adults	B-LIVB
:	O	O
Risk	B-DISO
factors	I-DISO
in	O	O
the	O	O
use	O	O
of	O	O
the	O	O
ALL	O
-	O
2009	O
protocol	O
to	O	O
analyze	O	O
well	O	O
-	O	O
known	O	O
risk	B-DISO
factors	I-DISO
(	O	O
RFs	B-DISO
)	O	O
,	O	O
such	O	O
as	O	O
age	B-PHYS
,	O	O
immunophenotype	B-PROC
,	O	O
baseline	O
leukocytosis	B-DISO
,	O	O
enhanced	O
lactate	B-CHEM
dehydrogenase	I-CHEM
(	O	O
LDH	B-CHEM
)	O	O
activity	B-PHYS
,	O	O
time	O	O
to	O	O
achieve	O	O
complete	O	O
remission	B-DISO
,	O	O
a	O	O
risk	B-LIVB
group	I-LIVB
,	O	O
and	O	O
cytogenetic	B-DISO
abnormalities	I-DISO
)	O	O
in	O	O
patients	B-LIVB
with	O	O
acute	B-DISO
lymphoblastic	I-DISO
leukemia	I-DISO
(	O	O
ALL	B-DISO
)	O	O
in	O	O
the	O	O
use	O	O
of	O	O
the	O	O
ALL	O
-	O
2009	O
protocol	O
.	O	O

The	O	O
protocol	O
covered	O	O
298	O	O
patients	B-LIVB
(	O	O
137	O	O
women	B-LIVB
(	O	O
including	O
13	O	O
pregnant	B-LIVB
women	I-LIVB
)	O	O
and	O	O
161	O	O
men	B-LIVB
)	O	O
aged	O	O
15	O	O
to	O	O
55	O	O
years	O	O
(	O	O
median	O	O
age	O	O
28	O	O
years	O	O
)	O	O
with	O	O
Ph	B-DISO
-	I-DISO
negative	I-DISO
ALL	I-DISO
.	O	O

The	O	O
phenotype	B-PHYS
was	O	O
unknown	O	O
in	O	O
6	O	O
patients	B-LIVB
.	O	O

Three	O	O
(	O	O
1	O	O
%	O	O
)	O	O
were	O	O
ascertained	O	O
to	O	O
have	O	O
a	O	O
biphenotypic	O	O
variant	O	O
.	O	O

182	O	O
(	O	O
62	O	O
.	O	O
4	O	O
%	O	O
)	O	O
patients	B-LIVB
were	O	O
found	O	O
to	O	O
have	O	O
B	B-DISO
-	I-DISO
cell	I-DISO
ALL	I-DISO
(	O	O
early	O	O
pre	B-DISO
-	I-DISO
B	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
51	O	O
)	O	O
;	O	O
common	O	O
ALL	B-DISO
(	O	O
n	O	O
=	O	O
92	O	O
)	O	O
,	O	O
and	O	O
pre	B-DISO
-	I-DISO
B	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
39	O	O
)	O	O
;	O	O
107	O	O
(	O	O
36	O	O
.	O	O
6	O	O
%	O	O
)	O	O
patients	B-LIVB
had	O	O
T	B-DISO
-	I-DISO
cell	I-DISO
ALL	I-DISO
(	O	O
early	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
56	O	O
)	O	O
;	O	O
thymic	B-ANAT
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
41	O	O
)	O	O
,	O	O
and	O	O
mature	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
.	O	O

According	O	O
to	O	O
the	O	O
baseline	O
clinical	O
and	O	O
laboratory	B-OBJC
parameters	B-DISO
(	O	O
leukocytosis	B-DISO
of	O	O
30·109	O	O
/	O	O
l	O	O
and	O	O
more	O	O
for	O	O
B	B-DISO
-	I-DISO
ALL	I-DISO
;	O	O
and	O	O
that	O	O
of	O	O
100·109	O	O
/	O	O
l	O	O
and	O	O
more	O	O
for	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
;	O	O
phenotype	B-PHYS
В	O	O
-	O	O
I	O	O
for	O	O
B	B-DISO
-	I-DISO
ALL	I-DISO
,	O	O
phenotype	B-PHYS
Т	O	O
-	O	O
I	O	O
-	O	O
II	O	O
-	O	O
IV	O	O
for	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
;	O	O
LDH	B-CHEM
activity	B-PHYS
was	O	O
more	O	O
than	O	O
twice	O	O
the	O	O
normal	O	O
values	O	O
;	O	O
the	O	O
presence	B-DISO
of	O	O
translocation	B-DISO
t	I-DISO
(	I-DISO
4	I-DISO
;	I-DISO
11	I-DISO
)	I-DISO
)	O	O
,	O	O
the	O	O
high	B-LIVB
-	I-LIVB
risk	I-LIVB
group	I-LIVB
included	O
most	O	O
patients	B-LIVB
with	O	O
B	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
110	O	O
(	O	O
72	O	O
.	O	O
8	O	O
%	O	O
)	O	O
)	O	O
and	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
n	O	O
=	O	O
76	O	O
(	O	O
76	O	O
%	O	O
)	O	O
)	O	O
.	O	O

Thirty	O	O
-	O	O
five	O	O
patients	B-LIVB
with	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
underwent	O	O
autologous	B-PROC
bone	I-PROC
marrow	I-PROC
transplantation	I-PROC
(	O	O
BMT	B-PROC
)	O	O
.	O	O

Allogeneic	B-PROC
BMT	I-PROC
was	O	O
performed	O
in	O	O
18	O	O
(	O	O
7	O	O
%	O	O
)	O	O
of	O	O
the	O	O
258	O	O
patients	B-LIVB
who	O	O
had	O	O
undergone	O	O
an	O	O
induction	B-PROC
phase	I-PROC
.	O	O

Five	O	O
-	O	O
year	O	O
overall	O
survival	O
for	O	O
all	O	O
the	O	O
patients	B-LIVB
included	O
in	O	O
the	O	O
investigation	B-PROC
was	O	O
59	O	O
%	O	O
;	O	O
relapse	B-PROC
-	I-PROC
free	I-PROC
survival	O	O
was	O	O
65	O	O
%	O	O
,	O	O
which	O	O
was	O	O
significantly	O	O
different	O	O
in	O	O
the	O	O
patients	B-LIVB
with	O	O
B	B-DISO
-	I-DISO
ALL	I-DISO
and	O	O
in	O	O
those	O	O
with	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
:	O	O
the	O	O
overall	O
survival	O
rates	O
were	O	O
53	O	O
.	O	O
3	O	O
and	O	O
67	O	O
.	O	O

5	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
1	O	O
)	O	O
;	O	O
the	O	O
relapse	O	O
-	O	O
free	O	O
survival	O	O
was	O	O
56	O	O
and	O	O
79	O	O
%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
005	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Multivariate	O
analysis	O
including	O
the	O	O
well	O	O
-	O	O
known	O	O
RFs	B-DISO
demonstrated	O	O
that	O	O
the	O	O
latter	O	O
for	O	O
T	B-DISO
-	I-DISO
ALL	I-DISO
were	O	O
of	O	O
no	O	O
independent	O	O
prognostic	O	O
value	O	O
and	O	O
only	O	O
the	O	O
patient	B-LIVB
's	I-LIVB
age	B-PHYS
was	O	O
identified	O	O
for	O	O
B	B-DISO
-	I-DISO
ALL	I-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
013	O	O
)	O	O
.	O	O

A	O	O
lower	O	O
chemotherapeutic	B-CHEM
load	O	O
and	O	O
a	O	O
small	O	O
number	O	O
of	O	O
allogeneic	B-PROC
BMTs	I-PROC
did	O	O
not	O	O
affect	O	O
total	O	O
positive	O	O
treatment	B-PROC
results	B-PHEN
in	O	O
adult	B-LIVB
patients	B-LIVB
with	O	O
ALL	B-DISO
,	O	O
by	O	O
complying	O	O
with	O	O
the	O	O
principle	O	O
achieving	O	O
the	O	O
continuity	O	O
of	O	O
cytostatic	B-CHEM
effects	O
and	O	O
by	O	O
preserving	O
the	O	O
total	O	O
cytostatic	B-CHEM
loading	O
dose	O
.	O	O

The	O	O
results	B-PHEN
of	O	O
the	O	O
Russian	B-GEOG
investigation	B-PROC
casts	O	O
some	O	O
doubt	O	O
on	O	O
the	O	O
necessity	O	O
of	O	O
using	O	O
very	O	O
intensive	O	O
consolidation	O	O
cycles	O	O
and	O	O
performing	O	O
a	O	O
large	O	O
number	O	O
of	O	O
allogeneic	B-PROC
BMTs	I-PROC
in	O	O
adult	B-LIVB
patients	B-LIVB
with	O	O
ALL	B-DISO
.	O	O

Gold	B-CHEM
-	O	O
Nanosponge	B-DEVI
-Based	O	O
Multistimuli	B-CHEM
-	I-CHEM
Responsive	I-CHEM
Drug	I-CHEM
Vehicles	I-CHEM
for	O	O
Targeted	O
Chemo	B-PROC
-	I-PROC
Photothermal	I-PROC
Therapy	I-PROC
Gold	B-CHEM
-	O	O
nanosponge	B-DEVI
-based	O	O
multistimuli	B-CHEM
-	I-CHEM
responsive	I-CHEM
drug	I-CHEM
vehicles	I-CHEM
are	O	O
constructed	O	O
for	O	O
combined	O	O
chemo	B-PROC
-	I-PROC
photothermal	I-PROC
therapy	I-PROC
with	O	O
pinpointed	O	O
drug	B-CHEM
delivery	O
and	O	O
release	O
capabilities	O	O
and	O	O
minimized	O	O
nonspecific	O
systemic	O
spread	O
of	O	O
drugs	B-CHEM
,	O	O
remarkably	O	O
enhancing	O
the	O	O
therapeutic	O
efficiency	O
while	O	O
minimizing	O	O
acute	O
side	B-DISO
effects	I-DISO
.	O	O

Multidetector	B-PROC
CT	I-PROC
of	O	O
expected	O
findings	B-DISO
and	O	O
complications	B-DISO
after	O	O
contemporary	O
inguinal	B-PROC
hernia	I-PROC
repair	I-PROC
surgery	B-PROC
Inguinal	B-PROC
hernia	I-PROC
repair	I-PROC
(	O	O
IHR	B-PROC
)	O	O
with	O	O
prosthetic	B-DEVI
mesh	B-DEVI
implantation	B-PROC
is	O	O
the	O	O
most	O	O
common	O	O
procedure	B-PROC
in	O	O
general	B-PROC
surgery	I-PROC
,	O	O
and	O	O
may	O	O
be	O	O
performed	O
using	O	O
either	O	O
an	O	O
open	O
or	O	O
laparoscopic	O
approach	O
.	O	O

This	O	O
paper	B-OBJC
provides	O	O
an	O	O
overview	O
of	O	O
contemporary	O
tension	O	O
-	O	O
free	O	O
IHR	B-PROC
techniques	O
and	O	O
materials	B-OBJC
,	O	O
and	O	O
illustrates	O	O
the	O	O
expected	O
postoperative	B-DISO
imaging	B-PHEN
findings	I-PHEN
and	O	O
iatrogenic	B-DISO
injuries	I-DISO
.	O	O

Emphasis	O	O
is	O	O
placed	O	O
on	O	O
multidetector	B-PROC
CT	I-PROC
,	O	O
which	O	O
represents	O	O
the	O	O
ideal	O
modality	O
to	O	O
comprehensively	O	O
visualize	O	O
the	O	O
operated	O
groin	B-ANAT
region	I-ANAT
and	O	O
deeper	O
intra	B-ANAT
-	I-ANAT
abdominal	I-ANAT
structures	I-ANAT
.	O	O

CT	B-PROC
consistently	O	O
depicts	O	O
seroma	B-DISO
,	O	O
mesh	B-DISO
infections	I-DISO
,	O	O
hemorrhages	B-DISO
,	O	O
bowel	B-ANAT
complications	B-DISO
and	O	O
urinary	B-ANAT
bladder	I-ANAT
injuries	B-DISO
,	O	O
and	O	O
thus	O	O
generally	O	O
provides	O	O
a	O	O
consistent	O
basis	O	O
for	O	O
therapeutic	O
choice	O
.	O	O

Since	O	O
radiologists	B-LIVB
are	O	O
increasingly	O
requested	O	O
to	O	O
investigate	O
suspected	O
iatrogenic	O
complications	B-DISO
,	O	O
this	O	O
paper	B-OBJC
aims	O	O
to	O	O
provide	O	O
an	O	O
increased	O
familiarity	B-PHYS
with	O	O
early	O
CT	B-PROC
studies	B-PROC
after	O	O
IHR	B-PROC
,	O	O
including	O	O
complications	B-DISO
and	O	O
normal	O
postoperative	B-DISO
appearances	O
such	O	O
as	O	O
focal	O
pseudolesions	B-DISO
,	O	O
in	O	O
order	O	O
to	O	O
avoid	B-PROC
misinterpretation	I-PROC
and	O	O
inappropriate	O
management	B-PROC
.	O	O

The	O	O
transcription	B-CHEM
factors	I-CHEM
MS188	B-CHEM
and	O	O
AMS	B-CHEM
form	O	O
a	O	O
complex	O
to	O	O
activate	O
the	O	O
expression	B-PHYS
of	O	O
CYP703A2	B-CHEM
for	O	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
in	O	O
Arabidopsis	B-LIVB
thaliana	I-LIVB
The	O	O
sexine	B-ANAT
layer	I-ANAT
of	O	O
pollen	B-LIVB
grain	I-LIVB
is	O	O
mainly	O	O
composed	O	O
of	O	O
sporopollenins	B-CHEM
.	O	O

The	O	O
sporophytic	B-ANAT
secretory	I-ANAT
tapetum	I-ANAT
is	O	O
required	O
for	O	O
the	O	O
biosynthesis	B-PHYS
of	I-PHYS
sporopollenin	I-PHYS
.	O	O

Although	O	O
several	O	O
enzymes	B-CHEM
involved	O
in	O	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
have	O	O
been	O	O
reported	O	O
,	O	O
the	O	O
regulatory	B-PHYS
mechanism	I-PHYS
of	O	O
these	O	O
enzymes	B-CHEM
in	O	O
tapetal	B-ANAT
layer	I-ANAT
remains	O	O
elusive	O	O
.	O	O

ABORTED	B-CHEM
MICROSPORES	I-CHEM
(	O	O
AMS	B-CHEM
)	O	O
and	O	O
MALE	B-CHEM
STERILE	I-CHEM
188	I-CHEM
/	O	O
MYB103	B-CHEM
/	O	O
MYB80	B-CHEM
(	O	O
MS188	B-CHEM
/	O	O
MYB103	B-CHEM
/	O	O
MYB80	B-CHEM
)	O	O
are	O	O
two	O	O
tapetal	B-ANAT
cell	I-ANAT
-specific	O	O
transcription	B-CHEM
factors	I-CHEM
required	O
for	O	O
pollen	B-PHYS
wall	I-PHYS
formation	I-PHYS
.	O	O

AMS	B-CHEM
functions	O
upstream	O
of	O	O
MS188	B-CHEM
.	O	O

Here	O	O
we	O	O
report	O	O
that	O	O
AMS	B-CHEM
and	O	O
MS188	B-CHEM
target	O
the	O	O
CYP703A2	O
gene	O
,	O	O
which	O	O
is	O	O
involved	O
in	O	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
.	O	O

We	O	O
found	O	O
that	O	O
AMS	B-CHEM
and	O	O
MS188	B-CHEM
were	O	O
localized	O
in	O	O
tapetum	B-ANAT
while	O	O
CYP703A2	B-CHEM
was	O	O
localized	O
in	O	O
both	O	O
tapetum	B-ANAT
and	O	O
locule	B-LIVB
.	O	O

Chromatin	B-PROC
immunoprecipitation	I-PROC
(	O	O
ChIP	B-PROC
)	O	O
showed	O	O
that	O	O
MS188	B-CHEM
directly	O	O
bound	O
to	O	O
the	O	O
promoter	B-CHEM
of	O	O
CYP703A2	O
and	O	O
luciferase	B-CHEM
-	I-CHEM
inducible	I-CHEM
assay	B-PROC
showed	O	O
that	O	O
MS188	B-CHEM
activated	O
the	O	O
expression	B-PHYS
of	O	O
CYP703A2	B-CHEM
.	O	O

Yeast	B-PROC
two	I-PROC
-	I-PROC
hybrid	I-PROC
and	O	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
(	O	O
EMSAs	B-PROC
)	O	O
further	O	O
demonstrated	O	O
that	O	O
MS188	B-CHEM
complexed	O
with	O	O
AMS	B-CHEM
.	O	O

The	O	O
expression	B-PHYS
of	O	O
CYP703A2	O
could	O	O
be	O	O
partially	O	O
restored	O	O
by	O	O
the	O	O
elevated	O
levels	O
of	O	O
MS188	B-CHEM
in	O	O
the	O	O
ams	B-CHEM
mutant	B-DISO
.	O	O

Therefore	O	O
,	O	O
our	O	O
data	O
reveal	O
that	O	O
MS188	B-CHEM
coordinates	O
with	O	O
AMS	B-CHEM
to	O	O
activate	O
CYP703A2	B-CHEM
in	O	O
sporopollenin	B-PHYS
biosynthesis	I-PHYS
of	O	O
plant	B-LIVB
tapetum	B-ANAT
.	O	O

Bioinformatic	O
analysis	B-PROC
of	O	O
RNA	O
-	O
seq	O
data	O
unveiled	O	O
critical	O
genes	O
in	O	O
rectal	B-DISO
adenocarcinoma	I-DISO
RNA	O
-	O
seq	O
data	O
of	O	O
rectal	B-DISO
adenocarcinoma	I-DISO
(	O	O
READ	B-DISO
)	O	O
were	O	O
analyzed	B-PROC
with	O	O
bioinformatics	O
tools	O
to	O	O
unveil	B-PHYS
potential	I-PHYS
biomarkers	I-PHYS
in	O	O
the	O	O
disease	B-DISO
.	O	O

RNA	O
-	O
seq	O
data	O
of	O	O
READ	B-DISO
were	O	O
downloaded	O	O
from	O	O
The	B-PROC
Cancer	I-PROC
Genome	I-PROC
Atlas	I-PROC
(	O	O
TCGA	B-PROC
)	O	O
database	O
.	O	O

Differential	O	O
analysis	B-PROC
was	O	O
performed	O
with	O	O
package	O
edgeR	O
.	O	O

False	O
discovery	O
rate	O
(	O	O
FDR	O
)	O	O
<	O	O
0	O	O
.	O	O
05	O	O
and	O	O
|log2	O	O
(	O	O
fold	O	O
change	O	O
)	O	O
|	O	O
>	O	O
1	O	O
were	O	O
set	O	O
as	O	O
cut	O	O
-	O	O
off	O	O
values	O	O
to	O	O
screen	O	O
out	O	O
differentially	O
expressed	O
genes	O
(	O	O
DEGs	O
)	O	O
.	O	O

Gene	B-PHYS
coexpression	I-PHYS
network	B-PHYS
was	O	O
constructed	O	O
with	O	O
package	O
Ebcoexpress	O
.	O	O

Gene	O
Ontology	O
enrichment	O	O
analysis	B-PROC
was	O	O
performed	O
for	O	O
the	O	O
DEGs	O
in	O	O
the	O	O
gene	B-PHYS
coexpression	I-PHYS
network	O
with	O	O
DAVID	B-OBJC
online	I-OBJC
tool	I-OBJC
.	O	O

Kyoto	O
Encyclopedia	O
of	O	O
Genes	O
and	O	O
Genomes	O
pathway	O	O
enrichment	O	O
analysis	B-PROC
was	O	O
also	O	O
performed	O
for	O	O
the	O	O
genes	O
with	O	O
KOBASS	B-OBJC
2	O	O
.	O	O

0	O	O
.	O	O

A	O	O
total	O	O
of	O	O
620	O	O
DEGs	O
,	O	O
3ated	O	O
genes	O
,	O	O
and	O	O
231	O	O
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
genes	O
,	O	O
were	O	O
identified	O
from	O	O
163	O	O
READ	B-DISO
samples	O	O
and	O	O
9	O	O
normal	O
controls	O
.	O	O

A	O	O
gene	B-PHYS
coexpression	I-PHYS
network	O
consisting	O	O
of	O	O
71	O	O
DEGs	O
and	O	O
253	O	O
edges	O	O
were	O	O
constructed	O	O
.	O	O

Genes	O
were	O	O
associated	O
with	O
ribosome	B-ANAT
and	O	O
focal	B-ANAT
adhesion	I-ANAT
functions	O
.	O	O

Three	O	O
modules	B-PHYS
were	O	O
identified	O
,	O	O
in	O	O
which	O	O
genes	O
were	O	O
involved	O	O
in	O	O
muscle	B-PHYS
contraction	I-PHYS
,	O	O
negative	B-PHYS
regulation	I-PHYS
of	I-PHYS
glial	I-PHYS
cell	I-PHYS
proliferation	I-PHYS
and	O	O
extracellular	B-PHYS
matrix	I-PHYS
organization	I-PHYS
functions	O
,	O	O
respectively	O	O
.	O	O

Several	O	O
critical	O	O
hub	O
genes	O
were	O	O
disclosed	O	O
,	O	O
such	O	O
as	O	O
RPS2	O
,	O	O
MMP1	O
,	O	O
MMP11	O
and	O	O
FAM83H	O
.	O	O

Thirteen	O	O
relevant	O
small	B-CHEM
molecule	I-CHEM
drugs	I-CHEM
were	O	O
identified	O
,	O	O
such	O	O
as	O	O
scriptaid	B-CHEM
and	O	O
spaglumic	B-CHEM
acid	I-CHEM
.	O	O

A	O	O
total	O	O
of	O	O
8	O	O
TFs	B-CHEM
and	O	O
5	B-CHEM
miRNAs	I-CHEM
were	O	O
acquired	O	O
,	O	O
such	O	O
as	O	O
MYC	O
,	O	O
NFY	B-CHEM
,	O	O
STAT5A	O
,	O	O
miR	B-CHEM
-	I-CHEM
29	I-CHEM
,	O	O
miR	B-CHEM
-	I-CHEM
200	I-CHEM
and	O	O
miR	B-CHEM
-	I-CHEM
19	I-CHEM
.	O	O

Several	O	O
critical	O	O
genes	O
and	O	O
relevant	O
drugs	B-PROC
,	O	O
TFs	B-CHEM
and	O	O
miRNAs	B-CHEM
were	O	O
revealed	O	O
in	O	O
READ	B-DISO
.	O	O

These	O	O
findings	O	O
could	O	O
advance	O	O
the	O	O
understanding	O	O
about	O	O
the	O	O
disease	B-DISO
and	O	O
benefit	O	O
therapy	O
development	O
.	O	O

Activation	O
of	O	O
ephrinB	O
-	O
EphB	O
receptor	O
signalling	O
in	O	O
rat	B-ANAT
spinal	I-ANAT
cord	I-ANAT
contributes	O	O
to	O	O
maintenance	O
of	O	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
(	O	O
DNP	B-DISO
)	O	O
is	O	O
severe	O
and	O	O
intractable	O
in	O	O
clinic	B-OBJC
.	O	O

The	O	O
specific	O
cellular	B-PHYS
and	O	O
molecular	B-PHYS
mechanisms	O
underlying	O	O
DNP	B-DISO
remain	O	O
elusive	O	O
and	O	O
its	O	O
treatment	O
are	O	O
limited	O
.	O	O

We	O	O
investigated	O
roles	O
of	O	O
EphB1	B-CHEM
receptor	I-CHEM
in	O	O
the	O	O
development	O	O
of	O	O
DNP	B-DISO
.	O	O

Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
was	O	O
produced	O	O
in	O	O
male	B-PHYS
,	O	O
adult	B-LIVB
,	O	O
Sprague	B-LIVB
-	I-LIVB
Dawley	I-LIVB
rats	I-LIVB
by	O	O
a	O	O
single	O	O
i	O	O
.	O	O

p	O	O
.	O	O

streptozotocin	B-CHEM
(	O	O
STZ	B-CHEM
)	O	O
or	O	O
alloxan	B-CHEM
.	O	O

Western	B-PROC
blot	I-PROC
analysis	I-PROC
and	O	O
immunohistochemistry	B-PROC
were	O	O
used	O	O
to	O	O
analyse	O	O
expression	B-PHYS
of	O	O
EphB1	B-CHEM
receptor	I-CHEM
as	O	O
well	O	O
as	O	O
the	O	O
activation	O
of	O	O
the	O	O
glial	B-ANAT
cells	I-ANAT
and	O	O
the	O	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokines	I-CHEM
in	O	O
the	O	O
spinal	B-ANAT
cord	I-ANAT
.	O	O

DNP	B-DISO
manifested	O
as	O	O
mechanical	B-DISO
allodynia	I-DISO
,	O	O
which	O	O
was	O	O
determined	O	O
by	O	O
measuring	O
incidence	O
of	O	O
foot	B-ANAT
withdrawal	O
in	O	O
response	B-PHYS
to	O	O
mechanical	O
indentation	O
of	O	O
the	O	O
hind	O
paw	B-ANAT
by	O	O
an	O	O
electro	B-OBJC
von	I-OBJC
Frey	I-OBJC
filament	I-OBJC
.	O	O

Diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
and	O	O
high	B-DISO
blood	I-DISO
glucose	I-DISO
were	O	O
exhibited	O	O
simultaneously	O
in	O	O
around	O	O
70	O	O
%	O	O
of	O	O
animals	B-LIVB
that	O	O
received	O	O
i	O	O
.	O	O

p	O	O
.	O	O

STZ	B-CHEM
or	O	O
alloxan	B-CHEM
.	O	O

Phosphorylation	B-PHYS
of	O	O
EphB1	B-CHEM
,	O	O
activation	O
of	O	O
the	O	O
astrocytes	B-ANAT
and	O	O
microglial	B-ANAT
cells	I-ANAT
,	O	O
and	O	O
level	O
of	O	O
tumour	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	B-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
and	O	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
1β	I-CHEM
in	O	O
the	O	O
spinal	B-ANAT
cord	I-ANAT
were	O	O
significantly	O	O
increased	O	O
in	O	O
rats	B-LIVB
with	O	O
DNP	B-DISO
.	O	O

Spinal	O
blocking	O
EphB1	B-CHEM
receptor	I-CHEM
activation	O
in	O	O
the	O	O
late	O	O
phase	O	O
after	O	O
STZ	B-CHEM
injection	B-PROC
significantly	O	O
suppressed	O
the	O	O
established	O	O
mechanical	B-DISO
allodynia	I-DISO
as	O	O
well	O	O
as	O	O
activation	O
of	O	O
the	O	O
astrocytes	B-ANAT
and	O	O
microglial	B-ANAT
cells	I-ANAT
and	O	O
activity	O
of	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
.	O	O

However	O	O
,	O	O
spinal	O
treatment	O
of	O	O
EphB1	B-CHEM
-	O	O
Fc	B-CHEM
in	O	O
the	O	O
early	O
phase	O
after	O	O
STZ	B-CHEM
injection	B-PROC
did	O	O
not	O	O
prevent	O	O
the	O	O
induction	O
of	O	O
DNP	B-DISO
.	O	O

EphB1	B-CHEM
receptor	I-CHEM
activation	O
in	O	O
the	O	O
spinal	B-ANAT
cord	I-ANAT
is	O	O
critical	O
to	O	O
the	O	O
maintenance	O
,	O	O
but	O	O
not	O	O
induction	O
of	O	O
diabetic	B-DISO
pain	B-DISO
.	O	O

EphB1	B-CHEM
receptor	I-CHEM
may	O	O
be	O	O
a	O	O
potential	O
target	O
for	O	O
relieving	B-PROC
the	O	O
established	O	O
diabetic	B-DISO
pain	B-DISO
.	O	O

Activation	O
of	O	O
EphB1	B-CHEM
receptor	I-CHEM
in	O	O
the	O	O
spinal	B-ANAT
cord	I-ANAT
is	O	O
critical	O
to	O	O
maintaining	O
the	O	O
established	O	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
,	O	O
but	O	O
not	O	O
to	O	O
diabetic	B-DISO
pain	B-DISO
induction	O
.	O	O

Spinal	O
blocking	O
EphB1	B-CHEM
receptor	I-CHEM
activation	O
suppresses	O
ongoing	O	O
diabetic	B-DISO
neuropathic	B-DISO
pain	I-DISO
.	O	O

Regulation	B-PHEN
of	O	O
bone	B-ANAT
homeostasis	B-PHEN
by	O	O
glucose	B-CHEM
Synthesis	B-PHEN
of	O	O
type	B-CHEM
Ⅰ	I-CHEM
collagen	I-CHEM
,	I-CHEM
a	O	O
m	O	O
ajor	O
c	O
omponent	O	O
of	O	O
the	O	O
b	O	O
one	O
matrix	O
,	O
p	O	O
recedes	O
t	O
he	O	O
expression	B-PHYS
of	O	O
R	O	O
unt	B-CHEM
-	I-CHEM
related	I-CHEM
transcription	I-CHEM
factor	I-CHEM
2	I-CHEM
(	I-CHEM
R	I-CHEM
unx2	O	O
)	O	O
,	O	O
a	O	O
master	O
regulator	O
in	O	O
osteoblast	B-PHYS
differentiation	I-PHYS
.	O	O

Thus	O	O
,	O	O
a	O	O
direct	O
link	O	O
between	O	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O	O
bone	B-PHYS
formation	I-PHYS
is	O	O
seemingly	B-DISO
absent	O
,	O	O
and	O	O
how	O	O
these	O	O
are	O	O
maintained	O
in	O	O
a	O	O
coordinated	O
matter	O	O
remains	O	O
unclear	B-DISO
.	O	O

It	O	O
was	O	O
recently	O
demonstrated	O	O
that	O	O
osteoblasts	B-ANAT
depend	O	O
on	O	O
glucose	B-CHEM
,	O	O
which	O	O
glucose	B-CHEM
transporter	I-CHEM
type	I-CHEM
1	I-CHEM
(	O	O
GLUT1	B-CHEM
)	O	O
takes	O	O
up	O	O
as	O	O
an	O	O
energy	B-DISO
source	I-DISO
,	O	O
and	O	O
it	O	O
was	O	O
found	B-DISO
that	O	O
glucose	B-PHYS
uptake	I-PHYS
promotes	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O	O
bone	B-PHYS
formation	I-PHYS
via	O	O
AMP	B-CHEM
-	I-CHEM
activated	I-CHEM
protein	I-CHEM
kinase	I-CHEM
.	O	O

It	O	O
was	O	O
also	O	O
shown	O	O
that	O	O
Runx2	B-CHEM
upregulates	B-PHYS
GLUT1	B-CHEM
expression	B-PHYS
,	O	O
and	O	O
this	O	O
Runx2	B-CHEM
-	O	O
GLUT1	B-CHEM
feedforward	O
regulation	B-PHEN
integrates	O
and	O	O
coordinates	O
osteoblast	B-PHYS
differentiation	I-PHYS
and	O	O
bone	B-PHYS
formation	I-PHYS
throughout	O
life	O
.	O	O

These	O	O
previous	O
findings	B-DISO
revealed	O
that	O	O
the	O	O
energy	B-PHYS
metabolism	I-PHYS
balance	B-PHYS
in	O	O
osteoblasts	B-ANAT
integrates	O
the	O	O
differentiation	B-PHYS
and	O	O
function	O
of	O	O
osteoblasts	B-ANAT
,	O	O
and	O	O
re	O
-	O
emphasized	O
the	O	O
importance	O
of	O	O
crosstalk	B-PHYS
between	O	O
bone	B-PHYS
and	O	O
sugar	B-PROC
metabolism	I-PROC
.	O	O

Chelation	B-CHEM
competition	I-CHEM
induced	O
polymerization	B-PHEN
(	O	O
CCIP	B-PHEN
)	O	O
:	O	O
construction	O
of	O	O
integrated	O	O
hollow	B-CHEM
polydopamine	I-CHEM
nanocontainers	B-OBJC
with	O	O
tailorable	O
functionalities	O
A	O	O
novel	O	O
'	O	O
chelation	B-CHEM
competition	I-CHEM
induced	O
polymerization	B-PHEN
'	O	O
route	O	O
was	O	O
developed	O	O
to	O	O
construct	O	O
hollow	B-CHEM
polydopamine	I-CHEM
nanocontainers	B-OBJC
with	O	O
tailorable	O
functionalities	O
.	O	O

The	O	O
mechanism	O	O
is	O	O
systematically	O	O
investigated	O	O
and	O	O
the	O	O
nanocontainers	B-OBJC
constructed	O
through	O	O
this	O	O
method	O	O
show	O	O
excellent	O	O
chemo	B-DISO
-	I-DISO
thermo	I-DISO
performance	I-DISO
in	O	O
vitro	O	O
.	O	O

This	O	O
strategy	O	O
is	O	O
facile	O	O
and	O	O
is	O	O
expected	O	O
to	O	O
be	O	O
used	B-DISO
for	O	O
the	O	O
construction	O
of	O	O
a	O	O
series	O	O
of	O	O
hollow	B-CHEM
polymer	I-CHEM
nanostructures	B-OBJC
.	O	O

Hemodynamic	B-PHYS
correlates	O	O
of	O	O
transient	B-DISO
cognitive	I-DISO
impairment	I-DISO
after	O	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
and	O	O
minor	B-DISO
stroke	I-DISO
:	O	O
A	O	O
transcranial	B-PROC
Doppler	I-PROC
study	I-PROC
Transient	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O	O
TCI	B-DISO
)	O	O
on	O	O
the	O	O
Mini	B-PROC
Mental	I-PROC
State	I-PROC
Evaluation	I-PROC
score	O
is	O	O
common	O	O
after	O	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
/	O	O
minor	B-DISO
stroke	I-DISO
and	O	O
might	O	O
identify	O
patients	B-LIVB
at	O	O
increased	O	O
risk	O
of	O	O
dementia	B-DISO
.	O	O

We	O	O
aimed	O
to	O	O
replicate	O
TCI	B-DISO
using	O	O
the	O	O
Montreal	O
Cognitive	O
Assessment	O
(	O	O
MoCA	O
)	O	O
,	O	O
compare	O
it	O	O
with	O	O
persistent	B-DISO
Mild	I-DISO
Cognitive	I-DISO
Impairment	I-DISO
(	O	O
PMCI	B-DISO
)	O	O
,	O	O
and	O	O
to	O	O
determine	O	O
whether	O	O
global	O
cerebral	B-ANAT
hemodynamic	B-PHYS
changes	O
could	O	O
explain	O	O
transient	O
impairment	O
.	O	O

Consecutive	O	O
patients	B-LIVB
with	O	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
/	O	O
minor	B-DISO
stroke	I-DISO
(	O	O
NIHSS	O	O
≤	O	O
3	O	O
)	O	O
were	O	O
assessed	O
with	O	O
the	O	O
MoCA	O
and	O	O
transcranial	B-PROC
Doppler	I-PROC
ultrasound	I-PROC
acutely	O
and	O	O
at	O	O
1	O	O
month	O	O
.	O	O

We	O	O
compared	O
patients	B-LIVB
with	O	O
TCI	B-DISO
(	O	O
baseline	O
MoCA	O
<	O	O
26	O	O
with	O	O
≥	O	O
2	O	O
points	O
increase	O
at	O	O
1	O	O
month	O	O
)	O	O
,	O	O
PMCI	B-DISO
(	O	O
MoCA	O
<	O	O
26	O	O
with	O	O
<	O	O
2	O	O
points	O
increase	O
)	O	O
,	O	O
and	O	O
no	B-DISO
cognitive	I-DISO
impairment	I-DISO
(	O	O
NCI	B-DISO
;	O	O
MoCA	O
≥	O	O
26	O	O
)	O	O
.	O	O

Of	O	O
326	O	O
patients	B-LIVB
,	O	O
46	O	O
(	O	O
14	O	O
.	O	O
1	O	O
%	O	O
)	O	O
had	O	O
PMCI	B-DISO
,	O	O
98	O	O
(	O	O
30	O	O
.	O	O
1	O	O
%	O	O
)	O	O
TCI	B-DISO
,	O	O
and	O	O
182	O	O
(	O	O
55	O	O
.	O	O

8	O	O
%	O	O
)	O	O
NCI	B-DISO
.	O	O

At	O	O
baseline	O
,	O	O
TCI	B-DISO
patients	B-LIVB
had	O	O
higher	B-DISO
systolic	I-DISO
blood	I-DISO
pressure	I-DISO
(	O	O
150	O	O
.	O	O
95	O	O
±	O	O
21	O	O
.	O	O

52	O	O
vs	O	O
144	O	O
.	O	O

86	O	O
±	O	O
22	O	O
.	O	O
44	O	O
mmHg	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
and	O	O
lower	O
cerebral	O
blood	O
flow	O
velocities	O
,	O	O
particularly	O	O
end	O
-	O
diastolic	O
velocity	O
(	O	O
30	O	O
.	O	O
16	O	O
±	O	O
9	O	O
.	O	O
63	O	O
vs	O	O
35	O	O
.	O	O

02	O	O
±	O	O
9	O	O
.	O	O
01	O	O
cm	O	O
/	O	O
s	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
mean	B-DISO
flow	I-DISO
velocity	I-DISO
(	O	O
48	O	O
.	O	O
95	O	O
±	O	O
12	O	O
.	O	O

72	O	O
vs	O	O
54	O	O
±	O	O
12	O	O
.	O	O
46	O	O
cm	O	O
/	O	O
s	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
than	O	O
those	O	O
with	O	O
NCI	B-DISO
,	O	O
but	O	O
similar	O	O
clinical	O
and	O	O
hemodynamic	B-PHYS
profiles	B-PROC
to	O	O
those	O	O
with	O	O
PMCI	B-DISO
.	O	O

Systolic	B-DISO
BP	I-DISO
fell	I-DISO
between	O	O
baseline	O
and	O	O
1	O	O
month	O	O
(	O	O
mean	O
reduction	B-PROC
=	O	O
14	O	O
.	O	O
01	O	O
±	O	O
21	O	O
.	O	O

26	O	O
mmHg	O	O
)	O	O
and	O	O
end	O
-	O
diastolic	O
velocity	O
and	O	O
mean	B-DISO
flow	I-DISO
velocity	I-DISO
increased	O
(	O	O
mean	O
increase	O
=	O	O
+	O	O
2	O	O
.	O	O
42	O	O
±	O	O
6	O	O
.	O	O

41	O	O
and	O	O
1	O	O
.	O	O
89	O	O
±	O	O
8	O	O
.	O	O
77	O	O
cm	O	O
/	O	O
s	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
but	O	O
these	O	O
changes	O
did	O	O
not	B-DISO
differ	I-DISO
between	O	O
patients	B-LIVB
with	O	O
TCI	B-DISO
,	O	O
PMCI	B-DISO
,	O	O
and	O	O
NCI	B-DISO
.	O	O

TCI	B-DISO
is	O	O
detectable	B-PHYS
with	O	O
the	O	O
MoCA	O
after	O	O
transient	B-DISO
ischemic	I-DISO
attack	I-DISO
and	O	O
minor	B-DISO
stroke	I-DISO
and	O	O
has	O	O
similar	O	O
clinical	O
and	O	O
hemodynamic	B-PHYS
profile	B-PROC
to	O	O
PMCI	B-DISO
.	O	O

However	O	O
,	O	O
TCI	B-DISO
does	O	O
not	O
appear	O
to	O	O
be	O	O
due	O	O
to	O	O
exaggerated	O
acute	O
reversible	O
global	O
hemodynamic	B-PHYS
changes	O
.	O	O

Impaired	O
autophagy	B-PHYS
in	O	O
macrophages	B-ANAT
promotes	O	O
inflammatory	B-DISO
eye	I-DISO
disease	I-DISO
Autophagy	B-PHYS
is	O	O
critical	O	O
for	O	O
maintaining	O	O
cellular	B-PHYS
homeostasis	I-PHYS
.	O	O

Organs	B-ANAT
such	O	O
as	O	O
the	O	O
eye	B-ANAT
and	O	O
brain	B-ANAT
are	O	O
immunologically	O
privileged	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
demonstrate	O	O
that	O	O
autophagy	B-PHYS
is	O	O
essential	O	O
for	O	O
maintaining	O	O
ocular	B-ANAT
immune	O
privilege	O	O
.	O	O

Deletion	B-PHYS
of	O	O
multiple	O
autophagy	B-PHYS
genes	O
in	O	O
macrophages	B-ANAT
leads	O	O
to	O	O
an	O	O
inflammation	B-DISO
-	I-DISO
mediated	I-DISO
eye	I-DISO
disease	I-DISO
called	O	O
uveitis	B-DISO
that	O	O
can	O	O
cause	O	O
blindness	B-DISO
.	O	O

Loss	O
of	O	O
autophagy	B-PHYS
activates	O
inflammasome	B-CHEM
-mediated	O	O
IL1B	B-CHEM
secretion	B-PHYS
that	O	O
increases	O	O
disease	O
severity	O
.	O	O

Inhibition	O
of	O	O
caspase	B-PHYS
activity	I-PHYS
by	O	O
gene	B-PHYS
deletion	I-PHYS
or	O	O
pharmacological	O
means	O	O
completely	O	O
reverses	B-DISO
the	I-DISO
disease	I-DISO
phenotype	I-DISO
.	O	O

Of	O	O
interest	O	O
,	O	O
experimental	O
uveitis	B-DISO
was	O	O
also	O	O
increased	O	O
in	O	O
a	O	O
model	O
of	O	O
Crohn	B-DISO
disease	I-DISO
,	O	O
a	O	O
systemic	B-DISO
autoimmune	B-DISO
disease	I-DISO
in	O	O
which	O	O
patients	B-LIVB
often	O	O
develop	O	O
uveitis	B-DISO
,	O	O
offering	O	O
a	O	O
potential	O	O
mechanistic	O	O
link	O	O
between	O	O
macrophage	B-ANAT
autophagy	B-PHYS
and	O	O
systemic	B-DISO
disease	I-DISO
.	O	O

These	O	O
findings	O	O
directly	O	O
implicate	O	O
the	O	O
homeostatic	B-PHEN
process	I-PHEN
of	O	O
autophagy	B-PHYS
in	O	O
blinding	B-PROC
eye	B-DISO
disease	I-DISO
and	O	O
identify	O	O
novel	O
pathways	O
for	O	O
therapeutic	B-PROC
intervention	I-PROC
in	O	O
uveitis	B-DISO
.	O	O

Conservation	O
of	O	O
the	O	O
Red	B-LIVB
Kite	I-LIVB
Milvus	B-LIVB
milvus	I-LIVB
(	O	O
Aves	B-LIVB
:	O	O
Accipitriformes	B-LIVB
)	O	O
Is	O	O
Not	O	O
Affected	O
by	O	O
the	O	O
Establishment	O	O
of	O	O
a	O	O
Broad	O	O
Hybrid	B-LIVB
Zone	O
with	O	O
the	O	O
Black	B-LIVB
Kite	I-LIVB
Milvus	B-LIVB
migrans	I-LIVB
migrans	I-LIVB
in	O	O
Central	B-GEOG
Europe	I-GEOG
Among	O	O
Accipitriformes	B-LIVB
sensu	O	O
stricto	O	O
,	O	O
only	O	O
a	O	O
few	O	O
species	O
have	O	O
been	O	O
reported	O
to	O	O
form	O	O
hybrid	B-LIVB
zones	O
;	O	O
these	O	O
include	O	O
the	O	O
red	B-LIVB
kite	I-LIVB
Milvus	B-LIVB
milvus	I-LIVB
and	O	O
black	B-LIVB
kite	I-LIVB
Milvus	B-LIVB
migrans	I-LIVB
migrans	I-LIVB
.	O	O

M	B-LIVB
.	I-LIVB

milvus	I-LIVB
is	O	O
endemic	O
to	O	O
the	O	O
western	O
Palearctic	O
and	O	O
has	O	O
an	O	O
estimated	O	O
total	O	O
population	O
of	O	O
20	O	O
-	O	O
24	O	O
,	O	O
000	O	O
breeding	B-PHYS
pairs	O
.	O	O

The	O	O
species	O
was	O	O
in	O	O
decline	O	O
until	O	O
the	O	O
1970s	O	O
due	O	O
to	O	O
persecution	O
and	O	O
has	O	O
declined	O	O
again	O	O
since	O	O
the	O	O
1990s	O	O
due	O	O
to	O	O
ingestion	B-PHEN
of	O	O
rodenticide	B-CHEM
-	I-CHEM
treated	I-CHEM
baits	I-CHEM
,	O	O
illegal	O
poisoning	B-DISO
and	O	O
changes	O	O
in	O	O
agricultural	O
practices	O
,	O	O
particularly	O	O
in	O	O
its	O	O
core	O
range	O
.	O	O

Whereas	O	O
F1	B-LIVB
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
×	O	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
hybrid	B-LIVB
offspring	B-LIVB
have	O	O
been	O	O
found	O	O
,	O	O
F2	B-LIVB
and	O	O
F3	B-LIVB
hybrids	B-LIVB
have	O	O
only	O	O
rarely	O	O
been	O	O
reported	O
,	O	O
with	O	O
low	O	O
nesting	O
success	O
rates	O
of	O	O
F1	B-LIVB
hybrids	B-LIVB
and	O	O
partial	O
hybrid	B-LIVB
sterility	O	O
likely	O	O
playing	O	O
a	O	O
role	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
analyzed	B-PROC
the	O	O
mitochondrial	B-ANAT
(	O	O
CO1	O
and	O	O
CytB	O
)	O	O
and	O	O
nuclear	B-ANAT
(	O	O
Myc	O
)	O	O
DNA	B-CHEM
loci	O
of	O	O
184	O	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
,	O	O
124	O	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
and	O	O
3	O	O
F1	B-LIVB
hybrid	B-LIVB
individuals	O	O
collected	O	O
across	O	O
central	B-GEOG
Europe	I-GEOG
.	O	O

In	O	O
agreement	O
with	O	O
previous	O	O
studies	B-PROC
,	O	O
we	O	O
found	O	O
low	O	O
heterozygosity	B-PHYS
in	O	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
regardless	O	O
of	O	O
locus	O
.	O	O

We	O	O
found	O	O
that	O	O
populations	O
of	O	O
both	O	O
examined	B-DISO
species	O
were	O	O
characterized	O
by	O	O
a	O	O
high	O	O
gene	B-PHYS
flow	I-PHYS
within	O	O
populations	O
,	O	O
with	O	O
all	O	O
of	O	O
the	O	O
major	O	O
haplotypes	B-PHYS
distributed	O	O
across	O	O
the	O	O
entire	O	O
examined	B-DISO
area	B-GEOG
.	O	O

Few	O	O
haplotypes	B-PHYS
displayed	O	O
statistically	O
significant	O
aggregation	O
in	O	O
one	O	O
region	B-GEOG
over	O	O
another	O	O
.	O	O

We	O	O
did	O	O
not	O	O
find	O	O
mitochondrial	B-CHEM
DNA	I-CHEM
of	O	O
one	O	O
species	O
in	O	O
individuals	O	O
with	O	O
the	O	O
plumage	B-ANAT
of	O	O
the	O	O
other	O	O
species	O
,	O	O
except	O	O
in	O	O
F1	B-LIVB
hybrids	B-LIVB
,	O	O
which	O	O
agrees	O	O
with	O	O
Haldane´s	O
Rule	O
.	O	O

It	O	O
remains	O	O
to	O	O
be	O	O
investigated	O
by	O	O
genomic	O
methods	O
whether	O	O
occasional	O	O
gene	B-PHYS
flow	I-PHYS
occurs	O	O
through	O	O
the	O	O
paternal	O
line	O	O
,	O	O
as	O	O
the	O	O
examined	B-DISO
Myc	O
gene	O
displayed	O	O
only	O	O
marginal	O	O
divergence	O
between	O	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
and	O	O
M	B-LIVB
.	I-LIVB

migr	I-LIVB
.	I-LIVB

migrans	I-LIVB
.	O	O

The	O	O
central	B-GEOG
Europe	I-GEOG
an	O	O
population	O
of	O	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
is	O	O
clearly	O	O
subject	O	O
to	O	O
free	O	O
intraspecific	O	O
gene	B-PHYS
flow	I-PHYS
,	O	O
which	O	O
has	O	O
direct	O	O
implications	O	O
when	O	O
considering	O	O
the	O	O
origin	O
of	O	O
individuals	O	O
in	O	O
M	B-LIVB
.	I-LIVB

milvus	I-LIVB
re	O	O
-	O	O
introduction	O	O
programs	O	O
.	O	O

Apixaban	B-CHEM
5	O	O
mg	O	O
Twice	O
Daily	O
and	O	O
Clinical	O
Outcomes	O
in	O	O
Patients	B-LIVB
With	O	O
Atrial	B-DISO
Fibrillation	I-DISO
and	O	O
Advanced	O
Age	B-PHYS
,	O	O
Low	O
Body	B-PHYS
Weight	I-PHYS
,	O	O
or	O	O
High	O
Creatinine	B-CHEM
:	O	O
A	O	O
Secondary	O
Analysis	O
of	O	O
a	O	O
Randomized	B-PROC
Clinical	I-PROC
Trial	I-PROC
In	O	O
the	O	O
Apixaban	B-CHEM
for	O	O
Reduction	O
of	O	O
Stroke	B-DISO
and	O	O
Other	O	O
Thromboembolic	B-DISO
Complications	I-DISO
in	O	O
Atrial	B-DISO
Fibrillation	I-DISO
(	O	O
ARISTOTLE	B-PROC
)	O	O
trial	B-PROC
,	O	O
the	O	O
standard	O	O
dose	O
of	O	O
apixaban	B-CHEM
was	O	O
5	O	O
mg	O	O
twice	O
daily	O
;	O	O
patients	B-LIVB
with	O	O
at	O	O
least	O	O
2	O	O
dose	O
-	O	O
reduction	O
criteria	O	O
-	O	O
80	O	O
years	O
or	O	O
older	O	O
,	O	O
weight	B-PHYS
60	O	O
kg	O	O
or	O	O
less	O	O
,	O	O
and	O	O
creatinine	B-DISO
level	I-DISO
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
or	O	O
higher	O	O
-	O	O
received	O	O
a	O	O
reduced	O
dose	O
of	O	O
apixaban	B-CHEM
of	O	O
2	O	O
.	O	O
5	O	O
mg	O	O
twice	O
daily	O
.	O	O

Little	O	O
is	O	O
known	O	O
about	O	O
patients	B-LIVB
with	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
who	O	O
received	O	O
the	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
.	O	O

To	O	O
determine	O	O
the	O	O
frequency	O
of	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
and	O	O
whether	O	O
the	O	O
effects	O
of	O
the	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
on	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
and	O	O
bleeding	B-DISO
varied	O	O
among	O	O
patients	B-LIVB
with	O	O
1	O	O
or	O	O
no	O	O
dose	O
-	O	O
reduction	O
criteria	O	O
.	O	O

Among	O	O
18	O	O
201	O	O
patients	B-LIVB
in	O	O
the	O	O
ARISTOTLE	B-PROC
trial	I-PROC
,	O	O
17	O	O
322	O	O
were	O	O
included	O	O
in	O	O
this	O	O
analysis	B-PROC
.	O	O

Annualized	O	O
event	O	O
rates	O	O
of	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
and	O	O
major	O	O
bleeding	B-DISO
and	O	O
hazard	O
ratios	O
(	O	O
HRs	O
)	O	O
and	O	O
95	O	O
%	O	O
CIs	O
were	O	O
evaluated	B-PROC
.	O	O

Interactions	O
between	O	O
the	O	O
effects	O
of	O
apixaban	B-CHEM
vs	O	O
warfarin	B-CHEM
and	O	O
the	O	O
presence	O	O
of	O	O
1	O	O
or	O	O
no	O	O
dose	O
-	O	O
reduction	O
criteria	O	O
were	O	O
assessed	O
.	O	O

The	O	O
first	O	O
patient	B-LIVB
was	O	O
enrolled	O	O
in	O	O
the	O	O
ARISTOTLE	B-PROC
trial	I-PROC
on	O	O
December	O	O
19	O	O
,	O	O
2006	O	O
,	O	O
and	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
was	O	O
completed	O	O
on	O	O
January	O	O
30	O	O
,	O	O
2011	O	O
.	O	O

Data	O
were	O	O
analyzed	O	O
from	O	O
January	O	O
2015	O	O
to	O	O
May	O	O
30	O	O
,	O	O
2016	O	O
.	O	O

Analysis	B-PROC
of	O	O
major	O	O
bleeding	B-DISO
included	O	O
events	O	O
during	O	O
study	B-PROC
drug	B-PROC
treatment	I-PROC
.	O	O

Analysis	B-PROC
of	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
was	O	O
based	O	O
on	O	O
intention	O
to	O	O
treat	O
.	O	O

Of	O	O
the	O	O
patients	B-LIVB
with	O	O
1	O	O
or	O	O
no	O	O
dose	O
-	O	O
reduction	O
criteria	O	O
assigned	O	O
to	O	O
receive	O	O
the	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
or	O	O
warfarin	B-CHEM
,	O	O
3966	O	O
had	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
;	O	O
these	O	O
patients	B-LIVB
had	O	O
higher	O	O
rates	O	O
of	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
(	O	O
HR	O
,	O	O
1	O	O
.	O	O
47	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
20	O	O
-	O	O
1	O	O
.	O	O
81	O	O
)	O	O
and	O	O
major	O	O
bleeding	B-DISO
(	O	O
HR	O
,	O	O
1	O	O
.	O	O
89	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
62	O	O
-	O	O
2	O	O
.	O	O
20	O	O
)	O	O
compared	O	O
with	O	O
those	O	O
with	O	O
no	O	O
dose	O
-	O	O
reduction	O
criteria	O	O
(	O	O
n	O	O
=	O	O
13	O	O
356	O	O
)	O	O
.	O	O

The	O	O
benefit	O
of	O	O
the	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
(	O	O
n	O	O
=	O	O
8665	O	O
)	O	O
compared	O	O
with	O	O
warfarin	B-CHEM
(	O	O
n	O	O
=	O	O
8657	O	O
)	O	O
on	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
in	O	O
patients	B-LIVB
with	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
94	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
0	O	O
.	O	O
66	O	O
-	O	O
1	O	O
.	O	O
32	O	O
)	O	O
and	O	O
no	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
77	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
0	O	O
.	O	O
62	O	O
-	O	O
0	O	O
.	O	O
97	O	O
)	O	O
were	O	O
similar	O	O
(	O	O
P	O	O
for	O	O
interaction	O	O
=	O	O
.36	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
the	O	O
benefit	O
of	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
compared	O	O
with	O	O
warfarin	B-CHEM
on	O	O
major	O	O
bleeding	B-DISO
in	O	O
patients	B-LIVB
with	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
68	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
0	O	O
.	O	O
53	O	O
-	O	O
0	O	O
.	O	O
87	O	O
)	O	O
and	O	O
no	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
(	O	O
HR	O
,	O	O
0	O	O
.	O	O
72	O	O
;	O	O
95	O	O
%	O	O
CI	O
,	O	O
0	O	O
.	O	O
60	O	O
-	O	O
0	O	O
.	O	O
86	O	O
)	O	O
were	O	O
similar	O	O
(	O	O
P	O	O
for	O	O
interaction	O	O
=	O	O
.71	O	O
)	O	O
.	O	O

Similar	O	O
patterns	O	O
were	O	O
seen	O	O
for	O	O
each	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
and	O	O
across	O	O
the	O	O
spectrum	O	O
of	O	O
age	B-PHYS
,	O	O
body	B-PHYS
weight	I-PHYS
,	O	O
creatinine	B-DISO
level	I-DISO
,	O	O
and	O	O
creatinine	B-CHEM
clearance	B-PHYS
.	O	O

Patients	B-LIVB
with	O	O
atrial	B-DISO
fibrillation	I-DISO
and	O	O
isolated	O	O
advanced	O	O
age	B-PHYS
,	O	O
low	O	O
body	B-PHYS
weight	I-PHYS
,	O	O
or	O	O
renal	B-DISO
dysfunction	I-DISO
have	O	O
a	O	O
higher	O	O
risk	O
of	O	O
stroke	B-DISO
or	O	O
systemic	O
embolism	O
and	O	O
major	O	O
bleeding	B-DISO
but	O	O
show	O	O
consistent	O	O
benefits	O
with	O	O
the	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
vs	O	O
warfarin	B-CHEM
compared	O	O
with	O	O
patients	B-LIVB
without	O	O
these	O	O
characteristics	O	O
.	O	O

The	O	O
5	O	O
mg	O	O
twice	O
daily	O
dose	O
of	O	O
apixaban	B-CHEM
is	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
and	O	O
appropriate	O	O
for	O	O
patients	B-LIVB
with	O	O
only	O	O
1	O	O
dose	O
-	O	O
reduction	O
criterion	O	O
.	O	O

clinicaltrials	O	O
.	O	O

gov	O	O
Identifier	O	O
:	O	O
NCT00412984	O	O
.	O	O

Objective	O
Assessment	B-PROC
of	O	O
Vergence	B-PHYS
after	O	O
Treatment	B-PROC
of	O	O
Concussion	B-DISO
-	O	O
Related	O
CI	B-DISO
:	O	O
A	O	O
Pilot	B-PROC
Study	I-PROC
To	O	O
evaluate	B-PROC
changes	O
in	O	O
objective	O
measures	O
of	O	O
disparity	O
vergence	O
after	O	O
office	B-PROC
-	I-PROC
based	I-PROC
vision	I-PROC
therapy	I-PROC
(	O	O
OBVT	B-PROC
)	O	O
for	O	O
concussion	B-DISO
-	O	O
related	O
convergence	B-DISO
insufficiency	I-DISO
(	O	O
CI	B-DISO
)	O	O
and	O	O
determine	O	O
the	O	O
feasibility	B-PROC
of	O	O
using	O	O
this	O	O
objective	O
assessment	B-PROC
as	O	O
an	O	O
outcome	O
measure	O
in	O	O
a	O	O
clinical	B-PROC
trial	I-PROC
.	O	O

This	O	O
was	O	O
a	O	O
prospective	O
,	O	O
observational	B-PROC
trial	I-PROC
.	O	O

All	O	O
participants	B-LIVB
were	O	O
treated	B-PROC
with	I-PROC
weekly	O
OBVT	B-PROC
with	O	O
home	O
reinforcement	B-PROC
.	O	O

Participants	B-LIVB
included	O
two	O	O
adolescents	B-LIVB
and	O	O
three	O	O
young	B-LIVB
adults	I-LIVB
with	O	O
concussion	B-DISO
-	O	O
related	O
,	O	O
symptomatic	O
CI	B-DISO
.	O	O

The	O	O
primary	O
outcome	O
measure	O
was	O	O
average	O
peak	B-DISO
velocity	I-DISO
for	O	O
4	O	O
°	O	O
symmetrical	B-DISO
convergence	B-PHYS
steps	O	O
.	O	O

Other	O	O
objective	O
outcome	O
measures	O
of	O	O
disparity	O
vergence	O
included	O
time	O
to	O	O
peak	B-DISO
velocity	I-DISO
,	O	O
latency	O
,	O	O
accuracy	O
,	O	O
settling	O
time	O
,	O	O
and	O	O
main	O	O
sequence	O
.	O	O

We	O	O
also	O	O
evaluated	B-PROC
saccadic	B-PHYS
eye	I-PHYS
movements	I-PHYS
using	O	O
the	O	O
same	O	O
outcome	O
measures	O
.	O	O

Changes	O
in	O	O
clinical	B-DISO
measures	I-DISO
(	O	O
near	B-DISO
point	I-DISO
of	I-DISO
convergence	I-DISO
,	O	O
positive	B-DISO
fusional	B-PHYS
vergence	I-PHYS
at	I-PHYS
near	I-PHYS
,	O	O
Convergence	O
Insufficiency	O
Symptom	O
Survey	O
[	O	O
CISS	O
]	O	O
score	O
)	O	O
were	O	O
evaluated	B-PROC
.	O	O

There	O	O
were	O	O
statistically	O
significant	O
and	O	O
clinically	O
meaningful	O
changes	O
in	O	O
all	O	O
clinical	B-DISO
measures	I-DISO
for	O	O
convergence	B-PHYS
.	O	O

Four	O	O
of	O	O
the	O	O
five	O	O
subjects	B-LIVB
met	O	O
clinical	O
success	O
criteria	O
.	O	O

For	O	O
the	O	O
objective	O
measures	O
,	O	O
we	O	O
found	O	O
a	O	O
statistically	O
significant	O
increase	O
in	O	O
peak	B-DISO
velocity	I-DISO
,	O	O
response	B-PHYS
accuracy	O
to	O	O
4	O	O
°	O	O
symmetrical	B-DISO
convergence	B-PHYS
and	O	O
divergence	O
step	O	O
stimuli	B-PHEN
,	O	O
and	O	O
the	O	O
main	O	O
sequence	O
ratio	O
for	O	O
convergence	B-PHYS
step	O	O
stimuli	B-PHEN
.	O	O

Objective	O
saccadic	B-PHYS
eye	I-PHYS
movements	I-PHYS
(	O	O
5	O	O
and	O	O
10	O	O
°	O	O
)	O	O
appeared	O	O
normal	O
pre	O	O
-	O	O
OBVT	B-PROC
and	O	O
did	O	O
not	O	O
show	O	O
any	O	O
significant	O
change	O
after	O	O
treatment	B-PROC
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
report	O
of	O	O
the	O	O
use	O	O
of	O	O
objective	O
measures	O
of	O	O
disparity	O
vergence	O
as	O	O
outcome	O
measures	O
for	O	O
concussion	B-DISO
-	O	O
related	O
convergence	B-DISO
insufficiency	I-DISO
.	O	O

These	O	O
measures	O
provide	O	O
additional	O
information	O
that	O	O
is	O	O
not	O	O
accessible	O
with	O	O
clinical	B-PROC
tests	I-PROC
about	O	O
underlying	O	O
physiological	O
mechanisms	O
leading	O	O
to	O	O
changes	O
in	O	O
clinical	B-DISO
findings	I-DISO
and	O	O
symptoms	B-DISO
.	O	O

The	O	O
study	B-PROC
results	B-PHEN
also	O	O
demonstrate	O	O
that	O	O
patients	B-LIVB
with	O	O
concussion	B-DISO
can	O	O
tolerate	O	O
the	O	O
visual	O
demands	B-PROC
(	O	O
over	O	O
200	O	O
vergence	B-PHYS
and	O	O
versional	O
eye	B-PHYS
movements	I-PHYS
)	O	O
during	O	O
the	O	O
25	O	O
-	O	O
minute	O	O
testing	O
time	O
and	O	O
suggest	O
that	O	O
these	O	O
measures	O
could	O	O
be	O	O
used	O	O
in	O	O
a	O	O
large	O
-	O
scale	O
randomized	B-PROC
clinical	I-PROC
trial	I-PROC
of	O	O
concussion	B-DISO
-	O	O
related	O
CI	B-DISO
as	O	O
outcome	O
measures	O
.	O	O

Extracellular	B-ANAT
Potassium	B-CHEM
and	O	O
Seizures	B-DISO
:	O	O
Excitation	O
,	O	O
Inhibition	O
and	O	O
the	O	O
Role	O	O
of	O	O
Ih	B-CHEM
Seizure	B-DISO
activity	I-DISO
leads	O	O
to	O	O
increases	O	O
in	O	O
extracellular	B-ANAT
potassium	B-CHEM
concentration	O
(	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
)	O	O
,	O	O
which	O	O
can	O	O
result	O	O
in	O	O
changes	O	O
in	O	O
neuronal	B-ANAT
passive	O
and	O	O
active	O
membrane	B-ANAT
properties	O	O
as	O	O
well	O	O
as	O	O
in	O	O
population	B-LIVB
activities	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
examined	O	O
how	O	O
extracellular	B-ANAT
potassium	B-CHEM
modulates	O	O
seizure	B-DISO
activities	I-DISO
using	O	O
an	O	O
acute	O	O
4	B-CHEM
-	I-CHEM
AP	I-CHEM
induced	O	O
seizure	B-DISO
model	O
in	O	O
the	O	O
neocortex	B-ANAT
,	O	O
both	O	O
in	O
vivo	O
and	O	O
in	O
vitro	O
.	O	O

Moderately	O	O
elevated	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
up	O	O
to	O	O
9	O	O
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
mM	O	O
prolonged	O
seizure	B-DISO
durations	O
and	O	O
shortened	O
interictal	O
intervals	O
as	O	O
well	O	O
as	O	O
depolarized	B-DISO
the	O	O
neuronal	B-ANAT
resting	B-PHYS
membrane	I-PHYS
potential	I-PHYS
(	O	O
RMP	B-PHYS
)	O	O
.	O	O

However	O	O
,	O	O
when	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
reached	O	O
higher	O	O
than	O	O
9	O	O
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
mM	O	O
,	O	O
seizure	B-DISO
like	I-DISO
events	I-DISO
(	O	O
SLEs	B-DISO
)	O	O
were	O	O
blocked	O
and	O	O
neurons	B-ANAT
went	O	O
into	O	O
a	O	O
depolarization	B-DISO
-	O	O
blocked	O
state	O	O
.	O	O

Spreading	O
depression	B-DISO
was	O	O
never	O	O
observed	O	O
as	O	O
the	O	O
blockade	O	O
of	O	O
ictal	B-DISO
events	I-DISO
could	O	O
be	O	O
reversed	O	O
within	O	O
1	O	O
-	O	O
2	O	O
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
min	O	O
after	O	O
the	O	O
raised	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
was	O	O
changed	O	O
back	O	O
to	O	O
control	O	O
levels	O	O
.	O	O

This	O	O
concentration	O
-dependent	O	O
dual	O	O
effect	O	O
of	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
was	O	O
observed	O	O
using	O	O
in	O
vivo	O
and	O	O
in	O
vitro	O
mouse	O
brain	O
preparations	O
as	O	O
well	O	O
as	O	O
in	O	O
human	B-LIVB
neocortical	B-ANAT
tissue	O
resected	O	O
during	O	O
epilepsy	B-DISO
surgery	B-PROC
.	O	O

Blocking	O
the	O	O
Ih	O	O
current	O	O
,	O	O
mediated	O	O
by	O	O
hyperpolarization	B-CHEM
-	I-CHEM
activated	I-CHEM
cyclic	I-CHEM
nucleotide	I-CHEM
-	I-CHEM
gated	I-CHEM
(	I-CHEM
HCN	I-CHEM
)	I-CHEM
channels	I-CHEM
,	O	O
modulated	O	O
the	O	O
elevated	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
influence	O
on	O	O
SLEs	B-DISO
by	O	O
promoting	O	O
the	O	O
high	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
inhibitory	O
actions	O
.	O	O

These	O	O
results	O	O
demonstrate	O	O
biphasic	O	O
actions	O	O
of	O	O
raised	O	O
[	O	O
K	B-CHEM
[	O	O
Formula	O	O
:	O	O
see	O	O
text	O	O
]	O	O
]	O	O
o	O	O
on	O	O
neuronal	B-ANAT
excitability	B-DISO
and	O	O
seizure	B-DISO
activity	I-DISO
.	O	O

Trends	O
in	O	O
traffic	B-DISO
fatalities	O
in	O	O
Mexico	B-GEOG
:	O	O
examining	B-DISO
progress	O
on	O	O
the	O	O
decade	O
of	O	O
action	O
for	O	O
road	B-OBJC
safety	B-PHEN
2011	O	O
-	O	O
2020	O	O
We	O	O
explore	O	O
demographic	O
,	O	O
temporal	O
and	O	O
geographic	B-DISO
patterns	I-DISO
of	O	O
256	O	O
,	O	O
588	O	O
road	B-OBJC
traffic	B-DISO
fatalities	O
from	O	O
1998	O	O
to	O	O
2013	O	O
in	O	O
Mexico	B-GEOG
,	O	O
in	O	O
context	O	O
of	O	O
UN´s	O
decade	O
of	O	O
action	O
for	O	O
road	B-OBJC
safety	B-PHEN
2010	O	O
-	O	O
2020	O	O
(	O	O
DARS	O	O
)	O	O
.	O	O

Combined	O
traffic	B-DISO
mortality	O
data	O
and	O	O
population	O
counts	O
were	O	O
analyzed	B-PROC
using	O	O
mixed	O
-	O
effects	O
logistic	B-PROC
regression	I-PROC
,	O	O
distinguishing	O	O
sex	O
-	O
age	O
groups	O
,	O	O
vulnerable	O
and	O	O
protected	B-DISO
road	B-OBJC
users	B-LIVB
,	O	O
and	O	O
municipal	B-GEOG
size	O
.	O	O

Rapid	B-DISO
growth	I-DISO
from	O	O
1998	O	O
to	O	O
2008	O	O
in	O	O
traffic	B-DISO
mortality	O
rates	O
has	O	O
been	O	O
reversed	O
since	O	O
2009	O	O
.	O	O

Most	O	O
deaths	B-DISO
averted	B-DISO
are	O	O
among	O	O
young	O
male	B-PHYS
protected	B-DISO
road	B-OBJC
users	B-LIVB
(	O	O
reduction	O
of	O	O
0	O	O
.	O	O
95	O	O
fatalities	O
per	O	O
100	O	O
,	O	O
000	O	O
per	O	O
year	O	O
in	O	O
males	B-PHYS
12	O	O
-	O	O
49	O	O
)	O	O
.	O	O

In	O	O
spite	O	O
of	O	O
a	O	O
steady	B-DISO
decrease	I-DISO
over	O	O
the	O	O
full	O	O
study	O
period	O
,	O	O
mortality	O
rates	O
remain	O	O
high	O
in	O	O
vulnerable	O
road	B-OBJC
users	B-LIVB
over	O	O
50	O	O
,	O	O
with	O	O
a	O	O
high	O
mortality	O
rate	O
of	O	O
26	O	O
per	O	O
100	O	O
,	O	O
000	O	O
males	B-PHYS
over	O	O
75	O	O
years	O	O
in	O	O
2013	O	O
.	O	O

Progress	O
on	O	O
the	O	O
reduction	O
of	O	O
deaths	B-DISO
advances	O
in	O	O
Mexico	B-GEOG
,	O	O
in	O	O
line	O	O
with	O	O
DARS	B-PHEN
targets	O
.	O	O

National	O
road	B-OBJC
safety	B-PHEN
efforts	O	O
require	O
strengthening	O
.	O	O

Initiatives	B-PHYS
should	O	O
target	O
vulnerable	O
road	B-OBJC
users	B-LIVB
,	O	O
specifically	O	O
adults	B-LIVB
>	O	O
50	O	O
years	O	O
in	O	O
urban	O
areas	O
.	O	O

Strengthening	O
of	O	O
drink	B-DISO
driving	I-DISO
programs	O
aimed	O	O
at	O	O
young	O
drivers	B-LIVB
/	O	O
occupants	B-LIVB
is	O	O
promising	O	O
.	O	O

Diagnostic	B-PHEN
Yield	I-PHEN
of	O	O
Routine	O
Stress	B-PROC
Testing	I-PROC
in	O	O
Low	O
and	O	O
Intermediate	B-DISO
Risk	I-DISO
Chest	B-DISO
Pain	I-DISO
Patients	B-LIVB
Under	O	O
40	O	O
Years	O	O
:	O	O
A	O	O
Systematic	O
Review	O
Chest	B-DISO
pain	I-DISO
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
frequent	O	O
causes	O
for	O	O
presentation	O	O
to	O	O
emergency	B-OBJC
departments	I-OBJC
(	O	O
EDs	B-OBJC
)	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
patients	B-LIVB
will	O	O
undergo	O	O
diagnostic	B-PROC
workup	I-PROC
including	O	O
stress	B-PROC
testing	I-PROC
to	O	O
rule	O	O
out	O	O
an	O	O
acute	B-DISO
coronary	I-DISO
syndrome	I-DISO
,	O	O
but	O	O
very	O	O
few	O	O
patients	B-LIVB
will	O	O
be	O	O
diagnosed	B-DISO
with	O	O
a	O	O
cardiac	B-DISO
cause	I-DISO
for	O	O
their	O	O
pain	B-DISO
.	O	O

Patients	B-LIVB
under	O	O
40	O	O
years	O	O
represent	O	O
a	O	O
lower	B-LIVB
risk	I-LIVB
group	I-LIVB
in	O	O
which	O	O
routine	O
stress	B-PROC
testing	I-PROC
may	O	O
be	O	O
of	O	O
little	O	O
benefit	O	O
.	O	O

This	O	O
systematic	O
review	O
sought	O	O
to	O	O
determine	O	O
the	O	O
diagnostic	B-PHEN
yield	I-PHEN
of	O	O
routine	O
stress	B-PROC
testing	I-PROC
in	O	O
low	O
-	O	O
and	O	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
chest	B-DISO
pain	I-DISO
patients	B-LIVB
under	O	O
40	O	O
years	O	O
.	O	O

Electronic	O
databases	O
were	O	O
searched	O	O
for	O	O
relevant	O
studies	B-PROC
.	O	O

The	O	O
quality	O	O
of	O	O
the	O	O
included	O	O
primary	B-PROC
studies	I-PROC
was	O	O
assessed	O
using	O	O
the	O	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
evidence	O	O
hierarchy	O	O
and	O	O
the	O	O
McMaster	O
Critical	O
Appraisal	O
Tool	O
for	O	O
Quantitative	O
Studies	O
.	O	O

Descriptive	O
statistics	O
summarized	O	O
the	O	O
findings	O
.	O	O

Five	O	O
primary	B-PROC
studies	I-PROC
were	O	O
included	O	O
in	O	O
the	O	O
review	O
(	O	O
all	O	O
level	O	O
III	O	O
-	O	O
3	O	O
evidence	O	O
)	O	O
;	O	O
7	O	O
additional	O	O
sources	O	O
of	O	O
relevant	O
data	O
were	O	O
also	O	O
included	O	O
.	O	O

Diagnostic	B-PHEN
yield	I-PHEN
of	O	O
routine	O
stress	B-PROC
testing	I-PROC
in	O	O
low	O
-	O	O
and	O	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
under	O	O
40	O	O
years	O	O
is	O	O
reported	O	O
between	O	O
0	O	O
%	O	O
and	O	O
1	O	O
.	O	O

1	O	O
%	O	O
.	O	O

Combined	O
data	O
from	O	O
included	O	O
primary	B-PROC
studies	I-PROC
demonstrated	O	O
just	O	O
4	O	O
out	O	O
of	O	O
1683	O	O
true	O
positive	O
stress	B-PROC
tests	I-PROC
(	O	O
0	O	O
.	O	O

24	O	O
%	O	O
)	O	O
,	O	O
only	O	O
one	O	O
of	O	O
which	O	O
was	O	O
definitively	O	O
confirmed	O	O
by	O	O
coronary	B-PROC
angiogram	I-PROC
;	O	O
additional	O
data	O
sources	O	O
identified	O	O
just	O	O
1	O	O
out	O	O
of	O	O
310	O	O
true	O
positive	O
stress	B-PROC
tests	I-PROC
(	O	O
0	O	O
.	O	O
32	O	O
%	O	O
)	O	O
.	O	O

Diagnostic	B-PHEN
yield	I-PHEN
of	O	O
routine	O
stress	B-PROC
testing	I-PROC
in	O	O
low	O
-	O	O
and	O	O
intermediate	B-DISO
-	I-DISO
risk	I-DISO
chest	B-DISO
pain	I-DISO
patients	B-LIVB
under	O	O
40	O	O
years	O	O
is	O	O
low	O	O
.	O	O

However	O	O
,	O	O
better	O	O
quality	O
studies	O
are	O	O
required	O	O
to	O	O
be	O	O
able	O	O
to	O	O
draw	O	O
definitive	O	O
conclusions	O
.	O	O

Transition	O
From	O	O
Hospital	B-OBJC
to	O	O
Home	O
in	O	O
Preterm	B-LIVB
Infants	I-LIVB
and	O	O
Their	O	O
Families	B-LIVB
When	O	O
the	O	O
day	O
of	O	O
discharge	B-PROC
from	O	O
a	O	O
neonatal	B-OBJC
intensive	I-OBJC
care	I-OBJC
unit	I-OBJC
(	O	O
NICU	B-OBJC
)	O	O
comes	O	O
for	O	O
the	O	O
parents	B-LIVB
of	O	O
newborn	B-LIVB
infants	I-LIVB
,	O	O
they	O	O
are	O	O
filled	O	O
with	O	O
long	O	O
-	O	O
awaited	O	O
joy	B-PHYS
and	O	O
happiness	B-PHYS
.	O	O

They	O	O
go	O	O
home	O
feeling	B-PHYS
as	O	O
parents	B-LIVB
,	O	O
away	O	O
from	O	O
scheduled	O
routines	O
of	O	O
the	O	O
hospital	B-OBJC
,	O	O
monitor	B-DISO
alarms	I-DISO
,	O	O
clinical	B-DISO
rounds	I-DISO
,	O	O
numerous	O
tests	B-PROC
,	O	O
and	O	O
so	O	O
on	O	O
.	O	O
What	O	O
do	O	O
we	O	O
know	O	O
about	O	O
what	O	O
happens	O
after	O	O
these	O	O
little	B-LIVB
patients	I-LIVB
and	O	O
their	O	O
families	B-LIVB
leave	O
the	O	O
NICU	B-OBJC
?	O	O
What	O	O
happens	O
from	O	O
the	O	O
point	O	O
of	O	O
leaving	O
the	O	O
hospital	B-OBJC
until	O	O
when	O	O
things	O	O
get	O	O
settled	O	O
and	O	O
life	O
becomes	O	O
perceived	B-PHYS
as	O	O
normal	O
?	O	O

This	O	O
article	O
presents	O	O
a	O	O
short	O	O
summary	O
of	O	O
research	B-PROC
conducted	O	O
with	O	O
the	O	O
vulnerable	B-LIVB
population	I-LIVB
of	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
and	O	O
preterm	B-LIVB
infants	I-LIVB
and	O	O
their	O	O
families	B-LIVB
postdischarge	B-PROC
.	O	O

Available	O	O
evidence	O
suggests	O	O
that	O	O
transition	O
to	O	O
home	O
after	O	O
hospital	B-PROC
discharge	I-PROC
,	O	O
a	O	O
phenomenon	B-PHEN
that	O	O
many	O	O
families	B-LIVB
experience	B-PHYS
,	O	O
is	O	O
challenging	O
and	O	O
requires	O	O
attention	B-PROC
from	O	O
clinicians	B-LIVB
and	O	O
researchers	B-LIVB
if	O	O
we	O	O
are	O	O
to	O	O
provide	O	O
effective	O
,	O	O
efficient	O
,	O	O
and	O	O
high	B-PROC
-	I-PROC
quality	I-PROC
care	I-PROC
.	O	O

Pivotal	O	O
debates	O
and	O	O
controversies	O
on	O	O
the	O	O
structure	B-ANAT
and	O	O
function	B-PHYS
of	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
:	O	O
setting	O	O
the	O	O
record	O
straight	O	O
Among	O	O
the	O	O
extant	O	O
air	B-LIVB
-	I-LIVB
breathing	I-LIVB
vertebrates	I-LIVB
,	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
is	O	O
structurally	B-ANAT
the	O	O
most	O	O
complex	O
and	O	O
functionally	O
the	O	O
most	O	O
efficient	O
gas	B-PHYS
exchanger	I-PHYS
.	O	O

Having	O	O
been	O	O
investigated	O	O
for	O	O
over	O	O
four	O	O
centuries	O	O
,	O	O
some	O	O
aspects	O
of	O	O
its	O	O
biology	O	O
have	O	O
been	O	O
extremely	O	O
challenging	O	O
and	O	O
highly	O	O
contentious	O	O
and	O	O
others	O	O
still	O	O
remain	O	O
unresolved	O	O
.	O	O

Here	O	O
,	O	O
while	O	O
assessing	O	O
the	O	O
most	O	O
recent	O	O
findings	B-DISO
,	O	O
four	O	O
notable	O	O
aspects	O
of	O	O
the	O	O
structure	B-ANAT
and	O	O
function	B-PHYS
of	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
are	O	O
examined	O	O
critically	O	O
to	O	O
highlight	O	O
the	O	O
questions	O
,	O	O
speculations	O
,	O	O
controversies	O
and	O	O
debates	O
that	O	O
have	O	O
arisen	O	O
from	O	O
past	O	O
research	B-PROC
.	O	O

The	O	O
innovative	O
techniques	O
and	O	O
experiments	B-PROC
that	O	O
were	O	O
performed	O	O
to	O	O
answer	O	O
particular	O	O
research	O
questions	O
are	O	O
emphasised	O	O
.	O	O

The	O	O
features	O
that	O	O
are	O	O
outlined	O	O
here	O	O
concern	O	O
the	O	O
arrangement	O	O
of	O	O
the	O	O
airways	B-ANAT
,	O	O
the	O	O
path	O
followed	O	O
by	O	O
the	O	O
inspired	B-OBJC
air	I-OBJC
,	O	O
structural	B-ANAT
features	O
of	O	O
the	O	O
lung	B-ANAT
and	O	O
the	O	O
air	B-ANAT
and	O	O
blood	B-ANAT
capillaries	I-ANAT
,	O	O
and	O	O
the	O	O
level	O	O
of	O	O
cellular	B-PHYS
defence	I-PHYS
in	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
.	O	O

Hitherto	O	O
,	O	O
based	O	O
on	O	O
association	O	O
with	O	O
the	O	O
proven	O	O
efficiency	O
of	O	O
naturally	O
evolved	O
and	O	O
human	O
-	O
made	O
counter	B-PHEN
-	I-PHEN
current	I-PHEN
exchange	I-PHEN
systems	I-PHEN
rather	O	O
than	O	O
on	O	O
definite	O	O
experimental	O
evidence	O
,	O	O
a	O	O
counter	B-PHEN
-	I-PHEN
current	I-PHEN
gas	I-PHEN
exchange	I-PHEN
system	I-PHEN
was	O	O
suggested	O	O
to	O	O
exist	O	O
in	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
and	O	O
was	O	O
used	O	O
to	O	O
explain	O	O
its	O	O
exceptional	O	O
efficiency	O
.	O	O

However	O	O
,	O	O
by	O	O
means	O	O
of	O	O
an	O	O
elegant	O	O
experiment	B-PROC
in	O	O
which	O	O
the	O	O
direction	O
of	O	O
the	O	O
air	B-OBJC
-	O	O
flow	B-PHEN
in	O	O
the	O	O
lung	B-ANAT
was	O	O
reversed	O
,	O	O
a	O	O
cross	B-PHEN
-	I-PHEN
current	I-PHEN
system	I-PHEN
was	O	O
shown	O	O
to	O	O
be	O	O
in	O	O
operation	O	O
instead	O	O
.	O	O

Studies	B-PROC
of	O	O
the	O	O
arrangement	O	O
of	O	O
the	O	O
airways	B-ANAT
and	O	O
the	O	O
blood	B-ANAT
vessels	I-ANAT
corroborated	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
cross	B-PHEN
-	I-PHEN
current	I-PHEN
system	I-PHEN
in	O	O
the	O	O
avian	B-LIVB
lung	B-ANAT
.	O	O

While	O	O
the	O	O
avian	B-LIVB
respiratory	B-ANAT
system	I-ANAT
is	O	O
ventilated	O
tidally	O	O
,	O	O
like	O	O
most	O	O
other	O	O
invaginated	B-DISO
gas	B-PHYS
exchangers	I-PHYS
,	O	O
the	O	O
lung	B-ANAT
,	O	O
specifically	O	O
the	O	O
paleopulmonic	B-ANAT
parabronchi	I-ANAT
,	O	O
is	O	O
ventilated	O
unidirectionally	O
and	O	O
continuously	O	O
in	O	O
a	O	O
caudocranial	B-ANAT
(	O	O
back	O
-	O
to	O
-	O
front	O
)	O	O
direction	O
by	O	O
synchronized	O
actions	O
of	O	O
the	O	O
air	B-ANAT
sacs	I-ANAT
.	O	O

The	O	O
path	O
followed	O	O
by	O	O
the	O	O
inspired	B-OBJC
air	I-OBJC
in	O	O
the	O	O
lung	B-ANAT
-	O	O
air	B-ANAT
sac	I-ANAT
system	B-ANAT
is	O	O
now	O	O
known	O	O
to	O	O
be	O	O
controlled	O
by	O	O
a	O	O
mechanism	O
of	O	O
aerodynamic	B-PHEN
valving	I-PHEN
and	O	O
not	O	O
by	O	O
anatomical	B-ANAT
valves	I-ANAT
or	O	O
sphincters	B-ANAT
,	O	O
as	O	O
was	O	O
previously	O	O
supposed	O	O
.	O	O

The	O	O
structural	B-ANAT
strength	O
of	O	O
the	O	O
air	B-ANAT
and	O	O
blood	B-ANAT
capillaries	I-ANAT
is	O	O
derived	O	O
from	O	O
:	O	O
the	O	O
interdependence	O
between	O	O
the	O	O
air	B-ANAT
and	O	O
blood	B-ANAT
capillaries	I-ANAT
;	O	O
a	O	O
tethering	O	O
effect	O	O
between	O	O
the	O	O
closely	O	O
entwined	O	O
respiratory	B-ANAT
units	I-ANAT
;	O	O
the	O	O
presence	O	O
of	O	O
epithelial	B-ANAT
-	O	O
epithelial	B-ANAT
cell	I-ANAT
connections	O
(	O	O
retinacula	O
or	O	O
cross	O	O
-	O	O
bridges	O	O
)	O	O
that	O	O
join	O	O
the	O	O
blood	B-ANAT
capillaries	I-ANAT
while	O	O
separating	O	O
the	O	O
air	B-ANAT
capillaries	I-ANAT
;	O	O
the	O	O
abundance	O
and	O	O
intricate	O
arrangement	O
of	O	O
the	O	O
connective	O
tissue	O
elements	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

collagen	B-CHEM
,	O	O
elastin	B-CHEM
,	O	O
and	O	O
smooth	B-ANAT
muscle	I-ANAT
fibres	I-ANAT
;	O	O
the	O	O
presence	O	O
of	O	O
type	B-CHEM
-	I-CHEM
IV	I-CHEM
collagen	I-CHEM
,	O	O
especially	O	O
in	O	O
the	O	O
basement	O
membranes	O
of	O	O
the	O	O
blood	B-ANAT
-	I-ANAT
gas	I-ANAT
barrier	I-ANAT
and	O	O
the	O	O
epithelial	B-ANAT
-	O	O
epithelial	B-ANAT
cell	I-ANAT
connections	O
;	O	O
and	O	O
a	O	O
putative	O	O
tensegrity	O
state	O
in	O	O
the	O	O
lung	B-ANAT
.	O	O

Notwithstanding	O	O
the	O	O
paucity	O	O
of	O	O
free	O
surface	O
pulmonary	B-ANAT
macrophages	I-ANAT
,	O	O
the	O	O
respiratory	O
surface	O
of	O	O
the	O	O
avian	B-LIVB
lung	B-ANAT
is	O	O
well	O	O
protected	O	O
from	O	O
pathogens	B-LIVB
and	O	O
particulates	B-OBJC
by	O	O
an	O	O
assortment	O	O
of	O	O
highly	O	O
efficient	O
phagocytic	B-ANAT
cells	I-ANAT
.	O	O

In	O	O
commercial	O	O
poultry	B-LIVB
production	O
,	O	O
instead	O	O
of	O	O
weak	O
pulmonary	B-ANAT
cellular	B-PHYS
defence	I-PHYS
,	O	O
stressful	O
husbandry	O
practices	O	O
such	O	O
as	O	O
overcrowding	B-DISO
,	O	O
force	B-DISO
-	I-DISO
feeding	I-DISO
,	O	O
and	O	O
intense	O
genetic	B-PROC
manipulation	I-PROC
for	O	O
rapid	O	O
weight	B-DISO
gain	I-DISO
and	O	O
egg	B-PHYS
production	I-PHYS
may	O	O
account	O	O
for	O	O
the	O	O
reported	O	O
susceptibility	B-PHYS
of	O	O
birds	B-LIVB
to	O	O
aerosol	B-OBJC
-	O	O
transmitted	O
diseases	B-DISO
.	O	O

Activation	B-PHYS
of	O	O
general	B-CHEM
control	I-CHEM
nonderepressible	I-CHEM
2	I-CHEM
kinase	I-CHEM
protects	B-DISO
human	B-LIVB
glomerular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
from	O	O
harmful	O	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O	O
induced	O
molecular	B-PHYS
pathways	I-PHYS
Considering	O	O
the	O	O
referred	O	O
beneficial	O	O
effects	O	O
of	O	O
protein	B-CHEM
restriction	O
on	O	O
diabetic	B-DISO
nephropathy	I-DISO
(	O	O
DN	B-DISO
)	O	O
and	O	O
the	O	O
role	O	O
of	O	O
renal	B-ANAT
endothelium	O
in	O	O
its	O	O
pathogenesis	B-DISO
,	O	O
we	O	O
evaluated	B-PROC
the	O	O
effect	O	O
of	O	O
general	B-CHEM
control	I-CHEM
nonderepressible	I-CHEM
2	I-CHEM
(	I-CHEM
GCN2	I-CHEM
)	I-CHEM
kinase	I-CHEM
activation	B-PHYS
,	O	O
a	O	O
sensor	B-DEVI
of	O	O
amino	B-CHEM
acid	I-CHEM
deprivation	O
,	O	O
on	O	O
known	O	O
detrimental	O	O
molecular	B-PHYS
pathways	I-PHYS
in	O	O
primary	O	O
human	B-LIVB
glomerular	B-ANAT
endothelial	I-ANAT
cells	I-ANAT
(	O	O
GEnC	B-ANAT
)	O	O
.	O	O

GEnC	B-ANAT
were	O	O
cultured	B-PROC
under	O	O
normal	O	O
or	O	O
high	B-DISO
-glucose	I-DISO
conditions	I-DISO
in	O	O
the	O	O
presence	O	O
or	O	O
not	O	O
of	O	O
the	O	O
GCN2	B-CHEM
kinase	I-CHEM
activator	B-PHYS
,	O	O
tryptophanol	B-CHEM
.	O	O

Glucose	B-CHEM
transporter	I-CHEM
1	I-CHEM
(	O	O
GLUT1	B-CHEM
)	O	O
expression	B-PHYS
was	O	O
assessed	O
by	O	O
western	B-PROC
blotting	I-PROC
and	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
using	O	O
a	O	O
fluorogenic	B-CHEM
probe	I-CHEM
.	O	O

Activities	B-PHYS
of	O	O
glyceraldehyde	B-CHEM
3	I-CHEM
-	I-CHEM
phosphate	I-CHEM
dehydrogenase	I-CHEM
(	O	O
GAPDH	B-CHEM
)	O	O
and	O	O
protein	B-CHEM
kinase	I-CHEM
C	I-CHEM
(	O	O
PKC	B-CHEM
)	O	O
were	O	O
assessed	O
by	O	O
commercial	B-PROC
activity	I-PROC
assays	I-PROC
,	O	O
sorbitol	B-CHEM
colorimetrically	B-PROC
,	O	O
methylglyoxal	B-CHEM
by	O	O
ELISA	B-PROC
and	O	O
O	B-CHEM
-	I-CHEM
linked	I-CHEM
β	I-CHEM
-	I-CHEM
N	I-CHEM
-	I-CHEM
acetyl	I-CHEM
glucosamine	I-CHEM
(	I-CHEM
O	I-CHEM
-	I-CHEM
GlcNAc	I-CHEM
)	I-CHEM
-	I-CHEM
modified	I-CHEM
proteins	I-CHEM
by	O	O
western	B-PROC
blotting	I-PROC
.	O	O

High	B-DISO
glucose	I-DISO
induced	O
GLUT1	B-CHEM
expression	B-PHYS
,	O	O
increased	O
ROS	B-CHEM
and	O	O
inhibited	O
GAPDH	B-CHEM
.	O	O

Also	O	O
it	O	O
increased	O
the	O	O
polyol	B-CHEM
pathway	B-PHYS
product	O	O
sorbitol	B-CHEM
,	O	O
PKC	B-CHEM
activity	B-PHYS
,	O	O
the	O	O
level	O	O
of	O	O
the	O	O
O	B-CHEM
-	I-CHEM
GlcNAc	I-CHEM
-	I-CHEM
modified	I-CHEM
proteins	I-CHEM
that	O	O
produced	O	O
by	O	O
the	O	O
hexosamine	B-CHEM
pathway	B-PHYS
and	O	O
the	O	O
advanced	B-CHEM
glycation	I-CHEM
endproducts	I-CHEM
'	I-CHEM
precursor	O
methylglyoxal	B-CHEM
.	O	O

Co	B-PROC
-	I-PROC
treatment	I-PROC
of	O	O
GEnC	B-ANAT
with	O	O
tryptophanol	B-CHEM
restored	O	O
the	O	O
above	O	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O	O
induced	O
alterations	O	O
.	O	O

Activation	B-PHYS
of	O	O
GCN2	B-CHEM
kinase	I-CHEM
protects	O	O
GEnC	B-ANAT
from	O	O
high	B-DISO
-	I-DISO
glucose	I-DISO
-	O	O
induced	O
harmful	O	O
molecular	B-PHYS
pathways	I-PHYS
.	O	O

By	O	O
inhibiting	O	O
concurrently	O
many	O	O
pathways	B-PHYS
involved	O	O
in	O	O
DN	B-DISO
pathogenesis	B-DISO
,	O	O
GCN2	B-CHEM
kinase	I-CHEM
may	O	O
serve	O	O
as	O	O
a	O	O
pharmaceutical	O
target	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
DN	B-DISO
.	O	O

microRNA	B-CHEM
-	I-CHEM
145	I-CHEM
Mediates	O	O
the	O	O
Inhibitory	O
Effect	O
of	O	O
Adipose	O
Tissue	O
-Derived	O	O
Stromal	B-ANAT
Cells	I-ANAT
on	O	O
Prostate	B-DISO
Cancer	I-DISO
Adipose	B-ANAT
-	I-ANAT
derived	I-ANAT
stromal	I-ANAT
cell	I-ANAT
(	I-ANAT
ASC	I-ANAT
)	I-ANAT
,	O	O
known	O	O
as	O	O
one	O	O
of	O	O
the	O	O
mesenchymal	B-ANAT
stem	I-ANAT
cells	I-ANAT
(	I-ANAT
MSCs	I-ANAT
)	I-ANAT
,	O	O
is	O	O
a	O	O
promising	O	O
tool	O	O
for	O	O
regenerative	O
medicine	O
;	O	O
however	O	O
,	O	O
the	O	O
effect	O
of	O	O
ASCs	B-ANAT
on	O	O
tumor	B-DISO
growth	I-DISO
has	O	O
not	O	O
been	O	O
studied	O	O
sufficiently	O	O
.	O	O

We	O	O
investigated	O
the	O	O
hypothesis	O
that	O	O
ASCs	B-ANAT
have	O	O
an	O	O
inhibitory	O
effect	O
on	O	O
metastatic	B-DISO
tumor	I-DISO
progression	I-DISO
.	O	O

To	O	O
evaluate	O
the	O	O
in	O
vitro	O
inhibitory	O
effect	O
of	O	O
ASCs	B-ANAT
on	O	O
metastatic	B-DISO
prostate	I-DISO
cancer	I-DISO
(	I-DISO
PCa	I-DISO
)	I-DISO
,	O	O
direct	O	O
coculture	B-PROC
and	O	O
indirect	O	O
separate	O	O
culture	B-PROC
experiments	I-PROC
with	O	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cells	I-ANAT
and	O	O
human	B-LIVB
ASCs	B-ANAT
were	O	O
performed	O	O
,	O	O
and	O	O
ASCs	B-ANAT
were	O	O
administered	O
to	O	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	I-ANAT
-derived	O	O
tumor	B-DISO
-bearing	O	O
nude	B-LIVB
mice	I-LIVB
for	O	O
in	O
vivo	O
experiment	B-PROC
.	O	O

We	O	O
also	O	O
performed	O	O
exosome	B-ANAT
microRNA	B-CHEM
(	I-CHEM
miRNA	I-CHEM
)	I-CHEM
array	B-PROC
analysis	I-PROC
to	O	O
explore	O	O
a	O	O
mechanistic	O
insight	O
into	O	O
the	O	O
effect	O
of	O	O
ASCs	B-ANAT
on	O	O
PCa	B-ANAT
cell	I-ANAT
proliferation	B-PHYS
/	O	O
apoptosis	B-PHYS
.	O	O

Both	O	O
in	O
vitro	O
and	O	O
in	O
vivo	O
experiments	B-PROC
exhibited	O	O
the	O	O
inhibitory	O
effect	O
of	O	O
ASCs	B-ANAT
on	O	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	B-PHYS
proliferation	I-PHYS
,	O	O
inducing	O	O
apoptosis	B-PHYS
and	O	O
PCa	B-DISO
growth	B-DISO
,	O	O
respectively	O	O
.	O	O

Among	O	O
upregulated	B-PHYS
miRNAs	B-CHEM
in	O	O
ASCs	B-ANAT
compared	O	O
with	O	O
fibroblasts	B-ANAT
,	O	O
we	O	O
focused	O	O
on	O	O
miR	O
-	O
145	O
,	O	O
which	O	O
was	O	O
known	O	O
as	O	O
a	O	O
tumor	O
suppressor	O
.	O	O

ASC	B-ANAT
-derived	O	O
conditioned	B-CHEM
medium	I-CHEM
(	I-CHEM
CM	I-CHEM
)	I-CHEM
significantly	O	O
inhibited	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cell	B-PHYS
proliferation	I-PHYS
,	O	O
inducing	O	O
apoptosis	B-PHYS
,	O	O
but	O	O
the	O	O
effect	O
was	O	O
canceled	O	O
by	O	O
miR	O
-	O
145	O
knockdown	B-PROC
in	O	O
ASCs	B-ANAT
.	O	O

ASC	B-ANAT
miR	O
-	O
145	O
knockdown	B-PROC
CM	B-CHEM
also	O	O
reduced	O	O
the	O	O
expression	B-PHYS
of	O	O
Caspase	B-CHEM
3	I-CHEM
/	O	O
7	B-CHEM
with	O	O
increased	O	O
antiapoptotic	B-CHEM
protein	B-CHEM
,	O	O
BclxL	B-CHEM
,	O	O
expression	B-PHYS
in	O	O
PC3M	B-ANAT
-	I-ANAT
luc2	I-ANAT
cells	I-ANAT
.	O	O

This	O	O
study	B-PROC
provides	O	O
preclinical	O
data	O	O
that	O	O
ASCs	B-ANAT
inhibit	O
PCa	B-DISO
growth	B-DISO
,	O	O
inducing	O	O
PCa	B-DISO
cell	B-ANAT
apoptosis	B-PHYS
with	O	O
reduced	O	O
activity	O
of	O	O
BclxL	B-CHEM
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
by	O	O
miR	O
-	O
145	O
,	O	O
including	O	O
exosomes	B-ANAT
released	O	O
from	O	O
ASCs	B-ANAT
,	O	O
suggesting	O	O
that	O	O
ASC	B-ANAT
administration	O
could	O	O
be	O	O
a	O	O
novel	O	O
and	O	O
promising	O	O
therapeutic	O
strategy	O	O
in	O	O
patients	B-LIVB
with	O	O
PCa	B-DISO
.	O	O

Visual	B-PROC
Analytics	I-PROC
for	O	O
Pattern	B-PHYS
Discovery	I-PHYS
in	O	O
Home	B-PROC
Care	I-PROC
.	O	O

Clinical	O
Relevance	O
for	O	O
Quality	O
Improvement	O
Visualization	B-PHYS
can	O	O
reduce	O	O
the	O	O
cognitive	O
load	O
of	O
information	O
,	O	O
allowing	O	O
users	O	O
to	O	O
easily	O	O
interpret	O
and	O	O
assess	B-PROC
large	I-PROC
amounts	I-PROC
of	I-PROC
data	I-PROC
.	O	O

The	O	O
purpose	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
examine	O	O
home	O
health	O
data	O
using	O	O
visual	B-PROC
analysis	I-PROC
techniques	I-PROC
to	O	O
discover	O	O
clinically	O
salient	O
associations	O
between	O	O
patient	B-PHYS
characteristics	I-PHYS
with	O	O
problem	O
-	O
oriented	O
health	O
outcomes	O
of	O	O
older	B-PROC
adult	I-PROC
home	I-PROC
health	I-PROC
patients	I-PROC
during	O	O
the	O	O
home	B-PROC
health	I-PROC
service	I-PROC
period	O	O
.	O	O

Knowledge	O
,	O	O
Behavior	O
and	O	O
Status	O
ratings	O
at	O	O
discharge	B-PROC
as	O	O
well	O	O
as	O	O
change	O	O
from	O	O
admission	B-PROC
to	O	O
discharge	B-PROC
that	O	O
was	O	O
coded	O	O
using	O	O
the	O	O
Omaha	O
System	O
was	O	O
collected	O	O
from	O	O
a	O	O
dataset	O
on	O	O
988	O	O
de	O	O
-	O	O
identified	O	O
patient	O
data	O
from	O	O
15	O	O
home	O
health	O
agencies	O
.	O	O

SPSS	O
Visualization	O
Designer	O
v1	O
.	O

0	O
was	O	O
used	O	O
to	O	O
visually	B-PROC
analyze	I-PROC
patterns	I-PROC
between	O	O
independent	O	O
and	O	O
outcome	O	O
variables	O	O
using	O	O
heat	O
maps	O
and	O	O
histograms	B-OBJC
.	O	O

Visualizations	B-PHYS
suggesting	O	O
clinical	B-DISO
salience	I-DISO
were	O	O
tested	O
for	O	O
significance	O	O
using	O	O
correlation	B-PROC
analysis	I-PROC
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	B-LIVB
was	O	O
80	O	O
years	O	O
,	O	O
with	O	O
the	O	O
majority	O	O
female	B-PHYS
(	O	O
66	O	O
%	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
150	O	O
visualizations	B-PHYS
,	O	O
69	O	O
potentially	O	O
meaningful	O
patterns	O
were	O	O
statistically	O	O
evaluated	O	O
through	O	O
bivariate	O
associations	O
,	O	O
revealing	O	O
21	O	O
significant	O	O
associations	O
.	O	O

Further	O	O
,	O	O
14	O	O
associations	O
between	O	O
episode	O	O
length	O	O
and	O	O
Charlson	O
co	O
-	O
morbidity	O
index	O
mainly	O	O
with	O	O
urinary	O
related	O	O
diagnoses	B-DISO
and	I-DISO
problems	I-DISO
remained	O	O
significant	O	O
after	O	O
adjustment	O	O
analyses	O	O
.	O	O

Through	O	O
visual	B-PROC
analysis	I-PROC
,	O	O
the	O	O
adverse	O	O
association	O
of	O	O
the	O	O
longer	O	O
home	B-PROC
health	I-PROC
episode	I-PROC
length	O	O
and	O	O
higher	O	O
Charlson	O
co	O
-	O
morbidity	O
index	O
with	O	O
behavior	B-DISO
or	I-DISO
status	I-DISO
outcomes	I-DISO
for	O	O
patients	B-LIVB
with	O	O
impaired	B-DISO
urinary	I-DISO
function	I-DISO
was	O	O
revealed	O	O
.	O	O

We	O	O
have	O	O
demonstrated	O	O
the	O	O
use	O	O
of	O	O
visual	B-PROC
analysis	I-PROC
to	O	O
discover	O	O
novel	O	O
patterns	O	O
that	O	O
described	O	O
high	O	O
-	O	O
needs	O	O
subgroups	O
among	O	O
the	O	O
older	O
home	O
health	O
patient	O
population	O
.	O	O

The	O	O
effective	O	O
presentation	O	O
of	O	O
these	O	O
data	O
patterns	O
can	O	O
allow	O	O
clinicians	B-LIVB
to	O	O
identify	O	O
areas	O	O
of	O	O
patient	O
improvement	O
,	O	O
and	O	O
time	O	O
periods	O	O
that	O	O
are	O	O
most	O	O
effective	O	O
for	O	O
implementing	O	O
home	B-PROC
health	I-PROC
interventions	I-PROC
to	O	O
improve	O	O
patient	B-PROC
outcomes	I-PROC
.	O	O

Initial	O	O
experience	B-PHYS
using	O	O
a	O	O
femtosecond	B-PROC
laser	I-PROC
cataract	I-PROC
surgery	I-PROC
system	B-DEVI
at	O	O
a	O	O
UK	O	O
National	O
Health	O
Service	O
cataract	O
surgery	O
day	O
care	O
centre	O
To	O	O
describe	O	O
the	O	O
initial	O	O
outcomes	O
following	O	O
installation	O
of	O	O
a	O	O
cataract	B-PROC
surgery	I-PROC
laser	B-DEVI
system	I-DEVI
.	O	O

National	O
Health	O
Service	O
cataract	O
surgery	O
day	O
care	O
unit	O
in	O	O
North	B-GEOG
London	I-GEOG
,	O	O
UK	B-GEOG
.	O	O
158	O	O
eyes	B-ANAT
of	O	O
150	O	O
patients	B-LIVB
undergoing	O	O
laser	B-PROC
-	I-PROC
assisted	I-PROC
cataract	I-PROC
surgery	I-PROC
.	O	O

Laser	B-PROC
cataract	I-PROC
surgery	I-PROC
using	O	O
the	O	O
AMO	B-DEVI
Catalys	I-DEVI
femtosecond	I-DEVI
laser	I-DEVI
platform	I-DEVI
.	O	O

intraoperative	B-DISO
complications	I-DISO
including	O	O
anterior	B-DISO
and	O	O
posterior	B-DISO
capsule	I-DISO
tears	I-DISO
.	O	O

docking	B-PROC
to	O	O
the	O	O
laser	B-DEVI
platform	I-DEVI
,	O	O
successful	O	O
treatment	B-PROC
delivery	I-PROC
,	O	O
postoperative	B-PHYS
visual	I-PHYS
acuities	I-PHYS
.	O	O

Mean	O
case	O	O
age	B-PHYS
was	O	O
67	O	O
.	O	O

7±10	O	O
.	O	O

8	O	O
years	O
(	O	O
range	O	O
29	O	O
-	O	O
88	O	O
years	O
)	O	O
.	O	O

Docking	B-PROC
was	O	O
successful	O	O
in	O	O
94	O	O
%	O	O
(	O	O
148	O	O
/	O	O
158	O	O
cases	O
)	O	O
,	O	O
and	O	O
in	O	O
4	O	O
%	O	O
(	O	O
6	O	O
/	O	O
148	O	O
cases	O
)	O	O
of	O	O
these	O	O
,	O	O
the	O	O
laser	O
delivery	O
was	O	O
aborted	O	O
part	O	O
way	O	O
during	O	O
delivery	O
due	O	O
to	O	O
patient	B-LIVB
movement	B-PHYS
.	O	O

A	O	O
total	O	O
of	O	O
32	O	O
surgeons	B-LIVB
,	O	O
of	O	O
grades	O
from	O	O
junior	B-LIVB
trainee	I-LIVB
to	O	O
consultant	B-LIVB
,	O	O
performed	O	O
the	O	O
surgeries	B-PROC
.	O	O

Median	O
case	O
number	O
per	O	O
surgeon	B-LIVB
was	O	O
3	O	O
(	O	O
range	O	O
from	O	O
1	O	O
-	O	O
20	O	O
)	O	O
.	O	O

The	O	O
anterior	O
capsulotomy	B-PROC
was	O	O
complete	O	O
in	O	O
99	O	O
.	O	O

3	O	O
%	O	O
of	O	O
cases	O
,	O	O
there	O	O
were	O	O
no	O	O
anterior	O
capsule	B-DISO
tears	I-DISO
(	O	O
0	O	O
%	O	O
)	O	O
.	O	O

There	O	O
were	O	O
3	O	O
cases	O
with	O	O
posterior	B-DISO
capsule	I-DISO
rupture	I-DISO
requiring	O	O
anterior	O
vitrectomy	B-PROC
,	O	O
and	O	O
1	O	O
with	O	O
zonular	B-DISO
dialysis	I-DISO
requiring	O	O
anterior	O
vitrectomy	B-PROC
(	O	O
4	O	O
/	O	O
148	O	O
eyes	B-ANAT
,	O	O
2	O	O
.	O	O
7	O	O
%	O	O
)	O	O
.	O	O

These	O	O
4	O	O
cases	O
were	O	O
performed	O	O
by	O	O
trainee	B-LIVB
surgeons	I-LIVB
,	O	O
and	O	O
were	O	O
either	O	O
their	O	O
first	O	O
laser	B-PROC
cataract	I-PROC
surgery	I-PROC
(	O	O
2	O	O
surgeons	B-LIVB
)	O	O
or	O	O
their	O	O
first	O	O
and	O	O
second	O	O
laser	B-PROC
cataract	I-PROC
surgeries	I-PROC
(	O	O
1	O	O
surgeon	B-LIVB
)	O	O
.	O	O

Despite	O	O
the	O	O
learning	O	O
curve	O	O
,	O	O
docking	B-PROC
and	O	O
laser	O
delivery	O
were	O	O
successfully	O	O
performed	O	O
in	O	O
almost	O	O
all	O	O
cases	O
,	O	O
and	O	O
surgical	O
complication	O
rates	O
and	O	O
visual	O
outcomes	O
were	O	O
similar	O	O
to	O	O
those	O	O
expected	O	O
based	O	O
on	O	O
national	O
data	O
.	O	O

Complications	B-DISO
were	O	O
predominately	O	O
confined	O	O
to	O	O
trainee	B-LIVB
surgeons	I-LIVB
,	O	O
and	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
intraoperative	O
pupil	B-PROC
constriction	I-PROC
appeared	O	O
unrelated	O	O
to	O	O
the	O	O
laser	O
-	O
performed	O
steps	O
.	O	O

Transforming	B-CHEM
Growth	I-CHEM
Factor	I-CHEM
Beta	I-CHEM
1	I-CHEM
(	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
)	O	O
in	O	O
Thyroid	B-DISO
Cancer	I-DISO
Patients	B-LIVB
:	O	O
a	O	O
View	O	O
from	O	O
the	O	O
Peripheral	B-ANAT
Blood	I-ANAT
Transforming	B-CHEM
growth	I-CHEM
factor	I-CHEM
beta	I-CHEM
(	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
)	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
many	O	O
pathophysiological	O
conditions	O
,	O	O
including	O	O
cancer	B-DISO
.	O	O

The	O	O
level	O
of	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
in	O	O
patients	B-LIVB
with	O	O
differentiated	B-DISO
thyroid	I-DISO
cancer	I-DISO
(	O	O
DTC	B-DISO
)	O	O
has	O	O
not	O	O
been	O	O
examined	B-DISO
so	O	O
far	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
measure	O	O
TGF	B-CHEM
-	I-CHEM
β	I-CHEM
concentration	O
in	O	O
serum	B-ANAT
samples	I-ANAT
and	O	O
in	O	O
PHA	B-CHEM
-	O	O
stimulated	B-PHYS
whole	B-ANAT
blood	I-ANAT
culture	B-PROC
in	O
vitro	O
and	O	O
to	O	O
analyze	B-PROC
possible	O	O
associations	O	O
of	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
levels	O
with	O	O
leukocyte	B-ANAT
,	O	O
lymphocyte	B-ANAT
and	O	O
platelets	B-ANAT
counts	B-PROC
,	O	O
the	O	O
histological	O
type	O	O
of	O	O
thyroid	B-DISO
cancer	I-DISO
,	O	O
and	O	O
stage	B-PROC
of	I-PROC
disease	I-PROC
.	O	O

TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
was	O	O
measured	O	O
in	O	O
22	O	O
DTC	B-DISO
patients	B-LIVB
and	O	O
20	O	O
healthy	O
controls	B-LIVB
using	O	O
the	O	O
duoSet	B-DEVI
ELISA	I-DEVI
Development	I-DEVI
kit	I-DEVI
for	O	O
human	B-CHEM
TGF	I-CHEM
-	I-CHEM
β1	I-CHEM
.	O	O

The	O	O
concentration	O
of	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
in	O	O
serum	B-ANAT
samples	I-ANAT
from	O	O
both	O	O
groups	B-LIVB
correlated	O	O
positively	O	O
with	O	O
the	O	O
platelet	B-ANAT
counts	B-PROC
.	O	O

There	O	O
was	O	O
no	O	O
statistically	O
significant	O
difference	O	O
in	O	O
the	O	O
serum	O
concentrations	O
of	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
between	O	O
DTC	B-DISO
patients	B-LIVB
and	O	O
control	B-LIVB
subjects	I-LIVB
,	O	O
but	O	O
PHA	B-CHEM
stimulated	B-PHYS
whole	B-ANAT
blood	I-ANAT
cultures	B-PROC
of	O	O
DTC	B-DISO
patients	B-LIVB
produced	O	O
less	O	O
TGF	B-CHEM
-	I-CHEM
β1	I-CHEM
than	O	O
those	O	O
from	O	O
controls	B-LIVB
.	O	O

Additional	O	O
studies	B-PROC
are	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
significance	O
of	O	O
these	O	O
in	O
vitro	O
findings	B-DISO
.	O	O

P	B-CHEM
-	I-CHEM
glycoprotein	I-CHEM
traffics	O
from	O	O
the	O	O
nucleus	B-ANAT
to	O	O
the	O	O
plasma	B-ANAT
membrane	I-ANAT
in	O	O
rat	B-ANAT
brain	I-ANAT
endothelium	O
during	O	O
inflammatory	B-DISO
pain	I-DISO
P	B-CHEM
-	I-CHEM
glycoprotein	I-CHEM
(	O	O
PgP	B-CHEM
)	O	O
,	O	O
a	O	O
drug	B-CHEM
efflux	O
pump	O
in	O	O
blood	B-ANAT
-	I-ANAT
brain	I-ANAT
barrier	I-ANAT
endothelial	B-ANAT
cells	I-ANAT
,	O	O
is	O	O
a	O	O
major	O	O
clinical	O
obstacle	O
for	O	O
effective	O	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
.	O	O

Identifying	B-PROC
PgP	B-CHEM
regulatory	O
pathways	O
that	O	O
can	O	O
be	O	O
exploited	O	O
clinically	O	O
is	O	O
critical	O	O
for	O	O
improving	O	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
.	O	O

We	O	O
previously	O	O
found	O	O
that	O	O
PgP	B-PHYS
activity	I-PHYS
increases	O
in	O	O
rat	B-ANAT
brain	I-ANAT
microvessels	B-ANAT
concomitant	O
with	O	O
decreased	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-PROC
delivery	I-PROC
in	O	O
response	O	O
to	O	O
acute	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
we	O	O
tested	O	O
the	O	O
hypothesis	O	O
that	O	O
PgP	B-CHEM
traffics	O
to	O	O
the	O	O
luminal	O
plasma	B-ANAT
membrane	I-ANAT
of	O	O
the	O	O
microvessel	B-ANAT
endothelial	B-ANAT
cells	I-ANAT
from	O	O
intracellular	O
stores	O
during	O	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
.	O	O

Using	O	O
immunofluorescence	B-PROC
microscopy	I-PROC
,	O	O
we	O	O
detected	B-DISO
PgP	B-CHEM
in	O	O
endothelial	B-ANAT
cell	I-ANAT
nuclei	B-ANAT
and	O	O
in	O	O
the	O	O
luminal	O
plasma	B-ANAT
membrane	I-ANAT
in	O	O
control	B-LIVB
animals	I-LIVB
.	O	O

Following	O	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
,	O	O
luminal	O
PgP	B-CHEM
staining	B-PROC
increased	O
while	O	O
staining	B-PROC
in	O	O
the	O	O
nucleus	B-ANAT
decreased	O
.	O	O

Biochemical	B-PROC
analysis	I-PROC
of	O	O
nuclear	B-ANAT
PgP	B-CHEM
content	O
confirmed	O	O
our	O	O
visual	O
observations	O
.	O	O

Peripheral	O
inflammatory	B-DISO
pain	I-DISO
also	O	O
increased	O
endothelial	B-ANAT
cell	I-ANAT
luminal	O
staining	B-PROC
of	O	O
polymerase	O
1	O
and	O
transcript	O
release	O
factor	O
/	O	O
cavin1	O
and	O	O
serum	O
deprivation	O
response	O
protein	O
/	O	O
cavin2	O
,	O	O
two	O	O
caveolar	B-CHEM
scaffold	I-CHEM
proteins	I-CHEM
,	O	O
without	O	O
changing	O	O
caveolin1	B-CHEM
or	O	O
protein	O
kinase	O
C	O
delta	O
binding	O
protein	O
/	O	O
cavin3	O
location	O
.	O	O

Our	O	O
data	O
(	O	O
a	O	O
)	O	O
indicate	O	O
that	O	O
PgP	B-CHEM
traffics	O
from	O	O
stores	O
in	O	O
the	O	O
nucleus	B-ANAT
to	O	O
the	O	O
endothelial	B-ANAT
cell	I-ANAT
luminal	B-ANAT
membrane	I-ANAT
in	O	O
response	O	O
to	O	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
;	O	O
(	O	O
b	O	O
)	O	O
provide	O	O
an	O	O
explanation	O	O
for	O	O
our	O	O
previous	O	O
observation	B-PROC
that	O	O
peripheral	O
inflammatory	B-DISO
pain	I-DISO
inhibits	O
central	B-ANAT
nervous	I-ANAT
system	I-ANAT
drug	B-CHEM
uptake	B-PHYS
;	O	O
and	O	O
(	O	O
c	O	O
)	O	O
suggest	O	O
a	O	O
novel	O
regulatory	B-DISO
mechanism	I-DISO
for	O	O
PgP	B-PHYS
activity	I-PHYS
in	O	O
rat	B-ANAT
brain	I-ANAT
.	O	O

Gene	O
Expression	O
Profile	O
in	O	O
the	O	O
Liver	B-ANAT
of	O	O
Sheep	B-LIVB
Infected	B-DISO
with	O	O
Cystic	B-DISO
Echinococcosis	I-DISO
Cystic	B-DISO
Echinococcosis	I-DISO
(	O	O
CE	B-DISO
)	O	O
,	O	O
caused	O	O
by	O	O
infection	B-DISO
with	O	O
the	O	O
Echinococcus	O
granulosus	O
(	O	O
E	O
.	O
granulosus	O
)	O	O
,	O	O
represents	O	O
considerable	O	O
health	O
problems	B-DISO
in	O	O
both	O	O
humans	B-LIVB
and	O	O
livestock	B-LIVB
.	O	O

Nevertheless	O	O
,	O	O
the	O	O
genetic	O
program	O
that	O	O
regulates	O	O
the	O	O
host	B-PHYS
response	I-PHYS
to	O	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
is	O	O
largely	O	O
unknown	O
.	O	O

Previously	O	O
,	O	O
using	O	O
microarray	B-PROC
analysis	I-PROC
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
innate	B-PHYS
immunity	I-PHYS
played	O	O
a	O	O
vital	O	O
role	O	O
in	O	O
the	O	O
E	O
.	O

granulosus	O
defense	O
of	O	O
the	O	O
intestine	O
tissue	O
where	O	O
E	O
.	O

granulosus	O
first	O	O
invaded	O
.	O	O

Subsequently	O	O
,	O	O
we	O	O
turned	O	O
our	O	O
attention	O	O
to	O	O
investigating	O
the	O	O
molecular	O
immune	B-PHYS
mechanism	O
in	O	O
its	O	O
organ	B-ANAT
target	O
,	O	O
the	O	O
liver	B-ANAT
,	O	O
which	O	O
is	O	O
where	O	O
the	O	O
E	O
.	O

granulosus	O
metacestodes	B-PHYS
are	O	O
established	O
and	O	O
live	O
for	O	O
very	O	O
long	O
periods	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
the	O	O
microarray	B-PROC
-	I-PROC
based	I-PROC
methodology	I-PROC
was	O	O
used	O	O
to	O	O
study	O	O
gene	O
expression	O
profiles	O
in	O	O
the	O	O
liver	B-ANAT
of	O	O
sheep	B-LIVB
infected	B-DISO
with	O	O
E	O
.	O

granulosus	O
at	O	O
8	O	O
weeks	O
post	O
infection	B-DISO
,	O	O
corresponding	O	O
to	O	O
the	O	O
early	O
cystic	O
established	O
phase	O
.	O	O

A	O	O
total	O	O
of	O	O
6	O	O
female	B-PHYS
-1	O	O
-	O	O
year	O
-old	O	O
healthy	O
Kazakh	B-LIVB
sheep	I-LIVB
were	O	O
used	O	O
for	O	O
the	O	O
experiments	B-PROC
.	O	O

Three	O	O
Kazakh	B-LIVB
sheep	I-LIVB
were	O	O
orally	B-ANAT
infected	B-DISO
with	O	O
E	O
.	O

granulosus	O
eggs	O
,	O	O
and	O	O
the	O	O
others	O	O
remained	O	O
untreated	O	O
and	O	O
served	O	O
as	O	O
controls	B-LIVB
.	O	O

Sheep	B-LIVB
were	O	O
humanely	B-PROC
euthanized	I-PROC
and	O	O
necropsized	B-PROC
at	O	O
8	O	O
weeks	O
post	O
-	O	O
infection	B-DISO
(	O	O
the	O	O
early	O
stage	O
of	O	O
cyst	O
established	O
)	O	O
.	O	O

The	O	O
microarray	B-PROC
was	O	O
used	O	O
to	O	O
detect	B-DISO
differential	B-PHYS
hepatic	I-PHYS
gene	I-PHYS
expression	I-PHYS
between	O	O
CE	B-DISO
infection	B-DISO
sheep	B-LIVB
and	O	O
healthy	O
controls	O
at	O	O
this	O	O
time	O	O
point	O	O
.	O	O

Real	B-PROC
-	I-PROC
time	I-PROC
PCR	I-PROC
was	O	O
used	O	O
to	O	O
validate	O	O
the	O	O
microarray	B-PROC
data	O
.	O	O

We	O	O
found	O	O
that	O	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
induces	O
153	O	O
differentially	B-PHYS
expressed	I-PHYS
genes	O
in	O	O
the	O	O
livers	B-ANAT
of	O	O
infected	B-DISO
sheep	B-LIVB
compared	O
with	O	O
healthy	O
controls	O
.	O	O

Among	O	O
them	O	O
,	O	O
87	O	O
genes	O
were	O	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
,	O	O
and	O	O
66	O	O
genes	O
were	O	O
notably	O	O
down	B-PHYS
-	I-PHYS
regulated	I-PHYS
.	O	O

Functional	B-PHYS
analysis	B-PROC
showed	O	O
that	O	O
these	O	O
genes	O
were	O	O
associated	O
with	O
three	O	O
major	O	O
functional	O
categories	O	O
:	O	O
(	O	O
a	O	O
)	O	O
metabolism	B-PHYS
,	O	O
(	O	O
b	O	O
)	O	O
the	O	O
immune	B-ANAT
system	I-ANAT
and	O	O
(	O	O
c	O	O
)	O	O
signaling	B-PHYS
and	O	O
transport	B-PHYS
.	O	O

Deeper	O	O
analysis	B-PROC
indicated	O	O
that	O	O
complement	O	O
together	O	O
with	O	O
other	O	O
genes	O
associated	O
with	O
metabolism	B-PHYS
,	O	O
played	O	O
important	O
roles	O	O
in	O	O
the	O	O
defense	O
of	O	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
.	O	O

The	O	O
present	O	O
study	B-PROC
identified	O	O
genes	B-PROC
profiling	I-PROC
in	O	O
the	O	O
liver	B-ANAT
tissue	I-ANAT
of	O	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
in	O	O
sheep	B-LIVB
.	O	O

The	O	O
expression	B-PHYS
pattern	O
obtained	O	O
here	O	O
could	O	O
be	O	O
helpful	O	O
for	O	O
understanding	O	O
the	O	O
molecular	O
immunity	B-PHYS
mechanisms	O
of	O	O
host	B-PHYS
responses	I-PHYS
to	O	O
E	B-DISO
.	I-DISO

granulosus	I-DISO
infection	I-DISO
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
necessary	O	O
to	O	O
carry	O	O
out	O	O
further	O	O
studies	O	O
to	O	O
evalute	O	O
the	O	O
role	O	O
of	O	O
these	O	O
genes	O
.	O	O

Juicer	O
Provides	O
a	O	O
One	O	O
-	O	O
Click	O	O
System	O	O
for	O	O
Analyzing	B-PROC
Loop	B-PROC
-	I-PROC
Resolution	I-PROC
Hi	I-PROC
-	I-PROC
C	I-PROC
Experiments	I-PROC
Hi	B-PROC
-	I-PROC
C	I-PROC
experiments	I-PROC
explore	O	O
the	O	O
3D	O
structure	O
of	O	O
the	O	O
genome	O
,	O	O
generating	O
terabases	O
of	O
data	O
to	O	O
create	O	O
high	B-PROC
-	I-PROC
resolution	I-PROC
contact	O
maps	O
.	O	O

Here	O	O
,	O	O
we	O	O
introduce	O	O
Juicer	O
,	O	O
an	O	O
open	O
-	O
source	O
tool	O
for	O	O
analyzing	O	O
terabase	O
-	O
scale	O
Hi	O
-	O
C	O
datasets	O
.	O	O

Juicer	O
allows	O	O
users	B-LIVB
without	O
a	O	O
computational	O
background	O
to	O	O
transform	B-PROC
raw	O
sequence	O
data	O
into	O	O
normalized	O	O
contact	O
maps	O
with	O	O
one	O	O
click	O	O
.	O	O

Juicer	O
produces	O	O
a	O	O
hic	O
file	O
containing	O	O
compressed	O
contact	O
matrices	O
at	O	O
many	O	O
resolutions	O
,	O	O
facilitating	O	O
visualization	B-PHYS
and	O	O
analysis	B-PROC
at	O	O
multiple	O
scales	O
.	O	O

Structural	O
features	O
,	O	O
such	O	O
as	O	O
loops	B-ANAT
and	O	O
domains	B-PHYS
,	O	O
are	O	O
automatically	O
annotated	O
.	O	O

Juicer	O
is	O	O
available	O	O
as	O	O
open	O
source	O
software	B-OBJC
at	O	O
http	O	O
:	O	O
/	O	O
/	O	O
aidenlab	O	O
.	O	O

org	O	O
/	O	O
juicer	O	O
/	O	O
.	O	O

An	O	O
Encapsulation	B-PHEN
of	O	O
Gene	O
Signatures	O
for	O	O
Hepatocellular	B-DISO
Carcinoma	I-DISO
,	O	O
MicroRNA	B-CHEM
-	I-CHEM
132	I-CHEM
Predicted	O
Target	O
Genes	O
and	O	O
the	O	O
Corresponding	O
Overlaps	O
Previous	O	O
studies	B-PROC
have	O	O
demonstrated	O	O
that	O	O
microRNA	B-CHEM
-	I-CHEM
132	I-CHEM
plays	O	O
a	O	O
vital	O	O
part	O	O
in	O	O
and	O	O
is	O	O
actively	O	O
associated	O
with	O
several	O	O
cancers	B-DISO
,	O	O
with	O	O
its	O	O
tumor	B-PHYS
-	I-PHYS
suppressive	I-PHYS
role	I-PHYS
in	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
confirmed	O
.	O	O

The	O	O
current	O	O
study	B-PROC
employed	O	O
multiple	O
bioinformatics	O
techniques	O
to	O	O
establish	O	O
gene	O
signatures	O
for	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
,	O	O
microRNA	B-CHEM
-	I-CHEM
132	I-CHEM
predicted	O
target	O
genes	O
and	O	O
the	O	O
corresponding	O
overlaps	O
.	O	O

Various	O	O
assays	B-PROC
were	O	O
performed	O
to	O	O
explore	O	O
the	O	O
role	O
and	O	O
cellular	B-PHYS
functions	I-PHYS
of	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
in	O	O
HCC	B-DISO
and	O	O
a	O	O
successive	B-PROC
panel	I-PROC
of	O	O
tasks	O	O
was	O	O
completed	O
,	O	O
including	O	O
NLP	O
analysis	B-PROC
,	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
target	O
genes	O
prediction	O
,	O	O
comprehensive	O
analyses	B-PROC
(	O	O
gene	O
ontology	O
analysis	O
,	O	O
pathway	O
analysis	O
,	O	O
network	O
analysis	O
and	O	O
connectivity	O
analysis	B-PROC
)	O	O
,	O	O
and	O	O
analytical	O
integration	O
.	O	O

Later	O	O
,	O	O
HCC	B-DISO
-	O	O
related	O
and	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
-	O	O
related	O
potential	O
targets	O
,	O	O
pathways	B-PHYS
,	O	O
networks	B-PHYS
and	O	O
highlighted	O	O
hub	O
genes	O
were	O	O
revealed	O
as	O	O
well	O	O
as	O	O
those	O	O
of	O	O
the	O	O
overlapped	O
section	O
.	O	O

MiR	B-CHEM
-	I-CHEM
132	I-CHEM
was	O	O
effective	O
in	O	O
both	O	O
impeding	O
cell	B-PHYS
growth	I-PHYS
and	O	O
boosting	O
apoptosis	B-PHYS
in	O	O
HCC	B-DISO
cell	B-ANAT
lines	I-ANAT
.	O	O

A	O	O
total	O	O
of	O	O
fifty	O
-	O
nine	O
genes	O
were	O	O
obtained	O	O
from	O	O
the	O	O
analytical	O
integration	O
,	O	O
which	O	O
were	O	O
considered	O
to	O	O
be	O	O
both	O	O
HCC	B-DISO
-	O	O
and	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
-	O	O
related	O
.	O	O

Moreover	O	O
,	O	O
four	O	O
specific	O	O
pathways	B-PHYS
were	O	O
unveiled	O	O
in	O	O
the	O	O
network	O
analysis	O
of	O	O
the	O	O
overlaps	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

adherens	B-ANAT
junction	I-ANAT
,	O	O
VEGF	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
,	O	O
neurotrophin	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
,	O	O
and	O	O
MAPK	B-PHYS
signaling	I-PHYS
pathway	I-PHYS
.	O	O

The	O	O
tumor	B-PHYS
-	I-PHYS
suppressive	I-PHYS
role	I-PHYS
of	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
in	O	O
HCC	B-DISO
has	O	O
been	O	O
further	O	O
confirmed	O
by	O
in	O
vitro	O
experiments	B-PROC
.	O	O

Gene	O
signatures	O
in	O	O
the	O	O
study	B-PROC
identified	O	O
the	O	O
potential	O
molecular	O
mechanisms	O
of	O	O
HCC	B-DISO
,	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
and	O	O
their	O	O
established	O	O
associations	O
,	O	O
which	O	O
might	O	O
be	O	O
effective	O
for	O	O
diagnosis	B-PROC
,	O	O
individualized	O
treatments	B-PROC
and	O	O
prognosis	B-PROC
of	O	O
HCC	B-DISO
patients	B-LIVB
.	O	O

However	O	O
,	O	O
combined	O
detections	B-PROC
of	O	O
miR	B-CHEM
-	I-CHEM
132	I-CHEM
with	O	O
other	O	O
bio	B-PHYS
-	I-PHYS
indicators	I-PHYS
in	O	O
clinical	B-PROC
practice	I-PROC
and	O	O
further	O	O
in	O
vitro	O
experiments	B-PROC
are	O	O
needed	O
.	O	O

Prevalence	O
and	O	O
Hospital	B-PROC
Management	I-PROC
of	O	O
Amphotericin	B-CHEM
B	I-CHEM
Deoxycholate	I-CHEM
-Related	O	O
Toxicities	B-DISO
during	O	O
Treatment	B-PROC
of	O	O
HIV	B-DISO
-	O	O
Associated	B-DISO
Cryptococcal	B-DISO
Meningitis	I-DISO
in	O	O
South	B-GEOG
Africa	I-GEOG
We	O	O
aimed	O	O
to	O	O
establish	O	O
the	O	O
prevalence	O
of	O	O
amphotericin	B-CHEM
B	I-CHEM
deoxycholate	I-CHEM
(	O	O
AmBd	B-CHEM
)	O	O
-	O	O
related	O	O
toxicities	B-DISO
among	O	O
South	B-LIVB
African	I-LIVB
patients	B-LIVB
with	O	O
cryptococcosis	B-DISO
and	O	O
determine	O	O
adherence	O
to	O	O
international	O
recommendations	O
to	O	O
prevent	B-PROC
,	O	O
monitor	B-PROC
and	O	O
manage	O	O
AmBd	B-CHEM
-related	O	O
toxicities	B-DISO
.	O	O

Clinical	O
data	O
were	O	O
collected	O
from	O	O
cases	O
of	O	O
laboratory	B-DISO
-	I-DISO
confirmed	I-DISO
cryptococcosis	I-DISO
at	O	O
25	O	O
hospitals	B-OBJC
,	O	O
October	O	O
2012	O	O
-February	O	O
2013	O	O
.	O	O

Anemia	B-DISO
was	O	O
defined	O	O
as	O	O
hemoglobin	B-CHEM
(	O	O
Hb	B-CHEM
)	O	O
concentration	O
<	O	O
10	O	O
g	O	O
/	O	O
dl	O	O
,	O	O
hypokalemia	B-DISO
as	O	O
serum	B-PROC
potassium	I-PROC
(	O	O
K	B-PROC
)	O	O
<	O	O
3	O	O
.	O	O
4	O	O
mEq	O	O
/	O	O
L	O	O
and	O	O
nephrotoxicity	B-DISO
as	O	O
an	O	O
increase	O
in	O	O
serum	B-PROC
creatinine	I-PROC
(	O	O
Cr	B-PROC
)	O	O
to	O	O
>	O	O
1	O	O
.	O	O

1	O	O
times	O	O
the	O	O
upper	O
limit	O
of	O
normal	O
.	O	O

To	O	O
determine	O	O
adherence	B-DISO
to	O	O
toxicity	B-DISO
prevention	O
recommendations	O
,	O	O
we	O	O
documented	O	O
whether	O	O
baseline	O
Hb	B-PROC
,	O	O
K	B-PROC
and	O	O
Cr	B-PROC
tests	I-PROC
were	O	O
performed	O	O
,	O	O
whether	O	O
pre	B-DISO
-	I-DISO
emptive	I-DISO
hydration	I-DISO
and	O	O
IV	O	O
potassium	B-CHEM
chloride	I-CHEM
(	O	O
KCl	B-CHEM
)	O	O
was	O	O
administered	O
prior	O
to	O	O
80	O	O
%	O	O
and	O	O
60	O	O
%	O	O
of	O	O
AmBd	B-CHEM
doses	O
and	O	O
whether	O	O
daily	O
oral	B-CHEM
KCl	I-CHEM
supplementation	B-CHEM
was	O	O
given	O	O
≥60	O	O
%	O	O
of	O	O
the	O	O
time	O	O
.	O	O

To	O	O
determine	O	O
adherence	O
to	O	O
monitoring	B-PROC
recommendations	I-PROC
,	O	O
we	O	O
ascertained	O	O
whether	O	O
a	O	O
daily	O
fluid	B-PROC
chart	I-PROC
was	O	O
completed	O	O
,	O	O
Hb	B-CHEM
was	O	O
monitored	B-PROC
weekly	O
and	O	O
K	B-PROC
or	O	O
Cr	B-PROC
were	O	O
monitored	B-PROC
bi	O
-	O
weekly	O
.	O	O

Of	O	O
846	O	O
patients	B-LIVB
,	O	O
clinical	O
data	O
were	O	O
available	O	O
for	O	O
76	O	O
%	O	O
(	O	O
642	O	O
/	O	O
846	O	O
)	O	O
,	O	O
82	O	O
%	O	O
(	O	O
524	O	O
/	O	O
642	O	O
)	O	O
of	O	O
whom	O	O
received	O	O
AmBd	B-CHEM
.	O	O

Sixty	O	O
-	O	O
four	O	O
per	O	O
cent	O	O
(	O	O
n	O	O
=	O	O
333	O	O
)	O	O
had	O	O
documented	O	O
baseline	O
laboratory	B-PROC
tests	I-PROC
,	O	O
40	O	O
%	O	O
(	O	O
n	O	O
=	O	O
211	O	O
)	O	O
were	O	O
given	O	O
pre	B-DISO
-	I-DISO
emptive	I-DISO
hydration	I-DISO
and	O	O
14	O	O
%	O	O
(	O	O
n	O	O
=	O	O
72	O	O
)	O	O
and	O	O
19	O	O
%	O	O
(	O	O
n	O	O
=	O	O
101	O	O
)	O	O
received	O	O
intravenous	O
and	O	O
oral	B-CHEM
KCl	I-CHEM
.	O	O

While	O	O
on	O	O
AmBd	B-CHEM
,	O	O
88	O	O
%	O	O
(	O	O
n	O	O
=	O	O
452	O	O
)	O	O
had	O	O
fluid	B-PROC
monitoring	I-PROC
;	O	O
27	O	O
%	O	O
(	O	O
n	O	O
=	O	O
142	O	O
)	O	O
,	O	O
45	O	O
%	O	O
(	O	O
n	O	O
=	O	O
235	O	O
)	O	O
and	O	O
44	O	O
%	O	O
(	O	O
n	O	O
=	O	O
232	O	O
)	O	O
had	O	O
Hb	B-PHEN
,	O	O
K	B-PHEN
and	O	O
Cr	B-DISO
levels	I-DISO
monitored	B-PROC
.	O	O

Toxicities	B-DISO
developed	O	O
frequently	O
during	O	O
treatment	B-PROC
:	O	O
anemia	B-DISO
,	O	O
16	O	O
%	O	O
(	O	O
86	O	O
/	O	O
524	O	O
)	O	O
;	O	O
hypokalemia	B-DISO
,	O	O
43	O	O
%	O	O
(	O	O
226	O	O
/	O	O
524	O	O
)	O	O
and	O	O
nephrotoxicity	B-DISO
,	O	O
32	O	O
%	O	O
(	O	O
169	O	O
/	O	O
524	O	O
)	O	O
.	O	O

AmBd	B-CHEM
-related	O	O
toxicities	B-DISO
occurred	O
frequently	O
but	O	O
were	O	O
potentially	O	O
preventable	O	O
with	O	O
adequate	O
monitoring	B-PROC
,	O	O
supplemental	B-OBJC
fluid	I-OBJC
and	O	O
electrolyte	B-PROC
therapies	I-PROC
.	O	O

BJN	B-OBJC
Awards	I-OBJC
2016	O	O
:	O	O
IV	B-PROC
therapy	I-PROC
Claire	O	O
Rickard	O	O
Professor	B-LIVB
of	O	O
Nursing	B-LIVB
,	O	O
National	O	O
Health	O	O
and	O	O
Medical	O	O
Research	O	O
Council	O	O
(	O	O
NHMRC	O	O
)	O	O
Centre	B-LIVB
of	I-LIVB
Research	I-LIVB
Excellence	I-LIVB
in	O	O
Nursing	B-LIVB
,	O	O
Griffith	O	O
University	O	O
,	O	O
was	O	O
awarded	B-OBJC
second	O	O
place	O	O
in	O	O
the	O	O
BJN	B-OBJC
Awards	I-OBJC
2016	O	O
for	O	O
IV	B-PROC
Therapy	I-PROC
Nurse	B-LIVB
of	O	O
the	O	O
Year	O
.	O	O

Here	O	O
she	O	O
talks	O	O
about	O	O
the	O	O
she	O	O
has	O	O
done	O	O
to	O	O
be	O	O
recognised	O	O
in	O	O
this	O	O
field	B-PROC
.	O	O

Recent	O
blood	B-DISO
pressure	I-DISO
trends	O
in	O	O
adolescents	B-LIVB
from	O	O
China	B-GEOG
,	O	O
Korea	B-GEOG
,	O	O
Seychelles	B-GEOG
and	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O	O
1997	O	O
-	O	O
2012	O	O
Although	O	O
the	O	O
prevalence	O
of	O	O
obesity	B-DISO
is	O	O
increasing	O
worldwide	B-GEOG
,	O	O
secular	O
trends	O
in	O	O
elevated	B-DISO
blood	I-DISO
pressure	I-DISO
(	O	O
BP	B-DISO
)	O	O
differ	O	O
across	O	O
populations	B-LIVB
.	O	O

We	O	O
aimed	O
to	O	O
compare	O
recent	O
BP	B-DISO
and	O	O
obesity	B-DISO
trends	O
in	O	O
adolescents	B-LIVB
aged	B-PHYS
10	O	O
-	O	O
19	O	O
years	O
in	O	O
China	B-GEOG
,	O	O
Korea	B-GEOG
,	O	O
Seychelles	B-GEOG
and	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
.	O	O

Data	O
in	O	O
adolescents	B-LIVB
aged	B-PHYS
10	O	O
-	O	O
19	O	O
years	O
came	O	O
from	O	O
China	B-GEOG
(	O	O
1997	O	O
-	O	O
2011	O	O
,	O	O
n	O	O
=	O	O
8025	O	O
)	O	O
,	O	O
Korea	B-GEOG
(	O	O
1998	O	O
-	O	O
2012	O	O
,	O	O
n	O	O
=	O	O
10	O	O
119	O	O
)	O	O
,	O	O
Seychelles	B-GEOG
(	O	O
1998	O	O
-	O	O
2012	O	O
,	O	O
n	O	O
=	O	O
27	O	O
569	O	O
)	O	O
and	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
(	O	O
1999	O	O
-	O	O
2012	O	O
,	O	O
n	O	O
=	O	O
14	O	O
580	O	O
)	O	O
.	O	O

Elevated	B-DISO
BP	I-DISO
was	O	O
defined	O
as	O	O
SBP	B-PHYS
or	O	O
DBP	B-PHYS
equal	O	O
to	O	O
or	O	O
above	O	O
the	O	O
referent	O
sex	B-PHYS
,	O	O
age	B-PHYS
and	O	O
height	O
-	O
specific	O
95th	O
percentile	O
of	O
the	O
US	O
Fourth	O
Report	O
.	O	O

Overweight	B-DISO
and	O	O
obesity	B-DISO
were	O	O
defined	O
using	O	O
criteria	O
of	O	O
the	O	O
International	O
Obesity	O
Task	O
Force	O
.	O	O

Between	O	O
1997	O	O
-	O	O
2000	O	O
and	O	O
2011	O	O
-	O	O
2012	O	O
,	O	O
the	O	O
prevalence	O
of	O	O
elevated	B-DISO
BP	I-DISO
decreased	O
in	O	O
Korea	B-GEOG
and	O	O
did	O	O
not	O	O
change	O	O
substantially	O	O
in	O	O
China	B-GEOG
and	O	O
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
.	O	O

The	O	O
prevalence	O
of	O	O
elevated	B-DISO
BP	I-DISO
increased	O
in	O	O
Seychelles	B-GEOG
.	O	O

In	O	O
2011	O	O
-	O	O
2012	O	O
,	O	O
the	O	O
prevalence	O
of	O	O
elevated	B-DISO
BP	I-DISO
was	O	O
1	O	O
.	O	O

7	O	O
%	O	O
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O	O
3	O	O
.	O	O
8	O	O
%	O	O
in	O	O
China	B-GEOG
,	O	O
3	O	O
.	O	O
7	O	O
%	O	O
in	O	O
Korea	B-GEOG
and	O	O
14	O	O
.	O	O

3	O	O
%	O	O
in	O	O
Seychelles	B-GEOG
.	O	O

The	O	O
prevalence	O
of	O	O
overweight	B-DISO
and	O	O
obesity	B-DISO
increased	O
over	O
time	O
and	O	O
reached	O	O
in	O	O
2011	O	O
-	O	O
2012	O	O
41	O	O
.	O	O

2	O	O
%	O	O
in	O	O
the	O	O
United	B-GEOG
States	I-GEOG
of	I-GEOG
America	I-GEOG
,	O	O
18	O	O
.	O	O
6	O	O
%	O	O
in	O	O
China	B-GEOG
,	O	O
25	O	O
.	O	O
2	O	O
%	O	O
in	O	O
Korea	B-GEOG
and	O	O
27	O	O
.	O	O

4	O	O
%	O	O
in	O	O
Seychelles	B-GEOG
.	O	O

Elevated	B-DISO
BP	I-DISO
was	O	O
strongly	O	O
associated	O
with	O
obesity	B-DISO
in	O	O
all	O	O
countries	B-GEOG
.	O	O

Although	O	O
the	O	O
prevalence	O
of	O	O
obesity	B-DISO
increased	O
markedly	O
in	O	O
the	O	O
four	O	O
countries	B-GEOG
,	O	O
secular	O
BP	O
trends	O
in	O	O
adolescents	B-LIVB
differed	O	O
in	O	O
countries	B-GEOG
of	O	O
different	O
regions	B-GEOG
.	O	O

CT	B-PROC
-guided	O	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
of	O	O
abdominal	B-ANAT
and	O	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
with	O	O
the	O	O
coaxial	B-PROC
technique	I-PROC
using	O	O
MPR	B-PROC
images	O
To	O	O
demonstrate	O	O
the	O	O
advantages	O	O
of	O	O
CT	B-PROC
-guided	O	O
fine	B-PROC
-	I-PROC
needle	I-PROC
aspiration	I-PROC
(	O	O
FNA	B-PROC
)	O	O
of	O	O
abdominal	B-ANAT
and	O	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
with	O	O
the	O	O
coaxial	B-PROC
technique	I-PROC
using	O	O
MPR	B-PROC
images	O
.	O	O

The	O	O
study	O	O
included	O	O
retrospectively	B-DISO
50	O	O
patients	B-LIVB
who	O	O
underwent	O	O
CT	B-PROC
-guided	O	O
FNA	B-PROC
of	O	O
abdominal	B-ANAT
and	O	O
/	O	O
or	O	O
retroperitoneal	B-ANAT
small	O
lesion	O	O
(	O	O
<	O	O
30	O	O
mm	O	O
)	O	O
.	O	O

Patients	B-LIVB
with	O	O
suspected	O
lymphomas	B-DISO
or	O	O
sarcomas	B-DISO
were	O	O
excluded	O	O
.	O	O

Cytology	O
reports	O
were	O	O
the	O	O
reference	O
standard	O
.	O	O

The	O	O
cytology	O
was	O	O
diagnostic	O
in	O	O
48	O	O
/	O	O
50	O	O
biopsies	B-PROC
(	O	O
96	O	O
%	O	O
)	O	O
:	O	O
out	O	O
of	O	O
41	O	O
neoplastic	O
lesions	B-DISO
(	O	O
85	O	O
%	O	O
)	O	O
,	O	O
37	O	O
were	O	O
malignant	B-DISO
(	O	O
90	O	O
.	O	O
2	O	O
%	O	O
)	O	O
and	O	O
4	O	O
were	O	O
benign	O
(	O	O
9	O	O
.	O	O
8	O	O
%	O	O
)	O	O
;	O	O
7	O	O
out	O	O
of	O	O
48	O	O
were	O	O
non	B-DISO
-	I-DISO
neoplastic	I-DISO
(	O	O
14	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

No	B-DISO
procedural	B-DISO
complications	I-DISO
were	O	O
observed	O	O
(	O	O
0	O	O
%	O	O
)	O	O
.	O	O

By	O	O
using	O	O
MPR	B-PROC
images	O
there	O	O
is	O	O
an	O	O
effective	O
improvement	O
in	O	O
coaxial	O
CT	B-PROC
-guided	O	O
FNA	B-PROC
of	O	O
abdominal	B-ANAT
and	O	O
retroperitoneal	B-ANAT
small	O
lesions	B-DISO
.	O	O

A	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
on	O	O
the	O	O
efficacy	O
and	O	O
safety	B-PHEN
of	O	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
in	O	O
depression	B-DISO
therapy	B-PROC
in	O	O
comparison	O
with	O	O
selective	B-CHEM
serotonin	I-CHEM
reuptake	I-CHEM
inhibitors	I-CHEM
in	O	O
adults	B-LIVB
The	O	O
aim	O
of	O	O
the	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O
the	O	O
efficacy	O
and	O	O
safety	B-PHEN
of	O	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
and	O	O
selective	B-CHEM
serotonin	I-CHEM
reuptake	I-CHEM
inhibitors	I-CHEM
(	O	O
SSRIs	B-CHEM
)	O	O
in	O	O
the	O	O
treatment	O
of	O	O
depression	B-DISO
.	O	O

Databases	O
were	O	O
searched	O	O
for	O	O
studies	B-PROC
comparing	O	O
efficacy	O
and	O	O
/	O	O
or	O	O
safety	B-PHEN
of	O	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
with	O	O
SSRIs	B-CHEM
in	O	O
depression	B-DISO
from	O	O
1966	O	O
to	O	O
April	O
2015	O	O
.	O	O

Stata	B-OBJC
software	I-OBJC
was	O	O
used	O	O
for	O	O
statistical	B-PROC
analysis	I-PROC
.	O	O

Twenty	O	O
-	O	O
seven	O	O
studies	B-PROC
met	O	O
the	O	O
study	B-PROC
entry	O	O
criteria	O	O
.	O	O

A	O	O
total	O	O
of	O	O
3	O	O
,	O	O
126	O	O
patients	B-LIVB
with	O	O
depression	B-DISO
were	O	O
included	O	O
.	O	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
did	O	O
not	O	O
differ	O	O
from	O	O
SSRIs	B-CHEM
in	O	O
clinical	B-DISO
response	I-DISO
,	O	O
remission	B-DISO
,	O	O
and	O	O
mean	O
reduction	O
in	O	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
score	O
.	O	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
had	O	O
a	O	O
significantly	O
lower	O
rate	O	O
of	O	O
adverse	B-DISO
events	I-DISO
compared	O	O
to	O	O
SSRIs	B-CHEM
(	O	O
summary	O
relative	O
risk	O
:	O	O
0	O	O
.	O	O
77	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
:	O	O
0	O	O
.	O	O
70	O	O
,	O	O
0	O	O
.	O	O
84	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
00	O	O
)	O	O
and	O	O
had	O	O
fewer	O	O
withdrawals	O	O
due	O	O
to	O	O
adverse	B-DISO
events	I-DISO
.	O	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
had	O	O
superior	O	O
safety	B-PHEN
in	O	O
the	O	O
management	O	O
of	O	O
patients	B-LIVB
with	O	O
depression	B-DISO
.	O	O

Both	O	O
St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
and	O	O
SSRIs	B-CHEM
are	O	O
effective	O
in	O	O
treating	O
mild	O
-	O
to	O
-	O
moderate	O
depression	B-DISO
.	O	O

St	B-CHEM
John	I-CHEM
's	I-CHEM
wort	I-CHEM
extract	I-CHEM
is	O	O
safer	B-DISO
than	O	O
SSRIs	B-CHEM
.	O	O

Redistribution	O
of	O	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
and	O	O
calcium	B-CHEM
ions	I-CHEM
in	O	O
nerve	B-ANAT
terminals	I-ANAT
following	O	O
end	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
side	I-PROC
neurorrhaphy	I-PROC
:	O	O
ionic	B-PROC
imaging	I-PROC
analysis	I-PROC
by	O	O
TOF	B-PROC
-	I-PROC
SIMS	I-PROC
The	O	O
P	B-CHEM
/	I-CHEM
Q	I-CHEM
-	I-CHEM
type	I-CHEM
voltage	I-CHEM
-	I-CHEM
dependent	I-CHEM
calcium	I-CHEM
channel	I-CHEM
(	O	O
Cav2	B-CHEM
.	I-CHEM
1	I-CHEM
)	O	O
in	O	O
the	O	O
presynaptic	B-ANAT
membranes	I-ANAT
of	O	O
motor	B-ANAT
nerve	I-ANAT
terminals	B-ANAT
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
regulating	B-PHYS
Ca	I-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
transport	I-PHYS
,	O	O
resulting	O	O
in	O	O
transmitter	B-CHEM
release	O	O
within	O	O
the	O	O
nervous	B-ANAT
system	I-ANAT
.	O	O

The	O	O
recovery	B-PHYS
of	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
-dependent	O	O
signal	B-PHYS
transduction	I-PHYS
on	O	O
motor	B-ANAT
end	I-ANAT
plates	I-ANAT
(	O	O
MEPs	B-ANAT
)	O	O
and	O	O
innervated	B-PHYS
muscle	O
may	O	O
directly	O	O
reflect	O	O
nerve	B-PHYS
regeneration	I-PHYS
following	O	O
peripheral	B-DISO
nerve	I-DISO
injury	I-DISO
.	O	O

Although	O	O
the	O	O
functional	O	O
significance	O	O
of	O	O
calcium	B-CHEM
channels	I-CHEM
and	O	O
the	O	O
levels	O
of	O	O
Ca	B-PHYS
(	I-PHYS
2	I-PHYS
+	I-PHYS
)	I-PHYS
signalling	I-PHYS
in	O	O
nerve	B-PHYS
regeneration	I-PHYS
are	O	O
well	O	O
documented	O	O
,	O	O
little	O	O
is	O	O
known	O	O
about	O	O
calcium	B-PHYS
channel	I-PHYS
expression	I-PHYS
and	O	O
its	O	O
relation	O	O
with	O	O
the	O	O
dynamic	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
ion	I-CHEM
distribution	B-PHYS
at	O	O
regenerating	O	O
MEPs	B-ANAT
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
end	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
side	I-PROC
neurorrhaphy	I-PROC
(	O	O
ESN	B-PROC
)	O	O
was	O	O
performed	O	O
as	O	O
an	O	O
in	B-PROC
vivo	I-PROC
model	I-PROC
of	O	O
peripheral	B-DISO
nerve	I-DISO
injury	I-DISO
.	O	O

The	O	O
distribution	B-PHYS
of	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
at	O	O
regenerating	O	O
MEPs	B-ANAT
following	O	O
ESN	B-PROC
was	O	O
first	O	O
detected	O	O
by	O	O
time	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
flight	I-PROC
secondary	I-PROC
ion	I-PROC
mass	I-PROC
spectrometry	I-PROC
,	O	O
and	O	O
the	O	O
specific	O	O
localization	O
and	O	O
expression	B-PHYS
of	O	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
were	O	O
examined	O	O
by	O	O
confocal	B-PROC
microscopy	I-PROC
and	O	O
western	B-PROC
blotting	I-PROC
.	O	O

Compared	O	O
with	O	O
other	O	O
fundamental	O	O
ions	O	O
,	O	O
such	O	O
as	O	O
Na	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
and	O	O
K	B-CHEM
(	I-CHEM
+	I-CHEM
)	I-CHEM
,	O	O
dramatic	O	O
changes	O	O
in	O	O
the	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
were	O	O
detected	O	O
along	O	O
with	O	O
the	O	O
progression	O	O
of	O	O
MEP	B-ANAT
regeneration	B-PHYS
.	O	O

The	O	O
re	O	O
-	O	O
establishment	O	O
of	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
and	O	O
intensity	O	O
were	O	O
correlated	O	O
with	O	O
the	O	O
functional	B-DISO
recovery	I-DISO
of	O	O
muscle	O
in	O	O
ESN	B-PROC
rats	B-LIVB
.	O	O

Furthermore	O	O
,	O	O
the	O	O
re	O	O
-	O	O
clustering	O	O
of	O	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
channels	I-CHEM
after	O	O
ESN	B-PROC
at	O	O
the	O	O
nerve	B-ANAT
terminals	I-ANAT
corresponded	O	O
with	O	O
changes	O	O
in	O	O
the	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
distribution	B-PHYS
.	O	O

These	O	O
results	B-PHEN
indicated	O	O
that	O	O
renewal	O	O
of	O	O
the	O	O
Cav2	B-CHEM
.	I-CHEM

1	I-CHEM
distribution	B-PHYS
within	O	O
the	O	O
presynaptic	B-ANAT
nerve	I-ANAT
terminals	I-ANAT
may	O	O
be	O	O
necessary	O	O
for	O	O
initiating	O	O
a	O	O
proper	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
influx	B-PHYS
and	O	O
shortening	O	O
the	O	O
latency	B-DISO
of	O	O
muscle	B-PHYS
contraction	I-PHYS
during	O	O
nerve	B-PHYS
regeneration	I-PHYS
.	O	O

Chitinibacter	B-LIVB
fontanus	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O	O
isolated	O
from	O	O
a	O	O
spring	B-PHEN
A	O	O
bacterial	B-LIVB
strain	I-LIVB
,	O	O
designated	O	O
STM	B-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
,	O	O
was	O	O
isolated	O
from	O	O
a	O	O
spring	B-PHEN
in	O	O
Taiwan	B-GEOG
and	O	O
characterized	O
using	O	O
a	O	O
polyphasic	O
taxonomy	O
approach	O
.	O	O

Cells	B-ANAT
of	O	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
were	O	O
Gram	B-LIVB
-	I-LIVB
staining	I-LIVB
-	I-LIVB
negative	I-LIVB
,	I-LIVB
aerobic	I-LIVB
,	O	O
poly	B-CHEM
-	I-CHEM
	I-CHEM
-	I-CHEM
hydroxybutyrate	I-CHEM
-accumulating	O	O
,	O	O
motile	B-DISO
by	O	O
a	O	O
single	B-ANAT
polar	I-ANAT
flagellum	I-ANAT
,	O	O
rod	O
-	O
shaped	O
that	O	O
were	O	O
surrounded	O	O
by	O	O
a	O	O
thick	O	O
capsule	B-ANAT
and	O	O
forming	O	O
milky	O
white	O
colored	O
colonies	B-ANAT
.	O	O

Growth	B-PHYS
occurred	O	O
at	O	O
15	O	O
-	O	O
37	O	O
oC	O	O
(	O	O
optimum	O
,	O	O
25	O	O
-	O	O
30	O	O
°	O	O
C	O	O
)	O	O
,	O	O
at	O	O
pH	O
6	O	O
-	O	O
8	O	O
(	O	O
optimum	O
,	O	O
pH	O
6	O	O
-	O	O
7	O	O
)	O	O
and	O	O
with	O	O
0	O	O
-	O	O
2	O	O
%	O	O
NaCl	B-CHEM
(	O	O
optimum	O
,	O	O
0	O	O
-	O	O
1	O	O
%	O	O
)	O	O
.	O	O

Phylogenetic	B-PROC
analyses	I-PROC
based	O	O
on	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
showed	O	O
that	O	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
belonged	O	O
to	O	O
the	O	O
genus	O
Chitinibacter	B-LIVB
and	O	O
was	O	O
most	O	O
closely	O	O
related	O	O
to	O	O
Chitinibacter	B-LIVB
tainanensis	I-LIVB
S1	I-LIVB
T	I-LIVB
with	O	O
sequence	O
similarity	O	O
of	O	O
97	O	O
.	O	O

3	O	O
%	O	O
.	O	O

Strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
contained	O	O
summed	O
feature	O
3	O
(	O	O
comprising	O	O
C16	B-CHEM
:	I-CHEM
17c	I-CHEM
and	O	O
/	O	O
or	O	O
C16	B-CHEM
:	I-CHEM
16c	I-CHEM
)	I-CHEM
and	O	O
C	O	O
16	B-CHEM
:	I-CHEM
0	I-CHEM
as	O	O
the	O	O
predominant	O	O
f	O	O
atty	B-CHEM
acids	I-CHEM
.	I-CHEM

The	O	O
major	O	O
h	O	O
ydroxyl	B-CHEM
fatty	I-CHEM
acids	I-CHEM
were	O	O
C12	B-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
and	O	O
C16	B-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
.	O	O

The	O	O
polar	B-PROC
lipid	I-PROC
profile	I-PROC
consisted	O	O
of	O	O
phosphatidylethanolamine	B-CHEM
,	O	O
phosphatidylglycerol	B-CHEM
,	O	O
diphosphatidylglycerol	B-CHEM
,	O	O
an	O	O
uncharacterized	O
aminophospholipid	B-CHEM
,	O	O
an	O	O
uncharacterized	O
glycolipid	B-CHEM
and	O	O
an	O	O
uncharacterized	O
phospholipid	B-CHEM
.	O	O

The	O	O
major	O	O
isoprenoid	B-CHEM
quinone	I-CHEM
was	O	O
Q	B-CHEM
-	I-CHEM
8	I-CHEM
.	O	O

The	O	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O	O
the	O	O
genomic	B-CHEM
DNA	I-CHEM
was	O	O
52	O	O
.	O	O

4	O	O
mol	O	O
%	O	O
.	O	O

The	O	O
DNA	B-PROC
-	I-PROC
DNA	I-PROC
hybridization	I-PROC
value	O	O
for	O	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
with	O	O
Chitinibacter	B-LIVB
tainanensis	I-LIVB
S1	I-LIVB
T	I-LIVB
was	O	O
less	O	O
than	O	O
47	O	O
%	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
phylogenetic	B-PROC
inference	I-PROC
and	O	O
phenotypic	O
data	O
,	O	O
strain	B-LIVB
STM	I-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
should	O	O
be	O	O
classified	O
as	O	O
a	O	O
novel	O
species	O
,	O	O
for	O	O
which	O	O
the	O	O
name	O	O
Chitinibacter	B-LIVB
fontanus	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O	O
proposed	O	O
.	O	O

The	O	O
type	O	O
strain	B-LIVB
is	O	O
STM	B-LIVB
-	I-LIVB
7	I-LIVB
T	I-LIVB
(	O	O
=	B-LIVB
BCRC	I-LIVB
80923	I-LIVB
T	I-LIVB
=	I-LIVB
LMG	I-LIVB
29289	I-LIVB
T	I-LIVB
=	I-LIVB
KCTC	I-LIVB
42982	I-LIVB
T	I-LIVB
)	O	O
.	O	O

Functional	O
Impairment	O
in	O	O
Children	B-LIVB
With	O	O
Externalizing	B-DISO
Behavior	I-DISO
Disorders	I-DISO
:	O	O
Psychometric	B-PROC
Properties	O
of	O	O
the	O	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
in	O	O
a	O	O
German	B-GEOG
Clinical	B-OBJC
Sample	I-OBJC
To	O	O
examine	O	O
the	O	O
psychometric	B-PROC
properties	O
of	O	O
a	O	O
German	B-GEOG
adaptation	O	O
of	O	O
the	O	O
Weiss	O
Functional	O
Impairment	O
Rating	O
Scale	O
-	O
Parent	O
Report	O
(	O	O
WFIRS	O
-	O
P	O
)	O	O
in	O	O
a	O	O
clinical	B-OBJC
sample	I-OBJC
of	O	O
children	B-LIVB
(	O	O
4	O	O
-	O	O
12	O	O
years	O
)	O	O
with	O	O
externalizing	B-DISO
behavior	I-DISO
disorders	I-DISO
.	O	O

Data	O
were	O	O
collected	O
within	O	O
two	O	O
clinical	B-PROC
trials	I-PROC
(	O	O
N	O	O
=	O	O
264	O	O
)	O	O
.	O	O

Factorial	O
validity	O
,	O	O
reliability	O
,	O	O
and	O	O
divergent	O
validity	O
from	O	O
symptoms	B-DISO
of	O	O
ADHD	B-DISO
and	O	O
oppositional	B-DISO
defiant	I-DISO
disorder	I-DISO
(	O	O
ODD	B-DISO
)	O	O
were	O	O
assessed	O
.	O	O

Confirmatory	O
factor	O
analyses	O
revealed	O
that	O	O
a	O	O
bifactor	O
model	O
consistent	O
with	O
the	O	O
theoretical	O
assumption	O
of	O	O
a	O	O
general	O
construct	O
of	O	O
impairment	O
(	O	O
total	O	O
scale	O	O
)	O	O
and	O	O
additional	O
specific	O
factors	O
(	O	O
subscales	O	O
)	O	O
provided	O	O
satisfactory	O
data	O
fit	O
.	O	O

Model	O
-based	O	O
reliability	O
estimates	O
showed	O	O
that	O	O
both	O	O
the	O	O
general	O
construct	O
and	O	O
specific	O
factors	O
accounted	O	O
for	O	O
item	O	O
variance	O
.	O	O

Internal	O	O
consistencies	O
were	O	O
>	O	O
.70	O	O
,	O	O
part	O	O
-	O	O
whole	O	O
corrected	O	O
item	O	O
-	O	O
scale	O	O
correlations	O
mostly	O	O
>	O	O
.30	O	O
.	O	O

Correlations	O
between	O	O
the	O	O
WFIRS	O
-	O
P	O
Scales	O
and	O	O
ADHD	B-DISO
and	O	O
ODD	B-DISO
symptoms	B-DISO
were	O	O
low	O
to	O	O
moderate	O
.	O	O

The	O	O
results	O
support	O	O
the	O	O
factorial	O
validity	O
,	O	O
reliability	O
,	O	O
and	O	O
divergent	O
validity	O
of	O	O
the	O	O
WFIRS	O
-	O
P	O
.	O	O

The	O	O
role	O
of	O	O
sub	B-ANAT
-	I-ANAT
hippocampal	I-ANAT
versus	O	O
hippocampal	B-ANAT
regions	I-ANAT
in	O	O
bitemporal	B-DISO
lobe	I-DISO
epilepsies	I-DISO
We	O	O
aimed	O	O
at	O	O
better	O	O
delineating	O	O
the	O	O
functional	O
anatomical	B-PHYS
organization	I-PHYS
of	O	O
bitemporal	B-DISO
lobe	I-DISO
epilepsy	I-DISO
.	O	O

We	O	O
studied	O	O
the	O	O
epileptogenic	B-ANAT
zone	I-ANAT
(	O	O
EZ	B-ANAT
)	O	O
by	O	O
quantifying	O
the	O	O
epileptogenicity	O
of	O	O
brain	B-ANAT
structures	I-ANAT
explored	O	O
by	O	O
depth	B-DEVI
electrodes	I-DEVI
in	O	O
patients	B-LIVB
investigated	O	O
by	O	O
stereoelectroencephalography	B-PROC
(	O	O
SEEG	B-PROC
)	O	O
.	O	O

We	O	O
compared	O	O
15	O	O
patients	B-LIVB
with	O	O
bilateral	B-DISO
mesial	I-DISO
temporal	I-DISO
lobe	I-DISO
epilepsy	I-DISO
(	O	O
BTLE	B-DISO
)	O	O
and	O	O
15	O	O
patients	B-LIVB
with	O	O
unilateral	B-DISO
mesial	I-DISO
temporal	I-DISO
lobe	I-DISO
epilepsy	I-DISO
(	O	O
UTLE	B-DISO
)	O	O
.	O	O

This	O	O
quantification	O
was	O	O
performed	O	O
using	O	O
the	O	O
'	O	O
Epileptogenicity	O
Index	O
'	O	O
(	O	O
EI	O
)	O	O
.	O	O

Age	B-PHYS
at	O	O
epilepsy	B-DISO
onset	I-DISO
,	O	O
and	O	O
epilepsy	B-DISO
duration	O
,	O	O
were	O	O
not	B-DISO
statistically	I-DISO
different	I-DISO
in	O	O
both	O	O
groups	O
.	O	O

UTLE	B-DISO
patients	B-LIVB
more	O	O
frequently	O	O
displayed	O	O
maximal	O
epileptogenicity	O
in	O	O
hippocampal	B-ANAT
structures	I-ANAT
,	O	O
whereas	O	O
BTLE	B-DISO
patients	B-LIVB
had	O	O
maximal	O
values	O
in	O	O
subhippocampal	B-ANAT
areas	I-ANAT
(	O	O
entorhinal	B-ANAT
cortex	I-ANAT
,	O	O
temporal	B-ANAT
pole	I-ANAT
,	O	O
parahippocampal	O
cortex	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
different	O
organization	B-PHYS
of	O	O
the	O	O
EZ	B-ANAT
in	O	O
the	O	O
two	O	O
groups	O
.	O	O

BTLE	B-DISO
was	O	O
associated	O
with	O
more	O	O
involvement	O	O
of	O	O
subhippocampal	B-ANAT
regions	I-ANAT
,	O	O
a	O	O
result	O	O
in	O	O
agreement	O	O
with	O	O
known	O	O
anatomical	O
connections	O
between	O	O
the	O	O
two	O	O
temporal	B-ANAT
lobes	I-ANAT
.	O	O

What	O	O
can	O	O
the	O	O
Canadians	B-LIVB
and	O	O
Americans	B-LIVB
learn	B-PHYS
from	O	O
each	O	O
other	O	O
's	O	O
health	O
care	O
systems	O
?	O	O

Numerous	O	O
papers	O
have	O	O
been	O	O
written	O	O
comparing	O
the	O	O
Canadian	B-LIVB
and	O	O
US	B-GEOG
healthcare	O
systems	O
,	O	O
and	O	O
a	O	O
number	O	O
of	O	O
health	O
policy	O
experts	B-LIVB
have	O	O
recommended	O
that	O	O
the	O	O
Americans	B-LIVB
implement	O
their	O	O
single	B-PROC
-	I-PROC
payer	I-PROC
system	I-PROC
to	O	O
save	O	O
12	O	O
-	O	O
20	O	O
%	O	O
of	O	O
its	O	O
healthcare	O
expenditures	O
.	O	O

This	O	O
paper	O
is	O	O
different	O	O
in	O	O
that	O	O
it	O	O
assumes	O	O
that	O	O
neither	O	O
country	B-GEOG
will	O	O
undertake	O	O
a	O	O
significant	O
philosophic	O
or	O	O
structural	O
change	O
in	O	O
their	O	O
healthcare	O
system	O
,	O	O
but	O	O
there	O	O
are	O	O
lessons	O	O
to	O	O
be	O	O
learned	B-PHYS
that	O	O
are	O	O
inherent	O	O
in	O	O
one	O	O
that	O	O
could	O	O
be	O	O
a	O	O
major	O	O
breakthrough	O
for	O	O
the	O	O
other	O	O
.	O	O

Following	O	O
the	O	O
model	B-GEOG
in	O	O
Canada	B-GEOG
and	O	O
in	O	O
Western	B-GEOG
Europe	I-GEOG
,	O	O
the	O	O
USA	B-GEOG
could	O	O
implement	O
universal	O
health	B-PROC
insurance	I-PROC
so	O	O
that	O	O
the	O	O
32	O	O
.	O	O
0	O	O
million	O	O
(	O	O
2015	O	O
)	O	O
Americans	B-LIVB
still	O	O
uninsured	B-LIVB
would	O	O
have	O	O
at	O	O
least	O	O
minimal	O
coverage	O
when	O	O
incurring	O	O
medical	O
expenditures	O
.	O	O

Also	O	O
,	O	O
the	O	O
USA	B-GEOG
could	O	O
use	O	O
smart	B-OBJC
cards	I-OBJC
to	O	O
evaluate	B-PROC
eligibility	I-PROC
and	O	O
to	O	O
process	B-PHEN
health	B-PROC
insurance	I-PROC
claims	I-PROC
;	O	O
these	O	O
changes	O	O
resulting	O
in	O
an	O	O
estimated	O
15	O	O
%	O	O
reduction	O
in	O	O
US	B-GEOG
health	O
expenditures	O
without	O	O
adversely	O	O
effecting	O
access	O
or	O	O
quality	B-PROC
of	I-PROC
care	I-PROC
.	O	O

Such	O	O
a	O	O
strategy	O	O
would	O	O
result	O
in	O	O
the	O	O
eventual	O	O
loss	O
of	O	O
2	O	O
.	O	O
5	O	O
million	O	O
white	O
-	O
collar	O
jobs	O
at	O	O
hospitals	B-OBJC
,	O	O
physician	B-OBJC
offices	I-OBJC
and	O	O
insurance	O
companies	O
,	O	O
a	O	O
long	O
-	O
term	O
economic	O
gain	O
.	O	O

Only	O	O
a	O	O
few	O	O
would	O	O
agree	O	O
with	O	O
the	O	O
statement	O	O
that	O	O
Canada	B-GEOG
already	O	O
functions	O
with	O	O
a	O	O
multi	O
-	O
payer	O
reimbursement	O
system	O
as	O	O
evidenced	O	O
by	O	O
(	O	O
1	O	O
)	O	O
a	O	O
federal	O
-	O	O
provincial	B-GEOG
,	O	O
tax	O
-	O	O
supported	O
plan	B-PROC
,	O	O
administered	O	O
by	O	O
each	O	O
of	O	O
the	O	O
provinces	B-GEOG
,	O	O
providing	O	O
universal	O
coverage	O
for	O	O
hospital	B-OBJC
and	O	O
physician	B-PROC
services	I-PROC
and	O	O
(	O	O
2	O	O
)	O	O
roughly	O	O
60	O	O
%	O	O
of	O	O
its	O	O
residents	B-LIVB
receiving	O	O
employer	O
-	O
paid	O
health	B-PROC
insurance	I-PROC
benefits	O
,	O	O
underwritten	O	O
primarily	O	O
by	O	O
investor	O	O
-	O	O
owned	O	O
plans	O	O
,	O	O
that	O	O
are	O	O
less	O	O
than	O	O
effective	O
to	O	O
reimburse	O
for	O	O
pharmaceuticals	B-PROC
,	O	O
dental	B-PROC
and	O	O
other	O	O
healthcare	B-PROC
services	I-PROC
.	O	O

What	O	O
could	O	O
be	O	O
learned	O	O
from	O	O
the	O	O
USA	B-GEOG
and	O	O
particularly	O	O
from	O	O
Western	B-GEOG
European	I-GEOG
countries	I-GEOG
is	O	O
possibly	O	O
implementing	O
an	O	O
approach	O	O
,	O	O
whereby	O	O
at	O	O
least	O	O
upper	O
-	O
income	O
Canadians	B-LIVB
could	O	O
opt	O	O
out	O	O
of	O	O
their	O	O
federal	O
-	O	O
provincial	B-GEOG
plan	B-PROC
and	O	O
purchase	O	O
private	O
insurance	O
coverage	O
-	O	O
being	O	O
eligible	O	O
for	O	O
far	O	O
more	O	O
comprehensive	O	O
""""	O	O
private	O	O
""""	O	O
benefits	O	O
for	O	O
hospital	B-OBJC
,	O	O
physician	B-PROC
,	O	O
pharmaceutical	B-PROC
,	O	O
dental	B-PROC
and	O	O
other	O	O
healthcare	B-PROC
services	I-PROC
.	O	O

Aside	O	O
from	O	O
generating	O	O
billions	O	O
of	O	O
additional	O	O
needed	O	O
revenues	O
from	O	O
the	O	O
private	B-LIVB
sector	I-LIVB
,	O	O
it	O	O
could	O	O
(	O	O
1	O	O
)	O	O
help	O	O
eliminate	O
long	O	O
waits	O	O
for	O	O
non	O	O
-	O	O
emergent	O	O
physicians	O	O
'	O	O
care	O	O
by	O	O
appointing	O	O
newly	O	O
minted	O	O
specialists	B-LIVB
to	O	O
their	O	O
medical	B-LIVB
staffs	I-LIVB
;	O	O
(	O	O
2	O	O
)	O	O
offer	O	O
prompt	O
admissions	B-PROC
for	O	O
elective	B-DISO
cases	I-DISO
to	O	O
""""	O	O
private	B-OBJC
""""	O	O
wings	B-OBJC
of	I-OBJC
hospitals	I-OBJC
;	O	O
(	O	O
3	O	O
)	O	O
increase	O
available	O	O
funding	O
for	O	O
what	O	O
is	O	O
currently	O
an	O	O
undercapitalized	B-DISO
system	O
;	O	O
(	O	O
4	O	O
)	O	O
enhance	O
the	O	O
system	O	O
's	O	O
sluggish	B-DISO
operations	O
;	O	O
and	O	O
(	O	O
5	O	O
)	O	O
encourage	O	O
more	O	O
competition	O
among	O	O
various	O	O
providers	O	O
.	O	O

Although	O	O
such	O	O
a	O	O
two	O
-	O
tier	O
approach	O
,	O	O
such	O	O
as	O	O
available	O	O
in	O	O
the	O	O
USA	B-GEOG
and	O	O
elsewhere	O	O
,	O	O
is	O	O
politically	O	O
dead	O	O
on	O	O
arrival	O	O
in	O	O
Canada	B-GEOG
today	O	O
,	O	O
private	O
insurance	O
being	O	O
already	O	O
legal	O
and	O	O
commonly	O	O
available	O	O
there	O	O
.	O	O

Interestingly	O	O
,	O	O
this	O	O
recommended	O
solution	O	O
is	O	O
utilized	O	O
in	O	O
most	O	O
western	B-GEOG
European	I-GEOG
countries	I-GEOG
where	O	O
there	O	O
is	O	O
a	O	O
higher	O	O
percentagea	O
than	O	O
in	O	O
Canada	B-GEOG
of	O	O
public	O
(	O	O
versus	O	O
private	O	O
)	O	O
funding	O
of	O	O
their	O	O
total	O	O
health	O
expenditures	O
.	O	O

Because	O	O
of	O	O
various	O	O
vested	O	O
interests	O	O
,	O	O
attempts	O
to	O	O
implement	O
any	O	O
of	O	O
the	O	O
aforementioned	O	O
proposals	O	O
will	O	O
undoubtedly	O	O
result	O
in	O	O
considerable	O	O
political	O
rancor	B-PHYS
.	O	O

There	O	O
is	O	O
greater	O	O
likelihood	O	O
,	O	O
however	O	O
,	O	O
that	O	O
the	O	O
Canadians	B-LIVB
because	O	O
their	O	O
need	O	O
to	O	O
be	O	O
more	O	O
effective	O
and	O	O
efficient	O
in	O	O
their	O	O
delivery	B-PROC
of	I-PROC
care	I-PROC
,	O	O
and	O	O
their	O	O
overall	O	O
long	O
-	O
term	O
fiscal	O
outlook	O	O
will	O	O
agree	B-DISO
to	O	O
the	O	O
further	O	O
privatization	O
of	O	O
their	O	O
healthcare	O
system	O
before	O	O
the	O	O
Americans	B-LIVB
will	O	O
mandate	O	O
universal	O	O
access	O	O
,	O	O
use	O	O
the	O	O
smart	B-OBJC
card	I-OBJC
to	O	O
process	O	O
insurance	O
eligibility	O
and	O	O
claims	O	O
or	O	O
will	O	O
impose	O	O
price	O	O
controls	O
on	O	O
high	O	O
-	O	O
tech	O	O
services	O	O
and	O	O
on	O	O
pharmaceuticals	B-CHEM
.	O	O

Copyright	O	O
©	O	O
2016	O	O
John	O	O
Wiley	O	O
&	O	O
Sons	O	O
,	O	O
Ltd	O	O
.	O	O

Stressful	O
life	B-PHYS
events	I-PHYS
and	O	O
leucocyte	B-DISO
telomere	I-DISO
length	I-DISO
:	O	O
Do	O	O
lifestyle	B-PHYS
factors	I-PHYS
,	O	O
somatic	O
and	O	O
mental	B-PHYS
health	I-PHYS
,	O	O
or	O	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
mediate	O	O
this	O	O
relationship	O
?	O	O

Results	O	O
from	O	O
a	O	O
cohort	B-LIVB
of	O	O
Danish	B-LIVB
men	I-LIVB
born	B-PHYS
in	O	O
1953	O	O
Exposure	O
to	O
psychosocial	O
stress	B-DISO
is	O	O
associated	O
with	O
increased	O	O
risk	O
of	O	O
a	O	O
number	O	O
of	O	O
somatic	O
and	O	O
mental	B-DISO
disorders	I-DISO
with	O	O
relation	O
to	O	O
immune	B-ANAT
system	I-ANAT
functioning	O
.	O	O

We	O	O
aimed	O	O
to	O	O
explore	O	O
whether	O	O
stressful	O
events	O
in	O	O
early	O	O
and	O	O
recent	O	O
life	O
was	O	O
associated	O
with	O
leucocyte	B-DISO
telomere	I-DISO
length	I-DISO
(	O	O
TL	B-DISO
)	O	O
,	O	O
which	O	O
is	O	O
assumed	O	O
to	O	O
reflect	O	O
the	O	O
accumulated	B-DISO
burden	O	O
of	O	O
inflammation	B-DISO
and	O	O
oxidative	B-DISO
stress	I-DISO
occurring	O	O
during	O	O
the	O	O
life	O
course	O
.	O	O

We	O	O
specifically	O	O
aimed	O	O
to	O	O
address	O
whether	O	O
childhood	O
constitutes	O	O
a	O	O
sensitive	O
period	O
and	O	O
how	O	O
much	O	O
of	O	O
the	O	O
relation	O
between	O	O
stressful	O
life	O	O
events	O	O
and	O	O
TL	B-DISO
is	O	O
mediated	O	O
through	O	O
somatic	O
and	O	O
mental	B-PHYS
health	I-PHYS
,	O	O
lifestyle	O
,	O	O
and	O	O
markers	B-PHYS
of	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
inflammation	I-DISO
.	O	O

A	O	O
cohort	B-LIVB
of	O	O
Danish	B-LIVB
men	I-LIVB
born	B-PHYS
in	O	O
1953	O	O
has	O	O
been	O	O
followed	O	O
since	O	O
birth	B-PHYS
in	O	O
the	O	O
Metropolit	B-LIVB
Cohort	I-LIVB
.	O	O

These	O	O
men	B-LIVB
underwent	O	O
a	O	O
health	B-PROC
examination	I-PROC
including	O	O
blood	B-PROC
sampling	I-PROC
in	O	O
2010	O	O
and	O	O
a	O	O
subset	O	O
of	O	O
324	O	O
also	O	O
had	O	O
a	O	O
quantitative	B-PROC
PCR	I-PROC
-	I-PROC
based	I-PROC
measurement	I-PROC
of	O	O
TL	B-DISO
.	O	O

The	O	O
relation	O
between	O	O
stressful	O
life	B-PHYS
events	I-PHYS
and	O	O
TL	B-DISO
was	O	O
analysed	O	O
using	O	O
structural	B-PROC
equation	I-PROC
modelling	I-PROC
,	O	O
which	O	O
also	O	O
provided	O	O
an	O	O
estimate	O
of	O	O
the	O	O
proportion	O
of	O	O
the	O	O
total	O	O
effect	O
mediated	O	O
by	O	O
somatic	O
and	O	O
mental	B-PHYS
health	I-PHYS
(	O	O
cardiovascular	B-DISO
disease	I-DISO
,	O	O
body	B-DISO
mass	I-DISO
and	O	O
depressive	B-DISO
mood	I-DISO
)	O	O
,	O	O
lifestyle	B-PHYS
factors	I-PHYS
,	O	O
and	O	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
(	O	O
C	B-CHEM
-	I-CHEM
reactive	I-CHEM
protein	I-CHEM
(	O	O
CRP	B-CHEM
)	O	O
,	O	O
interleukin	B-CHEM
(	I-CHEM
IL	I-CHEM
)	I-CHEM
-	I-CHEM
6	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O	O
.	O	O

Total	O
number	O
of	O	O
stressful	O
events	O
experienced	B-PHEN
during	O
the	O	O
life	O
course	O
was	O	O
not	O	O
associated	O
with	O
TL	B-DISO
.	O	O

In	O	O
terms	O	O
of	O	O
sensitive	O
periods	O
,	O	O
we	O	O
found	O	O
that	O	O
number	O
of	O	O
stressful	O
events	O
in	O	O
childhood	O
was	O	O
associated	O
with	O
shorter	B-DISO
TL	I-DISO
(	O	O
βper	O	O
number	O	O
stressful	O
events	O
in	O	O
childhood	O
=	O	O
-0	O	O
.	O	O

02	O	O
(	O	O
SE	O	O
=	O	O
-	O	O
0	O	O
.	O	O
02	O	O
)	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

This	O	O
relation	O
was	O	O
particularly	O	O
strong	O	O
for	O	O
being	O	O
placed	O	O
away	O	O
from	O	O
home	O
(	O	O
β	O	O
=	O	O
-	O	O
0	O	O
.	O	O
16	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
000	O	O
)	O	O
.	O	O

Thirty	O	O
percent	O	O
of	O	O
the	O	O
total	O	O
effect	O
of	O	O
stressful	O
events	O
in	O	O
childhood	O
on	O	O
TL	B-DISO
was	O	O
mediated	O	O
by	O	O
the	O	O
included	O	O
variables	O
,	O	O
with	O	O
the	O	O
largest	O	O
proportion	O
being	O	O
mediated	O	O
through	O	O
depressive	B-DISO
mood	I-DISO
(	O	O
16	O	O
%	O	O
)	O	O
and	O	O
CRP	B-CHEM
(	O	O
9	O	O
%	O	O
)	O	O
.	O	O

This	O	O
study	O	O
suggests	O	O
that	O	O
stressful	O
events	O
in	O	O
childhood	O
are	O	O
associated	O
with	O
shorter	B-DISO
TL	I-DISO
in	O	O
middle	B-LIVB
-	I-LIVB
aged	I-LIVB
men	I-LIVB
and	O	O
that	O	O
part	O	O
of	O	O
this	O	O
relation	O
is	O	O
explained	O	O
by	O	O
depressive	B-DISO
mood	I-DISO
and	O	O
low	B-DISO
grade	I-DISO
inflammation	I-DISO
.	O	O

Description	O
of	O	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
gen	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	O	O
isolated	O
from	O	O
coastal	O
sediment	O
,	O	O
proposal	O
of	O	O
Marinilabiliales	B-LIVB
ord	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB

and	O	O
transfer	O
of	O	O
Marinilabiliaceae	B-LIVB
,	O	O
Prolixibacteraceae	B-LIVB
and	O	O
Marinifilaceae	B-LIVB
to	O	O
the	O	O
order	O
Marinilabiliales	B-LIVB
A	O	O
Gram	B-LIVB
-	I-LIVB
stain	I-LIVB
-	I-LIVB
negative	I-LIVB
,	O	O
facultatively	B-LIVB
anaerobic	I-LIVB
,	O	O
moderately	B-LIVB
halophilic	I-LIVB
,	O	O
filamentous	O
,	O	O
non	B-LIVB
-	I-LIVB
motile	I-LIVB
bacterium	I-LIVB
,	O	O
designated	O
FA102	B-LIVB
T	I-LIVB
,	O	O
was	O	O
isolated	O
from	O	O
marine	B-PHEN
sediment	I-PHEN
of	O	O
the	O	O
coast	O
of	O	O
Weihai	B-GEOG
,	I-GEOG
China	I-GEOG
.	O	O

Phylogenetic	B-PROC
analysis	I-PROC
based	O
on	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	I-CHEM
sequences	I-CHEM
showed	O
that	O	O
strain	O
FA102	B-LIVB
T	I-LIVB
formed	O	O
a	O	O
distinct	O
evolutionary	B-PHYS
lineage	O
within	O	O
the	O	O
family	O
Marinifilaceae	B-LIVB
and	O	O
its	O	O
closest	B-DISO
relative	I-DISO
was	O	O
Marinifilum	B-LIVB
fragile	I-LIVB
JCM	I-LIVB
15579	I-LIVB
T	I-LIVB
(	O	O
93	O	O
.	O	O
2	O	O
%	O	O
sequence	O
similarity	O
)	O	O
.	O	O

The	O	O
DNA	B-CHEM
G	O
+	O
C	O
content	O
of	O	O
the	O	O
novel	O
strain	O
was	O	O
36	O	O
.	O	O

5	O	O
mol	O	O
%	O	O
.	O	O

The	O	O
predominant	O
cellular	B-ANAT
fatty	B-CHEM
acids	I-CHEM
and	O	O
respiratory	O
quinone	B-CHEM
were	O	O
iso	B-CHEM
-	I-CHEM
C15	I-CHEM
:	I-CHEM
0	I-CHEM
and	O	O
iso	B-CHEM
-	I-CHEM
C15	I-CHEM
:	I-CHEM
0	I-CHEM
3	I-CHEM
-	I-CHEM
OH	I-CHEM
,	O	O
and	O	O
MK	B-CHEM
-	I-CHEM
7	I-CHEM
,	O	O
respectively	O
.	O	O

On	O	O
the	O	O
basis	O
of	O	O
the	O	O
phylogenetic	O
,	O	O
phenotypic	B-PHYS
and	O	O
physiological	O
data	O
,	O	O
strain	O
FA102	B-LIVB
T	I-LIVB
represents	O
a	O	O
novel	O
genus	O
and	O	O
species	O
,	O	O
for	O	O
which	O	O
the	O	O
name	O	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
gen	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
,	I-LIVB
sp	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
is	O	O
proposed	O
.	O	O

The	O	O
type	O
strain	O
of	O	O
Ancylomarina	B-LIVB
subtilis	I-LIVB
is	O	O
FA102	B-LIVB
T	I-LIVB
(	O	O
=	O	O
KCTC	B-LIVB
42257	I-LIVB
T	I-LIVB
=	O	O
DSM	B-LIVB
28825	I-LIVB
T	I-LIVB
=	O	O
CICC	B-LIVB
10902	I-LIVB
T	I-LIVB
)	O	O
.	O	O

Furthermore	O	O
,	O	O
a	O	O
new	O
order	O
named	O	O
Marinilabiliales	B-LIVB
is	O	O
proposed	O
to	O	O
accommodate	B-DISO
three	O	O
families	O
previously	O
classified	O
in	O	O
the	O	O
order	O
Bacteroidales	B-LIVB
.	O	O

Marinilabiliales	B-LIVB
ord	I-LIVB
.	I-LIVB

nov	I-LIVB
.	I-LIVB
encompasses	O	O
the	O	O
families	O
Marinilabiliaceae	B-LIVB
,	O	O
Prolixibacteraceae	B-LIVB
and	O	O
Marinifilaceae	B-LIVB
.	O	O

Treatment	B-PROC
for	O	O
Rheumatoid	B-DISO
Arthritis	I-DISO
and	O	O
Risk	B-DISO
of	O	O
Alzheimer	B-DISO
's	I-DISO
Disease	I-DISO
:	O	O
A	O	O
Nested	B-PROC
Case	I-PROC
-	I-PROC
Control	I-PROC
Analysis	I-PROC
It	O	O
is	O	O
increasingly	O
becoming	O	O
accepted	O
that	O	O
inflammation	B-DISO
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
(	O	O
AD	B-DISO
)	O	O
,	O	O
as	O	O
several	O
immune	B-ANAT
-related	O	O
genes	O
have	O	O
been	O	O
associated	O
with	O
AD	B-DISO
.	O	O

Among	O	O
these	O	O
is	O	O
tumor	B-CHEM
necrosis	I-CHEM
factor	I-CHEM
(	I-CHEM
TNF	I-CHEM
)	I-CHEM
-	I-CHEM
α	I-CHEM
,	O	O
a	O	O
proinflammatory	B-CHEM
cytokine	I-CHEM
known	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
autoimmune	B-DISO
disorders	I-DISO
,	O	O
including	O	O
rheumatoid	B-DISO
arthritis	I-DISO
(	O	O
RA	B-DISO
)	O	O
.	O	O

Although	O	O
AD	B-DISO
and	O	O
RA	B-DISO
appear	O	O
to	O	O
involve	O	O
similar	O
pathological	B-DISO
mechanisms	I-DISO
through	O	O
the	O	O
production	B-PHEN
of	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
,	I-CHEM
the	O	O
relationship	O
between	O	O
AD	B-DISO
and	O	O
RA	B-DISO
remains	O	O
unknown	O
.	O	O

To	O	O
determine	O	O
the	O	O
relative	O
risk	O
of	O	O
AD	B-DISO
among	O	O
RA	B-DISO
patients	B-LIVB
and	O	O
non	O	O
-	O	O
RA	B-DISO
patients	B-LIVB
,	O	O
and	O	O
whether	O	O
anti	B-PROC
-	I-PROC
TNF	I-PROC
therapy	I-PROC
for	O	O
RA	B-DISO
was	O	O
associated	O
with	O
a	O	O
lower	O
risk	B-DISO
of	O	O
AD	B-DISO
in	O	O
RA	B-DISO
patients	B-LIVB
.	O	O

We	O	O
performed	O	O
a	O	O
nested	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
of	O	O
more	O	O
than	O	O
8	O	O
.	O	O
5	O	O
million	O	O
commercially	O	O
insured	O
adults	B-LIVB
(	O	O
aged	O	O
≥18	O	O
years	O	O
)	O	O
in	O	O
all	O	O
50	O	O
US	B-GEOG
states	I-GEOG
,	O	O
Puerto	B-GEOG
Rico	I-GEOG
,	O	O
and	O	O
US	B-GEOG
Virgin	I-GEOG
Islands	I-GEOG
in	O	O
the	O	O
Verisk	O
Health	O
claims	O
database	O
.	O	O

We	O	O
derived	O	O
a	O	O
sub	B-LIVB
-	I-LIVB
cohort	I-LIVB
of	O	O
subjects	O	O
with	O	O
a	O	O
diagnosis	B-DISO
of	O	O
RA	B-DISO
(	O	O
controls	B-LIVB
)	O	O
,	O	O
or	O	O
RA	B-DISO
and	O	O
AD	B-DISO
(	O	O
cases	O
)	O	O
,	O	O
matching	B-PROC
cases	O
and	O	O
controls	O	O
based	O	O
on	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
exposure	B-PROC
assessment	I-PROC
period	I-PROC
,	O	O
and	O	O
methotrexate	B-PROC
treatment	I-PROC
.	O	O

We	O	O
also	O	O
assessed	B-PROC
relative	I-PROC
risk	I-PROC
of	O	O
AD	B-DISO
following	O	O
exposure	O
to	O
standard	O
RA	B-DISO
therapies	B-PROC
,	O	O
including	O	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
(	O	O
infliximab	B-CHEM
,	O	O
adalimumab	B-CHEM
,	O	O
etanercept	B-CHEM
)	O	O
,	O	O
methotrexate	B-CHEM
,	O	O
prednisone	B-CHEM
,	O	O
sulfasalazine	B-CHEM
,	O	O
and	O	O
rituximab	B-CHEM
.	O	O

Odds	O
ratios	O
were	O	O
adjusted	O	O
for	O	O
comorbidities	O
,	O	O
including	O	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
,	O	O
diabetes	B-DISO
mellitus	I-DISO
,	O	O
and	O	O
peripheral	B-DISO
vascular	I-DISO
disease	I-DISO
.	O	O

AD	B-DISO
was	O	O
more	O	O
prevalent	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
among	O	O
RA	B-DISO
patients	B-LIVB
(	O	O
0	O	O
.	O	O
79	O	O
%	O	O
)	O	O
than	O	O
among	O	O
those	O	O
without	O
RA	B-DISO
(	O	O
0	O	O
.	O	O
11	O	O
%	O	O
)	O	O
.	O	O

Chronic	B-DISO
conditions	I-DISO
such	O	O
as	O	O
coronary	B-DISO
artery	I-DISO
disease	I-DISO
(	O	O
odds	O
ratio	O
[	O	O
OR	O
]	O	O
1	O	O
.	O	O
48	O	O
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
1	O	O
.	O	O
04	O	O
-	O	O
2	O	O
.	O	O
05	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
)	O	O
,	O	O
diabetes	B-DISO
(	O	O
OR	O
1	O	O
.	O	O

86	O	O
;	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
32	O	O
-	O	O
2	O	O
.	O	O
62	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0004	O	O
)	O	O
,	O	O
and	O	O
peripheral	B-DISO
vascular	I-DISO
disease	I-DISO
(	O	O
OR	O
1	O	O
.	O	O
61	O	O
;	O	O
95	O	O
%	O	O
CI	O
1	O	O
.	O	O
06	O	O
-	O	O
2	O	O
.	O	O
43	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
significantly	O	O
increased	O	O
the	O	O
relative	O
risk	O
of	O	O
AD	B-DISO
among	O	O
RA	B-DISO
patients	B-LIVB
.	O	O

Exposure	O
to	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
as	O	O
a	O	O
class	O
,	O	O
but	O	O
not	O	O
other	O	O
immunosuppressive	B-CHEM
drugs	I-CHEM
studied	O	O
,	O	O
was	O	O
associated	O
with	O
lowered	O
risk	B-DISO
of	O	O
AD	B-DISO
among	O	O
RA	B-DISO
patients	B-LIVB
(	O	O
unadjusted	O	O
OR	O
0	O	O
.	O	O
44	O	O
;	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
22	O	O
-	O	O
0	O	O
.	O	O
87	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
;	O	O
adjusted	O	O
OR	O
0	O	O
.	O	O
45	O	O
;	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
23	O	O
-	O	O
0	O	O
.	O	O
90	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O	O
that	O	O
of	O	O
the	O	O
three	O	O
anti	B-CHEM
-	I-CHEM
TNF	I-CHEM
agents	I-CHEM
studied	O	O
,	O	O
only	O	O
etanercept	B-CHEM
(	O	O
unadjusted	O	O
OR	O
,	O	O
0	O	O
.	O	O

33	O	O
;	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
08	O	O
-	O	O
0	O	O
.	O	O
94	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
03	O	O
;	O	O
adjusted	O	O
OR	O
0	O	O
.	O	O
30	O	O
;	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
08	O	O
-	O	O
0	O	O
.	O	O
89	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
was	O	O
associated	O
with	O
a	O	O
decreased	O
risk	B-DISO
of	O	O
AD	B-DISO
in	O	O
RA	B-DISO
patients	B-LIVB
.	O	O

There	O	O
is	O	O
an	O	O
increased	O
risk	B-DISO
of	O	O
AD	B-DISO
in	O	O
the	O	O
studied	O	O
RA	B-DISO
population	O
.	O	O

The	O	O
relative	O
risk	O
of	O	O
AD	B-DISO
among	O	O
RA	B-DISO
subjects	O	O
was	O	O
lowered	O
in	O	O
those	O	O
exposed	O
to	O
etanercept	B-CHEM
.	O	O

Anti	B-PROC
-	I-PROC
TNF	I-PROC
therapy	I-PROC
with	O	O
etanercept	B-CHEM
shows	O	O
promise	O
as	O	O
a	O	O
potential	O
treatment	B-PROC
for	O	O
AD	B-DISO
.	O	O

Health	O
-	O
Related	O
Quality	O
of	O
Life	O
in	O	O
Patients	B-LIVB
With	O	O
α1	B-DISO
Antitrypsin	I-DISO
Deficency	I-DISO
:	O	O
A	O	O
Cross	B-PROC
Sectional	I-PROC
Study	I-PROC
Measures	O	O
of	O	O
health	O
related	O
quality	O
of	O
life	O
(	O	O
HRQoL	O
)	O	O
in	O	O
patients	B-LIVB
with	O	O
α1	B-DISO
-	I-DISO
antitrypsin	I-DISO
deficiency	I-DISO
(	O	O
AATD	B-DISO
)	O	O
can	O	O
help	O	O
to	O	O
determine	O	O
the	O	O
impact	O
of	O	O
the	O	O
disease	B-DISO
and	O	O
provide	O	O
an	O	O
important	O	O
insight	O	O
into	O	O
the	O	O
intervention	B-PROC
outcomes	O
.	O	O

There	O	O
is	O	O
few	O	O
data	O
regarding	O	O
this	O	O
issue	O	O
in	O	O
the	O	O
literature	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
assess	O
the	O	O
relationship	O
between	O	O
HRQoL	O
and	O	O
gender	B-PHYS
,	O	O
functional	O
parameters	B-DISO
and	O	O
history	B-DISO
of	O	O
hospitalizations	B-PROC
in	O	O
patients	B-LIVB
with	O	O
AATD	B-DISO
.	O	O

This	O	O
is	O	O
a	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
of	O	O
26	O	O
patients	B-LIVB
with	O	O
severe	O
AATD	B-DISO
recruited	O	O
in	O	O
the	O	O
pulmonology	O
outpatient	B-OBJC
clinic	I-OBJC
at	O	O
a	O	O
tertiary	B-OBJC
care	I-OBJC
medical	I-OBJC
center	I-OBJC
.	O	O

Social	O
-	O
demographic	O
,	O	O
clinical	O
and	O	O
functional	O
parameters	B-DISO
were	O	O
recorded	O	O
and	O	O
HRQoL	O
was	O	O
assessed	O
with	O	O
the	O	O
Portuguese	B-LIVB
version	O
of	O	O
the	O	O
medical	B-PROC
outcome	I-PROC
study	I-PROC
short	O
form	O
-	O
36	O
(	O
SF	O
-	O
36	O
)	O
self	O
-	O
administered	O
questionnaire	O
.	O	O

Older	B-LIVB
patients	B-LIVB
,	O	O
females	B-LIVB
and	O	O
patients	B-LIVB
with	O	O
at	O	O
least	O	O
one	O	O
hospitalization	B-PROC
in	O	O
the	O	O
previous	O	O
year	O	O
due	O	O
to	O	O
respiratory	B-DISO
disease	I-DISO
had	O	O
statistical	O	O
lower	O
scores	O
in	O	O
some	O	O
dimensions	O
of	O	O
the	O	O
SF	O
-	O
36	O
questionnaire	O
.	O	O

Superior	O
FEV1	B-DISO
and	O	O
higher	O
distance	O
mark	B-OBJC
in	O	O
the	O	O
6	O	O
-	O	O
min	O	O
walking	B-PROC
test	I-PROC
distance	I-PROC
influenced	O
positively	B-DISO
several	O	O
dimensions	O
of	O	O
the	O	O
questionnaire	O
.	O	O

Higher	O
scores	O
in	O	O
the	O	O
mMRC	O
scale	O
influenced	O
negatively	B-DISO
the	O	O
HRQoL	O
.	O	O

These	O	O
data	O
suggests	O	O
that	O	O
older	B-LIVB
and	O	O
female	B-LIVB
patients	B-LIVB
with	O	O
AATD	B-DISO
have	O	O
worse	B-DISO
HRQoL	O
.	O	O

Hospitalizations	B-PROC
and	O	O
functional	O
markers	O	O
of	O	O
respiratory	B-DISO
disease	I-DISO
progression	B-DISO
influenced	O
negatively	B-DISO
the	O	O
HRQoL	O
,	O	O
suggesting	O	O
that	O	O
the	O	O
SF	O
-	O
36	O
questionnaire	O
could	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
outcome	O
for	O	O
AATD	B-DISO
patients	B-LIVB
with	O	O
lung	B-ANAT
involvement	O
.	O	O

Disparities	O
in	O	O
treatment	O
and	O	O
survival	O
for	O	O
women	B-LIVB
with	O	O
endometrial	B-DISO
cancer	I-DISO
:	O	O
A	O	O
contemporary	O
national	B-PROC
cancer	I-PROC
database	I-PROC
registry	I-PROC
analysis	I-PROC
The	O	O
study	O	O
aim	O	O
was	O	O
to	O	O
identify	O	O
contemporary	O
socioeconomic	O
,	O	O
racial	O
,	O	O
ethnic	O
,	O	O
and	O	O
facility	O
-	O
related	O
factors	O
associated	O
with	O
stage	O
at	O
diagnosis	O
,	O	O
receipt	O
of	O	O
cancer	B-DISO
treatment	O
,	O	O
and	O	O
survival	O
in	O	O
women	B-LIVB
with	O	O
endometrial	B-DISO
cancer	I-DISO
(	O	O
EC	B-DISO
)	O	O
.	O	O

Women	B-LIVB
diagnosed	O	O
with	O	O
EC	B-DISO
between	O	O
1998	O	O
and	O	O
2010	O	O
were	O	O
identified	O	O
from	O	O
the	O	O
National	O
Cancer	O
Database	O
.	O	O

Variables	O
associated	O
with	O
the	O	O
outcomes	O
of	O	O
interest	O	O
were	O	O
assessed	O
using	O	O
multivariable	O
Cox	O
proportional	O
hazards	O
and	O	O
logistic	B-PROC
regression	I-PROC
.	O	O

Among	O	O
228	O	O
,	O	O
511	O	O
women	B-LIVB
identified	O
,	O	O
the	O	O
percentage	O
of	O	O
blacks	B-LIVB
with	O	O
stage	O
IIIC	O
/	O
IV	O
disease	O
at	O
diagnosis	O
was	O	O
nearly	O	O
twice	O	O
that	O	O
of	O	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
whites	I-LIVB
(	O	O
17	O	O
.	O	O
8	O	O
%	O	O
vs	O	O
9	O	O
.	O	O
8	O	O
%	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Patients	B-LIVB
with	O	O
advanced	O
disease	O
who	O	O
were	O	O
insured	O	O
with	O	O
Medicare	O
were	O	O
less	O	O
likely	O	O
to	O	O
receive	O
standard	B-PROC
-	I-PROC
of	I-PROC
-	I-PROC
care	I-PROC
postoperative	B-PROC
radiotherapy	I-PROC
and	O	O
/	O	O
or	O	O
chemotherapy	B-PROC
than	O	O
those	O	O
with	O	O
private	O
insurance	O
(	O	O
odds	O
ratio	O
:	O	O
OR	O
0	O	O
.	O	O
80	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
as	O	O
were	O	O
those	O	O
residing	O
in	O	O
the	O	O
South	O
(	O	O
reference	O
)	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
Northeast	O
,	O	O
Atlantic	B-GEOG
,	O	O
Great	B-GEOG
Lakes	I-GEOG
,	O	O
and	O	O
Midwest	B-GEOG
regions	I-GEOG
(	O	O
OR	O
1	O	O
.	O	O

3	O	O
-	O	O
1	O	O
.	O	O
7	O	O
,	O	O
all	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Those	O	O
residing	O
in	O	O
the	O	O
Mountain	B-GEOG
region	I-GEOG
were	O	O
even	O	O
less	O	O
likely	O	O
to	O	O
receive	O
appropriate	O	O
treatment	O
(	O	O
OR	O
0	O	O
.	O	O

7	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Five	O	O
-	O	O
year	O	O
stage	B-PHYS
IIIC	I-PHYS
/	I-PHYS
IV	I-PHYS
survival	O
was	O	O
42	O	O
.	O	O

8	O	O
%	O	O
for	O	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
whites	I-LIVB
vs	O	O
24	O	O
.	O	O

6	O	O
%	O	O
for	O	O
blacks	B-LIVB
(	O	O
hazard	O
ratio	O
1	O	O
.	O	O
3	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Other	O	O
factors	O
associated	O
with	O
inferior	O	O
5	O	O
-	O	O
year	O	O
survival	O
included	O	O
payer	B-LIVB
status	O
(	O	O
not	O	O
insured	O	O
,	O	O
Medicaid	O
,	O	O
Medicare	O
,	O	O
vs	O	O
private	O	O
,	O	O
ORs	O
1	O	O
.	O	O

2	O	O
-	O	O
1	O	O
.	O	O
3	O	O
,	O	O
all	O	O
P	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
and	O	O
treatment	O
at	O	O
low	B-OBJC
-	I-OBJC
volume	I-OBJC
centers	I-OBJC
(	O	O
<	O	O
5	O	O
vs	O	O
≥30cases	O	O
/	O	O
year	O	O
,	O	O
HR	O
1	O	O
.	O	O
3	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Socioeconomic	O
,	O	O
geographic	O
and	O	O
facility	O
-	O
related	O
factors	O
predict	O	O
advanced	B-DISO
endometrial	I-DISO
cancer	I-DISO
stage	B-PHYS
,	O	O
failure	O	O
to	O	O
receive	O
cancer	B-PROC
care	I-PROC
,	O	O
and	O	O
shorter	O	O
survival	O
.	O	O

Black	B-LIVB
women	B-LIVB
had	O	O
especially	O	O
poor	O	O
survival	O
.	O	O

Nationwide	B-PROC
standardization	I-PROC
and	O	O
concentration	B-PROC
of	O	O
treatment	O
at	O	O
high	B-OBJC
-	I-OBJC
volume	I-OBJC
centers	I-OBJC
may	O	O
improve	O	O
outcomes	O
.	O	O

Readily	O	O
Accessible	O
and	O	O
Predictable	O
Naphthalene	B-CHEM
-Based	O	O
Two	B-CHEM
-	I-CHEM
Photon	I-CHEM
Fluorophore	I-CHEM
with	O	O
Full	O	O
Visible	B-PHEN
-	O	O
Color	O
Coverage	O
Herein	O	O
we	O	O
report	O	O
22	B-CHEM
acedan	I-CHEM
-derived	O	O
,	O	O
two	B-CHEM
-	I-CHEM
photon	I-CHEM
fluorophores	I-CHEM
with	O	O
synthetic	O
feasibility	O	O
and	O	O
full	O	O
coverage	O
of	O	O
visible	B-PHEN
wavelength	O
emission	O	O
.	O	O

The	O	O
emission	B-PHEN
wavelengths	O
were	O	O
predicted	O
by	O	O
computational	B-PROC
analysis	I-PROC
,	O	O
which	O	O
enabled	O	O
us	O	O
to	O	O
visualize	O
multicolor	O
images	O
by	O	O
two	B-OBJC
-	I-OBJC
photon	I-OBJC
excitation	O
with	O	O
single	O	O
wavelength	O
,	O	O
and	O	O
to	O	O
design	O
a	O	O
turn	O	O
-	O	O
on	O	O
,	O	O
two	B-PHEN
-	I-PHEN
photon	I-PHEN
fluorescence	I-PHEN
sensor	B-OBJC
for	O	O
endogenous	O
H2	B-CHEM
O2	I-CHEM
in	O	O
Raw	B-ANAT
264	I-ANAT
.	I-ANAT

7	I-ANAT
macrophage	I-ANAT
and	O	O
rat	B-ANAT
brain	I-ANAT
hippocampus	B-ANAT
ex	O
vivo	O
.	O	O

Optimal	O
Duration	O
of	O	O
Coronary	B-PROC
Ligation	I-PROC
and	O	O
Reperfusion	B-PROC
for	O	O
Reperfusion	B-DISO
Injury	I-DISO
Study	B-PROC
in	O	O
a	O	O
Rat	B-LIVB
Model	B-DEVI
Reperfusion	B-DISO
injury	I-DISO
(	O	O
RI	B-DISO
)	O	O
has	O	O
an	O	O
important	O
impact	O
on	O	O
the	O	O
clinical	O
prognosis	B-PHYS
for	O	O
patients	B-LIVB
with	O	O
acute	B-DISO
myocardial	I-DISO
injury	I-DISO
who	O	O
had	O	O
their	O	O
coronary	O
blood	B-PHYS
flow	I-PHYS
reestablished	O
.	O	O

However	O	O
,	O	O
no	O	O
studies	B-PROC
to	O	O
date	O	O
have	O	O
investigated	O
the	O	O
timeframe	O
of	O	O
coronary	B-DISO
occlusion	I-DISO
and	O	O
reperfusion	B-PROC
effects	O
on	O	O
RI	B-DISO
.	O	O

A	O	O
total	O	O
of	O	O
100	O	O
rats	B-LIVB
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O
based	O	O
on	O	O
the	O	O
coronary	B-PROC
ligation	I-PROC
period	O
:	O	O
30	O	O
,	O	O
60	O	O
,	O	O
120	O	O
,	O	O
and	O	O
180	O	O
min	O	O
,	O	O
and	O	O
each	O	O
group	O
was	O	O
further	O	O
divided	O	O
into	O	O
5	O	O
subgroups	O
with	O	O
different	O
reperfusion	B-PROC
periods	O
:	O	O
0	O	O
,	O	O
30	O	O
,	O	O
60	O	O
,	O	O
120	O	O
,	O	O
and	O	O
180	O	O
min	O	O
.	O	O

R0	O	O
was	O	O
the	O	O
baseline	O
of	O	O
each	O	O
subgroup	O
.	O	O

All	O	O
animals	B-LIVB
received	O	O
the	O	O
same	O	O
protocols	O
for	O	O
designed	O
ligation	B-PROC
and	O	O
reperfusion	B-PROC
periods	O
.	O	O

Evans	B-CHEM
blue	I-CHEM
and	O	O
2	B-CHEM
,	I-CHEM
3	I-CHEM
,	I-CHEM
5	I-CHEM
-	I-CHEM
triphenyltetrazolium	I-CHEM
chloride	I-CHEM
were	O	O
used	O	O
to	O	O
distinguish	O	O
different	O
myocardial	B-DISO
injury	I-DISO
areas	O
:	O	O
area	O
at	O
risk	O
(	O	O
AAR	O
)	O	O
and	O	O
myocardial	B-DISO
necrosis	I-DISO
.	O	O

The	O	O
differences	O
of	O	O
the	O	O
ratios	O
of	O	O
the	O	O
necrotic	B-PHYS
area	O
to	O	O
AAR	O
between	O	O
each	O	O
subgroup	O
and	O	O
baseline	O
were	O	O
further	O	O
averaged	O
to	O	O
calculate	O
an	O	O
overall	O
value	O
of	O	O
each	O	O
heart	B-ANAT
.	O	O

The	O	O
relative	O	O
RI	B-DISO
percentages	O
showed	O	O
significant	O
differences	O
(	O	O
0	O	O
.	O	O
8	O	O
±	O	O
2	O	O
.	O	O

3	O	O
%	O	O
,	O	O
4	O	O
.	O	O
9	O	O
±	O	O
3	O	O
.	O	O

3	O	O
%	O	O
,	O	O
10	O	O
.	O	O
8	O	O
±	O	O
3	O	O
.	O	O
1	O	O
%	O	O
,	O	O
and	O	O
20	O	O
.	O	O
3	O	O
±	O	O
3	O	O
.	O	O

6	O	O
%	O	O
respectively	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
at	O	O
different	O
time	O
points	O
of	O	O
reperfusion	B-PROC
but	O	O
not	O	O
at	O	O
different	O
time	O
points	O
of	O	O
ligation	B-PROC
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
593	O	O
)	O	O
.	O	O

The	O	O
effects	O
of	O	O
different	O
time	O
courses	O
in	O	O
RI	B-DISO
showed	O	O
that	O	O
the	O	O
L120R180	O	O
group	O
(	O	O
43	O	O
.	O	O

4	O	O
±	O	O
2	O	O
.	O	O

3	O	O
%	O	O
)	O	O
had	O	O
the	O	O
highest	O
RI	B-DISO
difference	O
with	O	O
the	O	O
baseline	O
group	O
.	O	O

Maximal	O
RI	B-DISO
occurred	O	O
at	O	O
the	O	O
timeframe	O
of	O	O
L120R180	O	O
in	O	O
our	O	O
animal	B-DEVI
model	I-DEVI
.	O	O

This	O	O
result	O
may	O	O
be	O	O
utilized	O	O
to	O	O
assess	O
the	O	O
substantial	O	O
benefits	O
of	O	O
RI	B-PROC
therapies	I-PROC
in	O	O
an	O	O
experimental	B-DISO
rat	I-DISO
model	I-DISO
setting	O	O
.	O	O

Dimerization	B-PHEN
of	O	O
EGFR	B-CHEM
and	O	O
HER2	B-CHEM
induces	O	O
breast	B-DISO
cancer	I-DISO
cell	B-PHYS
motility	I-PHYS
through	O	O
STAT1	B-CHEM
-dependent	O	O
ACTA2	B-CHEM
induction	O
The	O	O
dimerization	B-PHEN
of	O	O
EGFR	B-CHEM
and	O	O
HER2	B-CHEM
is	O	O
associated	O	O
with	O	O
poor	O	O
prognosis	B-PROC
such	O	O
as	O	O
induction	O
of	O	O
tumor	B-DISO
growth	I-DISO
and	O	O
cell	B-DISO
invasion	I-DISO
compared	O
to	O	O
when	O	O
EGFR	B-CHEM
remains	O	O
as	O	O
a	O	O
homodimer	B-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
mechanism	O
for	O	O
events	O	O
after	O	O
dimerization	B-PHEN
in	O	O
breast	B-DISO
cancer	I-DISO
models	B-DEVI
is	O	O
not	O	O
clear	O	O
.	O	O

We	O	O
found	O	O
that	O	O
expressions	B-PHYS
of	O	O
alpha	B-CHEM
-	I-CHEM
smooth	I-CHEM
muscle	I-CHEM
actin	I-CHEM
(	O	O
ACTA2	B-CHEM
)	O	O
and	O	O
signal	B-CHEM
transducer	I-CHEM
and	I-CHEM
activator	I-CHEM
of	I-CHEM
transcription	I-CHEM
1	I-CHEM
(	O	O
STAT1	B-CHEM
)	O	O
significantly	O	O
increased	O
with	O	O
transient	O	O
or	O	O
stable	O	O
overexpression	B-PHYS
of	O	O
HER2	B-CHEM
in	O	O
EGFR	B-CHEM
-	O	O
positive	B-DISO
breast	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O	O

ACTA2	B-CHEM
and	O	O
STAT1	B-CHEM
expression	B-PHYS
was	O	O
also	O	O
increased	O
in	O	O
HER2	B-CHEM
-	O	O
positive	B-DISO
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O	O

In	O	O
contrast	O	O
,	O	O
ACTA2	B-CHEM
expression	B-PHYS
was	O	O
decreased	O
by	O	O
HER2	B-CHEM
siRNA	I-CHEM
.	O	O

Next	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
co	O	O
-	O	O
relation	O	O
between	O	O
STAT1	B-CHEM
and	O	O
ACTA2	B-CHEM
expression	B-PHYS
.	O	O

Basal	O	O
ACTA2	B-CHEM
expression	B-PHYS
was	O	O
significantly	O	O
decreased	O
by	O	O
treatment	B-PROC
with	O	O
the	O	O
STAT1	B-CHEM
inhibitor	I-CHEM
fludarabine	B-CHEM
or	O	O
the	O	O
JAK2	B-CHEM
inhibitor	I-CHEM
AG490	B-CHEM
.	O	O

In	O	O
contrast	O	O
,	O	O
ACTA2	B-CHEM
expression	B-PHYS
was	O	O
increased	O
by	O	O
STAT1	B-CHEM
overexpression	B-PHYS
.	O	O

Levels	O	O
of	O	O
ACTA2	B-CHEM
,	O	O
STAT1	B-CHEM
,	O	O
and	O	O
HER2	B-CHEM
were	O	O
increased	O
and	O	O
relapse	O	O
free	O
survival	O
was	O	O
decreased	O
in	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
breast	B-DISO
cancer	I-DISO
patients	B-LIVB
.	O	O

We	O	O
also	O	O
investigated	O
the	O	O
effect	O	O
of	O	O
ACTA2	B-CHEM
on	O	O
cell	B-PHYS
motility	I-PHYS
,	O	O
which	O	O
was	O	O
suppressed	O
by	O	O
ACTA2	B-CHEM
shRNA	I-CHEM
overexpression	B-PHYS
in	O	O
MDA	B-ANAT
-	I-ANAT
MB231	I-ANAT
HER2	B-CHEM
and	O	O
4T1	B-ANAT
mammary	I-ANAT
carcinoma	I-ANAT
cells	I-ANAT
.	O	O

The	O	O
number	O	O
of	O	O
lung	B-DISO
metastatic	I-DISO
nodules	I-DISO
was	O	O
significantly	O	O
decreased	O
in	O	O
ACTA2	B-CHEM
knockdown	B-LIVB
mice	I-LIVB
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
demonstrated	O	O
that	O	O
induction	O
of	O	O
ACTA2	B-CHEM
by	O	O
EGFR	B-CHEM
and	O	O
HER2	B-CHEM
dimerization	B-PHEN
was	O	O
regulated	O	O
through	O	O
a	O	O
JAK2	B-CHEM
/	O	O
STAT1	B-CHEM
signaling	B-PHYS
pathway	I-PHYS
,	O	O
and	O	O
aberrant	O	O
ACTA2	B-CHEM
expression	B-PHYS
accelerated	O	O
the	O	O
invasiveness	B-DISO
and	O	O
metastasis	B-DISO
of	O	O
breast	B-DISO
cancer	I-DISO
cells	B-ANAT
.	O	O

Association	O
of	O	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
with	O	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O	O
patients	B-LIVB
with	O	O
coronary	B-DISO
chronic	I-DISO
total	I-DISO
occlusion	I-DISO
There	O	O
are	O	O
limited	O
data	O
regarding	O	O
the	O	O
efficacy	O
of	O	O
β	B-CHEM
-	I-CHEM
blockers	I-CHEM
for	O	O
secondary	B-PROC
prevention	I-PROC
in	O	O
patients	B-LIVB
with	O	O
coronary	B-DISO
chronic	I-DISO
total	I-DISO
occlusion	I-DISO
(	O	O
CTO	B-DISO
)	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
investigated	O
the	O	O
association	O
of	O	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
with	O	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O	O
CTO	B-DISO
patients	B-LIVB
.	O	O

From	O	O
March	O	O
2003	O	O
to	O	O
February	O	O
2012	O	O
,	O	O
a	O	O
total	O	O
of	O	O
2024	O	O
CTO	B-DISO
patients	B-LIVB
treated	O	O
with	O	O
either	O	O
medical	B-PROC
therapy	I-PROC
alone	O	O
or	O	O
revascularization	B-PROC
were	O	O
enrolled	O	O
in	O	O
the	O	O
study	B-PROC
.	O	O

We	O	O
assessed	O	O
1596	O	O
patients	B-LIVB
with	O	O
stable	O	O
ischemic	B-DISO
heart	I-DISO
disease	I-DISO
and	O	O
divided	O	O
them	O	O
into	O	O
the	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O	O
n	O	O
=	O	O
932	O	O
)	O	O
and	O	O
the	O	O
no	O
-	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O	O
n	O	O
=	O	O
664	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
outcome	O
was	O	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
.	O	O

The	O	O
median	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
was	O	O
3	O	O
.	O	O

9	O	O
(	O	O
interquartile	O
range	O
:	O	O
2	O	O
.	O	O
0	O	O
-	O	O
6	O	O
.	O	O
2	O	O
)	O	O
years	O	O
.	O	O

All	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
occurred	O	O
in	O	O
11	O	O
.	O	O

6	O	O
%	O	O
patients	B-LIVB
in	O	O
the	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
and	O	O
13	O	O
.	O	O

6	O	O
%	O	O
patients	B-LIVB
in	O	O
the	O	O
no	O
-	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O	O
hazard	O
ratio	O
[	O	O
HR	O
]	O	O
:	O	O
0	O	O
.	O	O
81	O	O
,	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
:	O	O
0	O	O
.	O	O
61	O	O
-	O	O
1	O	O
.	O	O
08	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
15	O	O
)	O	O
.	O	O

In	O	O
the	O	O
propensity	O
score	O
-	O	O
matched	B-LIVB
population	I-LIVB
(	O	O
570	O	O
pairs	O	O
)	O	O
,	O	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
occurred	O	O
in	O	O
12	O	O
.	O	O

3	O	O
%	O	O
patients	B-LIVB
in	O	O
the	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
and	O	O
12	O	O
.	O	O

8	O	O
%	O	O
patients	B-LIVB
in	O	O
the	O	O
no	O
-	O	O
β	B-CHEM
-	I-CHEM
blocker	I-CHEM
group	O
(	O	O
HR	O
:	O	O
0	O	O
.	O	O
93	O	O
,	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
67	O	O
-	O	O
1	O	O
.	O	O
29	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O
66	O	O
)	O	O
.	O	O

In	O	O
subgroup	O
analysis	B-PROC
,	O	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
was	O	O
associated	O
with	O
better	O	O
outcome	O
,	O	O
in	O	O
terms	O	O
of	O	O
all	B-DISO
-	I-DISO
cause	I-DISO
death	I-DISO
,	O	O
in	O	O
patients	B-LIVB
with	O	O
CTO	B-DISO
of	O	O
the	O	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
coronary	I-ANAT
artery	I-ANAT
and	O	O
Synergy	O	O
Between	O	O
PCI	B-PROC
with	O	O
Taxus	O	O
and	O	O
Cardiac	B-PROC
Surgery	I-PROC
(	O	O
SYNTAX	O	O
)	O	O
score	O
≥23	O	O
(	O	O
P	O	O
for	O	O
interaction	O
=	O	O
0	O	O
.	O	O
01	O	O
and	O	O
0	O	O
.	O	O
02	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
conclusion	O
,	O	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
was	O	O
not	O	O
associated	O
with	O
favorable	O
long	O
-	O
term	O
clinical	B-DISO
outcomes	I-DISO
in	O	O
stable	O	O
CTO	B-DISO
patients	B-LIVB
,	O	O
regardless	O
of	O	O
treatment	B-PROC
strategy	O	O
.	O	O

However	O	O
,	O	O
β	B-PROC
-	I-PROC
blocker	I-PROC
therapy	I-PROC
might	O	O
be	O	O
beneficial	O	O
in	O	O
a	O	O
highly	O
selective	O	O
group	O
of	O	O
CTO	B-DISO
patients	B-LIVB
with	O	O
a	O	O
high	O
ischemic	B-DISO
burden	I-DISO
.	I-DISO

Derivation	O
of	O	O
a	O	O
Predictive	O
Score	O
for	O	O
Hemorrhagic	B-DISO
Progression	O
of	O	O
Cerebral	B-DISO
Contusions	I-DISO
in	O	O
Moderate	B-DISO
and	O	O
Severe	B-DISO
Traumatic	I-DISO
Brain	I-DISO
Injury	I-DISO
After	O	O
traumatic	B-DISO
brain	I-DISO
injury	I-DISO
(	O	O
TBI	B-DISO
)	O	O
,	O	O
hemorrhagic	B-DISO
progression	O
of	O	O
contusions	B-DISO
(	O	O
HPCs	B-DISO
)	O	O
occurs	O	O
frequently	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
established	O
predictive	O
score	O
to	O	O
identify	O	O
high	B-DISO
-	I-DISO
risk	I-DISO
patients	B-LIVB
for	O	O
HPC	B-DISO
.	O	O

Consecutive	O
patients	B-LIVB
who	O	O
were	O	O
hospitalized	B-DISO
(	O	O
2008	O	O
-	O	O
2013	O	O
)	O	O
with	O	O
non	O	O
-	O	O
penetrating	O	O
moderate	B-DISO
or	O	O
severe	B-DISO
TBI	I-DISO
were	O	O
studied	O	O
.	O	O

The	O	O
primary	O
outcome	O
was	O	O
HPC	B-DISO
,	O	O
defined	O	O
by	O	O
both	O	O
a	O	O
relative	O	O
increase	O
in	O	O
contusion	B-DISO
volume	O
by	O	O
≥30	O	O
%	O	O
and	O	O
an	O	O
absolute	O
increase	O
by	O	O
≥10	O	O
mL	O	O
on	O	O
serial	O
imaging	O
.	O	O

Logistic	O
regression	O
models	O
were	O	O
created	O
to	O	O
identify	O	O
independent	O	O
risk	B-DISO
factors	I-DISO
for	O	O
HPC	B-DISO
.	O	O

The	O	O
HPC	B-DISO
Score	O
was	O	O
then	O	O
derived	O
based	O	O
on	O	O
the	O	O
final	O
model	O
.	O	O

Among	O	O
a	O	O
total	O	O
of	O	O
286	O	O
eligible	O	O
patients	B-LIVB
,	O	O
61	O	O
(	O	O
21	O	O
%	O	O
)	O	O
patients	B-LIVB
developed	O	O
HPC	B-DISO
.	O	O

On	O	O
univariate	B-PROC
analyses	I-PROC
,	O	O
HPC	B-DISO
was	O	O
associated	O
with	O
older	B-PHYS
age	I-PHYS
,	O	O
higher	B-DISO
initial	I-DISO
blood	I-DISO
pressure	I-DISO
,	O	O
antiplatelet	B-CHEM
medications	I-CHEM
,	O	O
anticoagulants	B-CHEM
,	O	O
subarachnoid	B-DISO
hemorrhage	I-DISO
(	O	O
SAH	B-DISO
)	O	O
subdural	B-DISO
hematoma	I-DISO
(	O	O
SDH	B-DISO
)	O	O
,	O	O
skull	B-DISO
fracture	I-DISO
,	O	O
frontal	B-ANAT
contusion	B-DISO
,	O	O
larger	O
contusion	B-DISO
volume	O
,	O	O
and	O	O
shorter	O
interval	O
from	O	O
injury	B-DISO
to	O	O
initial	B-PROC
CT	I-PROC
.	O	O

In	O	O
the	O	O
final	O
model	O
,	O	O
SAH	B-DISO
(	O	O
OR	O
6	O	O
.	O	O

33	O	O
,	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
80	O	O
-	O	O
22	O	O
.	O	O
23	O	O
)	O	O
,	O	O
SDH	B-DISO
(	O	O
OR	O
3	O	O
.	O	O
46	O	O
,	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
39	O	O
-	O	O
8	O	O
.	O	O
63	O	O
)	O	O
,	O	O
and	O	O
skull	B-DISO
fracture	I-DISO
(	O	O
OR	O
2	O	O
.	O	O
67	O	O
,	O	O
95	O	O
%	O	O
CI	O
,	O	O
1	O	O
.	O	O
28	O	O
-	O	O
5	O	O
.	O	O
58	O	O
)	O	O
were	O	O
associated	O
with	O
HPC	B-DISO
.	O	O

Based	O	O
on	O	O
these	O	O
factors	O
,	O	O
the	O	O
HPC	B-DISO
Score	O
was	O	O
derived	O
(	O	O
SAH	B-DISO
=	O	O
2	O	O
points	O	O
,	O	O
SDH	B-DISO
=	O	O
1	O	O
point	O	O
,	O	O
and	O	O
skull	B-DISO
fracture	I-DISO
=	O	O
1	O	O
point	O	O
)	O	O
.	O	O

This	O	O
score	O
had	O	O
an	O	O
area	O	O
under	O	O
the	O	O
receiver	O
operating	O
curve	O
of	O	O
0	O	O
.	O	O

77	O	O
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
score	O
of	O	O
0	O	O
-	O	O
2	O	O
had	O	O
a	O	O
4	O	O
.	O	O
0	O	O
%	O	O
incidence	O
of	O	O
HPC	B-DISO
,	O	O
while	O	O
patients	B-LIVB
with	O	O
a	O	O
score	O
of	O	O
3	O	O
-	O	O
4	O	O
had	O	O
a	O	O
34	O	O
.	O	O

6	O	O
%	O	O
incidence	O
of	O	O
HPC	B-DISO
.	O	O

A	O	O
simple	O	O
HPC	B-DISO
Score	O
was	O	O
developed	O	O
for	O	O
early	O	O
risk	O
stratification	O
of	O	O
HPC	B-DISO
in	O	O
patients	B-LIVB
with	O	O
moderate	B-DISO
or	O	O
severe	B-DISO
TBI	I-DISO
.	O	O

Intensive	O	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O	O
can	O	O
do	O	O
treatment	O
)	O	O
with	O	O
participation	O
of	O	O
support	O	O
partners	B-LIVB
in	O	O
persons	B-LIVB
with	O	O
relapsing	B-DISO
remitting	I-DISO
multiple	I-DISO
sclerosis	I-DISO
:	O	O
observation	B-PROC
of	O	O
improved	B-DISO
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
quality	O
of	O
life	O
,	O	O
anxiety	B-DISO
and	O	O
depression	B-DISO
1	O	O
year	O
later	O	O
In	O	O
persons	B-LIVB
with	O	O
multiple	B-DISO
sclerosis	I-DISO
(	O	O
MS	B-DISO
)	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
positively	B-DISO
affects	O	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O	O
HRQoL	O
)	O	O
and	O	O
physical	O
activity	O
.	O	O

In	O	O
a	O	O
previous	O	O
study	O	O
we	O	O
observed	O
that	O	O
6	O	O
months	O
after	O	O
an	O	O
intensive	O	O
3	O	O
-	O	O
day	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O	O
Can	O	O
Do	O	O
treatment	O
)	O	O
with	O	O
the	O	O
participation	O
of	O	O
support	O	O
partners	B-LIVB
,	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O	O
HRQoL	O
had	O	O
improved	B-DISO
in	O	O
persons	B-LIVB
with	O	O
relapsing	B-DISO
remitting	I-DISO
MS	I-DISO
(	O	O
RRMS	B-DISO
)	O	O
.	O	O

Given	O	O
the	O	O
chronic	O
nature	O
of	O
the	O
disease	O
,	O	O
it	O	O
is	O	O
important	O	O
to	O	O
know	O	O
whether	O	O
these	O	O
beneficial	O
changes	O
may	O	O
last	O	O
.	O	O

Can	O	O
Do	O	O
treatment	O
was	O	O
given	O	O
to	O	O
60	O	O
persons	B-LIVB
with	O	O
MS	B-DISO
and	O	O
their	O	O
support	O	O
partners	B-LIVB
.	O	O

At	O	O
baseline	O
and	O	O
12	O	O
months	O
after	O	O
treatment	B-PROC
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
control	O
,	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
function	O
,	O	O
physical	O
and	O	O
mental	B-PHYS
HRQoL	O
,	O	O
anxiety	B-DISO
,	O	O
depression	B-DISO
and	O	O
fatigue	B-DISO
were	O	O
assessed	O
via	O	O
self	B-PROC
-	I-PROC
report	I-PROC
questionnaires	O
.	O	O

Differences	O
were	O	O
tested	O
via	O	O
a	O	O
paired	O
t	O
test	O
.	O	O

Of	O	O
the	O	O
57	O	O
persons	B-LIVB
with	O	O
MS	B-DISO
that	O	O
completed	O
the	O	O
baseline	O
assessment	O
and	O	O
the	O	O
3	O	O
-	O	O
day	O
treatment	O
,	O	O
38	O	O
filled	O	O
in	O	O
the	O	O
12th	O	O
month	O
questionnaires	O
(	O	O
response	B-DISO
rate	O
66	O	O
.	O	O

7	O	O
%	O	O
)	O	O
,	O	O
22	O	O
with	O	O
RRMS	B-DISO
and	O	O
14	O	O
with	O	O
progressive	O
MS	B-DISO
.	O	O

In	O	O
the	O	O
RR	B-DISO
group	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
control	O
had	O	O
increased	O
by	O	O
20	O	O
.	O	O

2	O	O
%	O	O
and	O	O
physical	O
HRQoL	O
by	O	O
15	O	O
.	O	O
0	O	O
%	O	O
,	O	O
and	O	O
depression	B-DISO
and	O	O
anxiety	B-DISO
had	O	O
decreased	O
by	O	O
29	O	O
.	O	O

8	O	O
and	O	O
25	O	O
.	O	O
9	O	O
%	O	O
,	O	O
respectively	O	O
(	O	O
all	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
;	O	O
the	O	O
changes	O
in	O	O
mental	B-PHYS
HRQoL	O
(	O	O
+17	O	O
%	O	O
)	O	O
and	O	O
fatigue	B-DISO
(	O	O
-20	O	O
%	O	O
)	O	O
failed	O
to	O	O
be	O	O
statistically	O
significant	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

087	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
080	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
the	O	O
progressive	O
group	O
no	O	O
changes	O
suggestive	O
of	O
improvement	O
were	O	O
seen	O	O
.	O	O

The	O	O
findings	O
suggest	O
that	O	O
a	O	O
3	O	O
-	O	O
day	O
intensive	O	O
social	O
cognitive	B-PROC
treatment	I-PROC
(	O	O
Can	O	O
Do	O	O
treatment	O
)	O	O
with	O	O
the	O	O
participation	O
of	O	O
support	O	O
partners	B-LIVB
may	O	O
have	O	O
long	O
lasting	O
beneficial	O
effects	O
on	O	O
the	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O	O
HRQoL	O
in	O	O
persons	B-LIVB
with	O	O
RRMS	B-DISO
;	O	O
and	O	O
that	O	O
improvements	O
in	O	O
anxiety	B-DISO
and	O	O
depression	B-DISO
,	O	O
not	O	O
seen	O	O
in	O	O
the	O	O
6	O	O
-	O	O
month	O
study	O	O
,	O	O
may	O	O
yet	O	O
develop	O
at	O	O
12	O	O
months	O
.	O	O

Perineal	B-DISO
injuries	I-DISO
and	O	O
birth	B-DISO
positions	I-DISO
among	O	O
2992	O	O
women	B-LIVB
with	O	O
a	O	O
low	B-DISO
risk	I-DISO
pregnancy	I-DISO
who	O	O
opted	O	O
for	O	O
a	O	O
homebirth	B-DISO
Whether	O	O
certain	O	O
birth	B-DISO
positions	I-DISO
are	O	O
associated	O
with	O
perineal	B-DISO
injuries	I-DISO
and	O	O
severe	O
perineal	O
trauma	O
(	O	O
SPT	O
)	O	O
is	O	O
still	O	O
unclear	B-DISO
.	O	O

The	O	O
objective	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
describe	O	O
the	O	O
prevalence	O
of	O	O
perineal	B-DISO
injuries	I-DISO
of	O	O
different	O	O
severity	O
in	O	O
a	O	O
low	O
-	O
risk	O
population	B-LIVB
of	O	O
women	B-LIVB
who	O	O
planned	O	O
to	O	O
give	O	O
birth	B-DISO
at	I-DISO
home	I-DISO
and	O	O
to	O	O
compare	O	O
the	O	O
prevalence	O
of	O	O
perineal	B-DISO
injuries	I-DISO
,	O	O
SPT	O
and	O	O
episiotomy	B-PROC
in	O	O
different	O	O
birth	B-DISO
positions	I-DISO
in	O	O
four	O	O
Nordic	B-GEOG
countries	I-GEOG
.	O	O

A	O	O
population	B-LIVB
-based	O	O
prospective	B-PROC
cohort	I-PROC
study	I-PROC
of	O	O
planned	O	O
home	B-DISO
births	I-DISO
in	O	O
four	O	O
Nordic	B-GEOG
countries	I-GEOG
.	O	O

To	O	O
assess	O
medical	O
outcomes	O
a	O	O
questionnaire	O
completed	O	O
after	O	O
birth	B-PHYS
by	O	O
the	O	O
attending	O	O
midwife	B-LIVB
was	O	O
used	O	O
.	O	O

Descriptive	B-PROC
statistics	I-PROC
,	O	O
bivariate	O
analysis	O
and	O	O
logistic	B-PROC
regression	I-PROC
were	O	O
used	O	O
to	O	O
analyze	O	O
the	O	O
data	O
.	O	O

Two	O	O
thousand	O	O
nine	O	O
hundred	O	O
ninety	O	O
-	O	O
two	O	O
women	B-LIVB
with	O	O
planned	O	O
home	B-DISO
births	I-DISO
,	O	O
who	O	O
birthed	O	O
spontaneously	O	O
at	O	O
home	O
or	O	O
after	O	O
transfer	B-PROC
to	I-PROC
hospital	I-PROC
,	O	O
between	O	O
2008	O	O
and	O	O
2013	O	O
were	O	O
included	O	O
.	O	O

The	O	O
prevalence	O
of	O	O
SPT	O
was	O	O
0	O	O
.	O	O

7	O	O
%	O	O
and	O	O
the	O	O
prevalence	O
of	O	O
episiotomy	B-PROC
was	O	O
1	O	O
.	O	O
0	O	O
%	O	O
.	O	O

There	O	O
were	O	O
differences	O	O
between	O	O
the	O	O
countries	O	O
regarding	O	O
all	O	O
maternal	B-DISO
characteristics	O
.	O	O

No	O	O
association	O	O
between	O	O
flexible	O
sacrum	B-ANAT
positions	O
and	O	O
sutured	O
perineal	B-DISO
injuries	I-DISO
was	O	O
found	O	O
(	O	O
OR	O
1	O	O
.	O	O
02	O	O
;	O	O
95	O	O
%	O	O
CI	O
0	O	O
.	O	O
86	O	O
-	O	O
1	O	O
.	O	O
21	O	O
)	O	O
or	O	O
SPT	O
(	O	O
OR	O
0	O	O
.	O	O

68	O	O
;	O	O
CI	O
95	O	O
%	O	O
0	O	O
.	O	O
26	O	O
-	O	O
1	O	O
.	O	O
79	O	O
)	O	O
.	O	O

Flexible	O
sacrum	B-ANAT
positions	O
were	O	O
associated	O
with	O
fewer	O	O
episiotomies	B-PROC
(	O	O
OR	O
0	O	O
.	O	O

20	O	O
;	O	O
CI	O
95	O	O
%	O	O
0	O	O
.	O	O
10	O	O
-	O	O
0	O	O
.	O	O
54	O	O
)	O	O
.	O	O

A	O	O
low	O	O
prevalence	O
of	O	O
SPT	O
and	O	O
episiotomy	B-PROC
was	O	O
found	O	O
among	O	O
women	B-LIVB
opting	O	O
for	O	O
a	O	O
home	B-DISO
birth	I-DISO
in	O	O
four	O	O
Nordic	B-GEOG
countries	I-GEOG
.	O	O

Women	B-LIVB
used	O	O
a	O	O
variety	O	O
of	O	O
birth	B-DISO
positions	I-DISO
and	O	O
a	O	O
majority	O	O
gave	O	O
birth	B-PHYS
in	O	O
flexible	O
sacrum	B-ANAT
positions	O
.	O	O

No	O	O
associations	O	O
were	O	O
found	O	O
between	O	O
flexible	O
sacrum	B-ANAT
positions	O
and	O	O
SPT	O
.	O	O

Flexible	O
sacrum	B-ANAT
positions	O
were	O	O
associated	O
with	O
fewer	O	O
episiotomies	B-PROC
.	O	O

Parallel	O
-	O
processing	O
continuous	B-DEVI
-	I-DEVI
flow	I-DEVI
device	I-DEVI
for	O	O
optimization	O
-	O	O
free	O
polymerase	B-PROC
chain	I-PROC
reaction	I-PROC
A	O	O
parallel	O
-	O
processing	O
four	B-PROC
-	I-PROC
station	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
(	O	O
PCR	B-PROC
)	O	O
device	B-OBJC
has	O	O
been	O	O
developed	O	O
,	O	O
which	O	O
performs	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
PCR	B-PROC
without	O	O
optimization	O
of	O	O
the	O	O
annealing	B-PHYS
temperature	O
.	O	O

Since	O	O
the	O	O
annealing	B-PHYS
temperature	O
of	O	O
each	O	O
station	B-OBJC
can	O	O
be	O	O
controlled	O
independently	O
,	O	O
the	O	O
device	B-OBJC
covers	O
an	O	O
annealing	B-PHYS
temperature	O
range	O
of	O	O
50	O	O
-	O	O
68	O	O
°	O	O
C	O	O
,	O	O
which	O	O
is	O	O
wide	O
enough	O	O
to	O	O
perform	O
PCR	B-PROC
for	O	O
any	O	O
DNA	O
fragment	O
regardless	O	O
of	O	O
its	O	O
optimum	O
annealing	B-PHYS
condition	O
.	O	O

This	O	O
arrangement	O
lets	O	O
us	O	O
continuously	O
obtain	O
an	O	O
amplified	B-PHEN
amount	O
of	O	O
a	O	O
DNA	O
fragment	O
at	O	O
least	O	O
from	O	O
one	O	O
of	O	O
the	O	O
stations	B-OBJC
.	O	O

The	O	O
device	B-OBJC
consists	O	O
of	O	O
four	O	O
identical	O
cylindrical	O
stations	B-OBJC
(	O	O
diameter	O
20	O	O
mm	O	O
,	O	O
height	B-PHYS
55	O	O
mm	O	O
)	O	O
.	O	O

A	O	O
polytetrafluoroethylene	B-CHEM
capillary	B-DEVI
reactor	I-DEVI
(	O	O
length	O
2	O	O
m	O	O
,	O	O
I	O	O
.	O	O

D	O	O
.	O	O

100	O	O
μm	O	O
,	O	O
O	O	O
.	O	O
D	O	O
.	O	O

400	O	O
μm	O	O
)	O	O
is	O	O
wound	O
helically	O
up	O
around	O
each	O	O
station	B-OBJC
.	O	O

The	O	O
whole	O	O
assembly	O
is	O	O
designed	O
to	O	O
minimize	O
the	O	O
number	O
of	O	O
heating	B-DEVI
blocks	I-DEVI
(	O	O
for	O	O
providing	O
temperatures	O
of	O	O
denaturation	B-PHYS
,	O	O
annealing	B-PHYS
,	O	O
and	O	O
extension	O
)	O	O
to	O	O
be	O	O
seven	O	O
and	O	O
to	O	O
shape	O
a	O	O
compact	B-DISO
cube	O
(	O	O
height	B-PHYS
55	O	O
mm	O	O
,	O	O
base	O
60	O	O
mm	O	O
×	O	O
60	O	O
mm	O	O
)	O	O
.	O	O

The	O	O
reproducibility	O
for	O	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
PCR	B-PROC
is	O	O
reasonably	O	O
high	O
(	O	O
run	O
-to	O	O
-	O	O
run	O
and	O	O
station	B-OBJC
-to	O	O
-	O	O
station	B-OBJC
relative	O	O
standard	O
deviation	O
of	O	O
their	O	O
amplification	B-PHYS
is	O	O
lower	O	O
than	O	O
6	O	O
%	O	O
and	O	O
about	O	O
4	O	O
%	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Performance	O
on	O	O
the	O	O
optimization	O
-	O	O
free	O
DNA	B-PHYS
amplification	I-PHYS
has	O	O
been	O	O
evaluated	B-PROC
with	O	O
four	O	O
DNA	B-ANAT
samples	I-ANAT
with	O	O
different	O
annealing	B-PHYS
conditions	O
and	O	O
product	B-OBJC
sizes	O
(	O	O
323	O	O
,	O	O
608	O	O
,	O	O
828	O	O
,	O	O
and	O	O
1101	O	O
bp	O	O
)	O	O
,	O	O
which	O	O
has	O	O
demonstrated	O
that	O	O
in	O	O
all	O	O
cases	O
,	O	O
PCR	B-PROC
is	O	O
successful	O
at	O	O
least	O	O
on	O	O
one	O	O
station	B-OBJC
.	O	O

In	O	O
addition	O
,	O	O
three	O	O
DNA	O
fragment	O
s	O	O
with	O	O
different	O
lengths	O
(	O	O
323	O	O
,	O	O
1101	O	O
,	O	O
and	O	O
2836	O	O
bp	O	O
)	O	O
have	O	O
been	O	O
successfully	O
amplified	B-PHEN
in	O	O
a	O	O
segmented	O
-	O	O
flow	B-PHEN
mode	O
without	O	O
the	O	O
carry	O	O
-	O	O
over	O	O
contamination	O
between	O	O
segments	O
.	O	O

This	O	O
result	O
suggests	O	O
that	O	O
this	O	O
device	B-OBJC
could	O	O
serve	O	O
as	O	O
the	O	O
PCR	B-PROC
module	O
of	O	O
a	O	O
continuous	B-PHEN
-	I-PHEN
flow	I-PHEN
high	B-PROC
-	I-PROC
throughput	I-PROC
on	I-PROC
-	I-PROC
line	I-PROC
total	I-PROC
DNA	I-PROC
analysis	I-PROC
system	O
integrating	O
all	O	O
necessary	O	O
modules	O
from	O	O
cell	B-ANAT
lysis	B-DISO
/	O	O
DNA	B-PROC
extraction	I-PROC
to	O	O
PCR	B-PROC
product	B-OBJC
analysis	B-PROC
.	O	O

S	B-PHYS
-	I-PHYS
Nitrosylation	I-PHYS
Induces	O	O
Structural	O
and	O	O
Dynamical	O
Changes	O
in	O	O
a	O	O
Rhodanese	B-CHEM
Family	I-CHEM
Protein	B-CHEM
S	B-PHYS
-	I-PHYS
Nitrosylation	I-PHYS
is	O	O
well	O	O
established	O	O
as	O	O
an	O	O
important	O	O
post	B-PHYS
-	I-PHYS
translational	I-PHYS
regulator	I-PHYS
in	O	O
protein	B-PHYS
function	I-PHYS
and	O	O
signaling	B-PHEN
.	O	O

However	O	O
,	O	O
relatively	O	O
little	O	O
is	O	O
known	O	O
about	O	O
its	O	O
structural	O
and	O	O
dynamical	O
consequences	O
.	O	O

We	O	O
have	O	O
investigated	O
the	O	O
effects	O
of	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
on	O	O
the	O	O
rhodanese	O
domain	O
of	O	O
the	O	O
Escherichia	B-LIVB
coli	I-LIVB
integral	B-CHEM
membrane	I-CHEM
protein	I-CHEM
YgaP	B-CHEM
by	O	O
NMR	B-PHEN
,	O	O
X	B-PROC
-	I-PROC
ray	I-PROC
crystallography	I-PROC
,	O	O
and	O	O
mass	B-PROC
spectrometry	I-PROC
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
the	O	O
active	B-CHEM
cysteine	I-CHEM
in	O	O
the	O	O
rhodanese	O
domain	O
of	O	O
YgaP	B-CHEM
is	O	O
subjected	O	O
to	O	O
two	O	O
competing	O	O
modifications	B-PHYS
:	O	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
and	O	O
S	B-PHYS
-	I-PHYS
sulfhydration	I-PHYS
,	O	O
which	O	O
are	O	O
naturally	O	O
occurring	O	O
in	O
vivo	O
.	O	O

It	O	O
has	O	O
been	O	O
observed	O	O
that	O	O
in	O
addition	O
to	O
inhibition	O
of	O	O
the	O	O
sulfur	B-PHYS
transfer	I-PHYS
activity	I-PHYS
,	O	O
S	B-PHYS
-	I-PHYS
nitrosylation	I-PHYS
of	O	O
the	O	O
active	O
site	O
residue	O	O
Cys63	B-CHEM
causes	O	O
an	O	O
increase	O	O
in	O	O
slow	B-PHEN
motion	I-PHEN
and	O	O
a	O	O
displacement	O
of	O	O
helix	O
5	O
due	O	O
to	O	O
a	O	O
weakening	O
of	O	O
the	O	O
interaction	O
between	O	O
the	O	O
active	O
site	O
and	O	O
the	O	O
helix	O
dipole	O
.	O	O

These	O	O
findings	B-DISO
provide	O	O
an	O	O
example	O	O
of	O	O
how	O	O
nitrosative	B-PHYS
stress	I-PHYS
can	I-PHYS
exert	I-PHYS
action	I-PHYS
at	O	O
the	O	O
atomic	O
level	O
.	O	O

Expressing	O
sexuality	O
in	O	O
nursing	B-OBJC
homes	I-OBJC
.	O	O

The	O	O
experience	O
of	O	O
older	B-LIVB
women	I-LIVB
:	O	O
A	O	O
qualitative	B-PROC
study	I-PROC
In	O	O
nursing	B-OBJC
homes	I-OBJC
,	O	O
a	O	O
number	O	O
of	O	O
barriers	O
to	O	O
the	O	O
expression	O
of	O	O
sexuality	O
exist	O
,	O	O
such	O	O
as	O	O
the	O	O
lack	B-DISO
of	I-DISO
privacy	I-DISO
,	O	O
certain	O	O
attitudes	B-PHYS
on	O	O
behalf	O	O
of	O	O
the	O	O
staff	B-LIVB
and	O	O
the	O	O
family	B-LIVB
,	O	O
the	O	O
lack	O	O
of	O	O
a	O	O
sexual	B-LIVB
partner	I-LIVB
,	O	O
and	O	O
physical	B-DISO
limitations	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
describe	O	O
the	O	O
lived	O
experience	O
of	O	O
sexuality	O
in	O	O
elderly	B-LIVB
Spanish	I-LIVB
women	I-LIVB
residing	O	O
in	O	O
nursing	B-OBJC
homes	I-OBJC
.	O	O

A	O	O
qualitative	B-PROC
phenomenological	I-PROC
approach	I-PROC
was	O	O
followed	O	O
.	O	O

Data	O
were	O	O
collected	B-PROC
over	O	O
an	O	O
18	O	O
-	O	O
month	O
period	O
between	O	O
2013	O	O
and	O	O
2015	O	O
.	O	O

Purposeful	O	O
sampling	O
was	O	O
conducted	O	O
with	O	O
Spanish	B-LIVB
residents	I-LIVB
in	O	O
nursing	B-OBJC
homes	I-OBJC
in	O	O
Madrid	B-GEOG
.	O	O

Data	O
were	O	O
collected	O	O
using	O	O
unstructured	O
and	O
semi	O
-	O
structured	O
interviews	O
.	O	O

The	O	O
data	O
were	O	O
analyzed	B-PROC
using	O	O
thematic	B-PROC
analysis	I-PROC
.	O	O

Twenty	O	O
female	B-PHYS
residents	B-LIVB
participated	O	O
.	O	O

Three	O	O
main	O	O
themes	O
emerged	O	O
from	O	O
the	O	O
data	O
:	O	O
a	O	O
)	O	O
expressing	O
sexuality	O
,	O	O
b	O	O
)	O	O
sexuality	O
as	O	O
a	O	O
duty	B-PROC
and	O	O
c	O	O
)	O	O
respecting	O	O
vows	O
.	O	O

Female	B-PHYS
residents	B-LIVB
reported	O	O
key	O	O
elements	O	O
influencing	O	O
how	O	O
they	O	O
manage	B-PROC
their	O	O
sexuality	O
in	O	O
Nursing	B-OBJC
Homes	I-OBJC
.	O	O

These	O	O
results	O	O
serve	O	O
to	O	O
improve	O	O
our	O	O
understanding	O	O
regarding	O	O
the	O	O
expression	O
of	O	O
sexuality	O
in	O	O
older	B-PHYS
female	I-PHYS
nursing	B-OBJC
home	I-OBJC
residents	B-LIVB
.	O	O

Assessing	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
and	O	O
the	O	O
effect	O
of	O	O
timing	O
of	O	O
vaccination	B-PROC
on	O	O
immunogenicity	B-PHEN
,	O	O
reactogenicity	B-DISO
and	O	O
efficacy	B-DISO
of	I-DISO
vaccines	I-DISO
in	O	O
young	O
children	B-LIVB
:	O	O
study	O
protocol	O
for	O	O
an	O	O
individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
Disease	B-DISO
incidence	O
differs	O	O
between	O	O
males	B-PHYS
and	O	O
females	B-PHYS
for	O	O
some	O	O
infectious	B-DISO
or	O	O
inflammatory	B-DISO
diseases	I-DISO
.	O	O

Sex	B-PHYS
-	I-PHYS
differences	I-PHYS
in	O	O
immune	B-PHYS
responses	I-PHYS
to	O	O
some	O	O
vaccines	B-CHEM
have	O	O
also	O	O
been	O	O
observed	O	O
,	O	O
mostly	O	O
to	O	O
viral	B-CHEM
vaccines	I-CHEM
in	O	O
adults	B-LIVB
.	O	O

Little	O	O
evidence	O
is	O	O
available	O
on	O	O
whether	O	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
occur	O	O
in	O	O
response	B-DISO
to	O	O
immunisation	B-PROC
in	O	O
infancy	O
even	O	O
though	O	O
this	O	O
is	O	O
the	O	O
age	B-LIVB
group	I-LIVB
in	O	O
which	O	O
most	O	O
vaccines	B-CHEM
are	O	O
administered	O
.	O	O

Factors	O
other	O	O
than	O	O
sex	B-PHYS
,	O	O
such	O	O
as	O	O
timing	O
or	O	O
coadministration	B-PROC
of	O	O
other	O	O
vaccines	B-CHEM
,	O	O
can	O	O
also	O	O
influence	O
the	O	O
immune	B-PHYS
response	I-PHYS
to	O	O
vaccination	B-PROC
.	O	O

Individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
of	O	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
of	O	O
vaccines	B-CHEM
in	O	O
healthy	O	O
infants	B-LIVB
and	O	O
young	O
children	B-LIVB
will	O	O
be	O	O
conducted	O	O
.	O	O

Fully	O	O
anonymised	O	O
data	O
from	O	O
∼170	O	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
of	O	O
v	O	O
accines	B-CHEM
for	O	O
diphtheria	B-DISO
,	O	O
tetanus	B-DISO
,	O	O
Bordetella	B-LIVB
pertussis	I-LIVB
,	O	O
polio	B-DISO
,	O	O
Haemophilus	B-LIVB
influenzae	I-LIVB
type	I-LIVB
B	I-LIVB
,	O	O
hepatitis	B-DISO
B	I-DISO
,	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
,	O	O
Neisseria	B-LIVB
meningitidis	I-LIVB
,	O	O
measles	B-DISO
,	O	O
mumps	B-DISO
,	O	O
rubella	B-DISO
,	O	O
varicella	B-DISO
and	O	O
rotavirus	B-LIVB
will	O	O
be	O	O
combined	O	O
for	O	O
analysis	B-PROC
.	O	O

Outcomes	O
include	O	O
measures	O
of	O	O
immunogenicity	B-PHEN
(	O	O
immunoglobulins	B-CHEM
)	O	O
,	O	O
reactogenicity	B-DISO
,	O	O
safety	B-PHEN
and	O	O
disease	B-DISO
-specific	O	O
clinical	O
efficacy	O
.	O	O

Data	O
from	O	O
trials	B-PROC
of	O	O
vaccines	B-CHEM
containing	O	O
similar	O	O
components	B-OBJC
will	O	O
be	O	O
combined	O	O
in	O	O
hierarchical	O
models	O
and	O	O
the	O	O
effect	O
of	O	O
sex	B-PHYS
and	O	O
timing	O
of	O	O
vaccinations	B-PROC
estimated	O	O
for	O	O
each	O	O
outcome	O
separately	O	O
.	O	O

Systematic	O
reviews	O
of	O	O
published	O
estimates	O	O
of	O	O
sex	B-PHYS
-	I-PHYS
differences	I-PHYS
cannot	O	O
adequately	O	O
answer	B-PROC
questions	I-PROC
in	O	O
this	O	O
field	O
since	O	O
such	O	O
comparisons	O
are	O	O
never	O	O
the	O	O
main	O	O
purpose	O
of	O	O
a	O	O
clinical	B-PROC
trial	I-PROC
,	O	O
thus	O	O
a	O	O
large	O
degree	O
of	O	O
reporting	B-PROC
bias	O
exists	O
in	O	O
the	O	O
published	O
literature	O
.	O	O

Recent	O	O
improvements	O
in	O	O
the	O	O
widespread	O
availability	O
of	O
individual	B-LIVB
participant	B-LIVB
data	O
from	O	O
randomised	B-PROC
controlled	I-PROC
trials	I-PROC
makes	O	O
it	O	O
feasible	O	O
to	O	O
conduct	O	O
extensive	O
individual	B-LIVB
participant	B-LIVB
data	O
meta	B-PROC
-	I-PROC
analyses	I-PROC
which	O	O
were	O	O
previously	O
impossible	B-DISO
,	O	O
thereby	O	O
reducing	O
the	O	O
effect	O
of	O	O
publication	B-OBJC
or	O	O
reporting	B-PROC
bias	O
on	O	O
the	O	O
understanding	B-PHYS
of	O	O
the	O	O
infant	B-LIVB
immune	B-PHYS
response	I-PHYS
.	O	O

Preliminary	O
results	O
will	O	O
be	O	O
available	O
in	O	O
2016	O	O
with	O	O
final	O	O
results	O
available	O
in	O	O
2019	O	O
.	O	O

No	O
ethics	O
review	O
is	O	O
required	O	O
for	O	O
secondary	O
analyses	O
of	O	O
anonymised	O	O
data	O
.	O	O

Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
temperature	O
/	O	O
pH	O
sensitive	O
hydrogels	B-CHEM
for	O	O
drug	B-CHEM
controlled	I-CHEM
release	I-CHEM
Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
temperature	O
/	O	O
pH	O
sensitive	O
hydrogels	B-CHEM
were	O	O
prepared	O	O
by	O	O
the	O	O
crosslinking	B-PHYS
copolymerization	I-PHYS
of	O	O
xylan	B-CHEM
with	O	O
N	B-CHEM
-	I-CHEM
isopropylacrylamide	I-CHEM
(	O	O
NIPAm	B-CHEM
)	O	O
and	O	O
acrylic	B-CHEM
acid	I-CHEM
(	O	O
AA	B-CHEM
)	O	O
using	O	O
N	B-CHEM
,	I-CHEM
Ń	I-CHEM
-	I-CHEM
methylenebis	I-CHEM
-	I-CHEM
acrylamide	I-CHEM
(	O	O
MBA	B-CHEM
)	O	O
as	O	O
a	O	O
cross	B-CHEM
-	I-CHEM
linker	I-CHEM
and	O	O
2	B-CHEM
,	I-CHEM
2	I-CHEM
-	I-CHEM
dimethoxy	I-CHEM
-	I-CHEM
2	I-CHEM
-	I-CHEM
phenylacetophenone	I-CHEM
as	O	O
a	O	O
photoinitiator	B-CHEM
via	O	O
ultraviolet	B-PHEN
irradiation	I-PHEN
.	O	O

The	O	O
influence	O
of	O	O
the	O	O
NIPAm	B-CHEM
,	O	O
AA	B-CHEM
and	O	O
MBA	B-CHEM
amount	O	O
on	O	O
properties	O	O
of	O	O
xylan	B-CHEM
-	I-CHEM
based	I-CHEM
hydrogels	B-CHEM
was	O	O
discussed	O	O
.	O	O

The	O	O
morphology	O
and	O	O
interactions	O
of	O	O
hydrogels	B-CHEM
were	O	O
characterized	O
by	O	O
SEM	B-PROC
and	O	O
FTIR	B-PROC
.	O	O

The	O	O
lower	O
critical	O
solution	O
temperature	O
(	O	O
LCST	O
)	O	O
of	O	O
hydrogels	B-CHEM
was	O	O
investigated	O
by	O	O
DSC	B-PROC
.	O	O

The	O	O
results	B-DISO
indicated	O	O
that	O	O
the	O	O
LCST	O
of	O	O
hydrogels	B-CHEM
emerged	O	O
at	O	O
around	O	O
34°C	O	O
and	O	O
increased	O	O
with	O	O
increasing	O	O
the	O	O
AA	B-CHEM
content	O	O
.	O	O

The	O	O
drug	B-CHEM
encapsulation	B-PHEN
efficiency	O
of	O	O
as	O	O
-	O	O
prepared	O	O
hydrogels	B-CHEM
reached	O	O
to	O	O
97	O	O
.	O	O
60	O	O
%	O	O
and	O	O
the	O	O
cumulative	O
release	B-PHEN
rate	O
of	O	O
acetylsalicylic	B-CHEM
acid	I-CHEM
was	O	O
90	O	O
.	O	O
12	O	O
%	O	O
and	O	O
26	O	O
.	O	O
35	O	O
%	O	O
in	O	O
the	O	O
intestinal	B-ANAT
and	O	O
gastric	B-ANAT
fluid	I-ANAT
,	O	O
respectively	O	O
.	O	O

Xylan	B-CHEM
-	I-CHEM
based	I-CHEM
hydrogels	B-CHEM
were	O	O
proved	O	O
to	O	O
be	O	O
biocompatible	O
with	O	O
NIH3T3	B-ANAT
cell	I-ANAT
by	O	O
MTT	B-PROC
assay	I-PROC
and	O	O
showed	O	O
the	O	O
promising	O	O
application	O	O
as	O	O
drug	B-CHEM
carriers	I-CHEM
for	O	O
the	O	O
intestinal	B-ANAT
-	O	O
targeted	O
oral	B-PROC
drug	I-PROC
delivery	I-PROC
.	O	O

Isolation	B-PROC
and	O	O
prebiotic	B-CHEM
activity	O
of	O	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
polysaccharides	B-CHEM
fractions	O
from	O	O
the	O	O
bamboo	B-OBJC
shoots	I-OBJC
(	O	O
Phyllostachys	B-LIVB
praecox	I-LIVB
)	O	O
The	O	O
water	B-CHEM
-	I-CHEM
soluble	I-CHEM
polysaccharides	B-CHEM
from	O	O
bamboo	B-OBJC
shoots	I-OBJC
(	O	O
Phyllostachys	B-LIVB
praecox	I-LIVB
)	O	O
(	O	O
WBP	B-CHEM
)	O	O
were	O	O
isolated	O
,	O	O
and	O	O
the	O	O
characterizations	O
as	O	O
well	O	O
as	O	O
prebiotic	B-CHEM
activities	O
were	O	O
investigated	O
.	O	O

The	O	O
yield	O
of	O	O
WBP	B-CHEM
was	O	O
7	O	O
.	O	O

58±0	O	O
.	O	O

31	O	O
%	O	O
under	O	O
optimal	O	O
hot	B-CHEM
-	I-CHEM
water	I-CHEM
extraction	B-PROC
conditions	O	O
.	O	O

Two	O	O
fractions	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O
,	O	O

WBP	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
WBP	B-CHEM
-	I-CHEM
2	I-CHEM
with	O	O
molecular	O
weight	O
of	O	O
83	O	O
.	O	O

50kDa	O	O
and	O	O
80	O	O
.	O	O

08kDa	O	O
,	O	O
respectively	O	O
,	O	O
were	O	O
purified	O	O
by	O	O
chromatography	B-PROC
.	O	O

Both	O	O
the	O	O
polysaccharides	B-CHEM
fractions	O
were	O	O
identified	O	O
as	O	O
heteropolysaccharides	B-CHEM
-	I-CHEM
protein	I-CHEM
complexes	I-CHEM
composed	O	O
of	O	O
15	O	O
kinds	O	O
of	O	O
common	O	O
amino	B-CHEM
acids	I-CHEM
in	O	O
protein	B-CHEM
part	O	O
and	O	O
rhamnose	B-CHEM
,	O	O
arabinose	B-CHEM
,	O	O
xylose	B-CHEM
,	O	O
mannose	B-CHEM
,	O	O
glucose	B-CHEM
and	O	O
galactose	B-CHEM
in	O	O
different	O	O
molar	O
ratios	O
in	O	O
polysaccharide	B-CHEM
part	O	O
.	O	O

The	O	O
existence	O	O
of	O	O
α	O
-	O
and	O	O
β	O
-	O
glycosidic	O
linkages	O
between	O	O
the	O	O
sugar	B-CHEM
units	O	O
was	O	O
confirmed	O	O
by	O	O
FTIR	B-PROC
and	O	O
NMR	B-PROC
spectra	I-PROC
.	O	O

Compared	O	O
with	O	O
the	O	O
blank	O	O
control	O	O
and	O	O
the	O	O
reference	O	O
of	O	O
FOS	O	O
,	O	O
WBP	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
WBP	B-CHEM
-	I-CHEM
2	I-CHEM
significantly	O	O
increased	O	O
the	O	O
numbers	O	O
of	O	O
Bifidobacterium	B-LIVB
adolescentis	I-LIVB
and	O	O
Bifidobacterium	B-LIVB
bifidum	I-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
which	O	O
contributed	O	O
to	O	O
the	O	O
production	O
of	O	O
organic	B-CHEM
acids	I-CHEM
,	O	O
suggesting	O	O
that	O	O
the	O	O
polysaccharides	B-CHEM
have	O	O
potential	O
prebiotic	B-CHEM
properties	O
.	O	O

Combination	O	O
of	O	O
diagnostic	B-PROC
laparoscopy	I-PROC
and	O	O
intraoperative	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
for	O	O
the	O	O
early	B-PROC
detection	I-PROC
of	O	O
intestinal	B-DISO
ischemia	I-DISO
not	O	O
detectable	B-PHYS
at	O	O
CT	B-PROC
scan	I-PROC
Acute	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
is	O	O
the	O	O
most	O	O
severe	O	O
gastrointestinal	B-DISO
complication	I-DISO
of	O	O
acute	B-DISO
aortic	I-DISO
dissection	I-DISO
.	O	O

The	O	O
timing	O	O
of	O	O
diagnosis	B-DISO
is	O	O
of	O	O
major	O	O
importance	O	O
,	O	O
in	O	O
fact	O	O
the	O	O
recognition	O	O
of	O	O
acute	B-DISO
mesenteric	I-DISO
ischemia	I-DISO
often	O	O
occurs	O	O
too	O	O
late	O	O
due	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
unspecific	O	O
symptoms	B-DISO
and	O	O
lack	O	O
of	O	O
reliable	O	O
exams	O	O
.	O	O

Recently	O	O
,	O	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
has	O	O
been	O	O
adopted	O	O
in	O	O
order	O	O
to	O	O
measure	O	O
blood	B-PHYS
perfusion	I-PHYS
and	O	O
microcirculation	B-PHYS
.	O	O

We	O	O
decided	O	O
to	O	O
perform	O	O
a	O	O
diagnostic	B-PROC
laparoscopy	I-PROC
with	O	O
the	O	O
support	O	O
of	O	O
intra	O
-	O
operative	O
near	O	O
-	O	O
infrared	O	O
indocyanine	B-PROC
green	I-PROC
fluorescence	I-PROC
angiography	I-PROC
,	O	O
in	O	O
order	O	O
to	O	O
detect	O	O
an	O	O
initial	O	O
intestinal	B-DISO
ischemia	I-DISO
in	O	O
a	O	O
68	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	B-LIVB
previously	O	O
treated	B-PROC
with	I-PROC
a	O	O
TEVAR	B-PROC
procedure	I-PROC
for	O	O
a	O	O
type	B-DISO
-	I-DISO
B	I-DISO
aortic	I-DISO
dissection	I-DISO
.	O	O

The	O	O
fluorescence	B-PROC
system	I-PROC
demonstrated	O	O
an	O	O
hypoperfused	O
area	O
in	O	O
the	O	O
ascending	B-ANAT
colon	I-ANAT
,	O	O
therefore	O	O
an	O	O
ileocholic	B-PROC
resection	I-PROC
was	O	O
thus	O	O
performed	O	O
.	O	O

Opening	O	O
the	O	O
operatory	O	O
specimen	B-OBJC
,	O	O
the	O	O
mucosa	O
of	O	O
the	O	O
colon	O
appeared	O	O
totally	O	O
ischemic	B-DISO
,	I-DISO
whilst	O	O
the	O	O
serosa	O
was	O	O
normal	O	O
.	O	O

When	O	O
ischemia	B-DISO
occurs	O	O
,	O	O
the	O	O
oxygen	B-PHYS
supply	I-PHYS
is	O	O
interrupted	O	O
,	O	O
hence	O	O
the	O	O
necrosis	B-PHYS
of	O	O
the	O	O
enteral	O	O
mucosa	O
occurs	O	O
within	O	O
3h	O	O
,	O	O
whilst	O	O
the	O	O
necrosis	B-PHYS
of	O	O
the	O	O
full	B-DISO
thickness	I-DISO
of	I-DISO
the	I-DISO
bowel	I-DISO
wall	I-DISO
occurs	O	O
within	O	O
6h	O	O
.	O	O

A	O	O
diagnosis	B-DISO
during	O	O
these	O	O
""""	O	O
golden	O
hours	O
""""	O	O
is	O	O
of	O	O
major	O	O
importance	O	O
for	O	O
a	O	O
successful	O	O
treatment	B-PROC
.	O	O

The	O	O
combination	O	O
of	O	O
laparoscopy	B-PROC
and	O	O
UV	B-PROC
light	I-PROC
and	O	O
fluorescein	B-CHEM
dye	I-CHEM
should	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
invaluable	O	O
diagnostic	B-PROC
procedure	I-PROC
for	O	O
the	O	O
diagnosis	B-DISO
of	O	O
early	O
stage	O
acute	B-DISO
bowel	I-DISO
ischemia	I-DISO
which	O	O
is	O	O
not	O	O
visible	O	O
at	O	O
instrumental	B-PROC
examinations	I-PROC
nor	O	O
with	O	O
diagnostic	B-PROC
laparoscopy	I-PROC
.	O	O

An	O	O
ultrasensitive	O
electrochemiluminescence	B-PROC
sensor	B-OBJC
based	O	O
on	O	O
reduced	B-CHEM
graphene	I-CHEM
oxide	I-CHEM
-	O	O
copper	B-CHEM
sulfide	I-CHEM
composite	O
coupled	O	O
with	O	O
capillary	B-PROC
electrophoresis	I-PROC
for	O	O
determination	B-PROC
of	O	O
amlodipine	B-CHEM
besylate	I-CHEM
in	O	O
mice	B-LIVB
plasma	B-ANAT
A	O	O
new	O	O
electrochemiluminescence	B-PROC
(	O	O
ECL	B-PROC
)	O	O
sensor	B-OBJC
based	O	O
on	O	O
reduced	B-CHEM
graphene	I-CHEM
oxide	I-CHEM
-	O	O
copper	B-CHEM
sulfide	I-CHEM
(	O	O
rGO	B-CHEM
-	O	O
CuS	B-CHEM
)	O	O
composite	O
coupled	O	O
with	O	O
capillary	B-PROC
electrophoresis	I-PROC
(	O	O
CE	B-PROC
)	O	O
was	O	O
constructed	O	O
for	O	O
the	O	O
ultrasensitive	O
detection	B-PROC
of	O	O
amlodipine	B-CHEM
besylate	I-CHEM
(	O	O
AML	B-CHEM
)	O	O
for	O	O
the	O	O
first	O	O
time	O	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
rGO	B-CHEM
-	O	O
CuS	B-CHEM
composite	O
was	O	O
synthesized	O	O
by	O	O
one	O	O
-	O	O
pot	O	O
hydrothermal	O
method	O
and	O	O
used	O	O
for	O	O
electrode	B-DEVI
modification	B-DISO
.	O	O

The	O	O
electrochemical	B-PROC
and	O	O
ECL	B-PROC
behaviors	O	O
of	O	O
the	O	O
sensor	B-OBJC
were	O	O
investigated	O
.	O	O

More	O	O
than	O	O
5	O	O
-	O	O
fold	O	O
enhance	O
in	O	O
ECL	B-PROC
intensity	O
was	O	O
observed	O
after	O	O
modified	O	O
with	O	O
rGO	B-CHEM
-	O	O
CuS	B-CHEM
composite	O
.	O	O

The	O	O
results	B-PHEN
can	O	O
be	O	O
ascribed	O	O
to	O	O
the	O	O
presence	O
of	O	O
rGO	B-CHEM
-	O	O
CuS	B-CHEM
composite	O
on	O	O
the	O	O
electrode	B-DEVI
surface	O
that	O	O
facilitates	O	O
the	O	O
electron	O
transfer	O
rate	O
between	O	O
the	O	O
electroactive	O
center	O
of	O	O
Ru	B-CHEM
(	I-CHEM
bpy	I-CHEM
)	I-CHEM
3	I-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
and	O	O
the	O	O
electrode	B-DEVI
.	O	O

The	O	O
ECL	B-PROC
sensor	B-OBJC
was	O	O
coupled	O
with	O	O
CE	B-PROC
to	O	O
improve	O	O
the	O	O
selectivity	B-PHEN
and	O	O
the	O	O
CE	B-PROC
-	O	O
ECL	B-PROC
parameters	B-DISO
that	O	O
affect	O	O
separation	O
and	O	O
detection	B-PROC
were	O	O
optimized	O	O
.	O	O

Under	O	O
the	O	O
optimum	O
conditions	O	O
,	O	O
the	O	O
linear	O
ranges	O
for	O	O
AML	B-CHEM
was	O	O
0	O	O
.	O	O
008	O	O
-	O	O
5	O	O
.	O	O

0μg	O	O
/	O	O
mL	O	O
with	O	O
a	O	O
detection	O
limit	O
of	O	O
2	O	O
.	O	O

8ng	O	O
/	O	O
mL	O	O
(	O	O
S	O	O
/	O	O
N	O	O
=	O	O
3	O	O
)	O	O
.	O	O

The	O	O
method	B-PROC
displayed	O	O
the	O	O
advantages	O	O
of	O	O
high	B-PHEN
sensitivity	I-PHEN
,	O	O
good	B-PHEN
selectivity	I-PHEN
,	O	O
wide	O	O
linear	O
range	O
,	O	O
low	O	O
detection	O
limit	O
and	O	O
fine	O
reproducibility	O
,	O	O
and	O	O
was	O	O
used	O	O
to	O	O
analyze	O	O
AML	B-CHEM
in	O	O
mice	B-LIVB
plasma	B-ANAT
with	O	O
a	O	O
satisfactory	O	O
result	B-PHEN
,	O	O
which	O	O
holds	O	O
a	O	O
great	O	O
potential	O
in	O	O
the	O	O
field	O	O
of	O	O
pharmaceutical	B-PROC
analysis	I-PROC
.	O	O

Metabolic	B-PHYS
shift	B-DISO
of	O	O
the	O	O
kynurenine	B-CHEM
pathway	O
impairs	O
alcohol	O
and	O	O
cocaine	B-DISO
seeking	I-DISO
and	O	O
relapse	B-PHEN
The	O	O
glutamatergic	B-PHYS
system	I-PHYS
plays	O	O
a	O	O
key	O	O
role	O	O
in	O	O
the	O	O
maintenance	O
of	O
drug	O
use	O
and	O	O
development	O
of	O	O
drug	O
-	O
related	O
conditioned	O
behaviours	O
.	O	O

In	O	O
particular	O	O
,	O	O
hyper	B-PHYS
-	I-PHYS
glutamatergic	I-PHYS
activity	I-PHYS
and	O	O
N	B-CHEM
-	I-CHEM
methyl	I-CHEM
-	I-CHEM
D	I-CHEM
-	I-CHEM
aspartate	I-CHEM
receptor	I-CHEM
(	O	O
NMDAR	B-CHEM
)	O	O
activation	B-PHYS
may	O	O
drive	O	O
drug	B-DISO
craving	I-DISO
and	O	O
relapse	B-PHEN
.	O	O

Inhibition	B-PHYS
of	O	O
kynurenine	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
monooxygenase	I-CHEM
(	O	O
KMO	B-CHEM
)	O	O
shifts	B-DISO
the	O	O
metabolic	B-PHYS
kynurenine	B-CHEM
pathway	O
towards	O	O
production	O
of	O	O
kynurenic	B-CHEM
acid	I-CHEM
,	O	O
which	O	O
leads	O	O
to	O	O
a	O	O
reduction	B-PROC
of	O	O
glutamatergic	B-PHYS
/	O	O
NMDAR	B-CHEM
activity	B-PHYS
via	O	O
different	O	O
mechanisms	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
investigated	O
whether	O	O
drug	B-DISO
-	I-DISO
seeking	I-DISO
and	O	O
relapse	B-PHEN
behaviour	O
could	O	O
be	O	O
modified	O
by	O
the	O	O
metabolic	B-PHYS
shift	B-DISO
of	O	O
endogenous	O
kynurenine	B-CHEM
pathway	O
.	O	O

An	O	O
inhibitor	B-CHEM
of	O	O
kynurenine	B-CHEM
-	I-CHEM
3	I-CHEM
-	I-CHEM
monooxygenase	I-CHEM
(	O	O
KMO	B-CHEM
)	O	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
(	O	O
4	O	O
and	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
its	O	O
prodrug	B-CHEM
JM6	B-CHEM
(	O	O
100	O	O
and	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
tested	O
in	O	O
two	O	O
behavioural	B-LIVB
rat	I-LIVB
models	I-LIVB
for	O	O
drug	B-DISO
seeking	I-DISO
and	O	O
relapse	B-PHEN
-the	O	O
alcohol	B-DISO
deprivation	I-DISO
effect	I-DISO
(	O	O
ADE	B-DISO
)	O	O
model	B-LIVB
in	O	O
long	O
-	O
term	O
alcohol	O
-	O
drinking	O
rats	B-LIVB
and	O	O
the	O	O
model	B-LIVB
of	O	O
cue	O
-	O
induced	O
reinstatement	O
of	O	O
alcohol	O
-	O
and	O	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviour	I-DISO
.	O	O

Our	O	O
results	O	O
show	O	O
that	O	O
relapse	B-PHEN
-like	O	O
alcohol	O
drinking	O
during	O	O
the	O	O
ADE	B-DISO
was	O	O
abolished	O	O
by	O	O
repeated	O	O
intraperitoneal	B-PROC
administration	I-PROC
of	O	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
and	O	O
significantly	O	O
reduced	O
by	O	O
its	O	O
oral	O
prodrug	B-CHEM
JM6	B-CHEM
.	O	O

Cue	O
-	O
induced	O
reinstatement	O
of	O	O
both	O	O
alcohol	O
-	O
and	O	O
cocaine	B-DISO
-	I-DISO
seeking	I-DISO
behaviour	I-DISO
was	O	O
also	O	O
abolished	O	O
by	O	O
administration	B-PROC
of	O	O
Ro61	B-CHEM
-	I-CHEM
8048	I-CHEM
.	O	O

Pharmacological	B-CHEM
enhancement	O
of	O	O
endogenous	O
kynurenic	B-CHEM
acid	I-CHEM
levels	O
provides	O	O
a	O	O
novel	O
treatment	O
strategy	O
to	O	O
interfere	O
with	O
glutamatergic	B-PHYS
/	O	O
NMDAR	B-CHEM
activity	B-PHYS
as	O	O
well	O	O
as	O	O
with	O	O
craving	B-DISO
and	O	O
relapse	B-PHEN
in	O	O
alcohol	O
-	O
dependent	O
patients	O
and	O
drug	O
addicts	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
analgesic	B-CHEM
efficacy	O
of	O	O
oral	O
ketorolac	B-CHEM
versus	O	O
intramuscular	O
tramadol	B-CHEM
after	O	O
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
:	O	O
A	O	O
parallel	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
randomized	B-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
clinical	B-PROC
trial	I-PROC
Preemptive	B-PROC
analgesia	I-PROC
is	O	O
considered	O	O
an	O	O
alternative	O
for	O	O
treating	O
the	O	O
postsurgical	B-DISO
pain	I-DISO
of	O	O
third	B-ANAT
molar	I-ANAT
removal	B-PROC
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
preemptive	B-PROC
analgesic	I-PROC
efficacy	O
of	O	O
oral	O
ketorolac	B-CHEM
versus	O	O
intramuscular	O
tramadol	B-CHEM
after	O	O
a	O	O
mandibular	B-ANAT
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
.	O	O

A	O	O
parallel	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
,	O	O
randomized	B-PROC
,	O	O
placebo	B-PROC
-	I-PROC
controlled	I-PROC
clinical	B-PROC
trial	I-PROC
was	O	O
carried	O	O
out	O	O
.	O	O

Thirty	O	O
patients	B-LIVB
were	O	O
randomized	B-PROC
into	O	O
two	O	O
treatment	B-PROC
groups	O
using	O	O
a	O	O
series	O	O
of	O	O
random	O	O
numbers	O	O
:	O	O
Group	O
A	O
,	O	O
oral	O
ketorolac	B-CHEM
10	O	O
mg	O	O
plus	O	O
intramuscular	O
placebo	B-CHEM
(	O	O
1	O	O
mL	O	O
saline	B-OBJC
solution	I-OBJC
)	O	O
;	O	O
or	O	O
Group	O
B	O
,	O	O
oral	O
placebo	B-CHEM
(	O	O
similar	O	O
tablet	B-CHEM
to	O	O
oral	O
ketorolac	B-CHEM
)	O	O
plus	O	O
intramuscular	O
tramadol	B-CHEM
50	O	O
mg	O	O
diluted	O
in	O	O
1	O	O
mL	O	O
saline	B-OBJC
solution	I-OBJC
.	O	O

These	O	O
treatments	B-PROC
were	O	O
given	O	O
30	O	O
min	O	O
before	O	O
the	O	O
surgery	B-PROC
.	O	O

We	O	O
evaluated	B-PROC
the	O	O
time	O	O
of	O	O
first	O	O
analgesic	B-CHEM
rescue	I-CHEM
medication	I-CHEM
,	O	O
pain	B-PHYS
intensity	I-PHYS
,	O	O
total	O
analgesic	O
consumption	O
and	O	O
adverse	B-DISO
effects	I-DISO
.	O	O

Patients	B-LIVB
taking	O	O
oral	O
ketorolac	B-CHEM
had	O	O
longer	O
time	O
of	O	O
analgesic	B-DISO
covering	I-DISO
and	O	O
less	O
postoperative	B-DISO
pain	I-DISO
when	O	O
compared	O	O
with	O	O
patients	B-LIVB
receiving	O	O
intramuscular	O
tramadol	B-CHEM
.	O	O

According	O	O
to	O	O
the	O	O
VAS	B-PROC
and	O	O
UAC	B-DEVI
results	O
,	O	O
this	O	O
study	O	O
suggests	O	O
that	O	O
10	O	O
mg	O	O
of	O	O
oral	O
ketorolac	B-CHEM
had	O	O
superior	O	O
analgesic	B-DISO
effect	I-DISO
than	O	O
50	O	O
mg	O	O
of	O	O
tramadol	B-CHEM
when	O	O
administered	O	O
before	O	O
a	O	O
mandibular	B-ANAT
third	B-ANAT
molar	I-ANAT
surgery	B-PROC
.	O	O

Estrogen	B-CHEM
and	O	O
Progesterone	B-CHEM
hormone	B-CHEM
receptor	B-PHYS
expression	I-PHYS
in	O	O
oral	B-DISO
cavity	I-DISO
cancer	I-DISO
Recent	O	O
studies	O	O
have	O	O
shown	O	O
an	O	O
increase	O
in	O	O
the	O	O
incidence	O
of	O	O
oral	B-DISO
squamous	I-DISO
cell	I-DISO
carcinoma	I-DISO
(	O	O
OSCC	B-DISO
)	O	O
in	O	O
younger	O
patients	B-LIVB
.	O	O

The	O	O
hypothesis	O
that	O	O
tumors	B-DISO
could	O	O
be	O	O
hormonally	B-CHEM
induced	O
during	O	O
pregnancy	B-PHYS
or	O	O
in	O	O
young	O
female	B-PHYS
patients	B-LIVB
without	O	O
the	O	O
well	O	O
-	O	O
known	O	O
risk	B-DISO
factors	I-DISO
alcohol	B-DISO
or	O	O
tobacco	B-DISO
abuse	I-DISO
seems	O	O
to	O	O
be	O	O
plausible	O	O
.	O	O

Estrogen	B-CHEM
Receptor	I-CHEM
alpha	I-CHEM
(	O	O
ERα	B-CHEM
)	O	O
and	O	O
Progesterone	B-CHEM
Receptor	I-CHEM
(	O	O
PR	B-CHEM
)	O	O
expression	B-PHYS
were	O	O
analyzed	B-PROC
in	O	O
normal	O	O
oral	B-ANAT
mucosa	I-ANAT
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
,	O	O
oral	B-DISO
precursor	I-DISO
lesions	I-DISO
(	O	O
simple	B-DISO
hyperplasia	I-DISO
,	O	O
n	O	O
=	O	O
11	O	O
;	O	O
squamous	B-DISO
intraepithelial	I-DISO
neoplasia	I-DISO
,	O	O
SIN	B-DISO
I	I-DISO
-	I-DISO
III	I-DISO
,	O	O
n	O	O
=	O	O
35	O	O
)	O	O
,	O	O
and	O	O
OSCC	B-DISO
specimen	B-OBJC
.	O	O

OSCCs	B-DISO
were	O	O
stratified	O
in	O	O
a	O	O
young	O
female	B-PHYS
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
study	O	O
cohort	B-LIVB
and	O	O
older	B-LIVB
patients	B-LIVB
(	O	O
n	O	O
=	O	O
46	O	O
)	O	O
.	O	O

In	O	O
the	O	O
young	O
female	B-PHYS
study	O	O
cohort	B-LIVB
three	O	O
patients	B-LIVB
(	O	O
n	O	O
=	O	O
3	O	O
/	O	O
7	O	O
)	O	O
developed	O	O
OSCC	B-DISO
during	O	O
or	O	O
shortly	O	O
after	O	O
pregnancy	B-PHYS
.	O	O

Breast	B-DISO
cancer	I-DISO
tissues	O
were	O	O
used	O	O
as	O	O
positive	O
control	O
for	O	O
ERα	B-CHEM
and	O	O
PR	B-CHEM
expression	B-PHYS
.	O	O

ERα	B-CHEM
expression	B-PHYS
was	O	O
found	O	O
in	O	O
four	O	O
oral	B-DISO
precursor	I-DISO
lesions	I-DISO
(	O	O
squamous	B-DISO
intraepithelial	I-DISO
neoplasia	I-DISO
,	O	O
SIN	B-DISO
I	I-DISO
-	I-DISO
III	I-DISO
,	O	O
n	O	O
=	O	O
4	O	O
/	O	O
35	O	O
,	O	O
11	O	O
%	O	O
)	O	O
and	O	O
in	O	O
five	O	O
OSCC	B-DISO
specimen	B-OBJC
(	O	O
n	O	O
=	O	O
5	O	O
/	O	O
46	O	O
,	O	O
11	O	O
%	O	O
)	O	O
.	O	O

The	O	O
five	O	O
ERα	B-CHEM
positive	B-DISO
OSCC	B-DISO
samples	B-OBJC
were	O	O
older	B-LIVB
male	B-PHYS
patients	B-LIVB
.	O	O

All	O	O
patients	B-LIVB
within	O	O
the	O	O
young	O
female	B-PHYS
study	O	O
cohort	B-LIVB
were	O	O
negatively	B-DISO
stained	O	O
for	O	O
both	O	O
ERα	B-CHEM
and	O	O
PR	B-CHEM
.	O	O

ER	B-CHEM
expression	B-PHYS
could	O	O
be	O	O
regarded	O	O
as	O	O
a	O	O
seldom	O
risk	B-DISO
factor	I-DISO
for	O	O
OSCC	B-DISO
.	O	O

PR	B-CHEM
expression	B-PHYS
seems	O	O
to	O	O
be	O	O
not	O	O
relevant	O
for	O	O
the	O	O
development	O
of	O	O
OSCC	B-DISO
.	O	O

Homeostasis	B-PHEN
of	O	O
chosen	O	O
bioelements	B-CHEM
in	O	O
organs	B-ANAT
of	O	O
rats	B-LIVB
receiving	O
lithium	B-CHEM
and	O	O
/	O	O
or	O	O
selenium	B-CHEM
Lithium	B-CHEM
is	O	O
an	O	O
essential	O	O
trace	B-CHEM
element	I-CHEM
,	O	O
widely	O	O
used	O	O
in	O	O
medicine	B-CHEM
and	O	O
its	O	O
application	O
is	O	O
often	O	O
long	O
-	O
term	O
.	O	O

Despite	O	O
beneficial	O
effects	O
,	O	O
its	O	O
administration	B-PROC
can	O	O
lead	O	O
to	O	O
severe	O
side	O
effects	O
including	O	O
hyperparathyroidism	B-DISO
,	O	O
renal	B-DISO
and	O	O
thyroid	B-DISO
disorders	I-DISO
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
current	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	O	O
the	O	O
influence	O
of	O	O
lithium	B-CHEM
and	O	O
/	O	O
or	O	O
selenium	B-CHEM
treatment	O
on	O	O
magnesium	B-CHEM
,	O	O
calcium	B-CHEM
and	O	O
silicon	B-CHEM
levels	O
in	O	O
rats	B-LIVB
'	O	O
organs	B-ANAT
as	O	O
well	O	O
as	O	O
the	O	O
possibility	O	O
of	O	O
using	O	O
selenium	B-CHEM
as	O	O
an	O	O
adjuvant	O
in	O	O
lithium	B-CHEM
therapy	B-PROC
.	O	O

The	O	O
study	B-PROC
was	O	O
performed	O	O
on	O	O
rats	B-LIVB
divided	O	O
into	O	O
four	O	O
groups	O
(	O	O
six	O	O
animals	B-LIVB
each	O	O
)	O	O
:	O	O
control	B-LIVB
-	O	O
treated	O
with	O	O
saline	B-OBJC
;	O	O
Li	B-CHEM
-	O	O
treated	O
with	O	O
Li2CO3	B-CHEM
(	O	O
2	O	O
.	O	O
7	O	O
mg	O	O
Li	B-CHEM
/kg	O	O
b	O	O
.	O	O

w	O	O
.	O	O
)	O	O
;	O	O
Se	B-CHEM
-	O	O
treated	O
with	O	O
Na2SeO3·H2O	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
mg	O	O
Se	B-CHEM
/kg	O	O
b	O	O
.	O	O

w	O	O
.	O	O
)	O	O
;	O	O
Se	B-CHEM
+	O	O
Li	B-CHEM
-	O	O
treated	O
simultaneously	O	O
with	O	O
Li2CO3	B-CHEM
and	O	O
Na2SeO3·H2O	B-CHEM
(	O	O
2	O	O
.	O	O
7	O	O
mg	O	O
Li	B-CHEM
/kg	O	O
b	O	O
.	O	O
w	O	O
.	O	O
and	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
Se	B-CHEM
/kg	O	O
b	O	O
.	O	O
w	O	O
.	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
administration	B-PROC
was	O	O
performed	O
in	O	O
form	O	O
of	O	O
water	B-CHEM
solutions	I-CHEM
by	O	O
stomach	B-DEVI
tube	I-DEVI
once	O	O
a	O	O
day	O
for	O	O
3	O	O
weeks	O
.	O	O

In	O	O
the	O	O
organs	B-ANAT
(	O	O
liver	B-ANAT
,	O	O
kidney	B-ANAT
,	O	O
brain	B-ANAT
,	O	O
spleen	B-ANAT
,	O	O
heart	B-ANAT
,	O	O
lung	B-ANAT
and	O	O
femoral	O
muscle	O
)	O	O
the	O	O
concentrations	O
of	O	O
magnesium	B-CHEM
,	O	O
calcium	B-CHEM
and	O	O
silicon	B-CHEM
were	O	O
determined	O	O
.	O	O

Magnesium	B-CHEM
was	O	O
increased	O
in	O	O
liver	B-ANAT
of	O	O
Se	B-CHEM
and	O	O
Se	B-CHEM
+	O	O
Li	B-CHEM
given	O	O
rats	B-LIVB
.	O	O

Lithium	B-CHEM
decreased	O
tissue	O
Ca	B-CHEM
and	O	O
co	B-PROC
-	I-PROC
administration	I-PROC
of	O	O
selenium	B-CHEM
reversed	O
this	O	O
effect	O
.	O	O

Silicon	B-CHEM
was	O	O
not	O	O
affected	O
by	O	O
any	O	O
treatment	O
.	O	O

The	O	O
beneficial	O
effect	O
of	O	O
selenium	B-CHEM
on	O	O
disturbances	O
of	O	O
calcium	B-CHEM
homeostasis	B-PHEN
let	O	O
suggest	O	O
that	O	O
further	O	O
research	B-PROC
on	O	O
selenium	B-CHEM
application	O	O
as	O	O
an	O	O
adjuvant	O
in	O	O
lithium	B-CHEM
therapy	B-PROC
is	O	O
worth	O	O
being	O	O
performed	O
.	O	O

Studying	B-PROC
neuroprotective	O
effect	O
of	O	O
Atorvastatin	B-CHEM
as	O	O
a	O	O
small	B-CHEM
molecule	I-CHEM
drug	B-CHEM
on	O	O
high	B-DISO
glucose	I-DISO
-	O	O
induced	O
neurotoxicity	B-DISO
in	O	O
undifferentiated	O
PC12	B-ANAT
cells	I-ANAT
:	O	O
role	O
of	O	O
NADPH	B-CHEM
oxidase	I-CHEM
Overproduction	O
of	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
by	O	O
NADPH	B-CHEM
oxidase	I-CHEM
(	O	O
NOX	B-CHEM
)	O	O
activation	B-PHYS
has	O	O
been	O	O
considered	O
the	O	O
essential	O
mechanism	O
induced	O
by	O	O
hyperglycemia	B-DISO
in	O	O
various	O	O
tissues	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O
comprehensive	O
study	B-PROC
on	O	O
the	O	O
role	O
of	O	O
NOXs	B-CHEM
in	O	O
high	B-DISO
glucose	I-DISO
(	O	O
HG	B-DISO
)	O	O
-	O	O
induced	O
toxic	B-DISO
effect	I-DISO
in	O	O
neural	O
tissues	O
.	O	O

Recently	O	O
,	O	O
a	O	O
therapeutic	O
strategy	B-PHYS
in	O	O
oxidative	O
related	O
pathologies	O
has	O	O
been	O	O
introduced	O
by	O	O
blocking	O
the	O	O
undesirable	O
actions	O
of	O	O
NOX	B-CHEM
enzymes	I-CHEM
by	O	O
small	B-CHEM
molecules	I-CHEM
.	O	O

The	O	O
protective	B-DISO
roles	O
of	O	O
Statins	B-CHEM
in	O	O
ameliorating	O
oxidative	B-DISO
stress	I-DISO
by	O	O
NOX	B-CHEM
inhibition	B-PHYS
have	O	O
been	O	O
shown	O	O
in	O	O
some	O	O
tissues	O
except	O	O
neural	O
.	O	O

We	O	O
hypothesized	O
then	O	O
,	O	O
that	O	O
different	O
NOXs	B-CHEM
may	O	O
have	O	O
role	O
in	O	O
HG	B-DISO
-	O	O
induced	O
neural	B-DISO
cell	I-DISO
injury	I-DISO
.	O	O

Furthermore	O	O
,	O	O
we	O	O
postulate	O
that	O	O
Atorvastatin	B-CHEM
as	O	O
a	O	O
small	B-CHEM
molecule	I-CHEM
may	O	O
modulate	O
this	O	O
NOXs	B-PHYS
activity	I-PHYS
to	O	O
protect	B-DISO
neural	B-ANAT
cells	I-ANAT
.	O	O

Undifferentiated	O
PC12	B-ANAT
cells	I-ANAT
were	O	O
treated	B-PROC
with	I-PROC
HG	B-DISO
(	O	O
140	O	O
mM	O	O
/	O	O
24	O
h	O
)	O	O
in	O	O
the	O	O
presence	B-DISO
and	O	O
absence	O
of	O	O
Atorvastatin	B-CHEM
(	O	O
1	O	O
μM	O	O
/	O	O
96	O
h	O
)	O	O
.	O	O

The	O	O
cell	B-PHYS
viability	I-PHYS
was	O	O
measured	O
by	O	O
MTT	B-PROC
assay	I-PROC
and	O	O
the	O	O
gene	O
and	O	O
protein	B-PHEN
expressions	I-PHEN
profile	I-PHEN
of	O	O
NOX	B-CHEM
(	O	O
1	O	O
-	O	O
4	O	O
)	O	O
were	O	O
determined	O
by	O
RT	B-PROC
-	I-PROC
PCR	I-PROC
and	O	O
western	B-PROC
blotting	I-PROC
,	O	O
respectively	O	O
.	O	O

Levels	O
of	O	O
ROS	B-CHEM
and	O	O
malondialdehyde	B-CHEM
(	O	O
MDA	B-CHEM
)	O	O
were	O	O
also	O	O
evaluated	O
.	O	O

Gene	B-PHYS
and	O	O
protein	B-PHYS
expression	I-PHYS
levels	O
of	O	O
NOX	B-CHEM
(	O	O
1	O	O
-	O	O
4	O	O
)	O	O
and	O	O
consequently	B-DISO
ROS	B-CHEM
and	O	O
MDA	B-CHEM
levels	O
were	O	O
elevated	O
in	O	O
HG	B-DISO
-	O	O
treated	O
PC12	B-ANAT
cells	I-ANAT
.	O	O

Atorvastatin	B-CHEM
could	O	O
significantly	O
decrease	O
HG	B-DISO
-	O	O
induced	O
NOXs	B-CHEM
,	O	O
ROS	B-CHEM
and	O	O
MDA	B-CHEM
elevation	O
and	O	O
improve	B-DISO
impaired	O
cell	B-PHYS
viability	I-PHYS
.	O	O

It	O	O
can	O	O
be	O	O
concluded	O
that	O	O
HG	B-DISO
could	O	O
elevate	O
NOXs	B-PHYS
activity	I-PHYS
,	O	O
ROS	B-CHEM
and	O	O
MDA	B-CHEM
levels	O
in	O	O
neural	O
tissues	O
and	O	O
Atorvastatin	B-CHEM
as	O	O
a	O	O
small	B-CHEM
molecule	I-CHEM
NOX	B-CHEM
inhibitor	I-CHEM
drug	I-CHEM
may	O	O
prevent	O
and	O	O
delay	O
diabetic	B-DISO
complications	I-DISO
,	O	O
particularly	O	O
neuropathy	B-DISO
.	O	O

Substance	B-DISO
use	I-DISO
and	O	O
sexual	B-PHYS
function	I-PHYS
in	O	O
juvenile	B-DISO
idiopathic	I-DISO
arthritis	I-DISO
To	O	O
evaluate	O	O
alcohol	O
/	O	O
tobacco	O
/	O	O
illicit	O
drug	O
use	O
and	O	O
sexual	B-PHYS
function	I-PHYS
in	O	O
adolescent	B-LIVB
juvenile	B-DISO
idiopathic	I-DISO
arthritis	I-DISO
(	O	O
JIA	B-DISO
)	O	O
and	O	O
healthy	O
controls	O
.	O	O

174	O	O
adolescents	B-LIVB
with	O	O
pediatric	O
rheumatic	B-DISO
diseases	I-DISO
were	O	O
selected	O	O
.	O	O

A	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
with	O	O
54	O	O
JIA	B-DISO
patients	B-LIVB
and	O	O
35	O	O
controls	B-LIVB
included	O	O
demographic	O
/	O	O
anthropometric	B-PROC
data	O
and	O	O
puberty	B-DISO
markers	O
assessments	O
,	O	O
physician	B-LIVB
-conducted	O	O
CRAFFT	B-PROC
(	O	O
car	B-OBJC
/	O	O
relax	O
/	O	O
alone	O
/	O	O
forget	B-DISO
/	O	O
friends	B-LIVB
/	O	O
trouble	O
)	O	O
screen	O	O
tool	O	O
for	O	O
substance	B-DISO
abuse	I-DISO
/	O	O
dependence	B-DISO
high	B-DISO
risk	I-DISO
and	O	O
a	O	O
questionnaire	O
that	O	O
evaluated	B-PROC
sexual	B-PHYS
function	I-PHYS
,	O	O
bullying	B-DISO
and	O	O
alcohol	O
/	O	O
tobacco	O
/	O	O
illicit	O
drug	O
use	O
.	O	O

Clinical	O
/	O	O
laboratorial	O
data	O
and	O	O
treatment	B-PROC
were	O	O
also	O	O
assessed	O
in	O	O
JIA	B-DISO
.	O	O

The	O	O
median	O
current	O
age	O
was	O	O
similar	O	O
between	O	O
JIA	B-DISO
patients	B-LIVB
and	O	O
controls	B-LIVB
[	O	O
15	O	O
(	O	O
10	O	O
-	O	O
19	O	O
)	O	O
vs	O	O
.	O	O

15	O	O
(	O	O
12	O	O
-	O	O
18	O	O
)	O	O
years	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
506	O	O
]	O	O
.	O	O

Frequencies	O	O
of	O	O
alcohol	O
/	O	O
tobacco	O
/	O	O
illicit	O
drug	O
use	O
were	O	O
high	O
and	O	O
similar	O	O
in	O	O
both	O	O
JIA	B-DISO
and	O	O
controls	B-LIVB
(	O	O
43	O	O
%	O	O
vs	O	O
.	O	O

46	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
829	O	O
)	O	O
.	O	O

However	O	O
,	O	O
age	B-PHYS
at	O	O
alcohol	O
onset	O
was	O	O
significantly	O
higher	O
in	O	O
those	O	O
with	O	O
JIA	B-DISO
[	O	O
15	O	O
(	O	O
11	O	O
-	O	O
18	O	O
)	O	O
vs	O	O
.	O	O

14	O	O
(	O	O
7	O	O
-	O	O
18	O	O
)	O	O
years	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
032	O	O
]	O	O
,	O	O
particularly	O	O
in	O	O
polyarticular	B-DISO
onset	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
040	O	O
)	O	O
.	O	O

High	B-DISO
risk	I-DISO
for	O	O
substance	B-DISO
abuse	I-DISO
/	O	O
dependence	B-DISO
(	O	O
CRAFFT	B-PROC
score	O
≥2	O	O
)	O	O
was	O	O
found	O	O
in	O	O
both	O	O
groups	B-LIVB
(	O	O
13	O	O
%	O	O
vs	O	O
.	O	O

15	O	O
%	O	O
,	O	O
p	O	O
=	O	O
1	O	O
.	O	O
000	O	O
)	O	O
,	O	O
likewise	O	O
bullying	B-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
088	O	O
)	O	O
.	O	O

Further	O	O
analysis	B-PROC
of	O	O
JIA	B-DISO
patients	B-LIVB
regarding	O	O
alcohol	O
/	O	O
tobacco	O
/	O	O
illicit	O
drug	O
use	O
showed	O	O
that	O	O
the	O	O
median	O
current	O
age	O
[	O	O
17	O	O
(	O	O
14	O	O
-	O	O
19	O	O
)	O	O
vs	O	O
.	O	O

13	O	O
(	O	O
10	O	O
-	O	O
19	O	O
)	O	O
years	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
]	O	O
and	O	O
education	O	O
years	O
[	O	O
11	O	O
(	O	O
6	O	O
-	O	O
13	O	O
)	O	O
vs	O	O
.	O	O

7	O	O
(	O	O
3	O	O
-	O	O
12	O	O
)	O	O
years	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
]	O	O
were	O	O
significant	O
higher	O
in	O	O
those	O	O
that	O	O
used	O	O
substances	O	O
.	O	O

Sexual	O
activity	O
was	O	O
significantly	O
higher	O
in	O	O
the	O	O
former	O	O
group	O	O
(	O	O
48	O	O
%	O	O
vs	O	O
.	O	O

7	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

A	O	O
positive	B-DISO
correlation	O
was	O	O
evidenced	O	O
between	O	O
CRAFFT	B-PROC
score	O
and	O	O
current	O
age	O
in	O	O
JIA	B-DISO
patients	B-LIVB
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

032	O	O
,	O	O
r	O	O
=	O	O
+	O	O
0	O	O
.	O	O
296	O	O
)	O	O
.	O	O

A	O	O
high	B-DISO
risk	I-DISO
for	O	O
substance	B-DISO
abuse	I-DISO
/	O	O
dependence	B-DISO
was	O	O
observed	O	O
in	O	O
both	O	O
JIA	B-DISO
and	O	O
controls	B-LIVB
.	O	O

JIA	B-DISO
substance	B-LIVB
users	I-LIVB
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
sexual	B-DISO
intercourse	I-DISO
.	O	O

Therefore	O	O
,	O	O
routine	B-DISO
screening	I-DISO
is	O	O
suggested	O	O
in	O	O
all	O	O
visits	O	O
of	O	O
JIA	B-DISO
adolescents	B-LIVB
.	O	O

NLRP3	B-CHEM
protects	B-DISO
alveolar	B-ANAT
barrier	I-ANAT
integrity	O
by	O	O
an	O	O
inflammasome	B-CHEM
-	O	O
independent	O
increase	O
of	O	O
epithelial	B-ANAT
cell	I-ANAT
adherence	O
Bacterial	B-DISO
pneumonia	I-DISO
is	O	O
a	O	O
major	O	O
cause	O
of	O	O
acute	B-DISO
lung	I-DISO
injury	I-DISO
and	O	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
,	O	O
characterized	O
by	O	O
alveolar	B-ANAT
barrier	I-ANAT
disruption	O
.	O	O

NLRP3	B-CHEM
is	O	O
best	O	O
known	O	O
for	O	O
its	O	O
ability	B-PHYS
to	O	O
form	O	O
inflammasomes	B-CHEM
and	O	O
to	O	O
regulate	B-PHEN
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
18	I-CHEM
production	B-PHEN
in	O	O
myeloid	B-ANAT
cells	I-ANAT
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
NLRP3	B-CHEM
protects	B-DISO
the	O	O
integrity	O
of	O	O
the	O	O
alveolar	B-ANAT
barrier	I-ANAT
in	O	O
a	O	O
mouse	B-LIVB
model	I-LIVB
of	O	O
Streptococcus	B-LIVB
pneumoniae	I-LIVB
-	O	O
induced	O
pneumonia	B-DISO
,	O	O
and	O	O
ex	O
vivo	O
upon	O	O
treatment	O
of	O	O
isolated	O
perfused	O
and	O	O
ventilated	O
lungs	B-ANAT
with	O	O
the	O	O
purified	O
bacterial	B-CHEM
toxin	I-CHEM
,	O	O
pneumolysin	B-CHEM
.	O	O

We	O	O
reveal	O
that	O	O
the	O	O
preserving	O
effect	O
of	O	O
NLRP3	B-CHEM
on	O	O
the	O	O
lung	B-ANAT
barrier	I-ANAT
is	O	O
independent	O
of	O	O
inflammasomes	B-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
and	O	O
IL	B-CHEM
-	I-CHEM
18	I-CHEM
.	O	O

NLRP3	B-CHEM
improves	B-DISO
the	O	O
integrity	O
of	O	O
alveolar	B-ANAT
epithelial	I-ANAT
cell	I-ANAT
monolayers	I-ANAT
by	O	O
enhancing	O	O
cellular	B-PROC
adherence	O
.	O	O

Collectively	O	O
,	O	O
our	O	O
study	B-PROC
uncovers	O	O
a	O	O
novel	O
function	O
of	O	O
NLRP3	B-CHEM
by	O	O
demonstrating	O	O
that	O	O
it	O	O
protects	B-DISO
epithelial	B-ANAT
barrier	I-ANAT
function	O	O
independently	O
of	O	O
inflammasomes	B-CHEM
.	O	O

Regulation	B-PHEN
of	O	O
the	O	O
host	B-LIVB
immune	B-ANAT
system	I-ANAT
by	O	O
helminth	O
parasites	O
Helminth	B-DISO
parasite	I-DISO
infections	I-DISO
are	O	O
associated	O
with	O
a	O	O
battery	O	O
of	O	O
immunomodulatory	B-PHYS
mechanisms	I-PHYS
,	O	O
which	O	O
impact	O	O
all	O	O
facets	O	O
of	O	O
the	O	O
host	B-LIVB
immune	B-PHYS
response	I-PHYS
to	O	O
ensure	O	O
their	O	O
persistence	O
within	O	O
the	O	O
host	B-LIVB
.	O	O

This	O	O
broad	B-PHYS
-	I-PHYS
spectrum	I-PHYS
modulation	I-PHYS
of	O	O
host	B-LIVB
immunity	B-PHYS
has	O	O
intended	O
and	O	O
unintended	O
consequences	O
,	O	O
both	O	O
advantageous	O
and	O	O
disadvantageous	O
.	O	O

Thus	O	O
the	O	O
host	B-LIVB
may	O	O
benefit	O	O
from	O	O
suppression	O
of	O	O
collateral	B-DISO
damage	I-DISO
during	O	O
parasite	O
infection	B-DISO
,	O	O
and	O	O
from	O	O
reduced	O	O
allergic	B-DISO
,	O	O
autoimmune	B-DISO
and	O	O
inflammatory	B-DISO
reactions	I-DISO
.	O	O

However	O	O
,	O	O
helminth	B-DISO
infection	I-DISO
can	O	O
also	O	O
be	O	O
detrimental	O
in	O	O
reducing	O	O
vaccine	O	O
responses	O	O
,	O	O
increasing	O	O
susceptibility	B-PHYS
to	O	O
co	B-DISO
-	I-DISO
infection	I-DISO
,	O	O
and	O	O
potentially	O	O
reducing	O	O
tumor	B-DISO
immunosurveillance	B-PHYS
.	O	O

In	O	O
this	O	O
review	O
we	O	O
will	O	O
summarize	O	O
the	O	O
panoply	O	O
of	O	O
immunomodulatory	B-PHYS
mechanisms	I-PHYS
used	O	O
by	O	O
helminths	O
,	O	O
their	O	O
potential	O	O
utility	O	O
in	O	O
human	B-LIVB
disease	B-DISO
,	O	O
and	O	O
prospective	O	O
areas	O	O
of	O	O
future	O
research	B-PROC
.	O	O

Intravascular	O
Inflammation	B-DISO
Triggers	O
Intracerebral	O
Activated	O
Microglia	B-ANAT
and	O	O
Contributes	O	O
to	O	O
Secondary	B-DISO
Brain	I-DISO
Injury	I-DISO
After	O	O
Experimental	O
Subarachnoid	B-DISO
Hemorrhage	I-DISO
(	O	O
eSAH	B-DISO
)	O	O
Activation	O
of	O	O
innate	B-PHYS
immunity	I-PHYS
contributes	O	O
to	O	O
secondary	B-DISO
brain	I-DISO
injury	I-DISO
after	O	O
experimental	O
subarachnoid	B-DISO
hemorrhage	I-DISO
(	O	O
eSAH	B-DISO
)	O	O
.	O	O

Microglia	B-ANAT
accumulation	B-DISO
and	O	O
activation	O
within	O	O
the	O	O
brain	B-ANAT
has	O	O
recently	O	O
been	O	O
shown	O	O
to	O	O
induce	O	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
after	O	O
eSAH	B-DISO
.	O	O

In	O	O
isolated	O
mouse	B-LIVB
brain	B-ANAT
capillaries	B-ANAT
after	O	O
eSAH	B-DISO
,	O	O
we	O	O
show	O	O
a	O	O
significantly	O	O
increased	O	O
gene	B-PHYS
expression	I-PHYS
for	O	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O	O
ICAM	O
-	O
1	O
)	O	O
and	O	O
P	O
-	O
selectin	O
.	O	O

Hence	O	O
,	O	O
we	O	O
hypothesized	O
that	O	O
extracerebral	O
intravascular	O
inflammatory	B-DISO
processes	I-DISO
might	O	O
initiate	O	O
the	O	O
previously	O	O
reported	B-PROC
microglia	B-ANAT
accumulation	B-DISO
within	O	O
the	O	O
brain	B-ANAT
tissue	I-ANAT
.	O	O

We	O	O
therefore	O	O
induced	O	O
eSAH	B-DISO
in	O	O
knockout	B-LIVB
mice	I-LIVB
for	O	O
ICAM	O
-	O
1	O
(	O	O
ICAM	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
)	O	O
and	O	O
P	O
-	O
selectin	O
glycoprotein	O
ligand	O
-	O
1	O
(	O	O
PSGL	O
-	O
1	O
(	O
-	O
/	O
-	O
)	O
)	O	O
to	O	O
find	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
neutrophil	B-ANAT
-	O	O
endothelial	B-ANAT
interaction	B-PHYS
within	O	O
the	O	O
first	O	O
7	O	O
days	O	O
after	O	O
the	O	O
bleeding	B-DISO
in	O	O
a	O	O
chronic	O
cranial	O
window	B-DEVI
model	I-DEVI
.	O	O

This	O	O
inhibition	O
of	O	O
neutrophil	B-PHYS
recruitment	I-PHYS
to	O	O
the	O	O
endothelium	B-ANAT
results	O	O
in	O	O
significantly	O	O
ameliorated	B-DISO
microglia	B-ANAT
accumulation	B-DISO
and	O	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
in	O	O
knockout	B-LIVB
animals	I-LIVB
in	O	O
comparison	O	O
to	O	O
controls	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
an	O	O
outside	O	O
-	O	O
in	O	O
activation	O
of	O	O
the	O	O
CNS	B-ANAT
innate	I-ANAT
immune	B-ANAT
system	I-ANAT
at	O	O
the	O	O
vessel	B-ANAT
/	O	O
brain	B-ANAT
interface	O	O
following	O	O
eSAH	B-DISO
.	O	O

Microglia	B-ANAT
cells	B-ANAT
,	O	O
as	O	O
part	O	O
of	O	O
the	O	O
brain	B-ANAT
's	I-ANAT
innate	B-PHYS
immune	I-PHYS
system	I-PHYS
,	O	O
are	O	O
triggered	O
by	O	O
an	O	O
inflammatory	B-DISO
reaction	I-DISO
in	O	O
the	O	O
microvasculature	B-PHYS
after	O	O
eSAH	B-DISO
,	O	O
thus	O	O
contributing	O	O
to	O	O
neuronal	B-PHYS
cell	I-PHYS
death	I-PHYS
.	O	O

This	O	O
finding	O	O
offers	O	O
a	O	O
whole	O	O
range	O	O
of	O	O
new	O	O
research	B-PROC
targets	O
,	O	O
as	O	O
well	O	O
as	O	O
possible	O	O
therapy	O
options	O	O
for	O	O
patients	B-LIVB
suffering	O	O
from	O	O
eSAH	B-DISO
.	O	O

Evaluation	O	O
of	O	O
nutraceutical	B-DISO
and	O	O
antinutritional	B-DISO
properties	I-DISO
in	O	O
barnyard	B-LIVB
and	O	O
finger	B-OBJC
millet	I-OBJC
varieties	O
grown	O	O
in	O	O
Himalayan	O
region	O
Five	O	O
elite	O	O
varieties	O
of	O	O
barnyard	B-LIVB
(	O	O
Echinochloa	B-LIVB
frumentacea	I-LIVB
)	O	O
and	O	O
finger	B-LIVB
(	O	O
Eleusine	B-LIVB
coracana	I-LIVB
)	O	O
growing	O	O
at	O	O
northwestern	O
Himalaya	O
were	O	O
investigated	O
for	O	O
nutraceutical	B-DISO
and	O	O
antinutritional	B-DISO
properties	I-DISO
.	O	O

Barnyard	B-OBJC
millet	I-OBJC
contained	O	O
higher	O	O
amount	O
of	O	O
crude	B-CHEM
fiber	I-CHEM
,	O	O
total	B-OBJC
dietary	I-OBJC
fiber	I-OBJC
,	O	O
tryptophan	B-CHEM
content	O
,	O	O
total	B-CHEM
carotenoids	I-CHEM
,	O	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
compared	O	O
to	O	O
the	O	O
finger	B-OBJC
millet	I-OBJC
whereas	O	O
the	O	O
finger	B-OBJC
millet	I-OBJC
contains	O	O
higher	O	O
amount	O
of	O	O
methionine	B-CHEM
and	O	O
ascorbic	B-CHEM
acid	I-CHEM
as	O	O
compared	O	O
to	O	O
the	O	O
barnyard	B-OBJC
millet	I-OBJC
.	O	O

The	O	O
secondary	B-CHEM
metabolites	I-CHEM
of	O	O
biological	B-PHEN
functions	I-PHEN
were	O	O
analyzed	O	O
and	O	O
found	O	O
that	O	O
barnyard	B-OBJC
millet	I-OBJC
contained	O	O
the	O	O
higher	O	O
amount	O
of	O	O
polyphenols	B-CHEM
,	O	O
tannins	B-CHEM
and	O	O
ortho	B-CHEM
-	I-CHEM
dihydroxy	I-CHEM
phenol	I-CHEM
content	O
compared	O	O
to	O	O
finger	B-OBJC
millet	I-OBJC
.	O	O

Among	O	O
antinutitional	B-CHEM
compounds	I-CHEM
barnyard	B-OBJC
millet	I-OBJC
contained	O	O
lower	O	O
phytic	B-CHEM
acid	I-CHEM
content	O
compare	O	O
to	O	O
finger	B-OBJC
millet	I-OBJC
whereas	O	O
no	B-DISO
significant	I-DISO
difference	I-DISO
in	O	O
trypsin	B-PHYS
inhibition	I-PHYS
activity	I-PHYS
of	O	O
barnyard	B-OBJC
millet	I-OBJC
and	O	O
finger	B-OBJC
millet	I-OBJC
varieties	O
were	O	O
found	O	O
.	O	O

Barnyard	B-OBJC
millet	I-OBJC
contained	O	O
higher	O	O
acid	B-CHEM
phosphatase	I-CHEM
,	O	O
α	B-CHEM
-	I-CHEM
galactosidase	I-CHEM
and	O	O
α	B-PHYS
-	I-PHYS
amylase	I-PHYS
inhibitor	I-PHYS
activity	I-PHYS
compared	O	O
to	O	O
finger	B-OBJC
millet	I-OBJC
.	O	O

Finger	B-OBJC
millet	I-OBJC
seeds	I-OBJC
contained	O	O
about	O	O
10	O	O
-	O	O
13	O	O
folds	O	O
higher	O	O
calcium	B-CHEM
content	O
and	O	O
double	O	O
amount	O
of	O	O
manganese	B-CHEM
content	O
in	O	O
comparison	O	O
to	O	O
barnyard	B-OBJC
millet	I-OBJC
seeds	I-OBJC
.	O	O

Present	O	O
study	O	O
suggests	O	O
that	O	O
barnyard	B-OBJC
millet	I-OBJC
varieties	O
studied	O	O
under	O	O
present	O	O
investigation	O	O
were	O	O
found	O	O
nutritionally	O	O
superior	O	O
compared	O	O
to	O	O
finger	B-OBJC
millet	I-OBJC
varieties	O
.	O	O

Amphetamine	B-DISO
Withdrawal	I-DISO
Differentially	O	O
Increases	O	O
the	O	O
Expression	B-PHYS
of	O	O
Organic	B-CHEM
Cation	I-CHEM
Transporter	I-CHEM
3	I-CHEM
and	O	O
Serotonin	B-CHEM
Transporter	I-CHEM
in	O	O
Limbic	B-ANAT
Brain	B-ANAT
Regions	I-ANAT
Amphetamine	B-DISO
withdrawal	I-DISO
increases	O	O
anxiety	B-DISO
and	O	O
stress	B-DISO
sensitivity	O	O
related	O	O
to	O	O
blunted	O
ventral	O
hippocampus	B-ANAT
(	O	O
vHipp	B-ANAT
)	O	O
and	O	O
enhances	O	O
the	O	O
central	B-ANAT
nucleus	I-ANAT
of	I-ANAT
the	I-ANAT
amygdala	I-ANAT
(	O	O
CeA	B-ANAT
)	O	O
serotonin	B-CHEM
responses	B-PHYS
.	O	O

Extracellular	B-ANAT
serotonin	B-CHEM
levels	O
are	O	O
regulated	O	O
by	O	O
the	O	O
serotonin	B-CHEM
transporter	I-CHEM
(	O	O
SERT	B-CHEM
)	O	O
and	O	O
organic	B-CHEM
cation	I-CHEM
transporter	I-CHEM
3	I-CHEM
(	O	O
OCT3	B-CHEM
)	O	O
,	O	O
and	O	O
vHipp	B-ANAT
OCT3	B-CHEM
expression	B-PHYS
is	O	O
enhanced	O	O
during	O	O
24	O
hours	O
of	O	O
amphetamine	B-DISO
withdrawal	I-DISO
,	O	O
while	O	O
SERT	B-CHEM
expression	B-PHYS
is	O	O
unaltered	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
tested	O	O
whether	O	O
OCT3	B-CHEM
and	O	O
SERT	B-CHEM
expression	B-PHYS
in	O	O
the	O	O
CeA	B-ANAT
is	O	O
also	O	O
affected	O	O
during	O	O
acute	O	O
withdrawal	B-DISO
to	O	O
explain	O	O
opposing	O	O
regional	O	O
alterations	O	O
in	O	O
limbic	B-ANAT
serotonergic	B-PHYS
neurotransmission	I-PHYS
and	O	O
if	O	O
respective	O	O
changes	O	O
continued	O	O
with	O	O
two	O
weeks	O
of	O	O
withdrawal	B-DISO
.	O	O

We	O	O
also	O	O
determined	O	O
whether	O	O
changes	O	O
in	O	O
transporter	B-CHEM
expression	B-PHYS
were	O	O
confined	O	O
to	O	O
these	O	O
regions	O	O
.	O	O

Male	B-PHYS
rats	B-LIVB
received	O	O
amphetamine	B-CHEM
or	O	O
saline	B-OBJC
for	O	O
two	O
weeks	O
followed	O	O
by	O	O
24	O
hours	O
or	O	O
two	O
weeks	O
of	O	O
withdrawal	B-DISO
,	O	O
with	O	O
transporter	B-CHEM
expression	B-PHYS
measured	O	O
using	O	O
Western	B-PROC
immunoblot	I-PROC
.	O	O

OCT3	B-CHEM
and	O	O
SERT	B-CHEM
expression	B-PHYS
increased	O	O
in	O	O
the	O	O
CeA	B-ANAT
at	O	O
both	O	O
withdrawal	B-DISO
timepoints	O	O
.	O	O

In	O	O
the	O	O
vHipp	B-ANAT
,	O	O
OCT3	B-CHEM
expression	B-PHYS
increased	O	O
only	O	O
at	O	O
24	O
hours	O
of	O	O
withdrawal	B-DISO
,	O	O
with	O	O
an	O	O
equivalent	O	O
pattern	O	O
seen	O	O
in	O	O
the	O	O
dorsomedial	B-ANAT
hypothalamus	I-ANAT
.	O	O

No	B-DISO
changes	I-DISO
were	O	O
evident	O	O
in	O	O
any	O	O
other	O	O
regions	B-ANAT
sampled	O	O
.	O	O

These	O	O
regionally	O	O
specific	O	O
changes	O	O
in	O	O
limbic	B-ANAT
OCT3	B-CHEM
and	O	O
SERT	B-CHEM
expression	B-PHYS
may	O	O
partially	O	O
contribute	O	O
to	O	O
the	O	O
serotonergic	B-CHEM
imbalance	B-DISO
and	O	O
negative	B-DISO
affect	I-DISO
during	O	O
amphetamine	B-DISO
withdrawal	I-DISO
.	O	O

Nutritional	O
aspects	O
of	O	O
night	O
eating	B-PHYS
and	O	O
its	O	O
association	O
with	O
weight	B-PHYS
status	O
among	O	O
Korean	B-LIVB
adolescents	B-LIVB
A	O	O
growing	O
body	O	O
of	O	O
research	B-PROC
has	O	O
indicated	O	O
that	O	O
night	O
eating	B-PHYS
could	O	O
be	O	O
associated	O
with	O
poor	B-DISO
diet	I-DISO
quality	O
and	O	O
negative	B-DISO
health	O
outcomes	O
.	O	O

This	O	O
study	O
examined	O	O
the	O	O
nutritional	O
aspects	O
of	O	O
night	O
eating	B-PHYS
,	O	O
its	O	O
related	O	O
factors	O
,	O	O
and	O	O
the	O	O
association	O
between	O	O
night	O
eating	B-PHYS
and	O	O
body	B-PHYS
weight	I-PHYS
among	O	O
Korean	B-LIVB
adolescents	B-LIVB
.	O	O

This	O	O
study	O
analysed	O	O
the	O	O
data	O
from	O	O
a	O	O
one	O	O
day	O
24	O	O
-	O	O
hour	O	O
dietary	B-PROC
recall	I-PROC
as	O	O
well	O	O
as	O	O
a	O	O
demographic	B-PROC
survey	I-PROC
of	O	O
1	O	O
,	O	O
738	O	O
Korean	B-LIVB
adolescents	B-LIVB
aged	O	O
12	O	O
to	O	O
18	O	O
-	O	O
years	O
-old	O	O
obtained	O	O
from	O	O
the	O	O
2010	O	O
-	O	O
2012	O	O
Korea	B-GEOG
National	B-PROC
Health	I-PROC
and	I-PROC
Nutrition	I-PROC
Examination	I-PROC
Survey	I-PROC
.	O	O
'	O	O
Night	O
eating	B-PHYS
'	O	O
was	O	O
defined	O	O
as	O	O
consuming	O	O
25	O	O
%	O	O
or	O	O
more	O	O
of	O	O
one	O	O
's	O	O
daily	O
energy	O
intake	O
between	O	O
21	O	O
:	O	O
00	O	O
and	O	O
06	O	O
:	O	O
00	O	O
.	O	O

Subjects	B-LIVB
complying	O	O
with	O	O
the	O	O
preceding	O	O
condition	O
were	O	O
classified	O	O
as	O	O
'	O	O
night	O
eaters	B-LIVB
'	O	O
,	O	O
whereas	O	O
the	O	O
rest	O	O
were	O	O
considered	O	O
'	O	O
non	B-LIVB
-	I-LIVB
night	I-LIVB
eaters	I-LIVB
'	O	O
.	O	O

Logistic	O
regression	O
analysis	O
examined	O	O
factors	O
related	O	O
to	O	O
night	O
eating	B-PHYS
.	O	O

Multiple	O
linear	O
regression	O
analyses	O
were	O	O
used	O	O
to	O	O
examine	O	O
the	O	O
relationship	O
between	O	O
night	O
eating	B-PHYS
and	O	O
BMI	B-PHYS
z	O
-	O
scores	O
,	O	O
whereas	O	O
multinomial	O
logistic	O
regression	O
analysis	O
was	O	O
used	O	O
to	O	O
examine	O	O
the	O	O
relationship	O
between	O	O
night	O
eating	B-PHYS
and	O	O
weight	B-PHYS
status	O
.	O	O

About	O	O
21	O	O
%	O	O
of	O	O
Korean	B-LIVB
adolescents	B-LIVB
appeared	O	O
to	O	O
be	O	O
night	O
eaters	B-LIVB
.	O	O

Night	O
eaters	B-LIVB
showed	O	O
increased	O
breakfast	O
skipping	B-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
higher	O	O
energy	O
intake	O
from	O	O
snacks	B-OBJC
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
greater	O	O
proportion	O
of	O
energy	O
intake	O
from	O
fat	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

029	O	O
)	O	O
,	O	O
and	O	O
lower	O
Dietary	O
Diversity	O
Scores	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
008	O	O
)	O	O
than	O	O
non	B-LIVB
-	I-LIVB
night	I-LIVB
eaters	I-LIVB
.	O	O

Male	B-PHYS
adolescents	B-LIVB
presented	O	O
1	O	O
.	O	O
9	O	O
times	O
higher	O	O
odds	O	O
of	O	O
being	O	O
night	O
eaters	B-LIVB
than	O	O
females	B-PHYS
.	O	O

Adolescents	B-LIVB
whose	O	O
both	O	O
parents	B-LIVB
were	O	O
night	O
eaters	B-LIVB
were	O	O
4	O	O
.	O	O
4	O	O
times	O
as	O	O
likely	O	O
to	O	O
be	O	O
night	O
eaters	B-LIVB
as	O	O
those	O	O
whose	O	O
neither	O	O
parents	B-LIVB
were	O	O
.	O	O

Female	B-PHYS
adolescents	B-LIVB
showed	O	O
a	O	O
significant	O	O
relationship	O
between	O	O
night	O
eating	B-PHYS
and	O	O
BMI	B-PHYS
z	O
-	O
scores	O
(	O	O
β	O	O
=	O	O
0	O	O
.	O	O
28	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

004	O	O
)	O	O
.	O	O

However	O	O
,	O	O
night	O
eating	B-PHYS
did	O	O
not	O	O
increase	O
odds	O	O
of	O	O
being	O	O
overweight	B-DISO
or	O	O
obese	B-DISO
in	O	O
adolescents	B-LIVB
.	O	O

Night	O
eating	B-PHYS
in	O	O
Korean	B-LIVB
adolescents	B-LIVB
was	O	O
related	O	O
to	O	O
undesirable	B-DISO
dietary	I-DISO
behaviours	I-DISO
and	O	O
low	B-DISO
diet	I-DISO
quality	I-DISO
in	O	O
general	O	O
as	O	O
well	O	O
as	O	O
higher	O	O
BMI	B-PHYS
z	O
-	O
scores	O
in	O	O
females	B-PHYS
.	O	O

Male	B-PHYS
gender	B-PHYS
and	O	O
parental	B-LIVB
night	O
eating	B-PHYS
appeared	O	O
to	O	O
be	O	O
the	O	O
factors	O
that	O	O
significantly	O	O
increased	O
odds	O	O
of	O	O
night	O
eating	B-PHYS
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
night	O
eating	B-PHYS
should	O	O
be	O	O
considered	O	O
when	O	O
designing	O	O
nutrition	B-PROC
education	I-PROC
or	O	O
intervention	B-PROC
programs	I-PROC
targeting	O	O
adolescents	B-LIVB
.	O	O

Observation	B-PROC
of	O	O
Network	O
Dynamics	B-PHEN
of	O	O
Ryanodine	B-CHEM
Receptors	I-CHEM
on	O	O
Skeletal	O
Muscle	O
Sarcoplasmic	B-ANAT
Reticulum	I-ANAT
Membranes	I-ANAT
Rabbit	B-LIVB
muscle	O
vesicles	B-ANAT
derived	O	O
from	O	O
sarcoplasmic	B-ANAT
reticulum	I-ANAT
were	O	O
used	O	O
as	O	O
a	O	O
material	B-DEVI
in	I-DEVI
studying	I-DEVI
networks	O
of	O	O
ryanodine	B-CHEM
receptors	I-CHEM
by	O	O
cryo	B-PHEN
electron	B-PROC
tomography	I-PROC
.	O	O

Three	B-PROC
-	I-PROC
dimensional	I-PROC
analysis	I-PROC
reveals	O	O
the	O	O
dynamical	B-PHEN
features	O
of	O	O
these	O	O
networks	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
the	O	O
connection	O
angles	O
were	O	O
rotated	O
along	O	O
the	O	O
transmembrane	B-ANAT
axis	O
of	O	O
ryanodine	B-CHEM
receptors	I-CHEM
.	O	O

Majority	O	O
of	O	O
the	O	O
connections	O
was	O	O
observed	O	O
at	O	O
domains	O
6	O
/	O
6	O
of	O	O
ryanodine	B-CHEM
receptors	I-CHEM
while	O	O
a	O	O
small	O
group	O
of	O	O
connections	O
were	O	O
showed	O	O
at	O	O
domains	O
9	O
/	O
10	O
.	O	O

The	O	O
flexible	O
rotation	O
and	O	O
connection	O
shift	O
seem	O	O
to	O	O
facilitate	O	O
the	O	O
extension	O
of	O	O
an	O	O
annular	O
network	O
on	O	O
the	O	O
wall	B-ANAT
of	I-ANAT
the	I-ANAT
sarcoplasmic	I-ANAT
reticulum	I-ANAT
in	O	O
a	O	O
triad	B-ANAT
.	O	O

Effects	O
of	O
Montelukast	B-CHEM
in	O	O
an	O	O
Experimental	O
Model	O
of	O	O
Acute	B-DISO
Pancreatitis	I-DISO
BACKGROUND	O	O
We	O	O
evaluated	B-PROC
the	O	O
hematological	O
,	O	O
biochemical	O
,	O	O
and	O	O
histopathological	O
effects	O
of	O
Montelukast	B-CHEM
on	O	O
pancreatic	B-ANAT
damage	O
in	O	O
an	O	O
experimental	O	O
acute	B-DISO
pancreatitis	I-DISO
model	B-DISO
created	O	O
by	O	O
cerulein	B-CHEM
in	O	O
rats	B-LIVB
before	O	O
and	O	O
after	O	O
the	O	O
induction	O
of	O	O
pancreatitis	B-DISO
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
Forty	O	O
rats	B-LIVB
were	O	O
divided	O	O
into	O	O
4	O	O
groups	B-LIVB
with	O	O
10	O	O
rats	B-LIVB
each	O	O
.	O	O

The	O	O
study	B-LIVB
groups	I-LIVB
were	O	O
:	O	O
the	O	O
Cerulein	B-CHEM
(	O	O
C	B-CHEM
)	O	O
group	B-LIVB
,	O	O
the	O	O
Cerulein	B-CHEM
+	O	O
early	O
Montelukast	B-CHEM
(	O	O
CMe	O	O
)	O	O
group	B-LIVB
,	O	O
the	O	O
Cerulein	B-CHEM
+	O	O
late	O
Montelukast	B-CHEM
(	O	O
CMl	O	O
)	O	O
group	B-LIVB
,	O	O
and	O	O
the	O	O
Control	B-LIVB
group	I-LIVB
.	O	O

The	O	O
pH	O
,	O	O
pO2	B-PHYS
,	O	O
pCO2	B-PHEN
,	O	O
HCO3	B-CHEM
,	O	O
leukocyte	B-ANAT
,	O	O
hematocrit	B-DISO
,	O	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O	O
and	O	O
lipase	B-CHEM
values	O
were	O	O
measured	O	O
in	O	O
the	O	O
arterial	B-ANAT
blood	I-ANAT
samples	I-ANAT
taken	O	O
immediately	O	O
before	O	O
rats	B-LIVB
were	O	O
killed	O	O
.	O	O

RESULTS	O	O
There	O	O
were	O	O
statistically	O
significant	O
differences	O
between	O	O
the	O	O
C	B-CHEM
group	B-LIVB
and	O	O
the	O	O
Control	B-LIVB
group	I-LIVB
in	O	O
the	O	O
values	O
of	O	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O	O
lipase	B-CHEM
,	O	O
blood	B-ANAT
leukocyte	I-ANAT
,	O	O
hematocrit	B-DISO
,	O	O
pH	O
,	O	O
pO2	B-PHYS
,	O	O
pCO2	B-PHEN
,	O	O
HCO3	B-CHEM
,	O	O
and	O	O
pancreatic	B-ANAT
water	O
content	O
,	O	O
and	O	O
also	O	O
in	O	O
each	O	O
of	O	O
the	O	O
values	O
of	O	O
edema	B-DISO
,	O	O
inflammation	B-DISO
,	O	O
vacuolization	B-DISO
,	O	O
necrosis	B-PHYS
,	O	O
and	O	O
total	O	O
histopathological	O
score	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

When	O	O
the	O	O
CMl	O	O
group	B-LIVB
and	O	O
C	B-CHEM
group	B-LIVB
were	O	O
compared	O	O
,	O	O
no	O	O
statistically	O
significant	O
differences	O
were	O	O
found	O	O
in	O	O
any	O	O
parameter	B-DISO
analyzed	O	O
.	O	O

When	O	O
the	O	O
CMe	O	O
group	B-LIVB
was	O	O
compared	O	O
with	O	O
the	O	O
C	B-CHEM
group	B-LIVB
,	O	O
pancreatic	B-CHEM
amylase	I-CHEM
,	O	O
lipase	B-CHEM
,	O	O
pH	O
,	O	O
PO2	B-PHYS
,	O	O
pCO2	B-PHEN
,	O	O
HCO3	B-CHEM
,	O	O
pancreatic	B-ANAT
water	O
content	O
,	O	O
histopathological	O
edema	B-DISO
,	O	O
inflammation	B-DISO
,	O	O
and	O	O
total	O	O
histopathological	O
score	O	O
values	O
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
groups	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Finally	O	O
,	O	O
when	O	O
the	O	O
CMe	O	O
group	B-LIVB
and	O	O
the	O	O
Control	B-LIVB
group	I-LIVB
were	O	O
compared	O	O
,	O	O
significant	O	O
differences	O
were	O	O
found	O	O
in	O	O
all	O	O
except	O	O
2	O	O
(	O	O
leukocyte	B-ANAT
and	O	O
pO2	B-PHYS
)	O	O
parameters	B-DISO
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
Leukotriene	B-CHEM
receptor	I-CHEM
antagonists	I-CHEM
used	O	O
in	O	O
the	O	O
late	B-PROC
phases	I-PROC
of	O	O
pancreatitis	B-DISO
might	O	O
not	O	O
result	O	O
in	O	O
any	O	O
benefit	O
;	O	O
however	O	O
,	O	O
when	O	O
they	O	O
are	O	O
given	O	O
in	O	O
the	O	O
early	O
phases	O
or	O	O
prophylactically	O	O
,	O	O
they	O	O
may	O	O
decrease	O	O
pancreatic	B-ANAT
damage	O
.	O	O

Functional	O	O
characterization	O	O
of	O	O
the	O	O
Aspergillus	B-LIVB
nidulans	I-LIVB
glucosylceramide	B-CHEM
pathway	B-PHYS
reveals	O	O
that	O	O
LCB	B-CHEM
Δ8	B-PHYS
-	I-PHYS
desaturation	I-PHYS
and	O	O
C9	B-PHYS
-	I-PHYS
methylation	I-PHYS
are	O	O
relevant	O	O
to	O	O
filamentous	B-PHYS
growth	I-PHYS
,	O	O
lipid	B-PHYS
raft	I-PHYS
localization	I-PHYS
and	O	O
Psd1	B-CHEM
defensin	I-CHEM
activity	O
C8	B-CHEM
-	I-CHEM
desaturated	I-CHEM
and	I-CHEM
C9	I-CHEM
-	I-CHEM
methylated	I-CHEM
glucosylceramide	I-CHEM
(	O	O
GlcCer	B-CHEM
)	O	O
is	O	O
a	O	O
fungal	B-LIVB
-specific	O	O
sphingolipid	B-CHEM
that	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
growth	B-PHYS
and	O	O
virulence	B-PHEN
of	O	O
many	O	O
species	O
.	O	O

In	O	O
this	O	O
work	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
contribution	O	O
of	O	O
Aspergillus	B-LIVB
nidulans	I-LIVB
sphingolipid	B-CHEM
Δ8	I-CHEM
-	I-CHEM
desaturase	I-CHEM
(	O	O
SdeA	B-CHEM
)	O	O
,	O	O
sphingolipid	B-CHEM
C9	I-CHEM
-	I-CHEM
methyltransferases	I-CHEM
(	O	O
SmtA	B-CHEM
/	O	O
SmtB	B-CHEM
)	O	O
and	O	O
glucosylceramide	B-CHEM
synthase	I-CHEM
(	O	O
GcsA	B-CHEM
)	O	O
to	O	O
fungal	B-LIVB
phenotypes	B-PHYS
,	O	O
sensitivity	O	O
to	O	O
Psd1	B-CHEM
defensin	I-CHEM
and	O	O
Galleria	O
mellonella	O
virulence	B-PHEN
.	O	O

We	O	O
showed	O	O
that	O	O
ΔsdeA	B-PHYS
accumulated	O	O
C8	B-CHEM
-	I-CHEM
saturated	I-CHEM
and	I-CHEM
unmethylated	I-CHEM
GlcCer	I-CHEM
,	O	O
while	O	O
gcsA	O
deletion	B-PHYS
impaired	O
GlcCer	B-CHEM
synthesis	O	O
.	O	O

Although	O	O
increased	O	O
levels	O	O
of	O	O
unmethylated	B-CHEM
GlcCer	I-CHEM
were	O	O
observed	O	O
in	O	O
smtA	O
and	O	O
smtB	O
mutants	B-DISO
,	O	O
ΔsmtA	B-PHYS
and	O	O
wild	O
-	O
type	O
cells	B-ANAT
showed	O	O
a	O	O
similar	O	O
9	B-CHEM
,	I-CHEM
Me	I-CHEM
-	I-CHEM
GlcCer	I-CHEM
content	O	O
,	O	O
reduced	O	O
by	O	O
50	O	O
%	O	O
in	O	O
the	O	O
smtB	O
disruptant	B-DISO
.	O	O

The	O	O
compromised	O	O
9	B-CHEM
,	I-CHEM
Me	I-CHEM
-	I-CHEM
GlcCer	I-CHEM
production	O	O
in	O	O
the	O	O
ΔsmtB	B-PHYS
strain	B-LIVB
was	O	O
not	O	O
accompanied	O	O
by	O	O
reduced	O	O
filamentation	B-PHYS
or	O	O
defects	O
in	O	O
cell	O
polarity	O
.	O	O

When	O	O
combined	O	O
with	O	O
the	O	O
smtA	O
deletion	B-PHYS
,	O	O
smtB	O
repression	B-PHYS
significantly	O	O
increased	O	O
unmethylated	B-CHEM
GlcCer	I-CHEM
levels	O	O
and	O	O
compromised	O	O
filamentous	B-PHYS
growth	I-PHYS
.	O	O

Furthermore	O	O
,	O	O
sdeA	O
and	O	O
gcsA	O
mutants	B-DISO
displayed	O	O
growth	B-PHYS
defects	O
and	O	O
raft	B-ANAT
mislocalization	O	O
,	O	O
which	O	O
were	O	O
accompanied	O	O
by	O	O
reduced	B-DISO
neutral	I-DISO
lipids	I-DISO
levels	I-DISO
and	O	O
attenuated	O	O
G	O
.	O

mellonella	O
virulence	B-PHEN
in	O	O
the	O	O
ΔgcsA	B-PHYS
strain	B-LIVB
.	O	O

Finally	O	O
,	O	O
ΔsdeA	B-PHYS
and	O	O
ΔgcsA	B-PHYS
showed	O	O
increased	O	O
resistance	O	O
to	O	O
Psd1	B-CHEM
,	O	O
suggesting	O	O
that	O	O
GlcCer	B-CHEM
synthesis	O	O
and	O	O
fungal	B-LIVB
sphingoid	O
base	O
structure	O
specificities	O	O
are	O	O
relevant	O	O
not	O	O
only	O	O
to	O	O
differentiation	O	O
but	O	O
also	O	O
to	O	O
proper	O	O
recognition	O	O
by	O	O
this	O	O
antifungal	B-CHEM
defensin	B-CHEM
.	O	O

Subepidermal	B-ANAT
Calcified	O
Nodules	O
of	O	O
the	O	O
Eyelid	B-ANAT
Differ	O	O
in	O	O
Children	B-LIVB
and	O	O
Adults	B-LIVB
Subepidermal	B-ANAT
calcified	O
nodule	O
of	O	O
the	O	O
eyelid	B-ANAT
is	O	O
considered	O	O
as	O	O
one	O	O
of	O	O
the	O	O
types	O
of	O	O
calcinosis	B-DISO
cutis	I-DISO
.	O	O

It	O	O
generally	O	O
occurs	O
in	O	O
children	B-LIVB
,	O	O
and	O	O
is	O	O
not	O	O
known	O	O
to	O	O
be	O	O
associated	O
with	O
systemic	B-DISO
disease	I-DISO
.	O	O

The	O	O
authors	B-LIVB
report	B-PROC
histopathological	O
and	O	O
clinical	B-PHYS
findings	I-PHYS
in	O	O
14	O	O
cases	O
of	O	O
subepidermal	B-ANAT
calcified	O
nodule	O
of	O	O
the	O	O
eyelid	B-ANAT
,	O	O
including	O	O
3	O	O
older	B-LIVB
patients	B-LIVB
with	O	O
unique	O	O
microscopic	O
features	O
.	O	O

Clinical	O
records	O
and	O	O
pathological	O
materials	B-OBJC
were	O	O
critically	O	O
reviewed	O
in	O	O
each	O	O
case	O
,	O	O
including	O	O
von	B-PROC
kossa	I-PROC
,	O	O
CD3	B-CHEM
,	O	O
CD20	B-CHEM
,	O	O
and	O	O
CD68	B-CHEM
stains	I-CHEM
.	O	O

The	O	O
14	O	O
cases	O
presented	O	O
clinically	O
as	O	O
nodular	O
eyelid	B-DISO
lesions	I-DISO
.	O	O

All	O	O
were	O	O
treated	O
with	O	O
surgical	B-PROC
excision	I-PROC
.	O	O

The	O	O
authors	B-LIVB
found	O	O
2	O	O
distinct	O	O
histopathological	O
patterns	O
which	O	O
correlated	O
with	O	O
the	O	O
patients	B-LIVB
'	O	O
age	B-PHYS
.	O	O

In	O	O
young	O
patients	B-LIVB
,	O	O
the	O	O
authors	B-LIVB
observed	O	O
multiple	O
,	O	O
small	O
calcified	B-DISO
bodies	I-DISO
within	O	O
the	O	O
dermis	O
surrounded	O
by	O	O
chronic	B-DISO
inflammation	I-DISO
and	O	O
granulomatous	B-DISO
foreign	I-DISO
body	I-DISO
reaction	I-DISO
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
in	O	O
elderly	B-LIVB
patients	B-LIVB
,	O	O
lesions	B-DISO
were	O	O
characterized	O
by	O	O
a	O	O
single	O
,	O	O
large	O
,	O	O
well	B-PHYS
-	I-PHYS
demarcated	I-PHYS
amorphous	I-PHYS
calcified	I-PHYS
deposit	I-PHYS
surrounded	O
by	O	O
fibrous	O
tissue	O
,	O	O
without	O	O
chronic	B-DISO
inflammation	I-DISO
or	O	O
foreign	B-DISO
body	I-DISO
reaction	I-DISO
.	O	O

One	O	O
of	O	O
these	O	O
patients	B-LIVB
,	O	O
a	O	O
70	O	O
-	O	O
year	O
-	O
old	O
man	B-LIVB
,	O	O
also	O	O
suffered	O	O
from	O	O
gout	O	O
.	O	O

The	O	O
presence	B-DISO
of	O	O
subepidermal	B-ANAT
calcified	O
nodule	O
was	O	O
not	O	O
documented	B-PROC
as	O	O
a	O	O
preoperative	O
diagnostic	O
possibility	O
in	O	O
any	O	O
of	O	O
the	O	O
cases	O
.	O	O

Subepidermal	B-ANAT
calcified	O
nodule	O
of	O	O
the	O	O
eyelid	B-ANAT
is	O	O
a	O	O
rare	O
condition	O
,	O	O
but	O	O
should	O	O
be	O	O
considered	O	O
in	O	O
any	O	O
patient	B-LIVB
presenting	O	O
with	O	O
a	O	O
painless	O
white	B-DISO
to	I-DISO
yellowish	I-DISO
colored	I-DISO
nodule	I-DISO
of	O	O
the	O	O
ocular	B-ANAT
adnexa	I-ANAT
,	O	O
particularly	O	O
during	O	O
the	O	O
teenage	O
years	O
.	O	O

Clinicians	B-LIVB
and	O	O
pathologists	B-LIVB
should	O	O
be	O	O
aware	O	O
that	O	O
this	O	O
entity	B-OBJC
has	O	O
a	O	O
distinct	O	O
appearance	O
and	O	O
could	O	O
be	O	O
associated	O
with	O
systemic	B-DISO
conditions	I-DISO
in	O	O
elderly	B-LIVB
patients	B-LIVB
.	O	O

Cover	B-OBJC
Image	O
,	O	O
Volume	O	O
117	O	O
,	O	O
Number	O	O
10	O	O
,	O	O
October	O	O
2016	O	O
Cover	B-OBJC
:	O	O
The	O	O
cover	B-OBJC
image	O
,	O	O
by	O	O
Jacqueline	O	O
May	O	O
Bentel	O	O
et	O	O
al	O	O
.	O	O
,	O	O
is	O	O
based	O	O
on	O	O
the	O	O
Article	O
Activity	B-PHYS
of	O	O
ABCG2	B-CHEM
Is	O	O
Regulated	O	O
by	O	O
Its	O	O
Expression	B-PHYS
and	O	O
Localization	O
in	O	O
DHT	B-CHEM
and	O	O
Cyclopamine	B-CHEM
-	O	O
Treated	O
Breast	B-ANAT
Cancer	I-ANAT
Cells	I-ANAT
,	O	O
DOI	O	O
:	O	O
10	O	O
.	O	O
1002	O	O
/	O	O
jcb	O	O
.	O	O
25523	O	O
.	O	O

What	O	O
kind	O	O
of	O	O
processing	O
is	O	O
survival	B-PHYS
processing	I-PHYS
?	O	O
:	O	O
Effects	O	O
of	O	O
different	O	O
types	O	O
of	O	O
dual	O
-	O
task	O
load	O
on	O	O
the	O	O
survival	B-PHYS
processing	I-PHYS
effect	O	O
Words	B-PHYS
judged	I-PHYS
for	O	O
their	O	O
relevance	O	O
in	O	O
a	O	O
survival	O
context	O
are	O	O
remembered	O	O
better	O	O
than	O	O
words	B-PHYS
processed	I-PHYS
in	O	O
non	O
-	O
survival	O
contexts	O
.	O	O

This	O	O
phenomenon	B-PHEN
is	O	O
known	O	O
as	O	O
the	O	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
.	O	O

Recently	O	O
,	O	O
inconsistent	B-DISO
results	I-DISO
were	O	O
reported	O	O
on	O	O
whether	O	O
the	O	O
size	O
of	O	O
the	O	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
is	O	O
affected	O	O
by	O	O
cognitive	O
load	O
.	O	O

Whereas	O	O
Kroneisen	B-LIVB
,	O	O
Rummel	B-LIVB
,	O	O
and	O	O
Erdfelder	B-LIVB
(	O	O
Memory	B-PHYS
22	O	O
:	O	O
92	O	O
-	O	O
102	O	O
,	O	O
2014	O	O
)	O	O
observed	O	O
that	O	O
the	O	O
survival	B-PHYS
processing	I-PHYS
effect	I-PHYS
vanishes	O	O
under	O	O
dual	O
-	O
task	O
conditions	O
,	O	O
Stillman	B-LIVB
,	O	O
Coane	B-LIVB
,	O	O
Profaci	B-LIVB
,	O	O
Howard	B-LIVB
,	O	O
and	O	O
Howard	B-LIVB
(	O	O
Memory	O
&	O
Cognition	O
42	O	O
:	O	O
175	O	O
-	O	O
185	O	O
,	O	O
2014	O	O
,	O	O
Experiment	O	O
1	O	O
)	O	O
found	O	O
that	O	O
the	O	O
size	O
of	O	O
survival	B-PHYS
processing	I-PHYS
effect	O	O
is	O	O
essentially	O	O
unaffected	O	O
by	O	O
a	O	O
cognitively	B-PHYS
demanding	I-PHYS
secondary	I-PHYS
task	I-PHYS
.	O	O

In	O	O
three	O	O
experiments	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
differences	O	O
between	O	O
these	O	O
studies	O	O
to	O	O
achieve	O	O
a	O	O
better	O	O
understanding	B-PHYS
of	O	O
dual	O
-	O
task	O
effects	O
on	O	O
the	O	O
survival	O
-	O
processing	O
advantage	O
.	O	O

In	O	O
the	O	O
first	O	O
experiment	O	O
,	O	O
we	O	O
replicated	O	O
Stillman	B-LIVB
et	O	O
al	O	O
.	O	O

's	O	O
results	O	O
using	O	O
their	O	O
dual	O
-	O
task	O
conditions	O
combined	O	O
with	O	O
a	O	O
sample	O	O
more	O	O
than	O	O
twice	O	O
as	O	O
large	O	O
as	O	O
theirs	O	O
.	O	O

In	O	O
the	O	O
second	O	O
experiment	O	O
,	O	O
we	O	O
compared	O	O
dual	O
-	O
task	O
conditions	O
that	O	O
differed	O	O
regarding	O	O
how	O	O
strongly	O	O
the	O	O
secondary	B-PHYS
task	I-PHYS
taxed	I-PHYS
(	O	O
a	O	O
)	O	O
working	B-PHYS
memory	I-PHYS
load	O
(	O	O
maintenance	O
of	O
one	O
vs	O
.	O

several	O
items	O
)	O	O
and	O	O
(	O	O
b	O	O
)	O	O
processing	B-DISO
demands	I-DISO
(	O	O
switching	B-PHYS
vs	I-PHYS
.	I-PHYS
time	I-PHYS
-	I-PHYS
sharing	I-PHYS
between	I-PHYS
tasks	I-PHYS
)	O	O
.	O	O

A	O	O
third	O	O
experiment	B-PROC
focussed	O	O
on	O	O
low	O
(	O
i	O
.	O

e	O
.	O
,	O
single	O
-	O
item	O
)	O
load	O
under	O	O
time	O
-	O
sharing	O
processing	O
conditions	O
.	O	O

Results	O	O
consistently	O	O
showed	O	O
that	O	O
the	O	O
survival	B-PHYS
processing	I-PHYS
effect	O	O
persisted	O	O
under	O	O
low	O
load	O
but	O	O
vanished	O	O
when	O	O
the	O	O
number	O	O
of	O	O
items	O	O
held	O	O
in	O	O
working	B-PHYS
memory	I-PHYS
increased	O	O
beyond	O	O
one	O	O
,	O	O
irrespective	O	O
of	O	O
processing	B-DISO
demands	I-DISO
.	O	O

Implications	O	O
of	O	O
these	O	O
findings	O	O
for	O	O
explanations	O	O
of	O	O
the	O	O
survival	O
-	O
processing	O
advantage	O
are	O	O
discussed	O	O
.	O	O

A	O	O
randomized	B-PROC
trial	I-PROC
of	O	O
Plasma	B-CHEM
-	I-CHEM
Lyte	I-CHEM
A	I-CHEM
and	O	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
sodium	I-CHEM
chloride	I-CHEM
in	O	O
acute	B-DISO
pediatric	I-DISO
gastroenteritis	I-DISO
Compare	O	O
the	O	O
efficacy	O
and	O	O
safety	O	O
of	O	O
Plasma	B-CHEM
-	I-CHEM
Lyte	I-CHEM
A	I-CHEM
(	O	O
PLA	B-CHEM
)	O	O
versus	O	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
sodium	I-CHEM
chloride	I-CHEM
(	O	O
NaCl	B-CHEM
)	O	O
intravenous	B-PROC
(	I-PROC
IV	I-PROC
)	I-PROC
fluid	I-PROC
replacement	I-PROC
in	O	O
children	B-LIVB
with	O	O
moderate	O	O
to	O	O
severe	B-DISO
dehydration	I-DISO
secondary	O	O
to	O	O
acute	B-DISO
gastroenteritis	I-DISO
(	O	O
AGE	B-DISO
)	O	O
.	O	O

Prospective	B-PROC
,	O	O
randomized	B-PROC
,	O	O
double	B-PROC
-	I-PROC
blind	I-PROC
study	I-PROC
conducted	O	O
at	O	O
eight	O	O
pediatric	O
emergency	B-OBJC
departments	I-OBJC
(	O	O
EDs	B-OBJC
)	O	O
in	O	O
the	O	O
US	B-GEOG
and	O	O
Canada	B-GEOG
(	O	O
NCT	O	O
#	O	O
01234883	O	O
)	O	O
.	O	O

The	O	O
primary	O
outcome	O
measure	O
was	O	O
serum	B-PHEN
bicarbonate	I-PHEN
level	I-PHEN
at	O	O
4	O	O
h	O	O
.	O	O

Secondary	O
outcomes	O
included	O	O
safety	O	O
and	O	O
tolerability	B-PROC
.	O	O

The	O	O
hypothesis	O
was	O	O
that	O	O
PLA	B-CHEM
would	O	O
be	O	O
superior	O	O
to	O	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
in	O	O
improvement	B-PROC
of	I-PROC
4	I-PROC
-	I-PROC
h	I-PROC
bicarbonate	I-PROC
.	O	O

Patients	B-LIVB
(	O	O
n	O	O
=	O	O
100	O	O
)	O	O
aged	O	O
≥6	O	O
months	O	O
to	O	O
<	O	O
11	O	O
years	O	O
with	O	O
AGE	B-DISO
-induced	O	O
moderate	O	O
-	O	O
to	O	O
-	O	O
severe	B-DISO
dehydration	I-DISO
were	O	O
enrolled	O	O
.	O	O

Patients	B-LIVB
with	O	O
a	O	O
baseline	O
bicarbonate	B-PHEN
level	I-PHEN
≤22	O	O
mEq	O	O
/	O	O
L	O	O
formed	O
the	O	O
modified	O
intent	O
to	O
treat	O
(	O	O
mITT	O
)	O	O
group	B-LIVB
.	O	O

At	O	O
baseline	O
,	O	O
the	O	O
treatment	B-PROC
groups	B-LIVB
were	O	O
comparable	O	O
except	O	O
that	O	O
the	O	O
PLA	B-CHEM
group	B-LIVB
was	O	O
older	O	O
.	O	O

At	O	O
hour	O	O
4	O	O
,	O	O
the	O	O
PLA	B-CHEM
group	B-LIVB
had	O	O
greater	O	O
increases	B-DISO
in	I-DISO
serum	I-DISO
bicarbonate	I-DISO
from	O	O
baseline	O
than	O	O
did	O	O
the	O	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
group	B-LIVB
(	O	O
mean	O	O
±	O	O
SD	O	O
at	O	O
4	O	O
h	O	O
:	O	O
18	O	O
±	O	O
3	O	O
.	O	O
74	O	O
vs	O	O
18	O	O
.	O	O
0	O	O
±	O	O
3	O	O
.	O	O
67	O	O
;	O	O
change	O	O
from	O	O
baseline	O
of	O	O
1	O	O
.	O	O

6	O	O
and	O	O
0	O	O
.	O	O
0	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
.004	O	O
)	O	O
.	O	O

Both	O	O
treatment	B-PROC
groups	B-LIVB
received	O	O
similar	O	O
fluid	O
volumes	O
.	O	O

The	O	O
PLA	B-CHEM
group	B-LIVB
had	O	O
less	O	O
abdominal	B-DISO
pain	I-DISO
and	O	O
better	O	O
dehydration	B-DISO
scores	O	O
at	O	O
hour	O	O
2	O	O
(	O	O
both	O	O
P	O	O
=	O	O
.03	O	O
)	O	O
but	O	O
not	O	O
at	O	O
hour	O	O
4	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
15	O	O
and	O	O
0	O	O
.	O	O
08	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

No	O	O
patient	B-LIVB
experienced	O	O
clinically	O
relevant	O
worsening	O
of	O	O
laboratory	B-PHEN
findings	I-PHEN
or	O	O
physical	B-PROC
examination	I-PROC
,	O	O
and	O	O
hospital	O
admission	O
rates	O
were	O	O
similar	O
.	O	O

One	O	O
patient	B-LIVB
in	O	O
each	O	O
treatment	B-PROC
group	B-LIVB
developed	O	O
hyponatremia	B-DISO
.	O	O

Four	O	O
patients	B-LIVB
developed	O	O
hyperkalemia	B-DISO
(	O	O
PLA	B-CHEM
:	O	O
1	O	O
,	O	O
0	B-CHEM
.	I-CHEM
9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
:	O	O
3	O	O
)	O	O
.	O	O

In	O	O
comparison	O
with	O	O
0	B-CHEM
.	I-CHEM

9	I-CHEM
%	I-CHEM
NaCl	I-CHEM
,	O	O
PLA	B-CHEM
for	O	O
rehydration	B-PROC
in	O	O
children	B-LIVB
with	O	O
AGE	B-DISO
was	O	O
well	O	O
tolerated	O	O
and	O	O
led	O	O
to	O	O
more	O	O
rapid	O	O
improvement	B-PROC
in	I-PROC
serum	I-PROC
bicarbonate	I-PROC
and	O	O
dehydration	B-DISO
score	O	O
.	O	O

NCT	O	O
#	O	O
01234883	O	O
(	O	O
Registration	O	O
Date	O	O
:	O	O
November	O	O
3	O	O
,	O	O
2010	O	O
)	O	O
.	O	O

Impact	O
of	O	O
systemic	O
alitretinoin	B-CHEM
treatment	B-PROC
on	O	O
skin	B-PHYS
barrier	I-PHYS
gene	B-PHYS
and	O	O
protein	B-PHYS
expression	I-PHYS
in	O	O
patients	B-LIVB
with	O	O
chronic	B-DISO
hand	I-DISO
eczema	I-DISO
Chronic	B-DISO
hand	I-DISO
eczema	I-DISO
(	O	O
CHE	B-DISO
)	O	O
is	O	O
a	O	O
common	O	O
inflammatory	B-DISO
skin	I-DISO
disease	I-DISO
that	O	O
affects	O	O
approximately	O
10	O	O
%	O	O
of	O	O
the	O	O
population	B-LIVB
.	O	O

Systemic	O
alitretinoin	B-CHEM
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
effective	O
in	O	O
patients	B-LIVB
with	O	O
CHE	B-DISO
who	O	O
are	O	O
refractory	O
to	O	O
topical	B-CHEM
corticosteroids	I-CHEM
.	O	O

To	O	O
analyse	O	O
the	O	O
impact	O
of	O	O
alitretinoin	B-CHEM
on	O	O
the	O	O
skin	B-PHYS
barrier	I-PHYS
genes	O
and	O	O
protein	B-PHYS
expression	I-PHYS
in	O	O
the	O	O
skin	B-DISO
lesions	I-DISO
of	O	O
patients	B-LIVB
with	O	O
CHE	B-DISO
.	O	O

Fifteen	O	O
patients	B-LIVB
with	O	O
CHE	B-DISO
were	O	O
treated	B-PROC
with	I-PROC
30	O	O
mg	O	O
daily	O
of	O	O
alitretinoin	B-CHEM
for	O	O
up	O	O
to	O	O
27	O	O
weeks	O
.	O	O

Disease	O
severity	O
was	O	O
assessed	O
using	O	O
a	O	O
clinical	O
score	O
.	O	O

Skin	B-PROC
biopsies	I-PROC
from	O	O
all	O	O
the	O	O
patients	B-LIVB
were	O	O
evaluated	B-PROC
before	O
and	O	O
after	O
therapy	B-PROC
for	O	O
the	O	O
expression	B-PHYS
of	O	O
Ki	B-CHEM
-	I-CHEM
67	I-CHEM
,	O	O
various	O	O
skin	B-PHYS
barrier	I-PHYS
genes	O
and	O	O
thymic	B-CHEM
stromal	I-CHEM
lymphopoietin	I-CHEM
(	O	O
TSLP	B-CHEM
)	O	O
by	O	O
real	B-PROC
-	I-PROC
time	I-PROC
quantitative	I-PROC
polymerase	I-PROC
chain	I-PROC
reaction	I-PROC
and	O	O
immunohistochemistry	B-PROC
.	O	O

After	O	O
alitretinoin	B-CHEM
application	O	O
,	O	O
an	O	O
improvement	O
in	O	O
the	O	O
clinical	O
severity	O
of	O	O
CHE	B-DISO
was	O	O
observed	O	O
in	O	O
the	O	O
majority	O
of	O	O
patients	B-LIVB
.	O	O

Analysis	B-PROC
of	O	O
skin	B-PROC
biopsies	I-PROC
before	O
treatment	B-PROC
showed	O	O
a	O	O
significant	O
increase	O
in	O	O
Ki	O
-	O
67	O
-	O	O
positive	B-DISO
cells	B-ANAT
in	O	O
the	O	O
suprabasal	B-ANAT
layer	I-ANAT
and	O	O
a	O	O
dysregulated	B-PHYS
expression	I-PHYS
of	O	O
various	O	O
skin	B-PHYS
barrier	I-PHYS
genes	O
,	O	O
such	O	O
as	O	O
claudin	O
1	O
,	O	O
loricrin	O
,	O	O
filaggrin	O
and	O	O
cytokeratin	O
10	O
,	O	O
which	O	O
were	O	O
normalized	B-PROC
after	O	O
treatment	B-PROC
.	O	O

TSLP	B-CHEM
was	O	O
significantly	O	O
upregulated	B-PHYS
in	O	O
patients	B-LIVB
with	O	O
CHE	B-DISO
and	O	O
also	O	O
normalized	B-PROC
after	O	O
alitretinoin	B-CHEM
treatment	B-PROC
and	O	O
negatively	B-DISO
correlated	O
with	O	O
filaggrin	B-CHEM
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
barrier	O	O
genes	O
and	O	O
proteins	B-CHEM
was	O	O
normalized	B-PROC
following	O	O
treatment	B-PROC
with	O	O
alitretinoin	B-CHEM
in	O	O
patients	B-LIVB
with	O	O
CHE	B-DISO
.	O	O

The	O	O
change	O
in	O	O
expression	B-PHYS
levels	O
of	O	O
these	O	O
genes	O
correlated	O
with	O	O
the	O	O
clinical	O
efficacy	O
,	O	O
suggesting	O	O
that	O	O
alitretinoin	B-CHEM
exhibits	O	O
a	O	O
disease	B-DISO
-	O	O
modifying	O
activity	O
.	O	O

TSLP	B-CHEM
is	O	O
upregulated	B-PHYS
in	O	O
CHE	B-DISO
and	O	O
seems	O	O
to	O	O
counteract	O	O
filaggrin	B-CHEM
expression	B-PHYS
in	O	O
the	O	O
skin	B-ANAT
.	O	O

Patient	B-LIVB
adoption	O
of	O	O
an	O	O
internet	B-OBJC
based	O
diabetes	B-DISO
medication	B-PROC
tool	B-OBJC
to	O	O
improve	B-DISO
adherence	O
:	O	O
A	O	O
pilot	B-PROC
study	I-PROC
To	O	O
investigate	O
the	O	O
effect	O
of	O	O
a	O	O
video	O
intervention	O
,	O	O
Managing	B-PROC
Your	O	O
Diabetes	B-DISO
Medicines	B-CHEM
,	O	O
on	O	O
patient	B-LIVB
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
problems	O
with	O	O
using	O
medication	B-PROC
,	O	O
and	O	O
medication	B-PROC
adherence	O
in	O	O
a	O	O
rural	B-DISO
,	O	O
mostly	O	O
African	B-LIVB
American	I-LIVB
population	I-LIVB
.	O	O

Patients	B-LIVB
selected	O	O
their	O	O
problem	B-DISO
areas	O
in	O	O
medication	B-PROC
use	O
and	O	O
watched	O	O
one	O	O
of	O	O
nine	O	O
2	O	O
-	O	O
min	O	O
videos	O
with	O	O
a	O	O
research	B-PROC
assistant	B-LIVB
at	O	O
a	O	O
clinic	B-OBJC
or	O	O
pharmacy	O
and	O	O
were	O	O
given	O	O
an	O	O
access	O
code	O
to	O	O
watch	O	O
all	O	O
the	O	O
videos	O
at	O	O
their	O	O
convenience	O
.	O	O

Outcomes	O
were	O	O
measured	O
at	O	O
baseline	O
and	O	O
3	O	O
-	O	O
month	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Fifty	O	O
-	O	O
one	O	O
patients	B-LIVB
were	O	O
enrolled	O	O
;	O	O
84	O	O
%	O	O
were	O	O
African	B-LIVB
American	I-LIVB
and	O	O
80	O	O
%	O	O
were	O	O
female	B-PHYS
(	O	O
mean	O	O
age	O	O
:	O	O
54	O	O
years	O	O
)	O	O
.	O	O

Seventy	O	O
-	O	O
three	O	O
percent	O	O
watched	O	O
at	O	O
least	O	O
one	O	O
module	O
after	O	O
the	O	O
initial	O
visit	B-PROC
.	O	O

Improve	B-DISO
d	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
was	O	O
associated	O
with	O
a	O	O
decrease	O
in	O	O
concerns	O
about	O	O
medications	B-PROC
(	O	O
r	O	O
=	O	O
-	O	O
0	O	O
.	O	O
64	O	O
)	O	O
.	O	O

Low	O
literate	B-DISO
patients	B-LIVB
experienced	B-PHYS
greater	O
improvement	B-DISO
in	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
than	O	O
more	O	O
literate	B-DISO
patients	B-LIVB
(	O	O
t	O	O
=	O	O
2	O	O
.	O	O
54	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
.	O	O

Patients	B-LIVB
'	O	O
mean	O
number	O
of	O	O
problems	O
declined	O
from	O	O
6	O	O
.	O	O

14	O	O
to	O	O
5	O	O
.	O	O
03	O	O
.	O	O

The	O	O
number	O
of	O	O
patients	B-LIVB
with	O	O
high	O
or	O	O
medium	O
adherence	O
rose	O	O
from	O	O
33	O	O
%	O	O
at	O	O
baseline	O
to	O	O
43	O	O
%	O	O
at	O	O
3	O	O
-	O	O
month	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

A	O	O
practical	O
,	O	O
customized	O
video	O
intervention	O
may	O	O
help	O	O
improve	B-DISO
patient	B-LIVB
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
reduce	O
problems	O
with	O	O
medication	B-PROC
use	O
,	O	O
and	O	O
improve	B-DISO
medication	B-PROC
adherence	O
in	O	O
diabetes	B-DISO
patients	B-LIVB
.	O	O

Providers	O
should	O	O
consider	O
implementing	O
technology	O
-	O	O
based	O
interventions	O
in	O	O
the	O	O
clinic	B-OBJC
to	O	O
address	O
common	O
problems	O
that	O	O
patients	B-LIVB
have	O	O
with	O	O
self	B-PROC
-	I-PROC
management	I-PROC
.	O	O

Reduced	O
susceptibilities	O
to	O	O
biocides	B-CHEM
and	O	O
resistance	O
to	O	O
antibiotics	B-CHEM
in	O	O
food	B-OBJC
-	O	O
associated	O
bacteria	B-LIVB
following	O	O
exposure	O
to	O
quaternary	B-CHEM
ammonium	I-CHEM
compounds	I-CHEM
Our	O	O
aim	O	O
was	O	O
to	O	O
assess	O
the	O	O
effects	O
of	O	O
step	O	O
-	O	O
wise	O	O
exposure	O
to	O
didecyl	B-CHEM
dimethyl	I-CHEM
ammonium	I-CHEM
chloride	I-CHEM
(	O	O
DDAC	B-CHEM
)	O	O
on	O	O
the	O	O
antimicrobial	B-DISO
(	I-DISO
antibiotics	I-DISO
and	I-DISO
biocides	I-DISO
)	I-DISO
susceptibilities	I-DISO
of	O	O
food	B-OBJC
-	O	O
associated	O
bacterial	B-LIVB
strains	I-LIVB
.	O	O

Adaptive	O
responses	B-PHYS
of	O	O
bacterial	B-LIVB
strains	I-LIVB
were	O	O
investigated	O
by	O	O
exposing	O
the	O	O
strains	B-LIVB
daily	O
to	O	O
increasing	O
subinhibitory	B-PHEN
concentrations	I-PHEN
of	O	O
DDAC	B-CHEM
for	O	O
7	O	O
days	O
.	O	O

Following	O	O
adaptation	B-PHEN
to	O	O
DDAC	B-CHEM
,	O	O
a	O	O
threefold	O	O
increase	O
in	O	O
the	O	O
minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
(	O	O
MIC	B-PROC
)	O	O
values	O
for	O	O
this	O	O
biocide	B-CHEM
was	O	O
observed	O
in	O	O
48	O	O
%	O	O
of	O	O
the	O	O
Escherichia	B-LIVB
coli	I-LIVB
and	O	O
Listeria	B-LIVB
monocytogenes	I-LIVB
strains	I-LIVB
,	O	O
and	O	O
3	O	O
%	O	O
of	O	O
the	O	O
Salmonella	B-LIVB
strains	I-LIVB
.	O	O

Reduced	O
susceptibility	O
to	O	O
other	O	O
biocides	B-CHEM
was	O	O
found	O	O
with	O	O
the	O	O
most	O	O
important	O	O
increase	O
in	O	O
MIC	B-PROC
for	O	O
benzalkonium	B-CHEM
chloride	I-CHEM
(	O	O
BC	B-CHEM
)	O	O
and	O	O
a	O	O
commercial	B-OBJC
biocide	B-CHEM
formulation	I-CHEM
(	O	O
Galox	B-CHEM
Horizon	I-CHEM
)	O	O
containing	O	O
DDAC	B-CHEM
and	O	O
glutaraldehyde	B-CHEM
,	O	O
for	O	O
all	O	O
species	O
except	O	O
Salmonella	B-LIVB
.	O	O

Increase	O
in	O	O
antibiotic	B-CHEM
MIC	B-PROC
values	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
in	O	O
terms	O	O
of	O	O
antibiotic	B-CHEM
numbers	O
and	O	O
of	O	O
magnitude	O
(	O	O
from	O	O
4	O	O
-	O	O
to	O	O
32	O	O
-	O	O
fold	O	O
increase	O
)	O	O
and	O	O
,	O	O
to	O	O
a	O	O
lesser	O
extent	O
,	O	O
in	O	O
Salmonella	B-LIVB
strains	I-LIVB
.	O	O

Most	O	O
of	O	O
these	O	O
strains	B-LIVB
had	O	O
acquired	O	O
resistance	O
to	O	O
ampicillin	B-CHEM
,	O	O
cefotaxime	B-CHEM
,	O	O
ceftazidime	B-CHEM
,	O	O
chloramphenicol	B-CHEM
and	O	O
ciprofloxacin	B-CHEM
.	O	O

The	O	O
effects	O
of	O	O
exposure	O
to	O
DDAC	B-CHEM
on	O	O
biocides	B-CHEM
and	O	O
antibiotics	B-CHEM
susceptibilities	O
depend	O	O
upon	O	O
the	O	O
bacteria	B-LIVB
species	O
.	O	O

Extensive	O
use	O
of	O
DDAC	B-CHEM
at	O	O
subinhibitory	B-PHEN
concentrations	I-PHEN
may	O	O
lead	O	O
to	O	O
the	O	O
development	O
of	O	O
antibiotic	B-CHEM
-	O	O
resistant	O
bacteria	B-LIVB
and	O	O
may	O	O
represent	O	O
a	O	O
public	O	O
health	O	O
issue	O	O
.	O	O

Analgesic	B-DISO
and	O	O
anti	O
-	O
inflammatory	O
actions	O
on	O	O
bradykinin	B-CHEM
route	O	O
of	O	O
a	O	O
polysulfated	B-CHEM
fraction	I-CHEM
from	O	O
alga	O
Ulva	B-LIVB
lactuca	I-LIVB
We	O	O
investigated	O
structural	O
features	O
of	O	O
polysaccharides	B-CHEM
from	O	O
Ulva	B-LIVB
lactuca	I-LIVB
and	O	O
their	O	O
effects	O	O
on	O	O
the	O	O
classical	B-DEVI
models	I-DEVI
of	O	O
nociception	B-PHYS
and	O	O
inflammation	B-DISO
.	O	O

Crude	B-OBJC
extract	I-OBJC
was	O	O
obtained	O	O
by	O	O
enzymatic	B-PROC
digestion	I-PROC
and	O	O
isolated	O
by	O	O
ion	B-PROC
exchange	I-PROC
chromatography	I-PROC
on	O	O
DEAE	B-CHEM
-	I-CHEM
cellulose	I-CHEM
.	O	O

The	O	O
fraction	B-CHEM
with	O	O
higher	O	O
yield	O
was	O	O
used	O	O
in	O	O
the	O	O
tests	B-PROC
(	O	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
)	O	O
.	O	O

Swiss	B-LIVB
mice	I-LIVB
received	O	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
(	O	O
1	O	O
,	O	O
3	O	O
or	O	O
9mg	O	O
/	O	O
kg	O	O
;	O	O
i	O	O
.	O	O

v	O	O
.	O	O
)	O	O
,	O	O
30min	O	O
prior	O	O
to	O	O
injection	O
of	O	O
0	O	O
.	O	O
8	O	O
%	O	O
-	O	O
acetic	B-CHEM
acid	I-CHEM
or	O	O
1	O	O
%	O	O
-	O	O
formalin	B-CHEM
or	O	O
prior	O	O
to	O	O
a	O	O
thermal	B-PHEN
stimulus	I-PHEN
.	O	O

At	O	O
same	O	O
doses	O
,	O	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
was	O	O
tested	O
on	O	O
Wistar	B-LIVB
rats	I-LIVB
on	O	O
paw	B-ANAT
edema	B-DISO
elicited	O	O
by	O	O
different	O	O
irritants	B-CHEM
(	O	O
carrageenan	B-CHEM
,	O	O
dextran	B-CHEM
,	O	O
bradykinin	B-CHEM
,	O	O
histamine	B-CHEM
or	O	O
serotonin	B-CHEM
)	O	O
.	O	O

The	O	O
results	B-DISO
of	O	O
infrared	O
characterization	O
indicated	O	O
the	O	O
presence	O	O
of	O	O
hydroxyl	B-CHEM
groups	I-CHEM
,	O	O
sulfate	B-CHEM
,	O	O
uronic	B-CHEM
acid	I-CHEM
and	O	O
glycosidic	B-PHEN
linkages	I-PHEN
in	O	O
all	O	O
SP	B-CHEM
fractions	I-CHEM
spectrums	O
.	O	O

SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
decreased	O
significantly	O
the	O	O
antinociception	B-PHYS
in	O	O
response	B-PHYS
to	O	O
acetic	B-CHEM
acid	I-CHEM
or	O	O
formalin	B-CHEM
(	O	O
second	O	O
phase	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
hot	B-PROC
-	I-PROC
plate	I-PROC
test	I-PROC
,	O	O
suggesting	O	O
that	O	O
its	O	O
analgesia	B-PROC
occurs	O
through	O	O
a	O	O
peripheral	O
mechanism	O
.	O	O

SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
did	O	O
not	O	O
reduce	O
carrageenan	B-CHEM
-	O	O
induced	O
paw	B-ANAT
edema	B-DISO
as	O	O
supported	O	O
by	O	O
both	O	O
histological	B-PHYS
and	O	O
myeloperoxidase	B-PHYS
activity	I-PHYS
assessments	B-PROC
.	O	O

However	O	O
,	O	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
(	O	O
1mg	O	O
/	O	O
kg	O	O
;	O	O
s	O	O
.	O	O

c	O	O
.	O	O
)	O	O
reduced	O
dextran	B-CHEM
-elicited	O	O
edema	B-DISO
,	O	O
showing	O	O
vascular	B-ANAT
anti	O
-	O
inflammatory	O
effect	O
,	O	O
with	O	O
bradykinin	B-CHEM
as	O	O
major	O	O
target	O
because	O	O
it	O	O
did	O	O
not	O	O
reduce	O
histamine	B-CHEM
-	O	O
and	O	O
serotonin	B-CHEM
-	O	O
induced	O
paw	B-ANAT
edemas	B-DISO
.	O	O

Therefore	O	O
,	O	O
SP	B-CHEM
-	I-CHEM
Ul	I-CHEM
acts	O	O
on	O	O
bradykinin	B-CHEM
pathway	B-PHYS
in	O	O
its	O	O
antinociceptive	B-PHYS
and	O	O
anti	O
-	O
inflammatory	O
responses	O
.	O	O

The	O	O
relationships	O
between	O	O
symptoms	B-DISO
and	O	O
quality	O
of	O
life	O
over	O	O
the	O	O
course	O
of	O	O
cognitive	B-PROC
-	I-PROC
behavioral	I-PROC
therapy	I-PROC
for	O	O
panic	B-DISO
disorder	I-DISO
in	O	O
Japan	B-GEOG
This	O	O
study	B-PROC
examined	B-DISO
the	O	O
relationships	O
between	O	O
changes	O
in	O	O
symptoms	B-DISO
and	O	O
changes	O
in	O	O
quality	O
of	O
life	O
(	O	O
QOL	O
)	O	O
during	O	O
cognitive	B-PROC
-	I-PROC
behavioral	I-PROC
therapy	I-PROC
(	O	O
CBT	B-PROC
)	O	O
for	O	O
panic	B-DISO
disorder	I-DISO
(	O	O
PD	B-DISO
)	O	O
.	O	O

We	O	O
treated	O
198	O	O
PD	B-DISO
patients	B-LIVB
with	O	O
group	O	O
CBT	B-PROC
in	O	O
Japan	B-GEOG
.	O	O

Using	O	O
multiple	O
regression	O
analysis	O
,	O	O
we	O	O
examined	B-DISO
the	O	O
associations	O
between	O	O
changes	O
in	O	O
QOL	O
and	O	O
changes	O
in	O	O
PD	B-DISO
symptoms	B-DISO
or	O	O
comorbid	B-DISO
psychological	I-DISO
symptoms	I-DISO
during	O	O
CBT	B-PROC
.	O	O

Changes	O
in	O	O
anticipatory	B-DISO
anxiety	I-DISO
,	O	O
agoraphobic	B-DISO
fear	I-DISO
/	O	O
avoidance	B-PHYS
,	O	O
and	O	O
somatization	B-DISO
were	O	O
significant	O	O
predictors	O
of	O	O
changes	O
in	O	O
some	O	O
aspects	O	O
of	O	O
QOL	O
.	O	O

It	O	O
might	O	O
be	O	O
useful	O	O
to	O	O
decrease	O	O
somatization	B-DISO
,	O	O
anticipatory	B-DISO
anxiety	I-DISO
,	O	O
and	O	O
agoraphobic	B-DISO
fear	I-DISO
to	O	O
improve	O	O
QOL	O
in	O	O
CBT	B-PROC
for	O	O
PD	B-DISO
.	O	O

Coupling	O
of	O	O
TRPV6	B-CHEM
and	O	O
TMEM16A	B-CHEM
in	O	O
epithelial	B-ANAT
principal	I-ANAT
cells	I-ANAT
of	O	O
the	O	O
rat	B-ANAT
epididymis	I-ANAT
The	O	O
epididymis	B-ANAT
establishes	O	O
a	O	O
congenial	O
environment	O
for	O	O
sperm	B-PHYS
maturation	I-PHYS
and	O	O
protection	B-DISO
.	O	O

Its	O	O
fluid	B-ANAT
is	O	O
acidic	O
,	O	O
and	O	O
the	O	O
calcium	B-CHEM
concentration	O
is	O	O
low	O
and	O	O
declines	O	O
along	O	O
the	O	O
length	O
of	O	O
the	O	O
epididymal	B-ANAT
tubule	I-ANAT
.	O	O

However	O	O
,	O	O
our	O	O
knowledge	O	O
of	O	O
ionic	B-PHYS
currents	I-PHYS
and	O	O
mechanisms	O
of	O	O
calcium	B-PHYS
homeostasis	I-PHYS
in	O	O
rat	B-ANAT
epididymal	I-ANAT
epithelial	B-ANAT
cells	I-ANAT
remains	O	O
enigmatic	O	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
to	O	O
better	O	O
understand	O	O
calcium	B-PHYS
regulation	I-PHYS
in	O	O
the	O	O
epididymis	B-ANAT
,	O	O
we	O	O
use	O	O
the	O	O
patch	B-PROC
-	I-PROC
clamp	I-PROC
method	I-PROC
to	O	O
record	O	O
from	O	O
single	O	O
rat	B-LIVB
cauda	B-ANAT
epididymal	I-ANAT
principal	B-ANAT
cells	I-ANAT
.	O	O

We	O	O
detect	B-DISO
a	O	O
constitutively	O	O
active	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
current	B-PHYS
with	O	O
characteristics	O
that	O	O
match	O	O
the	O	O
epithelial	O
calcium	B-CHEM
channel	I-CHEM
TRPV6	B-CHEM
.	O	O

Electrophysiological	B-PROC
and	O	O
pharmacological	B-PROC
data	I-PROC
also	O	O
reveal	O	O
a	O	O
constitutively	O	O
active	B-CHEM
calcium	I-CHEM
-	I-CHEM
activated	I-CHEM
chloride	I-CHEM
conductance	I-CHEM
(	O	O
CaCC	B-CHEM
)	O	O
.	O	O

Removal	O	O
of	O	O
extracellular	B-ANAT
calcium	B-CHEM
attenuates	O
not	O	O
only	O	O
the	O	O
TRPV6	B-CHEM
-like	O	O
conductance	O
,	O	O
but	O	O
also	O	O
the	O	O
CaCC	B-CHEM
.	O	O

Lanthanide	B-CHEM
block	O
is	O	O
time	O
dependent	O
such	O	O
that	O	O
the	O	O
TRPV6	B-CHEM
-like	O	O
component	O	O
is	O	O
inhibited	B-PHYS
first	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
CaCC	B-CHEM
.	O	O

The	O	O
putative	O	O
CaCC	B-CHEM
blocker	B-CHEM
niflumic	B-CHEM
acid	I-CHEM
partially	O	O
inhibits	B-PHYS
whole	B-ANAT
-	I-ANAT
cell	I-ANAT
currents	B-PHYS
,	O	O
whereas	O	O
La	B-CHEM
(	I-CHEM
3	I-CHEM
+	I-CHEM
)	I-CHEM
almost	O	O
abolishes	O	O
whole	B-ANAT
-	I-ANAT
cell	I-ANAT
currents	B-PHYS
in	O	O
principal	B-ANAT
cells	I-ANAT
.	O	O

Membrane	B-PHYS
potential	I-PHYS
measurements	O
reveal	O	O
an	O	O
interplay	O	O
between	O	O
La	B-CHEM
(	I-CHEM
3	I-CHEM
+	I-CHEM
)	I-CHEM
-	O	O
sensitive	B-CHEM
ion	I-CHEM
channels	I-CHEM
and	O	O
those	O	O
that	O	O
are	O	O
sensitive	O
to	O	O
the	O	O
specific	O
TMEM16A	B-CHEM
inhibitor	B-CHEM
tannic	B-CHEM
acid	I-CHEM
.	O	O

In	O
vivo	O
perfusion	B-PROC
of	O	O
the	O	O
cauda	B-ANAT
epididymal	I-ANAT
tubule	I-ANAT
shows	O	O
a	O	O
substantial	O	O
rate	O	O
of	O	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
reabsorption	B-PHYS
from	O	O
the	O	O
luminal	O
side	O
,	O	O
which	O	O
is	O	O
dose	O	O
-	O	O
dependently	O	O
suppressed	O
by	O	O
ruthenium	B-CHEM
red	I-CHEM
,	O	O
a	O	O
putative	O	O
blocker	B-CHEM
of	O	O
epithelial	O
Ca	B-CHEM
(	I-CHEM
2	I-CHEM
+	I-CHEM
)	I-CHEM
channels	I-CHEM
and	O	O
CaCC	B-CHEM
.	O	O

Finally	O	O
,	O	O
we	O	O
discover	O	O
messenger	B-CHEM
RNA	I-CHEM
for	O	O
both	O	O
TRPV6	B-CHEM
and	O	O
TMEM16A	B-CHEM
in	O	O
the	O	O
rat	B-ANAT
epididymis	I-ANAT
and	O	O
show	O	O
that	O	O
their	O	O
proteins	B-CHEM
colocalize	O
in	O	O
the	O	O
apical	B-ANAT
membrane	I-ANAT
of	O	O
principal	B-ANAT
cells	I-ANAT
.	O	O

Collectively	O	O
,	O	O
these	O	O
data	O
provide	O	O
evidence	O
for	O	O
a	O	O
coupling	O
mechanism	O
between	O	O
TRPV6	B-CHEM
and	O	O
TMEM16A	B-CHEM
in	O	O
principal	B-ANAT
cells	I-ANAT
that	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
regulation	B-PHYS
of	I-PHYS
calcium	I-PHYS
homeostasis	I-PHYS
in	O	O
the	O	O
epididymis	B-ANAT
.	O	O

Challenges	O	O
Caring	B-PROC
for	O	O
Adults	B-LIVB
With	O	O
Congenital	B-DISO
Heart	I-DISO
Disease	I-DISO
in	O	O
Pediatric	O
Settings	O	O
:	O	O
How	O	O
Nurses	B-LIVB
Can	O	O
Aid	O	O
in	O	O
the	O	O
Transition	B-PHEN
As	O	O
surgery	B-PROC
for	O	O
complex	O	O
congenital	B-DISO
heart	I-DISO
disease	I-DISO
is	O	O
becoming	O	O
more	O	O
advanced	O	O
,	O	O
an	O	O
increasing	O	O
number	O	O
of	O	O
patients	B-LIVB
are	O	O
surviving	O	O
into	O	O
adulthood	O
,	O	O
yet	O	O
many	O	O
of	O	O
these	O	O
adult	B-LIVB
patients	B-LIVB
remain	O	O
in	O	O
the	O	O
pediatric	O
hospital	O
system	O
.	O	O

Caring	B-PROC
for	O	O
adult	B-LIVB
patients	B-LIVB
is	O	O
often	O	O
a	O	O
challenge	O	O
for	O	O
pediatric	B-LIVB
nurses	I-LIVB
,	O	O
because	O	O
the	O	O
nurses	B-LIVB
have	O	O
less	O	O
experience	O	O
and	O	O
comfort	O	O
with	O	O
adult	B-PROC
care	I-PROC
,	O	O
medications	B-PROC
,	O	O
comorbid	B-DISO
conditions	I-DISO
,	O	O
and	O	O
rehabilitation	O
techniques	O
.	O	O

As	O	O
these	O	O
patients	B-LIVB
age	O	O
,	O	O
the	O	O
increased	O
risk	O
of	O	O
complications	B-DISO
and	O	O
comorbid	B-DISO
conditions	I-DISO
from	O	O
their	O	O
heart	B-DISO
disease	I-DISO
may	O	O
complicate	O	O
their	O	O
care	B-PROC
further	O	O
.	O	O

Although	O	O
these	O	O
patients	B-LIVB
are	O	O
admitted	B-PROC
on	O	O
a	O	O
pediatric	B-OBJC
unit	I-OBJC
,	O	O
nurses	B-LIVB
can	O	O
aid	O	O
in	O	O
promoting	O	O
their	O	O
independence	O
and	O	O
help	O	O
prepare	O	O
them	O	O
to	O	O
transition	B-PHEN
into	O	O
the	O	O
adult	B-OBJC
medical	I-OBJC
system	I-OBJC
.	O	O

Nurses	B-LIVB
,	O	O
the	O	O
comprehensive	B-PROC
medical	I-PROC
teams	I-PROC
,	O	O
and	O	O
patients	B-LIVB
'	O	O
families	B-LIVB
can	O	O
all	O	O
effectively	O	O
influence	O
the	O	O
process	O	O
of	O	O
preparing	O	O
these	O	O
patients	B-LIVB
for	O	O
transition	B-PHEN
to	O	O
adult	B-PROC
care	I-PROC
.	O	O

Coffee	B-OBJC
-	O	O
Antihypertensive	B-CHEM
Drug	I-CHEM
Interaction	O
:	O	O
A	O	O
Hemodynamic	B-PHYS
and	O	O
Pharmacokinetic	B-PROC
Study	I-PROC
With	O	O
Felodipine	B-CHEM
A	O	O
period	O
of	O	O
abstinence	O
from	O	O
coffee	B-OBJC
to	O	O
permit	O
caffeine	B-CHEM
elimination	B-PHYS
appears	O
to	O	O
enable	O	O
increased	O
blood	B-PHYS
pressure	I-PHYS
on	O	O
subsequent	O
exposure	O
.	O	O

We	O	O
hypothesized	O
that	O	O
this	O	O
would	O	O
offset	O
the	O	O
antihypertensive	B-CHEM
effect	O
of	O	O
the	O	O
dihydropyridine	B-CHEM
calcium	I-CHEM
channel	I-CHEM
blocker	I-CHEM
felodipine	B-CHEM
.	O	O

A	O	O
randomized	B-PROC
,	O	O
single	O
-	O
dose	O
,	O	O
crossover	B-PROC
study	I-PROC
assessed	O
hemodynamic	B-PHYS
and	O	O
pharmacokinetic	B-PHYS
effects	I-PHYS
following	O	O
2	O
days	O
without	O
coffee	B-OBJC
and	O	O
caffeine	B-CHEM
-	O	O
containing	O
foods	B-OBJC
.	O	O

Consistently	O
brewed	O
black	B-OBJC
coffee	I-OBJC
(	O	O
2×300ml	O	O
)	O	O
,	O	O
felodipine	B-CHEM
maximum	O
recommended	O
dose	O
(	O	O
10	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
coffee	B-OBJC
plus	O
felodipine	B-CHEM
were	O	O
tested	O
in	O	O
middle	B-LIVB
-	I-LIVB
aged	I-LIVB
normotensive	B-DISO
subjects	B-LIVB
.	O	O

Pretreatment	O
plasma	B-ANAT
caffeine	B-PROC
concentrations	I-PROC
were	O	O
unquantifiable	O
.	O	O

After	O	O
coffee	B-OBJC
,	O	O
blood	B-PHYS
pressure	I-PHYS
changes	O
(	O	O
mm	O
Hg	O
)	O	O
averaged	O
over	O	O
study	B-PROC
hours	O
1	O	O
-	O	O
4	O	O
were	O	O
increased	O
for	O	O
brachial	O
systolic	O
(	O	O
7	O	O
.	O	O
6	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
diastolic	B-PHYS
(	O	O
4	O	O
.	O	O
9	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
aortic	B-ANAT
systolic	O
(	O	O
7	O	O
.	O	O
4	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
,	O	O
pulse	B-PROC
(	O	O
3	O	O
.	O	O
0	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
augmentation	O
(	O	O
1	O	O
.	O	O
4	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
relative	O	O
to	O	O
baseline	O
.	O	O

After	O	O
coffee	B-OBJC
plus	O
felodipine	B-CHEM
,	O	O
they	O	O
were	O	O
higher	O
for	O	O
brachial	O
systolic	O
(	O	O
4	O	O
.	O	O
0	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
and	O	O
diastolic	B-PHYS
(	O	O
3	O	O
.	O	O
9	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
and	O	O
aortic	B-ANAT
systolic	O
(	O	O
4	O	O
.	O	O
6	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
compared	O
to	O	O
felodipine	B-CHEM
alone	O	O
.	O	O

The	O	O
pressor	B-CHEM
effects	O
of	O	O
coffee	B-OBJC
and	O	O
its	O	O
modulation	O
by	O	O
felodipine	B-CHEM
were	O	O
variable	O
among	O	O
individuals	B-LIVB
.	O	O

Coffee	B-OBJC
containing	O	O
caffeine	B-CHEM
(	O	O
127	O	O
mg	O	O
)	O	O
caused	O	O
maximum	O
pressor	B-CHEM
effect	O
.	O	O

Caffeine	B-CHEM
and	O	O
felodipine	B-CHEM
pharmacokinetics	B-PHYS
were	O	O
similar	O
for	O	O
coffee	B-OBJC
and	O	O
felodipine	B-CHEM
given	O	O
alone	O	O
or	O	O
in	O	O
combination	O
indicating	O	O
an	O	O
interaction	O
having	O	O
a	O	O
pharmacodynamic	B-PHEN
basis	O
.	O	O

Plasma	B-ANAT
felodipine	B-CHEM
concentration	O
-	O	O
diastolic	B-PHYS
blood	B-PHYS
pressure	I-PHYS
reduction	O
relationship	O
shifted	O	O
with	O	O
coffee	B-OBJC
such	O	O
that	O	O
doubling	O
the	O	O
felodipine	B-CHEM
concentration	O
would	O	O
eliminate	O
the	O	O
pressor	B-CHEM
effect	O
.	O	O

However	O	O
,	O	O
this	O	O
may	O	O
increase	O
the	O	O
risk	O
of	O	O
adverse	B-DISO
drug	I-DISO
events	I-DISO
particularly	O	O
during	O
the	O	O
timeframe	O	O
without	O
coffee	B-OBJC
.	O	O

Intermittent	O
coffee	B-OBJC
ingestion	B-PHEN
might	O	O
complicate	O
hypertension	B-DISO
diagnosis	B-DISO
and	O	O
management	B-PROC
for	O	O
many	O	O
individuals	B-LIVB
.	O	O

Elevated	O
Serum	B-ANAT
Krebs	B-CHEM
von	I-CHEM
den	I-CHEM
Lungen	I-CHEM
-	I-CHEM
6	I-CHEM
in	O	O
Early	O
Disease	B-DISO
Predicts	O
Subsequent	O
Deterioration	B-PHEN
of	O	O
Pulmonary	B-PHYS
Function	I-PHYS
in	O	O
Patients	B-LIVB
with	O	O
Systemic	B-DISO
Sclerosis	I-DISO
and	O	O
Interstitial	B-DISO
Lung	I-DISO
Disease	I-DISO
To	O	O
identify	O	O
predictors	O
of	O	O
poor	O	O
prognosis	B-PROC
in	O	O
patients	B-LIVB
with	O	O
systemic	B-DISO
sclerosis	I-DISO
(	O	O
SSc	B-DISO
)	O	O
associated	O
with	O
interstitial	B-DISO
lung	I-DISO
disease	I-DISO
(	O	O
ILD	B-DISO
)	O	O
.	O	O

Fifty	O	O
patients	B-LIVB
with	O	O
early	O
-	O
stage	O
SSc	B-DISO
-	O	O
ILD	B-DISO
who	O	O
had	O	O
never	O	O
received	O	O
disease	B-DISO
-	O	O
modifying	O
drugs	B-CHEM
and	O	O
were	O	O
either	O	O
observed	O	O
for	O	O
≥	O	O
10	O	O
years	O
or	O	O
died	B-PHYS
from	O	O
ILD	B-DISO
-related	O	O
causes	B-DISO
were	O	O
enrolled	O	O
.	O	O

The	O	O
baseline	O
variables	O
of	O	O
patients	B-LIVB
who	O	O
developed	O
endstage	B-DISO
lung	I-DISO
disease	I-DISO
(	O	O
ESLD	B-DISO
)	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
patients	B-LIVB
who	O	O
remained	O	O
ESLD	B-DISO
-	O	O
free	O
,	O	O
and	O	O
the	O	O
Cox	O
proportional	O
hazard	O
model	O
was	O	O
used	O	O
to	O	O
identify	O	O
initial	O
factors	O
that	O	O
correlated	O
with	O	O
ESLD	B-DISO
development	O
.	O	O

Sixteen	O	O
patients	B-LIVB
(	O	O
32	O	O
%	O	O
)	O	O
developed	O
ESLD	B-DISO
during	O	O
173	O	O
.	O	O

5	O	O
±	O	O
64	O	O
.	O	O

7	O	O
months	O
of	O	O
followup	B-PROC
.	O	O

Elevated	O
serum	B-ANAT
Krebs	B-CHEM
von	I-CHEM
den	I-CHEM
Lungen	I-CHEM
-	I-CHEM
6	I-CHEM
(	O	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
)	O	O
at	O	O
initial	O
assessment	B-PROC
was	O	O
highly	O	O
correlated	O
with	O	O
ESLD	B-DISO
development	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
0002	O	O
)	O	O
.	O	O

Receiver	B-PROC
-	I-PROC
operating	I-PROC
characteristic	I-PROC
curve	I-PROC
analysis	I-PROC
revealed	O
that	O	O
a	O	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
value	O	O
of	O	O
1273	O	O
U	O	O
/	O	O
ml	O	O
effectively	O	O
discriminated	O
patients	B-LIVB
who	O	O
developed	O
ESLD	B-DISO
from	O	O
those	O	O
who	O	O
did	O	O
not	O	O
.	O	O

Patients	B-LIVB
with	O	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
>	O	O
1273	O	O
U	O	O
/	O	O
ml	O	O
were	O	O
less	O	O
likely	O	O
to	O	O
remain	O	O
ESLD	B-DISO
-	O	O
free	O
compared	O
with	O	O
those	O	O
with	O	O
lower	O	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
levels	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

Multivariate	O
analysis	O
showed	O	O
that	O	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
>	O	O
1273	O	O
U	O	O
/	O	O
ml	O	O
was	O	O
the	O	O
most	O	O
reliable	O	O
predictor	O
of	O	O
ESLD	B-DISO
development	O
(	O	O
OR	O
51	O	O
.	O	O

2	O	O
,	O	O
95	O	O
%	O	O
CI	O
7	O	O
.	O	O
6	O	O
-	O	O
343	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
initial	O
KL	B-CHEM
-	I-CHEM
6	I-CHEM
level	O
correlated	O
with	O	O
the	O	O
forced	B-DISO
vital	I-DISO
capacity	I-DISO
(	O	O
FVC	B-DISO
)	O	O
decline	O
rate	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O
58	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

The	O	O
natural	O	O
course	O
of	O	O
SSc	B-DISO
-	O	O
ILD	B-DISO
is	O	O
highly	O
variable	O
.	O	O

Baseline	O
serum	B-ANAT
KL	B-CHEM
-	I-CHEM
6	I-CHEM
is	O	O
a	O	O
biomarker	B-PHYS
potentially	O	O
useful	O	O
for	O	O
predicting	O
FVC	B-DISO
decline	O
.	O	O

Polymorphisms	O
in	O	O
Inflammatory	O
Mediator	O
Genes	O
and	O	O
Risk	O
of	O	O
Preeclampsia	B-DISO
in	O	O
Taiyuan	O
,	O	O
China	B-GEOG
Excessive	O
maternal	B-DISO
inflammatory	B-DISO
response	I-DISO
is	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	B-DISO
of	O	O
preeclampsia	B-DISO
.	O	O

Few	O	O
epidemiologic	B-PROC
studies	I-PROC
have	O	O
investigated	O
the	O	O
associations	O
between	O	O
genetic	B-PHEN
variations	I-PHEN
in	O	O
the	O	O
inflammatory	O
mediator	O
genes	O
and	O	O
preeclampsia	B-DISO
risk	O
,	O	O
and	O	O
these	O	O
studies	B-PROC
have	O	O
reached	O	O
inconsistent	O	O
results	O	O
.	O	O

We	O	O
examined	O	O
31	O	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O	O
IL	O
-	O
1A	O
,	O	O
IL	O
-	O
1B	O
,	O	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
2RA	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
,	O	O
IL	O
-	O
6	O
,	O	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O	O
TNFSF11	O
,	O	O
TNFRSF11A	O
,	O	O
IL	O
-	O
28RA	O
,	O	O
IRAK4	O
,	O	O
and	O	O
KIT	O
genes	O
and	O	O
the	O	O
risk	O
of	O	O
preeclampsia	B-DISO
and	O	O
its	O	O
clinical	O
subtypes	O
in	O	O
a	O	O
nested	B-PROC
case	I-PROC
-	I-PROC
control	I-PROC
study	I-PROC
including	O	O
203	O	O
preeclampsia	B-DISO
cases	O
and	O	O
233	O	O
controls	B-LIVB
.	O	O

We	O	O
found	O	O
that	O	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O	O
and	O	O
TNFSF11	O
were	O	O
associated	O
with	O
the	O	O
risk	O
of	O	O
preeclampsia	B-DISO
.	O	O

Although	O	O
the	O	O
significant	O
associations	O
observed	O	O
for	O	O
preeclampsia	B-DISO
overall	O
were	O	O
mainly	O	O
seen	O	O
for	O	O
late	O
-	O
onset	O
preeclampsia	B-DISO
and	O	O
severe	O
preeclampsia	B-DISO
,	O	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
(	O	O
rs2229238	O
)	O	O
and	O	O
TNFSF11	O
(	O	O
rs9525643	O
)	O	O
polymorphisms	O
were	O	O
associated	O
with	O
the	O	O
risk	O
of	O	O
early	O	O
-	O	O
onset	O	O
preeclampsia	B-DISO
.	O	O

TNFSF11	O
(	O	O
rs2200287	O
and	O	O
rs2148072	O
)	O	O
polymorphisms	O
were	O	O
associated	O
with	O
risk	O
of	O	O
mild	O	O
preeclampsia	B-DISO
.	O	O

Our	O	O
study	B-PROC
provided	O	O
the	O	O
first	O	O
evidence	O
that	O	O
genetic	B-PHEN
variations	I-PHEN
in	O	O
inflammatory	O
mediator	O
genes	O
IL	B-CHEM
-	I-CHEM
1R1	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
6R	I-CHEM
,	O	O
TNFSF11	O
,	O	O
and	O	O
IL	B-CHEM
-	I-CHEM
5RA	I-CHEM
were	O	O
associated	O
with	O
preeclampsia	B-DISO
risk	O
,	O	O
and	O	O
the	O	O
risk	O
varied	O	O
by	O	O
preeclampsia	B-DISO
subtypes	O
.	O	O

Preoperative	O
ultrasonographic	B-PROC
findings	B-DISO
of	O	O
internal	B-ANAT
jugular	I-ANAT
veins	I-ANAT
and	O	O
carotid	B-ANAT
arteries	I-ANAT
in	O	O
kidney	B-DISO
transplant	I-DISO
recipients	I-DISO
Hemodialysis	B-PROC
via	O	O
the	O	O
internal	B-ANAT
jugular	I-ANAT
vein	I-ANAT
(	O	O
IJV	B-ANAT
)	O	O
has	O	O
been	O	O
widely	O	O
used	O	O
for	O	O
patients	B-LIVB
with	O	O
end	B-DISO
stage	I-DISO
renal	I-DISO
disease	I-DISO
(	O	O
ESRD	B-DISO
)	O	O
patients	B-LIVB
,	O	O
as	O	O
they	O	O
have	O	O
a	O	O
higher	B-DISO
risk	I-DISO
of	O	O
arterial	B-DISO
diseases	I-DISO
.	O	O

We	O	O
investigated	O	O
the	O	O
ultrasonographic	B-PROC
findings	B-DISO
of	O	O
the	O	O
IJV	B-ANAT
and	O	O
carotid	B-ANAT
artery	I-ANAT
(	O	O
CA	B-ANAT
)	O	O
in	O	O
recipients	B-LIVB
of	O	O
kidney	B-PROC
transplantation	I-PROC
(	O	O
KT	B-PROC
)	O	O
and	O	O
identified	O	O
factors	O	O
influencing	O	O
IJV	B-DISO
/	O	O
CA	B-DISO
abnormalities	I-DISO
.	O	O

We	O	O
enrolled	O	O
120	O	O
adult	B-LIVB
KT	B-PROC
recipients	B-LIVB
.	O	O

Patients	B-LIVB
in	O	O
group	O
A	O
(	O	O
n	O	O
=	O	O
57	O	O
)	O	O
had	O	O
a	O	O
history	B-DISO
of	I-DISO
IJV	B-ANAT
hemodialysis	B-PROC
,	O	O
while	O	O
those	O	O
in	O	O
group	O
B	O
(	O	O
n	O	O
=	O	O
63	O	O
)	O	O
were	O	O
not	O	O
yet	O	O
on	O	O
dialysis	B-PROC
or	O	O
undergoing	O	O
dialysis	B-PROC
methods	I-PROC
not	O	O
involving	O	O
the	O	O
IJV	B-ANAT
.	O	O

The	O	O
day	O
before	O	O
surgery	B-PROC
,	O	O
we	O	O
evaluated	O	O
the	O	O
state	O	O
of	O	O
the	O	O
IJV	B-ANAT
and	O	O
CA	B-ANAT
using	O	O
ultrasonography	B-PROC
.	O	O

We	O	O
followed	O	O
patients	B-LIVB
with	O	O
IJV	B-DISO
stenosis	I-DISO
for	O	O
six	O
months	O
after	O	O
KT	B-PROC
.	O	O

Ultrasonography	B-PROC
revealed	O	O
that	O	O
four	O	O
patients	B-LIVB
(	O	O
7	O	O
%	O	O
)	O	O
in	O	O
group	O
A	O
had	O	O
IJV	B-DISO
abnormalities	I-DISO
,	O	O
while	O	O
no	O	O
patients	B-LIVB
in	O	O
group	O
B	O
had	O	O
abnormalities	B-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
118	O	O
)	O	O
.	O	O

Of	O	O
the	O	O
four	O	O
patients	B-LIVB
with	O	O
abnormalities	B-DISO
,	O	O
one	O	O
with	O	O
57	O	O
.	O	O

4	O	O
%	O	O
stenosis	B-DISO
normalized	O	O
during	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

However	O	O
,	O	O
another	O	O
patient	B-LIVB
with	O	O
90	O	O
.	O	O

1	O	O
%	O	O
stenosis	B-DISO
progressed	O	O
to	O	O
occlusion	B-DISO
,	O	O
while	O	O
the	O	O
two	O	O
patients	B-LIVB
with	O	O
total	O	O
occlusion	B-DISO
remained	O	O
the	O	O
same	O	O
.	O	O

Twenty	O	O
patients	B-LIVB
in	O	O
group	O
A	O
(	O	O
n	O	O
=	O	O
11	O	O
)	O	O
and	O	O
B	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
had	O	O
several	O	O
CA	B-DISO
abnormalities	I-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
462	O	O
)	O	O
.	O	O

Upon	O	O
multivariate	O
analysis	O
with	O	O
stepwise	O	O
selection	O	O
,	O	O
height	B-PHYS
and	O	O
age	B-PHYS
were	O	O
significantly	O	O
correlated	O	O
with	O	O
IJV	B-DISO
stenosis	I-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

043	O	O
,	O	O
odds	O	O
ratio	O	O
=	O	O
0	O	O
.	O	O
9	O	O
)	O	O
and	O	O
CA	B-DISO
abnormality	I-DISO
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
012	O	O
,	O	O
odds	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O
1	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

IJV	B-DISO
abnormalities	I-DISO
(	O	O
especially	O	O
with	O	O
a	O	O
history	B-DISO
of	I-DISO
IJV	B-ANAT
hemodialysis	B-PROC
)	O	O
and	O	O
CA	B-DISO
abnormalities	I-DISO
may	O	O
be	O	O
present	O	O
in	O	O
ESRD	B-DISO
patients	B-LIVB
.	O	O

Therefore	O	O
,	O	O
we	O	O
recommend	O	O
ultrasonographic	B-PROC
evaluation	B-PROC
before	O	O
catheterization	B-PROC
.	O	O

Lipid	B-CHEM
digestibility	B-DISO
and	O	O
energy	O
content	O
of	O	O
distillers	O
'	O
corn	B-CHEM
oil	I-CHEM
in	O	O
swine	B-LIVB
and	O	O
poultry	B-LIVB
Two	O	O
experiments	B-PROC
were	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
DE	O
and	O	O
ME	O
and	O	O
apparent	B-DISO
total	I-DISO
tract	I-DISO
digestibility	I-DISO
of	O	O
ether	B-CHEM
extract	B-OBJC
of	O	O
3	O	O
distillers	O
'	O
corn	B-CHEM
oil	I-CHEM
(	O	O
DCO	B-CHEM
;	O	O
4	O	O
.	O	O
9	O	O
,	O	O
12	O	O
.	O	O

8	O	O
,	O	O
or	O	O
13	O	O
.	O	O

9	O	O
%	O	O
free	B-CHEM
fatty	I-CHEM
acids	I-CHEM
[	O	O
FFA	B-CHEM
]	O	O
)	O	O
samplescompared	O	O
with	O	O
a	O	O
sample	B-OBJC
of	O	O
refined	B-CHEM
corn	I-CHEM
oil	I-CHEM
(	O	O
CO	B-CHEM
;	O	O
0	O	O
.	O	O
04	O	O
%	O	O
FFA	B-CHEM
)	O	O
and	O	O
an	O	O
industrially	O
hydrolyzed	B-CHEM
high	I-CHEM
-	I-CHEM
FFA	I-CHEM
DCO	B-CHEM
(	O	O
93	O	O
.	O	O

8	O	O
%	O	O
FFA	B-CHEM
)	O	O
in	O	O
young	O
pigs	B-LIVB
and	O	O
growing	B-LIVB
broilers	I-LIVB
.	O	O

In	O	O
Exp	O	O
.	O	O
1	O	O
,	O	O
54	O	O
barrows	B-LIVB
(	O	O
initial	O	O
age	B-PHYS
=	O	O
28	O	O
d	O	O
)	O	O
were	O	O
fed	O
a	O	O
common	O
diet	B-OBJC
for	O	O
7	O	O
d	O	O
and	O	O
then	O	O
fed	O
their	O	O
allotted	O	O
dietary	B-OBJC
treatment	O
(	O	O
either	O	O
100	O	O
%	O	O
basal	B-OBJC
diet	I-OBJC
or	O	O
1	O	O
of	O	O
5	O	O
test	B-PROC
diets	I-PROC
consisting	O	O
of	O	O
90	O	O
%	O	O
basal	B-OBJC
diet	I-OBJC
plus	O
10	O	O
%	O	O
test	O	O
lipid	B-CHEM
)	O	O
for	O	O
the	O	O
next	O	O
7	O	O
d	O	O
in	O	O
group	B-OBJC
pens	I-OBJC
(	O	O
9	O	O
pigs	B-LIVB
/	O	O
pen	B-OBJC
)	O	O
.	O	O

For	O	O
the	O	O
next	O	O
10	O	O
d	O	O
,	O	O
pigs	B-LIVB
were	O	O
moved	O	O
to	O	O
individual	O	O
metabolism	B-OBJC
crates	I-OBJC
for	O	O
continued	O
diet	B-OBJC
and	O	O
crate	B-OBJC
adaptation	B-PHYS
and	O	O
to	O	O
a	O	O
twice	O
-	O
daily	O
feeding	B-PROC
regimen	I-PROC
.	O	O

Pigs	B-LIVB
remained	O	O
on	O	O
their	O	O
respective	O	O
diets	B-OBJC
for	O	O
a	O	O
4	O	O
-	O	O
d	O	O
total	O
fecal	B-PROC
and	O	O
urine	B-PROC
collection	I-PROC
period	O
.	O	O

For	O	O
Exp	O	O
.	O	O

2	O	O
,	O	O
567	O	O
male	B-PHYS
broilers	B-LIVB
were	O	O
obtained	O
from	O	O
a	O	O
commercial	O
hatchery	O
(	O	O
1	O	O
d	O	O
of	O	O
age	B-PHYS
)	O	O
and	O	O
reared	O
in	O	O
grower	B-OBJC
battery	I-OBJC
cages	I-OBJC
that	O	O
contained	O
9	O	O
chicks	B-LIVB
per	O	O
cage	B-OBJC
.	O	O

Broilers	B-LIVB
were	O	O
fed	O
a	O	O
common	O
corn	B-LIVB
-	O	O
soybean	B-OBJC
meal	O
starter	B-OBJC
diet	I-OBJC
from	O	O
placement	B-PROC
until	O	O
the	O	O
beginning	O
of	O	O
the	O	O
trial	B-PROC
(	O	O
19	O	O
d	O	O
of	O	O
age	B-PHYS
)	O	O
.	O	O

Birds	B-LIVB
were	O	O
then	O	O
randomly	O
assigned	O
to	O	O
1	O	O
of	O	O
6	O	O
dietary	B-OBJC
treatments	O
(	O	O
94	O	O
%	O	O
basal	B-OBJC
diet	I-OBJC
plus	O
6	O	O
%	O	O
dextrose	B-CHEM
or	O	O
94	O	O
%	O	O
basal	B-OBJC
diet	I-OBJC
plus	O
6	O	O
%	O	O
test	O	O
lipid	B-CHEM
substituted	O	O
for	O	O
dextrose	B-CHEM
)	O	O
on	O	O
d	O	O
19	O	O
and	O	O
were	O	O
allowed	O	O
an	O	O
8	O	O
-	O	O
d	O	O
dietary	B-OBJC
acclimation	B-PHYS
period	O
followed	O
by	O
a	O	O
48	O	O
-	O	O
h	O	O
energy	B-PROC
balance	I-PROC
assay	I-PROC
.	O	O

In	O	O
Exp	O	O
.	O	O

1	O	O
,	O	O
the	O	O
DCO	B-CHEM
sample	B-OBJC
with	O	O
12	O	O
.	O	O
8	O	O
%	O	O
FFA	B-CHEM
contained	O
the	O	O
lowest	O
(	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
DE	O
(	O	O
8	O	O
,	O	O
036	O	O
kcal	O	O
/	O	O
kg	O	O
)	O	O
content	O
compared	O
with	O	O
the	O	O
0	O	O
.	O	O
04	O	O
%	O	O
refined	B-CHEM
CO	I-CHEM
sample	B-OBJC
and	O	O
the	O	O
4	O	O
.	O	O
9	O	O
or	O	O
93	O	O
.	O	O

8	O	O
%	O	O
FFA	B-CHEM
DCO	B-CHEM
samples	B-OBJC
(	O	O
8	O	O
,	O	O
814	O	O
,	O	O
8	O	O
,	O	O
828	O	O
,	O	O
and	O	O
8	O	O
,	O	O
921	O	O
kcal	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
with	O	O
the	O	O
DCO	B-CHEM
source	B-DISO
containing	O
13	O	O
.	O	O

9	O	O
%	O	O
FFA	B-CHEM
having	O	O
intermediate	O
DE	O
(	O	O
8	O	O
,	O	O
465	O	O
kcal	O	O
/	O	O
kg	O	O
)	O	O
content	O
.	O	O

The	O	O
ME	O
content	O
of	O	O
these	O	O
lipid	B-CHEM
sources	B-DISO
also	O	O
differed	O	O
among	O	O
treatments	O
(	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
,	O	O
following	O
trends	O	O
similar	O
to	O	O
their	O	O
DE	O
values	O
,	O	O
with	O	O
no	B-DISO
differences	I-DISO
noted	O	O
for	O	O
ME	O
as	O	O
a	O	O
percentage	O
of	O	O
DE	O
(	O	O
>	O	O
0	O	O
.	O	O
35	O	O
)	O	O
content	O
among	O	O
the	O	O
lipids	B-CHEM
evaluated	O
.	O	O

In	O	O
Exp	O	O
.	O	O

2	O	O
,	O	O
lipids	B-CHEM
containing	O
0	O	O
.	O	O
04	O	O
,	O	O
4	O	O
.	O	O
9	O	O
,	O	O
12	O	O
.	O	O
8	O	O
,	O	O
and	O	O
13	O	O
.	O	O

9	O	O
%	O	O
FFA	B-CHEM
had	O	O
similar	O
nitrogen	O
corrected	O
apparent	O
ME	O
(	O	O
AME	O
)	O	O
values	O
(	O	O
8	O	O
,	O	O
072	O	O
,	O	O
7	O	O
,	O	O
936	O	O
,	O	O
8	O	O
,	O	O
036	O	O
,	O	O
and	O	O
7	O	O
,	O	O
694	O	O
respectively	O	O
)	O	O
,	O	O
except	O	O
for	O	O
the	O	O
industrially	B-CHEM
hydrolyzed	I-CHEM
DCO	I-CHEM
sample	B-OBJC
containing	O
93	O	O
.	O	O

8	O	O
%	O	O
FFA	B-CHEM
,	O	O
which	O	O
contained	O
6	O	O
,	O	O
276	O	O
kcal	O	O
/	O	O
kg	O	O
(	O	O
<	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

Using	O	O
published	O
prediction	O
equations	O
,	O	O
the	O	O
predicted	O
DE	O
of	O	O
these	O	O
lipids	B-CHEM
for	O	O
swine	B-LIVB
was	O	O
3	O	O
.	O	O

5	O	O
%	O	O
greater	O
than	O	O
the	O	O
values	O
determined	O	O
in	O	O
Exp	O	O
.	O	O

1	O	O
for	O	O
all	O	O
lipid	B-CHEM
sources	B-DISO
,	O	O
except	O	O
for	O	O
the	O	O
DCO	B-CHEM
sample	B-OBJC
containing	O
93	O	O
.	O	O

8	O	O
%	O	O
FFA	B-CHEM
,	O	O
which	O	O
the	O	O
predicted	O
DE	O
was	O	O
underestimated	O	O
.	O	O

Likewise	O	O
,	O	O
the	O	O
predicted	O
AME	O
of	O	O
these	O	O
lipids	B-CHEM
for	O	O
broilers	B-LIVB
was	O	O
7	O	O
.	O	O
4	O	O
%	O	O
greater	O
than	O	O
the	O	O
determined	O	O
AMEn	O
(	O	O
Exp	O	O
.	O	O
2	O	O
)	O	O
for	O	O
all	O	O
lipid	B-CHEM
sources	B-DISO
.	O	O

Voices	O	O
:	O	O
A	O	O
Conversation	O
with	O	O
Allen	B-LIVB
J	I-LIVB
.	I-LIVB

Wilcox	I-LIVB
Allen	B-LIVB
James	I-LIVB
Wilcox	I-LIVB
was	O	O
born	O	O
on	O	O
30	O	O
September	O	O
1946	O	O
in	O	O
Columbus	B-GEOG
,	I-GEOG
OH	I-GEOG
.	O	O

He	O	O
studied	O	O
medicine	O
at	O	O
the	O	O
University	B-OBJC
of	I-OBJC
Michigan	I-OBJC
,	O	O
graduated	O	O
in	O	O
1973	O	O
,	O	O
and	O	O
after	O	O
a	O	O
rotating	O	O
internship	B-PROC
,	O	O
he	O	O
completed	B-DISO
a	I-DISO
master	I-DISO
's	I-DISO
degree	I-DISO
in	O	O
maternal	O
and	O
child	O
health	O
(	O	O
1976	O	O
)	O	O
and	O	O
a	O	O
PhD	O
in	O	O
epidemiology	O
(	O	O
1979	O	O
)	O	O
at	O	O
the	O	O
University	B-OBJC
of	I-OBJC
North	I-OBJC
Carolina	I-OBJC
in	O	O
Chapel	B-GEOG
Hill	I-GEOG
.	O	O

After	O	O
graduation	B-PROC
,	O	O
he	O	O
went	O	O
to	O	O
work	O
at	O	O
the	O	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
(	O	O
NIEHS	O
,	O	O
one	O	O
of	O	O
the	O	O
US	O
National	O
Institutes	O
of	O
Health	O
)	O	O
in	O	O
Durham	B-GEOG
,	I-GEOG
NC	I-GEOG
,	O	O
where	O	O
he	O	O
has	O	O
spent	O	O
his	O	O
career	O
.	O	O

He	O	O
developed	O	O
a	O	O
research	B-PROC
program	I-PROC
in	O	O
reproductive	O	O
and	O	O
perinatal	O
epidemiology	O
,	O	O
a	O	O
relatively	O	O
unexplored	O	O
area	O	O
at	O	O
the	O	O
time	O	O
.	O	O

His	O	O
studies	O	O
include	O	O
the	O	O
early	B-DISO
pregnancy	I-DISO
study	O	O
,	O	O
which	O	O
documented	B-PROC
the	O	O
extent	O	O
of	O	O
subclinical	O
pregnancy	B-DISO
loss	I-DISO
in	O	O
humans	B-LIVB
and	O	O
established	O
the	O	O
fertile	O
days	O
of	O	O
a	O	O
woman	B-LIVB
's	I-LIVB
menstrual	B-PHYS
cycle	I-PHYS
.	O	O

He	O	O
served	O	O
as	O	O
the	O	O
Chief	B-LIVB
of	I-LIVB
the	O	O
Epidemiology	O
Branch	B-LIVB
from	O	O
1991	O	O
to	O	O
2001	O	O
,	O	O
and	O	O
as	O	O
Editor	B-LIVB
-	I-LIVB
in	I-LIVB
-	I-LIVB
Chief	I-LIVB
of	O	O
the	O	O
journal	B-OBJC
EPIDEMIOLOGY	O
from	O	O
2001	O	O
to	O	O
2014	O	O
.	O	O

His	O	O
textbook	B-OBJC
,	O	O
Fertility	B-OBJC
and	I-OBJC
Pregnancy	I-OBJC
-	I-OBJC
An	I-OBJC
Epidemiologic	I-OBJC
Perspective	I-OBJC
,	O	O
was	O	O
published	O
by	O	O
Oxford	O
University	O
Press	O
in	O	O
2010	O	O
.	O	O

He	O	O
was	O	O
elected	O
to	O	O
the	O	O
American	O
Epidemiological	O
Society	O
in	O	O
1989	O	O
,	O	O
and	O	O
served	O	O
as	O	O
its	O	O
president	O
in	O	O
2003	O	O
.	O	O

He	O	O
also	O	O
served	O	O
as	O	O
president	O
of	O	O
the	O	O
Society	O
of	O
Pediatric	O
and	O
Perinatal	O
Epidemiological	O
Research	O
(	O	O
1996	O	O
)	O	O
and	O	O
the	O	O
president	O
of	O	O
the	O	O
Society	O
of	O
Epidemiological	O
Research	O
(	O	O
1998	O	O
)	O	O
.	O	O

He	O	O
holds	O	O
adjunct	O	O
teaching	B-PROC
appointments	O
at	O	O
the	O	O
University	B-OBJC
of	I-OBJC
North	I-OBJC
Carolina	I-OBJC
,	O	O
Harvard	B-OBJC
University	I-OBJC
,	O	O
and	O	O
the	O	O
University	B-OBJC
of	I-OBJC
Bergen	I-OBJC
(	O	O
Norway	B-GEOG
)	O	O
,	O	O
which	O	O
awarded	B-OBJC
him	O	O
an	O	O
honorary	O
doctoral	O
degree	O
in	O	O
2008	O	O
.	O	O

Hierarchical	O	O
Address	O	O
Event	O	O
Routing	O	O
for	O	O
Reconfigurable	O	O
Large	O
-	O
Scale	O
Neuromorphic	O
Systems	O
We	O	O
present	O	O
a	O	O
hierarchical	O	O
address	O	O
-	O	O
event	O	O
routing	O	O
(	O	O
HiAER	O	O
)	O	O
architecture	O
for	O	O
scalable	O	O
communication	O
of	O	O
neural	B-ANAT
and	O	O
synaptic	B-ANAT
spike	O
events	O
between	O	O
neuromorphic	B-OBJC
processors	I-OBJC
,	O	O
implemented	O	O
with	O	O
five	O	O
Xilinx	B-OBJC
Spartan	I-OBJC
-	I-OBJC
6	I-OBJC
field	I-OBJC
-	I-OBJC
programmable	I-OBJC
gate	I-OBJC
arrays	I-OBJC
and	O	O
four	O	O
custom	O	O
analog	O	O
neuromophic	B-OBJC
integrated	I-OBJC
circuits	I-OBJC
serving	O	O
262k	O	O
neurons	B-ANAT
and	O	O
262	O	O
M	O	O
synapses	B-ANAT
.	O	O

The	O	O
architecture	O
extends	O	O
the	O	O
single	O	O
-	O	O
bus	O	O
address	O	O
-	O	O
event	O	O
representation	O	O
protocol	O
to	O	O
a	O	O
hierarchy	O	O
of	O	O
multiple	O
nested	O
buses	O
,	O	O
routing	O
events	O
across	O	O
increasing	O	O
scales	O	O
of	O	O
spatial	O
distance	O
.	O	O

The	O	O
HiAER	O	O
protocol	O
provides	O	O
individually	O	O
programmable	O	O
axonal	B-ANAT
delay	O
in	O	O
addition	O	O
to	O	O
strength	O	O
for	O	O
each	O	O
synapse	B-ANAT
,	O	O
lending	O	O
itself	O	O
toward	O	O
biologically	O	O
plausible	O	O
neural	B-PHYS
network	I-PHYS
architectures	I-PHYS
,	O	O
and	O	O
scales	O	O
across	O	O
a	O	O
range	O	O
of	O	O
hierarchies	O	O
suitable	O	O
for	O	O
multichip	B-OBJC
and	O	O
multiboard	B-OBJC
systems	I-OBJC
in	O	O
reconfigurable	O	O
large	O
-	O
scale	O
neuromorphic	O
systems	O
.	O	O

We	O	O
show	O	O
approximately	O	O
linear	O
scaling	O
of	O	O
net	O
global	O
synaptic	O
event	O
throughput	O	O
with	O	O
number	O	O
of	O	O
routing	O
nodes	O
in	O	O
the	O	O
network	O
,	O	O
at	O	O
$	O	O
3	O	O
.	O	O

6x10	O	O
^	O	O
7	O	O
$	O	O
synaptic	B-ANAT
events	O
per	O	O
second	O	O
per	O	O
16k	O	O
-	O	O
neuron	B-ANAT
node	O
in	O	O
the	O	O
hierarchy	O	O
.	O	O

A	O	O
closer	O	O
look	O	O
at	O	O
school	B-OBJC
bonding	B-PHYS
among	O	O
African	B-LIVB
American	I-LIVB
adolescents	B-LIVB
in	O	O
low	B-LIVB
-	I-LIVB
income	I-LIVB
communities	I-LIVB
:	O	O
A	O	O
latent	B-PROC
class	I-PROC
analysis	I-PROC
Positive	B-DISO
school	B-OBJC
bonding	B-PHYS
is	O	O
a	O	O
significant	O
precursor	O
to	O	O
students	B-LIVB
'	O	O
school	B-OBJC
success	O
.	O	O

However	O	O
,	O	O
African	B-LIVB
American	I-LIVB
youth	B-LIVB
report	O	O
lower	O
school	B-OBJC
success	O
compared	O	O
with	O	O
their	O	O
White	B-LIVB
counterparts	I-LIVB
.	O	O

This	O	O
study	B-PROC
examined	O	O
correlates	O
of	O	O
school	B-OBJC
bonding	B-PHYS
among	O	O
633	O	O
African	B-LIVB
American	I-LIVB
youth	B-LIVB
who	O	O
were	O	O
recruited	O
from	O	O
community	B-LIVB
settings	I-LIVB
in	O	O
Chicago	B-GEOG
.	O	O

Major	O
findings	B-DISO
indicated	O	O
that	O	O
negative	B-DISO
peer	I-DISO
norms	I-DISO
,	O	O
exposure	O
to	O
community	B-DISO
violence	I-DISO
,	O	O
and	O	O
poor	O
mental	B-PHYS
health	I-PHYS
were	O	O
negatively	B-DISO
correlated	O
with	O	O
school	B-OBJC
bonding	B-PHYS
,	O	O
while	O	O
parental	O
monitoring	O
,	O	O
positive	B-DISO
self	I-DISO
-	I-DISO
regard	I-DISO
,	O	O
and	O	O
future	O
orientation	B-PHYS
were	O	O
correlated	O
with	O	O
higher	O
school	B-OBJC
motivation	B-PHYS
.	O	O

Students	B-LIVB
classified	O
as	O	O
having	O	O
high	O
or	O	O
moderate	O
school	B-OBJC
bonding	B-PHYS
were	O	O
more	O	O
likely	O	O
to	O	O
live	O
with	O	O
both	O	O
parents	B-LIVB
,	O	O
experience	B-PHYS
higher	O
levels	O
of	O	O
parental	O
monitoring	O
,	O	O
and	O	O
exhibit	B-DISO
positive	I-DISO
self	I-DISO
-	I-DISO
regard	I-DISO
.	O	O

Implications	O	O
are	O	O
discussed	O	O
in	O	O
view	O	O
of	O	O
these	O	O
findings	B-DISO
.	O	O

Prevalence	O
of	O	O
depression	B-DISO
in	O	O
patients	B-LIVB
of	O	O
type	B-DISO
2	I-DISO
diabetes	I-DISO
mellitus	I-DISO
:	O	O
A	O	O
cross	B-PROC
sectional	I-PROC
study	I-PROC
in	O	O
a	O	O
tertiary	B-OBJC
care	I-OBJC
centre	I-OBJC
The	O	O
present	O	O
study	B-PROC
aims	O
to	O	O
study	B-PROC
the	O	O
prevalence	O
of	O	O
depression	B-DISO
in	O	O
patients	B-LIVB
with	O	O
uncomplicated	B-DISO
type	I-DISO
II	I-DISO
diabetes	I-DISO
mellitus	I-DISO
and	O	O
to	O	O
find	O	O
its	O	O
association	O
with	O	O
various	O	O
socio	O
-	O
demographic	O
factors	O
in	O	O
the	O	O
same	O	O
.	O	O

A	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
,	O	O
single	O
interview	O
study	B-PROC
was	O	O
performed	O	O
in	O	O
an	O	O
outpatient	B-OBJC
department	I-OBJC
of	O	O
an	O	O
endocrinology	O
institute	O
.	O	O

Total	O	O
80	O	O
type	B-DISO
II	I-DISO
DM	I-DISO
patients	I-DISO
without	I-DISO
any	I-DISO
associated	I-DISO
complications	I-DISO
of	O	O
diabetes	B-DISO
were	O	O
included	O	O
in	O	O
this	O	O
study	B-PROC
.	O	O

To	O	O
diagnose	B-DISO
Depressive	B-DISO
Episode	I-DISO
,	O	O
structured	B-PROC
clinical	I-PROC
interview	I-PROC
for	O	O
DSM	O
V	O
was	O	O
applied	O	O
.	O	O

Severity	O
of	O	O
depression	B-DISO
was	O	O
assessed	O
by	O	O
Hamilton	O
Rating	O
Scale	O
for	O
Depression	O
(	O	O
HAM	O
-	O
D	O
)	O	O
.	O	O

To	O	O
assess	B-PROC
socio	O
-	O
demographic	O
characteristics	O
of	O	O
the	O	O
patients	B-LIVB
,	O	O
all	O	O
of	O	O
them	O	O
were	O	O
evaluated	B-PROC
with	O	O
a	O	O
semi	O
-	O
structured	O
socio	O
-	O
demographic	O
performa	O	O
.	O	O

38	O	O
.	O	O

75	O	O
%	O	O
patients	B-LIVB
(	O	O
N	O	O
=	O	O
31	O	O
)	O	O
were	O	O
found	O	O
to	O	O
be	O	O
suffering	B-DISO
from	O	O
depression	B-DISO
.	O	O

Among	O	O
them	O	O
48	O	O
.	O	O

38	O	O
%	O	O
were	O	O
moderately	O
depressed	O
and	O	O
none	O	O
were	O	O
suffering	B-DISO
from	O	O
very	O	O
severe	O
depression	B-DISO
.	O	O

Significant	O
association	O
was	O	O
not	O	O
found	O	O
between	O	O
depression	B-DISO
and	O	O
socio	O
-	O
demographic	O
factors	O
of	O	O
age	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
920	O	O
)	O	O
,	O	O
gender	B-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
251	O	O
)	O	O
,	O	O
economic	O
profile	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
583	O	O
)	O	O
,	O	O
local	B-PHYS
background	I-PHYS
of	I-PHYS
the	I-PHYS
patient	I-PHYS
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
646	O	O
)	O	O
,	O	O
educational	B-DISO
qualification	I-DISO
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
935	O	O
)	O	O
and	O	O
marital	O
status	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
644	O	O
)	O	O
.	O	O

Similarly	O	O
no	O	O
association	O
was	O	O
found	O	O
with	O	O
duration	O
of	O	O
diabetes	B-DISO
,	O	O
HbA1c	B-CHEM
and	O	O
BMI	B-PHYS
.	O	O

Exclusion	O
of	O	O
complicated	O
cases	O
didn	O	O
'	O	O
t	O	O
seem	O	O
to	O	O
influence	O
overall	O
prevalence	O
of	O	O
depression	B-DISO
,	O	O
although	O	O
reduction	O
in	O	O
severity	O
was	O	O
apparent	O	O
.	O	O

Thus	O	O
even	O	O
in	O	O
those	O	O
diabetic	B-DISO
patients	B-LIVB
who	O	O
are	O	O
leading	O	O
a	O	O
complication	B-DISO
free	I-DISO
life	O
,	O	O
a	O	O
detailed	O	O
psychiatric	O
analysis	B-PROC
to	O	O
rule	O	O
out	O	O
depression	B-DISO
is	O	O
mandatory	O	O
.	O	O

Evaluation	B-PROC
of	O	O
Spontaneous	O
Bone	B-PHYS
Regeneration	I-PHYS
after	O	O
Enucleation	B-PROC
of	O	O
Large	O
Cysts	B-DISO
of	O	O
the	O	O
Jaws	B-ANAT
using	O	O
Radiographic	B-PHEN
Computed	B-PROC
Software	B-OBJC
Spontaneous	O
regeneration	B-PHYS
of	I-PHYS
bone	I-PHYS
is	O	O
commonly	O
seen	O	O
in	O	O
the	O	O
small	O
surgical	B-PROC
defects	O
caused	O	O
by	O	O
enucleation	B-PROC
of	O	O
cysts	B-DISO
.	O	O

However	O	O
,	O	O
in	O	O
case	O	O
of	O	O
large	O
surgical	B-PROC
defects	O
caused	O	O
by	O	O
the	O	O
enucleation	B-PROC
,	O	O
spontaneous	O
regeneration	B-PHYS
of	I-PHYS
bone	I-PHYS
is	O	O
a	O	O
rare	O
phenomenon	B-PHEN
and	O	O
it	O	O
depends	O
on	O	O
factors	O
,	O	O
such	O	O
as	O	O
age	B-PHYS
of	O	O
the	O	O
patient	B-LIVB
,	O	O
intact	O
periosteum	O
,	O	O
and	O	O
proper	O	O
stabilization	B-PROC
.	O	O

The	O	O
study	B-PROC
included	O
16	O	O
patients	B-LIVB
,	O	O
who	O	O
reported	B-PROC
to	O	O
the	O	O
department	B-OBJC
of	I-OBJC
oral	I-OBJC
and	I-OBJC
maxillofacial	I-OBJC
surgery	I-OBJC
with	O	O
the	O	O
complaint	B-DISO
of	O	O
pain	B-DISO
and	O	O
swelling	B-DISO
in	O	O
the	O	O
jaws	B-ANAT
diagnosed	B-DISO
as	O	O
cyst	B-DISO
.	O	O

The	O	O
sample	O
included	O
equal	O	O
numbers	O
of	O	O
male	B-PHYS
and	O	O
female	B-PHYS
subjects	B-LIVB
aged	B-PHYS
between	O	O
15	O	O
and	O	O
40	O	O
years	O	O
.	O	O

Panoramic	B-PROC
radiographs	I-PROC
were	O	O
taken	O	O
pre	O
-	O
and	O	O
postoperatively	O
on	O	O
day	O	O
2	O	O
of	O	O
the	O	O
enucleation	B-PROC
.	O	O

The	O	O
dimensions	O
of	O	O
the	O	O
cyst	B-DISO
were	O	O
evaluated	B-PROC
on	O	O
the	O	O
radiograph	B-PROC
according	O	O
to	O	O
the	O	O
proforma	O
.	O	O

Subsequent	O
radiographs	B-PROC
were	O	O
taken	O	O
at	O	O
regular	O
intervals	O
of	O	O
1	O	O
.	O	O

5	O	O
,	O	O
3	O	O
,	O	O
and	O	O
6	O	O
months	O	O
using	O	O
standard	O
parameters	O
and	O	O
were	O	O
analyzed	B-PROC
using	O	O
MCID	O
™	O
analysis	O
software	B-OBJC
of	O	O
imaging	B-PROC
research	I-PROC
.	O	O

Mean	O
reduction	B-PROC
was	O	O
seen	O	O
in	O	O
up	O	O
to	O	O
39	O	O
and	O	O
60	O	O
%	O	O
in	O	O
the	O	O
cystic	O
cavity	B-DISO
size	O
and	O	O
increase	O
in	O	O
the	O	O
mean	O
density	O
up	O	O
to	O	O
59	O	O
and	O	O
90	O	O
.	O	O

2	O	O
%	O	O
at	O	O
3	O	O
and	O	O
6	O	O
months	O	O
intervals	O
respectively	O	O
.	O	O

Spontaneous	O
bone	B-PHYS
regeneration	I-PHYS
was	O	O
seen	O	O
even	O	O
after	O	O
primary	O
closure	B-PROC
of	O	O
the	O	O
large	O
cystic	O
defect	O
without	O	O
the	O	O
need	O
for	O	O
placement	B-PROC
of	O	O
foreign	B-OBJC
substances	I-OBJC
or	O	O
grafts	B-CHEM
and	O	O
it	O	O
also	O	O
eliminated	O
the	O	O
complications	B-DISO
resulting	O
from	O
placement	B-PROC
of	O	O
foreign	B-OBJC
substance	I-OBJC
.	O	O

Further	O	O
studies	B-PROC
are	O	O
required	O
in	O	O
a	O	O
larger	O
sample	O
with	O	O
longer	O
follow	B-PROC
-	I-PROC
up	I-PROC
durations	O
to	O	O
confirm	O
the	O	O
outcome	O
of	O
the	O
present	O
work	O
for	O	O
the	O	O
benefit	O
of	O	O
patients	B-LIVB
.	O	O

The	O	O
present	O
study	B-PROC
depicted	O	O
that	O	O
spontaneous	O
bone	B-PHYS
regeneration	I-PHYS
can	O	O
occur	O	O
with	O	O
accepted	O
results	B-DISO
after	O	O
simple	O
enucleation	B-PROC
of	O	O
jaw	B-ANAT
cyst	B-DISO
without	O	O
the	O	O
aid	O
of	O	O
any	O	O
graft	B-CHEM
material	I-CHEM
.	O	O

Hence	O	O
,	O	O
simple	O
enucleation	B-PROC
may	O	O
be	O	O
considered	O
as	O	O
a	O	O
first	B-PROC
line	I-PROC
of	I-PROC
treatment	I-PROC
modality	O
for	O	O
cystic	O
lesion	B-DISO
of	O	O
the	O	O
jaws	B-ANAT
.	O	O

This	O	O
simplifies	O	O
the	O	O
surgical	B-PROC
procedure	I-PROC
,	O	O
decreases	O
the	O	O
economic	O
and	O	O
biologic	O
costs	O
,	O	O
and	O	O
reduces	B-PROC
the	O	O
risk	O
of	O	O
postoperative	B-DISO
complications	I-DISO
.	O	O

Follow	B-PROC
-	I-PROC
up	I-PROC
is	O	O
necessary	O	O
along	O	O
with	O	O
patient	B-LIVB
's	I-LIVB
compliance	O
for	O	O
the	O	O
success	O
of	O
treatment	O
.	O	O

Scar	O
Assessment	B-PROC
After	O	O
Breast	O
Augmentation	O
Surgery	O
with	O	O
Axillary	B-PROC
Incision	I-PROC
versus	O	O
Inframammary	B-ANAT
Fold	I-ANAT
Incision	B-PROC
:	O	O
Long	O
-	O
Term	O
Follow	B-PROC
-	I-PROC
Up	I-PROC
in	O	O
Chinese	B-LIVB
Patients	B-LIVB
The	O	O
inframammary	B-ANAT
fold	I-ANAT
(	O	O
IMF	B-ANAT
)	O	O
incision	B-PROC
is	O	O
widely	O	O
used	O	O
in	O	O
Western	O
countries	O
for	O	O
breast	O
augmentation	O
surgery	O
,	O	O
whereas	O	O
the	O	O
axillary	B-PROC
incision	I-PROC
is	O	O
the	O	O
dominant	O
approach	O
used	O	O
in	O	O
China	B-GEOG
,	O	O
because	O	O
many	O	O
Chinese	B-LIVB
surgeons	B-LIVB
believe	O	O
that	O	O
the	O	O
Asian	B-LIVB
population	I-LIVB
has	O	O
a	O	O
higher	B-DISO
risk	I-DISO
of	O	O
developing	O	O
hypertrophic	B-DISO
scars	I-DISO
.	O	O

However	O	O
,	O	O
comparative	B-PROC
data	O
of	O	O
scar	O
assessment	B-PROC
through	O	O
different	O	O
incisions	B-PROC
in	O	O
Chinese	B-LIVB
patients	B-LIVB
are	O	O
scarce	B-DISO
.	O	O

The	O	O
aims	O	O
of	O	O
the	O	O
study	B-PROC
were	O	O
as	O	O
follows	O	O
:	O	O
(	O	O
1	O	O
)	O	O
to	O	O
evaluate	O
the	O
outcomes	O
of	O	O
scar	O
assessment	B-PROC
using	O	O
the	O	O
Vancouver	O
scar	O
scale	O
(	O	O
VSS	O
)	O	O
,	O	O
combined	O
with	O	O
patient	O
satisfaction	O
scoring	O
,	O	O
in	O	O
the	O	O
scar	O
assessment	B-PROC
after	O	O
breast	O
augmentation	O
surgery	O
;	O	O
(	O	O
2	O	O
)	O	O
to	O	O
compare	O
the	O	O
long	O
-	O
term	O
cosmetic	B-OBJC
effects	O
of	O	O
surgical	O
scars	O
between	O	O
axillary	B-PROC
and	O	O
IMF	B-ANAT
incisions	B-PROC
.	O	O

Consecutive	O
patients	B-LIVB
coming	O	O
to	O	O
our	O	O
department	B-OBJC
for	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
care	I-PROC
at	O	O
least	O	O
1	O	O
year	O
after	O	O
primary	O
breast	O
augmentation	O
surgeries	O
with	O	O
axillary	B-PROC
and	O	O
IMF	B-ANAT
incisions	B-PROC
between	O	O
January	O	O
1	O	O
,	O	O
2014	O	O
and	O	O
December	O	O
31	O	O
,	O	O
2014	O	O
were	O	O
included	O	O
in	O	O
the	O	O
research	B-PROC
.	O	O

Internal	O
consistency	O
,	O	O
inter	O
-	O
rater	O
reliability	O
,	O	O
and	O	O
convergent	O
validity	O
were	O	O
examined	B-DISO
for	O	O
the	O	O
VSS	O
and	O	O
patient	O
satisfaction	O
scoring	O
.	O	O

The	O	O
baseline	O
characteristics	O
and	O	O
scar	O
scores	O
were	O	O
tested	O
using	O	O
the	O	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
and	O	O
Student	O
's	O
t	O
test	O
between	O	O
the	O	O
two	O	O
groups	B-LIVB
.	O	O

Sixty	O	O
-	O	O
one	O	O
patients	B-LIVB
underwent	O	O
implantation	B-PROC
surgeries	B-PROC
through	O	O
the	O	O
axillary	B-PROC
incisions	I-PROC
,	O	O
and	O	O
17	O	O
patients	B-LIVB
through	O	O
the	O	O
IMF	B-ANAT
incisions	B-PROC
.	O	O

There	O	O
were	O	O
no	O	O
significant	O
differences	O	O
in	O	O
age	B-PHYS
,	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
time	O
,	O	O
body	B-PHYS
mass	I-PHYS
index	I-PHYS
,	O	O
implant	B-DEVI
volume	O
,	O	O
or	O	O
implant	O
projection	O
between	O	O
groups	B-LIVB
.	O	O

Reliability	O
and	O
validity	O
of	O	O
the	O	O
VSS	O
and	O	O
patient	O
satisfaction	O
scoring	O
were	O	O
satisfactory	O
.	O	O

The	O	O
scores	O
of	O	O
pigmentation	B-PHYS
were	O	O
higher	O
in	O	O
the	O	O
IMF	B-ANAT
group	B-LIVB
than	O	O
those	O	O
in	O	O
the	O	O
axilla	B-PROC
group	B-LIVB
with	O	O
statistical	O
significance	O
(	O	O
P	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
scores	O
of	O	O
other	O	O
subscales	O
,	O	O
overall	O	O
VSS	O
scores	O
,	O	O
and	O	O
patient	O
satisfaction	O
were	O	O
not	O	O
statistically	O
significant	O
.	O	O

The	O	O
scars	O
were	O	O
significantly	O
longer	O
in	O	O
the	O	O
axilla	B-PROC
group	B-LIVB
compared	O
with	O	O
the	O	O
IMF	B-ANAT
group	B-LIVB
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
VSS	O
combined	O
with	O	O
patient	O
satisfaction	O
scoring	O
constitutes	O	O
an	O	O
effective	O
tool	B-OBJC
to	O	O
evaluate	B-PROC
incision	B-PROC
scars	O
after	O	O
augmentation	B-PROC
mammaplasty	I-PROC
.	O	O

Scars	O
in	O	O
the	O	O
axilla	B-PROC
and	O	O
IMF	B-ANAT
can	O	O
achieve	O	O
comparable	O	O
cosmetic	B-OBJC
effects	O
and	O	O
patient	O
satisfaction	O
in	O	O
Chinese	B-LIVB
women	B-LIVB
.	O	O

Chinese	B-LIVB
patients	B-LIVB
with	O	O
proper	O	O
indications	O
can	O	O
receive	O	O
breast	O
augmentation	O
surgery	O
through	O	O
the	O	O
IMF	B-ANAT
incision	B-PROC
,	O	O
with	O	O
fewer	O
risks	O
and	O	O
less	O
trauma	B-DISO
,	O	O
and	O	O
get	O	O
satisfactory	O
scar	O
appearance	O
as	O	O
through	O	O
the	O	O
axillary	B-PROC
incision	I-PROC
.	O	O

This	O	O
journal	O
requires	O	O
that	O	O
authors	B-LIVB
assign	O
a	O	O
level	B-DISO
of	I-DISO
evidence	I-DISO
to	O	O
each	O	O
article	O
.	O	O

For	O	O
a	O	O
full	O	O
description	O	O
of	O	O
these	O	O
Evidence	O	O
-	O	O
Based	O	O
Medicine	O	O
ratings	O	O
,	O	O
please	O	O
refer	O	O
to	O	O
the	O	O
Table	O	O
of	O	O
Contents	O	O
or	O	O
the	O	O
online	O	O
Instructions	O	O
to	O	O
Authors	O	O
www	O	O
.	O	O

springer	O	O
.	O	O

com	O	O
/	O	O
00266	O	O
.	O	O

MicroRNA	B-CHEM
-	I-CHEM
26a	I-CHEM
protects	B-DISO
against	O
cardiac	B-DISO
hypertrophy	I-DISO
via	O	O
inhibiting	O
GATA4	O
in	O	O
rat	B-LIVB
model	B-LIVB
and	O	O
cultured	B-ANAT
cardiomyocytes	I-ANAT
.	O	O

Pathological	O
cardiac	B-DISO
hypertrophy	I-DISO
is	O	O
characterized	O	O
by	O	O
deleterious	O
changes	O
developed	O	O
in	O	O
cardiovascular	B-DISO
diseases	I-DISO
,	O	O
whereas	O	O
microRNAs	B-CHEM
(	O	O
miRNAs	B-CHEM
)	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
mediation	O	O
of	O	O
cardiac	B-DISO
hypertrophy	I-DISO
.	O	O

To	O	O
investigate	O
the	O	O
role	O	O
of	O	O
microRNA	B-CHEM
-	I-CHEM
26a	I-CHEM
(	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
)	O	O
in	O	O
regulating	B-DISO
cardiac	I-DISO
hypertrophy	I-DISO
and	O	O
its	O	O
functioning	B-PHYS
mechanisms	O
,	O	O
overexpression	B-PHYS
and	O	O
suppression	B-PHYS
of	O	O
miR	O
-	O
26a	O
via	O	O
its	O	O
mimic	B-PHYS
and	O	O
inhibitor	B-CHEM
in	O	O
a	O	O
transverse	O
abdominal	B-ANAT
aortic	B-DISO
constriction	I-DISO
(	O	O
TAAC	B-DISO
)	O	O
-	O	O
induced	O
rat	B-LIVB
model	B-LIVB
and	O	O
in	O	O
angiotensin	B-CHEM
II	I-CHEM
(	O	O
Ang	B-CHEM
II	I-CHEM
)	O	O
-	O	O
induced	O
cardiomyocytes	B-ANAT
(	O	O
CMs	B-ANAT
)	O	O
was	O	O
performed	O	O
.	O	O

In	O	O
the	O	O
rat	B-LIVB
model	B-LIVB
,	O	O
the	O	O
heart	O
weight	O
(	O	O
HW	O
)	O	O
compared	O	O
with	O	O
the	O	O
body	B-PHYS
weight	I-PHYS
(	O	O
BW	B-PHYS
)	O	O
,	O	O
the	O	O
CM	B-ANAT
area	O
,	O	O
and	O	O
expression	O
of	O	O
the	O	O
hypertrophy	B-DISO
-	O	O
associated	O
factors	O
,	O	O
atrial	B-CHEM
natriuretic	I-CHEM
factor	I-CHEM
(	O	O
ANF	B-CHEM
)	O	O
and	O	O
ß	B-CHEM
-	I-CHEM
myosin	I-CHEM
heavy	I-CHEM
chain	I-CHEM
(	O	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
)	O	O
,	O	O
were	O	O
assessed	O
.	O	O

In	O	O
CMs	B-ANAT
,	O	O
the	O	O
protein	B-PHYS
synthesis	I-PHYS
rate	O
was	O	O
determined	O	O
using	O	O
a	O	O
leucine	B-PROC
incorporation	I-PROC
assay	I-PROC
.	O	O

Mutation	B-PHYS
of	O	O
the	O	O
GATA	O
-	O
binding	O
protein	O
4	O
(	O	O
GATA4	O
)	O	O
3	O
'	O
-	O
untranslated	O
region	O
(	O	O
UTR	O
)	O	O
and	O	O
overexpression	B-PHYS
of	O	O
GATA4	O
were	O	O
performed	O	O
to	O	O
confirm	O	O
whether	O	O
GATA4	O
is	O	O
the	O	O
target	O
of	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
was	O	O
significantly	O	O
downregulated	B-PHYS
in	O	O
the	O	O
heart	O
tissue	O
of	O	O
the	O	O
rat	B-LIVB
model	B-LIVB
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
Ang	B-CHEM
II	I-CHEM
-	O	O
induced	O
CMs	B-ANAT
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

The	O	O
TAAC	B-DISO
-	O	O
induced	O
rat	B-LIVB
model	B-LIVB
exhibited	O	O
a	O	O
higher	O
HW	O
/	O	O
BW	B-PHYS
ratio	O
,	O	O
a	O	O
larger	O
CM	B-ANAT
area	O
,	O	O
and	O	O
higher	O
expression	B-PHYS
levels	O
of	O	O
ANF	B-CHEM
and	O	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
.	O	O

CMs	B-ANAT
,	O	O
upon	O	O
Ang	B-CHEM
II	I-CHEM
treatment	B-PROC
,	O	O
also	O	O
demonstrated	O	O
a	O	O
larger	O	O
CM	B-ANAT
area	O
,	O	O
higher	O
levels	O
of	O	O
ANF	B-CHEM
and	O	O
ß	B-CHEM
-	I-CHEM
MHC	I-CHEM
,	O	O
as	O	O
well	O	O
as	O	O
accelerated	O
protein	B-PHYS
synthesis	I-PHYS
.	O	O

miR	B-CHEM
-	I-CHEM
26a	I-CHEM
was	O	O
not	O	O
able	O	O
to	O	O
regulate	B-PHEN
GATA4	O
with	O	O
mutations	B-PHYS
in	O	O
the	O	O
3	O
'	O
-	O
UTR	O
,	O	O
indicating	O	O
that	O	O
GATA4	O
was	O	O
the	O	O
direct	O	O
target	O
of	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
.	O	O

Overexpression	B-PHYS
of	O	O
GATA4	O
abrogated	O	O
the	O	O
inhibitory	B-PHYS
functions	I-PHYS
of	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
in	O	O
cardiac	B-DISO
hypertrophy	I-DISO
.	O	O

Taken	O	O
together	O	O
,	O	O
the	O	O
present	O	O
study	O	O
suggested	O	O
an	O	O
anti	B-DISO
-	I-DISO
hypertrophic	I-DISO
role	O
of	O	O
miR	B-CHEM
-	I-CHEM
26a	I-CHEM
in	O	O
cardiac	B-DISO
hypertrophy	I-DISO
,	O	O
possibly	O	O
via	O	O
inhibition	O
of	O	O
GATA4	O
.	O	O

These	O	O
findings	B-DISO
may	O	O
be	O	O
useful	O	O
in	O	O
terms	O	O
of	O	O
facilitating	O	O
cardiac	B-ANAT
treatment	B-PROC
,	O	O
with	O	O
potential	O
therapeutic	O
targets	O
and	O	O
strategies	O	O
.	O	O

Membrane	B-PHYS
Protein	I-PHYS
Solubilization	I-PHYS
and	O	O
Composition	B-PHEN
of	O	O
Protein	B-CHEM
Detergent	B-CHEM
Complexes	B-CHEM
Membrane	B-CHEM
proteins	I-CHEM
are	O	O
typically	B-PHYS
expressed	I-PHYS
in	O	O
heterologous	O
systems	O
with	O	O
a	O	O
view	O	O
to	O	O
in	B-PROC
vitro	I-PROC
characterization	O
.	O	O

A	O	O
critical	O
step	O
in	O	O
the	O	O
preparation	O
of	O	O
membrane	B-CHEM
proteins	I-CHEM
after	O	O
expression	B-PHYS
in	O	O
any	O	O
system	O
is	O	O
the	O	O
solubilization	B-PHYS
of	I-PHYS
the	I-PHYS
protein	I-PHYS
in	O	O
aqueous	B-CHEM
solution	I-CHEM
,	O	O
typically	O	O
using	O	O
detergents	B-CHEM
and	O	O
lipids	B-CHEM
,	O	O
to	O	O
obtain	O	O
the	O	O
protein	B-CHEM
in	O	O
a	O	O
form	O	O
suitable	O
for	O	O
purification	O
,	O	O
structural	B-PROC
or	O	O
functional	O
analysis	B-PROC
.	O	O

This	O	O
process	B-PHEN
is	O	O
particularly	O	O
difficult	O	O
as	O	O
the	O	O
objective	O	O
is	O	O
to	O	O
prepare	O	O
the	O	O
protein	B-CHEM
in	O	O
an	O	O
unnatural	O
environment	O
,	O	O
a	O	O
protein	B-CHEM
detergent	B-CHEM
complex	B-CHEM
,	O	O
separating	O	O
it	O	O
from	O	O
its	O	O
natural	O
lipid	B-CHEM
partners	O	O
while	O	O
causing	O	O
the	O	O
minimum	O
destabilization	B-PHYS
or	O	O
modification	B-DISO
of	O	O
the	O	O
structure	O
.	O	O

Although	O	O
the	O	O
process	B-PHEN
is	O	O
difficult	O
,	O	O
and	O	O
relatively	O	O
hard	O	O
to	O	O
master	O	O
,	O	O
an	O	O
increasing	O
number	O	O
of	O	O
membrane	B-CHEM
proteins	I-CHEM
have	O	O
been	O	O
successfully	O
isolated	O
after	O	O
expression	B-PHYS
in	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
systems	O
.	O	O

In	O	O
this	O	O
chapter	O	O
we	O	O
give	O	O
a	O	O
general	O
protocol	O
for	O	O
preparing	O	O
protein	B-CHEM
detergent	B-CHEM
complexes	B-CHEM
that	O	O
is	O	O
aimed	O	O
at	O	O
guiding	O	O
the	O	O
reader	O	O
through	O	O
the	O	O
different	O	O
critical	O
steps	O
.	O	O

In	O	O
the	O	O
second	O	O
part	O	O
of	O	O
the	O	O
chapter	O	O
we	O	O
illustrate	O	O
how	O	O
to	O	O
analyze	B-PROC
the	O	O
composition	B-PHEN
of	O	O
protein	B-CHEM
detergent	B-CHEM
complexes	B-CHEM
;	O	O
this	O	O
analysis	B-PROC
is	O	O
important	O	O
as	O	O
it	O	O
has	O	O
been	O	O
found	O	O
that	O	O
compositional	B-PHEN
variation	O
often	O	O
causes	O	O
irreproducible	O	O
results	O	O
.	O	O

Systematic	O
Quantification	O
of	O	O
GPCR	B-CHEM
/	O	O
cAMP	B-CHEM
-	O	O
Controlled	O
Protein	B-CHEM
Kinase	I-CHEM
A	I-CHEM
Interactions	B-PHYS
The	O	O
diffusible	O
second	B-CHEM
messenger	I-CHEM
cyclic	B-CHEM
AMP	I-CHEM
(	O	O
cAMP	B-CHEM
)	O	O
originates	O	O
from	O	O
multiple	O	O
G	B-CHEM
protein	I-CHEM
-	I-CHEM
coupled	I-CHEM
receptor	I-CHEM
(	O	O
GPCR	B-CHEM
)	O	O
cascades	O	O
activating	O
the	O	O
intracellular	O
key	O	O
effector	O	O
protein	B-CHEM
kinase	I-CHEM
A	I-CHEM
(	O	O
PKA	B-CHEM
)	O	O
.	O	O

Spatially	O
and	O	O
temporally	O
restricted	O
cAMP	B-CHEM
-	O	O
fluxes	B-PHEN
are	O	O
directly	O	O
sensed	O	O
by	O	O
macromolecular	B-CHEM
PKA	B-ANAT
complexes	I-ANAT
.	O	O

The	O	O
consequences	O
are	O	O
alterations	O
of	O	O
molecular	B-PHYS
interactions	I-PHYS
,	O	O
which	O	O
lead	O	O
to	O	O
activation	O
of	O	O
compartmentalized	O	O
PKA	B-PHYS
phosphotransferase	I-PHYS
activities	I-PHYS
,	O	O
regulating	O	O
a	O	O
vast	O	O
array	O	O
of	O	O
cellular	B-PHYS
functions	I-PHYS
.	O	O

To	O	O
decode	O	O
cell	O
-	O
type	O
and	O	O
cell	B-ANAT
-	I-ANAT
compartment	I-ANAT
specific	O	O
PKA	B-CHEM
functions	O	O
,	O	O
the	O	O
spatio	B-PROC
-	I-PROC
temporal	I-PROC
dynamics	I-PROC
of	O	O
small	B-PHYS
molecule	I-PHYS
:	I-PHYS
protein	I-PHYS
interactions	I-PHYS
,	O	O
protein	B-PHYS
:	I-PHYS
protein	I-PHYS
interactions	I-PHYS
(	O	O
PPIs	B-PHYS
)	O	O
,	O	O
cAMP	B-CHEM
-	O	O
mobilization	B-PHYS
,	O	O
and	O	O
phosphotransferase	B-PHYS
activities	I-PHYS
need	O	O
to	O	O
be	O	O
determined	O	O
directly	O	O
in	O	O
the	O	O
appropriate	O	O
cellular	O
context	O
.	O	O

A	O	O
collection	O
of	O	O
cell	B-CHEM
-	I-CHEM
based	I-CHEM
reporters	I-CHEM
has	O	O
been	O	O
developed	O	O
to	O	O
either	O	O
visualize	O
or	O	O
quantitatively	O
measure	O
kinase	B-PHYS
activities	I-PHYS
or	O	O
PKA	B-ANAT
complex	I-ANAT
formation	B-PHYS
/	O	O
dissociation	B-PHYS
.	O	O

In	O	O
this	O	O
review	O	O
,	O	O
we	O	O
list	O	O
a	O	O
collection	O
of	O	O
unimolecular	O
and	O	O
bimolecular	O
PKA	B-CHEM
biosensors	B-DEVI
,	O	O
followed	O	O
by	O	O
the	O	O
specification	O	O
of	O	O
the	O	O
modular	O
design	O
of	O	O
a	O	O
Renilla	B-CHEM
luciferase	I-CHEM
based	O	O
protein	B-PROC
-	I-PROC
fragment	I-PROC
complementation	I-PROC
assay	I-PROC
(	O	O
PCA	B-PROC
)	O	O
platform	O	O
for	O	O
measuring	O
PKA	B-CHEM
network	B-PHYS
interactions	I-PHYS
.	O	O

We	O	O
discuss	O	O
the	O	O
application	O	O
spectrum	B-PROC
of	O	O
the	O	O
PCA	B-PROC
reporter	B-CHEM
to	O	O
identify	B-DISO
,	O	O
quantify	O
,	O	O
and	O	O
dissect	O
dynamic	O
and	O	O
transient	O
PKA	B-ANAT
complexes	I-ANAT
downstream	O
of	O	O
specific	O	O
GPCR	B-CHEM
activities	O
.	O	O

We	O	O
specify	O	O
the	O	O
implementation	O
of	O	O
a	O	O
PCA	B-PROC
PKA	B-CHEM
platform	O	O
to	O	O
systematically	O
quantify	O
the	O	O
concurrent	O
involvement	O
of	O	O
receptor	B-CHEM
-	O	O
cAMP	B-PHYS
signaling	I-PHYS
,	O	O
post	B-PHYS
-	I-PHYS
translational	I-PHYS
modifications	I-PHYS
,	O	O
and	O	O
kinase	B-CHEM
subunit	I-CHEM
mutations	B-PHYS
/	O	O
perturbations	O
in	O	O
PKA	B-PHYS
activation	I-PHYS
.	O	O

The	O	O
systematic	O
quantification	O
of	O	O
transient	O
PKA	B-CHEM
network	B-PHYS
interactions	O
will	O	O
contribute	O	O
to	O	O
a	O	O
better	O	O
understanding	O	O
how	O	O
GPCR	B-CHEM
-recognized	O	O
input	O	O
signals	B-PHEN
are	O	O
streamlined	O	O
through	O	O
the	O	O
compartmentalized	O	O
and	O	O
cAMP	B-CHEM
-	O	O
interacting	O
PKA	B-CHEM
signalosome	B-ANAT
.	O	O

The	O	O
role	O
of	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
the	O	O
distribution	O
of	O	O
body	B-PHYS
fat	I-PHYS
in	O	O
decreasing	B-DISO
the	O	O
number	O
of	O	O
prostate	B-PROC
rebiopsies	I-PROC
To	O	O
assess	O
the	O	O
usefulness	O
of	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
measured	O
by	O	O
bioelectrical	B-PHYS
impedance	I-PHYS
audiometry	B-PROC
to	O	O
avoid	O	O
rebiopsies	B-PROC
in	O	O
patients	B-LIVB
with	O	O
persistently	O
high	B-DISO
prostate	I-DISO
-	I-DISO
specific	I-DISO
antigen	I-DISO
(	I-DISO
PSA	I-DISO
)	I-DISO
levels	I-DISO
.	O	O

A	O	O
prospective	B-PROC
study	I-PROC
was	O	O
conducted	O	O
with	O	O
92	O	O
patients	B-LIVB
who	O	O
underwent	O	O
prostate	B-PROC
rebiopsy	I-PROC
due	O	O
to	O	O
high	O	O
PSA	O	O
levels	O	O
with	O	O
negative	B-DISO
results	I-DISO
in	O	O
the	O	O
rectal	B-PROC
examination	I-PROC
and	O	O
a	O	O
lack	O
of	O	O
preneoplastic	B-DISO
lesions	B-DISO
.	O	O

The	O	O
patients	B-LIVB
previously	O	O
had	O	O
their	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
levels	O
measured	O
and	O	O
had	O	O
undergone	O	O
an	O	O
impedance	B-PROC
audiometry	I-PROC
test	I-PROC
using	O	O
the	O	O
abdominal	B-ANAT
Fat	B-DEVI
Analyser	I-DEVI
AB	I-DEVI
-	I-DEVI
140	I-DEVI
TANITA	I-DEVI
system	I-DEVI
.	O	O

We	O	O
calculated	O
the	O	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curves	O
for	O	O
the	O	O
PSA	B-PHEN
levels	I-PHEN
,	O	O
%	O	O
PSA	B-CHEM
,	O	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
and	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
PSA	B-CHEM
density	O
.	O	O

Twenty	O	O
-	O	O
five	O	O
patients	B-LIVB
were	O	O
diagnosed	B-DISO
with	O	O
prostate	B-DISO
cancer	I-DISO
.	O	O

These	O	O
patients	B-LIVB
had	O	O
significantly	O
higher	O
PSA	B-CHEM
,	O	O
PSAd	B-CHEM
and	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
values	O
and	O	O
a	O	O
tendency	O	O
towards	O	O
higher	O
internal	B-PHYS
organ	I-PHYS
fat	I-PHYS
levels	O
and	O	O
lower	O
%	O	O
PSA	B-CHEM
readings	O
(	O	O
p	O	O
=	O	O
.	O	O

001	O	O
,	O	O
p	O	O
=	O	O
.	O	O

003	O	O
,	O	O
p	O	O
=	O	O
.	O	O

001	O	O
,	O	O
p	O	O
=	O	O
.	O	O

24	O	O
and	O	O
P	O	O
=	O	O
0	O	O
.	O	O
28	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
ROC	O
curve	O
showed	O	O
an	O	O
area	O
under	O	O
the	O	O
curve	O
for	O	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
and	O	O
PSA	B-CHEM
of	O	O
.82	O	O
and	O	O
.81	O	O
,	O	O
respectively	O	O
.	O	O

Using	O	O
the	O	O
cutoff	O
points	O
for	O	O
95	O	O
%	O	O
sensitivity	O
and	O	O
using	O	O
the	O	O
3	O	O
criteria	O
as	O	O
an	O	O
indication	O
of	O
rebiopsy	B-PROC
,	O	O
74	O	O
%	O	O
of	O	O
the	O	O
biopsies	B-PROC
would	O	O
have	O	O
been	O	O
spared	O	O
,	O	O
leaving	O	O
undiagnosed	B-DISO
only	O	O
1	O	O
patient	B-LIVB
with	O	O
clinically	O
significant	O
cancer	B-DISO
-	O	O
Gleason	B-DISO
score	I-DISO
>	O	O
7	O	O
(	O	O
4	O	O
+	O	O
3	O	O
)	O	O
-	O	O
.	O	O

The	O	O
positive	O
and	O	O
negative	O
predictive	O
values	O
for	O	O
the	O	O
set	O
of	O	O
variables	O
were	O	O
higher	O
than	O
for	O	O
each	O	O
one	O	O
separately	O	O
(	O	O
PPV	O	O
:	O	O
66	O	O
/	O	O
NPV	O	O
:	O	O
63	O	O
)	O	O
.	O	O

The	O	O
cost	O
of	O	O
both	O	O
determinations	B-PROC
was	O	O
82	O	O
euros	O
.	O	O

Our	O	O
results	O
suggest	O	O
that	O	O
measuring	O
IGF	B-CHEM
-	I-CHEM
1	I-CHEM
could	O	O
significantly	O
decrease	O
the	O	O
number	O
of	O	O
unnecessary	B-PROC
rebiopsies	B-PROC
in	O	O
an	O	O
inexpensive	O	O
and	O	O
safe	O	O
manner	O	O
.	O	O

Adenosine	B-CHEM
A2A	I-CHEM
receptors	I-CHEM
in	O	O
the	O	O
olfactory	B-ANAT
bulb	I-ANAT
suppress	O
rapid	B-PHYS
eye	I-PHYS
movement	I-PHYS
sleep	I-PHYS
in	O	O
rodents	B-LIVB
Rapid	B-DISO
eye	I-DISO
movement	I-DISO
(	I-DISO
REM	I-DISO
)	I-DISO
sleep	I-DISO
behavior	I-DISO
disorder	I-DISO
in	O	O
humans	B-LIVB
is	O	O
often	O	O
accompanied	O	O
by	O	O
a	O	O
reduced	O
ability	B-DISO
to	I-DISO
smell	I-DISO
and	O	O
detect	B-PHYS
odors	I-PHYS
,	O	O
and	O	O
olfactory	B-DISO
bulbectomized	I-DISO
rats	B-LIVB
exhibit	O	O
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O	O
suggesting	O	O
that	O	O
the	O	O
olfactory	B-ANAT
bulb	I-ANAT
(	O	O
OB	B-ANAT
)	O	O
is	O	O
involved	O	O
in	O	O
REM	B-PHYS
-	I-PHYS
sleep	I-PHYS
regulation	B-PHEN
.	O	O

However	O	O
,	O	O
the	O	O
molecular	B-PHYS
mechanism	I-PHYS
of	O	O
REM	B-PHYS
-	I-PHYS
sleep	I-PHYS
regulation	B-PHEN
by	O	O
the	O	O
OB	B-ANAT
is	O	O
unknown	O	O
.	O	O

Adenosine	B-CHEM
promotes	O	O
sleep	B-PHYS
and	O	O
its	O	O
A2A	B-CHEM
receptors	I-CHEM
(	O	O
A2AR	B-CHEM
)	O	O
are	O	O
expressed	B-PHYS
in	O	O
the	O	O
OB	B-ANAT
.	O	O

We	O	O
hypothesized	O	O
that	O	O
A2AR	B-CHEM
in	O	O
the	O	O
OB	B-ANAT
regulate	B-PHEN
REM	B-PHYS
sleep	I-PHYS
.	O	O

Bilateral	B-PROC
microinjections	I-PROC
of	O	O
the	O	O
A2AR	B-CHEM
antagonist	I-CHEM
SCH58261	I-CHEM
into	O	O
the	O	O
rat	B-LIVB
OB	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O	O
whereas	O	O
microinjections	B-PROC
of	O	O
the	O	O
A2AR	B-CHEM
agonist	I-CHEM
CGS21680	I-CHEM
decreased	O
REM	B-PHYS
sleep	I-PHYS
.	O	O

Similar	O	O
to	O	O
the	O	O
A2AR	B-CHEM
antagonist	I-CHEM
,	O	O
selective	O	O
A2AR	O
knockdown	B-PROC
by	O	O
adeno	B-LIVB
-	I-LIVB
associated	I-LIVB
virus	I-LIVB
carrying	O	O
short	B-CHEM
-	I-CHEM
hairpin	I-CHEM
RNA	I-CHEM
for	O	O
A2AR	O
in	O	O
the	O	O
rat	B-LIVB
OB	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
.	O	O

Using	O	O
chemogenetics	O
on	O	O
the	O	O
basis	O	O
of	O	O
designer	B-CHEM
receptors	I-CHEM
exclusively	O	O
activated	O
by	O	O
designer	B-CHEM
drugs	I-CHEM
,	O	O
we	O	O
demonstrated	O	O
that	O	O
the	O	O
inhibition	B-PHYS
of	O	O
A2AR	B-CHEM
neurons	B-ANAT
increased	O
REM	B-PHYS
sleep	I-PHYS
,	O	O
whereas	O	O
the	O	O
activation	O
of	O	O
these	O	O
neurons	B-ANAT
decreased	O
REM	B-PHYS
sleep	I-PHYS
.	O	O

Moreover	O	O
,	O	O
using	O	O
a	O	O
conditional	O	O
anterograde	B-PROC
axonal	I-PROC
tract	I-PROC
-	I-PROC
tracing	I-PROC
approach	I-PROC
,	O	O
we	O	O
found	O	O
that	O	O
OB	B-ANAT
A2AR	B-CHEM
neurons	B-ANAT
innervate	O	O
the	O	O
piriform	B-ANAT
cortex	I-ANAT
and	O	O
olfactory	B-ANAT
tubercle	I-ANAT
.	O	O

These	O	O
novel	O	O
findings	O	O
indicate	O	O
that	O	O
adenosine	B-CHEM
suppresses	O
REM	B-PHYS
sleep	I-PHYS
via	O	O
A2AR	B-CHEM
in	O	O
the	O	O
OB	B-ANAT
of	O	O
rodents	B-LIVB
.	O	O

Geometric	O
morphometrics	B-PROC
reveals	O	O
restrictions	O
on	O	O
the	O	O
shape	O
of	O	O
the	O	O
female	B-PHYS
os	B-ANAT
coxae	I-ANAT
The	O	O
methodology	O
for	O	O
sex	B-PHEN
determination	I-PHEN
in	O	O
human	B-ANAT
skeletal	I-ANAT
remains	O	O
depends	O	O
on	O	O
the	O	O
different	O	O
bone	B-ANAT
morphologies	O
presented	O	O
by	O	O
men	B-LIVB
and	O	O
women	B-LIVB
.	O	O

Due	O	O
to	O	O
their	O	O
direct	O	O
implications	O	O
in	O	O
reproduction	B-PHYS
,	O	O
the	O	O
whole	O	O
pelvis	B-ANAT
,	O	O
particularly	O	O
the	O	O
os	B-ANAT
coxae	I-ANAT
,	O	O
shows	O	O
different	O	O
characteristics	O
in	O	O
either	O	O
sex	B-PHYS
.	O	O

The	O	O
sacrum	B-ANAT
and	O	O
the	O	O
os	B-ANAT
coxae	I-ANAT
constitute	O	O
the	O	O
birth	B-ANAT
cana	I-ANAT
l	O	O
.	O	O

In	O	O
this	O	O
research	O	O
study	O	O
,	O	O
the	O	O
os	B-ANAT
coxae	I-ANAT
shape	O
is	O	O
analyzed	O	O
using	O	O
geometric	O
morphometrics	B-PROC
,	O	O
providing	O	O
information	O
on	O	O
morphology	O
,	O	O
regardless	O	O
of	O	O
size	B-PHYS
or	O	O
any	O	O
other	O	O
factor	O	O
beyond	O	O
the	O	O
geometry	O
itself	O	O
.	O	O

A	O	O
total	O	O
of	O	O
46	O	O
adult	B-LIVB
ossa	B-ANAT
coxae	I-ANAT
from	O	O
a	O	O
Spanish	B-LIVB
archaeological	O
collection	B-PROC
were	O	O
studied	O	O
using	O	O
geometric	O
morphometrics	B-PROC
.	O	O

The	O	O
results	O	O
show	O	O
that	O	O
there	O	O
is	O	O
a	O	O
restriction	O
on	O	O
the	O	O
shape	O
of	O	O
female	B-PHYS
os	B-ANAT
coxae	I-ANAT
.	O	O

In	O	O
contrast	O	O
,	O	O
male	B-PHYS
os	B-ANAT
coxae	I-ANAT
presents	O	O
a	O	O
greater	O	O
range	O	O
of	O	O
variation	O
.	O	O

The	O	O
biological	B-DISO
reason	I-DISO
for	O	O
this	O	O
difference	O	O
is	O	O
the	O	O
obstetrical	O
dilemma	O
;	O	O
a	O	O
concept	O
defined	O	O
as	O	O
the	O	O
anatomical	O
conflict	O
between	O	O
bipedalism	B-PHYS
and	O	O
the	O	O
full	O	O
-	O	O
term	O	O
birth	B-PHYS
of	O	O
a	O	O
neonate	B-LIVB
whose	O	O
large	B-DISO
head	I-DISO
requires	O	O
greater	O	O
dimensions	O
in	O	O
the	O	O
pelvic	B-ANAT
cavity	I-ANAT
.	O	O

Our	O	O
experimental	O
data	O
reinforce	O	O
the	O	O
validity	O
of	O	O
the	O	O
obstetrical	O
dilemma	O
as	O	O
source	O	O
of	O	O
the	O	O
restriction	O
on	O	O
the	O	O
shape	O
of	O	O
female	B-PHYS
ossa	B-ANAT
coxae	I-ANAT
.	O	O

Additionally	O	O
,	O	O
according	O	O
to	O	O
the	O	O
results	B-DISO
obtained	O	O
,	O	O
size	B-PHYS
itself	O	O
does	O	O
not	O	O
represent	O	O
a	O	O
condition	O
for	O	O
belonging	O	O
to	O	O
one	O	O
sex	B-PHYS
or	O	O
another	O	O
.	O	O

Single	B-PROC
-	I-PROC
cell	I-PROC
analyses	I-PROC
of	O	O
X	B-DISO
Chromosome	I-DISO
inactivation	I-DISO
dynamics	B-PHEN
and	O	O
pluripotency	O
during	O	O
differentiation	B-PHYS
Pluripotency	O
,	O	O
differentiation	B-PHYS
,	O	O
and	O	O
X	B-DISO
Chromosome	I-DISO
inactivation	I-DISO
(	O	O
XCI	B-DISO
)	O	O
are	O	O
key	O	O
aspects	O	O
of	O	O
embryonic	B-PHYS
development	I-PHYS
.	O	O

However	O	O
,	O	O
the	O	O
underlying	O	O
relationship	O
and	O	O
mechanisms	O
among	O	O
these	O	O
processes	B-PHEN
remain	O	O
unclear	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
systematically	O
dissected	O
these	O	O
features	O	O
along	O	O
developmental	O
progression	O
using	O	O
mouse	B-ANAT
embryonic	I-ANAT
stem	I-ANAT
cells	I-ANAT
(	O	O
mESCs	B-ANAT
)	O	O
and	O	O
single	B-ANAT
-	I-ANAT
cell	I-ANAT
RNA	B-PROC
sequencing	I-PROC
with	O	O
allelic	O
resolution	O
.	O	O

We	O	O
found	O	O
that	O	O
mESCs	B-ANAT
grown	O	O
in	O	O
a	O	O
ground	B-CHEM
state	I-CHEM
2i	I-CHEM
condition	I-CHEM
displayed	O	O
transcriptomic	O
profiles	O
diffused	O	O
from	O	O
preimplantation	B-PROC
mouse	B-ANAT
embryonic	I-ANAT
cells	I-ANAT
,	O	O
whereas	O	O
EpiStem	B-ANAT
cells	I-ANAT
closely	O	O
resembled	O	O
the	O	O
post	B-PROC
-	I-PROC
implantation	I-PROC
epiblast	B-ANAT
.	O	O

Sex	B-PHYS
-related	O	O
gene	B-PHYS
expression	I-PHYS
varied	O	O
greatly	O	O
across	O	O
distinct	O	O
developmental	O
states	O
.	O	O

We	O	O
also	O	O
identified	O	O
novel	B-PHYS
markers	I-PHYS
that	O	O
were	O	O
highly	O
enriched	O	O
in	O	O
each	O	O
developmental	O
state	O
.	O	O

Moreover	O	O
,	O	O
we	O	O
revealed	O	O
that	O	O
several	O	O
novel	O
pathways	O
,	O	O
including	O	O
PluriNetWork	O
and	O	O
Focal	B-ANAT
Adhesion	I-ANAT
,	O	O
were	O	O
responsible	B-DISO
for	I-DISO
the	O	O
delayed	O	O
progression	O
of	O	O
female	B-PHYS
EpiStem	B-ANAT
cells	I-ANAT
.	O	O

Importantly	O	O
,	O	O
we	O	O
""""	O	O
digitalized	O
""""	O	O
XCI	B-DISO
progression	O
using	O	O
allelic	O
expression	B-PHYS
of	O	O
active	O
and	O
inactive	O
X	B-ANAT
Chromosomes	I-ANAT
and	O	O
surprisingly	O	O
found	O	O
that	O	O
XCI	B-DISO
states	O
exhibited	O	O
profound	O	O
variability	O	O
in	O	O
each	O	O
developmental	O
state	O
,	O	O
including	O	O
the	O	O
2i	O
condition	O
.	O	O

XCI	B-DISO
progression	O
was	O	O
not	O	O
tightly	O	O
synchronized	O
with	O	O
loss	O
of	O	O
pluripotency	O
and	O	O
increase	O
of	O	O
differentiation	B-PHYS
at	O	O
the	O	O
single	B-ANAT
-	I-ANAT
cell	I-ANAT
level	O	O
,	O	O
although	O	O
these	O	O
processes	B-PHEN
were	O	O
globally	O	O
correlated	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
highly	O
expressed	O
genes	O
,	O	O
including	O	O
core	O	O
pluripotency	O
factors	O	O
,	O	O
were	O	O
in	O	O
general	O	O
biallelically	O
expressed	B-PHYS
.	O	O

Taken	O	O
together	O	O
,	O	O
our	O	O
study	O	O
sheds	O	O
light	O	O
on	O	O
the	O	O
dynamics	B-PHEN
of	O	O
XCI	B-DISO
progression	O
and	O	O
the	O	O
asynchronicity	O
between	O	O
pluripotency	O
,	O	O
differentiation	O
,	O	O
and	O	O
XCI	B-DISO
.	O	O

Can	O	O
We	O	O
Predict	O
Burnout	B-DISO
among	O	O
Student	B-LIVB
Nurses	I-LIVB
?	O	O
An	O	O
Exploration	O	O
of	O	O
the	O	O
ICWR	O
-	O
1	O
Model	O
of	O	O
Individual	B-LIVB
Psychological	O
Resilience	O
The	O	O
nature	O	O
of	O	O
nursing	O
work	O
is	O	O
demanding	B-PROC
and	O	O
can	O	O
be	O	O
stressful	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
shown	O	O
a	O	O
high	O
rate	O
of	O	O
burnout	B-DISO
among	O	O
employed	B-DISO
nurses	B-LIVB
.	O	O

Recently	O	O
,	O	O
efforts	O	O
have	O	O
been	O	O
made	O	O
to	O	O
understand	O	O
the	O	O
role	O	O
of	O	O
resilience	O
in	O	O
determining	O	O
the	O	O
psychological	O
adjustment	O
of	O	O
employed	B-DISO
nurses	B-LIVB
.	O	O

A	O	O
theoretical	O
model	O
of	O	O
resilience	O
was	O	O
proposed	O	O
recently	O	O
that	O	O
includes	O
several	O
constructs	O
identified	O	O
in	O	O
the	O	O
literature	O
related	O	O
to	O	O
resilience	O
and	O	O
to	O	O
psychological	B-PHYS
functioning	I-PHYS
.	O	O

As	O	O
nursing	B-LIVB
students	I-LIVB
are	O	O
the	O	O
future	O
of	O	O
the	O	O
nursing	O
workforce	B-LIVB
it	O	O
is	O	O
important	O
to	O	O
advance	O
our	O	O
understanding	O	O
of	O	O
the	O	O
determinants	O
of	O	O
resilience	O
in	O	O
this	O	O
population	B-LIVB
.	O	O

Student	B-LIVB
nurses	I-LIVB
who	O	O
had	O	O
completed	O
their	O	O
final	O
practicum	B-PROC
were	O	O
invited	O	O
to	O	O
participate	O	O
in	O	O
an	O	O
online	O
survey	O
measuring	O
the	O	O
key	O	O
constructs	O
of	O	O
the	O	O
ICWR	O
-	O
1	O
model	O
.	O	O

422	O	O
students	B-LIVB
from	O	O
across	O	O
Australia	B-GEOG
and	O	O
Canada	B-GEOG
completed	O
the	O	O
survey	O
between	O	O
July	O	O
2014	O	O
and	O	O
July	O	O
2015	O	O
.	O	O

As	O	O
well	O	O
as	O	O
several	O
key	O	O
demographics	O
,	O	O
trait	B-DISO
negative	I-DISO
affect	I-DISO
,	O	O
mindfulness	B-PHYS
,	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
,	O	O
coping	O
,	O	O
resilience	O
,	O	O
and	O	O
burnout	B-DISO
were	O	O
measured	O
.	O	O

We	O	O
used	O	O
structural	B-PROC
equation	I-PROC
modeling	I-PROC
and	O	O
found	O	O
support	O	O
for	O	O
the	O	O
major	O
pathways	O
of	O	O
the	O	O
model	O
;	O	O
namely	O	O
that	O	O
resilience	O
had	O	O
a	O	O
significant	O
influence	O
on	O	O
the	O	O
relationship	O
between	O	O
mindfulness	B-PHYS
,	O	O
self	B-PHYS
-	I-PHYS
efficacy	I-PHYS
and	O	O
coping	O
,	O	O
and	O	O
psychological	O
adjustment	O
(	O	O
burnout	B-DISO
scores	O
)	O	O
.	O	O

Furthermore	O	O
,	O	O
as	O	O
predicted	O
,	O	O
Neuroticism	B-DISO
moderated	O	O
the	O	O
relationship	O
between	O	O
coping	O
and	O	O
burnout	B-DISO
.	O	O

Results	O	O
are	O	O
discussed	O	O
in	O	O
terms	O	O
of	O	O
potential	O
approaches	O
to	O	O
supporting	O	O
nursing	B-LIVB
students	I-LIVB
who	O	O
may	O	O
be	O	O
at	O
risk	O
of	O	O
burnout	B-DISO
.	O	O

Prevalence	O
of	O	O
Psychoactive	B-CHEM
Substance	I-CHEM
Consumption	O
in	O	O
People	B-LIVB
With	O	O
Obesity	B-DISO
The	O	O
aim	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
evaluate	B-PROC
the	O	O
prevalence	O
and	O	O
the	O	O
kind	O	O
of	O	O
psychoactive	B-CHEM
substances	I-CHEM
consumed	O
by	O	O
people	B-LIVB
with	O	O
obesity	B-DISO
.	O	O

Patients	B-LIVB
were	O	O
included	O	O
at	O	O
their	O	O
first	O	O
visit	O	O
for	O	O
bariatric	B-PROC
surgery	I-PROC
.	O	O

Socio	B-PROC
-	I-PROC
demographic	I-PROC
characteristics	O
,	O	O
anxiety	B-DISO
,	O	O
depressive	B-DISO
disorders	I-DISO
and	O	O
psychoactive	B-CHEM
substance	I-CHEM
consumption	O
were	O	O
assessed	B-PROC
.	O	O

The	O	O
prevalence	O
of	O	O
psychoactive	B-CHEM
substance	I-CHEM
consumption	O
was	O	O
compared	O
to	O	O
that	O	O
of	O	O
the	O	O
general	B-LIVB
population	I-LIVB
reported	B-PROC
by	O	O
the	O	O
French	O
National	O
Institute	O
of	O
Prevention	O
and	O
Health	O
Education	O
.	O	O

One	O	O
hundred	O	O
(	O	O
100	O	O
)	O	O
patients	B-LIVB
were	O	O
consecutively	O	O
recruited	O	O
:	O	O
60	O	O
women	B-LIVB
(	O	O
mean	O	O
age	B-PHYS
41	O	O
±	O	O
14	O	O
years	O
)	O	O
and	O	O
40	O	O
men	B-LIVB
(	O	O
mean	O	O
age	B-PHYS
46	O	O
±	O	O
13	O	O
years	O
)	O	O
.	O	O

Sixty	O	O
-	O	O
seven	O	O
percent	O	O
of	O	O
subjects	B-LIVB
consumed	O
alcohol	O
.	O	O

Consumption	O
rates	O
of	O	O
cannabis	B-CHEM
(	O	O
21	O	O
%	O	O
vs	O	O
.	O	O
10	O	O
%	O	O
)	O	O
,	O	O
cocaine	B-CHEM
(	O	O
7	O	O
.	O	O
0	O	O
%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
8	O	O
%	O	O
)	O	O
and	O	O
amphetamine	B-CHEM
(	O	O
6	O	O
.	O	O
0	O	O
%	O	O
vs	O	O
.	O	O

0	O	O
.	O	O
3	O	O
%	O	O
)	O	O
were	O	O
significantly	O
(	O	O
p	O	O
<	O	O
.0001	O	O
)	O	O
higher	O
in	O	O
people	B-LIVB
with	O	O
obesity	B-DISO
than	O	O
in	O	O
the	O	O
general	B-LIVB
population	I-LIVB
.	O	O

People	B-LIVB
with	O	O
obesity	B-DISO
have	O	O
an	O	O
excess	O
risk	O
of	O	O
amphetamine	B-CHEM
,	O	O
cocaine	B-CHEM
and	O	O
cannabis	B-CHEM
consumption	O
.	O	O

This	O	O
consumption	O
may	O	O
increase	O
the	O	O
risk	O
of	O	O
cardiovascular	B-DISO
and	O	O
psychiatric	O
morbidity	O
and	O	O
should	O	O
therefore	O	O
be	O	O
detected	B-PROC
before	O	O
surgery	O
.	O	O

Comparison	O	O
of	O	O
semiologies	O
between	O	O
tilt	O	O
-	O	O
induced	O	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
and	O	O
psychogenic	B-DISO
nonepileptic	B-DISO
seizures	I-DISO
We	O	O
sought	O	O
to	O	O
characterize	O	O
the	O	O
clinical	O
features	O
of	O	O
tilt	O	O
-	O	O
induced	O	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
(	O	O
PNSC	B-DISO
)	O	O
from	O	O
a	O	O
cohort	B-LIVB
of	O	O
young	O
patients	B-LIVB
and	O	O
to	O	O
compare	O	O
the	O	O
semiologies	O
between	O	O
PNSC	B-DISO
and	O	O
EEG	B-PROC
-confirmed	O	O
psychogenic	B-DISO
nonepileptic	B-DISO
seizures	I-DISO
(	O	O
PNES	B-DISO
)	O	O
.	O	O

A	O	O
PNSC	B-DISO
diagnosis	B-DISO
was	O	O
made	O	O
if	O	O
a	O	O
clinical	O
event	O
occurred	O	O
during	O	O
tilt	B-PROC
-	I-PROC
table	I-PROC
testing	I-PROC
that	O	O
the	O	O
patient	B-LIVB
regarded	O	O
as	O	O
fainting	B-DISO
,	O	O
but	O	O
neither	B-DISO
hypotension	B-DISO
nor	O	O
EEG	B-PROC
changes	O
were	O	O
present	O	O
.	O	O

A	O	O
diagnosis	B-DISO
of	O	O
PNSC	B-DISO
was	O	O
made	O	O
in	O	O
17	O	O
.	O	O

6	O	O
%	O	O
of	O	O
all	O	O
patients	B-LIVB
referred	O	O
during	O	O
the	O	O
15	O	O
-	O	O
month	O	O
study	O	O
period	O
.	O	O

Cohorts	B-LIVB
with	O	O
psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
(	O	O
n	O	O
=	O	O
40	O	O
)	O	O
and	O	O
PNES	B-DISO
(	O	O
n	O	O
=	O	O
40	O	O
)	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
age	B-PHYS
(	O	O
15	O	O
.	O	O

5±2	O	O
.	O	O

2	O	O
versus	O	O
14	O	O
.	O	O

6±2	O	O
.	O	O

7	O	O
,	O	O
p	O	O
=	O	O
.	O	O

11	O	O
)	O	O
or	O	O
female	B-PHYS
gender	I-PHYS
(	O	O
80	O	O
%	O	O
versus	O	O
72	O	O
.	O	O
5	O	O
%	O	O
,	O	O
p	O	O
=	O	O
.	O	O

43	O	O
)	O	O
.	O	O

Psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
events	O	O
were	O	O
briefer	O	O
than	O	O
PNES	B-DISO
events	O	O
(	O	O
median	O	O
:	O	O
45	O	O
versus	O	O
201	O	O
.	O	O

5s	O	O
,	O	O
p	O	O
<	O	O
.	O	O
001	O	O
)	O	O
.	O	O

Negative	B-DISO
motor	I-DISO
signs	I-DISO
(	O	O
head	B-DISO
drop	I-DISO
,	O	O
body	B-DISO
limpness	I-DISO
)	O	O
predominated	O	O
in	O	O
PNSC	B-DISO
(	O	O
85	O	O
%	O	O
versus	O	O
20	O	O
%	O	O
,	O	O
p	O	O
<	O	O
.	O	O
001	O	O
)	O	O
,	O	O
while	O	O
the	O	O
positive	B-DISO
motor	I-DISO
signs	I-DISO
of	O	O
convulsion	B-DISO
occurred	O	O
more	O	O
often	O	O
with	O	O
PNES	B-DISO
(	O	O
90	O	O
%	O	O
versus	O	O
30	O	O
%	O	O
,	O	O
p	O	O
<	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Behavioral	B-DISO
arrest	I-DISO
(	O	O
25	O	O
%	O	O
versus	O	O
32	O	O
.	O	O
5	O	O
%	O	O
,	O	O
p	O	O
=	O	O
.	O	O

46	O	O
)	O	O
and	O	O
eye	B-DISO
closure	I-DISO
(	O	O
85	O	O
%	O	O
versus	O	O
72	O	O
.	O	O
5	O	O
%	O	O
,	O	O
p	O	O
=	O	O
.	O	O

21	O	O
)	O	O
did	O	O
not	O	O
differ	O	O
between	O	O
PNSC	B-DISO
and	O	O
PNES	B-DISO
.	O	O

Patients	B-LIVB
with	O	O
PNSC	B-DISO
were	O	O
more	O	O
likely	O	O
to	O	O
be	O	O
tearful	B-DISO
before	O	O
(	O	O
30	O	O
%	O	O
versus	O	O
7	O	O
.	O	O

5	O	O
%	O	O
,	O	O
p	O	O
=	O	O
.	O	O

02	O	O
)	O	O
and	O	O
after	O	O
(	O	O
62	O	O
.	O	O
5	O	O
%	O	O
versus	O	O
7	O	O
.	O	O
5	O	O
%	O	O
,	O	O
p	O	O
<	O	O
.	O	O

001	O	O
)	O	O
an	O	O
event	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
although	O	O
overlap	O
exists	O	O
,	O	O
the	O	O
features	O
of	O	O
PNSC	B-DISO
generally	O	O
appear	O	O
similar	O	O
to	O	O
neurally	B-DISO
mediated	I-DISO
syncope	I-DISO
,	O	O
while	O	O
the	O	O
features	O
of	O	O
PNES	B-DISO
generally	O	O
appear	O	O
similar	O	O
to	O	O
epileptic	B-DISO
seizures	I-DISO
.	O	O

Psychogenic	B-DISO
nonsyncopal	I-DISO
collapse	I-DISO
and	O	O
PNES	B-DISO
likely	O	O
represent	O	O
similar	O	O
disorders	B-DISO
that	O	O
differ	O	O
primarily	O	O
by	O	O
clinical	O
semiologies	O
and	O	O
referral	O	O
patterns	O	O
.	O	O

Medication	B-PROC
Intervention	I-PROC
for	O	O
Chronic	B-DISO
Kidney	I-DISO
Disease	I-DISO
Patients	B-LIVB
Transitioning	O
from	O	O
Hospital	B-OBJC
to	O	O
Home	O
:	O	O
Study	B-PROC
Design	I-PROC
and	O	O
Baseline	O
Characteristics	O
The	O	O
hospital	B-PROC
readmission	I-PROC
rate	O
in	O	O
the	O	O
population	B-LIVB
with	O	O
chronic	B-DISO
kidney	I-DISO
disease	I-DISO
(	O	O
CKD	B-DISO
)	O	O
is	O	O
high	O	O
and	O	O
strategies	O	O
to	O	O
reduce	O	O
this	O	O
risk	O
are	O	O
urgently	O	O
needed	O
.	O	O

The	O	O
CKD	B-DISO
-	O	O
Medication	B-PROC
Intervention	I-PROC
Trial	I-PROC
(	O	O
CKD	B-DISO
-	O	O
MIT	B-PROC
;	O	O
www	O
.	O
clinicaltrials	O
.	O

gov	O
;	O
NCTO1459770	O
)	O	O
is	O	O
a	O	O
single	B-PROC
-	I-PROC
blind	I-PROC
(	O	O
investigators	B-LIVB
)	O	O
,	O	O
randomized	B-PROC
,	O	O
clinical	B-PROC
trial	I-PROC
conducted	O	O
at	O	O
Providence	B-PROC
Health	I-PROC
Care	I-PROC
in	O	O
Spokane	B-GEOG
,	I-GEOG
Washington	I-GEOG
.	O	O

Study	B-LIVB
participants	I-LIVB
are	O	O
hospitalized	B-LIVB
patients	I-LIVB
with	O	O
CKD	B-DISO
stages	O
3	O	O
-	O	O
5	O	O
(	O	O
not	O	O
treated	B-PROC
with	I-PROC
kidney	B-PROC
replacement	I-PROC
therapy	I-PROC
)	O	O
and	O	O
acute	B-DISO
illness	I-DISO
.	O	O

The	O	O
study	O
intervention	O
is	O	O
a	O	O
pharmacist	B-LIVB
-	I-LIVB
led	I-LIVB
,	O	O
home	B-PROC
-	I-PROC
based	I-PROC
,	O	O
medication	B-PROC
management	I-PROC
intervention	B-PROC
delivered	O
within	O	O
7	O	O
days	O
after	O	O
hospital	B-PROC
discharge	I-PROC
.	O	O

The	O	O
primary	O
outcome	O
is	O	O
a	O	O
composite	O	O
of	O	O
hospital	B-PROC
readmissions	I-PROC
and	O	O
visits	O	O
to	O	O
emergency	B-OBJC
departments	I-OBJC
and	O	O
urgent	B-OBJC
care	I-OBJC
centers	I-OBJC
for	O	O
90	O	O
days	O
following	O	O
hospital	B-PROC
discharge	I-PROC
.	O	O

Secondary	O
outcomes	O
are	O	O
achievements	O
of	O	O
guideline	O
-	O
based	O
targets	O
for	O	O
CKD	B-DISO
risk	B-DISO
factors	I-DISO
and	O	O
complications	B-DISO
.	O	O

Enrollment	B-PROC
began	O	O
in	O	O
February	O
2012	O	O
and	O	O
ended	O	O
in	O	O
May	O
2015	O	O
.	O	O

At	O	O
baseline	O
,	O	O
the	O	O
age	B-PHYS
of	O	O
participants	B-LIVB
was	O	O
69	O	O
±	O	O
11	O	O
years	O
(	O	O
mean	O	O
±	O	O
SD	O	O
)	O	O
,	O	O
50	O	O
%	O	O
(	O	O
77	O	O
of	O	O
155	O	O
)	O	O
were	O	O
women	B-LIVB
,	O	O
83	O	O
%	O	O
(	O	O
117	O	O
of	O	O
141	O	O
)	O	O
had	O	O
hypertension	B-DISO
and	O	O
56	O	O
%	O	O
(	O	O
79	O	O
of	O	O
141	O	O
)	O	O
had	O	O
diabetes	B-DISO
.	O	O

At	O	O
baseline	O
,	O	O
the	O	O
estimated	B-PROC
glomerular	I-PROC
filtration	I-PROC
rate	O
was	O	O
41	O	O
±	O	O
14	O	O
ml	O	O
/	O	O
min	O	O
/	O	O
1	O	O
.	O	O
73	O	O
m2	O	O
and	O	O
urine	B-PROC
albumin	I-PROC
-	I-PROC
to	I-PROC
-	I-PROC
creatinine	I-PROC
ratio	I-PROC
was	O	O
43	O	O
mg	O	O
/	O	O
g	O	O
(	O	O
interquartile	O
range	O
8	O	O
-	O	O
528	O	O
mg	O	O
/	O	O
g	O	O
)	O	O
.	O	O

The	O	O
most	O	O
frequent	O	O
diagnosis	O
category	O
for	O	O
the	O	O
index	O	O
hospital	B-PROC
admission	I-PROC
was	O	O
cardiovascular	B-DISO
diseases	I-DISO
at	O	O
34	O	O
%	O	O
(	O	O
53	O	O
of	O	O
155	O	O
)	O	O
,	O	O
but	O	O
the	O	O
most	O	O
common	O	O
single	B-DISO
diagnosis	I-DISO
for	O	O
admission	B-PROC
was	O	O
community	O
-	O
acquired	O
acute	B-DISO
kidney	I-DISO
injury	I-DISO
at	O	O
10	O	O
%	O	O
(	O	O
16	O	O
of	O	O
155	O	O
)	O	O
.	O	O

Participants	B-LIVB
in	O	O
CKD	B-DISO
-	O	O
MIT	B-PROC
are	O	O
typical	O	O
of	O	O
acutely	B-DISO
ill	I-DISO
hospitalized	B-LIVB
patients	I-LIVB
with	O	O
CKD	B-DISO
.	O	O

A	O	O
medication	B-PROC
management	I-PROC
intervention	B-PROC
after	O	O
hospital	B-PROC
discharge	I-PROC
is	O	O
under	O	O
study	B-PROC
to	O	O
reduce	O
post	O
-	O	O
hospitalization	B-PROC
acute	B-PROC
care	I-PROC
utilization	O
and	O	O
to	O	O
improve	O	O
CKD	B-DISO
management	B-PROC
.	O	O

DEPRESSION	B-DISO
,	O	O
ANXIETY	B-DISO
,	O	O
STRESS	B-DISO
,	O	O
AND	O	O
THEIR	O	O
ASSOCIATED	O
FACTORS	O
AMONG	O	O
CORPS	B-LIVB
MEMBERS	I-LIVB
SERVING	O	O
IN	O	O
KEBBI	O
STATE	O
Depression	B-DISO
,	O	O
anxiety	B-DISO
and	O	O
stress	B-DISO
,	O	O
are	O	O
not	O	O
only	O	O
health	B-DISO
problems	I-DISO
by	O	O
themselves	O	O
,	O	O
but	O	O
also	O	O
associated	O
with	O
other	O	O
negative	B-DISO
health	O
consequences	O
.	O	O

The	O	O
national	O
youth	O
service	O
is	O	O
usually	O	O
characterized	O
by	O	O
a	O	O
number	O	O
of	O	O
new	O	O
challenges	O	O
and	O	O
experiences	B-PHYS
which	O	O
may	O	O
require	O	O
life	O
style	O
adjustments	O
by	O	O
the	O	O
corps	B-LIVB
member	I-LIVB
.	O	O

However	O	O
,	O	O
no	O	O
previous	O	O
study	O	O
on	O	O
psychological	B-PHYS
factors	I-PHYS
has	O	O
been	O	O
conducted	O	O
among	O	O
corps	B-LIVB
members	I-LIVB
.	O	O

This	O	O
study	B-PROC
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
prevalence	O
of	O	O
depression	B-DISO
,	O	O
anxiety	B-DISO
and	O	O
,	O	O
stress	B-DISO
and	O	O
their	O	O
associated	O
factors	O
among	O	O
corps	B-LIVB
members	I-LIVB
serving	O	O
in	O	O
Kebbi	O
state	O
.	O	O

A	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
study	I-PROC
was	O	O
conducted	O	O
among	O	O
264	O	O
corps	B-LIVB
members	I-LIVB
from	O	O
four	O	O
local	O
government	O
areas	O
of	O	O
the	O	O
state	B-GEOG
.	O	O

Selection	O	O
of	O	O
the	O	O
local	O
government	O
areas	O
and	O	O
the	O	O
individual	O	O
participants	B-LIVB
was	O	O
by	O	O
simple	B-PROC
random	I-PROC
sampling	I-PROC
.	O	O

Data	O
was	O	O
collected	O	O
from	O	O
May	O
to	O	O
June	O
2014	O	O
using	O	O
a	O	O
self	O
-	O
administered	O
questionnaire	O
.	O	O

Data	O
analysis	O
used	O	O
chi	O
-	O
square	O
test	O
to	O	O
identify	O	O
the	O	O
relationship	O
between	O	O
categorical	O
variables	O
and	O	O
multivariate	B-PROC
logistic	I-PROC
regression	I-PROC
to	O	O
identify	O	O
the	O	O
independent	O	O
factors	O
for	O	O
depression	B-DISO
,	O	O
anxiety	B-DISO
and	O	O
stress	B-DISO
each	O	O
.	O	O

The	O	O
response	O
rate	O
was	O	O
97	O	O
%	O	O
.	O	O

Most	O	O
of	O	O
the	O	O
respondents	B-LIVB
were	O	O
males	B-PHYS
(	O	O
63	O	O
.	O	O
6	O	O
%	O	O
)	O	O
,	O	O
single	B-LIVB
(	O	O
85	O	O
.	O	O
5	O	O
%	O	O
)	O	O
,	O	O
and	O	O
above	O	O
20	O	O
years	O
of	O	O
age	B-PHYS
(	O	O
71	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
prevalences	O
of	O	O
depression	B-DISO
,	O	O
anxiety	B-DISO
and	O	O
stress	B-DISO
among	O	O
the	O	O
respondents	B-LIVB
were	O	O
36	O	O
.	O	O

4	O	O
%	O	O
,	O	O
54	O	O
.	O	O

5	O	O
%	O	O
and	O	O
18	O	O
.	O	O
2	O	O
%	O	O
respectively	O	O
.	O	O

The	O	O
independent	O	O
factors	O
for	O	O
depression	B-DISO
were	O	O
;	O	O
being	O	O
from	O	O
the	O	O
North	B-GEOG
central	I-GEOG
(	O	O
OR	O
=	O	O
5	O	O
.	O	O

99	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
2	O	O
.	O	O
194	O	O
-	O	O
16	O	O
.	O	O
354	O	O
)	O	O
or	O	O
South	B-GEOG
-	I-GEOG
south	I-GEOG
;	O	O
and	O	O
the	O	O
perception	B-PHYS
of	O	O
earning	O
enough	O	O
income	O
(	O	O
OR	O
=	O	O
2	O	O
.	O	O
987	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
062	O	O
-	O	O
8	O	O
.	O	O
400	O	O
)	O	O
.	O	O

For	O	O
anxiety	B-DISO
,	O	O
male	B-PHYS
gender	I-PHYS
(	O	O
OR	O
=	O	O
0	O	O
.	O	O
411	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
169	O	O
-	O	O
0	O	O
.	O	O
999	O	O
)	O	O
;	O	O
and	O	O
being	O	O
from	O	O
the	O	O
North	B-GEOG
central	I-GEOG
were	O	O
significant	O	O
risk	B-DISO
factors	I-DISO
(	O	O
OR	O
=	O	O
3	O	O
.	O	O

731	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
1	O	O
.	O	O
450	O	O
-	O	O
9	O	O
.	O	O
599	O	O
)	O	O
.	O	O

Being	O	O
above	O	O
26	O	O
years	O
of	O	O
age	B-PHYS
was	O	O
an	O	O
independent	O	O
risk	B-DISO
factor	I-DISO
for	O	O
stress	B-DISO
(	O	O
OR	O
=	O	O
0	O	O
.	O	O
083	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
018	O	O
-	O	O
0	O	O
.	O	O
381	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
those	O	O
who	O	O
had	O	O
ever	O	O
schooled	B-DISO
outside	O	O
their	O	O
towns	B-GEOG
of	O	O
residence	O
were	O	O
less	O	O
likely	O	O
to	O	O
be	O	O
stressed	B-PHYS
compared	O	O
to	O	O
those	O	O
who	O	O
had	O	O
never	O	O
(	O	O
OR	O
=	O	O
0	O	O
.	O	O
30	O	O
;	O	O
95	O	O
%	O	O
CI	O
:	O	O
0	O	O
.	O	O
110	O	O
-	O	O
0	O	O
.	O	O
855	O	O
)	O	O
.	O	O

All	O	O
other	O	O
factors	O
did	O	O
not	O	O
show	O	O
any	O	O
significant	O
association	O
with	O	O
any	O	O
of	O	O
the	O	O
outcome	O
variables	O
in	O	O
multivariate	O
analysis	O
.	O	O

In	O	O
conclusion	O
,	O	O
the	O	O
prevalences	O
of	O	O
depression	B-DISO
,	O	O
anxiety	B-DISO
and	O	O
stress	B-DISO
are	O	O
high	O
among	O	O
corps	B-LIVB
members	I-LIVB
serving	O	O
in	O	O
Kebbi	O
state	O
.	O	O

There	O	O
is	O	O
need	O	O
to	O	O
expand	O	O
the	O	O
scope	O	O
of	O	O
this	O	O
study	B-PROC
to	O	O
a	O	O
national	O
level	O
so	O	O
as	O	O
to	O	O
get	O	O
a	O	O
bigger	O	O
picture	O	O
of	O	O
the	O	O
problem	B-DISO
.	O	O

Direct	O
Repair	B-PROC
of	O	O
Lumbar	B-ANAT
Pars	I-ANAT
Interarticularis	I-ANAT
Defects	O
by	O	O
Utilizing	O
Intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
Arm	I-DEVI
-	I-DEVI
Based	I-DEVI
Navigation	I-DEVI
and	O	O
Microendoscopic	B-PROC
Techniques	I-PROC
A	O	O
retrospective	B-PROC
analysis	I-PROC
of	O	O
the	O	O
clinical	B-DISO
outcomes	I-DISO
of	O	O
eight	O	O
patients	B-LIVB
with	O	O
the	O	O
lumbar	B-ANAT
pars	I-ANAT
interarticulars	I-ANAT
defects	O
treated	B-DISO
by	O	O
direct	O
repair	B-PROC
with	O	O
the	O	O
aid	O
of	O	O
intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
arm	I-DEVI
based	I-DEVI
navigation	I-DEVI
and	O	O
microendoscopic	B-PROC
techniques	I-PROC
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
investigate	O
the	O	O
efficacy	O
and	O	O
safety	B-PHEN
of	O	O
direct	O
screw	B-DEVI
repair	B-PROC
by	O	O
using	O
minimally	B-PROC
invasive	I-PROC
surgery	I-PROC
for	O	O
the	O	O
lumbar	B-ANAT
pars	I-ANAT
interarticulars	I-ANAT
defects	O
in	O	O
a	O	O
pilot	B-PROC
study	I-PROC
.	O	O

Direct	O
repair	B-PROC
of	O	O
pars	B-ANAT
interarticulars	I-ANAT
defects	O
has	O	O
been	O	O
used	O
to	O	O
treat	B-PROC
young	B-LIVB
adult	I-LIVB
patients	B-LIVB
.	O	O

Reports	O
concerning	O
direct	O
repair	B-PROC
by	O	O
minimally	B-PROC
invasive	I-PROC
techniques	I-PROC
for	O	O
pars	B-ANAT
interarticulars	I-ANAT
defects	O
are	O	O
quite	O	O
rare	O
.	O	O

Review	O
of	O	O
medical	O
records	O
identified	O
eight	O	O
consecutive	O
patients	B-LIVB
treated	B-DISO
with	O	O
intraoperative	B-DEVI
O	I-DEVI
-	I-DEVI
arm	I-DEVI
based	I-DEVI
navigation	I-DEVI
and	O	O
microendoscopic	B-PROC
techniques	I-PROC
.	O	O

Debridement	B-PROC
and	O	O
autograft	B-PROC
of	O	O
pars	B-ANAT
interarticularis	I-ANAT
defects	O
was	O	O
performed	O
under	O	O
microendoscopic	B-PROC
procedure	I-PROC
.	O	O

Then	O	O
,	O	O
percutaneous	O
bilateral	O
intralaminar	O
screws	B-DEVI
were	O	O
inserted	B-PROC
by	O	O
utilizing	O
intraoperative	B-DEVI
navigation	I-DEVI
.	O	O

The	O	O
clinical	O
and	O	O
radiological	O
data	O
were	O	O
collected	O
and	O	O
analyzed	B-PROC
retrospectively	O
.	O	O

Eight	O	O
patients	B-LIVB
had	O	O
a	O	O
mean	O
age	B-PHYS
of	O	O
28	O	O
.	O	O

4	O	O
years	O	O
,	O	O
and	O	O
five	O	O
were	O	O
30	O	O
years	O	O
or	O	O
younger	O
at	O	O
the	O	O
time	O
of	O	O
treatment	B-PROC
.	O	O

Symptoms	B-DISO
included	O
axial	O
back	B-DISO
pain	I-DISO
in	O	O
100	O	O
%	O	O
of	O	O
patients	B-LIVB
without	O	O
concomitant	O
radiculopathy	B-DISO
.	O	O

Autograft	B-PROC
was	O	O
used	O
in	O	O
all	O	O
cases	O
.	O	O

The	O	O
average	O
follow	B-PROC
-	I-PROC
up	I-PROC
duration	O
was	O	O
27	O	O
.	O	O

4	O	O
months	O	O
with	O	O
a	O	O
range	O
of	O	O
20	O	O
to	O	O
33	O	O
months	O	O
.	O	O

Symptoms	B-DISO
resolved	B-DISO
completely	O
or	O	O
partially	O
in	O	O
all	O	O
patients	B-LIVB
.	O	O

Low	B-DISO
back	I-DISO
pain	I-DISO
visual	B-PHYS
analog	I-PHYS
scores	I-PHYS
decrease	O
from	O	O
preoperative	O
6	O	O
.	O	O

8	O	O
to	O	O
postoperative	O
1	O	O
.	O	O
4	O	O
of	O	O
eight	O	O
cases	O
.	O	O

Of	O	O
16	O	O
pars	B-ANAT
defects	O
,	O	O
healing	B-PHYS
was	O	O
observed	O
in	O	O
13	O	O
(	O	O
81	O	O
.	O	O

3	O	O
%	O	O
)	O	O
at	O	O
last	O	O
radiological	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

One	O	O
patient	B-LIVB
with	O	O
bilateral	B-DISO
fusion	I-DISO
failure	I-DISO
refused	O
revision	B-PROC
surgery	I-PROC
because	O	O
of	O	O
mild	B-DISO
complaint	I-DISO
.	O	O

No	B-DISO
complications	I-DISO
such	O	O
as	O	O
dural	B-DISO
tear	I-DISO
,	O	O
nerve	B-DISO
root	I-DISO
injury	I-DISO
,	O	O
and	O	O
infection	B-DISO
occurred	O
.	O	O

Minimally	B-PROC
invasive	I-PROC
direct	O
repair	B-PROC
of	O	O
the	O	O
pars	B-ANAT
interarticularis	I-ANAT
defects	O
with	O	O
intralaminar	O
screws	B-DEVI
by	O	O
using	O
microendoscopic	B-PROC
system	I-PROC
and	O	O
navigation	B-DEVI
procedure	I-DEVI
can	O	O
provide	O
safe	O	O
and	O	O
effective	O
treatment	B-PROC
of	O	O
spondylolysis	B-DISO
with	O	O
satisfactory	O
clinical	O
and	O	O
radiological	O
outcomes	O
,	O	O
which	O	O
need	O
some	O	O
special	B-DEVI
tools	I-DEVI
with	O	O
steep	O
learning	B-PHYS
curve	I-PHYS
.	O	O

4	O	O
.	O	O

Evidence	O
-Based	O	O
Review	O
and	O	O
Survey	O
of	O	O
Expert	O
Opinion	O
of	O	O
Reconstruction	B-PROC
of	O	O
Metastatic	B-DISO
Spine	I-DISO
Tumors	I-DISO
Systematic	O
review	O
and	O	O
consensus	O
expert	O
opinion	O
.	O	O

To	O	O
provide	O	O
surgeons	B-LIVB
and	O	O
other	O	O
health	B-LIVB
care	I-LIVB
professionals	I-LIVB
with	O	O
guidelines	O
for	O	O
surgical	B-PROC
reconstruction	I-PROC
of	O	O
metastatic	B-DISO
spine	B-DISO
disease	I-DISO
based	O	O
on	O	O
evidence	O
and	O	O
expert	O
opinion	O
.	O	O

The	O	O
surgical	B-PROC
treatment	I-PROC
of	O	O
spinal	B-DISO
metastases	I-DISO
is	O	O
controversial	O	O
.	O	O

Specifically	O	O
two	O	O
aspects	O	O
of	O	O
surgical	B-PROC
reconstruction	I-PROC
are	O	O
addressed	O	O
in	O	O
this	O	O
study	O	O
:	O	O
(	O	O
i	O	O
)	O	O
choice	O	O
of	O	O
bone	B-PROC
graft	I-PROC
used	O	O
during	O
surgery	B-PROC
for	O	O
metastatic	B-DISO
spine	I-DISO
tumors	I-DISO
and	O	O
(	O	O
ii	O	O
)	O	O
the	O	O
design	O
of	O	O
reconstruction	B-PROC
or	O	O
construct	B-CHEM
to	O	O
stabilize	B-DISO
.	O	O

A	O	O
systematic	O
review	O
of	O	O
the	O	O
available	O
medical	O
literature	O
from	O	O
1980	O	O
to	O	O
2015	O	O
was	O	O
conducted	O	O
,	O	O
and	O	O
combined	O
with	O	O
consensus	O
expert	O
opinion	O
from	O	O
a	O	O
recent	O	O
survey	O
of	O	O
spine	B-ANAT
surgeons	B-LIVB
who	O	O
treat	B-PROC
metastatic	B-DISO
spine	I-DISO
tumors	I-DISO
.	O	O

There	O	O
is	O	O
very	O	O
little	O	O
evidence	O
in	O	O
the	O	O
literature	O
to	O	O
provide	O	O
guidance	B-PROC
on	O	O
the	O	O
use	O
of	O
bone	B-PROC
graft	I-PROC
in	O	O
metastatic	B-DISO
tumor	I-DISO
reconstruction	B-PROC
.	O	O

There	O	O
is	O	O
little	O	O
evidence	O
in	O	O
the	O	O
literature	O
to	O	O
support	O	O
the	O	O
preferential	O	O
use	O
of	O
one	O	O
graft	O
type	O
over	O	O
the	O	O
other	O	O
.	O	O

Approximately	O	O
,	O	O
41	O	O
%	O	O
of	O	O
respondents	B-LIVB
said	O	O
they	O	O
used	O	O
bone	B-PROC
graft	I-PROC
or	O	O
bone	B-PROC
graft	I-PROC
substitutes	B-CHEM
to	O	O
accomplish	O	O
fusion	B-PROC
.	O	O

There	O	O
were	O	O
17	O	O
studies	B-PROC
that	O	O
described	O	O
the	O	O
use	O
of	O
a	O	O
prefabricated	B-DEVI
prosthetic	I-DEVI
,	O	O
10	O	O
studies	B-PROC
describing	O	O
the	O	O
use	O
of	O
polymethyl	B-CHEM
methacrylate	I-CHEM
(	O	O
PMMA	B-CHEM
)	O	O
bone	B-CHEM
cement	I-CHEM
,	O	O
and	O	O
only	O	O
three	O	O
studies	B-PROC
describing	O	O
the	O	O
use	O
of	O
bone	B-PROC
graft	I-PROC
for	O	O
anterior	O
column	B-ANAT
reconstruction	B-PROC
.	O	O

The	O	O
use	O
of	O
structural	B-PROC
allograft	I-PROC
was	O	O
most	O	O
popular	O	O
among	O	O
the	O	O
experts	B-LIVB
for	O	O
anterior	O
reconstruction	B-PROC
,	O	O
followed	O
by	O
cage	B-DEVI
reconstruction	B-PROC
,	O	O
and	O	O
PMMA	B-CHEM
bone	B-CHEM
cement	I-CHEM
.	O	O

Achieving	O	O
bony	B-ANAT
union	I-ANAT
may	O	O
be	O	O
of	O	O
importance	O
for	O	O
the	O	O
maintenance	O
of	O	O
spinal	B-ANAT
stability	O
in	O	O
the	O	O
long	O
term	O
after	O	O
reconstruction	B-PROC
.	O	O

Whether	O	O
bony	B-ANAT
union	I-ANAT
is	O	O
required	O
for	O	O
patients	B-LIVB
with	O	O
shorter	O
life	O
expectancies	O
is	O	O
debatable	O	O
.	O	O

The	O	O
literature	O
supports	O	O
the	O	O
use	O
of	O
anterior	O
reconstruction	B-PROC
with	O	O
either	O	O
a	O	O
prefabricated	B-DEVI
prosthetic	I-DEVI
or	O	O
PMMA	B-CHEM
bone	B-CHEM
cement	I-CHEM
.	O	O

It	O	O
also	O	O
supports	O	O
the	O	O
use	O
of	O
an	O	O
anterior	O
construct	B-CHEM
reinforced	O	O
with	O	O
bilateral	O
posterior	O
instrumentation	O
when	O	O
performing	B-PROC
a	O	O
three	B-PROC
-	I-PROC
column	I-PROC
reconstruction	I-PROC
.	O	O

N	O	O
/	O	O
A	O	O
.	O	O

The	O	O
value	O	O
of	O	O
transesophageal	B-PROC
echocardiography	I-PROC
for	O	O
embolic	B-DISO
strokes	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
Our	O	O
aim	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
diagnostic	B-PROC
yield	I-PROC
of	O	O
transesophageal	B-PROC
echocardiography	I-PROC
(	O	O
TEE	B-PROC
)	O	O
in	O	O
consecutive	O	O
patients	B-LIVB
with	O	O
ischemic	B-DISO
stroke	I-DISO
(	O	O
IS	B-DISO
)	O	O
fulfilling	O	O
the	O	O
diagnostic	O
criteria	O
of	O	O
embolic	B-DISO
strokes	I-DISO
of	I-DISO
undetermined	I-DISO
source	I-DISO
(	O	O
ESUS	B-DISO
)	O	O
.	O	O

We	O	O
prospectively	O	O
evaluated	O	O
consecutive	O	O
patients	B-LIVB
with	O	O
acute	O	O
IS	B-DISO
satisfying	O	O
ESUS	B-DISO
criteria	O	O
who	O	O
underwent	O	O
in	O	O
-	O	O
hospital	B-OBJC
TEE	B-PROC
examination	I-PROC
in	O	O
3	O	O
tertiary	B-OBJC
care	I-OBJC
stroke	I-OBJC
centers	I-OBJC
during	O
a	O
12	O
-	O
month	O
period	O
.	O	O

We	O	O
also	O	O
performed	O	O
a	O	O
systematic	O
review	O
and	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
estimating	I-PROC
the	O	O
cumulative	O	O
effect	O	O
of	O	O
TEE	B-PROC
findings	B-DISO
on	O	O
therapeutic	O
management	O
for	O	O
secondary	B-PROC
stroke	I-PROC
prevention	I-PROC
among	O	O
different	O	O
IS	B-DISO
subgroups	O	O
.	O	O

We	O	O
identified	O	O
61	O	O
patients	B-LIVB
with	O	O
ESUS	B-DISO
who	O	O
underwent	B-PROC
investigation	I-PROC
with	O	O
TEE	B-PROC
(	O	O
mean	O	O
age	O	O
44	O	O
±	O	O
12	O	O
years	O	O
,	O	O
49	O	O
%	O	O
men	B-LIVB
,	O	O
median	O	O
NIH	O
Stroke	O
Scale	O
score	O
=	O	O
5	O	O
points	O	O
[	O	O
interquartile	O
range	O
:	O	O
3	O	O
-	O	O
8	O	O
]	O	O
)	O	O
.	O	O

TEE	B-PROC
revealed	O	O
additional	O	O
findings	B-DISO
in	O	O
52	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interval	O
[	O	O
CI	O
]	O	O
:	O	O
40	O	O
%	O	O
-	O	O
65	O	O
%	O	O
)	O	O
of	O	O
the	O	O
study	B-LIVB
population	I-LIVB
.	O	O

TEE	B-PROC
findings	B-DISO
changed	O	O
management	O	O
(	O	O
initiation	O
of	O	O
anticoagulation	B-PROC
therapy	I-PROC
,	O	O
administration	B-PROC
of	O	O
IV	B-PROC
antibiotic	I-PROC
therapy	I-PROC
,	O	O
and	O	O
patent	B-PROC
foramen	I-PROC
ovale	I-PROC
closure	I-PROC
)	O	O
in	O	O
10	O	O
(	O	O
16	O	O
%	O	O
[	O	O
95	O	O
%	O	O
CI	O
:	O	O
9	O	O
%	O	O
-	O	O
28	O	O
%	O	O
]	O	O
)	O	O
patients	B-LIVB
.	O	O

The	O	O
pooled	O
rate	O
of	O	O
reported	O	O
anticoagulation	B-PROC
therapy	I-PROC
attributed	O	O
to	O	O
abnormal	B-DISO
TEE	B-PROC
findings	B-DISO
among	O	O
3	O	O
,	O	O
562	O	O
acute	O	O
IS	B-DISO
patients	B-LIVB
included	O	O
in	O	O
the	O	O
meta	B-PROC
-	I-PROC
analysis	I-PROC
(	O	O
12	O	O
studies	O	O
)	O	O
was	O	O
8	O	O
.	O	O

7	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O
:	O	O
7	O	O
.	O	O
3	O	O
%	O	O
-	O	O
10	O	O
.	O	O
4	O	O
%	O	O
)	O	O
.	O	O

In	O	O
subgroup	B-PROC
analysis	I-PROC
,	O	O
the	O	O
rates	O	O
of	O	O
initiation	O
of	O	O
anticoagulation	B-PROC
therapy	I-PROC
on	O	O
the	O	O
basis	O	O
of	O	O
TEE	B-PROC
investigation	O	O
did	O	O
not	O	O
differ	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
315	O	O
)	O	O
among	O	O
patients	B-LIVB
with	O	O
cryptogenic	O
stroke	O
(	O	O
6	O	O
.	O	O
9	O	O
%	O	O
[	O	O
95	O	O
%	O	O
CI	O
:	O	O
4	O	O
.	O	O
9	O	O
%	O	O
-	O	O
9	O	O
.	O	O
6	O	O
%	O	O
]	O	O
)	O	O
,	O	O
ESUS	B-DISO
(	O	O
8	O	O
.	O	O
1	O	O
%	O	O
[	O	O
95	O	O
%	O	O
CI	O
:	O	O
3	O	O
.	O	O
4	O	O
%	O	O
-	O	O
18	O	O
.	O	O
1	O	O
%	O	O
]	O	O
)	O	O
,	O	O
and	O	O
IS	B-DISO
(	O	O
9	O	O
.	O	O
4	O	O
%	O	O
[	O	O
95	O	O
%	O	O
CI	O
:	O	O
7	O	O
.	O	O
5	O	O
%	O	O
-	O	O
11	O	O
.	O	O
8	O	O
%	O	O
]	O	O
)	O	O
.	O	O

Abnormal	O	O
TEE	B-PROC
findings	B-DISO
may	O	O
decisively	O	O
affect	O	O
the	O	O
selection	O	O
of	O	O
appropriate	O
therapeutic	B-PROC
strategy	I-PROC
in	O	O
approximately	O	O
1	O	O
of	O	O
7	O	O
patients	B-LIVB
with	O	O
ESUS	B-DISO
.	O	O

Trans	O
-	O
oral	O
fine	B-PROC
needle	I-PROC
aspiration	I-PROC
cytology	I-PROC
in	O	O
cervical	B-ANAT
(	I-ANAT
C1	I-ANAT
and	I-ANAT
C2	I-ANAT
)	I-ANAT
vertebral	I-ANAT
lesions	B-DISO
:	O	O
a	O	O
novel	O	O
diagnostic	B-PROC
approach	I-PROC
Fine	B-PROC
needle	I-PROC
aspiration	I-PROC
(	I-PROC
FNA	I-PROC
)	I-PROC
cytology	I-PROC
is	O	O
a	O	O
relatively	O	O
non	O
-	O
invasive	O
method	O	O
for	O	O
diagnosing	B-DISO
both	O	O
superficial	B-DISO
and	O	O
deep	B-DISO
-	I-DISO
seated	I-DISO
neoplastic	I-DISO
and	O	O
non	B-DISO
-	I-DISO
neoplastic	I-DISO
lesions	I-DISO
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
diagnostic	O
utility	O
of	O	O
trans	O
-	O
oral	O
FNA	B-PROC
in	O	O
cervical	B-ANAT
(	I-ANAT
C1	I-ANAT
and	I-ANAT
C2	I-ANAT
)	I-ANAT
vertebral	I-ANAT
and	O	O
paravertebral	B-ANAT
lesions	B-DISO
.	O	O

Eighteen	O	O
FNA	B-PROC
cases	O	O
of	O	O
cervical	B-ANAT
vertebral	I-ANAT
and	O	O
paravertebral	B-ANAT
lesions	B-DISO
performed	O	O
by	O	O
a	O	O
trans	O
-	O
oral	O
route	O
without	O	O
any	O	O
image	B-PROC
-	I-PROC
guidance	I-PROC
between	O	O
1995	O	O
and	O	O
2014	O	O
were	O	O
retrieved	O	O
from	O	O
the	O	O
archives	O	O
of	O	O
the	O	O
cytology	O
department	O
at	O	O
PGIMER	O
,	O	O
Chandigarh	O
and	O	O
reviewed	O	O
.	O	O

Out	O	O
of	O	O
18	O	O
cases	O	O
,	O	O
a	O	O
definite	O	O
diagnosis	B-DISO
was	O	O
given	O	O
in	O	O
15	O	O
cases	O	O
(	O	O
83	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

The	O	O
commonest	O	O
diagnosis	B-DISO
seen	O	O
was	O	O
granulomatous	B-DISO
inflammation	I-DISO
consistent	O	O
with	O	O
tuberculosis	B-DISO
(	O	O
33	O	O
.	O	O
3	O	O
%	O	O
)	O	O
.	O	O

Trans	O
-	O
oral	O
FNA	B-PROC
is	O	O
a	O	O
quick	O	O
,	O	O
inexpensive	O	O
and	O	O
relatively	O	O
safe	O	O
outpatient	B-PROC
procedure	I-PROC
for	O	O
sampling	O	O
C1	B-ANAT
and	I-ANAT
C2	I-ANAT
vertebral	I-ANAT
and	O	O
paravertebral	B-ANAT
lesions	B-DISO
,	O	O
which	O	O
are	O	O
clinically	B-PHYS
and	O	O
radiologically	O
difficult	O	O
to	O	O
approach	O	O
.	O	O

It	O	O
helps	O	O
in	O	O
the	O	O
early	B-PROC
diagnosis	I-PROC
and	O	O
management	B-PROC
of	I-PROC
these	I-PROC
patients	I-PROC
.	O	O

Mediation	O
Analysis	O
for	O	O
Health	B-DISO
Disparities	I-DISO
Research	B-PROC
Social	O	O
epidemiologists	B-LIVB
often	O	O
seek	O	O
to	O	O
determine	O	O
the	O	O
mechanisms	O
that	O	O
underlie	O	O
health	B-DISO
disparities	I-DISO
.	O	O

This	O	O
work	O	O
is	O	O
typically	O	O
based	O	O
on	O	O
mediation	O
procedures	O
that	O	O
may	O	O
not	O	O
be	O	O
justified	O	O
with	O	O
exposures	B-DISO
of	O	O
common	O
interest	B-PHYS
in	O	O
social	O
epidemiology	O
.	O	O

In	O	O
this	O	O
analysis	O
,	O	O
we	O	O
explored	O	O
the	O	O
consequences	O
of	O
using	O	O
standard	O
approaches	O
,	O	O
referred	O	O
to	O	O
as	O	O
the	O	O
difference	O
and	O	O
generalized	O
product	O
methods	O
,	O	O
when	O	O
mediator	O
-	O
outcome	O
confounders	O
are	O	O
associated	O	O
with	O	O
the	O	O
exposure	B-DISO
.	O	O

We	O	O
compared	O	O
these	O	O
with	O	O
inverse	O
probability	O
-weighted	O	O
marginal	O	O
structural	B-OBJC
models	I-OBJC
,	O	O
the	O	O
structural	O
transformation	O
method	O
,	O	O
doubly	B-DISO
robust	O
g	O
-	O
estimation	O
of	O	O
a	O	O
structural	B-DEVI
nested	I-DEVI
model	I-DEVI
,	O	O
and	O	O
doubly	B-DISO
robust	O
targeted	O	O
minimum	O
loss	O
-based	O	O
estimation	O
.	O	O

We	O	O
used	O	O
data	O
on	O	O
900	O	O
,	O	O
726	O	O
births	B-PHYS
from	O	O
2003	O	O
to	O	O
2007	O	O
in	O	O
the	O	O
Penn	B-PROC
Moms	I-PROC
study	I-PROC
,	O	O
conducted	O	O
in	O	O
Pennsylvania	B-GEOG
,	O	O
to	O	O
assess	O	O
the	O	O
extent	O	O
to	O	O
which	O	O
breastfeeding	B-PHYS
prior	O
to	O
hospital	B-PROC
discharge	I-PROC
explained	O	O
the	O	O
racial	B-DISO
disparity	I-DISO
in	O	O
infant	O
mortality	O
.	O	O

Overall	O	O
,	O	O
for	O
every	O
1	O	O
,	O	O
000	O	O
births	B-PHYS
,	O	O
3	O	O
.	O	O
36	O	O
more	O	O
infant	B-DISO
deaths	I-DISO
occurred	O	O
among	O	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
black	I-LIVB
women	I-LIVB
relative	O	O
to	O	O
all	O	O
other	O	O
women	B-LIVB
(	O	O
95	O	O
%	O	O
confidence	O
interva	O
l	O	O
:	O	O
2	O	O
.	O	O
78	O	O
,	O	O
3	O	O
.	O	O
93	O	O
)	O	O
.	O	O

Using	O	O
the	O	O
difference	O	O
and	O	O
generalized	O
product	O
methods	O
to	O	O
assess	O	O
the	O	O
disparity	B-DISO
that	O	O
would	O	O
remain	O	O
if	O	O
everyone	O	O
breastfed	B-PHYS
prior	O
to	O
discharge	B-PROC
suggested	O	O
a	O	O
complete	O
elimination	O
of	O	O
the	O	O
disparity	B-DISO
(	O	O
risk	O
difference	O
=	O	O
-0	O	O
.	O	O

87	O	O
per	O	O
1	O	O
,	O	O
000	O	O
births	B-PHYS
;	O	O
95	O	O
%	O	O
confidence	O
interval	O
:	O	O
-1	O	O
.	O	O
39	O	O
,	O	O
-0	O	O
.	O	O
35	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
doubly	B-DISO
robust	O
methods	O	O
suggested	O
a	O	O
reduction	B-PROC
in	O	O
the	O	O
disparity	B-DISO
to	O	O
2	O	O
.	O	O

45	O	O
(	O	O
95	O	O
%	O	O
confidence	O
interva	O
l	O	O
:	O	O
2	O	O
.	O	O
20	O	O
,	O	O
2	O	O
.	O	O
71	O	O
)	O	O
more	O	O
infant	B-DISO
deaths	I-DISO
per	O	O
1	O	O
,	O	O
000	O	O
births	B-PHYS
among	O	O
non	B-LIVB
-	I-LIVB
Hispanic	I-LIVB
black	I-LIVB
women	I-LIVB
.	O	O

Standard	O
approaches	O
for	O	O
mediation	O
analysis	O
in	O	O
health	B-DISO
disparities	I-DISO
research	O	O
can	O	O
yield	O	O
misleading	O
results	O
.	O	O

Integrating	O
Evidence	O
From	O	O
Systematic	O
Reviews	O
,	O	O
Qualitative	B-PROC
Research	I-PROC
,	O	O
and	O	O
Expert	B-LIVB
Knowledge	O
Using	O	O
Co	O
-	O
Design	O
Techniques	O
to	O	O
Develop	O	O
a	O	O
Web	B-OBJC
-Based	O	O
Intervention	B-PROC
for	O	O
People	B-LIVB
in	O	O
the	O	O
Retirement	B-DISO
Transition	O
Integrating	O
stakeholder	B-LIVB
involvement	O
in	O	O
complex	O
health	O
intervention	B-PROC
design	O
maximizes	O	O
acceptability	O
and	O	O
potential	O	O
effectiveness	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
little	O	O
methodological	O
guidance	O
about	O	O
how	O	O
to	O	O
integrate	O
evidence	O
systematically	O
from	O	O
various	O	O
sources	O
in	O	O
this	O	O
process	B-PHEN
.	O	O

Scientific	O
evidence	O
derived	O	O
from	O	O
different	O	O
approaches	O
can	O	O
be	O	O
difficult	O	O
to	O	O
integrate	O
and	O	O
the	O	O
problem	B-DISO
is	O	O
compounded	O	O
when	O	O
attempting	O	O
to	O	O
include	O	O
diverse	O
,	O	O
subjective	O
input	O
from	O	O
stakeholders	B-LIVB
.	O	O

The	O	O
intent	O	O
of	O	O
the	O	O
study	B-PROC
was	O	O
to	O	O
describe	O	O
and	O	O
appraise	O	O
a	O	O
systematic	O
,	O	O
sequential	O
approach	O
to	O	O
integrate	O
scientific	O
evidence	O
,	O	O
expert	B-LIVB
knowledge	O
and	O	O
experience	B-PHYS
,	O	O
and	O	O
stakeholder	B-LIVB
involvement	O
in	O	O
the	O	O
co	O
-	O
design	O
and	O	O
development	O
of	O	O
a	O	O
complex	O
health	O
intervention	B-PROC
.	O	O

The	O	O
development	O
of	O	O
a	O	O
Web	B-OBJC
-based	O	O
lifestyle	O
intervention	B-PROC
for	O	O
people	B-LIVB
in	O	O
retirement	B-DISO
is	O	O
used	O	O
as	O	O
an	O	O
example	O	O
.	O	O

Evidence	O
from	O	O
three	O	O
systematic	O
reviews	O
,	O	O
qualitative	B-PROC
research	I-PROC
findings	O
,	O	O
and	O	O
expert	B-LIVB
knowledge	O
was	O	O
compiled	O	O
to	O	O
produce	O	O
evidence	O
statements	O
(	O	O
stage	O
1	O	O
)	O	O
.	O	O

Face	O
validity	O
of	O	O
these	O	O
statements	O
was	O	O
assessed	O
by	O	O
key	O	O
stakeholders	B-LIVB
in	O	O
a	O	O
co	O
-	O
design	O
workshop	O
resulting	O	O
in	O	O
a	O	O
set	O	O
of	O	O
intervention	B-PROC
principles	O
(	O	O
stage	O
2	O	O
)	O	O
.	O	O

These	O	O
principles	O
were	O	O
assessed	O
for	O	O
face	O
validity	O
in	O	O
a	O	O
second	O	O
workshop	O
,	O	O
resulting	O	O
in	O	O
core	O
intervention	B-PROC
concepts	O
and	O	O
hand	O
-	O
drawn	O
prototypes	O
(	O	O
stage	O
3	O	O
)	O	O
.	O	O

The	O	O
outputs	O
from	O	O
stages	O
1	O	O
-	O	O
3	O	O
were	O	O
translated	O
into	O	O
a	O	O
design	O
brief	O
and	O	O
specification	O
(	O	O
stage	O
4	O	O
)	O	O
,	O	O
which	O	O
guided	O	O
the	O	O
building	O
of	O	O
a	O	O
functioning	O
prototype	O
,	O	O
Web	B-OBJC
-based	O	O
intervention	B-PROC
(	O	O
stage	O
5	O	O
)	O	O
.	O	O

This	O	O
prototype	O
was	O	O
de	O	O
-	O	O
risked	O	O
resulting	O	O
in	O	O
an	O	O
optimized	O	O
functioning	O
prototype	O
(	O	O
stage	O
6	O	O
)	O	O
,	O	O
which	O	O
was	O	O
subject	O	O
to	O	O
iterative	O	O
testing	O
and	O	O
optimization	O
(	O	O
stage	O
7	O	O
)	O	O
,	O	O
prior	O	O
to	O	O
formal	O	O
pilot	B-LIVB
evaluation	O
.	O	O

The	O	O
evidence	O
statements	O
(	O	O
stage	O
1	O	O
)	O	O
highlighted	O	O
the	O	O
effectiveness	O
of	O	O
physical	O
activity	O
,	O	O
dietary	B-OBJC
and	O	O
social	O
role	O
interventions	B-PROC
in	O	O
retirement	B-DISO
;	O	O
the	O	O
idiosyncratic	B-DISO
nature	I-DISO
of	O	O
retirement	B-DISO
and	O	O
well	O
-	O
being	O
;	O	O
the	O	O
value	O
of	O	O
using	O	O
specific	O	O
behavior	O
change	O
techniques	O
including	O	O
those	O	O
derived	O	O
from	O	O
the	O	O
Health	B-PROC
Action	I-PROC
Process	I-PROC
Approach	I-PROC
;	O	O
and	O	O

the	O	O
need	O	O
for	O	O
signposting	O	O
to	O	O
local	O
resources	O
.	O	O

The	O	O
intervention	B-PROC
principles	O
(	O	O
stage	O
2	O	O
)	O	O
included	O	O
the	O	O
need	O	O
to	O	O
facilitate	O	O
self	O	O
-	O	O
reflection	O	O
on	O	O
available	O	O
resources	O
,	O	O
personalization	B-DISO
,	O	O
and	O	O
promotion	B-PROC
of	O	O
links	O
between	O	O
key	O	O
lifestyle	O
behaviors	O
.	O	O

The	O	O
core	O
concepts	O
and	O	O
hand	O
-	O
drawn	O
prototypes	O
(	O	O
stage	O
3	O	O
)	O	O
had	O	O
embedded	O	O
in	O	O
them	O	O
the	O	O
importance	O	O
of	O	O
time	O
use	O
and	O	O
work	O
exit	O
planning	O
,	O	O
personalized	B-DISO
goal	I-DISO
setting	I-DISO
,	O	O
and	O	O
acceptance	O
of	O	O
a	O	O
Web	B-OBJC
-based	O	O
intervention	B-PROC
.	O	O

The	O	O
design	O
brief	O	O
detailed	O	O
the	O	O
features	O
and	O	O
modules	O
required	O	O
(	O	O
stage	O
4	O	O
)	O	O
,	O	O
guiding	O
the	O	O
development	O
of	O	O
wireframes	O
,	O	O
module	O
content	O
and	O	O
functionality	O
,	O	O
virtual	B-LIVB
mentors	I-LIVB
,	O	O
and	O	O
intervention	B-PROC
branding	O
(	O	O
stage	O
5	O	O
)	O	O
.	O	O

Following	O	O
an	O	O
iterative	O	O
process	B-PHEN
of	O	O
intervention	B-PROC
testing	O
and	O	O
optimization	O
(	O	O
stage	O
6	O	O
)	O	O
,	O	O
the	O	O
final	O	O
Web	B-OBJC
-based	O	O
intervention	B-PROC
prototype	O
of	O	O
LEAP	O
(	O	O
Living	O
,	O	O
Eating	B-PHYS
,	O	O
Activity	O
,	O	O
and	O	O
Planning	O
in	O	O
retirement	B-DISO
)	O	O
was	O	O
produced	O	O
(	O	O
stage	O
7	O	O
)	O	O
.	O	O

The	O	O
approach	O
was	O	O
resource	O
intensive	O	O
and	O	O
required	O	O
a	O	O
multidisciplinary	B-LIVB
team	I-LIVB
.	O	O

The	O	O
design	O
expert	B-LIVB
made	O	O
an	O	O
invaluable	O	O
contribution	O	O
throughout	O	O
the	O	O
process	B-PHEN
.	O	O

Our	O	O
sequential	O
approach	O
fills	O	O
an	O	O
important	O	O
methodological	O
gap	O
in	O	O
the	O	O
literature	O
,	O	O
describing	O	O
the	O	O
stages	O
and	O	O
techniques	O
useful	O	O
in	O	O
developing	O	O
an	O	O
evidence	O
-based	O	O
complex	O
health	O
intervention	B-PROC
.	O	O

The	O	O
systematic	O
and	O	O
rigorous	O
integration	O
of	O	O
scientific	O
evidence	O
,	O	O
expert	B-LIVB
knowledge	O
and	O	O
experience	B-PHYS
,	O	O
and	O	O
stakeholder	B-LIVB
input	O
has	O	O
resulted	O	O
in	O	O
an	O	O
intervention	B-PROC
likely	O	O
to	O	O
be	O	O
acceptable	O	O
and	O	O
feasible	O	O
.	O	O

Transcriptome	B-PROC
profiling	I-PROC
of	O	O
the	O	O
green	B-LIVB
alga	I-LIVB
Spirogyra	B-LIVB
pratensis	I-LIVB
(	O	O
Charophyta	B-LIVB
)	O	O
suggests	O	O
an	O	O
ancestral	O	O
It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
ethylene	B-CHEM
regulates	O	O
a	O	O
diverse	O	O
set	O	O
of	O	O
developmental	B-PHYS
and	O	O
stress	B-DISO
-	I-DISO
related	I-DISO
processes	I-DISO
in	O	O
angiosperms	B-LIVB
,	O	O
yet	O	O
its	O	O
roles	O	O
in	O	O
early	O	O
diverging	O	O
embryophytes	B-LIVB
and	O	O
algae	O
are	O	O
poorly	O	O
understood	O	O
.	O	O

Recently	O	O
,	O	O
it	O	O
was	O	O
shown	O	O
that	O	O
ethylene	B-CHEM
functions	O	O
as	O	O
a	O	O
hormone	B-CHEM
in	O	O
the	O	O
charophyte	B-LIVB
green	B-LIVB
alga	I-LIVB
Spirogyra	B-LIVB
pratensis	I-LIVB
.	O	O

Since	O	O
land	B-LIVB
plants	I-LIVB
evolved	O
from	O	O
Charophytes	B-LIVB
,	O	O
this	O	O
implies	O	O
conservation	O
of	O	O
ethylene	B-CHEM
as	O	O
a	O	O
hormone	B-CHEM
in	O	O
green	B-LIVB
plants	I-LIVB
for	O	O
at	O	O
least	O	O
450	O	O
million	O	O
of	O	O
years	O	O
.	O	O

However	O	O
,	O	O
the	O	O
physiological	O
role	O	O
of	O	O
ethylene	B-CHEM
in	O	O
charophyte	B-LIVB
algae	O
remained	O	O
unknown	O	O
.	O	O

In	O	O
order	O	O
to	O	O
gain	O	O
insight	O	O
into	O	O
ethylene	B-PHYS
responses	I-PHYS
in	O	O
Spirogyra	B-LIVB
,	O	O
we	O	O
used	O	O
mRNA	B-CHEM
sequencing	B-PROC
to	O	O
measure	O
changes	O
in	O	O
gene	B-PHYS
expression	I-PHYS
over	O	O
time	O	O
in	O	O
Spirogyra	B-LIVB
filaments	B-ANAT
in	O	O
response	B-PHYS
to	I-PHYS
an	I-PHYS
ethylene	I-PHYS
treatment	O
.	O	O

Our	O	O
analyses	O
show	O	O
that	O	O
at	O	O
the	O	O
transcriptional	B-PHYS
level	O
,	O	O
ethylene	B-CHEM
predominantly	O	O
regulates	B-DISO
three	O	O
processes	O	O
in	O	O
Spirogyra	B-LIVB
:	O	O
(	O	O
1	O	O
)	O	O
modification	B-DISO
of	O	O
the	O	O
cell	B-ANAT
wall	I-ANAT
matrix	I-ANAT
by	O	O
expansins	B-CHEM
and	O	O
xyloglucan	B-CHEM
endotransglucosylases	I-CHEM
/	O	O
hydrolases	B-CHEM
,	O	O
(	O	O
2	O	O
)	O	O
down	B-PHYS
-	I-PHYS
regulation	I-PHYS
of	O	O
chlorophyll	B-PHYS
biosynthesis	I-PHYS
and	O	O
photosynthesis	B-PHEN
and	O	O
(	O	O
3	O	O
)	O	O
activation	O
of	O	O
abiotic	B-PHYS
stress	I-PHYS
responses	I-PHYS
.	O	O

We	O	O
confirmed	O	O
that	O	O
the	O	O
photosynthetic	B-PHEN
capacity	O
and	O	O
chlorophyll	B-CHEM
content	O
was	O	O
reduced	O
by	O	O
an	O	O
ethylene	B-CHEM
treatment	O
and	O	O
that	O	O
several	O	O
abiotic	B-PHYS
stress	I-PHYS
conditions	I-PHYS
could	O	O
stimulate	B-PROC
cell	B-PHYS
elongation	I-PHYS
in	O	O
an	O	O
ethylene	B-CHEM
-dependent	O	O
manner	O	O
.	O	O

We	O	O
also	O	O
found	O	O
that	O	O
the	O	O
Spirogyra	B-LIVB
transcriptome	O
only	O	O
harbors	O	O
10	O	O
ethylene	O
responsive	O
transcription	O
factor	O
(	O	O
ERF	O
)	O	O
homologs	O
,	O	O
several	O	O
of	O	O
which	O	O
are	O	O
regulated	O	O
by	O	O
ethylene	B-CHEM
.	O	O

These	O	O
results	O	O
provide	O	O
an	O	O
initial	O	O
understanding	O	O
of	O	O
the	O	O
hormonal	O
responses	B-PHYS
induced	O	O
by	O	O
ethylene	B-CHEM
in	O	O
Spirogyra	B-LIVB
,	O	O
and	O	O
help	O	O
to	O	O
reconstruct	O	O
the	O	O
role	O	O
of	O	O
ethylene	B-CHEM
in	O	O
ancestral	O	O
charophytes	B-LIVB
prior	O	O
to	O	O
the	O	O
origin	O	O
of	O	O
land	B-LIVB
plants	I-LIVB
.	O	O

Simultaneous	O
thrombosis	B-DISO
of	O	O
multiple	B-ANAT
coronary	I-ANAT
arteries	I-ANAT
in	O	O
a	O	O
patient	B-LIVB
with	O	O
rheumatoid	B-DISO
arthritis	I-DISO
We	O	O
present	O	O
a	O	O
case	O
of	O	O
simultaneous	O
coronary	B-DISO
thrombosis	I-DISO
of	I-DISO
the	I-DISO
left	I-DISO
main	I-DISO
,	O	O
the	O	O
left	B-ANAT
anterior	I-ANAT
descending	I-ANAT
artery	I-ANAT
and	O	O
the	O	O
right	B-ANAT
coronary	I-ANAT
artery	I-ANAT
in	O	O
a	O	O
patient	B-LIVB
,	O	O
recently	O	O
diagnosed	B-PROC
with	O	O
rheumatoid	B-DISO
arthritis	I-DISO
.	O	O

Mediastinal	B-DISO
mass	I-DISO
diagnosed	B-DISO
by	O	O
endobronchial	B-PROC
ultrasound	I-PROC
as	O	O
recurrent	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
in	O	O
a	O	O
post	O
-	O	O
liver	B-PROC
transplantation	I-PROC
patient	B-LIVB
We	O	O
presented	O	O
a	O	O
rare	O	O
case	O
of	O	O
recurrent	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
after	O	O
liver	B-PROC
transplant	I-PROC
manifested	O
as	O	O
an	O	O
isolated	O
mediastinal	B-DISO
mass	I-DISO
.	O	O

A	O	O
62	O	O
-	O	O
year	O
-	O	O
old	B-LIVB
man	I-LIVB
was	O	O
referred	O	O
for	O	O
evaluation	O	O
of	O	O
atypical	B-DISO
chest	I-DISO
pain	I-DISO
and	O	O
abnormal	B-DISO
finding	I-DISO
of	O	O
a	O	O
computed	B-PROC
tomography	I-PROC
of	I-PROC
the	I-PROC
chest	I-PROC
.	O	O

He	O	O
had	O	O
history	B-DISO
of	O	O
chronic	B-DISO
hepatitis	I-DISO
C	I-DISO
liver	I-DISO
cirrhosis	I-DISO
and	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
underwent	O	O
orthotopic	B-PROC
liver	I-PROC
transplant	I-PROC
as	O	O
a	O	O
curative	B-DISO
treatment	I-DISO
three	O
years	O
earlier	O
.	O	O

The	O	O
computed	B-PROC
tomography	I-PROC
of	I-PROC
the	I-PROC
chest	I-PROC
demonstrated	O	O
paratracheal	B-DISO
mediastinal	I-DISO
lymphadenopathy	I-DISO
.	O	O

He	O	O
subsequently	O
underwent	O	O
endobronchial	B-PROC
ultrasound	I-PROC
with	I-PROC
transbronchial	I-PROC
needle	I-PROC
aspiration	I-PROC
(	O	O
EBUS	B-PROC
-	I-PROC
TBNA	I-PROC
)	O	O
.	O	O

The	O	O
right	B-ANAT
paratracheal	I-ANAT
lymph	I-ANAT
node	I-ANAT
station	I-ANAT
4R	I-ANAT
was	O	O
sampled	O	O
.	O	O

Rapid	O	O
on	O	O
-	O	O
site	O	O
cytology	O
evaluation	O
demonstrated	O	O
recurrent	O
metastatic	B-DISO
hepatocellular	I-DISO
carcinoma	I-DISO
.	O	O

Pulmonologist	B-LIVB
should	O	O
be	O	O
cognizant	O
of	O	O
diagnostic	O
utility	O	O
of	O	O
EBUS	B-PROC
-	I-PROC
TBNA	I-PROC
in	O	O
this	O	O
clinical	O
setting	O
as	O	O
more	O	O
transplant	B-DISO
patients	B-LIVB
on	O	O
immunosuppressive	B-CHEM
medications	I-CHEM
with	O	O
enlarged	O	O
mediastinal	B-DISO
lymphadenopathy	I-DISO
of	O	O
unknown	O
origin	O
will	O	O
be	O	O
referred	O
for	O	O
further	O
evaluation	O	O
.	O	O

Phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
inhibitors	I-CHEM
:	O	O
Irrational	B-DISO
use	O
in	O	O
Saudi	B-GEOG
Arabia	I-GEOG
To	O	O
identify	B-PHYS
the	O	O
criteria	O
of	O	O
phosphodiesterase	B-CHEM
type	I-CHEM
5	I-CHEM
inhibitor	I-CHEM
(	O	O
PDE5i	B-CHEM
)	O	O
users	B-LIVB
and	O	O
to	O	O
analyse	B-PROC
the	O	O
knowledge	O
,	O	O
attitude	B-PHYS
,	O	O
and	O	O
practices	B-PHYS
of	O	O
PDE5i	B-CHEM
use	O
amongst	O	O
Saudi	O
men	O
.	O	O

A	O	O
web	B-OBJC
-	O	O
based	O
,	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O	O
conducted	O	O
in	O	O
Saudi	B-GEOG
Arabia	I-GEOG
between	O	O
January	O
and	O	O
April	O
2015	O	O
.	O	O

Sexually	B-DISO
active	I-DISO
adult	B-LIVB
men	B-LIVB
were	O	O
interviewed	O
using	O
a	O	O
website	O
questionnaire	O
designed	O	O
by	O	O
the	O	O
authors	B-LIVB
.	O	O

Descriptive	O
statistics	O
were	O	O
used	O
to	O	O
analyse	B-PROC
the	O	O
data	O
.	O	O

In	O	O
all	O	O
,	O	O
1008	O	O
men	B-LIVB
participated	O
in	O	O
the	O	O
survey	O
with	O	O
378	O	O
(	O	O
37	O	O
.	O	O
5	O	O
%	O	O
)	O	O
reporting	B-PROC
use	O
of	O	O
PDE5i	B-CHEM
.	O	O

Of	O	O
those	O	O
using	O
PDE5i	B-CHEM
,	O	O
144	O	O
(	O	O
38	O	O
.	O	O

1	O	O
%	O	O
)	O	O
reported	B-PROC
erectile	B-DISO
dysfunction	I-DISO
and	O	O
234	O	O
(	O	O
61	O	O
.	O	O

9	O	O
%	O	O
)	O	O
reported	B-PROC
normal	O
erection	B-PHYS
(	O	O
recreational	B-CHEM
users	B-LIVB
)	O	O
.	O	O

We	O	O
found	O	O
several	O	O
demographic	O
features	O
,	O	O
including	O	O
high	B-DISO
education	I-DISO
level	I-DISO
,	O	O
health	O
field	O
occupation	O
,	O	O
high	B-DISO
income	I-DISO
,	O	O
smoking	O
,	O	O
and	O	O
increased	O
frequency	O
of	O	O
sexual	B-PHYS
intercourse	I-PHYS
amongst	O	O
the	O	O
PDE5i	B-CHEM
users	B-LIVB
.	O	O

Most	O	O
of	O	O
the	O	O
PDE5i	B-CHEM
users	B-LIVB
(	O	O
92	O	O
.	O	O
3	O	O
%	O	O
)	O	O
had	O	O
knowledge	O
about	O	O
PDE5i	B-CHEM
and	O	O
84	O	O
.	O	O

1	O	O
%	O	O
of	O	O
them	O	O
bought	O	O
it	O	O
without	O	O
medical	O
prescription	O
.	O	O

The	O	O
most	O	O
commonly	O	O
used	O
PDE5i	B-CHEM
was	O	O
tadalafil	B-CHEM
(	O	O
46	O	O
.	O	O
1	O	O
%	O	O
)	O	O
and	O	O
most	O	O
of	O	O
the	O	O
users	B-LIVB
(	O	O
79	O	O
.	O	O
9	O	O
%	O	O
)	O	O
reported	B-PROC
improvement	O
in	O	O
their	O	O
sexual	O
activity	O
after	O	O
PDE5i	B-CHEM
usage	O
.	O	O

Amongst	O	O
the	O	O
recreational	B-PHYS
users	B-LIVB
,	O	O
the	O	O
main	O	O
reasons	B-DISO
for	O	O
PDE5i	B-CHEM
usage	O
were	O	O
curiosity	O
(	O	O
38	O	O
.	O	O
5	O	O
%	O	O
)	O	O
and	O	O
improving	O
self	B-PHYS
-	I-PHYS
confidence	I-PHYS
(	O	O
25	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

Of	O	O
them	O	O
,	O	O
69	O	O
.	O	O
2	O	O
%	O	O
reported	B-PROC
benefits	O
from	O	O
PDE5i	B-CHEM
usage	O
,	O	O
mainly	O	O
in	O	O
the	O	O
form	O	O
of	O	O
enhancement	O
of	O	O
erection	B-PHYS
(	O	O
36	O	O
.	O	O
7	O	O
%	O	O
)	O	O
and	O	O
increasing	O
erection	B-DISO
duration	I-DISO
(	O	O
31	O	O
.	O	O
2	O	O
%	O	O
)	O	O
.	O	O

PDE5i	B-CHEM
use	O
appears	O	O
to	O	O
be	O	O
frequent	O
in	O	O
Saudi	B-GEOG
Arabia	I-GEOG
.	O	O

Most	O	O
of	O	O
the	O	O
users	B-LIVB
had	O	O
knowledge	O
about	O	O
PDE5i	B-CHEM
and	O	O
claimed	O	O
to	O	O
get	O	O
benefits	O
from	O	O
it	O	O
,	O	O
even	O	O
if	O	O
used	O
as	O	O
a	O	O
recreational	B-CHEM
drug	I-CHEM
.	O	O

Microarray	B-PROC
-	I-PROC
Based	I-PROC
Analysis	I-PROC
of	O	O
Methylation	B-PHYS
of	O	O
1st	O
Trimester	O
Trisomic	B-ANAT
Placentas	I-ANAT
from	O	O
Down	B-DISO
Syndrome	I-DISO
,	O	O
Edwards	B-DISO
Syndrome	I-DISO
and	I-DISO
Patau	I-DISO
Syndrome	I-DISO
Methylation	B-PHYS
-based	O	O
non	O
-	O
invasive	O
prenatal	O
testing	O
of	O
fetal	O
aneuploidies	O
is	O	O
an	O	O
alternative	O
method	B-PROC
that	O	O
could	O	O
possibly	O	O
improve	B-DISO
fetal	B-PROC
aneuploidy	I-PROC
diagnosis	I-PROC
,	I-PROC
especially	I-PROC
for	I-PROC
trisomy	I-PROC
13	I-PROC
(	I-PROC
T13	I-PROC
)	I-PROC
and	I-PROC
trisomy	I-PROC
18	I-PROC
(	I-PROC
T18	I-PROC
)	I-PROC
.	O	O

Our	O	O
aim	O
was	O	O
to	O	O
study	B-PROC
the	O	O
methylation	B-PHYS
landscape	O
in	O	O
placenta	B-ANAT
DNA	B-CHEM
from	O	O
trisomy	B-DISO
13	I-DISO
,	I-DISO
18	I-DISO
and	I-DISO
21	I-DISO
pregnancies	B-PHYS
in	O	O
an	O	O
attempt	O	O
to	O	O
find	O	O
trisomy	B-DISO
-specific	O	O
methylation	B-PHYS
differences	O
better	O	O
suited	O	O
for	O	O
non	O
-	O
invasive	O
prenatal	B-PROC
diagnosis	I-PROC
.	O	O

We	O	O
have	O	O
conducted	O	O
high	B-PROC
-	I-PROC
resolution	I-PROC
methylation	B-PHYS
specific	O	O
bead	B-PROC
chip	I-PROC
microarray	I-PROC
analyses	I-PROC
assessing	O
more	O	O
than	O	O
450	O	O
,	O	O
000	O	O
CpGs	B-CHEM
analyzing	O	O
placentas	B-ANAT
from	O	O
12	O	O
T21	B-DISO
pregnancies	B-PHYS
,	O	O
12	O	O
T18	B-DISO
pregnancies	B-PHYS
and	O	O
6	O	O
T13	B-DISO
pregnancies	B-PHYS
.	O	O

We	O	O
have	O	O
compared	O	O
the	O	O
methylation	B-PHYS
landscape	O
of	O	O
the	O	O
trisomic	B-ANAT
placentas	I-ANAT
to	O	O
the	O	O
methylation	B-PHYS
landscape	O
from	O	O
normal	O
placental	B-ANAT
DNA	B-CHEM
and	O	O
to	O	O
maternal	B-DISO
blood	B-ANAT
cell	I-ANAT
DNA	B-CHEM
.	O	O

Comparing	O	O
trisomic	B-ANAT
placentas	I-ANAT
to	O	O
normal	O
placentas	B-ANAT
we	O	O
identified	O	O
217	O	O
and	O	O
219	O	O
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
for	O	O
CVS	B-PROC
T18	B-DISO
and	O	O
CVS	B-PROC
T13	B-DISO
,	O	O
respectively	O	O
(	O	O
delta	O	O
β	O	O
>	O	O
0	O	O
.	O	O
2	O	O
,	O	O
FDR	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
but	O	O
only	O	O
three	O	O
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
for	O	O
T21	B-DISO
.	O	O

However	O	O
,	O	O
the	O	O
methylation	B-PHYS
differences	O
was	O	O
only	O	O
modest	O	O
(	O	O
delta	O	O
β	O	O
<	O	O
0	O	O
.	O	O
4	O	O
)	O	O
,	O	O
making	O	O
them	O	O
less	O	O
suitable	O	O
as	O	O
diagnostic	B-PHYS
markers	I-PHYS
.	O	O

Gene	O
ontology	O
enrichment	O
analysis	B-PROC
revealed	O
that	O	O
the	O	O
gene	O
set	O
connected	O
to	O	O
the	O	O
T18	B-DISO
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
was	O	O
highly	O
enriched	O	O
for	O	O
GO	O
terms	O	O
related	O	O
to	O	O
""""	O	O
DNA	B-PHYS
binding	I-PHYS
""""	O	O
and	O	O
""""	O	O
transcription	B-PHYS
factor	I-PHYS
binding	I-PHYS
""""	O	O
coupled	O
to	O	O
the	O	O
RNA	B-CHEM
polymerase	I-CHEM
II	I-CHEM
transcription	B-PHYS
.	O	O

In	O	O
the	O	O
gene	O
set	O
connected	O
to	O	O
the	O	O
T13	B-DISO
differentially	O
methylated	B-PHYS
CpGs	B-CHEM
we	O	O
found	O	O
no	B-DISO
significant	I-DISO
enrichments	O
.	O	O

Assessment	B-PROC
of	O	O
Early	O
Treatment	B-PHYS
Response	I-PHYS
With	O	O
DWI	B-PROC
After	O	O
CT	B-PROC
-Guided	O	O
Radiofrequency	B-PROC
Ablation	I-PROC
of	O	O
Functioning	O
Adrenal	B-DISO
Adenomas	I-DISO
The	O	O
objective	O	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
establish	O	O
the	O	O
suitability	O	O
of	O	O
the	O	O
apparent	O
diffusion	O
coefficient	O
(	O	O
ADC	O
)	O	O
as	O	O
a	O	O
parameter	O
for	O	O
evaluating	O	O
early	O
treatment	B-PHYS
response	I-PHYS
after	O	O
percutaneous	O
ablation	B-PROC
of	O	O
functional	O
adrenal	B-DISO
adenomas	I-DISO
.	O	O

Seventeen	O	O
adult	B-LIVB
patients	B-LIVB
with	O	O
functioning	O	O
adrenal	B-DISO
adenomas	I-DISO
underwent	O	O
radiofrequency	B-PROC
ablation	I-PROC
.	O	O

Serum	B-ANAT
hormone	B-CHEM
levels	O
were	O	O
analyzed	B-PROC
before	O	O
and	O	O
up	O	O
to	O	O
6	O	O
months	O
after	O	O
ablation	B-PROC
.	O	O

MRI	B-PROC
findings	B-DISO
(	O	O
nodule	O
size	O
in	O	O
cm	O	O
,	O	O
signal	O
intensity	O
index	O
,	O	O
ADC	O
maps	O
,	O	O
and	O	O
nodule	O
-	O
to	O
-	O
muscle	O
ADC	O
ratio	O
)	O	O
were	O	O
analyzed	B-PROC
before	O	O
and	O	O
up	O	O
to	O	O
30	O	O
days	O
after	O	O
ablation	B-PROC
.	O	O

A	O	O
consensus	O
review	O
of	O	O
all	O	O
scans	B-PROC
was	O	O
performed	O	O
by	O	O
two	O	O
attending	O	O
abdominal	B-LIVB
imaging	I-LIVB
radiologists	I-LIVB
.	O	O

The	O	O
procedure	O	O
was	O	O
considered	O	O
successful	O	O
if	O	O
serum	B-ANAT
hormone	B-CHEM
levels	O
normalized	B-PROC
and	O	O
no	B-DISO
contrast	O
enhancement	O
of	O	O
the	O	O
adrenal	B-ANAT
lesion	B-DISO
was	O	O
seen	O	O
on	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
MRI	B-PROC
.	O	O

Of	O	O
17	O	O
patients	B-LIVB
who	O	O
underwent	O	O
radiofrequency	B-PROC
ablation	I-PROC
,	O	O
complete	B-DISO
response	I-DISO
was	O	O
achieved	O	O
in	O	O
16	O	O
patients	B-LIVB
with	O	O
partial	B-DISO
response	I-DISO
in	O	O
one	O	O
patient	B-LIVB
.	O	O

Of	O	O
the	O	O
four	O	O
parameters	O
of	O	O
interest	O	O
,	O	O
only	O	O
ADC	O
maps	O
and	O	O
nodule	O
-	O
to	O
-	O
muscle	O
ADC	O
ratio	O
showed	O	O
statistically	O
significant	O
differences	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

This	O	O
prospective	B-PROC
study	I-PROC
suggests	O	O
that	O	O
apparent	O
diffusion	O
coefficient	O
values	O	O
may	O	O
help	O	O
radiologists	B-LIVB
monitor	B-PROC
early	O
treatment	B-PHYS
response	I-PHYS
after	O	O
CT	B-PROC
-guided	O	O
radiofrequency	B-PROC
ablation	I-PROC
of	O	O
functioning	O	O
adrenal	B-DISO
adenomas	I-DISO
.	O	O

TLR	B-CHEM
and	O	O
NLRP3	B-CHEM
inflammasome	B-CHEM
-	O	O
dependent	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
to	O	O
tumor	O
-	O
derived	O
autophagosomes	B-ANAT
(	O	O
DRibbles	B-ANAT
)	O	O
Autophagosomes	B-ANAT
derived	O
from	O	O
tumor	B-ANAT
cells	I-ANAT
,	O	O
also	O	O
referred	O	O
to	O	O
as	O	O
defective	B-ANAT
ribosomal	I-ANAT
products	I-ANAT
in	O	O
blebs	B-DISO
(	O	O
DRibbles	B-ANAT
)	O	O
,	O	O
have	O	O
been	O	O
previously	O	O
shown	O	O
to	O	O
stimulate	O
potent	O	O
T	B-ANAT
-	I-ANAT
cell	I-ANAT
responses	B-PHYS
and	O	O
mediate	O	O
tumor	B-PHYS
regression	I-PHYS
when	O	O
used	O	O
as	O	O
therapeutic	O
cancer	B-CHEM
vaccines	I-CHEM
in	O	O
multiple	O
preclinical	O
cancer	B-DISO
models	I-DISO
.	O	O

In	O	O
this	O	O
report	O
,	O	O
we	O	O
investigated	O
the	O	O
underlining	O	O
mechanisms	O
by	O	O
which	O	O
DRibbles	B-ANAT
induced	O
T	B-PHYS
-	I-PHYS
cell	I-PHYS
activation	I-PHYS
,	O	O
particularly	O	O
how	O	O
DRibbles	B-ANAT
activated	B-PHYS
antigen	B-ANAT
-	I-ANAT
presenting	I-ANAT
cells	I-ANAT
(	O	O
APCs	B-ANAT
)	O	O
.	O	O

We	O	O
found	O	O
that	O	O
DRibbles	B-ANAT
could	O	O
induce	O
a	O	O
rapid	O	O
differentiation	B-PHYS
of	O	O
monocytes	B-ANAT
and	O	O
DC	B-ANAT
precursor	I-ANAT
(	I-ANAT
pre	I-ANAT
-	I-ANAT
DC	I-ANAT
)	I-ANAT
cells	I-ANAT
into	O	O
functional	O
APCs	B-ANAT
.	O	O

DRibbles	B-ANAT
triggered	O
innate	B-PHYS
receptor	I-PHYS
signaling	I-PHYS
via	O	O
Toll	B-CHEM
-	I-CHEM
like	I-CHEM
Receptors	I-CHEM
(	I-CHEM
TLR	I-CHEM
)	I-CHEM
-	I-CHEM
2	I-CHEM
,	O	O
TLR4	B-CHEM
,	O	O
TLR7	B-CHEM
,	O	O
TLR8	B-CHEM
,	O	O
and	O	O
nucleotide	B-CHEM
-	I-CHEM
binding	I-CHEM
oligomerization	I-CHEM
domain	I-CHEM
-	I-CHEM
containing	I-CHEM
protein	I-CHEM
2	I-CHEM
(	O	O
NOD2	B-CHEM
)	O	O
,	O	O
but	O	O
not	O	O
TLR3	B-CHEM
,	O	O
TLR5	B-CHEM
,	O	O
or	O	O
TLR9	B-CHEM
.	O	O

DRibbles	B-ANAT
induced	O
PBMCs	B-ANAT
to	O	O
produce	O	O
pro	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
cytokines	I-CHEM
,	O	O
such	O	O
as	O	O
IL	B-CHEM
-	I-CHEM
6	I-CHEM
,	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
,	O	O
TNF	B-CHEM
-	I-CHEM
α	I-CHEM
,	O	O
and	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
.	O	O

DRibbles	B-ANAT
induced	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
release	O
from	O	O
PBMC	B-ANAT
or	O	O
THP	B-ANAT
-	I-ANAT
1	I-ANAT
cells	I-ANAT
without	O	O
LPS	B-CHEM
priming	O
,	O	O
but	O	O
required	O	O
the	O	O
core	O
machinery	O
of	O	O
NLRP3	B-ANAT
inflammasomes	I-ANAT
.	O	O

Active	O
endocytosis	B-PHYS
was	O	O
required	O	O
for	O	O
inflammasome	B-PHYS
activation	I-PHYS
and	O	O
cross	B-PHYS
presentation	I-PHYS
,	O	O
and	O	O
blocking	O
endosome	B-ANAT
acidification	B-PHYS
or	O	O
the	O	O
ER	B-PHYS
-	I-PHYS
associated	I-PHYS
degradation	I-PHYS
(	I-PHYS
ERAD	I-PHYS
)	I-PHYS
pathway	I-PHYS
resulted	O	O
in	O	O
opposite	O	O
effects	O
on	O	O
these	O	O
two	O	O
processes	B-PHEN
.	O	O

Our	O	O
data	O
show	O	O
that	O	O
DRibbles	B-ANAT
could	O	O
induce	O
strong	O	O
innate	B-PHYS
immune	I-PHYS
responses	I-PHYS
via	O	O
multiple	O
pattern	B-CHEM
recognition	I-CHEM
receptors	I-CHEM
,	O	O
and	O	O
explain	O	O
why	O	O
DRibbles	B-ANAT
could	O	O
function	O
as	O	O
excellent	O	O
antigen	B-CHEM
carriers	O
to	O	O
induce	O
adaptive	B-PHYS
immune	I-PHYS
responses	I-PHYS
to	O	O
both	O	O
tumor	B-ANAT
cells	I-ANAT
and	O	O
viruses	B-LIVB
.	O	O

In	O	O
contrast	O	O
to	O	O
the	O	O
well	O	O
-	O	O
established	O	O
inhibitory	B-PHYS
effect	I-PHYS
of	O	O
autophagy	B-PHYS
on	O	O
the	O	O
inflammasome	B-PHYS
activation	I-PHYS
of	O	O
APCs	B-ANAT
,	O	O
our	O	O
study	B-PROC
demonstrates	O	O
that	O	O
isolated	O
autophagosomes	B-ANAT
(	O	O
DRibbles	B-ANAT
)	O	O
from	O	O
antigen	B-CHEM
donor	B-ANAT
cells	I-ANAT
activate	B-PHYS
inflammasomes	I-PHYS
by	O	O
providing	O	O
first	O
and	O	O
second	O
signals	B-PHEN
required	O	O
for	O	O
IL	B-CHEM
-	I-CHEM
1β	I-CHEM
production	O
by	O	O
PMBC	B-ANAT
.	O	O

Self	B-PHYS
-	I-PHYS
assembled	I-PHYS
half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
polyhedral	O
cages	B-CHEM
via	O	O
flexible	O
Schiff	B-CHEM
-	I-CHEM
base	I-CHEM
ligands	I-CHEM
:	O	O
an	O	O
unusual	O	O
macrocycle	B-CHEM
-to	O	O
-	O	O
cage	B-CHEM
conversion	O
An	O	O
edge	O
-directed	O	O
strategy	O	O
was	O	O
adopted	O	O
to	O	O
construct	O	O
highly	O
ordered	O
polyhedral	O
structures	O
using	O	O
flexible	O
functions	O
.	O	O

Half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
M6	B-CHEM
(	I-CHEM
L1	I-CHEM
)	I-CHEM
4	I-CHEM
octahedral	O
and	O	O
M8	B-CHEM
(	I-CHEM
L2	I-CHEM
)	I-CHEM
4	I-CHEM
cubic	O
cages	B-CHEM
have	O	O
been	O	O
assembled	B-PHYS
by	O	O
flexible	O
Schiff	B-CHEM
-	I-CHEM
base	I-CHEM
ligands	I-CHEM
upon	O	O
coordination	O	O
to	O	O
Cp	B-CHEM
*	I-CHEM
Rh	I-CHEM
(	I-CHEM
iii	I-CHEM
)	I-CHEM
organometallic	I-CHEM
acceptors	I-CHEM
.	O	O

In	O	O
particular	O	O
,	O	O
the	O	O
rearrangement	B-PHEN
from	O	O
a	O	O
Rh	B-CHEM
(	I-CHEM
iii	I-CHEM
)	I-CHEM
-based	O	O
half	B-CHEM
-	I-CHEM
sandwich	I-CHEM
M2	B-CHEM
(	I-CHEM
HL1	I-CHEM
)	I-CHEM
2	I-CHEM
macrocycle	B-CHEM
to	O	O
M6	B-CHEM
(	I-CHEM
L1	I-CHEM
)	I-CHEM
4	I-CHEM
cage	B-CHEM
was	O	O
found	O	O
to	O	O
occur	O	O
in	O	O
a	O	O
solution	B-OBJC
.	O	O

Neonatal	B-DISO
infections	I-DISO
:	O	O
Case	O
definition	O
and	O	O
guidelines	O
for	O	O
data	B-PROC
collection	I-PROC
,	O	O
analysis	B-PROC
,	O	O
and	O	O
presentation	O
of	O	O
immunisation	B-PROC
safety	O
data	O
Maternal	B-DISO
vaccination	B-PROC
is	O	O
an	O	O
important	O	O
area	O	O
of	O	O
research	B-PROC
and	O	O
requires	O	O
appropriate	O	O
and	O	O
internationally	O	O
comparable	O	O
definitions	O
and	O	O
safety	O
standards	O
.	O	O

The	O	O
GAIA	B-LIVB
group	I-LIVB
,	O	O
part	O	O
of	O	O
the	O	O
Brighton	B-LIVB
Collaboration	I-LIVB
was	O	O
created	O	O
with	O	O
the	O	O
mandate	O	O
of	O	O
proposing	O	O
standardised	O	O
definitions	O
applicable	O	O
to	O	O
maternal	B-DISO
vaccine	B-CHEM
research	B-PROC
.	O	O

This	O	O
study	B-PROC
proposes	O	O
international	O	O
definitions	O
for	O	O
neonatal	B-DISO
infections	I-DISO
.	O	O

The	O	O
neonatal	B-DISO
infections	I-DISO
GAIA	B-LIVB
working	B-LIVB
group	I-LIVB
performed	O	O
a	O	O
literature	O
review	O
using	O	O
Medline	O
,	O	O
EMBASE	O
and	O	O
the	O	O
Cochrane	O
collaboration	O
and	O	O
collected	O	O
definitions	O
in	O	O
use	O	O
in	O	O
neonatal	O
and	O	O
public	O
health	O
networks	O
.	O	O

The	O	O
common	O	O
criteria	O
derived	O
from	O	O
the	O	O
extensive	O	O
search	O	O
formed	O	O
the	O	O
basis	O	O
for	O	O
a	O	O
consensus	O
process	O
that	O	O
resulted	O	O
in	O	O
three	O	O
separate	O	O
definitions	O
for	O	O
neonatal	B-LIVB
blood	B-DISO
stream	I-DISO
infections	I-DISO
(	O	O
BSI	B-DISO
)	O	O
,	O	O
meningitis	B-DISO
and	O	O
lower	B-DISO
respiratory	I-DISO
tract	I-DISO
infections	I-DISO
(	O	O
LRTI	B-DISO
)	O	O
.	O	O

For	O	O
each	O	O
definition	O
three	O	O
levels	O	O
of	O	O
evidence	O	O
are	O	O
proposed	O	O
to	O	O
ensure	O	O
the	O	O
applicability	O	O
of	O	O
the	O	O
definitions	O
to	O	O
different	O	O
settings	O	O
.	O	O

Recommendations	O	O
about	O	O
data	B-PROC
collection	I-PROC
,	O	O
analysis	B-PROC
and	O	O
presentation	O
are	O	O
presented	O	O
and	O	O
harmonized	B-PROC
with	O	O
the	O	O
Brighton	B-LIVB
Collaboration	I-LIVB
and	O	O
GAIA	B-LIVB
format	O
and	O	O
other	O	O
existing	O	O
international	O
standards	O
for	O	O
study	B-PROC
reporting	B-PROC
.	O	O

Beneficial	O
effects	O
of	O	O
dark	B-OBJC
chocolate	I-OBJC
on	O	O
exercise	O
capacity	O
in	O	O
sedentary	O
subjects	B-LIVB
:	O	O
underlying	O	O
mechanisms	O
.	O	O

A	O	O
double	B-PROC
blind	I-PROC
,	O	O
randomized	B-PROC
,	O	O
placebo	B-PROC
controlled	I-PROC
trial	B-PROC
In	O	O
heart	B-DISO
failure	I-DISO
patients	B-LIVB
the	O	O
consumption	B-PHYS
of	O	O
(	B-CHEM
-	I-CHEM
)	I-CHEM
-	I-CHEM
epicatechin	I-CHEM
(	O	O
(	B-CHEM
-	I-CHEM
)	I-CHEM
-	I-CHEM
Epi	I-CHEM
)	O	O
-	O	O
rich	O	O
cocoa	B-OBJC
can	O	O
restore	O	O
skeletal	O
muscle	O
(	O	O
SkM	O
)	O	O
mitochondrial	B-ANAT
structure	O
and	O	O
decrease	O
biomarkers	B-PHYS
of	O	O
oxidative	B-DISO
stress	I-DISO
.	O	O

However	O	O
,	O	O
nothing	O	O
is	O	O
known	O	O
about	O	O
its	O	O
effects	O
on	O	O
exercise	O
capacity	O
and	O	O
underlying	O	O
mechanisms	O
in	O	O
normal	O
,	O	O
sedentary	O
subjects	B-LIVB
.	O	O

Twenty	O	O
normal	O
,	O	O
sedentary	O
subjects	B-LIVB
(	O	O
∼50	O	O
years	B-LIVB
old	I-LIVB
)	O	O
were	O	O
randomized	B-PROC
to	O	O
placebo	B-PROC
or	O	O
dark	B-OBJC
chocolate	I-OBJC
(	O	O
DC	B-OBJC
)	O	O
groups	O
and	O	O
consumed	O
20	O	O
g	O	O
of	O	O
the	O	O
products	O	O
for	O	O
3	O	O
months	O
.	O	O

Subjects	B-LIVB
underwent	O	O
before	O	O
and	O	O
after	O	O
treatment	B-PROC
,	O	O
bicycle	B-PROC
ergometry	I-PROC
to	O	O
assess	B-PROC
VO2	B-DISO
max	I-DISO
and	O	O
work	O
,	O	O
SkM	B-PROC
biopsy	I-PROC
to	O	O
assess	B-PROC
changes	O	O
in	O	O
mitochondrial	B-ANAT
density	O
,	O	O
function	O
and	O	O
oxidative	B-DISO
stress	I-DISO
and	O	O
blood	B-PROC
sampling	I-PROC
to	O	O
assess	B-PROC
metabolic	O
endpoints	O
.	O	O

Seventeen	O	O
subjects	B-LIVB
completed	O	O
the	O	O
trial	B-PROC
.	O	O

In	O	O
the	O	O
DC	B-OBJC
group	O	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
VO2	B-DISO
max	I-DISO
increased	O
(	O	O
17	O	O
%	O	O
increase	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
056	O	O
)	O	O
as	O	O
well	O	O
as	O	O
maximum	O	O
work	O
(	O	O
watts	O
)	O	O
achieved	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
026	O	O
)	O	O
with	O	O
no	O	O
changes	O	O
with	O	O
placebo	B-PROC
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
.	O	O

The	O	O
DC	B-OBJC
group	O	O
evidenced	O	O
increases	O
in	O	O
HDL	B-CHEM
levels	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

005	O	O

)	O	O

and	O	O

decreased	O
triglycerides	B-CHEM
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
07	O	O
)	O	O
.	O	O

With	O	O
DC	B-OBJC
,	O	O
SkM	O
evidenced	O	O
significant	O
increases	O
in	O	O
protein	B-CHEM
levels	O	O
for	O	O
LKB1	B-CHEM
,	O	O
AMPK	B-CHEM
and	O	O
PGC1α	B-CHEM
and	O	O
in	O	O
their	O	O
active	O
forms	O	O
(	O	O
phosphorylated	B-PHYS
AMPK	B-CHEM
and	O	O
LKB1	B-CHEM
)	O	O
as	O	O
well	O	O
as	O	O
in	O	O
citrate	B-PHYS
synthase	I-PHYS
activity	I-PHYS
while	O	O
no	O	O
changes	O	O
were	O	O
observed	O	O
in	O	O
mitochondrial	B-ANAT
density	O
.	O	O

With	O	O
DC	B-OBJC
,	O	O
significant	O
increases	O
in	O	O
SkM	O
reduced	O	O
glutathione	B-CHEM
levels	O	O
and	O	O
decreases	O
in	O	O
protein	B-PHYS
carbonylation	I-PHYS
were	O	O
observed	O	O
.	O	O

Improvements	O	O
in	O	O
maximum	O	O
work	O
achieved	O	O
and	O	O
VO2	B-DISO
max	I-DISO
may	O	O
be	O	O
due	O	O
to	O	O
DC	B-OBJC
activation	O
of	O	O
upstream	O	O
control	O	O
systems	O	O
and	O	O
enhancement	O	O
of	O	O
SkM	O
mitochondria	B-ANAT
efficiency	O
.	O	O

Larger	O	O
clinical	B-PROC
studies	I-PROC
are	O	O
warranted	O	O
to	O	O
confirm	O	O
these	O	O
observations	B-PROC
.	O	O

Dysplasia	B-DISO
discrimination	O
in	O	O
intestinal	B-ANAT
-	O	O
type	O
neoplasia	B-DISO
of	O	O
the	O	O
esophagus	B-ANAT
and	O	O
colon	B-ANAT
via	O
digital	B-PROC
image	I-PROC
analysis	I-PROC
Determining	O	O
gastrointestinal	B-ANAT
tract	I-ANAT
dysplasia	B-DISO
level	O
is	O	O
clinically	O	O
important	O	O
but	O	O
can	O	O
be	O	O
difficult	O
,	O
and	O	O
given	O	O
this	O	O
challenge	O	O
,	O	O
we	O	O
investigated	O
colonic	B-ANAT
and	O	O
esophageal	O
dysplastic	B-DISO
progression	O
using	O	O
digital	B-PROC
image	I-PROC
analysis	I-PROC
(	O	O
IA	B-PROC
)	O	O
.	O	O

Whole	O	O
slide	O
images	O
were	O	O
obtained	O	O
for	O	O
colonic	O	O
normal	O	O
mucosa	O	O
(	O	O
NCM	O	O
)	O	O
,	O	O
hyperplastic	B-DISO
polyps	I-DISO
(	O	O
HP	B-DISO
)	O	O
,	O	O
conventional	O	O
tubular	B-DISO
adenomas	I-DISO
(	O	O
TA	B-DISO
)	O	O
,	O	O
and	O	O
adenomas	B-DISO
with	O	O
high	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O	O
HGD	B-DISO
)	O	O
,	O	O
and	O	O
esophageal	B-DISO
intestinal	I-DISO
metaplasia	I-DISO
negative	B-DISO
for	O	O
dysplasia	B-DISO
(	O	O
IM	B-DISO
)	O	O
,	O	O
indefinite	B-DISO
for	I-DISO
dysplasia	I-DISO
(	O	O
IFD	B-DISO
)	O	O
,	O	O
low	B-DISO
-	I-DISO
grade	I-DISO
dysplasia	I-DISO
(	O	O
LGD	B-DISO
)	O	O
,	O	O
and	O	O
HGD	B-DISO
.	O	O

Characteristic	O	O
nuclei	O	O
were	O	O
circumscribed	O	O
,	O	O
and	O	O
parameters	O	O
discriminating	O	O
groups	O	O
included	O	O
nuclear	O
circumference	O
(	O	O
μm	O	O
)	O	O
,	O	O
area	O
(	O	O
μm	O	O
(	O	O
2	O	O
)	O	O
)	O	O
,	O	O
and	O	O
15	O	O
positive	B-PROC
pixel	I-PROC
count	I-PROC
(	I-PROC
PPC	I-PROC
)	I-PROC
algorithm	I-PROC
IA	I-PROC
measurements	O
.	O	O

In	O	O
colon	B-DISO
polyps	I-DISO
and	O	O
esophageal	O
lesions	B-DISO
,	O	O
average	B-DISO
nuclear	I-DISO
area	I-DISO
and	O	O
circumference	O
ranged	O
30	O	O
-	O	O
108	O	O
.	O	O

6	O	O
μm	O	O
(	O	O
2	O	O
)	O	O
and	O	O
27	O	O
.	O	O
5	O	O
-	O	O
48	O	O
.	O	O
9	O	O
μm	O	O
,	O	O
respectively	O	O
.	O	O

Differences	O	O
for	O	O
average	B-DISO
nuclear	I-DISO
area	I-DISO
and	O	O
circumference	O
met	O	O
statistical	O
significance	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
between	O	O
diagnostic	O
groups	O
in	O	O
the	O	O
esophagus	B-ANAT
and	O	O
colon	B-ANAT
,	O	O
except	O	O
for	O	O
IM	B-DISO
versus	O	O
IFD	B-DISO
nuclear	O	O
area	O	O
.	O	O

Pixel	O
intensity	O
(	O	O
brightness	O
)	O	O
separated	O	O
lesions	B-DISO
within	O	O
both	O	O
groups	O	O
with	O	O
statistical	O
significance	O
except	O	O
for	O	O
colonic	B-DISO
TAs	I-DISO
versus	O	O
HPs	B-DISO
and	O	O
esophageal	B-DISO
LGD	I-DISO
versus	O	O
IM	O	O
.	O	O

HGD	B-DISO
nuclei	O	O
in	O	O
both	O	O
groups	O	O
demonstrated	O	O
more	O	O
pixel	O
staining	O	O
heterogeneity	O
than	O	O
other	O	O
lesions	B-DISO
.	O	O

Hierarchical	B-PROC
clustering	I-PROC
and	O	O
principal	O
component	O
analysis	O
demonstrated	O	O
that	O	O
lesions	B-DISO
with	O	O
similar	O	O
diagnoses	B-DISO
tended	O	O
to	O	O
cluster	O
together	O	O
on	O	O
a	O	O
low	O	O
-	O	O
to	O	O
high	O	O
-	O	O
grade	O	O
spectrum	O	O
.	O	O

Our	O	O
results	O	O
confirm	O	O
that	O	O
quantitative	B-PROC
IA	I-PROC
is	O	O
an	O	O
effective	O
adjunct	O
reflecting	O	O
dysplasia	B-DISO
in	O	O
colon	B-DISO
polyps	I-DISO
and	O	O
Barrett	B-DISO
esophagus	I-DISO
lesions	B-DISO
.	O	O

Nuclear	B-DISO
area	I-DISO
,	O	O
circumference	O
,	O	O
and	O	O
PPC	O
algorithm	O
findings	O	O
distinguished	O	O
lesions	B-DISO
in	O	O
a	O	O
statistically	O
significant	O
manner	O	O
.	O	O

This	O	O
suggests	O	O
utility	O	O
for	O	O
future	O	O
studies	O	O
on	O	O
similar	O	O
methods	O	O
,	O	O
which	O	O
may	O	O
provide	O	O
an	O	O
adjunctive	O
ancillary	O
technique	O
for	O	O
pathologists	B-LIVB
and	O	O
enhance	O
patient	B-PROC
care	I-PROC
.	O	O

Unintentional	B-DISO
Injuries	I-DISO
in	O	O
Children	B-LIVB
Up	O	O
to	O	O
Six	O	O
Years	O
of	O	O
Age	B-PHYS
and	O	O
Related	O	O
Parental	B-LIVB
Knowledge	O
,	O	O
Attitudes	B-PHYS
,	O	O
and	O	O
Behaviors	O
in	O	O
Italy	B-GEOG
To	O	O
describe	O	O
risk	B-DISO
factors	I-DISO
associated	O
with	O
unintentional	B-DISO
injuries	I-DISO
among	O	O
children	B-LIVB
aged	O	O
<	O	O
6	O	O
years	O
and	O	O
to	O	O
examine	O	O
parents	B-LIVB
'	O	O
level	O	O
of	O	O
knowledge	O
,	O	O
attitudes	B-PHYS
,	O	O
and	O	O
behaviors	O
about	O	O
pediatric	O
injuries	B-DISO
and	O	O
related	O	O
preventive	O
measures	O
.	O	O

A	O	O
cross	B-PROC
-	I-PROC
sectional	I-PROC
survey	I-PROC
was	O	O
conducted	O	O
between	O	O
May	O
and	O	O
July	O
2015	O	O
on	O	O
a	O	O
random	B-PROC
sample	I-PROC
of	O	O
794	O	O
parents	B-LIVB
of	O	O
3	O	O
-	O	O
to	O	O
6	O	O
-	O	O
year	O	O
-	O	O
old	O	O
children	B-LIVB
through	O	O
a	O	O
self	O
-	O
administered	O
anonymous	O
questionnaire	O
.	O	O

A	O	O
total	O	O
of	O	O
409	O	O
parents	B-LIVB
participated	O	O
.	O	O

Two	O	O
-	O	O
thirds	O	O
of	O	O
the	O	O
children	B-LIVB
had	O	O
experienced	O	O
at	O	O
least	O	O
1	O	O
unintentional	B-DISO
injury	I-DISO
in	O	O
the	O	O
previous	O	O
12	O	O
months	O
.	O	O

More	O	O
than	O	O
one	O	O
-	O	O
half	O	O
of	O	O
these	O	O
children	B-LIVB
were	O	O
boys	B-LIVB
.	O	O

The	O	O
leading	B-DISO
cause	I-DISO
was	O	O
falls	B-DISO
;	O	O
the	O	O
injuries	B-DISO
occurred	O	O
mainly	O	O
at	O	O
home	O
,	O	O
and	O	O
only	O	O
9	O	O
.	O	O
2	O	O
%	O	O
were	O	O
brought	O	O
for	O	O
attention	O	O
to	O	O
an	O	O
emergency	B-OBJC
department	I-OBJC
.	O	O

Parents	B-LIVB
who	O	O
did	O	O
not	O	O
believe	O	O
that	O	O
it	O	O
is	O	O
possible	O	O
to	O	O
prevent	O	O
unintentional	B-DISO
injuries	I-DISO
were	O	O
more	O	O
likely	O	O
to	O	O
have	O	O
had	O	O
a	O	O
child	B-LIVB
injured	O
.	O	O

Approximately	O	O
70	O	O
%	O	O
of	O	O
respondents	B-LIVB
were	O	O
aware	B-PHYS
of	O	O
security	O
measures	O
to	O	O
prevent	O	O
pediatric	O
injuries	B-DISO
,	O	O
and	O	O
this	O	O
knowledge	O
was	O	O
more	O	O
prevalent	O	O
in	O	O
older	O	O
parents	B-LIVB
and	O	O
in	O	O
those	O	O
with	O	O
at	O	O
least	O	O
a	O	O
college	B-PROC
level	I-PROC
of	I-PROC
education	I-PROC
compared	O	O
with	O	O
those	O	O
with	O	O
a	O	O
middle	B-PROC
school	I-PROC
education	I-PROC
.	O	O

The	O	O
perceived	B-PHYS
utility	O	O
of	O	O
education	B-PROC
about	O	O
preventive	O
measures	O
of	O	O
pediatric	O
injuries	B-DISO
had	O	O
a	O	O
mean	O
value	O
of	O	O
8	O	O
.	O	O

9	O	O
on	O	O
a	O	O
Likert	O
scale	O
of	O	O
1	O	O
-	O	O
10	O	O
(	O	O
1	O	O
,	O	O
not	O	O
useful	O	O
,	O	O
to	O	O
10	O	O
,	O	O
very	O	O
useful	O	O
)	O	O
and	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
mothers	B-LIVB
.	O	O

This	O	O
study	O	O
highlights	O	O
a	O	O
clear	O	O
need	O	O
for	O	O
public	B-PROC
health	I-PROC
educational	B-PROC
programs	I-PROC
for	O	O
parents	B-LIVB
regarding	O	O
prevention	O
of	O	O
unintentional	B-DISO
injuries	I-DISO
in	O	O
children	B-LIVB
as	O	O
a	O	O
valuable	O	O
tool	O	O
to	O	O
increase	O	O
safety	B-PHEN
and	O	O
injury	B-PROC
prevention	I-PROC
and	O	O
to	O	O
reduce	O
risks	O
,	O	O
because	O	O
the	O	O
majority	O	O
of	O	O
such	O	O
injuries	B-DISO
occur	O	O
at	O	O
home	O
.	O	O

Aeromonas	B-LIVB
salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
strains	B-LIVB
isolated	O	O
from	O	O
Chinese	B-LIVB
freshwater	I-LIVB
fish	I-LIVB
contain	O	O
a	O	O
novel	O	O
genomic	B-CHEM
island	I-CHEM
and	O	O
possible	O	O
regional	O
-	O
specific	O
mobile	B-CHEM
genetic	I-CHEM
elements	I-CHEM
profiles	O	O
Two	O	O
strains	B-LIVB
of	O	O
Aeromonas	B-LIVB
salmonicida	I-LIVB
,	O	O
YK	B-LIVB
and	O	O
BG	B-LIVB
,	O	O
were	O	O
isolated	O	O
from	O	O
largemouth	B-LIVB
bronze	I-LIVB
gudgeon	I-LIVB
and	O	O
northern	B-LIVB
whitefish	I-LIVB
in	O	O
China	B-GEOG
,	O	O
and	O	O
identified	O	O
as	O	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
based	O	O
on	O	O
phylogenetic	B-PROC
analysis	I-PROC
of	O	O
vapA	O
and	O	O
16S	B-CHEM
rRNA	I-CHEM
gene	O
sequences	O
.	O	O

YK	B-LIVB
and	O	O
BG	B-LIVB
originated	O	O
from	O	O
freshwater	B-LIVB
fish	I-LIVB
,	O	O
one	O	O
of	O	O
which	O	O
belonged	O	O
to	O	O
the	O	O
cyprinid	B-LIVB
family	I-LIVB
,	O	O
and	O	O
the	O	O
strains	B-LIVB
showed	O	O
a	O	O
difference	O	O
in	O	O
virulence	B-PHEN
.	O	O

Subsequently	O	O
,	O	O
we	O	O
performed	O	O
whole	O	O
genome	B-PROC
sequencing	I-PROC
of	O	O
the	O	O
strains	B-LIVB
,	O	O
and	O	O
comparison	O	O
of	O	O
their	O	O
genomic	O
sequences	O
to	O	O
the	O	O
genome	O
of	O	O
the	O	O
A449	B-LIVB
reference	I-LIVB
strain	I-LIVB
revealed	O	O
various	O	O
genomic	B-PHYS
rearrangements	I-PHYS
,	O	O
including	O	O
a	O	O
new	O	O
variant	O	O
of	O	O
the	O	O
genomic	B-CHEM
island	I-CHEM
AsaGEI	B-CHEM
in	O	O
BG	B-LIVB
,	O	O
designated	O	O
as	O	O
AsaGEI2c	B-CHEM
This	O	O
is	O	O
the	O	O
first	O	O
report	O	O
on	O	O
a	O	O
GEI	B-PHYS
of	O	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
strain	I-LIVB
from	O	O
China	B-GEOG
.	O	O

Furthermore	O	O
,	O	O
both	O	O
YK	B-LIVB
and	O	O
BG	B-LIVB
strains	O	O
contained	O	O
a	O	O
Tn7	B-CHEM
transposon	I-CHEM
inserted	O	O
at	O	O
the	O	O
same	O	O
position	O	O
in	O	O
the	O	O
chromosome	B-ANAT
.	O	O

Finally	O	O
,	O	O
IS	B-PHYS
-	I-PHYS
dependent	I-PHYS
rearrangements	I-PHYS
on	O	O
pAsa5	B-CHEM
are	O	O
deemed	O	O
likely	O	O
to	O	O
have	O	O
occurred	O	O
,	O	O
with	O	O
omission	B-DISO
of	O	O
the	O	O
resD	O
gene	O
in	O	O
both	O	O
strains	B-LIVB
as	O	O
well	O	O
as	O	O
omission	B-DISO
of	O	O
genes	O
related	O	O
to	O	O
the	O	O
IncF	B-CHEM
conjugal	O	O
transfer	O	O
system	O	O
in	O	O
the	O	O
YK	B-LIVB
isolate	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
can	O	O
infect	B-DISO
non	B-LIVB
-	I-LIVB
salmonids	I-LIVB
(	O	O
cyprinids	B-LIVB
)	O	O
in	O	O
addition	O	O
to	O	O
salmonids	B-LIVB
,	O	O
and	O	O
that	O	O
AsaGEI2c	B-CHEM
might	O	O
be	O	O
useful	O	O
as	O	O
a	O	O
geographical	B-CHEM
indicator	I-CHEM
of	O	O
Chinese	O	O
A	B-LIVB
.	I-LIVB

salmonicida	I-LIVB
subsp	I-LIVB
.	I-LIVB

salmonicida	I-LIVB
isolates	O	O
.	O	O

Evaluation	B-PROC
of	O	O
Pharmacokinetics	B-PHYS
,	O	O
and	O	O
Bioavailability	O
of	O	O
Higher	O
Doses	O
of	O	O
Tocotrienols	B-CHEM
in	O	O
Healthy	O
Fed	O	O
Humans	B-LIVB
Tocotrienols	B-CHEM
has	O	O
been	O	O
known	O	O
to	O	O
lower	B-DISO
serum	I-DISO
lipid	I-DISO
parameters	I-DISO
below	O	O
500	O	O
mg	O	O
/	O	O
d	O	O
,	O	O
while	O	O
increase	B-DISO
lipid	I-DISO
parameters	I-DISO
at	O	O
higher	O
dose	O
of	O	O
750	O	O
mg	O	O
/	O	O
d	O	O
.	O	O

δ	B-CHEM
-	I-CHEM
Tocotrienol	I-CHEM
has	O	O
a	O	O
novel	O	O
inflammatory	O
property	O
of	O	O
concentration	O
-	O
dependent	O
inhibition	O
and	O	O
activation	O
.	O	O

Therefore	O	O
,	O	O
inhibition	O
(	O	O
anti	O
-	O
inflammatory	O
)	O	O
property	O
of	O	O
tocotrienols	B-CHEM
at	O	O
low	O
doses	O
is	O	O
useful	O	O
for	O	O
cardiovascular	B-DISO
disease	I-DISO
,	O	O
whereas	O	O
,	O	O
activation	O
(	O	O
pro	O
-	O
inflammatory	O
)	O	O
property	O
using	O	O
high	O
dose	O
is	O	O
found	O	O
effective	O
for	O	O
treatments	B-PROC
of	O	O
various	O	O
types	O	O
of	O	O
cancer	B-DISO
.	O	O

We	O	O
have	O	O
recently	O	O
described	O	O
plasma	B-ANAT
bioavailability	O
of	O	O
125	O	O
mg	O	O
/	O	O
d	O	O
,	O	O
250	O	O
mg	O	O
/	O	O
d	O	O
and	O	O
500	O	O
mg	O	O
/	O	O
d	O	O
doses	O
of	O	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
in	O	O
healthy	O
fed	O	O
subjects	B-LIVB
,	O	O
which	O	O
showed	O	O
dose	O
-	O
dependent	O
increases	B-DISO
in	I-DISO
area	I-DISO
under	I-DISO
the	I-DISO
curve	I-DISO
(	O	O
AUC	O
)	O	O
and	O	O
maximum	O
concentration	O
(	O	O
Cmax	O
)	O	O
.	O	O

Hence	O	O
,	O	O
in	O	O
the	O	O
current	O	O
study	O	O
,	O	O
higher	O
doses	O
of	O	O
tocotrienols	B-CHEM
have	O	O
used	O	O
to	O	O
analyze	O	O
its	O	O
effect	O	O
on	O	O
plasma	B-ANAT
pharmacokinetic	O
parameters	O
.	O	O

To	O	O
evaluate	B-PROC
the	O	O
safety	B-PHEN
and	O	O
bioavailability	O
of	O	O
higher	O
doses	O
(	O	O
750	O	O
mg	O	O
and	O	O
1000	O	O
mg	O	O
)	O	O
of	O	O
annatto	B-CHEM
-based	O	O
tocotrienols	B-CHEM
in	O	O
healthy	O
fed	O	O
subjects	B-LIVB
.	O	O

All	O	O
four	O	O
isomers	O
(	O	O
α	O	O
-	O	O
,	O	O
β	O	O
-	O	O
,	O	O
γ	O	O
-	O	O
,	O	O
δ	O	O
-	O	O
)	O	O
of	O	O
tocols	B-CHEM
(	O	O
tocotrienols	B-CHEM
and	O	O
tocopherols	B-CHEM
)	O	O
present	O	O
in	O	O
the	O	O
plasmas	B-ANAT
of	O	O
subjects	B-LIVB
were	O	O
quantified	O	O
and	O	O
analyzed	B-PROC
for	O	O
various	O	O
pharmacokinetic	O
parameters	O
.	O	O

An	O	O
open	B-PROC
-	I-PROC
label	I-PROC
,	O	O
randomized	B-PROC
study	I-PROC
was	O	O
performed	O	O
to	O	O
analyze	O	O
pharmacokinetics	B-PHYS
and	O	O
bioavailability	O
of	O	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
in	O	O
6	O	O
healthy	O
fed	O	O
subjects	B-LIVB
.	O	O

All	O	O
subjects	B-LIVB
(	O	O
3	O	O
/	O	O
dose	O
)	O	O
were	O	O
randomly	O	O
assigned	O
to	O	O
one	O	O
of	O	O
each	O	O
dose	O
of	O	O
750	O	O
mg	O	O
or	O	O
1000	O	O
mg	O	O
.	O	O

Blood	B-ANAT
samples	I-ANAT
were	O	O
collected	O	O
at	O	O
0	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
4	O	O
,	O	O
6	O	O
,	O	O
8	O	O
h	O	O
intervals	O	O
and	O	O
all	O	O
isomers	O
of	O	O
α	B-CHEM
-	I-CHEM
,	O	O
β	B-CHEM
-	I-CHEM
,	O	O
γ	B-CHEM
-	I-CHEM
,	O	O
δ	B-CHEM
-	I-CHEM
tocotrienols	I-CHEM
,	O	O
and	O	O
tocopherols	B-CHEM
in	O	O
plasmas	B-ANAT
were	O	O
quantified	O	O
by	O	O
HPLC	B-PROC
.	O	O

Oral	B-PROC
administration	I-PROC
of	O	O
750	O	O
and	O	O
1000	O	O
mg	O	O
/	O	O
d	O	O
of	O	O
tocotrienols	B-CHEM
resulted	O	O
in	O	O
dose	O
-	O
dependent	O
increases	O
in	O	O
plasmas	B-ANAT
(	O	O
ng	O	O
/	O	O
ml	O	O
)	O	O
AUC	O
t0	O	O
-	O	O
t8	O	O
6621	O	O
,	O	O
7450	O	O
;	O	O
AUC	O
t0	O	O
-	O	O
∞	O	O
8688	O	O
,	O	O
9633	O	O
;	O	O
AUMC	O
t0	O	O
-	O	O
∞	O	O
52497	O	O
,	O	O
57199	O	O
;	O	O
MRT	O
6	O	O
.	O	O

04	O	O
,	O	O
5	O	O
.	O	O
93	O	O
;	O	O
Cmax	O
1444	O	O
,	O	O
1592	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
of	O	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
isomer	I-CHEM
.	O	O

Moreover	O	O
,	O	O
both	O	O
doses	O
also	O	O
resulted	O	O
in	O	O
plasmas	B-ANAT
Tmax	O
3	O	O
.	O	O
33	O	O
-	O	O
4	O	O
h	O	O
;	O	O
elimination	O
half	O
-	O
life	O
(	O	O
t1	O
/	O
2	O
h	O	O
)	O	O
2	O	O
.	O	O
74	O	O
,	O	O
2	O	O
.	O	O
68	O	O
;	O	O
time	O
of	O
clearance	O
(	O	O
Cl	O
-	O
T	O
,	O	O
l	O	O
/	O	O
h	O	O
)	O	O
0	O	O
.	O	O
086	O	O
,	O	O
0	O	O
.	O	O

078	O	O
;	O	O
volume	O
of	O
distribution	O
(	O	O
Vd	O
/	O
f	O
,	O	O
mg	O	O
/	O	O
h	O	O
)	O	O
0	O	O
.	O	O
34	O	O
,	O	O
0	O	O
.	O	O
30	O	O
;	O	O
and	O	O
elimination	O
rate	O
constant	O
(	O	O
ke	O
;	O	O
h	O	O
(	O	O
-	O	O
1	O	O
)	O	O
)	O	O
0	O	O
.	O	O
25	O	O
,	O	O
0	O	O
.	O	O
17	O	O
,	O	O
respectively	O	O
of	O	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
isomer	I-CHEM
.	O	O

Similar	O	O
results	B-DISO
of	O	O
these	O	O
parameters	B-DISO
were	O	O
reported	B-PROC
for	O	O
γ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O	O
β	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O	O
α	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
,	O	O
δ	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O	O
γ	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O	O
and	O	O
β	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
,	O	O
except	O	O
for	O	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
.	O	O

This	O	O
study	O	O
has	O	O
described	O	O
pharmacokinetics	B-PHYS
using	O	O
higher	O
doses	O
of	O	O
750	O	O
mg	O	O
/	O	O
d	O	O
and	O	O
1000	O	O
mg	O	O
/	O	O
d	O	O
of	O	O
δ	B-CHEM
-	I-CHEM
tocotrienol	I-CHEM
.	O	O

These	O	O
results	B-DISO
confirmed	O
earlier	O	O
findings	O	O
that	O	O
Tmax	O
was	O	O
3	O	O
-	O	O
4	O	O
h	O	O
for	O	O
all	O	O
isomers	O
of	O	O
tocotrienols	B-CHEM
and	O	O
tocopherols	B-CHEM
except	O	O
for	O	O
α	B-CHEM
-	I-CHEM
tocopherol	I-CHEM
(	O	O
6	O	O
h	O	O
)	O	O
.	O	O

These	O	O
higher	O
doses	O
of	O	O
tocotrienols	B-CHEM
were	O	O
found	O	O
safe	O	O
in	O	O
humans	B-LIVB
and	O	O
may	O	O
be	O	O
useful	O	O
for	O	O
treatments	B-PROC
of	O	O
various	O	O
types	O	O
of	O	O
cancer	B-DISO
,	O	O
diabetes	B-DISO
,	O	O
and	O	O
Alzheimer	B-DISO
's	I-DISO
disease	I-DISO
.	O	O

The	O	O
effect	O
of	O	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
supplementation	B-PROC
on	O	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
and	O	O
weight	B-DISO
changes	I-DISO
in	O	O
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
:	O	O
A	O	O
randomized	B-PROC
controlled	I-PROC
trial	I-PROC
Acceleration	B-PHEN
in	O	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
helps	O	O
faster	O
improvement	O
and	O	O
decreased	O
probability	O
of	O	O
the	O	O
transfer	O	O
of	O	O
TB	B-DISO
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
we	O	O
aimed	O
to	O	O
investigate	O
the	O	O
effect	O
of	O	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
supplementation	B-PROC
on	O	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
and	O	O
weight	B-DISO
changes	I-DISO
in	O	O
smear	B-DISO
positive	I-DISO
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
in	O	O
Iran	B-GEOG
.	O	O

In	O	O
this	O	O
double	O	O
blind	O	O
clinical	B-PROC
study	I-PROC
,	O	O
TB	B-DISO
patients	B-LIVB
were	O	O
divided	O
into	O	O
intervention	B-PROC
,	O	O
(	O	O
n	O	O
=	O	O
43	O	O
)	O	O
receiving	O
500	O	O
mg	O	O
green	B-CHEM
tea	I-CHEM
extract	I-CHEM
(	O	O
GTE	B-CHEM
)	O	O
,	O	O
and	O	O
control	B-LIVB
groups	I-LIVB
(	O	O
n	O	O
=	O	O
40	O	O
)	O	O
receiving	O
placebo	B-CHEM
for	O	O
two	O
months	O
,	O	O
using	O	O
balanced	B-PROC
randomization	I-PROC
.	O	O

Random	B-PROC
allocation	I-PROC
and	O	O
allocation	O
concealment	O
were	O	O
observed	O
.	O	O

Height	B-PHYS
and	I-PHYS
weight	I-PHYS
were	O	O
measured	O
at	O	O
the	O	O
beginning	O
,	O	O
and	O	O
two	O	O
and	O	O
six	O	O
months	O
post	O
-	O
treatment	O
.	O	O

Evaluations	B-PROC
were	O	O
performed	O
on	O	O
three	O	O
slides	B-DEVI
,	O	O
using	O	O
the	O	O
ZiehlNeelsen	B-PROC
method	I-PROC
.	O	O

Independent	O
and	O	O
paired	O
t	O
test	O
,	O	O
McNemar	O
's	O
,	O	O
Wilcoxon	O
,	O	O
Kaplan	O
-	O
Meier	O
,	O	O
Cox	O
regression	O
model	O
and	O	O
Log	O
-	O
Rank	O
test	O
were	O	O
utilized	O
.	O	O

Statistical	O
significance	O
was	O	O
set	O	O
at	O	O
p	O	O
<	O	O
0	O	O
.	O	O
05	O	O
.	O	O

This	O	O
trial	B-PROC
was	O	O
registered	B-PROC
under	O	O
IRCT201212232602N11	O	O
.	O	O

The	O	O
interventional	B-PROC
changes	O
and	O	O
the	O	O
interactive	O
effect	O
of	O	O
intervention	B-PROC
on	O	O
weight	B-PHYS
were	O	O
not	B-DISO
significant	I-DISO
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

In	O	O
terms	O	O
of	O	O
shortening	O
the	O	O
duration	O
of	O	O
conversion	B-PROC
,	O	O
the	O	O
case	O
to	O
control	O
proportion	O
showed	O
a	O	O
significant	O
difference	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
032	O	O
)	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
Cox	O
regression	O
model	O
,	O	O
the	O	O
hazard	O
ratio	O
of	O	O
the	O	O
relative	O
risk	O
of	O	O
delay	O
in	O	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
was	O	O
3	O	O
.	O	O

7	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
002	O	O
)	O	O
in	O	O
the	O	O
higher	O
microbial	O
load	O
group	B-LIVB
compared	O
to	O	O
the	O	O
placebo	B-CHEM
group	B-LIVB
and	O	O
0	O	O
.	O	O
54	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O
31	O	O
-	O	O
0	O	O
.	O	O
94	O	O
)	O	O
in	O	O
the	O	O
intervention	B-PROC
compared	O
to	O	O
the	O	O
placebo	B-CHEM
group	B-LIVB
.	O	O

GTE	B-CHEM
decreases	B-DISO
the	O	O
risk	O
of	O	O
delay	O
in	O	O
sputum	B-PROC
smear	I-PROC
conversion	B-PROC
,	O	O
but	O	O
has	O	O
no	O	O
effect	O
on	O	O
weight	B-DISO
gain	I-DISO
.	O	O

Moreover	O	O
,	O	O
it	O	O
may	O	O
be	O	O
used	O	O
as	O	O
an	O	O
adjuvant	B-PROC
therapy	I-PROC
for	O	O
faster	O
rehabilitation	O
for	O	O
pulmonary	B-DISO
TB	I-DISO
patients	B-LIVB
.	O	O

Reduction	O
in	O	O
Hospital	B-OBJC
-	I-OBJC
Wide	I-OBJC
Clinical	B-PROC
Laboratory	I-PROC
Specimen	I-PROC
Identification	I-PROC
Errors	O
following	O	O
Process	O
Interventions	O
:	O	O
A	O	O
10	O	O
-	O	O
Year	O
Retrospective	B-PROC
Observational	I-PROC
Study	I-PROC
Accurate	O
patient	B-PROC
identification	I-PROC
and	O	O
specimen	B-PROC
labeling	I-PROC
at	O	O
the	O	O
time	O	O
of	O	O
collection	O	O
are	O	O
crucial	O
steps	O
in	O	O
the	O	O
prevention	B-PROC
of	O	O
medical	O
errors	O
,	O	O
thereby	O	O
improving	O
patient	B-PROC
safety	I-PROC
.	O	O

All	O	O
patient	B-ANAT
specimen	I-ANAT
identification	O
errors	O
that	O	O
occurred	O
in	O	O
the	O	O
outpatient	O
department	O
(	O	O
OPD	O
)	O	O
,	O	O
emergency	B-OBJC
department	I-OBJC
(	O	O
ED	B-OBJC
)	O	O
,	O	O
and	O	O
inpatient	O
department	O
(	O	O
IPD	O
)	O	O
of	O	O
a	O	O
3	O	O
,	O	O
800	O	O
-	O	O
bed	B-OBJC
academic	B-OBJC
medical	I-OBJC
center	I-OBJC
in	O	O
Taiwan	B-GEOG
were	O	O
documented	B-PROC
and	O	O
analyzed	B-PROC
retrospectively	O	O
from	O	O
2005	O	O
to	O	O
2014	O	O
.	O	O

To	O	O
reduce	O
such	O	O
errors	O
,	O	O
the	O	O
following	O	O
series	O
of	O	O
strategies	O
were	O	O
implemented	O	O
:	O	O
a	O	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O	O
the	O	O
ED	B-OBJC
and	O	O
IPD	O
in	O	O
2006	O	O
;	O	O
a	O	O
computer	B-PROC
-	I-PROC
assisted	I-PROC
barcode	O
positive	B-OBJC
patient	I-OBJC
identification	I-OBJC
system	I-OBJC
for	O	O
the	O	O
ED	B-OBJC
and	O	O
IPD	O
in	O	O
2007	O	O
and	O	O
2010	O	O
,	O	O
and	O	O
automated	O
sample	B-PROC
labeling	I-PROC
combined	O
with	O	O
electronic	B-PROC
identification	I-PROC
systems	I-PROC
introduced	O
to	O	O
the	O	O
OPD	O
in	O	O
2009	O	O
.	O	O

Of	O	O
the	O	O
2000345	O	O
specimens	B-ANAT
collected	O
in	O	O
2005	O	O
,	O	O
1023	O	O
(	O	O
0	O	O
.	O	O
0511	O	O
%	O	O
)	O	O
were	O	O
identified	B-DISO
as	O	O
having	O	O
patient	B-PROC
identification	I-PROC
errors	O
,	O	O
compared	O	O
with	O	O
58	O	O
errors	O
(	O	O
0	O	O
.	O	O
0015	O	O
%	O	O
)	O	O
among	O	O
3761238	O	O
specimens	B-ANAT
collected	O
in	O	O
2014	O	O
,	O	O
after	O	O
serial	O	O
interventions	B-PROC
;	O	O
this	O	O
represents	O	O
a	O	O
97	O	O
%	O	O
relative	O
reduction	O
.	O	O

The	O	O
total	O
number	O
(	O	O
rate	O
)	O	O
of	O	O
institutional	B-PROC
identification	I-PROC
errors	O
contributed	O	O
from	O	O
the	O	O
ED	B-OBJC
,	O	O
IPD	O
,	O	O
and	O	O
OPD	O
over	O	O
a	O	O
10	O	O
-	O	O
year	O
period	O
were	O	O
423	O	O
(	O	O
0	O	O
.	O	O
1058	O	O
%	O	O
)	O	O
,	O	O
556	O	O
(	O	O
0	O	O
.	O	O
0587	O	O
%	O	O
)	O	O
,	O	O
and	O	O
44	O	O
(	O	O
0	O	O
.	O	O
0067	O	O
%	O	O
)	O	O
errors	O
before	O
the	O	O
interventions	B-PROC
,	O	O
and	O	O
3	O	O
(	O	O
0	O	O
.	O	O
0007	O	O
%	O	O
)	O	O
,	O	O
52	O	O
(	O	O
0	O	O
.	O	O
0045	O	O
%	O	O
)	O	O
and	O	O
3	O	O
(	O	O
0	O	O
.	O	O
0001	O	O
%	O	O
)	O	O
after	O
interventions	B-PROC
,	O	O
representing	O	O
relative	O
99	O	O
%	O	O
,	O	O
92	O	O
%	O	O
and	O	O
98	O	O
%	O	O
reductions	O
,	O	O
respectively	O	O
.	O	O

Accurate	O
patient	B-PROC
identification	I-PROC
is	O	O
a	O	O
challenge	O	O
of	O	O
patient	B-PROC
safety	I-PROC
in	O	O
different	O	O
health	O
settings	O
.	O	O

The	O	O
data	B-DISO
collected	I-DISO
in	O	O
our	O	O
study	B-PROC
indicate	O	O
that	O	O
a	O	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O	O
computer	B-PROC
-	I-PROC
generated	I-PROC
positive	B-OBJC
identification	I-OBJC
systems	I-OBJC
,	O	O
and	O	O
interdisciplinary	O	O
cooperation	O	O
can	O	O
significantly	O	O
reduce	O
patient	B-PROC
identification	I-PROC
errors	O
.	O	O

Truncated	B-LIVB
Bovine	I-LIVB
Integrin	B-CHEM
Alpha	I-CHEM
-	I-CHEM
v	I-CHEM
/	I-CHEM
Beta	I-CHEM
-	I-CHEM
6	I-CHEM
as	O	O
a	O	O
Universal	B-PHYS
Capture	I-PHYS
Ligand	I-PHYS
for	O	O
FMD	B-DISO
Diagnosis	B-DISO
Foot	B-DISO
-	I-DISO
and	I-DISO
-	I-DISO
mouth	I-DISO
disease	I-DISO
(	O	O
FMD	B-DISO
)	O	O
is	O	O
endemic	B-DISO
in	O	O
many	O	O
regions	O
of	O	O
the	O	O
world	B-LIVB
and	O	O
is	O	O
one	O	O
of	O	O
the	O	O
most	O	O
prevalent	O	O
epizootic	B-PHEN
animal	B-DISO
diseases	I-DISO
.	O	O

FMD	B-DISO
affects	O	O
livestock	B-LIVB
,	O	O
such	O	O
as	O	O
cattle	B-LIVB
,	O	O
sheep	B-LIVB
,	O	O
goats	B-LIVB
and	O	O
pigs	B-LIVB
,	O	O
and	O	O
causes	O	O
enormous	O
economic	O
losses	O
due	O	O
to	O	O
reduced	O	O
productivity	O
and	O	O
trade	O
restrictions	O
.	O	O

Preparedness	B-DISO
and	O	O
early	B-PROC
diagnosis	I-PROC
are	O	O
essential	O
for	O	O
effective	B-PROC
control	I-PROC
of	O	O
FMD	B-DISO
.	O	O

Many	O	O
diagnostic	B-PROC
assays	I-PROC
are	O	O
dependent	O
on	O	O
raising	O	O
high	O
-	O
affinity	O
,	O	O
anti	B-LIVB
-	I-LIVB
FMD	I-LIVB
virus	I-LIVB
(	O	O
FMDV	B-LIVB
)	O	O
serotype	B-CHEM
-	I-CHEM
specific	I-CHEM
antibodies	I-CHEM
in	O	O
small	O	O
animals	B-LIVB
(	O	O
rabbits	B-LIVB
and	O	O
guinea	B-LIVB
pigs	I-LIVB
)	O	O
that	O	O
give	O	O
broad	O	O
virus	B-LIVB
coverage	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
soluble	O
,	O	O
truncated	O
forms	O
of	O	O
bovine	B-LIVB
αvβ6	B-CHEM
bind	B-PHYS
FMDV	B-LIVB
in	O	O
an	O	O
authentic	O	O
RGD	B-CHEM
and	O	O
divalent	B-PHYS
cation	I-PHYS
dependent	I-PHYS
interaction	I-PHYS
and	O	O
can	O	O
be	O	O
used	O	O
as	O	O
the	O	O
trapping	B-CHEM
reagent	I-CHEM
in	O	O
a	O	O
FMDV	B-LIVB
sandwich	B-PROC
ELISA	I-PROC
.	O	O

In	O	O
addition	O	O
,	O	O
inclusion	O
of	O	O
FLAG	B-CHEM
or	O	O
His	B-CHEM
tags	I-CHEM
facilitates	O	O
simple	O	O
purification	B-PROC
without	O	O
the	O	O
loss	O
of	O	O
virus	B-PHEN
binding	I-PHEN
.	O	O

We	O	O
also	O	O
provide	O	O
evidence	O
that	O	O
when	O	O
combined	O
with	O	O
a	O	O
guinea	B-LIVB
pig	I-LIVB
polyclonal	B-ANAT
serum	I-ANAT
,	O	O
or	O	O
serotype	B-CHEM
-	I-CHEM
specific	I-CHEM
monoclonal	I-CHEM
antibodies	I-CHEM
,	O	O
the	O	O
integrin	B-CHEM
can	O	O
be	O	O
used	O	O
to	O	O
detect	B-DISO
viruses	B-LIVB
representative	O	O
of	O	O
all	O	O
FMDV	B-LIVB
serotypes	I-LIVB
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
recombinant	B-LIVB
FMDV	I-LIVB
empty	B-ANAT
capsids	I-ANAT
,	O	O
with	O	O
stabilising	B-PHEN
disulphide	I-PHEN
bonds	I-PHEN
,	O	O
can	O	O
serve	O	O
as	O	O
an	O	O
antigen	B-CHEM
in	O	O
the	O	O
ELISA	B-PROC
and	O	O
can	O	O
therefore	O	O
replace	O	O
inactivated	B-CHEM
virus	I-CHEM
antigen	I-CHEM
as	O	O
a	O	O
positive	O
control	O
for	O	O
the	O	O
assay	B-PROC
.	O	O

Our	O	O
results	B-PHEN
demonstrate	O	O
the	O	O
potential	O
use	O	O
of	O	O
bovine	B-LIVB
αvβ6	B-CHEM
and	O	O
FMDV	B-LIVB
empty	B-ANAT
capsids	I-ANAT
in	O	O
FMD	B-DISO
diagnostic	B-PROC
assays	I-PROC
.	O	O

Novel	O
antibody	B-CHEM
probes	O	O
for	O	O
the	O	O
characterization	O
of	O	O
endosialin	B-CHEM
/	O	O
TEM	B-CHEM
-	I-CHEM
1	I-CHEM
Endosialin	B-CHEM
(	I-CHEM
Tumor	I-CHEM
Endothelial	I-CHEM
Marker	I-CHEM
-	I-CHEM
1	I-CHEM
(	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
)	I-CHEM
,	I-CHEM
CD248	I-CHEM
)	I-CHEM
is	O	O
primarily	O	O
expressed	O	O
on	O	O
pericytes	B-ANAT
of	O	O
tumor	B-DISO
-	O	O
associated	O
microvasculature	B-PHYS
,	O	O
tumor	B-DISO
-	O	O
associated	O
stromal	B-ANAT
cells	I-ANAT
and	O	O
directly	O	O
on	O	O
tumors	B-DISO
of	O	O
mesenchymal	B-ANAT
origin	I-ANAT
,	O	O
including	O	O
sarcoma	B-DISO
and	O	O
melanoma	B-DISO
.	O	O

While	O	O
the	O	O
function	O
of	O	O
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
is	O	O
incompletely	O	O
understood	O	O
,	O	O
studies	B-PROC
have	O	O
suggested	O	O
a	O	O
role	O	O
in	O	O
supporting	O	O
tumor	B-DISO
growth	I-DISO
and	O	O
invasion	B-DISO
thus	O	O
making	O	O
it	O	O
an	O	O
attractive	O	O
therapeutic	O
target	O
.	O	O

In	O	O
an	O	O
effort	O	O
to	O	O
further	O	O
understand	O	O
its	O	O
role	O	O
in	O	O
cancer	B-DISO
,	O	O
we	O	O
previously	O	O
developed	O	O
a	O	O
humanized	B-CHEM
anti	B-CHEM
-	I-CHEM
endosialin	I-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
monoclonal	B-CHEM
antibody	I-CHEM
(	O	O
mAb	B-CHEM
)	O	O
,	O	O
called	O	O
ontuxizumab	B-CHEM
(	O	O
MORAb	B-CHEM
-	I-CHEM
004	I-CHEM
)	O	O
for	O	O
testing	O
in	O	O
preclinical	B-PROC
and	O	O
clinical	B-PROC
studies	I-PROC
.	O	O

We	O	O
herein	O	O
report	O	O
on	O	O
the	O	O
generation	O
of	O	O
an	O	O
extensive	O	O
panel	O	O
of	O	O
recombinant	B-CHEM
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
protein	I-CHEM
extracellular	O
domain	O
(	O	O
ECD	O
)	O	O
fragments	B-CHEM
and	O	O
novel	O
mAbs	B-CHEM
against	O	O
ECD	O
motifs	O
.	O	O

The	O	O
domain	B-PHYS
-	I-PHYS
specific	I-PHYS
epitopes	B-CHEM
were	O	O
mapped	O
against	O	O
ECD	O
sub	O	O
-	O	O
domains	O	O
to	O	O
identify	O	O
those	O	O
that	O	O
can	O	O
detect	B-DISO
distinct	O	O
structural	O
motifs	O
and	O	O
can	O	O
be	O	O
potentially	O	O
formatted	O	O
as	O	O
probes	O	O
suitable	O	O
for	O	O
diagnostic	B-PROC
and	O	O
functional	O
studies	O
.	O	O

A	O	O
number	O	O
of	O	O
mAbS	B-CHEM
were	O	O
shown	O	O
to	O	O
cross	B-PROC
-	I-PROC
react	I-PROC
with	O	O
the	O	O
murine	B-CHEM
and	O	O
human	B-LIVB
protein	B-CHEM
,	O	O
potentially	O	O
allowing	O	O
their	O	O
use	O	O
in	O	O
human	B-LIVB
animal	B-LIVB
models	I-LIVB
and	O	O
corresponding	O	O
clinical	B-PROC
trials	I-PROC
.	O	O

In	O	O
addition	O	O
,	O	O
pairing	O	O
of	O	O
several	O	O
mAbs	B-CHEM
supported	O	O
their	O	O
use	O	O
in	O	O
immunoassays	B-PROC
that	O	O
can	O	O
detect	O	O
soluble	B-ANAT
endosialin	B-CHEM
/	I-CHEM
TEM	I-CHEM
-	I-CHEM
1	I-CHEM
(	O	O
sEND	B-CHEM
)	O	O
in	O	O
the	O	O
serum	B-ANAT
of	O	O
healthy	B-LIVB
subjects	I-LIVB
and	O	O
cancer	B-LIVB
patients	I-LIVB
.	O	O

Identification	O
of	O	O
novel	O
macrolides	B-CHEM
with	O	O
antibacterial	B-PHYS
,	O	O
anti	O
-	O
inflammatory	O
and	O	O
type	B-CHEM
I	I-CHEM
and	O	O
III	B-CHEM
IFN	I-CHEM
-	O	O
augmenting	B-DISO
activity	I-DISO
in	O	O
airway	B-ANAT
epithelium	O
Exacerbations	B-DISO
of	I-DISO
asthma	I-DISO
and	O	O
COPD	B-DISO
are	O	O
triggered	O
by	O
rhinoviruses	B-LIVB
.	O	O

Uncontrolled	O
inflammatory	B-PHYS
pathways	I-PHYS
,	O	O
pathogenic	B-LIVB
bacterial	O
burden	O
and	O	O
impaired	O
antiviral	B-PHYS
immunity	I-PHYS
are	O	O
thought	O	O
to	O	O
be	O	O
important	O	O
factors	O
in	O	O
disease	O
severity	O
and	O	O
duration	O
.	O	O

Macrolides	B-CHEM
including	O	O
azithromycin	B-CHEM
are	O	O
often	O	O
used	O	O
to	O	O
treat	O
the	O	O
above	O	O
diseases	B-DISO
,	O	O
but	O	O
exhibit	O
variable	O
levels	O
of	O	O
efficacy	O
.	O	O

Inhaled	B-CHEM
corticosteroids	I-CHEM
are	O	O
also	O	O
readily	O	O
used	O	O
in	O	O
treatment	O
,	O	O
but	O	O
may	O	O
lack	O
specificity	O
.	O	O

Ideally	O	O
,	O	O
new	O	O
treatment	O
alternatives	O	O
should	O	O
suppress	O
unwanted	O	O
inflammation	B-DISO
,	O	O
but	O	O
spare	O	O
beneficial	O	O
antiviral	B-PHYS
immunity	I-PHYS
.	O	O

In	O	O
the	O	O
present	O	O
study	B-PROC
,	O	O
we	O	O
screened	O	O
225	O	O
novel	O
macrolides	B-CHEM
and	O	O
tested	O
them	O	O
for	O	O
enhanced	O
antiviral	B-PHYS
activity	I-PHYS
against	O	O
rhinovirus	B-LIVB
,	O	O
as	O	O
well	O	O
as	O	O
anti	B-DISO
-	I-DISO
inflammatory	I-DISO
activity	I-DISO
and	O	O
activity	O
against	O	O
Gram	B-LIVB
-	I-LIVB
positive	I-LIVB
and	O	O
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
bacteria	I-LIVB
.	O	O

Primary	O
bronchial	B-ANAT
epithelial	I-ANAT
cells	I-ANAT
were	O	O
grown	O	O
from	O	O
10	O	O
asthmatic	B-LIVB
individuals	I-LIVB
and	O	O
the	O	O
effects	O
of	O	O
macrolides	B-CHEM
on	O	O
rhinovirus	B-LIVB
replication	B-PHYS
were	O	O
also	O	O
examined	B-DISO
.	O	O

Another	O	O
30	O	O
structurally	O	O
similar	O	O
macrolides	B-CHEM
were	O	O
also	O	O
examined	B-DISO
.	O	O

The	O	O
oleandomycin	B-CHEM
derivative	O
Mac5	B-CHEM
,	O	O
compared	O	O
with	O	O
azithromycin	B-CHEM
,	O	O
showed	O	O
superior	O	O
induction	O
(	O	O
up	O	O
to	O	O
5	O	O
-	O	O
fold	O	O
,	O	O
EC	O
50	O	O
=	O	O
5	O	O
-	O	O
11	O	O
μM	O	O
)	O	O
of	O	O
rhinovirus	B-LIVB
-	O	O
induced	O
type	O
I	O
IFNβ	O
,	O	O
type	O
III	O
IFNλ1	O
and	O	O
type	O
III	O
IFNλ2	O
/	O
3	O
mRNA	B-CHEM
and	O	O
the	O	O
IFN	B-CHEM
-	O	O
stimulated	B-PHEN
genes	O
viperin	O
and	O	O
MxA	O
,	O	O
yet	O	O
had	O	O
no	O
effect	O
on	O	O
IL	O
-	O
6	O
and	O	O
IL	O
-	O
8	O
mRNA	B-CHEM
.	O	O

Mac5	B-CHEM
also	O	O
suppressed	O
rhinovirus	B-LIVB
replication	B-PHYS
at	O	O
48	O	O
h	O
,	O	O
proving	O	O
antiviral	B-PHYS
activity	I-PHYS
.	O	O

Mac5	B-CHEM
showed	O	O
antibacterial	B-PHYS
activity	I-PHYS
against	O	O
Gram	B-LIVB
-	I-LIVB
positive	I-LIVB
Streptococcus	B-LIVB
pneumoniae	I-LIVB
;	O	O
however	O	O
,	O	O
it	O	O
did	O	O
not	O	O
have	O	O
any	O	O
antibacterial	B-PHYS
properties	I-PHYS
compared	O
with	O	O
azithromycin	B-CHEM
when	O	O
used	O	O
against	O	O
Gram	B-LIVB
-	I-LIVB
negative	I-LIVB
Escherichia	B-LIVB
coli	I-LIVB
(	O	O
as	O	O
a	O	O
model	O	O
organism	O	O
)	O	O
and	O	O
also	O	O
the	O	O
respiratory	B-LIVB
pathogens	I-LIVB
Pseudomonas	B-LIVB
aeruginosa	I-LIVB
and	O	O
non	O	O
-	O	O
typeable	O	O
Haemophilus	B-LIVB
influenzae	I-LIVB
.	O	O

Further	O	O
non	O	O
-	O	O
toxic	O	O
Mac5	B-CHEM
derivatives	O	O
were	O	O
identified	O
with	O	O
various	O	O
anti	O
-	O
inflammatory	O
,	O	O
antiviral	B-PHYS
and	O	O
antibacterial	B-PHYS
activities	I-PHYS
.	O	O

The	O	O
data	O
support	O	O
the	O	O
idea	O	O
that	O	O
macrolides	B-CHEM
have	O	O
antiviral	B-PHYS
properties	I-PHYS
through	O	O
a	O	O
mechanism	O
that	O	O
is	O	O
yet	O	O
to	O	O
be	O	O
ascertained	O	O
.	O	O

We	O	O
also	O	O
provide	O	O
evidence	O
that	O	O
macrolides	B-CHEM
can	O	O
be	O	O
developed	O	O
with	O	O
anti	O
-	O
inflammatory	O
,	O	O
antibacterial	B-PHYS
and	O	O
antiviral	B-PHYS
activity	I-PHYS
and	O	O
show	O	O
surprising	O	O
versatility	O	O
depending	O	O
on	O	O
the	O	O
clinical	O
need	O
.	O	O

Impact	O	O
of	O	O
AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
in	O	O
combination	O	O
with	O	O
chromosomal	B-ANAT
-mediated	O	O
mechanisms	O
on	O	O
clinical	O
quinolone	B-CHEM
resistance	B-PHEN
in	O	O
Escherichia	B-LIVB
coli	I-LIVB
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
is	O	O
the	O	O
most	O	O
prevalent	O	O
plasmid	B-CHEM
-mediated	O	O
fluoroquinolone	B-CHEM
(	O	O
FQ	B-CHEM
)	O	O
resistance	B-PHYS
mechanism	I-PHYS
in	O	O
Enterobacteriaceae	B-LIVB
.	O	O

We	O	O
aimed	O	O
to	O	O
analyse	O	O
the	O	O
interplay	O	O
between	O	O
this	O	O
plasmid	B-CHEM
-mediated	O	O
gene	O
and	O	O
chromosomal	B-ANAT
-mediated	O	O
quinolone	B-CHEM
resistance	B-PHYS
mechanisms	I-PHYS
on	O	O
both	O	O
FQ	B-CHEM
resistance	B-PHEN
and	O	O
bacterial	B-LIVB
fitness	B-PHYS
in	O	O
Escherichia	B-LIVB
coli	I-LIVB
.	O	O

E	B-LIVB
.	I-LIVB

coli	I-LIVB
ATCC	I-LIVB
25922	I-LIVB
and	O	O
derived	O	O
isogenic	B-LIVB
strains	I-LIVB
carrying	O	O
chromosomal	B-ANAT
-mediated	O	O
quinolone	B-CHEM
resistance	B-PHEN
modifications	B-PROC
(	O	O
Ser83Leu	B-PHYS
-	I-PHYS
Asp87Asn	I-PHYS
in	O	O
GyrA	B-CHEM
,	O	O
Ser80Arg	B-PHYS
in	O	O
ParC	B-CHEM
and	O	O
/	O	O
or	O	O
a	O	O
marR	B-PHYS
gene	I-PHYS
deletion	I-PHYS
)	O	O
were	O	O
electroporated	B-PROC
with	O	O
a	O	O
pBK	B-CHEM
-	I-CHEM
CMV	I-CHEM
vector	B-CHEM
encoding	O
AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
.	O	O

The	O	O
MICs	B-PHEN
of	O	O
FQs	B-CHEM
were	O	O
determined	O	O
by	O	O
microdilution	B-PROC
and	O	O
bactericidal	B-PHYS
activity	I-PHYS
was	O	O
determined	O	O
using	O	O
time	O
-	O
kill	O
curves	O
.	O	O

A	O	O
peritoneal	B-LIVB
sepsis	I-LIVB
murine	I-LIVB
model	I-LIVB
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
in	O
vivo	O
impact	O	O
.	O	O

Bacterial	B-LIVB
fitness	B-PHYS
was	O	O
analysed	O	O
using	O	O
growth	O	O
curves	O	O
and	O	O
competition	B-PROC
assays	I-PROC
.	O	O

The	O	O
presence	O	O
of	O	O
the	O	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
increased	O	O
the	O	O
MICs	B-PHEN
of	O	O
ciprofloxacin	B-CHEM
and	O	O
norfloxacin	B-CHEM
4	O	O
-	O	O
8	O	O
-	O	O
fold	O	O
for	O	O
all	O	O
E	B-LIVB
.	I-LIVB

coli	I-LIVB
genotypes	B-PHYS
,	O	O
independently	O	O
of	O	O
the	O	O
initial	O	O
resistance	B-PHEN
level	O	O
.	O	O

Combination	O	O
of	O	O
the	O	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
with	O	O
three	O	O
or	O	O
four	O	O
chromosomal	B-ANAT
mechanisms	O
was	O	O
necessary	O	O
to	O	O
reach	O	O
MIC	B-PHEN
values	I-PHEN
above	O	O
the	O	O
susceptible	O	O
category	O	O
.	O	O

Killing	O
curve	O
assays	O
showed	O	O
a	O	O
clear	O	O
selective	O	O
advantage	O	O
for	O	O
survival	O
in	O	O
strains	O
harbouring	O	O
the	O	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
(	O	O
up	O	O
to	O	O
7	O	O
log10	O	O
cfu	O	O
/	O	O
mL	O	O
after	O	O
24	O	O
h	O	O
)	O	O
.	O	O

AAC	B-CHEM
(	I-CHEM
6	I-CHEM
'	I-CHEM
)	I-CHEM
-	I-CHEM
Ib	I-CHEM
-	I-CHEM
cr	I-CHEM
significantly	O	O
reduced	O	O
the	O	O
ciprofloxacin	B-CHEM
efficacy	O	O
in	O
vivo	O
.	O	O

In	O	O
terms	O	O
of	O	O
bacterial	B-LIVB
fitness	B-PHYS
cost	I-PHYS
,	O	O
maximal	O	O
OD	O	O
was	O	O
significantly	O	O
lower	O	O
for	O	O
all	O	O
strains	O
harbouring	O	O
the	O	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
,	O	O
independently	O	O
of	O	O
chromosomal	B-DISO
mutations	I-DISO
associated	O	O
.	O	O

The	O	O
aac	O
(	O
6	O
'	O
)	O
-	O
Ib	O
-	O
cr	O
gene	O
,	O	O
in	O	O
spite	O	O
of	O	O
producing	O	O
low	O	O
-	O	O
level	O	O
resistance	B-PHEN
by	O	O
itself	O	O
,	O	O
plays	O	O
a	O	O
relevant	O	O
role	O	O
in	O	O
acquisition	O	O
of	O	O
a	O	O
clinical	O
level	O
of	O	O
ciprofloxacin	B-CHEM
and	O	O
norfloxacin	B-CHEM
resistance	B-PHEN
,	O	O
when	O	O
combined	O	O
with	O	O
three	O	O
or	O	O
four	O	O
chromosomal	B-DISO
mutations	I-DISO
,	O	O
both	O	O
in	O
vitro	O
and	O	O
in	O
vivo	O
.	O	O

Cluster	O
-	O	O
dependent	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
in	O	O
Enterobacter	B-LIVB
cloacae	I-LIVB
complex	I-LIVB
Aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
:	O	O
(	O	O
i	O	O
)	O	O
evaluate	B-PROC
whether	O	O
the	O	O
cluster	O
membership	O	O
could	O	O
have	O	O
an	O	O
impact	O
on	O	O
hetero	O
-	O
resistance	O
phenotype	B-PHYS
to	O	O
colistin	B-CHEM
in	O	O
the	O	O
Enterobacter	B-LIVB
cloacae	I-LIVB
complex	I-LIVB
(	O	O
ECC	B-LIVB
)	O	O
;	O	O
and	O	O
(	O	O
ii	O	O
)	O	O
determine	O	O
the	O	O
genetic	O
mechanism	O
of	O	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
in	O	O
ECC	B-LIVB
.	O	O

A	O	O
collection	O
of	O	O
124	O	O
clinical	O
isolates	B-CHEM
belonging	O	O
to	O	O
13	O	O
clusters	O
were	O	O
used	O	O
to	O	O
analyse	B-PROC
the	O	O
hetero	O
-	O
resistance	O
phenotype	B-PHYS
(	O	O
MICs	B-PROC
were	O	O
determined	O
using	O
the	O	O
broth	B-PROC
microdilution	I-PROC
method	I-PROC
,	O	O
Etest	B-PROC
and	O	O
population	B-PROC
analysis	I-PROC
profiling	I-PROC
)	O	O
.	O	O

Different	O
mutants	B-DISO
(	O	O
ΔphoP	O
,	O	O
ΔphoQ	O
,	O	O
ΔphoPQ	O
,	O	O
ΔpmrA	O
,	O	O
ΔpmrB	O
,	O	O
ΔpmrAB	O
,	O	O
ΔarnE	O
,	O	O
ΔarnF	O
and	O	O
ΔarnBCADTEF	O
)	O	O
were	O	O
constructed	O
and	O	O
tested	O
for	O	O
their	O	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
phenotype	B-PHYS
.	O	O

Based	O	O
on	O	O
broth	B-PROC
microdilution	I-PROC
and	O	O
Etest	B-PROC
results	B-PHEN
,	O	O
it	O	O
was	O	O
shown	O	O
that	O	O
the	O	O
hetero	O
-	O
resistance	O
to	O	O
colistin	B-CHEM
depended	O	O
on	O	O
the	O	O
cluster	O
:	O	O
strains	B-LIVB
from	O	O
clusters	O
I	O	O
,	O	O
II	O	O
,	O	O
IV	O	O
,	O	O
VII	O	O
,	O	O
IX	O	O
,	O	O
X	O	O
,	O	O
XI	O	O
and	O	O
XII	O	O
were	O	O
usually	O	O
hetero	O
-	O
resistant	O
,	O	O
whereas	O	O
those	O	O
from	O	O
clusters	O
III	O	O
,	O	O
V	O	O
,	O	O
VI	O	O
,	O	O
VIII	O	O
and	O	O
XIII	O	O
were	O	O
categorized	O
as	O	O
susceptible	O
.	O	O

However	O	O
,	O	O
for	O	O
some	O	O
cluster	O
V	O	O
and	O	O
VIII	O	O
strains	B-LIVB
,	O	O
a	O	O
small	O
proportion	O
(	O	O
<	O	O
10	O	O
(	O	O
-	O	O
7	O	O
)	O	O
)	O	O
of	O	O
cells	B-ANAT
appeared	O	O
resistant	O
when	O	O
tested	O
by	O	O
population	O	O
analysis	O	O
profiling	O	O
.	O	O

From	O	O
a	O	O
mechanistic	O	O
point	O	O
of	O	O
view	O	O
,	O	O
analysis	B-PROC
of	O	O
mutants	B-DISO
revealed	O
that	O	O
the	O	O
mechanism	O
of	O	O
hetero	O
-	O
resistance	O
was	O	O
mainly	O	O
due	O	O
to	O	O
the	O	O
expression	B-PHYS
of	O	O
the	O	O
arn	O
operon	O
and	O	O
the	O	O
phoP	B-CHEM
/	O	O
phoQ	B-CHEM
two	B-CHEM
-	I-CHEM
component	I-CHEM
regulatory	I-CHEM
system	I-CHEM
.	O	O

Because	O	O
the	O	O
colistin	B-CHEM
hetero	O
-	O
resistance	O
appeared	O	O
cluster	O
-	O	O
dependent	O
in	O	O
the	O	O
ECC	B-LIVB
,	O	O
it	O	O
should	O	O
be	O	O
advocated	O	O
to	O	O
determine	O	O
the	O	O
cluster	O
of	O	O
the	O	O
strain	B-LIVB
associated	O
with	O
the	O	O
infection	B-DISO
in	O	O
parallel	O	O
with	O	O
the	O	O
MIC	B-PROC
of	O	O
colistin	B-CHEM
.	O	O

The	O	O
resistance	O
mechanism	O
may	O	O
not	O	O
be	O	O
similar	O	O
to	O	O
other	O	O
Enterobacteriaceae	B-LIVB
since	O	O
only	O	O
the	O	O
two	B-CHEM
-	I-CHEM
component	I-CHEM
regulatory	I-CHEM
system	I-CHEM
PhoP	B-CHEM
/	O	O
PhoQ	B-CHEM
(	O	O
and	O	O
not	O	O
PmrA	B-CHEM
/	O	O
PmrB	B-CHEM
)	O	O
seemed	O	O
to	O	O
play	O	O
a	O	O
role	O	O
in	O	O
resistance	O
regulation	B-PHEN
.	O	O

Management	B-PROC
of	O	O
skin	B-DISO
and	I-DISO
soft	I-DISO
-	I-DISO
tissue	I-DISO
infections	I-DISO
at	O	O
a	O	O
community	O	O
teaching	B-OBJC
hospital	I-OBJC
using	O	O
a	O	O
severity	O
-	O
of	O
-	O
illness	O
tool	O
Skin	B-DISO
and	I-DISO
soft	I-DISO
-	I-DISO
tissue	I-DISO
infections	I-DISO
(	O	O
SSTIs	B-DISO
)	O	O
encompass	O	O
a	O	O
diverse	O
range	O
of	O	O
infections	B-DISO
of	O	O
varying	O	O
severity	O
.	O	O

The	O	O
Clinical	O
Resource	O
Efficiency	O
Support	O
Team	O
(	O
CREST	O
)	O
scoring	O
system	O
stratifies	O
patients	B-LIVB
into	O	O
four	O	O
classes	O
(	O	O
I	O	O
=	O	O
least	O	O
severe	O
to	O	O
IV	O	O
=	O	O
most	O	O
severe	O
)	O	O
based	O	O
on	O	O
the	O	O
Standardized	O
Early	O
Warning	O
Score	O
(	O	O
SEWS	O
)	O	O
.	O	O

The	O	O
objective	O
of	O	O
this	O	O
study	B-PROC
was	O	O
to	O	O
apply	O	O
CREST	O
to	O	O
hospitalized	B-LIVB
patients	I-LIVB
with	O	O
SSTIs	B-DISO
in	O	O
order	O	O
to	O	O
quantify	O	O
disease	O
severity	O
and	O	O
evaluate	B-PROC
appropriateness	O	O
of	O	O
antibiotic	B-CHEM
management	O	O
.	O	O

This	O	O
was	O	O
a	O	O
retrospective	B-PROC
,	O	O
hypothesis	O
-generating	O	O
,	O	O
single	O	O
-	O	O
centre	O	O
evaluation	B-PROC
of	O	O
hospitalized	B-LIVB
patients	I-LIVB
with	O	O
SSTIs	B-DISO
admitted	B-PROC
in	O	O
2011	O	O
.	O	O

Based	O	O
on	O	O
CREST	O
classification	O	O
,	O	O
the	O	O
empirical	O
antimicrobial	B-CHEM
choices	O	O
were	O	O
categorized	O
as	O	O
appropriate	O	O
,	O	O
over	B-PROC
-	I-PROC
treatment	I-PROC
or	O	O
under	B-PROC
-	I-PROC
treatment	I-PROC
.	O	O

A	O	O
total	O	O
of	O	O
369	O	O
patients	B-LIVB
were	O	O
screened	O	O
and	O	O
200	O	O
met	O	O
the	O	O
inclusion	O
criteria	O
.	O	O

The	O	O
majority	O	O
of	O	O
patients	B-LIVB
were	O	O
classified	O
as	O	O
either	O	O
CREST	O
class	O
I	O
(	O	O
n	O	O
=	O	O
68	O	O
)	O	O
or	O	O
class	O
I	O
I	O	O
(	O	O
n	O	O
=	O	O
102	O	O
)	O	O
.	O	O

Over	B-PROC
-	I-PROC
treatment	I-PROC
was	O	O
more	O	O
common	O	O
in	O	O
the	O	O
less	O	O
severe	O
classes	O
(	O	O
88	O	O
%	O	O
and	O	O
32	O	O
%	O	O
in	O	O
class	O
I	O
and	O	O
class	O
II	O
,	O	O
respectively	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
05	O	O
)	O	O
.	O	O

Sixty	O	O
-	O	O
three	O	O
percent	O
of	O	O
class	O
I	O
(	O	O
n	O	O
=	O	O
43	O	O
)	O	O
were	O	O
over	B-PROC
-	I-PROC
treated	I-PROC
due	O	O
to	O	O
both	O	O
the	O	O
use	O	O
of	O	O
intravenous	O
antibiotic	B-CHEM
s	O	O
when	O	O
oral	B-PROC
therapy	I-PROC
was	O	O
sufficient	O	O
and	O	O
use	O	O
of	O	O
unnecessarily	O	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotics	I-CHEM
.	O	O

In	O	O
contrast	O	O
,	O	O
25	O	O
%	O	O
(	O	O
n	O	O
=	O	O
26	O	O
)	O	O
of	O	O
class	O
II	O
were	O	O
over	B-PROC
-	I-PROC
treated	I-PROC
due	O	O
to	O	O
use	O	O
of	O	O
unnecessarily	O	O
broad	B-CHEM
-	I-CHEM
spectrum	I-CHEM
antibiotics	I-CHEM
.	O	O

Overall	O	O
clinical	B-DISO
failure	I-DISO
rates	O	O
remained	O	O
low	O	O
with	O	O
only	O	O
1	O	O
%	O	O
,	O	O
4	O	O
%	O	O
and	O	O
17	O	O
%	O	O
of	O	O
patients	B-LIVB
unable	O	O
to	O	O
achieve	O	O
initial	O	O
response	B-PHYS
in	O	O
class	O
II	O
,	O	O
class	O
III	O
and	O	O
class	O
IV	O
.	O	O

Retrospective	O
application	B-PROC
of	O	O
CREST	O
identified	O	O
opportunities	O	O
to	O	O
improve	O	O
the	O	O
management	B-PROC
of	O	O
SSTIs	B-DISO
.	O	O

CREST	O
can	O	O
be	O	O
of	O	O
great	O	O
value	O	O
in	O	O
discriminating	O	O
less	O	O
-	O	O
severe	O
SSTIs	B-DISO
,	O	O
which	O	O
can	O	O
be	O	O
treated	B-PROC
on	O	O
an	O	O
outpatient	B-LIVB
basis	O	O
.	O	O

Levels	O
of	O	O
bone	O
markers	B-PHYS
in	O	O
a	O	O
population	B-LIVB
of	O	O
infants	B-LIVB
exposed	I-LIVB
in	B-LIVB
utero	I-LIVB
and	O	O
during	O	O
breastfeeding	B-PHYS
to	O	O
tenofovir	B-CHEM
within	O	O
an	O	O
Option	B-PROC
B	I-PROC
+	I-PROC
programme	I-PROC
in	O	O
Malawi	B-GEOG
No	O
data	O
are	O	O
available	O	O
on	O	O
bone	B-PHYS
metabolism	I-PHYS
in	O	O
infants	B-LIVB
exposed	I-LIVB
to	O	O
tenofovir	B-CHEM
during	O	O
breastfeeding	B-PHYS
.	O	O

We	O	O
investigated	O
bone	B-PHYS
metabolism	I-PHYS
markers	B-PHYS
in	O	O
the	O	O
first	O	O
year	O
of	O	O
life	O
in	O	O
infants	B-LIVB
from	O	O
mothers	B-LIVB
who	O	O
received	O	O
tenofovir	B-CHEM
,	O	O
lamivudine	B-CHEM
and	O	O
efavirenz	B-CHEM
during	O	O
pregnancy	B-PHYS
and	O	O
12	O	O
months	O
of	O	O
breastfeeding	B-PHYS
in	O	O
a	O	O
national	B-PROC
Option	I-PROC
B	I-PROC
+	I-PROC
programme	I-PROC
in	O	O
Malawi	B-GEOG
.	O	O

Serum	B-ANAT
samples	B-OBJC
collected	O	O
at	O	O
6	O	O
and	O	O
12	O	O
months	O
in	O	O
tenofovir	B-CHEM
-	O	O
exposed	B-LIVB
infants	I-LIVB
and	O	O
in	O	O
a	O	O
small	O
sample	O
of	O	O
tenofovir	B-CHEM
-	O	O
unexposed	B-LIVB
infants	I-LIVB
from	O	O
the	O	O
same	O	O
clinical	B-OBJC
centre	I-OBJC
were	O	O
analysed	B-PROC
in	O	O
batches	O
for	O	O
levels	O
of	O	O
bone	B-CHEM
-	I-CHEM
specific	I-CHEM
alkaline	I-CHEM
phosphatase	I-CHEM
(	O	O
BAP	B-CHEM
;	O	O
marker	B-PHYS
of	O	O
bone	B-PHYS
formation	I-PHYS
)	O	O
and	O	O
of	O	O
C	B-CHEM
-	I-CHEM
terminal	I-CHEM
telopeptide	I-CHEM
of	I-CHEM
type	I-CHEM
I	I-CHEM
collagen	I-CHEM
(	O	O
CTX	B-CHEM
;	O	O
marker	B-PHYS
of	O	O
bone	B-PHYS
resorption	I-PHYS
)	O	O
.	O	O

Overall	O	O
,	O	O
136	O	O
tenofovir	B-CHEM
-	O	O
exposed	B-LIVB
infants	I-LIVB
were	O	O
evaluated	B-PROC
.	O	O

No	O	O
infant	B-LIVB
had	O	O
at	O	O
either	O	O
timepoint	O
CTX	B-CHEM
values	O
above	O	O
the	O	O
upper	O
normal	O
limit	O
,	O	O
while	O	O
most	O	O
of	O	O
them	O	O
had	O	O
at	O	O
6	O	O
and	O	O
12	O	O
months	O
levels	O
of	O	O
BAP	B-CHEM
above	O	O
the	O	O
upper	O
normal	O
limit	O
for	O	O
the	O	O
age	B-PHYS
range	O
.	O	O

Levels	O	O
of	O	O
bone	O
markers	B-PHYS
showed	O	O
no	O	O
differences	O
by	O	O
gender	B-PHYS
and	O	O
no	O	O
association	O
with	O	O
growth	B-DISO
parameters	I-DISO
.	O	O

Tenofovir	B-CHEM
-	O	O
unexposed	B-LIVB
and	O	O
-	O	O
exposed	B-LIVB
children	I-LIVB
had	O	O
similar	O
mean	O
levels	O
of	O	O
bone	O
markers	B-PHYS
at	O	O
6	O	O
months	O
(	O	O
CTX	B-CHEM
:	O	O
0	O	O
.	O	O

62	O	O
versus	O	O
0	O	O
.	O	O
55	O	O
ng	O	O
/	O	O
mL	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
122	O	O
;	O	O
BAP	B-CHEM
:	O	O
384	O	O
versus	O	O
362	O	O
U	O	O
/	O	O
L	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O
631	O	O
)	O	O
.	O	O

No	B-DISO
significant	I-DISO
association	O
between	O	O
treatment	B-PROC
with	O	O
tenofovir	B-CHEM
and	O	O
CTX	B-CHEM
or	O	O
BAP	B-CHEM
levels	O
was	O	O
found	O	O
.	O	O

The	O	O
high	O
levels	O
of	O	O
BAP	B-CHEM
,	O	O
coupled	O	O
to	O	O
the	O	O
normal	O
levels	O
observed	O
for	O	O
CTX	B-CHEM
,	O	O
might	O	O
reflect	O	O
primarily	O	O
skeletal	B-ANAT
growth	B-PHYS
.	O	O

Potential	O
negative	B-DISO
effects	O
of	O	O
prolonged	O
exposure	O
to	O
tenofovir	B-CHEM
through	O	O
breastfeeding	B-PHYS
cannot	O	O
however	O	O
be	O	O
excluded	O
and	O	O
longitudinal	B-PROC
studies	I-PROC
that	O	O
evaluate	B-PROC
bone	B-PHYS
mineralization	I-PHYS
status	O
in	O	O
children	B-LIVB
enrolled	O	O
in	O	O
Option	B-PROC
B	I-PROC
+	I-PROC
programmes	I-PROC
are	O	O
warranted	O	O
.	O	O

Breakthrough	O
viridans	B-DISO
streptococcal	I-DISO
bacteremia	I-DISO
in	O	O
allogeneic	B-PROC
hematopoietic	I-PROC
stem	I-PROC
cell	I-PROC
transplant	I-PROC
recipients	B-LIVB
receiving	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
in	O	O
a	O	O
Japanese	B-GEOG
hospital	B-OBJC
Breakthrough	O
viridans	B-DISO
streptococcal	I-DISO
bacteremia	I-DISO
(	O	O
VSB	B-DISO
)	O	O
in	O	O
patients	B-LIVB
with	O	O
hematological	B-DISO
malignancy	I-DISO
receiving	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
is	O	O
a	O	O
major	O
blood	B-DISO
stream	I-DISO
infection	I-DISO
(	O	O
BSI	B-DISO
)	O	O
occurring	O
during	O
febrile	B-DISO
neutropenia	I-DISO
.	O	O

However	O	O
,	O	O
clinical	O
data	O
focused	O
on	O	O
VSB	B-DISO
in	O	O
allogeneic	B-PROC
hematopoietic	I-PROC
stem	I-PROC
cell	I-PROC
transplant	I-PROC
(	O	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
)	O	O
recipients	B-LIVB
are	O	O
lacking	O
.	O	O

The	O	O
medical	O
records	O
of	O	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
recipients	B-LIVB
who	O	O
received	O
oral	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
between	O	O
January	O	O
2011	O	O
and	O	O
August	O	O
2013	O	O
at	O	O
Toranomon	B-OBJC
Hospital	I-OBJC
were	O	O
reviewed	O
to	O	O
evaluate	B-PROC
breakthrough	O
VSB	B-DISO
.	O	O

Stored	O	O
viridans	B-LIVB
streptococcal	I-LIVB
(	O	O
VGS	B-LIVB
)	O	O
species	O
were	O	O
identified	O
by	O	O
using	O
sodA	O
gene	O
sequencing	B-PROC
,	O	O
and	O	O
were	O	O
assessed	O
for	O	O
drug	B-PHEN
susceptibility	I-PHEN
.	O	O

Among	O	O
the	O	O
184	O	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
recipients	B-LIVB
on	O	O
levofloxacin	B-CHEM
prophylaxis	B-PROC
,	O	O
28	O	O
(	O	O
15	O	O
.	O	O
2	O	O
%	O	O
)	O	O
experienced	O	O
breakthrough	O
VSB	B-DISO
.	O	O

All	O	O
of	O	O
the	O	O
28	O	O
recipients	B-LIVB
with	O	O
VSB	B-DISO
were	O	O
treated	O
with	O	O
a	O	O
cefepime	B-CHEM
-	O	O
based	O
or	O	O
piperacillin	B-CHEM
/	I-CHEM
tazobactam	I-CHEM
-	O	O
based	O
regimen	B-PROC
.	O	O

The	O	O
susceptibility	B-PHEN
rates	O
of	O	O
the	O	O
VGS	B-LIVB
strains	B-LIVB
for	O	O
levofloxacin	B-CHEM
,	O	O
cefepime	B-CHEM
,	O	O
piperacillin	B-CHEM
/	I-CHEM
tazobactam	I-CHEM
,	O	O
meropenem	B-CHEM
,	O	O
and	O	O
vancomycin	B-CHEM
were	O	O
0	O	O
%	O	O
,	O	O
95	O	O
%	O	O
,	O	O
100	O	O
%	O	O
,	O	O
100	O	O
%	O	O
,	O	O
and	O	O
100	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Both	O	O
the	O	O
MIC50	B-PROC
(	O	O
minimum	B-PROC
inhibitory	I-PROC
concentration	I-PROC
)	O	O
and	O	O
the	O	O
MIC90	B-PROC
of	O	O
ceftazidim	B-CHEM
(	O	O
0	O	O
.	O	O
5	O	O
μg	O	O
/	O	O
mL	O	O
and	O	O
2	O	O
μg	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
)	O	O
were	O	O
higher	O
than	O	O
the	O	O
MIC90	B-PROC
of	O	O
all	O	O
the	O	O
other	O	O
anti	B-CHEM
-	I-CHEM
pseudomonal	I-CHEM
beta	I-CHEM
-	I-CHEM
lactams	I-CHEM
(	O	O
APBLs	B-CHEM
)	O	O
.	O	O

Only	O	O
1	O	O
VGS	B-LIVB
strain	B-LIVB
had	O	O
a	O	O
penicillin	B-CHEM
MIC	B-PROC
≥	O	O
2	O	O
μg	O	O
/	O	O
mL	O	O
by	O	O
the	O	O
Etest	B-PROC
(	O	O
3	O	O
.	O	O
6	O	O
%	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O
cases	O
with	O	O
acute	B-DISO
respiratory	I-DISO
distress	I-DISO
syndrome	I-DISO
(	O	O
ARDS	B-DISO
)	O	O
that	O	O
was	O	O
associated	O
with	O
VSB	B-DISO
,	O	O
although	O	O
the	O	O
rate	O
of	O	O
viridans	B-DISO
group	I-DISO
streptococcal	I-DISO
shock	I-DISO
syndrome	I-DISO
was	O	O
high	O
(	O	O
26	O	O
%	O	O
)	O	O
.	O	O

The	O	O
crude	O	O
30	O
-	O
day	O
mortality	O
rate	O
in	O	O
the	O	O
VSB	B-DISO
group	O
(	O	O
10	O	O
.	O	O
7	O	O
%	O	O
)	O	O
did	O	O
not	O
differ	O
significantly	O
from	O	O
that	O	O
in	O	O
the	O	O
BSI	B-DISO
without	O
VSB	B-DISO
group	O
(	O	O
9	O	O
.	O	O
3	O	O
%	O	O
)	O	O
or	O	O
non	O
-	O	O
BSI	B-DISO
group	O
(	O	O
7	O	O
.	O	O

0	O	O
%	O	O
)	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
77	O	O
)	O	O
.	O	O

Also	O	O
,	O	O
VSB	B-DISO
was	O	O
not	O
a	O	O
risk	B-DISO
factor	I-DISO
for	O	O
all	O	O
-	O	O
cause	O	O
mortality	O
up	O	O
to	O	O
60	O
days	O
following	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O
43	O	O
)	O	O
.	O	O

APBL	B-CHEM
with	O	O
increased	O
anti	B-DISO
-	I-DISO
VGS	I-DISO
activity	I-DISO
(	O	O
APBL	B-DISO
-	I-DISO
VA	I-DISO
)	O	O
monotherapy	B-PROC
would	O	O
typically	O	O
be	O	O
optimal	O
for	O	O
treating	O
the	O	O
VGS	B-LIVB
strains	B-LIVB
in	O	O
this	O	O
setting	O	O
.	O	O

Indication	O	O
of	O	O
adding	O	O
an	O	O
empiric	O	O
anti	B-CHEM
-	I-CHEM
gram	I-CHEM
-	I-CHEM
positive	I-CHEM
agent	I-CHEM
to	O	O
APBL	B-DISO
-	I-DISO
VA	I-DISO
for	O	O
treating	O
VSB	B-DISO
should	O	O
depend	O	O
on	O	O
local	O
factors	O
,	O	O
such	O	O
as	O	O
the	O	O
susceptibility	B-PHEN
results	O
.	O	O

In	O	O
addition	O	O
,	O	O
breakthrough	O
VSB	B-DISO
is	O	O
probably	O	O
not	O
a	O	O
major	O
cause	B-DISO
of	I-DISO
death	I-DISO
in	O	O
allo	B-PROC
-	I-PROC
HSCT	I-PROC
settings	O	O
,	O	O
where	O	O
beta	B-CHEM
-	I-CHEM
lactam	I-CHEM
non	B-LIVB
-	I-LIVB
susceptible	I-LIVB
VGS	I-LIVB
and	O	O
the	O	O
ARDS	B-DISO
are	O	O
rare	O
.	O	O

Enforcement	O
of	O	O
the	O	O
Emergency	O
Medical	O
Treatment	O
and	O
Labor	O
Act	O
,	O	O
2005	O	O
to	O	O
2014	O	O
We	O	O
determine	O	O
the	O	O
incidence	O
of	O	O
and	O	O
trends	O
in	O	O
enforcement	O
of	O	O
the	O	O
Emergency	O
Medical	O
Treatment	O
and	O
Labor	O
Act	O
(	O	O
EMTALA	O
)	O	O
during	O	O
the	O	O
past	O	O
decade	O	O
.	O	O

We	O	O
obtained	O	O
a	O	O
comprehensive	O	O
list	O	O
of	O	O
all	O	O
EMTALA	O
investigations	B-PROC
conducted	O	O
between	O	O
2005	O	O
and	O	O
2014	O	O
directly	O	O
from	O	O
the	O	O
Centers	O
for	O
Medicare	O
&	O
Medicaid	O
Services	O
(	O	O
CMS	O
)	O	O
through	O	O
a	O	O
Freedom	O
of	O
Information	O
Act	O
request	O
.	O	O

Characteristics	O	O
of	O	O
EMTALA	O
investigations	B-PROC
and	O	O
resulting	O	O
citation	O
for	O	O
violations	B-DISO
during	O	O
the	O	O
study	O	O
period	O	O
are	O	O
described	O	O
.	O	O

Between	O	O
2005	O	O
and	O	O
2014	O	O
,	O	O
there	O	O
were	O	O
4	O	O
,	O	O
772	O	O
investigations	B-PROC
,	O	O
of	O	O
which	O	O
2	O	O
,	O	O
118	O	O
(	O	O
44	O	O
%	O	O
)	O	O
resulted	O	O
in	O	O
citations	O
for	O	O
EMTALA	O
deficiencies	O
at	O	O
1	O	O
,	O	O
498	O	O
(	O	O
62	O	O
%	O	O
)	O	O
of	O	O
2	O	O
,	O	O
417	O	O
hospitals	B-OBJC
investigated	O	O
.	O	O

Investigations	O	O
were	O	O
conducted	O	O
at	O	O
43	O	O
%	O	O
of	O	O
hospitals	B-OBJC
with	O	O
CMS	O
provider	O	O
agreements	O	O
,	O	O
and	O	O
citations	O
issued	O	O
at	O	O
27	O	O
%	O	O
.	O	O

On	O	O
average	O	O
,	O	O
9	O	O
%	O	O
of	O	O
hospitals	B-OBJC
were	O	O
investigated	O	O
and	O	O
4	O	O
.	O	O

3	O	O
%	O	O
were	O	O
cited	O	O
for	O	O
EMTALA	O
violation	B-DISO
annually	O	O
.	O	O

The	O	O
proportion	O	O
of	O	O
hospitals	B-OBJC
subject	O	O
to	O	O
EMTALA	O
investigation	B-PROC
decreased	O	O
from	O	O
10	O	O
.	O	O

8	O	O
%	O	O
to	O	O
7	O	O
.	O	O
2	O	O
%	O	O
,	O	O
and	O	O
citations	O	O
from	O	O
5	O	O
.	O	O

3	O	O
%	O	O
to	O	O
3	O	O
.	O	O

2	O	O
%	O	O
,	O	O
between	O	O
2005	O	O
and	O	O
2014	O	O
.	O	O

There	O	O
were	O	O
3	O	O
.	O	O

9	O	O
EMTALA	O
investigations	B-PROC
and	O	O
1	O	O
.	O	O
7	O	O
citations	O
per	O	O
million	O	O
emergency	B-OBJC
department	I-OBJC
(	B-OBJC
ED	I-OBJC
)	O	O
visits	O
during	O	O
the	O	O
study	O	O
period	O	O
.	O	O

We	O	O
report	O	O
the	O	O
first	O	O
national	O
estimates	O
of	O	O
EMTALA	O
enforcement	B-DISO
activities	I-DISO
in	O	O
more	O	O
than	O	O
a	O	O
decade	O	O
.	O	O

Although	O	O
EMTALA	O
investigations	B-PROC
and	O	O
citations	O
were	O	O
common	O	O
at	O	O
the	O	O
hospital	B-PROC
level	I-PROC
,	O	O
they	O	O
were	O	O
rare	O	O
at	O	O
the	O	O
ED	B-OBJC
-	O	O
visit	O
level	O
.	O	O

CMS	O
actively	O	O
pursued	O	O
EMTALA	O
investigations	B-PROC
and	O	O
issued	O	O
citations	O	O
throughout	O	O
the	O	O
study	O	O
period	O	O
,	O	O
with	O	O
half	O	O
of	O	O
hospitals	B-OBJC
subject	O	O
to	O	O
EMTALA	O
investigations	B-PROC
and	O	O
a	O	O
quarter	O	O
receiving	O	O
a	O	O
citation	O
for	O	O
EMTALA	O
violation	B-DISO
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
declining	O
trend	O
in	O	O
enforcement	O
.	O	O

Further	O	O
investigation	B-PROC
is	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
effect	O	O
of	O	O
EMTALA	O
on	O	O
access	O	O
to	O	O
or	O	O
quality	O	O
of	O	O
emergency	B-PROC
care	I-PROC
.	O	O

A	O	O
new	O
and	O	O
consistent	O
parameter	O
for	O	O
measuring	O
the	O	O
quality	O
of	O	O
multivariate	O
analytical	O
methods	O
:	O	O
Generalized	O
analytical	O
sensitivity	O
Generalized	O
analytical	O
sensitivity	O
(	O	O
γ	O
)	O	O
is	O	O
proposed	O	O
as	O	O
a	O	O
new	O
figure	O	O
of	O	O
merit	O
,	O	O
which	O	O
can	O	O
be	O	O
estimated	O
from	O	O
a	O	O
multivariate	O
calibration	O
data	O
set	O
.	O	O

It	O	O
can	O	O
be	O	O
confidently	O
applied	O
to	O	O
compare	O
different	O
calibration	O
methodologies	O
,	O	O
and	O	O
helps	O
to	O	O
solve	O
literature	O
inconsistencies	O
on	O	O
the	O	O
relationship	O
between	O	O
classical	O
sensitivity	O
and	O	O
prediction	B-DISO
error	I-DISO
.	O	O

In	O	O
contrast	O
to	O	O
the	O	O
classical	O
plain	O	O
sensitivity	O
,	O	O
γ	O
incorporates	O
the	O	O
noise	B-PHEN
properties	I-PHEN
in	O	O
its	O	O
definition	O
,	O	O
and	O	O
its	O	O
inverse	O
is	O	O
well	O	O
correlated	O
with	O	O
root	O
mean	O
square	O
errors	B-DISO
of	I-DISO
prediction	I-DISO
in	O	O
the	O	O
presence	B-DISO
of	O	O
general	O	O
noise	B-PHEN
structures	I-PHEN
.	O	O

The	O	O
proposal	O
is	O	O
supported	O	O
by	O	O
studying	B-PROC
simulated	B-PROC
and	O	O
experimental	O
first	O
-	O
order	O
multivariate	O
calibration	O
systems	O
with	O	O
various	O
models	O
,	O	O
namely	O	O
multiple	O
linear	O
regression	O
,	O	O
principal	O
component	O
regression	O
(	O	O
PCR	O
)	O	O
and	O	O
maximum	O
likelihood	O
PCR	O
(	O	O
MLPCR	O
)	O	O
.	O	O

The	O	O
simulations	B-PROC
included	O	O
instrumental	B-OBJC
noise	B-PHEN
of	O	O
different	O
types	O
:	O	O
independently	B-DISO
and	O	O
identically	O
distributed	O
(	O	O
iid	O
)	O	O
,	O	O
correlated	O
(	O	O
pink	O
)	O	O
and	O	O
proportional	O
noise	B-PHEN
,	O	O
while	O	O
the	O	O
experimental	O
data	O
carried	B-DISO
noise	B-PHEN
which	O	O
is	O	O
clearly	B-DISO
non	O
-	O
iid	O
.	O	O

The	O	O
lost	O	O
art	O	O
of	O	O
the	O	O
splenorrhaphy	B-PROC
In	O	O
the	O	O
case	O	O
of	O	O
the	O	O
hemodynamically	B-DISO
unstable	I-DISO
child	B-LIVB
,	O	O
splenorrhaphy	B-PROC
is	O	O
preferred	O	O
to	O	O
splenectomy	B-PROC
to	O	O
avert	O	O
postsplenectomy	B-DISO
sepsis	B-DISO
.	O	O

However	O	O
,	O	O
successful	O	O
splenorrhaphy	B-PROC
requires	O	O
familiarity	B-PHYS
with	O	O
the	O	O
procedure	B-PROC
.	O	O

We	O	O
sought	O	O
to	O	O
determine	O	O
how	O	O
many	O	O
splenectomies	B-PROC
or	O	O
splenorrhaphies	B-PROC
for	O	O
trauma	B-DISO
the	O	O
average	O	O
pediatric	B-LIVB
surgeon	I-LIVB
can	O	O
be	O	O
expected	O	O
to	O	O
perform	O
during	O	O
their	O	O
career	O
.	O	O

The	O	O
Pediatric	O
Health	O
Information	O
System	O
(	O
PHIS	O
)	O
Database	O
was	O	O
queried	O	O
for	O	O
patients	B-LIVB
≤18	O	O
years	O
coded	O	O
with	O	O
an	O	O
International	O
Classification	O
of	O
Diseases	O
9th	O
Edition	O
diagnosis	O
code	O
of	O	O
a	O	O
splenic	B-DISO
injury	I-DISO
from	O	O
2004	O	O
to	O	O
2013	O	O
.	O	O

Age	B-PHYS
,	O	O
gender	B-PHYS
,	O	O
grade	O
of	O	O
splenic	B-DISO
injury	I-DISO
,	O	O
and	O	O
operations	B-PROC
performed	O
were	O	O
extracted	O
.	O	O

Numbers	O	O
of	O	O
pediatric	B-LIVB
surgeons	I-LIVB
per	O	O
hospital	B-OBJC
were	O	O
obtained	O	O
.	O	O

9567	O	O
children	B-LIVB
were	O	O
identified	O
.	O	O

2	O	O
.	O	O
1	O	O
%	O	O
underwent	O	O
a	O	O
splenectomy	B-PROC
and	O	O
0	O	O
.	O	O

8	O	O
%	O	O
underwent	O	O
a	O	O
splenorrhaphy	B-PROC
.	O	O

The	O	O
average	O	O
surgeon	B-LIVB
performed	O
0	O	O
.	O	O

6	O	O
(	O	O
SD	O	O
=	O	O
0	O	O
.	O	O

6	O	O
)	O	O
splenectomies	B-PROC
and	O	O
0	O	O
.	O	O

2	O	O
(	O	O
SD	O	O
=	O	O
0	O	O
.	O	O

4	O	O
)	O	O
splenorrhaphies	B-PROC
for	O	O
trauma	B-DISO
.	O	O

If	O	O
these	O	O
rates	O
remain	O	O
constant	O
over	O	O
time	O	O
,	O	O
the	O	O
average	O	O
surgeon	B-LIVB
would	O	O
perform	O
1	O	O
.	O	O

8	O	O
(	O	O
SD	O	O
=	O	O
1	O	O
.	O	O

7	O	O
)	O	O
splenectomies	B-PROC
and	O	O
0	O	O
.	O	O

6	O	O
(	O	O
SD	O	O
=	O	O
1	O	O
.	O	O

1	O	O
)	O	O
splenorrhaphies	B-PROC
for	O	O
trauma	B-DISO
over	O	O
a	O	O
30	O	O
-	O	O
year	O
surgical	O
career	O
.	O	O

Nonoperative	B-PROC
management	I-PROC
is	O	O
associated	O	O
with	O	O
a	O	O
host	O	O
of	O	O
benefits	O	O
,	O	O
but	O	O
has	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
experience	O
level	O
of	O	O
the	O	O
pediatric	B-LIVB
surgeons	I-LIVB
expected	O	O
to	O	O
perform	O
an	O	O
emergency	O	O
splenectomy	B-PROC
or	O	O
splenorrhaphy	B-PROC
when	O	O
the	O	O
unusual	O	O
occasion	O	O
arises	O	O
.	O	O

Isolation	B-PROC
,	O	O
structural	B-PROC
analysis	I-PROC
,	O	O
and	O	O
expression	B-PHYS
characteristics	O	O
of	O	O
the	O	O
maize	B-LIVB
nuclear	O
factor	O
Y	O
gene	O
families	O
NUCLEAR	B-CHEM
FACTOR	I-CHEM
-	I-CHEM
Y	I-CHEM
(	O	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
growth	B-PHYS
,	O	O
development	B-PHYS
,	O	O
and	O	O
response	B-PHYS
to	O	O
environmental	B-PHEN
stress	I-PHEN
.	O	O

A	O	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
complex	I-CHEM
,	O	O
which	O	O
consists	O	O
of	O	O
three	O	O
subunits	B-CHEM
,	O	O
NF	B-CHEM
-	I-CHEM
YA	I-CHEM
,	O	O
NF	B-CHEM
-	I-CHEM
YB	I-CHEM
,	O	O
and	O	O
,	O	O
NF	B-CHEM
-	I-CHEM
YC	I-CHEM
,	O	O
binds	O	O
to	O	O
CCAAT	O
sequences	O
in	O	O
a	O	O
promoter	B-CHEM
to	O	O
control	O
the	O	O
expression	B-PHYS
of	I-PHYS
target	I-PHYS
genes	I-PHYS
.	O	O

Although	O	O
NF	B-CHEM
-	I-CHEM
Y	I-CHEM
proteins	I-CHEM
have	O	O
been	O	O
reported	O	O
in	O	O
Arabidopsis	B-LIVB
and	O	O
rice	B-LIVB
,	O	O
a	O	O
comprehensive	O
and	O	O
systematic	B-PROC
analysis	I-PROC
of	O	O
ZmNF	O
-	O
Y	O
genes	O
has	O	O
not	O	O
yet	O	O
been	O	O
performed	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
functions	O	O
of	O	O
ZmNF	O
-	O
Y	O
genes	O
in	O	O
this	O	O
family	O	O
,	O	O
we	O	O
isolated	O	O
and	O	O
characterized	O	O
50	O
ZmNF	O
-	O
Y	O
(	O	O
14	O
ZmNF	O
-	O
YA	O
,	O	O
18	O
ZmNF	O
-	O
YB	O
,	O	O
and	O	O
18	O	O
ZmNF	O
-	O
YC	O
)	O	O
genes	O
in	O	O
an	O	O
analysis	B-PROC
of	O	O
the	O	O
maize	B-LIVB
genome	O
.	O	O

The	O	O
50	O	O
ZmNF	O
-	O
Y	O
genes	O
were	O	O
distributed	O	O
on	O	O
all	O	O
10	O	O
maize	B-LIVB
chromosomes	B-ANAT
,	O	O
and	O	O
12	O	O
paralogs	O
were	O	O
identified	O	O
.	O	O

Multiple	B-PROC
alignments	I-PROC
showed	O	O
that	O	O
maize	B-LIVB
ZmNF	B-CHEM
-	I-CHEM
Y	I-CHEM
family	I-CHEM
proteins	I-CHEM
had	O	O
conserved	O
regions	O
and	O	O
relatively	O	O
variable	O
N	O
-	O
terminal	O
or	O	O
C	O
-	O
terminal	O
domains	O
.	O	O

The	O	O
comparative	O	O
syntenic	O
map	B-PROC
illustrated	O	O
40	O	O
paralogous	O
NF	O
-	O
Y	O
gene	O
pairs	O	O
among	O	O
the	O	O
10	B-LIVB
maize	I-LIVB
chromosomes	B-ANAT
.	O	O

Microarray	B-PROC
data	O
showed	O	O
that	O	O
the	O	O
ZmNF	O
-	O
Y	O
genes	O
had	O	O
tissue	B-PHYS
-	I-PHYS
specific	I-PHYS
expression	I-PHYS
patterns	O	O
in	O	O
various	O	O
maize	B-LIVB
developmental	O
stages	O
and	O	O
in	O	O
response	B-PHYS
to	I-PHYS
biotic	I-PHYS
and	O	O
abiotic	B-PHYS
stresses	I-PHYS
.	O	O

The	O	O
results	O	O
suggested	O	O
that	O	O
ZmNF	O
-	O
YB2	O
,	O
4	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
and	O
16	O
and	O	O
ZmNF	O
-	O
YC6	O
,	O
8	O
,	O
and	O
15	O
were	O	O
induced	O	O
,	O	O
while	O	O
ZmNF	O
-	O
YA1	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
7	O
,	O
10	O
,	O
12	O
,	O
and	O
13	O
,	O	O
ZmNF	O
-	O
YB15	O
,	O	O
and	O	O
ZmNF	O
-	O
YC3	O
and	O
9	O
were	O	O
suppressed	O
by	O	O
drought	B-PHEN
stress	B-DISO
.	O	O

ZmNF	O
-	O
YA3	O
,	O	O
ZmNF	O
-	O
YA8	O
and	O	O
ZmNF	O
-	O
YA12	O
were	O	O
upregulated	B-PHYS
after	O	O
infection	B-DISO
by	O	O
the	O	O
three	O	O
pathogens	B-LIVB
,	O	O
while	O	O
ZmNF	O
-	O
YA1	O
and	O	O
ZmNF	O
-	O
YB2	O
were	O	O
suppressed	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
ZmNF	B-CHEM
-	I-CHEM
Ys	I-CHEM
may	O	O
have	O	O
significant	O	O
roles	O	O
in	O	O
the	O	O
response	B-PHYS
to	I-PHYS
abiotic	I-PHYS
and	O	O
biotic	B-PHYS
stresses	I-PHYS
.	O	O

How	O	O
do	O	O
different	O	O
delivery	O	O
schedules	O	O
of	O	O
tailored	B-PROC
web	B-PROC
-	I-PROC
based	I-PROC
physical	O
activity	O
advice	O	O
for	O	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
influence	O	O
intervention	B-PROC
use	O	O
and	O	O
efficacy	O
?	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
investigate	O
the	O	O
impact	O	O
of	O	O
differing	O	O
delivery	O	O
schedules	O	O
of	O	O
computer	B-PROC
-	I-PROC
tailored	I-PROC
physical	O
activity	O
modules	O	O
on	O	O
engagement	O	O
and	O	O
physical	O
activity	O
behaviour	O
change	O
in	O	O
a	O	O
web	B-PROC
-	I-PROC
based	I-PROC
intervention	I-PROC
targeting	O	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O	O

Insufficiently	O	O
active	O	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
(	O	O
n	O	O
=	O	O
492	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
receive	O	O
one	O	O
of	O	O
the	O	O
following	O	O
intervention	B-PROC
schedules	O
over	O	O
12	O	O
weeks	O	O
:	O	O
a	O	O
three	O	O
-	O	O
module	O
intervention	O	O
delivered	O	O
monthly	O
,	O	O
a	O	O
three	B-PROC
-	I-PROC
module	I-PROC
intervention	I-PROC
delivered	O	O
weekly	O
or	O	O
a	O	O
single	B-PROC
module	I-PROC
intervention	I-PROC
.	O	O

Engagement	O
with	O
the	O	O
website	O
(	O	O
number	O
of	O
logins	O
,	O	O
time	O
on	O
site	O
,	O	O
modules	O
viewed	O	O
,	O	O
action	O
plans	O
completed	O
)	O	O
was	O	O
measured	O	O
using	O	O
tracking	O
software	O
.	O	O

Other	O	O
outcomes	O
(	O	O
website	O
acceptability	O
,	O	O
physical	O
activity	O
behaviour	O
)	O	O
were	O	O
assessed	O	O
using	O	O
online	O
surveys	O
.	O	O

Physical	O
activity	O
outcomes	O
were	O	O
analysed	O	O
using	O	O
regression	O
models	O
for	O	O
both	O	O
study	O
completers	O
and	O	O
when	O	O
applying	O	O
intention	B-PROC
-	I-PROC
to	I-PROC
-	I-PROC
treat	I-PROC
(	O	O
using	O	O
multiple	O
imputation	O
)	O	O
.	O	O

Completers	O
allocated	O	O
to	O	O
the	O	O
monthly	O
module	O
group	O
rated	O	O
the	O	O
intervention	B-PROC
higher	O	O
(	O	O
b	O	O
=	O	O
2	O	O
.	O	O
2	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
0	O	O
.	O	O

02	O	O
-	O	O
4	O	O
.	O	O
53	O	O
)	O	O
on	O	O
acceptability	O	O
and	O	O
had	O	O
higher	O	O
levels	O	O
of	O	O
resistance	B-PROC
-	I-PROC
training	I-PROC
(	O	O
IRR	O	O
=	O	O
1	O	O
.	O	O
88	O	O
,	O	O
95	O	O
%	O	O
CI	O	O
=	O	O
1	O	O
.	O	O
16	O	O
-	O	O
3	O	O
.	O	O
04	O	O
)	O	O
than	O	O
those	O	O
in	O	O
the	O	O
single	O	O
module	O
group	O
.	O	O

When	O	O
accounting	O	O
for	O	O
missing	O	O
data	O	O
,	O	O
these	O	O
differences	O	O
were	O	O
no	O	O
longer	O	O
significant	O	O
.	O	O

The	O	O
completion	B-DISO
of	O	O
at	O	O
least	O	O
two	O	O
action	O	O
plans	O	O
was	O	O
higher	O	O
among	O	O
those	O	O
allocated	O	O
to	O	O
the	O	O
monthly	O
module	O
group	O
compared	O	O
to	O	O
those	O	O
in	O	O
the	O	O
weekly	O
module	O
group	O
(	O	O
53	O	O
vs	O	O
40	O	O
%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O
02	O	O
)	O	O
;	O	O
though	O	O
the	O	O
completion	O	O
of	O	O
at	O	O
least	O	O
two	O	O
modules	O
was	O	O
higher	O	O
in	O	O
the	O	O
weekly	O
module	O
group	O
compared	O	O
to	O	O
the	O	O
monthly	O
module	O
group	O	O
(	O	O
60	O	O
vs	O	O
46	O	O
%	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O
01	O	O
)	O	O
.	O	O

There	O	O
were	O	O
no	O	O
other	O	O
significant	O	O
between	O	O
group	O	O
differences	O	O
observed	O	O
.	O	O

This	O	O
study	O	O
provides	O	O
preliminary	O	O
evidence	O
that	O	O
web	B-PROC
-	I-PROC
based	I-PROC
computer	I-PROC
-	I-PROC
tailored	I-PROC
interventions	B-PROC
can	O	O
be	O	O
used	O	O
to	O	O
increase	O
physical	O
activity	O
among	O	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O	O

Further	O	O
,	O	O
there	O	O
were	O	O
some	O	O
outcome	O
differences	O	O
based	O	O
on	O	O
how	O	O
the	O	O
tailored	B-PROC
modules	O
were	O	O
delivered	O	O
,	O	O
with	O	O
the	O	O
most	O	O
favourable	O	O
outcomes	O
observed	O	O
in	O	O
the	O	O
monthly	O
delivery	O
group	O
.	O	O

This	O	O
study	O	O
will	O	O
be	O	O
useful	O	O
for	O	O
informing	O	O
the	O	O
design	O	O
of	O	O
future	O	O
web	O
-	O
based	O
interventions	O
targeting	O	O
breast	B-DISO
cancer	I-DISO
survivors	B-LIVB
.	O	O

Stress	B-DISO
and	O	O
binge	O
drinking	O
:	O	O
A	O	O
toxic	B-DISO
combination	O	O
for	O	O
the	O	O
teenage	O
brain	B-ANAT
Young	B-LIVB
adult	I-LIVB
university	O
students	O
frequently	O	O
binge	O
on	O	O
alcohol	O
and	O	O
have	O	O
high	O
stress	B-DISO
levels	I-DISO
.	O	O

Based	O	O
on	O	O
findings	O	O
in	O	O
rodents	B-LIVB
,	O	O
we	O	O
predicted	O	O
that	O	O
heavy	B-DISO
current	I-DISO
alcohol	I-DISO
use	I-DISO
and	O	O
elevated	O
stress	B-DISO
and	O	O
depression	B-DISO
scores	I-DISO
would	O	O
be	O	O
associated	O
with	O
deficits	O
on	O	O
high	O
interference	O
memory	B-PHYS
tasks	O
,	O	O
while	O	O
early	B-DISO
onset	I-DISO
,	O	O
prolonged	O	O
binge	O
patterns	O
would	O	O
lead	O	O
to	O	O
broader	O	O
cognitive	B-DISO
deficits	I-DISO
on	O	O
tests	O	O
of	O	O
associative	B-PHYS
encoding	I-PHYS
and	O	O
executive	B-PHYS
functions	I-PHYS
.	O	O

We	O	O
developed	O	O
the	O	O
Concentration	B-PHYS
Memory	B-PHYS
Task	O
,	O	O
a	O	O
novel	O	O
computerized	O
version	O
of	O	O
the	O	O
Concentration	B-PHYS
card	B-OBJC
game	I-OBJC
with	O	O
a	O	O
high	O
degree	O	O
of	O	O
interference	O
.	O	O

We	O	O
found	O	O
that	O	O
young	B-LIVB
adults	I-LIVB
with	O	O
elevated	O
stress	B-DISO
,	O	O
depression	B-DISO
,	O	O
and	O	O
alcohol	O
consumption	O
scores	O
were	O	O
impaired	O
in	O	O
the	O	O
Concentration	B-PHYS
Memory	B-PHYS
Task	O
.	O	O

We	O	O
also	O	O
analyzed	O
data	O
from	O	O
a	O	O
previous	O	O
study	O	O
,	O	O
and	O	O
found	O	O
that	O	O
higher	O
alcohol	O
consumption	O
scores	O
were	O	O
associated	O
with	O
impaired	O
performance	O
on	O	O
another	O	O
high	O
interference	O
memory	B-PHYS
task	O
,	O	O
based	O	O
on	O	O
Kirwan	O
and	O
Stark	O
's	O
Mnemonic	O
Similarity	O
Test	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
adolescent	B-LIVB
onset	O
of	O	O
binge	O
drinking	O
predicted	O	O
poorer	O
performance	O
on	O	O
broader	O	O
range	O	O
of	O	O
memory	B-PHYS
tests	O
,	O	O
including	O	O
a	O	O
more	O	O
systematic	O
test	O
of	O
spatial	O
recognition	O
memory	O
,	O	O
and	O	O
an	O	O
associative	B-PHYS
learning	I-PHYS
task	O
.	O	O

Our	O	O
results	B-DISO
are	O	O
broadly	O	O
consistent	O
with	O
findings	O	O
in	O	O
rodents	B-LIVB
that	O	O
acute	O
alcohol	O
and	O	O
stress	B-DISO
exposure	O	O
suppress	O
neurogenesis	B-PHYS
in	O	O
the	O	O
adult	B-LIVB
hippocampus	B-ANAT
,	O	O
which	O	O
in	O	O
turn	O	O
impairs	O
performance	O
in	O	O
high	O
interference	O
memory	B-PHYS
tasks	O
,	O	O
while	O	O
adolescent	B-LIVB
onset	O
binge	O
drinking	O
causes	O	O
more	O	O
extensive	O
brain	B-DISO
damage	I-DISO
and	O	O
cognitive	B-DISO
deficits	I-DISO
.	O	O

Vestibular	B-ANAT
-dependent	O	O
inter	O
-	O
stimulus	O
interval	O
effects	O
on	O	O
sound	B-PHYS
evoked	I-PHYS
potentials	I-PHYS
of	O	O
central	O
origin	O
Todd	O	O
et	O	O
al	O	O
.	O	O

(	O	O
2014ab	O	O
)	O	O
have	O	O
recently	O	O
demonstrated	O	O
the	O	O
presence	B-DISO
of	O	O
vestibular	B-ANAT
-dependent	O	O
contributions	O
to	O	O
auditory	B-PHYS
evoked	I-PHYS
potentials	I-PHYS
(	O	O
AEPs	B-PHYS
)	O	O
when	O	O
passing	O	O
through	O	O
the	O	O
vestibular	B-ANAT
threshold	O
as	O	O
determined	O	O
by	O	O
vestibular	B-PHEN
evoked	I-PHEN
myogenic	I-PHEN
potentials	I-PHEN
(	O	O
VEMPs	B-PHEN
)	O	O
,	O	O
including	O	O
a	O	O
particular	O	O
deflection	O
labeled	O
as	O	O
an	O	O
N42	O	O
/	O	O
P52	O	O
prior	O
to	O	O
the	O	O
long	O
-	O	O
latency	O
AEPs	B-PHYS
N1	O	O
and	O	O
P2	O	O
.	O	O

In	O	O
this	O	O
paper	O	O
we	O	O
report	B-PROC
the	O	O
results	B-DISO
of	O	O
an	O	O
experiment	B-PROC
to	O	O
determine	O	O
the	O	O
effect	O
of	O
inter	O
-	O
stimulus	O
interval	O
(	O	O
ISI	O
)	O	O
and	O	O
regularity	O
on	O	O
potentials	B-PHYS
recorded	O	O
above	O
and	O	O
below	O
VEMP	B-PHEN
threshold	O
.	O	O

Five	O	O
healthy	O
,	O	O
right	B-PHYS
-	I-PHYS
handed	I-PHYS
subjects	B-LIVB
were	O	O
recruited	O	O
and	O	O
evoked	B-PHYS
potentials	I-PHYS
were	O	O
recorded	O	O
to	O	O
binaurally	O	O
presented	O	O
sound	B-PROC
stimulation	I-PROC
,	O	O
above	O
and	O	O
below	O
vestibular	B-ANAT
threshold	O
,	O	O
at	O	O
seven	O	O
stimulus	B-PHEN
rates	O
with	O	O
ISIs	O
of	O	O
212	O	O
,	O	O
300	O	O
,	O	O
424	O	O
,	O	O
600	O	O
,	O	O
848	O	O
,	O	O
1200	O	O
and	O	O
1696	O	O
ms	O	O
.	O	O

The	O	O
inner	O	O
five	O	O
intervals	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

300	O	O
,	O	O
424	O	O
,	O	O
600	O	O
,	O	O
848	O	O
,	O	O
1200	O	O
ms	O	O
,	O	O
were	O	O
presented	O
twice	O	O
in	O	O
both	O	O
regular	O
and	O	O
irregular	O
conditions	O	O
.	O	O

ANOVA	O
on	O	O
the	O	O
global	O
field	O
power	O
(	O	O
GFP	O
)	O	O
were	O	O
conducted	O	O
for	O	O
each	O	O
of	O	O
four	O	O
waves	O	O
,	O	O
N42	O	O
,	O	O
P52	O	O
,	O	O
N1	O	O
and	O	O
P2	O	O
with	O	O
factors	O	O
of	O	O
intensity	O
,	O	O
ISI	O
and	O	O
regularity	O
.	O	O

Both	O	O
N42	O	O
and	O	O
P52	O	O
waves	O	O
showed	O	O
significant	O
ANOVA	O
effects	O
of	O
intensity	O
but	O	O
no	O	O
other	O	O
main	O	O
effects	O
or	O	O
interactions	O
.	O	O

In	O	O
contrast	O	O
both	O	O
N1	O	O
and	O	O
P2	O	O
showed	O	O
additional	O
effects	O
of	O
ISI	O
,	O	O
as	O	O
well	O	O
as	O	O
intensity	O
,	O	O
and	O	O
evidence	O
of	O
non	O
-	O	O
linear	O
interactions	O
between	O	O
ISI	O
and	O	O
intensity	O
.	O	O

A	O	O
source	B-PROC
analysis	I-PROC
was	O	O
carried	O	O
out	O	O
consistent	O
with	O
prior	O
work	O	O
suggesting	O	O
that	O	O
when	O	O
above	O
vestibular	B-ANAT
threshold	O
,	O	O
in	O
addition	O
to	O
bilateral	O
superior	O
temporal	B-ANAT
cortex	I-ANAT
,	O	O
ocular	B-ANAT
,	O	O
cerebellar	B-ANAT
and	O	O
cingulate	B-ANAT
sources	B-DISO
are	O	O
recruited	O	O
.	O	O

Further	O	O
statistical	B-PROC
analysis	I-PROC
of	O	O
the	O	O
source	B-DISO
currents	B-PHEN
indicated	O	O
that	O	O
the	O	O
origin	O	O
of	O	O
the	O	O
interactions	O
with	O	O
intensity	O
may	O	O
be	O	O
the	O	O
ISI	O
sensitivity	O
of	O	O
the	O	O
vestibular	B-ANAT
-dependent	O	O
sources	B-DISO
.	O	O

This	O	O
in	O	O
turn	O	O
may	O	O
reflect	O	O
a	O	O
specific	O
vestibular	B-ANAT
preference	O
for	O	O
stimulus	B-PHEN
rates	O
associated	O
with	O
locomotion	B-PHYS
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

rates	O
close	O	O
to	O	O
2	O	O
Hz	O	O
,	O	O
or	O	O
ISIs	O
close	O	O
to	O	O
500	O	O
ms	O	O
,	O	O
where	O	O
saccular	O
afferents	O
show	O	O
increased	O
gain	O
and	O	O
the	O	O
corresponding	O	O
reflexes	B-PHYS
are	O	O
most	O	O
sensitive	O
.	O	O

Differential	O
Immunohistochemical	B-PROC
Profiles	B-PROC
for	O	O
Distinguishing	O
Prostate	B-DISO
Carcinoma	I-DISO
and	O	O
Urothelial	B-DISO
Carcinoma	I-DISO
The	O	O
pathologic	O
distinction	O
between	O	O
high	O
-	O
grade	O
prostate	B-DISO
adenocarcinoma	I-DISO
(	O	O
PAC	B-DISO
)	O	O
involving	O	O
the	O	O
urinary	B-ANAT
bladder	I-ANAT
and	O	O
high	O
-	O
grade	O
urothelial	B-DISO
carcinoma	I-DISO
(	O	O
UC	B-DISO
)	O	O
infiltrating	B-DISO
the	O	O
prostate	B-ANAT
can	O	O
be	O	O
difficult	O
.	O	O

However	O	O
,	O	O
making	O	O
this	O	O
distinction	O
is	O	O
clinically	O
important	O
because	O	O
of	O	O
the	O	O
different	O
treatment	B-PROC
modalities	O
for	O	O
these	O	O
two	O	O
entities	B-OBJC
.	O	O

A	O	O
total	O	O
of	O	O
249	O	O
patient	B-LIVB
cases	O
(	O	O
PAC	B-DISO
,	O	O
111	O	O
cases	O
;	O	O
UC	B-DISO
,	O	O
138	O	O
cases	O
)	O	O
collected	O	O
between	O	O
June	O	O
1995	O	O
and	O	O
July	O	O
2009	O	O
at	O	O
Seoul	B-OBJC
St	I-OBJC
.	I-OBJC

Mary	I-OBJC
's	I-OBJC
Hospital	I-OBJC
were	O	O
studied	B-PROC
.	O	O

An	O	O
immunohistochemical	B-PROC
evaluation	B-PROC
of	O	O
prostatic	B-ANAT
markers	B-CHEM
(	O	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
antigen	I-CHEM
[	O	O
PSA	B-CHEM
]	O	O
,	O	O
prostate	B-CHEM
-	I-CHEM
specific	I-CHEM
membrane	I-CHEM
antigen	I-CHEM
[	O	O
PSMA	B-CHEM
]	O	O
,	O	O
prostate	B-CHEM
acid	I-CHEM
phosphatase	I-CHEM
[	O	O
PAP	B-CHEM
]	O	O
,	O	O
P501s	B-CHEM
,	O	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O	O
and	O	O
α	B-CHEM
-	I-CHEM
methylacyl	I-CHEM
coenzyme	I-CHEM
A	I-CHEM
racemase	I-CHEM
[	O	O
AMACR	B-CHEM
]	O	O
)	O	O
and	O	O
urothelial	O
markers	B-CHEM
(	O	O
CK34βE12	B-CHEM
,	O	O
p63	B-CHEM
,	O	O
thrombomodulin	B-CHEM
,	O	O
S100P	B-CHEM
,	O	O
and	O	O
GATA	B-CHEM
binding	I-CHEM
protein	I-CHEM
3	I-CHEM
[	O	O
GATA3	B-CHEM
]	O	O
)	O	O
was	O	O
performed	O
using	O	O
tissue	B-DEVI
microarrays	I-DEVI
from	O	O
each	O
tumor	B-DISO
.	O	O

The	O	O
sensitivities	O
of	O	O
prostatic	B-ANAT
markers	B-CHEM
in	O	O
PAC	B-DISO
were	O	O
100	O	O
%	O	O
for	O	O
PSA	B-CHEM
,	O	O
83	O	O
.	O	O
8	O	O
%	O	O
for	O	O
PSMA	B-CHEM
,	O	O
91	O	O
.	O	O

9	O	O
%	O	O
for	O	O
PAP	B-CHEM
,	O	O
93	O	O
.	O	O

7	O	O
%	O	O
for	O	O
P501s	B-CHEM
,	O	O
88	O	O
.	O	O

3	O	O
%	O	O
for	O	O
NKX	B-CHEM
3	I-CHEM
.	I-CHEM
1	I-CHEM
,	O	O
and	O	O
66	O	O
.	O	O

7	O	O
%	O	O
for	O	O
AMACR	B-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
urothelial	O
markers	B-CHEM
CK34βE12	B-CHEM
,	O	O
p63	B-CHEM
,	O	O
thrombomodulin	B-CHEM
,	O	O
S100P	B-CHEM
,	O	O
and	O	O
GATA3	B-CHEM
were	O	O
also	O	O
positive	B-DISO
in	O	O
1	O	O
.	O	O

8	O	O
%	O	O
,	O	O
0	O	O
%	O	O
,	O	O
0	O	O
%	O	O
,	O	O
3	O	O
.	O	O
6	O	O
%	O	O
,	O	O
and	O	O
0	O	O
%	O	O
of	O	O
PAC	B-DISO
,	O	O
respectively	O	O
.	O	O

The	O	O
sensitivities	O
of	O	O
urothelial	O
markers	B-CHEM
in	O	O
UC	B-DISO
were	O	O
75	O	O
.	O	O
4	O	O
%	O	O
for	O	O
CK34βE12	B-CHEM
,	O	O
73	O	O
.	O	O
9	O	O
%	O	O
for	O	O
p63	B-CHEM
,	O	O
45	O	O
.	O	O

7	O	O
%	O	O
for	O	O
thrombomodulin	B-CHEM
,	O	O
22	O	O
.	O	O
5	O	O
%	O	O
for	O	O
S100P	B-CHEM
,	O	O
and	O	O
84	O	O
.	O	O
8	O	O
%	O	O
for	O	O
GATA3	B-CHEM
.	O	O

Conversely	O	O
,	O	O
the	O	O
prostatic	B-ANAT
markers	B-CHEM
PSA	B-CHEM
,	O	O
PSMA	B-CHEM
,	O	O
PAP	B-CHEM
,	O	O
P501s	B-CHEM
,	O	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O	O
and	O	O
AMACR	B-CHEM
were	O	O
also	O	O
positive	B-DISO
in	O	O
9	O	O
.	O	O

4	O	O
%	O	O
,	O	O
0	O	O
.	O	O

7	O	O
%	O	O
,	O	O
18	O	O
.	O	O
8	O	O
%	O	O
,	O	O
0	O	O
.	O	O
7	O	O
%	O	O
,	O	O
0	O	O
%	O	O
,	O	O
and	O	O
8	O	O
.	O	O

7	O	O
%	O	O
of	O	O
UC	B-DISO
s	O	O
,	O	O
respectively	O	O
.	O	O

Prostatic	B-ANAT
and	O	O
urothelial	O
markers	B-CHEM
,	O	O
including	O	O
PSA	B-CHEM
,	O	O
NKX3	B-CHEM
.	I-CHEM
1	I-CHEM
,	O	O
p63	B-CHEM
,	O	O
thrombomodulin	B-CHEM
,	O	O
and	O	O
GATA3	B-CHEM
are	O	O
very	O	O
useful	O
for	O	O
differentiating	O
PAC	B-DISO
from	O	O
UC	B-DISO
.	O	O

The	O	O
optimal	O
combination	O
of	O	O
prostatic	B-ANAT
and	O	O
urothelial	O
markers	B-CHEM
could	O	O
improve	B-DISO
the	O	O
ability	B-DISO
to	O	O
differentiate	O
PAC	B-DISO
from	O	O
UC	B-DISO
pathologically	O
.	O	O

Vision	B-PHYS
Guides	O	O
Selection	O
of	O	O
Freeze	B-PHEN
or	O	O
Flight	B-PHEN
Defense	O
Strategies	B-PHYS
in	O	O
Mice	B-LIVB
In	O	O
prey	O
species	O
such	O	O
as	O	O
mice	B-LIVB
,	O	O
avoidance	B-PHYS
of	O	O
predators	O	O
is	O	O
key	O	O
to	O	O
survival	O
and	O	O
drives	O	O
instinctual	O	O
behaviors	O
like	O	O
freeze	B-PHEN
or	O	O
flight	B-PHEN
[	O	O
1	O	O
,	O	O
2	O	O
]	O	O
.	O	O

Sensory	B-PHYS
signals	I-PHYS
guide	I-PHYS
the	O	O
selection	O
of	O	O
appropriate	O
behavior	O
[	O	O
3	O	O
]	O	O
,	O	O
and	O	O
for	O	O
aerial	O	O
predators	O	O
only	O	O
vision	B-PHYS
provides	O
useful	O
information	O
.	O	O

Surprisingly	O	O
,	O	O
there	O	O
is	O	O
no	O
evidence	O
that	O	O
vision	B-PHYS
can	O	O
guide	O	O
the	O	O
selection	O
of	O	O
escape	O	O
strategies	B-PHYS
.	O	O

Fleeing	O
behavior	O
can	O	O
be	O	O
readily	O	O
triggered	O
by	O
a	O	O
rapidly	O
looming	O	O
overhead	O	O
stimulus	B-PHEN
[	O	O
4	O	O
]	O	O
.	O	O

Freezing	B-PHEN
behavior	O
,	O	O
however	O	O
,	O	O
has	O	O
previously	O	O
been	O	O
induced	O
by	O	O
real	O	O
predators	O	O
or	O	O
their	O	O
odors	B-PHEN
[	O	O
5	O	O
]	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
discover	O
that	O	O
a	O	O
small	O	O
moving	O	O
disk	O	O
,	O	O
simulating	O	O
the	O	O
sweep	B-PROC
of	O	O
a	O	O
predator	O	O
cruising	B-DISO
overhead	O	O
,	O	O
is	O	O
sufficient	O
to	O	O
induce	O
freezing	B-PHYS
response	I-PHYS
in	O	O
mice	B-LIVB
.	O	O

Looming	O	O
and	O	O
sweeping	B-PROC
therefore	O	O
provide	O
visual	B-DISO
triggers	I-DISO
for	O	O
opposing	O	O
flight	B-PHEN
and	O	O
freeze	B-PHEN
behaviors	O
and	O	O
provide	O
evidence	O
that	O	O
mice	B-LIVB
innately	O
make	O	O
behavioral	O
choices	O	O
based	O	O
on	O	O
vision	B-PHYS
alone	O	O
.	O	O

Short	O
-	O
term	O
effects	B-DISO
of	O	O
a	O	O
vibrotactile	O
neck	B-ANAT
-based	O	O
treatment	B-DEVI
device	I-DEVI
for	O	O
positional	B-DISO
obstructive	I-DISO
sleep	I-DISO
apnea	I-DISO
:	O	O
preliminary	O
data	O
on	O	O
tolerability	B-PROC
and	O	O
efficacy	B-PROC
Positional	O
supine	O
obstructive	B-DISO
sleep	I-DISO
apnea	I-DISO
syndrome	I-DISO
(	O	O
OSAS	B-DISO
)	O	O
characterizes	O	O
a	O	O
subgroup	O
of	O	O
patients	B-LIVB
suffering	B-DISO
from	O	O
OSAS	B-DISO
.	O	O

Several	O
devices	B-DEVI
designed	O	O
to	O	O
limit	O	O
supine	O
position	O
have	O	O
been	O	O
developed	O	O
,	O	O
but	O	O
evidences	O
of	O
their	O	O
efficacy	O
and	O	O
safety	O
are	O	O
lacking	O
.	O	O

It	O	O
is	O	O
unclear	B-DISO
whether	O	O
a	O	O
neck	B-ANAT
-	I-ANAT
worn	I-ANAT
vibrating	B-DEVI
device	I-DEVI
could	O	O
induce	O	O
positional	B-DISO
change	I-DISO
in	O	O
patients	B-LIVB
with	O	O
positional	B-DISO
OSAS	I-DISO
.	O	O

We	O	O
evaluated	B-PROC
the	O	O
efficacy	O
of	O	O
a	O	O
neck	B-ANAT
-worn	O	O
device	B-DEVI
to	O	O
induce	O
supine	O
avoidance	B-DISO
positional	O
feedback	O	O
over	O	O
a	O	O
short	O
-	O
term	O
trial	O	O
in	O	O
OSAS	B-DISO
patients	B-LIVB
and	O	O
its	O	O
impact	O
on	O	O
sleep	B-PHYS
quality	O
and	O	O
polysomnographyc	B-PROC
indexes	I-PROC
.	O	O

Twenty	O	O
patients	B-LIVB
with	O	O
positional	B-DISO
apneas	I-DISO
/	O	O
hypopneas	B-DISO
were	O	O
prospectively	B-PROC
studied	I-PROC
.	O	O

Baseline	O
characteristics	O
of	O	O
daytime	B-DISO
somnolence	I-DISO
and	O	O
risk	B-DISO
of	O	O
sleep	B-DISO
apnea	I-DISO
were	O	O
screened	B-PROC
and	O	O
the	O	O
efficacy	O
of	O	O
a	O	O
3	O	O
-	O	O
day	O	O
trial	O	O
of	O	O
supine	O
-	O	O
avoidance	B-DISO
therapy	B-PROC
by	O	O
vibrotactile	O
neck	B-ANAT
worn	I-ANAT
device	B-DEVI
assessed	O	O
by	O	O
reporting	O	O
the	O	O
self	O	O
-	O	O
perceived	O	O
change	O
in	O	O
quality	B-DISO
of	I-DISO
sleep	I-DISO
and	O	O
performing	O	O
cardio	B-PROC
-	I-PROC
respiratory	I-PROC
polysomnography	I-PROC
.	O	O

Comparison	O
between	O	O
baseline	B-DISO
and	O	O
treatment	B-DISO
results	I-DISO
was	O	O
performed	O
.	O	O

The	O	O
neck	B-ANAT
device	B-DEVI
produced	O	O
a	O	O
reduction	O
in	O	O
overall	O
apnea	O
-	O
hypopnea	O
index	O
(	O	O
AHI	O
)	O	O
(	O	O
mean	O	O
AHI	O
pre	O
=	O	O
16	O	O
.	O	O

8	O	O
/	O	O
h	O	O
and	O	O
post	O
=	O	O
4	O	O
.	O	O
4	O	O
/	O	O
h	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
,	O	O
oxygen	B-DISO
desaturation	I-DISO
(	O	O
pre	O
=	O	O
13	O	O
.	O	O

7	O	O

/	O	O
h	O	O
and	O	O
post	O
=	O	O
3	O	O
.	O	O
8	O	O
/	O	O
h	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
and	O	O
Respiratory	B-DISO
Disturbance	I-DISO
Indexes	I-DISO
(	O	O
RDI	B-DISO
)	O	O
(	O	O
20	O	O
.	O	O
0	O	O
/	O	O
h	O	O
vs	O	O
.	O	O

5	O	O
.	O	O
2	O	O
/	O	O
h	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O
0001	O	O
)	O	O
.	O	O

The	O	O
time	O	O
spent	O	O
in	O	O
supine	O
position	O
decreased	O
from	O	O
62	O	O
.	O	O

1	O	O
%	O	O
to	O	O
33	O	O
.	O	O

7	O	O
%	O	O
of	O	O
the	O	O
total	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O
001	O	O
)	O	O
.	O	O

However	O	O
,	O	O
the	O	O
impact	O
on	O	O
the	O	O
perceived	O	O
quality	B-DISO
of	I-DISO
sleep	I-DISO
was	O	O
unpredictable	B-DISO
.	O	O

The	O	O
neck	B-ANAT
position	O
therapy	B-DEVI
device	I-DEVI
is	O	O
effective	O
in	O	O
restricting	O
supine	O
sleep	B-PHYS
,	O	O
improving	O
AHI	O
and	O	O
related	O	O
polysomnographic	B-PROC
indexes	I-PROC
.	O	O

However	O	O
,	O	O
at	O	O
least	O	O
in	O	O
a	O	O
short	O
-	O
term	O
trial	O	O
,	O	O
it	O	O
seems	O	O
unable	B-DISO
to	O	O
improve	O
the	O	O
patient	B-LIVB
's	I-LIVB
sleep	B-PHYS
quality	O
.	O	O

Operative	B-DISO
surgical	I-DISO
nuances	I-DISO
of	O	O
modified	O
extradural	B-PROC
temporopolar	I-PROC
approach	I-PROC
with	O	O
mini	O
-	O
peeling	O
of	O	O
dura	B-ANAT
propria	I-ANAT
based	O	O
on	O	O
cadaveric	B-PROC
anatomical	I-PROC
study	I-PROC
of	O	O
lateral	O
cavernous	B-ANAT
structures	I-ANAT
Extradural	B-PROC
temporopolar	I-PROC
approach	I-PROC
(	O	O
ETA	B-PROC
)	O	O
has	O	O
been	O	O
modified	O
as	O	O
less	O	O
invasive	O	O
manner	O	O
and	O	O
named	O	O
as	O	O
trans	O
-	O
superior	O
orbital	B-ANAT
fissure	I-ANAT
(	O	O
SOF	B-ANAT
)	O	O
approach	B-PROC
with	O	O
mini	O
-	O
peeling	O
technique	O
.	O	O

The	O	O
present	O	O
study	O	O
discusses	O	O
the	O	O
operative	B-DISO
nuances	I-DISO
of	O	O
this	O	O
modified	O
technique	O
on	O	O
the	O	O
basis	O	O
of	O	O
cadaveric	B-PROC
study	I-PROC
of	O	O
lateral	O
cavernous	B-ANAT
structures	I-ANAT
.	O	O

In	O	O
five	O	O
consecutive	O
cadaveric	B-OBJC
specimens	I-OBJC
,	O	O
we	O	O
performed	O	O
an	O	O
extradural	B-ANAT
anterior	O
clinoidectomy	B-PROC
with	O	O
mini	O
-	O
peeling	O
of	O	O
the	O	O
dura	B-ANAT
propria	I-ANAT
to	O	O
expose	O	O
the	O	O
anterior	B-ANAT
clinoid	I-ANAT
process	I-ANAT
entirely	O	O
.	O	O

We	O	O
also	O	O
investigated	O	O
the	O	O
histological	O
characteristics	O
of	O	O
the	O	O
lateral	O
cavernous	B-ANAT
sinus	I-ANAT
(	O	O
CS	B-ANAT
)	O	O
between	O	O
the	O	O
dura	B-ANAT
propria	I-ANAT
and	O	O
periosteal	B-ANAT
dura	I-ANAT
at	O	O
the	O	O
SOF	B-ANAT
,	O	O
foramen	B-ANAT
rotundum	I-ANAT
(	O	O
FR	B-ANAT
)	O	O
,	O	O
and	O	O
foramen	O	O
ovale	O	O
(	O	O
FO	O	O
)	O	O
levels	O
,	O	O
and	O	O
of	O	O
each	O	O
trigeminal	B-ANAT
nerve	I-ANAT
division	I-ANAT
.	O	O

Coronal	B-PROC
histological	I-PROC
examination	I-PROC
of	O	O
the	O	O
lateral	O
wall	O
of	O	O
the	O	O
CS	B-ANAT
showed	O	O
invagination	B-DISO
of	O	O
the	O	O
dura	B-ANAT
propria	I-ANAT
and	O	O
periosteal	B-ANAT
dura	I-ANAT
into	O	O
the	O	O
SOF	B-ANAT
.	O	O

In	O	O
contrast	O	O
,	O	O
no	B-DISO
such	O	O
invagination	B-DISO
was	O	O
observed	O	O
at	O	O
the	O	O
levels	O
of	O	O
the	O	O
FR	B-ANAT
and	O	O
FO	O	O
.	O	O

This	O	O
finding	O
supports	O	O
the	O	O
technical	O	O
rationale	O	O
of	O	O
the	O	O
only	O	O
skeletonization	B-DISO
of	O	O
the	O	O
SOF	B-ANAT
for	O	O
peeling	O
of	O	O
the	O	O
dura	B-ANAT
propria	I-ANAT
but	O	O
not	O	O
FR	B-ANAT
.	O	O

In	O	O
addition	O	O
,	O	O
our	O	O
modified	O
ETA	B-PROC
method	O
needs	O	O
only	O	O
minimal	O
dural	B-PROC
incision	I-PROC
between	O	O
the	O	O
SOF	B-ANAT
and	O	O
FR	B-ANAT
where	O	O
no	O	O
cranial	B-ANAT
nerves	I-ANAT
are	O	O
present	O	O
.	O	O

Our	O	O
technical	B-PROC
modification	I-PROC
of	O	O
ETA	B-PROC
may	O	O
be	O	O
recommended	O	O
for	O	O
surgical	B-PROC
treatment	I-PROC
of	O	O
paraclinoid	B-DISO
lesions	I-DISO
to	O	O
reduce	O
the	O	O
risk	O
of	O	O
intraoperative	O
neurovascular	B-DISO
injury	I-DISO
.	O	O

A	O	O
Systematic	O
Review	O
of	O	O
the	O	O
Diagnostic	O
and	O	O
Prognostic	O
Value	O
of	O	O
Urinary	O
Protein	B-CHEM
Biomarkers	B-PHYS
in	O	O
Urothelial	B-DISO
Bladder	I-DISO
Cancer	I-DISO
For	O	O
over	O	O
80	O	O
years	O	O
,	O	O
cystoscopy	B-PROC
has	O	O
remained	O	O
the	O	O
gold	O
-	O
standard	O
for	O	O
detecting	B-DISO
tumours	B-DISO
of	O	O
the	O	O
urinary	B-ANAT
bladder	I-ANAT
.	O	O

Since	O	O
bladder	B-DISO
tumours	I-DISO
have	O	O
a	O	O
tendency	O	O
to	O	O
recur	B-PHEN
and	O	O
progress	B-DISO
,	O	O
many	O	O
patients	B-LIVB
are	O	O
subjected	O	O
to	O	O
repeated	O	O
cystoscopies	B-PROC
during	O	O
long	O
-	O
term	O
surveillance	B-PROC
,	O	O
with	O	O
the	O	O
procedure	B-PROC
being	O	O
both	O	O
unpleasant	O	O
for	O	O
the	O	O
patient	B-LIVB
and	O	O
expensive	O	O
for	O	O
healthcare	B-LIVB
providers	I-LIVB
.	O	O

The	O	O
identification	O
and	O	O
validation	B-PROC
of	O	O
bladder	B-DISO
tumour	I-DISO
specific	O	O
molecular	B-PHYS
markers	I-PHYS
in	O	O
urine	B-ANAT
could	O	O
enable	O	O
tumour	B-DISO
detection	B-DISO
and	O	O
reduce	O	O
reliance	O
on	O	O
cystoscopy	B-PROC
,	O	O
and	O	O
numerous	O	O
classes	O	O
of	O	O
biomarkers	B-PHYS
have	O	O
been	O	O
studied	O	O
.	O	O

Proteins	B-CHEM
represent	O	O
the	O	O
most	O	O
intensively	O	O
studied	O
class	O
of	O
biomolecule	O
in	O	O
this	O	O
setting	O	O
.	O	O

As	O	O
an	O	O
aid	O	O
to	O	O
researchers	B-LIVB
searching	O	O
for	O	O
better	O	O
urinary	O
biomarkers	B-PHYS
,	O	O
we	O	O
report	O	O
a	O	O
comprehensive	O
systematic	O
review	O
of	O	O
the	O	O
literature	O
and	O	O
a	O	O
searchable	O	O
database	O
of	O	O
proteins	B-CHEM
that	O	O
have	O	O
been	O	O
investigated	B-PROC
to	O	O
date	O	O
.	O	O

Our	O	O
objective	O	O
was	O	O
to	O	O
classify	O	O
these	O	O
proteins	B-CHEM
as	O	O
:	O	O
1	O	O
)	O	O
those	O	O
with	O	O
robustly	O	O
characterised	O	O
sensitivity	O
and	O
specificity	O
for	O	O
bladder	B-DISO
cancer	I-DISO
detection	B-DISO
;	O	O
2	O	O
)	O	O
those	O	O
that	O	O
show	O	O
potential	O	O
but	O	O
further	O	O
investigation	B-PROC
is	O	O
required	O	O
;	O	O
3	O	O
)	O	O
those	O	O
unlikely	O	O
to	O	O
warrant	O	O
further	O	O
investigation	B-PROC
;	O	O
and	O	O
4	O	O
)	O	O
those	O	O
investigated	B-PROC
as	O	O
prognostic	O
markers	O
.	O	O

This	O	O
work	O	O
should	O	O
help	O	O
to	O	O
prioritise	O	O
certain	O	O
biomarkers	B-PHYS
for	O	O
rigorous	B-PROC
validation	I-PROC
,	O	O
whilst	O	O
preventing	O
wasted	O	O
effort	O	O
on	O	O
proteins	B-CHEM
that	O	O
have	O	O
shown	O	O
no	O	O
association	O	O
whatsoever	O	O
with	O	O
the	O	O
disease	B-DISO
,	O	O
or	O	O
only	O	O
modest	O	O
biomarker	B-PHYS
performance	O	O
despite	O	O
large	O
-	O
scale	O
efforts	O
at	O	O
validation	B-PROC
.	O	O

Of	O	O
Kindlins	B-CHEM
and	O	O
Cancer	B-DISO
Kindlins	B-CHEM
are	O	O
4	O
.	O
1	O
-	O
ezrin	O
-	O
ridixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
containing	O	O
proteins	B-CHEM
.	O	O

There	O	O
are	O	O
three	O	O
kindlins	B-CHEM
in	O	O
mammals	B-LIVB
,	O	O
which	O	O
share	O	O
high	O
sequence	O
identity	O	O
.	O	O

Kindlin	B-CHEM
-	I-CHEM
1	I-CHEM
is	O	O
expressed	B-PHYS
primarily	O	O
in	O	O
epithelial	B-ANAT
cells	I-ANAT
,	O	O
kindlin	B-CHEM
-	I-CHEM
2	I-CHEM
is	O	O
widely	O	O
distributed	O
and	O	O
is	O	O
particularly	O	O
abundant	O
in	O	O
adherent	B-ANAT
cells	I-ANAT
,	O	O
and	O	O
kindlin	B-CHEM
-	I-CHEM
3	I-CHEM
is	O	O
expressed	B-PHYS
primarily	O	O
in	O	O
hematopoietic	B-ANAT
cells	I-ANAT
.	O	O

These	O	O
distributions	O
are	O	O
not	O	O
exclusive	O
;	O	O
some	O	O
cells	B-ANAT
express	B-PHYS
multiple	O
kindlins	B-CHEM
,	O	O
and	O	O
transformed	B-ANAT
cells	I-ANAT
often	O
exhibit	O	O
aberrant	O
expression	B-PHYS
,	O	O
both	O	O
in	O	O
the	O	O
isoforms	B-CHEM
and	O	O
the	O	O
levels	O
of	O	O
kindlins	B-CHEM
.	O	O

Great	O	O
interest	O	O
in	O	O
the	O	O
kindlins	B-CHEM
has	O	O
emerged	O	O
from	O	O
the	O	O
recognition	O	O
that	O	O
they	O	O
play	O	O
major	O
roles	O
in	O	O
controlling	B-PHEN
integrin	B-CHEM
function	B-PHYS
.	O	O

In	B-PROC
vitro	I-PROC
studies	I-PROC
,	O	O
in	B-PROC
vivo	I-PROC
studies	I-PROC
of	O	O
mice	B-LIVB
deficient	O
in	O	O
kindlins	B-CHEM
,	O	O
and	O	O
studies	B-PROC
of	O	O
patients	B-LIVB
with	O	O
genetic	O
deficiencies	O
of	O	O
kindlins	B-CHEM
have	O	O
clearly	O	O
established	O
that	O	O
they	O	O
regulate	O	O
the	O	O
capacity	O
of	O	O
integrins	B-CHEM
to	O	O
mediate	O
their	O	O
functions	O
.	O	O

Kindlins	B-CHEM
are	O	O
adaptor	B-CHEM
proteins	I-CHEM
;	O	O
their	O	O
function	O
emanate	O
from	O	O
their	O	O
interaction	O
with	O	O
binding	B-PHYS
partners	O	O
,	O	O
including	O	O
the	O	O
cytoplasmic	B-ANAT
tails	I-ANAT
of	O	O
integrins	B-CHEM
and	O	O
components	O	O
of	O	O
the	O	O
actin	B-ANAT
cytoskeleton	I-ANAT
.	O	O

The	O	O
purpose	O
of	O	O
this	O	O
review	O
is	O	O
to	O	O
provide	O	O
a	O	O
brief	O
overview	O
of	O	O
kindlin	B-CHEM
structure	B-CHEM
and	O	O
function	B-PHYS
,	O	O
a	O	O
consideration	B-DISO
of	O	O
their	O	O
binding	B-PHYS
partners	O	O
,	O	O
and	O	O
then	O	O
to	O	O
focus	O	O
on	O	O
the	O	O
relationship	O
of	O	O
each	O	O
kindlin	B-CHEM
family	B-CHEM
member	B-LIVB
with	O	O
cancer	B-DISO
.	O	O

In	O	O
view	O
of	O	O
many	O	O
correlations	O
of	O	O
kindlin	B-CHEM
expression	B-PHYS
levels	O
and	O	O
neoplasia	B-DISO
and	O	O
the	O	O
known	O	O
association	O
of	O	O
integrins	B-CHEM
with	O	O
tumor	B-DISO
progression	I-DISO
and	O	O
metastasis	B-DISO
,	O	O
we	O	O
consider	O
whether	O	O
regulation	O	O
of	O	O
kindlins	B-CHEM
or	O	O
their	O	O
function	O
would	O	O
be	O	O
attractive	O
targets	O
for	O	O
treatment	B-PROC
of	I-PROC
cancer	I-PROC
.	O	O

Well	O	O
,	O	O
I	O	O
Wouldn	O	O
'	O	O
t	O	O
be	O	O
Any	O	O
Worse	O	O
Off	O	O
,	O	O
Would	O	O
I	O	O
,	O	O
Than	O	O
I	O	O
am	O	O
Now	O	O
?	O	O
A	O	O
Qualitative	B-PROC
Study	I-PROC
of	O	O
Decision	B-PHYS
-	I-PHYS
Making	I-PHYS
,	O	O
Hopes	B-PHYS
,	O	O
and	O	O
Realities	O
of	O	O
Adults	B-LIVB
With	O	O
Type	B-DISO
1	I-DISO
Diabetes	I-DISO
Undergoing	O	O
Islet	B-PROC
Cell	I-PROC
Transplantation	I-PROC
For	O	O
selected	O	O
individuals	B-LIVB
with	O	O
type	B-DISO
1	I-DISO
diabetes	I-DISO
,	O	O
pancreatic	B-PROC
islet	I-PROC
transplantation	I-PROC
(	O	O
IT	B-PROC
)	O	O
prevents	O	O
recurrent	O	O
severe	O	O
hypoglycemia	B-DISO
and	O	O
optimizes	B-PROC
glycemia	I-PROC
,	O	O
although	O	O
ongoing	O	O
systemic	B-PROC
immunosuppression	I-PROC
is	O	O
needed	O	O
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
explore	O	O
candidates	B-LIVB
and	O	O
recipients	B-LIVB
'	O	O
expectations	O	O
of	O	O
transplantation	B-PROC
,	O	O
their	O	O
experience	O	O
of	O	O
being	O	O
on	O	O
the	O	O
waiting	B-DISO
list	I-DISO
,	O	O
and	O	O
(	O	O
for	O	O
recipients	B-LIVB
)	O	O
the	O	O
procedure	O	O
and	O	O
life	O	O
posttransplant	O
.	O	O

Cross	O	O
-	O	O
sectional	O	O
qualitative	O
research	B-PROC
design	I-PROC
using	O	O
semistructured	O	O
interviews	B-PROC
with	O	O
16	O	O
adults	B-LIVB
(	O	O
8	O	O
pretransplant	O
,	O	O
8	O	O
posttransplant	O
;	O	O
from	O	O
4	O	O
UK	B-GEOG
centers	B-OBJC
(	O	O
n	O	O
=	O	O
13	O	O
)	O	O
and	O	O
1	O	O
Canadian	B-GEOG
center	B-OBJC
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
)	O	O
.	O	O

Interviews	B-PROC
were	O	O
audio	B-PROC
-	I-PROC
recorded	I-PROC
,	O	O
transcribed	O	O
,	O	O
and	O	O
underwent	O	O
inductive	B-PROC
thematic	I-PROC
analysis	I-PROC
.	O	O

Interviewees	B-LIVB
were	O	O
aged	O	O
(	O	O
mean	O	O
±	O	O
SD	O	O
)	O	O
52	O	O
±	O	O
10	O	O
years	O
(	O	O
range	O	O
,	O	O
30	O	O
-	O	O
64	O	O
)	O	O
;	O	O
duration	O
of	O	O
diabetes	B-DISO
,	O	O
36	O	O
±	O	O
9	O	O
years	O
(	O	O
range	O	O
,	O	O
21	O	O
-	O	O
56	O	O
)	O	O
;	O	O
12	O	O
(	O	O
75	O	O
%	O	O
)	O	O
were	O	O
women	B-LIVB
.	O	O

Narrative	O	O
accounts	O	O
centered	O	O
on	O	O
expectations	O
,	O	O
hopes	B-PHYS
,	O	O
and	O	O
realities	O
;	O	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
;	O	O
waiting	O	O
and	O	O
uncertainty	O	O
;	O	O
the	O	O
procedure	O	O
,	O	O
hospital	O
stay	O
,	O	O
and	O	O
follow	B-PROC
-	I-PROC
up	I-PROC
.	O	O

Expected	O	O
benefits	O	O
included	O	O
fewer	O	O
severe	O	O
hypoglycemic	B-DISO
episodes	I-DISO
,	O	O
reduced	O
need	O	O
for	O	O
insulin	B-CHEM
,	O	O
preventing	O	O
onset	O	O
/	O	O
progression	O	O
of	O	O
complications	B-DISO
and	O	O
improved	O	O
psychological	B-DISO
well	I-DISO
-	I-DISO
being	I-DISO
.	O	O

These	O	O
were	O	O
realized	O	O
for	O	O
most	O	O
,	O	O
at	O	O
least	O	O
in	O	O
the	O	O
short	O	O
term	O	O
.	O	O

Most	O	O
interviewees	B-LIVB
described	O	O
well	O	O
-	O	O
informed	O	O
,	O	O
shared	O	O
decision	B-PHYS
-	I-PHYS
making	I-PHYS
with	O	O
clinicians	B-LIVB
and	O	O
family	B-LIVB
,	O	O
and	O	O
managing	O	O
their	O	O
expectations	O	O
.	O	O

Although	O	O
life	O	O
""""	O	O
on	O	O
the	O	O
list	O	O
""""	O	O
could	O	O
be	O	O
stressful	O
,	O	O
and	O	O
immunosuppressant	B-CHEM
side	B-DISO
effects	I-DISO
were	O	O
severe	O
,	O	O
interviewees	B-LIVB
reported	O	O
""""	O	O
no	B-DISO
regrets	B-PHYS
.	O	O
""""	O	O
Posttransplant	O
,	O	O
interviewees	B-LIVB
experienced	O	O
increased	O	O
confidence	B-PHYS
,	O	O
through	O	O
freedom	B-DISO
from	I-DISO
hypoglycemia	I-DISO
and	O	O
regained	O	O
glycemic	B-PROC
control	I-PROC
,	O	O
which	O	O
tempered	O	O
any	O	O
disappointment	O	O
about	O	O
continued	O	O
reliance	O	O
on	O	O
insulin	B-CHEM
.	O	O

Most	O	O
viewed	O	O
their	O	O
transplant	B-PROC
as	O	O
a	O	O
success	O	O
,	O	O
though	O	O
several	O	O
reflected	O	O
upon	O	O
setbacks	O	O
and	O	O
hidden	O	O
hopes	B-PHYS
for	O	O
becoming	O	O
""""	O	O
insulin	B-DISO
-	I-DISO
free	I-DISO
.	O	O
""""	O	O
Independently	O	O
undertaken	O	O
interviews	B-PROC
demonstrated	O	O
realistic	O	O
and	O	O
balanced	O	O
expectations	O	O
of	O	O
IT	B-PROC
and	O	O
indicate	O	O
how	O	O
to	O	O
optimize	O	O
the	O	O
process	O	O
and	O	O
support	O	O
for	O	O
future	O	O
IT	B-PROC
candidates	B-LIVB
.	O	O

Nonsteroidal	B-CHEM
Anti	I-CHEM
-	I-CHEM
Inflammatory	I-CHEM
Drugs	I-CHEM
and	O	O
Bone	B-DISO
-	I-DISO
Healing	I-DISO
:	O	O
A	O	O
Systematic	O
Review	O
of	O	O
Research	B-PROC
Quality	I-PROC
Nonsteroidal	B-CHEM
anti	I-CHEM
-	I-CHEM
inflammatory	I-CHEM
drugs	I-CHEM
(	O	O
NSAIDs	B-CHEM
)	O	O
are	O	O
often	O	O
avoided	O	O
by	O	O
orthopaedic	B-LIVB
surgeons	I-LIVB
because	O	O
of	O	O
their	O	O
possible	O	O
influence	O	O
on	O	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O	O

This	O	O
belief	O	O
stems	O	O
from	O	O
multiple	O	O
studies	B-PROC
,	O	O
in	O	O
particular	O	O
animal	B-LIVB
studies	I-LIVB
,	O	O
that	O	O
show	O	O
delayed	O
bone	B-DISO
-	I-DISO
healing	I-DISO
or	O	O
nonunions	O	O
associated	O	O
with	O	O
NSAID	B-CHEM
exposure	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
review	O
was	O	O
to	O	O
critically	O	O
analyze	B-PROC
the	O	O
quality	O
of	O	O
published	B-OBJC
literature	I-OBJC
that	O	O
evaluates	O	O
the	O	O
impact	O
of	O	O
NSAIDs	B-CHEM
on	O	O
clinical	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O	O

A	O	O
MEDLINE	O
and	O	O
Embase	O
search	O	O
was	O	O
conducted	O	O
to	O	O
identify	O	O
all	O	O
articles	O
relating	O	O
to	O	O
bone	B-DISO
and	O	O
fracture	B-PHYS
-	I-PHYS
healing	I-PHYS
and	O	O
the	O	O
utilization	O	O
of	O	O
NSAIDs	B-CHEM
.	O	O

All	O	O
human	B-PROC
studies	I-PROC
,	O	O
including	O	O
review	O
articles	O
,	O	O
were	O	O
identified	O	O
for	O	O
further	O	O
analysis	B-PROC
.	O	O

Non	B-OBJC
-	I-OBJC
English	I-OBJC
-	I-OBJC
language	I-OBJC
manuscripts	I-OBJC
and	O	O
in	O
vitro	O
and	O	O
animal	B-LIVB
studies	I-LIVB
were	O	O
excluded	O
.	O	O

A	O	O
total	O	O
of	O	O
twelve	O	O
clinical	O
articles	O
and	O	O
twenty	O	O
-	O	O
four	O	O
literature	O
reviews	O
were	O	O
selected	O	O
for	O	O
analysis	B-PROC
.	O	O

The	O	O
quality	O	O
of	O	O
the	O	O
clinical	B-PROC
studies	I-PROC
was	O	O
assessed	O	O
with	O	O
a	O	O
modified	O	O
Coleman	O
Methodology	O
Score	O
with	O	O
emphasis	O	O
on	O	O
the	O	O
NSAID	B-CHEM
utilization	O	O
.	O	O

Review	O
articles	O
were	O	O
analyzed	B-PROC
with	O	O
regard	O	O
to	O	O
variability	O
in	O	O
the	O	O
cited	O	O
literature	O
and	O	O
final	O	O
conclusions	O
.	O	O

The	O	O
mean	O	O
modified	O	O
Coleman	O
Methodology	O
Score	O
(	O	O
and	O	O
standard	O
deviation	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
032	O	O
)	O	O
in	O	O
clinical	B-PROC
studies	I-PROC
that	O	O
demonstrated	O	O
a	O	O
negative	O	O
effect	O	O
of	O	O
NSAIDs	B-CHEM
on	O	O
bone	B-DISO
-	I-DISO
healing	I-DISO
(	O	O
40	O	O
.	O	O
0	O	O
±	O	O
14	O	O
.	O	O

3	O	O
points	O	O
)	O	O
compared	O
with	O	O
those	O	O
that	O	O
concluded	O	O
that	O	O
NSAIDs	B-CHEM
were	O	O
safe	O	O
(	O	O
58	O	O
.	O	O
8	O	O
±	O	O
10	O	O
.	O	O

3	O	O
points	O	O
)	O	O
.	O	O

Review	O
articles	O
also	O	O
demonstrated	O	O
substantial	O	O
variability	O
in	O	O
the	O	O
number	O	O
of	O	O
cited	O	O
clinical	B-PROC
studies	I-PROC
and	O	O
overall	O	O
conclusions	O	O
.	O	O

There	O	O
were	O	O
only	O	O
two	O	O
meta	O
-	O
analyses	O
and	O	O
twenty	O	O
-	O	O
two	O	O
narrative	O
reviews	O
.	O	O

The	O	O
mean	O	O
number	O	O
(	O	O
and	O	O
standard	O
deviation	O
)	O	O
of	O	O
clinical	B-PROC
studies	I-PROC
cited	O	O
was	O	O
significantly	O	O
greater	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O
008	O	O
)	O	O
for	O	O
reviews	O
that	O	O
concluded	O	O
that	O	O
NSAIDs	B-CHEM
were	O	O
safe	O	O
(	O	O
8	O	O
.	O	O
0	O	O
±	O	O
4	O	O
.	O	O

8	O	O
)	O	O
compared	O	O
with	O	O
those	O	O
that	O	O
recommended	O	O
avoiding	O	O
them	O	O
(	O	O
2	O	O
.	O	O
1	O	O
±	O	O
2	O	O
.	O	O
1	O	O
)	O	O
.	O	O

Unanimously	O	O
,	O	O
all	O	O
reviews	O
admitted	O	O
to	O	O
the	O	O
need	O	O
for	O	O
prospective	O	O
randomized	B-PROC
controlled	I-PROC
trials	I-PROC
to	O	O
help	O	O
clarify	O	O
the	O	O
effects	O	O
of	O	O
NSAIDs	B-CHEM
on	O	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O	O

This	O	O
systematic	O
literature	O
review	O
highlights	O	O
the	O	O
great	O	O
variability	O
in	O	O
the	O	O
interpretation	O	O
of	O	O
the	O	O
literature	O
addressing	O	O
the	O	O
impact	O
of	O	O
NSAIDs	B-CHEM
on	O	O
bone	B-DISO
-	I-DISO
healing	I-DISO
.	O	O

Unfortunately	O	O
,	O	O
there	O	O
is	O	O
no	O	O
consensus	O	O
regarding	O	O
the	O	O
safety	O	O
of	O	O
NSAIDs	B-CHEM
following	O	O
orthopaedic	B-PROC
procedures	I-PROC
,	O	O
and	O	O
future	O	O
studies	B-PROC
should	O	O
aim	O	O
for	O	O
appropriate	O	O
methodological	B-PROC
designs	I-PROC
to	O	O
help	O	O
to	O	O
clarify	O	O
existing	O	O
discrepancies	B-DISO
to	O	O
improve	O	O
the	O	O
quality	B-PROC
of	I-PROC
care	I-PROC
for	O	O
orthopaedic	B-LIVB
patients	I-LIVB
.	O	O

This	O	O
systematic	O
review	O
highlights	O	O
the	O	O
limitations	O
in	O	O
the	O	O
current	O	O
understanding	O	O
of	O	O
the	O	O
effects	O
of	O	O
NSAIDs	B-CHEM
on	O	O
bone	B-DISO
healing	I-DISO
.	O	O

Thus	O	O
,	O	O
withholding	O	O
these	O	O
medications	B-CHEM
does	O	O
not	O	O
have	O	O
any	O	O
proven	O	O
scientific	O
benefit	O
to	O	O
patients	B-LIVB
and	O	O
may	O	O
even	O	O
cause	O	O
harm	B-DISO
by	O	O
increasing	O	O
narcotic	B-CHEM
requirements	O	O
in	O	O
cases	O	O
in	O	O
which	O	O
they	O	O
could	O	O
be	O	O
beneficial	O	O
for	O	O
pain	B-PROC
management	I-PROC
.	O	O

This	O	O
review	O	O
should	O	O
encourage	O	O
further	O	O
basic	O	O
-	O	O
science	O	O
and	O	O
clinical	B-PROC
studies	I-PROC
to	O	O
clarify	O	O
the	O	O
risks	O
and	O	O
benefits	O
of	O	O
anti	B-CHEM
-	I-CHEM
inflammatory	I-CHEM
medications	I-CHEM
in	O	O
the	O	O
postoperative	O
period	O
,	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
patient	B-LIVB
outcomes	O
.	O	O

The	O	O
nanocomposite	O
nature	O	O
of	O	O
bone	B-ANAT
drives	O	O
its	O	O
strength	O
and	O	O
damage	O
resistance	O
In	O	O
human	B-ANAT
bone	I-ANAT
,	O	O
an	O	O
amorphous	O
mineral	B-CHEM
serves	O	O
as	O	O
a	O	O
precursor	O
to	O	O
the	O	O
formation	O
of	O	O
a	O	O
highly	O	O
substituted	O	O
nanocrystalline	B-OBJC
apatite	B-CHEM
.	O	O

However	O	O
,	O	O
the	O	O
precise	O	O
role	O	O
of	O	O
this	O	O
amorphous	O
mineral	B-CHEM
remains	O	O
unknown	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
by	O	O
using	O	O
transmission	B-PROC
electron	I-PROC
microscopy	I-PROC
that	O	O
100	O	O
-	O	O
300	O	O
nm	O	O
amorphous	O
calcium	B-CHEM
phosphate	I-CHEM
regions	B-ANAT
are	O	O
present	O	O
in	O	O
the	O	O
disordered	O
phase	O
of	O	O
trabecular	O
bone	O
.	O	O

Nanomechanical	B-PROC
experiments	I-PROC
on	O	O
cylindrical	O
samples	B-OBJC
,	O	O
with	O	O
diameters	O
between	O	O
250	O	O
nm	O	O
and	O	O
3	O	O
,	O	O
000	O	O
nm	O	O
,	O	O
of	O	O
the	O	O
bone	B-ANAT
's	I-ANAT
ordered	O
and	O	O
disordered	O
phases	O
revealed	O	O
a	O	O
transition	O
from	O	O
plastic	B-PHEN
deformation	B-DISO
to	O	O
brittle	B-DISO
failure	B-DISO
and	O	O
at	O	O
least	O	O
a	O	O
factor	O	O
-	O	O
of	O	O
-	O	O
2	O	O
higher	O	O
strength	O
in	O	O
the	O	O
smaller	O
samples	B-OBJC
.	O	O

We	O	O
postulate	O	O
that	O	O
this	O	O
transition	O
in	O	O
failure	O
mechanism	O
is	O	O
caused	O	O
by	O	O
the	O	O
suppression	O
of	O	O
extrafibrillar	B-ANAT
shearing	B-PROC
in	O	O
the	O	O
smaller	O	O
samples	B-OBJC
,	O	O
and	O	O
that	O	O
the	O	O
emergent	O	O
smaller	O
-is	O	O
-	O	O
stronger	O
size	O
effect	O
is	O	O
related	O	O
to	O	O
the	O	O
sample	O
-	O
size	O
scaling	O
of	O	O
the	O	O
distribution	O	O
of	O	O
flaws	O	O
.	O	O

Our	O	O
findings	B-DISO
should	O	O
help	O	O
in	O	O
the	O	O
understanding	O	O
of	O	O
the	O	O
multi	O
-	O
scale	O
nature	O
of	O	O
bone	B-ANAT
and	O	O
provide	O	O
insights	O	O
into	O	O
the	O	O
biomineralization	B-PHYS
process	B-PHEN
.	O	O

Long	B-CHEM
noncoding	I-CHEM
RNA	I-CHEM
XIST	B-CHEM
acts	O	O
as	O	O
an	O	O
oncogene	O
in	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
by	O	O
epigenetically	B-PHYS
repressing	I-PHYS
KLF2	B-CHEM
expression	B-PHYS
Recently	O	O
,	O	O
long	B-CHEM
noncoding	I-CHEM
RNAs	I-CHEM
(	O	O
lncRNAs	B-CHEM
)	O	O
have	O	O
been	O	O
identified	O
as	O	O
critical	O	O
regulators	O
in	O	O
numerous	O
types	O	O
of	O	O
cancers	B-DISO
,	O	O
including	O	O
non	B-DISO
-	I-DISO
small	I-DISO
cell	I-DISO
lung	I-DISO
cancer	I-DISO
(	O	O
NSCLC	B-DISO
)	O	O
.	O	O

X	B-CHEM
inactivate	I-CHEM
-	I-CHEM
specific	I-CHEM
transcript	I-CHEM
(	O	O
XIST	B-CHEM
)	O	O
has	O	O
been	O	O
found	O	O
to	O	O
be	O	O
up	B-PHYS
-	I-PHYS
regulated	I-PHYS
and	O	O
acts	O	O
as	O	O
an	O	O
oncogene	O
in	O	O
gastric	B-DISO
cancer	I-DISO
and	O	O
hepatocellular	B-DISO
carcinoma	I-DISO
,	O	O
but	O	O
little	O	O
is	O	O
known	O	O
about	O	O
its	O	O
expression	B-PHYS
pattern	O
,	O	O
biological	B-PHEN
function	I-PHEN
and	O	O
underlying	O	O
mechanism	O
in	O	O
NSCLC	B-DISO
.	O	O

Here	O	O
,	O	O
we	O	O
identified	O
XIST	B-CHEM
as	O	O
an	O	O
oncogenic	O
lncRNA	B-CHEM
by	O	O
driving	O	O
tumorigenesis	B-DISO
in	O	O
NSCLC	B-DISO
.	O	O

We	O	O
found	O	O
that	O	O
XIST	B-CHEM
is	O	O
over	O	O
-	O	O
expressed	B-PHYS
in	O	O
NSCLC	B-DISO
,	O	O
and	O	O
its	O	O
increased	O
level	O
is	O	O
associated	O
with	O
shorter	B-DISO
survival	I-DISO
and	O	O
poorer	B-DISO
prognosis	I-DISO
.	O	O

Knockdown	B-PROC
of	O	O
XIST	B-CHEM
impaired	O
NSCLC	B-DISO
cells	B-PHYS
proliferation	I-PHYS
,	O	O
migration	B-PHYS
and	O	O
invasion	B-DISO
in	B-PROC
vitro	I-PROC
,	O	O
and	O	O
repressed	O	O
the	O	O
tumorigenicity	B-DISO
of	O	O
NSCLC	B-DISO
cells	O	O
in	B-PROC
vivo	I-PROC
.	O	O

Mechanistically	O	O
,	O	O
RNA	B-CHEM
immune	B-PROC
-	I-PROC
precipitation	I-PROC
(	O	O
RIP	B-PROC
)	O	O
and	O	O
RNA	B-CHEM
pull	B-PROC
-	I-PROC
down	I-PROC
experiment	I-PROC
demonstrated	O	O
that	O	O
XIST	B-CHEM
could	O	O
simultaneously	O	O
interact	O
with	O	O
EZH2	B-CHEM
to	O	O
suppress	O
transcription	B-PHYS
of	O	O
its	O	O
potential	O
target	O
KLF2	B-CHEM
.	O	O

Additionally	O	O
,	O	O
rescue	O	O
experiments	B-PROC
revealed	O
that	O	O
XIST	B-CHEM
'	O	O
s	O	O
oncogenic	O
functions	O
were	O	O
partly	O	O
depending	O	O
on	O	O
silencing	B-PHYS
KLF2	B-CHEM
expression	B-PHYS
.	O	O

Collectively	O	O
,	O	O
our	O	O
findings	B-DISO
expound	O	O
how	O	O
XIST	B-CHEM
over	O	O
-	O	O
expression	B-PHYS
endows	O	O
an	O	O
oncogenic	O
function	O
in	O	O
NSCLC	B-DISO
.	O	O

Assessing	O
the	O	O
physiological	O
relevance	O
of	O	O
alternate	O	O
architectures	O
of	O	O
the	O	O
p7	B-CHEM
protein	I-CHEM
of	O	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
in	O	O
different	O	O
environments	O
The	O	O
viroporin	B-PHEN
p7	B-CHEM
of	O	O
the	O	O
hepatitis	B-LIVB
C	I-LIVB
virus	I-LIVB
forms	O	O
multimeric	B-CHEM
channels	I-CHEM
eligible	O	O
for	O	O
ion	B-PHYS
transport	I-PHYS
across	O	O
the	O	O
endoplasmic	B-ANAT
reticulum	I-ANAT
membrane	I-ANAT
.	O	O

Currently	O	O
the	O	O
subject	O
of	O	O
many	O	O
studies	B-PROC
and	O	O
discussion	O	O
,	O	O
the	O	O
molecular	B-PHYS
assembly	I-PHYS
of	O	O
the	O	O
ion	B-CHEM
channel	I-CHEM
and	O	O
the	O	O
structural	O
characteristics	O
of	O	O
the	O	O
p7	B-CHEM
monomer	B-CHEM
are	O	O
not	O	O
yet	O	O
fully	O	O
understood	O	O
.	O	O

Structural	O
investigation	O
of	O	O
p7	B-CHEM
has	O	O
been	O	O
carried	O	O
out	O	O
only	O	O
in	O	O
detergent	B-CHEM
environments	O
,	O	O
making	O	O
the	O	O
interpretation	O	O
of	O	O
the	O	O
experimental	O	O
results	O	O
somewhat	O	O
questionable	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
analyze	B-PROC
by	O	O
means	O	O
of	O	O
molecular	O
dynamics	O
simulations	O
the	O	O
structure	O
of	O	O
the	O	O
p7	B-CHEM
monomer	B-CHEM
as	O	O
a	O	O
function	O	O
of	O	O
its	O	O
sequence	O
,	O	O
initial	O	O
conformation	O
and	O	O
environment	O
.	O	O

We	O	O
investigate	O	O
the	O	O
conductance	O
properties	O	O
of	O	O
three	O	O
models	B-DEVI
of	O	O
a	O	O
hexameric	B-CHEM
p7	B-CHEM
ion	B-CHEM
channel	I-CHEM
by	O	O
examining	O	O
ion	B-PHYS
translocation	I-PHYS
in	O	O
a	O	O
pure	O	O
lipid	B-ANAT
bilayer	I-ANAT
.	O	O

It	O	O
is	O	O
noteworthy	O	O
that	O	O
although	O	O
none	O	O
of	O	O
the	O	O
models	B-DEVI
reflects	O	O
the	O	O
experimentally	O	O
observed	O	O
trend	O	O
to	O	O
conduct	O	O
preferentially	O	O
cations	B-CHEM
,	O	O
we	O	O
were	O	O
able	O	O
to	O	O
identify	O	O
the	O	O
position	O
and	O	O
orientation	O
of	O	O
titratable	O	O
acidic	O
or	O
basic	O
residues	O
playing	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
ion	B-CHEM
selectivity	O
and	O	O
in	O	O
the	O	O
overall	O	O
conductance	O
of	O	O
the	O	O
channel	B-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
too	O	O
compact	O	O
a	O	O
packing	B-PHYS
of	O	O
the	O	O
monomers	B-CHEM
leads	O	O
to	O	O
channel	B-CHEM
collapse	B-PHEN
rather	O	O
than	O	O
formation	O	O
of	O	O
a	O	O
reasonable	O	O
pore	B-ANAT
,	O	O
amenable	O	O
to	O	O
ion	B-PHYS
translocation	I-PHYS
.	O	O

The	O	O
present	O	O
findings	O	O
are	O	O
envisioned	O	O
to	O	O
help	O	O
assess	O	O
the	O	O
physiological	O
relevance	O
of	O	O
p7	B-CHEM
ion	B-CHEM
channel	I-CHEM
models	B-DEVI
consisting	O	O
of	O	O
multimeric	O
structures	O
obtained	O	O
in	O	O
non	O	O
-	O	O
native	O	O
environments	O
.	O	O

Cartilage	B-DISO
inflammation	I-DISO
and	O	O
degeneration	B-DISO
is	O	O
enhanced	O
by	O	O
pro	O
-	O
inflammatory	O
(	B-ANAT
M1	I-ANAT
)	I-ANAT
macrophages	I-ANAT
in	O
vitro	O
,	O	O
but	O	O
not	O	O
inhibited	O
directly	O
by	O	O
anti	O
-	O
inflammatory	O
(	B-ANAT
M2	I-ANAT
)	I-ANAT
macrophages	I-ANAT
Macrophages	B-ANAT
play	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
the	O	O
progression	O
of	O	O
osteoarthritis	B-DISO
(	O	O
OA	B-DISO
)	O	O
.	O	O

Their	O	O
phenotype	B-PHYS
may	O	O
range	O	O
from	O	O
pro	O
-	O
inflammatory	O
to	O	O
anti	O
-	O
inflammatory	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
direct	O
effects	O
of	O
macrophage	B-ANAT
subtypes	O
on	O	O
cartilage	O
by	O	O
culturing	B-PROC
macrophage	B-ANAT
conditioned	B-CHEM
medium	I-CHEM
(	O	O
MCM	B-CHEM
)	O	O
on	O	O
human	B-LIVB
articular	O
cartilage	O
.	O	O

Human	B-LIVB
OA	B-DISO
cartilage	O
explants	B-PROC
were	O	O
cultured	B-PROC
with	O	O
MCM	B-CHEM
of	O	O
pro	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
M	I-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
,	O	O
or	O	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
M	I-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
or	O	O
M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O	O
human	B-LIVB
monocyte	B-ANAT
-	I-ANAT
derived	I-ANAT
macrophages	I-ANAT
.	O	O

To	O	O
assess	O
effects	O
of	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
,	O	O
the	O	O
cartilage	O
was	O	O
cultured	B-PROC
with	O	O
a	O	O
combination	O
of	O	O
MCM	B-CHEM
phenotypes	B-PHYS
as	O	O
well	O	O
as	O	O
pre	B-PHEN
-	I-PHEN
stimulated	I-PHEN
with	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
cartilage	O
before	O	O
culture	B-PROC
with	O	O
MCM	B-CHEM
.	O	O

The	O	O
reactions	O	O
of	O	O
the	O	O
explants	O	O
were	O	O
assessed	O
by	O	O
gene	B-PHYS
expression	I-PHYS
,	O	O
nitric	B-PHEN
oxide	I-PHEN
(	I-PHEN
NO	I-PHEN
)	I-PHEN
production	I-PHEN
and	O	O
release	O
of	O	O
glycosaminoglycans	B-CHEM
(	O	O
GAGs	B-CHEM
)	O	O
.	O	O

M	B-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
MCM	B-CHEM
affected	O	O
OA	B-DISO
cartilage	O
by	O	O
upregulation	B-PHYS
of	O	O
IL1B	B-CHEM
(	O	O
Interleukin	B-CHEM
1β	I-CHEM
)	O	O
,	O	O
IL6	B-CHEM
,	O	O
MMP13	B-CHEM
(	O	O
Matrix	B-CHEM
Metalloproteinase	I-CHEM
-	I-CHEM
13	I-CHEM
)	O	O
and	O	O
ADAMTS5	B-CHEM
(	O	O
A	B-CHEM
Disintegrin	I-CHEM
And	I-CHEM
Metalloproteinase	I-CHEM
with	I-CHEM
Thrombospondin	I-CHEM
Motifs	I-CHEM
-	I-CHEM
5	I-CHEM
)	O	O
,	O	O
while	O	O
inhibiting	O
ACAN	B-CHEM
(	O	O
aggrecan	B-CHEM
)	O	O
and	O	O
COL2A1	B-CHEM
(	O	O
collagen	B-CHEM
type	I-CHEM
II	I-CHEM
)	O	O
.	O	O

M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	O	O
upregulated	B-PHYS
IL1B	B-CHEM
and	O	O
Suppressor	B-CHEM
of	I-CHEM
cytokine	I-CHEM
signaling	I-CHEM
1	I-CHEM
(	O	O
SOCS1	B-CHEM
)	O	O
.	O	O

NO	B-PHEN
production	I-PHEN
and	O	O
GAG	B-CHEM
release	O
by	O	O
the	O	O
cartilage	O
was	O	O
increased	O
when	O	O
cultured	B-PROC
with	O	O
M	B-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
MCM	B-CHEM
.	O	O

M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
and	O	O
M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	I-CHEM
did	O	O
not	O	O
inhibit	O
the	O	O
effects	O
of	O
M	B-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
MCM	B-CHEM
of	O	O
neither	O	O
phenotype	B-PHYS
affected	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
pre	B-PHEN
-	I-PHEN
stimulated	I-PHEN
cartilage	O
,	O	O
in	O	O
which	O	O
an	O	O
inflammatory	O
gene	O
response	B-PHYS
was	O	O
deliberately	O
induced	O
.	O	O

M	B-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
macrophages	B-ANAT
have	O	O
a	O	O
prominent	O
direct	O
effect	O
on	O	O
OA	B-DISO
cartilage	O
,	O	O
while	O	O
M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
4	I-CHEM
)	I-CHEM
and	O	O
M	B-ANAT
(	O	O
IL	B-CHEM
-	I-CHEM
10	I-CHEM
)	I-CHEM
do	O	O
not	O	O
inhibit	O
the	O	O
effects	O
of	O
M	B-ANAT
(	O	O
IFNγ	B-CHEM
+	O	O
TNFα	B-CHEM
)	O	O
,	O	O
or	O	O
IFN	B-CHEM
γ	O	O
+	O	O
TNFα	B-CHEM
induced	O
inflammation	B-DISO
of	O	O
the	O	O
cartilage	O
.	O	O

Therapies	B-PROC
aiming	O	O
at	O	O
inhibiting	O
cartilage	B-DISO
degeneration	I-DISO
may	O	O
take	O	O
this	O	O
into	O	O
account	O	O
by	O	O
directing	O	O
suppression	B-PHYS
of	O	O
pro	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
or	O	O
stimulation	B-PHEN
of	O	O
anti	B-ANAT
-	I-ANAT
inflammatory	I-ANAT
macrophages	I-ANAT
.	O	O

The	O	O
genome	O
-scale	O	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
profile	B-PROC
of	O	O
BarR	B-CHEM
,	O	O
a	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
responsive	O
transcription	B-CHEM
factor	I-CHEM
in	O	O
the	O	O
archaeon	B-LIVB
Sulfolobus	B-LIVB
acidocaldarius	I-LIVB
The	O	O
Leucine	B-CHEM
-	I-CHEM
responsive	I-CHEM
Regulatory	I-CHEM
Protein	I-CHEM
(	O	O
Lrp	B-CHEM
)	O	O
family	B-CHEM
is	O	O
a	O	O
widespread	O	O
family	B-CHEM
of	O	O
regulatory	B-CHEM
transcription	I-CHEM
factors	I-CHEM
in	O	O
prokaryotes	B-LIVB
.	O	O

BarR	B-CHEM
is	O	O
an	O	O
Lrp	B-CHEM
-like	O	O
transcription	B-CHEM
factor	I-CHEM
in	O	O
the	O	O
model	O	O
archaeon	B-LIVB
Sulfolobus	B-LIVB
acidocaldarius	I-LIVB
that	O	O
activates	O
the	O	O
expression	B-PHYS
of	O	O
a	O	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
β	B-PHYS
-	I-PHYS
alanine	I-PHYS
degradation	I-PHYS
.	O	O

In	O	O
contrast	O	O
to	O	O
classical	O	O
Lrp	B-CHEM
-like	O	O
transcription	B-CHEM
factors	I-CHEM
,	O	O
BarR	B-CHEM
is	O	O
not	B-DISO
responsive	I-DISO
to	O	O
any	O	O
of	O	O
the	O	O
α	B-CHEM
-	I-CHEM
amino	I-CHEM
acids	I-CHEM
but	O	O
interacts	O	O
specifically	O	O
with	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
.	O	O

Besides	O	O
the	O	O
juxtaposed	O	O
β	O
-	O
alanine	O
aminotransferase	O
gene	O
,	O	O
other	O	O
regulatory	O	O
targets	O	O
of	O	O
BarR	B-CHEM
have	O	O
not	O	O
yet	O	O
been	O	O
identified	O	O
although	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
is	O	O
the	O	O
precursor	B-CHEM
of	O	O
coenzyme	B-CHEM
A	I-CHEM
and	O	O
thus	O	O
an	O	O
important	O	O
central	O	O
metabolite	B-CHEM
.	O	O

The	O	O
aim	O
of	O	O
this	O	O
study	B-PROC
is	O	O
to	O	O
extend	O	O
the	O	O
knowledge	O	O
of	O	O
the	O	O
DNA	B-PHYS
-	I-PHYS
binding	I-PHYS
characteristics	O
of	O	O
BarR	B-CHEM
and	O	O
of	O	O
its	O	O
corresponding	O	O
regulon	O
from	O	O
a	O	O
local	O
to	O	O
a	O	O
genome	O
-wide	O	O
perspective	O	O
.	O	O

We	O	O
characterized	O	O
the	O	O
genome	B-PROC
-	I-PROC
wide	I-PROC
binding	I-PROC
profile	I-PROC
of	O	O
BarR	B-CHEM
using	O	O
chromatin	B-PROC
immunoprecipation	I-PROC
combined	O	O
with	O	O
high	B-PROC
-	I-PROC
throughput	I-PROC
sequencing	I-PROC
(	O	O
ChIP	B-PROC
-	I-PROC
seq	I-PROC
)	O	O
.	O	O

This	O	O
revealed	O	O
21	O	O
genomic	O
binding	B-PHYS
loci	O
.	O	O

High	O	O
-	O	O
enrichment	O	O
binding	B-PHYS
regions	I-PHYS
were	O	O
validated	O	O
to	O	O
interact	O	O
with	O	O
purified	O	O
BarR	B-CHEM
protein	I-CHEM
in	O
vitro	O
using	O	O
electrophoretic	B-PROC
mobility	I-PROC
shift	I-PROC
assays	I-PROC
and	O	O
almost	O	O
all	O	O
targets	O	O
were	O	O
also	O	O
shown	O	O
to	O	O
harbour	O	O
a	O	O
conserved	O
semi	B-CHEM
-	I-CHEM
palindromic	I-CHEM
binding	O
motif	O
.	O	O

Only	O	O
a	O	O
small	O	O
subset	O	O
of	O	O
enriched	O	O
genomic	O
sites	O
are	O	O
located	O	O
in	O	O
intergenic	B-CHEM
regions	I-CHEM
at	O	O
a	O	O
relative	O	O
short	O	O
distance	O	O
to	O	O
a	O	O
promoter	B-CHEM
,	O	O
and	O	O
qRT	B-PROC
-	I-PROC
PCR	I-PROC
analysis	I-PROC
demonstrated	O	O
that	O	O
only	O	O
one	O	O
additional	O	O
operon	O
is	O	O
under	O	O
activation	B-PHYS
of	O	O
BarR	B-CHEM
,	O	O
namely	O	O
the	O	O
glutamine	O
synthase	O
operon	O
.	O	O

The	O	O
latter	O	O
is	O	O
also	O	O
a	O	O
target	O	O
of	O	O
other	O	O
Lrp	B-CHEM
-like	O	O
transcription	B-CHEM
factors	I-CHEM
.	O	O

Detailed	O	O
inspection	O	O
of	O	O
the	O	O
BarR	B-CHEM
ChIP	B-PHEN
-	I-PHEN
seq	I-PHEN
profile	I-PHEN
at	O	O
the	O	O
β	B-CHEM
-	I-CHEM
alanine	I-CHEM
aminotransferase	I-CHEM
promoter	I-CHEM
region	I-CHEM
in	O	O
combination	O
with	O	O
binding	O
motif	O
predictions	O	O
indicate	O	O
that	O	O
the	O	O
operator	B-CHEM
structure	I-CHEM
is	O	O
more	O	O
complicated	O
than	O	O
previously	O	O
anticipated	O	O
,	O	O
consisting	O	O
of	O	O
multiple	B-CHEM
(	I-CHEM
major	I-CHEM
and	I-CHEM
auxiliary	I-CHEM
)	I-CHEM
operators	I-CHEM
.	O	O

BarR	B-CHEM
has	O	O
a	O	O
limited	O
regulon	O
,	O	O
and	O	O
includes	O	O
also	O	O
glutamine	O
synthase	O
genes	O
besides	O	O
the	O	O
previously	O	O
characterized	O	O
β	O
-	O
alanine	O
aminotransferase	O
.	O	O

Regulation	B-PHEN
of	O	O
glutamine	B-CHEM
synthase	I-CHEM
is	O	O
suggestive	O	O
of	O	O
a	O	O
link	O	O
between	O	O
β	B-PHYS
-	I-PHYS
alanine	I-PHYS
and	O	O
α	B-PHYS
-	I-PHYS
amino	I-PHYS
acid	I-PHYS
metabolism	I-PHYS
in	O	O
S	B-LIVB
.	I-LIVB

acidocaldarius	I-LIVB
.	O	O

Furthermore	O	O
,	O	O
this	O	O
work	O	O
reveals	O	O
that	O	O
the	O	O
BarR	B-CHEM
regulon	O
overlaps	O	O
with	O	O
that	O	O
of	O	O
other	O	O
Lrp	B-CHEM
-like	O	O
regulators	O
.	O	O

Preclinical	O
fibrinolysis	B-PHYS
in	O	O
patients	B-LIVB
with	O	O
ST	B-DISO
-	I-DISO
segment	I-DISO
elevation	I-DISO
myocardial	I-DISO
infarction	I-DISO
in	O	O
a	O	O
rural	O
region	O
In	O	O
the	O	O
current	O
guidelines	O
for	O	O
the	O	O
treatment	B-PROC
of	O	O
patients	B-LIVB
with	O	O
ST	B-DISO
-	I-DISO
segment	I-DISO
elevation	I-DISO
myocardial	I-DISO
infarction	I-DISO
(	O	O
STEMI	B-DISO
)	O	O
,	O	O
the	O	O
European	O	O
Society	O	O
of	O	O
Cardiology	O	O
(	O	O
ESC	O	O
)	O	O
recommends	O
preclinical	O
fibrinolysis	B-PHYS
as	O	O
a	O	O
reperfusion	B-PROC
therapy	I-PROC
if	O	O
,	O	O
due	O	O
to	O	O
long	O	O
transportation	O
times	O
,	O	O
no	O	O
cardiac	B-PROC
catheterisation	I-PROC
is	O	O
available	O
within	O	O
90	O	O
-	O	O
120	O	O
min	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
little	O	O
remaining	O
in	O	O
-	O	O
depth	O	O
expertise	O
in	O	O
this	O	O
method	O
because	O	O
fibrinolysis	B-PHYS
is	O	O
presently	O
only	O	O
rarely	O
indicated	B-DISO
.	O	O

In	O	O
a	O	O
rural	O
area	O
in	O	O
southwestern	O
Germany	B-GEOG
,	O	O
where	O	O
an	O	O
emergency	B-PROC
primary	I-PROC
percutaneous	I-PROC
coronary	I-PROC
intervention	I-PROC
was	O	O
not	O	O
routinely	O
available	O
within	O	O
90	O	O
-	O	O
120	O	O
min	O
,	O	O
156	O	O
STEMI	B-DISO
patients	B-LIVB
underwent	O	O
fibrinolysis	B-PHYS
with	O	O
the	O	O
plasminogen	B-CHEM
activator	I-CHEM
reteplase	I-CHEM
,	O	O
performed	O
by	O
trained	O	O
emergency	B-PHEN
physicians	B-LIVB
.	O	O

The	O	O
practicality	O
of	O	O
the	O	O
treatment	B-PROC
,	O	O
as	O	O
well	O	O
as	O	O
complications	B-DISO
and	O	O
the	O	O
mortality	O
of	O	O
the	O	O
patients	B-LIVB
in	O	O
the	O	O
preclinical	O
phase	O
until	O	O
arrival	O
at	O	O
the	O	O
hospital	B-OBJC
,	O	O
were	O	O
retrospectively	B-PROC
studied	I-PROC
.	O	O

The	O	O
mean	O
time	O
from	O	O
onset	O
of	O
the	O	O
symptoms	B-DISO
to	O	O
first	O	O
medical	B-PROC
contact	I-PROC
was	O	O
114	O	O
±	O	O
116	O	O
min	O
.	O	O

The	O	O
mean	O
interval	O
to	O	O
the	O	O
start	O
of	O	O
fibrinolysis	B-PHYS
of	O	O
13	O	O
.	O	O
5	O	O
±	O	O
6	O	O
.	O	O
4	O	O
min	O
was	O	O
within	O	O
the	O	O
30	O	O
min	O
mandated	O
by	O	O
the	O	O
ESC	O	O
.	O	O

Patients	B-LIVB
with	O	O
inferior	B-DISO
STEMI	I-DISO
represented	O
the	O	O
largest	O
subgroup	O
.	O	O

Occurring	O	O
in	O	O
39	O	O
cases	B-LIVB
(	O	O
25	O	O
%	O	O
)	O	O
,	O	O
complications	B-DISO
due	O	O
to	O	O
infarction	B-DISO
were	O	O
relatively	O	O
common	O
during	O	O
the	O	O
prehospital	B-PROC
phase	O
,	O	O
including	O	O
15	O	O
cases	B-LIVB
(	O	O
9	O	O
.	O	O

6	O	O
%	O	O
)	O	O
of	O	O
cardiogenic	B-DISO
shock	I-DISO
,	O	O
but	O	O
in	O	O
all	O	O
cases	B-LIVB
the	O	O
complications	B-DISO
were	O	O
manageable	B-DISO
.	O	O

No	O	O
patient	B-LIVB
died	B-DISO
before	O	O
arrival	O
at	O	O
the	O	O
hospital	B-OBJC
.	O	O

As	O	O
lysis	B-DISO
-	O	O
associated	O
adverse	B-DISO
effects	I-DISO
,	O	O
merely	O	O
two	O	O
uncomplicated	O
mucosal	B-DISO
haemorrhages	I-DISO
and	O	O
one	O	O
case	O	O
of	O	O
mild	B-DISO
allergic	I-DISO
skin	I-DISO
reactions	I-DISO
were	O	O
seen	O
.	O	O

In	O	O
emergency	B-PHEN
situations	I-PHEN
with	O	O
long	O	O
transportation	O
times	O
to	O	O
the	O	O
nearest	O	O
suitable	O
cardiac	B-PROC
catheterisation	I-PROC
laboratory	B-OBJC
,	O	O
preclinical	O
fibrinolysis	B-PHYS
in	O	O
STEMI	B-DISO
still	O	O
represents	O	O
a	O	O
workable	O
method	O
.	O	O

Success	O
of	O	O
this	O	O
strategy	B-PHYS
requires	O	O
particularly	O	O
strong	B-PROC
training	I-PROC
of	O	O
the	O	O
emergency	B-PHEN
physicians	B-LIVB
in	O	O
ECG	B-PROC
and	O	O
lysis	B-DISO
therapy	B-PROC
,	O	O
and	O	O
co	O
-	O
operation	O
with	O	O
nearby	O	O
cardiac	B-OBJC
centres	I-OBJC
.	O	O

GH32	B-CHEM
family	I-CHEM
activity	B-PHYS
:	O	O
a	O	O
topological	O
approach	O	O
through	O	O
protein	O
contact	O
networks	O
The	O	O
application	O	O
of	O	O
Protein	O
Contact	O
Networks	O
methodology	O
allowed	O	O
to	O	O
highlight	O	O
a	O	O
novel	O	O
response	O	O
of	O	O
border	O
region	O
between	O	O
the	O	O
two	O	O
domains	O
to	O
substrate	O
binding	O
.	O	O

Glycoside	B-CHEM
hydrolases	I-CHEM
(	O	O
GH	B-CHEM
)	O	O
are	O	O
enzymes	B-CHEM
that	O	O
mainly	O	O
hydrolyze	B-PHEN
the	O	O
glycosidic	B-PHYS
bond	I-PHYS
between	O	O
two	O	O
carbohydrates	B-CHEM
or	O	O
a	O	O
carbohydrate	B-CHEM
and	O	O
a	O	O
non	B-CHEM
-	I-CHEM
carbohydrate	I-CHEM
moiety	I-CHEM
.	O	O

These	O	O
enzymes	B-CHEM
are	O	O
involved	O	O
in	O	O
many	O	O
fundamental	O	O
and	O	O
diverse	O	O
biological	B-PHEN
processes	I-PHEN
in	O	O
plants	B-LIVB
.	O	O

We	O	O
have	O	O
focused	O	O
on	O	O
the	O	O
GH32	B-CHEM
family	I-CHEM
,	O	O
including	O	O
enzymes	B-CHEM
very	O	O
similar	O	O
in	O	O
both	O	O
sequence	O
and	O	O
structure	B-CHEM
,	O	O
each	O	O
having	O	O
however	O	O
clear	O	O
specificities	O	O
of	O	O
substrate	B-CHEM
preferences	O
and	O	O
kinetic	O
properties	O
.	O	O

Structural	B-CHEM
and	O	O
topological	O
differences	O	O
among	O	O
proteins	B-CHEM
of	O	O
the	O	O
GH32	B-CHEM
family	I-CHEM
have	O	O
been	O	O
here	O	O
identified	O	O
by	O	O
means	O	O
of	O	O
an	O	O
emerging	O	O
approach	O	O
(	O	O
Protein	O
Contact	O
network	O
,	O	O
PCN	O
)	O	O
based	O	O
on	O	O
the	O	O
formalization	O	O
of	O	O
3D	O
structures	O
as	O	O
contact	O
networks	O
among	O	O
amino	O
-	O
acid	O
residues	O
.	O	O

The	O	O
PCN	O
approach	O	O
proved	O	O
successful	O	O
in	O	O
both	O	O
reconstructing	O	O
the	O	O
already	O	O
known	O	O
functional	O
domains	O
and	O	O
in	O	O
identifying	O	O
the	O	O
structural	B-CHEM
counterpart	O	O
of	O	O
the	O	O
properties	O	O
of	O	O
GH32	B-CHEM
enzymes	I-CHEM
,	O	O
which	O	O
remain	O	O
uncertain	O	O
,	O	O
like	O	O
their	O	O
allosteric	O
character	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
of	O	O
the	O	O
study	O	O
was	O	O
the	O	O
discovery	O	O
of	O	O
the	O	O
activation	B-PHYS
upon	O	O
binding	B-PHYS
of	I-PHYS
the	I-PHYS
border	I-PHYS
(	I-PHYS
cleft	I-PHYS
)	I-PHYS
region	I-PHYS
between	O	O
the	O	O
two	O	O
domains	O
.	O	O

This	O	O
reveals	O	O
the	O	O
allosteric	O
nature	O	O
of	O	O
the	O	O
enzymatic	B-PHYS
activity	I-PHYS
for	O	O
all	O	O
the	O	O
analyzed	O	O
forms	O	O
in	O	O
the	O	O
GH32	B-CHEM
family	I-CHEM
,	O	O
a	O	O
character	O	O
yet	O	O
to	O	O
be	O	O
highlighted	O	O
in	O	O
biochemical	B-PROC
studies	I-PROC
.	O	O

Furthermore	O	O
,	O	O
we	O	O
have	O	O
been	O	O
able	O	O
to	O	O
recognize	O	O
a	O	O
topological	O
signature	O
(	O	O
graph	O	O
energy	O	O
)	O	O
of	O	O
the	O	O
different	O	O
affinity	B-PHEN
of	O	O
the	O	O
enzymes	B-CHEM
towards	O	O
small	O	O
and	O	O
large	O	O
substrates	B-CHEM
.	O	O

In	O
vivo	O
assessment	B-PROC
of	O	O
periodontal	O
structures	O
and	O	O
measurement	O
of	O	O
gingival	B-ANAT
sulcus	I-ANAT
with	O	O
Optical	B-PROC
Coherence	I-PROC
Tomography	I-PROC
:	O	O
a	O	O
pilot	B-PROC
study	I-PROC
There	O	O
has	O	O
been	O	O
increasing	O	O
interest	O	O
on	O	O
the	O	O
development	O
of	O	O
clinically	O
acceptable	O
,	O	O
more	O	O
sensitive	O
and	O	O
specific	O
methods	O	O
for	O	O
non	O
-	O
invasive	O
diagnosis	B-DISO
in	O	O
Periodontics	O
.	O	O

In	O	O
this	O	O
pilot	B-PROC
study	I-PROC
,	O	O
the	O	O
performance	O	O
of	O	O
an	O	O
Optical	B-PROC
Coherence	I-PROC
Tomography	I-PROC
(	O	O
OCT	B-PROC
)	O	O
system	O	O
in	O	O
imaging	B-PROC
periodontal	O
structures	O
in	O	O
humans	B-LIVB
was	O	O
evaluated	B-PROC
.	O	O

Gingival	B-ANAT
sulcus	I-ANAT
depth	O
measurements	O
were	O	O
obtained	O
and	O	O
compared	O
with	O	O
traditional	O
probes	B-DEVI
.	O	O

In	O	O
total	O	O
,	O	O
445	O	O
sites	O
of	O	O
23	O	O
periodontally	O
healthy	O
individuals	B-LIVB
were	O	O
measured	O
by	O	O
3	O	O
instruments	B-DEVI
:	O	O
North	B-DEVI
Carolina	I-DEVI
manual	I-DEVI
probe	I-DEVI
,	O	O
Florida	B-DEVI
automated	I-DEVI
probe	I-DEVI
and	O	O
OCT	B-PROC
at	O	O
1325	O	O
nm	O	O
.	O	O

To	O	O
obtain	O	O
quantitative	O
measurements	O
from	O	O
OCT	B-PROC
images	O
,	O	O
the	O	O
gingival	B-ANAT
refractive	O
index	O
was	O	O
also	O	O
determined	O	O
.	O	O

Discomfort	B-DISO
/	O	O
pain	B-DISO
perception	B-PHYS
and	O	O
the	O	O
duration	O
of	O	O
examinations	B-PROC
were	O	O
compared	O
among	O	O
the	O	O
instruments	B-DEVI
.	O	O

The	O	O
analysis	O	O
of	O	O
OCT	B-PROC
images	O
allowed	O	O
the	O	O
identification	O	O
of	O	O
relevant	O	O
anatomic	O
dental	O
and	O	O
periodontal	O
regions	B-ANAT
.	O	O

The	O	O
average	O
sulcus	B-ANAT
depth	O
measured	O
by	O	O
OCT	B-PROC
,	O	O
0	O	O
.	O	O
85	O	O
±	O	O
0	O	O
.	O	O
27	O	O
mm	O	O
and	O	O
0	O	O
.	O	O
87	O	O
±	O	O
0	O	O
.	O	O
28	O	O
mm	O	O
,	O	O
was	O	O
lower	O	O
than	O	O
the	O	O
values	O	O
obtained	O	O
by	O	O
manual	O
and	O	O
automated	O
probing	B-PROC
.	O	O

Discomfort	B-DISO
/	O	O
pain	B-DISO
were	O	O
prevalent	O
for	O	O
traditional	O
probes	B-DEVI
,	O	O
which	O	O
are	O	O
invasive	O
methods	O
,	O	O
than	O	O
for	O	O
the	O	O
non	O
-	O
invasive	O
OCT	B-PROC
technique	O
.	O	O

OCT	B-PROC
has	O	O
the	O	O
potential	O
to	O	O
be	O	O
a	O	O
reliable	O	O
tool	B-OBJC
for	O	O
in	O
vivo	O
periodontal	O
tissues	O
evaluation	B-PROC
and	O	O
for	O	O
reproducible	O	O
sulcus	B-ANAT
depth	O
measurements	O
in	O	O
healthy	O
sites	O	O
.	O	O

Further	O	O
technological	O
advances	O
are	O	O
required	O	O
to	O	O
reduce	O
the	O	O
procedure	B-PROC
time	O
and	O	O
promote	O
evaluation	B-PROC
of	O	O
posterior	O
oral	B-ANAT
regions	I-ANAT
.	O	O

Photonic	O
assessment	B-PROC
of	O	O
periodontal	O
tissue	O
with	O	O
OCT	B-PROC
(	O	O
top	O
)	O	O
in	O	O
a	O	O
clinical	O
environment	O
,	O	O
showing	O	O
tooth	B-ANAT
/	O	O
gingiva	O
features	O
(	O	O
bottom	O
)	O	O
.	O	O

A	O	O
method	O
of	O	O
providing	O
engaging	O	O
formative	O
feedback	O
to	O	O
large	O
cohort	B-LIVB
first	O
-	O
year	O
physiology	O
and	O	O
anatomy	O
students	B-LIVB
A	O	O
growing	O	O
body	O	O
of	O	O
evidence	O
demonstrates	O
a	O	O
critical	O
role	O	O
for	O	O
effective	O
,	O	O
meaningful	O
feedback	B-PHYS
to	O	O
enhance	O
student	B-LIVB
learning	B-PHYS
.	O	O

Effective	O
feedback	B-PHYS
can	O	O
become	O	O
part	O
of	O
the	O	O
learning	B-PHYS
cycle	O
that	O	O
is	O	O
not	O	O
only	O	O
a	O	O
learning	B-PHYS
opportunity	B-PROC
for	O	O
the	O	O
student	B-LIVB
but	O	O
can	O	O
also	O	O
be	O	O
used	O	O
to	O	O
inform	O
the	O	O
teacher	B-LIVB
and	O	O
ongoing	O
curriculum	B-PROC
development	I-PROC
.	O	O

Feedback	B-PHYS
is	O	O
considered	O
particularly	O	O
important	O
during	O
the	O	O
first	O
year	O
of	O	O
university	B-OBJC
and	O	O
can	O	O
even	O	O
be	O	O
viewed	O	O
as	O	O
a	O	O
retention	O
strategy	O	O
that	O	O
can	O	O
help	O	O
attenuate	O
student	B-LIVB
performance	B-DISO
anxieties	I-DISO
and	O	O
solidify	O
perceptions	B-PHYS
of	O	O
academic	B-PROC
support	I-PROC
.	O	O

Unfortunately	O	O
,	O	O
the	O	O
provision	O	O
of	O	O
individualized	O
,	O	O
timely	O
feedback	B-PHYS
can	O	O
be	O	O
particularly	O	O
challenging	O	O
in	O	O
first	O
-	O
year	O
courses	O
as	O	O
they	O	O
tend	O	O
to	O	O
be	O	O
large	O
and	O	O
diverse	O
cohort	B-LIVB
classes	O
that	O	O
pose	O	O
challenges	O	O
of	O	O
time	O
and	O	O
logistics	O
.	O	O

Various	O	O
forms	O	O
of	O	O
generic	O	O
feedback	B-PHYS
can	O	O
provide	O
rapid	O
and	O	O
cost	O
-	O
effect	O
feedback	B-PHYS
to	O	O
large	O
cohorts	B-LIVB
but	O	O
may	O	O
be	O	O
of	O	O
limited	O
benefit	O
to	O	O
students	B-LIVB
other	O	O
than	O	O
signaling	O	O
weaknesses	B-DISO
in	O	O
knowledge	O
.	O	O

The	O	O
present	B-DISO
study	B-PROC
describes	O
a	O	O
method	O
that	O	O
was	O	O
used	O	O
to	O	O
provide	O
formative	O
task	O
-	O
related	O
feedback	O
to	O	O
a	O	O
large	O
cohort	B-LIVB
of	O	O
first	O
-	O
year	O
physiology	O
and	O	O
anatomy	O
students	B-LIVB
.	O	O

Based	O	O
on	O	O
student	B-LIVB
evaluations	B-PROC
presented	O
in	O	O
this	O	O
study	B-PROC
,	O	O
this	O	O
method	O
provided	O
feedback	B-PHYS
in	O	O
a	O	O
manner	O	O
that	O	O
engaged	O	O
students	B-LIVB
,	O	O
uncovered	O
underlying	B-DISO
misconceptions	I-DISO
,	O	O
facilitated	O	O
peer	B-LIVB
discussion	O
,	O	O
and	O	O
provided	O
opportunity	O	O
for	O	O
new	O
instruction	B-PROC
while	O	O
allowing	O
the	O	O
lecturer	B-LIVB
to	O	O
recognize	B-PHYS
common	O
gaps	O
in	O	O
knowledge	O
and	O	O
inform	O	O
ongoing	O
curriculum	B-PROC
development	I-PROC
.	O	O

SIRT2	B-CHEM
Deacetylates	B-PHYS
and	O	O
Inhibits	B-PHYS
the	I-PHYS
Peroxidase	I-PHYS
Activity	I-PHYS
of	O	O
Peroxiredoxin	B-CHEM
-	I-CHEM
1	I-CHEM
to	O	O
Sensitize	B-ANAT
Breast	I-ANAT
Cancer	I-ANAT
Cells	I-ANAT
to	O	O
Oxidant	B-DISO
Stress	I-DISO
-	O	O
Inducing	O
Agents	O	O
SIRT2	B-CHEM
is	O	O
a	O	O
protein	B-PHYS
deacetylase	I-PHYS
with	O	O
tumor	B-PHYS
suppressor	I-PHYS
activity	I-PHYS
in	O	O
breast	B-DISO
and	O	O
liver	B-DISO
tumors	I-DISO
where	O	O
it	O	O
is	O	O
mutated	B-DISO
;	O	O
however	O	O
,	O	O
the	O	O
critical	O	O
substrates	B-OBJC
mediating	O	O
its	O	O
antitumor	B-DISO
activity	I-DISO
are	O	O
not	O	O
fully	O	O
defined	O	O
.	O	O

Here	O	O
we	O	O
demonstrate	O	O
that	O	O
SIRT2	B-CHEM
binds	B-PHYS
,	O	O
deacetylates	B-PHYS
,	O	O
and	O	O
inhibits	B-PHYS
the	I-PHYS
peroxidase	I-PHYS
activity	I-PHYS
of	O	O
the	O	O
antioxidant	B-CHEM
protein	I-CHEM
peroxiredoxin	I-CHEM
(	O	O
Prdx	B-CHEM
-	I-CHEM
1	I-CHEM
)	O	O
in	O	O
breast	B-ANAT
cancer	I-ANAT
cells	I-ANAT
.	O	O

Ectopic	O
overexpression	B-PHYS
of	O	O
SIRT2	B-CHEM
,	O	O
but	O	O
not	O	O
its	O	O
catalytically	B-DISO
dead	I-DISO
mutant	I-DISO
,	O	O
increased	O
intracellular	O
levels	O
of	O	O
reactive	B-CHEM
oxygen	I-CHEM
species	I-CHEM
(	O	O
ROS	B-CHEM
)	O	O
induced	B-CHEM
by	I-CHEM
hydrogen	I-CHEM
peroxide	I-CHEM
,	I-CHEM
which	O	O
led	O	O
to	O	O
increased	O
levels	O
of	O	O
an	O	O
overoxidized	B-CHEM
and	I-CHEM
multimeric	I-CHEM
form	I-CHEM
of	I-CHEM
Prdx	I-CHEM
-	I-CHEM
1	I-CHEM
with	O	O
activity	B-CHEM
as	I-CHEM
a	I-CHEM
molecular	I-CHEM
chaperone	I-CHEM
.	O	O

Elevated	O
levels	O
of	O	O
SIRT2	O
sensitized	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O	O
intracellular	B-DISO
DNA	I-DISO
damage	I-DISO
and	O	O
cell	B-PHYS
death	I-PHYS
induced	I-PHYS
by	I-PHYS
oxidative	I-PHYS
stress	I-PHYS
,	O	O
as	O	O
associated	O	O
with	O	O
increased	O
levels	O
of	O	O
nuclear	B-CHEM
FOXO3A	I-CHEM
and	O	O
the	O	O
proapoptotic	B-CHEM
BIM	I-CHEM
protein	I-CHEM
.	O	O

In	O	O
addition	O	O
,	O	O
elevated	O
levels	O
of	O	O
SIRT2	B-CHEM
sensitized	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O	O
arsenic	B-CHEM
trioxide	I-CHEM
,	O	O
an	O	O
approved	O	O
therapeutic	B-OBJC
agent	I-OBJC
,	O	O
along	O	O
with	O	O
other	O	O
intracellular	B-CHEM
ROS	I-CHEM
-	O	O
inducing	B-CHEM
agents	I-CHEM
.	O	O

Conversely	O	O
,	O	O
antisense	B-CHEM
RNA	I-CHEM
-	O	O
mediated	O
attenuation	O
of	O	O
SIRT2	B-CHEM
reversed	O
ROS	B-CHEM
-	O	O
induced	B-DISO
toxicity	I-DISO
as	O	O
demonstrated	O	O
in	O	O
a	O	O
zebrafish	B-LIVB
embryo	B-ANAT
model	I-ANAT
system	I-ANAT
.	O	O

Collectively	O	O
,	O	O
our	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
tumor	B-PHYS
suppressor	I-PHYS
activity	I-PHYS
of	O	O
SIRT2	B-CHEM
requires	O	O
its	O	O
ability	O	O
to	O	O
restrict	O
the	O	O
antioxidant	B-PHYS
activity	I-PHYS
of	O	O
Prdx	B-CHEM
-	I-CHEM
1	I-CHEM
,	O	O
thereby	O	O
sensitizing	B-ANAT
breast	I-ANAT
cancer	I-ANAT
cells	I-ANAT
to	O	O
ROS	B-CHEM
-	O	O
induced	B-DISO
DNA	I-DISO
damage	I-DISO
and	O	O
cell	B-DISO
cytotoxicity	I-DISO
.	O	O

Cancer	O	O
Res	O	O
;	O	O
76	O	O
(	O	O
18	O	O
)	O	O
;	O	O
5467	O	O
-	O	O
78	O	O
.	O	O

©	O	O
2016	O	O
AACR	O	O
.	O	O

Grasping	B-PHYS
At	O	O
The	O	O
Moon	B-GEOG
:	O	O
Enhancing	O
Access	O
To	O	O
Careers	O
In	O	O
The	O	O
Health	O
Professions	O
A	O	O
former	O
HHS	O
secretary	B-LIVB
reflects	B-PHYS
on	O	O
what	O	O
's	O	O
needed	O	O
to	O	O
enable	O	O
more	O	O
minorities	B-LIVB
to	O	O
become	O	O
doctors	B-LIVB
and	O	O
other	O	O
health	B-LIVB
professionals	I-LIVB
.	O	O

Multivariate	O
Imaging	B-PROC
Genetics	B-PROC
Study	I-PROC
of	O	O
MRI	B-PROC
Gray	O
Matter	O
Volume	O
and	O	O
SNPs	O
Reveals	O	O
Biological	O
Pathways	O
Correlated	O
with	O	O
Brain	B-ANAT
Structural	O
Differences	O
in	O	O
Attention	B-DISO
Deficit	I-DISO
Hyperactivity	I-DISO
Disorder	I-DISO
Attention	B-DISO
deficit	I-DISO
hyperactivity	I-DISO
disorder	I-DISO
(	O	O
ADHD	B-DISO
)	O	O
is	O	O
a	O	O
prevalent	O
neurodevelopmental	B-DISO
disorder	I-DISO
affecting	O
children	B-LIVB
,	O	O
adolescents	B-LIVB
,	O	O
and	O	O
adults	B-LIVB
.	O	O

Its	O	O
etiology	O
is	O	O
not	O	O
well	O	O
understood	O	O
,	O	O
but	O	O
it	O	O
is	O	O
increasingly	O	O
believed	O	O
to	O	O
result	O
from	O	O
diverse	O
pathophysiologies	B-DISO
that	O	O
affect	O
the	O	O
structure	O
and	O	O
function	O
of	O	O
specific	O
brain	O
circuits	O
.	O	O

Although	O	O
one	O	O
of	O	O
the	O	O
best	O	O
-	O	O
studied	O	O
neurobiological	B-DISO
abnormalities	I-DISO
in	O	O
ADHD	B-DISO
is	O	O
reduced	O
fronto	B-ANAT
-	I-ANAT
striatal	I-ANAT
-	I-ANAT
cerebellar	I-ANAT
gray	I-ANAT
matter	I-ANAT
(	O	O
GM	O
)	O	O
volume	O
,	O	O
its	O	O
specific	O	O
genetic	O
correlates	O
are	O	O
largely	O	O
unknown	O
.	O	O

In	O	O
this	O	O
study	B-PROC
,	O	O
T1	B-PROC
-	I-PROC
weighted	I-PROC
MR	I-PROC
images	I-PROC
of	I-PROC
brain	I-PROC
structure	I-PROC
were	O	O
collected	O	O
from	O	O
198	O	O
adolescents	B-LIVB
(	O	O
63	O	O
ADHD	B-DISO
-	O	O
diagnosed	B-DISO
)	O	O
.	O	O

A	O	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O	O
Para	O
-	O
ICA	O
)	O	O
technique	O
-identified	O	O
imaging	B-PROC
genetic	O
relationships	O
between	O	O
regional	O
GM	O
volume	O
and	O	O
single	O
nucleotide	O
polymorphism	O
data	O
.	O	O

Para	O
-	O
ICA	O
analyses	O
extracted	O	O
14	O	O
components	O	O
from	O	O
genetic	O
data	O
and	O	O
9	O	O
from	O	O
MR	B-PROC
data	O
.	O	O

An	O	O
iterative	B-PROC
cross	I-PROC
-	I-PROC
validation	I-PROC
using	O	O
randomly	O	O
chosen	O	O
subsamples	O	O
indicated	O	O
acceptable	O	O
stability	O
of	O	O
these	O	O
ICA	O
solutions	O
.	O	O

A	O	O
series	O	O
of	O	O
partial	O
correlation	O
analyses	O
controlling	B-PHEN
for	O	O
age	B-PHYS
,	O	O
sex	B-PHYS
,	O	O
and	O	O
ethnicity	O
revealed	O	O
two	O	O
genotype	B-PHYS
-	I-PHYS
phenotype	I-PHYS
component	O
pairs	O
significantly	O	O
differed	O	O
between	O	O
ADHD	B-DISO
and	O	O
non	B-DISO
-	I-DISO
ADHD	I-DISO
groups	O
,	O	O
after	O	O
a	O	O
Bonferroni	O
correction	O
for	O	O
multiple	O
comparisons	O
.	O	O

The	O	O
brain	B-ANAT
phenotype	B-PHYS
component	O
not	O	O
only	O	O
included	O	O
structures	O
frequently	O	O
found	O	O
to	O	O
have	O	O
abnormally	O
low	O
volume	O
in	O	O
previous	O	O
ADHD	B-DISO
studies	B-PROC
but	O	O
was	O	O
also	O	O
significantly	O	O
associated	O
with	O
ADHD	B-DISO
differences	O	O
in	O	O
symptom	B-DISO
severity	I-DISO
and	O	O
performance	O
on	O	O
cognitive	O
tests	O
frequently	O	O
found	O	O
to	O	O
be	O	O
impaired	O	O
in	O	O
patients	B-LIVB
diagnosed	B-DISO
with	O	O
the	O	O
disorder	B-DISO
.	O	O

Pathway	O
analysis	O
of	O	O
the	O	O
genotype	B-PHYS
component	O
identified	O	O
several	O	O
different	O	O
biological	O
pathways	O
linked	O	O
to	O	O
these	O	O
structural	O
abnormalities	B-DISO
in	O	O
ADHD	B-DISO
.	O	O

Some	O	O
of	O	O
these	O	O
pathways	O
implicate	O	O
well	O	O
-	O	O
known	O	O
dopaminergic	B-PHYS
neurotransmission	I-PHYS
and	O	O
neurodevelopment	B-PHYS
hypothesized	O
to	O	O
be	O	O
abnormal	B-DISO
in	O	O
ADHD	B-DISO
.	O	O

Other	O	O
more	O	O
recently	O	O
implicated	O	O
pathways	O
included	O	O
glutamatergic	B-PHYS
and	O	O
GABA	B-PHYS
-	I-PHYS
eric	I-PHYS
physiological	I-PHYS
systems	I-PHYS
;	O	O
others	O	O
might	O	O
reflect	O	O
sources	O	O
of	O	O
shared	O	O
liability	O	O
to	O	O
disturbances	O	O
commonly	O	O
found	O	O
in	O	O
ADHD	B-DISO
,	O	O
such	O	O
as	O	O
sleep	B-DISO
abnormalities	I-DISO
.	O	O

